2010 Nursing Spectrum Drug Handbook

Patricia Dwyer Schull

Includes Full-Text Download
# Common abbreviations

The abbreviations below are commonly used by nurses. Not all of them, however, are acceptable. Those in red marked with a Clinical Alert logo were identified as contributing to medication errors in the National Patient Safety Goals of the Joint Commission and by the Institute for Safe Medication Practices. To avoid mistakes and to ensure Joint Commission compliancy, spell out the entire term.

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABG</td>
<td>arterial blood gas</td>
</tr>
<tr>
<td>a.c.</td>
<td>before meals</td>
</tr>
<tr>
<td>ACE</td>
<td>angiotensin-converting enzyme</td>
</tr>
<tr>
<td>ACLS</td>
<td>advanced cardiac life support</td>
</tr>
<tr>
<td>ACTH</td>
<td>adrenocorticotropic hormone</td>
</tr>
<tr>
<td>AD</td>
<td>right ear</td>
</tr>
<tr>
<td>ADH</td>
<td>antidiuretic hormone</td>
</tr>
<tr>
<td>ADLs</td>
<td>activities of daily living</td>
</tr>
<tr>
<td>AICD</td>
<td>automatic implantable cardiac defibrillator</td>
</tr>
<tr>
<td>AIDS</td>
<td>acquired immunodeficiency syndrome</td>
</tr>
<tr>
<td>ALP</td>
<td>alkaline phosphatase</td>
</tr>
<tr>
<td>ALT</td>
<td>alanine aminotransferase</td>
</tr>
<tr>
<td>APTT</td>
<td>activated partial thromboplastin time</td>
</tr>
<tr>
<td>AS</td>
<td>left ear</td>
</tr>
<tr>
<td>AST</td>
<td>aspartate aminotransferase</td>
</tr>
<tr>
<td>AU</td>
<td>each ear</td>
</tr>
<tr>
<td>AV</td>
<td>atrioventricular</td>
</tr>
<tr>
<td>B₁</td>
<td>beta₁</td>
</tr>
<tr>
<td>B₂</td>
<td>beta₂</td>
</tr>
<tr>
<td>BCLS</td>
<td>basic cardiac life support</td>
</tr>
<tr>
<td>b.i.d.</td>
<td>twice daily</td>
</tr>
<tr>
<td>BP</td>
<td>blood pressure</td>
</tr>
<tr>
<td>BSA</td>
<td>body surface area</td>
</tr>
<tr>
<td>B.T.</td>
<td>bedtime</td>
</tr>
<tr>
<td>BUN</td>
<td>blood urea nitrogen</td>
</tr>
<tr>
<td>ě</td>
<td>with</td>
</tr>
<tr>
<td>C</td>
<td>Celsius</td>
</tr>
<tr>
<td>cAMP</td>
<td>cyclic 3', 5' adenosine monophosphate</td>
</tr>
<tr>
<td>CBC</td>
<td>complete blood count</td>
</tr>
<tr>
<td>cc</td>
<td>cubic centimeter</td>
</tr>
<tr>
<td>CI</td>
<td>cardiac index</td>
</tr>
<tr>
<td>CK</td>
<td>creatine kinase</td>
</tr>
<tr>
<td>cm</td>
<td>centimeter</td>
</tr>
<tr>
<td>CMV</td>
<td>cytomegalovirus</td>
</tr>
<tr>
<td>CNS</td>
<td>central nervous system</td>
</tr>
<tr>
<td>COPD</td>
<td>chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>CR</td>
<td>controlled release</td>
</tr>
<tr>
<td>CV</td>
<td>cardiovascular</td>
</tr>
<tr>
<td>CVA</td>
<td>cerebrovascular accident</td>
</tr>
<tr>
<td>CYP</td>
<td>cytochrome</td>
</tr>
<tr>
<td>D₅W</td>
<td>dextrose 5% in water</td>
</tr>
<tr>
<td>DIC</td>
<td>disseminated intravascular coagulation</td>
</tr>
<tr>
<td>D/C</td>
<td>discharge, discontinue</td>
</tr>
<tr>
<td>dl</td>
<td>deciliter</td>
</tr>
<tr>
<td>DNA</td>
<td>deoxyribonucleic acid</td>
</tr>
<tr>
<td>ECG</td>
<td>electrocardiogram</td>
</tr>
<tr>
<td>EEG</td>
<td>electroencephalogram</td>
</tr>
<tr>
<td>EENT</td>
<td>eyes, ears, nose, and throat</td>
</tr>
<tr>
<td>F</td>
<td>Fahrenheit</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>g</td>
<td>gram</td>
</tr>
<tr>
<td>G</td>
<td>gauge</td>
</tr>
<tr>
<td>GABA</td>
<td>gamma-aminobutyric acid</td>
</tr>
<tr>
<td>GFR</td>
<td>glomerular filtration rate</td>
</tr>
<tr>
<td>GGT</td>
<td>gamma-glutamyltransferase</td>
</tr>
<tr>
<td>GI</td>
<td>gastrointestinal</td>
</tr>
<tr>
<td>GnRH</td>
<td>gonadotropin-releasing hormone</td>
</tr>
<tr>
<td>gr</td>
<td>grain</td>
</tr>
<tr>
<td>gtt</td>
<td>drops</td>
</tr>
<tr>
<td>G6PD</td>
<td>glucose-6-phosphate dehydrogenase</td>
</tr>
<tr>
<td>GU</td>
<td>genitourinary</td>
</tr>
<tr>
<td>H₁</td>
<td>histamine₁</td>
</tr>
<tr>
<td>H₂</td>
<td>histamine₂</td>
</tr>
<tr>
<td>HCL</td>
<td>hydrochloride</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>HCT</td>
<td>hematocrit</td>
</tr>
<tr>
<td>HDL</td>
<td>high-density lipoprotein</td>
</tr>
<tr>
<td>Hg</td>
<td>mercury</td>
</tr>
<tr>
<td>Hgb</td>
<td>hemoglobin</td>
</tr>
<tr>
<td>HIV</td>
<td>human immunodeficiency virus</td>
</tr>
<tr>
<td>HMG-CoA</td>
<td>3-hydroxy-3-methylglutaryl coenzyme A</td>
</tr>
<tr>
<td>HR</td>
<td>heart rate</td>
</tr>
<tr>
<td>h.s.</td>
<td>at bedtime</td>
</tr>
<tr>
<td>H.S.</td>
<td>half-strength</td>
</tr>
<tr>
<td>I.J.</td>
<td>injection</td>
</tr>
<tr>
<td>I.M.</td>
<td>intramuscular</td>
</tr>
<tr>
<td>I.N.</td>
<td>intranasal</td>
</tr>
<tr>
<td>INR</td>
<td>International Normalized Ratio</td>
</tr>
<tr>
<td>IPPB</td>
<td>intermittent positive-pressure breathing</td>
</tr>
<tr>
<td>IU</td>
<td>international unit</td>
</tr>
<tr>
<td>I.V.</td>
<td>intravenous</td>
</tr>
<tr>
<td>K</td>
<td>potassium</td>
</tr>
<tr>
<td>kg</td>
<td>kilogram</td>
</tr>
<tr>
<td>KVO</td>
<td>keep vein open</td>
</tr>
<tr>
<td>L</td>
<td>liter</td>
</tr>
<tr>
<td>lb</td>
<td>pound</td>
</tr>
<tr>
<td>LD</td>
<td>lactate dehydrogenase</td>
</tr>
<tr>
<td>LDL</td>
<td>low-density lipoprotein</td>
</tr>
<tr>
<td>m</td>
<td>meter</td>
</tr>
<tr>
<td>m²</td>
<td>square meters</td>
</tr>
<tr>
<td>µg</td>
<td>microgram</td>
</tr>
<tr>
<td>MAO</td>
<td>monoamine oxidase</td>
</tr>
<tr>
<td>mcg</td>
<td>microgram</td>
</tr>
<tr>
<td>MDI</td>
<td>metered-dose inhaler</td>
</tr>
<tr>
<td>mEq</td>
<td>milliequivalent</td>
</tr>
<tr>
<td>mg</td>
<td>milligram</td>
</tr>
<tr>
<td>MgSO₄</td>
<td>magnesium sulfate</td>
</tr>
<tr>
<td>ml</td>
<td>milliliter</td>
</tr>
<tr>
<td>mm</td>
<td>millimeter</td>
</tr>
<tr>
<td>mm³</td>
<td>cubic millimeters</td>
</tr>
<tr>
<td>mm Hg</td>
<td>millimeters of mercury</td>
</tr>
<tr>
<td>mmol</td>
<td>millimole</td>
</tr>
<tr>
<td>MS</td>
<td>morphine sulfate</td>
</tr>
<tr>
<td>MSO₄</td>
<td>morphine sulfate</td>
</tr>
<tr>
<td>Na</td>
<td>sodium</td>
</tr>
<tr>
<td>NA</td>
<td>not applicable</td>
</tr>
<tr>
<td>NaCl</td>
<td>sodium chloride</td>
</tr>
<tr>
<td>ng</td>
<td>nanogram</td>
</tr>
<tr>
<td>NG</td>
<td>nasogastric</td>
</tr>
<tr>
<td>N.P.O.</td>
<td>nothing by mouth</td>
</tr>
<tr>
<td>NSAID</td>
<td>nonsteroidal anti-inflammatory drug</td>
</tr>
<tr>
<td>O.D.</td>
<td>right eye</td>
</tr>
<tr>
<td>O.S.</td>
<td>left eye</td>
</tr>
<tr>
<td>OTC</td>
<td>over the counter</td>
</tr>
<tr>
<td>O.U.</td>
<td>each eye</td>
</tr>
<tr>
<td>oz</td>
<td>ounce</td>
</tr>
<tr>
<td>p.c.</td>
<td>after meals</td>
</tr>
<tr>
<td>PCA</td>
<td>patient-controlled analgesia</td>
</tr>
<tr>
<td>per</td>
<td>through, by</td>
</tr>
<tr>
<td>P.O.</td>
<td>by mouth</td>
</tr>
<tr>
<td>P.R.</td>
<td>by rectum</td>
</tr>
<tr>
<td>p.r.n.</td>
<td>as needed</td>
</tr>
<tr>
<td>PT</td>
<td>prothrombin time</td>
</tr>
<tr>
<td>PTT</td>
<td>partial thromboplastin time</td>
</tr>
<tr>
<td>PVC</td>
<td>premature ventricular contraction</td>
</tr>
<tr>
<td>q</td>
<td>every</td>
</tr>
<tr>
<td>Q.D.</td>
<td>every day</td>
</tr>
<tr>
<td>q.h.s.</td>
<td>at bedtime</td>
</tr>
<tr>
<td>q.i.d.</td>
<td>four times daily</td>
</tr>
<tr>
<td>Q.O.D.</td>
<td>every other day</td>
</tr>
<tr>
<td>RBC</td>
<td>red blood cell</td>
</tr>
<tr>
<td>RDA</td>
<td>recommended dietary allowance</td>
</tr>
<tr>
<td>RNA</td>
<td>ribonucleic acid</td>
</tr>
<tr>
<td>RSV</td>
<td>respiratory syncytial virus</td>
</tr>
<tr>
<td>SA</td>
<td>sinoatrial</td>
</tr>
<tr>
<td>S.C.</td>
<td>subcutaneous</td>
</tr>
<tr>
<td>SI</td>
<td>International System of Units</td>
</tr>
<tr>
<td>SIADH</td>
<td>syndrome of inappropriate antidiuretic hormone secretion</td>
</tr>
<tr>
<td>S.L.</td>
<td>sublingual</td>
</tr>
<tr>
<td>S.Q.</td>
<td>subcutaneous</td>
</tr>
<tr>
<td>SSRI</td>
<td>selective serotonin reuptake inhibitor</td>
</tr>
<tr>
<td>T₃</td>
<td>triiodothyronine</td>
</tr>
<tr>
<td>T₄</td>
<td>thyroxine</td>
</tr>
<tr>
<td>TCA</td>
<td>tricyclic antidepressant</td>
</tr>
<tr>
<td>t.i.d.</td>
<td>three times daily</td>
</tr>
<tr>
<td>T.I.W.</td>
<td>three times a week</td>
</tr>
<tr>
<td>tRNA</td>
<td>transfer ribonucleic acid</td>
</tr>
<tr>
<td>tsp</td>
<td>teaspoon</td>
</tr>
<tr>
<td>U</td>
<td>unit</td>
</tr>
<tr>
<td>USP</td>
<td>United States Pharmacopeia</td>
</tr>
<tr>
<td>VMA</td>
<td>vanillylmandelic acid</td>
</tr>
<tr>
<td>WBC</td>
<td>white blood cell</td>
</tr>
</tbody>
</table>
Notice

Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs.
2010 Nursing Spectrum DRUG Handbook

Patricia Dwyer Schull, MSN, RN
# Contents

<table>
<thead>
<tr>
<th>Common abbreviations</th>
<th>Inside front cover</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foreword</td>
<td>vii</td>
</tr>
<tr>
<td>Advisors</td>
<td>viii</td>
</tr>
<tr>
<td>Contributors and reviewers</td>
<td>ix</td>
</tr>
<tr>
<td>Preface and user’s guide</td>
<td>xii</td>
</tr>
</tbody>
</table>

## Part 1

### Drug monographs A to Z

<table>
<thead>
<tr>
<th>Safe drug administration</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug compatibilities</td>
<td>S2</td>
</tr>
<tr>
<td>Conversions and calculations</td>
<td>S6</td>
</tr>
<tr>
<td>Drug names that look or sound alike</td>
<td>S7</td>
</tr>
<tr>
<td>Tall Man Letters</td>
<td>S10</td>
</tr>
<tr>
<td>Tablets and capsules <em>not to crush</em></td>
<td>S11</td>
</tr>
<tr>
<td>Preventing and treating extravasation</td>
<td>S13</td>
</tr>
<tr>
<td>Identifying injection sites</td>
<td>S14</td>
</tr>
<tr>
<td>Monitoring blood levels</td>
<td>S16</td>
</tr>
<tr>
<td>Effects of dialysis on drug therapy</td>
<td>S18</td>
</tr>
<tr>
<td>Anaphylaxis: Treatment guidelines</td>
<td>S21</td>
</tr>
<tr>
<td>Adult cardiac arrest: Treatment guidelines</td>
<td>S22</td>
</tr>
<tr>
<td>Pediatric cardiac arrest: Treatment guidelines</td>
<td>S23</td>
</tr>
<tr>
<td>Acute coronary syndrome: Treatment guidelines</td>
<td>S24</td>
</tr>
<tr>
<td>Stroke: Treatment guidelines</td>
<td>S26</td>
</tr>
<tr>
<td>Guidelines for handling, preparing, and</td>
<td>S27</td>
</tr>
<tr>
<td>administering hazardous drugs</td>
<td></td>
</tr>
<tr>
<td>Managing poisoning and overdoses</td>
<td>S30</td>
</tr>
</tbody>
</table>

### Photogallery of common tablets and capsules   | P1-P16              |

## Part 2

<table>
<thead>
<tr>
<th>Drug classes</th>
<th>1255</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamins and minerals</td>
<td>1303</td>
</tr>
<tr>
<td>Herbs and supplements</td>
<td>1314</td>
</tr>
</tbody>
</table>
### Part 3
### Appendices

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common anesthetic drugs</td>
<td>1330</td>
</tr>
<tr>
<td>Common combination drug products</td>
<td>1342</td>
</tr>
<tr>
<td>Adult immunization schedule by age group</td>
<td>1346</td>
</tr>
<tr>
<td>Childhood immunization schedule by age group</td>
<td>1347</td>
</tr>
<tr>
<td>Adolescent immunization schedule by age group</td>
<td>1348</td>
</tr>
<tr>
<td>Normal laboratory values for blood tests</td>
<td>1349</td>
</tr>
<tr>
<td>Drug infusion rates</td>
<td>1352</td>
</tr>
<tr>
<td>Identifying life-threatening adverse reactions</td>
<td>1357</td>
</tr>
<tr>
<td>Potentially inappropriate drugs for elderly patients</td>
<td>1364</td>
</tr>
<tr>
<td>Hazardous drugs</td>
<td>1367</td>
</tr>
<tr>
<td>Most commonly used drugs in nursing specialties</td>
<td>1369</td>
</tr>
<tr>
<td>Top 200 most commonly prescribed drugs</td>
<td>1371</td>
</tr>
</tbody>
</table>

### Selected references                                   | 1374 |
### Index                                                    | 1376 |
As recent studies have shown, medication administration and poor communication about medications can lead to errors that result in patient harm. In the 2009 Comprehensive Accreditation Manual for Hospitals, the Joint Commission devotes a chapter to medication management, emphasizing the potential harm that drugs can cause despite their crucial role in the palliative, symptomatic, and curative treatment of disease.

Improving the safety of medication use is also one of the Joint Commission's National Patient Safety Goals. For the nurse, a critical step in improving safety is to ensure the "five rights"—right patient, right drug, right dosage, right time, and right route—before administering each dose. To these critical steps, I would add a sixth—the right drug reference, which you’re holding in your hands.

Nursing Spectrum Drug Handbook guides you through the often-complex maze of drug actions and potential interactions. This invaluable resource goes beyond just the basics, explaining how to adjust dosages for patients with certain illnesses and of certain ages. It presents FDA boxed warnings, elaborates on key administration steps and explains each drug’s pharmacologic actions, specifies indications and dosages, spells out contraindications and precautions, elaborates on key administration steps, lists adverse reactions, and explains how to monitor and teach patients who are receiving the drug.

According to the Institute for Healthcare Improvement and the Institute for Safe Medication Practices, poor communication of patients’ drug information accounts for up to half of all medication errors and up to 20% of adverse drug events in hospitals. Consequently, many patient safety initiatives—including another Joint Commission National Patient Safety Goal—focus on medication reconciliation, which hinges on communicating accurate information about the patient’s medications to other healthcare providers.

The continuum of medication administration—from prescribing and dispensing through administration—encompasses dozens of steps involving multiple care providers. Mistakes can happen anywhere along the line. Any nurse, whether novice or seasoned, can make a mistake. New nurse graduates and nurses who’ve recently returned to clinical care will find this handbook a “must have.” And all nurses will appreciate how quickly it helps them get up to speed on the drugs, dosages, and drug forms that have recently entered the market.

Giving drugs safely requires nurses to absorb a tremendous amount of information. This brings me to another reason why I highly recommend Nursing Spectrum Drug Handbook: the special 32-page section on “Safe drug administration.” To find it quickly, look for the colored-edge pages near the front. The first time you use it, you’ll quickly realize how valuable and timely this insert is. It covers such topics as drug compatibilities; look-alike, sound-alike drug names; drugs that shouldn’t be crushed; blood drug level monitoring; hazardous drug preparation and administration; and drug administration guidelines for life-threatening emergencies.

Nursing Spectrum Drug Handbook is tailored specifically to meet the needs of all nurses. The writers and editors have collected reams of drug data, selected the essential nuggets, organized drug monographs for optimal accessibility, customized the content and wording, and polished the copy. The result is a densely packed yet eminently friendly reference—the perfect all-in-one package offering everything a nurse needs to know to administer drugs in a safe, proficient manner.

Terris E. Kennedy, PhD, RN
Chief Nursing Officer, Vice President for Patient Care Services
Shore Memorial Hospital
Nassawadox, Virginia
Advisors

Vicki L. Buchda, RN, MS, CNAA
Vice-Chair
Division of Nursing Services
Mayo Clinic
Phoenix, Ariz.

Pamela R. Dellinger, RN, PhD, CHCR
Recruitment Specialist
Carolininas Medical Center-Lincoln
Lincolnton, N.C.

Gloria F. Donnelly, RN, PhD, FAAN
Dean and Professor
College of Nursing and Health Professions
Drexel University

Maureen Duff, RGN, SCM, Dip HV, MSc, FFNMRCSI
Teaching Fellow
Department of Nursing and Midwifery
University of Stirling
Scotland, UK

Harriet R. Feldman, RN, PhD, FAAN
Dean and Professor
Lienhard School of Nursing
Interim Dean, School of Education
Pace University
Pleasantville and New York, N.Y.

Ella Ferris, RN, MBA
Executive Vice President and Chief Nursing Executive
Saint Michael’s Hospital
Toronto, Ontario

Linda Groah, RN, MS, CNOR, CNAA, FAAN
Director of Hospital Operations
Kaiser Permanente Medical Center
San Francisco, Calif.

David Hawkins, PharmD
Professor and Dean
California Northstate College of Pharmacy
Sacramento, Calif.

Joyce E. Johnson, RN, PhD, CNAA, FAAN
Senior Vice President of Operations/Chief Nursing Officer
Georgetown University Hospital
Washington, D.C.

Peggy Kalowes, RN, PhD, CNS
Director
Center for Women’s Cardiac Health and Research
Heart and Vascular Institute
Long Beach Memorial Hospital
Long Beach, Calif.

Terris E. Kennedy, RN, PhD
Chief Nursing Officer
Vice President for Patient Care Services
Shore Memorial Hospital
Nassawadox, Va.

James A. Koestner, BS, PharmD
Critical Care Pharmacist
Vanderbilt University Medical Center
Nashville, Tenn.

Claire M. Young, RN, MBA
Chief Nursing Officer
Chair, Division of Nursing
The Cleveland Clinic Foundation
Cleveland, Ohio
Contributors and reviewers

Sue Apple, RN, DNSc  
Assistant Professor  
School of Nursing and Health Studies  
Georgetown University  
Washington, D.C.

Nancy Balkon, RN, PhD, ANP-C, APRN-CS  
Clinical Associate Professor  
Stony Brook University School of Nursing  
Stony Brook, N.Y.

Cathy L. Bartels, PharmD, FAAIM  
Associate Professor  
Creighton University Medical Center  
Omaha, Neb.

Barbara Barzoloski-O’Connor, RN, MSN, CIC  
Infection Control Manager  
Howard County General Hospital  
Columbia, Md.

Melanie Boock, RN, BSN  
Emergency Room Charge Nurse  
Vail Valley Medical Center  
Vail, Colo.

Vicky Borders-Hemphill, PharmD  
Drug Utilization Data Analyst  
Food and Drug Administration  
Silver Spring, Md.

Terry M. Bottomley, RN  
Charge Nurse  
Emergency Department  
Wooster Community Hospital  
Wooster, Ohio

Cheryl Bozman, BSN, RRT, RN-BC  
Information Systems Coordinator  
Nursing Education Department  
Henry Ford Wyandotte Hospital  
Wyandotte, Mich.

Jason Buckway, RN, BSN, MBA  
Director CV/Medical/GI Services  
McKay-Dee Hospital  
Intermountain Health Care  
Ogden, Utah

Joseph T. Catalano, RN, PhD  
Professor and Chairman  
Department of Nursing  
East Central University  
Ada, Okla.

Linda Carman Copel, PhD, APRN, BC, NCC, DAPA  
Associate Professor  
College of Nursing  
Villanova University  
Villanova, Pa.

Teresa Dowdell, PharmD  
Associate Professor  
College of Nursing  
University of South Florida  
Tampa

Julie M. Gerhart, MS, RPh  
Pharmacy Affairs Manager  
Merck & Co., Inc.  
West Point, Pa.

Cheryl A. Grandinetti, PharmD  
Senior Clinical Research Pharmacist  
Pharmaceutical Management Branch  
Cancer Therapy Evaluation Program  
Division of Cancer Treatment and Diagnosis  
National Cancer Institute  
Rockville, Md.

Franklin R. Grollman, PharmD, BCOP  
Clinical Pharmacist  
National Naval Medical Center  
Bethesda, Md.
Delilah S. Hall, RN, MSN, CNS, CMSRN, CRRN  
Clinical Nurse Specialist  
Center for Rehabilitation  
The Cleveland Clinic Foundation  
Cleveland, Ohio  

Helena M. Hardin, RN  
Clinical Manager  
Cardiac and Medical Intensive Care Unit  
Oakwood Hospital and Medical Center  
Dearborn, Mich.  

Nancy Hargis, RN, BSN  
Nurse Manager  
Emergency Department  
Shore Memorial Hospital  
Nassawadox, Va.  

Kathleen E. Jones, RN, CPN  
Freelance Author  
Westerville, Ohio  

Sandy Keefe, RN, MSN  
Freelance Nurse Writer  
El Dorado Hills, Calif.  

Frank J. Krivanek, PharmD  
Clinical Coordinator  
Director of Pharmacy Practice Residency Program  
Mount Carmel West  
Columbus, Ohio  

Nancy Laplante, RN, PhD  
Assistant Professor  
Division of Nursing and Health Sciences  
Neumann College  
Aston, Pa.  

Mary Jo Lombardo, RN, MSN, CEN  
Clinical Education Program Manager  
Howard County General Hospital  
Columbia, Md.  

Mary Jane McDevitt, RN, BS, CDE  
Nurse Manager  
Center for Diabetes  
Springfield Hospital  
Springfield, Pa.  

Keith M. Olsen, PharmD, FCCP, FCCM  
Professor and Chair  
Department of Pharmacy Practice  
University of Nebraska Medical Center  
Omaha  

Lois A. Piano, RN, MSN, EdD  
Senior Research Associate  
Curtis Analytic Partners  

Martha Polovich, RN, MN, AOCN  
Associate Director, Clinical Practice  
Duke Oncology Network  
Durham, N.C.  

Christine Price, PharmD  
Clinical Coordinator and PGY1 Residency Director  
Morton Plant Mease Health Care  
Clearwater, Fla.  

Barbara Putrycus, RN, MSN, CCRN  
Director Infection Control, Quality & Regulatory Compliance for Surgical Services  
Oakwood Hospital & Medical Center  
Dearborn, Mich.  

Michele Riccardi, PharmD  
Pharmacy Clinical Coordinator  
Midstate Medical Center  
Meriden, Conn.  

Minnie Bowen Rose, RN, BSN, MEd  
Clinical Consultant  
Atlantic City, N.J.  

Cynthia Saver, RN, MS  
President  
CLS Development, Inc.  
Columbia, Md.
Melinda K. Schott, RPh, PharmD
Clinical Pharmacist
Coram Healthcare
Wallingford, Conn.

AnnMarie Smith, RN, BSN, MA
Clinical Instructor
The Cleveland Clinic Foundation
Cleveland, Ohio

Mary E. Stassi, RN, C
Health Occupations Coordinator
St. Charles Community College
St. Peters, Mo.

Barbara Tassone, RN, CNP
Nurse Practitioner
Greater Baltimore Medical Center
Baltimore, Md.

Vera Usinowicz, RN, MS, CCRN, CCNS
Advanced Practice Nurse
Critical Care
The Valley Hospital
Ridgewood, N.J.

Jeannette Yeznach Wick, RPh, MBA, FASCP
Senior Clinical Research Pharmacist
National Cancer Institute
Bethesda, Md.
Like all nurses, you’re no doubt aware that medication errors are a huge problem whose causes are multifold and complex. A wide range of systemic, organizational, environmental, and individual factors—or a combination—can set the stage for a mistake with a patient’s drug regimen. If adverse drug events (ADEs) brought on by such errors were classified as a disease, they would rank as the fifth leading cause of death in the United States. Elderly patients alone experience 1.8 million ADEs every year.

Of course, nurses are front and center in the ADE spotlight. Up to 62% of medication errors occur during the drug administration phase, which is usually performed by nurses. Traditionally, medication errors have been blamed on individuals rather than systems, with individual nurses shouldering much of the blame (often without justification). Yet a significant number of errors stem from failures at the system level. Accordingly, over the last decade, the focus of efforts to reduce medication errors has shifted from the individual to the healthcare organization as a whole. To make drug administration safer, organizations must redesign their processes, systems, culture, and work environment to rectify the problems that cause or contribute to ADEs—excessive patient loads, worker fatigue, staffing shortages, illegible prescriber handwriting, flawed drug-dispensing systems, and misleading drug labels, to name a few.

While being at the front and center means you’re more likely to be blamed when a problem happens, it also gives you the opportunity to detect and intercept errors that occurred during the prescribing, transcribing, and dispensing stages. Serving as an early detection system for medication errors puts you in the best position to avert or minimize negative patient outcomes.

But this task isn’t easy in a fast-paced environment full of distractions, interruptions, and multiple stressors. In fact, the challenge can seem daunting. What’s more, even if your facility has made system changes aimed at reducing drug errors, you’re not off the hook. You’re still legally responsible for administering drugs safely.

Nurses have an ongoing need to obtain more knowledge about current and newly approved medications, as well as a duty to use evidence-based best practices when giving drugs. One study found that deficits in provider knowledge accounted for two-thirds of ADEs that led to patient deaths. To meet this challenge, you need a reliable, practical source of drug information written especially for nurses. Nursing Spectrum Drug Handbook 2010 fits the bill precisely.

From its first edition, this book has focused primarily on safe medication use. With each subsequent edition, we’ve added new safety-centered components and features to address newly introduced drugs, new uses for existing drugs, new drug concerns, and new evidence about the best medication administration practices. Over the past few years, as studies have shed more light on the causes of medication errors, as new drugs have been introduced, and as postmarketing ADE reports have been collected and analyzed, Nursing Spectrum Drug Handbook has been refined, updated, and augmented. In short, this book has grown—and so must you.
Targeting excellence

The quality, relevance, and success of any book for nurses hinge on whether it meets its audience's needs. To help us refine and update the book for this fifth edition, we took the same approach as with past editions, asking more than 60 practicing nurses, student nurses, nursing school deans, nursing executives, and pharmacists to review the previous edition. We also took to heart the valuable comments submitted by nurses who purchased the book. Most importantly, we’ve continually monitored the literature for pharmacotherapeutic research advances and innovations and emerging safety concerns.

Outstanding features

*Nursing Spectrum Drug Handbook 2010* continues to offer the outstanding features of previous editions while introducing new features reflecting recent research, readers’ and reviewers’ feedback, and the Joint Commission’s patient safety goals and other mandates. You’ll find alphabetically arranged drug monographs for approximately 1,000 generic drugs and 3,000 trade drugs. The information in these monographs has been reviewed and updated by dozens of practicing nurses and pharmacists, and then edited by our team of clinical and editorial experts.

Features of this edition include:
- new monographs for newly approved drugs and certain other medications
- new indications, dosages, off-label uses, and safety warnings for preexisting drugs
- generic and trade-name drugs available in Canada (marked by a maple leaf) and the United Kingdom (UK), which are marked with a special icon (•)
- red “Clinical Alert” logos (¶), which call attention to critical administration and safety considerations (especially for high-alert drugs)
- a scored tablet icon (¶) to instantly guide your eye to the “Indications and dosages” section
- Food and Drug Administration (FDA) boxed warnings in the monographs of all drugs that have such warnings
- special icons in the monographs of every hazardous drug (¶) or high-alert drug (¶)
- detailed administration guidelines for each drug, with specific instructions on oral, I.M., I.V., subcutaneous, and other routes when applicable
- life-threatening adverse reactions shown in boldface
- interactions with other drugs, diagnostic tests, foods, herbs and nutritional supplements, and behaviors
- patient monitoring guidelines, including ongoing assessment, follow-up laboratory test results that indicate adverse reactions, and warning signs of an untoward event
- crucial information to consider when giving the drug to elderly or pediatric patients
- drug-altering laboratory values
- an enhanced version of our popular full-color “Safe drug administration” insert, which includes the FDA’s list of recommended “tall man” names to distinguish drugs with look-alike or sound-alike names, along with guidelines for managing, preparing, and administering hazardous drugs
- several new appendices, including one on the Beers criteria for potentially inappropriate medications for elderly adults
- a photogallery of common tablets and capsules
- guidelines for preparing and administering hazardous drugs
- a comprehensive index so you can look up a drug by its generic name, trade name, or indications.

Drug administration guidelines

From the time a prescriber orders a drug to the time the patient receives it, the process of drug administration may involve anywhere from 80 to 200
individual steps. Missteps can happen at any point in this process—but you can help prevent some of these errors long before the dose is prepared.

**Evidence-based best practices of drug administration**

Best practices for preventing and detecting medication errors always start with patient assessment at the time of admission and should be performed whenever the patient’s symptoms change or a new symptom develops. During the initial patient evaluation, review the patient’s current drug regimen, obtain drug allergy information, measure height and weight, and check the diagnosis and other baseline data to help determine the patient’s risk of an adverse reaction. Also, make sure you’re familiar with the drug’s action, expected benefits, adverse reactions, and interaction potential in light of such patient factors as diagnosis and medical condition.

To further gauge your patient’s risk of an ADE, ask yourself these questions:

- Is the patient elderly? Advanced age increases the risk of an ADE.
- Is the drug you’re administering a high-alert or hazardous one? If so, find out what precautions you can take to reduce the chance of an ADE.
- Is the drug appropriate for the patient’s diagnosis? Is it the drug of choice for this diagnosis—or just the prescriber’s preference for reasons other than evidence, contraindications to alternative drugs, or a positive outcome?
- Is the patient receiving multiple drugs? Polypharmacy is extremely common, especially among older patients. The addition of each new drug increases the chance of an ADE by 10%. The more daily drugs, daily doses, and different prescribers and pharmacies involved in a patient’s regimen, the greater the risk of ADEs.
- Is the patient especially vulnerable to a harmful interaction, such as a drug-drug, drug-food, drug-herb, drug-alcohol, or drug-behavior interaction?
- Has the drug been prescribed based on an altered laboratory value caused by another drug?
- Is the patient a child? Pediatric patients are at increased risk for ADEs. Drug formulations and labeling generally are geared to adults; to administer a drug to a child, you may need to calculate the pediatric dosage or mix the drug in a certain way, which increases the risk of error. Also, a child’s body isn’t completely developed and thus less able to overcome the effects of an overdose or interaction.

**The “five rights” of drug administration**

Nurses are legally responsible for applying and ensuring the “five rights” of drug administration. To help achieve these goals, use the following strategies:

- **Right patient.** Always confirm the patient’s identity before administering a drug. Check his ID bracelet and ask him to state his name; then confirm his name, age, and allergies. The Joint Commission requires the use of two identifiers, such as the patient number, his telephone number, or his Social Security number. Ideally, match the ordered treatment to the patient using his name bracelet and ID number, comparing it to the drug order transcribed in the medication administration record (MAR). Be especially cautious if your patient is confused, because he may answer to the wrong name.
- **Right drug.** Giving the wrong drug is the most common type of medication error. It typically results from such factors as look-alike and sound-alike drug names, similar drug labels and packaging, and poor communication. Never try to decipher an illegible drug order, and never give a drug if you’re not sure why it was prescribed.

To make sure you give the right drug, match the drug label against the order
in the MAR three times—once when you remove the container from the patient’s drug drawer, again before you remove the dose from the container and, finally, before you return the container to the drawer or discard it. Never give a drug from a container that is unlabeled or has an unreadable label, and never borrow a drug from another patient.

In an effort to reduce “wrong-drug” and other medication errors, many hospitals have adopted newer technologies, such as bar-code point-of-care drug administration systems. When using such a system, keep in mind that it must be monitored regularly for problems and that staff members must receive adequate training in its use.

● **Right dosage.** Check the dosage against the order in the MAR. Determine if it’s appropriate based on the patient’s age, size, vital signs, and condition. If the dose needs to be measured, use appropriate equipment—for instance, an oral syringe rather than a parenteral syringe to measure an oral liquid drug. Be on the lookout for misinterpretation of orders, incorrect calculation of volumes and infusion rates, misreading of decimal points, and labeling errors.

  When administering a drug that can cause serious harm if given incorrectly (such as I.V. insulin or heparin) or when giving an infusion to a pediatric patient, always double-check the dosage and pump settings; then verify these with a colleague.

● **Right time.** Incorrect timing of drug administration accounted for 43% of medication errors reported in a 2002 study in the *Archives of Internal Medicine*. Although most medications are not time-sensitive, dose timing can be critical if the patient must maintain a specific blood drug level or to ensure accurate laboratory test values or avoid interactions with other drugs.

  Usually, a dose should be given within 30 minutes before or after the time specified in the order, in accordance with your facility’s established protocols. Always administer a dose as it’s prepared.

  To maximize the drug’s therapeutic efficacy, check whether it should be given with or without food and whether it could interact with or impede the absorption of concurrently administered drugs.

● **Right route.** Many drugs can be given by multiple routes. The prescriber chooses the route based on such factors as the patient’s condition and the desired onset of action. In turn, the prescribed dosage is based on the administration route. Generally, oral dosages of a given drug are greater than injected dosages, so a serious overdose may occur if a dose intended for oral administration is given by injection instead.

  Also, keep in mind that most serious error outcomes occur when the I.V. route is used. (Only a few high-risk drugs, such as warfarin, some chemotherapy drugs, and a few sedatives, are given orally.)

  Finally, be aware that some drugs or drug forms (for instance, sustained-release tablets or capsules) should never be crushed. Crushing can alter the dosage delivered, causing the patient to receive a bolus of a drug that’s meant to be released slowly over several hours.

**Additional nursing responsibilities**

Of course, nursing responsibilities don’t stop with these five rights. Documentation, monitoring, and patient teaching are also crucial.

After giving the drug, always document that it was administered. Document the dose as soon as it is given—never before. When documenting, use only accepted abbreviations and avoid those that are used rarely or that could be misread or misinterpreted.
Avoiding dangerous abbreviations

To help reduce medication errors, all healthcare team members must use abbreviations correctly. The Joint Commission mandates that healthcare organizations standardize a list of abbreviations, acronyms, and symbols that should not be used. Organizations must approve a minimum required list of prohibited abbreviations, which includes the first five items shown below. The Joint Commission also advises organizations to consider adding the remaining items to their "Do not use" list.

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Potential problem</th>
<th>Solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>U (for &quot;unit&quot;)</td>
<td>Mistaken as &quot;0,&quot; &quot;4,&quot; or &quot;cc&quot;</td>
<td>Write &quot;unit.&quot;</td>
</tr>
<tr>
<td>IU (for &quot;international unit&quot;)</td>
<td>Mistaken as &quot;IV&quot; (&quot;intra-venous&quot;) or 10 (&quot;ten&quot;)</td>
<td>Write &quot;international unit.&quot;</td>
</tr>
<tr>
<td>Q.D., Q.O.D. (for &quot;once daily,&quot; &quot;every other day&quot;)</td>
<td>Mistaken for each other. Period after &quot;Q&quot; may be mistaken for &quot;I&quot;; &quot;O&quot; may be mistaken for &quot;I.&quot;</td>
<td>Write &quot;daily&quot; or &quot;every other day.&quot;</td>
</tr>
<tr>
<td>Trailing zero (X.0 mg) (prohibited only for drug-related notations); lack of leading zero (.X mg)</td>
<td>Decimal point is missed.</td>
<td>Never write a zero by itself after decimal point (X mg); always use a zero before decimal point (0.X mg).</td>
</tr>
<tr>
<td>MS</td>
<td>Confused for one another. May mean &quot;morphine sulfate&quot; or &quot;magnesium sulfate.&quot;</td>
<td>Write &quot;morphine sulfate&quot; or &quot;magnesium sulfate.&quot;</td>
</tr>
<tr>
<td>MSO₄</td>
<td>Confused for one another. May mean &quot;morphine sulfate&quot; or &quot;magnesium sulfate.&quot;</td>
<td>Write &quot;morphine sulfate&quot; or &quot;magnesium sulfate.&quot;</td>
</tr>
<tr>
<td>MgSO₄</td>
<td>Confused for one another. May mean &quot;morphine sulfate&quot; or &quot;magnesium sulfate.&quot;</td>
<td>Write &quot;morphine sulfate&quot; or &quot;magnesium sulfate.&quot;</td>
</tr>
<tr>
<td>µg (for &quot;microgram&quot;)</td>
<td>Mistaken for &quot;mg&quot; (milligrams), resulting in 1,000-fold overdose</td>
<td>Write &quot;mcg.&quot;</td>
</tr>
<tr>
<td>H.S. (for &quot;half-strength&quot; or &quot;at bedtime&quot;)</td>
<td>Mistaken for &quot;half-strength&quot; or &quot;hour of sleep&quot; (&quot;at bedtime&quot;)</td>
<td>Write &quot;half-strength&quot; or &quot;at bedtime.&quot;</td>
</tr>
<tr>
<td>q.H.S. (for &quot;at bedtime&quot;)</td>
<td>Mistaken for &quot;every hour&quot;</td>
<td>Write &quot;at bedtime.&quot;</td>
</tr>
<tr>
<td>T.I.W. (for &quot;3 times a week&quot;)</td>
<td>Mistaken for &quot;3 times a day&quot; or &quot;twice weekly&quot;</td>
<td>Write &quot;3 times weekly&quot; or &quot;three times weekly.&quot;</td>
</tr>
<tr>
<td>S.C. or S.Q. (for &quot;subcutaneous&quot;)</td>
<td>Mistaken for &quot;S.L.&quot; (sublingual) or &quot;5 every&quot;</td>
<td>Write &quot;Sub-Q,&quot; &quot;subQ,&quot; or &quot;subcutaneously.&quot;</td>
</tr>
<tr>
<td>D/C (for &quot;discharge&quot;)</td>
<td>Misinterpreted as &quot;discontinue&quot;</td>
<td>Write &quot;discharge.&quot;</td>
</tr>
<tr>
<td>cc (for &quot;cubic centimeters&quot;)</td>
<td>Mistaken for &quot;U&quot; (units) if poorly written</td>
<td>Write &quot;ml&quot; for milliliters.</td>
</tr>
<tr>
<td>AS, AD, AU (for &quot;left ear,&quot; &quot;right ear,&quot; &quot;both ears&quot;)</td>
<td>Mistaken for OS, OD, or OU</td>
<td>Write &quot;left ear,&quot; &quot;right ear,&quot; or &quot;both ears.&quot;</td>
</tr>
</tbody>
</table>
If the patient refuses a medication, report this to the prescriber immediately. Then record his refusal on both the MAR and the patient’s record; include your initials, full name, and credentials on both records.

During the course of drug therapy, monitor the patient to determine drug efficacy and detect signs and symptoms of an adverse reaction or interaction. Teach the patient the name of the prescribed drug, its dosage, administration route, dosing frequency and times, and duration of therapy. Make sure he knows how to recognize the drug’s therapeutic effects, adverse reactions, and interactions with other drugs, foods, herbs, and behaviors.

Be aware that the Joint Commission’s 2009 National Patient Safety Goals mandate that healthcare facilities (and by extension, nurses) implement applicable practices that will improve or bring about the following:

- better communication among caregivers
- creation of a standardized list of abbreviations, symbols, and dose designations not to be used
- improved safety of drug use
- verification of all labels both verbally and visually by two qualified individuals, if the person preparing the drug is not the same person who will administer it
- accurate and complete medication reconciliation across the continuum of care
- reduction of the risk of patient harm stemming from falls caused by medications
- active involvement of patients in their own care (including teaching them about their drugs).

(See Avoiding dangerous abbreviations, page xvi, and the inside front cover, Common abbreviations.)

Understanding pregnancy risk categories

Whenever possible, pregnant women should avoid drug therapy. The risks of taking drugs during pregnancy range from relatively minor fetal defects (such as ear tags or extra digits) to fetal death.

When drug therapy is considered, the drug’s benefits to the mother must be weighed against the risk to the fetus. Ideally, the drug should provide clear benefits to the mother without harming the fetus. To help prescribers and pregnant patients assess a drug’s risk-to-benefit ratio, the Food and Drug Administration assigns one of five pregnancy risk categories to each drug. In addition, certain drugs are not rated.

Category A: No evidence of risk exists. Adequate, well-controlled studies in pregnant women don’t show an increased risk of fetal abnormalities during any trimester.

Category B: The risk of fetal harm is possible but remote. Animal studies show no fetal risk; however, controlled studies haven’t been done in humans. Or animal studies do show a risk to the fetus, but adequate studies in pregnant women haven’t shown such a risk.

Category C: Fetal risk can’t be ruled out. Although animal studies show risks, adequate, well-controlled human studies are lacking. Despite the potential fetal risks, use of the drug may be acceptable because of benefits to the mother.

Category D: Positive evidence of fetal risk exists. Nevertheless, potential benefits from the drug may outweigh the risk. For example, the drug may be acceptable in a life-threatening situation or serious disease if safer drugs can’t be used or are ineffective.

Category X: Contraindicated during pregnancy. Studies in animals or humans or reports of adverse reactions show evidence of fetal risk that clearly outweighs any possible benefit to the patient.

Category NR: Not rated.
Preface and user’s guide

User’s guide to *Nursing Spectrum Drug Handbook 2010*

This book is organized in three main parts.

**Part 1: A to Z drug monographs**

Part 1 presents individual drug monographs in alphabetical order by generic name.

Where applicable, the top banner of the monograph includes an icon or logo denoting that the drug is a high-alert drug (♦) or a hazardous drug (§). As defined by the Institute of Safe Medication Practices, high-alert drugs are those that can cause an increased risk of significant patient harm when used in error, and deserve special attention, caution, and safeguards.

Drugs designated as hazardous by the National Institute for Occupational Safety and Health, American Society of Health-System Pharmacists, and the Centers for Disease Control and Prevention include cancer chemotherapy agents, some antivirals, certain hormones, some bioengineered drugs, and selected miscellaneous drugs. These agents meet one or more of the following criteria: carcinogenicity, teratogenicity or other developmental toxicity, reproductive toxicity, organ toxicity at low doses, genotoxicity, or structure and toxicity profiles that mimic existing drugs determined to be hazardous by the above criteria. These drugs must be handled within an established safety program (see “Guidelines for preparing, handling, and administering hazardous drugs,” in the “Safe drug administration” insert).

Below the banner, each monograph is presented in the following order:

**Generic name.** A drug’s generic name is the nonproprietary name, typically assigned by the manufacturer. When more than one therapeutic form of the drug is available, generic names of these forms are listed alphabetically.

---

### Schedules of controlled substances

The Controlled Substances Act of 1970 regulates the production and distribution of stimulants, narcotics, depressants, hallucinogens, and anabolic steroids. Drugs regulated by this law fall into five categories, or schedules, based on their abuse potential, medicinal value, and harmfulness. Schedule I drugs are the most hazardous; schedule V drugs, the least hazardous.

**Schedule I:** High potential for abuse; no currently accepted medical use in the United States. Using the drug even under medical supervision is thought to be unsafe.

**Schedule II:** High potential for abuse; currently accepted medical use in the United States (or currently accepted medical use with severe restrictions). Abuse may lead to severe psychological or physical dependence. Emergency telephone orders for limited quantities may be authorized, but the prescriber must provide a written, signed prescription order.

**Schedule III:** Lower abuse potential than schedule I and II drugs; currently accepted medical use in the United States. Abuse may lead to a moderate or low degree of physical dependence or high psychological dependence. Telephone orders are permitted.

**Schedule IV:** Lower abuse potential than schedule I, II, or III drugs; currently accepted medical use in the United States. Abuse may lead to limited physical dependence or psychological dependence. Telephone orders are permitted.

**Schedule V:** Low abuse potential compared to drugs in other schedules; currently accepted medical use in the United States. Abuse may lead to limited physical dependence or to psychological dependence. Some schedule V drugs may be available in limited quantities without a prescription (if state law permits).
**High-alert drugs**

Certain drugs expose patients to an increased risk of significant harm when used in error. In 2007, the Institute for Safe Medication Practices (ISMP) updated its list of high-alert drugs based on voluntary medication error reports, harmful medication errors described in the literature, practitioner feedback, and expert reviews. The ISMP has identified both high-alert drug classes (or categories) and specific high-alert drugs.

### High-alert drug classes and categories
- adrenergic agonists, I.V.
- adrenergic antagonists, I.V.
- anesthetic agents, general, inhaled and I.V.
- antiarrhythmics, I.V.
- anticoagulants
- cardioplegic solutions
- chemotherapeutic agents
- dextrose (20% or greater)
- dialysis solutions
- epidural and intrathecal drugs
- glycoprotein IIb/IIIa inhibitors
- hypoglycemics, oral
- inotropic drugs, I.V.
- liposomal drug forms
- moderate sedation agents, I.V. (or oral agents for children)
- narcotics and opioids
- neuromuscular blocking agents
- radiocontrast agents, I.V.
- thrombolytics and fibrinolytics, I.V.
- total parenteral nutrition solutions

### Specific high-alert drugs
- amiodarone, I.V.
- colchicine, injection
- epoprostenol
- heparin, low molecular weight
- heparin, unfractionated, I.V.
- insulin, subcutaneous and I.V.
- lidocaine, I.V.
- magnesium sulfate injection
- methotrexate, oral nononcologic use
- oxytocin
- potassium chloride for injection
- potassium phosphates injection
- promethazine, I.V.
- sodium chloride injection
- sodium nitroprusside for injection
- sterile water for injection, inhalation, and irrigation in containers of 100 ml or more
- warfarin

---

**Trade names.** A drug’s common trade, or brand, name is the proprietary, trademarked name under which it’s marketed. Trade-name and generic drugs are therapeutically equivalent in strength, quality, performance, and use; when interchanged, they have the same effects and no differences. However, they may vary in preservatives, color, shape, labeling and, possibly, scoring. In the monographs, trade-name drugs available in Canada are marked with a maple leaf, and those available in the UK are marked with a for easy identification.

**Pharmacologic and therapeutic classes.** This section specifies the drug’s pharmacologic class (based on its pharmacologic properties and action—for example, sulfonamide or corticosteroid) and therapeutic class (based on approved therapeutic uses of the drug—for instance, antineoplastic or antihypertensive). Many drugs fall into multiple therapeutic classes.

**Pregnancy risk category.** This section lists the category assigned by the FDA to indicate the drug’s potential danger to the fetus when taken during pregnancy. (See Understanding pregnancy risk categories, page xvii.)

**Controlled substance schedule.** Narcotics, stimulants, and certain other drugs fall under the Controlled...
Substances Act. The Drug Enforcement Agency assigns each of these drugs a category, or schedule, based on its abuse potential and other factors. (See Schedules of controlled substances, page xviii.) When applicable, this section lists the drug’s assigned schedule.

**FDA boxed warning.** The FDA assigns a boxed warning if:

- the drug may cause an adverse reaction so serious (relative to the drug’s potential benefit) that prescribers must carefully weigh risk against benefit
- a serious adverse reaction can be prevented or reduced through careful patient selection, rigorous monitoring, avoiding certain concomitant therapy, adding another drug, managing the patient in a specific way, or avoiding use in a specific clinical situation
- the FDA approved the drug with restrictions to assure its safe use because it concluded that the drug can be used safely only if its distribution or use is restricted.

In this book, boxed warnings have been condensed and edited for space reasons. Be sure to review the complete package insert before administering the drug in question.

**Action.** This section summarizes how the drug achieves its therapeutic effect—the action that takes place when it reaches its target site and combines with cellular drug receptors to cause certain physiologic responses. When a drug’s action isn’t known or when researchers have proposed theories for the action but haven’t clarified it definitively, we state this fact.

**Availability.** This section lists the physical forms in which the drug is produced and dispensed, plus available strengths (the amount of active ingredient present) for each form.

**Indications and dosages.** Marked with a red scored tablet icon 🕵️‍♂️ for quick identification, this section details the drug’s FDA-approved indications for adults, children, infants, and neonates (when appropriate), along with recommended dosages, administration routes, and dosing frequency for each indication. The indications and dosages shown reflect current clinical trends, not unequivocal standards, and must be considered in light of the patient’s condition and diagnosis. (Although we’ve made every effort to ensure the accuracy of all dosages, we urge you to become familiar with the official package insert for each drug you administer.)

**Dosage adjustment.** This section tells which patient groups (such as children or elderly patients), diseases, or disorders (such as renal or hepatic dysfunction) may necessitate dosage adjustment.

**Off-label uses.** Here you’ll find a list of off-label (unlabeled or unapproved) uses of the drug, when applicable. Off-label drug use has become increasingly common as clinical research moves ahead of the FDA’s approval process. In some cases, off-label use has become the standard of care.

**Contraindications.** This section lists conditions that contraindicate use of the drug, such as preexisting diseases. As a rule, never give a drug to a patient who has a history of hypersensitivity to that drug.

Drugs commonly implicated in hypersensitivity reactions include antibiotics, histamines, iodides, phenothiazines, tranquilizers, anesthetics, diagnostic agents (such as iodinated contrast media), and biologic agents (such as insulin, vaccines, and antitoxins).

**Precautions.** For some patients, a specific drug may pose an increased risk of untoward effects—yet the physician prescribes it because, in his judgment, the potential benefits outweigh the risks. For instance, many drugs can be dangerous for elderly patients, pregnant or breastfeeding women, young children, and patients with renal or hepatic dysfunction. This section tells you which patients to whom you must
administer the drug cautiously. Precautions can be especially important if you're administering a high-alert drug. (See High-alert drugs, page xix.)

**Administration.** Here you'll find information to help you prepare the drug and administer it correctly and safely, regardless of the route—including whether to give it with or without food, how to mix it for I.V. or I.M. use, and what flow rate to use.

**Route, onset, peak, and duration.** Presented in table form, this section provides a pharmacokinetic profile—onset of action, peak blood level, and duration of action—for each route by which the drug is administered.

**Adverse reactions.** Occurring in roughly 30% of hospital patients, reactions can range from mild to life-threatening. They may arise immediately and suddenly, or take weeks or even months to develop.

Adverse reactions can be especially dangerous if a medication error occurs in a patient who’s receiving a high-alert drug. The sickest patients—those in intensive care—typically receive anywhere from 20 to 40 different drugs. These patients are the most vulnerable to adverse reactions, drug interactions, and life-threatening consequences of a medication error. In this section, we list the most commonly reported adverse reactions by body system. Life-threatening reactions appear in **boldface.**

**Interactions.** With Americans taking more prescription and nonprescription drugs than ever, you're likely to encounter patients experiencing the effects of drug interactions. Many people also take herbs and nutritional supplements that can interact with drugs to cause dangerous effects or to impede a drug's intended effect. This section presents documented and clinically significant interactions that may occur if the drug is used concurrently with other drugs, specific foods, and certain herbs or supplements, or if it’s combined with certain behaviors (for instance, smoking or alcohol use). It also describes the drug’s effects on diagnostic test results, which can be especially important for hospital patients.

**Patient monitoring.** Close patient monitoring is essential during drug therapy (and in some cases, even after therapy ends) to help gauge whether the drug is effective and to detect untoward reactions or interactions. Early detection of troublesome side effects or drug inefficacy allows timely adjustments in therapy and may prevent patient injury or avoid a treatment delay.

To monitor your patient effectively, you must be familiar with the drug you’re administering and its intended outcome. You must also determine whether this drug might interact with other drugs that your patient is receiving, and determine whether his medical condition, vital signs, or recent laboratory findings make him more vulnerable to interactions or adverse effects. This section discusses important nursing assessments and interventions to perform, such as monitoring blood drug levels to help determine the correct dosage and to prevent toxicity.

**Patient teaching.** The nurse’s responsibility for teaching patients about their care has never been greater. What’s more, patients are now demanding more information about their treatment. This section describes key teaching points you should cover with a patient who’s receiving the drug, including essential information needed to create a patient teaching plan and protect your patient even after discharge.

---

**Part 2: Drug classes, vitamins and minerals, herbs and supplements**

Part 2 presents collective monographs on therapeutic drug classes and abbreviated monographs on vitamins, minerals, herbs, and nutritional supplements. Monographs on therapeutic drug classes familiarize you with the
overall attributes of an entire drug class. These monographs also tell you which drugs the prescriber may order if a particular drug in the same class is unsuitable for your patient.

The use of herbal remedies and supplements is soaring—yet many users and healthcare practitioners are in the dark about these products’ adverse effects and potential interactions with prescription and over-the-counter drugs. This section gives basic information that may help your patients use herbs more safely.

Part 3: Appendices, references, and index
Appendices serve as handy references on important drug topics and related issues—everything from normal laboratory values for monitoring and detecting drug levels to the top 200 most commonly prescribed drugs.

Website, PDA download, and other bonuses
Our website, www.nursesdrughandbook.com, gives you 24-hour access to hundreds of drug monographs, online versions of the book’s safe drug administration insert, drug news (including new approvals and indications), and patient teaching aids on common drugs (which you can customize and give to patients). Also, this website will provide access to the full text of the Nursing Spectrum Drug Handbook 2010, which you can download free to your personal digital assistant.

I’m certain Nursing Spectrum Drug Handbook 2010 will continue to enhance your practice and help you continue to make drug therapy safer and more effective for your patients.

Acknowledgments
A project of this scope and intensity demands incredible effort, hard work, and the expertise of a dedicated team. I’m indeed fortunate to work with such a group, the MedVantage Publishing team. I want to thank them all; in particular, Minnie Rose, our clinical manager, whose patience, knowledge, and attention to detail add so much to the success of this project; also Kathy Goldberg, editorial manager; Karen Comerford, copyedit supervisor; Stephanie Peters, design manager; and Julia Knipe, administrator extraordinaire.

The entire McGraw-Hill team deserve a heartfelt thank you, especially John Williams, Phil Galea, Arushi Chawla, and Joseph Morita. Their continued support is, as always, much appreciated.

I also wish to thank our advisors, contributors, and reviewers for continuing to share their expertise—and their valuable time. A project like this wouldn’t be possible without them.

And a most-important thank you to all you wonderful nurses who give unselfishly of yourselves to ensure the best care and protection of your patients. I’m especially grateful to those of you who’ve written or e-mailed me with kind words for Nursing Spectrum Drug Handbook. I appreciate your enthusiastic support and will continue to work hard to bring you the tools you need to safeguard your patients.

Patricia Dwyer Schull, MSN, RN

About the author:
Patricia Dwyer Schull, President of MedVantage Publishing, has more than 20 years’ experience in medical and nursing publishing. Before establishing MedVantage Publishing, she held executive management positions with the top medical publishers in the world. She is the editor and author of many popular medical and nursing publications. Before entering the publishing industry, she practiced for many years as a professional nurse and held various nursing positions in hospital management, direct patient care, and staff education. She has a Master of Science degree in Nursing, a Bachelor of Science degree and a Registered Nurse Diploma.
Part 1

Drug monographs A to Z
Safe drug administration
Photogallery of common tablets and capsules
abacavir sulfate
Ziagen

Pharmacologic class: Carbocyclic nucleoside reverse transcriptase
Therapeutic class: Antiretroviral
Pregnancy risk category C

FDA BOXED WARNING
• Drug may cause serious and potentially fatal hypersensitivity reactions, including multi-organ syndrome marked by fever, rash, GI distress, malaise, fatigue, achiness, dyspnea, cough, and pharyngitis. Discontinue immediately if you suspect such a reaction. If hypersensitivity can’t be ruled out, discontinue permanently, even if other diagnoses are possible.
• After hypersensitivity reaction, never restart drug or other agents containing it, because more severe symptoms (including severe hypotension and death) may arise within hours.

Action
Converts via intracellular enzymes to active metabolite carbovir triphosphate, which inhibits activity of human immunodeficiency virus-1 (HIV-1) reverse transcriptase. Inhibits viral reproduction by interfering with DNA and RNA synthesis.

Availability
Oral solution: 20 mg/ml
Tablets: 300 mg

Indications and dosages
➢ HIV-1 infection
Adults: 300 mg P.O. b.i.d.

Children ages 3 months to 16 years: 8 mg/kg P.O. b.i.d., to a maximum dosage of 300 mg b.i.d.

Contraindications
• Hypersensitivity to drug
• Hepatic disease, lactic acidosis
• Breastfeeding
• Children younger than age 3 months

Precautions
Use cautiously in:
• impaired renal function, bone marrow suppression
• risk factors for hepatic disease
• elderly patients
• pregnant patients.

Administration
• Always give in combination with other antiretrovirals.

Adverse reactions
CNS: headache, weakness, insomnia
GI: nausea, vomiting, diarrhea, poor appetite, pancreatitis
Hematologic: neutropenia, severe anemia
Hepatic: hepatic failure
Metabolic: mild hyperglycemia, lactic acidosis
Skin: rash, erythema multiforme, toxic epidermal necrolysis
Other: body fat redistribution, Stevens-Johnson syndrome, fatal hypersensitivity reaction

Interactions
Drug-drug. Methadone: Increased oral methadone clearance
Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, creatine phosphokinase, gamma-glutamyltransferase, glucose, triglycerides: increased levels

Reactions in bold are life-threatening.
Safe drug administration

The following guidelines on preparing, administering, and monitoring drug therapy will help you ensure patient safety and drug effectiveness.
### Drug compatibilities

Use the table below to determine if you can safely mix two drugs together in the same syringe or administer them together through the same I.V. line.

**KEY**
- C: compatible
- I: incompatible
- *: conflicting data exist
- Blank space: no data available

|                  | acyclovir sodium | amikacin | amiodarone | amphotericin B | aztreonam | calcium chloride | calcium gluconate | cefazolin | cefepime | ceftazidime | clindamycin | cyclosporine | dexamethasone | digoxin | diltiazem | diphenhydramine | dobutamine | dopamine | enalaprilat | epinephrine | esmolol | famotidine | fluconazole | furosemide |
|------------------|------------------|----------|------------|----------------|-----------|-----------------|-------------------|-----------|----------|-------------|-------------|-------------|---------------|---------|-----------|---------------|-------------|---------|-----------|-----------|----------|
| acyclovir sodium | I                | I        | I          |                |           |                 |                   |           |          |             |             |             |               |         |           |               |             |         |           |           |          |
| amikacin         |                  | C        | I          | C              | I         | C               | I                 | I         | I        | C           |             |             |               |         |           |               |             |         |           |           |          |
| amiodarone       | C                |          |            |                |           |                 |                   |           |          |             |             |             |               |         |           |               |             |         |           |           |          |
| amphotericin B   | I                | C        | I          | I              | I         | I               | I                 |            |          |             |             |             |               |         |           |               |             |         |           |           |          |
| aztreonam        | C                | I        | C          | C              | C         | C               | C                 | I         | C        | C           |             |             |               |         |           |               |             |         |           |           |          |
| calcium chloride | C                | C        | C          | C              | C         | C               | C                 | C         | C        | C           |             |             |               |         |           |               |             |         |           |           |          |
| calcium gluconate| C                | C        | C          | I              | I         | C               | C                 | C         | C        | C           |             |             |               |         |           |               |             |         |           |           |          |
| cefazolin        | C                | I        | I          | I              |           |                 |                   | I         | I        |             |             |             |               |         |           |               |             |         |           |           |          |
| cefepime         | C                |          |            |                |           |                 |                   |           |          |             |             |             |               |         |           |               |             |         |           |           |          |
| ceftazidime      | I                | I        | C          | C              |           |                 |                   |           |          |             |             |             |               |         |           |               |             |         |           |           |          |
| clindamycin      | C                | C        | C          | I              | C         | C               | C                 | C         | C        |             |             |             |               |         |           |               |             |         |           |           |          |
| cyclosporine     | C                |          |            |                |           |                 |                   |           |          |             |             |             |               |         |           |               |             |         |           |           |          |
| dexamethasone    | C                | C        | C          | C              |           |                 |                   |           |          |             |             |             |               |         |           |               |             |         |           |           |          |
| digoxin          | I                |          |            |                |           |                 |                   |           |          |             |             |             |               |         |           |               |             |         |           |           |          |
| diltiazem        | I                | C        | C          | C              |           |                 |                   |           |          |             |             |             |               |         |           |               |             |         |           |           |          |
| diphenhydramine  | C                | *        | C          | C              |           |                 |                   |           |          |             |             |             |               |         |           |               |             |         |           |           |          |
| dobutamine       | I                | C        | C          | *              |           |                 |                   |           |          |             |             |             |               |         |           |               |             |         |           |           |          |
| dopamine         | I                | C        | I          | C              |           |                 |                   |           |          |             |             |             |               |         |           |               |             |         |           |           |          |
| enalaprilat      | C                | I        | C          | C              |           |                 |                   |           |          |             |             |             |               |         |           |               |             |         |           |           |          |
| epinephrine      | C                | C        | *          | *              |           |                 |                   |           |          |             |             |             |               |         |           |               |             |         |           |           |          |
| esmolol          | C                | C        | C          | C              |           |                 |                   |           |          |             |             |             |               |         |           |               |             |         |           |           |          |
| famotidine       | C                | C        | C          | C              |           |                 |                   |           |          |             |             |             |               |         |           |               |             |         |           |           |          |
| fluconazole      | C                | C        | C          | C              |           |                 |                   |           |          |             |             |             |               |         |           |               |             |         |           |           |          |
| furosemide       | *                | *        |           | I              |           |                 |                   |           |          |             |             |             |               |         |           |               |             |         |           |           |          |
### Drug compatibilities (continued)

<table>
<thead>
<tr>
<th>Drug</th>
<th>acyclovir sodium</th>
<th>amikacin</th>
<th>amiodarone</th>
<th>amphotericin B</th>
<th>aztreonam</th>
<th>calcium chloride</th>
<th>ceftazolin</th>
<th>cefepime</th>
<th>ceftazidime</th>
<th>clindamycin</th>
<th>clonazepam</th>
<th>clonidine</th>
<th>cyclosporine</th>
<th>dexamethasone</th>
<th>dabigatran</th>
<th>diphenhydramine</th>
<th>dopamine</th>
<th>enalaprilat</th>
</tr>
</thead>
<tbody>
<tr>
<td>heparin</td>
<td>I</td>
<td>I</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>I</td>
<td></td>
<td>C</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hydrocortisone</td>
<td>C</td>
<td>I</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>I</td>
<td>C</td>
<td>C</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hydromorphone hydrochloride</td>
<td>I</td>
<td></td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>I</td>
<td></td>
<td>C</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>imipenem and cilastatin sodium</td>
<td>I</td>
<td></td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>I</td>
<td></td>
<td>C</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>insulin</td>
<td>C</td>
<td>I</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>I</td>
<td></td>
<td>C</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>labetalol</td>
<td>C</td>
<td>I</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td></td>
<td>C</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>levofloxacin</td>
<td>C</td>
<td></td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>I</td>
<td></td>
<td>C</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>lorazepam</td>
<td>C</td>
<td></td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>I</td>
<td>C</td>
<td>C</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>magnesium</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>I</td>
<td></td>
<td>C</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>methylprednisolone</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>I</td>
<td>C</td>
<td>C</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>metoclopramide hydrochloride</td>
<td>C</td>
<td></td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>I</td>
<td></td>
<td>C</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>midazolam</td>
<td>C</td>
<td></td>
<td>C</td>
<td>C</td>
<td>I</td>
<td>C</td>
<td>I</td>
<td>C</td>
<td>C</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>milrinone</td>
<td>C</td>
<td></td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td></td>
<td>C</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>morphine</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td></td>
<td>C</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>nitroglycerin</td>
<td>C</td>
<td></td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>I</td>
<td></td>
<td>C</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>nitroprusside</td>
<td>*</td>
<td></td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>I</td>
<td></td>
<td>C</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>norepinephrine</td>
<td>C</td>
<td></td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>I</td>
<td></td>
<td>C</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ondansetron</td>
<td>C</td>
<td>I</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>I</td>
<td>C</td>
<td>C</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>phenylephrine</td>
<td>C</td>
<td></td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>I</td>
<td></td>
<td>C</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>potassium chloride</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>I</td>
<td></td>
<td>C</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sodium bicarbonate</td>
<td>C</td>
<td>I</td>
<td>C</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td></td>
<td>C</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>tobramycin</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>I</td>
<td>C</td>
<td>I</td>
<td></td>
<td>C</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>vancomycin</td>
<td>C</td>
<td>C</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>I</td>
<td></td>
<td>C</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>vecuronium</td>
<td>C</td>
<td></td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td>I</td>
<td></td>
<td>C</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>epinephrine</td>
<td>esmolol</td>
<td>famotidine</td>
<td>fluconazole</td>
<td>furosemide</td>
<td>heparin</td>
<td>hydrocortisone</td>
<td>hydromorphone hydrochloride</td>
<td>imipenem and cilastatin sodium</td>
<td>insulin</td>
<td>labetalol</td>
<td>levofoxacin</td>
<td>lorazepam</td>
<td>magnesium</td>
<td>methylprednisolone</td>
<td>metoclopramide hydrochloride</td>
<td>metoprolol</td>
<td>metronidazole</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------------</td>
<td>---------</td>
<td>------------</td>
<td>-------------</td>
<td>------------</td>
<td>---------</td>
<td>----------------</td>
<td>--------------------------------</td>
<td>----------------------------------</td>
<td>---------</td>
<td>-----------</td>
<td>-------------</td>
<td>-----------</td>
<td>-----------</td>
<td>------------------</td>
<td>-------------------------------</td>
<td>-----------</td>
<td>--------------</td>
</tr>
</tbody>
</table>

Safe drug administration
Conversions and calculations

Accurate conversions and calculations are crucial to ensuring safe drug administration. Use the tables below when you need to convert one unit to another, find equivalent measures, convert temperatures between Celsius and Fahrenheit, or calculate dosages or administration rates.

### Metric measures

**Solids**
- 1 milligram (mg) = 1,000 micrograms (mcg)
- 1 gram (g) = 1,000 mg
- 1 kilogram (kg) = 1,000 g

**Liquids**
- 1 milliliter (ml) = 1 cubic centimeter (cc)
- 1 ml = 1,000 microliters (mcl)
- 1 cc = 1,000 mcl
- 1 liter (L) = 1,000 ml
- 1 L = 1,000 cc

### Household to metric equivalents

- 1 teaspoon (tsp) = 5 ml
- 1 tablespoon (tbs) = 15 ml
- 1 ounce (oz) = 30 ml
- 2 tbs = 30 ml
- 1 oz = 30 g
- 1 pound (lb) = 454 g
- 2.2 lb = 1 kg
- 1 inch = 2.54 centimeters (cm)

### Temperature conversions

**To convert Celsius (°C) to Fahrenheit (°F)**

Use the following equation:

\[(°C \times \frac{9}{5}) + 32 = °F\]

*Example:* 38 °C times 9/5 is 68.4; 68.4 plus 32 equals 100.4 °F.

**To convert °F to °C**

\[(°F – 32) \times \frac{5}{9} = °C\]

*Example:* 98.6 °F minus 32 is 66.8.; 66.8 times 5/9 equals 37 °C.

### Calculating dosages and administration rates

**Concentration of solution in mg/ml**

\[\text{Concentration of solution in mg/ml} = \frac{\text{mg of drug}}{\text{ml of solution}}\]

**Infusion rate in mg/minute**

\[\text{Infusion rate in mg/minute} = \frac{\text{mg of drug}}{\text{ml of solution}} \times \text{flow rate (ml/hour)} \div 60 \text{ minutes}\]

**Concentration of solution in mcg/ml**

\[\text{Concentration of solution in mcg/ml} = \frac{\text{mg of drug} \times 1,000}{\text{ml of solution}}\]

**Infusion rate in mcg/minute**

\[\text{Infusion rate in mcg/minute} = \frac{\text{mg of drug} \times 1,000}{\text{ml of solution}} \times \text{flow rate (ml/hour)} \div 60 \text{ minutes} \div \text{weight in kg}\]

**Infusion rate in ml/hour**

\[\text{Infusion rate in ml/hour} = \frac{\text{ml of solution}}{\text{time in minutes}} \times \text{drip factor (gtt/ml)}\]
Drug names that look or sound alike

The drug names below can easily be confused, either verbally or in writing, because they either sound alike or have similar spellings. Generic names of these drugs appear in regular type; trade names are capitalized and in **boldface**.

<table>
<thead>
<tr>
<th>Accupril, Accutane</th>
<th>Calan, Colace</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accutane, Anturane</td>
<td>calcifediol, calcitriol</td>
</tr>
<tr>
<td>acetazolamide, acetoheptamidine</td>
<td>Captopril, captopril</td>
</tr>
<tr>
<td>acetylcholine, acetylcysteine</td>
<td>carboplatin, cisplatin</td>
</tr>
<tr>
<td>Aciphex, Aricept</td>
<td>Cardene, Cardizem</td>
</tr>
<tr>
<td>Aldactazide, Aldactone</td>
<td>Cardene, codeine</td>
</tr>
<tr>
<td>Aldomet, Aldoril</td>
<td>cefazolin, cefprozil</td>
</tr>
<tr>
<td>Aldoril, Elavil</td>
<td>cefotaxime, ceftriaxone</td>
</tr>
<tr>
<td>alfentanil, fentanyl, Sufenta, sufentanil</td>
<td>cefuroxime, deferococin</td>
</tr>
<tr>
<td>Allegra, Viagra</td>
<td>Cefzil, Kezol</td>
</tr>
<tr>
<td>alprazolam, diazepam, lorazepam, midazolam</td>
<td>Cefexa, Cerebyx</td>
</tr>
<tr>
<td>Altace, alteplase</td>
<td>chlorpromazine, chlorpropamide, promethazine</td>
</tr>
<tr>
<td>Alpent, Atrovent</td>
<td>ciprofloxacin, ofloxacin</td>
</tr>
<tr>
<td>amantadine, rimantadine</td>
<td>Clinoril, Clozaril</td>
</tr>
<tr>
<td>Ambien, Amen</td>
<td>clofazimine, clonidine, clozapine</td>
</tr>
<tr>
<td>Amicar, Amikin</td>
<td>clomiphene, clomipramine</td>
</tr>
<tr>
<td>amiloride, amiodarone, amlodipine</td>
<td>clonazepam, clorazepate</td>
</tr>
<tr>
<td>amitriptyline, nortriptyline</td>
<td>clonidine, quinidine</td>
</tr>
<tr>
<td>amoxicillin, Augmentin</td>
<td>clotrimazole, co-trimoxazole</td>
</tr>
<tr>
<td>Anafranil, enalapril</td>
<td>codeine, Lodine</td>
</tr>
<tr>
<td>Apresazide, Apresoline</td>
<td>Coreg, Zomig</td>
</tr>
<tr>
<td>ASA, 5-ASA</td>
<td>Cozaar, Zocor</td>
</tr>
<tr>
<td>Asacol, Os-Cal</td>
<td>cyclobenzaprine, cyproheptadine</td>
</tr>
<tr>
<td>Asocol, Os-Cal, Oxytrol</td>
<td>cycloserine, cyclosporine</td>
</tr>
<tr>
<td>Atarax, Ativan</td>
<td>dacarbazine, procarbazine</td>
</tr>
<tr>
<td>atenolol, timolol</td>
<td>dactinomycin, daunorubicin</td>
</tr>
<tr>
<td>Avandia, Avandryl</td>
<td>danazol, Dantrium</td>
</tr>
<tr>
<td>Avinza, Invanz</td>
<td>Darvon, Diovan</td>
</tr>
<tr>
<td>azithromycin, erythromycin</td>
<td>daunorubicin, idarubicin</td>
</tr>
<tr>
<td>baclofen, Bactroban</td>
<td>Decadron, Percodan</td>
</tr>
<tr>
<td>Benadryl, Bemyl, Benylin, Betalin</td>
<td>desipramine, imipramine</td>
</tr>
<tr>
<td>bepridil, Prepidil</td>
<td>Desogen, desonide</td>
</tr>
<tr>
<td>Betagan, BetaGen</td>
<td>desoximetasone, dexamethasone</td>
</tr>
<tr>
<td>Bumex, Buprenex</td>
<td>Desoxyn, digitoxin, digoxin</td>
</tr>
<tr>
<td>bupivacaine, ropivacaine</td>
<td>Diabeta, Zebeta</td>
</tr>
<tr>
<td>bupropion, buspirone</td>
<td>diazepam, Ditropan</td>
</tr>
</tbody>
</table>

(continued)
### Drug names that look or sound alike (continued)

<table>
<thead>
<tr>
<th>Diazoxide, Dyazide</th>
<th>Heparin, Hepsera, Hesan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dimenhydrinate, diphenhydramine</td>
<td>Hycodan, Vicodin</td>
</tr>
<tr>
<td>Diprivan, Ditropan</td>
<td>Hydralazine, hydroxyzine</td>
</tr>
<tr>
<td>Dipyridamole, disopyramide</td>
<td>Hydromorphone, morphine</td>
</tr>
<tr>
<td>Dobutamine, dopamine</td>
<td>Hyperstat, Nitrostat</td>
</tr>
<tr>
<td>Doxapram, doxazosin, doxepin, doxycycline</td>
<td>Imipenem, Omnipen</td>
</tr>
<tr>
<td>Doxil, Paxil, Plavix</td>
<td>Imipramine, Norpramin</td>
</tr>
<tr>
<td>Dronabinol, droperidol</td>
<td>Inderal, Inderide, Isordil</td>
</tr>
<tr>
<td>Dyclonine, dicyclomine</td>
<td>Intropin, Isoptin</td>
</tr>
<tr>
<td>Dynacin, DynaCirc</td>
<td>Keflex, Ketek</td>
</tr>
<tr>
<td>Echogen, Epogen</td>
<td>Klonopin, Clonidine</td>
</tr>
<tr>
<td>Elavil, Equanil, Mellaril</td>
<td>Lamasil, Lomotil</td>
</tr>
<tr>
<td>Eldepryl, enalapril</td>
<td>Lamictal, Lamisil</td>
</tr>
<tr>
<td>Elmiron, Imuran</td>
<td>Lamivudine, lamotrigine</td>
</tr>
<tr>
<td>Eloxatin, Exelon</td>
<td>Lanoxin, Lasix, Lonox</td>
</tr>
<tr>
<td>Enoxaparin, Enoxaparin sodium</td>
<td>Levatol, Lipitor</td>
</tr>
<tr>
<td>Estradiol, Estranal, Estranol</td>
<td>Levbid, Lithobid</td>
</tr>
<tr>
<td>Estradiol, Estrabon, Estratol</td>
<td>Levitra, Raptiva</td>
</tr>
<tr>
<td>Estraderm, Estratab, Estratest</td>
<td>Librax, Librium</td>
</tr>
<tr>
<td>Estrace, Estrogen, Estrogenic</td>
<td>Loniten, Lotensin, Lovastatin</td>
</tr>
<tr>
<td>Estrace, Estrogen, Estrogenic</td>
<td>Lorabid, Slo-bid</td>
</tr>
<tr>
<td>Estrace, Estrogen, Estrogenic</td>
<td>Losartan, valsartan</td>
</tr>
<tr>
<td>Estrace, Estrogen, Estrogenic</td>
<td>Mandol, nadolol</td>
</tr>
<tr>
<td>Flaricet, Fordan, Fordan</td>
<td>Maxidex, Maxzide</td>
</tr>
<tr>
<td>Flaxedil, Flexeril</td>
<td>Mazicon, Mevacor, Mivacron</td>
</tr>
<tr>
<td>Flomax, Fosamax</td>
<td>Mebendazole, methimazole</td>
</tr>
<tr>
<td>Flunisold, Flucononide</td>
<td>Melclizine, memantine</td>
</tr>
<tr>
<td>Fluoxetine, Fluvasiatria, Fluvoxamine, paroxetine</td>
<td>Melphalan, Mephyton</td>
</tr>
<tr>
<td>Flurazepam, temazepam</td>
<td>Meperidine, metoprolol</td>
</tr>
<tr>
<td>Folic acid, folinic acid</td>
<td>Mesantoin, Mestinon</td>
</tr>
<tr>
<td>Fosinopril, lisinopril, Risperdal</td>
<td>Metaprotenerol, metoprolol</td>
</tr>
<tr>
<td>Fosphenytoin, phenytoin</td>
<td>Methicillin, mezlocillin</td>
</tr>
<tr>
<td>Furosemide, torsemide</td>
<td>Methotrexate, metolazine</td>
</tr>
<tr>
<td>Glimepiride, glipizide, glyburide</td>
<td>Metoprolol, misoprostol</td>
</tr>
<tr>
<td>Granulex, Regranex</td>
<td>Minoxidil, Monopril</td>
</tr>
<tr>
<td>Guaifenesin, guanfacine</td>
<td>Mithramycin, mitomycin</td>
</tr>
<tr>
<td>Haldol, Stadol</td>
<td>Nadolol, nevivolol</td>
</tr>
<tr>
<td>Heparin, Hepsera, Hesan</td>
<td>Naloxone, naltrexone</td>
</tr>
<tr>
<td>Hycodan, Vicodin</td>
<td>Naprelan, Naprosyn</td>
</tr>
<tr>
<td>Hydralazine, hydroxyzine</td>
<td>Navane, Nubain</td>
</tr>
<tr>
<td>Hydromorphone, morphine</td>
<td>Nelfinavir, nevirapine</td>
</tr>
<tr>
<td>Hyperstat, Nitrostat</td>
<td>Neurontin, Noroxin</td>
</tr>
<tr>
<td>Imipenem, Omnipen</td>
<td>Niacinamide, nicardipine</td>
</tr>
<tr>
<td>Imipramine, Norpramin</td>
<td>Nicardipine, nifedipine, nimodipine</td>
</tr>
<tr>
<td>Inderal, Inderide, Isordil</td>
<td>Norpace, Norpramin</td>
</tr>
</tbody>
</table>
Ocufen, Ocuflox
olanzapine, olsalazine

Orinase, Ornade
oxaprozin, oxazepam
oxycodeone, OxyContin

paclitaxel, paclitaxel protein-bound particles
paclitaxel, paroxetine

Panadol, pindolol, Plendil
pencuronium, pipercuronium

Parlodel, pindolol
paroxetine, pralidoxime, pyridoxine
pentobarbital, phenobarbital
pentosan, pentostatin

Percocet, Percodan, Proct
Phenapen, Phenergan
phenelzine, Phenylzine
phentermine, phentolamine
pioglitazone, rosiglitazone

Pitocin, Pitressin
Pravachol, Prevacid
Pravachol, propranolol
prednisolone, prednisone, primidone

Premarin, Primaxin
ProAmatine, protamine
probenecid, Procanbid
promazine, promethazine

Proscar, Provera, Prozac
prostate, Protopen, Protropin

Quarzan, Questran
quinidine, quinine
ranitidine, rimantadine

Relpx, Revex, Revia
Reminyl, Robinul
reserpine, Risperdal

Restoril, Vistaril
Retrovir, ritonavir
ribavirin, riboflavin
rifabutin, rifampin

Rifadin, Rifamate, Rifater
Rifadin, Ritalin, ritodrine

Roxanol, Roxicet
Salbutamol, salmeterol
saquinavir, Sinequan
selegiline, Stelazine

Serentil, Serevent
Seroquel, Serzone
Solu-Cortef, Solu-Medrol
somatropin, sumatriptan

Spiriva, Stalevo
Sufenta, Survanta
sulfasalazine, sulfisoxazole
sumatriptan, zolmitriptan

Tambocor, tamoxifen
Tequin, Ticlid

terbinafine, terbutiline, terfenadine
terbutaline, tobutamide
terconazole, tioconazole
testolactone, testosterone

thiamine, Thorazine

Tiagabine, tizanidine
Timoptic, Viroptic
Tobradex, Tobrex
tolazamide, tobutamide
tolnaftate, Tornalate
tramadol, trazodone

Trandate, Tridate
Trendar, Trental
tretinoin, trientine

triamcinolone, Triaminicin, Triaminicol

triamicin, Triaminicin
triamterene, trimeprazine
trifluoperazine, triflupromazine

Ultracef, Ultracet
Urised, Urispas
valacyclovir, valganciclovir

Vancenase, Vanceril

Vanceril, Vansil
VePesid, Versed
verapamil, Verelan

Verelan, Virilon

vinblastine, vincristine, vindesine, vinorelbine

Wellbutrin, Wellcovorin, Wellferon
Xanax, Zantac
Zantac, Zyrtec
Zestril, Zostrix
Zocor, Zoloft
Zofran, Zosyn

Zymar, Zyprexa, Zyrtec
### Tall Man letters

In 2001, the Office of Generic Drugs requested manufacturers of some look-alike name pairs to voluntarily revise the appearance of their established names in order to minimize medication errors resulting from look-alike confusion. Manufacturers were encouraged to supplement their applications with revised labels and labeling that visually differentiated their established names with the use of “Tall Man” letters. The following is a list of the established names involved and the recommended revisions that highlight dissimilar letters by using upper and lower case for drugs that have similar letters.

<table>
<thead>
<tr>
<th>Established name</th>
<th>Recommended name</th>
</tr>
</thead>
<tbody>
<tr>
<td>acetazolamide</td>
<td>acetaZOLAMIDE</td>
</tr>
<tr>
<td>acetohexamide</td>
<td>acetaHEXAMIDE</td>
</tr>
<tr>
<td>bupropion</td>
<td>buPROPion</td>
</tr>
<tr>
<td>buspirone</td>
<td>busPIRone</td>
</tr>
<tr>
<td>chlorpromazine</td>
<td>chlorproMAZINE</td>
</tr>
<tr>
<td>chlorpropamide</td>
<td>chlorproPAMIDE</td>
</tr>
<tr>
<td>clomiphenene</td>
<td>clomiPHENE</td>
</tr>
<tr>
<td>clomipramine</td>
<td>clomiPRAMINE</td>
</tr>
<tr>
<td>cycloserine</td>
<td>cycloSERINE</td>
</tr>
<tr>
<td>cyclosporine</td>
<td>cycloSPORINE</td>
</tr>
<tr>
<td>daunorubicin</td>
<td>DAUNOrubicin</td>
</tr>
<tr>
<td>doxorubicin</td>
<td>DOXOrubicin</td>
</tr>
<tr>
<td>dimenhydrinate</td>
<td>dimenhyDRINATE</td>
</tr>
<tr>
<td>diphenhydramine</td>
<td>diphenhydrAMINE</td>
</tr>
<tr>
<td>dobutamine</td>
<td>DOBUTamine</td>
</tr>
<tr>
<td>dopamine</td>
<td>DOPamine</td>
</tr>
<tr>
<td>glipizide</td>
<td>glipiZIDE</td>
</tr>
<tr>
<td>glyburide</td>
<td>glyBURIDE</td>
</tr>
<tr>
<td>hydralazine</td>
<td>hydrALAZINE</td>
</tr>
<tr>
<td>hydroxyzine</td>
<td>hydrOXYzine</td>
</tr>
<tr>
<td>medroxyprogesterone</td>
<td>medroxyPROGESTERone</td>
</tr>
<tr>
<td>methylprednisolone</td>
<td>methylPREDNISolone</td>
</tr>
<tr>
<td>methyltestosterone</td>
<td>methylTESTOSTERone</td>
</tr>
<tr>
<td>mitoxantrone</td>
<td>mitoXANTRONE</td>
</tr>
<tr>
<td>nicardipine</td>
<td>NiCARDipine</td>
</tr>
<tr>
<td>nifedipine</td>
<td>NIFEdipine</td>
</tr>
<tr>
<td>prednisolone</td>
<td>prednisoLONE</td>
</tr>
<tr>
<td>prednisone</td>
<td>predniSONE</td>
</tr>
<tr>
<td>sulfadiazine</td>
<td>sulfADIAZINE</td>
</tr>
<tr>
<td>sulfinpodoxazole</td>
<td>sulfiSOXAZOLE</td>
</tr>
<tr>
<td>tolazamide</td>
<td>TOLAZamide</td>
</tr>
<tr>
<td>tolbutamide</td>
<td>TOLBUTamide</td>
</tr>
<tr>
<td>vinblastine</td>
<td>vinBLAStine</td>
</tr>
<tr>
<td>vincristine</td>
<td>vinCRIStine</td>
</tr>
</tbody>
</table>
Crushing extended-release or other long-acting oral drug forms can cause the ingredients to be released all at once instead of gradually. Similarly, crushing can break the coating of enteric-coated drugs, leading to GI irritation. Other drugs may taste bad or have carcinogenic or teratogenic potential when crushed. Never crush the trade-name drugs listed below.

<table>
<thead>
<tr>
<th>Tablets and capsules not to crush</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accutane</td>
</tr>
<tr>
<td>Aciphex</td>
</tr>
<tr>
<td>Adalat CC</td>
</tr>
<tr>
<td>Aggrenox</td>
</tr>
<tr>
<td>Allegra D</td>
</tr>
<tr>
<td>Arthrotec</td>
</tr>
<tr>
<td>Asacol</td>
</tr>
<tr>
<td>Bayer EC</td>
</tr>
<tr>
<td>Bellergal-S</td>
</tr>
<tr>
<td>Biaxin XL</td>
</tr>
<tr>
<td>Boniva</td>
</tr>
<tr>
<td>Calan SR</td>
</tr>
<tr>
<td>Carbatrol</td>
</tr>
<tr>
<td>Carbiset-TR</td>
</tr>
<tr>
<td>Cardene SR</td>
</tr>
<tr>
<td>Cardizem CD, LA, SR</td>
</tr>
<tr>
<td>Carter's Little Pills</td>
</tr>
<tr>
<td>Cartia XT</td>
</tr>
<tr>
<td>Carvedilol</td>
</tr>
<tr>
<td>Cclor CD</td>
</tr>
<tr>
<td>CellCept</td>
</tr>
<tr>
<td>Choledyl SA</td>
</tr>
<tr>
<td>Claritin-D</td>
</tr>
<tr>
<td>Colace</td>
</tr>
<tr>
<td>Colestid</td>
</tr>
<tr>
<td>Compazine Spansules</td>
</tr>
<tr>
<td>Concerta</td>
</tr>
<tr>
<td>Cotazym-S</td>
</tr>
<tr>
<td>Covera-HS</td>
</tr>
<tr>
<td>Creon</td>
</tr>
<tr>
<td>Cymbalta</td>
</tr>
<tr>
<td>Cytovene</td>
</tr>
<tr>
<td>Deconamine SR</td>
</tr>
<tr>
<td>Depakene</td>
</tr>
<tr>
<td>Depakote</td>
</tr>
<tr>
<td>Desoxyn Gradumets</td>
</tr>
<tr>
<td>Dexedrine Spansule</td>
</tr>
<tr>
<td>Diamox Sequels</td>
</tr>
<tr>
<td>Dilacor XR</td>
</tr>
<tr>
<td>Dilatrate-SR</td>
</tr>
<tr>
<td>Disobrom</td>
</tr>
<tr>
<td>Ditropan XL</td>
</tr>
<tr>
<td>Donnapan Extentabs</td>
</tr>
<tr>
<td>Donnazyme</td>
</tr>
<tr>
<td>Drixoral</td>
</tr>
<tr>
<td>Dulcolax</td>
</tr>
<tr>
<td>DynaCirc CR</td>
</tr>
<tr>
<td>Easprin</td>
</tr>
<tr>
<td>Ecotrin</td>
</tr>
<tr>
<td>Effexor XR</td>
</tr>
<tr>
<td>Entex LA</td>
</tr>
<tr>
<td>Erythromycin Base</td>
</tr>
<tr>
<td>Eskalith CR</td>
</tr>
<tr>
<td>Factive</td>
</tr>
<tr>
<td>Fentora</td>
</tr>
<tr>
<td>Feocyte</td>
</tr>
<tr>
<td>Feosol</td>
</tr>
<tr>
<td>Feratab</td>
</tr>
<tr>
<td>Ferro-Sequel</td>
</tr>
<tr>
<td>Flomax</td>
</tr>
<tr>
<td>Glucotrol XL</td>
</tr>
<tr>
<td>Guaired</td>
</tr>
<tr>
<td>Ilotycin</td>
</tr>
<tr>
<td>Indur</td>
</tr>
<tr>
<td>Inderal LA</td>
</tr>
<tr>
<td>Inderide LA</td>
</tr>
<tr>
<td>Indocin SR</td>
</tr>
<tr>
<td>Isoptin SR</td>
</tr>
<tr>
<td>Isordil Sublingual, Tembids</td>
</tr>
<tr>
<td>Isosorbide Dinitrate Sublingual</td>
</tr>
<tr>
<td>Kadian</td>
</tr>
<tr>
<td>Kaon-Cl</td>
</tr>
<tr>
<td>K-Dur</td>
</tr>
<tr>
<td>Klor-Con</td>
</tr>
<tr>
<td>Klotrix</td>
</tr>
<tr>
<td>K-Tab</td>
</tr>
<tr>
<td>Lebvid</td>
</tr>
<tr>
<td>Lexxel</td>
</tr>
<tr>
<td>Lithobid</td>
</tr>
<tr>
<td>Lodine XL</td>
</tr>
<tr>
<td>Name</td>
</tr>
<tr>
<td>-----------------------</td>
</tr>
<tr>
<td>Lodorane LD</td>
</tr>
<tr>
<td>Macrobid</td>
</tr>
<tr>
<td>Mestinon Timespans</td>
</tr>
<tr>
<td>Methylin ER</td>
</tr>
<tr>
<td>Micro-K Extencaps</td>
</tr>
<tr>
<td>Monafed</td>
</tr>
<tr>
<td>MS Contin</td>
</tr>
<tr>
<td>Naldecon</td>
</tr>
<tr>
<td>Naprelan</td>
</tr>
<tr>
<td>Nia-Bid</td>
</tr>
<tr>
<td>Niaspan</td>
</tr>
<tr>
<td>Nicotinic Acid</td>
</tr>
<tr>
<td>Nitroglyn</td>
</tr>
<tr>
<td>Nitrong</td>
</tr>
<tr>
<td>Nitrostat</td>
</tr>
<tr>
<td>Norflex</td>
</tr>
<tr>
<td>Norpace CR</td>
</tr>
<tr>
<td>Novafed A</td>
</tr>
<tr>
<td>Oramorph SR</td>
</tr>
<tr>
<td>OxyContin</td>
</tr>
<tr>
<td>Pancrease MT</td>
</tr>
<tr>
<td>PCE</td>
</tr>
<tr>
<td>Pentasa</td>
</tr>
<tr>
<td>Perdiem</td>
</tr>
<tr>
<td>Phazyme</td>
</tr>
<tr>
<td>Phyllocontin</td>
</tr>
<tr>
<td>Plendil</td>
</tr>
<tr>
<td>Pneumomist</td>
</tr>
<tr>
<td>Prelu-2</td>
</tr>
<tr>
<td>Prevacid</td>
</tr>
<tr>
<td>Prilosec</td>
</tr>
<tr>
<td>Pristiq</td>
</tr>
<tr>
<td>Pro-Banthine</td>
</tr>
<tr>
<td>Procardia</td>
</tr>
<tr>
<td>Proscar</td>
</tr>
<tr>
<td>Protonix</td>
</tr>
<tr>
<td>Proventil Repetabs</td>
</tr>
<tr>
<td>Prozoc</td>
</tr>
<tr>
<td>Quibron-T/SR</td>
</tr>
<tr>
<td>Quinaglute Dura-Tabs</td>
</tr>
<tr>
<td>Quinindex Extentabs</td>
</tr>
<tr>
<td>Respaire SR</td>
</tr>
<tr>
<td>Respbid</td>
</tr>
<tr>
<td>Revlimid</td>
</tr>
<tr>
<td>Reyataz</td>
</tr>
<tr>
<td>Ritalin-SR</td>
</tr>
<tr>
<td>Roxanol SR</td>
</tr>
<tr>
<td>Ru-Tuss</td>
</tr>
<tr>
<td>Sinemet CR</td>
</tr>
<tr>
<td>Slo-bid Gyrocaps</td>
</tr>
<tr>
<td>Slo-Niacin</td>
</tr>
<tr>
<td>Slo-Phyllin GG, Gyrocaps</td>
</tr>
<tr>
<td>Slow FE</td>
</tr>
<tr>
<td>Slow-K</td>
</tr>
<tr>
<td>Slow-Mag</td>
</tr>
<tr>
<td>Sorbitrate SA</td>
</tr>
<tr>
<td>Sprycel</td>
</tr>
<tr>
<td>Striant</td>
</tr>
<tr>
<td>Sudafed 12 Hour</td>
</tr>
<tr>
<td>Sular</td>
</tr>
<tr>
<td>Sustaire</td>
</tr>
<tr>
<td>Tasigna</td>
</tr>
<tr>
<td>Tavist-D</td>
</tr>
<tr>
<td>Tegetrol-XR</td>
</tr>
<tr>
<td>Teldrin</td>
</tr>
<tr>
<td>Ten-K</td>
</tr>
<tr>
<td>Tenuate Dospans</td>
</tr>
<tr>
<td>Tessalon Perles</td>
</tr>
<tr>
<td>Theobid Duracaps</td>
</tr>
<tr>
<td>Theochron</td>
</tr>
<tr>
<td>Theoclear LA</td>
</tr>
<tr>
<td>Theo-Dur</td>
</tr>
<tr>
<td>Theolair-SR</td>
</tr>
<tr>
<td>Theo-Sav</td>
</tr>
<tr>
<td>Theospans-SR</td>
</tr>
<tr>
<td>Theo-24</td>
</tr>
<tr>
<td>Theoevent</td>
</tr>
<tr>
<td>Theo-X</td>
</tr>
<tr>
<td>Thorazine Spansules</td>
</tr>
<tr>
<td>Tiazac</td>
</tr>
<tr>
<td>Toprol XL</td>
</tr>
<tr>
<td>T-Phyl</td>
</tr>
<tr>
<td>Tranxene-SD</td>
</tr>
<tr>
<td>Trental</td>
</tr>
<tr>
<td>Triaminic</td>
</tr>
<tr>
<td>Trilafon Repetabs</td>
</tr>
<tr>
<td>Trinalin Repetabs</td>
</tr>
<tr>
<td>Tuss-Ornade Spansules</td>
</tr>
<tr>
<td>Tylenol Extended Relief</td>
</tr>
<tr>
<td>Ultrase MT</td>
</tr>
<tr>
<td>Uniphyl</td>
</tr>
<tr>
<td>Verelan</td>
</tr>
<tr>
<td>Verelan</td>
</tr>
<tr>
<td>Volmax</td>
</tr>
<tr>
<td>Voltaren, XR</td>
</tr>
<tr>
<td>Wellbutrin SR, XL</td>
</tr>
<tr>
<td>Xanax-XR</td>
</tr>
<tr>
<td>ZORprin</td>
</tr>
<tr>
<td>Zyban</td>
</tr>
<tr>
<td>Zymase</td>
</tr>
</tbody>
</table>
Preventing and treating extravasation

Extravasation—escape of a vesicant drug into surrounding tissues—can result from a damaged vein or from leakage around a venipuncture site. Vesicant drugs (such as daunorubicin and vincristine) can cause severe tissue damage if extravasation occurs.

To help prevent extravasation, make sure the existing I.V. line is patent before you administer a drug by the I.V. route. Check patency by:

- inspecting the site for edema or pain
- flushing the I.V. line with 0.9% sodium chloride solution
- gently aspirating blood from the catheter.

Alternatively, you may insert a new I.V. catheter to ensure correct catheter placement. For vesicant drugs, consider using a central venous catheter.

If extravasation occurs, stop the infusion at once. Notify the physician to obtain treatment orders. Administer the antidote as ordered. Aspirate the remaining drug from the catheter before removing the I.V. line (unless you need the catheter to administer an antidote). If the extravasated drug was daunorubicin or doxorubicin, apply a cold compress to the area for 24 to 48 hours; if it was vinblastine or vincristine, apply a warm compress. Then elevate the affected extremity.

Administering antidotes

Antidotes for extravasation typically are either given through the existing I.V. line or injected subcutaneously around the infiltrated site using a 1-ml tuberculin syringe. Be sure to use a new needle for each antidote injection.

<table>
<thead>
<tr>
<th>Extravasated drug</th>
<th>Antidote and dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>● aminophylline</td>
<td>hyaluronidase: 15 units/ml, as 0.2 ml subcutaneous injection near extravasation site</td>
</tr>
<tr>
<td>● calcium solutions</td>
<td></td>
</tr>
<tr>
<td>● contrast media</td>
<td></td>
</tr>
<tr>
<td>● dextrose solutions</td>
<td></td>
</tr>
<tr>
<td>(concentrations of 10% or more)</td>
<td></td>
</tr>
<tr>
<td>● etoposide</td>
<td></td>
</tr>
<tr>
<td>● nafcillin</td>
<td></td>
</tr>
<tr>
<td>● potassium solutions</td>
<td></td>
</tr>
<tr>
<td>● teniposide</td>
<td></td>
</tr>
<tr>
<td>● total parenteral nutrition solutions</td>
<td></td>
</tr>
<tr>
<td>● vinblastine</td>
<td></td>
</tr>
<tr>
<td>● vincristine</td>
<td></td>
</tr>
<tr>
<td>● vindesine</td>
<td></td>
</tr>
<tr>
<td>● dactinomycin</td>
<td>ascorbic acid injection: 50 mg</td>
</tr>
<tr>
<td>● daunorubicin</td>
<td>hydrocortisone sodium succinate: 100 mg/ml: 50 to 200 mg</td>
</tr>
<tr>
<td>● doxorubicin</td>
<td></td>
</tr>
<tr>
<td>● dopamine</td>
<td>phentolamine: 5 to 10 mg diluted in 10 to 15 ml of normal saline solution, administered within 12 hours of extravasation</td>
</tr>
<tr>
<td>● epinephrine</td>
<td></td>
</tr>
<tr>
<td>● metaraminol</td>
<td></td>
</tr>
<tr>
<td>● norepinephrine</td>
<td></td>
</tr>
<tr>
<td>● mechlorethamine</td>
<td>sodium thiosulfate 10%: 10 ml</td>
</tr>
</tbody>
</table>
Identifying injection sites

Injection sites vary with administration route. The instructions below describe proper identification sites for I.M., subcutaneous, and I.V. drugs.

To begin, wash your hands, put on gloves, and locate the appropriate site. Clean the site with an alcohol pad, and administer the injection as described here.

**I.M. injections**

You can administer an I.M. injection into the muscles shown below. In these illustrations, specific injection sites are shaded.

**Deltoid site**
- Locate the lower edge of the acromial process.
- Insert the needle 1" to 2" below the acromial process at a 90-degree angle.

**Dorsogluteal site**
- Draw an imaginary line from the posterior superior iliac spine to the greater trochanter.
- Insert the needle at a 90-degree angle above and outside the drawn line.
- You can administer a Z-track injection through this site. After drawing up the drug, change the needle, displace the skin lateral to the injection site, withdraw the needle, and then release the skin.

**Ventrogluteal site**
- With the palm of your hand, locate the greater trochanter of the femur.
- Spread your index and middle fingers posteriorly from the anterior superior iliac spine to the furthest area possible. This is the correct injection site.
- Remove your fingers and insert the needle at a 90-degree angle.

**Vastus lateralis and rectus femoris sites**
- Find the lateral quadriceps muscle for the vastus lateralis, or the anterior thigh for the rectus femoris.
- Insert the needle at a 90-degree angle into the middle third of the muscle, parallel to the skin surface.
Subcutaneous injections

Subcutaneous drugs can be injected into the fat pads on the abdomen, buttocks, upper back, and lateral upper arms and thighs (shaded in the illustrations below). If your patient requires frequent subcutaneous injections, make sure to rotate injection sites.

- Gently gather and elevate or spread subcutaneous tissue.
- Insert the needle at a 45- or 90-degree angle, depending on the drug or the amount of subcutaneous tissue at the site.

I.V. injections

I.V. drugs can be injected into the veins of the arms and hands. The illustration on the right shows commonly used sites.

- Locate the vein using a tourniquet.
- Insert the catheter at a slight angle (about 10 degrees).
- Release the tourniquet when blood appears in the syringe or tubing.
- Slowly inject the drug into the vein.

Illustrator: Kevin A. Somerville
The table below shows therapeutic and toxic blood levels for selected drugs. Keep in mind that such levels may vary slightly among laboratories.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Therapeutic blood level</th>
<th>Toxic blood level</th>
</tr>
</thead>
<tbody>
<tr>
<td>acetaminophen</td>
<td>10 to 20 mcg/ml</td>
<td>&gt; 150 mcg/ml</td>
</tr>
<tr>
<td>alprazolam</td>
<td>0.025 to 0.102 mcg/ml</td>
<td>Not defined</td>
</tr>
<tr>
<td>amikacin</td>
<td>Peak: 25 to 35 mcg/ml</td>
<td>&gt; 35 mcg/ml</td>
</tr>
<tr>
<td></td>
<td>Trough: 5 to 10 mcg/ml</td>
<td>&gt; 10 mcg/ml</td>
</tr>
<tr>
<td>aminophylline</td>
<td>10 to 20 mcg/ml</td>
<td>&gt; 20 mcg/ml</td>
</tr>
<tr>
<td>amiodarone</td>
<td>1 to 2.5 mcg/ml</td>
<td>&gt; 2.5 mcg/ml</td>
</tr>
<tr>
<td>amitriptyline</td>
<td>120 to 250 ng/ml</td>
<td>&gt; 500 ng/ml</td>
</tr>
<tr>
<td>amobarbital</td>
<td>1 to 5 mcg/ml</td>
<td>&gt; 10 mcg/ml</td>
</tr>
<tr>
<td>atenolol</td>
<td>0.2 to 0.7 mcg/ml</td>
<td>35 mcg/ml</td>
</tr>
<tr>
<td>bepridil</td>
<td>1 to 2 ng/ml</td>
<td>&gt; 2 ng/ml</td>
</tr>
<tr>
<td>calcium</td>
<td>9 to 10.5 mg/dl</td>
<td>&gt; 12 mg/dl</td>
</tr>
<tr>
<td>carbamazepine</td>
<td>4 to 14 mcg/ml</td>
<td>&gt; 15 mcg/ml</td>
</tr>
<tr>
<td>clonazepam</td>
<td>10 to 80 ng/ml</td>
<td>&gt; 100 ng/ml</td>
</tr>
<tr>
<td>creatinine</td>
<td>0.6 to 1.2 mg/dl</td>
<td>&gt; 4 mg/dl</td>
</tr>
<tr>
<td>cyclosporine</td>
<td>50 to 300 ng/ml</td>
<td>&gt; 400 ng/ml</td>
</tr>
<tr>
<td>desipramine</td>
<td>115 to 300 ng/ml</td>
<td>&gt; 400 ng/ml</td>
</tr>
<tr>
<td>diazepam</td>
<td>0.5 to 2 mcg/ml</td>
<td>&gt; 3 mcg/ml</td>
</tr>
<tr>
<td>digoxin</td>
<td>0.8 to 2 ng/ml</td>
<td>Adults: &gt; 2.5 ng/ml Children: &gt; 3 ng/ml</td>
</tr>
<tr>
<td></td>
<td>Trough (&gt; 12 hours after dose): Heart failure: 0.8 to 1.5 ng/ml Arrhythmias: 1.5 to 2 ng/ml</td>
<td></td>
</tr>
<tr>
<td>diltiazem</td>
<td>0.05 to .40 mcg/ml</td>
<td>3.7 to 6.1 mcg/ml</td>
</tr>
<tr>
<td>diphenhydantoin</td>
<td>10 to 20 mcg/ml</td>
<td>20 to 50 mcg/ml</td>
</tr>
<tr>
<td>disopyramide</td>
<td>2 to 8 mcg/ml</td>
<td>&gt; 8 mcg/ml</td>
</tr>
<tr>
<td>ethosuximide</td>
<td>40 to 100 mcg/ml</td>
<td>&gt; 100 mcg/ml</td>
</tr>
<tr>
<td>flecainide</td>
<td>0.2 to 1 mcg/ml</td>
<td>&gt; 1 mcg/ml</td>
</tr>
<tr>
<td>fluconazole</td>
<td>5 to 15 mcg/ml</td>
<td>Not defined</td>
</tr>
<tr>
<td>fluoxetine</td>
<td>0.09 to 0.40 mcg/ml</td>
<td>Not defined</td>
</tr>
<tr>
<td>gentamicin</td>
<td>Peak: 4 to 12 mcg/ml</td>
<td>&gt; 12 mcg/ml</td>
</tr>
<tr>
<td></td>
<td>Trough: 1 to 2 mcg/ml</td>
<td>&gt; 2 mcg/ml</td>
</tr>
<tr>
<td>glucose</td>
<td>70 to 110 mg/dl</td>
<td>&gt; 300 mg/dl</td>
</tr>
<tr>
<td>glutethimide</td>
<td>2 to 6 mcg/ml</td>
<td>&gt; 5 mcg/ml</td>
</tr>
<tr>
<td>haloperidol</td>
<td>5 to 20 ng/ml</td>
<td>&gt; 20 ng/ml</td>
</tr>
<tr>
<td>hydromorphone</td>
<td>0.008 to 0.049 mcg/ml</td>
<td>Not defined</td>
</tr>
<tr>
<td>Drug</td>
<td>Therapeutic blood level</td>
<td>Toxic blood level</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-------------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>imipramine</td>
<td>225 to 300 ng/ml</td>
<td>&gt; 500 ng/ml</td>
</tr>
<tr>
<td>lidocaine</td>
<td>1.5 to 6 mcg/ml</td>
<td>&gt; 6 mcg/ml</td>
</tr>
<tr>
<td>lithium</td>
<td>0.6 to 1.2 mEq/L</td>
<td>&gt; 1.5 mEq/L</td>
</tr>
<tr>
<td>lorazepam</td>
<td>50 to 240 ng/ml</td>
<td>&gt; 300 to 600 ng/ml</td>
</tr>
<tr>
<td>magnesium</td>
<td>12 to 32 ng/ml</td>
<td>&gt; 80 to 120 ng/ml</td>
</tr>
<tr>
<td>meperidine</td>
<td>100 to 550 ng/ml</td>
<td>&gt; 1,000 ng/ml</td>
</tr>
<tr>
<td>meprobamate</td>
<td>6 to 12 mcg/ml</td>
<td>&gt; 60 mcg/ml</td>
</tr>
<tr>
<td>methotrexate</td>
<td>&gt; 0.01 mcmol</td>
<td>&gt; 10 mcmol/24 hr</td>
</tr>
<tr>
<td>methsuximide</td>
<td>10 to 40 mcg/ml</td>
<td>&gt; 44 mcg/ml</td>
</tr>
<tr>
<td>methylphenidate</td>
<td>0.01 to 0.06 mcg/ml</td>
<td>&gt; 0.8 mcg/ml</td>
</tr>
<tr>
<td>metoprolol</td>
<td>0.03 to 0.27 mcg/ml</td>
<td>Not defined</td>
</tr>
<tr>
<td>mezlocillin</td>
<td>35 to 45 mcg/ml</td>
<td>&gt; 45 mcg/ml</td>
</tr>
<tr>
<td>milrinone</td>
<td>150 to 250 ng/ml</td>
<td>&gt; 250 ng/ml</td>
</tr>
<tr>
<td>nifedipine</td>
<td>0.025 to 0.1 mcg/ml</td>
<td>&gt; 0.1 mcg/ml</td>
</tr>
<tr>
<td>nortriptyline</td>
<td>50 to 140 ng/ml</td>
<td>&gt; 300 ng/ml</td>
</tr>
<tr>
<td>oxazepam</td>
<td>0.2 to 1.4 mcg/ml</td>
<td>&gt; 2 mcg/ml</td>
</tr>
<tr>
<td>paroxetine</td>
<td>0.031 to 0.062 mcg/ml</td>
<td>Not defined</td>
</tr>
<tr>
<td>phenobarbital</td>
<td>10 to 40 mcg/ml</td>
<td>&gt; 40 mcg/ml</td>
</tr>
<tr>
<td>phenytoin</td>
<td>10 to 20 mcg/ml</td>
<td>&gt; 20 mcg/ml</td>
</tr>
<tr>
<td>potassium</td>
<td>3.5 to 5.0 mEq/L</td>
<td>&gt; 6 mEq/L</td>
</tr>
<tr>
<td>primidone</td>
<td>4 to 12 mcg/ml</td>
<td>&gt; 12 mcg/ml</td>
</tr>
<tr>
<td>procaainamide</td>
<td>4 to 8 mcg/ml</td>
<td>&gt; 10 mcg/ml</td>
</tr>
<tr>
<td>propranolol</td>
<td>50 to 200 ng/ml</td>
<td>&gt; 200 ng/ml</td>
</tr>
<tr>
<td>quinidine</td>
<td>2 to 5 mcg/ml</td>
<td>&gt; 5 mcg/ml</td>
</tr>
<tr>
<td>salicylates</td>
<td>100 to 300 mcg/ml</td>
<td>&gt; 300 mcg/ml</td>
</tr>
<tr>
<td>sertraline</td>
<td>0.055 to 0.25 mcg/ml</td>
<td>Not defined</td>
</tr>
<tr>
<td>sodium</td>
<td>135 to 145 mEq/L</td>
<td>&gt; 160 mEq/L</td>
</tr>
<tr>
<td>streptomycin</td>
<td>25 mcg/ml</td>
<td>&gt; 25 mcg/ml</td>
</tr>
<tr>
<td>tacrolimus</td>
<td>0.005 to 0.02 mcg/ml</td>
<td>&gt; 0.03 mcg/ml</td>
</tr>
<tr>
<td>theophylline</td>
<td>10 to 20 mcg/ml</td>
<td>&gt; 20 mcg/ml</td>
</tr>
<tr>
<td>tobramycin</td>
<td>Peak: 4 to 12 mcg/ml</td>
<td>&gt; 12 mcg/ml</td>
</tr>
<tr>
<td>Trough: 1 to 2 mcg/ml</td>
<td>&gt; 2 mcg/ml</td>
<td></td>
</tr>
<tr>
<td>tocainide</td>
<td>4 to 10 mcg/ml</td>
<td>Not defined</td>
</tr>
<tr>
<td>valproic acid</td>
<td>50 to 100 mcg/ml</td>
<td>&gt; 100 mcg/ml</td>
</tr>
<tr>
<td>vancomycin</td>
<td>Peak: 20 to 40 mcg/ml</td>
<td>&gt; 40 mcg/ml</td>
</tr>
<tr>
<td>Trough: 5 to 15 mcg/ml</td>
<td>&gt; 15 mcg/ml</td>
<td></td>
</tr>
<tr>
<td>verapamil</td>
<td>0.08 to 0.3 mcg/ml</td>
<td>Not defined</td>
</tr>
<tr>
<td>zolpidem</td>
<td>0.003 to 0.018 mcg/ml</td>
<td>Not defined</td>
</tr>
</tbody>
</table>
Effects of dialysis on drug therapy

A patient receiving a drug that’s removed by hemodialysis (HD) or peritoneal dialysis (PD) will need supplemental doses of that drug. The chart below shows which drugs are removed by dialysis and therefore will necessitate supplemental dosing during or after dialysis. Drugs listed as “unlikely” haven’t been studied; however, because of their chemical properties, dialysis is unlikely to remove them.

<table>
<thead>
<tr>
<th>Generic drug</th>
<th>Removed by HD</th>
<th>Removed by PD</th>
</tr>
</thead>
<tbody>
<tr>
<td>acetaminophen</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>acyclovir</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>adenosine</td>
<td>Unlikely</td>
<td>Unlikely</td>
</tr>
<tr>
<td>albumin</td>
<td>Unlikely</td>
<td>Unlikely</td>
</tr>
<tr>
<td>alendronate</td>
<td>No</td>
<td>No data</td>
</tr>
<tr>
<td>allopurinol</td>
<td>Yes</td>
<td>No data</td>
</tr>
<tr>
<td>alprazolam</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>amikacin</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>amiodarone</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>amitriptyline</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>amiodipine</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>amoxicillin</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>amphotericin B</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>ampicillin</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>ascorbic acid</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>aspirin</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>atenolol</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>atorvastatin</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>aztreonam</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>bleomycin</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>bumetanide</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>buspirone</td>
<td>No</td>
<td>No data</td>
</tr>
<tr>
<td>candesartan</td>
<td>No</td>
<td>No data</td>
</tr>
<tr>
<td>captopril</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>carbamazepine</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>carbenicillin</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>carbofuran</td>
<td>Yes</td>
<td>No data</td>
</tr>
<tr>
<td>carisoprodol</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>carmustine</td>
<td>No</td>
<td>No data</td>
</tr>
<tr>
<td>cefaclor</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>cefadroxil</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>cefazolin</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>cefepime</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>cefmetazole</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>cefonicid</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>cefoperazone</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>cefotaxime</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>cefotetan</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>cefoxitin</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>cepodoxime</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>ceftazidime</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>ceftriaxone</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>cefuroxime</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>cephalixin</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>chloramphenicol</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>chlorpheniramine</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>cimetidine</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>ciprofloxacin</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>citalopram</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>clindamycin</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>clofibrate</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>clonazepam</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>clonidine</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>codeine</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>colchicine</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>cyclophosphamide</td>
<td>Yes</td>
<td>No data</td>
</tr>
<tr>
<td>cyclosporine</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>dapsone</td>
<td>Yes</td>
<td>No data</td>
</tr>
<tr>
<td>desipramine</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>dexamethasone</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>diazepam</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>diazoxide</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>dicloxacillin</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>digoxin</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>diltilazem</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>diphenhydramine</td>
<td>Unlikely</td>
<td>Unlikely</td>
</tr>
<tr>
<td>divalproex</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>dobutamine</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>dopamine</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>doxazosin</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Generic drug</td>
<td>Removed by HD</td>
<td>Removed by PD</td>
</tr>
<tr>
<td>------------------------------</td>
<td>---------------</td>
<td>---------------</td>
</tr>
<tr>
<td>doxepin</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>doxycycline</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>drotrecogin alfa</td>
<td>Unlikely</td>
<td>Unlikely</td>
</tr>
<tr>
<td>edetate calcium</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>enalapril</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>epinephrine</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>eptoin alfa</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>erythromycin</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>esmolol</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>estradiol</td>
<td>No</td>
<td>No data</td>
</tr>
<tr>
<td>ethacrynic acid</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>etoposide</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>exoxaparin</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>famciclovir</td>
<td>Yes</td>
<td>No data</td>
</tr>
<tr>
<td>famotidine</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>felodipine</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>fenofibrate</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>filgrastim</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>flecainide</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>flucanazole</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>flucytosine</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>fluoxetine</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>folic acid</td>
<td>Yes</td>
<td>No data</td>
</tr>
<tr>
<td>foscarnet</td>
<td>Yes</td>
<td>No data</td>
</tr>
<tr>
<td>furosemide</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>gabapentin</td>
<td>Yes</td>
<td>No data</td>
</tr>
<tr>
<td>ganciclovir</td>
<td>Yes</td>
<td>No data</td>
</tr>
<tr>
<td>gemfibrozil</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>gentamicin</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>glyburide</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>haloperidol</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>heparin</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>hydralazine</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>hydrochlorothiazide</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>hydrocodone</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>hydromorphone</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>hydroxyzine</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>ibuprofen</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>ibutilide</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>imipenem</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>imipramine</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>indomethacin</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>insulin</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>irbesartan</td>
<td>No</td>
<td>No data</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Generic drug</th>
<th>Removed by HD</th>
<th>Removed by PD</th>
</tr>
</thead>
<tbody>
<tr>
<td>nadolol</td>
<td>Yes</td>
<td>No data</td>
</tr>
<tr>
<td>nafcillin</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>nalbuphine</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>naloxone</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>naltrexone</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>naproxen</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>neomycin</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>nicardipine</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>nifedipine</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>nitramide</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>nimodipine</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>nitrofurantoin</td>
<td>Yes</td>
<td>No data</td>
</tr>
<tr>
<td>nitroglycerin</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>nitroprusside</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>nortriptyline</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>octreotide</td>
<td>Yes</td>
<td>No data</td>
</tr>
<tr>
<td>ofloxacin</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>olanzapine</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>omeprazole</td>
<td>Unlikely</td>
<td>Unlikely</td>
</tr>
<tr>
<td>ondansetron</td>
<td>Unlikely</td>
<td>Unlikely</td>
</tr>
<tr>
<td>oxazepam</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>oxycodone</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>paclitaxel</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>pancuronium</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>pantoprazole</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>paricalcitol</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>paroxetine</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>penicillin</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>phenobarbital</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>phenytoin</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>piperacillin</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>pravastatin</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>prazosin</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>prednisone</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>primidone</td>
<td>Yes</td>
<td>No data</td>
</tr>
<tr>
<td>procainamide</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>promethazine</td>
<td>No</td>
<td>No data</td>
</tr>
<tr>
<td>propafenone</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>propoxyphene</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>propranolol</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>propylthiouracil</td>
<td>No</td>
<td>No data</td>
</tr>
<tr>
<td>pseudophedrine</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>quinapril</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>quinidine</td>
<td>No; removed</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>by hemoperfusion</td>
<td></td>
</tr>
<tr>
<td>quinine</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Generic drug</th>
<th>Removed by HD</th>
<th>Removed by PD</th>
</tr>
</thead>
<tbody>
<tr>
<td>ramipril</td>
<td>No</td>
<td>No data</td>
</tr>
<tr>
<td>ranitidine</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>reserpine</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>reteplase</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>rifampin</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>risperidone</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>ritodrine</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>ritonavir</td>
<td>Unlikely</td>
<td>No</td>
</tr>
<tr>
<td>rosiglitazone</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>rosuvastatin</td>
<td>No</td>
<td>No data</td>
</tr>
<tr>
<td>salsalate</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>sertraline</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>simvastatin</td>
<td>Unlikely</td>
<td>Unlikely</td>
</tr>
<tr>
<td>sotalol</td>
<td>Yes</td>
<td>No data</td>
</tr>
<tr>
<td>stavudine</td>
<td>Yes</td>
<td>No data</td>
</tr>
<tr>
<td>streptomyacin</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>sulfamethoxazole</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>sulfisoxazole</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>tamoxifen</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>temazepam</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>terazosin</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>tetracycline</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>theophylline</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>thiamine</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>ticarcillin</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>timolol</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>tirofiban</td>
<td>Yes</td>
<td>No data</td>
</tr>
<tr>
<td>tobramycin</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>torsemide</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>tramadol</td>
<td>No</td>
<td>No data</td>
</tr>
<tr>
<td>trimethoprim</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>valacyclovir</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>valproic acid</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>valsartan</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>vancomycin</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>venlafaxine</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>verapamil</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>vinblastine</td>
<td>Unlikely</td>
<td>Unlikely</td>
</tr>
<tr>
<td>vincristine</td>
<td>Unlikely</td>
<td>Unlikely</td>
</tr>
<tr>
<td>voriconazole</td>
<td>Yes</td>
<td>Unlikely</td>
</tr>
<tr>
<td>warfarin</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>zalcitabine</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td>ziprasidone</td>
<td>No</td>
<td>Unlikely</td>
</tr>
<tr>
<td>zolpidem</td>
<td>No</td>
<td>Unlikely</td>
</tr>
</tbody>
</table>
Anaphylaxis: Treatment guidelines

A hypersensitivity reaction may occur when a patient comes in contact with a certain agent, such as a drug, food, or other foreign protein. In some patients, this reaction progresses to life-threatening anaphylaxis, marked by sudden development of urticaria and respiratory distress. If this reaction continues, it may precipitate vascular collapse, leading to shock and, occasionally, death.

**Hypersensitivity reaction**

**Adults:** Epinephrine 0.2 to 0.5 ml of 1:1,000 solution subcutaneously or intramuscularly; repeat q 10 to 15 minutes to maximum dosage of 1 mg.

**Children:** Epinephrine 10 mcg/kg of 1:1,000 solution subcutaneously or intramuscularly, to maximum of 500 mcg/dose; may repeat q 15 minutes for 2 doses, then q 4 hours p.r.n.

**Adults or children:** Diphenhydramine 1 to 2 mg/kg I.V. or I.M.

**Admistrator CPR if patient loses circulation or breathing; follow Advanced Cardiac Life Support guidelines.**

**Anaphylaxis**

**Adults and children:** If bronchospasm occurs, give 1 to 2 nebulized treatments of inhaled bronchodilator and consider loading dose of 6 mg/kg theophylline I.V., followed by maintenance dose as indicated.

**Adults:** Epinephrine 0.2 to 0.5 ml of 1:1,000 solution subcutaneously or intramuscularly; repeat q 10 to 15 minutes to maximum dosage of 1 mg.

**Children:** Epinephrine 10 mcg/kg of 1:1,000 solution subcutaneously or intramuscularly; to maximum of 500 mcg/dose; may repeat dose q 15 minutes for 2 doses, then q 4 hours as needed

If patient doesn’t respond, dilute epinephrine to yield 1:10,000 solution. For adults, infuse at 1 mcg/minute; may titrate to 2 to 10 mcg/minute. For children, infuse at 0.1 mcg/kg/minute.

**KEY:**

CPR: cardiopulmonary resuscitation
Adult cardiac arrest: Treatment guidelines

If you suspect your patient is in cardiac arrest, take appropriate steps, as described below.

Assess responsiveness.

Unresponsive

Begin primary survey. Activate emergency response system. Call for defibrillator. 
Assess breathing (open airway; look, listen, and feel for breathing).

Not breathing

Give two breaths. Assess pulse, if pulseless, start chest compressions. Continue CPR for 2 minutes (5 cycles of 30 compressions to 2 breaths). Assess pulse and cardiac rhythm. Attach monitor or defibrillator.

No pulse

Initiate CPR (5 cycles of 30 compressions to 2 breaths) for 2 minutes. Assess cardiac rhythm.

VF or VT on monitor

Administer CPR until defibrillator charged: give 1 shock (360j for monophasic defibrillator; 200j for biphasic defibrillator). Immediately restart CPR for 2 minutes. After 2 minutes, check cardiac rhythm and pulse; if VF or VT, give 1 shock (360j for monophasic defibrillator or 200 to 300j for biphasic defibrillator). Start CPR immediately after the shock is delivered. Continue CPR for 2 minutes. Assess pulse and cardiac rhythm.

Asystole or PEA on monitor

Administer CPR for 2 minutes. After 2 minutes of CPR, check cardiac rhythm and pulse, then immediately restart CPR if PEA and asystole persist. Always verify asystole in 2 leads.

Conduct secondary ABCD survey

Airway: Attempt to insert airway device. Once an advanced airway is in place, give 8 to 10 breaths/minute and continuous chest compressions at 100 per minutes.
Breathing: Confirm and secure airway device; provide ventilation and oxygenation.
Circulation: Obtain I.V. or I.O. access, administer adrenergic drug; consider antiarrhythmics, buffer agents, and pacing. For asystole or PEA, give epinephrine 1 mg I.V.; repeat every 3 to 5 minutes. Give vasopressin 40 units to replace the first or second dose of epinephrine. For PEA with a rate less than 60/minute, consider atropine 1 mg every 3 to 5 minutes for a total dose of 3 mg. For VF/VT, give epinephrine 1 mg I.V or I.O.; repeat every 3 to 5 minutes. May use vasopressin 40 units to replace the first or second dose of epinephrine.
Differential diagnosis: Search for and treat reversible causes.

KEY
ABCD: airway, breathing, circulation, differential diagnosis
CPR: cardiopulmonary resuscitation
I.O.: intraosseous
PEA: pulseless electrical activity
VF: ventricular fibrillation
VT: ventricular tachycardia
Pediatric cardiac arrest: Treatment guidelines

For a pediatric patient in suspected cardiac arrest, take the following steps.

Assess responsiveness.

Unresponsive
Begin primary survey. Activate emergency response system. Attach monitor/defibrillator as soon as available. Assess breathing (open airway; look, listen, and feel for breathing).

Not breathing
Give two breaths that make the chest rise. Assess pulse. Start chest compressions (5 cycles of 30 compressions to 2 breaths) if patient is pulseless.

No pulse
Continue CPR. Assess heart rhythm.

VF or VT on monitor
Attempt defibrillation. Deliver 1 shock at 2 J/kg. Resume CPR immediately for 2 minutes. After 2 minutes, if VF or pulseless VT continues, deliver 1 shock at 4 J/kg. Give epinephrine I.V. or I.O. at 0.01 mg/kg. Resume CPR immediately for 2 minutes. After 2 minutes, if VF or pulseless VT continues, deliver 1 shock at 4 J/kg.

Asystole or PEA on monitor
Give epinephrine 0.01 mg/kg I.V. or I.O. Continue CPR for 2 minutes then reassess; pulse and cardiac rhythm. Always verify asystole in 2 leads.

Conduct secondary ABCD survey

Airway: Attempt to insert airway device.
Breathing: Confirm and secure airway device; ventilate and oxygenate.
Circulation: Obtain I.V. access; defibrillate and give drugs as appropriate.
*For VF/VT, give epinephrine 0.01 mg/kg (0.1 ml/kg of 1:10,000 solution) I.V. or I.O.; repeat q 3 to 5 minutes; then consider amiodarone or lidocaine. For asystole, give epinephrine 0.01 mg/kg (0.1 ml/kg of 1:10,000 solution) I.V. or I.O.; repeat q 3 to 5 minutes.
Differential diagnosis: Search for and treat reversible causes, including hypoxemia, hypovolemia, metabolic disorders, and thromboembolism.

KEY
ABDC: airway, breathing, circulation, differential diagnosis
CPR: cardiopulmonary resuscitation
I.O.: intraosseous
J: joules
PEA: pulseless electrical activity
VF: ventricular fibrillation
VT: ventricular tachycardia
Acute coronary syndrome: Treatment guidelines

Immediate assessment (within 10 minutes):
- Measure vital signs and oxygen saturation.
- Obtain I.V. access, 12-lead ECG, and initial serum cardiac marker levels.
- Perform brief history and physical exam; review/complete fibrinolytic eligibility and contraindications.
- Obtain initial electrolyte and coagulation studies and cardiac marker levels.
- Request and review portable chest x-ray within 30 minutes.

Start adjunctive treatments (as indicated; do not delay reperfusion therapy)
- Beta-adrenergic blockers I.V.
- Nitroglycerin I.V., heparin I.V.
- Clopidogrel, GPIIb/IIIa inhibitors, heparin (UFH or LMWH)

Choose reperfusion strategy based on local resources.
- Angiography
- PCI (angioplasty +/- stent)

Fibrinolytic therapy chosen:
- alteplase or
- reteplase or
- tenecteplase
Goal: Door-to-drug within 30 minutes

Primary PCI chosen:
- Door-to-balloon inflation within 90 minutes
- Experienced operators
- High-volume medical center
- Cardiac surgical capability

Time from symptom onset?
- < 12 hours
- > 12 hours

Assess initial 12-lead ECG.

Chest pain suggestive of ischemia

ST elevation or new LBBB (strongly suggests injury) • ST-elevation AMI

KEY
ACE: angiotensin-converting enzyme
AMI: acute myocardial infarction
APSAC: anisoylated plasminogen streptokinase activator complex
LBBB: left bundle-branch block
PCI: percutaneous coronary intervention
Immediate general treatment:
- Oxygen at 4 L/minute
- Aspirin 160 to 325 mg (may be given by EMS).
- Nitroglycerin S.L. or by spray or I.V.
- Morphine I.V. (if nitroglycerin does not relieve pain).

Use MONA as memory aid: Morphine, Oxygen, Nitroglycerin, Aspirin.

EMS personnel can perform immediate assessment and treatment, including 12-lead ECG and review for fibrinolytic eligibility and administering aspirin, nitroglycerin and morphine.

- ST depression or dynamic T-wave inversion (strongly suggests ischemia)
- High-risk unstable angina/non-ST-elevation AMI

Start adjunctive treatments (as indicated, no contraindications):
- Heparin (UFH or LMWH)
- Clopidogrel
- Glycoprotein IIb/IIIa inhibitors
- Nitroglycerin I.V.
- Beta-adrenergic receptor blockers

Meets criteria for unstable or new-onset angina? Or troponin positive?

Yes

- Non-diagnostic ECG: no ST segment or T-wave changes
- Intermediate- or low-risk unstable angina

No

Assess clinical status.

High-risk patient, defined by:
- persistent symptoms
- recurrent ischemia
- depressed left ventricular function
- widespread ECG changes
- previous AMI, PCI, or CABG.

Admit to monitored bed.
- Obtain serial serum markers (including troponin).
- Repeat ECG/continuous ST monitoring.
- Consider imaging study.

Evidence of ischemia or infarction?

No

Oxygen at 4 L/minute
Aspirin 160 to 325 mg (may be given by EMS).
Nitroglycerin S.L. or by spray or I.V.
Morphine I.V. (if nitroglycerin does not relieve pain).

High-risk patient, defined by:
- persistent symptoms
- recurrent ischemia
- depressed left ventricular function
- widespread ECG changes
- previous AMI, PCI, or CABG.

Admit to critical care unit.
- Continue or start treatment.
- Obtain serial cardiac markers and ECG.
- Consider imaging study.

Clinically stable?

No

Revascularization:
- PCI
- CABG

Yes

Discharge acceptable
- Arrange follow-up

No

Immediate general treatment:
- Oxygen at 4 L/minute
- Aspirin 160 to 325 mg (may be given by EMS).
- Nitroglycerin S.L. or by spray or I.V.
- Morphine I.V. (if nitroglycerin does not relieve pain).

Use MONA as memory aid: Morphine, Oxygen, Nitroglycerin, Aspirin.
This algorithm for the treatment of cerebrovascular accident (stroke) or suspected stroke is based on the one created by the American Heart Association.

**Suspected stroke**

**Within 10 minutes of ED arrival, conduct immediate general assessment and stabilization:**
- Assess ABCs and vital signs.
- Give oxygen if hypoxemic.
- Obtain I.V. access; draw blood.
- Check blood glucose level; treat accordingly.
- Obtain 12-lead ECG.
- Perform neurocheck.
- Alert stroke team.
- Obtain emergency non-contrast CT of the head.

**Within 25 minutes of ED arrival, conduct immediate neurological assessment by stroke team or designee:**
- Review patient history.
- Establish symptom onset.
- Perform neurological examination (NIH Stroke Scale or Canadian Neurological Scale).

**Within 45 minutes of ED arrival, review/read/evaluate CT—Does CT show evidence of hemorrhage?**

- **Yes**
  - Consult neurosurgery. Consider transfer if neurosurgery not available.
  - Treat for acute hemorrhage per neurosurgery protocols or plan of care
    - Reverse anticoagulants and bleeding disorder.
    - Monitor neurologic status.
    - Treat hypertension if patient is conscious.

- **No**
  - Patient is candidate for fibrinolytic therapy?
    - **No to above**
      - Within 60 minutes of ED arrival:
        - Obtain informed consent and review risks and benefits with patient and family
        - Begin fibrinolytic therapy.
        - Monitor neurologic status; obtain CT scan if condition deteriorates.
        - Monitor BP; treat as indicated.
        - Admit to CCU or stroke unit.
        - Withhold anticoagulants and antiplatelet drugs for 24 hours.
    - **Yes**
      - Within 25 minutes of ED arrival, conduct immediate neurological assessment by stroke team or designee:
        - Review patient history.
        - Establish symptom onset.
        - Perform neurological examination (NIH Stroke Scale or Canadian Neurological Scale).

- **Blood on LP**
  - If high suspicion of SAH despite negative CT, perform LP.
  - No blood on LP
  - Initiate ongoing therapies.

**Probable ischemic stroke; consider fibrinolytic therapy**
- CT scan exclusions?
- Improving neurologic deficits?
- Fibrinolytic exclusions?
- Symptom onset < 3 hours?

**Within 25 minutes of ED arrival, conduct immediate neurological assessment by stroke team or designee:**
- Review patient history.
- Establish symptom onset.
- Perform neurological examination (NIH Stroke Scale or Canadian Neurological Scale).

**Yes**
- Consult neurosurgery. Consider transfer if neurosurgery not available.
- Treat for acute hemorrhage per neurosurgery protocols or plan of care
  - Reverse anticoagulants and bleeding disorder.
  - Monitor neurologic status.
  - Treat hypertension if patient is conscious.

**No**
- Patient is candidate for fibrinolytic therapy?
  - **No to above**
    - Within 60 minutes of ED arrival:
      - Obtain informed consent and review risks and benefits with patient and family
      - Begin fibrinolytic therapy.
      - Monitor neurologic status; obtain CT scan if condition deteriorates.
      - Monitor BP; treat as indicated.
      - Admit to CCU or stroke unit.
      - Withhold anticoagulants and antiplatelet drugs for 24 hours.
  - **Yes**
    - Within 25 minutes of ED arrival, conduct immediate neurological assessment by stroke team or designee:
      - Review patient history.
      - Establish symptom onset.
      - Perform neurological examination (NIH Stroke Scale or Canadian Neurological Scale).

**No to above**
- Within 45 minutes of ED arrival, review/read/evaluate CT—Does CT show evidence of hemorrhage?
- **Yes**
  - Consult neurosurgery. Consider transfer if neurosurgery not available.
  - Treat for acute hemorrhage per neurosurgery protocols or plan of care
    - Reverse anticoagulants and bleeding disorder.
    - Monitor neurologic status.
    - Treat hypertension if patient is conscious.
- **No**
  - Patient is candidate for fibrinolytic therapy?
    - **No**
      - Within 60 minutes of ED arrival:
        - Obtain informed consent and review risks and benefits with patient and family
        - Begin fibrinolytic therapy.
        - Monitor neurologic status; obtain CT scan if condition deteriorates.
        - Monitor BP; treat as indicated.
        - Admit to CCU or stroke unit.
        - Withhold anticoagulants and antiplatelet drugs for 24 hours.
    - **Yes**
      - Within 25 minutes of ED arrival, conduct immediate neurological assessment by stroke team or designee:
        - Review patient history.
        - Establish symptom onset.
        - Perform neurological examination (NIH Stroke Scale or Canadian Neurological Scale).

**No**
- If high suspicion of SAH despite negative CT, perform LP.
- No blood on LP
- Initiate ongoing therapies.

**ABCs:** airway, breathing, and circulation
**BP:** blood pressure
**CCU:** critical care unit
**CT:** computed tomography
**ECG:** electrocardiogram
**ED:** emergency department
**LP:** lumbar puncture
**SAH:** subarachnoid hemorrhage
Guidelines for handling, preparing, and administering hazardous drugs

Healthcare professionals who work with or near hazardous drugs may be exposed to these agents in the air; on work surfaces, clothing, or medical equipment; or through contact with patient urine or feces. Hazardous drugs include many cancer chemotherapy agents, antivirals, hormones, and certain miscellaneous drugs. (Follow these hazardous drug guidelines for handling, preparation, and administration of all drugs with the special “hazardous drug” icon [ ] at the top of the monograph.)

The safety of healthcare workers who handle hazardous drugs is an ongoing concern. More than 5 million healthcare workers, including nurses, pharmacists, and physicians, are thought to be at risk. The greatest exposure occurs during preparation, administration, and disposal of these agents. In 2004, the National Institute for Occupational Safety and Health (NIOSH) issued an alert to inform workers of the possible risks of hazardous drugs. The alert included the following:

Warning! Working with or near hazardous drugs in healthcare settings may cause skin rashes, infertility, miscarriage, birth defects, and possibly leukemia or other cancers.

In 2006, the American Society of Health-System Pharmacists (ASHP) published revised guidelines on handling hazardous drugs. The following guidelines reflect the latest recommendations of ASHP, NIOSH, and the Centers for Disease Control and Prevention.

General preparation

- Read all material safety data sheets for each hazardous drug you handle.
- Prepare hazardous drugs in a controlled area designated for that purpose alone and restricted to authorized personnel. Identify these areas clearly with warning signs.
- Prepare hazardous drugs inside a ventilated cabinet with negative air pressure, to avoid spread of airborne drug contaminants and protect drugs that require sterile handling.
- Always work below eye level, within easy reach of a spill kit and a hazardous drug waste container.
- Use stringent sterile technique during any procedure in which sterile dosage forms are manipulated with needles and syringes.
- Whenever possible, use luer-lock syringes, I.V. administration sets, and connections, as these are less likely to separate during preparation.
- When supplemental protection is needed, use closed-system drug-transfer devices, glove bags, and needleless systems inside the ventilated cabinet.
- Know that hazardous drugs must be clearly labeled. Preparation and cleaning areas also need to be identified with warning signs or labels that are clear to non-English readers.

Personal protective equipment

Always wear personal protective equipment (PPE) during any activity involving hazardous drugs, including:
reconstituting or admixing these drugs
- handling vials or finished products
- opening drug packaging
- assembling the delivery system
- administering these drugs
- labeling hazardous containers
- disposing of drug-related waste
- handling excretions from patients who have received hazardous drugs.

Gloves
- Wear two pairs of powder-free gloves. Make sure the inner pair is beneath the cuff of your gown and the outer pair covers the outside cuff.
- Before donning gloves, inspect them for defects.
- Remove the outer gloves after wiping down the final drug preparation but before labeling or removing it from the designated area. Place these gloves in a containment bag.
- Use clean gloves (the inner pair) to wipe the surface of the container, put the label on the final preparation, and place the drug container into the pass-through.
- Don fresh gloves to complete the final check and place the container for transport.
- Change gloves every 30 minutes during compounding, or immediately if damaged or contaminated.

Gown
Wear a disposable, nonabsorbent gown made of polypropylene material with a closed front, long sleeves, and elastic cuffs.

Face and eye shield
Wear a face or eye shield (as appropriate) if splashes, sprays, or aerosolizations to the eyes, nose, or mouth are possible during drug handling or administration.

Proper sequence for donning PPE
After washing your hands, don the first pair of gloves, then the gown and face shield (as appropriate), and then the second pair of gloves (which should extend beyond the cuff of your gown).

Dose reconstitution
- Avoid pressurizing vial contents, as this may cause the drug to spray out around or through the needle. To avoid pressurization, draw air into the syringe to create negative pressure in the vial.
- Transfer small amounts of diluent slowly as equal volumes of air are removed.
- Keeping the needle in the vial, swirl contents slowly until they dissolve.
- Make sure the syringe is no more than three-quarters full when it holds the final drug dosage.

Dose withdrawal and transfer
- Keeping the vial inverted, withdraw only the proper amount of drug solution.
- Remove the needle with the vial upright, making sure the needle hub is clear.
- To withdraw a dose from an ampule, gently tap the neck of the ampule. Then wipe the neck with alcohol and attach a 5-micron filter needle to a syringe. Draw the solution through the needle, clearing it from the needle and hub.
- If the drug will be dispensed in the syringe, draw back the plunger to clear fluid from the needle and hub. Replace the needle with a locking cap, and then wipe and lock the syringe.
- When using a needleless system, use gauze pads at connection points to contain leaks.
- If the drug will be transferred to an I.V. bag or bottle, prime the I.V. set before adding the drug. Puncture only the septum of the injection port. After injecting the drug solution into the bag, wipe the port, container, and I.V. set (if attached).
- Once drug preparation is complete, seal the final product in a plastic bag or other sealable container for transport.

(continued)
before taking it out of the ventilated cabinet; then label it with a unique identifier. Seal and wipe all waste containers inside the ventilated cabinet before removal. Finally, remove your outer gloves and sleeve covers (if used) and bag them while still inside the ventilated cabinet.

### Administration

- Wash your hands and don gloves and gown. If spraying, splashing, or aerosolization is anticipated, wear a face shield or goggles.
- Visually examine the drug dose while it’s still in the transport bag. If it appears intact, remove it from the bag.
- Place an absorbent pad on the work or administration area to contain spills or contamination.

### Oral (noninjectable or nonparenteral) administration

- Oral hazardous drugs should be dispensed in the final dosage and form whenever possible.
- Avoid crushing tablets or opening capsules; instead, use liquid forms whenever possible.
- Never crush or compound an oral drug in an unprotected environment.
- Be aware that liquid hazardous drugs should be dispensed and maintained in sealable plastic bags.

### I.M. or subcutaneous administration

- Remove the syringe cap and connect the appropriate safety needle.
- Don’t expel air from the syringe or prime the safety needle.
- After administering the dose, discard the syringe (with safety needle attached) directly into an appropriate waste container.

### I.V. administration

- If priming is necessary at the administration site, prime the I.V. tubing with an I.V. solution that doesn’t contain a hazardous drug, or by using the backflow method.
- Place gauze pads under the connections at injection ports to catch leaks during administration.
- Use the transport bag as a containment bag for contaminated materials. Discard hazardous drug bags and bottles with their administration sets attached.

### Disposal and clean-up

- Handle hazardous wastes and contaminated materials separately from other trash.
- Wash surfaces contaminated with hazardous drugs with detergent, hypochlorite solution, and neutralizer, as appropriate.
- Clean and decontaminate work areas before and after each hazardous drug-handling activity and at the end of each shift. Clean up small spills immediately.
- Dispose of drug-contaminated syringes and needles in puncture-proof containers labeled “Chemotherapy waste” or “Hazardous waste.”
- Never push or force materials contaminated with hazardous drugs into waste containers.

### After exposure to a hazardous drug

- In case of skin contact with a cytotoxic drug, immediately remove contaminated clothing and wash the affected area with soap and water. Don’t scrub, because this will abrade the skin. Rinse the area thoroughly, and consult a physician for further treatment and monitoring.
- In case of eye contact, flush the affected eye with water or normal saline solution continuously for 15 minutes. Consult a physician for further treatment and monitoring.
- Document the exposure incident in your employee record and your facility’s medical surveillance log.
Managing poisonings and overdoses

This chart serves as a quick reference for managing poisonings and drug overdoses. For more detailed instructions, consult your local poison control center. To find your local center, call the American Association of Poison Control Centers at 1-800-222-1222 or visit http://www.aapcc.org/findyour.htm.

<table>
<thead>
<tr>
<th>Poison or drug</th>
<th>Antidote and dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>acetaminophen</td>
<td>acetylcysteine (Acetadote, Mucomyst)</td>
</tr>
<tr>
<td></td>
<td>Give P.O. as 5% solution by diluting with carbonated beverage or fruit juice.</td>
</tr>
<tr>
<td></td>
<td>Loading dose: 140 mg/kg followed by 17 additional doses of 70 mg/kg q 4 hours. Repeat dose if patient vomits within 1 hour of administration.</td>
</tr>
<tr>
<td></td>
<td>I.V. dose: 150 mg/kg over 15 minutes.</td>
</tr>
<tr>
<td></td>
<td>Maintenance dose: 50 mg/kg infused over 4 hours, followed by 100 mg/kg infused over 16 hours.</td>
</tr>
<tr>
<td>anticholinergic agents</td>
<td>physostigmine (Antilirium)</td>
</tr>
<tr>
<td>antihistamines atropine</td>
<td>Adults: 0.5 to 2 mg slow I.V. injection (not to exceed 1 mg/minute). May repeat q 20 minutes until response or adverse effects occur.</td>
</tr>
<tr>
<td></td>
<td>If initial dose is effective, additional doses of 1 to 4 mg may be given q 30 to 60 minutes as life-threatening signs (arrhythmias, seizures, deep coma) recur.</td>
</tr>
<tr>
<td></td>
<td>Children: 0.02 mg/kg I.M. or slow I.V. injection (not to exceed 0.5 mg/minute). May repeat q 5 to 10 minutes until therapeutic response occurs or maximum dosage of 2 mg is given.</td>
</tr>
<tr>
<td>arsenic trioxide</td>
<td>dimercaprol (BAL)</td>
</tr>
<tr>
<td></td>
<td>Adults: 3 mg/kg I.M. q 4 hours until immediate life-threatening toxicity has subsided. Thereafter, give penicillamine 250 mg P.O. up to maximum frequency of four times daily (maximum: 1 g/day).</td>
</tr>
<tr>
<td>benzodiazepines</td>
<td>flumazenil (Romazicon)</td>
</tr>
<tr>
<td></td>
<td>Adults: Initially, 0.2 mg I.V. injected over 30 seconds; follow with 0.3 mg if desired level of consciousness isn’t reached. May give further doses of 0.5 mg at 60-second intervals until therapeutic response occurs or cumulative dosage of 3 mg is given. If partial response is achieved at 3 mg, patients may rarely need additional doses up to a total of 5 mg. If sedation recurs, repeat dose at 20-minute intervals. Maximum dosage is 3 mg/hour.</td>
</tr>
<tr>
<td></td>
<td>Children: Initially 0.01 mg/kg (maximum dosage 0.2 mg) with repeat doses of 0.01 mg/kg (maximum dosage 0.2 mg) given q minute to maximum cumulative dosage of 1 mg.</td>
</tr>
<tr>
<td>calcium channel blockers</td>
<td>activated charcoal</td>
</tr>
<tr>
<td></td>
<td>Consider prehospital administration of activated charcoal as a slurry in patient with potentially toxic ingestion who is awake and able to protect airway. Use minimum of 240 ml water/30 g charcoal.</td>
</tr>
<tr>
<td></td>
<td>Adults and adolescents: Usual dosage, 25 to 100 g P.O.</td>
</tr>
<tr>
<td></td>
<td>Children ages 1 to 12: 25 to 50 g P.O. (or 0.5 to 1 g/kg)</td>
</tr>
<tr>
<td></td>
<td>Children &lt; age 1: 0.5 to 1 g/kg P.O.</td>
</tr>
<tr>
<td>Poison or drug</td>
<td>Antidote and dosage</td>
</tr>
<tr>
<td>---------------</td>
<td>---------------------</td>
</tr>
<tr>
<td><strong>calcium chloride</strong></td>
<td>Adults: If massive overdose occurs with hypotension remaining unresponsive to supportive measures, administer vaspressors (such as phenylephrine) as prescribed. Calcium gluconate 2 g/hour I.V. titrated to maintain blood pressure has been used successfully.</td>
</tr>
<tr>
<td><strong>cholinergic agonists</strong></td>
<td><strong>activated charcoal</strong> Administer charcoal as a slurry (240 ml water/30 g charcoal). <strong>Adults and adolescents:</strong> Usual dosage, 25 to 100 g P.O. <strong>Children ages 1 to 12:</strong> 25 to 50 g P.O. <strong>Children &lt; age 1:</strong> 1 g/kg P.O.</td>
</tr>
<tr>
<td><strong>atropine sulfate</strong></td>
<td>Atropine is the drug of choice for significant muscarinic symptoms. <strong>Adults:</strong> 2 to 4 mg I.V., repeated q 3 to 60 minutes as needed to control symptoms, then p.r.n. for 24 to 48 hours <strong>Children:</strong> 0.04 to 0.08 mg/kg I.V. (up to 4 mg), repeated q 5 to 60 minutes as needed</td>
</tr>
<tr>
<td><strong>epinephrine</strong></td>
<td>Epinephrine may help overcome severe cardiovascular or bronchoconstrictor responses. <strong>Adults:</strong> 0.1 to 1 mg subcutaneously</td>
</tr>
<tr>
<td><strong>digoxin</strong></td>
<td><strong>digoxin immune Fab (Digibind, DigiFab)</strong> Calculate dosage as number of 38-mg vials, using this formula: Digoxin level (in ng) × patient’s weight (in kg) divided by 100. Usual dosage range is four to six vials. If ingested amount of digoxin is unknown, give 10 to 20 vials (380 to 800 mg) I.V. over 30 minutes through a 0.22-micron filter. May give bolus dose if cardiac arrest is imminent.</td>
</tr>
<tr>
<td><strong>ethylene glycol</strong></td>
<td><strong>fomepizole (Antizol)</strong> Loading dose: 15 mg/kg I.V. over 30 minutes, followed by 10 mg/kg I.V. over 30 minutes q 12 hours for four doses Maintenance dose: 15 mg/kg I.V. over 30 minutes q 12 hours until ethylene glycol level falls below 20 mg/dl</td>
</tr>
<tr>
<td><strong>heparin</strong></td>
<td><strong>protamine sulfate</strong> Dosage is based on partial thromboplastin time; usually, 1 mg for each 100 units of heparin. Give I.V. over 10 minutes (maximum rate of 5 mg/minute) in doses not exceeding 50 mg. Patients allergic to fish, vasectomized or infertile men, and patients taking protamine-insulin products are at increased risk for protamine hypersensitivity.</td>
</tr>
<tr>
<td><strong>hypercalcemic emergency</strong></td>
<td><strong>edetate disodium (Endrate)</strong> <strong>Adults:</strong> 50 mg/kg/day by slow I.V. infusion over at least 3 hours, up to a maximum of 3 g/day. <strong>Children:</strong> 40 mg/kg/day by slow I.V. infusion over at least 3 hours, up to a maximum of 70 mg/kg/day. Dilute with normal saline solution or dextrose 5% in water; don’t infuse rapidly. Keep patient in bed for 15 minutes after infusion to avoid orthostatic hypotension. Keep I.V. calcium readily available, because drug may cause profound hypocalcemia, leading to tetany, seizures, arrhythmias, and respiratory arrest. Alternate I.V. sites daily to decrease risk of thrombophlebitis. <strong>Alert:</strong> Do not confuse drug with edetate calcium disodium, used as lead poisoning antidote.</td>
</tr>
</tbody>
</table>

(continued)
Managing poisonings and overdoses (continued)

<table>
<thead>
<tr>
<th>Poison or drug</th>
<th>Antidote and dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>iron</td>
<td>deferoxamine (Desferal)</td>
</tr>
<tr>
<td></td>
<td><strong>Acute iron intoxication:</strong> Initially, 1 g I.M., followed by 500 mg q 4 hours for two doses depending on clinical response, and then 500 mg q 4 to 12 hours, up to 6 g/day. May give I.V. infusion of 10 to 15 mg/kg/hour for first 1 g. Subsequent doses shouldn’t exceed 125 mg/hour. Maximum dosage is 6 g in 24 hours.</td>
</tr>
<tr>
<td></td>
<td><strong>Chronic iron intoxication:</strong> In adults, 1 to 2 g/day subcutaneously. In children, maximum dosage of 2 g/day subcutaneously.</td>
</tr>
<tr>
<td>opioid overdose and dependence</td>
<td>naloxone hydrochloride (Narcan)</td>
</tr>
<tr>
<td></td>
<td><strong>Opioid overdose</strong></td>
</tr>
<tr>
<td></td>
<td>Adults: 0.4 to 2 mg I.V., I.M., or subcutaneously; repeat q 2 to 3 minutes, p.r.n., up to 10 mg</td>
</tr>
<tr>
<td></td>
<td>If ordered, give initial adult dose of 0.1 mg I.V. to assess patient’s response. Give subsequent doses of 0.4 mg or less (undiluted) by direct injection over 15 seconds, or titrate based on response. As needed, give continuous I.V. infusion, diluting 2 mg of naloxone with 500 ml of normal saline solution or dextrose 5% in water for a final concentration of 4 mcg/ml; titrate based on patient’s response.</td>
</tr>
<tr>
<td></td>
<td><strong>Children &gt; age 5 or ≥ 20 kg:</strong> 2 mg/dose; repeat q 2 to 3 minutes.</td>
</tr>
<tr>
<td></td>
<td><strong>Children &lt; age 5 or &lt; 20 kg:</strong> 0.1 mg/kg; repeat q 2 to 3 minutes.</td>
</tr>
<tr>
<td></td>
<td><strong>Postoperative opioid-induced respiratory depression</strong></td>
</tr>
<tr>
<td></td>
<td>Adults: 0.1 to 0.2 mg I.V. q 2 to 3 minutes, p.r.n.</td>
</tr>
<tr>
<td></td>
<td>Children: 0.005 to 0.01 mg/kg q 2 to 3 minutes.</td>
</tr>
<tr>
<td></td>
<td><strong>Opioid dependence</strong></td>
</tr>
<tr>
<td></td>
<td>naltrexone (Depade, ReVia)</td>
</tr>
<tr>
<td></td>
<td>Adults: Initially, 25 mg P.O.; give an additional dose of 25 mg if no withdrawal symptoms occur within 1 hour. When patient is receiving 50 mg q 24 hours, a maintenance schedule of 50 to 150 mg/day P.O. may be used. Don’t initiate therapy until patient has been opiate-free for 7 to 10 days; do not begin for opioid dependence until a naloxone challenge test has been given.</td>
</tr>
<tr>
<td></td>
<td><strong>Alert:</strong> Do not confuse naltrexone with naloxone.</td>
</tr>
<tr>
<td>organophosphate insecticides</td>
<td>pralidoxime (Protopam)</td>
</tr>
<tr>
<td>Adults: 1 to 2 g I.V. in 100 ml of normal saline solution infused over 15 to 30 minutes. If pulmonary edema occurs, may give as 5% solution I.V. over 5 minutes. May repeat dose in 1 hour if muscle weakness persists; may give additional doses at 10- to 12-hour intervals cautiously if muscle weakness continues.</td>
<td></td>
</tr>
<tr>
<td>Children: 20 to 50 mg/kg (up to 1 g) in 250 ml normal saline solution I.V. over 30 minutes</td>
<td></td>
</tr>
<tr>
<td>warfarin</td>
<td>phytonadione (Vitamin K)</td>
</tr>
<tr>
<td>Adults: 2.5 to 10 mg subcutaneously, based on prothrombin time/International Normalized Ratio; may repeat in 6 to 8 hours as needed. In emergency, 2.5 to 25 mg slow I.V. (no faster than 1 mg/minute); may repeat 6 to 8 hours after first dose.</td>
<td></td>
</tr>
<tr>
<td>miscellaneous drug overdose</td>
<td>activated charcoal</td>
</tr>
<tr>
<td>Adults: 1 to 2 g/kg with at least a 10:1 ratio of activated charcoal to intoxicant (usual dose is 25 to 100 g charcoal in water or sorbitol) and administered P.O. or by nasogastric tube. Do not give doses greater than 100 g.</td>
<td></td>
</tr>
<tr>
<td>Children: 1 to 2 g/kg or 25 to 50 g charcoal.</td>
<td></td>
</tr>
<tr>
<td>The use of repeated oral charcoal with sorbitol doses is not recommended.</td>
<td></td>
</tr>
</tbody>
</table>
2010 Nursing Spectrum Drug Handbook
Photogallery of common tablets and capsules
This special section helps you identify unlabeled drugs that patients bring from home. It can also serve as a visual aid for patients who can’t recall the names of the drugs they’re taking. (Note: For more help in identifying medications, see the drug imprint codes at www.nursesdrughandbook.com.) Drugs are shown alphabetically by generic name; corresponding trade names also appear. Dosage forms appear in increasing order of strength.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Strengths</th>
</tr>
</thead>
<tbody>
<tr>
<td>alendronate sodium</td>
<td><strong>Fosamax</strong></td>
</tr>
<tr>
<td></td>
<td>5 mg</td>
</tr>
<tr>
<td></td>
<td>10 mg</td>
</tr>
<tr>
<td></td>
<td>35 mg</td>
</tr>
<tr>
<td></td>
<td>70 mg</td>
</tr>
<tr>
<td>alprazolam</td>
<td><strong>Xanax</strong></td>
</tr>
<tr>
<td></td>
<td>0.25 mg</td>
</tr>
<tr>
<td></td>
<td>0.5 mg</td>
</tr>
<tr>
<td></td>
<td>1 mg</td>
</tr>
<tr>
<td></td>
<td>2 mg</td>
</tr>
<tr>
<td>amlodipine besylate</td>
<td><strong>Norvasc</strong></td>
</tr>
<tr>
<td></td>
<td>2.5 mg</td>
</tr>
<tr>
<td></td>
<td>5 mg</td>
</tr>
<tr>
<td></td>
<td>10 mg</td>
</tr>
<tr>
<td>amlodipine besylate and benazepril</td>
<td><strong>Lotrel</strong></td>
</tr>
<tr>
<td>hydrochloride</td>
<td>2.5 mg/10 mg</td>
</tr>
<tr>
<td></td>
<td>5 mg/10 mg</td>
</tr>
<tr>
<td></td>
<td>5 mg/20 mg</td>
</tr>
<tr>
<td></td>
<td>5 mg/40 mg</td>
</tr>
<tr>
<td></td>
<td>10 mg/20 mg</td>
</tr>
<tr>
<td></td>
<td>10 mg/40 mg</td>
</tr>
<tr>
<td>amoxicillin trihydrate</td>
<td><strong>Amoxil</strong></td>
</tr>
<tr>
<td></td>
<td>125 mg</td>
</tr>
<tr>
<td></td>
<td>250 mg</td>
</tr>
<tr>
<td></td>
<td>500 mg</td>
</tr>
<tr>
<td></td>
<td>875 mg</td>
</tr>
<tr>
<td>Amoxicillin trihydrate</td>
<td><strong>Amoxicillin (continued)</strong></td>
</tr>
<tr>
<td>------------------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td></td>
<td>250 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Amoxicillin and clavulanate potassium</th>
<th><strong>Augmentin</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>200 mg/28.5 mg</td>
</tr>
<tr>
<td></td>
<td>500 mg/125 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Amphetamine sulfate combination</th>
<th><strong>Adderall</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5 mg</td>
</tr>
<tr>
<td></td>
<td>12.5 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Amphetamine sulfate combination</th>
<th><strong>Adderall XR</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5 mg</td>
</tr>
<tr>
<td></td>
<td>20 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Aripiprazole</th>
<th><strong>Abilify</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2 mg</td>
</tr>
<tr>
<td></td>
<td>15 mg</td>
</tr>
<tr>
<td>Drug</td>
<td>Tablet Brand</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>atomoxetine hydrochloride</td>
<td>Strattera</td>
</tr>
<tr>
<td>atorvastatin calcium</td>
<td>Lipitor</td>
</tr>
<tr>
<td>azithromycin</td>
<td>Zithromax</td>
</tr>
<tr>
<td>benazepril hydrochloride</td>
<td>Lotensin</td>
</tr>
<tr>
<td>bupropion hydrochloride</td>
<td>Wellbutrin</td>
</tr>
<tr>
<td>bupropion hydrochloride</td>
<td>Wellbutrin SR</td>
</tr>
<tr>
<td>carvedilol</td>
<td>Coreg</td>
</tr>
<tr>
<td>Drug Name</td>
<td>Common Name</td>
</tr>
<tr>
<td>-------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>cefprozil</td>
<td>Cefzil</td>
</tr>
<tr>
<td>celecoxib</td>
<td>Celebrex</td>
</tr>
<tr>
<td>cephalexin monohydrate</td>
<td>Keflex</td>
</tr>
<tr>
<td>ciprofloxacin hydrochloride</td>
<td>Cipro</td>
</tr>
<tr>
<td>citalopram hydrobromide</td>
<td>Celexa</td>
</tr>
<tr>
<td>clarithromycin</td>
<td>Biaxin</td>
</tr>
<tr>
<td>clarithromycin</td>
<td>Biaxin XL</td>
</tr>
<tr>
<td>clopidogrel bisulfate</td>
<td>Plavix</td>
</tr>
<tr>
<td>Medicine</td>
<td>Description</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>codeine/acetaminophen</td>
<td>Acetaminophen with Codeine</td>
</tr>
<tr>
<td>desloratadine</td>
<td>Clarinex</td>
</tr>
<tr>
<td>digoxin</td>
<td>Lanoxin</td>
</tr>
<tr>
<td>diltiazem hydrochloride</td>
<td>Tiazac</td>
</tr>
<tr>
<td>divalproex sodium</td>
<td>Depakote</td>
</tr>
<tr>
<td>divalproex sodium</td>
<td>Depakote ER</td>
</tr>
<tr>
<td>escitalopram oxalate</td>
<td>Lexapro</td>
</tr>
<tr>
<td>Drug Type</td>
<td>Brand</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>esomeprazole magnesium</td>
<td>Nexium</td>
</tr>
<tr>
<td>estrogens, conjugated</td>
<td>Premarin</td>
</tr>
<tr>
<td>ezetimibe</td>
<td>Zetia</td>
</tr>
<tr>
<td>fenofibrate</td>
<td>Tricor</td>
</tr>
<tr>
<td>fexofenadine hydrochloride</td>
<td>Allegra</td>
</tr>
<tr>
<td>fexofenadine hydrochloride and pseudoephedrine hydrochloride</td>
<td>Allegra-D</td>
</tr>
<tr>
<td>fluconazole</td>
<td>Diflucan</td>
</tr>
<tr>
<td></td>
<td>Medication</td>
</tr>
<tr>
<td>----------------</td>
<td>------------------</td>
</tr>
<tr>
<td>fluoxetine</td>
<td>Prozac</td>
</tr>
<tr>
<td>hydrochloride</td>
<td></td>
</tr>
<tr>
<td>fosinopril</td>
<td>Monopril</td>
</tr>
<tr>
<td>sodium</td>
<td></td>
</tr>
<tr>
<td>furosemide</td>
<td>Lasix</td>
</tr>
<tr>
<td>gabapentin</td>
<td>Neurontin</td>
</tr>
<tr>
<td>glimepiride</td>
<td>Amaryl</td>
</tr>
<tr>
<td>glipizide</td>
<td>Glucotrol</td>
</tr>
<tr>
<td>glipizide</td>
<td>Glucotrol XL</td>
</tr>
<tr>
<td>Category</td>
<td>Product</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Glyburide and metformin hydrochloride</td>
<td>Glucovance</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydrocodone bitartrate and acetaminophen</td>
<td>Lortab</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Ibuprofen</td>
<td>Motrin</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Irbesartan</td>
<td>Avapro</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Lansoprazole</td>
<td>Prevacid</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Levofloxacin</td>
<td>Levaquin</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Levothyroxine sodium</td>
<td>Levoxyl</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Medication</td>
<td>Dosage</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Synthroid</td>
<td>25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 300 mcg</td>
</tr>
<tr>
<td>Prinivil</td>
<td>2.5 mg, 5 mg, 10 mg, 20 mg, 40 mg</td>
</tr>
<tr>
<td>Zestril</td>
<td>2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg</td>
</tr>
<tr>
<td>Zestoretic</td>
<td>10 mg/12.5 mg, 20 mg/12.5 mg, 20 mg/25 mg</td>
</tr>
<tr>
<td>Ativan</td>
<td>0.5 mg, 1 mg, 2 mg</td>
</tr>
<tr>
<td>Cozaar</td>
<td>25 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>Losartan Potassium and Hydrochlorothiazide</td>
<td>Hyzaar</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>Memantine Hydrochloride</td>
<td>Namenda</td>
</tr>
<tr>
<td>Metformin Hydrochloride</td>
<td>Glucophage</td>
</tr>
<tr>
<td>Metformin Hydrochloride</td>
<td>Glucophage XR</td>
</tr>
<tr>
<td>Methylphenidate Hydrochloride</td>
<td>Concerta</td>
</tr>
<tr>
<td>Metoprolol Succinate</td>
<td>Toprol-XL</td>
</tr>
<tr>
<td>Montelukast Sodium</td>
<td>Singulair</td>
</tr>
<tr>
<td>Drug</td>
<td>Brand</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>nitrofurantoin macrocrystals</td>
<td>Macrodantin</td>
</tr>
<tr>
<td>nitrofurantoin monohydrate</td>
<td>Macrobid</td>
</tr>
<tr>
<td>olanzapine</td>
<td>Zyprexa</td>
</tr>
<tr>
<td>olmesartan medoxomil</td>
<td>Benicar</td>
</tr>
<tr>
<td>omeprazole</td>
<td>Prilosec</td>
</tr>
<tr>
<td>oxcarbazepine</td>
<td>Trileptal</td>
</tr>
<tr>
<td>oxybutynin chloride</td>
<td>Ditropan XL</td>
</tr>
<tr>
<td>oxycodone hydrochloride</td>
<td>OxyContin</td>
</tr>
<tr>
<td>pantoprazole sodium</td>
<td>Protonix</td>
</tr>
<tr>
<td>Product</td>
<td>Dosage</td>
</tr>
<tr>
<td>------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>paroxetine hydrochloride</td>
<td>Paxil</td>
</tr>
<tr>
<td></td>
<td>10 mg</td>
</tr>
<tr>
<td></td>
<td>20 mg</td>
</tr>
<tr>
<td></td>
<td>30 mg</td>
</tr>
<tr>
<td></td>
<td>40 mg</td>
</tr>
<tr>
<td>paroxetine hydrochloride</td>
<td>Paxil CR</td>
</tr>
<tr>
<td></td>
<td>12.5 mg</td>
</tr>
<tr>
<td></td>
<td>25 mg</td>
</tr>
<tr>
<td></td>
<td>37.5 mg</td>
</tr>
<tr>
<td>penicillin V potassium</td>
<td>Penicillin</td>
</tr>
<tr>
<td></td>
<td>250 mg</td>
</tr>
<tr>
<td></td>
<td>500 mg</td>
</tr>
<tr>
<td>phenytoin sodium (extended)</td>
<td>Dilantin</td>
</tr>
<tr>
<td></td>
<td>30 mg</td>
</tr>
<tr>
<td></td>
<td>100 mg</td>
</tr>
<tr>
<td>pioglitazone hydrochloride</td>
<td>Actos</td>
</tr>
<tr>
<td></td>
<td>15 mg</td>
</tr>
<tr>
<td></td>
<td>30 mg</td>
</tr>
<tr>
<td></td>
<td>45 mg</td>
</tr>
<tr>
<td>pravastatin sodium</td>
<td>Pravachol</td>
</tr>
<tr>
<td></td>
<td>10 mg</td>
</tr>
<tr>
<td></td>
<td>20 mg</td>
</tr>
<tr>
<td></td>
<td>40 mg</td>
</tr>
<tr>
<td></td>
<td>80 mg</td>
</tr>
<tr>
<td>propoxyphene napsylate and acetaminophen</td>
<td>Darvocet-N 50</td>
</tr>
<tr>
<td></td>
<td>50 mg</td>
</tr>
<tr>
<td>propoxyphene napsylate and acetaminophen</td>
<td>Darvocet-N 100</td>
</tr>
<tr>
<td></td>
<td>100 mg</td>
</tr>
<tr>
<td>quetiapine fumarate</td>
<td>Seroquel</td>
</tr>
<tr>
<td></td>
<td>25 mg</td>
</tr>
<tr>
<td></td>
<td>50 mg</td>
</tr>
<tr>
<td></td>
<td>100 mg</td>
</tr>
<tr>
<td></td>
<td>200 mg</td>
</tr>
<tr>
<td></td>
<td>300 mg</td>
</tr>
<tr>
<td></td>
<td>400 mg</td>
</tr>
<tr>
<td>Quinapril hydrochloride</td>
<td>Accupril</td>
</tr>
<tr>
<td>------------------------</td>
<td>----------</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Rabeprazole sodium</td>
<td>Aciphex</td>
</tr>
<tr>
<td>Raloxifene hydrochloride</td>
<td>Evista</td>
</tr>
<tr>
<td>Ramipril</td>
<td>Altace</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Risedronate sodium</td>
<td>Actonel</td>
</tr>
<tr>
<td>Risperidone</td>
<td>Risperdal</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Rosiglitazone maleate</td>
<td>Avandia</td>
</tr>
<tr>
<td>Drug Name</td>
<td>Brand</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Rosuvastatin</td>
<td>Crestor</td>
</tr>
<tr>
<td>Calcium</td>
<td></td>
</tr>
<tr>
<td>Sertraline Hydrochloride</td>
<td>Zoloft</td>
</tr>
<tr>
<td>Sildenafil Citrate</td>
<td>Viagra</td>
</tr>
<tr>
<td>Simvastatin</td>
<td>Zocor</td>
</tr>
<tr>
<td>Sumatriptan Succinate</td>
<td>Imitrex</td>
</tr>
<tr>
<td>Tadalafil</td>
<td>Cialis</td>
</tr>
<tr>
<td>Tamsulosin Hydrochloride</td>
<td>Flomax</td>
</tr>
<tr>
<td>Medicine</td>
<td>Brand</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>tolterodine</td>
<td>Detrol</td>
</tr>
<tr>
<td>tolterodine</td>
<td>Detrol LA</td>
</tr>
<tr>
<td>topiramate</td>
<td>Topamax</td>
</tr>
<tr>
<td>topiramate</td>
<td>Topamax Sprinkle</td>
</tr>
<tr>
<td>tramadol hydrochloride</td>
<td>Ultram</td>
</tr>
<tr>
<td>tramadol hydrochloride</td>
<td>Ultram (ER)</td>
</tr>
<tr>
<td>tramadol hydrochloride and acetaminophen</td>
<td>Ultrace</td>
</tr>
<tr>
<td>valacyclovir hydrochloride</td>
<td>Valtrex</td>
</tr>
</tbody>
</table>
### Photogallery of common tablets and capsules

| **valsartan** | **Diovan** | 80 mg | 160 mg | 320 mg |
| | | ![image](image1.png) | ![image](image2.png) | ![image](image3.png) |
| **valsartan and hydrochlorothiazide** | **Diovan HCT** | 80 mg/12.5 mg | 160 mg/12.5 mg | 160 mg/25 mg |
| | | ![image](image4.png) | ![image](image5.png) | ![image](image6.png) |
| | | 320 mg/12.5 mg | 320 mg/25 mg |
| | | ![image](image7.png) | ![image](image8.png) |
| **vardenafil hydrochloride** | **Levitra** | 2.5 mg | 5 mg | 10 mg | 20 mg |
| | | ![image](image9.png) | ![image](image10.png) | ![image](image11.png) | ![image](image12.png) |
| **venlafaxine hydrochloride** | **Effexor** | 25 mg | 37.5 mg | 50 mg |
| | | ![image](image13.png) | ![image](image14.png) | ![image](image15.png) |
| | | 75 mg | 100 mg |
| | | ![image](image16.png) | ![image](image17.png) |
| **venlafaxine hydrochloride** | **Effexor XR** | 37.5 mg | 75 mg | 150 mg |
| | | ![image](image18.png) | ![image](image19.png) | ![image](image20.png) |
| **warfarin sodium** | **Coumadin** | 1 mg | 2 mg | 2.5 mg |
| | | ![image](image21.png) | ![image](image22.png) | ![image](image23.png) |
| | | 3 mg | 4 mg | 5 mg |
| | | ![image](image24.png) | ![image](image25.png) | ![image](image26.png) |
| | | 6 mg | 7.5 mg | 10 mg |
| | | ![image](image27.png) | ![image](image28.png) | ![image](image29.png) |

©2009, SFI Medical Publishing
Drug/herbs. *St. John's wort:* decreased drug blood level and reduced drug effect

Drug/behaviors. *Alcohol use:* increased drug half-life and concentration

**Patient monitoring**
- Assess for severe lactic acidosis, especially in women and obese patients.
- Evaluate closely for signs and symptoms of hypersensitivity reaction, which can be fatal. These include fever, rash, fatigue, nausea, vomiting, diarrhea, abdominal pain, dyspnea, cough, and pharyngitis.
- Never restart therapy if patient has experienced a previous hypersensitivity reaction to this drug.
- Check for liver enlargement.
- Monitor CBC, serum electrolytes, and liver and kidney function test results.

**Patient teaching**
- Advise patient to take drug with food to minimize GI upset.
- Instruct patient to refrigerate drug but not to freeze it.
- Teach patient how to recognize hypersensitivity reaction. Instruct him to stop taking drug and contact prescriber immediately if signs or symptoms of such a reaction occur.
- Tell patient to contact prescriber if he develops a rash (possible sign of Stevens-Johnson syndrome).
- Inform patient that drug doesn’t cure HIV but lowers viral count.
- Instruct patient to obtain medication guide and warning card with each refill.
- Tell patient he’ll undergo frequent blood and urine testing during therapy.
- Advise patient to consult prescriber before drinking alcohol or using herbs.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

**FDA BOXED WARNING**
- Give only to patients whose regimens would otherwise include both abacavir sulfate and lamivudine.
- Abacavir component may cause serious and potentially fatal hypersensitivity reactions, including multi-organ syndrome marked by fever, rash, GI distress, malaise, fatigue, aches, dyspnea, cough, and pharyngitis. Discontinue immediately if you suspect such a reaction. If hypersensitivity can’t be ruled out, discontinue permanently, even if other diagnoses are possible.
- After hypersensitivity reaction, never restart drug or other agents containing it, because more severe symptoms (including severe hypotension and death) may arise within hours.
- Lactic acidosis and severe hepato-megaly with steatosis (including fatal cases) have occurred in patients receiving one or both components.
- Severe acute hepatitis B exacerbations have occurred in patients coinfected with hepatitis B virus and human immunodeficiency virus (HIV) after they discontinued lamivudine.

**Action**
Abacavir converts to its active metabolite (carbovir triphosphate), and lamivudine is phosphorylated to its active metabolite (lamivudine triphosphate) by intracellular enzymes.

---

**abacavir sulfate and lamivudine**

**Epzicom, Kavexa®**

**Pharmacologic class:** Nucleoside analogue

**Therapeutic class:** Antiretroviral agent

**Pregnancy risk category C**

---

**Canada**

**UK**

**Hazardous drug**

**High alert drug**
These metabolites inhibit activity of HIV-1 reverse transcriptase. Drug interferes with DNA and RNA synthesis, thereby inhibiting viral reproduction.

**Availability**
*Tablets:* 600 mg abacavir/300 mg lamivudine

**Indications and dosages**
- HIV-1 infection
  - **Adults:** 1 tablet P.O. daily

**Contraindications**
- Hypersensitivity to abacavir, lamivudine, or other product components
- Hepatic impairment

**Precautions**
Use cautiously in:
- treatment-experienced patients (cross-resistance may occur)
- concurrent hepatitis B infection
- renal impairment
- elderly patients
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

**Administration**
- Before administering, ask patient if he’s allergic to abacavir or lamivudine.
- Always give in combination with other antiretrovirals.
- Administer with plenty of water, with or without food.
- Know that drug isn’t recommended for patients who would require dosage adjustment, because tablet shouldn’t be broken.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- CNS: paresthesia, peripheral neuropathy, insomnia, depression or depressed mood, migraine, fatigue, malaise, weakness, dizziness, vertigo, anxiety, abnormal dreams, **seizures**
- GI: nausea, diarrhea, abdominal pain, gastritis, stomatitis, pancreatitis
- **Hematologic:** lymphadenopathy, splenomegaly, **anemia** (including pure red-cell aplasia and severe anemias progressing with therapy), aplastic anemia
- Hepatic: posttreatment exacerbation of hepatitis B, hepatic steatosis
- **Metabolic:** hyperglycemia, **lactic acidosis**
- **Musculoskeletal:** muscle weakness, rhabdomyolysis
- **Respiratory:** abnormal breath sounds, wheezing
- **Skin:** alopecia, toxic epidermal necrolysis, **erythema multiforme,** Stevens-Johnson syndrome
- **Other:** body fat redistribution, fever, allergic reactions including urticaria and **anaphylaxis**

**Interactions**
- **Drug-drug.** Nelfinavir, sulfamethoxazole/trimethoprim: increased lamivudine blood level
- **Drug-diagnostic tests.** Amylase, bilirubin, creatine kinase, glucose, lipase, triglycerides: elevated levels
  - Liver function tests: abnormal results
  - Platelet count: decreased
- **Drug-behaviors.** Alcohol use: increased abacavir blood level

**Patient monitoring**
- Monitor patients (especially women and overweight patients) for signs and symptoms of lactic acidosis.
- Monitor hepatic function closely during therapy and for at least several months afterward.

**Patient teaching**
- Advise patient not to use drug if he is allergic to abacavir or lamivudine.
- Tell patient to take drug with plenty of water, with or without food.

Reactions in **bold** are life-threatening.
Instruct patient to stop taking drug and get immediate medical attention if he experiences such allergic symptoms as fatigue, general ill feeling, achiness, rash, fever, difficulty breathing, cough, throat inflammation, or severe nausea, vomiting, diarrhea, or abdominal pain.

Caution patient never to take drug again if he experiences an allergic reaction.

- Tell patient to make sure he receives medication guide and warning card issued with each prescription and refill. Teach him to carry card at all times.
- Advise patient to contact prescriber right away if he develops symptoms of liver impairment (unusual tiredness, weakness, nausea, itching, yellowing of eyes or skin, tenderness on upper right side of abdomen, or flu-like symptoms).
- Tell patient not to stop taking drug without consulting prescriber. If he stops taking it for any reason other than allergic reaction, he must consult prescriber before restarting, because serious or life-threatening reactions may occur.
- Tell HIV-infected women not to breastfeed infants, to avoid risk of transmitting HIV infection.
- Inform patient that he’ll have regular blood tests during drug therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

**Action**

Inhibits T-cell activation by binding to CD80 and CD86, blocking interaction with CD28. (This interaction triggers costimulatory signal necessary for full activation of T cells, which are implicated in rheumatoid arthritis pathogenesis.)

**Availability**

*Powder for infusion (lyophilized):* 250 mg/15 ml in single-use vial

**Indications and dosages**

> To reduce signs and symptoms, slow progression of structural damage, and improve physical function in patients with moderately to severely active rheumatoid arthritis who’ve responded inadequately to one or more disease-modifying antirheumatic drugs or tumor necrosis factor (TNF) antagonists (such as adalimumab, etanercept, or infliximab)

**Adults weighing less than 60 kg (132 lb):** 500 mg I.V. given over 30 minutes at weeks 0, 2, and 4; thereafter, give every 4 weeks  
**Adults weighing 60 to 100 kg (132 to 220 lb):** 750 mg I.V. given over 30 minutes at weeks 0, 2, and 4; thereafter, give every 4 weeks  
**Adults weighing more than 100 kg:** 1g I.V. given over 30 minutes at weeks 0, 2, and 4; thereafter, give every 4 weeks

**Contraindications**

- Hypersensitivity to drug or its components

**Precautions**

Use cautiously in:

- increased risk of infection or history of recurrent infections, immunocompromised state, chronic obstructive pulmonary disease (COPD)
- concurrent use of concomitant TNF antagonists
- patients older than age 65
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

**Administration**
- Reconstitute each vial with 10 ml sterile water for injection, using only silicone-free disposable syringe included with product.
- During reconstitution, rotate vial by swirling gently. Avoid prolonged or vigorous agitation. Don’t shake.
- Further dilute reconstituted solution to volume of 100 ml with normal saline solution.
- Use silicone-free syringe to add drug to infusion bag or bottle, and mix gently. Resulting drug concentration should be 5 mg/ml for two vials, 7.5 mg/ml for three vials, or 10 mg/ml for four vials, respectively.
- Administer infusion over 30 minutes using infusion set and nonpyrogenic, low protein-binding filter.
- Complete infusion within 24 hours of vial reconstitution.
- Don’t infuse other drugs concurrently through same I.V. line.
- Watch for infusion-related reactions (hypotension or hypertension, dyspnea, nausea, dizziness, headache, flushing, urticaria, pruritus, rash, cough, or wheezing), which usually occur within 1 hour of administration. Be prepared to intervene appropriately.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- CNS: headache, dizziness
- CV: hypertension, hypotension
- EENT: nasopharyngitis
- GI: nausea, dyspepsia, diverticulitis
- GU: urinary tract infection, acute pyelonephritis
- Musculoskeletal: back pain, extremity pain
- Respiratory: cough, upper respiratory tract infection (including herpes zoster infection), pneumonia, wheezing, bronchitis, dyspnea
- Skin: rash, flushing, urticaria, pruritus
- Other: malignancies, infusion-related reactions, hypersensitivity reaction

**Interactions**
- Drug-drug. *Immunizations:* possible decrease in immunization efficacy

**Patient monitoring**
- Continue to monitor patient for infusion-related events.
- Assess patient’s overall health at each visit to evaluate infection status.
- Closely monitor COPD patient because of increased likelihood of adverse events.

**Patient teaching**
- Instruct patient to report signs and symptoms of infection.
- Caution patient to avoid immunizations during or within 3 months of stopping drug.
- Tell female with childbearing potential that pregnancy and breastfeeding aren’t recommended during therapy.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

---

**abciximab**

ReoPro

*Pharmacologic class: Platelet aggregation inhibitor*

*Therapeutic class: Antithrombotic, antiplatelet drug*

*Pregnancy risk category C*

**Action**
Inhibits fibrinogen binding and platelet-platelet interaction by impeding
fibrinogen binding to platelet receptor sites, thereby prolonging bleeding time

Availability
Injection: 2 mg/ml (5-ml vials containing 10 mg)

Indications and dosages
➢ Adjunct to aspirin and heparin to prevent acute cardiac ischemic complications in patients undergoing percutaneous coronary intervention (PCI)
Adults: 0.25 mg/kg I.V. bolus given 10 to 60 minutes before start of PCI, followed by infusion of 0.125 mcg/kg/minute for 12 hours. Maximum dosage is 10 mcg/minute.
➢ Adjunct to aspirin and heparin in patients with unstable angina who haven’t responded to conventional medical therapy and will undergo PCI within 24 hours
Adults: 0.25 mg/kg I.V. bolus, followed by 18- to 24-hour infusion of 10 mcg/minute, ending 1 hour after PCI

Contraindications
• Hypersensitivity to drug or murine proteins
• Active internal bleeding
• Bleeding diathesis
• Severe, uncontrolled hypertension
• Thrombocytopenia (< 100,000 cells/mm³)
• Neutropenia
• Aneurysm
• Arteriovenous malformation
• History of cerebrovascular accident
• Oral anticoagulant therapy within past 7 days (unless prothrombin time is < 1.2 times control)

Precautions
Use cautiously in:
• patients receiving drugs that affect hemostasis (such as thrombolytics, anticoagulants, or antiplatelet drugs)
• pregnant or breastfeeding patients.

Administration
• I.V. bolus dose may be given undiluted. For I.V. infusion, further dilute the desired dose with normal saline or D₅W.
• Give through separate I.V. line with no other drugs.
• Avoid noncompressible I.V. sites, such as subclavian or jugular vein.
➢ Stop continuous infusion after failed PCI.
• Restrict patient to bed rest for 6 to 8 hours after drug withdrawal or 4 hours after heparin withdrawal (whichever occurs first).
• After catheter removal, apply pressure to femoral artery for at least 30 minutes.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>30 min</td>
<td>48 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, anxiety, agitation, abnormal thinking, hypoesthesia, difficulty speaking, confusion, weakness, cerebral ischemia, coma
CV: pseudoaneurysm, palpitations, vascular disorders, arteriovenous fistula, hypotension, peripheral edema, weak pulse, intermittent claudication, bradycardia, ventricular or supraventricular tachycardia, atrial fibrillation or flutter, atrioventricular block, nodal arrhythmias, pericardial effusion, embolism, thrombophlebitis
EENT: abnormal or double vision
GI: nausea, vomiting, diarrhea, constipation, dyspepsia, ileus, gastroesophageal reflux, enlarged abdomen, dry mouth
GU: urinary tract infection, urine retention or urinary incontinence, painful or frequent urination, abnormal renal function, cystalgia, prostatitis
Hematologic: anemia, leukocytosis, thrombocytopenia, bleeding
Metabolic: diabetes mellitus, hyperkalemia

Canada UK Hazardous drug High alert drug
Musculoskeletal: myopathy, myalgia, increased muscle tension, reduced muscle stretching ability

Respiratory: pneumonia, crackles, rhonchi, bronchitis, pleurisy, **pleural effusion**, bronchospasm, pulmonary edema, **pulmonary embolism**

Skin: pallor, cellulitis, petechiae, pruritus, bullous eruptions, diaphoresis

Other: abscess, peripheral coldness, development of human antichimeric antibodies

Interactions

**Drug-drug.** Drugs that affect hemostasis (such as aspirin, dextran, dipyridamole, heparin, nonsteroidal anti-inflammatory drugs, oral anticoagulants, thrombolytics, and ticlopidine): increased bleeding risk

**Drug-diagnostic tests.** Activated partial thromboplastin time (APTT), clotting time, prothrombin time (PT): increased values

*Platelets:* decreased count

**Patient monitoring**

- Assess platelet count before, during, and after therapy.
-  Monitor catheter insertion site frequently for bleeding.
-  During catheter insertion and for 6 hours after catheter removal, frequently monitor digital pulse in leg where catheter was inserted.
  - Monitor CBC, PT, APTT, and International Normalized Ratio.
  - Minimize arterial or venous punctures, automatic blood pressure cuff use, I.M. injections, nasotracheal or nasogastric intubation, and urinary catheterization.
  - Use indwelling venipuncture device, such as heparin lock, to draw blood.

**Patient teaching**

- Tell patient what to expect during and after drug administration.
- Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
-  Instruct patient to immediately report unusual bleeding or bruising.
-  Caution patient to avoid activities that may cause injury. Advise him to use soft toothbrush and electric razor to avoid gum and skin injury.
-  Inform patient that he’ll undergo regular blood testing during therapy.
-  As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**acamprosate calcium**

*Campral*

**Pharmacologic class:** Gamma-aminobutyric acid (GABA) analogue

**Therapeutic class:** Detoxification agent

**Pregnancy risk category C**

**Action**

Unclear. May interact with glutamate and GABA neurotransmitter systems centrally, restoring balance between neuronal excitation and inhibition (which is altered by chronic alcoholism).

**Availability**

*Tablets (enteric-coated):* 333 mg

**Indications and dosages**

➢ To maintain abstinence from alcohol in patients with alcohol dependence who are abstinent when treatment begins

*Adults:* 2 tablets P.O. t.i.d.

**Dosage adjustment**

- Moderate renal impairment

**Contraindications**

- Hypersensitivity to drug
- Severe renal impairment

Reactions in **bold** are life-threatening.
Precautions
Use cautiously in:
• mild to moderate renal impairment
• suicidal ideation or behavior
• elderly patients
• breastfeeding patients
• children.

Administration
• Give without regard to meals.
• Don’t crush or break enteric-coated tablet.
• Know that drug helps maintain alcohol abstinence only when used as part of treatment program that includes counseling and support.

Route Onset Peak Duration
P.O. Unknown 3-8 hr Unknown

Adverse reactions
CNS: apathy, confusion, agitation, neurosis, malaise, somnolence, abnormal thinking, vertigo, asthenia, anxiety, depression, dizziness, insomnia, paresthesia, tremor, withdrawal syndrome headache, migraine, abnormal dreams, hallucinations, seizures, suicidal ideation or suicide attempt
CV: chest pain, palpitations, syncope, hypotension, angina pectoris, varicose veins, phlebitis, peripheral edema, orthostatic hypotension, vasodilation, tachycardia, hypertension, myocardial infarction
EENT: abnormal vision, amblyopia, hearing loss, tinnitus, rhinitis, pharyngitis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, belching, gastroenteritis, gastritis, esophagitis, hematemesis, dry mouth, anorexia, pancreatitis, rectal hemorrhage, GI hemorrhage
GU: urinary frequency, urinary tract infection, urinary incontinence, erectile dysfunction, increased or decreased libido, metrorrhagia, vaginitis

Hematologic: anemia, ecchymosis, eosinophilia, lymphocytosis, thrombocytopenia
Hepatic: hepatic cirrhosis
Metabolic: hyperglycemia, diabetes mellitus, hyperuricemia, gout, avitaminosis
Musculoskeletal: joint, muscle, neck, or back pain
Respiratory: cough, dyspnea, bronchitis, epistaxis, pneumonia, asthma
Skin: pruritus, sweating
Other: abnormal taste, increased thirst, increased appetite, weight gain or loss, pain, infection, flulike symptoms, chills, abscess, hermia, allergic reaction, accidental or intentional injury, intentional overdose

Interactions
Drug-drug. Naltrexone: increased acamprosate blood level
Drug-diagnostic tests. Bilirubin, eosinophils, lymphocytes: increased levels
Liver function tests: abnormal results
Red blood cells: decreased count

Patient monitoring
• Monitor patient for depression or expressed suicidal ideation.
• Monitor creatinine clearance during therapy.

Patient teaching
• Instruct patient to swallow tablet whole, with or without food.
• Advise patient to keep taking drug exactly as prescribed, even if he has a relapse. Encourage him to discuss any renewed alcohol consumption with prescriber.
• Instruct patient to contact prescriber immediately if he experiences seizure, chest pain, suicidal thoughts, or symptoms of liver problems (such as unusual tiredness or yellowing of skin or eyes).
• Caution patient to move slowly to a sitting or standing position, to avoid
dizziness or light-headedness from a sudden blood pressure decrease.
- Advise patient to avoid driving and other hazardous activities until he knows how drug affects concentration, alertness, vision, coordination, and physical dexterity.
- Instruct female patient to notify prescriber if she becomes or intends to become pregnant or to breastfeed during therapy.
- Inform patient that drug helps maintain abstinence from alcohol only when used as part of treatment program that includes counseling and support.
- Emphasize that drug doesn’t eliminate or diminish alcohol withdrawal symptoms.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**acarbose**

*Glucobay®, Prandase®, Precose*

**Pharmacologic class:** Alpha-glucosidase inhibitor

**Therapeutic class:** Hypoglycemic

**Pregnancy risk category B**

**Action**

Improves blood glucose control by slowing carbohydrate digestion in intestine and prolonging conversion of carbohydrates to glucose

**Availability**

*Tablets:* 25 mg, 50 mg, 100 mg

**Indications and dosages**

* Treatment of type 2 (non-insulin-dependent) diabetes mellitus when diet alone doesn’t control blood glucose

**Adults:** Initially, 25 mg P.O. t.i.d. Increase q 4 to 8 weeks as needed until maintenance dosage is reached. Maximum dosage is 100 mg P.O. t.i.d. for adults weighing more than 60 kg (132 lb); 50 mg P.O. t.i.d. for adults weighing 60 kg or less.

**Contraindications**

- Hypersensitivity to drug
- Renal dysfunction
- Type 1 diabetes mellitus, diabetic ketoacidosis
- GI disease
- Cirrhosis
- Colonic ulcers
- Inflammatory bowel disease
- Intestinal obstruction
- Pregnancy or breastfeeding

**Precautions**

Use cautiously in:

- patients receiving concurrent hypoglycemic drugs
- children.

**Administration**

- Give with first bite of patient’s three main meals.
- Know that drug prevents breakdown of table sugar (sucrose). Thus, mild hypoglycemia must be corrected with oral glucose (such as D-glucose or dextrose), and severe hypoglycemia may warrant I.V. glucose or glucagon injection.
- Be aware that drug may be used alone or in combination with insulin, metformin, or sulfonylureas (such as glipizide, glyburide, or glimepiride).

**Route**

<table>
<thead>
<tr>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>1 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

GI: diarrhea, abdominal pain, flatulence

Metabolic: hypoglycemia (when used with insulin or sulfonylureas)

Other: edema, hypersensitivity reaction (rash)
Interactions

Drug-drug. Activated charcoal, calcium channel blockers, corticosteroids, digestive enzymes, diuretics, estrogen, hormonal contraceptives, isoniazid, nicotinic acid, phenothiazines, phenytoin, sympathomimetics, thyroid products: decreased therapeutic effect of acarbose Digoxin: decreased digoxin blood level and reduced therapeutic effect Insulin, sulfonylureas: hypoglycemia

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase: increased levels Calcium, vitamin B6: decreased levels Hematocrit: decreased

Patient monitoring
- Monitor patient for hypoglycemia if he’s taking drug concurrently with insulin or sulfonylureas.
- Stay alert for hyperglycemia during periods of increased stress.
- Assess GI signs and symptoms to differentiate drug effects from those caused by paralytic ileus.
- Check 1-hour postprandial glucose level to gauge drug’s efficacy.
- Monitor liver function test results. Report abnormalities so that dosage adjustments may be made as needed.

Patient teaching
- Inform patient that drug may cause serious interactions with many common medications, so he should tell all prescribers he’s taking it.
- Teach patient about other ways to control blood glucose level, such as recommendations regarding diet, exercise, weight reduction, and stress management.
- Stress importance of testing urine and blood glucose regularly.
- Teach patient about signs and symptoms of hypoglycemia. Tell him that although this drug doesn’t cause hypoglycemia when used alone, hypoglycemic symptoms may arise if he takes it with other hypoglycemics.
- Urge patient to keep oral glucose on hand to correct mild hypoglycemia; inform him that sugar in candy won’t correct hypoglycemia.
- Inform patient that GI symptoms such as flatulence may result from delayed carbohydrate digestion in intestine.
- Advise patient to obtain medical alert identification and to carry or wear it at all times.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

acebutolol hydrochloride

Monitan™, Rhotral™, Sectral

Pharmacologic class: Beta-adrenergic blocker (selective)
Therapeutic class: Antihypertensive, antiarrhythmic (class II)
Pregnancy risk category B

Action
At low doses, selectively inhibits response to adrenergic stimulation by blocking cardiac beta1-adrenergic receptors (with little effect on beta2-adrenergic receptors of bronchial and vascular smooth muscle). At high doses, inhibits both beta1- and beta2-adrenergic receptors, causing airway resistance.

Availability
Capsules: 200 mg, 400 mg
Tablets: 100 mg, 200 mg, 400 mg

Indications and dosages
- Hypertension
Adults: Initially, 400 mg P.O. daily or 200 mg b.i.d.; optimal response usually occurs at 400 to 800 mg daily. For severe hypertension, increase dosage gradually to a maximum of 1,200 mg daily in two divided doses.

Canada UK Hazardous drug High alert drug
Premature ventricular arrhythmias

Adults: Initially, 200 mg P.O. b.i.d. Increase dosage gradually until optimum response occurs, usually at 600 to 1,200 mg daily.

Dosage adjustment
- Renal impairment
- Elderly patients

Off-label uses
- Acute phase of myocardial infarction (MI)
- Stable angina

Contraindications
- Hypersensitivity to drug
- Heart failure or cardiogenic shock
- Second- or third-degree heart block
- Severe bradycardia
- Obstructive airway disease
- Breastfeeding

Precautions
Use cautiously in:
- renal or hepatic impairment, inadequate cardiac function, peripheral or mesenteric vascular disease, hyperthyroidism, diabetes mellitus
- elderly patients
- pregnant patients
- children.

Administration
- Withhold drug and notify prescriber if patient’s apical pulse is below 60 beats/minute.
- Before surgery, notify anesthesiologist that patient is receiving drug.
- Avoid dosages above 800 mg daily in elderly patients.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O. (blood pressure effect)</td>
<td>1-1.5 hr</td>
<td>2-8 hr</td>
<td>12-24 hr</td>
</tr>
<tr>
<td>P.O. (antiarrhythmic effect)</td>
<td>1 hr</td>
<td>4-6 hr</td>
<td>Up to 10 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: fatigue, lethargy, insomnia, dizziness, depression, short-term memory loss, emotional lability, anxiety, confusion, headache, partial sensation loss, hemiparesis
CV: hypotension, chest pain, palpitations, peripheral vascular insufficiency, peripheral vasodilation, worsening arterial insufficiency, claudication, bradycardia, heart failure, intensified atrioventricular nodal block
EENT: dry burning eyes, abnormal or blurred vision, eye irritation and pain, conjunctivitis, tinnitus, pharyngitis
GI: nausea, vomiting, diarrhea, constipation, dyspepsia, abdominal pain, dry mouth, anorexia, mesenteric arterial thrombosis, ischemic colitis
GU: frequent or difficult urination, nocturia, diminished libido, impotence, Peyronie’s disease
Hematologic: agranulocytosis, nonthrombocytopenic purpura
Metabolic: type 2 diabetes mellitus, hypoglycemia in nondiabetic patients, increased hypoglycemic response to insulin
Musculoskeletal: joint, back, or muscle pain
Respiratory: dyspnea, wheezing, cough, shortness of breath, bronchospasm, bronchoconstriction
Skin: rash, pruritus, diaphoresis
Other: fever, thirst, edema, pneumonitis, pleurisy, lupus erythematosus-like illness, hypersensitivity reaction, pulmonary granuloma, pleuropulmonary fibrosis

Interactions
Drug-drug. Alpha agonists (such as nasal decongestants and other betaadrenergic blockers): increased risk of severe hypertension
Aluminum or calcium salts, barbiturates, cholestyramine, colestipol, indomethacin, nonsteroidal anti-inflammatory drugs, penicillin, rifampin, salicylates, sulfinpyrazone: decreased antihypertensive effect
Anticholinergics, hydralazine, methyl-dopa, prazosin: increased risk of bradycardia and hypotension
Beta₂-agonists (such as theophylline): decreased beta₂-agonist effect, possibly leading to bronchoconstriction
Calcium channel blockers (nondihydropyridine): synergistic effects
Cardiac glycosides: additive negative effect on sinoatrial (SA) or atrioventricular node conduction, slowing or completely suppressing SA node activity
Catecholamine-depleting drugs: marked bradycardia, hypertension, vertigo, syncope, and orthostatic blood pressure changes
Diuretics: increased hypotensive effect
Epinephrine: increased risk of blocked sympathomimetic effects
Ergot alkaloids: increased risk of peripheral ischemia and gangrene
Glyburide in patients with type 2 diabetes: decreased hypoglycemic effect
Lidocaine: increased lidocaine blood level and possible toxicity
Drug-diagnostic tests. Alkaline phosphatase, antinuclear antibody titers, bilirubin, blood urea nitrogen, lactate dehydrogenase, low-density lipoproteins, transaminases: increased levels
Glucose tolerance test: altered tolerance
Drug-herbs. Aloe, buckthorn bark or berry, cascara bark, rhubarb root, senna leaf or fruit: increased acebutolol effect
Ephedra (ma huang): arrhythmias

Patient monitoring
- Carefully monitor blood pressure during initial dosage titration. Notify prescriber of significant or abrupt blood pressure decrease.
- Observe for orthostatic hypotension, especially when giving drug with other antihypertensives.
- Watch closely for marked bradycardia or hypotension if giving drug with reserpine or other catecholamine-depleting agents.
- Be aware that drug may mask signs and symptoms of hypoglycemia in patients with diabetes mellitus or hyperthyroidism.

Patient teaching
- Teach patient how to take his pulse. Tell him to notify prescriber if pulse rate is below 60 beats/minute.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, alertness, and vision.
- Tell patient to watch for and report hypoglycemia signs and symptoms.
- Instruct patient with bronchospastic disease to keep bronchodilator on hand at all times.
- Instruct patient to store drug in tight container at room temperature, protected from light.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

acetaminophen
Abenol®, Acephen, Anadin Paracetamol®, Apo-Acetaminophen®, Aspirin Free Anacin, Atasol®, Calpol®, Cetaphen, Children’s Tylenol Soft Chews, Disprol®, Feverall, Galpamol®, Genapap, Genebs, Little Fevers, Mandanol®, Mapap, Nortemp, Nortemp Children’s, Novo-Gesic®, Pain Eze, Panadol®, Pediatrix®, Silapap, Tempra®, Tycolene, Tylenol 8 Hour, Tylenol, Tylenol Arthritis, Valorin

Pharmacologic class: Synthetic non-opioid \(p\)-aminophenol derivative
Therapeutic class: Analgesic, antipyretic
Pregnancy risk category B
Action
Unclear. Pain relief may result from inhibition of prostaglandin synthesis in CNS, with subsequent blockage of pain impulses. Fever reduction may result from vasodilation and increased peripheral blood flow in hypothalamus, which dissipates heat and lowers body temperature.

Availability
Caplets, capsules: 160 mg, 500 mg, 650 mg (extended-release)
Drops: 100 mg/ml
Elixir: 80 mg/2.5 ml, 80 mg/5 ml, 120 mg/5 ml, 160 mg/5 ml
Gelcaps: 500 mg
Liquid: 160 mg/5 ml, 500 mg/15 ml
Solution: 80 mg/1.66 ml, 100 mg/1 ml, 120 mg/2.5 ml, 160 mg/5 ml, 167 mg/5 ml
Suppositories: 80 mg, 120 mg, 125 mg, 300 mg, 325 mg, 650 mg
Suspension: 32 mg/ml, 160 mg/5 ml
Syrup: 160 mg/5 ml
Tablets ( chewable): 80 mg, 160 mg
Tablets ( extended-release): 160 mg, 325 mg, 500 mg, 650 mg
Tablets ( film-coated): 160 mg, 325 mg, 500 mg

Indications and dosages
Mild to moderate pain caused by headache, muscle ache, backache, minor arthritis, common cold, toothache, or menstrual cramps or fever
Adults: 325 to 650 mg P.O. q 4 to 6 hours, or 1,000 mg three or four times daily. Or two extended-release caplets or tablets P.O. q 8 hours, to a maximum dosage of 4,000 mg/day. Or 650 mg P.R. q 4 to 6 hours, to a maximum dosage of 4,000 mg/day.
Children: 10 to 15 mg/kg, or as indicated below:

Oral use

<table>
<thead>
<tr>
<th>Age</th>
<th>Usual dosage</th>
<th>Maximum dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>11-12 years</td>
<td>480 mg q 4 hr</td>
<td>5 doses in 24 hr</td>
</tr>
<tr>
<td>9-10 years</td>
<td>400 mg q 4 hr</td>
<td>5 doses in 24 hr</td>
</tr>
</tbody>
</table>

Rectal use

<table>
<thead>
<tr>
<th>Age</th>
<th>Usual dosage</th>
<th>Maximum dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 years and older</td>
<td>325-650 mg q 4 hr</td>
<td>4,000 mg/day</td>
</tr>
<tr>
<td>11-12 years</td>
<td>320-480 mg q 4 hr</td>
<td>2,880 mg/day</td>
</tr>
<tr>
<td>6-11 years</td>
<td>325 mg q 4 hr</td>
<td>2,600 mg/day</td>
</tr>
<tr>
<td>3-6 years</td>
<td>120-125 mg q 6 hr</td>
<td>720 mg/day</td>
</tr>
<tr>
<td>1-3 years</td>
<td>80 mg q 4 hr</td>
<td></td>
</tr>
<tr>
<td>3-11 months</td>
<td>80 mg q 6 hr</td>
<td></td>
</tr>
</tbody>
</table>

Dosage adjustment
- Renal or hepatic impairment

Contraindications
- Hypersensitivity to drug

Precautions
Use cautiously in:
- anemia, hepatic or renal disease
- elderly patients
- pregnant or breastfeeding patients
- children younger than age 2.

Administration
- Be aware that although most patients tolerate drug well, toxicity can occur with a single dose.
- Know that acetylcysteine may be ordered to treat acetaminophen toxicity, depending on patient’s blood drug level. Activated charcoal is used to treat acute, recent acetaminophen overdose (within 1 hour of ingestion).

Reactions in bold are life-threatening.
- Determine overdose severity by measuring acetaminophen blood level no sooner than 4 hours after overdose ingestion (to ensure that peak concentration has been reached).

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>0.5-1 hr</td>
<td>10-60 min</td>
<td>3-8 hr (dose dependent)</td>
</tr>
<tr>
<td>P.R.</td>
<td>0.5-1 hr</td>
<td>10-60 min</td>
<td>3-4 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

Hematologic: thrombocytopenia, hemolytic anemia, neutropenia, leukopenia, pancytopenia

Hepatic: jaundice, hepatotoxicity

Metabolic: hypoglycemic coma

Skin: rash, urticaria

Other: hypersensitivity reactions (such as fever)

**Interactions**

Drug-drug. Activated charcoal, cholestyramine, colestipol: decreased acetaminophen absorption
Barbiturates, carbamazepine, diflunisal, hydantoins, isoniazid, rifabutin, rifampin, sulfinpyrazone: increased risk of hepatotoxicity

Hormonal contraceptives: decreased acetaminophen efficacy

Oral anticoagulants: increased anticoagulant effect

Phenothiazines (such as chlorpromazine, fluphenazine, thioridazine): severe hypothermia

Zidovudine: increased risk of granulocytopenia

Drug-diagnostic tests. Home glucose measurement systems: altered results

Urine 5-hydroxyindole acetic acid: false-positive result

Drug-behaviors. Alcohol use: increased risk of hepatotoxicity

**Patient monitoring**

- Observe for acute toxicity and overdose. Signs and symptoms of acute toxicity are as follows—**Phase 1**: Nausea, vomiting, anorexia, malaise, diaphoresis. **Phase 2**: Right upper quadrant pain or tenderness, liver enlargement, elevated bilirubin and hepatic enzyme levels, prolonged prothrombin time, oliguria (occasional). **Phase 3**: Recurrent anorexia, nausea, vomiting, and malaise; jaundice; hypoglycemia; coagulopathy; encephalopathy; possible renal failure and cardiomyopathy. **Phase 4**: Either recovery or progression to fatal complete hepatic failure.

**Acetazolamide**

Acetazolamide™, AK-Zol,
Apo-Acetazolamide™, Diamox™,
Diamox Sequels

**Pharmacologic class:** Carbonic anhydrase inhibitor

**Therapeutic class:** Diuretic, antiglaucoma drug, anticonvulsant, altitude agent, urinary alkalinizer

**Pregnancy risk category C**
Acetazolamide

**Action**
Inhibits carbonic anhydrase in kidney, decreasing water reabsorption and increasing excretion of sodium, potassium, and bicarbonate. Lowers intraocular pressure by decreasing aqueous humor production. May raise seizure threshold by reducing carbonic anhydrase in CNS, thereby decreasing neuronal conduction.

**Availability**
- Capsules (sustained-release): 500 mg
- Injection: 500 mg/vial
- Tablets: 125 mg, 250 mg

**Indications and dosages**

- Open-angle (chronic simple) glaucoma (given with miotics)
  - **Adults:** 250 mg P.O. one to four times daily, or 500-mg sustained-release capsule P.O. once or twice daily. Don’t exceed total daily dosage of 1 g.
  - Preoperative treatment of closed-angle (secondary) glaucoma
  - **Adults:** 250 mg P.O. q 4 hours or 250 mg P.O. b.i.d.; in acute cases only, 500 mg P.O. followed by 125 to 250 mg P.O. q 4 hours. For rapid relief of increased intraocular pressure, 500 mg I.V., repeated in 2 to 4 hours; then 125 to 250 mg P.O. q 4 to 6 hours.
  - **Children:** 10 to 15 mg/kg/day P.O. in divided doses q 6 to 8 hours, or 5 to 10 mg/kg I.V. q 6 hours
  - Seizure disorder (given with other anticonvulsants)
  - **Adults and children:** 250 mg P.O. daily when given with another anticonvulant, or 8 to 30 mg/kg daily P.O. in one to four divided doses. Usual dosage range is 375 mg to 1 g daily.
  - Drug-induced edema or edema secondary to heart failure
  - **Adults:** Initially, 250 to 375 mg P.O. daily. If diuresis fails, give dose on alternate days, or give for 2 days alternating with day of rest.
  - **Children:** 5 mg/kg P.O. daily, or 150 mg/m² P.O. or I.V. once daily in morning

- Acute high-altitude (mountain) sickness
  - **Adults:** 500 mg to 1 g P.O. daily in divided doses, or sustained-release capsule q 12 to 24 hours. Dosing should begin 24 to 48 hours before ascent and continue during ascent and for 48 hours after reaching desired altitude. For rapid ascent, 1-g P.O. dose is recommended.

**Dosage adjustment**
- Mild renal failure

**Off-label uses**
- Acute pancreatitis
- Alkalosis after open-heart surgery
- Hereditary ataxia
- Peptic ulcer
- Periodic paralysis
- Renal calculi
- Phenobarbital or lithium overdose
- Hydrocephalus in infants

**Contraindications**
- Hypersensitivity to drug or sulfonamides
- Adrenocortical insufficiency
- Closed-angle glaucoma
- Severe pulmonary obstruction
- Severe renal disease, hypokalemia, hyponatremia
- Hepatic disease

**Precautions**
- Use cautiously in:
  - respiratory, renal, or hepatic disease; diabetes mellitus, hypercalcemia, gout, adrenocortical insufficiency
  - pregnant or breastfeeding patients.

**Administration**
- Before giving, ask if patient is pregnant. Drug may cause fetal toxicity.
- Direct I.V. administration is preferred. When giving by direct I.V. route, reconstitute 500-mg vial with more than 5 ml of sterile water for injection; administer over 1 minute.
- When giving drug intermittently by I.V. infusion, further dilute with normal saline solution or dextrose solution and infuse over 4 to 8 hours.
- Be aware that I.M. administration is painful because solution is alkaline.
- If necessary, crush tablets and mix in nonsweet, nonalcoholic syrup or non-glycerin solution.

<table>
<thead>
<tr>
<th>Route, I.M.</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1 hr</td>
<td>2-4 hr</td>
<td>8-12 hr</td>
</tr>
<tr>
<td>P.O. (sustained)</td>
<td>2 hr</td>
<td>8-12 hr</td>
<td>18-24 hr</td>
</tr>
<tr>
<td>I.V., I.M.</td>
<td>1-2 min</td>
<td>15-18 min</td>
<td>4-5 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: weakness, nervousness, irritability, drowsiness, confusion, dizziness, depression, tremor, headache, paresthesia, flaccid paralysis, seizures
EENT: transient myopia, tinnitus, hearing dysfunction, sensation of lump in throat
GI: nausea, vomiting, diarrhea, constipation, melena, abdominal distention, dry mouth, anorexia
GU: dysuria, hematuria, glycosuria, polyuria, crystalluria, renal colic, renal calculi, uremia, sulfonamide-like renal lesions, renal failure
Hematologic: thrombocytopenia, leukopenia, agranulocytosis, hemolytic anemia, thrombocytopenic purpura, pancytopenia, bone marrow depression with aplastic anemia
Hepatic: hepatic insufficiency
Metabolic: hypokalemia, hyperglycemia and glycosuria, hyperuricemia and gout, metabolic acidosis, hyperchloremic acidosis
Respiratory: hyperpnea
Skin: rash, pruritus, urticaria, photosensitivity, hirsutism, cyanosis
Other: altered taste and smell, weight loss, fever, excessive thirst, pain at I.M. injection site, hypersensitivity reaction, Stevens-Johnson syndrome

**Interactions**

**Drug-drug.** Amphetamines, procainamide, quinidine, tricyclic antidepressants: decreased excretion and enhanced or prolonged effect of these drugs, leading to toxicity
Amphotericin B, corticosteroids, corticotrophin, other diuretics: increased risk of hypokalemia
Lithium, phenobarbital, salicylates: increased excretion of these drugs, possibly reducing their efficacy
Methenamine compounds: inactivation of these drugs
Phenytoin, primidone: severe osteomalacia
Sulfonamides: increased risk of salicylate toxicity

**Drug-diagnostic tests.** Ammonia, bilirubin, calcium, chloride, glucose, uric acid: increased levels
Thyroid iodine uptake: decreased in patients with hyperthyroidism or normal thyroid function
Urinary protein (with some reagents): false-positive result

**Drug-behaviors.** Sun exposure: increased risk of photosensitivity

**Patient monitoring**

Evaluate for signs and symptoms of sulfonamide sensitivity; drug can cause fatal hypersensitivity.
Monitor laboratory test results for hematologic changes; blood glucose, potassium, bicarbonate, and chloride levels; and liver and kidney function changes.
Observe for signs and symptoms of bleeding tendency.
Monitor fluid intake and output.

**Patient teaching**

- Advise patient to take drug with food if GI upset occurs.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
Tell patient to eat potassium-rich foods (such as seafood, bananas, and oranges) if taking drug long term or receiving other potassium-depleting drugs.

Advise patient to avoid activities that can cause injury. Advise him to use soft toothbrush and electric razor to avoid gum and skin injury.

Tell patient to report significant numbness or tingling.

Inform patient that he’ll undergo regular blood testing during therapy.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

---

**Acetylcysteine (N-acetylcysteine)**

Acetadote, Mucomyst®, Mucomyst 10, Mucosil-10, Mucosil-20, Parovelex®

**Pharmacologic class:** N-acetyl derivative of naturally occurring amino acid (L-cysteine)

**Therapeutic class:** Mucolytic, acetaminophen antidote

**Pregnancy risk category B**

**Action**

Decreases viscosity of secretions, promoting secretion removal through coughing, postural drainage, and mechanical means. In acetaminophen overdose, maintains and restores hepatic glutathione, needed to inactivate toxic metabolites.

**Availability**

*Injection:* 200 mg/ml

*Solution:* 10%, 20%

---

**Indications and dosages**

**Mucolytic agent in adjunctive treatment of acute and chronic bronchopulmonary disease (bronchitis, bronchiectasis, chronic asthmatic bronchitis, emphysema, pneumonia, primary amyloidism of lungs, tuberculosis, tracheobronchitis), pulmonary complications of cystic fibrosis, atelectasis, or pulmonary complications related to surgery, posttraumatic chest conditions, tracheostomy care, or use during anesthesia**

**Adults and children:** Nebulization (face mask, mouthpiece, tracheostomy)—6 to 10 ml of 10% solution or 3 to 5 ml of 20% solution three or four times daily. Dosage range is 2 to 20 ml of 10% solution or 1 to 10 ml of 20% solution q 2 to 6 hours.

Nebulization (tent or croupette)—Volume of 10% or 20% solution that will maintain heavy mist for desired period

Instillation (direct)—1 to 2 ml of 10% to 20% solution q 1 hour p.r.n.

Instillation via syringe attached to percutaneous intratracheal catheter—2 to 4 ml of 10% solution or 1 to 2 ml of 20% solution q 1 to 4 hours

**Diagnostic bronchial studies**

**Adults and children:** Two to three doses of 2 to 4 ml of 10% solution or 1 to 2 ml of 20% solution by nebulization or intratracheal instillation before procedure

**Acetaminophen overdose**

**Adults, elderly patients, children:** Give immediately if 24 hours or less have elapsed since acetaminophen ingestion. Use the following protocol: empty stomach by lavage or emesis induction, and then have patient drink copious amounts of water. If activated charcoal has been given, perform lavage before giving acetylcysteine. Draw blood for acetaminophen plasma assay and baseline aspartate aminotransferase (AST), alanine aminotransferase (ALT), prothrombin time, bilirubin, blood glucose, blood urea

---

Reactions in **bold** are life-threatening.
nitrogen, electrolyte, and creatinine clearance levels. If ingested acetaminophen dose is in toxic range, give acetylcysteine 140 mg/kg P.O. as loading dose from 20% solution. Administer 17 maintenance doses of 70 mg/kg P.O. q 4 hours, starting 4 hours after loading dose. Repeat procedure until acetaminophen blood level is safe. If patient vomits loading dose or any maintenance dose within 1 hour of administration, repeat that dose.

Off-label uses
● Unstable angina

Contraindications
● Hypersensitivity to drug (except with antidotal use)
● Status asthmaticus (except with antidotal use)

Precautions
Use cautiously in:
● renal or hepatic disease, Addison’s disease, alcoholism, brain tumor, bronchial asthma, seizure disorder, hypothyroidism, respiratory insufficiency, psychosis
● elderly patients
● pregnant or breastfeeding patients.

Administration
● Separate administration times of this drug and antibiotics.
● Use plastic, glass, or stainless steel container when giving by nebulizer, because solution discolors on contact with rubber and some metals.
● Once solution is exposed to air, use within 96 hours.
● Dilute solution before administering for acetaminophen overdose, to reduce risk of vomiting, drug’s unpleasant odor, and irritating or sclerosing properties.
● Chill solution and have patient sip through straw, or, if necessary, give by nasogastric tube when administering for acetaminophen overdose.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30-60 min</td>
<td>1-2 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>Instillation</td>
<td>1 min</td>
<td>5-10 min</td>
<td>2-3 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, drowsiness, headache
CV: hypotension, hypertension, tachycardia
EENT: severe rhinorrhea
GI: nausea, vomiting, stomatitis, constipation, anorexia
Hepatic: hepatotoxicity
Respiratory: hemoptysis, tracheal and bronchial irritation, increased secretions, wheezing, chest tightness, bronchospasm
Skin: urticaria, rash, clamminess, angioedema
Other: tooth damage, chills, fever, hypersensitivity including anaphylaxis

Interactions
Drug-drug. Activated charcoal: increased absorption and decreased efficacy of acetylcysteine
Nitroglycerin: increased nitroglycerin effects, causing hypotension and headache
Drug-diagnostic tests. Liver function tests: abnormal results

Patient monitoring
● Monitor respirations, cough, and character of secretions.

Patient teaching
● Instruct patient to report worsening cough and other respiratory symptoms.
● Advise patient to mix oral form with juice or cola to mask bad taste and odor.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.
acetylsalicylic acid (aspirin)


Pharmacologic class: Nonsteroidal anti-inflammatory drug (NSAID)
Therapeutic class: Nonopioid analgesic, antipyretic, antiplatelet drug
Pregnancy risk category C (with full dose in third trimester: D)

Action
Reduces pain and inflammation by inhibiting prostaglandin production. Fever reduction mechanism unknown; may be linked to decrease in endogenous pyrogens in hypothalamus resulting from prostaglandin inhibition. Exerts antiplatelet effect by inhibiting synthesis of prostacyclin and thromboxane A₂.

Availability
Gum (chewable): 227 mg
Suppositories: 60 mg, 120 mg, 200 mg, 300 mg, 325 mg, 600 mg, 650 mg
Tablets: 81 mg, 325 mg, 500 mg
Tablets (chewable): 81 mg
Tablets (enteric-coated, delayed-release): 81 mg, 162 mg, 325 mg, 500 mg, 650 mg, 975 mg
Tablets (extended-release): 650 mg, 800 mg
Tablets (film-coated): 325 mg, 500 mg

Indications and dosages

Mild pain or fever
Adults: 325 to 500 mg P.O. q 3 hours, or 325 to 650 mg P.O. q 4 hours, or 650 to 1,000 mg P.O. q 6 hours, to a maximum dosage of 4,000 mg/day. Extended-release tablets—650 mg to 1,300 mg q 8 hours, not to exceed 3,900 mg/day; or 800 mg q 12 hours.
Children: 10 to 15 mg/kg P.O. or P.R. q 4 hours, not to exceed total daily dosage of 3.6 g, or up to 60 to 80 mg/kg/day. See chart below.

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Dosage (q 4 hr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12-14</td>
<td>648 mg</td>
</tr>
<tr>
<td>11-12</td>
<td>486 mg</td>
</tr>
<tr>
<td>9-10</td>
<td>405 mg</td>
</tr>
<tr>
<td>6-8</td>
<td>324 mg</td>
</tr>
<tr>
<td>4-5</td>
<td>243 mg</td>
</tr>
<tr>
<td>2-3</td>
<td>162 mg</td>
</tr>
</tbody>
</table>

Mild to moderate pain caused by inflammation (as in rheumatoid arthritis or osteoarthritis)
Adults: Initially, 2,400 to 3,600 mg P.O. daily in divided doses. Dosage may be increased by 325 to 1,200 mg daily at intervals of at least 1 week. Usual maintenance dosage is 3.6 to 5.4 g/day P.O. in divided doses, to a maximum dosage of 6 g/day.

Juvenile rheumatoid arthritis
Children: 60 to 130 mg/kg/day P.O. in children weighing 25 kg (55 lb) or less, or 2,400 to 3,600 mg P.O. daily in children weighing more than 25 kg P.O.; give in divided doses q 6 to 8 hours.

Acute rheumatic fever
Adults: 5 to 8 g/day P.O. in divided doses
Children: Initially, 100 mg/kg/day P.O. in individual doses for first 2 weeks; then maintenance dosage of 75 mg/kg/day P.O. in divided doses for next 4 to 6 weeks
To reduce the risk of transient ischemic attacks (TIAs) or cerebrovascular

Reactions in bold are life-threatening.
accident in men with a history of TIAs caused by emboli

**Adults:** 650 mg P.O. b.i.d or 325 mg P.O. q.i.d.

➢ To reduce the risk of myocardial infarction (MI) in patients with a history of MI or unstable angina

**Adults:** 75 to 325 mg/day P.O.

➢ Kawasaki disease

**Children:** Initially during acute febrile period, 80 to 180 mg/kg/day P.O. in four divided doses. Maintenance dosage is 3 to 10 mg/kg/day given as a single dose for up to 8 weeks or until platelet count and erythrocyte sedimentation rate return to normal.

➢ Thromboembolic disorders

**Adults:** 325 to 650 mg P.O. once or twice daily

**Contraindications**

- Hypersensitivity to salicylates, other NSAIDs, or tartrazine
- Renal impairment
- Severe hepatic impairment
- Hemorrhagic states or blood coagulation defects
- Vitamin K deficiency caused by dehydration
- Concurrent anticoagulant use
- Pregnancy (third trimester) or breastfeeding

**Precautions**

Use with extreme caution, if at all, in:

- hepatic disorders, anemia, asthma, gastritis, Hodgkin’s disease
- heart failure or other conditions in which high sodium content is harmful (buffered aspirin)
- patients receiving other salicylates or NSAIDs concurrently
- elderly patients
- children and adolescents.

**Administration**

➢ Never administer to child or adolescent who has signs or symptoms of chickenpox or flulike illness.

➢ Don’t give within 6 weeks after administration of live varicella virus vaccine, because of risk of Reye’s syndrome.

- Give with food or large amounts of water or milk to minimize GI irritation.
- Know that extended-release and enteric-coated forms are best for long-term therapy.
- Be aware that aspirin should be discontinued at least 1 week before surgery because it may inhibit platelet aggregation.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O. (tablets)</td>
<td>15-30 min</td>
<td>1-2 hr</td>
<td>4-6 hr</td>
</tr>
<tr>
<td>P.O. (chewable)</td>
<td>Rapid</td>
<td>Unknown</td>
<td>1-4 hr</td>
</tr>
<tr>
<td>P.O. (enteric-coated)</td>
<td>5-30 min</td>
<td>2-4 hr</td>
<td>8-12 hr</td>
</tr>
<tr>
<td>P.O. (extended)</td>
<td>5-30 min</td>
<td>1-4 hr</td>
<td>3-6 hr</td>
</tr>
<tr>
<td>P.R.</td>
<td>5-30 min</td>
<td>3-4 hr</td>
<td>1-4 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

EENT: hearing loss, tinnitus, ototoxicity

GI: nausea, vomiting, abdominal pain, dyspepsia, epigastric distress, heartburn, anorexia, GI bleeding

Hematologic: thrombocytopenia, hemolytic anemia, leukopenia, agranulocytosis, shortened red blood cell life span

Hepatic: hepatotoxicity

Metabolic: hyponatremia, hypokalemia, hypoglycemia

Respiratory: wheezing, hyperpnea, pulmonary edema with toxicity

Skin: rash, urticaria, bruising, angioedema

Other: hypersensitivity reactions, salicylism or acute toxicity

**Interactions**

Drug-drug. Acidifying drugs (such as ammonium chloride): increased salicylate blood level

Activated charcoal: decreased salicylate absorption
Alkalinizing drugs (such as antacids): decreased salicylate blood level
Angiotensin-converting enzyme (ACE) inhibitors: decreased antihypertensive effect
Anticoagulants, NSAIDs, thrombolytics: increased bleeding risk
Carbonic anhydrase inhibitors (such as acetazolamide): salicylism
Corticosteroids: increased salicylate excretion and decreased blood level
Furosemide: increased diuretic effect
Live varicella virus vaccine: increased risk of Reye’s syndrome
Methotrexate: decreased methotrexate excretion and increased blood level, causing greater risk of toxicity
Nizatidine: increased salicylate blood level
Spironolactone: decreased spironolactone effect
Sulfonylureas (such as chlorpropamide, tolbutamide): enhanced sulfonylurea effects
Tetracycline (oral): decreased absorption of tetracycline (with buffered aspirin)

Drug-diagnostic tests. Alanine amino-transferase, alkaline phosphatase, amylase, aspartate aminotransferase, coagulation studies, PaCO₂, uric acid: increased values
Cholesterol, glucose, potassium, protein-bound iodine, sodium, thyroxine, triiodothyronine: decreased levels
Pregnancy test, protirelin-induced thyroid stimulating hormone, radionuclide thyroid imaging, serum theophylline (Schack and Waxler method), urine catecholamines, urine glucose, urine hydroxyindoleacetic acid, urine ketones (ferric chloride method), urine vanillylmandelic acid: test interference
Tests using phenolsulfonphthalein as diagnostic agent: decreased urinary excretion of phenolsulfonphthalein
Urine protein: increased level

Drug-food. Urine-acidifying foods: increased salicylate blood level

Drug-herbs. Anise, arnica, cayenne, chamomile, clove, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng, horse chestnut, kelpware, licorice: increased bleeding risk

Drug-behaviors. Alcohol use: increased bleeding risk

Patient monitoring
- Watch for signs and symptoms of hypersensitivity and other adverse reactions, especially bleeding tendency.
- Stay alert for signs and symptoms of acute toxicity, such as diplopia, ECG abnormalities, generalized seizures, hallucinations, hyperthermia, oliguria, acute renal failure, incoherent speech, irritability, restlessness, tremor, vertigo, confusion, disorientation, mania, lethargy, laryngeal edema, anaphylaxis, and coma.
- Monitor elderly patients carefully because they’re at greater risk for salicylate toxicity.
- With prolonged therapy, frequently assess hemoglobin, hematocrit, International Normalized Ratio, and kidney function test results.
- Check salicylate blood levels frequently.
- Evaluate patient for signs and symptoms of ototoxicity (hearing loss, tinnitus, ataxia, and vertigo).

Patient teaching
- Tell patient to report ototoxicity symptoms, unusual bleeding, and bruising.
- Caution patient to avoid activities that may cause injury. Advise him to use soft toothbrush and electric razor to avoid gum and skin injury.
- Instruct patient to tell all prescribers he’s taking the drug, because it may cause serious interactions with many common medications.
- Tell patient not to take other over-the-counter preparations containing aspirin.

Reactions in **bold** are life-threatening.

Clinical alert
Inform patient that he may need to undergo regular blood testing during therapy.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

**Acitretin**

**Pharmacologic class:** Second-generation retinoid

**Therapeutic class:** Antipsoriatic

**Pregnancy risk category X**

**FDA BOXED WARNING**

- Drug may harm fetus and must not be used by pregnant patients, those who intend to become pregnant, or those who may not use reliable contraception during therapy and for at least 3 years afterward.
- Patient must commit to using two effective contraceptive forms simultaneously. At least one form must be primary, unless patient chooses absolute abstinence, has had a hysterectomy, or is postmenopausal.
- Drug should be prescribed only by clinicians with special competence in diagnosing and treating severe psoriasis, experience using systemic retinoids, and understanding of teratogenicity risk.
- Consider drug only for women with severe psoriasis unresponsive to other therapies or whose clinical condition contraindicates other therapies.
- Instruct patient not to donate blood during therapy and for at least 3 years afterward.

**Action**

Unclear. Promotes normal growth cycle of skin cells, possibly by targeting retinoid receptors in these cells and adjusting factors that affect epidermal proliferation and synthesis of RNA and DNA.

**Availability**

*Capsules:* 10 mg, 25 mg

**Indications and dosages**

- Severe psoriasis, including erythrodermic and generalized pustule types
- **Adults and elderly patients:** Initially, 25 to 50 mg/day P.O. as a single dose with main meal. If initial response is satisfactory, give maintenance dosage of 25 to 50 mg/day P.O.

**Off-label uses**

- Darier’s disease (keratosis follicularis)
- Lamellar ichthyosis (in children)
- Lichen planus
- Nonbullous and bullous ichthyosiform erythroderma
- Palmoplantar pustulosis
- Sjögren-Larsson syndrome

**Contraindications**

- Hypersensitivity to drug or paraben (used as preservative in gelatin capsule)
- Pregnancy or anticipated pregnancy within 3 years after drug discontinuation (drug has teratogenic and embryotoxic effects)
- Women of childbearing age who may not use reliable contraception during therapy and for at least 3 years after drug discontinuation
- Breastfeeding

**Precautions**

Use cautiously in:

- hepatic or renal impairment, diabetes mellitus, obesity
- elevated cholesterol or triglyceride levels
- elderly patients.
Administration

- Verify that patient isn’t pregnant before giving drug.
- Give as a single dose with main meal.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

**CNS:** headache, depression, insomnia, drowsiness, fatigue, migraine, rigors, abnormal gait, nerve inflammation, hyperesthesia, paresthesia, **pseudo-tumor cerebri**

**EENT:** abnormal or blurred vision, dry eyes, eye irritation, eyebrow and eyelash loss, eyelid inflammation, cataract, conjunctivitis, corneal epithelial abnormality, reduced night vision, photophobia, recurrent styes, earache, tinnitus, hearing loss, epistaxis, rhinitis, sinusitis, **papilledema**

**GI:** nausea, vomiting, diarrhea, constipation, abdominal pain, gastritis, stomatitis, esophagitis, melena, painful straining at stool, pancreatitis, lip inflammation and cracking, dry mouth, anorexia

**GU:** abnormal urine, dysuria, atrophic vaginitis, leukorrhea

**Hepatic:** abnormal hepatic function, jaundice, hepatitis

**Metabolic:** poor blood glucose control

**Musculoskeletal:** joint, muscle, back, and bone pain; arthritis; bone disorders; spinal bone overgrowth; increased muscle tone or rigidity; tendinitis

**Respiratory:** coughing, increased sputum, laryngitis

**Skin:** dry skin, pruritus, skin atrophy, skin peeling, abnormal skin odor, sticky skin, seborrhea, dermatitis, diaphoresis, cold clammy skin, skin infection, rash, pyrogenic granuloma, skin ulcers, skin fissures, sunburn, flushing, purpura, nail disorder, inflammation of tissue surrounding nails, abnormal hair texture, alopecia

**Other:** abnormal taste, glossitis, tongue ulcers, gingival bleeding, gingivitis, edema, thirst, hot flashes

Interactions

**Drug-drug.** *Glyburide:* increased blood glucose clearance

*Methotrexate:* increased risk of hepatotoxicity

*Oral contraceptives (“minipill”):* decreased contraceptive efficacy

**Drug-diagnostic tests.** *Alanine aminotransferase, aspartate aminotransferase, triglycerides:* increased levels

*Low-density lipoproteins:* decreased level

**Drug-behaviors.** *Alcohol use:* interference with acitretin elimination, possible drug toxicity

Patient monitoring

- Monitor patient who has early signs or symptoms of pseudotumor cerebri, such as headache, nausea, vomiting, and visual disturbances. Discontinue drug immediately if papilledema occurs.
- Check blood lipid levels before therapy begins and every 1 to 2 weeks during therapy.
- Monitor blood glucose levels and kidney and liver function test results.
- If drug causes open skin lesions resulting from dermatitis or blisters, watch for signs and symptoms of infection.
- Assess for pain, stinging, and itching. Apply cool compresses as needed for relief.
- Be aware that women taking this drug must avoid alcohol-containing foods, beverages, medications, and over-the-counter products during therapy and for 2 months afterward.

Patient teaching

- Instruct patient to take drug with main meal to minimize GI upset.
- Tell patient to avoid driving and other hazardous activities until he knows

Reactions in **bold** are life-threatening.
how drug affects concentration, alertness, and vision.

- Caution patient not to drink alcohol during therapy.

- Advise females to use effective contraception for at least 1 month before starting drug, throughout entire course of therapy, and for 3 years after discontinuing drug.
- Explain that disease may seem to worsen at start of therapy.
- Tell contact lens wearers that lens intolerance may develop.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

### Activated Charcoal

**Trade names:** Actidose, Actidose-Aqua, Bragg's Medicinal Charcoal, Carbomix, Charcadote, Char-Caps, Charco Caps, EZ-Char

**Pharmacologic class:** Carbon residue

**Therapeutic class:** Antiflatulent, antidote

**Pregnancy risk category C**

### Action

Binds to poisons, toxins, irritants, and drugs, forming a barrier between particulate material and GI mucosa that inhibits absorption of this material in GI tract. As an antiflatulent, reduces intestinal gas volume and relieves related discomfort.

### Availability

- **Capsules:** 260 mg
- **Granules:** 15 g/120 ml
- **Liquid:** 15 g/120 ml, 50 g/240 ml, 208 mg/1 ml
- **Oral suspension:** 12.5 g/60 ml, 15 g/75 ml, 25 g/120 ml, 30 g/120 ml, 50 g/240 ml
- **Powder:** 15, 30, 40, 130, 240 g/container

### Indications and dosages

- **Poisoning**
  - **Adults:** 25 to 100 g P.O. (or 1 g/kg, or about 10 times the amount of poison ingested) as a suspension in 120 to 240 ml (4 to 8 oz) of water
  - **Children:** Initially, 1 to 2 g/kg P.O. (or 10 times the amount of poison ingested) as a suspension in 120 to 240 ml (4 to 8 oz) of water

- **Flatulence**
  - **Adults:** 600 mg to 5 g P.O. as a single dose, or 975 mg to 3.9 g in divided doses

### Off-label uses

- Diarrhea
- GI distress
- Hypercholesterolemia

### Contraindications

None

### Precautions

Use cautiously in:

- patients who have aspirated corrosives or hydrocarbons and are vomiting.

### Administration

- Don’t try to give activated charcoal to semiconscious patient.
- If signs of aspiration occur, stop giving drug immediately to avoid fatal airway obstruction or infection.
- Administer by large-bore nasogastric tube after gastric lavage, as needed.
- Give within 30 minutes of poison ingestion when possible.
- Mix powder with tap water to form thick syrup. Add fruit juice or flavoring to improve taste.
- Be aware that drug inactivates ipecac syrup.
- Know that drug is ineffective in poisoning from ethanol, methanol, and iron salts.

📅 Canada 🌎 UK 🦾 Hazardous drug ✅ High alert drug
- Don’t give children more than one dose of drug product containing sorbitol (sweetener).
- When used for indications other than as antidote, give drug at least 2 hours before or 1 hour after other drugs.

### Route Onset Peak Duration

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Immediate</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

### Adverse reactions

**GI:** nausea, vomiting, diarrhea, constipation, black stools, intestinal obstruction

### Interactions

**Drug-drug.** Acetaminophen, barbiturates, carbamazepine, digitoxin, digoxin, furosemide, glutethimide, hydantoins, methotrexate, nizatidine, phenothiazines, phenylbutazones, procainophene, salicylates, sulfonamides, sulfonyleurea, tetracycline, theophyllines, tricyclic antidepressants, valproic acid: decreased absorption of these drugs

**Ipecac syrup:** ipecac absorption and inactivation

**Drug-food.** Milk, ice cream, sherbet: decreased absorptive activity of drug

### Patient monitoring

- Monitor patient for constipation.
- If patient vomits soon after receiving dose, ask prescriber if dose should be repeated.

### Patient teaching

- Instruct patient to drink six to eight glasses of fluid daily to prevent constipation.
- Tell patient that stools will be black as charcoal is excreted from body.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and foods mentioned above.

### acyclovir

**Acyclovir sodium**

*Zovirax*

**Pharmacologic class:** Acyclic purine nucleoside analogue

**Therapeutic class:** Antiviral

**Pregnancy risk category B**

### Action

Inhibits viral DNA polymerase, thereby inhibiting replication of viral DNA. Specific for herpes simplex types 1 (HSV-1) and 2 (HSV-2), varicella-zoster virus, Epstein-Barr virus, and cytomegalovirus (CMV).

### Availability

- **Capsules:** 200 mg
- **Cream:** 5% in 2-g tube
- **Injection:** 50 mg/ml
- **Ointment:** 5% in 15-g tube
- **Powder for injection:** 500 mg/vial, 1,000 mg/vial
- **Suspension:** 200 mg/5 ml
- **Tablets:** 400 mg, 800 mg

### Indications and dosages

- Acute treatment of herpes zoster (shingles)
  - **Adults:** 800 mg P.O. q 4 hours while awake (five times/day) for 7 to 10 days
  - **Initial episode of genital herpes**
  - **Adults:** 200 mg P.O. q 4 hours while awake (1,000 mg/day) for 10 days
  - **Chronic suppressive therapy for recurrent genital herpes episodes**
  - **Adults:** 400 mg P.O. b.i.d., or 200 mg P.O. three to five times daily for up to 12 months
  - **Intermittent therapy for recurrent genital herpes episodes**
  - **Adults:** 200 mg P.O. q 4 hours while awake (five times/day) for 5 days, initiated at first sign or symptom of recurrence

Reactions in **bold** are life-threatening.

*Clinical alert*
Management of initial episodes of genital herpes and limited, non-life-threatening mucocutaneous herpes simplex virus infections in immunocompromised patients

**Adults:** Apply approximately ½” ribbon of ointment per 4 square inches of surface area to sufficiently cover all lesions q 3 hours, six times daily for 7 days.

Treatment of recurrent herpes labialis (cold sores)

**Adults and adolescents ages 12 and older:** Apply cream to infected area five times daily for 4 days.

Varicella (chickenpox)

**Adults and children weighing more than 40 kg (88 lb):** 800 mg P.O. q.i.d. for 5 days

**Children older than age 2:** 20 mg/kg P.O. q.i.d. for 5 days

Mucosal and cutaneous HSV-1 and HSV-2 in immunocompromised patients

**Adults and children older than age 12:** 5 mg/kg 10 mg/kg I.V. infusion over 1 hour given q 8 hours for 7 days

**Children younger than age 12:** 10 mg/kg I.V. infusion over 1 hour given q 8 hours for 7 days

Herpes simplex encephalitis

**Adults and children older than age 12:** 10 mg/kg I.V. over 1 hour given q 8 hours for 10 days

**Children ages 3 months to 12 years:** 20 mg/kg I.V. over 1 hour given q 8 hours for 10 days

**Children from birth to 3 months:** 10 mg/kg I.V. over 1 hour given q 8 hours for 10 days

Varicella zoster infections in immunocompromised patients

**Adults and adolescents older than age 12:** 10 mg/kg 20 mg/kg I.V. over 1 hour given q 8 hours for 7 days

**Children younger than age 12:** 20 mg/kg I.V. over 1 hour given q 8 hours for 7 days

Dosage adjustment

- Renal impairment

**Obesity (adult dosage based on ideal weight)**

**Elderly patients**

**Off-label uses**

- Herpes zoster encephalitis
- CMV and HSV infection after bone marrow or kidney transplantation
- Infectious mononucleosis
- Varicella pneumonia

**Contraindications**

- Hypersensitivity to drug or valacyclovir

**Precautions**

Use cautiously in:

- preexisting serious neurologic, hepatic, pulmonary, or fluid or electrolyte abnormalities
- renal impairment
- obesity
- pregnant or breastfeeding patients.

**Administration**

- Make sure patient is adequately hydrated before starting therapy.
- Give single I.V. dose by infusion over at least 1 hour to minimize renal damage.
- Don’t give by I.V. bolus or by I.M. or subcutaneous route.
- Be aware that absorption of topical acyclovir is minimal.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O. Variable</td>
<td>1.5-2 hr</td>
<td>4 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V. Immediate</td>
<td>1 hr</td>
<td>8 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>Topical Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: aggressive behavior, dizziness, malaise, weakness, paresthesia, headache; with I.V. use—encephalopathic changes (lethargy, tremors, obtundation, confusion, hallucinations, agitation, seizures, coma)

CV: peripheral edema

EENT: vision abnormalities

GI: nausea, vomiting, diarrhea
GU: proteinuria, hematuria, crystaluria, vaginitis, candidiasis, changes in menses, vulvitis, oliguria, renal pain, renal failure, glomerulonephritis
Hematologic: anemia, lymphadenopathy, thrombocytopenia, thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (in immunocompromised patients), disseminated intravascular coagulation, hemolysis, leukopenia, leukoclastic vasculitis
Hepatic: jaundice, hepatitis
Musculoskeletal: myalgia
Skin: photosensitivity rash, pruritus, angioedema, alopecia, urticaria, severe local inflammatory reactions (with I.V. extravasation), toxic epidermal necrolysis, erythema multiforme
Other: gingival hyperplasia, fever, excessive thirst, pain at injection site, anaphylaxis, Stevens-Johnson syndrome

Interactions
Drug-drug. Interferon: additive effect
Nephrotoxic drugs: increased risk of nephrotoxicity
Probenecid: increased acyclovir blood level
Zidovudine: increased CNS effects, especially drowsiness
Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, bilirubin, blood urea nitrogen: increased levels

Patient monitoring
• Monitor fluid intake and output.
• Assess for signs and symptoms of encephalopathy.
• Evaluate patient frequently for adverse reactions, especially bleeding tendency.
• Monitor CBC with white cell differential and kidney function test results.

Patient teaching
• Instruct patient to keep taking drug exactly as prescribed, even after symptoms improve.
• Advise patient to drink enough fluids to ensure adequate urinary output.
• Tell patient to monitor urine output and report significant changes.
• Instruct patient to immediately report unusual bleeding or bruising.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
• Tell patient to use soft toothbrush and electric razor to avoid injury to gums and skin.
• Advise patient to avoid sexual intercourse when visible herpes lesions are present.
• Inform patient that he may need to undergo regular blood testing during therapy.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

adalimumab
Humira

Pharmacologic class: Biological modifier
Therapeutic class: Antirheumatic (disease-modifying), immuno-modulator

Pregnancy risk category B

FDA BOXED WARNING
• Tuberculosis (TB), invasive fungal infections, and other opportunistic infections (some fatal) have occurred in patients receiving drug. Treatment of latent TB infection reduces reactivation risk; however, active TB has developed...
in patients who tested negative for latent TB.

- Before and during therapy, evaluate patients for TB risk factors and test them for latent TB infection. Begin treatment of latent TB before starting drug. During therapy, monitor patients for signs and symptoms of active TB, even if they tested negative for latent TB.

**Action**

Human immunoglobulin (Ig) G1 monoclonal antibody that binds to human tumor necrosis factor (TNF), which plays a role in inflammation and immune responses. Also modulates biological responses induced or modulated by TNF.

**Availability**

*Injection (preservative-free):* 40 mg/0.8 ml

**Indications and dosages**

- To reduce signs and symptoms, slow disease progression, and improve physical function of moderately to severely active rheumatoid arthritis and to reduce signs and symptoms of psoriatic arthritis
  - **Adults:** 40 mg subcutaneously every other week alone or in combination with methotrexate or other disease modifying antirheumatic drugs

- To reduce signs and symptoms of ankylosing spondylitis
  - **Adults:** 40 mg subcutaneously every other week

- Crohn’s disease
  - **Adults:** Initially, 160 mg subcutaneously at week 0; 80 mg at week 2; then a maintenance dose of 40 mg every other week beginning at week 4. Initial dose may be given as four injections on 1 day or divided over 2 days.

**Contraindications**

- Hypersensitivity to drug

- Active infection, including chronic or localized infection

**Precautions**

Use cautiously in:

- preexisting or recent onset of demyelinating disorders, immunosuppression, or lymphoma
- elderly patients
- pregnant or breastfeeding patients
- children.

**Administration**

- Give subcutaneously; rotate injection sites.
- Be aware that patients not receiving methotrexate concurrently may benefit from dosage increase to 40 mg weekly.
- Store in refrigerator and protect from light.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcut</td>
<td>Slow</td>
<td>75-187 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: headache, demyelinating disease
CV: hypertension, arrhythmias
EENT: sinusitis
GI: nausea, vomiting, abdominal pain
GU: urinary tract infection, hematuria
Metabolic: hyperlipidemia, hypercholesterolemia
Musculoskeletal: back pain
Respiratory: upper respiratory tract infection
Skin: rash
Other: accidental injury, pain and swelling at injection site, flulike symptoms, lupuslike syndrome, fungal infection, allergic reactions, tuberculosis reactivation, malignancies

**Interactions**

Drug-drug. *Immunosuppressants (including corticosteroids):* serious infection
*Live-virus vaccines:* serious illness
*Drug-diagnostic tests.* *Alkaline phosphatase:* elevated level
Patient monitoring

- Monitor for signs and symptoms of infection if patient is receiving concurrent corticosteroids or other immunosuppressants (because of risk that infection may progress).
- Monitor CBC.

Patient teaching

- Teach patient how to recognize and report signs and symptoms of allergic response and other adverse reactions.
- Inform patient that drug lowers resistance to infection. Instruct him to immediately report fever, cough, breathing problems, and other infection symptoms.
- Instruct patient to minimize GI upset by eating small, frequent servings of healthy food and drinking plenty of fluids.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

adefovir dipivoxil

Hepsera

Pharmacologic class: Nucleotide reverse transcriptase inhibitor
Therapeutic class: Antiviral
Pregnancy risk category C

FDA BOXED WARNING

- Severe acute hepatitis exacerbations have occurred after drug withdrawal. Monitor hepatic function closely for at least several months in patients who discontinue drug or other anti–hepatitis B therapy; if appropriate, resume such therapy.
- Long-term therapy may cause nephrotoxicity in patients with or at risk for underlying renal dysfunction. Monitor renal function closely and adjust dosage as needed.
- Human immunodeficiency virus (HIV) resistance may occur during therapy in patients with chronic hepatitis B infection who have unrecognized or untreated HIV infection.
- Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) may occur with use of drug alone or combined with other antiretrovirals.

Action

Inhibits hepatitis B virus (HBV) DNA polymerase and suppresses HBV replication

Availability

Tablets: 10 mg

Indications and dosages

➣ Chronic HBV with active viral replication plus persistent elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or histologically active disease
Adults: 10 mg P.O. daily

Dosage adjustment

- Renal impairment

Contraindications

- Hypersensitivity to drug

Precautions

Use cautiously in:
- lactic acidosis, renal or hepatic impairment
- elderly patients
- pregnant or breastfeeding patients
- children.

Administration

- Offer HIV testing before starting therapy. (Drug may increase resistance to antiretrovirals in HIV patients.)
- Give with or without food.
Adverse reactions
CNS: headache
GI: nausea, vomiting, diarrhea, abdominal pain, flatulence, dyspepsia, anorexia, pancreatitis
GU: renal dysfunction
Hepatic: severe hepatomegaly with steatosis, hepatitis exacerbation (if therapy is withdrawn)
Metabolic: lactic acidosis
Respiratory: pneumonia
Other: fever, infection, pain, antiretroviral resistance in patients with unrecognized HIV

Interactions
Drug-drug. Acetaminophen, aspirin, indomethacin: granulocytopenia
Acyclovir, adriamycin, amphotericin B, benzodiazepines, cimetidine, dapsone, doxorubicin, experimental nucleotide analogue, fluconazole, fluycytosine, ganciclovir, indomethacin, interferon, morphine, phenytoin, probencid, sulfonamide, trimethoprim, vinblastine, vincristine: increased risk of nephrotoxicity
Drug-diagnostic tests. Amylase, blood glucose, blood urea nitrogen, creatine kinase, hepatic enzymes, lipase: elevated levels

Patient monitoring
• Monitor fluid intake and output.
• Watch for hematuria.
• Assess for signs and symptoms of lactic acidosis, especially in women and overweight patients.
• Check for liver enlargement.
• Monitor liver and kidney function test results.
• After therapy ends, monitor patient for evidence of serious hepatitis exacerbation.

Patient teaching
• Advise patient to take drug with or without food.
• Instruct patient to drink plenty of fluids to ensure adequate urine output.
• Advise patient to monitor urine output and color and to report significant changes.
• Tell patient that drug may cause weakness. Discuss appropriate lifestyle adjustments.
• Caution patient not to take over-the-counter analgesics without prescriber’s approval.
• Inform patient that he’ll undergo regular blood testing during therapy.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.
rapid I.V. bolus over 1 to 2 seconds. If desired effect isn’t achieved within 1 to 2 minutes, give 12 mg by rapid I.V. bolus; may repeat 12-mg I.V. bolus dose as needed. Maximum single dosage is 12 mg.

**Children weighing less than 50 kg (110 lb):** 0.05 to 0.1 mg/kg by rapid I.V. bolus. If this dosage proves ineffective, increase in 1 to 2 minutes by 0.05 mg/kg q 2 minutes, to a maximum single dosage of 0.3 mg/kg. Maximum single dosage is 12 mg.

**Adenoscan**—

- Diagnosis of coronary artery disease in conjunction with thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately during testing

**Adults:** 140 mcg/kg/minute by I.V. infusion over 6 minutes, for a total dosage of 0.84 mg/kg. Required dose of thallium-201 is injected at midpoint (after first 3 minutes) of Adenoscan infusion.

**Off-label uses**
- Diagnosis of supraventricular arrhythmias
- Pulmonary hypertension

**Contraindications**
- Hypersensitivity to drug
- Second- or third-degree AV block
- Sinus node disease
- Bronchoconstrictive lung disease

**Precautions**

Use cautiously in:
- asthma, angina
- elderly patients
- pregnant patients
- children.

**Administration**

- Don’t administer through central line (may cause asystole).
- Don’t give more than 12 mg Adenocard as a single dose.
- Don’t dilute Adenocard. Administer Adenocard by I.V. injection as a rapid bolus directly into vein whenever possible during cardiac monitoring.
  - After administering Adenocard, flush I.V. line immediately and rapidly with normal saline solution to drive drug into bloodstream.
  - Dilute a single dose of Adenoscan in sufficient normal saline solution to be given by continuous infusion over 6 minutes.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>10 sec</td>
<td>20-30 sec</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** light-headedness, dizziness, apprehension, headache, tingling in arms, numbness
**CV:** chest pain, palpitations, hypotension, ST-segment depression, first- or second-degree AV block, atrial tachyarrhythmias, other arrhythmias
**EENT:** blurred vision, tightness in throat
**GI:** nausea, pressure in groin
**Musculoskeletal:** discomfort in neck, jaw, and arms
**Respiratory:** chest pressure, dyspnea and urge to breathe deeply, hyperventilation
**Skin:** burning sensation, facial flushing, sweating
**Other:** metallic taste

**Interactions**

**Drug-drug.** Carbazepine: worsening of progressive heart block
Digoxin, verapamil: increased risk of ventricular fibrillation
Dipyridamole: increased adenosine effect
Theophylline: decreased adenosine effect

**Drug-food.** Caffeine: decreased adenosine effect

**Drug-herbs.** Aloe, buckthorn bark or berry, cascara sagrada, rhubarb root, senna leaf or fruits: increased adenosine effect
Guarana: decreased adenosine effect

Reactions in **bold** are life-threatening.
Drug-behaviors. Smoking: increased risk of tachycardia

Patient monitoring
- Monitor heart rhythm for new arrhythmias after administering dose.
- Check vital signs. Assess for chest pain or pressure, dyspnea, and sweating.
- Watch for bronchoconstriction in patients with asthma, emphysema, or bronchitis.
- Ask patient if he has recently used aloe, buckthorn, cascara sagrada, guarana, rhubarb root, or senna. If response is positive, notify prescriber.

Patient teaching
- Advise patient to report problems at infusion site.
- Tell patient he may experience 1 to 2 minutes of flushing, chest pain and pressure, and breathing difficulty during administration. Assure him that these effects will subside quickly.
- Advise patient to minimize GI upset by eating small, frequent servings of healthy food and drinking plenty of fluids.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, foods, herbs, and behaviors mentioned above.

Agalsidase beta
Fabrazyme, Fibrazyme

Pharmacologic class: Homodimeric glycoprotein
Therapeutic class: Recombinant human alpha-galactosidase enzyme
Pregnancy risk category B

Action
Provides exogenous source of alpha-galactosidase A (which is deficient in Fabry disease) and reduces deposits of globotriaosylceramide in kidney and other body tissues

Availability
Powder for reconstitution: 37 mg (5 mg/ml)

Indications and dosages
Fabry disease
Adults: 1 mg/kg I.V. q 2 weeks. Infuse no faster than 0.25 mg/minute; if tolerated, increase rate by 0.05 to 0.08 mg/minute in subsequent infusions.

Contraindications
None

Precautions
Use cautiously in:
- cardiac dysfunction
- pregnant or breastfeeding patients
- children.

Administration
- Premedicate with antipyretics, as prescribed.
- To reconstitute, slowly inject 7.2 ml of sterile water for injection into vial; then roll and tilt vial gently to mix drug.
- Don’t shake drug, and don’t use filter needles.
- Dilute reconstituted solution with normal saline injection to a final volume of 500 ml.
- Infuse through separate I.V. line; don’t mix with other drugs.

Route Onset Peak Duration
I.V. End of infusion 90 min Up to 5 hr

Adverse reactions
CNS: anxiety, depression, dizziness, paresthesias
CV: dependent edema, chest pain, cardiomegaly
EENT: rhinitis, sinusitis, laryngitis, pharyngitis
GI: nausea, dyspepsia
GU: testicular pain
Musculoskeletal: arthrosis, bone pain
Respiratory: bronchitis, bronchospasm
Skin: pallor
Other: pain, allergic reactions, infusion reactions (hypertension, chest tightness, dyspnea, fever, rigors, hypotension, abdominal pain, pruritus, myalgia, headache, urticaria)

Interactions
Drug-drug. Amiodarone, chloroquine, gentamicin, monobenzone: inhibition of intracellular agalsidase activity

Patient monitoring
- Watch closely for signs and symptoms of allergic or infusion reaction.
- Monitor vital signs and fluid intake and output. Stay alert for dependent edema, blood pressure changes, and chest pain.
- Measure temperature. Watch for signs and symptoms of infection (particularly EENT and respiratory infections).
- Evaluate patient’s mood. Report significant anxiety or depression.

Patient teaching
Teach patient to recognize and immediately report signs and symptoms of allergic or infusion reaction.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects mood, balance, and blood pressure.
- Advise patient to report signs and symptoms of infection (particularly EENT and respiratory infections).
- Inform patient that drug can cause depression and anxiety. Instruct him to notify prescriber if these effects occur.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

Reactions in bold are life-threatening.

Clinical alert
inhalation—2.5 mg three to four times daily by nebulization, delivered over 5 to 15 minutes.

**Children ages 6 to 12:** Tablets—2 mg P.O. three or four times daily; maximum daily dosage is 24 mg, given in divided doses. Extended-release tablets—4 mg q 12 hours; maximum daily dosage is 24 mg/kg given in divided doses. Syrup—2 mg (1 tsp or 5 ml) three or four times daily, not to exceed 24 mg.

**Children ages 2 to 12 weighing more than 15 kg (33 lb):** Solution for inhalation—2.5 mg three to four times/day by nebulization

**Children ages 2 to 6:** Syrup—Initially, 0.1 mg/kg P.O. t.i.d., not to exceed 2 mg (1 tsp) t.i.d. Maximum dosage is 4 mg (2 tsp) t.i.d.

➢ To prevent exercise-induced bronchospasm

**Adults and children older than age 4 (older than age 12 with Proventil):** Two inhalations 15 minutes before exercise

**Dosage adjustment**
- Sensitivity to beta-adrenergic stimulants
- Elderly patients

**Off-label uses**
- Chronic obstructive pulmonary disease
- Hyperkalemia with renal failure
- Preterm labor management

**Contraindications**
- Hypersensitivity to drug

**Precautions**
Use cautiously in:
- cardiac disease, hypertension, diabetes mellitus, glaucoma, seizure disorder, hyperthyroidism, exercise-induced bronchospasm, prostatic hypertrophy
- elderly patients
- pregnant or breastfeeding patients
- children.

**Administration**
- Give extended-release tablets whole; don’t crush or mix with food.
- Administer solution for inhalation by nebulization over 5 to 15 minutes, after diluting 0.5 ml of 0.5% solution with 2.5 ml of sterile normal saline solution.
- Know that children weighing less than 15 kg (33 lb) who require less than 2.5 mg/dose should receive 0.5% inhalation solution.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>15-30 min</td>
<td>2-3 hr</td>
<td>6-12 hr</td>
</tr>
<tr>
<td>P.O. (extended)</td>
<td>30 min</td>
<td>2-3 hr</td>
<td>12 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: dizziness, excitement, headache, hyperactivity, insomnia
CV: hypertension, palpitations, tachycardia, chest pain
EENT: conjunctivitis, dry and irritated throat, pharyngitis
GI: nausea, vomiting, anorexia, heartburn, GI distress, dry mouth
Metabolic: hypokalemia
Musculoskeletal: muscle cramps
Respiratory: cough, dyspnea, wheezing, paradoxical bronchospasm
Skin: pallor, urticaria, rash, angioedema, flushing, sweating
Other: tooth discoloration, increased appetite, hypersensitivity reaction

**Interactions**

Drug-drug. **Beta-adrenergic blockers:** inhibited albuterol action, possibly causing severe bronchospasm in asthmatic patients
**Digoxin:** decreased digoxin blood level
**MAO inhibitors:** increased cardiovascular adverse effects
**Oxytoxics:** severe hypotension
**Potassium-wasting diuretics:** ECG changes, hypokalemia
**Theophylline:** increased risk of theophylline toxicity

Canada UK ⚠️ Hazardous drug ☠️ High alert drug
Drug-food. Caffeine-containing foods and beverages (such as coffee, tea, chocolate): increased stimulant effect

Drug-herbs. Cola nut, ephedra (ma huang), guarana, yerba maté: increased stimulant effect

Patient monitoring
- Stay alert for hypersensitivity reactions and paradoxical bronchospasm. Stop drug immediately if these occur.
- Monitor serum electrolyte levels.

Patient teaching
- Tell patient to swallow extended-release tablets whole and not to mix them with food.
- Teach patient signs and symptoms of hypersensitivity reaction and paradoxical bronchospasm. Tell him to stop taking drug immediately and contact prescriber if these occur.
- Instruct patient to notify prescriber immediately if prescribed dosage fails to provide usual relief, because this may indicate seriously worsening asthma.
- Advise patient to limit intake of caffeine-containing foods and beverages and to avoid herbs unless prescriber approves.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Advise patient to establish effective bedtime routine and to take drug well before bedtime to minimize insomnia.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, foods, and herbs mentioned above.

FDA BOXED WARNING
- Give only to patients with normal cardiac and pulmonary function, as shown by thallium stress testing and pulmonary function testing. Use extreme caution when giving to patients with normal thallium stress test and normal pulmonary function tests who have a history of cardiac or pulmonary disease.
- Give under supervision of physician experienced in cancer chemotherapy, in setting where intensive care facilities and cardiopulmonary or intensive care specialists are available.
- Drug is linked to capillary leak syndrome, which causes hypotension and reduced organ perfusion (possibly severe and resulting in death).
- Before starting drug, preexisting bacterial infections must be treated, because drug may impair neutrophil function and increase disseminated infection risk. Patients with indwelling central lines are at special risk for infection with gram-positive microorganisms. Prophylactic antibiotics can help prevent staphylococcal infections.
- Withhold drug in patients who develop moderate to severe lethargy or somnolence; continued administration may cause coma.

Reactions in **bold** are life-threatening.
Action
Activates cellular immunity and inhibits tumor growth by increasing lymphocytes and cytokines, which lyse tumor cells

Availability
Injection: 22 million international units/vial

Indications and dosages
Metastatic renal cell carcinoma and metastatic melanoma
Adults older than age 18: 600,000 international units/kg I.V. given over 15 minutes q 8 hours for a maximum of 14 doses, followed by 9 days of rest. Repeat for another 14 doses, for a maximum of 28 doses per course.

Off-label uses
- Colorectal cancer
- Kaposi’s sarcoma
- Non-Hodgkin’s lymphoma

Contraindications
- Hypersensitivity to drug
- Arrhythmias, cardiac tamponade, seizures, severe GI bleeding, coma or toxic psychosis lasting more than 48 hours
- Organ allograft
- Abnormal thallium stress test or pulmonary function test results

Precautions
Use cautiously in:
- anemia, bacterial infections, heart disease, CNS metastases, hepatic disease, pulmonary disease, renal disease, thrombocytopenia
- pregnant or breastfeeding patients
- children.

Administration
- Make sure patient’s thallium stress test and pulmonary function test results are normal before giving.

Adverse reactions
CNS: dizziness, mental status changes, syncope, sensory or motor dysfunction, headache, fatigue, rigors, weakness, malaise, poor memory, depression, sleep disturbances, hallucinations
CV: bradycardia, sinus tachycardia, premature atrial complexes, premature ventricular contractions, arrhythmias, myocardial ischemia, cardiac arrest, capillary leak syndrome and severe hypotension, myocardial infarction
EENT: reversible vision changes, conjunctivitis
GI: nausea, vomiting, diarrhea, constipation, dyspepsia, abdominal pain, stomatitis, anorexia, intestinal perforation, ileus, GI bleeding
GU: hematuria, proteinuria, dysuria, renal failure, oliguria or anuria
Hematologic: anemia, purpura, eosinophilia, thrombocytopenia, coagulation disorders, leukopenia, leukocytosis
Hepatic: jaundice, ascites
Metabolic: hyperglycemia, hypoglycemia, acidosis, alkalosis
Musculoskeletal: joint and back pain, myalgia
Respiratory: cough, chest pain, tachypnea, wheezing, dyspnea, pulmonary congestion, pulmonary
edema, respiratory failure, apnea, pleural effusion

**Skin:** erythema, pruritus, rash, dry skin, petechiae, urticaria, exfoliative dermatitis

**Other:** weight gain or loss, fever, chills, edema, infection, pain or reaction at injection site, hypersensitivity reaction

**Interactions**

**Drug-drug.** Aminoglycosides, asparaginase, cytotoxic chemotherapy agents, doxorubicin, indomethacin, methotrexate: increased toxicity

**Antihypertensives:** increased hypotensive effect

**Glucocorticoids:** reduced antitumor effects

**Drug-diagnostic tests.** Alkaline phosphatase, bilirubin, glucose, blood urea nitrogen, creatinine, potassium, transaminases: increased levels

**Calcium, glucose, magnesium, phosphorus, potassium, protein sodium, uric acid:** decreased levels

**Patient monitoring**

- Monitor heart rate and rhythm, vital signs, and fluid intake and output.
- Assess for signs and symptoms of hypersensitivity reaction and infection.
- Monitor for adverse CNS effects. Report these immediately.
- Evaluate chest X-rays.
- Monitor CBC, electrolyte levels, and liver and kidney function test results.

**Patient teaching**

- Tell patient that drug lowers resistance to infections. Advise him to immediately report fever, cough, breathing problems, and other signs or symptoms of infection.

- Advise patient to immediately report chest pain, irregular or fast heart beats, easy bruising or bleeding, or abdominal pain.

- Instruct patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.

- Provide dietary counseling. Refer patient to dietitian if adverse GI effects significantly limit food intake.

- Notify patient that he’ll undergo blood testing and have chest X-rays taken during therapy.

- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**alemtuzumab**

Campath, MabCampath®

**Pharmacologic class:** Monoclonal antibody

**Therapeutic class:** Antineoplastic

**Pregnancy risk category C**

**FDA BOXED WARNING**

- Give under supervision of physician experienced in cancer chemotherapy.

- Drug may cause hematologic toxicity. Serious, and rarely fatal, cases of pancytopenia, thrombocytopenia, and autoimmune hemolytic anemia have occurred. Don’t give single doses exceeding 30 mg or cumulative doses exceeding 90 mg/week, because these increase pancytopenia risk.

- Drug may cause serious infusion reactions. Monitor patient carefully during infusion; if indicated, discontinue. Escalate dosage gradually to recommended maintenance dose when initiating therapy and if therapy is interrupted for 7 or more days.

- Serious and sometimes fatal bacterial, viral, fungal, and protozoan infections have occurred. Prophylaxis against *Pneumocystis carinii* pneumonia and

Reactions in **bold** are life-threatening.
herpesvirus infections has decreased but not eliminated such infections.

**Action**  
Binds to CD52 antigen on surface of B- and T-lymphocytes, monocytes, macrophages, "natural killer" cells, and granulocytes. Lyses leukemic cells and reduces tumor size.

**Availability**  
*Solution for injection: 30 mg/3 ml*

**Indications and dosages**  
**Chronic lymphocytic (B-cell) leukemia when fludarabine therapy fails**  
**Adults:** Initially, 3 mg/day I.V. given over 2 hours; if tolerated, increase to 10 mg/day, to a maximum single dose of 30 mg/day. Then give a maintenance dose of 30 mg three times weekly on nonconsecutive days (such as Monday, Wednesday, Friday) for up to 12 weeks.

**Dosage adjustment**  
- Hematologic toxicity

**Contraindications**  
- Type I hypersensitivity or anaphylactic reaction to drug or its components  
- Active systemic infection  
- Immunodeficiency (as in human immunodeficiency virus infection)

**Precautions**  
Use cautiously in:  
- pregnant or breastfeeding patients  
- children.

**Administration**  
- Withhold drug and contact prescriber if patient has signs or symptoms of systemic infection at time of scheduled infusion.  
- Don’t give by I.V. push or bolus.  
- Withdraw dose from ampule and filter with sterile, low-protein-binding, 5-micron filter.

- Dilute with 100 ml of normal saline solution or dextrose 5% in water.  
- Infuse over 2 hours.  
- Protect I.V. solution from light.

**Route** | **Onset** | **Peak** | **Duration**  
--- | --- | --- | ---  
I.V. | Unknown | Unknown | Unknown

**Adverse reactions**  
CNS: tremor, malaise, dizziness, depression, insomnia, drowsiness, weakness, headache, abnormal sensations, fatigue  
CV: peripheral edema, chest pain, hypotension, hypertension, tachycardia, **supraventricular tachycardia**  
EENT: rhinitis, pharyngitis, epistaxis  
GI: nausea, vomiting, constipation, diarrhea, dyspepsia, abdominal pain, stomatitis, anorexia  
Hematologic: anemia, **thrombocytopenia, pancytopenia, bone marrow hypoplasia, neutropenia, bone marrow depression**  
Metabolic: hypokalemia, hypomagnesemia  
Musculoskeletal: myalgia, bone or back pain  
Respiratory: cough, bronchitis, dyspnea, pneumonitis, **bronchospasm**  
Skin: herpes simplex infection, urticaria, pruritus, diaphoresis  
Other: edema, fever, candidiasis, infection, **infusion-related reactions, sepsis**

**Interactions**  
**Drug-drug. Live-virus vaccines:** decreased drug efficacy and increased adverse effects  
**Drug-diagnostic tests. CD4+ T-lymphocytes, hematocrit, hemoglobin, lymphocytes, neutrophils, platelets, red blood cells, white blood cells:** decreased values

**Patient monitoring**  
- Assess for hypotension during infusion.  
- Monitor vital signs frequently throughout entire course of therapy.  
- Monitor CBC, CD4+ level, electrolyte levels, and platelet count.
Patient teaching

Inform patient that drug lowers resistance to infection. Instruct him to immediately report fever, cough, breathing problems, sore throat, and other signs or symptoms.

Tell patient to immediately report irregular or fast heart beats or easy bruising or bleeding.

- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
- Instruct patient to follow regular bedtime routine and avoid bedtime stimulants.
- Encourage patient to discuss activity recommendations and pain management with prescriber.
- Inform patient that he’ll undergo regular blood testing during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Availability

Oral solution: 70 mg/75 ml in single-dose bottles
Tablets: 5 mg, 10 mg, 35 mg, 40 mg, 70 mg

Indications and dosages

- Paget’s disease of bone (men and women)
  - Adults: 40 mg P.O. daily for 6 months
- Prevention of osteoporosis in postmenopausal women
  - Adults: 5 mg P.O. daily or 35 mg P.O. once weekly for up to 7 years
- Glucocorticoid-induced osteoporosis in men and women
  - Adults: 5 mg P.O. daily. For postmenopausal women not receiving estrogen, recommended dosage is 10 mg P.O. once daily.
- Treatment of osteoporosis in postmenopausal women; treatment to increase bone mass in men with osteoporosis
  - Adults: 70-mg tablet or 70 mg oral solution P.O. weekly or 10-mg tablet P.O. daily

Contraindications

- Hypersensitivity to drug or its components
- Hypocalcemia
- Esophageal abnormalities such as stricture or achalasia, that delay esophageal emptying
- Inability to stand or sit upright for 30 minutes
- Increased risk of aspiration (oral solution)

Precautions

Use cautiously in:

- Severe renal insufficiency (creatinine clearance less than 35 ml/minute), esophageal disease, GI ulcers, gastritis, osteonecrosis of jaw
- pregnant or breastfeeding patients
- children.

Reactions in bold are life-threatening.
**Administration**
- Give with 6 to 8 oz of water 30 minutes before first food, beverage, or medication of day.
- Don’t give at bedtime or before patient arises for the day.
- Don’t give food, other beverages, or oral drugs for at least 30 minutes after giving tablets.
- Keep patient upright for at least 30 minutes after giving dose to avoid serious esophageal irritation.
- Follow oral solution with at least 60 ml (2 oz) of water to facilitate gastric emptying.
- Be aware that patients should receive supplemental calcium and vitamin D if dietary intake is inadequate.
- Be aware that aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) may worsen GI upset. Discuss alternative analgesics with prescriber.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1 mo</td>
<td>3-6 mo</td>
<td>3 wk-7 mo</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- CNS: headache
- CV: hypertension
- GI: nausea, vomiting, diarrhea, constipation, abdominal pain, acid regurgitation, esophageal ulcer, flatulence, dyspepsia, abdominal distention, dysphagia
- GU: urinary tract infection
- Hematologic: anemia
- Metabolic: hypomagnesemia, hypophosphatemia, hypokalemia, fluid overload
- Musculoskeletal: bone or muscle pain
- Skin: rash, redness, photosensitivity
- Other: abnormal taste

**Interactions**
- **Drug-drug.** Antacids, calcium supplements: decreased alendronate absorption
- NSAIDs, salicylates: increased risk of GI upset
- Ranitidine: increased alendronate effect

**Drug-diagnostic tests.** Calcium, phosphate: decreased levels
**Drug-food.** Any food, caffeine (as in coffee, tea, cocoa), mineral water, orange juice: decreased drug absorption

**Patient monitoring**
- Monitor for signs and symptoms of GI irritation, including ulcers.
- Monitor blood pressure.
- Evaluate blood calcium and phosphate levels.

**Patient teaching**
- Tell patient to immediately report serious vomiting, severe chest or abdominal pain, difficulty swallowing, or abdominal swelling.
- Instruct patient to take tablets first thing in the morning on an empty stomach, with 6 to 8 oz of water only.
- Instruct patient to follow oral solution with at least 60 ml (2 oz) of water.
- Tell patient not to lie down, eat, drink, or take other oral medications for 30 minutes after taking dose.
- Advise patient to take only those pain relievers suggested by prescriber. Inform him that some over-the-counter pain medications (such as aspirin and NSAIDs) may worsen drug’s adverse effects.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

**alfuzosin**
Besavar®, Uroxatral, Xatral®

**Pharmacologic class:** Alpha1-adrenergic receptor blocker
**Therapeutic class:** Benign prostatic hyperplasia agent
**Pregnancy risk category B**

@ Canada  ☼ UK  ☭ Hazardous drug  ☒ High alert drug
Action
Selectively inhibits alpha1-adrenergic receptors in lower urinary tract, relaxing smooth muscle in bladder neck and prostate.

Availability
Tablets (extended-release): 10 mg

Indications and dosages
Signs and symptoms of benign prostatic hyperplasia
Adults: 10 mg P.O. once daily with food, given at same meal each day

Contraindications
- Hypersensitivity to drug or its components
- Moderate or severe hepatic impairment
- Concomitant use of potent CYP-4503A4 inhibitors (such as itraconazole, ketoconazole, or ritonavir)

Precautions
Use cautiously until prostate cancer is ruled out. Also use cautiously in:
- coronary, hepatic, or renal insufficiency
- congenital or acquired QT prolongation.

Administration
- Administer with food.
- Don’t crush or break tablet.

Route Onset Peak Duration
P.O. Unknown 8 hr Unknown

Adverse reactions
CNS: dizziness, headache, fatigue
EENT: sinusitis, pharyngitis
GI: nausea, constipation, abdominal pain, dyspepsia
Respiratory: upper respiratory tract infection, bronchitis
Other: pain

Interactions
Drug-drug. Atenolol, cimetidine, diltiazem, itraconazole, ketoconazole, ritonavir: increased alfuzosin blood level

Drug-food. Any food: increased alfuzosin absorption

Patient monitoring
- Monitor patient for adverse reactions, such as dizziness.

Patient teaching
- Instruct patient to take drug with food at same time each day.
- Tell patient not to break, chew, or crush tablet.
- Caution patient to avoid driving and other hazardous activities until he knows if drug makes him dizzy.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and foods mentioned above.

aliskiren
Tekturna

Pharmacologic class: Direct renin inhibitor
Therapeutic class: Antihypertensive
Pregnancy risk category C (first trimester), D (second and third trimesters)

FDA BOXED WARNING
- When used during second or third trimester of pregnancy, drug may cause fetal injury and death. Discontinue as soon as possible when pregnancy is detected.

Action
Decreases plasma renin activity and inhibits conversion of angiotensinogen to angiotensin

Availability
Tablets: 150 mg, 300 mg

Reactions in bold are life-threatening.
Indications and dosages

➣ Hypertension (alone or in combination with other antihypertensives)

Adults: Initially, 150 mg P.O. once daily; may increase to 300 mg if blood pressure isn’t adequately controlled

Contraindications

None

Precautions

Use cautiously in:

• patients with severe renal dysfunction, nephrotic syndrome, renovascular hypertension, or history of dialysis
• diabetic patients (when combined with ACE inhibitors) because of hyperkalemia risk
• angioedema (laryngeal edema)
• females of childbearing age
• pregnant or breastfeeding patients
• children (safety and efficacy not established).

Administration

• Give consistently with or without food, but not with high-fat foods.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1-3 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: headache, fatigue
CV: dizziness, hypotension
EENT: nasopharyngitis
GI: diarrhea, gastroesophageal reflux
Musculoskeletal: back pain
Respiratory: upper respiratory tract infection, cough
Skin: rash
Other: edema, angioedema

Interactions

Drug-drug. Atorvastatin: increased aliskiren C and area under the curve (AUC) after multiple doses
Furosemide: diminished furosemide efficacy
Ketoconazole: increased aliskiren blood level

Irbesartan: reduced aliskiren C and AUC up to 50% after multiple doses

Drug-diagnostic tests. BUN, creatine kinase, potassium, serum creatinine, serum uric acid: increased values
Hematocrit, hemoglobin: decreased values

Drug-food. High-fat meals: decreased drug absorption

Patient monitoring

• Monitor routinely for hyperkalemia in patients with diabetes mellitus receiving concurrent ACE inhibitors.
• Stay alert for signs and symptoms of renal dysfunction.
• Monitor patient for angioedema; discontinue drug if signs and symptoms occur.

Patient teaching

• Instruct patient to take drug consistently with or without food, but not with high-fat foods.
• Advise female to tell prescriber if she’s pregnant or breastfeeding before taking drug.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

alitretinoin

Panretin

Pharmacologic class: Second-generation retinoid
Therapeutic class: Topical antineoplastic
Pregnancy risk category D

Action

Binds to and activates intracellular retinoid receptor subtypes, regulating expression of genes that control cellular differentiation and proliferation

Canada UK Hazardous drug High alert drug
Availability
Topical gel: 0.1%

Indications and dosages
➢ Treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma
Adults: Apply to lesions b.i.d., gradually increasing to t.i.d. or q.i.d. according to individual lesion tolerance

Contraindications
• Hypersensitivity to retinoids or other drug components

Precautions
Use cautiously in:
• photosensitivity
• concomitant use of insecticides containing diethyltoluamide (DEET)
• elderly patients
• pregnant or breastfeeding patients
• children.

Administration
• Apply generous amount of gel to affected area. Let it dry for 3 to 5 minutes before covering with clothing.

Adverse reactions
CNS: paresthesia
Skin: rash, pruritus, exfoliative dermatitis, skin disorder at application site (such as abrasion, burning, blisters, excoration, scab, cracking, crust ing, drainage, eschar, fissure, fissure, oozing, peeling, redness, or swelling), edema
Other: pain, increased sensitivity to sunlight or sun lamps

Interactions
Drug-behaviors. DEET-containing insect repellents: increased adverse reactions to DEET

Patient monitoring
• Monitor patient for serious adverse effects, especially burns caused by exposure to sunlight or sun lamps.

Patient teaching
• Instruct patient to apply generous amount of gel to affected skin area and let dry for 3 to 5 minutes before covering area with clothing.
• Caution patient to avoid applying gel to mucous membranes or to normal skin surrounding lesions.
• Inform patient that drug increases sensitivity to sunlight and that exposure to sunlight or sun lamps (even through window glass or on a cloudy day) may cause serious burn of treated areas. Caution him to avoid such exposure.
• Tell patient to avoid insect repellents containing DEET during therapy.
• Emphasize importance of keeping all medical appointments so prescriber can check progress and monitor for unwanted drug effects.
• Advise females of child-bearing potential to avoid becoming pregnant while using this drug.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the behaviors mentioned above.

allopurinol
Apo-Allopurinol®, Caplenol®, Cosuric®, Nu-purol®*, Rimapurin®, Zyloprim®, Zyloprim®

allopurinol sodium
Aloprim

Pharmacologic class: Xanthine oxidase inhibitor
Therapeutic class: Antigout drug
Pregnancy risk category C

Reactions in bold are life-threatening.
**Action**
Inhibits conversion of xanthine to uric acid and increases reutilization of hypoxanthine and xanthine for nucleic acid synthesis, thereby decreasing uric acid levels in both serum and urine.

**Availability**
*Powder for injection:* 500-mg vial  
*Tablets:* 100 mg, 300 mg

**Indications and dosages**

- **Gout in patients with frequent disabling attacks; gout resulting from hyperuricemia, acute or chronic leukemia, psoriasis, or multiple myeloma**
  - **Adults:** 200 to 300 mg P.O. daily in mild cases or 400 to 600 mg P.O. daily in severe cases, to a maximum dosage of 800 mg/day; or 200 to 400 mg/m²/day I.V. as a single infusion or in equally divided doses q 6, 8, or 12 hours to a maximum dosage of 600 mg/day
  - **Children ages 6 to 10:** 300 mg P.O. daily
  - **Children younger than age 6:** 150 mg P.O. daily

- **To prevent acute gout attacks**
  - **Adults:** 100 mg P.O. daily; increase by 100 mg at weekly intervals without exceeding maximum dosage of 800 mg, until uric acid level falls to 6 mg/dl or less

- **Recurrent calcium oxalate calculi**
  - **Adults:** 200 to 300 mg P.O. daily in single dose or divided doses

- **To prevent uric acid nephropathy during cancer chemotherapy**
  - **Adults:** 600 to 800 mg P.O. daily for 2 to 3 days, accompanied by high fluid intake

**Dosage adjustment**
- Renal impairment

**Off-label uses**
- Hematemesis caused by gastritis induced by nonsteroidal anti-inflammatory drugs
- Pain from acute pancreatitis
- Seizures refractory to standard therapy

**Contraindications**
- Hypersensitivity to drug

**Precautions**
Use cautiously in:
- acute gout attack, renal insufficiency, dehydration
- pregnant or breastfeeding patients.

**Administration**
- Reconstitute single-dose vial with 25 ml sterile water for injection. Further dilute with normal saline solution or D₅W to a concentration of 6 mg/ml or less.
- Infuse over 30 to 60 minutes.
- Don’t mix I.V. form with other drugs or give through same I.V. port as drugs that may be incompatible.
- Divide oral doses larger than 300 mg.
- Give oral form with or right after meals.
- Don’t give oral form with mineral water, orange juice, or caffeinated beverages.

**Route**

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>2-3 days</td>
<td>0.5-2 hr</td>
<td>1-2 wk</td>
</tr>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>0.5 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- **CNS:** drowsiness, dizziness, headache, peripheral neuropathy, neuritis, paresthesia
- **CV:** hypersensitivity vasculitis, necrotizing vasculitis
- **EENT:** retinopathy, cataract, epistaxis
- **GI:** nausea, vomiting, diarrhea, abdominal pain, dyspepsia, gastritis
- **GU:** exacerbation of gout and renal calculi, uremia, renal failure
- **Hematologic:** eosinophilia, anemia, thrombocytopenia, bone marrow depression, agranulocytosis, leukocytosis, aplastic anemia, leukopenia
- **Hepatic:** cholestatic jaundice, hepatomegaly, hepatitis, hepatic necrosis
- **Musculoskeletal:** myopathy, joint pain
- **Skin:** rash; alopecia; maculopapular, urticarial, or purpuric lesions; severe furunculosis of nose; ichthyosis; bruising; scaly or exfoliative erythema multiforme; toxic epidermal necrolysis
Other: abnormal taste, loss of taste, fever, chills

Interactions

Drug-drug. Amoxicillin, ampicillin, bacampicillin: increased risk of rash
Anticoagulants (except warfarin): increased anticoagulant effect
Antineoplastics: increased risk of myelosuppression
Azathioprine, mercaptopurine: inhibition of allopurinol metabolism
Chlorpropamide: increased hypoglycemic effects
Diazoxide, diuretics, mecamylamine, pyrazinamide: increased uric acid levels
Ethacrynic acid, thiazide diuretics: increased risk of allopurinol toxicity
Uricosurics: increased uric acid excretion
Urine-acidifying drugs (ammonium chloride, ascorbic acid, potassium or sodium phosphate): increased risk of renal calculi
Xanthines: increased theophylline levels

Drug-diagnostic tests. Alanine aminotransferase, alanine phosphatase, aspartate aminotransferase, bilirubin, eosinophils: increased levels
Granulocytes, hemoglobin, platelets, white blood cells: decreased levels

Drug-food. Caffeine-containing beverages and foods, mineral water, orange juice: decreased drug absorption, increased uric acid level

Drug-behaviors. Alcohol use: increased uric acid level

Patient monitoring

- Assess fluid intake and output. Intake should be sufficient to yield daily output of at least 2 L of slightly alkaline urine.
- Monitor uric acid level to help evaluate drug efficacy.

Patient teaching

- Instruct patient to promptly report painful urination, bloody urine, rash, eye irritation, or swelling of lips and mouth.
- Tell patient to take drug with food or milk, exactly as prescribed.
- Explain that gout attacks may not ease significantly until 2 to 6 weeks of therapy.
- Caution patient to avoid driving and other hazardous tasks until he knows how drug affects concentration and alertness.
- Advise patient to avoid alcohol, caffeine-containing beverages and foods, mineral water, and orange juice during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and behaviors mentioned above.

almotriptan malate

Axert

Pharmacologic class: Serotonin (5-hydroxytryptamine [5-HT]) receptor agonist

Therapeutic class: Vascular headache suppressant, antimigraine drug

Pregnancy risk category C

Action

Promotes vascular constriction and relieves migraine by stimulating specific 5-HT receptors in intracranial blood vessels and sensory trigeminal nerves

Availability

Tablets: 6.25 mg, 12.5 mg

Indications and dosages

Acute migraine

Adults: Single dose of 6.25 to 12.5 mg P.O. at first sign or symptom of migraine; may be repeated after 2 hours. Don’t exceed two doses in a 24-hour period.
Dosage adjustment
● Severe renal or hepatic impairment

Contraindications
● Hypersensitivity to drug
● Ischemic heart disease, history of myocardial infarction (MI), documented silent ischemia, symptoms or findings consistent with ischemic heart disease, cerebrovascular accident, uncontrolled hypertension, coronary artery vasospasm
● Ischemic bowel disease
● Basilar or hemiplegic migraine
● MAO inhibitor use in past 14 days
● Use of other 5-HT agonists or ergotamine-containing or ergot-type drugs within past 24 hours

Precautions
Use cautiously in:
● impaired renal or hepatic function
● cardiovascular risk factors
● pregnant or breastfeeding patients
● children younger than age 18 (use not recommended).

Administration
● Give with or without food.
● Wait at least 2 hours after initial dose before giving repeat dose.
● Don’t exceed two doses in 24 hours.
● Don’t give within 14 days of MAO inhibitors or within 24 hours of other 5-HT agonists or ergotamine-containing or ergot-type drugs.

Adverse reactions
CNS: headache, anxiety, dizziness, fatigue, malaise, weakness, cold or hot sensations, sedation, numbness, burning or tingling sensations
CV: blood pressure changes, palpitations, tachycardia, coronary artery vasospasm, MI, ventricular fibrillation, ventricular tachycardia

EENT: vision changes; nasal, throat, and mouth discomfort
GI: nausea, abdominal distress, dysphagia, dry mouth
Musculoskeletal: weakness, stiff neck, muscle pain
Respiratory: chest tightness or pressure
Skin: sweating, flushing

Interactions
Drug-drug. CYP2D6 inhibitors (erythromycin, itraconazole, ritonavir): increased almotriptan effect
Ergot derivatives, other 5-HT agonists: prolonged vasoactive action
Ketoconazole and other CYP3A inhibitors: increased almotriptan level, leading to toxicity
MAO inhibitors: decreased almotriptan absorption
Selective serotonin reuptake inhibitors: weakness, hyperreflexia, poor coordination

Patient monitoring
● Assess patient’s cardiovascular status, noting chest tightness or pressure.
● Monitor vital signs.

Patient teaching
Tell patient to immediately report chest tightness or pressure.
● Inform patient that he may take drug with or without food.
● If second dose is needed, tell patient to take it at least 2 hours after first.
● Caution patient not to take more than two doses in 24 hours.
● Instruct patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.
Alosetron hydrochloride
Lotronex

**Pharmacologic class:** Serotonin receptor antagonist

**Therapeutic class:** Agent for irritable bowel syndrome

**Pregnancy risk category B**

**FDA BOXED WARNING**

- Infrequent but serious GI problems have occurred, resulting in hospitalization and, rarely, blood transfusions, surgery, and death.
- Only physicians enrolled in GlaxoSmithKline’s Prescribing Program for Lotronex should prescribe Lotronex.
- Drug is indicated only for women with severe, diarrhea-predominant irritable bowel syndrome who don’t respond adequately to conventional therapy. Patient must read and sign agreement before receiving initial prescription.
- Discontinue immediately if patient develops constipation or ischemic colitis symptoms. Don’t resume therapy in patients who developed ischemic colitis. Patients with resolved constipation should resume only on advice of physician.

**Action**

Inhibits activation of nonselective cation channels, resulting in modulation of enteric nervous system

**Availability**

*Tablets*: 0.5 mg, 1 mg

**Indications and dosages**

- Women with severe, diarrhea-predominant irritable bowel syndrome (IBS) who have chronic symptoms not caused by anatomic or biochemical abnormalities and who are unresponsive to conventional therapy

**Adult women:** Initially, 0.5 mg P.O. b.i.d. If after 4 weeks dose is well tolerated but doesn’t adequately control IBS, may increase to 1 mg P.O. b.i.d.; therapy should be discontinued in patients not responding to 1 mg P.O. b.i.d. after 4 weeks.

**Contraindications**

- Concurrent use of fluvoxamine
- Severe hepatic impairment
- Current constipation or history of chronic or severe constipation
- History of complications related to constipation
- History of intestinal obstruction, stricture, toxic megacolon, GI perforation, or adhesion
- History of ischemic colitis, impaired intestinal circulation, thrombophlebitis, or hypercoagulable state
- Current Crohn’s disease or ulcerative colitis, active diverticulitis, or history of these disorders
- Inability to understand or comply with patient-physician agreement for drug

**Precautions**

Use cautiously in:

- hepatic insufficiency
- moderate CYP/A2 inhibitors, such as quinolone antibiotics and cimetidine (avoid use)
- elderly patients
- pregnant or breastfeeding patients
- children.

**Administration**

- Before administering, know that drug is approved with the following marketing restrictions: Ensure that patient understands that drug has serious risks, patient reads and signs patient-physician agreement, and patient follows directions in accompanying medication guide.

Reactions in bold are life-threatening.
Know that anatomical and biochemical abnormalities of GI tract should be ruled out before drug therapy starts.

Give with or without food.

Don’t administer drug if patient is constipated.

Stop therapy immediately if patient develops constipation or signs or symptoms of ischemic colitis.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>1 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: anxiety, malaise

CV: increased blood pressure, extrasystoles, tachyarrhythmias, arrhythmias

GI: nausea; constipation; GI pain, discomfort, or spasms; abdominal distention; regurgitation or gastroesophageal reflux; hemorrhoids; decreased salivation; dyspepsia; ischemic colitis; GI perforation; small-bowel mesenteric ischemia

GU: urinary frequency

Hematologic: hemorrhage

Respiratory: breathing disorders

Skin: sweating, urticaria

Other: fatigue, cramps, disturbed temperature regulation

Interactions

Drug-drug. CYP450 inducers or inhibitors: altered alosetron clearance

Fluvoxamine: increased alosetron concentration and half-life

Drug-diagnostic tests. Blood glucose, calcium, phosphate: increased or decreased level

Patient monitoring

Monitor patient closely for adverse reactions, especially such GI reactions as constipation or signs or symptoms of ischemic colitis.

Patient teaching

Make sure patient knows about drug’s marketing restrictions, which stipulate that she understands drug has serious risks, that she reads and signs patient-physician agreement, and that she follows directions in accompanying medication guide.

Tell patient to take drug exactly as prescribed, with or without food.

Instruct patient to contact prescriber immediately if she develops constipation or symptoms of insufficient blood flow to bowel (such as new or worsening pain in bowels or bloody bowel movements).

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

alprazolam

Apo-Alpraz®, Niravam, Novo-Alprazol®, Nu-Alpraz®, Xanax,
Xanax TS®, Xanax XR

Pharmacologic class: Benzodiazepine

Therapeutic class: Anxiolytic

Controlled substance schedule IV

Pregnancy risk category D

Action

Unclear. Thought to act at limbic, thalamic, and hypothalamic levels of CNS to produce sedative, anxiolytic, skeletal muscle relaxant, and anticonvulsant effects.

Availability

Solution: 1 mg/ml

Tablets (extended-release): 0.5 mg, 1 mg, 2 mg, 3 mg

Tablets (immediate-release): 0.25 mg, 0.5 mg, 1 mg, 2 mg

Tablets (orally disintegrating): 0.25 mg, 0.5 mg, 1 mg, 2 mg

Indications and dosages

Anxiety disorders
Adults: Initially, 0.25 to 0.5 mg P.O. t.i.d. Maximum dosage is 4 mg daily in divided doses.

**Elderly patients:** Initially, 0.25 mg P.O. two or three times daily. Maximum dosage is 4 mg daily in divided doses.

> Panic disorders

**Adults:** Immediate-release or orally disintegrating tablets—Initially, 0.5 mg P.O. t.i.d. Extended-release tablets—Initially, 0.5 to 1 mg P.O. daily. Usual dosage is 3 to 6 mg daily, with a maximum dosage of 10 mg daily. For all dosage forms, increase by a maximum of 1 mg daily at intervals of 3 to 4 days, with a maximum of 10 mg daily in divided doses.

**Dosage adjustment**
- Hepatic impairment

**Off-label uses**
- Agoraphobia
- Depression
- Premenstrual syndrome

**Contraindications**
- Hypersensitivity to benzodiazepines
- Narrow-angle glaucoma
- Labor and delivery
- Pregnancy or breastfeeding

**Precautions**
Use cautiously in:
- hepatic dysfunction
- history of attempted suicide or drug dependence
- elderly patients.

**Administration**
- Don’t give with grapefruit juice.
- Make sure patient swallows extended-release tablets whole without chewing or crushing.
- Mix oral solution with liquids or semisolid foods and instruct patient to consume entire amount immediately.
- Administer orally disintegrating tablets by placing tablet on patient’s tongue. If only one-half of scored tablet is used, discard unused portion immediately.

**Adverse reactions**

CNS: dizziness, drowsiness, depression, fatigue, light-headedness, disorientation, anger, hostility, euphoria, hypomanic episodes, restlessness, confusion, crying, delirium, headache, stupor, rigidity, tremor, paresthesia, vivid dreams, extrapyramidal symptoms

CV: bradycardia, tachycardia, hypertension, hypotension, palpitations, CV collapse

EENT: blurred or double vision, nystagmus, nasal congestion

GI: gastric disorders, dysphagia, anorexia, increased salivation, dry mouth

GU: menstrual irregularities, urinary retention, urinary incontinence, libido changes, gynecomastia

Hematologic: blood dyscrasias such as eosinophilia, agranulocytosis, leukopenia, and thrombocytopenia

Hepatic: hepatic dysfunction (including hepatitis)

Musculoskeletal: muscle rigidity, joint pain

Skin: dermatitis, rash, pruritus, urticaria, increased sweating

Other: weight loss or gain, hiccups, fever, edema, psychological drug dependence, drug tolerance

**Interactions**

**Drug-drug.** Antidepressants, antihistamines, opioids, other benzodiazepines: increased CNS depression

Barbiturates, rifampin: increased metabolism and decreased efficacy of alprazolam

Cimetidine, disulfiram, erythromycin, fluoxetine, hormonal contraceptives, isoniazid, ketoconazole, metoprolol, propanolone, propranolol, valproic
Acid: decreased metabolism and increased action of alprazolam
Digoxin: increased risk of digoxin toxicity
Levodopa: decreased antiparkinsonian effect
Theophylline: increased sedative effect
Tricyclic antidepressants (TCAs): increased TCA blood levels

Drug-diagnostic tests. Itraconazole, ketoconazole: increased alprazolam plasma level

Drug-food. Grapefruit juice: decreased drug metabolism and increased blood level

Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression

Drug-behaviors. Alcohol use: increased CNS depression
Smoking: decreased alprazolam efficacy

Patient monitoring
- Watch for excessive CNS depression if patient is concurrently taking antidepressants, other benzodiazepines, antihistamines, or opioids.
- If patient is taking TCAs concurrently, watch for increase in adverse TCA effects.
- Monitor CBC and liver and kidney function test results.
- Monitor vital signs and weight.
- Report signs of drug abuse, including frequent requests for early refills.

Patient teaching
- Instruct patient to swallow extended-release tablets whole without crushing or chewing.
- Tell patient that drug may make him more depressed, angry, or hostile. Urge him to contact prescriber immediately if he thinks he’s dangerous to himself or others.
- Inform patient that drug may cause tremors, muscle rigidity, and other movement problems. Advise him to report these effects to prescriber.

Caution patient not to stop taking drug suddenly. Withdrawal symptoms, including seizures, may occur unless drug is tapered carefully.
- Advise patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

alteplase (tissue plasminogen activator, recombinant)

Actilyse®, Activase, Activase rt-PA®, Cathflo Activase

Pharmacologic class: Plasminogen activator

Therapeutic class: Thrombolytic

Pregnancy risk category C

Action
Converts plasminogen to plasmin, which in turn breaks down fibrin and fibrinogen, thereby dissolving thrombus

Availability
Injection: 2-mg single-patient vials; 50-mg, 100-mg vials

Indications and dosages
- Lysis of thrombi obstructing coronary arteries in acute myocardial infarction (MI)
- 3-hour infusion—
- Adults: 100 mg I.V. over 3 hours as follows: 60 mg over first hour (give 6 to 10 mg as bolus over first 1 to 2 minutes), then 20 mg I.V. over second hour, then 20 mg I.V. over third hour
Adults weighing less than 65 kg (143 lb): 1.25 mg/kg I.V. in divided doses over 3 hours, not to exceed 100 mg

**Accelerated infusion—**

Adults weighing more than 67 kg (147 lb): Give total dosage of 100 mg as follows: 15 mg I.V. bolus over 1 to 2 minutes, then 50 mg I.V. over next 30 minutes, then 35 mg I.V. over next 60 minutes.

Adults weighing 67 kg (147 lb) or less: 15 mg I.V. bolus over 1 to 2 minutes, followed by 0.75 mg/kg I.V. over next 30 minutes (not to exceed 50 mg), followed by 0.5 mg/kg I.V. over next hour, not to exceed 35 mg

➤ Acute ischemic cerebrovascular accident (CVA)

**Adults:** 0.9 mg/kg I.V. over 1 hour, to a maximum dosage of 90 mg, with 10% of total dosage given as I.V. bolus within first minute

➤ Acute massive pulmonary embolism

**Adults:** 100 mg I.V. over 2 hours, followed by heparin

➤ Restoration of function of central venous access device

**Adults weighing 30 kg (66 lb) or more:** Cathflo Activase—2 mg/2-ml concentration instilled in dysfunctional catheter. If catheter function isn’t restored in 120 minutes after first dose, may give second dose.

**Adults weighing 10 kg (22 lb) to less than 30 kg:** Cathflo Activase—Use 110% of catheter lumen volume not to exceed 2 mg/2-ml concentration instilled in dysfunctional catheter. If catheter function isn’t restored in 120 minutes after first dose, may give second dose.

**Off-label uses**
- Small-vessel occlusion by microthrombi
- Peripheral arterial thromboembolism

**Contraindications**
- Hypersensitivity to drug or its components (Cathflo Activase)
- Seizures, stroke, aneurysm, intracranial neoplasm, bleeding diathesis

**Precautions**
Use cautiously in:
- hypersensitivity to anistreplase or streptokinase
- GI or genitourinary bleeding, ophthalmic hemorrhage, organ biopsy, severe hepatic or renal disease
- elderly patients
- pregnant or breastfeeding patients
- children.

**Administration**

➤ Be aware that intracranial hemorrhage must be ruled out before therapy begins.

➤ To treat acute ischemic CVA, give within 3 hours of initial signs or symptoms.

➤ If uncontrolled bleeding occurs, stop infusion and notify prescriber immediately.

- Give I.V. only, using controlled-infusion pump.
- Reconstitute with unpreserved sterile water for injection. May be further diluted with normal saline solution or D5W.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** cerebral hemorrhage, cerebral edema, CVA (with accelerated infusion)

**CV:** hypotension, bradycardia, recurrent ischemia, pericardial effusion, pericarditis, mitral regurgitation, electromechanical dissociation, arrhythmias, cardiogenic shock, heart failure, cardiac arrest, cardiac tamponade, myocardial rupture, embolization, venous thrombosis

**GI:** nausea, vomiting, GI bleeding

Reactions in **bold** are life-threatening.

**Clinical alert**
GU: GU tract bleeding
Hematologic: spontaneous bleeding, bone marrow depression
Musculoskeletal: musculoskeletal pain
Respiratory: pulmonary edema
Skin: bruising, flushing
Other: fever, edema, phlebitis or bleeding at I.V. site, hypersensitivity reaction (including rash, anaphylactic reaction, laryngeal edema), sepsis

Interactions
Drug-drug. Aspirin, drugs affecting platelet activity (such as abciximab, heparin, dipyridamole, oral anticoagulants, vitamin K antagonists): increased risk of bleeding
Drug-diagnostic tests. Blood urea nitrogen: elevated level

Patient monitoring
• Monitor vital signs, ECG, and neurologic status.
• Maintain strict bed rest.
• Watch for signs and symptoms of bleeding tendency and hemorrhage.
• Monitor patient on Cathflo Activase for GI bleeding, venous thrombosis, and sepsis.
• Evaluate results of clotting studies.

Patient teaching
• As appropriate, explain therapy and monitoring to patient and family.

aluminum hydroxide
AlternaGEL, Alu-Cap, Alu-Tab
Pharmacologic class: Inorganic salt
Therapeutic class: Antacid
Pregnancy risk category NR

Action
Dissolves in acidic gastric secretions, releasing anions that partially neutralize gastric hydrochloric acid. Also elevates gastric pH, inhibiting the action of pepsin (an effect important in peptic ulcer disease).

Availability
Capsules: 400 mg, 475 mg, 500 mg
Oral suspension: 320 mg/5 ml, 450 mg/5 ml, 600 mg/5 ml, 675 mg/5 ml
Tablets: 300 mg, 500 mg, 600 mg

Indications and dosages
Hyperacidity
Adults: 500 to 1,500 mg (tablet or capsule) P.O. 1 hour after meals and at bedtime; or 5 to 30 ml (oral suspension) between meals and at bedtime, as needed or directed

Off-label uses
• Bleeding from stress ulcers
• Gastroesophageal reflux disease

Contraindications
• Signs or symptoms of appendicitis or inflamed bowel

Precautions
Use cautiously in:
• gastric outlet obstruction, hypercalcemia, hypophosphatemia, massive upper GI hemorrhage
• patients using other aluminum products concurrently
• patients on dialysis
• pregnant or breastfeeding patients.

Administration
• Administer with water or fruit juice.
• Give 1 hour after meals and at bedtime.
• In reflux esophagitis, administer 20 to 40 minutes after meals and at bedtime.
• Don’t give within 1 to 2 hours of antibiotics, histamine2 (H2) blockers, iron preparations, corticosteroids, or enteric-coated drugs.
• Provide care as appropriate if patient becomes constipated.
Adverse reactions
CNS: malaise (with prolonged use), neurotoxicity, encephalopathy
GI: constipation, anorexia (with prolonged use), intestinal obstruction
Metabolic: hypophosphatemia (with prolonged use)
Musculoskeletal: osteomalacia and chronic phosphate deficiency with bone pain, malaise, muscle weakness (with prolonged use)
Other: aluminum toxicity

Interactions
Drug-drug. Allopurinol, anti-infectives (including quinolones, tetracyclines), corticosteroids, diflunisal, digoxin, ethambutol, H₂ blockers, hydantoins, iron salts, isoniazid, penicillamine, phenothiazines, salicylates, thyroid hormone, ticlopidine: decreased effects of these drugs
Enteric-coated drugs: premature release of these drugs in stomach
Drug-diagnostic tests. Gastrin: increased level
Phosphate: decreased level
Some imaging studies: test interference
Drug-food. Milk, other foods high in vitamin D: milk-alkali syndrome (nausea, vomiting, distaste for food, headache, confusion, hypercalcemia, hypercalciuria)

Patient monitoring
- Monitor long-term use of high doses if patient is on sodium-restricted diet. (Drug contains sodium.)
- Assess for GI bleeding.
- Watch for constipation.
- With long-term use, monitor blood phosphate level and assess for signs and symptoms of hypophosphatemia (anorexia, malaise, muscle weakness). Also monitor bone density.

Reactions in bold are life-threatening.
symptoms by increasing dopamine release, preventing dopamine reuptake into presynaptic neurons, stimulating dopamine receptors, or enhancing dopamine sensitivity.

Availability
Capsules (liquid-filled): 100 mg
Syrup: 50 mg/5 ml
Tablets: 100 mg

Indications and dosages
➣ Symptomatic treatment or prophylaxis of influenza type A virus in patients with respiratory conditions
Adults older than age 65 with normal renal function: 100 mg P.O. once daily
Adults to age 64 with normal renal function: 200 mg (tablets) or 4 tsp of syrup P.O. daily in a single dose, or 100 mg tablet or 2 tsp of syrup P.O. b.i.d.
Children ages 9 to 12: 100 mg P.O. q 12 hours
Children ages 1 to 9 or weighing less than 45 kg (99 lb): 4.4 to 8.8 mg/kg/day of syrup P.O. q 12 hours, not to exceed 150 mg daily
➣ Parkinson’s disease
Adults: Initially, 100 mg P.O. daily, increased to 100 mg b.i.d. if needed. If patient doesn’t respond adequately, give 200 mg b.i.d., up to 400 mg/day.
➣ Drug-induced extrapyramidal reactions
Adults: 100 mg P.O. b.i.d.; may increase dosage to maximum of 300 mg daily in divided doses

Dosage adjustment
● Renal impairment

Contraindications
● Hypersensitivity to drug

Precautions
Use cautiously in:
● cardiac disease, hepatic disease, renal impairment, seizure disorder, psychiatric problems
● untreated closed-angle glaucoma (use not recommended)
● elderly patients
● pregnant or breastfeeding patients.

Administration
● For antiviral use, start therapy within 24 to 48 hours of symptom onset and continue for 24 to 48 hours after symptoms resolve.
● When giving as prophylactic antiviral, start therapy as soon as possible and continue for at least 10 days after exposure to virus.
● When giving with influenza vaccine, continue drug for 2 to 3 weeks while patient develops antibody response to vaccine.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>48 hr</td>
<td>2 wk</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: depression, dizziness, drowsiness, insomnia, light-headedness, anxiety, irritability, hallucinations, confusion, ataxia, headache, nervousness, abnormal dreams, agitation, fatigue, delusions, aggressive behavior, manic reaction, psychosis, slurred speech, euphoria, abnormal thinking, amnesia, increased or decreased motor activity, paresthesia, tremor, abnormal gait, delirium, stupor, coma
CV: orthostatic hypotension, tachycardia, peripheral edema, heart failure, cardiac arrest, arrhythmias
EENT: blurred vision, mydriasis, keratitis, photosensitivity, optic nerve palsy, nasal congestion
GI: nausea, vomiting, diarrhea, constipation, dry mouth, dysphagia, anorexia
GU: urine retention, decreased libido
Hematologic: leukocytosis
Musculoskeletal: involuntary muscle contractions
Respiratory: tachypnea, acute respiratory failure, pulmonary edema
Skin: purplish skin discoloration, rash, pruritus, diaphoresis
Other: edema, fever, allergic reactions including anaphylaxis

Interactions

Drug-drug. Anticholinergics, antihistamines, phenothiazines, quinidine, tricyclic antidepressants: increased atropine-like adverse effects
CNS stimulants: increased CNS stimulation
Hydrochlorothiazide, triamterene: increased amantadine effects

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatine kinase, creatinine, gamma-glutamyltransferase, lactate dehydrogenase: increased levels

Drug-herbs. Angel’s trumpet, jimsonweed, scopolia: increased cardiac and anticholinergic-like effects

Drug-behaviors. Alcohol use: increased CNS adverse reactions

Patient monitoring

- Monitor patient for depression and suicidal ideation.
- Watch for mental status changes, especially in elderly patients.
- Stay alert for worsening of psychiatric problems if patient has a history of such problems or substance abuse.
- Monitor for orthostatic hypotension.
- Evaluate for signs and symptoms of fluid overload.
- Monitor kidney and liver function test results.

Patient teaching

- Caution patient that taking more than prescribed dosage may lead to serious adverse reactions or even death.
- Advise patient to establish effective bedtime routine and to take drug several hours before bedtime to minimize insomnia.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Advise patient to minimize GI upset by eating small, frequent servings of foods and drinking plenty of fluids.
- Instruct patient to contact prescriber if he develops signs or symptoms of depression.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

amifostine

Ethyol

Pharmacologic class: Organic thio-phosphate cytoprotective drug

Therapeutic class: Cytoprotectant

Pregnancy risk category C

Action

Undergoes conversion to free thiol, an active metabolite that reduces toxic effects of cisplatin on renal tissue

Availability

Powder for injection: 500-mg anhydrous base and 500 mg mannitol in 10-ml vials

Indications and dosages

➢ To reduce cumulative renal toxicity of cisplatin therapy in patients with ovarian cancer or non-small-cell lung cancer
Adults: 910 mg/m² I.V. daily as a 15-minute infusion, starting 30 minutes before chemotherapy
➢ To reduce moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head or neck cancer
Adults: 200 mg/m² I.V. daily as a 3-minute infusion, starting 15 to 30 minutes before chemotherapy

Reactions in bold are life-threatening.

Clinical alert
30 minutes before standard fraction radiation therapy

**Off-label uses**
- Protection against cisplatin- and paclitaxel-induced neurotoxicity

**Contraindications**
- Hypersensitivity to drug
- Hypotension

**Precautions**
Use cautiously in:
- arrhythmias, heart failure, ischemic heart disease, renal impairment, hearing impairment, hypocalcemia, myasthenia gravis, nausea, vomiting, hypotension, obesity
- history of cerebrovascular accident or transient ischemic attacks
- concurrent antihypertensive therapy that can’t be discontinued for 24 hours before amifostine therapy (not recommended)
- definitive radiotherapy (not recommended)
- elderly patients
- pregnant patients (safety and efficacy not established)
- breastfeeding patients
- children (safety and efficacy not established).

**Administration**
- Ensure that patient is adequately hydrated before starting drug.
- Give antiemetics before and during therapy.
- Reconstitute single-dose vial with 9.7 ml of sterile normal saline injection. May be further diluted with normal saline solution up to a concentration of 40 mg/ml.
- Don’t mix with other drugs or solutions.
- Know that drug also can be prepared in polyvinyl chloride bags.
- Don’t infuse longer than 15 minutes; doing so increases risk of adverse reactions.

**Adverse reactions**
- CNS: dizziness, drowsiness, rigors
- CV: hypotension
- GI: nausea, vomiting
- Metabolic: hypocalcemia
- Respiratory: dyspnea, sneezing
- Skin: flushing, rash, urticaria, erythema multiforme

**Interactions**
- Drug-drug. Antihypertensives: increased risk of hypotension
- Drug-diagnostic tests. Calcium: decreased level

**Patient monitoring**
- Monitor blood pressure every 5 minutes during infusion and immediately after infusion as clinically indicated.
- Assess for severe nausea and vomiting.
- Monitor fluid intake and output.
- Monitor blood calcium level. Give calcium supplements as ordered.

**Patient teaching**
- Emphasize importance of remaining supine during drug administration to prevent hypotension.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
- Provide dietary counseling. Refer patient to dietitian if adverse GI effects significantly limit food intake.
- Inform patient that sneezing is a normal effect of drug.
As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

amikacin sulfate
Amikin

Pharmacologic class: Aminoglycoside
Therapeutic class: Anti-infective
Pregnancy risk category D

FDA BOXED WARNING
- Observe patient closely because of potential ototoxicity and nephrotoxicity. Safety isn’t established for treatment exceeding 14 days.
- Neuromuscular blockade and respiratory paralysis have occurred after parenteral injection, topical use (as in orthopedic and abdominal irrigation), and oral use.
- Monitor renal function and eighth-nerve function closely, especially in patients with known or suspected renal impairment at onset of therapy, as well as those with initially normal renal function who develop signs of renal dysfunction during therapy.
- Avoid concurrent use with potent diuretics (such as furosemide and ethacrynic acid) because diuretics may cause ototoxicity. Also, I.V. diuretics may increase aminoglycoside toxicity by altering antibiotic serum and tissue levels.
- Avoid concurrent and sequential systemic, oral, or topical use of other neurotoxic or nephrotoxic products and other aminoglycosides. Advanced age and dehydration also may increase toxicity risk.

Action
Interferes with protein synthesis in bacterial cells by binding to 30S ribosomal subunit, leading to bacterial cell death

Availability
Injection: 50 mg/ml, 250 mg/ml

Indications and dosages
Severe systemic infections caused by sensitive strains of Pseudomonas aeruginosa, Escherichia coli, or Proteus, Klebsiella, Serratia, Enterobacter, Actinobacter, Providencia, Citrobacter, or Staphylococcus species
Adults, children, and older infants: 15 mg/kg/day I.V. or I.M. in two to three divided doses q 8 to 12 hours in 100 to 200 ml of dextrose 5% in water (D5W) over 30 to 60 minutes. Maximum dosage is 1.5 g/day.
Neonates: Initially, 10 mg/kg I.M., then 7.5 mg/kg I.M. q 12 hours
Uncomplicated urinary tract infections caused by susceptible organisms
Adults, children, and older infants: 250 mg I.M. or I.V. twice daily

Dosage adjustment
- Renal impairment (adults)
- Patients undergoing hemodialysis

Off-label uses
- Mycobacterium avium-intracellulare infection

Contraindications
- Hypersensitivity to aminoglycosides
- Breastfeeding

Precautions
Use cautiously in:
- decreased renal function, neuromuscular disorders
- parkinsonism, myasthenia gravis
- concurrent or serial use of other nephrotoxic and ototoxic drugs
- elderly patients
- pregnant patients.

Reactions in bold are life-threatening.
Administration

- Don’t physically mix amikacin with other drugs. Administer separately.
- For I.V. use, dilute in 100 to 200 ml of normal saline solution or D₅W and give over 30 to 60 minutes.
- Ensure adequate fluid intake to avoid dehydration.
- Draw peak blood level 1 hour after I.M. infusion or 30 to 60 minutes after I.V. infusion.
- Draw trough blood level just before next dose.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>30 min</td>
<td>8-12 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>Variable</td>
<td>1 hr</td>
<td>8-12 hr</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: dizziness, vertigo, tremor, numbness, depression, confusion, lethargy, headache, paresthesia, ataxia, neuromuscular blockade, seizures, neurotoxicity
CV: hypotension, hypertension, palpitations
EENT: nystagmus and other visual disturbances, ototoxicity, hearing loss, tinnitus
GI: nausea, vomiting, splenomegaly, stomatitis, increased salivation, anorexia
GU: azotemia, increased urinary excretion of casts, polyuria, painful urination, impotence, nephrotoxicity
Hematologic: purpura, eosinophilia, leukemoid reaction, aplastic anemia, neutropenia, agranulocytosis, leukopenia, thrombocytopenia, pancytopenia, hemolytic anemia
Hepatic: hepatomegaly, hepatic necrosis, hepatotoxicity
Musculoskeletal: joint pain, muscle twitching
Respiratory: apnea
Skin: rash, alopecia, urticaria, itching, exfoliative dermatitis
Other: weight loss, superinfection, pain and irritation at I.M. site

Interactions

Depolarizing and nondepolarizing neuromuscular junction blockers, general anesthetics: increased amikacin effect, possibly leading to respiratory depression
Dimenhydrinate: masking of ototoxicity signs and symptoms
Indomethacin: increased trough and peak amikacin levels
Parenteral penicillin: amikacin inactivation

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, lactate dehydrogenase, nonprotein nitrogen, nitrogen compounds (such as urea): increased levels
Calcium, potassium, magnesium, sodium: decreased levels
Reticulocytes: increased or decreased count

Patient monitoring

- Monitor kidney function test results and urine cultures, output, protein, and specific gravity.
- Monitor results of peak and trough drug blood levels.
- Evaluate for signs and symptoms of ototoxicity (hearing loss, tinnitus, ataxia, and vertigo).
- Assess for secondary superinfections, particularly upper respiratory tract infections.

Patient teaching

Inform patient that drug may cause hearing loss, seizures, and other neurologic problems. Tell him to report these symptoms immediately.
- Instruct patient to immediately report fever, cough, breathing problems, sore throat, and other signs and symptoms of infection.
Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

Instruct patient to notify prescriber if he’s urinating much more or much less than normal.

Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.

Inform patient that he’ll undergo regular blood and urine testing during therapy.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Aminocaproic acid
Amicar
Pharmacologic class: Carboxylic acid derivative
Therapeutic class: Antihemorrhagic, antifibrinolytic
Pregnancy risk category C

Action
Interferes with plasminogen activator substances and blocks action of fibrinolysin (plasmin)

Availability
Injection: 250 mg/ml
Syrup: 250 mg/ml
Tablets: 500 mg, 1,000 mg

Indications and dosages
Excessive bleeding caused by fibrinolysis
Adults: 5 g P.O. during first hour; then 1 to 1.25 g/hour until drug blood level of 0.13 mg/ml is reached and sustained and bleeding is controlled. Or 4 to 5 g in 250 ml of compatible diluent I.V.

Off-label uses
- Dental extractions
- Hemorrhage

Contraindications
- Hypersensitivity to drug
- Disseminated intravascular coagulation
- Neonates (injectable form)

Precautions
Use cautiously in:
- heart, hepatic, or renal failure
- upper urinary tract bleeding.

Administration
- Dilute I.V. form in normal saline solution, dextrose 5% in water, or Ringer’s solution for injection. Give at prescribed rate.
- Know that oral and I.V. doses are the same.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1 hr</td>
<td>2 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V.</td>
<td>1 hr</td>
<td>Unknown</td>
<td>3 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, malaise, headache, delirium, hallucinations, weakness, seizures
CV: hypotension, ischemia, thrombophlebitis, cardiomyopathy, bradyarrhythmias
EENT: conjunctival suffusion, tinnitus, nasal congestion
GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia
GU: intrarenal obstruction, renal failure
Hematologic: bleeding tendency, generalized thrombosis, agranulocytosis, leukopenia, thrombocytopenia

Reactions in bold are life-threatening.

Clinical alert
Musculoskeletal: myopathy, rhabdomyolysis
Respiratory: dyspnea, pulmonary embolism
Skin: rash, pruritus

Interactions
Drug-drug. Estrogens, hormonal contraceptives: increased risk of hypercoagulation
Activated prothrombin, prothrombin complex concentrates: increased signs of active intravascular clotting
Drug-diagnostic tests. Alanine aminotransferase, aldolase, aspartate aminotransferase, blood urea nitrogen, creatinine, creatine kinase, potassium: increased levels
Drug-herbs. Alfalfa, anise, arnica, astragalus, bilberry, black currant seed oil, capsaicin, cat’s claw, celery, chaparral, clove oil, dandelion, dong quai, evening primrose oil, feverfew, garlic, ginger, ginkgo, papaya extract, rhubarb, safflower oil, skullcap: increased anticoagulant effect
Coenzyme Q10, St. John’s wort: reduced anticoagulant effect

Patient monitoring
- Monitor vital signs, fluid intake and output, and ECG.
- Assess for signs and symptoms of thrombophlebitis and pulmonary embolism.
- Monitor neurologic status, especially for signs of impending seizure.
- Monitor kidney and liver function test results, serum electrolyte levels, and CBC with white cell differential.
- Evaluate for blood dyscrasias, particularly bleeding tendencies.

Patient teaching
- Tell patient that drug may significantly affect many body systems. Assure him that he’ll be monitored closely.
- Instruct patient to immediately report signs and symptoms of thrombophlebitis, pulmonary embolism, or unusual bleeding.
- Tell patient he’ll undergo frequent blood testing during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

aminophylline (theophylline, ethylenediamine)
Amnivent®, Phyllocontin®
Pharmacologic class: Xanthine
Therapeutic class: Bronchodilator
Pregnancy risk category C

Action
Unclear. Thought to directly relax smooth muscle of bronchial airways and increase pulmonary blood flow by inhibiting phosphodiesterase.

Availability
Injection: 250 mg/10 ml
Oral liquid: 105 mg/5 ml
Suppositories: 250 mg, 500 mg
Tablets: 100 mg, 200 mg

Indications and dosages
➣ Symptomatic relief of bronchospasm in patients with acute symptoms who require rapid theophyllinization
Adults (nonsmokers): 0.7 mg/kg/hour I.V. for first 12 hours. Maintenance dosage is 0.5 mg/kg/hour I.V.
Children ages 9 to 16: 1 mg/kg/hour I.V. for first 12 hours. Maintenance dosage is 0.8 mg/kg/hour I.V.
Children ages 6 months to 9 years: 1.2 mg/kg/hour I.V. for first 12 hours. Maintenance dosage is 1 mg/kg/hour I.V.
➣ Chronic bronchial asthma

Canada UK Hazardous drug High alert drug
Adults and children: Dosage is highly individualized. Common initial dosage is 16 mg/kg/24 hours I.V. or 400 mg/24 hours I.V. in divided doses at 6- or 8-hour intervals. If needed, dosage may be increased 25% at 3-day intervals.

Dosage adjustment
- Heart failure
- Hepatic disease
- Elderly patients
- Smokers

Off-label uses
- Dyspnea in patients with chronic obstructive pulmonary disease (COPD)

Contraindications
- Hypersensitivity to xanthine compounds or ethylenediamine
- Seizure disorders

Precautions
Use cautiously in:
- COPD, diabetes mellitus, glaucoma, renal or hepatic disease, heart failure or other cardiac or circulatory impairment, hypertension, hyperthyroidism, peptic ulcer, severe hypoxemia
- active peptic ulcer disease
- elderly patients
- neonates, infants, and young children.

Administration
- For I.V. use, dilute according to label directions and infuse at a rate no faster than 25 mg/minute.
- Don’t give in I.V. solutions containing invert sugar, fructose, or fat emulsions.
- Give oral form at meals with 8 oz of water.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O. (extended)</td>
<td>Variable</td>
<td>Variable</td>
<td>Variable</td>
</tr>
<tr>
<td>P.O. (liquid)</td>
<td>15-60 min</td>
<td>1-7 hr</td>
<td>Variable</td>
</tr>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>Immediate</td>
<td>6-8 hr</td>
</tr>
<tr>
<td>P.R.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: irritability, dizziness, nervousness, restlessness, headache, insomnia, stammering speech, abnormal behavior, mutism, unresponsiveness alternating with hyperactivity, seizures
CV: palpitations, sinus tachycardia, extrasystoles, marked hypotension, arrhythmias, circulatory failure
GI: nausea, vomiting, diarrhea, epigastric pain, hematemesis, gastroesophageal reflux, anorexia
GU: urine retention (in men with enlarged prostate), diuresis, increased excretion of renal tubular cells and red blood cells, proteinuria
Metabolic: hyperglycemia
Musculoskeletal: muscle twitching
Respiratory: tachypnea, respiratory arrest
Skin: flushing
Other: fever, hypersensitivity reactions (including exfoliative dermatitis and urticaria)

Interactions
Drug-drug. Adenosine: decreased antiarrhythmic effect of adenosine Barbiturates, nicotine, phenytoin, rifampin: decreased aminophylline blood level
Beta-adrenergic blockers: antagonism of aminophylline effects Calcium channel blockers, cimetidine, ciprofloxacin, disulfiram, erythromycin, hormonal contraceptives, influenza vaccine, interferon, methotrexate: elevated aminophylline blood level
Carbamazepine, isoniazid, loop diuretics (such as furosemide): increased or decreased aminophylline blood level
Ephedrine, other sympathomimetics: toxicity, arrhythmias
Lithium: increased lithium excretion

Drug-diagnostic tests. Aspartate aminotransferase, glucose: increased levels

Reactions in bold are life-threatening.
Drug-herbs. *Cayenne:* increased risk of aminophylline toxicity  

**Drug-behaviors.** *Smoking:* increased aminophylline elimination

**Patient monitoring**
- Monitor aminophylline blood level. Adjust dosage if patient has signs or symptoms of toxicity (tachycardia, headache, anorexia, nausea, vomiting, diarrhea, restlessness, and irritability).
  - Assess for arrhythmias, especially after giving loading dose.
  - Check vital signs and fluid intake and output.
  - Monitor patient’s response to drug, and assess pulmonary function test results.

**Patient teaching**
- Advise patient to take oral doses at meals with 8 oz of water.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Tell patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
- Advise patient to establish effective bedtime routine to minimize insomnia.
- Caution patient not to change aminophylline brands.
- If patient smokes, tell him to notify prescriber if he stops smoking; dosage may need to be adjusted.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

---

**amiodarone hydrochloride**

Amyben®, Cordarone, Cordarone X®, Pacerone  

**Pharmacologic class:** Benzofuran derivative  

**Therapeutic class:** Antiarrhythmic (class III)  

**Pregnancy risk category D**

**FDA BOXED WARNING**
- Because of substantial toxicity, drug is indicated only in patients with life-threatening arrhythmias.
- Drug may cause potentially fatal pulmonary toxicities, including hypersensitivity pneumonitis and interstitial/alveolar pneumonitis. Pulmonary toxicity is fatal about 10% of the time.
- Hepatic injury is common but usually mild, manifesting only as abnormal liver enzyme levels. However, overt hepatic disease can occur and, in rare cases, is fatal.
- Drug may exacerbate arrhythmias by reducing tolerance for them or making them harder to reverse. Arrhythmias and significant heart block or sinus bradycardia occur in 2% to 5% of patients.
- Even in patients at high risk for arrhythmic death in whom toxicity is an acceptable risk, drug poses major management problems. Therefore, other agents should be tried first whenever possible.
- Difficulty of using drug effectively and safely poses significant risk. Patients with indicated arrhythmias must be hospitalized to receive loading dose; response generally takes at least 1 week, but usually 2 or more.
**Action**
Prolongs duration and refractory period of action potential. Slows electrical conduction, electrical impulse generation from sinoatrial node, and conduction through accessory pathways. Also dilates blood vessels.

**Availability**
*Injection:* 50 mg/ml in 3-ml ampules
*Tablets:* 100 mg, 200 mg, 400 mg

**Indications and dosages**
**Life-threatening ventricular arrhythmias**

**Adults:** 150 mg in 100 ml of dextrose 5% in water (D₅W) by rapid I.V. infusion over 10 minutes; then dilute 900 mg in 500 ml of D₅W and administer 360 mg by slow I.V. infusion over next 6 hours; then 540-mg I.V. maintenance infusion over next 18 hours. Or 800 to 1,600 mg P.O. daily in one to two doses for 1 to 3 weeks; then 600 to 800 mg P.O. daily in one to two doses for 1 month; then 400-mg P.O. daily as maintenance dosage. All dosages are titrated to individual patient’s clinical needs.

**Off-label uses**
- Atrioventricular (AV) nodal reentry tachycardia (with parenteral use)
- Conversion of atrial fibrillation to normal sinus rhythm

**Contraindications**
- Hypersensitivity to drug or its components, including iodine
- Cardiogenic shock
- Second- or third-degree AV block
- Marked sinus bradycardia
- Breastfeeding
- Neonates

**Precautions**
Use cautiously in:
- electrolyte imbalances, severe pulmonary or hepatic disease, thyroid disorders
- history of heart failure
- elderly patients
- pregnant patients
- children.

**Administration**
- Know that I.V. amiodarone is a high-alert drug.
- Give loading dose only in hospital setting with continuous ECG monitoring.
- Administer oral loading dose in two equal doses with meals. Give maintenance dose daily or in two divided doses to minimize GI upset.
- Don’t give I.V. unless patient is on continuous ECG monitoring.
- Dilute I.V. drug with dextrose 5% in water and use in-line filter. Drug isn’t compatible with normal saline solution.
- Use central venous catheter when giving repeated doses. If possible, use dedicated catheter for drug.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Variable</td>
<td>3-7 hr</td>
<td>Wks-mos</td>
</tr>
<tr>
<td>I.V.</td>
<td>Hrs</td>
<td>Unknown</td>
<td>Variable</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** dizziness, fatigue, headache, insomnia, paresthesia, peripheral neuropathy, poor coordination, involuntary movements, tremor, sleep disturbances

**CV:** hypotension, **heart failure**, worsening arrhythmia, AV block, sinoatrial node dysfunction, bradycardia, asystole, cardiac arrest, cardiogenic shock, electromechanical dissociation, ventricular tachycardia

**EENT:** corneal microdeposits, corneal or macular degeneration, visual disturbances, dry eyes, eye discomfort, optic neuritis or neuropathy, scotoma, lens opacities, photophobia, visual halos, **papilledema**

**GI:** nausea, vomiting, constipation, abdominal pain, abnormal salivation, anorexia

**GU:** decreased libido

Reactions in **bold** are life-threatening.

Clinical alert
Hematologic: coagulation abnormalities, thrombocytopenia
Hepatic: nonspecific hepatic disorders, hepatic dysfunction
Metabolic: hypothyroidism, hyperthyroidism
Respiratory: cough, adult respiratory distress syndrome, pulmonary inflammation or fibrosis, pulmonary edema
Skin: flushing, photosensitivity, toxic epidermal necrolysis
Other: abnormal taste and smell, edema, fever, Stevens-Johnson syndrome

Interactions
Drug-drug. Anticoagulants: increased prothrombin time (PT)
Azole antifungals, fluoroquinolones, loratadine, macrolide antibiotics, trazodone: increased risk of life-threatening arrhythmias
Beta-adrenergic blockers: increased risk of bradycardia and hypotension
Calcium channel blockers: increased risk of AV block (with verapamil, diltiazem) or hypotension (with any calcium channel blocker)
Cholestyramine: decreased amiodarone blood level
Cimetidine, ritonavir: increased amiodarone blood level
Class I antiarrhythmics (disopyramide, flecainide, lidocaine, mexiletine, procainamide, quinidine): increased blood levels of these drugs, leading to toxicity
Cyclosporine: elevated cyclosporine and creatinine blood levels
Dextromethorphan: impaired dextromethorphan metabolism (with amiodarone therapy of 2 weeks or longer)
Digoxin: increased digoxin blood level, leading to toxicity
Fentanyl: increased bradycardia, hypotension
Methotrexate: impaired methotrexate metabolism, possibly causing toxicity (with amiodarone use longer than 2 weeks)
Phenytoin: decreased amiodarone blood level or increased phenytoin blood level (with amiodarone use longer than 2 weeks)
Protease inhibitors (atazanavir, indinavir, nelfinavir): possible increased amiodarone concentration
Rifampin: decreased amiodarone concentration
Theophylline: increased theophylline blood level (with amiodarone use longer than 1 week)
Drug-diagnostic tests. Kidney function tests: abnormal results
Drug-food. Grapefruit juice: increased drug concentration
Drug-herb. St. John’s wort: decreased drug blood level

Patient monitoring
- Monitor patient closely. Drug may cause serious or life-threatening adverse reactions.
- Watch for slow onset of life-threatening arrhythmias, especially after giving loading dose.
- Monitor ECG continuously during loading dose and when dosage is changed.
  - Check patient’s blood pressure, pulse, and heart rhythm regularly.
  - Assess for signs and symptoms of lung inflammation.
  - Monitor baseline and subsequent chest X-rays, as well as pulmonary, liver, and thyroid function test results.
  - Closely monitor patient who’s receiving other drugs concurrently because amiodarone can interact with many drugs. Check digoxin blood level if patient is receiving digoxin; monitor PT or International Normalized Ratio if patient is receiving anticoagulants.

Patient teaching
- Inform patient that drug may cause serious adverse reactions. Instruct him to report these immediately.
  - Tell patient to take oral doses with meals. Advise him to divide daily dose into two doses if drug causes GI upset.
Tell patient that adverse reactions are most common with high doses and may become more frequent after 6 months of therapy.

Inform patient that he’ll undergo regular blood testing, eye examinations, chest X-rays, and pulmonary function tests during therapy.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**amitriptyline hydrochloride**

Apo-Amitriptyline, Levate®, Novotriptyn®

*Pharmacologic class:* Tricyclic compound  
*Therapeutic class:* Antidepressant  
*Pregnancy risk category D*

**FDA BOXED WARNING**

Drug may increase risk of suicidal thinking and behavior in children and adolescents with major depressive disorder and other psychiatric disorders. Risk is greater during first few months of treatment, and must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family to observe patient closely and communicate with prescriber as needed.

Drug isn’t approved for use in pediatric patients.

**Action**

Unclear. Inhibits norepinephrine and serotonin reuptake at presynaptic neuron, increasing levels of these neurotransmitters in brain. Also has sedative, anticholinergic, and mild peripheral vasodilating effects.

**Availability**

*Injection:* 10 mg/ml  
*Syrup:* 10 mg/5 ml  
*Tablets:* 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg

**Indications and dosages**

**Depression**

*Adults:* 75 mg P.O. daily in divided doses; may increase gradually to 150 mg/day. Or start with 50 to 100 mg P.O. at bedtime and increase by 25 to 50 mg as needed, to a total dosage of 150 mg. Hospitalized patients initially may receive 100 mg P.O. daily, with gradual increases as needed to a total dosage of 300 mg P.O. With I.M. use, give 20 to 30 mg q.i.d.

**Dosage adjustment**

- Elderly patients
- Adolescents
- Outpatients

**Off-label uses**

- Analgesic adjunct for phantom limb pain or chronic pain

**Contraindications**

- Hypersensitivity to drug or other tricyclic antidepressants (TCAs)
- Acute recovery phase after myocardial infarction
- MAO inhibitor use within past 14 days
- Children younger than age 12

**Precautions**

Use cautiously in:

- seizures, cardiovascular disease, renal or hepatic impairment, urinary retention, hyperthyroidism, increased intraocular pressure, closed-angle glaucoma, prostatic hypertrophy, bipolar disorder, schizophrenia, paranoia
- elderly patients
- pregnant or breastfeeding patients.

Reactions in **bold** are life-threatening.

Clinical alert
Administration
- Administer full dose at bedtime to minimize orthostatic hypotension.
- Give injectable form by I.M. route only.
- Don’t withdraw drug suddenly. Instead, taper dosage gradually.
- If patient is scheduled for surgery, discuss dosage tapering with prescriber.
- Be aware that drug is often used in conjunction with psychotherapy.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>2-4 wk</td>
<td>2-6 wk</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.M.</td>
<td>2-3 wk</td>
<td>2-6 wk</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, fatigue, agitation, numbness, paresthesia, peripheral neuropathy, weakness, restlessness, panic, anxiety, dizziness, drowsiness, difficulty speaking, excitement, hypomania, psychosis exacerbation, extrapyramidal effects, poor coordination, hallucinations, insomnia, nightmares, seizures, coma, suicidal behavior or ideation (especially in children and adolescents)
CV: ECG changes, tachycardia, hypertension, orthostatic hypotension, arrhythmias, heart block, myocardial infarction
EENT: blurred vision, dry eyes, mydriasis, abnormal visual accommodation, increased intraocular pressure, tinnitus
GI: nausea, vomiting, constipation, dry mouth, epigastric pain, anorexia, paralytic ileus
GU: urinary retention, delayed voiding, urinary tract dilation, gynecomasia
Hematologic: agranulocytosis, thrombocytopenia, thrombocytopenic purpura, leukopenia
Metabolic: changes in blood glucose level
Skin: photosensitivity rash, urticaria, flushing, diaphoresis

Other: increased appetite, weight gain, high fever, edema, hypersensitivity reaction

Interactions
Drug-drug. Activated charcoal: decreased amitriptyline absorption
Adrenergics, anticholinergics, anticholinergic-like drugs: increased anticholinergic effects
Amiodarone, cimetidine, quinidine, ritonavir: increased amitriptyline effects
Barbiturates: decreased amitriptyline blood level, increased CNS and respiratory effects
Clonidine: hypertensive crisis
CNS depressants (including antihistamines, opioids, sedative-hypnotics): increased CNS depression
Drugs metabolized by CYP-4502D6 (such as other antidepressants, phenothiazines, carbamazepine, class 1C anti-arrhythmics): decreased amitriptyline clearance, possibly causing toxicity
Guanethidine: antagonism of antihypertensive action
Levodopa: delayed or decreased levodopa absorption, hypertension
MAO inhibitors: hypotension, tachycardia, potentially fatal reactions
Rifabutin, rifampin, rifapentine: decreased amitriptyline blood level and effects
Selective serotonin reuptake inhibitors: increased risk of toxicity
Sympathomimetics: increased pressor effect of direct-acting sympathomimetics (epinephrine, norepinephrine), possibly causing arrhythmias; decreased pressor effect of indirect-acting sympathomimetics (ephedrine, metaraminol)
Drug-diagnostic tests. Eosinophils, liver function tests: increased values
Glucose, granulocytes, platelets, white blood cells: increased or decreased levels
Drug-herbs. Angel’s trumpet, jimsonweed, scopolia: increased anticholinergic effects
Chamomile, hops, kava, skullcap, valerian: increased CNS depression
St. John’s wort: decreased drug blood level and reduced efficacy

Drug-behaviors. Alcohol use: increased CNS sedation
Smoking: increased drug metabolism and altered effects
Sun exposure: increased risk of photosensitivity reaction

Patient monitoring
- Evaluate for signs and symptoms of psychosis. If present, discuss possible dosage change with prescriber.
- Assess for changes in patient’s mood or mental status.
- Monitor for signs and symptoms of depression and assess for suicidal ideation (especially in child or adolescent).
- Check blood pressure for orthostatic hypertension.
- Monitor CBC with white cell differential, glucose levels, and liver function test results.

Patient teaching
- Instruct patient, parent, or caregiver to contact prescriber if severe mood changes or suicidal thoughts occur (especially if patient is child or adolescent).
- Tell patient that drug may cause temporary blood pressure decrease if he stands up suddenly. Advise him to rise slowly and carefully.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
- Inform patient that he’ll undergo frequent blood testing during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

Reactions in bold are life-threatening.
Administration
• Be aware that this drug may be given alone or with other drugs to relieve hypertension or angina.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>6-9 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, dizziness, drowsiness, light-headedness, fatigue, weakness, lethargy
CV: peripheral edema, angina, bradycardia, hypotension, palpitations
GI: nausea, abdominal discomfort
Musculoskeletal: muscle cramps, muscle pain or inflammation
Respiratory: shortness of breath, dyspnea, wheezing
Skin: rash, pruritus, urticaria, flushing

Interactions
Drug-drug. Beta-adrenergic blockers: increased risk of adverse effects
Fentanyl, nitrates, other antihypertensives, quinidine: additive hypotension
Drug-behaviors. Acute alcohol ingestion: additive hypotension

Patient monitoring
• Monitor patient for worsening angina.
• Monitor heart rate and rhythm and blood pressure, especially at start of therapy.
• Assess for heart failure; report signs and symptoms (peripheral edema, dyspnea) to prescriber promptly.
• Give sublingual nitroglycerin, as prescribed, if patient has signs or symptoms of acute myocardial infarction (especially when dosage is increased).

Patient teaching
• If patient also uses sublingual nitroglycerin, tell him he can take nitroglycerin as needed for acute angina.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• As appropriate, review all other significant adverse reactions, especially those related to the drugs and behaviors mentioned above.

amlodipine besylate and atorvastatin calcium
Caduet
Pharmacologic class: Calcium channel blocker, HMG-CoA reductase inhibitor
Therapeutic class: Antihypertensive, antianginal, lipid-lowering agent
Pregnancy risk category X

Action
Amlodipine inhibits influx of extracellular calcium ions, thereby decreasing myocardial contractility, relaxing coronary and vascular muscles, and reducing peripheral resistance. Atorvastatin inhibits HMG-CoA reductase, which catalyzes first step in cholesterol synthesis; this action reduces serum cholesterol and low-density lipoprotein (LDL) levels; atorvastatin also moderately increases concentration of high-density lipoproteins (HDLs).

Availability
Tablets: (amlodipine besylate/atorvastatin calcium) 2.5/10 mg, 2.5/20 mg, 2.5/40 mg, 5/10 mg, 5/20 mg, 5/40 mg, 5/80 mg, 10/10 mg, 10/20 mg, 10/40 mg, 10/80 mg

Indications and dosages
• Patients for whom treatment with both amlodipine and atorvastatin is appropriate, such as those with hypertension (used alone or combined with other antihypertensives), coronary artery disease, cardiovascular disease
prevention, heterozygous familial or nonfamilial hypercholesterolemia, homozygous familial hypercholesterolemia, elevated serum triglycerides, or dysbetalipoproteinemia

**Adults:** Dosage individualized based on efficacy of and tolerance for each component. Maximum amlodipine dosage: 10 mg P.O. daily; maximum atorvastatin dosage: 80 mg P.O. daily.

**Dosage adjustment**
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) more than three times upper limit of normal
- Small, frail, or elderly patients

**Contraindications**
- Hypersensitivity to drug or its components
- Active hepatic disease or unexplained persistent serum transaminase elevations
- Pregnant or breastfeeding patients

**Precautions**
Use cautiously in:
- hepatic or renal impairment; aortic stenosis; heart failure; hypotension; uncontrolled seizures; myopathy; severe metabolic, endocrine, or electrolyte disorders
- alcohol abuse
- concurrent use of fibric acid derivatives (such as gemfibrozil) or drugs that may decrease endogenous steroids (such as cimetidine, ketoconazole, spironolactone)
- elderly patients
- females of childbearing potential
- children (safety and efficacy not established).

**Administration**
- Before starting therapy, patient should attempt to control hypercholesterolemia with appropriate diet, exercise, and weight reduction (if obese) and should receive treatment for other underlying medical problems.
- Administer with or without food.
- Don’t give with grapefruit juice or antacids.
- Titrate dosage over 7 to 14 days. (Titration may be more rapid if warranted and if patient is assessed frequently.)
- Dosage of amlodipine, atorvastatin, or both may be increased, if appropriate, for additional antianginal, hypotensive, or lipid-lowering effect.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**Amlodipine component**
- **CNS:** dizziness, headache, fatigue, somnolence
- **CV:** palpitations, chest pain, arrhythmias
- **EENT:** abnormal vision, conjunctivitis, diplopia, eye pain, tinnitus
- **GI:** nausea, abdominal pain, dry mouth
- **GU:** frequent urination, urination disorder, nocturia
- **Hematologic:** purpura, leukopenia, thrombocytopenia
- **Metabolic:** hyperglycemia
- **Skin:** flushing, erythema multiforme
- **Other:** edema, increased sweating, thirst

**Atorvastatin component**
- **CNS:** headache, migraine, asthenia, insomnia, dizziness, malaise, depression, peripheral neuropathy, somnolence, amnesia, abnormal dreams, emotional lability, facial paralysis, incoordination, hyperkinesia, paresthesia, hypoesthesia, hypertonia
- **CV:** chest pain, palpitations, vasodilation, syncope, hypertension, orthostatic hypotension, phlebitis, angina pectoris, arrhythmias
- **EENT:** amblyopia, refraction disorder, eye hemorrhage, glaucoma, dry eyes,

Reactions in **bold** are life-threatening.
hearing loss, tinnitus, parosmia, epis-taxis, rhinitis, sinusitis, pharyngitis

**GI:** nausea, vomiting, diarrhea, consti-pation, abdominal pain, dyspepsia, flat-ulence, enteritis, gastroenteritis, colitis, gastritis, esophagitis, eructation, biliary pain, duodenal ulcer, gastric ulcer, pancreatitis, cholestatic jaundice, tenesmus, melena, dysphagia, cheilosis, glossitis, stomatitis, dry mouth, ulcerative stom-atitis, **rectal and gum hemorrhage**

**GU:** decreased libido, sexual dysfunc-tion, fibrocystic breasts, breast en-largement, metrorrhagia, epididymitis, abnormal ejaculation, urinary tract in-fecion, hematuria, albuminuria, uri-nary frequency, urinary incontinence, urinary retention, urinary urgency, nocturia, cystitis, dysuria, renal cal-culus, nephritis, **vaginal and uterine hemorrhage**

**Hematologic:** anemia, thrombocytopenia

**Hepatic:** abnormal liver function tests, hepatitis

**Metabolic:** gout

**Musculoskeletal:** back pain, arthralgia, myalgia, myositis, myasthenia, arthri-tis, neck rigidity, leg cramps, bursitis, tenosynovitis, tendon contracture

**Respiratory:** bronchitis, pneumonia, dyspnea, asthma

**Skin:** rash, pruritus, contact dermati-tis, alopecia, dry skin, acne, urticaria, eczema, seborrhea, skin ulcer, ecchy-mosis, petechiae, photosensitivity

**Other:** taste loss or alteration; appetite changes; weight gain; infection; lym-phadenopathy; accidental injury; flu-like syndrome; peripheral, facial, or general edema; allergic reaction

**Interactions**

**Drug-drug.** *Antacids, colestipol:* decreased atorvastatin level

*Azole antifungals, cyclosporine, erythro-myacin, fibric acid derivatives, niacin, other HMG-CoA inhibitors:* increased myopathy risk

*Beta-adrenergic blockers:* increased risk of adverse effects (amlodipine component)

*Cimetidine, ketoconazole, spironolac-tone:* decreased levels or activity of en-dogenous steroids (atorvastatin component)

*Digoxin:* increased digoxin level, in-creased risk of digoxin toxicity

*Fentanyl, nitrites, other antihyperten-sives, quinidine:* additive hypotension (amlodipine component)

*Hormonal contraceptives:* increased es-trogen level

**Drug-diagnostic tests.** *ALT, AST, creatinine kinase:* increased (atorvastatin component)

*Blood glucose:* increased or decreased

*CBCs, platelets:* decreased

**Drug-food.** *Grapefruit juice:* increased

**Drug-herb.** *Red yeast rice:* increased

**Drug-behaviors.** *Acute alcohol inges-tion:* additive hypotension (amlodipine component)

**Patient monitoring**

- Monitor heart rate and rhythm and blood pressure, especially at start of therapy.
- Monitor liver function tests before therapy starts, at 12 weeks, and after dosage increase; thereafter, monitor periodically.
- Watch for signs and symptoms of al-lergic response.
  - Monitor patient for worsening angina.
  - Assess for heart failure; promptly report signs and symptoms (peripheral edema, dyspnea).
- Monitor patients who develop transaminase elevations until these resolve.
  - Evaluate for muscle weakness (a symptom of myositis and possibly rhabdomyolysis).
- Measure blood glucose level regularly.
Patient teaching

- Tell patient drug may be taken with or without food.
- Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
- Instruct patient to avoid grapefruit juice during therapy.

Urge patient to immediately report unexplained muscle pain, tenderness, or weakness—especially if accompanied by malaise or fever.

Instruct patient to immediately report signs and symptoms of liver damage, such as nausea, fatigue, anorexia, jaundice, dark urine, light-colored stools, intense itching, or tender abdomen.

Tell patient to promptly report chest pain, swelling, or difficulty breathing.

- Caution patient to avoid driving and other hazardous activities until drug effects are known.
- Instruct patient to avoid alcohol use during therapy.
- Advise female with childbearing potential to avoid pregnancy and breastfeeding during therapy.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

disorder and other psychiatric disorders. Risk must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family to observe patient closely and communicate with prescriber as needed.

- Drug isn’t approved for use in pediatric patients.

Action

Unclear. Inhibits reuptake of norepinephrine or serotonin at presynaptic neuron, thereby increasing levels of these neurotransmitters in brain. Also has sedative, anticholinergic, and mild peripheral vasodilatory properties.

Availability

Tablets: 25 mg, 50 mg, 100 mg, 150 mg

Indications and dosages

Depression accompanied by anxiety or agitation, depression in patients with neurotic or reactive depressive disorders, endogenous and psychotic depression

Adults: Initially, 50 mg P.O. two or three times daily, increased to 100 mg two or three times daily by end of first week. If starting dosage (up to 300 mg/day) is tolerated but ineffective for at least 2 weeks, dosage may be increased. For outpatients, maximum suggested dosage is 400 mg/day; for hospitalized patients, 600 mg/day.

Dosage adjustment

- Elderly patients

Off-label uses

- Analgesic adjunct for phantom limb pain or chronic pain

Reactions in bold are life-threatening.
Contraindications
● Hypersensitivity to drug or other tricyclic antidepressants (TCAs)
● Acute recovery phase after myocardial infarction
● MAO inhibitor use within past 14 days

Precautions
Use cautiously in:
● renal or hepatic impairment, prostatic hypertrophy, hyperthyroidism, angle-closure glaucoma, bipolar disorder, schizophrenia
● elderly patients
● pregnant or breastfeeding patients
● children younger than age 16 (safety and efficacy not established).

Administration
Don’t give drug if patient has taken MAO inhibitors within past 14 days.
● If desired, give daily dose up to 300 mg at bedtime.
● If patient is scheduled for surgery, discuss need for dosage tapering with prescriber.

Adverse reactions
CNS: agitation, restlessness, fatigue, panic, anxiety, dizziness, drowsiness, difficulty articulating words, excitement, hypomania, psychosis exacerbation, extrapyramidal effects, tardive dyskinesia, poor coordination, hallucinations, headache, insomnia, nightmares, numbness, paresthesia, peripheral neuropathy, weakness, neuroleptic malignant syndrome, seizures, coma, suicidal behavior or ideation (especially in children and adolescents)
CV: ECG changes, hypertension, orthostatic hypotension, arrhythmias, heart block, myocardial infarction, tachycardia
EENT: blurred vision, dry eyes, mydriasis, abnormal visual accommodation, increased intraocular pressure, tinnitus
GI: nausea, vomiting, constipation, anorexia, epigastric pain, dry mouth, paralytic ileus
GU: urine retention, delayed voiding, urinary tract dilation, gynecomastia
Hematologic: agranulocytosis, thrombocytopenia, thrombocytopenic purpura, leukopenia
Metabolic: changes in blood glucose level
Skin: photosensitivity rash, urticaria, flushing, diaphoresis
Other: increased appetite, weight gain, high fever, edema, hypersensitivity reactions

Interactions
Drug-drug. Adrenergics, anticholinergics, anticholinergic-like drugs: increased anticholinergic effects
Amiodarone, cimetidine, quinidine, ritonavir: increased amoxapine effects
Barbiturates: reduced amoxapine blood level, increased CNS and respiratory effects
Clonidine: hypertensive crisis
CNS depressants (including antihistamines, opioids, sedative-hypnotics): increased CNS depression
Drugs metabolized by CYP450 2D6 (such as other antidepressants, carbamazepine, class IC antiarrhythmics, phenothiazines): decreased amoxapine clearance, possible toxicity
Guanethidine: antagonism of anti-hypertensive action
Levodopa: delayed or decreased levodopa absorption, hypertension
MAO inhibitors: hypotension, tachycardia, extreme excitation, fever, hyperpyrexia, seizures
Rifabutin, rifampin, rifapentine: decreased amoxapine blood level and effects
Selective serotonin reuptake inhibitors: increased toxicity
Sympathomimetics: increased pressor effects of direct-acting sympathomimetics (epinephrine, norepinephrine), possibly causing arrhythmias;
decreased pressor effects of indirect-acting sympathomimetics (ephedrine, metaraminol)

Valproic acid: increased valproic acid blood level, greater risk of adverse reactions

**Drug-diagnostic tests.** Eosinophils, liver function tests: increased values Glucose, granulocytes, platelets, white blood cells: increased or decreased values

**Drug-herbs.** Evening primrose: lower seizure threshold, increased risk of seizures

**Drug-behaviors.** Alcohol use: increased CNS sedation Smoking: increased metabolism and altered drug effects Sun exposure: increased risk of photosensitivity reactions

**Patient monitoring**
- **Watch for signs and symptoms of neuroleptic malignant syndrome (high fever, rapid pulse and breathing, profuse sweating).**
- Monitor patient for signs and symptoms of psychosis. If these occur, consult prescriber.
- Evaluate patient for development of tardive dyskinesia (involuntary movements of face, arms, legs, and trunk).
- Assess for changes in mood and mental status.
- Check blood pressure for orthostatic hypertension.
- **Watch for signs and symptoms of depression, and assess for suicidal ideation.**
- Monitor CBC with white cell differential, glucose level, and kidney and liver function test results.

**Patient teaching**
- **Tell patient to contact prescriber immediately if he develops high fever, rapid pulse and breathing, profuse sweating, changes in mental status, or involuntary movements.**

---

**amoxicillin**

amoxicillin trihydrate

Amix®, Amox®, Amoxident®, Amoxil, Apo-Amoxil®, Moxatag®, Novamoxin®, Nu-Amoxil®, Trimox

**Pharmacologic class:** Aminopenicillin

**Therapeutic class:** Anti-infective

**Pregnancy risk category B**

**Action**
Inhibits cell-wall synthesis during bacterial multiplication, leading to cell death. Shows enhanced activity toward gram-negative bacteria compared to natural and penicillinase-resistant penicillins.

Reactions in **bold** are life-threatening.
Availability
Capsules: 250 mg, 500 mg
Powder for oral suspension: 50 mg/ml and 125 mg/5 ml (pediatric), 200 mg/5 ml, 250 mg/5 ml, 400 mg/5 ml
Tablets: 500 mg, 875 mg
Tablets for oral suspension: 200 mg, 400 mg
Tablets (chewable): 125 mg, 200 mg, 250 mg, 400 mg

Indications and dosages
➣ Uncomplicated gonorrhea
Adults and children weighing at least 40 kg (88 lb): 3 g P.O. as a single dose
Children ages 2 and older weighing less than 40 kg (88 lb): 50 mg/kg P.O. given with probenecid 25 mg/kg P.O. as a single dose
➣ Bacterial endocarditis prophylaxis for dental, GI, and GU procedures
Adults: 2 g P.O. 1 hour before procedure
Children: 50 mg/kg P.O. 1 hour before procedure
➣ Lower respiratory tract infections caused by streptococci, pneumococci, non-penicillinase-producing staphylococci, and Haemophilus influenzae
Adults and children weighing more than 20 kg (44 lb): 875 mg P.O. q 12 hours or 500 mg P.O. q 8 hours
Children weighing less than 20 kg (44 lb): 45 mg/kg/day P.O. in divided doses q 12 hours or 40 mg/kg/day P.O. in divided doses q 8 hours
➣ Ear, nose, and throat infections caused by streptococci, pneumococci, non-penicillinase-producing staphylococci, and H. influenzae; GU infections caused by Escherichia coli, Proteus mirabilis, and Streptococcus faecalis
Adults and children weighing more than 20 kg (44 lb): 500 mg P.O. q 12 hours or 250 mg P.O. q 8 hours
Children weighing less than 20 kg (44 lb): 45 mg/kg/day P.O. in divided doses q 12 hours or 20 to 40 mg/kg P.O. in divided doses q 8 hours
➣ Eradication of Helicobacter pylori to reduce risk of duodenal ulcer recurrence
Adults: 1 g P.O. q 12 hours for 14 days in combination with clarithromycin and lansoprazole, or in combination with lansoprazole alone as 1 g t.i.d. for 14 days
➣ Postexposure anthrax prophylaxis
Adults: 500 mg P.O. t.i.d. for 60 days
Children: 80 mg/kg/day P.O. t.i.d. for 60 days
➣ Skin and skin-structure infections caused by streptococci (alpha- and beta-hemolytic strains), staphylococci, and E. coli
Adults: 500 mg P.O. q 12 hours to 250 mg P.O. q 8 hours. For severe infections, 875 mg P.O. q 12 hours or 500 mg P.O. q 8 hours.
Children older than age 3 months: 25 mg/kg/day P.O. in divided doses q 12 hours or 20 mg/kg/day P.O. in divided doses every 8 hours. For severe infections, 45 mg/kg/day P.O. in divided doses q 12 hours or 40 mg/kg/day P.O. in divided doses every 8 hours.

Dosage adjustment
● Renal impairment
● Hemodialysis
● Infants ages 3 months and younger

Off-label uses
● Chlamydia trachomatis infection in pregnant patients

Contraindications
● Hypersensitivity to drug or any penicillin

Precautions
Use cautiously in:
● severe renal insufficiency, infectious mononucleosis, hepatic dysfunction
● pregnant patients.

Administration
ียว Ask about history of penicillin allergy before giving.
Give with or without food.

Store liquid form in refrigerator when possible.

Know that maximum dosage for infants ages 3 months and younger is 30 mg/kg/day divided q 12 hours.

### Route Onset Peak Duration

| P.O. | 30 min | 1-2 hr | 8-12 hr |

### Adverse reactions

**CNS:** lethargy, hallucinations, anxiety, confusion, agitation, depression, dizziness, fatigue, hyperactivity, insomnia, behavioral changes, seizures (with high doses)

**GI:** nausea, vomiting, diarrhea, bloody diarrhea, abdominal pain, gastritis, stomatitis, glossitis, black “hairy” tongue, furry tongue, enterocolitis, pseudomembranous colitis

**GU:** vaginitis, nephropathy, interstitial nephritis

**Hematologic:** eosinophilia, anemia, thrombocytopenia, thrombocytic purpura, leukopenia, hemolytic anemia, agranulocytosis, bone marrow depression

**Hepatic:** cholestatic jaundice, hepatic cholestasis, cholestatic hepatitis, non-specific hepatitis

**Respiratory:** wheezing

**Skin:** rash

**Other:** superinfections (oral and rectal candidiasis), fever, anaphylaxis

### Interactions

**Drug-drug.** Allopurinol: increased risk of rash

Chloramphenicol, macrolides, sulfonamides, tetracycline: decreased amoxicillin efficacy

**Hormonal contraceptives:** decreased contraceptive efficacy

**Probenecid:** decreased renal excretion

**Drug-diagnostic tests.** Alanine aminotransferase, alkaline phosphatase, eosinophils, lactate dehydrogenase: increased levels

Granulocytes, hemoglobin, platelets, white blood cells: decreased levels

Direct Coombs’ test, urine glucose, urine protein: false-positive results

**Drug-food.** Any food: delayed or reduced drug absorption

**Drug-herbs.** Khat: decreased antimicrobial efficacy

### Patient monitoring

- Monitor for signs and symptoms of hypersensitivity reaction.
- Evaluate for seizures when giving high doses.
- Monitor patient’s temperature and watch for other signs and symptoms of superinfection (especially oral or rectal candidiasis).

### Patient teaching

- Instruct patient to immediately report signs and symptoms of hypersensitivity reactions, such as rash, fever, or chills.
- Tell patient he may take drug with or without food.
- Tell patient not to chew or swallow tablets for suspension, because they’re not meant to be dissolved in mouth.
- Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
- Tell patient taking hormonal contraceptives that drug may reduce contraceptive efficacy. Suggest she use alternative birth control method.
- Inform patient that drug lowers resistance to other types of infections. Instruct him to report new signs and symptoms of infection, especially in mouth or rectum.
- Tell parents they may give liquid form of drug directly to child or may mix it with foods or beverages.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

Reactions in **bold** are life-threatening.
Amoxicillin and clavulanate potassium

Apo-Amoxi-Clav®, Augmentin, Augmentin-Duo®, Augmentin ES-600, Augmentin XR, Clavulin®, Novo-Clavamoxin®

Pharmacologic class: Aminopenicillin
Therapeutic class: Anti-infective
Pregnancy risk category B

Action
Amoxicillin inhibits transpeptidase, preventing cross-linking of bacterial cell wall and leading to cell death. Addition of clavulanate (a beta-lactam) increases drug's resistance to beta-lactamase (an enzyme produced by bacteria that may inactivate amoxicillin).

Availability
Oral suspension: 125 mg amoxicillin with 31.25 mg clavulanic acid/5 ml, 200 mg amoxicillin with 28.5 mg clavulanic acid/5 ml, 250 mg amoxicillin with 62.5 mg clavulanic acid/5 ml, 400 mg amoxicillin with 57 mg clavulanic acid/5 ml, 600 mg amoxicillin with 42.9 mg clavulanic acid/5 ml
Tablets (chewable): 125 mg amoxicillin with 31.25 mg clavulanate, 200 mg amoxicillin with 28.5 mg clavulanate, 250 mg amoxicillin with 62.5 mg clavulanate, 400 mg amoxicillin with 57 mg clavulanate
Tablets (extended-release): 1,000 mg amoxicillin with 62.5 mg clavulanate
Tablets (film-coated): 250 mg amoxicillin with 125 mg clavulanate, 500 mg amoxicillin with 125 mg clavulanate, 875 mg amoxicillin with 125 mg clavulanate

Indications and dosages
➤ Lower respiratory tract infections, otitis media, sinusitis, skin and skin-structure infections, and urinary tract infections (UTIs) caused by susceptible strains of gram-negative and gram-positive organisms

Adults and children weighing more than 40 kg (88 lb): 500 mg q 12 hours or 250 mg P.O. q 8 hours (based on amoxicillin component). For severe infections, 875 mg P.O. q 12 hours or 500 mg P.O. q 8 hours.
➤ Serious infections and community-acquired pneumonia

Adults and children weighing more than 40 kg (88 lb): 875 mg P.O. q 12 hours or 500 mg P.O. q 8 hours

Infants and children ages 3 months and older weighing less than 40 kg (88 lb): 20 to 45 mg/kg/day P.O. in divided doses q 12 hours or 20 or 25 to 40 mg/kg/day in divided doses q 8 hours, based on severity of infection and amoxicillin component (125 mg/5 ml or 250 mg/5 ml suspension)

Infants younger than 3 months: 30 mg/kg/day P.O. (based on amoxicillin component) divided q 12 hours. (125 mg/5 ml oral suspension is recommended.)
➤ Recurrent or persistent acute otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis in children ages 2 and younger and in children who have received antibiotic therapy within last 3 months

Children ages 3 months to 12 years: 90 mg/kg/day of Augmentin ES-600 P.O. q 12 hours for 10 days

Dosage adjustment
● Severe renal impairment
● Hemodialysis
● Infants ages 3 months and younger

Contraindications
● Hypersensitivity to drug or any penicillin
● Phenylketonuria (some products)
● History of cholestatic jaundice or hepatic dysfunction associated with this drug
Precautions
Use cautiously in:
• severe renal insufficiency, infectious mononucleosis
• pregnant patients.

Administration
● Ask about history of penicillin allergy before giving.
● Give with or without food.
● Know that maximum dosage for infants ages 3 months and younger is 30 mg/kg/day divided q 12 hours.
● Be aware that 12-hour dosing is recommended to reduce diarrhea.

Route Onset Peak Duration
P.O. Unknown 1-2.5 hr 6-8 hr
P.O. Unknown 1-4 hr Unknown (extended)

Adverse reactions
CNS: lethargy, hallucinations, anxiety, confusion, agitation, depression, dizziness, fatigue, hyperactivity, insomnia, behavioral changes, seizures (with high doses)
GI: nausea, vomiting, diarrhea, abdominal pain, stomatitis, glossitis, gastritis, black “hairy” tongue, furry tongue, enterocolitis, pseudomembranous colitis
GU: vaginitis, nephropathy, interstitial nephritis
Hematologic: anemia, thrombocytopenia, thrombocytopenic purpura, leukopenia, hemolytic anemia, agranulocytosis, bone marrow depression, eosinophilia
Hepatic: cholestatic hepatitis
Respiratory: wheezing
Skin: rash
Other: superinfections (oral and rectal candidiasis), fever, anaphylaxis

Interactions
Drug-drug. Any food: enhanced clavulanate absorption

Chloramphenicol, macrolides, sulfonamides, tetracycline: decreased amoxicillin efficacy
Hormonal contraceptives: decreased contraceptive efficacy
Probenecid: decreased renal excretion and increased blood level of amoxicillin

Drug-food. Any food: enhanced clavulanate absorption

Drug-herbs. Khat: decreased antimicrobial effect

Patient monitoring
● Monitor patient carefully for signs and symptoms of hypersensitivity reaction.
● Monitor for seizures when giving high doses.
● Check patient’s temperature and watch for other signs and symptoms of superinfection, especially oral or rectal candidiasis.

Patient teaching
● Instruct patient to immediately report signs or symptoms of hypersensitivity reaction, such as rash, fever, or chills.
● Tell patient he may take drug with or without food.
● Inform patient that drug lowers resistance to some types of infections. Instruct him to report new signs or symptoms of infection (especially of mouth or rectum).
● Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
● Tell patient taking hormonal contraceptives that drug may reduce contraceptive efficacy. Suggest she use alternative birth control method.
● Inform parents that they may give liquid form of drug directly to child or may mix it with foods or beverages.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, foods, and herbs mentioned above.
amphotericin B cholesteryl sulfate
Amphocil®, Amphotec

amphotericin B desoxycholate
Fungilin®, Fungizone Intravenous

amphotericin B lipid complex
Abelcet

amphotericin B liposome®
AmBisome

Pharmacologic class: Systemic polyene antifungal
Therapeutic class: Antifungal
Pregnancy risk category B

FDA BOXED WARNING
• Amphotericin B desoxycholate should be used mainly to treat progressive and potentially life-threatening fungal infections. It shouldn’t be used to treat noninvasive forms of fungal disease (such as oral thrush, vaginal candidiasis, or esophageal candidiasis) in patients with normal neutrophil counts.

Action
Binds to sterols in fungal cell membrane, increasing permeability. This allows potassium to exit the cell, causing fungal impairment or death.

Availability
Amphotericin B cholesteryl sulfate—
Injection: 50 mg, 100 mg
Amphotericin B desoxycholate—
Injection: 50-mg vial

Indications and dosages
➢ Invasive aspergillosis
Adults: Amphotericin B desoxycholate—For patients with good cardio-renal function who tolerate test dose, give 0.25 to 0.3 mg/kg daily by slow I.V. infusion (0.1 mg/ml over 2 to 6 hours). Gradually increase to 0.5 to 0.6 mg/kg daily. Patients with neutropenia or rapidly progressing, potentially fatal infections may require higher dosages (1 to 1.5 mg/kg daily).
Adults and children ages 1 month and older: Amphotericin B liposome—3 to 5 mg/kg I.V. daily
➢ Invasive aspergillosis in patients with renal impairment or unacceptable toxicity who can’t tolerate or don’t respond to amphotericin B desoxycholate in effective doses
Adults and children: Amphotericin B cholesteryl sulfate—3 to 4 mg/kg daily reconstituted in sterile water for injection and diluted in dextrose 5% in water (D5W) and give by continuous infusion at 1 mg/kg/hour. Amphotericin B lipid complex—5 mg/kg daily I.V. prepared as 1-mg/ml infusion and delivered at a rate of 2.5 mg/kg/hour.
➢ Systemic histoplasmosis
Adults: Amphotericin B desoxycholate—If patient tolerates test dose, gradually increase from initial recommended dosage of 0.25 to 0.3 mg/kg daily by slow I.V. infusion (0.1 mg/ml over 2 to 6 hours) to usual dosage of 0.5 to 0.6 mg/kg daily I.V. for 4 to 8 weeks; higher dosages (0.7 to 1 mg) may be necessary for rapidly progressing, potentially fatal infections.
➢ Systemic coccidioidomycosis and blastomycosis

Oral suspension: 100 mg/ml in 24-ml bottles
Amphotericin B lipid complex—
Suspension for injection: 100 mg/20-ml vials
Amphotericin B liposome—
Injection: 50 mg

Canada UK Hazardous drug High alert drug
Adults: Amphotericin B desoxycholate—
If patient tolerates test dose, gradually increase from initial recommended dosage of 0.25 to 0.3 mg/kg daily by slow I.V. infusion (0.1 mg/ml over 2 to 6 hours) to usual dosage of 0.5 to 1 mg/kg daily I.V. for 4 to 12 weeks.

Systemic cryptococcosis
Adults: Amphotericin B desoxycholate—If patient tolerates test dose, gradually increase from initial recommended dosage of 0.25 to 0.3 mg/kg daily by slow I.V. infusion (0.1 mg/ml over 2 to 6 hours) to usual dosage of 0.3 to 1 mg/kg daily I.V. (with or without flucytosine) for 2 weeks to several months. For patients with human immunodeficiency virus (HIV) infection, usual dosage is 0.7 mg/kg daily I.V. for 4 weeks, followed by 0.7 mg/kg I.V. given on alternate days for 4 additional weeks. If patient can’t tolerate or doesn’t respond to amphotericin B desoxycholate, give amphotericin B cholesteryl sulfate at a dosage of 3 to 6 mg/kg daily I.V.

Adults and children ages 1 month and older: Amphotericin B lipid complex—5 mg/kg I.V. infusion daily for 6 weeks, followed by 12 weeks of oral fluconazole therapy. Amphotericin B liposome—6 mg/kg I.V. infusion daily.

Visceral leishmaniasis in immunocompetent patients
Adults and children: Amphotericin B desoxycholate—If patient tolerates test dose, gradually increase from initial recommended dosage of 0.25 to 0.3 mg/kg daily by slow I.V. infusion (0.1 mg/ml over 2 to 6 hours) to usual dosage of 0.4 to 0.6 mg/kg daily by slow I.V. infusion for 7 to 14 days (low-risk patients) or for 6 weeks (high-risk patients). For hepatosplenic candidiasis, 1 mg/kg daily I.V. given with oral flucytosine; for severe or refractory esophageal candidiasis in HIV-infected patients, 0.3 mg/kg daily I.V. for at least 5 to 7 days; for candiduria, 0.3 mg/kg daily I.V. for 3 to 5 days.

Adults and children ages 1 month and older: Amphotericin B liposome—3 to 5 mg/kg/day I.V. for 5 to 7 days

Systemic zygomycosis, including mucormycosis
Adults: Amphotericin B desoxycholate—If patient tolerates test dose, gradually increase from initial recommended dosage of 0.25 to 0.3 mg/kg daily by slow I.V. infusion (0.1 mg/ml over 2 to 6 hours) to usual dosage of 1 to 1.5 mg/kg daily I.V. for 2 to 3 months. For rhinocerebral phycomycosis form, total dosage is 3 g I.V.

Systemic disseminated sporotrichosis
Adults: Amphotericin B desoxycholate—If patient tolerates test dose, gradually increase from initial recommended dosage of 0.25 to 0.3 mg/kg daily by slow I.V. infusion (0.1 mg/ml over 2 to 6 hours) to usual dosage of 0.4 to 0.5 mg/kg daily I.V. for 2 to 3 months.

Cutaneous leishmaniasis
Adults and children: Amphotericin B desoxycholate—If patient tolerates test dose, gradually increase from initial recommended dosage of 0.25 to 0.3 mg/kg daily by slow I.V. infusion (0.1 mg/ml over 2 to 6 hours) until 0.5 to 1 mg/kg/day is reached; then give every other day. Usual duration is 3 to 12 weeks.

Visceral leishmaniasis in immunocompetent patients
Adults and children ages 1 month and older: Amphotericin B liposome—3 mg/kg given I.V. over 2 hours on
days 1 through 5, 14, and 21. Repeat course if initial treatment fails to clear parasites.

➤ Visceral leishmaniasis in immunocompromised patients

**Adults and children ages 1 month and older:** Amphotericin B liposome—4 mg/kg given I.V. over 2 hours on days 1 through 5, 10, 17, 24, 31, and 38

➤ Empiric therapy for presumed fungal infection in febrile, neutropenic patients

**Adults:** Amphotericin B desoxycholate—If patient tolerates test dose, gradually increase from initial recommended dosage of 0.25 to 0.3 mg/kg daily by slow I.V. infusion (0.1 mg/ml over 2 to 6 hours) to usual dosage of 0.25 to 1 mg/kg daily I.V. Amphotericin B liposome—3 mg/kg daily given I.V. over 120 minutes for 2 weeks

**Off-label uses**
- Chemoprophylaxis in immunocompromised patients
- Coccidioidal arthritis
- Prophylaxis of fungal infections in bone-marrow transplant recipients, patients with primary amoebic meningoencephalitis caused by *Naegleria fowleri*, and patients with ocular aspergillosis

**Contraindications**
- Hypersensitivity to drug and its components
- Severe respiratory distress

**Precautions**
Use cautiously in:
- renal impairment, electrolyte abnormalities
- pregnant or breastfeeding patients
- children.

**Administration**
- Know that amphotericin B should be given only by health care professionals thoroughly familiar with drug, its administration, and adverse reactions.

Before giving first dose of conventional amphotericin B (desoxycholate form), test dose may be ordered (due to widely varying tolerance and clinical status) as follows: 1 mg in 20 ml of D$_2$W over 20 to 30 minutes; monitor vital signs every 30 minutes for next 2 hours.

- Know that if desoxycholate form is discontinued for 1 week or longer, drug should be restarted at 0.25 mg/kg daily, with dosage then increased gradually.
- Pretreat with antihistamines, antipyretics, or corticosteroids, as prescribed.
- Give through separate I.V. line, using infusion pump and in-line filter with pores larger than 1 micron.
- Choose distal vein for I.V. site. Alternate sites regularly.
- Mix with sterile water to reconstitute. Don’t mix with sodium chloride, other electrolytes, or bacteriostatic products.
- Flush I.V. line with 5% dextrose injection before and after infusion.
- Keep dry form of drug away from light. Once mixed with fluid, solution can be kept in light for up to 8 hours.

Know that total daily dosage of amphotericin B desoxycholate form should never exceed 1.5 mg/kg.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>End of infusion</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** anxiety, confusion, headache, insomnia, weakness, depression, dizziness, drowsiness, hallucinations, speech difficulty, ataxia, vertigo, stupor, psychosis, **seizures**

**CV:** hypotension, hypertension, tachycardia, phlebitis, chest pain, orthostatic hypotension, vasodilation, **asystole**, atrial fibrillation, bradycardia,
cardiac arrest, shock, supraventricular tachycardia

**EENT:** double or blurred vision, amblyopia, eye hemorrhage, hearing loss, tinnitus, epistaxis, rhinitis, sinusitis, pharyngitis

**GI:** nausea, vomiting, diarrhea, melena, abdominal pain, abdominal distention, dry mouth, oral inflammation, oral candidiasis, anorexia, **GI hemorrhage**

**GU:** painful urination, hematuria, albuminuria, glycosuria, excessive urea buildup, urine of low specific gravity, nephrocalcinosis, **renal failure, renal tubular acidosis, oliguria, anuria**

**Hematologic:** eosinophilia; normochromic, normocytic, or hypochromic anemia; **leukocytosis; thrombocytopenia; leukopenia; agranulocytosis; coagulation disorders**

**Hepatic:** jaundice, **acute hepatic failure, hepatitis**

**Metabolic:** hypomagnesemia, hypokalemia, hypocalcemia, hypernatremia, hyperglycemia, dehydration, hypoproteinemia, hypervolemia, hyperlipidemia, **acidosis**

**Musculoskeletal:** muscle, joint, neck, or back pain

**Respiratory:** increased cough, hypoxia, lung disorders, hyperventilation, wheezing, dyspnea, hemoptysis, tachypnea, **asthma, bronchospasm, respiratory failure, pulmonary edema, pleural effusion**

**Skin:** discoloration, bruising, flushing, pruritus, urticaria, acne, rash, sweating, nodules, skin ulcers, alopecia, maculopapular rash

**Other:** gingivitis, fever, infection, peripheral or facial edema, weight changes, pain or reaction at injection site, tissue damage with extravasation, hypersensitivity reactions including **anaphylaxis**

**Interactions**

**Drug-drug.** *Antineoplastics (such as mechlorethamine):* renal toxicity, bronchospasm, hypotension

*Cardiac glycosides:* increased risk of digitalis toxicity (in potassium-depleted patients)

*Corticosteroids:* increased potassium depletion

*Cyclosporine, tacrolimus:* increased creatinine levels

*Flucytosine:* increased flucytosine toxicity

*Imidazoles ( clotrimazole, fluconazole, ketoconazole, miconazole):* antagonism of amphotericin B effects

*Leukocyte transfusion:* pulmonary reactions

*Nephrotoxic drugs (such as antibiotics, pentamidine):* increased risk of renal toxicity

*Thiazides:* increased electrolyte depletion

*Skeletal muscle relaxants:* increased skeletal muscle relaxation

*Zidovudine:* increased myelotoxicity and nephrotoxicity

**Drug-diagnostic tests.** *Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, gamma-glutamyltransferase, lactate dehydrogenase, nitrogenous compounds (urea), uric acid:* increased levels

*C Calcium, hemoglobin, magnesium, platelets, potassium, protein:* decreased levels

*Eosinophils, glucose, white blood cells:* increased or decreased levels

*Liver function tests:* abnormal results

*Prothrombin time:* prolonged

**Drug-herbs.** *Gossypol:* increased risk of renal toxicity

**Patient monitoring**

*Monitor for infusion-related reactions (fever, chills, hypotension, GI symptoms, breathing difficulties, and headache). Stop infusion and notify prescriber immediately if reaction occurs.*

*After giving test dose, monitor vital signs and temperature every 30 minutes for 2 to 4 hours, as ordered.*

• Assess fluid intake and output.
Monitor kidney and liver function test results and serum electrolyte levels.
Assess for signs and symptoms of ototoxicity (hearing loss, tinnitus, ataxia, and vertigo).

Patient teaching
- Advise patient to contact prescriber immediately if he has fever, chills, headache, vomiting, diarrhea, cough, or breathing problems.
- Instruct patient to report hearing loss, dizziness, or unsteady gait.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, alertness, and vision.
- Instruct patient to drink plenty of fluids.
- Tell patient to monitor urine output and report significant changes.
- Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

Ampicillin sodium
Apo-Ampi®, Novo-Ampicillin®, Nu-Ampi®, Penbritin®, Rimicillin®

Pharmacologic class: Aminopenicillin
Therapeutic class: Anti-infective
Pregnancy risk category B

Action
Destroy bacteria by inhibiting bacterial cell-wall synthesis during microbial multiplication

Availability
Capsules: 250 mg, 500 mg

Oral suspension: 125 mg/5 ml, 250 mg/5 ml
Powder for injection: 125 mg, 250 mg, 500 mg, 1 g, 2 g, 10 g

Indications and dosages
▶ Respiratory tract, skin, and soft-tissue infections caused by Haemophilus influenzae, staphylococci, and streptococci
Adults and children weighing 40 kg (88 lb) or more: 250 to 500 mg I.V. or I.M. q 6 hours
Adults and children weighing less than 40 kg (88 lb): 25 to 50 mg/kg/day I.M. or I.V. in divided doses q 6 to 8 hours
Adults and children weighing more than 20 kg (44 lb): 250 mg P.O. q 6 hours
Children weighing 20 kg (44 lb) or less: 50 mg/kg/day P.O. in divided doses q 6 to 8 hours
▶ Bacterial meningitis caused by Neisseria meningitidis, Escherichia coli, group B streptococci, or Listeria monocytogenes; septicemia caused by Streptococcus species, penicillin G–susceptible staphylococci, enterococci, E. coli, Proteus mirabilis, or Salmonella species
Adults: 150 to 200 mg/kg/day by continuous I.V. infusion or I.M. injection in equally divided doses q 3 to 4 hours, to a maximum dosage of 14 g
Children: 100 to 200 mg/kg/day I.V. in divided doses q 3 to 4 hours
▶ GI or urinary tract infections, including Neisseria gonorrhoeae infection in women
Adults and children weighing more than 40 kg (88 lb): 500 mg I.M. or I.V. q 6 hours
Adults and children weighing 40 kg (88 lb) or less: 50 to 100 mg/kg/day I.M. or I.V. in equally divided doses q 6 to 8 hours
▶ Endocarditis prophylaxis for dental, oral, or upper respiratory tract procedures

Canada UK Hazardous drug High alert drug
**Adults:** 2 g I.M. or I.V. within 30 minutes before procedure

**Children:** 50 mg/kg I.V. or I.M. within 30 minutes before procedure

- Prevention of bacterial endocarditis before GI or GU surgery or instrumentation

**High-risk adults:** 2 g I.M. or I.V. with gentamicin 1.5 mg/kg I.M. or I.V. within 30 minutes before procedure. Six hours later, give ampicillin 1 g I.M. or I.V., or amoxicillin 1 g P.O.

**High-risk children:** 50 mg/kg I.M. or I.V. with 1.5 mg/kg of gentamicin I.M. or I.V. within 30 minutes before procedure; 6 hours later, give ampicillin 25 mg/kg I.M. or I.V. or amoxicillin 25 mg/kg P.O.

**Moderate-risk adults:** 2 g I.M. or I.V. within 30 minutes before procedure

**Moderate-risk children:** 50 mg/kg I.M. or I.V. within 30 minutes before procedure

- **Prophylaxis for neonatal group B streptococcal disease**

**Adult women:** During labor, loading dose of 2 g I.V.; then 1 g I.V. q 4 hours until delivery

- N. gonorrhoeae infections

**Adults:** Single dose of 3.5 g P.O. given with 1 g probenecid

**Children weighing 40 kg (88 lb) or more:** 500 mg I.M. or I.V. q 6 hours

**Children weighing less than 40 kg (88 lb):** 50 mg/kg/day in divided doses q 6 to 8 hours

- Urethritis caused by N. gonorrhoeae (in males)

**Adults and children weighing 40 kg (88 lb) or more:** 500 mg I.V. or I.M., repeated 8 to 12 hours later

- **Prophylaxis against sexually transmitted diseases in adult rape victims**

**Adults:** 3.5 g P.O. with 1 g probenecid as a single dose

**Dosage adjustment**
- Renal impairment

**Contraindications**
- Hypersensitivity to penicillins, cephalosporins, imipenem, or other beta-lactamase inhibitors

**Precautions**
- Use cautiously in:
  - severe renal insufficiency, infectious mononucleosis
  - pregnant or breastfeeding patients

**Administration**
- Ask patient about history of penicillin allergy before giving.
- For I.V. use, mix powder with bacteriostatic water for injection in amount listed on label.
- For direct I.V. injection, give over 10 to 15 minutes. Don’t exceed 100 mg/minute.
- For intermittent I.V. infusion, mix with 50 to 100 ml of normal saline solution and give over 15 to 30 minutes.
- Change I.V. site every 48 hours.
- Give oral doses 1 hour before or 2 hours after meals.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30 min</td>
<td>2 hr</td>
<td>6-8 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>5 min</td>
<td>6-8 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>15 min</td>
<td>1 hr</td>
<td>6-8 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** lethargy, hallucinations, anxiety, confusion, agitation, depression, fatigue, dizziness, seizures

**CV:** vein irritation, thrombophlebitis, heart failure

**EENT:** blurred vision, itchy eyes

**GI:** nausea, vomiting, diarrhea, abdominal pain, enterocolitis, gastritis, stomatitis, glossitis, black “hairy” tongue, furry tongue, oral or rectal candidiasis, pseudomembranous colitis

**GU:** vaginitis, nephropathy, interstitial nephritis

**Hematologic:** anemia, eosinophilia, agranulocytosis, hemolytic anemia

Reactions in bold are life-threatening.

Clinical alert
leukopenia, thrombocytopenic purpura, thrombocytopenia, neutropenia
Hepatic: nonspecific hepatitis
Musculoskeletal: arthritis exacerbation
Respiratory: wheezing, dyspnea, hypoxia, apnea
Skin: rash, urticaria, fever, diaphoresis
Other: pain at injection site, superinfections, hyperthermia, hypersensitivity reaction, anaphylaxis, serum sickness

Interactions
Drug-drug. *Allopurinol* increased risk of rash
*Chloramphenicol* synergetic or antagonistic effects
*Hormonal contraceptives* decreased contraceptive effect, increased risk of breakthrough bleeding
*Probenecid* decreased renal excretion of ampicillin, increased ampicillin blood level
*Tetracyclines* reduced bactericidal effect

Drug-diagnostic tests. *Conjugated estrone, estradiol, estriol-glucuronide, total conjugated estriols* increased levels in pregnant patients
*Granulocytes, hemoglobin, platelets, white blood cells* decreased levels
*Coombs’ test, urine glucose* false-positive results
*Eosinophils* increased count

Drug-food. *Any food* reduced ampicillin efficacy

Patient teaching
- Tell patient to take oral dose with 8 oz of water 1 hour before or 2 hours after a meal.
- Instruct patient to immediately report signs and symptoms of hypersensitivity reaction, such as rash, fever, or chills.
- Inform patient that drug lowers resistance to certain other infections. Tell him to report new signs or symptoms of infection, especially in mouth or rectum.
- Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
- Instruct patient to promptly report unusual bleeding or bruising.
- Tell patient to avoid activities that can cause injury. Advise him to use soft toothbrush and electric razor to avoid gum and skin injury.
- Inform patient taking hormonal contraceptives that drug may reduce contraceptive efficacy. Advise her to use alternative birth control method.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

ampicillin sodium and sulbactam sodium

Unasyn

**Pharmacologic class:** Aminopenicillin/beta-lactamase inhibitor

**Therapeutic class:** Anti-infective

**Pregnancy risk category B**

**Action**
Destroys bacteria by inhibiting bacterial cell-wall synthesis during microbial multiplication. Addition of
sulbactam enhances drug’s resistance to beta-lactamase, an enzyme that can inactivate ampicillin.

**Availability**

*Injection:* Vials; piggyback vials containing 1.5 g (1 g ampicillin sodium and 0.5 g sulbactam sodium), 3 g (2 g ampicillin sodium and 1 g sulbactam sodium), and 15 g (10 g ampicillin sodium and 5 g sulbactam sodium)

**Indications and dosages**

- Intra-abdominal, gynecologic, and skin-structure infections caused by susceptible beta-lactamase-producing strains

**Adults and children weighing 40 kg (88 lb) or more:** 1.5 to 3 g (1 g ampicillin and 0.5 g sulbactam to 2 g ampicillin and 1 g sulbactam) I.M. or I.V. q 6 hours. Maximum dosage is 4 g sulbactam daily.

**Children ages 1 year and older:** 300 mg/kg/day (200 mg ampicillin/100 mg sulbactam) by I.V. infusion q 6 hours in equally divided doses

**Dosage adjustment**

- Renal impairment

**Contraindications**

- Hypersensitivity to penicillins, cephalosporins, imipenem, or other beta-lactamase inhibitors

**Precautions**

- Use cautiously in:
  - severe renal insufficiency, infectious mononucleosis
  - pregnant or breastfeeding patients.

**Administration**

- Ask patient about history of penicillin allergy before giving.
- Let vial stand several minutes until foam has evaporated before administering drug.
- Don’t mix I.V. form with other I.V. drugs.

**Adverse reactions**

- CNS: lethargy, hallucinations, anxiety, confusion, agitation, depression, fatigue, dizziness, seizures
- CV: vein irritation, thrombophlebitis, heart failure
- EENT: blurred vision, itchy eyes
- GI: nausea, vomiting, diarrhea, abdominal pain, enterocolitis, gastritis, stomatitis, glossitis, black “haired” tongue, furry tongue, oral and rectal candidiasis, pseudomembranous colitis
- GU: hematuria, hyaline casts in urine, vaginitis, nephropathy, interstitial nephritis
- Hematologic: anemia, eosinophilia, agranulocytosis, hemolytic anemia, leukopenia, thrombocytopenic purpura, thrombocytopenia, neutropenia
- Hepatic: nonspecific hepatitis
- Musculoskeletal: arthritis exacerbation
- Respiratory: wheezing, dyspnea, hypoxia, apnea
- Skin: rash, urticaria, diaphoresis
- Other: pain at injection site, fever, hyperthermia, superinfections, hypersensitivity reactions, anaphylaxis, serum sickness

**Interactions**

- **Drug-drug.** *Allopurinol:* increased risk of rash
  *Chloramphenicol:* synergistic or antagonistic effects

Reactions in bold are life-threatening.
Hormonal contraceptives: decreased contraceptive efficacy, increased risk of breakthrough bleeding
Probenecid: decreased renal excretion and increased blood level of ampicillin
Tetracyclines: reduced bactericidal effect

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatine kinase, creatinine, gamma-glutamyltransferase, eosinophils, lactate dehydrogenase: increased levels
Estradiol, estriol-glucuronide, granulocytes, hemoglobin, lymphocytes, neutrophils, platelets, white blood cells: decreased levels
Coombs’ test: false-positive result
Urinalysis: red blood cells, hyaline casts

Patient monitoring
- Monitor for signs and symptoms of hypersensitivity reaction.
- Check for signs and symptoms of infection at injection site.
- Monitor for seizures when giving high doses.
- Watch for bleeding tendency and hemorrhage.
- Check patient’s temperature and watch for other signs and symptoms of superinfection, especially oral or rectal candidiasis.
- Monitor CBC and liver function test results.

Patient teaching
- Instruct patient to immediately report signs and symptoms of hypersensitivity reaction, such as rash, fever, or chills.
- Tell patient to report signs and symptoms of infection or other problems at injection site.
- Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
- Inform patient that drug lowers resistance to certain infections. Instruct him to report new signs or symptoms of infection, especially in mouth or rectum.
- Tell patient to promptly report unusual bleeding or bruising.
- Inform patient taking hormonal contraceptives that drug may reduce contraceptive efficacy. Advise her to use alternative birth control method.
- Instruct patient to avoid activities that can cause injury. Advise him to use soft toothbrush and electric razor to avoid gum and skin injury.
- Inform patient that he may need to undergo regular blood testing during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Amyl Nitrite

Pharmacologic class: Coronary vasodilator
Therapeutic class: Antianginal
Pregnancy risk category C

Action
Relaxes vascular smooth muscle, thereby dilating large coronary vessels, decreasing systemic vascular resistance, reducing afterload, decreasing cardiac output, and relieving angina

Availability
Ampules: 0.3 ml

Indications and dosages
- Acute angina attack
Adults: 0.18 to 0.3 ml by inhalation, repeated in 3 to 5 minutes if needed
- Antidote for cyanide poisoning
Adults and children: 0.3 ml by inhalation for 15 to 30 seconds q 5 minutes until sodium nitrite infusion is available

Contraindications
- Hypersensitivity to drug

Precautions
Use cautiously in:
- glaucoma, hypotension, hyperthyroidism, severe anemia, early myocardial infarction
- elderly patients
- pregnant or breastfeeding patients.

Administration
- Crush ampule and wave under patient’s nose one to six times. If needed, repeat in 3 to 5 minutes.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhalation</td>
<td>30 sec</td>
<td>Unknown</td>
<td>3-5 min</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, dizziness, weakness, syncope, restlessness
CV: orthostatic hypotension, flushing, palpitations, tachycardia
EENT: increased intraocular pressure
GI: nausea, vomiting, fecal incontinence
GU: urinary incontinence
Hematologic: hemolytic anemia, methemoglobinemia
Skin: cutaneous vasodilation, rash, pallor, facial and neck flushing

Interactions
Drug-drug. Aspirin: increased amyl nitrite blood level and action
Calcium channel blockers: increased risk of symptomatic orthostatic hypotension
Sildenafil: increased risk of hypotension
Sympathomimetics: decreased antiangiinal effects, hypotension, tachycardia
Drug-behaviors. Alcohol use: severe hypotension, cardiovascular collapse

Patient monitoring
- Monitor vital signs. Stay alert for tachycardia and orthostatic hypotension.
- Assess for bowel and bladder incontinence.
- Monitor neurologic response. Watch closely for dizziness and syncope.
- Assess level of headache pain.
- In long-term therapy, monitor CBC.

Patient teaching
- Teach patient to crush capsule and wave it under his nose until angina is relieved (usually after one to six inhalations).
- Tell patient that drug often causes dizziness, orthostatic hypotension, and syncope. Advise him to sit or lie down until these effects subside.
- Inform patient that drug often causes headache. Instruct him to follow prescriber’s recommendations for pain relief.
- Tell patient that drug may cause fecal or urinary incontinence. Encourage him to use bathroom frequently to avoid accidents.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and behaviors mentioned above.

anagrelide hydrochloride
Agrylin, Xagrid

Pharmacologic class: Hematologic drug
Therapeutic class: Antiplatelet drug
Pregnancy risk category C

Action
Unclear. May reduce platelet production by decreasing megakaryocytic hyperplasia, thereby decreasing
platelet count and inhibiting platelet aggregation (at higher doses).

**Availability**
Capsules: 0.5 mg, 1 mg

**Indications and dosages**
➤ Essential thrombocytopenia
**Adults:** 0.5 mg P.O. q.i.d. or 1 mg P.O. b.i.d. for 1 week. Adjust as needed to lowest effective dosage that maintains platelet count below 600,000/mm³. Maximum dosage is 10 mg daily or 2.5 mg as a single dose.

**Dosage adjustment**
• Hepatic or renal disease

**Contraindications**
• Prolonged exposure to sunlight
• Women who are or may become pregnant

**Precautions**
Use cautiously in:
• renal, hepatic, or cardiac dysfunction
• pregnant or breastfeeding patients
• children younger than age 16.

**Administration**
• Give 1 hour before or 2 hours after meals.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Immediate</td>
<td>1 hr</td>
<td>48 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
CNS: amnesia, confusion, depression, dizziness, drowsiness, weakness, headache, syncope, insomnia, migraine, nervousness, pain, paresthesia, malaise, seizures, cerebrovascular accident
CV: angina, chest pain, hypertension, palpitations, orthostatic hypotension, peripheral edema, vasodilation, arrhythmias, tachycardia, heart failure, hemorrhage, myocardial infarction, cardiomyopathy, cardiomegaly, atrial fibrillation, complete heart block, pericarditis

EENT: amblyopia, abnormal or double vision, visual field abnormalities, tinnitus, epistaxis, rhinitis, sinusitis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, melena, gastritis or duodenal ulcers, dyspepsia, aphthous stomatitis, anorexia, flatulence, gastritis, pancreatitis, GI hemorrhage
GU: painful urination, hematuria
Hematologic: lymphadenoma, bleeding tendency, anemia, thrombocytopenia
Metabolic: dehydration
Musculoskeletal: leg cramps; joint, back, muscle, neck pain
Respiratory: bronchitis, dyspnea, pneumonia, respiratory disease, asthma, pulmonary infiltrates, pulmonary fibrosis, pulmonary hypertension
Skin: bruising, pruritus, rash, alopecia, urticaria, skin disease, photosensitivity reaction
Other: chills, fever, flulike symptoms, edema

**Interactions**
Drug-drug. Sucralfate: interference with anagrelide absorption
Drug-diagnostic tests. Hemoglobin, platelets: decreased values
Hepatic enzymes: elevated values
Drug-food. Any food: decreased drug bioavailability
Drug-herbs. Evening primrose oil, feverfew, garlic, ginger, ginkgo biloba, ginseng, grapeseed: increased anti-platelet effect

**Patient monitoring**
☞ Watch for signs and symptoms of vasodilation, heart failure, and arrhythmias in patients with cardiovascular disease.
• For first 2 weeks, monitor CBC and liver and kidney function test results.
• Monitor platelet count regularly until maintenance dosage is established.
• Check regularly for adverse reactions, especially bleeding tendency.
• Monitor blood pressure for orthostatic hypertension.
Patient teaching
● Instruct patient to take drug 1 hour before or 2 hours after meals.
● Tell patient that drug may cause a temporary blood pressure decrease if he sits or stands up suddenly. Tell him to rise slowly and carefully.

تسمم
● Instruct patient to report unusual bleeding or bruising or difficulty breathing.

تمشير
● Caution patient to avoid prolonged exposure to sunlight.
● Tell patient to avoid driving and other hazardous activities until he knows how drug affects concentration, alertness, and vision.
● Inform patient using hormonal contraceptives that drug may interfere with contraceptive efficacy. Advise her to use alternative birth control method.
● Tell patient to avoid activities that may cause injury. Tell him to use soft toothbrush and electric razor to avoid gum and skin injury.
● Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
● Notify patient that he’ll undergo regular blood testing during therapy.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

anakinra
Kineret

Pharmacologic class: Interleukin-1 (IL-1) blocker

Therapeutic class: Immunomodulator, antirheumatic

Pregnancy risk category B

Action
Inhibits binding of IL-1 with IL type I receptors, thereby mediating immunologic, inflammatory, and other physiologic responses

Availability
Prefilled glass syringes: 100 mg/0.67 ml

Indications and dosages
Moderately to severely active rheumatoid arthritis in patients ages 18 and older who don’t respond to disease-modifying antirheumatics alone

Adults: 100 mg/day subcutaneously, given at same time each day

Contraindications
● Hypersensitivity to drug or Escherichia coli–derived protein
● Serious infections

Precautions
Use cautiously in:
● immunosuppression, active infection, chronic illness, renal impairment
● elderly patients
● pregnant or breastfeeding patients
● children.

Administration

 olmadن
Withhold drug and notify prescriber if patient shows signs or symptoms of active infection.

 olmadن
Use extreme caution if patient is concurrently receiving drugs that block tumor necrosis factor (TNF), because of increased risk of serious infection.
● Give entire dose from prefilled syringe.
● Don’t freeze or shake syringe.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcut.</td>
<td>Slow</td>
<td>3-7 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>
Adverse reactions
CNS: headache
EENT: sinusitis
GI: nausea, diarrhea, abdominal pain
Hematologic: thrombocytopenia, neutropenia
Respiratory: upper respiratory tract infection
Skin: rash, pruritus, injection site reaction or bruising, rash, erythema, inflammation
Other: flulike symptoms, infections

Interactions
Drug-drug. Etanercept, infliximab, other drugs that block TNF: increased risk of serious infection
Live-virus vaccines: vaccine inefficacy
Drug-diagnostic tests. Neutrophils: decreased count

Patient monitoring
• Monitor CBC with white cell differential.
• Assess injection site for reactions.

Patient teaching
Tell patient to immediately report signs or symptoms of infection.
• Advise patient to report signs and symptoms of allergic response.
• Instruct patient to take drug at same time each day for best response.
• Teach patient about proper drug disposal (in puncture-resistant container). Also caution him against reusing needles, syringes, and drug product.
• Tell patient not to freeze or shake drug.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

anastrozole
Arimidex
Pharmacologic class: Nonsteroidal aromatase inhibitor
Therapeutic class: Antineoplastic
Pregnancy risk category D

Action
Reduces serum estradiol levels with no significant effect on adrenocorticoid or aldosterone level; decreases stimulating effect of estrogen on tumor growth

Availability
Tablets: 1 mg

Indications and dosages
Postmenopausal women with hormone receptor-unknown or hormone receptor-positive advanced breast cancer or with advanced breast cancer after tamoxifen therapy; adjuvant treatment for hormone receptor-positive breast cancer
Adults: 1 mg P.O. daily

Contraindications
• Pregnancy
• Children

Precautions
Use cautiously in:
• women of childbearing age
• breastfeeding patients.

Administration
• Verify that patient isn’t pregnant before giving drug.

Route Onset Peak Duration
P.O. >24 hr Unknown <6 days

Adverse reactions
CNS: headache, weakness, dizziness, depression, paresthesia, lethargy
CV: chest pain, peripheral edema, vasodilation, hypertension, thromboembolic disease
EENT: pharyngitis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, anorexia, dry mouth
GU: vaginal bleeding, leukorrhea, vaginal dryness, pelvic pain
Musculoskeletal: bone or back pain, muscle weakness
Respiratory: dyspnea, cough
Skin: rash
Other: food distaste, weight gain, swelling, hot flashes, flulike symptoms, tumor flare

Interactions
Drug-diagnostic tests. Hepatic enzymes, low-density lipoproteins, total cholesterol: increased levels

Patient monitoring
Check regularly for signs and symptoms of thromboembolic disease, especially dyspnea and chest pain.
Monitor for circulatory overload (suggested by peripheral edema, cough, and dyspnea).
Assess for signs and symptoms of depression. Evaluate patient for suicidal ideation.
Monitor liver function test results.

Patient teaching
Advise patient to immediately report signs and symptoms of thromboembolic disease and circulatory overload.
Emphasize importance of preventing pregnancy during therapy.
Tell patient to contact prescriber if she develops signs or symptoms of depression.
Caution patient to avoid driving and other hazardous activities until she knows how drug affects concentration and alertness.

Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
Inform patient that she’ll undergo regular blood testing during therapy.
As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

anidulafungin
Eraxis
Pharmacologic class: Semisynthetic echinocandin
Therapeutic class: Antifungal
Pregnancy risk category C

Action
Inhibits glucan synthase, an enzyme present in fungal (but not mammalian) cells; this action inhibits formation of 1,3-beta-D-glucan, an essential component of fungal cell wall.

Availability
Powder for injection (lyophilized): 50-mg single-use vial

Indications and dosages
Candidemia and other Candida infections (intra-abdominal abscess, peritonitis)
Adults: Single 200-mg loading dose by I.V. infusion on day 1, followed by 100 mg I.V. daily thereafter. Duration depends on clinical response; generally, therapy continues at least 14 days after last positive culture.
Esophageal candidiasis
Adults: Single 100-mg loading dose by I.V. infusion on day 1, followed by 50 mg I.V. daily thereafter. Treatment should continue for at least 14 days, and for at least 7 days after symptoms resolve; duration depends on clinical

Reactions in bold are life-threatening.
response. Due to risk of esophageal candidiasis relapse in patients with human immunodeficiency virus, suppressive antifungal therapy may be considered after treatment ends.

**Contraindications**
- Hypersensitivity to drug, its components, or other echinocandins

**Precautions**
Use cautiously in:
- hepatic impairment
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

**Administration**
- Don’t give by I.V. bolus.
- Reconstitute only with supplied diluent (20% dehydrated alcohol in water for injection).
- Further dilute only with 5% dextrose injection or normal saline solution, to yield infusion solution concentration of 0.5 mg/ml.
- Give by I.V. infusion within 24 hours of reconstitution.
- Don’t infuse at a rate exceeding 1.1 mg/minute.
- Don’t dilute with other solutions or infuse through same I.V. line with other drugs or electrolytes.

**Adverse reactions**
- CNS: headache
- CV: hypotension, phlebitis
- GI: aggravated dyspepsia, nausea, vomiting
- Hematologic: neutropenia, leukopenia
- Respiratory: dyspnea
- Skin: rash, urticaria, pruritus, flushing
- Other: fever

**Interactions**
**Drug-diagnostic tests.** Alanine aminotransferase, aspartate aminotransferase, gamma glutamyltransferase: increased

**Patient monitoring**
- If patient has abnormal liver function tests during therapy, monitor for evidence of worsening hepatic function and weigh risks and benefits of continuing therapy.
- Monitor for rash, urticaria, flushing, dyspnea, and hypotension. (However, these are rare when drug is administered slowly.)

**Patient teaching**
- Instruct patient to report rash, itching, unusual bruising or bleeding, unusual tiredness, or yellowing of skin or eyes.
- Advise patient to report troublesome side effects such as GI upset.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the tests mentioned above.

**antihemophilic factor (AHF, factor VIII)**
Advate, Alphanate, Hemofil M, Koate-DVI, Kogenate FS, Monarc-M, Monoclate-P, Recombinate, ReFacto

**Pharmacologic class:** Hemostatic
**Therapeutic class:** Antihemophilic
**Pregnancy risk category C**

**FDA BOXED WARNING**
- Drug is made from human plasma and may contain infectious agents. Plasma donor screening, testing, and inactivation or removal methods reduce this risk.
Action
Promotes conversion of prothrombin to thrombin (necessary for hemostasis and blood clotting). Also replaces missing or deficient clotting factors, thereby controlling or preventing bleeding.

Availability
I.V. injection: 250, 500, 1,000, or 1,500 international units/vial in numerous preparations

Indications and dosages
Spontaneous hemorrhage in patients with hemophilia A (factor VIII deficiency)
Adults and children: Dosage is highly individualized, calculated as follows: AHF required (international units) equals weight (kg) multiplied by desired factor VIII increase (% of normal) multiplied by 0.5.

To control bleeding, desired factor VIII level is 20% to 40% of normal for minor hemorrhage; 30% to 60% of normal for moderate hemorrhage; or 60% to 100% of normal for severe hemorrhage. To prevent spontaneous hemorrhage, desired factor VIII level is 5% of normal.

Contraindications
• Hypersensitivity to drug or to mouse, hamster, or bovine protein

Precautions
Use cautiously in:
• hepatic disease
• blood types A, B, and AB
• patients receiving factor VIII inhibitors
• pregnant patients
• neonates and infants.

Administration
• Before giving, verify that patient has no history of hypersensitivity to drug or to mouse, hamster, or bovine protein.
• Follow prescriber’s instructions regarding hepatitis B prophylaxis before starting therapy.
• Refrigerate concentrate until ready to reconstitute drug; then warm to room temperature before mixing.
• Roll bottle gently between hands until drug is well-mixed.
• Give a single dose over 5 to 10 minutes at rate of 2 to 10 ml/minute, as appropriate.
• After drug is reconstituted, don’t refrigerate, shake, or store near heat.
• Don’t mix with other I.V. solutions.
• Use plastic (not glass) syringe and filter.

Adverse reactions
CNS: headache; lethargy; fatigue; dizziness; jitteriness; drowsiness; depersonalization; tingling in arms, ears, and face
CV: chest tightness, angina pectoris, tachycardia, slight hypotension, thrombosis
EENT: blurred or abnormal vision, eye disorder, otitis media, epistaxis, rhinitis, sore throat
GI: nausea, vomiting, diarrhea, constipation, stomachache, abdominal pain, gastroenteritis, anorexia,
Hematologic: forehead bruises, increased bleeding tendency, thrombocytopenia, hemolytic anemia, intravascular hemolysis, hyperfibrinogenemia
Hepatic: hepatitis B transmission
Musculoskeletal: myalgia, muscle weakness, bone pain, finger pain
Respiratory: dyspnea, coughing, wheezing, bronchospasm
Skin: rash, acne, flushing, diaphoresis, urticaria
Other: taste changes, allergic reaction, fever, chills, cold feet, cold sensations, infected hematoma,

Reactions in bold are life-threatening.
stinging at injection site, anaphylaxis, human immunodeficiency virus transmission

Interactions
Drug-diagnostic tests. Bilirubin, creatine kinase: increased levels
Hemoglobin, platelets: decreased values

Patient monitoring
- Monitor for signs and symptoms of anaphylaxis and hemolysis.
- Watch for bleeding tendency and hemorrhaging.
  - Check vital signs regularly.
  - Monitor CBC and coagulation studies.
- Assess for severe headache (may indicate intracranial hemorrhage).

Patient teaching
- Tell patient to immediately report signs and symptoms of allergic response or bleeding tendency.
- Caution patient not to use aspirin during therapy.
- Instruct patient to contact prescriber if drug becomes less effective.
- Tell patient to report signs or symptoms of hepatitis B.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, alertness, and vision.
- Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
- Notify patient that he’ll undergo regular blood testing during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

antithrombin III, human (AT-III, heparin cofactor 1)

Thrombate III

Pharmacologic class: Blood derivative, coagulation inhibitor
Therapeutic class: Antithrombin
Pregnancy risk category B

Action
Inactivates thrombin and activated forms of factors IXa, Xa, Xla, and XIIa, thereby inhibiting coagulation and thromboembolism formation

Availability
Injection: 500 international units, 1,000 international units

Indications and dosages
Thromboembolism related to AT-III deficiency

Adults: Initial dosage is individualized to amount required to increase AT-III activity to 120% of normal (determined 20 minutes after administration). Usual infusion rate is 50 to a maximum of 100 international units/minute I.V. Dosage calculation is based on anticipated 1.4% increase in plasma AT-III activity produced by 1 international unit/kg of body weight.

Use this formula to calculate dosage: Required dosage (international units) equals desired activity (%) minus baseline AT-III activity (%) multiplied by weight (kg) divided by 1.4 (international units/kg).

Maintenance dosage is individualized to amount required to maintain AT-III activity at 80% of normal.

Contraindications
None
Precautions
Use cautiously in:
● pregnant or breastfeeding patients
● children (safety and efficacy not established).

Administration
● Reconstitute drug concentrate with 10 ml of sterile water, normal saline solution, or dextrose 5% in water.
● Use filter needle provided by manufacturer to draw up solution.
● Don’t shake vial.
● Know that drug may be diluted further in same solution if desired.
● Don’t mix with other solutions.
● Infuse over 10 to 20 minutes.
● Administer within 3 hours of reconstitution.

If adverse reactions occur, decrease infusion rate or, if indicated, stop infusion until symptoms disappear.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>Unknown</td>
<td>4 days</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, light-headedness, headache
CV: vasodilation, reduced blood pressure, chest pain
EENT: perception of “film” over eyes
GI: nausea, sensation of intestinal fullness
GU: diuresis
Musculoskeletal: muscle cramps
Respiratory: dyspnea, shortness of breath
Skin: urticaria, oozing lesions, hives, hematoma
Other: foul taste, chills, fever

Interactions
Drug-drug. Heparin: increased anticoagulant effect

Patient monitoring
● Monitor AT-III activity levels regularly.

Watch for signs and symptoms of too-rapid infusion, such as dyspnea and hypertension.
● Monitor vital signs and temperature.
● Assess fluid intake and output to detect dehydration.

Patient teaching
Instruct patient to immediately report chest tightness, dizziness, and fever.
Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
Advise patient to minimize GI upset and unpleasant taste by eating small, frequent servings of healthy food and drinking plenty of fluids.
Tell patient that he’ll undergo regular blood testing during therapy.
As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

apomorphine hydrochloride
APO-go®, Apokyn

Pharmacologic class: Dopaminergic, dopamine-receptor agonist
Therapeutic class: Antiparkinsonian
Pregnancy risk category C

Action
Unclear. May stimulate postsynaptic dopamine D2-type receptors in caudate-putamen of brain.

Availability
Ampules: 10 mg/ml in 2- and 3-ml cartridges

Indications and dosages
Acute intermittent treatment of hypomobility and “off” (“end-of-dose
wearing off” and unpredictable “on/off”) episodes associated with Parkinson’s disease

**Adults:** 0.2-ml (2-mg) test dose injected subcutaneously during “off” state in setting where medical personnel can monitor blood pressure. If patient tolerates test dose, give 0.2 ml subcutaneously p.r.n. to treat “off” episodes no sooner than 2 hours after previous dose. Establish dosage based on tolerance and efficacy; increase in 0.1-ml (1 mg) increments, usually to 0.3 to 0.4 ml. Maximum dosage, 0.6 ml up to five times daily.

Patient who tolerates but doesn’t respond to test dose may receive 0.4 ml (4 mg) at next observed “off” period, but no sooner than 2 hours after initial 0.2-ml test dose. If patient tolerates 0.4-ml test dose, give starting dosage of 0.3 ml (3 mg) p.r.n. to treat “off” episodes. If needed, increase in increments of 0.1 ml every few days on outpatient basis.

If patient doesn’t tolerate 0.4-ml test dose, 0.3-ml test dose may be given during separate “off” period no sooner than 2 hours after 0.4-ml test dose.

If patient tolerates 0.3-ml test dose, starting dosage should be 0.2 ml p.r.n. to treat existing “off” episodes. If needed and if patient tolerates 0.2-ml dose, dosage can be increased to 0.3 ml after several days; in this case, it ordinarily shouldn’t be increased to 0.4 ml on outpatient basis.

**Dosage adjustment**
- Mild or moderate renal impairment

**Contraindications**
- Hypersensitivity to drug or its components
- Concurrent use of 5-hydroxytryptamine₃ (5-HT₃) antagonists (such as alosetron, dolasetron, granisetron, ondansetron, palonosetron)

**Precautions**
Use cautiously in:
- renal or hepatic impairment
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

**Administration**
- If prescribed, give trimethobenzamide (antiemetic) for 3 days before starting apomorphine and continuing throughout therapy.
- Give only by subcutaneous injection. Don’t give I.V. because this may cause serious adverse events, such as I.V. crystallization of apomorphine, leading to thrombus formation and pulmonary embolism.
- Titrate dosage based on efficacy and patient tolerance.
- Check supine and standing blood pressure before giving test dose and 20, 40, and 60 minutes after. If patient experiences clinically significant orthostatic hypotension in response to test dose, don’t give drug.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcut</td>
<td>Unknown</td>
<td>10-60 minutes</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
CNS: drowsiness, somnolence, dizziness, hallucinations, confusion, syncope, dyskinesias
CV: orthostatic hypotension, chest pain, chest pressure, angina, cardiac valvulopathy
EENT: rhinorrhea
GI: nausea, vomiting, retroperitoneal fibrosis
GU: priapism
Respiratory: pulmonary infiltrates, pleural effusion, pleural thickening
Other: yawning, edema of extremities, injection site reactions, abuse potential, allergic reactions
Interactions
Drug-drug. Antihypertensive agents, vasodilators: increased incidence of hypotension, myocardial infarction, serious pneumonia, serious falls, bone and joint injuries
Dopamine antagonists: decreased apomorphine efficacy
5-HT<sub>3</sub> antagonists: profound hypotension
Drug-behaviors. Alcohol use: additive drowsiness and somnolence

Patient monitoring
- Monitor for serious cardiovascular and respiratory adverse reactions.
- Monitor for unexpected somnolence, which may interfere with daily activities.

Patient teaching
- Instruct patient to take drug as described in patient instruction leaflet.
- Make sure patient knows that dosages are in milliliters, not milligrams.
- Instruct patient to rotate injection site.
- Inform patient that drug may cause hallucinations and unexpected sleepiness.
- Tell patient drug may cause blood pressure to drop. Caution him to rise slowly from sitting or lying position.
- Urge patient to consult prescriber before taking other drugs.
- Caution patient not to use alcohol during therapy.
- Advise patient to avoid driving and other hazardous activities until drug effects are known.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

Reactions in bold are life-threatening.

aprepitant
Emend

Pharmacologic class: Substance P and neurokinin-1 antagonist
Therapeutic class: Adjunctive antiemetic
Pregnancy risk category B

Action
Augments antiemetic activity of ondansetron (a 5-hydroxytryptamine<sub>3</sub>-receptor antagonist) and dexamethasone. Also inhibits cisplatin-induced emesis.

Availability
Capsules: 40 mg, 80 mg, 125 mg

Indications and dosages
➢ To prevent acute and delayed nausea and vomiting caused by highly emetogenic cancer chemotherapy
Adults: 125 mg P.O. 1 hour before chemotherapy on day 1; then 80 mg P.O. once daily in morning on days 2 and 3. Give with 12 mg dexamethasone P.O. and 32 mg ondansetron I.V. on day 1, and with 8 mg dexamethasone P.O. on days 2 to 4.
➢ Prevention of postoperative nausea and vomiting
Adults: 40 mg P.O. once within 3 hours before induction anesthesia

Contraindications
- Hypersensitivity to drug
- Concurrent pimozide, terfenadine, astemizole, or cisapride therapy
- Breastfeeding

Precautions
Use cautiously in:
- patients receiving concurrent warfarin or CYP3A4 inhibitors
- pregnant patients.
Administration

- Give 1 hour before chemotherapy on day 1, together with other antiemetics as prescribed.
- Give on mornings of days 2 and 3.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: dizziness, neuropathy, headache, insomnia, asthenia, fatigue
EENT: tinnitus
GI: nausea, vomiting, constipation, diarrhea, epigastric discomfort, gastritis, heartburn, abdominal pain, anorexia
Hematologic: neutropenia
Other: fever, dehydration, hiccups

Interactions

Drug-drug. CYP3A4 inducers (carbamazepine, phenytoin, rifampin): decreased aprepitant blood level
CYP3A4 inhibitors (azole antifungals, clarithromycin, nefazodone, ritonavir): increased aprepitant blood level
Dexamethasone, methylprednisolone: increased steroid exposure
Docetaxel, etoposide, ifosfamide, imatinib, irinotecan, paclitaxel, vinblastine, vincristine, vinorelbine: increased blood levels of these drugs
Hormonal contraceptives: decreased contraceptive efficacy
Paroxetine: decreased efficacy of either drug
Pimozide: increased blood level and toxic effects of aprepitant
Tolbutamide, warfarin: CYP2C9 induction, decreased efficacy of these drugs

Patient teaching

- Tell patient that drug may cause CNS effects. Explain that he’ll be monitored to ensure his safety.
- Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, hearing, strength, balance, and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

argatroban

Acova

Pharmacologic class: L-arginine–derived thrombin inhibitor
Therapeutic class: Anticoagulant
Pregnancy risk category B

Action

Binds rapidly to site of thrombi, neutralizing conversion of fibrinogen to fibrin, activation of coagulation factors, and platelet aggregation (processes required for thrombus formation)

Availability

Injection: 100 mg/ml in 2.5-ml vials

Indications and dosages

➣ Treatment or prophylaxis of thrombosis in patients with heparin-induced thrombocytopenia
Adults: 2 mcg/kg/minute as a continuous I.V. infusion, to a maximum dosage of 10 mcg/kg/minute. Adjust dosage as needed to maintain activated
partial thromboplastin time (APTT) at 1.5 to 3 times initial baseline value (not to exceed 100 seconds).

Anticoagulation during percutaneous coronary intervention in patients who have or are at risk for heparin-induced thrombocytopenia

**Adults:** Start continuous I.V. infusion at 25 mcg/kg/minute and give loading dose of 350 mcg/kg by I.V. bolus over 3 to 5 minutes. Check activated clotting time (ACT) 5 to 10 minutes after bolus dose is given; adjust dosage until ACT is between 300 and 450 seconds. If ACT is below 300 seconds, give additional I.V. bolus dose of 150 mcg/kg; then increase infusion rate to 30 mcg/kg/minute, and check ACT after 5 to 10 minutes. If ACT exceeds 450 seconds, decrease infusion rate to 15 mcg/kg/minute, and check ACT after 5 to 10 minutes. Maintain adjusted infusion dosage once therapeutic ACT has been reached.

**Dosage adjustment**

- Hepatic impairment

**Contraindications**

- Hypersensitivity to drug
- Overt major bleeding

**Precautions**

Use cautiously in:
- hepatic impairment or disease, intracranial bleeding
- pregnant or breastfeeding patients
- children younger than age 18.

**Administration**

- Stop all parenteral anticoagulants before starting argatroban.
- Dilute in normal saline solution, dextrose 5% in water, or lactated Ringer’s solution to a concentration of 1 mg/ml.
- Inject contents of 2.5-ml vial into 250-ml bag of diluent.
- Protect solution from direct sunlight.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration of infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>1-3 hr</td>
<td></td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** headache
**CV:** hypotension, unstable angina, atrial fibrillation, cardiac arrest, ventricular tachycardia, cerebrovascular disorders
**GI:** nausea, vomiting, diarrhea, abdominal pain, anorexia, GI bleeding
**GU:** urinary tract infection, minor GU tract bleeding and hematuria, renal dysfunction
**Hematologic:** groin bleeding, brachial bleeding, hypoprothrombinemia, thrombocytopenia, bleeding or hemorrhage
**Respiratory:** cough, dyspnea, pneumonia, hemoptysis
**Skin:** rash, bleeding at puncture site
**Other:** allergic reaction, pain, infection, fever, sepsis, anaphylaxis

**Interactions**

**Drug-drug.** Oral anticoagulants: prolonged prothrombin time, increased International Normalized Ratio, increased risk of bleeding
**Thrombolytics:** increased risk of intracranial bleeding
**Drug-diagnostic tests.** Hematocrit, hemoglobin: decreased values

**Patient monitoring**

- Monitor patient for signs and symptoms of anaphylaxis.
- Evaluate patient for bleeding tendency and hemorrhage.
- Assess neurologic status and vital signs frequently.
- Monitor CBC and coagulation studies, especially partial thromboplastin time.
- Check for signs and symptoms of serious arrhythmias and hypotension.

Reactions in **bold** are life-threatening.  

ément
Patient teaching

- Instruct patient to immediately report allergic reaction and unusual bleeding or bruising.
- Tell patient to avoid activities that can cause injury. Advise him to use a soft toothbrush and electric razor to avoid gum and skin injury.
- Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
- Tell patient that he’ll undergo regular blood testing during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

FDA BOXED WARNING

- Drug increased mortality in elderly patients with dementia-related psychosis. Although causes of death were varied, most appeared to be cardiovascular or infectious. Drug isn’t approved to treat dementia-related psychosis.

Action

Unclear. Thought to exert partial agonist activity at central dopamine D2 and type 1A serotonin (5-HT1A) receptors and antagonistic activity at serotonin 5-HT2A receptors. Also has alpha-adrenergic and histamine1-blocking properties.

Availability

Injection: 9.75 mg/1.3 ml (7.5 mg/ml)
Oral solution: 1 mg/ml
Tablets: 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg
Tablets (orally disintegrating): 10 mg, 15 mg

Indications and dosages

- Schizophrenia
  Adults: 10 to 15 mg P.O. daily. If needed, increase to 30 mg daily after 2 weeks.
  Adolescents ages 13 to 17: Initially, 2 mg P.O. daily; increase to 5 mg P.O. after 2 days. Then increase to 10 mg P.O. after 2 additional days. Subsequent dosage intervals should occur in increments no greater than 5 mg, up to a maximum of 30 mg.
  To maintain stability in schizophrenic patients
  Adults: 15 mg P.O. daily. Therapy may continue for up to 26 weeks with periodic evaluations.
  Adolescents ages 13 to 17: General recommendation, continue responding patients beyond the acute response but at the lowest dosage needed to maintain remission.
- Acute manic and mixed episodes associated with bipolar disorder
  Adults: 30 mg P.O. daily for up to 3 weeks
- Agitation associated with schizophrenia or bipolar mania
  Adults: Usual dosage, 5.25 to 15 mg I.M. as single dose. Recommended dosage is 9.75 mg I.M. as single dose. No additional benefit was demonstrated for 15 mg compared to 9.75 mg. Lower dosage of 5.25 mg may be considered when clinical factors warrant. If agitation warranting second dose persists following initial dose, cumulative dosages up to total of 30 mg/day
may be given. However, efficacy of repeated doses in agitated patients hasn't been systematically evaluated in controlled clinical trials. Also, safety of total daily doses greater than 30 mg or injections given more frequently than every 2 hours hasn't been adequately evaluated in clinical trials. If ongoing aripiprazole therapy is clinically indicated, oral aripiprazole ranging from 10 to 30 mg/day P.O. should replace aripiprazole injection as soon as possible.

> Adjunctive treatment of major depressive disorder

**Adults:** Initially, 2 to 5 mg P.O. daily. May increase up to 15 mg daily at increments of up to 5 mg/day at intervals of no less than 1 week.

### Dosage adjustment

- Concurrent use of potent CYP3A4 inhibitors (such as ketoconazole), CYP2D6 inhibitors (such as fluoxetine, paroxetine, quinidine), or CYP3A4 inducers (such as carbamazepine)

### Contraindications

- Hypersensitivity to drug

### Precautions

Use cautiously in:
- cerebrovascular disease, hypotension, seizure disorder, suicidal ideation
- high risk for aspiration pneumonia
- pregnant or breastfeeding patients
- elderly patients (with dementia-related psychosis)
- children and adolescents (safety and efficacy not established).

### Administration

- Give with or without food.
- Don't administer with grapefruit juice.
- Be aware that oral solution may be substituted for tablets on a mg-to-mg basis up to 25-mg dose. Patients receiving 30 mg of tablets should receive 25 mg of oral solution.

### Adverse reactions

**CNS:** dizziness, insomnia, akathisia, agitation, anxiety, headache, light-headedness, drowsiness, tremor, tardive dyskinesia, seizures, neuroleptic malignant syndrome, increased suicide risk

**CV:** orthostatic hypotension, hypertension, peripheral edema, chest pain, bradycardia, tachycardia

**EENT:** rhinitis

**GI:** nausea, vomiting, diarrhea, constipation, jaundice, abdominal pain, esophageal motility disorders

**GU:** urinary incontinence

**Respiratory:** cough

**Skin:** rash

**Other:** fever

### Interactions

**Drug-drug.** *CNS depressants:* increased sedation

*Drugs that induce CYP3A4:* decreased aripiprazole effect

*Drugs that inhibit CYP3A4 or CYP2D6:* serious toxic effects

*Other antipsychotic agents:* increased extrapyramidal effects

**Drug-herbs.** *Kava:* increased CNS depression

**Drug-behaviors.** *Alcohol use:* increased sedation

### Patient monitoring

- Watch for signs and symptoms of depression, and evaluate patient for suicidal ideation.
- Monitor neurologic status closely. Watch for tardive dyskinesia.
- Evaluate patient for neuroleptic malignant syndrome (fever, altered mental status, rigid muscles,
arsenic trioxide
Trisenox

Pharmacologic class: Nonmetallic element, white arsenic

Therapeutic class: Antineoplastic

Pregnancy risk category D

FDA BOXED WARNING

- Give under supervision of physician experienced in managing patients with acute leukemia.
- Some patients with acute promyelocytic leukemia (APL) treated with drug have had symptoms similar to retinoic-acid-acute promyelocytic leukemia (RA-APL) or APL differentiation syndrome, marked by fever, dyspnea, weight gain, pulmonary infiltrates, and pleural or pericardial effusions. Syndrome can be fatal; at first sign, give high-dose steroids immediately, regardless of patient’s white blood cell count; continue steroids for at least 3 days or longer until signs and symptoms abate. Most patients don’t require arsenic trioxide termination during treatment of APL differentiation syndrome.
- Drug may prolong QT interval and cause complete atrioventricular block. QT prolongation can lead to torsades de pointes–type ventricular arrhythmia, which can be fatal.
- Before starting therapy, obtain 12-lead ECG and assess serum electrolyte (potassium, calcium, and magnesium) and creatinine levels. Correct electrolyte abnormalities and, if possible, discontinue drugs known to cause QT prolongation. During therapy, maintain potassium level above 4 mEq/L and magnesium level above 1.8 mg/dL. If patient reaches absolute QT interval value above 500 msec, reassess and take immediate action to correct concomitant risk factors.

Action
Unclear. May cause morphologic changes and DNA fragmentation in promyelocytic leukemia cells, causing cell death and degradation of or damage to PML/RAR alpha (a fusion protein).
Availability
Injection: 1 mg/ml

Indications and dosages
> APL in patients who have relapsed or are refractory to retinoid and anthracycline chemotherapy
Adults and children ages 5 and older:
Induction phase—0.15 mg/kg I.V. daily until bone marrow remission occurs, to a maximum of 60 doses. Consolidation phase—0.15 mg/kg I.V. daily for 25 doses over 5 weeks, starting 3 to 6 weeks after completion of induction phase.

Contraindications
• Hypersensitivity to drug
• Pregnancy

Precautions
Use cautiously in:
• renal impairment, cardiac abnormalities
• elderly patients
• breastfeeding patients
• children.

Administration
⚠ Know that drug is carcinogenic. Follow facility policy for preparing and handling antineoplastics.
• Dilute in 100 to 250 ml of dextrose 5% in water or normal saline solution.
• Don’t mix with other drugs.
• Infuse over 1 to 2 hours (may infuse over 4 hours if patient has vasomotor reaction).

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, insomnia, paresthesia, dizziness, tremor, drowsiness, anxiety, confusion, agitation, rигors, weakness, seizures, coma
CV: ECG abnormalities, palpitations, chest pain, hypotension, hypertension, tachycardia, prolonged QT interval, torsades de pointes
EENT: blurred vision, painful red eye, dry eyes, eye irritation, swollen eyelids, tinnitus, earache, nasopharyngitis, postnasal drip, epistaxis, sinusitis, sore throat
GI: nausea, vomiting, constipation, diarrhea, abdominal pain, fecal incontinence, dyspepsia, dry mouth, mouth blisters, oral candidiasis, anorexia, GI hemorrhage
GU: urinary incontinence, intermenstrual bleeding, renal impairment, oliguria, renal failure, vaginal hemorrhage
Hematologic: anemia, lymphopenopathy, leukocytosis, thrombocytopenia, neutropenia, disseminated intravascular coagulation, hemorrhage
Metabolic: hypokalemia, hypomagnesemia, hyperglycemia, acidosis, hypoglycemia, hyperkalemia
Musculoskeletal: joint, muscle, bone, back, neck, or limb pain
Respiratory: dyspnea, cough, hypoxia, wheezing, crackles, tachypnea, decreased breath sounds, crepitation, hemoptysis, rhonchi, upper respiratory tract infection, pleural effusion
Skin: flushing, erythema, pallor, bruising, petechiae, pruritus, dermatitis, dry skin, hyperpigmentation, urticaria, skin lesions, herpes simplex infection, local exfoliation, diaphoresis, night sweats
Other: fever, facial edema, weight gain or loss, bacterial infection, pain and edema at injection site, hypersensitivity reaction, sepsis

Interactions
Drug-drug. Drugs that can cause electrolyte abnormalities (such as amphotericin B, diuretics): increased risk of electrolyte abnormalities
Drugs that can prolong QT interval (antiarrhythmics, thioridazines, some quinolones): increased QT-interval prolongation

Reactions in bold are life-threatening.

Clinical alert
Drug-diagnostic tests. *Alanine aminotransferase, aspartate aminotransferase, calcium, magnesium, white blood cells:* increased levels  
*Glucose, potassium:* altered levels  
*Hemoglobin, neutrophils, platelets:* decreased values

Patient monitoring
- Watch for signs and symptoms of APL differentiation syndrome (fever, dyspnea, weight gain, pulmonary infiltrates, and pleural or pericardial effusions).
- Evaluate vital signs and neurologic status.
- Obtain baseline ECG; monitor ECG at least weekly.
- Assess for arrhythmias and conduction disorders.
- Discontinue drug and notify prescriber if patient develops syncope, tachycardia, or arrhythmias.
- Monitor serum electrolyte levels, CBC, and coagulation studies.
- Assess for hypoglycemia and hyperglycemia if patient is diabetic.

Patient teaching
- Watch for signs and symptoms of APL differentiation syndrome.
- Tell patient that drug increases risk of serious infection. Instruct him to report signs or symptoms of infection.
- Emphasize importance of avoiding pregnancy during therapy.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Tell patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
- Advise patient to establish effective bedtime routine to minimize insomnia.
- Notify patient that he’ll undergo regular blood testing during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

asparaginase
*Elspar, Kidrolase*

**Pharmacologic class:** Enzyme

**Therapeutic class:** Antineoplastic (miscellaneous)

**Pregnancy risk category C**

**FDA BOXED WARNING**
- Give in hospital under supervision of physician experienced in cancer chemotherapy, because of possibility of severe reactions (including anaphylaxis and sudden death). Be prepared to treat anaphylaxis at each administration. Prescriber must weigh drug’s risks and benefits carefully for each patient.
- Follow special handling procedures.

**Action**
Hydrolyzes asparagine (an amino acid needed for malignant cell growth in acute lymphocytic leukemia), resulting in leukemic cell death

**Availability**
*Injection:* 10,000 international units/vial (with mannitol)

**Indications and dosages**
- Acute lymphocytic leukemia (given with other drugs, such as prednisone or vincristine, as part of antineoplastic regimen)

**Children:** 1,000 international units/kg I.V. daily for 10 successive days, with
Asparaginase initiated on day 22 of regimen, or 6,000 international units/m² I.M. on days 4, 7, 10, 13, 16, 19, 22, 25, and 28

➤ Sole agent used to induce remission of acute lymphocytic leukemia

**Adults and children:** 200 international units/kg I.V. daily for 28 days

➤ Drug desensitization regimen

**Adults and children:** Initially, 1 international unit I.V. Then double the dosage q 10 minutes until total planned daily dosage has been given.

**Contraindications**
- Hypersensitivity to drug
- Pancreatitis or history of pancreatitis

**Precautions**

Use cautiously in:
- bone marrow depression, hepatic or renal disease, CNS depression, clotting abnormalities, infection
- pregnant or breastfeeding patients
- women of childbearing age.

**Administration**

Administer intradermal skin test as ordered at start of therapy and when drug hasn’t been given for 1 week or more.

- Follow prescriber’s orders for drug desensitization when indicated (usually before therapy starts and again during retreatment).

Know that drug may be carcinogenic, mutagenic, or teratogenic. Follow appropriate facility policy for handling and preparing.

- Before starting drug, give allopurinol as prescribed to lower risk of neuropathy.
- Add sterile water or normal saline solution (5 ml for I.V. dose, 2 ml for I.M. dose) to powdered drug in vial.
- Filter through 5-micron filter.
- For I.V. use, inject into normal saline solution or dextrose 5% in water and infuse over 30 minutes.

- For I.M. use, give a maximum of 2 ml at any one site.
- Don’t use solution unless it’s clear.

If drug touches skin or mucous membranes, rinse with copious amounts of water for at least 15 minutes.
- Provide adequate fluid intake to prevent tumor lysis.

**Route** | **Onset** | **Peak** | **Duration**
--- | --- | --- | ---
I.V. | Immediate | Immediate | 23-33 days
I.M. | Immediate | 14-24 hr | 23-33 days

**Adverse reactions**

CNS: confusion, drowsiness, depression, hallucinations, fatigue, agitation, headache, lethargy, irritability, seizures, coma, intracranial hemorrhage and fatal bleeding

GI: nausea, vomiting, anorexia, abdominal cramps, stomatitis, hemorrhagic pancreatitis, fulminant pancreatitis

GU: glycosuria, polyuria, uric acid nephropathy, uremia, renal failure

Hematologic: anemia, leukopenia, hypofibrinogenemia, depression of clotting factor synthesis, bone marrow depression

Hepatic: fatty liver changes, hepatotoxicity

Metabolic: hyperglycemia, hyperuricemia, hypocalcemia, hyperammonemia, hypoglycemia

Musculoskeletal: joint pain

Skin: rash, urticaria

Other: chills, fever, weight loss, hypersensitivity reactions, anaphylaxis, fatal hyperthermia

**Interactions**

Drug-drug. **Methotrexate:** decreased methotrexate efficacy

**Prednisone:** hyperglycemia, increased drug toxicity

**Vincristine:** hyperglycemia, increased drug toxicity, increased risk of neuropathy

Reactions in **bold** are life-threatening.

**Clinical alert**
Drug-diagnostic tests. *Alanine aminotransferase, ammonia, aspartate aminotransferase, blood urea nitrogen, glucose, uric acid:* increased levels  
*Calcium, hemoglobin, white blood cells:* decreased levels  
*Thyroid function tests:* interference with test interpretation

**Patient monitoring**
- **»** Observe for signs and symptoms of anaphylaxis.  
- **»** Monitor for bleeding and hemorrhage. Watch closely for signs and symptoms of intracranial hemorrhage.  
  - Assess vital signs, temperature, and neurologic status.  
  - Monitor CBC, blood and urine glucose levels, and liver, kidney, and bone marrow function test results.  
  - Monitor fluid intake and output.

**Patient teaching**
- **»** Instruct patient to immediately report allergic response, severe abdominal pain, and unusual bleeding or bruising.  
  - Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.  
  - Advise patient to drink plenty of fluids to ensure adequate urine output.  
  - Tell patient to monitor urine output and report significant changes.  
  - Instruct patient to avoid activities that can cause injury. Tell him to use soft toothbrush and electric razor to avoid injury to gums and skin.  
  - Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.  
  - Tell patient that he’ll undergo regular blood testing during therapy.  
  - As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**FDA BOXED WARNING**
- Caution patients with coronary artery disease (CAD) not to discontinue drug abruptly, because this may cause severe angina exacerbation, myocardial infarction, and ventricular arrhythmias. (The last two complications may occur with or without preceding angina exacerbation.) With planned drug discontinuation, observe patients carefully and advise them to minimize physical activity; if angina worsens or acute coronary insufficiency develops, drug should be reinstituted promptly, at least temporarily. Because CAD is common and may go unrecognized, abrupt withdrawal may pose a risk even in patients treated only for hypertension.

**Action**
Selectively blocks beta₁-adrenergic (myocardial) receptors; decreases cardiac output, peripheral resistance, and myocardial oxygen consumption. Also depresses renin secretion without affecting beta₂-adrenergic (pulmonary, vascular, uterine) receptors.

**Availability**
*Tablets:* 25 mg, 50 mg, 100 mg

**Indications and dosages**
- **Hypertension**
Adults: Initially, 50 mg P.O. once daily, increased to 100 mg after 7 to 14 days if needed

➢ Angina pectoris
Adults: Initially, 50 mg P.O. once daily, increased to 100 mg after 7 days if needed. Some patients may require up to 200 mg daily.

➢ Acute myocardial infarction
Adults: 50 mg tablet P.O., then give 50 mg P.O. in 12 hours. Maintenance dosage is 100 mg P.O. daily or 50 mg b.i.d. for 6 to 9 days.

Dosage adjustment
• Renal impairment
• Elderly patients

Contraindications
• Cardiogenic shock
• Sinus bradycardia
• Greater than first-degree heart block
• Heart failure (unless secondary to tachyarrhythmia treatable with beta-adrenergic blockers)

Precautions
Use cautiously in:
• renal failure, hepatic impairment, pulmonary disease, diabetes mellitus, thyrotoxicosis
• pregnant or breastfeeding patients
• children.

Administration
 nível Adjust initial and subsequent dosages downward depending on clinical observations, including pulse rate and blood pressure.
_levels Don’t discontinue drug suddenly. Instead, taper dosage over 2 weeks.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1 hr</td>
<td>2 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: fatigue, lethargy, vertigo, drowsiness, dizziness, depression, disorientation, short-term memory loss

CV: hypertension, intermittent claudication, cold arms and legs, orthostatic hypotension, bradycardia, arrhythmias, heart failure, cardiogenic shock, myocardial infarction

EENT: blurred vision, dry eyes, eye irritation, conjunctivitis, stuffy nose, rhinitis, pharyngitis, laryngospasm

GI: nausea, vomiting, diarrhea, constipation, gastric pain, flatulence, anorexia, ischemic colitis, retroperitoneal fibrosis, acute pancreatitis, mesenteric arterial thrombosis

GU: impotence, decreased libido, dysuria, nocturia, Peyronie’s disease, renal failure

Hematologic: agranulocytosis

Hepatic: hepatomegaly

Metabolic: hypoglycemia

Musculoskeletal: muscle cramps, back and joint pain

Respiratory: dyspnea, wheezing, respiratory distress, bronchospasm, bronchial obstruction, pulmonary emboli

Other: decreased exercise tolerance, allergic reaction, fever, development of antinuclear antibodies, hypersensitivity reaction

Interactions
Drug-drug. Amiodarone, cardiac glycosides, diltiazem, verapamil: increased myocardial depression, causing excessive bradycardia and heart block

Amphetamines, cocaine, ephedrine, nor epinephrine, phenylephrine, pseudo ephedrine: excessive hypertension, bradycardia

Ampicillin, calcium salts: decreased antihypertensive and antianginal effects

Aspirin, bismuth subsalicylate, magnesium salicylate, nonsteroidal anti inflammatory drugs: decreased antihypertensive effect

Clonidine: life-threatening blood pressure increase after clonidine withdrawal or simultaneous withdrawal of both drugs

Dobutamine, dopamine: decrease in beneficial beta-cardiovascular effects

Reactions in bold are life-threatening.
Lidocaine: increased lidocaine levels, greater risk of toxicity
MAO inhibitors: bradycardia
Prazosin: increased risk of orthostatic hypotension
Reserpine: increased hypotension, marked bradycardia
Theophylline: decreased theophylline elimination

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, antinuclear antibody titer, blood urea nitrogen, creatinine, lactate dehydrogenase, platelets, potassium, uric acid: increased levels Glucose: increased or decreased level Insulin tolerance test: false result

Drug-behaviors. Alcohol use: increased hypotension

Patient monitoring
• Watch for signs and symptoms of hypersensitivity reaction.
• Monitor vital signs (especially blood pressure), ECG, and exercise tolerance.
• Check closely for hypotension in hemodialysis patients.
• Monitor blood glucose level regularly if patient is diabetic; drug may mask signs and symptoms of hypoglycemia.

Patient teaching
• Instruct patient to immediately report signs and symptoms of allergic response, breathing problems, and chest pain.
• Advise patient to take drug at same time every day.
• Inform patient that he may experience serious reactions if he stops taking drug suddenly. Advise him to consult prescriber before discontinuing.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• Tell patient that drug may cause a temporary blood pressure decrease if he stands or sits up suddenly. Instruct him to rise slowly and carefully.
• Inform women that drug shouldn’t be taken during pregnancy. Urge them to report planned or suspected pregnancy.
• Tell men that drug may cause erectile dysfunction. Advise them to discuss this issue with prescriber.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

atomoxetine hydrochloride
Strattera
Pharmacologic class: Selective noradrenergic reuptake inhibitor
Therapeutic class: Central nervous system agent
Pregnancy risk category C

FDA BOXED WARNING
• Drug may increase risk of suicidal ideation in children or adolescents with attention deficit hyperactivity disorder (ADHD). Risk must be balanced with clinical need. Observe patient closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family to observe patient closely and communicate with prescriber as needed.
• Drug is approved for ADHD in pediatric and adult patients. It’s not approved for major depressive disorder.

Action
Unclear. May block norepinephrine reuptake at neuronal synapse.

Availability
Capsules: 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg

加拿大
英国
危险药物
高警示药物
Indications and dosages

➣ Acute treatment of ADHD

Children and adolescents weighing 70 kg (154 lb) or less: Initially, total daily dose of approximately 0.5 mg/kg P.O.; increase after minimum of 3 days to target total daily dose of approximately 1.2 mg/kg given either as single daily dose in morning or as evenly divided doses in morning and late afternoon or early evening. Total daily dosage in children and adolescents shouldn’t exceed 1.4 mg/kg or 100 mg, whichever is less.

Children, adolescents, and adults weighing more than 70 kg (154 lb): Initially, total daily dose of 40 mg P.O.; increase after minimum of 3 days to target total daily dose of approximately 80 mg given either as single daily dose in morning or as evenly divided doses in morning and late afternoon or early evening. After 2 to 4 additional weeks, dosage may be increased to maximum of 100 mg in patients who haven’t achieved optimal response. Maximum recommended total daily dosage is 100 mg.

➣ Maintenance and extended treatment of ADHD

Children ages 6 to 15: In general, continue dosage at which patient experienced continuous response.

Dosage adjustment

• Hepatic impairment
• Concurrent use of potent CYP2D6 inhibitors (such as fluoxetine, paroxetine, quinidine) in children weighing less than 70 kg (154 lb)

Contraindications

• Hypersensitivity to drug
• Closed-angle glaucoma
• MAO inhibitor use within past 14 days

Precautions

Use cautiously in:

• hypotension; impaired renal, cardiac, cerebrovascular, hepatic, or endocrine function
• pregnant or breastfeeding patients
• children younger than age 6.

Administration

• Give as a single dose in morning, or give half of total daily dose in morning and other half in late afternoon or early evening.

Don’t give to patient who has taken MAO inhibitors within past 14 days.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>1-2 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: aggression, insomnia, dizziness, drowsiness, headache, irritability, crying, mood swings, fatigue, rigors
CV: orthostatic hypotension, palpitations, tachycardia
EENT: rhinorrhea, sinusitis
GI: nausea, vomiting, constipation, upper abdominal pain, flatulence, dyspepsia, dry mouth
GU: urinary retention, urinary hesitancy, dysmenorrhea, erectile problems, ejaculation failure, impotence, prostatitis
Musculoskeletal: muscle pain
Respiratory: cough
Skin: dermatitis, sweating
Other: fever, hot flashes, growth retardation (in children), decreased appetite, weight loss

Interactions

Drug-drug. Albuterol: increased cardiovascular effects
MAO inhibitors: hyperthermia, myoclonus, rapid changes in vital signs
Potent CYP2D6 inhibitors: increased atomoxetine effects in children weighing less than 70 kg (154 lb)
Vasopressors: hypertensive crisis

Reactions in bold are life-threatening.

Clinical alert
Patient monitoring
- Monitor growth in children.
- Assess for weight loss.
- Check blood pressure and pulse, especially after dosage changes.
- Monitor for changes in mood, sleep patterns, and behavior.
- Evaluate for urinary hesitancy or urinary retention and sexual dysfunction.
- Provide dietary counseling. Refer patient to dietitian if adverse GI effects significantly limit food intake.

Patient teaching
- To minimize insomnia, advise patient to establish effective bedtime routine and to take drug in single morning dose or in divided half-doses in morning and late afternoon or early evening.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

atorvastatin calcium
Lipitor

Pharmacologic class: HMG-CoA reductase inhibitor
Therapeutic class: Lipid-lowering agent
Pregnancy risk category X

Action
Inhibits HMG-CoA reductase, which catalyzes first step in cholesterol synthesis; this action reduces concentrations of serum cholesterol and low-density lipoproteins (LDLs), linked to increased risk of coronary artery disease (CAD). Also moderately increases concentration of high-density lipoproteins (HDLs), associated with decreased risk of CAD.

Availability
Tablets: 10 mg, 20 mg, 40 mg, 80 mg

Indications and dosages
- Adjunct to diet for controlling LDL, total cholesterol, apo-lipoprotein B, and triglyceride levels and to increase HDL levels in patients with primary hypercholesterolemia and mixed dyslipidemia; primary dysbetalipoproteinemia in patients unresponsive to diet alone; adjunct to diet to reduce elevated triglyceride levels
  Adults: Initially, 10 mg P.O. daily; increase to 80 mg P.O. daily if needed. Adjust dosage according to patient’s cholesterol level.
- Adjunct to other lipid-lowering treatments in patients with homozygous familial hypercholesterolemia
  Adults: 10 to 80 mg P.O. daily
- Adjunct to diet to decrease total cholesterol, LDL, and apo-lipoprotein B levels in boys and postmenarchal girls ages 10 to 17 with familial and nonfamilial heterozygous hypercholesterolemia
  Boys and girls: Initially, 10 mg P.O. daily; adjust dosage upward or downward based on lipid levels. Maximum dosage is 20 mg daily.
- Prevention of cardiovascular disease in patients without clinically evident coronary heart disease (CHD) but with multiple CHD risk factors
  Adults: 10 mg P.O. daily
- Prevention of stroke and myocardial infarction in patients with type 2 diabetes who have multiple risk factors for CHD but without clinically evident CHD
  Adults: Dosage individualized according to patient characteristics, such as goal of therapy and response according
to National Cholesterol Education Program guidelines

**Contraindications**
- Hypersensitivity to drug or its components
- Active hepatic disease or unexplained, persistent serum transaminase elevations
- Pregnancy or breastfeeding

**Precautions**
Use cautiously in:
- hypotension, uncontrolled seizures, myopathy, alcoholism
- severe metabolic, endocrine, or electrolyte disorders
- women of childbearing age
- children younger than age 18.

**Administration**
- Give with or without food.
- Don’t give with grapefruit juice or antacids.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1-2 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** amnesia, abnormal dreams, emotional lability, headache, hyperactivity, poor coordination, malaise, paresthesia, peripheral neuropathy, drowsiness, syncope, weakness

**CV:** orthostatic hypotension, palpitations, phlebitis, vasodilation

**Arrhythmias**

**EENT:** amblyopia, altered refraction, glaucoma, eye hemorrhage, dry eyes, hearing loss, tinnitus, epistaxis, sinusitis, pharyngitis

**GI:** nausea, vomiting, diarrhea, constipation, abdominal cramps, abdominal or biliary pain, colitis, indigestion, dyspepsia, flatulence, stomach ulcers, gastrointestinal, melena, tenesmus, glossitis, mouth sores, dry mouth, dysphagia, esophagitis, pancreatitis, rectal hemorrhage

**GU:** hematuria, nocturia, dysuria, urinary frequency or urgency, urinary retention, cystitis, nephritis, renal calculi, abnormal ejaculation, decreased libido, erectile dysfunction, epididymitis

**Hematologic:** anemia, thrombocytopenia

**Hepatic:** jaundice, hepatic failure, hepatitis

**Metabolic:** hyperglycemia, hypoglycemia

**Musculoskeletal:** bursitis, joint pain, back pain, leg cramps, gout, muscle pain or aches, myositis, myasthenia gravis, neck rigidity, torticollis, rhabdomyolysis

**Respiratory:** dyspnea, pneumonia, bronchitis

**Skin:** alopecia, acne, contact dermatitis, eczema, dry skin, pruritus, rash, urticaria, skin ulcers, seborrhea, photosensitivity, diaphoresis, toxic epidermal necrolysis

**Other:** taste loss, gingival bleeding, fever, facial paralysis, facial or generalized edema, flulike symptoms, infection, appetite changes, weight gain, allergic reaction, Stevens-Johnson syndrome

**Interactions**

**Drug-drug.** Antacids, colestipol, efavirenz, rifampin: decreased atorvastatin blood level

Azole antifungals, clarithromycin, cyclosporine, diltiazem, erythromycin, fibrin acid derivatives, immunosuppressants, niacin, other HMG-CoA reductase inhibitors, protease inhibitors: increased risk of myopathy or rhabdomyolysis

Digoxin: increased digoxin level, greater risk of toxicity

Hormonal contraceptives: increased estrogen level

**Drug-diagnostic tests.** Alanine aminotransferase, aspartate aminotransferase, creatine kinase: increased levels

Reactions in **bold** are life-threatening.
Drug-food. *Grapefruit juice:* increased drug blood level, greater risk of adverse effects
Drug-herbs. *Red yeast rice:* increased risk of adverse effects

Patient monitoring
- Monitor patient for signs and symptoms of allergic response.
- Evaluate for muscle weakness (a symptom of myositis and possibly rhabdomyolysis).
- Be aware that reduction in dosage and periodic monitoring of creatine kinase level may be considered for patients taking drugs that may increase atorvastatin level.
- Monitor liver function test results and blood lipid levels.

Patient teaching
- Tell patient he may take drug with or without food.
- Advise patient to immediately report allergic response, irregular heart beats, unusual bruising or bleeding, unusual tiredness, yellowing of skin or eyes, or muscle weakness.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, alertness, and vision.
- Inform patient taking hormonal contraceptives that drug increases estrogen levels. Instruct her to tell all prescribers she’s taking drug.
- Tell men that drug may cause erectile dysfunction and abnormal ejaculation. Encourage them to discuss these issues with prescriber.
- Tell patient he’ll undergo regular blood testing during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

---

**atropine sulfate**

**AtroPen**

**atropine sulfate ophthalmic**

**Isopto Atropine**

**Pharmacologic class:** Anticholinergic (antimuscarinic)
**Therapeutic class:** Antiarrhythmic
**Pregnancy risk category C**

**Action**

Inhibits acetylcholine at parasympathetic neuroeffector junction of smooth muscle and cardiac muscle, blocking sinoatrial (SA) and atrioventricular (AV) nodes. These actions increase impulse conduction and raise heart rate. In ophthalmic use, blocks cholinergic stimulation to iris and ciliary bodies, causing pupillary dilation and accommodation paralysis.

**Availability**

*Injection:* 0.05 mg/ml, 0.1 mg/ml, 0.3 mg/ml, 0.4 mg/ml, 0.5 mg/ml, 0.8 mg/ml, 1 mg/ml

*Ophthalmic solution:* 0.5%, 1%, 2%

*Tablets:* 0.4 mg

**Indications and dosages**

➢ Bradyarrhythmias, symptomatic bradycardia

**Adults:** 0.5 to 1 mg by I.V. push repeated q 3 to 5 minutes as needed, to a maximum dosage of 2 mg

**Children:** 0.01 mg/kg I.V. to a maximum dosage of 0.4 mg or 0.3 mg/m². May repeat I.V. dose q 4 to 6 hours.

➢ Antidote for anticholinesterase insecticide poisoning

**Adults:** 2 to 3 mg I.V. repeated q 5 to 10 minutes until symptoms disappear or a toxic level is reached. For severe poisoning, 6 mg q hour.
Children: 0.05 mg/kg I.M. or I.V. repeated q every 10 to 30 minutes until symptoms disappear or a toxic level is reached ➢ Preoperatively to diminish secretions and block cardiac vagal reflexes

**Adults and children weighing more than 40.8 kg (90 lb):** 0.4 to 0.6 mg I.M., I.V., or subcutaneously 30 to 60 minutes before anesthesia

**Children weighing 29.5 to 40.8 kg (65 to 90 lb):** 0.4 mg I.M., I.V., or subcutaneously 30 to 60 minutes before anesthesia

**Children weighing 18.1 to 29.5 kg (40 to 65 lb):** 0.3 mg I.M., I.V., or subcutaneously 30 to 60 minutes before anesthesia

**Children weighing 10.9 to 18.1 kg (24 to 40 lb):** 0.2 mg I.M., I.V., or subcutaneously 30 to 60 minutes before anesthesia

**Children weighing 7.3 to 10.9 kg (16 to 24 lb):** 0.15 mg I.M., I.V., or subcutaneously 30 to 60 minutes before anesthesia

**Children weighing 3.2 to 7.3 kg (7 to 16 lb):** 0.1 mg I.M., I.V., or subcutaneously 30 to 60 minutes before anesthesia ➢ Peptic ulcer disease, functional GI disorders (such as hypersecretory states)

**Adults:**
- 0.4 to 0.6 mg P.O. q 4 to 6 hours
- 0.01 mg/kg or 0.3/m² P.O. q 4 to 6 hours

**Adults:**
- 0.1 to 0.25 mg P.O. q.i.d.

**Children:**
- Instill one or two drops of 0.5% solution into eye(s) b.i.d. for 1 to 3 days before examination.

**Off-label uses**
- Cholinergic-mediated bronchial asthma

**Contraindications**
- Hypersensitivity to drug or other belladonna alkaloids
- Acute narrow-angle glaucoma
- Adhesions between iris and lens (ophthalmic form)
- Obstructive GI tract disease
- Unstable cardiovascular status
- Asthma
- Myasthenia gravis
- Thyrotoxicosis
- Infants ages 3 months and younger

**Precautions**
Use cautiously in:
- chronic renal, hepatic, pulmonary, or cardiac disease
- intra-abdominal infection, prostatic hypertrophy
- elderly patients
- pregnant or breastfeeding patients
- children.

**Administration**
- For I.V. dose, infuse directly into large vein or I.V. tubing over at least 1 minute.
- Be aware that doses of 0.5 mg may cause paradoxical bradycardia because of central or peripheral parasympathomimetic effects of low doses in adults.
- Don’t administer oral dose within 1 hour of giving antacids.
- Be aware that patients with Down syndrome may be unusually sensitive to drug.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>0.5-2 hr</td>
<td>1-2 hr</td>
<td>4-6 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>2-4 min</td>
<td>4-6 hr</td>
</tr>
<tr>
<td>I.M., subcut.</td>
<td>Rapid</td>
<td>15-50 min</td>
<td>4-6 hr</td>
</tr>
</tbody>
</table>

Reactions in **bold** are life-threatening.
Adverse effects
CNS: headache, restlessness, ataxia, disorientation, delirium, insomnia, dizziness, drowsiness, agitation, nervousness, confusion, excitement
CV: palpitations, bradycardia, tachycardia
EENT: photophobia, blurred vision, increased intraocular pressure, mydriasis, cycloplegia, nasal congestion
GI: nausea, vomiting, constipation, bloating, dyspepsia, ileus, abdominal distention (in infants), dysphagia, dry mouth
GU: urinary retention, urinary hesitancy, impotence
Skin: decreased sweating, flushing, urticaria, dry skin
Other: thirst, anaphylaxis

Interactions
Drug-drug. Amantadine, antiarrhythmics, anticholinergics, antihistamines, antiparkinsonian drugs, glutethimide, meperidine, muscle relaxants, phenothiazines, tricyclic antidepressants: increased atropine effects
Antacids, antidiarrheals: decreased atropine absorption
Antimyasthenics: decreased intestinal motility
Cyclopropane: ventricular arrhythmias
Ketoconazole, levodopa: decreased absorption of these drugs
Metoclopramide: decreased effect of atropine on GI motility
Potassium chloride wax-matrix tablets: increased severity of mucosal lesions
Drug-herbs. Jaborandi tree, pill-bearing spurge: decreased drug effect
Jimsonweed: changes in cardiovascular function
Squaw vine: reduced metabolic breakdown of drug
Drug-behaviors. Sun exposure: increased risk of photophobia

Patient monitoring
Watch closely for signs and symptoms of anaphylaxis.

Patient teaching
Instruct patient to immediately report allergic response.
Inform patient that headache, eye pain, and blurred vision may signal glaucoma. Tell him to report these symptoms at once.
Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, alertness, and vision.
Encourage patient to establish an effective bedtime routine to minimize insomnia.
Tell patient to apply pressure to inside corner of eye during instillation of ophthalmic solution and for 1 to 2 minutes afterward.
As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, herbs, and behaviors mentioned above.

azacitidine
Vidaza

Pharmacologic class: Pyrimidine antimetabolite
Therapeutic class: Antineoplastic
Pregnancy risk category D

Action
Unclear. Thought to exert antineoplastic effect by causing DNA hypomethylation and direct cytotoxicity on abnormal hematopoietic bone marrow cells. Cytotoxicity causes death of
rapidly growing cells, including cancer cells no longer responsive to normal growth control mechanisms.

**Availability**

*Powder for injection (lyophilized):* 100-mg single-use vials

**Indications and dosages**

- Treatment of the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusion), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia

**Adults:** For first treatment cycle: 75 mg/m² subcutaneously or I.V. daily for 7 days; for subsequent treatment cycles, repeat cycle every 4 weeks. Dosage may be increased to 100 mg/m² if beneficial effect doesn’t occur after two cycles and no toxicity (other than nausea and vomiting) develops. Patient should be treated for at least four cycles. Continue therapy as long as patient benefits from it.

**Dosage adjustment**

- Based on hematologic response (after administration of recommended dosage for first cycle)
- Unexplained serum bicarbonate reduction below 20 mEq/L
- Unexplained blood urea nitrogen or serum creatinine elevation

**Off-label uses**

- Acute myeloid leukemia

**Contraindications**

- Hypersensitivity to drug or mannitol
- Advanced malignant hepatic tumor

**Precautions**

Use cautiously in:

- impaired renal or hepatic function, myelodysplastic syndrome
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

**Administration**

- Obtain CBC, liver function tests, and serum creatinine level before starting drug.
- For subcutaneous administration, reconstitute with 4 ml sterile water for injection. Inject diluent slowly into vial; invert vial two or three times and rotate gently until uniform suspension appears. Resulting suspension (which will be cloudy) contains azacitidine 25 mg/ml.
- Invert syringe two to three times and gently roll between palms for 30 seconds immediately before administration.
- When giving subcutaneously, divide doses above 4 ml equally in two syringes, and inject subcutaneously in separate sites.
- Administer within 1 hour after reconstitution.
- When giving subcutaneously, rotate sites for each injection (thigh, abdomen, or upper arm). Give new injection at least 1” from old site and never into tender, bruised, red, or hard area.
- For I.V. administration, reconstitute each vial with 10 ml sterile water for injection. Vigorously shake or roll bottle until all solids have dissolved.
- Prepare I.V. solution by adding reconstituted drug to 50- to 100-ml infusion bag of normal saline solution injection or lactated Ringer’s injection.
- Administer I.V. solution over 10 to 40 minutes; administration must be completed within 1 hour of vial reconstitution.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>Subcut.</td>
<td>Unknown</td>
<td>30 min</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Reactions in **bold** are life-threatening.
Adverse reactions
CNS: fatigue, headache, confusion, dizziness, anxiety, aggravated fatigue, depression, insomnia, lethargy, weakness, rigors, malaise, hypoesthesia, cerebral hemorrhage
CV: chest pain, cardiac murmur, tachycardia, hypotension, peripheral edema, syncope
EENT: rhinorrhea, epistaxis, sinusitis, nasopharyngitis, pharyngitis, postnasal drip, eye hemorrhage
GI: nausea, vomiting, diarrhea, constipation, anorexia, abdominal pain or tenderness, abdominal distention, dyspepsia, hemorrhoids, dysphagia, gingival bleeding, oral mucosal petechiae, stomatitis, tongue ulcers, mouth hemorrhage
GU: dysuria, urinary tract infection
Hematologic: anemia, thrombocytopenia, leukopenia, neutropenia, febrile neutropenia, lymphadenopathy, aggravated anemia, postprocedural hemorrhage, pancytopenia, bone marrow failure
Musculoskeletal: myalgia, muscle cramps, arthralgia, limb pain, back pain
Respiratory: cough (possibly productive), dyspnea, exertional or exacerbated dyspnea, upper respiratory tract infection, pneumonia, crackles, wheezing, decreased breath sounds, pleural effusion, rhonchi, atelectasis
Skin: lesion, rash, pruritus, herpes simplex, increased sweating, urticaria, dry skin, skin nodule, erythema, pallor, cellulitis
Other: decreased appetite, weight loss, fever, pitting edema, hematoma, night sweats, peripheral swelling, infection site reaction, transfusion reaction, chest-wall pain, postprocedural or other pain, neutropenic sepsis, septic shock
Interactions
Drug-diagnostic tests. Potassium: decreased

Patient monitoring
- Monitor CBC during therapy.
- Monitor liver function tests and serum creatinine frequently.
- Watch for renal tubular acidosis (serum bicarbonate level below 20 mEq/L associated with alkaline urine and hypokalemia, and serum potassium level below 3 mEq/L).

Patient teaching
- Instruct patient to call prescriber immediately if rash, easy bruising or bleeding, or respiratory symptoms develop.
- Advise male patient not to father a child during therapy.
- Caution female of childbearing potential to avoid pregnancy and breastfeeding during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions, especially those related to the tests mentioned above.

Azathioprine
Apo-Azathioprine®, Azasan, Gen-Azathioprine®, Immunoprin®, Imuran, Novo-Azathioprine®
Pharmacologic class: Purine antagonist
Therapeutic class: Immunosuppressant
Pregnancy risk category D

FDA BOXED WARNING
- Drug may cause chronic immunosuppression, increasing neoplasia risk. Physicians using it should be familiar with this risk and with possible hematologic toxicities and mutagenic potential in both sexes.
Action
Prevents proliferation and differentiation of activated B and T cells by interfering with synthesis of purine, DNA, and RNA

Availability
Injection: 100-mg vial
Tablets: 25 mg, 50 mg, 75 mg, 100 mg

Indications and dosages
➢ To prevent rejection of kidney transplant
Adults and children: Initially, 3 to 5 mg/kg/day P.O. or I.V. as a single dose. Give on day of transplantation or 1 to 3 days before day of transplantation; then 3 to 5 mg/kg/day I.V. after surgery until patient can tolerate P.O. route. Maintenance dosage is 1 to 3 mg/kg/day P.O.
➢ Rheumatoid arthritis
Adults and children: Initially, 1 mg/kg P.O. or I.V. in one or two daily doses. Increase dosage in steps at 6 to 8 weeks and thereafter at 4-week intervals; use dosage increments of 0.5 mg/kg/day, to a maximum dosage of 2.5 mg/kg/day. Once patient stabilizes, decrease in decrements of 0.5 mg/kg/day to lowest effective dosage.

Dosage adjustment
● Renal disease
● Concurrent allopurinol therapy
● Elderly patients

Off-label uses
● Crohn's disease
● Myasthenia gravis
● Chronic ulcerative colitis

Contraindications
● Hypersensitivity to drug
● Pregnancy or breastfeeding

Precautions
Use cautiously in:
● chickenpox, herpes zoster, impaired hepatic or renal function, decreased bone marrow reserve
● previous therapy with alkylating agents (cyclophosphamide, chlorambucil, melphalan) for rheumatoid arthritis
● elderly patients
● women of childbearing age.

Administration
● Give after meals.
● Be aware that I.V. administration is intended for use only when patients can’t tolerate oral medications.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>P.O.</td>
<td>6-8 wks</td>
<td>12 wks</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: malaise
EENT: retinopathy
GI: nausea, vomiting, diarrhea, stomatitis, esophagitis, anorexia, mucositis, pancreatitis
Hematologic: anemia, thrombocytopenia, leukopenia, pancytopenia
Hepatic: jaundice, hepatotoxicity
Musculoskeletal: muscle wasting, joint and muscle pain
Skin: rash, alopecia
Other: chills, fever, serum sickness, neoplasms, serious infection

Interactions
Drug-drug. Allopurinol: increased therapeutic and adverse effects of azathioprine
Angiotensin-converting enzyme (ACE) inhibitors, co-trimoxazole: severe leukopenia
Anticoagulants, cyclosporine: decreased actions of these drugs
Atracurium, pancuronium, tubocurarine, vecuronium: reversal of these drugs’ actions
Drugs affecting bone marrow and bone marrow cells (such as ACE inhibitors, co-trimoxazole): severe leukopenia

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase,

Reactions in bold are life-threatening.
amylase, aspartate aminotransferase, bilirubin: increased levels
Albumin, hemoglobin, uric acid: decreased levels
Urine uric acid: decreased level

Drug-herbs. Astragalus, echinacea, melatonin: interference with immunosuppressant action

Patient monitoring
- Monitor CBC, platelet level, and liver function test results.
- Assess for signs and symptoms of hepatotoxicity (clay-colored stools, pruritus, jaundice, and dark urine).
- Watch for signs and symptoms of infection.
- Monitor for bleeding tendency and hemorrhage.

Patient teaching
- Tell patient that drug lowers resistance to infection. Instruct him to immediately report fever, cough, breathing problems, chills, and other symptoms.
- Instruct patient to immediately report unusual bleeding or bruising.
- Tell patient that drug effects may not be obvious for up to 8 weeks in immunosuppression and up to 12 weeks for rheumatoid arthritis relief.
- Emphasize importance of avoiding pregnancy during therapy and for 4 months afterward.
- Caution patient to avoid activities that may cause injury. Tell him to use soft toothbrush and electric razor to avoid gum and skin injury.
- Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
- Tell patient he’ll undergo regular blood testing during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

azithromycin, azithromycin dihydrate
Zithromax, Zmax

Pharmacologic class: Macrolide
Therapeutic class: Anti-infective
Pregnancy risk category B

Action
Bactericidal and bacteriostatic; inhibits protein synthesis after binding with 50S ribosomal subunit of susceptible organisms. Demonstrates cross-resistance to erythromycin-resistant gram-positive strains and resistance to most strains of Enterococcus faecalis and methicillin-resistant Staphylococcus aureus.

Availability
Oral suspension: 100 mg/5 ml in 15-ml bottles; 200 mg/5 ml in 15-ml, 22.5-ml, and 30-ml bottles
Oral suspension (Zmax extended-release): 2-g bottle
Powder for injection: 500 mg in 10-ml vials
Powder for oral suspension: 100 mg/5 ml, 200 mg/5 ml, 1,000 mg/packet
Tablets: 250 mg, 500 mg, 600 mg
Tablets (Tri-Pak): three 500-mg tablets
Tablets (Z-Pak): six 250-mg tablets

Indications and dosages
- Mild community-acquired pneumonia
Adults: 500 mg P.O. on first day, then 250 mg/day for next 4 days. Or, 2 g P.O. as single dose (extended-release oral suspension).
Children ages 6 months and older: 10 mg/kg P.O. (no more than 500 mg/dose) on day 1, then 5 mg/kg (no more than 250 mg/dose) for 4 more days
- Community-acquired pneumonia caused by Chlamydia pneumoniae,
**Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, Legionella pneumophila, Moraxella catarrhalis, and S. aureus**

**Adults and adolescents ages 16 and older:** 500 mg I.V. daily for at least two doses, then 500 mg P.O. daily for a total of 7 to 10 days

**Children ages 6 months to 16 years:** 10 mg/kg P.O. as a single dose on day 1, then 5 mg/kg P.O. on days 2 through 5

➢ Pharyngitis and tonsillitis

**Adults:** 500 mg P.O. on day 1, then 250 mg/day for next 4 days, to a total dosage of 1.5 g

**Children ages 2 and older:** 12 mg/kg P.O. daily for 5 days. Maximum dosage is 500 mg.

➢ Skin and skin-structure infections

**Adults:** 500 mg P.O. on first day, then 250 mg/day for next 4 days, to total dosage of 1.5 g

➢ Acute bacterial sinusitis

**Adults:** 500 mg P.O. daily for 3 days; or, 2 g P.O. as single dose (extended-release oral suspension)

**Children ages 6 months and older:** 10 mg/kg (maximum, 500 mg) P.O. daily for 3 days

➢ Mild to moderate acute exacerbation of chronic obstructive pulmonary disease

**Adults:** 500 mg/day for 3 days or 500 mg P.O. on day 1, then 250 mg P.O. daily on days 2 through 5; or, 2 g P.O. (extended-release oral suspension) as single dose

➢ Pelvic inflammatory disease caused by *Chlamydia trachomatis, Neisseria gonorrhoeae, or Mycoplasma hominis*

**Adults:** 500 mg I.V. daily on days 1 and 2, then 250 mg P.O. daily for a total of 7 days. If anaerobes are suspected, give continually with appropriate anti-anaerobic antibiotic, as ordered.

➢ Nongonococcal urethritis or cervicitis caused by *C. trachomatis*; genital ulcers caused by *Haemophilus ducreyi* (chancroid)

**Adults:** 1g P.O. as a single dose

➢ Urethritis and cervicitis caused by *N. gonorrhoeae*

**Adults:** 2 g P.O. as a single dose

➢ To prevent disseminated *Mycobacterium avium* complex disease in patients with advanced human immunodeficiency virus

**Adults:** 1.2 g P.O. once weekly (given alone or with rifabutin)

➢ Acute otitis media

**Children ages 6 months and older:** 30 mg/kg as a single dose or 10 mg/kg once daily for 3 days; or 10 mg/kg as a single dose on day 1, followed by 5 mg/kg on days 2 through 5

**Off-label uses**

● Uncomplicated gonococcal infections of cervix, urethra, rectum, and pharynx

**Contraindications**

● Hypersensitivity to drug, erythromycin, or other macrolide anti-infectives

**Precautions**

Use cautiously in:

● severe hepatic impairment, severe renal insufficiency, prolonged QT interval

● breastfeeding patients.

**Administration**

● Obtain specimens for culture and sensitivity testing before starting therapy.

● Administer tablets and single-dose packets with or without food.

● Give oral suspension 1 hour before meals or 2 hours afterward. With 1-g packet, or single 2-g bottles, mix entire contents in 2 oz of water.

♫ Don’t administer as I.V. bolus or I.M. injection.

● For I.V. use, reconstitute 500-mg vial with 4.8 ml of sterile water for injection.
As appropriate, dilute solution further using normal or half-normal saline solution, dextrose 5% in water, or lactated Ringer’s solution. Infuse injection over no less than 60 minutes. Infuse 1 mg/ml over 3 hours or 2 mg/2 ml over 1 hour. Know that 1,000-mg packet and extended-release oral suspension aren’t for pediatric use.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>PO</td>
<td>Rapid</td>
<td>2.5-3.2 hr</td>
<td>24 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>End of infusion</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, drowsiness, fatigue, headache, vertigo
CV: chest pain, palpitations
GI: nausea, diarrhea, abdominal pain, cholestatic jaundice, dyspepsia, flatulence, melena, *pseudomembranous colitis*
GU: nephritis, vaginitis, candidiasis
Metabolic: hyperglycemia, hyperkalemia
Skin: photosensitivity, rashes, angioedema

Interactions
Drug-drug. Antacids containing aluminum or magnesium: decreased peak azithromycin blood level
Arrhythmias (such as amiodarone, quinidine): increased risk of life-threatening arrhythmias
Carbamazepine, cyclosporine, digoxin, dihydroergotamine, ergotamine, hexobarbital, phenoxytine, theophylline, triazolam: increased blood levels of these drugs
HMG-CoA reductase inhibitors (such as atorvastatin, lovastatin): increased risk of myopathy or rhabdomyolysis
Pimozide: prolonged QT interval, ventricular tachycardia
Warfarin: increased International Normalized Ratio

Drug-food. Any food: decreased absorption of multidose oral suspension

Drug-behaviors. *Sun exposure:* photosensitivity

Patient monitoring
- Monitor temperature, white blood cell count, and culture and sensitivity results.
- Assess for signs and symptoms of infection.
- Monitor patients at risk for cardiac arrhythmia.

Patient teaching
- Tell patient he may take tablets with or without food.
- Advise patient to take suspension 1 hour before or 2 hours after meals.
- Remind patient to complete entire course of therapy as ordered, even after symptoms improve.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, foods, and behaviors mentioned above.

**aztreonam**

**Azactam**

**Pharmacologic class:** Monobactam

**Therapeutic class:** Anti-infective

**Pregnancy risk category B**

**Action**
Inhibits bacterial cell-wall synthesis during active multiplication by binding with penicillin-binding protein 3, resulting in cell-wall destruction

**Availability**
Powder for injection: 500-mg vial, 1-g vial, 2-g vial, 1g/50-ml I.V. bag, 2 g/50-ml I.V. bag

**Indications and dosages**
Infections caused by susceptible gram-negative organisms
**Adults:** For urinary tract infections, 500 mg or 1 g IM or IV q 8 or 12 hours; for moderately severe systemic infections, 1 or 2 g IM or IV q 8 or 12 hours; for severe or life-threatening infections, 2 g IM or IV q 6 or 8 hours. Maximum dosage is 8 g/day.

**Children:** For mild to moderate infections, 30 mg/kg IM or IV q 8 hours; for moderate to severe infections, 30 mg/kg IM or IV q 6 or 8 hours. Maximum dosage is 120 mg/kg/day.

**Dosage adjustment**
- Severe renal failure

**Contraindications**
- Hypersensitivity to drug or its components

**Precautions**
Use cautiously in:
- renal or hepatic impairment
- elderly patients
- pregnant or breastfeeding patients.

**Administration**
- Flush IV tubing with compatible solution before and after giving drug.
- Compatible solutions include 0.9% sodium chloride injection, 5% or 10% dextrose injection, Ringer’s or lactated Ringer’s injection, 5% dextrose and 0.9% sodium chloride injection, and 5% dextrose and 0.45% sodium chloride injection.
- After adding diluent to vial or infusion bottle, shake immediately and vigorously.
- For IV bolus injection, reconstitute powder for injection by adding 6 to 10 ml of sterile water for injection. Inject prescribed dosage into tubing of compatible IV solution slowly over 3 to 5 minutes.
- For intermittent IV infusion, reconstitute powder for injection by adding compatible IV solution to yield a concentration not exceeding 20 mg/ml. Administer prescribed dosage over 20 to 60 minutes.

- Thaw commercially available frozen drug at room temperature and give by intermittent IV infusion only.
- For IM injection, reconstitute powder for injection by adding 3 ml of sterile water for injection or 0.9% sodium chloride injection.
- Give IM injection deep into large muscle mass.

**Adverse reactions**
- CNS: dizziness, confusion, seizures
- CV: phlebitis, thrombophlebitis
- EENT: diplopia, tinnitus
- GI: nausea, vomiting, diarrhea (including diarrhea associated with *Clostridium difficile*), pseudomembranous colitis
- Hematologic: neutropenia, pancytopenia
- Hepatic: hepatitis
- Respiratory: bronchospasm
- Skin: rash, toxic epidermal necrolysis
- Other: altered taste, angioedema, anaphylaxis

**Interactions**
- **Drug-drug.** Aminoglycosides: increased risk of nephrotoxicity and ototoxicity
- Beta-lactamase-inducing antibiotics (such as cefoxitin, imipenem): antagonism with aztreonam
- Furosemide, probenecid: increased aztreonam levels

**Drug-diagnostic tests.** Alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, eosinophils, platelets, prothrombin time (PT), partial thromboplastin time (PTT): increased values
- Coombs’ test: positive result
- Neutrophils: decreased count

Reactions in **bold** are life-threatening.
Patient monitoring
- Assess patient closely for signs and symptoms of pseudomembranous colitis.
- Monitor patient carefully for hypersensitivity reaction, especially if he’s allergic to penicillin, carbapenems, or cephalosporins.
  - Monitor CBC with differential, AST, ALT, PT, PTT, and serum creatinine values.
  - Monitor renal and hepatic function.

Patient teaching
- Instruct patient to immediately report severe diarrhea or signs or symptoms of hypersensitivity reaction, such as rash or difficulty breathing.
- Tell female patient to notify prescriber if she is pregnant or breastfeeding.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

baclofen
Apo-Baclofen®, Baclofen, Gen-Baclofen®, Kemstro, Lioresal, Lioresal Intrathecal, Liotec®, Lyflex®, Nu-Baclo®, PMS-Baclofen®

Pharmacologic class: Skeletal muscle relaxant
Therapeutic class: Antispasmodic
Pregnancy risk category C

FDA BOXED WARNING
- With intrathecal form, abrupt withdrawal may cause high fever, altered mental status, exaggerated rebound spasticity, and muscle rigidity; in rare cases, patient progresses to rhabdomyolysis, multisystem failure, and death. To prevent abrupt withdrawal, pay careful attention to programming and monitoring of infusion system, refill scheduling and procedures, and pump alarms. Advise patients and caregivers of importance of keeping scheduled refill visits, and teach about early drug withdrawal symptoms. Give special attention to patients at apparent risk (those with spinal cord injuries at T6 or above, communication problems, or history of withdrawal symptoms from oral or intrathecal baclofen).

Action
Relaxes muscles by acting specifically at spinal end of upper motor neurons

Availability
Intrathecal injection: 10 mg/20 ml (500 mcg/ml), 10 mg/5 ml (2,000 mcg/ml)
Tablets: 10 mg, 20 mg

Indications and dosages
- Reversible spasticity associated with multiple sclerosis or spinal cord lesions
  Adults: Initially, 5 mg P.O. t.i.d. May increase by 5 mg q 3 days to a maximum dosage of 80 mg/day.
  Children ages 4 and older: 25 to 1,200 mcg/day by intrathecal infusion; (average is 275 mcg/day); dosage determined by response during screening phase.
- Severe spasticity in patients who don’t respond to or can’t tolerate oral baclofen
  Adults: Screening phase—Before pump implantation and intrathecal infusion, give test dose to check responsiveness. Administer 1 ml of 50 mcg/ml dilution over 1 minute by barbotage into intrathecal space. Within 4 to 8 hours, muscle spasms should become less severe or frequent and muscle tone should decrease; if patient’s response is
inadequate, give second test dose of 75 mcg/1.5 ml 24 hours after first dose. If patient is still unresponsive, may give final test dose of 100 mcg/2 ml 24 hours later. Patients unresponsive to 100-mcg dose aren't candidates for intrathecal baclofen. Following appropriate responsiveness, adjust dosage to twice the screening dose and give over 24 hours. If screening dose efficacy is maintained for 12 hours, don’t double the dosage. After 24 hours, increase dosage slowly as needed and tolerated by 10% to 30% daily.

Maintenance therapy—During prolonged maintenance therapy, adjust daily dosage by 10% to 40% as needed and tolerated to maintain adequate control of symptoms. Maintenance dosage ranges from 12 mcg to 2,000 mcg daily.

Dosage adjustment
- Renal impairment
- Seizure disorders
- Elderly patients

Off-label uses
- Cerebral palsy
- Tardive dyskinesia
- Trigeminal neuralgia

Contraindications
- Hypersensitivity to drug
- Rheumatic disorders

Precautions
Use cautiously in:
- renal impairment
- epilepsy
- patients who use spasticity to maintain posture and balance
- elderly patients
- pregnant or breastfeeding patients
- children.

Administration
- Give oral doses with food or milk.
- Dilute only with sterile, preservative-free sodium chloride for injection.
- Know that intrathecal infusion should be performed only by personnel who have been trained in the procedure.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2-3 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>Intrathecal</td>
<td>0.5-1 hr</td>
<td>4 hr</td>
<td>4-8 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, drowsiness, fatigue, confusion, depression, headache, insomnia, hypotonia, difficulty speaking, seizures
CV: edema, hypotension, hypertension, palpitations
EENT: blurred vision, tinnitus, nasal congestion
GI: nausea, vomiting, constipation
GU: urinary frequency, dysuria, erectile dysfunction
Metabolic: hyperglycemia
Skin: pruritus, rash, sweating
Other: weight gain, hypersensitivity reactions

Interactions
Drug-drug. CNS depressants: increased baclofen effect
MAO inhibitors: increased CNS depression, hypotension
Tricyclic antidepressants, drugs causing CNS depression: hypotonia, increased CNS depression
Drug-diagnostic tests. Alkaline phosphatase, aspartate aminotransferase, glucose: increased levels
Drug-behaviors. Alcohol use: CNS depression

Patient monitoring
- During intrathecal infusion, check pump often for proper functioning and check catheter for patency.
- Monitor patient’s response continually to determine appropriate dosage adjustment.
- Observe closely for signs and symptoms of overdose (drowsiness, light-headedness, dizziness, respiratory depression), especially during initial screening and titration. No specific

Reactions in bold are life-threatening.
antidote exists. Immediately remove any solution from pump; if patient has respiratory depression, intubate until drug is eliminated.

**Patient teaching**
- Advise patient to take oral dose with food or milk.
- Instruct patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Caution patient not to discontinue drug therapy abruptly. Doing so may cause hallucinations and rebound spasticity.
- Advise patient to avoid alcohol and other depressants such as sedatives while taking drug.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

---

**balsalazide disodium**
Colazal, Colazide®

*Pharmacologic class:* GI agent  
*Therapeutic class:* Anti-inflammatory  
*Pregnancy risk category B*

**Action**
Metabolized in colon to mesalamine and then to 5-aminosalicylic acid, both of which are thought to exert local anti-inflammatory effect by inhibiting prostaglandin and acid metabolites.

**Availability**
*Capsules:* 750 mg

**Indications and dosages**
- Mildly to moderately active ulcerative colitis

**Adults:** Usual dosage, three 750-mg capsules P.O. t.i.d. (6.75 g daily) for up to 8 weeks; some patients may require 12 weeks.

**Children ages 5 to 17:** Usual dosage, either three 750-mg capsules P.O. t.i.d (6.75 g daily) for up to 8 weeks, or one 750-mg capsule P.O. t.i.d. (2.25 g daily) for up to 8 weeks.

**Contraindications**
- Hypersensitivity to balsalazide, salicylates, or mesalamine

**Precautions**
Use cautiously in:
- renal impairment
- pyloric stenosis
- breastfeeding patients
- children younger than age 5 (safety and efficacy not established).

**Administration**
- Advise patient to swallow capsules whole, either always with or always without food.
- For those patients who can’t swallow capsules whole, carefully open capsules and sprinkle contents on applesauce and have patient swallow contents immediately without chewing.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1-2 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- **CNS:** headache, insomnia, dizziness, anxiety, confusion, agitation, **coma**  
- **EENT:** blurred vision, eye irritation, tinnitus, earache, epistaxis, sinusitis, sore throat, nasopharyngitis  
- **GI:** nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia, oral blisters, oral candidiasis, **GI hemorrhage**  
- **GU:** urinary tract infection  
- **Musculoskeletal:** arthralgia; myalgia; bone, back, neck, or limb pain  
- **Respiratory:** cough, upper respiratory tract infection

[Canada](#)  [UK](#)  [Hazardous drug](#)  [High alert drug](#)
Skin: erythema
Other: generalized pain

Interactions
Drug-drug. Oral antibiotics: interference with balsalazide action

Patient monitoring
- Assess character and frequency of stools.
- Monitor CBC and liver and kidney function test results.

Patient teaching
- Instruct patient to take drug only as directed.
- Instruct patient to carefully open capsules and sprinkle contents on applesauce and swallow contents immediately without chewing if patient can’t swallow capsules whole.
- Tell patient that teeth and tongue staining may occur when drug is taken by sprinkling on applesauce.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

Action
Blocks specific interleukin-2 (IL-2) receptor sites on activated T lymphocytes. Specific binding competitively inhibits IL-2–mediated activation and differentiation of lymphocytes responsible for cell-mediated immunity. Also impairs immunologic response to antigenic challenges.

Availability
Powder for injection: 10 mg, 20 mg in single-use vials

Indications and dosages
- Prevention of acute organ rejection in kidney transplantation

Adults and children weighing 35 kg (77 lb) or more: 20 mg I.V. 2 hours before transplantation surgery, then 20 mg I.V. 4 days after surgery. Withhold second dose if complications, hypersensitivity reaction, or graft loss occurs.

Children weighing less than 35 kg (77 lb): 10 mg I.V. 2 hours before transplantation surgery, then 10 mg I.V. 4 days after surgery. Withhold second dose if complications, hypersensitivity reaction, or graft loss occurs.

Contraindications
- Hypersensitivity to drug
- Pregnancy or breastfeeding

Precautions
Use cautiously in:
- elderly patients
- females of childbearing age.

Administration
- Give by central or peripheral I.V. route only.
- Reconstitute by adding 5 ml of sterile water for injection to vial for bolus injection, or dilute with normal saline solution or dextrose 5% in water to a volume of 50 ml and infuse over 20 to 30 minutes. Discard any
remaining product after preparing each dose.

- Don't infuse other drugs simultaneously through same I.V. line.
- Know that drug should be used only as part of regimen that includes cyclosporine and corticosteroids.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>2 hr</td>
<td>Unknown</td>
<td>36 days</td>
</tr>
</tbody>
</table>

### Adverse reactions

**CNS:** headache, insomnia, paresthesia, dizziness, drowsiness, tremor, anxiety, confusion, coma, seizures

**CV:** palpitations, edema, chest pain, ECG abnormalities, hypotension, hypertension, prolonged QT interval

**EENT:** blurred vision, eye irritation, tinnitus, earache, epistaxis, nasopharyngitis, sinusitis

**GI:** nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia, oral blisters, oral candidiasis, GI hemorrhage

**GU:** urinary incontinence, intermenstrual bleeding, oliguria, renal failure

**Hematologic:** anemia, disseminated intravascular coagulation, hemorrhage, neutropenia, thrombocytopenia

**Metabolic:** hypokalemia, hypomagnesemia, hyperglycemia, acidosis, hypoglycemia, hyperkalemia

**Musculoskeletal:** bone, back, neck, or limb pain

**Respiratory:** dyspnea, cough, hypoxia, tachypnea, hemoptysis, upper respiratory tract infection, pleural effusions

**Skin:** bruising, pruritus, dermatitis, skin lesions, diaphoresis, night sweats, erythema, hyperpigmentation, urticaria

**Other:** fever, lymphadenopathy, facial edema, bacterial infection, herpes simplex infection, injection site erythema, hypersensitivity reaction, sepsis

### Interactions

**Drug-drug.** Immunosuppressants: additive immunosuppression

**Drug-diagnostic tests.** Calcium, glucose, potassium: increased or decreased levels

Hemoglobin, neutrophils, platelets: decreased values

Triglycerides: increased levels

White blood cells: decreased levels

**Drug-herbs.** Astragalus, echinacea, melatonin: interference with immunosuppressant action

### Patient monitoring

- Watch for signs and symptoms of hypersensitivity reaction. Keep emergency drugs at hand in case these occur.
- Monitor vital signs and observe patient frequently during I.V. infusion.
- Monitor laboratory values and drug blood level.

### Patient teaching

- Teach patient about purpose of therapy. Explain that drug decreases the risk of acute organ rejection.
- Tell patient he may be more susceptible to infection because of drug's immunosuppressant effect.
- Inform patient that he'll need lifelong immunosuppressant drug therapy.
- Advise women of childbearing age to use reliable contraception before, during, and for 2 months after therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.
**beclomethasone dipropionate**

AeroBec®, Apo-Beclomethasone®, Asmabec®, Beclodisk®, Beclo forte®, Beconase AQ Nasal Spray, Filair®, Hayfever Relief®, Nasobec®, Pollenase Nasal®, QVAR, Rivanase®

**Pharmacologic class:** Corticosteroid  
**Therapeutic class:** Anti-inflammatory agent  
**Pregnancy risk category C**

**Action**
Unclear. May decrease inflammation by stabilizing leukocytic lysosomal membrane, decreasing number and activity of inflammatory cells, inhibiting bronchoconstriction (leading to direct smooth muscle relaxation), and reducing airway hyperresponsiveness.

**Availability**
*Inhalation aerosol:* 40-mcg metered inhalation in 7.3-g canister; 80-mcg metered inhalation in 7.3-g canister  
*Inhalation capsules:* 100 mcg, 200 mcg  
*Nasal spray:* 0.042% (25-g bottle containing 180 metered inhalations)

**Indications and dosages**

- **Children ages 5 to 11:** When previous therapy was bronchodilator alone, 40 mcg by oral inhalation (QVAR) b.i.d.; maximum of 80 mcg b.i.d. When previous therapy was inhaled steroid, 40 mcg by oral inhalation (QVAR) b.i.d.; maximum of 80 mcg b.i.d.
  - Seasonal or perennial rhinitis

- **Adults and children ages 12 and older:** One or two inhalations (42 to 84 mcg Beconase AQ Nasal Spray) in each nostril b.i.d.

- **Children ages 6 to 12:** One inhalation (42 mcg Beconase AQ Nasal Spray) in each nostril b.i.d.

**Contraindications**
- Hypersensitivity to drug  
- Status asthmaticus

**Precautions**
Use cautiously in:
- active untreated infections, diabetes mellitus, glaucoma, underlying immunosuppression  
- patients receiving concurrent systemic corticosteroids  
- pregnant or breastfeeding patients  
- children younger than age 6.

**Administration**
- Use spacer device to ensure proper delivery of dose and to help prevent candidiasis and hoarseness.  
- After inhalation, tell patient to hold his breath for a few seconds before exhaling.  
- For greater efficacy, wait 1 minute between inhalations.  
- If patient is also receiving a bronchodilator, administer it at least 15 minutes before beclomethasone.  
- Discontinue drug after 3 weeks if symptoms don’t improve markedly.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhalation (nasal)</td>
<td>5-7 days</td>
<td>3 wk</td>
<td>Unknown</td>
</tr>
<tr>
<td>Inhalation (oral)</td>
<td>1-4 wk</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Reactions in bold are life-threatening.
Adverse reactions
CNS: headache
EENT: cataracts, nasal irritation or congestion, epistaxis, perforated nasal septum, nasopharyngeal or oropharyngeal fungal infections, hoarseness, throat irritation
GI: esophageal candidiasis
Metabolic: adrenal suppression
Respiratory: cough, wheezing, bronchospasm
Skin: urticaria, angioedema
Other: anosmia, Churg-Strauss syndrome, hypersensitivity reactions

Interactions
None significant

Patient monitoring
- Assess patient’s mouth daily for signs of fungal infection.
- Observe patient for proper inhaler use.

Patient teaching
- Instruct patient to hold inhaled drug in airway for several seconds before exhaling and to wait 1 minute between inhalations.
- Advise patient to rinse mouth after using inhaler and to wash and dry inhaler thoroughly to help prevent fungal infections and sore throat.
- Encourage patient to document use of drug and his response in a diary.
- If patient is also using a bronchodilator, teach him to use it at least 15 minutes before beclomethasone.
- As appropriate, review all other significant and life-threatening adverse reactions.

benazepril hydrochloride
Apo-Benazepril®, Lotensin

Pharmacologic class: Angiotensin-converting enzyme (ACE) inhibitor
Therapeutic class: Antihypertensive
Pregnancy risk category C (first trimester), D (second and third trimesters)

FDA BOXED WARNING
- When used during second or third trimester of pregnancy, drug may cause fetal injury and death. Discontinue as soon as possible when pregnancy is detected.

Action
Inhibits conversion of angiotensin I to angiotensin II, a vasoconstrictor that stimulates adrenal glands and promotes aldosterone secretion, thereby reducing sodium and water reabsorption and ultimately decreasing blood pressure. Decreased angiotensin also causes increased potassium level and fluid loss.

Availability
Tablets: 5 mg, 10 mg, 20 mg, 40 mg

Indications and dosages
Hypertension
Adults: Initially, 5 to 10 mg/day P.O. as a single dose. Increase gradually to a maintenance dosage of 20 to 40 mg/day as a single dose or in two divided doses. (Start with 5 mg/day in patients receiving diuretics.)

Dosage adjustment
- Renal impairment

Off-label uses
- Myocardial infarction
- Nephropathy
Contraindications
- Hypersensitivity to drug
- Angioedema (hereditary or idiopathic)
- Pregnancy (particularly in second and third trimesters)

Precautions
Use cautiously in:
- renal or hepatic impairment, hypovolemia, hyponatremia, aortic stenosis, hypertrophic cardiomyopathy, cerebrovascular or cardiac insufficiency
- patients receiving concurrent diuretics
- black patients
- elderly patients
- breastfeeding patients
- children.

Administration
- Use extreme caution if patient has family history of angioedema.
- When giving concurrently with diuretics, know that drug may cause excessive hypotension. If possible, stop diuretic therapy 2 to 3 days before starting benazepril.
- Give with or without food.
- Know that drug may be used alone or in conjunction with other antihypertensives.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>0.5-1 hr</td>
<td>3-4 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, drowsiness, fatigue, syncope, light-headedness, headache, insomnia
CV: angina pectoris, hypotension, tachycardia
EENT: sinusitis
GI: diarrhea, nausea, anorexia
GU: proteinuria, erectile dysfunction, decreased libido, renal failure
Hematologic: agranulocytosis
Metabolic: hyperkalemia
Respiratory: cough, dyspnea, bronchitis, asthma, eosinophilic pneumonitis

Skin: rash, angioedema
Other: fever, altered taste

Interactions
Drug-drug. Allopurinol: increased risk of hypersensitivity reaction
Antacids: decreased benazepril absorption
Antihypertensives, diuretics, general anesthetics, nitrates, phenothiazines: excessive hypotension
Cyclosporine, indomethacin, potassium-sparing diuretics, potassium supplements: hyperkalemia
Lithium: increased lithium blood level, greater risk of lithium toxicity
Nonsteroidal anti-inflammatory drugs: blunting of antihypertensive response

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, potassium: increased levels
Antinuclear antibodies: positive result
Sodium: decreased level

Drug-food. Salt substitutes containing potassium: hyperkalemia

Drug-herbs. Capsaicin: cough

Drug-behaviors. Acute alcohol ingestion: increased hypotension

Patient monitoring
- Monitor for signs and symptoms of angioedema, including laryngeal edema and shock.
- Measure blood pressure regularly.
- Monitor CBC, electrolyte levels, kidney and liver function test results, and urinary protein level.

Patient teaching
- Tell patient to immediately report change in urination pattern, difficulty breathing, or swelling of throat or lips.
- Instruct patient to record blood pressure at various intervals daily.
- Tell patient to report dizziness, fainting, or light-headedness during initial therapy.

Reactions in bold are life-threatening.
Advise patient to increase fluid intake during exercise and in hot weather.
Caution patient to avoid salt substitutes, which may cause hyperkalemia.
As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

bendamustine hydrochloride
Treanda

Pharmacologic class: Alkylating agent
Therapeutic class: Antineoplastic

Pregnancy risk category D

Action
Unclear. Dissociates into electrophilic alkyl groups, which form covalent bonds with electron-rich nucleophilic moieties; bifunctional covalent linkage may cause cell death via several pathways. Acts against both quiescent and dividing cells.

Availability
Lyophilized powder for injection: 100 mg in 20-ml single-use vials (with mannitol)

Indications and dosages
➤ Chronic lymphocytic leukemia
Adults: 100 mg/m² by I.V. infusion over 30 minutes on days 1 and 2 of 28-day cycle for up to six cycles

Dosage adjustment
• Hematologic toxicity

Off-label uses
• Non-Hodgkin's lymphoma

Contraindications
• Hypersensitivity to drug or mannitol
• Creatinine clearance levels less than 40 ml/minute
• Moderate or severe hepatic impairment

Precautions
Use cautiously in:
• mild or moderate renal impairment (not recommended in creatinine clearance less than 40 ml/minute)
• mild hepatic impairment (not recommended in moderate or severe hepatic impairment)
• myelosuppression
• concurrent use of CYP1A2 inhibitors or inducers
• pregnant or breastfeeding patients
• children (safety and efficacy not established).

Administration
• Give drug by I.V. infusion only.
• Reconstitute with 20 ml sterile water for injection. Wait until powder dissolves completely (approximately 5 minutes).
• Immediately transfer (within 30 minutes of reconstitution) to 500-ml infusion bag of normal saline injection. After transferring, thoroughly mix infusion bag contents. Admixture should be clear and colorless to slightly yellow.

Stay alert for infusion reactions. Signs and symptoms include fever, chills, pruritus, and rash. Rarely, severe anaphylactic and anaphylactoid reactions have occurred. Monitor patient and discontinue drug if severe reaction arises. Consider measures to prevent severe reactions, including antihistamines, antipyretics, and corticosteroids in subsequent cycles if patient had previous infusion reaction.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>End of infusion</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Canada  UK  Hazardous drug  High alert drug
Adverse reactions

CNS: asthenia, fatigue, malaise, weakness, somnolence, headache

CV: worsening hypertension

EENT: nasopharyngitis

GI: nausea, vomiting, diarrhea, constipation, dry mouth, mucosal inflammation, stomatitis

Hematologic: myelosuppression (anemia, leukopenia, lymphopenia, neutropenia, thrombocytopenia)

Metabolic: hyperuricemia

Respiratory: cough, pneumonia

Skin: rash, pruritus, toxic skin reactions, bullous exanthema

Other: fever, chills, infection, herpes simplex, weight loss, tumor lysis syndrome, sepsis, infusion reactions and anaphylaxis, hypersensitivity reaction

Interactions

Drug-drug. CYP1A2 inducers (such as omeprazole): potentially decreased bendamustine blood level and increased active metabolite levels

CYP1A2 inhibitors (such as ciprofloxacin, fluvoxamine): potentially increased bendamustine blood level and decreased active metabolite levels

Drug-diagnostic tests. ALT, AST, bilirubin, uric acid: increased levels

Creatinine: altered level

Hemoglobin, lymphocytes, neutrophils, platelets, white blood cells: decreased levels

Potassium, uric acid: increased levels

Drug-behaviors. Smoking: potentially decreased bendamustine blood level and increased active metabolite levels

Patient monitoring

• Closely monitor complete blood count with differential and renal and hepatic function test results.

• Monitor for skin reactions, including rash, toxic reactions, and bullous exanthema. Such reactions may be progressive and worsen with further treatment. In severe or progressive skin reaction, withhold or discontinue drug.

• Watch for tumor lysis syndrome, especially during first treatment cycle. Signs and symptoms include irregular heartbeat, shortness of breath, high potassium level, high uric acid level, and impaired mental ability. Without intervention, acute renal failure and death may occur. Take preventive measures, as ordered, including maintaining adequate volume status, close monitoring of blood chemistry, and allopurinol administration during first 2 weeks of therapy in high-risk patients.

Patient teaching

• Instruct patient to report unusual bleeding or bruising, fever, chills, and lip or mouth sores.

• Inform patient that drug may increase risk of infection. Advise patient to wash hands frequently, wear mask in public places, and avoid people with infections.

• Advise female that drug may harm fetus; caution her to avoid becoming pregnant. If patient is pregnant during therapy or becomes pregnant, inform her of risk to fetus.

• Urge breastfeeding patient to seek guidance to help her decide whether to discontinue breastfeeding or discontinue drug.

• Caution male patient of drug’s potential risk to reproductive capacity.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.
benztropine mesylate
Apo-Benztropine®, Cogentin, PMS
Benztropine®

**Pharmacologic class:** Anticholinergic  
**Therapeutic class:** Antiparkinsonian  
**Pregnancy risk category C**

**Action**  
Inhibits cholinergic excitatory pathways and restores balance of dopamine and acetylcholine in CNS, thereby decreasing excess salivation, rigidity, and tremors (parkinsonian symptoms)

**Availability**  
*Injection:* 1 mg/ml in 2-ml ampules  
*Tablets:* 0.5 mg, 1 mg, 2 mg

**Indications and dosages**
- **Parkinsonism**  
  **Adults:** Initially, 1 to 2 mg/day P.O. or I.M. at bedtime or in two or four divided doses. Dosage range is 0.5 to 6 mg/day.
- **Acute dystonic reactions**  
  **Adults:** Initially, 1 to 2 mg I.M. or I.V., then 1 to 2 mg P.O. b.i.d.
- **Drug-induced extrapyramidal reactions** (except tardive dyskinesia)  
  **Adults:** 1 to 4 mg P.O. or I.M. once or twice daily

**Dosage adjustment**  
- Elderly patients

**Off-label uses**  
- Excessive salivation

**Contraindications**  
- Hypersensitivity to drug  
- Angle-closure glaucoma  
- Tardive dyskinesia  
- Children younger than age 3

**Precautions**  
Use cautiously in:  
- seizure disorders, arrhythmias, tachycardia, hypertension, hypotension, hepatic or renal dysfunction, alcoholism, prostatic hypertrophy  
- elderly patients  
- pregnant or breastfeeding patients.

**Administration**  
- Give after meals to prevent GI upset.  
- Crush tablets if patient has difficulty swallowing them.  
- Know that I.V. route is seldom used.  
- Be aware that entire dose may be given at bedtime. (Drug has long duration of action.)

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1-2 hr</td>
<td>Unknown</td>
<td>24 hr</td>
</tr>
<tr>
<td>I.V., I.M.</td>
<td>15 min</td>
<td>Unknown</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**  
**CNS:** confusion, depression, dizziness, hallucinations, headache, weakness, memory impairment, nervousness, delusions, euphoria, paresthesia, sensation of heaviness in limbs, **toxic psychosis**  
**CV:** hypotension, palpitations, **tachycardia, arrhythmias**  
**EENT:** blurred vision, diplopia, mydriasis, angle-closure glaucoma  
**GI:** nausea, constipation, dry mouth, ileus  
**GU:** urinary hesitancy or retention, dysuria, difficulty maintaining erection  
**Musculoskeletal:** paratonia, muscle weakness and cramps  
**Skin:** rash, urticaria, decreased sweating, dermatoses

**Interactions**  
**Drug-drug.** *Antacids, antidiarrheals:* decreased benztropine absorption  
*Antihistamines, bethanechol, disopyramide, phenothiazines, quinidine, tricyclic antidepressants:* additive anticholinergic effects
Drug-herbs. Angel’s trumpet, jimsonweed, scopolia: increased anticholinergic effects

Drug-behaviors. Alcohol use: increased sedation

Patient monitoring
- Monitor blood pressure closely, especially in elderly patients.
- Monitor fluid intake and output; check for urinary retention.
- Assess for signs and symptoms of ileus, including constipation and abdominal distention.

Patient teaching
- Advise patient to use caution during activities that require physical or mental alertness, because drug causes sedation.
- Tell patient to avoid increased heat exposure.
  Caution patient not to stop therapy abruptly.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, herbs, and behaviors mentioned above.

betamethasone
Betnelan®, Celestone

betamethasone acetate and sodium phosphate
Celestone Soluspan

Pharmacologic class: Glucocorticoid (inhalation)

Therapeutic class: Antiasthmatic, anti-inflammatory (steroidal)

Pregnancy risk category C

Action
Stabilizes lysosomal neutrophils and prevents their degranulation, inhibits synthesis of lipoxygenase products and prostaglandins, activates anti-inflammatory genes, and inhibits various cytokines

Availability
Solution for injection: 3 mg betamethasone sodium phosphate with 3 mg betamethasone acetate/ml
Suspension for injection (acetate, phosphate): 6 mg (total)/ml
Syrup: 0.6 mg/5 ml
Tablets: 0.6 mg
Tablets (effervescent): 0.5 mg
Tablets (extended-release): 1 mg

Indications and dosages
- Inflammatory, allergic, hematologic, neoplastic, autoimmune, and respiratory diseases; prevention of organ rejection after transplantation surgery
  Adults: 0.6 to 7.2 mg/day P.O. as single daily dose or in divided doses; or up to 9 mg I.M. of betamethasone acetate and sodium phosphate suspension.
- Bursitis or tenosynovitis
  Adults: 1 ml of suspension intrabursally
- Rheumatoid arthritis or osteoarthritis
  Adults: 0.5 to 2 ml of suspension intra-articularly

Off-label uses
- Respiratory distress syndrome

Contraindications
- Hypersensitivity to drug
- Breastfeeding

Precautions
Use cautiously in:
- systemic infections, hypertension, osteoporosis, diabetes mellitus, glaucoma, renal disease, hypothyroidism, cirrhosis, diverticulitis, thromboembolic disorders, seizures, myasthenia gravis, heart failure, ocular herpes simplex, emotional instability

Reactions in bold are life-threatening.
• patients receiving systemic corticosteroids
• pregnant patients
• children younger than age 6.

Administration
• Give as a single daily dose before 9:00 A.M.
• Give oral dose with food or milk.
• Administer I.M. injection deep into gluteal muscle (may cause tissue atrophy).
   ▶ Don’t give betamethasone acetate I.V.
• Be aware that typical suspension dosage ranges from one-third to one-half of oral dosage given q 12 hours.
   ▶ To avoid adrenal insufficiency, taper dosage slowly and under close supervision when discontinuing.
• Know that drug may be given with other immunosuppressants.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1-2 hr</td>
<td>3-25 days</td>
</tr>
<tr>
<td>I.M. (acetate/ phosphate)</td>
<td>1-3 hr</td>
<td>Unknown</td>
<td>1 wk</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, nervousness, depression, euphoria, psychoses, increased intracranial pressure
CV: hypertension, thrombophlebitis, thromboembolism
EENT: cataracts, burning and dryness of eyes, rebound nasal congestion, sneezing, epistaxis, nasal septum perforation, difficulty speaking, oropharyngeal or nasopharyngeal fungal infections
GI: nausea, vomiting, anorexia, dry mouth, esophageal candidiasis, peptic ulcers
Metabolic: decreased growth, hyperglycemia, cushingoid appearance, adrenal insufficiency or suppression
Musculoskeletal: muscle wasting, muscle pain, osteoporosis, aseptic joint necrosis
Respiratory: cough, wheezing, bronchospasm

Skin: facial edema, rash, contact dermatitis, acne, ecchymosis, hirsutism, petechiae, urticaria, angioedema
Other: loss of taste, bad taste, weight gain or loss, Churg-Strauss syndrome, increased susceptibility to infection, hypersensitivity reaction

Interactions
Drug-drug. Amphotericin B, loop and thiazide diuretics, ticarcillin: additive hypokalemia
Barbiturates, phenytoin, rifampin: stimulation of betamethasone metabolism, causing decreased drug effects
Digoxin: increased risk of digoxin toxicity
Fluoroquinolones (such as ciprofloxacin, norflaxacin): increased risk of tendon rupture
Hormonal contraceptives: blockage of betamethasone metabolism
Insulin, oral hypoglycemics: increased betamethasone dosage requirement, diminished hypoglycemic effects
Live-virus vaccines: decreased antibody response to vaccine, increased risk of neurologic complications
Nonsteroidal anti-inflammatory drugs: increased risk of adverse GI effects

Drug-diagnostic tests. Calcium, potassium: decreased levels
Cholesterol, glucose: increased levels
Nitroblue tetrazolium test for bacterial infection: false-negative result

Drug-herbs. Echinacea: increased immune-stimulating effects
Ginseng: increased immune-modulating effects

Drug-behaviors. Alcohol use: increased risk of gastric irritation and GI ulcers

Patient monitoring
• Monitor weight daily and report sudden increase, which suggests fluid retention.
• Monitor blood glucose level for hyperglycemia.
• Assess serum electrolyte levels for sodium and potassium imbalances.
• Watch for signs and symptoms of infection (which drug may mask).

Patient teaching
• Advise patient to report signs and symptoms of infection.
• Tell patient to report visual disturbances (long-term drug use may cause cataracts).
• Instruct patient to eat low-sodium, high potassium diet.
• Advise patient to carry medical identification describing drug therapy.
• Inform female patients that drug may cause menstrual irregularities.

Caution patient not to stop taking drug abruptly.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

bethanechol chloride
Duvoid®, Mytonachol®, Mytonine®, PMS-Bethanecol Chloride®, Urecholine

Pharmacologic class: Cholinergic
Therapeutic class: Urinary and GI tract stimulant
Pregnancy risk category C

Action
Stimulates parasympathetic nervous system and cholinergic receptors, leading to increased muscle tone in bladder and increased frequency of ureteral peristaltic waves. Also stimulates gastric motility, increases gastric tone, and restores rhythmic GI peristalsis.

Availability
Injection: 5 mg/ml
Tablets: 5 mg, 10 mg, 25 mg, 50 mg

Indications and dosages
➣ Postpartal and postoperative nonobstructive urinary retention; urinary retention caused by neurogenic bladder
Adults: 10 to 50 mg P.O. three to four times daily; dosage may be determined by giving 5 or 10 mg q hour until response occurs or a total of 50 mg has been given. Alternatively, 5 mg subcutaneously three to four times daily; dosage may be determined by giving 2.5 mg subcutaneously q 15 to 30 minutes until response occurs or a total of four doses has been given.

Contraindications
• Hypersensitivity to drug
• GI or GU tract obstruction
• Hyperthyroidism
• Active or latent asthma
• Bradycardia
• Hypotension
• Atrioventricular conduction defects
• Coronary artery disease
• Seizure disorders
• Parkinsonism
• Peptic ulcer disease

Precautions
Use cautiously in:
• sensitivity to cholinergics or their effects and tartrazine (some products)
• pregnant or breastfeeding patients
• children.

Administration
• Give drug on empty stomach 1 hour before or 2 hours after a meal to help prevent nausea and vomiting.

Don’t give I.M or I.V. Doing so may cause severe symptoms of cholinergic overstimulation, including circulatory collapse and cardiac arrest.
• Keep atropine on hand to counteract severe adverse effects.

Route Onset Peak Duration
P.O. 30-90 min 1 hr 6 hr
Subcut. 5-15 min 15-30 min 2 hr

Reactions in bold are life-threatening.
Adverse reactions
CNS: headache, malaise, seizures
CV: bradycardia, hypotension, heart block, syncope with cardiac arrest
EENT: excessive lacrimation, miosis
GI: nausea, vomiting, diarrhea, abdominal discomfort, belching
GU: urinary urgency
Respiratory: increased bronchial secretions, bronchospasm
Skin: diaphoresis, flushing
Other: hypothermia

Interactions
Drug-drug. Anticholinergics: decreased bethanechol efficacy
Cholinesterase inhibitors: additive cholinergic effects
Depolarizing neuromuscular blockers: decreased blood pressure
Ganglionic blockers: severe hypotension
Procainamide, quinidine: antagonism of cholinergic effects
Drug-herbs. Angel's trumpet, jimsonweed, scopolia: antagonism of cholinergic effects

Patient monitoring
- Monitor blood pressure. Be aware that hypertensive patients may experience sudden blood pressure drop.
- Stay alert for orthostatic hypotension, a common adverse effect.
- Monitor vital signs and respiration for 30 to 60 minutes after subcutaneous injection.
- Monitor fluid intake and output and residual urine volume.

Patient teaching
- Tell patient that drug is usually effective within 90 minutes of administration.
- Advise patient to take oral dose on empty stomach 1 hour before or 2 hours after a meal to avoid GI upset.
- Instruct patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness from blood pressure decrease.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

bevacizumab
Avastin

Pharmacologic class: Monoclonal antibody
Therapeutic class: Immunologic agent
Pregnancy risk category C

FDA BOXED WARNING
- Drug may cause GI perforation, in some cases leading to death. Include such perforation in differential diagnosis of patients who experience abdominal pain during therapy. Discontinue permanently in patients with GI perforation.
- Drug may lead to potentially fatal wound dehiscence. Discontinue permanently in patients with wound dehiscence requiring medical intervention.
- Serious and, in some cases fatal, hemoptysis has occurred in patients with non-small-cell lung cancer who received chemotherapy and bevacizumab. Don’t give to patients with recent hemoptysis.

Action
Binds to vascular endothelial growth factor, preventing or reducing microvascular formation and growth and inhibiting metastatic disease progression

Availability
Solution for injection: 25 mg/ml in 4-ml and 16-ml vials
**Indications and dosages**

First-line treatment of metastatic cancer of colon or rectum (used in combination with 5-fluorouracil [5-FU]-based chemotherapy)

**Adults:** 5 mg/kg I.V. infusion q 14 days until disease progression occurs when used with 5-FU, irinotecan, and leucovorin or 10 mg/kg I.V. infusion q 14 days until disease progression occurs when used with 5-FU, oxaliplatin, and leucovorin

Unresectable, locally advanced, recurrent or metastatic nonsquamous, non-small-cell lung cancer

**Adults:** 15 mg/kg I.V. infusion q 3 weeks

**Contraindications**

None

**Precautions**

Use cautiously in:
- hypersensitivity to drug
- cardiovascular disease
- development of immunogenicity
- patients sensitive to infusion reactions
- patients recovering from major surgery
- recent history of hemoptysis (Don’t administer drug.)
- patients with proteinuria
- elderly patients
- pregnant or breastfeeding patients
- children.

**Administration**

- Withdraw necessary amount to obtain required dose, and dilute in 100 ml of 0.9% sodium chloride injection.
- Don’t mix or administer drug with dextrose solutions.
- Don’t deliver by I.V. push or bolus.
- Initially, infuse drug over 90 minutes. If patient tolerates infusion well, infuse over 60 minutes the second time; if he continues to tolerate it well, infuse each dose over 30 minutes thereafter.

- Withhold dose if hypertension occurs.
- Stop infusion if patient develops hypertensive crisis, severe bleeding, abdominal pain (may signal intra-abdominal abscess or GI perforation), wound dehiscence, or urinary problems.
- Be aware that drug shouldn’t be given within 28 days after major surgery and that therapy should be suspended several weeks before elective surgery.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: asthenia, dizziness, headache, confusion, syncope, abnormal gait, reversible leukoencephalopathy syndrome

CV: hypotension, hypertension, hypertensive crisis, heart failure, deep-vein thrombosis, intra-abdominal thrombosis, thromboembolism

EENT: excess lacrimation, visual disturbances, severe epistaxis

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, stomatitis, dyspepsia, flatulence, colitis, dry mouth, anorexia, GI perforation, intra-abdominal abscess

GU: proteinuria, urinary frequency or urgency, nephrotic syndrome

Hematologic: leukopenia, neutropenia, hemorrhage

Hepatic: bilirubinemia

Metabolic: hypokalemia, hyponatremia

Musculoskeletal: myalgia

Respiratory: upper respiratory tract infection, dyspnea, massive hemoptysis

Skin: wound-healing complications, wound dehiscence

Other: abnormal taste, altered voice, pain, weight loss, transfusion reaction

**Interactions**

Drug-drug. *Irinotecan:* increased concentration of irinotecan metabolite

Reactions in bold are life-threatening.

Clinical alert
Drug-diagnostic tests. Leukocytes, potassium, sodium: decreased levels
Urine protein: increased level

Patient monitoring
- Monitor patient closely for signs and symptoms of thromboembolism and GI perforation (such as abdominal pain, vomiting, and constipation).
- Stay alert for delayed wound healing and wound dehiscence.
  - Assess blood pressure frequently.
  - Monitor CBC with differential and urine protein and serum electrolyte levels.

Patient teaching
- Tell patient to call prescriber immediately if he experiences dizziness, severe bleeding, stomach pain, or urinary problems or if a wound opens.
  - Instruct patient to tell prescriber if he has been exposed to chickenpox or if he has gout, heart disease, viral infection, urinary problems, hepatic disease, or another form of cancer.
  - Advise patient to tell prescriber if he has surgery planned; drug may delay wound healing.
  - Caution patient not to get immunizations unless prescriber approves.
  - Instruct female patient to tell prescriber if she is pregnant, plans to become pregnant, or is breast-feeding.
  - As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

bicalutamide

Apo-Bicalutamide,* Casodex, Dom-Bicalutamide,* Gen-Bicalutamide,* Novo-Bicalutamide,* PHL-Bicalutamide,* PMS-Bicalutamide,* Ratio-Bicalutamide,* Sandoz Bicalutamide

Pharmacologic class: Nonsteroidal antiandrogen
Therapeutic class: Antineoplastic
Pregnancy risk category X

Action
Antagonizes effects of androgen at cellular level by binding to androgen receptors on target tissues

Availability
Tablets: 50 mg

Indications and dosages
Metastatic prostate cancer
Adults: 50 mg P.O. once daily

Contraindications
- Hypersensitivity to drug
- Women who are or may become pregnant

Precautions
Use cautiously in:
- previous hypersensitivity or serious adverse reaction to flutamide or nilutamide
- moderate to severe hepatic impairment
- children.

Administration
- Know that drug is given in combination with luteinizing hormone-releasing hormone (LHRH).
- Administer at same time each day.
**Route** | **Onset** | **Peak** | **Duration**
---|---|---|---
P.O. | Unknown | 31 hr | Unknown

### Adverse reactions

**CNS:** headache, weakness, dizziness, depression, hypertonia, paresthesia, lethargy  
**CV:** chest pain, peripheral edema, vasodilation, hypertension, **thromboembolic disease**  
**EENT:** pharyngitis, bronchitis  
**GI:** nausea, vomiting, diarrhea, constipation, abdominal pain, anorexia, dry mouth  
**GU:** urinary tract infection, impotence  
**Musculoskeletal:** bone and back pain  
**Respiratory:** dyspnea, cough  
**Skin:** rash, alopecia  
**Other:** food distaste, weight gain, edema, pain, hot flashes, flulike symptoms

### Interactions

**Drug-drug.** Warfarin: increased bicalutamide effects  
**Drug-diagnostic tests.** Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, cholesterol, BUN, creatinine: increased levels  
**Hemoglobin, white blood cells:** decreased values

### Patient monitoring
- Monitor prostate-significant antigen levels, CBC, and liver and kidney function test results.  
- If patient is receiving warfarin concurrently, evaluate prothrombin time and International Normalized Ratio.

### Patient teaching
- Instruct patient to take drug at same time each day, along with prescribed LHRH analog.  
- Tell patient that any drug-related hair loss should reverse once therapy ends.  
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

### bisacodyl

**Alophen, Apo-Bisacodyl, Biolax, Bisac-Evac, Carter’s Little Pills, Correctol, Doxidan, Dulcolax, Femilax, Fleet Stimulant Laxative, Gent lax, Laxoberal**

**Pharmacologic class:** Stimulant laxative  
**Therapeutic class:** Laxative  
**Pregnancy risk category B**

### Action

Unclear. Thought to stimulate colonic mucosa, producing parasympathetic reflexes that enhance peristalsis and increase water and electrolyte secretion, thereby causing evacuation of colon.

### Availability

**Enema:** 0.33 mg/ml, 10 mg/ml  
**Powder for rectal solution:** 1.5 mg bisacodyl and 2.5 g tannic acid  
**Suppositories (rectal):** 5 mg, 10 mg  
**Tablets (enteric-coated):** 5 mg

### Indications and dosages

- Constipation; bowel cleansing for childbirth, surgery, and endoscopic examination

**Adults and children ages 12 and older:** 5 to 15 mg P.O. or 10 mg P.R. as a single dose  
**Children older than age 3:** 5 to 10 mg or 0.3 mg/kg P.O. as a single dose  
**Children ages 2 and older:** 5 to 10 mg P.R. as a single dose  
**Children younger than age 2:** 5 mg P.R. as a single dose

Reactions in **bold** are life-threatening.
Contraindications
- Hypersensitivity to drug
- Intestinal obstruction
- Gastroenteritis
- Appendicitis

Precautions
Use cautiously in:
- hypersensitivity to tannic acid
- severe cardiovascular disease, anal or rectal fissures
- pregnant or breastfeeding patients.

Administration
- Make sure patient swallows tablets whole without chewing.
- Don’t give tablets within 1 hour of dairy products or antacids (may break down enteric coating).
- Know that drug should be used only for short periods.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>6-12 hr</td>
<td>Variable</td>
<td>Variable</td>
</tr>
<tr>
<td>P.R.</td>
<td>15-60 min</td>
<td>Variable</td>
<td>Variable</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, syncope
GI: nausea, vomiting, diarrhea (with high doses), abdominal pain, burning sensation in rectum (with suppositories), laxative dependence, protein-losing enteropathy
Metabolic: hypokalemia, fluid and electrolyte imbalances, tetany, alkalosis
Musculoskeletal: muscle weakness (with excessive use)

Interactions
Drug-drug. Antacids: gastric irritation, dyspepsia
Drug-diagnostic tests. Calcium, magnesium, potassium: decreased levels Phosphate, sodium: increased levels
Drug-food. Dairy products: gastric irritation

Patient monitoring
- Assess stools for frequency and consistency.
- Monitor patient for electrolyte imbalances and dehydration.

Patient teaching
- Instruct patient to swallow (not chew) enteric-coated tablets no sooner than 1 hour before or after ingesting antacids or dairy products. Tell him not to chew tablets.
- Advise patient not to use bisacodyl or other laxatives habitually because this may lead to laxative dependence.
- Suggest other ways to prevent constipation, such as by eating more fruits, vegetables, and whole grains to increase dietary bulk and by drinking 8 to 10 glasses of water daily.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

bismuth subsalicylate
Bismatrol, Bismatrol Maximum Strength, Diotame, Kao-Tin, Kaopectate, Kaopectate Extra Strength, Kaopectol, Malax Total Stomach Relief, Pepto-Bismol, Pepto-Bismol Bismuth Maximum Strength, Pink Bismuth

Pharmacologic class: Adsorbent
Therapeutic class: Antidiarrheal, antibiotic, antiulcer drug
Pregnancy risk category C

Action
Promotes intestinal adsorption of fluids and electrolytes and decreases synthesis of intestinal prostaglandins.
Adsorbent action removes irritants from stomach and soothes irritated bowel lining. Also shows antibacterial activity to eradicate *Helicobacter pylori*.

**Availability**
*Liquid*: 130 mg/15 ml, 262 mg/15 ml, 525 mg/15 ml (maximum strength)
*Tablets*: 262 mg
*Tablets (chewable)*: 262 mg, 300 mg

**Indications and dosages**

> Adjunctive therapy for mild to moderate diarrhea, nausea, abdominal cramping, heartburn, and indigestion accompanying diarrheal illnesses

**Adults**: Two tablets or 30 ml P.O. (15 ml of maximum strength) q 30 minutes, or two tablets or 60 ml (30 ml of extra/ maximum strength) q 60 minutes as needed. Don’t exceed 4.2 g in 24 hours.

**Children ages 9 to 12**: One tablet or 15 ml P.O. (7.5 ml of maximum strength) q 30 to 60 minutes. Don’t exceed 2.1 g in 24 hours.

**Children ages 6 to 9**: 10 ml (5 ml of maximum strength) P.O. q 30 to 60 minutes. Don’t exceed 1.4 g in 24 hours.

**Children ages 3 to 6**: 5 ml (2.5 ml of maximum strength) P.O. q 30 to 60 minutes. Don’t exceed 704 mg in 24 hours.

Uter disease caused by *H. pylori*

**Adults**: Two tablets or 30 ml P.O. q.i.d. (15 ml of maximum strength)

**Off-label uses**
- Chronic infantile diarrhea
- Norwalk virus–induced gastroenteritis

**Contraindications**
- Hypersensitivity to aspirin
- Elderly patients with fecal impaction
- Children or adolescents during or after recovery from chickenpox or flulike illness

**Precautions**
Use cautiously in:
- diabetes mellitus, gout
- patients taking concurrent aspirin
- elderly patients
- pregnant or breastfeeding patients
- infants.

**Administration**
- Know that tablets should be chewed or dissolved in mouth before swallowing.
- Be aware that drug is usually given with antibiotics (such as tetracycline or amoxicillin) when prescribed for ulcer disease.

**Route** | **Onset** | **Peak** | **Duration**
---|---|---|---
P.O. | 1 hr | Unknown | Unknown

**Adverse reactions**

| EENT: | tinnitus, tongue discoloration |
| GI: | nausea, vomiting, diarrhea, constipation, gray-black stools, fecal impaction |
| Respiratory: | tachypnea |
| Other: | salicylate toxicity |

**Interactions**

- **Drug-drug**: *Aspirin, other salicylates*: salicylate toxicity
  *Corticosteroids, probenecid (large doses), sulfinpyrazone*: decreased bismuth efficacy
  *Enoxacin*: decreased enoxacin bioavailability
  *Methotrexate*: increased risk of bismuth toxicity
  *Tetracycline*: decreased tetracycline absorption

- **Drug-diagnostic tests**: *Radiologic GI tract examination*: test interference

**Patient monitoring**
- Monitor fluid intake and electrolyte levels.
- Monitor stool frequency and appearance.
- Assess infants and debilitated patients for fecal impaction.

Reactions in **bold** are life-threatening.
Patient teaching
- Instruct patient to chew tablets or dissolve them in mouth before swallowing.
- Inform patient that drug may turn stools gray-black temporarily.
- Tell patient to notify prescriber if he has diarrhea with fever for more than 48 hours.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Dosage adjustment
- Renal or hepatic impairment

Contraindications
- Hypersensitivity to drug
- Sinus bradycardia
- Second- or third-degree heart block
- Cardiogenic shock
- Heart failure
- Children (safety and efficacy not established)

Precautions
Use cautiously in:
- renal or hepatic impairment, pulmonary disease, asthma, diabetes mellitus, thyrotoxicosis, peripheral vascular disease
- patients undergoing anesthesia or major surgery
- elderly patients
- pregnant or breastfeeding patients.

Administration
- Give with or without food, but be consistent to minimize variations in absorption.
- Be aware that drug may be given alone or added to diuretic therapy.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30-60 min</td>
<td>2 hr</td>
<td>12-15 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, depression, paresthesia, sleep disturbances, hallucinations, memory loss, slurred speech
CV: bradycardia, peripheral vascular insufficiency, claudication, hypotension, sinoatrial or atrioventricular (AV) node block, second- or third-degree heart block, heart failure, pulmonary edema, cerebrovascular accident, arrhythmias
EENT: blurred vision, dry eyes, conjunctivitis, tinnitus, rhinitis, pharyngitis
GI: nausea, vomiting, diarrhea, constipation, gastric pain, gastritis, flatulence, anorexia, ischemic colitis, acute

bisoprolol fumarate
Apo-Bisoprolol, Bisoprolol, Cardicor, Emcor, Emcor LS, Monocor, Novo-Bisoprolol, PMS-Bisoprolol, Sandoz Bisoprolol, Zebeta

Pharmacologic class: Beta1-adrenergic blocker
Therapeutic class: Antihypertensive
Pregnancy risk category C

Action
Blocks beta1-adrenergic receptors of sympathetic nervous system in heart and kidney, thereby decreasing myocardial excitability, myocardial oxygen consumption, cardiac output, and renin release from kidney. Also lowers blood pressure without affecting beta2-adrenergic (pulmonary, vascular, and uterine) receptor sites.

Availability
Tablets: 5 mg, 10 mg

Indications and dosages
Hypertension
Adults: Initially, 2.5 to 5 mg P.O. daily. Dosages up to 20 mg P.O. daily have been used.
bivalirudin

**Pharmacologic class:** Thrombin inhibitor

**Therapeutic class:** Anticoagulant

**Pregnancy risk category B**

**Action**

Selectively inhibits thrombin by binding to its receptor sites, causing inactivation
of coagulation factors V, VIII, and XII and thus preventing conversion of fibrinogen to fibrin

Availability
Powder for injection: 250 mg/vial

Indications and dosages
» Patients with unstable angina who are undergoing percutaneous transluminal coronary angioplasty (PTCA); patients with or at risk for heparin-induced thrombocytopenia or heparin-induced thrombocytopenia and thrombosis syndrome undergoing percutaneous coronary intervention
Adults: 0.75 mg by I.V. bolus followed by 1.75 mg/kg/hour by I.V. infusion for duration of procedure. Five minutes after bolus is administered, an activated clotting time should be obtained and an additional bolus of 0.3 mg/kg should be given if needed. Continuation of infusion for up to 4 hours postprocedure is optional, and at discretion of treating physician. After 4 hours, an additional I.V. infusion may be initiated at rate of 0.2 mg/kg/hour for up to 20 hours if needed.

Dosage adjustment
• Renal impairment
• Dialysis patients

Off-label uses
• PCTA (regardless of history of unstable angina)
• Anticoagulation during orthopedic surgery

Contraindications
• Hypersensitivity to drug
• Active major bleeding

Precautions
Use cautiously in:
• renal impairment, severe hepatic dysfunction, bacterial endocarditis, cerebrovascular accident, severe hypertension, heparin-induced thrombocytopenia, thrombosis syndrome
• diseases associated with increased risk of bleeding
• concurrent use of other platelet aggregation inhibitors
• pregnant or breastfeeding patients
• children.

Administration
• For I.V. injection and infusion, add 5 ml of sterile water to each 250-mg vial; gently mix until dissolved. Further dilute in 50 ml of dextrose 5% in water or normal saline solution for injection to a final concentration of 5 mg/ml.
• Don’t mix with other drugs.
• Don’t give by I.M. route.
• Know that drug is intended for use with aspirin.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>Immediate</td>
<td>1-2 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, anxiety, nervousness, insomnia
CV: hypotension, hypertension, bradycardia, ventricular fibrillation
GI: nausea, vomiting, abdominal pain, dyspepsia, severe spontaneous GI bleeding
GU: urinary retention, severe spontaneous GU bleeding
Hematologic: severe spontaneous bleeding
Musculoskeletal: pelvic or back pain
Other: fever, pain at injection site

Interactions
Drug-drug. Abciximab, anticoagulants (including heparin, low-molecular-weight heparins, and heparinoids), thrombolytics, ticlopidine, warfarin: increased risk of bleeding
Drug-diagnostic tests. Activated partial thromboplastin time, prothrombin time: increased
Drug-herbs. Ginkgo biloba: increased risk of bleeding
**Patient monitoring**

- Monitor blood pressure, hemoglobin, and hematocrit. Be aware that decrease in blood pressure or hematocrit may signal hemorrhagic event.
- Monitor venipuncture site closely for bleeding.

**Patient teaching**

- Instruct patient to immediately report bleeding, bruising, or tarry stools.
- Tell patient to avoid activities that can cause injury. Advise him to use soft toothbrush and electric razor to avoid gum and skin injury.

**bleomycin sulfate**

Blenoxane

**Pharmacologic class:** Antitumor antibiotic

**Therapeutic class:** Antineoplastic

**Pregnancy risk category D**

**FDA BOXED WARNING**

- Give under supervision of physician in facility with adequate diagnostic and treatment resources.
- Pulmonary fibrosis is most severe toxicity, and most often presents as pneumonitis progressing to pulmonary fibrosis. Occurrence is highest in elderly patients and those receiving more than 400 units total dose.

**Action**

Unclear. Appears to inhibit DNA synthesis and, to a lesser degree, RNA and protein synthesis. Binds to DNA, causing severing of single DNA strands.

**Availability**

*Injection:* 15-unit vials, 30-unit vials

**Indications and dosages**

- **Hodgkin's lymphoma**
  - **Adults:** 10 to 20 units/m² I.V., I.M., or subcutaneously once or twice weekly. After 50% response, maintenance dosage is 1 unit/m² I.M. or I.V. daily or 5 units/m² I.M. or I.V. weekly.

- **Malignant pleural effusion; prevention of recurrent pleural effusions**
  - **Adults:** 60 units dissolved in 50 to 100 mg of normal saline solution, given through thoracostomy tube

- **Squamous cell carcinoma of head, neck, skin, penis, cervix, or vulva; non-Hodgkin’s lymphoma; testicular carcinoma**
  - **Adults and children ages 12 and older:** 10 to 20 units/m² I.V., I.M., or subcutaneously once or twice weekly.

**Dosage adjustment**

- Renal impairment
- Elderly patients

**Off-label uses**

- Esophageal carcinoma
- Hemangioma
- AIDS-related Kaposi’s sarcoma
- Osteosarcoma
- Verrucous carcinoma
- Warts

**Contraindications**

- Hypersensitivity to drug
- Pregnancy or breastfeeding

**Precautions**

Use cautiously in:

- renal or pulmonary impairment
- elderly patients
- females of childbearing age

**Administration**

- Wash hands before and after preparing drug; wear gloves during handling and preparation.
- For I.M. or subcutaneous use, reconstitute 15-unit vial with 1 to 5 ml and 30-unit vial with 2 to 10 ml of sterile water for injection, normal saline.
solution for injection, or bacteriostatic water for injection.
- For I.V. infusion, dissolve contents of 15- or 30-unit vial in 5 or 10 ml, respectively, of normal saline solution for injection.
- For intrapleural use, dissolve each 60 units in 50 to 100 ml of normal saline solution for injection, then administer through thoracostomy tube. Clamp tube after instilling drug. During next 4 hours, reposition patient from supine to right and left lateral positions several times. Then unclamp tube and restart suction.
- Premedicate patient with aspirin, as prescribed, to reduce risk of drug fever.

Know that cumulative dosages above 400 units should be given with extreme caution because of increased risk of pulmonary toxicity.

Know that in patients with lymphoma, anaphylactoid reaction may occur. Such patients should receive 2 units or less for the first two doses. If no reaction occurs, recommended doses may be given.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>10-20 min</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.M., subcut.</td>
<td>15-20 min</td>
<td>30-60 min</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: disorientation, weakness, aggressive behavior
CV: hypotension, peripheral vasoconstriction
GI: vomiting, diarrhea, anorexia, stomatitis
Hematologic: anemia, leukopenia, thrombocytopenia
Hepatic: hepatotoxicity
Metabolic: hyperuricemia
Respiratory: dyspnea, crackles, pulmonary fibrosis, pneumonitis
Skin: alopecia, erythema, rash, urticaria, vesicles, striae, hyperpigmentation, mucocutaneous toxicity
Other: fever, chills, weight loss, anaphylactic reaction

Interactions
Drug-drug. Anesthetics: increased oxygen requirement
Antineoplastics: increased risk of hematologic and pulmonary toxicity
Cardiac glycosides: decreased cardiac glycoside blood level
Cisplatin: decreased bleomycin elimination, increased risk of toxicity
Fosphenytoin, phenytoin: decreased blood levels of these drugs
Vinblastine: increased risk of Raynaud’s syndrome

Drug-diagnostic tests. Uric acid: increased level

Patient monitoring
- Assess baseline pulmonary function status before initiating therapy; monitor throughout therapy.
- Monitor chest X-rays and assess breath sounds to detect signs of pulmonary toxicity.
- Assess oral cavity for sores, ulcers, pain, and bleeding.
- Monitor infusion site for irritation, burning, and signs of infection.
- Evaluate closely for signs and symptoms of drug fever.

Patient teaching
- Tell patient to avoid spicy, hot, or rough foods (may cause GI upset).
- Urge patient to use reliable contraceptive method during therapy.
- Tell patient not to receive vaccinations without consulting prescriber.
- Instruct patient to immediately notify prescriber if breathing difficulties, fever, or chills occur.
- Tell patient to avoid activities that can cause injury. Advise him to use soft toothbrush and electric razor to avoid gum and skin injury.
- Inform patient that drug may cause hair loss but that hair will grow back after treatment ends.
- As appropriate, review all other significant and life-threatening adverse
reactions and interactions, especially those related to the drugs and tests mentioned above.

bortezomib
Velcade

Pharmacologic class: Proteasome inhibitor
Therapeutic class: Antineoplastic
Pregnancy risk category D

Action
Inhibits proteasomes (enzyme complexes that regulate protein homeostasis within cells). Reversibly inhibits chymotrypsin-like activity at 26S proteasome, leading to activation of signaling cascades, cell-cycle arrest, and apoptosis.

Availability
Powder for reconstitution (preservative-free): 3.5 mg (contains 35 mg of mannitol)

Indications and dosages
Relapsed multiple myeloma, patients with mantle cell lymphoma who have received at least one prior therapy
Adults: 1.3 mg/m² I.V. twice weekly for 2 weeks (days 1, 4, 8, and 11), followed by 10-day rest period (days 12 to 21). Allow at least 72 hours to elapse between doses. One treatment cycle equals 21 days (3 weeks).

Dosage adjustments
- Peripheral neuropathy
- Grade 3 nonhematologic events
- Grade 4 hematologic events

Contraindications
- Hypersensitivity to drug, mannitol, or boron
- Pregnancy or breastfeeding

Precautions
Use cautiously in:
- peripheral neuropathy, dehydration, hepatic or renal impairment
- history of syncope or cardiovascular disorders
- children.

Administration
- Reconstitute drug in vial with 3.5 ml of normal saline for injection.
- Give by I.V. push over 3 to 5 seconds.
- Reconstituted solution must be used within 8 hours.

Route Onset Peak Duration
I.V. Unknown Unknown Unknown

Adverse reactions
CNS: headache, insomnia, dizziness, anxiety, peripheral neuropathy
CV: tachycardia, hypotension
EENT: throat tightness
GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia
Hematologic: eosinophilia, anemia, thrombocytopenia, neutropenia
Metabolic: dehydration, pyrexia
Respiratory: cough, dyspnea, upper respiratory tract infection
Skin: rash, pruritus, urticaria
Other: altered taste, increased or decreased appetite, fever, chills, edema

Interactions
Drug-drug. CYP3A4 inducers (including amiodarone, carbamazepine, nefirapine, phenobarbital, phenytoin, and rifampin): possible decrease in bortezomib serum level and efficacy
CYP3A4 inhibitors (including amiodarone, cimetidine, clarithromycin, delavirdine, diltiazem, disulfiram,

Reactions in bold are life-threatening.

Clinical alert
**erythromycin, fluoxetine, fluvoxamine, nefazodone, nevirapine, propoxyphene, quinupristin, verapamil, zafirlukast, and zileuton:** possible increase in bortezomib serum level and efficacy

**Drug-food.** *Grapefruit juice:* increased bortezomib blood level, greater risk of toxicity

**Patient monitoring**
- Monitor vital signs and temperature. Especially watch for tachycardia, fever, and hypotension.
- Monitor nutritional and hydration status for changes caused by GI adverse effects.
- Monitor CBC with white cell differential, and watch for signs and symptoms of blood dyscrasias.
- Monitor respiratory status, watching for dyspnea, cough, and other signs and symptoms of upper respiratory tract infection.

**Patient teaching**
- Inform patient that drug can cause serious blood dyscrasias. Teach him which signs and symptoms to report right away.
- Tell patient drug may cause other significant adverse reactions. Reassure him he will be closely monitored.
- Instruct patient to move slowly when sitting or standing up to avoid dizziness or light-headedness from sudden blood pressure drop.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Advise patient to minimize adverse GI effects by eating small frequent servings of healthy food and ensuring adequate fluid intake.
- Tell patient to immediately report signs and symptoms of upper respiratory tract infection.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and foods mentioned above.

---

**bosentan**

**Tracleer**

**Pharmacologic class:** Endothelin-receptor antagonist, vasodilator

**Therapeutic class:** Antihypertensive

**Pregnancy risk category X**

**FDA BOXED WARNING**
- Drug causes at least 3 x ULN (upper limit of normal) of alanine aminotransferase and aspartate aminotransferase levels in about 11% of patients (along with elevated bilirubin in a few cases). These changes indicate potentially serious hepatic injury. Obtain serum transaminase levels before therapy begins and then monthly.
- Transaminase elevations warrant close attention. Avoid giving drug to patients with baseline transaminase levels more than 3 x ULN, because monitoring for hepatic injury may be more difficult. Stop therapy if transaminase elevations are accompanied by indications of hepatic injury or if bilirubin level is 2 x ULN or higher.
- Rare postmarketing cases of unexplained hepatic cirrhosis occurred after prolonged therapy in patients with multiple comorbidities and drug therapies.
- Drug is contraindicated in pregnancy because it’s likely to cause major birth defects. Exclude pregnancy before therapy starts, and instruct patient to use reliable contraceptive method. Caution patient not to use hormonal contraceptives alone, because drug may render these ineffective; instruct her to use additional forms of contraception. Obtain monthly pregnancy tests.
Because of potential hepatic injury and to reduce risk of fetal exposure, drug may be prescribed only through Tracleer Access Program.

**Action**
Binds to and blocks receptor sites for endothelin A and B in endothelium and vascular smooth muscle. This action reduces elevated endothelin levels in patients with pulmonary arterial hypertension, and inhibits vasoconstriction resulting from endothelin-1 (ET-1).

**Availability**
*Tablets: 62.5 mg, 125 mg*

**Indications and dosages**
➢ To improve exercise ability and slow clinical deterioration in patients with pulmonary arterial hypertension who have World Health Organization class III or class IV symptoms

**Adults:** Initially, 62.5 mg P.O. b.i.d. for 4 weeks; increase to maintenance dosage of 125 mg P.O. b.i.d. In patients older than age 12 who weigh less than 40 kg (88 lb), initial and maintenance dosages are 62.5 mg b.i.d.

**Dosage adjustment**
• Moderate to severe hepatic dysfunction
• Hepatic injury in patients with alanine aminotransferase or aspartate aminotransferase elevations

**Contraindications**
• Hypersensitivity to drug
• Severe hepatic impairment
• Patients receiving concurrent cyclosporine or glyburide
• Pregnancy or breastfeeding
• Children younger than age 12 (safety and efficacy not established)

**Precautions**
Use cautiously in:
• mitral stenosis
• elderly patients.

---

**Administration**
• Give tablets in morning and evening, with or without food.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Variable</td>
<td>3-5 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
CNS: headache, fatigue
CV: edema, hypotension, palpitations
EENT: nasopharyngitis
GI: dyspepsia
Hepatic: hepatic dysfunction, hepatic injury, hepatotoxicity
Skin: pruritus, flushing

**Interactions**
**Drug-drug.** Cyclosporine: decreased cyclosporine blood level, increased bosentan blood level
Glyburide: decreased blood levels of both drugs, increased risk of hepatic damage
Hormonal contraceptives: decreased bosentan efficacy
Ketoconazole: increased bosentan blood level and effects
Simvastatin and other statins: decreased effects of these drugs

**Drug-diagnostic tests.** Hematocrit, hemoglobin: decreased values
Transaminases: increased values

**Patient monitoring**
• Assess serum transaminase levels within first 3 days of therapy and then monthly.
• Evaluate hemoglobin level 1 month after therapy and then every 3 months.
• Assess female patient for pregnancy every month during therapy.

**Patient teaching**
• Tell patient to take drug with or without food in morning and evening.
• Caution female patient to avoid pregnancy, and discuss reliable contraceptive methods. Instruct her to
contact prescriber immediately if she thinks she may be pregnant.

- Inform patient that he’ll undergo CBC measurement and liver function testing regularly during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

botulinum toxin type A
Botox, Botox Cosmetic, Vistabel®, Xeomin®

botulinum toxin type B
Myobloc, NeuroBloc®

Pharmacologic class: Neurotoxin
Therapeutic class: Neuromuscular blocker
Pregnancy risk category C

Action
Blocks neuromuscular transmission by binding to receptor sites on motor nerve terminals and inhibiting acetylcholine release, thereby causing localized muscle denervation. As a result, local muscle paralysis occurs, which leads to muscle atrophy and reinnervation due to development of new acetylcholine receptors.

Availability
Toxin type A—
Powder for injection: 100 units/vial
Toxin type B—
Solution for injection: 5,000-units/ml vial

Indications and dosages
Toxin type A
➢ Temporary improvement in appearance of moderate to severe glabellar lines associated with corrugator or procerus muscle activity

Adults ages 65 and younger: Botox cosmetic only—Total of 20 units (0.5-ml solution) injected I.M. as divided doses of 0.1 ml into each of five sites: two in each corrugator muscle and one in procerus muscle. Injection usually needs to be repeated q 3 to 4 months to maintain effect.

➢ Blepharospasm
Adults: 1.25 to 2.5 units injected into medial and lateral pretarsal orbicularis oculi of upper eyelid and lateral pretarsal orbicularis oculi of lower eyelid

➢ Strabismus
Adults: 1.25 to 5 units injected into eyelid (dosage varies with strabismus severity). Dose can be repeated in 7 to 14 days if patient has adequate response; with inadequate response, dosage may be doubled.

Toxin types A and B
➢ To relax skeletal muscles and reduce severity of abnormal head position and neck pain associated with cervical dystonia

Adults: Botox—Usual dosage is 236 units injected I.M. locally into affected muscles. Dosage ranges from 198 to 300 units. Myobloc—2,500 to 5,000 units I.M. injected locally into affected muscles.

Contraindications
- Hypersensitivity to drug
- Active infection at injection site

Precautions
Use cautiously in:
- cardiovascular disease, peripheral neuropathy, neuromuscular disorders
- inflammation at injection site
- pregnant or breastfeeding patient
- children younger than age 12.

Administration
Toxin type A
- Reconstitute toxin type A by slowly injecting preservative-free normal saline solution into drug vial.
- Rotate vial gently to mix drug; then draw up at least 20 units (0.5-ml solution) and expel air bubbles.
- Remove needle used for reconstitution, and attach 30G needle. Then inject drug as divided doses of 0.1 ml into each of five sites (two in each corrugator muscle, one in procerus muscle).
- Prepare eye with several drops of local anesthetic and ocular decongestant, as prescribed, several minutes before injection for blepharospasm or strabismus.
- Be aware that only trained medical personnel should inject this drug.

**Toxin type B**
- Draw up prescribed dose from preservative-free, 3.5-ml single-use vial.
- Don’t shake vial.
- Divide prescribed dose and inject locally into affected muscles.

### Route Onset Peak Duration

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.M.</td>
<td>Mins-hrs</td>
<td>Unknown</td>
<td>3-4 mo</td>
</tr>
<tr>
<td>I.M. (blepharospasm)</td>
<td>3 days</td>
<td>1-2 wk</td>
<td>3 mo</td>
</tr>
<tr>
<td>I.M. (strabismus)</td>
<td>1-2 days</td>
<td>Unknown</td>
<td>1-2 wk</td>
</tr>
</tbody>
</table>

### Adverse reactions
- CNS: headache, dizziness
- CV: hypertension, **arrhythmias**, myocardial infarction (MI)
- EENT: blepharoptosis, conjunctivitis, keratitis, eye dryness, double vision, tearing, increased sensitivity to light, sinusitis, pharyngitis
- GI: nausea, dyspepsia, difficulty swallowing
- Musculoskeletal: back pain, neck pain, muscle weakness
- Respiratory: pneumonia, bronchitis, upper respiratory tract infection
- Skin: skin tightness, ecchymosis
- Other: tooth disorder, injection site redness, edema, or pain, flulike

Reactions in **bold** are life-threatening.

### Interactions
**Drug-drug.** Aminoglycosides, anticholinesterase compounds, clindamycin, lincomycin, magnesium sulfate, other neuromuscular blockers (such as succinylcholine), polymyxin B, quinidine: increased risk of adverse effects

### Patient monitoring
- Stay alert for signs and symptoms of anaphylaxis, particularly after first dose.
- Monitor vital signs and ECG, watching for evidence of hypertension, arrhythmias, and MI.
- Assess effect of drug on affected muscles; check for paralysis.
- Monitor temperature. Watch for signs and symptoms of respiratory and EENT infections as well as flulike symptoms.

### Patient teaching
- Teach patient about desired effect of injection. Advise patient to report paralysis.
- Instruct patient to report signs and symptoms of infection, particularly flulike illness and EENT and respiratory infections.
- Inform patient being treated for blepharospasm (uncontrollable blinking) that he may experience transient eyelid drooping, corneal inflammation, double vision, dry eyes, tearing, and light sensitivity.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.
bromocriptine mesylate

Apo-Bromocriptine⃝, Dom-Bromocriptine⃝, Parlodel, PMS-Bromocriptine⃝

Pharmacologic class: Ergot-derivative dopamine agonist
Therapeutic class: Antiparkinsonian
Pregnancy risk category B

Action
Directly stimulates dopamine receptors in hypothalamus, causing release of prolactin-inhibitory factors and thereby relieving akinesia, rigidity, and tremors associated with Parkinson’s disease. Also restores testicular or ovarian function and suppresses lactation.

Availability
Capsules: 5 mg
Tablets: 2.5 mg

Indications and dosages
➣ Parkinson’s disease
Adults: Initially, 1.25 mg P.O. b.i.d. Increase by 2.5 mg/day q 14 to 28 days depending on therapeutic response. Usual therapeutic dosage is 10 to 40 mg/day.

➣ Acromegaly
Adults: Initially, 1.25 to 2.5 mg/day P.O. for 3 days. Increase up to 1.25 to 2.5 mg/day q 3 to 7 days. Usual therapeutic dosage is 20 to 30 mg/day; not to exceed 100 mg/day.

➣ Hyperprolactinemia
Adults: Initially, 1.25 to 2.5 mg/day P.O. Increase gradually q 3 to 7 days up to 2.5 mg two to three times daily.

➣ Neuroleptic malignant syndrome
Adults: Initially, 5 mg P.O. once daily. Increase up to 20 mg/day.

➣ Pituitary tumors
Adults: Initially, 1.25 mg P.O. b.i.d. to t.i.d. Adjust dosage gradually over several weeks to a maintenance dosage of 10 to 20 mg/day given in divided doses.

Contraindications
- Hypersensitivity to drug or other ergot derivatives
- Severe peripheral vascular disease
- Uncontrolled hypertension
- Breastfeeding

Precautions
Use cautiously in:
- impaired hepatic or cardiac function, renal disease, hypertension, pituitary tumor
- psychiatric disorders
- galactose intolerance, severe lactose deficiency, glucose-galactose malabsorption (use not recommended)
- pregnant patients
- children younger than age 15.

Administration
- Give with meals or milk.
- If desired, give at bedtime to minimize dizziness and nausea.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>2 hr</td>
<td>8 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: confusion, headache, dizziness, fatigue, delusions, nervousness, mania, insomnia, nightmares, seizures, cerebrovascular accident
CV: hypotension, palpitations, extrasystoles, arrhythmias, bradycardia, acute myocardial infarction
EENT: blurred vision, diplopia, burning sensation in eyes, nasal congestion
GI: nausea, vomiting, diarrhea, constipation, abdominal cramps, anorexia, dry mouth, GI hemorrhage
GU: urinary incontinence, polyuria, urinary retention
Musculoskeletal: leg cramps
Skin: urticaria, coolness and pallor of fingers and toes, rash on face and arms, alopecia

Canada UK Hazardous drug High alert drug
Other: metallic taste, digital vasospasm (in acromegaly use only)

Interactions

Drug-drug. Amitriptyline, estrogens, haloperidol, hormonal contraceptives, imipramine, loxapine, MAO inhibitors, phenothiazines, progesterins, reserpine: interference with bromocriptine effects

Cyclosporine: inhibition of cyclosporine metabolism, leading to cyclosporine toxicity

Erythromycin: increased bromocriptine blood level and greater risk of adverse effects

Levodopa: additive effects of bromocriptine

Risperidone: increased prolactin blood level, interference with bromocriptine effects

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, blood urea nitrogen, creatine kinase, growth hormone, uric acid: increased levels

Drug-herbs. Chaste tree fruit: decreased bromocriptine effects

Drug-behaviors. Alcohol use: disulfiram-like reaction

Patient monitoring

• Monitor blood pressure to detect hypotension.
• When giving drug for hyperprolactinemia, monitor serum prolactin.
• When giving drug for acromegaly, monitor growth hormone levels to help guide dosage adjustment.
• In long-term use, monitor respiratory, hepatic, cardiovascular, and renal function.

Patient teaching

♫ Caution patient not to drink alcohol because of risk of severe reaction.
• Advise patient to have regular dental exams. Drug causes dry mouth, possibly resulting in caries and periodontal disorders.

To minimize constipation, instruct patient to exercise regularly, increase dietary fiber intake, and drink plenty of fluids (3,000 ml daily).
• Advise patient who doesn’t desire pregnancy to use reliable contraceptive, because drug may restore fertility.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

---

**brompheniramine**

Bromfenac, Brove X, Dimetane, Dimetapp Allergy, Nasahist B, ND-Stat

**Pharmacologic class:** Histamine antagonist

**Therapeutic class:** Antihistamine

**Pregnancy risk category C**

**Action**

Antagonizes effects of histamine at histamine-1 receptor sites, but doesn’t bind to or inactivate histamine. Also shows anticholinergic, antipruritic, and sedative activity.

**Availability**

Capsules (liquigels): 4 mg
Elixir: 2 mg/5 ml
Suspension: 12 mg/5 ml
Tablets: 4 mg, 8 mg, 12 mg
Tablets (extended-release): 8 mg, 12 mg

**Indications and dosages**

Symptomatic relief of allergic symptoms caused by histamine release;

---

Reactions in **bold** are life-threatening.
severe allergic or hypersensitivity reactions

**Adults and children ages 12 and older:** 4 to 8 mg P.O. three to four times daily, or 8 to 12 mg extended-release tablets P.O. two or three times daily. Maximum dosage is 36 mg/day.

**Children ages 6 to 12:** 2 mg P.O. q 4 to 6 hours as needed, not to exceed 12 mg/day

**Children ages 2 to 6:** 1 mg P.O. q 4 to 6 hours p.r.n., not to exceed 6 mg/day

**Contraindications**
- Hypersensitivity to drug
- Coronary artery disease
- Urinary retention
- Pyloroduodenal obstruction
- Peptic ulcer
- MAO inhibitor use within past 14 days
- Breastfeeding

**Precautions**
Use cautiously in:
- angle-closure glaucoma, hepatic disease, hyperthyroidism, hypertension, bronchial asthma
- elderly patients
- pregnant patients.

**Administration**
- Give with food if GI upset occurs.
- Don’t break or crush extended-release tablets.
- Shake oral suspension well before measuring dose.
- Check elixir and suspension doses carefully, because the mg/ml varies widely between the two liquids.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>15-60 min</td>
<td>2-5 hr</td>
<td>3-24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- CNS: drowsiness, sedation, dizziness, excitation, irritability, syncope, tremor
- CV: hypertension, hypotension, palpitations, tachycardia, extrasystole, arrhythmias, bradycardia

**Interactions**
- **Drug-drug.** CNS depressants (including opioids and sedative-hypnotics): additive CNS depression
- MAO inhibitors: intensified, prolonged anticholinergic effects

**Drug-diagnostic tests.** Allergy tests: false results
- Granulocytes, platelets: decreased counts

**Drug-behaviors.** Alcohol use: increased CNS depression

**Patient monitoring**
- Monitor respiratory status.
- Stay alert for urinary retention, urinary frequency, and painful or difficult urination. Discontinue drug if these problems occur.
- With long-term use, monitor CBC.
- Monitor elderly patient for dizziness, sedation, and hypotension.
- If patient takes over-the-counter antihistamines, monitor him closely to avoid potential overdose.

**Patient teaching**
- Advise patient to take drug with meals if GI upset occurs.
- Instruct patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
Caution patient to avoid alcohol while taking drug.

Urge patient to tell all prescribers which drugs and over-the-counter preparations he’s taking.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

**budesonide**

Budenofalk®, Easyhaler Budesonide®, Entocort CR®, Entocort EC, Entocort Enema®, Novolizer Budesonide®, Pulmicort Flexhaler, Pulmicort Respules, Rhinocort Aqua

**Pharmacologic class:** Corticosteroid (inhalation)

**Therapeutic class:** Antiasthmatic, steroidal anti-inflammatory

**Pregnancy risk category B (intranasal, inhalation); C (oral)**

**FDA BOXED WARNING**

- Pulmicort Respules is meant only for inhalation by compressed air-driven jet nebulizers (not ultrasonic devices). It must not be injected. Read patient instructions before using.

**Action**

Decreases inflammation by inhibiting migration of inflammatory mediators to injury site, where it reverses dilation and increases vessel permeability. Also decreases plasma exudation and mucus secretions within airway.

**Indications and dosages**

- **Maintenance treatment of asthma as prophylactic therapy**
  - **Adults:** 360 mcg (powder for oral inhalation) inhaled b.i.d. For some patients, 180 mcg inhaled b.i.d. may be appropriate. Maximum dosage is 720 mcg b.i.d.
  - **Children ages 6 to 17:** 180 mcg (powder for oral inhalation) inhaled b.i.d. For some patients, dosage of 360 mcg inhaled b.i.d. may be appropriate. Maximum dosage is 360 mcg b.i.d.
  - **Seasonal or perennial allergic rhinitis**
    - **Adults and children ages 6 and older:** Two sprays in each nostril in morning and evening, or four sprays in each nostril in morning. Maintenance dosage is fewest number of sprays needed to control symptoms.
  - **Mild to moderate active Crohn’s disease involving ileum, ascending colon, or both**
    - **Adults:** 9 mg P.O. daily for up to 8 weeks. For recurring episodes of active Crohn’s disease, 8-week course can be repeated and tapered to 6 mg P.O. daily for 2 weeks before complete cessation.

**Dosage adjustment**

- Moderate to severe hepatic disease

**Contraindications**

- Hypersensitivity to drug
- Status asthmaticus

**Precautions**

Use cautiously in:

**Availability**

- **Capsules (extended-release):** 3 mg
- **Inhalation powder:** 90 mcg (Pulmicort Flexhaler), 180 mcg (Pulmicort Flexhaler)
- **Inhalation suspension (Respules):** 0.25 mg/2 ml, 0.5 mg/2 ml, 1 mg/ml
- **Nasal spray:** 32 mcg/metered spray (7-g canister)

Reactions in **bold** are life-threatening.
• renal disease, hepatic disease, heart
failure, active untreated infections, sys-
temic infections, hypertension, osteopo-
rosis, diabetes mellitus, glaucoma, under-
lying immunosuppression, hypothyroidism, diverticulitis, nonspecific
erucerative colitis, recent intestinal
anastomoses, thromboembolic disor-
ders, seizures, myasthenia gravis, ocu-
lar herpes simplex infection
• patients receiving concurrent systemic
corticosteroids
• pregnant or breastfeeding patients
• children younger than age 6.

Administration
• If patient also uses a bronchodilator,
give that drug at least 15 minutes before
budesonide.
• Know that using a spacer reduces
risk of candidiasis and hoarseness.
• Make sure patient swallows capsules
whole without crushing or chewing
them.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>0.5-10 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>Inhalation</td>
<td>Immediate</td>
<td>1-2 wk</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

(nasal)

Adverse reactions
CNS: headache, nervousness, depres-
sion, euphoria, psychoses, increased
intracranial pressure
CV: hypertension, Churg-Strauss syn-
drome, thrombophlebitis, throm-
boembolism
EENT: cataracts, nasal congestion,
nasal burning or dryness, epistaxis,
perforated nasal septum, hoarseness,
nasopharyngeal and oropharyngeal
fungal infections
GI: nausea, vomiting, peptic ulcers,
anorexia, esophageal candidiasis, dry
mouth
Metabolic: hyperglycemia, decreased
growth (in children), cushingoid
appearance (moon face, buffalo
hump), adrenal suppression or
insufficiency

Musculoskeletal: muscle wasting,
muscle pain, osteoporosis, aseptic joint
necrosis
Respiratory: cough, wheezing, re-
bound congestion, bronchospasm
Skin: facial edema, rash, petechiae,
contact dermatitis, acne, bruising, hir-
sutism, urticaria
Other: bad taste, anosmia, weight gain
or loss, increased susceptibility to in-
fec tion, angioedema, hypersensitivity
reaction

Interactions
Drug-drug. Amphotericin B, mezlocillin,
piperacillin, thiazide and loop diuretics,
ticarcillin: additive hypokalemia
Digoxin: increased risk of digoxin
toxicity
Erythromycin, indinavir, itraconazole,
 ketoconazole, ritonavir, saquinavir:
increased blood level and effects of
budesonide
Fluoroquinolones: increased risk of ten-
don rupture
Hormonal contraceptives: blockage of
budesonide metabolism
Insulin, oral hypoglycemics: increased
budesonide requirement
Live-virus vaccines: decreased antibody
response to vaccine, increased risk of
adverse effects from budesonide
Nonsteroidal anti-inflammatory drugs
(including aspirin): increased risk of
adverse GI effects
Phenobarbital, phenytoin, rifampin:
decreased budesonide efficacy
Somatrem, somatropin: decreased re-
sponse to budesonide
Drug-food. Grapefruit, grapefruit juice:
increased blood level and effects of
budesonide
High-fat meal: delayed peak budes-
onide concentration

Patient monitoring
• Monitor respiratory status to evalu-
ate drug efficacy.

Stay alert for hypersensitivity reac-
tions, especially angioedema.
- Evaluate liver function test results.
- Periodically observe patient for proper inhaler use.
- Assess oral cavity for infection.

**Patient teaching**
- Teach patient proper use of inhaler.
- Tell patient to swallow capsules whole without crushing or chewing them.
- Instruct patient to contact prescriber immediately if he develops itching, rash, fever, swelling of face and neck, or difficulty breathing.
- Encourage patient to document medication use and his response in diary.
- Advise patient to report signs and symptoms of fungal infections of mouth.
- Tell female patient to inform prescriber if she is pregnant or plans to become pregnant.
- Caution patient to avoid exposure to chickenpox and measles, if possible.
- Emphasize importance of rinsing mouth after each inhaler treatment and washing and drying inhaler thoroughly after each use.
- Instruct patient to avoid high-fat meals, grapefruit, and grapefruit juice.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and foods mentioned above.

**FDA BOXED WARNING**
- Drug is a potent diuretic; excessive amounts may cause profound diuresis with fluid and electrolyte depletion. Give only under careful medical supervision; adjust dosage and dosing schedule to patient’s needs.

**Action**
Inhibits reabsorption of sodium and chloride in distal renal tubules and ascending limb of loop of Henle; increases renal excretion of water, sodium, chloride, magnesium, hydrogen, and calcium. Also reduces increased fluid volume caused by renal vasodilation.

**Availability**
- **Injection:** 0.25 mg/ml
- **Tablets:** 0.5 mg, 1 mg, 2 mg

**Indications and dosages**
- Edema caused by heart failure or hepatic or renal disease; adult nocturia
  - **Adults:** 0.5 to 2 mg/day P.O. as a single dose; up to two additional doses may be given q 4 to 5 hours (up to 10 mg/day). Or 0.5 to 1 mg I.V. or I.M., repeated q 2 to 3 hours as needed, up to 10 mg/day.
  - **Hypertension**
  - **Adults:** 0.5 mg/day P.O. Maximum dosage is 5 mg/day.

**Dosage adjustment**
- Renal impairment
- Elderly patients

**Off-label uses**
- Drug-related edema
- Hypercalcemia

**Contraindications**
- Hypersensitivity to drug or sulfonamides
- Uncorrected electrolyte imbalances
- Hepatic coma
- Anuria and oliguria

---

**bumetanide**
Bumetanide Injection, Bumex

**Pharmacologic class:** Loop diuretic
**Therapeutic class:** Antihypertensive
**Pregnancy risk category C**

Reactions in **bold** are life-threatening.
Precautions
Use cautiously in:
- severe hepatic disease, electrolyte depletion, diabetes mellitus, worsening azotemia
- elderly patients
- pregnant or breastfeeding patients
- children younger than age 18.

Administration
- Know that oral or I.V. route is preferred, because I.M. administration may cause pain at injection site.
- Be aware that drug may be given alone or with other antihypertensives.
- Dilute with dextrose 5% in water, normal saline solution, or lactated Ringer’s injection.
- Give I.V. dose slowly over 2 minutes.
- Give P.O. form with food or milk.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30–60 min</td>
<td>1 hr</td>
<td>3–6 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Within min</td>
<td>15–45 min</td>
<td>3–6 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>40 min</td>
<td>1–2 hr</td>
<td>4–6 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, headache, insomnia, nervousness, vertigo, weakness, paresthesia, confusion, fatigue, hand-flapping tremor, encephalopathy
CV: hypotension, ECG changes, chest pain, thrombophlebitis, arrhythmias
EENT: blurred vision, nystagmus, hearing loss, tinnitus
GI: nausea, vomiting, diarrhea, constipation, dyspepsia, gastric irritation, dry mouth, anorexia, acute pancreatitis
GU: polyuria, nocturia, glycosuria, premature ejaculation, difficulty maintaining erection, oliguria, renal failure
Hepatic: jaundice
Metabolic: dehydration, hyperglycemia, hyperuricemia, hypokalemia, hypomagnesemia, hypochloremic alkalosis
Musculoskeletal: arthralgia; muscle cramps, aching, or tenderness
Skin: photosensitivity, hives, rash, pruritus, urticaria, diaphoresis
Other: pain, nipple tenderness

Interactions
Drug-drug. Aminoglycosides, cisplatin: increased risk of ototoxicity
Amphotericin B, corticosteroids, mezlocillin, other diuretics, piperacillin, stimulant laxatives: additive hypokalemia
Anticoagulants, thrombolytics: increased bumetanide effects
Antihypertensives, nitrates: additive hypotension
Cardiac glycosides: increased risk of digoxin toxicity
Lithium: decreased lithium excretion, possible lithium toxicity
Neuromuscular blockers: prolonged neuromuscular blockade
Nonsteroidal anti-inflammatory drugs, probenecid: inhibition of diuretic response
Drug-diagnostic tests. Blood urea nitrogen (BUN), cholesterol, creatinine, glucose, nitrogenous compounds: increased levels
Calcium, magnesium, platelets, potassium, sodium: decreased levels
Drug-herbs. Dandelion: interference with diuretic activity
Ginseng: resistance to diuresis
Licorice: rapid potassium loss
Drug-behaviors. Acute alcohol ingestion: additive hypotension

Patient monitoring
- Weigh patient at start of therapy, and monitor weight throughout therapy.
- Monitor blood pressure regularly.
- Monitor serum electrolyte, uric acid, glucose, and BUN levels.
- Monitor elderly patients for extreme blood pressure changes, orthostatic hypotension, and dehydration.
Patient teaching
- Advise patient to take drug in morning to prevent nocturia, and to take second dose (if required) in late afternoon.
- Instruct patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness from sudden blood pressure drop.
- Caution patient to avoid alcohol because of increased risk of hypotension.
- Advise patient to eat foods high in potassium. Provide other dietary counseling as appropriate to help prevent or minimize electrolyte imbalances.
- Instruct patient to weigh himself often to help detect fluid retention.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

buprenorphine hydrochloride
Buprenex, Burinex®, Subutex, Temgesic®, Transtec®

Pharmacologic class: Opioid agonist-antagonist
Therapeutic class: Opioid analgesic
Controlled substance schedule III
Pregnancy risk category C

Action
Unclear. May bind to opiate receptors in CNS, altering perception of and response to painful stimuli while causing generalized CNS depression. Also has partial antagonist properties, which may lead to opioid withdrawal effects in patients with physical drug dependence.

Availability
Injection: 300 mcg (0.3 mg)/ml
Tablets (sublingual): 2 mg, 8 mg

Indications and dosages
Moderate to severe pain
Adults: 0.3 mg I.M. or slow I.V. q 6 hours as needed. Repeat initial dose after 30 to 60 minutes.
Children ages 2 to 12: 2 to 6 mcg (0.002 to 0.006 mg)/kg I.M. or slow I.V. q 4 to 6 hours
Opioid dependence
Adults: 12 to 16 mg/day S.L.

Dosage adjustment
- Elderly patients

Contraindications
- Hypersensitivity to drug
- Elderly patients
- MAO inhibitor use within 14 days

Precautions
Use cautiously in:
- increased intracranial pressure (ICP); respiratory impairment; severe renal, hepatic, or pulmonary disease; hypothyroidism; adrenal insufficiency; undiagnosed abdominal pain; prostatic hypertrophy; systemic lupus erythematosus; gout; kyphoscoliosis; diabetes mellitus; alcoholism
- elderly patients
- pregnant or breastfeeding patients
- children younger than age 13.

Administration
- Mix with lactated Ringer’s injection, dextrose 5% in water, or normal saline solution.
- Give I.V. dose slowly over no less than 2 minutes. Drug may cause respiratory depression (especially initial dose).
- When giving I.M., rotate injection sites to prevent induration and abscess.
- If patient is immobilized, reposition him frequently and keep head of bed elevated.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>2 min</td>
<td>6 hr</td>
</tr>
<tr>
<td>I.M., S.L.</td>
<td>15 min</td>
<td>1 hr</td>
<td>6 hr</td>
</tr>
</tbody>
</table>

Reactions in bold are life-threatening.
Adverse reactions
CNS: confusion, malaise, hallucinations, dizziness, euphoria, headache, unusual dreams, psychosis, slurred speech, paresthesia, depression, tremor, agitation, seizures, coma, increased ICP
CV: hypertension, hypotension, palpitations, tachycardia, Wenckebach (Mobitz Type 1) block, bradycardia
EENT: blurred vision, diplopia, amblyopia, miosis, conjunctivitis, tinnitus
GI: nausea, vomiting, constipation, flatulence, ileus, dry mouth
GU: urinary retention
Respiratory: hypoventilation, dyspnea, cyanosis, apnea, respiratory depression
Skin: diaphoresis, pruritus
Other: physical or psychological drug dependence, drug tolerance

Interactions
Drug-drug. Antidepressants, antihistamines, sedative-hypnotics: additive CNS depression
MAO inhibitors: increased CNS and respiratory depression, increased hypotension
Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression
Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring
● Check hepatic function before and during therapy.
● Monitor respiratory status throughout therapy. Respiratory rate of 12 breaths/minute or less may warrant withholding dose or decreasing dosage.

Patient teaching
● Instruct patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness from sudden blood pressure drop.
● Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
● Advise patient to increase daily fluid intake to help prevent constipation.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, herbs, and behaviors mentioned above.

bupropion hydrochloride
Budeprion SR, Budeprion XL, Wellbutrin, Wellbutrin SR, Wellbutrin XL, Zyban

Pharmacologic class: Aminoketone
Therapeutic class: Second-generation antidepressant, smoking-cessation aid
Pregnancy risk category C

FDA BOXED WARNING
● Although drug isn’t indicated for depression, it contains same active ingredient as antidepressants Wellbutrin, Wellbutrin SR, and Wellbutrin XL. Antidepressants increase risk of suicidal thinking and behavior in children and adolescents with major depressive disorder and other psychiatric disorders. Risk is greater during first few months of treatment, and must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family to observe patient closely and communicate with prescriber as needed.
● Drug isn’t approved for use in pediatric patients.
**Action**
Unclear. Thought to decrease neuronal reuptake of dopamine, serotonin, and norepinephrine in CNS. Action as smoking-cessation aid may result from noradrenergic or dopaminergic activity.

**Availability**
*Tablets: 75 mg, 100 mg*
*Tablets (sustained-release): 100 mg, 150 mg, 200 mg*

**Indications and dosages**

➤ **Depression**

**Adults:** Initially, 100 mg P.O. b.i.d. (morning and evening). After 3 days, may increase to 100 mg t.i.d. After 4 weeks, may increase to a maximum dosage of 450 mg/day in divided doses. No single dose should exceed 150 mg. With total daily dosage of 300 mg, wait at least 6 hours between doses; with total daily dosage of 450 mg, wait at least 4 hours between doses. Alternatively, give one 150-mg sustained-release tablet daily; increase to 150-mg sustained-release tablet b.i.d. based on clinical response.

➤ **Smoking cessation**

**Adults:** 150-mg sustained-release tablet once daily for 3 days, then 150-mg sustained-release tablet b.i.d. for 7 to 12 weeks. Space doses at least 8 hours apart.

**Contraindications**
- Hypersensitivity to drug
- Seizures
- Anorexia nervosa or bulimia
- MAO inhibitor use within past 14 days
- Acute alcohol or sedative withdrawal

**Precautions**
Use cautiously in:
- renal or hepatic impairment, unstable cardiovascular status
- elderly patients
- pregnant or breastfeeding patients
- children.

**Administration**
- Be aware that sustained-release tablets should be swallowed whole and not crushed or chewed.
- Single dose shouldn’t exceed 150 mg for immediate-release tablets or 200 mg for sustained-release tablets.
- Avoid bedtime doses because they may worsen insomnia.
- Know that drug shouldn’t be withdrawn abruptly.

**Adverse reactions**

*CNS:* agitation, headache, insomnia, mania, psychoses, depression, dizziness, drowsiness, tremor, anxiety, nervousness, seizures
*CV:* hypertension, hypotension, tachycardia, palpitations, complete atrioventricular block
*EENT:* blurred vision, amblyopia, auditory disturbances, epistaxis, rhinitis, pharyngitis
*GI:* nausea, vomiting, dyspepsia, abdominal pain, flatulence, mouth ulcers, dry mouth
*GU:* urinary frequency, nocturia, vaginal irritation, testicular swelling
*Metabolic:* hyperglycemia, changes in libido, hypoglycemia, syndrome of inappropriate antidiuretic hormone secretion
*Musculoskeletal:* arthralgia, myalgia, leg cramps, twitching, neck pain
*Respiratory:* bronchitis, increased cough, dyspnea
*Skin:* photosensitivity, dry skin, pruritus, rash, urticaria, diaphoresis, skin temperature changes
*Other:* altered taste, increased or decreased appetite, weight gain or loss,

Reactions in **bold** are life-threatening.
hot flashes, fever, allergic reaction, flu-like symptoms

Interactions
Drug-drug. Benzodiazepine withdrawal, corticosteroids, other antidepressants, over-the-counter stimulants, phenothiazines, theophylline: increased risk of seizures Cimetidine: inhibited bupropion metabolism Desipramine, paroxetine, ritonavir, sertraline: possibly increased bupropion blood level Levodopa, MAO inhibitors: increased risk of adverse reactions

Drug-diagnostic tests. Glucose: increased level

Drug-behaviors. Alcohol use or cessation: increased risk of seizures Sun exposure: increased risk of photosensitivity

Patient monitoring
- Monitor blood pressure, ECG, CBC, and renal and hepatic function. Monitor tricyclic antidepressant (TCA) blood level if patient’s taking TCAs concurrently.
- Be aware that if patient is also on nicotine patch for smoking cessation, the combination may cause or increase risk of hypertension.
- Check for oral and dental problems.

Patient teaching
- Instruct patient to swallow sustained-release tablets without crushing or chewing.
- Caution patient not to discontinue drug abruptly.
- Emphasize importance of frequent oral hygiene. (Dry mouth increases risk of caries and dental problems.)
- Caution patient to avoid alcohol, because it may increase risk of seizures.
- Advise patient to keep regular appointments for periodic blood tests and hepatic and renal studies.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

buspirone hydrochloride
BuSpar

Pharmacologic class: Azaspirodecane-dione
Therapeutic class: Anxiolytic
Pregnancy risk category B

Action
Unclear. Thought to bind to serotonin and dopamine receptors in CNS, increasing dopamine metabolism and impulse formation. Also thought to inhibit neuronal firing and reduce serotonin turnover.

Availability
Tablets: 5 mg, 7.5 mg, 10 mg, 15 mg, 30 mg

Indications and dosages
> Anxiety disorders; anxiety symptoms
Adults: 7.5 mg P.O. b.i.d.; increase by 5 mg/day q 2 to 3 days as needed (not to exceed 60 mg/day). Common dosage is 20 to 30 mg/day in divided doses.

Off-label uses
- Parkinsonian syndrome
- Symptomatic relief of depression

Contraindications
- Hypersensitivity to drug
- Severe renal or hepatic impairment
- MAO inhibitor use within past 14 days

Precautions
Use cautiously in:
- patients receiving concurrent anxiolytics or psychotropics
Administration

- Give with food to minimize GI upset.
- Know that full benefit of drug therapy may take up to 2 weeks.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>7-10 days</td>
<td>3-4 wk</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: dizziness, drowsiness, nervousness, headache, insomnia, weakness, personality changes, numbness, paresthesia, tremor, dream disturbances
CV: chest pain, palpitations, tachycardia, hypertension, hypotension
EENT: blurred vision, conjunctivitis, tinnitus, nasal congestion, sore throat
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dry mouth
GU: dysuria, urinary frequency or hesitancy, menstrual irregularities, menstrual spotting, libido changes
Musculoskeletal: myalgia
Respiratory: chest congestion, hyperventilation, dyspnea
Skin: rash, alopecia, blisters, pruritus, dry skin, easy bruising, edema, flushing, clammy skin, excessive sweating
Other: altered taste or smell, fever

Interactions

Drug-drug. Erythromycin, itraconazole: increased buspirone blood level
MAO inhibitors: hypertension
Trazodone: increased risk of adverse hepatic effects

Drug-food. Grapefruit juice: increased buspirone blood level and effects

Drug-herbs. Hops, kava, skullcap, valerian: increased CNS depression

Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring

- Monitor mental status closely.
- Assess hepatic and renal function regularly to detect drug toxicity.

Patient teaching

- Instruct patient to take drug with food.
- Advise patient not to use drug to manage everyday stress or tension.
- Instruct patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Caution patient to avoid alcohol because it increases CNS depression.
- Emphasize importance of keeping follow-up appointments to check progress.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, foods, herbs, and behaviors mentioned above.

busulfan

Busilvex®, Busulfex, Myleran

Pharmacologic class: Alkylating agent

Therapeutic class: Antineoplastic

Pregnancy risk category D

FDA BOXED WARNING

- Drug causes profound myelosuppression at recommended dosage. Give under supervision of physician experienced in allogeneic hematopoietic stem cell transplantation, cancer chemotherapy, and management of severe pancytopenia, in facility with adequate diagnostic and treatment resources.

Action

Unclear. Thought to interfere with bacterial cell-wall synthesis by cross-linking strands of DNA and disrupting RNA transcription, which causes cell to rupture and die. Exhibits minimal immunosuppressant activity.
Availability
Injection: 6 mg/ml in 10-ml ampules
Tablets: 2 mg

Indications and dosages
➣ Chronic myelogenous leukemia
Adults: 4 to 8 mg P.O. daily until white blood cell (WBC) count decreases to 15,000/mm³; then discontinue drug until WBC count rises to 50,000/mm³, and then resume as needed.
Children: 0.06 to 0.12 mg/kg/day P.O. or 1.8 to 4.6 mg/m²/day P.O. Adjust dosage to maintain WBC count at approximately 20,000/mm³. Drug should be withheld when WBC count decreases to approximately 15,000/mm³.
➣ Allogenic hematopoietic stem cell transplantation
Adults: 0.8 mg/kg I.V. q 6 hours for 4 days. Starting 6 hours after 16th dose of busulfan injection, give cyclophosphamide 60 mg/kg/day I.V. over 1 hour for 2 days.

Off-label uses
● Adjunctive therapy in ovarian cancer
● Bone marrow transplantation

Contraindications
● Hypersensitivity to drug
● Patients not definitively diagnosed with chronic myelogenous leukemia
● Pregnancy or breastfeeding

Precautions
Use cautiously in:
● active infections, decreased bone marrow reserve, chronic debilitating disease, depressed neutrophil and platelet counts, seizure disorders, obesity
● patients receiving concurrent myelosuppressive or radiation therapy
● females of childbearing age.

Administration
● Give oral doses on empty stomach.
● When administering I.V., withdraw dose from ampule using 5-micron filter needle. Remove filter needle and use new needle to add busulfan to diluent.

- Dilute for injection using dextrose 5% in water or normal saline solution.
- Infuse I.V. dose over 2 hours, using an infusion pump.
- Flush I.V. catheter before and after each infusion with 5 ml D₅W or normal saline solution.

Be aware that drug is highly toxic and has a narrow therapeutic index.
- Maintain vigorous hydration to reduce risk of renal toxicity.
- Handle patient gently to avoid bruising.

Adverse reactions
CNS: anxiety, confusion, depression, dizziness, headache, insomnia, weakness, encephalopathy, seizures, cerebral hemorrhage, coma
CV: chest pain, hypotension, hypertension, tachycardia, ECG changes, heart block, left-sided heart failure, thrombosis, pericardial effusion, ventricular extrasystole, atrial fibrillation, arrhythmias, cardiac tamponade, cardiomegaly
EENT: cataracts, ear disorders, epistaxis, pharyngitis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, abdominal enlargement, pancreatitis, hematemesis, dry mouth, stomatitis, anorexia
GU: dysuria, hematuria, sterility, gynecomastia, oliguria
Hematologic: myelosuppression
Hepatic: hepatitis, hepatomegaly
Metabolic: hypokalemia, hypomagnesemia, hypophosphatemia, hyperuricemia, hyperglycemia
Musculoskeletal: arthralgia, myalgia, back pain
Respiratory: hyperventilation, dyspnea, pulmonary fibrosis
Skin: pruritus, rash, acne, alopecia, erythema nodosum, exfoliative dermatitis, hyperpigmentation
Other: allergic reactions, chills, fever, injection site infection or inflammation

Interactions
Drug-drug. Anticoagulants, aspirin, nonsteroidal anti-inflammatory drugs: increased risk of bleeding
Live-virus vaccines: decreased antibody response to vaccine, increased risk of adverse reactions
Myelosuppressants: additive bone marrow depression
Nephrotoxic and ototoxic drugs (such as aminoglycosides, loop diuretics): additive nephrotoxicity and ototoxicity
Thioguanine: increased risk of hepatotoxicity
Drug-diagnostic tests. Alkaline phosphatase, aspartate aminotransferase, bilirubin, nitrogenous compounds (urea): increased levels
Hemoglobin, WBCs: decreased values

Patient monitoring
- Monitor patient closely for adequate hydration.
- Check for signs and symptoms of local or systemic infections.
- Assess for bleeding and excessive bruising.
- Evaluate oral hygiene regularly.
- Monitor CBC and WBC and platelet counts daily if patient is receiving I.V. busulfan.
- Monitor renal and hepatic function.
- Know that diffuse pulmonary fibrosis (“busulfan lung”) is a rare but potentially life-threatening complication, with symptom onset as late as 10 years after therapy.

Patient teaching
- Inform patient that drug doesn’t cure leukemia but may induce remission.
- Advise patient to drink plenty of fluids to avoid dehydration.
- Instruct patient to immediately report inability to eat or drink. Prescriber may add another drug to improve appetite.
- Inform patient that he’s at increased risk for infection. Advise him to avoid contact with people with known infections and to avoid public transportation, if possible.
- Tell patient he’s at increased risk for bleeding and bruising.
- Advise patient to avoid activities that can cause injury and to use soft toothbrush and electric razor to avoid gum and skin injury.
- Inform patient that he’ll undergo frequent blood testing to monitor drug effects.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**butorphanol tartrate**

APO-Butorphanol®, PMS-Butorphanol®, Stadol

**Pharmacologic class:** Opioid agonist-antagonist

**Therapeutic class:** Opioid analgesic

**Controlled substance schedule IV**

**Pregnancy risk category C**

**Action**
Alters perception of and emotional response to pain by binding with opioid receptors in brain, causing CNS depression. Also exerts antagonistic activity at opioid receptors, which reduces risk of toxicity, drug dependence, and respiratory depression.
Availability
Injection: 1 mg/ml, 2 mg/ml
Nasal spray: 10 mg/ml

Indications and dosages
Moderate to severe pain
Adults: 1 to 4 mg I.M. q 3 to 4 hours as needed, not to exceed 4 mg/dose. Or 0.5 to 2 mg I.V. q 3 to 4 hours as needed. With nasal spray, 1 mg (one spray in one nostril) q 3 to 4 hours, repeated in 60 to 90 minutes if needed.
Labor pains
Adults: 1 to 2 mg I.V. or I.M., repeated after 4 hours as needed
Preoperative anesthesia
Adults: 2 mg I.M. 60 to 90 minutes before surgery
Balanced anesthesia
Adults: 2 mg I.V. shortly before anesthesia induction, or 0.5 to 1 mg I.V. in increments during anesthesia

Dosage adjustment
• Renal or hepatic impairment
• Elderly patients

Off-label uses
• Headache
• Symptomatic relief of ureteral colic

Contraindications
• Hypersensitivity to drug

Precautions
Use cautiously in:
• head injury, ventricular dysfunction, coronary insufficiency, respiratory disease, renal or hepatic dysfunction
• history of drug abuse.

Administration
• Make sure solution is clear and free of particulates before giving.
• When using nasal spray, insert tip of the sprayer about ¼” into nostril, point tip backwards, and administer one spray.
• Be aware that I.V. route is preferred for severe pain.

Know that drug may cause infant respiratory distress in neonate of pregnant patient, especially if given within 2 hours of delivery.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>2-3 min</td>
<td>30-60 min</td>
<td>3-4 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>10-15 min</td>
<td>30-60 min</td>
<td>3-4 hr</td>
</tr>
<tr>
<td>Intranasal</td>
<td>15 min</td>
<td>1-2 hr</td>
<td>4-5 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: drowsiness, sedation, dizziness, tremor, irritability, syncope, stimulation
CV: hypertension, hypotension, palpitations, bradycardia, tachycardia, extrasystole, arrhythmias
EENT: blurred vision, nasal congestion or dryness, dry or sore throat
GI: nausea, vomiting, constipation, epigastric distress, dry mouth, GI obstruction
GU: urinary retention or hesitancy, dysuria, early menses, decreased libido, erectile dysfunction
Hematologic: hemolytic anemia, hypoplastic anemia, thrombocytopenia, agranulocytosis, leukopenia, pancytopenia
Respiratory: thickened bronchial secretions, chest tightness, wheezing
Skin: urticaria, rash, diaphoresis
Other: increased or decreased appetite, weight gain, local stinging, anaphylactic shock, hypersensitivity reaction (with I.V. use)

Interactions
Drug-drug. CNS depressants: additive CNS effects
Drugs-herbs. Kava, St. John’s wort, valerian: increased CNS depression
Drug-behaviors. Alcohol use: additive CNS effects

Patient monitoring
• Monitor respiratory status closely, especially after I.V. administration.
• Watch for signs and symptoms of withdrawal in long-term use and in opioid-dependent patients.
• Assess elderly patient closely for sensitivity to drug.

Patient teaching
• Teach patient how to use nasal spray properly.
• Emphasize importance of using drug exactly as prescribed.
• Caution patient that drug may be habit-forming.
• Advise patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and behaviors mentioned above.

calcitonin (salmon)

APC-Calculiton, Calcimar, Caltin, Fortical, Miacalcic®, Miacalcin, Miacalcin Nasal Spray, Sandoz Calcitonin

Pharmacologic class: Hormone (calcium-lowering)

Therapeutic class: Hypocalcemic

Pregnancy risk category C

Action
Directly affects bone, kidney, and GI tract. Decreases osteoclastic osteolysis in bone; also reduces mineral release and collagen breakdown in bone and promotes renal excretion of calcium. In pain relief, acts through prostaglandin inhibition, pain threshold modification, or beta-endorphin stimulation.

Availability
Injection: 0.5 mg/ml (human), 1 mg/ml (human), 200 international units/ml in 2-ml vials (salmon)
Nasal spray (salmon): 200 international units/actuation, metered nasal spray in 3.7 ml-bottle

Indications and dosages
➢ Postmenopausal osteoporosis
Adults: Calcitonin (salmon)—100 international units/day I.M. or subcutaneously, or 200 international units/day intranasally with concurrent supplemental calcium and vitamin D
➢ Paget’s disease of bone (osteitis deformans)
Adults: Calcitonin (salmon)—Initially, 100 international units/day I.M. or subcutaneously; after titration, maintenance dosage is 50 to 100 international units daily or every other day (three times weekly). Calcitonin (human)—0.5 mg I.M. or subcutaneously daily, reduced to 0.25 mg daily.
➢ Hypercalcemia
Adults: Calcitonin (salmon)—4 international units/kg I.M. or subcutaneously q 12 hours; after 1 or 2 days, may increase to 8 international units/kg q 12 hours; after 2 more days, may increase further, if needed, to 8 international units q 6 hours.

Contraindications
• Hypersensitivity to drug or salmon
• Pregnancy or breastfeeding

Precautions
Use cautiously in:
• renal insufficiency, pernicious anemia
• children.

Administration
➢ Before salmon calcitonin therapy begins, perform skin test, if prescribed. Don’t give drug if patient has positive reaction. Have epinephrine available.
• Bring nasal spray to room temperature before using.
• Give intranasal dose as one spray in one nostril daily; alternate nostrils every day.
• To minimize adverse effects, give at bedtime.
• Rotate injection sites to decrease inflammatory reactions.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.M., subcut.</td>
<td>15 min</td>
<td>4 hr</td>
<td>8-24 hr</td>
</tr>
<tr>
<td>Intranasal</td>
<td>Rapid</td>
<td>0.5 hr</td>
<td>1 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, weakness, dizziness, paresthesia
CV: chest pain
EENT: epistaxis, nasal irritation, rhinitis
GI: nausea, vomiting, diarrhea, epigastric pain or discomfort
GU: urinary frequency
Musculoskeletal: arthralgia, back pain
Respiratory: dyspnea
Skin: rash
Other: altered taste, allergic reactions including facial flushing, swelling, and anaphylaxis

Interactions
Drug-drug. Previous use of bisphosphonates (alendronate, etidronate, pamidronate, risedronate): decreased response to calcitonin

Patient monitoring
• Monitor for adverse reactions during first few days of therapy.
• Assess alkaline phosphatase level and 24-hour urinary excretion of hydroxyproline.
• Check urine for casts.
• Monitor serum electrolyte and calcium levels.

Patient teaching
• Instruct patient to take drug before bedtime to lessen GI upset. Tell him to call prescriber if he can’t maintain his usual diet because of GI upset.
• Inform patient using nasal spray that runny nose, sneezing, and nasal irritation may occur during first several days as he adjusts to spray.
• Instruct patient to bring nasal spray to room temperature before using.
• Advise patient to blow nose before using spray, to take intranasal dose as one spray in one nostril daily, and to alternate nostrils with each dose.
• Tell patient to discard unrefrigerated bottles of calcitonin (salmon) nasal spray after 30 days.
• Encourage patient to consume a diet rich in calcium and vitamin D.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

calcium acetate
Phos-Ex®, PhosLo, PhosLo Gelcap

calcium carbonate

calcium chloride
Calciject®

calcium citrate
Cal-Citrate-225, Citracal, Citracal Liquitabs, Citrus Calcium
calcium glubionate
Calcionate, Calciquid

calcium gluceptate

calcium gluconate

calcium lactate
Cal-Lac

tricalcium phosphate
Posture

Pharmacologic class: Mineral
Therapeutic class: Dietary supplement, electrolyte replacement agent
Pregnancy risk category C (calcium acetate, chloride, gluionate, gluceptate, phosphate), NR (calcium carbonate, citrate, gluconate, lactate)

Action
Increases serum calcium level through direct effects on bone, kidney, and GI tract. Decreases osteoclastic osteolysis by reducing mineral release and collagen breakdown in bone.

Availability
Calcium acetate—
Gelcaps: 667 mg
Tablets: 667 mg
Calcium carbonate—
Capsules: 1,250 mg
Lozenges: 600 mg
Oral suspension: 1,250 mg
Powder: 6.5 g
Tablets: 650 mg, 1,250 mg, 1,500 mg
Tablets (chewable): 750 mg, 1,000 mg, 1,250 mg
Tablets (gum): 300 mg, 450 mg, 500 mg
Calcium chloride—
Injection: 10% solution
Calcium citrate—
Tablets: 950 mg
Calcium gluionate—
Syrup: 1.8 g/5 ml (contains 115 mg of elemental calcium)
Calcium gluceptate—
Injection: 22% solution
Calcium gluconate—
Injection: 10% solution
Tablets: 500 mg, 650 mg, 975 mg
Calcium lactate—
Tablets: 325 mg, 500 mg, 650 mg
Tricalcium phosphate—
Tablets: 600 mg

Clinical alert
Reactions in bold are life-threatening.

Indications and dosages
➢ Hypocalcemic emergency
Adults: 7 to 14 mEq I.V. of 10% calcium gluconate solution, 2% to 10% calcium chloride solution, or 22% calcium gluceptate solution
Children: 1 to 7 mEq calcium gluconate I.V.
Infants: Up to 1 mEq calcium gluconate I.V.
➢ Hypocalcemic tetany
Adults: 4.5 to 16 mEq calcium gluconate I.V., repeated as indicated until tetany is controlled
Children: 0.5 to 0.7 mEq/kg calcium gluconate I.V. three to four times daily as indicated until tetany is controlled
Neonates: 2.4 mEq/kg calcium gluconate I.V. daily in divided doses
➢ Cardiac arrest
Adults: 0.027 to 0.054 mEq/kg calcium chloride I.V., 4.5 to 6.3 mEq calcium gluceptate I.V., or 2.3 to 3.7 mEq calcium gluconate I.V.
Children: 0.27 mEq/kg calcium chloride I.V., repeated in 10 minutes if needed. Check calcium level before giving additional doses.
➢ Magnesium intoxication
Adults: Initially, 7 mEq I.V.; subsequent dosages based on patient response
➢ Exchange transfusions
Adults: 1.35 mEq calcium gluconate I.V. with each 100 ml of citrated blood
➢ Hyperphosphatemia in patients with end-stage renal disease
Adults: Two tablets P.O. daily, given in divided doses t.i.d. with meals. May increase gradually to bring serum phosphate level below 6 mg/dl, provided hypercalcemia doesn't develop.
Dietary supplement
Adults: 500 mg to 2 g P.O. daily

Off-label uses
- Osteoporosis

Contraindications
- Hypersensitivity to drug
- Ventricular fibrillation
- Hypercalcemia and hypophosphatemia
- Cancer
- Renal calculi
- Pregnancy or breastfeeding

Precautions
Use cautiously in:
- renal insufficiency, pernicious anemia, heart disease, sarcoidosis, hyperparathyroidism, hypoparathyroidism
- history of renal calculi
- children.

Administration
- When infusing I.V., don’t exceed a rate of 200 mg/minute.
- Keep patient supine for 15 minutes after I.V. administration to prevent orthostatic hypotension.
- Administer P.O. doses 1 to 1½ hours after meals.
- Know that I.M. or subcutaneous administration is never recommended.
- Be aware that I.V. route is preferred in children.
- Be alert for extravasation, which causes tissue necrosis.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>Immediate</td>
<td>0.5-2 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, weakness, dizziness, syncope, paresthesia
CV: mild blood pressure decrease, bradycardia, arrhythmias, cardiac arrest (with rapid I.V. injection)
GI: nausea, vomiting, diarrhea, constipation, epigastric pain or discomfort
GU: urinary frequency, renal calculi
Metabolic: hypercalcemia
Musculoskeletal: joint pain, back pain
Respiratory: dyspnea
Skin: rash
Other: altered or chalky taste, excessive thirst, allergic reactions (including facial flushing, swelling, tingling, tenderness in hands, and anaphylaxis)

Interactions
Drug-drug. Atenolol, fluoroquinolones, tetracycline: decreased bioavailability of these drugs
Calcium channel blockers: decreased calcium effects
Cardiac glycosides: increased risk of cardiac glycoside toxicity
Iron salts: decreased iron absorption
Sodium polystyrene sulfonate: metabolic alkalosis
Verapamil: reversal of verapamil effects
Drug-diagnostic tests. Calcium: increased level

Drug-food. Foods containing oxalic acid (such as spinach), phytic acid (such as whole grain cereal), or phosphorus (such as dairy products): interference with calcium absorption

Patient monitoring
- Monitor calcium levels frequently, especially in elderly patients.

Patient teaching
- Instruct patient to consume plenty of milk and dairy products during therapy.
- Refer patient to dietitian for help in meal planning and preparation.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.
**calcium polycarbophil**
Equalactin, FiberCon, Fiber-Lax, Konsyl

**Pharmacologic class:** Bulk-forming agent  
**Therapeutic class:** Laxative  
**Pregnancy risk category NR**

**Action**  
Absorbs water, thereby expanding and increasing bulk and moisture content of stool; increased bulk promotes peristalsis and bowel movement.

**Availability**  
Tablets: 500 mg  
Tablets (chewable): 500 mg, 1,250 mg

**Indications and dosages**  
➤ Constipation  
Adults and children ages 12 and older: 1 g P.O. q.i.d. as needed. Maximum dosage is 6 g daily.  
Children ages 7 to 12: 500 mg P.O. one to three times daily as needed. Maximum dosage is 3 g daily.  
Children ages 3 to 6: 500 mg P.O. b.i.d. as needed. Maximum dosage is 1.5 g daily.  
➤ Diarrhea; irritable bowel syndrome  
Adults and children ages 12 and older: 1 g P.O. q.i.d. as needed. Maximum dosage is 6 g daily.  
Children ages 7 to 12: 500 mg P.O. one to three times daily as needed. Maximum dosage is 3 g in a 24-hour period.  
Children ages 3 to 6: 500 mg P.O. b.i.d. as needed. Maximum dosage is 1.5 g daily.

**Contraindications**  
➤ GI obstruction  
➤ Difficulty swallowing

**Precautions**  
Use cautiously in:  
• pregnant or breastfeeding patients  
• children.

**Administration**  
• Give with at least 8 oz of water or other fluid.  
• Administer at least 2 hours before or after other drugs.  
• Make sure patient maintains adequate fluid intake.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>12-24 hr</td>
<td>3 days</td>
<td>Variable</td>
</tr>
</tbody>
</table>

**Adverse reactions**  
CV: chest pain  
GI: nausea, vomiting, abdominal pain, flatulence, rectal bleeding, **intestinal obstruction**  
Respiratory: difficulty breathing  
Other: laxative dependence

**Interactions**  
Drug-drug. **Tetracyclines:** impaired tetracycline absorption  
Drug-herbs. **Lily of the valley, pheasant’s eye, squill:** increased risk of adverse drug reactions

**Patient monitoring**  
➤ Monitor patient for difficulty breathing and signs and symptoms of intestinal obstruction.  
• Assess for rectal bleeding and for failure to respond to drug.  
• Monitor fluid intake and output, and assess hydration status regularly.

**Patient teaching**  
• Instruct patient to take each dose with at least 8 oz of water or other fluid.  
• Advise patient to space doses at least 2 hours apart from other drugs.  
➤ Urge patient to seek immediate medical attention if he experiences chest pain, vomiting, difficulty breathing, or rectal bleeding.

Reactions in **bold** are life-threatening.
Advise patient to tell prescriber if he’s taking other drugs or if he has abdominal pain, nausea, vomiting, or a sudden change in bowel habits lasting 2 weeks or longer.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and herbs mentioned above.

calfactant
Infasurf

**Pharmacologic class:** Natural lung surfactant

**Therapeutic class:** Lung surfactant

**Pregnancy risk category NR**

**Action**
Adsorbs rapidly to air: liquid interface of lung alveoli, stabilizing and modifying surface tension. Restores adequate pressure volumes, gas exchange, and overall lung compliance.

**Availability**
Suspension for intratracheal injection: 6 ml in single-dose vials

**Indications and dosages**
- To prevent respiratory distress syndrome (RDS) in at-risk premature infants; treatment of infants who develop RDS
- Premature infants: 3 ml/kg at birth intratracheally q 12 hours, up to three doses. Initial dose must be administered as two 1.5-ml/kg doses.

**Contraindications**
None

**Precautions**
Use cautiously in:
- altered ventilation requirements

- risk of cyanosis, bradycardia, or airway obstruction.

**Administration**
- Know that drug is intended for intratracheal administration and should be given only by neonatologists or other clinicians experienced in neonatal intubation and ventilatory management in facilities with adequate personnel, equipment, and drugs.
- Don’t dilute drug or shake vial.
- Be aware that drug must be drawn into syringe through 20G or larger needle, taking care to avoid excessive foaming. Needle must be removed before drug is delivered through endotracheal tube.
- Know that infant must receive continuous monitoring before, during, and after drug administration.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intratrach.</td>
<td>Rapid</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- CV: bradycardia
- Respiratory: requirement for manual ventilation or reintubation, airway obstruction, reflux of drug into endotracheal tube, cyanosis

**Interactions**
None significant

**Patient monitoring**
- Monitor infant’s respiratory status continuously during and after drug administration.

**Patient teaching**
- Teach parents about treatment and assure them that infant will be monitored carefully.
candesartan cilexetil
Amias®, Atacand

Pharmacologic class: Angiotensin II receptor antagonist
Therapeutic class: Antihypertensive
Pregnancy risk category C (first trimester), D (second and third trimesters)

FDA BOXED WARNING
● When used during second or third trimester of pregnancy, drug may cause fetal injury and death. Discontinue as soon as possible when pregnancy is detected.

Action
Blocks aldosterone-producing and vasoconstrictive effects of angiotensin II at various receptor sites, including vascular smooth muscle and adrenal glands

Availability
Tablets: 4 mg, 8 mg, 16 mg, 32 mg

Indications and dosages
➣ Hypertension
Adults: 16 mg P.O. daily. Start at lower dosage if patient is receiving diuretics or is volume depleted. Range is 2 to 32 mg/day as a single dose or divided in two doses.

Dosage adjustment
● Renal impairment
● Hepatic insufficiency

Contraindications
● Hypersensitivity to drug
● Pregnancy or breastfeeding
● Children (safety and efficacy not established)

Precautions
Use cautiously in:
● heart failure, renal or hepatic impairment, obstructive biliary disorders
● volume- or salt-depleted patients receiving high doses of diuretics
● black patients
● females of childbearing age.

Administration
● Give with or without food.
● Supervise patient closely if he is receiving concurrent diuretics or is otherwise at risk for intravascular volume depletion.
● Know that diuretic may be added to regimen if candesartan alone doesn’t control blood pressure.

Route Onset Peak Duration
P.O. 2-4 hr 6-8 hr 24 hr

Adverse reactions
CNS: dizziness, syncope, fatigue, headache
CV: hypotension, chest pain, peripheral edema, mitral or aortic valve stenosis
EENT: ear congestion or pain, sinus disorders, sore throat
GI: nausea, diarrhea, constipation, abdominal pain, dry mouth
GU: albuminuria, renal failure
Hepatic: hepatitis
Metabolic: gout, hyperkalemia
Musculoskeletal: arthralgia, back pain, muscle weakness
Respiratory: upper respiratory tract infection, cough, bronchitis
Other: dental pain, fever

Interactions
Drug-drug. Diuretics, other antihypertensives: increased risk of hypotension
Lithium: increased lithium blood level
Nonsteroidal anti-inflammatory drugs: decreased antihypertensive effect
Potassium-sparing diuretics, potassium supplements: increased risk of hyperkalemia

Reactions in bold are life-threatening.

Clinical alert
Drug-food. Salt substitutes containing potassium: increased risk of hyperkalemia

Drug-herbs. Ephedra (ma huang), licorice, yohimbine: decreased antihypertensive effect

Patient monitoring
● Monitor electrolyte levels and kidney and liver function test results.
● Assess blood pressure regularly to gauge drug efficacy.
● Closely monitor patient with renal dysfunction who is receiving concurrent diuretics.

Patient teaching
● Teach patient about lifestyle changes that help control blood pressure, such as proper diet, exercise, stress reduction, smoking cessation, and moderation of alcohol intake.
● Instruct patient to use reliable birth control method and to contact prescriber if she suspects she’s pregnant.
● Caution patient not to take herbs without consulting prescriber.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, foods, and herbs mentioned above.

capecitabine
Xeloda

Pharmacologic class: Fluoropyrimidine, antimetabolite (pyrimidine analog)

Therapeutic class: Antineoplastic

Pregnancy risk category D

FDA BOXED WARNING
● In patients receiving concomitant oral coumarin-derivative anticoagulants (such as warfarin and phenprocoumon), monitor International Normalized Ratio (INR) or prothrombin time (PT) frequently to allow appropriate anticoagulant dosage adjustment. Altered coagulation parameters, bleeding, and death have occurred in patients taking this drug combination. Postmarketing reports show significant INR and PT increases in patients stabilized on anticoagulants when capecitabine therapy began. Age older than 60 and cancer diagnosis independently increase coagulopathy risk.

Action
Enzymatically converts to 5-fluouracil, which injures cells by interfering with DNA synthesis, cell division, RNA processing, and protein synthesis

Availability
Tablets: 150 mg, 500 mg

Indications and dosages
Metastatic breast cancer resistant to both paclitaxel and a chemotherapy regimen that includes anthracycline; metastatic colorectal cancer when treatment with fluoropyrimidine therapy alone is preferred

Adults: Initially, 2,500 mg/m²/day P.O. in two divided doses for 2 weeks, followed by a 1-week rest period; administered in 3-week cycles

Dosage adjustment
● Renal impairment
● Hepatic impairment
● Elderly patients

Contraindications
● Hypersensitivity to drug
● Severe renal impairment
● Pregnancy or breastfeeding

Precautions
Use cautiously in:
● mild to moderate renal impairment, hepatic impairment, severe diarrhea,
coronary artery disease, intestinal disease, infection, coagulopathy
● children younger than age 18.

**Administration**
● Give with water within 30 minutes after a meal.
● If dosage must be lowered because of toxicity, don’t increase dosage later.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1.5-2 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
CNS: dizziness, fatigue, headache, insomnia, paresthesia
CV: edema
EENT: eye irritation
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia, stomatitis, intestinal obstruction
Hematologic: anemia, lymphopenia, neutropenia, thrombocytopenia
Metabolic: dehydration
Musculoskeletal: myalgia, limb pain
Skin: dermatitis, alopecia, nail disorder, hand and foot syndrome (palmar-plantar erythrodysesthesia)
Other: fever

**Interactions**
Drug-drug. Antacids: increased capecitabine blood level
Leucovorin: increased cytotoxicity
Live-virus vaccines: impaired ability to mount an immune response to vaccine
Phenytoin: increased phenytoin blood level
Warfarin: increased risk of bleeding
Drug-diagnostic tests. Bilirubin: increased level
Hemoglobin, neutrophils, platelets, white blood cells: decreased levels

**Patient monitoring**
● Monitor patient for signs and symptoms of toxicity. Be prepared to reduce dosage or withhold drug when indicated.
● Stay alert for signs and symptoms of infection.

● Carefully assess fluid and electrolyte status if patient has severe diarrhea.
● Monitor weight, CBC, International Normalized Ratio, prothrombin time, and kidney and liver function test results.
● Evaluate closely for adverse reactions in patients older than age 80.

**Patient teaching**
● Advise patient to take drug with water within 30 minutes after a meal.
● Instruct patient to immediately report nausea, vomiting, diarrhea, mouth ulcers, swollen joints, temperature above 100.5°F (38°C), and other signs or symptoms of infection.
● Tell patient to expect dosage adjustments during therapy.
● Urge patient to use reliable birth control method because drug may harm fetus if she becomes pregnant.
● Caution patient not to breastfeed during therapy.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

---

**captopril**
Acepril®, Apo-Capto®, Capoten, Dom-Captopril, Gen-Captopril®, Med-Captopril

**Pharmacologic class:** Angiotensin-converting enzyme (ACE) inhibitor

**Therapeutic class:** Antihypertensive

**Pregnancy risk category C** (first trimester), **D** (second and third trimesters)

Reactions in **bold** are life-threatening.
FDA BOXED WARNING

- When used during second or third trimester of pregnancy, drug may cause fetal injury and death. Discontinue as soon as possible when pregnancy is detected.

### Action

Prevents conversion of angiotensin I to angiotensin II, which leads to decreased vasoconstriction and, ultimately, to lower blood pressure. Also decreases blood pressure by increasing plasma renin secretion from kidney and reducing aldosterone secretion from adrenal cortex. Decreased aldosterone secretion prevents sodium and water retention.

### Availability

**Tablets:** 12.5 mg, 25 mg, 50 mg, 100 mg

### Indications and dosages

#### Hypertension

**Adults:** 12.5 to 25 mg P.O. two to three times daily; may be increased up to 150 mg/day at 1- to 2-week intervals. Usual dosage is 50 mg t.i.d. If patient is receiving diuretics, start with 6.25 to 12.5 mg P.O. two to three times daily. If blood pressure isn’t adequately controlled after 1 to 2 weeks, add diuretic, as prescribed. If further blood pressure decrease is needed, dosage may be raised to 150 mg P.O. t.i.d. while patient continues on diuretic. Maximum dosage is 450 mg/day.

#### Heart failure

**Adults:** Usual initial dosage is 25 mg P.O. t.i.d. After increasing to 50 mg P.O. t.i.d. (if indicated), do not increase dosage further for 2 weeks, to determine satisfactory response. Don’t exceed 450 mg/day.

#### Left ventricular dysfunction after myocardial infarction

**Adults:** 6.25 mg P.O. as a test dose, followed by 12.5 mg t.i.d. May increase up to 50 mg t.i.d.

#### Diabetic nephropathy

**Adults:** 25 mg P.O. t.i.d.

### Dosage adjustment

- Renal impairment

### Off-label uses

- Bartter’s syndrome
- Hypertension associated with scleroderma
- Management of hypertensive crisis
- Raynaud’s syndrome
- Rheumatoid arthritis
- Severe childhood hypertension

### Contraindications

- Hypersensitivity to drug or other ACE inhibitors
- Angioedema (hereditary or idiopathic)
- Pregnancy

### Precautions

Use cautiously in:

- renal or hepatic impairment, hypovolemia, hyponatremia, aortic stenosis and hypertrophic cardiomyopathy, cardiac or cerebrovascular insufficiency, systemic lupus erythematosus
- family history of angioedema
- black patients with hypertension
- elderly patients
- breastfeeding patients
- children.

### Administration

- Discontinue other antihypertensives 1 week before starting captopril, if possible.
- Give 1 hour before meals on empty stomach.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>0.25-1 hr</td>
<td>1-1.5 hr</td>
<td>6-12 hr</td>
</tr>
</tbody>
</table>

---

**Canada**  
**UK**  
**Hazardous drug**  
**High alert drug**
### Adverse reactions

**CNS:** headache, dizziness, drowsiness, fatigue, weakness, insomnia  
**CV:** angina pectoris, tachycardia, hypotension  
**EENT:** sinusitis  
**GI:** nausea, diarrhea, anorexia  
**GU:** proteinuria, erectile dysfunction, decreased libido, gynecomastia, renal failure  
**Hematologic:** anemia, agranulocytosis, leukopenia, pancytopenia, thrombocytopenia  
**Metabolic:** hyperkalemia  
**Respiratory:** cough, asthma, bronchitis, dyspnea, eosinophilic pneumonitis  
**Skin:** rash, angioedema  
**Other:** altered taste, fever

### Interactions

**Drug-drug.** *Allopurinol:* increased risk of hypersensitivity reaction  
*Antacids:* decreased captopril absorption  
*Antihypertensives, general anesthetics that lower blood pressure, nitrates, phenothiazines:* additive hypotension  
*Cyclosporine:* hyperkalemia  
*Digoxin, lithium:* increased blood levels of these drugs, increased risk of toxicity  
*Epoetin alfa:* additive hyperkalemia  
*Indomethacin:* reduced antihypertensive effect of captopril  
*Nonsteroidal anti-inflammatory drugs:* decreased antihypertensive response  
*Potassium-sparing diuretics, potassium supplements:* hyperkalemia  
*Probencid:* decreased elimination and increased blood level of captopril  

**Drug-food.** *Any food:* decreased captopril absorption  
*Salt substitutes containing potassium:* hyperkalemia  
**Drug-herbs.** *Capsaicin, yohimbine:* cough  
**Drug-behaviors.** *Acute alcohol ingestion:* additive hypotension

### Patient monitoring

- Monitor for sudden blood pressure drop within 3 hours of initial dose if patient is receiving concurrent diuretics and on a low-sodium diet.  
- Monitor hematologic, kidney, and liver function test results.  
- Check for proteinuria monthly and after first 9 months of therapy.

### Patient teaching

- Tell patient to take drug 1 hour before meals on empty stomach.  
- Advise patient to report fever, rash, sore throat, mouth sores, fast or irregular heartbeat, chest pain, or cough.  
- Inform patient that dizziness, fainting, and light-headedness usually disappear once his body adjusts to drug.  
- Tell patient his ability to taste may decrease during first 2 to 3 months of therapy.  
- Caution patient to avoid over-the-counter medications unless approved by prescriber.  
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

---

Reactions in **bold** are life-threatening.  

---

*Clinical alert*
**carbamazepine**

Apo-Carbamazepine®, Arbil®, Bio-Carbamazepine®, Carbegen®, Carbamaz®, Carbatrol, Dom-Carbamazepine®, Epimaz®, Epitol, Equetro, Gen-Carbamazepine®, Mazepine®, Novo-Carbamazepine®, Nu-Carbamazepine®, PHL-Carbamazepine®, PMS-Carbamazepine®, Sandoz Carbamazepine®, Tegretol, Tegretol-XR

**Pharmacologic class:** Iminostilbene derivative  
**Therapeutic class:** Anticonvulsant  
**Pregnancy risk category D**

**FDA BOXED WARNING**

- Prescriber should be thoroughly familiar with prescribing information, particularly regarding use with other drugs (especially those that increase toxicity potential).
- Drug has been linked to aplastic anemia and agranulocytosis.
- Transient or persistent decreases in platelet or white blood cell (WBC) counts have occurred, but data aren’t available to accurately estimate incidence or outcome. Rarely, leukopenia cases progressed to aplastic anemia or agranulocytosis.
- Obtain complete pretreatment hematologic tests as baseline. If WBC or platelet count drops during therapy, monitor closely. Consider withdrawing drug if evidence of significant bone marrow depression develops.

**Action**

Unclear. Chemically related to tricyclic antidepressants (TCAs). Anticonvulsant action may result from reduction in polysynaptic responses and blocking of post-tetanic potentiation.

**Availability**

- Capsules (extended-release): 200 mg, 300 mg
- Oral suspension: 100 mg/5 ml
- Tablets: 200 mg
- Tablets (chewable): 100 mg, 200 mg
- Tablets (extended-release): 100 mg, 200 mg, 400 mg

**Indications and dosages**

➤ Prophylaxis of generalized tonic-clonic, mixed, and complex-partial seizures

**Adults and children ages 12 and older:** Initially, 200 mg P.O. b.i.d. (tablets) or 100 mg q.i.d. (oral suspension). Increase by up to 200 mg/day q 7 days until therapeutic blood levels are reached. Usual maintenance dosage is 600 to 1,200 mg/day in divided doses q 6 to 8 hours. In children ages 12 to 15, don’t exceed 1 g/day. Give extended-release forms b.i.d.

**Children ages 6 to 12:** Initially, 100 mg P.O. b.i.d. (tablets) or 50 mg q.i.d. (oral suspension). Increase by up to 100 mg weekly until therapeutic levels are reached. Usual maintenance dosage is 400 to 800 mg/day. Don’t exceed 1 g/day. Give extended-release forms b.i.d.

**Children younger than age 6:** Initially, 10 to 20 mg/kg/day P.O. in two or three divided doses. May increase by up to 100 mg/day at weekly intervals. Usual maintenance dosage is 250 to 350 mg/day. Don’t exceed 400 mg/day.

➤ Trigeminal neuralgia

**Adults:** Initially, 100 mg b.i.d. (tablets) or 50 mg q.i.d. (oral suspension). Increase by up to 200 mg/day until pain relief occurs; then give maintenance dosage of 200 to 1,200 mg/day in divided doses. Usual maintenance range is 400 to 800 mg/day.
Off-label uses
- Alcohol, cocaine, or benzodiazepine withdrawal
- Atypical psychoses
- Central diabetes insipidus
- Mood disorders
- Neurogenic pain

Contraindications
- Hypersensitivity to drug or TCAs
- MAO inhibitor use within past 14 days
- Bone marrow depression
- Pregnancy or breastfeeding

Precautions
Use cautiously in:
- cardiac disease, hepatic disease, increased intraocular pressure, mixed seizure disorders, glaucoma
- elderly males with prostatic hypertrophy
- psychiatric patients.

Administration
- Don’t give within 14 days of MAO inhibitor.
- Give tablets with meals; may give extended-release capsules without regard to meals.
- Don’t give with grapefruit juice.
- If desired, contents of extended-release capsules may be sprinkled over food; however, capsule and contents shouldn’t be crushed or chewed.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Up to</td>
<td>4-5 hr</td>
<td>6-12 hr</td>
</tr>
<tr>
<td></td>
<td>1 mo</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P.O.</td>
<td>Up to</td>
<td>2-12 hr</td>
<td>12 hr</td>
</tr>
<tr>
<td></td>
<td>(extended)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 mo</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: ataxia, drowsiness, fatigue, psychosis, syncope, vertigo, headache, worsening of seizures
CV: hypertension, hypotension, arrhythmias, atrioventricular block, aggravation of coronary artery disease, heart failure

EENT: blurred vision, diplopia, nystagmus, corneal opacities, conjunctivitis, pharyngeal dryness
GI: nausea, vomiting, diarrhea, abdominal pain, stomatitis, glossitis, dry mouth, anorexia
GU: urinary hesitancy, retention, or frequency; albuminuria; glycosuria; erectile dysfunction
Hematologic: eosinophilia, lymphadenopathy, agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia
Hepatic: hepatitis
Metabolic: syndrome of inappropriate antidiuretic hormone secretion
Respiratory: pneumonitis
Skin: photosensitivity, rash, urticaria, diaphoresis, erythema multiforme, Stevens-Johnson syndrome
Other: weight gain, chills, fever

Interactions
Drug-drug. Acetaminophen: increased risk of acetaminophen-induced hepatotoxicity, decreased acetaminophen efficacy
Anticoagulants, bupropion: increased metabolism of these drugs, causing decreased efficacy
Barbiturates: decreased barbiturate blood level, increased carbamazepine blood level
Charcoal: decreased carbamazepine absorption
Cimetidine, danazol, diltiazem: increased carbamazepine blood level
Cyclosporine, felbamate, felodipine, haloperidol: decreased blood levels of these drugs
Doxycycline: shortened doxycycline half-life and reduced antimicrobial effect
Hormonal contraceptives: decreased contraceptive efficacy, possibly leading to pregnancy
Hydantoins: increased or decreased hydantoin blood level, decreased carbamazepine blood level

Reactions in bold are life-threatening.
Isoniazid: increased risk of carbamazepine toxicity and isoniazid hepatotoxicity
Lithium: increased risk of CNS toxicity
Macrolide antibiotics (such as clarithromycin and erythromycin), propoxyphene, selective serotonin reuptake inhibitors (such as fluoxetine and fluvoxamine), verapamil: increased carbamazepine blood level, greater risk of toxicity
MAO inhibitors: high fever, hypertension, seizures, and possibly death
Nondepolarizing neuromuscular blockers: shortened carbamazepine duration of action
TCAs: increased carbamazepine blood level and greater risk of toxicity, decreased TCA blood level
Valproic acid: decreased valproic acid blood level with possible loss of seizure control, variable changes in carbamazepine blood level

**Drug-diagnostic tests.** Blood urea nitrogen, eosinophils, liver function tests: increased values
Granulocytes, hemoglobin, platelets, thyroid function tests, white blood cells: decreased values

**Drug-food.** Grapefruit juice: increased drug blood level and effects

**Drug-herbs.** Plantain (psyllium seed): inhibited GI absorption of drug

**Patient monitoring**

- Monitor patient closely. Institute seizure precautions if drug must be withdrawn suddenly.
- Assess for history of psychosis; drug may activate symptoms.
- Monitor baseline hematologic, kidney, and liver function test results.
- During dosage adjustments, monitor vital signs and fluid intake and output. Stay alert for fluid retention, renal failure, and cardiovascular complications.
- With high doses, monitor CBC weekly for first 3 months and then monthly to detect bone marrow depression.

**Patient teaching**

- Tell patient that he may sprinkle contents of extended-release capsules over food, but that he shouldn’t crush or chew capsule or contents.
- Advise patient that coating on extended-release capsules may be visible in stools because it isn’t absorbed.
- Tell patient to take drug with meals to minimize GI upset.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, alertness, and vision.
- Advise patient to avoid excessive sun exposure and to wear protective clothing and sunscreen.
- Inform female patient that drug may interfere with hormonal contraception. Advise her to use alternative birth-control method.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

**carbidopa-levodopa**


**Pharmacologic class:** Dopamine agonist

**Therapeutic class:** Antiparkinsonian

**Pregnancy risk category C**

**Action**

After conversion to dopamine in CNS, levodopa acts as a neurotransmitter,
relieving symptoms of Parkinson’s disease. Carbidopa prevents destruction of levodopa, making more levodopa available to be decarboxylated to dopamine in brain.

**Availability**

*Tablets*: 10 mg carbidopa/100 mg levodopa, 25 mg carbidopa/100 mg levodopa, 25 mg carbidopa/250 mg levodopa

*Tablets (extended-release)*: 25 mg carbidopa/100 mg levodopa, 50 mg carbidopa/200 mg levodopa

**Indications and dosages**

> Idiopathic Parkinson’s disease; parkinsonism; symptomatic parkinsonism

*Conventional tablets—*

**Adults not currently receiving levodopa:** Initially, 10 mg carbidopa/100 mg levodopa P.O. three to four times daily or 25 mg carbidopa/100 mg levodopa t.i.d.; may be increased q 1 to 2 days until desired effect occurs

**Adults converting from levodopa alone (less than 1.5 g/day):** Initially, 25 mg carbidopa/100 mg levodopa three to four times daily; may be increased q 1 to 2 days until desired effect occurs

**Adults converting from levodopa alone (more than 1.5 g/day):** Initially, 25 mg carbidopa/250 mg levodopa three to four times daily; may be increased q 1 to 2 days until desired effect occurs

*Extended-release tablets—*

**Adults not currently receiving levodopa:** Initially, 50 mg carbidopa/200 mg levodopa P.O. b.i.d., with doses spaced at least 6 hours apart

**Adults converting from standard carbidopa-levodopa:** Initiate therapy with at least 10% more levodopa content/day (may need up to 30% more) given at 4- to 8-hour intervals while awake; wait 3 days between dosage changes. Some patients may need higher dosages and shorter dosing intervals.

**Contraindications**

- Hypersensitivity to drug or tartrazine
- Angle-closure glaucoma
- MAO inhibitor use within past 14 days
- Malignant melanoma
- Breastfeeding

**Precautions**

Use cautiously in:

- cerebrovascular, renal, hepatic, or endocrine disease
- history of cardiac, psychiatric, or ulcer disease
- abrupt drug discontinuation or dosage
- pregnant patients
- children ages 18 and under (safety not established).

**Administration**

- Give dose as close as possible to time ordered to ensure stable drug blood level.
- Know that giving extended-release form with food increases drug bioavailability.
- If patient needs general anesthesia, continue drug therapy as appropriate (if he’s allowed to have oral fluids and drugs).

Be aware that drug shouldn’t be withdrawn abruptly.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>40-120 min</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: anxiety, dizziness, hallucinations, memory loss, headache, numbness, confusion, insomnia, nightmares, delusions, psychotic changes, depression, dementia, poor coordination, worsening hand tremor
CV: cardiac irregularities, palpitations, orthostatic hypotension

EENT: blurred vision, diplopia, mydriasis, eyelid twitching, difficulty swallowing

GI: nausea, vomiting, diarrhea, constipation, abdominal pain or discomfort, flatulence, excessive salivation, dry mouth, anorexia, upper GI hemorrhage (with history of peptic ulcer)

GU: urinary retention, urinary incontinence, dark urine

Hematologic: hemolytic anemia, leukopenia

Hepatic: hepatotoxicity

Musculoskeletal: muscle twitching, involuntary or spasmodic movements

Respiratory: hyperventilation

Skin: melanoma, flushing, rash, abnormally dark sweat

Other: altered or bitter taste, burning sensation of tongue, tooth grinding (especially at night), weight changes, hot flashes, hiccups

Interactions

Drug-drug. Anticholinergics: decreased carbidopa-levodopa absorption

Antihypertensives: additive hypotension

Haloperidol, papaverine, phenothiazines, phentoin, reserpine: reversal of carbidopa-levodopa effects

Inhalation hydrocarbon anesthetics: increased risk of arrhythmias

MAO inhibitors: hypertensive reactions

Methyldopa: altered efficacy of carbidopa-levodopa, increased risk of adverse CNS reactions

Pyridoxine: antagonism of carbidopa-levodopa effects

Selegiline: increased risk of adverse reactions

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, lactate dehydrogenase, low-density lipoproteins, protein-bound iodine, uric acid: increased levels

Coombs’ test: false-positive result

Granulocytes, hemoglobin, platelets, white blood cells: decreased values

Urine glucose, urine ketones: test interference

Drug-food. Foods rich in pyridoxine (liver, yeast, cereals): reversal of carbidopa-levodopa effects

Drug-herbs. Kava: decreased carbidopa-levodopa efficacy

Octacosanol: worsening of dyskinesia

Drug-behaviors. Cocaine use: increased risk of adverse reactions to carbidopa-levodopa

Patient monitoring

- Monitor patient for orthostatic hypotension.
- Assess patient’s need for drug “holiday” if his response to drug decreases.

Patient teaching

Inform patient that muscle and eyelid twitching may indicate toxicity. Tell him to report these symptoms immediately.

Caution patient not to stop taking drug abruptly.

- Instruct patient to swallow extended-release tablets whole without crushing or chewing them.
- Advise patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness caused by sudden blood pressure drop.
- Tell patient that drug may darken or discolor his urine and sweat.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.
carbidopa-levodopa-entacapone

Stalevo

**Pharmacologic class:** Dopamine agonist
**Therapeutic class:** Antiparkinsonian
**Pregnancy risk category C**

**Action**
After conversion to dopamine in CNS, levodopa acts as a neurotransmitter, relieving symptoms of Parkinson’s disease. Carbidopa prevents destruction of levodopa, making more levodopa available to be decarboxylated to dopamine in brain. Entacapone increases levodopa blood level by more than 30% and prolongs levodopa’s effects.

**Availability**
*Tablets:* 12.5 mg carbidopa/50 mg levodopa/200 mg entacapone; 25 mg carbidopa/100 mg levodopa/200 mg entacapone; 37.5 mg carbidopa/150 mg levodopa/200 mg entacapone; 50 mg carbidopa/200 mg levodopa/200 mg entacapone

**Indications and dosages**
*Idiopathic Parkinson’s disease; postencephalitic parkinsonism; symptomatic parkinsonism resulting from carbon monoxide or manganese intoxication*

**Adults:** Optimal daily dosage determined by careful individual titration. Target carbidopa dosage is 70 mg to 100 mg P.O. daily, not to exceed 200 mg; maximum entacapone dosage is 1,600 mg P.O. daily. Patients should receive no more than eight tablets daily.

**Contraindications**
- Hypersensitivity to drug
- Malignant melanoma (or history of this disease)
- MAO inhibitor use within 14 days
- Angle-closure glaucoma
- Undiagnosed skin lesions
- Breastfeeding

**Precautions**
Use cautiously in:
- biliary obstruction, renal disease, cerebrovascular disease, endocrine disorders, hepatic impairment, psychiatric disorders
- history of cardiac disease or GI ulcers
- pregnant patients
- children younger than age 18 (safety not established).

**Administration**
- Give with meals if GI upset occurs.
- Don’t crush or break tablets.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2-3 hr</td>
<td>12 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
CNS: involuntary movements, bradykinesia, anxiety, dizziness, hallucinations, memory loss, psychiatric problems, trismus, increased hand tremor, headache, numbness, weakness, confusion, insomnia, nightmares, delusions, psychotic changes, depression, dementia
CV: cardiac irregularities, palpitations, orthostatic hypotension, *arrhythmias*
EENT: blurred vision, blepharospasm, mydriasis, diplopia
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dysphagia, burning sensation, flatulence, anorexia, *upper GI hemorrhage*
GU: urinary retention, urinary incontinence, dark urine
Hematologic: *hemolytic anemia, leukopenia*
Hepatic: hepatotoxicity
Musculoskeletal: muscle twitching
Respiratory: hiccups, hyperventilation, *pulmonary infiltrates*

Reactions in **bold** are life-threatening.
Skin: melanoma, rash, flushing, abnormally dark sweat
Other: sialorrhea, weight changes, hot flashes

Interactions
Drug-drug. Ampicillin, chloramphenicol, cholestyramine, erythromycin, probenecid, rifampin: interference with biliary excretion, additive increase in entacapone blood level
Anticholinergics: decreased levodopa absorption
Antihypertensives: additive hypotension
Haloperidol, papaverine, phenothiazines, phenytoin, reserpine: reversal of levodopa effects
Inhalation hydrocarbon anesthetics: increased risk of arrhythmias
MAO inhibitors: severe hypertension
Methyldopa: altered levodopa efficacy, increased risk of adverse CNS effects
Pyridoxine: antagonism of levodopa’s beneficial effects

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, lactate dehydrogenase, protein-bound iodine, uric acid: increased levels
Coombs’ test: false-positive result
Granulocytes, hemoglobin, platelets, white blood cells: decreased values
Urine glucose and ketone tests: test interference

Drug-food. Foods high in protein: reduced absorption of carbidopa-levodopa-entacapone
Foods high in pyridoxine: reversal of levodopa effects

Drug-herbs. Kava: decreased levodopa efficacy
Octacosanol: worsening of dyskinesia

Patient monitoring
- Monitor patient closely for mental changes, especially psychosis and depression. Report suicidal ideation immediately.
- Assess neurologic status closely to evaluate drug efficacy and identify adverse effects.
- Monitor CBC with white cell differential; also monitor liver function test results.
- Evaluate vital signs. Watch for arrhythmias, orthostatic hypotension, and respiratory problems.
- Assess fluid intake and output. Check for urinary problems.

Patient teaching
- Inform patient or caregiver that drug may cause significant neurologic effects. Instruct him to report anxiety, dizziness, hallucinations, memory loss, increased hand tremor, headache, confusion, nightmares, and depression.
- Tell patient or caregiver to report breathing problems.
- Teach patient or caregiver about recommended home modifications and other safety measures to reduce risk of injury.
- Advise patient to rise slowly and carefully. Drug may cause blood pressure to drop if he sits up or stands suddenly.
- Caution patient to avoid hazardous activities until disease is well controlled and he knows how drug affects concentration, alertness, vision, and motor function.
- Advise patient to minimize GI upset by eating small, frequent servings of healthy food and ensuring adequate fluid intake.
- Tell patient he’ll undergo regular blood testing while taking this drug.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.
carboplatin

**Pharmacologic class:** Alkylating agent  
**Therapeutic class:** Antineoplastic  
**Pregnancy risk category D**

**FDA BOXED WARNING**
- Give under supervision of physician experienced in cancer chemotherapy, in facility with adequate diagnostic and treatment resources.  
- Bone marrow suppression is dose-related and may be severe, resulting in infection and bleeding. Anemia may be cumulative and warrant transfusions.  
- Vomiting is a common adverse effect.  
- Anaphylactic-like reactions may occur within minutes of administration.

**Action**  
Inhibits DNA synthesis by causing cross-linking of parent DNA strands; interferes with RNA transcription, causing growth imbalance that leads to cell death. Cell-cycle-phase nonspecific.

**Availability**  
*Injection:* 50-mg, 150-mg, and 450-mg vials

**Indications and dosages**  
Initial treatment of advanced ovarian cancer or palliative treatment of ovarian cancer unresponsive to other chemotherapeutic modalities  
**Adults:** Initially, 300 mg/m² I.V. (given with cyclophosphamide) at 4-week intervals. For refractory tumors, 360 mg/m² I.V. as a single dose; may be repeated at 4-week intervals, depending on response. However, single dose shouldn’t be repeated until neutrophil count is at least 2,000/mm³ and platelet count at least 100,000/mm³. Subsequent dosages are based on blood counts.

**Dosage adjustment**  
- Renal impairment  
- Reduced bone marrow reserve

**Off-label uses**  
- Advanced endometrial cancer  
- Advanced or recurrent squamous cell carcinoma of head and neck  
- Relapsed and refractory acute leukemia  
- Small-cell lung cancer  
- Testicular cancer

**Contraindications**  
- Hypersensitivity to drug, cisplatin, or mannitol  
- Pregnancy or breastfeeding

**Precautions**  
Use cautiously in:  
- hearing loss, electrolyte imbalances, renal impairment, active infections, diminished bone marrow reserve  
- females of childbearing age.

**Administration**  
- Premedicate with antiemetics, as prescribed.  
- When preparing and administering drug, follow facility protocol for handling cytotoxic drugs.  
- Reconstitute powder for injection by adding sterile water for injection, 0.9% sodium chloride injection, or 5% dextrose injection, as appropriate, to provide 10-mg/ml solution. Drug may be further diluted to concentrations as low as 0.5 mg/ml.  
- Don’t use with needles or I.V. sets containing aluminum.  
- Administer I.V. infusion over at least 15 minutes.  
- Make sure patient maintains adequate fluid intake.  
- Know that drug is given in combination with other agents.

Reactions in bold are life-threatening.
<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>21 days</td>
<td>28 days</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: weakness, dizziness, confusion, peripheral neuropathy, cerebrovascular accident
CV: heart failure, embolism
EENT: visual disturbances, ototoxicity
GI: nausea, vomiting, constipation, diarrhea, abdominal pain, stomatitis
GU: gonadal suppression, nephrotoxicity
Hematologic: anemia, leukopenia, thrombocytopenia, neutropenia
Hepatic: hepatitis
Metabolic: hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia
Respiratory: bronchospasm
Skin: alopecia, rash, urticaria, erythema, pruritus
Other: altered taste, hypersensitivity reactions, anaphylaxis

**Interactions**

Drug-drug. Live-virus vaccines: decreased antibody response to vaccine, increased risk of adverse reactions
Myelosuppressants: additive bone marrow depression
Nephrotoxic or ototoxic drugs (such as aminoglycosides, loop diuretics): additive nephrotoxicity or ototoxicity
Phenytoin: decreased phenytoin blood level

Drug-diagnostic tests. Alkaline phosphatase (ALP), aspartate aminotransferase (AST), blood urea nitrogen, creatinine: increased values
Electrolytes, hematocrit, hemoglobin, neutrophils, platelets, red blood cells, white blood cells: decreased values

**Patient monitoring**

- Assess for signs and symptoms of hypersensitivity reactions.
- Monitor CBC to help detect drug-induced anemia and other hematologic reactions.

- Monitor ALP, AST, and total bilirubin levels.
- Evaluate fluid and electrolyte balance.

**Patient teaching**

- Instruct patient to report signs and symptoms of allergic response and other adverse reactions, such as breathing problems, mouth sores, rash, itching, and reddened skin.
- Advise patient to report unusual bleeding or bruising.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Urge patient to avoid activities that can cause injury. Advise him to use soft toothbrush and electric razor to avoid gum and skin injury.
- Instruct patient to drink plenty of fluids to ensure adequate urinary output.
- Provide dietary counseling and refer patient to dietitian as needed if GI adverse effects significantly limit food intake.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

---

carisoprodol

**Pharmacologic class:** Carbamate derivative

**Therapeutic class:** Centrally acting skeletal muscle relaxant

**Controlled substance schedule IV**
(in some states)

**Pregnancy risk category C**

- Canada
- UK
- Hazardous drug
- High alert drug
Action
Unknown. May modify central perception of pain without modifying pain reflexes. Skeletal muscle relaxation may result from sedative properties or from inhibition of activity in descending reticular formation and spinal cord.

Availability
Tablets: 250 mg, 350 mg

Indications and dosages
➣ Adjunctive treatment of muscle spasms associated with acute painful musculoskeletal conditions
Adults: 350 mg P.O. q.i.d.
➣ Relief of discomfort associated with acute painful musculoskeletal conditions
Adults: 250 to 350 mg P.O. t.i.d. and at bedtime

Contraindications
● Hypersensitivity to drug or meprobamate
● Porphyria or suspected porphyria

Precautions
Use cautiously in:
● severe hepatic or renal disease
● history of substance abuse
● pregnant or breastfeeding patients
● children ages 12 and younger.

Administration
● Give last daily dose at bedtime.
● Administer with food if GI upset occurs.
● If patient can’t swallow tablets, mix with syrup, chocolate, or jelly.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30 min</td>
<td>1-2 hr</td>
<td>4-6 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, drowsiness, agitation, ataxia, depression, headache, insomnia, vertigo, tremor, depression
CV: hypotension, tachycardia

GI: nausea, vomiting, epigastric distress
Hematologic: eosinophilia, leukopenia
Respiratory: asthma attacks
Skin: flushing (especially of face), rash, pruritus, erythema multiforme
Other: hiccups, fever, psychological drug dependence, anaphylactic shock

Interactions
Drug-drug. Antihistamines, opioids, sedative-hypnotics: additive CNS depression
Drug-diagnostic tests. Eosinophils: increased count
Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression
Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring
● When giving to breastfeeding patient, watch for signs of sedation and GI upset in infant.
● Monitor range of motion, stiffness, and discomfort level.
● Know that drug is metabolized to meprobamate. Monitor for drug dependence, especially in patients with history of substance abuse.

Patient teaching
● Tell patient that psychological drug dependence may occur.
● Instruct patient to avoid over-the-counter drugs and alcohol, because they may increase CNS depression.
● Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.
carmustine
BiCNU, Gliadel Wafer

Pharmacologic class: Alkylating agent
Therapeutic class: Antineoplastic
Pregnancy risk category D

FDA BOXED WARNING
- Give under supervision of physician experienced in cancer chemotherapy.
- Most common and severe toxic effect is bone marrow suppression—notably thrombocytopenia and leukopenia, which may contribute to bleeding and overwhelming infections in already compromised patient. Monitor blood counts weekly for at least 6 weeks after dose. Don’t give courses more often than every 6 weeks.

Action
Unclear. Thought to interfere with bacterial cell-wall synthesis by cross-linking strands of DNA and disrupting RNA transcription, causing cell to rupture and die. Exhibits minimal immunosuppressant activity.

Availability
intracavitary wafer implant: 7.7 mg (available in packages of eight wafers)
powder for injection: 100-mg vials

Indications and dosages
- Brain tumor; multiple myeloma; Hodgkin’s disease; other lymphomas
Adults and children: 150 to 200 mg/m² I.V. as a single dose q 6 to 8 weeks, or 75 to 100 mg/m²/day for 2 days q 6 weeks, or 40 mg/m²/day for 5 days q 6 weeks. Repeat dose q 6 weeks if platelet count exceeds 100,000/mm³ and white blood cell (WBC) count exceeds 4,000/mm³.

- Adjunct to brain surgery
Adults: Up to 61.6 mg (eight wafers) implanted in surgical cavity created during brain tumor resection

Dosage adjustment
- Based on WBC and platelet counts

Off-label uses
- Mycosis fungoides

Contraindications
- Hypersensitivity to drug
- Radiation therapy
- Chemotherapy
- Pregnancy or breastfeeding

Precautions
Use cautiously in:
- infection; depressed bone marrow reserve; respiratory, hepatic, or renal impairment
- females of childbearing age

Administration
- Know that drug may be used alone or in conjunction with other treatments, such as surgery or radiation.
- Follow facility policy when preparing, administering, and handling drug.
- Reconstitute drug by dissolving vial of 100 mg with 3 ml of sterile dehydrated alcohol (provided with drug), followed by 27 ml of sterile water for injection; yields solution with concentration of 3.3 mg carmustine/ml. Solution may be further diluted with 5% dextrose injection and delivered by I.V. infusion over 1 to 2 hours.
- Know that infusion lasting less than 1 hour causes intense pain and burning at I.V. site.
- Infuse solution in glass containers only; drug is unstable in plastic I.V. bags.
- Know that skin contact with reconstituted drug may cause transient hyperpigmentation. If contact occurs, wash skin thoroughly with soap and water.
- Be aware that oxidized regenerated cellulose may be placed over wafers to

Canada UK Hazardous drug High alert drug
secure them against surgical cavity surface.

- Know that resection cavity should be irrigated after wafer placement and that dura should be closed in watertight fashion.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>15 min</td>
<td>6 wk</td>
</tr>
<tr>
<td>Intra-cavitary</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: ataxia, drowsiness
GI: nausea, vomiting, diarrhea, esophagitis, stomatitis, anorexia
GU: azotemia, renal failure, nephrotoxicity
Hematologic: anemia, leukopenia, thrombocytopenia, cumulative bone marrow depression, bone marrow dysplasia
Hepatic: hepatotoxicity
Respiratory: pulmonary fibrosis, pulmonary infiltrates
Skin: alopecia, hyperpigmentation, facial flushing, abnormal bruising
Other: I.V. site pain, secondary malignancies

Interactions

Drug-drug. Anticoagulants, aspirin, nonsteroidal anti-inflammatory drugs: increased risk of bleeding
Antineoplastics: additive bone marrow depression
Cimetidine: potentiation of bone marrow depression
Digoxin, phenytoin: decreased blood levels of these drugs
Live-virus vaccines: decreased antibody response to vaccines, increased risk of adverse reactions

Drug-diagnostic tests. Alkaline phosphatase, aspartate aminotransferase, bilirubin, nitrogenous compounds (urea): increased levels
Hemoglobin, WBCs: decreased values

Drug-behaviors. Smoking: increased risk of respiratory toxicity

Patient monitoring

- Assess baseline kidney and liver function tests.
- Monitor CBC for up to 6 weeks after giving dose to detect delayed bone marrow toxicity.
- Know that pulmonary function tests should be performed before therapy begins and regularly throughout therapy to assess for toxicity.

Patient teaching

- Instruct patient to report signs and symptoms of allergic response and other adverse reactions.
- Inform patient that severe flushing may follow I.V. dose but should subside in 2 to 4 hours.
- Tell patient to avoid activities that can cause injury. Advise him to use soft toothbrush and electric razor to avoid gum and skin injury.
- Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
- Instruct patient to monitor urinary output and report significant changes.
- Inform patient that drug may cause hair loss.
- Advise patient that he’ll undergo regular blood testing during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

carteolol hydrochloride

Ocupress, Teoptic

**Pharmacologic class:** Beta-adrenergic blocker (nonselective)

**Therapeutic class:** Antianginal, antihypertensive

**Pregnancy risk category C**
Action
Blocks stimulation of cardiac beta\textsubscript{1}-
adrenergic receptor sites and pul-
monary beta\textsubscript{2}-adrenergic receptor
sites. Shows intrinsic sympathomimet-
ic activity, causing slowing of heart
rate, decreased myocardial excitability,
reduced cardiac output, and decreased
renin release from kidney. Also reduces
intraocular pressure.

Availability
Tablets: 2.5 mg, 5 mg
Ophthalmic solution: 1%
Skin: pruritus, rash, sweating
Other: drug-induced lupuslike syndrome, anaphylaxis

Interactions
Drug-drug. Adrenergics: antagonism of carteolol effects
Allergen immunotherapy: increased risk of anaphylaxis
Amphetamines, ephedrine, epinephrine, norepinephrine, phenylephrine, pseudoephedrine: unopposed alpha-adrenergic stimulation, causing excessive hypertension and bradycardia
Antihypertensives, nitrates: additive hypotension
Clonidine: increased hypotension and bradycardia, exaggerated withdrawal phenomenon
Digoxin: additive bradycardia
Dobutamine, dopamine: decrease in beneficial cardiovascular effects
General anesthetics, I.V. phentoyin, verapamil: additive myocardial depression
Insulin, oral hypoglycemics: altered efficacy of these drugs
MAO inhibitors: hypertension
Nonsteroidal anti-inflammatory drugs: decreased antihypertensive effect
Thyroid preparations: decreased carteolol efficacy

Drug-diagnostic tests. Blood urea nitrogen, lipoproteins, potassium, triglycerides, uric acid: increased levels
Glucose or insulin tolerance test: test interference

Drug-behaviors. Acute alcohol ingestion: additive hypotension
Cocaine use: unopposed alpha-adrenergic stimulation, causing excessive hypertension and bradycardia
Sun exposure: photophobia

Patient monitoring
- Monitor for disorientation, agitation, visual disturbances, dizziness, ataxia and euphoria. Symptoms usually subside over several hours.
- Weigh patient daily and measure fluid intake and output to detect fluid retention.
- Evaluate renal function.
- Assess blood glucose level regularly if patient has diabetes mellitus.

Patient teaching
- Caution patient not to stop using oral drug abruptly, because doing so may cause serious reactions.
- Instruct patient to take last dose at bedtime.
- Instruct patient to report breathing problems immediately.
- Tell patient to report dizziness, confusion, depression, respiratory problems, or rash.
- Advise patient to move slowly when sitting up or standing to avoid dizziness or light-headedness from sudden blood pressure drop.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Inform male patient that drug may cause erectile dysfunction. Advise him to discuss this issue with prescriber.
- Teach patient proper use of eyedrops. Tell him to wash hands first, not to touch dropper tip to any surface, and not to use drops when contact lenses are in eyes.
- Inform patient that although eye-drops commonly cause stinging and blurred vision, he should notify prescriber if these symptoms are severe.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

Reactions in bold are life-threatening.
**carvedilol**
Apo-Carvedilol, Coreg, Dom-Carvedilol, Eucardic

**carvedilol phosphate**
Coreg CR, Novo-Carvedilol, PHL-Carvedilol, PMS-Carvedilol

**Pharmacologic class:** Beta-adrenergic blocker (nonselective)
**Therapeutic class:** Antihypertensive
**Pregnancy risk category C**

**Action**
Blocks stimulation of cardiac beta_1_-adrenergic receptor sites and pulmonary beta_2_-adrenergic receptor sites. Shows intrinsic sympathomimetic activity, causing slowing of heart rate, decreased myocardial excitability, reduced cardiac output, and decreased renin release from kidney.

**Availability**
Capsules (extended-release): 10 mg, 20 mg, 40 mg, 80 mg  
Tablets: 3.125 mg, 6.25 mg, 12.5 mg, 25 mg

**Indications and dosages**

> **Hypertension**

**Adults:** Initially, 6.25 mg P.O. b.i.d. (Coreg). May be increased q 7 to 14 days to a maximum dosage of 25 mg b.i.d. Or, 20 mg P.O. daily (Coreg CR). If tolerated, using standing systolic pressure about 1 hour after dosing, maintain dosage of Coreg CR for 7 to 14 days; then increase to 40 mg once daily if needed based on trough systolic standing blood pressure. Maintain this dosage for 7 to 14 days and adjust to 80 mg once daily if tolerated and needed. Total daily dose of Coreg CR shouldn’t exceed 80 mg.

> Heart failure caused by ischemia or cardiomyopathy

**Adults:** Initially, 3.125 mg P.O. b.i.d. (Coreg) for 2 weeks. May increase to 6.25 mg b.i.d. Dosage may be doubled q 2 weeks as tolerated, not to exceed 25 mg b.i.d. in patients weighing less than 85 kg (187 lb) or 50 mg b.i.d. in patients weighing more than 85 kg. Or, 10 mg P.O. daily (Coreg CR) for 2 weeks. If tolerated, increase dosage to 20 mg, 40 mg, and 80 mg over successive intervals of at least 2 weeks.

> Left ventricular dysfunction following myocardial infarction

**Adults:** Initially, 6.25 mg P.O. b.i.d. (Coreg); increase after 3 to 10 days to 12.5 mg b.i.d. (based on tolerability), then increase to target dosage of 25 mg b.i.d. A lower starting dose (3.125 mg b.i.d.) or slower titration may be used if clinically indicated. Or, 20 mg P.O. once daily (Coreg CR); increase after 3 to 10 days to 40 mg daily (based on tolerability), then increase to target dose of 80 mg daily. A lower starting dose may be used (10 mg daily) or the rate of up titration may be slowed if clinically indicated.

**Off-label uses**
- Angina pectoris
- Idiopathic cardiomyopathy

**Contraindications**
- Hypersensitivity to drug
- Uncompensated heart failure
- Pulmonary edema
- Cardiogenic shock
- Bradycardia or heart block
- Severe hepatic impairment
- Bronchial asthma, bronchospasm

**Precautions**
Use cautiously in:
- renal or hepatic impairment, pulmonary disease, diabetes mellitus, hypoglycemia, thyrotoxicosis, peripheral
vascular disease, hypotension, respiratory depression
- elderly patients
- pregnant or breastfeeding patients
- children.

Administration
- Ensure that patient is hemodynamically stable and fluid retention has been minimized before starting therapy.
- Give immediate-release form with food to slow absorption and minimize orthostatic hypotension.
- Give extended-release form in the morning with food and instruct patient to swallow capsule whole.
- For patients who can’t swallow capsules whole, carefully open capsules and sprinkle contents on applesauce; have patient swallow contents immediately without chewing. Don’t use warm applesauce; doing so could affect the modified-release properties of this formulation.
- When drug is used to treat heart failure, check apical pulse before administering. If it’s below 60 beats/minute, withhold dosage and contact prescriber.
- When drug is used for hypertension, check standing systolic pressure about 1 hour after dosing for use as a guide for patient tolerance.
- Be aware that addition of diuretic may cause additive effects and may worsen orthostatic hypotension.
- Know that full antihypertensive effect takes 7 to 14 days.

Reactions in bold are life-threatening.

Route Onset Peak Duration
P.O. Within 1 hr 1-2 hr 12 hr

Adverse reactions
CNS: dizziness, fatigue, anxiety, depression, insomnia, memory loss, nightmares, headache, pain

CV: orthostatic hypotension, peripheral vasoconstriction, angina pectoris, chest pain, hypertension, bradycardia, heart failure, atrioventricular block

EENT: blurred or abnormal vision, dry eyes, stuffy nose, rhinitis, sinusitis, pharyngitis

GI: nausea, diarrhea, constipation

GU: urinary tract infection, hematuria, albuminuria, decreased libido, erectile dysfunction, renal dysfunction

Hematologic: bleeding, purpura, thrombocytopenia

Metabolic: hypovolemia, hypervolemia, hyperglycemia, hyponatremia, hyperuricemia, glycosuria, gout, hypoglycemia

Musculoskeletal: arthralgia, back pain, muscle cramps

Respiratory: wheezing, upper respiratory tract infection, dyspnea, bronchitis, bronchospasm, pulmonary edema

Skin: pruritus, rash

Other: weight gain, lupuslike syndrome, viral infection, anaphylaxis

Interactions
Drug-drug. Antihypertensives: additive hypotension
Calcium channel blockers, general anesthetics, I.V. phenytoin: additive myocardial depression
Cimetidine: increased carvedilol toxicity
Clonidine: increased hypotension and bradycardia, exaggerated withdrawal phenomenon
Digoxin: additive bradycardia
Dobutamine, dopamine: decrease in beneficial cardiovascular effects
Insulin, oral hypoglycemics: altered efficacy of these drugs
MAO inhibitors: hypertension
Nonsteroidal anti-inflammatory drugs: decreased antihypertensive action
Rifampin, thyroid preparations: decreased carvedilol efficacy
Theophyllines: reduced theophylline elimination, antagonistic effect that decreases theophylline or carteolol efficacy
Drug-diagnostic tests. *Antinuclear antibodies:* increased titers
*Blood urea nitrogen, glucose, lipoproteins, potassium, triglycerides, uric acid:* increased levels

**Drug-food.** *Any food:* delayed drug absorption

**Drug-behaviors.** *Acute alcohol ingestion:* additive hypotension

**Patient monitoring**
- Watch for signs and symptoms of hypersensitivity reaction.
- Assess baseline CBC and kidney and liver function test results.
- Monitor vital signs (especially blood pressure), ECG, and exercise tolerance. Drug may alter cardiac output and cause ineffective airway clearance.
- Weigh patient daily and measure fluid intake and output to detect fluid retention.
- Measure blood glucose regularly if patient has diabetes mellitus. Drug may mask signs and symptoms of hypoglycemia.

**Patient teaching**
- Instruct patient to take drug with food exactly as prescribed.
- Tell patient to take extended-release capsule in the morning with food, to swallow capsule whole, and not to chew, crush, or divide its contents.
- Instruct patient who can’t swallow capsule whole to carefully open capsule, sprinkle contents on cool or cold applesauce, and swallow contents immediately without chewing. Tell patient not to store mixture for future use.
- Caution patient not to stop taking drug abruptly, because serious reactions may result.
- Advise patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness from sudden blood pressure drop.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Inform male patient that drug may cause erectile dysfunction. Advise him to discuss this issue with prescriber.
- Advise patient to use soft-bristled toothbrush and electric razor to avoid gum and skin injury.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and behaviors mentioned above.

---

**caspofungin acetate**
*Cancidas*

**Pharmacologic class:** Echinocandin

**Therapeutic class:** Antifungal

**Pregnancy risk category C**

**Action**
Inhibits synthesis of beta (1, 3)-D-glucan, an important component of cell wall in *Aspergillus* and other fungal cells. This inhibition leads to cell rupture and death.

**Availability**
Lyophilized powder for injection:
- 50 mg and 70 mg in single-use vials

**Indications and dosages**
- **Invasive aspergillosis in patients refractory to or intolerant of other therapies**
  - **Adults ages 18 and older:** 70 mg I.V. as a single loading dose on first day, followed by 50 mg/day thereafter
  - **Children ages 3 months to 17 years:** 70 mg/m² I.V. as a single loading dose on first day, followed by 50 mg/m²/day thereafter. Maximum loading dosage and daily maintenance dosage
shouldn’t exceed 70 mg, regardless of calculated dosage.

➢ Esophageal candidiasis

Adults ages 18 and older: 50 mg I.V. daily

Children ages 3 months to 17 years: 70 mg/m² I.V. as a single loading dose on first day, followed by 50 mg/m²/day thereafter. Maximum loading dosage and daily maintenance dosage shouldn’t exceed 70 mg, regardless of calculated dosage.

➢ Candidemia and other Candida infections (intra-abdominal abscesses, peritonitis, and pleural-space infections)

Adults ages 18 and older: 70 mg I.V. as a single loading dose on first day, followed by 50 mg/day thereafter. Continue therapy for at least 14 days after last positive culture. Consistently neutropenic patient may require longer course of therapy.

Children ages 3 months to 17 years: 70 mg/m² I.V. as a single loading dose on first day, followed by 50 mg/m²/day thereafter. Maximum loading dosage and daily maintenance dosage shouldn’t exceed 70 mg, regardless of calculated dosage.

➢ Empirical therapy for presumed fungal infections in febrile neutropenic patients

Adults ages 18 and older: 70 mg I.V. as a single loading dose on first day, followed by 50 mg/day thereafter. Continue therapy until neutropenia resolves, for at least 14 days in patients with fungal infections, or for at least 7 days after both neutropenia and symptoms resolve. If patient tolerates 50-mg dosage well but doesn’t obtain adequate response, increase daily dosage to 70 mg.

Children ages 3 months to 17 years: 70 mg/m² I.V. as a single loading dose on first day, followed by 50 mg/m²/day thereafter. Maximum loading dosage and daily maintenance dosage shouldn’t exceed 70 mg, regardless of calculated dosage.

Dosage adjustment
● Moderate hepatic insufficiency (adults)

Contraindications
● Hypersensitivity to drug or its components

Precautions
Use cautiously in:
● hepatic impairment
● renal insufficiency
● concurrent cyclosporine use
● pregnant or breastfeeding patients.

Administration

◆ Don’t mix with other drugs or with diluents containing dextrose.
● Reconstitute powder using 10.8 ml of normal saline solution for injection, sterile water for injection, or bacteriostatic water for injection. Mix gently until solution is clear. Add to I.V. bag or bottle containing 250 ml of normal, half-normal, or quarter-normal saline solution for injection or lactated Ringer’s solution. Don’t exceed concentration of 0.5 mg/ml.
◆ Don’t give by I.V. bolus.
● Administer by slow I.V. infusion over 1 hour.
● Know that in patients with human immunodeficiency virus, oral therapy may be given to help prevent oropharyngeal candidiasis relapse.
● Be aware that adults taking rifampin concurrently should receive 70-mg daily dosage.
● Know that dosage may need to be increased in patients receiving nevirapine, efavirenz, carbamazepine, dexamethasone, or phenytoin.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>9-11 hr</td>
<td>40-50 hr</td>
</tr>
</tbody>
</table>

Reactions in bold are life-threatening.
Adverse reactions
CNS: headache
CV: tachycardia, phlebitis, hypotension, hypertension (children)
GI: nausea, vomiting, diarrhea, abdominal pain
GU: nephrotoxicity
Hematologic: anemia
Metabolic: hypokalemia, hyperkalemia
Musculoskeletal: pain, myalgia, back pain
Respiratory: tachypnea, cough, dyspnea, crackles, pneumonia, respiratory distress (children), pleural effusion, respiratory failure
Skin: erythema, pruritus (children), rash
Other: graft-versus-host disease, central line infection (children), chills, mucosal inflammation, peripheral edema, pyrexia, infusion-related reactions, septic shock

Interactions
Drug-drug. Carbamazepine, dexamethasone, efavirenz, nelfinavir, nevirapine, phenytoin, rifampin: reduced caspofungin blood level
Cyclosporine: markedly increased caspofungin blood level, transient ALT and AST increases
Tacrolimus: possible change in tacrolimus blood level
Drug-diagnostic tests. Albumin, hematocrit, hemoglobin, magnesium, potassium, total protein (children), white blood cells: decreased levels
ALP, ALT, AST, bilirubin, calcium, conjugated bilirubin, creatinine, eosinophils, glucose, urea: increased levels
Potassium: decreased or increased level (children)
Urinary red blood cells: positive

Patient monitoring
● Monitor closely for signs and symptoms of infusion-related reactions (pyrexia, chills, flushing, hypotension, hypertension, tachycardia, dyspnea, tachypnea, anaphylaxis). Be prepared to provide supportive care as needed.
● Monitor I.V. site carefully for phlebitis and other complications.
● Monitor complete blood count and serum electrolyte levels. Stay alert for signs and symptoms of hypokalemia.
● Monitor vital signs, especially for tachycardia and tachypnea.
● Closely monitor liver function tests; watch for evidence of worsening hepatic function.

Patient teaching
● Instruct patient to immediately report signs or symptoms of infusion-related reaction, such as fever, chills, flushing, rapid heart beat, difficult or rapid breathing, or rash.
● Tell patient drug may cause problems in vein used for infusion. Tell him to immediately report pain, swelling, or other symptoms.
● Instruct patient to report headache, nausea, or other unusual or troublesome symptoms.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

_cefaclor_
Apo-Cefaclor®, Distaclor®, PMS-Cefaclor®, Raniclor
Pharmacologic class: Second-generation cephalosporin
Therapeutic class: Anti-infective
Pregnancy risk category B

Action
Interferes with bacterial cell-wall synthesis, causing cell to rupture and die
Availability
Capsules: 250 mg, 500 mg
Oral suspension: 125 mg/5 ml, 187 mg/5 ml, 250 mg/5 ml, 375 mg/5 ml
Tablets (extended-release): 375 mg, 500 mg

Indications and dosages
➣ Uncomplicated skin infections caused by Staphylococcus aureus
Adults and children ages 16 and older: 375 mg P.O. (extended-release tablet) q 12 hours for 7 to 10 days
➣ Pharyngitis and tonsillitis not caused by Haemophilus influenzae
Adults and children ages 16 and older: 375 mg P.O. (extended-release tablet) q 12 hours for 10 days
➣ Chronic bronchitis and acute bronchitis not caused by H. influenzae
Adults and children ages 16 and older: 500 mg P.O. (extended-release tablet) q 12 hours for 7 days
➣ Otitis media caused by staphylococci; lower respiratory tract infections caused by H. influenzae, S. pyogenes, and S. pneumoniae; pharyngitis and tonsillitis caused by S. pyogenes; urinary tract infections caused by Klebsiella species, Escherichia coli, Proteus mirabilis, and coagulase-negative staphylococci
Adults and children ages 13 to 17: 250 mg P.O. q 8 hours. For severe infections, 500 mg P.O. q 8 hours.
Children: 20 mg/kg/day P.O. in divided doses q 8 hours. For serious infections, 40 mg/kg/day P.O. in divided doses q 8 hours. Maximum dosage is 1 g/day.

Dosage adjustment
● Renal insufficiency
● Elderly patients

Contraindications
● Hypersensitivity to cephalosporins or penicillins

Precautions
Use cautiously in:
● renal impairment, phenylketonuria
● history of GI disease (especially colitis)
● emaciated patients
● elderly patients
● pregnant or breastfeeding patients
● children.

Administration
● Obtain specimens for culture and sensitivity testing as necessary before starting therapy.
● Be aware that cross-sensitivity to penicillins may occur.
● Give extended-release tablets with food to enhance absorption.
● Don’t give antacids within 2 hours of extended-release form.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>30-60 min</td>
<td>6-12 hr</td>
</tr>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1.5-2.5 hr</td>
<td>12 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, lethargy, paresthesia, syncope, seizures
CV: hypotension, palpitations, chest pain, vasodilation
EENT: hearing loss
GI: nausea, vomiting, diarrhea, abdominal cramps, oral candidiasis, pseudomembranous colitis
GU: vaginal candidiasis, nephrotoxicity
Hematologic: lymphocytosis, eosinophilia, bleeding tendency, hemolytic anemia, hypoprothrombinemia, neutropenia, thrombocytopenia, agranulocytosis, bone marrow depression
Hepatic: hepatic failure, hepatomegaly
Musculoskeletal: arthralgia
Respiratory: dyspnea
Skin: urticaria, maculopapular or erythematous rash
Other: chills, fever, superinfection, anaphylaxis, serum sickness

Reactions in bold are life-threatening.

Clinical alert
Interactions

Drug-drug. Aminoglycosides, loop diuretics: increased risk of nephrotoxicity
Antacids: decreased absorption of extended-release cefaclor tablets
Chloramphenicol: antagonistic effect
Probencid: decreased excretion and increased blood level of cefaclor

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, eosinophils, gamma-glutamyltransferase, lactate dehydrogenase: increased levels
Coombs’ test, urinary 17-ketosteroids, nonenzyme-based urine glucose tests (such as Clinitest): false-positive results
Hemoglobin, platelets, white blood cells: decreased values

Patient monitoring
- Assess CBC and kidney and liver function test results.
- With long-term therapy, obtain monthly Coombs’ test.
- Monitor for signs and symptoms of superinfection and other serious adverse reactions.

Patient teaching
- Instruct patient to take drug with food or milk to reduce GI upset.
- Advise patient to complete entire course of therapy even if he feels better.
- Tell patient to report signs and symptoms of allergic response and other adverse reactions, such as rash, easy bruising, bleeding, severe GI problems, or difficulty breathing.
- Instruct patient to avoid taking antacids within 2 hours of extended-release cefaclor.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

cefadroxil

Baxan®, Novo-Cefadroxil

Pharmacologic class: First-generation cephalosporin
Therapeutic class: Anti-infective
Pregnancy risk category B

Action
Interferes with bacterial cell-wall synthesis, causing cell to rupture and die

Availability
Capsules: 500 mg
Oral suspension: 125 mg/5 ml, 250 mg/5 ml, 500 mg/5 ml
Tablets: 1 g

Indications and dosages
Pharyngitis and tonsillitis caused by beta-hemolytic streptococci
Adults: 1 g/day P.O. or 500 mg P.O. b.i.d. for 10 days
Children: 30 mg/kg/day P.O. in divided doses q 12 hours for 10 days
Skin infections caused by staphylococci and streptococci
Adults: 1 g/day P.O. or 500 mg P.O. q 12 hours
Children: 30 mg/kg/day P.O. in divided doses q 12 hours
Urinary tract infections caused by Proteus mirabilis, Escherichia coli, and Klebsiella species
Adults: 1 to 2 g/day P.O. in divided doses q 12 hours
Children: 30 mg/kg/day P.O. in divided doses q 12 hours

Dosage adjustment
- Renal insufficiency
- Elderly patients

Off-label uses
- Bone and joint infections
- Unspecified respiratory infections
Contraindications
● Hypersensitivity to cephalosporins or penicillins

Precautions
Use cautiously in:
● renal impairment, phenylketonuria
● history of GI disease (especially colitis)
● elderly patients
● pregnant or breastfeeding patients
● children.

Administration
● Obtain specimens for culture and sensitivity testing as necessary before starting therapy.
● Give with or without food.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>1.5-2 hr</td>
<td>12-24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, lethargy, paresthesia, syncope, seizures
CV: hypotension, palpitations, chest pain, vasodilation
EENT: hearing loss
GI: nausea, vomiting, diarrhea, cramps, oral candidiasis, pseudomembranous colitis
GU: vaginal candidiasis, nephrotoxicity
Hematologic: lymphocytosis, eosinophilia, bleeding tendency, hemolytic anemia, hypoprothrombinemia, neutropenia, thrombocytopenia, agranulocytosis, bone marrow depression
Hepatic: hepatic failure, hepatomegaly
Musculoskeletal: arthralgia
Respiratory: dyspnea
Skin: urticaria, maculopapular or erythematous rash
Other: chills, fever, superinfection, anaphylaxis

Interactions
Drug-drug: Aminoglycosides, loop diuretics: increased risk of nephrotoxicity
Probenecid: decreased excretion and increased blood level of cefadroxil

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, eosinophils, gamma-glutamyltransferase, lactate dehydrogenase: increased levels
Coombs’ test, urinary 17-ketosteroids, nonenzyme-based urine glucose tests (such as Clinitest): false-positive results
Hemoglobin, platelets, white blood cells: decreased values

Patient monitoring
● Assess baseline CBC and kidney and liver function test results.
● Monitor for signs and symptoms of superinfection and other serious adverse reactions.
● Be aware that cross-sensitivity to penicillins may occur.
● With long-term therapy, obtain monthly Coombs’ test.

Patient teaching
● Advise patient to take drug with food or milk if GI upset occurs.
● Instruct patient to complete entire course of therapy even if he feels better.
● Tell patient to report signs and symptoms of allergic response and other adverse reactions, such as rash, easy bruising, bleeding, severe GI problems, wheezing, or difficulty breathing.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Reactions in **bold** are life-threatening.
Action
Interferes with bacterial cell-wall synthesis, causing cell to rupture and die

Availability
*Powder for injection:* 250 mg, 500 mg, 1 g, 5 g, 10 g, 20 g
*Premixed containers:* 500 mg/50 ml in dextrose 5% in water (D5W), 1 g/50 ml in D5W

Indications and dosages

**Adults:** For mild infections, 250 to 500 mg q 8 hours I.V. or I.M. For moderate to severe infections, 500 to 1,000 mg I.V. or I.M. q 6 to 8 hours. For life-threatening infections, 1,000 to 1,500 mg I.M. or I.V. q 6 hours, to a maximum dosage of 6 g/day.

**Children:** For mild to moderate infections, 25 to 50 mg/kg/day I.V. or I.M. in divided doses t.i.d. or q.i.d. For severe infections, 100 mg/kg/day I.V. or I.M. in divided doses t.i.d. or q.i.d.

➤ Acute uncomplicated urinary tract infections (UTIs) caused by *E. coli*, *Klebsiella* species, *P. mirabilis*, and strains of *Enterococcus* and *Enterobacter* species

**Adults:** 1 g I.V. or I.M. q 12 hours

➤ Surgical prophylaxis

**Adults:** 1 g I.V. or I.M. 30 to 60 minutes before surgery, then 0.5 to 1 g I.V. or I.M. q 6 to 8 hours for 24 hours. If surgery exceeds 2 hours, another 0.5- to 1-g dose I.M. or I.V. may be given intraoperatively.

➤ Pneumococcal pneumonia

**Adults:** 500 mg I.M. or I.V. infusion q 12 hours

Dosage adjustment
● Renal impairment
● Elderly patients

Contraindications
● Hypersensitivity to cephalosporins or penicillins

Precautions
Use cautiously in:
● renal impairment, phenylketonuria
● history of GI disease (especially colitis)
● emaciated patients
● elderly patients
● pregnant or breastfeeding patients
● children.

Administration
● Obtain specimens for culture and sensitivity testing as needed before starting therapy.
● For intermittent I.V. infusion, administer in volume-control set or in separate, secondary I.V. container over 30 to 60 minutes.
● For direct I.V. injection, dilute reconstituted dose in 5 ml of sterile water for injection and administer slowly over 3 to 5 minutes.
● For I.M. use, reconstitute with sterile water for injection, bacteriostatic water, or normal saline solution for injection. Shake well until dissolved.
● Inject I.M. into large muscle mass.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>End of infusion</td>
<td>6-12 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>Rapid</td>
<td>1-2 hr</td>
<td>6-12 hr</td>
</tr>
</tbody>
</table>
Adverse reactions

CNS: headache, lethargy, confusion, hemiparesis, paresthesia, syncope, seizures
CV: hypotension, palpitations, chest pain, vasodilation
EENT: hearing loss
GI: nausea, vomiting, diarrhea, abdominal cramps, oral candidiasis, pseudomembranous colitis
GU: vaginal candidiasis, nephrotoxicity
Hematologic: lymphocytosis, eosinophilia, bleeding tendency, hemolytic anemia, hypoprothrombinemia, neutropenia, thrombocytopenia, agranulocytosis, bone marrow depression
Hepatic: hepatic failure, hepato-megaly
Musculoskeletal: arthralgia
Respiratory: dyspnea
Skin: urticaria, maculopapular or erythematous rash
Other: chills, fever, superinfection, anaphylaxis, serum sickness

Interactions

Drug-drug. Aminoglycosides, loop diuretics: increased risk of nephrotoxicity
Anticoagulants: increased anticoagulant effect
Chloramphenicol: antagonistic effect
Probenecid: decreased excretion and increased blood level of cefazolin

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, eosinophils, gamma-glutamyltransferase, lactate dehydrogenase: increased levels
Coombs’ test, urinary 17-ketosteroids, nonenzyme-based urine glucose tests (such as Clinitest): false-positive results
Hemoglobin, platelets, white blood cells: decreased values

Drug-behaviors. Alcohol use: acute alcohol intolerance (disulfiram-like reaction) if alcohol is consumed within 72 hours of drug administration

Patient monitoring

If patient is receiving high doses, monitor for extreme confusion, tonic-clonic seizures, and mild hemiparesis.
- Monitor CBC, prothrombin time, and kidney and liver function test results.
- Watch for signs and symptoms of superinfection and other serious adverse reactions.
- Be aware that cross-sensitivity to penicillins may occur.

Patient teaching

- Tell patient to report reduced urinary output, persistent diarrhea, bruising, or bleeding.
- Instruct patient to take drug exactly as prescribed and to complete full course of therapy even when he feels better.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

Pharmacologic class: Third-generation cephalosporin

Therapeutic class: Anti-infective

Pregnancy risk category B

Action

Interferes with bacterial cell-wall synthesis and division by binding to cell wall, causing cell to die. Active against gram-negative and gram-positive bacteria, with expanded activity against gram-negative bacteria. Exhibits minimal immunosuppressant activity.

Availability

Capsules: 300 mg
Oral suspension: 125 mg/5 ml in 60- and 100-ml bottles

Reactions in bold are life-threatening.

Clinical alert
Indications and dosages

➣ Acute bacterial otitis media caused by *Haemophilus influenzae*, *Streptococcus pneumoniae*, and *Moraxella catarrhalis*

**Adults and children ages 13 and older:**
300 mg P.O. q 12 hours or 600 mg P.O. q 24 hours for 10 days

**Children ages 6 months to 12 years:**
7 mg/kg P.O. q 12 hours for 5 to 10 days or 14 mg/kg P.O. q 24 hours for 10 days

➣ Uncomplicated skin and soft-tissue infections caused by *Staphylococcus aureus* and *Streptococcus pyogenes*

**Adults and children ages 13 and older:**
300 mg P.O. q 12 hours for 10 days. Maximum dosage is 600 mg/day.

➣ Acute maxillary sinusitis caused by *H. influenzae*, *S. pneumoniae*, and *M. catarrhalis*

**Adults and children ages 13 and older:**
300 mg P.O. q 12 hours or 600 mg P.O. q 24 hours for 10 days. Maximum dosage is 600 mg/day.

**Children ages 6 months to 12 years:**
7 mg/kg P.O. q 12 hours or 14 mg/kg P.O. q 24 hours for 10 days

➣ Pharyngitis or tonsillitis caused by *S. pyogenes*, chronic bronchitis caused by *H. influenzae*, *S. pneumoniae*, and *M. catarrhalis*

**Adults and children ages 13 and older:**
300 mg P.O. q 12 hours for 5 to 10 days or 600 mg P.O. q 24 hours for 10 days. Maximum dosage is 600 mg/day.

➣ Community-acquired pneumonia caused by *H. influenzae*, *Haemophilus parainfluenzae*, *S. pneumoniae*, and *M. catarrhalis*

**Adults and children ages 13 and older:**
300 mg P.O. q 12 hours for 10 days. Maximum dosage is 600 mg/day.

Dosage adjustment

● Renal impairment

Precautions

Use cautiously in:
- renal impairment, phenylketonuria
- history of GI disease (especially colitis)
- elderly patients
- pregnant or breastfeeding patients
- children.

Administration

● Obtain specimens for culture and sensitivity tests as necessary before starting therapy.
● Give with or without food.
● Administer 2 hours before or after iron supplements or antacids containing aluminum or magnesium.
● Give capsules, if possible, to diabetic patients (oral suspension contains 2.86 g of sucrose per teaspoon).

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>2-4 hr</td>
<td>12-24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: headache, lethargy, paresthesia, syncope, seizures
CV: hypotension, palpitations, chest pain, vasodilation
EENT: hearing loss
GI: nausea, vomiting, diarrhea, abdominal cramps, oral candidiasis, pseudomembranous colitis
GU: vaginal candidiasis, nephrotoxicity
Hematologic: lymphocytosis, eosinophilia, bleeding tendency, hemolytic anemia, hypoprothrombinemia, neutropenia, thrombocytopenia, agranulocytosis, bone marrow depression
Hepatic: hepatomegaly, hepatic failure
Musculoskeletal: arthralgia
Respiratory: dyspnea
Skin: chills, fever, urticaria, maculopapular or erythematous rash
Other: superinfection, anaphylaxis, serum sickness

Interactions

Drug-drug. Aminoglycosides, loop diuretics: increased risk of nephrotoxicity
Antacids, iron-containing preparations: decreased cefdinir absorption
Probenecid: decreased excretion and increased blood level of cefdinir

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, eosinophils, gamma-glutamyltransferase, lactate dehydrogenase: increased levels Coombs’ test, urinary 17-ketosteroids, nonenzyme-based urine glucose tests (such as Clinitest): false-positive results Hemoglobin, platelets, white blood cells: decreased values

Drug-herbs. Angelica, anise, arnica, asafetida, bogbean, boldo, celery, chamomile, clove, danshen, fenugreek, feverfew, garlic, ginger, ginkgo, horse chestnut, horseradish, licorice, meadowsweet, onion, ginseng, papain, passionflower, poplar, prickly ash, quassia, red clover, turmeric, wild carrot, wild lettuce, willow: increased risk of bleeding

Patient monitoring
- Monitor CBC and kidney and liver function test results.
- Monitor for signs and symptoms of superinfection and other serious adverse reactions.

Patient teaching
- Tell patient he may take drug with or without food.
- Instruct patient to report persistent diarrhea (more than four episodes daily) and other adverse effects.
- If patient uses antacids or iron-containing preparations (such as iron supplements), tell him to take these 2 hours before or after cefdinir.
- Inform patient that drug may temporarily discolor stools.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

Reactions in bold are life-threatening.

---

**cefepime hydrochloride**

**Maxipime**

**Pharmacologic class:** Fourth-generation cephalosporin

**Therapeutic class:** Anti-infective

**Pregnancy risk category B**

**Action**
Interferes with bacterial cell-wall synthesis and division by binding to cell wall, causing cell to die. Active against gram-negative and gram-positive bacteria, with expanded activity against gram-negative bacteria. Exhibits minimal immunosuppressant activity.

**Availability**
Powder for injection: 500-mg vial, 1-g vial, 2-g vial; 1 g/15 ml vial

**Indications and dosages**
- Urinary tract infections (UTIs) caused by *Escherichia coli*, *Klebsiella pneumoniae*, and *Proteus mirabilis*
  - Adults: 500 mg to 1g by I.V. infusion or I.M. q 12 hours for 7 to 10 days
  - Severe UTIs caused by *E. coli* or *K. pneumoniae*: moderate to severe skin infections caused by *Staphylococcus aureus* or *Streptococcus pyogenes*
  - Adults: 2 g by I.V. infusion q 12 hours for 10 days
  - Febrile neutropenia
- Adults and children ages 2 months to 16 years: 2 g by I.V. infusion q 8 hours for 7 days
- Complicated intra-abdominal infections caused by alpha-hemolytic streptococci, *E. coli*, *K. pneumoniae*, *Pseudomonas aeruginosa*, *Enterobacter* species, or *Bacteroides fragilis*
  - Adults: 2 g by I.V. infusion q 12 hours for 7 to 10 days (given with metronidazole)

---

Clinical alert

---
Moderate to severe pneumonia caused by *K. pneumoniae*, *P. aeruginosa*, *Enterobacter* species, or *Streptococcus pneumoniae*

**Adults:** 1 to 2 g by I.V. infusion q 12 hours for 10 days

**Dosage adjustment**
- Renal impairment

**Contraindications**
- Hypersensitivity to cephalosporins or penicillins

**Precautions**
Use cautiously in:
- renal impairment, phenylketonuria
- history of GI disease
- elderly patients
- pregnant or breastfeeding patients
- children.

**Administration**
- Obtain specimens for culture and sensitivity testing as needed before starting therapy.
- Don’t mix with ampicillin (at concentrations above 40 mg/ml), metronidazole, aminoglycosides, or aminophylline if ordered concurrently. Give each drug separately.
- For I.V. infusion, use small I.V. needle and infuse into large vein over 30 to 60 minutes.
- For I.M. administration, inject deep into large muscle.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>End of infusion</td>
<td>12 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>Rapid</td>
<td>1-2 hr</td>
<td>12 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- CNS: headache, lethargy, paresthesia, syncope, seizures
- CV: phlebitis, hypotension, palpitations, chest pain, vasodilation, thrombophlebitis
- EENT: hearing loss
- GI: nausea, vomiting, diarrhea, abdominal cramps, oral candidiasis, pseudomembranous colitis
- GU: vaginal candidiasis, nephrotoxicity
- Hematologic: lymphocytosis, eosinophilia, bleeding tendency, hemolytic anemia, hypoprothrombinemia, neutropenia, thrombocytopenia, agranulocytosis, bone marrow depression
- Hepatic: hepatic failure, hepatomegaly
- Musculoskeletal: arthralgia
- Respiratory: dyspnea
- Skin: urticaria, maculopapular or erythematous rash, redness, swelling, induration
- Other: chills, fever, superinfection, pain at I.M. site, phlebitis at I.V. site, anaphylaxis, serum sickness

**Interactions**
- Drug-drug. Aminoglycosides, loop diuretics: increased risk of nephrotoxicity
- Probenecid: decreased excretion and increased blood level of cefepime
- Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, eosinophils, gamma-glutamyltransferase, lactate dehydrogenase: increased levels
- Coombs’ test, urinary 17-ketosteroids, nonenzyme-based urine glucose tests (such as Clinitest): false-positive results
- Hemoglobin, platelets, white blood cells: decreased values
- Drug-herbs. Angelica, anise, arnica, asafetida, bogbean, boldo, celery, chamomile, clove, danshen, fenugreek, feverfew, garlic, ginger, ginkgo, ginseng, horse chestnut, horseradish, licorice, meadowsweet, onion, papain, passionflower, poplar, prickly ash, quassia, red clover, turmeric, wild carrot, wild lettuce, willow: increased risk of bleeding

♂ Canada ♂ UK ❌ Hazardous drug ❌ High alert drug
Patient monitoring
- Assess baseline CBC and kidney and liver function test results.
- Monitor for signs and symptoms of superinfection and other serious adverse reactions.
- Monitor for inflammation at infusion site.
- Be aware that cross-sensitivity to penicillins may occur.

Patient teaching
- Instruct patient to report reduced urinary output, persistent diarrhea, bruising, petechiae, or bleeding.
- Caution patient not to take herbs without consulting prescriber.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

cefixime
Suprax

Pharmacologic class: Third-generation cephalosporin
Therapeutic class: Anti-infective
Pregnancy risk category B

Action
Interferes with bacterial cell-wall synthesis and division by binding to cell wall, causing cell to die. Active against gram-negative and gram-positive bacteria, with expanded activity against gram-negative bacteria. Exhibits minimal immunosuppressant activity.

Availability
Oral suspension: 100 mg/5 ml
Tablets: 200 mg, 400 mg

Indications and dosages
Uncomplicated gonorrhea caused by Neisseria gonorrhoeae
Adults and children weighing more than 50 kg (110 lb): 400 mg P.O. daily
Uncomplicated urinary tract infections caused by Escherichia coli and Proteus mirabilis; otitis media caused by Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pyogenes; pharyngitis and tonsillitis caused by S. pyogenes; acute bronchitis and acute exacerbation of chronic bronchitis caused by H. influenzae and Streptococcus pneumoniae
Adults and children older than age 12 or weighing more than 50 kg (110 lb): 400 mg P.O. daily or 200 mg P.O. q 12 hours
Children ages 12 and younger or weighing 50 kg (110 lb) or less: 8 mg/kg P.O. daily or 4 mg/kg P.O. q 12 hours

Dosage adjustment
- Renal impairment

Contraindications
- Hypersensitivity to cephalosporins or penicillins

Precautions
Use cautiously in:
- renal impairment, phenylketonuria
- history of GI disease
- elderly patients
- pregnant or breastfeeding patients
- children.

Administration
- Obtain specimens for culture and sensitivity testing as necessary before starting therapy.
- Know that drug may be taken with food.
- Be aware that suspension should be given for otitis media because it provides higher serum concentration.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>2-6 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

Reactions in bold are life-threatening.
Adverse reactions
CNS: headache, lethargy, paresthesia, syncope, seizures
CV: hypotension, palpitations, chest pain, vasodilation
EENT: hearing loss
GI: nausea, vomiting, diarrhea, abdominal cramps, oral candidiasis, pseudomembranous colitis
GU: vaginal candidiasis, nephrotoxicity
Hematologic: lymphocytosis, eosinophilia, bleeding tendency, hemolytic anemia, hypoprothrombinemia, neutropenia, thrombocytopenia, agranulocytosis, bone marrow depression
Hepatic: hepatic failure, hepatomegaly
Musculoskeletal: arthralgia
Respiratory: dyspnea
Skin: urticaria, maculopapular or erythematous rash
Other: chills, fever, superinfection, anaphylaxis, serum sickness

Interactions
Drug-drug. Aminoglycosides, loop diuretics: increased risk of nephrotoxicity
Probenecid: decreased excretion and increased blood level of cefixime
Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, eosinophils, gamma-glutamyltransferase, lactate dehydrogenase: increased levels
Coombs’ test, urinary 17-ketosteroids, nonenzyme-based urine glucose tests (such as Clinitest): false-positive results
Hemoglobin, platelets, white blood cells: decreased values
Drug-herbs. Angelica, anise, arnica, asafetida, bogbean, boldo, celery, chamomile, clove, danshen, fenugreek, feverfew, garlic, ginger, ginkgo, ginseng, horse chestnut, horseradish, licorice, meadowsweet, onion, papain, passionflower, poplar, prickly ash, quassia, red clover, turmeric, wild carrot, wild lettuce, willow: increased risk of bleeding

Patient monitoring
- Monitor baseline CBC and kidney and liver function test results.
- Monitor for signs and symptoms of superinfection and other serious adverse reactions.
- Be aware that cross-sensitivity to penicillins may occur.

Patient teaching
- Tell patient to take once-daily doses at same time each day.
- Advise patient to take drug exactly as prescribed and to continue to take full amount prescribed even when he feels better.
- Instruct patient to report signs and symptoms of allergic response and other adverse reactions, such as rash, easy bruising, bleeding, severe GI problems, or difficulty breathing.
- Caution patient not to take herbs without consulting prescriber.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

cefotaxime sodium
Clavulanate

Pharmacologic class: Third-generation cephalosporin
Therapeutic class: Anti-infective
Pregnancy risk category B

Action
Interferes with bacterial cell-wall synthesis and division by binding to cell wall, causing cell to die. Active against gram-negative and gram-positive bacteria, with expanded
activity against gram-negative bacteria. Exhibits minimal immunosuppressant activity.

**Availability**
*Powder for injection:* 1 g, 2 g, 10 g  
*Premixed containers:* 1 g/50 ml, 2 g/50 ml

**Indications and dosages**

- **Perioperative prophylaxis**  
  **Adults and children weighing more than 50 kg (110 lb):** 1 g I.V. or I.M. 30 to 90 minutes before surgery  
  **Prophylaxis in patients undergoing cesarean delivery**  
  **Adults:** 1 g I.V. or I.M. as soon as umbilical cord is clamped  
  **Gonococcal urethritis and cervicitis**  
  **Adults weighing more than 50 kg (110 lb):** 500 mg I.M. as a single dose  
  **Rectal gonorrhea (females)**  
  **Adults weighing more than 50 kg (110 lb):** 500 mg I.M. as a single dose  
  **Rectal gonorrhea (males)**  
  **Adults weighing more than 50 kg (110 lb):** 1 g I.M. as a single dose  
  **Disseminated gonorrhea**  
  **Adults and children weighing 50 kg (110 lb) or more:** 1 g by I.V. infusion q 8 hours  
  **Uncomplicated infections caused by susceptible organisms**  
  **Adults and children weighing 50 kg (110 lb) or more:** 1 g I.V. or I.M. q 12 hours  
  **Children ages 1 month to 12 years weighing less than 50 kg (110 lb):** 50 to 180 mg/kg/day I.V. or I.M. in four to six divided doses  
  **Moderate to severe infections caused by susceptible organisms**  
  **Adults and children weighing 50 kg (110 lb) or more:** 1 to 2 g I.V. or I.M. q 8 hours  
  **Life-threatening infections caused by susceptible organisms**  
  **Adults and children weighing 50 kg (110 lb) or more:** 2 g by I.V. infusion q 4 hours. Maximum dosage is 12 g/day.

- **Septicemia and other infections that commonly require antibiotics in higher doses**  
  **Adults and children weighing 50 kg (110 lb) or more:** 2 g by I.V. infusion q 6 to 8 hours

**Dosage adjustment**

- Renal impairment

**Contraindications**

- Hypersensitivity to cephalosporins or penicillins

**Precautions**

Use cautiously in:

- renal impairment, phenylketonuria  
- history of GI disease  
- elderly patients  
- pregnant or breastfeeding patients  
- children.

**Administration**

- Obtain specimens for culture and sensitivity testing as necessary before starting therapy.  
- Reconstitute powder for I.V. injection with at least 10 ml of sterile water, and give over 3 to 5 minutes. For intermittent infusion, drug may be diluted further with 50 or 100 ml of normal saline solution or dextrose 5% in water (D₅W) and given over 30 minutes.  
- Reconstituted drug may be diluted further for a continuous I.V. infusion of up to 1,000 ml with a compatible solution, such as normal saline solution, dextrose 5% or 10% in water, or D₅W and normal saline solution. Give over 6 to 24 hours, depending on concentration.  
- Don’t use diluents with pH above 7.5 (such as sodium bicarbonate).  
- Rotate infusion sites.  
- Inject I.M. deep into large muscle mass. Divide 2-g dose in half and inject into separate large muscle masses.

Reactions in bold are life-threatening.  

*Clinical alert*
Route Onset Peak Duration
I.V. Rapid End of infusion 4-12 hr
I.M. Rapid 0.5 hr 4-12 hr

Adverse reactions
CNS: headache, lethargy, paresthesia, syncope, seizures
CV: hypotension, palpitations, chest pain, vasodilation
EENT: hearing loss
GI: nausea, vomiting, diarrhea, abdominal cramps, oral candidiasis, pseudomembranous colitis
GU: vaginal candidiasis, nephrotoxicity
Hematologic: lymphocytosis, eosinophilia, bleeding tendency, hemolytic anemia, hypoprothrombinemia, neutropenia, thrombocytopenia, agranulocytosis, bone marrow depression
Hepatic: hepatic failure, hepatomegaly
Musculoskeletal: arthralgia
Respiratory: dyspnea
Skin: urticaria, maculopapular or erythematous rash
Other: chills, fever, superinfection, pain at I.M. injection site, anaphylaxis, serum sickness

Interactions
Drug-drug. Aminoglycosides, loop diuretics: increased risk of nephrotoxicity Probenecid: decreased excretion and increased blood level of cefotaxime
Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, eosinophils, gamma-glutamyltransferase, lactate dehydrogenase: increased levels Coombs’ test, urinary 17-ketosteroids, nonenzyme-based urine glucose tests (such as Clinitest): false-positive results Hemoglobin, platelets, white blood cells: decreased values
Drug-herbs. Angelica, anise, arnica, asafetida, bogbean, boldo, celery, chamomile, clove, danshen, fenugreek, feverfew, garlic, ginger, ginkgo, ginseng, horse chestnut, horseradish, licorice, meadowsweet, onion, papain, passionflower, poplar, prickly ash, quassia, red clover, turmeric, wild carrot, wild lettuce, willow: increased risk of bleeding

Patient monitoring
- Monitor CBC and kidney and liver function test results.
- Monitor for signs and symptoms of superinfection and other serious adverse reactions.
- Be aware that cross-sensitivity to penicillins may occur.

Patient teaching
- Advise patient to report reduced urinary output, persistent diarrhea, bruising, and bleeding.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

cefotaxin sodium
Pharmacologic class: Second-generation cephalosporin
Therapeutic class: Anti-infective
Pregnancy risk category B

Action
Interferes with bacterial cell-wall synthesis and division by binding to cell wall, causing cell to die. Active against gram-negative and gram-positive bacteria, with expanded activity against gram-negative bacteria. Exhibits minimal immunosuppressant activity.

Availability
Powder for injection: 1 g, 2 g
Premixed containers: 1 g/50 ml in dextrose 5% in water (D₅W), 2 g/50 ml in D₅W

Indications and dosages

Respiratory tract infections, skin infections, bone and joint infections, urinary tract infections, gynecologic infections, septicemia

Adults: For most infections, 1 g I.M. or I.V. q 6 to 8 hours. For severe infections, 1 g I.M. or I.V. q 4 hours or 2 g I.M. or I.V. q 6 to 8 hours. For life-threatening infections, 2 g I.V. q 4 hours or 3 g I.V. q 6 hours.

Children ages 3 months and older:
For most infections, 13.3 to 26.7 mg/kg I.M. or I.V. q 4 hours or 20 to 40 mg/kg q 6 hours.

Preoperative prophylaxis

Adults: 1 to 2 g I.V. within 60 minutes of incision, then q 6 hours for up to 24 hours.

Dosage adjustment

• Renal failure

Contraindications

• Hypersensitivity to cephalosporins or penicillins

Precautions

Use cautiously in:
• renal impairment, hepatic disease, or biliary obstruction
• history of GI disease
• elderly patients
• children.

Administration

• Obtain specimens for culture and sensitivity testing as necessary before starting therapy.
• Reconstitute 1-g dose with 10 ml of sterile water; reconstitute 2-g dose with 10 to 20 ml.
• For direct I.V. injection, give 10 ml of sterile water with each gram of cefoxitin over 3 to 5 minutes. Inject into large vein and rotate sites, or give through existing I.V. tubing.
• For intermittent or continuous I.V. infusion, add reconstituted drug to compatible solution, such as D₅W, normal saline solution, or D₅W and normal saline solution.
• For I.M. injection, reconstitute each gram with 2 ml of sterile water or 2 ml of 0.5% lidocaine hydrochloride (without epinephrine).
• Inject I.M. deep into large muscle mass; divide 2-g dose in half and inject into separate large muscle masses.
• Know that dry powder and solution may darken, but this does not alter drug efficacy.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>End of infusion</td>
<td>4-8 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>Rapid</td>
<td>30 min</td>
<td>4-8 hr</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: headache, lethargy, paresthesia, syncope, seizures
CV: hypotension, palpitations, chest pain, vasodilation, thrombophlebitis
EENT: hearing loss
GI: nausea, vomiting, diarrhea, abdominal cramps, oral candidiasis, pseudomembranous colitis
GU: vaginal candidiasis, nephrotoxicity
Hematologic: lymphocytosis, eosinophilia, bleeding tendency, hemolytic anemia, hypoprothrombinemia, neutropenia, thrombocytopenia, agranulocytosis, bone marrow depression
Hepatic: hepatic failure, hepatomegaly
Musculoskeletal: arthralgia
Respiratory: dyspnea
Skin: urticaria, maculopapular or erythematosus rash
Other: chills, fever, superinfection, pain at I.M. site, anaphylaxis, serum sickness

Reactions in bold are life-threatening.
Interactions

Drug-drug. Aminoglycosides, loop diuretics: increased risk of nephrotoxicity
Probenecid: decreased excretion and increased blood level of cefoxitin

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, eosinophils, gamma-glutamyltransferase, lactate dehydrogenase: increased levels
Coombs’ test, urinary 17-ketosteroids, nonenzyme-based urine glucose tests (such as Clinitest): false-positive results
Hemoglobin, platelets, white blood cells: decreased values

Patient monitoring

- Assess CBC and kidney and liver function test results.
- Monitor fluid intake and output. Report significant decrease in output.
- Monitor for signs and symptoms of superinfection and other serious adverse reactions.
- Be aware that cross-sensitivity to penicillins may occur.

Patient teaching

- Instruct patient to report reduced urinary output, persistent diarrhea, bruising, and bleeding.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Action

Interferes with bacterial cell-wall synthesis and division by binding to cell wall, causing cell to die. Active against gram-negative and gram-positive bacteria, with expanded activity against gram-negative bacteria. Exhibits minimal immunosuppressant activity.

Availability

Oral suspension: 50 mg/5 ml, 100 mg/5 ml
Tablets: 100 mg, 200 mg

Indications and dosages

➣ Acute community-acquired pneumonia caused by Haemophilus influenzae or Streptococcus pneumoniae

Adults and children ages 13 and older: 200 mg P.O. q 12 hours for 14 days
➣ Acute bacterial or chronic bronchitis

Adults and children ages 13 and older: 200 mg P.O. q 12 hours for 10 days
➣ Uncomplicated gonorrhea; rectal gonococcal infection caused by Neisseria gonorrhoeae

Adults: 200 mg P.O. as a single dose
➣ Uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Staphylococcus saprophyticus

Adults: 100 mg P.O. q 12 hours for 7 days
➣ Skin and soft-tissue infections caused by Staphylococcus aureus and Streptococcus pyogenes

Adults and children ages 13 and older: 400 mg P.O. q 12 hours for 7 to 14 days
➣ Acute otitis media caused by H. influenzae, S. pneumoniae, and Moraxella catarrhalis

Children ages 5 months to 12 years: 5 mg/kg P.O. q 12 hours (maximum of 200 mg/dose) or 10 mg/kg q 24 hours (maximum of 400 mg/dose) for 10 days
➣ Tonsillitis and pharyngitis caused by S. pyogenes

Adults and children ages 13 and older: 100 mg P.O. q 12 hours for 5 to 10 days
Children ages 2 months to 12 years:
5 mg/kg P.O. q 12 hours for 5 to 10 days

Dosage adjustment
● Renal impairment

Contraindications
● Hypersensitivity to cephalosporins or penicillins

Precautions
Use cautiously in:
● renal impairment, phenylketonuria
● history of GI disease
● elderly patients
● pregnant or breastfeeding patients
● children.

Administration
● Obtain specimens for culture and sensitivity testing as necessary before starting therapy.
● Give tablets with food to enhance absorption. Oral suspension may be given with or without food.
● Don’t give antacids within 2 hours of cefpodoxime.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2-3 hr</td>
<td>12 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, lethargy, paresthesia, syncope, seizures
CV: hypotension, palpitations, chest pain, vasodilation
EENT: hearing loss
GI: nausea, vomiting, diarrhea, abdominal cramps, oral candidiasis, pseudomembranous colitis
GU: vaginal candidiasis, nephrotoxicity
Hematologic: lymphocytosis, eosinophilia, bleeding tendency, hemolytic anemia, hypoprothrombinemia, neutropenia, thrombocytopenia, agranulocytosis, bone marrow depression
Hepatic: hepatic failure, hepatomegaly
Musculoskeletal: arthralgia

Respiratory: dyspnea
Skin: urticaria, maculopapular or erythematous rash
Other: chills, fever, superinfection, anaphylaxis, serum sickness

Interactions
Drug-drug. Aminoglycosides, loop diuretics: increased risk of nephrotoxicity
Antacids: decreased cefpodoxime absorption
Probenecid: decreased excretion and increased blood level of cefpodoxime

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, eosinophils, gamma-glutamyltransferase, lactate dehydrogenase: increased levels
Coombs’ test, urinary 17-ketosteroids, nonenzyme-based urine glucose tests (such as Clinitest): false-positive results
Hemoglobin, platelets, white blood cells: decreased values

Drug-herbs. Angelica, anise, arnica, asafetida, bogbean, boldo, celery, chamomile, clove, danshen, fenugreek, feverfew, garlic, ginger, ginkgo, ginseng, horse chestnut, horseradish, licorice, meadowsweet, onion, papain, passionflower, poplar, prickly ash, quassia, red clover, turmeric, wild carrot, wild lettuce, willow: increased risk of bleeding

Patient monitoring
● Assess CBC and kidney and liver function test results.
● Monitor for signs and symptoms of superinfection and other serious adverse reactions.
● Be aware that cross-sensitivity to penicillins may occur.

Patient teaching
● Instruct patient to take drug with food or milk to reduce GI distress and enhance absorption.
● Advise patient not to take antacids within 2 hours of drug.

Reactions in **bold** are life-threatening.
Tell patient to continue to take full amount prescribed even when he feels better.

Instruct patient to report signs and symptoms of allergic response and other adverse reactions, such as rash, easy bruising, bleeding, severe GI problems, or difficulty breathing.

If patient is being treated for gonorrhea, instruct him to have partner tested and treated (as needed) and to use barrier contraception to prevent reinfection.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

## Cefprozil

**Apo-Cefprozil**, **Cefzil**, **Ran-Cefprozil**, **Sandoz Cefprozil**

**Pharmacologic class:** Second-generation cephalosporin

**Therapeutic class:** Anti-infective

**Pregnancy risk category B**

### Action

Interferes with bacterial cell-wall synthesis and division by binding to cell wall, causing cell to die. Active against gram-negative and gram-positive bacteria, with expanded activity against gram-negative bacteria. Exhibits minimal immunosuppressant activity.

### Availability

**Powder for suspension:** 125 mg/5 ml, 250 mg/5 ml

**Tablets:** 250 mg, 500 mg

### Indications and dosages

- **Uncomplicated skin infections caused by Staphylococcus aureus and Streptococcus pyogenes**
- **Adults and children ages 13 and older:** 250 to 500 mg P.O. q 12 hours or 500 mg P.O. daily for 10 days
  - Pharyngitis or tonsillitis caused by *S. pyogenes*

- **Adults and children ages 13 and older:** 500 mg P.O. daily for at least 10 days
  - Acute bronchitis; acute bacterial chronic bronchitis caused by *Streptococcus pneumoniae, Haemophilus influenzae,* and *Moraxella catarrhalis*

- **Adults and children ages 13 and older:** 500 mg P.O. q 12 hours for 10 days
  - Acute sinusitis caused by *S. pneumoniae, H. influenzae,* and *M. catarrhalis*

- **Adults and children ages 13 and older:** 250 mg P.O. q 12 hours for 10 days; for moderate to severe infections, 500 mg P.O. q 12 hours for 10 days

- **Children ages 6 months to 12 years:**
  - 7.5 mg/kg P.O. q 12 hours for 10 days; for moderate to severe infections, 15 mg/kg P.O. q 12 hours for 10 days
  - Otitis media caused by *S. pneumoniae, H. influenzae,* and *M. catarrhalis*

- **Children ages 6 months to 12 years:**
  - 15 mg/kg P.O. q 12 hours for 10 days

### Dosage adjustment

- Renal impairment

### Contraindications

- Hypersensitivity to cephalosporins or penicillins
- Renal failure

### Precautions

Use cautiously in:

- renal or hepatic impairment
- pregnant or breastfeeding patients
- children.

### Administration

- Obtain specimens for culture and sensitivity testing as necessary before starting therapy.
- Give drug with food.
ceftazidime 215

Action
Interferes with bacterial cell-wall synthesis and division by binding to cell wall, causing cell to die. Active

Patient monitoring
- Stay alert for life-threatening reactions, including anaphylaxis, serum sickness-like reaction, Stevens-Johnson syndrome, and pseudomembranous colitis.
  - Monitor neurologic status, particularly for signs and symptoms of impending seizures.
  - Monitor kidney and liver function test results and assess fluid intake and output.
  - Monitor CBC with white cell differential, prothrombin time, and bleeding time. Watch for signs and symptoms of blood dyscrasias, especially hypoprothrombinemia.
  - Monitor temperature. Stay alert for signs and symptoms of superinfection.

Patient teaching
- Advise patient to immediately report rash, bleeding tendency, or CNS changes.
- Teach patient to recognize signs and symptoms of superinfection, and instruct him to report these right away.
- Tell patient to take drug with food.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

Reactions in **bold** are life-threatening.

Clinical alert

---

**Route Onset Peak Duration**
P.O. Unknown 6-10 hr 24-28 hr

**Adverse reactions**
CNS: headache, dizziness, drowsiness, hyperactivity, hypotonia, insomnia, confusion, **seizures**
GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia, **pseudomembranous colitis**
GU: hematuria, vaginal candidiasis, genital pruritus, **renal dysfunction, toxic nephropathy**
Hematologic: eosinophilia, aplastic anemia, hemolytic anemia, hemorhage, bone marrow depression, **hypoprothrombinemia**
Hepatic: **hepatic dysfunction**
Skin: toxic epidermal necrolysis, diaper rash, **erythema multiforme, Stevens-Johnson syndrome**
Other: allergic reactions, carnitine deficiency, drug fever, superinfection, **serum sickness-like reaction, anaphylaxis**

**Interactions**
Drug-drug. **Aminoglycosides:** increased risk of nephrotoxicity
**Antacids containing aluminum or magnesium, histamine₂-receptor antagonists:** increased cefprozil absorption
**Probenecid:** decreased excretion and increased blood level of cefprozil

Drug-diagnostic tests. **Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, eosinophils, gamma-glutamyltransferase, lactate dehydrogenase, white blood cells in urine:** increased levels
**Blood glucose, Coombs’ test, urine glucose tests using Benedict’s solution:** false-positive results
**Platelets, white blood cells:** decreased counts

Drug-food. **Moderate- or high-fat meal:** increased drug bioavailability

ceftazidime
Fortaz, Fortum®, Tazicef

**Pharmacologic class:** Third-generation cephalosporin
**Therapeutic class:** Anti-infective
**Pregnancy risk category B**

---

Reactions in **bold** are life-threatening.
against gram-negative and gram-positive bacteria, with expanded activity against gram-negative bacteria. Exhibits minimal immunosuppressant activity.

**Availability**
*Powder for injection:* 500 mg, 1 g, 2 g, 6 g, 10 g
*Premixed containers:* 1 g/50 ml, 2 g/50 ml

**Indications and dosages**

Skin infections; bone and joint infections; urinary tract and gynecologic infections, including gonorrhea; respiratory tract infections; intra-abdominal infections; septicemia

**Adults and children ages 12 and older:**
For most infections, 500 mg to 2 g I.V. or I.M. q 8 to 12 hours. For pneumonia and skin infections, 0.5 to 1 g I.V. or I.M. q 8 to 12 hours. For bone and joint infections, 2 g I.V. or I.M. q 12 hours. For severe and life-threatening infections, 2 g I.V. q 8 hours. For complicated urinary tract infections (UTIs), 500 mg q 8 to 12 hours. For uncomplicated UTIs, 250 mg I.M. or I.V. q 12 hours.

**Children ages 1 month to 12 years:**
30 to 50 mg/kg I.V. q 8 hours

**Neonates younger than 4 weeks:**
30 mg/kg I.V. q 12 hours

**Dosage adjustment**
- Renal impairment

**Off-label uses**
- Febrile neutropenia
- Prophylaxis of perinatal infections

**Contraindications**
- Hypersensitivity to cephalosporins or penicillins

**Precautions**
Use cautiously in:
- renal impairment, hepatic disease, biliary obstruction, phenylketonuria
- history of GI disease
- elderly patients
- pregnant or breastfeeding patients
- children.

**Administration**
- Obtain specimens for culture and sensitivity testing as necessary before starting therapy.
- Reconstitute powder for injection with sterile water, following manufacturer’s directions for amount of diluent to use.
- For I.V. injection, dilute in sterile water as directed, and give single dose over 3 to 5 minutes. Inject into large vein; rotate injection sites.
- For intermittent I.V. infusion, dilute further with 100 ml of sterile water or another compatible fluid, such as normal saline solution or dextrose 5% in water. Infuse over 30 minutes.
- Don’t dilute with sodium bicarbonate.
- For I.M. injection, reconstitute with sterile water, bacteriostatic water, or 0.5% or 1% lidocaine hydrochloride.
- When giving I.M., inject deep into large muscle mass.

**Route** | **Onset** | **Peak** | **Duration**
--- | --- | --- | ---
I.V. | Rapid | End of infusion | 6-12 hr
I.M. | Rapid | 1 hr | 6-12 hr

**Adverse reactions**
- CNS: headache, confusion, hemiparesis, lethargy, paresthesia, syncope, asterixis, neuromuscular excitability (with increased drug blood levels in renally impaired patients), seizures, encephalopathy
- CV: hypotension, palpitations, chest pain, vasodilation
- EENT: hearing loss
- GI: nausea, vomiting, diarrhea, abdominal cramps, oral candidiasis, pseudomembranous colitis
- GU: vaginal candidiasis, nephrotoxicity

- Canada
- UK
- Hazardous drug
- High alert drug
Hematologic: lymphocytosis, eosinophilia, bleeding tendency, hemolytic anemia, hypoprothrombinemia, neutropenia, thrombocytopenia, agranulocytosis, bone marrow depression
Hepatic: hepatic failure, hepatomegaly
Musculoskeletal: arthralgia
Respiratory: dyspnea
Skin: urticaria, maculopapular or erythematous rash
Other: chills, fever, superinfection, I.M. site pain, anaphylaxis, serum sickness

Interactions
Drug-drug. Aminoglycosides, loop diuretics: increased risk of nephrotoxicity
Chloramphenicol: antagonism of ceftriaxone’s effects
Probenecid: decreased excretion and increased blood level of ceftazidime

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, eosinophils, gamma-glutamyltransferase, lactate dehydrogenase: increased levels
Hemoglobin, platelets, white blood cells: decreased values
Coombs’ test, urinary 17-ketosteroids, nonenzyme-based urine glucose tests (such as Clinitest): false-positive results

Drug-herbs. Angelica, anise, arnica, asafetida, bogbean, boldo, celery, chamomile, clove, danishen, fenugreek, feverfew, garlic, ginger, ginkgo, ginseng, horse chestnut, horseradish, licorice, meadowsweet, onion, papain, passionflower, poplar, prickly ash, quassia, red clover, turmeric, wild carrot, wild lettuce, willow: increased risk of bleeding

Patient monitoring
• Monitor for signs and symptoms of superinfection and other serious adverse reactions.
• Be aware that cross-sensitivity to penicillins may occur.

Patient teaching
• Instruct patient to report reduced urine output, persistent diarrhea, bruising, and bleeding.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

ceftibuten
Cedax

Pharmacologic class: Third-generation cephalosporin
Therapeutic class: Anti-infective
Pregnancy risk category B

Action
Interferes with bacterial cell-wall synthesis and division by binding to cell wall, causing cell to die. Active against gram-negative and gram-positive bacteria, with expanded activity against gram-negative bacteria. Exhibits minimal immunosuppressant activity.

Availability
Capsules: 400 mg
Oral suspension: 90 mg/5 ml, 180 mg/5 ml

Indications and dosages
• Acute bacterial exacerbations of chronic bronchitis caused by Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae; pharyngitis and tonsillitis caused by Streptococcus pyogenes; acute bacterial
otitis media caused by *H. influenzae*, *M. catarrhalis*, and *S. pyogenes*

**Adults and children ages 12 and older:**
400 mg P.O. q 24 hours for 10 days

**Children ages 12 and younger:** 9 mg/kg P.O. daily for 10 days. Maximum dosage shouldn’t exceed 400 mg daily.

**Dosage adjustment**
- Renal impairment

**Off-label uses**
- Urinary tract infections

**Contraindications**
- Hypersensitivity to cephalosporins and penicillins

**Precautions**
Use cautiously in:
- renal impairment, hepatic disease, biliary obstruction, phenylketonuria
- history of GI disease
- elderly patients
- pregnant or breastfeeding patients
- children.

**Administration**
- Obtain specimens for culture and sensitivity testing as necessary before starting therapy.
- Give oral suspension at least 1 hour before or 2 hours after a meal.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>3 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
CNS: headache, lethargy, paresthesia, syncope, seizures
CV: hypotension, palpitations, chest pain, vasodilation
EENT: hearing loss
GI: nausea, vomiting, diarrhea, abdominal cramps, oral candidiasis, pseudomembranous colitis
GU: vaginal candidiasis, nephrotoxicity
Hematologic: lymphocytosis, eosinophilia, bleeding tendency, hemolytic anemia, hypoprothrombinemia, neutropenia, thrombocytopenia, agranulocytosis, bone marrow depression
Hepatic: hepatic failure, hepatomegaly
Musculoskeletal: arthralgia
Respiratory: dyspnea
Skin: urticaria, easy bruising, maculopapular or erythematous rash
Other: chills, fever, superinfection, anaphylaxis, serum sickness

**Interactions**
Drug-drug. *Aminoglycosides, loop diuretics:* increased risk of nephrotoxicity
*Probenecid:* decreased excretion and increased blood level of ceftibuten

**Drug-diagnostic tests.** *Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, eosinophils, gamma-glutamyltransferase, lactate dehydrogenase:* increased levels
*Coombs’ test, urinary 17-ketosteroids, nonenzyme-based urine glucose tests (such as Clinitest):* false-positive results
*Hemoglobin, platelets, white blood cells:* decreased values

**Drug-herbs.** *Angelica, anise, arnica, asafetida, bogbean, boldo, celery, chamomile, clove, danshen, fenugreek, feverfew, garlic, ginkgo, ginseng, horse chestnut, horseradish, licorice, meadowsweet, onion, papain, passionflower, poplar, prickly ash, quassia, red clover, turmeric, wild carrot, wild lettuce, willow:* increased risk of bleeding

**Patient monitoring**
- Assess CBC and kidney and liver function test results.
- Monitor for signs and symptoms of superinfection and other serious adverse reactions.
- Be aware that cross-sensitivity to penicillins may occur.
Patient teaching
- Instruct patient to take oral suspension at least 1 hour before or 2 hours after a meal.
- Inform diabetic patient that oral suspension contains 1 g sucrose per teaspoon.
- Advise patient to continue to take full amount prescribed even when he feels better.
- Tell patient to report signs and symptoms of allergic response and other adverse reactions, such as rash, easy bruising, bleeding, severe GI problems, or difficulty breathing.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

Indications and dosages
- Infections of respiratory system, bones, joints, and skin; septicemia
  Adults: 1 to 2 g/day I.M. or I.V. or in equally divided doses q 12 hours. Maximum daily dosage is 4 g.
  Uncomplicated gonorrhea
  Adults: 250 mg I.M. as a single dose
  Surgical prophylaxis
  Adults: 1 g I.V. as a single dose within 1 hour before start of surgical procedure
  Meningitis
  Adults: 1 g to 2 g I.V. q 12 hours for 10 to 14 days
  Children: Initially, 100 mg/kg/day I.M. or I.V. (not to exceed 4 g). Then 100 mg/kg/day I.M. or I.V. once daily or in equally divided doses q 12 hours (not to exceed 4 g) for 7 to 14 days.
  Otitis media
  Children: 50 mg/kg I.M. as a single dose; maximum of 1 g/day.
  Skin and skin-structure infections
  Children: 50 to 75 mg/kg/day I.V. or I.M. once or twice daily. Maximum dosage is 2 g daily.
  Other serious infections
  Children: 50 to 75 mg/kg/day I.V. or I.M. once or twice daily

Dosage adjustments
- Hepatic dysfunction with significant renal impairment

Off-label uses
- Disseminated gonorrhea
- Endocarditis
- Epididymitis
- Gonorrhea-associated meningitis
- Lyme disease
- Neisseria meningitides carriers
- Pelvic inflammatory disease

Contraindications
- Neonates (28 days or younger)

Precautions
Use cautiously in:
- hypersensitivity to cephalosporins or penicillins, allergies

ceftriaxone sodium
Rocephin

Pharmacologic class: Third-generation cephalosporin
Therapeutic class: Anti-infective
Pregnancy risk category B

Action
Interferes with bacterial cell-wall synthesis and division by binding to cell wall, causing cell to die. Active against gram-negative and gram-positive bacteria, with expanded activity against gram-negative bacteria. Exhibits minimal immunosuppressant activity.

Availability
Powder for injection: 250 mg, 500 mg, 1 g, 2 g
Premixed containers: 1 g/50 ml, 2 g/50 ml

Reactions in bold are life-threatening.
renal impairment, hepatic disease, gallbladder disease, phenylketonuria
• history of GI disease, diarrhea following antibiotic therapy
• pregnant or breastfeeding patients.

Administration
• Obtain specimens for culture and sensitivity testing as necessary before starting therapy.
• Be aware that drug mustn’t be given with or within 48 hours of calcium-containing I.V. solutions, including calcium-containing continuous infusions such as parenteral nutrition, because of risk of precipitation of ceftriaxone calcium salt (particularly in neonates).
• Know that drug for I.V. injection is compatible with sterile water, normal saline solution, dextrose 5% in water (D5W), half-normal saline solution, and D5W and normal saline solution.
• After reconstituting, dilute further to desired concentration for intermittent I.V. infusion. Infuse over 30 minutes.
• For I.M. use, reconstitute powder for injection with compatible solution by adding 0.9 ml of diluent to 250-mg vial, 1.8 ml to 500-mg vial, 3.6 ml to 1-g vial, or 7.2 ml to 2-g vial, to yield a concentration averaging 250 mg/ml.
• Divide high I.M. doses equally and administer in two separate sites. Inject deep into large muscle mass.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>End of infusion</td>
<td>12-24 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>Rapid</td>
<td>1-2 hr</td>
<td>12-24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, confusion, hemiparesis, lethargy, paresthesia, syncope, seizures
CV: hypotension, palpitations, chest pain, vasodilation
EENT: hearing loss
GI: nausea, vomiting, diarrhea, abdominal cramps, oral candidiasis, pseudomembranous colitis, pancreatitis, *Clostridium difficile*-associated diarrhea
GU: vaginal candidiasis
Hematologic: lymphocytosis, eosinophilia, bleeding tendency, hemolytic anemia, hypoprothrombinemia, neutropenia, thrombocytopenia, agranulocytosis, bone marrow depression
Hepatic: jaundice, hepatomegaly
Musculoskeletal: arthralgia
Respiratory: dyspnea
Skin: urticaria, maculopapular or erythematous rash
Other: chills, fever, superinfection, pain at I.M. injection site, anaphylaxis, serum sickness

Interactions
Drug-drug. Aminoglycosides, loop diuretics: increased risk of nephrotoxicity
Calcium-containing solutions: possibly fatal reactions caused by ceftriaxone calcium precipitates
Probenecid: decreased excretion and increased blood level of ceftriaxone
Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, eosinophils, gamma-glutamyltransferase, lactate dehydrogenase: increased levels
Coombs’ test, urinary 17-ketosteroids, nonenzyme-based urine glucose tests (such as Clinitest): false-positive results
Hemoglobin, platelets, white blood cells: decreased values

Drug-herbs. Angelica, anise, arnica, asafetida, bogbean, boldo, celery, chamomile, clove, dansen, fenugreek, feverfew, garlic, ginger, ginkgo, ginseng, horse chestnut, horseradish, licorice, meadowsweet, onion, papain, passionflower, poplar, prickly ash, quassia, red clover, turmeric, wild carrot, wild lettuce, willow: increased risk of bleeding.

加拿大
英国
有害药物
高风险药物
Patient monitoring

- Monitor for extreme confusion, tonic-clonic seizures, and mild hemiparesis when giving high doses.
- Monitor coagulation studies.
- Assess CBC and kidney and liver function test results.
- Monitor for signs and symptoms of superinfection and other serious adverse reactions.
- Be aware that cross-sensitivity to penicillins and cephalosporins may occur.

Patient teaching

- Instruct patient to report persistent diarrhea, bruising, or bleeding.
- Caution patient not to use herbs unless prescriber approves.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

cefuroxime axetil
Apo-Cefuroxime®, Ceftin, Ratio-Cefuroxime®, Zinnat®

cefuroxime sodium
Zinacef

Pharmacologic class: Second-generation cephalosporin
Therapeutic class: Anti-infective
Pregnancy risk category B

Action
Interferes with bacterial cell-wall synthesis and division by binding to cell wall, causing cell to die. Active against gram-negative and gram-positive bacteria, with expanded activity against gram-negative bacteria.

Exhibits minimal immunosuppressant activity.

Availability
Oral suspension: 125 mg/5 ml
Powder for injection: 750 mg, 1.5 g, 7.5 g
Premixed containers: 750 mg/50 ml, 1.5 g/50 ml
Tablets: 125 mg, 250 mg, 500 mg

Indications and dosages

Moderate to severe infections, including those of skin, bone, joints, urinary or respiratory tract, gynecologic infections

Adults and children ages 12 and older:
- 750 mg to 1.5 g I.M. or I.V. q 8 hours for 5 to 10 days or 250 to 500 mg P.O. q 12 hours
- 200 to 240 mg/kg I.V. daily in divided doses q 6 to 8 hours

Gonorrhea
- Adults: 750 mg to 1.5 g I.M. or I.V. as a single dose, or 1.5 g I.M. (750 mg in two separate sites), given with 1 g probenecid P.O.

Bacterial meningitis
- Adults and children ages 12 and older: Up to 3 g I.V. or I.M. q 8 hours
- Children ages 3 months to 12 years: 200 to 240 mg/kg I.V. daily in divided doses q 6 to 8 hours

Otitis media
- Children ages 3 months to 12 years:
  - 15 mg/kg P.O. q 12 hours (oral suspension) for 10 days, or 250 mg (tablets) P.O. q 12 hours for 10 days
  - 20 mg/kg/day P.O. in two divided doses for 10 days as oral suspension (maximum 500 mg/day)

Pharyngitis; tonsillitis
- Adults and children ages 13 and older: 250 mg P.O. b.i.d. for 10 days

Dosage adjustment
- Renal impairment (for injectable formulation)
Contraindications
● Hypersensitivity to cephalosporins or penicillins
● Carnitine deficiency

Precautions
Use cautiously in:
● renal or hepatic impairment
● pregnant or breastfeeding patients
● children.

Administration
● Reconstitute drug in vial with sterile water for injection.
● Give by direct I.V. injection over 3 to 5 minutes into large vein or flowing I.V. line.
● For intermittent I.V. infusion, reconstitute drug with 100 ml of dextrose 5% in water or normal saline solution; administer over 15 minutes to 1 hour. For continuous infusion, give in 500 to 1,000 ml of compatible solution; infuse over 6 to 24 hours.
● Inject I.M. doses deep into large muscle mass.
● Give oral form with food.
● Be aware that tablets and oral suspension are exchangeable on a milligram-for-milligram basis.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2 hr</td>
<td>8-12 hr</td>
</tr>
<tr>
<td>I.V., I.M.</td>
<td>Rapid</td>
<td>End of infusion</td>
<td>6-12 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, hyperactivity, hypotonia, seizures
GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia, pseudomembranous colitis
GU: hematuria, vaginal candidiasis, renal dysfunction, acute renal failure
Hematologic: hemolytic anemia, aplastic anemia, hemorrhage
Hepatic: hepatic dysfunction
Metabolic: hyperglycemia

Skin: toxic epidermal necrolysis, erythema multiforme, Stevens-Johnson syndrome
Other: allergic reaction, drug fever, superinfection, anaphylaxis

Interactions
Drug-drug. Antacids containing aluminum or magnesium, histamine2-receptor antagonists: increased cefuroxime absorption
Probenecid: decreased excretion and increased blood level of cefuroxime
Drug-diagnostic tests. Blood glucose, Coombs’ test, urine glucose tests using Benedict’s solution: false-positive results
Glucose, hematocrit: decreased levels
White blood cells in urine: increased level
Drug-food. Moderate- or high-fat meal: increased drug bioavailability

Patient monitoring
● Monitor patient for life-threatening adverse effects, including anaphylaxis, Stevens-Johnson syndrome, and pseudomembranous colitis.
● Monitor neurologic status, particularly for signs of impending seizures.
● Monitor kidney and liver function test results and intake and output.
● Monitor CBC with differential and prothrombin time; watch for signs and symptoms of blood dyscrasias.
● Monitor temperature; watch for signs and symptoms of superinfection.

Patient teaching
● Advise patient to immediately report rash or bleeding tendency.
● Instruct patient to take drug with food every 12 hours as prescribed.
● Teach patient how to recognize signs and symptoms of superinfection. Instruct him to report these right away.
● Advise patient to report CNS changes.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially
celecoxib
Celebrex

Pharmacologic class: Nonsteroidal cyclooxygenase-2 (COX-2) inhibitor, nonsteroidal anti-inflammatory drug (NSAID)

Therapeutic class: Antirheumatic

Pregnancy risk category C

FDA BOXED WARNING

- Drug may increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke (which can be fatal). Risk may increase with duration of use, and may be greater in patients who have cardiovascular disease or risk factors for it.
- Drug is contraindicated for perioperative pain in setting of coronary artery bypass graft surgery.
- Drug increases risk of serious GI adverse events, including bleeding, ulcers, and stomach or intestinal perforation, which can be fatal. These events can occur at any time during therapy and without warning. Elderly patients are at greater risk.

Action
Exhibits anti-inflammatory, analgesic, and antipyretic action due to inhibition of COX-2 enzyme

Availability
Capsules: 100 mg, 200 mg

Indications and dosages
- Ankylosing spondylitis, osteoarthritis

Adults: 200 mg/day P.O. as a single dose or 100 mg P.O. b.i.d
  ➢ Rheumatoid arthritis

Adults: 100 to 200 mg P.O. b.i.d.
  ➢ Adjunctive treatment in familial adenomatous polyposis to decrease the number of adenomatous colorectal polyps

Adults: 400 mg P.O. b.i.d.
  ➢ Acute pain or primary dysmenorrhea

Adults: 400 mg P.O. once, plus one additional 200 mg-dose as needed on first day; then 200 mg b.i.d. as needed

Dosage adjustment
- Hepatic impairment
- Patients weighing less than 50 kg (110 lb)

Contraindications
- Hypersensitivity to drug, sulfonamides, or other NSAIDs
- Advanced renal disease
- Severe hepatic impairment
- Sensitivity precipitated by aspirin
- Third trimester of pregnancy
- Breastfeeding

Precautions
Use cautiously in:
- renal insufficiency, hypertension
- history of asthma, urticaria, renal disease, hepatic dysfunction, heart failure
- patients on long-term NSAID therapy
- elderly patients
- pregnant patients in first or second trimester
- children younger than age 18 (safety not established).

Administration
- When administering doses higher than 200/mg daily, give with food or milk to improve drug absorption.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>3 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Reactions in bold are life-threatening.
Adverse reactions
CNS: dizziness, drowsiness, headache, insomnia, fatigue, stroke
CV: angina, tachycardia, peripheral edema, myocardial infarction
EENT: ophthalmic effects, tinnitus, epistaxis, pharyngitis, rhinitis, sinusitis
GI: nausea, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, dry mouth, GI bleeding
GU: menorrhagia, renal failure
Hematologic: eosinophilia, ecchymosis, neutropenia, leukopenia, pancytopenia, thrombocytopenia, agranulocytosis, granulocytopenia, aplastic anemia, bone marrow depression
Hepatic: hepatotoxicity
Metabolic: hyperchloremia, hypophosphatemia
Musculoskeletal: back pain, leg cramps
Respiratory: upper respiratory tract infection
Skin: rash
Other: anaphylaxis

Interactions
Drug-drug. Angiotensin-converting enzyme inhibitors, furosemide, thiazides: reduced celecoxib efficacy
Antacids containing aluminum and magnesium: decreased celecoxib blood level
Aspirin (regular doses): increased risk of GI bleeding and GI ulcers
Fluconazole, lithium: increased blood levels of these drugs
Warfarin: increased risk of bleeding
Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen: increased levels
Hematocrit, hemoglobin: decreased values
Drug-herbs. Dong quai, feverfew, garlic, ginger, horse chestnut, red clover: increased risk of bleeding
White willow: increased risk of GI ulcers
Drug-behaviors. Long-term alcohol use, smoking: GI irritation and bleeding

Patient monitoring
- Monitor CBC, electrolyte levels, creatinine clearance, occult fecal blood test, and liver function test results every 6 to 12 months.

Patient teaching
- Advise patient to immediately report bloody stools, vomiting of blood, or signs or symptoms of liver damage (nausea, fatigue, lethargy, pruritus, yellowing of eyes or skin, tenderness in upper right abdomen, or flulike symptoms).
- Instruct patient to take drug with food or milk.
- Tell patient to avoid aspirin and other NSAIDs (such as ibuprofen and naproxen) during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

cephalexin
Apo-Cephalex, Biocef, Dom-Cephalexin, Keflex, Novo-Lexin, Nu-Cephalex, Panixine DisperDose, PMS-Cephalexin

Pharmacologic class: First-generation cephalosporin

Therapeutic class: Anti-infective

Pregnancy risk category B

Action
Interferes with bacterial cell-wall synthesis, causing cell to rupture and die. Active against many gram-positive bacteria; shows limited activity against gram-negative bacteria.
Availability
Capsules: 250 mg, 333 mg, 500 mg, 750 mg
Oral suspension: 100 mg/ml, 125 mg/5 ml, 250 mg/5 ml
Tablets: 250 mg, 500 mg
Tablets for oral suspension (DisperDose): 125 mg, 250 mg

Indications and dosages
➣ Respiratory tract infections caused by streptococci; skin and skin-structure infections caused by methicillin-sensitive staphylococci and streptococci; bone infections caused by methicillin-sensitive staphylococci or Proteus mirabilis; genitourinary infections caused by Escherichia coli, P. mirabilis, and Klebsiella species; Haemophilus influenzae, methicillin-sensitive staphylococcal, streptococcal, and Moraxella catarrhalis infections
Adults: 1 to 4 g P.O. daily in divided doses (usually 250 mg P.O. q 6 hours). For uncomplicated cystitis, skin and soft-tissue infections, and streptococcal pharyngitis, 500 mg P.O. q 12 hours.
Children: 25 to 50 mg/kg/day P.O. in divided doses
➣ Otitis media caused by S. pneumoniae
Children: 75 to 100 mg/kg/day P.O. in four divided doses

Dosage adjustment
● Renal impairment

Contraindications
● Hypersensitivity to cephalosporins or penicillin

Precautions
Use cautiously in:
● renal impairment, phenylketonuria
● history of GI disease
● debilitated or emaciated patients
● elderly patients
● pregnant or breastfeeding patients.

Administration
● Give with or without food.
● Be aware that DisperDose tablet is intended for suspension. Mix with water before administering.
● Refrigerate oral suspension.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>1 hr</td>
<td>6-12 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: fever, headache, lethargy, paresthesia, syncope, seizures
CV: edema, hypotension, vasodilation, palpitations, chest pain
EENT: hearing loss
GI: nausea, vomiting, diarrhea, abdominal cramps, oral candidiasis, pseudomembranous colitis
GU: vaginal candidiasis, nephrotoxicity
Hematologic: lymphocytosis, eosinophilia, bleeding tendency, hemolytic anemia, neutropenia, thrombocytopenia, agranulocytosis, bone marrow depression
Musculoskeletal: joint pain
Respiratory: dyspnea
Skin: rash, maculopapular and erythematous urticaria
Other: superinfection, chills, pain, allergic reaction, hypersensitivity reactions including anaphylaxis, serum sickness

Interactions
Drug-drug. Aminoglycosides, loop diuretics: increased risk of nephrotoxicity Chloramphenicol: antagonistic effect Probenecid: increased cephalaxin blood level
Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, eosinophils, lactate dehydrogenase, lymphocytes: increased values
Coombs’ test: false-positive result (especially in neonates whose mothers received drug before delivery)
Granulocytes, neutrophils, white blood cells: decreased counts

Reactions in bold are life-threatening.
Patient monitoring

- Assess for signs and symptoms of serious adverse reactions, including hypersensitivity, severe diarrhea, and bleeding.
- During long-term therapy, monitor CBC and liver and kidney function test results.

Patient teaching

- Instruct patient to stop taking drug and contact prescriber immediately if he develops rash or difficulty breathing.
- Tell patient to take drug with full glass of water.
- Instruct patient to mix DisperDose tablet with water before taking.
- Advise patient to report severe diarrhea.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

### cetirizine hydrochloride

**Aller-Relief**, **Allergy Relief**, **Benadryl Allergy Oral Solution**, **Benadryl One a Day**, **Piriteze**, **Pollenshield Hayfever**, **Reactine**, **Zirtec**, **Zyrtec**

**Pharmacologic class:** Histamine<sub>1</sub>-receptor antagonist (peripherally selective)

**Therapeutic class:** Allergy, cold, and cough agent; antihistamine

**Pregnancy risk category B**

**Action**

Antagonizes histamine’s effects at histamine<sub>1</sub>-receptor sites, preventing allergic response. Also has mild bronchodilatory effects and blocks histamine-induced bronchoconstriction in asthma.

**Availability**

- **Syrup:** 5 mg/5 ml
- **Tablets:** 5 mg, 10 mg

**Indications and dosages**

- **Allergic symptoms caused by histamine release**
  - **Adults and children older than age 6:** 5 to 10 mg P.O. daily
  - **Children ages 2 to 5:** 2.5 mg to 5 mg P.O. daily

**Dosage adjustment**

- Renal impairment
- Hepatic impairment

**Contraindications**

- Hypersensitivity to drug or hydroxyzine
- Acute asthma attacks
- Angle-closure glaucoma
- Pyloroduodenal obstruction
- Breastfeeding

**Precautions**

Use cautiously in:

- renal impairment, significant hepatic dysfunction
- elderly patients
- pregnant patients
- children younger than age 2 (safety not established).

**Administration**

- Give with or without food.
- Administer at same time each day.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30 min</td>
<td>1-4 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- **CNS:** dizziness, drowsiness, fatigue
- **CV:** palpitations, edema
- **EENT:** pharyngitis
- **GI:** nausea, vomiting, abdominal distress, dry mouth
- **Musculoskeletal:** myalgia, joint pain

 respiring drug ✔️ UK ✔️ Hazardous drug ✗ High alert drug
Respiratory: bronchospasm  
Skin: photosensitivity, rash, angioedema  
Other: fever  

Interactions  
Drug-drug. CNS depressants: additive CNS effects  
Theophylline: decreased cetirizine clearance  
Drug-diagnostic tests. Allergy skin tests: false-negative results  
Drug-behaviors. Alcohol use: additive CNS effects  
Sun exposure: photosensitivity  

Patient monitoring  
• Monitor creatinine levels in patients with renal dysfunction.  
• Assess hepatic enzyme levels in patients with hepatic disease.  

Patient teaching  
• Tell patient to take with full glass of water.  
• Inform patient that drug may impair alertness and that alcohol may exaggerate this effect.  
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.  
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.  

FDA BOXED WARNING  
• Drug may cause severe infusion reactions (rarely fatal). Approximately 90% of such reactions occur with first infusion. If severe reaction occurs, stop infusion immediately and discontinue therapy permanently.  
• Cardiopulmonary arrest, sudden death, or both occurred in 2% of patients with squamous-cell carcinoma of head and neck who received drug plus radiation therapy (compared to none of 212 patients treated with radiation therapy alone). Fatal events occurred within 1 to 43 days after last drug administration. When combined with radiation therapy, drug should be used cautiously in head and neck cancer patients with known coronary artery disease, congestive heart failure, and arrhythmias. Monitor serum electrolyte levels closely during and after therapy.  

Action  
Binds to EGFR, competitively inhibiting binding of epidermal growth factor and other ligands and blocking phosphorylation and activation of receptor-associated kinases. These actions lead to cell growth inhibition, apoptosis induction, and decreased matrix metalloproteinases and vascular endothelial growth factor.  

Availability  
Solution for injection: 50-ml single-use vial containing 100 mg  

Indications and dosages  
EGFR-expressing metastatic colorectal carcinoma, used alone in patients intolerant to irinotecan-based chemotherapy or in combination with irinotecan in patients refractory to irinotecan-based therapy  
Adults: 400 mg/m² initial loading dose given as 120-minute I.V. infusion  

Reactions in bold are life-threatening.
followed by maintenance dose of 250 mg/m² infused I.V. over 60 minutes

Locally or regionally advanced squamous-cell carcinoma of head and neck, in combination with radiation therapy

Adults: 400 mg/m² as initial loading dose (first infusion) given as 120-minute I.V. infusion 1 week before initiation of radiation therapy. For recommended weekly maintenance dose (all other infusions), 250 mg/m² infused I.V. over 60 minutes weekly for duration of radiation therapy (6 to 7 weeks) given 1 hour before radiation therapy.

Recurrent or metastatic squamous-cell carcinoma of head and neck (used alone) in patients for whom platinum-based therapy has failed

Adults: Initially, 400-mg/m² I.V. infusion followed by 250 mg/m² I.V. weekly until disease progresses or unacceptable toxicity occurs

Off-label uses
- Cancers that overexpress EGFR

Dosage adjustment
- Mild to moderate infusion (Grade 1 or 2) reaction
- Severe acneiform rash
- Acute onset or worsening of pulmonary symptoms

Contraindications
None

Precautions
Use cautiously in:
- hypersensitivity to murine proteins or drug components
- dermatologic or pulmonary toxicities
- patients receiving concurrent radiation therapy and cisplatin
- patients receiving concurrent radiation therapy who have history of coronary artery disease, arrhythmias, and congestive heart failure
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

Administration
- As ordered, premedicate with histamine₁-antagonist (such as 50 mg diphenhydramine I.V.).
- Use low-protein-binding, 0.22 micrometer in-line filter placed as close to patient as possible.
- Don’t give by I.V. push or bolus.
- Don’t shake or dilute vial.
- Administer by I.V. infusion pump or syringe pump.
- Piggyback drug to patient’s infusion line.
- Give initial dose over 2 hours at a rate of 5 ml/minute; give subsequent weekly doses over 1 hour. Maximum infusion rate shouldn’t exceed 5 ml/minute.
- At end of infusion, flush I.V. lines with normal saline solution.
- Observe patient closely for 1 hour after infusion (or longer in patients who experience infusion reactions). Severe and life-threatening infusion reactions have occurred, including rapid-onset airway obstruction (bronchospasm, stridor, hoarseness), urticaria, and hypotension.
- Permanently reduce infusion rate by 50% if patient experiences mild or moderate infusion reaction. Immediately and permanently discontinue drug in patient who experiences severe (Grade 3 or 4) infusion reaction.
- Expect patients with colorectal cancer to undergo immunohistochemical testing for EGFR expression using DakoCytomation EGFR pharmDx test kit.
- Make sure appropriate medical resources for treatment of severe infusion reactions are available during infusion.
- Interrupt therapy if patient develops acute onset or worsening of pulmonary symptoms. Discontinue therapy if pneumonitis or lung infiltrates are confirmed.
- For first occurrence of severe acneiform rash, delay infusion 1 to
2 weeks; if condition improves, continue therapy at 250 mg/m²; if no improvement occurs, withdraw drug. For second occurrence, delay infusion 1 to 2 weeks; if condition improves, reduce dosage to 200 mg/m²; if no improvement occurs, withdraw drug. For third occurrence, delay infusion for 1 to 2 weeks; if condition improves, reduce dosage to 150 mg/m²; if no improvement occurs, withdraw drug. On fourth occurrence, withdraw drug.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, insomnia, depression, malaise, asthenia
CV: cardiopulmonary arrest
EENT: conjunctivitis
GI: abdominal pain, diarrhea, nausea, vomiting, constipation, stomatitis, dyspepsia, anorexia
GU: renal failure
Hematologic: leukopenia, anemia
Metabolic: dehydration, electrolyte abnormalities
Musculoskeletal: back pain
Respiratory: dyspnea, increased cough, interstitial lung disease, pulmonary embolus
Skin: acneiform rash, alopecia, skin disorder, nail disorder, pruritus
Other: weight loss, fever, pain, infection, peripheral edema, severe infusion reaction

Interactions
Drug-diagnostic tests. Calcium, magnesium: decreased
Drug-behaviors. Sun exposure: exacerbated skin reactions

Patient monitoring
- Watch for signs and symptoms of infusion reaction.
- Monitor patient for hypomagnesemia and hypocalcemia during therapy and for 8 weeks afterward.
- Closely monitor serum electrolytes (including serum magnesium, potassium, and calcium) during therapy and after combination drug and radiation therapy in patients with history of coronary artery disease, arrhythmias, and heart failure.
- Monitor patient with dermatologic toxicities for inflammatory or infectious sequelae.
- Watch for pulmonary toxicities in patient with history of interstitial pneumonitis or pulmonary fibrosis. Be prepared to interrupt or discontinue therapy and intervene appropriately.
- Monitor for potentially serious cardiotoxicity if patient is receiving drug in combination with radiation therapy and cisplatin.
- Stay alert for severe diarrhea and electrolyte depletion.

Patient teaching
▶ Urge patient to immediately report rash, which may indicate skin toxicity.
▶ Instruct patient to immediately report new or worsening respiratory or cardiovascular symptoms.
- Advise patient to use sunscreen and wear a hat when outdoors and to limit sun exposure, because sunlight can exacerbate skin reactions.
- Caution female with childbearing potential that drug may cause pregnancy loss or pose hazard to fetus.
- Advise female to discontinue breast-feeding during therapy and for 60 days after last dose.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests and behaviors mentioned above.

Reactions in **bold** are life-threatening.
chlordiazepoxide
Aquachloral, PMS-Chlordiazepoxide, Somnote

Pharmacologic class: CNS agent
Therapeutic class: Sedative-hypnotic
Controlled substance schedule IV
Pregnancy risk category C

Action
Unclear. Thought to produce CNS depression by converting into its metabolite, trichloroethanol.

Availability
Capsules: 250 mg, 500 mg
Suppositories: 324 mg, 500 mg, 648 mg
Syrup: 250 mg/ml, 500 mg/ml

Indications and dosages
➣ Nighttime sedation
Adults: 500 mg to 1 g P.O. or P.R. 15 to 30 minutes before bedtime, not to exceed 2 g
Children: 50 mg/kg/day P.O., to a maximum dosage of 1 g given as a single dose or in divided doses
➣ Sedation
Adults: 250 mg P.O. or P.R. t.i.d. after meals
Children: 25 mg/kg/day P.O. or P.R., to a maximum daily dosage of 500 mg, given as a single dose or in divided doses

Contraindications
● Hypersensitivity to drug or tartrazine
● Coma, CNS depression, esophagitis, ulcer disease
● Pregnancy or breastfeeding

Precautions
Use cautiously in:
● hepatic dysfunction, severe renal impairment
● elderly patients.

Administration
● Know that drug may take 45 to 60 minutes to achieve adequate preprocedural sedation in children.
● When giving to children for preprocedural sedation, be aware that drug may cause unpredictable or paradoxical effects.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30 min</td>
<td>1 hr</td>
<td>4-8 hr</td>
</tr>
<tr>
<td>P.R.</td>
<td>0.5-1 hr</td>
<td>Unknown</td>
<td>4-8 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, drowsiness, nightmares, ataxia, paradoxical stimulation, hangover, delirium, light-headedness, hallucinations, confusion
GI: nausea, vomiting, diarrhea, flatulence
Hematologic: eosinophilia, leukopenia
Skin: hypersensitivity reactions
Other: physical and psychological drug dependence

Interactions
Drug-drug. CNS depressants (including antidepressants, antihistamines, narcotics, sedating antipsychotic drugs, and other sedative-hypnotics): excessive CNS depression
Furosemide: diaphoresis, flushing, nausea, uneasiness, variable blood pressure
Oral anticoagulants: increased risk of bleeding
Phenytoin: decreased phenytoin blood level

Drug-diagnostic tests. Eosinophils: increased count
Urinary 17-hydroxycorticosteroids: interference with test interpretation
White blood cells: decreased count

Drug-behaviors. Alcohol use: excessive CNS and respiratory depression

Patient monitoring
● Monitor respiratory status, including oxygen saturation (using pulse oximetry), especially in children.
• Assess creatinine levels in patients with chronic renal disease.
• Monitor hepatic enzyme levels in patients with chronic hepatic disease.
• After giving drug to child, turn down room lights and minimize other stimulation.

Patient teaching
• Instruct patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• Caution patient not to drink alcohol during therapy.
• When administering to a child, instruct parents to minimize stimulation to decrease risk of paradoxical reaction.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

chlorambucil
Leukeran

Pharmacologic class: Alkylating agent, nitrogen mustard
Therapeutic class: Antineoplastic, immunosuppressant
Pregnancy risk category D

FDA BOXED WARNING
• Drug may suppress bone marrow function severely and is carcinogenic.
• Drug causes infertility and is probably mutagenic and teratogenic.

Action
Interacts with cellular DNA to produce cytotoxic cross-linkage, which disrupts cell function. Cell-cycle-phase nonspecific.

Availability
Tablets: 2 mg

Indications and dosages
Chronic lymphocytic leukemia, malignant lymphoma, Hodgkin’s disease
Adults: Initially, 0.1 to 0.2 mg/kg/day P.O. for 3 to 6 weeks as a single dose or in divided doses. Maintenance dosage is based on CBC but shouldn’t exceed 0.1 mg/kg/day.

Off-label uses
• Idiopathic membranous nephropathy
• Meningoencephalitis associated with Behçet’s disease
• Rheumatoid arthritis

Contraindications
• Hypersensitivity to drug or other alkylating agents
• Pregnancy or breastfeeding

Precautions
Use cautiously in:
• hematopoietic depression, infection, other chronic debilitating diseases
• history of seizures or head trauma
• patients who have undergone radiation or other chemotherapy
• elderly patients
• females of childbearing age
• children (safety and efficacy not established).

Administration
• Before starting therapy, assess for history of seizures or head trauma.
• After full-course radiation or chemotherapy, wait 4 weeks before giving full doses (because of bone marrow vulnerability).
• To minimize GI effects, drug may be given at bedtime with antiemetic, especially if high dosage is prescribed.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>
Adverse reactions
CNS: peripheral neuropathy, tremor, confusion, agitation, ataxia, flaccid paresis, seizures
EENT: keratitis
GI: nausea, vomiting, diarrhea
GU: sterile cystitis, amenorrhea, sterility, decreased sperm count
Hematologic: anemia, leukopenia, thrombocytopenia, neutropenia, bone marrow depression
Hepatic: jaundice, hepatotoxicity
Metabolic: hyperuricemia
Musculoskeletal: muscle twitching
Respiratory: interstitial pneumonitis, pulmonary fibrosis
Skin: rash, erythema multiforme, epidermal necrolysis, Stevens-Johnson syndrome
Other: drug fever, allergic reaction, secondary malignancies

Interactions
Drug-drug. Anticoagulants, aspirin: increased risk of bleeding
Immunosuppressants, myelosuppressants: additive bone marrow depression
Live-virus vaccines: decreased antibody response to vaccine, increased risk of adverse reactions
Drug-diagnostic tests. Alanine amino-transferase, alkaline phosphatase, aspartate aminotransferase, uric acid: increased levels (may reflect hepatotoxicity)
Granulocytes, hemoglobin, neutrophils, platelets, red blood cells, white blood cells (WBCs): decreased counts
Drug-herbs. Astragalus, echinacea, melatonin: interference with immunosuppressant action

Patient monitoring
● Monitor CBC with white cell differential and platelet count weekly.
● Monitor WBC count every 3 to 4 days.
● Assess liver function test results.

Patient teaching
● Instruct patient to immediately report unusual bleeding or bruising, fever, nausea, vomiting, rash, chills, sore throat, cough, shortness of breath, seizures, amenorrhea, unusual lumps or masses, flank or stomach pain, joint pain, lip or mouth sores, or yellowing of skin or sclera.
● Tell patient to take drug with full glass of water.
● Inform patient that drug may increase his risk for infection. Advise him to wash hands frequently, wear a mask in public places, and avoid people with infections.
● Instruct patient to contact prescriber before receiving vaccines.
● Advise female patient to use reliable contraception.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

chloramphenicol
Chloromycetin Ophthalmic,
Kemicetine*, Novochlorocap*, Pentamycetin*
Pharmacologic class: Dichloroacetic acid derivative
Therapeutic class: Anti-infective
Pregnancy risk category NR

FDA BOXED WARNING
● Bone marrow hypoplasia (including aplastic anemia and death) has been reported after topical use. Don’t give drug when less potentially dangerous agents could be effective.

Action
Exerts bacteriostatic activity by binding with 50S subunit of ribosome and inhibiting protein synthesis
Availability
Injection: 1-g vial
Ointment (ophthalmic): 10 mg/g
Powder for solution (ophthalmic): 25 mg/vial
Solution (ophthalmic): 5 mg/ml

Indications and dosages
➣ Serious infections when less potentially dangerous drugs are ineffective or contraindicated
Adults: 50 to 100 mg/kg/day I.V. in divided doses q 6 hours, to a maximum dosage of 4 g/day
Children: 50 to 75 mg/kg/day I.V. in divided doses q 6 hours
➣ Bacteremia or meningitis
Children: 50 to 100 mg/kg/day I.V. in divided doses q 6 hours
➣ Ocular infections
Adults and children: Instill two drops of ophthalmic solution in each eye q.i.d. As supplement to solution, apply small amount of ophthalmic ointment to conjunctival sac at bedtime. (Solution and ointment may be used together or alone.)

Dosage adjustment
• Hepatic or renal impairment

Off-label uses
• Unspecified acne

Contraindications
• Hypersensitivity to drug
• Severe renal or hepatic impairment
• Prophylaxis for bacterial infections
• Acute porphyria

Precautions
Use cautiously in:
• hepatic disease, renal disease, bone marrow depression
• pregnant or breastfeeding patients
• infants and children.

Administration
• Dilute parenteral dose with aqueous solution (for example, water for injection or dextrose 5% in water injection) to at least 100 mg/ml.
• Give parenteral form by I.V. injection over at least 1 minute. For intermittent infusion, drug may be diluted further in 50 to 100 ml of dextrose 5% in water and given over 10 to 30 minutes.
• Don’t give drug I.M.

Know that drug may cause serious reactions (because of its narrow therapeutic window) and should be used only when safer anti-infectives are ineffective or contraindicated.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>1-2 hr</td>
<td>8 hr</td>
</tr>
<tr>
<td>Ophthalmic</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: confusion, delirium, depression, headache, peripheral neuropathy
EENT: optic neuritis, vision loss
GI: nausea, vomiting, diarrhea, abdominal pain, glossitis, colitis, pruritus ani, dry mouth
Hematologic: reticulocytopenia, aplastic anemia, bone marrow depression, granulocytopenia, hypoplastic anemia, leukopenia, thrombocytopenia
Skin: rash, itching, urticaria, contact dermatitis, angioedema
Other: fever, anaphylaxis, gray syndrome in neonates

Interactions
Drug-drug. Aminoglycosides, penicillins: decreased activity of these drugs
Barbiturates: increased barbiturate level, decreased chloramphenicol blood level
Hepatic enzyme inducers: decreased chloramphenicol blood level
Hydantoins: increased hydantoin blood level
Iron salts: increased iron level
Myelosuppressants, drugs that cause blood dyscrasias: increased bone marrow depression

Reactions in bold are life-threatening.
Vitamin B₁₂: antagonism of hematopoietic response  
Warfarin: enhanced warfarin action  
Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, hemoglobin, platelets, red blood cells, white blood cells: altered values

Patient monitoring  
- Monitor patient for signs and symptoms of aplastic anemia, which may occur weeks or months after therapy ends.  
- Monitor CBC count closely.  
- Assess hepatic enzyme levels in patients with hepatic disease.  
- Monitor creatinine levels in patients with renal insufficiency or failure.

Patient teaching  
- Instruct patient to report bleeding or bruising, even if therapy ended several weeks or months earlier.  
- Tell patient to report rash or itching.  
- Caution patient to avoid pregnancy during therapy. If she’s using hormonal contraceptives, advise her to use additional birth control method (drug may make hormonal contraceptives ineffective).  
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

chlordiazepoxide hydrochloride  
Apo-Chlordiazepoxide, Librium  
Pharmacologic class: Benzodiazepine  
Therapeutic class: Anxiolytic, sedative-hypnotic  
Controlled substance schedule IV  
Pregnancy risk category D

Action  
Unknown. May potentiate effects of gamma-aminobutyric acid (an inhibitory neurotransmitter) by increasing neuronal membrane permeability; may depress CNS at limbic and subcortical levels of brain. Anxiolytic effect occurs at doses well below those that cause sedation or ataxia.

Availability  
Capsules: 5 mg, 10 mg, 25 mg  
Injection: 100-mg ampules

Indications and dosages  
➤ Mild to moderate anxiety  
Adults: 5 to 10 mg P.O. three to four times daily  
➤ Severe anxiety  
Adults: Initially, 50 to 100 mg I.M. or I.V.; then 25 to 50 mg P.O. three to four times daily as needed  
➤ Preoperative apprehension or anxiety  
Adults: 5 to 10 mg P.O. three to four times daily for several days before surgery or 50 to 100 mg I.M. 1 hour before surgery  
➤ Acute alcohol withdrawal  
Adults: Initially, 50 to 100 mg I.V. or I.M. Repeat dose as needed up to 300 mg/day.

Dosage adjustment  
- Hepatic impairment  
- Age 65 or older

Contraindications  
- Hypersensitivity to drug, other benzodiazepines, or tartrazine  
- CNS depression  
- Uncontrolled severe pain  
- Porphyria  
- Pregnancy or breastfeeding  
- Children younger than age 6

Precautions  
Use cautiously in:  
- hepatic dysfunction, severe renal impairment  
- debilitated or elderly patients.
Administration

- Dilute I.V. preparation with 5 ml of normal saline solution. Administer slowly over at least 1 minute.
- When giving I.M., use 2 ml of special I.M. diluent. Inject slowly and deeply into gluteus muscle.
- Don’t use I.M. diluent for I.V. preparation.
- After I.V. or I.M. administration, observe patient closely and enforce bedrest for at least 3 hours.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>0.5-4 hr</td>
<td>Up to 24 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>1-5 min</td>
<td>Unknown</td>
<td>0.25-1 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>15-30 min</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: dizziness, drowsiness, hangover, headache, depression, paradoxical stimulation
EENT: blurred vision
GI: nausea, vomiting, constipation, diarrhea
Hematologic: agranulocytosis
Hepatic: jaundice
Skin: rash
Other: physical or psychological drug dependence, drug tolerance, pain at I.M. site

Interactions

Drug-drug. Antidepressants, antihistamines, opioids: additive CNS depression
Barbiturates, rifampin: decreased chlordiazepoxide efficacy
Cimetidine, disulfiram, fluoxetine, hormonal contraceptives, isoniazid, ketoconazole, metoprolol, propoxyphene, propranolol, valproic acid: enhanced chlordiazepoxide effect
Levodopa: decreased levodopa efficacy

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, bilirubin: increased levels
Granulocytes: decreased count
Metyrapone test: decreased response

Radioactive iodine uptake test (123I or 131I): decreased uptake
Urine 17-ketogenic steroids, urine 17-ketosteroids: altered test results

Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression

Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring

- Monitor CBC and hepatic enzyme levels in prolonged therapy.
- Monitor renal and hepatic studies.
- Assess patient for apnea, bradycardia, and hypotension.

Patient teaching

- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Advise patient to avoid alcohol during therapy.
- Tell patient not to stop taking drug abruptly. Instruct him to discuss dosage-tapering schedule with prescriber.
- Caution female patient not to take drug if she’s pregnant or might become pregnant during therapy. Advise her to use reliable contraception.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

chloroquine phosphate

**Pharmacologic class:** 4-aminoquinolone derivative

**Therapeutic class:** Antimalarial, amebicide

**Pregnancy risk category C**
FDA BOXED WARNING

● Drug is indicated for treating malaria and extraintestinal amebiasis.
● Before prescribing, clinician should be familiar with complete package insert contents.

Action
Unknown. Antimalarial action may occur through inhibition of protein synthesis and alteration of DNA in susceptible parasites.

Availability
Tablets: 250 mg (150-mg base), 500 mg (300-mg base)

Indications and dosages

Uncomplicated acute malarial attacks
Adults: Initially, 1 g (600-mg base) P.O., then an additional 500 mg (300-mg base) P.O. 6 hours later and a single dose of 500 mg (300-mg base) P.O. on second and third days. Or initially, 160- to 200-mg base I.M., repeated in 6 hours (800-mg base maximum dosage during first 24 hours); continue for 3 days until total dosage of 1.5-g base has been given. Switch to oral therapy as soon as possible.
Children: Initially, 10 mg (base)/kg P.O., then 5 mg (base)/kg 6 hours, 24 hours, and 36 hours later; don’t exceed recommended adult dosage. Or initially, 5 mg (base)/kg I.M. repeated 6 hours later, 18 hours after second dose, and then 24 hours after third dose; don’t exceed recommended adult dosage.

Malaria prophylaxis
Adults: 500 mg (300-mg base) P.O. weekly 1 to 2 weeks before visiting endemic area and continued for 4 weeks after leaving area. If therapy starts after malaria exposure, initial dosage is 600-mg base P.O. in two divided doses given 6 hours apart.
Children: 5 mg (base)/kg P.O. weekly for 1 to 2 weeks before visiting endemic area and continued for 4 weeks after leaving area, to a maximum dosage of 300 mg weekly. If treatment starts after exposure, 10 mg (base)/kg P.O. in two divided doses 6 hours apart and continued for 8 weeks after leaving area.

Extraintestinal amebiasis
Adults: Initially, 1 g (600-mg base) P.O. daily for 2 days, then 500 mg (300-mg base) daily for 2 to 3 weeks. When oral therapy isn’t tolerated, give 160- to 200-mg base I.M. daily for 10 to 12 days; switch to oral therapy as soon as possible.
Children: 10 mg (base)/kg P.O. once daily for 2 to 3 weeks, to a maximum dosage of 300 mg (base) daily

Off-label uses
● Lupus erythematosus
● Rheumatoid arthritis

Contraindications
● Hypersensitivity to drug
● Retinal and visual field changes
● Porphyria

Precautions
Use cautiously in:
● severe GI, neurologic, or blood disorders; hepatic impairment; G6PD deficiency; neurologic disease; eczema; alcoholism
● pregnant patients
● children.

Administration
● For obese patient, determine weight-based dosages from lean body weight. (Drug is stored in body tissues and eliminated slowly.)

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1-3 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Children: 10 mg (base)/kg P.O. once daily for 2 to 3 weeks, to a maximum dosage of 300 mg (base) daily

Off-label uses
● Lupus erythematosus
● Rheumatoid arthritis

Contraindications
● Hypersensitivity to drug
● Retinal and visual field changes
● Porphyria

Precautions
Use cautiously in:
● severe GI, neurologic, or blood disorders; hepatic impairment; G6PD deficiency; neurologic disease; eczema; alcoholism
● pregnant patients
● children.
Adverse reactions
CNS: mild and transient headache, personality changes, dizziness, vertigo neuropathy, seizures
CV: hypotension, ECG changes
EENT: blurred vision, difficulty focusing, reversible corneal changes, irreversible retinal damage leading to vision loss, scotomas, ototoxicity, tinnitus, nerve deafness
GI: nausea, vomiting, diarrhea, abdominal pain, stomatitis, anorexia
Hematologic: agranulocytosis, aplastic anemia, hemolytic anemia, thrombocytopenia
Skin: lichen planus eruptions, skin and mucosal pigmentation changes, pruritus, pleomorphic skin eruptions

Interactions
Drug-drug. Aluminum and magnesium salts, kaolin: decreased GI absorption of chloroquine
Ampicillin: reduced ampicillin bioavailability
Cimetidine: decreased hepatic metabolism of chloroquine
Cyclosporine: sudden increase in cyclosporine blood level
Drug-diagnostic tests. Granulocytes, hemoglobin, platelets: decreased values
Drug-behaviors. Sun exposure: exacerbation of drug-induced dermatoses

Patient monitoring
• Monitor hepatic enzyme levels in patients with hepatic disease.
• Assess creatinine levels in patients with renal insufficiency or failure.
• In long-term therapy (as for lupus or rheumatoid arthritis), be aware that desired effects may be delayed for up to 6 months.
• Be aware that drug is secreted in breast milk but not in sufficient amounts to prevent malaria in infant.

Patient teaching
• Tell patient to take drug with food at evenly spaced intervals.

chlorothiazide

Diuril

Pharmacologic class: Thiazide
Therapeutic class: Diuretic, anti-hypertensive
Pregnancy risk category B

Action
Increases sodium and water excretion and inhibits sodium reabsorption in distal tubule, thereby promoting excretion of chloride, potassium, magnesium, and bicarbonate

Availability
Oral suspension: 250 mg/5 ml
Powder for injection: 500 mg
Tablets: 250 mg, 500 mg

Indications and dosages
Edema associated with heart failure, renal dysfunction, cirrhosis, corticosteroid therapy, or estrogen therapy
Adults: 0.5 to 1 g P.O. daily as a single dose or in two divided doses
Children ages 3 to 6 months: 10 to 20 mg/kg P.O. daily as a single dose or in two divided doses

Reactions in **bold** are life-threatening.
Mild to moderate hypertension

**Adults:** 0.5 to 1 g P.O. daily as a single dose or in divided doses. Adjust dosage to blood pressure response.

**Children:** 10 to 20 mg/kg P.O. daily as a single dose or in two divided doses, not to exceed 375 mg/day (2.5 to 7.5 ml or ½ to 1½ tsp of oral suspension) in infants up to age 2, or 1 g/day in children ages 2 to 12. Infants younger than 6 months may require up to 30 mg/kg daily in two divided doses.

**Contraindications**
- Hypersensitivity to drug, other thiazides, benzodiazepines, sulfonamides, or tartrazine
- Anuria
- Gout
- Systemic lupus erythematosus
- Glucose tolerance abnormalities
- Hyperparathyroidism
- Bipolar disorder
- Breastfeeding

**Precautions**
Use cautiously in:
- renal or severe hepatic impairment
- pregnant patients.

**Administration**
- Be aware that drug is given I.V. in emergency use and for patients unable to receive oral form. I.V. dosage is individualized; use smallest dosage needed to achieve response.
- Know that drug is not safe for I.M. or subcutaneous use, and that I.V. use in children is not recommended.
- Be aware that drug may be ineffective in patients with renal insufficiency.
- Rarely, patients may require up to 2 g/day in divided doses.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>2 hr</td>
<td>4 hr</td>
<td>6-12 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>15 min</td>
<td>30 min</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- **CNS:** dizziness, drowsiness, lethargy, headache, insomnia, nervousness, vertigo, paresthesia, confusion, fatigue, asterixis, encephalopathy
- **CV:** hypotension, ECG changes, chest pain, thrombophlebitis, arrhythmias
- **EENT:** nyctagmus
- **GI:** nausea, vomiting, abdominal cramps, pancreatitis, anorexia
- **GU:** polyuria, nocturia, erectile dysfunction, loss of libido

**Hematologic:** blood dyscrasias

**Hepatic:** jaundice, hepatitis

**Metabolic:** dehydration, hypovolemia, hyperglycemia, hypokalemia, hypocalcemia, hypomagnesemia, hypernatremia, hypophosphatemia, hyperuricemia, gout attack, hypochloremic alkalosis

**Musculoskeletal:** muscle cramps or spasms

**Skin:** photosensitivity, rash, urticaria, flushing

**Other:** fever, weight loss, hypersensitivity reactions

**Interactions**
- **Drug-drug.** *Allopurinol:* increased risk of hypersensitivity reaction
  - *Amphotericin B, corticosteroids, mezlocillin, piperacillin, ticarcillin:* additive hypokalemia
  - *Antihypertensives, barbiturates, nitrates, opiates:* increased hypotension
  - *Cholestyramine, colestipol:* increased chlorothiazide absorption
  - *Digoxin:* increased risk of hypokalemia
  - *Lithium:* decreased lithium excretion, lithium toxicity
  - Nonsteroidal anti-inflammatory drugs: decreased chlorothiazide efficacy

- **Drug-diagnostic tests.** *Bilirubin, serum and urine glucose (in diabetic patients), calcium, creatinine, uric acid:* increased levels
  - *Cholesterol, low-density lipoproteins (LDLs), triglycerides:* decreased levels
  - *Magnesium, potassium, protein-bound iodine, sodium:* decreased levels
  - *Urine calcium:* decreased level
Drug-herbs. *Ginkgo*: decreased anti-hypertensive effect  
*Licorice, stimulant laxative herbs (aloe, cascara sagrada, senna)*: increased risk of hypokalemia  
Drug-behaviors. *Acute alcohol ingestion*: additive hypotension  
*Sun exposure*: increased risk of photosensitivity

Patient monitoring  
- Monitor blood pressure.  
- Assess electrolyte, bilirubin, creatinine, uric acid, magnesium, cholesterol, LDL, and triglyceride levels.  
- Monitor urine calcium level.  
- Evaluate blood and urine glucose levels in patients with diabetes.

Patient teaching  
- Advise patient to take drug in morning to avoid sleep interruptions caused by nighttime voiding.  
- Instruct patient to immediately report yellowing of eyes or skin, nausea, vomiting, diarrhea, fatigue, or lethargy.  
- Advise patient not to stop taking drug abruptly. Advise him to discuss dosagetapering schedule with prescriber.  
- Caution patient to use alcohol cautiously, if at all.  
- Inform patient that drug makes him prone to dehydration. Tell him to stay indoors in hot weather and to increase fluid intake if he sweats more than usual.  
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

---

**chlorpheniramine maleate**  
Allercalm®, Allerief®, Calimol®, Chlorphen, Chlor-Trimeton, Chlor-Trimeton Allergy 4 Hour, Chlor-Trimeton Allergy 8 Hour, Chlor-Trimeton Allergy 12 Hour, Chlor-Tripolon®, Diabetic Tussin Allergy Relief, Novo-Pheniram®, Piriton®, QDall AR, Teldrin

**Pharmacologic class:** Propylamine (nonselective)  
**Therapeutic class:** Antihistamine; allergy, cold, and cough remedy  
**Pregnancy risk category B**

**Action**  
Antagonizes effects of histamine at histamine2-receptor sites, preventing histamine-mediated responses

**Availability**  
Capsules (sustained-release): 8 mg, 12 mg  
Syrup: 1 mg/5 ml, 2 mg/5 ml, 2.5 mg/5 ml  
Tablets: 4 mg, 8 mg, 12 mg  
Tablets (chewable): 2 mg  
Tablets (timed-release): 8 mg, 12 mg

**Indications and dosages**  
> Allergy symptoms; management of anaphylaxis and transfusion reactions  
**Adults:** 4 mg q 4 to 6 hours P.O. or 8 to 12 mg P.O. of sustained-release form q 8 to 12 hours. Maximum dosage is 24 mg/day.  
**Children ages 6 to 12:** 2 mg P.O. q 4 to 6 hours daily. Maximum dosage is 12 mg/day.

**Dosage adjustment**  
- Glaucoma  
- Gastric ulcer  
- Hyperthyroidism  
- Heart disease

Reactions in **bold** are life-threatening.  
-----

---

Clinical alert
Contraindications
● Hypersensitivity to drug
● Acute asthma attacks
● Stenosing peptic ulcer
● Breastfeeding

Precautions
Use cautiously in:
● hepatic or renal disease, asthma, angle-closure glaucoma, prostatic hypertrophy
● elderly patients
● pregnant patients (safety not established).

Administration
● Don’t crush or break timed-release tablets or sustained-release capsules.
● Discontinue drug 4 days before allergy skin tests. (Drug may cause false-negative reactions.)

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>15-30 min</td>
<td>1-2 hr</td>
<td>4-12 hr</td>
</tr>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>(sustained)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, drowsiness, excitation (in children), sedation, poor coordination, fatigue, confusion, restlessness, nervousness, tremor, headache, hysteria, tingling sensation, sensation of heaviness and weakness in hands
CV: palpitations, hypotension, bradycardia, tachycardia, extrasystoles, arrhythmias
EENT: blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, nasal congestion, dry nose, dry throat, sore throat
GI: nausea, vomiting, diarrhea, constipation, epigastric distress, anorexia, dry mouth, GI obstruction
GU: urinary retention, urinary hesitancy, dysuria, early menses, decreased libido, erectile dysfunction
Hematologic: hemolytic anemia, hypoplastic anemia, thrombocytopenia, leukopenia, pancytopenia, agranulocytosis
Respiratory: thickened bronchial secretions, chest tightness, wheezing
Skin: urticaria, rash, photosensitivity, diaphoresis
Other: chills, increased appetite, weight gain, anaphylactic shock

Interactions
Drug-drug. Anticholinergics, anticholinergic-like drugs (such as some antidepressants, atropine, haloperidol, phenothiazines, quinidine, disopyramide): additive anticholinergic effects
CNS depressants (such as opioids, sedative-hypnotics): additive CNS depression
MAO inhibitors: intensified, prolonged anticholinergic effects
Drug-diagnostic tests. Allergy skin tests: false-negative reactions
Drug-behaviors. Alcohol use: additive CNS depression
Sun exposure: photosensitivity

Patient monitoring
● Assess for urinary retention and frequency.
● Monitor respiratory status throughout therapy.

Patient teaching
● Advise patient to take with full glass of water.
● Tell patient not to crush timed-release tablets or sustained-release capsules. Instruct him to swallow them whole.
● Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
● Advise parents to give dose to children in evening, because morning doses may cause inattention in school.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.
chlorpromazine hydrochloride

Apo-Chlorpromazine
Novo-Chlorpromazine

Pharmacologic class: Phenothiazine
Therapeutic class: Antipsychotic, anxiolytic, antiemetic
Pregnancy risk category C

Action
Unknown. May block postsynaptic dopamine receptors in brain and depress areas involved in wakefulness and emesis. Also possesses anticholinergic, antihistaminic, and adrenergic-blocking properties.

Availability
Capsules (sustained-release): 30 mg, 75 mg, 150 mg, 200 mg, 300 mg
Injection: 25 mg/ml
Oral concentrate: 30 mg/ml, 40 mg/ml, 100 mg/ml
Suppositories: 25 mg, 100 mg
Syrup: 10 mg/5 ml, 25 mg/5 ml, 100 mg/5 ml
Tablets: 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Indications and dosages
➣ Acute schizophrenia or mania
Adults: Hospitalized patients—Initially, 25 mg I.M; if necessary, give an additional 25 to 50 mg in 1 hour. Increase dosage gradually, as needed, for several days (up to 400 mg q 4 to 6 hours in exceptionally severe cases) until symptoms are controlled; then give 500 mg P.O. daily. In less acutely disturbed patients, 25 mg P.O. t.i.d., increased gradually until effective dosage is reached (usually 400 mg P.O. daily). Acutely disturbed outpatients—Initially, 10 mg P.O. three or four times daily or 25 mg P.O. two or three times daily. In more severe cases, 25 mg P.O. t.i.d.; after 1 or 2 days, increase daily dosage by 20 to 50 mg at semiweekly intervals until effective dosage is reached.
Children ages 6 months to 12 years: 0.55 mg/kg P.O. (15 mg/m²) q 4 to 6 hours as needed, or 0.55 mg/kg I.M. (15 mg/m²) q 6 to 8 hours (not to exceed 40 mg/day in children ages 6 months to 5 years, or 75 mg/day in children ages 6 to 12), or 1 mg/kg P.R. q 6 to 8 hours p.r.n.
➣ Nausea and vomiting
Adults: 10 to 25 mg P.O. q 4 to 6 hours, increased if necessary; or 25 mg I.M. If no hypertension occurs, give 25 to 50 mg I.M. q 3 to 4 hours as needed until vomiting stops; then switch to oral dosing or one 100-mg suppository q 6 to 8 hours p.r.n.
➣ Nausea and vomiting during surgery
Adults: 12.5 mg I.M., repeated in 30 minutes p.r.n. if no hypotension occurs; or 2 mg I.V. at 2-minute intervals (not to exceed 25 mg)
Children ages 6 months to 12 years: 0.275 mg/kg I.M.; may repeat in 30 minutes as needed
➣ Preoperative sedation
Adults: 25 to 50 mg P.O. 2 to 3 hours before surgery, or 12.5 to 25 mg I.M. 1 to 2 hours before surgery
Children ages 6 months to 12 years: 0.55 mg/kg P.O. (15 mg/m²) 2 to 3 hours before surgery, or 0.55 mg/kg I.M. 1 to 2 hours before surgery
➣ Intractable hiccups
Adults: 25 to 50 mg P.O. three to four times daily. If symptoms continue for 2 to 3 days, give 25 to 50 mg I.M.; if symptoms still persist, give 25 to 50 mg by slow I.V. infusion with patient positioned flat in bed.
➣ Acute intermittent porphyria
Adults: 25 to 50 mg P.O. three to four times daily. Drug is usually discontinued after several weeks, but some patients require maintenance doses.
Or 25 mg I.M. t.i.d. until patient can tolerate oral doses.

- **Tetanus**
  - **Adults:** 25 to 50 mg P.O. three to four times daily (given with barbiturates, as prescribed). Total dosage and frequency determined by patient response.
  - **Children ages 6 months to 12 years:** 0.55 mg/kg I.M. or 0.55 mg/kg I.V. q 6 to 8 hours

### Dosage adjustment
- Age over 60

### Off-label uses
- Anxiety disorders
- Migraine
- Phencyclidine (PCP) psychosis

### Contraindications
- Hypersensitivity to drug, other phe-nothiazines, sulfites (injection), benzyl alcohol (sustained-release capsules)
- Angle-closure glaucoma
- Bone marrow depression
- Severe hepatic or cardiovascular disease

### Precautions
Use cautiously in:
- cardiac disease, diabetes mellitus, respiratory disease, prostatic hypertrophy, CNS tumors, epilepsy, intestinal obstruction
- elderly patients
- pregnant or breastfeeding patients
- children.

### Administration
- Know that I.V. infusion is recommended only for severe hiccups.
- When giving by I.V. infusion for intractable hiccups, dilute in 500 to 1,000 ml of normal saline solution and infuse slowly.
- For direct I.V. injection, dilute to 1 mg/ml using normal saline solution. Administer at a rate of at least 1 mg/minute for adults or 2 mg/minute for children.
- When giving I.M., use Z-track injection method to minimize tissue irritation.
- Don’t inject subcutaneously.
- Know that in preoperative use, drug increases risk of neuromuscular excitation and hypotension when followed by barbiturate anesthetics.

### Route Onset Peak Duration
<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30-60 min</td>
<td>Unknown</td>
<td>4-6 hr</td>
</tr>
<tr>
<td>P.O.</td>
<td>30-60 min</td>
<td>Unknown</td>
<td>10-12 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.M.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>4-8 hr</td>
</tr>
<tr>
<td>P.R.</td>
<td>1-2 hr</td>
<td>Unknown</td>
<td>3-4 hr</td>
</tr>
</tbody>
</table>

### Adverse reactions
- CNS: sedation, drowsiness, extrapyramidal reactions, tardive dyskinesia, pseudoparkinsonism, neuroleptic malignant syndrome, seizures
- CV: tachycardia, hypotension (especially with I.M. or I.V. use)
- EENT: blurred vision, dry eyes, lens opacities, nasal congestion
- GI: constipation, ileus, anorexia, dry mouth
- GU: urinary retention, menstrual irregularities, galactorrhea, gynecomastia, inhibited ejaculation, priapism
- Hematologic: eosinophilia, agranulocytosis, leukopenia, hemolytic anemia, aplastic anemia, thrombocytopenia
- Hepatic: jaundice, hepatitis
- Skin: rash, photosensitivity, pigmentation changes, sterile abscess
- Other: allergic reactions, hyperthermia, pain at injection site

### Interactions
- **Drug-drug.** Activated charcoal, adsorbant anti-diarrheals, antacids: decreased chlorpromazine absorption
- Antidepressants, antihistamines, general anesthetics, MAO inhibitors, opioids, sedative-hypnotics: additive CNS depression
Antihistamines, disopyramide, quinidine, tricyclic antidepressants (TCAs): increased anticholinergic effects
Antihypertensives: additive hypotension
Barbiturates: increased metabolism and decreased efficacy of chlorpromazine
Bromocriptine: decreased bromocriptine efficacy
Epinephrine: antagonism of peripheral vasoconstriction, epinephrine reversal
Guanethidine: inhibition of antihypertensive effects
Lithium: disorientation, loss of consciousness, extrapyramidal symptoms
Meperidine: excessive sedation and hypotension
Norepinephrine: reduced pressor effect, elimination of bradycardia
Phenytoin: altered phenytoin blood level, lowered seizure threshold
Pimozide: increased risk of potentially serious CV reactions
Propranolol: increased blood levels of both drugs
TCAs: increased TCA blood levels and effects
Valproic acid: decreased elimination and increased effects of valproic acid

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin: increased levels
Granulocytes, hematocrit, hemoglobin, platelets, white blood cells: decreased values
Pregnancy tests: false-positive or false-negative result
Urine bilirubin: false-positive result

Drug-herbs. Angel’s trumpet, jimsonweed, scopolia: increased anticholinergic effects
Chamomile, hops, kava, skullcap, valerian: increased CNS depression
St. John’s wort: photosensitivity
Yohimbe: increased risk of toxicity

Drug-behaviors. Alcohol use: increased CNS depression
Sun exposure: increased risk of photosensitivity

Patient monitoring
• Monitor blood pressure closely during I.V. infusion.
  ❁ Stay alert for signs and symptoms of neuroleptic malignant syndrome (hyperpyrexia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, diaphoresis, and arrhythmias). Stop drug immediately if these occur.
• Assess for extrapyramidal symptoms.

Patient teaching
• Tell patient to take capsules or tablets with a full glass of water, with or without food.
• Instruct patient not to crush sustained-release capsules.
• Tell patient to mix oral concentrate in juice, soda, applesauce, or pudding.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

chlorpropamide
Apo-Chlorpropamide, Diabinese, Novo-Propamide

Pharmacologic class: Sulfonylurea
Therapeutic class: Hypoglycemic
Pregnancy risk category C

Action
Unclear. Thought to reduce blood glucose level primarily by stimulating secretion of endogenous insulin from pancreatic beta cells.

Availability
Tablets: 100 mg, 250 mg

Reactions in bold are life-threatening.
Indications and dosages

➣ To lower glucose level in patients with non-insulin-dependent (type 2) diabetes mellitus

**Adults:** 250 mg P.O. daily with breakfast, increased as necessary to a maximum dosage of 750 mg daily

➣ To convert from insulin therapy to oral hypoglycemic therapy

**Adults:** For patient on 40 units of insulin or less, stop insulin and start chlorpropamide at 250 mg P.O. daily. If patient is receiving more than 40 units of insulin, start chlorpropamide at 250 mg P.O. daily, with insulin dosage reduced 50%; further insulin decreases depend on patient response.

**Dosage adjustment**
- Renal impairment
- Debilitated patients
- Elderly patients

**Off-label uses**
- Diabetes insipidus

**Contraindications**
- Hypersensitivity to drug
- Diabetic ketoacidosis
- Insulin-dependent (type 1) diabetes mellitus

**Precautions**
Use cautiously in:
- insulin hypersensitivity, hepatic or renal impairment, severe infection, trauma, major surgery
- elderly patients
- pregnant or breastfeeding patients

**Administration**
- Give before meals for best results.
- If drug causes GI upset, give with food.
- To prevent hypoglycemia, adjust dosage during times of stress, illness, or decreased caloric intake.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1 hr</td>
<td>2-4 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- CNS: paresthesia, fatigue, dizziness, vertigo, malaise, headache
- CV: increased risk of CV mortality
- EENT: tinnitus
- GI: nausea, heartburn, epigastric distress
- GU: tea-colored urine
- Hematologic: leukopenia, thrombocytopenia, aplastic anemia, agranulocytosis, hemolytic anemia
- Hepatic: cholestatic jaundice
- Metabolic: dilutional hyponatremia, prolonged hypoglycemia
- Skin: rash, pruritus, erythema, urticaria
- Other: hypersensitivity reaction, disulfiram-like reaction

**Interactions**

**Drug-drug.** Anabolic steroids, chloramphenicol, clofibrate, guanethidine, MAO inhibitors, salicylates, sulfonamides: increased hypoglycemia

Beta-adrenergic blockers: prolonged hypoglycemia

Corticosteroids, glucagon, rifampin, thiazide diuretics: decreased hypoglycemic response

Hydantoins: increased hydantoin blood level

Oral anticoagulants: increased hypoglycemic activity

**Drug-diagnostic tests.** Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, cholesterol, creatinine, lactate dehydrogenase: increased levels

Glucose, granulocytes, hemoglobin, platelets, sodium, white blood cells: decreased values

**Drug-herbs.** Bitter melon, burdock, dandelion, eucalyptus, ginkgo, marshmallow: increased hypoglycemic activity

**Drug-behaviors.** Alcohol use: altered glycemic control (most commonly leading to hypoglycemia), disulfiram-like reaction
Patient monitoring
- Assess serum electrolyte levels before starting therapy.
- Watch for signs and symptoms of jaundice.
- Monitor patient for fluid and electrolyte imbalances.
- Check blood pressure frequently.
- Monitor urine for ketones and glucose.

Patient teaching
- If patient takes drug once daily, instruct him to take dose before breakfast. If he takes it more than once daily, advise him to take doses before meals.
- Teach patient how to recognize signs and symptoms of hypoglycemia (such as shaking, irritability, flushed skin, and inability to think clearly). Tell him to keep orange juice or other high-energy food available at all times to raise blood glucose level quickly. Instruct him to report hypoglycemia promptly.
- Advise patient to immediately report yellowing of eyes or skin.
- Teach patient how to test urine or blood for glucose. Stress the need for regular testing.
- If patient is switching from insulin, instruct him to test his urine three times a day for glucose and ketones and to immediately report positive results.
- Emphasize importance of following recommendations regarding diet, exercise, and weight loss (if needed) to help control diabetes.
- Urge patient to consult prescriber before breastfeeding. Drug may cause hypoglycemia in infant.
- Caution patient not to take over-the-counter weight-loss, cough, cold, or allergy preparations without consulting prescriber.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

chlorthalidone

Apo-Chlorthalidone®, Hygroton, Hygroton®, Novo-Thalidone®, Thalitone, Uridon®

Pharmacologic class: Thiazide-like diuretic
Therapeutic class: Diuretic, antihypertensive
Pregnancy risk category B

Action
Unclear. Enhances excretion of sodium, chloride, and water by interfering with transport of sodium ions across renal tubular epithelium. Also may dilate arterioles.

Availability
Tablets: 15 mg, 25 mg, 50 mg, 100 mg

Indications and dosages
- Edema associated with heart failure, renal dysfunction, cirrhosis, corticosteroid therapy, and estrogen therapy
  Adults: 50 to 100 mg/day (30 to 60 mg Thalitone) P.O. or 100 mg every other day (60 mg Thalitone) P.O., up to 200 mg/day (120 mg Thalitone) P.O.
- Management of mild to moderate hypertension
  Adults: 25 mg/day (15 mg Thalitone) P.O. Based on patient response, may increase to 50 mg/day (30 to 50 mg Thalitone) P.O., then up to 100 mg/day (except Thalitone) P.O.

Contraindications
- Hypersensitivity to drug, other thiazides, sulfonylureas, or tartrazine
- Renal decompensation

Precautions
Use cautiously in:
- renal or severe hepatic disease, abnormal glucose tolerance, gout,
systemic lupus erythematosus, hyperparathyroidism, bipolar disorder
• elderly patients
• pregnant or breastfeeding patients.

Administration
• Know that dosages above 25 mg/day are likely to increase potassium excretion without further increasing sodium excretion or reducing blood pressure.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>2 hr</td>
<td>4 hr</td>
<td>48-72 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, vertigo, drowsiness, lethargy, confusion, headache, insomnia, nervousness, paresthesia, asterixis, nystagmus, encephalopathy
CV: hypotension, ECG changes, chest pain, arrhythmias, thrombophlebitis
GI: nausea, vomiting, cramping, anorexia, pancreatitis
GU: polyuria, nocturia, erectile dysfunction, loss of libido
Hematologic: blood dyscrasias
Metabolic: gout attack, dehydration, hyperglycemia, hypokalemia, hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia, hyperuricemia, hyperlipidemia, hypochloremic alkalosis
Musculoskeletal: muscle cramps, muscle spasms
Skin: flushing, photosensitivity, hives, rash, exfoliative dermatitis, toxic epidermal necrolysis
Other: fever, weight loss, hypersensitivity reactions

Interactions
Drug-drug. Allopurinol: increased risk of hypersensitivity reaction
Amphotericin B, corticosteroids, mezlocillin, piperacillin, ticarcillin: additive hypokalemia
Antihypertensives, barbiturates, nitrates, opiates: increased hypotension

Cholestyramine, colestipol: decreased chlorthalidone blood level
Digoxin: increased risk of hypokalemia
Lithium: increased risk of lithium toxicity
Nonsteroidal anti-inflammatory drugs: decreased diuretic effect
Drug-diagnostic tests. Bilirubin, calcium, creatinine, uric acid: increased levels
Glucose (in diabetic patients): increased blood and urine levels
Magnesium, potassium, protein-bound iodine, sodium, urine calcium: decreased levels

Drug-herbs. Ginkgo: decreased antihypertensive effects
Licorice, stimulant laxative herbs (aloe, cascara sagrada, senna): increased risk of potassium depletion
Drug-behaviors. Acute alcohol ingestion: additive hypotension
Sun exposure: increased risk of photosensitivity

Patient monitoring
• Closely monitor patient with renal insufficiency.
• Assess for signs and symptoms of hematologic disorders.
• Monitor CBC with white cell differential and serum uric acid and electrolyte levels.
• Assess for signs and symptoms of hypersensitivity reactions, especially dermatitis.
• Watch for fluid and electrolyte imbalances.

Patient teaching
• Instruct patient to consume a low-sodium diet containing plenty of potassium-rich foods and beverages (such as bananas, green leafy vegetables, and citrus juice).
• Caution patient to avoid driving and other hazardous activities until he knows whether drug makes him dizzy or affects concentration and alertness.
• Tell patient with diabetes to check urine or blood glucose level frequently.
As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

**chlorzoxazone**

Parafon Forte DSC, Strifon Forte

**Pharmacologic class:** Autonomic nervous system agent  
**Therapeutic class:** Skeletal muscle relaxant (centrally acting)  
**Pregnancy risk category C**

**Action**  
Unclear. Thought to act on spinal cord and subcortical levels of brain, inhibiting multisynaptic reflex arcs responsible for skeletal muscle activity.

**Availability**  
*Caplets:* 250 mg, 500 mg  
*Tablets:* 250 mg, 500 mg

**Indications and dosages**  
➢ Adjunct to rest and physical therapy in treatment of muscle spasms associated with acute, painful musculoskeletal conditions  
**Adults:** 250 to 750 mg P.O. three to four times daily

**Contraindications**  
• Hypersensitivity to drug  
• Hepatic impairment

**Precautions**  
Use cautiously in:  
• underlying cardiovascular disease, renal impairment  
• children (safety not established).

**Administration**  
• If desired, crush tablets and mix contents with food or water.

**Adverse reactions**

CNS: dizziness, drowsiness, light-headedness, malaise, headache, overstimulation, tremor  
GI: nausea, vomiting, constipation, diarrhea, heartburn, abdominal distress, anorexia  
GU: orange or purplish-red urine  
**Hepatic: hepatic dysfunction**  
Skin: allergic dermatitis, urticaria, erythema, pruritus, petechiae, ecchymosis, angioedema  
**Other:** allergic reactions

**Interactions**

Drug-drug. CNS depressants (including antihistamines, antidepressants, opioids, sedative-hypnotics): increased risk of CNS depression  
**Drug-diagnostic tests.** Alanine aminotransferase, alkaline phosphatase, bilirubin: increased levels  
**Drug-herbs.** Chamomile, hops, kava, skullcap, valerian: increased CNS depression  
**Drug-behaviors.** Alcohol use: increased sedation

**Patient monitoring**  
➢ Stay alert for signs and symptoms of hepatic dysfunction. Withhold drug and notify prescriber if these occur.  
• Monitor hepatic enzyme and serum electrolyte levels.

**Patient teaching**  
➢ Instruct patient to promptly report yellowing of eyes or skin.  
• Caution patient not to consume alcohol during therapy.  
• Instruct patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
Tell patient that drug may turn his urine orange or purplish-red.
As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

**cholestyramine**
LoCHOLEST, LoCHOLEST Light, Novo-Cholamine, Novo-Cholamine Light, Prevalite, Questran, Questran Light

**Pharmacologic class:** Bile acid sequestrant
**Therapeutic class:** Lipid-lowering agent
**Pregnancy risk category C**

**Action**
Combines with bile acid in GI tract to form insoluble complex excreted in feces. Complex regulates and increases cholesterol synthesis, thereby decreasing serum cholesterol and low-density lipoprotein levels.

**Availability**
Powder for suspension; powder for suspension with aspartame: 4 g cholestyramine/packet or scoop

**Indications and dosages**
Primary hypercholesterolemia and pruritus caused by biliary obstruction; primary hyperlipidemia

**Adults:** Initially, 4 g P.O. once or twice daily. May increase as needed and tolerated, up to 24 g/day in six divided doses.

**Off-label uses**
- Antibiotic–induced pseudomembranous colitis
- Adjunct in infantile diarrhea
- Digoxin toxicity

**Contraindications**
- Hypersensitivity to drug, its components, or other bile-acid sequestering resins
- Complete biliary obstruction
- Phenylketonuria (suspension containing aspartame)

**Precautions**
Use cautiously in:
- history of constipation or abnormal intestinal function
- pregnant patients
- children.

**Administration**
- Mix powder with soup, cereal, pulpy fruit, juice, milk, or water.
- Administer 1 hour before or 4 to 6 hours after other drugs.
- Be aware that fat-soluble vitamin supplements may be necessary with long-term drug use.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>24-48 hr</td>
<td>1-3 wk</td>
<td>2-4 wk</td>
</tr>
</tbody>
</table>
Interactions
Drug-drug. Acetaminophen, amiodarone, clindamycin, clofibrate, corticosteroids, digoxin, diuretics, fat-soluble vitamins (A, D, E, and K), gemfibrozil, glipizide, imipramine, methotrexate, methyl dopa, mycophenolate, niacin, nonsteroidal anti-inflammatory drugs, penicillin, phenytoin, phosphates, propranolol, tetracyclines, tolbutamide, thyroid preparations, ursodiol, warfarin: decreased absorption and effects of these drugs
Drug-diagnostic tests. Alkaline phosphatase: increased level
Hemoglobin: decreased value
Prothrombin time: increased

Patient monitoring
● Monitor CBC with white cell differential and liver function test results.
● If bleeding or bruising occurs, monitor prothrombin time. Drug may reduce vitamin K absorption.
● Watch for constipation, especially in patients with coronary artery disease. Take appropriate steps to prevent this problem.

Patient teaching
インストラクション patient to immediately report yellowing of skin or eyes or easy bruising or bleeding.
● Tell patient to take drug 1 hour before or 4 to 6 hours after other drugs.
● Teach patient about role of diet in controlling cholesterol level and preventing constipation.
● Instruct patient to avoid inhaling or ingesting raw powder. Tell him to mix powder with food, juice, or milk before consuming.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Reactions in bold are life-threatening.

FDA BOXED WARNING
● Drug is indicated only for treatment of cytomegalovirus (CMV) retinitis in patients with AIDS.
● Renal impairment is major toxicity. As few as one or two doses have caused acute renal failure resulting in dialysis or contributing to death. To reduce possible nephrotoxicity, prehydrate with I.V. normal saline solution and give probenecid with each drug infusion. Monitor renal function within 48 hours before each dose, and modify dosage as indicated.
● Drug is contraindicated in patients receiving other nephrotoxic agents.
● Drug may cause neutropenia. Monitor neutrophil counts during therapy.
● In animal studies, drug was carcinogenic and teratogenic and caused hypospermia.

Action
Exerts antiviral effect by interfering with DNA synthesis of CMV, thereby inhibiting viral replication

Availability
Solution for injection: 75 mg/ml in 5-ml, single-use vials

Indications and dosages
CMV retinitis in AIDS patients
Adults: 5 mg/kg I.V. infused over 1 hour q week for 2 continuous weeks; then 5 mg/kg I.V. once q 2 weeks as a maintenance dose
Dosage adjustment
- Renal impairment

Contraindications
- Hypersensitivity to drug, probenecid, or other sulfa-containing agents
- Creatinine level above 1.5 mg/dl, calculated creatinine clearance of 55 ml/minute or less, or urine protein level of 100 mg/dl or higher
- Concurrent use of nephrotoxic drugs

Precautions
Use cautiously in:
- renal impairment
- elderly patients
- pregnant or breastfeeding patients
- children younger than age 12 (safety and efficacy not established).

Administration
- Be aware that drug carries a high risk of nephrotoxicity. Follow administration instructions carefully, including preinfusion and postinfusion hydration with I.V. normal saline solution.
- Premedicate with probenecid 2 g P.O., as prescribed, 3 hours before starting cidofovir infusion.
- Before starting infusion, give 1 L of normal saline solution over 1 to 2 hours.
- Mix I.V. dose in 100 ml of normal saline solution and infuse over 1 hour using infusion pump.
- Give 1 L of normal saline solution during or immediately after cidofovir infusion (unless contraindicated).
- Administer probenecid 1 g 2 hours and 8 hours after infusion ends, as prescribed.
- If drug touches skin, flush thoroughly with water.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>End of infusion</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, seizures, coma
EENT: decreased intraocular pressure
GI: nausea, vomiting, diarrhea, anorexia, oral candidiasis
GU: proteinuria, nephrotoxicity
Hematologic: neutropenia
Hepatic: hepatomegaly
Metabolic: metabolic acidosis
Musculoskeletal: muscle contractions
Respiratory: dyspnea, increased cough
Skin: rash, alopecia
Other: pain, fever, chills, infection, pain at I.V. site

Interactions
Drug-drug. Nephrotoxic drugs: increased risk of nephrotoxicity
Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, blood urea nitrogen, creatinine, lactate dehydrogenase: increased values
Bicarbonate, creatinine clearance, hemoglobin, neutrophils, platelets: decreased values

Patient monitoring
- Assess white blood cell count and creatinine and urine protein levels within 48 hours of each dose.
- Closely monitor intraocular pressure and visual acuity.
- Monitor hepatic enzyme levels in patients with hepatic disease.

Patient teaching
- Tell patient to immediately report fever, vision changes, nausea, vomiting, rash, or urinary output changes.
- Instruct patient to take probenecid, as prescribed, before each dose and to have regular eye examinations.
- Urge female patient of childbearing age to use effective contraception during and for 1 month after therapy.
- Instruct male patients to use barrier contraception during and for 3 months after therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially
those related to the drugs and tests mentioned above.

cilostazol
Pletal

**Pharmacologic class:** Quinolone derivative  
**Therapeutic class:** Antiplatelet agent  
**Pregnancy risk category C**

**FDA BOXED WARNING**
- Drug and several of its metabolites inhibit phosphodiesterase III. Several drugs with this effect decreased survival in patients with class III-IV congestive heart failure (CHF). Drug is contraindicated in patients with CHF of any severity.

**Action**
Unclear. Thought to inhibit phosphodiesterase III by increasing cyclic adenosine monophosphate in platelets and blood vessels, causing vasodilation and enhancing cardiac contractility and coronary blood flow.

**Availability**
Tablets: 50 mg, 100 mg

**Indications and dosages**
- Intermittent claudication

**Adults:** 100 mg P.O. b.i.d. at least 30 minutes before or 2 hours after breakfast and dinner

**Dosage adjustment**
- Concurrent use of diltiazem, erythromycin, itraconazole, ketoconazole, or omeprazole

**Contraindications**
- Hypersensitivity to drug  
- Heart failure

**Precautions**
Use cautiously in:
- cardiovascular disorders  
- patients receiving other antiplatelet agents concurrently  
- pregnant or breastfeeding patients  
- children (safety and efficacy not established).

**Administration**
- Give with water 30 minutes before or 2 hours after patient consumes food or milk.  
- Don’t give with grapefruit juice.  
- Be aware that although response may occur within 2 to 3 weeks, patient should continue therapy for up to 12 weeks or as prescribed.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Gradual</td>
<td>4-6 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- CNS: dizziness, headache, vertigo  
- CV: tachycardia  
- GI: abdominal pain, abnormal stools, dyspepsia, flatulence  
- EENT: rhinitis, pharyngitis  
- Musculoskeletal: back pain, myalgia  
- Respiratory: increased cough  
- Other: infection

**Interactions**
- **Drug-drug.** CYP3A4 and CYP2C19 inhibitors, diltiazem, erythromycin, macrolides, omeprazole: increased cilostazol blood level  
- **Drug-food.** Grapefruit juice, high-fat meals: increased cilostazol blood level  
- **Drug-behaviors.** Smoking: decreased exposure to cilostazol

**Patient monitoring**
- Monitor cardiovascular status.  
- Closely monitor patient if he’s receiving other antiplatelet drugs.

**Patient teaching**
- Instruct patient to take drug with full glass of water, 30 minutes before or 2 hours after food or milk.
Advise patient to report nausea, vomiting, or abdominal pain.
- Instruct patient not to smoke, because smoking impedes drug effects.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, foods, and behaviors mentioned above.

**cimetidine**

**Apo-Cimetidine**, **Dyspamet**, **Galenmet**, **Novo-Cimetine**, **Nu-Cimet**, **Tagamet HB**

**Pharmacologic class:** Histamine₂-receptor antagonist  
**Therapeutic class:** Antiulcer drug  
**Pregnancy risk category B**

**Action**  
Competitively inhibits histamine action at histamine₂-receptor sites of gastric parietal cells, thereby inhibiting gastric acid secretion

**Availability**  
**Oral liquid:** 200 mg/5 ml, 300 mg/5 ml  
**Solution for injection:** 300 mg/2-ml vials, 300 mg/50 ml premixed in normal saline solution  
**Tablets:** 100 mg, 200 mg, 300 mg, 400 mg, 600 mg, 800 mg

**Indications and dosages**  
➤ Active duodenal ulcer (short-term therapy)  
**Adults and children older than age 16:** 800 mg P.O. at bedtime or 300 mg P.O. q.i.d. with meals and at bedtime  
➤ Gastric hypersecretory conditions (such as Zollinger-Ellison syndrome); intractable ulcers  
**Adults and children older than age 16:** 300 mg P.O. q.i.d. with meals and at bedtime; in hospitalized patients, 300 mg I.M. or I.V. q 6 hours  
➤ Erosive gastroesophageal reflux disease  
**Adults and children older than age 16:** 1,600 mg P.O. daily in divided doses (800 mg b.i.d. or 400 mg q.i.d.) for 12 weeks  
➤ Prevention of stress-induced upper GI bleeding in critically ill patients  
**Adults and children older than age 16:** 50 mg/hour as a continuous I.V. infusion  
➤ Heartburn; acid indigestion  
**Adults and children older than age 16:** 200 mg (two tablets of over-the-counter product only) P.O. up to b.i.d. Give maximum dosage no longer than 2 weeks continuously, unless directed by prescriber.

**Dosage adjustment**  
- Renal impairment

**Off-label uses**  
- Acetaminophen overdose  
- Adjunctive therapy in burns  
- Barrett’s esophagus  
- Renal cancer  
- Anaphylaxis

**Contraindications**  
- Hypersensitivity to drug  
- Alcohol intolerance (oral drug forms)

**Precautions**  
Use cautiously in:  
- renal impairment  
- elderly patients  
- pregnant or breastfeeding patients.
**Administration**
- Give P.O. doses with meals.
- Give I.M. doses undiluted.
- Dilute I.V. doses in normal saline solution or other compatible solution.
- Administer I.V. injection over at least 5 minutes; may give intermittent infusion over 15 to 20 minutes.
- Give continuous I.V. infusion at a rate of 37.5 mg/hour over 24 hours, using an infusion pump.
- When giving drug to prevent stress ulcers, administer by continuous I.V. infusion at a rate of 50 mg/hour.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30 min</td>
<td>45-90 min</td>
<td>4-5 hr</td>
</tr>
<tr>
<td>I.V., I.M.</td>
<td>10 min</td>
<td>30 min</td>
<td>4-5 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** confusion, dizziness, drowsiness, hallucinations, agitation, psychosis, depression, anxiety, headache

**GI:** diarrhea

**GU:** reversible erectile dysfunction, gynecomastia

**Other:** pain at I.M. injection site

**Interactions**

**Drug-drug.** *Calcium channel blockers, carbamazepine, chloroquine, lidocaine, metformin, metronidazole, moricizine, pentoxifylline, phenytoin, propafenone, quinidine, quinine, some benzodiazepines, some beta-adrenergic blockers (chlor Diazepoxide, diazepam, midazolam), sulfonylureas, tacrine, theophylline, triamterene, tricyclic antidepressants, valproic acid, warfarin:* decreased metabolism of these drugs, possible toxicity

**Drug-diagnostic tests.** *Creatinine, transaminases:* increased levels

*Parathyroid hormone:* decreased level

*Prolactin (after I.V. bolus of cimetidine):* increased level

*Skin tests using allergenic extracts:* false-negative results (drug should be discontinued 24 hours before testing)

**Drug-food.** *Caffeine-containing foods and beverages (such as coffee, chocolate):* increased cimetidine blood level, increased risk of toxicity

**Drug-herbs.** *Pennyroyal:* change in formation rate of herb’s toxic metabolite

*Yerba maté:* decreased yerba maté clearance, possible toxicity

**Drug-behaviors.** *Alcohol use:* increased blood alcohol level

*Smoking:* reversed cimetidine effects

**Patient monitoring**
- Monitor creatinine levels in patients with renal insufficiency or failure.
- Assess elderly or chronically ill patients for confusion (which usually resolves once drug therapy ends).

**Patient teaching**
- Inform patient with gastric ulcer that ulcer may take up to 2 months to heal. Advise him not to discontinue therapy, even if he feels better, without first consulting prescriber. Ulcer may recur if therapy ends too soon.
- Advise patient not to take over-the-counter cimetidine for more than 2 weeks continuously, except with prescriber’s advice and supervision.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

---

**cinacalcet hydrochloride**

*Mimpara®, Sensipar*

**Pharmacologic class:** Calcimimetic

**Therapeutic class:** Endocrine and metabolic agent

**Pregnancy risk category C**

Reactions in **bold** are life-threatening.
Action
Directly lowers parathyroid hormone (PTH) levels by increasing sensitivity of calcium-sensing receptors to extracellular calcium

Availability
Tablets: 30 mg, 60 mg, 90 mg

Indications and dosages
> Secondary hyperparathyroidism in patients with chronic renal disease who are on dialysis
Adults: Dosage individualized; recommended starting dosage is 30 mg P.O. daily. Measure serum calcium and phosphorus levels within 1 week and intact parathyroid hormone (iPTH) 1 to 4 weeks after initiation or dosage adjustment; titrate dosage no more often than every 2 to 4 weeks through sequential doses of 60 mg, 90 mg, 120 mg, and 180 mg P.O. once daily to recommended target iPTH for chronic renal disease patients on dialysis of 150 to 300 pg/ml.

> Hypercalcemia in patients with parathyroid carcinoma
Adults: Recommended starting dosage is 30 mg P.O. twice daily, titrated every 2 to 4 weeks through sequential doses of 60 mg and 90 mg twice daily, and 90 mg three or four times daily as needed to normalize serum calcium level.

Dosage adjustment
- Decreased calcium or iPTH level
- Concurrent use or discontinuation of strong CYP3A4 inhibitors (such as erythromycin, itraconazole, or ketoconazole)

Contraindications
- Hypersensitivity to drug or its components

Precautions
Use cautiously in:
- decreased serum calcium level, moderate or severe hepatic impairment
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

Administration
- Don’t initiate therapy if serum calcium level is less than lower limit of normal range (8.4 mg/dl).
- Administer tablets whole with food or shortly after a meal.
- If iPTH level decreases below recommended target range (150 to 300 pg/ml), reduce dosage of cinacalcet and vitamin D sterols or discontinue therapy.
- During titration, monitor serum calcium level frequently; if level drops below normal, take appropriate measures to increase it, such as providing supplemental calcium, initiating or increasing dosage of calcium-based phosphate binder or vitamin D sterols, or withholding cinacalcet temporarily.
- Adjust dosage and closely monitor iPTH and calcium levels if patient is receiving or discontinuing a strong CYP3A4 inhibitor.

Route Onset Peak Duration
P.O. Unknown 2-6 hr Unknown

Adverse reactions
CNS: dizziness, asthenia
CV: hypertension
GI: nausea, vomiting, diarrhea, anorexia
Musculoskeletal: myalgia
Other: chest pain (noncardiac)

Interactions
Drug-drug. Amitriptyline: increased amitriptyline and nortriptyline (active metabolite) exposure
Drugs metabolized by CYP4502D6 (such as flecainide, thioridazine, most tricyclic antidepressants, vinblastine): increased blood levels of either drug
Ketoconazole and other strong CYP3A4 inhibitors: increased cinacalcet exposure

Drug-diagnostic tests. Calcium: decreased
Patient monitoring
- Closely monitor iPTH and serum calcium levels throughout therapy in patients with moderate to severe hepatic impairment and in those who start or discontinue therapy with strong CYP3A4 inhibitor.
- Monitor iPTH level carefully to ensure that it doesn’t fall below 100 pg/ml because adynamic bone disease may develop.
- Measure serum calcium and phosphorus levels within 1 week and iPTH level 1 to 4 weeks after initiation or dosage adjustment. Once maintenance dosage is established, measure serum calcium and phosphorus levels approximately monthly and iPTH level every 1 to 3 months.
- Monitor serum calcium level closely in patient with history of seizure disorders.

Patient teaching
- Instruct patient to take tablets whole with food or shortly after a meal.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Fluoroquinolones for systemic use are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in patients usually over age 60, with concomitant use of corticosteroids, and in kidney, heart, and lung transplant recipients.

Action
Inhibits bacterial DNA synthesis by inhibiting DNA gyrase in susceptible gram-negative and gram-positive organisms

Availability
Injection: 200 mg/20 ml, 400 mg/40 ml, 200 mg/100 ml premixed in dextrose 5% in water (D₅W), 400 mg/200 ml premixed in D₅W, 1,200 mg/120-ml bulk package
Ophthalmic ointment: 3.5-g tube
Ophthalmic solution: 2.5-ml and 5-ml plastic dispensers
Oral suspension: 5 g/100 ml (5%), 10 g/100 ml (10%)
Tablets: 250 mg, 500 mg, 750 mg
Tablets (extended-release): 500 mg, 1,000 mg

Indications and dosages
- Acute sinusitis
  Adults: 500 mg P.O. q 12 hours or 400 mg I.V. q 12 hours for 10 days
- Prostatitis
  Adults: 500 mg P.O. q 12 hours or 400 mg I.V. q 12 hours for 28 days
- Intra-abdominal infections
  Adults: 500 mg P.O. q 12 hours or 400 mg I.V. q 12 hours for 7 to 14 days
- Febrile neutropenic patients
  Adults: 400 mg I.V. q 8 hours for 7 to 14 days
- Gonorrhea
  Adults: 500 mg P.O. as a single dose
- Infectious diarrhea
  Adults: 500 mg P.O. q 12 hours for 5 to 7 days
- Inhalation anthrax (postexposure)
  Adults: 500 mg P.O. q 12 hours for 60 days or 400 mg I.V. q 12 hours for 60 days

Reactions in bold are life-threatening.
Children: 15 mg/kg P.O. q 12 hours for 60 days (not to exceed 500 mg/dose), or 10 mg/kg I.V. q 12 hours for 60 days, not to exceed 400 mg/dose

Infections of lower respiratory tract, skin and skin structures, bones, and joints

Adults: 500 to 750 mg P.O. q 12 hours or 400 mg I.V. q 8 hours for 7 to 14 days. Severe bone and joint infections may necessitate up to 6 weeks of therapy.

Nosocomial pneumonia

Adults: 400 mg I.V. q 8 hours for 10 to 14 days

Typhoid fever

Adults: 500 mg P.O. q 12 hours for 10 days

Urinary tract infections

Adults: 250 to 500 mg P.O. q 12 hours, or 500 to 1,000 mg Cipro XR P.O. daily, or 200 to 400 mg I.V. q 12 hours for 3 days in acute uncomplicated infection or for 7 to 14 days in mild to severe complicated infection

Peyelonephritis

Adults: 1,000 mg Cipro XR P.O. daily for 7 to 14 days

Bacterial conjunctivitis caused by susceptible organisms

Adults: 0.5" ribbon of ophthalmic ointment applied to conjunctival sac t.i.d. on first 2 days, then 0.5" ribbon b.i.d. for 5 days. Or one to two drops of ophthalmic solution applied to conjunctival sac q 2 hours while awake for 2 days, then one or two drops q 4 hours while awake for 5 days.

Corneal ulcers caused by susceptible organisms

Adults: Two drops of ophthalmic solution instilled into affected eye q 15 minutes for first 6 hours, then two drops into affected eye q 30 minutes for remainder of first day. On second day, two drops of ophthalmic solution hourly; on days 3 through 14, two drops q 4 hours.

Dosage adjustment
- Renal impairment or insufficiency

Off-label uses
- Chancroid
- Cystic fibrosis
- Pseudomembranous colitis caused by anti-infectives

Contraindications
- Hypersensitivity to drug or other fluoroquinolones
- Concomitant administration of tizanidine

Precautions
Use cautiously in:
- cirrhosis, renal impairment, underlying CNS disease
- elderly patients
- pregnant or breastfeeding patients
- children younger than age 18.

Administration
- Infuse I.V. dose over at least 1 hour, using pump to ensure 1-hour duration.
  - Know that too-rapid I.V. infusion increases risk of anaphylaxis and other adverse reactions.
- Be aware that oral suspension isn’t suitable for use in nasogastric tube.
  - Know that treatment with ophthalmic solution may be continued after 14 days if corneal re-epithelialization hasn’t occurred.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>1-2 hr</td>
<td>12 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>End of infusion</td>
<td>12 hr</td>
</tr>
<tr>
<td>Ophthal.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: agitation, headache, restlessness, confusion, delirium, toxic psychosis
CV: orthostatic hypotension, vasculitis
EENT: nystagmus; with ophthalmic use—blurred vision; burning, stinging, irritation, itching, tearing, and redness
of eyes; eyelid itching, swelling, or crusting; sensitivity to light
GI: nausea, vomiting, diarrhea, constipation, abdominal pain or discomfort, dyspepsia, dysphagia, flatulence, pancreatitis, pseudomembranous colitis
GU: albuminuria, candiduria, renal calculi
Hematologic: methemoglobinemia, agranulocytosis, hemolytic anemia
Hepatic: jaundice, hepatic necrosis
Metabolic: jaundice, hepatic necrosis
Musculoskeletal: myalgia, myoclonus, tendinitis, tendon rupture
Skin: rash, exfoliative dermatitis, toxic epidermal necrolysis, erythema multiforme
Other: altered taste, anosmia, exacerbation of myasthenia gravis, overgrowth of nonsusceptible organisms, hypersensitivity reactions including anaphylaxis and Stevens-Johnson syndrome

Interactions
Drug-drug. Antacids, bismuth subsalicylate, iron salts, sucralfate, zinc salts: decreased ciprofloxacin absorption
Cyclosporine: transient creatinine increase
Hormonal contraceptives: reduced contraceptive efficacy
Oral anticoagulants: increased anticoagulant effects
Phenytoin: increased or decreased phenytoin blood level
Probenecid: decreased renal elimination of ciprofloxacin, causing increased blood level
Theophylline: increased theophylline blood level, greater risk of toxicity
Tizanidine: significantly elevated tizanidine plasma level

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, cholesterol, glucose, lactate dehydrogenase, potassium, triglycerides: increased levels
Prothrombin time: prolonged

Drug-food. Caffeine: interference with caffeine clearance
Concurrent tube feedings, milk or yogurt (when consumed alone with ciprofloxacin): impaired drug absorption

Drug-herbs. Fennel: decreased drug absorption

Patient monitoring
- In patients with renal insufficiency, assess creatinine level before giving first dose and at least once a week during prolonged therapy. Monitor drug blood level closely.
- Watch for signs and symptoms of serious adverse reactions, including GI problems, jaundice, tendon problems, and hypersensitivity reactions.

Patient teaching
- Tell patient to take drug 2 hours after a meal.
- Advise patient not to take drug with dairy products alone or with caffeinated beverages.
- Instruct patient to swallow microcapsules in oral suspension whole without chewing.
- Advise patient to drink 8 oz of water every hour while awake to ensure adequate hydration.
- Instruct patient to stop taking drug and notify prescriber at first sign of rash or tendon pain, swelling, or inflammation.
- Advise patient taking hormonal contraceptives to use supplemental birth control method, such as condoms, because drug reduces contraceptive efficacy.
- Inform breastfeeding patient that drug is excreted in breast milk and can affect infant’s bone growth. Advise her to consult prescriber before using drug.
- Teach patient how to use eye ointment or solution.

Reactions in bold are life-threatening.
Tell patient not to touch eye dropper tip to any surface, to avoid contamination.
- Caution patient with bacterial conjunctivitis not to wear contact lenses.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

**Action**
Inhibits DNA synthesis by causing intrastrand and interstrand cross-linking of DNA

**Availability**
*Injection:* 1 mg/ml in 50-mg and 100-mg vials

**Indications and dosages**
➤ Metastatic testicular tumors
**Adults:** 20 mg/m² I.V. daily for 5 days/cycle, repeated q 3 to 4 weeks
➤ Metastatic ovarian cancer
**Adults:** 75 to 100 mg/m² I.V., repeated q 4 weeks in combination with cyclophosphamide; or 100 mg/m² q 4 weeks as a single agent
➤ Advanced bladder cancer
**Adults:** 50 to 70 mg/m² I.V. q 3 to 4 weeks as a single agent; dosage depends on whether patient has undergone radiation or chemotherapy.

**Off-label uses**
- Cervical cancer
- Squamous cell carcinoma

**Contraindications**
- hypersensitivity to drug or other platinum-containing compounds
- Severe impairment of renal function
- Severe myelosuppression
- Hearing impairment
- Pregnancy or breastfeeding

**Precautions**
Use cautiously in:
- mild to moderate renal impairment, active infection, myelosuppression, chronic debilitating illness, heart failure, electrolyte abnormalities
- females of childbearing age.

**Administration**
- Prepare drug with equipment that doesn’t contain aluminum.
- Give 2 L of I.V. fluids, as prescribed, 8 to 12 hours before drug infusion to help prevent toxicity.
● Dilute each dose in 2 L of dextrose 5% in 1/4 or 1/2 saline solution or 0.9% normal saline solution. Do not use dextrose 5% in water.
● Infuse each liter over 3 to 4 hours to minimize toxicity. In well-hydrated patients with good renal function, infusions of 100 to 500 ml may be given over 30 minutes.
● Follow facility policy for handling and disposal of antineoplastics.
● If solution contacts skin, wash immediately and thoroughly with soap and water. If solution contacts mucosa, flush with water immediately.
● Protect drug from light.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>18-23 days</td>
<td>39 days</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: malaise, weakness, seizures
EENT: ototoxicity, tinnitus
GI: severe nausea, vomiting, diarrhea
GU: sterility, nephrotoxicity
Hematologic: anemia, leukopenia, thrombocytopenia
Hepatic: hepatotoxicity
Metabolic: hypocalcemia, hypokalemia, hypomagnesemia, hyperuricemia
Skin: alopecia
Other: phlebitis at I.V. site, anaphylaxis

**Interactions**

Drug-drug. Amphotericin B, loop diuretics: increased risk of hypokalemia and hypomagnesemia
Antineoplastics: additive bone marrow depression
Live-virus vaccines: decreased antibody response to vaccine, increased risk of adverse reactions
Nephrotoxic drugs (such as aminoglycosides): additive nephrotoxicity
Ototoxic drugs (such as loop diuretics): additive ototoxicity
Phenytoin: reduced phenytoin blood level

**Drug-diagnostic tests.** Aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, uric acid: increased levels
Calcium, magnesium, phosphate, potassium, sodium: decreased levels
Coombs’ test: positive result

**Patient monitoring**

● Before starting therapy and before each subsequent dose, assess renal function test results and CBC with white cell differential.
● Monitor neurologic status, hepatic enzyme and uric acid levels, and audiogram results.
● Monitor urine output closely.

**Patient teaching**

● Instruct patient to drink 8 oz of water every hour while awake.
● Advise patient to promptly report bleeding, bruising, hearing loss, yellowing of skin or eyes, decreased urine output, or suspected infection.
● Tell patient that drug may cause hair loss.
● Instruct female patient to use reliable contraception; drug can harm fetus.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**citalopram hydrobromide**

Celexa

**Pharmacologic class:** Selective serotonin reuptake inhibitor

**Therapeutic class:** Antidepressant

**Pregnancy risk category C**

Reactions in **bold** are life-threatening.
FDA BOXED WARNING

- Drug may increase risk of suicidal thinking and behavior in children and adolescents with major depressive disorder and other psychiatric disorders, especially during first few months of therapy. Risk must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family to observe patient closely and communicate with prescriber as needed.
- Drug isn’t approved for use in pediatric patients.

Action
Unclear. Thought to potentiate serotonergic activity in CNS by inhibiting neuronal uptake of serotonin.

Availability
Oral solution: 10 mg/5 ml
Orally disintegrating tablets (ODT): 10 mg, 20 mg, 30 mg, 40 mg
Tablets: 10 mg, 20 mg, 40 mg

Indications and dosages
> Depression
Adults: Initially, 20 mg P.O. daily; may increase by 20 mg/day at weekly intervals, up to 60 mg/day. Usual dosage is 40 mg/day. For ODT, start with 20 mg tablet dissolved on the tongue daily; may increase to 40 mg daily; may further increase to 60 mg daily.

Dosage adjustment
- Hepatic impairment
- Elderly patients

Off-label uses
- Alcoholism
- Panic disorder
- Premenstrual dysphoria
- Social phobia

Contraindications
- Hypersensitivity to drug
- MAO inhibitor use within 14 days

Precautions
Use cautiously in:
- severe renal impairment, hepatic impairment, conditions likely to cause altered metabolism or hemodynamic responses
- history of mania or seizure disorder
- elderly patients
- pregnant patients
- children (safety not established).

Administration
⚠️ Don’t give within 14 days of MAO inhibitor; life-threatening interactions may occur.

Route Onset Peak Duration
P.O. 1-4 wk Unknown Unknown

Adverse reactions
CNS: apathy, confusion, drowsiness, insomnia, migraine, weakness, agitation, amnesia, anxiety, dizziness, fatigue, poor concentration, tremor, paresthesia, deepening of depression, suicide attempt
CV: orthostatic hypotension, tachycardia
EENT: abnormal visual accommodation
GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia, flatulence, increased saliva, dry mouth, increased appetite, anorexia
GU: polyuria, amenorrhea, dysmenorrhea, ejaculatory delay, erectile dysfunction, decreased libido
Musculoskeletal: joint pain, myalgia
Respiratory: cough
Skin: rash, pruritus, diaphoresis, photosensitivity
Other: altered taste, fever, yawning, weight changes

Interactions
Drug-drug. Carbamazepine: decreased citalopram blood level
Centrally acting drugs (such as antihistamines, opioids, sedative-hypnotics): additive CNS effects

Erythromycin, itraconazole, ketoconazole, omeprazole: increased citalopram blood level

5-hydroxytryptamine1 receptor agonists (such as sumatriptan, zolmitriptan): increased risk of adverse reactions

Lithium: potentiation of serotonergic effects

MAO inhibitors: life-threatening reactions

Tricyclic antidepressants (TCAs): altered TCA pharmacokinetics

Drug-herbs. St. John’s wort, S-adenosylmethionine (SAM-e): increased risk of serotonergic reactions, including serotonin syndrome

Drug-behaviors. Alcohol use: additive CNS depression
Sun exposure: photosensitivity

Patient monitoring
• If patient is receiving lithium concurrently, watch closely for potentiation of serotonergic effects.
• Assess for evidence of drug efficacy.

Patient teaching
• Instruct patient to take drug with full glass of water at same time every day.
• Advise patient (especially child or adolescent) to immediately report suicidal thoughts or extreme depression.
• Instruct patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness caused by sudden blood pressure decrease.
• Tell patient several weeks may pass before he starts to feel better.
• Advise patient to avoid alcohol during therapy.
• Tell male patient he may experience inadequate filling of penile erectile tissue. Advise him to consult prescriber if he experiences adverse sexual effects.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, herbs, and behaviors mentioned above.

clarithromycin
Biaxin Filmtab, Biaxin Granules, Biaxin XL Filmtab, Clarosip®, Klaricid®

Pharmacologic class: Macrolide
Therapeutic class: Anti-infective, antiulcer drug
Pregnancy risk category B

Action
Reversibly binds to 50S ribosomal subunit of susceptible bacterial organisms, blocking protein synthesis

Availability
Granules for oral suspension: 125 mg/5 ml, 250 mg/5 ml
Tablets: 250 mg, 500 mg
Tablets (extended-release): 500 mg

Indications and dosages
➣ Pharyngitis or tonsillitis caused by Streptococcus pyogenes
Adults: 250 mg P.O. q 12 hours for 10 days
➣ Acute maxillary sinusitis caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae
Adults: 500 mg P.O. q 12 hours for 14 days or two 500-mg extended-release tablets P.O. q 24 hours for 14 days
Children: 7.5 mg/kg P.O. q 12 hours for 10 days
➣ Acute exacerbation of chronic bronchitis caused by H. influenzae, Haemophilus parainfluenzae, M. catarrhalis, or S. pneumoniae
Adults: 500 mg P.O. q 12 hours for 7 to 14 days or two 500-mg extended-release tablets P.O. q 24 hours for 7 days

Reactions in **bold** are life-threatening.

Clinical alert
Community-acquired pneumonia caused by *S. pneumoniae*, *Mycoplasma pneumoniae*, or *Chlamydia pneumoniae*; acute exacerbation of chronic bronchitis caused by *S. pneumoniae* or *M. catarrhalis*

**Adults:** 250 mg P.O. q 12 hours for 7 to 14 days or two 500-mg extended-release tablets P.O. q 24 hours for 7 days

**Children:** 7.5 mg/kg P.O. q 12 hours for 10 days

Community-acquired pneumonia caused by *H. influenzae*

**Adults:** 250 mg P.O. q 12 hours for 7 days or two 500-mg extended-release tablets P.O. q 24 hours for 7 days

Community-acquired pneumonia caused by *H. parainfluenzae* or *M. catarrhalis*

**Adults:** Two 500-mg extended-release tablets P.O. q 24 hours for 7 days

Uncomplicated skin and skin-structure infections

**Adults:** 250 mg P.O. q 12 hours for 7 to 14 days

Eradication of *Helicobacter pylori* as part of triple therapy with amoxicillin and omeprazole or lansoprazole

**Adults:** 500 mg P.O. q 12 hours for 10 to 14 days

Eradication of *H. pylori* as part of dual therapy with omeprazole or ranitidine

**Adults:** 500 mg P.O. t.i.d. for 14 days

Mycobacterial infections

**Adults:** 500 mg P.O. b.i.d.

**Children:** 7.5 mg/kg P.O. b.i.d., up to 500 mg b.i.d.

Acute otitis media

**Children:** 7.5 mg/kg P.O. q 12 hours for 10 days

**Dosage adjustment**

- Renal or hepatic impairment

**Off-label uses**

- *Borrelia burgdorferi* infection

**Contraindications**

- Hypersensitivity to drug, erythromycin, or other macrolide anti-infectives
- Concurrent use of astemizole, cisapride, or pimozide
- Cardiac disease

**Precautions**

Use cautiously in:

- severe renal or hepatic impairment
- pregnant or breastfeeding patients

**Administration**

- Obtain specimens for culture and sensitivity testing as appropriate before starting therapy.
- Give with or without food.

Don’t give concurrently with astemizole (no longer available in U.S.), cisapride, or pimozide.

- Don’t refrigerate oral suspension.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2 hr</td>
<td>12 hr</td>
</tr>
<tr>
<td>P.O. (extended)</td>
<td>Unknown</td>
<td>4 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- CNS: headache
- CV: ventricular arrhythmias
- GI: nausea, diarrhea, abdominal pain or discomfort, dyspepsia

**Other:** abnormal taste

**Interactions**

**Drug-drug.** Astemizole, cisapride, pimozide: increased risk of arrhythmias and sudden death

Carbamazepine, digoxin, theophylline: increased blood levels of these drugs, greater risk of toxicity

Digoxin: increased digoxin blood level, causing digoxin toxicity

HMG-CoA reductase inhibitors (such as lovastatin, simvastatin): rhabdomyolysis

Zidovudine: increased or decreased peak zidovudine blood level

**Drug-diagnostic tests.** Alkaline phosphatase, blood urea nitrogen: increased values

Prothrombin time: increased

White blood cells: decreased count

← Canada  🇬🇧 UK  ⚠️ Hazardous drug  ☢️ High alert drug
Patient monitoring
- Monitor hepatic enzyme and creatinine levels during long-term therapy.
- Assess cardiovascular status.

Patient teaching
- Advise patient to take drug with full glass of water, either with food or on an empty stomach.
- Tell patient using oral suspension not to refrigerate it, and to discard it 14 days after mixing.
- Tell patient to swallow extended-release tablets whole.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

clindamycin hydrochloride
Apo-Clindamycin®, Cleocin, Dalacin C

clindamycin palmitate hydrochloride
Cleocin Pediatric, Dalacin C Flavored Granules

clindamycin phosphate
Cleocin Phosphate, Cleocin T, Clindagel, ClindaMax, Clindets, Dalacin C Phosphate®, Dalacin T®, Zindaclin®

Pharmacologic class: Lincosamide
Therapeutic class: Anti-infective
Pregnancy risk category B

FDA BOXED WARNING
- To reduce development of bacterial resistance and maintain drug efficacy, use only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

- Drug may cause pseudomembranous colitis, ranging from mild to life-threatening. Consider this diagnosis in patients who develop diarrhea after drug administration.
- If diagnosis of pseudomembranous colitis has been established, initiate therapeutic measures. Mild cases usually respond to drug withdrawal alone. In moderate to severe cases, consider giving fluids and electrolytes, protein supplements, and antibacterial drug effective against Clostridium difficile colitis.
- Diarrhea, colitis, and pseudomembranous colitis may first appear up to several weeks after clindamycin therapy ends.
- Reserve drug for serious infections when less toxic antimicrobials are inappropriate. Don’t use for nonbacterial infections, such as most upper respiratory tract infections.

Action
Inhibits protein synthesis in susceptible bacteria at level of 50S ribosome, thereby inhibiting peptide bond formation and causing cell death

Availability
Capsules: 75 mg, 150 mg, 300 mg
Granules for oral suspension: 75 mg/5 ml
Injection: 150 mg base/ml
Topical: 1% gel, lotion, single-use applicators, solution, and suspension
Vaginal cream: 2%
Vaginal suppositories (ovules): 100 mg

Indications and dosages
- Severe infections caused by sensitive organisms (such as Bacteroides fragilis, Clostridium perfringens, Fusobacterium, pneumococci, staphylococci, and streptococci)

Adults: 300 to 450 mg P.O. q 6 hours, or (for other than C. perfringes) 1.2 to 2.7 g/day I.M. or I.V. in two to four equally divided doses

Reactions in bold are life-threatening.
**Children:** 16 to 20 mg/kg/day P.O. (hydrochloride) in three to four equally divided doses, or 13 to 25 mg/kg/day P.O. (palmitate hydrochloride) in three to four equally divided doses  
**Neonates younger than 1 month:** 15 to 20 mg/kg/day I.M. or I.V. in three to four equally divided doses  
> Acute pelvic inflammatory disease  
**Adults:** 900 mg I.V. q 8 hours (given with gentamicin)  
> Acne vulgaris  
**Adults and children older than age 12:** Apply a thin film of topical gel, lotion, or solution locally to affected area b.i.d.  

**Off-label uses**  
- Bacterial vaginosis (phosphate)  
- *Chlamydia trachomatis* infection in females  
- CNS toxoplasmosis in AIDS patients (given with pyrimethamine)  
- *Pneumocystis jiroveci* pneumonia (given with primaquine)  
- Rosacea (lotion)  

**Contraindications**  
- Hypersensitivity to drug or lincomycin  

**Precautions**  
Use cautiously in:  
- renal or hepatic impairment  
- known alcohol intolerance  
- pregnant patients  
- neonates.  

**Administration**  
- Give oral doses with full glass of water, with or without food.  
> Don’t give as I.V. bolus injection.  
- Dilute I.V. solution to a concentration of 18 mg/ml using normal saline solution, dextrose 5% in water, or lactated Ringer’s solution. Infuse no faster than 30 mg/minute.  
- Don’t administer I.M. dosages above 600 mg.  
- Inject I.M. doses deep into large muscle mass to prevent induration and sterile abscess.  

**Adverse reactions**  
**GI:** nausea, vomiting, diarrhea, abdominal pain, esophagitis, *pseudo-membranous colitis*  
**Hematologic:** neutropenia, leukopenia, agranulocytosis, thrombocytopenia purpura  
**Hepatic:** jaundice, hepatic dysfunction  
**Skin:** maculopapular rash, generalized morbilliform-like rash  
**Other:** bitter taste (with I.V. use), phlebitis at I.V. site, induration and sterile abscess (with I.M. use), anaphylaxis  

**Interactions**  
**Drug-drug.** *Erythromycin:* antagonistic effect  
*Kaolin/pectin:* decreased GI absorption of clindamycin  
**Hormonal contraceptives:** decreased contraceptive efficacy  
**Neuromuscular blockers:** enhanced neuromuscular blockade  
**Drug-diagnostic tests.** *Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, creatine kinase:* increased levels  
*Platelets, white blood cells:* transient decrease in counts  

**Patient monitoring**  
- Monitor creatinine level closely in patients with renal insufficiency.  
- Monitor hepatic enzyme levels in patients with hepatic disease.  
- Assess for signs and symptoms of hypersensitivity reactions, including anaphylaxis.  
- Assess for diarrhea and signs and symptoms of colitis.
Patient teaching
- Tell patient to take drug with food if it causes stomach upset.
- Urge patient to contact prescriber immediately if he develops rash, unusual fatigue, or yellowing of skin or eyes or if diarrhea occurs during or after treatment.
- Tell patient that I.V. use may cause bitter taste. Reassure him that this effect will resolve on its own.
- Caution patient not to rely on condoms or diaphragm for contraception for 72 hours after using vaginal preparation; drug may weaken latex products and cause breakage.
- Instruct patient taking hormonal contraceptives to use supplemental birth control method, such as condoms (unless she’s using a vaginal preparation); drug may reduce hormonal contraceptive efficacy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Availability
Solution for injection: 1 mg/ml (20 mg in 20-ml flint vials)

Indications and dosages
Relapsed or refractory acute lymphoblastic leukemia after at least two previous regimens
Children and adults ages 1 to 21:
52 mg/m²/day by I.V. infusion over 2 hours daily for 5 consecutive days every 2 to 6 weeks, depending on toxicity and response

Dosage adjustment
- Hypotension
- Systemic inflammatory response syndrome (SIRS)
- Capillary leak syndrome (CLS)
- Substantial creatinine and bilirubin elevations

Contraindications
None

Precautions
Use cautiously in:
- renal or hepatic impairment, active infection, dehydration, hypotension
- adults older than age 21
- pregnant or breastfeeding patients.

Administration
- Filter through sterile 0.2-micron syringe filter, and dilute further with D₅W or normal saline solution for injection before I.V. infusion. Resulting admixture may be stored at room temperature but must be used within 24 hours of preparation.
- To prevent incompatibilities, don’t give other drugs through same I.V. line.
- Administer continuous I.V. fluids throughout 5 days of treatment to reduce effects of tumor lysis and other adverse events. Give allopurinol, as ordered, if hyperuricemia is expected.
Prophylactic steroids (such as 100 mg/m² hydrocortisone on days 1 through 3) may help prevent SIRS and CLS. If early signs or symptoms of these life-threatening syndromes occur, stop drug immediately and start appropriate supportive measures.

- Withdraw drug immediately if patient develops significant signs or symptoms of SIRS or CLS (such as hypotension); consider giving steroids, diuretics, and albumin. Drug may be reestablished (generally at lower dosage) when patient is stable.
- Stop drug if hypotension occurs during 5 days of treatment. If hypotension is transient and resolves without pharmacologic intervention, reestablish drug (generally at lower dosage).
- If creatinine or bilirubin level rises substantially, discontinue drug. Drug may be reestablished (possibly at lower dosage) when patient is stable and organ function returns to baseline.
- Know that after recovery or return to baseline organ function, treatment cycles are repeated about every 2 to 6 weeks. Dosage is based on body surface area, calculated using actual height and weight before start of each cycle.
- Avoid concurrent administration of hepatotoxic or renotoxic drugs during 5 days of treatment.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- **CNS**: dizziness, headache, somnolence, tremor, anxiety, depression, lethargy, fatigue, irritability, rigors
- **CV**: tachycardia, flushing, hypertension, hypotension
- **EENT**: sore throat, epistaxis
- **GI**: nausea, vomiting, diarrhea, constipation, abdominal pain, anorexia, gingival bleeding, oral candidiasis
- **GU**: hematuria
- **Hematologic**: febrile neutropenia, neutropenia, anemia, thrombocytopenia
- **Hepatic**: hepatomegaly, jaundice
- **Musculoskeletal**: arthralgia, back pain, myalgia, limb pain
- **Respiratory**: pneumonia, cough, dyspnea, pleural effusion, respiratory distress
- **Skin**: contusion, dermatitis, herpes simplex, dry skin, erythema, palmar-planter erythrodynesthesia, petechiae, pruritus, cellulitis
- **Other**: decreased appetite, weight loss, edema, injection site pain, mucosal inflammation, pain, fever, bacteremia, sepsis, staphylococcal infection, transfusion reaction

**Interactions**

- **Drug-drug.** Hepatotoxic or renotoxic drugs: additive toxicity
- **Drug-diagnostic tests.** Alanine aminotransferase, aspartate aminotransferase, bilirubin: increased
- **Drug-herbs.** Alpha-lipoic acid, coenzyme Q10: decreased chemotherapeutic efficacy
- **Glutamine:** possible increase in tumor growth

**Patient monitoring**

- Assess hepatic and renal function before and during therapy.
- Closely monitor respiratory status and blood pressure during infusion.
- Monitor hematologic status carefully during therapy; drug may cause severe bone marrow depression, resulting in neutropenia, anemia, and thrombocytopenia.
- Monitor for signs and symptoms of tumor lysis syndrome or cytokine release (such as tachypnea, tachycardia, hypotension, and pulmonary edema), which could progress to SIRS, CLS, or organ dysfunction.
- Closely monitor patients receiving drugs that affect blood pressure or cardiac function.

**Patient teaching**

- Teach patient about appropriate measures to avoid dehydration caused...
by vomiting and diarrhea. Tell patient to seek medical advice if signs and symptoms of dehydration occur (such as dizziness, light-headedness, fainting spells, or decreased urine output).
- Advise female with childbearing potential to avoid pregnancy during therapy.
- Caution breastfeeding patient to discontinue breastfeeding during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

---

**clomiphene citrate**
(clomifene)

*Clomid, Milophene, Serophene*

**Pharmacologic class:** Chlorotrianisene derivative

**Therapeutic class:** Fertility drug, ovulation stimulant

**Pregnancy risk category X**

**Action**

Binds with estrogen receptors in cytoplasm, increasing secretion of follicle-stimulating hormone, luteinizing hormone, and gonadotropin in hypothalamus and pituitary gland. These actions induce ovulation.

**Availability**

*Tablets: 50 mg*

**Indications and dosages**

➢ Ovarian failure

**Adults:** 50 mg/day P.O. for 5 days starting at any time in patients with no recent uterine bleeding; or 50 mg/day P.O. starting on fifth day of menstrual cycle. If ovulation doesn’t occur, increase to 100 mg/day P.O. for 5 days. Start next course of therapy as early as 30 days after previous course. If patient doesn’t respond after three courses, no further doses are recommended.

**Off-label uses**

- Male sterility (controversial)

**Contraindications**

- Hepatic disease
- Organic intracranial lesions
- Uncontrolled thyroid or adrenal dysfunction
- Ovarian cyst
- Abnormal uterine bleeding or bleeding of undetermined origin
- Pregnancy

**Precautions**

None

**Administration**

- Obtain pregnancy test before therapy begins.
- Be aware that patient should undergo pelvic and eye examinations before starting therapy.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>5-8 days</td>
<td>Unknown</td>
<td>6 wk</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: nervousness, insomnia, dizziness, light-headedness
CV: vasomotor flushing
EENT: visual disturbances
GI: nausea; vomiting; abdominal discomfort, distention, and bloating
GU: breast tenderness, ovarian enlargement, multiple pregnancies, birth defects in resulting pregnancies, ovarian hyperstimulation syndrome, uterine bleeding

**Interactions**

None significant

**Patient monitoring**

- Monitor patient for bleeding and other adverse reactions.
Patient teaching
- Instruct patient to immediately report signs and symptoms of ovarian hyperstimulation syndrome, including nausea, vomiting, diarrhea, abdominal or pelvic pain, and swelling in hands or legs.
- Tell patient to report bleeding.
- Advise patient not to take drug if she is or may become pregnant.
- Inform patient that drug increases risk of multiple births, which heightens maternal risk.
- As appropriate, review all other significant and life-threatening adverse reactions.

clomipramine hydrochloride
Anafranil, Anafranil SR\*, Apo-Clomipramine\*, Co Clomipramine\*, Dom-Clomipramine, Gen-Clomipramine\*, Med-Clomipramine\*, Novo-Clopamine\*, PHL-Clomipramine\*, PMS-Clomipramine\*, Ratio Clomipramine\*

Pharmacologic class: Tricyclic antidepressant (TCA)
Therapeutic class: Antiobsessional agent, antidepressant

Pregnancy risk category C

FDA BOXED WARNING
- Drug may increase risk of suicidal thinking and behavior in children and adolescents with major depressive disorder and other psychiatric disorders. Risk must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family to observe patient closely and communicate with prescriber as needed.
- Drug isn’t approved for use in pediatric patients, except those with obsessive-compulsive disorder.

Action
Unknown. Selectively inhibits norepinephrine and serotonin reuptake at presynaptic neurons in brain; also possesses moderate anticholinergic properties.

Availability
Capsules: 25 mg, 50 mg, 75 mg

Indications and dosages
- Obsessive-compulsive disorder
  Adults: Initially, 25 mg/day P.O., increased over 2 weeks to 100 mg/day given in divided doses. May be increased further over several weeks, up to 250 mg/day given in divided doses.
  Children ages 10 to 17: Initially, 25 mg/day P.O., increased over 2 weeks to 3 mg/kg/day or 100 mg/day (whichever is smaller) given in divided doses. May be increased further to 3 mg/kg/day or 200 mg/day (whichever is smaller) given in divided doses.

Dosage adjustment
- Elderly patients

Off-label uses
- Panic disorder

Contraindications
- Hypersensitivity to drug or other TCAs
- Recent myocardial infarction (MI)
- Concurrent MAO inhibitor or clonidine use

Precautions
Use cautiously in:
- glaucoma, hyperthyroidism, prostatic hypertrophy, preexisting cardiovascular disease
- elderly patients
- pregnant or breastfeeding patients
- children younger than age 10 (safety not established).

**Administration**
- Don’t give with grapefruit juice.
- Once stabilizing dosage is reached, entire daily dose may be given at bedtime.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2-6 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** lethargy, sedation, weakness, aggressive behavior, extrapyramidal reactions, poor concentration, feeling of unreality, delusions, anxiety, restlessness, panic, asthenia, syncope, insomia, seizures, suicidal ideation or behavior (especially in child or adolescent)

**CV:** orthostatic hypotension, hypertension, ECG changes, tachycardia, palpitations, vasculitis, arrhythmias, MI, precipitation of heart block

**EENT:** blurred vision, dry eyes, vestibular disorder, nasal congestion, laryngitis

**GI:** nausea, vomiting, constipation, abdominal cramps, belching, epigastric distress, flatulence, dysphagia, increased salivation, stomatitis, parotid gland swelling, black tongue, dry mouth, paralytic ileus

**GU:** urinary retention, urinary hesitancy, urinary tract dilation, male sexual dysfunction, testicular swelling, gynecomastia, breast enlargement, menstrual irregularities, galactorrhea, libido changes

**Hematologic:** eosinophilia, purpura, anemia, bone marrow depression, agranulocytosis, thrombocytopenia, leukopenia

**Metabolic:** hyperthermia, hypothermia, syndrome of inappropriate antidiuretic hormone secretion

**Musculoskeletal:** muscle weakness

**Skin:** sweating, dry skin, photosensitivity, rash, pruritus, petechiae, flushing

**Other:** abnormal taste, chills, edema, increased appetite, weight gain

**Interactions**

**Drug-drug.**
- Adrenergics, anticholinergics: additive adrenergic or anticholinergic effects
- Cimetidine, hormonal contraceptives, phenothiazines, selective serotonin reuptake inhibitors: increased clomipramine effects, greater risk of toxicity
- Clonidine: hypertensive crisis
- CNS depressants (including antihistamines, opioid analgesics, sedative-hypnotics): additive CNS depression
- Disulfiram: transient delirium
- Guanethidine: interference with anti-hypertensive response
- MAO inhibitors: severe or life-threatening adverse reactions
- Levofoxacin, moxifloxacin: increased risk of adverse cardiovascular reactions

**Drug-diagnostic tests.**
- Blood glucose, prolactin: elevated levels

**Drug-food.**
- Grapefruit juice: increased clomipramine blood level and effects

**Drug-herbs.**
- Chamomile, hops, kava, skullcap, valerian: increased CNS depression
- S-adenosylmethionine (SAM-e), St. John’s wort: increased serotonergic effects, possibly causing serotonin syndrome

**Drug-behaviors.**
- Alcohol use: additive CNS depression
- Nicotine use: increased metabolism and decreased efficacy of clomipramine
- Sun exposure: photosensitivity

**Patient monitoring**
- Monitor patient for cardiovascular, CNS, and hematologic adverse reactions.
- Assess for suicidal ideation. If necessary, institute suicide precautions.
Patient teaching

- Advise patient (especially children or their parents) to immediately report suicidal thoughts or severe depression.
- Instruct patient not to drink grapefruit juice during therapy.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Instruct patient to avoid alcohol, because it increases drowsiness.
- Tell patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness caused by sudden blood pressure drop.
- Caution patient not to stop taking drug abruptly, because this may cause nausea, headache, or malaise.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

Availability

Rapidly disintegrating tablets (wafers):
0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg
Tablets: 0.5 mg, 1 mg, 2 mg

Indications and dosages

- Absence seizures (Lennox-Gastaut syndrome); akinetic and myoclonic seizures

Adults: Initially, 1.5 mg/day P.O. in three divided doses; may increase by 0.5 to 1 mg q 3 days until seizures are adequately controlled or drug intolerance occurs. Maximum dosage is 20 mg/day.

Infants and children ages 10 and younger or weighing 30 kg (66 lb) or less: Initially, 0.01 to 0.03 mg/kg/day P.O. Give total dosage (not to exceed 0.05 mg/kg/day) in two to three equally divided doses. Increase by no more than 0.25 to 0.5 mg q 3 days until dosage of 0.1 to 0.2 mg/kg/day is reached, seizures are adequately controlled, or drug intolerance occurs.

Off-label uses

- Acute manic episodes of bipolar disorder
- Multifocal tic disorders
- Neuralgias
- Parkinsonian dysarthria
- Periodic leg movements occurring during sleep
- Adjunctive treatment of schizophrenia

Contraindications

- Hypersensitivity to drug or other benzodiazepines
- Severe hepatic disease
- Acute angle-closure glaucoma

Precautions

Use cautiously in:
- renal impairment, chronic respiratory disease, open-angle glaucoma
- history of porphyria
- pregnant or breastfeeding patients
- children.

clonazepam

Alti-Clonazepam, Apo-Clonazepam, Clonapam, Co Clonazepam, Dom-Clonazepam, Gen-Clonazepam, Klonopin, Klonopin Wafer, Novo-Clonazepam, PHL-Clonazepam, PMS-Clonazepam, Ratio Clonazepam, Rivotril

Pharmacologic class: Benzodiazepine
Therapeutic class: Anticonvulsant
Controlled substance schedule IV
Pregnancy risk category D

Action

Unknown. May enhance activity of gamma-aminobutyric acid, an inhibitory neurotransmitter in CNS.
Administration

- Be aware that overdose may cause fatal respiratory depression or cardiovascular collapse.
- Give tablets with water, and make sure patient swallows them whole.
- Administer orally disintegrating tablet (wafer) as follows: after opening pouch, peel back foil on blister, but don’t push tablet through foil. Immediately after opening blister, use dry hands to remove tablet, and place it in patient’s mouth. Wafer can be easily swallowed with or without water because it disintegrates rapidly in saliva.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>20-60 min</td>
<td>1-2 hr</td>
<td>6-12 hr</td>
</tr>
<tr>
<td>P.O. (wafer)</td>
<td>Rapid</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: ataxia, fatigue, drowsiness, behavioral changes, depression, dizziness, nervousness, reduced intellectual ability
CV: palpitations
EENT: abnormal eye movements, blurred vision, diplopia, nystagmus, sinusitis, rhinitis, pharyngitis
GI: constipation, diarrhea, hypersalivation
GU: dysuria, nocturia, urinary retention, dysmenorrhea, delayed ejaculation, erectile dysfunction
Hematologic: anemia, eosinophilia, leukopenia, thrombocytopenia
Hepatic: hepatitis
Musculoskeletal: myalgia
Respiratory: increased respiratory secretions, upper respiratory tract infection, cough, bronchitis, respiratory depression
Other: appetite changes, fever, physical or psychological drug dependence, drug tolerance, allergic reaction

Interactions

Drug-drug. Antidepressants, antihistamines, opioids, other benzodiazepines: additive CNS depression

Barbiturates, rifampin: increased metabolism and decreased efficacy of clonazepam
Cimetidine, disulfiram, fluoxetine, hormonal contraceptives, isoniazid, ketoconazole, metoprolol, propoxyphene, propranolol, valproic acid: decreased clonazepam metabolism
Phenytoin: decreased clonazepam blood level

Drug-diagnostic tests. Eosinophils, liver function tests: increased values
Platelets, white blood cells: decreased counts

Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression

Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring

- Monitor patient for respiratory depression. Assess respiratory rate and quality, oxygen saturation (using pulse oximetry), and mental status.
- Monitor hematologic and liver function test results.

Patient teaching

- Instruct patient to immediately report easy bleeding or bruising or yellowing of skin or eyes.
- Teach patient how to take rapidly disintegrating wafer.
- Advise patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Caution patient not to stop taking drug abruptly. Advise him to consult prescriber for dosage-tapering schedule if he wishes to discontinue drug.
- Advise patient not to drink alcohol, which may increase drowsiness, dizziness, and risk of seizures.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

Reactions in bold are life-threatening.
Clonidine
Catapres-TTS

Clonidine hydrochloride
Apo-Clonidine, Catapres, Dixarit, Dom-Clonidine, Duraclon, Novo-Clonidine, Nu-Clonidine

Pharmacologic class: Centrally acting sympatholytic
Therapeutic class: Antihypertensive
Pregnancy risk category C

FDA BOXED WARNING

- Before use, dilute clonidine hydrochloride 500-µg/mL strength product in appropriate solution.
- Epidural form (clonidine hydrochloride) isn’t recommended for obstetric, postpartum, or perioperative pain management. In these cases, risk of hemodynamic instability may be unacceptable, except in rare patients for whom potential benefits may outweigh possible risks.

Action
Stimulates alpha-adrenergic receptors in CNS, decreasing sympathetic outflow, inhibiting vasoconstriction, and ultimately reducing blood pressure. Also prevents transmission of pain impulses by inhibiting pain pathway signals in brain.

Availability
Solution for epidural injection: 100 mcg/ml in 10-ml vials, 500 mcg/ml in 10-ml vials
Tablets: 25 mcg (0.025 mg), 100 mcg (0.1 mg), 200 mcg (0.2 mg), 300 mcg (0.3 mg)
Transdermal systems: 2.5 mg total released as 0.1 mg/24 hours (TTS 1), 5 mg total released as 0.2 mg/24 hours (TTS 2), 7.5 mg total released as 0.3 mg/24 hours (TTS 3)

Indications and dosages

- Mild to moderate hypertension
  Adults: 0.1 mg P.O. b.i.d. (morning and bedtime) alone or with other antihypertensives; increase in increments of 0.1 mg/day q week until desired response occurs. Or, one transdermal system applied once q 7 days to hairless area of intact skin on upper outer arm or chest.
  Severe pain in cancer patients unresponsive to opioids alone
  Adults: Initially, 30 mcg/hour by continuous epidural infusion, titrated upward or downward depending on patient response

Dosage adjustment
- Renal impairment

Off-label uses
- Acute alcohol withdrawal
- Akathisia
- Diarrhea
- Prolonged surgical anesthesia

Contraindications
- Hypersensitivity to drug
- Hypersensitivity to components of adhesive layer (transdermal form)
- Infection at epidural injection site, bleeding problems (epidural use)
- Concurrent anticoagulant therapy

Precautions
Use cautiously in:
- renal insufficiency, serious cardiac or cerebrovascular disease
- elderly patients
- pregnant or breastfeeding patients.

Administration
- For epidural use, dilute drug solution in normal saline solution, as ordered.

Canada UK Hazardous drug High alert drug
To minimize sedative effects, give largest portion of maintenance P.O. dose at bedtime.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30-60 min</td>
<td>2-4 hr</td>
<td>8-12 hr</td>
</tr>
<tr>
<td>Epidural</td>
<td>Rapid</td>
<td>19 min</td>
<td>Variable</td>
</tr>
<tr>
<td>Transdermal</td>
<td>Slow</td>
<td>2-3 days</td>
<td>7 days</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** drowsiness, depression, dizziness, nervousness, nightmares  
**CV:** hypotension (especially with epidural use), palpitations, bradycardia  
**GI:** nausea, vomiting, constipation, dry mouth  
**GU:** urinary retention, nocturia, erectile dysfunction  
**Metabolic:** sodium retention  
**Skin:** rash, sweating, pruritus, dermatitis  
**Other:** weight gain, withdrawal phenomenon

**Interactions**

**Drug-drug:**  
- Amphetamines, beta-adrenergic blockers, MAO inhibitors, prazosin, tricyclic antidepressants: decreased antihypertensive effect  
- Beta-adrenergic blockers: increased withdrawal phenomenon  
- CNS depressants (including antihistamines, opioids, sedative-hypnotics): additive sedation  
- Epidurally administered local anesthetics: prolonged clonidine effects  
- Levodopa: decreased levodopa efficacy  
- Myocardial depressants (including beta-adrenergic blockers): additive bradycardia  
- Other antihypertensives, nitrates: additive hypotension  
- Verapamil: increased risk of adverse cardiovascular reactions

**Drug-herbs:**  
- Capsicum: reduced antihypertensive effect

**Drug-behaviors:**  
- Alcohol use: increased sedation

**Patient monitoring**

- Monitor patient for signs and symptoms of adverse cardiovascular reactions.  
- Frequently assess vital signs, especially blood pressure and pulse.  
- Monitor patient for drug tolerance and efficacy.

**Patient teaching**

- Instruct patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness caused by sudden blood pressure decrease.  
  - Caution patient not to stop taking drug abruptly.  
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, herbs, and behaviors mentioned above.

---

**clopidogrel bisulfate**

**Plavix**

**Pharmacologic class:** Platelet aggregation inhibitor  
**Therapeutic class:** Antiplatelet drug  
**Pregnancy risk category B**

**Action**

Inhibits platelet aggregation by blocking binding of adenosine diphosphate to platelets, thereby preventing thrombus formation

**Availability**

*Tablets:* 75 mg, 300 mg

**Indications and dosages**

- To reduce atherosclerotic events in patients with recent myocardial infarction (MI) or cerebrovascular accident and in those with established peripheral arterial disease or acute coronary syndrome

Reactions in **bold** are life-threatening.
Adults: 75 mg/day P.O.
➢ Acute coronary syndrome (unstable angina or non-Q-wave MI)
Adults: 300 mg P.O. as a loading dose, then 75 mg/day P.O.

Contraindications
● Hypersensitivity to drug
● Active pathologic bleeding

Precautions
Use cautiously in:
● severe hepatic impairment, GI bleeding, ulcer disease
● increased risk of bleeding
● pregnant or breastfeeding patients
● children.

Administration
● Give with or without food.
● Know that drug may need to be discontinued 5 days before surgery.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Variable</td>
<td>60 min</td>
<td>3-4 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: depression, dizziness, fatigue, headache
CV: chest pain, hypertension
EENT: epistaxis, rhinitis
GI: diarrhea, abdominal pain, dyspepsia, gastritis, GI bleeding
Hematologic: bleeding, neutropenia, thrombotic thrombocytopenic purpura
Metabolic: hypercholesterolemia, gout
Musculoskeletal: joint pain, back pain
Respiratory: cough, dysnea, bronchitis, upper respiratory tract infection, bronchospasm
Skin: pruritus, rash, angioedema
Other: hypersensitivity reactions, anaphylactic reactions

Interactions
Drug-drug. Abciximab, aspirin, eptifibatide, heparin, heparinoids, nonsteroidal anti-inflammatory drugs (NSAIDs), thrombolytics, ticlopidine, tirofiban, warfarin: increased risk of bleeding
Fluvastatin, many NSAIDs, phenytoin, tamoxifen, tolbutamide, torsemide: interference with metabolism of these drugs
Drug-diagnostic tests. Bilirubin, hepatic enzymes, nonprotein nitrogen, total cholesterol, uric acid: increased levels
Platelets: decreased count
Drug-herbs. Anise, arnica, chamomile, clove, fenugreek, feverfew, garlic, ginger, ginkgo, ginseng: increased risk of bleeding

Patient monitoring
● Monitor hemoglobin and hematocrit periodically.
● Monitor patient for unusual bleeding or bruising; drug significantly increases risk of bleeding.
● Advise patient to contact prescriber before taking over-the-counter products, particularly nonsteroidal anti-inflammatory drugs.
● Assess for occult GI blood loss if patient is receiving naproxen concurrently with clopidogrel.

Patient teaching
⚠️ Advise patient to immediately report unusual or acute chest pain, respiratory difficulty, rash, unresolved bleeding, diarrhea, GI distress, nosebleed, or acute headache.
● Instruct patient to tell all health care providers that he's taking clopidogrel, especially if surgery is scheduled or new drugs are prescribed.
● Advise patient to contact prescriber before taking over-the-counter products, particularly nonsteroidal anti-inflammatory drugs.
● Tell patient drug may cause headache and dizziness. Caution him to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
● Advise patient to minimize adverse GI effects by eating small, frequent meals or chewing gum.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially
those related to the drugs, tests, and herbs mentioned above.

**clorazepate dipotassium**
Apo-Clorazepate, Novo-Clopate, Tranxene, Tranxene-SD, Tranxene-SD Half Strength, Tranxene-T

*Pharmacologic class:* Benzodiazepine  
*Therapeutic class:* Anticonvulsant, anxiolytic  
*Controlled substance schedule IV*  
*Pregnancy risk category D*

**Action**
Unclear. Thought to potentiate effects of gamma-aminobutyric acid and other neurotransmitters, promoting inhibitory neurotransmission at excitatory synapses.

**Availability**
*Capsules:* 3.75 mg, 7.5 mg, 15 mg  
*Tablets:* 3.75 mg, 7.5 mg, 11.25 mg, 15 mg, 22.5 mg

**Indications and dosages**

- **Anxiety**
  - **Adults:** 7.5 to 15 mg P.O. two to four times daily  
  - **Adjunctive therapy in partial seizure disorder**
    - **Adults and children older than age 12:** Initially, 7.5 mg P.O. t.i.d.; increase by no more than 7.5 mg/week. Don't exceed 90 mg/day.
    - **Children ages 9 to 12:** Initially, 7.5 mg P.O. b.i.d; increase by no more than 7.5 mg/week. Don’t exceed 60 mg/day.  
    - **Management of alcohol withdrawal**
      - **Adults:** Initially, 30 mg P.O., followed by 15 mg P.O. two to four times daily on first day. On second day, give 45 to 90 mg P.O. in divided doses, then decrease gradually over subsequent days to 7.5 mg to 15 mg P.O. daily.

**Dosage adjustment**
- Elderly or debilitated patients

**Contraindications**
- Benzodiazepine hypersensitivity
- Acute angle-closure glaucoma
- Psychosis
- Concurrent ketoconazole or itraconazole therapy
- Children younger than age 9

**Precautions**
Use cautiously in:
- depression or suicidal ideation
- psychotic reaction
- elderly patients
- females of childbearing age
- pregnant or breastfeeding patients.

**Administration**
- If GI upset occurs, give with food.
- When discontinuing therapy after long-term use, taper dosage gradually over 4 to 8 weeks to avoid withdrawal symptoms.
- Take suicide precautions if patient is depressed or anxious.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>1-2 hr</td>
<td>Days</td>
</tr>
</tbody>
</table>

**Adverse reactions**
*CNS:* dizziness, drowsiness, lethargy, sedation, depression, fatigue, nervousness, confusion, irritability, headache, slurred speech, difficulty articulating words, stupor, rigidity, tremor, poor coordination  
*CV:* hypertension, hypotension, palpitations  
*EENT:* blurred or double vision  
*GI:* dry mouth  
*Hematologic:* neutropenia  
*Hepatic:* jaundice  
*Skin:* rash, diaphoresis  
*Other:* weight gain or loss, drug dependence or tolerance

**Interactions**
*Drug-drug.* Antacids: altered clorazepate absorption rate

Reactions in **bold** are life-threatening.
Antidepressants, antihistamines, opioids: additive CNS depression
Barbiturates, MAO inhibitors, other antidepressants, phenothiazines: potentiation of clorazepate effects
Cimetidine, disulfiram, fluoxetine, hormonal contraceptives, isoniazid, itraconazole, ketoconazole, metoprolol, propranoephene, propranolol, valproic acid: decreased clorazepate metabolism, causing enhanced drug action or markedly increased CNS effects
Levodopa: decreased antiparkinsonian effect
Probenecid: rapid onset or prolonged action of clorazepate
Rifampin: increased metabolism and decreased efficacy of clorazepate
Theophylline: decreased sedative effect of clorazepate

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase: increased levels

Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression

Drug-behaviors. Alcohol use: increased CNS depression
Smoking: decreased drug absorption

Patient monitoring
- Assess for pregnancy before initiating therapy.
- Evaluate patient for depression, drug dependence, and drug tolerance.
- Monitor blood counts and liver function test results during long-term therapy; drug may cause neutropenia and jaundice.

Patient teaching
- Instruct patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Tell patient to avoid smoking and use of alcohol or other CNS depressants.

Caution patient not to stop therapy abruptly, because withdrawal symptoms may occur.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

clozapine
Apo-Clozapine, Clozaril, Denazapine, Fazaclod ODT, Gen-Clozapine, PMS-Clozapine, Zaponex

Pharmacologic class: Dibenzodiazepine derivative
Therapeutic class: Antipsychotic agent
Pregnancy risk category B

FDA BOXED WARNING
- Because of significant agranulocytosis risk, use only to treat severely ill patients with schizophrenia who don’t respond to standard antipsychotic drugs, or to reduce risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who risk reexperiencing suicidal behavior. Obtain baseline white blood cell (WBC) and absolute neutrophil counts before therapy, regularly during therapy, and for at least 4 weeks afterward.
- Drug is associated with seizures; likelihood increases at higher doses. Use caution when giving to patients with history of seizures or other predisposing factors. Instruct patient not to engage in activities in which sudden loss of consciousness could cause serious risk to self or others.
- Drug may increase risk of fatal myocarditis, especially during first month of therapy. Discontinue promptly if myocarditis is suspected.
Orthostatic hypotension with or without syncope may occur. Rarely, collapse is profound and accompanied by respiratory or cardiac arrest, or both. Orthostatic hypotension is more likely during initial titration when dosage is raised rapidly. In patients who’ve had even brief interval off drug (2 or more days since last dose), start with 12.5 mg once or twice daily.

During initial therapy, collapse and respiratory and cardiac arrest may occur. Use caution when initiating therapy.

Drug increased risk of death in elderly patients with dementia-related psychosis; most deaths have been cardiovascular or infectious. Drug isn’t approved for dementia-related psychosis.

**Action**
Unclear. Thought to interfere with dopamine binding in limbic system of CNS, with high affinity for dopamine4 receptors. May antagonize adrenergic, cholinergic, histaminergic, and serotonergic receptors.

**Availability**
Tablets: 25 mg, 100 mg
Tablets (orally disintegrating): 25 mg, 100 mg

**Indications and dosages**

Schizophrenia in patients unresponsive to other therapies

**Adults:** 12.5 mg P.O. daily or b.i.d.; increase daily in 25- to 50-mg increments, as tolerated, to target dosage of 300 to 450 mg/day by end of second week. Make subsequent dosage increases once or twice weekly in increments of 100 mg or less, to a maximum dosage of 900 mg/day P.O. in divided doses.

**Dosage adjustment**
- Renal impairment
- Elderly patients

**Contraindications**
- Hypersensitivity to drug
- Uncontrolled seizures
- Severe CNS depression or coma
- Concurrent use of drugs that cause agranulocytosis or bone marrow depression

**Precautions**
Use cautiously in:
- hypersensitivity to phenothiazines
- cardiac, hepatic, or renal impairment; CNS tumors; diabetes mellitus; history of seizures; prostatic hypertrophy; intestinal obstruction; paralytic ileus; angle-closure glaucoma
- elderly patients
- pregnant or breastfeeding patients
- children.

**Administration**

- Obtain WBC count before starting therapy. Don’t give drug if WBC count is below 3,500/mm³.
- When discontinuing drug, taper dosage gradually over 1 to 2 weeks.
- Be aware that orally disintegrating tablets are meant to dissolve in mouth.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2.5 hr</td>
<td>4-12 hr</td>
</tr>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>(orally disint.)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Adverse reactions**
CNS: sedation, drowsiness, dizziness, vertigo, headache, tremor, insomnia, disturbed sleep, nightmares, agitation, lethargy, fatigue, weakness, confusion, anxiety, parkinsonism, slurred speech, depression, restlessness, extrapyramidal reactions, tardive dyskinesia, akathisia, syncope, neuroleptic malignant syndrome, autonomic disturbances, seizures
CV: hypotension, tachycardia, ECG changes, chest pain, myocarditis
EENT: blurred vision, dry eyes, nasal congestion, sinusitis

**Reactions in bold are life-threatening.**

---

Reactions in **bold** are life-threatening.
GI: nausea, vomiting, constipation, dyspepsia, salivation, dry mouth, anorexia
GU: urinary retention, urinary incontinence, urinary frequency and urgency, inhibited ejaculation
Musculoskeletal: muscle spasms, rigidity, back and muscle pain
Hematologic: agranulocytosis, leukopenia, hemolytic anemia, aplastic anemia, thrombocytopenia, neutropenia, eosinophilia
Respiratory: dyspnea, respiratory arrest
Skin: rash, sweating, Stevens-Johnson syndrome
Other: weight gain, fever

Interactions
Drug-drug. Anticholinergics, antihypertensives, digoxin, warfarin: increased effects of these drugs
Cimetidine, erythromycin: increased therapeutic and toxic effects of clozapine
Epinephrine: increased hypotension
Fluoxetine, fluvoxamine, paroxetine, sertraline: increased clozapine blood level
Phenytoin, rifampin: decreased clozapine blood level
Psychoactive drugs: additive psychoactive effect
Drug-diagnostic tests. Granulocytes, hematocrit, hemoglobin, platelets, white blood cells: decreased values
Liver function tests: abnormal values
Pregnancy test: false-positive result
Drugs-food. Caffeine: increased clozapine blood level
Drug-herbs. Angel’s trumpet, jimsonweed, scopolia: increased anticholinergic effects
Nutmeg: decreased clozapine efficacy
St. John’s wort: decreased clozapine blood level
Drug-behaviors. Alcohol use: increased CNS depression
Smoking: decreased clozapine blood level

Patient monitoring
Monitor WBC count weekly for first 6 months of therapy; if it’s normal, WBC testing can be reduced to every other week. Notify prescriber immediately if WBC count decreases or agranulocytosis occurs.
- Monitor ECG and liver function test results.
- If drug must be withdrawn abruptly, monitor patient for psychosis and cholinergic rebound (headache, nausea, vomiting, diarrhea).
- Continue to monitor WBC count weekly for 4 weeks after therapy ends.

Patient teaching
- Tell patient to allow orally disintegrating tablet to dissolve in mouth.
- Teach patient about significant risk of agranulocytosis; tell him he’ll need to undergo weekly blood testing to check for this blood disorder. Mention that clozapine tablets are available only through a special program that ensures required blood monitoring.
- Advise patient to immediately report new onset of lethargy, weakness, fever, sore throat, malaise, mucous membrane ulcers, flulike symptoms, or other signs and symptoms of infection.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

coagulation factor VIIa (recombinant)
NovoSeven, NovoSeven RT

Pharmacologic class: Coagulation factor VIIa
Therapeutic class: Antihemophilic agent
Pregnancy risk category C
**Action**
Promotes hemostasis by activating intrinsic pathway of coagulation cascade to form fibrin

**Availability**
Lyophilized powder for injection: 1.2 mg/vial, 2.4 mg/vial, 4.8 mg/vial (refrigerated formulation); 1 mg/vial, 2 mg/vial, 5 mg/vial (room-temperature formulation)

**Indications and dosages**
- Bleeding episodes in patients with hemophilia A or B who have inhibitors to factor VIII or IX and in patients with acquired hemophilia
  **Adults:** 90 mcg/kg I.V. bolus q 2 hours until hemostasis occurs or therapy is deemed ineffective
- Prevention of bleeding in surgical interventions or invasive procedures in patients with hemophilia A or B who have inhibitors to factor VIII or IX and in patients with acquired hemophilia
  **Adults:** Initially, 90 mcg/kg I.V. immediately before intervention and repeated at 2-hour intervals for duration of surgery. For minor surgery, administer postsurgical doses by I.V. bolus infusion at 2-hour intervals for first 48 hours and then at 2- to 6-hour intervals until healing has occurred. For major surgery, administer postsurgical doses by I.V. bolus infusion at 2-hour intervals for 5 days, followed by 4-hour intervals until healing has occurred. Administer additional bolus doses, if required.
- Congenital factor VII deficiency
  **Adults:** 15 to 30 mcg/kg I.V. q 4 to 6 hours until hemostasis is achieved. Effective treatment has been achieved with dosages as low as 10 mcg/kg.
- Acquired hemophilia
  **Adults:** 70 to 90 mcg/kg I.V., repeated q 2 to 3 hours until hemostasis is achieved

**Contraindications**
- Hypersensitivity to drug or to mouse, hamster, or bovine products

**Precautions**
Use cautiously in:
- pregnant or breastfeeding patients
- children.

**Administration**
- Give by I.V. bolus only over 2 to 5 minutes, depending on dosage.
- Reconstitute only with specified volume of sterile water for injection.
- Don’t mix with infusion solutions.
- Administer within 3 hours of reconstituting.

**Adverse reactions**
CNS: headache
CV: hypertension, hypotension, bradycardia
GU: renal dysfunction
Hematologic: purpura, hemorrhage, hemarthrosis, disseminated intravascular coagulation, coagulation disorders, decreased fibrinogen plasma, thrombosis
Musculoskeletal: arthrosis
Skin: pruritus, rash
Other: fever, edema, pain, redness or reaction at injection site, hypersensitivity reaction

**Interactions**
Drug-drug. Activated prothrombin complex concentrates, prothrombin complex concentrates: risk of potential interaction (though not evaluated)

**Patient monitoring**
- Monitor for signs and symptoms of coagulation activation or thrombosis.
- Be aware that laboratory coagulation parameters may be used as adjunct to clinical evaluation of hemostasis to monitor drug efficacy and treatment

Reactions in **bold** are life-threatening.
schedule. However, these parameters lack direct correlation with achievement of hemostasis.

**Patient teaching**
- Instruct patient to report swelling, pain, burning, or itching at infusion site.
- Tell patient to inform prescriber if she’s pregnant or intends to become pregnant.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

**codeine phosphate**

**codeine sulfate**

**Pharmacologic class:** Opioid agonist  
**Therapeutic class:** Opioid analgesic, antitussive  
**Controlled substance schedule II**  
**Pregnancy risk category C**

**Action**
Binds to opioid receptors in CNS, altering perception of painful stimuli. Causes generalized CNS depression, decreases cough reflex, and reduces GI motility.

**Availability**
- *Injection (phosphate):* 30 mg/ml, 60 mg/ml  
- *Oral solution (phosphate):* 10 mg/5 ml, 15 mg/5 ml  
- *Tablets (sulfate):* 15 mg, 30 mg, 60 mg; 30 mg, 60 mg (soluble)

**Indications and dosages**
- **Pain**  
  - **Adults:** 15 to 60 mg P.O. or 15 to 60 mg (phosphate) I.M., I.V., or subcutaneously q 4 to 6 hours. Usual daily dosage is 30 mg; maximum daily dosage is 360 mg.  
  - **Children ages 1 and older:** 0.5 mg/kg or 15 mg/m² P.O., I.M., or subcutaneously q 4 to 6 hours  
  - **Cough**  
    - **Adults:** 10 to 20 mg P.O. q 4 to 6 hours as needed. Don’t exceed 120 mg/day.  
    - **Children ages 6 to 12:** 5 to 10 mg P.O. q 4 to 6 hours as needed. Don’t exceed 60 mg/day.  
    - **Children ages 2 to 6:** 2.5 to 5 mg P.O. q 4 to 6 hours as needed. Don’t exceed 30 mg/day.

**Dosage adjustment**
- Elderly or debilitated patients

**Contraindications**
- Hypersensitivity to narcotics  
- Labor and delivery of premature neonate  
- Premature neonates

**Precautions**
Use cautiously in:
- severe renal, hepatic, or pulmonary disease  
- adrenal insufficiency, head trauma, hypothyroidism, increased intracranial pressure, prostatic hypertrophy, undiagnosed abdominal pain, alcoholism  
- elderly patients  
- pregnant or breastfeeding patients.

**Administration**
- If GI upset occurs, give with food.  
- Titrate dosage for appropriate analgesic effect.  
- When changing administration route, be aware that oral dose is two-thirds as effective as parenteral dose.  
- Don’t give I.V. to children.  
- If overdose occurs, give naloxone I.V. as prescribed. Repeat administration as needed (up to manufacturer’s recommended maximum dosage) to reverse toxic effects.
Don’t mix with other solutions; drug is incompatible with other drugs.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30-45 min</td>
<td>1-2 hr</td>
<td>4 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>10-30 min</td>
<td>30-60 min</td>
<td>4 hr</td>
</tr>
<tr>
<td>Subcut.</td>
<td>10-30 min</td>
<td>Unknown</td>
<td>4 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: confusion, sedation, malaise, agitation, euphoria, floating feeling, headache, hallucinations, unusual dreams, apathy, mood changes
CV: hypotension, bradycardia, peripheral vasodilation, reduced peripheral resistance
EENT: blurred or double vision, miosis, reddened sclera
GI: nausea, vomiting, constipation, decreased gastric motility
GU: urinary retention, urinary tract spasms, urinary urgency
Respiratory: suppressed cough reflex, respiratory depression
Skin: flushing, sweating
Other: physical or psychological drug dependence, drug tolerance

Interactions
Drug-drug. Antidepressants, antihistamines, sedative-hypnotics: additive CNS depression
Nalbuphine, pentazocine: decreased analgesic effect
Opioid partial agonists (buprenorphine, butorphanol, nalbuphine, pentazocine): precipitation of opioid withdrawal in physically dependent patients
Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression
Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring
- Monitor vital signs and CNS status.
- Assess pain level and efficacy of pain relief.
- Evaluate patient for adverse reactions.

Stay alert for overdose signs and symptoms, such as CNS and respiratory depression, GI cramping, and constipation.
- Assess other drugs in patient’s drug regimen for those that could cause additive or adverse interactions.
- Monitor patient for signs and symptoms of drug dependence or tolerance.

Patient teaching
- With oral use, advise patient to minimize adverse GI effects by taking doses with food or milk.
- Tell patient to notify prescriber promptly if he experiences shortness of breath or difficulty breathing or if nausea, vomiting, or constipation become pronounced.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, alertness, vision, coordination, and physical dexterity.
- Instruct patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness from sudden blood pressure decrease.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, herbs, and behaviors mentioned above.

colchicine

Pharmacologic class: Colchicum alkaloid
Therapeutic class: Antigout drug
Pregnancy risk category C

Action
Unclear. Antigout action may occur through white blood cell (WBC) migration and reduced lactic acid production.
by WBCs. This action in turn decreases uric acid deposition, kinetin formation, and phagocytosis, leading to reduction in inflammatory response.

**Availability**

*Injection*: 0.5 mg/ml  
*Tablets*: 0.5 mg, 0.6 mg

### Indications and dosages

- **Acute gouty arthritis**
  - **Adults**: Initially, 0.6 to 1.2 mg P.O.; then 0.6 to 1.2 mg P.O. q 1 to 2 hours or until relief occurs, adverse GI reactions occur, or patient has received a total cumulative dosage of 8 mg. Or 2 mg I.V., followed by 0.5 mg I.V. q 6 hours p.r.n., not to exceed 4 mg daily.

- **Prophylaxis for recurrent gouty arthritis**
  - **Adults**: In patients who have one yearly attack or less, 0.6 mg P.O. daily 3 days per week. In patients who have more than one yearly attack, 0.6 mg P.O. daily; in severe cases, 1 to 1.8 mg P.O. daily.

### Dosage adjustment
- Mild hepatic or renal impairment

### Off-label uses
- Hepatic cirrhosis
- Chronic progressive multiple sclerosis
- Pyoderma gangrenosum associated with Crohn’s disease
- Psoriasis
- Dermatitis herpetiformis

### Contraindications
- Hypersensitivity to drug
- Blood dyscrasias
- Serious GI, renal, hepatic, or cardiac disorders

### Precautions
Use cautiously in:
- renal impairment
- elderly or debilitated patients
- pregnant or breastfeeding patients
- children (safety not established).

### Administration
- Know that I.V. colchicine is a high-alert drug.
- Initiate therapy at first sign of acute gout attack.
- Don’t administer I.M. or subcutaneously, because severe local irritation may occur.
- Don’t dilute with 5% dextrose in water. If dilution is required, use normal saline solution injection.
- For I.V. injection, give by slow I.V. push over 2 to 5 minutes.
- Know that GI reactions may be troublesome in patients with peptic ulcer or irritable bowel.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>12 hr</td>
<td>24-72 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>Rapid</td>
<td>Rapid</td>
</tr>
</tbody>
</table>

### Adverse reactions
- **CNS**: peripheral neuritis, neuropathy
- **GI**: nausea, vomiting, diarrhea, abdominal pain
- **GU**: anuria, hematuria, reversible azoospermia, renal impairment
- **Hematologic**: purpura, agranulocytosis, aplastic anemia, thrombocytopenia
- **Metabolic**: vitamin B₁₂, malabsorption
- **Musculoskeletal**: myopathy
- **Skin**: dermatosis, alopecia
- **Other**: hypersensitivity reactions

### Interactions
- **Drug-drug. Cyclosporine**: colchicine-induced myopathy
- Vitamin B₁₂: reversible vitamin malabsorption
- **Drug-diagnostic tests. Alkaline phosphatase, aspartate aminotransferase**: increased levels
- Hematocrit, hemoglobin, platelets: decreased values
- Urine hemoglobin, urinary red blood cells: false-positive results
Drug-food. Caffeine-containing foods and beverages: decreased colchicine effect

Drug-herbs. Herbal teas, St. John’s wort: decreased drug effect

Drug-behaviors. Alcohol use: increased uric acid level

Patient monitoring

- Monitor patient for signs and symptoms of toxicity (nausea, vomiting, abdominal pain, bloody diarrhea, burning sensation, muscle weakness, oliguria, hematuria, ascending paralysis, delirium, and seizures). Discontinue drug if these occur.
- Monitor CBC and renal function test results regularly.
- Be aware that patient may need opioids to control drug-induced diarrhea (especially if he’s receiving maximum colchicine dosage).

Patient teaching

- Instruct patient to report rash, sore throat, fever, tiredness, weakness, numbness, or tingling.
- Tell patient to immediately report muscle tremors, weakness, fatigue, bruising, bleeding, yellowing of eyes or skin, pale stools, dark urine, severe vomiting, watery or bloody diarrhea, or abdominal pain.
- Advise patient to increase fluid intake to prevent renal calculi (unless prescriber wants him to restrict fluids).
- Instruct patient to avoid alcohol, herbal teas, and caffeine during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

colesevelam hydrochloride

Cholestagel®, Welchol

Pharmacologic class: Bile acid sequestrant

Therapeutic class: Antihyperlipidemic

Pregnancy risk category B

Action
Binds bile acids in GI tract and forms insoluble complex, impeding bile acid reabsorption and promoting its excretion. As a result, cholesterol and low-density lipoprotein (LDL) levels decrease.

Availability
Tablets: 625 mg

Indications and dosages

- Adjunct to diet and exercise to reduce LDL cholesterol in patients with primary hypercholesterolemia; as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Adults: Three tablets (1,875 mg) P.O. b.i.d., or six tablets (3,750 mg) once daily. Maximum daily dosage is 4,375 mg.

Contraindications
- Hypersensitivity to drug
- Bowel obstruction
- Vitamin K deficiency

Precautions
Use cautiously in:
- serum triglyceride level above 300 mg/dl
- children (safety and efficacy not established).

Administration
- Give with meals and fluids.
- Ensure that patient swallows tablets whole without crushing or chewing.
Know that drug may be used alone or with HMG-CoA reductase inhibitor.

Store tablets at room temperature.

### Route Onset Peak Duration

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2 wk</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

### Adverse reactions

**CNS:** headache, anxiety, vertigo, dizziness, insomnia, fatigue, syncope
**EENT:** tinnitus
**GI:** nausea, vomiting, diarrhea, constipation, abdominal discomfort, flatulence, fecal impaction, loose stools, fatty stools, rectal or hemorrhoidal bleeding, other GI bleeding
**GU:** increased libido

**Hematologic:** anemia, bleeding tendency

**Metabolic:** malabsorption of vitamins A, D, E, and K

**Musculoskeletal:** back, muscle, or joint pain

**Skin:** bruising

### Interactions

**Drug-drug.** Fat-soluble vitamins (A, D, E, and K): decreased vitamin absorption

### Pharmacologic class:

Bile acid sequestrant

### Therapeutic class:

Antihyperlipidemic

### Pregnancy risk category: NR

### Action

Binds bile acids in GI tract and forms insoluble complex, impeding bile acid reabsorption and promoting its excretion. As a result, cholesterol and low-density lipoprotein levels decrease.

### Availability

**Granules for suspension:** 5 g/packet or scoop

**Tablets:** 1 g

### Indications and dosages

**Primary hypercholesterolemia**

**Adults:**
- **Granules—** 5 g P.O. once or twice daily; may increase q 1 to 2 months up to 30 g/day P.O. given in one or two divided doses.
- **Tablets—** 2 g P.O. once or twice daily; may increase q 1 to 2 months up to 16 g/day P.O. given in one or two divided doses.

### Off-label uses

- Digoxin toxicity

### Contraindications

- Hypersensitivity to drug

### Precautions

Use cautiously in:
- history of constipation
- breastfeeding patients
- children (safety and efficacy not established).

### Administration

- Mix granules with at least 90 ml of liquid, and stir until completely mixed.
Give tablets with large amount of water.
Administer other drugs 1 hour before or 4 hours after colestipol.

**Route** | **Onset** | **Peak** | **Duration**
--- | --- | --- | ---
P.O. | 24-48 hr | 1 mo | 1 mo

### Adverse reactions

**CNS:** dizziness, headache, vertigo, anxiety, syncope, fatigue
**CV:** chest pain
**GI:** nausea, vomiting, constipation, abdominal discomfort, fecal impaction, flatulence, fatty stools, hemorrhoids, perianal irritation, tongue irritation
**Metabolic:** deficiency of vitamins A, D, E, and K and folic acid, hyperchloremic acidosis
**Musculoskeletal:** osteoporosis, backache, muscle and joint pain, arthritis
**Skin:** irritation, rashes

### Interactions

**Drug-drug:** Amiodarone, corticosteroids, digoxin, diuretics, fat-soluble vitamins (A, D, E, K), folic acid, gemfibrozil, imipramine, methotrexate, mycophenolate, nonsteroidal anti-inflammatory drugs, penicillin G, phosphates, propranolol, tetracyclines, thyroid preparations, ursodiol: decreased absorption of these drugs (when given orally)

**Drug-diagnostic tests:** Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, phosphorus: increased levels

**Prothrombin time:** prolonged

### Patient monitoring

- Monitor lipid levels frequently during first few months of therapy and periodically thereafter.
- Evaluate patient for signs and symptoms of abnormal bleeding.
- Be aware that prolonged use may increase bleeding tendency (from hypoprothrombinemia resulting from vitamin K deficiency). As prescribed and needed, give oral or parenteral vitamin K to reverse this effect.

### Patient teaching

- Instruct patient to take granules with 3 to 4 oz of water, fruit juice, soup with high fluid content, cereal, or pulpy fruits (crushed).
- Tell patient to swallow tablets whole, one at a time, and not to crush, cut, or chew them.
- Inform patient that drug may interfere with absorption of many other drugs. Advise him to take other drugs 1 hour before or 4 hours after colestipol.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

---

**cortisone acetate**

**Pharmacologic class:** Glucocorticoid

**Therapeutic class:** Adrenocorticoid

**Pregnancy risk category C**

### Action

Unclear. Reduces inflammation, possibly by suppressing cell-mediated immune reactions; decreasing white blood cell, monocyte, and eosinophil counts; reducing binding of immunoglobulins to cell surface receptors; and inhibiting interleukin synthesis. Also stabilizes lysosomal membranes, curbs polymorphonuclear leukocyte migration, interrupts phagocytosis, and diminishes antibody formation in infected and injured tissues.

### Availability

- **Injection:** 50 mg/ml
- **Tablets:** 5 mg, 10 mg, 25 mg

Reactions in **bold** are life-threatening.
Indications and dosages

- Asthma; adrenal insufficiency; chronic inflammatory, allergic, hematologic, neoplastic, and autoimmune disorders; prevention of organ rejection in organ transplant recipients (given with other immunosuppressants)

**Adults:** 25 to 300 mg P.O. daily, or 20 to 300 mg I.M. daily or on alternate days. Individualize dosage based on disease and patient response.

Dosage adjustment
- Renal impairment
- Elderly patients

Contraindications
- Hypersensitivity to drug
- Systemic fungal infections

Precautions

Use cautiously in:
- renal insufficiency, cirrhosis, diabetes mellitus, diverticulitis, nonspecific ulcerative colitis, recent intestinal anastomoses, peptic ulcer (active or latent), heart failure, hypertension, thromboembolic disorders, hypoprothrombinaemia, myasthenia gravis, glaucoma, ocular herpes simplex, osteoporosis, seizures, underlying immunosuppression, systemic infections, active untreated infections
- emotional instability or psychotic tendency
- pregnant or breastfeeding patients
- children.

Administration

- To help prevent peptic ulcer, give large doses between meals with antacids.
- If possible, administer before 9 A.M. (Exogenous corticosteroids are less likely to suppress adrenocortical activity when given at time of maximal activity.)

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>2 hr</td>
<td>1.25-1.5 days</td>
</tr>
<tr>
<td>I.M.</td>
<td>24-48 hr</td>
<td>Variable</td>
<td>Variable</td>
</tr>
</tbody>
</table>

Adverse reactions

- **CNS:** depression, euphoria, psychosis, vertigo, headache, increased intracranial pressure, seizures
- **CV:** hypertension, thrombophlebitis, thromboembolism
- **EENT:** cataracts, glaucoma, exophthalmos, increased intraocular pressure
- **GI:** nausea, abdominal distention, pancreatitis, peptic ulcers, ulcerative esophagitis
- **GU:** menstrual irregularities
- **Metabolic:** sodium retention, fluid retention, potassium loss, carbohydrate intolerance, negative nitrogen balance, hyperglycemia, cushingoid appearance (moon face, buffalo hump), hypokalemic acidosis
- **Musculoskeletal:** muscle wasting, osteoporosis, aseptic joint necrosis, muscle pain or weakness, vertebral compression fractures, steroid myopathy, tendon rupture, decreased growth (in children)
- **Skin:** decreased wound healing, bruising, fragile skin, petechiae, urticaria, facial erythema, diaphoresis, hirsutism
- **Other:** weight gain or loss, facial edema, increased susceptibility to or masking of infection, hypersensitivity reactions

Interactions

- **Drug-drug.** *Anticoagulants:* increased or decreased anticoagulant blood level
- *Barbiturates, phenytoin, rifampin:* decreased cortisone effects
- *Digoxin:* increased risk of digitalis toxicity
- *Estrogens, hormonal contraceptives:* increased cortisone effects
- *Fluoroquinolones:* increased risk of tendon rupture
- *Itraconazole, ketoconazole:* increased cortisone blood level
- *Live-virus vaccines:* decreased antibody response to vaccine, increased risk of adverse reactions
- *Somatrem, somatropin:* inhibition of growth-promoting effect
Thiazide and loop diuretics: additive hypokalemia

Drugs-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, cholesterol, glucose: increased levels Calcium, potassium: decreased levels Nitroblue tetrazolium test: false-negative result

Drug-herbs. Echinacea: increased immune-stimulating effects Ginseng: increased immune-modulating response

Patient monitoring
- Monitor patient closely for signs and symptoms of infection. Be aware that drug may mask these.
- Watch for weight gain, edema, and signs and symptoms of hypokalemia.
- Measure blood pressure regularly to detect hypertension.
- When discontinuing drug after long-term therapy, taper dosage gradually. Abrupt withdrawal may be fatal.
- With long-term therapy, evaluate patient for negative nitrogen balance; drug may cause protein catabolism. Also check vital signs and evaluate laboratory findings (including 2-hour postprandial blood glucose level, potassium level, and chest X-ray) at regular intervals.
- Monitor upper GI X-rays in patients with suspected peptic ulcer disease or significant dyspepsia or gastric distress.

Patient teaching
- Advise patient to take drug with meal or snack.
- Tell patient taking single daily dose or alternate-day doses to take drug in morning before 9 A.M. Instruct patient taking multiple daily doses to take doses at evenly spaced intervals throughout day.
- Instruct patient to carry identification stating that he’s on long-term steroid therapy.
- Tell patient to report unusual weight gain, leg or foot swelling, muscle weakness, puffy face, cold, or infection.
- Caution patient never to stop therapy abruptly, because doing so may cause life-threatening adrenal insufficiency.
- Tell patient to contact prescriber immediately if signs or symptoms of adrenal insufficiency follow dosage reduction or drug discontinuation.
- Inform patient that he’ll require continued supervision after discontinuing drug, because his disease or disorder may suddenly recur.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

Cromolyn sodium

Apo-Cromolyn, Crolom, Gastrocrom, Intal, Nalcrom, Nasalcrom, Nu-Cromolyn, Solu-Crom

Pharmacologic class: Chromone derivative

Therapeutic class: Mast cell stabilizer, antiasthmatic, ophthalmic decongestant

Pregnancy risk category B

Action
Inhibits release of histamine and reacting substances of anaphylaxis from mast cells, stabilizing the cell membrane and reducing the allergic response and inflammatory reaction.
**Availability**

*Aerosol spray for inhalation:* 800 mcg/spray in 8.1-g container (112 sprays) or 14.2-g container (200 sprays)

*Nasal solution:* 40 mg/ml (5.2 mg/spray) in 13-ml container (100 sprays) or 26-ml container (200 sprays)

*Ophthalmic solution:* 4%

*Oral solution:* 100 mg/5 ml

*Solution for nebulization:* 10 mg/ml

**Indications and dosages**

> Prevention of exercise-induced bronchospasm; adjunct in prevention of allergic disorders, including rhinitis and asthma

**Adults and children ages 5 and older:**
One aerosol spray in each nostril (5.2 mg/spray) q.i.d., or two metered-dose sprays using inhaler at regular intervals or shortly before exposure to triggering event

**Children ages 2 to 5:** 20 mg q.i.d. via nebulization at regular intervals or no more than 1 hour before exposure to triggering event

➢ Mastocytosis

**Adults and children ages 13 and older:** 200 mg P.O. q.i.d.

**Children ages 2 to 12:** 100 mg P.O. q.i.d.

➢ Vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis

**Adults and children ages 4 and older:**
One to two drops of ophthalmic solution in each eye four to six times daily at regular intervals

**Off-label uses**

* Proctitis
* Ulcerative colitis
* Urticaria

**Contraindications**

* Hypersensitivity to drug
* Status asthmaticus

**Precautions**

Use cautiously in:
* renal or hepatic impairment, acute bronchospasm attacks

* pregnant or breastfeeding patients
* children younger than age 5

**Administration**

* Administer oral form 30 minutes before meals and at bedtime.
* Before giving by inhalation, shake canister gently.
* Don’t immerse canister in water.
* Before using nasal spray, have patient clear nasal passages by blowing nose.
* Don’t expose solutions to direct sunlight.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O., inhalation, nasal, ophthalmic</td>
<td>&lt;1 wk</td>
<td>2-4 wk</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

*CNS:* headache, drowsiness, dizziness

*EENT:* nasal irritation, sneezing, epistaxis, postnasal drip (with nasal solution); stinging of eyes, lacrimation (with ophthalmic solution)

*GI:* nausea, diarrhea, stomachache, swollen parotid glands

*GU:* difficult or painful urination, urinary frequency

*Musculoskeletal:* myopathy

*Respiratory:* wheezing, cough, bronchospasm

*Skin:* erythema, rash, urticaria, angioedema

*Other:* altered taste, substernal burning, allergic reactions including anaphylaxis, serum sickness

**Interactions**

None significant

**Patient monitoring**

* Monitor pulmonary function periodically.
* Evaluate patient for signs and symptoms of overdose, including bronchospasm and difficult or painful urination.

📅 Canada  🌍 UK  🎧 Hazardous drug  🚫 High alert drug
Patient teaching
With nebulizer—
● Instruct patient to prepare nebulizer according to package instructions, to clear as much mucus as possible before use, and to rinse mouth after each use (to help prevent opportunistic infections and reduce unpleasant aftertaste).

With nasal form—
● Teach patient how to instill nasal spray as directed.
● Tell patient that drug may cause unpleasant taste, but that rinsing mouth and performing frequent oral care may help. Also inform him that drug may cause headache.
● Advise patient to report increased sneezing; nasal burning, stinging, or irritation; sore throat; hoarseness; or nosebleed.

With oral form—
● Tell patient to take oral form 30 minutes before meals.

With ophthalmic form—
● Instruct patient to wash hands before using.
● Teach patient how to instill drops: Instruct him to tilt his head back and look up, place drops inside lower eyelid, close his eye, and roll eyeball in all directions. Tell him not to blink for about 30 seconds, and then to apply gentle pressure to inner corner of eye for 30 seconds.
● Caution patient not to let applicator tip touch eye or any other surface.
● Tell patient drug may cause temporary stinging of eye or blurred vision.
● Advise patient not to wear contact lenses during therapy.

With all forms—
● As appropriate, review all other significant adverse reactions.

---

cyclobenzaprine hydrochloride

Amrix, Apo-Cyclobenzaprine\textsuperscript{a}, Dom-Cyclobenzaprine\textsuperscript{a}, Flexeril, Novo-Cycloprine\textsuperscript{a}, PHL-Cyclobenzaprine\textsuperscript{a}, PMS-Cyclobenzaprine\textsuperscript{a}, Ratio-Cyclobenzaprine\textsuperscript{a}, Riva-Cyclobenzaprine\textsuperscript{a}

**Pharmacologic class:** Autonomic nervous system drug  
**Therapeutic class:** Skeletal muscle relaxant (centrally acting)  
**Pregnancy risk category B**

**Action**
Unclear. Thought to act primarily at brain stem (and to a lesser extent at spinal cord level) to relieve skeletal muscle spasms of local origin without altering muscle function.

**Availability**
- **Capsules (extended-release):** 15 mg, 30 mg  
- **Tablets:** 5 mg, 10 mg

**Indications and dosages**
- Adjunct to rest and physical therapy to relieve muscle spasm associated with acute, painful musculoskeletal conditions

**Adults:** 5 mg P.O. t.i.d. (immediate-release tablet). May increase to 10 mg P.O. t.i.d. (immediate-release tablet) as needed. Or, 15 mg (extended-release capsule) P.O. daily; some patients may need up to 30 mg/day, given as one 30-mg (extended-release capsule) P.O. daily or two 15-mg (extended-release capsules) P.O. daily.

**Contraindications**
- Hypersensitivity to drug
- Acute recovery phase after myocardial infarction (MI)

---

Reactions in **bold** are life-threatening.
• Heart failure
• Arrhythmias
• Hyperthyroidism
• MAO inhibitor use within past 14 days

Precautions
Use cautiously in:
● cardiovascular disease, closed-angle glaucoma, hepatic impairment, increased intraocular pressure, urinary retention
● elderly patients
● pregnant or breastfeeding patients
● children younger than age 15.

Administration

Don’t give within 14 days of MAO inhibitor. Drug interaction may cause hypertensive crisis and severe seizures.

• Give extended-release capsule at approximately the same time each day.
• Know that drug shouldn’t be used for more than 3 weeks.
• Be aware that drug may not be first-line agent for elderly patients because of its anticholinergic effects.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O. (capsules)</td>
<td>Unknown</td>
<td>7-8 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>P.O. (tablets)</td>
<td>1 hr</td>
<td>4-6 hr</td>
<td>12-24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: dizziness, drowsiness, syncope, confusion, fatigue, headache, nervousness, decreased mental acuity, irritability, weakness, insomnia, depression, disorientation, delusions, peripheral neuropathy, abnormal gait, Bell’s palsy, EEG changes, extrapyramidal symptoms, cerebrovascular accident

CV: vasodilation, tachycardia, chest pain, hypotension, MI, heart block

EENT: blurred vision

GI: nausea, constipation, dyspepsia, swollen parotid glands, mouth inflammation, discolored tongue, dry mouth, paralytic ileus

GU: galactorrhea, urinary retention, urinary frequency, gynecomastia, testicular swelling, libido changes, erectile dysfunction

Hematologic: purpura, eosinophilia, bone marrow depression, leukopenia, thrombocytopenia

Metabolic: hyperglycemia, hypoglycemia, syndrome of inappropriate diuretic hormone secretion

Musculoskeletal: muscle ache

Respiratory: dyspnea

Skin: photosensitization, alopecia, angioedema

Other: unpleasant taste, weight gain or loss, edema

Interactions

Drug-drug. Anticholinergics, anticholinergic-like drugs (including antidepressants, antihistamines, disopyramide, haloperidol, phenothiazines): additive anticholinergic effects

Antihistamines, CNS depressants, opioids, sedative-hypnotics: additive CNS depression

Guanadrel, guanethidine: reduction in or blockage of these drugs’ actions

MAO inhibitors: hyperpyretic crisis, seizures, death

Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression

Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring

• Assess for adverse CNS effects, such as drowsiness, dizziness, and decreased mental acuity.
• Monitor patient for evidence of drug interactions, especially when giving drug with CNS depressants.

Patient teaching

• Tell patient to take extended-release capsule at approximately the same time each day.
• Tell patient that drug may cause dry mouth.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, alertness, and vision.
• Advise patient not to use alcohol, sedatives, pain medications, over-the-counter preparations, or herbs without consulting prescriber.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, herbs, and behaviors mentioned above.

Cyclophosphamide
Endoxana®, Procytox®

Pharmacologic class: Alkylating agent, nitrogen mustard
Therapeutic class: Antineoplastic
Pregnancy risk category D

Action
Unclear. Thought to prevent cell division by cross-linking DNA strands, thereby interfering with growth of susceptible cancer cells.

Availability
Powder for injection: 100 mg, 200 mg, 500 mg, 1 g, 2 g
Tablets: 25 mg, 50 mg

Indications and dosages
➣ Hodgkin’s disease; malignant lymphoma; multiple myeloma; leukemia; advanced mycosis fungoides; neuroblastoma; ovarian cancer; breast cancer; and certain other tumors
Adults: Initially, 40 to 50 mg/kg I.V. in divided doses over 2 to 5 days, or 10 to 15 mg/kg I.V. q 10 days, or 3 to 5 mg/kg I.V. twice weekly.
Children: Initially, 2 to 8 mg/kg or 60 to 250 mg/m² P.O. or I.V. daily in divided doses for 6 or more days.

Maintenance dosage is 2 to 5 mg/kg or 50 to 150 mg/m² P.O. twice weekly.
> Biopsy-proven nephrotic syndrome in children
Children: 2.5 to 3 mg/kg/day P.O. for 60 to 90 days

Off-label uses
• Severe rheumatologic conditions
• Selected cases of severe progressive rheumatoid arthritis and systemic lupus erythematosus

Contraindications
• Hypersensitivity to drug
• Severe bone marrow depression

Precautions
Use cautiously in:
• renal or hepatic impairment, adrenalectomy, mild to moderate bone marrow depression, other chronic debilitating illnesses
• females of childbearing age
• pregnant patients
• breast feeding patients (use not recommended).

Administration
• Verify that patient isn’t pregnant before administering.
• Follow facility procedures for safe handling, administration, and disposal of chemotherapeutic drugs.
• Administer tablets on empty stomach. If drug causes severe GI upset, give with food.
• Don’t cut or crush tablets.
• Know that dosage may need to be decreased if drug is given with other antineoplastics.
• Dilute each 100 mg of powder with 5 ml of sterile water for injection, to yield 20 mg/mL. Further dilute with compatible fluid, such as 5% dextrose injection, 5% dextrose and normal saline solution for injection, 5% dextrose and Ringer’s injection, lactated Ringer’s injection, or half-normal saline solution for injection.

Reactions in bold are life-threatening.
For I.V. injection, give each 100 mg over at least 1 minute. When giving dosages above 500 mg diluted in 100 to 250 ml of compatible solution, administer over 20 to 60 minutes.

- Use solution prepared with bacteriostatic water for injection within 24 hours if stored at room temperature or within 6 days if refrigerated.
- To minimize bladder toxicity, increase patient’s fluid intake during therapy and for 1 to 2 days afterward. Most adults require fluid intake of at least 2 L/day.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O., I.V.</td>
<td>7 days</td>
<td>7-15 days</td>
<td>21 days</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CV:** cardiotoxicity  
**GI:** nausea, vomiting, diarrhea, abdominal pain or discomfort, stomatitis, oral mucosal ulcers, anorexia, hemorrhagic colitis  
**GU:** urinary bladder fibrosis, hematuria, amenorrhea, decreased sperm count, sterility, acute hemorrhagic cystitis, renal tubular necrosis, hemorrhagic ureteral inflammation  
**Hematologic:** anemia, leukopenia, thrombocytopenia, bone marrow depression, neutropenia  
**Hepatic:** jaundice  
**Metabolic:** hyperuricemia  
**Respiratory:** interstitial pulmonary fibrosis  
**Skin:** nail and pigmentation changes, alopecia  
**Other:** poor wound healing, infections, allergic reactions including anaphylaxis, secondary cancer

**Interactions**

**Drug-drug.** Allopurinol, thiazide diuretics: increased risk of leukopenia  
**Digoxin:** decreased digoxin blood level  
**Cardiotoxic drugs (such as cytarabine, daunorubicin, doxorubicin):** additive cardiotoxicity  

Chloramphenicol: prolonged cyclophosphamide half-life  
**Phenobarbital:** increased risk of cyclophosphamide toxicity  
**Quinolones:** decreased antimicrobial effect  
**Succinylcholine:** prolonged neuromuscular blockade  
**Warfarin:** increased anticoagulant effect

**Drug-diagnostic tests.** Hemoglobin, platelets, pseudocholinesterase, red blood cells (RBCs), white blood cells: decreased values  
**Uric acid:** increased level

**Patient monitoring**

- Assess infusion site for signs of extravasation.  
- Monitor hematologic profile to determine degree of hematopoietic suppression. Be aware that leukopenia is an expected drug effect and is used to help determine dosage.  
- Monitor urine regularly for RBCs, which may precede hemorrhagic cystitis.

**Patient teaching**

- Tell patient to take tablets on empty stomach. However, if GI upset occurs, instruct him to take them with food.  
- Advise patient to promptly report unusual bleeding or bruising, fever, chills, sore throat, cough, shortness of breath, seizures, lack of menstrual flow, unusual lumps or masses, flank or stomach pain, joint pain, mouth or lip sores, or yellowing of skin or eyes.  
- Instruct patient to drink 2 to 3 L of fluids daily (unless prescriber has told him to restrict fluids).  
- Tell patient that drug may cause hair loss, but that hair usually grows back after treatment ends.  
- Advise female patient to use barrier contraception during therapy and for 1 month afterward.  
- Advise breastfeeding women not to breastfeed while taking this drug.
As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**cyclosporine**
Apo-Cyclosporine*, Gengraf, Neoral, Sandimmune, Sandoz Cyclosporine

**cyclosporine ophthalmic emulsion**
Restasis, Sandimmun®

*Pharmacologic class:* Polypeptide antibiotic

*Therapeutic class:* Immunosuppressant

*Pregnancy risk category C*

**FDA BOXED WARNING**

- Drug should be prescribed only by physicians experienced in managing systemic immunosuppressive therapy for indicated disease. At doses used for solid-organ transplantation, it should be prescribed only by physicians experienced in immunosuppressive therapy and management of organ transplant recipients. Patient should be managed in facility with adequate laboratory and medical resources. Physician responsible for maintenance therapy should have complete information needed for patient follow-up.
- Neoral may increase susceptibility to infection and neoplasia. In kidney, liver, and heart transplant patients, drug may be given with other immunosuppressants.
- Sandimmune should be given with adrenal corticosteroids but not other immunosuppressants. In transplant patients, increased susceptibility to infection and development of lymphoma and other neoplasms may result from increased immunosuppression.
- Sandimmune and Neoral aren’t bioequivalent. Don’t use interchangeably without physician supervision.
- In patients receiving Sandimmune soft-gelatin capsules and oral solution, monitor at repeated intervals (due to erratic absorption).

**Action**
Unclear. Thought to act by specific, reversible inhibition of immunocompetent lymphocytes in G0-G1 phase of cell cycle. Preferentially inhibits T lymphocytes; also inhibits lymphokine production. Ophthalmic action is unknown.

**Availability**
- Capsules: 25 mg, 100 mg
- Injection: 50 mg/ml
- Oral solution: 100 mg/ml
- Solution (ophthalmic): 0.05% (0.4 ml in 0.9 ml single-use vial)

**Indications and dosages**

➢ **Psoriasis**
- **Adults:** Neoral only—1.25 mg/kg PO b.i.d. for 4 weeks. Based on patient response, may increase by 0.5 mg/kg/day once q 2 weeks, to a maximum dosage of 4 mg/kg/day.
- Gengraf only—2.5 mg/kg PO daily given in two divided doses; after 8 weeks, may increase to a maximum dosage of 4 mg/kg/day.

➢ **Severe active rheumatoid arthritis**
- **Adults:** Neoral only—1.25 mg/kg PO b.i.d. May adjust dosage by 0.5 to 0.75 mg/kg/day after 8 weeks and again after 12 weeks, to a maximum dosage of 4 mg/kg/day. If no response occurs after 16 weeks, discontinue therapy.
- Gengraf only—2.5 mg/kg PO daily given in two divided doses; after 8 weeks, may increase to a maximum dosage of 4 mg/kg/day.

➢ To prevent organ rejection in kidney, liver, or heart transplantation

Reactions in **bold** are life-threatening.
Adults and children: Sandimmune only—Initially, 15 mg/kg P.O. 4 to 12 hours before transplantation, then daily for 1 to 2 weeks postoperatively. Reduce dosage by 5% weekly to a maintenance level of 5 to 10 mg/kg/day. Or 5 to 6 mg/kg I.V. as a continuous infusion 4 to 12 hours before transplantation.

To increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca

Adults: 1 drop in each eye b.i.d. given 12 hours apart

Off-label uses
- Aplastic anemia
- Atopic dermatitis

Contraindications
- Hypersensitivity to drug and any ophthalmic components
- Rheumatoid arthritis, psoriasis in patients with abnormal renal function, uncontrolled hypertension, cancer (Gengraf, Neoral)
- Active ocular infections (ophthalmic use)

Precautions
Use cautiously in:
- hepatic impairment, renal dysfunction, active infection, hypertension
- herpes keratitis (ophthalmic use)
- pregnant or breastfeeding patients
- children younger than age 16 (safety and efficacy not established for ophthalmic use).

Administration
- For I.V. infusion, dilute as ordered with dextrose 5% in water or 0.9% normal saline solution. Administer over 2 to 6 hours.
- Mix Neoral solution with orange juice or apple juice to improve its taste.
- Dilute Sandimmune oral solution with milk, chocolate milk, or orange juice. Be aware that grapefruit and grapefruit juice affect drug metabolism.
- In postoperative patients, switch to P.O. dosage as tolerance allows.
- Be aware that Sandimmune and Neoral aren’t bioequivalent. Don’t use interchangeably.
- Before administering eyedrops, invert unit-dose vial a few times to obtain a uniform, white, opaque emulsion.
- Know that eyedrops can be used concomitantly with artificial tears, allowing a 15-minute interval between products.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1.5-3.5 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>1-2 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Ophthal. (undetectable blood levels)

Adverse reactions
CNS: tremor, headache, confusion, paresthesia, insomnia, anxiety, depression, lethargy, weakness
CV: hypertension, chest pain, myocardial infarction
EENT: visual disturbances, hearing loss, tinnitus, rhinitis; (with ophthalmic use) ocular burning, conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, itching, stinging, blurring
GI: nausea, vomiting, diarrhea, constipation, abdominal discomfort, gastritis, peptic ulcer, mouth sores, difficulty swallowing, anorexia, upper GI bleeding, pancreatitis
GU: gynecomastia, hematuria, nephrotoxicity, renal dysfunction, glomerular capillary thrombosis
Hematologic: anemia, leukopenia, thrombocytopenia
Metabolic: hyperglycemia, hypomagnesemia, hyperuricemia, hyperkalemia, metabolic acidosis
Musculoskeletal: muscle and joint pain
Respiratory: cough, dyspnea, *Pneumocystis jiroveci pneumonia*, bronchospasm

Skin: acne, hirsutism, brittle fingernails, hair breakage, night sweats

Other: gum hyperplasia, flulike symptoms, edema, fever, weight loss, hiccups, anaphylaxis

Interactions

The following interactions pertain to oral and I.V. routes only.

**Drug-drug.** Acyclovir, aminoglycosides, amphotericin B, cimetidine, diclofenac, gentamicin, ketoconazole, melphalan, naproxen, ranitidine, sulindac, sulfamethoxazole, tacrolimus, tobramycin, trimethoprim, vancomycin: increased risk of nephrotoxicity

Allopurinol, amiodarone, bromocriptine, clarithromycin, colchicine, danazol, diltiazem, erythromycin, fluconazole, imipenem and cilastatin, itraconazole, ketoconazole, methylprednisolone, nicardipine, prednisolone, quinupristin/dalfopristin, verapamil: increased cyclosporine blood level

Azathioprine, corticosteroids, cyclophosphamide: increased immunosuppression

Carbamazepine, isoniazid, nafcillin, octreotide, orlistat, phenobarbital, phenytoin, rifabutin, rifampin, ticlopidine: decreased cyclosporine blood level

Digoxin: decreased digoxin clearance

*Live-virus vaccines*: decreased antibody response to vaccine

Lovastatin: decreased lovastatin clearance, increased risk of myopathy and rhabdomyolysis

*Potassium-sparing diuretics*: increased risk of hyperkalemia

**Drug-diagnostic tests.** Alanine aminotransferase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, glucose, low-density lipoproteins: increased levels

Hemoglobin, platelets, white blood cells: decreased values

**Drug-food.** Grapefruit, grapefruit juice: decreased cyclosporine metabolism, increased cyclosporine blood level

*High-fat diet*: decreased drug absorption (Neoral)

**Drug-herbs.** *Alfalfa sprouts, astragalus, echinacea, licorice*: interference with immunosuppressant action

*St. John’s wort*: reduced cyclosporine blood level, possibly leading to organ rejection

Patient monitoring

- Observe patient for first 30 to 60 minutes of infusion. Monitor frequently thereafter.
- Monitor cyclosporine blood level, electrolyte levels, and liver and kidney function test results.
- Assess for signs and symptoms of hyperkalemia in patients receiving concurrent potassium-sparing diuretic.

Patient teaching

- Advise patient to dilute Neoral oral solution with orange or apple juice (preferably at room temperature) to improve its flavor.
- Instruct patient to use glass container when taking oral solution. Tell him not to let solution stand before drinking, to stir solution well and then drink all at once, and to rinse glass with same liquid and then drink again to ensure that he takes entire dose.
- Tell patient taking Neoral to avoid high-fat meals, grapefruit, and grapefruit juice.
- Advise patient to dilute Sandimmune oral solution with milk, chocolate milk, or orange juice to improve its flavor.
- Instruct patient to invert vial a few times to obtain a uniform, white, opaque emulsion before using eyedrops and to discard vial immediately after use.

Reactions in **bold** are life-threatening.

Clinical alert
• Inform patient that eyedrops can be used with artificial tears but to allow 15-minute interval between products.
• Caution patient not to wear contact lenses because of decreased tear production; however, if contact lenses are used, advise patient to remove them before administering eyedrops and to reinsert 15 minutes after administration.
• Inform patient that he’s at increased risk for infection. Caution him to avoid crowds and exposure to illness.
• Instruct patient not to take potassium supplements, herbal products, or dietary supplements without consulting prescriber.
• Tell patient he’ll need to undergo repeated laboratory testing during therapy.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

### ciproheptadine hydrochloride
Periactin®, Periactin,
PMS-Cyproheptadine

**Pharmacologic class:** Piperidine (nonselective)  
**Therapeutic class:** Antihistamine  
**Pregnancy risk category B**

### Action
Antagonizes effects of histamine at histamine1-receptor sites, preventing histamine-mediated responses. Also blocks effects of serotonin, causing increased appetite.

### Availability
- **Syrup:** 2 mg/5 ml  
- **Tablets:** 4 mg

### Indications and dosages
- **Allergy symptoms caused by histamine release** (including seasonal and perennial allergic rhinitis); chronic urticaria; angioedema; dermographism; cold urticaria; adjunctive therapy for anaphylactic reactions
  - **Adults:** Initially, 4 mg P.O. q 8 hours. Maintenance dosage is 4 to 20 mg/day in three divided doses, to a maximum dosage of 0.5 mg/kg/day.
  - **Children ages 7 to 14:** 2 to 4 mg P.O. q 12 hours. Don’t exceed 16 mg/day.
  - **Children ages 2 to 6:** 2 mg P.O. q 12 hours. Don’t exceed 12 mg/day.

### Off-label uses
- Vascular cluster headaches

### Contraindications
- Hypersensitivity to drug  
- Alcohol intolerance (syrup only)  
- Bladder neck obstruction  
- Angle-closure glaucoma  
- Ulcer disease  
- Symptomatic prostatic hypertrophy  
- MAO inhibitor use within past 14 days

### Precautions
Use cautiously in:
- hepatic impairment  
- elderly patients  
- pregnant patients (safety not established)  
- breastfeeding patients.

### Administration
- Give with food or milk to decrease GI upset.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>15-60 min</td>
<td>1-2 hr</td>
<td>8 hr</td>
</tr>
</tbody>
</table>

### Adverse reactions
- **CNS:** drowsiness, dizziness, excitation (especially in children), fatigue, sedation, hallucinations, disorientation, tremor
CV: palpitations, hypotension, arrhythmias
EENT: blurred vision, nasal dryness and congestion, dry throat
GI: constipation, dry mouth
GU: urinary retention, urinary frequency, ejaculatory inhibition, early menses
Respiratory: thickened bronchial secretions
Skin: rash, photosensitivity
Other: weight gain

Interactions
Drug-drug. CNS depressants (including opioid analgesics, sedative-hypnotics): increased CNS depression
MAO inhibitors: intensified, prolonged anticholinergic effects
Drug-diagnostic tests. Allergy skin tests: false-negative reactions
Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring
- Monitor patient for excessive anticholinergic effects.
- Assess for excessive CNS depression.
- Discontinue drug 4 days before diagnostic skin testing.

Patient teaching
- Advise patient to take drug with food to minimize GI upset.
- Caution patient not to use other CNS depressants, sleep aids, or alcohol during therapy.
- Instruct patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

FDA BOXED WARNING
- Drug should be given only by physicians experienced in cancer chemotherapy. For induction therapy, patients should be in facility with adequate resources to monitor drug tolerance and treat drug toxicity. Main toxic effect is bone marrow suppression with leukopenia, thrombocytopenia, and anemia. Less serious toxicities include nausea, vomiting, diarrhea, abdominal pain, oral ulcers, and hepatic dysfunction.
- Prescriber must weigh possible benefit against known toxic effects and should be familiar with complete package insert information.
- Give DepoCyt (liposomal injection) only under supervision of physician experienced with intrathecal cancer chemotherapy, in facility with adequate diagnostic and treatment resources. In all clinical studies, chemical arachnoiditis (manifested mainly by nausea, vomiting, headache, and fever) was common adverse event; unless treated, it may be fatal. Patients receiving DepoCyt should receive dexamethasone concurrently to mitigate arachnoiditis symptoms.

Action
Unclear. Cytotoxic effect may stem from inhibition of DNA polymerase by drug’s active metabolite.

Reactions in bold are life-threatening.
Availability
Injection (conventional form): 20 mg
Liposomal injection for intrathecal use (sustained-release): 50 mg/5-ml vial
Powder for injection (conventional form): 100 mg, 500 mg, 1g, 2 g

Indications and dosages
➣ To induce remission of acute non-lymphocytic leukemia
Adults: Injection (conventional form)—100 mg/m²/day by continuous I.V. infusion on days 1 through 7, or 100 mg/m² I.V. q 12 hours on days 1 through 7, given with other antineoplastics
➣ Meningeal leukemia
Adults: Injection (conventional form)—5 to 75 mg/m²/day intrathecally for 4 days, or once q 4 days. Most common dosage is 30 mg/m² q 4 days until cerebrospinal fluid is normal.
➣ Lymphomatous meningitis
Adults: Liposomal injection—50 mg intrathecally q 14 days for two doses (at weeks 1 and 3); then q 14 days for three doses (at weeks 5, 7, and 9), with one additional dose at week 13; then q 28 days for four doses

Contraindications
● Hypersensitivity to drug
● Active meningeal infection (liposomal form)

Precautions
Use cautiously in:
● renal or hepatic disease, active infection, decreased bone marrow reserve, other chronic illnesses
● pregnant or breastfeeding patients.

Administration
● Follow facility procedures for safe handling, administration, and disposal of chemotherapeutic drugs.
● For I.V. injection, reconstitute each 100 mg with 5 ml of diluent (if necessary), and give each 100-mg dose over 1 to 3 minutes. For I.V. infusion, dilute further with 50 to 100 ml of dextrose 5% in water or normal saline solution, and infuse over 30 minutes to 24 hours (depending on dosage and concentration).
● Be aware that conventional and liposomal forms can be administered intrathecally.

Don’t use intrathecal route for formulations containing benzyl alcohol.
● When giving conventional form intrathecally, reconstitute with autologous spinal fluid or preservative-free normal saline solution for injection. Use immediately.
● Patients receiving intrathecal cytarabine should be treated concurrently with dexamethasone to mitigate symptoms of chemical arachnoiditis.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>Intrathecal</td>
<td>Rapid</td>
<td>5 hr</td>
<td>14-28 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: malaise, dizziness, headache, neuritis, neurotoxicity, chemical arachnoiditis
CV: chest pain, thrombophlebitis
EENT: conjunctivitis
GI: nausea, vomiting, diarrhea, abdominal pain, anal ulcers, esophagitis, esophageal ulcers, oral ulcers (in 5 to 10 days), anorexia, bowel necrosis
GU: urinary retention, renal dysfunction
Hematologic: anemia, megaloblastosis, reticulocytopenia, leukopenia, thrombocytopenia
Hepatic: hepatic dysfunction
Metabolic: hyperuricemia
Musculoskeletal: muscle ache, bone pain
Respiratory: pneumonia, shortness of breath
Skin: rash, pruritus, freckling, skin ulcers, urticaria, alopecia
Other: flulike symptoms, edema, infection, fever, cellulitis at injection site, anaphylaxis, infection (mild to fatal)

Interactions
Drug-drug. Digoxin: decreased digoxin blood level
Fluorocytosine: decreased fluorocytosine blood level
Gentamicin: decreased gentamicin effects
Drug-diagnostic tests. Hemoglobin, platelets, red blood cells, reticulocytes, white blood cells: decreased values
Megaloblasts, uric acid: increased levels

Patient monitoring
• Observe for signs and symptoms of cytarabine syndrome (malaise, fever, muscle ache, bone pain, occasional chest pain, maculopapular rash, and conjunctivitis).
• When giving liposomal form, assess for signs and symptoms of chemical arachnoiditis, such as neck rigidity and pain, nausea, vomiting, headache, fever, and back pain.
• Monitor liver function test results, CBC with differential, platelet count, blood urea nitrogen, and serum creatinine and uric acid levels.
• Observe closely for signs and symptoms of infection, which could become severe and fatal.

Patient teaching
• Tell patient to contact prescriber immediately if he develops signs or symptoms of infection, cytarabine syndrome (malaise, fever, muscle ache, bone pain, chest pain, rash, eye infection), or chemical arachnoiditis (neck rigidity or pain, nausea, vomiting, headache, fever, or back pain).
• Tell patient that drug makes him more susceptible to infection. Advise him to avoid crowds and exposure to illness.
• Advise patient to increase fluid intake, to promote uric acid excretion.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

FDA BOXED WARNING
• Give under supervision of physician experienced in cancer chemotherapy.
• Hematopoietic depression is most common toxicity; hepatic necrosis has also occurred.
• Drug is carcinogenic and teratogenic in animals.
• Prescriber must weigh potential benefit against toxicity risk.

Action
Unclear. Thought to inhibit DNA synthesis by acting as purine analog. Also causes alkylation and may interact with sulphhydryl groups.

Availability
Injection: 100-mg and 200-mg vials

Indications and dosages
Hodgkin’s disease
Adults: 150 mg/m² I.V. daily for 5 days in combination with other drugs, repeated q 4 weeks. Or 375 mg/m² I.V. on first day of combination therapy, repeated q 15 days.

Reactions in bold are life-threatening.
Metastatic malignant melanoma
Adults: 2 to 4.5 mg/kg I.V. daily for 10 days, repeated q 4 weeks. Or 250 mg/ m² I.V. daily for 5 days, repeated q 3 weeks.

Off-label uses
- Malignant pheochromocytoma

Contraindications
- Hypersensitivity to drug

Precautions
Use cautiously in:
- hepatic dysfunction, impaired bone marrow function
- pregnant or breastfeeding patients
- children.

Administration
- Follow facility procedures for safe handling, administration, and disposal of chemotherapeutic drugs.
- Reconstitute with sterile water for injection according to manufacturer’s directions.
- Further dilute reconstituted drug with 5% dextrose in water or normal saline solution.
- Administer over 30 to 60 minutes by I.V. infusion only.
- Take steps to prevent extravasation, which may cause tissue damage and severe pain.

Adverse reactions
CNS: malaise, paresthesia
GI: nausea, vomiting, dyspepsia, anorexia
Hematologic: anemia, leukopenia, thrombocytopenia, bone marrow depression
Musculoskeletal: myalgia
Skin: dermatitis, erythematous or urticarial rash, alopecia, flushing, photosensitivity
Others: flu-like symptoms, fever, hypersensitivity reactions including anaphylaxis

Interactions
Drug-diagnostic tests. Platelets, red blood cells, white blood cells: decreased counts
Drug-behaviors. Sun exposure: photosensitivity reaction

Patient monitoring
- Frequently monitor CBC with white cell differential and platelet count. Know that hematopoietic depression is the most common toxicity and can be fatal.
- Assess infusion site closely for extravasation.

Patient teaching
- Instruct patient to immediately report pain, burning, or swelling at infusion site; numbness in arms or legs; gait changes; respiratory distress; difficulty breathing; rash; or easy bruising or bleeding.
- Advise patient to minimize GI distress by eating small, frequent servings of healthy food and drinking plenty of fluids.
- Tell patient he’ll undergo regular blood testing during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests and behaviors mentioned above.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**daclizumab**
Zenapax

**Pharmacologic class**: Immunomodulator, humanized immunoglobulin G₁ monoclonal antibody

**Therapeutic class**: Immunosuppressant

**Pregnancy risk category C**
FDA BOXED WARNING

- Drug should be prescribed only by physician experienced in immunosuppressive therapy and managing organ transplant recipients, and given by trained personnel in facility with adequate diagnostic and treatment resources.
- Prescribing physician should have complete information needed for patient follow-up.

Action
Binds to alpha subunit of high-affinity interleuken-2 (IL-2) receptor complex, inhibiting IL-2 binding and blocking critical pathway in cellular immune response against allografts. Also impedes immunologic response to antigens.

Availability
Injection: 25 mg/5 ml

Indications and dosages
- Prevention of acute organ rejection in kidney transplantation
- Adults: 1 mg/kg by I.V. infusion, usually for five doses. Give first dose no more than 24 hours before transplantation; give remaining doses at 14-day intervals.

Contraindications
- Hypersensitivity to drug

Precautions
Use cautiously in:
- elderly patients
- pregnant or breastfeeding patients
- children.

Administration
- Know that drug is given as part of immunosuppressive combination therapy.
- Don’t give by direct I.V. injection.
- Mix diluted dose with 50 ml of sterile normal saline solution.
- Deliver through peripheral or central vein over 15 minutes.

Adverse reactions
CNS: headache, tremor, dizziness, prickly sensations, insomnia, fatigue, weakness, depression, anxiety
CV: tachycardia, chest pain, hypotension, hypertension, thrombosis
EENT: blurred vision, rhinitis, pharyngitis
GI: nausea, vomiting, constipation, diarrhea, abdominal pain, abdominal distention, flatulence, epigastric pain, heartburn, dyspepsia, gastritis, hemorrhoids
GU: kidney enlargement, urinary tract bleeding, dysuria, urinary retention, renal insufficiency, oliguria, renal tubular necrosis
Hematologic: bleeding
Metabolic: diabetes mellitus, dehydration, fluid overload
Musculoskeletal: myalgia; joint, back, or leg pain
Respiratory: dyspnea, cough, hypoxia, crackles, crepitus, rhonchi, congestion, abnormal or decreased breath sounds, hemoptysis, upper respiratory tract infection, atelectasis, pleural effusion
Skin: acne, wound infection, impaired wound healing
Other: lymphocele (cystic mass), pain, edema at injection site, peripheral edema, cellulitis, cytomegalovirus infection, shivering, fever

Interactions
None significant

Reactions in bold are life-threatening.

Clinical alert
Patient monitoring

- Monitor bone marrow function and CBC and platelet count frequently.
- Assess cardiovascular, respiratory, and renal function during infusion and periodically between infusions.
- Monitor blood glucose level, especially in patients receiving high-dose corticosteroids concurrently with daclizumab.

Patient teaching

- Explain that drug’s purpose is to prevent transplant rejection.
- Instruct patient to immediately report difficulty breathing or swallowing, tightness in jaw or throat, chest pain, or pain at infusion site.
- Tell patient to promptly report changes in urinary pattern, unusual bleeding or bruising, rash, fever, and other adverse effects.
- Inform patient that drug increases risk of infection. Caution him to avoid crowds and exposure to illness.
- As appropriate, review all other significant and life-threatening adverse reactions.

**dalteparin sodium**

Fragmin

*Pharmacologic class:* Low-molecular-weight heparin

*Therapeutic class:* Anticoagulant

*Pregnancy risk category B*

**FDA BOXED WARNING**

- When epidural or spinal anesthesia or spinal puncture is used, patients receiving or scheduled to receive thromboprophylactic drugs may develop epidural or spinal hematoma, which can result in long-term or permanent paralysis. Risk increases with use of indwelling epidural catheter for analgesia administration or concomitant use of drugs affecting hemostasis (such as nonsteroidal anti-inflammatory drugs, platelet inhibitors, or other anticoagulants). Traumatic or repeated epidural or spinal puncture also may increase risk. Before neuraxial intervention, physician should weigh drug’s potential benefit against risk.
- Monitor patient frequently for signs and symptoms of neurologic impairment. If these occur, provide urgent treatment.

**Action**

Inhibits thrombus and clot formation by blocking factor Xa and thrombin

**Availability**

*Solution for injection (prefilled syringes):* 12,500 units/0.5 ml, 15,000 units/0.6 ml, 18,000 units/0.72 ml, 5,000 units/0.2 ml, 7,500 units/0.3 ml, 10,000 units/0.4 ml

*Solution for injection (multidose vials):* 95,000 units/3.8 ml, 95,000 units/9.5 ml

*Solution for injection (single-dose graduated syringe):* 10,000 units/1 ml

**Indications and dosages**

> Extended treatment of symptomatic venous thromboembolism (VTE), including proximal deep vein thrombosis (DVT) and pulmonary embolism (PE) to reduce recurrence of VTE in patients with cancer

*Adults:* Recommended dosing: for first 30 days of treatment, give 200 international units/kg total body weight subcutaneously once daily. Give at dose of approximately 150 international units/kg subcutaneously once daily during months 2 through 6. Safety and efficacy beyond 6 months not established. Total daily dose
shouldn’t exceed 18,000 international units.
➢ To prevent DVT, which can lead to PE in patients undergoing hip and abdominal surgery who are at risk for thromboembolic complications

**Adults:** *Abdominal surgery*—2,500 international units subcutaneously 1 to 2 hours before surgery; then once daily for 5 to 10 days. For high-risk patients, 5,000 international units subcutaneously on evening before surgery; then once daily for 5 to 10 days. For cancer patients, 2,500 international units subcutaneously 1 to 2 hours before surgery; repeat dose 12 hours later, then give 5,000 international units subcutaneously every day for 5 to 10 days. *Hip replacement surgery*—5,000 international units subcutaneously 10 to 14 hours before surgery; repeat dose 4 to 8 hours after surgery, then give 5,000 international units daily for 5 to 10 days. Or, 2,500 international units subcutaneously within 2 hours before surgery, followed by 2,500 international units subcutaneously 4 to 8 hours after surgery (allowing at least 6 hours between doses), followed by 5,000 international units subcutaneously daily for 5 to 10 days. Or, 2,500 international units subcutaneously 4 to 8 hours after surgery, followed by 5,000 international units subcutaneously daily for 5 to 10 days.

➢ Patients with severely restricted mobility during acute illness

**Adults:** 5,000 international units subcutaneously daily for 12 to 14 days

➢ Extended treatment of symptomatic venous thromboembolism in patients with cancer

**Adults:** For first 30 days of treatment, 200 international units/kg subcutaneously daily. Total daily dosage shouldn’t exceed 18,000 international units. Give approximately 150 international units/kg subcutaneously daily during months 2 through 6. Total daily dosage shouldn’t exceed 18,000 international units.

➢ To prevent ischemic complications in patients with unstable angina and non-Q-wave myocardial infarction

**Adults:** 120 international units/kg (not to exceed 10,000 international units) subcutaneously q 12 hours (concurrently with aspirin P.O.) for 5 to 8 days

### Dosage adjustment
- Renal insufficiency
- Thrombocytopenia

### Off-label uses
- Systemic anticoagulation

### Contraindications
- Hypersensitivity to drug, heparin, pork products, sulfites, or benzyl alcohol
- Active major bleeding
- Thrombocytopenia
- Patients with unstable angina or non-Q-wave myocardial infarction who are undergoing regional anesthesia; cancer patients with symptomatic VTE who are undergoing regional anesthesia

### Precautions
Use cautiously in:
- bacterial endocarditis, bleeding disorders, hemorrhagic stroke, severe uncontrolled hypertension, GI ulcer, severe renal or hepatic insufficiency, hypertensive or diabetic retinopathy
- history of thrombocytopenia from heparin use
- history of congenital or acquired bleeding disorder
- recent CNS or ophthalmologic surgery
- recent GI disease
- spinal or epidural anesthesia
- pregnant or breastfeeding patients
- children (safety not established).
Administration
- Know that dalteparin sodium is a high-alert drug.
- Administer by subcutaneous route only. Don’t give by I.M. or I.V. route.
  - To minimize bruising at injection site, massage site with ice before giving injection.
  - To give subcutaneous injection, have patient either sit up or lie down. Inject in U-shaped area around navel, upper outer side of thigh, or upper outer quadrangle of buttock. Rotate injection sites daily.
  - Don’t use interchangeably with heparin or other low-molecular-weight heparins.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcut.</td>
<td>20-60 min</td>
<td>3-5 hr</td>
<td>12 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
Hematologic: anemia, ecchymosis, bleeding, thrombocytopenia, hemorrhage
Skin: rash, urticaria
Other: pain, irritation, and hematoma at injection site; fever; edema

Interactions
Drug-drug. Antiplatelet drugs (aspirin, clopidogrel, dipyridamole, ticlopidine), thrombolytics, warfarin: increased risk of bleeding
Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase: increased levels
Platelets: decreased count
Drug-herbs. Anise, arnica, chamomile, clove, feverfew, garlic, ginger, ginkgo, ginseng: increased risk of bleeding

Patient monitoring
- Monitor patient for increased risk of bleeding if he’s receiving concomitant drugs that affect platelet function.
  - Monitor CBC and platelet count.
  - Monitor stools for occult blood.

Patient teaching
- Teach patient proper injection technique if self-administering at home.
- Tell patient that drug may cause him to bleed easily. To avoid injury, advise him to brush teeth with soft toothbrush, use electric razor, and avoid scissors and sharp knives.
- Advise patient to immediately report bleeding, bruising, dizziness, light-headedness, itching, rash, fever, swelling, or difficulty breathing.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

Danazol
Cyclomen®, Danol®
Pharmacologic class: Androgen (synthetic)
Therapeutic class: Sex hormone
Pregnancy risk category X

FDA BOXED WARNING
- Drug is contraindicated during pregnancy. Patient must have negative pregnancy test immediately before therapy starts, and should use nonhormonal contraceptive method during therapy.
  - If patient becomes pregnant during therapy, discontinue drug and inform her of potential fetal risk.
  - Drug may cause thromboembolism and thrombotic events, including life-threatening or fatal stroke.
  - With long-term use, drug may cause peliosis hepatitis and benign hepatic adenoma. Use lowest dosage that provides adequate protection.
  - Drug has been linked to benign intracranial hypertension (pseudotumor
cerebri). Screen for early signs and symptoms, including headache, nausea, vomiting, and visual disturbances.

**Action**
Suppresses pituitary-ovarian axis, probably through a combination of depressed hypothalamic-pituitary response to reduced estrogen production, altered sex hormone metabolism, and interaction with sex hormone receptors.

**Availability**
*Capsules:* 50 mg, 100 mg, 200 mg

**Indications and dosages**

- **Moderate endometriosis amenable to hormonal management**
  - **Adults and adolescents:** 400 mg P.O. b.i.d for up to 9 months. In milder cases, 100 to 200 mg P.O. b.i.d. initially, with dosage adjustments based on patient response.
  - **Fibrocystic breast disease**
  - **Adults and adolescents:** 100 to 200 mg P.O. b.i.d. for 2 to 6 months
  - **Hereditary angioedema**
  - **Adults and adolescents:** 200 mg P.O. two to three times daily. If possible, decrease dosage by 50% or less q 1 to 3 months. If acute angioedema attack occurs, increase dosage up to 200 mg/day.

**Off-label uses**
- Menorrhagia
- Precocious puberty

**Contraindications**
- Hypersensitivity to drug
- Abnormal GU tract bleeding
- Porphyria
- Severe hepatic, renal, or cardiac disease
- Pregnancy or breastfeeding

**Precautions**
Use cautiously in:
- coronary artery disease, conditions aggravated by edema
- mild to moderate hepatic disease
- children.

**Administration**
- Verify that patient isn’t pregnant before initiating therapy. Start therapy during menstruation.
- Don’t give to female of childbearing age unless she’s willing and able to use barrier contraception during therapy.
- Give with food or milk.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O. (endome-triosis)</td>
<td>Unknown</td>
<td>6-8 wk</td>
<td>60-90 days</td>
</tr>
<tr>
<td>P.O. (fibro-cyst.)</td>
<td>1 mo</td>
<td>2-6 mo</td>
<td>1 yr</td>
</tr>
<tr>
<td>P.O. (angio-edema)</td>
<td>Unknown</td>
<td>1-3 mo</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

_-CNS:_ headache, tremor, emotional lability, irritability, nervousness, anxiety, depression, sleep disorders, epilepsy exacerbation, benign intracranial hypertension
_-CV:_ increased blood pressure, palpitations, tachycardia, thrombotic events, myocardial infarction
_-EENT:_ cataracts, blurred vision, nasal congestion, papilledema
_-GI:_ nausea, vomiting, constipation, indigestion, gastroenteritis, anorexia, pancreatitis
_-GU:_ hematuria; amenorrhea; menstrual cycle disturbances (spotting, altered cycle); anovulation; vaginal dryness; changes in breast size; clitoral enlargement; testicular atrophy; abnormalities in semen volume, viscosity, mobility, and sperm count; decreased libido
_-Hematologic:_ reversible erythrocytosis, eosinophilia, polycythemia, thrombocytosis, leukocytosis, leukopenia, thrombocytopenia, splenic peliosis
_-Hepatic:_ cholestatic jaundice, peliosis hepatitis, hepatic adenoma, malignant hepatic tumor

Reactions in **bold** are life-threatening.
Metabolic: increased insulin requirement (in diabetic patients)
Musculoskeletal: muscle cramps, spasms, pain, or fasciculations; joint pain and swelling; joint “lock-up”; pain in back, neck, or limbs; carpal tunnel syndrome
Skin: acne, hirsutism, oily skin, rash, photosensitivity, yellowing of skin and sclera, pigmentation changes, seborrhea, sweating
Other: weight gain, edema, deepening of voice, Stevens-Johnson syndrome

Interactions
Drug-drug. Carbamazepine: increased carbamazepine blood level
Cyclosporine, tacrolimus: increased blood levels of these drugs, increased risk of nephrotoxicity
Insulin, oral hypoglycemics: increased blood glucose level and insulin resistance, necessitating adjustment of insulin or oral hypoglycemic dosages
Warfarin: prolonged prothrombin time

Drug-diagnostic tests. Creatine kinase, glucagon, glucose, hepatic enzymes, low-density lipoproteins, plasma proteins, sex hormone-binding globulins: increased levels
Glucose tolerance, thyroid function: altered test results
High-density lipoproteins: decreased level

Patient monitoring
Assess for early indications of benign intracranial hypertension, such as headache, nausea, vomiting, and visual disturbances. Screen for papilledema; if present, refer patient to neurologist immediately.
Watch for hepatic problems. Long-term use is linked to peliosis hepatitis and hepatic tumors, which may be silent until complicated by acute, life-threatening intra-abdominal hemorrhage.

Monitor patient for thromboembolism and thrombophlebitis.
Check CBC with white cell differential and liver and kidney function test results regularly.

Patient teaching
Advise female of childbearing age to use barrier contraception, because drug causes fetal abnormalities.
Inform female patient that drug frequently causes amenorrhea after 6 to 8 weeks of therapy.
Instruct female patient to report masculinizing effects, such as facial hair or deepening of voice.
Tell male patient that drug may cause sperm reduction during therapy.
Instruct patient to promptly report signs and symptoms of fluid retention (swelling of ankles, feet, or hands; difficulty breathing; sudden weight gain), change in urine or stool color, yellowing of eyes and skin, and easy bruising or bleeding.
As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Dantrolene sodium
Dantrium, Dantrium Intravenous

Pharmacologic class: Hydantoin derivative
Therapeutic class: Skeletal muscle relaxant (direct-acting), malignant hyperthermia agent
Pregnancy risk category C
FDA BOXED WARNING

- Drug may be hepatotoxic and should be used only for recommended conditions. Daily doses of 400 mg are less likely to cause fatal and nonfatal hepatitis than daily doses above 800 mg. Overt hepatitis is most common during months 3 and 12, but may occur at any time; females, patients older than age 35, and those receiving concurrent therapy are at higher risk. Use only in conjunction with liver monitoring. Monitor liver function at baseline and regularly during therapy. Discontinue drug if values are abnormal.
- Use lowest possible effective dose. If no benefit occurs after 45 days, discontinue.

Action
Relaxes skeletal muscle by affecting excitation-contraction coupling response at site beyond myoneural junction, probably by interfering with calcium release from sarcoplasmic reticulum

Availability
Capsules: 25 mg, 50 mg, 100 mg
Powder for injection: 20 mg/vial

Indications and dosages
- Chronic spasticity resulting from upper motor neuron disorders, such as multiple sclerosis, cerebral palsy, or spinal cord injury
  Adults: Initially, 25 mg P.O. daily, increased gradually in 25-mg increments, if needed, up to 100 mg two or three times daily, to a maximum dosage of 400 mg P.O. daily. Maintain dosage level for 4 to 7 days to gauge patient response.
  Children: Initially, 0.5 mg/kg P.O. daily for 7 days, increased to 0.5 mg/kg P.O. t.i.d. for 7 days; then 1 mg/kg P.O. t.i.d. for 7 days; then 2 mg/kg t.i.d., as needed. Don’t exceed 100 mg P.O. q.i.d.

- Malignant hyperthermic crisis
  Adults and children: Initially, 1 mg/kg by I.V. push, repeated as needed up to a cumulative dosage of 10 mg/kg/day
  To prevent or minimize malignant hyperthermia in patients who require surgery
  Adults and children: 4 to 8 mg/kg P.O. daily in three or four divided doses for 1 to 2 days before surgery; give last dose 3 to 4 hours before surgery. Or 2.5 mg/kg I.V. infused over 1 hour before anesthetics are given.
  To prevent recurrence of malignant hyperthermic crisis
  Adults: 4 to 8 mg/kg daily P.O. in four divided doses for up to 3 days after initial hyperthermic crisis

Off-label uses
- Heat stroke
- Neuroleptic malignant syndrome

Contraindications
- Active hepatic disease (oral form)
- Patients who use spasticity to maintain posture or balance (oral form)
- Breastfeeding

Precautions
Use cautiously in:
- cardiac, hepatic, or respiratory dysfunction or impairment
- women (especially pregnant women)
- adults older than age 35
- children younger than age 5.

Administration
- For I.V. use, add 60 ml of sterile water for injection to each vial; shake until solution is clear. Protect from direct light and use within 6 hours.
- Give therapeutic or emergency dose by rapid I.V. push. Administer follow-up dose over 2 to 3 minutes.
- Prevent extravasation when giving I.V. Drug has high pH and causes tissue irritation.

Reactions in **bold** are life-threatening.
### Adverse reactions

**CNS:** dizziness, drowsiness, fatigue, malaise, weakness, confusion, depression, insomnia, nervousness, headache, light-headedness, speech disturbances, seizures

**CV:** tachycardia, blood pressure fluctuations, phlebitis, **heart failure**

**EENT:** double vision, excessive tearing

**GI:** nausea, vomiting, diarrhea, constipation, abdominal cramps, GI reflux and irritation, hematemesis, difficulty swallowing, anorexia, **GI bleeding**

**GU:** urinary frequency, dysuria, nocturia, urinary incontinence, hematuria, crystalluria, prostatitis

**Hematologic:** aplastic anemia, leukopenia, thrombocytopenia, lymphocytic lymphoma

**Hepatic:** hepatitis

**Musculoskeletal:** myalgia, backache

**Respiratory:** suffocating sensation, respiratory depression, pleural effusion with pericarditis

**Skin:** rash, urticaria, pruritus, eczematous eruptions, sweating, photosensitivity, abnormal hair growth

**Other:** altered taste, chills, fever, edema

### Interactions

**Drug-drug.** CNS depressants: increased CNS depression

*Estrogen:* increased risk of hepatotoxicity

*Verapamil (I.V.):* cardiovascular collapse (when given with I.V. dantrolene)

**Drug-diagnostic tests.** Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen: increased values

**Drug-behaviors.** Alcohol use: increased CNS depression

*Sun exposure:* phototoxicity

### Patient monitoring

- Obtain baseline liver function test results; monitor periodically during therapy.
- Monitor ECG, serum electrolytes, and urine output regularly.
- With long-term oral therapy, monitor patient for signs and symptoms of hepatotoxicity. Be prepared to discontinue drug if these occur.
- Assess for muscle weakness, poor coordination, and reduced reflexes before and during therapy. Drug may weaken muscles and impair ambulation.

### Patient teaching

- Instruct patient receiving prolonged oral therapy to immediately report weakness, malaise, fatigue, nausea, rash, itching, severe diarrhea, bloody or black tarry stools, or yellowing of skin or eyes.
- Inform patient that drug may cause drowsiness, dizziness, or light-headedness.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

---

**darbepoetin alfa**

**Aranesp**

**Pharmacologic class:** Recombinant human erythropoietin

**Therapeutic class:** Hematopoietic

**Pregnancy risk category C**
FDA BOXED WARNING

- Use lowest dose that will increase hemoglobin gradually to lowest level sufficient to avoid need for red blood cell (RBC) transfusion.
- Drug increases risk of death and serious cardiovascular events when given to target hemoglobin level above 12 g/dL.
- In patients receiving radiation therapy for advanced head and neck cancer, drug shortens time to tumor progression when given to target hemoglobin level above 12 g/dL.
- In patients receiving chemotherapy for metastatic breast cancer, drug shortens overall survival and increases deaths from disease progression at 4 months when given to target hemoglobin level above 12 g/dL.
- In patients with active cancer who are receiving neither chemotherapy nor radiation therapy, drug increases risk of death when given to target hemoglobin level of 12 g/dL. Drug isn’t indicated for these patients.
- Patients who received epoetin alfa preoperatively to reduce need for allogeneic RBC transfusion but weren’t receiving prophylactic anticoagulation had higher incidence of deep vein thrombosis. Dalteparin isn’t approved to reduce need for RBC transfusion.

Action
Stimulates erythropoiesis in bone marrow, increasing red blood cell production

Availability
Albumin solution for injection: 25 mcg/ml, 40 mcg/ml, 60 mcg/ml, 100 mcg/ml, 150 mcg/ml, 200 mcg/ml, 300 mcg/ml, 500 mcg/ml
Polysorbate solution for injection: 25 mcg/ml, 40 mcg/ml, 60 mcg/ml, 100 mcg/ml, 150 mcg/ml, 200 mcg/ml, 300 mcg/ml

Indications and dosages
> Anemia caused by chronic renal failure
Adults: Initially, 0.45 mcg/kg I.V. or subcutaneously as a single dose once weekly. Titrate dosage to maintain target hemoglobin concentration no higher than 12 g/dl. Adjust dosage no more often than once monthly.
> Chemotherapy-induced anemia in patients with nonmyeloid malignancies
Adults: 2.25 mcg/kg I.V. or subcutaneously q week. Titrate dosage to maintain target hemoglobin concentration no higher than 12 g/dl.

Contraindications
- Hypersensitivity to drug
- Uncontrolled hypertension

Precautions
Use cautiously in:
- anemia; thalassemia; porphyria; seizures; underlying hematologic disease, including hemolytic and sickle cell anemia
- pregnant or breastfeeding patients
- children.

Administration
- Give by subcutaneous or I.V. injection only.
- Don’t dilute or give with other drug solutions.
- Don’t shake. Vigorous shaking may denature drug, making it biologically inactive.
- Give single I.V. dose over 1 minute.
- Discard unused portion. (Drug contains no preservative.)

Route Onset Peak Duration
I.V., subcut. 2-6 wk Unknown Unknown

Adverse reactions
CNS: dizziness, headache, fatigue, weakness, seizures, transient ischemic attack, cerebrovascular accident

Reactions in bold are life-threatening.
CV: hypertension, hypotension, chest pain, peripheral edema, arrhythmias, heart failure, cardiac arrest, myocardial infarction, vascular access thrombosis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain
Metabolic: fluid overload
Musculoskeletal: myalgia; joint, back, and limb pain
Respiratory: cough, upper respiratory tract infection, dyspnea, bronchitis
Skin: pruritus
Other: fever, flulike symptoms, infection, pain at injection site

Interactions
None significant

Patient monitoring
- Assess hemoglobin concentration before starting therapy and then weekly during therapy.
- Observe closely for serious CNS and cardiovascular adverse reactions.
- Know that supplemental iron is recommended for patients with serum ferritin level below 100 mcg/ml or serum transferrin saturation below 20%.

Patient teaching
- Tell patient to report chest pain or other pain, muscle tremors, weakness, and cough or other respiratory symptoms.
- If patient will self-administer drug, tell him to follow exact directions for injection and needle disposal.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Advise patient to minimize GI upset by eating small, frequent servings of healthy food and drinking plenty of fluids.
- Tell patient he'll undergo frequent blood testing during therapy to help determine correct dosage.
- As appropriate, review all other significant and life-threatening adverse reactions.

---

darifenacin hydrobromide
Emselex®, Enablex

Pharmacologic class: Anticholinergic
Therapeutic class: Renal and genitourinary agent
Pregnancy risk category C

Action
Competitively antagonizes muscarinic receptors, reducing contractions of urinary bladder smooth muscle

Availability
Tablets (extended-release): 7.5 mg, 15 mg

Indications and dosages
➣ Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency
Adults: Initially, 7.5 mg P.O. daily; may increase to 15 mg P.O. daily as early as 2 weeks after therapy begins

Dosage adjustment
- Moderate hepatic impairment
- Concurrent use of potent CYP3A4 inhibitors (such as clarithromycin, itraconazole, ketoconazole, nefazodone, nelfinavir, and ritonavir)

Contraindications
- Hypersensitivity to drug or its components
- Urinary retention, gastric retention, uncontrolled angle-closure glaucoma, or increased risk for these conditions
Precautions
Use cautiously in:
- decreased GI motility (such as severe constipation, ulcerative colitis, or myasthenia gravis), controlled angle-closure glaucoma, hepatic impairment
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

Administration
- Administer tablets whole with liquid (with or without food) once daily.
- Make sure patient doesn’t chew, crush, or divide them.
- Know that drug isn’t recommended for patients with severe hepatic impairment.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>5.2-7.6 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, asthenia
CV: hypertension
EENT: dry eyes, abnormal vision, dry throat, bronchitis, pharyngitis, rhinitis, sinusitis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, dry mouth
GU: urinary tract infection or disorder, vaginitis
Musculoskeletal: back pain, arthralgia
Skin: dry skin, rash, pruritus
Other: abnormal taste, weight gain, accidental injury, flulike syndrome, pain, peripheral edema, heat prostration

Interactions
Drug-drug. Anticholinergics: increased frequency or severity of adverse reactions
CYP4502D6 inhibitors: increased darifenacin exposure and blood level
Drugs metabolized by CYP2D6 (such as flecainide, thioridazine, and tricyclic antidepressants): increased blood levels of these drugs

Patient monitoring
- Monitor liver function tests frequently; withdraw drug if liver function tests show severe hepatic impairment.
- Monitor urinary function periodically.

Patient teaching
- Instruct patient to take tablets whole with liquid, with or without food. Tell him not to chew, divide, or crush them.
- Inform patient that some over-the-counter products such as antihistamines may increase risk of side effects.
- Caution patient that drug may cause heat prostration; describe signs and symptoms.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

Darunavir ethanolate
Prezista
Pharmacologic class: Protease inhibitor
Therapeutic class: Antiretroviral
Pregnancy risk category B

Action
Inhibits human immunodeficiency virus-1 (HIV-1) protease, preventing formation of mature virus particles

Availability
Tablets: 300 mg

Indications and dosages
HIV infection in adults who’ve previously received antiretrovirals
Adults: 600 mg (two 300-mg tablets) P.O. twice daily, taken with ritonavir or other antiretrovirals
Contraindications
- Hypersensitivity to drug or its components (including sulfa)
- Concurrent administration with drugs highly dependent on CYP3A for clearance and for which elevated levels are linked to serious or life-threatening events (including astemizole, cisapride, dihydroergotamine, ergonovine, ergotamine, methylergonovine, midazolam, pimozide, terfenadine, and triazolam)

Precautions
Use cautiously in:
- diabetes mellitus, hemophilia, hepatic dysfunction or disease
- concurrent use of carbamazepine, lovastatin, phenobarbital, phenytoin, rifampin, simvastatin, or St. John’s wort (use not recommended)
- elderly patients
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

Administration
- Give twice daily with ritonavir and food.
- Don’t give concurrently with astemizole, cisapride, dihydroergotamine, ergonovine, ergotamine, methylergonovine, midazolam, pimozide, terfenadine, or triazolam.

Adverse reactions
CNS: asthenia, fatigue, headache, transient ischemic attack, confusion, disorientation, anxiety, irritability, altered mood, memory impairment, vertigo, rigors, peripheral neuropathy, paresthesia, hypoesthesia, somnolence, nightmares
CV: tachycardia, hypertension, myocardial infarction
EENT: nasopharyngitis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, abdominal distention, flatulence, dry mouth, anorexia
GU: renal insufficiency, nephrolithiasis, polyuria, gynecomastia, acute renal failure
Metabolic: diabetes mellitus, polydipsia, obesity
Musculoskeletal: arthralgia, myalgia, extremity pain, osteopenia, osteoporosis
Respiratory: dyspnea, cough
Skin: allergic dermatitis, eczema, inflammation, toxic skin eruption, dermatitis medicamentosa, hyperhidrosis, folliculitis, maculopapular rash, alopecia, erythema multiforme, Stevens-Johnson syndrome
Other: body fat redistribution, lipoatrophy, decreased appetite, hiccups, pyrexia, night sweats, hyperthermia, peripheral edema, immune reconstitution syndrome (inflammatory response to indolent or residual opportunistic infections)

Interactions
Drug-drug. Amiodarone, atorvastatin, bepridil, clarithromycin, cyclosporine, felodipine, fluticasone propionate (inhalement), lidocaine (systemic), nicardipine, nifedipine, pravastatin, quinidine, sildenafil, sirolimus, tacrolimus, taladafil, trazodone, vardenafl: increased blood levels of these drugs
Astemizole, cisapride, terfenadine: increased risk of serious or life-threatening reactions (such as arrhythmias)
Carbamazepine, dexamethasone (systemic), phenobarbital, phenytoin, rifampin: decreased darunavir blood level
Efavirenz: decreased blood levels of both drugs
Ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine): increased risk of acute ergot toxicity

Canada UK 🚫 Hazardous drug 🚫 High alert drug
Hormonal contraceptives: decreased ethinyl estradiol blood level; may decrease contraceptive efficacy

Itraconazole, ketoconazole: increased blood levels of these drugs and darunavir

Lopinavir/ritonavir, saquinavir: decreased effects of these drugs

Lovastatin, pimozide, simvastatin: increased risk of myopathy

Methadone, voriconazole, warfarin: decreased blood levels of these drugs

Midazolam, triazolam: increased risk of respiratory depression or increased sedation

Paroxetine, sertraline: decreased effects of these drugs

Rifabutin: increased rifabutin blood level, decreased darunavir blood level (when given with ritonavir)

Voriconazole: decreased voriconazole and increased darunavir blood levels

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, gamma-glutamyltransferase, lipase, lipids, partial thromboplastin time, plasma prothrombin time, total cholesterol, triglycerides, uric acid: increased levels

Bicarbonate, calcium, lymphocytes, platelets, total absolute neutrophils, white blood cells: decreased levels

Bilirubin, serum glucose, sodium: increased or decreased levels

Drug-food. Any food: increased drug absorption

Drug-herbs. St. John’s wort: decreased darunavir blood level

Patient monitoring

- During initial treatment phase, stay alert for immune reconstitution syndrome.
- Monitor liver function studies frequently in patients with preexisting hepatic dysfunction or disease.
- Monitor blood glucose levels frequently in patients with diabetes mellitus.

- Carefully monitor patient receiving antiarrhythmics and HMG-CoA reductase inhibitors while taking this drug.
- Monitor International Normalized Ratio when giving drug with warfarin.

Patient teaching

- Instruct patient to take drug with ritonavir and food, as prescribed.
- Advise patient to inform prescriber of other drugs and supplements he’s taking (including vitamins and herbs) before starting drug or taking new medication.
- Urge patient to immediately report side effects (especially rash).
- Emphasize that drug doesn’t cure HIV infection.
- Advise patient using hormonal contraceptives to use alternative contraceptive method while taking this drug.
- Advise patients who are pregnant or recently gave birth not to breastfeed because of risk of passing HIV infection to infant and potentially serious adverse drug reactions.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

Reactions in bold are life-threatening.

Clinical alert
overexpressing BCR-ABL; this inhibition allows bone marrow to resume production of normal red cells, white cells, and platelets.

**Availability**

_Tables:_ 20 mg, 50 mg, 70 mg, 100 mg (film-coated)

**Indications and dosages**

- Chronic phase of CML in patients with resistance or intolerance to prior therapy, including imatinib
  
  **Adults:** 100 mg P.O. daily in morning or evening

- Accelerated or myeloid or lymphoid blast phase CML in patients with resistance or intolerance to prior therapy, including imatinib; Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) in patients with resistance or intolerance to prior therapy
  
  **Adults:** 140 mg P.O. daily in two divided doses (70 mg b.i.d.) in morning and evening

**Dosage adjustment**

- Myelosuppression

**Contraindications**

None

**Precautions**

Use cautiously in:

- hepatic impairment

- myelosuppression

- concomitant use of anticoagulants, aspirin, or NSAIDs

- patients at risk for fluid retention or QT interval prolongation (including those with hypokalemia, hypomagnesemia, or congenital long-QT syndrome; those taking antiarrhythmics or other drugs that lead to QT prolongation; and cumulative high-dose anthracycline therapy)

- concurrent use of drugs that inhibit platelet function or anticoagulants

- pregnant or breastfeeding patients

- children younger than age 18 (safety and efficacy not established).

**Administration**

- Correct hypokalemia or hypomagnesemia before starting drug.

- Know that patients with CML or Ph+ ALL should have shown resistance to or intolerance of imatinib mesylate.

- Don’t crush or cut tablets. Administer whole with or without food, but not with grapefruit juice.

- If tablets are inadvertently crushed or broken, wear disposable chemotherapy gloves. Pregnant personnel should avoid exposure to crushed or broken tablets.

- If patient needs antacid, give antacid at least 2 hours before or 2 hours after dasatinib.

- Know that hematopoietic growth factor may be used in patients with resistant myelosuppression.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>0.5-6 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

_CNS:_ headache, fatigue, asthenia, neuropathy, peripheral neuropathy, dizziness, somnolence, insomnia, depression, malaise, **CNS bleeding**

_CV:_ palpitations, flushing, hypertension, **prolonged QT interval, congestive heart failure, pericardial effusion, arrhythmia**

_EENT:_ visual disorder, dry eye

_GI:_ diarrhea, nausea, vomiting, mucositis, stomatitis, dyspepsia, abdominal distention, constipation, gastritis, oral soft-tissue disorder, colitis, enterocolitis, anorexia, appetite disturbances, dysphagia, abdominal pain, anal fissure, upper GI ulcer, esophagitis

_Hematologic:_ myelosuppression (anemia, neutropenia, thrombocytopenia,
pancytopenia), febrile neutropenia, hemorrhage, GI bleeding
Metabolic: fluid retention
Musculoskeletal: arthralgia, myalgia, inflammation, weakness
Respiratory: dyspnea, upper respiratory tract infection, pneumonia, pneumonitis, cough, lung infiltration, pleural effusion, pulmonary edema, pulmonary hypertension
Skin: rash, pruritus, acne, alopecia, dry skin, hyperhidrosis, urticaria, dermatitis
Other: fever, chills, infection, herpesvirus infection, ascites, generalized edema, pain, chest pain, dysgeusia, weight changes, temperature intolerance, contusion, sepsis

Interactions
Drug-drug. Antacids: reduced dasatinib plasma concentration
Anticoagulants, platelet inhibitors (such as aspirin, NSAIDs): increased risk of bleeding
CYP3A4 substrates with narrow therapeutic index (such as alfentanil, astemizole, cisapride, cyclosporine, ergot alkaloids, fentanyl, pimozide, quinidine, simvastatin, sirolimus, tacrolimus, terfenadine): potentially increased concentration of these drugs
H₂ antagonists or proton-pump inhibitors (such as famotidine, omeprazole), strong CYP3A4 inducers (such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifabutin, rifampin: reduced dasatinib blood level
Strong CYP3A4 inhibitors (such as atazanavir, clarithromycin, indinavir,itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole): increased dasatinib blood level

Drug-diagnostic tests. Calcium, neutrophils, phosphorus, platelets: decreased levels
ALT, AST, bilirubin, creatinine: increased levels

Drug-food. Grapefruit juice: increased dasatinib blood level
Drug-herbs. St. John’s wort: unpredictable decrease in dasatinib blood level

Patient monitoring
Monitor patient for QT prolongation and hemorrhage.
- Be aware that severe thrombocytopenia, neutropenia, and anemia are more common in patients with advanced-phase CML or Ph+ ALL than in those with chronic-phase CML. Monitor complete blood count weekly for first 2 months and then monthly thereafter, or as indicated.
- Monitor hepatic function tests.
- Be prepared to manage transaminase or bilirubin elevations with dosage reduction or therapy interruption.
- Stay alert for fluid retention. Be prepared to manage with supportive care measures, such as diuretics or short courses of steroids.
- Monitor calcium levels. Some patients who develop Grade 3 or 4 hypocalcemia during therapy may recover with oral calcium supplementation.

Patient teaching
- Instruct patient to take tablet whole with or without food. Caution patient not to break, crush, or cut tablet.
- Advise patient to avoid grapefruit juice.
- Instruct patient to immediately report fever or chills (and other signs or symptoms of infection), unusual bleeding or bruising, shortness of breath, swelling, or weight gain.
- Instruct patient to report troublesome nausea, vomiting, diarrhea, headache, musculoskeletal pain, fatigue, or rash.

Reactions in bold are life-threatening.
- Teach patient that drug may increase risk of infection. Advise patient to wash hands frequently, wear a mask in public places, and avoid people with infections.
- Inform lactose-intolerant patient that drug contains lactose.
- Advise patient to avoid St. John’s wort, NSAIDs (such as ibuprofen), and over-the-counter drugs that contain aspirin during therapy.
- Advise female patient that drug may harm fetus. Caution her to avoid becoming pregnant. If drug is used during pregnancy or patient becomes pregnant while taking it, inform her of potential hazard to fetus.
- Advise breastfeeding patient to discuss with prescriber whether to discontinue breastfeeding or drug, taking into account importance of drug to mother.
- Advise male taking drug to use condom, to avoid getting partner pregnant.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, food, and herbs mentioned above.

**daunorubicin citrate liposome**

*DaunoXome*

**Pharmacologic class:** Anthracycline glycoside  
**Therapeutic class:** Antibiotic antineoplastic  
**Pregnancy risk category D**

**FDA BOXED WARNING**

- Monitor cardiac function regularly during therapy, because of potential cardiotoxicity and congestive heart failure. Also monitor cardiac function in patients who have cardiac disease or received previous anthracyclines.
- Severe myelosuppression may occur.
- Give under supervision of experienced physician.
- Reduce dosage in patients with hepatic impairment.
- Drug may cause triad of back pain, flushing, and chest tightness. Triad usually occurs within first 5 minutes of infusion, subsides with infusion interruption, and doesn’t recur when infusion resumes at slower rate.

**Action**

Inhibits DNA synthesis and DNA-dependent RNA synthesis through intercalation. Formulation increases selectivity of daunorubicin for solid tumors; may increase permeability of tumor neovasculature to some particles in drug’s size range.

**Availability**

*Injection:* 2 mg/ml

**Indications and dosages**

- First-line cytotoxic therapy for advanced Kaposi’s sarcoma associated with human immunodeficiency virus (HIV)
- **Adults:** 40 mg/m² I.V. over 1 hour. Repeat q 2 weeks until evidence of disease progression or other complications occur.

**Dosage adjustment**

- Renal or hepatic impairment

**Contraindications**

- Hypersensitivity to drug

**Precautions**

Use cautiously in:
- renal or hepatic impairment, bone marrow depression, cardiac disease, gout, infections
- pregnant or breastfeeding patients.
**Administration**
- Follow facility policy for preparing and handling antineoplastics.
- Dilute 1:1 with 5% dextrose injection.
- Don’t use in-line filter for I.V. infusion.
- If prescribed, premedicate with allopurinol to help prevent hyperuricemia.
- Take steps to prevent extravasation.
- Protect solution from light.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** headache, fatigue, malaise, confusion, depression, dizziness, drowsiness, emotional lability, anxiety, hallucinations, syncope, tremors, rigors, insomnia, neuropathy, amnesia, hyperactivity, abnormal thinking, meningitis, seizures

**CV:** hypertension, chest pain, palpitations, myocardial infarction, cardiac arrest

**EENT:** abnormal vision, conjunctivitis, eye pain, hearing loss, earache, tinnitus, rhinitis, sinusitis

**GI:** nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, gastritis, enlarged spleen, fecal incontinence, hemorrhoids, tenesmus, melena, difficulty swallowing, dry mouth, mouth inflammation, GI hemorrhage

**GU:** dysuria, nocturia, polyuria

**Hematologic:** thrombocytopenia, neutropenia

**Hepatic:** hepatomegaly

**Metabolic:** hyperuricemia, dehydration

**Musculoskeletal:** joint pain, myalgia, muscle rigidity, back pain, abnormal gait

**Respiratory:** dyspnea, cough, hemoptysis, increased sputum, pulmonary infiltrations, pulmonary hypertension

**Skin:** pruritus, dry skin, seborrhea, folliculitis, alopecia, sweating

**Other:** bleeding gums, dental caries, altered taste, lymphadenopathy, opportunistic infections, fever, hot flashes, hiccups, thirst, infusion site inflammation, edema, allergic reactions

**Interactions**

**Drug-diagnostic tests.** *Granulocytes:* decreased count  
*Uric acid:* increased level

**Patient monitoring**
- Assess cardiac, renal, and hepatic function before each course of treatment.
- Determine left ventricular ejection fraction before and during therapy.
- Evaluate CBC with white cell differential before each dose. Withhold dose if granulocyte count is below 750 cells/mm³.
- Monitor serum uric acid level.

**Patient teaching**
- Instruct patient to immediately report swelling, pain, burning, or redness at infusion site, as well as persistent nausea, vomiting, diarrhea, chest pain, arm or leg swelling, difficulty breathing, palpitations, rapid heartbeat, yellowing of skin or eyes, abdominal pain, or bloody stools.
- Tell patient drug makes him more susceptible to infection. Advise him to avoid crowds and exposure to illness.
- Advise patient to minimize GI upset by eating small, frequent servings of healthy food, drinking plenty of fluids, and chewing gum.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

Reactions in **bold** are life-threatening.
daunorubicin hydrochloride
Cerubidine

**Pharmacologic class:** Anthracycline glycoside

**Therapeutic class:** Antibiotic anti-neoplastic

**Pregnancy risk category D**

---

**FDA BOXED WARNING**

- Administer into rapidly flowing I.V. infusion; never give I.M. or subcutaneously. Severe local tissue necrosis results if extravasation occurs.
- Myocardial toxicity (manifested most severely as potentially fatal congestive heart failure) may occur during therapy or months to years afterward. Incidence increases with total cumulative dose exceeding 550 mg/m² in adults, 300 mg/m² in children older than age 2, or 10 mg/kg in children younger than age 2.
- Therapeutic doses cause severe myelosuppression. Drug should be given only by physician experienced in leukemia chemotherapy, in facility with adequate diagnostic and treatment resources for monitoring drug tolerance and treating toxicity. Physician and facility must be capable of responding rapidly and completely to severe hemorrhagic conditions and overwhelming infection.
- Reduce dosage in patients with hepatic or renal impairment.

---

**Action**

Antimitotic and cytotoxic. Forms complexes with DNA by intercalation between base pairs. Inhibits topoisomerase II activity by stabilizing topoisomerase II complex; causes breaks in single- and double-stranded DNA. May also inhibit polymerase activity, influence regulation of gene expression, and cause free radical damage to DNA.

**Availability**

*Injection:* 5 mg/ml

*Lyophilized powder for injection:* 21.4 mg, 53.5 mg

---

**Indications and dosages**

**Acute nonlymphocytic leukemia**

- **Adults older than age 60:** 30 mg/m²/day I.V. on days 1, 2, and 3 of first course and on days 1 and 2 of subsequent courses; given with cytarabine I.V. infusion (7 days for first course, 5 days for subsequent courses)
- **Adults younger than age 60:** 45 mg/m²/day I.V. on days 1, 2, and 3; given with cytarabine I.V. infusion (7 days for first course, 5 days for subsequent courses)

**Acute lymphocytic leukemia**

- **Adults:** 45 mg/m²/day I.V. on days 1, 2, and 3; vincristine I.V. on days 1, 8, and 15; prednisone P.O. on days 1 through 22, then tapered between days 22 and 29; then asparaginase I.V. on days 22 to 32
- **Children ages 2 and older:** 25 mg/m²/day I.V. on first day every week; may be given in combination with vincristine I.V. on first day every week and prednisone P.O. daily

---

**Dosage adjustment**

- Renal or hepatic impairment

---

**Contraindications**

- Hypersensitivity to drug

---

**Precautions**

Use cautiously in:

- renal or hepatic impairment, bone marrow depression, cardiac disease, gout, infections
- elderly patients
- pregnant or breastfeeding patients.
**Administration**
- Follow facility policy for preparing and handling antineoplastics.
- If prescribed, premedicate with allopurinol to help prevent hyperuricemia.
- Give by I.V. route only.
- Reconstitute vial contents with 4 ml of sterile water for injection to yield 5 mg/ml solution.
- Don’t mix with other drugs or heparin.
- Withdraw desired dosage into syringe containing 10 to 15 ml of normal saline solution; then inject into tubing or sidearm of compatible, rapidly flowing I.V. solution over 3 to 5 minutes. For intermittent infusion, mix with 100 ml of normal saline solution and infuse over 30 to 45 minutes.
- Take care to prevent extravasation, because drug causes severe local tissue necrosis. If extravasation occurs, stop infusion immediately; according to facility policy, intervene to avoid severe tissue necrolysis, severe cellulitis, thrombophlebitis, and painful induration.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- CV: cardiotoxicity
- GI: acute nausea, vomiting, GI mucosal inflammation
- GU: urine discoloration
- Hematologic: bone marrow depression
- Metabolic: hyperuricemia
- Skin: rash, contact dermatitis, urticaria, reversible alopecia

**Interactions**
- Drug-drug. Other antineoplastic, hepatotoxic, or myelosuppressive drugs: increased risk of toxicity
- Drug diagnostic tests. Granulocytes: decreased count
- Uric acid: increased level

**Patient monitoring**
- Observe I.V. site closely for extravasation.
- Monitor cardiac, renal, and hepatic function before each course of treatment.
- Evaluate CBC with white cell differential before each dose. Withhold dose if granulocyte count is below 750 cells/mm³.
- Monitor serum uric acid level.

**Patient teaching**
- Instruct patient to immediately report swelling, pain, burning, or redness at infusion site, as well as persistent nausea, vomiting, diarrhea, bloody stools, abdominal or chest pain, swollen arm or leg, difficulty breathing, palpitations, rapid heartbeat, or yellowing of skin or eyes.
- Inform patient that drug makes him more susceptible to infection. Caution him to avoid crowds and exposure to illness.
- Advise patient to minimize GI upset by eating small, frequent servings of healthy food, drinking plenty of fluids, and chewing gum.
- Tell patient that drug may redden his urine.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**deferasirox**

**Exjade**

**Pharmacologic class**: Iron-chelating agent

**Therapeutic class**: Antidote

**Pregnancy risk category B**

Reactions in bold are life-threatening.
**Action**
Binds selectively to iron

**Availability**
*Tablets for oral suspension:* 125 mg, 250 mg, 500 mg

**Indications and dosages**
- **Chronic iron overload caused by blood transfusions**
  - **Adults and children ages 2 and older:** Initially, 20 mg/kg (calculated to nearest whole tablet) P.O. daily on empty stomach at least 30 minutes before a meal, preferably at same time each day. Don’t exceed 30 mg/kg daily.

**Dosage adjustment**
- Serum creatinine elevation
- Severe, persistent liver enzyme elevations

**Contraindications**
- Hypersensitivity to drug or its components

**Precautions**
Use cautiously in:
- serum creatinine elevation, liver enzyme elevation, severe rash
- pregnant or breastfeeding patients.

**Administration**
- Make sure patient doesn’t swallow tablets whole.
- Disperse tablets completely in water, orange juice, or apple juice; have patient consume suspension immediately. If residue remains, resuspend it in small amount of liquid and have patient swallow it. Disperse doses lower than 1 g in 3.5 oz liquid; disperse doses higher than 1 g in 7 oz liquid.
- Adjust dosage every 3 to 6 months in increments of 5 to 10 mg/kg based on ferritin levels, treatment goals, and response.

**Route** | **Onset** | **Peak** | **Duration**
--- | --- | --- | ---
P.O. | Unknown | 1.5–4 hr | Unknown

**Adverse reactions**
- **CNS:** headache, fatigue, dizziness
- **EENT:** cataract, retinal disorder, increased intraocular pressure, ear infection, hearing loss, rhinitis, nasopharyngitis, pharyngolaryngeal pain, pharyngitis, acute tonsillitis
- **GI:** nausea, vomiting, diarrhea, abdominal pain
- **Musculoskeletal:** arthralgia, back pain
- **Respiratory:** cough, respiratory tract infection, bronchitis
- **Skin:** rash, urticaria
- **Other:** fever, influenza

**Interactions**
- **Drug-drug.** *Aluminum-containing antacids:* possible binding with antacid
- **Drug-diagnostic tests.** *Liver function tests, serum creatinine:* increased
- **Drug-food.** *Any food:* increased deferasirox bioavailability

**Patient monitoring**
- Perform baseline auditory and ophthalmic testing; repeat every 12 months.
- Monitor serum ferritin levels monthly.
- Monitor renal and hepatic function frequently.

**Patient teaching**
- Instruct patient to take drug on empty stomach at least 30 minutes before food, preferably at same time each day.
- Instruct patient to place tablets in water, orange juice, or apple juice and stir until completely dissolved. Tell him not to chew or swallow them.
- Advise patient not to take aluminum-containing antacids during therapy.
- Tell patient drug may cause vision and hearing disturbances, necessitating routine ophthalmic and auditory testing.
- Caution patient to avoid driving and other hazardous activities until drug effects are known.
- As appropriate, review all other significant adverse reactions and
interactions, especially those related to the drugs, tests, and foods mentioned above.

delavirdine mesylate
Rescriptor

**Pharmacologic class:** Nonnucleoside reverse transcriptase inhibitor

**Therapeutic class:** Antiretroviral

**Pregnancy risk category C**

**Action**
Binds to reverse transcriptase enzyme, blocking RNA-dependent and DNA-dependent DNA polymerase synthesis

**Availability**
*Tablets:* 100 mg, 200 mg

**Indications and dosages**
> Human immunodeficiency virus (HIV)–1 infection

**Adults:** 400 mg P.O. t.i.d.

**Contraindications**
- Hypersensitivity to drug
- Concurrent use of alprazolam, astemizole, ergot derivatives, midazolam, pimozide, terfenadine, or triazolam

**Precautions**
Use cautiously in:
- hepatic impairment
- pregnant or breastfeeding patients
- children younger than age 16 (safety and efficacy not established).

**Administration**
- Know that drug is usually given with at least two other antiretrovirals.
- If patient can’t swallow tablets, dissolve 100-mg tablets in water by adding four tablets to at least 3 oz of water; let stand for a few minutes and then stir until completely dissolved. Have patient swallow entire mixture immediately. Then add small amount of water to glass and have him swallow this mixture to ensure that he consumes entire dose.
- Give 200-mg tablets intact; don’t dissolve in water.
- If patient has achlorhydria, give drug with acidic beverage, such as orange juice.

> Don’t give concurrently with alprazolam, astemizole or terfenadine (no longer available in U.S.), ergot derivatives, midazolam, pimozide, or triazolam.

**Route Onset Peak Duration**

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** confusion, disorientation, dizziness, drowsiness, agitation, amnesia, changes in dreams, hallucinations, hyperesthesia, poor concentration, mania, nervousness, restlessness, para-noia, paresthesia, tremor, migraine, neuropathy, paralysis, **seizures**

**CV:** abnormal heart rate and rhythm, peripheral vascular disorder, peripheral edema, hypertension, orthostatic hypotension, cardiac insufficiency, **cardiomyopathy**

**EENT:** blurred or double vision, nystagmus, conjunctivitis, dry eyes, scleral yellowing, ear pain, otitis media, tinnitus, epistaxis, rhinitis

**GI:** nausea, diarrhea, constipation, abdominal pain or cramps, dyspepsia, abdominal distention, bloody stools, colitis, diverticulitis, enteritis, gastro-enteritis, gastroesophageal reflux, mouth and tongue irritation and ulcers, increased saliva, difficulty swallowing, **GI bleeding, pancreatitis**

**GU:** hematuria, polyuria, chromaturia, proteinuria, nocturia, urinary tract infection, renal calculi, kidney pain, gynecmastia, erectile dysfunction, epididymitis, hemospermia, testicular

Reactions in **bold** are life-threatening.

**Clinical alert**
pain, vaginal candidiasis, amenorrhea, irregular uterine bleeding

**Hematologic:** purpura, spleen disorders, eosinophilia, **granulocytosis,** disseminated intravascular coagulation, leukopenia, neutropenia, pancytopenia, hemolytic anemia

**Hepatic:** hepatotoxicity, hepatic failure, hepatomegaly

**Metabolic:** hypomagnesemia, hyperglycemia, hyperuricemia, hypocalemia, hyponatremia, hypoglycemia, hyperkalemia, metabolic acidosis

**Musculoskeletal:** joint pain, arthritis, bone disorders, myalgia, muscle cramps, muscle weakness, bone pain, bone disorders, tendon disorders, tenosynovitis, neck pain and rigidity, limb pain, tetany, rhabdomyolysis

**Respiratory:** pulmonary congestion, dyspnea, pneumonia

**Skin:** pallor, bruising, yellowing of skin, dermal leukocytoblastic vasculitis, dermatitis, skin dryness and discoloration, erythema, folliculitis, herpes zoster or herpes simplex infection, petechiae, pruritic rash, seborrhea, alopecia, skin nodules, urticaria, sebaceous or epidermal cyst, angioedema, **erythema multiforme**

**Other:** tooth abscess, toothache, gingivitis, gum hemorrhage, weight gain or loss, fever, lymphadenopathy, adenopathy, increased thirst, hiccups, facial edema, pain, abscess, bacterial infection, *Mycobacterium tuberculosis* infection, body fat redistribution, hypersensitivity reaction, sepsis, Stevens-Johnson syndrome

**Interactions**

**Drug-drug.** Alprazolam, astemizole, cisapride, ergot derivatives, midazolam, pimozide, terfenadine: increased risk of serious or life-threatening adverse reactions

Antacids, histamine₂-receptor antagonists: reduced delavirdine absorption

Bepridil, clarithromycin, estrogen, hormonal contraceptives, indinavir, lopinavir-ritonavir, saquinavir, sildenafil, warfarin: increased blood levels of these drugs

Carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin: loss of virologic response, resistance to delavirdine

Cholesterol-lowering HMG-CoA reductase inhibitors cleared by the CYP3A4 pathway: increased risk of myopathy and rhabdomyolysis

Dexamethasone: decreased delavirdine blood level

Didanosine: decreased blood levels of both drugs

Fluoxetine, ketoconazole: 50% increase in delavirdine blood level

**Drug-diagnostic tests.** Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, creatinine, lipase, gamma-glutamyl transpeptidase, triglycerides: increased levels

Granulocytes, hemoglobin, neutrophils, platelets, red blood cells, white blood cells: decreased values

Partial thromboplastin time, prothrombin time: increased

**Drug-herbs.** St. John’s wort: loss of virologic response or resistance to delavirdine

**Patient monitoring**

- Monitor liver function test results frequently when giving drug concurrently with saquinavir.
- Check electrolyte and uric acid levels regularly.
- Monitor patient for serious hepatic, cardiovascular, and CNS problems and hypersensitivity reactions.

**Patient teaching**

- Tell patient he can take drug with or without food.
- If patient can’t swallow tablets, teach him how to dissolve 100-mg tablets in water.
- Tell patient to discontinue drug and consult prescriber immediately if he develops severe rash accompanied...
by fever, blistering, oral lesions, conjunctivitis, swelling, or muscle aches.

Tell patient to promptly report unusual fatigue, yellowing of skin or eyes, unusual bruising or bleeding, muscle weakness, or signs and symptoms of infection.

Advise patient that rash is a major adverse effect, usually occurring 1 to 3 weeks after therapy starts and resolving in 3 to 14 days. Instruct him to report rash promptly.

- Inform patient that drug doesn’t cure HIV or reduce its transmission.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

---

**denileukin diftitox**

*Ontak*

**Pharmacologic class:** Biological response modifier

**Therapeutic class:** Antineoplastic

**Pregnancy risk category C**

---

**FDA BOXED WARNING**

- Give only under supervision of physician experienced in cancer chemotherapy, in facility equipped and staffed for cardiopulmonary resuscitation where patient can be monitored closely.

---

**Action**

Recombinant DNA–derived cytotoxic protein. Interacts with interleukin-2 (IL-2) receptors on cell surface and inhibits cellular protein synthesis, causing cell death.

**Availability**

*Frozen solution for injection:* 150 mcg/ml

---

**Indications and dosages**

- **Persistent or recurrent cutaneous T-cell lymphoma that expresses CD25 component of IL-2 receptor**

  **Adults:** 9 or 18 mcg/kg/day I.V. infused over 15 minutes for 5 consecutive days q 21 days

**Contraindications**

- Hypersensitivity to drug, its components, diphtheria toxin, or IL-2

**Precautions**

Use cautiously in:

- cardiovascular disease
- elderly patients
- pregnant or breastfeeding patients
- children (safety and efficacy not established)

**Administration**

- Follow facility procedures for safe handling, administration, and disposal of chemotherapeutic agents.
- Administer by I.V. infusion only. Don’t give by I.V. bolus.
- Dilute I.V. dose further with normal saline to concentration of at least 15 mcg/ml. Infuse over at least 15 minutes.
- Premedicate with acetaminophen, nonsteroidal anti-inflammatory drugs, and antihistamines, as ordered, to minimize infusion-related events.
- Gently swirl vial to mix, but avoid vigorous agitation.
- Don’t mix with other drugs.
- Don’t deliver through in-line filter.
- Infuse over at least 15 minutes.
- During infusion, observe closely for signs and symptoms of hypersensitivity reaction.

**Route** | **Onset** | **Peak** | **Duration**
--- | --- | --- | ---
I.V. | Variable | Variable | Variable

**Adverse reactions**

CNS: dizziness, paresthesia, nervousness, confusion, insomnia, syncope, headache

Reactions in **bold** are life-threatening.
CV: hypotension, hypertension, vasodilation, tachycardia, chest pain, capillary leak syndrome (with extravasation), thrombosis, arrhythmias
EENT: rhinitis, pharyngitis, laryngospasm
GI: nausea, vomiting, diarrhea, constipation, flatulence, dyspepsia, difficulty swallowing, anorexia
GU: hematuria, albuminuria, pyuria
Hematologic: anemia, thrombocytopenia, leukopenia
Musculoskeletal: myalgia, back or joint pain
Metabolic: hypoalbuminemia, hypocalcemia, hypokalemia, dehydration
Respiratory: dyspnea, cough, lung disorder
Skin: rash, pruritus, sweating
Other: weight loss, edema, flulike symptoms, injection site reaction, hypersensitivity reactions including anaphylaxis

Interactions
Drug-drug. Live-virus vaccines: decreased antibody reaction
Drug-diagnostic tests. Albumin, calcium, potassium: decreased levels
Urine creatinine: increased level

Patient monitoring
- Monitor patient closely during first infusion and for 24 hours afterward.
- Evaluate patient for vascular leak syndrome (marked by at least two of the following: edema, hypotension, hypoalbuminemia).
- Monitor CBC, blood chemistry panel, renal and hepatic function, and albumin level. Repeat all tests weekly during therapy.

Patient teaching
- Instruct patient to immediately report chest pain, difficulty breathing, chills, burning at infusion site, or throat tightness, redness, swelling, or pain.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Inform patient that drug makes him more susceptible to infection. Advise him to avoid crowds and exposure to illness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

---

desipramine hydrochloride

Apo-Desipramine®, Dom-Desipramine®, Norpramin, Novo-Desipramine®, Nu-Desipramine®, PHL-Desipramine®, PMS-Desipramine®, Ratio-Desipramine®

Pharmacologic class: Tricyclic antidepressant
Therapeutic class: Antidepressant
Pregnancy risk category C

FDA BOXED WARNING
- Drug may increase risk of suicidal thinking and behavior in children and adolescents with major depressive disorder and other psychiatric disorders. Risk must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family to observe patient closely and communicate with prescriber as needed.
- Drug isn’t approved for use in pediatric patients.
Action
Inhibits norepinephrine or serotonin reuptake at presynaptic neuron

Availability
Tablets: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg

Indications and dosages
➣ Depression
Adults: Initially, 100 to 200 mg/day P.O. Increase gradually if needed to a maximum dosage of 300 mg/day.
Adolescents and elderly adults: 25 to 100 mg/day P.O. as a single dose or in divided doses. Increase gradually if needed to a maximum dosage of 150 mg/day.

Off-label uses
● Arthritis pain
● Cancer pain
● Diabetic or peripheral neuropathy
● Tic douloureux

Contraindications
● Hypersensitivity to drug
● Recovery phase of myocardial infarction (MI)
● MAO inhibitor use within past 14 days

Precautions
Use cautiously in:
● cardiovascular disorders, glaucoma, thyroid disorders, history of seizure disorders, mania, hypomania, adults with major depressive disorder
● urinary retention
● adolescents and children.

Administration
● Before giving drug, measure patient’s sitting and supine blood pressure to assess for orthostasis.
● Give full dose at bedtime to avoid daytime drowsiness.
● Discontinue drug 2 days before surgery.

Don’t give within 14 days of MAO inhibitor, because potentially fatal reaction may occur.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>4-6 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: sedation, weakness, anxiety, restlessness, insomnia, delusions, confusion, agitation, hallucinations, disorientation, extrapyramidal reactions, EEG changes, neuroleptic malignant syndrome, seizures, suicidal behavior or ideation (especially in child or adolescent)
CV: hypotension, hypertension, tachycardia, palpitations, arrhythmias, MI, heart block
EENT: blurred vision, dry eyes, laryngitis
GI: nausea, vomiting, constipation, abdominal cramps, epigastric distress, difficulty swallowing, parotid gland swelling, mouth inflammation, dry mouth, black tongue
GU: urinary retention, delayed voiding, urinary tract dilation, testicular swelling, erectile or other male sexual dysfunction, gynecomastia, menstrual irregularities, galactorrhea, increased or decreased libido
Hematologic: purpura, eosinophilia, bone marrow depression, agranulocytosis, thrombocytopenia
Metabolic: syndrome of inappropriate antidiuretic hormone secretion
Musculoskeletal: muscle weakness
Skin: dry skin, photosensitivity, rash, pruritus, petechiae, sweating
Other: peculiar taste, weight gain, edema, hypothermia, flushing, withdrawal symptoms with abrupt drug cessation (dizziness, nausea, vomiting, headache, malaise, sleep disturbances, hyperthermia, irritability, worsening of depression), sudden death (in children)

Reactions in bold are life-threatening.

Clinical alert
Interactions

**Drug-drug.** Adrenergics, anticholinergics: additive adrenergic or anticholinergic effects

- Cimetidine, phenothiazines, quinidine, selective serotonin reuptake inhibitors: increased desipramine effects, possible toxicity
- Clonidine: hypertensive crisis
- CNS depressants (antihistamines, opioid analgesics, sedative-hypnotics): additive CNS depression
- MAO inhibitors: hyperpyretic crisis, severe seizures, death
- Sparfloxacin: increased risk of adverse cardiovascular reactions

**Drug-diagnostic tests.** Glucose: increased or decreased level

**Drug-food.** Grapefruit juice: increased drug blood level and effects

**Drug-herbs.** Chamomile, hops, kava, skullcap, valerian: increased CNS depression
- S-adenosylmethionine (SAM-e), St. John’s wort: adverse serotonergic effects, including serotonin syndrome

**Drug-behaviors.** Alcohol use: increased response to alcohol
- Smoking: increased metabolism and decreased efficacy of desipramine

Patient monitoring

- Assess for suicidal tendencies before starting therapy.
- Monitor blood glucose level and CBC with white cell differential during therapy.
- Watch for severe CNS, cardiovascular, and hematologic adverse reactions.

Patient teaching

- Tell patient to take full dose at bedtime to avoid daytime drowsiness.
- Urge patient to promptly report chest pain or easy bruising or bleeding.
- Inform patient that desired therapeutic effect may take 2 to 3 weeks.

---

**desloratadine**

Aerius®, Clarinex, Clarinex RediTabs, Neoclarityn®

**Pharmacologic class:** Peripherally selective piperidine, selective histamine₁-receptor antagonist

**Therapeutic class:** Antihistamine (nonsedating, second generation)

**Pregnancy risk category C**

**Action**

Suppresses histamine release at peripheral histamine₁-receptor sites

**Availability**

- **Syrup:** 2.5 mg/5 ml
- **Tablets:** 5 mg
- **Tablets (orally disintegrating):** 2.5 mg, 5 mg

**Indications and dosages**

- Seasonal and perennial allergic rhinitis; chronic idiopathic urticaria and allergies caused by indoor and outdoor allergens; pruritus; to reduce number and size of hives

**Adults and children ages 12 and older:** 5 mg/day P.O.

**Children ages 6 to 11:** 1 tsp (2.5 mg/5 ml syrup) P.O. once daily

---

- Canada
- UK
- Hazardous drug
- High alert drug
Children ages 12 months to 5 years: ½ tsp (1.25 mg in 2.5 ml syrup) P.O. once daily

Children ages 6 to 11 months: 2 ml (1 mg syrup) P.O. once daily

**Dosage adjustment**
- Hepatic or renal impairment

**Contraindications**
- Hypersensitivity to drug, its components, or loratadine

**Precautions**
Use cautiously in:
- renal or hepatic impairment
- elderly patients
- pregnant or breastfeeding patients
- children younger than age 12 (safety and efficacy not established, except syrup).

**Administration**
- Give with or without food.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1 hr</td>
<td>3 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
CNS: dizziness, drowsiness, fatigue, headache
CV: tachycardia, palpitations
EENT: pharyngitis, dry throat
GI: nausea, dyspepsia, dry mouth
GU: dysmenorrhea
Musculoskeletal: myalgia
Other: flulike symptoms, hypersensitivity reaction

**Interactions**
**Drug-diagnostic tests.** Bilirubin, hepatic enzymes: increased values
Skin tests: interference with positive reaction to dermal reactivity indicators

**Patient monitoring**
- Monitor hepatic and renal function test results.

---

**Patient teaching**
- Tell patient he may take drug with or without food.
- Instruct patient to report rapid heartbeat, shortness of breath, rash, persistent flulike symptoms, or muscle ache.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the tests mentioned above.

**desmopressin acetate**
(1-deamino-8-D-arginine vasopressin)
Apo-Desmopressin®, DDAVP, DesmO-Melt®, DesmoSpray®, Minirin, Stimate

**Pharmacologic class:** Posterior pituitary hormone
**Therapeutic class:** Antidiuretic hormone
**Pregnancy risk category B**

**Action**
Enhances water reabsorption by increasing permeability of renal collecting ducts to adenosine monophosphate and water, thereby reducing urinary output and increasing urine osmolality. Also increases factor VIII (antihemophilic factor) activity.

**Availability**
Injection: 4 mcg/ml in single-dose 1-ml ampules and multidose 10-ml vials
Intranasal solution: 0.1 mg/ml, 1.5 mg/ml
Intranasal spray (DDAVP): 0.1 mg/ml (10 mcg/spray) in 5-ml spray pump bottle
Tablets: 0.1 mg, 0.2 mg

Reactions in **bold** are life-threatening.
Indications and dosages

Diabetes insipidus

Adults and children older than age 12:
0.05 mg P.O. b.i.d.; adjust dosage based on patient response. Or 0.1 to 0.4 ml (10 to 40 mcg) daily intranasally as a single dose or in two or three divided doses. Or 0.5 ml (2 mcg) to 1 ml (4 mcg) daily I.V. or subcutaneously, usually in two divided doses.

Children ages 3 months to 12 years:
0.05 to 0.3 ml/day intranasally in one or two divided doses

Hemophilia A; von Willebrand’s disease type I

Adults and children: 0.3 mcg/kg I.V.; may repeat dose if needed. Or 300 mcg of intranasal solution containing 1.5 mcg/ml; for patients weighing less than 50 kg (110 lb), total dosage of 150 mcg (one spray of solution containing 1.5 mcg/ml into a single nostril) is usually sufficient. If needed to maintain hemostasis during surgery, give intranasal dose 2 hours before surgery or give I.V. dose 30 minutes before surgery.

Off-label uses

- Chronic autonomic failure (such as nocturnal polyuria, overnight weight loss, morning orthostatic hypotension)

Contraindications

- Hypersensitivity to drug
- Moderate to severe renal impairment
- Hemophilia A with factor VIII levels less than or equal to 5%
- Von Willebrand’s disease type IIB
- Impaired level of consciousness (intranasal form)

Precautions

Use cautiously in:
- coronary artery disease, hypertensive cardiovascular disease, fluid and electrolyte imbalances
- breastfeeding patients.

Administration

- Adjust morning and evening dosages as appropriate to minimize frequent urination and risk of water intoxication.
- Give I.V. dose (diluted in normal saline solution) by infusion over 15 to 30 minutes.
- Monitor pulse and blood pressure throughout I.V. infusion

When giving to child with diabetes insipidus, carefully restrict fluid intake to prevent hyponatremia and water intoxication.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1 hr</td>
<td>1-5 hr</td>
<td>8-12 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>15-30 min</td>
<td>Unknown</td>
<td>4-12 hr</td>
</tr>
<tr>
<td>Intranasal</td>
<td>1 hr</td>
<td>1-1.5 hr</td>
<td>8-12 hr</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: headache, dizziness, insomnia
CV: slight blood pressure increase, chest pain, palpitations
EENT: rhinitis, epistaxis, sore throat
GI: nausea, abdominal pain
GU: vulvar pain
Respiratory: cough
Other: local erythema, flushing, swelling or burning after injection

Interactions

Drug-drug. Carbamazepine, chlorpropanide, pressor drugs: potentiation of desmopressin effects

Patient monitoring

- Monitor urine volume and specific gravity, plasma and urine osmolality, and electrolyte levels in patients with diabetes insipidus.
- Monitor factor VIII antigen levels, activated partial thromboplastin time, and bleeding time in patients with hemophilia.

When giving to child with diabetes insipidus, carefully monitor fluid intake and output.
Patient teaching

- Instruct patient to take drug exactly as prescribed and not to interchange strengths or delivery systems.
- Teach patient how to use prescribed delivery system if taking drug by other than oral route.
- Instruct patient with diabetes insipidus to avoid overhydration and to weigh himself daily. Tell him to report weight gain or swelling of arms or legs.
- If patient is using nasal spray, teach him to inspect nasal membranes regularly and to report increased nasal congestion or swelling.
- Caution elderly patient not to increase fluid intake beyond that sufficient to satisfy thirst.
- Instruct patient to report headache, respiratory difficulty, nausea, or abdominal pain to prescriber.
- As appropriate, review all significant adverse reactions and interactions, especially those related to the drugs mentioned above.

FDA BOXED WARNING

- Drug may increase risk of suicidal thinking and behavior in children and adolescents with major depressive disorder and other psychiatric disorders. Risk must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family and caregivers to observe patient closely and communicate with prescriber as needed.
- Drug isn’t approved for use in children.

Action

Potentiates serotonin and norepinephrine in CNS

Availability

Tablets (extended-release): 50 mg, 100 mg

Indications and dosages

➤ Major depressive disorder

Adults: 50 mg P.O. daily

Dosage adjustment

- Severe renal impairment and end-stage renal disease
- Hepatic impairment (dosages above 100 mg daily not recommended)

Contraindications

- Hypersensitivity to drug, its components, or venlafaxine
- Within 14 days of an MAO inhibitor

Precautions

Use cautiously in:
- renal impairment, hypertension, cardiovascular or cerebrovascular disease, lipid metabolism disorders, abnormal bleeding, interstitial lung disease, eosinophilic pneumonia, seizure disorder, bipolar disorder or family history of mania or hypomania, increased intraocular pressure, increased risk of angle-closure glaucoma
- concurrent use of selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) (use not recommended)
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

Administration

- Make sure hypertension is controlled before therapy starts.

Reactions in bold are life-threatening.
• Give tablets whole with or without food at same time each day. Don’t break, dissolve, or divide tablets.
• Reduce dosage gradually when discontinuing drug.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>7.5 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

### Adverse reactions

**CNS:** dizziness, insomnia, somnolence, anxiety, fatigue, irritability, abnormal dreams, hypomania, mania, seizures

**CV:** hypertension

**EENT:** mydriasis, blurred vision, tinnitus

**GI:** nausea, vomiting, diarrhea, constipation, dry mouth

**GU:** male sexual function disorder

**Hematologic:** abnormal bleeding

**Respiratory:** interstitial lung disease, eosinophilic pneumonia

**Skin:** hyperhidrosis

**Other:** decreased appetite, weight loss

### Interactions

**Drug-drug.** Aspirin, NSAIDs, other drugs that affect coagulation: increased risk of bleeding

Drugs metabolized by CYP2D6 (such as despiramine): increased blood levels of these drugs

Drugs metabolized by CYP3A4 (such as midazolam): decreased blood levels of these drugs

MAO inhibitors, serotonergics (lithium, SNRIs, SSRIs, tricyclic antidepressants, triptans), tramadol: potentially life-threatening serotonin syndrome

Potent CYP3A4 inhibitors: increased desvenlafaxine blood level

**Drug-diagnostic tests.** Cholesterol, triglycerides: increased levels

Sodium: decreased level

Urine protein: transient elevation

**Drug-food.** Triptophan supplements: potentially life-threatening serotonin syndrome

**Drug-herb.** St. John’s wort: potentially life-threatening serotonin syndrome

### Patient monitoring

• Monitor patient’s blood pressure regularly during therapy.
• Monitor cholesterol and triglyceride levels.

- Monitor patient closely for clinical worsening, suicidality, and unusual behavior changes, especially during first few months of therapy and after dosage changes.

- Monitor for progressive dyspnea, cough, or chest discomfort, which may signal serious lung disorders.

- Observe for signs and symptoms of hyponatremia (headache, poor concentration, memory impairment, confusion, weakness, and unsteadiness), especially in elderly patients.

- After discontinuing drug, monitor for dysphoric mood, irritability, agitation, dizziness, paresthesia, anxiety, confusion, headache, lethargy, insomnia, tinnitus, and seizures.

### Patient teaching

• Instruct patient to take tablets whole with or without food at same time each day. Caution patient not to chew, break, crush, dissolve, or divide tablets.

• Tell patient that full drug effects may take several weeks; advise patient not to stop taking drug.

• Caution patient not to discontinue drug abruptly.

- Advise patient’s family or caregiver to monitor patient, especially for suicidality or new or worsening symptoms.

- Instruct patient to immediately report unusual bruising or bleeding.

- Advise patient not to take over-the-counter drugs containing aspirin or NSAIDs without consulting prescriber.

- Instruct patient to avoid herbs (especially St. John’s wort) unless prescriber approves.

- Caution patient to avoid hazardous activities until drug’s effects on concentration and alertness are known.
Tell patient that inert matrix tablet may appear in stool, but active drug has already been absorbed.

Advise female patient to notify prescriber if she is pregnant, intends to become pregnant, or is breastfeeding.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

dexamethasone
Apo-Dexamethasone®, Dexasone

dexamethasone sodium phosphate

Pharmacologic class: Glucocorticoid
Therapeutic class: Anti-inflammatory
Pregnancy risk category C

Action
Unclear. Reduces inflammation by suppressing polymorphonuclear leukocyte migration, reversing increased capillary permeability, and stabilizing leukocyte lysosomal membranes. Also suppresses immune response (by reducing lymphatic activity), stimulates bone marrow, and promotes protein, fat, and carbohydrate metabolism.

Availability
Elixir: 0.5 mg/5 ml
Oral solution: 0.5 mg/5 ml, 1 mg/ml
Solution for injection (sodium phosphate): 4 mg/ml, 10 mg/ml, 20 mg/ml, 24 mg/ml
Tablets: 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg

Indications and dosages

Adults: 0.75 to 9 mg/day (dexamethasone) P.O. as a single dose or in divided doses; in severe cases, much higher dosages may be needed. Dosage requirements vary and must be individualized based on disease and patient response.

Cerebral edema
Adults: Initially, 10 mg (sodium phosphate) I.V., followed by 4 mg I.M. q 6 hours. Then reduce dosage gradually over 5 to 7 days.

Suppression test for Cushing’s syndrome
Adults: 1 mg P.O. at 11 P.M. or 0.5 mg P.O. q 6 hours for 48 hours (with urine collection testing, as ordered)

Off-label uses

- Acute altitude sickness
- Bacterial meningitis
- Bronchopulmonary dysplasia in preterm infants
- Hirsutism
- Suppression test for detection, diagnosis, or management of depression

Contraindications

- Hypersensitivity to drug, benzyl alcohol, bisulfites, EDTA, creatinine, polysorbate 80, or methylparaben
- Systemic fungal infections

Precautions
Use cautiously in:

- renal insufficiency, cirrhosis, diabetes mellitus, diverticulitis, GI disease, cardiovascular disease, hypoprothrombinemia, hypothyroidism, myasthenia gravis, glaucoma, osteoporosis, infections, underlying immunosuppression, psychotic tendencies
- pregnant or breastfeeding patients
- children.

Administration

- Give P.O. dose with food or milk.
- When giving I.M., inject deep into gluteal muscle; rotate sites as needed.

Reactions in bold are life-threatening.

Clinical alert
For I.V. use, drug may be given undiluted as a single dose over 1 minute or added to dextrose or I.V. saline solutions and given as an intermittent infusion at prescribed rate.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1-2 hr</td>
<td>2.75 days</td>
</tr>
<tr>
<td>I.V.</td>
<td>1 hr</td>
<td>1 hr</td>
<td>Variable</td>
</tr>
<tr>
<td>I.M.</td>
<td>1 hr</td>
<td>1 hr</td>
<td>6 days</td>
</tr>
</tbody>
</table>

(sodium phosphate)

**Adverse reactions**

**CNS:** headache, malaise, vertigo, psychiatric disturbances, **increased intracranial pressure, seizures**

**CV:** hypotension, thrombophlebitis, myocardial rupture after recent myocardial infarction, thromboembolism

**EENT:** cataracts

**GI:** nausea, vomiting, abdominal distention, dry mouth, anorexia, **peptic ulcer, bowel perforation, pancreatitis, ulcerative esophagitis**

**Metabolic:** decreased carbohydrate tolerance, hyperglycemia, cushingoid appearance (moon face, buffalo hump), decreased growth (in children), latent diabetes mellitus, sodium and fluid retention, negative nitrogen balance, **adrenal suppression, hypokalemic alkalosis**

**Musculoskeletal:** muscle wasting, muscle pain, osteoporosis, aseptic joint necrosis, tendon rupture, long bone fractures

**Skin:** diaphoresis, angioedema, erythema, rash, pruritus, urticaria, contact dermatitis, acne, decreased wound healing, bruising, skin fragility, petechiae

**Other:** facial edema, weight gain or loss, increased susceptibility to infection, hypersensitivity reactions

**Interactions**

**Drug-drug.** Barbiturates, phenytoin, rifampin: decreased dexamethasone effects

Digoxin: increased risk of digoxin toxicity

Ephedrine: increased dexamethasone clearance

Estrogen, hormonal contraceptives: blocking of dexamethasone metabolism

Fluoroquinolones: increased risk of tendon rupture

Itraconazole, ketoconazole: increased dexamethasone blood level and effects

Live-virus vaccines: decreased antibody response to vaccine, increased risk of adverse reactions

Loop and thiazide diuretics: additive hypokalemia

Nonsteroidal anti-inflammatory drugs: increased risk of GI adverse effects

Somatrem, somatropin: decreased response to these drugs

**Drug-diagnostic tests.** Calcium, potassium: decreased levels

Cholesterol, glucose: increased levels

Nitroblue tetrazolium test: false-negative result

**Drug-herbs.** Echinacea: increased immune-stimulating effect

Ginseng: potentiation of immune-modulating response

**Drug-behaviors.** Alcohol use: increased risk of gastric irritation and GI ulcers

**Patient monitoring**

- Monitor blood glucose level closely in diabetic patients receiving drug orally.
- Monitor hemoglobin and potassium levels.
- Assess for occult blood loss.

In long-term therapy, never discontinue drug abruptly. Dosage must be tapered gradually.

**Patient teaching**

Instruct patient to immediately report sudden weight gain, swelling of face or limbs, excessive nervousness or sleep disturbances, excessive body hair growth, vision changes, difficulty breathing, muscle weakness, persistent abdominal pain, or change in stool color.
• Tell patient to take oral drug with or after meals.
• Advise patient to report vision changes.
• Inform patient that drug makes him more susceptible to infection. Advise him to avoid crowds and exposure to illness.

Caution patient not to stop taking drug abruptly.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

### dexmethylphenidate hydrochloride

**Focalin, Focalin XR**

**Pharmacologic class:** Methylphenidate derivative  
**Therapeutic class:** CNS stimulant  
**Controlled substance schedule II**  
**Pregnancy risk category C**

**FDA BOXED WARNING**

• Give cautiously to patient with history of drug dependence or alcoholism. Chronic abuse can cause marked tolerance and psychological dependence with abnormal behavior. Frank psychotic episodes may occur, especially with parenteral abuse. During withdrawal from abusive use, provide careful supervision, as severe depression may occur.
• Withdrawal after prolonged therapeutic use may unmask symptoms of underlying disorder that may require follow-up.

### Action

Thought to block norepinephrine and dopamine reuptake, increasing the concentration of these neurotransmitters in extraneuronal space

### Availability

**Capsules (extended-release):** 5 mg, 10 mg, 15 mg, 20 mg  
**Tablets:** 2.5 mg, 5 mg, 10 mg

### Indications and dosages

> **Attention deficit hyperactivity disorder**

**Adults and children older than age 6:**

**Tablets**—In patients not receiving methylphenidate concurrently, 2.5 mg P.O. b.i.d. at least 4 hours apart; increase as needed in 2.5- to 5-mg increments to a maximum of 10 mg b.i.d. (Individualize dosage according to patient needs and response.) In patients receiving methylphenidate concurrently, start with half of methylphenidate dosage; maximum dosage is 10 mg P.O. b.i.d.  

**Capsules**—In adults not receiving methylphenidate concurrently, 10 mg P.O. daily in morning; increase as needed in 10-mg increments approximately weekly to maximum of 20 mg daily. In children not receiving methylphenidate concurrently, 5 mg daily in morning; increase as needed in 5-mg increments approximately weekly to maximum of 20 mg daily. In adults and children receiving methylphenidate concurrently, start with half of methylphenidate total daily dosage.

### Contraindications

• Hypersensitivity to drug  
• Glaucoma  
• Anxiety, agitation, tension  
• Family history or diagnosis of Tourette syndrome  
• MAO inhibitor use within past 14 days

### Precautions

Use cautiously in:
• hypertension, depression, seizures, cardiovascular disorders, psychosis, drug abuse

Reactions in **bold** are life-threatening.
• pregnant or breastfeeding patients
• children under age 6 (safety and efficacy not established).

Administration
• Administer at same time each day without regard to meals.
• Give last dose at least 8 hours before bedtime to prevent insomnia.
• Know that regular-release tablets may be switched to same daily dosage as extended-release capsules.
• If necessary, open capsules, sprinkle contents over spoonful of applesauce, and administer immediately.
• Don’t give within 14 days of MAO inhibitor use.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O. (capsules)</td>
<td>Unknown</td>
<td>1.5-6.5 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>P.O. (tablets)</td>
<td>Variable</td>
<td>1-1.5 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: nervousness, insomnia, dizziness, drowsiness, headache, dyskinesia, chorea, Tourette syndrome, toxic psychosis
CV: increased or decreased heart rate and blood pressure, tachycardia, angina, palpitations, arrhythmias
EENT: blurred vision, visual accommodation problems
GI: nausea, abdominal pain
Hematologic: anemia, leukopenia, thrombocytopenia
Hepatic: hepatic dysfunction, hepatic coma
Skin: rash, alopecia
Other: fever, decreased appetite, weight loss, psychological drug dependence, drug tolerance, growth suppression in children (with long-term use)

Interactions
Drug-drug. Anticoagulants, phenobarbital, phenytoin, primidone, selective serotonin reuptake inhibitors, tricyclic antidepressants: inhibited metabolism and additive effects of these drugs
Antihypertensives, pressor agents (dopamine, epinephrine): decreased efficacy of these drugs
MAO inhibitors: severe hypertensive crisis

Patient monitoring
• Monitor blood pressure closely, especially in patients receiving antihypertensives concurrently.
• Evaluate cardiac status. Report palpitations and other signs and symptoms of arrhythmias.
• During prolonged therapy, regularly monitor CBC with white cell differential and platelet count.

Patient teaching
• Advise patient or parents that drug should be taken at same time each day.
• Instruct patient not to crush or chew capsule. If patient is unable to swallow capsules whole, advise him to open capsules, sprinkle contents over spoonful of applesauce, and take immediately.
• Tell patient or parents that drug usually is discontinued if symptoms don’t improve within 1 month.
• Instruct parents to monitor child’s height and weight, because CNS stimulants have been associated with growth suppression.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

dextroamphetamine sulfate
Dexedrine Spansule, DextroStat

Pharmacologic class: Amphetamine
Therapeutic class: Sympathomimetic amine, CNS stimulant
Controlled substance schedule II
Pregnancy risk category C
**FDA BOXED WARNING**

- Drug has high abuse potential. Prolonged use may lead to drug dependence. Stay alert for possibility of patient obtaining drug for nontherapeutic use or distribution. Drug should be prescribed sparingly.
- Misuse may cause sudden death and serious cardiovascular events.

**Action**

Produces CNS and respiratory stimulation by promoting release of norepinephrine from nerve terminals.

**Availability**

Capsules (sustained-release): 5 mg, 10 mg, 15 mg
Tablets: 5 mg, 10 mg

**Indications and dosages**

- **Attention deficit hyperactivity disorder**
  - Adults: 5 to 60 mg P.O. daily in divided doses
  - **Children ages 6 and older:** 5 mg P.O. once or twice daily, increased by 5 mg at weekly intervals
  - **Children ages 3 to 5:** 2.5 mg P.O. daily, increased by 2.5 mg at weekly intervals

- **Narcolepsy**
  - Adults: 5 to 60 mg P.O. daily as a single dose or in divided doses
  - **Children ages 12 and older:** 10 mg P.O. daily, increased by 10 mg at weekly intervals until desired response occurs or adult dosage is reached
  - **Children ages 6 to 11:** 5 mg P.O. daily, increased by 5 mg at weekly intervals until desired response occurs or adult dosage is reached

**Contraindications**

- Hypersensitivity to drug or tartrazine
- Glaucoma
- Psychotic disorders, agitated states
- Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension
- Hyperthyroidism
- MAO inhibitor use within past 14 days
- Pregnancy or breastfeeding

**Precautions**

Use cautiously in:
- cardiovascular disease, hypertension, diabetes mellitus
- history of substance abuse
- elderly patients.

**Administration**

- Make sure patient swallows sustained-release capsules whole without chewing or crushing.
- Before starting therapy, perform complete cardiac evaluation, including ECG and echocardiogram.
- Give last daily dose at least 6 hours before patient’s bedtime.
- Don’t give within 14 days of MAO inhibitor, because potentially fatal reaction may occur.

**Adverse reactions**

CNS: hyperactivity, insomnia, restlessness, tremor, depression, dizziness, headache, irritability
CV: palpitations, tachycardia, hypertension, hypotension, arrhythmias
GI: nausea, vomiting, constipation, diarrhea, abdominal cramps, dry mouth
GU: erectile dysfunction, increased libido
Skin: urticaria
Other: metallic taste, decreased appetite, physical or psychological drug dependence

**Interactions**

Drug-drug. Acetazolamide, sodium bicarbonate: urine alkalization, leading to increased dextroamphetamine effects

Reactions in **bold** are life-threatening.
Adrenergic blockers: additive effects
Ammonium chloride, ascorbic acid (large doses): urine acidification, leading to decreased dextroamphetamine effects
Beta-adrenergic blockers, tricyclic antidepressants: increased risk of adverse cardiovascular effects
Guanethidine: reversal of hypotensive effect
MAO inhibitors: hypertensive crisis
Phenothiazines: decreased dextroamphetamine effects
Selective serotonin reuptake inhibitors: increased risk of serotonin syndrome

Drug-diagnostic tests. Plasma corticosteroids: increased levels
Drug-food. Caffeine: increased stimulant effect
Drug-herbs. Caffeine-containing herbs, ephedra (ma huang): increased stimulant effect

Patient monitoring
- Interrupt therapy or reduce dosage periodically to assess drug efficacy in patients with behavior disorders.
- Monitor patient for new or worsening aggressive behavior.
- Monitor blood and urine glucose levels carefully in diabetic patient.
Drug may alter regular insulin requirements.

Patient teaching
- Tell patient to swallow sustained-release capsules whole with liquid without chewing or crushing.
- Advise patient to take drug early in day to avoid insomnia.
- Instruct patient to immediately notify prescriber if chest pain, irregular pulse, or worsening aggressive behavior occurs.
- Instruct patient to avoid driving and other hazardous activities until he knows how drug affects him.
- Caution patient not to stop therapy abruptly but to taper dosage gradually.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

dextromethorphan hydrobromide

Adult Dry Cough®, Balminil DM®, Broncho-Grippol-DM®, Calmylin #1®, Creo-Terpin, Creomulsion, Delsym, DexAlone, ElixiSure Cough, Hold DM, Koffex-DM®, Neo-DM®, PediaCare Infants Long-Acting Cough, Robitussin CoughGels, Robitussin for Dry Coughs®, Robitussin Maximum Strength Cough Suppressant, Robitussin Pediatric Cough, Sedatuss®, Vicks Vaposyrup for Dry Cough®, Vicks 44 Cough Relief
Pharmacologic class: Levorphanol derivative
Therapeutic class: Antitussive (nonnarcotic)
Pregnancy risk category C

Action
Depresses cough reflex through direct effect on cough center in medulla. Has no expectorant action and does not inhibit ciliary action. Although related to opioids structurally, lacks analgesic and addictive properties.

Availability
Gelcaps: 15 mg, 30 mg
Liquid: 3.5 mg/5 ml, 5 mg/5 ml, 7.5 mg/5 ml, 15 mg/5 ml
Lozenges: 5 mg, 7.5 mg
Oral suspension (extended-release): 30 mg/5 ml
Syrup: 7.5 mg/5 ml, 10 mg/15 ml

Canada UK Hazardous drug High alert drug
Indications and dosages

Cough caused by minor viral upper respiratory tract infections or inhaled irritants

**Adults and children over age 12:** 10 to 20 mg P.O. q 4 hours, or 30 mg P.O. q 6 to 8 hours, or 60 mg of extended-release form P.O. b.i.d. (not to exceed 120 mg/day)

**Children ages 6 to 12:** 5 to 10 mg P.O. q 4 hours, or 15 mg P.O. q 6 to 8 hours, or 30 mg of extended-release form P.O. q 12 hours (not to exceed 60 mg/day)

**Children ages 2 to 6:** 2.5 to 5 mg P.O. q 4 hours, or 7.5 mg q 6 to 8 hours, or 15 mg of extended-release form P.O. q 12 hours (not to exceed 30 mg/day)

Dosage adjustment

- Elderly patients

Contraindications

- Hypersensitivity to drug
- Chronic productive cough
- MAO inhibitor use within past 14 days

Precautions

Use cautiously in:
- tartrazine sensitivity
- diabetes mellitus (with sucrose-containing drug products)
- pregnant or breastfeeding patients
- children younger than age 2 (safety not established).

Administration

- Don’t administer lozenges to children younger than age 6.
- Don’t give within 14 days of MAO inhibitors.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>15-30 min</td>
<td>Unknown</td>
<td>3-6 hr</td>
</tr>
<tr>
<td>P.O. (extended)</td>
<td>Unknown</td>
<td>Unknown</td>
<td>9-12 hr</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: dizziness and sedation
GI: nausea, vomiting, stomach pain

Interactions

**Drug-drug.** Amiodarone, fluoxetine, quinidine: increased dextromethorphan blood level, greater risk of adverse reactions

Antidepressants, antihistamines, opioids, sedative-hypnotics: additive CNS depression

MAO inhibitors, sibutramine: serotonin syndrome (nausea, confusion, blood pressure changes)

**Drug-behaviors.** Alcohol use: additive CNS depression

Patient monitoring

- Monitor cough frequency and type, and assess sputum characteristics.
- Assess hydration status. Increase patient’s fluid input to help moisten secretions.

Patient teaching

- Advise patient to avoid irritants, such as smoking, dust, and fumes. Suggest use of humidifier to filter air pollutants.
- Inform patient that treatment aims to decrease coughing frequency and intensity without completely eliminating protective cough reflex.
- Instruct patient to contact health care provider if cough lasts more than 7 days.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and behaviors mentioned above.

---

**dextrose (d-glucose)**

BD Glucose, Glucose, Insta-Glucose

**Pharmacologic class:** Monosaccharide

**Therapeutic class:** Carbohydrate caloric nutritional supplement

**Pregnancy risk category C**

Reactions in **bold** are life-threatening.
Action
Prevents protein and nitrogen loss; promotes glycogen deposition and ketone accumulation (through osmotic diuretic action)

Availability
Injection: 2.5%, 5%, 10%, 20%, 25%, 30%, 40%, 50%, 60%, 70%
Oral gel: 40%
Tablets (chewable): 5 g

Indications and dosages
➣ Insulin-dependent hypoglycemia
Adults and children: Initially, 10 to 20 g P.O., repeated in 10 to 20 minutes if needed based on blood glucose level; or 20 to 50 ml by I.V. infusion or injection of 50% solution given at 3 ml/minute. Maintenance dosage is 10% to 15% solution by continuous I.V. infusion until blood glucose level reaches therapeutic range.
Infants and neonates: 2 ml/kg of 10% to 25% solution by slow I.V. infusion until blood glucose level reaches therapeutic range
➣ Calorie replacement
Adults and children: 2.5%, 5%, or 10% solution given through peripheral I.V. line, with dosage tailored to patient’s need for fluid or calories; or 10% to 70% solution given through large central vein if needed (typically mixed with amino acids or other solution)

Off-label uses
● Varicose veins
● Insulin-secreting islet-cell adenoma

Contraindications
● Hypersensitivity to drug
● Hyperglycemia, diabetic coma
● Hemorrhage
● Heart failure

Precautions
Use cautiously in:
● renal, cardiac, or hepatic impairment; diabetes mellitus.

Administration
● Use aseptic technique when preparing solution. Bacteria thrive in high-glucose environments.
□ Infuse concentrations above 10% through central vein.
● Don’t infuse concentrated solution rapidly, because doing so may cause hyperglycemia and fluid shifts.
□ Never stop infusion abruptly.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>10-20 min</td>
<td>40 min</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V.</td>
<td>2-3 min</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: confusion, loss of consciousness
CV: hypertension, phlebitis, venous thrombosis, heart failure
GU: glycosuria, osmotic diuresis
Metabolic: hyperglycemia, hypervolemia, hypovolemia, electrolyte imbalances, hyperosmolar coma
Respiratory: pulmonary edema
Skin: flushing, urticaria
Other: chills, fever, dehydration, injection site reaction, infection

Interactions
Drug-drug. Corticosteroids, corticotropin: increased risk of fluid and electrolyte imbalances
Drug-diagnostic tests. Glucose: increased level

Patient monitoring
□ Monitor infusion site frequently to prevent irritation, tissue sloughing, necrosis, and phlebitis.
● Check blood glucose level at regular intervals.
● Monitor fluid intake and output.
● Weigh patient regularly.
● Assess patient for confusion.

Patient teaching
● Teach patient how to recognize signs and symptoms of hypoglycemia and hyperglycemia.
● Provide instructions on glucose self-monitoring.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**diazepam**

Apo-Diazepam®, Bio-Diazepam®, Dialar®, Diastat, Diazemuls®, Diazepam Intensol, Novo-Dipam®, PMS-Diazepam®, Stesolid®, Tensium®, Valclair®, Valium, Vivol®

**Pharmacologic class:** Benzodiazepine

**Therapeutic class:** Anxiolytic, anti-convulsant, sedative-hypnotic, skeletal muscle relaxant (centrally acting)

**Controlled substance schedule IV**

**Pregnancy risk category D**

**Action**

Produces anxiolytic effect and CNS depression by stimulating gamma-aminobutyric acid receptors. Relaxes skeletal muscles of spine by inhibiting polysynaptic afferent pathways. Controls seizures by enhancing presynaptic inhibition.

**Availability**

_Injection:_ 5 mg/ml

_Oral solution:_ 1 mg/ml, 5 mg/5 ml

_Rectal gel delivery system:_ 2.5 mg, 10 mg, 15 mg, 20 mg

_Sterile emulsion for injection:_ 5 mg/ml

_Tablets:_ 2 mg, 5 mg, 10 mg

**Indications and dosages**

➢ Anxiety disorders

_Adults:_ 2 to 10 mg P.O. two to four times daily, depending on symptom severity. Alternatively, for moderate anxiety, 2 to 5 mg I.V., repeated in 3 to 4 hours if needed. For severe anxiety, 5 to 10 mg I.V., repeated in 3 to 4 hours if needed.

**Children age 6 months and older:** 1 to 2.5 mg P.O. three to four times daily; may increase gradually as needed

➢ _Before cardioversion_  

_Adults:_ 5 to 15 mg I.V. 5 to 10 minutes before cardioversion

➢ _Before endoscopy_  

_Adults:_ Usually, 10 mg I.V. is sufficient; may be increased to 20 mg I.V. Alternatively, 5 to 10 mg I.M. 30 minutes before endoscopy.

➢ _Status epilepticus and severe recurrent convulsive seizures_  

_Adults:_ 5 to 10 mg I.V. slowly, repeated as needed q 10 to 15 minutes, to a maximum of 30 mg; may repeat regimen if needed in 2 to 4 hours. May give I.M. if I.V. delivery is impossible.

**Children ages 5 and older:** 1 mg I.V. slowly q 2 to 5 minutes, to a maximum of 10 mg; repeat in 2 to 4 hours if needed. May give I.M. if I.V. delivery is impossible.

**Children over 1 month to 5 years:** 0.2 to 0.5 mg I.V. slowly q 2 to 5 minutes, to a maximum of 5 mg I.V. May give I.M. if I.V. delivery is impossible.

➢ _Adjunctive use in selected refractory patients with epilepsy_  

**Adults and children ages 12 and older:** 0.2 mg/kg P.R. May repeat 4 to 12 hours later.

**Children ages 6 to 11:** 0.3 mg/kg P.R. May repeat 4 to 12 hours later.

**Children ages 2 to 5:** 0.5 mg/kg P.R. May repeat 4 to 12 hours later.

➢ _Muscle spasm associated with local pathology, cerebral palsy, athetosis, “stiff-man” syndrome, or tetanus_  

_Adults:_ 2 to 10 mg P.O. three to four times daily. Or initially, 5 to 10 mg I.V. or I.M., repeated in 3 to 4 hours if needed. Tetanus may necessitate higher dosages.

**Elderly or debilitated patients:** Initially, 2 to 2.5 mg P.O. once or twice daily,

Reactions in **bold** are life-threatening.
increased gradually as needed and tolerated

**Children ages 5 and older:** 5 to 10 mg I.M. or I.V., repeated q 3 to 4 hours as needed to control tetanus spasm

**Children over 1 month to 5 years:** 1 to 2 mg I.M. or I.V. slowly, repeated q 3 to 4 hours as needed to control tetanus spasm

» Acute alcohol withdrawal

**Adults:** Initially, 10 mg P.O. three to four times during first 24 hours, decreased to 5 mg P.O. three to four times daily p.r.n. Or initially, 10 mg I.M. or I.V.; then 5 to 10 mg I.M. or I.V. in 3 to 4 hours p.r.n.

**Off-label uses**
- Panic attacks
- Adjunct to general anesthesia

**Contraindications**
- Hypersensitivity to drug, other benzodiazepines, alcohol, or tartrazine
- Coma or CNS depression
- Narrow-angle glaucoma

**Precautions**
Use cautiously in:
- hepatic dysfunction, severe renal impairment
- elderly patients
- pregnant or breastfeeding patients (use not recommended)
- children.

**Administration**
- Give P.O. dose with or without food.
- Administer I.V. infusion slowly into large vein, taking at least 1 minute for each 5 mg in adults or at least 3 minutes for each 0.25 mg/kg in children.
- Know that I.V. route is preferred over I.M. route because of slow or erratic I.M. absorption.
- Don’t mix with other drugs or solutions in syringe or container.
- Enforce bed rest for at least 3 hours after I.V. injection.

- Give I.M. injection deeply and slowly into large muscle mass.
- If desired, mix oral solution with liquid or soft food.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30-60 min</td>
<td>1-2 hr</td>
<td>Up to 24 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>1-5 min</td>
<td>15-30 min</td>
<td>15-60 min</td>
</tr>
<tr>
<td>I.M.</td>
<td>Within 20 min</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td>P.R.</td>
<td>Unknown</td>
<td>1-2 hr</td>
<td>4-12 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- CNS: dizziness, drowsiness, lethargy, depression, light-headedness, disorientation, anger, manic or hypomanic episodes, restlessness, paresthesia, headache, slurred speech, dysarthria, stupor, tremor, dystonia, vivid dreams, extrapyramidal reactions, mild paradoxical excitation
- CV: bradycardia, tachycardia, hypertension, hypotension, palpitations, cardiovascular collapse
- EENT: blurred vision, diplopia, nystagmus, nasal congestion
- GI: nausea, vomiting, diarrhea, constipation, gastric disorders, difficulty swallowing, increased salivation
- GU: urinary retention or incontinence, menstrual irregularities, gynecomastia, libido changes
- Hematologic: blood dyscrasias including eosinophilia, leukopenia, agranulocytosis, and thrombocytopenia
- Hepatic: hepatic dysfunction
- Musculoskeletal: muscle rigidity, muscular disturbances
- Respiratory: respiratory depression
- Skin: dermatitis, rash, pruritus, urticaria, diaphoresis
- Other: weight gain or loss, decreased appetite, edema, hiccups, fever, physical or psychological drug dependence or tolerance
Interactions

Drug-drug. Antidepressants, antihistamines, barbiturates, opioids: additive CNS depression
Cimetidine, disulfiram, fluoxetine, hormonal contraceptives, isoniazid, ketoconazole, metoprolol, propoxyphene, propranolol, valproic acid: decreased metabolism and enhanced action of diazepam

Digoxin: increased digoxin blood level, possible toxicity
Levodopa: decreased levodopa efficacy
Rifampin: increased metabolism and decreased efficacy of diazepam
Theophylline: decreased sedative effect of diazepam

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, lactate dehydrogenase: increased levels
Neutrophils, platelets: decreased counts

Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression

Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring
- Monitor vital signs and respiratory and neurologic status.
- Supervise ambulation, especially in elderly patients.
- Monitor CBC and kidney and liver function test results.

Avoid sudden drug withdrawal. Taper dosage gradually to termination of therapy.

Patient teaching
- Inform patient he may take drug with or without food; recommend taking it with food if it causes stomach upset.
- Teach caregiver how to administer rectal gel system, if prescribed.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Tell patient to notify prescriber immediately if easy bruising or bleeding occurs.
- Instruct patient to move slowly when sitting up or standing, to avoid dizziness from blood pressure decrease. Advise him to dangle legs briefly before getting out of bed.
- Advise patient not to stop taking drug abruptly.
- Advise patient to avoid alcohol and other depressants such as sedatives while taking drug.
- Tell female patient not to take drug if she is pregnant or plans to breastfeed.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

Pharmacologic class: Vasodilator
Therapeutic class: Antihypertensive (nondiuretic), antihypoglycemic
Pregnancy risk category C

Action
Unclear. Relaxes peripheral arterioles of smooth-muscle cells and reduces peripheral vascular resistance as a result of vasodilation.

Availability
Capsules: 50 mg
Injection: 15 mg/ml in 20-ml ampules
Oral suspension: 50 mg/ml

Indications and dosages
Hypertensive crisis
Adults and children: 1 to 3 mg/kg
I.V. bolus, to a maximum dosage of 150 mg q 5 to 15 minutes until
adequate response occurs. Repeat as needed q 4 hours or more.

Hypoglycemia secondary to hyper-insulinism

Adults and children: 3 to 8 mg/kg P.O. daily in two to three divided doses q 8 to 12 hours

Newborn and infants: 3.3 mg/kg P.O. q 8 hours

Off-label uses
- Pregnancy-induced hypertension
- Obesity

Contraindications
- Hypersensitivity to drug, thiazides, or sulfonamides
- Compensatory hypertension
- Pheochromocytoma
- Dissecting aortic aneurysm

Precautions
Use cautiously in:
- fluid and electrolyte imbalances; impaired renal, hepatic, cerebral, or cardiac circulation
- pregnant or breastfeeding patients
- children.

Administration
- Keep patient recumbent during I.V. administration and for at least 30 minutes afterward.
- Give single I.V. doses over 10 to 30 seconds. Continuous I.V. infusion can be given at a constant rate (7.5 to 30 mg/minute) until adequate response occurs.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1 hr</td>
<td>Unknown</td>
<td>8 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>1 min</td>
<td>2-5 min</td>
<td>2-12 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, light-headedness, dizziness, weakness, euphoria, seizures, paralysis, cerebral ischemia
CV: ECG changes, orthostatic hypotension, angina pectoris, myocardial ischemia, myocardial infarction, arrhythmias, shock, supraventricular tachycardia, heart failure

EENT: optic nerve damage
GI: nausea, vomiting, diarrhea, constipation, abdominal discomfort, dry mouth
GU: breast tenderness
Metabolic: hyperglycemia, hyperuricemia, fluid and electrolyte imbalances, sodium and water retention
Skin: inflammation (with extravasation), diaphoresis, flushing
Other: sensation of warmth, edema, pain (with extravasation)

Interactions
Drug-drug. Antihypertensives (such as beta-adrenergic blockers, hydralazine, methyldopa, minoxidil, nitrates, prazosin, reserpine): additive hypotension
Hydantoins: decreased hydantoin blood level
Sulfonylureas: hyperglycemia
Thiazide diuretics: increased diazoxide effects

Drug-diagnostic tests. Blood urea nitrogen, glucose, serum sodium, uric acid: increased levels
Eosinophils, hematocrit, hemoglobin, platelets, white blood cells: decreased values

Patient monitoring
♫ Measure blood pressure every 5 minutes for first 15 to 30 minutes of infusion or until patient stabilizes.
- Monitor ECG and pulse continuously during and after infusion. Be aware that tachycardia may immediately follow I.V. infusion.
- Assess fluid status; promptly report intake and output changes. If fluid retention occurs, give diuretic, as prescribed.
- Inspect I.V. site regularly for infiltration or extravasation.
- Observe closely for signs and symptoms of heart failure.
- Monitor diabetic patient for loss of glycemic control.
Patient teaching

- Instruct patient to immediately report chest pain, dizziness, and severe headache.
- Tell patient to weigh himself daily and report significant gains.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

diclofenac potassium
Cataflam, Novo-Difenac-K\(^*\), Novo-Difenac-SR\(^*\)

diclofenac sodium
Apo-Diclo\(^*\), Dom-Diclofenac\(^*\), Diclofex\(^*\), Fenactol\(^*\), Novo-Difenac\(^*\), Nu-Diclo\(^*\), PMS-Diclofenac\(^*\), Voltaren, Voltaren XR, Voltarol\(^*\)

**Pharmacologic class:** Cyclooxygenase inhibitor, nonsteroidal anti-inflammatory drug (NSAID)

**Therapeutic class:** Nonopioid analgesic, antiarthritic

**Pregnancy risk category C**

FDA BOXED WARNING

- Drug may increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke. Risk may increase with duration of use. Patients with cardiovascular disease or risk factors for it may be at greater risk.
- Drug increases risk of serious GI adverse events, including bleeding, ulcers, and stomach or intestinal perforation. These events can occur at any time during use and without warning. Elderly patients are at greater risk.

**Action**

Unclear. Thought to block activity of cyclooxygenase, thereby inhibiting inflammatory responses of vasodilation and swelling and blocking transmission of painful stimuli.

**Availability**

*Tablets*: 50 mg, 75 mg
*Tablets (delayed-release)*: 25 mg, 50 mg, 75 mg
*Tablets (extended-release)*: 100 mg

**Indications and dosages**

- **Analgesia; dysmenorrhea**
  - **Adults**: Initially, 100 mg P.O., then 50 mg t.i.d. as needed
- **Rheumatoid arthritis**
  - **Adults**: Initially, 50 mg P.O. three to four times daily. After initial response, reduce to lowest dosage that controls symptoms. Usual maintenance dosage is 25 mg t.i.d.
- **Osteoarthritis**
  - **Adults**: Initially, 50 mg P.O. two to three times daily. After initial response, reduce to lowest dosage that controls symptoms.
- **Ankylosing spondylitis**
  - **Adults**: 25 mg P.O. four to five times daily. After initial response, reduce to lowest dosage that controls symptoms.

**Dosage adjustment**

- Renal impairment
- Elderly patients

**Off-label uses**

- Post-radial keratotomy symptoms
- Dental pain

**Contraindications**

- Hypersensitivity to drug or its components, other NSAIDs, or aspirin
- Active GI bleeding or ulcer disease

Reactions in **bold** are life-threatening.
Precautions
Use cautiously in:
● severe cardiovascular, renal, or hepatic disease; bleeding tendency
● history of porphyria or asthma
● concurrent anticoagulant use
● elderly patients
● pregnant or breastfeeding patients
● children.

Administration
● Give on empty stomach 1 hour before or after a meal.
● If drug causes GI upset, give with milk or meals.
● Make sure patient swallows extended-release form whole without chewing or crushing.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>10 min</td>
<td>1 hr</td>
<td>8 hr</td>
</tr>
<tr>
<td>P.O. (delayed)</td>
<td>30 min</td>
<td>2-3 hr</td>
<td>8 hr</td>
</tr>
<tr>
<td>P.O. (extended)</td>
<td>Unknown</td>
<td>5-6 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, drowsiness, headache
CV: hypertension
EENT: tinnitus
GI: diarrhea, abdominal pain, dyspepsia, heartburn, peptic ulcer, GI bleeding, GI perforation
GU: dysuria, frequent urination, hematuria, proteinuria, nephritis, acute renal failure
Hematologic: prolonged bleeding time
Hepatic: hepatotoxicity
Skin: eczema, photosensitivity, rash, contact dermatitis, dry skin, exfoliation
Other: allergic reactions (including edema), anaphylaxis

Interactions
Drug-drug. Anticoagulants, antiplatelet agents, cephalosporins, plicamycin, thrombolytics: increased risk of bleeding
Antihypertensives, diuretics: decreased efficacy of these drugs
Antineoplastics: increased risk of hematologic adverse reactions

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, blood urea nitrogen, creatinine, electrolytes, lactate dehydrogenase, urine uric acid: increased values
Bleeding time: prolonged
Hematocrit, hemoglobin, platelets, serum uric acid, urine electrolytes, white blood cells: decreased values
Drug-herbs. Anise, arnica, chamomile, clove, dong quai, fenugreek, feverfew, garlic, ginger, ginkgo, ginseng, and others: increased risk of bleeding
Drug-behaviors. Alcohol use: increased risk of adverse GI effects

Patient monitoring
● Monitor hepatic and renal function.
● Observe for and report signs and symptoms of bleeding.
● Assess for hypertension.
● Monitor sodium and potassium levels in patients receiving potassium-sparing diuretics.
● Weigh patient to detect fluid retention. Report gain of more than 2 lb in 24 hours.

Patient teaching
● Instruct patient to take drug on empty stomach 1 hour before or after a meal.
● Advise patient not to lie down for 15 to 30 minutes after taking drug, to minimize esophageal irritation.
● Instruct patient to immediately report signs or symptoms of hypersensitivity reactions (rash, swelling of face or throat, shortness of breath) or liver impairment (unusual tiredness,
weakness, nausea, yellowing of skin or eyes, tenderness on right upper side of abdomen, flulike symptoms).

- Instruct patient to stop taking drug and contact prescriber promptly if he experiences ringing or buzzing in ears, dizziness, GI discomfort, or bleeding.
- Caution patient not to take over-the-counter analgesics during diclofenac therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

**dicyclomine (dicycloverine)**

Bentyl, Bentylol®, Diclophen®, Formulex®, Lomine®, Merbentyl®, Protylol®

*Pharmacologic class:* Anticholinergic

*Therapeutic class:* Antispasmodic

*Pregnancy risk category B*

**Action**

Thought to exert direct effect on GI smooth muscle by inhibiting acetylcholine at receptor sites, thereby reducing GI tract motility and tone

**Availability**

*Capsules:* 10 mg, 20 mg  
*Solution for injection:* 10 mg/ml  
*Syrup:* 10 mg/5 ml  
*Tablets:* 10 mg, 20 mg

**Indications and dosages**

➣ Irritable bowel syndrome in patients unresponsive to usual interventions

*Adults:* 20 mg P.O. or I.M. q.i.d.; may increase up to 160 mg/day

**Contraindications**

- Hypersensitivity to drug
- GI or genitourinary tract obstruction
- Severe ulcerative colitis
- Reflux esophagitis
- Unstable cardiovascular status
- Glaucoma
- Myasthenia gravis
- Breastfeeding
- Infants younger than 6 months

**Precautions**

Use cautiously in:

- hepatic or renal impairment, autonomic neuropathy, cardiovascular disease, prostatic hypertrophy
- elderly patients
- pregnant patients (safety not established).

**Administration**

- Give 30 to 60 minutes before meals; give bedtime dose at least 2 hours after evening meal.
- Don’t administer by I.V. route.
- Don’t give by I.M. route for more than 2 days.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O., I.M.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

*CNS:* confusion, drowsiness, light-headedness (with I.M. use), psychosis  
*CV:* palpitations, tachycardia  
*EENT:* blurred vision, increased intraocular pressure  
*GI:* nausea, vomiting, constipation, heartburn, decreased salivation, dry mouth, *paralytic ileus*  
*GU:* urinary hesitancy or retention, erectile dysfunction, decreased lactation  
*Skin:* decreased sweating, rash, itching, urticaria  
*Other:* pain and redness at I.M. site, allergic reactions including *anaphylaxis*
Interactions

**Drug-drug.** *Adsorbent antidiarrheals, antacids:* decreased dicyclomine absorption
*Cyclopropane anesthetics:* increased risk of cardiovascular adverse reactions
*Oral drugs:* altered absorption of these drugs
*Potassium (oral):* increased GI mucosal lesions
*Other anticholinergics (including antihistamines, disopyramide, quinidine):* additive anticholinergic effects

**Drug-diagnostic tests.** *Gastric acid secretion test:* antagonism of pentagastrin and histamine (testing agents)

Patient monitoring
- Stay alert for anaphylaxis.
- Monitor vital signs and fluid intake and output. Ask patient about palpitations.
- Assess for light-headedness, confusion, and rash after I.M. injection.
- Evaluate patient’s vision, particularly for blurring and other signs and symptoms of increasing intraocular pressure.
- Assess bowel pattern, particularly for signs and symptoms of paralytic ileus.

Patient teaching
- Instruct patient to take drug 30 to 60 minutes before meals and to take bedtime dose at least 2 hours after evening meal.
- Advise patient not to take antacids or adsorbent antidiarrheals within 2 hours of dicyclomine.
- Urge patient to promptly report rash, abdominal pain, decreased urinary output, or absence of bowel movements.
- Caution patient to avoid driving or other hazardous activities until he knows how drug affects concentration, vision, and alertness.
- Instruct patient to avoid exposure to high temperatures and to immediately notify prescriber if fever and decreased sweating occur in high environmental temperature.
- Advise patient to minimize GI upset by eating small, frequent servings of healthy food and drinking plenty of fluids.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**didanosine (ddl, 2,3-dideoxyinosine)**

| Videx, Videx EC |

**Pharmacologic class:** Nucleoside reverse transcriptase inhibitor

**Therapeutic class:** Antiretroviral, antiviral

**Pregnancy risk category B**

**FDA BOXED WARNING**
- Pancreatitis has occurred when drug was used alone or in combination regimens in treatment-naïve or treatment-experienced patients. Suspend therapy in patients with suspected pancreatitis; discontinue in patients with confirmed pancreatitis.
- Drug may cause lactic acidosis and severe hepatomegaly with steatosis when used alone or in combination with other antiretrovirals. Fatal lactic acidosis has occurred in pregnant women receiving didanosine-stavudine combination with other antiretrovirals. In pregnant patients, use this combination with caution and only if benefit clearly outweighs risk.

**Action**
Inhibits replication of human immunodeficiency virus (HIV) by disrupting synthesis of DNA polymerase, an enzyme crucial to DNA and RNA formation.
Availability
Capsules (delayed-release): 125 mg, 200 mg, 250 mg, 400 mg
Powder for oral solution (buffered): 100 mg/packet, 167 mg/packet, 250 mg/packet
Powder for oral solution (pediatric): 2 g in 4-oz glass bottle, 4 g in 8-oz glass bottle

Indications and dosages
➣ HIV infection
Adults weighing 60 kg (132 lb) or more: 400 mg (capsules) P.O. once daily, or 250 mg (buffered powder) P.O. q 12 hours
Adults weighing less than 60 kg (132 lb): 250 mg (capsules) P.O. once daily, or 167 mg (buffered powder) P.O. q 12 hours
Children: 120 mg/m² (powder for oral solution, pediatric) P.O. q 12 hours

Dosage adjustment
• Renal impairment

Contraindications
• Hypersensitivity to drug

Precautions
Use cautiously in:
• renal or hepatic impairment, peripheral neuropathy, hyperuricemia
• elderly patients
• pregnant or breastfeeding patients
• children.

Administration
• Know that drug is usually given in conjunction with other antiretrovirals.
• Give on empty stomach 30 minutes before or 2 hours after a meal.
• Don’t administer with fruit juice.
• Know that pharmacist must prepare pediatric powder for oral solution by diluting with water and antacid to a concentration of 10 mg/ml.
• Be aware that delayed-release capsules aren’t intended for use in children.

Route Onset Peak Duration
P.O. Unknown 0.5-1 hr Unknown

Adverse reactions
CNS: dizziness, anxiety, abnormal thinking, hypoesthesia, agitation, confusion, hypotonia, asthenia, peripheral neuropathy, seizures, coma
CV: peripheral coldness, palpitations, hypotension, bradycardia, weak pulse, pseudoaneurysm, incomplete atrioventricular (AV) block, complete AV block, nodal arrhythmias, ventricular tachycardia, thrombophlebitis, embolism
EENT: diplopia, abnormal vision, ocular hypotony, iritis, retinal detachment
GI: nausea, vomiting, diarrhea, abdominal enlargement, dyspepsia, ileus, GI reflux, hematemesis, dysphagia, dry mouth, pancreatitis
GU: urinary retention, frequency, or incontinence; dysuria; cystalgia; prostatitis; renal dysfunction; nephrotoxicity
Hematologic: anemia, leukocytosis, thrombocytopenia, bleeding, neutropenia
Hepatic: hepatomegaly with steatosis
Metabolic: diabetes mellitus, hyperkalemia, lactic acidosis
Musculoskeletal: muscle contractions
Respiratory: pneumonia, crackles, rhonchi, bronchitis, pleurisy, dyspnea, wheezing, pleural effusion, pulmonary edema, pulmonary embolism, bronchospasm
Skin: diaphoresis, pallor, rash, urticaria, pruritus, bullous eruption, petchiae, cellulitis, abscess
Other: edema, development of human antichimeric antibodies

Interactions
Drug-drug. Allopurinol, ganciclovir (oral), ribavirin, tenofovir: increased didanosine blood level
Amprenavir, delavirdine, indinavir, ritonavir, saquinavir: altered didanosine pharmacokinetics

Reactions in bold are life-threatening.
Antacids, other drugs that increase gastric pH: increased risk of didanosine toxicity
Co-trimoxazole, pentamidine: increased risk of pancreatic toxicity
Dapsone, fluoroquinolones, ketoconazole: decreased blood levels of these drugs
Itraconazole: decreased itraconazole blood level
Methadone: 50% decrease in didanosine blood level

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, uric acid: increased levels
Granulocytes, hemoglobin, platelets, white blood cells: decreased values

Drug-food. Any food: decreased rate and extent of drug absorption

Patient monitoring
Run Monitor for signs and symptoms of pancreatitis. Report these to prescriber immediately.
Run Assess carefully for signs and symptoms of lactic acidosis, such as dizziness, light-headedness, and bradycardia.
- Monitor for signs and symptoms of peripheral neuropathy.
- In patients with renal impairment, watch for drug toxicity and hypermagnesemia (suggested by muscle weakness and confusion).

Patient teaching
- Tell patient to take drug on empty stomach.
- Advise patient using buffered powder to mix it with water, not juice, and to let powder dissolve for several minutes before taking.
- Instruct patient to immediately report abdominal pain, nausea, or vomiting.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

digoxin

Apo-Digoxin®, Digitek, Lanoxin, PMS Digoxin

Pharmacologic class: Cardiac glycoside
Therapeutic class: Inotropic, antiarrhythmic
Pregnancy risk category C

Action
Increases force and velocity of myocardial contraction and prolongs refractory period of atrioventricular (AV) node by increasing calcium entry into myocardial cells. Slows conduction through sinoatrial and AV nodes and produces antiarrhythmic effect.

Availability
Capsules: 0.05 mg, 0.1 mg, 0.2 mg
Elixir (pediatric): 0.05 mg/ml
Injection: 0.05 mg/ml, 0.1 mg/ml, 0.25 mg/ml
Tablets: 0.125 mg, 0.25 mg, 0.5 mg

Indications and dosages
- Heart failure; tachyarrhythmias; atrial fibrillation and flutter; paroxysmal atrial tachycardia
Adults: For rapid digitalizing, 0.6 to 1 mg I.V. over 24 hours, with 50% of total dosage given initially and additional fractions given at 4- to 8-hour intervals; or digitalizing dose of 0.75 to 1.25 mg P.O. over 24 hours, with 50% of total dosage given initially and additional fractions given at 4- to 8-hour intervals. Maintenance dosage is 0.063 to 0.5 mg/day (tablets) or 0.35 to 0.5 mg/day (gelatin capsules), depending on lean body weight, renal function, and drug blood level.
Children older than age 10: For rapid digitalizing, 8 to 12 mcg/kg I.V. over 24 hours, with 50% of total dosage given initially and additional fractions given at 4- to 8-hour intervals; or digitalizing dose of 10 to 15 mcg/kg P.O. over 24 hours, with 50% of total dosage given initially and additional fractions given at 6- to 8-hour intervals. Maintenance dosage is 25% to 35% of loading dosage, given daily as a single dose (determined by renal function).

Children ages 5 to 10: For rapid digitalizing, 15 to 30 mcg/kg I.V. over 24 hours, with 50% of total dosage given initially and additional fractions given at 4- to 8-hour intervals; or digitalizing dose of 20 to 35 mcg/kg P.O. over 24 hours, with 50% of total dosage given initially and additional fractions given at 6- to 8-hour intervals. Maintenance dosage is 25% to 35% of loading dosage, given daily in two divided doses (determined by renal function).

Children ages 2 to 5: For rapid digitalizing, 25 to 35 mcg/kg I.V. over 24 hours, with 50% of total dosage given initially and additional fractions given at 4- to 8-hour intervals; or digitalizing dose of 30 to 40 mcg/kg P.O. over 24 hours, with 50% of total dosage given initially and additional fractions given at 6- to 8-hour intervals. Maintenance dosage is 25% to 35% of loading dosage, given daily in two divided doses (determined by renal function).

Children ages 1 to 24 months: For rapid digitalizing, 30 to 50 mcg/kg I.V. over 24 hours, with 50% of total dosage given initially and additional fractions given at 4- to 8-hour intervals; or digitalizing dose of 35 to 60 mcg/kg P.O. over 24 hours, with 50% of total dosage given initially and additional fractions given at 6- to 8-hour intervals. Maintenance dosage is 25% to 35% of loading dosage, given daily in two divided doses (determined by renal function).

Infants (full-term): For rapid digitalizing, 20 to 30 mcg/kg I.V. over 24 hours, with 50% of total dosage given initially and additional fractions given at 4- to 8-hour intervals; or digitalizing dose of 25 to 35 mcg/kg P.O. over 24 hours, with 50% of total dosage given initially and additional fractions given at 6- to 8-hour intervals. Maintenance dosage is 25% to 35% of loading dosage, given daily in two divided doses (determined by renal function).

Infants (premature): For rapid digitalizing, 15 to 25 mcg/kg I.V. over 24 hours, with 50% of total dosage given initially and additional fractions given at 4- to 8-hour intervals; or digitalizing dose of 20 to 30 mcg/kg P.O. over 24 hours, with 50% of total dosage given initially and additional fractions given at 6- to 8-hour intervals. Maintenance dosage is 20% to 30% of loading dosage, given daily in two divided doses (determined by renal function).

Dosage adjustment
- Renal impairment
- Hyperthyroidism
- Elderly patients

Off-label uses
- Supraventricular tachyarrhythmias
- Intrauterine tachyarrhythmias

Contraindications
- Hypersensitivity to drug
- Uncontrolled ventricular arrhythmias
- AV block
- Idiopathic hypertrophic subaortic stenosis
- Constrictive pericarditis

Precautions
Use cautiously in:
- renal or hepatic impairment, electrolyte imbalances, myocardial infarction, thyroid disorders
- obesity
- elderly patients
- pregnant or breastfeeding patients.

Reactions in bold are life-threatening.
Administration
• Administer I.V. drug undiluted, or dilute with sterile water for injection, normal saline solution, or dextrose 5% in water as directed.

Know that drug has narrow therapeutic index, so dosage must be monitored regularly and patient must be monitored for signs and symptoms of toxicity.
• Know that for rapid effect, initial digitalizing dose generally is given in several divided doses over 12 to 24 hours.
• Be aware that dosages used for atrial arrhythmias generally are higher than those used for inotropic effect.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>0.5-2 hr</td>
<td>2-6 hr</td>
<td>2-4 days</td>
</tr>
<tr>
<td>I.V.</td>
<td>5-30 min</td>
<td>1-5 hr</td>
<td>2-4 days</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: fatigue, headache, asthenia
CV: bradycardia, ECG changes, arrhythmias
EENT: blurred or yellow vision
GI: nausea, vomiting, diarrhea
GU: gynecomastia
Hematologic: thrombocytopenia
Other: decreased appetite

Interactions
Drug-drug. Amiodarone, cyclosporine, diclofenac, diltaiazem, propafenone, quinidine, quinine, verapamil: increased digoxin blood level, possibly leading to toxicity
Amphotericin B, corticosteroids, meglolcin, piperaclilin, thiazide and loop diuretics, ticarcillin: hypokalemia, increased risk of digoxin toxicity
Antacids, cholestyramine, colestipol, kaolin/pectin: decreased digoxin absorption
Beta-adrenergic blockers, other antiarrhythmics (including disopyramide, quinidine): additive bradycardia
Laxatives (excessive use): hypokalemia, increased risk of digoxin toxicity
Spironolactone: reduced digoxin clearance, increased risk of digoxin toxicity
Thyroid hormones: decreased digoxin efficacy

Drug-diagnostic tests. Creatine kinase: increased level

Drug-food. High-fiber meal: decreased digoxin absorption

Drug-herbs. Coca seed, coffee seed, cola seed, guarana seed, horsetail, licorice, natural stimulants (such as aloe), yerba mate: increased risk of digoxin toxicity and hypokalemia

Ephedra (ma huang): arrhythmias
Hawthorn: increased risk of adverse cardiovascular effects
Indian snakeroot: bradycardia
Psyllium: decreased digoxin absorption
St. John’s wort: decreased blood level and effects of digoxin

Patient monitoring
• Assess apical pulse regularly for 1 full minute. If rate is less than 60 beats/minute, withhold dose and notify prescriber.

Monitor for signs and symptoms of drug toxicity (such as nausea, vomiting, visual disturbances, arrhythmias, and altered mental status). Be aware that therapeutic digoxin levels range from 0.5 to 2 ng/ml.
• Monitor ECG and blood levels of digoxin, potassium, magnesium, calcium, and creatinine.
• Stay alert for hypocalcemia. Know that this condition may predispose patient to digoxin toxicity and may decrease digoxin efficacy.

Watch closely for hypokalemia and hypomagnesemia. Know that digoxin toxicity may occur with these conditions despite digoxin blood levels below 2 ng/ml.

Patient teaching
• Tell patient to take drug at same time every day.

Instruct patient not to stop drug abruptly.
• Instruct patient not to take over-the-counter drugs without prescriber’s approval.

Teach patient how to recognize and report signs and symptoms of digoxin toxicity.

• Stress importance of follow-up testing as directed by prescriber.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

**diltiazem hydrochloride**


**Pharmacologic class:** Calcium channel blocker

**Therapeutic class:** Antianginal, antiarrhythmic (class IV), antihypertensive

**Pregnancy risk category C**

**Action**

Inhibits calcium from entering myo-cardial and vascular smooth-muscle cells, thereby depressing myocardial and smooth-muscle contraction and decreasing impulse formation and conduction velocity. As a result, systolic and diastolic pressures decrease.

**Availability**

Capsules (extended-release, sustained-release): 60 mg, 90 mg, 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg

Injection: 5 mg/ml in 10-ml vials, 25-mg ready-to-use syringes, 100-mg Monovial

Tablets: 30 mg, 60 mg, 90 mg, 120 mg

**Indications and dosages**

> Angina pectoris and vasospastic (Prinzmetal’s) angina; hypertension; supraventricular tachyarrhythmias; atrial flutter or fibrillation

**Adults:** 30 to 90 mg P.O. three to four times daily (tablets), or 60 to 120 mg P.O. b.i.d. (sustained-release), or 180 to 240 mg P.O. once daily (extended-release), adjusted after 14 days as needed, up to a total daily dosage of 360 mg. Or 0.25 mg/kg by I.V. bolus over 2 minutes; if response is inadequate after 15 minutes, may give 0.35 mg/kg over 2 minutes; may follow with continuous I.V. infusion at 10 mg/hour (at a range of 5 to 15 mg/hour) for up to 24 hours.

**Dosage adjustment**

• Severe hepatic or renal impairment

• Elderly patients

**Off-label uses**

• Unstable angina, coronary artery bypass graft surgery

• Tardive dyskinesia

• Migraine

• Hyperthyroidism

• Raynaud’s phenomenon

**Contraindications**

• Hypersensitivity to drug

• Atrial flutter or fibrillation associated with shortened refractory period (Wolff-Parkinson-White syndrome, with I.V. use)

• Recent myocardial infarction or pulmonary congestion

• Cardiogenic shock, concurrent I.V. beta-blocker therapy, ventricular tachycardia, neonates (with I.V. use,
because of benzyl alcohol in syringe formulation

- Sick sinus syndrome, second- or third-degree atrioventricular block (except in patients with ventricular pacemakers)
- Hypotension (systolic pressure below 90 mm Hg)

**Precautions**

Use cautiously in:

- severe hepatic or renal impairment, heart failure
- history of serious ventricular arrhythmias
- concurrent use of I.V. diltiazem and I.V. beta blockers
- elderly patients
- pregnant or breastfeeding patients
- children (safety not established).

**Administration**

- When giving I.V., dilute in dextrose 5% in water or normal saline solution.
- Give I.V. bolus dose over 2 minutes; a second bolus may be given after 15 minutes.
- Administer continuous I.V. infusion at a rate of 5 to 15 mg/hour.
- When giving by continuous I.V. infusion, make sure emergency equipment is available and that patient has continuous ECG monitoring with frequent blood pressure monitoring.
  - Don’t crush tablets or sustained-release capsules; they must be swallowed whole.
- Withhold dose if systolic blood pressure falls below 90 mm Hg, diastolic pressure is below 60 mm Hg, or apical pulse is slower than 60 beats/minute.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30 min</td>
<td>2-3 hr</td>
<td>6-8 hr</td>
</tr>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>12 hr</td>
</tr>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>14 hr</td>
<td>Up to 24 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>2-5 min</td>
<td>2-4 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** headache, abnormal dreams, anxiety, confusion, dizziness, drowsiness, nervousness, psychiatric disturbances, asthenia, paresthesia, syncope, tremor

**CV:** peripheral edema, bradycardia, chest pain, hypotension, palpitations, tachycardia, arrhythmias, heart failure

**EENT:** blurred vision, tinnitus, epistaxis

**GI:** nausea, vomiting, diarrhea, constipation, dyspepsia, dry mouth

**GU:** urinary frequency, dysuria, nocturia, polyuria, gynecomastia, sexual dysfunction

**Hematologic:** anemia, leukopenia, thrombocytopenia

**Metabolic:** hyperglycemia

**Musculoskeletal:** joint stiffness, muscle cramps

**Respiratory:** cough, dyspnea

**Skin:** rash, dermatitis, flushing, diaphoresis, photosensitivity, pruritus, urticaria, erythema multiforme

**Other:** unpleasant taste, gingival hyperplasia, weight gain, decreased appetite, Stevens-Johnson syndrome

**Interactions**

**Drug-drug.** Beta-adrenergic blockers, digoxin, disopyramide, phenytoin: bradycardia, conduction defects, heart failure

Carbamazepine, cyclosporine, quinidine: decreased diltiazem metabolism, increased risk of toxicity

Cimetidine, ranitidine: increased blood level and effects of diltiazem

Fentanyl, nitrates, other antihypertensives, quinidine: additive hypotension

HMG-CoA reductase inhibitors, imipramine, sirolimus, tacrolimus: increased blood levels of these drugs

Lithium: decreased lithium blood level, reduced antimanic control

Nonsteroidal anti-inflammatory drugs: decreased antihypertensive effect of diltiazem

Theophylline: increased theophylline effects

352 diltiazem hydrochloride

Canada UK Hazardous drug High alert drug
Drug-diagnostic tests. Hepatic enzymes: increased levels

Drug-food. Grapefruit juice: increased blood level and effects of diltiazem

Drug-behaviors. Acute alcohol ingestion: additive hypotension

Patient monitoring
- Check blood pressure and ECG before starting therapy, and monitor closely during dosage adjustment period. Withhold dose if systolic pressure is below 90 mm Hg.
- Monitor for signs and symptoms of heart failure and worsening arrhythmias.
- Supervise patient during ambulation.

Patient teaching
- Instruct patient to swallow extended-release capsules whole and not to crush or chew them.
- Advise patient to change position slowly to minimize light-headedness and dizziness.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and behaviors mentioned above.

dimenhydrinate

Apo-Dimenhydrinate®, Arlevert®, Dramamine, Dramanate®, Gravol®, PMS-Dimenhydrinate®, Travamine®

Pharmacologic class: Anticholinergic
Therapeutic class: Antiemetic, anti-vertigo agent
Pregnancy risk category B

Action
Prevents nausea and vomiting by inhibiting vestibular stimulation of chemoreceptor trigger zone and inhibiting stimulation of vomiting center in brain

Availability
Capsules: 50 mg
Capsules (extended-release): 25 mg
Elixir: 12.5 mg/5 ml, 15 mg/5 ml
Injection: 50 mg/ml
Liquid: 12.5 mg/4 ml, 15.62 mg/5 ml
Suppositories: 50 mg, 100 mg
Tablets: 50 mg
Tablets (chewable): 50 mg

Indications and dosages
➣ Prevention and treatment of nausea, vomiting, dizziness, and vertigo

Adults and children ages 12 and older:
50 to 100 mg P.O. q 4 hours (not to exceed 400 mg/day), or 50 to 100 mg P.R. q 6 to 8 hours, or 50 mg I.M. or I.V. q 4 hours p.r.n.

Children ages 6 to 12:
25 to 50 mg P.O. q 6 to 8 hours (not to exceed 150 mg/day), or 25 to 50 mg P.R. q 8 to 12 hours, or 1.25 mg/kg I.M. (37.5 mg/m²) q 6 hours p.r.n.

Children ages 2 to 6:
12.5 to 25 mg P.O. q 6 to 8 hours (not to exceed 75 mg/day)

Contraindications
- Hypersensitivity to drug or tartrazine
- Alcohol intolerance

Precautions
Use cautiously in:
- angle-closure glaucoma, seizure disorders, prostatic hypertrophy
- children younger than age 2

Administration
- For I.V. use, dilute with dextrose 5% in water or normal saline solution.
- Give each 50-mg I.V. dose over 2 minutes.
Don’t administer by I.V. route to premature or low-birth-weight infants. Solution contains benzyl alcohol, which can cause fatal “gasing” syndrome.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>15-60 min</td>
<td>1-2 hr</td>
<td>3-6 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>Unknown</td>
<td>3-6 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>20-30 min</td>
<td>1-2 hr</td>
<td>3-6 hr</td>
</tr>
<tr>
<td>P.R.</td>
<td>30-45 min</td>
<td>Unknown</td>
<td>6-12 hr</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: drowsiness, dizziness, headache, paradoxical stimulation (in children)
CV: hypotension, palpitations
EENT: blurred vision, tinnitus
GI: diarrhea, constipation, dry mouth
GU: dysuria, urinary frequency
Skin: photosensitivity
Other: decreased appetite, pain at I.M. site

Interactions

Drug-drug. Disopyramide, quinidine, tricyclic antidepressants: increased anticholinergic effects
MAO inhibitors: intensified and prolonged anticholinergic effects
Other CNS depressants (such as antihistamines, opioids, sedative-hypnotics): additive CNS depression
Ototoxic drugs (such as aminoglycosides, ethacrynic acid): masking of signs or symptoms of ototoxicity

Drug-diagnostic tests. Allergy skin tests: false-negative results

Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring

- Assess for lethargy and drowsiness.
- Monitor for dizziness, nausea, and vomiting (possible indicators of drug toxicity).

Patient teaching

- To prevent motion sickness, advise patient to take drug 30 minutes before traveling and to repeat dose before meals and at bedtime.
- Instruct patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Caution patient to avoid alcohol and sedative-hypnotics during therapy.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

**dinoprostone (prostaglandin E2, PGE2)**

Cervidil Vaginal Insert, Prepidil Endocervical Gel, Propress®, Prostin E2 Vaginal Suppository

**Pharmacologic class:** Oxytocic, prostaglandin

**Therapeutic class:** Abortifacient, cervical ripening agent

**Pregnancy risk category C**

**FDA BOXED WARNING**

- Dinoprostone vaginal suppository should be given only by trained personnel who adhere strictly to recommended dosages, in hospital that can provide immediate intensive care and acute surgical facilities.

**Action**

Initiates strong contractions of uterine smooth muscle by stimulating myometrium and promoting cervical softening, effacement, and dilation

**Availability**

Endocervical gel: 0.5 mg in 3-g gel vehicle in prefilled syringe with catheter
Vaginal insert: 10 mg
Vaginal suppositories: 20 mg

**Indications and dosages**

- **Cervical ripening**
  - **Adults:** 0.5 mg endocervical gel vaginally; if response is poor, may repeat in 6 hours (not to exceed 1.5 mg in 24 hours). Or one 10-mg vaginal insert.
  - **To induce abortion**
  - **Adults:** One 20-mg vaginal suppository; repeat q 3 to 5 hours (not to exceed total dosage of 240 mg or duration of 48 hours).

**Contraindications**

- Hypersensitivity to prostaglandins or additives in gel or suppository
- Active genital herpes infection
- Acute pelvic inflammatory disease
- Ruptured membranes, placenta previa, or unexplained vaginal bleeding during pregnancy

**Precautions**

Use cautiously in:

- pulmonary, cardiac, renal, or hepatic disease; asthma; hypotension; adrenal disorders; diabetes mellitus; epilepsy; glaucoma
- multiparity.

**Administration**

- Keep patient supine for 15 to 30 minutes after gel administration and for 10 minutes after administering suppository to prevent drug expulsion.
- Store suppositories in freezer; bring to room temperature before using.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaginal (gel)</td>
<td>Rapid</td>
<td>30-45 min</td>
<td>Unknown</td>
</tr>
<tr>
<td>Vaginal (insert)</td>
<td>Rapid</td>
<td>Unknown</td>
<td>12 hr</td>
</tr>
<tr>
<td>Vaginal (suppository)</td>
<td>10 min</td>
<td>Unknown</td>
<td>2-3 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- CNS: headache, drowsiness, syncope
- CV: hypotension, hypertension
- GI: nausea, vomiting, diarrhea
- GU: urinary tract infection, vaginal or uterine pain, uterine contractile abnormalities, warm vaginal sensation, uterine hypertonicity, uterine rupture
- Musculoskeletal: back pain
- Respiratory: cough, dyspnea, wheezing
- Other: allergic reactions including chills, fever, and anaphylaxis

**Interactions**

**Drug-drug. Other oxytocics:** increased oxytocic effects

**Patient monitoring**

- Monitor uterine contractions and observe for excessive vaginal bleeding and cramping. Record sanitary pad count.
- Monitor vital signs and assess for drug-induced fever. Report significant blood pressure and pulse changes.
- Assess for wheezing, chest pain, and dyspnea.
- Evaluate for GI upset. To minimize, give antiemetic before dinoprostone therapy.

**Patient teaching**

- Advise patient to stay in supine position, as prescribed, after administration.
- Instruct patient to report fever, bleeding, or abdominal cramps.
- Tell patient to avoid douches, tampons, tub baths, and sexual intercourse for at least 2 weeks after receiving drug.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

Reactions in **bold** are life-threatening.
diphenhydramine hydrochloride

Aler-Cap, Aler-Dryl, Allerdryl, AllerMax, Banophen, Benadryl, Benadryl Allergy, Benadryl Child Chesty Cough, Benadryl Dye-Free Allergy, Children’s Allergy Fastmelt, Compoz Nighttime Sleep Aid, Diphen AF, Diphenhist, Genahist, Histergan, Hydramine, Mandalyn Paedetriac, Nightcalm, Nytol, PMS-Diphenhydramine, Siladryl, Simply Sleep, Sleepeaze, Sominex, Twilite, Unisom Maximum Strength SleepGels

**Pharmacologic class:** Ethanolamine derivative, nonselective histamine-1 receptor antagonist

**Therapeutic class:** Antihistamine, antitussive, antiemetic, antivertigo agent, antidyskinetic

**Pregnancy risk category B**

**Action**
Interferes with histamine effects at histamine-1-receptor sites; prevents but doesn’t reverse histamine-mediated response. Also possesses CNS depressant and anticholinergic properties.

**Availability**
- Capsules: 25 mg, 50 mg
- Elixir: 12.5 mg/5 ml
- Injection: 10 mg/ml, 50 mg/ml
- Strips (orally disintegrating): 12.5 mg, 25 mg
- Syrup: 12.5 mg/5 ml
- Tablets: 25 mg, 50 mg
- Tablets (chewable): 12.5 mg, 25 mg
- Tablets (orally disintegrating): 12.5 mg

**Indications and dosages**
- Allergy symptoms caused by histamine release (including anaphylaxis, seasonal and perennial allergic rhinitis, and allergic dermatoses); nausea; vertigo
  - **Adults and children over age 12:** 25 to 50 mg P.O. q 4 to 6 hours, or 10 to 50 mg I.V. or I.M. q 2 to 3 hours p.r.n. (Some patients may need up to 100 mg.) Don’t exceed 400 mg/day.
  - **Children ages 6 to 12:** 12.5 to 25 mg P.O. q 4 to 6 hours, or 1.25 mg/kg (37.5 mg/m²) I.M. or I.V. q.i.d. Don’t exceed 150 mg/day.
  - **Children ages 2 to 5:** 6.25 mg P.O. q 4 to 6 hours. Don’t exceed 37.5 mg/day.
- **Cough**
  - **Adults:** 25 mg P.O. q 4 hours p.r.n. Don’t exceed 150 mg/day.
  - **Children ages 6 to 12:** 12.5 mg P.O. q 4 hours. Don’t exceed 75 mg/day.
  - **Children ages 2 to 5:** 6.25 mg P.O. q 4 hours. Don’t exceed 37.5 mg/24 hours.
- **Dyskinesia; Parkinson’s disease**
  - **Adults:** Initially, 25 mg P.O. t.i.d.; may be increased to a maximum of 50 mg q.i.d.
- **Mild nighttime sedation**
  - **Adults:** 50 mg P.O. 20 to 30 minutes before bedtime

**Dosage adjustment**
- Elderly patients

**Off-label uses**
- Drug-induced extrapyramidal reactions

**Contraindications**
- Hypersensitivity to drug
- Alcohol intolerance
- Acute asthma attacks
- MAO inhibitor use within past 14 days
- Breastfeeding
- Neonates, premature infants

**Precautions**
Use cautiously in:
- severe hepatic disease, angle-closure glaucoma, seizure disorders, prostatic hypertrophy, cardiovascular disease, hyperthyroidism

© Canada ☮ UK ☠ Hazardous drug ☘ High alert drug
• elderly patients
• pregnant patients (safety not established)
• children younger than age 2 (safety not established).

Administration
• For motion sickness, administer 30 minutes before activity.
• For I.V. use, check compatibility before mixing with other drugs.
• Inject I.M. dose deep into large muscle mass; rotate sites.
• Discontinue drug 4 days before allergy skin testing to avoid misleading results.

Don’t give within 14 days of MAO inhibitors.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>15-60 min</td>
<td>1-4 hr</td>
<td>4-8 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>Unknown</td>
<td>4-8 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>20-30 min</td>
<td>1-4 hr</td>
<td>4-8 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: drowsiness, dizziness, headache, paradoxical stimulation (especially in children)
CV: hypotension, palpitations, tachycardia
EENT: blurred vision, tinnitus
GI: diarrhea, constipation, dry mouth
GU: dysuria, urinary frequency or retention
Skin: photosensitivity
Other: decreased appetite, pain at I.M. injection site

Interactions
Drug-drug. Antihistamines, opioids, sedative-hypnotics: additive CNS depression
Disopyramide, quinidine, tricyclic antidepressants: increased anticholinergic effects
MAO inhibitors: intensified and prolonged anticholinergic effects
Drug-diagnostic tests. Skin allergy tests: false-negative results

Hemoglobin, platelets: decreased values
Drug-herbs. Angel’s trumpet, jimson weed, scopolia: increased anticholinergic effects
Chamomile, hops, kava, skullcap, valerian: increased CNS depression
Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring
• Monitor cardiovascular status, especially in patients with cardiovascular disease.
• Supervise patient during ambulation. Use side rails as necessary.

Patient teaching
• Advise patient to avoid alcohol and other depressants such as sedatives while taking drug.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

Reactions in bold are life-threatening.
Action
Acts on smooth muscle of GI tract by decreasing peristalsis, which inhibits motility. (Small amount of atropine is added to reduce abuse potential.)

Availability
Liquid: 2.5 mg diphenoxylate and 0.025 mg atropine/5 ml
Tablets: 2.5 mg diphenoxylate and 0.025 mg atropine

Indications and dosages
➤ Diarrhea
Adults: Initially, 5 mg P.O. three to four times daily, then 5 mg/day as needed (not to exceed 20 mg/day). Decrease dosage when desired response occurs.
Children: Initially, 0.3 to 0.4 mg/kg P.O. (liquid only) daily in four divided doses. Decrease dosage when desired response occurs.

Dosage adjustment
• Elderly patients

Contraindications
• Hypersensitivity to drug
• Obstructive jaundice
• Diarrhea associated with pseudomembranous colitis or enterotoxin-producing bacteria
• Angle-closure glaucoma
• Concurrent MAO inhibitor use
• Children younger than age 2

Precautions
Use cautiously in:
• inflammatory bowel disease; prostatic hypertrophy; severe hepatic disease (use with extreme caution)
• concurrent use of drugs that cause physical dependence; history of physical drug dependence
• elderly patients
• pregnant or breastfeeding patients
• children (safety not established in children younger than age 12).

Administration
❖ Don’t confuse brand name Lomotil with Lamictal (an anticonvulsant). Serious errors have been reported.
• Withhold drug if patient has severe fluid or electrolyte imbalance.
• Administer with food if GI upset occurs.
❖ Don’t give within 14 days of MAO inhibitors.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>45-60 min</td>
<td>2 hr</td>
<td>3-4 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, confusion, drowsiness, headache, insomnia, nervousness
CV: tachycardia
EENT: blurred vision, dry eyes
GI: nausea, vomiting, constipation, epigastric distress, ileus, dry mouth
GU: urinary retention
Skin: flushing

Interactions
Drug-drug. CNS depressants (including antihistamines, sedative-hypnotics, opioids): increased CNS depression
Anticholinergic-like drugs (including tricyclic antidepressants, disopyramide): increased anticholinergic effects
MAO inhibitors: hypertensive crisis

Drug-diagnostic tests. Amylase: increased level

Drug-herbs. Angel’s trumpet, jimsonweed, scopolia: increased anticholinergic effects

Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring
❖ Assess for and report abdominal distention and signs or symptoms of decreased peristalsis.
• Watch for signs and symptoms of dehydration.
• Assess frequency and consistency of bowel movements.
Patient teaching
- Instruct patient to report persistent diarrhea.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Tell patient that prolonged use may lead to dependence.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

**Dipyridamole**

Apo-Dipyridamole FC®, Apo-Dipyridamole SC®, Persantin®, Persantine

**Pharmacologic class:** Platelet adhesion inhibitor

**Therapeutic class:** Antiplatelet agent, diagnostic agent (coronary vasodilator)

**Pregnancy risk category B**

**Action**
Unclear. May reduce platelet aggregation by inhibiting phosphodiesterase, adenosine uptake, or formation of thromboxane A₂. Produces vasodilation, thereby increasing coronary blood flow.

**Availability**
- Injection: 10 mg/2 ml
- Tablets: 25 mg, 50 mg, 75 mg, 100 mg

**Indications and dosages**
- To prevent thromboembolism in patients with prosthetic heart valves
- **Adults:** 75 to 100 mg P.O. q.i.d.
- Alternative to exercise in thallium myocardial perfusion imaging
  - **Adults:** 0.57 mg/kg I.V. infused over 4 minutes (0.142 mg/kg/minute). Maximum I.V. dosage is 60 mg.

**Off-label uses**
- Prevention of myocardial reinfarction (given with aspirin)
- Thrombotic thrombocytopenia purpura

**Contraindications**
- Hypersensitivity to drug

**Precautions**
Use cautiously in:
- hypotension, platelet defects
- pregnant or breastfeeding patients (safety not established)
- children younger than age 12 (safety not established).

**Administration**
- Know that drug is usually given with warfarin when used to prevent thromboembolism.
- Dilute I.V. solution with dextrose 5% in water or normal or half-normal saline solution, as directed.
- Give single I.V. dose over 4 minutes.
- When used as diagnostic agent, administer within 5 minutes of thallium injection.
- Give oral form with a full glass of water at least 1 hour before or 2 hours after meals. If gastric distress occurs, give with food.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>6.5 min</td>
<td>30 min</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- **CNS:** dizziness, headache, syncope; transient cerebral ischemia or weakness (with I.V. use)
- **CV:** hypotension, arrhythmias, myocardial infarction (all with I.V. use)
GI: nausea, vomiting diarrhea, dyspepsia
Hematologic: prolonged bleeding time
Respiratory: bronchospasm (with I.V. use)
Skin: rash, flushing (with I.V. use)

Interactions
Drug-drug. Anticoagulants, cefamandole, cefoperazone, cefotetan, nonsteroidal anti-inflammatory drugs, plicamycin, sulfipyrazone, thrombolytics, valproic acid: increased risk of bleeding
Aspirin: increased effect on platelet aggregation
Theophylline: negation of dipyridamole effects during thallium imaging

Drug-behaviors. Alcohol use: increased risk of hypotension

Patient monitoring
• Monitor for therapeutic efficacy, including improved exercise tolerance and decreased need for nitrates.
• Assess platelet and coagulation studies regularly.
• Monitor ECG and vital signs, especially blood pressure.

Patient teaching
• Advise patient to take drug 1 hour before or 2 hours after meals for best absorption.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and behaviors mentioned above.

FDA BOXED WARNING
• Drug has known proarrhythmic properties and doesn’t improve survival in patients without life-threatening arrhythmias. Use only for patients with life-threatening ventricular arrhythmias.

Action
Slows diastolic depolarization rate, reduces upstroke velocity, and prolongs duration of action potential and refractory period. Also decreases disparity in refractoriness between infarcted and adjacent normally perfused myocardium.

Availability
Capsules: 100 mg, 150 mg
Capsules (extended-release): 100 mg, 150 mg
Tablets (extended-release): 150 mg

Indications and dosages
Ventricular tachycardia and other ventricular arrhythmias not severe enough to require cardioversion
Adults weighing more than 50 kg (110 lb): Initially, 200 to 300 mg P.O. as a loading dose, then 150 mg P.O. q 6 hours (conventional capsules) or 300 mg P.O. q 12 hours (extended-release forms)
Adults weighing 50 kg (110 lb) or less:
100 mg P.O. q 6 hours (conventional capsules) or 200 mg P.O. q 12 hours (extended-release capsules)

Children ages 12 to 18: 6 to 15 mg/kg P.O. daily in four divided doses given q 6 hours

Children ages 4 to 11: 10 to 15 mg/kg P.O. daily in four divided doses given q 6 hours

Children ages 1 to 3: 10 to 20 mg/kg P.O. daily in four divided doses given q 6 hours

Children younger than age 1: 10 to 30 mg/kg P.O. daily in four divided doses given q 6 hours

Dosage adjustment
- Renal or hepatic insufficiency
- Acute myocardial infarction

Off-label uses
- Paroxysmal supraventricular tachycardia

Contraindications
- Hypersensitivity to drug
- Cardiogenic shock
- Second- or third-degree heart block
- Sick sinus syndrome
- Congenital QT prolongation

Precautions
Use cautiously in:
- heart failure, left ventricular dysfunction, conduction abnormalities, hepatic or renal insufficiency, prostate enlargement, myasthenia gravis, glaucoma, diabetes mellitus
- pregnant or breastfeeding patients
- children.

Administration
- Start therapy 6 to 12 hours after last quinidine dose or 3 to 6 hours after last procainamide dose.
- Don’t administer within 48 hours before or 24 hours after verapamil.

- Don’t crush extended-release capsules or tablets; they must be swallowed whole.

Know that patient with atrial flutter or fibrillation should receive digicards before starting disopyramide therapy to ensure that drug doesn’t increase ventricular rate.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>2 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>4.9 ± 1.4 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, agitation, depression, fatigue, headache, nervousness, acute psychosis, syncope
CV: chest pain, orthostatic hypotension, heart failure, heart block, arrhythmias
EENT: blurred vision, angle-closure glaucoma, dry eyes, dry nose
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, bloating, flatulence, dry mouth
GU: urinary hesitancy or retention, erectile dysfunction
Hematologic: anemia, thrombocytopenia, agranulocytosis
Hepatic: jaundice
Metabolic: hypokalemia, hypoglycemia
Musculoskeletal: muscle weakness, myalgia
Respiratory: dyspnea
Skin: rash, pruritus, dermatoses
Other: edema, decreased appetite, weight gain

Interactions
Drug-drug. Antiarrhythmics, fluoroquinolones: widened QRS complex or QT interval
Anticholinergics: increased risk of adverse effects
Clarithromycin, erythromycin: increased disopyramide blood level

Reactions in bold are life-threatening.
Phenytoin: increased disopyramide metabolism and decreased disopyramide blood level
Rifampin: decreased disopyramide blood level

**Drug-diagnostic tests.** Blood urea nitrogen, creatinine, hepatic enzymes, lipids: increased levels
Glucose, hematocrit, hemoglobin: decreased levels

**Drug-herbs.** Aloe, buckthorn bark or berry, cascara sagrada bark, senna pod or leaf: increased drug action
Jimsonweed: increased risk of adverse cardiovascular effects

**Patient monitoring**
- Check apical pulse before administering. Withhold dose if rate is below 60 or above 120 beats/minute.
- Monitor ECG for complete heart block.
- Assess closely for signs and symptoms of heart failure.
- Evaluate for signs and symptoms of fluid retention, such as rapid weight gain.
- Monitor electrolyte levels regularly, checking especially for hypokalemia.

**Patient teaching**
- Instruct patient to swallow extended-release capsules and tablets whole and not to crush or chew them.
- Instruct patient to take drug exactly as prescribed and not to stop drug without consulting prescriber.
- Tell patient to weigh himself daily and report weekly gain of more than 2 lb (1 kg).
- Instruct patient to watch for and promptly report ankle swelling.
- Advise patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness from sudden blood pressure decrease.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

### dobutamine hydrochloride

**Pharmacologic class:** Sympathomimetic, adrenergic

**Therapeutic class:** Inotropic

**Pregnancy risk category B**

**Action**
Stimulates beta₁-adrenergic receptors of heart, causing a positive inotropic effect that increases myocardial contractility and stroke volume. Also reduces peripheral vascular resistance, decreases ventricular filling pressure, and promotes atrioventricular conduction.

**Availability**
*Injection:* 12.5 mg/ml in 20-ml vials

**Indications and dosages**
* Short-term treatment of cardiac decompensation caused by depressed contractility (such as during refractory heart failure); adjunct in cardiac surgery
* **Adults:** 2.5 to 10 mcg/kg/minute I.V. as a continuous infusion, adjusted to hemodynamic response

**Dosage adjustment**
- Elderly patients

**Off-label uses**
- Adjunct in myocardial infarction (MI) and septic shock
- Diagnosis of coronary artery disease (echocardiography stress test, ventriculography, computed tomography)

**Contraindications**
- Hypersensitivity to drug
Idiopathic hypertrophic subaortic stenosis

Precautions
Use cautiously in:
- hypertension, MI, atrial fibrillation, hypovolemia
- pregnant or breastfeeding patients
- children.

Administration
- As needed, correct hypovolemia before starting therapy by giving volume expanders, as prescribed.
- Use infusion pump or microdrip I.V. infusion set.
- Dilute with dextrose 5% in water or normal saline solution to at least 50 ml of solution. Know that drug is incompatible with alkaline solutions, such as sodium bicarbonate injection.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>1-2 min</td>
<td>10 min</td>
<td>Brief</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache
CV: hypertension, hypotension, tachycardia, premature ventricular contractions, angina, palpitations, nonspecific chest pain, phlebitis
GI: nausea, vomiting
Metabolic: hypokalemia
Respiratory: dyspnea, asthma attacks
Skin: extravasation with tissue necrosis
Other: hypersensitivity reactions including anaphylaxis

Interactions
Drug-drug. Beta-adrenergic blockers: increased alpha-adrenergic effects
Bretylium: potentiation of vasopressor activity
Cyclopropane, halothane: serious arrhythmias
Guanethidine: decreased hypotensive effects
Thyroid hormone: increased cardiovascular effects

Tricyclic antidepressants: potentiation of cardiovascular and vasopressor effects

Drug-herbs. Rue: increased inotropic potential

Patient monitoring
- Monitor ECG and blood pressure continuously during administration.
- Monitor cardiac output, pulmonary capillary wedge pressure, and central venous pressure.
- Monitor fluid intake and output and watch for signs and symptoms of worsening heart failure.
- Assess electrolyte levels. Stay especially alert for hypokalemia.

Patient teaching
- Instruct patient to report anginal pain, headache, leg cramps, and shortness of breath.
- Explain need for close observation and monitoring.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and herbs mentioned above.

Reactions in bold are life-threatening.
history of platinum-based chemotherapy and is receiving drug as a single agent at dosage of 100 mg/m².

- Generally, drug shouldn’t be given to patients with bilirubin level above upper limit of normal (ULN) or those with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) above 1.5 x ULN concomitant with alkaline phosphatase (ALP) level above 2.5 x ULN. Bilirubin elevations or transaminase abnormalities concurrent with ALP abnormalities increases patient’s risk for grade 4 neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated transaminase elevations above 1.5 x ULN have higher rate of grade 4 febrile neutropenia, but without increased incidence of toxic death. Before each cycle, obtain bilirubin, ALT or AST, and ALP values and have physician review them.

- Don’t give to patients with neutrophil count below 1,500 cells/mm³. Obtain frequent blood cell counts to monitor for neutropenia (which may be severe and cause infection).

- Severe hypersensitivity reactions and fatal anaphylaxis (rare) have occurred in patients who received recommended 3-day dexamethasone premedication. If hypersensitivity reaction occurs, discontinue docetaxel immediately and give appropriate therapy. Don’t give drug to patients with history of severe hypersensitivity reactions to it or other drugs containing polysorbate 80. Severe fluid retention may occur despite dexamethasone premedication regimen.

### Indications and dosages

- Metastatic breast cancer unresponsive to previous regimens
  **Adults:** 60 to 100 mg/m² I.V. over 1 hour q 3 weeks

- Adjuvant treatment of operable node-positive breast cancer
  **Adults:** 75 mg/m² 1 hour after doxorubicin 50 mg/m² and cyclophosphamide 500 mg/m² q 3 weeks for six courses

- Metastatic non-small-cell lung cancer; androgen-independent (hormone refractory) metastatic prostate cancer
  **Adults:** 75 mg/m² I.V. over 1 hour q 3 weeks

- Gastric adenocarcinoma; head and neck cancer
  **Adults:** 75 mg/m² as a 1-hour infusion, followed by cisplatin as a 1- to 3-hour infusion (both on day 1 only), followed by fluorouracil given as a 24-hour continuous I.V. infusion for 5 days, starting at the end of the cisplatin infusion. Treatment is repeated q 3 weeks.

### Dosage adjustment

- Febrile neutropenia

### Contraindications

- Hypersensitivity to drug or polysorbate 80
- Hepatic impairment
- Neutrophil count below 1,500 cells/mm³

### Precautions

Use cautiously in:
- females of childbearing age
- pregnant or breastfeeding patients.

### Administration

- Assess bilirubin, ALT, AST, and ALP levels before starting each cycle of drug therapy.
- Premedicate patient with oral corticosteroids before docetaxel administration to reduce fluid retention and severity of hypersensitivity reactions.
• Premedicate patient with antiemetics and hydrate with I.V. fluids, as prescribed, before cisplatin administration.
  ❗ Don’t let drug concentrate contact plasticized polyvinyl chloride equipment or devices.
• Know that when used for prostate cancer, drug must be given with prednisone, as prescribed.
• Dilute with accompanying diluent solution; rotate vial gently to mix. Once foam has largely dissipated, withdraw prescribed amount of drug and mix in glass or polypropylene bottle or in plastic bag with 250 ml of normal saline solution or dextrose 5% in water.
• Mix solution thoroughly and infuse over 1 hour, using polyethylene-lined infusion set.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>Unknown</td>
<td>7 days</td>
</tr>
</tbody>
</table>

### Adverse reactions

**CNS:** fatigue, asthenia, neurosensory deficits, peripheral neuropathy  
**CV:** peripheral edema, **cardiac tamponade, pericardial effusion**  
**GI:** nausea, vomiting, diarrhea, stomatitis, ascites  
**Hematologic:** anemia, **thrombocytopenia, leukopenia**  
**Musculoskeletal:** myalgia, joint pain  
**Respiratory:** bronchospasm, pulmonary edema  
**Skin:** alopecia, rash, dermatitis, desquamation, erythema, nail disorders  
**Other:** edema, hypersensitivity reactions including **anaphylaxis**

### Interactions

**Drug-drug.** Antineoplastics: additive bone marrow depression  
Cyclosporine, erythromycin, ketoconazole, troleandomycin: significant change in docetaxel effects  
**Live-virus vaccines:** increased risk of infection

### Patient monitoring

 ➡️ Watch for signs and symptoms of anaphylaxis or other hypersensitivity reactions, especially with first two doses.  
• Monitor vital signs and fluid intake and output. Watch for signs and symptoms of fluid overload and bronchospasm.  
• Monitor CBC, and assess for signs and symptoms of blood dyscrasias.  
• Closely monitor neutrophil and platelet counts before and during therapy.  
• Observe I.V. site frequently for extravasation.  
• Assess neurologic status to detect neurosensory deficits and peripheral neuropathy.

### Patient teaching

• Instruct patient to weigh himself daily and to immediately report sudden weight gain or difficulty breathing.  
 ➡️ Tell patient to report signs and symptoms of blood dyscrasias. Inform him that he’ll undergo frequent blood testing to monitor these effects.  
 ➡️ Advise patient to immediately report rash or difficulty breathing.  
• Inform patient that nail disorders and hair loss are common with docetaxel use, but that hair and nails will grow back after therapy ends.  
• Advise female patient of childbearing age to use effective contraception during therapy and to notify prescriber if she suspects pregnancy.  
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.
**docusate calcium**

Apo-Docusate Calcium®, Calax®, DC Softgels, Novo-Docusate Calcium®, PMS-Docusate Calcium®, Ratio-Docusate Calcium®, Soflax C®, Stool Softener DC, Surfak Liquigels

**docusate sodium**

Apo-Docusate Sodium®, Colace, Correctol Stool Softener®, Diocto, Dioctyl®, Docusol®, Dom-Docusate Sodium®, D.O.S. Softgels, D-S-S, DulcoEase®, Genasoft Softgels, Nor-galax®; Novo Docusate®, PHL-Docusate Sodium®, PMS-Docusate Sodium®, Ratio-Docusate Sodium®, Selax®, Silace

**Pharmacologic class:** Emollient  
**Therapeutic class:** Stool softener, surfactant  
**Pregnancy risk category C**

**Action**  
Increases absorption of liquid into stool, resulting in softening of fecal mass. Also promotes electrolyte and water secretion into colon.

**Availability**  
**docusate calcium**  
Capsules: 240 mg  
Capsules (soft gels): 240 mg  
**docusate sodium**  
Capsules: 50 mg, 100 mg, 250 mg  
Capsules (soft gels): 100 mg, 250 mg  
Liquid: 150 mg/15 ml  
Syrup: 50 mg/15 ml, 60 mg/15 ml, 20 mg/5 ml, 100 mg/30 ml, 150 mg/15 ml  
Tablets: 100 mg

**Indications and dosages**  
➤ Stool softener  
**Adults and children older than age 12:**  
240 mg (docusate calcium) or 50 to 200 mg (docusate sodium) P.O. daily until bowel movements are normal  
**Children ages 6 to 12:** 40 to 120 mg (docusate sodium) P.O. daily  
**Children ages 3 to 6:** 20 to 60 mg (docusate sodium) P.O. daily

**Contraindications**  
• Hypersensitivity to drug  
• Abdominal pain, nausea, or vomiting  
• Intestinal obstruction

**Precautions**  
Use cautiously in:  
• pregnant or breastfeeding patients.

**Administration**  
• Give tablets and capsules with full glass of water.  
• Give liquid solution with milk or fruit juice.  
• Be aware that excessive or long-term use may lead to laxative dependence.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>24-48 hr</td>
<td>Unknown</td>
<td>Unknown (up to 5 days)</td>
</tr>
</tbody>
</table>

**Adverse reactions**  
**EENT:** throat irritation  
**GI:** nausea, diarrhea, mild cramps  
**Skin:** rash  
**Other:** bitter taste, decreased appetite, laxative dependence

**Interactions**  
**Drug-drug.** Mineral oil: increased mineral oil absorption, causing toxicity  
Warfarin: decreased warfarin effects (with high doses)

**Patient monitoring**  
• If diarrhea occurs, withhold drug and notify prescriber.
Know that therapeutic efficacy usually becomes apparent 1 to 3 days after first dose.

**Patient teaching**
- Instruct patient to drink sufficient fluids with each dose and to increase fluid intake during the day.
- Advise patient to prevent constipation by increasing fluids and consuming more dietary fiber (as in fruits and bran).
- Inform patient that excessive or prolonged use may lead to laxative dependence.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

---

**dolasetron mesylate**

Anzemet

**Pharmacologic class:** Selective serotonin subtype 3 (5-HT₃) receptor antagonist  
**Therapeutic class:** Antiemetic  
**Pregnancy risk category B**

**Action**
Blocks serotonin activation at receptor sites in vagal nerve terminals and in chemoreceptor trigger zone in CNS, decreasing the vomiting reflex

**Availability**
*Injection:* 12.5 mg/0.625-ml ampules, 20 mg/ml in 5-ml vials  
*Tablets:* 50 mg, 100 mg

**Indications and dosages**
- **Chemotherapy-induced nausea and vomiting**
- **Adults:** 100 mg P.O. 1 hour before chemotherapy or 1.8 mg/kg I.V. 30 minutes before chemotherapy  
- **Children ages 2 to 16:** 1.8 mg/kg P.O. within 1 hour before chemotherapy or 1.8 mg/kg I.V. (not to exceed 100 mg) 30 minutes before chemotherapy  

**Prevention or treatment of postoperative nausea and vomiting**
- **Adults:** 100 mg P.O. within 2 hours before surgery or 12.5 mg I.V. 15 minutes before cessation of anesthesia (for prevention) or as soon as nausea or vomiting begins (for treatment)  
- **Children ages 2 to 16:** 1.2 mg/kg P.O. (up to 100 mg/dose) within 2 hours before surgery or 0.35 mg/kg I.V. (up to 12.5 mg) 15 minutes before cessation of anesthesia (for prevention) or as soon as nausea or vomiting begins (for treatment)

**Contraindications**
- Hypersensitivity to drug  
- Arrhythmias

**Precautions**
Use cautiously in:
- risk factors for prolonged cardiac conduction intervals  
- pregnant or breastfeeding patients (safety not established)

**Administration**
- Give oral dose at least 1 hour before chemotherapy for best results.  
- To prevent postoperative nausea, give oral dose within 2 hours before surgery.  
- If patient has difficulty swallowing tablet, injection solution may be mixed with apple or apple-grape juice and given orally.  
- For I.V. use, give 100 mg single dose undiluted over 30 seconds. For I.V. infusion, dilute in normal saline solution, dextrose 5% in water, or lactated Ringer’s solution to 50 ml, and give single dose over at least 15 minutes. Don’t mix with other drugs.  
- Flush I.V. line before and after infusion.

---

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1-2 hr</td>
<td>Up to 24 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>15-30 min</td>
<td>Up to 24 hr</td>
</tr>
</tbody>
</table>

Reactions in **bold** are life-threatening.
Adverse reactions
CNS: headache (increased in cancer patients), dizziness, fatigue, syncope
CV: bradycardia, tachycardia, ECG changes, hypertension, hypotension
GI: diarrhea, constipation, dyspepsia, abdominal pain
GU: urinary retention, oliguria
Skin: pruritus, rash
Other: chills, fever, decreased appetite

Interactions
Drug-drug. Antiarrhythmics, anthracycline (high cumulative doses), diuretics, drugs that prolong QTc interval: increased risk of conduction abnormalities
Drugs that affect hepatic microsomal enzymes: altered dolasetron blood level
Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase: increased levels

Patient monitoring
● Monitor closely for excessive diuresis.
   Watch for ECG changes, including prolonged PR interval and widened QRS complex, especially in patients receiving antiarrhythmics concurrently.

Patient teaching
● Instruct patient to take drug 1 to 2 hours before chemotherapy.
● Inform patient that drug commonly causes headache.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

donepezil hydrochloride

Pharmacologic class: Acetylcholinesterase inhibitor
Therapeutic class: Anti-Alzheimer’s agent
Pregnancy risk category C

Action
Reversibly inhibits acetylcholinesterase hydrolysis in CNS, leading to increased acetylcholine level and temporary cognitive improvement in patients with Alzheimer’s disease

Availability
Tablets: 5 mg, 10 mg
Tablets (orally disintegrating): 5 mg, 10 mg

Indications and dosages
• Mild to moderate Alzheimer’s disease
   Adults: Initially, 5 mg P.O. daily at bedtime. After 4 to 6 weeks, may increase dosage to 10 mg.
• Severe Alzheimer’s disease
   Adults: 10 mg P.O. daily

Contraindications
• Hypersensitivity to drug or piperidine derivatives
• Pregnancy or breastfeeding

Precautions
Use cautiously in:
• cardiovascular disease, chronic obstructive pulmonary disease (COPD)
• history of ulcers, GI bleeding, or sick sinus syndrome
• concurrent use of nonsteroidal anti-inflammatory drugs (NSAIDs).

Administration
• Give with or without food.
• For best response, give at bedtime.
Route | Onset | Peak | Duration
--- | --- | --- | ---
P.O. | Unknown | 3-4 hr | Unknown

**Adverse reactions**

CNS: headache, dizziness, vertigo, fatigue, depression, aggression, irritability, restlessness, nervousness, paresthesia, insomnia, abnormal dreams, tremor, aphasia, **seizures**

CV: chest pain, bradycardia, hypertension, hypotension, vasodilation, **atrial fibrillation**

EENT: cataracts, blurred vision, eye irritation, sore throat

GI: nausea, vomiting, diarrhea, bloating, epigastric pain, fecal incontinence, **GI bleeding**

GU: urinary frequency, increased libido

**Hepatic: hepatotoxicity**

**Metabolic:** dehydration

**Musculoskeletal:** muscle cramps, arthritis, bone fracture

**Respiratory:** dyspnea, bronchitis

**Skin:** pruritus, urticaria, bruising, diaphoresis, rash, flushing

**Other:** toothache, decreased appetite, weight loss, hot flashes, influenza

**Interactions**

**Drug-drug.** *Anticholinergics:* reduced donepezil effects

*Anticholinesterases, cholinomimetics:* synergistic effects

*Carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin:* accelerated donepezil elimination

**NSAIDs:** increased risk of GI bleeding

**Drug-herbs.** *Jaborandi tree, pill-bearing spurge:* increased risk of drug toxicity

**Patient teaching**

- Advise patient to take drug at bedtime.
- Instruct patient to allow orally disintegrating tablet to dissolve under tongue and then follow with a glass of water.
- Inform patient that drug may slow the heart rate, leading to fainting episodes.
- Instruct patient to immediately report signs or symptoms of GI ulcers (“coffee-ground” vomitus, black tarry stools, and abdominal pain), irregular heart beat, unusual tiredness, or yellowing of skin or eyes.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and herbs mentioned above.

**dopamine hydrochloride**

**Intropin**

**Pharmacologic class:** Catecholamine, adrenergic

**Therapeutic class:** Inotropic, vasopressor

**Pregnancy risk category C**

**FDA BOXED WARNING**

- Dilute full-strength injection before administering.
- If extravasation occurs, infiltrate area promptly with 10 to 15 ml of saline solution containing 5 to 10 mg phentolamine to prevent sloughing and necrosis. Use syringe with fine hypodermic needle, and infiltrate solution liberally throughout area. Give phentolamine as soon as possible; its

Reactions in **bold** are life-threatening.  

Clinical alert
sympathetic blockade causes immediate local hyperemic changes if area is infiltrated within 12 hours.

**Action**
Causes norepinephrine release (mainly on dopaminergic receptors), leading to vasodilation of renal and mesenteric arteries. Also exerts inotropic effects on heart, which increases the heart rate, blood flow, myocardial contractility, and stroke volume.

**Availability**
*Injection for dilution:* 40 mg/ml, 80 mg/ml, 160 mg/ml
*Premixed injection:* 0.8 mg/ml, 1.6 mg/ml, 3.2 mg/ml in 250 ml and 500 ml of dextrose 5% in water

**Indications and dosages**
➢ Shock; hemodynamic imbalance; hypotension; heart failure

**Adults and children:** 2 to 5 mcg/kg/minute by I.V. infusion. Titrate dosage to desired response; may increase infusion by 1 to 4 mcg/kg/minute at 10- to 30-minute intervals. Maximum dosage is 50 mcg/kg/minute.

**Contraindications**
- Hypersensitivity to drug or bisulfites
- Tachyarrhythmias, ventricular fibrillation
- Pheochromocytoma

**Precautions**
Use cautiously in:
- hypovolemia, myocardial infarction, occlusive vascular disease, diabetic endarteritis, atrial embolism
- concurrent MAO inhibitor use
- pregnant or breastfeeding patients
- children.

**Administration**
- Give I.V. infusion using metered pump or other device that controls flow.

- Add 200 to 400 mg of dopamine to 250 to 500 ml of normal saline solution, 5% dextrose injection, 5% dextrose and half-normal saline solution, or 5% dextrose in lactated Ringer’s solution.
- Infuse into large (preferably central) vein to minimize extravasation.
- Don’t give concurrently with MAO inhibitors. Reduce dosage if patient has received MAO inhibitor recently.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>1-2 min</td>
<td>Unknown</td>
<td>&lt;10 min</td>
</tr>
</tbody>
</table>

**Adverse reactions**
*CNS:* headache
*CV:* palpitations, hypotension, angina, ECG changes, tachycardia, vasoconstriction, arrhythmias
*EENT:* mydriasis
*GI:* nausea, vomiting
*Metabolic:* azotemia, hyperglycemia
*Respiratory:* dyspnea, asthma attacks
*Skin:* piloerection
*Other:* irritation at injection site, gangrene of extremities (with high doses for prolonged periods or in occlusive vascular disease)

**Interactions**
*Drug-drug.* Alpha- or beta-adrenergic blockers: antagonism of dopamine effects
*Ergot alkaloids:* extreme blood pressure increase
*Guanethidine:* decreased cardiostimulatory effects
*Inhalation anesthetics:* increased risk of hypertension, arrhythmias
*MAO inhibitors:* hypertensive crisis
*Oxytocics:* severe, persistent hypotension
*Phenytoin:* seizures, severe hypotension, bradycardia
*Tricyclic antidepressants:* decreased pressor response

**Drug-diagnostic tests**. Glucose, nitrogenous compounds, urine catecholamines: increased levels
Patient monitoring
- Monitor blood pressure, pulse, urinary output, and pulmonary artery wedge pressure during infusion.
- Inspect I.V. site regularly for irritation. Avoid extravasation.
- Monitor color and temperature of extremities.
- Never stop infusion abruptly, because this may cause severe hypotension. Instead, taper gradually.

Patient teaching
- Explain the need for close observation during infusion.
- Instruct patient to report adverse reactions and I.V. site discomfort.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**doripenem monohydrate**
Doribax

**Pharmacologic class:** Carbapenem  
**Therapeutic class:** Anti-infective  
**Pregnancy risk category B**

**Action**
Acts against aerobic and anaerobic gram-positive and gram-negative bacteria

**Availability**  
*Powder for reconstitution for infusion:* 500 mg single-use vials

**Indications and dosages**
- Complicated intra-abdominal infections caused by *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Bacteroides caccae*, *Bacteroides fragilis*, *Bacteroides thetaiotaomicron*, *Bacteroides uniformis*, *Bacteroides vulgatus*, *Streptococcus intermedius*, *Streptococcus constellatus*, and *Peptostreptococcus micros*;
- Complicated urinary tract infections (UTIs), such as pyelonephritis caused by *E. coli* (including cases with concurrent bacteremia), *K. pneumoniae*, *Proteus mirabilis*, *P. aeruginosa*, and *Acinetobacter baumannii*

**Adults ages 18 and older:** 500 mg q 8 hours by I.V. infusion over 1 hour; continue for 5 to 14 days for complicated intra-abdominal infections and 10 days for complicated UTIs, with possible extension to 14 days for patients with concurrent bacteremia

**Dosage adjustment**
- Renal impairment

**Contraindications**
- Serious hypersensitivity to drug or other carbapenems
- History of anaphylactic reactions to beta-lactams

**Precautions**
Use cautiously in:
- renal impairment
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

**Administration**
- Don’t use constituted suspension for direct injection; dilute further before giving by I.V. infusion.
- To prepare 500-mg dose, constitute vial with 10 ml sterile water for injection or normal saline solution for injection, and shake gently to form suspension; resulting concentration is 50 mg/ml. Withdraw suspension using syringe with 21G needle, and add it to infusion bag containing 100 ml normal saline solution or 5% dextrose; shake gently until clear. Final infusion solution concentration is 4.5 mg/ml.

Reactions in **bold** are life-threatening.  

**Clinical alert**
To prepare 250-mg dose, constitute vial with 10 ml sterile water for injection or normal saline solution for injection, and shake gently to form suspension. Resulting concentration is 50 mg/ml. Withdraw suspension using syringe with 21G needle, and add it to infusion bag containing 100 ml normal saline solution for injection or 5% dextrose; shake gently until clear. Remove 55 ml of this solution from bag and discard. Infuse remaining solution, which contains 250 mg (4.5 mg/ml).

To prepare infusions in Baxter Mini-bag Plus infusion bags, see infusion bag manufacturer’s instructions.

Know that infusion solutions range from clear and colorless to clear and slightly yellow. Color variations within this range don’t affect product potency.

Don’t mix with or physically add to solutions containing other drugs.

Don’t administer by inhalation.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: headache  
CV: phlebitis  
GI: nausea, diarrhea, oral candidiasis, *Clostridium difficile–associated diarrhea*  
GU: vulvomycotic infection  
Hematologic: anemia  
Respiratory: pneumonitis (with inhalation use)  
Skin: rash, allergic or bullous dermatitis, erythema, macular and papular eruptions, urticaria, erythema multiforme  
Other: hypersensitivity reactions (including anaphylaxis)

**Interactions**

**Drug-drug.** *Probenecid:* reduced doripenem renal clearance  
*Valproic acid:* decreased valproic acid level and loss of seizure control  
**Drug-diagnostic tests.** *ALT, AST,* liver enzymes, transaminases: increased levels

**Patient monitoring**

- Closely monitor patient for diarrhea.  
  - If allergic reaction occurs, discontinue drug and intervene for serious anaphylactic reactions by giving epinephrine and taking other emergency measures as ordered and needed, including oxygen, I.V. fluids and antihistamines, corticosteroids, pressor amines, and airway management.  
- Monitor renal function in patients with moderate to severe renal impairment.

**Patient teaching**

- Tell patient to immediately report rash, diarrhea, or difficulty breathing.  
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**dornase alfa**

**Pulmozyme**

**Pharmacologic class:** Recombinant human deoxyribonuclease I  
**Therapeutic class:** Cystic fibrosis agent, mucolytic enzyme, respiratory inhalant  
**Pregnancy risk category B**

**Action**

Selectively cleaves to DNA in sputum, decreasing viscosity of pulmonary secretions

**Availability**

*Inhalation solution:* 2.5-mg ampule (1 mg/ml)

**Indications and dosages**

To reduce respiratory tract infections and improve pulmonary function
Adults and children older than age 5:
One ampule (2.5 mg) inhaled once daily

**Contraindications**
- Hypersensitivity to drug, its components, or products derived from Chinese hamster ovary cells
- Status asthmaticus
- Respiratory tract infection

**Precautions**
Use cautiously in:
- nonasthmatic bronchial disease,
- asthma controlled by bronchodilators
- pregnant or breastfeeding patients.

**Administration**
- Don’t shake or dilute drug.
- Use only with approved nebulizer.
- Discard cloudy or discolored solution.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhalation</td>
<td>3-7 days</td>
<td>9 days</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- **CV:** chest pain
- **EENT:** conjunctivitis, rhinitis, pharyngitis, hemoptysis, voice changes
- **Respiratory:** dyspnea, increased sputum, wheezing
- **Skin:** rash, urticaria, pruritus
- **Other:** hypersensitivity reactions

**Interactions**
None known

**Patient monitoring**
- Assess patient periodically. Report improvement in dyspnea and sputum clearance.
- Monitor for signs and symptoms of hypersensitivity reaction.

**Patient teaching**
- Teach patient how to use nebulizer.
- Instruct patient to report rash, hives, and itching.
- As appropriate, review all other significant adverse reactions mentioned above.

Reactions in **bold** are life-threatening.
awakens. Don’t infuse longer than 2 hours or give more than 3 g/day.

Off-label uses
- Laryngospasm secondary to postoperative tracheal extubation
- Apnea of prematurity
- Postoperative shivering

Contraindications
- Hypersensitivity to drug
- Cardiovascular disorders, severe hypotension
- Cerebrovascular accident
- Head injury, seizures
- Respiratory failure, restrictive respiratory disease
- Neonates

Precautions
Use cautiously in:
- bronchial asthma, arrhythmias, increased intracranial pressure, hyperthyroidism, pheochromocytoma, metabolic disorders
- concurrent use of mechanical ventilation
- pregnant or breastfeeding patients.

Administration
- Ensure adequate airway and oxygenation before administering.
- Give I.V. slowly to avoid hemolysis.
- Know that doxapram is compatible with 5% and 10% dextrose in water and with normal saline solution.
- Don’t mix with thiopental sodium, bicarbonate, or aminophylline, because precipitates or gas may form.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>20-40 sec</td>
<td>1-2 min</td>
<td>5-12 min</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: weakness, dizziness, drowsiness, headache, dysarthria, dysphonia, disorientation, hyperactivity, paresthesia, loss of consciousness, seizures
CV: hypotension, bradycardia, chest pain or tightness, heart rate changes, thrombophlebitis, atrioventricular block, arrhythmias, cardiac arrest
EENT: lacrimation, diplopia, miosis, conjunctival hyperemia, sneezing, laryngospasm
GI: nausea, vomiting, diarrhea, abdominal cramps, increased salivation, dysphagia
GU: urinary frequency or incontinence, albuminuria
Musculoskeletal: muscle cramps, fasciculations
Respiratory: dyspnea, increased secretions, cough, hyperventilation, tachypnea, rebound hypoventilation bronchospasm
Skin: rash, diaphoresis, flushing
Other: burning or hot sensation in genitalia and perineal areas, hiccups

Interactions
Drug-drug. General anesthetics: increased risk of self-limiting arrhythmias
MAO inhibitors, sympathomimetics: potentiation of adverse cardiovascular effects
Skeletal muscle relaxants: masking of residual effects of these drugs
Drug-diagnostic tests. Blood urea nitrogen: increased level
Erythrocytes, hematocrit, hemoglobin, red blood cells, white blood cells: decreased levels

Patient monitoring
- Assess blood pressure, pulse, deep tendon reflexes, airway, and arterial blood gas values before starting therapy and frequently during infusion.
- Monitor I.V. site frequently for irritation and thrombophlebitis.
- Discontinue infusion immediately if hypotension or dyspnea suddenly develops.

Patient teaching
- Instruct patient to report adverse reactions promptly.
- As appropriate, review all other significant and life-threatening adverse
reactions and interactions, especially those related to the drugs and tests mentioned above.

doazosin mesylate
Cardozin XL®, Cardura, Cardura XL, Doxadura

**Pharmacologic class:** Sympatholytic, peripherally acting antiadrenergic

**Therapeutic class:** Antihypertensive

**Pregnancy risk category C**

**Action**
Blocks alpha₁-adrenergic receptors, promoting vasodilation. Also reduces urethral resistance, relieving obstruction and improving urine flow and other symptoms of benign prostatic hypertrophy (BPH).

**Availability**
Tablets: 1 mg, 2 mg, 4 mg, 8 mg

**Indications and dosages**

**➣ Hypertension**
**Adults:** 1 mg P.O. once daily. May increase dosage gradually q 2 weeks, up to 2 to 16 mg daily, as needed.

**➣ BPH**
**Adults:** 1 mg P.O. once daily. May increase dosage gradually, up to 8 mg daily, as needed.

**Off-label uses**
- Pheochromocytoma
- Syndrome X

**Contraindications**
- Hypersensitivity to drug or quinazoline derivatives

**Precautions**
Use cautiously in:
- renal or hepatic impairment, heart failure
- elderly patients
- pregnant or breastfeeding patients
- children (safety not established)

**Administration**
- Give initial dose at bedtime to minimize orthostatic hypotension and syncope.
- Know that incidence of orthostatic hypotension increases greatly when daily dosage exceeds 4 mg and that it usually occurs within 6 hours of administration.

**Adverse reactions**

**CNS:** dizziness, vertigo, headache, depression, drowsiness, fatigue, nervousness, weakness, asthenia

**CV:** orthostatic hypotension, chest pain, palpitations, tachycardia, arrhythmias

**EENT:** abnormal or blurred vision, conjunctivitis, epistaxis, rhinitis, pharyngitis

**GI:** nausea, vomiting, diarrhea, constipation, abdominal discomfort, flatulence, dry mouth

**GU:** decreased libido, sexual dysfunction

**Respiratory:** dyspnea

**Musculoskeletal:** joint pain, arthritis, gout, myalgia

**Skin:** flushing, rash, pruritus

**Other:** edema

**Interactions**

**Drug-drug. Clonidine, nitrates, other antihypertensives:** decreased antihypertensive effect

**Drug-diagnostic tests. Neutrophils, white blood cells:** decreased counts

**Drug-herbs. Butcher’s broom:** decreased doxazosin effects

**Drug-behaviors. Alcohol use:** additive hypotension

Reactions in bold are life-threatening.
Patient monitoring
- Monitor blood pressure with patient lying down and standing up every 2 to 6 hours after initial dose or after a dosage increase (when orthostatic hypotension is most likely to occur).

Patient teaching
- Caution patient not to drive or perform other activities requiring alertness for 12 to 24 hours after first dose.
- Tell patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness from sudden blood pressure decrease.
- Advise patient to report episodes of dizziness or palpitations.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

Doxepin hydrochloride
Apo-Doxepin®, Novo-Doxepin®, Prudoxin, Sinepin®, Xepin®, Zonalon

Pharmacologic class: Tricyclic antidepressant
Therapeutic class: Antidepressant, anxiolytic, antipruritic
Pregnancy risk category C

FDA BOXED WARNING
- Drug may increase risk of suicidal thinking and behavior in children and adolescents with major depressive disorder and other psychiatric disorders. Risk must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family and caregivers to observe patient closely and communicate with prescriber as needed.
- Drug isn’t approved for use in pediatric patients.

Action
Unknown. May prevent reuptake of norepinephrine, serotonin, or both at presynaptic neurons, increasing levels of these neurotransmitters in CNS. Exact mechanism in pruritus also unknown, but drug is a potent histamine1- and histamine2-blocker.

Availability
Capsules: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg
Cream (topical): 5% in 30-g tube
Oral concentrate: 10 mg/ml

Indications and dosages
- Endogenous depression; anxiety
Adults: Initially, 25 mg P.O. t.i.d., increased as needed up to 150 mg daily in outpatients and 300 mg daily in hospitalized patients.
Elderly adults: Initially, 25 to 50 mg P.O. daily; may be increased as needed
- Short-term relief of histamine-mediated pruritus of moderate severity accompanying such conditions as eczematous dermatitis
Adults: Apply a thin film of cream to skin q.i.d., with 3 to 4 hours between applications, for a maximum of 8 days.

Contraindications
- Hypersensitivity to drug or other dibenzoxepins
- Glaucoma
- Predisposition to urinary retention
- MAO inhibitor use within past 14 days

Precautions
Use cautiously in:
- cardiovascular disease, prostatic enlargement, seizures
- elderly patients
- pregnant or breastfeeding patients.

**Administration**
- If desired, mix contents of capsule with food.
- Dilute oral concentrate with 120 ml of water, milk, or juice. Be aware that drug is incompatible with carbonated beverages.
- Know that drug may be given at bedtime to prevent daytime sleepiness.
  ❗ Don’t give within 14 days of MAO inhibitor, because drug interaction may cause cardiovascular instability.
  ❗ Avoid concurrent use of other CNS depressants, because inadvertent overdose may occur.
- With topical cream, don’t apply to broken skin or use occlusive dressings, because doing so increases dermal absorption.
- Be aware that drug is usually given in conjunction with psychotherapy when used for depression.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>Topical</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- **CNS:** fatigue, sedation, agitation, confusion, hallucinations, drowsiness, dizziness, extrapyramidal reactions, poor concentration, syncope, seizures, cerebrovascular accident, increased risk of suicide or suicidal ideation (especially in child or adolescent)
- **CV:** hypotension, orthostatic hypotension, hypertension, vasculitis, ECG changes, tachycardia, palpitations, arrhythmias, myocardial infarction, heart block
- **EENT:** blurred vision, increased intraocular pressure, lacrimation, tinnitus, nasal congestion
- **GI:** nausea, constipation, dry mouth, paralytic ileus
- **GU:** urinary retention, delayed voiding, urinary tract dilation, gynecomastia, galactorrhea, menstrual irregularities, testicular swelling, libido changes
- **Hematologic:** purpura, bone marrow depression, eosinophilia, agranulocytosis, thrombocytopenia, leukopenia
- **Metabolic:** hyperglycemia, hypoglycemia
- **Skin:** photosensitivity, rash, urticaria, pruritus, diaphoresis, flushing, petechiae, alopecia, local burning, stinging, tingling, irritation, or rash (with topical use)
- **Other:** increased appetite, weight gain or loss, hyperthermia, chills, edema, drug-induced fever, hypersensitivity reactions

**Interactions**
- **Drug-drug.** Barbiturates, CNS depressants (including antihistamines, clonidine, opioids, sedative-hypnotics): additive CNS depression
  Carbamazepine, class IC antiarrhythmics (flecainide, propafenone), other antidepressants, other CYP450-2D6 inhibitors (amiodarone, cimetidine, quinidine, ritonavir), phenothiazines: increased doxepin blood level and effects
  Clonidine: hypertensive crisis
  Guanethidine: antagonism of antihypertensive effects
  Levodopa: delayed or decreased levodopa absorption, hypertension
  MAO inhibitors: tachycardia, seizures, potentially fatal reactions
  Rifamycin: decreased doxepin effects
  Selective serotonin reuptake inhibitors: increased risk of toxicity

- **Drug-diagnostic tests.** Bilirubin, hepatic enzymes: increased levels
  Glucose: increased or decreased level
  Liver function tests: altered results
- **Drug-herbs.** Angel’s trumpet, jimsonweed, scopolia: increased anticholinergic effects

Reactions in **bold** are life-threatening.
Chamomile, hops, kava, skullcap, valerian: increased CNS depression
Evening primrose oil: additive or synergistic effects
S-adenosylmethionine (SAM-e), St. John’s wort, yohimbe: serotonin syndrome

Drug-behaviors. Alcohol use: increased CNS depression
Smoking: increased drug metabolism and altered effects
Sun exposure: increased risk of photosensitivity reactions

Patient monitoring
- Record mood changes and watch for suicidal tendencies, especially in child or adolescent.
- Assess bowel elimination pattern. Increase fluids and administer stool softeners as ordered to ease constipation.
- Monitor fluid intake and output. Report changes in voiding pattern.
- Monitor liver function test results, CBC with white cell differential, and glucose level.

Patient teaching
- Advise patient on long-term therapy not to stop taking drug abruptly because this may lead to nausea, headache, and malaise.
- Instruct patient and significant other, as appropriate, to monitor mental status carefully and to immediately report increased depression or suicidal thoughts or behavior (especially when used in child or adolescent).
- Tell patient to promptly report easy bruising or bleeding.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Instruct patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness from sudden blood pressure decrease.
- Explain that drowsiness and dizziness usually subside after several weeks.
- Tell patient that using topical cream on more than 10% of body surface area may cause drowsiness.
- Caution patient using topical cream not to apply it to broken skin and not to use occlusive dressings. Also tell him to avoid contact with eyes and to rinse eyes thoroughly with warm water if contact occurs.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

**doxorubicin hydrochloride**
Adriamycin PFS, Adriamycin RDF, Rubex

**Pharmacologic class:** Anthracycline

**Therapeutic class:** Antibiotic antineoplastic

**Pregnancy risk category D**

- Administer I.V. only—never I.M. or subcutaneously. Extravasation causes severe local tissue necrosis.
- Myocardial toxicity may occur during therapy or months to years afterward. Risk factors (cardiovascular disease, previous or concurrent radiotherapy to mediastinal or pericardial area, previous therapy with doxorubicin or other anthracyclines or anthracediones, and concomitant use of other cardiotoxic drugs) may increase myocardial toxicity risk. Toxicity may occur at higher or lower cumulative doses even in patients without cardiac risk factors. Pediatric patients...
have increased risk of delayed cardioxicity.
- Secondary acute myelogenous leukemia (AML) may occur. Refractory secondary leukemia is more common when drug is given in combination with DNA-damaging antineoplastics, when patients have been heavily pre-treated with cytotoxic drugs, and with dosage escalation. Pediatric patients also are at risk for secondary AML.
- Reduce dosage in hepatic impairment.
- Drug may cause severe myelosuppression.
- Give under supervision of physician experienced in cancer chemotherapy.

**Action**
Unclear. Thought to inhibit DNA and RNA synthesis by forming complex with DNA. Also exerts immunosuppressive activity. Cell-cycle-S-phase specific.

**Availability**
*Injection (preservative-free): 2 mg/ml*
*Powder for injection: 10 mg, 20 mg, 50 mg, 100 mg, 150 mg*

**Indications and dosages**
- Solid tumors, including bladder, breast, lung, stomach, and thyroid cancers; malignant lymphomas, including Hodgkin’s disease; acute leukemia; chronic lymphocytic leukemia; multiple myeloma; Wilms’ tumor; neuroblastoma
- **Adults**: 60 to 75 mg/m² I.V. as a single dose at 21-day cycles, or 30 mg/m² I.V. as a single daily dose on first to third days of 4-week cycle, or 20 mg/m² I.V. once weekly. Maximum cumulative dosage is 550 mg/m².

**Dosage adjustment**
- Bone marrow depression
- Impaired cardiac or hepatic function

**Off-label uses**
- Endometrial carcinoma, islet cell carcinoma

**Contraindications**
- Hypersensitivity to drug
- Severe bone marrow depression
- Previous treatment with maximum cumulative doses of doxorubicin, other anthracyclines, or anthrancenes

**Precautions**
Use cautiously in:
- cardiac disease, hepatic impairment, depressed bone marrow reserve, CNS metastases, brain tumor, malignant melanoma, renal carcinoma
- elderly patients
- females of childbearing age
- pregnant or breastfeeding patients
- children.

**Administration**
- Follow facility policy for handling and preparing antineoplastics.
  - Don’t dilute solution with bacteriostatic diluent. Don’t mix with other drugs.
- Dilute as directed with normal saline solution to a final concentration of 2 mg/ml.
- Administer slowly over 3 to 5 minutes into tubing of free-flowing I.V. infusion of normal saline solution or dextrose 5% in water.
- Deliver into large vein using butterfly needle. Avoid veins over joints or extremities with compromised venous or lymphatic drainage.
- Avoid rapid infusion, because this may increase risk of acute infusion-related reactions (back pain, chest tightness, flushing).
- If extravasation occurs, stop infusion immediately, apply ice, and notify prescriber.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>2 hr</td>
<td>24-36 days</td>
</tr>
</tbody>
</table>

Reactions in **bold** are life-threatening.
Adverse reactions
CNS: drowsiness, dizziness, asthenia, fatigue, malaise, paresthesia, headache, depression, insomnia, anxiety, emotional lability
CV: chest pain, hypotension, tachycardia, peripheral edema, cardiomyopathy, heart failure, arrhythmias, pericardial effusion
GI: nausea, vomiting, diarrhea, constipation, enlarged abdomen, abdominal pain, dyspepsia, oral candidiasis, moniliasis, stomatitis, glossitis, esophagitis, dysphagia
GU: albuminuria, hyperuricosuria, red urine
Hematologic: anemia, leukopenia, thrombocytopenia, neutropenia, bone marrow depression
Metabolic: hyperglycemia, hypocalcemia
Musculoskeletal: myalgia, back pain
Respiratory: dyspnea, increased cough, pneumonia
Skin: rash, dry skin, pruritus, skin discoloration, alopecia, diaphoresis, exfoliative dermatitis, palmar-plantar erythrodysesthesia
Other: abnormal taste, infection, chills, fever, herpes zoster, injection site reactions, allergic reactions including anaphylaxis, acute infusion-associated reactions

Interactions
Drug-drug. Antineoplastics: additive bone marrow depression
Cyclophosphamide: increased risk of hemorrhagic cystitis, increased cardiotoxicity
Cyclosporine: profound and prolonged hematologic toxicity, increased risk of coma and seizures
Dactinomycin (in children): increased risk of pneumonitis
Live-virus vaccines: decreased antibody response to vaccine, increased risk of adverse reactions
Mercaptopurine: hepatitis

Paclitaxel (if given first): reduced doxorubicin clearance, increased incidence and severity of neutropenia and stomatitis
Phenobarbital: increased clearance and decreased effects of doxorubicin
Phenytoin: decreased phenytoin blood level
Progesterone: increased incidence and severity of neutropenia and thrombocytopenia
Streptozocin: increased doxorubicin half-life
Verapamil: increased doxorubicin blood level

Drug-diagnostic tests. Alkaline phosphatase, bilirubin, glucose, prothrombin time, serum and urine uric acid: increased levels
Calcium, hemoglobin, neutrophils, platelets, white blood cells (WBCs): decreased levels

Patient monitoring
🧥 Watch for acute life-threatening arrhythmias, which may occur during or within a few hours after administration.
🧥 Monitor for cardiomyopathy and subsequent heart failure with chronic overdose (more common in children).
● Stay alert for erythematous streaking along vein next to injection site, which may indicate too-rapid infusion.
● Watch for nausea and vomiting. Administer antiemetics as needed.
🧥 Check for superinfection or hemorrhage caused by persistent bone marrow depression (but expect WBC counts as low as 1,000/mm³ during therapy).
🧥 Watch closely for infusion-related reactions and anaphylaxis.
● Monitor CBC, hepatic profile, coagulation tests, ejection fraction, and glucose, uric acid, bilirubin, and calcium blood levels.

Patient teaching
🧧 Advise patient to promptly report irregular heartbeats, easy bruising or bleeding, or signs of hypersensitivity reaction, such as a rash.
● Caution patient to avoid people with colds, flu, or other contagious illnesses.
● Explain that drug may cause complete but reversible hair loss.
● Inform patient that drug may turn urine red for 1 or 2 days.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Caelyx®, Doxil, Myocet®

**Pharmacologic class:** Anthracycline

**Therapeutic class:** Antibiotic antineoplastic

**Pregnancy risk category D**

**FDA BOXED WARNING**

- Drug may cause cardiotoxicity. Myocardial damage may lead to heart failure and may occur as total cumulative dose (which includes previous use of other anthracyclines or anthrancenediones) approaches 550 mg/m². Toxicity may occur at lower cumulative doses in patients who have had previous mediastinal irradiation or are receiving concurrent cyclophosphamides.
- Acute infusion-related reactions occur in up to 10% of patients. They usually resolve over several hours to 1 day after infusion ends; in some patients, they resolve with slower infusion rate. Serious and sometimes life-threatening allergic or anaphylactoid-like infusion reactions may occur. Keep emergency equipment and drugs to treat reaction available for immediate use.
- Drug may cause severe myelosuppression.
- Reduce dosage in hepatic impairment.
- Accidental substitution of liposomal form for doxorubicin hydrochloride may cause severe adverse effects. Don’t substitute on mg-per-mg basis.

**Action**

Unclear. Thought to inhibit DNA and RNA synthesis by forming complex with DNA. Also exerts immunosuppressive activity. Liposomal encapsulation increases uptake by tumors, prolongs drug action, and may decrease toxicity. Cell-cycle–S-phase specific.

**Availability**

*Liposomal dispersion for injection:*

20 mg/10 ml in 10-ml vials

**Indications and dosages**

- **AIDS-related Kaposi’s sarcoma**
  - **Adults:** 20 mg/m² I.V. once q 3 weeks

- **Metastatic ovarian carcinoma**
  - **Adults:** Initially, 50 mg/m² I.V. at a rate of 1 mg/minute q 4 weeks for at least four courses. If no adverse reactions occur, increase infusion rate to complete the infusion over 1 hour.

**Dosage adjustment**

- Hepatic impairment

**Contraindications**

- Hypersensitivity to drug
- Malignant melanoma
- CNS metastases
- Bone marrow depression
- Cardiac disease
- Breastfeeding

**Precautions**

Use cautiously in:
- hepatic impairment, brain tumor, renal carcinoma, myelosuppression
- elderly patients
- females of childbearing age
- pregnant patients
- children.

Reactions in **bold** are life-threatening.
Administration
● Follow facility policy for handling and preparing antineoplastics.
● Dilute dose (up to 90 mg) in 250 ml of dextrose 5% in water. Don’t use any other diluent.
  ▶ Don’t dilute solution with bacteriostatic diluent. Don’t mix with other drugs.
● Don’t use in-line filter.
● Administer slowly by I.V. infusion at initial rate of 1 mg/minute. If no infusion reaction occurs, increase rate to complete infusion over 1 hour. Don’t give as I.V. bolus.
  ▶ Avoid rapid infusion, which may increase the risk of infusion-related reactions (back pain, chest tightness, flushing).
  ▶ If extravasation occurs, stop infusion immediately, apply ice, and notify prescriber.
● Don’t give I.M. or subcutaneously.
● Know that drug is a translucent red dispersion, not a clear solution.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>10 days</td>
<td>14 days</td>
<td>21-24 days</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: drowsiness, dizziness, asthenia, fatigue, malaise, paresthesia, headache, depression, insomnia, anxiety, emotional lability
CV: chest pain, hypotension, tachycardia, peripheral edema, cardiomyopathy, heart failure, arrhythmias, pericardial effusion
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, enlarged abdomen, dyspepsia, moniliasis, stomatitis, glossitis, oral candidiasis, esophagitis, dysphagia
GU: albuminuria, red urine
Hematologic: anemia, leukopenia, thrombocytopenia, neutropenia, bone marrow depression
Hepatic: jaundice
Metabolic: hypocalcemia, hyperglycemia

Musculoskeletal: myalgia, back pain, hand-foot syndrome
Respiratory: dyspnea, increased cough, pneumonia
Skin: rash, dry skin, pruritus, skin discoloration, alopecia, diaphoresis, exfoliative dermatitis, palmar-plantar erythrodysesthesia
Other: altered taste, fever, chills, infection, herpes zoster, injection site reactions, allergic reactions including anaphylaxis, acute infusion reaction

Interactions
Drug-drug. Antineoplastics: additive bone marrow depression
Cyclophosphamide: increased risk of hemorrhagic cystitis
Cyclosporine: profound and prolonged hematologic toxicity, increased risk of coma and seizures, increased cardiotoxicity
Dactinomycin (in children): increased risk of pneumonitis
Live-virus vaccines: decreased antibody response to vaccine, increased risk of adverse reactions
Mercaptopurine: hepatitis
Paclitaxel (if administered first): reduced doxorubicin clearance, increased incidence and severity of neutropenia and stomatitis
Phenobarbital: increased clearance and decreased effects of doxorubicin
Phenytoin: decreased phenytoin blood level
Progestrone: increased risk and severity of neutropenia and thrombocytopenia
Streptozocin: prolonged doxorubicin half-life
Verapamil: increased doxorubicin blood level

Drug-diagnostic tests. Alkaline phosphatase, bilirubin, glucose, prothrombin time, serum and urine uric acid: increased levels
Calcium, hemoglobin, neutrophils, platelets, white blood cells: decreased levels
Patient monitoring

- Observe patient closely for anaphylaxis and bleeding problems.
- Stay alert for acute life-threatening arrhythmias, which may occur during or within a few hours after administration.
- Assess for cardiomyopathy and subsequent heart failure with chronic overdose (more common in children).
- Monitor closely for acute infusion reaction.
  - Assess for and report liver engorgement and yellowing of skin or eyes.
  - Check CBC, coagulation tests, hepatic profile, and bilirubin, glucose, calcium and uric acid levels.
  - Watch for nausea and vomiting. Give antiemetics, as needed and prescribed.
  - Assess for constipation and give fluids and stool softeners, as needed and prescribed.

Patient teaching

- Instruct patient to immediately report shortness of breath; tingling or burning, redness, flaking, bothersome swelling, small blisters, or small sores on palms of hands or soles of feet; rash, chest pain, or palpitations.
- Advise patient to avoid people with colds, flu, or other contagious illnesses.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

doxycycline

Adoxa, Oracea, Vibramycin

doxycycline calcium

Vibramycin Calcium

doxycycline hyclate

Alodox, Apo-Doxy®, Doryx, Doxy 100, Doxytab, Novo-Doxylin®, Oraxyl, Periostat, Vibramycin-D®, Vibramycin Hyclate, Vibra-Tabs

doxycycline monohydrate

Monodox

Pharmacologic class: Tetracycline
Therapeutic class: Anti-infective
Pregnancy risk category D

Action
Unclear. Thought to inhibit bacterial protein synthesis at 30S and 50S ribosomal subunit and to alter cytoplasmic membrane of susceptible organisms.

Availability
Capsules: 20 mg, 50 mg, 100 mg
Capsules (coated pellets): 75 mg, 100 mg
Powder for injection: 100 mg, 200 mg
Powder for oral suspension: 25 mg/5 ml
Syrup: 50 mg
Tablets: 20 mg, 50 mg, 75 mg, 100 mg

Indications and dosages
Infections caused by various organisms, including Mycoplasma, Chlamydia, and Rickettsia organisms, and Borrelia burgdorferi
Adults and children weighing more than 45 kg (99 lb): 100 mg P.O. q 12 hours on first day, followed by 100 to 200 mg P.O. once daily; or 50 to 100 mg P.O. q 12 hours; or 200 mg I.V. once daily; or 100 mg I.V. q 12 hours on first
day, followed by 100 to 200 mg I.V. once daily; or 50 to 100 mg I.V. q 12 hours

**Children weighing 45 kg (99 lb) or less:**
- 2.2 mg/kg P.O. q 12 hours on first day, followed by 2.2 to 4.4 mg/kg/day P.O. once daily; or 1.1 to 2.2 mg/kg P.O. q 12 hours; or 4.4 mg/kg I.V. once daily; or 2.2 mg/kg I.V. q 12 hours on first day, followed by 2.2 to 4.4 mg/kg I.V. once daily; or 1.1 to 2.2 mg/kg I.V. q 12 hours

➤ Gonorrhea in penicillin-allergic patients

**Adults and children weighing more than 45 kg (99 lb):**
- 100 mg P.O. q 12 hours for 7 days; or 300 mg P.O. initially, followed by another 300 mg P.O. 1 hour later

➤ Lyme disease

**Adults and children weighing more than 45 kg (99 lb):**
- 100 mg P.O. b.i.d. for 10 to 30 days

➤ Periodontitis

**Adults and children weighing more than 45 kg (99 lb):**
- 20 mg P.O. b.i.d. for up to 9 months

➤ Anthrax

**Adults and children weighing more than 45 kg (99 lb):**
- 100 mg P.O. b.i.d. for 60 days; or 100 mg I.V. q 12 hours for 60 days, changing to oral route when appropriate

**Children weighing 45 kg (99 lb) or less:**
- 2.2 mg/kg P.O. b.i.d. for 60 days; or 100 mg I.V. q 12 hours for 60 days, changing to oral route when appropriate

➤ Prevention of malaria caused by *Plasmodium falciparum* in short-term travelers (less than 4 months)

**Adults:**
- 100 mg/day P.O. starting 1 to 2 days before travel begins and continuing during and for 4 weeks after travel

**Children:**
- 2 mg/kg/day P.O., up to adult dosage of 100 mg/day, starting 1 to 2 days before travel begins and continuing during and for 4 weeks after travel

**Off-label uses**
- Traveller’s diarrhea
- Pleural effusion

**Contraindications**
- Hypersensitivity to drug, other tetracyclines, or bisulfites (with some drug products)

**Precautions**
- Use cautiously in:
  - renal disease, hepatic impairment, nephrogenic diabetes insipidus, cachexia
  - pregnant or breastfeeding patients
  - children younger than age 8.

**Administration**
- Obtain specimens for culture and sensitivity testing, as ordered, before first dose.
  - Don’t give in conjunction with methoxyflurane anesthetic. Severe or fatal kidney damage may result.
  - Reconstitute powder for injection with dextrose 5% in water, normal saline solution, lactated Ringer’s solution, or dextrose 5% in lactated Ringer’s solution.
  - Don’t infuse solutions with concentrations above 1 mg/ml.
  - Infuse 100-mg dose over at least 1 hour.
  - Complete infusion within 12 hours of dilution, unless diluted with lactated Ringer’s solution or dextrose 5% in lactated Ringer’s solution; in this case, complete infusion within 6 hours.

**Adverse reactions**
- **CNS:** paresthesia, pseudotumor cerebri
- **CV:** phlebitis, thrombophlebitis, pericarditis

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1-2 hr</td>
<td>1.5-4 hr</td>
<td>12 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>End of infusion</td>
<td>12 hr</td>
</tr>
</tbody>
</table>

**Hazardous drug**

Canada  UK  Hazardous drug  High alert drug
**EENT:** vestibular reactions, hoarseness, pharyngitis

**GI:** nausea, vomiting, diarrhea, esophagitis, epigastric distress, enterocolitis, anogenital lesions or inflammation, glossitis, oral candidiasis, black hairy tongue, **pancreatitis**

**GU:** dark yellow or brown urine, vaginal candidiasis

**Hematologic:** hemolytic anemia, neutropenia, thrombocytopenia

**Hepatic:** hepatotoxicity

**Musculoskeletal:** bone growth retardation (in children younger than age 8)

**Skin:** photosensitivity, maculopapular or erythematous rash, hyperpigmentation, urticaria

**Other:** tooth enamel defects, increased appetite, phlebitis at I.V. site, superinfection, hypersensitivity reactions including **anaphylaxis**

**Interactions**

**Drug-drug.** Adsorbent antidiarrheals; antacids; calcium, iron, and magnesium preparations: decreased doxycycline absorption

Barbiturates, carbamazepine, hormonal contraceptives containing estrogen, phenytoin, rifampicin: decreased doxycycline efficacy

Cholestyramine, colestipol: decreased oral absorption of doxycycline

Methoxyflurane: increased nephrotoxicity

Penicillin: decreased penicillin activity

Sucralfate: prevention of doxycycline absorption from GI tract

Warfarin: enhanced warfarin effects

**Drug-diagnostic tests.** Alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, bilirubin, blood urea nitrogen (BUN), eosinophils: increased levels

Hemoglobin, neutrophils, platelets, white blood cells: decreased levels

Urine catecholamines: false elevations

**Drug-food.** Calcium-containing foods: decreased drug absorption

**Drug-behaviors.** Alcohol use: decreased anti-infective effect of doxycycline

Sun exposure: increased risk of photosensitivity

**Patient monitoring**

- Evaluate I.V. site regularly. Apply cool compresses as needed.
- Monitor for hypersensitivity reactions, including anaphylaxis.
- Monitor hepatic profile, CBC, BUN, and creatinine levels.
- Assess for hypercoagulability in patients taking warfarin concurrently.
- Monitor for digoxin toxicity in patients taking digoxin concurrently.

**Patient teaching**

- Advise patient to take with 8 oz of water to ensure passage into stomach.
- Tell patient to take on empty stomach at least 1 hour before meals or 2 hours afterwards.
- Instruct patient to take at least 1 hour before bedtime to prevent esophagitis.
- Tell patient to immediately report painful swallowing, abdominal pain, easy bruising or bleeding, or signs of hypersensitivity (such as rash).
- Advise female patient to tell prescriber if she is pregnant.
- Instruct patient to avoid alcohol use and large amounts of calcium-containing foods (such as dairy products and some green leafy vegetables, such as spinach).
- Stress importance of good oral hygiene.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and behaviors mentioned above.

Reactions in **bold** are life-threatening.
**dronabinol**
Marinol

**Pharmacologic class:** Cannabinoid  
**Therapeutic class:** Antiemetic  
**Controlled substance IV**  
**Pregnancy risk category B**

**Action**  
Unknown. May exert antiemetic effect by inhibiting vomiting control mechanism in medulla oblongata.

**Availability**  
Capsules: 2.5 mg, 5 mg, 10 mg

**Indications and dosages**  
➤ Prevention of nausea and vomiting caused by chemotherapy  
**Adults and children:** Initially, 5 mg/m² P.O. 1 to 3 hours before chemotherapy. Repeat dose q 2 to 4 hours after chemotherapy, up to four to six doses per day. If 5-mg/m² dose is ineffective and patient has no significant adverse reactions, dosage may be increased in increments of 2.5 mg/m² to a maximum dosage of 15 mg/m².  
➤ Appetite stimulant  
**Adults and children:** Initially, 2.5 mg P.O. b.i.d. May reduce dosage to 2.5 mg/day given as a single evening or bedtime dose. Maximum dosage is 10 mg P.O. b.i.d.

**Contraindications**  
• Hypersensitivity to cannabinoids or sesame oil  
• Breastfeeding

**Precautions**  
Use cautiously in:  
• hypertension, heart disease, bipolar disorder, schizophrenia, drug abuse, seizures  
• pregnant patients.

**Administration**  
• When used to stimulate appetite, give before lunch and dinner.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30-60 min</td>
<td>2-4 hr</td>
<td>4-6 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**  
CNS: drowsiness, anxiety, impaired coordination, irritability, depression, headache, hallucinations, memory loss, paresthesia, ataxia, paranoia, disorientation, nightmares, speech difficulties, syncope, **suicidal ideation**  
CV: tachycardia, hypotension, hypertension  
EENT: visual disturbances, tinnitus  
GI: dry mouth  
Skin: facial flushing, diaphoresis

**Interactions**  
**Drug-drug.** Anticholinergics, antihistamines, tricyclic antidepressants: increased tachycardia and hypertension  
**CNS depressants:** increased CNS depression  
**Ritonavir:** increased dronabinol blood level and risk of toxicity  
**Drug-behaviors.** Alcohol use: increased CNS depression

**Patient monitoring**  
• Monitor vital signs for hypotension and tachycardia.  
➤ Check for adverse CNS reactions. Report significant depression, paranoid reaction, or emotional lability.  
• Monitor nutritional status and hydration.

**Patient teaching**  
• Teach patient about drug’s significant adverse CNS and cardiovascular effects. Emphasize that he should take it only as prescribed and needed.  
➤ Advise patient (and significant other) to immediately report depression, suicidal thoughts, paranoid reactions, seizures, and other serious CNS reactions.

* Canada  
* UK  
* Hazardous drug  
* High alert drug
Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and behaviors mentioned above.

**droperidol**

Inapsine

**Pharmacologic class:** Butyrophenone  
**Therapeutic class:** General anesthetic, antiemetic  
**Pregnancy risk category C**

**FDA BOXED WARNING**

- QT prolongation and torsades de pointes may occur at or below recommended doses, even in patients with no known risk factors. (Risk factors for prolonged QT syndrome include heart failure, bradycardia, cardiac hypertrophy, hypokalemia, hypomagnesemia, age older than 65, alcohol abuse, and use of diuretics, drugs that prolong the QT interval, benzodiazepines, volatile anesthetics, or I.V. opioids.) Some cases have been fatal. Reserve drug for patients with refractory disease. Use with extreme caution in patients at risk for prolonged QT interval.

- Drug is contraindicated in patients with known or suspected QT prolongation.

**Action**

Produces marked sedation by directly blocking subcortical receptors. Produces antiemetic effect by blocking CNS receptors in chemoreceptor trigger zone.

**Availability**

*Injection:* 2.5 mg/ml in 1-ml, 2-ml, and 5-ml ampules and in 2-ml, 5-ml, and 10-ml vials

**Indications and dosages**

➤ Perioperative nausea and vomiting

- **Adults:** Initially, 2.5 mg I.M. or I.V. Additional doses of 1.25 mg may be given. Dosages are highly individualized according to patient’s age, weight, physical status, and underlying pathologic condition.

- **Children ages 2 to 12:** Initially, 0.1 mg/kg I.M. or I.V. Additional doses up to a total of 2.5 mg may be given. Dosages are highly individualized according to patient’s age, weight, physical status, and underlying clinical condition.

**Dosage adjustment**

- Elderly or debilitated patients
- High-risk patients (such as patients over age 65 and those with heart failure, alcohol abuse, or other factors that predispose to prolonged QT interval)
- Patients who have received other CNS depressants (such as analgesics or anesthetics)

**Contraindications**

- Hypersensitivity to drug
- Known or suspected QT-interval prolongation (more than 440 millisec in males or 450 millisec in females)

**Precautions**

Use cautiously in:

- severe cardiac or renal disease, diabetes mellitus, respiratory insufficiency, prostatic hypertrophy, angle-closure glaucoma, CNS depression, CNS tumors, intestinal obstruction, bone marrow depression
- elderly patients
- pregnant or breastfeeding patients
- children younger than age 2.

Reactions in **bold** are life-threatening.
**Administration**
- Know that the drug is indicated to ease perioperative nausea and vomiting only in patients who don’t respond adequately to other treatment.
- Be aware that the drug doesn’t need to be diluted for I.V. or I.M. use.
- Give by slow I.V. injection, or inject I.M. into large muscle.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V., I.M.</td>
<td>3-10 min</td>
<td>30 min</td>
<td>2-4 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: weakness, dysarthria, dysphonia, dizziness, extrapyramidal reactions, headache, postoperative hallucinatory episodes with transient depression, tremor, irritability, paresthesia, aggression, vertigo, ataxia, loss of consciousness, seizures, neuroleptic malignant syndrome

CV: chest pain, hypertension, hypotension, vasodilation, arrhythmias, atrial fibrillation

EENT: cataracts, blurred vision, eye irritation, sore throat

GI: nausea, vomiting, diarrhea, abdominal cramps, bloating, epigastric pain, fecal incontinence, increased salivation, dysphagia

GU: urinary frequency, increased libido

Hepatic: cholestatic jaundice

Metabolic: dehydration

Musculoskeletal: muscle cramps, arthritis, bone fractures

Respiratory: bronchitis, dyspnea

Skin: bruising, rash, urticaria, facial sweating, diaphoresis, pruritus, flushing

Other: toothache, weight loss, hot flashes, influenza, chills

**Interactions**

**Drug-drug.** Antihypertensives, nitrates: additive hypertension

CNS depressants (including antidepressants, antihistamines, opioids): additive CNS depression

Drugs that induce hypokalemia or hypomagnesemia (such as diuretics and laxatives and supraphysiologic use of steroid hormones with mineralocorticoid activity): possible precipitation, QT interval prolongation

Drugs that prolong QTc interval (such as antidepressants, class I or III antiarrhythmics, antimalarials, calcium channel blockers, some antihistamines, some neuroleptics): increased risk of conduction abnormalities

**Drug-herbs.** Chamomile, hops, kava, skullcap, valerian: increased CNS depression

**Drug-behaviors.** Alcohol use: additive CNS depression

**Patient monitoring**

- Monitor QT interval; report prolongation. Also watch for torsades de pointes.
- Know that the drug may cause sudden death at high doses (above 25 mg) in patients at risk for arrhythmias.
- Monitor for signs and symptoms of neuroleptic malignant syndrome, such as hyperthermia, severe extrapyramidal symptoms, altered mental status, stupor, coma, hypertension, tachycardia, pallor, or diaphoresis. (However, this syndrome is rare.)
- Assess vital signs frequently. Stay alert for orthostatic hypotension and tachycardia. Keep I.V. fluids and vasoressors on hand to treat pronounced hypotension.
- Don’t place hypotensive patient in Trendelenburg position because this may deepen anesthesia, precipitating respiratory arrest.
- Avoid abrupt position changes.
- Observe for signs and symptoms of respiratory compromise if the drug is used concurrently with narcotics.

**Patient teaching**

- Advise patient not to drink alcohol or take CNS depressants for 24 hours after receiving drug.

加拿大 UK 范围 冠状病毒 疫苗 封锁 COVID-19 一半国家 高危药物 警告
Tell patient drug may cause extreme drowsiness for several days after administration.
- Caution patient not to drive or perform other activities requiring mental alertness.
- Instruct patient to change positions slowly.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, herbs, and behaviors mentioned above.

**drotrecogin alfa (activated)
Xigris**

*Pharmacologic class:* Activated protein C (recombinant)

*Therapeutic class:* Antisepsis drug

*Pregnancy risk category C*

**Action**

**Availability**
*Powder for injection (lyophilized): 5 mg, 20 mg*

**Indications and dosages**

- Severe sepsis

  **Adults:** 24 mcg/kg/hour I.V. for a total duration of 96 hours

**Contraindications**
- Hypersensitivity to drug or its components
- Intracranial neoplasm or lesion or evidence of cerebral herniation
- Intracranial or intraspinal surgery within past 2 months
- Hemorrhagic stroke within past 3 months
- Severe head trauma or trauma with increased risk of bleeding
- Active bleeding or high risk of bleeding
- Patients undergoing bone marrow therapy
- Current use of epidural catheter

**Precautions**
Use cautiously in:
- intracranial arteriovenous malformation, chronic severe hepatic disease, recent GI bleeding
- concurrent use of heparin, thrombolytics, oral anticoagulants, or aspirin
- pregnant patients
- children (safety and efficacy not established).

**Administration**
- Mix with normal saline solution, lactated Ringer’s solution, or dextrose 5% in water.
- Prepare immediately before use.
  Hang infusion bag within 3 hours of reconstitution; complete infusion within 12 hours after preparation.
- Administer only through infusion pump.
- Don’t infuse with any other drug.
- Give entire regimen over 96 hours.
  - Discontinue drug 2 hours before invasive procedures.
  - Be aware that once hemostasis occurs, drug therapy may resume immediately after uncomplicated invasive procedures or 12 hours after major invasive procedures (such as surgery).

**Adverse reactions**
CNS: intracranial hemorrhage
GI: intra-abdominal, retroperitoneal, or other GI tract bleeding

Reactions in bold are life-threatening.

© Clinical alert
GU: bleeding
Hematologic: bleeding
Skin: bruising
Other: skin and soft-tissue bleeding, intrathoracic bleeding

Interactions
Drug-drug. Anticoagulants, aspirin, glycoprotein IIb/IIIa inhibitors, indomethacin, thrombolytics: increased risk of bleeding
Drug-diagnostic tests. Activated partial thromboplastin time (APTT), prothrombin time (PT): prolonged Hematocrit: decreased

Patient monitoring
-know that no antidote exists. Monitor closely for signs and symptoms of hemorrhage. Stop infusion if clinically significant bleeding occurs.
- Monitor PT and CBC (especially platelet count).
- Realize that drug may variably prolong APTT and thus doesn’t reliably indicate coagulopathy.

Patient teaching
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

FDA BOXED WARNING
- Drug may increase risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders, especially during first few months of therapy. Risk must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family and caregivers to observe patient closely and communicate with prescriber as needed.
- Drug isn’t approved for use in children.

Action
Unknown. May potentiate serotonergic and noradrenergic activity in CNS.

Availability
Capsules (delayed-release): 20 mg, 30 mg, 60 mg

Indications and dosages
- Major depressive disorder
  Adults: 40 mg/day (20 mg b.i.d.) P.O. to 60 mg/day (once daily or as 30 mg b.i.d.) P.O. If needed, start at 30 mg P.O. once daily for 1 week so patient can adjust to drug before increasing to 60 mg/day. If dosage is increased above 60 mg/day, use increments of 30 mg/day. Some patients may require maintenance dosage of 60 mg once daily for several months or longer.
  - Generalized anxiety disorder
    Adults: For most patients, recommended starting dose is 60 mg P.O. once daily. If needed, start at 30 mg P.O. once daily for 1 week so patient can adjust to drug before increasing to 60 mg/day. If dosage is increased above 60 mg/day, use increments of 30 mg/day.
  - Diabetic peripheral neuropathic pain
    Adults: 60 mg P.O. once daily. For patients with unknown tolerance, consider starting at lower dosage.
  - Fibromyalgia

Duloxetine hydrochloride
Cymbalta, Yentreve
Pharmacologic class: Selective serotonin and norepinephrine reuptake inhibitor
Therapeutic class: Antidepressant
Pregnancy risk category C

FDA BOXED WARNING
- Drug may increase risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders, especially during first few months of therapy. Risk must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family and caregivers to observe patient closely and communicate with prescriber as needed.
- Drug isn’t approved for use in children.

Action
Unknown. May potentiate serotonergic and noradrenergic activity in CNS.

Availability
Capsules (delayed-release): 20 mg, 30 mg, 60 mg

Indications and dosages
- Major depressive disorder
  Adults: 40 mg/day (20 mg b.i.d.) P.O. to 60 mg/day (once daily or as 30 mg b.i.d.) P.O. If needed, start at 30 mg P.O. once daily for 1 week so patient can adjust to drug before increasing to 60 mg/day. If dosage is increased above 60 mg/day, use increments of 30 mg/day. Some patients may require maintenance dosage of 60 mg once daily for several months or longer.
  - Generalized anxiety disorder
    Adults: For most patients, recommended starting dose is 60 mg P.O. once daily. If needed, start at 30 mg P.O. once daily for 1 week so patient can adjust to drug before increasing to 60 mg/day. If dosage is increased above 60 mg/day, use increments of 30 mg/day.
  - Diabetic peripheral neuropathic pain
    Adults: 60 mg P.O. once daily. For patients with unknown tolerance, consider starting at lower dosage.
  - Fibromyalgia

Duloxetine hydrochloride
Cymbalta, Yentreve
Pharmacologic class: Selective serotonin and norepinephrine reuptake inhibitor
Therapeutic class: Antidepressant
Pregnancy risk category C

FDA BOXED WARNING
- Drug may increase risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders, especially during first few months of therapy. Risk must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family and caregivers to observe patient closely and communicate with prescriber as needed.
- Drug isn’t approved for use in children.

Action
Unknown. May potentiate serotonergic and noradrenergic activity in CNS.

Availability
Capsules (delayed-release): 20 mg, 30 mg, 60 mg

Indications and dosages
- Major depressive disorder
  Adults: 40 mg/day (20 mg b.i.d.) P.O. to 60 mg/day (once daily or as 30 mg b.i.d.) P.O. If needed, start at 30 mg P.O. once daily for 1 week so patient can adjust to drug before increasing to 60 mg/day. If dosage is increased above 60 mg/day, use increments of 30 mg/day. Some patients may require maintenance dosage of 60 mg once daily for several months or longer.
  - Generalized anxiety disorder
    Adults: For most patients, recommended starting dose is 60 mg P.O. once daily. If needed, start at 30 mg P.O. once daily for 1 week so patient can adjust to drug before increasing to 60 mg/day. If dosage is increased above 60 mg/day, use increments of 30 mg/day.
  - Diabetic peripheral neuropathic pain
    Adults: 60 mg P.O. once daily. For patients with unknown tolerance, consider starting at lower dosage.
  - Fibromyalgia

Duloxetine hydrochloride
Cymbalta, Yentreve
Pharmacologic class: Selective serotonin and norepinephrine reuptake inhibitor
Therapeutic class: Antidepressant
Pregnancy risk category C

FDA BOXED WARNING
- Drug may increase risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders, especially during first few months of therapy. Risk must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family and caregivers to observe patient closely and communicate with prescriber as needed.
- Drug isn’t approved for use in children.

Action
Unknown. May potentiate serotonergic and noradrenergic activity in CNS.

Availability
Capsules (delayed-release): 20 mg, 30 mg, 60 mg

Indications and dosages
- Major depressive disorder
  Adults: 40 mg/day (20 mg b.i.d.) P.O. to 60 mg/day (once daily or as 30 mg b.i.d.) P.O. If needed, start at 30 mg P.O. once daily for 1 week so patient can adjust to drug before increasing to 60 mg/day. If dosage is increased above 60 mg/day, use increments of 30 mg/day. Some patients may require maintenance dosage of 60 mg once daily for several months or longer.
  - Generalized anxiety disorder
    Adults: For most patients, recommended starting dose is 60 mg P.O. once daily. If needed, start at 30 mg P.O. once daily for 1 week so patient can adjust to drug before increasing to 60 mg/day. If dosage is increased above 60 mg/day, use increments of 30 mg/day.
Adults: Initially, 30 mg P.O. daily for 1 week so patient can adjust to drug before increasing to 60 mg P.O. once daily. Some patients may respond to starting dosage. Base continued therapy on patient response.

Dosage adjustment
• Renal impairment

Contraindications
• MAO inhibitor use within past 14 days
• Uncontrolled narrow-angle glaucoma

Precautions
Use cautiously in:
• hepatic insufficiency, severe renal impairment, or chronic hepatic disease (use not recommended)
• hyponatremia, seizure disorder, controlled narrow-angle glaucoma, conditions that slow gastric emptying, urinary hesitancy and frequency
• history of mania
• concurrent use of potent CYP1A2 inhibitors (such as fluoroquinolones, thioridazine, or serotonin precursors) (avoid use)
• concurrent use of 5-hydroxytryptamine receptor agonist (triptan) or other CNS-acting drugs
• heavy alcohol use
• pregnant patients
• breastfeeding patients (use not recommended)
• children, adolescents, and young adults.

Administration
• Assess blood pressure before starting therapy.
• Give without regard to meals.
• Make sure patient swallows capsule whole without chewing or crushing it. Don’t sprinkle contents onto food or mix with liquids.
• Don’t give within 14 days of MAO inhibitors; don’t give MAO inhibitors within 5 days of duloxetine withdrawal.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>6 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: fatigue, somnolence, dizziness, asthenia, headache, agitation, abnormal dreams, tremor, insomnia, anxiety, worsening of depression, increased risk of suicide or suicidal ideation (especially in child or adolescent)
CV: orthostatic hypotension, syncope
EENT: blurred vision, mydriasis, nasal congestion, laryngopharyngeal pain
GI: nausea, vomiting, diarrhea, constipation, dyspepsia, dysgeusia, dry mouth
GU: abnormal orgasm, erectile or ejaculatory dysfunction, delayed ejaculation, decreased libido, frequent daytime urination
Hematologic: abnormal bleeding (echymoses, hematomas, epistaxis, petechiae, life-threatening hemorrhage)
Hepatic: hepatotoxicity
Musculoskeletal: muscle cramp, pain, and spasms
Respiratory: cough, upper respiratory tract infection
Skin: increased sweating, hot flashes, rash, pruritus
Other: pyrexia, seasonal allergy, yawning, decreased appetite, weight loss, serotonin syndrome

Interactions
Drug-drug. Aspirin, NSAIDs, other drugs that affect coagulation: increased risk of bleeding
Drugs metabolized by CYP2D6 (such as phenothiazines, tricyclic antidepressants, type 1C antiarrhythmics): increased blood levels of these drugs
Highly protein-bound drugs: increased free concentrations of these drugs, potentially causing adverse reactions
MAO inhibitors: serious and potentially fatal interactions

Reactions in bold are life-threatening.
Potent CYP1A2 inhibitors (such as cimetidine, fluvoxamine, quinolone antibiotics), potent CYP2D6 inhibitors (such as fluoxetine, paroxetine, quinidine): increased duloxetine blood level

Serotonergic drugs (such as linezolid, lithium, tramadol, triptans): increased risk of serotonin syndrome

Thioridazine: increased risk of serious ventricular arrhythmias and sudden death

Warfarin: altered anticoagulant effect, including increased bleeding

**Drug-diagnostic tests.** ALP, ALT, AST, creatine kinase: increased levels
Sodium: decreased level

**Drug-herbs.** St. John’s wort: increased risk of serotonin syndrome

**Drug-behaviors.** Alcohol use: increased risk of hepatic damage
Smoking: decreased duloxetine bioavailability

**Patient monitoring**

- Monitor patient’s mental status carefully. Stay alert for mood changes and signs of suicidal ideation, especially in child or adolescent.
- Monitor liver function test results and creatinine level for evidence of hepatic impairment.
- Watch for potentially life-threatening serotonin syndrome, especially with concomitant use of serotonergic drugs (including triptans) or drugs that impair serotonin metabolism (including MAO inhibitors). Signs and symptoms may include mental status changes (agitation, hallucinations, coma), autonomic instability (tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (hyperreflexia, incoordination) and GI upset (nausea, vomiting, diarrhea).
- Monitor blood pressure periodically during therapy.
- Watch for signs and symptoms of hyponatremia, such as headache, poor concentration, memory impairment, confusion, weakness, and unsteadiness.

If these occur, consider discontinuing drug and provide treatment as appropriate.
- Know that in diabetic patients, small increases in fasting blood glucose, glycosylated hemoglobin, and total cholesterol levels may occur.
- If concurrent triptan use is warranted, observe patient closely, especially at start of therapy and during dosage increases.
- Carefully monitor patient receiving warfarin when duloxetine is begun or discontinued.
  - Don’t stop drug abruptly. Taper dosage gradually.

**Patient teaching**

- Advise patient to take drug without regard to meals.
- Instruct patient to swallow capsules whole without chewing or crushing. Tell patient not to sprinkle contents onto food or mix with liquids.
- Advise patient (and parent or significant other as appropriate) to monitor mental status carefully and immediately report increased depression or suicidal thoughts or behavior (especially in child or adolescent).
- Instruct patient to report signs and symptoms of liver damage (unexplained flu-like symptoms, itching, right upper abdominal tenderness, dark urine, or yellow skin).
- Tell patient not to stop taking drug abruptly and that dosage will be tapered gradually when drug is discontinued.
- Caution patient to avoid driving and other hazardous activities until drug’s effects on concentration and alertness are known.
- Advise patient to rise slowly from a sitting or lying position to avoid sudden blood pressure drop.
- Instruct patient to avoid heavy alcohol use during therapy because of increased risk of liver damage.
Caution patient to avoid NSAIDs, aspirin, and other drugs that affect coagulation unless prescriber approves.
- Instruct patient not to use herbs, especially St. John’s wort, without consulting prescriber.
- Tell female patient to notify prescriber if she is pregnant or breastfeeding or plans to become pregnant or to breastfeed.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

**dutasteride**

Avodart

**Pharmacologic class:** Synthetic 4-azasteroid compound

**Therapeutic class:** 5-alpha-reductase inhibitor, sex hormone

**Pregnancy risk category X**

**Action**
Inhibits 5-alpha-reductase, an intracellular enzyme present in liver, skin, and prostate that’s required for conversion of testosterone to 5-alpha-dihydrotestosterone (DHT). DHT appears to be the principal androgen responsible for stimulating prostatic growth.

**Availability**
Capsules: 0.5 mg

**Indications and dosages**
- Symptomatic benign prostatic hypertrophy (alone or in combination with tamsulosin)
  - Adults: 0.5 mg P.O. daily

**Contraindications**
- Hypersensitivity to drug, its components, other 5-alpha-reductase inhibitors, xanthines (such as coffee, theobromine), or ethylenediamine
- Women
- Children

**Precautions**
Use cautiously in:
- hepatic impairment.

**Administration**
- Don’t handle drug if you’re pregnant or plan to become pregnant.
- Don’t open or crush capsule.
- Give without regard to food.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>2-3 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

GI: dyspepsia
GU: decreased libido, decreased ejaculatory volume, erectile dysfunction, gynecomastia

**Interactions**

**Drug-drug.** Cimetidine, ciprofloxacin, diltiazem, ketoconazole, other drugs metabolized by CYP450-3A4 pathway, ritonavir, verapamil: increased dutasteride blood level

**Drug-diagnostic tests.** Prostate-specific antigen (PSA): decreased level Thyroid-stimulating hormone: increased level

**Patient monitoring**
- Monitor fluid intake and output. Assess for ease of starting urine stream and for urinary urgency or frequency.
- Check baseline PSA level; reevaluate at 3 to 6 months.

**Patient teaching**
- Tell patient to take drug with full glass of water without crushing or opening capsule.
- Instruct patient not to take capsule if it’s cracked or leaking.
- Inform patient that drug decreases testosterone production in prostate.
Tell patient to report dysuria and uri
nary urgency.

Advise patient not to donate blood for at least 6 months after final dose.

Inform patient that drug may de
crease ejaculatory volume.

Explain that sexual side effects eventu
ally will subside.

As appropriate, review all other sig
nificant adverse reactions and interac
tions, especially those related to the
drugs and tests mentioned above.


efavirenz

Pharmacologic class: Nonnucleoside reverse transcriptase inhibitor
Therapeutic class: Antiretroviral
Pregnancy risk category D

Action
Inhibits human immunodeficiency virus (HIV) reverse transcriptase (required for transcription of HIV-1 RNA to DNA), leading to viral cell death

Availability
Capsules: 50 mg, 100 mg, 200 mg
Tablets: 600 mg

Indications and dosages
HIV infection (given with one or more additional antiretrovirals)
Adults and children older than age 3 and weighing more than 40 kg (88 lb): 600 mg P.O. once daily
Children weighing 32.5 to 40 kg (71.5 to 88 lb): 400 mg P.O. once daily
Children weighing 25 to 32.5 kg (55 to 71.5 lb): 350 mg P.O. once daily

Contraindications
• Hypersensitivity to drug
• Concurrent use of astemizole, cisa
pride, midazolam, triazolam, ergot de
rivatives, voriconazole, or bepridil

Precautions
Use cautiously in:
• hypercholesterolemia, hepatic impair
ment, concurrent use of hepatotoxic drugs, mental illness, or substance abuse
• concurrent use of St. John’s wort (use not recommended)
• pregnant or breastfeeding patients
• children.

Administration
• Give on empty stomach.
• Know that drug is given with other antiretrovirals.

Route Onset Peak Duration
P.O. Rapid 3-5 hr 24 hr

Adverse reactions
CNS: dizziness, drowsiness, fatigue, in
somnia, abnormal dreams, hypothes
tia, depression, headache, poor con
centration, nervousness, anxiety, CNS depression, suicidal ideation
CV: arrhythmias
GI: nausea, diarrhea, flatulence, ab
dominal pain, dyspepsia
GU: hematuria, renal calculi
Hepatic: hepatotoxicity
Respiratory: respiratory depression
Skin: rash, diaphoresis, pruritus, ery
thema multiforme, toxic epidermal necrolysis, Stevens-Johnson syndrome
Other: increased appetite

Canada UK Hazardous drug High alert drug
Interactions

Drug-drug. Azole antifungals (ketoconazole, voriconazole): decreased anti-fungal plasma concentration, increased efavirenz plasma concentration. Calcium channel blockers: possible decreased calcium channel blocker concentration. Clarithromycin, indinavir: reduced blood levels of these drugs. CNS depressants (including antidepressants, antihistamines, opioids): increased CNS depression. CYP450 inducers (including phenobarbital, rifabutin, rifampin): increased clearance and decreased blood level of efavirenz. CYP450 inhibitors, ergot alkaloids, estrogen, midazolam, ritonavir, triazolam: increased blood levels of these drugs, greater risk of serious adverse reactions (including arrhythmias, CNS and respiratory depression, and hepatotoxicity). HMG-CoA reductase inhibitors: decreased plasma concentration of atorvastatin, pravastatin, and simvastatin. Hormonal contraceptives: increased ethinyl estradiol blood level. Protease inhibitors: decreased plasma level and efficacy of these drugs. Saquinavir: decreased saquinavir blood level. Warfarin: increased or decreased warfarin effects.

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase, total cholesterol, triglycerides: increased levels. Urine cannabinoid test: false-positive result.


Drug-behaviors. Alcohol use: increased CNS depression.

Patient monitoring

- Monitor dietary intake and hepatic and lipid profile.
- Closely monitor patients with hepatic failure.
- Record mood changes and stay alert for suicidal ideation or behavior.
- Be aware that drug may cause hypercholesterolemia.
- Know that amount of HIV in blood may increase if patient stops drug therapy even briefly.

Patient teaching

- Instruct patient to take with full glass of water, preferably at bedtime to improve tolerance of CNS effects. Also tell him to avoid taking drug with high-fat meals.
- Inform patient that drug must be taken in combination with other antiretrovirals.
- Tell patient that drug doesn’t cure HIV or AIDS and that he can still transmit virus to others.
- Advise patient to report suicidal thoughts and other psychiatric symptoms.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Tell female patient to immediately inform prescriber if she becomes pregnant.
- Advise female patient to use adequate contraceptive measures for 12 weeks after discontinuing drug.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

Reactions in bold are life-threatening.
eletriptan hydrobromide
Relpax

Pharmacologic class: 5-hydroxytryptamine-1 (5-HT$_{1}$) receptor agonist
Therapeutic class: Antimigraine agent
Pregnancy risk category C

Action
Binds with serotonin 5-HT$_{1B}$ receptors on intracranial blood vessels and serotonin 5-HT$_{1D}$ receptors on sensory nerve endings, constricting cranial arteries and thereby relieving migraine

Availability
Tablets: 20 mg, 40 mg

Indications and dosages
- Migraine with or without aura

Adults: Initially, 20 to 40 mg P.O.; may repeat in 2 hours if headache returns after initial improvement. Maximum recommended single dosage is 40 mg.

Contraindications
- Hypersensitivity to drug
- Basilar and hemiplegic migraine
- Severe hepatic disease
- Ischemic heart disease
- Peripheral vascular disease
- Cerebrovascular syndromes
- Uncontrolled hypertension
- Ischemic bowel disease
- Within 24 hours of another serotonin agonist or ergot-type drug

Precautions
Use cautiously in:
- hepatic or renal impairment, diabetes mellitus, hypercholesterolemia, cardiac disorders
- pregnant or breastfeeding patients
- children.

Administration
- Give first dose as soon as migraine symptoms arise.
- Be aware that first dose should be given under close supervision to patients with coronary artery disease.
- If headache improves but then recurs, give second dose at least 2 hours after first.
- Be aware that drug’s safety in treating an average of more than three headaches within a 30-day period has not been established.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>2 hr</td>
<td>2-3 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, insomnia, drowsiness, headache, fatigue, anxiety, paresthesia, asthenia, cerebrovascular ischemia
CV: chest pain, palpitations, hypertension, cardiovascular ischemia
GI: nausea, vomiting, diarrhea, dry mouth
Musculoskeletal: muscle weakness
Respiratory: chest tightness or pressure
Skin: flushing
Other: hot or cold sensation

Interactions
Drug-drug. Antihistamines, ergotamine, ergot derivatives: increased vasospastic effects
CYP450-3A4 inhibitors (such as clarithromycin, ketoconazole, propranolol): increased eletriptan blood level
MAO inhibitors: increased eletriptan effects

Patient monitoring
- Monitor vital signs and assess for chest pain, tightness, or pressure.

Patient teaching
- Instruct patient to take first dose as soon as migraine symptoms occur. If headache improves but then recurs,
advise him to take second dose at least 2 hours after first.
- Caution patient to avoid driving and other hazardous activities until drug no longer affects concentration and alertness.
- Tell patient to report chest pain, pressure, or tightness.
- Inform patient that drug won’t prevent migraines and isn’t effective against other headache types.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

emtricitabine
Emtriva

*Pharmacologic class:* Nucleoside reverse transcriptase inhibitor

*Therapeutic class:* Antiretroviral

*Pregnancy risk category B*

**FDA BOXED WARNING**

- Drug has caused lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) when used alone or in combination with other antiretrovirals.
- Drug isn’t indicated for chronic hepatitis B virus (HBV) infection. Safety and efficacy haven’t been established in patients co-infected with HBV and human immunodeficiency virus (HIV). Discontinuation has led to severe acute HBV exacerbations. Monitor hepatic function closely.

**Action**
Inhibits activity of HIV-1 reverse transcriptase by competing with natural substrate and by its incorporation into nascent viral DNA, thereby halting viral replication

**Availability**
Capsules: 200 mg
Oral solution: 10 mg/ml in 170-ml bottles

**Indications and dosages**

> *HIV-1 infection, with other antiretrovirals*

**Adults ages 18 and older:**
- 200-mg capsule P.O. daily or 240 mg (24 ml) oral solution P.O. once daily

**Children ages 3 months to 17 years weighing more than 33 kg (73 lb):**
- 200-mg capsule P.O. once daily

**Children ages 3 months to 17 years weighing less than 33 kg (73 lb):**
- 6 mg/kg oral solution P.O. daily to maximum of 240 mg (24 ml) once daily

**Children ages 0 to 3 months:**
- 3 mg/kg oral solution P.O. once daily

**Dosage adjustment**
- Renal impairment

**Contraindications**
- Hypersensitivity to drug or its components

**Precautions**
Use cautiously in:
- renal impairment
- increased risk for lactic acidosis or hepatic impairment
- obese patients
- elderly patients
- children (safety and efficacy not established).

**Administration**
- Give with or without food.
- Know that drug must be given with other antiretrovirals.
- Know that capsule can be given to child weighing more than 33 kg if child can swallow an intact capsule.

Reactions in **bold** are life-threatening.
### Adverse reactions

**CNS:** dizziness, headache, insomnia, abnormal dreams, depression, peripheral neuritis or neuropathy, paresthesia

**EENT:** rhinitis

**GI:** nausea, vomiting, diarrhea, abdominal pain, dyspepsia

**Hepatic: hepatotoxicity**

**Metabolic:** cushingoid appearance (buffalo hump, moon face), **lactic acidosis**

**Musculoskeletal:** joint pain, myalgia

**Respiratory:** increased cough

**Skin:** rash, skin discoloration (hyperpigmentation on palms and soles)

**Other:** body fat redistribution

### Interactions

**Drug-drug.** Tenofovir disoproxil fumarate: increased emtricitabine effect

**Drug-diagnostic tests.** Alanine aminotransferase, amylase, aspartate aminotransferase, bilirubin, creatine kinase, lipase, triglycerides: increased levels

**Glucose:** increased or decreased level

**Neutrophils:** decreased count

### Patient monitoring

- Monitor closely (especially in females and obese patients) for signs and symptoms of lactic acidosis and hepatotoxicity, even if patient doesn’t have marked transaminase elevations.
- Assess neurologic status, checking especially for depression, peripheral neuropathy, and paresthesia.
- Monitor neutrophil count, lipid panel, liver function tests, and blood glucose level.
- Monitor patient closely for several months after drug withdrawal. Severe, acute exacerbations of hepatitis B virus (HBV) have been reported after discontinuation in patients co-infected with HBV and HIV.
- Monitor nutritional and hydration status in light of GI adverse effects and underlying disease.
- Watch for cushingoid appearance and body fat redistribution.

### Patient teaching

- Tell patient to take a missed dose as soon as he remembers. However, if it’s almost time for next dose, tell him to skip the missed dose and take next dose as scheduled.
- Instruct patient not to change dosage or stop taking drug unless prescriber approves.
- Tell patient drug should be taken only in combination with other drugs that treat HIV.
- Instruct patient not to take this drug if already taking Altripla (combination of efavirenz, emtricitabine, and tenofovir), Combivir (combination of lamivudine and zidovudine), Epivir (lamivudine), Epzicom (combination of abacavir and lamivudine), Trizivir (combination of abacavir, lamivudine, and zidovudine), or Truvada (combination of emtricitabine and tenofovir), because these drugs contain the same or similar ingredients.
- Instruct patient to immediately report signs or symptoms of lactic acidosis—unusual tiredness or muscle pain, difficulty breathing, stomach pain with nausea and vomiting, coldness, dizziness or light-headedness, or fast or irregular heartbeat.
- Instruct patient to immediately report signs or symptoms of liver problems—unusual tiredness, yellowing of skin or eyes, dark urine, light-colored feces, appetite loss, nausea, or pain in lower abdominal area.
- Advise patient to report adverse CNS reactions and to use good judgment about driving and other hazardous activities.
• Caution patient that drug may cause depression. Tell him to notify prescriber if he develops symptoms.
• Inform patient that drug may cause body fat redistribution, dark areas on palms and soles, and rash.
• Tell female patient to inform prescriber if she is pregnant or plans to become pregnant.
• Caution HIV-positive patient not to breastfeed.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

emtricitabine and tenofovir disoproxil fumarate
Truvada

Pharmacologic class: Nucleoside/nucleotide reverse-transcriptase inhibitor combination
Therapeutic class: Antiretroviral
Pregnancy risk category B

FDA BOXED WARNING
• Lactic acidosis and hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogues alone or in combination with other antiretrovirals.
• Drug isn’t indicated for chronic hepatitis B virus (HBV) infection; safety and efficacy haven’t been established for patients with HBV and human immunodeficiency virus (HIV) co-infection. Severe acute HBV exacerbations have been reported in patients with HBV and HIV co-infection. Monitor hepatic function closely in these patients. If appropriate, initiation of anti–hepatitis B therapy may be warranted.

Action
Inhibits activity of HIV-1 reverse transcriptase by competing with natural substrate and by its incorporation into nascent viral DNA, thereby halting viral replication. Tenofovir disoproxil fumarate inhibits activity of HIV-1 reverse transcriptase by competing with the natural substrate deoxyadenosine 5’-triphosphate and by its incorporation into viral DNA, resulting in chain termination.

Availability
Tablets: 200 mg emtricitabine/300 mg tenofovir disoproxil fumarate

Indications and dosages
HIV-1 infection in adults in combination with other antiretrovirals
Adults: 1 tablet P.O. daily

Dosage adjustment
• Renal impairment

Contraindications
• Hypersensitivity to drug or its components

Precautions
Use cautiously in:
• renal impairment
• increased risk of lactic acidosis or hepatic impairment
• concurrent use of efavirenz, emtricitabine, tenofovir, lamivudine, or nephrotoxic drugs (use not recommended)
• HIV-1 and HBV coinfections
• decreased bone density
• obese patients
• elderly patients
• children younger than age 18 (safety and efficacy not established).

Administration
• Assess creatinine clearance before starting therapy.
• Give with or without food.
● Don’t give with drug products containing lamivudine.
● Know that drug is usually given with other antiretrovirals.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>1-2 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: headache, insomnia, abnormal dreams, asthenia, dizziness, depressive disorder, neuropathy, peripheral neuropathy, peripheral neuritis, paresthesia
CV: chest pain
EENT: rhinitis
GI: nausea, vomiting, diarrhea, abdominal pain, anorexia, dyspepsia, flatulence, pancreatitis
GU: hematuria, glycosuria, proteinuria, proximal tubulopathy, renal insufficiency, acute tubular necrosis, renal failure, acute renal failure, Fanconi syndrome
Hepatic: hepatotoxicity
Metabolic: cushingoid appearance (buffalo hump, moon face), hypophosphatemia, lactic acidosis
Musculoskeletal: arthralgia, myalgia, back pain
Respiratory: dyspnea, increased cough, pneumonia
Skin: sweating, rash, pruritus, urticaria, skin discoloration (hyperpigmentation of palms and soles)
Other: weight loss, fever, allergic reaction, body fat redistribution; immune reconstitution syndrome

Interactions

Drug-drug. Acyclovir, adefovir dipivoxil, cidofovir, ganciclovir, valacyclovir, valganciclovir: increased concentration of emtricitabine/tenofovir
Atazanavir, lopinavir/ritonavir: increased tenofovir concentration
Didanosine: increased didanosine concentration

Drug-diagnostic tests. Alanine aminotransferase, bilirubin, creatine kinase, creatinine, lipase, urine and serum glucose: increased levels
Neutrophils: decreased count

Patient monitoring

Monitor patient closely (especially female or obese patient) for signs and symptoms of lactic acidosis and hepatotoxicity, even if patient doesn’t have marked transaminase elevations.

● Assess neurologic status, especially for depression, peripheral neuropathy, and paresthesia.

● Monitor neutrophil count, lipid panel, liver function test results, and blood glucose level.

● Monitor renal function closely, especially if patient is receiving nephrotoxic agents.

● Monitor bone mineral density in patients with history of pathologic fractures or who are at risk for osteopenia.

● Monitor for signs and symptoms of immune reconstitution syndrome, especially during initial phase of combination antiretroviral treatment when patient whose immune system responds may develop inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, cytomegalovirus, Pneumocystis jirovecii pneumonia, or tuberculosis), which may necessitate further evaluation and treatment.

Monitor patient closely for several months after drug withdrawal. Severe, acute exacerbations of hepatitis B virus (HBV) have been reported after discontinuation in patients co-infected with HBV and HIV.

● Monitor nutritional and hydration status in light of GI adverse effects and underlying disease.

● Watch for cushingoid appearance and body fat redistribution.
Patient teaching

- Instruct patient not to change dosage or stop taking drug unless prescriber approves.
- Advise patient to immediately report signs or symptoms of lactic acidosis—unusual tiredness or muscle pain, difficulty breathing, stomach pain with nausea and vomiting, coldness, dizziness or light-headedness, and fast or irregular heartbeat.
- Instruct patient to immediately report signs and symptoms of liver problems—unusual tiredness, yellowing of skin or eyes, dark urine, light-colored feces, appetite loss, nausea, and lower abdominal pain.
- Advise patient to notify prescriber of adverse CNS reactions and to use good judgment about driving and other hazardous activities.
- Inform patient that drug may cause depression. Tell him to notify prescriber if he develops symptoms.
- Inform patient that drug may cause body fat redistribution, rash, and dark areas on palms and soles.
- Advise patient to tell prescriber if he has bone problems before taking drug.
- Tell female patient to inform prescriber if she is pregnant or plans to become pregnant.
- Caution HIV-positive patient not to breastfeed.
- If patient misses a dose, instruct him to take it as soon as he remembers. However, if it’s almost time for next dose, tell him to skip the missed dose and take next dose as scheduled.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

enalapril maleate

Apo-Enalapril™, CO Enalapril™, Gen-Enalapril™, Innovace™, Novo-Enalapril™, PMS-Enalapril™, Ratio-Enalapril™, Riva-Enalapril™, Sandoz-Enalapril™, Taro-Enalapril™, Vasotec

enalaprilat

Vasotec IV

Pharmacologic class: Angiotensin-converting enzyme (ACE) inhibitor
Therapeutic class: Antihypertensive
Pregnancy risk category C (first trimester), D (second and third trimesters)

FDA BOXED WARNING

- When used during second or third trimester of pregnancy, drug can cause fetal injury and even death. Discontinue as soon as pregnancy is detected.

Action

Inhibits conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; inactivates bradykinin and prostaglandins. Also increases plasma renin and potassium levels and reduces aldosterone levels, resulting in systemic vasodilation.

Availability

Injection: 1.25 mg/ml
Tablets: 2.5 mg, 5 mg, 10 mg, 20 mg

Indications and dosages

Hypertension

Adults: For patients not taking concomitant diuretics—initially, 5 mg P.O. once daily, increased after 1 to 2 weeks as needed to a maintenance dosage of 10 to 40 mg P.O. daily given as a single dose or in two divided doses; or

Reactions in bold are life-threatening.
1.25 mg I.V. q 6 hours. For patients taking diuretics—initially, 2.5 mg P.O. or 0.625 mg I.V.

**Children:** 0.08 mg/kg P.O. once daily; may be increased based on blood pressure response up to 5 mg daily. Maximum dosage is 0.58 mg/kg/dose.

> **Heart failure**

**Adults:** Initially, 2.5 mg P.O. once or twice daily, increased after 1 to 2 weeks as needed to maintenance dosage of 5 to 40 mg P.O. daily given as a single dose or in two divided doses

> **Asymptomatic left ventricular dysfunction**

**Adults:** Initially, 2.5 mg P.O. once or twice daily, increased after 1 to 2 weeks as needed to a maximum of 20 mg/day in divided doses

**Dosage adjustment**

- Renal impairment

**Off-label uses**

- Diabetic nephropathy
- Hypertensive emergency

**Contraindications**

- Hypersensitivity to drug or other ACE inhibitors
- Angioedema
- Pregnancy

**Precautions**

Use cautiously in:

- renal or hepatic impairment, hypovolemia, hyponatremia, aortic stenosis, hypertrophic cardiomyopathy, cerebrovascular or cardiac insufficiency
- concurrent diuretic use
- elderly patients
- breastfeeding patients
- children.

**Administration**

- Give oral doses with food or beverage.
- Discontinue diuretics for 2 to 3 days before starting drug, if possible.

- Know that I.V. administration is usually reserved for patients who cannot take P.O. form.
- Be aware that I.V. administration isn’t recommended for pediatric patients.
- Administer I.V. dose either undiluted or diluted in 50 ml of dextrose 5% in water, normal saline solution, dextrose 5% in normal saline solution, or dextrose 5% in lactated Ringer’s solution.
- Give single I.V. dose by push or piggyback over 5 minutes. If patient is at risk for hypotension, infusion may be given over 1 hour.
- Be aware that black patients have a higher risk of angioedema.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1 hr</td>
<td>4-6 hr</td>
<td>24 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>15 min</td>
<td>3-4 hr</td>
<td>6 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: dizziness, fatigue, headache, insomnia, drowsiness, vertigo, asthenia, paresthesia, ataxia, confusion, depression, nervousness, **cerebrovascular accident**

CV: orthostatic hypotension, palpitations, angina pectoris, tachycardia, peripheral edema, **arrhythmias**, **cardiac arrest**

EENT: sinusitis

GI: nausea, vomiting, constipation, dyspepsia, abdominal pain, dry mouth, **pancreatitis**

GU: proteinuria, urinary tract infection, erectile dysfunction, decreased libido, **oliguria**

Hematologic: **agranulocytosis**, **bone marrow depression**

Hepatic: **hepatitis**

Metabolic: hyponatremia, **hyperkalemia**

Respiratory: cough, upper respiratory tract infection, asthma, bronchitis, dyspnea, **eosinophilic pneumonitis**

Skin: rash, alopecia, photosensitivity, diaphoresis, exfoliative dermatitis, **angioedema**, **erythema multiforme**

🔬 Canada 🇬🇧 UK 🦂 Hazardous drug ☢ High alert drug
Other: altered taste, fever, increased appetite, anaphylactoid reactions

Interactions
Drug-drug. Allopurinol: increased risk of hypersensitivity reaction
Antacids: decreased enalapril absorption
Cyclosporine, indomethacin, potassium-sparing diuretics, potassium supplements: hyperkalemia
Digoxin, lithium: increased blood levels of these drugs, possible toxicity
Diuretics, nitrates, other antihypertensives, phenothiazines: additive hypotension
Nonsteroidal anti-inflammatory drugs: decreased antihypertensive response
Rifampin: decreased enalapril efficacy

Drug-diagnostic tests. Alanine amino-transferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen (BUN), creatinine, potassium: increased levels
Antinuclear antibodies: positive titer
Sodium: decreased level

Drug-food. Salt substitutes containing potassium: hyperkalemia

Drug-herbs. Capsaicin: increased incidence of cough

Drug-behaviors. Acute alcohol ingestion: additive hypotension
Sun exposure: photosensitivity reaction

Patient monitoring
Assess for rapid blood pressure drop leading to cardiovascular collapse, especially when giving with diuretics.
In patient with renal insufficiency or renal artery stenosis, monitor for worsening renal function.
After initial dose, observe patient closely for at least 2 hours until blood pressure has stabilized. Then continue to observe for additional hour.
Monitor vital signs, fluid intake and output, and daily weight.
Supervise patient during ambulation until effects of drug are known.

Patient teaching
Inform patient that drug’s full effect may not occur for several weeks.
Advise patient to report persistent dry cough with nasal congestion. Tell patient to immediately report swelling of face, eye area, tongue, lips, hands, or feet; rash, hives, or severe itching; unexplained fever; unusual tiredness; yellowing of skin or eyes; abdominal pain; or easy bruising.
Instruct patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness from sudden blood pressure decrease.
As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

Patient monitoring
Assess for rapid blood pressure drop leading to cardiovascular collapse, especially when giving with diuretics.
In patient with renal insufficiency or renal artery stenosis, monitor for worsening renal function.
After initial dose, observe patient closely for at least 2 hours until blood pressure has stabilized. Then continue to observe for additional hour.
Monitor vital signs, fluid intake and output, and daily weight.
Supervise patient during ambulation until effects of drug are known.

Patient teaching
Inform patient that drug’s full effect may not occur for several weeks.
Advise patient to report persistent dry cough with nasal congestion. Tell patient to immediately report swelling of face, eye area, tongue, lips, hands, or feet; rash, hives, or severe itching; unexplained fever; unusual tiredness; yellowing of skin or eyes; abdominal pain; or easy bruising.
Instruct patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness from sudden blood pressure decrease.
As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

Patient monitoring
Assess for rapid blood pressure drop leading to cardiovascular collapse, especially when giving with diuretics.
In patient with renal insufficiency or renal artery stenosis, monitor for worsening renal function.
After initial dose, observe patient closely for at least 2 hours until blood pressure has stabilized. Then continue to observe for additional hour.
Monitor vital signs, fluid intake and output, and daily weight.
Supervise patient during ambulation until effects of drug are known.

Patient teaching
Inform patient that drug’s full effect may not occur for several weeks.
Advise patient to report persistent dry cough with nasal congestion. Tell patient to immediately report swelling of face, eye area, tongue, lips, hands, or feet; rash, hives, or severe itching; unexplained fever; unusual tiredness; yellowing of skin or eyes; abdominal pain; or easy bruising.
Instruct patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness from sudden blood pressure decrease.
As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.
Children ages 6 to 16: 2 mg/kg subcutaneously b.i.d. in upper arm, anterior thigh, or abdomen. Maximum dosage is 90 mg b.i.d.

Contraindications
- Hypersensitivity to drug or its components

Precautions
Use cautiously in:
- increased risk of pneumonia
- injection site reaction
- concurrent use of anticoagulants
- hemophilia or other coagulant disorders
- elderly patients
- children younger than age 6 (safety and efficacy not established).

Administration
- Rotate injection sites.
- Be aware that preferred injection sites are upper arm, anterior thigh, and abdomen.
- Reconstitute with 1.1 ml of sterile water for injection, and gently tap vial for 10 seconds. Then gently roll vial between hands or allow vial to stand until product dissolves completely (could take up to 45 minutes).
- Know that drug is usually given with other antiretrovirals.
- Use reconstituted solution immediately.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcut.</td>
<td>Unknown</td>
<td>4 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: fatigue, asthenia, insomnia, depression, anxiety, peripheral neuropathy
EENT: conjunctivitis, sinusitis
GI: nausea, diarrhea, upper abdominal pain, dry mouth, anorexia, pancreatitis
Hematologic: lymphadenopathy
Musculoskeletal: limb pain, myalgia
Respiratory: cough, pneumonia
Skin: folliculitis

Other: taste disturbance, decreased appetite, weight loss, herpes simplex infection, injection site reactions (erythema, induration, nodules, cysts, mild to moderate pain, infection), flu-like illness, hypersensitivity reactions

Interactions
Drug-diagnostic tests. Alanine aminotransferase, amylase, aspartate aminotransferase, creatine kinase, eosinophils, gamma-glutamyltransferase, lipase, triglycerides: increased levels
Hemoglobin: decreased level

Patient monitoring
- Inspect injection sites frequently for adverse reactions.
- Monitor CBC with white cell differential, lipid panel, liver function test results, and gastric enzymes levels.
- Watch for hypersensitivity reactions.
- Monitor nutritional and hydration status in light of GI adverse effects and underlying disease.

Patient teaching
- Teach patient (or caregiver) how to reconstitute and self-administer drug, as appropriate.
- Instruct patient not to change dosage or stop taking drug unless prescriber approves.
- Tell patient to immediately report signs or symptoms of hypersensitivity reaction (such as rash, fever, nausea and vomiting, and chills).
- Teach patient how to recognize signs and symptoms of injection site reaction. Tell him to contact prescriber if these occur, especially if they last more than 7 days.
- Advise female patient to notify prescriber if she is pregnant or plans to become pregnant.
- Tell HIV-infected patient not to breastfeed.
- If patient misses a dose, instruct him to take it as soon as he remembers.
However, if it’s almost time for next dose, tell him to skip the missed dose and take next dose on schedule.

- As appropriate, review all other significant adverse reactions and interactions, especially those related to the tests mentioned above.

enoxaparin sodium
Clexane®, Lovenox 3

**Pharmacologic class:** Low-molecular-weight heparin  
**Therapeutic class:** Anticoagulant  
**Pregnancy risk category B**

**FDA BOXED WARNING**

- During epidural or spinal anesthesia or puncture, patients receiving drug or scheduled to receive it for thromboprophylaxis are at risk for epidural or spinal hematoma, which can lead to long-term or permanent paralysis. Risk increases with use of indwelling epidural catheter for analgesia administration and with concurrent use of drugs affecting hemostasis (such as nonsteroidal anti-inflammatory drugs [NSAIDs], platelet inhibitors, and other anticoagulants). Risk also rises with traumatic or repeated epidural or spinal puncture. Before neuraxial intervention, physician should weigh drug’s potential benefit against risk.

- Monitor patient frequently for signs and symptoms of neurologic impairment.

**Action**

Inhibits thrombus and clot formation by blocking factor Xa and factor IIa. This inhibition accelerates formation of antithrombin III-thrombin complex (a coagulation inhibitor), thereby deactivating thrombin and preventing conversion of fibrinogen to fibrin.

**Availability**

*Solution for injection:* 30 mg/0.3 ml, 40 mg/0.4 ml, 60 mg/0.6 ml, 80 mg/0.8 ml, 120 mg/0.8 ml, 100 mg/1 ml, 150 mg/1 ml (all in prefilled syringes); 300 mg/3 ml (in multidose vials)

**Indications and dosages**

➤ Patients at risk for thromboembolic complications due to severely restricted mobility during acute illness

Adults: 40 mg subcutaneously daily for up to 14 days

➤ Prevention of pulmonary embolism and deep-vein thrombosis (DVT) after abdominal surgery

Adults: 40 mg subcutaneously 2 hours before surgery, repeated 24 hours after initial dose (provided hemostasis has been established) and continued once daily for 7 to 10 days until risk of DVT has diminished

➤ Prevention of pulmonary embolism and DVT after hip or knee replacement surgery

Adults: 30 mg subcutaneously 12 to 24 hours after surgery (provided hemostasis has been established), repeated q 12 hours for 7 to 10 days until risk of DVT has diminished. Alternatively, hip-replacement patient may receive 40 mg subcutaneously 12 hours before surgery and then once daily for 3 weeks, for a total of 4 weeks of therapy.

➤ Prevention of ischemic complications of unstable angina or non-Q-wave myocardial infarction

Adults: 1 mg/kg subcutaneously q 12 hours, given with aspirin 100 to 325 mg P.O. once daily until patient is clinically stable

➤ Hospitalized patients with acute DVT with or without pulmonary embolism (PE) (given with warfarin sodium)

Adults: 1 mg/kg subcutaneously q 12 hours or 1.5 mg/kg subcutaneously
once daily for 5 to 7 days until therapeutic effect is established. Warfarin therapy usually begins within 72 hours of enoxaparin injection.

Outpatients with acute DVT without PE (given with warfarin sodium)

**Adults:** 1 mg/kg subcutaneously q 12 hours for 5 to 7 days until therapeutic effect is established. Warfarin therapy usually begins within 72 hours of enoxaparin injection.

### Dosage adjustment
- Patients weighing less than 45 kg (99 lb)
- Creatinine clearance below 30 ml/minute

### Off-label uses
- Prevention of clots associated with hemodialysis
- Prevention of thrombosis during pregnancy

### Contraindications
- Hypersensitivity to drug, heparin, sulfites, benzyl alcohol, or pork products
- Thrombocytopenia
- Active major bleeding

### Precautions
Use cautiously in:
- Severe hepatic or renal disease, retinopathy (hypertensive or diabetic), uncontrolled hypertension, hemorrhagic stroke, bacterial endocarditis, GI bleeding or other bleeding disorders
- Recent history of ulcer disease, history of congenital or acquired bleeding disorder, history of thrombocytopenia related to heparin use
- Recent CNS surgery
- Pregnant or breastfeeding patients
- Children

### Administration
- Be aware that enoxaparin is a high-alert drug.
- Use tuberculin syringe with multidose vial to ensure accurate dosage.
- Don’t expel air bubble from syringe before administering.
- Inject drug deep subcutaneously with patient in supine position. Alternate left and right anterolateral and posterolateral abdominal wall sites.
- Don’t rub injection site.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcut.</td>
<td>Unknown</td>
<td>3-5 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

### Adverse reactions
- **CNS:** dizziness, headache, insomnia, confusion, cerebrovascular accident
- **CV:** edema, chest pain, atrial fibrillation, heart failure
- **GI:** nausea, chest pain, atrial fibrillation, heart failure
- **GU:** urinary retention
- **Hematologic:** anemia, bleeding tendency, thrombocytopenia, hemorrhage
- **Metabolic:** hyperkalemia
- **Skin:** bruising, pruritus, rash, urticaria
- **Other:** fever, pain, irritation, or erythema at injection site

### Interactions
- **Drug-drug.** Warfarin, other drugs that affect platelet function (including abciximab, aspirin, clopidogrel, dextran, dihydropyridine, eptifibatide, NSAIDs, some penicillins, ticlopidine, tirofiban): increased risk of bleeding
- **Drug-diagnostic tests.** Hepatic enzymes: reversible increases
- **Hemoglobin, platelets:** decreased levels
- **Drug-herbs.** Anise, arnica, chamomile, clove, feverfew, garlic, ginger, ginkgo, ginseng: increased risk of bleeding

### Patent monitoring
- Monitor CBC and platelet counts. Watch for signs and symptoms of bleeding or bruising.
- Monitor fluid intake and output. Watch for fluid retention and edema.
Patient teaching
- If patient will self-administer drug, teach proper injection technique.
- Instruct patient to promptly report irregular heart beat, unusual bleeding or bruising, rash, or hives.
- Teach patient safety measures to avoid bruising or bleeding.
- Advise patient to weigh himself regularly and to report gains.
- Instruct patient to inform dentists and other health care professionals about enoxaparin use.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

entacapone
Comtan, Comtess®

Pharmacologic class: Catechol O-methyltransferase (COMT) inhibitor
Therapeutic class: Antidyskinetic
Pregnancy risk category C

Action
Inhibits COMT, the primary enzyme involved in metabolizing levodopa. This inhibition increases levodopa blood level and duration of action, easing symptoms of Parkinson’s disease.

Availability
Tablets: 200 mg

Indications and dosages
- Adjunctive treatment of idiopathic Parkinson’s disease in patients experiencing wearing off of carbidopa-levodopa effects
Adults: 200 mg P.O. with each carbidopa-levodopa dose, to a maximum of eight times daily (1,600 mg)

Contraindications
- Hypersensitivity to drug

Precautions
Use cautiously in:
- hepatic or renal dysfunction, hypertension, heart disease
- pregnant and breastfeeding patients.

Administration
- Give without regard to food.
- Administer at same time as carbidopa-levodopa. Make sure patient swallows tablet whole.
- Don’t withdraw drug abruptly.

Route  Onset  Peak  Duration
P.O.  Variable  1 hr  Unknown

Adverse reactions
CNS: dizziness, depression, drowsiness, disorientation, memory loss, agitation, delusions, hallucinations, paranoia, euphoria, dyskinesia, hyperkinesia, light-headedness, paresthesia, heaviness of limbs, numbness of fingers
CV: tachycardia, orthostatic hypotension, hypertension
GI: nausea, vomiting, epigastric pain, flatulence
GU: urine discoloration
Respiratory: upper respiratory tract infection, dyspnea, sinus congestion
Other: fever

Interactions
Drug-drug. Ampicillin, chloramphenicol, cholestyramine, erythromycin, probenecid, rifampin: decreased entacapone excretion
Bitolterol, dobutamine, dopamine, epinephrine, isoeitherine, isoproterenol, methyl dopa, norepinephrine: increased heart rate, increased risk of arrhythmias, excessive blood pressure changes
MAO inhibitors: increased risk of toxicity

Drug-behaviors. Alcohol use: increased risk of adverse reactions

Reactions in bold are life-threatening.

Clinical alert
Patient monitoring
- Monitor vital signs, watching especially for orthostatic hypotension.
- Evaluate neurologic status closely. Check for hallucinations and new onset or exacerbation of dyskinesia.
- Assess respiratory status, particularly for dyspnea and signs and symptoms of upper respiratory tract infection.
- Monitor nutritional and hydration status if patient experiences vomiting.

Patient teaching
- Instruct patient to swallow tablet whole and to take it at same time as carbidopa-levodopa.
- Caution patient not to stop taking drug abruptly.
- Advise patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness from sudden blood pressure decrease.
- Caution patient to avoid driving and other hazardous activities until drug no longer affects concentration and alertness.
- Instruct patient (and caregiver) to institute safety measures at home to prevent injury related to disease or drug’s adverse CNS effects.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and behaviors mentioned above.

entecavir
Baraclude

Pharmacologic class: Guanosine nucleoside analogue
Therapeutic class: Antiviral
Pregnancy risk category C

FDA BOXED WARNING
- Drug may cause lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) when used alone or in combination with antiretrovirals.
- Severe acute hepatitis B exacerbations have occurred in patients who discontinued anti–hepatitis B therapy, including entecavir. Monitor hepatic function for at least several months after discontinuation. If appropriate, initiate anti–hepatitis B therapy.
- When used to treat chronic hepatitis B, drug may cause human immunodeficiency virus (HIV) resistance to HIV nucleoside reverse transcriptase inhibitors in patients with untreated HIV infection. Therapy isn’t recommended for HIV/hepatitis B virus (HBV) co-infected patients except those also receiving highly active antiretroviral therapy.

Action
Competes with natural substrate deoxyguanosine triphosphate to inhibit HBV polymerase (reverse transcriptase)

Availability
Oral solution: 0.05 mg/ml
Tablets: 0.5 mg, 1 mg

Indications and dosages
- Chronic HBV infection with evidence of active viral replication and either persistent serum transaminase elevations or histologically active disease
- Adolescents and adults ages 16 and older: In patients who haven’t received previous nucleosides, 0.5 mg P.O. daily 2 hours before or 2 hours after a meal. In patients with a history of hepatitis B viremia while receiving lamivudine or known lamivudine-resistant mutations, 1 mg P.O. daily 2 hours before or 2 hours after a meal.
Dosage adjustment
- Creatinine clearance below 50 ml/minute

Contraindications
- Hypersensitivity to drug or its components

Precautions
Use cautiously in:
- liver transplant recipients who are receiving or have received immunosuppressants that may affect renal function
- elderly patients
- pregnant or breastfeeding patients
- children younger than age 16.

Administration
- Administer at least 2 hours before or after a meal.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>0.5-1.5 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, dizziness, fatigue
GI: nausea, diarrhea, dyspepsia, increased GI enzymes
Hematologic: hematuria
Hepatic: HBV exacerbation, severe hepatomegaly
Metabolic: glycosuria, lactic acidosis

Interactions
Drug-drug. Drugs that reduce renal function or compete for active tubular secretion: increased blood levels of either drug
Drug-diagnostic tests. Alanine aminotransferase, amylase, aspartate aminotransferase, lipase, glucose, serum creatinine, total bilirubin: increased

Patient monitoring
- Monitor renal function before and during therapy, especially in liver transplant recipients who are receiving or have received immunosuppressants that may affect renal function.
- Monitor liver function closely for evidence of HBV exacerbation for at least several months after drug discontinuation.
- Monitor for lactic acidosis (associated with nucleoside analogues).

Patient teaching
- Instruct patient to take drug on empty stomach (at least 2 hours before or after a meal).
- Teach patient about signs and symptoms of lactic acidosis and importance of contacting prescriber if these occur.
- Instruct patient to immediately report worsening symptoms, such as increased yellowing of skin or eyes, dark urine, or fatigue.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

epinephrine
Primatene Mist, Twinject
epinephrine bitartrate
Bronitin Mist
epinephrine hydrochloride
Adrenalin Chloride®, Anapen®, Epi-E-Z Pen®, EpiPen, EpiPen Jr.

Pharmacologic class: Sympathomimetic (direct acting)
Therapeutic class: Bronchodilator, mydriatic
Pregnancy risk category C

Action
Stimulates alpha- and beta-adrenergic receptors, causing relaxation of cardiac and bronchial smooth muscle and
dilation of skeletal muscles. Also decreases aqueous humor production, increases aqueous outflow, and dilates pupils by contracting dilator muscle.

**Availability**
- **Aerosol inhaler:** 160 mcg, 200 mcg, 220 mcg, 250 mcg
- **Auto-injector for I.M. injection:** 1:2,000 (0.5 mg/ml)
- **Injection:** 0.1 mg/ml, 0.5 mg/ml, 1 mg/ml
- **Ophthalmic drops:** 0.5%, 1%, 2%

**Indications and dosages**

- Bronchodilation; anaphylaxis; hypersensitivity reaction
  - **Adults:** 0.1 to 0.5 ml of 1:1,000 solution subcutaneously or I.M., repeated q 10 to 15 minutes p.r.n. Or 0.1 to 0.25 ml of 1:10,000 solution I.V. slowly over 5 to 10 minutes; may repeat q 5 to 15 minutes p.r.n. or follow with a continuous infusion of 1 mcg/minute, increased to 4 mcg/minute p.r.n. For emergency treatment, EpiPen delivers 0.3 mg I.M. of 1:1,000 epinephrine.
- **Children:** For emergency treatment, EpiPen Jr. delivers 0.15 mg I.M. of 1:2,000 epinephrine.

- Acute asthma attack
  - **Adults and children ages 4 and older:** 160 to 250 mcg metered aerosol (equivalent to one inhalation); repeat once after 1 minute, if needed. Don’t give subsequent doses for at least 3 hours. Or one to three deep inhalations of 1% solution with hand-held nebulizer, repeated q 3 hours p.r.n.
  - To restore cardiac rhythm in cardiac arrest
    - **Adults:** 0.5 to 1 mg I.V., repeated q 3 to 5 minutes, if needed. If no response, may give 3 to 5 mg I.V. q 3 to 5 minutes.
  - Chronic simple glaucoma
    - **Adults:** One drop in affected eye once or twice daily. Adjust dosage to meet patient’s needs.

**Contraindications**
- Hypersensitivity to drug, its components, or sulfites
- Angle-closure glaucoma
- Cardiac dilatation, cardiac insufficiency
- Cerebral arteriosclerosis, organic brain syndrome
- Shock with use of general anesthetics and halogenated hydrocarbons or cyclosporine
- MAO inhibitor use within past 14 days
- Labor
- Breastfeeding

**Precautions**

Use cautiously in:
- hypertension, hyperthyroidism, diabetes, prostatic hypertrophy
- elderly patients
- pregnant patients
- children.

**Administration**

- In anaphylaxis, use I.M. route, not subcutaneous route, if possible.
- Inject EpiPen and EpiPen Jr. only into anterolateral aspect of thigh. Don’t inject into buttocks or give I.V.
- Be aware that not all epinephrine solutions can be given I.V. Check manufacturer’s label.
- For I.V. injection, give each 1-mg dose over at least 1 minute. For continuous infusion, use rate of 1 to 10 mcg/minute, adjusting to desired response.
- Use Epi-Pen Jr. for patients weighing less than 30 kg (66 lb).
- Don’t give within 14 days of MAO inhibitors.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>5 min</td>
<td>Short</td>
</tr>
<tr>
<td>I.M.</td>
<td>Variable</td>
<td>Unknown</td>
<td>1-4 hr</td>
</tr>
<tr>
<td>Subcut.</td>
<td>5-15 min</td>
<td>0.5 hr</td>
<td>1-4 hr</td>
</tr>
<tr>
<td>Inhalation</td>
<td>1-5 min</td>
<td>Unknown</td>
<td>1-3 hr</td>
</tr>
</tbody>
</table>

**Route Onset Peak Duration**

- **I.V.** Immediate 5 min Short
- **I.M.** Variable Unknown 1-4 hr
- **Subcut.** 5-15 min 0.5 hr 1-4 hr
- **Inhalation** 1-5 min Unknown 1-3 hr
Adverse reactions

CNS: nervousness, anxiety, tremor, vertigo, headache, disorientation, agitation, drowsiness, fear, dizziness, asthenia, cerebral hemorrhage, cerebrovascular accident (CVA)

CV: palpitations, widened pulse pressure, hypertension, tachycardia, angina, ECG changes, ventricular fibrillation, shock

GI: decreased urinary output, urinary retention, dysuria

Respiratory: dyspnea, pulmonary edema

Skin: urticaria, pallor, diaphoresis, necrosis

Other: hemorrhage at injection site

Interactions

Drug-drug. Alpha-adrenergic blockers: hypotension from unopposed beta-adrenergic effects

Antihistamines, thyroid hormone, tricyclic antidepressants: severe sympathomimetic effects

Beta-adrenergic blockers (such as propranolol): vasodilation and reflex tachycardia

Cardiac glycosides, general anesthetics: increased risk of ventricular arrhythmias

Diuretics: decreased vascular response

Doxapram, mazindol, methylphenidate: enhanced CNS stimulation or pressor effects

Ergot alkaloids: decreased vasoconstriction

Guanadrel, guanethidine: enhanced pressor effects of epinephrine

Levodopa: increased risk of arrhythmias

Levothyroxine: potentiation of epinephrine effects

MAO inhibitors: increased risk of hypertensive crisis

Drug-diagnostic tests. Glucose: transient elevation

Lactic acid: elevated level (with prolonged use)

Patient monitoring


• Assess drug’s effect on underlying problem (such as anaphylaxis or asthma attack), and repeat dose as needed.

rutop Monitor neurologic status, particularly for decreased level of consciousness and other signs and symptoms of cerebral hemorrhage or CVA.

• Monitor fluid intake and output, watching for urinary retention or decreased urinary output.

• Inspect injection site for hemorrhage or skin necrosis.

Patient teaching

• Teach patient who uses auto-injector how to use syringe correctly, when to inject drug, and when to repeat doses.

• Teach patient who uses hand-held nebulizer correct use of equipment and drug. Explain indications for both initial dose and repeat doses.

• Inform patient that drug may cause serious adverse effects. Tell him which symptoms to report.

• If patient will self-administer drug outside of health care setting, explain need for prompt evaluation by a health care provider to ensure that underlying disorder has been corrected.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Reactions in bold are life-threatening.
Epirubicin hydrochloride
Ellence, Pharmorubicin PMS®

Pharmacologic class: Anthracycline
Therapeutic class: Antibiotic antineoplastic
Pregnancy risk category D

FDA BOXED WARNING

- Extravasation during administration causes severe local tissue necrosis.
- Myocardial toxicity, manifested most severely by potentially fatal heart failure, may occur during therapy or months to years afterward. Risk rises rapidly with increasing total cumulative doses above 900 mg/m²; exceed this cumulative dose only with extreme caution. Active or dormant cardiovascular disease, previous or concurrent radiotherapy to mediastinal or pericardial area, previous anthracycline or anthracenedione therapy, or concurrent use of other cardiotoxic drugs may increase myocardial toxicity risk. Toxicity may occur at lower cumulative doses even if patient has no cardiac risk factors.
- Secondary acute myelogenous leukemia (AML) has occurred in breast cancer patients who’ve received this drug. Refractory AML is more common when drug is given in combination with DNA-damaging antineoplastic, when patients have been heavily pretreated with cytotoxic drugs, or when epirubicin dosage has been escalated.
- Reduce dosage in patients with hepatic impairment.
- Drug may cause severe myelosuppression.
- Give under supervision of physician experienced in cancer chemotherapy.

Action
Unknown. Forms complex with DNA by intercalation with nucleotide base pairs, causing inhibition of DNA, RNA, and protein synthesis.

Availability
Injection: 2 mg/ml, in 5 ml-, 25 ml-, 75 ml-, and 100-ml vials
Powder for injection (lyophilized): 50-mg single-dose vial

Indications and dosages

- Adjunctive therapy in patients with axillary-node tumor involvement after resection of primary breast cancer
  - Adults: 100 to 120 mg/m² by I.V. infusion over 3 to 5 minutes on first day of each cycle or divided equally in two doses on days 1 and 8 of each cycle; repeat cycle q 3 to 4 weeks for six cycles in conjunction with cyclophosphamide and fluorouracil.

Dosage adjustment

- Hepatic and severe renal impairment
- Hematologic or Grade 3 or 4 non-hematologic toxicity and neutropenic fever

Off-label uses

- Cancer of bladder, lung, nasopharynx, endometrium, and ovaries

Contraindications

- Hypersensitivity to drug, other anthracyclines, or anthracenediones
- Severe myocardial insufficiency, recent myocardial infarction, severe arrhythmias
- Severe hepatic dysfunction
- Baseline neutrophil count below 1,500/mm³
- Previous treatment with anthracyclines up to the maximum cumulative doses

Precautions

Use cautiously in:
- heart disease, hepatic disease

Canada UK Hazardous drug High alert drug
● previous or recent radiation therapy
● pregnant or breastfeeding patients
● children.

**Administration**

● Be aware that drug may be given with antibiotics.
● Know that previous anthracycline use must be considered when determining dosage because of increased risk of heart failure.
● Follow facility policy for administration and disposal of carcinogenic drugs.

Avoid extravasation. If patient complains of burning or stinging, switch infusion to a different vein.

● Administer premixed solution over 3 to 5 minutes into tubing of free-flowing I.V. line containing dextrose 5% in water or normal saline solution.
● Direct I.V. push is not recommended because of extravasation risk.
● If patient develops facial flushing or red streak in the vein being infused, slow infusion rate.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: lethargy
CV: cardiomyopathy, heart failure
EENT: conjunctivitis, keratitis
GI: nausea, vomiting, diarrhea, mucositis
GU: reddish urine, amenorrhea

**Hematologic:** anemia, leukopenia, neutropenia, thrombocytopenia

Skin: alopecia; rash; pruritus; darkening of soles, palms, or nails

Other: increased appetite, infection, fever, hot flashes, tissue necrosis

**Interactions**

**Drug-drug.** *Calcium channel blockers:* increased risk of heart failure
*Cimetidine:* increased epirubicin blood level

**Drug-diagnostic tests.** *Hemoglobin, neutrophils, platelets, white blood cells:* decreased values

**Patient monitoring**

* Monitor vital signs, left ventricular ejection fraction, and cardiovascular status carefully. Watch for signs and symptoms of cardiomyopathy and heart failure.
* Assess nutritional status and hydration in light of GI adverse effects.
* Monitor CBC with white cell differential and watch for signs and symptoms of blood dyscrasias.
* Check temperature. Stay alert for fever and other signs or symptoms of infection.

**Patient teaching**

* Inform patient that drug may cause tissue damage at injection site. Tell him to report pain, burning, or swelling.
* Instruct patient to immediately report sudden weight gain, swelling, or shortness of breath.
* Tell patient to promptly report unusual bruising or bleeding, fever, or signs and symptoms of infection.
* Explain that drug will cause hair loss but that hair should grow back within a few months after therapy.
* Advise female patient that drug may cause premature menopause or permanent cessation of menses.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

*Live-virus vaccines:* increased risk of infection

*Trastuzumab:* increased risk of cardiac dysfunction

Reactions in **bold** are life-threatening.
eplerenone

Inspra

Pharmacologic class: Aldosterone receptor blocker

Therapeutic class: Antihypertensive

Pregnancy risk category B

Action

Binds to and blocks aldosterone receptors, disrupting normal sodium and water reabsorption and causing sodium and water excretion to increase. These actions reduce blood volume and blood pressure.

Availability

Tablets: 25 mg, 50 mg

Indications and dosages

➢ Hypertension

Adults: 50 mg/day P.O. as a single dose. After 4-week trial, may increase to 50 mg P.O. b.i.d. if necessary.

➢ Heart failure; post-myocardial infarction (MI)

Adults: Initially, 25 mg P.O. once daily. After 4 weeks, may increase to maximum dosage of 50 mg P.O. once daily.

Contraindications

• Hypersensitivity to drug
• Hyperkalemia
• Potassium supplements or potassium-sparing diuretics
• Type 2 diabetes mellitus with microalbuminuria
• Severe renal impairment

Precautions

Use cautiously in:
• hepatic impairment
• pregnant or breastfeeding patients
• children (safety and efficacy not established).

Administration

• Give with or without food.
• Know that drug may be given alone or with other antihypertensives.

Route | Onset | Peak | Duration
--- | --- | --- | ---
P.O. | Slow | 1.5 hr | Unknown

Adverse reactions

CNS: headache, dizziness, fatigue
CV: angina, MI
GI: diarrhea, abdominal pain
GU: albuminuria, vaginal bleeding, changes in sexual function, gynecomastia and breast pain (in men)

Metabolic: hypercholesterolemia, hyperkalemia

Respiratory: cough

Other: flulike symptoms

Interactions

Drug-drug. Angiotensin-converting enzyme inhibitors, potassium-sparing diuretics, potassium supplements: increased risk of hyperkalemia
CYP450-3A4 inhibitors: serious toxic effects
Lithium: increased risk of toxicity
Nonsteroidal anti-inflammatory drugs: decreased hypertensive effect of eplerenone

Patient monitoring

• Monitor electrolyte levels, and watch for signs and symptoms of hyperkalemia.
• Check vital signs, and ask patient about chest pain.
• Monitor lipid panel.
• Assess for new onset of persistent dry cough or flulike symptoms.

Patient teaching

➢ Advise patient to immediately report chest pain, flulike symptoms, or persistent dry cough.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

Canada UK Hazardous drug High alert drug
Inform patient that drug may affect sexual function. Encourage him to discuss this issue with prescriber.

Advise female patient to discuss pregnancy or breastfeeding with prescriber before starting drug.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

---

**epoetin alfa**

Epogen, Eprex®, Procrit

**Pharmacologic class:** Recombinant human erythropoietin

**Therapeutic class:** Biological response modifier

**Pregnancy risk category C**

---

**FDA BOXED WARNING**

- Use lowest dosage that will gradually increase hemoglobin to lowest level sufficient to avoid need for red blood cell (RBC) transfusion.
- Drug may increase risk of death and serious cardiovascular events when given to target hemoglobin above 12 g/dL.
- Drug may shorten time to tumor progression in patients with advanced head and neck cancer receiving radiation therapy when given to target hemoglobin above 12 g/dL. It may shorten overall survival and increase deaths from disease progression at 4 months in patients with metastatic breast cancer receiving chemotherapy when given to target hemoglobin above 12 g/dL and may increase risk of death when given to target hemoglobin of 12 g/dL in patients with active cancer receiving neither chemotherapy nor radiation therapy. Drug isn’t indicated for these patients.
- When drug is given preoperatively to reduce allogeneic RBC transfusions, higher incidence of deep vein thrombosis occurred in patients not receiving prophylactic anticoagulation.

---

**Action**

Binds to erythropoietin, stimulating mitotic activity of erythroid progenitor cells in bone marrow and causing release of reticulocytes from bone marrow into bloodstream, where they become mature RBCs.

---

**Availability**

*Injection:* 2,000 units/ml, 3,000 units/ml, 4,000 units/ml, 10,000 units/ml; 10,000 units/ml and 20,000 units/ml in multidose vials

---

**Indications and dosages**

> Anemia associated with chronic renal failure

**Adults:** Initially, 50 to 100 units/kg I.V. or subcutaneously three times weekly. May be increased after 8 weeks if hematocrit is still below target range.

> Anemia caused by zidovudine therapy in patients with human immunodeficiency virus infection

**Adults:** 100 units/kg I.V. or subcutaneously three times weekly for 8 weeks or until hematocrit level is adequate. If desired response isn’t reached after 8 weeks, dosage may be increased by 50 to 100 units/kg I.V. or subcutaneously three times weekly; after 4 to 8 weeks, dosage may be further increased, as prescribed, to a maximum dosage of 300 units/kg I.V. or subcutaneously three times weekly.

> Anemia associated with cancer chemotherapy

**Adults:** 150 units/kg subcutaneously three times weekly for 8 weeks or until hematocrit level is adequate. If desired response isn’t reached after 8 weeks, dosage may be increased to a maximum...
of 300 units/kg subcutaneously three times weekly.

➢ To reduce need for blood transfusion in surgical patients

**Adults:** 300 units/kg subcutaneously daily for 10 days before surgery, on day of surgery, and for 4 days after surgery; or 600 units/kg subcutaneously weekly starting 3 weeks before surgery, followed by additional dose on day of surgery

➢ Anemia in children with chronic renal failure who are on dialysis

**Children ages 1 month to 16 years:** 50 units/kg I.V. or subcutaneously three times weekly. Maintenance dosage is individualized to maintain hematocrit within target range.

### Contraindications
- Hypersensitivity to drug, human albumin, or products derived from mammal cells
- Uncontrolled hypertension

### Precautions
Use cautiously in:
- renal insufficiency
- pregnant or breastfeeding patients
- children.

### Administration
- For I.V. use, give single dose by direct I.V. injection over at least 1 minute, and follow with saline flush.
- If patient is on hemodialysis, administer drug into venous return line of dialysis tubing after patient completes dialysis session.
- Know that supplemental iron may be needed to support erythropoiesis and avoid iron depletion.

Avoid using multidose vials in premature infants because of benzyl alcohol content.

### Route Onset Peak Duration

<table>
<thead>
<tr>
<th></th>
<th>I.V.</th>
<th>Immediate</th>
<th>Immediate</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Subcut.</td>
<td>Unknown</td>
<td>5-24 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

### Adverse reactions

| CNS      | headache, paresthesia, fatigue, dizziness, asthenia, seizures |
| CV       | hypertension, increased clotting of arteriovenous grafts |
| GI       | nausea, vomiting, diarrhea |
| Metabolic| hyperuricemia, hyperphosphatemia, hyperkalemia |
| Musculoskeletal | joint pain |
| Respiratory | cough, dyspnea |
| Skin     | rash, urticaria |
| Other    | fever, edema, injection site pain |

### Interactions

**Drug-diagnostic tests.** Blood urea nitrogen, creatinine, phosphate, potassium, uric acid: increased levels

### Patient monitoring
- Monitor vital signs and cardiovascular status, especially for hypertension and edema.
- Assess arteriovenous graft for patency, because drug may increase clotting at graft.
- Monitor electrolyte and uric acid levels. Watch closely for hyperuricemia, hyperkalemia, and hyperphosphatemia.
- Check temperature for fever.
- Monitor neurologic status for signs and symptoms of impending seizure.
- Evaluate nutritional status and hydration in light of GI adverse effects.

### Patient teaching

- Instruct patient to monitor weight and blood pressure regularly and to immediately report hypertension, sudden weight gain, or swelling.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, motor skills, and alertness.
- Tell patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
- Advise female patient to discuss pregnancy or breastfeeding with prescriber before starting drug.
As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

eprosartan mesylate
Teveten

**Pharmacologic class:** Angiotensin II receptor antagonist  
**Therapeutic class:** Antihypertensive  
**Pregnancy risk category C** (first trimester), **D** (second and third trimesters)

### FDA BOXED WARNING

- When used during second or third trimester of pregnancy, drug may cause fetal injury or even death. Discontinue as soon as pregnancy is detected.

### Action

Blocks aldosterone-stimulating and vasoconstrictive effects of angiotensin II at receptor sites in vascular smooth muscles and adrenal glands, decreasing vascular resistance

### Availability

*Tablets:* 400 mg, 600 mg

### Indications and dosages

#### Hypertension

**Adults:** 600 mg P.O. once daily or in divided doses b.i.d.

### Contraindications

- Hypersensitivity to drug
- Pregnancy or breastfeeding

### Precautions

Use cautiously in:

- hypotension, heart failure, renal or hepatic impairment, obstructive biliary disorders, volume or sodium depletion  
- concurrent high-dose diuretic therapy  
- females of childbearing age  
- children younger than age 18 (safety not established)

### Administration

- Give initial dose in supervised medical setting, and monitor blood pressure for 2 hours after administration.  
- Know that drug may be given alone or with other antihypertensives.  
- Be aware that black patients have a higher risk of angioedema.  
- Be prepared to treat transient hypotension by placing patient in supine position and giving I.V. normal saline infusion as needed.

### Route Onset Peak Duration

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>6 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

### Adverse reactions

**CNS:** dizziness, fatigue, headache, syncope

**CV:** hypotension, chest pain, peripheral edema

**EENT:** sinus disorders

**GI:** nausea, diarrhea, constipation, abdominal pain, dry mouth

**GU:** albuminuria, renal failure

**Hepatic:** hepatitis

**Metabolic:** gout, hyperkalemia

**Musculoskeletal:** joint pain, back pain, muscle weakness

**Respiratory:** upper respiratory tract infection, cough, bronchitis

**Skin:** angioedema

**Other:** dental pain, fever, facial edema

### Interactions

**Drug-drug.** *Antihypertensives, diuretics:* increased risk of hypotension  
*Nonsteroidal anti-inflammatory drugs:* decreased antihypertensive effect of eprosartan

Reactions in **bold** are life-threatening.
Potassium-sparing diuretics, potassium supplements: increased risk of hyperkalemia

Drug-diagnostic tests. Absolute neutrophil count, hemoglobin, platelets, white blood cells: decreased
Albumin, creatinine, liver function tests, serum BUN: elevated levels

Drug-food. Salt substitutes containing potassium: increased risk of hyperkalemia

Drug-herbs. Ephedra (ma huang): antagonism of eprosartan action

Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring
- Monitor vital signs, particularly for hypotension after administration.
- Assess cardiovascular status, especially for chest pain, syncope, and edema.
- Monitor liver and kidney function test results, watching for drug-induced hepatitis or renal failure.
- Assess respiratory status. Stay alert for dry, persistent cough and signs and symptoms of respiratory infections.
- Monitor electrolyte levels, and watch for signs and symptoms of hyperkalemia.

Patient teaching
- Instruct patient to take drug at same time each day, with or without food.
- Inform patient that drug may cause angioedema. Instruct him to immediately report facial or lip swelling, fever, or sore throat.
- Advise patient to immediately report chest pain, fainting, decreased urine output, unusual tiredness, yellowing of skin or eyes, or swelling.
- Tell female patient to contact prescriber right away if she suspects she’s pregnant.
- Caution female not to breastfeed while taking drug.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

---

### eptifibatide

**Integrilin**

**Pharmacologic class:** Platelet aggregation inhibitor

**Therapeutic class:** Antiplatelet agent

**Pregnancy risk category B**

**Action**

Decreases platelet aggregation by binding to platelet-receptor glycoprotein, preventing binding of fibrinogen to platelets, which causes thrombus formation

**Availability**

**Injection:** 10-ml vial (2 mg/ml), 100-ml vial (0.75 mg/ml)

**Indications and dosages**

- **Acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction)**
  - **Adults:** 180 mcg/kg I.V. bolus over 1 to 2 minutes, followed by a continuous infusion of 2 mcg/kg/minute for up to 72 hours
- **Prevention of thrombosis related to percutaneous coronary intervention (PCI)**
  - **Adults:** 180 mcg/kg I.V. bolus immediately before PCI, then a continuous infusion of 2 mcg/kg/minute, followed by a second 180-mcg/kg bolus 10 minutes after first bolus. Continue infusion until discharge or for up to 24 hours.

**Dosage adjustment**

- Renal impairment

**Contraindications**

- Hypersensitivity to drug or its components
Severe hypertension
- Bleeding disorders or evidence of active abnormal bleeding within previous 30 days
- Renal dialysis
- Recent cerebrovascular accident
- Recent surgery
- Current or planned administration of another parenteral Gp IIb/IIIa inhibitor

Precautions
Use cautiously in:
- Renal insufficiency
- Creatinine level below 2 mg/dl
- Platelet count below 100,000/mm³
- Elderly patients
- Pregnant or breastfeeding patients
- Children (safety and efficacy not established).

Administration
- Withdraw single bolus dose from 10-ml vial into syringe, and give by I.V. push over 1 to 2 minutes. Follow single I.V. bolus dose with continuous I.V. infusion given undiluted from 100-ml vial spiked with infusion set connected to infusion control device.
- Don’t administer through same I.V. line as furosemide.

Route | Onset | Peak | Duration
--- | --- | --- | ---
I.V. | Immediate | Immediate | 4-6 hr

Adverse reactions
CNS: headache, dizziness, asthenia, syncope
CV: hypotension
GI: nausea, diarrhea, constipation
GU: hematuria
Hematologic: bleeding tendency, thrombocytopenia
Skin: flushing
Other: bleeding at femoral access site

Interactions
Drug-drug. Clopidogrel, dipyridamole, nonsteroidal anti-inflammatory drugs, oral anticoagulants, thrombolytics, ticlopidine: increased risk of bleeding
Other platelet aggregation inhibitors: serious bleeding

Drug-diagnostic tests. Platelets: decreased count

Drug-herbs. Most commonly used herbs: increased anticoagulant effect of eptifibatide

Patient monitoring
- Monitor vital signs and assess cardiovascular status, especially for syncope and hypotension.
- Monitor coagulation studies, CBC, and platelet count. Watch for signs and symptoms of abnormal bleeding or bruising and hematuria.
- Check carefully for bleeding at all sites of invasive procedures, particularly femoral access site.

Patient teaching
- Tell patient drug may cause serious adverse effects but can help prevent a heart attack. Reassure him that he’ll be closely monitored during therapy. Instruct patient to immediately report fainting or abnormal bruising or bleeding.
- Teach patient safety measures to avoid bruising or bleeding.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

erlotinib
Tarceva

Pharmacologic class: Epidermal growth factor receptor (EGFR) inhibitor
Therapeutic class: Antineoplastic
Pregnancy risk category D

Reactions in **bold** are life-threatening.
**Action**
Unclear. Drug inhibits intracellular phosphorylation of tyrosine kinase associated with EGFR, which is expressed on cell surface of both normal cells and cancer cells.

**Availability**
*Tablets:* 25 mg, 100 mg, 150 mg

**Indications and dosages**

- Locally advanced or metastatic non-small-cell lung cancer after failure of at least one chemotherapy regimen
  **Adults:** 150 mg P.O. at least 1 hour before or 2 hours after food ingestion, continued until disease progresses or unacceptable toxicity occurs

- First-line treatment of locally advanced, unresectable, or metastatic pancreatic cancer (given with gemcitabine)
  **Adults:** 100 mg P.O. daily at least 1 hour before or 2 hours after food ingestion, continued until disease progresses or unacceptable toxicity occurs

**Dosage adjustment**
- Severe diarrhea
- Pretreatment with CYP3A4 inducers
- Concurrent use of potent CYP3A4 inhibitors (such as ketoconazole)
- Acute onset of new or progressing pulmonary symptoms

**Off-label uses**
- Colorectal and renal cell cancer
- Malignant glioma

**Contraindications**
None

**Precautions**
Use cautiously in:
- hepatic impairment, diarrhea, pulmonary symptoms, suspected interstitial lung disease (such as pneumonitis, interstitial pneumonia, obliterative bronchiolitis, pulmonary fibrosis, adult respiratory distress syndrome, or lung filtration)
- concurrent warfarin therapy
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

**Administration**
- Give at least 1 hour before or 2 hours after food ingestion.
- Know that concurrent administration with platinum-based chemotherapy has no clinical benefit and isn’t recommended in patients with locally advanced or metastatic non-small-cell lung cancer.
- Reduce dosage in 50-mg decrements in patients with severe diarrhea who don’t respond to loperamide or become dehydrated, those with severe skin reactions, and those receiving strong CYP3A4 inhibitors.
- Interrupt therapy if patient develops acute onset of new or progressing pulmonary symptoms pending diagnostic evaluation. If interstitial lung disease develops, discontinue drug and administer appropriate interventions.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>4 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- **CNS:** fatigue
- **EENT:** conjunctivitis, keratoconjunctivitis sicca
- **GI:** nausea, vomiting, diarrhea, abdominal pain, anorexia, stomatitis
- **Respiratory:** dyspnea, cough, **interstitial lung disease**
- **Skin:** rash, pruritus, dry skin
- **Other:** infection

**Interactions**
- **Drug-drug.** CYP3A4 inhibitors (such as clarithromycin, indinavir, itraconazole, ketoconazole, ritonavir, saquinavir, telithromycin): increased erlotinib blood level
CYP3A4 inducers (such as carbamazepine, phenobarbital, phenytoin, rifampin): decreased erlotinib blood level
Warfarin, other coumarin anticoagulants: elevated INR, increased bleeding risk

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, bilirubin: increased
Liver function tests: abnormal

Drug-food. Any food: increased erlotinib bioavailability

Drug-herb. Coenzyme Q10: decreased chemotherapy efficacy
St. John’s wort: decreased erlotinib blood level

Drug-behaviors. Smoking: decreased erlotinib plasma concentration

Patient monitoring
- Perform periodic liver function testing.
- Advise patient not to smoke while taking drug.
- Monitor INR and prothrombin time regularly in patients receiving warfarin, other coumarin anticoagulants, or nonsteroidal anti-inflammatory drugs.
- Monitor for signs and symptoms of respiratory disorders.

Patient teaching
- Advise patient to seek immediate medical attention for severe or persistent diarrhea, nausea, vomiting, anorexia, eye irritation, or onset or worsening of unexplained shortness of breath or cough.
- Advise patient not to smoke while taking drug.
- Caution female with childbearing potential to avoid pregnancy during therapy.
- Advise breastfeeding patient to stop breastfeeding during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

Reactions in bold are life-threatening.
## Precautions
Use cautiously in:
- seizure disorder
- pregnant or breastfeeding patients
- children (not recommended in infants younger than age 3 months).

## Administration
- Reconstitute for I.V. use by adding to vial 10 ml of sterile or bacteriostatic water or normal saline for injection. Don’t use diluents containing dextrose.
- Further dilute reconstituted drug in 50 ml of normal saline solution; infuse over 30 minutes. Don’t mix or infuse with other drugs.
- Reconstitute for I.M. use by adding 3.2 ml of 1% lidocaine to vial and shaking well.
- Inject I.M. dose deep into large muscle mass, such as gluteus maximus or lateral thigh.

### Route Onset Peak Duration
| I.V. | Rapid | 30 min | Unknown |
| I.M. | 10 min | 2.3 hr | Unknown |

## Adverse reactions
- CNS: headache, dizziness, asthenia, fatigue, insomnia, altered mental status, anxiety, **seizures**
- CV: hypotension, hypertension, chest pain, phlebitis, **thrombophlebitis**, arrhythmias, heart failure
- EENT: pharyngitis
- GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, gastroesophageal reflux disease, **pseudomembranous colitis**
- GU: vaginitis
- Hepatic: hepatotoxicity
- Respiratory: crackles, cough, dyspnea, wheezing, **respiratory distress**
- Skin: rash, **erythema multiforme**, Stevens-Johnson syndrome, toxic epidermal necrolysis

## Other: fever, pain, induration, and inflammation at I.V. site; edema; hypersensitivity reactions including **anaphylaxis**

## Interactions
**Drug-drug.** **Probencid:** increased blood level and half-life of ertapenem

## Patient monitoring
- Monitor vital signs, ECG, and cardiovascular status closely. Stay alert for arrhythmias, edema, respiratory distress, and other signs and symptoms of heart failure.
- Assess neurologic status, and watch for signs of impending seizure.
- Monitor bowel pattern, and stay alert for signs and symptoms of pseudomembranous colitis.
- Inspect injection site for evidence of thrombophlebitis and induration.
- Watch for indications of erythema multiforme (sore throat, rash, cough, iris lesions, mouth sores, fever). Report early signs before condition progresses to Stevens-Johnson syndrome, and stay alert for other hypersensitivity reactions (including anaphylaxis).

## Patient teaching
- Tell patient to notify nurse right away if drug causes pain or swelling at injection site.
- Inform patient that drug can be toxic to many organ systems. Tell him to promptly report significant adverse reactions.
- Tell female patient to inform prescriber of pregnancy or breastfeeding before taking drug.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.
**erythromycin**
Apo-Erythro®, Apo-Erythro-EC, Diomycin®, Erybid®, Erymax®, Ery-Tab, Erythromid®, PCE®, Rommix®, Tiloryth®

**erythromycin ethylsuccinate**
Apo-Erythro-ES®, E.E.S., EryPed

**erythromycin lactobionate**
Erythrocin

**erythromycin stearate**
Erythrocin Stearate

**erythromycin (topical)**
Akne-Mycin, A/T/S, E-Glades, E-Solve 2, Erycette, Eryderm, Erygel, Sans-Acne®, Stiemycin®

**Pharmacologic class:** Macrolide

**Therapeutic class:** Anti-infective

**Pregnancy risk category B**

**Action**
Binds with 50S subunit of susceptible bacterial ribosomes, suppressing protein synthesis in bacterial cells and causing cell death

**Availability**

**erythromycin base**
Capsules (delayed-release): 250 mg
Ointment (ophthalmic): 0.5%
Tablets: 250 mg, 500 mg
Tablets (delayed-release, enteric-coated): 250 mg, 333 mg, 500 mg
Tablets (particles in tablets): 333 mg, 500 mg

**erythromycin ethylsuccinate**
Oral suspension: 200 mg/5 ml, 400 mg/5 ml
Powder for suspension: 100 mg/2.5 ml, 200 mg/5 ml, 400 mg/5 ml

**erythromycin lactobionate**
Powder for injection: 500 mg, 1 g

**erythromycin stearate**
Tablets (film-coated): 250 mg, 500 mg

**erythromycin (topical)**
Gel: 2%
Ointment: 2%
Solution: 2%
Swabs: 2%

**Indications and dosages**

➤ Pelvic inflammatory disease

**Adults:** 500 mg (base) I.V. q 6 hours for 3 days, then 250 mg (base, estolate, or stearate) or 400 mg (ethylsuccinate) q 6 hours for 7 days

➤ Syphilis

**Adults:** 500 mg (base, estolate, or stearate) P.O. q.i.d. for 14 days

➤ Most upper and lower respiratory tract infections; otitis media; skin infections; Legionnaires’ disease

**Adults:** 250 mg P.O. q 6 hours, or 333 mg P.O. q 8 hours, or 500 mg P.O. q 12 hours (base, estolate, or stearate); or 400 mg P.O. q 6 hours or 800 mg P.O. q 12 hours (ethylsuccinate); or 250 to 500 mg I.V. (up to 1 g) q 6 hours (gluceptate or lactobionate)

**Children:** 30 to 50 mg/kg/day (base, estolate, ethylsuccinate, or lactobionate) I.V. or P.O., in divided doses q 6 hours when giving I.V. and q 6 to 8 hours when giving P.O. Maximum dosage is 2 g/day for base or estolate, 3.2 g/day for ethylsuccinate, and 4 g/day for lactobionate.

➤ Intestinal amebiasis

**Adults:** 250 mg (base, estolate, or stearate) or 400 mg (ethylsuccinate) P.O. q 6 hours for 10 to 14 days

**Children:** 30 to 50 mg/kg/day (base, estolate, ethylsuccinate, or stearate) P.O. in divided doses over 10 to 14 days

➤ Prophylaxis of ophthalmia neonatorum caused by *Neisseria gonorrhoeae* or *Chlamydia trachomatis*

**Neonates:** 0.5- to 1-cm ribbon of ointment into each lower conjunctival sac once

---

Reactions in **bold** are life-threatening.
Treatment of Conjunctivitis of the newborn caused by susceptible organisms

**Neonates**: 50 mg/kg/day (ethylsuccinate) P.O. in four divided doses for at least 14 days

**Pertussis**

**Children**: 40 to 50 mg/kg/day (estolate preferred) P.O. in four divided doses for 14 days

**Pneumonia of infancy**

**Infants**: 50 mg/kg/day (estolate or ethylsuccinate) P.O. in four divided doses for at least 3 weeks

**Acne**

**Adults and children older than age 12**: 2% ointment, gel, or solution applied topically b.i.d.

**Dosage adjustment**

- Hepatic impairment

**Off-label uses**

- Chancroid

**Contraindications**

- Hypersensitivity to drug or tartrazine
- Concurrent use of astemizole, cisapride, pimozide, or terfenadine
- Hepatic impairment (with estolate)
- Pregnancy (with estolate)

**Precautions**

Use cautiously in:

- myasthenia gravis
- hepatic disease.

**Administration**

- Be aware that ventricular arrhythmias and sudden death may occur if drug is given concurrently with potent CYP3A inhibitors (such as clarithromycin, diltiazem, nitroimidazole antifungal agents, protease inhibitors, verapamil, and troleandomycin).
- Give erythromycin ethylsuccinate and delayed-release products without regard to meals, but avoid giving with grapefruit juice.
- Give erythromycin base or stearate 1 hour before or 2 hours after meals for optimal absorption.
- Follow label directions to reconstitute drug for I.V. use. For intermittent infusion, infuse each 250 mg in at least 100 ml of normal saline solution over 20 to 60 minutes. Continuous infusion may be given over 6 to 24 hours as directed.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1 hr</td>
<td>1-4 hr</td>
<td>6-12 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>End of infusion</td>
<td>6-12 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- CV: torsades de pointes, arrhythmias
- EENT: ototoxicity
- GI: nausea, vomiting, diarrhea, abdominal pain or cramps
- Hepatic: hepatic dysfunction, hepatitis
- Skin: rash
- Other: increased appetite, aggravation of weakness in myasthenia gravis, allergic reactions, superinfection, phlebitis at I.V. site

**Interactions**

**Drug-drug.** Alfentanil, alprazolam, bromocriptine, buspirone, carbamazepine, clozapine, cyclosporine, diazepam, disopyramide, ergot alkaloids, felodipine, methylprednisolone, midazolam, tacrolimus, theophylline, triazolam, vinblastine, warfarin: increased blood levels and risk of toxicity from these drugs

Clindamycin, lincomycin: antagonism of erythromycin’s effects

CYP3A inhibitors: increased erythromycin blood level, with risk of ventricular arrhythmias and sudden death

Digoxin: increased digoxin blood level

HMG-CoA reductase inhibitors: increased risk of myopathy and rhabdomyolysis

Hormonal contraceptives: decreased contraceptive efficacy
Astemizole, cisapride, pimozide, sparfloxacin, terfenadine: increased risk of serious arrhythmias
Rifabutin, rifampin: decreased erythromycin effects, increased risk of adverse GI reactions
Theophylline: increased theophylline blood level, decreased erythromycin blood level

**Drug-diagnostic tests.** Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin: increased levels
**Urine catecholamines:** false elevations

**Drug-food.** Grapefruit juice: increased erythromycin blood level

**Patient monitoring**
- Check temperature, and watch for signs and symptoms of superinfection.
- Monitor liver function tests. Watch for signs and symptoms of hepatotoxicity.
- Assess patient’s hearing for signs of ototoxicity.

**Patient teaching**
- Instruct patient to take with 8 oz of water 1 hour before or 2 hours after meals, and to avoid grapefruit juice.
- If drug causes GI upset, encourage patient to take it with food.
- Tell patient not to swallow chewable tablets whole and not to chew or crush enteric-coated tablets.
- Advise patient to immediately report irregular heart beats, unusual tiredness, yellowing of skin or eyes, or signs and symptoms of new infection.
- Tell patient he’ll undergo periodic blood tests to monitor liver function.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

---

**escitalopram oxalate**

**Cipralex®, Lexapro**

**Pharmacologic class:** Selective serotonin reuptake inhibitor
**Therapeutic class:** Antidepressant

**Pregnancy risk category C**

---

**FDA BOXED WARNING**

- Drug may increase risk of suicidal thinking and behavior in children and adolescents with major depressive disorder and other psychiatric disorders. Risk is greater during first few months of treatment, and must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family to observe patient closely and communicate with prescriber as needed.
- Drug isn’t approved for use in pediatric patients.

**Action**

Prevents serotonin reuptake by CNS neurons, making more serotonin available in brain and thereby relieving depression

**Availability**

- **Oral solution:** 5 mg/5 ml
- **Tablets:** 5 mg, 10 mg, 20 mg

**Indications and dosages**

- **Major depression**
- **Adults:** Initially, 10 mg P.O. daily as a single dose. After at least 1 week, may increase to 20 mg P.O. daily, as needed.
- **Elderly adults and patients with hepatic impairment:** Maximum dosage of 10 mg P.O. daily as a single dose
Generalized anxiety disorder

**Adults:** 10 mg/day P.O. as a single dose in the morning or evening, increased to 20 mg/day P.O. as needed

**Contraindications**
- Hypersensitivity to drug
- Concurrent use of pimozide
- MAO inhibitor use within past 14 days

**Precautions**
Use cautiously in:
- renal or hepatic impairment, suicidal tendency
- elderly patients
- pregnant or breastfeeding patients.

**Administration**
- Give with or without food.
- Don’t give within 14 days of MAO inhibitor.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Slow</td>
<td>3.5-6.5 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- **CNS:** drowsiness, dizziness, insomnia, fatigue, **increased risk of suicide or suicidal ideation** (especially in child or adolescent)
- **EENT:** rhinitis, sinusitis
- **GI:** nausea, vomiting, diarrhea, constipation, dyspepsia, abdominal pain, dry mouth
- **GU:** ejaculatory disorders, erectile dysfunction, anorgasmia (in females), decreased libido
- **Other:** increased appetite, flulike symptoms, **serotonin syndrome**

**Interactions**
- **Drug-drug.** *Carbamazepine, lithium:* decreased effects of escitalopram
  *Citalopram:* increased risk of serious toxic effects
  *MAO inhibitors:* increased escitalopram blood level and risk of toxicity
  *Pimozide:* prolonged QT interval
- **Triptans:** weakness, hyperreflexia, incoordination
- **Drug-herbs.** *Ginkgo, St. John’s wort:* increased risk of adverse effects
- **Drug-behaviors.** *Alcohol use:* increased motor impairment

**Patient monitoring**
- Assess patient’s mood closely. Watch for signs and symptoms of increased depression or suicidal ideation (especially in child or adolescent).
- Monitor patient’s prescription refills to help detect drug hoarding or overuse.
- Check nutritional and hydration status in light of GI adverse effects.
- When drug is discontinued, monitor for dysphoric mood, irritability, agitation, dizziness, sensory disturbances, anxiety, confusion, headache, lethargy, emotional lability, and insomnia.

**Patient teaching**
- Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
- Inform patient that full drug effect may take up to 4 weeks. Caution him not to overuse drug.
- Tell patient (and parent or significant other as appropriate) to contact prescriber immediately if depression worsens or suicidal thoughts develop (especially in child or adolescent).
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, herbs, and behaviors mentioned above.
esmolol hydrochloride
Brevibloc

**Pharmacologic class:** Beta-adrenergic blocker (cardioselective)

**Therapeutic class:** Antiarrhythmic, antihypertensive

**Pregnancy risk category C**

**Action**
Blocks stimulation of beta-adrenergic receptors (primarily beta<sub>1</sub> receptors), thereby reducing atrioventricular conduction and cardiac output and decreasing blood pressure

**Availability**
*Injection:* 10 mg/ml

**Indications and dosages**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supraventricular tachycardia</td>
<td>Adults: Initially, a loading dose of 500 mcg/kg/minute by I.V. infusion over 1 minute, followed by a maintenance infusion of 50 mcg/kg/minute over 4 minutes. If desired response doesn’t occur after 5 minutes, repeat loading dose and increase maintenance infusion to 100 mcg/kg/minute for 4 minutes. Repeat sequence as needed, with maintenance dosage increased in increments of 50 mcg/kg/minute, to a maximum maintenance infusion of 200 mcg/kg/minute for 48 hours.</td>
</tr>
<tr>
<td>Sinus tachycardia or hypertension</td>
<td>Adults: Initially, 80 mg (1 mg/kg) by I.V. bolus over 30 seconds; then, if needed, 150 mcg/kg/minute by I.V. infusion, to a maximum of 300 mcg/kg/minute</td>
</tr>
</tbody>
</table>

**Off-label uses**
- Acute myocardial ischemia

**Contraindications**
- Hypersensitivity to drug
- Heart failure
- Heart block greater than third degree
- Sinus bradycardia
- Cardiogenic shock

**Precautions**
Use cautiously in:
- renal impairment, diabetes, bronchospasm, cardiac disease, cerebrovascular insufficiency, peripheral vascular disease, hyperthyroidism, myasthenic conditions
- pregnant or breastfeeding patients.

**Administration**
- Be aware that compatible solutions include 5% dextrose for injection, 5% dextrose in lactated Ringer’s injection, 5% dextrose in Ringer’s injection, and lactated Ringer’s injection.
- Don’t mix with 5% sodium bicarbonate injection.
- Large fluid volumes may be needed to infuse drug. Use caution when excessive fluids could be harmful.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>30 min</td>
<td>30 min after infusion</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- **CNS:** anxiety, depression, dizziness, drowsiness, headache, agitation, fatigue, confusion, speech disorders, asthenia
- **CV:** peripheral ischemia, chest pain, bradycardia, hypotension
- **GI:** nausea, vomiting, heartburn
- **GU:** urinary retention
- **Respiratory:** wheezing, dyspnea
- **Skin:** flushing, pallor, erythema
- **Other:** altered taste, fever, chills, edema, midscapular pain, inflammation or induration at infusion site

**Interactions**

- **Drug-drug.** *Alpha<sub>1</sub>-adrenergic blockers:* exaggerated antihypertensive effect
  *Catecholamines, reserpine:* increased bradycardia and hypotension
  *Digoxin:* increased digoxin blood level

Reactions in **bold** are life-threatening.
Morphine: increased esmolol blood level  
Succinylcholine: prolonged neuromuscular blockade  
Drug-herbs. Ephedra (ma huang), St. John’s wort, yohimbe: decreased antihypertensive effect

**Patient monitoring**  
- Monitor vital signs and ECG, particularly for hypotension.  
- Assess neurologic status, and institute safety measures as needed.  
- Monitor fluid intake and output, watching for urinary retention.  
- Check I.V. site regularly.

**Patient teaching**  
- Explain to patient that drug is an emergency measure to control blood pressure, arrhythmias, or heart rate.  
- Ensure patient he’ll be closely monitored throughout drug therapy.  
- Tell patient to report pain or redness at I.V. site.  
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and herbs mentioned above.

---

**esomeprazole magnesium**  
Nexium

**Pharmacologic class:** Proton pump inhibitor  
**Therapeutic class:** Antiulcer agent  
**Pregnancy risk category C**

**Action**  
Reduces gastric acid production by inhibiting enzyme activity in gastric parietal cells, preventing transport of hydrogen ions into gastric lumen

**Availability**  
*Capsules (delayed-release):* 20 mg, 40 mg

---

**Indications and dosages**  
- Treatment of gastroesophageal reflux disease (GERD); healing of erosive esophagitis  
  **Adults:** 20 to 40 mg P.O. once daily for 4 to 8 weeks  
  **Children ages 1 to 11 weighing 20 kg (44 lb) or more:** 10 or 20 mg P.O. daily for 8 weeks  
  **Children ages 1 to 11 weighing less than 20 kg (44 lb):** 10 mg P.O. daily for 8 weeks  
- Treatment of GERD; maintenance of healing of erosive esophagitis  
  **Adults:** 20 mg P.O. once daily  
  **Symptomatic GERD**  
  **Adults:** 20 mg P.O. once daily for 4 weeks.  
  **Children ages 12 to 17:** 20 or 40 mg P.O. daily for up to 8 weeks  
  **Children ages 1 to 11:** 10 mg P.O. daily for up to 8 weeks  
- *Helicobacter pylori* eradication to decrease risk of duodenal ulcer recurrence  
  **Adults:** 40 mg P.O. once daily for 10 days, given in combination with amoxicillin 1,000 mg b.i.d. for 10 days and with clarithromycin 500 mg b.i.d. for 10 days  
- Treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome  
  **Adults:** 40 mg P.O. b.i.d.  
- Risk reduction of NSAID-associated gastric ulcer  
  **Adults:** 20 or 40 mg P.O. once daily for up to 6 months

**Contraindications**  
- Hypersensitivity to drug or its components

**Precautions**  
- Use cautiously in:  
  - severe hepatic impairment
- pregnant or breastfeeding patients
- children younger than age 18 (safety not established).

**Administration**
- Give 1 hour before or 2 hours after a meal.
- Know that contents of capsules may be mixed with applesauce.
- Don’t crush capsules or pellets.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>1.6 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- **CNS:** headache, dizziness, asthenia, vertigo, apathy, anxiety, paresthesia, insomnia, abnormal dreams
- **EENT:** sinusitis, epistaxis
- **GI:** nausea, vomiting, diarrhea, constipation, abdominal pain, flatulence, dry mouth
- **Respiratory:** upper respiratory tract infection, cough
- **Skin:** rash, inflammation, urticaria, pruritus, alopecia, dry skin

**Interactions**
- **Drug-drug.** Digoxin, iron salts, ketoconazole: altered absorption and effects of these drugs
- **Drug-diagnostic tests.** Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, creatinine, uric acid: increased levels
- Hemoglobin, platelets, potassium, sodium, thyroxine, white blood cells: altered levels

**Patient monitoring**
- Monitor neurologic status, especially for dizziness, headache, paresthesia, and asthenia.
- Watch for signs and symptoms of EENT and respiratory infections.
- Assess nutritional and hydration status in light of adverse GI effects.
- Check for rash and other signs of hypersensitivity.
- Monitor liver function test results if patient is on long-term therapy.

**Patient teaching**
- Instruct patient to take drug 1 hour before or 2 hours after a meal.
- If patient has trouble swallowing capsule, tell him to open it, sprinkle pellets into soft food (such as applesauce), and take right away.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Advise female patient to tell prescriber if she's pregnant or breastfeeding.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**Reactions in bold are life-threatening.**

---

**estradiol**
- Bedol®, Elestrin, Elleste®, Elleste-Solo®, Estrace, Estring, Estrogel, Gynodiol, Innofem, Oestrogel®, Progynova®, Sandrena®, Vagifem, Zumenon®

**estradiol acetate**
- Femring, Femtrace

**estradiol cypionate**
- Depo-Estradiol

**estradiol hemihydrate**
- Estrasorb

**estradiol transdermal system**
- Alora, Climara, Estraderm, Estradot®, Evorel®, Fematrix®, Femseven®, Menostar, Vivelle

---

Clinical alert
estradiol valerate
Climaval®, Delestrogen, Femogex

Pharmacologic class: Estrogen
Therapeutic class: Hormone
Pregnancy risk category X

FDA BOXED WARNING

- Drug increases endometrial cancer risk in postmenopausal women.
- Drug may increase risk of cardiovascular disease, breast cancer, and dementia.
- Drug shouldn’t be used during pregnancy.
- Warnings may vary somewhat among specific brands. See package insert for complete warning information.

Action
Binds to nuclear receptors in responsive tissues (such as female genital organs, breasts, and pituitary gland), enhancing DNA, RNA, and protein synthesis. In androgen-dependent prostate cancer, competes for androgen receptor sites, inhibiting androgen activity. Also decreases pituitary release of follicle-stimulating hormone and luteinizing hormone.

Availability
Injection (cypionate in oil): 5 mg/ml
Injection (valerate in oil): 10 mg/ml, 20 mg/ml, 40 mg/ml
Tablets: 0.5 mg, 1 mg, 1.5 mg, 2 mg
Tablets (film-coated): 25.8 mcg estradiol hemidrate (equivalent to 25 mcg estradiol)
Transdermal system: 25 mcg/24-hour release rate, 37.5 mcg/24-hour release rate, 50 mcg/24-hour release rate, 75 mcg/24-hour release rate, 100 mcg/24-hour release rate
Vaginal cream: 100 mcg/g
Vaginal ring: 2 mg released over 90 days
Vaginal tablets: 25 mcg

Indications and dosages

> Symptoms of menopause, atrophic vaginitis, female hypogonadism, ovarian failure, and osteoporosis
Adults: 0.5 to 2 mg (estradiol) P.O. daily continuously or cyclically. Or 1 to 5 mg (cypionate) or 10 to 20 mg (valerate) I.M. monthly. Or 50- or 100-mcg/24-hour transdermal patch applied twice weekly (Alora, Estraderm) or weekly (Climara). Or 25-mcg/24-hour patch applied q 7 days (FemPatch) or 37.5- to 100-mcg transdermal patch applied twice weekly (Vivelle). Or 2 to 4 g (0.2 to 0.4 mg) vaginal cream (estradiol) applied daily for 1 to 2 weeks, then decreased to 1 to 2 g/day for 1 to 2 weeks, then a maintenance dose of 1 g one to three times weekly for 3 weeks, then off for 1 week; repeat cycle once vaginal mucosa has been restored. Or 2-mg vaginal ring q 3 months or 25-mcg vaginal tablet once daily for 2 weeks, then twice weekly.

> Postmenopausal breast cancer
Adults: 10 mg P.O. t.i.d. (estradiol)

> Prostate cancer
Adults: 1 to 2 mg P.O. t.i.d. (estradiol) or 30 mg I.M. q 1 to 2 weeks (valerate)

Contraindications
- Hypersensitivity to drug or its components
- Thromboembolic disease (current or previous)
- Undiagnosed vaginal bleeding
- Breast or reproductive system cancer (except in metastatic disease)
- Estrogen-dependent neoplasms
- Pregnancy

Precautions
Use cautiously in:
- cardiovascular, hepatic, or renal disease
- breastfeeding patients.
Administration

- Inject I.M. dose deep into large muscle mass; rotate injection sites.
- If switching from oral to transdermal estrogen, apply patch 1 week after withdrawal of oral therapy.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Slow</td>
<td>Days</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.M.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>3-4 days</td>
</tr>
<tr>
<td>Transdermal</td>
<td>Unknown</td>
<td>Unknown</td>
<td>7 days</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(Estraderm)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>90 days</td>
</tr>
<tr>
<td>Vaginal ring</td>
<td>Unknown</td>
<td>Unknown</td>
<td>(Climara)</td>
</tr>
<tr>
<td>Vaginal tablet</td>
<td>Unknown</td>
<td>Unknown</td>
<td>3-4 days</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: headache, dizziness, lethargy, depression
CV: hypertension, myocardial infarction (MI), thromboembolism
EENT: contact lens intolerance, worsening of myopia or astigmatism
GI: nausea, vomiting, bowel obstruction with vaginal ring (rare)
GU: amenorrhea, dysmenorrhea, breakthrough bleeding, cervical erosions, decreased libido, vaginal candidiasis, erectile dysfunction, testicular atrophy, gynecomastia, breast pain or tenderness
Hepatic: jaundice
Metabolic: sodium and fluid retention, hypercalcemia, hyperglycemia
Musculoskeletal: leg cramps
Skin: oily skin, acne, pigmentation changes, urticaria
Other: weight loss or gain, edema, increased appetite, toxic shock syndrome with vaginal ring (rare)

Interactions

Drug-drug. Insulin, oral hypoglycemics, warfarin: altered requirements for these drugs

Drug-diagnostic tests. Antithrombin III, folate, low-density lipoproteins, pyridoxine, total cholesterol, urine pregnanediol: decreased levels
Cortisol; factors VII, VIII, IX, and X; glucose; high-density lipoproteins; phospholipids; prolactin; prothrombin; sodium; triglycerides: increased levels
Metyrapone test: false decrease
Thyroid function tests: false interpretation

Drug-behaviors. Smoking: increased risk of adverse CV reactions

Patient monitoring

- Monitor vital signs and cardiovascular status, especially for hypertension, thromboembolism, and MI.
- Be aware that a few cases of ring adherence to the vaginal wall have occurred, which may require evaluation of wall ulceration and erosion.
- Assess vision.
- In diabetic patient, monitor blood glucose level and watch for signs and symptoms of hyperglycemia.

Patient teaching

- Instruct patient to place transdermal patch on clean, dry skin area.
- Teach proper technique for use of vaginal tablet, ring, or cream, as appropriate.
- Tell patient drug may cause loss of libido (in women) or erectile dysfunction (in men). Encourage patient to discuss these issues with prescriber.
- Teach patient to recognize and immediately report signs and symptoms of thromboembolism.
- Caution patient not to take drug if she is or plans to become pregnant.
- Advise patient that drug may worsen nearsightedness or astigmatism and make contact lenses uncomfortable.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

Reactions in bold are life-threatening.
estrogens, conjugated
C.E.S.*, Congest*, Premarin, Premarin Intravenous

**Pharmacologic class:** Estrogen  
**Therapeutic class:** Replacement hormone, antineoplastic, antiosteoroporotic  
**Pregnancy risk category X**

---

**FDA BOXED WARNING**
- Drug increases endometrial cancer risk in postmenopausal women.  
- Drug may increase risk of cardiovascular disease, breast cancer, and dementia.  
- Drug shouldn’t be used during pregnancy.  
- Warnings may vary somewhat among specific brands. See package insert for complete warning information.

---

**Action**
Bind to nuclear receptors in responsive tissues (such as female genital organs, breasts, and pituitary gland), enhancing DNA, RNA, and protein synthesis. In androgen-dependent prostate cancer, compete for androgen receptor sites, inhibiting androgen activity. Also decrease pituitary release of follicle-stimulating and luteinizing hormones.

**Availability**
- **Powder for injection:** 25 mg/5 ml  
- **Tablets:** 0.3 mg, 0.625 mg, 0.9 mg, 1.25 mg  
- **Vaginal cream:** 0.625 mg/g

---

**Indications and dosages**
- Ovariectomy; primary ovarian failure  
  **Adults:** 1.25 mg P.O. daily continuously or in cycles of 3 weeks on and 1 week off

---

▸ Osteoporosis and menopausal symptoms  
- **Adults:** 0.3 to 1.25 mg P.O. daily continuously or in cycles of 3 weeks on and 1 week off

▸ Female hypogonadism  
- **Adults:** 0.3 to 0.625 mg P.O. daily, given in cycles of 3 weeks on and 1 week off

▸ Inoperable breast cancer in men and postmenopausal women  
- **Adults:** 10 mg P.O. t.i.d. for 3 months or more

▸ Inoperable prostate carcinoma  
- **Adults:** 1.25 to 2.5 mg P.O. t.i.d.

▸ Uterine bleeding caused by hormonal imbalance  
- **Adults:** 25 mg I.M. or I.V., repeated in 6 to 12 hours if necessary

▸ Atrophic vaginitis  
- **Adults:** 0.5 to 2 g (vaginal cream) intravaginally daily in cycles of 3 weeks on and 1 week off

---

**Contraindications**
- Hypersensitivity to drug or its components  
- Thromboembolic disease (current or previous)  
- Undiagnosed vaginal bleeding  
- Breast or reproductive system cancer (except metastatic disease)  
- Estrogen-dependent neoplasms  
- Pregnancy

---

**Precautions**
Use cautiously in:  
- cardiovascular disease, severe hepatic or renal disease, asthma, bone disease, migraine, seizures, breast disease  
- family history of breast or genital tract cancer  
- breastfeeding patients.

---

**Administration**
- Know that drug is compatible with dextrose 5% in water and normal saline solution.
Adverse reactions
CNS: headache, dizziness, lethargy, depression, asthenia, paresthesia, syncope, cerebrovascular accident (CVA), seizures
CV: hypertension, chest pain, myocardial infarction (MI), thromboembolism
EENT: contact lens intolerance, worsening of myopia or astigmatism, otitis media, sinusitis, rhinitis, pharyngitis
GI: nausea, vomiting, diarrhea, abdominal cramps, bloating, enlarged abdomen, dyspepsia, flatulence, gastritis, gastroenteritis, hemorrhoids, colitis, gallbladder disease, anorexia, pancreatitis
GU: urinary incontinence, dysuria, urinary tract infection, amenorrhea, dysmenorrhea, endometrial hyperplasia, vaginal candidiasis, leukorrhea, vaginal hemorrhage, genital eruptions, gynecomastia, breast tenderness, breast enlargement or secretion, reduced libido, erectile dysfunction, testicular atrophy, increased risk of breast cancer, endometrial cancer, hemolytic uremic syndrome
Hepatic: cholestatic jaundice, hepatic adenoma
Metabolic: hyperglycemia, hypercalcemia, sodium and fluid retention, reduced carbohydrate tolerance
Musculoskeletal: leg cramps, back pain, skeletal pain
Respiratory: upper respiratory tract infection, bronchitis, pulmonary embolism
Skin: acne, oily skin, pigmentation changes, urticaria, pruritus, erythema nodosum, hemorrhagic eruption, skin hypertrophy, hirsutism, alopecia, erythema multiforme

Other: edema, weight changes, increased appetite, hypersensitivity reaction

Interactions
Drug-drug. Corticosteroids: enhanced corticosteroid effects
CYP450 inducers (such as barbiturates, rifampin): decreased estrogen efficacy
Hypoglycemics, warfarin: altered requirement for these drugs
Phenytoin: loss of seizure control
Tamoxifen: interference with tamoxifen effects
Tricyclic antidepressants: reduced antidepressant effects

Drug-diagnostic tests. Antithrombin III, folate, low-density lipoproteins, pyridoxine, total cholesterol, urine pregnanediol: decreased values
Cortisol; factors VII, VIII, IX, and X; glucose; high-density lipoproteins; phospholipids; prolactin; prothrombin; sodium; triglycerides: increased values
Metyrapone test: false decrease
Thyroid function tests: false interpretation

Drug-food. Caffeine: increased caffeine blood level

Drug-herbs. Black cohosh: increased risk of adverse reactions
Red clover: interference with estrogen effects
Saw palmetto: antiestrogenic effects
St. John’s wort: decreased drug blood level and effects

Drug-behaviors. Smoking: increased risk of adverse cardiovascular reactions

Patient monitoring
- Monitor liver function test results and assess abdomen for enlarged liver.
- Evaluate patient for breast tenderness and swelling. As needed, give analgesics and apply cool compresses.
- Monitor fluid intake and output, and weigh patient daily.
Know that drug increases risk of thromboembolism, CVA, and MI.
- Check serum phosphatase level in patients with prostate cancer.
- Monitor calcium, glucose, and folic acid levels.
- Evaluate bone density annually.

Patient teaching
- Teach patient to recognize and report signs and symptoms of thromboembolism.
- Caution patient not to take drug if she is or plans to become pregnant.
- Tell patient to report breakthrough vaginal bleeding.
- Recommend that patient have routine breast examinations.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

Action
Bind to nuclear receptors in responsive tissues (such as female genital organs, breasts, and pituitary gland), enhancing DNA, RNA, and protein synthesis. In androgen-dependent prostate cancer, compete for androgen receptor sites, inhibiting androgen activity. Also decrease pituitary release of follicle-stimulating hormone and luteinizing hormone.

Availability
*Tablets:* 0.3 mg, 0.625 mg, 1.25 mg, 2.5 mg

Indications and dosages
- Moderate to severe vasomotor symptoms or atrophic vaginitis
  - Adults: 0.3 to 1.25 mg P.O. daily, adjusted to lowest effective dosage; usually given in cycles of 3 weeks on, 1 week off
  - Female hypogonadism
  - Adults: 2.5 to 7.5 mg P.O. daily in divided doses for 20 days, followed by 10-day rest period. If no bleeding occurs, repeat same dosing schedule. If bleeding occurs before end of rest period, start 20-day estrogen-progestin cycle, with progestin P.O. given during last 5 days of estrogen therapy.
- Inoperable prostate cancer
  - Adults: 1.25 to 2.5 mg P.O. t.i.d.
- Selected breast cancers (inoperable, progressing)
  - Adults: 10 mg P.O. t.i.d. for at least 3 months
- Prevention of osteoporosis
  - Adults: Initially, 0.3 mg P.O. daily, increased as needed to a maximum of 1.25 mg/day

Contraindications
- Hypersensitivity to drug or its components
- Thromboembolic disease (current or previous)
- Undiagnosed vaginal bleeding
- Breast and reproductive cancers (except metastatic disease)
- Estrogen-dependent neoplasms
- Pregnancy
Precautions
Use cautiously in:
● cardiovascular disease, severe hepatic or renal disease, asthma, bone disease, migraines, seizures, breast nodules, fibrocystic breasts
● family history of breast or genital tract cancer
● breastfeeding patients.

Administration
● Administer with food or fluids.
● Give cyclically as prescribed, except when used palliatively for cancer treatment.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Slow</td>
<td>Days</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, dizziness, lethargy, depression, asthenia, paresthesia, syncope, increased risk of cerebrovascular accident (CVA), seizures CV: hypertension, chest pain, myocardial infarction (MI), thromboembolism EENT: contact lens intolerance, worsening of myopia or astigmatism, otitis media, sinusitis, rhinitis, pharyngitis GI: nausea, vomiting, diarrhea, dyspepsia, flatulence, gastritis, gastroenteritis, enlarged abdomen, hemorrhoids, colitis, gallbladder disease, anorexia, pancreatitis GU: urinary incontinence, dysuria, amenorrhea, dysmenorrhea, endometrial hyperplasia, urinary tract infection, leukorrhea, vaginal discomfort or pain, vaginal hemorrhage, genital eruptions, gynecomastia, breast tenderness, breast enlargement or secretion, reduced libido, erectile dysfunction, testicular atrophy, increased risk of breast cancer, endometrial cancer, hemolytic uremic syndrome Hepatic: cholestatic jaundice, hepatic adenoma Metabolic: hyperglycemia, hypercalcemia, sodium and fluid retention, reduced carbohydrate tolerance

Musculoskeletal: leg cramps, back pain, skeletal pain
Respiratory: upper respiratory tract infection, bronchitis, pulmonary embolism
Skin: acne, increased pigmentation, urticaria, pruritus, erythema nodosum, hemorrhagic eruption, alopecia, hirsutism
Other: increased appetite, weight changes, edema, flulike symptoms, hypersensitivity reactions

Interactions
Drug-drug. Corticosteroids: enhanced corticosteroid effects CYP450 inducers (such as barbiturates, rifampin): decreased estrogen efficacy Hypoglycemics, warfarin: altered requirement for these drugs Phenytoin: loss of seizure control Tamoxifen: interference with tamoxifen efficacy Tricyclic antidepressants: reduced antidepressant effect

Drug-diagnostic tests. Antithrombin III, folate, low-density lipoproteins, pyridoxine, total cholesterol, urine pregnanediol: decreased values Cortisol; factors VII, VIII, IX, and X; glucose; high-density lipoproteins; phospholipids; prolactin; prothrombin; sodium; triglycerides: increased values Metyrapone test: false decrease Thyroid function tests: false interpretation

Drug-food. Caffeine: increased caffeine blood level

Drug-herbs. Black cohosh: increased risk of adverse reactions Red clover: interference with estrogen therapy Saw palmetto: antiestrogenic effects St. John’s wort: decreased drug blood level and effects

Drug-behaviors. Smoking: increased risk of adverse cardiovascular reactions

Patient monitoring
● Monitor fluid intake and output, and weigh patient daily.

Reactions in bold are life-threatening.

Clinical alert

estrogens, esterified 435
Evaluate patient for breast tenderness and swelling. As needed, administer analgesics and apply cool compresses.

Know that drug increases risk of thromboembolism, CVA, and MI.

Monitor liver function test results, and assess abdomen for enlarged liver.

Check serum phosphatase level in patients with prostate cancer, and adjust dosage as appropriate.

Monitor calcium, glucose, and folic acid levels.

Patient teaching

Teach patient to recognize and immediately report signs and symptoms of thromboembolism.

Caution patient not to take drug if she is or plans to become pregnant.

Teach patient how to perform breast self-examination. Emphasize importance of monthly checks.

Tell patient to report breakthrough vaginal bleeding.

Mention that drug may cause contact lens intolerance. Advise patient to report vision changes.

Inform male patient that drug may cause gynecomastia.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

eszopiclone

Lunesta

Pharmacologic class: Nonbenzodiazepine

Therapeutic class: Hypnotic

Controlled substance schedule IV

Pregnancy risk category C

Action

Unclear. Effect may result from interaction with GABA-receptor complexes at binding domains near or allosterically coupled with benzodiazepine receptors.

Availability

Tablets: 1 mg, 2 mg, 3 mg

Indications and dosages

Insomnia

Nonelderly adults: 2 mg P.O. immediately before bedtime. Drug may be initiated at, or dosage may be increased to, 3 mg if indicated clinically. In patients also receiving potent CYP3A4 inhibitors, starting dosage shouldn’t exceed 1 mg.

Elderly adults: 1 mg P.O. immediately before bedtime. Dosage may be increased to 2 mg if indicated clinically. If patient’s chief complaint is difficulty staying asleep, recommended dosage is 2 mg P.O. immediately before bedtime.

Dosage adjustment

- Hepatic impairment
- Concomitant use of other CNS depressants

Contraindications

None

Precautions

Use cautiously in:

- hepatic impairment, respiratory compromise, depression
- pregnant or breastfeeding patients
- children younger than age 18 (safety and efficacy not established).

Administration

Don’t give with or immediately after a heavy, high-fat meal because this may slow drug absorption and reduce efficacy.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1 hr</td>
<td>6 hr</td>
</tr>
</tbody>
</table>

Canada | UK | Hazardous drug | High alert drug
**Adverse reactions**

**CNS:** headache, anxiety, confusion, depression, dizziness, hallucinations, nervousness, abnormal dreams

**CV:** chest pain, peripheral edema

**GI:** nausea, vomiting, diarrhea, dyspepsia, cholelithiasis, dry mouth

**GU:** urinary tract infection, decreased libido, dysmenorrhea, gynecomastia (in males)

**Respiratory:** respiratory infection

**Skin:** rash, pruritus

**Other:** unpleasant taste, viral infection, neuralgia, facial edema, allergic reaction

**Interactions**

**Drug-drug.** *CYP3A4 inhibitors (such as itraconazole, ketoconazole, ritonavir, troleandomycin):* increased eszopiclone blood level

**CYP3A4 inducers (such as rifampin):** decreased eszopiclone blood level

**Drug-food.** *Heavy, high-fat meal:* slowed drug absorption and reduced efficacy

**Drug-behaviors.** *Alcohol use:* additive effects on psychomotor performance

**Patient monitoring**

- Before starting therapy, evaluate patient to help eliminate physical or psychiatric causes of insomnia.
- Know that after rapid dosage decrease or abrupt drug withdrawal, patient may experience signs and symptoms similar to those associated with withdrawal from other CNS depressants.

**Patient teaching**

- Instruct patient not to take drug with or immediately after a heavy, high-fat meal.
- Advise patient to take drug immediately before bedtime; otherwise, short-term memory impairment, hallucinations, incoordination, dizziness, and light-headedness may occur.
- Caution patient not to engage in hazardous activities after taking drug.
- Tell patient drug may have some effect the next day; advise him to use extreme care when driving or performing other hazardous activities until drug effects are known.
- Caution patient not to take drug with other psychotropics, anticonvulsants, antihistamines, or other drugs that cause CNS depression.
- Advise patient not to take drug with alcohol.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, foods, and behaviors mentioned above.

---

**etanercept**

*Enbrel*

**Pharmacologic class:** Immunomodulator

**Therapeutic class:** Antiarthritic

**Pregnancy risk category B**

---

**FDA BOXED WARNING**

- Infections, including bacterial sepsis and tuberculosis leading to hospitalization or death, have occurred in patients taking etanercept.
- Patients should be educated about signs and symptoms of infection and closely monitored for infection during and after drug therapy. Patients who develop an infection should be evaluated for appropriate antimicrobial treatment; drug should be discontinued in patients who develop a serious infection.
- Tuberculosis has occurred in patients receiving tumor necrosis factor (TNF) blockers, including etanercept. Tuberculosis may be due to reactivation of latent tuberculosis infection or new infection.

Reactions in **bold** are life-threatening.
• Risk of reactivation of latent tuberculosis infection has shown to be lower with etanercept than with TNF-blocking monoclonal antibodies.
• Patients should be evaluated for tuberculosis risk factors and tested for latent tuberculosis infection before drug initiation and during therapy. Treatment should be initiated before start of drug therapy, as appropriate.
• Some patients who tested negative for latent tuberculosis before receiving drug have developed active tuberculosis.

Action
Reacts with and deactivates free-floating tumor necrosis factor, responsible for inflammation

Availability
Powder for injection: 25 mg in multiple-use vial
Prefilled syringe (single-use): 50 mg/ml

Indications and dosages
Moderately to severely active rheumatoid arthritis; ankylosing spondylitis; psoriatic arthritis
Adults: 50 mg subcutaneously q week given as a single injection. Dosages above 50 mg/week are not recommended.

Chronic moderate to severe plaque psoriasis
Adults ages 18 and older: 50 mg subcutaneously twice weekly (given 3 or 4 days apart) for 3 months, followed by reduction to a maintenance dosage of 50 mg weekly

Polyarticular-course juvenile rheumatoid arthritis
Children ages 4 to 17: 0.8 mg/kg subcutaneously q week, to a maximum of 50 mg weekly

Contraindications
• Hypersensitivity to drug or its components
• Sepsis

Precautions
Use cautiously in:
• immunosuppression, chronic infection, heart failure
• latex allergy (needle cover of diluent syringe contains latex)
• elderly patients
• pregnant or breastfeeding patients
• children younger than age 4.

Administration
• Inject subcutaneously into thigh, abdomen, or upper arm.
• For adult, use single-use, 50 mg/ml prefilled syringe.
• For child weighing 63 kg (138 lb) or more, use single-use, 50 mg/ml prefilled syringe for weekly dose; for child weighing 31 to 62 kg (68 to 137 lb), administer total weekly dose from multiple-use vial as two injections on same day or 3 or 4 days apart; for child weighing less than 31 kg (68 lb), give as a single weekly injection using multiple-use vial.
• Rotate injection sites.

Route Onset Peak Duration
Subcut. Slow 72 hr Unknown

Adverse reactions
CNS: asthenia, headache, depression, dizziness, paresthesia, fatigue, demyelinating disorders (such as multiple sclerosis and myelitis), cerebral hemorrhage, seizures, cerebrovascular accident (CVA)
CV: hypotension, hypertension, chest pain, deep-vein thrombosis, thrombophlebitis, myocardial ischemia, myocardial infarction (MI), heart failure
EENT: ocular inflammation, pharyngitis, rhinitis, sinusitis
GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia, anorexia, cholecystitis, abdominal abscess, GI hemorrhage, intestinal perforation, pancreatitis
GU: pyelonephritis, membranous glomerulonephropathy
Hematologic: anemia, aplastic anemia, leukopenia, pancytopenia, thrombocytopenia
Metabolic: hypomagnesemia
Musculoskeletal: bursitis, polymyositis, joint pain
Respiratory: cough, congestion, dyspnea, bronchitis, pneumonia, pulmonary embolism, interstitial lung disease
Skin: flushing, cellulitis, pruritus, rash, cutaneous vasculitis, urticaria, alopecia, angioedema
Other: altered taste, weight gain, adenopathy, fever, irritation at injection site, peripheral edema, flulike symptoms, autoantibody formation, lupus-like syndrome, serious infections

Interactions
None significant

Patient monitoring
☞ Watch for signs and symptoms of pancytopenia and infection.
☞ Monitor for evidence of GI bleeding, lupus-like syndrome, and serious hypersensitivity reactions. Stop therapy immediately if these occur.
• Monitor CBC and coagulation studies.
☞ Check for signs and symptoms of cardiac compromise and cerebrovascular events.
• Monitor pulmonary function test results periodically to assess lung status.
• Assess patient’s ability to self-administer drug.
• Check for irritation at injection site. As needed, apply cool compresses.
• Examine eyes for conjunctival dryness. As needed, apply artificial tears.

Patient teaching
☞ Tell patient to withhold dose and contact prescriber if he develops signs or symptoms of infection or is exposed to anyone with chickenpox.
☞ Tell patient to immediately report hypersensitivity reaction, neurologic or respiratory problems, sudden weight gain, chest pain, or easy bruising or bleeding.
• Teach patient or caregiver how to administer drug and handle and dispose of equipment.
• Caution patient not to get live-virus vaccines.
• Tell female to inform prescriber if she is pregnant or breastfeeding.
• As appropriate, review all other significant and life-threatening adverse reactions mentioned above.

ethambutol hydrochloride
Etibi®, Myambutol

Pharmacologic class: Synthetic antitubercular
Therapeutic class: Antitubercular, antileprotic
Pregnancy risk category B

Action
Unknown. Thought to interfere with RNA synthesis of bacterial metabolites, decreasing mycobacterial replication.

Availability
Tablets: 100 mg, 400 mg

Indications and dosages
Adjuvant in tuberculosis and atypical mycobacterial infection caused by Mycobacterium tuberculosis
Adults and adolescents: In patients who haven’t received previous

Reactions in bold are life-threatening.
antitubercular therapy, 15 mg/kg P.O. daily. In patients who have received previous antitubercular therapy, 25 mg/kg P.O. daily, decreased after 60 days to 15 mg/kg daily.

**Dosage adjustment**
- Renal impairment

**Contraindications**
- Hypersensitivity to drug

**Precautions**
Use cautiously in:
- impaired renal or hepatic function, cataracts, optic neuritis, recurrent eye inflammation, diabetic retinopathy, gout
- pregnant patients
- children younger than age 13.

**Administration**
- Obtain specimens for culture and sensitivity testing, as necessary, before starting therapy and periodically throughout therapy.
- Give with food.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>2-4 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
CNS: confusion, disorientation, malaise, dizziness, hallucinations, headache, peripheral neuritis
EENT: optic neuritis, blurred vision, decreased visual acuity, red-green color blindness, eye pain
GI: nausea, vomiting, abdominal pain, GI upset, anorexia
Hematologic: eosinophilia, thrombocytopenia
Hepatic: transient hepatic impairment
Metabolic: hyperuricemia, hypoglycemia
Musculoskeletal: joint pain, gouty arthritis
Respiratory: bloody sputum, pulmonary infiltrates

**Skin:** rash, pruritus, toxic epidermal necrolysis
**Other:** fever, anaphylactoid reactions

**Interactions**
**Drug-drug.** Aluminum salts: delayed and reduced ethambutol absorption
Other neurotoxic drugs: increased risk of neurotoxicity
**Drug-diagnostic tests.** Alanine aminotransferase, aspartate aminotransferase, bilirubin, uric acid: increased levels
Glucose: decreased level

**Patient monitoring**
- Watch for serious adverse reactions, such as thrombocytopenia, respiratory problems, and anaphylactoid reactions.
- Monitor liver function tests, CBC, and blood urea nitrogen, creatinine glucose, and serum uric acid levels.
- Give analgesics for drug-induced pain, as prescribed.
- Observe for signs and symptoms of gout.

**Patient teaching**
- Instruct patient to take with 8 oz of water. If stomach upset occurs, advise him to take with food.
- If patient must take antacids, advise him to take only aluminum-free antacids.
- Tell patient to immediately report easy bruising or bleeding, respiratory problems, or signs and symptoms of hypersensitivity reactions.
- Advise patient to report vision changes and to have annual eye exams. Reassure him that visual disturbances will subside within several weeks to months after drug is discontinued.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.
**etidronate disodium**  
Didronel, Didronel PMO®

**Pharmacologic class:** Bisphosphonate  
**Therapeutic class:** Bone resorption inhibitor, hypocalcemic agent  
**Pregnancy risk category B** (oral use), **C** (I.V. use)

**Action**  
Blocks calcium absorption, slowing bone metabolism and reducing bone resorption and formation

**Availability**  
*Injection:* 300 mg/ampule in 6-ml ampules  
*Tablets:* 200 mg, 400 mg

**Indications and dosages**

- **Paget’s disease**  
  **Adults:** 5 to 10 mg/kg P.O. daily as a single dose for up to 6 months, or 11 to 20 mg/kg P.O. daily for up to 3 months

- **Heterotopic ossification after hip replacement**  
  **Adults:** 20 mg/kg P.O. daily for 1 month before and 3 months after surgery

- **Heterotopic ossification in spinal cord injury**  
  **Adults:** Initially, 20 mg/kg P.O. daily for 2 weeks, decreased to 10 mg/kg P.O. daily for 10 weeks

- **Hypercalcemia related to cancer**  
  **Adults:** 7.5 mg/kg/day I.V. infused over at least 2 hours for 3 consecutive days; may continue infusion for up to 7 days if necessary. P.O. dosing may begin after last infusion.

**Contraindications**  
- Hypersensitivity to drug or its components  
- Severe renal impairment  
- Osteomalacia (tablets)

**Precautions**  
Use cautiously in:  
- moderate renal impairment, long bone fractures, heart failure, hypocalcemia, hypovitaminosis D  
- pregnant or breastfeeding patients  
- children (safety not established)

**Administration**  
- For I.V. use, dilute with 250 ml of normal saline solution. Infuse slowly over at least 2 hours.  
- Give oral dose with water or juice 2 hours before meals.  
- Make sure patient doesn’t eat for 2 hours after receiving dose.  
- Know that therapy longer than 3 months is not recommended.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O. (Paget’s)</td>
<td>1 mo</td>
<td>Unknown</td>
<td>1 yr</td>
</tr>
<tr>
<td>P.O. (ossif.)</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Several mo</td>
</tr>
<tr>
<td>I.V. (hypercalc.)</td>
<td>24 hr</td>
<td>3 days</td>
<td>11 days</td>
</tr>
</tbody>
</table>

**Adverse reactions**

*All reactions occur only with I.V. use unless otherwise noted.*

- **CNS:** seizures  
- **GI:** nausea, constipation, stomatitis  
- **Hematologic:** anemia  
- **Metabolic:** hypomagnesemia, hypophosphatemia, fluid overload  
- **Musculoskeletal:** bone pain and tenderness, fractures (all with oral use)  
- **Respiratory:** dyspnea  
- **Skin:** rash (with oral use)  
- **Other:** taste loss, metallic taste, fever

**Interactions**

- **Drug-drug.** Antacids; buffers containing aluminum, calcium, iron, or magnesium; mineral supplements: decreased etidronate absorption  
- Calcitonin: additive hypocalcemic effect  
- Warfarin: increased prothrombin time

**Drug-diagnostic tests.** Blood urea nitrogen (BUN), creatinine: increased levels

Reactions in **bold** are life-threatening.
Calcium, magnesium: decreased levels
Liver function tests: elevated values

Drug-food. Foods high in aluminum, calcium, iron, or magnesium: decreased etidronate absorption

Patient monitoring
- Monitor fluid intake and output.
- Watch for seizures.
- Monitor patient for GI discomfort. Divide doses as needed to ease symptoms.
- Assess bowel pattern. If constipation occurs, increase fluids and administer stool softeners, as prescribed.
- Monitor calcium, phosphorus, magnesium, creatinine, and BUN levels; liver function tests; and bone scans.

Patient teaching
- Instruct patient not to take drug with food because of decreased drug absorption.
- Tell patient not to consume high-calcium products, such as milk or antacids, within 2 hours of taking dose.
- Stress importance of eating a diet high in vitamin D and calcium.
- Advise patient to report bone pain or decreased range of motion.
- As appropriate, review all other significant adverse and life-threatening reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

etodolac
Apo-Etodolac®, Eccoxolac®, Gen-Etodolac®, Taro-Ultradol, Ultradol®

Pharmacologic class: Pyranocarboxylic acid, nonsteroidal anti-inflammatory drug (NSAID)

Therapeutic class: Nonopioid analgesic

Pregnancy risk category C (first and second trimesters), D (third trimester)

FDA BOXED WARNING
- Drug may increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk may increase with duration of use. Patients with cardiovascular disease or risk factors for it may be at greater risk.
- Drug is contraindicated for perioperative pain in setting of coronary artery bypass graft surgery.
- Drug increases risk of serious adverse GI events, including bleeding, ulcers, and perforation of stomach or intestines, which can be fatal. Elderly patients are at greater risk.

Action
Blocks activity of cyclooxygenase (which is needed for prostaglandin synthesis), easing pain and reducing inflammation

Availability
Capsules: 200 mg, 300 mg
Tablets: 400 mg, 500 mg
Tablets (extended-release): 400 mg, 500 mg, 600 mg

Indications and dosages

Adults: 300 mg P.O. two or three times daily; or 400 mg, 500 mg, or 600 mg P.O. b.i.d.; or 400 to 1,000 mg P.O. (extended-release tablets) once daily

Mild to moderate pain
Adults: 200 to 400 mg P.O. q 6 to 8 hours, not to exceed 1,200 mg/day

Contraindications
- Hypersensitivity to drug or its components
- Concurrent use of other NSAIDs
- Active GI bleeding or ulcer disease

Precautions
Use cautiously in:
- severe cardiovascular, renal, or hepatic disease
• elderly patients
• breastfeeding patients
• children (safety not established).

Administration
• Give with food or antacids to reduce GI upset.
• Make sure patient swallows extended-release tablets whole without crushing or chewing.
• Withhold drug several days before invasive surgery, as ordered.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30 min</td>
<td>1-2 hr</td>
<td>4-12 hr</td>
</tr>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>3-12 hr</td>
<td>6-12 hr</td>
</tr>
</tbody>
</table>

(extended)

Adverse reactions
CNS: dizziness, malaise, weakness, depression, nervousness
CV: hypertension
EENT: blurred vision, tinnitus
GI: nausea, vomiting, constipation, diarrhea, flatulence, dyspepsia, peptic ulcer, duodenitis, intestinal ulceration, gastritis, melena
GU: dysuria, urinary frequency, polyuria, renal failure
Hematologic: thrombocytopenia
Hepatic: cholestatic jaundice, cholestatic hepatitis, hepatic necrosis
Skin: rash, skin peeling, cutaneous vasculitis with purpura, hyperpigmentation
Other: fluid retention, chills, fever, allergic reaction

Interactions
Drug-drug. Aminoglycosides: elevated aminoglycoside blood level (in premature infants)
Anticoagulants: prolonged prothrombin time
Beta-adrenergic blockers: reduced antihypertensive effect
Bisphosphonates: increased risk of gastric ulcers
Cholestryramine: decreased etodolac absorption
Cyclosporine: increased risk of nephrotoxicity
Diuretics: decreased diuretic effect
Lithium: increased lithium blood level, greater risk of toxicity
Methotrexate: increased risk of methotrexate toxicity
Phenytoin: increased phenytoin blood level
Salicylates: decreased etodolac blood level

Drug-diagnostic tests. Bleeding time: prolonged
Blood urea nitrogen (BUN), creatinine, hepatic enzymes: increased levels
Urine bilirubin, urine ketones: false-positive results
Drug-herbs. Arnica, chamomile, clove, dong quai, feverfew, garlic, ginkgo, ginseng: increased risk of bleeding
White willow: increased etodolac effects
Drug-behaviors. Alcohol use: increased risk of adverse effects
Sun exposure: phototoxicity

Patient monitoring
• Monitor CBC, liver function tests, BUN, creatinine level, and coagulation studies.
• Assess for GI bleeding and gastric upset. Administer antacids as needed and prescribed.
• Know that drug may cause false-positive urine bilirubin and urine ketone test results.

Monitor patient for signs and symptoms of thrombocytopenia and increased bleeding time.
• Assess for fluid retention and weigh patient daily.
• Watch for decreased blood pressure control in hypertensive patients.

Patient teaching
• Instruct patient to take with meals if possible.

Reactions in bold are life-threatening.

Clinical alert
Tell patient to swallow extended-release tablets whole without crushing or chewing.

Instruct patient to immediately report unusual bleeding or bruising, change in urination pattern, unusual tiredness, or yellowing of skin or eyes.

Advise patient to avoid activities that can cause injury.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

**etongestrel and ethinyl estradiol vaginal ring**

**NuvaRing**

*Pharmacologic class:* Sex hormone  
*Therapeutic class:* Contraceptive  
*Pregnancy risk category X*

**FDA BOXED WARNING**

- This product does not protect against human immunodeficiency virus infection and other sexually transmitted diseases.

**Action**

Inhibits ovulation by altering cervical mucosa and endometrium of uterus. This inhibition prevents sperm from entering the uterus, thereby preventing implantation.

**Availability**

*Vaginal ring:* 0.12 mg etonogestrel and 0.015 mg ethinyl estradiol delivered daily over 3 weeks

**Indications and dosages**

- To prevent pregnancy

  **Adults:** Place one ring into vagina and leave in place for 3 weeks, then remove for 1 week. Insert next ring on same day of week as in previous cycle.

**Contraindications**

- Hypersensitivity to drug or its components
- Breast and uterine cancers or other known or suspected estrogen-dependent neoplasms
- Valvular heart disease with complications  
- Thromboembolic disease (current or previous)
- Severe hypertension
- Diabetes with vascular involvement
- Headache with focal neurologic symptoms
- Hepatic tumors, cholestatic jaundice
- Major surgery with prolonged immobilization
- Undiagnosed vaginal bleeding
- Patients older than age 35 who smoke more than 15 cigarettes daily
- Pregnancy or breastfeeding

**Precautions**

Use cautiously in:

- underlying cardiovascular disease, severe hepatic or renal disease, asthma, bone disease, migraines, breast disease, seizures, sexually transmitted diseases
- family history of breast or genital tract cancers.

**Administration**

- Be aware that the best way to insert ring is with patient lying down, squatting, or standing and one leg raised.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaginal</td>
<td>Rapid</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- **CNS:** headache, dizziness, lethargy, depression, increased risk of cerebrovascular accident, seizures
- **CV:** hypertension, myocardial infarction, thromboembolism
- **EENT:** worsening of myopia or astigmatism
GI: nausea, vomiting, abdominal cramps, bloating, **pancreatitis**
GU: amenorrhea, loss of libido, vaginal candidiasis, breast tenderness, breast enlargement or secretion, **increased risk of endometrial and breast cancer**
Hepatic: cholestatic jaundice, **hepatic adenoma**
Metabolic: sodium and fluid retention
Respiratory: pulmonary embolism
Other: increased appetite, weight changes, edema

**Interactions**

**Drug-drug.** Acetaminophen: decreased acetaminophen blood level
Anti-infectives, barbiturates, carbamazepine, fosphenytoin, rifampin: decreased contraceptive efficacy
Corticosteroids: increased corticosteroid effects
Cyclosporine: increased risk of cyclosporine toxicity
CYP3A4 inhibitors (such as itraconazole, ketoconazole): increased hormone levels
Dantrolene, other hepatotoxic drugs: increased risk of hepatotoxicity
Hypoglycemics, warfarin: altered requirements for these drugs
Miconazole (vaginal capsules): increased hormone levels
Phenytoin: loss of seizure control
Protease inhibitors: increased contraceptive metabolism
Tamoxifen: interference with tamoxifen efficacy
Tricyclic antidepressants: reduced antidepressant effects

**Drug-diagnostic tests.** Antithrombin III, folate, low-density lipoproteins, pyridoxine, total cholesterol: decreased levels
Cortisol; factors VII, VIII, IX, and X; glucose; high-density lipoproteins; phospholipids; prolactin; prothrombin; sodium; triglycerides: increased levels

**Drug-food.** Caffeine: increased caffeine blood level

**Drug-herbs.** Black cohosh: increased risk of adverse reactions
Red clover: interference with contraceptive action
Saw palmetto: antiestrogenic effects
St. John’s wort: decreased contraceptive blood level and effects

**Patient monitoring**

- Assess blood pressure frequently.
- Monitor patient for depression.
- Watch for jaundice and liver engorgement.
- Check for dry eyes. Administer artificial tears as needed.
- Monitor glucose, calcium, and electrolyte levels and lipid profile.

**Drug-behaviors.** Smoking: increased risk of adverse cardiovascular reactions

**Patient teaching**

- Explain that for continued contraception, a new implant must be inserted exactly 1 week after old one is removed, even if patient is menstruating.
- Tell patient to insert and remove ring on same day of week and at same time of day.
- Tell patient that if ring slips out, she should replace it within 3 hours to ensure adequate contraceptive protection.
- Inform patient that smoking during therapy may increase risk of blood clots, phlebitis, and stroke.
- Teach patient to immediately report signs and symptoms of depression, sudden chest pain, difficulty breathing, or yellowing of skin or eyes.
- Teach patient how to perform breast self-examinations. Emphasize importance of monthly checks.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.
etoposide (VP-16-213)
Eposin®, Toposar, VePesid

etoposide phosphate
Etopophos

**Pharmacologic class:** Podophyllotoxin derivative

**Therapeutic class:** Antineoplastic

**Pregnancy risk category D**

---

**FDA BOXED WARNING**

- Give under supervision of physician experienced in cancer chemotherapy. Severe myelosuppression may occur, resulting in infection or bleeding.

---

**Action**

Damages DNA before mitosis by inhibiting topoisomerase II enzyme. This action impairs DNA synthesis and inhibits selected cancer cell growth. Cell-cycle-phase specific.

**Availability**

- **Capsules:** 50 mg
- **Injection:** 20 mg/ml
- **Powder for injection (phosphate):** 100 mg in single-dose vials

**Indications and dosages**

- **Testicular cancer**
  - **Adults:** 50 to 100 mg/m² I.V. daily for 5 days. Or 100 mg/m² I.V. on days 1, 3, and 5, with course repeated q 3 to 4 weeks.
  - **Small-cell carcinoma of lung**
  - **Adults:** 70 mg/m² (rounded up or down to nearest 50 mg) P.O. daily for 4 days, then a maximum of 100 mg/m² (rounded up or down to nearest 50 mg) P.O. daily for 5 days every 3 to 4 weeks. Alternatively, 35 mg/m² I.V. daily for 4 days, then a maximum of 50 mg/m² I.V. daily for 5 days q 3 to 4 weeks.

---

**Dosage adjustment**

- Renal impairment

**Off-label uses**

- AIDS-related Kaposi’s sarcoma
- Wilms’ tumor
- Neuroblastoma
- Malignant lymphoma
- Hodgkin’s disease
- Ovarian neoplasms

**Contraindications**

- Hypersensitivity to drug or its components

**Precautions**

Use cautiously in:

- active infections, decreased bone marrow reserve, renal or hepatic impairment
- pregnant patients and patients with childbearing potential
- breastfeeding patients
- children (safety and efficacy not established)

**Administration**

- For I.V. concentrations above 0.4 mg/ml, mix each 100 mg with 250 to 500 ml of dextrose 5% in water or normal saline solution, to help prevent crystallization.
- Give I.V. infusion over 30 to 60 minutes. Don’t use in-line filter.

Avoid rapid infusion, which may cause severe hypotension and bronchospasm.

- Administer with antiemetics, as prescribed.
- Wear disposable gloves when handling. If drug comes into contact with skin, wash thoroughly with soap and water.
- Be aware that drug is given with other chemotherapeutic agents.

**Route** | **Onset** | **Peak** | **Duration**
--- | --- | --- | ---
P.O., I.V. | 7-14 days | 9-16 days | 20 days

**Adverse reactions**

CNS: drowsiness, fatigue, headache, vertigo, peripheral neuropathy

---

Canada  UK  Hazardous drug  High alert drug
CV: hypotension (with I.V. use), heart failure, myocardial infarction
GI: nausea, vomiting, stomatitis
GU: sterility
Hematologic: anemia, leukopenia, thrombocytopenia, bone marrow depression
Hepatic: hepatotoxicity
Metabolic: hyperuricemia
Musculoskeletal: muscle cramps
Respiratory: pulmonary edema, bronchospasm
Other: alopecia, fever, phlebitis at I.V. site, allergic reactions including anaphylaxis

Interactions
Drug-drug. Live-virus vaccines: increased risk of adverse reactions
Other antineoplastics: additive bone marrow depression
Drug-diagnostic tests. Hemoglobin, neutrophils, platelets, red blood cells, white blood cells: decreased values
Uric acid: increased level

Patient monitoring
- Monitor blood pressure during and after infusion. Stop infusion if severe hypotension occurs.
- With I.V. use, monitor infusion rate closely to prevent infusion reactions.
- Throughout infusion, check I.V. site for extravasation, which may cause thrombophlebitis.
- Keep diphenhydramine, hydrocortisone, epinephrine, and artificial airway at hand in case anaphylaxis occurs.
- Assess for CNS adverse effects. Assist patient during ambulation as needed.
- Monitor for signs and symptoms of bone marrow depression.
- Monitor CBC, liver function tests, and blood urea nitrogen and creatinine levels. Report platelet count below 50,000/mm³ or neutrophil count below 500/mm³.

Patient teaching
- Instruct patient to inspect mouth daily for ulcers and bleeding gums.
- Tell patient to immediately report difficulty breathing or signs and symptoms of allergic reaction.
- Caution female of childbearing age to avoid pregnancy and breastfeeding during drug therapy.
- Instruct patient to move slowly when sitting up or standing, to avoid light-headedness or dizziness from sudden blood pressure decrease.
- Tell patient drug may cause hair loss.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

etravirine
Intelicence

Pharmacologic class: Nonnucleoside reverse transcriptase inhibitor (NNRTI)
Therapeutic class: Antiretroviral
Pregnancy risk category B

Action
Blocks human immunodeficiency virus (HIV) reverse transcriptase, an enzyme necessary for HIV replication. Blockade leads to reduced viral load and increased CD4+ cell count, which in turn help prevent other infections when drug is given with other antiretrovirals.

Availability
Tablets: 100 mg

Indications and dosages
HIV-1 infection in antiretroviral treatment–experienced adults with evidence of viral replication and HIV-1 strains resistant to an NNRTI and other

Reactions in bold are life-threatening.

Clinical alert
antiretrovirals, given in combination with other antiretrovirals

**Adults:** 200 mg P.O. b.i.d.

**Contraindications**
None

**Precautions**
Use cautiously in:
- elderly patients
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

**Administration**
- Administer after a meal.
  - Don’t give with tipranavir/ritonavir, fosamprenavir/ritonavir, atazanavir/ritonavir, protease inhibitors administered without ritonavir, other NNRTIs, or St. John’s wort.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2.5-4 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** paresthesia, somnolence, seizure, hypoesthesia, amnesia, hypersomnia, tremor, disorientation, insomnia, anxiety, sleep disorder, abnormal dreams, confusional state, nervousness, nightmares, fatigue, peripheral neuropathy, headache, **hemorrhagic stroke**

**CV:** syncope, angina pectoris, hypertension, myocardial infarction, atrial fibrillation

**EENT:** blurred vision, vertigo

**GI:** nausea, vomiting, diarrhea, constipation, abdominal pain, gastrointestinal reflux disease, flatulence, gastritis, abdominal distention, rectching, hematemesis, stomatitis, pancreatitis, anorexia, dry mouth

**GU:** gynecomastia, renal failure

**Hematologic:** anemia, hemolytic anemia

**Hepatic:** cytolytic hepatitis, hepatic steatosis, hepatitis, hepatomegaly

**Metabolic:** diabetes mellitus, dyslipidemia, body fat redistribution or accumulation

**Respiratory:** exertional dyspnea, bronchospasm

**Skin:** rash, hyperhidrosis, prurigo, dry skin, lipohypertrophy, lipodystrophy, Stevens-Johnson syndrome, erythema multiforme

**Other:** sluggishness, night sweats, facial edema, immune reconstitution syndrome, hypersensitivity reaction, angioneurotic edema

**Interactions**

**Drug-drug.** Amiodarone, bepridil, disopyramide, flecainide, lidocaine (systemic), lovastatin, mexiletine, propafenone, quinidine, simvastatin: decreased blood levels of these drugs

Atazanavir/ritonavir: significant decrease in atazanavir blood level with loss of atazanavir therapeutic effect

Atorvastatin: possible increase in effects of both drugs

Carbamazepine, dexamethasone (systemic), efavirenz, nevirapine, phenobarbital, phenytin, rifabutin, rifampin, rifapentine, ritonavir, tipranavir/ritonavir: significant decrease in atazanavir blood level and loss of therapeutic effect

Clarithromycin: decreased clarithromycin blood level

Diazepam, fluvastatin, voriconazole, warfarin: increased blood levels of these drugs

Fluconazole, lopinavir/ritonavir, posaconazole: increased etravirine blood level

Immunosuppressants (cyclosporine, sirolimus, tacrolimus): possible change in blood levels of these drugs

Itraconazole, ketoconazole: decreased blood levels of these drugs, increased etravirine blood level

Methadone: possible change in methadone effects

Protease inhibitors (amprenavir, atazanavir, indinavir, nelfinavir) given without low-dose ritonavir: significant change in blood levels of these drugs

Saquinavir/ritonavir: reduced etravirine blood level
Sildenafil: possible decrease in sildenafil effect

**Drug-diagnostic tests.** ALP, amylase, AST, cholesterol, creatinine, glucose, lipase, low-density lipoproteins, triglycerides: increased levels
Hemoglobin, neutrophils, platelets: decreased levels

**Drug-food.** Any food: increased etravirine levels

**Drug-herbs.** St. John’s wort: significant decrease in etravirine blood level and loss of therapeutic effect

**Patient monitoring**
- Monitor patient closely for rash; discontinue therapy if severe rash develops.
- Be aware that immune reconstitution syndrome may occur in patients receiving combination antiretroviral therapy. During initial phase of therapy, patient whose immune system responds may develop inflammatory response to indolent or residual opportunistic infections (such as *Mycobacterium avium* complex, cytomegalovirus, *Pneumocystis jiroveci* pneumonia, and tuberculosis), which may necessitate further evaluation and treatment.
- Monitor International Normalized Ratio when giving drug concomitantly with warfarin.
- Watch for new-onset diabetes mellitus, exacerbation of preexisting diabetes, and hyperglycemia.

**Patient teaching**
- Tell patient to take drug after a meal exactly as prescribed.
- Instruct patient unable to swallow tablets whole to disperse tablets in glass of water, stir dispersion well, drink it immediately, then rinse glass with water several times and completely swallow each rinse to ensure that entire dose is consumed.
- Inform patient that drug doesn’t cure HIV infection or reduce risk of passing HIV to others through sexual contact, needle sharing, or blood exposure.
- Advise patient that drug may interact with many other drugs and herbs (especially St. John’s wort). Tell patient to discuss use of other drugs and herbs with prescriber.
- Advise patient to immediately report rash or new infections.
- Inform patient that drug may lead to body fat redistribution or accumulation and that the cause and long-term effects of these conditions are unknown.
- Advise female patient to notify prescriber if she is pregnant or intends to become pregnant.
- Because of potential HIV transmission and adverse reactions in breastfeeding infants, instruct women receiving this drug not to breastfeed.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

**exemestane**

**Aromasin**

**Pharmacologic class:** Aromatase inhibitor

**Therapeutic class:** Hormonal antineoplastic

**Pregnancy risk category D**

**Action**
Inhibits conversion of androgens to estrogen, which reduces estrogen concentrations and limits cancer cell growth in estrogen-dependent breast tumors

**Availability**
*Tablets:* 25 mg

**Indications and dosages**
- Advanced breast cancer
- **Adults:** 25 mg P.O. once daily after a meal
Contraindications
● Hypersensitivity to drug or its components

Precautions
Use cautiously in:
● moderate to severe hepatic insufficiency or renal impairment
● concurrent use of estrogen-containing drugs
● premenopausal women
● pregnant or breastfeeding patients
● children (safety and efficacy not established).

Administration
● Administer after meals with a full glass of water.
● Know that drug shouldn’t be taken by premenopausal women or by patients receiving drugs that contain estrogen.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1-2 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, dizziness, confusion, asthenia, fatigue, weakness, hypoesthesia, paresthesia, pain, anxiety, insomnia, depression
CV: hypertension, chest pain
EENT: sinusitis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia
GU: urinary tract infection
Musculoskeletal: pathologic fractures, arthritis, back pain, skeletal pain
Respiratory: dyspnea, cough, bronchitis, upper respiratory tract infection
Skin: rash, itching, alopecia, diaphoresis
Other: increased appetite, fever, hot flashes, infection, flulike symptoms, edema, lymphedema

Interactions
Drug-drug. CYP3A4 inducers: decreased exemestane blood level

Patient monitoring
● Monitor vital signs, especially blood pressure.
● Check for adverse GI reactions. Give antiemetics, as prescribed, for nausea and vomiting.
● Assess bowel elimination pattern. Increase fluids and administer stool softeners, as needed, to ease constipation.
● Monitor pain level. Administer analgesics, as prescribed, to relieve pain.
● Monitor liver function tests, CBC, and blood urea nitrogen, creatinine, and electrolyte levels.

Patient teaching
● Advise patient to take with full glass of water after a meal.
● Tell patient to report depression, insomnia, or excessive anxiety.
● Instruct patient to wear cotton clothing to let skin breathe if drug causes increased sweating or hot flashes.
● As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

exenatide acetate
Byetta
Pharmacologic class: Incretin mimetic
Therapeutic class: Hypoglycemic
Pregnancy risk category C

Action
Mimics enhancement of glucose-dependent insulin secretion and several other antihyperglycemic actions of incretins

Availability
Solution for injection: 250 mcg/ml as 60 doses in 5-mcg-per-dose/1.2-ml
prefilled pen, 250 mcg/ml as 60 doses in 10-mcg-per-dose/2.4-ml prefilled pen

**Indications and dosages**

> Adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus taking metformin, a sulfonylurea, a thiazolidinedione, a combination of metformin and a sulfonylurea, or a combination of metformin and a thiazolidinedione, but who haven’t achieved adequate glycemic control

**Adults:** 5 mcg injected subcutaneously in thigh, abdomen, or upper arm twice daily within 60 minutes before morning and evening meals. Dosage can be increased to 10 mcg after 1 month of therapy, based on clinical response.

**Dosage adjustment**
- Concurrent sulfonylurea use

**Contraindications**
- Hypersensitivity to drug or its components

**Precautions**
Use cautiously in:
- severe renal impairment or end-stage renal disease, acute pancreatitis, severe GI disease
- concurrent use of insulin, thiazolidinediones, D-phenylalanine derivatives, meglitinides, or alpha-glucosidase inhibitors
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

**Administration**
- Administer oral drugs 1 hour before exenatide. For oral drugs that must be taken with food, administer these with a light meal or snack when exenatide isn't given.
- Discard pen 30 days after first use, even if some drug remains. Don’t freeze, and don’t use drug if it has been frozen.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2.1 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- CNS: dizziness, headache, asthenia, jitteriness
- GI: nausea, vomiting, diarrhea, dyspepsia, gastroesophageal reflux disease
- **Metabolic:** hypoglycemia (especially with concurrent sulfonylurea)
- **Skin:** excessive sweating
- **Other:** decreased appetite, general injection site reaction, hypersensitivity reaction

**Interactions**
- **Drug-drug.** Anti-infectives, hormonal contraceptives: possible slowing of GI transit time
- **Drug-behaviors.** Alcohol use: reduced blood glucose level

**Patient monitoring**
- Monitor serum glucose level frequently, especially in patients also receiving sulfonylureas.
- Monitor renal function tests periodically.

**Patient teaching**
- Instruct patient to take drug 1 hour before morning and evening meals.
- Teach patient how to self-administer drug with prefilled pen.
- Tell patient to do a new pen set-up one time only, when starting a new prefilled pen.
- Advise patient to discard pen 30 days after first use, even if some drug remains.
- Caution patient not to freeze drug and not to use it if it has been frozen.
- **Teach patient to recognize and immediately report signs and symptoms of hypoglycemia and diabetic ketoacidosis.**
- Advise patient to avoid alcohol during therapy.
● Instruct breastfeeding patient to either discontinue breastfeeding or stop taking drug.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and behaviors mentioned above.

**ezetimibe**
Ezetrol®, Zetia

**Pharmacologic class:** Cholesterol absorption inhibitor

**Therapeutic class:** Antihyperlipidemic

**Pregnancy risk category C**

**Action**
Inhibits cholesterol absorption in intestine, decreasing intestinal delivery of cholesterol to liver and increasing systemic cholesterol clearance. Net effect is decreased serum cholesterol level.

**Availability**
Tablets: 10 mg

**Indications and dosages**

- Adjunct to diet and exercise in primary hypercholesterolemia; adjunct to other lipid-lowering drugs in homozygous familial hypercholesterolemia; adjunct to diet in homozygous sitosterolemia
- **Adults:** 10 mg/day P.O.

**Contraindications**
- Hypersensitivity to drug or its components
- Active hepatic disease or unexplained, persistent transaminase elevations (when given with HMG-CoA reductase inhibitors)
- Pregnancy (when given with HMG-CoA reductase inhibitors)

**Precautions**
Use cautiously in:
- renal or hepatic impairment
- elderly patients
- pregnant patients not receiving HMG-CoA reductase inhibitors
- breastfeeding patients
- children younger than age 10.

**Administration**
- Give with or without food.
- Be aware that drug may be given concurrently with HMG-CoA reductase inhibitor (such as atorvastatin or simvastatin).
- Give at least 2 hours before or 4 hours after bile acid sequestrant (if prescribed).

**Route** | **Onset** | **Peak** | **Duration**
--- | --- | --- | ---
P.O. | Moderate | 4-12 hr | Unknown

**Adverse reactions**
- CNS: headache, dizziness, fatigue
- EENT: pharyngitis, sinusitis
- GI: nausea, vomiting, diarrhea, abdominal pain, flatulence, dyspepsia, dry mouth, anorexia
- **Musculoskeletal:** back pain, myalgia, joint pain
- **Respiratory:** pneumonia, upper respiratory tract infection
- **Other:** viral infection

**Interactions**

**Drug-drug.**
- Cholestyramine: decreased ezetimibe blood level
- Cyclosporine, fenofibrate, gemfibrozil: increased ezetimibe blood level
- Fibrates: increased risk of cholesterol excretion into gallbladder
- Immunosuppressants: increased immunosuppression and bone marrow depression

**Drug-diagnostic tests.**
- Liver function tests: increased values

**Patient monitoring**
- Monitor hepatic and lipid profiles.
- Assess for and report unexplained muscle pain.
Patient teaching
- Teach patient about role of diet, exercise, and weight loss in lowering cholesterol levels.
- Instruct patient to report GI upset.
- Caution female patient to avoid pregnancy during therapy.
- Advise patient to use hard candy or gum to relieve dry mouth.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Indications and dosages
➢ High LDL levels in primary hypercholesterolemia or mixed hyperlipidemia
Adults: Dosage individualized, usually starting with Vytorin 10/20 P.O. daily. Patients requiring less aggressive LDL reduction may begin with Vytorin 10/10; patients needing LDL reductions of more than 55% may start with Vytorin 10/40.
➢ Elevated total cholesterol and LDL levels in homozygous familial hypercholesterolemia
Adults: Initially, Vytorin 10/40 or Vytorin 10/80 P.O. in evening

Dosage adjustment
- Severe renal insufficiency
- Moderate hepatic insufficiency

Contraindications
- Hypersensitivity to drug or its components
- Active hepatic disease or unexplained, persistent transaminase elevations
- Pregnancy or breastfeeding

Precautions
Use cautiously in:
- severe renal insufficiency
- history of hepatic disease
- substantial alcohol consumption
- concurrent cyclosporine therapy.

Administration
- Know that patient should be placed on standard cholesterol-lowering diet before receiving drug and should continue on this diet throughout therapy.
- Be aware that cholesterol and liver function tests should be done before therapy starts.
- Don’t give to patient with severe renal insufficiency unless he has previously tolerated 5 mg or more of simvastatin.

Reactions in bold are life-threatening.

Clinical alert
Give at least 2 hours before or 4 hours after bile acid sequestrant (if prescribed).

Don’t give with grapefruit juice.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: fatigue, headache

EENT: sinusitis, pharyngitis

GI: nausea, diarrhea, abdominal pain

Hepatic: hepatotoxicity (rare)

Musculoskeletal: arthralgia, myalgia, back pain, pain in extremities, myopathy, rhabdomyolysis (rare)

Respiratory: cough, upper respiratory tract infection

Other: influenza, hypersensitivity reactions

**Interactions**

**Drug-drug.** Amiodarone, verapamil: increased risk of myopathy and rhabdomyolysis

Cholestyramine: decreased ezetimibe blood level with further LDL reduction

Cyclosporine: increased ezetimibe blood level

CYP3A4 inhibitors (clarithromycin, cyclosporine, erythromycin, itraconazole, ketoconazole, nefazodone, protease inhibitors), gemfibrozil and other fibrates, niacin (in doses above 1 g/day): increased risk of myopathy

Digoxin: increased digoxin blood level

Warfarin: modest anticoagulant potentiation

**Drug-diagnostic tests.** Creatine kinase (CK), hepatic enzymes: increased levels

**Drug-food.** Grapefruit juice: increased risk of myopathy

Oat bran: impaired drug absorption

**Drug-herbs.** Chaparral, comfrey, eucalyptus, germander, jin bu huan, kava, skullcap, valerian: possible additive hepatotoxicity

St. John’s wort: significant reduction in simvastatin bioavailability

**Patient monitoring**

- Monitor cholesterol levels and liver function test results before therapy starts and thereafter as indicated.

- Closely monitor patients with complicated medical histories, especially those with renal insufficiency from long-standing diabetes.

- Watch for unexplained muscle pain, tenderness, or weakness. Report this finding promptly and check CK level closely for evidence of myopathy.

- Discontinue drug if myopathy is diagnosed or suspected.

- Be aware that patients taking Vytorin 10/80 should have an additional liver function test before therapy starts, 3 months after titration, and periodically during first year.

**Patient teaching**

- Instruct patient to take 2 hours before or 4 hours after bile acid sequestrant (if prescribed).

- Advise patient not to take with large amounts of grapefruit juice.

- Teach patient about role of diet, exercise, and weight loss in lowering cholesterol.

- Tell patient that myopathy can occur when therapy starts or during dosage titration. Instruct him to immediately report unexplained muscle pain or tenderness or weakness.

- Advise patient to tell all prescribers he’s taking this drug before starting any new drug.

- Caution female patient not to become pregnant or breastfeed while taking drug.

- Tell patient to limit or avoid alcohol use during therapy.

- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

- Canada

- UK

- Hazardous drug

- High alert drug
factor IX (human)
AlphaNine SD, Immune VH®, Mononine

factor IX (recombinant)
BeneFix

factor IX complex
Bebulin VH, Defix®, Hipfix®, Octaplex®, Profilnine SD, Proplex T (heat-treated), Replenine®

Pharmacologic class: Blood modifier
Therapeutic class: Antihemophilic
Pregnancy risk category C

Action
Converts fibrinogen to fibrin, increasing levels of clotting factors

Availability
Powder for injection: Various strengths; units specified on label

Indications and dosages
Factor IX deficiency (hemophilia B or Christmas disease); anticoagulant overdose
Adults and children: Dosage individualized; drug administered I.V. Use following equations to calculate approximate units needed:
Human product—1 unit/kg times body weight (in kg) times desired increase in factor IX level, expressed as percentage of normal
Recombinant product—1.2 units/kg times body weight (in kg) times desired increase in factor IX level, expressed as percentage of normal
Proplex T—0.5 unit/kg times body weight (in kg) times desired increase in factor IX level, expressed as percentage of normal

Off-label uses
- Hepatic dysfunction
- Esophagitis
- Unspecified GI hemorrhage (human product)

Contraindications
- Hypersensitivity to mouse or hamster protein (with BeneFix)
- Fibrinolysis

Precautions
Use cautiously in:
- recent surgery
- pregnant patients
- children younger than age 6 (safety and efficacy not established).

Administration
Give by slow I.V. infusion. Average infusion rate is 100 units (2 to 3 ml)/minute; don’t exceed 10 ml/minute.
- If prescribed, administer hepatitis B vaccine before giving factor IX.
- Know that dosage is highly individualized according to degree of factor IX deficiency, patient’s weight, and bleeding severity.
- Don’t use glass syringe. Don’t shake reconstituted solution or mix with other I.V. solutions.

Route Onset Peak Duration
I.V. Immediate 10-30 min Unknown

Adverse reactions
CNS: light-headedness, paresthesia, headache
CV: blood pressure changes, thromboembolic reactions, myocardial infarction (MI)
EENT: allergic rhinitis
GI: nausea, vomiting
Hematologic: disseminated intravascular coagulation (DIC)
Respiratory: pulmonary embolism

Reactions in bold are life-threatening.
**Skin:** rash, flushing, diaphoresis, pruritus, urticaria  
**Other:** altered taste, fever, chills, burning sensation in jaw and skull, pain at I.V. injection site, hypersensitivity reactions including anaphylaxis

**Interactions**  
**Drug-drug.** Aminocaproic acid: increased risk of thrombosis

**Patient monitoring**  
- Be aware that factor IX complex may transmit hepatitis.  
- Closely monitor vital signs during infusion.  
- Observe for hemolytic reaction. If it occurs, stop infusion, flush line with saline solution, and notify prescriber immediately.  
- Monitor I.V. injection site closely.  
- Monitor coagulation studies closely. Know that drug may cause thromboembolic disorders, including MI and DIC.

**Patient teaching**  
- Inform patient that drug may transmit diseases.  
- Tell patient to immediately report signs and symptoms of hypersensitivity reaction, including rash, hives, tightness in chest, wheezing, shortness of breath, and swelling of throat or lips.  
- Advise patient to immediately report unusual bleeding or bruising.  
- Caution patient to avoid activities that can cause injury.  
- Tell patient to wear medical identification stating that he has a blood-clotting disorder.  
- Instruct patient to notify surgeon or dentist of his blood-clotting disorder before surgery or invasive dental procedures.  
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

**famciclovir**  
Apo-Famciclovir®, Famvir, PMS-Famciclovir®, Sandoz Famciclovir®

**Pharmacologic class:** Synthetic nucleoside  
**Therapeutic class:** Antiviral  
**Pregnancy risk category B**

**Action**  
Converts to penciclovir and selectively inhibits DNA polymerase and viral DNA synthesis

**Availability**  
Tablets: 125 mg, 250 mg, 500 mg

**Indications and dosages**  
➤ Acute herpes zoster infection (shingles)  
**Adults:** 500 mg P.O. q 8 hours for 7 days  
➤ Recurrent genital herpes in immunocompetent patients  
**Adults:** 1,000 mg P.O. b.i.d. for 1 day, starting as soon as symptoms appear  
➤ Suppression of recurrent genital herpes  
**Adults:** 250 mg P.O. b.i.d. for up to 1 year  
➤ Recurrent herpes simplex infection in patients with human immunodeficiency virus  
**Adults:** 500 mg P.O. b.i.d. for 7 days  
➤ Herpes labialis (oral herpes simplex) in immunocompetent patients  
**Adults:** 1,500 mg P.O. as a one-time dose given as soon as symptoms appear

**Dosage adjustment**  
- Renal impairment
Contraindications
- Hypersensitivity to drug or its components

Precautions
Use cautiously in:
- renal or hepatic impairment
- elderly patients
- pregnant or breastfeeding patients
- children younger than age 18.

Administration
- Know that for best response, therapy should begin within 6 hours of onset of genital herpes symptoms or lesions.
- Give with or without food.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, fatigue, dizziness, drowsiness, paresthesia, insomnia
EENT: pharyngitis, sinusitis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, anorexia
Musculoskeletal: back pain, joint pain
Skin: pruritus, rash
Other: fever

Interactions
Drug-drug. Digoxin: increased digoxin blood level, increased risk of toxicity
Probenecid: increased blood level of penciclovir (active antiviral compound of famciclovir)

Patient monitoring
- When giving concurrently with digoxin, monitor digoxin blood level and evaluate for digoxin toxicity.
- Monitor CBC, blood urea nitrogen, creatinine, and electrolyte levels.
- Be aware that drug may take several weeks to reach therapeutic level.
- Know that renal failure may raise blood drug level, increasing the risk of adverse reactions.
- Avoid direct contact with infected areas. Wash hands frequently and wear gloves during patient contact.

Patient teaching
- Instruct patient to take with food or milk to avoid upset stomach.
- Inform patient that drug doesn’t cure herpes but only decreases pain and itching by allowing sores to heal and preventing new ones from forming.
- Advise patient to wear loose-fitting clothing to avoid irritating lesions.
- Tell patient to report rash or itching.
- Instruct female patient to tell prescriber if she is pregnant or breastfeeding.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

famotidine
Apo-Famotidine, Gen-Famotidine, Maalox H2 Acid Controller, Mylanta AR, Novo-Famotidine, Nu-Famotidine, Pepcid, Pepcid AC, Ulcidine, Ultra Heartburn Relief

Pharmacologic class: Histamine2-receptor antagonist
Therapeutic class: Antiulcer drug

Pregnancy risk category B

Action
Blocks action of histamine at histamine2-receptor sites in gastric parietal cells, inhibiting gastric acid secretion and stabilizing pepsin

Availability
Gelcaps: 10 mg
Oral suspension: 40 mg/5 ml

Reactions in bold are life-threatening.
Solution for injection: 10 mg/ml, 20 mg/50 ml of normal saline solution  
Tablets: 10 mg, 20 mg, 40 mg  
Tablets (chewable): 10 mg  
Tablets (orally disintegrating): 20 mg, 40 mg

Indications and dosages

- Active duodenal ulcers and benign gastric ulcers  
  Adults: 40 mg P.O. once daily at bedtime or 20 mg P.O. b.i.d. for up to 8 weeks

- Prophylaxis of duodenal ulcers  
  Adults: 20 mg P.O. once daily at bedtime

- Gastroesophageal reflux disease  
  Adults: 20 mg P.O. b.i.d. for up to 6 weeks. Maximum dosage is 40 mg b.i.d. for up to 12 weeks.

Children ages 1 to 16: 1 mg/kg P.O. daily in two divided doses, to a maximum of 40 mg b.i.d.

Infants ages 3 months to 1 year: 0.5 mg/kg P.O. b.i.d. for up to 8 weeks

Infants younger than age 3 months: 0.5 mg/kg P.O. once daily for up to 8 weeks

- Gastric hypersecretory conditions (such as Zollinger-Ellison syndrome)  
  Adults: Initially, 20 mg P.O. q 6 hours, increased as needed to 160 mg q 6 hours

- Hospitalized patients with pathologic hypersecretory conditions or ulcers; patients who can’t take oral drugs  
  Adults: 20 mg I.V. q 12 hours

- Prevention or treatment of heartburn, acid indigestion, and sour stomach (Pepcid AC only)  
  Adults: For prevention, 10 mg P.O. 1 hour before eating, or 10-mg chewable tablet 15 minutes before eating, to a maximum of 20 mg/24 hours for up to 2 weeks. For symptomatic treatment, 10 mg P.O. once or twice daily.

Dosage adjustment

- Renal impairment

Contraindications

- Hypersensitivity to drug or other histamine₂-receptor antagonists
- Alcohol intolerance (some oral liquid products)

Precautions

Use cautiously in:

- renal impairment
- elderly patients
- pregnant or breastfeeding patients.

Administration

- Be aware that drug usually is given in one daily dose to patients with renal insufficiency.
- Give P.O. form with foods or liquids.
- Dilute I.V. form with 10 ml dextrose 5% in water or normal saline solution (100 ml) for I.V. piggyback administration.
- Deliver by I.V. push over 2 minutes or intermittent infusion over 30 minutes.
- Know that drug may cause transient irritation at I.V. site.

Route | Onset | Peak | Duration  
P.O.  | Within 1 hr | 1-4 hr | 6-12 hr  
I.V.  | Rapid | 0.5-3 hr | 8-15 hr

Adverse reactions

CNS: dizziness, headache, paresthesia, asthenia  
CV: palpitations  
GI: nausea, diarrhea, constipation, dry mouth, anorexia  
EENT: orbital edema, conjunctival redness, tinnitus  
Musculoskeletal: musculoskeletal pain  
Skin: flushing, acne, dry skin  
Other: altered taste, fever, pain at injection site, hypersensitivity reactions

Interactions

Drug-food. Caffeine-containing foods: increased gastric irritation  
Drug-herbs. Yerba mate: decreased famotidine clearance  
Drug-behaviors. Alcohol use, smoking: increased gastric irritation
Patient monitoring
- Assess patient for GI signs and symptoms.
- Monitor blood urea nitrogen and creatinine levels in patients with renal impairment.

Patient teaching
- Tell patient that drug is most effective when taken at bedtime.
- Inform patient that pain relief may not begin until several days after therapy starts.
- Caution patient to avoid alcohol, caffeine, and smoking because they may increase gastric irritation.
- Tell female patient to inform prescriber if she is pregnant or breastfeeding.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the foods, herbs, and behaviors mentioned above.

**felodipine**

Cardioplen®, Felotens®, Keloc®, Neofel®, Plendil, Renedil®, Vascalpha®

*Pharmacologic class:* Calcium channel blocker  
*Therapeutic class:* Antihypertensive, antianginal  
*Pregnancy risk category C*

**Action**
Impedes extracellular calcium ion movement across membranes of myocardial muscle cells, depressing myocardial contractility and impulse formation; slows impulse conduction velocity and dilates coronary arteries and peripheral arterioles. Net effect is reduced cardiac workload and lower blood pressure.

**Availability**
Tablets (extended-release): 2.5 mg, 5 mg, 10 mg

**Indications and dosages**

> Hypertension  
**Adults:** Initially, 5 mg P.O. daily. Depending on response, may decrease to 2.5 mg or increase to a maximum of 10 mg P.O. daily at 2-week intervals.

**Dosage adjustment**
- Hepatic impairment
- Elderly patients

**Off-label uses**
- Heart failure
- Angina pectoris or vasospastic (Prinzmetal’s) angina

**Contraindications**
- Hypersensitivity to drug

**Precautions**
Use cautiously in:
- cardiac disease, arrhythmias, severe hepatic or renal impairment
- elderly patients
- pregnant or breastfeeding patients
- children (safety not established).

**Administration**
- Give without regard to meals.
- Make sure patient swallows tablet whole without crushing or chewing.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1 hr</td>
<td>2-4 hr</td>
<td>Up to 24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** headache, drowsiness, dizziness, syncope, nervousness, anxiety, psychiatric disturbances, paresthesia, insomnia, asthenia, confusion, irritability  
**CV:** chest pain, peripheral edema, hypotension, palpitations, tachycardia, angina, arrhythmias, myocardial infarction, atrioventricular block  
**EENT:** rhinorrhea, sneezing, pharyngitis

Reactions in **bold** are life-threatening.
GI: nausea, vomiting, diarrhea, constipation, abdominal discomfort, dyspepsia, abdominal cramps, flatulence, dry mouth
Hematologic: anemia
Musculoskeletal: back pain
Respiratory: bronchitis
Skin: dermatitis, rash, pruritus, urticaria, erythema
Other: dysgeusia, gingival hyperplasia, facial edema, thirst, warm sensation

Interactions
Drug-drug. Antifungals, cimetidine, erythromycin, propranolol, ranitidine: increased felodipine blood level, increased risk of toxicity
Barbiturates, hydantoins: decreased felodipine blood level
Beta-adrenergic blockers, digoxin, disopyramide, phenytoin: bradycardia, conduction defects, heart failure
Fentanyl, nitrates, other antihypertensives, quinidine: additive hypotension
Nonsteroidal anti-inflammatory drugs: decreased antihypertensive effects
Drug-food. Grapefruit juice: increased felodipine blood level and effects
Drug-behaviors. Acute alcohol ingestion: additive hypotension

Patient monitoring
- Don’t give to patient with heart block unless he has a pacemaker.
- Use extreme caution when administering to patients with pulmonary hypertension, renal insufficiency, heart failure, or compromised ventricular function (especially those receiving beta-adrenergic blockers concurrently).
- Monitor fluid intake and output, and weigh patient daily.
- Monitor ECG and vital signs. Assess for signs and symptoms of heart block.
- Assess for reflex tachycardia, angina, and sustained hypotension.
- Check hepatic profile and alkaline phosphatase level in patients with hepatic impairment.

Patient teaching
- Tell patient drug controls but doesn’t cure high blood pressure, so he should keep taking it even if he feels well.
- Instruct patient to move slowly when rising, to avoid light-headedness or dizziness from sudden blood pressure decrease.
- Explain that exercise and hot weather may increase drug’s hypotensive effects.
- Tell patient to report peripheral edema, persistent headache, or flushing.
- Advise patient to use hard candy or gum if dry mouth or thirst occurs.
- Tell female patient to inform prescriber if she is pregnant or breastfeeding.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, foods, and behaviors mentioned above.

fenofibrate
Antara, Apo-Fenofibrate, Fenogal, Lipantil, Lipofen, Lofibra, Nu-Fenofibrate, Tricor, Triglide, Supralip

Pharmacologic class: Fibric acid derivative
Therapeutic class: Antihyperlipidemic
Pregnancy risk category C

Action
Inhibits triglyceride synthesis in liver, reducing levels of low- and very-low-density lipoproteins. Also increases uric acid secretion.

Availability
Capsules: 50 mg, 150 mg
Capsules (micronized): 43 mg, 67 mg, 130 mg, 134 mg, 200 mg
Tablets: 48 mg, 50 mg, 54 mg, 145 mg, 160 mg
**Indications and dosages**

- Adjunct to dietary therapy to reduce elevated low-density lipoproteins, (LDL)-C, total cholesterol, triglycerides, and apolipoprotein B; to increase high-density lipoprotein-C level in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)

**Adults:** 1 tablet (145 or 160 mg), 1 capsule (150 mg), or 1 micronized capsule (130 or 200 mg) P.O. daily

- Hypertriglyceridemia

**Adults:** Initially, 50 to 150 mg P.O. daily (capsule); 43 to 200 mg P.O. daily (micronized capsule); 48 to 160 mg P.O. daily (tablet)

**Dosage adjustment**

- Renal impairment
- Elderly patients

**Off-label uses**

- Polymetabolic syndrome X

**Contraindications**

- Hypersensitivity to drug
- Hepatic disease or unexplained, persistent liver function test abnormalities
- Severe renal impairment
- Gallbladder disease
- Breastfeeding

**Precautions**

Use cautiously in:

- pancreatitis, cholelithiasis
- patients receiving warfarin concurrently
- pregnant patients
- children.

**Administration**

- Before giving, be aware of potentially serious interactions, such as with nephrotoxic drugs.
- Administer with meals.
- Give bile acid sequestrants at least 1 hour before or 4 to 6 hours after fenofibrate.

---

**Adverse reactions**

**CNS:** drowsiness, dizziness, fatigue, headache, migraine, insomnia, depression, vertigo, nervousness, anxiety, paresthesia, hypotonia, neuralgia

**CV:** tachycardia, varicose veins, phlebitis, angina, hypertension, hypotension, peripheral vascular disease, vasodilation, ECG abnormalities, coronary artery disease, arrhythmias, ventricular extrasystoles, myocardial infarction, atrial fibrillation

**EENT:** conjunctivitis, abnormal vision, cataracts, refraction disorder, otitis media, rhinitis, sinusitis, pharyngitis, laryngitis

**GI:** nausea, vomiting, diarrhea, constipation, abdominal pain, flatulence, dyspepsia, gastritis, gastroenteritis, esophagitis, duodenal or peptic ulcer, colitis, cholelithiasis, cholecystitis, rectal disorder, rectal hemorrhage

**GU:** urinary frequency, dysuria, cystitis, urethral stricture, prostatic disorder, gynecomastia, vaginal candidiasis, decreased libido, renal dysfunction

**Hematologic:** eosinophilia, anemia, lymphadenopathy, thrombocytopenia, leukopenia

**Hepatic:** fatty liver deposits

**Metabolic:** hyperuricemia, gout, hypoglycemia

**Musculoskeletal:** back, muscle, or joint pain; myositis; arthritis; tenosynovitis; arthrosis; bursitis

**Respiratory:** respiratory disorders, bronchitis, increased cough, dyspnea, pneumonia, asthma

**Skin:** rash, pruritus, urticaria, bruising, acne, eczema, diaphoresis, dermatitis, herpes simplex, herpes zoster, alopecia, nail disorder

**Other:** weight loss or gain, edema, fever, flu-like symptoms, hypersensitivity reactions

Reactions in **bold** are life-threatening.

---

**Route** | **Onset** | **Peak** | **Duration**
---|---|---|---
P.O. | Variable | 6-8 hr | Unknown
Interactions

Drug-drug. **Bile acid sequestrants** (resins): decreased absorption and efficacy of fenofibrate

**Immunosuppressants, other nephrotoxic drugs:** increased risk of renal toxicity

**Oral anticoagulants:** increased risk of bleeding

**Statins (such as simvastatin):** rhabdomyolysis, acute renal failure

**Drug-diagnostic tests.** Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, blood urea nitrogen, creatinine, gamma-glutamyltransferase, uric acid: increased values

Granulocytes, hemoglobin, neutrophils, platelets, white blood cells (WBCs): decreased values

**Liver function tests:** abnormal results

**Drug-food.** Any food: increased drug absorption

**Drug-behaviors.** Alcohol use: elevated triglyceride level

Patient monitoring

- Assess creatine kinase and lipid levels and liver function test results.
- Monitor CBC and WBC count. Expect these to decrease at start of therapy, then stabilize.

Patient teaching

- Instruct patient to take with meals for best effect.
- Remind patient that he still needs to follow a triglyceride-lowering diet.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Advise patient to minimize GI upset by eating frequent, small servings of food and drinking plenty of fluids.
- Tell patient that drug may take up to 2 months to alter lipid values.
- Inform breastfeeding patient that she must choose between taking fenofibrate and breastfeeding.
- Tell female patient to inform prescriber if she is pregnant.

- Inform patient that he’ll undergo regular blood testing.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and behaviors mentioned above.
Short-term (up to 4 hours) blood pressure reduction in hospitalized children

**Hospitalized children:** Dosages highly individualized based on rate and magnitude of desired blood pressure decrease. Dosages of 0.2 mcg/kg/minute I.V. were used initially in clinical trials; dosage increases up to 0.3 to 0.5 mcg/kg/minute q 20 to 30 minutes for up to 4 hours were well tolerated; dosages above 0.8 mcg/kg/minute have produced tachycardia with no additional benefit.

**Contraindications**
- Hypersensitivity to drug or sulfites

**Precautions**
Use cautiously in:
- glaucoma, increased intraocular pressure (IOP), tachycardia, hypotension, hypokalemia, hepatic disease
- patients receiving concurrent beta-adrenergic blockers.

**Administration**
- Don’t give as I.V. bolus. Give only by slow, continuous I.V. infusion using infusion pump, at a concentration of 40 mcg/ml or less (60 mcg/ml or less for children).
- Be aware that compatible solutions are 0.9% sodium chloride injection and 5% dextrose injection.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>15 min</td>
<td>20 min</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- CNS: anxiety, dizziness, headache, light-headedness, insomnia, nervousness
- CV: angina pectoris, nonspecific chest pain, hypotension, palpitations, ST-segment and T-wave changes, tachycardia, bradycardia, heart failure, ischemic heart disease, myocardial infarction
- EENT: increased IOP, nasal congestion

**GI:** nausea, vomiting, diarrhea, constipation, abdominal pain and fullness

**GU:** urinary tract infection, oliguria

**Hematologic:** leukocytosis, bleeding tendency

**Metabolic:** hypokalemia

**Musculoskeletal:** leg cramps, back pain

**Respiratory:** dyspnea, upper respiratory tract infection

**Skin:** diaphoresis, flushing

**Other:** injection site pain, fever, hypersensitivity reactions including anaphylaxis

**Interactions**

- **Drug-drug.** Beta-adrenergic blockers: increased hypotension
- Dopamine antagonists, metoclopramide: decreased fenoldopam effects

- **Drug-diagnostic tests.** Aminotransferase, blood urea nitrogen, creatinine, glucose, lactate dehydrogenase, potassium: decreased levels

**Patient monitoring**
- Watch closely for signs and symptoms of anaphylaxis or severe asthma.
- Check blood pressure carefully at least every 15 minutes to detect hypotension, especially in patient with acute cerebral infarction or hemorrhage.
- When desired blood pressure decrease occurs, discontinue therapy or taper dosage as ordered.
- Know that patients with asthma are at higher risk for sulfite sensitivity.
- Assess respiratory and cardiac status regularly.
- Monitor potassium level closely.
- Evaluate fluid intake and urinary output.

**Patient teaching**
- Tell patient to immediately report signs or symptoms of anaphylaxis or breathing problems.
- Tell patient that drug may cause rapid heart rate and excessively lower blood pressure, possibly resulting in dizziness.

Reactions in **bold** are life-threatening.
fentanyl citrate
Fentora, Sublimaze

fentanyl transdermal system
Duragesic, Durogesic®, Ionsys, Matrifén®, Ran-Fentanyl®, Ratio-Fentanyl®

fentanyl transmucosal
Actiq, Fentanyl Oralet

Pharmacologic class: Opioid agonist
Therapeutic class: Opioid analgesic, anesthesia adjunct
Controlled substance schedule II
Pregnancy risk category C

FDA BOXED WARNING

- Actiq and Fentora are indicated only for managing breakthrough pain in cancer patients already receiving and tolerant to opioids. Opioid-tolerant patients are those taking at least 60 mg morphine daily, 25 mcg transdermal fentanyl hourly, 30 mg oxycodone daily, 8 mg oral hydromorphone daily, or equianalgesic dose of another opioid for 1 week or longer.
- Actiq and Fentora are contraindicated for managing acute or postoperative pain (including headache or migraine), because life-threatening hypoventilation can arise at any dosage in patients not taking chronic opioids. Don’t administer to opioid-nontolerant patients, including those with only as-needed prior exposure.
- When prescribing, don’t convert patients on a mcg-per-mcg basis from Actiq to Fentora. Carefully consult Initial Dosing Recommendations table.
- When dispensing, don’t substitute Fentora for other fentanyl products because differences exist in their pharmacokinetic profile. Substitution may result in fatal overdose.
- Use special care when administering Fentora. If breakthrough pain episode isn’t relieved after 30 minutes, patients may take only one additional dose using same strength and must wait at least 4 hours before taking another dose.
- Inform patients and caregivers that Actiq and Fentora can be fatal to a child. Instruct them to keep all units out of children’s reach and to discard opened units properly.
- Fentora and Duragesic are for use only in opioid-tolerant patients. They contain a high concentration of potent Schedule II opioid agonist, with highest potential for abuse and risk of fatal overdose due to respiratory depression. These drugs are subject to criminal diversion. High fentanyl content in patches may be a particular target for abuse and diversion. When prescribing or dispensing these drugs, consider the increased risk of misuse, abuse, or diversion.
- Serious adverse events (including deaths) in patients treated with Fentora have been reported. Deaths occurred as a result of improper patient selection (such as use in opioid nontolerant patients) or improper dosing.
- Duragesic is indicated for managing persistent moderate to severe chronic pain that can’t be managed by other means. Use only in patients already receiving opioids who have demonstrated opioid tolerance and need total daily dose at least equivalent to Duragesic 25 mcg/hour.
- Duragesic is contraindicated in management of postoperative, acute, mild, or intermittent pain; and in patients who need short-term opioid analgesia.
- Fentanyl levels peak between 24 and 72 hours of treatment; serious or life-threatening hypoventilation may arise during initial Duragesic application period.
• Concomitant use of Duragesic or Fentora with potent CYP450 3A4 inhibitors may raise fentanyl blood level, possibly increasing or prolonging adverse effects and causing potentially fatal respiratory depression. Closely monitor patients receiving this combination for an extended time; adjust dosage if needed.

• Duragesic safety hasn’t been established in children younger than age 2. Administer only to opioid-tolerant children age 2 or older.

• Overestimating Duragesic dosage when converting patients from another opioid can lead to fatal overdose with first dose. Patients who’ve had serious adverse events (including overdose) must be monitored and treated for at least 24 hours.

• Use of damaged or cut Duragesic patch can lead to rapid release of contents and absorption of potentially fatal dose.

**Action**

Binds to specific opioid receptors in CNS, inhibiting pain pathways, altering pain perception, and increasing pain threshold

**Availability**

*Injection:* 0.05 mg/ml

*Tablets (buccal):* 100 mcg, 200 mcg, 300 mcg, 400 mcg, 600 mcg, 800 mcg

*Transdermal system:* 25 mcg/hour, 50 mcg/hour, 75 mcg/hour, 100 mcg/hour

*Transmucosal lozenges:* 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,200 mcg, 1,600 mcg

**Indications and dosages**

➢ Breakthrough pain in opioid-tolerant patients with cancer

**Adults:** One 200-mcg lozenge dissolved in mouth over 15 minutes; additional unit may be given 15 minutes later. If patient needs more than 1 unit per episode (evaluated over several episodes), dosage may be increased; for optimal use or titration, don’t exceed 4 units daily. For patient not being converted from Actiq, give 100 mcg (Fentora). For patient being converted from Actiq, follow dosing recommendations below for Fentora.

<table>
<thead>
<tr>
<th>Current Actiq (lozenges) dosage (mcg)</th>
<th>Initial Fentora (tablets) dosage (mcg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>200</td>
<td>100</td>
</tr>
<tr>
<td>400</td>
<td>100</td>
</tr>
<tr>
<td>600</td>
<td>200</td>
</tr>
<tr>
<td>800</td>
<td>200</td>
</tr>
<tr>
<td>1,200</td>
<td>2 × 200</td>
</tr>
<tr>
<td>1,600</td>
<td>2 × 200</td>
</tr>
</tbody>
</table>

If breakthrough pain doesn’t ease after 30 minutes, give another dose once, using same strength previously given. Administer maximum of two doses for any breakthrough episode. Wait at least 4 hours before giving Fentora for another breakthrough episode.

➢ Management of chronic pain in patients requiring opioid analgesics

**Adults:** Initially, 25 mcg/hour (transdermal system); no more than 25 mcg/hour in patients who haven’t been receiving opioids. To calculate dosage for patients already receiving opioids, assess 24-hour requirement for current opioid. Using equianalgesic table in prescribing information, convert to equivalent amount of morphine per 24 hours; then convert morphine dosage to appropriate dosage of transdermal fentanyl. During initial application, keep short-acting opioids on hand to treat breakthrough pain; morphine 10 mg I.M. or 60 mg P.O. q 4 hours (60 mg/24 hours I.M. or 360 mg/24 hours P.O.) is roughly equivalent to transdermal fentanyl 100 mcg/hour. For most patients, transdermal patch lasts 72 hours, but some require new patch q 48 hours.
Short-term analgesia during anesthesia and immediate preoperative and postoperative periods

**Adults:** Individualized; 0.05 to 0.1 mg (Sublimaze) I.M. 30 to 60 minutes before surgery and as adjunct to general anesthesia; total dosage is 0.002 mg/kg. Maintenance dosage during surgery is 0.025 to 0.1 mg I.V. or I.M. Postoperatively, 0.05 to 0.1 mg I.M. to control pain, tachypnea, or emergence delirium; repeat in 1 to 2 hours if needed.

**Children ages 2 to 12:** Individualized; 2 to 3 mcg/kg (Sublimaze) I.V. depending on vital signs, or 5 to 15 mcg/kg (Fentanyl Oralet) transmucosally

General anesthesia (with oxygen only)

**Adults:** Individualized; 0.05 to 0.1 mg/kg (Sublimaze) I.V. for high-dose therapy. Up to 0.12 mg/kg may be necessary.

**Adjunct to regional anesthesia**

**Adults:** Individualized; 0.05 to 0.1 mg (Sublimaze) I.M. or slow I.V. over 1 to 2 minutes

**Dosage adjustment**
- Elderly patients

**Contraindications**
- Hypersensitivity to drug or transdermal adhesive (with fentanyl transdermal)
- Opioid-nontolerant patient
- Intermittent pain (on as-needed basis)
- Management of acute or mild pain
- Management of postoperative pain (Actiq, Duragesic, fentanyl transdermal, Fentora)
- Significant respiratory depression, especially in unmonitored settings without resuscitation equipment
- Known or suspected paralytic ileus

**Precautions**
Use cautiously in:
- diabetes mellitus, severe or chronic pulmonary or hepatic disease, cardiovascular disease, CNS tumors, adrenal insufficiency, hypothyroidism, renal impairment, head injury or increased intracranial pressure (use with extreme caution)
- concurrent use of CNS depressants
- alcoholism or drug abuse
- MAO inhibitor use within 14 days (not recommended)
- elderly patients
- pregnant patients
- labor and delivery
- breastfeeding patients (not recommended)
- children younger than age 2 (Duragesic, Sublimaze), younger than age 16 (Actiq), or younger than age 18 (Fentora) (safety not established).

**Administration**
- Before applying transdermal patch, clip hair at site; don’t use razor. Wash area with clean water only; dry well.
- Apply transdermal patch to nonirritated, nonirradiated flat surface. Press firmly in place for 30 seconds.
- In elderly patients, don’t initiate fentanyl patch at dosages above 25 mcg/hour unless patient is already receiving more than 135 mg/day of oral morphine or equivalent.
- Don’t open buccal tablet blister pack until ready to administer; don’t push tablet through blister backing.
- Be aware that in some patients, dosages of both Fentora and maintenance (around-the-clock) opioid analgesic may need to be adjusted to provide ongoing relief of breakthrough pain. Generally, Fentora dosage should be increased if patient needs more than one dose per breakthrough pain episode for several consecutive episodes.
- Inject I.V. dose slowly over 3 to 5 minutes.
- Keep opioid antagonist (naloxone) and emergency equipment available when giving drug I.V.
- Be aware that drug isn’t recommended for control of mild or intermittent pain.
Adverse reactions
CNS: headache, dizziness, vertigo, floating feeling, lethargy, confusion, light-headedness, nervousness, hallucinations, delirium, insomnia, anxiety, fear, mood changes, tremor, sedation, coma, seizures
CV: palpitations, hypotension, hypertension, tachycardia, bradycardia, arrhythmias, circulatory depression, cardiac arrest, shock
EENT: blurred vision, diplopia, laryngospasm
GI: nausea, vomiting, constipation, biliary tract spasm, dry mouth, anorexia
GU: urinary retention or hesitancy, ureteral or vesical sphincter spasm, decreased libido, erectile dysfunction
Musculoskeletal: skeletal and thoracic muscle rigidity
Respiratory: slow and shallow respirations, suppressed cough reflex, apnea, bronchospasm
Skin: local skin irritation (with transdermal system), rash, urticaria, pruritus, dia- phoresis, flushing, erythema, cold sensitivity
Other: oral mucosal reactions (at application site with buccal tablets), physical or psychological drug dependence, drug tolerance, pain or phlebitis at injection site

Interactions
Drug-drug. Barbiturate anesthetics: decreased effects of both drugs
Buprenorphine, dezocine, nalbuphine: decreased analgesic effect
CNS depressants (antidepressants, general anesthetics, other opioid analgesics, sedative-hypnotics, skeletal muscle relaxants),
CYP4503A4 inhibitors: profound sedation, hypoventilation, and hypotension
CYP4503A4 inducers (such as phenytoin, rifabutin, rifapentin): possible decrease in fentanyl blood level
CYP4503A4 inhibitors (such as amiodarone, amprenavir, aprepitant, clarithromycin, diltiazem, erythromycin, fluconazole, fosamprenavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, troleandomycin, verapamil): increased fentanyl blood level with increased adverse reactions, leading to greater risk of toxicity (including fatal respiratory depression)
MAO inhibitors: severe, unpredictable reactions
Opioid antagonists, partial-antagonist opioid analgesics: withdrawal in physically dependent patients
Drug-diagnostic tests. Amylase, lipase: increased levels
Granulocytes, hemoglobin, neutrophils, platelets, white blood cells: decreased levels
Drug-food. Grapefruit, grapefruit juice: increased fentanyl blood level, increased risk of toxicity
Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression
Drug-behaviors. Alcohol use: profound sedation, hypoventilation, and hypotension

Patient monitoring
Assess for muscle rigidity in patients receiving high doses; discuss need for neuromuscular blockers with prescriber. Patient receiving blocker will need ventilator.
- Monitor respiratory and cardiovascular function and urine output.
- With transdermal system, monitor patient’s pain level often to determine if patch is effective for 72 hours or needs to be replaced after 48 hours. Know that drug level rises gradually for first 24 hours after patch is applied; supplemental analgesics may be needed then.

Reactions in bold are life-threatening.
If patient develops fever, assess for signs and symptoms of opioid toxicity, as more drug is absorbed at higher body temperatures.

If adverse reactions to transdermal system occur, monitor patient for at least 12 hours after patch removal.

Carefully monitor hematologic studies and hepatic enzyme levels.

Patient teaching

Caution patient to keep transmucosal (lozenge) form out of children’s reach even though it is supplied in individually sealed, child-resistant pouch. One lozenge can be fatal to a child.

Instruct patient to place lozenge between cheek and gum and suck on it for 15 minutes without chewing or swallowing.

Teach patient proper technique for applying and disposing of transdermal patch.

Tell patient that transdermal form is absorbed more rapidly if skin is warm from fever or hot environment. Instruct patient to avoid electric blankets, heating pads, heat lamps, hot tubs, and heated water beds and to promptly report fever or a move to a hot climate.

Instruct patient not to open buccal tablet blister pack until ready to use. Teach patient to peel back blister backing to expose buccal tablet and not to push tablet through blister.

Caution patient not to break, suck, chew, or swallow buccal tablet.

Instruct patient to place buccal tablet between upper cheek and gum near rear molar until it dissolves, and to swallow remnants with a glass of water after 30 minutes.

Instruct patient to use alternate sides of mouth when taking subsequent doses of buccal tablets.

Tell patient to avoid grapefruit and grapefruit juice while taking drug.

Advise patient not to breastfeed while taking drug.

Caution patient to avoid driving and other hazardous activities until drug’s effects on concentration and alertness are known.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

### fexofenadine hydrochloride

**Pharmacologic class:** Peripherally selective piperidine, selective histamine₁-receptor antagonist

**Therapeutic class:** Antihistamine (nonsedating type), second-generation

**Pregnancy risk category C**

**Action**

Blocks effects of histamine at peripheral histamine₁-receptor sites, decreasing allergy signs and symptoms

**Availability**

- Capsules: 60 mg
- Oral suspension: 30 mg/5 ml (6 mg/ml)
- Tablets: 30 mg, 60 mg, 180 mg
- Tablets (orally disintegrating): 30 mg

**Indications and dosages**

- **Seasonal allergic rhinitis; chronic idiopathic urticaria**
  - Adults and children age 12 and older: 60 mg P.O. b.i.d. or 180 mg once daily (conventional tablets)
  - Children ages 6 to 11: 30 mg P.O. b.i.d (conventional tablets or ODT tablets)
  - **Seasonal allergic rhinitis**
  - Children ages 2 to 11: 30 mg P.O. b.i.d. (oral suspension and ODT)
  - **Chronic idiopathic urticaria**
Children ages 6 months to less than 2 years: 15 mg P.O. b.i.d. (oral suspension and ODT)

**Dosage adjustment**
- Renal impairment

**Contraindications**
- Hypersensitivity to drug, terfenadine, or their components

**Precautions**
Use cautiously in:
- renal impairment
- concurrent ketoconazole or erythromycin therapy
- elderly patients
- pregnant or breastfeeding patients.

**Administration**
- Give capsules and conventional tablets with water; don’t give with apple, orange, or grapefruit juice.
- Don’t remove orally disintegrating tablets from original blister package until time of administration.
- Administer orally disintegrating tablets on an empty stomach; allow tablets to disintegrate on the tongue and then have patient swallow tablets with or without water.
- Don’t break or use partial orally disintegrating tablets
- Know that orally disintegrating tablets contain phenylalanine.
- Don’t give antacids within 2 hours of fexofenadine.

**Adverse reactions**

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Within 1 hr</td>
<td>2-3 hr</td>
<td>12-24 hr</td>
</tr>
</tbody>
</table>

CNS: drowsiness, fatigue, headache
EENT: otitis media
GI: nausea, dyspepsia
Metabolic: dysmenorrhea
Respiratory: upper respiratory tract infection
Other: viral infection

**Interactions**

**Drug-drug.** Antacids containing aluminum and magnesium: decreased absorption and efficacy of fexofenadine

**Drug-diagnostic tests.** Skin allergy tests: false-negative results

**Drug-food.** Apple, orange, and grapefruit juice: decreased absorption and efficacy of fexofenadine

**Patient monitoring**
- Monitor renal function.
- Watch for signs and symptoms of viral infection.

**Patient teaching**
- Instruct patient to take conventional tablets with water, and not with apple, orange, or grapefruit juice.
- Instruct patient not to remove orally disintegrating tablets from original blister package until time of administration.
- Instruct patient to take orally disintegrating tablets on an empty stomach at least 1 hour before or 2 hours after a meal, to allow tablet to disintegrate on the tongue, and then to swallow with or without water. Advise patient not to chew tablets.
- Tell patient not to break or use partial orally disintegrating tablets.
- Tell patient to stop taking drug 4 days before diagnostic skin tests, to avoid interference with test results.
- Advise patient to report signs or symptoms of viral infection, especially upper respiratory tract infection.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Advise female patient to inform prescriber if she is pregnant or breastfeeding.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.
filgrastim
Neupogen

**Pharmacologic class:** Granulocyte colony–stimulating factor

**Therapeutic class:** Hematopoietic stimulator, antineutropenic

**Pregnancy risk category C**

**Action**
Induces formation of neutrophil progenitor cells by binding directly to receptor on surface granulocyte, stimulating cell proliferation and differentiation. Also potentiates effects of mature neutrophils and reduces fever and risk of infection associated with severe neutropenia.

**Availability**
*SingleJect prefilled syringes:* 300 mcg, 480 mcg
*Vial for injection:* 300 mcg/ml, 480 mcg/1.6 ml

**Indications and dosages**
➢ To prevent infection after myelosuppressive chemotherapy

**Adults:** 5 mcg/kg/day by subcutaneous injection or I.V. infusion over 15 to 30 minutes, or continuous subcutaneous or continuous I.V. infusion, increased by 5 mcg/kg with each chemotherapy cycle if needed

➢ Neutropenia after bone marrow transplantation

**Adults:** 10 mcg/kg/day I.V. over 4 or 24 hours or as a continuous subcutaneous infusion over 24 hours

➢ To enhance peripheral blood progenitor cell collection in autologous hematopoietic stem cell transplantation

**Adults:** 10 mcg/kg/day by subcutaneous injection or as continuous subcutaneous infusion, starting 4 days before first leukapheresis procedure and continuing until last day of leukapheresis

➢ Neutropenia in congenital neutropenia

**Adults:** 6 mcg/kg subcutaneously b.i.d.

➢ Neutropenia in idiopathic or cyclic neutropenia

**Adults:** 5 mcg/kg/day subcutaneously

**Off-label uses**
- AIDS
- Aplastic anemia
- Hairy cell leukemia
- Myelodysplasia

**Contraindications**
- Hypersensitivity to drug, its components, or *Escherichia coli*–derived proteins

**Precautions**
Use cautiously in:
- patients receiving lithium or other drugs that can potentiate neutrophil release
- breastfeeding patients.

**Administration**
- Know that drug may be injected into venous return line of dialysis tubing after dialysis is completed.

➢ To dilute for I.V. administration, use dextrose 5% in water. Never use saline solution, because it may cause drug to precipitate.
- Administer single dose intermittently over 15 to 30 minutes or by continuous infusion over 4 to 24 hours.
- Don’t mix with other drugs, and don’t shake.
- Don’t give within 24 hours of chemotherapy, bone marrow transplantation, or radiation therapy.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>5-60 min</td>
<td>24 hr</td>
<td>1-7 days</td>
</tr>
<tr>
<td>Subcut.</td>
<td>5-60 min</td>
<td>2-8 hr</td>
<td>1-7 days</td>
</tr>
</tbody>
</table>

Canada UK Hazardous drug High alert drug
Adverse reactions
CNS: headache, weakness
CV: chest pain, hypotension, transient supraventricular tachycardia, myocardial infarction, arrhythmias
EENT: sore throat
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, splenomegaly, stomatitis
GU: bleeding
Hematologic: leukocytosis, sickle cell crisis, thrombocytopenia, splenic rupture
Metabolic: hyperuricemia
Musculoskeletal: bone, joint, muscle, arm, or leg pain
Respiratory: dyspnea, cough
Skin: pruritus, rash, erythema, alopecia, cutaneous necrotic vasculitis
Other: fever, mucositis, pain at injection site, edema, hypersensitivity reactions

Interactions
Drug-drug. Lithium: increased neutrophil production
Topotecan: prolonged neutropenia
Vincristine: increased risk of severe atypical peripheral neuropathy
Drug-diagnostic tests. Alkaline phosphatase, creatinine, lactate dehydrogenase, uric acid: increased levels
Platelets: decreased count

Patient monitoring
- Obtain CBC with platelet count before starting therapy; monitor these counts often thereafter.
- Monitor cardiovascular status carefully.
- Assess for signs and symptoms of sickle cell crisis and splenic rupture.

Patient teaching
- Teach patient how to recognize and promptly report signs and symptoms of allergic response.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Advise patient to discuss possible need for iron supplements, vitamin B₁₂, and folic acid with prescriber.
- Teach patient how to monitor blood pressure at home.
- Advise patient to minimize GI upset by eating small, frequent servings of food and drinking adequate fluids.
- Tell female patient to inform prescriber if she is breastfeeding.
- Inform patient that he’ll undergo regular blood testing during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

finasteride
Propecia, Proscar

Pharmacologic class: Androgen inhibitor
Therapeutic class: Sex hormone, hair regrowth stimulant
Pregnancy risk category X

Action
Suppresses dihydrotestosterone levels by inhibiting the hepatic enzyme 5-alpha reductase, which converts testosterone to dihydrotestosterone in prostate, liver, and skin

Availability
Tablets: 1 mg (Propecia), 5 mg (Proscar)

Indications and dosages
- Symptomatic benign prostatic hypertrophy (BPH)
  Adults: 5 mg P.O. daily
- To reduce risk of progression of BPH symptoms
  Adults: 5 mg P.O. daily (Proscar) given with doxazosin

Reactions in bold are life-threatening.
Male-pattern baldness

Adults: 1 mg P.O. daily

Off-label uses
- Acne in women
- Hirsutism

Contraindications
- Hypersensitivity to drug
- Females
- Children

Precautions
Use cautiously in:
- hepatic impairment, obstructive uropathy.

Administration
- Give with or without food.
- Know that female patients who are or may be pregnant shouldn’t handle crushed or broken tablets. (Tablets are coated, so handling of intact tablets doesn’t pose a problem.)

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O. (BPH)</td>
<td>Unknown</td>
<td>8 hr</td>
<td>24 hr</td>
</tr>
<tr>
<td>P.O. (baldness)</td>
<td>3 mo</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, headache, asthenia
EENT: lip swelling
GU: erectile dysfunction, decreased ejaculate volume, decreased libido, testicular pain, gynecomastia
Musculoskeletal: back pain
Skin: rash

Interactions
Drug-drug. *Theophylline*: increased theophylline clearance
Drug-diagnostic tests. *Prostate-specific antigen (PSA)*: 50% decrease

Patient monitoring
- Carefully evaluate sustained PSA increases during therapy.
- Monitor fluid intake and output closely.

Patient teaching
- Tell patient he may take drug with or without food.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Inform patient that he may experience erectile dysfunction and decreased ejaculate. Advise him to discuss these issues with prescriber.
- Caution female caregiver or companion who is or may be pregnant not to handle crushed or broken tablets.
- Tell patient he may need at least 6 months of therapy for BPH treatment and at least 3 months to see improvement in male-pattern baldness.
- Inform patient with BPH that he’ll undergo periodic digital rectal exams.
- Instruct patient not to donate blood for at least 1 month after last dose.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and tests mentioned above.
Drug isn’t recommended for patients with chronic atrial fibrillation.

Patients who received drug for atrial flutter have experienced 1:1 atrioventricular conduction. Paradoxical increase in ventricular rate also may occur in patients with atrial fibrillation who receive drug.

Action
Inhibits fast sodium channels of myocardial cell membrane. Also slows conduction, shortens action potential, stops paroxysmal reentrant supraventricular tachycardia, and decreases conduction in accessory pathways in Wolff-Parkinson-White syndrome.

Availability
Tablets: 50 mg, 100 mg, 150 mg

Indications and dosages

> Supraventricular tachyarrhythmias (including paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation or flutter)

Adults: Initially, 50 mg P.O. q 12 hours, increased by 50 mg b.i.d. q 4 days until desired response occurs or maximum daily dosage of 300 mg is reached.

> Sustained, life-threatening ventricular tachycardia

Adults: Initially, 100 mg P.O. q 12 hours, increased by 50 mg b.i.d. q 4 days until desired response occurs or maximum daily dosage of 400 mg is reached.

Dosage adjustment
• Heart failure
• Renal impairment

Off-label uses
• Ventricular arrhythmias
• Wolff-Parkinson-White syndrome

Contraindications
• Hypersensitivity to drug
• Preexisting atrioventricular block or right bundle-branch block

• Recent MI
• Cardiogenic shock

Precautions
Use cautiously in:
• heart failure, renal impairment
• patients taking concurrent amiodarone, beta-adrenergic blockers, disopyramide, or verapamil
• pregnant or breastfeeding patients
• children (safety not established).

Administration
• Initiate therapy only in hospital setting with trained personnel and continuous ECG monitoring.
• Before giving, correct hypokalemia or hyperkalemia.
• Be aware that dosage may be reduced once arrhythmias have been adequately controlled.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2-3 hr</td>
<td>12 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, anxiety, fatigue, headache, depression, malaise, tremor, weakness, hypoesthesia, paresthesia
CV: chest pain, palpitations, second- or third-degree heart block, heart failure, new or worsening arrhythmias
EENT: blurred vision, visual disturbances, corneal deposits
GI: nausea, vomiting, constipation, abdominal pain, dyspepsia, anorexia
Hepatic: hepatitis
Respiratory: dyspnea
Skin: rash, diaphoresis
Other: edema, fever

Interactions
Drug-drug. Acidifying drugs: increased renal elimination, decreased efficacy of flecainide (with urine pH below 5)
Alkalizing drugs: increased flecainide blood level, possible toxicity
Amiodarone: doubling of flecainide blood level

Reactions in bold are life-threatening.
Beta-adrenergic blockers: increased blood levels of both drugs
Beta-adrenergic blockers, disopyramide, verapamil: additive myocardial depressant effect
Digoxin: 15% to 25% increase in digoxin blood level
Other antiarrhythmics (including calcium channel blockers): increased risk of arrhythmias

Drug-diagnostic tests. Alkaline phosphatase: increased level (with prolonged therapy)

Drug-food. Foods that decrease urine pH below 5 (such as acidic juices): increased renal elimination and possibly decreased efficacy of drug
Foods that increase urine pH above 7 (as in strict vegetarian diets): increased drug blood level

Drug-behaviors. Smoking: increased plasma clearance and decreased efficacy of drug

Patient monitoring
- Monitor ECG for worsening arrhythmias.
- Measure pacing threshold 1 week before therapy starts and again after 1 week of therapy.
- Monitor potassium and flecainide blood levels.
- Assess respiratory status regularly.
- Monitor hepatic function tests.

Patient teaching
- Instruct patient to immediately report cardiac or respiratory symptoms, unusual tiredness, or yellowing of skin or eyes.
- Tell patient drug may cause numbness. Advise him to avoid injury to areas with sensory impairment.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, alertness, and vision.
- Advise patient to minimize GI upset by eating small, frequent servings of food and drinking adequate fluids.
- Tell female patient to inform prescriber if she is pregnant or breastfeeding.
- Inform patient that he’ll undergo regular blood testing during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and behaviors mentioned above.

fluconazole


Pharmacologic class: Synthetic azole
Therapeutic class: Systemic antifungal
Pregnancy risk category C

Action
Alters cellular membrane, increasing permeability and leakage of essential elements needed for fungal growth. At higher concentrations, may be fungicidal.

Availability
Injection: 2 mg/ml in 100- or 200-ml bottles or containers
Powder for oral suspension: 50 mg/5 ml in 35-ml bottle, 200 mg/5 ml in 35-ml bottle
Tablets: 50 mg, 100 mg, 150 mg, 200 mg

Indications and dosages
Oropharyngeal candidiasis
Adults: 200 mg P.O. or I.V. on first day, followed by 100 mg/day for at least 2 weeks
Children: 6 mg/kg P.O. or I.V. on first day, followed by 3 mg/kg/day for at least 2 weeks

➤ Esophageal candidiasis

Adults: 200 mg P.O. or I.V. on first day, followed by 100 mg/day for 3 weeks and then for 2 weeks after symptom resolution. Up to 400 mg/day may be used in severe cases.

Children: 6 mg/kg P.O. or I.V. on first day, followed by 3 mg/kg/day for at least 2 weeks after symptom resolution

➤ Candidal urinary tract infection; peritonitis

Adults: 50 to 200 mg P.O. or I.V. daily

➤ Systemic candidiasis

Adults: 400 mg P.O. or I.V. on first day, followed by 200 mg/day for 4 weeks and for at least 2 weeks after symptom resolution

Children: 6 to 12 mg/kg/day P.O. or I.V.

➤ Vaginal candidiasis

Adults: 150 mg P.O. as a single dose

➤ Cryptococcal meningitis

Adults: 400 mg P.O. or I.V. on first day, followed by 200 or 400 mg/day for 10 to 12 weeks after cerebrospinal fluid (CSF) is negative

➤ Suppression of cryptococcal meningitis in patients with AIDS

Adults: 200 mg/day P.O. or I.V.

➤ To prevent candidiasis after bone marrow transplantation

Adults: 400 mg/day P.O. or I.V. for several days before and 7 days after neutrophil count rises above 1,000 cells/mm³

Dosage adjustment

• Renal impairment
• Elderly patients

Contraindications

• Hypersensitivity to drug or its components

Precautions

Use cautiously in:

• hypersensitivity to other azole antifungals
• renal impairment or hepatic disease
• potentially proarrhythmic conditions
• pregnant or breastfeeding patients
• children younger than 6 months.

Administration

➤ Limit single I.V. infusion to 200 mg/hour or less, using infusion pump.
• Don’t piggyback with other I.V. infusions.
• Keep overwrap on I.V. bag until just before use.
• Know that plastic container may be opaque (from moisture absorbed during sterilization). This doesn’t affect drug and will decrease over time.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Slow</td>
<td>1-2 hr</td>
<td>2-4 days</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>1 hr</td>
<td>2-4 days</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: headache, dizziness
CV: QT interval prolongation, torsades de pointes
GI: nausea, vomiting, diarrhea, dyspepsia, abdominal discomfort
Hematologic: leukopenia, thrombocytopenia
Hepatic: hepatotoxicity
Skin: rash, pruritus, exfoliative skin disorders (including Stevens-Johnson syndrome)
Other: altered taste, anaphylaxis

Interactions

Drug-drug. Alfentanil, cyclosporine, phenytoin, rifabutin, tacrolimus, theophylline, zidovudine: increased blood levels of these drugs, greater risk of toxicity
Benzodiazepines, buspirone, losartan, nisoldipine, tricyclic antidepressants, zolpidem: increased blood levels and effects of these drugs

Reactions in bold are life-threatening.
CYP3A4 inducers: inhibited CYP3A4 enzyme system, altered actions of CYP3A4 inducers (with fluconazole dosages above 200 mg/day)
Glipizide, glyburide, tolbutamide: increased hypoglycemic effect of these drugs
Rifampin: increased rifampin blood level, decreased fluconazole blood level
Thiazide diuretics: increased fluconazole blood level
Warfarin: increased warfarin activity

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, bilirubin, gamma-glutamyltransferase, hepatic enzymes: increased levels Platelets, white blood cells: decreased counts

Patient monitoring
● Stay alert for signs and symptoms of anaphylaxis. Stop drug immediately if these occur.
● Monitor liver function test results and hematologic studies.
● Assess for rash; if lesions develop, monitor patient. Stop drug and notify prescriber if lesions progress (may signal Stevens-Johnson syndrome).
● Be aware that patients with human immunodeficiency virus have greater risk of adverse reactions.

Patient teaching
● Teach patient how to recognize and immediately report signs and symptoms of allergic response.
● Urge patient to contact prescriber if rash occurs, to determine whether Stevens-Johnson syndrome is developing.
● Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
● Advise patient to minimize GI upset by eating frequent, small servings of food and drinking adequate fluids.

● Tell female patient to inform prescriber if she is pregnant or breastfeeding.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

flucytosine
Ancobon, Ancotil®

Pharmacologic class: Fluorinated pyrimidine analog
Therapeutic class: Antifungal
Pregnancy risk category C

FDA BOXED WARNING
● Use with extreme caution in renal impairment. Closely monitor hematologic, renal, and hepatic status of all patients. Review instructions thoroughly before administration.

Action
Unclear. Thought to interfere with protein synthesis in cells of susceptible fungi after conversion to fluorouracil.

Availability
Capsules: 250 mg, 500 mg

Indications and dosages
Severe fungal infections caused by susceptible strains of Candida species (including septicemia, endocarditis, urinary tract infections [UTIs]), and pulmonary infections and Cryptococcus species (including meningitis, pulmonary infections, and UTIs)
Adults: 50 to 150 mg/kg P.O. daily in four equally divided doses q 6 hours
Dosage adjustment
- Renal impairment (glomerular filtration rate below 50 ml/minute)

Off-label uses
- Chromomycosis

Contraindications
- Hypersensitivity to drug or other antifungals

Precautions
Use cautiously in:
- renal impairment, underlying hepatic disease, bone marrow depression
- pregnant or breastfeeding patients
- children (safety not established).

Administration
- Give capsules a few at a time over 15 minutes to minimize nausea and vomiting.
- Know that drug is rarely used alone. Expect to give another antifungal or amphotericin B concurrently.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Variable</td>
<td>2 hr</td>
<td>10-12 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, dizziness, confusion, hallucinations, vertigo, psychosis, ataxia, paresthesia, parkinsonism, peripheral neuropathy
CV: chest pain, cardiac arrest
EENT: hearing loss
GI: nausea, vomiting, diarrhea, dyspepsia, ulcerative colitis, abdominal discomfort, anorexia, duodenal ulcer, hemorrhage
GU: azotemia, crystalluria, renal failure
Hematologic: eosinophilia, anemia, leukopenia, aplastic anemia, thrombocytopenia, bone marrow depression, agranulocytosis
Hepatic: jaundice
Metabolic: hypokalemia, hypoglycemia
Respiratory: dyspnea, respiratory arrest
Skin: rash, pruritus, urticaria, photosensitivity

Reactions in bold are life-threatening.

Interactions
Drug-drug. Amphotericin B: synergistic effects, increased risk of toxicity
Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, gamma-glutamyltransferase: increased levels
Glucose, granulocytes, hemoglobin, platelets, potassium, white blood cells: decreased levels

Patient monitoring
- Monitor kidney and liver function test results.
- Carefully monitor blood glucose level and hematologic test results.
- Assess for serious cardiovascular, renal, respiratory, and hematologic adverse reactions.
- Evaluate electrolyte levels, particularly potassium.
- Assess for signs and symptoms of bleeding.

Patient teaching
- Advise patient to take capsules over 15-minute period to reduce GI upset.
- Instruct patient to immediately report unusual bleeding or bruising.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Instruct patient to minimize GI upset by eating frequent, small servings of food and drinking adequate fluids.
- Advise female patient to inform prescriber if she is pregnant or breastfeeding.
- Tell patient he’ll undergo regular blood testing during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Clinical alert
flunisolide

APO-Flunisolide®, Nasarel, PMS-Flunisolide®, Ratio-Flunisolide®, Rhinalar Nasal Mist®

Pharmacologic class: Intranasal steroid
Therapeutic class: Respiratory inhalant
Pregnancy risk category C

Action
Unknown. Thought to diminish capillary permeability and suppress migration of polymorphonuclear leukocytes, decreasing inflammation.

Availability
Spray solution: 25 ml (each actuation delivers approximately 25 mcg)

Indications and dosages
➣ Relief of seasonal or perennial rhinitis

Adults: Two sprays in each nostril b.i.d.; may increase to two sprays in each nostril t.i.d. Maximum daily dose is eight sprays in each nostril. For maintenance, after desired clinical effect occurs, reduce dosage to smallest amount needed to control symptoms.

Children ages 6 to 14: One spray in each nostril t.i.d. or two sprays in each nostril b.i.d.; maximum daily dose is four sprays in each nostril. For maintenance, after desired clinical effect occurs, reduce dosage to smallest amount needed to control symptoms.

Contraindications
• Hypersensitivity to drug or its components
• Untreated local infections of nasal mucosa

Precautions
Use cautiously in:

• localized Candida albicans infection; tuberculosis; untreated fungal, bacterial, or systemic viral infections; ocular herpes simplex
• patients receiving immunosuppressive therapy.

Administration
• Don’t increase dosage or discontinue drug abruptly.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhalation</td>
<td>Unknown</td>
<td>10-30 min</td>
<td>Unknown (nasal)</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, light-headedness, nervousness, dizziness
EENT: cataracts; glaucoma; blurred vision; conjunctivitis; increased intraocular pressure; lacrimation; dry, irritated eyes; tinnitus; otitis; otitis media; rhinorrhea; rhinitis; nasal irritation, burning, and dryness; nasal stuffiness and pain; sneezing; nasal ulcer; epistaxis; localized Candida albicans nasal infections; nasal mucosa ulcerations; nasal septum perforation; throat discomfort, soreness, and dryness; mild nasopharyngeal irritation; pharyngitis; dry mucous membranes; nasal and sinus congestion; sinusitis; hoarseness, voice changes
GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia, dry mouth
Metabolic: hyperadrenocorticism
Musculoskeletal: myalgia, arthralgia, aseptic necrosis of femoral head
Respiratory: wheezing, dyspnea, increased cough, bronchitis, bronchospasm, asthma symptoms
Skin: rash, pruritus, urticaria, contact dermatitis, alopecia, herpes simplex infection
Other: altered taste and smell, facial edema, fever, flulike symptoms, aches and pains, infections, angioedema, anaphylaxis

Canada UK Hazardous drug High alert drug
**Interactions**

**Drug-diagnostic tests.** *Aspartate aminotransferase:* increased level

**Patient monitoring**

- Monitor patient closely for serious adverse reactions, including anaphylaxis, angioedema, hyperadrenocorticism, and serious infections.

**Patient teaching**

- Teach patient to recognize and immediately report serious adverse reactions.
- Teach patient proper use of drug. Caution him not to use more than prescribed amount; doing so may cause serious side effects.
- Tell patient maximum drug effects may not occur for several weeks.
- Tell patient to avoid people with measles, chickenpox, and other transmissible infections.
- Caution patient to withhold dose and contact prescriber if infection occurs.
- Instruct female patient to tell prescriber if she becomes pregnant.
- Tell female patient not to breastfeed without consulting prescriber.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

**FLOXURACIL**

(5-fluorouracil, 5-FU)

*Adrucil, Efudex, Fluoroplex*

**Pharmacologic class:** Antimetabolite

**Therapeutic class:** Antineoplastic

**Pregnancy risk category D**

**FDA BOXED WARNING**

- Patient should be hospitalized during first course of treatment, as drug may cause severe toxic reactions.

**Action**

Inhibits DNA and RNA synthesis, leading to death of rapid-growing neoplastic cells. Cell-cycle–S-phase specific.

**Availability**

- **Cream:** 1%, 5%
- **Injection:** 50 mg/ml in 10-ml ampules and 10-, 20-, and 100-ml vials
- **Solution:** 1%, 2%, 5%

**Indications and dosages**

- **Advanced colorectal cancer**
  - **Adults:** 370 mg/m² I.V. for 5 days, preceded by leucovorin 200 mg/m² daily for 5 days; may be repeated q 4 to 5 weeks. No single daily dose should exceed 800 mg.
  - **Colon, rectal, breast, gastric, and pancreatic cancer**
    - **Adults:** Initially, 12 mg/kg/day I.V. for 4 days; then 6 mg/kg I.V. on days 6, 8, 10, and 12. Maximum dosage is 800 mg/day. For maintenance, start 30 days after last dose. If no toxicity, use dosage from first course. If toxicity occurs, give 10 to 15 mg/kg/week as single dose after toxicity subsides. Don’t exceed 1 g/week.
  - **Actinic (solar) keratoses**
    - **Adults:** 1% solution or cream applied once or twice daily to lesions on head, neck, or chest; 2% to 5% solution or cream may be needed for other areas.
  - **Superficial basal cell carcinoma**
    - **Adults:** 5% solution or cream applied b.i.d. for 3 to 6 weeks (up to 12 weeks)

**Contraindications**

- Hypersensitivity to drug or its components
- Bone marrow depression

Reactions in **bold** are life-threatening.
• Dihydropyrimidine dehydrogenase enzyme deficiency (with topical route)
• Poor nutritional status
• Serious infection
• Pregnancy or breastfeeding

Precautions
Use cautiously in:
• renal or hepatic impairment, infections, edema, ascites
• obese patients.

Administration

Consult facility’s cancer protocols to ensure correct dosage, administration technique, and cycle length.
• Give antiemetic before fluorouracil, as ordered, to reduce GI upset.
• Know that drug may be given without dilution by direct I.V. injection over 1 to 3 minutes.
• For I.V. infusion, dilute with dextrose 5% in water, sterile water, or normal saline solution in plastic bag (not glass bottle). Infusion may be given over a period of 24 hours or more.

Be aware of the importance of leucovorin rescue with fluorouracil therapy, if prescribed.
• Check infusion site frequently to detect extravasation.
• Use nonmetal applicator or appropriate gloves to apply topical form.
• Avoid applying topical form to mucous membranes or irritated skin.
• Don’t use occlusive dressings over topical form.
• Know that pyridoxine may be given with fluorouracil to reduce risk of palmar-plantar erythrodysesthesia (hand-foot syndrome).

Route Onset Peak Duration
I.V. 1-9 days 9-21 days 30 days
Topical Unknown Unknown Unknown

Adverse reactions
CNS: confusion, disorientation, euphoria, ataxia, headache, weakness, malaise, acute cerebellar syndrome or dysfunction
CV: angina, myocardial ischemia, thrombophlebitis
EENT: vision changes, photophobia, lacrimation, lacrimal duct stenosis, nystagmus, epistaxis
GI: nausea, vomiting, diarrhea, stomatitis, anorexia, GI ulcer, GI bleeding
Hematologic: anemia, leukopenia, thrombocytopenia
Skin: alopecia, maculopapular rash, melanosis of nails, nail loss, palmar-plantar erythrodysesthesia, photosensitivity, local inflammation reaction (with cream), dermatitis
Other: fever, anaphylaxis

Interactions
Drug-drug. Bone marrow depressants (including other antineoplastics): additive bone marrow depression
Irinotecan: dehydration, neutropenia, sepsis
Leucovorin calcium: increased risk of fluorouracil toxicity
Live-virus vaccines: decreased antibody response to vaccine, increased risk of adverse reactions
Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, lactate dehydrogenase, urinary 5-hydroxyindoleacetic acid: increased levels
Albumin, granulocytes, platelets, red blood cells, white blood cells (WBCs): decreased levels

Drug-behaviors. Sun exposure: increased risk of phototoxicity

Patient monitoring
Watch for signs and symptoms of toxicity, especially stomatitis and diarrhea. If these occur, stop drug and notify prescriber. Note that toxicity may take 1 to 3 weeks to develop.
• Monitor CBC, WBC and platelet counts, and kidney and liver function test results.
● Assess fluid intake and output.
● With long-term use, watch for serious rash on hands and feet. If it occurs, consult prescriber regarding need for pyridoxine.
● Assess for bleeding tendency.
● Monitor blood glucose level in patients at risk for hyperglycemia.

**Patient teaching**

- Emphasize importance of taking leucovorin as prescribed with high-dose therapy.
- Instruct patient to report signs and symptoms of toxicity, particularly stomatitis and diarrhea. Tell him that these may not occur for 1 to 3 weeks.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Tell patient to avoid activities that can cause injury. Instruct him to use soft toothbrush and electric razor to avoid gum and skin injury.
- Advise patient to minimize GI upset by eating frequent, small servings of food and drinking adequate fluids.
- Tell patient that drug may cause reversible hair loss.
- Inform patient that he’ll undergo regular blood testing during therapy.
- Advise female to inform prescriber immediately if she is pregnant. Caution her not to breastfeed.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

**FDA BOXED WARNING**

- Drug may increase risk of suicidal thinking and behavior in children and adolescents with major depressive disorder (MDD) and other psychiatric disorders, especially during first few months of therapy. Risk must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family and caregivers to observe patient closely and communicate with prescriber as needed.
- Prozac is approved for use in pediatric patients with MDD and obsessive-compulsive disorder.

**Action**

Selectively inhibits serotonin reuptake in CNS; has little to no effect on norepinephrine and dopamine reuptake.

**Availability**

- **Capsules:** 10 mg, 20 mg, 40 mg
- **Capsules (delayed-release):** 90 mg
- **Oral solution:** 20 mg/5 ml
- **Tablets:** 10 mg

**Indications and dosages**

- Depression; obsessive-compulsive disorder

**Adults:** 20 mg/day P.O. in morning. After several weeks, may increase by

Reactions in **bold** are life-threatening.
20 mg/day at weekly intervals. Give dosages above 20 mg/day in two divided doses (morning and noon); don’t exceed 80 mg/day. In depression, patients stabilized on 20 mg/day may be switched to 90-mg/week delayed-release capsules (Prozac Weekly) 7 days after last 20-mg dose.

➤ Bulimia nervosa

Adults: 60 mg/day P.O.; may be titrated upward over several days

➤ Premenstrual dysphoric disorder

Adults: 20 mg/day P.O., not to exceed 80 mg/day

➤ Panic disorder

Adults: 10 mg/day P.O. for 1 week; then, if needed, increase to 20 mg/day. Dosage increases of up to 60 mg/day may be considered after several weeks if patient doesn’t respond to lower dosage.

Dosage adjustment

● Hepatic impairment
● Elderly patients

Off-label uses

● Diabetic peripheral neuropathy
● Alcoholism
● Bipolar II disorder
● Borderline personality disorder
● Narcolepsy
● Posttraumatic stress disorder
● Schizophrenia
● Social phobia

Contraindications

● Hypersensitivity to drug
● MAO inhibitor use within past 14 days

Precautions

Use cautiously in:

● hepatic or renal impairment, diabetes mellitus, cardiovascular disease
● history of seizures
● pregnant or breastfeeding patients.

Administration

⚠ Be aware that drug should be discontinued 5 weeks before MAO inhibitor therapy begins.

• Give before 2 P.M. to prevent nighttime insomnia.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>6-8 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: anxiety, drowsiness, headache, insomnia, abnormal dreams, dizziness, fatigue, nervousness, hypomania, mania, weakness, tremor, seizures, suicidal ideation

CV: chest pain, palpitations, prolonged QTc interval

EENT: visual disturbances, stuffy nose, sinusitis, pharyngitis

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, dry mouth, anorexia

GU: urinary frequency, sexual dysfunction, dysmenorrhea

Metabolic: hypouricemia, hypocalcemia, hyponatremia, hyperglycemia, hypoglycemia

Musculoskeletal: joint, back, or muscle pain

Respiratory: cough, upper respiratory tract infection, dyspnea, respiratory distress

Skin: diaphoresis, pruritus, erythema nodosum, flushing, rash

Other: abnormal taste, weight loss, fever, flulike symptoms, hot flashes, allergic reactions, hypersensitivity reactions

Interactions

Drug-drug. Adrenergics: increased sensitivity to adrenergics, increased risk of serotonin syndrome

Alprazolam: decreased metabolism and increased effects of alprazolam

Antihistamines, opioids, other antidepressants, sedative-hypnotics: additive CNS depression

Buspirone: potentiation of fluoxetine effects, increased risk of seizures

482 fluoxetine hydrochloride
Carbamazepine, clozapine, digoxin, haloperidol, lithium, phenytoin, warfarin: increased blood levels of these drugs, greater risk of adverse reactions

CYP450-2D6 inducers: increased effects of these drugs

Cyproheptadine: decrease in or reversal of fluoxetine effects

Digoxin, warfarin, other highly protein-bound drugs: increased risk of adverse reactions to either drug

Efavirenz, ritonavir, saquinavir, other CYP450 inhibitors: increased risk of serotonin syndrome

MAO inhibitors: confusion, agitation, seizures, hypertension, and hyperpyrexia (serotonin syndrome)

Other antidepressants, phenothiazines, risperidone, tryptophan: increased risk of adverse reactions

Ritonavir: increased ritonavir blood level

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, blood urea nitrogen, creatine kinase, electrolytes, glucose: increased levels

Drug-herbs. S-adenosylmethionine (SAM-e), St. John’s wort: increased risk of serotonin syndrome

Drug-behaviors. Alcohol use: additive CNS depression

Patient monitoring

- Monitor patient for signs and symptoms of depression. Assess for suicidal ideation.
- Evaluate neurologic status, watching especially for seizures.
- Monitor cardiovascular status, particularly for prolonged QTc interval.
- Assess weight regularly. Watch for signs of eating disorders.

Patient teaching

- Encourage patient to establish effective bedtime routine to minimize sleep disorders.
- Tell patient drug may take 4 weeks or longer to be fully effective.

Reactions in bold are life-threatening.

Instruct patient to contact prescriber if he develops worsening depression or has suicidal thoughts.

- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Instruct patient to minimize adverse GI effects by eating frequent, small servings of healthy food and drinking adequate fluids.
- Advise patient to discuss anti-itching medicines with prescriber if rash develops.
- Tell female patient to inform prescriber if she is pregnant or breastfeeding.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

fluphenazine decanoate
Fluphenazine Omega®, Modecate, Modecate®

fluphenazine hydrochloride
Apo-Fluphenazine®, Moditen®, PMS-Fluphenazine®

Pharmacologic class: Phenothiazine, dopaminergic blocker

Therapeutic class: Anxiolytic, antipsychotic

Pregnancy risk category C

Action
Unclear. May alter postsynaptic mesolimbic dopamine receptors in brain and reduce release of hypothalamic and hypophysal hormones thought to depress reticular activating system, thereby preventing psychotic symptoms.
Availability
fluphenazine decanoate
Depot injection: 25 mg/ml
fluphenazine hydrochloride
Elixir: 2.5 mg/5 ml
Injection: 2.5 mg/ml
Oral concentrate: 5 mg/ml
Tablets: 1 mg, 2.5 mg, 5 mg, 10 mg

Indications and dosages
➣ Psychotic disorders
Adults: 2.5 to 10 mg/day (hydrochloride) P.O. in divided doses q 6 to 8 hours or as a single dose at bedtime; typical daily dosage is 1 to 5 mg; give oral doses above 20 mg/day with caution. Or initially, 1.25 mg I.M., divided and given q 6 to 8 hours. Parenteral hydrochloride dosage is one-third to one-half of oral dosage. Or 12.5 to 25 mg I.M. or subcutaneously (decanoate); base subsequent dosage and dosing intervals of 1 to 4 weeks on patient response; don’t exceed 100 mg.

Dosage adjustment
• Elderly patients

Contraindications
• Hypersensitivity to drug, sulfites (with injectable form), or benzyl alcohol
• Angle-closure glaucoma
• Bone marrow depression
• Severe hepatic or cardiovascular disease

Precautions
Use cautiously in:
• diabetes, respiratory disease, prostatic hypertrophy, CNS tumors
• elderly patients
• pregnant or breastfeeding patients (safety not established)
• children with acute illnesses, infections, gastroenteritis, or dehydration.

Administration
 Emblem Be aware that parenteral form is for I.M. and subcutaneous use only. Don’t give I.V.
• Don’t give parenteral form to comatose or severely depressed patient.
• Use gloves when handling. To prevent contact dermatitis, keep drug away from clothing and skin.
• Dilute concentrated oral forms in juice, milk, or semisolid food just before administering.
• Give long-acting, oil-based preparations with dry needle of at least 21G.
• Be aware that antacids and adsorbent antidiarrheals may decrease adsorption of fluphenazine. Give 1 hour before or 2 hours after fluphenazine.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>&lt;1 hr</td>
<td>0.5 hr</td>
<td>6-8 hr</td>
</tr>
<tr>
<td>I.M. (HCl)</td>
<td>1 hr</td>
<td>1.5-2 hr</td>
<td>6-8 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>24-72 hr</td>
<td>Unknown</td>
<td>1-6 wk</td>
</tr>
<tr>
<td>Subcut.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: drowsiness, sedation, extrapyramidal reactions, tardive dyskinesia, pseudoparkinsonism, neuroleptic malignant syndrome, seizures
CV: hypotension, tachycardia
EENT: blurred vision, dry eyes, lens opacities, nasal congestion
GI: constipation, dry mouth, anorexia, paralytic ileus
GU: urinary retention, menstrual irregularities, inhibited ejaculation, priapism, gynecomastia, lactation
Hematologic: eosinophilia, hemolytic anemia, aplastic anemia, agranulocytosis, leukopenia, thrombocytopenia
Hepatic: jaundice, hepatitis
Metabolic: galactorrhea, hyperthermia
Skin: photosensitivity, rash
Other: allergic reactions, pain at injection site, sterile abscess
Interactions

Drug-drug. Activated charcoal, adsorbent antidiarrheals, antacids: decreased fluphenazine adsorption
Anticholinergics: decreased fluphenazine effects
Antidepressants, antihistamines, general anesthetics, MAO inhibitors, opioid analgesics, sedative-hypnotics: additive CNS depression
Antihistamines, disopyramide, quinidine, tricyclic antidepressants (TCAs): increased risk of anticholinergic effects
Antihypertensives: additive hypotension
Barbiturates: increased fluphenazine metabolism and decreased efficacy
Bromocriptine: decreased bromocriptine efficacy
Guanethidine: inhibition of antihypertensive effects
Lithium: disorientation, unconsciousness, extrapyramidal symptoms
Meperidine: excessive sedation and hypotension
Ofloxacin: increased QTc interval
Phenytoin: increased or decreased phenytoin blood level
Pimozide: increased risk of potentially serious cardiovascular reactions
Propranolol: increased blood levels of both drugs
TCAs: increased blood levels and effects of TCAs

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin: increased levels
Granulocytes, hematocrit, hemoglobin, leukocytes, platelets: decreased values
Pregnancy tests: false-positive or false-negative result
Urine bilirubin: false-positive result

Drug-behaviors. Alcohol use: increased CNS depression
Sun exposure: increased risk of photosensitivity

Patient monitoring

Monitor patient for signs and symptoms of neuroleptic malignant syndrome (extrapyramidal symptoms, hyperthermia, autonomic symptoms).
Stop giving drug and notify prescriber immediately if patient shows signs or symptoms of blood dyscrasias (fever, infection, sore throat, cellulitis, or weakness).
• Observe for tardive dyskinesia.
• Watch for bleeding tendency.
• Monitor CBC, bilirubin level, and liver function test results.
• Assess kidney function and ophthalmic test results in patients on long-term therapy.

Patient teaching
Tell patient not to stop taking drug suddenly, because serious adverse effects may occur.
• Advise patient to report urinary retention or constipation.
Instruct patient to immediately report unusual bleeding or bruising.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, alertness, and vision.
• Tell patient to avoid activities that can cause injury. Advise him to use soft toothbrush and electric razor to avoid gum and skin injury.
• Inform patient that he’ll undergo regular blood testing during therapy.
• Tell female patient to inform prescriber if she is pregnant or breastfeeding.
As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

Reactions in bold are life-threatening.
flurazepam hydrochloride
Apo-Flurazepam®, Bio-Flurazepam, Dalmane, Novo-Flupam®, PMS-Flurazepam®, Somnol®, Som Pam®

Pharmacologic class: Benzodiazepine
Therapeutic class: Sedative-hypnotic
Controlled substance IV
Pregnancy risk category X

Action
Depresses CNS at limbic, thalamic, and hypothalamic levels by enhancing inhibitory neurotransmitter effect of gamma-aminobutyric acid on neuronal excitability

Availability
Capsules: 15 mg, 30 mg

Indications and dosages
➣ Short-term management of insomnia (less than 4 weeks)
Adults: 15 to 30 mg P.O. at bedtime

Dosage adjustment
● Elderly or debilitated patients

Contraindications
● Hypersensitivity to drug or other benzodiazepines
● Preexisting CNS depression
● Angle-closure glaucoma
● Pregnancy or breastfeeding

Precautions
Use cautiously in:
● hepatic dysfunction
● history of suicide attempt or drug dependence
● elderly patients
● children younger than age 15 (safety not established).

Administration
● Before starting therapy, evaluate patient’s mental status and check kidney and liver function tests and CBC.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>15-45 min</td>
<td>0.5-1 hr</td>
<td>7-8 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, daytime drowsiness, headache, lethargy, confusion, poor concentration, depression, paradoxical excitation, ataxia
EENT: blurred vision
GI: nausea, vomiting, diarrhea, constipation, dyspepsia, abdominal pain
Respiratory: sleep apnea
Skin: rash
Other: abnormal taste, hangover, physical or psychological drug dependence, drug tolerance

Interactions
Drug-drug. Antidepressants, antihistamines, opioids: additive CNS depression
Barbiturates, rifampin: increased flurazepam metabolism, decreased efficacy
Cimetidine, disulfiram, fluoxetine, hormonal contraceptives, isoniazid, ketoconazole, metoprolol, propoxyphene, propranolol, valproic acid: decreased flurazepam metabolism, enhanced efficacy
Levodopa: decreased levodopa efficacy
Theophylline: decreased sedative effects of flurazepam

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, total and direct bilirubin: increased levels

Drug-herbs. Chamomile, hops, kava, skullcap, valerian: additive CNS depression

Drug-behaviors. Alcohol use: additive CNS depression
Smoking: increased drug metabolism and clearance
Patient monitoring
- With long-term use, watch for signs and symptoms of physical or psychological dependence.
- Monitor patient’s mental status, especially for depression and suicidal ideation.
- Watch for signs of drug hoarding or overuse.
- Monitor CBC and liver and kidney function tests.

Patient teaching
- Urge patient (and significant other as appropriate) to report signs and symptoms of depression or suicidal thoughts or actions.
- Advise female patient to immediately tell prescriber if she is pregnant. Caution her not to breastfeed.
- Inform patient that drug may cause physical or psychological dependence.
- Advise patient to minimize GI upset by eating frequent, small servings of food and drinking adequate fluids.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

flutamide

**Pharmacologic class:** Antiandrogen  
**Therapeutic class:** Antineoplastic  
**Pregnancy risk category D**

Action
Exerts potent antiandrogenic activity at cellular level by inhibiting androgen uptake or nuclear binding of androgen

Availibility
**Capsules:** 125 mg

Indications and dosages
- Metastatic prostate cancer
  - Adults: 250 mg P.O. t.i.d. q 8 hours, given with luteinizing hormone-releasing hormone (LHRH) analog. Total daily dosage is 750 mg.

Off-label uses
- Benign prostatic hypertrophy

Contraindications
- Hypersensitivity to drug  
- Severe hepatic impairment  
- Sleep apnea  
- Women

Precautions
None

FDA BOXED WARNING
- Postmarketing hospitalizations and deaths from hepatic failure have occurred. Evidence of hepatic injury includes elevated serum transaminase levels, jaundice, hepatic encephalopathy, and death related to acute hepatic failure. In some patients, hepatic injury reversed after drug withdrawal. Approximately half of reported cases occurred within first 3 months of therapy.
- Measure serum transaminase levels before therapy begins. Drug isn’t recommended if alanine aminotransferase (ALT) values exceed twice the upper limit of normal (ULN). Once therapy begins, measure transaminase levels monthly for first 4 months and periodically thereafter. Obtain liver function tests at first sign of hepatic dysfunction. If patient has jaundice or ALT level exceeding 2 x ULN, discontinue drug immediately and follow liver function tests closely until they resolve.

Reactions in **bold** are life-threatening.
Administration

- Be aware that leuprolide acetate is the most common LHRH analog given with flutamide.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Variable</td>
<td>2 hr</td>
<td>72 hr</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: drowsiness, confusion, depression, anxiety, nervousness, paresthesia
CV: peripheral edema, hypertension
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia, dry mouth
GU: erectile dysfunction, loss of libido, gynecomastia, hot flashes
Hematologic: anemia, leukopenia, thrombocytopenia
Hepatic: hepatitis
Skin: rash, photosensitivity

Interactions

Drug-drug. Warfarin: increased prothrombin time
Drug-diagnostic tests. Alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, creatine kinase: increased levels
Hemoglobin, platelets, white blood cells: decreased levels
Drug-herbs. Chaparral, comfrey, eucalyptus, germander, pennyroyal, skullcap, valerian: increased risk of hepatotoxicity
Drug-behaviors. Sun exposure: increased risk of photosensitivity

Patient monitoring

- Monitor CBC and liver function tests.
- Watch for bleeding tendency and signs and symptoms of hepatic damage (jaundice, vomiting, dark yellow or brown urine).
- Monitor blood pressure.

Patient teaching

- Instruct patient to immediately report unusual bleeding or bruising.
- Tell patient to avoid activities that can cause injury. Advise him to use soft toothbrush and electric razor to avoid gum and skin injury.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Instruct patient to minimize GI upset by eating frequent, small servings of healthy food.
- Tell patient he'll undergo regular blood testing during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

fluticasone propionate
Cutivate, Flixonase®, Flixotide®, Flonase, Flovent, Flovent HFA

fluticasone furoate
Avamys®, Veramyst

Pharmacologic class: Corticosteroid
Therapeutic class: Respiratory inhalant (Flovent, Flonase), anti-inflammatory drug (Cutivate)

Pregnancy risk category C

Action
Unknown. Has potent vasoconstrictive and anti-inflammatory properties.

Availability
fluticasone propionate
Inhalation aerosol (Flovent): 44 mcg, 110 mcg, 220 mcg
Nasal spray (Flonase): 50 mcg
Topical cream (Cutivate): 0.005%
Topical ointment (Cutivate): 0.005%

fluticasone furoate
Nasal spray (Veramyst): 27.5 mcg fluticasone furoate in each 50-microliter spray in 10-g bottle containing 120 sprays

Canada UK Hazardous drug High alert drug
**Indications and dosages**

Prophylaxis of asthma (Flovent)

**Adults and children ages 12 and older:** Initial dosage is based on previous therapy (see chart below). Once stability is achieved, titrate to lowest effective dosage.

**Recommended Flovent dosages**

<table>
<thead>
<tr>
<th>Previous therapy</th>
<th>Starting dosage</th>
<th>Maximum dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bronchodilator alone</td>
<td>88 mcg inhaled orally b.i.d.</td>
<td>440 mcg inhaled orally b.i.d.</td>
</tr>
<tr>
<td>Inhaled corticosteroid</td>
<td>88-220 mcg inhaled orally b.i.d.</td>
<td>440 mcg inhaled orally b.i.d.</td>
</tr>
<tr>
<td>Oral corticosteroid</td>
<td>880 mcg inhaled orally b.i.d.</td>
<td>880 mcg inhaled orally b.i.d.</td>
</tr>
</tbody>
</table>

Seasonal and perennial allergic and nonallergic rhinitis (Flonase)

**Adults:** Two sprays in each nostril daily or one spray in each nostril b.i.d. After first few days, may reduce dosage to one spray in each nostril daily; some patients may find p.r.n. use of two sprays in each nostril daily effective for symptom control. Maximum dosage is 200 mcg daily (two sprays in each nostril).

**Adolescents and children ages 4 and older:** Initially, one spray in each nostril daily. If patient doesn’t respond, may increase to two sprays in each nostril. Once adequate control is achieved, reduce dosage to one spray in each nostril daily.

Symptoms of seasonal and perennial allergic rhinitis (Veramyst)

**Adults and adolescents age 12 and older:** 110 mcg (2 sprays per nostril) once daily

**Children ages 2 to 11:** 55 mcg (1 spray per nostril) once daily

Inflammatory and pruritic manifestations of corticosteroid-responsive atopic dermatoses

**Adults and children ages 3 months and older:** Apply thin film of Cutivate cream to affected skin area once or twice daily.

Other corticosteroid-responsive dermatoses

**Adults and children ages 3 months and older:** Apply thin film of Cutivate cream to affected skin area b.i.d.

**Contraindications**

- Hypersensitivity to drug or its components
- Primary treatment of status asthmaticus or other acute asthma episodes necessitating intensive measures (Flovent)
- Severe allergy to milk proteins

**Precautions**

Use cautiously in:

- recurrent epistaxis, recent nasal septal ulcer, nasal surgery, or trauma
- severe hepatic disease (Veramyst)
- glaucoma and cataracts
- tuberculosis; respiratory tract infection; fungal, bacterial, viral, or parasitic infections; ocular herpes simplex
- hypercorticism and adrenal suppression (when used at higher than recommended dosages or in susceptible persons)
- concurrent use of other CYP3A inhibitors (such as ketoconazole; use not recommended with ritonavir)
- *Candida albicans* infection (Veramyst)
- elderly patients (Flonase, Veramyst)
- pregnant or breastfeeding patients (Flovent, Flonase, Veramyst)
- children (Flovent)
- children younger age than 4 (Flonase)
- children younger than age 2 (Veramyst).

**Administration**

- Know that Flonase may cause immediate hypersensitivity reaction (contact dermatitis).

Reactions in **bold** are life-threatening.
Be aware that topical ointment should be used in adults only.

Prime Veramyst nasal spray before first use, when not used for more than 30 days, or if cap has been left off bottle for 5 days or more.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral or nasal</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

### Adverse reactions

**CNS:** Cutivate ointment—light-headedness; Flonase—headache, dizziness; Flovent—headache, dizziness, giddiness; Veramyst—headache

**EENT:** Flonase—cataract, glaucoma, increased intraocular pressure, epistaxis, nasal burning or irritation, bloody nasal mucus, runny nose, pharyngitis; Flovent—nasal congestion, nasal septum perforation, nasal discharge, nasal sinus pain, sinusitis, rhinitis, allergic rhinitis, pharyngitis, dysphonia; Veramyst—cataract, glaucoma, increased intraocular pressure, epistaxis, pharyngolaryngeal pain, nasal ulceration

**GI:** Flonase—nausea, vomiting, diarrhea, abdominal pain; Flovent—nausea, vomiting, diarrhea, dyspepsia, stomach disorder, oral candidiasis

**GU:** Flovent—dysmenorrhea

**Metabolic:** Veramyst—hypercorticism and adrenal suppression

**Musculoskeletal:** Flonase—aches and pains; Flovent—joint pain, limb pain, sprain, strain, aches and pains; Veramyst—back pain

**Respiratory:** Flonase—asthma symptoms, cough, bronchitis, wheezing (rare); Flovent—upper respiratory tract infection, influenza, bronchitis, chest congestion, bronchospasm; Veramyst—cough

**Skin:** Cutivate cream—pruritus, skin dryness, skin burning, erythematous rash, dusky erythema, eczema exacerbation, skin irritation, urticaria; Cutivate ointment—skin burning or irritation, hypertrichosis, increased erythema, hives; Flovent—urticaria, rash, skin eruption

**Other:** Cutivate cream or ointment—numbness of fingers, facial or nonfacial telangiectasia; Flonase—fever, flulike symptoms, hypersensitivity reaction; Flovent—dental problems, fever, immediate or delayed hypersensitivity reactions, angioedema; Veramyst—pyrexia

### Interactions

**Drug-drug.** Ketoconazole, other strong CYP3A inhibitors: increased fluticasone exposure (with Flonase, Flovent, Veramyst)

Ritonavir: increased systemic corticosteroid effects (with Flonase, Flovent, Veramyst)

**Drug-diagnostic tests.** Adrenocorticotrophic hormone stimulation test, plasma cortisol test, urinary free cortisol test: interference with test results

### Patient monitoring

- Monitor patient for withdrawal symptoms after Flovent is discontinued.
- Stay alert for systemic corticosteroid effects when administering Flovent, Flonase, or Veramyst.
- Observe for reduced growth rate in child or adolescent using Flovent, Flonase or Veramyst.
- When giving Flovent, watch for eosinophilic conditions, such as Churg-Strauss syndrome.
- When giving Flonase, assess for epistaxis, wheezing, nasal septum perforation, cataracts, glaucoma, and increased intraocular pressure (rare reaction).
- When giving Veramyst, assess for epistaxis, nasal septum perforation, cataracts, glaucoma, and increased intraocular pressure (rare reaction).

### Patient teaching

- Tell patient to take drug exactly as prescribed.
Teach patient proper use of prescribed form.

Advise patient to immediately report signs of allergic reaction.

Caution patient to avoid exposure to people with chickenpox or measles.

Advise female patient taking Flonase, Flovent, or Veramyst to inform prescriber if she is pregnant or breastfeeding.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

---

**fluvastatin sodium**

Lescol, Lescol XL

**Pharmacologic class:** HMG-CoA reductase inhibitor  
**Therapeutic class:** Antihyperlipidemic  
**Pregnancy risk category X**

**Action**

Competitively inhibits HMG-CoA reductase, an enzyme needed to synthesize cholesterol. This inhibition reduces cholesterol concentration in hepatic cells, which in turn increases synthesis of low-density lipoprotein (LDL) receptors, enhances LDL uptake, and ultimately reduces plasma cholesterol concentration.

**Availability**

*Capsules:* 20 mg, 40 mg  
*Tablets (extended-release):* 80 mg

**Indications and dosages**

> Adjunctive therapy to reduce LDL cholesterol (LDL-C), total cholesterol, triglyceride, and apolipoprotein B levels  

**Adults:** For LDL-C reduction of less than 25%, initial dosage is 20 mg daily at bedtime. For reduction of at least 25%, initial dosage is 40 mg P.O. (capsules) daily at bedtime; may increase if necessary to 40 mg (capsules) P.O. b.i.d. or 80 mg (extended-release tablet) P.O. daily in evening. Maximum dosage is 80 mg/day.

Secondary prevention of cardiovascular events in patients with coronary heart disease who have undergone percutaneous intervention procedures

**Contraindications**

- Hypersensitivity to drug  
- Active hepatic disease  
- Severe renal impairment  
- Pregnancy or breastfeeding

**Precautions**

Use cautiously in:

- hypotension, mild to moderate renal impairment, severe metabolic disorders, visual disturbances, alcoholism  
- patients receiving concurrent azole antifungals  
- females of childbearing age  
- children younger than age 18 (safety not established).

**Administration**

- Know that before starting drug, patient should be on standard cholesterol-lowering diet and weight-control and physical exercise programs, if appropriate.  
- Give with or without food.  
- Be aware that drug works better when taken in evening.  
- If patient is also receiving bile-acid resin, give fluvastatin at bedtime at least 4 hours after resin.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1-2 wk</td>
<td>4-6 wk</td>
<td>Unknown</td>
</tr>
<tr>
<td>P.O. (extended)</td>
<td>2 wk</td>
<td>4 wk</td>
<td>Unknown</td>
</tr>
</tbody>
</table>
Adverse reactions
CNS: amnesia, malaise, drowsiness, weakness, emotional lability, facial paralysis, syncope, headache, poor coordination, hyperkinesia, paresthesia, peripheral neuropathy
CV: orthostatic hypotension, phlebitis, 
EENT: amblyopia, altered refraction, eye hemorrhage, glaucoma, dry eyes, hearing loss, tinnitus, epistaxis, sinusitis, pharyngitis
GI: nausea, vomiting, diarrhea, constipation, dyspepsia, flatulence, abdominal pain or cramps, gastroenteritis, colitis, stomach ulceration, dysphagia, esophagitis, stomatitis, melena, tenesmus, rectal hemorrhage, pancreatitis
GU: urinary frequency, urinary retention, nocturia, dysuria, hematuria, cystitis, decreased libido, epididymitis, erectile dysfunction, renal calculi, nephritis
Hematologic: anemia, thrombocytopenia
Hepatic: jaundice, hepatitis
Metabolic: hyperglycemia, hypoglycemia
Musculoskeletal: joint pain, back pain, leg cramps, gout, bursitis, myasthenia gravis, myositis, torticollis
Respiratory: dyspnea, pneumonia, bronchitis
Skin: acne, alopecia, contact dermatitis, eczema, diaphoresis, rash, urticaria, skin ulcers, seborrhea, photosensitivity
Other: gingival hemorrhage, appetite changes, weight gain, fever, facial or generalized edema, flulike symptoms, infection, allergic reaction

Interactions
Drug-drug. Antacids, cholestyramine, colestipol: decreased fluvastatin blood level
Antifungals, cyclosporine, erythromycin, niacin, other HMG-CoA inhibitors: increased risk of myopathy
Cimetidine, omeprazole, ranitidine: increased fluvastatin blood level
Digoxin: increased digoxin blood level
Phenytoin: increased blood levels of both drugs
Rifampin: increased fluvastatin metabolism, decreased blood level

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, creatine kinase (CK): increased levels

Drug-herbs. Comfrey, germander, jin bu huan, pennyroyal, skullcap, valerian: increased risk of hepatotoxicity
Red yeast rice: increased risk of adverse reactions

Drug-behaviors. Alcohol use: increased risk of hepatotoxicity

Patient monitoring
- Watch for allergic reaction to drug.
- Assess for myositis. If patient has muscle pain, monitor CK level.
- Monitor lipid levels and liver function test results.
- Watch for bleeding tendencies.
- In patients receiving phenytoin, monitor closely when fluvastatin therapy begins or fluvastatin dosage is changed.

Patient teaching
- Instruct patient to take in evening for best effect.
- Advise patient to maintain standard cholesterol-lowering diet and weight-control and physical exercise programs, as appropriate.
- Instruct patient to immediately report unusual bleeding or bruising, irregular heart beat, muscle aches or pains, yellowing of eyes or skin, or unusual tiredness.
- Teach patient how to recognize and report signs and symptoms of allergic response.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, alertness, and vision.
- Advise women of childbearing age to use effective contraception and to stop drug immediately and notify prescriber if pregnancy occurs.
- Inform male patient that drug may cause erectile dysfunction and abnor-
  mal ejaculation.
- Tell patient that full effect of drug may take up to 4 weeks.
- Tell patient to move slowly when ris-
  ing, to avoid dizziness from sudden
  blood pressure decrease.
- As appropriate, review all other sig-
  nificant and life-threatening adverse
  reactions and interactions, especially
  those related to the drugs, tests, herbs,
  and behaviors mentioned above.

**fluvoxamine maleate**

Apo-Fluvoxamine®, Co
Fluvax®, Dom-Fluvoxamine®,
Faverin®, Luvox CR, Novo-
Fluvoxamine®, Nu-Fluvoxamine®,
PHL-Fluvoxamine®, PMS-
Fluvoxamine®, Ratio-Fluvoxamine®,
Riva-Fluvoxamine®, Sandoz
Fluvax

**Pharmacologic class:** Selective
serotonin reuptake inhibitor (SSRI)

**Therapeutic class:** Antidepressant,
antiobsessive agent

**Pregnancy risk category C**

**FDA BOXED WARNING**

- Drug may increase risk of suicidal
  thinking and behavior in children and
  adolescents with major depressive dis-
  order and other psychiatric disorders,
  especially during first few months of
  therapy. Risk must be balanced with
  clinical need, as depression itself in-
  creases suicide risk. With patient of any
  age, observe closely for clinical worsen-
  ing, suicidality, and unusual behavior
  changes when therapy begins. Advise
  family and caregivers to observe
  patient closely and communicate with
  prescriber as needed.
- Drug isn’t approved for use in pedi-
  atric patients except those with
  obsessive-compulsive disorder.

**Action**

Selectively inhibits serotonin reuptake
in neurons. This inhibition is thought to
relieve depression and reduce be-
aviors related to obsessive-compulsive
disorder (OCD).

**Availability**

Capsules (extended-release): 100 mg,
150 mg
Tablets: 25 mg, 50 mg, 100 mg

**Indications and dosages**

> **OCD**

**Adults:** Initially, 50 mg P.O. daily at
bedtime; may increase by 50 mg q 4 to
7 days until desired effect occurs (not
to exceed 300 mg/day). If daily dosage
exceeds 100 mg, give in two equally di-
vided doses; if doses aren’t equal, give
larger dose at bedtime. As needed, ad-
just dosage periodically to maintain
lowest effective dosage that controls
symptoms (immediate-release
formulation)

**Children ages 8 to 17:** Initially, 25 mg
at bedtime; may increase by 25 mg/day
q 4 to 7 days until desired effect occurs
(up to 200 mg/day for patients up to age
11 or up to 300 mg for adolescents). If
daily dosage exceeds 50 mg, give in di-
vided doses, with larger dose at bedtime
(immediate-release formulation).

> **OCD; social anxiety disorder**

**Adults:** 100 mg P.O. once daily at bed-
time; titrate in 50-mg increments
weekly, to a maximum of 300 mg/day
(extended-release formulation).

**Dosage adjustment**

- Hepatic impairment
- Elderly patients

Reactions in bold are life-threatening.
Off-label uses
- Autism
- Anxiety disorders

Contraindications
- Hypersensitivity to drug or other SSRIs
- MAO inhibitor use within past 14 days

Precautions
Use cautiously in:
- cardiovascular disease, hepatic or renal impairment, mania, seizures, suicidal tendency
- elderly patients
- labor and delivery
- pregnant or breastfeeding patients.

Administration
- Give with or without food.
- Discontinue 5 weeks before MAO inhibitor therapy is set to begin.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>2-8 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, drowsiness, headache, insomnia, nervousness, anxiety, apathy, manic or psychotic reactions, depression, hypokinesia or hyperkinesia, tremor, suicide or suicidal ideation (especially in child or adolescent)
CV: hypertension, orthostatic hypotension, palpitations, tachycardia
EENT: sinusitis
GI: nausea, vomiting, diarrhea, constipation, dyspepsia, flatulence, dry mouth, dysphagia, anorexia
GU: decreased libido, sexual dysfunction, anorgasmia
Musculoskeletal: hypertonia, myoclonus, twitching
Respiratory: cough, dyspnea
Skin: diaphoresis
Other: abnormal taste, tooth disorder, dental caries, edema, weight gain or loss, chills, fever, flu-like symptoms, yawning, hot flashes, allergic reactions, hypersensitivity reaction

Interactions
Drug-drug. Beta-adrenergic blockers (such as propranolol), carbamazepine, lithium, L-tryptophan, methadone, some benzodiazepines, theophylline, tolbutamide, warfarin: decreased fluvoxamine metabolism, increased effects
Clozapine: increased clozapine blood level and risk of toxicity
MAO inhibitors: serotonin syndrome
Tricyclic antidepressants: increased fluvoxamine blood level

Drug-tests. Hepatic enzyme levels: increased

Drug-behaviors. Smoking: decreased fluvoxamine efficacy

Patient monitoring
- Watch closely for signs and symptoms of depression and suicidal ideation (especially in child or adolescent).
- Assess patient’s appetite. Report weight gain or loss.
- Monitor liver function test results.
- Monitor cardiovascular status, particularly blood pressure.

Patient teaching
- Instruct patient to swallow extended-release capsules whole and not to break, crush, or chew them.
- Instruct patient or caregiver (especially with child or adolescent patient) to recognize and immediately report signs of suicidal intent or expressions of suicidal ideation.
- Inform patient that drug may take several weeks to be fully effective.
- Recommend establishing effective bedtime routine to minimize insomnia.
- Instruct female patient to notify prescriber if she becomes or intends to become pregnant. Caution her not to breastfeed.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant and life-threatening adverse
reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

### fondaparinux sodium

**Arixtra**

**Pharmacologic class:** Selective factor Xa inhibitor

**Therapeutic class:** Anticoagulant, antithrombotic

**Pregnancy risk category B**

---

### FDA BOXED WARNING

- During epidural or spinal anesthesia or puncture, patients receiving drug or scheduled to receive it for thromboprophylaxis are at risk for epidural or spinal hematoma, which can lead to long-term or permanent paralysis. Risk increases with use of indwelling epidural catheter for analgesia administration and with concurrent use of drugs affecting hemostasis (such as nonsteroidal anti-inflammatory drugs, platelet inhibitors, and other anticoagulants). Risk also rises with traumatic or repeated epidural or spinal puncture. Before neuraxial intervention, physician should weigh drug’s potential benefit against risk.

- Monitor patient frequently for signs and symptoms of neurologic impairment. If these occur, provide urgent treatment.

---

### Actions

Selectively inhibits factor Xa, disrupting blood coagulation and inhibiting thrombin formation and thrombus development

### Availability

**Injection:** 2.5 mg/0.5 ml in single-dose syringe

### Indications and dosages

- Prevention of deep-vein thrombosis after hip fracture surgery or hip or knee replacement surgery

  **Adults:** 2.5 mg subcutaneously 6 to 8 hours after surgery, once hemostasis occurs; usual duration is 5 to 9 days (up to 11 days) given daily. After hip fracture surgery, extended prophylactic course of up to 24 additional days is recommended; some patients have tolerated a total course of 32 days.

- Deep-vein thrombosis and pulmonary emboli

  **Adults:** 5 mg subcutaneously once daily for patients weighing less than 50 kg (110 lb), 7.5 mg subcutaneously for patients weighing 50 to 100 kg (110 to 220 lb) or 10 mg subcutaneously for patients weighing more than 100 kg (220 lb) for 5 days and until therapeutic oral anticoagulant effect occurs (as shown by International Normalized Ratio of 2 to 3). Usual duration of therapy is 5 to 9 days, but may continue for up to 26 days.

### Dosage adjustment

- Renal impairment

### Contraindications

- Hypersensitivity to drug
- Bacterial endocarditis
- Severe renal disease
- Active major bleeding
- Patients weighing less than 50 kg (110 lb) who have undergone hip fracture, hip replacement, or knee replacement surgery

### Precautions

Use cautiously in:

- diabetic retinopathy, hepatic disease, blood dyscrasias, heparin-induced thrombocytopenia, severe hypertension, alcoholism
- patients older than age 75

Reactions in **bold** are life-threatening.
• pregnant or breastfeeding patients
• children (safety and efficacy not established).

**Administration**

- Withhold for at least 6 to 8 hours after surgery, to minimize risk of major bleeding.
- Give by subcutaneous injection only. Don’t give I.M.
- Rotate injection sites among fatty tissue areas on left and right anterolateral and posterolateral abdominal walls.
- Don’t expel air bubble from syringe; doing so may reduce amount of drug delivered.
- Listen for slight click when plunger is fully released. After drug has been injected, needle retracts and white safety indicator is visible.
- Don’t mix with other injections or infusions.
- Know that when drug is used to treat deep-vein thrombosis and pulmonary emboli, concomitant warfarin treatment should begin as soon as possible (usually within 72 hours).

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcut.</td>
<td>Rapid</td>
<td>3 hr</td>
<td>72 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** depression, dizziness, asthenia, headache, abnormal thinking, confusion, insomnia, neuropathy

**CV:** hypotension

**GI:** nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, dry mouth, anorexia

**GU:** urinary retention, urinary tract infection

**Hematologic:** anemia, hematoma, purpura, minor bleeding, **major bleeding, thrombocytopenia, retroperitoneal hemorrhage, postoperative hemorrhage**

**Metabolic:** hypokalemia

**Skin:** bullous eruption

**Other:** increased wound drainage, injection site bleeding, pain, edema, fever

**Interactions**

**Drug-drug.** *Anticoagulants:* increased risk of bleeding

**Drug-herbs.** *Anise, astragalus, bilberry, black currant, bladder wrack, bogbean, boldo, borage, buchu, capsaicin, cat’s claw, celery, chaparral, cinchona, clove oil, dandelion, dong quai, fenugreek, feverfew, garlic, ginger, ginkgo, papaya, red clover, rhubarb, safflower oil, skullcap, tan-shen:* additive anticoagulant effect

*St. John’s wort:* reduced anticoagulant effect

**Patient monitoring**

- Monitor CBC, platelet count, creatinine level, and renal function tests. Assess stools for occult blood.
- Monitor vital signs, temperature, and fluid intake and output.
- Stay alert for bleeding tendency, especially postoperative hemorrhage.
- Check for increased wound drainage after surgery.
- In patient undergoing concomitant neuraxial anesthesia or spinal puncture, watch for neurologic impairment (indicating possible spinal or epidural hematoma).
- Discontinue drug if severe renal impairment occurs.

**Patient teaching**

- Instruct patient to immediately report bleeding.
- Caution patient to avoid activities that can cause injury. Tell him to use soft toothbrush and electric razor to avoid gum and skin injury.
- Tell patient that he’ll undergo regular blood testing during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and herbs mentioned above.
**formoterol fumarate**

Atimos Modulite®, Foradil®, Foradil Aerolizer, Oxeze®, Oxis®, Perforomist

**Pharmacologic class:** Sympathomimetic; long-acting, selective beta₂-adrenergic receptor agonist  
**Therapeutic class:** Bronchodilator  
**Pregnancy risk category C**

---

**FDA BOXED WARNING**

- Drug may increase risk of asthma-related death. Give only as additional therapy for patients not adequately controlled on other asthma-controller medications or whose disease severity clearly warrants treatment with two maintenance therapies.  
- In large placebo-controlled study, increase in asthma-related deaths occurred in patients receiving salmeterol; this finding may apply to formoterol.

---

**Action**

Stimulates intracellular adenylate cyclase, relaxing bronchial smooth muscle and inhibiting release of mediators of immediate hypersensitivity

**Availability**

*Capsules for oral inhalation (used with Aerolizer inhaler): 12 mcg*

**Indications and dosages**

> Long-term maintenance of asthma; prevention or long-term maintenance of bronchospasm in patients with chronic obstructive pulmonary disease  
**Adults and children ages 5 and older:** Contents of 1 capsule inhaled orally via Aerolizer q 12 hours

> Acute prevention of exercise-induced bronchospasm (on occasional, as-needed basis)  
**Adults and children ages 5 and older:** Contents of 1 capsule inhaled orally via Aerolizer at least 15 minutes before start of exercise. Wait 12 hours after initial dose before giving repeat dose.

---

**Contraindications**

- Hypersensitivity to drug or its components  
- Tachyarrhythmias

**Precautions**

Use cautiously in:  
- acute asthma symptoms, deteriorating asthma, cardiovascular disorders, seizure disorders, thyrotoxicosis, diabetes, possible hypokalemia  
- patients older than age 75  
- labor  
- pregnant or breastfeeding patients  
- children younger than age 5.

**Administration**

- Be aware that drug is not intended for acute asthma attacks.  
- Use capsules only with Aerolizer inhaler supplied.  
- Keep capsules in blister until immediately before use.  
- Make sure patient doesn’t swallow capsules.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhalation</td>
<td>Rapid</td>
<td>5 min</td>
<td>12 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- CNS: tremor, dizziness, insomnia, anxiety  
- CV: chest pain  
- EENT: sinusitis, pharyngitis, tonsillitis  
- GI: dry mouth  
- Metabolic: hypokalemia, hyperglycemia  
- Musculoskeletal: muscle cramps, back pain, leg cramps

Reactions in **bold** are life-threatening.
Respiratory: bronchitis, chest infection, dyspnea, upper respiratory tract infection, increased sputum
Skin: pruritus, rash
Other: dysphonia, viral infection, fever

Interactions
Drug-drug. Adrenergics: potentiation of formoterol’s sympathomimetic effects
Beta-adrenergic blockers: partial or total inhibition of formoterol’s effects
Cardiac glycosides, methylxanthines, potassium-wasting diuretics, steroids: potentiation of formoterol’s hypokalemic effects, increased risk of arrhythmias
Disopyramide, MAO inhibitors, quinidine, phenothiazines, procainamide, tricyclic antidepressants: prolonged QTc interval, increased risk of ventricular arrhythmias
Halogenated hydrocarbon anesthetics: increased risk of arrhythmias
Levodopa, levothyroxine, oxytocin: impaired cardiac tolerance of formoterol

Drug-diagnostic tests. Blood glucose: increased level
Potassium: decreased level

Drug-behaviors. Alcohol use: impaired cardiac tolerance of formoterol

Patient monitoring
• Monitor pulmonary function test results.
• Monitor potassium and glucose levels.

Patient teaching
• Teach patient how to use capsules and Aerolizer inhaler provided.
• Instruct patient to keep capsules in blisters until immediately before use.
• Caution patient not to swallow capsules.
• Tell patient not to use drug for acute asthma attacks.
• Instruct patient to contact prescriber immediately if difficulty in breathing persists after using drug or if condition worsens.
• Caution patient to take drug exactly as prescribed and not to stop therapy even if he feels better.
• Tell patient to consult prescriber if he has been taking inhaled, short-acting drugs on a regular basis.
• Advise female patient to tell prescriber if she is pregnant or breastfeeding or if she plans to become pregnant.
• Caution patient to avoid alcohol during therapy.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.
Adults (protease inhibitor–experience): 700 mg P.O. b.i.d. with ritonavir 100 mg b.i.d.

Children ages 2 and older: Calculate dosage based on weight, but don’t exceed adult dosage. When given in combination with ritonavir, fosamprenavir tablets may be used for children weighing at least 39 kg (86 lb); ritonavir capsules may be used for those weighing at least 33 kg (73 lb). See table below for more information.

Pediatric dosages

<table>
<thead>
<tr>
<th>Therapy-naive children ages 2 to 5</th>
<th>30 mg/kg (oral suspension) P.O. b.i.d., not to exceed adult dosage of 1,400 mg b.i.d.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapy-naive children ages 6 and older</td>
<td>30 mg/kg P.O. b.i.d. or 18 mg/kg plus ritonavir 3 mg/kg b.i.d., not to exceed adult dosage of fosamprenavir 700 mg plus ritonavir 100 mg b.i.d.*</td>
</tr>
<tr>
<td>Therapy-experienced children ages 6 and older</td>
<td>18 mg/kg (oral suspension) P.O. plus ritonavir 3 mg/kg b.i.d., not to exceed adult dosage of fosamprenavir 700 mg b.i.d. plus ritonavir 100 mg b.i.d. Or 1,400 mg (tablets) P.O. b.i.d. for children weighing at least 47 kg when given without ritonavir.*</td>
</tr>
</tbody>
</table>

*Patients weighing at least 39 kg (86 lb) who are also taking ritonavir may receive oral suspension or tablets; those weighing at least 47 kg (104 lb) who aren’t taking ritonavir may receive oral suspension or tablets.

Dosage adjustment
- Mild, moderate and severe hepatic impairment

Contraindications
- Hypersensitivity to drug or amprenavir
- Concomitant use of drugs that depend highly on CYP3A4 for clearance and for which elevated blood levels may lead to serious or life-threatening events (such as some antiarrhythmics, antimycobacterials, ergot derivatives, GI motility agents, HMG co-reductase inhibitors, neuroleptics, nonnucleoside reverse transcriptase inhibitors, and sedative-hypnotics)
- Coadministration with ritonavir in patients receiving flecainide or propafenone
- Concomitant use of St. John’s wort

Precautions
Use cautiously in:
- sulfa allergy
- hepatic impairment
- diabetes mellitus
- elderly patients
- pregnant or breastfeeding patients
- children younger than age 2 (safety and efficacy not established).

Administration
- Assess cholesterol and triglyceride levels and hepatic function tests before starting therapy.
- Give oral suspension to adults without food and to children with food.
- Administer tablets with or without food.

Route | Onset | Peak | Duration
--- | --- | --- | ---
P.O. | Unknown | 1.5-4 hr | Unknown

Adverse reactions
CNS: headache
GI: nausea, vomiting, diarrhea, abdominal pain
Hematologic: spontaneous bleeding (in hemophiliacs), acute hemolytic anemia
Metabolic: diabetes mellitus, body fat redistribution or accumulation
Skin: pruritus, maculopapular rash, severe or life-threatening skin reactions
Other: immune reconstitution syndrome

Interactions
Drug-drug. Antimycobacterials (rifampin): decreased fosamprenavir blood level, possible loss of virologic response and possible resistance to fosamprenavir or to its protease inhibitor.
class (concomitant rifampin use contraindicated)

Amitriptyline, amlodipine, atorvastatin, benzodiazipines (alprazolam, clorazepate, diazepam, flurazepam), bepridil, cyclosporine, diltiazem, esomepразole, felodipine, fluticasone, imipramine, isradipine, itraconazole, ketoconazole, lidocaine (systemic), nicardipine, nifedipine, nimodipine, nisoldipine, quinidine, rapamycin, rosuvastatin, tacrolimus, trazodone, verapamil: increased blood levels of these drugs

Carbamazepine, cimetidine, dexamethasone, efavirenz, famotidine, nizatidine, phenobarbital, phenytoin, ranitidine, saquinavir: decreased fosamprenavir blood levels

Cisapride, pimozide: possible serious or life-threatening reactions, such as arrhythmias (concomitant use with fosamprenavir contraindicated)

CYP3A4 inducers: significant decrease in fosamprenavir blood level and reduced therapeutic effect

CYP3A4 inhibitors: increased fosamprenavir blood level and increased incidence of adverse effects

Delavirdine: possible loss of virologic response and possible resistance to delavirdine

Ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine): serious or life-threatening reactions such as acute ergot toxicity (concomitant use with fosamprenavir contraindicated)

Flecainide, propafenone: increased risk of serious, life-threatening cardiac arrhythmias (concomitant use contraindicated)

HIV protease inhibitors (lopinavir/ritonavir): decreased blood levels of both drugs

Hormonal contraceptives: possible changes in hormone levels and liver enzyme elevations (if used in combination with fosamprenavir and ritonavir)

Indinavir, nelfinavir: increased fosamprenavir blood level

Lovastatin, simvastatin: increased risk of serious reactions such as myopathy, including rhabdomyolysis (concomitant use with fosamprenavir contraindicated)

Methodone: decreased methadone blood level

Midazolam, triazolam: serious or life-threatening reactions, such as prolonged or increased sedation or respiratory depression (concomitant use with fosamprenavir contraindicated)

Nevirapine: decreased fosamprenavir and increased nevirapine blood levels

Paroxetine (in combination with fosamprenavir and ritonavir): decreased paroxetine blood level

PDE5 inhibitors (such as sildenafil): increased risk of adverse reactions (such as hypotension, visual changes, priapism)

Phenytoin (in combination with fosamprenavir and ritonavir): increased fosamprenavir, decreased phenytoin blood level

Rifabutin: increased rifabutin and metabolite blood levels

Warfarin: altered blood levels

Drug-diagnostic tests. ALT, AST, glucose, lipase, triglycerides: increased levels

Drug-food. High-fat meal: reduced fosamprenavir effect

Drug-herbs. St. John’s wort: significant decrease in fosamprenavir blood level with loss of therapeutic effect and possible resistance to fosamprenavir or its protease inhibitor class (concomitant use contraindicated)

Patient monitoring

Monitor patient closely for rash; discontinue drug if severe rash or moderate rash plus systemic symptoms develops.

Be aware that immune reconstitution syndrome has occurred in patients treated with combination antiretroviral
therapy. During initial phase of such therapy, patients whose immune system responds may develop inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium complex, cytomegalovirus, Pneumocystis jiroveci pneumonia, and tuberculosis), which may necessitate further evaluation and treatment.

- Closely monitor International Normalized Ratio if patient is receiving warfarin concomitantly.
- Closely monitor hepatic function tests during therapy.
- Periodically monitor cholesterol and triglyceride levels.
- Watch for new-onset diabetes mellitus, exacerbation of preexisting diabetes, and hyperglycemia.

**Patient teaching**

- Advise adult patient to take oral suspension without food.
- Tell caregivers to give oral suspension with food to child.
- Instruct patient to shake oral suspension bottle vigorously before each use; mention that refrigeration may improve taste.
- Instruct patient to take tablets with or without food.
- Advise patient to immediately report new infections or rash, which may become severe and potentially life-threatening.
- Inform patient that drug doesn’t cure HIV infection or reduce risk of passing HIV to others through sexual contact, needle sharing, or blood exposure.
- Tell patient that drug may cause body fat redistribution or accumulation and that the cause and long-term health effects of this condition aren’t known.
- Advise patient that drug may interact with many drugs and herbs (especially St. John’s wort). Caution patient to discuss use of herbs and other drugs with prescriber.
- Advise male receiving PDE5 inhibitors (such as sildenafil, tadalafil, vardenafil) that he may be at increased risk for adverse events, including hypotension, visual changes, and priapism. Instruct him to promptly report symptoms.
- Advise patient taking hormonal contraceptives to use alternative contraception during therapy because hormone levels may be altered and liver enzyme levels may increase.
- Advise female to notify prescriber if she is pregnant or intends to become pregnant.
- Instruct women not to breastfeed while taking drug.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, food, and herbs mentioned above.

**fosinopril sodium**

APO-Fosinopril®, Gen-Fosinopril®, Lin-Fosinopril®, Monopril, Novo-Fosinopril®, PMS-Fosinopril®, Ran-Fosinopril®, Ratio-Fosinopril®, Riva-Fosinopril®, Staril®

**Pharmacologic class:** Angiotensin-converting enzyme (ACE) inhibitor

**Therapeutic class:** Antihypertensive

**Pregnancy risk category C** (first trimester), **D** (second and third trimesters)

**FDA BOXED WARNING**

- When used during second or third trimester of pregnancy, drug may cause fetal injury or even death. Discontinue as soon as pregnancy is detected.

Reactions in **bold** are life-threatening.
Action
Prevents conversion of angiotensin I to the vasoconstrictor angiotensin II, thereby reducing sodium and water retention and enhancing blood flow in circulatory system

Availability
Tablets: 10 mg, 20 mg, 40 mg

Indications and dosages

- **Hypertension**
  - Adults: 10 mg P.O. daily. May increase as required up to 80 mg/day; typical range is 20 to 40 mg P.O. daily.

- **Heart failure**
  - Adults: 10 mg P.O. daily. May increase over several weeks up to 40 mg/day; typical range is 20 to 40 mg/day.

Dosage adjustment
- Renal impairment

Off-label uses
- Adjunct in myocardial infarction
- Nephropathy

Contraindications
- Hypersensitivity to drug or other ACE inhibitors
- Angioedema (hereditary or idiopathic)
- Pregnancy

Precautions
Use cautiously in:
- aortic stenosis, cardiomyopathy, cerebrovascular or cardiac insufficiency, renal or hepatic impairment, hyponatremia, hypovolemia
- black patients with hypertension
- patients receiving diuretics concurrently
- elderly patients
- breastfeeding patients (safety not established)
- children (safety not established).

Administration
- Don’t administer within 2 hours of antacids.
- Give with or without food, but avoid giving with high-potassium foods or potassium supplements.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Within 1 hr</td>
<td>2-6 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
- CNS: dizziness, drowsiness, fatigue, headache, insomnia, weakness, vertigo
- CV: hypotension, angina pectoris, tachycardia
- EENT: sinusitis
- GI: nausea, vomiting, diarrhea, anorexia
- GU: proteinuria, erectile dysfunction, decreased libido, renal failure
- Hematologic: agranulocytosis, bone marrow depression
- Metabolic: hyperkalemia
- Respiratory: cough, bronchitis, dyspnea, asthma, eosinophilic pneumonitis
- Skin: rash, angioedema
- Other: altered taste, fever, hypersensitivity reactions including anaphylaxis

Interactions
Drug-drug. *Allopurinol*: increased risk of hypersensitivity reaction
*Antacids*: decreased fosinopril absorption
*Antihypertensives, diuretics, general anesthetics, nitrates, phenothiazines*: additive hypotension
*Cyclosporine, indomethacin, potassium-sparing diuretics, potassium supplements*: hyperkalemia
*Digoxin, lithium*: increased blood levels of these drugs, greater risk of toxicity
*Indomethacin*: decreased hypertensive effects

Drug-diagnostic tests. *Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, potassium*: increased levels
*Antinuclear antibody titer*: false-positive result

Canada  UK  Hazardous drug  High alert drug
Sodium: decreased level

**Drug-food.** Salt substitutes containing potassium: hyperkalemia

**Drug-hers.** Capsaicin: increased incidence of cough

**Drug-behaviors.** Acute alcohol ingestion: additive hypotension

**Patient monitoring**
- Monitor cardiovascular, respiratory, and neurologic status.
- Monitor CBC and liver and kidney function tests.
- Measure blood pressure to assess drug efficacy and detect hypotension.
- Assess patient’s potassium intake; monitor serum potassium level.
- Monitor signs and symptoms of angioedema and anaphylaxis. If these occur, withdraw drug and contact prescriber immediately.

**Patient teaching**
- Instruct patient to immediately report rash or difficulty breathing.
- Tell patient to report dizziness, fainting, bleeding tendency, change in urination pattern, swelling, or persistent cough.
- Encourage patient to drink enough fluids to stay well hydrated.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Instruct female patient to notify prescriber if she suspects she is pregnant.
- Tell patient that he will undergo regular blood testing during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

**fosphenytoin sodium**
Cerebyx, Pro-Epanutin®

**Pharmacologic class:** Hydantoin

**Therapeutic class:** Anticonvulsant

**Pregnancy risk category D**

**Action**
Thought to regulate neuronal membrane by promoting sodium excretion from neurons. This action prevents hyperexcitability and excessive stimulation, which inhibits spread of seizure activity. Lacks general CNS depressant effect.

**Availability**
Injection: 150 mg in 2-ml vials (100 mg phenytoin sodium), 750 mg in 10-ml vials (500 mg phenytoin sodium)

**Indications and dosages**
- Status epilepticus

**Adults:** 15 to 20 mg phenytoin sodium equivalent (PE)/kg I.V. at 100 to 150 mg PE/minute as a loading dose, then 4 to 6 mg (PE)/kg I.V. daily for maintenance

- To prevent seizures during neurosurgery

**Adults:** 10 to 20 mg PE/kg I.M. or I.V. as a loading dose, then 4 to 6 mg PE/kg I.M. or I.V. daily for maintenance

**Dosage adjustment**
- Hepatic disease
- Renal impairment
- Elderly patients

**Contraindications**
- Hypersensitivity to drug
- Adams-Stokes syndrome
- Arrhythmias

**Precautions**
Use cautiously in:
- hepatic or renal impairment, severe cardiac or respiratory disease

Reactions in bold are life-threatening.
- elderly patients
- pregnant or breastfeeding patients (safety not established).

**Administration**
- Know that drug is a phenytoin prodrug and is given in PE units to avoid the need to perform molecular weight-based adjustments when converting between fosphenytoin and phenytoin sodium.
- For I.V. use, dilute in dextrose 5% in water or normal saline solution.
- Don’t give faster than 150 mg PE/minute. Too-rapid infusion causes hypotension.
  - Check ECG, vital signs, and overall patient status continuously during infusion and for 10 to 20 minutes afterward.
- When giving I.M., rotate injection sites.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>Unknown</td>
<td>Up to 24 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>Unknown</td>
<td>30 min</td>
<td>Up to 24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- CNS: ataxia, agitation, dizziness, drowsiness, dysarthria, dyskinesia, speech disorder, extrapyramidal syndrome, headache, nervousness, weakness, confusion, hyperesthesia, paresthesia, cerebral edema, coma, intracranial hypertension
- CV: hypotension, tachycardia
- EENT: diplopia, nystagmus, tinnitus
- GI: nausea, vomiting, constipation, dry mouth, anorexia
- GU: pink, red, or reddish-brown urine
- Hematologic: lymphadenopathy, aplastic anemia, agranulocytosis, leukopenia, megaloblastic anemia, thrombocytopenia
- Hepatic: hepatitis
- Metabolic: hypocalcemia, hypokalemia, hyperglycemia, increased glucose tolerance

**Musculoskeletal:** back or pelvic pain, osteomalacia  
**Skin:** hypertrichosis, rash, pruritus, exfoliative dermatitis, Stevens-Johnson syndrome  
**Other:** gingival hyperplasia, altered taste, fever, facial edema, weight loss, injection site pain, allergic reactions

**Interactions**
- **Drug-drug.** Amiodarone, benzodiazepines, chloramphenicol, cimetidine, disulfiram, estrogens, felbamate, fluconazole, fluoxetine, halothane, influenza vaccine, isoniazid, itraconazole, ketoconazole, methylphenidate, miconazole, omeprazole, phenothiazines, phenylbutazone, salicylates, sulfonylamides, tolbutamide, trazodone: increased fosphenytoin blood level  
- Antidepressants, antihistamines, opioids, sedative-hypnotics: additive CNS depression  
- Barbiturates, carbamazepine, reserpine: decreased fosphenytoin blood level  
- Corticosteroids, cyclosporine, doxycycline, estrogens, felbamate, methadone, quinidine, rifampin: altered effects of these drugs  
- Dopamine: additive hypotension  
- Lidocaine, propranolol: additive cardiac depression  
- Streptozocin, theophylline: decreased efficacy of these drugs  
- Warfarin: initial increase in warfarin effects in patients stabilized on warfarin therapy, followed by decreased response to warfarin

**Drug-diagnostic tests.** Alkaline phosphatase, glucose, hepatic enzymes: increased levels  
- Dexamethasone, metyrapone: test interference  
- Glucose tolerance test: decreased tolerance  
- Potassium, thyroxine: decreased levels  
- Thyroid function tests: decreased values  

**Drug-behaviors.** Acute alcohol ingestion: increased drug blood level, additive CNS depression

Canada  UK  Hazardous drug  High alert drug
Chronic alcohol ingestion: decreased drug blood level

Patient monitoring
• Be prepared to slow administration or stop therapy if significant cardiovascular reactions occur.
• Monitor neurologic status carefully, especially for evidence of increasing intracranial pressure.
• Assess for rash. Withhold drug and notify prescriber if it occurs.
• Monitor phenytoin blood level after drug has metabolized to phenytoin (about 2 hours after I.V. dose or 4 hours after I.M. dose).
• Monitor electrolyte levels.
• Evaluate blood glucose level. Watch for hyperglycemia in patients with diabetes.

Patient teaching
• Inform patient that he may experience sensory disturbances during I.V. administration.
• Advise patient to immediately report adverse effects, particularly rash.
• Tell patient that drug may turn his urine pink, red, or reddish brown.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

---

**frovatriptan succinate**

*Frova, Migard®*

**Pharmacologic class:** Serotonin 5-hydroxytryptamine (5-HT) \(_1\)-receptor agonist

**Therapeutic class:** Antimigraine agent

**Pregnancy risk category C**

---

**Action**
Binds selectively to serotonin receptors on cranial arteries, causing vasoconstriction and decreased blood flow

**Availability**
Tablets: 2.5 mg

**Indications and dosages**

- **Acute migraine**
  
  **Adults:** 2.5 mg P.O. as a single dose at first symptom of migraine. If migraine returns, may repeat after 2 hours. Maximum of three doses in 24 hours (7.5 mg/day).

**Contraindications**
• Hypersensitivity to drug or its components
• Cerebrovascular disorders
• Ischemic heart disease or history of myocardial infarction
• Uncontrolled hypertension
• Peripheral vascular disease
• Hemiplegic or basilar migraine
• Within 24 hours of another 5-HT\(_1\)-receptor agonist or ergotamine-containing or ergot-type drug

**Precautions**
Use cautiously in:
• patients receiving selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)
• pregnant or breastfeeding patients
• children (safety and efficacy not established).

**Administration**
• Give one tablet with plenty of fluids at first symptom of migraine.
• If headache returns, administer another tablet after 2 hours.
• Don’t exceed three tablets in 24-hour period.
• Give first dose under close supervision if patient has coronary artery disease or other risk factors.

Reactions in **bold** are life-threatening.
Don’t give within 24 hours of another 5-HT<sub>1</sub>-receptor agonist or ergotamine-containing or ergot-type drug.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Variable</td>
<td>2-4 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

### Adverse reactions

**CNS:** dizziness, headache, anxiety, malaise, fatigue, weakness, drowsiness, paresthesia, sensation loss  
**CV:** palpitations, tightness in chest, **myocardial infarction** (MI)  
**EENT:** abnormal vision, tinnitus, rhinitis  
**GI:** nausea, diarrhea, dyspepsia, abdominal pain  
**Musculoskeletal:** skeletal or muscle pain  
**Skin:** flushing, diaphoresis, photosensitivity  
**Other:** altered taste, hot or cold sensations

### Interactions

**Drug-drug.** Ergot alkaloids, other serotonin 5-HT<sub>1</sub>-receptor agonists: prolonged vasoactive reactions  
Hormonal contraceptives, propranolol: increased frovatriptan bioavailability  
SSRIs, SNRIs: serotonin syndrome (including mental state changes, hyperreflexia, nausea, vomiting)

**Drug-behaviors.** Sun exposure: increased risk of photosensitivity

### Patient monitoring

- Assess for cardiovascular reactions, especially signs and symptoms of MI.  
- Monitor neurologic status, particularly for indications of cerebrovascular accident.  
- Check for rash and itching.

### Patient teaching

- Instruct patient to take one tablet with plenty of fluids at first symptom of migraine.

- Tell patient he may take second tablet 2 hours after first if migraine returns.  
- Advise patient to immediately report chest pain.  
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.  
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and behaviors mentioned above.

### fulvestrant

**Faslodex**

**Pharmacologic class:** Estrogen receptor antagonist  
**Therapeutic class:** Antineoplastic  
**Pregnancy risk category D**

### Action

Inhibits cell division by binding with and downgrading estrogen receptor protein in breast cancer cells

### Availability

Prefilled syringes: 125 mg/2.5 ml, 250 mg/5 ml

### Indications and dosages

- Hormone receptor–positive advanced metastatic breast cancer in postmenopausal women with disease progression who have received anti-estrogen therapy  
**Adults:** 250 mg I.M. q month as a single 5-ml injection or two concomitant 2.5-ml injections

### Contraindications

- Hypersensitivity to drug  
- Pregnancy
Precautions
Use cautiously in:
- bleeding disorders, hepatic dysfunction, thrombocytopenia
- breastfeeding patients.

Administration
- Expel air bubble from syringe before giving injection.
- Administer I.M. injection slowly.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.M.</td>
<td>Slow</td>
<td>2-3 days</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: depression, light-headedness, dizziness, headache, hallucinations, vertigo, insomnia, paresthesia, anxiety, weakness
CV: chest pain, vasodilation, peripheral edema
EENT: pharyngitis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, anorexia
GU: urinary tract infection, pelvic pain
Hematologic: anemia
Musculoskeletal: back pain, bone pain, arthritis
Respiratory: dyspnea, increased cough
Skin: flushing, rash, diaphoresis
Other: food distaste, fever, hot flashes, injection site reactions, pain, flulike symptoms

Interactions
Drug-drug. Anticoagulants: increased bleeding risk

Patient monitoring
- Monitor CBC.
- Assess liver function test results.

Patient teaching
- Advise patient to report signs and symptoms of infection, especially urinary tract infection.
- Caution patient to avoid driving and other hazardous activities until she knows how drug affects concentration and alertness.

\[\text{Clinical alert}\]
Tell patient to notify prescriber immediately if she thinks she is pregnant.
- Teach patient comfort measures to minimize hot flashes and rash.
- Instruct patient to minimize GI upset and sore throat by eating frequent, small servings of healthy food and drinking adequate fluids.
- Tell patient that drug may cause headache, muscle aches, or bone pain. Encourage her to discuss activity recommendations and pain management with prescriber.
- Advise patient to establish effective bedtime routine to minimize sleep disorders.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

furosemide
Apo-Furosemide®, Bio-Furosemide®, Dom-Furosemide®, Frusol®, Lasix, Lasix Special®, Novosemide®, Nu-Furosemide®, PMS-Furosemide®

Pharmacologic class: Sulfonamide loop diuretic
Therapeutic class: Diuretic, antihypertensive
Pregnancy risk category C

Action
Unclear. Thought to inhibit sodium and chloride reabsorption from ascending loop of Henle and distal renal tubules. Increases potassium excretion and plasma volume, promoting renal excretion of water, sodium, chloride, magnesium, hydrogen, and calcium.

Reactions in **bold** are life-threatening.
Availability
Injection: 10 mg/ml
Oral solution: 10 mg/ml, 40 mg/5 ml
Tablets: 20 mg, 40 mg, 80 mg

Indications and dosages
➢ Acute pulmonary edema
Adults: 40 mg I.V. given over 1 to 2 minutes. If adequate response doesn’t occur within 1 hour, give 80 mg I.V. over 1 to 2 minutes.
➢ Edema caused by heart failure, hepatic cirrhosis, or renal disease
Adults: Initially, 20 to 80 mg/day P.O. as a single dose; may increase in 20- to 40-mg increments P.O. q 6 to 8 hours until desired response occurs. Thereafter, may give once or twice daily. For maintenance, dosage may be reduced in some patients or carefully titrated upward to 600 mg P.O. daily in severe edema. Usual I.M. or I.V. dosage is 20 to 40 mg as a single injection; if response inadequate, second and each succeeding dose may be increased in 20-mg increments and given no more often than q 2 hours until desired response occurs. Single dose may then be given once or twice daily.
Infants and children: 2 mg/kg P.O. (oral solution) as a single dose. As necessary, increase in increments of 1 or 2 mg/kg q 6 to 8 hours to a maximum of 6 mg/kg/dose. For maintenance, give minimum effective dosage.
➢ Hypertension
Adults: 40 mg P.O. b.i.d. If satisfactory response doesn’t occur, other antihypertensives may be added before furosemide dosage is increased. However, dosage may be titrated upward as needed and tolerated to a maximum of 240 mg P.O. daily in two or three divided doses.

Off-label uses
● Hypercalcemia associated with cancer

Contraindications
● Hypersensitivity to drug or other sulfonamides
● Anuria

Precautions
Use cautiously in:
● diabetes mellitus, severe hepatic disease
● elderly patients
● pregnant or breastfeeding patients
● neonates.

Administration
● Know that I.V. or I.M. injection is given when patient requires rapid onset of diuresis or can’t receive oral doses.
● Be aware that I.V. dose may be given by direct injection over 1 to 2 minutes.
● For I.V. infusion, dilute in dextrose 5% in water, normal saline solution, or lactated Ringer’s solution.
☒ Don’t infuse more than 4 mg/minute.
● Give oral doses in morning with food. If second dose is prescribed, give in afternoon.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30-60 min</td>
<td>1-2 hr</td>
<td>6-8 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>5 min</td>
<td>20-60 min</td>
<td>2 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>10-30 min</td>
<td>30 min</td>
<td>4-8 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, headache, vertigo, weakness, lethargy, paresthesia, drowsiness, restlessness, light-headedness
CV: hypotension, orthostatic hypotension, tachycardia, volume depletion, necrotizing angitis, thrombophlebitis, arrhythmias
EENT: blurred vision, xanopsia, hearing loss, tinnitus
GI: nausea, vomiting, diarrhea, constipation, dyspepsia, oral and gastric irritation, cramping, anorexia, dry mouth, acute pancreatitis
GU: excessive and frequent urination, nocturia, glycosuria, bladder spasm, oliguria, interstitial nephritis
Hematologic: anemia, purpura, leukopenia, thrombocytopenia, hemolytic anemia
Hepatic: jaundice
Metabolic: hyperglycemia, hyperuricemia, dehydration, hypokalemia, hypomagnesemia, hypocalcemia, hypochloremic alkalosis
Musculoskeletal: muscle pain, muscle cramps
Skin: photosensitivity, rash, diaphoresis, urticaria, pruritus, exfoliative dermatitis, erythema multiforme
Other: fever, transient pain at I.M. injection site

Interactions
Drug-drug. Aminoglycosides, ethacrynic acid, other ototoxic drugs: increased risk of ototoxicity
Amphotericin B, corticosteroids, corticotropin, potassium-wasting diuretics, stimulant laxatives: additive hypokalemia
Antihypertensives, diuretics, nitrates: additive hypotension
Cardiac glycosides: increased risk of glycoside toxicity and fatal arrhythmias
Clofibrate: exaggerated diuretic response, muscle pain and stiffness
Hydantoins, nonsteroidal anti-inflammatory drugs, probenecid: diuresis inhibition
Insulin, oral hypoglycemics: decreased hypoglycemic effect
Lithium: decreased lithium excretion, possible toxicity
Norepinephrine: decreased arterial response to norepinephrine
Propranolol: increased propranolol blood level
Salicylates: increased risk of salicylate toxicity at lower dosages than usual
Succinylcholine: potentiation of succinylcholine effect
Sucralfate: decreased naturietic and antihypertensive effects of furosemide

Sulfonylureas: decreased glucose tolerance, resulting in hyperglycemia
Theophyllines: altered, enhanced, or inhibited theophylline effects
Tubocurarine: antagonism of tubocurarine effects

Drug-diagnostic tests. Blood urea nitrogen (BUN): transient increase
Calcium, magnesium, platelets, potassium, sodium: decreased levels
Cholesterol, creatinine, glucose, nitrogenous compounds: increased levels

Drug-herbs. Dandelion: interference with drug’s diuretic effect
Ephedra (ma huang), ginseng: decreased furosemide efficacy
Licorice: rapid potassium loss

Drug-behaviors. Acute alcohol ingestion: additive hypotension
Sun exposure: increased risk of photosensitivity

Patient monitoring
● Watch for signs and symptoms of ototoxicity.
● Assess for other evidence of drug toxicity (arrhythmias, renal dysfunction, abdominal pain, sore throat, fever).
● Monitor CBC, BUN, and electrolyte, uric acid, and CO₂ levels.
● Monitor blood pressure, pulse, fluid intake and output, and weight.
● Assess blood glucose levels in patients with diabetes mellitus.
● Monitor dietary potassium intake. Watch for signs and symptoms of hypokalemia.

Patient teaching
● Instruct patient to take in morning with food (and second dose, if prescribed, in afternoon), to prevent nocturia.
● Tell patient that drug may cause serious interactions with many common drugs. Instruct him to tell all prescribers he’s taking it.
● Instruct patient to report signs and symptoms of ototoxicity (hearing loss,
ranging in ears, vertigo) and other drug toxicities.

- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Instruct patient to move slowly when rising, to avoid dizziness from sudden blood pressure decrease.
- Encourage patient to discuss need for potassium and magnesium supplements with prescriber.
- Caution patient to avoid alcohol and herbs while taking this drug.
- Inform patient that he’ll undergo regular blood testing during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

**Indications and dosages**

**Adjunctive treatment of partial seizures**

**Adults and children older than age 12:** Initially, 300 mg P.O. t.i.d. Usual range is 900 to 1,800 mg/day in three divided doses.

**Children ages 5 to 12:** Initially, 10 to 15 mg/kg/day P.O. in three divided doses, titrated upward over 3 days to 25 to 35 mg/kg/day in three divided doses.

**Children ages 3 to 4:** Initially, 10 to 15 mg/kg/day P.O. in three divided doses, titrated upward over 3 days to 40 mg/kg/day in three divided doses.

**Postherpetic neuralgia**

**Adults:** Initially, 300 mg P.O. as a single dose on day 1; then 600 mg in two divided doses on day 2 and 900 mg in three divided doses on day 3. Then titrate upward as needed to 1,800 mg/day given in three divided doses.

**Dosage adjustment**

- Renal impairment

**Off-label uses**

- Bipolar disorder
- Migraine prophylaxis
- Tremor associated with multiple sclerosis

**Contraindications**

- Hypersensitivity to drug

**Precautions**

Use cautiously in:

- renal insufficiency
- elderly patients
- pregnant or breastfeeding patients
• children younger than age 3 (safety not established).

**Administration**
• Give with or without food.
• Administer first dose at bedtime to reduce adverse effects.
• Don’t give within 2 hours of antacids.
• Give daily doses no more than 12 hours apart.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>2-4 hr</td>
<td>8 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
**CNS:** drowsiness, anxiety, dizziness, malaise, vertigo, weakness, ataxia, altered reflexes, hyperkinesia, paresthesia, tremor, amnesia, abnormal thinking, difficulty concentrating, hostility, emotional lability
**CV:** hypertension, peripheral edema
**EENT:** abnormal vision, nystagmus, diplopia, amblyopia, rhinitis, pharyngitis, dry throat
**GI:** nausea, vomiting, constipation, flatulence, dyspepsia, anorexia, dry mouth
**GU:** erectile dysfunction
**Hematologic:** leukopenia
**Musculoskeletal:** joint, back, or muscle pain; fractures
**Respiratory:** cough
**Skin:** pruritus, abrasion
**Other:** dental abnormalities, gingivitis, facial edema, increased appetite, weight gain

**Interactions**
**Drug-drug.** *Antacids:* decreased gabapentin absorption
*Antihistamines, CNS depressants, sedative-hypnotics:* increased risk of CNS depression

**Drug-behaviors.** *Alcohol use:* increased risk of CNS depression

**Patient monitoring**
• Evaluate neurologic status and motor function.
• Assess WBC count.
• Monitor blood pressure.

**Patient teaching**
• Tell patient he may take with or without food.
• Advise patient to take first dose at bedtime to reduce adverse effects.
• Caution patient not to stop taking drug suddenly. Dosage must be tapered to minimize seizure risk.
• Instruct patient to avoid driving and other hazardous activities until he knows how drug affects concentration, alertness, motor function, and vision.
• Tell patient that drug may cause joint pain, muscle aches, or bone pain. Encourage him to discuss activity recommendations and pain management with prescriber.
• Advise parents that drug may cause emotional lability and poor concentration in children. Tell them to contact prescriber if these problems occur.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

**Drug-herbs.** *Chamomile, hops, kava, skullcap, valerian:* increased risk of CNS depression

Reactions in **bold** are life-threatening.
**Galantamine Hydrobromide**

Razadyne, Razadyne ER, Reminyl®, Reminyl XL®

**Pharmacologic class:** Cholinesterase inhibitor  
**Therapeutic class:** Anti-Alzheimer’s agent  
**Pregnancy risk category B**

**Action**  
Unclear. May reversibly inhibit acetylcholinesterase, increasing concentration of acetylcholine (necessary for nerve impulse transmission) in brain synapses.

**Availability**  
Capsules (extended-release): 8 mg, 16 mg, 24 mg  
Oral solution: 4 mg/ml  
Tablets: 4 mg, 8 mg, 12 mg

**Indications and dosages**  
- **Mild to moderate dementia of Alzheimer’s disease**  
**Adults:** Initially, 4 mg P.O. b.i.d. If patient tolerates dosage well after at least 4 weeks of therapy, increase to 8 mg P.O. b.i.d. May increase to 12 mg P.O. b.i.d. after at least 4 weeks at previous dosage. Recommended range is 16 to 24 mg daily in two divided doses. Or initially, 8 mg P.O. daily (Razadyne ER). If patient tolerates dosage after at least 4 weeks, increase to 16 mg P.O. daily. Further increase to 24 mg P.O. daily should be attempted after minimum of 4 weeks at 16 mg/day.

**Dosage adjustment**  
- Moderate hepatic or renal impairment

**Off-label uses**  
- Vascular dementia

---

**Contraindications**  
- Hypersensitivity to drug  
- Severe hepatic or renal impairment  
- Pregnancy or breastfeeding  
- Children

**Precautions**  
Use cautiously in:  
- asthma, chronic obstructive pulmonary disease, GI bleeding, moderate hepatic or renal impairment, Parkinson’s disease, seizures.

**Administration**  
- Before giving, make sure patient is well hydrated, to minimize GI upset.  
- Give with morning and evening meals.  
- Give with antiemetics as needed.  
- Use pipette to add oral solution to beverage; have patient drink it right away.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**  
- CNS: depression, dizziness, headache, tremor, insomnia, drowsiness, fatigue, syncope  
- CV: bradycardia  
- EENT: rhinitis  
- GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia, anorexia  
- GU: urinary tract infection, hematuria  
- Hematologic: anemia  
- Other: weight loss

**Interactions**  
- **Drug-drug**  
  Anticholinergics: antagonism of anticholinergic activity  
  Cholinergics: synergistic effects  
  Cimetidine, erythromycin, ketoconazole, paroxetine: increased galantamine bioavailability

**Patient monitoring**  
- Assess fluid intake and output to ensure adequate hydration, which helps reduce GI upset.  
- Monitor cognitive status.
● Evaluate patient for cardiac conduction abnormalities. Assess pulse regularly for bradycardia.
● Observe for bleeding tendencies.
 ● Assess for depression and suicidal ideation.

Patient teaching
● Instruct caregiver in proper technique for using oral pipette.
● Teach caregiver how to measure patient’s pulse. Tell him to report slow pulse right away.
● Recommend frequent, small servings of healthy food and adequate fluids to minimize GI upset.
 ● Tell patient or caregiver to watch for and report signs and symptoms of depression.
● Advise patient or caregiver to establish effective bedtime routine.
● Caution caregiver to prevent patient from performing hazardous activities until adverse reactions are known.
● As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

Ganciclovir (DHPG)
Cymevene®, Cytovene, Valcyte®, Vitraset

Pharmacologic class: Acyclic purine nucleoside analog of 2’-deoxyguanosine
Therapeutic class: Antiviral
Pregnancy risk category C

FDA BOXED WARNING
● Drug may lead to granulocytopenia, anemia, and thrombocytopenia. In animal studies, it was carcinogenic and teratogenic and caused aspermatogenesis.

● Drug is indicated only to treat cytomegalovirus (CMV) retinitis in immunocompromised patients and to prevent CMV disease in at-risk transplant patients.

Action
Inhibits binding of deoxyguanosine triphosphate to DNA polymerase by terminating DNA synthesis, thereby inhibiting viral replication

Availability
Capsules: 250 mg, 500 mg
Injection: 500 mg/vial
Intravitreal implant: 4.5 mg

Indications and dosages
➢ Prevention of CMV in advanced human immunodeficiency virus (HIV) infection
Adults: 1,000 mg P.O. t.i.d.
➢ Prevention of CMV in transplant recipients
Adults: 5 mg/kg I.V. q 12 hours for 7 to 14 days; then 5 mg/kg/day 7 days per week or 6 mg/kg/day 5 days per week
➢ CMV retinitis in immunocompromised patients
Adults and children ages 9 and older: Intravitreal implant (4.5 mg) placed during intraocular surgery
Adults and children older than 3 months: Initially, 5 mg/kg I.V. q 12 hours for 14 to 21 days, followed by a maintenance dosage of 5 mg/kg/day 7 days per week or 6 mg/kg 5 days per week. For P.O. maintenance, 1,000 mg P.O. t.i.d. or 500 mg P.O. q 3 hours while patient is awake.

Dosage adjustment
● Renal impairment
● Elderly patients

Off-label uses
● CMV gastroenteritis, CMV pneumonia

Reactions in bold are life-threatening.
Contraindications
- Hypersensitivity to drug or acyclovir
- Neutropenia or thrombocytopenia
- Contraindications for intraocular surgery, such as external infections or thrombocytopenia (with intravitreal implant)
- Breastfeeding

Precautions
Use cautiously in:
- renal impairment
- history of cytopenic reactions
- pregnant patients
- children younger than age 9 (with intravitreal implant).

Administration
- Follow facility policy for handling and disposing of antineoplastic drugs. (Drug shares some properties with antitumor agents.)
- Be aware that safety and efficacy of I.V. use haven’t been established for congenital or neonatal CMV disease, treatment of established CMV disease other than retinitis, or use in nonimmunocompromised individuals.
- Don’t let powder in capsules or I.V. solution contact skin, eyes, or mucous membranes. If contact occurs, wash skin thoroughly with soap and water, or flush eyes with water.
- Reconstitute 500-mg vial with 10 ml of sterile water; shake vial to dissolve drug. Then dilute drug again in 50 to 250 ml of compatible I.V. solution.
- If patient is on fluid restriction, dilute to a concentration of 10 mg/ml or less.
- Administer a single dose by I.V. infusion slowly (over at least 1 hour), using infusion pump or microdrip (60 gtt/ml).
- Give I.V. solution within 24 hours of dilution to reduce risk of bacterial contamination.
- Don’t give by I.V. bolus or by I.M. or subcutaneous route.
- Administer oral doses with food.
- Be aware that intravitreal implant is designed to release drug over 5 to 8 months. Once drug is depleted (as shown by retinitis progression), implant may be removed and replaced.
- Handle intravitreal implant carefully by suture tab only, to avoid damage to polymer coating. (Damage could increase rate of drug release.)

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Slow</td>
<td>2-4 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

intravit.

Adverse reactions
CNS: ataxia, confusion, dizziness, headache, drowsiness, tremor, abnormal thinking, agitation, amnesia, neuropathy, paresthesia, seizures, coma
CV: hypertension, hypotension, phlebitis, arrhythmias
EENT: vision loss for 2 to 4 weeks, vitreous loss, vitreous hemorrhage, cataract, retinal detachment, uveitis, endophthalmitis (all with intravitreal implant)
GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia, flatulence, anorexia, dry mouth
Hematologic: anemia, agranulocytosis, thrombocytopenia, leukopenia
Respiratory: pneumonia
Skin: rash, diaphoresis, pruritus
Other: fever; infection; chills; inflammation, pain, and phlebitis at injection site; sepsis

Interactions
Drug-drug. Amphotericin B, cyclosporine, other nephrotoxic drugs: increased risk of renal impairment and ganciclovir toxicity
Cilastatin, imipenem: increased seizure activity
Cytotoxic drugs: increased toxic effects
Immunosuppressants: increased immunologic and bone marrow depression
Probenecid: increased ganciclovir blood level
Zidovudine: increased risk of agranulocytosis

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, creatinine, gamma-glutamyltransferase: increased values
Granulocytes, hemoglobin, neutrophils, platelets, white blood cells: decreased values
Liver function tests: abnormal results

Patient monitoring
- Monitor liver function test results.
- Monitor neutrophil and platelet counts.
- Assess fluid intake and output to ensure adequate hydration.
- Make sure patient has regular ophthalmic examinations during both induction and maintenance therapy.
  - Monitor neurologic status closely; watch for seizures and coma.
  - Check for signs and symptoms of infection, particularly sepsis.

Patient teaching
- Advise patient to immediately report signs and symptoms of infection, including those at infusion site.
- Instruct patient to immediately report easy bruising or bleeding.
- Instruct patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Caution female patient not to breastfeed.
- Inform patient that drug may cause birth defects. Tell females to use effective birth control during therapy; advise males to use barrier contraception during and for 90 days after therapy.
  - Caution patient not to open or crush capsule. If powder from capsule contacts skin or eyes, tell him to wash skin thoroughly with soap and water or flush eyes with water.
- Instruct patient to minimize GI upset by eating frequent, small servings of healthy food.
- Tell patient he’ll undergo regular blood testing during therapy.
- Explain that drug doesn’t cure CMV retinitis and that patient should have eye exams every 4 to 6 weeks during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

ganirelix acetate
Orgalutran

Pharmacologic class: Gonadotropin-releasing hormone (GnRH) antagonist
Therapeutic class: Sex hormone
Pregnancy risk category X

Action
Competitively blocks GnRH receptors on pituitary gonadotroph, suppressing secretion of gonadotropin and luteinizing hormone (LH) and thereby preventing ovulation

Availability
Prefilled syringe: 250 mcg/0.5 ml

Indications and dosages
To inhibit premature LH surges during controlled ovarian hyperstimulation
Adult women: 250 mcg subcutaneously daily during early to mid-follicular phase

Contraindications
- Hypersensitivity to drug, its components, GnRH, or GnRH analogs
- Known or suspected pregnancy

Reactions in bold are life-threatening.
Precautions
Use cautiously in:
● GnRH sensitivity
● latex sensitivity (packaging contains natural rubber latex)
● breastfeeding patients.

Administration
Know that pregnancy must be excluded before therapy begins.
● Inject into abdomen (around navel) or upper thigh.
● Be aware that drug is given with follicle-stimulating hormone (FSH).
After starting FSH on day 2 or 3 of menstrual cycle, patient receives ganirelix on morning of day 7 or 8 and continues this drug until adequate follicular response occurs. Then human chorionic gonadotropin is given and FSH and ganirelix are discontinued.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcut.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache
GI: nausea, abdominal pain of GI tract origin
GU: abdominal pain of gynecologic origin, vaginal bleeding, ovarian hyperstimulation syndrome
Other: injection site reaction, fetal death

Interactions
Drug-diagnostic tests. Hematocrit, total bilirubin: decreased values
Neutrophils: altered count (8.3/mm³ or greater)

Patient monitoring
Monitor patient for adverse effects, especially ovarian hyperstimulation.
● Monitor total bilirubin level and CBC with white cell differential.

Patient teaching
● Inform patient about possible adverse reactions.
● Teach patient about duration of treatment and required monitoring procedures.
Urge patient to tell prescriber if she is pregnant before starting drug.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

---

gatifloxacin
Zymar

Pharmacologic class: Fluoroquinolone
Therapeutic class: Anti-infective
Pregnancy risk category C

Action
Inhibits bacterial DNA gyrase (enzyme involved in bacterial DNA replication, transcription, and repair) in susceptible gram-negative and gram-positive aerobic and anaerobic bacteria

Availability
Ophthalmic solution: 0.3% (5 ml in 8-ml bottle with dropper)

Indications and dosages
Bacterial conjunctivitis caused by susceptible strains of Corynebacterium propinquaum, Haemophilus influenzae, Staphylococcus epidermidis, Staphylococcus aureus, Streptococcus mitis, and Streptococcus pneumoniae

Adults and children ages 1 and older: One drop every 2 hours in affected eye(s) while awake, up to eight times daily on days 1 and 2; then one drop up to four times daily while awake on days 3 to 7

---

Canada UK Hazardous drug High alert drug
Contraindications
- Hypersensitivity to drug, its components, or other quinolones

Precautions
Use cautiously in:
- pregnant or breastfeeding patients
- children younger than age 1.

Administration
- Don’t inject subconjunctivally.
- Don’t administer directly into anterior or chamber of eye.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ophthalmic</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache
EENT: reduced visual acuity, conjunctival irritation or hemorrhage, increased lacrimation, keratitis, papillary conjunctivitis, chemosis, dry eye, eye discharge, eye irritation or redness, eye pain, eyelid edema
Other: abnormal taste, superinfection (with prolonged use), allergic reaction

Interactions
None

Patient monitoring
- Stop drug and immediately report signs or symptoms of allergic reaction, including rash, itching, swelling, dizziness, and trouble breathing.

Patient teaching
- Teach patient how to use eyedrops. Caution him not to let dropper tip touch eye, finger, or other surfaces.
- If patient is also using other types of eyedrops, instruct him to wait at least 5 minutes after administering gatifloxacin before applying them.
- Instruct patient to stop taking drug and contact prescriber immediately if rash, itching, swelling, dizziness, or difficulty breathing occurs.

- Advise patient to avoid driving and other hazardous activities until drug effects are known.
- Caution patient with bacterial conjunctivitis not to wear contact lenses.
- As appropriate, review all other significant adverse reactions.

gefitinib
Iressa

Pharmacologic class: Epidermal growth factor receptor inhibitor
Therapeutic class: Antineoplastic
Pregnancy risk category D

Action
Unclear. Inhibits tyrosine kinase action, which inhibits cell growth and reproduction. May also inhibit angiogenesis in tumor cells.

Availability
Tablets: 250 mg

Indications and dosages
Locally advanced or metastatic non-small-cell lung cancer after failure of platinum-based and docetaxel chemotherapy
Adults: 250 mg P.O. daily

Dosage adjustment
- Patients with diarrhea or skin reactions, pulmonary symptoms, or ocular symptoms
- Patients taking CYP3A4 inducers concurrently

Contraindications
- Severe hypersensitivity to drug or its components

Precautions
Use cautiously in:
- hepatic impairment or hepatotoxicity
pregnant or breastfeeding patients

Administration

• Give with or without food.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>3-7 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: asthenia
EENT: amblyopia, conjunctivitis, eye pain and corneal ulcer
GI: diarrhea, nausea, vomiting, mouth ulcers, anorexia
Respiratory: dyspnea, interstitial lung disease
Skin: acne, rash, dry skin, pruritus, vesiculobullous rash
Other: peripheral edema, weight loss

Interactions

Drug-drug. Histamine_2-receptor antagonists (such as cimetidine, ranitidine), phenytoin, rifampin: decreased gefitinib blood level
Itraconazole, ketoconazole: increased gefitinib blood level
Metoprolol: increased metoprolol exposure
Warfarin: increased International Normalized Ratio (INR), increased bleeding events

Drug-diagnostic tests. Alkaline phosphatase, bilirubin, hepatic enzymes: increased levels

Patient monitoring

• Monitor INR and watch for signs and symptoms of bleeding if patient is also receiving warfarin.
• Monitor liver function test results.
  Watch for dehydration if patient has severe or persistent diarrhea, anorexia, nausea, or vomiting.
  If patient experiences worsening pulmonary symptoms, severe diarrhea, skin reactions, or ocular symptoms, expect to stop therapy until cause is determined or problems resolve.
  Discontinue therapy if interstitial lung disease is confirmed.

Patient teaching

• Tell patient to take with or without food.
  Instruct patient to immediately report severe or persistent diarrhea, anorexia, nausea, vomiting, increased shortness of breath or cough, eye irritation, or new symptoms.
• Caution female of childbearing age not to become pregnant.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

gemcitabine hydrochloride

Pharmacologic class: Antimetabolite (pyrimidine analog)
Therapeutic class: Antineoplastic
Pregnancy risk category D

Action
Kills malignant cells undergoing DNA synthesis; arrests progression of cells at G1/S border

Availability
Powder for injection: 200 mg in 10-ml vial, 1 g in 50-ml vial

Indications and dosages

Pancreatic cancer
Adults: 1,000 mg/m^2 I.V. q week for 7 weeks, followed by 1 week of rest. May continue with cycles of once-weekly administration for 3 weeks, followed by 1 week of rest.
Non-small-cell lung cancer (given with cisplatin)

**Adults:** 1,000 mg/m² I.V. on days 1, 8, and 15 of 28-day cycle; or 1,250 mg/m² on days 1 and 8 of 21-day cycle. Cisplatin also given on day 1.

Breast cancer (combined with paclitaxel after failure of anthracyline-containing adjuvant chemotherapy, unless anthracyclines were contraindicated)

**Adults:** 1,250 mg/m² I.V. over 30 minutes on days 1 and 8 of 21-day cycle, with paclitaxel given on day 1 before gemcitabine

Advanced ovarian cancer after 6-month failure on platinum-based therapy (combined with carboplatin)

**Adults:** 1,000 mg/m² I.V. over 30 minutes on days 1 and 8 of each 21-day cycle, with carboplatin given on day 1 after gemcitabine administration

**Dosage adjustment**
- Bone marrow depression

**Off-label uses**
- Bladder cancer

**Contraindications**
- Hypersensitivity to drug

**Precautions**
- Use cautiously in:
  - hepatic or renal impairment
  - females of childbearing age
  - pregnant or breastfeeding patients.

**Administration**
- Follow facility policy for preparing, handling, and administering carcinogetic, mutagenic, and teratogenic drugs.
- Add 5 ml of preservative-free normal saline solution to 200-mg vial, or add 25 ml of this solution to 1-g vial. Shake vial to dissolve drug.
- Reconstitute drug to a concentration of 40 mg/ml. If necessary, dilute further to a concentration of 1 mg/ml.

Infuse each dose over 30 minutes. (Infusions lasting longer than 1 hour increase toxicity risk.)

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** paresthesia

**GI:** nausea, vomiting, diarrhea, stomatitis

**GU:** hematuria, proteinuria, hemolytic uremic syndrome, renal failure

**Hematologic:** anemia, leukopenia, thrombocytopenia

**Respiratory:** dyspnea, bronchospasm

**Skin:** alopecia, rash, cellulitis

**Other:** flulike symptoms, fever, edema, injection site reactions, anaphylactoid reactions

**Interactions**

**Drug-drug.** Live-virus vaccines: decreased antibody response to vaccine, increased risk of adverse reactions

**Other antineoplastics:** additive bone marrow depression

**Drug-diagnostic tests.** Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin: transient increases

**Blood urea nitrogen, serum creatinine:** increased levels

**Patient monitoring**
- Stop infusion and notify prescriber immediately if patient has signs or symptoms of allergic reaction.
- Monitor liver and kidney function test results.
- Monitor CBC with white cell differential (particularly neutrophil and platelet counts) before each dose.
- Assess degree of bone marrow depression. Expect dosage changes based on blood counts.
- Watch for signs and symptoms of infection and bleeding tendencies, even after drug therapy ends.
- Evaluate respiratory status regularly.

Reactions in **bold** are life-threatening.
Monitor temperature, especially during first 12 hours of therapy.

**Patient teaching**
- Instruct patient to stop taking drug and immediately report signs or symptoms of allergic reaction.
- Advise patient to immediately report signs or symptoms of infection (especially flulike symptoms).
- Instruct patient to report unusual bleeding or bruising, change in urination pattern, or difficulty breathing.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Advise patient to avoid activities that can cause injury. Tell him to use soft toothbrush and electric razor to avoid gum and skin injury.
- Tell patient to minimize GI upset by eating frequent, small servings of healthy food.
- Inform patient that he’ll undergo blood testing periodically throughout therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**gemfibrozil**

Apo-Gemfibrozil, Dom-Gemfibrozil, Gen-Gemfibrozil, Lopid, Novo-Gemfibrozil, Nu-Gemfibrozil, PMS-Gemfibrozil, Riva-Gemfibrozil

**Pharmacologic class:** Fibric acid derivative  
**Therapeutic class:** Antihyperlipidemic  
**Pregnancy risk category C**

**Action**
Inhibits peripheral lipolysis, resulting in decreased triglyceride levels. Also inhibits synthesis and increases clearance of very-low-density lipoproteins.

**Availability**
*Tablets: 600 mg*

**Indications and dosages**
- Type IIb hyperlipidemia in patients without coronary artery disease who don’t respond to other treatments; adjunctive therapy for types IV and V hyperlipidemia  
  - **Adults:** 1,200 mg P.O. daily in two divided doses

**Contraindications**
- Hypersensitivity to drug  
- Gallbladder disease  
- Severe renal dysfunction  
- Hepatic dysfunction

**Precautions**
Use cautiously in:  
- renal impairment, cholelithiasis, diabetes, hypothyroidism  
- pregnant or breastfeeding patients  
- children (safety not established).

**Administration**
- Give 30 minutes before a meal.  
- Know that before starting drug and throughout therapy, patient should use dietary measures and exercise, as appropriate, to control hyperlipidemia.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>2-5 days</td>
<td>4 wk</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
CNS: fatigue, hypoesthesia, paresthesia, drowsiness, syncope, vertigo, dizziness, headache, seizures  
CV: vasculitis  
EENT: cataracts, blurred vision, retinal edema, hoarseness
GI: nausea, vomiting, diarrhea, abdominal or epigastric pain, heartburn, flatulence, gallstones, dry mouth
GU: dysuria, erectile dysfunction, decreased male fertility
Hematologic: eosinophilia, anemia, bone marrow hypoplasia, leukopenia, thrombocytopenia
Hepatic: hepatotoxicity
Metabolic: hypoglycemia
Musculoskeletal: joint, back, or muscle pain; myasthenia; myopathy; synovitis; myositis; rhabdomyolysis
Respiratory: cough
Skin: alopecia, rash, urticaria, eczema, pruritus, angioedema
Other: abnormal taste, chills, weight loss, increased risk of bacterial and viral infection, lupuslike syndrome, anaphylaxis

Interactions
Drug-drug. Chenodiol, ursodiol: decreased gemfibrozil efficacy
Cyclosporine: decreased cyclosporine effects
HMG-CoA reductase inhibitors: increased risk of rhabdomyolysis
Sulfonylureas: increased hypoglycemic effects
Warfarin: increased bleeding risk

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, creatine kinase (CK), glucose, lactate dehydrogenase: increased values
Hematocrit, hemoglobin, potassium, white blood cells: decreased values

Patient teaching
- Tell patient to take drug 30 minutes before breakfast and dinner.
- Advise patient to immediately report signs or symptoms of anaphylaxis (such as difficulty breathing or rash) or other allergic reactions.
- Instruct patient to immediately report unusual bleeding or bruising or muscle pain.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Stress importance of diet and exercise in lowering lipid levels.
- Inform patient that he’ll undergo regular blood testing during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Clinical alert
Reactions in bold are life-threatening.
Action
Inhibits DNA synthesis by inhibiting DNA gyrase and topoisomerase IV, enzymes needed for bacterial growth

Availability
Tablets: 320 mg

Indications and dosages
➣ Acute exacerbation of chronic bronchitis caused by susceptible organisms
  Adults: 320 mg P.O. daily for 5 days
➣ Mild to moderate community-acquired pneumonia caused by susceptible organisms
  Adults: 320 mg P.O. daily for 5 days

Dosage adjustment
● Renal impairment

Contraindications
● Hypersensitivity to drug
● History of prolonged QTc interval

Precautions
Use cautiously in:
● epilepsy or history of seizures
● pregnant or breastfeeding patients
● children younger than age 18 (safety not established).

Administration
● Give at same time every day with plenty of fluids, with or without food.
● Make sure patient swallows tablet whole without chewing.
● Don’t give iron, multivitamins, didanosine, sucralfate, or antacids containing magnesium or aluminum within 3 hours of gemifloxacin.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>0.5-2 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: fatigue, headache, insomnia, drowsiness, nervousness, dizziness, tremor, vertigo, seizures, loss of consciousness
CV: hypotension, prolonged QTc interval, cardiovascular collapse, shock
EENT: vision abnormality, pharyngitis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, gastritis, gastroenteritis, flatulence, anorexia, dry mouth, pseudomembranous colitis
GU: genital candidiasis, vaginitis, acute renal insufficiency or failure, interstitial nephritis
Hematologic: eosinophilia, anemia, leukopenia, granulocytopenia, thrombocytopenia
Hepatic: jaundice, hepatitis, acute hepatic necrosis, hepatic failure
Metabolic: hyperglycemia
Musculoskeletal: joint, back, or muscle pain; leg cramps; tendinitis; rupture of shoulder, hand, or Achilles tendon
Respiratory: dyspnea, pneumonia
Skin: rash, urticaria, pruritus, eczema, flushing, photosensitivity, angioedema
Other: altered taste, hot flashes, fungal infection, hypersensitivity reaction

Interactions
Drug-drug. Antacids containing aluminum or magnesium, didanosine, iron, multivitamins, sucralfate: reduced gemifloxacin absorption
Antiarrhythmics (class IA, such as quinidine and procainamide, and class III, such as amiodarone and sotalol), antipsychotics, erythromycin, tricyclic antidepressants: increased risk of prolonged QTc interval
Sucralfate: decreased gemifloxacin bioavailability

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, bilirubin: increased levels

Drug-behaviors. Sun exposure: increased risk of photosensitivity

Patient monitoring
● Stay alert for signs and symptoms of hypersensitivity reaction and other serious adverse reactions.
Monitor ECG in patients at risk for prolonged QTc interval.

Watch for signs and symptoms of tendinitis or tendon rupture.

**Patient teaching**

- Instruct patient to take drug at same time each day, with or without food.
- Teach patient how to recognize and report signs and symptoms of allergic response.
- Advise patient to take iron, vitamins, antacids, didanosine, or sucralfate 3 hours before or 2 hours after gemifloxacin.
- Instruct patient to stop taking drug and immediately report signs or symptoms of hypersensitivity reaction, severe diarrhea, change in urination pattern, easy bruising or bleeding, unusual tiredness, or yellowing of eyes or skin.
- Advise patient to stop taking drug and immediately report sudden severe pain in shoulder, hand, or Achilles tendon.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

---

**FDA BOXED WARNING**

- Observe patient closely for potential ototoxicity and nephrotoxicity. Safety isn’t established in therapy exceeding 14 days.
- Neuromuscular blockade and respiratory paralysis have occurred after administration.
- Monitor renal function and eighth-nerve function closely, especially in patients with known or suspected renal impairment at onset of therapy, as well as those with initially normal renal function who develop signs of renal dysfunction during therapy.
- Avoid concurrent use with potent diuretics (such as furosemide and ethacrynic acid), because diuretics may cause ototoxicity. Also, I.V. diuretics may increase gentamicin toxicity by altering antibiotic serum and tissue levels.
- Avoid concurrent and sequential systemic, oral, or topical use of other neurotoxic or nephrotoxic products and other aminoglycosides. Advanced age and dehydration also may increase toxicity risk.
- Drug may harm fetus when given to pregnant women.

---

**Action**

Destroys gram-negative bacteria by irreversibly binding to 30S subunit of bacterial ribosomes and blocking protein synthesis, resulting in misreading of genetic code and separation of ribosomes from messenger RNA.

**Availability**

- Cream: 0.1%
- Injection: 10 mg/ml (pediatric), 40 mg/ml (adult)
- I.V. infusion (premixed in normal saline solution): 40 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 120 mg
- Ointment: 0.1%
- Ointment (ophthalmic): 0.3% (base)
- Solution (ophthalmic): 0.3% (base)

---

Reactions in **bold** are life-threatening.

---

**gentamicin sulfate**

- Alcomycin, Cidomycin, Diogent, Garamycin, Gentacidin, Gentak, Genticin, PMS-Gentamicin, Ratio-Gentamicin

**Pharmacologic class:** Aminoglycoside

**Therapeutic class:** Anti-infective

**Pregnancy risk category D** (parenteral), C (topical)
**Indications and dosages**

- Serious infections caused by *Pseudomonas aeruginosa*, *Escherichia coli*, and *Proteus*, *Klebsiella*, *Serratia*, *Enterobacter*, *Citrobacter*, or *Staphylococcus* species

  **Adults:** 3 mg/kg/day in three divided doses I.M. or I.V. infusion q 8 hours. For life-threatening infections, up to 5 mg/kg/day in three to four divided doses; reduce to 3 mg/kg/day as indicated.

  **Children:** 2 to 2.5 mg/kg q 8 hours I.M. or I.V. infusion

  **Infants older than 1 week:** 2.5 mg/kg q 8 hours I.M. or I.V. infusion

  **Neonates younger than 1 week, pre-term infants:** 2.5 mg/kg q 12 hours I.M. or I.V. infusion. In preterm infants of less than 32 weeks’ gestational age, 2.5 mg/kg q 18 hours or 3 mg/kg q 24 hours also may produce satisfactory peak and trough blood levels.

- **Endocarditis prophylaxis before surgery**

  **Adults:** 1.5 mg/kg I.M. or I.V. 30 minutes before surgery, to a maximum of 80 mg. As prescribed, give with ampicillin or vancomycin.

  **Children:** 2 mg/kg I.M. or I.V. 30 minutes before surgery, to a maximum of 80 mg

- **External ocular infections caused by susceptible organisms**

  **Adults and children:** One to two drops of ophthalmic solution in eye q 4 hours. For serious infections, up to two drops q hour, or ophthalmic ointment applied to lower conjunctival sac two to three times daily.

- **Treatment and prevention of superficial burns caused by susceptible bacteria**

  **Adults and children older than age 1:** Gently rub small amounts of drug topically on affected area three or four times daily.

**Dosage adjustment**

- Renal impairment
- Cystic fibrosis

**Contraindications**

- Hypersensitivity to drug or other aminoglycosides

**Precautions**

- Use cautiously in:
  - neuromuscular disease, renal impairment, hearing impairment
  - sulfite sensitivity (with parenteral use)
  - obese patients
  - elderly patients
  - pregnant or breastfeeding patients
  - infants, neonates, and premature infants.

**Administration**

- Before starting therapy, obtain specimens as needed for culture and sensitivity testing.
- For I.V. infusion, dilute with 50 to 200 ml of dextrose 5% in water (D₅W) or normal saline solution, and administer over 30 minutes to 2 hours.
- After infusion, flush line with normal saline solution or D₅W.
- Obtain peak drug blood level 30 minutes after 30-minute infusion; obtain trough level within 30 minutes of next scheduled dose.
- Give cephalosporin or parenteral penicillin 1 hour before or after gentamicin, as prescribed.
- Know that for topical treatment of burns, gauze dressings may be applied.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>30-90 min</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.M.</td>
<td>Unknown</td>
<td>30-90 min</td>
<td>Unknown</td>
</tr>
<tr>
<td>Topical, ophthalmic</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- CNS: dizziness, vertigo, tremors, numbness, depression, confusion, lethargy,
headache, paresthesia, neuromuscular blockade, seizures, neurotoxicity

EENT: visual disturbances, dry eyes, nystagmus, photophobia, ototoxicity, hearing loss, tinnitus

GI: nausea, vomiting, stomatitis, increased salivation, splenomegaly, anorexia

GU: increased urinary casts, polyuria, dysuria, erectile dysfunction, azotemia, nephrotoxicity

Hematologic: eosinophilia, leukemoid reaction, hemolytic anemia, aplastic anemia, neutropenia, agranulocytosis, leukopenia, thrombocytopenia, pancytopenia

Hepatic: hepatomegaly, hepatotoxicity, hepatic necrosis

Musculoskeletal: joint pain, muscle twitching

Respiratory: apnea

Skin: exfoliative dermatitis, rash, pruritus, urticaria, purpura, alopecia

Other: weight loss, superinfection, pain and irritation at I.M. injection site

Patient monitoring

- Watch for signs and symptoms of hypersensitivity reactions.
- Know that drug blood level monitoring is especially important in therapy lasting more than 5 days, acute or chronic renal impairment, extracellular fluid volume changes, obesity, infants younger than 3 months, concomitant use of nephrotoxic drugs, patients requiring higher doses or dosage interval adjustments (such as those with cystic fibrosis, endocarditis, or critical illness), and patients with signs or symptoms of nephrotoxicity or ototoxicity.
- Assess fluid intake and output, urine specific gravity, and urinalysis for signs of nephrotoxicity.
- Monitor CBC, BUN, creatinine level, and creatinine clearance.
- Weigh patient regularly.
- Assess for signs and symptoms of ototoxicity (hearing loss, tinnitus, ataxia, and vertigo).

Patient teaching

- Teach patient to recognize and immediately report signs and symptoms of hypersensitivity reaction, infection, unusual tiredness, yellowing of skin or eyes, and muscle twitching.
- Advise patient to report signs and symptoms of ototoxicity (hearing loss, ringing in ears, vertigo).
- Instruct patient to drink plenty of fluids to ensure adequate urine output.
- Tell patient to monitor urine output and report significant changes.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Reactions in **bold** are life-threatening.
glatiramer acetate
Copaxone

**Pharmacologic class:** Immuno-modulator  
**Therapeutic class:** Multiple sclerosis agent  
**Pregnancy risk category B**

**Action**  
Unknown. Thought to alter immune processes believed to be responsible for pathogenesis of multiple sclerosis.

**Availability**  
*Injection:* 20 mg lyophilized glatiramer acetate and 40 mg mannitol in single-use 2-ml vial (1-ml vial of sterile water for injection included for reconstitution)

**Indications and dosages**  
➢ To reduce frequency of relapses in relapsing-remitting multiple sclerosis  
**Adults:** 20 mg/day subcutaneously

**Contraindications**  
- Hypersensitivity to drug

**Precautions**  
Use cautiously in:  
- pregnant or breastfeeding patients  
- children (safety and efficacy not established).

**Administration**  
- Give only by subcutaneous injection into arms, abdomen, hips, or thighs.  
- Administer immediately after preparing. Discard unused portion.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcut.</td>
<td>Slow</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**  
CNS: abnormal dreams, agitation, anxiety, confusion, emotional lability, migraine, nervousness, speech disorder, stupor, tremor, weakness, vertigo  
CV: chest pain, hypertension, palpitations, tachycardia, peripheral edema  
EENT: eye disorder, nystagmus, ear pain, rhinitis  
GI: nausea, vomiting, diarrhea, anorexia, gastroenteritis, other GI disorder, oral candidiasis, salivary gland enlargement, ulcerative stomatitis  
GU: urinary urgency, hematuria, erectile dysfunction, amenorrhea, dysmenorrhea, menorrhagia, abnormal Papnicolaou smear, vaginal candidiasis, vaginal hemorrhage  
Hematologic: ecchymosis, lymphadenopathy  
Musculoskeletal: joint, back, or neck pain; foot drop; hypertonia  
Respiratory: bronchitis, dyspnea, hyperventilation  
Skin: eczema, erythema, diaphoresis, pruritus, rash, skin atrophy, skin nodules, urticaria, warts  
Other: dental caries, facial edema, weight gain, herpes simplex, herpes zoster, cysts, chills, flulike symptoms, pain at injection site

**Interactions**  
None reported

**Patient monitoring**  
➢ Assess for immediate postinjection reaction, including flushing, chest pain, anxiety, breathing problems, and hives.  
- Watch for transient chest pain, but be aware that this problem doesn’t seem to be clinically significant.  
- Check for vaginal bleeding.  
- Watch for signs and symptoms of infection.

**Patient teaching**  
➢ Teach patient how to prepare and self-administer drug. Supervise him the first time he does so.  
➢ Teach patient to recognize and immediately report signs and symptoms.
of postinjection reaction. Tell him this reaction may occur right away or up to several months after first dose.

- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Instruct patient to report signs or symptoms of infection or vaginal hemorrhage.
- Provide dietary counseling. Refer patient to dietitian if adverse GI effects significantly affect food intake.
- As appropriate, review all other significant and life-threatening adverse reactions.

**glimepiride**

Amaryl, Apo-Glimepiride®, CO Glimepiride®, Novo-Glimepiride®, PMS-Glimepiride®, Ratio-Glimepiride®, Sandoz Glimepiride®

**Pharmacologic class:** Sulfonylurea  
**Therapeutic class:** Hypoglycemic  
**Pregnancy risk category C**

**Action**

Lowers blood glucose level by stimulating insulin release from pancreas, increasing insulin sensitivity at receptor sites, and decreasing hepatic glucose production. Also increases peripheral tissue sensitivity to insulin and causes mild diuresis.

**Availability**

*Tablets:* 1 mg, 2 mg, 4 mg

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1 hr</td>
<td>2-3 hr</td>
<td>&gt;24 hr</td>
</tr>
</tbody>
</table>

Reactions in **bold** are life-threatening.

Daily. When patient reaches 2 mg/day, increase no more than 2 mg q 1 to 2 weeks, depending on glycemic control. Maximum dosage is 8 mg/day.

> Adjunct to insulin therapy in type 2 diabetes mellitus when diet, exercise, or glimepiride alone prove ineffective  
**Adults:** 8 mg P.O. daily with low-dose insulin, given with first main meal. Based on glycemic control, raise insulin dosage weekly as prescribed.

> Adjunct to metformin therapy in type 2 diabetes mellitus when diet, exercise, and glimepiride or metformin alone prove ineffective  
**Adults:** 1 to 4 mg/day P.O. with first main meal, increased gradually to a maximum of 8 mg/day P.O. Give with metformin if response to glimepiride monotherapy isn’t adequate; adjust dosage based on glycemic response to determine minimum effective dosage.

**Dosage adjustment**

- Renal or hepatic impairment  
- Adrenal or pituitary insufficiency

**Contraindications**

- Hypersensitivity to drug  
- Diabetic coma or ketoacidosis  
- Severe renal, hepatic, or endocrine disease  
- Pregnancy or breastfeeding

**Precautions**

Use cautiously in:

- mild to moderate hepatic or renal disease; cardiovascular disease; impaired thyroid, pituitary, or adrenal function  
- elderly patients.

**Administration**

- Check baseline creatinine level for normal renal function before giving first dose.  
- Give with first meal of day.
Adverse reactions
CNS: dizziness, drowsiness, headache, weakness
CV: increased CV mortality risk
EENT: blurred vision
GI: nausea, vomiting, diarrhea, constipation, cramps, heartburn, epigastric distress, anorexia
Hematologic: aplastic anemia, leukopenia, pancytopenia, thrombocytopenia, agranulocytosis
Hepatic: cholestatic jaundice, hepatitis
Metabolic: hyponatremia, hypoglycemia
Skin: rash, erythema, maculopapular eruptions, urticaria, eczema, angioedema, photosensitivity
Other: increased appetite

Interactions
Drug-drug. Androgens (such as testosterone), chloramphenicol, clofibrate, guanethidine, MAO inhibitors, nonsteroidal anti-inflammatory drugs (except diclofenac), salicylates, sulfonamides, tricyclic antidepressants: increased risk of hypoglycemia
Beta-adrenergic blockers: altered response to glimepiride, necessitating dosage change; prolonged hypoglycemia (with nonselective agents)
Calcium channel blockers, corticosteroids, estrogens, hydantoins, hormonal contraceptives, isoniazid, nicotinic acid, phenothiazines, phenytoin, rifampin, sympathomimetics, thiazide diuretics, thyroid preparations: decreased hypoglycemic effect of glimepiride
Warfarin: initially increased, then decreased, effects of both drugs

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, cholesterol, liver function tests: increased values
Glucose, granulocytes, hemoglobin, platelets, white blood cells: decreased values

Drug-herbs. Agoral marshmallow, aloe (oral), bitter melon, burdock, chromium, coenzyme Q10, dandelion, eucalyptus, fenugreek: additive hypoglycemic effects
Glucosamine: impaired glycemic control

Drug-behaviors. Alcohol use: disulfiram-like reaction
Sun exposure: increased risk of photosensitivity

Patient monitoring
- Monitor CBC with white cell differential, electrolyte levels, and blood chemistry results.
- Monitor blood glucose level regularly. Assess glycosylated hemoglobin level every 3 to 6 months.
- Evaluate kidney and liver function test results frequently, especially in patients with impairments.
- Assess neurologic status. Report cognitive or sensory impairment.

Patient teaching
- Instruct patient to self-monitor his blood glucose level as prescribed.
- Teach patient how to recognize signs and symptoms of hypoglycemia and hyperglycemia.
- Stress importance of diet and exercise to help control diabetes.
- Instruct patient to wear or carry medical identification describing his condition.
- Advise patient to keep sugar source readily available at all times in case of hypoglycemia.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Tell patient he will undergo regular blood testing during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.
glipizide
Glibenese®, Glucotrol, Glucotrol XL, Minodiab

Pharmacologic class: Sulfonylurea
Therapeutic class: Hypoglycemic
Pregnancy risk category C

Action
Lowers blood glucose level by stimulating insulin release from pancreas, increasing insulin sensitivity at receptor sites, and decreasing hepatic glucose production. Also increases peripheral tissue sensitivity to insulin and causes mild diuresis.

Availability
Tablets: 5 mg, 10 mg
Tablets (extended-release): 5 mg, 10 mg

 indica tions and dosages
To control blood glucose in type 2 (non-insulin-dependent) diabetes mellitus in patients who have some pancreatic function and don’t respond to diet therapy
Adults: 5 mg/day P.O. initially, increased as needed after several days (range is 2.5 to 40 mg/day). Give extended-release tablet once daily; maximum dosage is 20 mg/day. Give daily dosage above 15 mg in two divided doses.
Conversion from insulin therapy
Adults: With insulin dosage above 20 units/day, start with usual glipizide dosage and reduce insulin dosage by 50%. With insulin dosage of 20 units/day or less, insulin may be discontinued when glipizide therapy starts.

Dosage adjustment
• Hepatic or renal impairment
• Elderly patients

Contraindications
• Hypersensitivity to drug
• Severe renal, hepatic, thyroid, or other endocrine disease
• Uncontrolled infection, serious burns, or trauma
• Diabetic ketoacidosis
• Pregnancy or breastfeeding

Precautions
Use cautiously in:
• mild to moderate hepatic, renal, or cardiovascular disease; impaired thyroid, pituitary, or adrenal function
• elderly patients.

Administration
• Check baseline creatinine level for normal renal function before giving first dose.
• Give daily dose (extended-release) at breakfast.
• Administer immediate-release tablets 30 minutes before a meal (preferably breakfast). If patient takes two daily doses, give second dose before dinner.

Reactions in bold are life-threatening.

Clinical alert
Interactions

Drug-drug. Androgens (such as testosterone), chloramphenicol, clofibrate, guanethidine, MAO inhibitors, nonsteroidal anti-inflammatory drugs (except diclofenac), salicylates, sulfonamides, tricyclic antidepressants: increased risk of hypoglycemia

Beta-adrenergic blockers: altered response to glipizide, requiring dosage change; prolonged hypoglycemia (with nonselective beta blockers)

Calcium channel blockers, corticosteroids, estrogens, hydantoins, hormonal contraceptives, isoniazid, nicotinic acid, phenothiazines, phenytoin, rifampin, sympathomimetics, thiazide diuretics, thyroid preparations: decreased hypoglycemic effect

Warfarin: initially increased, then decreased, effects of both drugs

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, cholesterol: increased values

Glucose, granulocytes, hemoglobin, platelets, white blood cells: decreased values

Drug-herbs. Aloe (oral), bitter melon, burdock, chromium, coenzyme Q10, dandelion, eucalyptus, fenugreek: additive hypoglycemic effects

Glucosamine: impaired glycemic control

Drug-behaviors. Alcohol use: disulfiram-like reaction

Patient monitoring

- Monitor blood glucose level, especially during periods of increased stress.
- Evaluate CBC and renal function tests.
- If patient is ill or has abnormal laboratory values, monitor electrolyte, ketone, glucose, pH, lactate dehydrogenase, and pyruvate levels.
- Monitor cardiovascular status.

Patient teaching

- Advise patient to take daily dose of extended-release tablets with breakfast or immediate-release tablet 30 minutes before breakfast (and second dose, if prescribed, before dinner).
- Advise patient to monitor blood glucose level as instructed by prescriber.
- Tell patient he may need supplemental insulin during times of stress or when he can’t maintain adequate oral intake.
- Teach patient how to recognize signs and symptoms of hypoglycemia and hyperglycemia.
- Stress importance of diet and exercise to help control diabetes.
- Instruct patient to wear or carry medical identification describing his condition.
- Advise patient to keep sugar source at hand at all times in case of hypoglycemia.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Tell patient he’ll undergo regular blood testing during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

glucagon

GlucaGen

Pharmacologic class: Antihypoglycemic

Therapeutic class: Insulin antagonist

Pregnancy risk category B
Action
Increases blood glucose concentration by converting glycogen in liver to glucose. Also relaxes GI smooth muscle.

Availability
*Powder for injection:* 1-mg vials

**Indications and dosages**

- **Severe hypoglycemia**
  - Adults and children weighing more than 20 kg (44 lb): 1 mg subcutaneously, I.M., or I.V.
  - Children weighing 20 kg (44 lb) or less: 20 to 30 mcg/kg or 0.5-mg dose subcutaneously, I.M., or I.V.
- **Diagnostic aid for radiologic examination**
  - Adults: 0.25 to 2 mg I.V. or 1 to 2 mg I.M. before radiologic procedure

**Contraindications**
- Hypersensitivity to drug
- Pheochromocytoma

**Precautions**
Use cautiously in:
- cardiac disease, adrenal insufficiency, chronic hypoglycemia
- history suggesting insulinoma or pheochromocytoma
- elderly patients
- pregnant or breastfeeding patients

**Administration**
- Use only in hypoglycemic emergencies for patients with diabetes mellitus.
- Mix drug in 1-mg vial with 1 ml of diluent supplied by manufacturer.
- For I.V. injection, give 1 mg over 1 minute.
- Use drug immediately after preparing; discard unused portion.
- Patient should respond within 15 minutes. Because of potential serious adverse reactions linked to prolonged cerebral hypoglycemia, give I.V. glucose if patient fails to respond to glucagon.
- Give patient carbohydrate-rich foods as soon as he’s alert.

**Adverse reactions**

- CV: hypotension
- GI: nausea, vomiting
- Metabolic: hypokalemia (with overdose)
- Respiratory: bronchospasm, respiratory distress
- Skin: urticaria, rash

**Interactions**

- **Drug-drug.** Anticoagulants: enhanced anticoagulant effect
- **Drug-diagnostic tests.** Potassium: decreased level

**Patient monitoring**

- Monitor blood glucose level.
- Monitor patient for aspiration.
- Assess blood pressure, electrolyte levels, and respiratory status.

**Patient teaching**

- Teach patient and family members the proper technique and timing for using this emergency drug.
- Emphasize importance of contacting prescriber right away if hypoglycemic emergency occurs.
- Tell caregiver or family member to arouse patient immediately and give additional carbohydrate by mouth as soon as patient can tolerate it.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**Route** | **Onset** | **Peak** | **Duration**
--- | --- | --- | ---
I.V. | Immediate | 30 min | 60-90 min
I.M., subcut. | 4-10 min | Unknown | 12-32 min

Reactions in bold are life-threatening.

*Clinical alert*
**glyburide**

(glibenclamide)

Apo-Glyburide®, Daonil®, DiaBeta,
Dom-Glyburide®, Euglucon®,
Gen-Glybe®, Glynase PresTab,
Micronase, Novo-Glyburide®,
Nu-Glyburide®, PMS-Glyburide®,
Ratio-Glyburide®, Riva-Glyburide®,
Sandoz Glyburide®, Semi-Daonil®

**Pharmacologic class:** Sulfonylurea

**Therapeutic class:** Hypoglycemic

**Pregnancy risk category B**

---

**Action**

Increases insulin binding and sensitivity at receptor sites, stimulating insulin release from beta cells in pancreas and reducing blood glucose level. Also decreases production of basal glucose in liver, enhances sensitivity of peripheral tissue to insulin, inhibits platelet aggregation, and causes mild diuresis.

**Availability**

*Tablets:* 1.25 mg, 2.5 mg, 5 mg

*Tablets (micronized):* 1.5 mg, 3 mg, 6 mg

---

**Indications and dosages**

➤ To control blood glucose in type 2 (non-insulin-dependent) diabetes mellitus in patients who have some pancreatic function and don’t respond to diet therapy

**Adults:** Initially, 2.5 to 5 mg (regular tablets) P.O. daily; range is 1.25 to 20 mg/day as a single dose or in divided doses. Or initially, 1.5 to 3 mg (micronized tablets) P.O. daily, with range of 0.75 to 12 mg/day; give dosages above 6 mg in two divided doses.

➤ Conversion from insulin therapy

**Adults:** If patient takes less than 20 units of insulin daily, give 2.5 to 5 mg glyburide daily; with insulin dosage of 20 to 40 units/day, give 5 mg glyburide; with insulin dosage above 40 units/day, give 5 mg glyburide daily or 3 mg (micronized tablets) P.O. daily and reduce insulin dosage by 50%.

---

**Dosage adjustment**

- Hepatic or renal failure
- Elderly patients

**Contraindications**

- Hypersensitivity to drug
- Type 1 (insulin-dependent) diabetes
- Severe renal, hepatic, thyroid or other endocrine disease
- Pregnancy or breastfeeding

**Precautions**

Use cautiously in:

- mild to moderate hepatic, renal, or cardiovascular disease; impaired thyroid, pituitary, or adrenal function
- infection, stress, or dietary changes
- elderly patients.

**Administration**

Know that micronized glyburide is not bioequivalent to regular glyburide.

- Check baseline creatinine level for normal renal function before giving first dose.
- Give daily dose at breakfast; for patient receiving drug b.i.d., give second dose at dinner.
- Adjust dosage slowly if patient is taking metformin.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>45-60 min</td>
<td>1.5-3 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: dizziness, drowsiness, headache, weakness

CV: increased CV mortality risk

EENT: visual accommodation changes, blurred vision
GI: nausea, vomiting, diarrhea, constipation, cramps, heartburn, epigastric distress, anorexia

Hematologic: aplastic anemia, leukopenia, thrombocytopenia, agranulocytosis, pancytopenia

Hepatic: cholestatic jaundice, hepatitis

Metabolic: hyponatremia, hypoglycemia

Skin: rash, pruritus, urticaria, eczema, erythema, photosensitivity, angioedema

Other: increased appetite

Interactions

Drug-drug. Androgens (such as testosterone), chloramphenicol, clofibrate, guanethidine, MAO inhibitors, non-steroidal anti-inflammatory drugs (except diclofenac), salicylates, sulfonamides, tricyclic antidepressants: increased risk of hypoglycemia

Beta-adrenergic blockers: altered response to glyburide, requiring increased or decreased dosage; prolonged hypoglycemia (with nonselective agents)

Calcium channel blockers, corticosteroids, estrogens, hydantoins, hormonal contraceptives, isoniazid, nicotinic acid, phenothiazines, phenytoin, rifampin, sympathomimetics, thiazide diuretics, thyroid preparations: decreased hypoglycemic effect of glyburide

Warfarin: initially increased, then decreased, effects of both drugs

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, cholesterol: increased values

Glucose, granulocytes, hemoglobin, platelets, white blood cells: decreased values

Drug-herbs. Agoral marshmallow, aloe (oral), bitter melon, burdock, chromium, coenzyme Q10, dandelion, eucalyptus, fenugreek: increased hypoglycemic effect

Glucosamine: impaired glycemic control

Drug-behaviors. Alcohol use: disulfiram-like reaction

Reactions in bold are life-threatening.

Patient monitoring

- Monitor blood glucose level, especially during periods of increased stress.
- Monitor CBC and renal function test results.
- If patient is ill or has abnormal laboratory findings, monitor electrolyte, ketone, glucose, pH, lactate dehydrogenase, and pyruvate levels.
- Evaluate cardiovascular status.

Patient teaching

- Advise patient to take daily dose with breakfast (and second dose, if prescribed, with dinner).
- Teach patient how to self-monitor his glucose level as prescribed; tell him to report significant changes.
- Inform patient that he may need supplemental insulin during times of stress or when he can’t maintain adequate oral intake.
- Teach patient how to recognize signs and symptoms of hypoglycemia and hyperglycemia.
- Instruct patient to keep sugar source available at all times.
- Encourage patient to drink plenty of fluids.
- Stress importance of diet and exercise in helping to control diabetes.
- Advise patient to wear or carry medical identification stating he has diabetes.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Tell patient he’ll undergo regular blood testing during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

Clinical alert
glycopyrrolate (glycopyrronium®)
Robinul, Robinul Forte

Pharmacologic class: Anticholinergic
Therapeutic class: Antispasmodic, antimuscarinic, parasympatholytic
Pregnancy risk category B

Action
Inhibits action of acetylcholine on muscarinic receptors that mediate effects of parasympathetic postganglionic impulses. This inhibition relaxes cardiac smooth muscle, inhibits vagal reflexes, and decreases tracheal and bronchial secretions.

Availability
Injection: 0.2 mg/ml
Tablets: 1 mg, 2 mg

Indications and dosages

Adjunct in peptic ulcer disorders
Adults: 1 mg P.O. t.i.d. or 2 mg (Forte) two to three times daily, to a maximum of 8 mg/day; or 0.1 to 0.2 mg I.M. or I.V. three or four times daily

To diminish secretions and block cardiac vagal reflexes before surgery
Adults and children ages 2 and older: 0.0044 mg/kg I.M. 30 to 60 minutes before anesthesia
Children ages 1 month to 2 years: 0.0088 mg/kg I.M. 30 to 60 minutes before anesthesia

To diminish or block cholinergic effects caused by anticholinesterase
Adults and children: 0.2 mg I.V. for each 1 mg neostigmine or 5 mg pyridostigmine. May give I.V. undiluted or with dextrose injection by infusion.

Off-label uses
- Sweating

Contraindications
- Hypersensitivity to drug
- Arrhythmias
- Chronic obstructive pulmonary disease
- GI disease, infection, atony or ileus
- Myasthenia gravis
- Glaucoma
- Obstructive uropathy
- Severe prostatic hypertrophy

Precautions
Use cautiously in:
- cardiovascular disease, heart failure, hypertension, renal or hepatic disease, Down syndrome, hyperthyroidism, hiatal hernia, ulcerative colitis, mild to moderate prostatic hypertrophy, autonomic neuropathy, spasticity, suspected brain damage
- pregnant or breastfeeding patients.

Administration
- Give oral dose 30 to 60 minutes before meals.
- For I.V. injection, give either undiluted or diluted with dextrose 5% or 10% in water or saline solution. Give each 0.2 mg over 1 to 2 minutes.

Keep resuscitation equipment on hand to treat curare-like effects of overdose.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>8-12 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>1 min</td>
<td>Unknown</td>
<td>3-7 hr</td>
</tr>
<tr>
<td>I.M., subcut.</td>
<td>15-30 min</td>
<td>30-45 min</td>
<td>3-7 hr</td>
</tr>
</tbody>
</table>
Adverse reactions
CNS: weakness, nervousness, insomnia, drowsiness, dizziness, headache, confusion, excitement
CV: palpitations, tachycardia
EENT: blurred vision, photophobia, mydriasis, increased intraocular pressure, cyclopia
GI: nausea, vomiting, constipation, abdominal distention, epigastric distress, heartburn, gastroesophageal reflux, dry mouth, paralytic ileus
GU: urinary hesitancy or retention, lactation suppression, erectile dysfunction
Skin: urticaria, decreased sweating or anhidrosis
Other: loss of taste, fever, allergic reaction, irritation at I.M. injection site, anaphylaxis, malignant hyperthermia

Interactions
Drug-drug. Amantadine, antihistamines, antiparkinsonian drugs, disopyramide, glutethimide, meperidine, phenothiazines, procainamide, quinidine, tricyclic antidepressants: additive anticholinergic effects

Patient monitoring
Check for signs and symptoms of anaphylaxis and malignant hyperthermia.
- Monitor neurologic and cardiovascular status.
- Assess for curare-like effects (neuromuscular blockade leading to muscle weakness and possible paralysis), which indicate overdose.
- Assess fluid intake and output. Have patient void before each dose to avoid urinary retention.

Patient teaching
- Advise patient to take oral dose 30 to 60 minutes before meals.
- Tell patient to immediately report signs and symptoms of serious adverse effects, especially anaphylaxis.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, and alertness.
- Tell patient to minimize GI upset by eating frequent, small servings of food and drinking adequate fluids.
- Advise patient to report urinary hesitancy or retention.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

Reactions in **bold** are life-threatening.

---

goserelin acetate
Zoladex, Zoladex LA, Zoladex 3-Month

Pharmacologic class: Gonadotropin-releasing hormone analog
Therapeutic class: Antineoplastic, hormone
Pregnancy risk category D (breast cancer), X (endometriosis)

Action
Synthetic form of luteinizing hormone-releasing hormone (LHRH); inhibits gonadotropin production by acting directly on pituitary gland. Enhances release of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone, lowering testosterone and estradiol levels.

Availability
Implant: 3.6 mg, 10.8 mg (in preloaded syringes)

Indications and dosages
- Palliative treatment of advanced prostate cancer
Adults: 3.6 mg subcutaneously q 4 weeks or 10.8 mg subcutaneously q 12 weeks into upper abdominal wall
Adjunct to radiation therapy and flutamide in stage B2-C prostate cancer

**Adults:** 3.6 mg subcutaneously q 4 weeks starting on day 1 of radiation or during last week of radiation. Alternatively, 3.6 mg subcutaneously 8 weeks before radiation, then 10.8 mg on day 28 or 3.6 mg at 4-week intervals starting 8 weeks before radiation, for a total of four doses (two depots before and two during radiation therapy).

Palliative treatment of advanced breast cancer in pre- and perimenopausal women

**Adults:** 3.6 mg subcutaneously q 4 weeks. If serum estradiol doesn’t fall to postmenopausal levels, may increase to 7.2 mg q 4 weeks.

Endometriosis

**Adults ages 18 and older:** 3.6 mg subcutaneously q 4 weeks, continued for 6 months

Endometrial thinning before ablation for dysfunctional uterine bleeding

**Adults:** 3.6 mg subcutaneously 4 weeks before surgery. Alternatively, initial 3.6-mg dose may be followed 4 weeks later by a second 3.6-mg dose, with surgery 2 to 4 weeks after second dose.

Contraindications
- Hypersensitivity to drug or its components or to LHRH or LHRH-agonist analogs
- Undiagnosed vaginal bleeding
- Pregnancy or breastfeeding

Precautions
Use cautiously in:
- risk factors for osteoporosis
- chronic alcohol or tobacco use
- patients receiving drugs that affect bone density
- children younger than age 18 (safety not established).

Administration
- Administer pretreatment pregnancy test to female of childbearing age.
- Know that drug should be given only by a clinician experienced in its use.
- Implant is placed subcutaneously into upper abdominal wall using aseptic technique. Give local anesthetic and stretch skin with one hand. Insert needle into subcutaneous fat, then change needle angle until it parallels abdominal wall. Push needle in until hub touches patient’s skin, and withdraw about 1 ml before depressing plunger all the way.
- Don’t aspirate after inserting needle. Blood will be visible in syringe if needle enters blood vessel.

Don’t give by I.V. route.
- Be aware that 10.8-mg implant should not be used in women.
- Be aware that if implant must be removed, it can be located by ultrasound.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcut.</td>
<td>Unknown</td>
<td>2-4 wk</td>
<td>End of therapy</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: headache, anxiety, depression, dizziness, fatigue, insomnia, lethargy, pain, emotional lability, weakness, **cerebrovascular accident**

CV: vasodilation, chest pain, hypertension, palpitations, peripheral edema, **myocardial infarction, arrhythmias**

EENT: blurred vision

GI: nausea, vomiting, diarrhea, constipation, ulcer, anorexia

GU: urinary obstruction, lower urinary tract symptoms, breast swelling or tenderness, vaginitis, amenorrhea, infertility, decreased libido, erectile dysfunction, other sexual dysfunction, decreased testicular size, **renal insufficiency**

Hematologic: anemia

Musculoskeletal: increased bone pain, joint pain, decreased bone density

Metabolic: gout, hyperglycemia, hypercalcemia

Respiratory: dyspnea, chronic obstructive pulmonary disease, upper respiratory tract infection
Skin: rash, acne, diaphoresis, seborrhea
Other: hirsutism, chills, fever, hot flashes, infection, weight gain

Interactions
Drug-diagnostic tests. Calcium, glucose, high- and low-density lipoproteins, triglycerides: increased levels
FSH, LH: initially increased, then decreased, levels

Patient monitoring
- Assess menstrual symptoms and watch for breakthrough bleeding.
- Monitor neurologic status. Watch closely for signs and symptoms of cerebrovascular accident.
- Monitor cardiovascular and respiratory status.

Patient teaching
- Advise female patient to avoid pregnancy and to use a nonhormonal contraceptive method.
- Instruct patient to call prescriber if menstrual bleeding persists or breakthrough bleeding occurs.
- Inform patient that menstruation may be delayed after therapy ends.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

Granisetron hydrochloride
Granisol, Kytril, Sancuso

Pharmacologic class: 5-hydroxytryptamine₃ antagonist
Therapeutic class: Antiemetic
Pregnancy risk category B

Action
Binds to serotonin receptors in chemoreceptor trigger zone and vagal nerve terminals, blocking serotonin release and controlling nausea and vomiting

Availability
Injection: 1 mg/ml
Oral solution: 2 mg/10 ml in 30-ml bottles
Tablets: 1 mg
Transdermal system (patch): 52-cm² patch (containing 34.3 mg granisetron delivering 3.1 mg/24 hours)

Indications and dosages
＞ To prevent nausea and vomiting caused by chemotherapy
Adults and children ages 2 to 16: For I.V. use, 10 mcg/kg I.V. within 30 minutes before chemotherapy. For P.O. use (adults only), 1 mg P.O. b.i.d., with first dose given at least 1 hour before chemotherapy and second dose given 12 hours later on days when chemotherapy is administered; or 2 mg P.O. daily at least 1 hour before chemotherapy. For transdermal use (adults only), apply patch for up to 7 days.
＞ To prevent nausea and vomiting caused by radiation therapy
Adults: 2 mg P.O. daily within 1 hour of radiation therapy
＞ Acute postoperative nausea and vomiting
Adults: 1 mg I.V. undiluted, administered over 30 seconds

Contraindications
- Hypersensitivity to drug

Precautions
Use cautiously in:
- pregnant or breastfeeding patients
- children younger than age 18 (safety of P.O. and transdermal use not established)
- children younger than age 2 (safety of I.V. use not established).
Administration
- For I.V. infusion, dilute with 20 to 50 ml of normal saline solution or dextrose 5% in water.
- Infuse I.V. over 5 minutes, starting 30 minutes before chemotherapy.
- For direct I.V. injection, give undiluted over 30 seconds.
- Don’t mix I.V. form with other drugs.
- For P.O. use, give first dose 1 hour before chemotherapy and second dose 12 hours after first.
- Apply a single transdermal patch to upper outer arm for 24 to 48 hours before chemotherapy.
- Remove patch a minimum of 24 hours after chemotherapy completion. Patch may be worn up to 7 days depending on duration of chemotherapy.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>1 hr</td>
<td>24 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>30 min</td>
<td>Up to 24 hr</td>
</tr>
<tr>
<td>Transdermal</td>
<td>Unknown</td>
<td>48 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, anxiety, stimulation, weakness, drowsiness, dizziness
CV: hypertension
GI: nausea, vomiting, diarrhea, constipation, abdominal pain
Hematologic: anemia, leukopenia, thrombocytopenia
Skin: alopecia, application site reactions (patch)
Other: altered taste, decreased appetite, fever, chills, shivering

Interactions
Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase: increased levels
Electrolytes: altered levels
Hemoglobin, platelets, white blood cells: decreased levels
Drug-herbs. Horehound: enhanced serotonergic effects

Patient monitoring
- Monitor hepatic enzyme levels and CBC with white cell differential.
- Monitor temperature and blood pressure. Have patient use caution when ambulating, to avoid orthostatic hypotension.
- Know that patch may be degraded by direct exposure to natural or artificial sunlight.

Patient teaching
- Instruct patient to apply a single transdermal patch to upper outer arm 24 to 48 hours before chemotherapy.
- Instruct patient to remove patch by gently peeling it off in a minimum of 24 hours after chemotherapy completion.
- Instruct patient to remove patch if a severe or generalized skin reaction (such as rash or itching) occurs.
- Advise patient to avoid direct exposure of application site to natural or artificial sunlight by covering site with clothing while wearing patch and for 10 days after patch removal.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Advise patient to minimize GI upset by eating frequent, small servings of healthy food.
- Tell patient he’ll undergo regular blood testing during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests and herbs mentioned above.
guaifenesin (glyceryl guaiacolate)

Balminil Expectorant®, Benilyn Childrens Chesty Coughs®, Benylin-E®, Calmylin Expectorant®, Diabetic Tussin EX, Genatuss, Koffex Expectorant®, Mucinex, Organidin NR, Phanacin XPECT, Pneumomist, Resyl®, Robitussin, Robitussin Chesty Cough®, Scot-tussin Expectorant, Siltussin SA, Tixylix Chesty Cough®, Venos for Kids®, Vicks Vaposyrup for Chesty Coughs®

Pharmacologic class: Propanediol derivative
Therapeutic class: Expectorant
Pregnancy risk category C

Action
Exerts vasoconstrictive action that leads to decreased edema and congestion. Also increases respiratory secretions and reduces mucus viscosity.

Availability
Capsules: 200 mg
Oral solution: 100 mg/5 ml, 200 mg/5 ml
Syrup: 100 mg/5 ml
Tablets: 100 mg, 200 mg, 400 mg
Tablets (extended-release): 600 mg

Indications and dosages

Cough due to upper respiratory tract infection
Adults: 200 to 400 mg P.O. q 4 hours (not to exceed 2,400 mg/day), or 600 mg P.O. (extended-release) q 12 hours (not to exceed 1,200 mg/day)
Children ages 6 to 12: 100 to 200 mg P.O. q 4 hours (not to exceed 1,200 mg/day), or 600 mg P.O. (extended-release) q 12 hours (not to exceed 1,200 mg/day)

Children ages 2 to 6: 50 to 100 mg P.O. q 4 hours (not to exceed 600 mg/day)

Contraindications
- Hypersensitivity to drug
- Alcohol intolerance (with some products)

Precautions
Use cautiously in:
- diabetes mellitus, cough lasting more than 1 week or accompanied by fever, rash, or headache
- patients receiving disulfiram concurrently
- pregnant patients.

Administration
- Give with full glass of water.

Route Onset Peak Duration

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30 min</td>
<td>Unknown</td>
<td>4-6 hr</td>
</tr>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>12 hr (extended)</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, dizziness
GI: nausea, vomiting, diarrhea, stomach pain
Skin: rash, urticaria

Interactions
Drug-diagnostic tests. Urinary 5-hydroxyindoleacetic acid, vanillylmandelic acid: inaccurate results

Patient monitoring
- Assess cough quality and productivity. Reevaluate treatment if cough persists and is accompanied by fever or headache.

Patient teaching
- Tell patient to take with 8 oz of water and to drink plenty of fluids.
- Instruct patient to contact prescriber if cough lasts more than 1 week.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the tests mentioned above.

---

**guanfacine**

**Tenex**

**Pharmacologic class:** Centrally acting antiadrenergic

**Therapeutic class:** Antiadrenergic-sympatholytic, antihypertensive

**Pregnancy risk category B**

**Action**
Stimulates central alpha2-adrenergic receptors, reducing sympathetic nerve impulses from vasomotor center to heart and blood vessels

**Availability**
*Tablets:* 1 mg, 2 mg

**Indications and dosages**

- **Hypertension**
  - **Adults:** 1 mg P.O. at bedtime. If response unsatisfactory after 3 to 4 weeks, increase to 2 mg P.O. at bedtime.

**Off-label uses**
- Attention deficit hyperactivity disorder
- Treatment of heroin withdrawal
- Hypertension in pregnancy

**Contraindications**
- Hypersensitivity to drug

**Precautions**
Use cautiously in:
- chronic renal or hepatic failure

---

**Adverse reactions**
- CNS: somnolence, insomnia, dizziness, headache, fatigue, amnesia, confusion, depression, hypokinesia, asthenia, malaise, paresthesia, paresis
- CV: bradycardia, palpitations, substernal pain
- EENT: conjunctivitis, iritis, vision disturbance, tinnitus, rhinitis
- GI: nausea, diarrhea, constipation, abdominal pain, dyspepsia, dysphagia, dry mouth
- GU: erectile dysfunction, decreased libido
- Musculoskeletal: leg cramps
- Respiratory: dyspnea
- Skin: dermatitis, pruritus, purpura, sweating
- Other: taste perversion

**Interactions**

- **Drug-drug.** *CNS depressants:* additive sedation
- *Phenobarbital, phenytoin:* decreased elimination half-life and blood level of guanfacine

- **Drug-behaviors.** *Alcohol use:* additive sedation
Patient monitoring
- Monitor patient for evidence of drug efficacy.
- Monitor patient closely during drug withdrawal.

Patient teaching
- Tell patient to take drug at bedtime to reduce daytime sleepiness.
- Caution patient not to stop taking drug abruptly.
- Advise patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Tell patient to avoid alcohol during therapy.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and behaviors mentioned above.

FDA BOXED WARNING
- Drug increased mortality in elderly patients with dementia-related psychosis. Although causes of death were varied, most appeared to be cardiovascular or infectious. Drug isn’t approved for treatment of dementia-related psychosis.

Action
Unknown. Thought to block postsynaptic dopamine receptors in brain and increase dopamine turnover rate, inhibiting signs and symptoms of psychosis.

Availability
Injection (decanoate): 50 mg/ml, 100 mg/ml
Injection (lactate): 5 mg/ml
Oral concentrate (lactate): 2 mg/ml
Tablets: 0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg, 20 mg

Indications and dosages
➤ Symptomatic treatment of psychotic disorders or Tourette syndrome
Adults: For moderate symptoms, 0.5 to 2 mg P.O. two to three times daily. For severe symptoms or chronic or resistant disorder, 3 to 5 mg P.O. two to three times daily, to a maximum of 100 mg daily if needed. Adjust subsequent dosages carefully based on response and tolerance. Alternatively, 2 to 5 mg I.M. (lactate) may be given for prompt control of acutely agitated patient with moderate to severe symptoms; based on response, subsequent doses may be given q hour.
➤ Schizophrenia in patients who need prolonged parenteral antipsychotic therapy
Adults: For patient previously stabilized on oral haloperidol, initial I.M. dose (decanoate) is 10 to 20 times the previous daily P.O. haloperidol equivalent, depending on patient’s stability on low
or high P.O. dosage. Initially, I.M. dosage shouldn’t exceed 100 mg. If conversion requires dosage above 100 mg, give balance in 3 to 7 days. Maintenance dosage is 10 to 15 times the previous daily P.O. dosage, depending on response.

Psychotic disorders

Children ages 3 to 12 or weighing 15 to 40 kg (33 to 88 lb): 0.05 to 0.15 mg/kg/day P.O. in two or three divided doses. May be increased by 0.5 mg daily given in two or three divided doses at 5- to 7-day intervals, depending on response and tolerance.

Nonpsychotic behavior disorder; Tourette syndrome; hyperactivity

Children ages 3 to 12 or weighing 15 to 40 kg (33 to 88 lb): 0.05 to 0.075 mg/kg/day P.O. in two or three divided doses

Dosage adjustment

• Elderly or debilitated patients

Off-label uses

• Nausea and vomiting
• Infantile autism
• Intractable hiccups

Contraindications

• Hypersensitivity to drug, tartrazine, sesame oil, or benzyl alcohol (with some products)
• Severe CNS depression or comatose states
• Parkinson’s disease

Precautions

Use cautiously in:
• torsades de pointes, QT interval prolongation
• patients with allergies
• hepatic disease, bone marrow depression, cardiac disease, respiratory insufficiency, CNS tumors
• history of seizures, patients receiving anticonvulsants, EEG abnormalities
• concurrent anticoagulant use
• elderly patients
• pregnant or breastfeeding patients

• children (parenteral form not recommended).

Administration

• Be aware that torsades de pointes and QT interval prolongation have occurred in patients receiving haloperidol, especially when drug is given I.V. or in doses higher than recommended. Haloperidol isn’t approved for I.V. use.

Don’t give decanoate form I.V.
• Administer decanoate form by deep I.M. injection using 21G needle. Two injections may be necessary; maximum volume shouldn’t exceed 3 ml.
• Know that recommended interval between I.M. injections is 4 weeks.
• Dilute oral concentrate in water, soda, or juice (orange, apple, tomato) immediately before administering.
• Be aware that patient should be switched from parenteral form to oral form as soon as possible.
• Know that parenteral form is not recommended in children.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>3-6 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V. (lactate)</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.M. (decanoate)</td>
<td>20-30 min</td>
<td>30-45 min</td>
<td>4-8 hr</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: confusion, drowsiness, restlessness, extrapyramidal reactions, sedation, lethargy, insomnia, vertigo, tardive dyskinesia, seizures, neuroleptic malignant syndrome

CV: hypotension, hypertension, tachycardia, ECG changes, torsades de pointes (with I.V. use)

EENT: blurred vision, dry eyes

GI: constipation, ileus, dry mouth, anorexia

GU: urinary retention, menstrual irregularities, gynecostasia, priapism

Hematologic: anemia, leukocytosis, leukopenia
Hepatic: jaundice, drug-induced hepatitis
Metabolic: galactorrhea
Respiratory: dyspnea, respiratory depression, bronchospasm, laryngospasm
Skin: diaphoresis, photosensitivity, rash
Other: hyperpyrexia, hypersensitivity reactions

Interactions
Drug-drug. Antidepressants, antihistamines, atropine, disopyramide, phenothiazines, quinidine, other anticholinergics: additive anticholinergic effects
Antihypertensives, nitrates: additive hypotension
CNS depressants (including antihistamines, opioid analgesics, sedative-hypnotics): additive CNS depression
Epinephrine: severe hypotension and tachycardia
Levodopa, pergolide: decreased therapeutic effects of haloperidol
Lithium: acute encephalopathic syndrome
Methyldopa: dementia
Rifampin: decreased haloperidol plasma level

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, thyroid function tests: increased values
Arterial blood gases, bicarbonate: altered values
White blood cells: increased or decreased count

Drug-herbs. Angel’s trumpet, jimsonweed, scopolia: antagonism of cholinergic effects
Chamomile, hops, kava, skullcap, valerian: increased CNS depression
Nutmeg: reduced haloperidol efficacy

Drug-behaviors. Acute alcohol ingestion: additive hypotension

Patient monitoring
Monitor cardiovascular status closely, especially for ECG changes, blood pressure changes, torsades de pointes, and atypical rapid ventricular tachycardia, which may progress to ventricular fibrillation (with I.V. use).
- Assess respiratory status.
- Monitor liver function test results and CBC with white cell differential.
- With prolonged use, assess for tardive dyskinesia (which may occur months or even years after starting drug).

Patient teaching
- Tell patient to dilute oral concentrate with water, cola, or juice immediately before taking.
- Instruct patient to immediately report signs or symptoms of serious adverse reactions, such as unusual weakness, yellowing of skin or eyes, difficulty breathing, or symptoms of neuroleptic malignant syndrome (such as fever, muscle pain or rigidity, rapid or irregular pulse, increased sweating, change in urination pattern, or decreased mental acuity).
- Advise patient to minimize GI upset by eating frequent, small servings of food and drinking adequate fluids.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

Reactions in bold are life-threatening.

heparin sodium
Pharmacologic class: Antithrombotic
Therapeutic class: Anticoagulant
Pregnancy risk category C
Action
Inhibits thrombus by preventing conversion of prothrombin to thrombin and fibrinogen to fibrin, preventing clot formation. Doesn’t lyse existing clot, but prevents clot enlargement and extension.

Availability
Solution for flushes: 1-unit/ml, 2-units/ml, 10-units/ml, 100-units/ml syringes; 100-units/ml vials
Solution for injection: 1,000 units/ml, 10,000 units/ml, 20,000 units/ml, 40,000 units/ml in single-dose vials; 1,000 units/ml, 2,000 units/ml, 5,000 units/ml, 10,000 units/ml, 20,000 units/ml in multidose vials; 1,000 units/ml, 2,500 units/ml, 5,000 units/ml, 10,000 units/ml in unit-dose syringes

Indications and dosages
➢ Therapeutic anticoagulation
Adults: 10,000 units I.V. by intermittent bolus, then 5,000 to 10,000 units I.V. q 4 to 6 hours. Or 5,000 units by I.V. injection, then 20,000 to 40,000 units I.V. over 24 hours (about 1,000 units/hour or 15 to 18 units/kg/hour). Or 5,000 units I.V., followed by initial deep subcutaneous dose of 10,000 to 20,000 units, then 8,000 to 10,000 units q 8 hours or 15,000 to 20,000 units q 12 hours.
Children: Initially, 50 units/kg by I.V. drip, then 100 units/kg by I.V. drip q 4 hours. Or 20,000 units/m2/24 hours by continuous I.V. infusion.
➢ To prevent thromboembolism
Adults: 5,000 units subcutaneously q 8 to 12 hours (may begin 2 hours before surgery) given for 7 days or until patient is fully ambulatory
➢ To prevent blood clotting during cardiovascular surgery
Adults: At least 150 units/kg I.V. (300 units/kg if procedure less than 60 minutes; 400 units/kg if more than 60 minutes)

➢ I.V. flush
Adults and children: 10 to 100 units/ml I.V. heparin sodium solution to fill heparin lock set

Off-label uses
➢ Prophylaxis of left ventricular thrombi
➢ Prophylaxis of cerebrovascular accident after myocardial infarction

Contraindications
➢ Hypersensitivity to drug
➢ Bleeding disorders
➢ Severe thrombocytopenia
➢ Patients who can’t undergo regular blood coagulation tests

Precautions
Use cautiously in:
➢ severe hepatic or renal disease, bacterial endocarditis, hypertension, retinopathy, ulcer disease
➢ recent CNS or ophthalmic surgery
➢ immediate postpartum period
➢ women older than age 60
➢ pregnant patients.

Administration
➢ Know that I.V. heparin sodium is a high-alert drug.
➢ Draw baseline blood sample for clotting studies before starting drug.
➢ Use infusion pump to administer I.V. dose. Check regularly to ensure that infusion rate is correct.
➢ For I.V. use, give each 1,000-unit dose or single-dose injection over at least 1 minute. Give continuous infusion over 4 to 24 hours, depending on dose and volume of infusion solution.
➢ Draw blood for partial thromboplastin time (PTT) from opposite arm 4 hours after continuous I.V. infusion begins.
➢ Put note at patient’s bedside to remind personnel to apply pressure dressings after withdrawing blood.
➢ With intermittent I.V. drug infusion, withdraw blood 30 minutes before dose, using arm without I.V. infusion.
• For subcutaneous dose, inject slowly between iliac crests in lower abdomen, deep into subcutaneous fat layer. Leave needle in place for 10 seconds before withdrawing. Don’t massage area after injection. Alternate subcutaneous sites every 12 hours.
• Have protamine available as heparin agonist.

Don’t give I.M.

Don’t give heparin products containing benzyl alcohol to premature infants.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>5-10 min</td>
<td>2-6 hr</td>
</tr>
<tr>
<td>Subcut.</td>
<td>20-60 min</td>
<td>2-4 hr</td>
<td>8-12 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**EENT:** rhinitis

**Hematologic:** anemia, thrombocytopenia, bleeding, severely prolonged clotting time

**Hepatic:** hepatitis

**Metabolic:** hyperkalemia

**Musculoskeletal:** osteoporosis (with long-term use)

**Skin:** irritation, rash, urticaria, hematoma, ulceration, cutaneous or subcutaneous necrosis, pruritus, alopecia (with long-term use)

**Other:** fever, pain at injection site, hypersensitivity reactions, white clot syndrome, anaphylactoid reactions

**Interactions**

**Drug-drug.** Antihistamines, digoxin, nicotine, tetracyclines: decreased anticoagulant effect of heparin

Cefamandole, cefmetazole, cefoperazone, cefotetan, plicamycin, quinidine, valproic acid, other drugs that cause hypoprothrombinemia; drugs that affect platelet function (including abciximab, aspirin, clopidogrel, dextran, diprydamole, eptifibatide, nonsteroidal anti-inflammatory drugs, some penicillins, thrombolytics, ticlopidine, tirofiban): increased bleeding risk

**Drug-diagnostic tests.** Alanine aminotransferase, aspartate aminotransferase, free fatty acids, thyroxine, triiodothyronine resin: increased levels

Cholesterol, triglycerides: decreased levels

$^{125}\text{I}$ fibrinogen uptake: false-negative result

Prothrombin time: prolonged

**Drug-herbs.** Anise, arnica, chamomile, clove, dong quai, feverfew, garlic, ginger, ginseng: increased bleeding risk

**Drug-behaviors.** Smoking: increased bleeding risk

**Patient monitoring**

• Monitor infusion rate closely, even when using infusion pump.
• Evaluate patient’s vital signs.

Watch for signs and symptoms of anaphylactoid reaction.

Assess for white clot syndrome (new thrombus formation in association with thrombocytopenia caused by irreversible platelet aggregation).

Stay alert for signs and symptoms of bleeding tendency.

• Check hematocrit, PTT, and platelet count frequently.

• Monitor liver function test results.

• In long-term therapy, periodically assess stool for occult blood.

• Monitor potassium level in patients with diabetes or renal disease. (Drug may cause hyperkalemia.)

**Patient teaching**

• If patient will self-administer drug, teach proper technique and emphasize need to rotate injection sites.

Advise patient that nosebleed, blood in urine, or black stools may be first sign of overdose and should be reported immediately.

Tell patient to immediately report other unusual bleeding or bruising.

Urge patient to avoid activities that can cause injury. Advise him to use soft toothbrush and electric razor to avoid gum and skin injury.

Reactions in bold are life-threatening.
Tell patient he will undergo regular blood testing during therapy.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

**hydralazine hydrochloride**

Apo-Hydralazine, Apresoline, Novo-Hylazin, Nu-Hydral

**Pharmacologic class:** Peripheral vasodilator

**Therapeutic class:** Antihypertensive

**Pregnancy risk category C**

**Action**
Relaxes vascular smooth muscles of arteries and arterioles, causing peripheral vasodilation and decreasing peripheral vascular resistance. These actions decrease blood pressure and increase heart rate, stroke volume, and cardiac output.

**Availability**
- **Injection:** 20 mg/ml
- **Tablets:** 10 mg, 25 mg, 50 mg, 100 mg

**Indications and dosages**

- **Hypertension**
  - **Adults:** Initially, 10 mg P.O. q.i.d. After 2 to 4 days, may increase to 25 mg P.O. q.i.d. for remainder of first week; may then increase further to 50 mg P.O. q.i.d., up to 300 mg/day. Once maintenance dosage is established, may give in two daily doses.
  - **Children:** Initially, 0.75 mg/kg/day P.O. in four divided doses; may increase gradually over 3 to 4 weeks to 7.5 mg/kg or 200 mg/day
  - **Neonates:** 0.5 mg/kg P.O., I.M., or I.V. q 4 to 6 hours

**Contraindications**
- Hypersensitivity to drug or tartrazine
- Coronary artery disease
- Mitral valvular rheumatic heart disease

**Precautions**
Use cautiously in:
- suspected CV or cerebrovascular disease, severe renal or hepatic disease
- pregnant or breastfeeding patients
- children.

**Administration**
- Administer oral form with food.
- Inject I.V. form slowly over 1 minute. Monitor blood pressure response continuously.
- Draw up and use parenteral drug immediately; solution changes color after contact with metal needle.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>45 min</td>
<td>2 hr</td>
<td>3-8 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>10-20 min</td>
<td>15-30 min</td>
<td>3-8 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>10-30 min</td>
<td>1 hr</td>
<td>3-8 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- **CNS:** dizziness, drowsiness, headache, peripheral neuritis
- **CV:** tachycardia, angina, orthostatic hypotension, arrhythmias
- **EENT:** lacrimation, nasal congestion
- **GI:** nausea, vomiting, diarrhea, constipation, anorexia
- **Metabolic:** sodium retention
- **Musculoskeletal:** joint pain, arthritis
- **Skin:** rash, blisters, flushing, pruritus, urticaria
- **Other:** chills, fever, lymphadenopathy, edema, lupuslike syndrome

**Interactions**

**Drug-drug.** Antihypertensives, nitrates: additive hypotension

- Epinephrine: reduced pressor response to epinephrine
- Metoprolol, propranolol: increased blood levels of both drugs
- **MAO inhibitors:** increased hypotension
Drug-diagnostic tests. Coombs’ test: positive result
Granulocytes, hemoglobin, neutrophils, platelets, red blood cells, white blood cells: decreased levels

Drug-behaviors. Alcohol use: additive hypotensive response

Patient monitoring
• Monitor CBC, lupus erythematosus cell studies, and antinuclear antibody titers before and periodically during therapy.
• Monitor blood pressure, pulse rate and regularity, and daily weight.
• To avoid rapid blood pressure drop, taper dosage gradually before discontinuing.
  ➢ Assess for lupuslike signs and symptoms, including joint pain, fever, myalgia, pharyngitis, and splenomegaly.
• Watch for peripheral neuritis. If it occurs, expect to give pyridoxine.

Patient teaching
• Tell patient to take tablets with food.
• Instruct patient to move slowly when rising (especially in morning on awakening), to avoid dizziness from sudden blood pressure decrease.
  ➢ Instruct patient to immediately report fever, muscle and joint aches, or sore throat.
• Tell patient to report chest pain or numbness or tingling of hands or feet.
• To minimize GI upset, advise patient to eat small, frequent meals.
• Caution patient not to discontinue drug abruptly, because severe hypertension may result.
• As appropriate, review other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

hydrochlorothiazide

Apo-Hydro®, Diuchlor H®, Hydro-Par, Microzide, Neo-Codema®, Novo-Hydrazide®, PMS-Hydrochlorothiazide®, Urozide®

Pharmacologic class: Thiazide diuretic
Therapeutic class: Diuretic, antihypertensive
Pregnancy risk category B

Action
Increases sodium and water excretion by inhibiting sodium reabsorption in distal tubules; promotes excretion of chloride, potassium, magnesium, and bicarbonate. Also may produce arteriolar dilation, reducing blood pressure.

Availability
Capsules: 12.5 mg
Oral solution: 10 mg/ml, 100 mg/ml
Tablets: 12.5 mg, 25 mg, 50 mg, 100 mg

Indications and dosages
➢ Edema caused by heart failure, renal dysfunction, cirrhosis, corticosteroid therapy, or estrogen therapy
Adults: 25 to 100 mg P.O. daily as a single dose or in divided doses. Maximum dosage is 200 mg/day.

➢ Mild to moderate hypertension
Adults: Initially, 12.5 mg daily P.O.; then, based on blood pressure response, may give 12.5 to 50 mg/day P.O. Higher dosages may be given in refractory cases.

Children ages 2 to 12: 1 to 2 mg/kg/day P.O. in single dose or two divided doses, not to exceed 100 mg/day
Children younger than age 2: 1 to 2 mg/kg P.O. as single dose or divided doses, not to exceed 37.5 mg/day; infants less than age 6 months may require dosage of 3 mg/kg/day in two divided doses.
Off-label uses
- Hypercalcemia
- Ménière’s disease

Contraindications
- Hypersensitivity to drug, other thiazides, sulfonamides, or tartrazine
- Renal decompensation or anuria

Precautions
Use cautiously in:
- renal or severe hepatic impairment, fluid or electrolyte imbalances, gout, systemic lupus erythematosus, hyperparathyroidism, glucose tolerance abnormalities, bipolar disorder
- elderly patients
- pregnant or breastfeeding patients.

Administration
- Give with food or milk if GI upset occurs.
- Administer early in day so diuretic effect doesn’t disturb sleep.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>2 hr</td>
<td>3-6 hr</td>
<td>6-12 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, drowsiness, lethargy, headache, insomnia, nervousness, vertigo, asthenia, astere克斯is, paresthesias, confusion, fatigue, encephalopathy
CV: chest pain, orthostatic hypotension, ECG changes, thrombophlebitis, arrhythmias
EENT: nystagmus
GI: nausea, vomiting, epigastric distress, anorexia, pancreatitis
GU: polyuria, nocturia, erectile dysfunction, loss of libido, renal failure
Hematologic: anemia, hemolytic anemia, agranulocytosis, leukopenia, thrombocytopenia
Hepatic: jaundice, hepatitis
Metabolic: dehydration, gout, hyperglycemia, hypokalemia, hypocalcemia, hypovolemia, hypomagnesemia, hyponatremia, hypophosphatemia, hyperuricemia, hypochloremic alkalosis
Musculoskeletal: muscle cramps
Skin: photosensitivity, urticaria, rash, dermatitis, purpura, alopecia, flushing
Other: fever, weight loss, anaphylaxis

Interactions
Drug-drug. Adrenocorticotropic hormone, corticosteroids: increased risk of intensified electrolyte depletion, particularly hypokalemia
Allopurinol: increased risk of hypersensitivity reaction
Amphotericin B, corticosteroids, digoxin, mezlocillin, piperacillin, ticarcillin: increased risk of hypokalemia
Antihypertensives, barbiturates, nitrates, opioids: increased hypotension
Cholestyramine, colestipol: decreased hydrochlorothiazide absorption
Digoxin: increased risk of hypokalemia
Insulin, oral hypoglycemics: possible decreased hypoglycemic effect
Lithium: decreased excretion and increased blood level of lithium
Nondepolarizing skeletal muscle relaxants (such as tubocurarine): increased skeletal muscle relaxant effect
Nonsteroidal anti-inflammatory drugs: decreased hydrochlorothiazide efficacy
 Vaspressors: decreased pressor effect
Drug-diagnostic tests. Bilirubin, blood and urine glucose (in diabetic patients), calcium, creatinine, uric acid: increased levels
Cholesterol, low-density lipoproteins, magnesium, potassium, protein-bound iodine, sodium, triglycerides, urinary calcium: decreased levels
Drug-herbs. Dandelion: interference with diuretic activity
Ginkgo: decreased antihypertensive effect
Licorice, stimulant laxative herbs (aloe, cascara sagrada, senna): increased risk of hypokalemia
Drug-behaviors. Alcohol use: increased hypotension
Sun exposure: increased risk of photosensitivity
Patient monitoring
- Monitor blood pressure, fluid intake and output, and daily weight.
- Assess electrolyte levels, especially potassium. Monitor for signs and symptoms of hypokalemia.
- Monitor blood urea nitrogen and creatinine levels.
- Check blood glucose level in diabetic patients.
- Assess for signs and symptoms of gout attacks in patients with gouty arthritis.

Patient teaching
- Advise patient to take with food or milk if GI upset occurs.
- Tell patient to take early in day to avoid nighttime urination.
- Instruct patient to track intermittent doses on calendar.
- Tell patient to weigh himself daily, at same time on same scale and wearing same clothes.
- Instruct patient to report decreased urination, swelling, unusual bleeding or bruising, dizziness, fatigue, numbness, and muscle weakness or cramping.
- Instruct patient to move slowly when sitting up or standing, to avoid dizziness from sudden blood pressure decrease.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

**hydrocodone bitartrate and acetaminophen**

**hydrocodone bitartrate and aspirin**

**hydrocodone bitartrate and ibuprofen**
- Vicoprofen

**hydrocodone bitartrate and homatropine methylbromide**
- Hycodan

**Pharmacologic class:** Opioid agonist/nonopioid analgesic combination

**Therapeutic class:** Opioid analgesic; allergy, cold, and cough remedy (antitussive)

**Controlled substance schedule III**

**Pregnancy risk category C**

**Action**
- Blocks release of inhibitory neurotransmitters, altering perception of and emotional response to pain. Hydrocodone/ibuprofen combination raises pain threshold by nonselectively inhibiting cyclooxygenase; prostaglandin synthesis then decreases and anti-inflammatory and analgesic effects occur.

**Availability**
- hydrocodone bitartrate and acetaminophen
  - Capsules: 5 mg hydrocodone (hyd.)/500 mg acetaminophen (acet.)
  - Elixir/oral solution: 2.5 mg hyd./167 mg acet./5 ml

Reactions in **bold** are life-threatening.
Tablets: 2.5 mg hyd./500 mg acet.; 5 mg hyd./325 mg acet.; 5 mg hyd./400 mg acet.; 5 mg hyd./500 mg acet.; 7.5 mg hyd./325 mg acet.; 7.5 mg hyd./400 mg acet.; 7.5 mg hyd./500 mg acet.; 7.5 mg hyd./650 mg acet.; 7.5 mg hyd./750 mg acet.; 10 mg hyd./325 mg acet.; 10 mg hyd./400 mg acet.; 10 mg hyd./500 mg acet.; 10 mg hyd./650 mg acet.; 10 mg hyd./660 mg acet.; 10 mg hyd./750 mg acet.

hydrocodone bitartrate and aspirin
Tablets: 5 mg hyd./500 mg aspirin
hydrocodone bitartrate and ibuprofen
Tablets: 7.5 mg hyd./200 mg ibuprofen
hydrocodone bitartrate and homatropine methylbromide
Syrup: 1.5 mg/5 ml, 5 mg/5 ml
Tablets: 1.5 mg, 5 mg

Indications and dosages

Moderate to severe pain
Adults: 2.5 to 10 mg P.O. q 4 to 6 hours p.r.n. When giving hydrocodone/acetaminophen, don’t exceed 60 mg/day; when giving hydrocodone/ibuprofen, don’t exceed 37.5 mg/day.
Children: 0.15 to 0.2 mg/kg P.O. q 6 hours

Cough
Adults: One tablet or 5 ml (syrup) q 4 to 6 hours as needed; don’t exceed 6 tablets or 30 ml syrup in 24 hours.
Children ages 6 to 12: One-half tablet or 2.5 ml (syrup) q 4 to 6 hours as needed; don’t exceed 3 tablets or 15 ml syrup in 24 hours.

Contraindications
• Hypersensitivity to hydrocodone, acetaminophen, aspirin, ibuprofen, or homatropine methylbromide (for corresponding combination products) or to alcohol, aspartame, saccharine, sugar, or tartrazine (with some products)

Precautions
Use cautiously in:
• severe renal, hepatic, or pulmonary disease; increased intracranial pressure; hypothyroidism; adrenal insufficiency; prostatic hypertrophy; thrombocytopenia; alcoholism
• elderly patients
• pregnant or breastfeeding patients.

Administration
In patients receiving concurrent MAO inhibitors, know that hydrocodone may produce severe, unpredictable reactions. Initial dosage may need to be 25% lower than usual dosage.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>10-30 min</td>
<td>30-60 min</td>
<td>4-6 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: confusion, drowsiness, sedation, dysphoria, euphoria, floating feeling, hallucinations, headache, anxiety, depression, fatigue, insomnia, lethargy, nervousness, slurred speech, tremor, asthenia, unusual dreams
CV: orthostatic hypotension, bradycardia, peripheral edema, palpitations, arrhythmias
EENT: blurred vision, vision changes, diplopia, miosis, tinnitus, pharyngitis, rhinitis, sinusitis
GI: nausea, vomiting, constipation, dysphagia, esophagitis, dyspepsia, flatulence, gastritis, gastroenteritis, mouth ulcers, dry mouth, anorexia
GU: urinary retention or frequency, erectile dysfunction
Respiratory: respiratory depression, bronchitis, dyspnea
Skin: pruritus, urticaria, diaphoresis, flushing
Other: physical or psychological drug dependence, drug tolerance

Interactions
Drug-drug. Angiotensin-converting enzyme inhibitors: decreased therapeutic effects of these drugs
Antihistamines, sedative-hypnotics: additive CNS depression
Buprenorphine, butorphanol, nalbuphine, pentazocine: precipitation of opioid withdrawal in physically dependent patients
Buprenorphine, pentazocine: decreased analgesia
Lithium: increased lithium blood level (with hydrocodone/ibuprofen only)
MAO inhibitors: severe, unpredictable reactions
Methotrexate: increased methotruxate blood level
Naloxone: withdrawal symptoms
Oral anticoagulants: increased risk of GI bleeding (with hydrocodone/ibuprofen only)

**Drug-diagnostic tests.** Amylase, lipase: increased levels

**Drug-herbs.** Chamomile, hops, kava, skullcaps, valerian: increased CNS depression

**Drug-behaviors.** Alcohol use: increased CNS depression

**Patient monitoring**
- In prolonged use, monitor for psychological and physical dependence.
- Watch closely for withdrawal symptoms when drug is discontinued.
- Assess elderly patients carefully for adverse reactions.
- Monitor for signs and symptoms of drug overdose, including nausea, vomiting, blurred vision, cool and clammy skin, dizziness, confusion, dyspnea, respiratory depression, bradycardia, hearing loss, tinnitus, headache, and mood or behavior changes.

**Patient teaching**
- Tell patient drug may cause drowsiness. Caution him to avoid driving and other hazardous activities until CNS effects are known.
- Inform patient that prolonged use may lead to physical or psychological dependence.
- Caution patient to avoid alcohol during therapy.
- Instruct patient to move slowly when sitting up or standing, to avoid dizziness from sudden blood pressure decrease.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

**Clinical alert**
Reactions in **bold** are life-threatening.
Injection: 25 mg/ml, 50 mg/ml; 100 mg/vial, 250 mg/vial, 500 mg/vial, 1,000 mg/vial
Intrarectal aerosol foam: 90 mg
Oral suspension: 10 mg/5 ml
Retention enema: 100 mg/60 ml
Spray (topical): 1%
Tablets: 5 mg, 10 mg, 20 mg

Indications and dosages

➣ Replacement therapy in adrenocortical insufficiency; hypercalcemia due to cancer; arthritis; collagen diseases; dermatologic diseases; autoimmune and hematologic disorders; trichinosis; ulcerative colitis; multiple sclerosis; proctitis; nephrotic syndrome; aspiration pneumonia
hydrocortisone, hydrocortisone cypionate—
Adults and children: 20 to 240 mg/day P.O.
hydrocortisone acetate (suspension)—
Adults and children: 5 to 75 mg by intra-articular injection (depending on joint size) q 2 to 3 weeks
hydrocortisone acetate (intrarectal foam)—
Adults and children: One applicatorful of intrarectal foam daily or b.i.d. for 2 to 3 weeks; then one applicatorful every other day
hydrocortisone sodium phosphate—
Adults and children: 15 to 240 mg/day subcutaneously, I.M., or I.V., adjusted according to response
hydrocortisone sodium succinate—
Adults and children: 100 to 500 mg I.M. or I.V.; may repeat at 2-, 4-, or 6-hour intervals, depending on response and condition
hydrocortisone retention enema—
Adults and children: 100 mg P.R. at bedtime for 21 nights or until desired response; patient should retain enema for at least 1 hour.
➢ Itching and inflammation caused by skin conditions
Adults and children: Thin film of topical preparation applied to affected

Off-label uses

● Phlebitis
● Stomatitis

Contraindications

● Hypersensitivity to drug, alcohol, bisulfites, or tartrazine (with some products)
● Systemic fungal infections
● Concurrent use of other immunosuppressant corticosteroids
● Concurrent administration of live-virus vaccines

Precautions

Use cautiously in:
● hypertension, osteoporosis, glaucoma, renal or GI disease, hypothyroidism, cirrhosis, thromboembolic disorders, myasthenia gravis, heart failure
● pregnant or breastfeeding patients
● children ages 6 and younger (safety not established).

Administration

● Give oral form with food or milk to avoid GI upset.
● Give I.V. injection of sodium succinate form over 30 seconds to a few minutes.
● Know that drug may be given as intermittent or continuous I.V. infusion. Dilute in normal saline solution, dextrose 5% in water, or dextrose 5% in normal saline solution.
● Inject I.M. deep into gluteal muscle. Rotate injection sites to prevent muscle atrophy.
● Be aware that subcutaneous administration may cause muscle atrophy or sterile abscess.

Never abruptly discontinue high-dose or long-term systemic therapy.
● Know that systemic forms typically are used for adrenal replacement rather than inflammation.
* Be aware that occlusive dressings, heat, hydration, inflammation, denuding, and thinning of skin increase topical drug absorption.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1-2 hr</td>
<td>1-2 hr</td>
<td>1-1.5 days</td>
</tr>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>Unknown</td>
<td>1-1.5 days</td>
</tr>
<tr>
<td>I.M.</td>
<td>Rapid</td>
<td>4-8 hr</td>
<td>1-1.5 days</td>
</tr>
<tr>
<td>P.R.</td>
<td>Slow</td>
<td>3-5 days</td>
<td>4-6 days</td>
</tr>
<tr>
<td>Spray (topical), subcut.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** headache, nervousness, depression, euphoria, personality changes, psychoses, vertigo, paresthesia, insomnia, restlessness, conus medullaris syndrome, **meningitis, increased intracranial pressure, seizures**

**CV:** hypotension, hypertension, thrombophlebitis, heart failure, shock, fat embolism, thromboembolism, arrhythmias

**EENT:** cataracts, glaucoma, increased intraocular pressure, epistaxis, nasal congestion, perforated nasal septum, dysphonia, hoarseness, nasopharyngeal or oropharyngeal fungal infections

**GI:** nausea, vomiting, esophageal candidiasis or ulcer, abdominal distention, dry mouth, **rectal bleeding, peptic ulceration, pancreatitis**

**Hematologic:** purpura

**Metabolic:** sodium and fluid retention, hypokalemia, hypocalcemia, hyperglycemia, hypercholesterolemia, amenorrhea, growth retardation, diabetes mellitus, cushingoid appearance, **hypothalamic-pituitary-adrenal suppression with secondary adrenal insufficiency** (with abrupt withdrawal or high-dose, prolonged use)

**Musculoskeletal:** osteoporosis, aseptic joint necrosis, muscle pain or weakness, steroid myopathy, loss of muscle mass, tendon rupture, spontaneous fractures

**Respiratory:** cough, wheezing, rebound congestion, **bronchospasm**

**Skin:** rash, pruritus, urticaria, contact dermatitis, acne, bruising, hirsutism, petechiae, striae, acneiform lesions, skin fragility and thinness, angioedema

**Other:** altered taste; anosmia; appetite changes; weight gain; facial edema; increased susceptibility to infection; masking or aggravation of infection; adhesive arachnoiditis; injection site pain, burning, or atrophy; immunosuppression; hypersensitivity reactions including **anaphylaxis**

**Interactions**

**Drug-drug.** Amphotericin B, loop and thiazide diuretics, mezlocillin, piperacillin, ticarcillin: additive hypokalemia

Fluoroquinolones: increased risk of tendon rupture

Hormonal contraceptives: prolonged half-life and increased effects of hydrocortisone

Insulin, oral hypoglycemics: increased requirements for these drugs

Live-virus vaccines: decreased antibody response to vaccine, increased risk of adverse reactions

Nonsteroidal anti-inflammatory drugs: increased risk of adverse GI reactions

Phenobarbital, phenytoin, rifampin: decreased hydrocortisone efficacy

Somatrem: inhibition of growth-promoting effect

**Drug-diagnostic tests.** Calcium, potassium, thyroxine, triiodothyronine: decreased levels

Cholesterol, glucose: increased levels

Digoxin assays: false elevation (with some test methods)

Nitroblue tetrazolium test: false-negative result

**Drug-herbs.** Echinacea: increased immunostimulation

Ginseng: potentiation of immunomodulation

**Drug-behaviors.** Alcohol use: increased risk of gastric irritation and GI ulcers

Reactions in **bold** are life-threatening.
Patient monitoring

- In high-dose therapy (which should not exceed 48 hours), watch closely for signs and symptoms of depression or psychotic episodes.
- Monitor blood pressure, weight, and electrolyte levels regularly.
- Assess blood glucose levels in diabetic patients. Expect to increase insulin or oral hypoglycemic dosage.
- Monitor patient’s response during weaning from drug. Watch for adrenal crisis, which may occur if drug is discontinued too quickly.

Patient teaching

- Instruct patient to take daily P.O. dose with food by 8 A.M.
- Urge patient to immediately report unusual weight gain, face or leg swelling, epigastric burning, vomiting of blood, black tarry stools, irregular menstrual cycles, fever, prolonged sore throat, cold or other infection, or worsening of symptoms.
- Tell patient using topical form not to apply occlusive dressing unless instructed by prescriber.
- Advise patient to discontinue topical drug and notify prescriber if local irritation occurs.
- Instruct patient to eat small, frequent meals and to take antacids as needed to minimize GI upset.
- Tell patient that response to drug will be monitored regularly.
- Caution patient not to stop taking drug abruptly.
- In long-term use, instruct patient to have regular eye exams.
- Instruct patient to wear medical identification stating that he’s taking this drug.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

hydromorphone hydrochloride

Dilaudid, Dilaudid-5, Dilaudid-HP, Hydromorph Contin®, Hydromorph-IR®, Palladone®, Palladone SR®, PHL-Hydromorphone®, PMS-Hydromorphone®

Pharmacologic class: Opioid agonist
Therapeutic class: Opioid analgesic, antitussive
Controlled substance schedule II
Pregnancy risk category C (with long-term use or at term with high doses: D)

FDA BOXED WARNING

- Drug is a potent Schedule II opioid agonist with highest abuse potential and risk of causing respiratory depression. Alcohol, other opioids, and CNS depressants potentiate respiratory depressant effects, increasing risk of potentially fatal respiratory depression.

Action
Binds to opiate receptors in spinal cord and CNS, altering perception of and response to painful stimuli while producing generalized CNS depression. Also subdues cough reflex and decreases GI motility.

Availability
Injection: 1 mg/ml, 2 mg/ml, 4 mg/ml, 10 mg/ml
Powder for injection (lyophilized): 250-mg vials (high-potency)
Oral solution: 5 mg/5 ml
Rectal suppositories: 3 mg
Tablets: 2 mg, 3 mg, 4 mg, 8 mg
Indications and dosages

Moderate to severe pain

Adults weighing more than 50 kg (110 lb): 2 mg P.O. (tablets) q 4 to 6 hours p.r.n. For more severe pain, 4 mg P.O. (tablets) may be given q 4 to 6 hours. If pain increases in severity, analgesia isn’t adequate, or tolerance develops, a gradual increase in dosage may be required. Or 2.5 to 10 mg P.O. (oral solution) q 4 to 6 hours p.r.n as directed by clinical situation. Or 1 to 2 mg subcutaneously, I.M., or I.V. q 4 to 6 hours p.r.n; or 3 mg P.R. q 6 to 8 hours p.r.n. Adjust dosage based on pain severity, underlying disease, and patient’s age and size.

Contraindications

- Hypersensitivity to narcotics or bisulfites
- Acute or severe bronchial asthma or upper respiratory tract obstruction

Precautions

Use cautiously in:

- increased intracranial pressure; severe renal, hepatic, or pulmonary disease; hypothyroidism; adrenal insufficiency; prostatic hypertrophy; alcoholism
- concurrent use of MAO inhibitors
- elderly patients
- pregnant or breastfeeding patients.

Administration

Be aware that high-potency hydromorphone (Dilaudid-HP) is a highly concentrated solution and shouldn’t be confused with standard parenteral formulations of hydromorphone or other opioids. Overdose and death may result.

- Know that high-potency formulation is recommended for opioid-tolerant patients who require larger than usual doses of opioids to gain adequate pain relief.
- For maximal analgesic effect, give before pain becomes severe.

Adverse reactions

CNS: confusion, sedation, dysphoria, euphoria, floating feeling, hallucinations, headache, unusual dreams, anxiety, dizziness, drowsiness
CV: hypotension, hypertension, palpitations, bradycardia, tachycardia
EENT: blurred vision, diplopia, miosis, nystagmus, tinnitus, laryngeal edema, laryngospasm
GI: nausea, vomiting, constipation, abdominal cramps, biliary tract spasm, anorexia
GU: urinary retention, dysuria
Hepatic: hepatotoxicity
Respiratory: dyspnea, wheezing, bronchospasm, respiratory depression
Skin: flushing, diaphoresis
Other: physical or psychological drug dependence; drug tolerance; injection site pain, redness, or swelling

Interactions

Drug-drug. Antidepressants, antihistamines, MAO inhibitors, sedative-hypnotics: additive CNS depression Anti hypertensives, diuretics, guanadrel, guanethidine, mecamylamine: increased risk of hypotension Atropine, belladonna alkaloids, difenoxin, diphenoxylate, kaolin and pectin,

Reactions in **bold** are life-threatening.

Clinical alert
loperamide, paregoric: increased risk of CNS depression, severe constipation
Barbiturates: increased sedation
Buprenorphine, butorphanol, nalbuphine, pentazocine: precipitation of opioid withdrawal in physically dependent patients
Nalbuphine, pentazocine: decreased analgesia

Drug-diagnostic tests. Amylase, lipase: increased levels

Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression

Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring

With I.V. use, monitor for respiratory depression. Keep resuscitation equipment and naloxone nearby.
- Assess for signs and symptoms of physical or psychological drug dependence.
- Monitor for constipation.

Patient teaching

Instruct patient to take drug exactly as prescribed before pain becomes severe, but caution him that drug may be habit-forming.
- Tell patient to take oral form with food to avoid GI upset.
- Advise patient to report difficulty breathing, nausea, vomiting, or dizziness.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Tell patient to avoid alcohol while taking drug.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

hydroxychloroquine sulfate
Apo-Hydroxychloroquine®, Gen-Hydroxychloroquine®, Plaquenil

Pharmacologic class: 4-aminoquinolone
Therapeutic class: Antimalarial, antirheumatic, anti-inflammatory (disease-modifying)
Pregnancy risk category C

FDA BOXED WARNING

- Familiarize yourself completely with contents of the manufacturer’s package insert before administering or prescribing this drug.

Action
Unknown. Thought to interfere with inhibition of protein synthesis and DNA replication, leading to parasitic death.

Availability
Tablets: 200 mg (155 mg base); 200 mg hydroxychloroquine sulfate is equivalent to 155 mg of hydroxychloroquine base

Indications and dosages

➣ Malaria prophylaxis (dosages expressed as mg of base)
Adults: 310 mg P.O. q week, starting 1 to 2 weeks before entering endemic area and continuing for 4 weeks after leaving area
Children: 5 mg/kg P.O. q week, starting 1 to 2 weeks before entering endemic area and continuing for 4 weeks after leaving area
➣ Acute malarial attack (dosages expressed as mg of base)
Adults: Initially, 620 mg P.O., then 310 mg 6 hours, 24 hours, and 48 hours later
Children: Initially, 10 mg/kg P.O., then 5 mg/kg 6 hours, 24 hours, and 48 hours later
  ➢ Rheumatoid arthritis
Adults: 400 to 600 mg/day P.O. for 4 to 12 weeks, then reduced by 50%
  ➢ Systemic lupus erythematosus
Adults: 400 mg P.O. once or twice daily for several months, then reduced to 200 to 400 mg daily, depending on response

Contraindications
 ● Hypersensitivity to drug or chloroquine
 ● Retinal or visual field changes
 ● Long-term therapy in children

Precautions
Use cautiously in:
 ● hepatic or renal impairment, G6PD deficiency, psoriasis, bone marrow depression, alcoholism
 ● obese patients
 ● pregnant or breastfeeding patients
 ● children.

Administration
 ● Give with food or milk.
 ● For malaria prophylaxis, schedule doses on same day each week.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2-4.5 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: anxiety, apathy, confusion, fatigue, headache, psychoses, mood swings, irritability, neuromyopathy, peripheral neuritis, seizures
CV: ECG changes, hypotension
EENT: visual disturbances, retinopathy, keratopathy, ototoxicity, tinnitus
GI: nausea, vomiting, diarrhea, abdominal cramps, anorexia
Hematologic: leukopenia, agranulocytosis, aplastic anemia, thrombocytopenia
Hepatic: jaundice, hepatotoxicity
Musculoskeletal: muscle weakness

Skin: dermatoses, rash, pruritus, pigmentation changes, pleomorphic skin eruption, worsened psoriasis, alopecia, bleaching of hair
Other: weight loss

Interactions
Drug-diagnostic tests. Granulocytes, hemoglobin, platelets: decreased values
Drug-behaviors. Sun exposure: exacerbation of drug-induced dermatoses

Patient monitoring
 ≠ Monitor for signs and symptoms of overdose, such as nausea, vomiting, drowsiness, visual disturbances, cardiovascular collapse, and seizures.
 ≠ Watch for adverse reactions.

Patient teaching
 ● Advise patient to take with food or milk.
 ≠ Instruct patient to immediately report such adverse reactions as vision changes, nausea, vomiting, drowsiness, mental changes, mood swings, headache, ringing in ears, muscle weakness, rash, bleeding, bruising, and yellowing of skin and eyes.
 ● In long-term therapy, advise patient to have regular eye exams.
 ● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

hydroxyurea
Droxia, Hydrea

Pharmacologic class: Antimetabolite
Therapeutic class: Antineoplastic
Pregnancy risk category D

Reactions in bold are life-threatening.
FDA BOXED WARNING

- Drug may cause severe and even life-threatening adverse effects. Administer under supervision of physician experienced in using drug to treat sickle cell anemia.
- Drug damages genes, chromosomes, and DNA and may be carcinogenic. Secondary leukemias have occurred in patients receiving it as long-term therapy for myeloproliferative disorders. Prescriber and patient must carefully weigh potential benefits against undefined risk of secondary cancers.

Action
Unknown. May inhibit enzyme necessary for DNA synthesis without disrupting RNA or protein synthesis.

Availability
Capsules: 200 mg, 300 mg, 400 mg, 500 mg

Indications and dosages
- Head and neck cancer; ovarian cancer; malignant melanoma
  Adults: 60 to 80 mg/kg (2 to 3 g/m²) P.O. as a single daily dose q 3 days, or 20 to 30 mg/kg/day P.O. as a single dose. Begin therapy 7 days before radiation.
  - Resistant chronic myelogenous leukemia
  Adults: 20 to 30 mg/kg/day P.O. in one or two divided doses
  - Sickle cell anemia
  Adults and children: 15 mg/kg/day P.O. as a single dose. May increase by 5 mg/kg/day P.O. q 12 weeks, up to 35 mg/kg/day.

Off-label uses
- Thrombocythemia
- Human immunodeficiency virus

Contraindications
- Hypersensitivity to drug or tartrazine
- Bone marrow depression
- Severe anemia or thrombocytopenia

Precautions
Use cautiously in:
- renal or hepatic impairment
- obese patients
- females of childbearing age
- elderly patients.

Administration
- Provide frequent mouth care.

Adverse reactions
CNS: drowsiness, malaise, confusion, dizziness, headache
GI: nausea, vomiting, diarrhea, constipation, stomatitis, anorexia
GU: dysuria, hyperuricemia, infertility, renal tubular dysfunction
Hematologic: anemia, megaloblastosis, leukopenia, thrombocytopenia, bone marrow depression
Hepatic: hepatitis
Metabolic: hyperuricemia
Skin: alopecia, erythema, pruritus, rash, urticaria, exacerbation of post-radiation erythema
Other: chills, fever

Interactions
Drug-drug. Live-virus vaccines: decreased antibody response to vaccine, increased risk of adverse reactions
Myelosuppressants: additive bone marrow depression
Drug-diagnostic tests. Blood urea nitrogen, creatinine, uric acid: increased values
Hemoglobin, platelets, red blood cells, white blood cells: decreased values
Mean corpuscular volume: transient increase
**Patient monitoring**
- Assess CBC weekly.
- Closely monitor patient with renal or hepatic impairment. Check kidney and liver function tests often.
- Assess fluid status. Make sure patient drinks 10 to 12 glasses of water daily.

**Patient teaching**
- Advise patient to mark dates for drug doses, diagnostic tests, and treatments on calendar.
- Instruct patient to immediately report easy bruising, bleeding, unusual tiredness, or yellowing of skin or eyes.
- Tell patient to report such adverse effects as appetite loss, nausea, vomiting, oral lesions, constipation, diarrhea, confusion, dizziness, headache, and rash.
- Instruct female patient to use barrier contraception.
- Tell patient he will undergo regular blood testing to monitor drug effects.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

---

**hydroxyzine hydrochloride**

Apo-Hydroxyzine®, Atarax®, Novo-Hydroxyzin®, Nu-Hydroxyzine®, PMS-Hydroxyzine®, Riva-Hydroxyzine®, Ucerax®

**hydroxyzine pamoate**

Vistaril

**Pharmacologic class:** Piperazine derivative

**Therapeutic class:** Anxiolytic, anti-histamine, sedative-hypnotic

**Pregnancy risk category NR**

---

**Action**
Unknown. Anxiolytic and sedative effects may stem from suppression of activity in subcortical levels of CNS. Antihistamine effects may result from histamine suppression at cellular receptor sites.

**Availability**
- **Capsules:** 25 mg, 50 mg, 100 mg (pamoate)
- **Injection:** 25 mg/ml, 50 mg/ml
- **Oral suspension:** 25 mg/5 ml (pamoate)
- **Syrup:** 10 mg/5 ml
- **Tablets:** 10 mg, 25 mg, 50 mg

**Indications and dosages**

- **Psychiatric emergencies; acute or chronic alcoholism**
  - **Adults:** 50 to 100 mg I.M. immediately, then q 4 to 6 hours p.r.n.
  - **Nausea and vomiting; adjunct in pre- and postoperative sedation**
  - **Adults:** 25 to 100 mg I.M. q 4 to 6 hours
  - **Children:** 1.1 mg/kg I.M. q 4 to 6 hours
- **Anxiety**
  - **Adults and children ages 6 and older:** 50 to 100 mg P.O. q.i.d.
  - **Children younger than age 6:** 50 mg P.O. daily in divided doses
- **Pruritus**
  - **Adults:** 25 mg P.O. three or four times daily
  - **Children ages 6 and older:** 50 to 100 mg P.O. daily in divided doses
  - **Children younger than age 6:** 50 mg P.O. daily in divided doses

**Off-label uses**
- Seasonal allergic rhinitis

**Contraindications**
- Hypersensitivity to drug or cetirizine
- Early pregnancy

**Precautions**
Use cautiously in:
- severe hepatic dysfunction
- elderly patients.
Administration

Don’t administer I.V. or subcutaneously (may cause tissue necrosis).
• Use Z-track method for I.M. injection. Inject deep into large muscle (preferably, upper outer quadrant of buttock).

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O., I.M.</td>
<td>15-30 min</td>
<td>2-4 hr</td>
<td>4-6 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: drowsiness, agitation, dizziness, headache, asthenia, ataxia
GI: nausea, constipation, dry mouth
GU: urinary retention
Respiratory: wheezing
Skin: flushing
Other: bitter taste, hypersensitivity reaction, pain or abscess at I.M. injection site

Interactions
Drug-drug. Anticholinergics, antidepressants, antihistamines, phenothiazines, quinidine: additive effects of these drugs
Antidepressants, antihistamines, opioids, sedative-hypnotics, other CNS depressants: additive CNS depression
Drug-diagnostic tests. Skin tests using allergen extracts: false-negative results
Drug-herbs. Angel’s trumpet, jimsonweed, scopolia: increased anticholinergic effects
Chamomile, hops, kava, skullcap, valerian: increased CNS depression
Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring
• Monitor closely for CNS depression and oversedation, especially if patient is receiving other CNS depressants.
• Assess for adverse effects, especially in elderly patients.
• Monitor liver function test results in patients with hepatic impairment.

Patient teaching
• Tell patient to contact prescriber if he experiences wheezing, muscle spasms, or incoordination.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• Instruct patient to avoid alcohol while taking drug.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

hyoscyamine
Cystospaz

hyoscyamine sulfate
Anaspaz, Hyospaz, Levisn, Levisn/SL, Symax, Symax-SL, Symax-SR

Pharmacologic class: Anticholinergic
Therapeutic class: Antispasmodic
Pregnancy risk category C

Action
Competitively inhibits acetylcholine action at autonomic nerve sites, relaxing smooth muscle and decreasing glandular secretions

Availability
hyoscyamine
Tablets: 0.15 mg
hyoscyamine sulfate
Capsules (timed-release): 0.375 mg
Elixir: 0.125 mg/5 ml
Injection: 0.5 mg/ml
Oral solution: 0.125 mg/ml
Tablets: 0.125 mg
Tablets (extended-release): 0.375 mg
Tablets (orally disintegrating): 0.125 mg
Tablets (sublingual): 0.125 mg
Indications and dosages

- Adjunct in GI tract disorders; pain and hypersecretion in pancreatitis; cystitis; renal colic; infant colic; acute rhinitis; rigidity, tremors, and hyperhidrosis in Parkinson’s disease; partial heart block due to vagal activity.

**Adults and children ages 12 and older:**
0.125 to 0.25 mg (sulfate) P.O. or S.L. two to four times daily, or 0.375 to 0.75 mg (extended-release sulfate) P.O. q 12 hours, or 0.25 to 0.5 mg (sulfate) subcutaneously, I.M., or I.V. two to four times daily p.r.n.

**Children ages 2 to 12:** In children weighing approximately 50 kg (110 lb), 0.125 mg (sulfate) P.O. q 4 hours p.r.n.; in children weighing approximately 20 kg (40 lb), 0.0625 mg P.O. (sulfate); in children weighing approximately 10 kg (22 lb), 0.031 to 0.033 mg (sulfate) P.O. Don’t exceed 0.75 mg/day.

**Children ages 2 and younger:** In children weighing approximately 7 kg (15 lb), 0.025 (sulfate) P.O. q 4 hours p.r.n.; in children weighing approximately 5 kg (11 lb), 0.0208 mg (sulfate) P.O. q 4 hours p.r.n.; in children weighing approximately 3.4 kg (7.5 lb), 0.0167 mg (sulfate) P.O. q 4 hours p.r.n.; in children weighing approximately 2.3 kg (5 lb), 0.0125 mg (sulfate) P.O. q 4 hours p.r.n.

- Before endoscopy or hypotonic duodenography
  - Adults: 0.25 to 0.5 mg (sulfate) subcutaneously, I.M., or I.V. 5 to 10 minutes before procedure

- Preoperatively to inhibit salivation and excessive respiratory secretions
  - **Adults and children older than age 2:** 5 mcg/kg (sulfate) I.M., I.V., or subcutaneously 30 to 60 minutes before anesthesia induction

- Muscarinic toxicity
  - **Adults:** 1 to 2 mg (sulfate) I.V. Additional 1-mg doses may be given I.M. or I.V. q 3 to 10 minutes until muscarinic signs and symptoms subside; doses may be repeated if needed. Patient may need up to 25 mg during first 24 hours. For maintenance, 0.5 to 1 mg P.O. at intervals of several hours until signs and symptoms disappear.

Contraindications

- Hypersensitivity to anticholinergics, alcohol, sulfites, or tartrazine
- Angle-closure glaucoma, synechia
- GU or GI obstructive disease, severe ulcerative colitis
- Renal or hepatic disease
- Neonates or premature infants

Precautions

- Use cautiously in:
  - cardiovascular disease, prostatic hypertrophy, reflux esophagitis, brain damage, autonomic neuropathy, hyperthyroidism, glaucoma, Down syndrome, spastic paralysis
  - elderly patients
  - pregnant (safety not established) or breastfeeding patients
  - infants and small children.

Administration

- Administer 30 to 60 minutes before meals and at bedtime.
- Give bedtime dose at least 2 hours after last evening meal or snack.
- Be aware that hyoscyamine is given P.O. only, whereas hyoscyamine sulfate may be given P.O., I.M., I.V., sublingually, or subcutaneously.
- Know that a cholinesterase reactivator (pralidoxime) is given concomitantly to treat muscarinic toxicity.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>20-30 min</td>
<td>0.5-1 hr</td>
<td>4-12 hr</td>
</tr>
<tr>
<td>P.O. (extended)</td>
<td>20-30 min</td>
<td>40-90 min</td>
<td>12 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>2 min</td>
<td>15-30 min</td>
<td>4 hr</td>
</tr>
<tr>
<td>I.M., subcut.</td>
<td>Unknown</td>
<td>15-30 min</td>
<td>4-12 hr</td>
</tr>
<tr>
<td>S.L.</td>
<td>5-20 min</td>
<td>0.5-1 hr</td>
<td>4 hr</td>
</tr>
</tbody>
</table>

Reactions in **bold** are life-threatening.

![Clinical alert](h)
Adverse reactions
CNS: confusion, excitement, nervousness, dizziness, light-headedness, headache, insomnia
CV: palpitations, tachycardia
EENT: blurred vision, cycloplegia, increased intraocular pressure, mydriasis, photophobia
GI: nausea, vomiting, constipation, bloating, dry mouth, paralytic ileus
GU: urinary hesitancy or retention, erectile dysfunction, lactation suppression
Skin: flushing, decreased sweating, urticaria, local irritation (with I.M., I.V., or subcutaneous use)
Other: altered taste, allergic reactions (including fever), heat intolerance, anaphylaxis

Interactions
Drug-drug. Amantadine, antihistamines, antiparkinsonian drugs, disopyramide, glutethimide, meperidine, procainamide, quinidine, tricyclic antidepressants: increased anticholinergic effects
Antacids: decreased hyoscyamine absorption
Atenolol: increased atenolol effects
Ketoconazole: interference with absorption of both drugs
Methotrimeprazine: increased risk of extrapyramidal effects
Phenothiazines: decreased phenothiazine effects, increased anticholinergic effects
Drug-herbs. Jimsonweed: adverse cardiovascular effects

Patient monitoring
- Watch for adverse reactions.
- Check for mental status changes, such as confusion.
- Evaluate fluid intake and output.
- Assess patient’s response to temperature changes (especially hot weather). Drug may cause heat intolerance, predisposing patient to heat stroke.

Patient teaching
- Tell patient to take on empty stomach 30 to 60 minutes before meals and at least 2 hours after last evening meal or snack.
- Instruct patient with urinary hesitancy to empty bladder before taking.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and herbs mentioned above.

ibandronate sodium
Boniva, Boniva Injection, Bonviva

ibandronic acid

Pharmacologic class: Bisphosphonate
Therapeutic class: Calcium regulator
Pregnancy risk category C

Action
Inhibits osteoclast activity and reduces bone resorption and turnover; in postmenopausal women, reduces elevated bone turnover rate, leading to (on average) net gain in bone mass

Availability
Solution for injection: 3 mg/3 ml in single-use prefilled glass syringes
Tablets (film-coated): 2.5 mg, 150 mg

Indications and dosages
➣ Osteoporosis treatment and prevention in postmenopausal women
Adults: 2.5-mg tablet P.O. daily, or 150-mg tablet P.O. once monthly on same date each month
Osteoporosis treatment in post-menopausal women

**Adults:** 3 mg I.V. injection every 3 months

**Contraindications**
- Hypersensitivity to drug or its components
- Uncorrected hypocalcemia
- Inability to stand or sit upright for at least 60 minutes (after oral administration)

**Precautions**
Use cautiously in:
- severe renal impairment
- patients who develop jaw osteonecrosis during therapy
- concurrent use of aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), or other bisphosphonates
- pregnant or breastfeeding patients
- children younger than age 18 (safety and efficacy not established).

**Administration**
- With patient standing or sitting upright, give oral dose with 6 to 8 oz water at least 60 minutes before first food or drink (other than water) of day or before administering other oral drugs or supplements (including calcium, antacids, and vitamins).
- Give with plain water only; some mineral waters may have higher calcium concentration and shouldn’t be used.
- Don’t let patient chew or suck tablet because this may cause oropharyngeal ulcers.
- Keep patient upright for at least 60 minutes after oral dose to avoid serious esophageal irritation.
- Give parenteral formulation only by I.V. injection over 15 to 30 seconds.
- Don’t mix parenteral formulation with calcium-containing solutions or other I.V. drugs.
- If patient misses I.V. dose, give it as soon as possible; thereafter, give dose every 3 months from date of last injection. Don’t administer more often than every 3 months.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>0.5-2 hr</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- **CNS:** insomnia, asthenia, headache, fatigue, dizziness, vertigo, nerve root lesion
- **CV:** hypertension
- **EENT:** pharyngitis
- **GI:** constipation, diarrhea, vomiting, abdominal pain, dysphagia, esophagitis, gastric ulcer, dyspepsia, gastritis, esophageal ulcer
- **GU:** urinary tract infection
- **Metabolic:** hypercholesterolemia
- **Musculoskeletal:** osteonecrosis (mainly in jaw), localized osteoarthritis and muscle cramp, joint disorder, joint pain, muscle pain, back pain, extremity pain, arthritis
- **Respiratory:** upper respiratory tract infection, bronchitis, pneumonia
- **Skin:** rash
- **Other:** tooth disorder, influenza, infection, injection site reaction, allergic reaction

**Interactions**
- **Drug-drug.** Aspirin, NSAIDs: additive GI irritation
- Drugs containing calcium and other multivalent cations (such as aluminum, iron, magnesium), including antacids, supplements, and vitamins: interference with ibandronate absorption
- **Drug-diagnostic tests.** Alkaline phosphatase, calcium: decreased
- Bone-imaging agents: interference with test results
- **Drug-food.** Milk, mineral water, other foods and beverages: interference with ibandronate absorption, reducing drug’s bioavailability and effect on bone mineral density (when patient

Reactions in **bold** are life-threatening.
consumes food or beverage less than 60 minutes after ibandronate dose)

**Patient monitoring**
- Monitor creatinine clearance in patients with mild or moderate renal impairment.
- Monitor for signs and symptoms of GI irritation (including ulcers) after oral administration.
- Evaluate serum calcium and phosphate levels.
- Monitor for hypocalcemia and other disturbances of bone and mineral metabolism; administer effective treatment before therapy starts.
- Monitor patient for adequate intake of supplemental calcium and vitamin D during therapy, as appropriate.

**Patient teaching**
- Advise patient to read patient information leaflet carefully before starting drug.
- Instruct patient to take drug first thing in morning on empty stomach with 6 to 8 oz of plain water only.
- Instruct patient not to chew or suck tablet because this may cause throat ulcers.
- Instruct patient not to eat, drink, or take other oral medications for 60 minutes after taking tablet.
- Instruct patient not to lie down for at least 60 minutes after taking drug.
- Advise patient to take once-monthly tablet (150 mg) on same date each month.
- If patient misses once-monthly dose and next scheduled dose is more than 7 days away, instruct her to take one 150-mg tablet in morning after the day she remembers it and then resume taking one 150-mg tablet every month in morning of chosen day, per original schedule. However, if next scheduled dose is only 1 to 7 days away, tell her to wait until next scheduled dose.

---

**ibritumomab tiuxetan**

*Zevalin*

**Pharmacologic class:** Monoclonal antibody

**Therapeutic class:** Antineoplastic

**Pregnancy risk category D**

---

**FDA BOXED WARNING**

- Deaths from infusion reactions have occurred within 24 hours of infusion of rituximab (essential component of ibritumomab tiuxetan regimen), with roughly 80% occurring after first infusion. Signs and symptoms include hypoxia, pulmonary infiltrate, adult respiratory distress syndrome, myocardial infarction, ventricular fibrillation, and cardiogenic shock. If infusion reaction occurs, discontinue rituximab, In-111 Zevalin, and Y-90 Zevalin infusions and provide supportive treatment.
Y-90 Zevalin regimen causes severe, prolonged cytopenias in most patients. Don’t give to patients with 25% or greater lymphoma bone marrow involvement or impaired marrow reserve, (such as those who have had previous myeloablative therapy or those with platelet counts below 100,000/mm³, neutrophil counts below 1,500/mm³, or hypocellular bone marrow or marked reduction in bone marrow precursors).

Ibritumomab tiuxetan regimen has caused severe cutaneous and mucocutaneous reactions, with some deaths. Patients experiencing such reactions shouldn’t receive further regimen components and should seek prompt medical evaluation.

Don’t exceed maximum Y-90 Zevalin dose of 32 mCi (1,184 MBq).

Y-90 Zevalin should not be given to patients with altered biodistribution, as determined by In-111 Zevalin imaging.

In-111 Zevalin and Y-90 Zevalin should be used only by healthcare professionals qualified in safe radionuclide use and handling.

Action
Binds indium-111 (In-111) or yttrium-90 (Y-90) with free amino groups of lysines and arginines within antibody; binds specifically to CD20 antigen, found on surface of normal and malignant B lymphocytes. Radioactive component of Y-90 causes cellular damage via free radicals in target cells.

Availability
Injection: 3.2 mg/2 ml (two Zevalin kits containing four vials each)

Indications and dosages
Non-Hodgkin’s lymphoma
Adults: Two-step regimen that includes pre-dose of rituximab

Step 1: Single I.V. infusion of 250 mg/m² rituximab at 50 mg/hour; increase rate by 50 mg/hour q 30 minutes, to a maximum of 400 mg/hour. If hypersensitivity or infusion-related reaction occurs, slow or interrupt infusion; if symptoms improve, may resume at 50% of previous rate. Within 4 hours of rituximab dose, 5 mCi of In-111 Zevalin I.V. should be given over 10 minutes.

Step 2: 7 to 9 days after step 1, I.V. infusion of 250 mg/m² rituximab at 100 mg/hour (50 mg/hour if infusion-related reaction occurred during first rituximab dose); increase by 100 mg/hour q 30 minutes, to a maximum of 400 mg/hour, as tolerated. Within 4 hours of rituximab dose, give 0.3 to 0.4 mCi/kg of Y-90 Zevalin I.V. over 10 minutes, not to exceed absolute maximum allowable dose of 32 mCi.

Contraindications
- Hypersensitivity to any drug in therapeutic regimen or its components or to murine products
- Pregnancy or breastfeeding

Precautions
Use cautiously in:
- cardiac conditions
- elderly patients.

Administration
Assess for human antimurine antibody before treatment. If result is positive, patient may experience hypersensitivity reaction.

Premedicate patient with acetaminophen and diphenhydramine, as ordered, before each rituximab infusion.

Know that ibritumomab should be used only as part of a regimen that combines ibritumomab and rituximab.

Give ibritumomab by slow I.V. infusion over 10 minutes; monitor closely.

Don’t give by I.V. push.

Take steps to prevent extravasation of Y-90 Zevalin. If extravasation occurs, immediately stop infusion and restart in another vein.

Reactions in bold are life-threatening.
• Don’t give Y-90 Zevalin if platelet count is less than 100,000/mm³.
• Follow facility policy on radiation precautions to protect patients, visitors, and medical personnel from radiation exposure.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: dizziness, anxiety, headache, insomnia, asthenia
CV: hypotension, peripheral edema
EENT: rhinitis, epistaxis, throat irritation
GI: nausea, vomiting, diarrhea, constipation, anorexia, dyspepsia, abdominal pain or enlargement, melena
Hematologic: anemia, thrombocytopenia, neutropenia, pancytopenia, hemorrhage
Musculoskeletal: joint pain, myalgia, back pain
Respiratory: increased cough, dyspnea, apnea, bronchospasm
Skin: flushing, bruising, diaphoresis, petechiae, pruritus, rash, urticaria, angioedema
Other: bacterial infection, I.V. site irritation, fever, chills, generalized pain, tumor pain, hypersensitivity reactions including anaphylaxis, myeloid malignancies, dysplasias

**Interactions**

None significant

**Patient monitoring**

- Institute infection control protocols. Protect patient from potential sources of infection.
- Assess CBC and platelet count before starting therapy. Monitor regularly during and after therapy.
- Monitor patient for hypersensitivity reactions, which can be fatal and usually occur within 30 minutes to 2 hours of administration.
- Be alert for for unusual bleeding or bruising.

**Patient teaching**

- Instruct patient to promptly report difficulty breathing, rash, fever, chills, severe GI distress, black tarry stools, illness or injury, or unusual bleeding or bruising.
- Tell patient that drug increases his risk of infection. Instruct him to avoid crowds and potential or known sources of infection.
- Advise patient to eat small, frequent meals and take antiemetic drugs to control nausea and vomiting, as needed and prescribed.
- Advise patient that he’ll undergo blood testing during therapy to monitor drug effects.
- As appropriate, review all other significant and life-threatening adverse reactions mentioned above.

**ibuprofen**


**Pharmacologic class:** Nonsteroidal anti-inflammatory drug (NSAID)

**Therapeutic class:** Analgesic, anti-pyretic, anti-inflammatory

**Pregnancy risk category B** (third trimester: D)
FDA BOXED WARNING

- Drug may increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke. Risk may increase with duration of use, and may be greater in patients who have cardiovascular disease or risk factors for it.
- Drug is contraindicated for perioperative pain in setting of coronary artery bypass graft surgery.
- Drug increases risk of serious GI adverse events, including bleeding, ulcers, and stomach or intestinal perforation, which can be fatal. These events can occur at any time during therapy and without warning. Elderly patients are at greater risk.

Action
Unknown. Thought to inhibit cyclooxygenase, an enzyme needed for prostaglandin synthesis.

Availability
Capsules (liquigels): 200 mg
Oral suspension: 100 mg/5 ml
Pediatric drops: 50 mg/1.25 ml
Tablets: 100 mg, 200 mg, 400 mg, 600 mg, 800 mg
Tablets (chewable): 50 mg, 100 mg

Indications and dosages
- Rheumatoid arthritis; osteoarthritis
 
Adults: 1.2 to 3.2 g/day P.O. in three to four divided doses
- Mild to moderate pain
  
Adults: 400 mg P.O. q 4 to 6 hours p.r.n.
- Primary dysmenorrhea
  
Adults: 400 mg P.O. q 4 hours p.r.n.
- Juvenile arthritis
  
Children: 30 to 40 mg/kg/day P.O. in three or four divided doses. Daily dosages above 50 mg/kg aren’t recommended.
- Fever reduction; pain relief
  
Children ages 6 to 12: 5 mg/kg P.O. if temperature is below 102.5° F (39.2° C) or 10 mg/kg if temperature is above 102.5° F. Maximum daily dosage is 40 mg/kg.

Off-label uses
- Migraine and tension headaches

Contraindications
- Hypersensitivity to drug or other NSAIDs
- Pregnancy

Precautions
Use cautiously in:
- severe cardiovascular, renal, or hepatic disease; GI disease; asthma; chronic alcohol use
- elderly patients
- breastfeeding patients.

Administration
- Ideally, give 1 hour before or 2 hours after meal. If GI upset occurs, give with meals.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O. (analgesic)</td>
<td>30 min</td>
<td>1-2 hr</td>
<td>4-6 hr</td>
</tr>
<tr>
<td>P.O. (anti-inflam.)</td>
<td>7 days</td>
<td>1-2 wk</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, dizziness, drowsiness, nervousness, aseptic meningitis
CV: arrhythmias
EENT: amblyopia, blurred vision, tinnitus
GI: nausea, vomiting, constipation, dyspepsia, abdominal discomfort, GI bleeding
GU: cystitis, hematuria, azotemia, renal failure
Hematologic: anemia, prolonged bleeding time, aplastic anemia, neutropenia, pancytopenia, thrombocytopenia, leukopenia, agranulocytosis
Hepatic: hepatitis
Metabolic: hyperglycemia, hypoglycemia
Respiratory: bronchospasm

Reactions in bold are life-threatening.
### Skin
- rash, pruritus, urticaria, **Stevens-Johnson syndrome**

### Other
- edema, allergic reactions including **anaphylaxis**

### Interactions

#### Drug-drug
- **Antihypertensives, diuretics:** decreased efficacy of these drugs
- **Aspirin and other NSAIDs, corticosteroids:** additive adverse GI effects
- **Cefamandole, cefoperazone, cefotetan, drugs affecting platelet function (including abciximab, clopidogrel, eptifibatide, ticlopidine, tirofiban), plicamycin, thrombolytics, valproic acid, warfarin:** increased risk of bleeding
- **Cyclosporine:** increased risk of nephrotoxicity
- **Digoxin:** slightly increased digoxin blood level
- **Lithium:** increased lithium blood level, greater risk of lithium toxicity
- **Metotrexate:** increased risk of methotrexate toxicity
- **Probenecid:** increased risk of ibuprofen toxicity

#### Drug-diagnostic tests
- **Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, blood urea nitrogen, creatinine, lactate dehydrogenase, potassium:** increased values
- **Bleeding time:** prolonged
- **Creatinine clearance, glucose, hematocrit, hemoglobin, platelets, white blood cells:** decreased values

#### Drug-herbs
- **Anise, arnica, chamomile, clove, dong quai, fenugreek, feverfew, garlic, ginger, ginkgo, ginseng, licorice:** increased risk of bleeding
- **White willow:** additive adverse GI effects

#### Drug-behaviors
- **Alcohol use:** additive adverse GI effects
- **Sun exposure:** phototoxicity

### Patient monitoring
- Monitor for desired effect.
- Watch for GI upset, adverse CNS effects (such as headache and drowsiness), and hypersensitivity reaction.
- Stay alert for GI bleeding and ulcers, especially in long-term therapy.
- In long-term therapy, assess renal and hepatic function regularly.

### Patient teaching
- Tell patient to take with full glass of water, with food, or after meals to minimize GI upset.
- To help prevent esophageal irritation, instruct patient to avoid lying down for 30 to 60 minutes after taking dose.
- Instruct patient to immediately report irregular heartbeats, black tarry stools, vision changes, unusual tiredness, yellowing of skin or eyes, change in urination pattern, difficulty breathing, finger or ankle swelling, weight gain, itching, rash, fever, or sore throat.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, alertness, and balance.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

### ibutilide fumarate

**Pharmacologic class:** Ibutilide derivative

**Therapeutic class:** Antiarrhythmic (class III)

**Pregnancy risk category C**

**FDA BOXED WARNING**

- Drug can cause potentially fatal arrhythmias—particularly sustained polymorphic ventricular tachycardia, usually in association with QT prolongation (torsades de pointes). In studies, these arrhythmias arose within several hours of administration. They can be...
Reversed if treated promptly. Drug must be given in setting of continuous ECG monitoring and by personnel trained in identifying and treating acute ventricular arrhythmias. Patients with atrial fibrillation of more than 2 to 3 days’ duration must be adequately anticoagulated, generally for at least 2 weeks.

- Patients with chronic atrial fibrillation tend to revert after conversion to sinus rhythm, and treatments to maintain sinus rhythm carry risks. Therefore, patients to be treated with drug should be selected carefully, with expected benefits of maintaining sinus rhythm outweighing drug’s immediate risks and risks of maintenance therapy, and with drug offering benefits over alternative management.

**Action**

Prolongs myocardial action potential by slowing repolarization and atrioventricular (AV) conduction

**Availability**

*Solution:* 0.1 mg/ml in 10-ml vials

**Indications and dosages**

- To convert atrial fibrillation or flutter to sinus rhythm

  - **Adults weighing more than 60 kg (132 lb):** 1 vial (1 mg) by I.V. infusion over 10 minutes. May repeat after 10 minutes if arrhythmia persists.

  - **Adults weighing less than 60 kg (132 lb):** 0.1 ml/kg (0.01 mg/kg) by I.V. infusion over 10 minutes. May repeat after 10 minutes if arrhythmia persists.

**Contraindications**

- Hypersensitivity to drug or its components

**Precautions**

Use cautiously in:

- ventricular and AV arrhythmias
- pregnant or breastfeeding patients.

**Administration**

- Monitor ECG continuously during and after infusion. Stop infusion immediately if ventricular tachycardia occurs.
- As appropriate, administer diluted or undiluted. To dilute, add 10-ml vial to 50 ml of normal saline solution or dextrose 5% in water, to yield a concentration of 0.017 mg/ml.
- Infuse over 10 minutes.
- Don’t give with amiodarone, disopyramide, quinidine, procainamide, or sotalol, because of increased risk of dangerous arrhythmias.

**Adverse reactions**

**CNS:** headache, light-headedness, dizziness, numbness or tingling in arms

**CV:** hypotension, hypertension, bradycardia, *bundle-branch block*, *ventricular extrasystoles*, *ventricular arrhythmias*, *ventricular tachycardia*, *AV heart block*, *heart failure*

**GI:** nausea

**GU:** renal failure

**Interactions**

**Drug-drug.** Amiodarone, disopyramide, quinidine, procainamide, sotalol: increased risk of dangerous arrhythmias

Antihistamines, phenothiazines, tricyclic antidepressants: increased proarrhythmic effect (prolonged QT interval)

**Patient monitoring**

- Before giving, assess electrolyte levels and correct abnormalities (especially involving potassium and magnesium), because hypokalemia and hypomagnesemia can lead to arrhythmias.
- Watch for premature ventricular contractions, sinus tachycardia, sinus bradycardia, and heart block.
- Monitor ECG during and for at least 4 hours after infusion.

Reactions in **bold** are life-threatening.
Keep emergency equipment (defibrillator, emergency cart and drug box, oxygen, suction, and intubation equipment) at hand during and for at least 4 hours after infusion.

- Monitor prothrombin time, International Normalized Ratio, and activated partial thromboplastin time if patient is receiving anticoagulant therapy.

Patient teaching

- Instruct patient to immediately report chest pain, dizziness, numbness, palpitations, headache, or difficulty breathing.
- Tell patient he’ll be monitored closely for at least 4 hours after drug administration.

idarubicin hydrochloride

Idamycin PFS, Zavedos

Pharmacologic class: Anthracycline antibiotic
Therapeutic class: Antineoplastic
Pregnancy risk category D

FDA BOXED WARNING

- Administer slowly I.V.—never I.M. or subcutaneously. Extravasation may cause severe local tissue necrosis.
- Drug may cause myocardial toxicity leading to heart failure, especially in patients who have received prior anthracyclines or have preexisting cardiac disease.
- Severe bone marrow depression can occur when drug is used at effective therapeutic doses.
- Reduce dosage in hepatic or renal impairment.
- Give under supervision of physician experienced in using leukemia chemotherapeutic drugs, in facility with adequate diagnostic and treatment resources.

Action

Inhibits nucleic acid synthesis by disrupting DNA and RNA polymerase, causing cell death

Availability

Injection: 1 mg/ml

Indications and dosages

- Acute myeloid leukemia

Adults: 12 mg/m²/day by slow I.V. injection over 10 to 15 minutes for 3 days. As prescribed, give with cytarabine by continuous I.V. infusion for 7 days, or give cytarabine as I.V. bolus followed by 5 days of cytarabine by continuous I.V. infusion. Second course may be given, depending on response.

Dosage adjustment

- Renal or hepatic impairment
- Severe mucositis

Off-label uses

- Acute nonlymphocytic and chronic myelogenous leukemias
- Non-Hodgkin’s lymphoma
- Breast cancer

Contraindications

- Hypersensitivity to drug
- Pregnancy or breastfeeding

Precautions

Use cautiously in:

- renal or hepatic impairment
- bone marrow depression
- previous treatment with anthracyclines or cardiotoxic drugs
- cardiac disease.

Administration

- When preparing, wear goggles and gloves, because exposure may cause severe skin reaction. If exposure occurs, wash affected area immediately with soap and water. For eye exposure, follow standard eye irrigation procedure.
- Reconstitute 5-, 10-, or 20-mg vial with 5, 10, or 20 ml of normal saline
solution, respectively, to yield a concentration of 1 mg/ml.

- Give slowly over 10 to 15 minutes into I.V. tubing that is infusing normal saline solution or dextrose 5% in water.
  - Don’t administer subcutaneously or I.M. (may cause tissue necrosis).
- If severe mucositis occurs, delay second course (if prescribed) until full recovery; then reduce dosage by 25%.

### Adverse reactions

**CNS:** headache, mental status changes, peripheral neuropathy, **seizures**

**CV:** chest pain, **heart failure, atrial fibrillation, myocardial infarction, arrhythmias**

**GI:** nausea, vomiting, diarrhea, cramps, mucositis, **GI hemorrhage**

**GU:** red urine, **renal failure**

**Hematologic:** bone marrow depression

**Hepatic:** hepatic function changes

**Metabolic:** hyperuricemia

**Skin:** alopecia, urticaria, bullous erythematous rash on palms and soles, erythema at previously irradiated site, tissue necrosis or urticaria at injection site

**Other:** fever, infection, hypersensitivity reaction

### Interactions

**Drug-drug.** *Alkaline solutions, heparin: incompatibility*

### Patient monitoring

- Assess serum uric acid level and CBC.
- Monitor hemodynamic status and cardiac output. Assess for S3 heart sound (which signals heart failure).
- Assess fluid intake and output. Make sure patient is adequately hydrated, to prevent hyperuricemia.

### Patient teaching

- Instruct patient to immediately report unusual bleeding or bruising, difficulty breathing, or sudden weight gain.
- Tell patient to eat small, frequent meals.
- Advise patient to keep follow-up appointments for assessment, regular blood testing, and monitoring of drug effects.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

### ifosfamide

**Ifex, Mitoxana**

**Pharmacologic class:** Alkylating agent, nitrogen mustard

**Therapeutic class:** Antineoplastic

**Pregnancy risk category D**

### FDA BOXED WARNING

- Give under supervision of physician experienced in using cancer chemotherapy, in facility with adequate diagnostic and treatment resources. Adverse urotoxic effects (especially hemorrhagic cystitis) and CNS toxicities (such as confusion and coma) have occurred; these effects may warrant drug discontinuation.
- Severe myelosuppression may occur.

Reactions in bold are life-threatening.
Action
Alkylates DNA, interfering with replication and synthesis of susceptible cells and ultimately causing cell death

Availability
Injection: 1 g or 3 g in single-dose vials

Indications and dosages
➣ Germ-cell testicular cancer
Adults: 1.2 g/m²/day by I.V. infusion over 30 minutes for 5 days. May repeat q 3 weeks or after recovery from hematologic toxicity.

Off-label uses
• Acute leukemia
• Breast, lung, ovarian, and pancreatic cancer
• Malignant lymphomas
• Sarcomas

Contraindications
• Hypersensitivity to drug
• Severe bone marrow depression
• Pregnancy or breastfeeding

Precautions
Use cautiously in:
• impaired renal or hepatic function, mild to moderate bone marrow depression.

Administration
• Follow facility policy for handling antineoplastic agents.
• Know that drug is usually given with other antineoplastics and hemorrhagic cystitis agent.
• To reconstitute, add sterile water or bacteriostatic water to vial, and shake gently.
• Mix 20 ml of diluent with 1-g vial or 60 ml of diluent with 3-g vial, to yield a concentration of 50 mg/ml. For smaller concentrations, dilute solution further with normal saline solution, dextrose 5% in water, lactated Ringer’s solution, or sterile water.
• Administer I.V. slowly over at least 30 minutes.

Route Onset Peak Duration
I.V. Immediate Unknown Unknown

Adverse reactions
CNS: drowsiness, confusion, ataxia, hallucinations, depressive psychosis, dizziness, disorientation, cranial nerve dysfunction, coma, seizures
CV: phlebitis
GI: nausea, vomiting, diarrhea, anorexia, stomatitis
GU: hematuria, bladder fibrosis, gonadal suppression, nephrotoxicity, hemorrhagic cystitis
Hematologic: anemia, leukopenia, thrombocytopenia, bone marrow depression
Metabolic: metabolic acidosis
Skin: alopecia
Other: infection, secondary neoplasms

Interactions
Drug-diagnostic tests. Hepatic enzymes, uric acid: increased levels Platelets, white blood cells: decreased counts

Patient monitoring
• Monitor hematopoietic function tests (such as CBC with white cell differential) before therapy and weekly during therapy.
• Assess fluid intake and output. Ensure fluid intake of at least 2 L daily to prevent bladder toxicity.
⊗ Monitor urine output for hematuria and hemorrhagic cystitis. Administer mesna (protective drug), as indicated and prescribed.

Patient teaching
⊗ Tell patient to immediately report jaundice, unusual bleeding or bruising, bloody urine, pain on urination, fever, chills, sore throat, cough, difficulty breathing, unusual lumps or masses,
mouth sores, or pain in flank, stomach, or joints.

- Instruct patient to maintain adequate hydration and nutrition. Advise him to drink 10 to 12 glasses of fluid each day.
- Inform patient that drug may cause hair loss.
- Advise both male and female patients to use reliable contraception during and immediately after therapy, because drug may cause severe birth defects.
- Urge patient to keep regular follow-up appointments for blood tests and monitoring of drug effects.
- As appropriate, review other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

imatinib mesylate

Gleevec, Glivec®

**Pharmacologic class:** Protein-tyrosine kinase inhibitor  
**Therapeutic class:** Antineoplastic  
**Pregnancy risk category D**

**Action**  
Inhibits proliferation of Bcr-Abl tyrosine kinase, an abnormal chromosome protein found in most patients with chronic myeloid leukemia (CML). This inhibition suppresses tumor growth.

**Availability**  
Tablets: 100 mg, 400 mg

**Indications and dosages**

- Philadelphia chromosome–positive (Ph+) CML  
**Adults:** During chronic phase, 400 mg P.O. daily as a single dose; during accelerated phase or blast crisis, 600 mg P.O. daily as a single dose. May increase to 600 mg P.O. daily during chronic phase or to 800 mg P.O. daily (400 mg b.i.d.) during accelerated phase or blast crisis in absence of severe adverse drug reaction and severe non-leukemia-related neutropenia or thrombocytopenia in following circumstances: disease progression at any time, failure to achieve satisfactory hematologic response after at least 3 months of treatment, failure to achieve cytogenetic response after 6 to 12 months of treatment, or loss of previously achieved hematologic or cytogenetic response.

- Newly diagnosed Ph+ CML  
**Children:** 340 mg/m²/day P.O. as once-daily dose; or, daily dose may be split into two (once in morning and once in evening). Daily dose not to exceed 600 mg.

- Ph+ chronic-phase CML recurrent after stem cell transplant or resistant to interferon-alpha therapy  
**Children:** 260 mg/m²/day P.O. as once-daily dose; or, daily dose may be split into two (once in morning and once in evening).

- Relapsed/refractory Ph+ acute lymphoblastic leukemia  
**Adults:** 600 mg P.O. daily as single dose

- Myelodysplastic/myeloproliferative diseases  
**Adults:** 400 mg P.O. daily as single dose

- Aggressive systemic mastocytosis (ASM)  
**Adults:** Recommended dosage is 400 mg P.O. daily as single dose for patients without D816V c-Kit mutation. If c-Kit mutational status is unknown or unavailable, 400 mg daily may be considered for patients with ASM not responding satisfactorily to other therapies. For patients with ASM associated with eosinophilia, a starting dose of 100 mg P.O. daily is recommended. Dosage increase from 100 to 400 mg for these patients may be considered in absence of adverse drug reactions if assessments show insufficient response to therapy.

- Hypereosinophilic syndrome/chronic eosinophilic leukemia

Reactions in bold are life-threatening.
**Adults:** Recommended dosage is 400 mg P.O. daily as single dose

- Dermatofibrosarcoma protuberans

**Adults:** Recommended dosage is 800 mg P.O. daily (given as 400 mg twice daily)

- Kit (CD117)-positive unresectable or metastatic malignant GI stromal tumors

**Adults:** 400 to 600 mg P.O. daily

**Dosage adjustment**
- Hepatic or hematologic impairment
- Concurrent use of potent CYP3A4 inducers, such as rifampin or phenytoin

**Contraindications**
- Hypersensitivity to drug or its components

**Precautions**
Use cautiously in:
- renal or hepatic impairment
- pregnant or breastfeeding patients
- children younger than age 2 (safety and efficacy not established).

**Administration**
- Give with meal and large glass of water.
- Disperse tablets in glass of water or apple juice for patients unable to swallow tablets. Place required number of tablets in appropriate volume of beverage (approximately 50 ml for 100-mg tablet, and 200 ml for 400-mg tablet) and stir with spoon. Administer suspension immediately after complete disintegration of tablets.

**Adverse reactions**
- CNS: headache, fatigue, asthenia, malaise, insomnia, headache, cerebral hemorrhage
- GI: nausea, vomiting, diarrhea, constipation, anorexia, abdominal pain or cramps, dyspepsia, GI hemorrhage
- Hematologic: anemia, hemorrhage, neutropenia, thrombocytopenia
- Metabolic: hypokalemia, fluid retention
- Musculoskeletal: myalgia, muscle cramps, musculoskeletal or joint pain
- Respiratory: cough, dyspnea, pneumonia
- Skin: rash, pruritus, night sweats, petechiae
- Other: weight gain, edema, fever

**Interactions**
- **Drug-drug.** Cyclosporine, dihydropyridine calcium channel blockers, pimozide, some HMG-CoA reductase inhibitors, triazolobenzodiazepines: increased blood levels of these drugs
- CYP450-3A4 inducers (such as carbamazepine, dexamethasone, phenobarbital, phenytoin): increased metabolism and decreased blood level of imatinib
- CYP450-3A4 inhibitors (such as clarithromycin, erythromycin, itraconazole, ketoconazole): decreased metabolism and increased blood level of imatinib
- Warfarin: altered warfarin metabolism

**Drug-diagnostic tests.** Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, creatinine, hepatic enzymes: increased values
- Hemoglobin, neutrophils, platelets, potassium: decreased values

**Drug-herbs.** St. John's wort: decreased imatinib effects

**Patient monitoring**
- Monitor for GI distress. Provide small, frequent meals; consult dietitian if nausea and vomiting persist.
- Monitor CBC before therapy starts and regularly during therapy. Expect to adjust dosage if bone marrow depression occurs.
- Evaluate for signs and symptoms of bleeding, edema, and fluid retention.
• Measure daily weight and fluid intake and output.

**Patient teaching**
• Advise patient to take with a meal and a large glass of water.
• Instruct patient to avoid potential sources of infection, such as crowds and people with known infections.
• Tell patient drug may cause sudden weight gain and fluid retention. Instruct him to weigh himself daily.
• Advise patient to immediately report sudden weight gain, swelling, difficulty breathing, signs or symptoms of infection, unusual bleeding or bruising, or jaundice.
• Tell patient he’ll undergo frequent blood testing to monitor drug effects.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

---

**imipenem and cilastatin sodium**
Primaxin

*Pharmacologic class:* Carbapenem

*Therapeutic class:* Anti-infective

*Pregnancy risk category C*

### Action
Acts against many gram-positive and gram-negative organisms by binding to bacterial cell wall, causing cell death. Addition of cilastatin prevents renal inactivation of imipenem, resulting in increased urinary concentration. Imipenem resists actions of many enzymes that degrade most other penicillins and penicillin-like drugs.

### Availability

**Powder for I.M. injection:** 500 mg imipenem/500 mg cilastatin, 750 mg imipenem/750 mg cilastatin  
**Powder for I.V. injection:** 250 mg imipenem/250 mg cilastatin, 500 mg imipenem/500 mg cilastatin

### Indications and dosages

> Lower respiratory tract infections, urinary tract infections, abdominal infections, gynecologic infections, skin infections, bone and joint infections, endocarditis, and polymicrobial infections

**Adults:** For mild infections, 250 to 500 mg I.V. q 6 hours; for moderate infections, 500 mg I.V. q 6 to 8 hours or 1 g I.V. q 8 hours; for serious infections, 500 mg I.V. q 6 hours to 1 g q 6 to 8 hours or 500 to 750 mg I.M. q 12 hours

**Children:** 15 to 25 mg/kg I.V. q 6 hours or 10 to 15 mg/kg I.M. q 6 hours  
**Infants ages 4 weeks to 3 months:** 25 mg/kg I.V. q 6 hours  
**Infants ages 1 to 4 weeks:** 25 mg/kg I.V. q 8 hours  
**Infants age 1 week and younger:** 25 mg/kg I.V. q 12 hours

### Dosage adjustment
• Renal impairment

### Contraindications
• Hypersensitivity to drug, penicillins, or cephalosporins

### Precautions
Use cautiously in:
• seizure disorders, renal impairment  
• history of multiple hypersensitivity reactions  
• elderly patients  
• pregnant or breastfeeding patients.

### Administration
• For I.V. use, reconstitute each 250- or 500-mg vial with 10 ml of diluent; shake well.

Reactions in **bold** are life-threatening.
For piggyback infusion, add 250- or 500-mg I.V. dose to 100 ml of diluent; shake solution until clear and drug has dissolved completely.

- Infuse doses of 500 mg or less over 20 to 30 minutes; infuse doses of 750 to 1,000 mg over 40 to 60 minutes.
- Slow infusion rate if patient experiences nausea, vomiting, dizziness or sweating.
- For I.M. use, inject into large muscle.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>End of infusion</td>
<td>6-8 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>Rapid</td>
<td>1-2 hr</td>
<td>12 hr</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: dizziness, drowsiness, seizures
CV: hypotension
GI: nausea, vomiting, diarrhea, pseudomembranous colitis
Hematologic: eosinophilia
Skin: rash, pruritus, diaphoresis, urticaria
Other: phlebitis at I.V. site, fever, superinfection, allergic reactions including anaphylaxis

Interactions

Drug-drug. Cyclosporine, ganciclovir: increased risk of seizures
Probenecid: decreased renal excretion of imipenem

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, lactate dehydrogenase: increased values
Direct Coombs’ test: positive result
Hematocrit, hemoglobin: decreased

Patient monitoring

Stay alert for seizures in patients with brain lesions, head trauma, or other CNS disorders and in those receiving more than 2 g daily.
Monitor closely for severe diarrhea and hypersensitivity reaction.
Assess tissue or fluid culture results obtained before and during therapy.

- Monitor for signs and symptoms of infection, such as fever and elevated white blood cell count. Also evaluate for bacterial and fungal superinfection.
- Monitor electrolyte levels, especially sodium.

Patient teaching

- Caution patient to report discomfort at I.V. site.
- Instruct patient to report rash, hives, difficulty breathing, and signs or symptoms of superinfection (such as diarrhea, mouth sores, and vaginal itching or discharge).
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**imipramine hydrochloride**

Apo-Imipramine*, Impril*, Novopramine*, PMS-Imipramine*, Tofranil

**imipramine pamoate**

Tofranil-PM

Pharmacologic class: Dibenzazepine derivative
Therapeutic class: Tricyclic antidepressant
Pregnancy risk category C

FDA BOXED WARNING

- Drug may increase risk of suicidal thinking and behavior in children and adolescents with major depressive disorder and other psychiatric disorders, especially during first few months of therapy. Risk must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age who has or has had depression, suicidal thoughts may occur during treatment. Treatment decision for a patient taking this drug for depression should be based upon the importance of the indication relative to the risk of suicide. The patient should be closely observed for suicidal ideation or behavior. Where appropriate, family should be asked to join in close observation.

Hazardous drug

High alert drug
age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family and caregivers to observe patient closely and communicate with prescriber as needed.

- Drug isn’t approved for use in pediatric patients.

**Action**
Unknown. May block reuptake of nor-epinephrine and serotonin at neuronal membrane, potentiating their effects.

**Availability**
Capsules: 75 mg, 100 mg, 125 mg, 150 mg (pamoate)
Tablets: 10 mg, 25 mg, 50 mg (hydrochloride)

**Indications and dosages**

- **Endogenous depression**
  
  **Adults:** 75 to 100 mg P.O. daily in divided doses. Don’t exceed 200 mg/day for outpatients or 300 mg/day for inpatients.
  
  **Elderly patients, adolescents:** 30 to 40 mg P.O. daily in divided doses, up to 100 mg/day

- **Functional enuresis**
  
  **Children:** 25 mg P.O. daily 1 hour before bedtime. If necessary, increase by 25 mg/day at weekly intervals, up to 75 mg P.O. daily in children ages 12 and older or up to 50 mg P.O. daily in children younger than age 12.

- **Attention deficit hyperactivity disorder**
  
  **Children ages 6 and older:** 2 to 5 mg/ kg P.O. daily in two or three divided doses

**Off-label uses**

- Diabetic neuropathy

**Contraindications**

- Hypersensitivity to drug or bisulfites
- Untreated angle-closure glaucoma
- MAO inhibitor use within past 14 days

**Precautions**
Use cautiously in:
- cardiovascular disease, prostatic enlargement, seizures, urinary retention
- elderly patients
- pregnant or breastfeeding patients.

**Administration**

- Don’t give concurrently with MAO inhibitors. Interaction may lead to hypotension, tachycardia, and potentially fatal reactions.
- Give with food or milk if GI upset occurs.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>30 min-2 hr</td>
<td>2-6 wk</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- **CNS:** fatigue, sedation, agitation, confusion, hallucinations, drowsiness, dizziness, syncope, extrapyramidal effects, poor concentration, cerebrovascular accident, seizures, suicidal behavior or ideation (especially in child or adolescent)
- **CV:** hypotension, ECG changes, hypertension, vasculitis, palpitations, tachycardia, arrhythmias, myocardial infarction, heart block
- **EENT:** blurred vision, increased intraocular pressure (IOP), lacrimation, tinnitus, nasal congestion
- **GI:** diarrhea, dry mouth, paralytic ileus
- **GU:** urinary retention, urinary tract dilation, gynecomastia, menstrual irregularities, galactorrhea, testicular swelling, libido changes, erectile dysfunction
- **Hematologic:** eosinophilia, purpura, bone marrow suppression, agranulocytosis, thrombocytopenia, leukopenia
- **Hepatic:** hepatitis
- **Metabolic:** hyperthermia, hyperglycemia, hypoglycemia
- **Skin:** flushing, diaphoresis, photosensitivity, rash, urticaria, pruritus, petechiae, alopecia

Reactions in bold are life-threatening.

**Clinical alert**
Other: increased appetite, weight gain or loss, edema, drug fever, chills, hypersensitivity reactions

Interactions
Drug-drug. Adrenergics: increased hypertensive effect
Carbamazepine, class IC antiarrhythmics, other antidepressants, phenothiazines: additive effects of imipramine
CNS depressants: additive CNS depression
Clonidine: decreased clonidine effects
CYP450-2D6 inhibitors (such as amiodarone, cimetidine, quinidine, ritonavir): increased imipramine effects
Guanethidine: prevention of therapeutic response to imipramine
Levodopa: delayed or decreased levodopa absorption, hypertension
MAO inhibitors: hypotension, tachycardia, potentially fatal reactions
Selective serotonin reuptake inhibitors: increased blood level
Sparfloxacin: increased risk of cardiovascular reactions
Drug-diagnostic tests. Alkaline phosphatase, bilirubin: elevated levels
Glucose: increased or decreased level
Liver function tests: altered values
Drug-herbs. Angel’s trumpet, jimsonweed, scopolia: increased anticholinergic effects
Chamomile, hops, kava, skullcap, valerian: increased CNS depression
Evening primrose oil: additive or synergistic effects
S-adenosylmethionine (SAM-e), St. John’s wort: serotonin syndrome
Drug-behaviors. Alcohol use: increased CNS depression
Smoking: increased metabolism and altered effects of imipramine
Sun exposure: increased risk of photosensitivity

Patient monitoring
Closely monitor patient’s mood and assess his risk for self-harm. Limit drug access if he may be suicidal.
- Assess for urinary retention and increased IOP in patients with history of urinary retention or angle-closure glaucoma.
- Monitor blood pressure before and during therapy and before dosage increases.
- Watch for arrhythmias in patients with history of cardiac disease.
- During withdrawal, monitor for adverse effects, such as headache, malaise, nausea, vomiting, and sleep disturbances.
- Assess for signs and symptoms of infection. Monitor CBC with white cell differential.

Patient teaching
Teach patient or caregiver to recognize and immediately report signs of suicidal intent or expressions of suicidal ideation (especially in child or adolescent).
- Instruct patient to eat small, frequent meals to minimize GI upset.
- Inform patient that drug may cause changes in sexual function, such as erectile dysfunction and decreased libido.
- Tell patient to immediately report seizure, chest pain, abdominal pain or bloating, easy bruising or bleeding, unusual tiredness, or yellowing of skin or eyes.
- Advise patient to report fever, chills, sore throat, dry mouth, excessive sedation, difficulty urinating, or palpitations.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.
immune globulin for I.M. use (IGIM)
GammaSTAN S/D

immune globulin for I.V. use, human (IGIV)

Pharmacologic class: Immune serum
Therapeutic class: Antibody-production stimulator
Pregnancy risk category C

FDA BOXED WARNING

- IGIV (human) products have been linked to renal dysfunction, acute renal failure (ARF), osmotic nephrosis, and death. Patients predisposed to ARF include those with preexisting renal insufficiency, diabetes mellitus, age older than 65, volume depletion, sepsis, or paraproteinemia and those receiving known nephrotoxic drugs. In these patients, give drug at minimum rate of infusion feasible. IGIV products containing sucrose accounted for disproportionate share of renal dysfunction and acute renal failure reports.

Action
Improves immunity by binding to and neutralizing pathogens, thereby increasing antibodies against bacterial, viral, parasitic, and mycoplasmic antigens. Acts through antimicrobial and antitoxin neutralization.

Availability
Injection: 2- and 10-ml vials (IGIM)
Powder for injection: 1-, 2.5-, 3-, 5-, 6-, 10-, and 12-g vials (IGIV)
Solution (5%): 10-, 50-, 100-, 200-, and 250-ml vials (IGIV)
Solution (10%): 10-, 25-, 50-, 100-, and 200-ml vials (IGIV)

Indications and dosages
➢ To prevent hepatitis A
Adults traveling to areas where hepatitis A is common: 0.02 ml/kg I.M. if staying less than 3 months; 0.06 ml/kg repeated q 4 to 6 months if staying 3 months or longer
Adults with household or institutional contacts: 0.02 ml/kg I.M.
➢ To prevent or reduce severity of measles in susceptible persons
Adults and children: 0.2 ml/kg to 0.25 ml/kg I.M. within 6 days of exposure to measles
➢ Exposure to measles in immunocompromised children
Children: 0.5 ml/kg I.M. as soon as possible after exposure
➢ Varicella in immunocompromised patients
Adults: 0.6 to 1.2 ml/kg I.M. as soon as possible if varicella-zoster immune globulin is unavailable
➢ To reduce risk of infection and fetal damage in females exposed to rubella during early pregnancy
Adults: 0.55 ml/kg I.M.
➢ Immunoglobulin deficiency
Adults: Initially, 1.3 ml/kg I.M., followed in 3 to 4 weeks by 0.66 ml/kg, up to 100 mg/kg q 3 to 4 weeks
➢ Immunodeficiency
Gamimune N—
Adults and children: 100 to 200 mg/kg I.V. or 2 to 4 ml/kg (10%) I.V. monthly
Gammagard S/D—
Adults and children: 200 to 400 mg/kg I.V. then monthly in doses based on response
Gammar-P IV—

Reactions in bold are life-threatening.

Clinical alert
Adults: 200 to 400 mg/kg I.V. q 3 to 4 weeks

Children and adolescents: 200 mg/kg I.V. q 3 to 4 weeks

Iveegam EN—

Adults and children: 200 mg/kg I.V. monthly; may increase up to 800 mg/kg/month based on response

Panglobulin—

Adults and children: 200 mg/kg I.V. monthly, increased to 300 mg/kg/month. In some patients, infusion frequency may be increased.

Panglobulin NF/Carimune NF—

Adults and children: 0.2 g/kg I.V. monthly. If response inadequate, dosage may be increased to 0.3 g/kg or infusion frequency may be increased.

Polygam S/D—

Adults and children: 100 to 400 mg/kg I.V. monthly

Sandoglobulin—

Adults and children: 100 to 400 mg/kg I.V. monthly. In patients with previously untreated agammaglobulinemia or hypogammaglobulinemia, first infusion may be increased to 300 mg/kg or infusion frequency may be increased.

Venoglobulin—

Adults and children: 200 mg/kg I.V. monthly, increased up to 400 mg/kg/month. In some patients, infusion frequency may be increased.

➣ Idiopathic thrombocytopenic purpura

Gamimune N—

Adults and children: 400 mg/kg I.V. for 5 consecutive days, or 1,000 mg/kg/day for 1 day or for 2 consecutive days

Gammagard S/D—

Adults and children: 1,000 mg/kg I.V. Up to three doses may be given on alternating days, dependent on platelet count.

Panglobulin—

Adults and children: Initially, 0.4 g/kg I.V. for 2 to 5 consecutive days

Polygam S/D—

Adults and children: 1 g/kg I.V. Depending on response, additional doses may be given.

Venoglobin-S—

Adults and children: 2,000 mg/kg I.V. over 5 days or less for induction therapy; then 1,000 mg/kg p.r.n. to maintain platelet count of 30,000/mm³ in children or 20,000/mm³ in adults or to prevent bleeding episodes between infusions

➣ Kawasaki disease

Gammagard S/D—

Adults and adolescents: 1 g/kg I.V. as a single dose; alternatively, 400 mg/kg/day for 4 consecutive days with aspirin

Iveegam EN—

Adults and children: 400 mg/kg/day I.V. with aspirin

Polygam S/D—

Adults and children: 1 g/kg I.V. as a single dose, or 400 mg/kg I.V. for 4 consecutive days starting within 7 days of fever onset. Give with aspirin, as prescribed.

Sandoglobulin—

Adults and children: 400 mg/kg I.V. for 2 to 5 consecutive days. If platelet count falls below 30,000/mm³ or significant bleeding occurs, may give 0.4 g/kg as a single infusion, increased to 0.8 or 1 g/kg as a single infusion, depending on response.

Venoglobulin S—

Adults and children: 2 g/kg I.V. infused over 10 to 12 hours with aspirin

➣ To prevent bacterial infection in patients with hypogammaglobulinemia or recurrent bacterial infection associated with B-cell chronic lymphocytic leukemia

Adults and adolescents: 400 mg/kg I.V. (Gammagard S/D or Polygam S/D) q 3 to 4 weeks

➣ To reduce risk of graft-versus-host disease, interstitial pneumonia, septicemia, and other infections during first 100 days after bone marrow transplantation

Canada  UK  Hazardous drug  High alert drug
Adults ages 20 and older: 500 mg/kg I.V. (Gamimune N) 7 days before and 2 days before transplantation, then weekly through 90th day after transplantation
> To prevent bacterial infection in children with human immunodeficiency virus
Children: 400 mg/kg I.V. (Gamimune N) q 28 days

Off-label uses
- Chronic inflammatory demyelinating polyneuropathy
- Guillain-Barré syndrome

Contraindications
- Hypersensitivity to drug or its components
- Selective immunoglobulin A deficiency

Precautions
Use cautiously in:
- bleeding disorders, renal impairment
- pregnant patients.

Administration
ียว Before giving, determine if patient has risk factors for acute renal failure (such as use of nephrotoxic drugs; history of diabetes mellitus, renal insufficiency, sepsis, volume depletion, or paraproteinemia; age 65 or older).
- For I.V. use, decrease infusion rate by 50% to 25% for patients at risk for renal dysfunction.
ียง Give IGIM by I.M. route only; give IGIV by I.V. route only.
- If sterile laminar airflow conditions aren’t available for drug reconstitution, administer immediately; discard unused portion.
- Don’t shake vigorously, because foaming may occur. Know that cold drug or diluent may take up to 20 minutes to dissolve.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>21-28 days</td>
</tr>
<tr>
<td>I.M.</td>
<td>Unknown</td>
<td>2 days</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, malaise
CV: chest pain, tachycardia, thromboembolism
GI: nausea, vomiting, abdominal pain
Musculoskeletal: joint pain, back pain, myalgia
Respiratory: dyspnea
Skin: pruritus
Other: chills, lymphadenopathy, pain at injection site, anaphylaxis

Interactions
Drug-drug. Live-virus vaccines: decreased antibody response to vaccine

Patient monitoring
ียง Watch for acute inflammatory reaction in patients receiving drug for first time (usually appears within 30 to 60 minutes after infusion begins), in those whose last treatment was more than 8 weeks earlier, and when initial infusion rate exceeds 1 ml/minute.
- Monitor vital signs continuously during I.V. infusion. Stay alert for hypotension.
- Assess fluid volume status and blood urea nitrogen and creatinine levels.
- After infusion ends, monitor patient closely for nausea, vomiting, drowsiness, and severe headache.

Patient teaching
ียง Instruct patient to report symptoms occurring during or after therapy.
- Advise patient to avoid live-virus vaccines for 3 months after therapy; drug may delay or inhibit body’s response to vaccine.
- As appropriate, review all significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

Reactions in bold are life-threatening.
**Inamrinone Lactate**

**Pharmacologic class:** Bipyridine derivative  
**Therapeutic class:** Inotropic, vaso-dilator  
**Pregnancy risk category C**

**Action**
Inhibits cyclic adenosine monophosphate (cAMP) phosphodiesterase activity in myocardium, increasing cellular levels of cAMP (which regulates intracellular and extracellular calcium levels). These actions increase myocardial contraction force. Also relaxes and dilates vascular smooth muscle, decreasing preload and afterload.

**Availability**
Injection: 5 mg/ml in 20-ml ampules

**Indications and dosages**
> Short-term management of heart failure  
**Adults:** Initially, 0.75 mg/kg I.V. bolus over 2 to 3 minutes; may give additional bolus of 0.75 mg/kg over 30 minutes. Then begin maintenance infusion of 5 to 10 mcg/kg/minute. Maximum daily dosage is 10 mg/kg.

**Off-label uses**
- Open-heart surgery

**Contraindications**
- Hypersensitivity to drug or bisulfites

**Precautions**
Use cautiously in:
- renal or hepatic disease, atrial fibrillation or flutter, severe aortic or pulmonic valvular disease, acute phase of myocardial infarction  
- elderly patients  
- pregnant or breastfeeding patients  
- children.

**Administration**
- Administer either undiluted or diluted in normal or half-normal saline solution to yield a concentration of 1 to 3 mg/ml, as prescribed. Don’t mix with solutions containing dextrose.  
- Give I.V. bolus over 2 to 3 minutes, followed by maintenance infusion using infusion pump or microdrip (60 gtt/ml) at recommended dosage.  
- Protect drug from light.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>2-5 min</td>
<td>10 min</td>
<td>30-120 min</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- CV: hypotension, arrhythmias  
- GI: nausea, vomiting  
- Hematologic: thrombocytopenia  
- Hepatic: hepatotoxicity  
- Other: hypersensitivity reaction

**Interactions**
- **Drug-drug.** Cardiac glycosides: increased inotropic effects  
  Disopyramide: excessive hypotension  
- **Drug-herbs.** Aloe, buckthorn bark, cascara sagrada, ephedra (ma huang), senna leaf: increased drug action

**Patient monitoring**
- Monitor vital signs frequently. Expect to slow or stop infusion if significant hypotension occurs.  
- Monitor hemodynamic indicators (including cardiac output, cardiac index, central venous pressure, and pulmonary artery wedge pressure) to assess drug efficacy.  
- Be aware that patient receiving vigorous diuretic therapy may have insufficient cardiac filling to adequately respond to inamrinone, in which case cautious liberalization of fluid and electrolytes intake may be indicated.  
- Assess daily weight and fluid intake and output.  
- Watch closely for ventricular arrhythmias, especially if patient has atrial flutter or atrial fibrillation.
• Assess for signs and symptoms of thrombocytopenia, such as bleeding or bruising.
• Monitor platelet count and electrolyte levels before and during therapy.

Patient teaching
• Instruct patient to report dizziness or light-headedness.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and herbs mentioned above.

indapamide
Apo-Indapamide®, Dom-Indapamide®, Gen-Indapamide®, Lozide®, Lozol, Natrilix®, Nindaxa®, Novo-Indapamide®, Nu-Indapamide®, PHL-Indapamide®, PMS-Indapamide®, Riva-Indapamide®

Pharmacologic class: Thiazide-like diuretic
Therapeutic class: Diuretic, antihypertensive
Pregnancy risk category B

Action
Increases sodium and water excretion by inhibiting sodium reabsorption in distal tubule; enhances excretion of sodium, chloride, potassium, and water. May cause arteriolar vasodilation.

Availability
Tablets: 1.25 mg, 2.5 mg

Indications and dosages
Edema caused by heart failure
Adults: 2.5 mg P.O. daily in morning. After 1 week, may increase to 5 mg/day.
Mild to moderate hypertension

Adults: 1.25 mg P.O. daily in morning. May increase q 4 weeks, up to 5 mg/day.

Contraindications
• Hypersensitivity to drug, other thiazide-like drugs, or tartrazine
• Anuria

Precautions
Use cautiously in:
• renal or severe hepatic impairment, ascites, fluid or electrolyte imbalances, gout, systemic lupus erythematosus, impaired glucose tolerance, hyperparathyroidism, bipolar disorder
• pregnant or breastfeeding patients.

Administration
• Administer with food or milk to reduce GI upset.
• Give early in day to avoid nocturia.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O. (single dose)</td>
<td>1-2 hr</td>
<td>2 hr</td>
<td>36 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, light-headedness, headache, restlessness, insomnia, lethargy, fatigue, drowsiness, asthenia, depression, anxiety, nervousness, paresthesia, irritability, agitation
CV: orthostatic hypotension, palpitations, premature ventricular contractions, arrhythmias
EENT: blurred vision, rhinorrhea
GI: nausea, vomiting, diarrhea, constipation, bloating, epigastric distress, gastric irritation, abdominal pain or cramps, dry mouth, anorexia
GU: nocturia, polyuria, glycosuria, erectile dysfunction
Metabolic: dehydration, gout, hyperglycemia, hypokalemia, hypocalcemia, hypomagnesemia, hyponatremia, hypovolemia, hypophosphatemia, hyperuricemia, hypochloremic alkalosis
Musculoskeletal: muscle cramps and spasms

Reactions in bold are life-threatening.
Skin: flushing, rash, urticaria, pruritus, photosensitivity, cutaneous vasculitis, necrotizing vasculitis
Other: weight loss

Interactions

Drug-drug. Amphotericin B, corticosteroids: additive hypokalemia
Antihypertensives, nitrates: additive hypotension
Cholestyramine, colestipol: decreased indapamide absorption
Lithium: decreased lithium excretion, increased risk of lithium toxicity
Sulfonlureas: decreased hypoglycemic efficacy

Drug-diagnostic tests. Bilirubin, blood and urine glucose (in diabetic patients), blood urea nitrogen (BUN), calcium, creatinine, uric acid: increased values
Cholesterol, low-density lipoproteins, magnesium, potassium, protein-bound iodine, sodium, triglycerides, urinary calcium: decreased values

Drug-herbs. Ginkgo: decreased antihypertensive effect
Licorice, stimulant laxative herbs (aloe, cascara sagrada, senna): increased risk of hypokalemia

Drug-behaviors. Acute alcohol ingestion: additive hypotension
Sun exposure: increased risk of photosensitivity

Patient monitoring

Assess for signs and symptoms of hypokalemia, including ventricular arrhythmias, muscle weakness, and cramping.
- Monitor BUN, creatinine, and electrolyte levels.
- Assess daily weight and fluid intake and output.
- Monitor blood pressure response to drug.
- Watch for signs and symptoms of orthostatic hypotension.

Patient teaching

- Advise patient to consume potassium-rich foods, such as oranges, bananas, potatoes, and spinach.
- Instruct patient to move slowly when sitting up or standing, to avoid dizziness from sudden blood pressure decrease.
- Tell patient to weigh himself daily on same scale at same time of day while wearing similar clothing. Instruct him to report gain of more than 2 lb (0.9 kg) in 1 day or 5 lb (2.2 kg) in 1 week.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

indinavir sulfate
Crixivan

Pharmacologic class: Protease inhibitor
Therapeutic class: Antiretroviral
Pregnancy risk category C

Action
Inhibits replication, function, and maturation of human immunodeficiency virus (HIV) protease, an enzyme essential to formation of infectious virus. As a result, further spread of virus is prevented.

Availability
Capsules: 100 mg, 200 mg, 333 mg, 400 mg

Indications and dosages
HIV infection
Adults: 800 mg P.O. q 8 hours
Dosage adjustment
- Mild to moderate hepatic insufficiency secondary to cirrhosis

Contraindications
- Hypersensitivity to drug or its components
- Concurrent use of amiodarone, ergot derivatives, cisapride, pimozide, or oral midazolam, triazolam, aprazolam

Precautions
Use cautiously in:
- renal or severe hepatic impairment, history of renal calculi
- pregnant or breastfeeding patients
- children.

Administration
- Know that drug is usually given with other antiretrovirals.
- Give with full glass of water on empty stomach 1 hour before or 2 hours after meals.
- If GI upset occurs, give with a light meal.
- Don’t give concurrently with cisapride (not available in U.S.), ergot derivatives, midazolam, pimozide, or triazolam.

Route Onset Peak Duration
P.O. Rapid 0.8 hr 8 hr

Adverse reactions
CNS: depression, dizziness, headache, drowsiness, malaise, asthenia
CV: angina, myocardial infarction
EENT: oral paresthesia
GI: nausea, vomiting, diarrhea, abdominal pain or distention, dyspepsia, acid regurgitation, pancreatitis
GU: dysuria, crystalluria, nephrolithiasis or urolithiasis leading to renal insufficiency or failure, interstitial nephritis
Hematologic: anemia, acute hemolytic anemia, increased spontaneous bleeding (in hemophiliacs)
Hepatic: jaundice, hepatic dysfunction, hepatic failure

Metabolic: new onset or exacerbation of diabetes mellitus, hyperglycemia
Musculoskeletal: joint or back pain
Respiratory: cough, dyspnea
Skin: urticaria, rash, pruritus
Other: abnormal taste, increased or decreased appetite, body fat redistribution or accumulation, fever, anaphylactoid reactions

Interactions
Drug-drug. Azole antifungals, delavirdine, interleukins: elevated indinavir blood level, greater risk of toxicity
Cisapride, ergot derivatives, midazolam, pimozide, triazolam: CYP3A4 inhibition by indinavir, leading to increased blood levels of these drugs and dangerous reactions
Didanosine, efavirenz, rifamycins: decreased indinavir effects
Drug-diagnostic tests. Alanine aminotransferase, amylase, aspartate aminotransferase, bilirubin, cholesterol, glucose, triglycerides: increased values
Hemoglobin, neutrophils, platelets: decreased values
Drug-food. Any food: decreased indinavir absorption
Drug-herbs. St. John’s wort: decreased indinavir blood level

Patient monitoring
- Assess fluid intake and output to ensure adequate hydration and help prevent nephrolithiasis or urolithiasis.
- Monitor for adverse GI and CNS effects.
- Evaluate liver function test results. Assess for hyperbilirubinemia.
- Monitor cholesterol, glucose, and CBC with white cell differential.

Patient teaching
- Tell patient to take 1 hour before or 2 hours after meals with a full glass of water.
- If GI upset occurs, advise patient to take with a light meal.
Instruct patient to report severe nausea or diarrhea, fever, chills, flank pain, urine or stool color changes, yellowing of skin or eyes, or personality changes.

- Tell patient that drug doesn’t cure HIV infection and that its long-term effects are largely unknown.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

Drug increases risk of serious GI adverse events, including bleeding, ulcers, and stomach or intestinal perforation, which can be fatal. These events can occur at any time during therapy and without warning. Elderly patients are at greater risk.

**Action**

Unknown. Thought to inhibit cyclooxygenase, an enzyme needed for prostaglandin synthesis.

**Availability**

Capsules: 25 mg, 50 mg
Capsules (sustained-release): 75 mg
Oral suspension: 25 mg/5 ml

**Indications and dosages**

- Rheumatoid arthritis; osteoarthritis; ankylosing spondylitis
  
  **Adults:** 25 to 50 mg P.O. two or three times daily, not to exceed 200 mg daily; or one 75-mg sustained-release capsule P.O. once or twice daily

- Acute gouty arthritis
  
  **Adults:** 50 mg P.O. t.i.d. until pain is tolerable; then reduce dosage rapidly and, finally, discontinue drug. Don’t give sustained-release form.

- Acute bursitis or tendinitis of shoulder
  
  **Adults:** 75 to 150 mg P.O. daily in three or four divided doses. Discontinue once inflammation is controlled.

**Off-label uses**

- Bartter’s syndrome
- Pericarditis

**Contraindications**

- Hypersensitivity to drug, its components, or other NSAIDs
- Active GI bleeding
- Concurrent diflunisal use

**Precautions**

Use cautiously in:
- severe cardiovascular, renal, or hepatic disease

**FDA BOXED WARNING**

- Drug may increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke (which can be fatal). Risk may increase with duration of use, and may be greater in patients who have cardiovascular disease or risk factors for it.
- Drug is contraindicated for perioperative pain in setting of coronary artery bypass graft surgery.

**Pharmacologic class:** Nonsteroidal anti-inflammatory drug (NSAID)

**Therapeutic class:** Anti-inflammatory, analgesic, antipyretic

**Pregnancy risk category B** (third trimester: D)
- history of ulcer disease
- elderly patients
- pregnant or breastfeeding patients
- children ages 14 and younger (efficacy not established).

**Administration**
- Give with food, full glass of water, or antacids to reduce GI upset.
- Don’t open or crush capsules.
- For arthritis, give up to 100 mg of daily dose at bedtime as needed to reduce nighttime pain and morning stiffness.
- Don’t give sustained-release form to patients with gouty arthritis.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O. (analgesic)</td>
<td>30 min</td>
<td>0.5-2 hr</td>
<td>4-6 hr</td>
</tr>
<tr>
<td>P.O. (sustained, analgesic)</td>
<td>30 min</td>
<td>Unknown</td>
<td>4-6 hr</td>
</tr>
<tr>
<td>P.O. (regular or sustained, anti-inflam.)</td>
<td>Up to 7 days</td>
<td>1-2 wk</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- CNS: headache, dizziness, drowsiness, fatigue, vertigo, depression, **seizures**
- EENT: tinnitus
- GI: nausea, vomiting, diarrhea, constipation, abdominal pain or cramps, dyspepsia, ulcers, **GI bleeding**
- Other: allergic reactions including **anaphylaxis**

**Interactions**
**Drug-drug.** *Antihypertensives, diuretics:* decreased efficacy of these drugs *Corticosteroids, other NSAIDs:* additive adverse GI reactions *Cyclosporine:* increased risk of nephrotoxicity *Diflunisal:* potentially fatal GI hemorrhage *Lithium, methotrexate, zidovudine:* increased risk of toxicity from these drugs *Probenecid:* increased risk of indomethacin toxicity

**Drug-diagnostic tests.** *Dexamethasone suppression test:* false-negative result

**Drug-herbs.** *Anise, arnica, chamomile, clove, dong quai, feverfew, garlic, ginger, ginkgo, ginseng:* increased bleeding risk

**Patient monitoring**
- Assess for dizziness, drowsiness, headache, fatigue, and exacerbation of depression, epilepsy, or parkinsonism.
- Monitor for drug efficacy, indicated by improved joint mobility, pain relief, and decreased inflammation.
- Monitor urine output for marked reduction.
- Watch for signs and symptoms of GI bleeding and ulcers.

**Patient teaching**
- Tell patient to take with food, full glass of water, or antacid to reduce GI upset.
- Advise patient not to open or crush capsules.
- Inform breastfeeding patient that indomethacin enters breast milk and may cause seizures in infant. Advise her to use a different infant feeding method during therapy.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, balance, and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

---

**infliximab**

*Remicade*

**Pharmacologic class:** Monoclonal antibody

**Therapeutic class:** Antirheumatic, GI anti-inflammatory

**Pregnancy risk category C**
FDA BOXED WARNING

- Drug increases risk of infection, including progression to serious infections leading to hospitalization or death. Infections have included bacterial sepsis, tuberculosis (TB), and invasive fungal and other opportunistic infections. Teach patients signs and symptoms of infection; monitor closely for these during and after treatment, and ensure that patient has access to appropriate medical care. If infection occurs, evaluate for appropriate antimicrobial therapy; for serious infection, discontinue drug.
- Evaluate patient for TB risk factors and test for latent TB infection before and during therapy. Start treatment of latent TB before therapy.
- Rare postmarketing cases of hepatosplenic T-cell lymphoma have occurred in adolescents and young adults with Crohn’s disease. This lymphoma is highly aggressive and usually fatal. All cases have occurred in patients receiving concomitant azathioprine or 6-mercaptopurine.

Action
Neutralizes and prevents activity of tumor necrosis factor-alpha (TNF-alpha) by binding to soluble and transmembrane forms of TNF and inhibiting its receptors, resulting in anti-inflammatory and antiproliferative activity. Reduces rate of joint destruction in rheumatoid arthritis and eases symptoms of Crohn’s disease.

Availability
Powder for injection: 100 mg/vial

Indications and dosages
- Rheumatoid arthritis (given with methotrexate)
  Adults: Initially, 3 mg/kg I.V., followed by 3 mg/kg 2 and 6 weeks after initial dose, then q 8 weeks. In partial responders, dosage may be adjusted up to 10 mg/kg or treatment may be repeated as often as q 4 weeks.
- Crohn’s disease
  Adults: 5 mg/kg I.V. as a single infusion, starting as induction regimen at 0, 2, and 6 weeks, then a maintenance regimen of 5 mg/kg q 8 weeks. For patients who respond initially but then stop responding, dosage of 10 mg/kg may be warranted.
- Ulcerative colitis
  Adults: 5 mg/kg I.V. given as induction therapy at 0, 2, and 6 weeks, followed by 5 mg/kg I.V. every 8 weeks thereafter

Off-label uses
- Complicated ankylosing spondylitis
- Sarcoidosis

Contraindications
- Hypersensitivity to drug, murine proteins, or other drug components
- Heart failure (NYHA class III or IV)

Precautions
Use cautiously in:
- history of tuberculosis (TB), active infection, or exposure to TB
- elderly patients
- pregnant or breastfeeding patients
- children (safety not established).

Administration
- Know that latent TB should be treated before infliximab therapy begins.
- To reconstitute, use 21G or smaller needle to add 10 ml of sterile water to each vial. To mix, swirl (don’t shake). Solution may foam and appear clear or light yellow.
- Withdraw volume equal to amount of reconstituted drug from 250-ml polypropylene or polyolefin infusion bag or glass bottle of normal saline solution. Slowly add reconstituted drug to infusion bag or bottle, and gently mix. Use within 3 hours.
- Know that concentration of infusion should be 0.4 mg/ml to 4 mg/ml.
• Give I.V. infusion over at least 2 hours. Use polyethylene-lined infusion set equipped with in-line filter, with pore size of 1.2 microns or less.
• Discard unused portions of infusion solution.
• Don’t give to patient with active infection.
• Be aware that patient who doesn’t respond by week 14 isn’t likely to respond, and therapy should cease.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>1-2 wk</td>
<td>Unknown</td>
<td>12-48 wk</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: fatigue, headache, anxiety, depression, dizziness, insomnia
CV: chest pain, hypertension, hypotension, tachycardia, peripheral edema, worsening of heart failure
EENT: conjunctivitis, rhinitis, sinusitis, laryngitis, pharyngitis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, ulcerative stomatitis, intestinal obstruction
GU: dysuria, urinary frequency, urinary tract infection
Hematologic: hematoma, pancytopenia
Musculoskeletal: arthritis, joint pain, back pain, myalgia, involuntary muscle contractions
Respiratory: upper respiratory tract infection, bronchitis, cough, dyspnea
Skin: acne, diaphoresis, dry skin, bruising, eczema, erythema, flushing, pruritus, urticaria, rash, alopecia
Other: oral pain, tooth pain, moniliasis, chills, hot flashes, flulike symptoms, herpes simplex, herpes zoster, lupuslike syndrome, infections, hypersensitivity reaction, anaphylaxis

**Interactions**

Drug-drug. Vaccines: decreased antibody response to vaccine
Drug-diagnostic tests. Antinuclear antibodies: positive titer

**Hepatic enzymes**: increased values
**Hemoglobin**: decreased value

**Patient monitoring**

- Stay alert for signs and symptoms of hypersensitivity reaction, including fever, chills, itching, rash, chest pain, dyspnea, facial flushing, and headache.
- Watch for evidence of infection, especially in patients who have chronic infections or are receiving immunosuppressants. Drug increases risk of life-threatening opportunistic infections and TB.
- Monitor platelets and CBC with white cell differential.
- Assess for heart failure in patients with history of cardiac disease.

**Patient teaching**

- Instruct patient to report signs or symptoms of hypersensitivity reaction, such as fever, chills, itching, rash, chest pain, dyspnea, and facial flushing (may occur up to 12 days after therapy).
- Tell patient to report infection symptoms, such as fever, burning on urination, cough, or sore throat.
- Advise patient to avoid potential infection sources, such as crowds and people with known infections.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.
insulin glulisine, recombinant
Apidra

insulin lispro protamine, human
Humalog Mix 50/50, Humalog Mix 75/25 Z

isophane insulin suspension (NPH insulin)
Humulin N, Novolin N

isophane insulin suspension (NPH) and insulin injection (regular)
Humulin 50/50 (50% isophane insulin and 50% insulin injection), Humulin 70/30 (70% isophane insulin and 30% insulin injection), Humulin 70/30 PenFill, Novolin 70/30, Novolin 70/30 PenFill

Pharmacologic class: Pancreatic hormone
Therapeutic class: Hypoglycemic
Pregnancy risk category B

Action
Promotes glucose transport, which stimulates carbohydrate metabolism in skeletal and cardiac muscle and adipose tissue. Also promotes phosphorylation of glucose in liver, where it is converted to glycogen. Directly affects fat and protein metabolism, stimulates protein synthesis, inhibits release of free fatty acids, and indirectly decreases phosphate and potassium.

Availability
Glulisine, recombinant: 100 units/ml in 10-ml vials
Isophane suspension, injection (regular): 70 units NPH and 30 units regular insulin/ml (100 units/ml total), 50 units NPH and 50 units regular insulin/ml (100 units/ml total)
Isophane suspension (NPH insulin): 100 units/ml
Lispro: 100 units/ml in 10-ml vials and 1.5-ml cartridges
Regular insulin injection: 100 units/ml
Regular U-500 (concentrated), insulin human injection: 500 units/ml
Zinc suspension, extended (ultralente): 100 units/ml
Zinc suspension (lente insulin): 100 units/ml

Indications and dosages
▷ Type 1 (insulin-dependent) diabetes mellitus; type 2 (non-insulin-dependent) diabetes mellitus unresponsive to diet and oral hypoglycemics
Adults and children: In newly diagnosed diabetes, total of 0.5 to 1 unit/kg/day subcutaneously as part of multidose regimen of short- and long-acting insulin. Dosage individualized based on patient’s glucose level, adjusted to premeal and bedtime glucose levels. Reserve concentrated insulin (500 units/ml) for patients requiring more than 200 units/day.
▷ Diabetic ketoacidosis
Adults and children: Loading dose of 0.15 units/kg (nonconcentrated regular insulin) I.V. bolus, followed by continuous infusion of 0.1 unit/kg/hour until glucose level drops. Then administer subcutaneously, adjusting dosage according to glucose level.

Contraindications
• Hypersensitivity to drug or its components
• Hypoglycemia

Precautions
Use cautiously in:
• hepatic or renal impairment, hypothyroidism, hyperthyroidism

Canada UK Hazardous drug High alert drug
• elderly patients
• pregnant or breastfeeding patients
• children.

**Administration**

Be aware that insulin is a high-alert drug whether given subcutaneously or I.V.

Don’t give insulin I.V. (except nonconcentrated regular insulin), because anaphylactic reaction may occur.

When mixing two types of insulin, draw up regular insulin into syringe first.

For I.V. infusion, mix regular insulin only with normal or half-normal saline solution, as prescribed, to yield a concentration of 1 unit/ml. Give every 50 units I.V. over at least 1 minute.

Rotate subcutaneous injection sites to prevent lipodystrophy.

Administer mixtures of regular and NPH or regular and lente insulins within 5 to 15 minutes of mixing.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V. (regular)</td>
<td>10-30 min</td>
<td>15-30 min</td>
<td>Unknown</td>
</tr>
<tr>
<td>Subcut. (glulisine)</td>
<td>Rapid</td>
<td>Unknown</td>
<td>Short</td>
</tr>
<tr>
<td>Subcut. (lente)</td>
<td>1-2.5 hr</td>
<td>7-15 hr</td>
<td>24 hr</td>
</tr>
<tr>
<td>Subcut. (lispro)</td>
<td>15 min</td>
<td>30-90 min</td>
<td>6-8 hr</td>
</tr>
<tr>
<td>Subcut. (lispro/protamine mix; regular U-500 conc.)</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>Subcut. (NPH)</td>
<td>1-1.5 hr</td>
<td>4-12 hr</td>
<td>24 hr</td>
</tr>
<tr>
<td>Subcut. (regular)</td>
<td>30-60 min</td>
<td>2-4 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>Subcut. (ultralente)</td>
<td>8 hr</td>
<td>10-30 hr</td>
<td>&gt;36 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**Metabolic:** hypokalemia, sodium retention, hypoglycemia, rebound hyperglycemia (Somogyi effect)

**Skin:** urticaria, rash, pruritus

**Other:** edema; lipodystrophy; lipo hypertrophy; erythema, stinging, or warmth at injection site; allergic reactions including anaphylaxis

**Interactions**

**Drug-drug.** Acetazolamide, albuterol, antiretrovirals, asparaginase, calcitonin, corticosteroids, cyclophosphamide, danazol, dextrothyroxine, diazoxide, diltiazem, diuretics, dobutamine, epinephrine, estrogens, hormonal contraceptives, isoniazid, morphine, niacin, phenothiazines, phentoyin, somatropin, terbutaline, thyroid hormones: decreased hypoglycemic effect

Anabolic steroids, angiotensin-converting enzyme inhibitors, calcium, chloroquine, clofibrate, clonidine, disopyramide, fluoxetine, guanethidine, mebendazole, MAO inhibitors, octreotide, oral hypoglycemics, phenylbutazone, propoxyphene, pyridoxine, salicylates, sulfinpyrazone, sulfonylurides, tetracyclines: increased hypoglycemic effect

Beta-adrenergic blockers (nonselective): masking of some hypoglycemia symptoms, delayed recovery from hypoglycemia

Lithium carbonate: decreased or increased hypoglycemic effect

Pentamidine: increased hypoglycemic effect, possibly followed by hyperglycemia

**Drug-diagnostic tests.** Glucose, inorganic phosphate, magnesium, potassium: decreased levels

Liver and thyroid function tests: interference with test results

Urine vanillylmandelic acid: increased level

**Drug-herbs.** Basil, burdock, glucosamine, sage: altered glycemic control

Chromium, coenzyme Q10, dandelion, eucalyptus, fenugreek, marshmallow: increased hypoglycemic effect

Garlic, ginseng: decreased blood glucose level

Reactions in bold are life-threatening.
Drug-behaviors. Alcohol use: increased hypoglycemic effect
Marijuana use: increased blood glucose level
Smoking: increased blood glucose level, decreased response to insulin

Patient monitoring
- Monitor glucose level frequently to assess drug efficacy and appropriateness of dosage.
- Watch blood glucose level closely if patient is converting from one insulin type to another or is under unusual stress (as from surgery or trauma).
- Monitor for signs and symptoms of hypoglycemia. Keep glucose source at hand in case hypoglycemia occurs.
- Assess for signs and symptoms of hyperglycemia, such as polydipsia, polyphagia, polyuria, and diabetic ketoacidosis (as shown by blood and urinary ketones, metabolic acidosis, extremely elevated blood glucose level).
- Monitor for glycosuria.
- Closely evaluate kidney and liver function test results in patients with renal or hepatic impairment.

Patient teaching
- Teach patient how to administer insulin subcutaneously as appropriate.
- Advise patient to draw up regular insulin into syringe first when mixing two types of insulin. Caution him not to change order of mixing insulins.
- Instruct patient to rotate subcutaneous injection sites and keep a record of sites used, to prevent fatty tissue breakdown.
- Teach patient how to recognize and report signs and symptoms of hypoglycemia and hyperglycemia. Advise him to carry a glucose source at all times.
- Instruct patient to store insulin in refrigerator (not freezer).
- Teach patient how to monitor and record blood glucose level and, if indicated, urine glucose and ketone levels.

- Tell patient that dietary changes, activity, and stress can alter blood glucose level and insulin requirements.
- Instruct patient to wear medical identification stating that he is diabetic and takes insulin.
- Advise patient to have regular medical, vision, and dental exams.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

insulin aspart
(rDNA origin)
NovoLog

insulin aspart and insulin aspart protamine
NovoLog Mix 70/30

Pharmacologic class: Pancreatic hormone
Therapeutic class: Hypoglycemic
Pregnancy risk category C

Action
Short-acting insulin form. Promotes glucose transport, which stimulates carbohydrate metabolism in skeletal and cardiac muscle and adipose tissue. Also promotes phosphorylation of glucose in liver, where it’s converted to glycogen. Directly affects fat and protein metabolism, stimulates protein synthesis, inhibits release of free fatty acids, and indirectly decreases phosphate and potassium.

Availability
Injection (NovoLog): 100 units/ml in 10-ml vials and 3-ml PenFill cartridges
Injection (NovoLog Mix 70/30): 100 units/ml in 10-ml vials, 3-ml PenFill cartridges, and 3-ml FlexPen prefilled syringes

**Indications and dosages**

Type 1 (insulin-dependent) diabetes mellitus; type 2 (non-insulin-dependent) diabetes mellitus

**Adults and children ages 6 and older:**

**Insulin aspart**—Dosage tailored to patient’s needs, given subcutaneously in divided doses 5 to 10 minutes before meals. Insulin aspart provides 50% to 70% of dose; intermediate or long-acting insulin provides remainder. Dosage range is 0.5 to 1 unit/kg/day in divided doses based on meals. Insulin aspart provides 50% to 70% of dose; intermediate or long-acting insulin provides remainder. Dosage range is 0.5 to 1 unit/kg/day in divided doses based on meals. Insulin aspart and insulin aspart protamine—Give subcutaneously b.i.d., 15 minutes before morning and evening meals. For monotherapy, initial dosage is 0.4 to 0.6 unit/kg/day in two divided doses. Titrate in increments of 2 to 4 units q 3 to 4 days to achieve target fasting plasma glucose level. When given with oral hypoglycemics, initial dosage is 0.2 to 0.3 unit/kg/day.

**Contraindications**

- Hypersensitivity to drug or its components
- Hypoglycemia

**Precautions**

Use cautiously in:
- hepatic or renal impairment, hypothyroidism, hyperthyroidism
- elderly patients
- pregnant or breastfeeding patients
- children.

**Administration**

- Be aware that insulin is a high-alert drug.
- Know that drug is bioavailable as regular human insulin but has a faster onset and shorter duration.
- Give by subcutaneous route only, 5 to 10 minutes (15 minutes for Novolog Mix 70/30) before a meal.
- When mixing insulin aspart with intermediate or long-acting insulin, draw up insulin aspart into syringe first.
- Don’t mix insulin aspart protamine with any other insulin.
- When giving insulin aspart by pump, don’t mix with other insulins.
- Rotate injection sites to prevent lipodystrophy.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcut.</td>
<td>15 min</td>
<td>1-3 hr</td>
<td>3-5 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**Metabolic:** hypokalemia, sodium retention, **hypoglycemia, rebound hyperglycemia (Somogyi effect)**

**Musculoskeletal:** myalgia

**Skin:** urticaria, rash, pruritus

**Other:** edema; lipodystrophy; lipohypertrophy; redness, warmth, or stinging at injection site; allergic reactions including **anaphylaxis**

**Interactions**

**Drug-drug.** Acetazolamide, albuterol, antiretrovirals, asparaginase, calcitonin, corticosteroids, cyclophosphamide, danazol, dextrothyroxine, diazoxide, diltiazem, diuretics, dobutamine, epinephrine, estrogens, hormonal contraceptives, isoniazid, morphine, niacin, phenothiazines, phenytoin, somatropin, terbutiline, thyroid hormones: decreased hypoglycemic effect

Anabolic steroids, angiotensin-converting enzyme inhibitors, calcium, chloroquine, clofibrate, clonidine, disopyramide, fluoxetine, guanethidine, mebendazole, MAO inhibitors, octreotide, oral hypoglycemics, phenylbutazone, propoxyphene, pyridoxine, salicylates, sulfipyrazone, sulfonamides, tetracyclines: increased hypoglycemic effect

**Beta-adrenergic blockers (nonselective):** masking of some hypoglycemia signs

Reactions in **bold** are life-threatening.

**Clinical alert**
and symptoms, delayed recovery from hypoglycemia
Lithium carbonate: decreased or increased hypoglycemic effect
Pentamidine: increased hypoglycemic effect, possibly followed by hyperglycemia

**Drug-diagnostic tests.** Glucose, inorganic phosphate, magnesium, potassium: decreased levels
Liver and thyroid function studies: test interference
Urine vanillylmandelic acid: increased level

**Drug-herbs.** Basil, bee pollen, burdock, glucosamine, sage: altered glycemic control
Chromium, coenzyme Q10, dandelion, eucalyptus, fenugreek, marshmallow: increased hypoglycemic effect
Garlic, ginseng: decreased blood glucose level

**Drug-behaviors.** Alcohol use: increased hypoglycemic effect
Marijuana use: increased blood glucose level
Smoking: increased blood glucose level, decreased response to insulin

**Patient monitoring**
- Monitor blood glucose level frequently to gauge drug efficacy and appropriateness of dosage.
- Watch blood glucose level closely if patient is converting from one insulin type to another or is under unusual stress (as from surgery or trauma).
- Stay alert for signs and symptoms of hypoglycemia. Keep glucose source at hand.
- Assess for evidence of hyperglycemia, such as polydipsia, polyphagia, polyuria, and diabetic ketoacidosis (as shown by urine and blood ketones, metabolic acidosis, extremely elevated blood glucose level, and hypovolemia).
- Monitor for glycosuria.
- Closely monitor kidney and liver function test results in patients with renal or hepatic impairment.

**Patient teaching**
- Teach patient how to administer insulin subcutaneously or by injection pen.
- If patient must mix insulin aspart with intermediate or long-acting insulin, instruct him to draw up insulin aspart into syringe first.
- Tell patient not to mix any other insulin with mixture of insulin aspart and insulin aspart protamine.
- Advise patient to rotate subcutaneous injection sites and keep a record of sites used, to help prevent fatty tissue breakdown.
- Teach patient how to recognize and report signs and symptoms of hypoglycemia and hyperglycemia. Advise him to always carry a glucose source.
- Inform patient that changes in diet, activity, and stress level affect blood glucose levels and insulin requirements.
- Teach patient how to monitor and record blood glucose level and, if indicated, urine glucose and ketone levels.
- Tell patient to wear medical identification stating that he is diabetic and takes insulin.
- Instruct patient to have regular medical, vision, and dental exams.
- Tell female patient to contact prescriber if she is pregnant or plans to become pregnant.
- Advise patient to store insulin in refrigerator, not freezer.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.
**insulin glargine**  
**(rDNA origin)**  
Lantus

**Pharmacologic class:** Pancreatic hormone  
**Therapeutic class:** Hypoglycemic  
**Pregnancy risk category C**

**Action**
Long-acting insulin form. Promotes glucose transport, which stimulates carbohydrate metabolism in skeletal and cardiac muscle and adipose tissue. Also promotes phosphorylation of glucose in liver, where it’s converted to glycogen. Directly affects fat and protein metabolism, stimulates protein synthesis, inhibits release of free fatty acids, and indirectly decreases phosphate and potassium.

**Availability**
*Injection:* 100 units/ml in 10-ml vials and 3-ml cartridges

**Indications and dosages**

- **Type 1 (insulin-dependent) diabetes mellitus and type 2 (non-insulin-dependent) diabetes mellitus in patients who need long-acting insulin**  
  **Adults and children ages 6 and older:** Subcutaneous injection daily at same time each day, with dosage based on blood glucose level
  
- **Conversion from another insulin type in patients with type 1 diabetes mellitus who need long-acting insulin**  
  **Adults and children ages 6 and older:** For patients switching from once-daily NPH or ultralente human insulin, start glargine at same dosage as current insulin dosage. For patients taking twice-daily NPH or ultralente human insulin, reduce initial glargine dosage by approximately 20% of current insulin dosage during week 1; then adjust based on blood glucose level.

- **Type 2 diabetes mellitus in patients receiving oral hypoglycemics**  
  **Adults:** Dosage highly individualized based on glucose levels and response

**Contraindications**
- Hypersensitivity to drug or its components  
- Hypoglycemia

**Precautions**
Use cautiously in:
- pregnant or breastfeeding patients  
- children.

**Administration**

- Be aware that insulin is a high-alert drug.  
- Give by subcutaneous route only, at same time each day.  
- Don’t mix in solution with other drugs, including other insulins.  
- Before drawing up insulin into syringe, roll vial between hands to ensure uniform dispersion; don’t shake.  
- Rotate injection sites to prevent lipodystrophy.

**Adverse reactions**

- **Metabolic:** rebound hyperglycemia (Somogyi effect), hypoglycemia  
- **Skin:** urticaria, rash, pruritus, redness, stinging, or warmth at injection site  
- **Other:** edema, lipodystrophy, lipo-hypertrophy, allergic reactions including anaphylaxis

**Interactions**

- **Drug-drug.** Acetazolamide, albuterol, antiretrovirals, asparaginase, calcitonin, corticosteroids, cyclophosphamide, danazol, dextrothyroxine, diazoxide, diltiazem, diuretics, dobutamine, epinephrine, estrogens, hormonal contraceptives,

Reactions in **bold** are life-threatening.

---

**Clinical alert**
isoniazid, morphine, niacin, phenothiazines, phenytoin, somatropin, terbutaline, thyroid hormones: decreased hypoglycemic effect

Anabolic steroids, angiotensin-converting enzyme inhibitors, calcium, chloroquine, clofibrate, clonidine, disopyramide, fluoxetine, guanethidine, mebendazole, MAO inhibitors, octreotide, oral hypoglycemics, phenylbutazone, propanolol, pyridoxine, salicylates, sulfinpyrazone, sulfonamides, tetracyclines: increased hypoglycemic effect

Beta-adrenergic blockers (nonselective): masking of some hypoglycemia signs and symptoms, delayed recovery from hypoglycemia

Lithium carbonate: altered hypoglycemic effect

Pentamidine: increased hypoglycemic effect, possibly followed by hyperglycemia

**Drug-diagnostic tests.** Glucose, inorganic phosphate, magnesium, potassium: decreased levels

Liver and thyroid function studies: test interference

Urine vanillylmandelic acid: increased level

**Drug-herbs.** Basil, bee pollen, burdock, glucosamine, sage: altered glycemic control

Chromium, coenzyme Q10, dandelion, eucalyptus, fenugreek, marshmallow: increased hypoglycemic effect

Garlic, ginseng: decreased blood glucose level

**Drug-behaviors.** Alcohol use: increased hypoglycemic effect

Marijuana use: increased blood glucose level

Smoking: increased blood glucose level, decreased response to insulin

---

**Patient monitoring**

- Monitor blood glucose level frequently to assess drug efficacy and appropriateness of dosage.
- Watch blood glucose level closely if patient is converting from one insulin type to another or is under unusual stress (as from surgery or trauma).

  - Check for signs and symptoms of hypoglycemia (such as CNS changes). Keep glucose source at hand.

  - Monitor for signs and symptoms of hyperglycemia, such as polydipsia, polyphagia, polyuria, and diabetic ketoacidosis (blood and urine ketones, metabolic acidosis, extremely elevated glucose level, hypovolemia).

  - Monitor for glycosuria.

  - Closely monitor kidney and liver function test results in patients with renal or hepatic impairment.

**Patient teaching**

- Instruct patient how to administer insulin subcutaneously.

  - Teach patient how to recognize and report signs and symptoms of hypoglycemia and hyperglycemia. Advise him to always carry glucose source.

  - Advise patient to rotate subcutaneous injection sites and keep a record of sites used.

  - Teach patient how to monitor and record blood glucose level and, if indicated, urine glucose and ketone levels.

  - Inform patient that changes in diet, activity, and stress level can affect blood glucose level and insulin requirements.

  - Advise patient to wear medical identification stating that he is diabetic and takes insulin.

  - As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.
interferon alfa-n3
Alferon N

Pharmacologic class: Immunomodulator
Therapeutic class: Immunologic agent, antiviral
Pregnancy risk category C

FDA BOXED WARNING

- Drug may cause or worsen fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Monitor patient closely with periodic clinical and laboratory evaluations. Discontinue drug in patients with persistently severe or worsening signs or symptoms of these conditions. In many cases, these disorders resolve after withdrawal.

Action
Binds to membrane receptors on viral cells, inducing protein synthesis, inhibiting viral replication, and suppressing cell proliferation. Increases phagocytosis by macrophages, enhances expression of human leukocyte antigen, and augments lymphocyte cytotoxicity.

Availability
Injection: 5 million international units/ml

Indications and dosages
Refractory or recurring external condylomata acuminata (genital warts)
Adults ages 18 and older: 0.05 ml (250,000 international units) injected intraleosionally into base of each wart twice weekly for up to 8 weeks

Contraindications
- Hypersensitivity to human interferon alfa proteins or any product component
- Anaphylactic sensitivity to mouse immunoglobulin, egg protein, or neomycin

Precautions
Use cautiously in:
- fertile males and females
- debilitated patients
- pregnant or breastfeeding patients
- children younger than age 18.

Administration
- Use 30G needle to administer intraleosional injection.

Route | Onset | Peak | Duration
--- | --- | --- | ---
Intrales. | Not measurable | | |

Adverse reactions
CNS: vasovagal reaction, fatigue, dizziness, insomnia, decreased concentration, depression, nervousness, malaise, headache
EENT: visual disturbances, nasal and sinus drainage, pharyngitis, epistaxis, throat tightness, tongue hyperesthesia
GI: increased salivation
GU: dysuria
Musculoskeletal: arthralgia, back pain, myalgia, muscle cramps
Skin: sweating, generalized pruritus, papular rash on neck, photosensitivity
Other: strange taste in mouth, fever, chills, swollen left inguinal lymph node, tingling sensation of legs and feet, hot sensation of soles, heat intolerance, hot flashes, flulike symptoms, itching and pain at injection site, hypersensitivity reactions including anaphylaxis

Interactions
Drug-diagnostic tests. White blood cells (WBCs): decreased

Reactions in bold are life-threatening.
Patient monitoring
- Monitor WBC count.
- Watch closely for hypersensitivity reactions, including anaphylaxis.

Patient teaching
- Assure patient that flulike symptoms will subside with repeated doses.
- Tell patient to immediately report signs and symptoms of hypersensitivity reaction, such as hives, difficulty breathing, wheezing, and tightness in chest.
- Tell female patient to inform prescriber if she is or plans to become pregnant. Caution her not to breastfeed.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

interferon alfa-2b, recombinant
Intron A, Viraferon
Pharmacologic class: Biological response modifier
Therapeutic class: Antineoplastic, antiviral
Pregnancy risk category C

FDA BOXED WARNING
- Drug may cause or worsen fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Monitor patient closely with periodic clinical and laboratory evaluations. Discontinue drug in patients with persistently severe or worsening signs or symptoms of these conditions. In many cases, these disorders resolve after withdrawal.

Action
Unknown. Antitumor and antiviral activity may stem from direct antiproliferative action against tumor or viral cells, inhibition of viral replication, and modulation of host immune response.

Availability
Injection: 3 million international units/0.5-ml vial, 5 million international units/0.5-ml vial, 10 million international units/1-ml vial; 18 million international units/3.2-ml vial, 25 million international units/3.2-ml vial
Powder for injection (vial with diluent): 3 million, 5 million, 10 million, 18 million, 25 million, and 50 million international units

Indications and dosages
➣ Chronic hepatitis C
Adults: 3 million international units subcutaneously or I.M. three times weekly. If patient tolerates therapy and alanine aminotransferase (ALT) level is normal after 16 weeks, continue for 18 to 24 weeks. If ALT doesn’t normalize, drug may be withdrawn.
➣ Chronic hepatitis B
Adults: 30 to 35 million international units subcutaneously or I.M. weekly for 16 weeks, given as 5 million international units daily or 10 million international units three times weekly
➣ Hairy cell leukemia
Adults: 2 million international units/m² I.M. or subcutaneously three times weekly for 6 months or longer
➣ AIDS-related Kaposi’s sarcoma
Adults: 30 million international units/m² subcutaneously or I.M. three times weekly. Continue dosage unless intolerance occurs or disease advances rapidly.
➣ Malignant melanoma (as adjunct to surgery)
Adults: 20 million international units/m² I.V. for 5 consecutive days per week for 4 weeks; then a maintenance dosage of 10 million international units/m² subcutaneously three times weekly for 48 weeks. Withhold drug if adverse reactions occur; when reactions ease, resume at half of previous dosage. Withdraw if reactions persist.

Condyloma acuminatum (genital or venereal warts)

Adults: 1 million international units/lesion given intralesionally three times weekly for 3 weeks

Aggressive follicular non-Hodgkin's lymphoma

Adults: 5 million international units subcutaneously three times weekly for up to 18 months (given with chemotherapy regimen containing anthracycline)

Off-label uses
• Adjuvant treatment of malignant melanoma
• Hepatitis D

Contraindications
• Hypersensitivity to drug or its components
• Autoimmune disorders
• Female partners of males receiving drug

Precautions
Use cautiously in:
• cardiac or pulmonary disease; bone marrow, autoimmune, seizure, or psychiatric disorders
• diabetic patients prone to ketoacidosis
• pregnant or breastfeeding patients
• children.

Administration
• Administer by subcutaneous, I.M., I.V., or intralesional route. For I.V. use, reconstitute with diluent provided by manufacturer (bacteriostatic water for injection), according to chart provided. Mix gently, draw drug up into sterile syringe, and inject into 100 ml of normal saline solution. Infuse slowly over 20 minutes.
• Give antiemetics, as needed and prescribed, for nausea and vomiting.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>15-60 min</td>
<td>4 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>Unknown</td>
<td>2-12 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>Subcut.</td>
<td>Unknown</td>
<td>3-12 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>Intrales.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, confusion, paresthesia, rigors, lethargy, depression, difficulty thinking or concentrating, insomnia, anxiety, fatigue, asthenia, amnesia, malaise, nervousness, drowsiness, suicidal ideation
CV: chest pain, hypertension, palpitations, arrhythmias
EENT: visual disturbances, stye, hearing disorders, nasal congestion, sinusitis, rhinitis, pharyngitis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, eructation, stomatitis, dry mouth, intestinal obstruction
GU: gynecomastia, impaired fertility in women, transient erectile dysfunction
Hematologic: anemia, leukopenia, thrombocytopenia, neutropenia
Metabolic: hyperglycemia, hypocalcemia
Musculoskeletal: joint pain, back pain, myalgia
Respiratory: cough, dyspnea
Skin: flushing, rash, dry skin, pruritus, alopecia, dermatitis, diaphoresis
Other: gingivitis, flu-like symptoms, candidiasis, edema, weight loss

Interactions
Drug-drug. Aminophylline, theophylline: reduced clearance of these drugs
CNS depressants: additive CNS effects
Live-virus vaccines: decreased antibody response to vaccine, increased risk of adverse reactions
Zidovudine: synergistic effects

**Drug-diagnostic tests.** Alkaline phosphatase, ALT, aspartate aminotransferase, bilirubin, blood urea nitrogen, calcium, creatinine, fasting glucose, lactate dehydrogenase, neutralizing antibodies, phosphate, uric acid: increased levels
Hemoglobin, platelets, white blood cells: decreased values
International Normalized Ratio, partial thromboplastin time, prothrombin time: increased values

**Patient monitoring**
- Before therapy and monthly during therapy, assess CBC with white cell differential, bone marrow hairy cells, glucose and electrolyte levels, and liver and kidney function tests.
- Discontinue therapy if neutrophil count drops below 500 cells/mm².
- Monitor fluid intake and output. Keep patient well hydrated.
- Assess for GI upset. Provide small, frequent meals and antiemetics to ease severe nausea and vomiting.
- Monitor for mental status changes, depression, and suicidal ideation.
- Assess for bleeding and bruising.
- Institute infection-control measures. Monitor for signs and symptoms of infection.

**Patient teaching**
- Teach patient or caregiver how to prepare and give drug subcutaneously or I.M., rotate injection sites, and track dosing schedule and injection sites on calendar.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, alertness, and vision.
- Inform female patient that drug is linked to fetal abnormalities. Advise her not to get pregnant during therapy, and to use barrier contraception.
- Tell female patient not to breastfeed.
- Advise patient to avoid potential infection sources, such as crowds and people with known infections.
- Tell patient to eat small, frequent meals to combat nausea, vomiting, and loss of appetite.
- Inform male patient that drug may cause transient erectile dysfunction.
- Instruct patient to immediately report depression, suicidal thoughts, mental status changes, signs or symptoms of infection (such as fever, chills, sore throat), unusual bleeding or bruising, dizziness, palpitations, or chest pain.
- Tell patient he’ll need regular follow-up examinations and blood tests to gauge drug effects.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

---

**interferon alfacon-1**
**Infergen**

**Pharmacologic class:** Biological response modifier

**Therapeutic class:** Antiviral

**Pregnancy risk category C**

**FDA BOXED WARNING**
- Drug may cause or worsen fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Monitor patient closely with periodic clinical and laboratory evaluations. Discontinue drug in patients with persistently severe or worsening signs or symptoms of these conditions.
In many cases, these disorders resolve after withdrawal.

**Action**
Binds to membrane receptors on viral cells, inducing protein synthesis, inhibiting viral replication, and suppressing cell proliferation. Increases phagocytosis, enhances expression of human leukocyte antigen, and augments lymphocyte cytotoxicity.

**Availability**
*Injection:* 9-mcg/0.3-ml vials, 15-mcg/0.5-ml vials

**Indications and dosages**
- Chronic hepatitis C
  - **Adults:** 9 mcg subcutaneously as a single dose three times weekly for 24 weeks. Wait at least 48 hours between doses.

**Off-label uses**
- Hair cell leukemia

**Contraindications**
- Hypersensitivity to drug or *Escherichia coli*–derived products

**Precautions**
Use cautiously in:
- thyroid disorders, bone marrow depression, hepatic or cardiac disease, seizure disorders, compromised CNS function, severe psychiatric disorders
- pregnant or breastfeeding patients
- children age 18 and younger.

**Administration**
- Give by subcutaneous route only.
- Give antiemetics for nausea and vomiting, as needed and prescribed.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcut.</td>
<td>Unknown</td>
<td>24-36 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- **CNS:** dizziness, confusion, rigors, paresthesia, lethargy, depression,
- difficulty thinking or concentrating, insomnia, anxiety, fatigue, amnesia, nervousness, drowsiness, asthenia, malaise, **suicidal ideation**
- **CV:** chest pain, hypertension, palpitations, **arrhythmias**
- **EENT:** visual disturbances, sty, hearing disorders, nasal congestion, rhinitis, sinusitis, pharyngitis
- **GI:** nausea, vomiting, diarrhea, constipation, abdominal pain, flatulence, eructation, stomatitis, dry mouth, anorexia, **intestinal obstruction**
- **GU:** impaired fertility in women, gynecomastia, erectile dysfunction
- **Hematologic:** anemia, **leukopenia,** **thrombocytopenia,** **neutropenia**
- **Metabolic:** hyperglycemia, hypocalcemia
- **Musculoskeletal:** joint pain, back pain, myalgia
- **Respiratory:** cough, dyspnea
- **Skin:** rash, dryness, pruritus, flushing, alopecia, candidiasis, dermatitis, diaphoresis
- **Other:** gingivitis, flulike symptoms, edema, weight loss

**Interactions**
- **Drug-drug.** Drugs metabolized by CYP450: altered blood levels of both drugs
- **Drug-diagnostic tests.** *Granulocytes,* *hemoglobin,* *platelets,* *white blood cells:* decreased values
  - Alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, International Normalized Ratio, lactate dehydrogenase, neutralizing antibodies, phosphorus, prothrombin time, triglycerides, uric acid: increased values

**Patient monitoring**
- **Clinical alert** Before and regularly during therapy, assess CBC with white cell differential and hepatitis C virus antibodies.
- Assess fluid intake and output. Keep patient well hydrated.
Monitor for GI upset. Provide small, frequent meals and give antiemetics, as prescribed, to ease severe nausea and vomiting.

Stay alert for depression, mental status changes, psychosis, and suicidal ideation (especially in patients with history of mental illness).

Assess for bleeding and bruising.

Institute infection-control measures. Monitor for signs and symptoms of infection.

Watch for flulike symptoms.

Patient teaching

- Teach patient or caregiver how to administer drug subcutaneously, rotate injection sites, and track dosing schedule and injection sites on calendar.
- Advise patient to avoid sources of potential infection, such as crowds and people with known infections.
- Tell patient to eat small, frequent meals to combat nausea, vomiting, and appetite loss.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, alertness, and vision.
- Tell female patient that drug is linked to fetal abnormalities. Advise her not to get pregnant during therapy, and to use barrier contraception.
- Instruct patient to immediately report symptoms of infection (fever, chills, sore throat), unusual bleeding or bruising, mental status changes, dizziness, palpitations, or chest pain.
- Tell patient he'll need regular follow-up examinations and blood tests to gauge drug effects.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

interferon beta-1a
Avonex, Rebif

interferon beta-1b
Betaferon®, Betaseron

Pharmacologic class: Biological response modifier
Therapeutic class: Antiviral, immunoregulator
Pregnancy risk category C

Action
Binds and competes with specific receptors on cell surface, inducing various interferon-induced gene products. Also inhibits proliferation of T cells.

Availability
Lyophilized powder for injection (beta-1a): 22 mcg (6 million international units; Rebif), 33 mcg (6.6 million international units; Avonex), 44 mcg (12 million international units; Rebif)
Powder for injection (beta-1b): 0.3 mg (9.6 million international units; Betaseron)
Prefilled syringes (beta-1a): 30 mcg/0.5 ml (Avonex)

Indications and dosages
To reduce frequency of exacerbations in relapsing-remitting multiple sclerosis
Adults ages 18 and older: 8.8 mcg Rebif subcutaneously three times weekly, increased over a 4-week period to 44 mcg three times weekly. Or 30 mcg Avonex I.M. once a week. Or 8 million international units (0.25 mg) Betaseron subcutaneously every other day.

Contraindications
- Hypersensitivity to drug, its components, or albumin
Precautions
Use cautiously in:
- cardiac disease, seizure disorders, mental disorders, depression, suicidal tendencies
- women of childbearing age
- pregnant or breastfeeding patients
- children ages 18 and younger.

Administration
- Reconstitute Avonex (I.M. injection) and Rebif (subcutaneous injection) using diluent provided, according to instructions provided.
- Reconstitute Betaseron (subcutaneous injection) using 1.2 ml of diluent supplied by manufacturer, to yield a concentration of 0.25 mg/ml. Swirl gently to mix; don’t shake. Use reconstituted drug within 3 hours; discard unused portion.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.M.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>Subcut.</td>
<td>Unknown</td>
<td>1-8 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, confusion, rigors, paresthesia, lethargy, depression, difficulty thinking or concentrating, insomnia, anxiety, fatigue, amnesia, nervousness, drowsiness, asthenia, malaise, suicidal ideation
CV: chest pain, hypertension, palpitations, arrhythmias
EENT: visual disturbances, stye, hearing disorders, nasal congestion, sinusitis, rhinitis, pharyngitis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, eructation, stomatitis, dry mouth, intestinal obstruction
GU: gynecomastia, breast pain, early or delayed menses, menstrual bleeding or spotting, shortened duration of menstrual flow, menorrhagia
Hematologic: anemia, neutropenia, leukopenia, thrombocytopenia
Metabolic: hypocalcemia
Musculoskeletal: joint pain, back pain, myalgia, myasthenia
Respiratory: cough, dyspnea
Skin: rash, dry skin, pruritus, flushing, alopecia, dermatitis, diaphoresis
Other: gingivitis, fulike symptoms, weight loss, edema, candidiasis, lymphadenopathy, inflammation, pain

Interactions
Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, glucose, lactate dehydrogenase, neutralizing antibodies, phosphorus, uric acid: increased values Hemoglobin, neutrophils, white blood cells: decreased values

Patient monitoring
Before therapy and monthly during therapy, assess CBC with white cell differential, glucose and electrolyte levels, and liver and kidney function tests.
- Assess fluid intake and output. Keep patient well hydrated.
- Watch for GI upset. Provide small, frequent meals to minimize nausea and vomiting.
- Monitor for mental status changes, depression, and suicidal ideation.
- Evaluate for bleeding and bruising.
- Institute infection-control measures. Monitor for infection symptoms.

Patient teaching
- Teach patient or caregiver how to administer drug subcutaneously or I.M., rotate injection sites, and track dosing schedule and injection sites on calendar.
- Advise patient to avoid sources of potential infection, such as crowds and people with known infections.
- Tell patient to eat small, frequent meals to combat nausea, vomiting, and appetite loss.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, alertness, and vision.

Reactions in bold are life-threatening.
Tell patient to contact prescriber immediately if depression or suicidal ideation occurs.

- Inform female patient that drug is linked to fetal abnormalities. Advise her not to get pregnant during therapy, and to use barrier contraception. Tell her to consult prescriber before breastfeeding.

Instruct patient to immediately report signs or symptoms of infection (such as fever, chills, sore throat, aching), unusual bleeding or bruising, mental status changes, dizziness, palpitations, or chest pain.

- Tell patient he’ll need regular follow-up examinations and blood tests to monitor drug effects.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

### interferon gamma-1b

**Actimmune, Immukin**

**Pharmacologic class:** Biological response modifier

**Therapeutic class:** Antineoplastic

**Pregnancy risk category C**

### Action

Enhances cellular toxicity and killer cell activity and promotes generation of oxygen metabolites in phagocytes, resulting in destruction of microorganisms.

### Availability

**Injection:** 100 mcg (2 million international units)/0.5-ml vial

### Indications and dosages

- Chronic granulomatous disease; severe malignant osteopetrosis

### Adults with body surface area (BSA) above 0.5 m²:

- 50 mcg/m² (1 million international units/m²²) subcutaneously three times weekly

### Adults with BSA of 0.5 m² or less:

- 1.5 mcg/kg subcutaneously three times weekly in deltoid or anterior thigh

### Contraindications

- Hypersensitivity to drug, its components, or *Escherichia coli*-derived products

### Precautions

Use cautiously in:

- thyroid disorders, bone marrow depression, hepatic or cardiac disease, seizure disorders, compromised CNS function
- pregnant or breastfeeding patients
- children ages 18 and younger.

### Administration

- Administer into deltoid muscle by subcutaneous route only.
- Give at bedtime if flulike symptoms occur.
- Provide antiemetics to ease nausea and vomiting, as prescribed.

### Adverse reactions

**CNS:** dizziness, confusion, paresthesia, lethargy, depression, difficulty thinking or concentrating, insomnia, anxiety, fatigue, amnesia, nervousness, drowsiness, asthenia, malaise

**CV:** chest pain, hypertension, palpitations, arrhythmias

**GI:** nausea, vomiting, diarrhea, constipation, abdominal pain, *pancreatitis*

**GU:** proteinuria

**Hematologic:** anemia, leukopenia, thrombocytopenia, neutropenia

**Musculoskeletal:** joint pain, back pain, myalgia

**Skin:** flushing, rash, dry skin, erythema

### Route | Onset | Peak | Duration
--- | --- | --- | ---
Subcut | Unknown | 7 hr | Unknown

**Canada** | **UK** | **Hazardous drug** | **High alert drug**
Other: flulike symptoms, weight loss, edema, hypersensitivity reaction

Interactions
Drug-drug. Bone marrow depressants: increased bone marrow depression

Zidovudine: increased zidovudine blood level

Drug-diagnostic tests. Hepatic enzymes: increased levels
Neutrophils, platelets: decreased counts

Patient monitoring

- Before and monthly during therapy, assess CBC with white cell differential, glucose and electrolyte levels, and liver and kidney function tests.
- Assess fluid intake and output. Keep patient well hydrated.
- Monitor for GI upset. Provide small, frequent meals or antiemetics to ease severe nausea and vomiting.
- Monitor patient for mental status changes and depression.
- Assess for flulike symptoms. If these occur, give drug at bedtime and provide supportive care, such as rest and acetaminophen for headache and fever.

Patient teaching

- Teach patient or caregiver how to administer drug subcutaneously, rotate injection sites, and track dosing schedule and injection sites on calendar.
- Tell patient to contact prescriber immediately if depression occurs.
- Advise patient to eat small, frequent meals to combat nausea, vomiting, and appetite loss.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Inform female patient that drug is linked to fetal abnormalities. Advise her not to get pregnant during therapy, and to use barrier contraception.
- Tell female patient to consult prescriber before breastfeeding.
- Tell patient he’ll need regular follow-up examinations and blood tests to monitor drug effects.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

ipratropium bromide

Pharmacologic class: Anticholinergic
Therapeutic class: Allergy, cold, and cough remedy; bronchodilator
Pregnancy risk category B

Action
Inhibits cholinergic receptors in bronchial smooth muscle, decreasing level of cyclic guanosine monophosphate and dilating bronchioles. When used locally, inhibits secretions from glands lining the nasal mucosa.

Availability

Aerosol inhaler: 18 mcg/spray in 14-g canister (200 inhalations)
Nasal spray: 0.03% solution (21 mcg/spray in 30-ml bottle, 345 sprays/bottle); 0.06% solution (42 mcg/spray in 15-ml bottle, 165 sprays/bottle)
Solution for inhalation: 0.02% in single-dose vials

Indications and dosages

- Chronic obstructive pulmonary disease; bronchospasm; asthma; perennial rhinitis; common cold

Reactions in bold are life-threatening.
**Aerosol**—
*Aerosol*—
**Adults:** Two inhalations (36 mcg) q.i.d. Don’t exceed 12 inhalations in 24 hours.

**Inhalation solution**—
*Aerosol*—
**Adults:** 500 mcg three to four times daily by oral nebulizer. Space doses 6 to 8 hours apart as needed.

**Nasal spray (0.03% solution)**—
*Inhalation solution*—
**Adults and children ages 6 and older:** Two sprays (42 mcg) per nostril two to three times daily (total daily dosage of 168 to 252 mcg)

**Nasal spray (0.06% solution)**—
*Inhalation solution*—
**Adults and children ages 12 and older:** Two sprays (84 mcg) per nostril three to four times daily (total daily dosage of 504 to 672 mcg)

**Contraindications**
- Hypersensitivity to drug, its components, atropine, belladonna alkaloids, bromide, fluorocarbons, or soy lecithin and related foods (such as soybeans, peanuts)

**Precautions**
Use cautiously in:
- acute bronchospasm, bladder neck obstruction, prostatic hypertrophy, glaucoma, urinary retention, undiagnosed abdominal pain
- elderly patients
- pregnant or breastfeeding patients
- children ages 5 and younger (safety not established)

**Administration**
- Give by inhalation or intranasal route as directed.
- When using nasal spray, prime with seven actuations to initiate pump. Give two actuations if spray hasn’t been used within past 24 hours.
- With aerosol inhaler, prime new inhaler with three sprays. Also prime with three sprays if inhaler hasn’t been used within past 24 hours.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhalation</td>
<td>5-15 min</td>
<td>1-2 hr</td>
<td>3-4 hr (up to 8 hr)</td>
</tr>
<tr>
<td>Intranasal</td>
<td>15 min</td>
<td>Unknown</td>
<td>6-12 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
*CNS:* dizziness, headache, nervousness
*CV:* hypotension, palpitations, chest pain
*ENT:* blurred vision, epistaxis, nasal dryness and irritation (with nasal spray), sore throat
*GI:* nausea, vomiting, GI irritation
*Musculoskeletal:* back pain
*Respiratory:* cough, upper respiratory tract infection, bronchitis, increased sputum, oropharyngeal edema, bronchospasm
*Skin:* rash
*Other:* flulike symptoms, hypersensitivity reactions including *anaphylaxis*

**Interactions**
*Drug-drug.* *Antihistamines, disopyramide, phenothiazines:* additive anticholinergic effects

*Drug-herbs.* *Jaborandi, pill-bearing spurge:* decreased drug effects

**Patient monitoring**
- Evaluate for urinary retention. Have patient void before giving drug.
- Ensure proper fit of mouthpiece or face mask.
- Monitor patient’s response to therapy, vital signs, and neurologic, cardiovascular, and respiratory status.
- Monitor fluid intake and output. Keep patient well hydrated.

**Patient teaching**
- Teach patient how to use nasal spray or inhaler.
- Advise patient to rinse mouth after each dose to minimize throat irritation and dryness.
- Caution patient to keep drug out of eyes. If contact occurs, instruct him to
rinse eyes with cool water and call prescriber right away.
- Caution patient to avoid driving and other dangerous activities if drug causes dizziness or blurred vision.
- Tell patient drug may cause GI upset, nausea, vomiting, or cough.
- Instruct patient to promptly report vision changes, rash, or palpatations.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and herbs mentioned above.

irbesartan
Aprovel®, Avapro

Pharmacologic class: Angiotensin II receptor antagonist
Therapeutic class: Antihypertensive
Pregnancy risk category C (first trimester), D (second and third trimesters)

FDA BOXED WARNING
- When used during second or third trimester of pregnancy, drug may cause fetal injury and even death. Discontinue as soon as pregnancy is detected.

Action
Blocks aldosterone-secreting and potent vasoconstrictive effects of angiotensin II at tissue receptor sites, which reduces vasoconstriction and lowers blood pressure

Availability
Tablets: 75 mg, 150 mg, 300 mg

Indications and dosages
- Hypertension
Adults: 150 mg/day P.O.; may increase to 300 mg/day

Children ages 13 to 16:
- 150 mg/day P.O.; may increase to 300 mg/day

Children ages 6 to 12:
- 75 mg/day P.O.; may increase to 150 mg/day
- Hypertension in volume-depleted or hemodialysis patients receiving diuretics
Adults: Initially, 75 mg/day P.O.

Off-label uses
- Nephropathy in patients with type 2 diabetes and hypertension

Contraindications
- Hypersensitivity to drug
- Bilateral renal artery stenosis
- Pregnancy (second and third trimesters)

Precautions
Use cautiously in:
- heart failure, volume or sodium depletion, renal disease, hepatic impairment
- black patients
- females of childbearing age
- breastfeeding patients
- children ages 18 and younger (safety not established).

Administration
- Administer with or without food.
- Know that drug may be given with other antihypertensive drugs.

Route Onset Peak Duration
P.O. Unknown Within 2 hr 24 hr

Adverse reactions
- CNS: dizziness, fatigue, headache, syncope
- CV: orthostatic hypotension, chest pain, peripheral edema
- EENT: conjunctivitis, vision disturbance, ear pain, sinus disorders
- GI: nausea, diarrhea, constipation, abdominal pain, dry mouth
- GU: albuminuria, renal failure
- Metabolic: gout, hyperkalemia
- Musculoskeletal: joint pain, back pain, muscle weakness

Reactions in bold are life-threatening.

Clinical alert
Respiratory: upper respiratory tract infection, cough, bronchitis
Other: dental pain

Interactions
Drug-drug. Diuretics, other antihypertensives: increased risk of hypotension
Lithium: increased lithium blood level
Nonsteroidal anti-inflammatory drugs: decreased antihypertensive effects
Potassium-sparing diuretics, potassium supplements: increased risk of hyperkalemia

Drug-diagnostic tests. Albumin: increased level

Drug-food. Salt substitutes containing potassium: increased risk of hyperkalemia

Patient monitoring
• Monitor vital signs, especially blood pressure.
• Watch for signs and symptoms of orthostatic hypotension.
• Watch blood pressure closely when volume depletion may cause hypotension (as in diaphoresis, nausea, vomiting, diarrhea, and postoperative period).
• Assess fluid intake and output. Keep patient well hydrated, especially if he’s receiving diuretics concurrently.
• Monitor blood urea nitrogen and creatinine levels.

Patient teaching
• Tell patient he may take with or without food.
• Instruct patient to change position slowly and to stay well hydrated, to minimize blood pressure decrease when rising.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• Tell female patient that drug has been linked to fetal injury and deaths. Caution her not to get pregnant during therapy. Advise her to use barrier contraception.
• Instruct female patient to report pregnancy.
• Instruct patient to report fever, chills, dizziness, severe vomiting, diarrhea, and dehydration.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

irinotecan hydrochloride
Campto®, Camptosar

Pharmacologic class: Topoisomerase inhibitor
Therapeutic class: Hormonal anti-neoplastic
Pregnancy risk category D

FDA BOXED WARNING
• Give under supervision of physician experienced in using cancer chemotherapy, in facility with adequate diagnostic and treatment resources.
• Drug can cause both early and late forms of diarrhea that may be severe. Early diarrhea (arising during or shortly after drug infusion) may be accompanied by cholinergic symptoms; atropine may prevent or relieve it. Late diarrhea (generally arising more than 24 hours after administration) can be life-threatening and prolonged, and may lead to dehydration, electrolyte imbalance, or sepsis. For late diarrhea, give loperamide promptly.
• Drug may cause severe myelosuppression.
Action
Inhibits topoisomerase 1 (an enzyme that allows DNA replication) by binding to it. This action prevents religation of DNA strand, which results in breakage of double-stranded DNA and cell death.

Availability
Injection: 20 mg/ml in 2-ml and 5-ml vials

Indications and dosages
Metastatic colorectal cancer or recurrence or progression of metastatic colorectal cancer after fluorouracil (5-FU) therapy
Adults: 125 mg/m² I.V. infused over 90 minutes on days 1, 8, 15, and 22, followed by a 2-week rest; given with leucovorin and 5-FU. Or, 180 mg/m² I.V. infused over 90 minutes on days 1, 15, and 29 with leucovorin, 5-FU bolus, and 5-FU infusion followed by a 2-week rest. Or as monotherapy, 125 mg/m² I.V. infused over 90 minutes weekly for 4 weeks, followed by a 2-week rest period; or, 350 mg/m² I.V. infused over 90 minutes q 3 weeks as long as tolerable. Adjust dosage in increments based on tolerance and age.

Off-label uses
• Most cancers

Contraindications
• Hypersensitivity to drug
• Concurrent atazanavir use
• Pregnancy or breastfeeding

Precautions
Use cautiously in:
• bone marrow depression, severe diarrhea
• patients undergoing radiation therapy
• elderly patients
• children.

Administration
Follow facility policy for handling antineoplastics. If skin contact occurs, wash with soap and water immediately and thoroughly. If mucous membrane contact occurs, flush with water.
• Dilute in dextrose 5% in water or normal saline solution, to a concentration of 0.12 to 1.1 mg/ml.
• Infuse within 6 hours if drug is stored at room temperature or within 24 hours if refrigerated.
• Give single dose by I.V. infusion over 90 minutes.
• Administer antiemetic to ease nausea and vomiting, as needed and prescribed.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>1-2 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: insomnia, dizziness, asthenia, headache, akathisia
CV: vasodilation, orthostatic hypotension
EENT: rhinitis
GI: nausea, vomiting, constipation, diarrhea, flatulence, dyspepsia, abdominal pain or enlargement, stomatitis, anorexia
Hematologic: anemia, neutropenia, leukopenia, thrombocytopenia
Hepatic: hepatotoxicity
Metabolic: dehydration
Musculoskeletal: back pain
Respiratory: dyspnea, increased cough
Skin: alopecia, diaphoresis, rash
Other: weight loss, edema, fever, pain, chills, minor infections

Interactions
Drug-drug. Dexamethasone: increased risk of lymphocytopenia
Diuretics: increased risk of dehydration
Laxatives: increased risk of diarrhea
Other antineoplastic: additive adverse effects
Drug-diagnostic tests. Alkaline phosphatase: increased level

Reactions in bold are life-threatening.

Clinical alert
Hemoglobin, neutrophils, white blood cells: decreased values

**Patient monitoring**
- Assess CBC before each infusion. Withhold dose if neutrophil count is below 1,500 cells/mm³.
- Monitor infusion site for extravasation; if it occurs, flush with sterile water and apply ice.
- Assess fluid intake and output. Keep patient well hydrated.
- Monitor oral intake. Evaluate for nausea and vomiting.
- Assess for diarrhea. In severe diarrhea, expect to decrease dosage or withhold dose.
- Institute infection-control protocols to help prevent infection.
- Monitor liver function test results.

**Patient teaching**
- Inform patient that blood tests will be done before each dose.
- Instruct patient to report pain at infusion site; severe nausea or vomiting; severe, increased, or bloody diarrhea; infection; or injury.
- Instruct patient to immediately report unusual tiredness or yellowing of skin or eyes.
- Tell patient that drug increases his risk of infection. Advise him to avoid crowds and other potential infection sources.
- Caution female patient not to breastfeed or become pregnant during therapy. Recommend barrier contraception.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

---

**iron dextran**
Cosmofer®, DexFerrum, InFeD

**Pharmacologic class:** Trace element
**Therapeutic class:** Iron supplement
**Pregnancy risk category C**

**FDA BOXED WARNING**
- Parenteral use has caused anaphylactic-type reactions, some resulting in death. Use only in patients with clearly established indications when laboratory tests confirm iron deficiency not amenable to oral iron therapy. Give drug only where resuscitation techniques and treatment of anaphylactic and anaphylactoid shock are readily available.

**Action**
Replenishes depleted stores of iron (a component of hemoglobin) in bone marrow

**Availability**
Injection: 50 mg/ml

**Indications and dosages**
- Iron-deficiency anemia in patients who can’t tolerate oral iron

**Adults and children weighing more than 15 kg (33 lb):** Dosage individualized based on patient’s weight and hemoglobin (Hgb) value, using the following formula: Dosage (ml) = 0.0442 (desired Hgb minus patient’s Hgb) times lean body weight (LBW) plus the product of 0.26 times LBW

Give test dose before starting I.V. or I.M. therapy: For I.V. use, administer test dose of 0.5 ml (25 mg) I.V. over 30 seconds to 5 minutes; if no reactions occur within 1 hour, give remainder of therapeutic dose I.V.; repeat this dose
daily. For I.M. use, give test dose of 0.5 ml (25 mg) by Z-track method; if no reactions occur, give daily doses not exceeding 100 mg I.M. in adults, 50 mg I.M. in children weighing more than 10 kg (22 lb), or 25 mg in infants weighing less than 5 kg (11 lb).

Iron replacement caused by blood loss

Adults: Dosage individualized based on the following formula: Replacement iron (in mg) = blood loss (in ml) times hematocrit

Contraindications
- Hypersensitivity to drug, alcohol, tartrazine, or sulfites
- Acute phase of infectious renal disease or hemolytic anemia

Precautions
Use cautiously in:
- autoimmune disorders, arthritis, severe hepatic impairment
- elderly patients
- breastfeeding patients
- children.

Administration
- For I.M. administration, inject by Z-track method into upper outer quadrant of gluteal muscle.
- For intermittent I.V. infusion, administer undiluted at a rate no faster than 1 ml/minute.
- Don’t give with oral iron preparations.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V., I.M.</td>
<td>4 days</td>
<td>1-2 wk</td>
<td>Wks-mos</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, headache, syncope, seizures
CV: chest pain, tachycardia, hypotension
GI: nausea, vomiting
Hematologic: hemochromatosis, hemolysis, hemosiderosis
Musculoskeletal: joint pain, myalgia

Respiratory: dyspnea
Other: abnormal or metallic taste, tooth discoloration, fever, lymphadenopathy, hypersensitivity reactions including anaphylaxis

Interactions
None significant

Patient monitoring
- Monitor for hypersensitivity reaction. Keep epinephrine and other emergency supplies on hand in case reaction occurs.
- Assess serum ferritin levels regularly, because these levels correlate with iron stores.
- In patients with rheumatoid arthritis, monitor for acute exacerbation of joint pain and swelling. Provide appropriate comfort measures.
- Watch for signs and symptoms of iron overload, including decreased activity, sedation, and GI or respiratory tract bleeding.

Patient teaching
- Caution patient not to take oral iron preparations or vitamins containing iron during therapy.
- Instruct patient to report difficulty breathing, itching, or rash.
- Tell patient he’ll undergo periodic blood testing to monitor his response to therapy.
- As appropriate, review all other significant and life-threatening adverse reactions mentioned above.

**iron sucrose**
Venofer

**Pharmacologic class:** Trace element
**Therapeutic class:** Iron supplement
**Pregnancy risk category B**
**Action**
Replenishes depleted stores of iron (a component of hemoglobin) in bone marrow

**Availability**
*Aqueous complex for injection*: 20 mg elemental iron/ml in 5-ml single-use vials (100 mg of elemental iron)

**Indications and dosages**
- Iron-deficiency anemia in hemodialysis patients concurrently receiving erythropoietin
  - **Adults**: 100 mg of elemental iron (5 ml) I.V. directly into dialysis line or by slow injection or infusion during dialysis session (up to three times weekly) for 10 doses (total of 1,000 mg)

**Off-label uses**
- Autologous blood donation
- Bloodless surgery

**Contraindications**
- Hypersensitivity to drug, alcohol, tartrazine, or sulfites
- Hemolytic anemias and other anemias not caused by iron deficiency
- Primary hemochromatosis

**Precautions**
Use cautiously in:
- autoimmune disorders, arthritis, severe hepatic impairment
- elderly patients
- breastfeeding patients
- children.

**Administration**
- Give test dose only if ordered: 50 mg (2.5 ml) I.V. over 3 to 10 minutes.
- Dilute 100 mg of elemental iron in no more than 100 ml of normal saline solution; infuse slowly I.V. over at least 15 minutes.
- Administer I.V. directly into dialysis line or by infusion at 20 mg/minute, not to exceed 100 mg/injection.
- Don’t give with oral iron preparations.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>4 days</td>
<td>1-2 wk</td>
<td>Wks-mos</td>
</tr>
</tbody>
</table>

**Adverse reactions**
*CNS*: dizziness, headache, syncope, seizures
*CV*: chest pain, tachycardia, hypotension
*GI*: nausea, vomiting
*Hematologic*: hemochromatosis, hemolysis, *hemosiderosis*
*Musculoskeletal*: muscle cramps, aches, or weakness; joint pain
*Respiratory*: dyspnea
*Other*: abnormal or metallic taste, tooth discoloration, fever, lymphadenopathy, allergic reactions including *anaphylaxis*

**Interactions**
None significant

**Patient monitoring**
- Monitor for hypersensitivity reaction. Keep epinephrine and other emergency supplies available in case reaction occurs.
- Assess hemoglobin, hematocrit, serum ferritin, and transferrin saturation levels before, during, and after therapy.
- Monitor blood pressure. Stay alert for hypotension.
- Watch for signs and symptoms of iron overload, such as decreased activity, sedation, and GI or respiratory tract bleeding.

**Patient teaching**
- Caution patient not to take oral iron preparations or vitamin supplements containing iron during therapy.
- Instruct patient to report dyspnea, itching, or rash.
- Tell patient he’ll undergo periodic blood testing to monitor his response to therapy.
As appropriate, review all other significant and life-threatening adverse reactions mentioned above.

**isocarboxazid**
Marplan

**Pharmacologic class:** MAO inhibitor  
**Therapeutic class:** Antidepressant  
**Pregnancy risk category C**

**FDA BOXED WARNING**
- Drug may increase risk of suicidal thinking and behavior in children and adolescents with major depressive disorder and other psychiatric disorders, especially during first few months of therapy. Risk must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family and caregivers to observe patient closely and communicate with prescriber as needed.
- Drug isn’t approved for use in pediatric patients.

**Action**
Nonselectively inhibits hydrazine MAO, an enzyme system thought to raise biogenic amine levels in brain

**Availability**
*Tablets: 10 mg*

**Indications and dosages**

- **Depression**

  - **Adults:** Initially, 10 mg P.O. b.i.d. If tolerated, may increase in increments of 1 tablet q 2 to 4 days, to achieve dosage of 4 tablets/day by end of week. May then increase in increments of up to 20 mg/week, if needed and tolerated, to a maximum of 60 mg/day given in two to four divided doses. Once maximum clinical response occurs, dosage may be lowered slowly over several weeks if it doesn’t jeopardize therapeutic response.

**Contraindications**
- Hypersensitivity to drug
- Concurrent use of other MAO inhibitors, dibenzazepine derivatives, selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), sympathomimetics (including amphetamines), certain CNS depressants (including opioids), sedatives, antihypertensives, antihistamines, thiazide diuretics, anesthetics, bupropion, buspirone, or dextromethorphan
- Known or suspected cerebrovascular defect
- Hypertension, cardiovascular disease
- Severe or frequent headache
- Pheochromocytoma
- Hepatic disease, abnormal liver function tests
- Renal disease
- Consumption of tyramine-rich foods (such as aged cheeses) or excessive amounts of caffeine

**Precautions**
Use cautiously in:
- hyperthyroidism, seizure disorders, hypotension, diabetes mellitus, myocardial ischemia, hypomania
- patients switching MAO inhibitors
- suicidal or drug-dependent patients
- elderly patients
- pregnant or breastfeeding patients
- children younger than age 16 (safety and efficacy not established).

**Administration**
- If hypertensive crisis occurs, withdraw drug immediately and give phenolamine 5 mg I.V. slowly, as ordered.
- Ask patient about other drugs he’s using. MAO inhibitors can cause dangerous interactions with many drugs.
Know that psychotropics should be withheld for 14 days after isocarboxazid withdrawal.

### Route Onset Peak Duration

<p>| | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

### Adverse reactions

**CNS:** drowsiness, anxiety, forgetfulness, hyperactivity, lethargy, sedation, syncope, headache, insomnia, sleep disturbance, tremor, myoclonic jerks, paresthesia, dizziness, suicidal behavior or ideation (especially in child or adolescent)

**CV:** orthostatic hypotension, palpitations, hypertensive crisis

**GI:** nausea, diarrhea, constipation, dry mouth

**GU:** urinary frequency, urinary hesitancy, erectile dysfunction

**Hepatic:** jaundice, hepatotoxicity

**Musculoskeletal:** heavy feeling

**Skin:** sweating

**Other:** chills

### Interactions

**Drug-drug.** Amphetamines, CNS depressants, dextromethorphan, dibenzazepine derivatives and other TCAs, other MAO inhibitors, SSRIs (such as fluoxetine, paroxetine), sympathomimetics: hypertensive crisis, seizures, fever, diaphoresis, excitation, delirium, tremor, coma, circulatory collapse

Anesthetics: severe hypotension

Antidepressants, bupropion, buspirone: hypertension

Antihypertensives, beta-adrenergic blockers, thiazide diuretics: increased hypotensive effects

Dextromethorphan, tryptophan: hypertension, excitation, hyperpyrexia

Disulfiram: severe toxicity

Epinephrine, guanadrel, guanethidine, norepinephrine, reserpine, vasoconstrictors: hypertensive crisis

Insulin, oral hypoglycemics: additive hypoglycemia

**Meperidine:** severe hypertension or hypotension, respiratory depression, seizures, malignant hyperpyrexia, excitation, peripheral vascular collapse, coma, death

### Drug-diagnostic tests.

Liver function tests: altered results

### Drug-food.

**Excessive caffeine consumption:** nervousness, shakiness, rapid heartbeat, anxiety

Foods high in tyramine, such as cheese (especially aged cheeses), sour cream, Chianti wine, sherry, beer (including nonalcoholic beer), liqueurs, pickled herring, anchovies, caviar, liver, canned figs, raisins, bananas, avocados, soy sauce, sauerkraut, pods of broad beans (such as fava beans), yeast extracts, meat extracts, meat prepared with tenderizers, dry sausage: hypertensive crisis

### Drug-behaviors.

**Alcohol use:** potential for severe hypertension, excitation, seizures, delirium, hyperpyrexia, circulatory collapse, coma, death

### Patient monitoring

- Monitor blood pressure frequently. Drug may cause hypertensive crisis.
- Watch for increased depression and suicidal ideation, especially in child or adolescent.
- Monitor liver function tests. Assess for jaundice and signs and symptoms of hepatic dysfunction; discontinue drug and notify prescriber if these occur.

### Patient teaching

- Explain importance of taking drug exactly as prescribed.
- Caution patient not to stop therapy suddenly. Dosage must be tapered.
- Instruct patient to immediately report occipital headache, palpitations, stiff neck, nausea, sweating, dilated pupils, and photophobia (indications of hypertensive crisis).
- Tell patient to immediately report rash, hives, itching, shortness of breath,
wheezing, cough, or swelling of face, lips, tongue, or throat.

 ADVISED patient (or caregiver, as appropriate) to monitor his mental status carefully and immediately report increased depression or suicidal thoughts or behavior (especially in child or adolescent).

 Stress importance of avoiding certain foods and beverages (especially those containing tyramine) and over-the-counter preparations during and for 14 days after therapy. Inform patient that pharmacist can provide complete list of foods to avoid.
 ● Instruct patient to tell all prescribers he’s taking drug.

 CAUTION patient not drink alcohol or consume excessive amounts of caffeine.
 ● Advise patient to rise slowly from a lying or sitting position, to avoid dizziness.
 ● Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, and alertness.
 ● Tell patient to discontinue drug at least 10 days before elective surgery.
 ● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and behaviors mentioned above.

### FDA BOXED WARNING

- Severe and sometimes fatal hepatitis has occurred, even after many months of treatment. Risk increases with age until 64, then decreases after age 65. Risk also rises with daily alcohol consumption. Monitor patients carefully and interview them monthly. For persons aged 35 and older, also measure liver enzymes before therapy starts and periodically throughout. Isoniazid-associated hepatitis usually arises during first 3 months of therapy. Hepatitis risk also increases with daily alcohol use, chronic hepatic disease, and injection drug use. Recent report suggests increased risk of fatal hepatitis among women; risk may also increase during postpartum period. If adverse effects or signs and symptoms of hepatic damage occur, discontinue drug promptly.

- Tuberculosis patients with isoniazid-associated hepatitis should receive appropriate treatment with alternative drugs. If isoniazid must be restarted, do so only after symptoms and laboratory abnormalities resolve. Restart in small and gradually increasing doses, and withdraw drug immediately at any indication of recurrent liver involvement. Defer preventive treatment in patients with acute hepatic disease.

### Action

Inhibits cell-wall biosynthesis by interfering with lipid and nucleic acid DNA synthesis in tubercle bacilli cells

### Availability

**Injection:** 100 mg/ml
**Syrup:** 50 mg/5 ml
**Tablets:** 100 mg, 300 mg

### Indications and dosages

- **Active tuberculosis (TB)**
  - **Adults:** 5 mg/kg P.O. or I.M. (maximum of 300 mg/day) daily as a single
dose, or 15 mg/kg (maximum of 900 mg/day) two to three times weekly; given with other agents

**Children**: 10 to 15 mg/kg P.O. or I.M. (maximum of 300 mg/day) daily as a single dose, or 20 to 40 mg/kg (maximum of 900 mg/day) two to three times weekly

➢ To prevent TB in patients exposed to active disease

**Adults**: 300 mg P.O. daily as a single dose for 6 to 12 months

**Children and infants**: 10 mg/kg P.O. daily as a single dose for up to 12 months

**Off-label uses**
- *Mycobacterium kansasii* infection

**Contraindications**
- Hypersensitivity to drug
- Acute hepatic disease or previous hepatitis caused by isoniazid therapy

**Precautions**
Use cautiously in:
- severe renal impairment, diabetes, diabetic retinopathy, ocular defects, chronic alcoholism, hepatic damage
- Black or Hispanic women
- pregnant or breastfeeding patients
- children ages 13 and younger.

**Administration**
- Give on empty stomach 1 hour before or 2 hours after meals. If GI upset occurs, administer with food.
- Administer parenterally only if patient can’t receive oral form.
- Use cautiously in diabetic or alcoholic patients and those at risk for neuropathy.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O., I.M.</td>
<td>Rapid</td>
<td>1-2 hr</td>
<td>Up to 24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
CNS: peripheral neuropathy, dizziness, memory impairment, slurred speech, psychosis, toxic encephalopathy, seizures

**Interactions**

**Drug-drug.**
- *Aluminum-containing antacids*: decreased isoniazid absorption
- *Bacille Calmette-Guérin vaccine*: ineffective vaccination
- *Carbamazepine*: increased carbamazepine blood level
- *Disulfiram*: psychotic reactions, incoordination
- *Hepatotoxic drugs*: increased risk of hepatotoxicity
- *Ketoconazole*: decreased ketoconazole blood level and efficacy
- *Other antituberculars*: additive CNS toxicity
- *Phenytoin*: inhibition of phenytoin metabolism

**Drug-diagnostic tests.**
- *Albumin*: increased level

**Drug-food.**
- *Foods containing tyramine*: hypertensive crisis, other severe reactions

**Drug-behaviors.**
- *Alcohol use*: increased risk of hepatitis

**Patient monitoring**
- Assess hepatic enzyme levels.
- Watch for adverse reactions, such as peripheral neuropathy.

**Patient teaching**
- Advise patient to take once daily on empty stomach, 1 hour before or 2 hours after meals. If GI upset occurs, tell him to take with small amount of food.
• Caution patient to avoid foods containing tyramine (such as cheese, fish, salami, red wine, and yeast extracts), because drug-food interaction may cause chills, diaphoresis, and palpitations.
• Teach patient with peripheral neuropathy to take care to prevent burns and other injuries.
• Instruct patient to report anorexia, nausea, vomiting, jaundice, dark urine, and numbness or tingling of hands or feet.
• Tell patient he’ll need periodic medical and eye examinations and blood tests to gauge drug effects.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and behaviors mentioned above.

Isoproterenol hydrochloride
Isuprel

Pharmacologic class: Sympathomimetic, beta1-adrenergic and beta2-adrenergic agonist

Therapeutic class: Vasopressor, bronchodilator, antiasthmatic

Pregnancy risk category C

Action
Acts on beta2-adrenergic receptors, causing relaxation of bronchial smooth muscle; acts on beta1-adrenergic receptors in heart, causing positive inotropic and chronotropic effects and increasing cardiac output. Also lowers peripheral vascular resistance in skeletal muscle and inhibits antigen-induced histamine release.

Availability
Injection: 20 mcg/ml, 200 mcg/ml

Indications and dosages
➢ Shock
Adults and children: 0.5 to 5 mcg/minute by continuous I.V. infusion
➢ Heart block; ventricular arrhythmias
Adults: Initially, 0.02 to 0.06 mg I.V., then 0.01 to 0.2 mg I.V. or 5 mcg/minute I.V. Or initially, 0.2 mg I.M., then 0.02 to 1 mg I.M., depending on response. Or initially, 0.2 mg subcutaneously, then 0.15 to 0.2 mg subcutaneously, depending on response.
➢ Bronchospasm during anesthesia
Adults: 0.01 to 0.02 mg I.V., repeated when necessary

Contraindications
• Angina pectoris
• Angle-closure glaucoma
• Tachyarrhythmias
• Tachycardia or heart block caused by digitalis intoxication
• Ventricular arrhythmias that warrant inotropic therapy
• Labor, delivery, breastfeeding

Precautions
Use cautiously in:
• renal impairment, unstable vasomotor disorders, hypertension, coronary insufficiency, chronic obstructive pulmonary disease, diabetes mellitus, hyperthyroidism
• history of cerebrovascular accident or seizures
• elderly patients.

Administration
• Give each 0.02-mg I.V. dose by direct injection over 1 minute, or by I.V. infusion, as ordered. Always use continuous infusion pump to deliver infusion.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>Unknown</td>
<td>&lt;1 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>Subcut.</td>
<td>Immediate</td>
<td>Unknown</td>
<td>2hr</td>
</tr>
</tbody>
</table>

Reactions in bold are life-threatening.
Adverse reactions
CNS: tremors, anxiety, insomnia, headache, dizziness, asthenia, nervousness
CV: palpitations, tachycardia, angina, rapid blood pressure changes, arrhythmias, cardiac arrest, Stokes-Adams attacks
EENT: pharyngitis, visual blurring
GI: nausea, vomiting, heartburn
Metabolic: hyperglycemia
Respiratory: bronchitis, dyspnea, increased sputum, pulmonary edema, bronchospasm
Skin: diaphoresis
Other: parotid gland swelling (with prolonged use), pallor

Interactions
Drug-drug. Cyclopropane, epinephrine, halogenated general anesthetics: increased risk of arrhythmias
Propranolol, other beta-adrenergic blockers: antagonism of bronchodilating effects
Drug-diagnostic tests. Glucose: increased level

Patient monitoring
• During I.V. administration, monitor ECG and vital signs carefully.
• Assess patient's response to drug and adjust I.V. infusion rate accordingly.
• Closely monitor arterial blood gas values, urine output, and central venous pressure.
⚠️ Stay alert for rebound bronchospasm.

Patient teaching
• Assure patient that he'll be monitored closely.

isosorbide dinitrate

isosorbide mononitrate
Angeze®, Chemydur®, Cibral®, Cibral XL®, Dynamin®, Dynamin XL®, Elantan®, Elantan LA®, Imazin XL®, Imdur®, Imo LA®, Isib®, ISMO, Isodur®, Ketanodur®, Modisal®, Monigen®, Monigen XL®, Monit®, Monit LS®, Monoket, Monox®®, Monoxam SR®, Monomax XL®, Monomil®, Monosorb®, Trangina®, Trangina XL®, Xismox®, Zemon®, Zemon XL®

Pharmacologic class: Nitrate
Therapeutic class: Antianginal
Pregnancy risk category C

Action
Promotes peripheral vasodilation and reduces preload and afterload, decreasing myocardial oxygen consumption and increasing cardiac output. Also dilates coronary arteries, increasing blood flow and improving collateral circulation.

Availability
isosorbide dinitrate
Capsules: 40 mg
Capsules (extended-release): 40 mg
Tablets: 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg
Tablets (chewable): 5 mg, 10 mg
Tablets (extended-release): 20 mg, 40 mg
Tablets (sublingual): 2.5 mg, 5 mg, 10 mg
isosorbide mononitrate
Tablets: 10 mg, 20 mg
**Indications and dosages**

> Treatment and prophylaxis in situations likely to provoke acute angina pectoris

**Adults:** 2.5 to 5 mg S.L. May repeat dose q 5 to 10 minutes for a total of three doses in 15 to 30 minutes.

> Prophylaxis of angina pectoris

**Adults:** 5 to 40 mg P.O. (dinitrate conventional tablets) two to three times daily. Or 5 to 20 mg (mononitrate conventional tablets) b.i.d. Or 30 to 60 mg (mononitrate extended-release tablets) once daily. After several days, dosage may be increased to 120 mg (given as single 120-mg tablet or two 60-mg tablets) once daily. Rarely, 240 mg/day (mononitrate extended-release tablets) may be needed.

**Off-label uses**

- Heart failure

**Contraindications**

- Hypersensitivity to drug
- Severe anemia
- Acute myocardial infarction
- Angle-closure glaucoma
- Concurrent sildenafil therapy

**Precautions**

Use cautiously in:
- head trauma, volume depletion
- elderly patients
- pregnant or breastfeeding patients
- children.

**Administration**

- Give oral form 30 minutes before or 1 to 2 hours after a meal. Make sure patient swallows tablets or capsules whole.
- Have patient wet S.L. tablet with saliva before placing it under tongue. To avoid tingling sensation, have him place tablet in buccal pouch.

---

### Route Onset Peak Duration

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O. (dinitrate)</td>
<td>15-40 min</td>
<td>Unknown</td>
<td>4 hr</td>
</tr>
<tr>
<td>P.O. (dinitrate, extended)</td>
<td>30 min</td>
<td>Unknown</td>
<td>≤12 hr</td>
</tr>
<tr>
<td>P.O. (mononitrate)</td>
<td>30-60 min</td>
<td>Unknown</td>
<td>7 hr</td>
</tr>
<tr>
<td>P.O. (mononitrate, extended)</td>
<td>Unknown</td>
<td>Unknown</td>
<td>12 hr</td>
</tr>
<tr>
<td>S.L. (dinitrate)</td>
<td>2-5 min</td>
<td>Unknown</td>
<td>1-2 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** dizziness, headache, apprehension, asthenia, syncope

**CV:** orthostatic hypotension, tachycardia, paradoxical bradycardia, rebound hypertension

**EENT:** sublingual burning (with S.L. route)

**GI:** nausea, vomiting, dry mouth, abdominal pain

**Skin:** flushing

**Interactions**

**Drug-drug.** *Aspirin:* increased isosorbide blood level and effects

*Beta-adrenergic blockers, calcium channel blockers, phenothiazines:* additive hypotension

*Dihydroergotamine:* antagonism of dihydroergotamine effects

*Sildenafil:* severe and potentially fatal hypotension

**Drug-diagnostic tests.** *Cholesterol:* decreased level

*Methemoglobin, urine vanillylmandelic acid:* increased levels

**Patient monitoring**

- Monitor ECG and vital signs closely, especially blood pressure.

⚠️ In suspected overdose, assess for signs and symptoms of increased intracranial pressure.
Monitor arterial blood gas values and methemoglobin levels.

**Patient teaching**
- Teach patient to take oral drug 30 minutes before or 1 to 2 hours after a meal.
- Inform patient that drug may cause headache. Advise him to treat headache as usual and not to alter drug schedule. If headache persists, tell him to contact prescriber.
- Instruct patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness from sudden blood pressure decrease.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

---

**isradipine**
DynaCirc CR, Prescal

**Pharmacologic class:** Calcium channel blocker  
**Therapeutic class:** Antihypertensive  
**Pregnancy risk category C**

**Action**
Inhibits calcium ion movement across cell membranes of cardiac and arterial muscles, relaxing coronary and peripheral vascular smooth muscle. This action reduces diastolic blood pressure, enhances left ventricular function, and improves ejection rates; it also reduces mean vascular and systemic vascular resistance, increasing cardiac output and improving stroke volume.

**Availability**
Capsules: 2.5 mg, 5 mg  
Tablets (controlled-release): 5 mg, 10 mg

**Indications and dosages**
- **Hypertension**

**Adults:** Initially, 2.5 mg P.O. b.i.d. as monotherapy or combined with a thiazide diuretic (regular-release capsules); may increase in increments of 5 mg/day at 2- to 4-week intervals, to a maximum of 20 mg/day. Or, 5 to 10 mg P.O. (controlled-release) daily as monotherapy or combined with a thiazide diuretic.

**Contraindications**
- Hypersensitivity to drug or other calcium channel blockers

**Precautions**
Use cautiously in:
- heart disease, hypotension, hepatic or renal disease, GI hypermotility or obstruction (controlled-release form)
- concurrent use of beta-adrenergic blockers
- elderly patients
- pregnant or breastfeeding patients
- children.

**Administration**
- Give with or without food.
- Don’t give with grapefruit juice.
- Don’t crush or break controlled-release tablets. Make sure patient swallows them whole.

**Adverse reactions**
- **CNS:** dizziness, headache, fatigue, syncope, sleep disturbances
- **CV:** peripheral edema, tachycardia, hypotension, chest pain, **arrhythmias**
- **GI:** nausea, vomiting, constipation, abdominal pain or distention, dry mouth
- **GU:** nocturia, urinary frequency
- **Hematologic:** leukopenia
- **Hepatic:** hepatitis
- **Skin:** rash, pruritus, urticaria
- **Other:** flushing

---

- Canada  
- UK  
- Hazardous drug  
- High alert drug
Interactions

Drug-drug. Atracurium, gallamine, pancuronium, tubocurarine, vecuronium: increased respiratory depression
Beta-adrenergic blockers: increased cardiac depression
Carbamazepine, digoxin, prazosin, quinidine: increased blood levels of these drugs

Drug-food. Grapefruit juice: increased drug absorption

Patient monitoring
- Monitor vital signs closely, especially blood pressure.
- Assess liver function test results.
- Monitor for arrhythmias and peripheral edema.

Patient teaching
- Tell patient he may take with or without food, but not with grapefruit juice.
- Instruct patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness from sudden blood pressure decrease.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Teach patient with heart, kidney, or liver disease to watch for and promptly report adverse reactions.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and foods mentioned above.

FDA BOXED WARNING
- Don’t administer capsules to treat onychomycosis in patients with evidence of ventricular dysfunction, such as current or previous heart failure. If heart failure signs or symptoms occur during therapy, discontinue drug.
- Concurrent use of cisapride, dofavastilide, levactylmethadol (levome-thadyl), pimozone, or quinidine with itraconazole capsules or oral solution is contraindicated. Itraconazole is a potent CYP3A4 inhibitor and may raise blood levels of drugs metabolized by this pathway. Serious cardiovascular events (including QT prolongation, torsades de pointes, ventricular tachycardia, cardiac arrest, and sudden death) have occurred in patients taking these drugs concurrently with itraconazole.

Action
Prevents ergosterol synthesis in fungal cell membranes, altering membrane permeability

Availability
Capsules: 100 mg
Oral solution: 10 mg/ml

Indications and dosages
- Aspergillosis; blastomycosis; histoplasmosis
Adults: 200 to 400 mg P.O. daily for at least 3 months until patient is cured. In life-threatening infections, loading dose of 200 mg P.O. t.i.d. for 3 days, then 200 to 400 mg P.O. daily until cured.
- Esophageal candidiasis
Adults: 100 to 200 mg of oral solution daily, swished in mouth for several seconds and swallowed, for at least 3 weeks; continue for 2 weeks after symptoms resolve.
- Oropharyngeal candidiasis
Adults: 200 mg of oral solution daily, swished in mouth for several seconds and swallowed, for 1 to 2 weeks
Onychomycosis; tinea unguium

Adults: For toenails, 200 mg P.O. daily for 12 weeks. For fingernails, 200 mg b.i.d. for 1 week; wait 3 weeks, then repeat dosage for 1 week.

Contraindications
- Hypersensitivity to drug or its components
- Fungal meningitis
- Ventricular dysfunction, heart failure (in onychomycosis use)
- Concomitant use of astemizole, cisapride, dofetilide, lovastatin, midazolam, pimozide, quinidine, simvastatin, or triazolam
- Pregnancy or anticipated pregnancy (in onychomycosis use)

Precautions
Use cautiously in:
- hypersensitivity to other azole derivatives
- renal impairment (with I.V. use), hepatic disorders, achlorhydria, hypochlorhydria
- breastfeeding patients
- children (safety and efficacy not established).

Administration
- Obtain specimens for fungal cultures, as needed, before starting therapy.
- Administer capsule with a full meal.
- Give oral solution without food when possible.
- Be aware that liquid and tablets aren’t interchangeable.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Slow</td>
<td>4-6 hr</td>
<td>4-6 days</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, headache, fatigue, malaise
CV: peripheral edema, tachycardia, heart failure
EENT: rhinitis
GI: nausea, vomiting, constipation, abdominal pain, flatulence, anorexia, dyspepsia
GU: albuminuria, erectile dysfunction
Hepatic: jaundice, hepatotoxicity (including hepatic failure and death)
Metabolic: hypokalemia
Musculoskeletal: myalgia, bursitis, rhabdomyolysis
Respiratory: pulmonary edema
Skin: flushing, rash, pruritus, urticaria, increased sweating, herpes zoster infection
Other: fever, pain

Interactions
Drug-drug. Alfentanil, antihistamines (minimally sedating agents, such as fexofenadine, loratadine), antineoplastics (busulfan, docetaxel, vinca alkaloids), anxiolytics, benzodiazepines, cyclosporine, delavirdine, digoxin, immunosuppressants, methylprednisolone, protease inhibitors, tacrolimus, tolterodine, tretinoin: increased blood levels of these drugs
Amiodarone, anabolic steroids, androgens, antithyroid drugs, carmustine, chloroquine, dantrolene, daunorubicin, disulfiram, estrogens, gold salts, hormonal contraceptives, hydroxychloroquine, mercaptopurine, methotrexate, methylprednisolone, naltrexone (with long-term use), valproic acid: increased risk of hepatic damage
Amphotericin B: reduced or inhibited amphotericin B effects
Antacids, anticonvulsants, antituberculosis, cyclophosphamide, histamine2-receptor blockers, isoniazid, proton pump inhibitors (such as lansoprazole, omeprazole), reverse transcriptase inhibitors, sucralose: reduced itraconazole blood level
Antipsychotics, antiarrhythmics (such as quinidine, dofetilide), anxiolytics, astemizole, cisapride: increased risk of serious cardiovascular effects
Calcium channel blockers: increased risk of edema, possible increase in itraconazole’s effect
Carbamazepine, carbipoda, levodopa: altered blood levels of these drugs

Canada UK Hazardous drug High alert drug
Didanosine, vinblastine, vincristine, xanthine bronchodilators: decreased efficacy of these drugs

Digoxin: increased digoxin blood level, possible digoxin toxicity

HMG-CoA reductase inhibitors, miconazole: inhibited metabolism of these drugs, increased risk of skeletal muscle toxicity (including rhabdomyolysis)

Macrolide antibiotics: increased itraconazole blood level

Oral hypoglycemics: severe blood glucose decrease

Quetiapine, sildenafil: increased efficacy of these drugs

Warfarin: enhanced anticoagulant effect

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, blood urea nitrogen, gamma-glutamyltransferase, serum creatinine: increased levels

Potassium, magnesium: decreased levels

Drug-food. Any food, cola: increased itraconazole blood level

Grapefruit juice: decreased blood level and reduced therapeutic effects of itraconazole

Drug-herbs. Chaparral, comfrey, germander, jin bu huan, kava: increased risk of hepatic damage

Drug-behaviors. Alcohol consumption: toxic reaction, hepatic damage

Patient monitoring

• In patient with hepatic dysfunction, monitor hepatic enzyme levels.
  ☢️ Monitor for signs and symptoms of hepatic dysfunction (jaundice, fatigue, nausea, vomiting, dark urine, pale stools), heart failure, muscle disorder, and pulmonary or peripheral edema.

• Monitor potassium level. Stay alert for hypokalemia.

Patient teaching

• Tell patient he may take capsule with a full meal. If he's using oral solution, advise him to take it without food.

• Inform patient that drug interacts with many other drugs. Advise him to tell all prescribers he's taking it.

• Teach patient to recognize and immediately report signs and symptoms of hepatic dysfunction, persistent muscle pain, and heart failure.

•Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

• Advise female patient of childbearing potential to use effective contraception during and for 1 month after therapy. Caution her not to breastfeed.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

ketoconazole

Apo-Ketoconazole®, Dactarin Gold®, Dandrazol®, Extina, Kryoxol, Nizoral, Nizoral A-D, Novo-Ketoconazole®, Nu-Ketocon®, Nu-Ketoconazole®, Ratio-Ketoconazole®, Xolegel

Pharmacologic class: Imidazole

Therapeutic class: Antifungal

Pregnancy risk category C

FDA BOXED WARNING

• Oral form has been linked to hepatic toxicity, including some deaths. Inform patient of this risk, and monitor closely.

• Concurrent use of astemizole, cisapride, or terfenadine with ketoconazole tablets is contraindicated, because
serious cardiovascular adverse events (including death, ventricular tachycardia, and torsades de pointes) have occurred.

**Action**
Alters fungal cell membranes, resulting in increased permeability, growth inhibition, and ultimately, cell death.

**Availability**
- Cream: 2%
- Shampoo: 1%, 2%
- Tablets: 200 mg

**Indications and dosages**
- **Blastomycosis; chronic mucocutaneous candidiasis; oral thrush; candiduria; coccidioidomycosis; histoplasmosis; chromomycosis; paracoccidioidomycosis; mucocutaneous or vaginal candidiasis**
  - **Adults:** 200 to 400 mg P.O. daily
  - **Children ages 2 and older:** 3.3 to 6.6 mg/kg P.O. as a single daily dose. Duration depends on infection: 1 to 2 weeks; other systemic mycoses, 6 months; recalcitrant dermatophyte infections involving glabrous skin, 4 weeks. Chronic mucocutaneous candidiasis requires maintenance therapy.
- **Scaling caused by dandruff or seborrheic dermatitis**
  - **Adults:** 2% shampoo applied topically twice weekly for 4 weeks, then as needed to control symptoms, with at least 3 days between applications; or 1% shampoo applied topically q 3 to 4 days for up to 8 weeks, then as needed to control dandruff.
- **Tinea corporis; tinea cruris; tinea versicolor; tinea pedis, cutaneous candidiasis**
  - **Adults:** 2% cream applied topically to affected areas daily for 2 weeks (except for tinea pedis, which may require 6 weeks of therapy)

**Contraindications**
- Hypersensitivity to drug or its components
- Concurrent oral astemizole, cisapride, triazolam, or terfenadine therapy

**Precautions**
Use cautiously in:
- renal or hepatic disease, achlorhydria
- pregnant or breastfeeding patients
- children younger than age 2.

**Administration**
- Apply cream to damp skin of affected area and wide surrounding area.
- To use shampoo, wet hair, then apply shampoo and massage into scalp for 1 minute. Leave on for 5 minutes before rinsing. Rinse and repeat, this time leaving shampoo on scalp for 3 minutes before rinsing.
- Don’t apply shampoo to broken or inflamed skin.
- In achlorhydria, dissolve 200-mg tablet in 4 ml of 0.2N hydrochloric acid solution.
- Withhold antacids for at least 2 hours after giving oral ketoconazole.

**Adverse reactions**
- CNS: headache, nervousness, dizziness, drowsiness, severe depression, suicidal ideation
- EENT: photophobia
- GI: nausea, vomiting, diarrhea, abdominal pain, anorexia
- GU: erectile dysfunction, gynecomastia
- Hematologic: purpura, hemolytic anemia, thrombocytopenia, leukopenia
- Hepatic: hepatotoxicity

Canada  UK  Hazardous drug  High alert drug
**Metabolic:** hyperlipidemia  
**Skin:** pruritus, rash, dermatitis, urticaria, severe irritation, stinging, alopecia, abnormal hair texture, scalp pustules, oily skin, dry hair and scalp  
**Other:** fever, chills, allergic reaction

**Interactions**  
**Drug-drug.** Antacids, anticholinergics, histamine₂-receptor antagonists: decreased ketoconazole absorption  
Cyclosporine: increased cyclosporine blood level  
Isoniazid, rifampin: increased ketoconazole metabolism  
Theophylline: decreased theophylline blood level  
Topical corticosteroids: increased corticosteroid absorption  
Triazolam (oral): increased triazolam effects  

**Drug-diagnostic tests.** Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase: increased levels  
Hemoglobin, platelets, white blood cells: decreased levels  

**Drug-herbs.** Yew: inhibited ketoconazole metabolism

**Patient monitoring**  
- Assess for suicidal ideation and signs and symptoms of depression.  
- Monitor for evidence of hepatotoxicity, such as nausea, fatigue, jaundice, dark urine, and pale stools.  
- With long-term therapy, stay alert for adrenal crisis.

**Patient teaching**  
- Advise patient to watch for signs and symptoms of depression and to immediately report suicidal thoughts.  
- Teach patient to recognize and immediately report signs and symptoms of hepatotoxicity, such as unusual tiredness or yellowing of skin or eyes.  
- Advise patient not to take antacids for at least 2 hours after oral ketoconazole.

- Instruct patient to apply cream to damp skin of affected area and wide surrounding area.  
- Tell patient to wet hair before applying shampoo and to massage into scalp for 1 minute; then leave on for 5 minutes before rinsing off. Tell him to shampoo again, leaving it on for 3 minutes this time before rinsing.  
- Caution patient not to apply shampoo to broken or inflamed skin.  
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

---

**ketorolac tromethamine**  
Acular, Acular LS, Apo-Ketorolac

**Pharmacologic class:** Nonsteroidal anti-inflammatory drug (NSAID)  
**Therapeutic class:** Analgesic, antipyretic, anti-inflammatory  
**Pregnancy risk category** C (first and second trimesters), D (third trimester)

**FDA BOXED WARNING**  
- Drug is indicated for short-term management (up to 5 days in adults) of moderately severe acute pain that requires opioid-level analgesia. It’s not indicated for minor or chronic painful conditions. Drug carries many risks; NSAID-related adverse events can be serious in certain patients, especially when used inappropriately. Raising dosage beyond recommendations increases risk of serious adverse events and won’t provide better efficacy.  
- Drug can cause peptic ulcers, GI bleeding, and perforation and is
contraindicated in patients with active peptic ulcer disease, recent GI bleeding or perforation, or history of peptic ulcer disease or GI bleeding.

- Drug is contraindicated in advanced renal impairment and patients at risk for renal failure.
- Drug inhibits platelet function and is contraindicated in patients with suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis, or high risk of bleeding.
- Drug is contraindicated as prophylactic analgesic before major surgery, and intraoperatively when hemostasis is critical.
- Hypersensitivity reactions ranging from bronchospasm to anaphylactic shock have occurred. Ensure that appropriate counteractive measures are available when giving first dose of injection form. Drug is contraindicated in known hypersensitivity to ketorolac or allergic reaction to aspirin or other NSAID.
- Drug is contraindicated for intrathecal or epidural administration (due to alcohol content), during labor and delivery (may impede fetal circulation and inhibit uterine contractions), in breastfeeding women (due to potential adverse effects of prostaglandin-inhibiting drugs on neonates), and in patients currently receiving aspirin or NSAIDs (due to cumulative risk of serious NSAID-related adverse effects).
- Tablet form is indicated only as continuation therapy to injection form, and combined duration of use of both forms mustn’t exceed 5 days.
- For tablets, recommended total daily dose (maximum 40 mg) is significantly lower than for injection (maximum 120 mg).
- Adjust dosage in patients age 65 and older, those weighing less than 50 kg (110 lb), and those with moderately elevated serum creatinine level. With injection form, don’t exceed 60 mg (total daily dose) in these patients. Injection form is indicated as single-dose therapy in pediatric patients, not to exceed 30 mg for I.M. use or 15 mg for I.V. use.

Action
Interferes with prostaglandin biosynthesis by inhibiting cyclooxygenase pathway of arachidonic acid metabolism; also acts as potent inhibitor of platelet aggregation

Availability
Injection: 15 mg/ml in 1-ml preloaded syringes, 30 mg/ml in 1- and 2-ml preloaded syringes
Ophthalmic solution: 0.4%, 0.5%
Tablets: 10 mg

Indications and dosages
Moderately severe acute pain
Adults younger than age 65: Initially, 30 mg I.V. or 60 mg I.M. as a single dose, or 30 mg I.M. or I.V. q 6 hours, not to exceed 120 mg/day. To switch to P.O. therapy, give 20 mg P.O. initially for patients who received single 30-mg I.V. or 60-mg I.M. dose, followed by 10 mg P.O. q 4 to 6 hours as needed (not to exceed 40 mg/day or 5 days).
Children ages 2 to 16: 1 mg/kg I.M. as a single dose, to a maximum of 30 mg; or one dose of 0.5 mg/kg I.V., to a maximum of 15 mg
Ocular itching caused by seasonal allergic conjunctivitis
Adults and children ages 3 and older: One drop of 0.5% ophthalmic solution (Acular) instilled into affected eye q.i.d.
Postoperative ocular inflammation related to cataract extraction
Adults and children ages 3 and older: One drop of 0.5% ophthalmic solution (Acular) instilled into operative eye q.i.d., starting 24 hours after surgery and continuing for 2 weeks
To reduce ocular pain, burning, or stinging after corneal refractive surgery
Adults and children ages 3 and older: One drop of 0.4% ophthalmic solution
Acular LS) instilled into operative eye q.i.d. for up to 4 days

**Dosage adjustment**
- Mild to moderate renal impairment
- Elderly patients
- Patients weighing less than 50 kg

**Contraindications**
- Hypersensitivity to drug, its components, aspirin, or other NSAIDs
- Concurrent use of aspirin, other NSAIDs, or probenecid
- Peptic ulcer disease
- GI bleeding or perforation
- Advanced renal impairment, risk of renal failure
- Increased risk of bleeding, suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis
- Prophylactic use before major surgery, intraoperative use when hemostasis is critical
- Labor and delivery
- Breastfeeding

**Precautions**
Use cautiously in:
- mild to moderate renal impairment, cardiovascular disease
- elderly patients
- pregnant patients
- children.

**Administration**
- Be aware that oral therapy is indicated only as continuation of parenteral therapy.
  - Know that parenteral therapy shouldn’t exceed 20 doses in 5 days.
- For I.V. use, dilute with normal saline solution, dextrose 5% in water, dextrose 5% and normal saline solution, Ringer’s solution, or lactated Ringer’s solution.
- Administer single I.V. bolus over 1 to 2 minutes.
- Inject I.M. dose slowly and deeply.
- Don’t give by epidural or intrathecal injection.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2-3 hr</td>
<td>≥4-6 hr</td>
</tr>
<tr>
<td>I.V., I.M.</td>
<td>10 min</td>
<td>1-2 hr</td>
<td>≥6 hr</td>
</tr>
<tr>
<td>Ophthalmic</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- CNS: drowsiness, headache, dizziness
- CV: hypertension
- EENT: tinnitus
- GI: nausea, vomiting, diarrhea, constipation, flatulence, dyspepsia, epigastric pain, stomatitis
- Hematologic: thrombocytopenia
- Skin: rash, pruritus, diaphoresis
- Other: excessive thirst, edema, injection site pain

**Interactions**
- **Drug-drug.** Angiotensin-converting enzyme inhibitors, beta-adrenergic blockers: decreased antihypertensive effect
  - Anticoagulants: prolonged prothrombin time
  - Aspirin: altered ketorolac distribution, metabolism, and excretion; increased risk of serious adverse reactions
  - Cholestyramine: decreased ketorolac absorption
  - Corticosteroids, other NSAIDs: additive adverse GI effects
  - Diuretics: decreased diuretic effect
  - Hydantoins, lithium: increased blood levels and greater risk of toxicity of these drugs
  - Methotrexate: increased risk of methotrexate toxicity
  - Probenecid: increased risk of ketorolac toxicity

- **Drug-diagnostic tests.** Bleeding time: prolonged for 24 to 48 hours after therapy ends

- **Drug-herbs.** Anise, arnica, chamomile, clove, dong quai, feverfew, garlic, ginger, ginkgo, ginseng: increased risk of bleeding

Reactions in **bold** are life-threatening.

Clinical alert
Patient monitoring
- Monitor for adverse reactions, especially prolonged bleeding time and CNS reactions.
- Check I.M. injection site for hematoma and bleeding.
- Monitor fluid intake and output.

Patient teaching
- Inform patient that drug is meant only for short-term pain management.
- Tell patient to immediately report bleeding and adverse CNS reactions.
- Advise patient to minimize GI upset by eating small, frequent servings of healthy foods.
- Instruct patient to avoid aspirin products and herbs during therapy.
- Teach patient how to use eye drops, if prescribed.
- Caution female patient not to take drug if she is breastfeeding.
- Advise patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

Action
Blocks stimulation of beta<sub>1</sub>- and beta<sub>2</sub>-adrenergic receptor sites and alpha<sub>1</sub>-adrenergic receptors, decreasing myocardial contractile force and enhancing coronary artery blood flow and myocardial perfusion. Net effect is decreased heart rate and blood pressure.

Availability
Injection: 5 mg/ml
Tablets: 100 mg, 200 mg, 300 mg

Indications and dosages
- Hypertension
  - Adults: Initially, 100 mg P.O. b.i.d., alone or combined with a diuretic; may increase by 100 mg b.i.d. q 2 to 3 days as needed. Usual range is 400 to 800 mg/day in two divided doses; up to 2.4 g/day have been given.
  - Hypertensive crisis
  - Adults: Initially, 20 mg I.V. bolus over 2 minutes, then I.V. injection of 40 to 80 mg q 10 minutes until blood pressure falls to desired level; maximum dosage is 300 mg. Alternatively, 50 to 200 mg by continuous I.V. infusion at 2 mg/minute; continue infusion until desired blood pressure is reached. Follow I.V. dosing with P.O. dosing.
  - Conversion from I.V. to P.O. dosing
  - Hospitalized adults: Discontinue I.V. therapy when desired blood pressure is reached; start P.O. dosing when supine diastolic pressure begins to rise. Initial P.O. dosage is 200 mg, followed 6 to 12 hours later with additional dose of 200 to 400 mg P.O., depending on blood pressure response. Then titrate at 1-day intervals to dosage ranging from 400 to 2,400 mg/day P.O. in two or three divided doses.

Dosage adjustment
- Chronic hepatic disease
- Elderly patients
Off-label uses
- Hypertension secondary to pheochromocytoma or clonidine withdrawal

Contraindications
- Hypersensitivity to drug
- Bronchospastic disease
- Overt heart failure, cardiogenic shock
- Second- or third-degree atrioventricular block
- Severe bradycardia
- Conditions associated with severe and prolonged hypotension

Precautions
Use cautiously in:
- hepatic impairment, pulmonary disease, diabetes mellitus, hyperthyroidism, thyrotoxicosis
- elderly patients
- pregnant or breastfeeding patients
- children.

Administration
- Know that drug may be given as I.V. bolus or continuous infusion.
- Be aware that drug may be given undiluted for I.V. bolus injection. For continuous infusion, dilute in dextrose 5% in water or normal saline solution, and deliver with infusion control pump.
- Don’t mix with 5% sodium bicarbonate injection.
- Give direct I.V. injection over 2 minutes at 10-minute intervals.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>20 min-2 hr</td>
<td>1-4 hr</td>
<td>8-12 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>2-5 min</td>
<td>5 min</td>
<td>16-18 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: fatigue, asthenia, anxiety, depression, dizziness, paresthesia, drowsiness, insomnia, memory loss, nightmares, mental status changes
CV: orthostatic hypotension, peripheral vasoconstriction, bradycardia, arrhythmias, heart failure

EENT: blurred vision, dry eyes, nasal congestion
GI: nausea, diarrhea, constipation
GU: erectile dysfunction, decreased libido
Hematologic: purpura, agranulocytosis, thrombocytopenia
Metabolic: hyperglycemia, hypoglycemia
Musculoskeletal: joint pain, back pain, muscle cramps
Respiratory: wheezing, bronchospasm, pulmonary edema
Skin: rash, pruritus

Interactions
Drug-drug. Adrenergic bronchodilators, theophylline: decreased efficacy of these drugs
Antihypertensives, nitrates: additive hypotension
Cimetidine, propranolol: increased labetalol effects
Digoxin: additive bradycardia
Dobutamine, dopamine: reduced beneficial cardiovascular effects of these drugs
General anesthetics, verapamil: additive myocardial depression
Insulin, oral hypoglycemics: altered hypoglycemic efficacy
MAO inhibitors: hypertension
Nonsteroidal anti-inflammatory drugs: decreased antihypertensive action

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, antinuclear antibodies, aspartate aminotransferase, blood urea nitrogen, glucose, liver function tests, low-density lipoproteins, potassium, triglycerides, uric acid: increased values

Patient monitoring
- Monitor ECG and vital signs, especially blood pressure.
- Assess cardiovascular, respiratory, and neurologic status closely to detect adverse reactions.
- Monitor CBC, blood glucose level, and liver function tests.
Patient teaching

- Instruct patient to immediately report adverse reactions, such as easy bruising or bleeding or respiratory problems.
- Tell patient he may feel dizzy when starting therapy, especially if he’s also taking a diuretic.
- Advise patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness from sudden blood pressure decrease.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, and alertness.
- Emphasize need for follow-up care and regular blood pressure monitoring.

- Caution patient not to stop taking drug abruptly, because this may cause myocardial infarction or worsen angina.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

lactulose


Pharmacologic class: Osmotic
Therapeutic class: Laxative
Pregnancy risk category B

Action

Produces osmotic effect, which increases water content in colon and enhances peristalsis. Breakdown products in colon lead to acidification of colonic contents, softening of feces, and decreased ammonia absorption from colon to systemic circulation. These effects reduce blood ammonia level in portal-system encephalopathy.

Availability

Powder (single-use packets): 10 g, 20 g
Syrup: 10 g/15 ml

Indications and dosages

Constipation
Adults: 10 to 20 g (15 to 30 ml) P.O. daily; may increase to 60 ml daily p.r.n.

Portal-system encephalopathy
Adults: 20 to 30 g (30 to 45 ml) P.O. three or four times daily until two or three soft stools are produced daily. Therapy may continue over long term. Or, 300 ml P.O. with 700 ml of water or normal saline solution. Or, as retention enema by rectal balloon catheter, repeated q 4 to 6 hours.

Contraindications

- Patients requiring low-galactose diet

Precautions

Use cautiously in:
- diabetes mellitus
- elderly patients
- pregnant or breastfeeding patients
- children.

Administration

- Don’t give concurrently with other laxatives.
- Dilute contents of single-use packet in 4 oz of water or juice.
- Dilute syrup with water or fruit juice to mask taste.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>24-48 hr</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

GI: nausea, vomiting, diarrhea, intestinal cramps, abdominal distention, flatulence
Metabolic: hyperglycemia (in diabetic patients), hypokalemia, hypernatremia

Interactions
Drug-drug. Anti-infectives: decreased lactulose efficacy
Other laxatives: interference with response to lactulose (in patients with hepatic encephalopathy)
Drug-diagnostic tests. Blood ammonia: 25% to 50% decrease
Glucose: increased level (in diabetic patients)
Potassium: decreased level
Sodium: increased level

Patient monitoring
• Watch for adverse GI reactions.
• Check stool consistency and frequency.
• Monitor electrolyte levels, especially in elderly patients.
• Check blood glucose level in diabetic patients.

Patient teaching
• Instruct patient to dissolve contents of single-use packet in 4 oz of water or juice.
• Suggest that patient dilute syrup with water or juice to mask taste.
• Tell patient drug may cause flatulence and intestinal cramps at first, but these symptoms usually subside.
• Inform patient that excessive use may cause diarrhea and excessive fluid loss.
• Encourage patient to drink adequate fluids and to report signs and symptoms of dehydration.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

lamivudine
Epivir, Epivir-HBV, 3TC, Heptovir, Zeffix
Pharmacologic class: Nucleoside reverse transcriptase inhibitor
Therapeutic class: Antiretroviral
Pregnancy risk category C

FDA BOXED WARNING
• Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have occurred when drug was used alone or in combination with other nucleoside analogues.
• Epivir tablets and oral solution (used to treat human immunodeficiency virus [HIV] infection) contain higher dose of active ingredient (lamivudine) than Epivir-HBV tablets and oral solution (used to treat chronic hepatitis B). Patients with HIV should receive only dosing forms appropriate for HIV treatment.
• After Epivir discontinuation, severe acute hepatitis B exacerbations have occurred in patients co-infected with hepatitis B virus (HBV) and HIV. Monitor hepatic function closely for at least several months in these patients. If appropriate, begin anti–hepatitis B therapy.

Action
Inhibits HIV reverse transcription by viral DNA chain termination. Impedes RNA- and DNA-dependent DNA polymerase activities.

Availability
Oral solution: 5 mg/ml and 10 mg/ml in 240-ml bottles
Tablets: 100 mg, 150 mg, 300 mg

Reactions in bold are life-threatening.
Indications and dosages

➢ HIV infection (given with other antiretrovirals)

Adults and children older than age 16: 150 mg P.O. b.i.d. or 300 mg P.O. daily

Children ages 3 months to 16 years: 4 mg/kg P.O. b.i.d. to a maximum of 150 mg P.O. b.i.d.

➢ Chronic HBV

Adults: 100 mg (Epivir-HBV) P.O. once daily

Children ages 2 to 17: 3 mg/kg (Epivir-HBV) P.O. once daily, to a maximum of 100 mg P.O. daily

Dosage adjustment

● Renal impairment

Contraindications

● Hypersensitivity to drug or its components

Precautions

Use cautiously in:

● impaired renal function, history of hepatic disease, obesity, granulocyte count below 1,000/mm³

● long-term therapy

● elderly patients

● women (especially if pregnant)

● children.

Administration

● Give with or without food.

Be aware that Epivir contains 150 mg lamivudine and Epivir-HBV contains 100 mg lamivudine. Strengths are not interchangeable.

Know that when given to patients with unrecognized or untreated HIV, Epivir-HBV is likely to cause rapid emergence of HIV resistance.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>0.9 hr</td>
<td>12 hr</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: fatigue, headache, insomnia, malaise, asthenia, depression, dizziness, paresthesia, peripheral neuropathy, seizures

GI: nausea, vomiting, diarrhea, anorexia, abdominal discomfort, dyspepsia, splenomegaly, pancreatitis

Hematologic: anemia, neutropenia

Hepatic: hepatomegaly with steatosis

Metabolic: hyperglycemia, lactic acidosis

Musculoskeletal: muscle, joint, or bone pain; muscle weakness; myalgia; rhabdomyolysis

Respiratory: cough, abnormal breath sounds, wheezing

Skin: alopecia, rash, urticaria, erythema multiforme, Stevens-Johnson syndrome

Other: lymphadenopathy, body fat redistribution, hypersensitivity reactions including anaphylaxis

Interactions

Drug-drug. Co-trimoxazole: increased lamivudine blood level

Zalcitabine: interference with effects of both drugs

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, creatine kinase, liver function tests: increased levels

Hemoglobin, hematocrit, neutrophils: decreased levels

Patient monitoring

● Check vital signs regularly.

● Monitor CBC and platelet count frequently. Watch for evidence of bone marrow toxicity.

● Monitor blood glucose level and kidney and liver function test results.

● Assess neurologic and mental status. Report signs or symptoms of depression.

● Closely monitor obese patients, women, and patients with a history of hepatic disease; they’re at increased risk for lactic acidosis and severe hepatomegaly with steatosis.

● Monitor HIV patients for co-infection
with HBV (which may recur when drug is withdrawn).

**Patient teaching**
- Tell patient he may take with or without food.
- Advise patient to minimize GI upset by eating small, frequent servings of healthy food and drinking plenty of fluids.
- Tell HIV patient that drug doesn’t cure virus or prevent its transmission and that opportunistic infections may occur. Advise him to take appropriate precautions during sex.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Caution HIV patient not to breastfeed, because of risk of passing infection to infant.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**lamotrigine**

Apo-Lamotrigine®, Gen-Lamotrigine®, Lamictal, Lamictal Chewable Dispersible, Novo-Lamotrigine®, PMS-Lamotrigine®, Ratio-Lamotrigine®

**Pharmacologic class:** Phenyltriazine  
**Therapeutic class:** Anticonvulsant  
**Pregnancy risk category C**

**FDA BOXED WARNING**
- Drug has been linked to serious rashes (including Stevens-Johnson syndrome) requiring hospitalization and drug discontinuation; one rash-related death occurred. Rare postmarketing cases of toxic epidermal necrolysis and rash-related death have occurred worldwide. Nearly all cases of life-threatening rashes have arisen within 2 to 8 weeks of treatment initiation. However, isolated cases have been reported after prolonged treatment (such as 6 months). Withdraw drug at first sign of rash, unless rash clearly isn’t drug-related. However, know that withdrawal may not prevent rash from becoming life-threatening or permanently disabling or disfiguring.

**Action**
Unknown. Thought to block sodium channel membranes, which in turn inhibits release of the neurotransmitters glutamate and aspartate in brain.

**Availability**
*Tablets:* 25 mg, 100 mg, 150 mg, 200 mg  
*Tablets (chewable):* 2 mg, 5 mg, 25 mg

**Indications and dosages**
- Partial seizures, generalized seizures of Lennox-Gastaut syndrome, and primary generalized tonic-clonic seizures in patients receiving valproate

**Adults and children ages 12 and older:**  
25 mg P.O. every other day during weeks 1 and 2; then 25 mg daily during weeks 3 and 4. Then week 5 onwards to maintenance, increase dosage by 25 to 50 mg/day every 1 to 2 weeks. Usual maintenance dosage is 100 to 400 mg/day in one or two divided doses. For those taking valproate alone, maximum dosage is 200 mg/day.

**Children ages 2 to 12:** 0.15 mg/kg/day P.O. (rounded down to nearest whole tablet) in one or two divided doses during weeks 1 and 2; then 0.3 mg/kg/day P.O. (rounded down to nearest whole tablet) in one or two divided doses during weeks 3 and 4. Then week 5 onwards to maintenance,
increase every 1 to 2 weeks as 0.3 mg/kg/day (rounded down to nearest whole tablet) added to previously administered daily dose. Usual maintenance dosage is 1 to 5 mg/kg/day. Maximum dosage is 200 mg/day in one or two divided doses. For patients taking valproate alone, maintenance dosage is 1 to 3 mg/kg/day. May need to increase maintenance dose by as much as 50% in patients weighing less than 30 kg (66 lb), based on clinical response.

Partial seizures, generalized seizures of Lennox-Gastaut syndrome, and primary generalized tonic-clonic seizures in patients receiving antiepileptic drugs (AEDs) other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate

Adults and children ages 12 and older: 25 mg P.O. every day during weeks 1 and 2; then 50 mg daily during weeks 3 and 4. Increase by 50 mg/day every 1 to 2 weeks. Usual maintenance dosage is 225 to 375 mg/day in two divided doses.

Children ages 2 to 12: 0.3 mg/kg/day P.O. in one or two divided doses (rounded down to nearest whole tablet) during weeks 1 and 2; then 0.6 mg/kg/day P.O. in two divided doses (rounded down to nearest whole tablet) during weeks 3 and 4. Then week 5 onwards to maintenance, increase every 1 to 2 weeks as 0.6 mg/kg/day (rounded down to nearest whole tablet) added to previously administered daily dose. Usual maintenance dosage is 4.5 to 7.5 mg/kg/day (maximum, 300 mg/day) in two divided doses. May need to increase maintenance dose by as much as 50% in patients weighing less than 30 kg, based on clinical response.

Conversion to monotherapy for seizures in patients receiving carbamazepine, phenytoin, phenobarbital, primidone, or valproate as a single agent

Adults and children ages 16 and older: Usual maintenance dosage is 500 mg/day P.O. in two divided doses.

Conversion from carbamazepine, phenytoin, phenobarbital, or primidone to monotherapy with lamotrigine for seizures

Adults and children ages 16 and older: 50 mg/day P.O. during weeks 1 and 2; then 100 mg/day in two divided doses during weeks 3 and 4. Then week 5 onwards to maintenance, increase by 100 mg/day every 1 to 2 weeks. Usual maintenance dosage is 300 to 500 mg/day in two divided doses. After achieving lamotrigine maintenance dosage of 500 mg/day P.O., withdraw
concomitant AED by 20% decrements each week over a 4-week period.

Conversion from adjunctive therapy with valproate to monotherapy with lamotrigine for seizures

Adults and children ages 16 and older:
Achieve lamotrigine dosage of 200 mg/day P.O. and maintain previous stable valproate dosage. Maintain lamotrigine dosage of 200 mg/day and decrease valproate dosage to 500 mg/day by decrements no greater than 500 mg/day; maintain regimen for 1 week. Then increase lamotrigine dosage 300 mg/day while simultaneously decreasing valproate to 250 mg/day; maintain regimen for 1 week. Then discontinue valproate completely and increase lamotrigine dosage by 100 mg/day every week to 500 mg/day.

Maintenance treatment of bipolar I disorder to delay time to occurrence of mood episodes in patients treated with standard therapy for acute mood episodes

Adults: Target dosage is 200 mg P.O. daily titrated over 7 weeks (or 100 mg daily in patients taking valproate, or 400 mg daily in patients not taking valproate who are receiving carbamazepine, rifampin, phenytoin, phenobarbital, or primidone). If other psychotropic drugs are withdrawn following stabilization, adjust lamotrigine dosage as indicated.

Dosage adjustment
● Moderate to severe hepatic dysfunction
● Renal impairment
● Heart disease
● Starting or stopping estrogen-containing oral hormonal contraceptives
● Concurrent use of valproate

Off-label uses
● Drug-resistant seizures
● Mood stabilization in rapid-cycling bipolar II disorder

Contraindications
● Hypersensitivity to drug or its components

Precautions
Use cautiously in:
● renal or hepatic impairment or other diseases or conditions that affect metabolism or elimination
● concurrent use of other anticonvulsants or estrogen-containing oral contraceptives
● history of allergy to or rash from other AEDs
● pregnant or breastfeeding patients
● children younger than age 2 children younger than age 18 with mood disorders (safety and efficacy).

Administration
● Give with or without food.
● Don’t crush or break regular tablets; make sure patient swallows them whole.
● Crush chewable tablets or mix in diluted fruit juice if patient can’t chew them.
● Be aware that effectiveness of drug in treating acute mood episodes hasn’t been established.

Be aware that abrupt drug withdrawal may induce seizures. If drug must be discontinued, decrease dosage by 50% per week over at least 2 weeks.

Don’t confuse Lamictal with other drugs having sound-alike names (such as Lamisil, Lomotil, and Ludiomil).

Route Onset Peak Duration
P.O. Unknown 1.4-4.8 hr Unknown

Adverse reactions
CNS: dizziness, vertigo, headache, drowsiness, ataxia, incoordination, insomnia, sleep disorders, tremor, depression, anxiety, irritability, impaired memory, poor concentration, emotional lability, racing thoughts, dysarthria, malaise, asthenia, somnolence, amnesia, hypoesthesia, decreased

Reactions in bold are life-threatening.
or increased reflexes, fatigue, migraine, dream abnormality, suicidal ideation, seizures
CV: palpitations, hemorrhage
EENT: diplopia, nystagmus, blurred vision, possible long-term ophthalmologic effects, ear disorder, rhinitis, episcleritis, sinusitis, pharyngitis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, dry mouth, anorexia, peptic ulcer, flatulence, rectal hemorrhage
GU: dysmenorrhea, amenorrhea, vaginitis, increased libido, urinary tract infection, urinary frequency, penis disorder
Musculoskeletal: muscle spasm, neck pain, back pain, arthralgia, myalgia
Respiratory: cough, dyspnea, bronchitis, bronchospasm
Skin: pruritus, contact dermatitis, dry skin, sweating, photosensitivity, eczema, alopecia, rash, urticaria, erythema multiforme, toxic epidermal necrolysis, Stevens-Johnson syndrome
Other: infection, pain, weight changes, chest pain, accidental injury, lymphadenopathy, flulike syndrome, fever, tooth disorder, edema, peripheral edema, facial edema, hypersensitivity reactions (rare) including anaphylaxis

Interactions
Drug-drug. Carbamazepine, phenobarbital, phenytoin, primidone: decreased lamotrigine steady-state level
Estrogen-containing oral contraceptives, rifampin: increased lamotrigine clearance
Folate inhibitors (such as methotrexate, co-trimoxazole): additive effects of lamotrigine
Topiramate: increased topiramate concentrations
Valproate: decreased lamotrigine clearance, increased steady-state level

Drug-diagnostic tests. Liver function tests: abnormal

Drug-behaviors. Sun exposure: photosensitivity

Patient monitoring
Watch for signs and symptoms of hypersensitivity reaction (Stevens-Johnson syndrome or anaphylaxis).
Monitor patient with bipolar disorder closely for clinical worsening and suicidality.
- Monitor vital signs regularly.
- Monitor CNS status carefully, noting adverse reactions and changes in seizure pattern.
- Monitor lamotrigine blood levels, especially during dosage adjustments.

Patient teaching
- Tell patient or caregiver that drug may be taken with or without food.
- Instruct patient or caregiver that regular tablets must be swallowed whole without crushing or breaking.
- Instruct patient or caregiver to crush chewable tablets or mix them in diluted fruit juice if patient can’t chew them. Tell patient to add dispersed tablets to approximately 1 teaspoon of liquid in glass or spoon, mix solution when tablets are completely dispersed, and then take entire amount immediately.
- Inform patient or caregiver that dosage is adjusted slowly, as indicated.
- Advise patient or caregiver to stop drug and notify prescriber immediately at first sign of rash.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.
**lansoprazole**
Prevacid, Prevacid SoluTab, Zoton®

**Pharmacologic class:** Gastric acid pump inhibitor  
**Therapeutic class:** Antiulcer drug  
**Pregnancy risk category B**

**Action**  
Inhibits activity of proton pump in gastric parietal cells, decreasing gastric acid production

**Availability**  
Capsules (delayed-release): 15 mg, 30 mg  
Granules for oral suspension (delayed-release, enteric-coated): 15 mg, 30 mg  
Prevpac (combination product for *Helicobacter pylori* infection): daily pack containing two 30-mg lansoprazole capsules, four 500-mg amoxicillin capsules, and two 500-mg clarithromycin tablets  
Prevacid NapraPAC 375 (combination product for reducing risk of ulcers from nonsteroidal anti-inflammatory drugs [NSAIDs]): weekly pack containing seven 15-mg Prevacid capsules and fourteen 375-mg Naprosyn tablets  
Prevacid NapraPAC 500 (combination product for reducing risk of ulcers from NSAIDs): weekly pack containing seven 15-mg Prevacid capsules and fourteen 500-mg Naprosyn tablets  
Prevacid SoluTab (delayed-release, orally disintegrating tablet): 15 mg, 30 mg

**Indications and dosages**

- **Active duodenal ulcer**  
  **Adults:** 15 mg P.O. daily for 4 weeks  
- **Maintenance of healed duodenal ulcer**  
  **Adults:** 15 mg P.O. daily  
- **H. pylori eradication, to reduce risk of duodenal ulcer recurrence**  
  **Adults:** In triple therapy, 30 mg lansoprazole P.O., 1 g amoxicillin P.O., and 500 mg clarithromycin P.O. q 12 hours for 10 or 14 days. In dual therapy, 30 mg lansoprazole P.O. and 1 g amoxicillin P.O. q 8 hours for 14 days.  
- **Benign gastric ulcer**  
  **Adults:** 30 mg P.O. daily for up to 8 weeks  
- **Gastric ulcer associated with NSAIDs**  
  **Adults:** 30 mg P.O. once daily for up to 8 weeks  
- **To reduce risk of NSAID-associated gastric ulcer**  
  **Adults:** 15 mg P.O. daily for up to 12 weeks  
- **Gastroesophageal reflux disease**  
  **Adults and children ages 12 to 17:** 15 mg P.O. daily for up to 8 weeks  
  **Children ages 1 to 11 weighing more than 30 kg (66 lb):** 30 mg P.O. daily for up to 12 weeks  
  **Children ages 1 to 11 weighing 30 kg (66 lb) or less:** 15 mg P.O. daily for up to 12 weeks  
- **Erosive esophagitis**  
  **Adults and children ages 12 to 17:** 30 mg P.O. daily for up to 8 weeks. Some patients may require 8 additional weeks.  
  **Children ages 1 to 11 weighing more than 30 kg (66 lb):** 30 mg P.O. daily for up to 12 weeks  
  **Children ages 1 to 11 weighing 30 kg (66 lb) or less:** 15 mg P.O. daily for up to 12 weeks  
- **To maintain healing of erosive esophagitis**  
  **Adults:** 15 mg P.O. daily  
- **Pathologic hypersecretory conditions (including Zollinger-Ellison syndrome)**  
  **Adults:** Initially, 60 mg P.O. daily, to a maximum of 90 mg P.O. b.i.d. Divide daily dosages over 120 mg.

Reactions in bold are life-threatening.  

---

**Clinical alert**

> H. pylori eradication, to reduce risk of duodenal ulcer recurrence  
> Adults: In triple therapy, 30 mg lansoprazole P.O., 1 g amoxicillin P.O., and 500 mg clarithromycin P.O. q 12 hours for 10 or 14 days. In dual therapy, 30 mg lansoprazole P.O. and 1 g amoxicillin P.O. q 8 hours for 14 days.  
> Benign gastric ulcer  
> Adults: 30 mg P.O. daily for up to 8 weeks  
> Gastric ulcer associated with NSAIDs  
> Adults: 30 mg P.O. once daily for up to 8 weeks  
> To reduce risk of NSAID-associated gastric ulcer  
> Adults: 15 mg P.O. daily for up to 12 weeks  
> Gastroesophageal reflux disease  
> Adults and children ages 12 to 17: 15 mg P.O. daily for up to 8 weeks  
> Children ages 1 to 11 weighing more than 30 kg (66 lb): 30 mg P.O. daily for up to 12 weeks  
> Children ages 1 to 11 weighing 30 kg (66 lb) or less: 15 mg P.O. daily for up to 12 weeks  
> Erosive esophagitis  
> Adults and children ages 12 to 17: 30 mg P.O. daily for up to 8 weeks. Some patients may require 8 additional weeks.  
> Children ages 1 to 11 weighing more than 30 kg (66 lb): 30 mg P.O. daily for up to 12 weeks  
> Children ages 1 to 11 weighing 30 kg (66 lb) or less: 15 mg P.O. daily for up to 12 weeks  
> To maintain healing of erosive esophagitis  
> Adults: 15 mg P.O. daily  
> Pathologic hypersecretory conditions (including Zollinger-Ellison syndrome)  
> Adults: Initially, 60 mg P.O. daily, to a maximum of 90 mg P.O. b.i.d. Divide daily dosages over 120 mg.
Dosage adjustment
● Significant hepatic insufficiency

Contraindications
● Hypersensitivity to drug or its components

Precautions
Use cautiously in:
● phenylketonuria (orally disintegrating tablets), severe hepatic impairment
● elderly patients
● pregnant or breastfeeding patients
● children younger than age 18.

Administration
● Give oral form before meals.
● If patient has difficulty swallowing delayed-release capsule, open it and sprinkle contents onto small amount of soft food, such as applesauce or pudding. Don't crush or let patient chew drug.
● When giving orally disintegrating tablet, place tablet on patient's tongue and let it disintegrate until particles can be swallowed.
● Know that orally disintegrating tablet contains phenylalanine.
● When giving oral suspension, empty packet contents into container with 2 tbsp water. Stir contents well, and have patient drink immediately. Don't give oral suspension through nasogastric (NG) tube.
● When injecting contents of delayed-release capsule through NG tube, open capsule and mix granules with 40 ml apple juice. Then rinse tube with additional apple juice to clear.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>Unknown</td>
<td>&gt;24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, confusion, anxiety, malaise, paresthesia, abnormal thinking, depression, dizziness, syncope, cerebrovascular accident
CV: chest pain, hypertension, hypotension, myocardial infarction, shock

EENT: visual field deficits, otitis media, tinnitus, epistaxis
GI: nausea, diarrhea, abdominal pain, cholelithiasis, ulcerative colitis, esophageal ulcer, hematemesis, stomatitis, dysphagia, GI hemorrhage
GU: renal calculi, erectile dysfunction, abnormal menses, breast tenderness, gynecomastia
Hematologic: anemia
Respiratory: cough, bronchitis, asthma
Skin: urticaria, alopecia, acne, pruritus, photosensitivity

Interactions
Drug-drug. Drugs requiring acidic pH (such as ampicillin esters, digoxin, iron salts, itraconazole, ketoconazole): decreased absorption of these drugs
Sucralfate: decreased lansoprazole absorption
Theophylline: increased theophylline clearance

Drug-food. Any food: decreased rate and extent of GI drug absorption

Drug-herbs. Male fern: inactivation of herb
St. John’s wort: increased risk of photosensitivity

Patient monitoring
● Monitor for GI adverse reactions.
● Assess nutritional status and fluid balance to identify significant problems.

Patient teaching
● Instruct patient to take before meals.
● If patient has difficulty swallowing, tell him to open delayed-release capsule and sprinkle contents onto small amount of soft food (such as applesauce or pudding). Emphasize that he must not crush or chew drug.
● Tell patient to take orally disintegrating tablet by placing it on tongue and letting it disintegrate.
● Instruct patient to take oral suspension by emptying packet contents into container with 2 tbsp water. Tell him to
stir contents well and drink immediately.
● Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, foods, and herbs mentioned above.

lanthanum carbonate
Fosrenol

**Pharmacologic class:** Phosphate binder

**Therapeutic class:** Renal and genitourinary agent

**Pregnancy risk category C**

**Action**
Dissociates in acidic environment of upper GI tract to release lanthanum ions, which bind dietary phosphate released from food during digestion and inhibit phosphate absorption by forming highly insoluble lanthanum phosphate complexes

**Availability**
*Tablets (chewable):* 250 mg, 500 mg

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Indications and dosages**
➢ To reduce serum phosphate level in patients with end-stage renal disease

**Adults:** Initially, 750 to 1,500 mg P.O. (chewed) daily in divided doses with meals; titrate every 2 to 3 weeks until serum phosphate falls to acceptable level.

**Contraindications**
None

**Precautions**
Use cautiously in:

- acute peptic ulcer, Crohn’s disease, ulcerative colitis, bowel obstruction
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

**Administration**
● Give before meals; ensure that patient chews tablets completely before swallowing.

**Adverse reactions**

**CNS:** headache

**CV:** hypotension

**GI:** nausea, vomiting, diarrhea, constipation, abdominal pain

**Metabolic:** hypercalcemia

**Respiratory:** bronchitis, rhinitis

**Other:** dialysis graft complication or occlusion

**Drug-diagnostic tests.** Serum calcium: increased

**Patient monitoring**
● Monitor serum calcium and phosphate levels periodically.

**Patient teaching**
● Instruct patient to take drug with or immediately after meals and to chew tablets completely before swallowing.
● Advise patient to discuss any planned dietary changes with prescriber.
● Inform female patient with childbearing potential that drug isn’t recommended during pregnancy.
● Instruct female patient to tell prescriber if she’s breastfeeding.
● As appropriate, review all other significant adverse reactions and interactions, especially those related to the tests mentioned above.

Reactions in **bold** are life-threatening.
leflunomide
Apo-Leflunomide®, Arava, Novo-Leflunomide®, PMS-Leflunomide®, Sandoz Leflunomide®

Pharmacologic class: Immune modulator
Therapeutic class: Antirheumatic
Pregnancy risk category X

FDA BOXED WARNING
- Rule out pregnancy before starting therapy. Drug is contraindicated in pregnant women and in women of childbearing age who don’t use reliable contraception. Caution patient to avoid pregnancy during therapy or before completing drug elimination procedure after treatment.

Action
Inhibits T-cell pyrimidine biosynthesis, tyrosine kinases, and dihydroorotate dehydrogenase, blocking structural damage caused by inflammatory response to autoimmune process. Also shows analgesic, antipyretic, and histamine-blocking activity.

Availability
Tablets: 10 mg, 20 mg

Indications and dosages
- Active rheumatoid arthritis
Adults: 100 mg P.O. daily for 3 days, then a maintenance dosage of 20 mg daily. If intolerance occurs, decrease to 10 mg daily.

Dosage adjustment
- Hepatic enzyme elevations

Contraindications
- Hypersensitivity to drug or its components
- Immunocompromised state, including bone marrow dysplasia and severe uncontrolled infection
- Hepatic impairment, evidence of hepatitis B or C
- Live-virus vaccinations
- Pregnancy or breastfeeding

Precautions
Use cautiously in:
- renal insufficiency
- men attempting to father a child
- children younger than age 18.

Administration
- Give with or without food.
- Be aware that drug has a long half-life. To eliminate from bloodstream, give 8 g cholestyramine P.O. t.i.d. for 11 days.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1 mo</td>
<td>3-6 mo</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, dizziness, asthenia
CV: chest pain, hypertension
EENT: rhinitis, sinusitis, pharyngitis
GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia, gastroenteritis, mouth ulcers, anorexia
GU: urinary tract infection
Hepatic: hepatotoxicity
Metabolic: hypokalemia
Musculoskeletal: joint pain or disorders, back pain, leg cramps, synovitis, tenosynovitis
Respiratory: bronchitis, increased cough, pneumonia, respiratory infection
Skin: alopecia, rash, dry skin, eczema, pruritus
Other: weight loss, pain, infection, allergic reactions, flulike symptoms

Interactions
Drug-drug. Activated charcoal, cholestyramine: rapid, steep drop in blood level of leflunomide’s active metabolite
Methotrexate, other hepatotoxic drugs: increased risk of hepatotoxicity
Rifampin: increased blood level of leflunomide’s active metabolite

**Drug-diagnostic tests.** Alanine aminotransferase, aspartate aminotransferase: increased levels

**Patient monitoring**

- Check vital signs closely.
- Watch for signs and symptoms of hepatotoxicity.
- Assess cardiovascular and respiratory status carefully to detect adverse reactions.
- Monitor electrolyte levels and liver function tests.
- Stay alert for signs and symptoms of urinary tract infection.
- Observe patient closely after dosage reduction. Metabolite levels may take several weeks to fall.

**Patient teaching**

- Tell patient he may take with or without food.
- Advise patient to immediately report unusual tiredness or yellowing of skin or eyes.
- Tell patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Inform female of childbearing age that drug may harm fetus. Tell her to contact prescriber immediately if she suspects pregnancy.
- Caution female not to breastfeed without consulting prescriber.
- Advise male planning to father a child to consult prescriber, because drug can harm fetus.
- Tell patient he’ll undergo regular blood testing to check liver function.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

---

**lenalidomide**

**Revlid**

**Pharmacologic class:** Thalidomide analogue

**Therapeutic class:** Antineoplastic, immunomodulator

**Pregnancy risk category X**

**FDA BOXED WARNING**

- If taken during pregnancy, drug may cause fetal death or severe, life-threatening birth defects. Advise females to avoid pregnancy. Drug is available only under RevAssist distribution program, in which only registered prescribers and pharmacists can prescribe and dispense it to registered patients who meet certain conditions. For information, visit www.REVLIMID.com or call 1-888-423-5436.
- Drug has been linked to hematologic toxicity (including significant neutropenia and thrombocytopenia); 80% of patients with myelodysplastic syndrome (MDS) associated with deletion 5q cytogenic abnormality have required dose delays or dosage reductions. For patients with these syndromes, monitor complete blood count (CBC) weekly for first 8 weeks of therapy and at least monthly thereafter. Patients may require dose delay, dosage reduction, or both and require blood product support, growth factors, or both.
- Drug may increase risk of deep vein thrombosis and pulmonary embolism in patients with multiple myeloma who receive it in combination with
dexamethasone. Stay alert for signs and symptoms, such as shortness of breath, chest pain, and arm or leg swelling. Prescriber must consider patient’s risk factors when deciding whether to use prophylaxis.

**Action**
Inhibits secretion of proinflammatory cytokines and increases secretion of anti-inflammatory cytokines from peripheral mononuclear cells

**Availability**
Capsules: 5 mg, 10 mg, 15 mg, 25 mg

**Indications and dosages**
> Transfusion-dependent anemia caused by low- or intermediate-1-risk MDS associated with deletion 5q cytogenetic abnormality (with or without additional cytogenetic abnormalities)

**Adults:** 10 mg P.O. daily
> Multiple myeloma, given with dexamethasone

**Adults:** 25 mg P.O. daily with water given as single 25-mg capsule on days 1 to 21 of repeated 28-day cycles. Recommended dexamethasone dosage is 40 mg/day on days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for first four cycles of therapy, then 40 mg P.O. daily on days 1 to 4 every 28 days.

**Dosage adjustment**
- Thrombocytopenia
- Neutropenia

**Contraindications**
- Hypersensitivity to drug or its components
- Pregnancy

**Precautions**
Use cautiously in:
- renal impairment
- elderly patients
- patients with childbearing potential
- breastfeeding patients
- children (safety and efficacy not established).

**Administration**
- Be aware that patient must be able to reliably follow instructions and must understand conditions of RevAssist program to be eligible for drug.
- Administer drug with water.
- Know that before drug is prescribed, female patient should have two negative pregnancy tests (with sensitivity of at least 50 mIU/ml).

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>40 min - 1.5 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
CNS: dizziness, headache, hypoesthesia, peripheral neuropathy, insomnia, depression, rigors, fatigue
CV: hypertension, palpitations
EENT: epistaxis, rhinitis, pharyngitis, nasopharyngitis, sinusitis
GI: diarrhea, loose stools, constipation, nausea, vomiting, abdominal pain, anorexia, dry mouth, dysgeusia
GU: urinary tract infection, dysuria
Hematologic: anemia, thrombocytopenia, neutropenia, leukopenia, febrile neutropenia
Metabolic: hypokalemia, hypomagnesemia, hypothyroidism
Musculoskeletal: arthralgia, back pain, muscle cramps, limb pain, myalgia
Respiratory: cough, dyspnea, exertional dyspnea, bronchitis, upper respiratory tract infection, pneumonia
Skin: pruritus, rash, dry skin, contusion, ecchymosis, erythema
Other: fever, peripheral edema, pain, chest pain, cellulitis, night sweats, increased sweating

**Interactions**
Drug-drug. Digoxin: increased digoxin level
Drug-diagnostic tests. Magnesium, potassium, thyroid function: decrease in levels or function
Patient monitoring
- Monitor CBC weekly for first 3 months, then at least monthly.
- Watch carefully for electrolyte disorders and abnormal thyroid function tests.

Patient teaching
- Instruct patient to swallow capsules whole with water and not to open, chew, or crush them.
- Advise patient to report unusual symptoms or persistence or worsening of known symptoms.
- Urge female patient to use two effective contraceptive methods simultaneously for at least 4 weeks before starting therapy, during therapy, during dosage interruptions, and for 4 weeks after therapy ends. Emphasize that she must use contraception even if she has a history of infertility (unless she has had a hysterectomy).
- Instruct female patient to stop taking drug if she misses a period, has unusual menstrual bleeding, stops using contraception, or suspects pregnancy.
- Advise patient to immediately report unprotected sexual contact or suspected pregnancy.
- Instruct male patient to use latex condom during sexual contact with female of childbearing potential.
- Inform patients they can’t donate blood during therapy.
- Tell male patients they can’t donate sperm or semen during therapy.
- As appropriate, review all other significant or life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

lepirudin
Refludan

Pharmacologic class: Thrombin inhibitor
Therapeutic class: Anticoagulant
Pregnancy risk category B

Action
Binds with thrombin, blocking its thrombogenic activity

Availability
Powder for injection: 50 mg

Indications and dosages
Heparin-induced thrombocytopenia and associated thromboembolic disease
Adults: Initially, 0.4 mg/kg by I.V. bolus over 15 to 20 seconds (to a maximum of 44 mg), followed by 0.15 mg/kg as a continuous I.V. infusion (to a maximum of 16.5 mg/hour) for 2 to 10 days, or longer if needed

Dosage adjustment
- Renal impairment
- Elderly patients

Contraindications
- Hypersensitivity to drug, its components, or hirudin

Precautions
Use cautiously in:
- renal or hepatic disease, bleeding, bacterial endocarditis
- recent cerebrovascular accident or neurosurgery
- pregnant or breastfeeding patients
- children.

Reactions in bold are life-threatening.

Clinical alert
Administration

- Check activated partial thromboplastin time (APTT) before therapy starts.

Administer I.V. bolus slowly, over at least 15 to 20 seconds.
- Follow bolus with continuous I.V. infusion for 2 to 10 days.
- To reconstitute, mix with sterile water for injection or 0.9% sodium chloride injection.
- For further dilution, use 0.9% sodium chloride injection or 5% dextrose injection.
- Base dosage adjustments on APTT measured 4 hours after drug initiation and then at least once daily.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: depression
CV: heart failure, pericardial effusion, ventricular fibrillation
GI: GI bleeding
GU: hematuria, abnormal renal function
Hematologic: hemorrhage, thrombocytopenia
Respiratory: pneumonia, hemoptysis
Skin: rash, pruritus, urticaria
Other: chills, fever, bleeding at injection site, excessive wound bleeding, multisystem failure, sepsis, anaphylaxis

Interactions

Drug-drug. Cefamandole, cefopazzone, cefotetan, clopidogrel, eptifibatide, nonsteroidal anti-inflammatory drugs, oral anticoagulants, platelet aggregation inhibitors, plicamycin, thrombolytics, ticlopidine, tirofiban, valproic acid: increased risk of bleeding

Drug-diagnostic tests. Liver function tests: increased values

Patient teaching

- Assess fluid intake and output and monitor creatine clearance.
- Watch closely for signs and symptoms of bleeding.
- Monitor CBC with white cell differential; assess liver function tests.
- Check for adverse effects, particularly signs and symptoms of infection, multisystem failure, and cardiovascular or respiratory problems.

Patient monitoring

- Check vital signs frequently.
- Monitor APTT at least daily. Target range is 1.5 to 2.5.

Drug class: Aromatase inhibitor
Therapeutic class: Antineoplastic
Pregnancy risk category D

Action

Inhibits aromatase, an enzyme that promotes conversion of estrogen precursors to estrogen. This inhibition reduces circulating estrogen levels and stops progression of breast cancer.

Availability

Tablets: 2.5 mg

Indications and dosages

Metastatic or advanced breast cancer in postmenopausal women; early
breast cancer in postmenopausal women who have received 5 years of anti-estrogen therapy
Adults: 2.5 mg P.O. daily

Contraindications
• Hypersensitivity to drug or its components

Precautions
Use cautiously in:
• severe hepatic impairment
• pregnant or breastfeeding patients
• children (safety not established).

Administration
• Give with or without meals.

Route Onset Peak Duration
P.O. Unknown 2-3 days Unknown

Adverse reactions
CNS: anxiety, depression, dizziness, drowsiness, fatigue, headache, vertigo, asthenia
CV: chest pain, hypertension
EENT: blurred vision
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia
Metabolic: hypercalcemia
Musculoskeletal: musculoskeletal or joint pain, fractures
Respiratory: cough, dyspnea, pleural effusion
Skin: alopecia, pruritus, rash, diaphoresis
Other: hot flashes, edema, weight gain, angioedema, anaphylactic reactions

Interactions
Drug-diagnostic tests. Cholesterol, gamma-glutamyltransferase: increased levels

Patient monitoring
• Check vital signs and assess cardiovascular and respiratory status.
• Monitor renal and hepatic function, electrolyte levels, and lipid panels.
• Assess for adverse CNS effects, including depression. Institute safety measures as needed to prevent injury.

Patient teaching
• Tell patient she can take with or without food.
• Instruct patient to weigh herself regularly and report significant changes.
• Advise patient and family to watch for signs and symptoms of depression.
• Tell patient to minimize GI upset by eating small, frequent servings of healthy food and drinking plenty of fluids.
• Caution patient to avoid driving and other hazardous activities until she knows how drug affects concentration and alertness.
• Inform patient that treatment is long term. Urge her to keep follow-up appointments with prescriber.
• Tell patient to inform prescriber if she is pregnant or breastfeeding.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

leucovorin calcium (citrovorum factor, folinic acid)
Calcium Folate®, Lederfolin®, Refolinon®

Pharmacologic class: Water-soluble vitamin

Therapeutic class: Vitamin, antidote to folic acid antagonist, antianemic, antineoplastic adjunct

Pregnancy risk category C

Action
Counteracts therapeutic and toxic effects of folic acid antagonists; may
enhance therapeutic and toxic effects of fluoropyrimidines used in cancer therapy. Also supplements folic acid in folic acid deficiency.

**Availability**

*Injection (expressed as base):* 10 mg/vial, 50 mg/vial, 100 mg/vial, 200 mg/vial, 350 mg/vial, 500 mg/vial

*Injection, preservative-free (expressed as base):* 10 mg/vial, 50 mg/vial, 200 mg/vial, 350 mg/vial, 500 mg/vial

*Tablets:* 5 mg, 15 mg, 25 mg

**Indications and dosages**

- **Leucovorin rescue after high-dose methotrexate therapy**
  - **Adults:** 15 mg (approximately 10 mg/m²) P.O., I.M., or I.V. q 6 hours, starting 24 hours after methotrexate infusion begins and continuing until serum methotrexate level drops below $10^{-8}$ M. If 24-hour serum creatinine level rises 50% over baseline or if 24-hour methotrexate level exceeds $5 \times 10^{-6}$ M or 48-hour level exceeds $9 \times 10^{-7}$ M, increase leucovorin dosage to 100 mg/m² I.V. q 3 hours and continue hydration and urinary alkalization until methotrexate level drops below $10^{-8}$ M.
  - **To reduce toxicity and counteract effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonist**
  - **Adults:** 15 mg (roughly 10 mg/m²) I.M., I.V., or P.O. q 6 hours until serum methotrexate level drops below $10^{-8}$ M. If 24-hour serum creatinine level rises 50% over baseline or if 24-hour methotrexate level exceeds $5 \times 10^{-6}$ M or 48-hour level exceeds $9 \times 10^{-7}$ M, increase leucovorin dosage to 100 mg/m² I.V. q 3 hours and continue hydration and urinary alkalization until methotrexate level drops below $10^{-8}$ M.

**Megaloblastic anemia secondary to folic acid deficiency**

- **Adults:** Up to 1 mg I.M. daily

**Dosage adjustment**

- In leucovorin rescue after high-dose methotrexate therapy: delayed early or late methotrexate elimination (serum methotrexate level still above 0.2 µM at 72 hours and above 0.05 µM [$5 \times 10^{-8}$] at 96 hours after administration)

**Contraindications**

- Treatment of pernicious anemia and other megaloblastic anemias caused by vitamin B₁₂ deficiency

**Precautions**

- Use cautiously in:
  - anemia (when vitamin B₁₂ deficiency has been ruled out)
  - patients receiving 5-FU concomitantly
  - pregnant or breastfeeding patients
  - children.

**Administration**

- Recheck leucovorin dosage in current published protocols before giving as methotrexate rescue.
- Give parenterally in patients with GI toxicity, nausea, or vomiting.
- Reconstitute leucovorin injection with sterile or bacteriostatic water for injection containing benzyl alcohol. (When giving with 5-FU for colorectal cancer in dosages above 10 mg/m², reconstitute only with sterile water for injection.)
- Don’t mix leucovorin injection with 5-FU, because precipitation will occur.
Give I.V. leucovorin slowly (no faster than 160 mg/minute) because of calcium content. Large doses may be infused over 1 to 6 hours as directed. Don’t give intrathecally; drug may be harmful or fatal by this route.

- Be aware that P.O. dosages above 25 mg are not recommended.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>20-30 min</td>
<td>60 to 90 min</td>
<td>3-6 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>&lt;5 min</td>
<td>Unknown</td>
<td>3-6 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>10-20 min</td>
<td>35 to 60 min</td>
<td>3-6 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**Skin:** urticaria

**Other:** allergic sensitization reactions, anaphylactoid reactions

**Interactions**

**Drug-drug. 5-FU:** enhanced fluorouracil toxicity

**Methotrexate, other folic acid antagonists:** negated therapeutic and toxic effects of these drugs

**Phenobarbital, phenytoin, primidone:** negated anticonvulsant effect, increased frequency of seizures in susceptible children

**Patient monitoring**

- Monitor serum creatinine and methotrexate levels every 24 hours.
- Monitor closely for adverse reactions. Continue leucovorin therapy, hydration, and urinary alkalization until serum methotrexate level drops below $10^{-8}$ M.
- Monitor CBC with white cell differential and platelet count before leucovorin/5-FU therapy starts. Repeat weekly during first two courses and then once each cycle at anticipated white blood cell nadir.
- Check electrolyte levels and liver function tests before each treatment for first three cycles. Thereafter, check before every other cycle.

- Assess for adequate hydration when giving with 5-FU or high-dose methotrexate.
- Watch for hypersensitivity reactions, especially anaphylactoid reactions.

**Patient teaching**

- Teach patient about drug and protocol.
- Stress importance of taking leucovorin as prescribed with high-dose methotrexate therapy. Emphasize that it’s not just a vitamin.
- Tell patient to immediately report signs or symptoms of allergic reaction, such as hives.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

---

**leuprolide acetate**

(Leuprolin®)

Eligard, Lupron, Lupron Depot, Lupron Depot-Ped, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron-3 Month SR Depot, Prostap®, Viadur

**Pharmacologic class:** Gonadotropin-releasing hormone (GnRH) analog

**Therapeutic class:** Antineoplastic

**Pregnancy risk category X**

**Action**

Inhibits and desensitizes GnRH receptors, thus inhibiting gonadotropin secretion when given continuously. This inhibition causes initial increase and then profound decrease in luteinizing hormone and follicle-stimulating hormone levels and, ultimately, reduces testosterone and estrogen sex hormones.

---

**Reactions in bold are life-threatening.**

**Clinical alert**
Availability
Eligard Depot: 7.5 mg, 22.5 mg, 30 mg, 45 mg
Implant (12-month): 72 mg (65 mg free base)
Injection: 1 mg/0.2 ml
Lupron Depot injection: 3.75 mg/ml, 7.5 mg/ml
Lupron Depot-3 month injection: 11.25 mg, 22.5 mg
Lupron Depot-4 month injection: 30 mg
Lupron Depot-Ped injection: 7.5 mg, 11.25 mg, 15 mg

Indications and dosages
➢ Advanced prostate cancer
Adults: 1 mg subcutaneously daily (1 mg/0.2-ml formulation). For Lupron Depot formulation, 7.5 mg I.M. monthly, 22.5 mg I.M. q 3 months, or 30 mg I.M. q 4 months. For Eligard formulation, 7.5 mg subcutaneously monthly, 22.5 mg subcutaneously q 3 months, 30 mg subcutaneously q 4 months, or 45 mg subcutaneously q 6 months. For Viadur formulation, place one implant subcutaneously for 12-month use.
➢ Endometriosis
Adults: 3.75 mg I.M. (depot injection) as a single injection once monthly, or 11.25 mg I.M. q 3 months. Duration is up to 6 months.
➢ Adjunct to iron therapy in anemia caused by uterine leiomyomas
Adults: 3.75 mg I.M. monthly or 11.25 mg I.M. q 3 months as a single dose. Recommended duration is 6 months or less.
➢ Central precocious puberty
Children: 50 mcg/kg/day subcutaneously as a single injection, increased in increments of 10 mcg/kg/day as needed
Children weighing more than 37.5 kg (82.5 lb): Initially, 15 mg of Depot-Ped I.M. q 4 weeks, increased in increments of 3.75 mg q 4 weeks as needed
Children weighing 25 to 37.5 kg (55 to 82.5 lb): Initially, 11.25 mg of

Contraindications
● Hypersensitivity to drug, its components, GnRH, or other GnRH analogs
● Undiagnosed abnormal vaginal bleeding
● Pregnancy or breastfeeding

Precautions
Use cautiously in:
● renal, hepatic, or cardiac impairment.

Administration
● Give Eligard within 30 minutes of mixing. After this time, discard.
● Administer Lupron injection immediately after mixing. Otherwise, discard.
● Administer Lupron Depot-Ped only under prescriber’s supervision.

Route Onset Peak Duration
I.M. depot 4 hr Variable 1, 3, 4 mo
Implant Unknown Unknown 1 yr
Subcut. (prec. puberty) 1 wk Unknown 4-12 wk after therapy
Subcut. (endometriosis, cancer) 2-4 wk After 1-2 mo 2-3 mo after therapy

Adverse reactions
CNS: anxiety, depression, dizziness, drowsiness, asthenia, fatigue, headache, vertigo, syncope, mood changes
CV: palpitations, angina, arrhythmias, myocardial infarction
EENT: blurred vision
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia
GU: urinary frequency, hematuria, decreased testes size, erectile dysfunction, decreased libido, gynecomastia

Hematologic: anemia, thrombocytopenia

Respiratory: dyspnea, pleural rub, worsening of pulmonary fibrosis, pulmonary embolism

Skin: alopecia, pruritus, rash, diaphoresis

Other: sour taste, edema, hot flashes, anaphylaxis

Interactions

Drug-diagnostic tests. Blood urea nitrogen, creatinine: increased levels

Pituitary-gonadal system tests: misleading results during and for up to 3 months after therapy

Patient monitoring

• Observe injection site for local reactions.
  ❌ Monitor cardiovascular and respiratory status carefully to detect serious adverse reactions.
  • Evaluate neurologic status. Institute safety measures as needed to prevent injury.
  • Periodically monitor serum testosterone and prostate-specific antigen levels.

Patient teaching

• Inform patient that localized reaction may occur at injection site. Tell him to contact prescriber if symptoms don’t resolve.
  • Advise patient and family to watch for and report signs or symptoms of depression.
  • Tell patient drug may cause libido changes or erectile dysfunction. Encourage him to discuss these problems with prescriber.
  • Teach patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
  ❌ Instruct female of childbearing age to use reliable contraception during therapy. Tell her to stop drug immediately and contact prescriber if she suspects pregnancy.
  ❌ Tell female patient not to breastfeed.
  • Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
  • As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

levalbuterol hydrochloride

Xopenex HFA

Pharmacologic class: Adrenergic beta₂ agonist

Therapeutic class: Bronchodilator

Pregnancy risk category C

Action

Binds to beta₂-adrenergic receptors on bronchial cell membrane, stimulating the intracellular enzyme adenylate cyclase to convert adenosine triphosphate to cyclic-3′,5′-adenosine monophosphate. This action relaxes smooth muscles, dilates bronchioles, and increases diuresis.

Availability

Solution for inhalation: 0.31 mg/3 ml, 0.63 mg/3 ml, 1.25 mg/3 ml

Indications and dosages

> Prevention and treatment of bronchospasm

Adults and children ages 12 and older: 0.63 to 1.25 mg by oral inhalation via nebulizer q 6 to 8 hours

Children ages 6 to 11: 0.31 to 0.63 mg by oral inhalation via nebulizer t.i.d.

Reactions in bold are life-threatening.
Contraindications
• Hypersensitivity to drug or racemic albuterol

Precautions
Use cautiously in:
• renal, hepatic, or cardiac impairment; hyperthyroidism; diabetes mellitus; hypertension; prostatic hypertrophy; angle-closure glaucoma; seizures
• pregnant patients.

Administration
• Use only with nebulizer system designed for this drug.
• Keep unopened vials in foil pouch. Once pouch is opened, use within 2 weeks.
• If vial is removed from pouch, protect from light and use within 1 week.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhalation</td>
<td>10-17 min</td>
<td>1.5 hr</td>
<td>5-6 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: anxiety, dizziness, hypotonia, insomnia, migraine, headache, nervousness, paresthesia, syncope, tremor
CV: chest pain, hypertension, hypotension, tachycardia
EENT: rhinitis, sinusitis, dry throat
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia, dry mouth
Metabolic: hypokalemia
Musculoskeletal: muscle cramps, myalgia
Respiratory: cough, dyspnea, asthma exacerbation, paradoxical bronchospasm
Other: sour taste, flulike symptoms, lymphadenopathy, chills

Interactions
Drug-drug. Aerosol bronchodilators: increased action of both drugs
Antidepressants: increased risk of adverse cardiovascular effects
Beta-adrenergic blockers: inhibition of levalbuterol effect
Digoxin: decreased digoxin blood level
Loop and thiazide diuretics: increased risk of hypokalemia
Drug-food. Caffeine-containing foods and beverages: increased stimulation
Drug-herbs. Cola nut, ephedra (ma huang), guarana, yerba maté: increased stimulation

Patient monitoring
• Monitor vital signs and ECG closely.
• Assess cardiovascular and neurologic status. Institute safety measures as needed to prevent injury.
• Monitor for paradoxical bronchospasm. If it occurs, stop drug therapy and notify prescriber immediately.
• Check electrolyte levels for hypokalemia.
• Assess patient’s response to drug. Contact prescriber if patient needs more frequent doses for same effect.

Patient teaching
• Teach patient how to prepare drug, administer it with nebulizer, and maintain and clean nebulizer.
• Advise patient to continue treatment for about 5 to 15 minutes or until mist no longer forms in nebulizer reservoir.
• Tell patient to immediately report increased difficulty breathing or tightness in chest.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, foods, and herbs mentioned above.
**levetiracetam**

Apo-Levetiracetam, Co
Levetiracetam, Dom-Levetiracetam, Keppra, Keppra XR,
PHL-Levetiracetam,
PMS-Levetiracetam

**Pharmacologic class:** Pyrrolidine derivative

**Therapeutic class:** Anticonvulsant

**Pregnancy risk category C**

**Action**
Unknown. Thought to prevent seizures by inhibiting nerve impulses in hippocampus of brain. Chemically unrelated to other anticonvulsants.

**Availability**

*Oral solution:* 100 mg/ml  
*Solution for injection:* 500 mg/5 ml in single-use 5-ml vial  
*Tablets:* 250 mg, 500 mg, 750 mg, 1,000 mg  
*Tablets (extended-release):* 500 mg

**Indications and dosages**

*Adjunctive treatment of partial-onset seizures in patients with epilepsy*

**Adults and children ages 16 and older:** Initially, 500 mg P.O. (immediate-release preparations) b.i.d. May increase by 1,000 mg/day q 2 weeks to a maximum daily dosage of 3,000 mg, as needed. Or, initially 1,000 mg P.O. (extended-release tablets) once daily. Adjust in increments of 1,000 mg q 2 weeks to a maximum daily dosage of 3,000 mg, as appropriate. Or, when oral administration is temporarily not feasible, give initial daily I.V. dosage equivalent to total daily dosage and frequency of oral drug.

**Children ages 4 to 15:** Initially, 20 mg/kg/day P.O. (immediate-release preparations) in two divided doses (10 mg/kg b.i.d.). Increase daily dosage every 2 weeks by increments of 20 mg/kg to recommended daily dosage of 60 mg/kg (30 mg/kg b.i.d). If patient can’t tolerate daily dosage of 60 mg/kg, reduce daily dosage.

*Myoclonic seizures in patients with juvenile myoclonic epilepsy*

**Children ages 16 and older:** Initially, 500 mg I.V. b.i.d. Increase dosage by 1,000 mg/day every 2 weeks to recommended total daily dosage of 3,000 mg.

**Children ages 12 and older:** Initially, 500 mg P.O. (immediate-release tablets or oral solution) b.i.d. Increase dosage by 1,000 mg/day every 2 weeks to the recommended total daily dose of 3,000 mg.

*Primary generalized tonic-clonic seizures*

**Adults and children ages 16 and older:** Initially, 1,000 mg P.O. b.i.d. Increase dosage by 1,000 mg/day every 2 weeks to the recommended total daily dose of 3,000 mg.

**Children ages 6 to 15:** Initially, 10 mg/kg P.O. b.i.d. Increase daily dosage every 2 weeks by increments of 20 mg/kg to recommended total daily dosage of 60 mg/kg (30 mg/kg b.i.d.).

**Dosage adjustment**

- Renal impairment (especially in dialysis patients)

**Contraindications**

- Hypersensitivity to drug or its components

**Precautions**

Use cautiously in:
- renal, hepatic, or cardiac impairment
- psychosis
- pregnant or breastfeeding patients
- children younger than age 16 (safety and efficacy not established).

**Administration**

- Give oral form with or without food.
● Know that patients weighing 44 lb (20 kg) or less should be given oral solution.
● Be aware that injection form is intended for temporary use when oral route isn’t feasible.

Be aware that injection form is for I.V. use only and must be diluted before administering.
● Dilute 500 mg/ml in 100 ml 0.9% normal saline injection, lactated Ringer’s injection, or dextrose 5% injection. Withdraw 5 ml, 10 ml, or 15 ml for 500-mg, 1,000-mg, or 1,500-mg dose, respectively.
● Administer as a 15-minute I.V. infusion.

Don’t discontinue suddenly. Instead, taper dosage gradually.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>1 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>P.O. (ext-rel.)</td>
<td>Unknown</td>
<td>4 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: aggression, anger, irritability, mental or mood changes, asthenia, ataxia, dizziness, drowsiness, somnolence, fatigue, nervousness, depression, anxiety, amnesia, hostility, coordination difficulties, headache, paresthesia, vertigo
EENT: diplopia, pharyngitis, rhinitis, sinusitis
GI: nausea, vomiting, anorexia
Hematologic: neutropenia, leukopenia
Respiratory: cough
Other: infection, pain

Interactions
Drug-herbs. *Evening primrose oil*: lowered seizure threshold

Patient monitoring
● Measure temperature and watch for signs and symptoms of infection.

Monitor neurologic status. Report signs that patient is dangerous to himself or others.
● Evaluate nutritional status. Report signs of anorexia.

Patient teaching
● Tell patient to take with or without food.
● Instruct patient to swallow extended-release tablets whole and not to chew, break, or crush them.

Advise family to contact prescriber if patient poses a danger to himself or others.

Caution patient not to stop taking drug abruptly, because doing so may increase seizure activity.
● Teach patient and family about adverse CNS reactions, and tell them to report these promptly. Urge them to take safety measures to prevent injury.
● Instruct patient to avoid activities that require mental alertness until CNS reactions are known.
● Inform patient that he’ll undergo periodic blood testing during therapy.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the herbs mentioned above.

levocetirizine
dihydrochloride

*Xyzal*

**Pharmacologic class:** Histamine$_1$ (H$_1$)–receptor antagonist

**Therapeutic class:** Antihistamine

**Pregnancy risk category B**
Action
Exerts principal antihistaminic effects via selective inhibition of H1 receptors.

Availability
*Oral solution*: 2.5 mg/5 ml (0.5 mg/ml)
*Tablets*: 5 mg

Indications and dosages
> Symptoms of allergic rhinitis (seasonal and perennial); uncomplicated skin manifestations of chronic idiopathic urticaria

**Adults and children ages 12 and older:**
5 mg P.O. daily in evening

**Children ages 6 to 11:** 2.5 mg P.O. daily in evening; don’t exceed recommended dosage.

Dosage adjustment
- Renal impairment.
- Hepatic impairment.

Contraindications
- Hypersensitivity to drug, its components, or cetirizine
- End-stage renal disease
- Hemodialysis
- Renal impairment (children ages 6 to 11)

Precautions
Use cautiously in:
- renal impairment
- pregnant patients
- elderly patients
- breastfeeding patients (use not recommended)
- children younger than age 6 (safety and efficacy not established).

Administration
- Give with or without food.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>0.5 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: somnolence, fatigue, asthenia

Interactions
**Drug-drug.** Ritonavir: increased levocetirizine blood level and half-life, decreased clearance.

**Drug-behaviors.** Alcohol use: increased risk of impaired CNS function.

Patient monitoring
- Stay alert for excessive CNS depression.
- Closely monitor renal function tests in patients with renal impairment.

Patient teaching
- Tell patient drug can be taken with or without food.
- Instruct patient to avoid alcohol and other depressants, such as sleeping pills, unless prescriber approves.
- Caution patient to avoid hazardous activities until drug’s effects on concentration and alertness are known.
- Advise female patient to notify prescriber if she is pregnant or intends to become pregnant.
- Tell breastfeeding patient to discontinue breastfeeding during therapy.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and behaviors mentioned above.

**levofloxacin**
Iquix, Levaquin, Novo-Levofloxacin®, Oftaquix®, Quixin, Tavanic®

Pharmacologic class: Fluoroquinolone
Therapeutic class: Anti-infective
Pregnancy risk category C

Reactions in bold are life-threatening.
FDA BOXED WARNING

Fluoroquinolones for systemic use are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in patients usually over age 60, with concomitant use of corticosteroids, and in kidney, heart, and lung transplant recipients.

Action
Inhibits the enzyme DNA gyrase in susceptible gram-negative and gram-positive aerobic and anaerobic bacteria, interfering with bacterial DNA synthesis.

Availability
**Ophthalmic solution:** Quixin—0.5% (5 mg/ml), Iquix—1.5%
**Premixed solution for injection:** 250 mg/50 ml, 500 mg/100 ml, 750 mg/150 ml
**Solution for injection (concentrated):** 500 mg/20 ml
**Tablets:** 250 mg, 500 mg, 750 mg

Indications and dosages

- **Acute bacterial exacerbation of chronic bronchitis**
  - **Adults:** 500 mg I.V. or P.O. q 24 hours for 7 days

- **Community-acquired pneumonia**
  - **Adults:** 500 mg I.V. or P.O. q 24 hours for 7 to 14 days, or 750 mg I.V. or P.O. q 24 hours for 5 days

- **Nosocomial pneumonia caused by methicillin-susceptible strains of Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae; complicated skin and skin-structure infections**
  - **Adults:** 750 mg I.V. or P.O. q 24 hours for 7 to 14 days

- **Acute bacterial sinusitis caused by S. pneumoniae, H. influenzae, or Moraxella catarrhalis**
  - **Adults:** 500 mg I.V. or P.O. q 24 hours for 10 to 14 days or 750 mg P.O. or I.V. q 24 hours for 5 days

- **Uncomplicated skin and skin-structure infections**
  - **Adults:** 500 mg I.V. or P.O. q 24 hours for 7 to 10 days

- **Complicated urinary tract infections; acute pyelonephritis caused by E. coli**
  - **Adults:** 250 mg I.V. or P.O. q 24 hours for 10 days or 750 mg P.O. or I.V. q 24 hours for 5 days

- **Uncomplicated urinary tract infections**
  - **Adults:** 250 mg I.V. or P.O. q 24 hours for 3 days

- **Chronic bacterial prostatitis**
  - **Adults:** 500 mg I.V. or P.O. q 24 hours for 28 days.

- **Conjunctivitis**

- **Adults and children ages 1 and older:**
  - One or two drops of 0.5% ophthalmic solution into affected eye q 2 hours while awake on days 1 and 2 (up to eight times daily); then one or two drops q 4 hours while awake on days 3 through 7 (up to four times daily)

- **Corneal ulcers**

- **Adults and children ages 6 and older:**
  - On days 1 to 3, one or two drops of 1.5% ophthalmic solution instilled into affected eye(s) q 30 minutes to 1 hour while awake and q 4 to 6 hours after retiring; thereafter, one or two drops q 1 to 4 hours while awake until treatment completion

- **Inhalational anthrax (postexposure)**

- **Adults and children ages 6 months and older weighing more than 50 kg (110 lb):**
  - 500 mg P.O. or I.V. q 24 hours for 60 days

- **Children ages 6 months and older weighing less than 50 kg (110 lb):**
  - 8 mg/kg P.O. or I.V., not to exceed 250 mg/dose q 12 hours for 60 days

Dosage adjustment
- Renal impairment

Canada
UK
Hazardous drug
High alert drug
**Contraindications**
- Hypersensitivity to drug, its components, or other quinolones

**Precautions**
Use cautiously in:
- bradycardia, acute myocardial ischemia, prolonged QTc interval, cirrhosis, renal impairment, underlying CNS disease, uncorrected hypocalcemia
- elderly patients
- pregnant or breastfeeding patients
- children younger than age 18 (except in ophthalmic use).

**Administration**
- Be aware that oral and I.V. dosages are identical.
- Give parenteral form by I.V. route only. Drug isn’t for I.M., subcutaneous, intrathecal, or intraperitoneal use.
- To prepare I.V. infusion, use compatible solution, such as 0.9% sodium chloride injection, dextrose 5% and 0.9% sodium chloride injection, dextrose 5% in water, or dextrose 5% in lactated Ringer’s solution.
- Infuse over 60 to 90 minutes, depending on dosage. Don’t infuse with other drugs.
- Avoid rapid or bolus I.V. administration, because this may cause severe hypotension
- Flush I.V. line before and after infusion.
- Give oral doses 2 hours before or after sucralfate, iron, antacids containing magnesium or aluminum, or multivitamins with zinc.
- Give oral form without regard to food, but don’t give with milk or yogurt alone.
- Be aware that the two ophthalmic preparations have different indications.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>1-2 hr</td>
<td>24 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>End of infusion</td>
<td>24 hr</td>
</tr>
<tr>
<td>Ophth.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- **CNS:** dizziness, headache, insomnia, seizures
- **CV:** chest pain, palpitations, hypotension
- **EENT:** photophobia, sinusitis, pharyngitis
- **GI:** nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, pseudomembranous colitis
- **GU:** vaginitis
- **Hematologic:** lymphocytopenia
- **Metabolic:** hyperglycemia, hypoglycemia
- **Musculoskeletal:** back pain, tendon rupture, tendinitis
- **Skin:** photosensitivity
- **Other:** altered taste, reaction and pain at I.V. site, hypersensitivity reactions including Stevens-Johnson syndrome

**Interactions**
- **Drug-drug.** Antacids containing aluminum or magnesium, didanosine (tablets), iron salts, sucralfate, zinc salts: decreased levofloxacin absorption
- Cimetidine: interference with levofloxacin elimination
- Nonsteroidal anti-inflammatory drugs: increased risk of CNS stimulation and seizures

**Drug-diagnostic tests.** Glucose: increased or decreased level
- Lymphocytes: decreased count
- EEG: abnormal findings

**Drug-food.** Concurrent tube feedings, milk, yogurt: impaired levofloxacin absorption

**Drug-herbs.** Dong quai, St. John’s wort: phototoxicity
- Fennel: decreased levofloxacin absorption

**Drug-behaviors.** Sun exposure: phototoxicity

**Patient monitoring**
- Check vital signs, especially blood pressure. Too-rapid infusion can cause hypotension.

Reactions in **bold** are life-threatening.
- Closely monitor patients with renal insufficiency.
- Monitor blood glucose level closely in diabetic patients.
  - Assess for severe diarrhea, which may indicate pseudomembranous colitis.
  - Watch for hypersensitivity reaction. Discontinue drug immediately if rash or other signs or symptoms occur.
  - Watch for signs and symptoms of tendinitis or tendon rupture.

**Patient teaching**

- Tell patient to stop taking drug and contact prescriber if he experiences signs or symptoms of hypersensitivity reaction (rash, hives, or other skin reactions) or severe diarrhea (which may indicate pseudomembranous colitis).
- Instruct patient to stop taking drug and notify prescriber immediately if tendon pain, swelling, or inflammation occurs.
  - Instruct patient not to take with milk, yogurt, multivitamins containing zinc or iron, or antacids containing aluminum or magnesium.
  - Teach patient proper use of eye drops. Tell him to avoid touching applicator tip to eye, finger, or any other object.
  - Caution patient to avoid driving and other activities that require mental alertness until CNS effects of drug are known.
  - As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

---

**levonorgestrel**

Levonelle®, Mirena, Plan B

**Pharmacologic class:** Contraceptive, intrauterine device (Mirena); oral contraceptive, progestin-only pill (Plan B)

**Therapeutic class:** Contraceptive

**Pregnancy risk category X** (Mirena), NR (Plan B)

**Action**

Unclear. Mirena may enhance local contraceptive efficacy by thickening the cervical mucus (which prevents passage of sperm into uterus), inhibiting sperm capacitation or survival, and altering the endometrium. Plan B is thought to prevent ovulation or fertilization.

**Availability**

Intrauterine system (Mirena): 52 mg levonorgestrel

Two-tablet, single course of treatment (Plan B): 0.75 mg levonorgestrel per tablet

**Indications and dosages**

- Intrauterine contraception for up to 5 years

**Adults:**

- One intrauterine system (Mirena) inserted into uterus for up to 5 years
  - Emergency contraception to prevent pregnancy

**Adults:**

- One tablet (Plan B) P.O. within 72 hours after unprotected intercourse, with second tablet taken 12 hours after first tablet

**Contraindications**

Mirena—

- Hypersensitivity to drug or its components
- Known or suspected pregnancy
- Congenital or acquired uterine anomaly
- Acute pelvic inflammatory disease (PID) or history of PID (unless patient had subsequent intrauterine pregnancy)
- Postpartum endometritis or infected abortion within past 3 months
- Known or suspected uterine or cervical neoplasia or unresolved abnormal Papanicolaou (Pap) test
- Untreated acute cervicitis or vaginitis
- Acute hepatic disease or hepatic tumor (benign or malignant)
- Genital bleeding of unknown cause
- Conditions associated with increased risk of infection
- Genital actinomycosis
- Previously inserted intrauterine device that has not been removed
- Known or suspected breast cancer
- History of ectopic pregnancy or conditions that predispose to it

**Plan B**
- Hypersensitivity to drug or its components
- Known or suspected pregnancy
- Undiagnosed abnormal genital bleeding

**Precautions**
Use Mirena cautiously in:
- diabetes mellitus
- breastfeeding patients.
Use Plan B cautiously in:
- coagulopathy
- diabetes mellitus
- patients receiving anticoagulants concurrently.

**Administration**
- Know that Mirena should be inserted under aseptic conditions by health care professional familiar with procedure.
- Verify that patient isn’t pregnant before Mirena insertion.
- Know that Plan B should be given as soon as possible within 72 hours of unprotected sexual intercourse. Drug isn’t suitable as long-term contraceptive.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1.6 ± 0.7 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>Intrauterine</td>
<td>No peaks or troughs</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Adverse reactions**

- **CNS:** headache (Mirena, Plan B), fatigue, dizziness (Plan B), severe headache, migraine, nervousness, depression (Mirena)
- **CV:** hypertension (Mirena)
- **EENT:** sinusitis (Mirena)
- **GI:** nausea, vomiting, abdominal pain (Mirena, Plan B), diarrhea (Plan B), intestinal perforation or obstruction (Mirena)
- **GU:** breast tenderness (Mirena, Plan B); lighter or heavier menstrual bleeding (Plan B); breast pain; increased progesterone levels; ovarian cysts; dysmenorrhea; amenorrhea; spotting; erratic or prolonged menstrual bleeding; pelvic infection; vaginitis; cervicitis; dyspareunia; leukorrhea; decreased libido; abnormal Pap smear; expulsion, embedment in myometrium, adhesions, **cervical or ureteral perforation** (Mirena)
- **Hematologic:** anemia (Mirena)
- **Hepatic:** jaundice (Mirena)
- **Musculoskeletal:** back pain (Mirena)
- **Respiratory:** upper respiratory tract infection (Mirena)
- **Skin:** skin disorder, acne, eczema, hair loss (Mirena)
- **Other:** water retention, weight gain, sepsis (Mirena)

**Interactions**

- **Drug-drug.** Hepatic enzyme-inducing drugs (such as barbiturates, carbamazepine, phenytoin, rifampin): decreased Plan B efficacy
- **Drug-diagnostic tests.** Glucose: altered level (Mirena)

**Patient monitoring**
- Monitor blood pressure.
- Watch for adverse reactions, especially changes in menstrual bleeding.
• Monitor blood glucose level in diabetic patients.
• Check liver function tests frequently.

Patient teaching
• Tell patient taking either product that drug does not prevent HIV or other sexually transmitted diseases.
• Teach patient using Mirena how to check (after menstrual period) to make sure thread still protrudes from cervix. Caution her not to pull on thread, because this could cause displacement.
• Explain that for maximum efficacy, patient should take Plan B as soon as possible after unprotected sex.
• Inform patient that Plan B isn’t intended for routine contraception and doesn’t terminate existing pregnancy.
• Tell patient to report adverse reactions.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Availability
*Injection: 2 mg/ml
*Tablets: 2 mg

Indications and dosages

Pain
Adults: 2 mg P.O. q 3 to 6 hours p.r.n., provided patient is assessed for hypoventilation and excessive sedation. Range is 8 to 16 mg over 24 hours in nontolerant patients (daily dosages above 16 mg aren’t recommended). Alternatively, 2 mg subcutaneously or I.V.; may increase to 3 mg p.r.n. For cancer patients and in other situations in which long-term opioid therapy is indicated, daily dosage is approximately one-twelfth of daily oral morphine dosage; however, therapy should be individualized.

Preoperative analgesia
Adults: 1 to 2 mg subcutaneously 90 minutes before surgery

Dosage adjustment
• Hepatic or renal insufficiency
• Elderly patients

Contraindications
• Hypersensitivity to drug or other opioid agonists
• Bronchial asthma
• Increased intracranial pressure
• Respiratory depression
• Acute alcoholism

Precautions
Use cautiously in:
• renal or hepatic dysfunction, chronic obstructive pulmonary disease, acute abdominal conditions, cardiovascular disease, seizure disorders, cerebral arteriosclerosis, Addison’s disease, prostatic hypertrophy, toxic psychosis
• pregnant or breastfeeding patients
• children.

levorphanol tartrate
Levo-Dromoran

Pharmacologic class: Synthetic opioid agonist
Therapeutic class: Opioid analgesic
Controlled substance schedule II
Pregnancy risk category C

Action
Inhibits adenylate cyclase, which regulates release of pain neurotransmitters (acetylcholine, dopamine, substance P, and gamma-aminobutyric acid). Also stimulates mu and kappa opioid receptors, altering perception of and emotional response to pain.
Administration

Make sure resuscitation equipment is available before starting therapy.
- Give I.V. injection slowly, administering each 2 mg over at least 4 to 5 minutes. Monitor patient response.
- Know that I.V. route is preferred in emergencies only.
- After parenteral administration, place patient in supine position with legs elevated to minimize adverse reactions.
- Be aware that 2 mg of levorphanol tartrate is analgesically equivalent to 10 to 15 mg of morphine and 100 mg of meperidine.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>10-60 min</td>
<td>90-120 min</td>
<td>4-5 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>20 min</td>
<td>4-5 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>Unknown</td>
<td>60 min</td>
<td>4-5 hr</td>
</tr>
<tr>
<td>Subcut.</td>
<td>Unknown</td>
<td>60-90 min</td>
<td>4-5 hr</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: personality disorders, nervousness, insomnia, hypokinesia, dyskinesia, drowsiness, light-headedness, dizziness, depression, delusions, confusion, amnesia, sedation, euphoria, delirium, mood changes, coma, seizures
CV: palpitations, hypotension, tachycardia, bradycardia, shock, peripheral circulatory collapse, cardiac arrest
EENT: diplopia, abnormal vision
GI: nausea, vomiting, constipation, abdominal pain, dyspepsia, increased colonic motility (in patients with chronic ulcerative colitis), dry mouth
GU: dysuria, urinary retention or hesitancy, ureteral or vesicle sphincter spasms, decreased libido, oliguria
Hepatic: biliary tract spasms, hepatic failure
Respiratory: suppressed cough reflex, hyperventilation, periodic apnea
Skin: urticaria, rash, pruritus, cyanosis, facial flushing

Other: injection site pain, redness, or swelling; physical or psychological drug dependence

Interactions

Drug-drug. Alfentanil, fentanyl, sufentanil, other CNS depressants: increased CNS and respiratory depression, increased risk of hypotension
Anticholinergics: increased risk of severe constipation
Antidiarrheals (such as atropine, difenoxin, kaolin, loperamide), antihypertensives: increased risk of hypotension
Buprenorphine, naloxone, naltrexone: decreased levorphanol efficacy
Metoclopramide: antagonism of metoclopramide effects
Neuromuscular blockers: increased risk of prolonged CNS and respiratory depression

Drug-diagnostic tests. Amylase, lipase: increased levels

Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring

- Check vital signs and respiratory status, and monitor ECG carefully.
- Evaluate fluid intake and output.
- Assess neurologic status. Institute safety precautions as needed to prevent injury.
- Watch for signs and symptoms of depression.
- Monitor liver and kidney function tests.

Patient teaching

- With parenteral use, explain need for continuous vital sign and ECG monitoring.
- To minimize adverse effects, instruct patient to lie supine after parenteral administration, if possible.
- Instruct patient or caregiver to report adverse reactions immediately.
- Tell patient or caregiver to use safety measures as needed to prevent injury and to report significant problems.
• Instruct patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

levothyroxine sodium
(L-thyroxine, T4)
Eltroxin®, Euthyrox®, Evox®, Levo-T, Levolet, Levothroid, Levoxyl, Nu-Thyro®, Soloxine, Synthroid, Unithroid

Pharmacologic class: Synthetic thyroxine hormone
Therapeutic class: Thyroid hormone replacement
Pregnancy risk category A

FDA BOXED WARNING
• Drug shouldn’t be used alone or with other agents to treat obesity or weight loss. In euthyroid patients, doses within range of daily hormonal requirements are ineffective for weight loss. Larger doses may cause serious or life-threatening toxicity, particularly when given with sympathomimetic amines (such as those used for anorectic effects).

Action
Synthetic form of thyroxine that replaces endogenous thyroxine, increasing thyroid hormone levels. Thyroid hormones help regulate cell growth and differentiation and increase metabolism of lipids, protein, and carbohydrates.

Availability
Powder for injection: 200 mcg/vial in 6- and 10-ml vials, 500 mcg/vial in 6- and 10-ml vials
Tablets: 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 300 mcg

Indications and dosages
Hypothyroidism; treatment or prevention of euthyroid goiter
Adults: For healthy adults younger than age 50 and those over age 50 who have recently been treated or undergone short-term therapy, start at full replacement dosage of 1.7 mcg/kg P.O. daily, given 30 minutes to 1 hour before breakfast. For patients older than age 50 or younger than age 50 with heart disease, 25 to 50 mcg P.O. daily, increased q 4 to 6 weeks. In severe hypothyroidism, initial dosage is 12.5 to 25 mcg P.O. daily, adjusted by 25 mcg daily q 2 to 4 weeks. For patients who can’t tolerate oral doses, adjust I.M. or I.V. dosage to roughly half of oral dosage.
Congenital hypothyroidism
Children older than age 12 who have completed puberty and growth: 1.7 mcg/kg P.O. daily
Children older than age 12 who have not completed puberty and growth: Up to 150 mcg or 2 to 3 mcg/kg P.O. daily
Children ages 6 to 12: 4 to 5 mcg/kg P.O. daily
Children ages 1 to 5: 5 to 6 mcg/kg P.O. daily
Infants ages 6 to 12 months: 6 to 8 mcg/kg P.O. daily
Infants ages 3 to 6 months: 8 to 10 mcg/kg P.O. daily
Infants up to 3 months old: 10 to 15 mcg/kg P.O. daily
Myxedema coma or stupor

**Adults:** 200 to 500 mcg I.V. as a solution containing 100 mcg/ml. Additional 100 to 300 mcg may be given on day 2 if significant improvement has not occurred. Convert to P.O. therapy when patient is clinically stable.

Thyroid-stimulating hormone suppression in well-differentiated thyroid cancers and thyroid nodules

**Adults:** Dosage individualized based on disease and patient

**Dosage adjustment**
- Cardiovascular disease
- Psychosis or agitation
- Elderly patients

**Contraindications**
- Hypersensitivity to drug, its components, or tartrazine
- Acute myocardial infarction
- Thyrotoxicosis
- Adrenal insufficiency

**Precautions**
Use cautiously in:
- cardiovascular disease, severe renal insufficiency, diabetes mellitus
- elderly patients
- pregnant or breastfeeding patients.

**Administration**
- Be aware that all dosages are highly individualized.
- Give tablets on an empty stomach 30 minutes to 1 hour before first meal of day.
- If patient can’t swallow tablets, crush them and sprinkle onto small amount of food, such as applesauce. For infants and children, dissolve tablets in small amount of water, nonsoybean formula, or breast milk and administer immediately.
- Don’t give oral form within 4 hours of bile acid sequestrants or antacids.
- Reconstitute Synthroid powder for injection with 5 ml of 0.9% sodium chloride injection. Shake until clear and use immediately.
  - For I.V. administration, give each 100 mcg over at least 1 minute.
  - Be aware that the various levothyroxine preparations aren’t bioequivalent. Patient should consistently use same brand or generic product, with dosing based on weight, age, physical condition, and symptom duration.
  - When drug is given for thyroid-stimulating hormone (TSH) suppression test, TSH suppression level is not well established and radioactive iodine (¹³¹I) is given before and after treatment course.

**Route** | **Onset** | **Peak** | **Duration**
--- | --- | --- | ---
P.O. | Unknown | Unknown | Unknown
I.V. | 6-8 hr | 24 hr | Unknown
I.M. | Unknown | Unknown | Unknown

**Adverse reactions**
- **CNS:** insomnia, irritability, nervousness, headache
- **CV:** tachycardia, angina pectoris, hypotension, hypertension, increased cardiac output, arrhythmias, cardiovascular collapse
- **GI:** vomiting, diarrhea, abdominal cramps
- **GU:** menstrual irregularities
- **Metabolic:** hyperthyroidism
- **Musculoskeletal:** accelerated bone maturation (in children), decreased bone density (in women on long-term therapy)
- **Skin:** alopecia (in children), diaphoresis
- **Other:** heat intolerance, weight loss

**Interactions**
- **Drug-drug.** Aminoglutethimide, amiodarone, anabolic steroids, antithyroid drugs, asparaginase, barbiturates, carbamazepine, chloral hydrate, cholestyramine, clofibrate, colistin, corticosteroids, danazol, diazepam, estrogens, ethionamide, fluorouracil, heparin (with I.V. use), insulin, lithium, methadone, mitotane, nitroprusside, oxyphenbutazone,

Reactions in **bold** are life-threatening.
perphenazine, phenylbutazone, phenytoin, propranolol, salicylates (large doses), sulfonylureas, thiazides: altered thyroid function test results

Antacids, bile acid sequestrants: interference with levothyroxine absorption

Anticoagulants: increased anticoagulant action

Beta-adrenergic blockers (selected): decreased beta blocker action

Cardiac glycosides: decreased cardiac glycoside blood level

Cholestyramine, colestipol: levothyroxine inefficacy

Theophylline: decreased theophylline clearance

Drug-diagnostic tests. Thyroid function tests: decreased values

Drug-food. Foods high in iron or fiber, soybeans: decreased drug absorption

Patient monitoring
- Check vital signs and ECG routinely.
- Monitor thyroid and liver function tests.
- Evaluate for signs and symptoms of overdose, including those of hyperthyroidism (weight loss, cardiac symptoms, abdominal cramps).
- Monitor closely for drug efficacy.
- Check patients with Addison's disease or diabetes mellitus for worsening of these conditions.
- Watch for signs and symptoms of bleeding tendency, especially in patients receiving anticoagulants concurrently.

Patient teaching
- Explain that patient may require lifelong therapy and must undergo regular blood testing.
- Tell patient or parent to report adverse effects, including signs or symptoms of hyperthyroidism or hypothyroidism.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Advise patient to avoid getting overheated, as in hot environments or during vigorous exercise.
- Tell parents that child being treated may lose hair during first few months of therapy. Reassure them that this effect usually is transient.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

lidocaine hydrochloride

Pharmacologic class: Amide

Therapeutic class: Antiarrhythmic (class IB), local anesthetic

Pregnancy risk category B

Action
Suppresses automaticity of ventricular cells, decreasing diastolic depolarization and increasing ventricular fibrillation threshold. Produces local anesthesia by reducing sodium permeability of sensory nerves, which blocks impulse generation and conduction.

Availability
Injection for I.M. use: 300 mg/3 ml (automatic injection device)
Injection for direct I.V. use: 1% and 2% in syringes and vials
Injection for I.V. infusion: 2 mg/ml, 4 mg/ml, 8 mg/ml
Injection for I.V. injection admixtures: 40 mg/ml, 100 mg/ml, 200 mg/ml
Patch: 5%
Topical cream: 0.5%, 4%
Indications and dosages

> Ventricular arrhythmias

**Adults:** Initially, 50 to 100 mg I.V. bolus given at rate of 25 to 50 mg/minute. If desired response doesn’t occur after 5 minutes, give repeat dose at 25 to 50 mg/minute; maximum dosage is 300 mg given over 1 hour. Maintenance dosage is 1 to 4 mg/minute by continuous I.V. infusion for no more than 24 hours.

**Children:** Initially, 1 mg/kg I.V. bolus, then repeated based on patient response; don’t exceed 5 mg/kg. Maintenance dosage is 30 mcg/kg/minute by continuous I.V. infusion.

> Caudal anesthesia (without epinephrine)

**Adults:** For obstetric analgesia, 200 to 300 mg caudally as 1% solution. For surgical anesthesia, 225 to 300 mg as 1.5% solution. For continuous caudal anesthesia, don’t repeat maximum dosage at intervals of less than 90 minutes.

> Epidural anesthesia (without epinephrine)

**Adults:** For lumbar analgesia, 250 to 300 mg epidurally as 1% solution. For surgical anesthesia, 225 to 300 mg as 1.5% solution. For continuous epidural anesthesia, don’t repeat maximum dosage at intervals of less than 90 minutes.

> I.V. regional infiltration (without epinephrine)

**Adults:** 50 to 300 mg I.V. as 0.5% solution. For I.V. regional anesthesia, maximum dosage is 4 mg/kg.

> I.V. local infiltration (without epinephrine)

**Children:** Up to 4.5 mg/kg I.V. as 0.25% to 1% solution

> Spinal anesthesia (without epinephrine)

**Adults:** For obstetric low-spinal or saddle-block anesthesia (normal vaginal delivery), 50 mg of 5% Xylocaine-MPF with glucose 7.5%, or 9 to 15 mg of 1.5% Xylocaine-MPF with dextrose 7.5%. For cesarean section, 75 mg of 5% Xylocaine-MPF with glucose 7.5%. For surgical anesthesia, 75 to 100 mg of 5% Xylocaine-MPF with glucose 7.5%.

> Paracervical anesthesia (without epinephrine)

**Adults:** For obstetric analgesia, 100 mg paracervically as 1% solution (each side). For paracervical block, maximum dosage is 200 mg over each 90-minute period (half administered on each side).

> Peripheral nerve block

**Adults:** For brachial nerve block, 225 to 300 mg as 1.5% solution. For dental nerve block, 20 to 100 mg as 2% solution with epinephrine 1:100,000 or 1:50,000. For intercostal nerve block, 30 mg as 1% solution. For pudendal nerve block, 100 mg as 1% solution. For paravertebral nerve block, 30 mg to 50 mg as 1% solution.

> Sympathetic nerve block (without epinephrine)

**Adults:** For cervical nerve block, 50 mg as 1% solution. For lumbar nerve block, 50 to 100 mg as 1% solution.

> Dental anesthesia

**Adults:** 1 to 5 ml of lidocaine 2% with epinephrine 1:50,000 or 1:100,000. Maximum dosage is less than 500 mg (7 mg/kg).

**Children:** 20 to 30 mg as 2% solution with epinephrine 1:100,000

> Topical anesthesia for skin or mucous membranes

**Adults:** Apply thin layer of gel, jelly, or ointment to skin or mucous membranes as needed before procedure; or apply 5% patch to most painful areas

Reactions in **bold** are life-threatening.
and intact skin (up to three patches at a time for up to 12 hours within a 24-hour period). For new denture fittings, use 5-g ointment (250 mg) per single dose or 20 g/day. For oropharyngeal use, apply to desired area or to instrument before insertion.

**Children:** Apply thin layer of ointment to skin or mucous membranes p.r.n. before procedure. Maximum dosage is 2.5 g ointment per 6 hours or 4.5 mg/kg.

- Prevention or treatment of pain during procedures involving male or female urethra

**Adults:** For female urethral examination, apply 3 to 5 ml of 2% jelly topically several minutes before exam. For male sounding or cystoscopy, apply 5 to 10 ml of 2% jelly topically before procedure, or apply 30 ml to fill or dilate urethra in divided doses using penile clamp for several minutes between doses. For male catheterization, apply 5 to 10 ml of 2% jelly to anterior urethra before procedure. Don’t use more than 600 mg/12 hours.

- Oral cavity disorders; pharyngeal disorders

**Adults:** For oral cavity disorders, 300 mg (15 ml) of viscous oral topical solution swished and then expelled, or applied with cotton swab q 3 hours p.r.n. For pharyngeal disorders, use same dosage, but solution may be swallowed.

**Children older than age 3:** Dosage individualized based on age, weight, and physical condition. Maximum dosage is 4.5 mg/kg q 3 hours.

**Children up to age 3:** 1.25 ml applied with swab q 3 hours

- Local anesthesia (oral or nasal mucosa)

**Adults:** 0.6 to 3 mg/kg or 40 to 200 mg of 4% topical solution, not to exceed 4.5 mg/kg or 300 mg (7.5 ml)

**Children:** Dosage individualized

---

**Off-label uses**
- Pediatric patients with cardiac arrest who develop frequent premature ventricular contractions
- Status epilepticus

**Contraindications**
- Hypersensitivity to drug, its components, or other amide local anesthetics
- Heart failure, cardiogenic shock, second- or third-degree heart block, intraventricular block in absence of a pacemaker
- Wolff-Parkinson-White or Adams-Stokes syndrome
- Severe hemorrhage, shock, or heart block (lidocaine with dextrose)
- Local infection at puncture site (lidocaine with dextrose)
- Septicemia (lidocaine with dextrose)

**Precautions**
Use cautiously in:
- renal or hepatic disorders, inflammation or sepsis in injection area
- labor or delivery
- breastfeeding patients.

**Administration**

- Know that I.V. lidocaine is a high-alert drug.
- Make sure resuscitation equipment and oxygen are available before giving I.V. lidocaine.
- Dilute injection in additive syringe and single-use vial according to manufacturer’s instructions before administering as I.V. infusion.
- Add 1 g lidocaine to 1 L dextrose 5% in water to yield a solution of 1 mg/ml.
- For I.V. bolus injection, give doses of 25 to 50 mg over at least 1 minute. Deliver continuous infusion by infusion pump no faster than 4 mg/minute.
- Know that too-rapid infusion may cause seizures.
- Be aware that drug can be given I.M. using 10% parenteral solution only.
Adverse reactions

CNS: anxiety; confusion; difficulty speaking; dizziness; hallucinations; lethargy; paresthesia; light-headedness; fatigue; drowsiness; headache; persistent sensory, motor, or autonomic deficit of lower spinal segment; septic meningitis; seizures

CV: bradycardia, hypotension, new or worsening arrhythmias, cardiac arrest

EENT: diplopia, abnormal vision

GI: nausea, vomiting, dry mouth

GU: urinary retention

Metabolic: methemoglobinemia

Respiratory: suppressed cough reflex, respiratory depression, respiratory arrest

Skin: rash; urticaria; pruritus; erythema; contact dermatitis; cutaneous lesions; tissue irritation, sloughing, and necrosis

Other: fever; edema; infection, burning, stinging, tenderness, and swelling at injection site; anaphylaxis

Interactions

Drug-drug. Beta-adrenergic blockers, cimetidine: increased lidocaine blood level

MAO inhibitors, tricyclic antidepressants: prolonged hypertension

Mexiletine, tocainide: additive cardiac effects

Phenytoin, procainamide: increased cardiac depression

Drug-diagnostic tests. Creatine kinase: increased level (with I.M. use)

Patient monitoring

Monitor vital signs and ECG continuously. Watch for cardiac depression.

Reactions in bold are life-threatening.
Seizures and deaths have occurred with repeat or prolonged application, and in rare cases after a single application used as directed. Use cautiously in infants, children, elderly patients, persons with other skin conditions, and in those weighing less than 110 lb (50 kg).

- Drug is contraindicated in premature infants and patients with uncontrolled seizure disorders.
- Instruct patient about proper drug use, amount to apply, how long to leave it on, and importance of avoiding retreatment.

**Action**
Absorbed through parasitic ova and arthropods, which stimulates parasitic nervous system and results in seizures and death of parasite

**Availability**
* Lotion: 1%
* Shampoo: 1%

**Indications and dosages**
- Secondary treatment of scabies
  - **Adults and children:** Apply enough lotion on dry skin to cover entire surface from neck down. Rub in well, and leave in place 12 hours. Then wash skin thoroughly.
  - Secondary treatment of Pediculosis capitis (head lice) or Pediculosis pubis (pubic lice)
  - **Adults and children:** Apply enough shampoo to dry hair (1 oz or less for short hair, 1½ oz for medium length hair, up to 2 oz for long hair) to thoroughly wet hair and skin or scalp of affected and surrounding hairy areas. Leave in place 12 hours. Then wash hair thoroughly.

**Contraindications**
- Hypersensitivity to drug or its components
- Seizure disorder
- Crusted (Norwegian) scabies and other conditions that may increase systemic drug absorption
- Premature neonates

**Precautions**
Use cautiously in:
- conditions that increase seizure risk (such as history of seizures, head injury, AIDS)
- skin conditions
- concurrent use of skin creams, oils, or ointments
- patients weighing less than 50 kg (110 lb)
- elderly patients
- breastfeeding patients
- infants or children.

**Administration**
- To apply, wear gloves made of nitrile, latex with neoprene, or sheer vinyl.
- Before applying lindane shampoo, use regular shampoo without conditioner; rinse and dry hair completely. Wait 1 hour before using lindane shampoo.
- Don’t use lindane lotion or shampoo with other lotions, creams, or oils.
- Thoroughly wash skin after lotion has been in place for 12 hours.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Topical</td>
<td>Unknown</td>
<td>6 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- CNS: dizziness, seizures, headache, anxiety, paresthesia
- EENT: irritation of eyes, nose, and throat (from vapor inhalation)
- GI: nausea and vomiting (from vapor inhalation)
- **Hematologic:** aplastic anemia (with prolonged use)
- **Skin:** dermatitis, urticaria, pruritus, alopecia
- **Other:** pain

**Interactions**
**Drug-drug.** Drugs that lower seizure threshold, antidepressants: increased seizure activity

---

Canada UK Hazardous drug High alert drug
Patient monitoring
- Monitor drug efficacy.

Patient teaching
- Emphasize that drug is for external use only, and that ingesting even small amounts can be fatal.
- If drug will be applied by another person, tell patient that this person must wear gloves made of nitrile, latex with neoprene, or sheer vinyl.
- Instruct patient using lindane lotion to wash, rinse, and dry skin well before applying lindane if skin has cream, lotion, ointment, or oil on it. If he takes a warm bath or shower before applying lindane, instruct him to let skin dry and cool down. Then tell him to apply lindane to dry skin, rub in well, leave on skin for 8 to 12 hours, and then remove it by washing thoroughly.
- Instruct patient using lindane shampoo to apply enough shampoo to dry hair to thoroughly wet the hair and skin or scalp of affected and surrounding hairy areas, and then rub shampoo thoroughly into hair and skin or scalp and let it sit for 4 minutes. Then tell him to add just enough water to work up a good lather, then rinse thoroughly and dry hair with clean towel. When hair is completely dry, instruct him to comb it with a fine-toothed comb to remove any remaining nits or nit shells. Tell him not to use shampoo in combination with oils, lotions, or creams.
- To avoid reinfestation, instruct patient to launder all recently worn or used clothing, bed linens, and towels in hot water.
- Caution patient to avoid contact with eyes when applying lotion or shampoo.
- Tell patient with scabies that sexual contacts and other close personal contacts should be examined and, if necessary, treated.
- Advise female patient to inform prescriber if she plans to breastfeed.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

linezolid
Zyvox, Zyvoxam

Pharmacologic class: Oxazolidinone
Therapeutic class: Anti-infective
Pregnancy risk category C

Action
Selectively binds to bacterial 23S ribosomal RNA of 50S subunit, preventing formation of essential component of bacterial protein synthesis. Bacteriostatic or bactericidal against gram-positive and some gram-negative bacteria.

Availability
Injection: 2 mg/ml
Powder for oral suspension: 100 mg/5 ml
Tablets: 400 mg, 600 mg

Indications and dosages
➣ Vancomycin-resistant Enterococcus faecium infections
Adults and children ages 12 and older: 600 mg P.O. or I.V. infusion q 12 hours for 14 to 28 days
Children from birth to age 11: 10 mg/kg I.V. q 8 hours for 14 to 28 days
➣ Nosocomial pneumonia; community-acquired pneumonia; complicated skin and skin-structure infections
Adults and children ages 12 and older: 600 mg P.O. or I.V. infusion q 12 hours for 10 to 14 days
Children from birth to age 11: 10 mg/kg P.O. or I.V. q 8 hours for 10 to 14 days
➣ Uncomplicated skin and soft-tissue infections

Reactions in bold are life-threatening.
Adults: 400 mg P.O. q 12 hours for 10 to 14 days
Adolescents: 600 mg P.O. or I.V. q 12 hours for 10 to 14 days
Children ages 5 to 11: 10 mg/kg P.O. or I.V. q 12 hours for 10 to 14 days
Children younger than age 5: 10 mg/kg P.O. or I.V. q 8 hours for 10 to 14 days

Contraindications
- Hypersensitivity to drug or its components

Precautions
Use cautiously in:
- hepatic dysfunction, hypertension, hyperthyroidism, pheochromocytoma, bone marrow depression, pseudomembranous colitis
- phenylketonuria (oral suspension only)
- pregnant or breastfeeding patients.

Administration
- Give oral drug with or without food.
- For I.V. injection, use single-use, ready-to-use infusion bag. Check for particulate matter before giving. Infuse over 30 minutes to 2 hours.
- For I.V. infusion, mix with dextrose 5% in water, normal saline solution, or lactated Ringer’s injection.
- Flush I.V. line before and after administering, to avoid incompatibilities.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>1-2 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: anxiety, confusion, difficulty speaking, dizziness, hallucinations, lethargy, paresthesia, light-headedness, fatigue, drowsiness, headache, seizures
GI: nausea, vomiting, diarrhea, gastritis, anorexia, dry mouth, pseudomembranous colitis

Hematologic: thrombocytopenia
Skin: rash, photosensitivity, diaphoresis
Other: fever, fungal infections

Interactions
Drug-drug. Antiplatelet drugs (such as aspirin, dipyridamole, nonsteroidal anti-inflammatory drugs): increased bleeding risk
MAO inhibitors, pseudoephedrine: increased risk of hypertension and associated adverse effects
Serotonergics: serotonin syndrome

Drug-diagnostic tests. Prothrombin time: altered

Drug-food. Tyramine-containing foods and beverages (such as beer; Chianti and certain other red wines; aged cheese; bananas; aged, cured, or spoiled meats; salted herring and other dried fish; avocado; bean curd; red plums; soy sauce; spinach; tofu, tomatoes; yeast): hypertension

Patient monitoring
- Monitor neurologic status. Institute safety measures as needed to prevent injury.
- Check I.V. site for infiltration.
- Watch for bleeding and signs and symptoms of other adverse reactions (especially pseudomembranous colitis).
- Monitor CBC, coagulation studies, and culture and sensitivity tests.

Patient teaching
- Tell patient he may take with or without food, but should avoid foods containing tyramine.
- Tell patient to promptly report bleeding or severe diarrhea.
- Instruct patient to minimize adverse GI effects by eating small, frequent servings of healthy food.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

liothyronine sodium (T₃)
Cytomel, Tertroxin®, Triostat

Pharmacologic class: Synthetic thyroxine hormone
Therapeutic class: Thyroid hormone replacement
Pregnancy risk category A

FDA BOXED WARNING

- Drug has been used (alone or with other agents) to treat obesity. In euthyroid patients, doses within range of daily hormonal requirements are ineffective for weight loss. Larger doses may cause serious or life-threatening toxicity, particularly when given with sympathomimetic amines (such as those used for anorectic effects).

Action

Synthetic form of triiodothyronine (T₃). Regulates cell growth and differentiation; increases metabolism of lipids, proteins, and carbohydrates; and enhances aerobic mitochondrial function. Also reduces tissue lactic acidosis.

Availability

Injection: 10 mcg/ml in 1-ml vials
Tablets: 5 mcg, 25 mcg, 50 mcg

Indications and dosages

➤ Thyroid hormone replacement in mild hypothyroidism
Adults: All dosages individualized. Initially, 25 mcg P.O. daily; may increase in increments of 12.5 to 25 mcg/day q 1 to 2 weeks. Usual maintenance dosage is 25 to 75 mcg P.O. daily.

➤ Myxedema
Adults: All dosages individualized. Initially, 5 mcg P.O. daily; increase in increments of 5 to 10 mcg/day q 1 to 2 weeks, up to 25 mcg/day. If response still isn’t adequate, increase by 5 mcg to 25 mcg P.O. daily q 1 to 2 weeks until desired response occurs. Usual maintenance dosage is 50 to 100 mcg/day P.O.

➤ Myxedema coma
Adults: Initially, 25 to 50 mcg I.V.; after 4 hours, reassess patient’s need for subsequent doses (up to 65 mcg in 24 hours). In cardiovascular disease, initial dosage is 10 to 20 mcg I.V.

➤ Simple goiter
Adults: All dosages individualized. Initially, 5 mcg P.O. daily. Increase by 5 to 10 mcg/day q 1 to 2 weeks, up to 25 mcg/day; then increase by 12.5 to 25 mcg P.O. daily q week until desired effect occurs. Usual maintenance dosage is 75 mcg P.O. daily.

Children or elderly adults: Initially, 5 mcg P.O. once daily. Increase by 5 mcg q 1 to 2 weeks until desired effect occurs.

➤ T₃ suppression test to distinguish hyperthyroidism from thyroid gland autonomy
Adults: 75 to 100 mcg P.O. daily for 7 days in conjunction with radioactive iodine

Dosage adjustment

- Severe, long-standing hypothyroidism
- Cardiovascular disease
- Psychosis or agitation
- Elderly patients

Contraindications

- Hypersensitivity to drug or its components
- Acute myocardial infarction
- Untreated thyrotoxicosis

Reactions in bold are life-threatening.
Uncorrected adrenal insufficiency and coexisting hypothyroidism

Artificial rewarming (I.V. form only)

**Precautions**

Use cautiously in:
- cardiovascular disease, severe renal insufficiency, uncorrected adrenocortical disorders, diabetes mellitus
- elderly patients
- pregnant or breastfeeding patients.

**Administration**

- Know that all dosages are highly individualized.
- Administer single oral dose in morning with or without food.
- Injectable form is for I.V. use only. Don’t give I.M.
- Infuse each 10-mcg dose over 1 minute.
- Give repeat I.V. doses more than 4 hours but less than 12 hours apart.
- Be aware that in T₃ suppression test, radioactive iodine (¹³¹I) is given before and after 7-day liothyronine course.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>24-72 hr</td>
<td>72 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** insomnia, irritability, nervousness, headache

**CV:** tachycardia, angina pectoris, hypotension, hypertension, increased cardiac output, arrhythmias, cardiovascular collapse

**GI:** vomiting, diarrhea, cramps

**GU:** menstrual irregularities

**Metabolic:** hyperthyroidism, hyperglycemia

**Musculoskeletal:** accelerated bone maturation (in children), decreased bone density (with long-term use in women)

**Skin:** alopecia (in children), diaphoresis

**Other:** weight loss, heat intolerance

**Interactions**

**Drug-drug.** Anabolic steroids, antithyroid drugs, asparaginase, barbiturates, carbamazepine, chloral hydrate, clofibrate, corticosteroids, danazol, estrogens, fluorouracil, heparin (with I.V. use), lithium, methadone, mitotane, oxyphenbutazone, perphenazine, phenylbutazone, phenytoin, propranolol, salicylates (large doses), sulfonylureas: altered thyroid function test results

Anticoagulants: increased anticoagulant action

Beta-adrenergic blockers (selected): impaired beta blocker action

Cardiac glycosides: decreased cardiac glycoside blood level

Cholestyramine, colestipol: liothyronine inefficacy

Theophyllines: decreased theophylline clearance

**Drug-diagnostic tests.** Thyroid function tests: altered values

**Drug-food.** Foods high in iron or fiber, soybeans: decreased drug absorption

**Patient monitoring**

Monitor for evidence of overdose, including signs and symptoms of hyperthyroidism (weight loss, cardiac symptoms, and abdominal cramps).

- In patients with Addison’s disease or diabetes mellitus, assess for evidence that these conditions are worsening. In diabetic patients, also monitor blood glucose level.
- Monitor vital signs and ECG routinely.
- Check thyroid and liver function tests.

**Patient teaching**

- Teach patient to take in morning with or without food.
- Explain that patient may require lifelong therapy and will need to undergo regular blood testing.
- Caution patient to avoid driving and other hazardous activities until he...
knows how drug affects concentration and alertness.

- Inform parents that hair loss may occur in children during first few months but that this effect is usually transient.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

**liotrix**

Thyrolar

**Pharmacologic class:** Synthetic thyroid hormone

**Therapeutic class:** Thyroid hormone replacement

**Pregnancy risk category A**

---

**FDA BOXED WARNING**

- Drug has been used (alone or with other agents) to treat obesity. In euthyroid patients, doses within range of daily hormonal requirements are ineffective for weight loss. Larger doses may produce serious or even life-threatening toxicity, particularly when given with sympathomimetic amines (such as those used for anorectic effects).

---

**Action**

Increases basal metabolic rate, helps regulate cell growth and differentiation, and enhances metabolism of lipids, proteins, and carbohydrates

**Availability**

*Tablets:* 12.5 mcg levothyroxine sodium and 3.1 mcg liothyronine sodium (Thyrolar-¼); 25 mcg levothyroxine sodium and 6.25 mcg liothyronine sodium (Thyrolar-½); 50 mcg levothyroxine sodium and 12.5 mcg liothyronine sodium (Thyrolar-1); 100 mcg levothyroxine sodium and 25 mcg liothyronine sodium (Thyrolar-2); 150 mcg levothyroxine sodium and 37.5 mcg liothyronine sodium (Thyrolar-3)

---

**Indications and dosages**

**Hypothyroidism**

**Adults:** All dosages individualized. Initially, one tablet Thyrolar-½ P.O., increased by one tablet Thyrolar-¼ P.O. daily until desired effect occurs. Usual maintenance dosage is one tablet Thyrolar-1 or Thyrolar-2 P.O. daily, adjusted within first 4 weeks based on laboratory results.

**Congenital hypothyroidism**

**Children older than age 12:** 18.75/75 mcg P.O. daily

**Children ages 6 to 11:** 12.5/50 to 18.75/75 mcg P.O. daily

**Children ages 1 to 5:** 9.35/37.5 to 12.5/50 mcg P.O. daily

**Children ages 6 to 12 months:** 6.25/25 to 9.35/37.5 mcg P.O. daily

**Children up to 6 months:** 3.1/12.5 to 6.25/25 mcg (Thyrolar-¼) P.O. daily

---

**Dosage adjustment**

- Severe, long-standing hypothyroidism
- Cardiovascular disease
- Psychosis or agitation
- Elderly patients

---

**Contraindications**

- Hypersensitivity to drug or its components
- Acute myocardial infarction
- Uncorrected thyrotoxicosis
- Uncorrected adrenal insufficiency and coexisting hypothyroidism

---

**Precautions**

Use cautiously in:

- cardiovascular disease, severe renal insufficiency, diabetes mellitus, uncorrected adrenocortical disorders
- elderly patients
- pregnant or breastfeeding patients.
Administration

- Know that all dosages are highly individualized.
- Administer single daily dose in morning with or without food.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>(levothyroxine)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>24-72 hr</td>
<td>72 hr</td>
</tr>
<tr>
<td>(liothyronine)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: insomnia, irritability, nervousness, headache
CV: angina pectoris, hypotension, hypertension, increased cardiac output, tachycardia, arrhythmias, cardiovascular collapse
GI: vomiting, diarrhea, cramps
GU: menstrual irregularities
Metabolic: hyperthyroidism
Musculoskeletal: accelerated bone maturation (in children), decreased bone density (with long-term use in women)
Skin: alopecia (in children), diaphoresis
Other: weight loss, heat intolerance

Interactions

Drug-drug. Aminoglutethimide, amiodarone, anabolic steroids, antithyroid drugs, asparaginase, barbiturates, carbamazepine, chloral hydrate, cholestyramine, clofibrate, colestipol, corticosteroids, danazol, diazepam, estrogens, ethionamide, fluorouracil, heparin (with I.V. use), insulin, lithium, methadone, mitotane, nitroprusside, oxphenbutazone, P-aminosalicylic acid, perphenazine, phenylbutazone, phenoxytin, propranolol, salicylates (large doses), sulfonylureas, thiazides: altered thyroid function test results
Anticoagulants: increased anticoagulant action
Beta-adrenergic blockers (selected): decreased beta blocker action
Cardiac glycosides: decreased cardiac glycoside blood level
Cholestyramine, colestipol: liotrix ineffectiveness
Theophyllines: decreased theophylline clearance
Drug-diagnostic tests. Thyroid function tests: decreased values
Drug-food. Foods high in iron or fiber, soybeans: decreased drug absorption

Patient monitoring

- Monitor for evidence of overdose, such as signs and symptoms of hyperthyroidism (weight loss, cardiac symptoms, abdominal cramps).
- Watch closely for signs and symptoms of undertreatment.
- In patients with Addison’s disease or diabetes mellitus, assess for signs that these conditions are worsening. In diabetic patients, monitor blood glucose level.
- Check vital signs and ECG routinely.
- Monitor thyroid and liver function tests.
- Assess for signs and symptoms of bleeding tendency, especially if patient’s taking anticoagulants.

Patient teaching

- Inform patient or parents that drug should be taken in morning with or without food.
- Explain that patient may require lifelong therapy and will need to undergo regular blood testing.
- Advise diabetic patient (or his parents) to monitor patient’s blood glucose level closely.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Inform parents that hair loss may occur in children during first few months of therapy but that this effect is usually transient.
- As appropriate, review all other significant and life-threatening adverse
reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

**lisdexamfetamine dimesylate**

Vyvanse

**Pharmacologic class:** Amphetamine prodrug

**Therapeutic class:** CNS stimulant

**Controlled substance schedule II**

**Pregnancy risk category C**

**FDA BOXED WARNING**

- Drug has high abuse potential. Prolonged use may lead to drug dependence. Stay alert for possibility of persons obtaining it for nontherapeutic use or distribution. Drug should be prescribed or dispensed sparingly.
- Drug misuse may cause sudden death and serious cardiovascular adverse events.

**Action**

Rapidly absorbed and converted to dextroamphetamine, which is responsible for CNS activity. Therapeutic action in attention deficit hyperactivity disorder (ADHD) is unknown.

**Availability**

Capsules: 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg

**Indications and dosages**

**ADHD**

**Adults and Children ages 6 to 12:** Individualize dosage based on therapeutic needs and response. For child starting treatment for first time or switching from another drug, recommended dosage is 30 mg P.O. once daily in morning. If daily dosage will be increased above 30 mg, adjust in increments of 10 to 20 mg/day at approximately weekly intervals. Maximum recommended dosage is 70 mg/day.

**Contraindications**

- Hypersensitivity or idiosyncratic reaction to sympathomimetic amines
- Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma, agitated state
- History of drug abuse
- During or within 14 days of MAO inhibitor therapy

**Precautions**

Use cautiously in:
- concurrent use of other sympathomimetics
eics, Tourette syndrome, hypertension or other cardiovascular conditions, preexisting psychosis (such as bipolar disorder)
electroencephalogram (EEG) abnormalities or seizures
gnant and breastfeeding patients
- adults
- children younger than age 6 or older than age 12 (safety and efficacy not established).

**Administration**

- Administer with or without food.
- Give in morning to avoid insomnia.
- Give capsules whole, or open and dissolve entire contents in glass of water. When using solution method, don’t divide single-capsule dose; make sure patient consumes solution immediately.

**Route Onset Peak Duration**

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: dizziness, headache, somnolence, insomnia, irritability, labile affect,
manic symptoms, dysphoria, euphoria, aggression, restlessness, tics, dyskinesia, psychomotor hyperactivity, psychotic episodes, depression, tremor, seizure, stroke
CV: palpitations, tachycardia, hypertension, ventricular hypertrophy, myocardial infarction, cardiomyopathy, sudden death
EENT: visual disturbances
GI: abdominal pain, nausea, vomiting, diarrhea, constipation, dry mouth, unpleasant taste
GU: libido changes, erectile dysfunction
Skin: rash, toxic epidermal necrolysis, urticaria, Stevens-Johnson syndrome
Other: decreased appetite, weight loss, growth suppression, fever, amphetamine tolerance and dependency, hypersensitivity reactions including angioedema and anaphylaxis

Interactions
Drug-drug. Adrenergic blockers: inhibited adrenergic blocker action
Antihistamines: decreased sedative effect of antihistamine
Antihypertensives: antagonism of antihypertensive effect
Chlorpromazine: inhibited stimulant effect
Desipramine, protriptyline (and possibly other tricyclic antidepressants): enhanced antidepressant activity, causing sustained rise in d-amphetamine concentration in brain
Ethosuximide: delayed intestinal absorption of this drug
Haloperidol: inhibited central stimulant effects
Lithium carbonate: inhibited anorectic and stimulatory effects of lisdexamfetamine
MAO inhibitors: slowed lisdexamfetamine metabolism, possibly leading to hypertensive crises
Meperidine: potentiated analgesic effect of meperidine

Methenamine therapy: increased amphetamine urinary excretion, causing reduced lisdexamfetamine blood level and efficacy
Norepinephrine: enhanced norepinephrine adrenergic effect
Phenobarbital, phenytoin: possible delayed intestinal absorption of these drugs, possible synergistic anticonvulsant action
Propoxyphene: increased risk of potentiated CNS stimulation (leading to life-threatening seizures in propoxyphene overdosage)

Drug-diagnostic tests. Plasma corticosteroids: increased levels
Urinary steroids: interference with results
Drug-herbs. Veratrum alkaloids, such as Veratrum album (white hellebore), V. escholtzii (American hellebore), and V. luteum (false unicorn): inhibited hypotensive effect of these herbs

Patient monitoring
● Before initiating therapy, evaluate patient and family for history of cardiovascular abnormalities, tics or Tourette syndrome (or exacerbation of these), EEG abnormalities, and seizures. Drug may lower seizure threshold.
● During early treatment phase, stay alert for worsening of aggressive behavior or hostility.
● Monitor blood pressure and pulse.
● Know that when possible, drug therapy should be interrupted occasionally to determine if behavioral symptoms recur to extent that necessitates continued therapy.
● Monitor patient for appropriate growth and weight gain.
● Watch for signs and symptoms of drug tolerance, dependence, and abuse.

Patient teaching
● Inform patient or caregiver that drug can be taken with or without food. Advise them that it should be taken in morning to help avoid insomnia.
Instruct patient to take capsule whole, or to open it and dissolve entire contents in glass of water, and consume solution immediately.

Advise patient or caregiver to watch for and report seizures, worsening of aggressive behavior, tics, or inappropriate growth or weight gain.

Instruct patient to avoid using herbs unless prescriber approves.

Caution patient to avoid hazardous activities until drug’s effects on concentration, coordination, and vision are known.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

---

**lisinopril**

Apo-Lisinopril®, Carace®, Co-Lisinopril®, Dom-Lisinopril®, Gen-Lisinopril®, Novo-Lisinopril®, PHL-Lisinopril®, Prinivil, Ratio-Lisinopril®, Riva-Lisinopril®, Zestril

**Pharmacologic class:** Angiotensin-converting enzyme (ACE) inhibitor  
**Therapeutic class:** Antihypertensive  
**Pregnancy risk category C** (first trimester), **D** (second and third trimesters)

---

**FDA BOXED WARNING**

- When used during second or third trimester of pregnancy, drug may cause fetal harm or death. Discontinue as soon as pregnancy is detected.

---

**Action**

Inhibits conversion of angiotensin I to angiotensin II (a potent vasoconstrictor), decreasing systemic vascular resistance, blood pressure, preload, and afterload. Also inactivates bradykinin and other vasodilatory prostaglandins, increases plasma renin levels, and reduces aldosterone levels.

---

**Availability**

Tablets: 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg

---

**Indications and dosages**

- **Hypertension**
  
  **Adults:** Initially, 10 mg P.O. daily, increased to a maintenance dosage of 20 to 40 mg/day. Maximum daily dosage is 80 mg. In patients on diuretics, start with 5 mg/day P.O.

- **Heart failure**
  
  **Adults:** 5 mg/day P.O. (Prinivil), increased in increments, as ordered, to a maximum of 20 mg/day as a single dose. Or 5 to 40 mg P.O. (Zestril) as a single daily dose given with digitalis and diuretics, increased in increments of no more than 10 mg at intervals of at least 2 weeks, to highest dosage tolerated; maximum dosage is 40 mg/day P.O.

- **Adjunctive therapy after acute myocardial infarction**
  
  **Adults:** Initially, 5 mg P.O., followed by 5 mg after 24 hours, 10 mg after 48 hours, and then 10 mg daily for 6 weeks (given with standard thrombolytic, aspirin, or beta-adrenergic blocker therapy). If systolic pressure is 120 mm Hg or lower, initial dosage is 2.5 mg for 2 days, then 2.5 to 5 mg/day.

---

**Dosage adjustment**

- Impaired renal function
- Heart failure with hyponatremia

---

**Contraindications**

- Hypersensitivity to drug or other ACE inhibitors
- Angioedema (hereditary, idiopathic, or ACE-inhibitor induced)
- Pregnancy (second and third trimesters)

---

Reactions in **bold** are life-threatening.
Precautions
Use cautiously in:
- renal impairment, hypertension, cerebrovascular or cardiac insufficiency
- family history of angioedema
- concurrent diuretic therapy
- black patients (in whom drug may be less effective in treating hypertension)
- elderly patients
- pregnant patients in first trimester
- breastfeeding patients
- children (safety not established).

Administration
- Give once a day in morning, with or without food.
  - Measure blood pressure before administering. Withhold drug, if appropriate, according to prescriber’s blood pressure parameters. Adjust dosage according to blood pressure response.
- Expect prescriber to add low-dose diuretic if lisinopril alone doesn’t control blood pressure.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1 hr</td>
<td>6 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, fatigue, headache, asthenia
CV: hypotension, orthostatic hypotension, syncope, chest pain, angina pectoris
GI: nausea, diarrhea, abdominal pain, anorexia
GU: erectile dysfunction, decreased libido, renal dysfunction
Metabolic: hyponatremia, hyperkalemia
Musculoskeletal: myalgia
Respiratory: cough, upper respiratory tract infection, bronchitis, dyspnea, asthma
Skin: rash, pruritus, angioedema
Other: altered taste, fever, anaphylaxis

Interactions
Drug-drug. Cyclosporine, potassium-sparing diuretics, potassium supplements: hyperkalemia
Diuretics, other antihypertensives: excessive hypotension
Indomethacin: reduced antihypertensive effect
Lithium: increased lithium blood level, greater risk of lithium toxicity
Nonsteroidal anti-inflammatory drugs: further deterioration in patients with renal compromise, decreased antihypertensive effects
Thiazides: hypokalemia

Drug-diagnostic tests. Blood urea nitrogen, creatinine, hematocrit, hemoglobin: slightly increased levels
Liver function tests, potassium: increased levels
Sodium: decreased level

Drug-food. Salt substitutes containing potassium: hyperkalemia

Drug-herbs. Capsaicin: cough
Ephedra (ma huang), licorice, yohimbine: antagonistic effects

Drug-behaviors. Acute alcohol ingestion: excessive hypotension

Patient monitoring
- Before and periodically during therapy, monitor CBC with white cell differential and kidney and liver function tests.
  - Monitor for signs and symptoms of angioedema or anaphylaxis. If these occur, discontinue drug and contact prescriber immediately.
- Check blood pressure frequently to assess drug efficacy. Monitor closely for hypotension, especially in patients also taking diuretics.
- Check vital signs and ECG regularly. Assess cardiovascular status carefully.
- Monitor respiratory and neurologic status.
- Assess potassium intake and blood potassium level.

Patient teaching
- Advise patient to take once a day in morning, with or without food.
  - Tell patient to immediately report fainting, continuing cough, rash,
itching, swelling (especially of face, lips, tongue, or throat), severe dizziness, difficulty breathing, extreme tiredness, or continuing nausea.

Instruct female patient to notify prescriber if she becomes pregnant.

Tell patient that drug may cause temporary blood pressure decrease if he stands up suddenly. Advise him to rise slowly and carefully.

Explain that drug may cause muscle aches or headache. Encourage patient to discuss activity recommendations and pain relief with prescriber.

Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

Instruct patient to avoid potassium-based salt substitutes or potassium supplements.

Tell patient he’ll undergo regular blood testing during therapy.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

**FDA BOXED WARNING**

- Lithium toxicity is closely related to lithium blood level and can occur at doses close to therapeutic levels. Before starting therapy, ensure that resources for prompt, accurate blood lithium testing are available.

**Action**

Unknown. Thought to disrupt sodium exchange and transport in nerves and muscles and control reuptake of neurotransmitters.

**Availability**

Capsules: 150 mg, 300 mg, 600 mg
Capsules (slow-release): 150 mg, 300 mg
Syrup (citrate): 300 mg (8 mEq lithium)/5 ml
Tablets: 300 mg
Tablets (controlled-release): 450 mg
Tablets (extended-release): 300 mg, 450 mg
Tablets (slow-release): 300 mg

**Indications and dosages**

- Manic episodes of bipolar disorder

  **Adults and children ages 12 and older:**
  900 to 1,800 mg P.O. daily in divided doses (for example, 300 to 600 mg t.i.d. or 450 to 900 mg b.i.d. of controlled- or slow-release form) to achieve blood level of 1 to 1.5 mEq/L; measure blood level twice weekly until patient stabilizes. Maintenance dosage is 900 to 1,200 mg/day in divided doses (for example, 300 to 400 mg t.i.d. or 450 to 600 mg b.i.d. of controlled- or slow-release form) to maintain blood level of 0.6 to 1.2 mEq/L. Monitor blood level at least q 2 months.

**Dosage adjustment**

- Impaired renal function
- Elderly patients

---

**lithium carbonate**


**lithium citrate**

PMS-Lithium Citrate®

**Pharmacologic class:** Miscellaneous CNS drug

**Therapeutic class:** Antimanic drug

**Pregnancy risk category D**

Reactions in **bold** are life-threatening.
Off-label uses
- Acute manic episodes in children
- Corticosteroid-induced psychosis
- Neutropenia secondary to antineoplastic therapy
- Tardive dyskinesia
- Alcoholism
- Bulimia

Contraindications
None

Precautions
Use cautiously in:
- hepatic or thyroid disease, severe cardiovascular or renal disease, diabetes mellitus, seizure disorders, systemic infections, brain trauma, organic brain syndrome, urinary retention, severe sodium depletion
- elderly patients
- pregnant or breastfeeding patients
- children (safety not established).

Administration
Be aware that dosages are individualized according to lithium blood level and response.
- Give with food or milk to minimize GI upset.
- Make sure patient swallows slow-release tablet whole without chewing or crushing.
- When switching patient from immediate-release to controlled- or slow-release form, give same total daily dosage.
- Know that immediate-release tablets typically are given three or four times daily, whereas controlled-release forms usually are given twice daily, roughly 12 hours apart.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>0.5-3 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>P.O. (controlled, slow-release)</td>
<td>Unknown</td>
<td>3-12 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, drowsiness, headache, tremor, tics, EEG changes, ataxia, choreoathetotic movements, abnormal tongue movements, extrapyramidal reactions, cogwheel rigidity, blackout spells, psychomotor retardation, slow mental functioning, slurred speech, startled response, restlessness, agitation, confusion, hallucinations, poor memory, worsening of organic brain syndrome, stupor, coma, epileptiform seizures
CV: bradycardia, ECG changes, hypotension, sinus node dysfunction with severe bradycardia and syncope, arrhythmias, peripheral circulatory collapse
EENT: blurred vision, nystagmus, tinnitus
GI: nausea, vomiting, diarrhea, abdominal pain, fecal incontinence, gastritis, flatulence, dyspepsia, anorexia, increased salivation, salivary gland swelling, dry mouth
GU: urinary incontinence, glycosuria, albuminuria, erectile or other sexual dysfunction, polyuria or other signs of nephrogenic diabetes insipidus, oliguria
Hematologic: leukocytosis
Metabolic: hypothyroidism or hyperthyroidism, goiter, hyperglycemia, hypercalcaemia, hyponatremia, hyperparathyroidism
Musculoskeletal: swollen or painful joints, muscle weakness, muscle fasciculations and twitching, clonic arm or leg movements, hypertonicity, hyperactive deep tendon reflexes, polyarthralgia
Skin: dry thin hair, alopecia, diminished or absent skin sensations, chronic folliculitis, eczema with dry skin, new onset or exacerbation of psoriasis, pruritus (with or without rash), cutaneous ulcers, angioedema
Other: altered, metallic, or salty taste; dental caries; weight gain; excessive thirst; polydipsia; fever; edema of lips, ankles, and wrists
Interactions

Drug-drug. Acetazolamide, alkalinizing agents (such as sodium bicarbonate), urea, verapamil, xanthines: decreased lithium blood level
Calcium channel blockers, carbamazepine, haloperidol, methyldopa: increased risk of neurotoxicity
Diuretics: increased sodium loss, increased risk of lithium toxicity
Fluoxetine, loop diuretics, metronidazole, nonsteroidal anti-inflammatory drugs: increased risk of lithium toxicity
Iodide salts: synergistic effects, increased risk of hypothyroidism
Neuromuscular blockers: prolonged neuromuscular blockade, severe respiratory depression
Phenothiazines: decreased phenothiazine blood level or increased lithium blood level, greater risk of neurotoxicity
Selective serotonin reuptake inhibitors: increased risk of tremor, confusion, dizziness, agitation, and diarrhea
Sympathomimetics: decreased pressor sensitivity
Tricyclic antidepressants: increased antidepressant effects

Drug-diagnostic tests. Albumin, creatinine, sodium, thyroxine, triiodothyronine: decreased levels
Calcium, glucose, 131I uptake, white blood cells (WBCs): increased levels

Drug-food. Caffeine-containing foods and beverages: decreased lithium blood level and efficacy

Drug-herbs. Caffeine-containing herbs (cola nut, guarana, yerba mate): decreased lithium blood level and efficacy

Patient monitoring

- Obtain baseline ECG and electrolyte levels before and periodically during therapy.
- Assess neurologic and psychiatric status. Institute safety measures as needed to prevent injury.
- Monitor lithium blood level, WBC count, and thyroid and kidney function tests.
- Assess cardiovascular status regularly.
- Monitor fluid intake and output. Watch for edema and weight gain.

Patient teaching

- Advise patient to take with food or milk to minimize GI upset.
- Instruct patient to swallow slow-release tablet whole without chewing or crushing.
- Tell patient that beneficial effects may take 1 to 3 weeks to appear.
- Advise patient to limit foods and beverages containing caffeine, because they may interfere with drug action.
- Tell patient to maintain adequate fluid intake.
- Explain that drug may cause adverse CNS effects. Advise patient to avoid activities requiring mental alertness until effects are known.
- Emphasize importance of having regular blood tests, to help detect and prevent serious adverse reactions.
- Instruct patient to carry appropriate medical identification at all times.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

---

**Iomustine**

CeeNU

**Pharmacologic class:** Alkylating drug (nitrosourea)

**Therapeutic class:** Antineoplastic

**Pregnancy risk category D**
FDA BOXED WARNING

- Give under supervision of physician experienced in cancer chemotherapy, in facility with adequate diagnostic and treatment resources. Most common and severe toxic effect is bone marrow suppression, which may contribute to bleeding and overwhelming infections in already compromised patients. Delayed bone marrow suppression is major toxicity, so monitor blood counts weekly for at least 6 weeks after dose. At recommended dosage, don’t give courses more often than every 6 weeks. Bone marrow toxicity is cumulative; consider adjusting dosage based on nadir blood counts from previous dose.

Action

Inactivates neoplastic cells by alkylating DNA, causing DNA structural modification and fragmentation. Thought to act in late G1 or early S phase of cell cycle.

Availability

Capsules: 10 mg, 40 mg, 100 mg
Dose pack: two 10-mg capsules, two 40-mg capsules, and 100-mg capsules

Indications and dosages

- Adjunctive therapy in primary and metastatic brain tumors; secondary therapy in Hodgkin’s disease
- Adults and children: As monotherapy, 130 mg/m² P.O. as a single dose q 6 weeks in previously untreated patients. In bone marrow suppression, initial dosage is 100 mg/m² P.O. q 6 weeks; don’t repeat dose until platelet count exceeds 100,000/mm³ and white blood cell (WBC) count exceeds 4,000/mm³. When given with other myelosuppressive drugs, adjust dosage accordingly.

Dosage adjustment

- Bone marrow depression (based on WBC and platelet counts)

Contraindications

- Hypersensitivity to drug

Precautions

Use cautiously in:
- renal or hepatic dysfunction, bone marrow depression
- pregnant or breastfeeding patients.

Administration

- Obtain CBC with white cell differential before starting therapy.
- Administer antiemetic before giving drug, as prescribed, to minimize nausea.
- Give 2 to 4 hours after meals to enhance absorption.
- If vomiting occurs shortly after administration, notify prescriber.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>10 min</td>
<td>3 hr</td>
<td>48 hr</td>
</tr>
</tbody>
</table>

Adverse reactions

- CNS: anxiety, confusion, dizziness, hallucinations, lethargy, headache, paresthesia, light-headedness, drowsiness, fatigue, seizures
- GI: nausea; vomiting; anorexia; sore mouth, lips, and throat; GI bleeding
- GU: amenorrhea, azoospermia, progressive azotemia, nephrotoxicity, renal failure
- Hematologic: anemia, leukopenia, thrombocytopenia, bone marrow depression
- Hepatic: hepatotoxicity
- Skin: alopecia
- Other: secondary cancers

Interactions

- Drug-drug. Anticoagulants, non-steroidal anti-inflammatory drugs: increased bleeding risk
- Myelosuppressants: increased bone marrow depression
Drug-diagnostic tests. Hemoglobin, platelets, red blood cells, WBCs: decreased values  
Liver function tests, nitrogenous compounds: increased values

Patient monitoring
- Watch for evidence of overdose, including bone marrow depression, nausea, and vomiting.
- Monitor CBC and platelet counts closely. Watch for signs and symptoms of bleeding and bruising.
  - Avoid I.M. injections if platelet count is below 100,000/mm³.
  - Check kidney, liver, and pulmonary function tests frequently.
  - Assess neurologic status carefully. Institute safety measures as needed to prevent injury.
- Watch for signs and symptoms of secondary cancers.

Patient teaching
- Instruct patient to contact prescriber if he vomits shortly after taking drug.
- Tell patient to immediately report easy bruising or bleeding, which may signal low platelet count.
- Advise patient to report changes in urination pattern.
- Instruct patient to avoid exposure to people with infections, because drug may make him more susceptible to infection.
- Caution female of childbearing age to use reliable contraception and to immediately report suspected or confirmed pregnancy.
- Advise female patient to inform prescriber if she is breastfeeding.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Advise patient to minimize GI side effects by eating small, frequent servings of healthy food.
- Inform patient that drug may cause hair loss.

- Tell patient he’ll undergo frequent blood testing during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

### loperamide hydrochloride


**Pharmacologic class:** Piperidine derivative  
**Therapeutic class:** Antidiarrheal  
**Pregnancy risk category B**

### Action
Inhibits peristalsis of intestinal wall musculature and intestinal contents. Also reduces fecal volume, increases fecal bulk, and minimizes fluid and electrolyte loss.

### Availability
Capsules: 2 mg  
Solution: 1 mg/5 ml  
Tablets: 2 mg  
Tablets (chewable): 2 mg

### Indications and dosages
- **Acute diarrhea**  
  - **Adults:** Initially, 4 mg P.O., then 2 mg after each loose stool. Usual maintenance dosage is 4 to 8 mg P.O. daily in

Reactions in bold are life-threatening.
divided doses, not to exceed 16 mg daily.

**Children ages 8 to 12 or weighing more than 30 kg (66 lb):** Initially, 2 mg P.O. t.i.d., then 1 mg/10 kg after each loose stool, not to exceed 6 mg daily.

**Children ages 6 to 8 or weighing 20 to 30 kg (44 to 66 lb):** Initially, 2 mg P.O. b.i.d., then 1 mg/10 kg after each loose stool, not to exceed 4 mg daily.

**Children ages 2 to 5 or weighing 13 to 20 kg (29 to 44 lb):** Initially, 1 mg P.O. t.i.d., then 1 mg/10 kg after each loose stool, not to exceed 3 mg daily.

➤ Acute diarrhea (treated with over-the-counter loperamide)

**Adults and children ages 12 and older:** Two caplets with 4 to 8 oz water after first loose stool, then one caplet (with 4 to 8 oz water) after each subsequent loose stool. Don’t exceed four caplets in 24 hours. Or give equivalent dosage in liquid form.

**Children ages 9 to 11 who weigh 27 to 43 kg (60 to 95 lbs):** One caplet with 4 to 8 oz water after first loose stool, then ½ caplet (with 4 to 8 oz water) after each subsequent loose stool. Don’t exceed three caplets in 24 hours. Or give equivalent dosage in liquid form.

**Children ages 6 to 8 who weigh 22 to 27 kg (48 to 59 lbs):** One caplet with 4 to 8 oz water after first loose stool, then ½ caplet with 4 to 8 oz water after each subsequent loose stool. Don’t exceed two caplets in 24 hours. Or give equivalent dosage in liquid form.

**Children younger than age 6:** Consult physician.

➤ Chronic diarrhea

**Adults:** Initially, 4 mg P.O., then 2 mg after each loose stool; reduce dosage as tolerated. Don’t exceed 16 mg daily for more than 10 days.

**Contraindications**
- Hypersensitivity to drug
- Abdominal pain of unknown cause (especially with fever)
- Acute diarrhea caused by enteroinvasive *Escherichia coli*, *Salmonella*, or *Shigella*
- Acute ulcerative colitis
- Bloody diarrhea with temperature above 38.3°C (101°F) (with OTC product)
- Pseudomembranous colitis associated with broad-spectrum anti-infectives
- Children younger than age 6

**Precautions**
Use cautiously in:
- hepatic disease
- elderly patients
- pregnant or breastfeeding patients
- children.

**Administration**
- Use patient’s weight to determine appropriate dosage (especially in children).

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1 hr</td>
<td>2.5-5 hr</td>
<td>10 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** drowsiness, dizziness

**GI:** nausea; vomiting; constipation; abdominal pain, distention, or discomfort; dry mouth; toxic megacolon (in patients with acute ulcerative colitis)

**Other:** allergic reactions

**Interactions**

**Drug-drug.** Antidepressants, antihistamines, other anticholinergics: additive anticholinergic effects

**CNS depressants (including antihistamines, opioid analgesics, sedative-hypnotics):** additive CNS depression

**Drug-herbs.** Chamomile, hops, kava, skullcap, valerian: increased CNS depression

**Drug-behaviors.** Alcohol use: increased CNS depression

**Patient monitoring**
- Watch for signs and symptoms of abdominal distention, which may
signal toxic megacolon in patient with ulcerative colitis.

- Assess bowel movements to evaluate drug efficacy and determine need for repeat doses.
- Monitor stool cultures as indicated.
- Check stool for occult blood as indicated.
- Evaluate fluid intake and output.
- Stay alert for CNS effects, especially in children.

**Patient teaching**

- Stress importance of maintaining high fluid intake to prevent dehydration.
- Instruct patient or parents to report fever, mucus in stool, or history of hepatic disease before using drug.
- Caution patient or parents to discontinue drug if symptoms worsen or diarrhea lasts longer than 2 days.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, herbs, and behaviors mentioned above.

**loratadine**

Aerius®, Alavert, Allertin, Claritin, Claritin RediTabs, Claritin

*Pharmacologic class:* Histamine<sub>1</sub>-receptor antagonist (second-generation)

*Therapeutic class:* Antihistamine (nonsedating)

*Pregnancy risk category B*

**Action**

Selective histamine<sub>1</sub>-receptor antagonist. Blocks peripheral effects of histamine release during allergic reactions, decreasing or preventing allergy symptoms.

**Availability**

*Syrup:* 1 mg/ml

**Indications and dosages**

- Seasonal allergies; chronic idiopathic urticaria
- **Adults and children ages 6 and older:** 10 mg P.O. daily
- **Children ages 2 to 5:** 5 mg P.O. daily

**Dosage adjustment**

- Renal or hepatic impairment

**Contraindications**

- Hypersensitivity to drug

**Precautions**

Use cautiously in:

- renal or hepatic impairment
- elderly patients
- pregnant patients
- children younger than age 2 (safety not established).

**Administration**

- Give once a day on empty stomach.
- Place rapidly disintegrating tablet on tongue; give with or without water.
- Use rapidly disintegrating tablets within 6 months of opening foil pouch and immediately after opening individual tablet blister.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1-3 hr</td>
<td>8-12 hr</td>
<td>&gt;24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- CNS: headache, nervousness, insomnia
- EENT: conjunctivitis, earache, epistaxis, pharyngitis
- GI: abdominal pain; dry mouth; diarrhea, stomatitis (in children)
- Skin: rash, photosensitivity, angioedema
- Other: tooth disorder (in children), fever, flulike symptoms, viral infections

**Interactions**

Drug-food. *Any food:* increased drug absorption

Reactions in **bold** are life-threatening.
Patient monitoring
● Watch for adverse reactions, especially in children.
● Assess patient’s response to drug.
● Watch for new symptoms or exacerbation of existing symptoms.

Patient teaching
● Advise patient to take exactly as prescribed, once a day on empty stomach.
● Tell patient to report persistent or worsening symptoms.
● Instruct patient to report adverse reactions, such as headache or nervousness.
● Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
● As appropriate, review all other significant adverse reactions and interactions, especially those related to the foods mentioned above.

Indications and dosages
▶ Anxiety
Adults: 2 to 3 mg P.O. daily in two or three divided doses. Maximum dosage is 10 mg daily.
▶ Insomnia
Adults: 2 to 4 mg P.O. at bedtime
▶ Premedication before surgery (as antianxiety agent, sedative-hypnotic, or amnestic)
Adults: 0.05 mg/kg (not to exceed 4 mg) deep I.M. injection at least 2 hours before surgery, or 0.044 mg/kg (not to exceed 2 mg) I.V. 15 to 20 minutes before surgery. For greater amnestic effect, give up to 0.05 mg/kg (not to exceed 4 mg) I.V. 15 to 20 minutes before surgery.
▶ Status epilepticus
Adults: 4 mg I.V. given slowly (no faster than 2 mg/minute). If seizures continue or recur after 10 to 15 minutes, repeat dose. If seizure control isn’t established after second dose, other measures should be used. Don’t exceed 8 mg in 12 hours.

Dosage adjustment
● Elderly or debilitated patients

Off-label uses
● Acute alcohol withdrawal syndrome

Contraindications
● Hypersensitivity to drug, other benzodiazepines, polyethylene or propylene glycol, or benzyl alcohol
● Acute angle-closure glaucoma
● Coma or CNS depression
● Hepatic or renal failure

Precautions
Use cautiously in:
● hepatic or renal impairment
● history of suicide attempt, drug abuse, depressive disorder, or psychosis
● elderly patients
● pregnant or breastfeeding patients.

lorazepam

Pharmacologic class: Benzodiazepine
Therapeutic class: Anxiolytic
Controlled substance schedule IV
Pregnancy risk category D

Action
Unknown. Thought to depress CNS at limbic system and disrupt neurotransmission in reticular activating system.

Availability
Injection: 2 mg/ml, 4 mg/ml
Solution (concentrated): 2 mg/ml
Tablets: 0.5 mg, 1 mg, 2 mg
Administration
- For I.V. use, dilute with equal volume of compatible diluent, such as normal saline solution or dextrose 5% in water. Keep resuscitation equipment and oxygen at hand.
- Give each 2 mg of I.V. dose slowly, over 2 to 5 minutes. Don’t exceed rate of 2 mg/minute.
- Don’t give parenteral form to children younger than age 18.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>15-45 min</td>
<td>1-6 hr</td>
<td>Up to 48 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>15-20 min</td>
<td>Up to 48 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>15-30 min</td>
<td>1-2 hr</td>
<td>Up to 48 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: amnesia, agitation, ataxia, depression, disorientation, dizziness, drowsiness, headache, incoordination, asthenia
CV (with too rapid I.V. administration): hypotension, bradycardia, tachycardia, apnea, cardiac arrest, cardiovascular collapse
EENT: blurred vision, diplopia, nystagmus
GI: nausea, abdominal discomfort
Other: increased or decreased appetite

Interactions
Drug-drug. CNS depressants (including antidepressants, antihistamines, benzodiazepines, sedative-hypnotics): additive CNS depression
Hormonal contraceptives: increased lorazepam clearance
Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression

Drug-behaviors. Alcohol use: increased CNS depression
Smoking: increased metabolism and decreased efficacy of lorazepam

Patient monitoring
- Monitor vital signs closely.
- Evaluate for amnesia.
- Watch closely for CNS depression. Institute safety precautions as needed to prevent injury.
- Monitor for signs and symptoms of overdose (such as confusion, hypotension, coma, and labored breathing).
- Assess liver function tests and CBC.

Patient teaching
- Tell patient and family about drug’s possible CNS effects. Recommend appropriate safety precautions.
- Explain that with long-term use, drug must be discontinued slowly (typically over 8 to 12 weeks).
- Instruct patient to avoid alcohol, because it increases drowsiness and other CNS effects.
- Caution patient to avoid smoking, because it speeds drug breakdown in body.
- Advise female patient to inform prescriber if she is pregnant or breastfeeding.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, herbs, and behaviors mentioned above.

Reactions in bold are life-threatening.
FDA BOXED WARNING

- When used during second or third trimester of pregnancy, drug may cause fetal harm or death. Discontinue as soon as pregnancy is detected.

Action
Blocks vasoconstricting and aldosterone-secreting effects of angiotensin II at various receptor sites, including vascular smooth muscle and adrenal glands. Also increases urinary flow and enhances excretion of chloride, magnesium, calcium, and phosphate.

Availability
Tablets: 25 mg, 50 mg, 100 mg

Indications and dosages

- **Hypertension**
  - **Adults:** Initially, 50 mg/day P.O.; range is 25 to 100 mg/day as a single dose or in two divided doses. May be used alone or with other drugs.

- **Children ages 6 and older:** 0.7 mg/kg P.O. daily, up to total of 50 mg
  - To prevent cerebrovascular accident (stroke) in hypertensive patients with left ventricular hypertrophy (LVH)
  - **Adults:** Initially, 50 mg P.O. daily, increased to 100 mg P.O. daily. May be given concurrently with hydrochlorothiazide.
  - **Nephropathy in patients with type 2 diabetes**
  - **Adults:** 50 mg/day P.O.; increase to 100 mg/day based on blood pressure response.

Dosage adjustment
- Hepatic impairment
- Concurrent diuretic therapy

Contraindications
- Hypersensitivity to drug or its components
- Pregnancy (second and third trimesters)

Precautions
Use cautiously in:
- heart failure, renal or hepatic impairment, obstructive biliary disorders
- high-dose diuretic therapy
- black patients
- pregnant patients (first trimester) or breastfeeding patients
- children younger than age 6 (safety not established).

Administration
- Administer with or without food.
- Know that if drug efficacy (measured at trough) is inadequate with once-daily dosing, prescriber may switch to twice-daily regimen using same or higher daily dosage.
- Be aware that drug may take 3 to 6 weeks to reach maximal efficacy.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
- **CNS:** dizziness, insomnia, headache, asthenia, fatigue
- **CV:** hypotension
- **EENT:** sinus disorders
- **GI:** nausea, vomiting, diarrhea, dyspepsia, abdominal pain
- **Metabolic:** hyperkalemia
- **Musculoskeletal:** joint pain, back pain, muscle cramps
- **Respiratory:** symptoms of upper respiratory infection, dry cough
- **Other:** hypersensitivity reactions including angioedema

Interactions
- **Drug-drug.** Diuretics, other antihypertensives: increased risk of hypotension
  - **Fluconazole:** inhibited losartan metabolism, increased antihypertensive effects
  - **Indomethacin:** decreased losartan effects
  - **Lithium:** decreased lithium metabolism
  - **Nonsteroidal anti-inflammatory drugs:** decreased renal function
Potassium-sparing diuretics, potassium supplements: hyperkalemia
*Rifamycins:* enhanced losartan metabolism, decreased antihypertensive effects

**Drug-diagnostic tests.** *Albumin:* increased level

**Drug-food.** *Salt substitutes containing potassium:* hyperkalemia

**Patient monitoring**
- Watch for angioedema and other hypersensitivity reactions.
- Monitor blood pressure to evaluate drug efficacy.
- Assess liver and kidney function tests and electrolyte levels.
- Stay alert for oliguria, progressive azotemia, and renal failure in patients with severe heart failure whose renal function depends on the renin-angiotensin-aldosterone system.
- Know that in black patients, losartan and other ACE inhibitors may be ineffective when used alone. Drug isn’t indicated for stroke prevention in black hypertensive patients with LVH.
- Be aware that drug may cause fetal injury or death when used during second or third trimester of pregnancy.

**Patient teaching**
- Instruct patient to avoid potassium supplements and salt substitutes containing potassium, unless directed by prescriber.
- Caution female patient not to take drug during second or third trimester of pregnancy. Advise her to contact prescriber immediately if she suspects pregnancy.
- Tell female patient to discuss breastfeeding with prescriber before taking.
- Instruct patient to immediately report hypersensitivity reactions, especially lip or eyelid swelling, throat tightness, and difficulty breathing.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

---

**lovastatin**


**Pharmacologic class:** HMG-CoA reductase inhibitor

**Therapeutic class:** Antihyperlipidemic

**Pregnancy risk category X**

**Action**
Inhibits HMG-CoA reductase, an enzyme crucial to cholesterol synthesis. Decreases total cholesterol and low-density lipoprotein (LDL) levels and increases high-density lipoprotein level.

**Availability**
- Tablets: 10 mg, 20 mg, 40 mg
- Tablets (extended-release): 10 mg, 20 mg, 40 mg, 60 mg

**Indications and dosages**
- To reduce LDL, total cholesterol, triglyceride, and apolipoprotein B levels

**Adults:** Initially, 20 mg P.O. daily. May be increased, as needed, at 4-week intervals to a maximum of 80 mg/day as a single dose or in divided doses. Or 20 mg P.O. (extended-release) daily. May be increased, as needed, at 4-week intervals to a maximum daily dosage of 60 mg.
- Heterozygous familial hypercholesterolemia in boys and postmenarchal girls ages 10 and older who have high

Reactions in **bold** are life-threatening.
LDL and cholesterol levels despite adequate trial of diet therapy

**Adolescents ages 10 to 17:** 10 to 40 mg P.O. daily, with adjustments made at 4-week intervals

### Dosage adjustment
- Severe renal insufficiency

### Off-label uses
- High-risk patients with diabetic dyslipidemia, familial dysbetalipoproteinemia, familial combined hyperlipidemia, or nephrotic hyperlipidemia

### Contraindications
- Hypersensitivity to drug, its components, or angiotensin-converting enzyme inhibitors
- Active hepatic disease or unexplained persistent hepatic enzyme elevation
- Concurrent gemfibrozil or azole antifungal therapy
- Pregnancy or breastfeeding

### Precautions
Use cautiously in:
- Cerebral arteriosclerosis, heart disease, renal impairment, severe acute infection, severe hypotension or hypertension, uncontrolled seizures, myopathy, visual disturbances, major surgery, trauma, alcoholism
- Severe metabolic, endocrine, or electrolyte problems
- Women of childbearing age
- Children

### Administration
- Give daily dose with evening meal.
- Increase dosage at intervals of 4 weeks or longer, as ordered.
- Don’t give with grapefruit juice (may increase drug blood level).
- Discontinue if alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level exceeds three times the upper limit of normal.

### Adverse reactions
- **CNS:** headache, dizziness, asthenia
- **EENT:** blurred vision, eye irritation
- **GI:** nausea, vomiting, constipation, diarrhea, abdominal pain or cramps, dyspepsia, flatulence
- **Hepatic:** hepatotoxicity
- **Musculoskeletal:** myalgia, cramps, rhabdomyolysis
- **Skin:** pruritus, rash, photosensitivity
- **Other:** hypersensitivity reaction

### Interactions
- **Drug-drug:** Azole antifungals, cyclosporine, erythromycin, folic acid derivatives, gemfibrozil, niacin: increased risk of myopathy and rhabdomyolysis
- Bile acid sequestrants: decreased lovastatin blood level
- Isradipine: increased lovastatin clearance
- Warfarin: increased prothrombin time, bleeding
- **Drug-diagnostic tests:** ALT, AST: increased levels
- **Drug-food:** Grapefruit juice: increased lovastatin blood level
- **Drug-herbs:** Red yeast rice: increased risk of adverse reactions
- Chaparral, comfrey, germander, jin bu huan, kava, pennyroyal, St. John’s wort: increased risk of hepatotoxicity

### Patient monitoring
- Obtain liver function tests before starting therapy, 6 and 12 weeks after therapy begins or dosage is increased, and periodically thereafter.

### Patient teaching
- Tell patient to take immediate-release tablets with evening meal or extended-release tablets at bedtime.
- Instruct patient not to break, crush, or chew extended-release tablets.
Emphasize importance of cholesterol-lowering diet and other therapies, such as exercise and weight control.

Instruct patient to report unexplained muscle pain, tenderness, or weakness, as well as signs or symptoms of hepatotoxicity (fever, malaise, abdominal pain, yellowing of skin or eyes, clay-colored stools, or tea-colored urine).

Advise patient to contact prescriber immediately if she is breastfeeding or suspects pregnancy.

Tell patient not to use herbs without consulting prescriber.

Inform patient that drug may cause photosensitivity. Caution him to avoid excessive sun or heat lamp light.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

loxapine succinate


**Pharmacologic class:** Tricyclic dibenzoxazepine derivative

**Therapeutic class:** Antipsychotic

**Pregnancy risk category C**

**Action**

Unknown. Thought to block neurotransmission of postsynaptic dopamine receptors in brain, alleviating psychotic symptoms.

**Availability**

*Capsules:* 5 mg, 10 mg, 25 mg, 50 mg

**Indications and dosages**

- Schizophrenia

**Adults:** 10 mg P.O. b.i.d. Dosage may be increased over first 7 to 10 days, up to 100 mg/day P.O. in two to four divided doses. Maximum dosage is 250 mg/day.

**Dosage adjustment**

- Elderly patients

**Contraindications**

- Hypersensitivity to drug or other dibenzoxazepines
- Coma or severe drug-induced CNS depression

**Precautions**

Use cautiously in:

- seizures, cerebral arteriosclerosis, severe hypotension, hypertension, glaucoma, breast cancer, hepatic disease, bone marrow depression, Parkinson's disease, blood dyscrasias, urinary retention, concurrent use of other CNS active drugs or anticholinergics
- pregnant or breastfeeding patients
- children younger than age 16.

**Administration**

- Give with or without food.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30 min</td>
<td>1.5–3 hr</td>
<td>12 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** drowsiness, insomnia, vertigo, headache, dizziness, weakness, akinesia, staggering or shuffling gait, slurred speech, agitation, extrapyramidal reactions, sedation, syncope, tardive dyskinesia, numbness, confusion, pseudoparkinsonism, EEG changes, seizures, neuroleptic malignant syndrome

**CV:** orthostatic hypotension, hypertension, ECG changes

**EENT:** blurred vision, ptosis, nasal congestion

**GI:** nausea, vomiting, constipation, dry mouth, paralytic ileus

**GU:** urinary retention

Reactions in **bold** are life-threatening.
Hematologic: leukopenia, agranulocytosis, thrombocytopenia  
Hepatic: hepatocellular injury with hepatic enzyme elevations  
Metabolic: polydipsia  
Musculoskeletal: muscle twitching  
Skin: rash, pruritus, seborrhea, photosensitivity, alopecia  
Other: weight gain or loss, hyperpyrexia, facial edema, hypersensitivity reactions  

**Interactions**  
**Drug-drug.** Anticholinergics, CNS depressants: additive effects  
Epinephrine: severe hypotension, tachycardia, decreased epinephrine effects  
**Drug-diagnostic tests.** Granulocytes, platelets, white blood cells: decreased counts  
Liver function tests: increased values  
**Drug-behaviors.** Alcohol use: increased CNS depression  

**Patient monitoring**  
- Measure blood pressure before and periodically during therapy.  
- Monitor hematologic studies and liver function tests.  
- Stay alert for evidence of neuroleptic malignant syndrome (extrapyramidal symptoms, hyperpyrexia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, arrhythmias, diaphoresis).  
- Assess for tardive dyskinesia (involuntary jerky movements of face, tongue, jaws, trunk, arms, and legs), especially in elderly women.  

**Patient teaching**  
- Tell patient to take with or without food.  
- Inform patient that drug may cause tardive dyskinesia. Describe symptoms.  
- Caution patient to avoid activities requiring mental concentration until drug’s effects are known.  

 negligence, tremors, involuntary muscle twitching, muscle stiffness, or yellowing of eyes or skin.  
- Instruct patient to move slowly when sitting up or standing, to avoid dizziness from sudden blood pressure decrease.  
- Caution patient to avoid alcohol use.  
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.  

**lubiprostone**  
Amitiza  
**Pharmacologic class:** Chloride channel activator  
**Therapeutic class:** GI motility enhancer  
**Pregnancy risk category C**  

**Action**  
Enhances chloride-rich intestinal fluid secretion without altering sodium and potassium serum concentrations; increases intestinal fluid secretion and intestinal motility, which promotes stool passage and relieves symptoms of chronic idiopathic constipation  

**Availability**  
Soft gelatin capsules: 8 mcg, 24 mcg  

**Indications and dosages**  
> Chronic idiopathic constipation  
**Adults:** 24 mcg P.O. twice daily  
> Treatment of irritable bowel syndrome with constipation in women  
**Adults ages 18 and older:** 8 mcg P.O. b.i.d.  

**Contraindications**  
- Hypersensitivity to drug or its components
History of mechanical GI obstruction

Precautions
Use cautiously in:
- severe diarrhea, hepatic or renal dysfunction
- pregnant or breastfeeding patients.

Administration
- Administer with food and water.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1.14 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, dizziness, hypoesthesia, fatigue, depression, anxiety, insomnia
CV: chest discomfort or pain, hypertension
EENT: sinusitis, nasopharyngitis, pharyngolaryngeal pain
GI: nausea, vomiting, diarrhea, constipation, abdominal distention, abdominal pain or discomfort, flatulence, dyspepsia, gastroesophageal reflux disease, gastroenteritis, dry mouth
GU: urinary tract infection
Musculoskeletal: arthralgia, back pain, extremity pain, muscle cramp
Respiratory: upper respiratory tract infection, influenza, bronchitis, dyspnea, cough
Other: weight gain, peripheral edema, fever, viral infection

Interactions
None

Patient monitoring
- Evaluate patient for signs and symptoms of mechanical obstruction before therapy begins.
- Assess patient periodically for continuing need for therapy.

Patient teaching
- Instruct patient not to break or chew capsule.
- Instruct patient not to take drug during episodes of severe diarrhea.
- Advise patient to report side effects, such as severe nausea, diarrhea, and dyspnea, to prescriber.
- Caution female patient with childbearing potential that drug may pose hazard to fetus.
- Advise breastfeeding patient that she should decide whether to discontinue breastfeeding or stop taking drug.
- As appropriate, review all other significant adverse reactions.

lymphocyte immune globulin (antithymocyte globulin equine, ATG, ATG equine, LIG)

Atgam
Pharmacologic class: Immunoglobulin
Therapeutic class: Immunosuppressant
Pregnancy risk category C

FDA BOXED WARNING
- Give drug under supervision of physician experienced in immunosuppressive therapy for treatment of renal transplant or asplastic anemia patients, in facility with adequate laboratory and supportive resources

Action
Unknown. Thought to inhibit cell-mediated immune response by altering function of or eliminating T lymphocytes in circulation.

Availability
Injection: 50 mg/ml in 5-ml ampules

Reactions in bold are life-threatening.
Indications and dosages

➢ To prevent acute renal allograft rejection

Adults and children: 15 mg/kg/day I.V. for 14 days, then switch to alternate-day dosing for 14 days (for a total of 21 doses in 28 days). Give first dose within 24 hours of transplantation.

➢ Acute renal allograft rejection

Adults and children: 10 to 15 mg/kg/day I.V. for 14 days, then may switch to alternate-day dosing for 14 days (for a total of 21 doses in 28 days). Start therapy at first sign of rejection.

➢ Aplastic anemia in patients ineligible for bone marrow transplantation

Adults and children: 10 to 20 mg/kg/day I.V. for 8 to 14 days; then may give additional alternate-day doses for a total of up to 21 doses in 28 days

Off-label uses

● Bone marrow, liver, and heart transplantation
● Multiple sclerosis
● Myasthenia gravis
● Scleroderma

Contraindications

● History of severe systemic reaction to lymphocyte immune globulin or other equine preparation

Precautions

Use cautiously in:

● severe renal or hepatic disease
● pregnant or breastfeeding patients
● children.

Administration

➢ Know that drug should be given only by health care professionals experienced in immunosuppressive therapy for treating aplastic anemia or renal transplant patients, in facilities equipped and staffed with adequate laboratory and supportive resources.

Because of high risk of anaphylaxis, perform intradermal skin test before first dose. Inject 0.1-ml dose of 1:1,000 dilution of LIG intradermally; a control test using 0.9% sodium chloride injection is injected contralaterally. Observe site every 15 to 20 minutes during first hour after injection, and monitor patient for systemic manifestations. Local reaction of 10 mm or greater with wheal, erythema, or both (with or without pseudopod formation and itching or marked local swelling) indicates positive test (which warrants consideration of alternate therapy). Systemic reaction (such as tachycardia, dyspnea, hypotension, or anaphylaxis) precludes LIG therapy.

● Premedicate with antipyretic, antihistamine, or corticosteroid, as prescribed, to minimize reactions.

For I.V. infusion, dilute prescribed dose in 250 to 1,000 ml of 0.45% or 0.9% sodium chloride injection. (Don’t dilute in dextrose solutions or highly acidic solutions.) Final concentration shouldn’t exceed 4 mg/ml. Infuse total daily dose over at least 4 hours.

● When adding drug to infusion container, invert container so air doesn’t enter. Gently swirl or rotate container to mix solution.

● Using in-line filter with pore size of 0.2 to 1 micron, infuse into central vein, shunt, or arteriovenous fistula over at least 4 hours.

● Be aware that drug is usually given concurrently with azathioprine and corticosteroids when used for allograft rejection.

Route Onset Peak Duration
I.V. Unknown Unknown Unknown

Adverse reactions

CNS: malaise, agitation, headache, dizziness, weakness, syncope, encephalitis, seizures
CV: hypotension, hypertension, chest pain, bradycardia, tachycardia, cardiac

Canada Hazardous drug UK High alert drug
irregularities, phlebitis, myocarditis, thrombophlebitis, heart failure
EENT: periorbital edema
GI: nausea, vomiting, diarrhea, stomatitis
Hematologic: leukopenia, agranulocytosis, thrombocytopenia, aplastic anemia
Hepatic: hepatosplenomegaly
Metabolic: hyperglycemia
Musculoskeletal: joint pain or stiffness, myalgia, back pain
Respiratory: dyspnea, pleural effusion
Skin: rash, pruritus, urticaria, diaphoresis, night sweats
Other: burning soles and palms, fever, chills, pain at infusion site, edema, lymphadenopathy, hypersensitivity reactions including serum sickness and anaphylaxis

Interactions
Drug-diagnostic tests. Creatinine, glucose, hepatic enzymes: increased values Hemoglobin, platelets, white blood cells: decreased values Kidney and liver function tests: abnormal results

Patient monitoring
During infusion, watch for signs and symptoms of hypersensitivity reaction, such as rash, respiratory distress, or chest, flank, or back pain. Be aware that this reaction may occur even with a negative skin test.
Discontinue drug if renal transplant patient develops signs or symptoms of anaphylaxis or severe thrombocytopenia or leukopenia.
Be aware that product derives from equine and human blood components and may transmit infections.
Monitor for signs and symptoms of infection, such as fever, malaise, and sore throat (caused by immunosuppression).

Patient teaching
Tell patient to immediately report adverse reactions during infusion (such as pain at infusion site) as well as systemic complaints (such as easy bruising or bleeding or signs of hypersensitivity reaction).
Instruct patient to avoid sources of infection, such as people with known infections. Tell him to promptly report signs or symptoms of infection.
Advise patient to immediately report evidence of serum sickness, including fever, joint pain, nausea, vomiting, lymphadenopathy, and rash.
Caution female patient not to take drug if she is pregnant.
Tell female patient to inform prescriber if she is breastfeeding.
As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

magnesium chloride
magnesium citrate
Citramag®, Citro-Mag®, Citroma
magnesium gluconate
Mag G, Magonate
magnesium hydroxide
Dulcolax Milk of Magnesia, Phillips Milk of Magnesia, Phillips Milk of Magnesia Concentrate
magnesium oxide
Mag-ox, Uro-Mag

Reactions in bold are life-threatening.
magnesium sulfate
Epsom Salts

**Pharmacologic class:** Mineral

**Therapeutic class:** Electrolyte replacement, laxative, antacid, anticonvulsant

**Pregnancy risk category A** (magnesium sulfate), **NR** (magnesium citrate, hydroxide, oxide), **unknown** (magnesium chloride, gluconate)

**Action**

Increases osmotic gradient in small intestine, which draws water into intestines and causes distention. These effects stimulate peristalsis and bowel evacuation. In antacid action, reacts with hydrochloric acid in stomach to form water and increase gastric pH. In anticonvulsant action, depresses CNS and blocks transmission of peripheral neuromuscular impulses.

**Availability**

**magnesium chloride**

*Injection:* 20%

**magnesium citrate**

*Oral solution:* 240-ml, 296-ml, and 300-ml bottles

**magnesium gluconate**

*Liquid:* 1,000 mg/5 ml

*Tablets:* 500 mg

**magnesium hydroxide**

*Liquid:* 400 mg/5 ml

*Liquid concentrate:* 800 mg/5 ml

*Tablets (chewable):* 300 mg

**magnesium oxide**

*Capsules:* 140 mg

*Tablets:* 250 mg, 400 mg, 420 mg, 500 mg

**magnesium sulfate**

*Granules (for oral use):* 120 g, 4 lb

*Injection:* 10%, 12.5%, 25%, 50%

**Indications and dosages**

- **Mild hypomagnesemia**
  - **Adults:** 1 g (2 ml of 50% sulfate solution) I.M. q 6 hours for four doses
  - **Children ages 6 to 11:** 5 to 10 g (sulfate granules) in 240 ml water; or a single dose of 2.5 to 5 ml P.O. (hydroxide) given with water; or a single dose of 7.5 to 15 ml P.O. (hydroxide concentrate); one bottle of oral solution (citrate), as directed

- **Severe hypomagnesemia treatment**
  - **Adults and children:** Dosage individualized based on severity of deficiency; may give citrate, gluconate, hydroxide, oxide, or sulfate.
  - **Supplemental magnesium in total parenteral nutrition (TPN)**
  - **Adults:** 8 to 24 mEq/day (sulfate) by I.V. infusion, added to TPN solution

- **Constipation**
  - **Adults and children ages 12 and older:** 15 g (sulfate granules) in 240 ml water; or 30 to 60 ml/day P.O. (hydroxide) given with water; or a single dose of 10 to 30 ml P.O. (hydroxide concentrate); one bottle of oral solution (citrate), as directed

- **Indigestion**
  - **Adults and children ages 12 and older:** 5 to 15 ml P.O. (hydroxide liquid) up to q.i.d. with water; or 2.5 to 7.5 ml P.O. daily (hydroxide concentrate); or one to two tablets (hydroxide); or 622 to 1,244 mg P.O. (hydroxide tablets) up to q.i.d.; or 4 to 12 ml oral solution (citrate), as directed

- **Hypomagnesemia prophylaxis**
  - **Adults and children:** Dosage based on normal recommended daily magnesium intake; may give citrate, gluconate, hydroxide, oxide, or sulfate.

- **Supplemental magnesium in total parenteral nutrition (TPN)**
  - **Adults:** 8 to 24 mEq/day (sulfate) by I.V. infusion, added to TPN solution

- **Constipation**
  - **Adults and children ages 12 and older:** 15 g (sulfate granules) in 240 ml water; or 30 to 60 ml/day P.O. (hydroxide) given with water; or a single dose of 10 to 30 ml P.O. (hydroxide concentrate); one bottle of oral solution (citrate), as directed

- **Mild hypomagnesemia**
  - **Adults:** 1 g (2 ml of 50% sulfate solution) I.M. q 6 hours for four doses

**Hazardous drug**

**High alert drug**
To prevent and control seizures in preeclampsia or eclampsia

**Adults:** 4 to 5 g 50% sulfate solution I.M. q 4 hours, as necessary; or 4 g 10% to 20% sulfate solution I.V., not to exceed 1.5 ml/minute of 10% solution; or 4 to 5 g I.V. infusion in 250 ml of 5% dextrose or sodium chloride solution, not to exceed 3 ml/minute

**Acute nephritis to control hypertension, encephalopathy, and seizures in children**

**Children:** 100 mg/kg 50% sulfate solution I.M. q 4 to 6 hours as needed; or 20 to 40 mg/kg 20% solution I.M., repeated as necessary

**Off-label uses**
- Bronchodilation in some asthmatic patients
- Post–myocardial infarction hypomagnesemia

**Contraindications**
- Hypermagnesemia
- Heart block
- Myocardial damage
- Active labor or within 2 hours of delivery

**Precautions**

Use cautiously in:
- renal insufficiency, abdominal pain, nausea and vomiting, rectal bleeding, anuria, hypocalcemia
- pregnant patients.

**Administration**

Be aware that magnesium sulfate injection is a high-alert drug.

- Know that I.V. use is reserved for life-threatening seizures.
- When giving magnesium sulfate I.V., don’t exceed concentration of 20% or infusion rate of 150 mg/minute, except in seizures caused by severe eclampsia. Too-rapid I.V. infusion may cause hypotension and asystole.
- When giving magnesium sulfate I.M. to adults, use concentration of 25% to 50%; when giving to infants and children, don’t exceed 20%.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>3-6 hr</td>
<td>4 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>Unknown</td>
<td>30 min</td>
</tr>
<tr>
<td>I.M.</td>
<td>60 min</td>
<td>Unknown</td>
<td>3-4 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- CNS (with I.V. use): confusion, decreased reflexes, dizziness, syncope, sedation, hypothermia, **paralysis**
- CV (with I.V. use): hypotension, arrhythmias, **circulatory collapse**
- GI: nausea, vomiting, cramps, flatulence, anorexia
- **Metabolic:** hypermagnesemia, hypocalcemia
- **Musculoskeletal** (with I.V. use): muscle weakness, flaccidity
- **Respiratory:** **respiratory paralysis**
- **Skin:** diaphoresis
- **Other:** allergic reaction, injection site reaction, laxative dependence (with repeated or prolonged use)

**Interactions**

- **Drug-drug:** Aminoquinolones, nitrofurantoin, penicillamine, tetracyclines: decreased absorption of these drugs (with oral magnesium)
- CNS depressants: additive effects
- Digoxin: heart block, conduction changes (with I.V. use)
- Enteric-coated drugs: faster dissolution of these drugs
- Neuromuscular blockers: increased effects of these drugs (with I.V. use)

**Drug-diagnostic tests.** Calcium, magnesium: increased levels (with I.V. use)

**Patient monitoring**

- When giving prolonged or repeated I.V. infusions, assess patellar reflex and monitor for respiratory rate of 16 breaths/minute or more.
- With I.V. use, monitor blood magnesium level (desired level is 3 to 6 mg/dl or 2.5 to 5 mEq/L). Check for signs
and symptoms of magnesium toxicity (hypotension, nausea, vomiting, ECG changes, muscle weakness, mental or respiratory depression, coma). Keep injectable calcium on hand to counteract magnesium toxicity.

- Monitor urine output, which should measure 100 ml or more every 4 hours.
- If I.V. magnesium was given before delivery, assess neonate for signs and symptoms of magnesium toxicity, such as neuromuscular or respiratory depression.
- Monitor electrolyte levels and liver function tests.

**Patient teaching**

- Teach patient about adverse reactions. Instruct him to report symptoms that occur during I.V. administration.
- Advise patient to consult prescriber before using magnesium if he’s taking other drugs. Magnesium may delay or enhance absorption of other drugs.
- Inform patient that repeated or prolonged use of magnesium citrate, hydroxide, or sulfate may cause laxative dependence. Inform him that healthy diet and exercise can reduce need for laxatives.
- Tell pregnant female to make sure prescriber knows she is pregnant before taking drug.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

---

**mannitol**

Osmitrol, Polyfusor®, Resectisol

*Pharmacologic class:* Osmotic diuretic

*Therapeutic class:* Diuretic

*Pregnancy risk category C*

---

**Action**

Increases osmotic pressure of plasma in glomerular filtrate, inhibiting tubular reabsorption of water and electrolytes (including sodium and potassium). These actions enhance water flow from various tissues and ultimately decrease intracranial and intraocular pressures; serum sodium level rises while potassium and blood urea levels fall. Also protects kidneys by preventing toxins from forming and blocking tubules.

**Availability**

*Injection: 5%, 10%, 15%, 20%, 25%*

*Solution: 5 g/100 ml*

**Indications and dosages**

- **Test dose for marked oliguria or suspected inadequate renal function**
  - **Adults:** 0.2 g/kg I.V. infusion (approximately 50 ml of 25% solution, 75 ml of 20% solution, or 100 ml of 15% solution) over 3 to 5 minutes. If urine flow doesn’t increase, second dose may be given; if response is inadequate after second dose, reevaluate patient.
  - **To prevent oliguria during cardiovascular and other surgeries**
    - **Adults:** 50 to 100 g I.V. infusion as 5% to 15% solution
    - **Acute oliguria**
      - **Adults:** Up to 100 g I.V. infusion as 15% to 25% solution
      - **Children:** 0.25 to 2 g/kg I.V. or 60 mg/m² as 15% to 20% solution over 2 to 6 hours
    - **To reduce intracranial pressure and brain mass**
      - **Adults:** 0.5 to 2 g/kg I.V. infusion as 15% to 25% solution given over 30 to 60 minutes
      - **Children:** 1 to 2 g/kg I.V. or 30 to 60 g/m² over 30 to 60 minutes. Small or debilitated patients may require smaller dose of 500 mg/kg
    - **To reduce intraocular pressure**
      - **Adults:** 0.5 to 2 g/kg I.V. infusion as 15% to 25% solution given over 30 to

---

*Canada* | *UK* | *Hazardous drug* | *High alert drug*
60 minutes. For preoperative use, give 60 to 90 minutes before surgery.

Children: 1 to 2 g/kg I.V. or 30 to 60 g/m² over 30 to 60 minutes. Small or debilitated patients may require smaller dose of 500 mg/kg.

➢ To promote diuresis in drug toxicity

Adults: 5% to 25% solution by I.V. infusion given continuously to maintain high urine output

Children: 2 g/kg I.V. of 5% to 10% solution given continuously to maintain high urine output

➢ Irrigation during transurethral resection of prostate

Adults: 2.5% to 5% solution instilled into bladder via indwelling urethral catheter, as needed

Contraindications
● Active intracranial bleeding (except during craniotomy)
● Anuria secondary to severe renal disease
● Progressive heart failure, pulmonary congestion, renal damage, or renal dysfunction after mannitol therapy begins
● Severe pulmonary congestion or pulmonary edema
● Severe dehydration

Precautions
Use cautiously in:
● Severe renal disease, heart failure, mild to moderate dehydration
● Pregnant or breastfeeding patients.

Administration
➢ Withhold drug until adequate renal function and urinary output are established.
● When administering for drug toxicity, give fluids and electrolytes to match fluid loss.
● Be aware that at low temperatures, solution may crystallize (especially concentrations above 15%). If crystals form, warm bottle in hot-water bath or dry-heat oven or autoclave, then cool to body temperature or lower before giving.

Don’t give electrolyte-free mannitol solutions with blood; when giving blood with mannitol, add 20 mEq or more of sodium chloride solution to each liter of mannitol solution to avoid pseudoagglutination.

➢ Know that drug may be given as continuous or intermittent I.V. infusion. Infuse at prescribed rate using infusion device and in-line filter. Give single I.V. dose over 30 to 90 minutes in adults.

Avoid extravasation, because it may cause local edema and tissue necrosis.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V. (diuresis)</td>
<td>1-3 hr</td>
<td>Unknown</td>
<td>Up to 8 hr</td>
</tr>
<tr>
<td>I.V. (intraocular press.)</td>
<td>Unknown</td>
<td>Unknown</td>
<td>4-8 hr</td>
</tr>
<tr>
<td>I.V. (intracranial press.)</td>
<td>30 min</td>
<td>Unknown</td>
<td>3-8 hr</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: dizziness, headache, seizures
CV: chest pain, hypotension, hypertension, tachycardia, thrombophlebitis, heart failure, vascular overload
EENT: blurred vision, rhinitis
GI: nausea, vomiting, diarrhea, dry mouth
GU: polyuria, urinary retention, osmotic nephrosis

Metabolic: dehydration, water intoxication, hypernatremia, hyponatremia, hypovolemia, hypokalemia, hyperkalemia, metabolic acidosis
Respiratory: pulmonary congestion
Skin: rash, urticaria
Other: pulmonary edema, extravasation with edema and tissue necrosis

Interactions

Drug-drug. Digoxin: increased risk of digoxin toxicity
Diuretics: increased therapeutic effects of mannitol
Lithium: increased urinary excretion of lithium

Reactions in bold are life-threatening.
Drug-diagnostic tests. Electrolytes: increased or decreased levels

Patient monitoring
- Monitor I.V. site carefully to avoid extravasation and tissue necrosis.
- In comatose patient, insert indwelling urinary catheter as ordered to monitor urine output.
- Monitor renal function tests, urinary output, fluid balance, central venous pressure, and electrolyte levels (especially sodium and potassium).
- Watch for excessive fluid loss and signs and symptoms of hypovolemia and dehydration.
- Assess for evidence of circulatory overload, including pulmonary edema, water intoxication, and heart failure.

Patient teaching
- Teach patient about importance of monitoring exact urinary output.
- Advise patient to report pain at infusion site as well as adverse reactions, such as increased shortness of breath or pain in back, legs, or chest.
- Tell patient drug may cause thirst or dry mouth. Emphasize that fluid restrictions are necessary, but that frequent mouth care should ease these symptoms.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

---

**mebendazole**

Boots Threadworm, Ovex®, Pripsen®, Vermox®

*Pharmacologic class:* Benzimidazole  
*Therapeutic class:* Antihelmintic  
*Pregnancy risk category C*

**Action**

Blocks glucose and other nutrient uptake in susceptible helminths, interfering with absorption

**Availability**

Tablets (chewable): 100 mg

**Indications and dosages**

- **Pinworm** (*Enterobius vermicularis*)
  - **Adults and children older than age 2:** 100 mg P.O. as a single dose. Repeat in 2 to 3 weeks, if necessary.

- **Whipworm** (*Trichuris trichiura*), roundworm (*Ascaris lumbricoides*), American hookworm (*Necator americanus*), common hookworm (*Ancylostoma duodenale*), and mixed infections
  - **Adults and children older than age 2:** 100 mg P.O. in morning and evening for 3 days. Repeat in 3 weeks, if necessary.

**Contraindications**

- Hypersensitivity to drug

**Precautions**

Use cautiously in:
- impaired hepatic function, Crohn’s ileitis, ulcerative colitis
- pregnant patients (use in first trimester only if benefit justifies risk to fetus)
- breastfeeding patients
- children younger than age 2.

**Administration**

- Know that tablets may be chewed, swallowed, or crushed and mixed with food.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2-5 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- GI: abdominal pain, diarrhea
- Other: fever

**Interactions**

- **Drug-drug.** *Carbamazepine, phenytoin:* increased mebendazole metabolism and decreased efficacy (with high doses)
Cimetidine: inhibited mebendazole metabolism and increased blood level

**Patient monitoring**
- In prolonged therapy, monitor hematologic and hepatic studies.
- Ask family members if they have signs or symptoms of pinworm; infection spreads easily.

**Patient teaching**
- Tell patient he may chew tablets, swallow them whole, or crush and mix with food.
- Inform patient that parasite removal from GI tract may take up to 3 days after treatment. If he is not cured after 3 weeks, he may need a second course.
- Advise patient not to prepare food for others.
- Teach patient to maintain strict hygiene to prevent reinfection. Instruct him to disinfect bathroom daily and change and launder clothing, bed linens, and towels daily.
- Advise patient that dietary restrictions, fasting, and laxatives aren’t necessary.
- Tell female patient to inform prescriber if she is pregnant or breastfeeding.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

---

**meclizine hydrochloride** *(meclozine)*

**Antivert, Bonamine®, Bonine, Dramamine Less Drowsy Formula, Sea-Legs®, Traveleeze®**

**Pharmacologic class:** Anticholinergic  
**Therapeutic class:** Antiemetic, anti-vertigo drug  
**Pregnancy risk category B**

**Action**
Decreases excitability of middle-ear labyrinth and depresses conduction in vestibular-cerebellar pathways

**Availability**
- **Tablets:** 12.5 mg, 25 mg, 50 mg
- **Tablets (chewable):** 25 mg

**Indications and dosages**
- **Motion sickness**
  - **Adults:** 25 to 50 mg P.O. 1 hour before travel. May repeat q 24 hours for duration of travel.
- **Vertigo associated with diseases affecting the vestibular system**
  - **Adults:** 25 to 100 mg P.O. daily in divided doses

**Contraindications**
- Hypersensitivity to drug

**Precautions**
Use cautiously in:
- prostatic hypertrophy, stenosing peptic ulcer, bladder neck obstruction, pyloroduodenal obstruction, arrhythmias, angle-closure glaucoma, bronchial asthma
- pregnant or breastfeeding patients
- children (younger than age 12).

**Administration**
- Know that tablets may be chewed or swallowed whole.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1 hr</td>
<td>Unknown</td>
<td>8-24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- **CNS:** drowsiness, fatigue, confusion, excitement, euphoria, nervousness, restlessness, insomnia, vertigo, visual and auditory hallucinations, **seizures**
- **CV:** hypotension, palpitations, tachycardia
- **EENT:** blurred vision, diplopia, tinnitus, dry nose, dry throat
- **GI:** nausea, vomiting, diarrhea, constipation, dry mouth, anorexia

Reactions in **bold** are life-threatening.
GU: difficulty urinating, urinary retention, urinary frequency
Skin: rash, urticaria

Interactions
Drug-drug. Anticholinergics (including some antihistamines, antidepressants, atropine, haloperidol, phenothiazines): additive anticholinergic effects
Antihistamines, CNS depressants (such as opioids, sedative-hypnotics): additive CNS depression
Drug-diagnostic tests. Skin tests using allergen extracts: false-negative results
Drug-behaviors. Alcohol use: additive CNS depression

Patient monitoring
- Discontinue drug, as ordered, at least 4 days before skin testing.
- Know that drug has anticholinergic effects.

Patient teaching
- Tell patient to take as prescribed to minimize adverse effects.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Advise patient to relieve dry mouth with hard candy or frequent sips of fluids.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

medroxyprogesterone acetate

Pharmacologic class: Hormone
Therapeutic class: Progestin
Pregnancy risk category X

FDA BOXED WARNING
- Injection form may cause significant bone density loss. Loss increases with duration of use and may not be completely reversible. It is unknown if use during adolescence or early adulthood reduces peak bone mass and increases risk for osteoporotic fracture later in life.
- Injection form should be used as long-term contraceptive (more than 2 years) only if other contraceptive methods are inadequate.

Action
Inhibits pituitary gonadotropin secretion, preventing follicular maturation, ovulation, and pregnancy

Availability
Suspension for depot injection: 150 mg/ml, 400 mg/ml
Suspension for depot subcutaneous injection: 104 mg/0.65 ml in prefilled single-use syringes
Tablets: 2.5 mg, 5 mg, 10 mg

Indications and dosages
- Secondary amenorrhea

Canada UK Hazardous drug High alert drug
Adults: 5 to 10 mg/day P.O. for 5 to 10 days, starting at any time during menstrual cycle
➤ Dysfunctional uterine bleeding; menses induction
Adults: 5 to 10 mg/day P.O. for 5 to 10 days, starting on day 16 or 21 of menstrual cycle
➤ To prevent estrogen-related endometrial changes in postmenopausal women
Adults: 2.5 to 5 mg/day P.O. given with 0.625 mg conjugated estrogens P.O. (monophasic regimen); or 5 mg/ day P.O. on days 15 to 28 of cycle, given with 0.625 mg conjugated estrogens P.O. daily throughout cycle (biphasic regimen)
➤ Management of endometriosis-associated pain
Adults: 104 mg (Depot-subcutaneous-Provera) in anterior thigh or abdomen q 12 to 14 weeks
➤ To prevent pregnancy
Adults: 150 mg (Depo-Provera) deep I.M. injection q 13 weeks or 104 mg (Depot-subcutaneous-Provera) in anterior thigh or abdomen q 12 to 14 weeks. Give first injection during first 5 days of normal menstrual period or first 5 postpartal days if patient isn’t breastfeeding, or during sixth postpartal week if patient is breastfeeding exclusively.
➤ Renal or endometrial cancer
Adults: 400 to 1,000 mg I.M.; may repeat weekly. If improvement occurs, decrease to 400 mg q month.

Off-label uses
• Advanced breast cancer

Contraindications
• Hypersensitivity to drug or its components
• Cerebrovascular or thromboembolic disease
• Hepatic dysfunction or disease
• Breast or genital cancer
• Undiagnosed vaginal bleeding
• Known or suspected pregnancy

Precautions
Use cautiously in:
• seizure disorder, renal or cardiovascular disease, asthma, diabetes mellitus, depression, migraine
• history of hepatic disease.

Administration
• Before starting therapy, obtain thorough history and physical examination, with emphasis on breast and pelvic organs. Also obtain Pap smear, and repeat annually during therapy.
• With contraceptive use, rule out pregnancy before first dose and when more than 14 weeks have passed since previous dose.
• For I.M. injection, inject deep into gluteal, deltoid, or anterior thigh muscle. Rotate injection sites.
• Be aware that when drug is used to prevent estrogen-related endometrial changes in postmenopausal women, lowest dosage should be used for shortest time, because treatment exceeding 1 year correlates with cancer. (Some combination products have 0.3 mg estrogen/1.5 mg progesterone or 0.45 mg estrogen/1.5 mg progesterone.)

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.M.</td>
<td>Wks-1 mo</td>
<td>1 mo</td>
<td>Unknown</td>
</tr>
<tr>
<td>Subcut.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: insomnia, migraine, nervousness, drowsiness, dizziness, fatigue, depression, mood changes
CV: thrombophlebitis, thromboembolism
EENT: diplopia, proptosis, retinal vascular lesions, papilledema
GI: abdominal pain, bloating
GU: amenorrhea, leukorrhea, spotting, cervical secretions, galactorrhea, breast tenderness and secretion, cervical erosions, pelvic pain, infertility

Reactions in bold are life-threatening.
Hepatic: jaundice  
Metabolic: fluid retention, hyperglycemia  
Musculoskeletal: leg cramps, back pain  
Respiratory: pulmonary embolism  
Skin: pruritus, urticaria, rash, acne, alopecia, hirsutism, cholasma, melasma, sterile abscesses, induration at I.M. site  
Other: weight and appetite changes, edema, angioedema, allergic reactions including anaphylaxis

Interactions
Drug-drug. Bromocriptine: decreased bromocriptine efficacy  
Carbamazepine, phenobarbital, phenytoin, rifampin: decreased contraceptive efficacy  
Drug-diagnostic tests. Alkaline phosphatase, low-density lipoproteins: increased levels  
High-density lipoproteins, pregnanediol excretion: decreased levels  
Thyroid hormone assays: altered results  
Drug-behaviors. Alcohol use: additive CNS depression

Patient monitoring
- Monitor patient for fluid retention and for signs and symptoms of thrombophlebitis, including pain, swelling, and redness of lower legs.  
  Assess for visual disturbances and headache. If ocular exam shows papilledema or retinal vascular lesions, drug should be discontinued.  
- Evaluate liver function tests.  
- Watch for abdominal pain, fever, malaise, jaundice, darkened urine, and clay-colored stools.

Patient teaching
- Advise patient that drug may cause nausea, vomiting, headache, abdominal pain, painful breast swelling, and abnormal bleeding pattern. Instruct her to report these effects if pronounced.  
  Tell patient to promptly report bloating, swelling, appetite loss, rash, yellowed skin, mood changes or depression, nervousness, dizziness, chest pain, shortness of breath, visual disturbances, or severe headache.  
- Teach patient how to perform breast self-exams.  
- Tell patient she must undergo yearly physical examinations with Pap smear.  
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

mefloquine hydrochloride
Apo-Mefloquine™, Lariam

Pharmacologic class: 4-quinoline-methanol derivative, quinine analog  
Therapeutic class: Antimalarial  
Pregnancy risk category C

Action
Unknown. Thought to increase intravesicular pH in parasite acid vesicles and form complexes with hemin, inhibiting parasite development.

Availability
Tablets: 250 mg

Indications and dosages
Acute malarial infection  
Adults: 1,250 mg P.O. as a single dose  
Children: 20 to 25 mg/kg P.O. in two divided doses given 6 to 8 hours apart  
Malaria prophylaxis  
Adults and children weighing more than 45 kg (99 lb): 250 mg P.O. once weekly on same day each week, starting 1 week before entering endemic area and continuing for 4 weeks after leaving area  
Children weighing 30 to 45 kg (66 to 99 lb): 187.5 mg P.O. q week
Children weighing 20 to 30 kg (44 to 66 lb): 125 mg P.O. q week
Children weighing 10 to 20 kg (22 to 44 lb): 62.5 mg P.O. q week
Children weighing 5 to 10 kg (11 to 22 lb): 31.25 mg P.O. q week

Contraindications
- Hypersensitivity to drug, related agents (quinine, quinidine), or excipients
- Prophylactic use in patients with active depression, recent history of depression, generalized anxiety disorder, psychosis, schizophrenia, other psychiatric disorders, or history of seizures

Precautions
Use cautiously in:
- cardiac disorders, seizure disorders
- pregnant or breastfeeding patients
- children.

Administration
- Don’t give on empty stomach. Administer with at least 240 ml of water.
- Know that after completing mefloquine therapy for acute malarial infection, patient should receive primaquine (or other 8-aminoquinolone) to prevent relapse.

Adverse reactions
CNS: dizziness, syncope, headache, psychotic changes, depression, hallucinations, confusion, anxiety, fatigue, vertigo, seizures
EENT: blurred vision, tinnitus
GI: nausea, vomiting, diarrhea, loose stools, abdominal discomfort, anorexia
Hematologic: leukopenia, thrombocytopenia
Musculoskeletal: myalgia
Skin: rash
Other: fever, chills

Interactions
Drug-drug. Beta-adrenergic blockers, quinidine, quinine: ECG abnormalities, cardiac arrest
Chloroquine, quinine: increased risk of seizures
Valproic acid: decreased valproic acid blood level, loss of seizure control

Drug-diagnostic tests. Hematocrit, platelets, white blood cells: decreased values
Transaminases: transient increases

Patient monitoring
- Monitor patient with acute Plasmodium vivax malaria who is at high risk for relapse. Because drug doesn’t eliminate exoerythrocytic (hepatic-phase) parasites, patient should receive primaquine after mefloquine therapy.
- Watch for psychiatric symptoms, such as acute anxiety, depression, restlessness, or confusion. These may precede more serious psychiatric events.
- Evaluate hepatic function during prolonged prophylactic therapy.
- In patients receiving related drugs (such as quinine, quinidine, or chloroquine) concurrently, be alert for ECG abnormalities and seizures. Separate administration times by at least 12 hours.
- Closely monitor patients with serious or life-threatening Plasmodium falciparum infection. Be aware that they should receive I.V. antimalarial drugs and that mefloquine may be used to complete course of therapy.

Patient teaching
- Tell patient to take with full glass of water and not on empty stomach.
- In prophylactic use, instruct patient to take first dose 1 week before departure and to continue therapy as prescribed upon return. Tell him to take drug on same day each week.
- Advise patient to report fever after returning from malarious area.

Reactions in bold are life-threatening.
Inform patient that malaria prophylaxis should include protective clothing, insect repellent, and bed netting.

Tell patient to immediately report psychiatric symptoms (such as acute anxiety, depression, restlessness, or confusion) and to stop taking drug.

Caution patient to avoid driving and other hazardous activities because drug may cause dizziness.

Instruct patient to have periodic ophthalmic exams, because drug may cause eye damage.

Tell female patient to inform prescriber if she is pregnant.

Advise female patient not to breastfeed while taking drug.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

megestrol acetate

Apo-Megestrol®, Megace, Megace ES, Megace-OS®, Nu-Megestrol

Pharmacologic class: Hormone
Therapeutic class: Progestin, antineoplastic, appetite stimulant
Pregnancy risk category D (tablets), X (suspension)

Action
Unknown. Thought to suppress growth of progestin-sensitive breast and endometrial tumors by inhibiting pituitary and adrenal function.

Availability
Oral suspension: 40 mg/ml
Oral suspension (concentrate): 625 mg/5 ml
Tablets: 20 mg, 40 mg

Indications and dosages

Breast cancer
Adults: 160 mg/day P.O. given as 40 mg P.O. q.i.d.

Endometrial cancer
Adults: 40 to 320 mg/day P.O. in divided doses

Anorexia, cachexia, or unexplained significant weight loss in AIDS patients
Adults: 800 mg (oral suspension only) P.O. daily, or 625 mg (oral suspension concentrate) P.O. daily

Off-label uses
- Endometriosis, endometrial hyperplasia
- Prostatic hypertrophy
- Contraception

Contraindications
- Hypersensitivity to drug or its components
- Known or suspected pregnancy (suspension only)

Precautions
Use cautiously in:
- diabetes mellitus, severe hepatic disease, renal disease, cardiovascular disease, seizure disorders, cerebral hemorrhage, migraine, asthma, undiagnosed vaginal bleeding, depression
- history of thrombophlebitis
- breastfeeding.

Administration
- Give with meals if GI upset occurs.

Route | Onset | Peak | Duration
---|---|---|---
P.O. | Unknown | 3-5 hr | Unknown

Adverse reactions
CNS: headache, insomnia, drowsiness, asthenia, confusion, neuropathy, hyperesthesia, abnormal thinking, paresthesias, depression, seizures
CV: hypertension, chest pain, thrombophlebitis, deep vein thrombosis
EENT: amblyopia, retinal thrombosis, pharyngitis
GI: nausea, vomiting, constipation, abdominal pain, flatulence, dyspepsia, dry mouth, increased salivation, oral candidiasis
GU: breast tenderness, breakthrough bleeding, decreased libido
Hematologic: anemia, leukopenia
Hepatic: hepatomegaly
Metabolic: hyperglycemia
Musculoskeletal: carpal tunnel syndrome, back pain
Respiratory: dyspnea, cough, pneumonia, pulmonary embolism
Skin: alopecia, rash, pruritus, sweating
Other: edema, fever, weight gain, herpes infection

Interactions
Drug-diagnostic tests. Lactate dehydrogenase: increased level

Patient monitoring
⚠️ Watch for signs and symptoms of thromboembolic disorders.
⚠️ Stay alert for visual disturbances, headache, abdominal pain, and hepatomegaly.
• Monitor glucose level in diabetic patients.

Patient teaching
• Inform patient that drug may cause back or abdominal pain, headache, nausea, vomiting, or breast tenderness.
⚠️ Tell patient to immediately report pain, swelling or redness of lower legs, chest or back pain, or shortness of breath.
• Advise patient to contact prescriber if adverse effects become pronounced or if other troublesome signs or symptoms occur.
• Urge patient to use reliable contraception.
⚠️ Instruct patient to immediately report suspected pregnancy.
• Caution female patient to avoid breastfeeding.

• Advise diabetic patient to monitor blood glucose level.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

FDA BOXED WARNING
• Drug may increase risk of serious cardiovascular thrombotic events, myocardial infarction (MI), and stroke. Risk may increase with duration of use. Patients with cardiovascular disease or risk factors for it may be at greater risk.
• Drug increases risk of serious GI adverse events, including bleeding, ulcers, and stomach or intestinal perforation. These events can occur at any time during use and without warning. Elderly patients are at greater risk.
• Drug is contraindicated for treatment of perioperative pain in setting of coronary artery bypass graft surgery.

Action
Unknown. Thought to reduce inflammation and pain by inhibiting prostaglandin synthesis of the enzyme cyclooxygenase.
Availability
Oral suspension: 7.5 mg/5 ml  
Tablets: 7.5 mg, 15 mg

Indications and dosages
➤ Osteoarthritis; rheumatoid arthritis  
Adults: 7.5 mg P.O. once daily; may increase to 15 mg/day  
➤ Juvenile arthritis  
Children ages 2 and older: 0.125 mg/kg P.O. once daily, up to a maximum of 7.5 mg

Contraindications
• Hypersensitivity to drug, its components, or other NSAIDs

Precautions
Use cautiously in:
• bleeding disorders, GI or cardiac disorders, severe renal impairment, severe hepatic disease, asthma, peptic ulcer disease  
• concurrent aspirin, oral anticoagulant, or corticosteroid therapy  
• elderly or debilitated patients  
• pregnant or breastfeeding patients.

Administration
• Before starting therapy, ask patient about aspirin sensitivity and allergies to other NSAIDs. If patient is dehydrated, provide adequate fluids.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>5-6 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, dizziness, syncope, malaise, fatigue, asthenia, depression, confusion, nervousness, drowsiness, insomnia, vertigo, tremor, paresthesia, anxiety, seizures  
CV: hypertension, hypotension, palpitations, angina, vasculitis, heart failure, arrhythmias, MI  
EENT: abnormal vision, conjunctivitis, hearing loss, tinnitus, pharyngitis  
GI: nausea, vomiting, diarrhea, constipation, colitis, GI ulcers with perforation, abdominal pain, dyspepsia, gastroesophageal reflux, esophagitis, flatulence, ulcerative stomatitis, dry mouth, pancreatitis, GI hemorrhage  
GU: urinary frequency, urinary tract infection, albuminuria, hematuria, renal failure  
Hematologic: anemia, purpura, leukopenia, thrombocytopenia  
Hepatic: hepatitis  
Musculoskeletal: joint pain, back pain  
Metabolic: dehydrogenation  
Respiratory: upper respiratory infection, dyspnea, coughing, asthma, bronchospasm  
Skin: rash, urticaria, pruritus, bullous eruption, sweating, alopecia, photosensitivity, angioedema  
Other: altered taste, increased appetite, weight gain or loss, hot flashes, fluid retention and edema, masking of infection symptoms, hypersensitivity reactions including anaphylaxis

Interactions
Drug-drug. Angiotensin-converting enzyme inhibitors: decreased antihypertensive effect  
Anticoagulants: increased risk of bleeding  
Aspirin: increased meloxicam blood level, increased risk of toxicity  
Cholestyramine: decreased meloxicam blood level  
Furosemide, thiazides: decreased diuretic effect  
Lithium: increased lithium blood level  
Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, gamma-glutamyl transferase: increased levels  
Hemoglobin, platelets, white blood cells: decreased values  
Drug-behaviors. Alcohol use, smoking: increased risk of GI irritation and bleeding
Patient monitoring
- Closely monitor patient with aspirin-sensitivity asthma, because of risk of severe bronchospasm.
- In prolonged therapy, monitor CBC and kidney and liver function tests.
- Assess for cardiovascular disorders and hepatotoxicity.
- Monitor patient for fluid retention and weight gain.

Patient teaching
- Instruct patient to immediately report signs and symptoms of hepatotoxicity, including right upper quadrant pain, nausea, fatigue, lethargy, pruritus, and jaundice.
- Tell patient to report abdominal pain, blood in stool or emesis, or black tarry stools.
- Instruct patient to avoid alcohol and smoking.
- Caution pregnant patient to avoid drug, especially during third trimester.
- Tell patient to consult prescriber before taking over-the-counter preparations.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

FDA BOXED WARNING
- Give under supervision of physician experienced in cancer chemotherapy, in facility with adequate diagnostic and treatment resources.
- Drug may cause severe bone marrow suppression leading to infection or bleeding. I.V. use causes greater myelosuppression than oral use, and also may lead to hypersensitivity reactions (including anaphylaxis).
- Drug may cause leukemia and is potentially mutagenic.

Action
Forms cross-links between strands of cellular DNA, disrupting DNA and RNA transcription and causing cell death

Availability
Powder for injection (melphalan hydrochloride): 50 mg
Tablets: 2 mg

Indications and dosages
> Multiple myeloma
Adults: Initially, 6 mg P.O. daily for 2 to 3 weeks, then discontinue drug for up to 4 weeks or until white blood cell (WBC) and platelet counts increase; then give maintenance dosage of 2 or 10 mg/day for 7 to 10 days, then withhold until WBC recovery followed by 2 mg/day maintenance or 0.15 mg/kg/day P.O. for 7 days or 0.25 mg/kg for 4 days, repeated q 4 to 6 weeks. For those who can’t tolerate oral therapy, 16 mg/m² by I.V. infusion over 15 to 20 minutes at 2-week intervals for four doses (usually with prednisone); I.V. dose can be repeated q 4 weeks after recovery from toxicity.
> Nonresectable advanced ovarian cancer
Adults: 0.2 mg/kg/day P.O. for 5 days q 4 to 5 weeks

melphalan (L-PAM, L-phenylalanine mustard, L-sarcolysin)
Alkeran

melphalan hydrochloride
Alkeran

Pharmacologic class: Alkylator
Therapeutic class: Antineoplastic
Pregnancy risk category D

Reactions in bold are life-threatening.
Dosage adjustment
● Renal impairment

Contraindications
● Hypersensitivity to drug
● Patients whose disease has shown previous drug resistance

Precautions
Use cautiously in:
● bone marrow depression, infection, renal disease
● previous radiation therapy
● patients with childbearing potential
● pregnant or breastfeeding patients
● children (safety and efficacy not established).

Administration
● Before starting therapy, obtain CBC with white cell differential and platelet count. Repeat periodically before each course.
● For I.V. use, reconstitute by rapidly injecting 10 ml of supplied diluent into vial with lyophilized powder. Shake until solution is clear (yields a concentration of 5 mg/ml).
● Dilute desired dosage in 0.9% sodium chloride injection to a concentration no greater than 0.45 mg/ml. Administer over 15 minutes, being sure to give entire dose within 60 minutes of reconstitution.

Minimize time between reconstitution, dilution, and administration, because solution is unstable.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>5 days</td>
<td>2-3 wk</td>
<td>5-6 wk</td>
</tr>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CV: hypotension, tachycardia, vasculitis
GI: nausea, vomiting, diarrhea, oral ulcers, stomatitis
GU: hyperuricemia, amenorrhea, gonadal suppression, infertility

Hematologic: anemia, purpura, bone marrow depression, leukopenia, thrombocytopenia
Hepatic: hepatotoxicity
Metabolic: hyperuricemia
Respiratory: dyspnea, interstitial pneumonitis, bronchospasm, fibrosis
Skin: rash, urticaria, pruritus, alopecia, sweating
Other: edema, extravasation at I.V. site, allergic reactions including anaphylaxis

Interactions
Drug-drug. Carmustine: increased pulmonary toxicity
Cimetidine: decreased GI absorption of melphalan
Cisplatin: increased risk of renal dysfunction, decreased melphalan clearance
Cyclosporine: increased risk of nephrotoxicity, severe renal failure
Interferon alfa: decreased melphalan blood level
Live-virus vaccines: decreased antibody response to vaccine
Myelosuppressants: additive toxicity
Nalidixic acid: increased risk of severe hemorrhagic necrotic enterocolitis (in children)

Drug-diagnostic tests. Hemoglobin, platelets, red blood cells, WBCs: decreased values
Nitrogenous compounds: increased levels

Drug-food. Any food: decreased absorption of oral melphalan

Patient monitoring
Monitor patient for thrombocytopenia and leukopenia. If platelet count exceeds 100,000/mm³ or WBC count is below 3,000/mm³, discontinue drug until peripheral blood counts recover.
Watch closely for indications of bone marrow depression, including infection, anemia, and bleeding.
After multiple courses, watch for acute hypersensitivity reaction. If it
occurs, discontinue drug and administer volume expanders, corticosteroids, or antihistamines, as prescribed.

● Watch for signs and symptoms of GI or pulmonary toxicity.
● Evaluate renal and hepatic function.

Patient teaching

● Tell patient to take oral tablets without food, because food may decrease drug absorption.
● Instruct patient to take entire daily oral dose at one time on empty stomach.

Inform patient to immediately report unusual bleeding or bruising, fever, chills, sore throat, shortness of breath, yellowing of skin or eyes, persistent cough, flank or stomach pain, joint pain, black tarry stools, rash, or unusual lumps or masses.
● Tell patient to consult prescriber before using over-the-counter medications.
● Advise patient to use reliable contraception.
● Caution patient to avoid breastfeeding.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

memantine

**Pharmacologic class:** N-methyl-D-aspartate receptor antagonist (NMDA)

**Therapeutic class:** Anti-Alzheimer’s agent

**Pregnancy risk category B**

**Action**

Unclear. Thought to act as a low- to moderate-affinity NMDA receptor antagonist, binding to NMDA receptor-operated channels. (Activation of these channels is thought to contribute to Alzheimer’s symptoms.)

**Availability**

- Oral solution: 2 mg/ml
- Tablets: 5 mg, 10 mg
- Tablets (titration pack): 28 tablets of 5 mg and 21 tablets of 10 mg

**Indications and dosages**

Moderate to severe Alzheimer’s-type dementia

**Adults:** Initially, 5 mg P.O. daily. Then titrate at intervals of at least 1 week in 5-mg increments, to a maximum of 10 mg P.O. b.i.d.

**Dosage adjustment**

● Moderate renal impairment

**Contraindications**

● Hypersensitivity to drug or its components

**Precautions**

Use cautiously in:

● neurologic conditions, moderate to severe renal impairment, genitourinary conditions that increase pH
● pregnant or breastfeeding patients.

**Administration**

● Give with or without food.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>3-7 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- CNS: dizziness, headache, syncope, aggressive reaction, confusion, somnolence, hallucinations, agitation, insomnia, vertigo, ataxia, abnormal gait, hypokinesia, anxiety, transient ischemic attack, cerebrovascular accident (CVA)
- CV: hypertension, cardiac failure
- EENT: cataract, conjunctivitis
- GI: nausea, vomiting, diarrhea, constipation, anorexia

Reactions in **bold** are life-threatening.
menotropins

Menopur, Repronex

Pharmacologic class: Hormone
Therapeutic class: Exogenous gonadotropin
Pregnancy risk category X

Action
Simulates action of follicle-stimulating hormone (FSH) by promoting follicular growth and maturation

Availability
Injection (powder or pellet for reconstitution): 75 international units luteinizing hormone (LH); 150 international units LH and 150 international units FSH activity/vial

Indications and dosages
Controlled ovarian stimulation in patients with oligoovulation
Women: Dosage individualized. Recommended dosage is 150 international units I.M. or subcutaneously daily during first 5 days of treatment, with subsequent dosages adjusted based on response. Adjust dosage no more often than every 2 days, and don’t exceed 75 to 150 international units per adjustment. Maximum daily dosage is 450 international units. Dosing beyond 12 days is not recommended. If response is appropriate, human chorionic gonadotropin (hCG) should be given I.M. 1 day after last menotropins dose.

Assisted reproductive technologies
Women: In patients who’ve received gonadotropin-releasing hormone agonists or antagonist pituitary suppression, recommended initial dosage is 225 international units I.M. or subcutaneously, with subsequent dosage adjustments based on response.
Adjust dosage no more often than every 2 days, and don’t exceed 75 to 150 international units per adjustment. Maximum daily dosage is 450 international units. Dosing beyond 12 days isn’t recommended. Once adequate follicular development appears, hCG is given to induce follicular maturation in preparation for oocyte retrieval.

**Contraindications**
- Hypersensitivity to drug
- High FSH levels (indicating primary ovarian failure)
- Abnormal bleeding of undetermined origin
- Uncontrolled thyroid or adrenal dysfunction
- Organic intracranial lesion (such as pituitary tumor)
- Causes of infertility other than anovulation (unless patient is candidate for in vitro fertilization)
- Ovarian cysts or enlargement not caused by polycystic ovarian syndrome
- Pregnancy

**Precautions**
Use cautiously in:
- renal or hepatic insufficiency (safety and efficacy not established)
- breastfeeding patients.

**Administration**
- Know that drug may be given either I.M. or subcutaneously.
- To reconstitute powder or pellet for injection, add accompanying 2 ml of 0.9% sodium chloride injection to vial.
- Inject immediately after reconstitution. Discard unused portion.
- Rotate injection sites.
- Use lower abdomen for subcutaneous injection.
- Withhold hCG if serum estradiol level exceeds 2,000 pg/ml or abdominal pain occurs.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.M.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>Subcut.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
CNS: headache, malaise, dizziness, **cerebrovascular accident**
CV: tachycardia, **venous thrombophlebitis, arterial occlusion, arterial thromboembolism**
GI: nausea, vomiting, diarrhea, abdominal cramps and distention, **hemoperitoneum**
GU: ovarian enlargement with pain, gynecomastia, ovarian cysts, multiple births, **ovarian hyperstimulation syndrome** (OHSS), ectopic pregnancy
Metabolic: electrolyte imbalances
Musculoskeletal: muscle aches, joint pain
Respiratory: dyspnea, tachypnea, atelectasis, **adult respiratory distress syndrome, pulmonary embolism, pulmonary infarction**
Skin: rash
Other: fever, hypersensitivity reaction, **anaphylaxis**

**Interactions**
None significant

**Patient monitoring**
- Know that before starting menotropins/hCG therapy to induce ovulation and pregnancy, patient should undergo gynecologic and endocrine evaluation with hysterosalpingogram to rule out pregnancy and neoplastic lesions.
- Assess patient to confirm anovulation. Obtain urinary gonadotropin levels as ordered to rule out primary ovarian failure. (Male partner’s fertility should be evaluated, also).
- In older females (who have greater risk of anovulatory disorders and endometrial cancer), assess cervical dilation and curettage results.
- Evaluate patient for expected ovarian stimulation without hyperstimulation.

Reactions in **bold** are life-threatening.
Monitor for early indications of OHSS—severe pelvic pain, nausea, vomiting, and weight gain. OHSS usually occurs 2 weeks after treatment ends, peaks 7 to 10 days after ovulation, and resolves with menses onset.

If OHSS occurs, drug is withdrawn and patient is hospitalized for bed rest, fluid and electrolyte management, and analgesics. Monitor daily fluid intake and output, weight, abdominal girth, hematocrit, serum and urinary electrolytes, urine specific gravity, blood urea nitrogen, and creatinine. Watch for hemoconcentration caused by fluid loss into peritoneal, pleural, and pericardial cavities. Stay alert for pulmonary and thromboembolic complications.

Assess male patient for pituitary insufficiency as possible cause of infertility.

Patient teaching
- Before therapy, teach patient about duration of treatment and necessary monitoring.
- Inform patient about risk of multiple births with menotropins and hCG use.
- For infertile females, encourage daily intercourse starting on day before hCG administration.
- As appropriate, review all other significant and life-threatening adverse reactions.

Action
Binds to and depresses opiate receptors in spinal cord and CNS, altering perception of and response to pain

Availability
Injection: 10 mg/ml, 25 mg/ml, 50 mg/ml, 75 mg/ml, 100 mg/ml
Oral solution: 500 mg/5 ml
Syrup: 50 mg/5 ml
Tablets: 50 mg, 100 mg

Indications and dosages
Moderate to severe pain
Adults: 50 to 150 mg P.O., I.M., or subcutaneously q 3 to 4 hours as needed
Children: 1.1 to 1.8 mg/kg P.O., I.M., or subcutaneously q 3 to 4 hours, not to exceed 100 mg/dose
Preoperative sedation
Adults: 50 to 100 mg I.M. or subcutaneously 30 to 90 minutes before anesthesia
Children: 1 to 2.2 mg/kg I.M. or subcutaneously 30 to 90 minutes before anesthesia. Don’t exceed adult dosage.
Support of anesthesia
Adults: Fractional doses (such as 10 mg/ml) by repeated slow I.V. injections or continuous I.V. infusion of a more dilute solution (such as 1 mg/ml). Dosages should be individualized.
Analgesia during labor
Adults: 50 to 100 mg I.M. or subcutaneously when contractions are regular. May repeat q 1 to 3 hours.

Contraindications
- Hypersensitivity to drug or bisulfites (with some injectable products)
- MAO inhibitor use within past 14 days

Precautions
Use cautiously in:
- head trauma; increased intracranial pressure (ICP); severe renal, hepatic, or pulmonary disease; hypothyroidism; adrenal insufficiency; extensive burns;
alcoholism; supraventricular tachycardia; seizure disorders
● undiagnosed abdominal pain or prostatic hyperplasia
● elderly or debilitated patients
● pregnant patients (not recommended before labor)
● labor (drug may cause respiratory depression in neonate)
● breastfeeding patients
● children.

Administration
● Give I.M. injection slowly into large muscle. Preferably, use diluted solution.
● Give oral solution or syrup in a half-glass of water to avoid topical anesthetic effect on mucous membranes.
● Be aware that drug is compatible with 5% dextrose and lactated Ringer’s solution, dextrose-saline solution combinations, and 2.5%, 5%, or 10% dextrose in water.

Know that drug is not compatible with soluble barbiturates, aminophylline, heparin, morphine sulfate, methicillin, phenytoin, sodium bicarbonate, iodide, sulfadiazine, or sulfisoxazole.
● Don’t give for chronic pain control, because of potential toxicity and dependence.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>15 min</td>
<td>60 min</td>
<td>2-4 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>5-7 min</td>
<td>2-4 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>10-15 min</td>
<td>30-50 min</td>
<td>2-4 hr</td>
</tr>
<tr>
<td>Subcut</td>
<td>10-15 min</td>
<td>40-60 min</td>
<td>2-4 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: confusion, sedation, dysphoria, euphoria, floating feeling, hallucinations, headache, unusual dreams, seizures
CV: hypotension, bradycardia, cardiac arrest, shock
EENT: blurred vision, diplopia, miosis
GI: nausea, vomiting, constipation, ileus, biliary tract spasms
GU: urinary retention
Respiratory: respiratory depression, respiratory arrest
Skin: flushing, sweating, induration
Other: pain at injection site, local irritation, physical or psychological drug dependence, drug tolerance

Interactions
Drug-drug. Antihistamines, sedative-hypnotics: additive CNS depression
Barbiturates, cinetidine, protease inhibitor antiretrovirals: increased respiratory and CNS depression
Chlorpromazine, thioridazine: increased risk of meperidine toxicity
MAO inhibitors, procarbazine: potentially fatal reaction
Opioid agonist-antagonists: precipitation of opioid withdrawal in physically dependent patients
Phenytoin: increased meperidine metabolism and decreased effects

Drug-diagnostic tests. Amylase, lipase: increased levels
Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression
Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring
 Monitor vital signs. Don’t give drug if patient has significant respiratory or CNS depression.
● Reassess patient’s pain level after administration.
● Watch for seizures, agitation, irritability, nervousness, tremors, twitches, and myoclonus in patients at risk for normeperidine accumulation (such as those with renal or hepatic impairment).
● Use with extreme caution in patients with head injury. Drug may increase ICP and cause adverse reactions that obscure clinical course.
● Closely monitor patients with acute abdominal pain. Drug may obscure

Reactions in bold are life-threatening.

Clinical alert
diagnosis and clinical course of GI condition.
● Evaluate bowel and bladder function.
● With long-term or repeated use, watch for psychological and physical drug dependence and tolerance.
  With pediatric patients, stay alert for increased risk of seizures.

Patient teaching
● Tell patient using oral solution or syrup to take drug with a half-glass of water to minimize local anesthetic effect.
● Caution patient to avoid driving and other hazardous activities, because drug may cause dizziness or drowsiness.
● Advise patient to avoid alcohol.
● Instruct ambulatory patient to change position slowly to avoid orthostatic hypotension.
● Tell female patient to inform prescriber if she is pregnant or breastfeeding.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

mercaptopurine
(6-mercaptopurine, 6-MP)
Purinethol, Puri-Nethol

Pharmacologic class: Antimetabolite
Therapeutic class: Antineoplastic
Pregnancy risk category D

FDA BOXED WARNING
● Don’t give drug unless diagnosis of acute lymphatic leukemia is confirmed and responsible physician knows how to assess response to chemotherapy.

Action
Inhibits DNA and RNA synthesis, suppressing growth of certain cancer cells

Availability
Tablets: 50 mg

Indications and dosages
► Maintenance therapy for acute lymphatic (lymphocytic, lymphoblastic) leukemia
Adults and children: On complete hematologic remission, 1.5 to 2.5 mg/kg/day P.O. as a single dose (combined with other agents as prescribed).

Contraindications
● Hypersensitivity to drug or its components
● Prior resistance to drug or thioguanine
● Breastfeeding

Precautions
Use cautiously in:
● renal or hepatic impairment
● decreased platelet or neutrophil counts after chemotherapy or radiation
● inherited thiopurine methyltransferase deficiency
● pregnant patients.

Administration
● Follow facility protocols regarding proper handling and disposal of drug.
  Don’t handle drug if you are pregnant.
● Be aware that total daily dosage is calculated to nearest multiple of 25 mg and given once daily.
  Be aware that when mercaptopurine is given with allopurinol, mercaptopurine dosage must be reduced to one-third to one-fourth of usual dosage to avoid severe toxicity.
Withdraw drug immediately if white blood cell (WBC) or platelet count falls rapidly or steeply.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

GI: nausea, vomiting, anorexia, diarrhea, GI ulcers, painful oral ulcers, pancreatitis
Hematologic: anemia, leukopenia, thrombocytopenia
Hepatic: jaundice, hepatotoxicity
Metabolic: hyperuricemia
Skin: rash, hyperpigmentation

**Interactions**

Drug-drug. Allopurinol (more than 300 mg), aminosalicylate derivatives (mesalazine, olsalazine, sulfasalazine): increased bone marrow depression
Warfarin: decreased anticoagulant effect

Drug-diagnostic tests. Hemoglobin, platelets, red blood cells, uric acid, WBCs: increased values

**Patient monitoring**

Watch for signs and symptoms of hepatotoxicity.
- Monitor weekly CBC with white cell differential and platelet count.
- Assess bone marrow aspiration and biopsy results, as necessary, to aid assessment of disease progression, resistance to therapy, and drug-induced marrow hypoplasia.
- Monitor serum uric acid level.
- Evaluate fluid intake and output.
- Monitor liver function tests and bilirubin level weekly at start of therapy, then monthly.

**Patient teaching**

Instruct patient to immediately report fever, sore throat, increased bleeding or bruising, or signs or symptoms of liver problems (right-sided abdominal pain, yellowing of skin or eyes, nausea, vomiting, clay-colored stools, or dark urine).
- Advise both male and female patients to use reliable contraception.
- Encourage patient to maintain adequate fluid intake.
- Caution patient not to get vaccinations without consulting prescriber.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**meropenem**

Meronem®, Merrem I.V.

**Pharmacologic class:** Carbapenem
**Therapeutic class:** Anti-infective
**Pregnancy risk category B**

**Action**
Inhibits bacterial cell-wall synthesis and penetrates gram-negative and gram-positive bacteria

**Availability**
Powder for injection: 500-mg and 1-g vials

**Indications and dosages**

> Intra-abdominal infections

**Adults:** 1 g I.V. q 8 hours over 15 to 30 minutes by infusion or over 3 to 5 minutes as a bolus injection

**Children weighing 50 kg (110 lb) or more:** 1 g I.V. q 8 hours over 15 to 30 minutes by infusion or over 3 to 5 minutes as a bolus injection

**Children ages 3 months and older weighing less than 50 kg (110 lb):** 20 mg/kg q 8 hours over 15 to 30 minutes by infusion or over 3 to 5 minutes as a bolus injection

> Bacterial meningitis

**Children weighing 50 kg (110 lb) or more:** 2 g I.V. q 8 hours over 15 to 30 minutes by infusion or over 3 to 5 minutes as a bolus injection

Reactions in bold are life-threatening.

Clinical alert
minutes by infusion or over 3 to 5 minutes as a bolus injection

**Children ages 3 month and older weighing less than 50 kg (110 lb):** 40 mg/kg q 8 hours over 15 to 30 minutes by infusion or over 3 to 5 minutes as a bolus injection, to a maximum of 2 g q 8 hours

➤ Complicated skin and skin-structure infections

**Adults:** 500 mg I.V. q 8 hours

### Dosage adjustment
- Renal impairment

### Off-label uses
- Acute pulmonary exacerbation caused by respiratory tract infection with susceptible organisms in cystic fibrosis patients

### Contraindications
- hypersensitivity to drug, its components, or other beta-lactams

### Precautions
Use cautiously in:
- sulfite sensitivity, renal disease, seizure disorder
- pregnant or breastfeeding patients
- children.

### Administration
- For I.V. bolus, add 10 or 20 ml of sterile water to 500-mg or 1-g vial, respectively, to yield a concentration of 50 mg/ml. Shake until clear. Administer single dose over 3 to 5 minutes.
- For intermittent I.V. infusion, piggyback vials can be reconstituted with compatible I.V. solution (0.9% sodium chloride or 5% dextrose) to yield a concentration of 2.5 to 50 mg/ml. Or vials can be reconstituted as for direct I.V. injection and added to compatible I.V. solution for further dilution. To reconstitute and administer ADD-Vantage systems, follow manufacturer’s instructions. Infuse drug over 15 to 30 minutes.

- Use diluted solution immediately, if possible.

### Route Onset Peak Duration
| I.V. | Unknown | 1 hr | Unknown |

### Adverse reactions
- **CNS:** headache, insomnia, dizziness, drowsiness, weakness, **seizures**
- **CV:** hypotension, phlebitis, palpitations, **heart failure, cardiac arrest, myocardial infarction**
- **GI:** nausea, vomiting, diarrhea, constipation, tongue discoloration, oral candidiasis, glossitis, **pseudomembranous colitis**
- **GU:** vaginal candidiasis
- **Hematologic:** anemia, eosinophilia, leukopenia, bone marrow depression, thrombocytopenia, neutropenia
- **Musculoskeletal:** myoclonus
- **Respiratory:** chest discomfort, dyspnea, hyperventilation
- **Skin:** rash, urticaria, pruritus, erythema at injection site
- **Other:** altered taste, fever, pain, fungal infection, **anaphylaxis**

### Interactions
**Drug-drug.** Probenecid: increased meropenem blood level

**Drug-diagnostic tests.** Alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, bilirubin, blood urea nitrogen, eosinophils, gamma-glutamyl transpeptidase, lactate dehydrogenase, lipase: increased values

Hematocrit, hemoglobin, platelets, neutrophils, white blood cells: decreased values

International Normalized Ratio, partial thromboplastin time, prothrombin time: increased or decreased values

### Patient monitoring
- Collect specimens for culture and sensitivity testing as needed. However, be aware that drug therapy may start pending results.
Monitor patient for hypersensitivity reaction or anaphylaxis. If either occurs, stop infusion immediately and initiate emergency treatment.

- Monitor for CNS irritability and seizures.
- In prolonged therapy, evaluate hematopoietic, renal, and hepatic function and watch for overgrowth of nonsusceptible organisms.
- If diarrhea occurs, check for pseudo-membranous colitis and obtain stool cultures.
- Obtain hearing tests in child being treated for bacterial meningitis.

Patient teaching
- Advise patient to report such adverse reactions as CNS irritability, diarrhea, rash, shortness of breath, or pain at infusion site.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

mesalamine

(5-aminosalicylic acid, 5-ASA, mesalazine, mesalazine)

Asacol, Canasa, Ipocol®, Lialda, Mesasal®, Mesren®, Mezavant, Novo-5-ASA-Ect®, Pentasa, Rowasa, Salofalk®

Pharmacologic class: 5-amino-2-hydroxybenzoic acid

Therapeutic class: GI anti-inflammatory drug

Pregnancy risk category B

Action
Unknown. Thought to act in colon, where it blocks cyclooxygenase and inhibits prostaglandin synthesis.

Availability
Capsules (extended-release): 250 mg, 500 mg
Rectal suspension: 4 g/60 ml
Suppositories: 1,000 mg
Tablets (delayed-release): 400 mg (Pentasa), 1.2 g (Lialda)

Indications and dosages

Active ulcerative colitis
Adults: 800 mg P.O. (Asacol delayed-release tablets) t.i.d. for 6 weeks
To induce remission in mildly to moderately active ulcerative colitis
Adults: 1 g P.O. (Pentasa extended-release capsules) q.i.d. for a total dosage of 4 g daily for up to 8 weeks. Or, two to four 1.2 g (Lialda) extended-release tablets P.O. once daily for total daily dose of 2.4 or 4.8 g for up to 8 weeks.
Active distal ulcerative colitis, procitosigmoiditis, or proctitis
Adults: 4-g enema (Rowasa 60 ml) P.R. daily at bedtime, retained for 8 hours. Continue for 3 to 6 weeks.
Active ulcerative proctitis
Adults: 500 mg (Canasa suppository) P.R. b.i.d., increased to t.i.d. if response inadequate after 2 weeks. Or 1,000 mg (suppository) P.R. at bedtime, continued for 3 to 6 weeks.
To maintain remission of ulcerative colitis
Adults: 1.6 g (Asacol) P.O. daily in divided doses

Contraindications
- Hypersensitivity to drug, its components, or salicylates

Precautions
Use cautiously in:
- severe hepatic or renal impairment
- allergy to sulfasalazine

Reactions in bold are life-threatening.

Clinical alert
● pyloric stenosis (delayed-release tablets)
● conditions predisposing to development of myocarditis or pericarditis
● pregnant or breastfeeding patients
● children younger than age 18 (safety and efficacy not established).

Administration
● Give Lialda tablets with meal.
● Make sure patient swallows tablets whole without crushing or chewing.
● For best effect, have patient retain suppository for 1 to 3 hours.

Route Onset Peak Duration
P.O. Unknown Unknown 6-8 hr
P.R. Unknown Unknown 24 hr

Adverse reactions
CNS: headache, dizziness, malaise, weakness
CV: chest pain, mesalamine-induced cardiac hypersensitivity reactions (myocarditis and pericarditis)
EENT: rhinitis, pharyngitis
GI: nausea, vomiting, diarrhea, eructation, flatulence, anal irritation (with rectal use), pancreatitis
GU: interstitial nephritis, renal failure
Musculoskeletal: back pain
Skin: alopecia, rash
Other: fever, acute intolerance syndrome, anaphylaxis, acute intolerance syndrome

Interactions
Drug-drug. Azathioprine, 6-mercaptopurine: increased potential for blood disorders
Nephrotoxic drugs (including nonsteroidal anti-inflammatory agents): increased risk of renal adverse reactions

Patient monitoring
● Monitor carefully for mesalamine-induced cardiac hypersensitivity reactions (myocarditis and pericarditis).

Closely monitor patients with history of allergic reactions to sulfasalazine or sulfite sensitivity (if using enema).
● Assess kidney and liver function before and periodically during therapy.
● Monitor for suppository efficacy, which should appear in 3 to 21 days. However, know that treatment usually continues for 3 to 6 weeks.

Watch for signs and symptoms of intolerance syndrome, such as cramping, acute abdominal pain, bloody diarrhea, fever, headache, and rash. If these occur, discontinue drug and notify prescriber.

Watch for signs and symptoms of intolerance syndrome, such as cramping, acute abdominal pain, bloody diarrhea, fever, headache, and rash. If these occur, discontinue drug. Drug may be restarted later only if clearly needed, under close medical supervision and at reduced dosage.

Patient teaching
● Instruct patient to swallow tablets or capsules whole.
● Tell patient to contact prescriber if partially intact tablets repeatedly appear in stools.
● Advise patient using suppository to avoid excessive handling and to retain suppository for 1 to 3 hours or longer for maximum benefit.
● Teach patient about proper enema administration. Tell him to stay in position for at least 30 minutes and, if possible, retain medication overnight.

Advise patient to immediately report breathing difficulties, allergic symptoms, cramping, acute abdominal pain, bloody diarrhea, fever, headache, or rash.
● As appropriate, review all other significant and life-threatening adverse reactions, especially those related to the drugs mentioned above.
mesna
Mesnex, Uromitexan

Pharmacologic class: Detoxifying agent
Therapeutic class: Hemorrhagic cystitis inhibitor
Pregnancy risk category B

Action
Reacts in kidney with urotoxic ifosfamide metabolites (acrolein and 4-hydroxy-ifosfamide), resulting in their detoxification. Also binds to double bonds of acrolein and to other urotoxic metabolites.

Availability
Injection: 100 mg/ml in 10-ml vials
Tablets (coated): 400 mg

Indications and dosages
➢ To prevent hemorrhagic cystitis in patients receiving ifosfamide
Adults: Combination I.V. and P.O. regimen—Single I.V. bolus dose of mesna at 20% of ifosfamide dosage, given at same time as ifosfamide, followed by two doses of mesna tablets P.O. at 40% of ifosfamide dosage given 2 and 6 hours after ifosfamide dose. I.V. regimen—I.V. bolus of mesna at 20% of ifosfamide dosage given at same time as ifosfamide, repeated 4 and 8 hours after each ifosfamide dose.

Dosage adjustment
● Children

Contraindications
● Hypersensitivity to drug or other thiol compounds

Precautions
Use cautiously in:
● autoimmune disorders
● pregnant or breastfeeding patients.

Administration
● Dilute with dextrose 5% in water, dextrose 5% in normal saline solution, dextrose 5% in 0.2% sodium chloride solution, dextrose 5% in 0.33% sodium chloride solution, dextrose 5% in 0.45% sodium chloride solution, normal saline solution, or lactated Ringer’s solution for injection.
● Give I.V. bolus over at least 1 minute with ifosfamide dose and at prescribed intervals after ifosfamide doses.
➢ Don’t use multidose vial (contains benzyl alcohol) in neonates or infants. In older children, use with caution.
● If patient vomits within 2 hours of oral mesna dose, repeat oral dose or switch to I.V. route.

Route Onset Peak Duration
P.O. Unknown 4-8 hr 24 hr
I.V. Unknown 1 hr 24 hr

Adverse reactions
CNS: fatigue, malaise, irritability, headache, dizziness, drowsiness, hyperesthesia, rigors
CV: hypertension, hypotension, ST-segment elevation, tachycardia
EENT: conjunctivitis, pharyngitis, rhinitis
GI: nausea, vomiting, diarrhea, constipation, anorexia, flatulence
Hematologic: hematuria
Musculoskeletal: back pain, joint pain, myalgia
Respiratory: coughing, tachypnea, bronchospasm
Skin: flushing, rash
Other: arm or leg pain, injection site reactions, fever, flulike symptoms, allergic reactions

Reactions in bold are life-threatening.

Clinical alert
Interactions

Drug-diagnostic tests. Hepatic enzymes: increased levels
Urinary erythrocytes: false-positive or false-negative results
Urine tests using Ames Multistix: false-positive for ketonuria

Patient monitoring

- Monitor nutritional and hydration status.
- Monitor vital signs and ECG. Watch closely for blood pressure changes and tachycardia.
- Assess body temperature. Stay alert for fever, flulike symptoms, and EENT infections.
- Monitor respiratory status carefully. Watch closely for cough, bronchospasm, and tachypnea.

Patient teaching

- Inform patient that drug may cause significant adverse effects. Reassure him that he will be monitored closely.
- Encourage patient to request analgesics or other pain-relief measures for headache, back or joint pain, hyperesthesia, or muscle ache.
- Advise patient to immediately report breathing difficulties and allergic symptoms.
- Inform patient about drug’s adverse CNS effects. Explain safety measures used to prevent injury.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

metaproterenol sulfate
(orciprenaline)

Alupent, Apo-Orciprenaline, Tanta Orciprenaline

Pharmacologic class: Sympathomimetic, selective beta2-adrenergic agonist
Therapeutic class: Bronchodilator
Pregnancy risk category C

Action
Relaxes beta2 (pulmonary) receptors, causing bronchodilation and inhibiting histamine release. Acts on beta1 (cardiac) receptors with weaker effect.

Availability
Aerosol solution for inhalation: 0.65 mg/ metered spray
Nebulizer solution: 0.4%, 0.6%
Syrup: 10 mg/5 ml
Tablets: 10 mg, 20 mg

Indications and dosages

- Bronchial asthma and reversible bronchospasm

Adults and children ages 9 and older or weighing more than 27 kg (60 lb): 20 mg P.O. three or four times daily
Children ages 6 to 9 or weighing less than 27 kg (60 lb): 10 mg P.O. three or four times daily

Aerosol solution for inhalation—
Adults and children ages 12 and older:
Two or three inhalations by metered aerosol (1.3 or 1.9 mg) q 3 to 4 hours, to a maximum of 12 inhalations (7.8 mg) in 24 hours. Alternatively, one plastic ampule of 0.4% or 0.6% solution for nebulization by intermittent positive-pressure breathing device (usually not given more than q 4 hours).
Contraindications
- Hypersensitivity to drug or its components
- Tachyarrhythmias

Precautions
Use cautiously in:
- unstable vasomotor system disorders, hypertension, coronary artery disease, peripheral or mesenteric vascular thrombosis, hyperthyroidism, chronic obstructive pulmonary disease complicated by degenerative heart disease, hypoxia, hypercapnia
- history of cerebrovascular accident or seizure disorders
- patients who’ve received general anesthesia
- labor and delivery
- pregnant or breastfeeding patients.

Administration
- If patient is using aerosol metered-dose inhaler, place mouthpiece well into his mouth and have him close lips tightly around it. Tell him to exhale completely through nose and then inhale slowly and deeply through mouth while activating inhaler. Have him hold his breath for a few seconds and then remove mouthpiece and exhale slowly. Wait about 2 minutes between inhalations. Rinse mouthpiece with water after use.
- Know that use of Aero-Chamber may aid proper drug delivery.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30 min</td>
<td>1 hr</td>
<td>4 hr or more</td>
</tr>
<tr>
<td>Inhalation (aerosol)</td>
<td>1 min</td>
<td>Unknown</td>
<td>1-5 hr</td>
</tr>
<tr>
<td>Inhalation (nebulizer)</td>
<td>5-30 min</td>
<td>Unknown</td>
<td>2-6 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: drowsiness, tremor, vertigo, headache, nervousness, restlessness, apprehension, anxiety, fear, CNS stimulation, hyperkinesia, insomnia, irritability, weakness
CV: tachycardia, hypertension, palpitations, anginal pain, cardiac arrest (with excessive use)
GI: nausea, vomiting, diarrhea, heartburn, dry mouth
Respiratory: cough, respiratory difficulty, bronchospasm, pulmonary edema, paradoxical bronchiolar constriction (with excessive use)
Skin: rash, sweating, pallor, flushing
Other: abnormal or bad taste, hypersensitivity reaction

Interactions
Drug-drug. Epinephrine, other sympathomimetics: increased risk of arrhythmias
MAO inhibitors, tricyclic antidepressants: potentiation of metaproterenol effects
Propranolol and other beta-adrenergic blockers: inhibition of bronchodilating effect

Patient monitoring
- Monitor patient for hypersensitivity reaction or paradoxical bronchospasm. If either occurs, discontinue drug immediately and implement alternative therapy and airway control measures.
- Monitor patient for effective use of aerosol inhaler or hand-held nebulizer.
- Assess for drug efficacy. Be aware that efficacy may decrease with prolonged use.
- Check for adverse effects.

Patient teaching
- Tell patient to take tablets with food if GI distress occurs.
- Teach patient proper use of metered-dose aerosol inhaler.
- Advise patient to remove canister and wash mouthpiece frequently.
- Caution patient not to increase number or frequency of inhalations without prescriber’s consent; cardiac arrest may occur with excessive use.
● If patient uses multiple drugs to control asthma, assess level of understanding regarding administration. Tell him to continue taking each drug as prescribed even if he feels better.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

metaxalone
Skelaxin

**Pharmacologic class:** Skeletal muscle relaxant

**Therapeutic class:** Autonomic agent

**Pregnancy risk category C**

**Action**
Unclear. Thought to depress CNS.

**Availability**
Tablets: 400 mg, 800 mg

**Indications and dosages**
> Acute, painful musculoskeletal conditions

**Adults and children older than age 12:**
800 mg P.O. t.i.d. to q.i.d.

**Contraindications**
- Hypersensitivity to drug or its components
- Significant renal or hepatic impairment
- History of drug-induced, hemolytic, or other anemias

**Precautions**
Use cautiously in:
- preexisting hepatic damage
- pregnant or breastfeeding patients
- children ages 12 and younger (safety not established).

**Administration**
- Give with full glass of water, with or without food.
- Know that drug should be used in conjunction with rest and physical therapy.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2-4.5 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** drowsiness, dizziness, headache, nervousness, irritability
**GI:** nausea, vomiting, GI upset
**Hematologic:** leukopenia, hemolytic anemia
**Hepatic:** jaundice
**Skin:** rash (with or without pruritus)
**Other:** hypersensitivity reaction, anaphylactoid reaction

**Interactions**

**Drug-drug.** Barbiturates, CNS depressants: enhanced sedative effect

**Drug-diagnostic tests.** Benedict’s tests: false-positive results
**Cephalin flocculation tests:** elevated results

**Drug-behaviors.** Alcohol use: increased sedation

**Patient monitoring**
- Monitor liver function tests and CBC with white cell differential.
- Watch for severe adverse reactions, such as leukopenia, hemolytic anemia, and anaphylactoid reactions.

**Patient teaching**
- Tell patient to take with full glass of water, with or without food.
- Advise patient to immediately report severe rash, difficulty breathing, unusual bruising or bleeding, yellowing of skin or eyes, or unusual tiredness or weakness.
- Instruct patient to take missed dose as soon as he remembers. However, if it’s almost time for next dose, tell him to skip missed dose and continue with regular dosing schedule.
Emphasize that drug should be used along with rest, physical therapy, and other measures to relieve discomfort.

Advise patient to use caution while driving or operating heavy machinery.

Caution female patient not to breastfeed while taking drug.

Tell patient to avoid alcohol during therapy because it increases drowsiness.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

FDA BOXED WARNING

Lactic acidosis is rare but serious (50% mortality) metabolic complication that can result from drug accumulation. Lactic acidosis is also linked to such conditions as diabetes mellitus and significant tissue hypoperfusion and hypoxemia. Lactic acidosis incidence in patients receiving drug is low; cases have occurred mainly in diabetics with significant renal insufficiency. Patients with unstable or acute heart failure at risk of hypoperfusion and hypoxemia are at increased lactic acidosis risk.

Lactic acidosis risk rises with age and degree of renal dysfunction, and may decrease significantly through regular renal monitoring and by using lowest effective dosage. Perform careful renal monitoring, especially in elderly patients. Withhold drug promptly if patient develops condition linked to hypoxemia, dehydration, or sepsis. Avoid giving drug to patients with hepatic disease, as hepatic impairment may significantly limit lactate clearance. Caution patient against excessive alcohol use during therapy, as alcohol potentiates drug effects on lactate metabolism. Temporarily withdraw drug before intravascular radiocontrast study or surgical procedure.

Suspect lactic acidosis in diabetic patient with metabolic acidosis who lacks evidence of ketoacidosis.

Lactic acidosis requires emergency treatment. Discontinue metformin immediately and begin general supportive measures promptly. Prompt hemodialysis is recommended to correct acidosis and remove accumulated drug, and can lead to prompt symptom reversal and recovery.

Action

Increases insulin sensitivity by decreasing glucose production and absorption in liver and intestines and enhancing glucose uptake and utilization

Availability

**Oral solution**: 100 mg/ml, 500 mg/5 ml

**Tablets**: 500 mg, 850 mg, 1,000 mg

**Tablets (extended-release)**: 500 mg, 750 mg

Reactions in **bold** are life-threatening.

Clinical alert

**metformin hydrochloride**

*Apo-Metformin*, Co Metformin, Dom-Metformin, Fortamet, Gen-Metformin, Glucophage, Glucophage XR, Glumetza, Glycon, Med Metformin, Metsof, Novo-Metformin, Nu-Metformin, PHL-Metformin, Ran-Metformin, Ratio-Metformin, Rhoxal-Metformin, Riomet, Riva-Metformin, Sandoz Metformin

Pharmacologic class: Biguanide

Therapeutic class: Hypoglycemic

Pregnancy risk category B
Indications and dosages

➣ Adjunct to diet and exercise to improve glycemic control in type 2 (non-insulin-dependent) diabetes mellitus

**Adults and children ages 17 and older:** Initially, 500 mg P.O. b.i.d.; may increase by 500 mg/week, up to 2,000 mg/day. If patient needs more than 2,000 mg/day, give in three divided doses (not to exceed 2,500 mg/day). Alternatively, 850 mg P.O. daily, increased by 850 mg q 2 weeks, up to 2,550 mg/day in divided doses (850 mg t.i.d.). *Extended-release tablets*—500 mg/day P.O. with evening meal; may increase by 500 mg weekly, up to 2,000 mg/day. If 2,000 mg once daily is inadequate, 1,000 mg may be given b.i.d.

**Children ages 10 to 16:** 500 mg P.O. b.i.d. Increase in increments of 500 mg weekly to a maximum of 2,000 mg daily in divided doses.

➤ Concurrent use with sulfonylurea or insulin in type 2 diabetes mellitus

**Adults and children ages 17 and older:** If patient hasn’t responded to maximum metformin dosage of 2,000 mg/day in 4 weeks, sulfonylurea may be added while metformin therapy continues at highest dosage (even if patient experienced primary or secondary failure on sulfonylurea). Adjust dosages of both drugs until glycemic control adequate. If response inadequate within 1 to 3 months of concurrent therapy, consider alternatives.

➤ Concurrent use with insulin in type 2 diabetes mellitus

**Adults ages 17 and older:** Continue current insulin dosage while starting metformin at 500 mg P.O. once daily. If response inadequate, increase metformin dosage by 500 mg after approximately 1 week and then by 500 mg weekly until glycemic control is achieved. Maximum metformin dosage is 2,500 mg. Optimally, decrease insulin dosage 10% to 25% when fasting plasma glucose level is below 120 mg/dl. Individualize dosage adjustments based on glycemic response.

Dosage adjustment

- Elderly or debilitated patients

Contraindications

- Hypersensitivity to drug
- Acute or chronic metabolic acidosis (including diabetic ketoacidosis) with or without coma
- Underlying renal dysfunction
- Heart failure requiring drug therapy

Precautions

Use cautiously in:
- renal impairment, myocardial infarction, cerebrovascular accident, hypoxia, sepsis, pituitary deficiency or hyperthyroidism, dehydration, hypoxemia, chronic alcohol use
- elderly or debilitated patients
- pregnant or breastfeeding patients
- children (safety not established).

Administration

- Administer with a meal.
- Make sure patient swallows extended-release tablets whole without crushing or chewing.
- Don’t administer extended-release tablets to children.
- Know that drug is given with diet therapy, sulfonylureas, or both.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2-4 hr</td>
<td>12 hr</td>
</tr>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>4-8 hr</td>
<td>24 hr</td>
</tr>
<tr>
<td>(extended)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adverse reactions

**GI:** diarrhea, nausea, vomiting, abdominal bloating

**Metabolic:** lactic acidosis

**Other:** unpleasant metallic taste, decreased vitamin B₁₂ level

Interactions

**Drug-drug.** *Amiloride, calcium channel blockers, digoxin, morphine,*
procainamide, quinidine, ranitidine, triamterene, trimethoprim, vancomycin: altered response to metformin
trimetidine, furosemide, nifedipine: increased metformin effects
Iodinated contrast media: increased risk of lactic acidosis
Drug-diagnostic tests. Urine ketones: false-positive results
Drug-herbs. Glucosamine: decreased glycemic control
Chromium, coenzyme Q10, fenugreek: additive hypoglycemic effects
Drug-behaviors. Alcohol use: increased metformin effects

Patient monitoring
• When switching from chlorpropamide, stay alert for hypoglycemia during first 2 weeks of metformin therapy; chlorpropamide may stay in body for prolonged time. Conversion from other standard oral hypoglycemics requires no transition period.
• Monitor blood glucose level closely. If it isn’t controlled after 4 weeks at maximum dosage, oral sulfonylurea may be added.
• Monitor kidney and liver function tests, particularly in elderly patients.
• Assess hematologic parameters and vitamin B₁₂ levels at start of therapy and periodically thereafter.
• Watch for signs and symptoms of lactic acidosis. Stop drug if acidosis occurs. To aid differential diagnosis, check electrolyte, ketone, glucose, blood pH, lactate, and metformin blood levels.
• Periodically monitor glucose and glycosylated hemoglobin levels to evaluate drug efficacy.

Patient teaching
• Teach patient about diabetes and importance of proper diet, exercise, weight control, and blood glucose monitoring.
• Inform patient that drug may cause diarrhea, nausea, and upset stomach.

Advising him to take it with meals to reduce these effects, and tell him that adverse effects often subside over time.

Teach patient to recognize and immediately report signs and symptoms of acidosis, such as weakness, fatigue, muscle pain, dyspnea, abdominal pain, dizziness, light-headedness, and slow or irregular heartbeat.
• Advise patient to report changes in health status (such as infection, persistent vomiting and diarrhea, or need for surgery). These may warrant dosage decrease or drug withdrawal.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

methadone hydrochloride eptadone
Dolophine, Metadol, Methadone HCl
Intensol, Methadose, Physeptone®, Synastone®
Pharmacologic class: Opioid agonist
Therapeutic class: Analgesic, opioid detoxification adjunct
Controlled substance schedule II
Pregnancy risk category C

FDA BOXED WARNING
• Deaths have occurred during drug initiation for opioid dependence. In some cases, deaths apparently resulted from respiratory or cardiac effects of methadone and too-rapid titration without considering drug accumulation. Make sure you understand drug’s pharmacokinetics, and be vigilant during treatment initiation and dosage titration. Caution patients against
self-medicating with CNS depressants at start of therapy.

- Prolonged QT intervals and serious arrhythmia (torsades de pointes) have occurred. Most cases involved patients being treated for pain with large, multiple daily doses.
- Federal law requires that when drug is used to treat opioid addiction in detoxification or maintenance programs, it can be dispensed only by treatment programs certified by the Substance Abuse and Mental Health Services Administration and approved by designated state authority. Certified treatment programs must dispense and use drug in oral form only and according to treatment requirements stipulated in Federal Opioid Treatment Standards. Failure to abide by regulations may lead to criminal prosecution, drug seizure, revocation of program approval, and injunction precluding program operation.

Action
Binds to and depresses opiate receptors in spinal cord and CNS, altering perception of and response to pain

Availability
*Injection*: 10 mg/ml  
*Oral solution*: 5 mg/5 ml, 10 mg/5 ml, 10 mg/ml (concentrate)  
*Tablets*: 5 mg, 10 mg  
*Tablets (dispersible diskettes)*: 40 mg

Indications and dosages

- **Opioid detoxification**  
  **Adults**: Initially, 15 to 20 mg/day P.O. to suppress withdrawal. Additional doses may be necessary if symptoms aren’t suppressed or if they reappear. Most patients are adequately stabilized on total daily dosage of 40 mg given in single or divided doses; however, some may need higher dosages. When patient is stable for 2 to 3 days, decrease dosage gradually at 2-day intervals. If patient can’t tolerate oral doses, give I.M. or subcutaneously (usually at about 25% of total daily P.O. dosage) in two injections.
  > To maintain opioid abstinence  
  **Adults**: Oral dosage highly individualized based on control of abstinence symptoms without respiratory depression or marked sedation. If patient can’t tolerate oral doses, give I.M. or subcutaneously (usually at about 25% of total daily P.O. dosage) in two injections.
  > Chronic and severe pain  
  **Adults**: For chronic pain, 2.5 to 10 mg P.O., I.M., or subcutaneously q 3 to 4 hours as needed; adjust dosage and dosing interval as needed. For severe chronic pain (as in terminal illness), 5 to 20 mg P.O. q 6 to 8 hours.
  **Children**: Dosage individualized.

Contraindications
- Hypersensitivity to drug or other opioid agonists

Precautions
Use cautiously in:
- head trauma; severe renal, hepatic, or pulmonary disease; hypothyroidism; adrenal insufficiency; undiagnosed abdominal pain; prostatic hypertrophy; urethral stricture; toxic psychosis; Addison’s disease; cor pulmonale; increased intracranial pressure; severe inflammatory bowel disease; severe CNS depression; hypercapnia; seizures; fever; alcoholism
- recent renal or hepatic surgery
- elderly or debilitated patients
- pregnant patients, patients in labor, or breastfeeding patients.

Administration
- Mix dispersible tablets with 120 ml of water or orange juice, citrus Tang, or other acidic fruit beverage.
- Dilute 10 mg/ml of oral solution with water or other liquid to at least 30 ml. In detoxification and maintenance
of opioid withdrawal, dilute solution in at least 90 ml of fluid.

- When used parenterally, I.M. route is preferred. Rotate injection sites.
- For detoxification and maintenance, give oral solution only, to reduce potential for parenteral abuse, hoarding, and accidental ingestion.
- Know that patients who can’t take oral drugs because of nausea or vomiting during detoxification or maintenance should be hospitalized and given methadone parenterally.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30-60 min</td>
<td>1.5-2 hr</td>
<td>4-6 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>10-20 min</td>
<td>1-2 hr</td>
<td>4-5 hr</td>
</tr>
<tr>
<td>subcut.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** amnesia, anxiety, confusion, poor concentration, delirium, delusions, depression, dizziness, drowsiness, euphoria, fever, hallucinations, headache, insomnia, lethargy, light-headedness, malaise, psychosis, restlessness, sedation, clouded sensorium, syncope, tremor, **seizures, coma**

**CV:** hypotension, palpitations, edema, bradycardia, **shock, cardiac arrest**

**EENT:** visual disturbances

**GI:** nausea, vomiting, constipation, ileus, biliary tract spasm, gastroesophageal reflux, indigestion, dysphagia, dry mouth, anorexia

**GU:** urinary hesitancy, urinary retention, prolonged labor, difficult ejaculation, erectile dysfunction

**Hematologic:** anemia, leukopenia, thrombocytopenia

**Musculoskeletal:** joint pain

**Respiratory:** depressed cough reflex, hypventilation, wheezing, **asthma exacerbation, atelectasis, pulmonary edema, bronchospasm, respiratory depression or arrest, apnea**

**Skin:** urticaria, pruritus, flushing, pallor, diaphoresis

**Other:** allergic reaction, hiccups, facial or injection site edema, pain, physical or psychological drug dependence, withdrawal symptoms

**Interactions**

**Drug-drug.** Amitriptyline, antihistamines, chloral hydrate, clomipramine, glutethimide, methocarbamol, MAO inhibitors, nortriptyline: increased CNS and respiratory depression

**Anticholinergics:** increased risk of severe constipation leading to ileus

**Antiemetics, general anesthetics, phenothiazines, sedative-hypnotics, tranquilizers:** coma, hypotension, respiratory depression, severe sedation

**Ascorbic acid, phenytoin, phosphate, potassium, rifampin:** decreased methadone blood level

**Cimetidine, fluvoxamine, protease inhibitors:** increased analgesia, CNS and respiratory depression

**Diuretics:** increased diuresis

**Hydroxyzine:** increased analgesia, CNS depression, and hypotension

**Paregoric, loperamide:** increased CNS depression, severe constipation

**Naloxone:** antagonism of methadone’s analgesic, CNS, and respiratory effects

**Naltrexone:** induction or worsening of withdrawal symptoms (when given within 7 days of methadone)

**Neuromuscular blockers:** increased or prolonged respiratory depression

**Drug-diagnostic tests.** Amylase, liver function tests: increased levels

**Drug-behaviors.** Alcohol use: increased CNS and respiratory depression

**Patient monitoring**

- Assess patient for relief of severe, chronic pain requiring around-the-clock dosing. Tailor dosage to patient’s pain level and drug tolerance.
- Monitor CNS, respiratory, and cardiovascular status.
- Watch for deepening sedation, which may increase with successive doses.
- Evaluate bowel and bladder function. Give laxatives if appropriate.
Monitor detoxification treatment closely. Short-term detoxification shouldn’t exceed 30 days; long-term detoxification, 180 days.

Assess patient on maintenance therapy for successful rehabilitation. Know that maintenance therapy should be part of comprehensive treatment plan that includes medical, vocational rehabilitative, employment, educational, and counseling services.

Patient teaching

Instruct patient to promptly report severe adverse reactions.

Tell patient he may take drug with food if GI upset occurs.

Tell ambulatory patient to change positions slowly to avoid orthostatic hypotension.

Caution patient not to discontinue drug abruptly.

Advise patient to avoid driving and other hazardous activities, because drug may cause drowsiness or dizziness.

Tell female patient to inform prescriber if she’s pregnant or breastfeeding.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

methimazole

Apo-Methimazole, Tapazole

Pharmacologic class: Thiomidazole derivative

Therapeutic class: Antithyroid drug

Pregnancy risk category D

Action

Directly interferes with thyroid synthesis by preventing iodine from combining with thyroglobulin, leading to decreased thyroid hormone levels

Availability

Tablets: 5 mg, 10 mg

Indications and dosages

Mild hyperthyroidism

Adults and adolescents: Initially, 15 mg P.O. daily in three equally divided doses at approximately 8-hour intervals. For maintenance, 5 to 15 mg/day in equally divided doses at approximately 8-hour intervals.

Children: Initially, 0.4 mg/kg/day in three divided doses at 8-hour intervals. For maintenance, approximately 0.2 mg/kg/day in three divided doses at 8-hour intervals.

Moderate hyperthyroidism

Adults and adolescents: Initially, 30 to 40 mg P.O. daily in three equally divided doses at approximately 8-hour intervals. For maintenance, 5 to 15 mg/day in three equally divided doses at approximately 8-hour intervals.

Children: 0.4 mg/kg/day P.O. as a single dose or in divided doses at 8-hour intervals. For maintenance, approximately 0.2 mg/kg/day as a single dose or in three divided doses at 8-hour intervals.

Severe hyperthyroidism

Adults and adolescents: Initially, 60 mg/day P.O. in three equally divided doses at approximately 8-hour intervals. For maintenance, 5 to 15 mg/day in three equally divided doses at approximately 8-hour intervals.

Children: Initially, 0.4 mg/kg/day P.O. as a single dose or in three divided doses at 8-hour intervals. For maintenance, approximately 0.2 mg/kg/day as a single dose or in three divided doses at 8-hour intervals.

Contraindications

- Hypersensitivity to drug
- Breastfeeding

- Canada
- UK
- Hazardous drug
- High alert drug
Precautions
Use cautiously in:
- bone marrow depression
- patients older than age 40
- pregnant patients.

Administration
- Give with meals as needed to reduce GI upset.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30-40 min</td>
<td>60 min</td>
<td>2-4 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, vertigo, paresthesia, neuritis, depression, neuropathy, CNS stimulation
GI: nausea, vomiting, constipation, epigastric distress, ileus, salivary gland enlargement, dry mouth, anorexia
GU: nephritis
Hematologic: thrombocytopenia, agranulocytosis, leukopenia, aplastic anemia
Hepatic: jaundice, hepatic dysfunction, hepatitis
Metabolic: hypothyroidism
Musculoskeletal: joint pain, myalgia
Skin: rash, urticaria, skin discoloration, pruritus, erythema nodosum, exfoliative dermatitis, abnormal hair loss
Other: fever, lymphadenopathy, lupus-like syndrome

Interactions
Drug-drug. Aminophylline, oxtriphylline, theophylline: decreased clearance of both drugs
Amiodarone, iodine, potassium iodide: decreased response to methimazole
Anticoagulants: altered requirements for both drugs
Beta-adrenergic blockers: altered beta blocker clearance
Digoxin: increased digoxin blood level

Drugs-diagnostic tests. Granulocytes, hemoglobin, platelets, white blood cells: decreased values

Reactions in bold are life-threatening.

Patient monitoring
- Check for agranulocytosis in patients older than age 40 and in those receiving more than 40 mg/day.
- Assess hematologic studies. Agranulocytosis usually occurs within first 2 months of therapy and is rare after 4 months.
- Monitor thyroid function tests periodically. Once hyperthyroidism is controlled, elevated thyroid-stimulating factor indicates need for dosage decrease.
- Assess liver function tests and check for signs and symptoms of hepatic dysfunction.
- Monitor patient for fever, sore throat, and other evidence of infection as well as for unusual bleeding or bruising.
- Assess patient for signs and symptoms of hypothyroidism, such as hard edema of subcutaneous tissue, drowsiness, slow mentation, dryness or loss of hair, decreased temperature, hoarseness, and muscle weakness.

Patient teaching
- Tell patient to take with meals if GI upset occurs.
- Advise patient to take exactly as prescribed to maintain constant blood level.
- Tell patient to report rash, fever, sore throat, unusual bleeding or bruising, headache, rash, yellowing of skin or eyes, abdominal pain, vomiting, or flu-like symptoms.
- Caution female patient not to breastfeed while taking drug.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.
methocarbamol
PMS-Methocarbamol®, Robaxin

**Pharmacologic class:** Autonomic nervous system agent  
**Therapeutic class:** Skeletal muscle relaxant (centrally acting)

**Pregnancy risk category C**

**Action**  
Unknown. Thought to depress central perception of pain without directly relaxing skeletal muscles or directly affecting motor endplate or motor nerves.

**Availability**  
*Injection:* 100 mg/ml in 10-ml ampules, 100 mg/ml in 10-ml vials  
*Tablets:* 500 mg, 750 mg

**Indications and dosages**  
> Adjunct in muscle spasms caused by acute, painful musculoskeletal conditions  
**Adults:** Initially, 1.5 g P.O. q.i.d. (up to 8 g/day) for 2 to 3 days, then 4 to 4.5 g/day P.O. in three to six divided doses; or 750 mg P.O. q 4 hours or 1 g P.O. q.i.d. or 1.5 g P.O. t.i.d. If oral dosing isn’t feasible or if condition is severe, give 1 to 3 g/day I.M. or I.V. for maximum of 3 days.

**Off-label uses**  
- Tetanus

**Contraindications**  
- Hypersensitivity to drug, its components, or polyethylene glycol (with parenteral form)  
- Renal impairment (with parenteral form)

**Precautions**  
Use cautiously in:  
- seizure disorders (with parenteral use)  
- pregnant or breastfeeding patients  
- children (safety not established).

**Administration**  
- For direct I.V. injection, administer slowly. Keep patient supine for 10 to 15 minutes afterward.  
- For I.V. infusion, dilute 1 g with up to 250 ml 5% dextrose or 0.9% sodium chloride injection.  
- Avoid extravasation; drug is hypertonic.  
- Don’t give subcutaneously.  
- For I.M. use, inject no more than 500 mg (5 ml of 10% injection) into each gluteal area.  
- Don’t use parenteral form in patients with renal impairment. Polyethylene glycol vehicle may irritate kidneys.  
- When giving for tetanus, crush and suspend tablets in water or saline solution, and give via nasogastric tube, if necessary.  
- Be aware that drug is usually given as part of regimen that includes rest and physical therapy.

**Adverse reactions**  
**CNS:** dizziness, light-headedness, drowsiness, syncope, **seizures** (with I.V. use)  
**CV:** bradycardia or hypotension (with I.V. use)  
**EENT:** blurred vision, conjunctivitis, nasal congestion  
**GI:** nausea, GI upset, anorexia  
**GU:** brown, black, or green urine  
**Musculoskeletal:** mild muscle incoordination (with I.V. or I.M. use)
Skin: flushing (with I.V. use), pruritus, rash, urticaria
Other: fever, pain at I.M. injection site, phlebitis at I.V. site, allergic reactions including anaphylaxis (with I.M. or I.V. use)

Interactions
Drug-drug. Antihistamines, CNS depressants (such as opioids, sedative-hypnotics): additive CNS depression
Drug-diagnostic tests. Urinary 5-hydroxyindoleacetic acid, urine vanillylmandelic acid: false elevations
Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression
Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring
- Assess for orthostatic hypotension, especially with parenteral use. Keep patient supine for 10 to 15 minutes after I.V. administration.
- Watch for anaphylaxis after I.M. or I.V. administration.
- Stay alert for bradycardia and syncope after I.V. or I.M. dose. As needed and prescribed, give epinephrine, corticosteroids, or antihistamines.
- Monitor I.V. site frequently to prevent sloughing and thrombophlebitis.

Patient teaching
- Tell patient that drug may turn urine brown, black, or green.
- Caution patient to avoid driving and other hazardous activities, because drug may cause drowsiness or dizziness.
- Instruct patient to move slowly when changing position, to avoid dizziness from sudden blood pressure decrease.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

Reactions in bold are life-threatening.
or pleural effusions. Monitor them carefully for toxicity; dosage may need to be reduced or drug may need to be stopped.

- Unexpectedly severe (sometimes fatal) bone marrow suppression and GI toxicity have occurred in patients receiving drug (usually in high doses) concurrently with nonsteroidal anti-inflammatory drugs (NSAIDs).
- Drug causes hepatotoxicity, fibrosis, and cirrhosis, but generally only after prolonged use. Acute liver enzyme elevations are common but usually transient and asymptomatic. Perform periodic liver biopsies in psoriasis patients receiving long-term therapy.
- Potentially dangerous lung disease may arise acutely at any time during therapy. Not always fully reversible, it has occurred at dosages as low as 7.5 mg/week.
- Interrupt therapy for diarrhea and ulcerative stomatitis; otherwise, hemorrhagic enteritis and death from intestinal perforation may occur.
- Malignant lymphomas may occur at low dosages and may not require cytotoxic treatment. Discontinue drug first; if lymphoma doesn’t regress, begin appropriate treatment.
- Drug may induce tumor lysis syndrome in patients with rapidly growing tumors.
- Severe and occasionally fatal skin reactions have occurred within days of single or multiple P.O., I.M., I.V., or intrathecal doses. Drug withdrawal has led to recovery.
- When given concomitantly with radiation therapy, drug may increase risk of soft-tissue necrosis and osteonecrosis.

### Action
Binds to dihydrofolate reductase, interfering with folic acid metabolism and inhibiting DNA synthesis and cellular replication.

### Availability

**Injection:** 20-mg, 25-mg, 50-mg, 100-mg, 250-mg, and 1,000-mg vials (lyophilized powder, preservative-free)

**Tablets:** 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg

### Indications and dosages

- **Acute lymphoblastic leukemia**
  - **Adults and children:** 3.3 mg/m² P.O. or I.M. daily for 4 to 6 weeks, then 20 to 30 mg/m² P.O. or I.M. weekly in two divided doses; given with corticosteroid. Alternatively, 2.5 mg/kg I.V. q 14 days.
  - **Meningeal leukemia**
  - **Adult and children:** 12 mg/m² (maximum of 15 mg) intrathecally at intervals of 2 to 5 days, repeated until cerebrospinal fluid cell count is normal
  - **Burkitt’s lymphoma**
  - **Adults:** In stages I and II, 10 to 25 mg P.O. daily for 4 to 8 days; in stage III, combined with other neoplastic drugs. Patients in all stages usually require several courses of therapy, with 7- to 10-day rest periods between courses.
  - **Mycosis fungoides**
  - **Adults:** 2.5 to 10 mg/day P.O. or 50 mg I.M. q week or 25 mg I.M. twice weekly
  - **Osteosarcoma**
  - **Adults:** As part of adjunctive regimen with other antineoplastics, initially 12 g/m² I.V. as 4-hour infusion, then 12 to 15 g/m² I.V. in subsequent 4-hour infusions given at weeks 4, 5, 6, 7, 11, 12, 15, 16, 29, 30, 44, and 45 until peak blood level reaches 1,000 micromoles. Leucovorin rescue must start 24 hours after methotrexate infusion begins; if patient can’t tolerate oral leucovorin, dose must be given I.M. or I.V. on same schedule.
  - **Trophoblastic tumors (choriocarcinoma, hydatidiform mole)**
  - **Adults:** 15 to 30 mg P.O. or I.M. daily for 5 days. Repeat course three to five times as required, with rest periods of at least 1 week between courses, until toxic symptoms subside.
Lymphosarcoma (stage III)

**Adults:** 0.625 to 2.5 mg/kg/day P.O., I.M., or I.V.

Psoriasis

**Adults:** After test dose, 2.5 mg P.O. at 12-hour intervals for three doses weekly, to a maximum of 30 mg weekly. Alternatively, 10 to 25 mg P.O., I.M., or I.V. as a single weekly dose, to a maximum of 30 mg weekly; decrease dosage when adequate response occurs.

Rheumatoid arthritis

**Adults:** 7.5 mg P.O. weekly as a single dose or divided as 2.5 mg q 12 hours for three doses weekly. May gradually increase, if needed, up to 20 mg/week; decrease when adequate response occurs.

Dosage adjustment

- Renal or hepatic impairment
- Elderly patients

Off-label uses

- Relapsing-remitting multiple sclerosis
- Refractory Crohn's disease

Contraindications

- Hypersensitivity to drug
- Psoriasis or rheumatoid arthritis in pregnant patients
- Breastfeeding

Precautions

Use cautiously in:

- severe myocardial, hepatic, or renal disease; decreased bone marrow reserve; active infection; hypotension; coma
- elderly patients
- patients with childbearing potential
- young children.

Administration

- Be aware that methotrexate is a high-alert drug.
- Know that patient must be adequately hydrated before therapy and urine must be alkalinized using sodium bicarbonate.

Follow facility policy for handling, preparing, and administering carcinogenic, mutagenic, and teratogenic drugs.

- Be aware that oral administration is preferred. Give oral dose 1 hour before or 2 hours after meals. (Food decreases absorption of tablets and reduces peak blood level.)
- Reconstitute powder for injection with preservative-free solution, such as 5% dextrose solution or 0.9% sodium chloride injection. Reconstitute 20-mg and 50-mg vials to yield a concentration no greater than 25 mg/ml. Reconstitute 1-g vial with 19.4 ml to yield a concentration of 50 mg/ml.
- For high-dose I.V. infusion, dilute in 5% dextrose solution. Administer each 10 mg over 1 minute or by infusion over 30 minutes to 4 hours as directed.
- For intrathecal use, reconstitute immediately before administration, using preservative-free solution (such as 0.9% sodium chloride for injection), to a concentration of 1 mg/ml.

For intrathecal or high-dose therapy, use preservative-free injection form.

- Avoid I.M. injections if platelet count is below 50,000/mm³.
- For osteosarcoma, make sure leucovorin rescue is used appropriately in patients receiving high methotrexate doses. Rescue usually starts 24 hours after methotrexate infusion begins.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1-2 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>Immediate</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.M.</td>
<td>Unknown</td>
<td>0.5-1 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>Intrathecal</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: malaise, fatigue, drowsiness, dizziness, headache, aphasia, hemiparesis, demyelination, **seizures**, **leukoencephalopathy**, chemical arachnoiditis (with intrathecal use)

Reactions in **bold** are life-threatening.
EENT: blurred vision, pharyngitis
GI: nausea, vomiting, stomatitis, hematemesis, melena, GI ulcers, enteritis, gingivitis, pharyngitis, anorexia, GI bleeding
GU: hematuria, cystitis, infertility, menstrual dysfunction, defective spermatogenesis, abortion, tubular necrosis, severe nephropathy, renal failure
Hematologic: anemia, leukopenia, thrombocytopenia, severe bone marrow depression
Hepatic: hepatotoxicity
Metabolic: hyperuricemia, diabetes mellitus
Musculoskeletal: joint pain, myalgia, osteonecrosis, osteoporosis (with long-term use in children)
Respiratory: dry nonproductive cough, pneumonitis, pulmonary fibrosis, pulmonary interstitial infiltrates
Skin: pruritus, rash, urticaria, alopecia, painful plaque erosions, photosensitivity
Other: chills, fever, increased susceptibility to infection, septicemia, anaphylaxis, sudden death

Interactions
Drug-drug. Activated charcoal: decreased blood level of oral or I.V. methotrexate
Folic acid derivatives: antagonism of methotrexate effects
Fosphenytoin, phenytoin: decreased blood levels of these drugs
Hepatotoxic drugs: increased risk of hepatotoxicity
NSAIDs, phenylbutazone, probenecid, salicylates, sulfonamides: increased methotrexate toxicity
Oral antibiotics: decreased methotrexate absorption
Penicillin, sulfonamide: increased methotrexate blood level
Procarbazine: increased nephrotoxicity
Theophylline: increased theophylline level

Vaccines: vaccine ineffectiveness

Drug-diagnostic tests. Hemoglobin, platelets, red blood cells, white blood cells: decreased values
Pregnancy tests: false-positive result
Protein-bound iodine, transaminases, uric acid: increased levels

Drug-food. Any food: delayed methotrexate absorption and decreased peak blood level

Drug-herbs. Astragalus, echinacea, melatonin: interference with methotrexate-induced immunosuppression

Drug-behaviors. Alcohol use: increased hepatotoxicity
Sun exposure: increased photosensitivity

Patient monitoring
- Watch for vomiting, diarrhea, or stomatitis, which may cause dehydration.
- Know that high-dose therapy may cause nephrotoxicity. Monitor renal function, hydration status, urine alkalization (for pH above 6.5), and methotrexate blood level.
- Assess for fever, sore throat, bleeding, increased bruising, and other signs and symptoms of hematologic compromise or infection.
- With high-dose or intrathecal therapy, watch for CNS toxicity.
- Monitor creatinine and methotrexate blood levels 24 hours after therapy starts and then daily. Adjust leucovorin dosage as prescribed.
- Check hematologic studies at least monthly; blood or platelet transfusions may be necessary.
- Monitor liver and kidney function studies every 1 to 3 months. Evaluate uric acid levels.
- Watch for signs and symptoms of pulmonary toxicity, such as fever, dry nonproductive cough, dyspnea, hypoxemia, and infiltrates on chest X-ray.
- Know that methotrexate exits slowly from third-space compartments (ascites, pleural effusions). Before therapy starts, fluid should be evacuated;
during therapy, monitor drug blood level.

Patient teaching

- Review dosing instructions carefully with patient to avoid toxicity. Tell patient with rheumatoid arthritis or psoriasis to take doses weekly.
- Advise patient to take oral doses 1 hour before or 2 hours after meals.
- Instruct patient to report diarrhea, abdominal pain, clay-colored or black tarry stools, fever, chills, sore throat, unusual bleeding or bruising, sores in or around mouth, cough or shortness of breath, yellowing of skin or eyes, dark or bloody urine, swelling of feet or legs, or joint pain.
- Tell patient to take temperature daily and to report fever or other signs or symptoms of infection.
- Instruct patient to drink 2 to 3 L of fluid each day.
- Advise male patients to use reliable contraception during and for at least 3 months after therapy. Advise female patients to use reliable contraception during and for one ovulatory cycle after therapy; also caution them not to breastfeed.
- Advise patient to avoid sun exposure and to use sunscreen and protective clothing (especially if he has psoriasis).
- Instruct patient to avoid alcohol.
- Tell patient he'll need to undergo blood tests during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

### methylcellulose

**Pharmacologic class:** Semisynthetic cellulose derivative

**Therapeutic class:** Bulk laxative

**Pregnancy risk category NR**

#### Action

Stimulates peristalsis by promoting water absorption into fecal matter and increasing bulk, resulting in bowel evacuation

#### Availability

**Powder:** 105 mg/g, 196 mg/g

#### Indications and dosages

- **Chronic constipation**
  - **Adults and children ages 12 and older:** Up to 6 g P.O. daily in divided doses of 0.45 to 3 g
  - **Children ages 6 to 11:** Up to 3 g P.O. daily in divided doses of 0.45 to 1.5 g

#### Contraindications

- Signs or symptoms of appendicitis or undiagnosed abdominal pain
- Partial bowel obstruction
- Dysphagia

#### Precautions

Use cautiously in:
- hepatitis
- intestinal ulcers
- laxative-dependent patients.

#### Administration

- Give with 8 oz of fluid.
- If patient is receiving maximum daily dosage, give in divided doses to reduce risk of esophageal obstruction.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>12-24 hr</td>
<td>&lt;3 days</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Reactions in **bold** are life-threatening.
Adverse reactions

GI: nausea; vomiting; diarrhea; severe constipation; abdominal distention; cramps; esophageal, gastric, small-intestine, or colonic strictures (with dry form); GI obstruction

Other: laxative dependence (with long-term use)

Interactions

Drug-drug. Antibiotics, digitalis, nitrofurantoin, oral anticoagulants, salicylates, tetracyclines: decreased absorption and action of these drugs

Patient monitoring

- Assess patient’s dietary habits. Consider factors that promote constipation, such as certain diseases and medications.
- Monitor patient for signs and symptoms of esophageal obstruction.
- Evaluate fluid and electrolyte balance in patients using laxatives excessively.

Patient teaching

- Instruct patient to take with a full glass (8 oz) of water.
- Advise patient to prevent or minimize constipation through adequate fluid intake (four to six glasses of water daily), proper diet, increased fiber intake, daily exercise, and prompt response to urge to defecate.
- Instruct patient to report chest pain or pressure, vomiting, and difficulty breathing (possible symptoms of GI obstruction).
- Caution patient not to use drug for more than 1 week without prescriber’s approval.
- Inform patient that chronic laxative use may lead to dependence.
- Tell patient to contact prescriber if constipation persists or if rectal bleeding or symptoms of electrolyte imbalance (muscle cramps, weakness, dizziness) occur.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

methyldopa

Aldomet®, Apo-Methyldopa♦, Novomedopa♦, Nu-Medopa♦

methyldopate hydrochloride

Pharmacologic class: Centrally acting antiadrenergic

Therapeutic class: Antihypertensive

Pregnancy risk category B

Action

Stimulates CNS alpha-adrenergic receptors, decreasing sympathetic stimulation to heart and blood vessels. Also reduces arterial pressure and plasma renin.

Availability

Injection: 50 mg/ml in 5- and 10-ml vials
Oral suspension (contains bisulfites): 250 mg/5 ml
Tablets: 125 mg, 250 mg, 500 mg

Indications and dosages

Hypertension

Adults: 250 mg P.O. two to three times daily for 2 days (not to exceed 500 mg/day in divided doses if used with other agents); may increase q 2 days as needed. Usual maintenance dosage is 500 mg to 2 g/day (not to exceed 3 g/day) P.O. in two to four divided doses or 250 to 500 mg I.V. q 6 hours (up to 1 g q 6 hours).

Children: 10 mg/kg/day (300 mg/m²/day) P.O. in two to four divided doses. May increase q 2 days up to 65 mg/kg/day (2 g/m²/day), or 3 g/day in divided
doses (whichever is lower) or 5 to 10 mg/kg I.V. q 6 hours; up to 65 mg/kg/day (2 g/m²/day), or 3 g/day in divided doses (whichever is lower).

**Contraindications**
- Hypersensitivity to drug or its components
- Pheochromocytoma
- Active hepatic disease or history of methyldopa-associated hepatic disorders
- MAO inhibitor use within past 14 days

**Precautions**
Use cautiously in:
- heart failure, edema, hemolytic anemia, hypotension, severe bilateral cerebrovascular disease
- dialysis patients
- elderly patients
- pregnant or breastfeeding patients.

**Administration**

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>4-6 hr</td>
<td>24-48 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>4-6 hr</td>
<td>10-16 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** headache, asthenia, weakness, dizziness, sedation, decreased mental acuity, depression, paresthesia, parkinsonism, Bell’s palsy, involuntary choreoathetotic movements

**CV:** bradycardia, edema, orthostatic hypotension, **myocarditis**

**EENT:** nasal congestion

**GI:** nausea, vomiting, diarrhea, constipation, abdominal distention, colitis, dry mouth, sialadenitis, sore or black tongue, **pancreatitis**

**GU:** breast enlargement, gynecomastia, failure to ejaculate, erectile dysfunction

**Hematologic:** eosinophilia, **hemolytic anemia**

**Hepatic:** hepatitis

**Other:** fever

**Interactions**

**Drug-drug.** Adrenergics, MAO inhibitors: excessive sympathetic stimulation
Amphetamines, barbiturates, nonsteroidal anti-inflammatory drugs, phenothiazines, tricyclic antidepressants: decreased antihypertensive effect

**Anesthetics, antihypertensives, nitrates:** additive hypotension

**Ferrous gluconate, ferrous sulfate:** decreased methyldopa blood level

**Haloperidol:** increased haloperidol effects, increased risk of psychoses

**Lithium:** increased risk of lithium toxicity

**Nonselective beta-adrenergic blockers:** paradoxical hypertension

**Tolbutamide:** increased tolbutamide effects

**Drug-diagnostic tests.** Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, potassium, prolactin, sodium, uric acid: increased levels

**Direct Coombs’ test:** positive result

**Liver function tests:** abnormal results

**Prothrombin time:** prolonged

**Drug-herbs.** Capsicum: reduced antihypertensive effects

**Drug-behaviors.** Alcohol use: increased hypotension

Reactions in **bold** are life-threatening.

Clinical alert
Patient monitoring
- Obtain direct Coombs’ test before therapy starts and 6 and 12 months later.
- Monitor periodic blood counts to detect adverse hematologic reactions.
- Monitor liver function tests and check for signs and symptoms of hepatic dysfunction (particularly during first 6 to 12 weeks of therapy).
- Check for edema or weight gain to help determine if diuretic should be added to regimen.
- Monitor blood pressure. Drug tolerance may occur during second and third months of therapy.

Patient teaching
- Tell patient that sedation usually occurs when therapy starts and during dosage titration. To lessen this effect, advise him to begin dosage titration in evening.
- Tell patient not to stop taking drug abruptly.
- Instruct patient to report fever, yellowing of skin or eyes, fatigue, abdominal pain, flulike symptoms, swelling, or significant weight gain.
- Inform patient that urine may darken after exposure to air.
- Advise patient to move slowly when changing position, to avoid dizziness from sudden blood pressure decrease.
- Caution patient to avoid driving and other hazardous activities until effects of drug are known or dosage titration is completed.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

methylNaltrexone bromide
Relistor

Pharmacologic class: Mu-opioid receptor antagonist (peripherally acting)
Therapeutic class: Opioid
Pregnancy risk category B

Action
Selectively antagonizes opioid binding at mu-opioid receptors (such as those in GI tract) while having restricted ability to cross blood-brain barrier, thereby decreasing constipating effects of opioids without altering analgesic effects on CNS

Availability
Solution for injection: 12 mg/0.6 ml in single-use vials

Indications and dosages
➢ Opioid-induced constipation in patients with advanced illness who are receiving palliative care and haven’t responded adequately to laxatives

Adults weighing 62 to less than 114 kg (136 to less than 251 lb): 12 mg subcutaneously every other day as needed, but no more frequently than one dose in 24 hours

Adults weighing 38 to less than 62 kg (84 to less than 136 lb): 8 mg subcutaneously every other day as needed, but no more frequently than one dose in 24 hours

Adults weighing outside above ranges: 0.15 mg/kg subcutaneously every other day as needed, but no more frequently than one dose in 24 hours

Dosage adjustment
- Severe renal impairment (creatinine clearance less than 30 ml/minute)
Contraindications
- Known or suspected mechanical GI obstruction

Precautions
Use cautiously in:
- renal impairment
- severe or persistent diarrhea
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

Administration
- Once drawn into syringe, if drug won’t be given immediately, store at ambient room temperature and administer within 24 hours.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>0.5 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness
GI: nausea, abdominal pain, diarrhea, flatulence

Interactions
None

Patient monitoring
- Monitor patient for severe or persistent diarrhea. Discontinue drug if it occurs.

Patient teaching
- Teach patient who will take drug at home how to prepare and administer it and discard supplies properly.
- Tell patient that if drug won’t be administered immediately after it’s drawn into syringe, it should be stored at ambient room temperature and administered within 24 hours.
- Inform patient that solution should be clear and colorless to pale yellow.
- Advise patient to stay near toilet facilities after receiving drug.
- Instruct patient to stop taking drug if severe or persistent diarrhea occurs.
- Tell patient that common side effects include transient abdominal pain, nausea, and vomiting. Advise patient to contact prescriber if these symptoms persist or worsen.
- Instruct patient to stop taking drug if opioid pain medication is discontinued.
- Advise female patient to tell prescriber if she is pregnant or breastfeeding or intends to become pregnant.
- As appropriate, review all other significant adverse reactions mentioned above.

methylergonovine maleate
Methergine

Pharmacologic class: Ergot alkaloid
Therapeutic class: Oxytocic
Pregnancy risk category C

Action
Directly stimulates vascular smooth-muscle contractions in uterus and cervix and decreases bleeding after delivery

Availability
Injection: 0.2 mg/ml
Tablets: 0.2 mg

Indications and dosages
- Prevention and treatment of postpartum hemorrhage
Adults: 0.2 mg I.M.; repeat q 2 to 4 hours as needed to a total of five doses. In emergencies, 0.2 mg I.V. over 1 minute. After initial I.M. or I.V. dose, 0.2 mg P.O. q 6 to 8 hours for 2 to 7 days; decrease dosage if cramping occurs.

Contraindications
- Hypersensitivity to drug
- Hypertension
- Toxemia

Reactions in bold are life-threatening.
- Pregnancy (except during third stage of labor)

**Precautions**

Use cautiously in:
- severe hepatic or renal disease, vascular disease, jaundice, sepsis
- patients in second stage of labor.

**Administration**

- Be aware that drug isn’t routinely given I.V. because of risk of severe hypotension and cerebrovascular accident (CVA). Monitor blood pressure and uterine contractions during administration.
- If I.V. use is necessary, give dose over 1 minute. Dose may be diluted in 5 ml of 0.9% sodium chloride injection.
- Be aware that prolonged therapy should be avoided because of ergotism risk.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>5-10 min</td>
<td>30 min</td>
<td>3 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>Unknown</td>
<td>45 min</td>
</tr>
<tr>
<td>I.M.</td>
<td>2-5 min</td>
<td>Unknown</td>
<td>3 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: dizziness, headache, hallucination, seizures, CVA (with I.V. use)
CV: hypertension, hypotension, transient chest pain, palpitations, thrombophlebitis
EENT: tinnitus, nasal congestion
GI: nausea, vomiting, diarrhea
GU: hematuria
Musculoskeletal: leg cramps
Respiratory: dyspnea
Skin: diaphoresis, rash, allergic reactions
Other: foul taste

**Interactions**

Drug-drug. *Dopamine, ergot alkaloids, oxytocin, regional anesthetics, vasoconstrictors:* excessive vasoconstriction

Drug-diagnostic tests. *Prolactin:* increased level

**Patient monitoring**

- Know that if used during third stage of labor, drug increases risk of hemorrhage and infection.
- When giving I.V., closely monitor blood pressure, pulse, uterine contractions, and bleeding.
- Monitor patient for adverse effects.

**Patient teaching**

- Inform patient and family of reason for using drug, and provide reassurance.
- Tell patient drug may cause nausea, vomiting, dizziness, increased blood pressure, headache, ringing in ears, chest pain, or shortness of breath. Advise her to report severe or troublesome symptoms.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**methylphenidate hydrochloride**

Apo-Methylphenidate®, Biphentin®, Concerta, Concerta XL®, Daytrana, Equasym®, Equasym XL®, Medikinet®, Medikinet XL®, Metadate CD, Metadate ER, Methylin, Methylin ER, PHL-Methylphenidate®, PMS-Methylphenidate®, Ritalin, Ritalin LA, Ritalin-SR, Tranquilyn

**Pharmacologic class:** Piperidine derivative

**Therapeutic class:** CNS stimulant

**Controlled substance schedule II**

**Pregnancy risk category C**
FDA BOXED WARNING

- Give cautiously to patients with history of drug dependence or alcoholism. Chronic abuse can cause marked tolerance and psychological dependence with abnormal behavior. Frank psychotic episodes may occur, especially with parenteral abuse. Supervise carefully during withdrawal from abusive use, as severe depression may occur. Withdrawal after prolonged therapeutic use may unmask symptoms of underlying disorder, possibly requiring follow-up.

Action

Increases release of norepinephrine, which stimulates impulse transmission in respiratory system and CNS. Net effect is increased mental alertness.

Availability

Capsules (extended-release): 10 mg, 20 mg, 30 mg, 40 mg
Tablets (chewable): 2.5 mg, 5 mg, 10 mg
Tablets (extended-release): 10 mg, 18 mg, 20 mg, 27 mg, 36 mg, 54 mg
Tablets (prompt-release): 5 mg, 10 mg, 20 mg
Tablets (sustained-release): 20 mg
Transdermal patch: 10 mg/9 hours, 15 mg/9 hours, 20 mg/9 hours, 30 mg/9 hours

Indications and dosages

- Adjunctive treatment of attention deficit hyperactivity disorder (ADHD)
  
  **Adults:** 5 to 20 mg P.O. (prompt-release tablets) two to three times daily. Once maintenance dosage is determined, may switch to extended-release.
  
  **Children older than age 6:** Initially, 5 mg P.O. (prompt-release tablets) before breakfast and lunch; increase by 5 to 10 mg at weekly intervals, not to exceed 60 mg/day. Once maintenance dosage is determined, may switch to extended-release.

If previous methylphenidate dosage was 10 mg b.i.d. or 20 mg sustained-release, give Ritalin LA 20 mg P.O. once daily. If previous dosage was 15 mg b.i.d., give Ritalin LA 30 mg P.O. once daily. If previous dosage was 20 mg b.i.d. or 40 mg sustained-release, give Ritalin LA 40 mg P.O. once daily. If previous dosage was 30 mg b.i.d. or 60 mg sustained-release, give Ritalin LA 60 mg P.O. once daily.

In all patients, Ritalin-SR or Metadate ER may be prescribed instead of prompt-release tablets when 8-hour dosage of those forms corresponds to titrated 8-hour dosage of prompt-release tablets.

**Concerta—**

**Adults:** If new to methylphenidate, initially 18 or 36 mg/day. Increase dosage by 18 mg/day at weekly intervals, not to exceed 72 mg/day. For patients currently using methylphenidate, dosing is based on current dosage regimen and clinical judgment.

**Children ages 6 and older who haven’t used methylphenidate previously:**

- Initially, 18 mg P.O. once daily in morning; may be titrated weekly up to 54 mg/day

**Children ages 6 and older using other methylphenidate forms:** 18 mg P.O. once daily in morning if previous dosage was 5 mg two to three times daily, or 20 mg P.O. daily (sustained-release); 36 mg once daily in morning if previous dosage was 10 mg two to three times daily or 40 mg daily (sustained-release); or 54 mg once daily in morning if previous dosage was 15 mg two to three times daily or 60 mg once daily (sustained-release)

**Metadate CD—**

**Children ages 6 and older:** Initially, 20 mg once daily; may adjust in weekly increments of 10 to 20 mg, to a maximum of 60 mg/day taken in morning

**Daytrana—**

**Adults:** If new to methylphenidate, initially 18 or 36 mg/day. Increase dosage by 18 mg/day at weekly intervals, not to exceed 72 mg/day. For patients currently using methylphenidate, dosing is based on current dosage regimen and clinical judgment.

**Children ages 6 and older who haven’t used methylphenidate previously:**

- Initially, 18 mg P.O. once daily in morning; may be titrated weekly up to 54 mg/day

**Children ages 6 and older using other methylphenidate forms:** 18 mg P.O. once daily in morning if previous dosage was 5 mg two to three times daily, or 20 mg P.O. daily (sustained-release); 36 mg once daily in morning if previous dosage was 10 mg two to three times daily or 40 mg daily (sustained-release); or 54 mg once daily in morning if previous dosage was 15 mg two to three times daily or 60 mg once daily (sustained-release)

**Concerta—**

**Adults:** If new to methylphenidate, initially 18 or 36 mg/day. Increase dosage by 18 mg/day at weekly intervals, not to exceed 72 mg/day. For patients currently using methylphenidate, dosing is based on current dosage regimen and clinical judgment.

**Children ages 6 and older who haven’t used methylphenidate previously:**

- Initially, 18 mg P.O. once daily in morning; may be titrated weekly up to 54 mg/day

**Children ages 6 and older using other methylphenidate forms:** 18 mg P.O. once daily in morning if previous dosage was 5 mg two to three times daily, or 20 mg P.O. daily (sustained-release); 36 mg once daily in morning if previous dosage was 10 mg two to three times daily or 40 mg daily (sustained-release); or 54 mg once daily in morning if previous dosage was 15 mg two to three times daily or 60 mg once daily (sustained-release)

**Metadate CD—**

**Children ages 6 and older:** Initially, 20 mg once daily; may adjust in weekly increments of 10 to 20 mg, to a maximum of 60 mg/day taken in morning

**Daytrana—**

Reactions in bold are life-threatening.
Children ages 6 and older: Apply patch to hip area 2 hours before effect is needed; remove 9 hours after application; titrate dosages as needed.

Narcolepsy Adults: 10 mg P.O. (Ritalin, Ritalin SR, or Metadate ER) two to three times daily, 30 to 45 minutes before a meal. Some patients may require up to 60 mg daily.

Off-label uses
- Depression in ill, elderly patients (such as those with cerebrovascular accident)
- To enhance analgesia and sedation in patients receiving opioids

Contraindications
- Hypersensitivity to drug or its components, including sucrose (Metadate CD)
- Glaucoma
- Motor tics, Tourette syndrome (or family history of syndrome)
- Marked anxiety, tension, agitation
- Severe hypertension, angina, arrhythmias, heart failure, recent myocardial infarction, hyperthyroidism, thyrotoxicosis
- Concurrent use of halogenated anesthetics
- MAO inhibitor use within past 14 days

Precautions
Use cautiously in:
- hypertension, seizure disorders
- psychosis
- suicidal or homicidal tendencies
- slow growth (children)
- elderly or debilitated patients
- pregnant or breastfeeding patients
- children younger than age 6.

Administration
Be aware that Metadate CD contains sucrose. Don’t give to patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency.

Don’t give Metadate CD on day of surgery.
- Don’t crush extended-release tablets or extended-release trilayer core tablets (Concerta).
- Have patient swallow extended-release capsules (Metadate CD, Ritalin LA) intact; or, if desired, sprinkle entire contents onto small amount (1 tbsp) of applesauce immediately before administration. (However, don’t sprinkle Ritalin LA onto warm applesauce because its release properties may be affected.) Give water after patient swallows dose.
- Don’t give extended-release tablets to initiate therapy or for daily use until dosage has been titrated using conventional tablets.
- Apply patch immediately after opening pouch to a clean, dry hip area and alternate hips daily.
- Don’t give within 14 days of MAO inhibitor use.
- To help prevent insomnia, give last daily dose of conventional tablets several hours before bedtime.
- Discontinue drug periodically in children who have responded to therapy, to assess patient’s condition. After withdrawal, improvement may be temporary or permanent.
- Be aware that therapy shouldn’t continue indefinitely.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1-3 hr</td>
<td>4-6 hr</td>
</tr>
<tr>
<td>P.O. (extended)</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Up to 8 hr</td>
</tr>
<tr>
<td>Transdermal</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: restlessness, tremor, dizziness, headache, irritability, hyperactivity, insomnia, akathisia, dyskinesia, reversible ischemic neurologic deficit, toxic psychosis
CV: hypertension, hypotension, palpitations, tachycardia, Raynaud’s phenomenon, sudden death (patients
with structural cardiac abnormalities or other serious heart problems)
**EENT:** blurred vision
**GI:** nausea, vomiting, diarrhea, constipation, cramps, dry mouth, anorexia
**Skin:** rash, contact sensitization
**Other:** metallic taste, fever, suppression of weight gain (in children), hypersensitivity reactions, physical or psychological drug dependence, drug tolerance, peripheral coldness

### Interactions

**Drug-drug.** *Anticonvulsants, phenylbutazone, selective serotonin reuptake inhibitors, tricyclic antidepressants, warfarin:* inhibited metabolism and increased effects of these drugs
*Guanethidine:* antagonism of hypotensive effect
*Halogenated anesthetics:* sudden blood pressure increase
*MAO inhibitors, vasopressors:* hypertensive crisis

**Drug-food.** *Caffeine-containing foods and beverages (such as coffee, cola, chocolate):* increased CNS stimulation

**Drug-herbs.** *Ephedra (ma huang), caffeine-containing herbs (such as cola nut, guarana, maté):* increased CNS stimulation

**Drug-behaviors.** *Alcohol use:* additive hypotension

### Patient monitoring
- Monitor patient periodically for drug tolerance and psychological dependence.
- Watch for adverse effects. Know that these usually can be controlled by adjusting schedule or dosage.
- Monitor for contact sensitization (erythema accompanied by edema, papules, vesicles) that does not significantly improve within 48 hours or spreads beyond the patch site. Discontinue drug if this occurs.
- Stay alert for tachycardia, abdominal pain, insomnia, anorexia, and weight loss (more common in children).
- Consider periodic hematologic and liver function tests, especially during prolonged therapy.
- Monitor blood pressure, especially in patients with history of hypertension.
- Evaluate child’s weight and growth patterns.
- Assess child for tics, which may develop in 15% to 30% of children using drug.

### Patient teaching
- Inform patient or parent that last daily dose should be taken several hours before bedtime to avoid insomnia.
- Make sure patient or parent understands how drug should be taken.
- Tell patient taking Concerta not to be concerned if tablet-like substance appears in stool.
- Teach caregiver how to use patch and to make sure that skin is clean, dry, and free of cuts or irritation.
- Tell caregiver not to allow child to use heat sources, such as heating pads or electric blankets, while wearing the patch.
- Instruct caregiver to report redness accompanied by swelling or solid bumps or blisters on the skin that do not significantly improve within 48 hours or spread beyond the patch site.
- Tell caregiver to replace the patch if it falls off, but total wear time for the day should remain 9 hours.
- Advise patient or parent to report insomnia, palpitations, vomiting, fever, or rash.
- Caution patient or parent that continual use may lead to psychological or physical dependence.
- Instruct patient to avoid driving and other hazardous tasks until drug effects are known.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, foods,
herbs, and behaviors mentioned above.

**methylprednisolone**
Medrol, Medrone

**methylprednisolone acetate**
Depo-Medrol, Depo-Medrone®, Unimed

**methylprednisolone sodium succinate**
A-Methapred, Solu-Medrol, Solu-Medrone®

*Pharmacologic class:* Glucocorticoid

*Therapeutic class:* Antiasthmatic, anti-inflammatory (steroidal), immunosuppressant

*Pregnancy risk category C*

**Action**
Unclear. Reduces inflammation and prevents edema by stabilizing membranes and reducing permeability of leukocytic cells. Suppresses immune system by interfering with antigen-antibody interactions of macrophages and T cells.

**Availability**
*Solution for injection:* 40 mg, 125 mg, 500 mg, 1 g, 2 g
*Suspension for injection:* 20 mg/ml, 40 mg/ml, 80 mg/ml
*Tablets:* 2 mg, 4 mg, 8 mg, 16 mg, 24 mg, 32 mg

**Indications and dosages**

>- Diseases and disorders of endocrine system, collagen, skin, eye, GI tract, respiratory system, or hematologic system; neoplastic diseases; allergies; edema; multiple sclerosis; tuberculous meningitis; trichinosis; rheumatic disorders; osteoarthritis; bursitis; localized inflammatory lesions
>- **Adults:** Methylprednisolone—4 to 160 mg P.O. daily in four divided doses, depending on disease or disorder. Acetate—40 to 120 mg I.M., or 4 to 80 mg by intra-articular or soft-tissue injection, or 20 to 60 mg by intralesional injection (depending on type, size, and location of inflammation); may be repeated at 1 to 5 weeks. Sodium succinate high-dose therapy—30 mg/kg I.V. over at least 30 minutes. May be repeated q 4 to 6 hours for 48 hours.

**Off-label uses**
- Lupus nephritis
- *Pneumocystis jiroveci* pneumonia in AIDS patients

**Contraindications**
- Hypersensitivity to drug or its component
- Systemic fungal infections
- Use in premature infants (with sodium succinate form, which contains benzyl alcohol)

**Precautions**
Use cautiously in:
- cardiovascular, hepatic, renal, or GI disease; active untreated infections; thromboembolic tendency; idiopathic thrombocytopenic purpura; osteoporosis; myasthenia gravis; hypothyroidism; glaucoma; ocular herpes simplex; vaccinia or varicella; seizure disorders; metastatic cancer
- pregnant or breastfeeding patients
- children.

**Administration**
- As needed and prescribed, give prophylactic antacids to prevent peptic ulcers in patients receiving high doses.
- When methylprednisolone acetate is substituted for oral form, know that
I.M. dosage should equal oral dosage and should be given once daily.

- Know that methylprednisolone acetate is not for I.V. use. It may be given I.M. or by intra-articular, intrale-sional, or soft-tissue injection.
- Be aware that methylprednisolone sodium succinate may be given I.M. or I.V. Reconstitute with bacteriostatic water for injection containing 0.9% benzyl alcohol, per manufacturer’s instructions.
- In long-term methylprednisolone therapy, alternate-day therapy should be considered.
- For direct I.V. injection, inject each 500-mg dose over 2 to 3 minutes or more. For I.V. infusion, further dilute in compatible I.V. solution (such as 5% dextrose, 0.9% sodium chloride, or 5% dextrose in 0.9% sodium chloride injection) and give over 10 to 20 minutes.
- Maintain patient on lowest effective dosage, to minimize adverse effects.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>2-3 hr</td>
<td>30-36 hr</td>
</tr>
<tr>
<td>I.M., I.V.</td>
<td>Rapid</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.M. (acetate)</td>
<td>6-48 hr</td>
<td>4-8 days</td>
<td>1-4 wk</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** headache, restlessness, nervousness, depression, euphoria, personality changes, psychoses, vertigo, paresthe-sias, insomnia, adhesive arachnoiditis, conus medullaris syndrome, increased intracranial pressure, seizures, meningitis

**CV:** hypotension, hypertension, arrhythmias, heart failure, shock, fat embolism, thrombophlebitis, thromboembolism

**EENT:** cataracts, glaucoma, increased intraocular pressure, nasal irritation, nasal septum perforation, sneezing, epistaxis, nasopharyngeal or oropharyngeal fungal infection, dys-phoria, hoarseness, throat irritation

**GI:** nausea, vomiting, abdominal disten-tion, rectal bleeding, dry mouth, anorexia, esophageal candidiasis, esophageal ulcer, peptic ulcer, pancreatitis

**GU:** amenorrhea, irregular menses

**Respiratory:** cough, wheezing, bronchospasm

**Metabolic:** decreased growth (in children), reduced carbohydrate tolerance, diabetes mellitus, hyperglycemia, sodium and fluid retention, hypokalemia, hypocalcemia, cushingoid state (with long-term use), hypothalamic-pitu-itary-adrenal suppression (with systemic use beyond 5 days), adrenal suppression (with long-term, high-dose use), acute adrenal insufficiency (with abrupt withdrawal)

**Musculoskeletal:** muscle wasting, osteoporosis, osteonecrosis, tendon rupture, aseptic joint necrosis, muscle pain and weakness, steroid myopathy, spontaneous fractures (with long-term use)

**Skin:** facial edema, rash, pruritus, ur ticaria, contact dermatitis, acne, decreased wound healing, bruising, hirsutism, thin and fragile skin, petechiae, purpura, striae, subcutaneous fat atrophy, skin atrophy, acneiform lesions, angioedema

**Other:** anosmia, bad taste, increased appetite, weight gain (with long-term use), Churg-Strauss syndrome, increased susceptibility to infection, aggravation or masking of infections, impaired wound healing, atrophy at in jection site, local pain and burning, irritation, hypersensitivity reaction

**Interactions**

**Drug-drug.** Amphotericin B, mezlocillin, piperacillin, thiazide and loop diuretics, ticarcillin: additive hypokalemia

Fluoroquinolones: increased risk of tendon rupture

Isoniazid, phenobarbital, phenytoin, rifampin: decreased methylprednisolone efficacy

Ketoconazole: decreased methylprednisolone clearance

Reactions in **bold** are life-threatening.
Live-virus vaccines: decreased antibody response to vaccine, increased risk of adverse reactions
Nonsteroidal anti-inflammatory drugs: increased risk of adverse GI effects
Oral anticoagulants: altered anticoagulant requirement

Drug-diagnostic tests. Calcium, potassium, thyroxine, triiodothyronine: decreased levels
Cholesterol, glucose: increased levels
Nitroblue tetrazolium test for bacterial infection: false-negative result

Drug-herbs. Echinacea: increased immune stimulation
Ginseng: immunomodulation

Drug-behaviors. Alcohol use: increased risk of gastric irritation and ulcers

Patient monitoring
- Monitor fluid and electrolyte balance, weight, and blood pressure.
- With long-term or high-dose use, assess for cushingoid effects, such as moon face, central obesity, acne, abdominal striae, hypertension, osteoporosis, myopathy, hyperglycemia, fluid and electrolyte imbalances, and increased susceptibility to infection.
- Check for signs and symptoms of steroid-induced psychosis (delirium, euphoria, insomnia, mood swings, personality changes, and depression).
- Monitor growth and development in children on prolonged therapy.
- Know that therapy beyond 6 months increases risk of osteoporosis. Obtain baseline bone density mass, and provide teaching about lifestyle factors (such as weight-bearing exercise, proper diet, moderation of alcohol intake, and smoking cessation) and possible need for calcium, vitamin D, or bisphosphonate therapy.
- With long-term use, withdraw drug gradually.
- After dosage reduction or drug withdrawal, monitor patient for signs and symptoms of adrenal insufficiency.

Patient teaching
- Tell patient to take with food to minimize GI upset.
- Advise patient on chronic therapy to have periodic eye exams and to carry medical identification that states he’s taking drug.
- Inform patient that drug increases risk for infection. Urge him to avoid exposure to people with infections such as measles and chickenpox. Tell him to contact prescriber if exposure occurs.
- Advise patient to report unusual weight gain, swelling, muscle weakness, black tarry stools, vomiting of blood, menstrual irregularities, sore throat, fever, or infection.
- Tell patient to immediately report signs or symptoms of adrenal insufficiency (including fatigue, appetite loss, nausea, vomiting, diarrhea, weight loss, weakness, and dizziness) after dosage reduction or drug withdrawal.
- Advise diabetic patient to monitor blood glucose level carefully.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

metoclopramide hydrochloride

Apo-Metoclop®, Gastrobid®, Gastromax®, Maxeran®, Maxolon®, Maxolon SR®, Nu-Metoclopramide®, Paramax®, PMS-Metoclopramide, Reglan

Pharmacologic class: Dopamine antagonist
Therapeutic class: Antiemetic, GI stimulant

Pregnancy risk category B
Action
Blocks dopamine receptors by disrupting CNS chemoreceptor trigger zone, increasing peristalsis and promoting gastric emptying

Availability
Injection: 5 mg/ml
Solution: 5 mg/5 ml
Solution (concentrated): 10 mg/ml
Tablets: 5 mg, 10 mg

Indications and dosages
➢ To prevent chemotherapy-induced vomiting
Adults: 1 to 2 mg/kg I.V. 30 minutes before chemotherapy, then q 2 hours for two doses, then q 3 hours for three additional doses
➢ To facilitate small-bowel intubation; radiologic examination when delayed gastric emptying interferes
Adults and children older than age 14: 10 mg I.V. as a single dose
Children ages 6 to 14: 2.5 to 5 mg I.V. as a single dose
Children younger than age 6: 0.1 mg/kg I.V. as a single dose
➢ Diabetic gastroparesis
Adults: 10 mg P.O. 30 minutes before meals and at bedtime for 2 to 8 weeks. If patient can’t tolerate P.O. doses, give same dosage I.V. or I.M.
➢ Gastroesophageal reflux
Adults: 10 to 15 mg P.O. 30 minutes before meals and at bedtime for up to 12 weeks. For prevention, single dose of 20 mg (some patients may respond to doses as small as 5 mg).
➢ Prevention of postoperative nausea and vomiting
Adults: 10 to 20 mg I.M. near end of surgical procedure. Repeat dose q 4 to 6 hours, as needed.

Dosage adjustment
● Renal impairment

Off-label uses
● Hiccups

Contraindications
● Hypersensitivity to drug
● Pheochromocytoma
● Parkinson’s disease
● Suspected GI obstruction, perforation, or hemorrhage
● History of seizure disorders

Precautions
Use cautiously in:
● diabetes mellitus
● history of depression
● elderly patients
● pregnant or breastfeeding patients
● children.

Administration
● Mix oral solution with water, juice, carbonated beverage, or semisolid food (such as applesauce or pudding) just before administration.
● Give I.M. or direct I.V. without further dilution.
● Administer low doses (10 mg or less) by direct I.V. injection slowly over 2 minutes. (Rapid injection may cause intense anxiety and restlessness followed by drowsiness.)
● For I.V. infusion, dilute with 50 ml of 5% dextrose in 0.9% sodium chloride solution, 5% dextrose in 0.45% sodium chloride solution, or lactated Ringer’s solution. Infuse over at least 15 minutes.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30-60 min</td>
<td>Unknown</td>
<td>1-2 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>1-3 min</td>
<td>Immediate</td>
<td>1-2 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>10-15 min</td>
<td>Unknown</td>
<td>1-2 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: drowsiness, restlessness, anxiety, depression, irritability, fatigue, lassitude, insomnia, tardive dyskinesia, parkinsonian-like reactions, extrapyramidal reactions, akathisia, dystonia
CV: hypertension, hypotension, arrhythmias

Reactions in bold are life-threatening.
GI: nausea, constipation, diarrhea, dry mouth  
GU: gynecomastia

**Interactions**  
**Drug-drug.** Anticholinergics, opioids: antagonism of metoclopramide’s GI motility effect  
Antidepressants, antihistamines, other CNS depressants (such as opioids, sedative-hypnotics): additive CNS depression  
Cimetidine, digoxin: decreased blood levels of these drugs  
General anesthetics: exaggerated hypotension  
Haloperidol, phenothiazines: increased risk of extrapyramidal reactions  
Levodopa: decreased metoclopramide efficacy  
MAO inhibitors: increased catecholamine release  
**Drug-diagnostic tests.** Aldosterone, prolactin: increased levels  
**Drug-behaviors.** Alcohol use: increased blood alcohol level, increased CNS depression

**Patient monitoring**  
- Monitor blood pressure during I.V. administration.  
- Stay alert for depression and other adverse CNS effects.  
- Watch for extrapyramidal reactions, which usually occur within first 24 to 48 hours of therapy. To reverse these symptoms, give diphenhydramine 50 mg I.M. or benztropine 1 to 2 mg I.M., as prescribed.  
- Check for development of parkinsonian-like symptoms, which may occur within first 6 months of therapy and usually subside within 2 to 3 months after withdrawal.  
- With long-term use, assess patient for tardive dyskinesia.  
- In diabetic patient, stay alert for gastric stasis. Insulin dosage may need to be adjusted.

**Patient teaching**  
- Tell patient to take 30 minutes before meals.  
- Instruct patient to report involuntary movements of face, eyes, or limbs.  
- Caution patient to avoid driving and other hazardous activities until drug’s effects are known.  
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

---

**metolazone**  
Metenix®, Zaroxolyn  

**Pharmacologic class:** Thiazide-like diuretic  
**Therapeutic class:** Diuretic, antihypertensive  
**Pregnancy risk category B**

**Action**  
Inhibits electrolyte reabsorption from ascending loop of Henle and decreases reabsorption of sodium and potassium in distal renal tubules, increasing plasma osmotic pressure and promoting diuresis

**Availability**  
Tablets: 2.5 mg, 5 mg, 10 mg

**Indications and dosages**  
▷ Hypertension  
Adult: 2.5 to 5 mg P.O. daily.  
▷ Edema caused by heart failure or renal disease  
Adults: 5 to 20 mg P.O. daily

**Contraindications**  
- Hypersensitivity to drug  
- Hepatic coma or precoma  
- Anuria
Precautions
Use cautiously in:
● severe hepatic or renal impairment,
gout, hyperparathyroidism, glucose
tolerance abnormalities, fluid or elec-
trolyte imbalances, bipolar disorders
● elderly patients
● pregnant or breastfeeding patients
● children (safety not established).

Administration
● Give in morning to avoid frequent
nighttime urination.
● Discontinue drug before parathyroid
function tests are performed.
● Be aware that metolazone is the only
thiazide-like diuretic that may cause
diuresis in patients with glomerular fil-
tration rates below 20 ml/minute.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1 hr</td>
<td>2 hr</td>
<td>12-24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: drowsiness, lethargy, vertigo,
paresthesia, weakness, headache, fatigue
CV: chest pain, hypotension, palpita-
tions, venous thrombosis, arrhyth-
mias
GI: nausea, vomiting, bloating, cramp-
ing, anorexia, pancreatitis
GU: polyuria, nocturia, erectile dys-
function, decreased libido
Hematologic: aplastic anemia, leuko-
penia, agranulocytosis
Hepatic: hepatitis
Metabolic: dehydration, hypercal-
cemia, hypomagnesemia, hyponatrem-
ia, hypophosphatemia, hypovolemia, hyperglycemia, hyperuricemia, hypo-
kalemia, hypochloremic alkalosis
Musculoskeletal: muscle cramps
Skin: photosensitivity, rashes
Other: chills

Interactions
Drug-drug. Amphotericin B, cortico-
steroids, mezlocillin, piperacillin, ticar-
cillin: additive hypokalemia
Antigout drugs: increased uric acid level
Antihypertensives, nitrates: additive
hypotension
Digoxin: increased risk of digoxin
toxicity
Lithium: decreased lithium excretion,
increased risk of lithium toxicity
Drug-diagnostic tests. Bilirubin, calci-
um, cholesterol, creatinine, low-density
lipoproteins, triglycerides, uric acid: in-
creased levels
Blood glucose, urine glucose: increased
levels in diabetic patients
Magnesium, potassium, protein-bound
iodine, sodium, urinary calcium: de-
creased levels
Drug-food. Any food: increased meto-
lazone absorption
Drug-herbs. Aloe, cascara sagrada, sen-
na: increased risk of hypokalemia
Drug-behaviors. Sun exposure: in-
creased risk of photosensitivity

Patient monitoring
● Monitor baseline and periodic elec-
trolyte, blood urea nitrogen, glucose,
and uric acid levels.
● Evaluate blood pressure regularly.

Watch for signs and symptoms of
hypokalemia, which may necessitate
potassium supplements, potassium-
rich diet, or potassium-sparing di-
uretic. Hypokalemia is particularly
dangerous to patients who are on
digitalis or have had ventricular
arrhythmias.
● Assess patient for fluid and elec-
trolyte imbalances.

Patient teaching
● Advise patient to take in morning to
avoid frequent nighttime urination.
● Tell patient he may take with food or
milk to prevent GI upset.

Instruct patient to report muscle
pain, weakness, or cramps; nausea;
vomiting; diarrhea; dizziness; restless-
ness; excessive thirst; fatigue; drowsi-
ness; increased pulse; or irregular heart
beats.
Inform patient that drug may cause gout attacks. Advise him to report sudden joint pain.

Instruct patient to use sunscreen and protective clothing to avoid photosensitivity.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

---

**FDA BOXED WARNING**

Exacerbations of angina pectoris and myocardial infarction (MI) may follow abrupt withdrawal of some beta blockers. When discontinuing long-term therapy, particularly in patients with ischemic heart disease, reduce dosage gradually over 1 to 2 weeks and monitor patient carefully. If angina worsens markedly or acute coronary insufficiency develops, reinstate drug promptly (at least temporarily) and take other appropriate measures to manage unstable angina. Caution patient not to interrupt or discontinue therapy without prescriber’s advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue drug abruptly even in patients treated only for hypertension.

---

**Action**

Blocks stimulation of beta_1_ (myocardial) adrenergic receptors, usually without affecting beta_2_ (pulmonary, vascular, uterine) adrenergic receptor sites

**Availability**

*Injection (tartrate): 1 mg/ml*

*Tablets: 50 mg, 100 mg*

*Tablets (extended-release, succinate): 25 mg, 50 mg, 100 mg, 200 mg*

**Indications and dosages**

- **Hypertension**
  
  **Adults:** 50 to 100 mg P.O. daily as a single dose or in two divided doses (conventional tablets) or once daily (extended-release tablets). May be increased q 7 days as needed, up to 450 mg/day (tartrate) or 400 mg (succinate extended-release).

- **Angina pectoris**
  
  **Adults:** 100 mg P.O. daily as a single dose or in two divided doses (conventional tablets) or once daily (extended-release tablets). May be increased q 7 days as needed, up to 400 mg.

- **MI**
  
  **Adults:** Three bolus injections of 5 mg I.V. given at 2-minute intervals. If patient tolerates I.V. dose, give 50 mg P.O. 15 minutes after last I.V. dose, and continue P.O. doses q 6 hours for 48 hours. For maintenance, 100 mg P.O. b.i.d. If patient doesn’t tolerate full I.V. dose, give 25 to 50 mg P.O. (depending on degree of intolerance), starting 15 minutes after last I.V. dose or when clinical
condition allows; discontinue drug if patient shows severe intolerance. As late treatment, 100 mg P.O. b.i.d. when clinical condition allows, continued for at least 3 months.

**Symptomatic heart failure**

**Adults:** 25 mg P.O. daily (extended-release tablets) in patients with NYHA Class II heart failure. Dosage may be doubled q 2 weeks, up to 200 mg/day or until highest tolerated dosage is reached. For more severe heart failure, start with 12.5 mg P.O. daily.

**Off-label uses**
- Ventricular arrhythmias, tachycardia
- Tremors
- Anxiety

**Contraindications**
- Sinus bradycardia, heart block greater than first degree, cardiogenic shock, overt cardiac failure (with Lopressor used for hypertension or angina)
- Heart rate below 45 beats/minute, second- or third-degree heart block, significant first-degree heart block; systolic pressure below 100 mm Hg; or moderate-to-severe cardiac failure (when Lopressor is used for MI)
- Hypersensitivity to drug or its components, severe bradycardia, heart block greater than first degree, cardiogenic shock, decompensated cardiac failure, sick sinus syndrome (unless permanent pacemaker is in place) (with Toprol-XL)

**Precautions**
Use cautiously in:
- renal or hepatic impairment, pulmonary disease, diabetes mellitus, thyrotoxicosis
- MAO inhibitor use within past 14 days
- pregnant or breastfeeding patients
- children (safety not established).

**Administration**
- Give metoprolol tartrate with or immediately after meals, because food enhances its absorption.
- Know that succinate extended-release tablets are scored and can be divided. However, tablet or half-tablet should be swallowed whole and not crushed or chewed.
- For I.V. administration, give each dose undiluted by direct injection over at least 1 minute.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>15 min</td>
<td>1 hr</td>
<td>6-12 hr</td>
</tr>
<tr>
<td>P.O.</td>
<td>15 min</td>
<td>6-12 hr</td>
<td>24 hr</td>
</tr>
<tr>
<td>(extended)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>20 min</td>
<td>5-8 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** fatigue, weakness, anxiety, depression, dizziness, drowsiness, insomnia, memory loss, mental status changes, nervousness, nightmares

**CV:** orthostatic hypotension, peripheral vasoconstriction, bradycardia, heart failure, pulmonary edema

**EENT:** blurred vision, stuffy nose

**GI:** nausea, vomiting, constipation, diarrhea, flatulence, gastric pain, heartburn, dry mouth

**GU:** urinary frequency, erectile dysfunction, decreased libido

**Hepatic:** hepatitis

**Metabolic:** hyperglycemia, hypoglycemia

**Respiratory:** wheezing, bronchospasm

**Musculoskeletal:** back pain, joint pain

**Skin:** rash

**Other:** drug-induced lupus syndrome

**Interactions**

**Drug-drug.** *Amphetamines, ephedrine, epinephrine, norepinephrine, phenylephrine, pseudoephedrine:* unopposed alpha-adrenergic stimulation (excessive hypertension, bradycardia)

*Antihypertensives, nitrates:* additive hypotension

Reactions in **bold** are life-threatening.
Digoxin: additive bradycardia
Dobutamine, dopamine: reduced cardiovascular benefits of these drugs
General anesthetics, phenytoin (I.V.), verapamil: additive myocardial depression
Insulin, oral hypoglycemics: altered efficacy of these drugs
MAO inhibitors: hypertension

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, blood urea nitrogen, glucose, lactate dehydrogenase, lipoproteins, potassium, triglycerides, uric acid: increased levels

Drug-food. Any food: enhanced drug absorption

Drug-behaviors. Acute alcohol ingestion: additive hypotension
Cocaine use: unopposed alpha-adrenergic stimulation (excessive hypertension, bradycardia)

Patient monitoring
- Measure blood pressure closely when starting therapy and titrating dosage. Once patient stabilizes, measure blood pressure every 3 to 6 months.
- Monitor blood pressure and pulse before I.V. administration. If patient is hypotensive or has bradycardia, consult prescriber before giving dose.
- Watch for orthostatic hypotension in at-risk patients, particularly the elderly.
- Assess glucose levels in diabetic patient. Be aware that drug may mask signs and symptoms of hypoglycemia.
- Monitor for signs and symptoms of hyperthyroidism. Know that drug may mask these. Reduce dosage gradually in hyperthyroid patients.

When discontinuing drug, reduce dosage gradually over 1 to 2 weeks.

Patient teaching
- Advise patient to take with or immediately after meals.
- Tell patient that extended-release tablets are scored and can be divided, but that he should swallow tablets or half-tablets whole and not crush or chew them.

Advise patient with heart failure to report signs or symptoms of worsening condition, including weight gain and increasing shortness of breath.
- Caution patient to avoid driving and other hazardous activities until drug effects are known.
- Instruct patient to notify health care providers (including dentists) that he is taking drug before having surgery.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and behaviors mentioned above.

metronidazole

Acea®, Anabact®, Apo-Metronidazole®, Elyzol®, Flagyl, Flagyl ER, Flagystatin®, Florazole ER, MetroCream, MetroGel, MetroGel-Vaginal, MetroLotion, Metrolyl®, Metrosa®, Metrotop®, Metrozol®, Neutratop®, Nidagel®, Noritate, Novo-Nidazol®, PMS-Metronidazole®, Rosasol®, Rozex, Zidoval®, Zyomet®

metronidazole hydrochloride

Flagyl IV

Pharmacologic class: Nitroimidazole derivative
Therapeutic class: Anti-infective, antiprotozoal
Pregnancy risk category B

Canada UK Hazardous drug High alert drug
FDA BOXED WARNING

• Drug is carcinogenic in mice and rats. Avoid unnecessary use; reserve drug for indicated conditions.

Action
Disturbs DNA synthesis in susceptible bacterial organisms

Availability
Capsules: 375 mg
Powder for injection: 5 mg/ml, 500-mg vials
Premixed injection: 500 mg/100 ml
Tablets: 250 mg, 500 mg
Tablets (extended-release): 750 mg
Topical cream, topical gel: 0.75% in 28.4-g tubes
Topical lotion: 0.75% in 59-ml bottle
Vaginal gel: 0.75% (37.5 mg/5-g applicator) in 70-g tubes

Indications and dosages
➤ Trichomoniasis
Adults: 2 g P.O. as a single dose or in two 1-g doses given on same day. Alternatively, 500 mg P.O. b.i.d. for 7 days.
➤ Bacterial infections
Adults: Initially, 15 mg/kg I.V., followed by 7.5 mg/kg I.V. q 6 hours, not to exceed 4 g/day for 7 to 10 days
➤ Amebiasis
Adults: 750 mg P.O. q 8 hours for 5 to 10 days
➤ Amebic liver abscess
Adults: 500 to 750 mg P.O. t.i.d. for 5 to 10 days. If drug can’t be given orally, administer 500 mg I.V. q 6 hours for 10 days.
Children: 35 to 50 mg/kg/day P.O. in three divided doses for 10 days, to a maximum of 750 mg/dose
➤ Bacterial vaginosis
Adults: In nonpregnant patients, 750 mg/day P.O. (extended-release) for 7 days or 5 g of 0.75% vaginal gel b.i.d. for 5 days. In pregnant patients, 250 mg P.O. t.i.d. for 7 days.
➤ Perioperative prophylaxis in colorectal surgery
Adults: Initially, 15 mg/kg I.V. infusion over 30 to 60 minutes, completed 1 hour before surgery; if necessary, 7.5 mg/kg I.V. infusion over 30 to 60 minutes at 6 and 12 hours after initial dose
➤ Rosacea
Adults: Rub a thin layer of topical lotion, gel, or cream onto entire affected area morning and evening. Improvement should occur within 3 weeks.

Contraindications
• Hypersensitivity to drug, other nitroimidazole derivatives, or parabens (topical form only)
• First-trimester pregnancy in patients with trichomoniasis

Precautions
Use cautiously in:
• severe hepatic impairment
• history of blood dyscrasias, seizures, or other neurologic problems
• breastfeeding patients
• children.

Administration
• Reconstitute powder for injection by adding 4.4 ml of sterile or bacteriostatic water for injection, 0.9% sodium chloride injection, or bacteriostatic sodium chloride injection to 500-mg vial. Further dilute resulting concentration (100 mg/ml) in 0.9% sodium chloride injection, 5% dextrose injection, or lactated Ringer’s injection solution to a concentration of 8 mg/ml or less. Infuse each I.V. dose over 1 hour.
• Be aware that for I.V. injection, drug need not be diluted or neutralized.
• Don’t use equipment containing aluminum to reconstitute or transfer reconstituted solution to diluent; solution may turn reddish-brown.
• Don’t interchange vaginal gel with topical gel, cream, or lotion.

Reactions in bold are life-threatening. 🔴 Clinical alert
mexiletine hydrochloride

Pharmacologic class: Lidocaine-like agent

Therapeutic class: Antiarrhythmic (class IB)

Pregnancy risk category C

---

**Route Onset Peak Duration**

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>1-3 hr</td>
<td>8 hr</td>
</tr>
<tr>
<td>P.O. (extended)</td>
<td>Rapid</td>
<td>Unknown</td>
<td>Up to 24 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>End of infusion</td>
<td>6-8 hr</td>
</tr>
<tr>
<td>Topical</td>
<td>Unknown</td>
<td>6-12 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>Vaginal</td>
<td>Unknown</td>
<td>6-12 hr</td>
<td>12 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: dizziness, headache, ataxia, vertigo, incoordination, insomnia, fatigue  
EENT: rhinitis, sinusitis, pharyngitis  
GI: nausea, vomiting, diarrhea, abdominal pain, furry tongue, glossitis, dry mouth, anorexia  
GU: dysuria, dark urine, incontinence  
Hematologic: leukopenia  
Skin: rash, urticaria, burning, mild skin dryness, skin irritation, transient redness (with topical forms)  
Other: unpleasant or metallic taste, superinfection, phlebitis at I.V. site

**Interactions**

Drug-drug. Azathioprine, fluorouracil: increased risk of leukopenia  
Cimetidine: decreased metronidazole metabolism, increased risk of toxicity  
Disulfiram: acute psychosis and confusion  
Lithium: increased lithium blood level  
Phenobarbital: increased metronidazole metabolism, decreased efficacy  
Warfarin: increased warfarin effects  

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase: altered levels  

Drug-behaviors. Alcohol use: disulfiram-like reaction

**Patient monitoring**

- Monitor I.V. site. Avoid prolonged use of indwelling catheter.  
- Evaluate hematologic studies, especially in patients with history of blood dyscrasias.

---

Patient teaching

- Advise patient to take drug with food if it causes GI upset. However, instruct him to take extended-release tablets 1 hour before or 2 hours after meals.  
- Tell patient with trichomoniasis to refrain from sexual intercourse or to have male partner wear a condom to prevent reinfection. Explain that asymptomatic sex partners should be treated simultaneously.  
- Advise patient to report fever, sore throat, bleeding, or bruising.  
- Inform patient that drug may cause metallic taste and may discolor urine deep brownish-red.  
- Tell patient using topical form to clean area thoroughly with mild cleanser before use and then wait 15 to 20 minutes before applying drug. Tell her she may apply cosmetics to skin after applying drug; with topical lotion, instruct her to let skin dry at least 5 minutes before applying cosmetics.  
- Tell female patient to consult prescriber if she is pregnant or plans to become pregnant.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.
FDA BOXED WARNING

● In study of patients with asymptomatic, non-life-threatening ventricular arrhythmias who had myocardial infarction more than 6 days but less than 2 years previously, excessive mortality or nonfatal cardiac arrest rate occurred in those treated with encainide or flecainide antiarrhythmics—compared with patients in carefully matched placebo-treated groups. Given drug’s known proarrhythmic properties and lack of evidence of improved survival for any antiarrhythmic in patients without life-threatening arrhythmias, reserve use of drug for patients with life-threatening ventricular arrhythmias.

● Abnormal liver function tests have occurred postmarketing, some cases in first few weeks of therapy. Most cases occurred in setting of congestive heart failure or ischemia, and their relationship to drug hasn’t been established.

Action
Decreases duration of action potential and effective refractory period in cardiac conduction tissue by altering sodium transport across myocardial cell membranes

Availability
Capsules: 150 mg, 200 mg, 250 mg

Indications and dosages
> Serious ventricular arrhythmias, including sustained ventricular tachycardia

Adults: Initially, 200 mg P.O. q 8 hours when rapid control isn’t essential; may adjust dosage by 50 to 100 mg q 2 to 3 days. When rapid control is needed, give initial loading dose of 400 mg P.O., followed by 200 mg in 8 hours.

Off-label uses
● Pain, dysesthesias, paresthesias associated with diabetes mellitus

Contraindications
● Cardiogenic shock
● Second- or third-degree heart block (in patients without pacemakers)

Precautions
Use cautiously in:
● sinus node or intraventricular conduction abnormalities, heart failure, hypotension, seizure disorder, severe hepatic impairment
● pregnant or breastfeeding patients
● children (safety not established).

Administration
Be aware that therapy should be initiated in hospital setting. Also, drug is reserved for life-threatening ventricular arrhythmias and shouldn’t be used to treat asymptomatic premature ventricular contractions.

● When switching patient to mexiletine from lidocaine, stop lidocaine infusion as soon as first oral mexiletine dose is given, but maintain I.V. line until heart rhythm is satisfactory.

● When switching patient to mexiletine from other class I oral antiarrhythmics, give mexiletine as prescribed and titrate to response.

Adverse reactions
CNS: dizziness, nervousness, confusion, fatigue, headache, sleep disorder, tremor, poor coordination, paresthesia
CV: chest pain, edema, palpitations, new or increased arrhythmias
EENT: blurred vision, tinnitus
GI: nausea, vomiting, heartburn
Hematologic: leukopenia, neutropenia, agranulocytosis, thrombocytopenia
Hepatic: hepatic necrosis

Reactions in bold are life-threatening.
Respiratory: dyspnea
Skin: rash

Interactions
Drug-drug. Antacids, atropine, opioids: slow mexiletine absorption
Cimetidine: increased or decreased mexiletine blood level
Metoclopramide: increased mexiletine absorption
Other antiarrhythmics: additive cardiac effects
Phenobarbital, phenytoin, rifampin: increased mexiletine metabolism, decreased efficacy
Theophylline: increased theophylline blood level, greater risk of toxicity
Urine acidifiers: increased mexiletine excretion, decreased blood level
Urine alkalinizers: decreased mexiletine excretion, increased blood level

Drug-diagnostic tests. Antinuclear antibodies: positive titers
Aspartate aminotransferase: transient increase
Platelets: decreased count (usually returns to normal within 1 month after drug withdrawal)

Drug-food. Foods that drastically alter urine pH: altered mexiletine blood level
Caffeine: 50% decrease in caffeine clearance

Drug-behaviors. Cigarette smoking: increased mexiletine metabolism, decreased efficacy

Patient monitoring
- Monitor vital signs and ECG frequently when initiating therapy.
- Evaluate liver function tests and hematologic studies.
- Watch for early evidence of toxicity (dizziness, tremor, poor coordination). With increasing toxicity, patient may develop hypotension, sinus bradycardia, ventricular arrhythmias, and seizures. Therapeutic mexiletine blood level is 0.5 to 2 mcg/ml.

Patient teaching
- Tell patient to take with food or antacids if adverse GI reactions occur.
- Advise patient to avoid dietary changes that would markedly alter urine pH.
- Inform patient that drug may cause nausea, vomiting, diarrhea, constipation, heartburn, dizziness, tremor, nervousness, poor coordination, changes in sleep pattern, headache, visual disturbances, tingling or numbness, ringing in ears, and palpitations or chest pain. Tell him to contact prescriber if these effects are bothersome or severe.
- Tell patient to immediately report tiredness, yellowing of skin or eyes, flu-like symptoms, fever, or sore throat.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and behaviors mentioned above.

micafungin sodium
Mycamine

Pharmacologic class: Semisynthetic lipopeptide (echinocandin)
Therapeutic class: Antifungal
Pregnancy risk category C

Action
Inhibits synthesis of 1,3-β-D-glucan, an essential component of fungal cell walls

Availability
Powder for reconstitution for infusion (lyophilized): 50-mg and 100-mg single-use vials

Indications and dosages
> Candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses
**Adults:** 100 mg daily by I.V. infusion over 1 hour for 15 days (range, 10 to 47 days)

- Esophageal candidiasis

**Adults:** 150 mg daily by I.V. infusion over 1 hour for 15 days (range, 10 to 30 days)

- Prophylaxis of *Candida* infections in patients undergoing hematopoietic stem-cell transplantation

**Adults:** 50 mg daily by I.V. infusion over 1 hour for 19 days (range, 6 to 51 days)

**Contraindications**
- Hypersensitivity to drug, its components, or other echinocandins

**Precautions**
Use cautiously in:
- renal or hepatic disease
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

**Administration**
- Administer by I.V. infusion only.
- Reconstitute with 5 ml normal saline solution injection (without bacteriostatic agent) or dextrose 5% injection added to 50-mg or 100 mg-vial to yield approximately 10 mg/ml or 20 mg/ml, respectively.
- To minimize excessive foaming, gently dissolve powder by swirling vial. Don’t shake vigorously.
- Protect diluted solution from light.
- Add reconstituted solution to 100 ml normal saline solution or 100 ml dextrose 5% before infusing.
- Flush existing I.V. line with normal saline solution before infusing drug.
- Infuse over 1 hour. Be aware that more rapid infusion increases risk of histamine-mediated reactions (rash, pruritus, facial swelling, vasodilation).
- If serious hypersensitivity (anaphylaxis or anaphylactoid) reaction occurs, immediately discontinue infusion and provide appropriate interventions.

### Route Onset Peak Duration
| P.O. | Unknown | Unknown | Unknown |

**Adverse reactions**

**CNS:** headache, insomnia, fatigue, rigors, dizziness, anxiety

**CV:** vasodilation, hypotension, hypertension, bradycardia, tachycardia, phlebitis, flushing, atrial fibrillation

**EENT:** epistaxis

**GI:** nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia, decreased appetite

**Hematologic:** anemia, thrombocytopenia, aggravated anemia, neutropenia, febrile neutropenia

**Metabolic:** fluid retention, fluid overload

**Musculoskeletal:** back pain

**Respiratory:** pneumonia, cough, dyspnea

**Skin:** rash, pruritus, decubitus ulcers, erythema

**Other:** facial swelling, injection-site reaction, infection, bacteremia, fever, mucosal inflammation, peripheral edema, sepsis, septic shock, hypersensitivity reaction (including anaphylaxis, anaphylactoid reactions, and shock)

**Interactions**

**Drug-drug.** *Itraconazole, nifedipine, sirolimus:* increased risk of toxicity

**Drug-diagnostic tests.** *ALP, ALT, AST, sodium:* increased levels

*Calcium, glucose, magnesium, potassium:* decreased levels

**Liver function tests:** abnormal

**Patient monitoring**
- If patient develops clinical or laboratory evidence of hematologic abnormalities, abnormal liver function tests, or electrolyte disorders, monitor closely for signs or symptoms.
that these conditions are getting worse. Risks against benefits of continuing therapy should be considered.

Patient teaching

- Instruct patient to contact prescriber if unusual symptoms develop or if preexisting symptoms persist or get worse.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

### midazolam hydrochloride

Apo-Midazolam, Hypnovel

**Pharmacologic class:** Benzodiazepine  
**Therapeutic class:** Anxiolytic, sedative-hypnotic, adjunct for general anesthesia induction  
**Controlled substance schedule IV**  
**Pregnancy risk category D**

#### FDA BOXED WARNING

- I.V. form is linked to respiratory depression and respiratory arrest, especially when used for sedation in non-critical care settings. In some cases, where this wasn’t recognized promptly and treated effectively, death or hypoxic encephalopathy resulted. Use I.V. form only in hospital or ambulatory care setting that provides continuous monitoring of respiratory and cardiac function. Ensure immediate availability of resuscitative drugs and equipment as well as personnel trained in their use and skilled in airway management. For deeply sedated pediatric patient, dedicated individual should monitor patient throughout procedure.
- Patients who are debilitated, older than age 60, or receiving concurrent opioids or other CNS depressants require lower dosages. Slowly titrate initial dose and all subsequent doses; give over at least 2 minutes and allow 2 or more additional minutes to fully evaluate sedative effect. In pediatric patients, calculate dosage on mg/kg basis, and titrate slowly.
- Don’t give by rapid injection to neonates. Severe hypotension and seizures may result.

### Action

Unknown. Thought to suppress CNS stimulation at limbic and subcortical levels by enhancing the effects of gamma-aminobutyric acid, an inhibitory neurotransmitter.

### Availability

- **Injection:** 1 mg/ml, 5 mg/ml  
- **Syrup:** 2 mg/ml

#### Indications and dosages

- **To induce general anesthesia**
  - Adults younger than age 55: 0.3 to 0.35 mg/kg I.V. over 20 to 30 seconds if patient hasn’t received premedication, or 0.15 to 0.35 mg/kg (usual dosage of 0.25 mg/kg) I.V. over 20 to 30 seconds if patient has received premedication. Wait 2 minutes to evaluate effect. Additional increments of 25% of initial dosage may be needed to complete induction.
- **Continuous infusion to initiate sedation**
  - Adults: When rapid sedation is required, give loading dose of 0.01 to 0.05 mg/kg I.V. slowly; repeat dose q 10 to 15 minutes until adequate sedation occurs. To maintain sedation, infuse at initial rate of 0.02 to 0.10 mg/kg/hour (1 to 7 mg/hour). Adjust infusion rate as needed.
- **Preoperative sedation, anxiolysis, and amnesia**
  - Adults: 0.07 to 0.08 mg/kg I.M. 30 minutes to 1 hour before surgery. For I.V. administration in healthy adults younger than age 60, give initial dose of 1 mg and titrate slowly to effect.
Some patients may respond adequately to 1-mg dose. Don’t give more than 2.5 mg over a 2-minute period. Total dosage above 5 mg is rarely necessary. Wait at least 2 minutes after additional doses to assess effect.

Anxiolysis and amnesia before diagnostic, therapeutic, and endoscopic procedures or anesthesia induction

Children: 0.25 to 0.5 mg/kg P.O. as a single dose. Maximum dosage is 20 mg.

Dosage adjustment

- Elderly patients
- Children or neonates

Contraindications

- Hypersensitivity to drug, its components, or other benzodiazepines
- Acute closed-angle glaucoma
- Allergy to cherries (syrup preparation)

Precautions

Use cautiously in:

- pulmonary disease, heart failure, renal impairment, severe hepatic impairment
- obese pediatric patients
- elderly or debilitated patients
- pregnant or breastfeeding patients
- children and neonates.

Administration

Keep oxygen and resuscitation equipment at hand in case severe respiratory depression occurs.

- Inject I.M. deep into large muscle mass.
- Know that drug may be mixed in same syringe as meperidine, atropine, scopolamine, or morphine.
- Dilute concentrate for I.V. infusion to 0.5 mg/ml using dextrose 5% in water or normal saline solution. Infuse over at least 2 minutes; then wait at least 2 minutes before giving second dose. Be aware that excessive dosage or rapid I.V. delivery may cause severe respiratory depression.
- Give oral form with liquid, but never with grapefruit juice.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>10-20 min</td>
<td>45-60 min</td>
<td>2-6 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>1.5-5 min</td>
<td>Rapid</td>
<td>2-6 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>15 min</td>
<td>15-60 min</td>
<td>2-6 hr</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: headache, oversedation, drowsiness, agitation and excitement (in children)

CV: hypotension, irregular pulse, bradycardia, arrhythmias, cardiac arrest

GI: nausea, vomiting

Respiratory: decreased respiratory rate, hiccups, apnea, respiratory arrest

Other: pain and tenderness at injection site

Interactions

Drug-drug. CNS depressants (such as some antidepressants, antihistamines, barbiturates, opioids, tranquilizers), respiratory depressants: potentiation of CNS effects of these drugs

Diltiazem, verapamil: increased midazolam blood level

Erythromycin: decreased midazolam clearance

Hormonal contraceptives: prolonged midazolam half-life

Rifampin: decreased midazolam blood level

Theophylline: increased sedative effect of midazolam

Drug-food. Grapefruit juice: increased bioavailability of oral midazolam

Drug-herbs. Chamomile, kava, skullcap, valerian: increased CNS depression

Drug-behaviors. Alcohol use: potentiation of midazolam effects

Patient monitoring

- Monitor vital signs, ECG, respiratory status, and oxygen saturation.
- Assess neurologic status closely, especially in pediatric patient.
- Watch for nausea and vomiting.

Reactions in **bold** are life-threatening.

Clinical alert
Patient teaching

- Advise patient that drug causes perioperative amnesia.
- If patient will use oral drug at home, instruct him to take it with liquid but never grapefruit juice.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Tell female patient to inform prescriber if she is pregnant or breastfeeding.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, foods, herbs, and behaviors mentioned above.

midodrine hydrochloride

Amatine®, Apo-Midodrine®, Orvaten, ProAmatine

Pharmacologic class: Alpha₁-adrenergic agonist
Therapeutic class: Antihypotensive, vasopressor
Pregnancy risk category C

FDA BOXED WARNING

- Drug can markedly increase supine blood pressure, and should be used in patients whose lives are considerably impaired despite standard clinical care. Indication for its use in treating symptomatic orthostatic hypotension rests mainly on an increase in systolic pressure measured 1 minute after standing. Currently, drug’s clinical benefits (mainly improved ability to perform activities of daily living) haven’t been verified.

Action

Forms active metabolite, desglymidodrine, an alpha₁-adrenergic agonist that activates alpha-adrenergic receptors in arteriolar and venous vasculature. This effect increases vascular resistance and ultimately raises blood pressure.

Availability

Tablets: 2.5 mg, 5 mg

Indications and dosages

> Symptomatic orthostatic hypotension

Adults: 10 mg P.O. t.i.d. during daytime hours with patient in upright position. Give first dose when patient arises in morning, second dose at midday, and third dose in late afternoon.

Dosage adjustment

- Renal impairment

Contraindications

- Severe coronary artery disease or organic heart disease
- Acute renal disease, urinary retention
- Pheochromocytoma
- Thyrotoxicosis
- Persistent, excessive supine hypertension

Precautions

Use cautiously in:
- renal or hepatic impairment, diabetes mellitus, vision problems
- pregnant or breastfeeding patients.

Administration

- Don’t give within 4 hours of bedtime.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>1-2 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: paresthesia
CV: vasodilation, bradycardia, supine hypertension
GI: abdominal pain, dry mouth
GU: urinary retention, frequency, or urgency  
Skin: rash, pruritus, piloerection  
Other: chills, increased pain

**Interactions**

**Drug-drug.** Alpha- and beta-adrenergic blockers, cardiac glycosides, steroids: increased risk of bradycardia, atrioventricular block  
Alpha-adrenergic blockers, fludrocortisone: increased risk of supine hypertension

**Patient monitoring**

- Monitor supine and sitting blood pressures closely. Report marked rise in supine blood pressure.  
- Stay alert for paresthesias.  
- Monitor kidney function studies and fluid intake and output. Watch for urinary frequency, urgency, or retention.

**Patient teaching**

- Instruct patient to take while in upright position.  
- Tell patient to take first dose as soon as he arises for the day, second dose at midday, and third dose in late afternoon (before 6 P.M.). Stress that doses must be taken at least 3 hours apart. Advise patient not to take drug after dinner or within 4 hours of bedtime.  
- Instruct patient to promptly report symptoms of supine hypertension (pounding in ears, blurred vision, headache).  
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, and alertness.  
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

---

**mifepristone (RU-486)**

*Mifegyne®, Mifeprex*

**Pharmacologic class:** Synthetic steroid  
**Therapeutic class:** Antiprogestational agent, abortifacient  
**Pregnancy risk category NR**

**FDA BOXED WARNING**

- Rare cases of serious and sometimes fatal infections and bleeding have followed spontaneous, surgical, and medical abortions, including after mifepristone use. Before starting drug, inform patient of risk of these serious events and discuss medication guide and patient agreement. Ensure that patient knows whom to call and what to do, including going to emergency department (ED) if none of provided contacts are reachable; if she experiences sustained fever, severe abdominal pain, prolonged heavy bleeding, or syncope; or if she has abdominal pain or discomfort or general malaise (including weakness, nausea, vomiting, or diarrhea) more than 24 hours after taking drug.  
- Patients with serious bacterial infections and sepsis may present without fever, bacteremia, or significant pelvic examination findings after abortion. Rare deaths have occurred in patients without fever, with or without abdominal pain, but with leukocytosis with marked left shift, tachycardia, hemococoncentration, and general malaise. Maintain high index of suspicion to rule out serious infection and sepsis.  
- Advise patient to take medication guide with her if she visits ED or another healthcare provider who didn’t prescribe drug, so provider will be aware that patient is undergoing medical abortion.
Action
Antagonizes progesterone receptor sites, inhibiting activity of endogenous and exogenous progesterone and stimulating uterine contractions, which causes fetus to separate from placental wall

Availability
*Tablets: 200 mg*

Indications and dosages
- **Termination of intrauterine pregnancy through day 49 of pregnancy**
  - **Adults:** On day 1, mifepristone 600 mg P.O. as a single dose. On day 3, misoprostol 400 mcg P.O. (unless abortion has been confirmed).

Contraindications
- Hypersensitivity to drug, misoprostol, or other prostaglandins
- Confirmed or suspected ectopic pregnancy or adnexal mass
- Chronic adrenal failure
- Bleeding disorders
- Concurrent anticoagulant therapy or long-term corticosteroid therapy
- Presence of intrauterine device (IUD)
- Inherited porphyrias

Precautions
Use cautiously in:
- cardiovascular, respiratory, renal, or hepatic disorders; hypertension; type 1 diabetes mellitus; anemia; jaundice; seizure disorder; cervicitis; infected endocervical lesions; acute vaginitis; uterine scarring.

Administration
- Before giving, make sure patient doesn’t have an IUD in place.
- Give only in health care facility under supervision of health care provider qualified to assess pregnancy stage and rule out ectopic pregnancy.
- Administer with fluids, but not with grapefruit juice.

- Confirm pregnancy termination 14 days after initial dose.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>90 min</td>
<td>11 days</td>
</tr>
</tbody>
</table>

Adverse reactions
- **CNS:** dizziness, fainting, headache, weakness, fatigue, insomnia, asthenia, anxiety, syncope, rigors
- **EENT:** sinusitis
- **GI:** nausea, vomiting, diarrhea, abdominal cramping, dyspepsia
- **GU:** vaginitis, leukorrhea, uterine cramping, pelvic pain, uterine hemorrhage
- **Hematologic:** anemia
- **Musculoskeletal:** leg pain, back pain
- **Skin:** fever
- **Other:** viral infections

Interactions
- **Drug-drug.** Carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin: decreased mifepristone blood level and effects
- **Drugs metabolized by CYP450-3A4:** decreased mifepristone metabolism and increased effects
- Erythromycin, itraconazole, ketoconazole: inhibited mifepristone metabolism and increased blood level

Drug-diagnostic tests. *Hematocrit, hemoglobin:* decreased values
Red blood cells: decreased count

Drug-food. *Grapefruit juice:* decreased mifepristone blood level and effects

Patient monitoring
- Assess vital signs, breath sounds, and bowel sounds.
- Monitor uterine contractions and type and amount of vaginal bleeding.
- Evaluate CBC.

Patient teaching
- After administration, tell patient she will need to return in 48 hours for a prostaglandin drug or to verify pregnancy termination.
Tell patient she will have contrac-
tions for 3 or more hours after receiv-
ning drug and that vaginal bleeding may
last 9 to 16 days.

Instruct patient to contact pre-
scriber if she has persistent or extreme-
ly heavy vaginal bleeding, extreme fa-
tigue, or orthostatic hypotension.

Caution patient that vaginal bleeding
does not prove that complete abortion
has occurred. Tell her she will need
follow-up appointment 2 weeks later
to verify pregnancy termination.

Inform patient that she is at risk for
pregnancy right after abortion is com-
plete. Encourage appropriate contra-
ceptive decision.

As appropriate, review all other sig-
nificant and life-threatening adverse
reactions and interactions, especially
those related to the drugs, tests, and
foods mentioned above.

**miglitol**

Glyset

**Pharmacologic class:** Alpha-
glucosidase inhibitor

**Therapeutic class:** Hypoglycemic

**Pregnancy risk category B**

**Action**

Inhibits alpha-glucosidases, which
convert oligosaccharides and disaccha-
drides to glucose. This inhibition causes
blood glucose reduction (especially in
postprandial hyperglycemia).

**Availability**

Tablets: 25 mg, 50 mg, 100 mg

**Indications and dosages**

Adjunct to diet in non-insulin-
dependent (type 2) diabetes mellitus
or combined with a sulfonylurea when
diet plus either miglitol or a
sulfonylurea alone doesn’t control
hyperglycemia

**Adults:** 25 mg P.O. t.i.d. with first bite
each of main meal. After 4 to 8 weeks,
may increase to 50 mg P.O. t.i.d. After
3 months, adjust dosage further based
on glycosylated hemoglobin (HbA1c)
level, to a maximum of 100 mg P.O.
t.i.d.

**Contraindications**

- Hypersensitivity to drug or its
components
- Insulin-dependent (type 1) diabetes
mellitus, diabetic ketoacidosis
- Chronic intestinal disorder associat-
ed with marked digestive or absorptive
disorders or conditions that may dete-
riorate due to increased gas formation
- Inflammatory bowel disease, colonic
ulceration, partial intestinal obstruc-
tion, or predisposition to intestinal
obstruction

**Precautions**

Use cautiously in:

- significant renal impairment (safety
not established)
- fever, infection, trauma, stress
- pregnant or breastfeeding patients
- children (safety not established).

**Administration**

- Give with first bite of three main meals.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2-3 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**GI:** abdominal pain, diarrhea, flatulence

**Skin:** rash

**Interactions**

**Drug-drug.** Digestive enzyme prepara-
tions (such as amylase), intestinal ab-
sorbents (such as charcoal): reduced
miglitol efficacy

**Digoxin, propranolol, ranitidine:** de-
creased bioavailability of these drugs

Reactions in **bold** are life-threatening.
Drug-diagnostic tests. Serum iron: below-normal level

Drug-food. Carbohydrates: increased diarrhea

Patient monitoring
- Monitor CBC, blood glucose, and HBA1c levels.
- Watch for hyperglycemia or hypoglycemia, especially if patient also takes insulin or oral sulfonlyureas.

Patient teaching
- Instruct patient to take drug three times daily with first bite of three main meals.
- Advise patient to take drug as prescribed. If appropriate, tell him he may need insulin during periods of increased stress, infection, or surgery.
- Teach patient about diabetes. Stress importance of proper diet, exercise, weight control, and blood glucose monitoring.
- Inform patient that sucrose (as in table sugar) and fruit juice don’t effectively treat miglitol-induced hypoglycemia. Advise him to use dextrose or glucagon instead to raise blood glucose level quickly.
- Tell patient drug may cause abdominal pain, diarrhea, and gas. Reassure him that these effects usually subside after several weeks.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

Action
Increases cellular levels of cyclic adenosine monophosphate, causing inotropic action that relaxes vascular smooth muscle and increases myocardial contractility

Availability
Injection: 1 mg/ml in 10-, 20-, and 50-ml vials
Injection (premixed): 200 mcg/ml in dextrose 5% in water (D₅W)

Indications and dosages
Heart failure
Adults: Initially, 50 mcg/kg I.V. bolus given slowly over 10 minutes, followed by continuous I.V. infusion of 0.375 to 0.75 mcg/kg/minute. Don’t exceed total daily dosage of 1.13 mg/kg.

Dosage adjustment
- Renal impairment

Contraindications
- Hypersensitivity to drug

Precautions
Use cautiously in:
- atrial flutter or fibrillation, supraventricular and ventricular arrhythmias, renal impairment, electrolyte abnormalities, decreased blood pressure, severe aortic or pulmonic valvular disease, acute phase of myocardial infarction (not recommended), electrolyte abnormalities, abnormal blood digoxin level
- elderly patients
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

Administration
- Dilute 1 mg/ml solution with half-normal saline solution, normal saline solution, or D₅W per manufacturer’s instructions.
Don’t administer through same I.V. line as furosemide or torsemide (precipitate will form).

- Deliver I.V. slowly over 10 minutes.
- Expect to titrate infusion rate depending on response.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>5-15 min</td>
<td>1-2 hr</td>
<td>3-6 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: headache
CV: hypotension, chest pain, angina, ventricular or supraventricular arrhythmias, ventricular tachycardia or fibrillation

**Interactions**

None significant

**Patient monitoring**

- Monitor vital signs and ECG. Watch closely for ventricular arrhythmias, sustained tachycardia, and fibrillation.
- Stop drug and contact prescriber immediately if patient’s systolic pressure drops 30 mm Hg or more.

**Patient teaching**

- Instruct patient to change position slowly, to avoid light-headedness or dizziness from hypotension.
- As appropriate, review all other significant and life-threatening adverse reactions.

---

**minocycline hydrochloride**

Aknemin®, Dentomycin®, Dom-Minocycline®, Dynacin, Gen-Minocycline®, Minocin, Novo-Minocycline®, PMS-Minocycline®, Ratio-Minocycline®, Riva-Minocycline®, Sandoz Minocycline®, Sebomin®, Sebren®, Solodyn

**Pharmacologic class:** Tetracycline

**Therapeutic class:** Anti-infective

**Pregnancy risk category D**

**Action**

Binds reversibly to 30S ribosome, inhibiting bacterial protein synthesis

**Availability**

Capsules: 50 mg, 75 mg, 100 mg
Capsules (pellet-filled): 50 mg, 100 mg
Microspheres (sustained-release): 1 mg
Suspension: 50 mg/5 ml
Tablets: 50 mg, 75 mg, 100 mg

**Indications and dosages**

- Infections caused by susceptible organisms
- **Adults:** Initially, 200 mg P.O. then 100 mg P.O. q 12 hours or 50 mg P.O. q 6 hours
- **Children ages 8 and older:** 4 mg/kg P.O. followed by 2 mg/kg q 12 hours
- **Gonorrhea in penicillin-sensitive patients**
  - **Adults:** Initially, 200 mg P.O., then 100 mg q 12 hours for at least 4 days
  - **Uncomplicated gonococcal urethritis in men**
  - **Adults:** 100 mg P.O. q 12 hours for 5 days
  - **Syphilis**
  - **Adults:** Initially, 200 mg P.O., then 100 mg q 12 hours for 10 to 15 days
  - **Acne**
  - **Adults:** 50 mg P.O. one to three times daily

Reactions in bold are life-threatening.
Dosage adjustment
● Renal impairment

Contraindications
● Hypersensitivity to drug, its components, or tetracyclines

Precautions
Use cautiously in:
● sulfite sensitivity, renal disease, hepatic impairment, nephrogenic diabetes insipidus
● cachectic or debilitated patients
● pregnant (last half of pregnancy) or breastfeeding patients
● children younger than age 8 (not recommended).

Administration
● Ask patient about sulfite sensitivity before giving.
● Give with 8 oz. of water, with or without food.
● Know that drug is used in penicillin-sensitive patients.

Route Onset Peak Duration
P.O. Unknown 1-4 hr Unknown

Adverse reactions
CNS: headache
CV: pericarditis
EENT: pharyngitis
GI: nausea, vomiting, diarrhea, oral candidiasis, stomatitis, mouth ulcers
GU: bladder or vaginal yeast infection
Metabolic: eosinophilia, hemolytic anemia, thrombocytopenia
Skin: photosensitivity, rash
Other: dental caries; dental infection; gingivitis; periodontitis; tooth disorder, pain, or discoloration; superinfection; hypersensitivity reactions including anaphylaxis

Interactions
Drug-drug. Adsorbent antidiarrheals: decreased minocycline absorption
Antacids containing aluminum, calcium, or magnesium; calcium, iron, and magnesium supplements; sodium bicarbonate: decreased minocycline absorption
Cholestyramine, colestipol: decreased oral absorption of minocycline
Hormonal contraceptives: decreased contraceptive efficacy
Methoxyflurane: nephrotoxicity
Penicillin: interference with bactericidal action of penicillin
Sucralfate: blocked absorption of minocycline
Warfarin: increased anticoagulant effect

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, bilirubin, blood urea nitrogen: increased levels
Hemoglobin, platelets, neutrophils, white blood cells: decreased levels
Urinary catecholamines: false elevation

Drug-food. Dairy products: decreased minocycline absorption

Drug-behaviors. Alcohol use: decreased antibiotic effect
Sun exposure: increased risk of photosensitivity reaction

Patient monitoring
● Assess patient’s oral health closely for dental problems.
● Monitor patient for superinfection, especially oral, bladder, and vaginal yeast infections.
● Evaluate CBC and renal and liver function tests frequently.
● Watch closely for hypersensitivity reactions, including anaphylaxis.

Patient teaching
● Tell patient he may take with or without food, followed by a full glass of water. Instruct him to space doses evenly over 24 hours and to take one dose 1 hour before bedtime.
● Advise patient not to take with antacids or iron, calcium, or magnesium products.
Instruct patient to immediately report fever, chills, skin rash, unusual bleeding or bruising, sore throat, or mouth pain or discomfort.

- Stress importance of good oral hygiene to minimize adverse oral and dental effects.
- Tell patient to complete entire course of therapy even after symptoms improve.
- Caution patient not to use outdated minocycline because it may cause serious kidney disease.
- Inform female patient that drug may make hormonal contraceptives ineffective. Urge her to use barrier contraception.
- Tell pregnant patient that drug may stain fetus’ teeth if taken during last half of pregnancy.
- Advise female patient to tell prescriber if she is breastfeeding.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and behaviors mentioned above.

**minoxidil**

Apo-Gain®, Gen-Minoxidil®, Loniten®, Minox®, Regaine®, Rogaine, Rogaine Extra Strength

**Pharmacologic class:** Peripheral vasodilator (direct-acting)

**Therapeutic class:** Antihypertensive, hair growth stimulant

**Pregnancy risk category C**

**FDA BOXED WARNING**

- Drug may cause serious adverse effects (such as pericardial effusion occasionally progressing to tamponade) and may exacerbate angina pectoris. Reserve it for hypertensive patients who respond inadequately to maximum therapeutic doses of diuretic and two other antihypertensives.
- Give under close supervision, usually concurrently with therapeutic doses of beta blocker to prevent tachycardia and increased myocardial workload. Usually, drug also must be given with diuretic to prevent serious fluid accumulation. Patients with malignant hypertension and those already receiving guanethidine should be hospitalized when therapy begins so they can be monitored to avoid too rapid, or large orthostatic, blood pressure decreases.

**Action**

Reduces blood pressure by relaxing vascular smooth muscle, causing vasodilation. Action in hair growth stimulation unclear; vasodilatory action may enhance microcirculation around hair follicles.

**Availability**

Tablets: 2.5 mg, 10 mg

Topical solution: 2%, 5%

**Indications and dosages**

- Severe symptomatic hypertension; hypertension associated with end-organ damage

**Adults and children ages 12 and older:** 5 mg/day as a single dose, increased carefully q 3 days. Usual range is 10 to 40 mg/day in single or divided doses. For rapid blood pressure control with careful monitoring, dosage may be adjusted q 6 hr. Maximum dosage is 100 mg/day.

**Children younger than age 12:** 0.2 mg/kg/day P.O. as a single dose. May increase in increments of 50% to 100% until blood pressure control is optimal. Usual range is 0.25 to 1 mg/kg/day; maximum recommended dosage is 50 mg/day.

- Male-pattern baldness; diffuse hair loss or thinning in women; adjunct to hair transplantation

Reactions in **bold** are life-threatening.
Adults: Apply 1 ml of 2% or 5% topical solution to affected area b.i.d. for 4 months or longer.

> Alopecia areata

Adults: Apply 1 ml of 2% or 5% topical solution to scalp b.i.d.

**Contraindications**
- Hypersensitivity to drug or its components
- Dissecting aortic aneurysm
- Pheochromocytoma

**Precautions**
Use cautiously in:
- recent MI, malignant hypertension, heart failure, angina pectoris, severe renal impairment
- concurrent guanethidine therapy
- pregnant or breastfeeding patients.

**Administration**
- Give oral form with meals to decrease GI upset.
  - If patient is also receiving guanethidine, discontinue that drug 1 to 3 days before starting minoxidil, to avoid severe orthostatic hypotension.
- Know that oral form is usually given with a beta-adrenergic blocker or diuretic to control hypertension.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30 min</td>
<td>2-3 hr</td>
<td>2-5 days</td>
</tr>
<tr>
<td>Topical</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
CV: ECG changes (such as T-wave changes), tachycardia, angina, pericardial effusion, cardiac tamponade, heart failure
GI: nausea, vomiting
Respiratory: pulmonary edema
Skin: hypertrichosis
Other: weight gain, edema

**Interactions**
**Drug-drug.** Antihypertensives, nitrates: additive hypotension

**Guanethidine:** severe orthostatic hypotension
**Nonsteroidal anti-inflammatory drugs:** decreased minoxidil efficacy

**Drug-diagnostic tests.** Alkaline phosphatase, blood urea nitrogen, creatinine, plasma renin activity, sodium: increased levels

Hematocrit, hemoglobin, red blood cells: decreased levels

**Patient monitoring**
- Monitor vital signs and ECG.
- Assess daily weight and fluid intake and output.
- Watch for hypertrichosis.
- Know that hematologic and renal values usually return to pretreatment levels with continued therapy.

**Patient teaching**
- Instruct patient to take oral form with meals to decrease GI upset.
- Advise patient to weigh himself daily and report sudden gains.
- Tell patient taking oral form that drug may darken, lengthen, and thicken body hair. Tell him to shave or use depilatory to reduce unwanted hair growth. Reassure him that unwanted growth will disappear 1 to 6 months after he stops taking drug.
  - Instruct patient to immediately report difficulty breathing (especially when lying down) or pain in chest, arm, or shoulder.
- Teach patient how to use topical form. Urge him to read package insert carefully.
- Caution patient not to use topical form on other body parts and not to let it contact mucous membranes.
- Tell patient using topical form that new scalp hair will be soft and barely visible. Caution him to use only 1 ml twice daily, regardless of amount of balding. Remind him not to stop using...
drug suddenly, because new hair growth will be lost.

- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**mirtazapine**


*Pharmacologic class:* Piperazinoazepine derivative

*Therapeutic class:* Tetracyclic antidepressant

*Pregnancy risk category C*

**FDA BOXED WARNING**

- Drug may increase risk of suicidal thinking and behavior in children and adolescents with major depressive disorder and other psychiatric disorders. Risk must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family and caregivers to observe patient closely and communicate with prescriber as needed.
- Drug isn’t approved for use in pediatric patients.

**Action**

Potentiates effects of norepinephrine and serotonin by blocking their synaptic reuptake. Also exerts anticholinergic activity by disrupting muscarinic receptors.

**Availability**

*Tablets: 15 mg, 30 mg, 45 mg*

*Tablets (orally disintegrating): 15 mg, 30 mg, 45 mg*

**Indications and dosages**

*Depression*

**Adults:** Initially, 15 mg/day as a single dose at bedtime; may increase dosage q 1 to 2 weeks up to 45 mg/day. For maintenance, 15 to 45 mg/day.

**Dosage adjustment**

- Renal or hepatic impairment
- Elderly patients

**Contraindications**

- Hypersensitivity to drug
- MAO inhibitor use within past 14 days

**Precautions**

Use cautiously in:
- hepatic or renal impairment
- history of seizures, cardiovascular or cerebrovascular disease, or psychiatric illness
- elderly patients
- pregnant or breastfeeding patients
- children (safety not established).

**Administration**

- Administer orally disintegrating tablet without water. Have patient place it on tongue until it melts. Make sure tablet isn’t broken.
- Be aware that drug is usually used in conjunction with psychotherapy.

**Clinical alert**

Don’t give within 14 days of MAO inhibitors.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1-2 wk</td>
<td>≥6 wk</td>
<td>Unknown</td>
</tr>
</tbody>
</table>
Adverse reactions
CNS: drowsiness, dizziness, abnormal dreams, abnormal thinking, asthenia, tremor, confusion, suicidal behavior or ideation (especially in child or adolescent)
CV: orthostatic hypotension, chest pain
EENT: sinusitis
GI: constipation, dry mouth
GU: urinary frequency, urinary tract infection
Hematologic: agranulocytosis
Musculoskeletal: back pain, myalgia
Respiratory: increased cough, dyspnea
Skin: photosensitivity
Other: flulike symptoms, edema, increased appetite, weight gain, increased thirst

Interactions
Drug-drug. Benzodiazepines, other CNS depressants: additive CNS depression
Drugs metabolized by CYP450 enzyme: altered metabolism of these drugs
MAO inhibitors: hypertension, seizures, death

Drug-diagnostic tests. Alanine aminotransferase, cholesterol, triglycerides: increased levels

Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression
S-adenosylmethionine (SAM-e), St. John’s wort: increased risk of serotonergic adverse effects (including serotonin syndrome)

Drug-behaviors. Alcohol use: additive CNS effects

Patient monitoring
• Monitor vital signs, especially for orthostatic hypotension.
• Assess neurologic status.
• Watch for weight gain caused by edema or increased appetite.
• Stay alert for urinary tract infection, sinusitis, and flulike symptoms.
• Monitor CBC with white cell differential. Stay alert for agranulocytosis.

Patient teaching
• Advise patient to take with food or milk to reduce GI upset.
• Tell patient he may crush conventional tablets if he can’t swallow them whole.
• Instruct patient to take orally disintegrating tablet without water. Tell him to place it on tongue until it melts and to make sure tablet isn’t broken.
• Advise patient that therapeutic effects may take 2 to 3 weeks.
• Tell patient to immediately report sore throat, fever, mouth sores, or other signs or symptoms of infection.
• Instruct patient (or parent) to immediately report suicidal thoughts or actions (especially in child or adolescent).
• Caution patient not to discontinue drug abruptly. Dosage must be tapered.
• If drug causes oversedation, tell patient to consult prescriber about taking entire daily dose at bedtime.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• Tell patient to avoid alcohol and to discuss herbal use with prescriber.
• Instruct patient to avoid exposure to excessive sunlight or sun lamps.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.
misoprostol
Apo-Misoprostol®, Cytotec, Novo-Misoprostol®, PMS-Misoprostol®

Pharmacologic class: Prostaglandin E₁ analog
Therapeutic class: Antiulcerative, cytoprotective agent
Pregnancy risk category X

FDA BOXED WARNING

- In pregnant women, drug can cause abortion, premature birth, or birth defects. Uterine rupture has occurred when drug was given to pregnant women to induce labor or to induce abortion beyond week 8 of pregnancy.
- Don’t give to pregnant women to reduce risk of nonsteroidal anti-inflammatory drug (NSAID)-induced ulcers.
- Advise patients of drug’s abortifacient property and warn them not to give it to others.
- Don’t use drug to reduce risk of NSAID-induced ulcers in women of childbearing potential unless patient is at high risk for complications from gastric ulcers linked to NSAIDs or at high risk for gastric ulcers. In such patients, drug may be prescribed if patient has had negative serum pregnancy test within 2 weeks before starting therapy; is able to comply with effective contraceptive measures; has received both oral and written warnings of drug’s hazards, risk of possible contraception failure, and danger to other women of childbearing potential should drug be taken by mistake; and will begin drug only on second or third day of next normal menstrual period.

Action
Reduces gastric acid secretion and increases gastric mucus and bicarbonate production, creating a protective coating on gastric mucosa

Availability
Tablets: 100 mcg, 200 mcg

Indications and dosages
➢ To prevent gastric ulcers caused by NSAIDs
Adults: 200 mcg q.i.d. with food, with last daily dose given at bedtime. If intolerance occurs, decrease to 100 mcg q.i.d.

Off-label uses
- Duodenal ulcer
- Pregnancy termination

Contraindications
- Prostaglandin hypersensitivity
- Pregnancy

Precautions
Use cautiously in:
- females of childbearing age
- breastfeeding patients
- children younger than age 18 (safety not established).

Administration
➢ Before starting therapy, make sure female patient understands dangers of taking drug while pregnant or breastfeeding.
- Be aware that drug should not be used in females of childbearing age, except those who need NSAIDs and are at high risk for complications from NSAID-associated gastric ulcers.
- For antiulcer use in females, start therapy on day 2 or 3 of normal menses.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>14-20 min</td>
<td>3-6 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache

Reactions in bold are life-threatening.
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence
GU: miscarriage, menstrual disorders, postmenopausal bleeding

Interactions
Drug-drug. Magnesium-containing antacids: increased risk of diarrhea

Patient monitoring
● Assess GI status. Report significant adverse reactions.
● Monitor menstrual pattern or postmenopausal bleeding. Report significant problems.

Patient teaching
● Instruct patient to take with food.
● Advise patient to report diarrhea, abdominal pain, and menstrual irregularities.
● Tell patient drug may cause spontaneous abortion. Stress importance of using reliable contraception.
● Instruct female patient using drug for ulcer treatment to start therapy on second or third day of normal menses.
● Caution patient not to take magnesium-containing antacids, which may worsen diarrhea.
● As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

mitomycin
Mutamycin

Pharmacologic class: Antitumor antibiotic
Therapeutic class: Antineoplastic
Pregnancy risk category C

FDA BOXED WARNING
● Give under supervision of physician experienced in cancer chemotherapy, in facility with adequate diagnostic and treatment resources.
● Most common and severe toxic effect is bone marrow suppression.
● Some patients receiving systemic drug have experienced hemolytic uremic syndrome, a serious complication consisting primarily of microangiopathic hemolytic anemia, thrombocytopenia, and irreversible renal failure. Syndrome may arise at any time during systemic therapy, but most cases occur at doses of 60 mg or higher. Blood product transfusion may exacerbate symptoms.

Action
Selectively inhibits DNA synthesis by causing cross-linking of DNA strands and suppressing RNA and protein synthesis, resulting in cell death

Availability
Injection: 5-mg, 20-mg, and 40-mg vials

Indications and dosages
Disseminated adenocarcinoma of stomach or pancreas (given with other chemotherapeutic agents); palliative treatment when other therapies fail
Adults: 20 mg/m² I.V. as a single dose. Repeat cycle q 6 to 8 weeks, adjusting dosage if necessary.

Dosage adjustment
● Reduced white blood cell or platelet count

Contraindications
● Hypersensitivity to drug
● Thrombocytopenia, coagulation disorders, increased bleeding tendency
Precautions
Use cautiously in:
● active infections, decreased bone marrow reserve, impaired hepatic function
● history of pulmonary disorders
● elderly patients
● pregnant or breastfeeding patients.

Administration
Follow facility policy for handling, administering, and disposing of mutagenic, teratogenic, and carcinogenic drugs.

Reconstitute 5-mg vial with 10 ml of sterile water. Shake, let mixture stand, and administer by direct I.V. injection through Y-tube or three-way stopcock. Infuse over 5 to 10 minutes through line with running infusion of normal saline solution or dextrose 5% in water.

Avoid extravasation and contact with skin, mucous membranes, and eyes.

Route Onset Peak Duration
I.V. Unknown Unknown Unknown

Adverse reactions
GI: nausea, vomiting, anorexia, mouth ulcers, stomatitis
GU: renal failure, hemolytic uremic syndrome
Hematologic: anemia, leukopenia, thrombocytopenia
Respiratory: pulmonary toxicity, interstitial pneumonitis
Skin: reversible alopecia; pruritus; desquamation; phlebitis, necrosis, and sloughing with I.V. site extravasation
Other: fever

Interactions
Drug-drug. Live-virus vaccines: decreased antibody response to vaccine, increased risk of adverse reactions
Other antineoplastics: additive bone marrow depression
Vinca alkaloids: respiratory toxicity

Patient monitoring
Closely monitor CBC with white cell differential and platelet count. Stay alert for evidence of blood dyscrasias.
Assess kidney function tests. Measure fluid intake and output and evaluate fluid balance.
Watch for signs and symptoms of hemolytic uremic syndrome (irritability, fatigue, pallor, and decreased urinary output).
Closely monitor I.V. site and skin integrity to prevent extravasation.
Assess respiratory status carefully to detect severe pulmonary problems.

Patient teaching
Teach patient to recognize and immediately report signs and symptoms of hemolytic uremic syndrome, blood dyscrasias, and renal failure.
Instruct patient to report cough or shortness of breath, even if it occurs several months after therapy ends.
Advise patient to limit exposure to infections and to avoid live vaccines.
Tell patient drug may cause hair loss. Discuss options for dealing with this problem.
As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

mitoxantrone hydrochloride
Novantrone, Onkotrone

Pharmacologic class: Antibiotic antineoplastic
Therapeutic class: Antineoplastic, immune modifier
Pregnancy risk category D
FDA BOXED WARNING

- Administer slowly into free-flowing I.V. infusion. Never give I.M, subcutaneously, intra-arterially, or intrathecally; severe local tissue damage may occur with extravasation.
- Except in acute nonlymphocytic leukemia, drug generally shouldn’t be given to patients with baseline neutrophil counts below 1,500/mm³. Obtain frequent peripheral blood cell counts on all patients to monitor for bone marrow depression.
- Myocardial toxicity, whose severe form manifests as potentially fatal congestive heart failure (CHF), may occur during therapy or months to years afterward. Risk increases with cumulative dose. In cancer patients, risk of symptomatic CHF is about 2.6% for those receiving up to a cumulative dose of 140 mg/m². Monitor patients for evidence of cardiotoxicity and ask about CHF symptoms before starting therapy. In multiple sclerosis (MS) patients who reach cumulative dose of 100 mg/m², monitor for evidence of cardiotoxicity before each subsequent dose; they shouldn’t receive cumulative dose above 140 mg/m².
- Active or dormant cardiovascular disease, previous or concomitant radiation to mediastinal or pericardial area, previous anthracycline or anthracedione therapy, or concurrent use of other cardiotoxic drugs may increase cardiotoxicity risk.
- Secondary acute myelogenous leukemia has occurred in cancer patients and MS patients who received drug. Refractory secondary leukemia is more common when drug is given with DNA-damaging antineoplastics, when patients have been heavily pretreated with cytotoxic drugs, or when dosages have been escalated.

Action
Selectively inhibits DNA synthesis by causing cross-linking of DNA strands and suppressing RNA and protein synthesis, resulting in cell death.

Availability
Injection: 2 mg/ml in 10-ml, 12.5-ml, and 15-ml vials

Indications and dosages
- Acute nonlymphocytic leukemia
  - Adults: For induction—12 mg/m²/day I.V. on days 1 to 3, with 100 mg/m² of cytosine arabinoside given for 7 days as a continuous I.V. infusion (over 24 hours) on days 1 through 7. If remission doesn’t occur, second course may follow, with mitoxantrone given for 2 days and cytosine arabinoside for 5 days at same daily dosages. For consolidation therapy—12 mg/m²/day mitoxantrone I.V. on days 1 and 2 and 100 mg/m² cytosine arabinoside I.V. as a continuous infusion over 24 hours on days 1 through 5, given 6 weeks after induction therapy.
  - Pain in patients with advanced hormone-refractory prostatic cancer
    - Adults: 12 to 14 mg/m² I.V. given over 15 to 30 minutes q 21 days
  - Multiple sclerosis
    - Adults: 12 mg/m² I.V. given over 5 to 15 minutes q 3 months. Maximum cumulative lifetime dosage is 140 mg/m².

Contraindications
- Hypersensitivity to drug

Precautions
Use cautiously in:
- bone marrow depression, heart failure, chronic debilitating illness, hepato-biliary dysfunction
- elderly patients
- pregnant or breastfeeding patients
- children.
Administration

Follow facility policy for handling, administering, and disposing of mutagenic, teratogenic, and carcinogenic drugs.

- Dilute with 50 ml or more of normal saline solution or dextrose 5% in water (D5W). Infuse I.V. over 3 to 5 minutes into running line of normal saline solution or D5W.
- Alternatively, dilute drug further in normal saline solution or D5W and infuse intermittently I.V. over 15 to 30 minutes.
- If extravasation occurs, stop infusion immediately.
- Avoid contact with skin, mucous membranes, and eyes.
- Be aware that drug isn’t indicated for primary progressive multiple sclerosis.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: headache, seizures
CV: heart failure, arrhythmias, cardiotoxicity
EENT: conjunctivitis, mucositis
GI: nausea, vomiting, diarrhea, abdominal pain, stomatitis, GI bleeding
GU: urinary tract infection, blue-green urine, renal failure
Hematologic: anemia, bone marrow depression, leukopenia, thrombocytopenia
Hepatic: jaundice, hepatotoxicity
Metabolic: hyperuricemia
Respiratory: cough, dyspnea
Skin: rash, petechiae, bruising, alopecia
Other: fever, infection, hypersensitivity reaction

Interactions

Drug-drug. Anthracycline antineoplastics (daunorubicin, doxorubicin, idarubicin): increased risk of cardiomyopathy
Live-virus vaccines: decreased antibody response to vaccine

Other antineoplastics: additive bone marrow depression

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, bilirubin, uric acid: increased levels

Patient monitoring

Monitor CBC with white cell differential. Watch for evidence of blood dyscrasias.
- Assess vital signs, ECG, and respiratory and cardiovascular status.
- Monitor kidney and liver function tests. Measure fluid intake and output and evaluate fluid balance.

Patient teaching

Advise patient to immediately report chest pain, seizure, easy bruising or bleeding, change in urination pattern, yellowing of skin or eyes, or difficulty breathing.
- Instruct patient to limit exposure to infections and to avoid live vaccines.
- Tell patient drug may turn urine blue-green.
- Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
- Tell female patient to inform prescriber if she is pregnant or breastfeeding.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Reactions in bold are life-threatening.
modafinil
Alertec®, Apo-Mofafinil®, Provigil

Pharmacologic class: Nonamphetamine CNS stimulant
Therapeutic class: Analpeptic
Controlled substance schedule IV
Pregnancy risk category C

Action
Unknown. Thought to stimulate CNS by decreasing the release of gamma-aminobutyric acid (a CNS depressant), thereby increasing mental alertness.

Availability
Tablets: 100 mg, 200 mg

Indications and dosages
➣ Narcolepsy
Adults: 200 mg/day P.O. as a single dose in morning

Dosage adjustment
• Severe hepatic impairment

Contraindications
• Hypersensitivity to drug

Precautions
Use cautiously in:
• recent myocardial infarction, unstable angina, severe hepatic impairment, hyperthyroidism, hypertension, glaucoma, anxiety
• history of left ventricular hypertrophy, ischemic ECG changes, chest pain, arrhythmias, or mitral valve prolapse with previous CNS stimulant use
• history of psychosis
• drug abuse
• pregnant or breastfeeding patients
• children (safety and efficacy not established).

Administration
• Give without food (food delays drug absorption).

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2-4 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, dizziness, nervousness, insomnia, depression, anxiety, amnesia, tremor, emotional lability
CV: hypertension, chest pain, vasodilation, hypotension, syncope, arrhythmias
EENT: abnormal vision, amblyopia, epistaxis, rhinitis, pharyngitis
GI: nausea, vomiting, diarrhea, dry mouth, anorexia
GU: abnormal urine, urinary retention, albuminuria, abnormal ejaculation
Hematologic: eosinophilia
Metabolic: hyperglycemia
Musculoskeletal: joint disorders, neck pain and rigidity
Respiratory: lung disorder, dyspnea, asthma
Skin: dry skin
Other: fever, chills, herpes simplex infection

Interactions
Drug-drug. Carbamazepine, phenobarbital, rifampin, other CYP3A4 inducers: decreased modafinil blood level
Cyclosporine, theophylline: decreased blood levels of these drugs
Diazepam, phenytoin, propranolol, tricyclic antidepressants, warfarin: increased blood levels of these drugs
Hormonal contraceptives: decreased contraceptive efficacy
Itraconazole, ketoconazole, other CYP3A4 inhibitors: increased modafinil blood level
Methylphenidate: delayed modafinil absorption

Drug-diagnostic tests. Aspartate aminotransferase, eosinophils, gamma-glutamyl transferase, glucose: increased levels
Hepatic enzymes: abnormal levels
Patient monitoring
- Monitor respiratory and cardiovascular status, including vital signs and ECG.
- Monitor neurologic status, including mood, motor function, cognition, and emotional lability.
- Monitor blood glucose level in diabetic patient.
- Monitor patient carefully if he is also receiving MAO inhibitors. (However, interaction studies with MAO inhibitors haven’t been done.)

Patient teaching
- Tell patient he may take with or without food, but that food may delay drug absorption up to 1 hour.
- Advise patient to immediately report chest pain, irregular heart beats, light-headedness, or fainting.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, motor function, and alertness.
- Instruct female patient to use reliable nonhormonal contraception during and for 1 month after therapy.
- Tell diabetic patient to monitor blood glucose level closely and stay alert for hyperglycemia.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

moexipril hydrochloride
Perdix®, Univasc

Pharmacologic class: Angiotensin-converting enzyme (ACE) inhibitor
Therapeutic class: Antihypertensive
Pregnancy risk category C (first trimester), D (second and third trimesters)

FDA BOXED WARNING
- When used during second or third trimester of pregnancy, drug may cause fetal harm or death. Discontinue drug as soon as possible when pregnancy is detected.

Action
Inhibits conversion of angiotensin I to the vasoconstrictor angiotensin II, inactivates bradykinin and other vasodilatory prostaglandins, increases plasma renin levels, and reduces aldosterone levels. Net effect is systemic vasodilation.

Availability
Tablets: 7.5 mg, 15 mg

Indications and dosages
Hypertension
Adults: 7.5 mg P.O. daily 1 hour before a meal; may increase if blood pressure control is inadequate. Range is 7.5 mg to 30 mg/day in one or two divided doses given 1 hour before a meal.

Dosage adjustment
- Renal impairment
- Concurrent diuretic therapy

Contraindications
- Hypersensitivity to drug
- Angioedema secondary to ACE inhibitor use

Precautions
Use cautiously in:
- renal or hepatic impairment, hypovolemia, hyponatremia, aortic stenosis or hypertrophic cardiomyopathy, cardiac or cerebrovascular insufficiency
- family history of angioedema
- concurrent diuretic therapy
- black patients
- elderly patients
- pregnant or breastfeeding patients
- children (safety not established).

Reactions in bold are life-threatening.
**Administration**
- Give 1 hour before meals (food reduces drug absorption).
- Adjust dosage, as ordered, according to blood pressure response.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30 min</td>
<td>6 hr</td>
<td>Up to 24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- CNS: dizziness, fatigue
- CV: chest pain, peripheral edema
- EENT: pharyngitis, sinusitis
- GI: nausea, diarrhea
- GU: urinary frequency
- Metabolic: hyperkalemia
- Musculoskeletal: myalgia
- Respiratory: upper respiratory infection, increased cough
- Skin: rash, flushing, angioedema
- Other: fever, flulike symptoms, hypersensitivity reaction

**Interactions**

**Drug-drug.** Allopurinol: increased risk of hypersensitivity reaction
- Antacids: decreased moexipril absorption
- Antihypertensives, general anesthetics, nitrates, phenothiazines: additive hypotension
- Cyclosporine, indomethacin, potassium-sparing diuretics, potassium supplements, salt substitutes: hyperkalemia
- Digoxin, lithium: increased blood levels of these drugs
- Diuretics: excessive hypotension
- Nonsteroidal anti-inflammatory drugs: blunted antihypertensive response

**Drug-diagnostic tests.** Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, potassium: increased levels
- Antinuclear antibody: positive titer
- Sodium: decreased level

**Drug-food.** Salt substitutes containing potassium: hyperkalemia

**Drug-behaviors.** Acute alcohol ingestion: additive hypotension

**Patient monitoring**
- Monitor vital signs and neurologic and cardiovascular status.
- Assess respiratory status, staying alert for persistent dry cough.
- Evaluate for allergic reactions and angioedema.
- Know that moexipril monotherapy is less effective in black patients, who may need additional concurrent antihypertensives.

**Patient teaching**
- Instruct patient to take 1 hour before a meal.
- Tell patient to report persistent dry cough and signs or symptoms of infection (especially upper respiratory infection).
- Advise patient to change position slowly (especially during first few days of therapy), to minimize hypotension and dizziness.
- Instruct patient to limit foods high in potassium and avoid salt substitutes containing potassium.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and behaviors mentioned above.

---

**montelukast sodium**

**Singulair**

**Pharmacologic class:** Leukotriene receptor antagonist

**Therapeutic class:** Antiasthmatic

**Pregnancy risk category B**

**Action**

Blocks action of leukotrienes, decreasing smooth muscle contractions and edema in bronchial airways and preventing inflammation and bronchospasm.
Availability
Oral granules: 4-mg base/packet
Tablets: 10 mg
Tablets (chewable): 4 mg, 5 mg

Indications and dosages

➤ Long-term asthma management

Adults and children ages 15 and older:
10-mg tablet P.O. daily in evening

Children ages 6 to 14:
5-mg chewable tablet P.O. daily in evening

Children ages 2 to 5:
4-mg chewable tablet or one 4-mg packet oral granules P.O. daily in evening

Children ages 12 to 23 months:
4-mg packet oral granules P.O. daily in evening

➤ Prevention of exercise-induced bronchoconstriction (EIB)

Adults and children ages 15 and older:
Single-dose, 10-mg tablet P.O. at least 2 hours before exercise; additional dose shouldn’t be taken within 24 hours. Patients already taking 1 tablet daily for another indication shouldn’t take an additional dose.

➤ Seasonal allergic rhinitis

Adults: 10 mg P.O. daily

Children ages 2 to 5:
4 mg P.O. daily either as either chewable tablet or packet of oral granules

➤ Perennial allergic rhinitis

Adults: 10 mg P.O. daily

Children ages 6 to 14:
5 mg P.O. daily as chewable tablet

Children ages 2 to 5:
4 mg P.O. daily as either chewable tablet or packet of oral granules

Children ages 6 to 23 months:
1 packet (4 mg) oral granules P.O. daily

Off-label use

• Chronic urticaria

Contraindications

• Hypersensitivity to drug or its components
• Status asthmaticus

Precautions

Use cautiously in:
• acute asthma attack, hepatic impairment, phenylketonuria
• children younger than age 15 when used for EIB prevention (safety not established)
• children younger than age 2 when used for seasonal allergy (safety not established)
• children younger than age 1 when used for asthma and allergic rhinitis (safety not established)
• pregnant or breastfeeding patients.

Administration

• Give with or without food.
• Administer oral granules either directly in mouth, dissolved in 1 teaspoon (5 mL) cold or room temperature baby formula or breast milk, or mixed with spoonful of cold or room temperature soft foods (applesauce, carrots, rice, or ice cream only). Don’t open packet until ready to use. After opening packet, administer full dose (with or without mixing with baby formula, breast milk, or food); dose must be given within 15 minutes. If granules have been mixed with baby formula, breast milk, or food, don’t store for future use.
• Ensure that patient taking drug for prevention of EIB has short-acting beta-agonist available for rescue.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>3-4 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>P.O. (chewable)</td>
<td>Unknown</td>
<td>2-2.5 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>P.O. (granules)</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: fatigue, headache, dizziness, asthenia
EENT: nasal congestion, otitis and sinusitis (in children)

Reactions in **bold** are life-threatening.
GI: abdominal pain; nausea and diarrhea (in children); dyspepsia; infectious gastroenteritis
Respiratory: cough
Skin: rash
Other: dental pain, influenza, fever

Interactions
Drug-drug. CYP450 inducers (such as phenobarbital, rifampin): decreased montelukast effects
Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, eosinophils: increased levels

Patient monitoring
- Assess eosinophil count.
- Monitor temperature. Watch for fever and other signs and symptoms of infection.

Patient teaching
- Advise patient (or caregiver) who has asthma or asthma and rhinitis to take drug in evening.
- Instruct patient (or caregiver) who has EIB not to take another dose within 24 hours of previous dose.
- Inform patient (or caregiver) that he may sprinkle granules onto soft foods (applesauce, carrots, rice, or ice cream only) and take immediately. Drug isn’t intended to be dissolved in any liquid other than breast milk or baby formula. Don’t store drug that has been mixed with food or liquids for future use.
- Instruct patient or caregiver that after opening packet of oral granules, dose must be taken within 15 minutes.
- Tell patient or caregiver that drug is for preventive use only, not for treatment of acute asthma attacks.
- Caution patient to avoid driving and other hazardous activities, because drug causes dizziness.
- Tell patient (or caregiver) to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.

As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

morphine hydrochloride
Doloral®, Morphitec®
morphine sulfate, morphine sulphate®

Pharmacologic class: Opioid agonist
Therapeutic class: Opioid analgesic
Controlled substance schedule II
Pregnancy risk category C

FDA BOXED WARNING
- Avinza (morphine sulfate) capsules are modified-release form indicated for once-daily P.O. administration to relieve moderate to severe pain requiring continuous, around-the-clock opioids for extended time. Instruct patients to swallow capsules whole or sprinkle contents on applesauce. Warn them never to chew, crush, or dissolve capsules or consume alcoholic beverages or use prescription or nonprescription drugs containing alcohol during therapy, as this may lead to
rapid release and absorption of potentially fatal dose.

- Intrathecal dosage of morphine sulfate injection is usually one-tenth of epidural dosage.

### Action
Interacts with opioid receptor sites, primarily in limbic system, thalamus, and spinal cord. This interaction alters neurotransmitter release, altering perception of and tolerance for pain.

### Availability
**morphine hydrochloride**
- Rectal suppositories: 20 mg, 30 mg
- Syrup: 1 mg/ml, 5 mg/ml, 10 mg/ml, 20 mg/ml, 50 mg/ml
- Tablets: 10 mg, 20 mg, 40 mg, 60 mg

**morphine sulfate**
- Capsules: 15 mg, 30 mg
- Capsules (extended-release): 10 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg, 90 mg, 100 mg, 120 mg, 200 mg
- Capsules (sustained-release): 10 mg, 20 mg, 30 mg, 50 mg, 60 mg, 100 mg
- Oral solution: 2 mg/ml, 4 mg/ml, 20 mg/ml (concentrate), 10 mg/5 ml, 20 mg/5 ml, 100 mg/5 ml
- Rectal suppositories: 5 mg, 10 mg, 20 mg, 30 mg
- Solution for epidural injection (extended-release, liposomal): 10 mg/ml, 15 mg/1.5 ml, 20 mg/2-ml vials
- Solution for epidural or intrathecal use (preservative free, for continuous microinfusion device): 10 mg/ml and 25 mg/ml in 20-ml vials
- Solution for epidural or I.V. injection (preservative-free): 0.5 mg/ml, 1 mg/ml
- Solution for I.M., I.V., or subcutaneous injection: 1 mg/ml, 2 mg/ml, 4 mg/ml, 5 mg/ml, 8 mg/ml, 10 mg/ml, 15 mg/ml, 25 mg/ml, 50 mg/ml
- Solution for I.V. injection (for patient-controlled analgesia [PCA] device): 1 mg/ml, 2 mg/ml, 3 mg/ml, 5 mg/ml
- Tablets (controlled-release, sustained-release): 15 mg, 30 mg, 60 mg, 100 mg, 200 mg
- Tablets (soluble): 10 mg, 15 mg, 30 mg

### Indications and dosages
**Severe to moderate pain**

**Oral use**—

- **Adults**: 5 to 30 mg P.O. (immediate-release) q 4 hours p.r.n. Or 20 mg P.O. (controlled-release, Kadian) once or twice daily p.r.n. Or 200 mg P.O. (MS Contin) in opioid-tolerant patients who require daily morphine-equivalent dosages above 400 mg.

**I.M. or subcutaneous use**—

- **Adults**: 5 to 20 mg/70 kg I.M. or subcutaneously q 4 hours p.r.n.

**I.V. use**—

- **Adults**: 2 to 10 mg/70 kg I.V. p.r.n. given slowly over 4 to 5 minutes. As a continuous I.V. infusion, 0.1 to 1 mg/ml in dextrose 5% in water delivered by controlled-infusion device.

**Rectal use**—

- **Adults**: 10 to 30 mg P.R. q 4 hours p.r.n.

**Epidural use**—

- **Adults**: Initially 5 mg (Astramorph PF, Duramorph) injected in lumbar region (may relieve pain up to 24 hours). If response isn't adequate within 1 hour, carefully give incremental doses of 1 to 2 mg p.r.n., up to 10 mg/24 hours. For continuous epidural infusion, 2 to 4 mg/24 hours. For epidural injection (DepoDur) before orthopedic leg surgery, recommended dosage is 15 mg; before lower abdominal or pelvic surgery, 10 to 15 mg. For cesarean section after umbilical cord clamping, recommended dosage is 10 mg.

**Intrathecal use**—

- **Adults**: Usual intrathecal dosage is one-tenth of epidural dosage; 0.2 to 1 mg as a single injection in lumbar area may relieve pain up to 24 hours.

### Dosage adjustment

- **Adults** weighing less than 50 kg (110 lb)

Reactions in **bold** are life-threatening.
● Elderly patients
● Children

**Contraindications**
- Hypersensitivity to drug, tartrazine, bisulfites, or alcohol
- Acute bronchial asthma
- Upper airway obstruction
- Respiratory depression
- GI obstruction, paralytic ileus

**Precautions**
Use cautiously in:
- head trauma; increased intracranial pressure; severe renal, hepatic, or pulmonary disease; hypothyroidism; adrenal insufficiency; prostatic hypertrophy
- elderly or debilitated patients
- pregnant or breastfeeding patients.

**Administration**
- For best response, give at pain onset.
- Give oral form with food or milk to minimize GI upset.
- If desired, crush immediate-release form and mix with food or fluids.
- Don’t crush or break extended-release form; remind patient to swallow it whole.
- If desired, open sustained-release capsules (Kadian) and sprinkle entire contents onto small amount of food (such as applesauce). Have patient consume mixture immediately without chewing, crushing, or dissolving pellets.
- When giving by direct I.V., dilute in at least 5 ml of sterile water for injection or normal saline solution. Give 2.5 to 10 mg over 4 to 5 minutes.
- For continuous I.V. infusion, use infusion pump or PCA pump. Titrate dosage to provide adequate pain relief.
- Don’t use parenteral form if it’s cloudy or contains visible particulates.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>60-120 min</td>
<td>4-5 hr</td>
</tr>
<tr>
<td>P.O. (extended)</td>
<td>Unknown</td>
<td>Unknown</td>
<td>8-24 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>20 min</td>
<td>4-5 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>10-30 min</td>
<td>30-60 min</td>
<td>4-5 hr</td>
</tr>
<tr>
<td>Subcut.</td>
<td>20 min</td>
<td>50-90 min</td>
<td>4-5 hr</td>
</tr>
<tr>
<td>Epidural</td>
<td>6-30 min</td>
<td>Unknown</td>
<td>Up to 24 hr</td>
</tr>
<tr>
<td>Epidural (ext., liposomal)</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>Intrathecal</td>
<td>Rapid (min)</td>
<td>Unknown</td>
<td>Up to 24 hr</td>
</tr>
<tr>
<td>P.R.</td>
<td>Unknown</td>
<td>20-60 min</td>
<td>4-5 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- CNS: confusion, sedation, dizziness, dysphoria, euphoria, floating feeling, hallucinations, headache, nightmares
- CV: hypotension, bradycardia
- EENT: blurred vision, diplopia, miosis
- GI: nausea, vomiting, constipation, dry mouth
- GU: urinary retention
- Respiratory: apnea, respiratory depression, respiratory arrest
- Skin: flushing, itching, sweating
- Other: physical or psychological drug dependence, drug tolerance

**Interactions**
- Drug-drug. **Antihistamines, barbiturates, clomipramine, sedative-hypnotics, tricyclic antidepressants:** additive CNS depression
- **Buprenorphine, butorphanol, dezocine, naltobuphine, pentazocine:** decreased analgesia
- **Cimetidine:** decreased morphine metabolism and increased effects
- **MAO inhibitors:** severe, unpredictable reactions
- **Mixed opioid agonist-antagonists:** precipitation of withdrawal symptoms in physically dependent patients
- **Warfarin:** increased anticoagulant effect
Drug-diagnostic tests. Amylase, lipase: increased levels
Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression
Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring
- Monitor vital signs. Contact prescriber if respiratory rate is 10 breaths/minutes or less.
- Assess pain character, location, and intensity.
- Monitor fluid intake and output. Stay alert for urinary retention.
- Monitor bowel elimination pattern. If constipation occurs, intervene as appropriate.
- Assess neurologic status. Implement safety measures as needed to prevent injury.
- Evaluate patient for signs and symptoms of physical or psychological dependence. Be watchful for drug hoarding.

Patient teaching
- Tell patient he may crush immediate-release form and mix with food or fluids.
- Advise patient not to crush or break extended-release form. Instruct him to swallow it whole.
- Tell patient he may open sustained-release capsule (Kadian), sprinkle entire contents of capsule onto a small amount of food (such as applesauce), and consume immediately. Stress importance of not chewing, crushing, or dissolving pellets.
- Advise patient to take drug at the first sign of pain, because continuous dosing is more effective than p.r.n. dosing. Pair Tell patient and caregiver that drug may cause respiratory depression. Instruct them to immediately report respiratory rate of 10 breaths/minute or less.
- Inform patient that drug may cause constipation or urinary retention. Encourage high-fiber diet and high fluid intake.
- Stress importance of taking drug only as prescribed. Point out that drug may cause psychological or physical dependence.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, and alertness.
- Teach patient and caregiver about appropriate safety measures to prevent injury.
- Caution patient to avoid alcohol and other CNS depressants during and for 24 hours after therapy.
- Advise patient to avoid herbs, which may worsen adverse CNS effects.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

moxifloxacin hydrochloride
Avelox, Vigamox

Pharmacologic class: Fluoroquinolone
Therapeutic class: Anti-infective
Pregnancy risk category C

FDA BOXED WARNING
- Fluoroquinolones for systemic use are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in patients usually over age 60, with concomitant use of corticosteroids, and in kidney, heart, and lung transplant recipients.
Action
Selectively inhibits DNA synthesis by disrupting DNA replication and transcription and suppressing protein synthesis, causing bacterial cell death.

Availability
*Injection (premixed)*: 400 mg/250-ml bag
*Ophthalmic solution*: 5% (3 ml in 6-ml bottle)
*Tablets*: 400 mg

**Indications and dosages**

**➣ Acute bacterial sinusitis**

**Adults**: 400 mg P.O. or I.V. q 24 hours for 10 days

**➣ Acute bacterial exacerbation of chronic bronchitis**

**Adults**: 400 mg P.O. or I.V. q 24 hours for 5 days

**➣ Community-acquired pneumonia**

**Adults**: 400 mg P.O. or I.V. q 24 hours for 7 to 14 days

**➣ Uncomplicated skin and skin-structure infections**

**Adults**: 400 mg P.O. or I.V. q 24 hours for 7 days

**➣ Bacterial conjunctivitis**

**Adults**: Instill one drop of ophthalmic solution into affected eye t.i.d. for 7 days.

**Contraindications**
- Hypersensitivity to drug, its components, or other fluoroquinolones
- Children younger than age 1 (ophthalmic use).

**Administration**
- Give premixed I.V. dose over 60 minutes. Avoid bolus or rapid infusion.
- Don’t mix with other drugs in same I.V. line.
- Know that although milk or yogurt may impair absorption of P.O. moxifloxacin, drug may be given with other calcium products.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Within 1 hr</td>
<td>1-3 hr</td>
<td>24 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>End of infusion</td>
<td>24 hr</td>
</tr>
<tr>
<td>Ophthalmic</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS**: dizziness, drowsiness, headache, confusion, light-headedness, insomnia, agitation, hallucinations, acute psychoses, tremor, seizures

**CV**: hypertension, vasodilation, tachycardia, prolonged QT interval, arrhythmias

**EENT**: conjunctivitis; decreased visual acuity; keratitis; eye dryness, discomfort, pain, pruritus, and hyperemia; subconjunctival hemorrhage; tearing; otitis media; pharyngitis; rhinitis (all with ophthalmic solution)

**GI**: nausea, diarrhea, abdominal pain, pseudomembranous colitis

**GU**: vaginitis

**Hematologic**: eosinophilia, thrombocytopenia, leukopenia

**Musculoskeletal**: joint pain, tendinitis, tendon rupture

**Respiratory**: increased cough (with ophthalmic solution)

**Skin**: rash, photosensitivity, phototoxicity, Stevens-Johnson syndrome

**Other**: altered taste, fever (with ophthalmic solution), phlebitis at I.V. site, superinfection, hypersensitivity reactions including anaphylaxis
Interactions

Drug-drug. Amiodarone, bepridil, disopyramide, erythromycin, pentamidine, phenothiazines, pimozide, procainamide, quinidine, sotalol, tricyclic antidepressants: increased risk of serious adverse cardiovascular reactions

Antacids, bismuth subsalicylate, iron salts, sucralfate, zinc salts: decreased moxifloxacin absorption

Theophylline: increased theophylline blood level and possible toxicity

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, lactate dehydrogenase, platelets: increased levels

Drug-food. Concurrent tube feedings, milk, yogurt: impaired absorption of P.O. moxifloxacin

Drug-herbs. Dong quai, St. John’s wort: phototoxicity

Fennel: decreased moxifloxacin absorption

Drug-behaviors. Sun exposure: phototoxicity

Patient monitoring

Watch for hypersensitivity reaction (such as anaphylaxis) and other allergic reactions, which may occur after initial dose.

- Monitor cardiovascular and neurologic status closely.

Stay alert for tendinitis and Achilles tendon rupture.

- Monitor CBC and liver function tests.

- Assess GI status. Report signs or symptoms of pseudomembranous colitis.

- Watch closely for superinfection.

Patient teaching

- Advise patient to take tablets once a day with or without food, 4 hours before or 8 hours after antacids, multivitamins, sucralfate, or preparations containing aluminum, magnesium, iron, or zinc.

Tell patient drug may cause serious allergic reactions even several days after therapy begins. Advise him to stop taking drug and report these reactions immediately.

Urge patient to stop taking drug and promptly report tendon pain, diarrhea with blood or pus, and signs and symptoms of superinfection.

- Teach patient how to use eye drops. Caution him to avoid touching applicator tip to eye, finger, or other object.

- Instruct patient being treated for bacterial conjunctivitis not to wear contact lenses.

- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

mupirocin (pseudomonic acid, pseudomonic acid A)

Bactroban, Bactroban Nasal 2%, Taro-Mupirocin

Pharmacologic class: Dermatologic agent

Therapeutic class: Anti-infective, topical

Pregnancy risk category B

Action

Inhibits bacterial protein and RNA synthesis by reversibly and specifically binding to bacterial isoleucyl-transfer RNA synthetase. Bactericidal.
**Availability**

*Intranasal ointment*: 2.15%
*Topical cream*: 2%
*Topical ointment*: 2%

**Indications and dosages**

> Impetigo

**Adults and children ages 2 months to 16 years:** Apply a small amount of ointment topically t.i.d. for 3 to 5 days. Reevaluate if no response.

> Infected traumatic skin lesions

**Adults and children ages 3 months to 16 years:** Apply a small amount of cream topically t.i.d. for 10 days.

> Nasal colonization of methicillin-resistant *Streptococcus aureus*

**Adults and children ages 12 and older:** Apply intranasal ointment (half of single-use tube to each nostril) topically to anterior nares b.i.d. for 5 days.

**Contraindications**

- Hypersensitivity to drug or its components

**Precautions**

Use cautiously in:

- moderate or severe renal impairment (with large doses)
- breastfeeding patients
- children younger than age 12 (intranasal ointment), younger than age 3 months (cream), or younger than age 2 months (ointment).

**Administration**

- After intranasal application, press nares together repeatedly to distribute drug.
- Avoid contact with eyes.
- Discontinue use if sensitization or severe local irritation occurs.
- If desired, cover affected area with gauze dressing after applying cream or ointment.
- Don’t use intranasal form with any other nasal spray.
- Don’t use Bactroban ointment on mucosal surfaces. Use Bactroban Nasal (mupirocin calcium ointment) intranasally.

- Know that although mupirocin isn’t absorbed systemically, polyethylene glycol (its water-miscible ointment base) may be absorbed from open wounds and damaged skin and may be excreted by the kidneys.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Topical, not systemically absorbed intranasal</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Adverse reactions**

- **CNS:** headache (with intranasal use)
- **EENT:** rhinitis, nasal stinging or burning, pharyngitis (all with intranasal use)
- **GI:** mouth and lip sores
- **Skin:** pruritus (with intranasal use); dry skin, rash, redness, stinging or pain, secondary wound infection
- **Other:** taste disorders (with intranasal use)

**Interactions**

None significant

**Patient monitoring**

- Monitor for drug efficacy.

**Patient teaching**

- Instruct patient to wash affected area with soap and water and dry it thoroughly, then apply small amount of drug to area and rub in gently. If desired, tell him to apply gauze dressing.
- Advise patient to complete entire course of therapy, even if symptoms disappear. Tell him to try not to miss doses.
- If patient misses a dose, tell him to apply dose as soon as he remembers. However, if it’s almost time for next dose, advise him to skip missed dose and resume regular dosing schedule.
- Advise patient to contact prescriber if skin infection doesn’t improve within 3 to 5 days or if it worsens.
Caution patient not to apply drug to eye or mucous membranes (except nasal form for intranasal use). As appropriate, review all other significant adverse reactions.

**muromonab-CD3**  
*Orthoclone OKT3*

**Pharmacologic class:** Murine monoclonal antibody  
**Therapeutic class:** Immunosuppressant  
**Pregnancy risk category C**

---

**FDA BOXED WARNING**

- Give under supervision of physician experienced in immunosuppressive therapy and management of solid-organ transplant patients, in facility equipped for cardiopulmonary resuscitation where patient can be monitored closely based on health status.
- Drug may cause anaphylactic and anaphylactoid reactions and occasionally life-threatening or lethal systemic, cardiovascular, and CNS reactions. Monitor patient's fluid status closely before and during therapy. Methylprednisolone pretreatment is recommended to minimize symptoms of cytokine release syndrome.

---

**Action**

Binds to and blocks function of T lymphocytes responsible for antigen recognition, thereby reversing graft rejection

**Availability**

*Injection:* 1 mg/1 ml in 5-ml ampules

---

**Indications and dosages**

- Acute allograft rejection in kidney transplant patients; steroid-resistant acute allograft rejection in heart and liver transplant patients  
- **Adults and children weighing more than 30 kg (66 lb):** 5 mg/day I.V. for 10 to 14 days  
- **Children weighing 30 kg (66 lb) or less:** 2.5 mg/day I.V. for 10 to 14 days

**Contraindications**

- Hypersensitivity to drug or other murine products  
- Uncompensated heart failure  
- Uncontrolled hypertension  
- Predisposition to or history of seizures  
- Antimouse antibody titer of 1:1000 or higher  
- Pregnancy or breastfeeding

**Precautions**

Use cautiously in:

- fever  
- children younger than age 2.

**Administration**

- In kidney transplant patients, know that therapy should start as soon as acute kidney rejection is diagnosed. In heart and liver transplant patients, therapy should start when physician determines that steroid therapy hasn’t reversed allograft rejection.  
- Know that drug must be given in facility equipped and staffed to treat cardiopulmonary arrest.  
- For I.V. bolus injection, draw solution into syringe through low-protein-binding 0.2- or 0.22-micron filter. Discard filter and attach needle-free adapter.  
- Administer bolus over less than 1 minute.  
- Give antipyretics to decrease fever and corticosteroids to reduce allergic response, as prescribed.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>Unknown</td>
<td>1 wk</td>
</tr>
</tbody>
</table>

Reactions in **bold** are life-threatening.
Adverse reactions
CNS: fatigue, headache, weakness, tremors, hallucinations, aseptic meningitis, cerebral edema, seizures, encephalopathy
CV: chest pain, hypertension, hypotension, heart failure, tachycardia, cardiac arrest, shock
EENT: vision loss, blurred vision, conjunctivitis, photophobia, tinnitus, otitis media
GI: nausea, vomiting, diarrhea
GU: oliguria, anuria
Respiratory: dyspnea, wheezing, severe pulmonary edema, adult respiratory distress syndrome (ARDS)
Skin: flushing
Other: fever, chills, flulike symptoms, infection, anaphylaxis, cytokine release syndrome

Interactions
Drug-drug. Indomethacin: increased muromonab blood level, encephalopathy and other adverse CNS effects
Live-virus vaccines: increased viral replication and effects
Other immunosuppressants: increased risk of infection
Drug-diagnostic tests. Blood urea nitrogen, creatinine: increased levels
Drug-herbs. Astragalus, echinacea, melatonin: interference with immunosuppressant effect

Patient monitoring
● Evaluate vital signs and cardiovascular status. Monitor ECG closely.

Assess neurologic status and respiratory status closely. Evaluate for evidence of aseptic meningitis, encephalopathy, cerebral edema, pulmonary edema, and ARDS.

Patient teaching
● Inform patient that drug can cause serious adverse reactions. Reassure him that he will be monitored closely and will receive interventions to relieve these reactions. Teach him which signs and symptoms to report immediately.
● Reassure patient that adverse reactions will subside as treatment progresses.
● Advise female patient to avoid becoming pregnant or breastfeeding during therapy.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.
may result from immunosuppression. Give drug under supervision of physician experienced in immunosuppressive therapy and management of renal, cardiac, or hepatic transplant patients, in facility with adequate diagnostic and treatment resources. Physician responsible for maintenance therapy should have complete information needed for patient follow-up.

Action
Inhibits binding of interleukin (IL)-1 to IL-1 receptors, preventing proliferation and differentiation of activated B and T cells. Binds to intracellular proteins to prevent T-cell activation, suppressing immune responses.

Availability
Capsules: 250 mg
Injection: 500 mg/vial
Oral suspension: 200 mg/ml (after constitution)
Tablets: 500 mg
Tablets (delayed-release): 180 mg, 360 mg

Indications and dosages
➢ To prevent organ rejection in patients receiving allogeneic kidney transplants
Adults: 1 g P.O. or I.V. b.i.d. or 720 mg P.O. b.i.d. (delayed-release), given with corticosteroids and cyclosporine
Children: 400 mg/m² P.O. b.i.d. (delayed-release), up to a maximum of 720 mg b.i.d; or 600 mg/m² P.O. b.i.d., up to a maximum daily dosage of 2 g/10 ml (oral suspension). Given with corticosteroids and cyclosporine.
➢ To prevent organ rejection in patients receiving allogeneic heart transplants
Adults: 1.5 g P.O. or I.V. b.i.d., given with corticosteroids and cyclosporine. May start I.V. therapy less than 24 hours after transplantation; switch to P.O. dosing when tolerated.
➢ To prevent organ rejection in patients receiving allogeneic liver transplants
Adults: 1.5 g b.i.d. P.O. or 1 g I.V. b.i.d., given with corticosteroids and cyclosporine

Dosage adjustment
• Severe chronic renal impairment
• Neutropenia

Contraindications
• Hypersensitivity to drug or its components, mycophenolic acid, or polysorbate 80 (I.V. form)

Precautions
Use cautiously in:
• lymphoma, cancer, neutropenia, renal disease, or GI disorders
• elderly patients
• pregnant or breastfeeding patients
• children (indicated for kidney transplant only).

Administration
• Give P.O. form at least 1 hour before or 2 hours after meals. To enhance absorption, don’t give with other drugs.
• Give delayed-released tablets whole. Don’t let patient crush or chew them.
• Know that pharmacist should mix oral solution before dispensing.

Be aware that drug is teratogenic. Avoid inhaling powder in capsules or letting powder contact skin, mucous membranes, or eyes. If contact occurs, wash skin thoroughly with soap and water or flush eyes with water.
• Know that delayed-release tablets aren’t interchangeable with immediate-release tablets, capsules, or oral suspension.
• For I.V. use, reconstitute with dextrose 5% in water and dilute to 6 mg/ml. Administer over 2 hours.

Don’t give by rapid I.V. push or bolus.

Reactions in bold are life-threatening.

Clinical alert
Route | Onset | Peak | Duration
--- | --- | --- | ---
P.O. | Unknown | 30-75 min | 7.5-18 hr
P.O. (delayed, Unknown Unknown Unknown suspension) | | | |
I.V. | Unknown | Unknown | 10-17 hr

Adverse reactions
- CNS: headache, dizziness, insomnia, asthenia, tremor
- CV: chest pain, hypertension, peripheral edema
- EENT: pharyngitis, oral moniliasis
- GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, GI hemorrhage
- GU: urinary tract infection, hematuria, renal tubular necrosis
- Hematologic: anemia, hypochromic anemia, leukocytosis, leukopenia, thrombocytopenia
- Metabolic: hypophosphatemia, hyperglycemia, hypokalemia, hyperkalemia
- Musculoskeletal: back pain
- Respiratory: dyspnea, cough, bronchitis, pneumonia
- Skin: acne, rash
- Other: pain, fever, opportunistic infections, fatal infections, sepsis, lymphoma and other cancers (especially of skin)

Interactions
- Drug-drug. Acyclovir, ganciclovir, other drugs that undergo renal tubular secretion: increased risk of toxicity from either drug
- Antacids containing aluminum or magnesium: decreased mycophenolate absorption
- Cholestyramine: reduced mycophenolate bioavailability
- Hormonal contraceptives: reduced contraceptive efficacy
- Phenytoin, theophylline: increased blood levels of both drugs
- Probenecid, salicylates: increased mycophenolate blood level

Drug-diagnostic tests. Cholesterol: increased level

Drug-herbs. Astragalus, echinacea, melatonin: interference with immunosuppressant effect

Patient monitoring
- Monitor CBC with white cell differential, electrolyte levels, lipid panel, blood chemistry, and liver function tests frequently.
- Evaluate vital signs. Assess cardiovascular and respiratory status carefully. Watch for signs and symptoms of bronchitis and pneumonia.
- Assess all body systems carefully for signs and symptoms of infection.
- Monitor patient closely for bleeding tendency.

Patient teaching
- Advise patient to take oral drug at least 1 hour before or 2 hours after meals. Tell him not to crush, break, or chew tablets, not to open or chew capsules, and not to take with other drugs.
- If capsule breaks, tell patient not to inhale powder or let it contact skin, mucous membranes, or eyes. If contact occurs, tell him to wash skin thoroughly with soap and water or flush eyes with water.
- Instruct patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Instruct patient to avoid crowds and people with known infections.
- Advise patient not to take herbs without consulting prescriber.
- Tell patient to avoid live-virus vaccines.
- Instruct patient to avoid excessive exposure to sunlight and ultraviolet light, because of increased risk of skin cancer.
Tell female patient to use abstinence or two other contraceptive methods during and for 6 weeks after therapy (even if she has a history of infertility). Urge her to report suspected pregnancy immediately.

- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

**nabilone**
Cesamet

**Pharmacologic class:** Synthetic cannabinoid  
**Therapeutic class:** Antiemetic  
**Controlled substance schedule II**  
**Pregnancy risk category C**

**Action**
Unclear. Drug has complex effects on CNS, including relaxation, drowsiness, and euphoria; antiemetic effect may result from interaction with cannabinoid receptor system in neural tissues.

**Availability**
Capsules: 1 mg

**Indications and dosages**

- Nausea and vomiting associated with cancer chemotherapy in patients who respond inadequately to conventional antiemetics  

**Adults:** 1 to 2 mg P.O. twice daily; give initial dose 1 to 3 hours before chemotherapy. Maximum daily dose, 6 mg given in divided doses three times daily.

**Contraindications**
- Hypersensitivity to drug or other cannabinoids

**Precautions**
Use cautiously in:
- hepatic or renal impairment, hypertension, cardiac disease, QT interval prolongation, psychiatric disorders (current or previous)  
- history of substance abuse  
- concurrent use of sedatives, hypnotics, other psychoactive drugs, or CNS depressants  
- concurrent alcohol use  
- pregnant or breastfeeding patients  
- elderly patients  
- children (safety and efficacy not established).

**Administration**
- On day of chemotherapy, give 1 to 3 hours before chemotherapeutic drug is administered.  
- To minimize adverse reactions, give recommended lower starting dosage and increase dosage as necessary.  
- Know that drug may be given two or three times daily during entire course of each chemotherapy cycle and, if needed, for 48 hours after last dose of each chemotherapy cycle.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- CNS: drowsiness, euphoria, dysphoria, inebriated feeling, mood swings, irritability, fatigue, malaise, ataxia, headache, poor concentration, disorientation, anxiety, depersonalization, depersonalization syndrome, speech disorder or disturbance, insomnia, abnormal dreams, vertigo, light-headedness, dizziness, orthostatic dizziness, twitching, depression,

Reactions in **bold** are life-threatening.  

Clinical alert
confusion, asthenia, sedation, hallucinations, paresthesia, memory disturbance, seizures, dystonia, numbness, akathisia, tremor, incoordination, toxic psychosis, paranoia, apathy, thought disorder, panic disorder, withdrawal, nervousness, phobic neurosis, emotional disorder, hyperactivity, hypotonia, sinus headache

CV: orthostatic hypotension

EENT: visual disturbances, pharyngitis, nasal congestion, dry throat, dry nose, nosebleed, voice change, thick tongue sensation

GI: nausea, dry mouth

GU: increased or decreased urination, urinary retention, urinary frequency

Metabolic: thirst

Musculoskeletal: muscle pain, back pain, neck pain, joint pain

Respiratory: dyspnea, wheezing, cough

Skin: excessive sweating, pruritus, rash, photosensitivity

Other: taste changes, increased appetite, fever, hot flashes, chills, unspecific pain, bacterial infection, chest pain, allergic reaction

Interactions

Drug-drug. Amitriptyline, amoxapine, desipramine, other tricyclics: additive tachycardia, hypertension, drowsiness

Amphetamines, cocaine, other sympathomimetics: additive hypertension, tachycardia, possible cardiotoxicity

Anticholinergics, antihistamines, tricyclic antidepressants: increased tachycardia and hypertension

Antihistamines, atropine, scopolamine, other anticholinergics: additive or superadditive tachycardia, drowsiness

Antihistamines, barbiturates, benzodiazepines, buspirone, lithium, muscle relaxants, opioids, other CNS depressants: additive drowsiness and CNS depression

Antipyrine, barbiturates: decreased clearance of these drugs

Disulfiram, fluoxetine: reversible hypomanic reaction

Opioids: cross-tolerance and mutual potentiation

Naltrexone: enhanced nabilone effects

Theophylline: increased theophylline metabolism

Drug-behaviors. Alcohol use: increased positive mood effects, increased CNS depression

Sun exposure: increased risk of skin reactions

Patient monitoring

● Ensure that patient remains under supervision of responsible adult, especially during initial use and dosage adjustments.

● Monitor vital signs for orthostatic hypotension and tachycardia.

Check for adverse CNS reactions. Report significant depression, paranoid reaction, or emotional lability. Be aware that adverse psychiatric reactions can last for 48 to 72 hours after treatment ends.

● Monitor for excessive use, abuse, or misuse of drug.

● Monitor patient’s nutritional and hydration status.

Patient teaching

● Instruct patient to take drug on day of chemotherapy 1 to 3 hours before chemotherapeutic drug is scheduled.

● Teach patient about significant CNS side effects (especially mood changes) and cardiovascular side effects. Stress importance of taking drug only as prescribed and needed.

● Inform patient that drug may cause additive CNS depression if used with alcohol or other CNS depressants (such as sleeping pills, tranquilizers, or anxiolytics).

Advise patient, family member, or caregiver to immediately report depression, suicidal thoughts, paranoid
reactions, and other serious CNS reactions.

- Caution patient to avoid driving and other hazardous activities until drug effects are known.
- Instruct breastfeeding patient not to use drug while breastfeeding.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and behaviors mentioned above.

---

**nabumetone**

Gen-Nabumetone®, Nabumetone®, Sandoz®, Novo-Nabumetone®, Relifex®

**Pharmacologic class:** Nonsteroidal anti-inflammatory drug (NSAID)

**Therapeutic class:** Antiarthritic

**Pregnancy risk category C** (first and second trimesters), **D** (third trimester)

---

**FDA BOXED WARNING**

- Drug may increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke. Risk may increase with duration of use. Patients with cardiovascular disease or risk factors for it may be at greater risk.
- Drug increases risk of serious GI adverse events, including bleeding, ulcers, and stomach or intestinal perforation. These events can occur at any time during use and without warning. Elderly patients are at greater risk.
- Drug is contraindicated for treatment of perioperative pain in setting of coronary artery bypass graft surgery.

---

**Action**

Unknown. Thought to stimulate anti-inflammatory response and block pain impulses by inhibiting cyclooxygenase, an enzyme needed for prostaglandin synthesis.

**Availability**

*Tablets:* 500 mg, 750 mg

**Indications and dosages**

- **Rheumatoid arthritis; osteoarthritis**

  **Adults:** 1,000 mg/day P.O. as a single dose or in two divided doses; may increase up to 2,000 mg/day

**Contraindications**

- Hypersensitivity to drug
- Active GI bleeding or ulcer disease
- History of aspirin- or NSAID-induced asthma, urticaria, or other allergic-type reaction
- Concurrent use of other NSAIDs
- Pregnancy (third trimester)

**Precautions**

Use cautiously in:

- severe cardiovascular, renal, or hepatic disease
- history of ulcer disease
- pregnant (first or second trimester) or breastfeeding patients
- children (safety and efficacy not established).

**Administration**

- Give with food or milk to increase absorption.
- In chronic therapy, use lowest effective dosage.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1-2 hr</td>
<td>5 hr</td>
<td>12-24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: dizziness, drowsiness, fatigue, headache, insomnia, malaise, nervousness

CV: vasculitis

EENT: abnormal vision, tinnitus

Reactions in **bold** are life-threatening.
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, stomatitis, dry mouth, GI bleeding
Skin: pruritus, rash, angioedema
Other: edema, fluid retention, allergic reactions including anaphylaxis

Interactions
Drug-drug. Acetaminophen: increased risk of adverse renal reactions (with chronic nabumetone use)
Anticoagulants, cefamandole, cefoperazone, cefotetan, clindamycin, erythromycin, ticlopidine, tirofiban, valproic acid: increased risk of bleeding
Antihypertensives, diuretics: decreased nabumetone efficacy
Antineoplastics: increased risk of adverse hematologic reactions
Aspirin, corticosteroids, other NSAIDs, potassium supplements: additive adverse GI effects
Cyclosporine: increased risk of renal toxicity
Insulins, oral hypoglycemics: increased hypoglycemic effect
Methotrexate: increased risk of methotrexate toxicity

Patient monitoring
Watch closely for signs and symptoms of angioedema, anaphylaxis, or other hypersensitivity reactions (including hives, swelling, shortness of breath, and abdominal pain).
- Assess vital signs.
- Monitor fluid intake and output.

Patient teaching
- Tell patient he may crush tablet if he can’t swallow it whole.
- To minimize GI upset, advise patient to take drug with food; eat small, frequent servings of healthy food; and drink plenty of fluids.
- Advise patient to continue taking drug for entire duration prescribed.
- Teach patient to recognize and immediately report signs and symptoms of hypersensitivity reaction and angioedema (hives, swelling, shortness of breath, abdominal pain).
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, strength, and alertness.
- Advise patient not to drink alcohol. Tell him to avoid aspirin, ibuprofen, and over-the-counter preparations (unless prescribed).
- Caution female patient not to take drug, especially during third trimester.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

nadolol
Apo-Nadolol®️️, Corgard,
Novo-Nadolol®️️

Pharmacologic class: Beta-adrenergic blocker (nonselective)
Therapeutic class: Antianginal, antihypertensive
Pregnancy risk category C

FDA BOXED WARNING
- Catecholamine hypersensitivity may occur after drug withdrawal. Angina exacerbation and in some cases, myocardial infarction have followed abrupt withdrawal. When discontinuing long-term nadolol, reduce dosage gradually over 1 to 2 weeks and monitor patient carefully. If angina worsens markedly or acute coronary insufficiency develops, reinstate drug promptly and take other appropriate measures to manage angina. Caution patient not to interrupt or stop therapy without physician’s advice. Because

Canada  UK  Hazardous drug  High alert drug
coronary artery disease is common and may be unrecognized, don’t discontinue drug abruptly, even in patients treated only for hypertension.

**Action**
Blocks stimulation of beta<sub>1</sub>- and beta<sub>2</sub>- adrenergic receptor sites, decreasing cardiac output and thereby slowing heart rate and reducing blood pressure.

**Availability**
*Tablets:* 20 mg, 40 mg, 80 mg, 120 mg, 160 mg

**Indications and dosages**

> Angina pectoris

**Adults:** Initially, 40 mg P.O. daily; may increase by 40 to 80 mg q 3 to 7 days p.r.n., up to a maximum of 240 mg/day

> Hypertension

**Adults:** Initially, 40 mg P.O. daily; may increase by 40 to 80 mg q 7 days p.r.n., up to 320 mg/day

**Dosage adjustment**
- Renal impairment

**Off-label uses**
- Hyperthyroidism
- Migraine headache
- Parkinson’s tremor

**Contraindications**
- Hypersensitivity to drug or other beta-adrenergic blockers
- Pulmonary edema or cardiogenic shock
- Sinus bradycardia or heart block
- Heart failure (unless secondary to tachyarrhythmia treatable with beta blockers)
- Bronchial asthma (including severe chronic obstructive pulmonary disease)

**Precautions**
Use cautiously in:
- renal or hepatic impairment, pulmonary disease, diabetes mellitus, thyrotoxicosis
- history of severe allergic reactions
- elderly patients
- pregnant or breastfeeding patients
- children (safety not established).

**Administration**
- Give with or without food.
- Be aware that drug may be given alone or with diuretic for hypertension.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>5 days</td>
<td>3-4 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: dizziness, fatigue, paresthesia, behavior changes, sedation
CV: bradycardia, peripheral vascular insufficiency (Raynaud’s phenomenon), heart failure
EENT: blurred vision, dry eyes, nasal congestion
GI: nausea, constipation, diarrhea, abdominal discomfort or bloating, indigestion, anorexia
Respiratory: bronchospasm
Skin: rash

**Interactions**

**Drug-drug.** Amphetamines, ephedrine, epinephrine, norepinephrine, phenylephrine, pseudoephedrine: severe vasoconstriction and bradycardia
Antihypertensives, nitrates: additive hypotension
Clonidine: increased hypotension and bradycardia
Digoxin: additive bradycardia
Diltiazem, general anesthetics, phenytoin (I.V.), verapamil: additive myocardial depression
Insulins, oral hypoglycemics: altered glycemic control
Nonsteroidal anti-inflammatory drugs: decreased antihypertensive action

Reactions in **bold** are life-threatening.
**Thyroid hormones:** decreased nadolol efficacy

**Drug-behaviors.** *Acute alcohol ingestion:* additive hypotension

**Cocaine use:** severe vasoconstriction, bradycardia

**Patient monitoring**
- Monitor vital signs and peripheral circulation. Notify prescriber of heart rate below 55 beats/minute.
- Assess for signs and symptoms of heart failure or bronchospasm.

**Patient teaching**
- Advise patient to take drug with meals and a bedtime snack to minimize GI upset.
- Teach patient how to measure pulse and blood pressure; tell him when to notify prescriber.
- Instruct patient to avoid over-the-counter products containing stimulants, such as some cold and flu remedies and nasal decongestants.
- Tell diabetic patient and family that drug may mask hypoglycemia symptoms. Advise patient to monitor urine or blood glucose regularly.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and behaviors mentioned above.

---

**nafarelin acetate**

*Synarel*

**Pharmacologic class:** Gonadotropin-releasing hormone (GnRH)

**Therapeutic class:** Hormone

**Pregnancy risk category X**

---

**Action**
Inhibits secretion of gonadotropin, a luteinizing hormone (LH)-releasing hormone. Initially increases pituitary production of LH and follicle-stimulating hormone (FSH), which ultimately leads to deactivation of testicular and ovarian functions.

**Availability**

*Nasal spray:* 2 mg/ml in 10-ml bottle (200 mcg/spray)

---

**Indications and dosages**

- **Endometriosis**

  - **Adults:** One spray (200 mcg) intranasally in one nostril in morning and one spray in other nostril in evening (400 mcg/day). May increase to one spray in each nostril in morning and evening (800 mcg/day).

- **Central precocious puberty**

  - **Children:** Two sprays in each nostril in morning and evening (1,600 mcg/day). May increase up to 1,800 mcg/day (three sprays in alternating nostrils t.i.d.).

**Contraindications**
- Hypersensitivity to GnRH, its analogs, or sorbitol
- Undiagnosed abnormal vaginal bleeding
- Pregnancy or breastfeeding

**Precautions**
Use cautiously in:
- rhinitis, ovarian cysts, major risk factors for bone density loss (such as chronic alcoholism or chronic corticosteroid use).

**Administration**
- Make sure patient isn’t pregnant before starting therapy.
- For endometriosis, start therapy on day 2 to day 4 of menstrual period.
- If patient needs topical decongestant, wait at least 2 hours after nafarelin dose before giving.
Know that retreatment for endometriosis isn’t recommended.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intranasal</td>
<td>Within 4 wk</td>
<td>3-4 wk</td>
<td>3-6 mo</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** emotional lability, headache, depression, insomnia  
**CV:** chest pain  
**EENT:** nasal irritation, rhinitis  
**GU:** vaginal dryness, bleeding, or discharge; menses cessation; transient breast enlargement; decreased libido  
**Musculoskeletal:** reduced bone density, myalgia  
**Respiratory:** dyspnea  
**Skin:** urticaria, rash, pruritus, acne, oily skin, hirsutism, transient pubic hair increase  
**Other:** weight changes, hot flashes, edema, body odor, hypersensitivity reaction

**Interactions**

**Drug-drug.** *Topical nasal decongestants:* reduced nafarelin absorption

**Patient monitoring**

- Monitor patient for emotional lability or depression.  
- Assess nasal mucosa for erosion.  
- Monitor vital signs. Weigh patient regularly; report edema.  
- Stay alert for adverse hormonal effects, including hot flashes, menses cessation followed by breakthrough bleeding, hirsutism, acne, decreased libido, and vaginal dryness.

**Patient teaching**

- Instruct patient to complete entire course of therapy. Advise her to keep enough of drug on hand to prevent interruption.  
- Inform patient that regular menstruation should cease after 4 to 6 weeks of therapy but that breakthrough bleeding may still occur.

Tell patient ovulation may still occur. Instruct her to use barrier contraception during therapy and to report suspected pregnancy.  
- Caution patient not to breastfeed.  
- Teach patient about adverse hormonal effects. Identify which signs and symptoms to report.  
- Inform patient that drug may cause emotional changes or depression. Advise her to report these to prescriber.  
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

**nafcillin sodium**

**Pharmacologic class:** Penicilllinase-resistant penicillin  
**Therapeutic class:** Anti-infective  
**Pregnancy risk category B**

**Action**

Inhibits cell-wall synthesis during microorganism multiplication; resists inactivation by staphylococcal penicillinase. Bactericidal.

**Availability**

*I.V. infusion (piggyback):* 1 g, 2 g

**Indications and dosages**

- **Systemic infections caused by penicillinase-producing staphylococci**
  - **Adults:** 500 mg I.V. q 4 hours; for more severe infections, 1 g I.V. q 4 hours. Duration depends on type and severity of infection.

**Dosage adjustment**

- **Children**

**Contraindications**

- Hypersensitivity to drug or other penicillins

Reactions in **bold** are life-threatening.
Precautions
Use cautiously in:
- cephalosporin hypersensitivity
- renal disorders, GI distress
- pregnant or breastfeeding patients
- children.

Administration
- Ask patient about penicillin allergy before giving.
- Reconstitute with normal saline solution, dextrose 5% in water (D₅W), dextrose 10% in water, half D₅W/normal saline solution, or half D₅W/lactated Ringer’s solution. Administer over 30 to 60 minutes. Don’t mix with other drugs in same solution.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>15 min</td>
<td>4 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: lethargy, hallucinations, anxiety, depression, twitching, coma, seizures
CV: thrombophlebitis
GI: nausea, vomiting, diarrhea
Hematologic: anemia, bone marrow depression, granulocytopenia
Skin: angioedema
Other: superinfection, vein irritation, hypersensitivity reactions including serum sickness and anaphylaxis

Interactions

Drug-drug. Aminoglycosides: synergistic effects
Cyclosporine: subtherapeutic cyclosporine blood level
Hormonal contraceptives: decreased contraceptive efficacy
Probencid: increased nafcillin blood level
Rifampin: antagonism (dose-dependent)
Warfarin: increased risk of bleeding

Drug-diagnostic tests. Granulocytes, neutrophils, platelets: decreased counts

Drug-herbs. Khat: delayed and reduced nafcillin absorption

Patient monitoring
- Assess for signs and symptoms of hypersensitivity reaction (including anaphylaxis, serum sickness, and angioedema), which may occur several days after therapy begins.
- Monitor neurologic status. Stay alert for seizures, depression, and hallucinations.
- Evaluate CBC with white cell differential.
- In prolonged therapy, assess for superinfection.

Patient teaching
- Instruct patient to complete entire course of therapy even if symptoms disappear.
- Teach patient to recognize and immediately report signs and symptoms of hypersensitivity reactions (including serum sickness and angioedema) as well as bleeding and easy bruising.
- Teach patient about signs and symptoms of superinfection. Instruct him to report these promptly.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects alertness and motor function.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

**nalbuphine hydrochloride**

**Nubain**

**Pharmacologic class:** Opioid agonist-antagonist

**Therapeutic class:** Analgesic, adjunct to anesthesia

**Pregnancy risk category C**
Action
Binds to opiate receptors in CNS, inhibiting ascending pain pathways. This inhibition alters perception of and response to painful stimuli.

Availability
Injection: 10 mg/ml, 20 mg/ml

Indications and dosages
Moderate to severe pain
Adults: 10 mg/70 kg I.V., I.M., or subcutaneously q 3 to 6 hours p.r.n., up to 160 mg/day. Maximum for single dose is 20 mg.

Adjunct to balanced anesthesia
Adults: 0.3 mg to 3 mg/kg I.V. over 10 to 15 minutes, followed by maintenance dose of 0.25 mg to 0.50 mg/kg I.V. in single doses p.r.n.

Contraindications
• Hypersensitivity to drug

Precautions
Use cautiously in:
• increased intracranial pressure, head trauma, myocardial infarction, severe heart disease, respiratory depression, renal or hepatic disease, impaired ventilation, hypothyroidism, adrenal insufficiency, prostatic hypertrophy, emotional instability, alcoholism
• history of substance abuse or dependence
• pregnant or breastfeeding patients
• children.

Administration
Make sure emergency resuscitation equipment and naloxone (antidote) are available before starting therapy.
• For I.M. use, inject deep into large muscle mass; rotate injection sites.
• When giving I.V. for pain, infuse undiluted over 2 to 3 minutes into vein or I.V. line with compatible solution (such as dextrose 5% in water, normal saline solution, or lactated Ringer’s solution).

Route Onset Peak Duration
I.V. 2-3 min 30 min 3-6 hr
I.M. 15 min 1 hr 3-6 hr
Subcut. 15 min Unknown 3-6 hr

Adverse reactions
CNS: dizziness, sedation, headache, vertigo
CV: hypertension, hypotension, tachycardia, bradycardia
EENT: miosis
GI: nausea, vomiting, dry mouth
Respiratory: dyspnea, respiratory depression
Skin: sweating, clammy skin
Other: hypersensitivity reactions including anaphylaxis

Interactions
Drug-drug. CNS depressants (including general anesthetics, MAO inhibitors, sedative-hypnotics, tranquilizers, tricyclic antidepressants): additive CNS effects
Drug-diagnostic tests. Amylase, lipase: increased levels
Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression
Drug-behaviors. Alcohol use: additive CNS and respiratory depression

Patient monitoring
• Monitor vital signs. Watch for respiratory depression and heart rate changes.
• Evaluate patient for CNS changes. Institute safety measures as needed to prevent injury.
Watch for hypersensitivity reactions, including anaphylaxis.

Patient teaching
• Instruct patient to change position slowly and carefully to avoid dizziness from sudden blood pressure decrease.
• Tell patient to avoid CNS depressants (including alcohol, sedative-hypnotics,
and some herbs) for at least 24 hours after taking nalbuphine.
- Advise patient to consult prescriber before taking herbs.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

**naproxen**

**naproxen sodium**

**Pharmacologic class:** Nonsteroidal anti-inflammatory drug (NSAID)

**Therapeutic class:** Nonopioid analgesic, antipyretic, anti-inflammatory

**Pregnancy risk category B** (first and second trimesters), **D** (third trimester)

---

**FDA BOXED WARNING**
- Drug may increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke (which can be fatal). Risk may increase with duration of use. Patients with cardiovascular disease or risk factors for it may be at greater risk.
- Drug increases risk of serious GI adverse events, including bleeding, ulcers, and stomach or intestinal perforation (which can be fatal). These events can occur at any time during use and without warning. Elderly patients are at greater risk.
- Drug is contraindicated for treatment of perioperative pain in setting of coronary artery bypass graft surgery.

---

**Action**
Unknown. Thought to inhibit prostaglandin synthesis.

**Availability**

**naproxen**
Oral suspension: 125 mg/5 ml
Suppositories: 500 mg
Tablets: 125 mg, 250 mg, 375 mg, 500 mg
Tablets (controlled-release): 375 mg, 500 mg
Tablets (delayed-release): 250 mg, 375 mg, 500 mg
Tablets (extended-release): 750 mg

**naproxen sodium**
Caplets, tablets: 220 mg, 275 mg, 550 mg

---

**Indications and dosages**

- Pain; osteoarthritis; ankylosing spondylitis; dysmenorrhea; bursitis; acute tendinitis

**Adults:** 250 to 500 mg (naproxen) P.O. b.i.d. (up to 1.5 g/day); 375 to 500 mg (naproxen delayed-release) P.O. t.i.d.; 250 mg, 375 mg, or 500 mg (naproxen oral suspension) P.O. b.i.d.; 275 to 550 mg (naproxen sodium) P.O. b.i.d. (up to 1.65 g/day); or 750 or 1,000 mg/day (naproxen controlled-release) P.O., not to exceed 1,500 mg/day

**Children:** 10 mg/kg P.O. daily in two divided doses (naproxen only)
Mild to moderate pain; primary
dysmenorrhea

**Adults:** Initially, 500 mg (naproxen) P.O., followed by 250 mg q 6 to 8 hours p.r.n., to a maximum of 1.25 g/day. Or initially, 550 mg (naproxen sodium) P.O., followed by 275 mg q 6 to 8 hours p.r.n., to a maximum of 1,375 mg/day. Or 1,000 mg/day (naproxen controlled-release) P.O., to a maximum of 1,500 mg/day for a limited time; then no more than 1,000 mg/day.

**Gout**

**Adults:** Initially, 750 mg (naproxen) P.O., followed by 250 mg q 8 hours; or initially, 825 mg (naproxen sodium) P.O., followed by 275 mg q 8 hours. Or 1,000 to 1,500 mg (naproxen controlled-release) P.O. once on day 1, followed by 1,000 mg daily.

**Contraindications**
- Hypersensitivity to drug or other NSAIDs
- Active GI bleeding or ulcer disease
- Asthma
- Pregnancy (third trimester)

**Precautions**
Use cautiously in:
- severe cardiovascular, renal, or hepatic disease
- history of ulcer disease
- chronic alcohol use or abuse
- pregnant (first and second trimesters) or breastfeeding patients
- children younger than age 2 (safety not established).

**Administration**
- Give with food or milk to avoid GI upset.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O. (analgesia)</td>
<td>1 hr</td>
<td>2-4 hr</td>
<td>8-12 hr</td>
</tr>
<tr>
<td>P.O. (anti-inflamm.)</td>
<td>14 days</td>
<td>2-4 wk</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- CNS: dizziness, drowsiness, headache, vertigo, light-headedness
- CV: palpitations, tachycardia
- EENT: visual disturbances, tinnitus, auditory disturbances
- GI: nausea, diarrhea, constipation, heartburn, abdominal pain, stomatitis, GI bleeding
- Skin: rash, pruritus, skin eruptions, sweating, photosensitivity
- Other: thirst, edema, allergic reactions including anaphylaxis

**Interactions**
- **Drug-drug.** Acetaminophen (chronic use), cyclosporine: increased risk of adverse renal effects
- Anticoagulants, thrombolytics: increased anticoagulant effect
- Antihypertensives, cefamandole, cefoperazone, cefotetan, diuretics, eptifibatide: decreased response
- Antineoplastics, methotrexate: increased risk of nephrotoxicity
- Aspirin: decreased naproxen efficacy
- Aspirin, corticosteroids, other NSAIDs: additive adverse GI effects
- Clopidogrel, plicamycin, ticlopidine, valproic acid: increased risk of bleeding
- Insulin, oral hypoglycemics: increased risk of hypoglycemia
- Lithium: increased lithium blood level and risk of nephrotoxicity
- Other photosensitizing agents: increased risk of photosensitivity
- Probencid: increased naproxen blood level, increased risk of toxicity

**Drug-diagnostic tests.** Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, blood urea nitrogen, creatinine, lactate dehydrogenase, potassium: increased levels
- **Bleeding time:** prolonged for up to 4 days after therapy ends
- Creatinine clearance, glucose, hematocrit, hemoglobin, leukocytes, platelets: decreased values

Reactions in **bold** are life-threatening.

**Clinical alert**
Urine 5-hydroxy-indoleacetic acid, urine steroids: test interference

**Drug-herbs.** Anise, arnica, chamomile, clove, dong quai, fenugreek, feverfew, garlic, ginger, ginkgo, ginseng, licorice: increased anticoagulant effect, increased risk of bleeding

**Patient monitoring**
- Monitor GI status. Stay alert for signs and symptoms of GI bleeding.
- In long-term use, assess CBC with white cell differential and coagulation studies, and monitor for visual and hearing impairment.
- Monitor cardiovascular status for tachycardia, palpitations, and edema.
- Monitor blood glucose level closely in diabetic patients.

**Patient teaching**
- Tell patient to take medication with food or milk followed by 8 oz of water, and to stay upright for 30 minutes afterward.
- Inform patient that he may crush or break regular tablets but must swallow extended-, delayed-, or controlled-release form whole.
- Tell patient that drug's full therapeutic effect may take up to 2 weeks.
- Caution patient not to exceed recommended dosage.
- Advise patient to use sunscreen to prevent photosensitivity reaction.
- Instruct patient not to take over-the-counter medications unless prescribed.
- Tell patient to consult prescriber before taking herbs.
- Caution pregnant patient not to take drug, especially during third trimester.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

**naratriptan hydrochloride**

**Amerge, Naramig®**

**Pharmacologic class:** Selective 5-hydroxytryptamine$_1$ (5-HT$_1$) agonist

**Therapeutic class:** Vascular headache suppressant, antimigraine drug

**Pregnancy risk category C**

**Action**
Binds with specific 5-HT$_1$ receptors in intracranial blood vessels and sensory trigeminal nerves, leading to vasoconstriction and migraine relief

**Availability**

*Tablets: 1 mg, 2.5 mg*

**Indications and dosages**

> Migraine headache

**Adults:** 1 or 2.5 mg P.O. as single dose; may repeat in 4 hours. Don’t exceed 5 mg in 24 hours; don’t use to treat more than four headaches per month.

**Dosage adjustment**
- Mild to moderate renal or hepatic impairment

**Contraindications**
- Hypersensitivity to drug or its components
- Hemiplegic or basilar headaches
- Severe renal, cardiovascular or hepatic impairment
- History of cerebrovascular or peripheral vascular conditions
- Ischemic bowel disease
- Uncontrolled hypertension
- Use of ergot-type drugs (such as dihydroergotamine) and other 5-HT$_1$ agonists within 24 hours
- MAO inhibitor use within past 14 days

**Canada** **UK** **Hazardous drug** **High alert drug**
Precautions
Use cautiously in:
● mild to moderate renal or hepatic impairment, cardiovascular risk factors
● elderly patients (not recommended)
● pregnant or breastfeeding patients
● children (safety not established).

Administration
● Know that drug does not prevent migraine.
● Give only if patient’s cardiovascular status has been evaluated and determined to be safe, and if first dose can be given under supervision.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30-60 min</td>
<td>2-3 hr</td>
<td>Up to 24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, drowsiness, malaise, fatigue, paresthesia
CV: coronary artery vasospasm, myocardial infarction, ventricular fibrillation or tachycardia
GI: nausea, vomiting
Other: pain or pressure sensation in throat or neck

Interactions
Drug-drug. Ergot-type compounds (dihydroergotamine, methysergide): prolonged vasospastic reaction
Hormonal contraceptives: increased naratriptan blood level and effects
MAO inhibitors: increased systemic exposure to naratriptan, increased risk of adverse reactions
Selective serotonin reuptake inhibitors: weakness, hyperreflexia, incoordination
Sibutramine: serotonin syndrome
Drug-herbs. S-adenosylmethionine (SAM-e), St. John’s wort: increased risk of adverse serotonergic effects
Drug-behaviors. Cigarette smoking: increased naratriptan metabolism

Patient monitoring
● Maintain especially close monitoring in patients with cardiovascular risk factors (such as hypertension, hypercholesterolemia, obesity, diabetes mellitus, cigarette smoking, strong family history), postmenopausal women, and men older than age 40.
● Assess vital signs and ECG.
● Monitor neurologic status closely. Institute safety measures as needed to prevent injury.

Patient teaching
● Tell patient to take at first sign of headache.
● Advise patient to take second dose (if approved) at least 4 hours after first dose if headache has not gone away completely or has returned.
● Caution patient not to take more than two tablets in a 24-hour period.
● Advise patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
● Tell patient to avoid cigarette smoking and to discuss herb use with prescriber.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, herbs, and behaviors mentioned above.

nateglinide
Starlix

Pharmacologic class: Amino acid derivative
Therapeutic class: Hypoglycemic
Pregnancy risk category C

Action
Decreases blood glucose level by stimulating insulin secretion from pancreatic beta cells; interacts with calcium and potassium channels in pancreas.
Availbility
Tablets: 60 mg, 120 mg

**Indications and dosages**

- To decrease glucose levels in type 2 (non-insulin-dependent) diabetes mellitus not adequately controlled by diet and exercise

**Adults:** 120 mg P.O. t.i.d. up to 30 minutes before meals, or 60 mg P.O. t.i.d. if patient is near glycosylated hemoglobin (HbA1c) goal

**Contraindications**

- Hypersensitivity to drug or its components
- Diabetic ketoacidosis
- Type 1 (insulin-dependent) diabetes mellitus

**Precautions**

Use cautiously in:

- renal or hepatic impairment, adrenal or pituitary insufficiency
- elderly or malnourished patients
- pregnant or breastfeeding patients.

**Administration**

- Give 30 minutes before meals. If meal is missed, don’t give dose.
- Know that drug may be given alone or with metformin.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>Within 1 hr</td>
<td>4 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- CNS: dizziness
- GI: diarrhea
- Metabolic: hypoglycemia
- Musculoskeletal: back pain, joint pain
- Respiratory: upper respiratory tract infection, bronchitis, coughing
- Other: flulike symptoms, trauma

**Interactions**

- Drug-drug. Beta-adrenergic blockers, MAO inhibitors, nonsteroidal anti-inflammatory drugs, salicylates: increased hypoglycemic effect
- Corticosteroids, sympathomimetics, thiazides, thyroid products: reduced hypoglycemic effect

**Drug-diagnostic tests.** Glucose: decreased level

**Patient monitoring**

- Monitor blood glucose and HbA1c levels.
- Assess pulmonary status for bronchitis, upper respiratory infection, and flulike signs and symptoms.
- Monitor musculoskeletal status. Check for back pain and arthropathy.
- Note GI complaints, and identify nutritional deficiencies.

**Patient teaching**

- Instruct patient to take dose up to 30 minutes before each main meal.
- Advise patient not to skip a meal. If he does, tell him to also skip accompanying nateglinide dose, to prevent hypoglycemia.
- Teach patient how to monitor blood and urine for glucose and ketones, as prescribed.
- Instruct patient to report adverse CNS effects and signs and symptoms of respiratory infection.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects sensation and balance.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**nebivolol**

**Bystolic**

**Pharmacologic class:** Beta-adrenergic blocker

**Therapeutic class:** Antihypertensive

**Pregnancy risk category C**
Action
Not fully known. The following factors may be involved: decreased heart rate, reduced myocardial contractility, decreased tonic sympathetic outflow to periphery from cerebrovasomotor centers, suppressed renin activity, vasodila-
tion, and decreased peripheral vascular resistance.

Availability
Tablets: 2.5 mg, 5 mg, 10 mg

Indications and dosages
➣ Hypertension
Adults: Individualized; 5 mg P.O. daily. If patient requires further blood pressure reduction, dosage may be increased at 2-week intervals up to 40 mg P.O. daily.

Dosage adjustment
● Moderate hepatic impairment or severe renal impairment (creatinine clearance less than 30 ml/minute)

Contraindications
● Hypersensitivity to drug or its components
● Severe bradycardia, heart block greater than first degree, cardiogenic shock, decompensated cardiac failure, sick sinus syndrome (unless permanent pacemaker is in place)
● Severe hepatic impairment

Precautions
Use cautiously in:
● moderate hepatic impairment
● severe renal impairment
● congestive heart failure (CHF)
● peripheral vascular disease
● bronchospastic disease (use not recommended)
● diabetic patients receiving hypoglycemic drugs
● known or suspected pheochromocytoma
● concurrent use of myocardial depressants, AV conduction inhibitors (such as cardiac glycosides and certain calcium antagonists), or antiarrhythmics (such as disopyramide)
● perioperative use with anesthetics that depress myocardial function (such as ether, cyclopropane, or trichloroethylene)
● pregnant patients
● breastfeeding patients (use not recommended)
● children (safety and efficacy not established).

Administration
● Give with or without food.
● Be aware that drug may be used alone or in combination with other antihypertensives.
● Know that drug shouldn’t be combined with other beta blockers. Closely monitor patients receiving catecholamine-depleting drugs (such as reserpine or guanethidine), because added beta blockade may decrease sympathetic activity excessively. In patients receiving nebivolol with clonidine, discontinue nebivolol for several days before gradually tapering clonidine.

Don’t withdraw drug abruptly; taper over 1 to 2 weeks when possible. Drug may mask signs and symptoms of hyperthyroidism, such as tachycardia; abrupt withdrawal may exacerbate signs and symptoms of hyperthyroidism or may trigger thyroid storm.

Route Onset Peak Duration
P.O. Unknown 1.5 to 4 hr Unknown

Adverse reactions
CNS: headache, fatigue, dizziness, insomnia
CV: bradycardia
GI: nausea, diarrhea
Respiratory: dyspnea
Skin: rash
Other: chest pain, peripheral edema

Interactions
Drug-drug. Antiarrhythmics (such as disopyramide), myocardial depressants

Reactions in bold are life-threatening.
or AV conduction inhibitors (such as cardiac glycosides and certain calcium antagonists): increased risk of slowed AV conduction and bradycardia

Cimetidine: increased d-nebivolol (active isomer) blood level

CYP2D6 inhibitors (such as fluoxetine, paroxetine, propafenone, quinidine): increased d-nebivolol blood level

Other beta-adrenergic blockers: excessive reduction of sympathetic activity

Sildenafil: decreased effect of sildenafil

Drug-diagnostic tests. Blood urea nitrogen, triglycerides, uric acid: increased levels

Cholesterol, high-density lipoproteins, platelet count: decreased

Patient monitoring

Be aware that beta blockade may further depress myocardial contractility and trigger more severe heart failure in patients with compensated CHF. If CHF worsens, consider discontinuing drug.

During perioperative use, closely monitor patients receiving anesthetics that depress myocardial function, such as ether, cyclopropane, or trichloroethylene. Also, know that if drug is withdrawn before major surgery, the heart’s impaired ability to respond to reflex adrenergic stimuli may increase risks of general anesthesia and surgery.

Because of significant negative inotropic and chronotropic effects in patients treated with verapamil- or diltiazem-type beta blockers or calcium channel blockers, use caution in patients treated concomitantly with these agents; monitor ECG and blood pressure.

Patient teaching

Tell patient drug may be taken with or without food.

Advise patient not to stop taking drug unless prescriber approves.

Instruct patient to immediately report difficulty breathing, increasing shortness of breath, excessively slow pulse, or weight gain.

Caution patient to avoid driving and other hazardous activities until drug’s effects on alertness are known.

Advise breastfeeding patient not to breastfeed during therapy.

As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

nefazodone hydrochloride

Pharmacologic class: Phenylpiperazine

Therapeutic class: Antidepressant

Pregnancy risk category C

FDA BOXED WARNING

Drug may increase risk of suicidal thinking and behavior in children and adolescents with major depressive disorder and other psychiatric disorders. Risk must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family and caregivers to observe patient closely and communicate with prescriber as needed.

Drug isn’t approved for use in pediatric patients.

Action

Potentiates effects of norepinephrine and serotonin by blocking synaptic reuptake in nerve cells and disrupting alpha_1-adrenergic receptors

Availability

Tablets: 50 mg, 100 mg, 150 mg, 200 mg, 250 mg
Indications and dosages

Major depression

Adults: Initially, 100 mg P.O. b.i.d. May increase weekly up to 600 mg/day in two divided doses.

Dosage adjustment
- Elderly patients

Contraindications
- Hypersensitivity to drug, its components, or other phenylpiperazines
- Active hepatic disease, baseline transaminase elevation, or previous drug withdrawal necessitated by hepatic damage
- MAO inhibitor use within past 14 days
- Concurrent cisapride (not available in U.S.), pimozide, carbamazepine, or triazolam therapy

Precautions
Use cautiously in:
- cardiovascular or cerebrovascular disease
- history of suicide attempt, drug abuse, or mania
- elderly patients
- pregnant or breastfeeding patients
- children younger than age 18 (safety not established).

Administration
- Give with food or milk if GI upset occurs.
- Know that tablets may be crushed.
- Don’t give concurrently with cisapride, pimozide, carbamazepine, or triazolam.
- Don’t give within 14 days of MAO inhibitors.

Route Onset Peak Duration
P.O. Days-wks Few wks Unknown

Adverse reactions
CNS: dizziness, asthenia, agitation, light-headedness, insomnia, drowsiness, confusion, weakness, headache, impaired memory, poor concentration, paresthesia, psychomotor retardation, tremor, suicidal behavior or ideation (especially in child or adolescent)
CV: hypotension, orthostatic hypotension, peripheral edema
EENT: abnormal or blurred vision, eye pain, tinnitus, pharyngitis
GI: nausea, vomiting, diarrhea, constipation, dyspepsia, dry mouth
GU: urinary frequency or retention, urinary tract infection
Hepatic: hepatotoxicity, hepatic failure
Respiratory: increased cough
Skin: rash, pruritus
Other: increased appetite, thirst, infection, chills, fever, flulike symptoms

Interactions
Drug-drug. Alprazolam, triazolam: increased blood level and effects of these drugs
Antihypertensives, nitrates: additive hypotension
Carbamazepine, cisapride, pimozide: increased nefazodone blood level, leading to toxicity
CNS depressants (including antihistamines, opioids, sedative-hypnotics): additive CNS depression
Digoxin: increased digoxin blood level
HMG-CoA reductase inhibitors: increased risk of myopathy
MAO inhibitors: potentially fatal reactions (hyperpyrexia, excitation, seizures, delirium, coma)

Drug-diagnostic tests. CBC, cholesterol, glucose, hematocrit: decreased levels
Hepatic enzymes: increased levels

Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression
S-adenosylmethionine (SAM-e), St. John’s wort: increased risk of adverse serotonergic effects, including serotonin syndrome

Reactions in bold are life-threatening.
Drug-behaviors. Acute alcohol ingestion: additive hypotension
Alcohol use: increased CNS depression

Patient monitoring
- Monitor vital signs with patient lying down, sitting, and standing. Notify prescriber if blood pressure drops 20 mm Hg.
- Assess CBC.
- Monitor liver function tests frequently. Notify prescriber of abnormal results.
- Closely monitor neurologic status.
- Evaluate patient for withdrawal symptoms (which may occur if therapy stops abruptly).
- Monitor closely for increasing depression and suicidal ideation (especially in child or adolescent).

Patient teaching
- Advise patient to take with food or milk to minimize GI upset.
- Tell patient to crush drug if he can’t swallow it whole.
- Inform patient that therapeutic response may take up to 4 weeks. Encourage him to keep taking drug as prescribed.
- Tell patient drug may cause adverse CNS effects. Advise him to report significant mood changes (especially depression or suicidal thoughts). Caution parent to report these problems in child or adolescent.
- Instruct patient to immediately report unusual tiredness, yellowing of skin or eyes, nausea, or anorexia.
- Instruct patient to rise slowly and carefully, to avoid dizziness from temporary blood pressure drop.
- Tell patient to avoid alcohol and to consult prescriber before taking herbs.
- Instruct patient not to stop taking drug abruptly. Dosage must be tapered.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

nelarabine
Arranon, Atriace
Pharmacologic class: Antimetabolite
Therapeutic class: Antineoplastic
Pregnancy risk category D

FDA BOXED WARNING
- Administer I.V. only.
- Give under supervision of physician experienced in use of cancer chemotherapy.
- Drug has caused severe neurologic events, including severe somnolence, seizures, and peripheral neuropathy. Demyelination-associated events also have occurred. Drug discontinuation doesn’t always lead to full recovery from these events. Monitor patient closely for neurologic changes; discontinue drug for serious neurologic events.

Action
Inhibits DNA synthesis in leukemic blasts, leading to cell death

Availability
Solution for injection: 250 mg/50 ml

Indications and dosages
T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in patients whose disease hasn’t responded to at least two chemotherapy regimens or who’ve relapsed after such therapy
Adults: 1,500 mg/m² I.V. undiluted over 2 hours on days 1, 3, and 5; repeat every 21 days. Continue therapy until disease progresses, unacceptable
toxicity occurs, patient becomes eligible for bone marrow transplant, or patient no longer benefits from therapy. **Children:** 650 mg/m² I.V. undiluted over 1 hour daily for 5 consecutive days; repeat every 21 days. Continue therapy until disease progresses, unacceptable toxicity occurs, patient becomes eligible for bone marrow transplant, or patient no longer benefits from therapy.

**Dosage adjustment**
- Neurologic or hematologic toxicity

**Contraindications**
- Hypersensitivity to drug or its components

**Precautions**
Use cautiously in:
- renal or hepatic dysfunction
- patients undergoing concurrent intrathecal chemotherapy
- patients previously treated with intrathecal chemotherapy or craniospinal irradiation
- concurrent administration of live vaccines (immunocompromised patients)
- elderly patients
- pregnant or breastfeeding patients.

**Administration**
- Administer undiluted.
- Infuse over 2 hours in adults or over 1 hour in children.
- In patients at risk for tumor lysis syndrome, take measures to prevent hyperuricemia (such as hydration, urine alkalinization, and allopurinol prophylaxis).
- Discontinue drug if serious neurologic adverse reactions occur.

**Route Onset Peak Duration**
| I.V. | Unknown | End of infusion | Unknown |

**Adverse reactions**
**CNS:** confusional state, insomnia, depression, headache, peripheral neuropathy, somnolence, paresthesia, hypoesthesia, fine motor dysfunction, neurologic disorder, tremor, ataxia, abnormal gait, dizziness, amnesia, balance disorder, sensory loss, demyelination, asthenia, fatigue, rigors, decreased level of consciousness, **seizures, cerebral hemorrhage, coma**
**CV:** tachycardia, chest pain, hypotension
**EENT:** blurred vision, epistaxis, sinusitis
**GI:** nausea, vomiting, diarrea, constipation, abdominal pain, abdominal distention, stomatitis, anorexia
**Hematologic:** anemia, **neutropenia, thrombocytopenia, leukopenia**
**Metabolic:** dehydration
**Musculoskeletal:** myalgia, arthralgia, back pain, muscle weakness, extremity pain
**Respiratory:** pneumonia, cough, dyspnea, exertional dyspnea, wheezing, pleural effusion
**Skin:** petechiae
**Other:** abnormal taste, infection, fever, edema, peripheral edema, pain, non-cardiac chest pain

**Interactions**
**Drug-drug.** Pentostatin: decreased nelarabine efficacy
**Drug-diagnostic tests.** Bilirubin, serum creatinine, transaminases: increased Blood albumin, CBC, calcium, glucose, magnesium, platelets, potassium: decreased

**Patient monitoring**
- Watch closely for neurologic events, such as somnolence, confusion, seizures, ataxia, motor incoordination, and peripheral neuropathy (which may not subside even after therapy ends).
- Know that previous craniospinal irradiation or current or previous intrathecal chemotherapy may increase patient’s risk of adverse neurologic events.
- Closely monitor patients with hepatic or renal dysfunction for adverse reactions.
- Monitor CBC regularly.

Reactions in **bold** are life-threatening.  

 cref
Patient teaching
- Instruct patient or caregiver to read patient information leaflet thoroughly.
- Urge patient or caregiver to immediately report neurologic symptoms, such as extreme sleepiness, confusion, seizures, unsteadiness or weakness on walking, difficulty with tasks such as buttoning clothing, and numbness and tingling in fingers, hands, or feet.
- Tell patient to immediately report easy bruising, bleeding, fever, or signs or symptoms of infection.
- Inform patient that he’ll need to undergo frequent blood tests.
- Instruct patient to avoid live virus vaccines.
- Caution patient to avoid driving and other hazardous activities until drug effects are known.
- Urge female with childbearing potential to avoid pregnancy and breastfeeding during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Availability
* Oral powder: 50 mg/1 g powder (1 g powder/level scoopful)
* Tablets: 250 mg, 625 mg

Indications and dosages
- HIV infection
  - Adults and children older than age 13: 750 mg P.O. t.i.d. or 1,250 mg b.i.d., given with other antiretrovirals
  - Children ages 2 to 13: 20 to 30 mg/kg P.O. t.i.d., given with a meal or light snack

Contraindications
- Hypersensitivity to drug or its components
- Concurrent use of astemizole, cisapride (not available in U.S.), amiodarone, dihydroergotamine, ergotamine, midazolam, quinidine, rifampin, terfenadine, or triazolam

Precautions
- Use cautiously in:
  - hemophilia, diabetes mellitus, hepatic impairment
  - phenylketonuria (oral powder contains phenylalanine)
  - breastfeeding patients.

Administration
- Give tablets with food.
- For adult who can’t swallow tablets whole, crush and mix in food or dissolve in small amount of water. Have patient consume mixture immediately, or refrigerate for up to 6 hours.
- For child who can’t swallow tablets, mix oral powder with small amount of water, formula, or milk. Have child consume mixture immediately, or refrigerate for up to 6 hours.
- Don’t mix powder with water in its original container.
- Don’t mix powder with acidic juice (combination produces bitter taste).
- Don’t give concurrently with amiodarone, astemizole, cisapride, nelfinavir mesylate

Viracept
Pharmacologic class: Protease inhibitor
Therapeutic class: Antiretroviral
Pregnancy risk category B

Action
Inhibits action of human immunodeficiency virus (HIV) protease and prevents cleavage of viral polyproteins, resulting in production of immature, noninfectious virus
dihydroergotamine, ergotamine, midazolam, quinidine, rifampin, terfenadine, or triazolam.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>2-4 hr</td>
<td>8 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: anxiety, depression, dizziness, drowsiness, emotional lability, headache, hyperkinesia, insomnia, malaise, migraine headache, sleep disorders, weakness, myasthenia, paresthesia, suicidal ideation, seizures

EENT: acute iritis, rhinitis, sinusitis, pharyngitis

GI: nausea, diarrhea, abdominal pain, flatulence

GU: nephrolithiasis, sexual dysfunction

Hematologic: anemia, leukopenia, thrombocytopenia

Metabolic: dehydration, hyperuricemia, hyperglycemia

Musculoskeletal: joint pain, arthritis, back pain, myalgia, myopathy

Respiratory: dyspnea, bronchospasm

Skin: pruritus, rash, sweating, fungal dermatitis, folliculitis, urticaria

Other: fever, body fat redistribution, allergic reactions

**Interactions**

Drug-drug. Amiodarone, dihydroergotamine, ergotamine, midazolam, quinidine, triazolam: excessive sedation, vasodilation, serious arrhythmias

Carbamazepine, phenobarbital, phenytoin, rifampin: decreased nelfinavir blood level and efficacy

Hormonal contraceptives: decreased contraceptive blood level and efficacy

Rifabutin: decreased rifabutin metabolism and effects

Drug-diagnostic tests. Lipids: increased levels

Drug-food. Most foods: enhanced drug absorption

Drug-herbs. St. John’s wort: decreased nelfinavir blood level and efficacy

**Patient monitoring**

⚠ Watch for signs and symptoms of depression and suicidal ideation.

- Evaluate neurologic status closely, particularly for seizures and sensorimotor dysfunction.
- Assess CBC, lipid panel, uric acid level, and HIV-specific tests.
- Watch for secondary infections, particularly fungal and EENT infections.

**Patient teaching**

- Advise patient to take with a meal or snack. Inform him that he may mix oral powder with nonacidic fluids.
- Tell patient he may take missed dose up to 1 hour before next scheduled dose.

⚠ Instruct patient to report depression or suicidal thoughts.

- Tell patient that drug may predispose him to other infections, especially fungal and EENT infections. Advise him to avoid crowds and to wash hands often and thoroughly.
- Tell patient with phenylketonuria (or caregiver) that powder contains phenylalanine.
- Instruct female patient to use reliable barrier contraception.
- Advise female patient not to breastfeed, because breast milk may transfer HIV to infant.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, strength, and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

Reactions in **bold** are life-threatening.
neomycin sulfate
Neo-Fradin, Nivemycin

**Pharmacologic class:** Aminoglycoside  
**Therapeutic class:** Anti-infective  
**Pregnancy risk category D**

**FDA BOXED WARNING**
- Systemic absorption follows oral use and may lead to toxic reactions. Observe patient closely for indications of toxicity. Neurotoxicity (including oto-toxicity) and nephrotoxicity have occurred, even at recommended doses. Perform serial, vestibular, and audiometric tests as well as renal function tests, especially in high-risk patients. Risk of nephrotoxicity and ototoxicity is greater in patients with renal impairment. Ototoxicity may be delayed, and patients developing cochlear damage won’t have symptoms during therapy; total or partial deafness may occur long after drug is stopped.
- Neuromuscular blockage and respiratory paralysis may follow oral use. Consider these risks, especially to patients receiving anesthetics or neuromuscular blockers (such as tubocurarine, succinylcholine, and decamethonium) and those receiving massive transfusions of citrated anticoagulated blood. If blockage occurs, calcium salts may reverse these phenomena, but patient may need mechanical respiratory assistance.
- Avoid concurrent or sequential systemic, oral, or topical use of other aminoglycosides or neurotoxic drugs, as toxicity may be additive.
- Advanced age and dehydration increase risk of toxicity.
- Avoid giving drug concurrently with potent diuretics, as some diuretics are ototoxic. Also, I.V. diuretics may enhance neomycin toxicity by altering its blood and tissue levels.

**Action**
Interferes with bacterial protein synthesis by binding to 30S ribosomal subunit, causing misreading of genetic code. Inaccurate peptide sequence then forms in protein chain, causing bacterial death.

**Availability**
- **Ointment:** 0.5%
- **Oral solution:** 125 mg/5 ml
- **Tablets:** 500 mg

**Indications and dosages**
- **Preoperative intestinal antisepsis**
  - **Adults:** 1 g P.O. q hour for four doses, then 1 g q 4 hours for 24 hours or 1 g at 19 hours, 18 hours, and 9 hours before surgery
- **Hepatic encephalopathy**
  - **Adults:** 4 to 12 g/day P.O. in divided doses
- **Superficial bacterial infections**
  - **Adults:** Apply ointment topically one to five times daily.

**Contraindications**
- Hypersensitivity to drug or other aminoglycosides
- Intestinal obstruction

**Precautions**
Use cautiously in:
- renal impairment, neuromuscular diseases (such as myasthenia gravis), hearing impairment
- obese patients
- elderly patients
- pregnant or breastfeeding patients
- children under age 18 (safety not established).

**Administration**
- Give preoperative dose before bowel surgery, after cathartic administration, as ordered.
neostigmine 813

Adverse reactions
CNS: neuromuscular blockade
EENT: ototoxicity (with prolonged, high-dose use)
GI: nausea, vomiting, diarrhea, malabsorption syndrome
GU: nephrotoxicity (with prolonged, high-dose use)
Other: superinfection

Interactions
Drug-drug. Acyclovir, amphotericin B, cephalosporin, cisplatin, other aminoglycosides, vancomycin: increased risk of ototoxicity and nephrotoxicity
Digoxin: decreased digoxin absorption
Dimenhydrinate: masking of ototoxicity symptoms
Oral anticoagulants: increased anticoagulant effect
Potent loop diuretics: increased risk of ototoxicity

Patient monitoring
● Assess for neuromuscular blockade, ototoxicity, and nephrotoxicity.
● Monitor kidney function tests.

Patient teaching
● Instruct patient to drink plenty of water.
● Tell patient to complete full course of therapy.
● Inform patient that drug may cause muscle weakness.
● Instruct patient to report hearing problems and change in urination pattern.
● Caution patient to avoid driving and other hazardous activities until he knows how drug affects neuromuscular status.
● Tell patient he’ll undergo frequent blood testing during therapy.

● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

neostigmine bromide
Prostigmin

neostigmine methylsulfate
PMS-Neostigmine Methylsulfate®, Prostigmin

Pharmacologic class: Anticholinesterase
Therapeutic class: Muscle stimulant
Pregnancy risk category C

Action
Inhibits enzyme acetylcholinesterase, leading to increased acetylcholine concentration at synapse and prolonged acetylcholine effects. Exerts direct cholinomimetic effect on skeletal muscle.

Availability
Injection (methylsulfate): 2 mg/ml, 1 mg/ml, 0.5 mg/ml, 0.25 mg/ml
Tablets (bromide): 15 mg

Indications and dosages
➤ Myasthenia gravis
Adults: 15 mg/day P.O.; may increase p.r.n. up to 375 mg/day; average dosage is 150 mg/day. Or 1 ml of 1:2,000 solution (0.5 mg) subcutaneously or I.M. based on response and tolerance.
➤ Postoperative abdominal distention and bladder atony
Adults: 0.5 to 1 mg I.M. or subcutaneously. If given for urinary retention and no response occurs within 1 hour, catheterize patient as ordered and repeat dose q 3 hours for five doses.

Reactions in bold are life-threatening.
Antidote for nondepolarizing neuromuscular blockers

**Adults:** 0.5 to 2.5 mg I.V.; repeat p.r.n. up to 5 mg. Precede initial dose with 0.6 to 1.2 mg atropine sulfate I.V., as ordered.

**Contraindications**
- Hypersensitivity to cholinergics or bromide
- Mechanical obstruction of GI or urinary tract
- Peritonitis

**Precautions**
Use cautiously in:
- asthma, peptic ulcer, bradycardia, arrhythmias, recent coronary occlusion, vagotonia, hyperthyroidism, seizure disorder
- pregnant or breastfeeding patients.

**Administration**
- Before giving, ensure that atropine sulfate is available to treat cholinergic crisis.
- Know that atropine may be combined with usual neostigmine dose to decrease risk of adverse reactions.
- Give oral form 1 hour before or 2 hours after a meal.
- Administer I.V. dose undiluted directly into vein or I.V. line. Give 0.5-mg dose slowly over 1 minute.
- Keep resuscitation equipment nearby.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>45-75 min</td>
<td>1-2 hr</td>
<td>2-4 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>4-8 min</td>
<td>1-2 hr</td>
<td>2-4 hr</td>
</tr>
<tr>
<td>I.M., subcut.</td>
<td>20-30 min</td>
<td>1-2 hr</td>
<td>2-4 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- **CNS:** dizziness, headache, drowsiness, asthenia, loss of consciousness
- **CV:** hypotension, tachycardia, bradycardia, atrioventricular (AV) block, cardiac arrest
- **EENT:** vision changes, lacrimation, miosis
- **GI:** nausea, vomiting, diarrhea, abdominal cramping, flatulence, increased peristalsis
- **GU:** urinary frequency
- **Musculoskeletal:** muscle cramps, spasms, and fasciculations; joint pain
- **Respiratory:** dyspnea, bronchospasm, respiratory depression, respiratory arrest, laryngospasm
- **Skin:** rash, urticaria, flushing
- **Other:** anaphylaxis

**Interactions**
- **Drug-drug.** Aminoglycosides, anticholinergics, atropine, corticosteroids, local and general anesthetics: reversal of anticholinergic effects
- Cholinergics: additive toxicity
- Kanamycin, neomycin, streptomycin: increased neuromuscular blockade
- Succinylcholine: potentiation of neuromuscular blockade, prolonged respiratory depression

**Patient monitoring**
- Monitor vital signs. Assess patient for hypotension, bradycardia or tachycardia, AV block, and evidence of impending cardiac arrest.
- Evaluate respiratory and neurologic status.

**Patient teaching**
- Instruct patient to take tablets 1 hour before or 2 hours after meals.
- Tell patient drug may alter his respiratory and cardiac status. Teach him to recognize and immediately report warning signs.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, muscle function, and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.
nesiritide
Natrecor

**Pharmacologic class:** Human B-type natriuretic peptide
**Therapeutic class:** Vasodilator
**Pregnancy risk category C**

**Action**
Binds to receptors on vascular smooth muscle and endothelial cells, causing smooth muscle relaxation and vasodilation. As a result, systemic and pulmonary pressures decrease and diuresis occurs.

**Availability**
*Injection:* 1.5 mg in single-use vials

**Indications and dosages**

> Acutely decompensated heart failure in patients who have dyspnea at rest or with minimal activity

**Adults:** 2 mcg/kg I.V. bolus, followed by continuous I.V. infusion of 0.01 mcg/kg/minute

**Contraindications**
- Hypersensitivity to drug or its components
- Systolic pressure below 90 mm Hg
- Primary therapy for cardiogenic shock

**Precautions**
Use cautiously in:
- restrictive or obstructive cardiomyopathy, constrictive pericarditis, pericardial tamponade, renal dysfunction, hypotension
- pregnant or breastfeeding patients.

**Administration**

♫ Know that nesiritide is a high-alert drug.
- For I.V. use, prime tubing before connecting to patient. Withdraw bolus and infuse over 60 seconds into I.V. port of tubing. Follow immediately with constant infusion delivering 0.01 mcg/kg/minute.
- Know that drug should be mixed and infused in dextrose 5% in water, normal saline solution, or dextrose in half-normal saline solution.
- Don’t mix with other drug solutions. Always administer through separate line.
- Know that nesiritide therapy beyond 48 hours has not been studied.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>15 min</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: dizziness, headache, insomnia, anxiety
CV: hypotension, angina pectoris, bradycardia, ventricular extrasystole, ventricular tachycardia
GI: nausea, vomiting, abdominal pain
Musculoskeletal: leg cramps, back pain
Respiratory: cough, hemoptysis, apnea
Other: injection site reactions

**Interactions**

Drug-drug. **Angiotensin-converting enzyme inhibitors, nitrates:** increased hypotension

*Bumetanide, enalaprilat, ethacrylate sodium, furosemide, heparin, hydralazine, insulin:* physical and chemical incompatibility with nesiritide

Drug-diagnostic tests. **Hematocrit, hemoglobin:** decreased values

**Patient monitoring**

- Monitor vital signs and pulmonary artery wedge pressure continuously during and for several hours after infusion.
- Assess cardiovascular status closely.

**Patient teaching**

♫ Tell patient he’ll be monitored closely during and for several hours after infusion.

Reactions in bold are life-threatening.
Inform patient that drug may cause serious adverse effects. Reassure him that he’ll receive appropriate interventions to relieve symptoms.

Instruct patient to report chest pain, dizziness, palpitations, and other uncomfortable symptoms.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Action
Inhibits human immunodeficiency virus (HIV) nonnucleoside reverse transcriptase by binding directly to reverse transcriptase and blocking RNA-dependent and DNA-dependent polymerase activity.

Availability
Oral suspension: 50 mg/5 ml
Tablets: 200 mg

Indications and dosages
➣ Treatment of HIV-1 infection
  Adults: 200 mg P.O. daily for 14 days, then 200 mg P.O. b.i.d., given in combination with other antiretrovirals.
  Children ages 15 days and older: 150 mg/m² P.O. once daily for 14 days, followed by 150 mg/m² b.i.d. thereafter. Total daily dosage shouldn’t exceed 400 mg for any patient.

Dosage adjustment
• Hepatic impairment
• Chronic hemodialysis

Off-label uses
• Prophylaxis of maternal-fetal HIV transmission

Contraindications
• Hypersensitivity to drug or its components

Precautions
Use cautiously in:
• impaired renal or hepatic function
• pregnant or breastfeeding patients
• children.
Administration

- Be aware that drug should be given alone for first 14 days to reduce incidence of rash.
- Give with or without food.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>4 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: paresthesia, headache, malaise, fatigue
GI: nausea, diarrhea, abdominal pain
Hematologic: agranulocytosis
Hepatic: hepatitis, hepatotoxicity, hepatic failure
Musculoskeletal: myalgia, pain
Skin: rash, blistering, toxic epidermal necrolysis, Stevens-Johnson syndrome
Other: fever

Interactions

Drug-drug. Antiarrhythmics, antifungals, calcium channel blockers, cancer chemotherapy, ergot alkaloids, immunosuppressants, motility agents, opiate agonists: possible decreased plasma concentrations of these drugs
Anticoagulants: possible increased or decreased anticoagulant plasma concentrations
Clarithromycin, efavirenz, indinavir, ketoconazole, methadone: decreased activity of these drugs
Ethinyl estradiol, norethindrone: decreased contraceptive plasma levels
Fluconazole: increased nevirapine level
Lopinavir/ritonavir: decreased lopinavir activity
Nelfinavir: decreased nelfinavir active metabolite, minimum nelfinavir concentration
Rifabutin: increased rifabutin level

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, bilirubin, gamma-glutamyltransferase: increased levels
Hemoglobin, neutrophils: decreased levels

Drug-herbs. St. John’s wort: decreased nevirapine blood level

Patient monitoring

- Check closely for rash (which may be first sign of Stevens-Johnson syndrome), especially during first 6 months of therapy.
- Monitor patient’s weight, temperature, and chest X-ray periodically.
- Assess patient’s appetite and energy and physical activity levels.
- Monitor liver function tests and CBC with white cell differential.

Patient teaching

- Tell patient he may take with or without food.
- Instruct patient to take missed dose as soon as he remembers. But if it’s almost time for next dose, tell him to skip missed dose. Caution him not to double the dose.
- Inform female patient that hormonal contraceptives, implants, or shots may be ineffective during nevirapine therapy. Urge her to use alternative birth-control method.
- Teach patient to recognize and immediately report rash, easy bruising or bleeding, and signs and symptoms of hepatotoxicity.
- Inform patient that nevirapine won’t cure HIV or prevent its transmission.
- Caution female not to breastfeed, because breast milk may transfer HIV to infant.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.
nicardipine
Cardene, Cardene IV, Cardene SR

**Pharmacologic class:** Calcium channel blocker  
**Therapeutic class:** Antianginal, antihypertensive  
**Pregnancy risk category C**

**Action**  
Inhibits calcium transport into myocardial and vascular smooth muscle cells, causing cardiac output and myocardial contractions to decrease

**Availability**  
Capsules: 20 mg, 30 mg  
Capsules (sustained-release): 30 mg, 45 mg, 60 mg  
Injection: 2.5 mg/ml in 10-ml ampules

**Indications and dosages**

- **FP** Chronic stable angina, given alone or with beta-adrenergic blockers  
  **Adults:** Titrate dosage individually, starting with 20 to 40 mg P.O. (immediate-release) t.i.d. Wait at least 3 days before increasing dosage.

- **FP** Hypertension, given alone or with other antihypertensives  
  **Adults:** Titrate dosage individually, starting with 20 mg P.O. (immediate-release) t.i.d. Wait at least 3 days before increasing dosage. Dosage range is 20 to 40 mg P.O. t.i.d. Patient may be switched to sustained-release capsules at nearest equivalent daily dosage of immediate-release capsules, starting with 30 mg P.O. b.i.d. Effective range is 30 to 60 mg/day.

- **FP** Short-term treatment of hypertension when oral therapy isn’t feasible or desirable  
  **Adults:** Continuous I.V. infusion of 0.5 mg/hour (equal to 20 mg P.O. q 8 hours), or 1.2 mg/hour (equal to 30 mg P.O. q 8 hours), or 2.2 mg/hour (equal to 40 mg P.O. q 8 hours)

**Off-label uses**
- Raynaud’s disease  
- Heart failure  
- Migraine

**Contraindications**
- Hypersensitivity to drug  
- Advanced aortic stenosis

**Precautions**

- Use cautiously in:  
  - hepatic or mild renal impairment  
  - hypotension, heart failure, significant left ventricular dysfunction  
  - pheochromocytoma  
  - pregnant or breastfeeding patients (safety not established)  
  - children younger than age 18 (safety not established).

**Administration**

- **FP** Give immediate-release capsules without regard to meals; if GI upset occurs, give with meals. Don’t give with grapefruit or grapefruit juice.

- **FP** Don’t open, crush, break, or let patient chew sustained-release capsules. Give with meals, but not with high-fat meals, grapefruit, or grapefruit juice.

- **FP** For I.V. use, dilute each 25-mg ampule with 240 ml of compatible I.V. fluid (such as dextrose 5% in water, normal saline solution, dextrose 5% with normal saline solution, or half-normal saline solution) to a concentration of 0.1 mg/ml.

- **FP** Don’t dilute with sodium bicarbonate 5% or lactated Ringer’s injection (incompatible).

- **FP** Don’t mix with furosemide, heparin, or thiopental.

- **FP** Give by slow I.V. infusion. Titrate dosage to blood pressure response.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>20 min</td>
<td>0.5-2 hr</td>
<td>8 hr</td>
</tr>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>12 hr</td>
</tr>
<tr>
<td>(sustained)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I.V.</td>
<td>Few min</td>
<td>45 min</td>
<td>Unknown</td>
</tr>
</tbody>
</table>
Adverse reactions
CNS: dizziness, headache, asthenia, drowsiness, paresthesia
CV: hypotension, peripheral edema, chest pain, increased angina, palpitations, tachycardia
GI: nausea, dyspepsia, dry mouth
Musculoskeletal: myalgia
Skin: flushing

Interactions
Drug-drug. Cimetidine: increased nifedipine blood level
Cyclosporine: increased cyclosporine blood level
Fentanyl anesthesia: increased hypotension

Drug-food. Grapefruit, grapefruit juice: increased drug blood level and effects
High-fat meal (sustained-release form): decreased drug blood level

Drug-herbs. Ephedra (ma huang), yohimbine: antagonism of drug’s antihypertensive effect
St. John’s wort: decreased nifedipine blood level

Drug-behaviors. Alcohol use: additive hypotension, increased drowsiness or dizziness

Patient monitoring
• Assess vital signs and cardiovascular status.
• Monitor fluid intake and output. Assess for signs and symptoms of heart failure.

Patient teaching
• Tell patient he may take immediate-release capsules without regard to meals. If GI upset occurs, advise him to take them with food, but not with grapefruit or grapefruit juice.
• Tell patient not to open, crush, break, or chew sustained-release capsules. Instruct him to take them with meals, but not with high-fat meals, grapefruit, or grapefruit juice.
• Tell patient to monitor blood pressure and report abnormal findings.

Advising patient to immediately report chest pain or blood pressure drop.
• Instruct patient to consult prescriber before drinking alcohol or taking herbs or over-the-counter drugs (especially cold remedies).
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, foods, herbs, and behaviors mentioned above.

nicotine
	nicotine inhaler

Nicostart Inhaler

nicotine nasal spray

Nicotrol NS

nicotine polacrilex
Commit, Nicorette, Nicotinell®

nicotine transdermal system
Clear Nicoderm CQ, Nicoderm CQ, Nicopatch®, Nicorette Patch®, NiQuitin®, Prostep®

Pharmacologic class: Cholinergic
Therapeutic class: Smoking deterrent
Pregnancy risk category C (gum), D (inhalation, nasal, transdermal)

Action
Supplies nicotine during controlled withdrawal from cigarette smoking. Binds selectively to nicotinic-cholinergic receptors in central and peripheral nervous systems, autonomic ganglia, adrenal medulla, and neuromuscular junction. At low doses, has a stimulating effect; at high doses, a reward effect.
Availability

Chewing gum: 2 mg, 4 mg
Inhalation: 42 cartridges/system, each containing 10 mg nicotine (delivers 4 mg)
Nasal spray: 10 mg/ml (0.5 mg/spray) in 10-ml bottles (100 doses)
Transdermal patch: 7 mg/day, 11 mg/day, 14 mg/day, 15 mg/day, 21 mg/day, 22 mg/day

Indications and dosages

➣ Adjunctive therapy (with behavior modification) for nicotine withdrawal

Transdermal system—

Adults: 21 mg/day transdermally (Habitrol) for 4 to 8 weeks, then 14 mg/day for 2 to 4 weeks, then 7 mg/day for 2 to 4 weeks, for a total of 8 to 16 weeks; patient must wear system 24 hours/day. Or 21 mg/day transdermally (Nicoderm CQ) for 6 weeks, then 14 mg/day for 2 weeks, then 7 mg/day for 2 weeks, for a total of 10 weeks; patient must wear system 24 hours/day. Or 15 mg/day transdermally (one Nicotrol patch) for 6 weeks; patient must wear system 16 hours/day, removing it at bedtime.

Adults, adolescents, and children weighing less than 45 kg (100 lb) who smoke fewer than 10 cigarettes daily or have underlying cardiovascular disease: 14 mg/day transdermally (Habitrol) for 4 to 8 weeks, then 7 mg/day for 2 to 4 weeks, for a total of 6 to 8 weeks; patient must wear system 24 hours/day. Or 14 mg/day transdermally (Nicoderm CQ) for 6 weeks, then 7 mg/day for 2 weeks, for a total of 8 weeks; patient must wear system 24 hours/day.

Nasal spray—

Adults: One spray intranasally in each nostril once or twice per hour, up to five times per hour or 40 times per day, for no longer than 6 months

Inhalation—

Adults: For optimal response, at least six cartridges inhaled daily for first 3

to 6 weeks, to a maximum of 16 cartridges daily for up to 12 weeks. Patient self-titrates dosage to required nicotine level (usually 6 to 16 cartridges daily), followed by gradual withdrawal over 6 to 12 weeks.

Chewing gum—

Adults: Use as needed depending on smoking urge or chewing rate, or use on fixed schedule q 1 to 2 hours. Initial requirement may range from 18 to 48 mg/day, not to exceed 60 mg/day.

Contraindications

• Hypersensitivity to drug or its components or to menthol (inhaler only)
• Allergy to adhesive (transdermal forms only)

Precautions

Use cautiously in:

• cardiovascular disease, hypertension, bronchospastic disease, diabetes mellitus, pheochromocytoma, peripheral vascular disease, hyperthyroidism, peptic ulcer disease, hepatic disease
• immediately after myocardial infarction, severe arrhythmia, or severe or worsening angina (use not recommended)
• skin disorders (transdermal form)
• dental disorders, esophagitis, pharyngitis, stomatitis (gum form)
• females of childbearing age
• pregnant or breastfeeding patients.
• children under age 18 (safety and efficacy not established).

Administration

• Apply patch when patient awakens and remove patch (as prescribed) at same time each day.
• Administer nasal spray regularly during first week, to help patient get used to irritant effects.
• With inhalation use, give at least six cartridges daily for first 3 to 6 weeks.
Encourage patient to titrate dosage to level required, followed by gradual withdrawal.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gum</td>
<td>Rapid</td>
<td>15-30 min</td>
<td>Unknown</td>
</tr>
<tr>
<td>Inhalation</td>
<td>Rapid</td>
<td>15 min</td>
<td>Unknown</td>
</tr>
<tr>
<td>Nasal spray</td>
<td>Rapid</td>
<td>4-15 min</td>
<td>Unknown</td>
</tr>
<tr>
<td>Transdermal (Habitrol)</td>
<td>Rapid</td>
<td>6-12 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>Transdermal (Nicoderm CQ)</td>
<td>Rapid</td>
<td>2-4 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: headache, dizziness, drowsiness, poor concentration, nervousness, weakness, paresthesia, insomnia, abnormal dreams

CV: chest pain, hypertension, tachycardia, atrial fibrillation

EENT: sinusitis; pharyngitis (with gum); mouth and throat irritation (with inhaler); nasopharyngeal irritation, rhinitis, sneezing, watering eyes, eye irritation (with nasal spray)

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dry mouth, dyspepsia; increased salivation, sore mouth (with gum)

GU: dysmenorrhea

Musculoskeletal: joint pain, back pain, myalgia; jaw ache (with gum)

Respiratory: increased cough (with nasal spray or inhaler), bronchospasm

Skin: burning at patch site, erythema, pruritus, cutaneous hypersensitivity, rash, sweating (all with transdermal patch)

Other: abnormal taste, increased appetite (with gum), allergy, hiccups

Interactions

Drug-drug. Acetaminophen, adrenergic antagonists (such as prazosin, labetalol), clozapine, furosemide, imipramine, oxazepam, pentozocine, propranolol and other beta-adrenergic blockers, theophylline: increased effects of these drugs

Bupropion: treatment-emergent hypertension

Insulin: decreased insulin requirement

Isoproterenol, phenylephrine: increased requirements for these drugs

Propoxyphene: decreased nicotine metabolism

Drug-food. Caffeine-containing foods and beverages: increased nicotine effects

Drug-behaviors. Cigarette smoking: increased nicotine metabolism and effects

Patient monitoring

- Assess for signs and symptoms of nicotine withdrawal (irritability, drowsiness, fatigue, headache).
- Watch for bronchospasm and evidence of nicotine toxicity (nausea, vomiting, diarrhea, increased salivation, headache, dizziness, visual disturbances).

Patient teaching

- Caution patient against any type of smoking during therapy. Urge him to immediately report chest tightness or difficulty breathing.
- If patient uses gum, advise him to chew one piece whenever nicotine craving occurs. Instruct him to chew it slowly until he feels a tingling sensation, then store it between cheek and gum until tingling disappears.
- Instruct patient to apply transdermal patch to clean, dry skin of upper arm or torso when he awakens; to keep it in place when showering, bathing, or swimming; and to remove it at same time each day.
- If patient uses nasal spray, instruct him to tilt head back slightly when spraying. Remind him not to sniff, swallow, or inhale through nose.
- If patient uses inhalation form, teach him to puff continuously for 20 minutes and to use at least six cartridges daily for first 3 to 6 weeks.
- As appropriate, review all significant and life-threatening adverse reactions

Reactions in bold are life-threatening.

Clinical alert
and interactions, especially those related to the drugs, foods, and behaviors mentioned above.

**nifedipine**


**Pharmacologic class:** Calcium channel blocker  
**Therapeutic class:** Antianginal, anti-hypertensive  
**Pregnancy risk category C**

**Action**  
Inhibits calcium transport into myocardial and vascular smooth muscle cells, suppressing contractions. Dilates main coronary arteries and arterioles and inhibits coronary artery spasm, increasing oxygen delivery to heart and decreasing frequency and severity of angina attacks.

**Availability**  
Capsules: 5 mg, 10 mg, 20 mg  
Tablets (extended-release): 10 mg, 20 mg, 30 mg, 60 mg, 90 mg

**indications and dosages**  
> Vasospastic (Prinzmetal’s) angina; chronic stable angina  
**Adults:** Initially, 10 mg P.O. (immediate-release) t.i.d. titrated over 7 to 14 days; usual effective range is 10 to 20 mg t.i.d., not to exceed 180 mg/day. Patient may be switched to extended-release at nearest equivalent of immediate-release daily dosage (for instance, 30-mg immediate-release dose may be switched to 90-mg extended-release dose). Total extended-release dosage should not exceed 90 mg/day.  
> Hypertension  
**Adults:** 30 to 60 mg/day P.O. (extended-release only) titrated over 7 to 14 days to a maximum of 120 mg/day

**Off-label uses**  
- Aortic regurgitation  
- Heart failure  
- Migraine  
- Prevention of labor

**Contraindications**  
- Hypersensitivity to drug

**Precautions**  
Use cautiously in:  
- chronic renal insufficiency  
- hypotension, aortic stenosis, heart failure, significant left ventricular dysfunction (especially when used with beta-adrenergic blockers), peripheral edema  
- elderly patients  
- pregnant or breastfeeding patients (safety not established)  
- children (safety not established).

**Administration**  
- Give immediate-release form with or without food. If GI upset occurs, give with meals, but never with grapefruit or grapefruit juice.  
- Don’t crush or break extended-release tablet. Make sure patient swallows it whole. Give on empty stomach, and not with grapefruit or grapefruit juice.  
- Know that Procardia XL and Adalat CC are not equivalent because of their pharmacokinetic differences.  
- Be aware that only extended-release tablets are used to treat hypertension.
### Route Onset Peak Duration

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>20 min</td>
<td>Unknown</td>
<td>6-8 hr</td>
</tr>
<tr>
<td>P.O. (Adalat PA)</td>
<td>Unknown</td>
<td>4 hr</td>
<td>12 hr</td>
</tr>
<tr>
<td>P.O. (Adalat CC, PA, XL)</td>
<td>Unknown</td>
<td>6 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

### Adverse reactions
- **CNS:** headache, dizziness, fatigue, asthenia, paresthesia, vertigo
- **CV:** peripheral edema, chest pain, hypotension
- **EENT:** epistaxis, rhinitis
- **GI:** nausea, constipation
- **GU:** urinary frequency, erectile dysfunction
- **Musculoskeletal:** leg cramps
- **Skin:** flushing, rash

### Interactions

#### Drug-drug
- **Beta-adrenergic blockers:** increased risk of heart failure, severe hypotension, or angina exacerbation
- **Cimetidine:** increased nifedipine blood level
- **Coumarin anticoagulants:** increased prothrombin time
- **Digoxin:** increased risk of digoxin toxicity
- **Quinidine:** decreased quinidine blood level

#### Drug-diagnostic tests
- **Antinuclear antibody, direct Coombs’ test:** false-positive results

#### Drug-food
- **Grapefruit, grapefruit juice:** increased nifedipine blood level and effects

#### Drug-herbs
- **Ephedra (ma huang), yohimbine:** antagonism of nifedipine effect
- **Ginkgo, ginseng:** increased nifedipine blood level
- **St. John’s wort:** decreased nifedipine blood level

#### Drug-behaviors
- **Alcohol use:** additive hypotension

### Patient monitoring
- Monitor vital signs and cardiovascular status. Stay alert for chest pain and edema.
- Watch for rash.

### Patient teaching
- Tell patient he may take immediate-release form with or without meals. If GI upset occurs, tell him to take it with meals, but never with grapefruit or grapefruit juice.
- Caution patient not to crush or break extended-release tablets. Tell him to swallow them whole. Advise him to take on empty stomach, and not with grapefruit or grapefruit juice.
- Inform patient that angina attacks may occur 30 minutes after a dose. Explain that these attacks are usually temporary and don’t mean that drug should be withdrawn.
- **Clinical alert** Tell patient to report rash immediately.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, balance, and alertness.
- Instruct patient to consult prescriber before taking herbs or over-the-counter drugs (especially cold remedies).
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

### Pharamacologic class
- **Protein-tyrosine kinase inhibitor**

### Therapeutic class
- **Antineoplastic**

### Pregnancy risk category
- **D**

Reactions in bold are life-threatening.
**FDA BOXED WARNING**

- Drug prolongs QT interval and may lead to sudden death. Don’t give to patients with hypokalemia, hypomagnesemia, or long-QT syndrome. Correct hypokalemia or hypomagnesemia before starting drug and monitor for these imbalances periodically. Avoid concomitant drugs known to prolong QT interval; also avoid strong CYP3A4 inhibitors. Instruct patient not to eat 2 hours before or 1 hour after taking dose. Obtain ECG to monitor QTc at baseline, 7 days after drug initiation, periodically thereafter, and after dosage adjustments.
- Use cautiously in patients with hepatic impairment.

**Action**
Inhibits proliferation of murine leukemic cell lines mediated by BCR-ABL kinase and human cell lines derived from patients with Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML)

**Availability**
Capsules: 200 mg

**Indications and dosages**
- Chronic-phase or accelerated-phase Ph+ CML in patients resistant or intolerant to previous imatinib therapy

**Adults:** 400 mg P.O. q 12 hours

**Dosage adjustment**
- QTc longer than 480 msec
- Hematologic toxicity
- Moderate or severe non-hematologic toxicity
- Concomitant use of CYP3A4 inducers

**Off-label uses**
- Ph+ acute lymphoblastic leukemia (ALL)

**Contraindications**
- Hypokalemia
- Hypomagnesemia
- Long-QT syndrome

**Precautions**
Use cautiously in:
- hepatic impairment.
- rare hereditary problems of galactose intolerance, severe lactase deficiency, or glucose-galactose malabsorption (use not recommended)
- myelosuppression
- electrolyte abnormalities
- history of pancreatitis
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

**Administration**
- Correct hypophosphatemia and hypokalemia before starting drug.
- Don’t give with food. Know that patient shouldn’t consume food for at least 2 hours before or 1 hour after dose.
- Administer capsule whole with water.
- Be aware that drug may be given in combination with hematopoietic growth factors, if indicated.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>3 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
CNS: headache, fatigue, asthenia, insomnia, dizziness, paresthesia, vertigo, intracranial hemorrhage
CV: palpitations, hypertension, flushing, QT interval prolongation and sudden death
EENT: dysphonia, nasopharyngitis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, abdominal discomfort, dyspepsia, flatulence, anorexia

(Systemic mastocytosis with c-kit receptor activation
- Hypereosinophilic syndrome

Canada  UK  Hazardous drug  High alert drug
Reactions in **bold** are life-threatening.

**Hematologic:** anemia, neutropenia, thrombocytopenia, leukopenia, pancytopenia, febrile neutropenia

**Hepatic:** hepatotoxicity

**Metabolic:** electrolyte abnormalities

**Musculoskeletal:** arthralgia, myalgia, extremity pain, bone pain, muscle spasms, back pain, chest pain

**Respiratory:** cough, dyspnea, exertional dyspnea, pneumonia

**Skin:** rash, pruritus, eczema, urticaria, alopecia, erythema, hyperhidrosis, dry skin

**Other:** fever, peripheral edema, night sweats, weight changes

### Interactions

**Drug-drug.** Drugs eliminated by CYP2B6, CYP2C8, or CYP2C9: decreased blood levels of these drugs

**Drug eliminated by CYP3A4 (such as warfarin), CYP2C8, CYP2C9, CYP2D6, or UGT1A1:** increased blood levels of these drugs

**Drugs that inhibit P-glycoprotein ABCB1:** increased nilotinib blood level

**Midazolam:** increased midazolam exposure

**P-glycoprotein substrates:** increased blood levels of these drugs

**Strong CYP3A4 inducers (such as carbamazepine, dexamethasone, phenytoin, rifabutin, rifampin, rifapentin, phenobarbital):** decreased nilotinib blood level

**Strong CYP3A4 inhibitors (such as atazanavir, clarithromycin, indinavir,itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole):** increased nilotinib blood level

**Drug-diagnostic tests.** Albumin, calcium, magnesium, neutrophils, phosphorus, platelets, sodium, white blood cells: decreased levels

**ALP, ALT, AST, bilirubin, blood glucose, creatinine, serum amylase, serum lipase:** increased levels

**Potassium:** increased or decreased level

**Drug-food.** Grapefruit products: increased nilotinib blood level

**High-fat meal:** increased nilotinib onset

**Drug-herbs.** *St. John’s wort:* decreased nilotinib blood level

### Patient monitoring

- Closely monitor for prolonged QT interval if patient has hepatic impairment or is receiving strong CYP3A4 inhibitors.
- Obtain complete blood count every 2 weeks for first 2 months of therapy and monthly thereafter, or as indicated.
- Periodically monitor electrolyte and lipase levels and liver function tests.

### Patient teaching

- Tell patient not to take drug with food and not to consume food for at least 2 hours before or 1 hour after dose.
- Advise patient to take capsules whole with water.
- Instruct patient to avoid grapefruit products and *St. John’s wort*.
- Tell lactose-intolerant patient that drug contains lactose.
- Instruct patient to immediately notify prescriber if symptoms of QTc prolongation (faintness or irregular heartbeat) occur.
- Urge patient to immediately report signs or symptoms of liver damage, such as nausea, fatigue, anorexia, yellowing of skin or eyes, dark urine, light-colored stools, itching, or abdominal tenderness.
- Advise female patient that drug may harm fetus. Caution her to avoid pregnancy.
- Advise breastfeeding patient to seek guidance to help her decide whether to discontinue breastfeeding or discontinue drug.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, food, and herbs mentioned above.
**nilutamide**

Anandron®, Nilandron

**Pharmacologic class:** Antiandrogen  
**Therapeutic class:** Antineoplastic  
**Pregnancy risk category C**

---

**FDA BOXED WARNING**

- Drug may cause interstitial pneumonitis. Though rare, interstitial changes have led to hospitalization and death postmarketing. Most cases occurred within first 3 months of therapy and reversed after drug was stopped. Obtain routine chest X-ray before starting treatment, and be prepared to obtain baseline pulmonary function tests if ordered. Instruct patient to report new or worsening shortness of breath; this symptom warrants immediate drug withdrawal pending evaluation.

---

**Action**

Inhibits testosterone uptake in target tissue, preventing normal androgenic response and arresting tumor growth in androgen-sensitive tissue

**Availability**

*Tablets:* 50 mg, 150 mg

**Indications and dosages**

- Metastatic prostate cancer (used with surgical castration)

**Adults:** 300 mg/day P.O. for 30 days, starting on day of or day after surgery; then 150 mg/day P.O.

**Contraindications**

- Hypersensitivity to drug or its components
- Severe hepatic or respiratory insufficiency

**Precautions**

Use cautiously in:
- renal impairment.

**Administration**

- Give with or without food.
- Start therapy on same day as or day after surgical castration.

**Route**  | **Onset** | **Peak** | **Duration**
---|---|---|---
P.O. | Rapid | Days | Wks

**Adverse reactions**

**CNS:** dizziness, depression, hyperesthesia, insomnia  
**CV:** hypertension, peripheral edema, heart failure  
**EENT:** abnormal vision, impaired dark and light adaptation, chromatopsia  
**GI:** nausea, vomiting, constipation, dyspepsia, anorexia  
**GU:** hematuria, nocturia, urinary tract infection, gynecomastia, testicular atrophy, decreased libido, erectile dysfunction  
**Hematologic:** anemia, aplastic anemia  
**Hepatic:** hepatitis  
**Respiratory:** dyspnea, upper respiratory infection, interstitial pneumonia  
**Other:** flulike symptoms, pain, fever, hot flushes, alcohol intolerance

**Interactions**

**Drug-drug.** Phenytoin, theophylline, vitamin K: increased risk of toxicity from these drugs  
**Drug-diagnostic tests.** Alanine aminotransferase, aspartate aminotransferase: increased levels  
**Drug-behaviors.** Alcohol use: disulfiram-like reaction

**Patient monitoring**

- Check for signs and symptoms of hepatitis. Monitor liver function tests.
- Monitor CBC.
- Assess fluid intake and output and weight. Watch for signs and symptoms of heart failure.
- Monitor respiratory status, including chest X-rays.
Patient teaching
- Advise patient he may take with or without food.
- Tell patient therapy will start on day of or day after surgical castration.
- Caution patient not to stop taking drug without consulting prescriber.
- Instruct patient to weigh himself daily and report sudden increases.
- Advise patient to report new onset or worsening of dyspnea as well as signs and symptoms of hepatotoxicity, such as nausea, vomiting, abdominal pain, unusual tiredness, or yellowing of skin or eyes.
- Advise patient to avoid alcohol during therapy, because serious adverse reactions may occur.
- Tell patient drug may impair his adaptation to darkness and light, which may cause difficulty driving at night or through tunnels.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, test, and behaviors mentioned above.

Action
Inhibits calcium transport into vascular smooth muscle cells, suppressing contractions; also dilates coronary and cerebral arteries.

Availability
Capsules: 30 mg

Indications and dosages
Subarachnoid hemorrhage
Adults: 60 mg P.O. q 4 hours for 21 days. Therapy should start within 96 hours of subarachnoid hemorrhage.

Dosage adjustment
- Hepatic impairment

Contraindications
None

Precautions
Use cautiously in:
- hepatic impairment, hypotension
- elderly patients
- pregnant or breastfeeding patients (safety not established)
- children (safety not established).

Administration
- Give at least 1 hour before or 2 hours after meals. Don’t let patient consume grapefruit or grapefruit juice within 1 hour before or 2 hours after dose.
- If patient can’t swallow capsule, puncture it with sterile needle and empty contents into syringe. Administer through nasogastric tube, then flush with normal saline solution (30 ml).

Adverse reactions
CNS: headache, depression
CV: hypotension, peripheral edema, ECG abnormalities, bradycardia, tachycardia
GI: nausea, diarrhea, abdominal discomfort

Reactions in bold are life-threatening.
Musculoskeletal: muscle cramps
Respiratory: dyspnea
Skin: acne, flushing, rash

Interactions
Drug-drug. Other calcium channel blockers: enhanced cardiovascular effects
Drug-diagnostic tests. Liver function tests: abnormal results
Drug-food. Any food: decreased drug blood level and effects
Grapefruit juice, grapefruit juice: increased drug blood level and effects
Drug-herbs. Ephedra (ma huang), yohimbine: antagonism of nimodipine effects
St. John’s wort: decreased drug blood level
Drug-behaviors. Alcohol use: increased hypotension

Patient monitoring
- Monitor weight and fluid intake and output. Stay alert for fluid retention.
- Assess neurologic status and mood, watching for signs of depression.
- Check vital signs and ECG.

Patient teaching
- Tell patient to complete full course of therapy (21 days).
- Advise patient to take on an empty stomach 1 hour before or 2 hours after a meal. Instruct him to not to consume grapefruit or grapefruit juice within 1 hour before or 2 hours after taking drug.
- Tell patient to report irregular heartbeat, shortness of breath, rash, or swollen hands or feet.
- Instruct patient to minimize GI upset by eating small, frequent meals.
- Advise patient to weigh himself daily and report sudden weight gain.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

nisoldipine
Sular, Syscor®

Pharmacologic class: Calcium channel blocker
Therapeutic class: Antihypertensive
Pregnancy risk category C

Action
Suppresses calcium transport into vascular smooth muscle cells. This suppression inhibits vasoconstriction and dilates coronary arteries, improving myocardial oxygen uptake.

Availability
Tablets (extended-release): 8.5 mg, 10 mg, 17 mg, 20 mg, 25.5 mg, 30 mg, 34 mg, 40 mg

Indications and dosages
Hypertension
Adults: Initially, 20 mg P.O. daily as a single dose; may increase by 10 mg daily q 7 days, up to 60 mg daily. Usual range is 20 to 40 mg daily.

Contraindications
- Hypersensitivity to drug or dihydropyridine calcium channel blockers

Precautions
Use cautiously in:
- heart failure and left ventricular dysfunction, hepatic impairment, renal disease, coronary artery disease, hypotension
- concurrent phenytoin use
- elderly patients
- pregnant or breastfeeding patients
- children (safety not established).

Administration
- Give with meals, but not with high-fat meals, grapefruit, or grapefruit juice.
• Don’t crush or break extended-release tablets. Make sure patient swallows them whole.
• Know that drug may be given alone or with other antihypertensives.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>6-12 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: headache, dizziness
CV: peripheral edema, chest pain, vasodilation, hypotension, palpitations
EENT: pharyngitis, sinusitis
GI: nausea
Skin: rash

**Interactions**

Drug-drug. Cimetidine: increased nisoldipine blood level
Phenytoin, other CYP3A4 inducers: decreased nisoldipine blood level and efficacy

Drug-food. Grapefruit juice: significantly increased drug blood level and effects
High-fat meal: decreased drug blood level

Drug-herbs. Ephedra (ma huang), yohimbine: antagonism of nimodipine effects
St. John's wort: decreased nimodipine blood level

Drug-behaviors. Alcohol use: increased hypotensive effects

**Patient monitoring**

• Check vital signs and ECG.
• Monitor fluid intake and output. Watch for peripheral edema.

**Patient teaching**

• Tell patient to swallow extended-release tablets whole and not to crush or break them.
• Advise patient to take with food, but not high-fat food. Recommend small, frequent meals.

• Instruct patient to avoid high-fat meals, alcohol, grapefruit, and grapefruit juice.
• Tell patient to immediately report irregular heart beat, shortness of breath, swelling, pronounced dizziness, rash, or chest pain.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, foods, herbs, and behaviors mentioned above.

**nitazoxanide**

**Alinia**

**Pharmacologic class:** Antiprotozoal

**Therapeutic class:** Anti-infective

**Pregnancy risk category B**

**Action**

Impedes pyruvate:ferredoxin oxidoreductase enzyme-dependent electron transfer reaction, which is essential to anaerobic energy metabolism

**Availability**

Oral suspension: 100 mg/5 ml
Tablets: 500 mg

**Indications and dosages**

Diarrhea caused by Giardia lamblia or Cryptosporidium parvum

**Adults and children ages 12 and older:**
500 mg (tablet or 25 ml suspension) P.O. every 12 hours with food for 3 days

**Children ages 4 to 11:**
200 mg (10 ml suspension) P.O. every 12 hours with food for 3 days

**Children ages 1 to 3:**
100 mg (5 ml suspension) P.O. every 12 hours with food for 3 days

**Contraindications**

• Hypersensitivity to drug or its components
Precautions
Use cautiously in:
• renal, hepatic, or biliary disease or dysfunction; immunodeficiency (including human immunodeficiency virus); diabetes mellitus (suspension)
• concurrent use of warfarin or other highly plasma protein–bound drugs
• elderly patients
• pregnant or breastfeeding patients
• children younger than age 11 (tablets) or age 1 (suspension).

Administration
• Give with food.
• Because a single tablet contains more nitazoxanide than recommended for pediatric dosing, don’t give tablets to children younger than age 11.
• Keep suspension container tightly closed and shake well before each use. Suspension may be stored for 7 days; after that, discard unused portion.

Adverse reactions
CNS: headache
GI: nausea, vomiting, diarrhea, abdominal pain

Interactions
Drug-drug. Warfarin and other highly plasma protein–bound drugs with narrow therapeutic index: competition for binding sites, resulting in increased nitazoxanide blood level and efficacy

Patient monitoring
• Monitor renal and liver function tests frequently in patients with renal, hepatic, or biliary dysfunction.
• Monitor blood glucose levels in diabetic patients taking oral suspension.

Patient teaching
• Instruct patient to take drug with food.

• Inform diabetic patient that oral suspension contains sucrose.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

nitrofurantoin
Apo-Nitrofurantoin®, Furadantin, Novo-Furantoin®
nitrofurantoin macrocrystals
Macrobid, Macrodantin
Pharmacologic class: 5-nitrofuran derivative
Therapeutic class: Anti-infective, urinary tract anti-infective
Pregnancy risk category B

Action
Inhibits bacterial enzymes required for normal cell activity at low concentrations; inhibits normal cell-wall synthesis at high concentrations

Availability
Capsules: 25 mg, 50 mg, 100 mg (macrocrystals)
Capsules (extended-release): 100 mg (macrocrystals)
Oral suspension: 25 mg/5 ml
Tablets: 50 mg, 100 mg (macrocrystals)

Indications and dosages
➢ Active urinary tract infections (UTIs)
Adults: 50 to 100 mg P.O. q.i.d. or 100 mg q 12 hours (extended-release), continued for 1 week, or for 3 days after urine becomes sterile
Children older than 1 month: 5 to 7 mg/kg/day P.O. in four divided doses, continued for 1 week, or for 3 days after urine becomes sterile
Chronic suppression of UTIs

Adults: 50 to 100 mg P.O. at bedtime
Children: 1 mg/kg/day P.O. in one or two divided doses

Contraindications
- Hypersensitivity to drug or parabens (oral suspension)
- Oliguria, anuria, or significant renal impairment
- Pregnancy near term (38 to 42 weeks’ gestation), imminent labor onset, labor and delivery
- Infants younger than 1 month

Precautions
Use cautiously in:
- diabetes mellitus, renal impairment
- blacks and patients of Mediterranean or near-Eastern descent (because of possible G6PD deficiency)
- elderly or debilitated patients
- pregnant (to week 32) or breastfeeding patients.

Administration
- As appropriate, obtain specimens for repeat urine culture and sensitivity tests before therapy.
- To avoid GI upset and increase drug bioavailability, give with food or milk.

Adverse reactions

CNS: dizziness, drowsiness, headache, asthenia, peripheral neuropathy, vertigo
CV: chest pain
EENT: nystagmus
GI: nausea, vomiting, diarrhea, abdominal pain, anorexia, parotitis, pancreatitis
Hematologic: eosinophilia, agranulocytosis, thrombocytopenia, leukopenia, granulocytopenia, G6PD deficiency anemia, hemolytic anemia, megaloblastic anemia
Hepatic: hepatitis, hepatic necrosis

Musculoskeletal: arthralgia, myalgia
Respiratory: asthma attacks, pulmonary hypersensitivity reactions including diffuse interstitial pneumonitis (with prolonged therapy)
Skin: rash, exfoliative dermatitis, alopecia, pruritus, urticaria, angioedema, photosensitivity, Stevens-Johnson syndrome
Other: drug fever, chills, superinfection (limited to urinary tract), hypersensitivity reactions including anaphylaxis, lupus-like syndrome

Interactions
Drug-drug. Anticholinergics: increased nitrofurantoin absorption and bioavailability
Drugs that can cause pulmonary toxicity: increased risk of pneumonitis
Hepatotoxic drugs: increased risk of hepatotoxicity
Magnesium salts: decreased nitrofurantoin absorption
Neurotoxic drugs: increased risk of neurotoxicity
Uricosurics (such as probenecid): decreased renal clearance and increased blood level of nitrofurantoin

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine: increased levels
Granulocytes, platelets, hemoglobin: decreased levels
Urine glucose tests using Benedict’s reagent or Fehling’s solution: false-positive results

Drug-food. Any food: increased drug bioavailability

Patient monitoring
- Monitor patient’s response to therapy. Assess urine culture and sensitivity tests.
  - Watch for and immediately report peripheral neuropathy.
  - Assess respiratory status. Watch for signs and symptoms of serious pulmonary hypersensitivity reaction.

Reactions in bold are life-threatening.
Monitor CBC and liver function tests closely. Stay alert for evidence of hematologic and hepatic disorders.

- Evaluate patient for rash.

**Patient teaching**

- Instruct patient to take with food or milk at regular intervals around the clock.
- Advise patient to complete entire course of therapy.
- Tell patient not to take magnesium-containing drugs (such as antacids) during therapy.
- Caution patient not to drive or perform other hazardous activities until he knows how drug affects vision, concentration, and alertness.

Tell patient to immediately report fever, chills, cough, chest pain, difficulty breathing, rash, bleeding or easy bruising, dark urine, yellowing of skin or eyes, numbness or tingling of fingers or toes, or intolerable GI distress.

- Advise female patient to avoid taking drug during pregnancy, especially near term.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

---

**nitroglycerin**

Minitran, Nitrek, Nitro-Dur, Nitroject®, Nitrolingual, Nitromist, Nitronal®, Nitroquick, Nitrostat

**Pharmacologic class:** Nitrate  
**Therapeutic class:** Antianginal  
**Pregnancy risk category C**

**Action**

Inhibits calcium transport into myocar-dial and vascular smooth muscle cells, suppressing contractions. Dilates main coronary arteries and arterioles, inhibits coronary artery spasm, increases oxygen delivery to heart, and reduces frequency and severity of angina attacks.

**Availability**

- **Capsules (extended-release):** 2.5 mg, 6.5 mg, 9 mg  
- **Injection:** 0.5 mg/ml, 5 mg/ml  
- **Ointment (transdermal):** 2%  
- **Solution for injection:** 25 mg/250 ml, 50 mg/250 ml, 50 mg/500 ml, 100 mg/250 ml, 200 mg/500 ml  
- **Spray (translingual):** 0.4 mg/spray in 14.5-g canister (200 doses)  
- **Tablets (buccal, extended-release):** 1 mg, 2 mg, 3 mg, 5 mg  
- **Tablets (extended-release):** 2.6 mg, 6.5 mg, 9 mg  
- **Tablets (sublingual):** 0.3 mg, 0.4 mg, 0.6 mg  
- **Transdermal system (patch):** 0.1 mg/hour, 0.2 mg/hour, 0.3 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 0.8 mg/hour

**Indications and dosages**

- **Management and prophylaxis of angina pectoris**
  
  **Adults:** For acute angina attack, 0.3 to 0.6 mg S.L., repeated q 5 minutes for 15 minutes p.r.n.; or one to two translingual sprays, repeated q 5 minutes for 15 minutes p.r.n. For long-term or prophylactic use, 1-mg extended-release buccal tablet q 5 hours, with dosage and frequency increased p.r.n.; or 2.5 to 9 mg (extended-release tablets) P.O. q 8 to 12 hours; or 1.3 to 6.5 mg (extended-release capsules) P.O. q 8 to 12 hours.

  **Hypertension during surgery; adjunct in heart failure**

  **Adults:** 5 mcg/minute I.V., increased by 5 mcg/minute q 3 to 5 minutes up to 20 mcg/minute, then increased by 10 to 20 mcg/minute q 3 to 5 minutes (dosage based on hemodynamic parameters)

  **Heart failure associated with acute myocardial infarction (MI)**
**Adults:** 12.5 to 25 mcg I.V., then a continuous infusion of 10 to 20 mcg/minute q 5 to 10 minutes; increase by 5 to 10 mcg/minute q 5 to 10 minutes as needed to a maximum of 200 mcg/minute.

**Contraindications**
- Hypersensitivity to drug, other organic nitrates, nitrites, or adhesives (transdermal form)
- Angle-closure glaucoma
- Orthostatic hypotension
- Hypotension or uncorrected hypovolemia (I.V. form)
- Early MI (S.L. form)
- Increased intracranial pressure (as from head trauma or cerebral hemorrhage)
- Severe anemia
- Pericardial tamponade or constrictive pericarditis
- Concurrent sildenafil therapy

**Precautions**
Use cautiously in:
- severe renal or hepatic impairment, glaucoma, hypertrophic cardiomyopathy
- hypovolemia, normal or decreased pulmonary capillary wedge pressure (with I.V. use)
- alcohol intolerance (with large I.V. doses)
- pregnant or breastfeeding patients
- children (safety not established).

**Administration**
- Administer tablets and capsules with water. Don’t crush, break, or let patient chew them.
- For S.L. use, administer under tongue or in buccal pouch; instruct patient not to swallow tablet. For acute angina, give at pain onset. For angina prophylaxis, give before activities that may cause anginal pain.
- For translingual use, spray directly onto oral mucosa. Don’t let patient inhale spray. Give at pain onset and as needed prophylactically before activities that trigger angina.
- For transdermal use, apply system to skin site with little hair and movement. Don’t apply to distal extremities. Rotate application sites to avoid irritation and sensitization.
- Apply transdermal ointment to skin by spreading prescribed amount over 6" × 6" area (using an applicator, not your fingers). Cover area with plastic wrap and tape. Rotate sites to reduce risk of irritation and inflammation.
- Know that solution for injection is a concentrate. Dilute with dextrose 5% in water or normal saline solution before giving by I.V. infusion.
- Don’t mix solution for injection with other drugs, and don’t give by direct I.V. injection.
- Be aware that solution for injection is affected by type of infusion set used and that dosage is based on use of conventional PVC tubing. When using nonabsorbent tubing, reduce dosage.
- For I.V. use, administer with infusion pump. Increase dosage in increments of 5 mcg/minute every 3 to 5 minutes p.r.n. to achieve desired blood pressure response. Once achieved, reduce dosage and lengthen dosage adjustment intervals.
- Don’t give concurrently with sildenafil (may cause life-threatening hypotension).

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>40-60 min</td>
<td>Unknown</td>
<td>8-12 hr</td>
</tr>
<tr>
<td>(extended)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>Unknown</td>
<td>Several min</td>
</tr>
<tr>
<td>Buccal</td>
<td>Unknown</td>
<td>Unknown</td>
<td>5 hr</td>
</tr>
<tr>
<td>(extended)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S.L.</td>
<td>1-3 min</td>
<td>Unknown</td>
<td>30-60 min</td>
</tr>
<tr>
<td>Transd.</td>
<td>20-60 min</td>
<td>Unknown</td>
<td>4-8 hr</td>
</tr>
<tr>
<td>(ointment)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transd.</td>
<td>40-60 min</td>
<td>Unknown</td>
<td>8-24 hr</td>
</tr>
<tr>
<td>(patch)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Translingual</td>
<td>2-4 min</td>
<td>Unknown</td>
<td>30-60 min</td>
</tr>
</tbody>
</table>

Reactions in **bold** are life-threatening.

**Clinical alert**
Adverse reactions
CNS: dizziness, headache
CV: hypotension, syncope
Hematologic: methemoglobinemia
Skin: contact dermatitis (with transdermal or ointment use), rash, exfoliative dermatitis, flushing

Interactions
Drug-drug. Antihypertensives, beta-adrenergic blockers, calcium channel blockers, haloperidol, phenothiazines: additive hypotension
Drugs with anticholinergic properties (antihistamines, phenothiazines, tricyclic antidepressants): decreased absorption of lingual, S.L., or buccal nitroglycerin
Sildenafil: increased risk of potentially fatal hypotension
Drug-diagnostic tests. Cholesterol: false elevation
Methemoglobin: significant levels (with excessive doses)
Urinary catecholamines, urine vanillylmandelic acid: increased levels
Drug-behaviors. Alcohol use, acute alcohol ingestion: increased risk of potentially fatal hypotension

Patient monitoring
With I.V. use, monitor blood pressure frequently. Titrate dosage to obtain desired results.
- With transdermal use, check for rash or skin irritation.
- Monitor patient for angina relief.

Patient teaching
- Instruct patient to place S.L. tablet directly under tongue and hold it there as it dissolves. Caution him not to chew or swallow tablet.
- Tell patient to use drug before physical activities that may cause angina.
- Instruct patient to take drug at pain onset and repeat every 5 minutes for three doses. If pain doesn’t subside, advise him to seek medical attention.
- Tell patient not to chew or crush sustained-release tablets.
- Advise patient to apply correct amount of ointment using applicator. Caution him to avoid rubbing site. Instruct him to cover ointment with plastic wrap and tape it, to wash hands after placement, and to rotate sites.
- Advise patient to consult prescriber or pharmacist before changing brands of transdermal system. Different brands may have different drug concentrations.
- As appropriate, review all significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

nitroprusside sodium
Nipride®, Nitropress
Pharmacologic class: Vasodilator
Therapeutic class: Antihypertensive
Pregnancy risk category C

FDA BOXED WARNING
- After reconstitution with appropriate diluent, drug isn’t suitable for direct injection. Dilute reconstituted solution further in sterile 5% dextrose injection before infusion.
- Drug may cause steep blood pressure decrease. In patients not properly monitored, this decrease can lead to irreversible ischemic injury or death. Give drug only when available equipment and personnel allow continuous blood pressure monitoring.
- Except when used briefly or at low infusion rates, drug gives rise to significant amount of cyanide ion, which can reach toxic, potentially lethal levels. Infusion at maximum dosage rate should never last more than 10 minutes. If blood pressure
isn’t adequately controlled after 10 minutes of maximum-rate infusion, end infusion immediately. Monitor acid-base balance and venous oxygen concentration, but be aware that, although these tests may indicate cyanide toxicity, they provide imperfect guidance.

- Review these warnings thoroughly before giving drug.

**Action**
Interferes with calcium influx and intracellular activation of calcium, causing peripheral vasodilation and direct blood pressure decrease

**Availability**

*Injection:* 50 mg/vial in 2 ml- and 5-ml vials

**Indications and dosages**

> Hypertensive emergencies; controlled hypotension during anesthesia

Adults and children: 0.3 to 10 mcg/kg/minute I.V., titrated to response

**Dosage adjustment**

- Hepatic insufficiency
- Renal impairment
- Elderly patients

**Contraindications**

- Hypertension caused by aortic coarctation or atioventricular shunting
- Acute heart failure caused by reduced peripheral vascular resistance
- Congenital (Leber’s) optic atrophy, tobacco amblyopia
- Inadequate cerebral circulation
- Moribund patients

**Precautions**

Use cautiously in:

- hepatic or renal disease, fluid and electrolyte imbalances, hypothyroidism
- elderly patients
- pregnant or breastfeeding patients
- children.

**Administration**

- Be aware that nitroprusside is a high-alert drug.
- Give only in settings with trained personnel and continuous blood pressure monitoring equipment.
- Dilute 50 mg in 2 to 3 ml of dextrose 5% in water (D₅W); then dilute in 250 to 1,000 ml of D₅W.
- Administer with microdrip regulator, infusion pump, or other device that allows precise flow rate measurement.
- Wrap infusion solution in aluminum foil or other opaque material to protect it from light.

**Route** | **Onset** | **Peak** | **Duration**
---|---|---|---
I.V. | 1-2 min | 1-10 min | 10 min

**Adverse reactions**

CNS: increased intracranial pressure
CV: ECG changes, bradycardia, tachycardia, **marked hypotension**
GI: ileus
Hematologic: decreased platelet aggregation, **methemoglobinemia**
Metabolic: hypothyroidism
Skin: rash, flushing
Other: pain, irritation, and venous streaking at injection site; too-rapid blood pressure decrease (causing apprehension, restlessness, palpitations, retrosternal discomfort, nausea, retching, abdominal pain, diaphoresis, headache, dizziness, muscle twitching); **thiocyanate or cyanide toxicity** (initially, tinnitus, miosis, and hyperreflexia) at blood level of 60 mg/L; **severe cyanide toxicity** (air hunger, confusion, lactic acidosis, death) at level of 200 mg/L

**Interactions**

**Drug-drug.** Enflurane, ganglionic blockers, halothane, negative inotropic drugs, volatile liquid anesthetics: severe hypotension

**Drug-diagnostic tests.** Creatinine: increased level

Methemoglobin: hemoglobin sequestration as methemoglobin

Reactions in **bold** are life-threatening.
Patient monitoring
- Measure blood pressure frequently (preferably with continuous arterial line) to detect rapid drop.
- Monitor injection site closely to avoid extravasation. Use central line whenever possible. Ensure that infusion rate is precisely controlled to prevent too-rapid infusion.
- Obtain baseline ECG and monitor for changes.
- Watch for signs and symptoms of cyanide toxicity (lactic acidosis, dyspnea, headache, vomiting, confusion, and loss of consciousness).

Patient teaching
- Tell patient he’ll be closely monitored during therapy.
- Instruct patient to immediately report headache, nausea, or pain at injection site.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

nizatidine

Pharmacologic class: Histamine₂ (H₂)-receptor antagonist
Therapeutic class: Antiulcer drug
Pregnancy risk category B

Action
Inhibits histamine action at H₂-receptor sites in gastric parietal cells, reducing gastric acid secretion and pepsin production

Availability
Capsules: 150 mg, 300 mg
Oral solution: 15 mg/ml
Tablets: 75 mg

Indications and dosages
Active duodenal ulcer
Adults: 300 mg P.O. daily at bedtime or 150 mg b.i.d. for up to 8 weeks
Maintenance of healed duodenal ulcers
Adults and children ages 12 and older: 150 mg P.O. daily at bedtime for up to 1 year
Esophagitis and associated heartburn caused by gastroesophageal reflux disease (GERD)
Adults: 150 mg P.O. b.i.d. for up to 12 weeks
Active benign gastric ulcer
Adults: 150 mg P.O. b.i.d. or 300 mg P.O. once daily at bedtime
Erosive esophagitis; GERD
Children ages 12 and older: 150 mg P.O. b.i.d. for up to 8 weeks

Dosage adjustment
- Moderate to severe renal impairment
- Elderly patients

Contraindications
- Hypersensitivity to drug or other H₂-receptor antagonists

Precautions
Use cautiously in:
- mild renal impairment
- elderly patients
- pregnant or breastfeeding patients
- children younger than age 12 (safety and efficacy not established).

Administration
- Give with or without food.
- If patient is to take drug twice daily, give one dose in morning and one at bedtime.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>0.5-3 hr</td>
<td>8-12 hr</td>
</tr>
</tbody>
</table>
Adverse reactions
CNS: dizziness, drowsiness, headache, anxiety, nervousness, insomnia, abnormal dreams, asthenia
CV: chest pain
EENT: amblyopia, sinusitis, rhinitis, pharyngitis
GI: nausea, vomiting, diarrhea, constipation, dyspepsia, abdominal pain, flatulence, anorexia, dry mouth
Hematologic: anemia
Musculoskeletal: back pain, myalgia
Respiratory: cough
Skin: rash, pruritus
Other: tooth disorder, infection, fever, pain

Interactions
Drug-drug. Salicylates (high doses): increased salicylate blood level
Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase: elevated levels Urobilinogen tests using Multistix: false-positive result
Drug-herbs. Pennyroyal: altered rate of herbal metabolite formation

Patient monitoring
● Monitor liver and renal function tests.
● Check temperature; watch for fever and other signs and symptoms of infection.

Patient teaching
● Advise patient to take once-daily dose at bedtime with or without food, or twice-daily doses in morning and at bedtime.
● Instruct patient to take exactly as prescribed. Caution him not to take other OTC drugs (especially aspirin).
● Tell patient to report signs and symptoms of infection.
● Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
● As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

norelgestromin/ethinyl estradiol
Evra®, Ortho Evra
Pharmacologic class: Estrogen
Therapeutic class: Hormone
Pregnancy risk category X

Action
Suppresses gonadotropin and inhibits ovulation by causing changes in cervical mucus and endometrium, thereby preventing egg implantation

Availability
Transdermal patch: 6 mg norelgestromin and 0.75 mg ethinyl estradiol (releases 150 mcg norelgestromin and 20 mcg ethinyl estradiol q 24 hours)

Indications and dosages
➢ To prevent pregnancy
Adults: Apply patch on day 1 of menstrual cycle (or first Sunday after period begins). Change patch weekly thereafter for 3 weeks (on same day each week), and then remove patch for fourth week. Repeat q month.

Contraindications
● Hypersensitivity to drug or its components
● Undiagnosed vaginal bleeding
● Breast or reproductive system cancer
● Thromboembolism, history of thromboembolic disease
● Coronary artery disease
● Valvular heart disease with complications
● Severe hypertension, diabetes with vascular involvement

Reactions in bold are life-threatening.
● Cerebrovascular disease
● Headache with focal neurologic symptoms
● Cholestatic jaundice of pregnancy, jaundice with previous hormonal contraceptive use
● Acute or chronic hepatic disease with abnormal liver function tests
● Hepatic adenomas or carcinomas
● Major surgery with prolonged immobilization
● Pregnancy or breastfeeding

Precautions
Use cautiously in:
● cardiovascular disease, severe hepatic or renal disease, asthma, bone disease, migraine, lipid disorders, fibrocystic breasts, increased risk for endometrial cancer, sexually transmitted diseases
● family history of breast or genital tract cancer
● abnormal mammogram.

Administration
● Apply patch to clean, dry, intact skin on buttock, abdomen, upper torso, or upper outer arm.
● Change patch on same day each week (except for fourth week, when patch is removed).

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transdermal</td>
<td>Rapid</td>
<td>2 days</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, dizziness, lethargy, depression, emotional lability, increased risk of cerebrovascular accident
CV: edema, hypertension, myocardial infarction, thromboembolism
EENT: contact lens intolerance, worsening of myopia or astigmatism
GI: nausea, vomiting, jaundice, abdominal cramps, bloating, anorexia, gallbladder disease, pancreatitis
GU: amenorrhea, dysmenorrhea, breakthrough bleeding, cervical erosion, vaginal candidiasis, breast tenderness, breast enlargement or secretion, menstrual cramps, libido loss, increased risk of breast or endometrial cancer
Hepatic: cholestatic jaundice, hepatic adenoma
Metabolic: hyperglycemia, hypercalcemia, sodium and water retention
Musculoskeletal: leg cramps
Respiratory: upper respiratory infection, pulmonary embolism
Skin: acne, oily skin, increased pigmentation, urticaria, patch site reaction
Other: increased appetite, weight changes

Interactions
Drug-drug. Acetaminophen, ascorbic acid, atorvastatin, miconazole (vaginal capsules): increased ethinyl estradiol blood level
Antibiotics, barbiturates, carbamazepine, fosphenytoin, phenobarbital, phenytoin, rifampin: decreased contraceptive efficacy
Corticosteroids: enhanced corticosteroid effects
Cyclosporine: increased risk of cyclosporine toxicity
CYP3A4 inhibitors (such as ketoconazole, itraconazole): increased hormone level
Dantrolene, other hepatotoxic drugs: increased risk of hepatotoxicity
Insulin, oral hypoglycemics, warfarin: altered requirements for these drugs
Protease inhibitors: increased contraceptive metabolism
Tamoxifen: interference with tamoxifen effects

Drug-diagnostic tests. Antithrombin III, folate, low-density lipoproteins, pyridoxine, total cholesterol, urine pregnanediol: decreased levels
Cortisol; factors VII, VIII, IX, and X; glucose; high-density lipoproteins; phospholipids; prolactin; prothrombin; sodium; triglycerides: increased levels
Metyrapone test: false decrease
Thyroid function tests: false interpretation
Drug-food. Caffeine: increased blood caffeine level
Drug-herbs. Black cohosh: increased adverse drug effects
Red clover: interference with hormonal therapy
Saw palmetto: antiestrogenic effects
St. John’s wort: decreased drug blood level and effects
Drug-behaviors. Smoking (15 or more cigarettes daily): increased risk of adverse cardiovascular reactions

Patient monitoring
- Evaluate menstrual pattern.
- Monitor blood pressure. Watch for signs and symptoms of thromboembolic disease (swelling or warmth in calf, sudden chest pain, shortness of breath).
- Check blood glucose level in diabetic patient.

Patient teaching
- Instruct patient to start using patch on first day of menstrual period or on first Sunday after period starts. Advise her to use calendar to keep track of which day each week to change patch.
- Tell patient to remove patch during fourth week of each cycle. Explain that she will have bleeding that week.
- Advise patient to check daily to ensure that patch is attached firmly to skin. Explain that if patch is detached for 1 day or less, she should try to re-attach it more firmly. If patch is detached for more than 1 day or for an unknown length of time, she should start with new patch and new calendar.
- Instruct patient to use alternative contraception during first week of patch use.
- Inform patient that smoking while using patch increases risk of thromboembolic disease and other serious cardiovascular reactions. Stress importance of not smoking. Tell her to immediately report swelling or warmth in calf, chest pain, or shortness of breath.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

norepinephrine bitartrate
Levophed, Noradrenaline

Pharmacologic class: Sympathomimetic
Therapeutic class: Alpha- and beta-adrenergic agonist, cardiac stimulant, vasopressor
Pregnancy risk category C

FDA BOXED WARNING
- If extravasation occurs, infiltrate area promptly with 10 to 15 ml of saline solution containing 5 to 10 mg phentolamine to prevent sloughing and necrosis. Use syringe with fine hypodermic needle, and infiltrate solution liberally throughout area. Give phentolamine as soon as possible; its sympathetic blockade causes immediate local hyperemic changes if area is infiltrated within 12 hours.

Action
Stimulates beta1 and alpha1 receptors in sympathetic nervous system, causing vasoconstriction, increased blood pressure, enhanced contractility, and decreased heart rate

Availability
Injection: 1 mg/ml

Indications and dosages
Severe hypotension
Adults: 8 to 12 mcg/minute I.V.; then titrate based on blood pressure response. For maintenance, 2 to 4 mcg/minute.
Contraindications
- Concurrent cyclopropane or halothane anesthesia
- Hypotension caused by blood volume deficit (except in emergencies until blood volume replacement is completed), profound hypoxia or hypercarbia
- Mesenteric or peripheral vascular thrombosis

Precautions
Use cautiously in:
- Sulfite sensitivity (some products), especially in asthmatic patients
- Arterial embolism, cardiac disease, peripheral vascular disease, hypertension, hyperthyroidism
- Patients receiving MAO inhibitors or tricyclic antidepressants concurrently
- Elderly patients
- Pregnant or breastfeeding patients
- Children (safety and efficacy not established).

Administration
- Mix with dextrose 5% in water or dextrose 5% in normal saline solution.
- Inspect solution to make sure it’s clear and colorless. Don’t infuse if it’s brown or pink.
- Administer through infusion pump. Titrate infusion rate to achieve and maintain low-normal systolic blood pressure (80 to 100 mm Hg).
- Continue infusion until adequate blood pressure and tissue perfusion persist without drug therapy.
- Gradually titrate dosage downward.
- To avoid extravasation, administer only into large vein (antecubital) or through central line. Don’t use femoral vein in patients who are elderly or have occlusive vascular disorders.
- To prevent delivery of large drug concentrations, avoid line stasis and flushing.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>Immediate</td>
<td>1-2 min after infusion ends</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, anxiety
CV: bradycardia, severe hypertension, arrhythmias
Respiratory: respiratory difficulty
Skin: irritation with extravasation, necrosis
Other: ischemic injury

Interactions
Drug-drug. Alpha-adrenergic blockers: antagonism of norepinephrine effects
Antihistamines, ergot alkaloids, guanethidine, MAO inhibitors, oxytocin, tricyclic antidepressants: severe hypertension
Bretylium, inhalation anesthetics: increased risk of arrhythmias

Patient monitoring
- Check blood pressure every 2 minutes until desired pressure is achieved. Recheck every 5 minutes for duration of infusion.
- Maintain continuous ECG monitoring and blood pressure monitoring.
- Be aware that headache may signal extreme hypertension and overdose.
- Monitor infusion site for extravasation.
- Watch for signs and symptoms of peripheral vascular insufficiency (decreased capillary refill, pale to cyanotic to black skin color).
- Never leave patient unattended during infusion.

Patient teaching
- When patient is alert, explain why he’s receiving drug.
- Reassure patient he’ll be monitored continuously until he’s stable.
norethindrone acetate
Aygestin

**Pharmacologic class:** Progesterone, hormone

**Therapeutic class:** Progesterone, hormone

**Pregnancy risk category X**

**Action**
Inhibits pituitary gonadotropin secretion, suppressing follicular maturation and ovulation and stimulating mammary tissue growth

**Availability**
Tablets: 5 mg

**Indications and dosages**

- Endometriosis
  - **Adults:** 5 mg P.O. daily for 2 weeks, increased in increments of 2.5 mg/day q 2 weeks until 15 mg daily is reached

- Amenorrhea; abnormal uterine bleeding
  - **Adults:** 2.5 to 10 mg P.O. daily starting on day 5 of menstrual cycle

**Contraindications**
- Hypersensitivity to drug
- Severe hepatic disease
- Thromboembolic disorders
- Breast or reproductive tract cancer
- Undiagnosed vaginal bleeding
- Missed abortion
- Pregnancy

**Precautions**
Use cautiously in:
- Hypertension, blood dyscrasias, bone marrow disease, hepatic or renal disease, gallbladder disease, heart failure, diabetes mellitus, depression, migraine, asthma, seizure disorder
- Family history of breast or reproductive tract cancer
- Breastfeeding patients

**Administration**
- Give with or without food.
- Know therapy may continue for 6 to 9 months or until breakthrough bleeding necessitates a temporary halt.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Variable</td>
<td>Unknown</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- CNS: migraine, depression, insomnia, drowsiness
- EENT: retinal vascular lesions, sudden partial or complete vision loss, proptosis, diplopia, papilledema
- GI: nausea
- GU: breakthrough bleeding, menstrual flow changes, amenorrhea, changes in cervical erosion and secretions, breast tenderness and secretion
- Hepatic: cholestatic jaundice
- Metabolic: fluid retention, decreased glucose tolerance
- Skin: rash, urticaria, acne, hirsutism, chloasma
- Other: edema, weight gain or loss, fever

**Interactions**

- **Drug-drug.** Hepatic enzyme-inducing drugs (such as carbamazepine, phenobarbital, phenytoin, rifampin): decreased norethindrone efficacy
- **Drug-diagnostic tests.** Alkaline phosphatase; amino acids; factors VII, VIII, IX, and X; nitrogen; pregnanediol: increased levels
- Gamma-glutamyltransferase, high-density lipoproteins: decreased levels
- **Drug-herbs.** Cola nut, guarana, yerba mate: increased CNS stimulation
- **St. John’s wort:** decreased contraceptive efficacy
- **Drug-behaviors.** Smoking: risk of serious cardiovascular reactions

**Patient monitoring**
- Monitor pretreatment and annual physical exams to check blood pressure, breasts, abdomen, pelvic organs, and Pap smear results.

Reactions in **bold** are life-threatening.
Assess for signs and symptoms of depression, especially in patients with history of depression. Stop giving drug if significant depression recurs.

- Check blood glucose level in diabetic patients.

Patient teaching
- Instruct patient to avoid pregnancy or to discontinue drug if she gets pregnant (may cause serious fetal anomalies or fetal death).
- Advise patient to discontinue drug and consult prescriber if she experiences sudden partial or complete vision loss.
- If patient is receiving drug to treat amenorrhea, tell her to mark administration days on calendar.
- Tell diabetic patient to monitor blood glucose level closely and to watch for hyperglycemia.
- Instruct patient to report breakthrough bleeding, spotting, change in menstrual flow, or amenorrhea.
- Caution patient not to smoke during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

norfloxacin
Chibroxin, Noroxin, Utinor®

Pharmacologic class: Fluoroquinolone
Therapeutic class: Anti-infective
Pregnancy risk category C

FDA BOXED WARNING
- Fluoroquinolones for systemic use are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in patients usually over age 60, with concomitant use of corticosteroids, and in kidney, heart, and lung transplant recipients.

Action
Inhibits bacterial DNA synthesis by blocking DNA gyrase in susceptible gram-negative and gram-positive aerobic and anaerobic bacteria

Availability
Ophthalmic solution: 0.3% in 5-ml bottle
Tablets: 400 mg

Indications and dosages
- Urinary tract infections (UTIs) caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis
  - Adults: 400 mg P.O. q 12 hours for 3 days
- UTIs caused by all organisms except E. coli, K. pneumoniae, and P. mirabilis
  - Adults: 400 mg P.O. q 12 hours for 7 to 10 days. For complicated UTIs, may give for up to 21 days.
- Gonorrhea
  - Adults: 800 mg P.O. as a single dose
  - Prostatitis caused by E. coli
  - Adults: 400 mg P.O. q 12 hours for 28 days
- Conjunctivitis caused by susceptible organisms
  - Adults and children ages 1 and older: One or two drops of ophthalmic solution instilled into affected eye(s) q.i.d. for up to 7 days. Depending on infection severity, first-day dosage may be one or two drops q 2 hours while awake.

Dosage adjustment
- Renal impairment

Contraindications
- Hypersensitivity to drug
- History of tendinitis or tendon rupture with fluoroquinolone use

Precautions
Use cautiously in:
- CNS diseases or disorders, renal impairment, cirrhosis, bradycardia, acute myocardial ischemia
• elderly patients
• pregnant or breastfeeding patients (safety not established except in postexposure inhalation or cutaneous anthrax).
• children younger than age 18 (except with ophthalmic solution).

**Administration**
• Give with glass of water 1 hour before or 2 hours after a meal.
• Don’t give antacids within 2 hours of norfloxacin.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>2-3 hr</td>
<td>12 hr</td>
</tr>
<tr>
<td>Ophthalmic</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** dizziness, light-headedness, drowsiness, headache, asthenia, insomnia, agitation, confusion, acute psychoses, hallucinations, tremors, increased intracranial pressure, seizures

**CV:** vasodilation, QT prolongation, arrhythmias

**EENT:** eye burning and discomfort, conjunctival hyperemia, corneal deposits, photophobia (all with ophthalmic use)

**GI:** nausea, diarrhea, abdominal pain, pancreatitis, pseudomembranous colitis

**GU:** interstitial cystitis, vaginitis

**Hematologic:** leukopenia

**Hepatic:** hepatitis

**Metabolic:** hyperglycemia, hypoglycemia

**Musculoskeletal:** tendinitis, tendon rupture

**Skin:** rash, hyperhidrosis, photosensitivity, phototoxicity, Stevens-Johnson syndrome

**Other:** altered taste, hypersensitivity reactions including anaphylaxis

**Antineoplastics:** decreased norfloxacin blood level

**Cimetidine:** interference with norfloxacin elimination

**Corticosteroids:** increased risk of tendon rupture

**Nitrofurantoin:** antagonism of norfloxacin’s antibacterial effects in GU tract

**Other fluoroquinolones:** increased risk of nephrotoxicity

**Probenecid:** decreased renal elimination of norfloxacin

**Theophylline:** increased theophylline blood level, greater risk of toxicity

**Warfarin:** increased anticoagulant effect

**Drug-diagnostic tests.** Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, eosinophils, lactate dehydrogenase, platelets: increased levels

**Hemoglobin, hematocrit:** decreased values

**Drug-food.** Caffeine: decreased hepatic metabolism of caffeine

**Milk or yogurt (consumed alone):** impaired drug absorption

**Tube feedings:** impaired drug absorption

**Drug-herbs.** Dong quai, St. John’s wort: phototoxicity

**Fennel:** decreased drug absorption

**Drug-behaviors.** Sun exposure: phototoxicity

**Patient monitoring**

• Monitor vital signs and cardiovascular status.

• Check fluid intake and output. Keep patient well-hydrated.

• Watch for signs and symptoms of tendinitis or tendon rupture.

• Assess patient’s response to therapy. Obtain specimens for repeat culture and sensitivity tests if he relapses or doesn’t improve.

• Monitor renal function.

**Patient teaching**

• Tell patient to take on empty stomach with full glass of water, 1 hour before or 2 hours after a meal.
● If patient needs antacid for GI upset, instruct him not to take it within 2 hours of norfloxacin.

Advising patient to stop taking drug and promptly report rash; severe GI problems; tendon pain, swelling, or inflammation; or weakness.

● Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

● Teach patient ways to counteract photosensitivity, such as by wearing sunglasses and avoiding excessive exposure to bright light.

● Teach patient how to use eye drops. Caution him not to touch dropper tip to any surface (including eye).

● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

● Drug isn’t approved for use in pediatric patients.

Action
Increases serotonin and norepinephrine release by blocking their reuptake by presynaptic neurons; also possesses anticholinergic properties

Availability
Capsules: 10 mg, 25 mg, 50 mg, 75 mg
Oral solution: 10 mg/5 ml

Indications and dosages

➣ Depression
Adults: 25 mg P.O. t.i.d. or q.i.d., up to a maximum of 150 mg daily

Dosage adjustment
• Elderly patients
• Adolescents

Off-label uses
• Postherpetic neuralgia
• Neurologic pain

Contraindications
• Hypersensitivity to drug or dibenazepines
• Acute recovery phase of myocardial infarction
• MAO inhibitor use within past 14 days

Precautions
Use cautiously in:
• asthma, cardiovascular disease, cardiac or hepatic disease, hyperthyroidism, increased intraocular pressure, angle-closure glaucoma, urinary retention, severe depression
• history of seizures

FDA BOXED WARNING
• Drug may increase risk of suicidal thinking and behavior in children and adolescents with major depressive disorder and other psychiatric disorders. Risk must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family and caregivers to observe patient closely and communicate with prescriber as needed.

nortriptyline hydrochloride
Allegron®, Apo-Nortriptyline®, Aventyl, Dom-Nortriptyline®, Gen-Nortriptyline®, Novo-Nortriptyline®, Norventyl®, Nu-Nortriptyline®, Pamelor, PMS-Nortriptyline®, Ratio-Nortriptyline®

Pharmacologic class: Tricyclic compound
Therapeutic class: Antidepressant
Pregnancy risk category D
• elderly patients (especially elderly men with prostatic hyperplasia)
• pregnant or breastfeeding patients
• children (use not recommended).

**Administration**

- Give as prescribed, either in divided doses three or four times daily or as single dose at bedtime.
- Administer with meals or snack to minimize stomach upset.

⚠️ Don't give within 14 days of MAO inhibitors.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>2-3 wk</td>
<td>6 wk</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** dizziness, drowsiness, fatigue, headache, lethargy, insomnia, agitation, confusion, extrapyramidal reactions, hallucinations, **seizures, suicidal behavior or ideation** (especially in child or adolescent)

**CV:** hypotension, ECG changes, palpitations, **heart block, arrhythmias, myocardial infarction, cerebrovascular accident**

**EENT:** blurred vision, dry eyes

**GI:** nausea, constipation, anorexia, dry mouth, **paralytic ileus**

**GU:** urinary retention, gynecomastia

**Hematologic:** blood dyscrasias

**Hepatic:** jaundice, **hepatotoxicity**

**Skin:** photosensitivity

**Other:** unpleasant taste, weight gain

**Interactions**

**Drug-drug.** Anticholinergics, anti-cholinergic-like drugs (including antidepressants, antihistamines, atropine, disopyramide, haloperidol, phenothiazines, quinidine): additive anticholinergic effects

**Antihypertensives:** poor therapeutic response to antihypertensives

**Antithyroid drugs:** increased risk of agranulocytosis

*Cimetidine, fluoxetine, hormonal contraceptives: increased nortriptyline blood level and possible toxicity

Clonidine: hypertensive crisis

CNS depressants (including antihistamines, opioids, sedative-hypnotics): additive CNS depression

Decongestants, vasoconstrictors: additive adrenergic effects

**MAO inhibitors:** hypertension, hyperpyrexia, seizures, death

**Drug-diagnostic tests.** Alkaline phosphatase, bilirubin: increased levels

Glucose: increased or decreased level

**Drug-herbs.** *Angel’s trumpet, belladonna, henbane, jimson weed, scoparia: increased anticholinergic effects

*Chamomile, hops, kava, skullcap, scoparia, valerian: increased CNS depression

*St. John’s wort: decreased drug blood level and efficacy

**Drug-behaviors.** Alcohol use: increased drowsiness, impaired motor skills

**Patient monitoring**

- Check vital signs and ECG.
- Monitor bladder and bowel function. Stay alert for urine retention and constipation.
- Assess neurologic status and document mood swings.
- Monitor liver function tests.

⚠️ Watch for suicidal tendency, especially in child or adolescent.

**Patient teaching**

- Explain that drug’s full effect may take 4 weeks.
- Tell patient drug may cause drowsiness or dizziness, but these effects should subside within a few weeks.

⚠️ Advise patient (and family as appropriate) to immediately report worsening depression or suicidal ideation, especially in child or adolescent.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects him.

Reactions in **bold** are life-threatening.

⚠️ Clinical alert
Tell patient to avoid alcohol and to consult prescriber before using herbs. As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

### Pharmacology Class and Therapeutic Class

**Pharmacologic class:** Antifungal  
**Therapeutic class:** Anti-infective  
**Pregnancy risk category:** A

### Action
Interferes with fungal cell-wall synthesis, inhibiting formation of ergosterols, increasing cell-wall permeability, and causing osmotic instability.

### Availability
- **Cream:** 100,000 units/g  
- **Ointment:** 100,000 units/g  
- **Powder:** 100,000 units/g  
- **Suspension:** 100,000 units/ml  
- **Tablets:** 500,000 units  
- **Troches:** 200,000 units  
- **Vaginal tablets:** 100,000 units

### Indications and Dosages

#### Candidiasis (topical use)
- **Adults and children:** Apply cream, ointment, or powder two or three times daily until healing is complete.
- **Oral candidiasis**
- **Adults:** 400,000 to 600,000 units (suspension) P.O. q.i.d. Have patient gargle and then swallow half of dose in each side of mouth.

#### Infants
- 200,000 units ( suspension) P.O. q.i.d. Use half of dose in each side of mouth.

#### Newborn and premature infants:
- 100,000 units ( suspension) P.O. q.i.d. Use half of dose in each side of mouth.

#### GI infections
- **Adults:** 500,000 to 1 million units (one to two tablets) P.O. t.i.d. Continue for 48 hours after desired response occurs.
- **Vaginal candidiasis**
- **Adults:** 100,000 units (one vaginal tablet) intravaginally daily for 2 weeks, or 100,000- to 500,000-unit applicatorful (cream) intravaginally once or twice daily for 2 weeks

### Contraindications
- Hypersensitivity to drug or its components

### Precautions
Use cautiously in:
- renal or hepatic disease, achlorhydria  
- pregnant or breastfeeding patients  
- children younger than age 2.

### Administration
- Give oral suspension by placing half of dose in each side of patient’s mouth. Instruct patient to hold suspension in mouth, swish it around, or gargle for several minutes before swallowing it.
- To prepare oral solution from powder, add one-eighth teaspoon to 120 ml of water and stir well. Give immediately.
- Advise patient to let troche dissolve slowly and completely in mouth. Tell her not to chew or swallow it whole.
- Know that nystatin vaginal tablets can be given orally to treat oral candidiasis.
- To apply cream, ointment, or powder, gently and thoroughly massage preparation into skin.
- Use applicator provided for vaginal administration.
Route | Onset | Peak | Duration
--- | --- | --- | ---
P.O., topical, vaginal | Unknown | Unknown | Unknown

**Adverse reactions**

**GI:** nausea, vomiting, diarrhea, GI distress, oral irritation

**GU:** vulvovaginal irritation (with intravaginal form)

**Skin:** pruritus, rash

**Interactions**

**Drug-drug.** Topical corticosteroids: increased corticosteroid absorption

**Drug-behaviors.** Latex contraceptive use: damage to contraceptive (with intravaginal use)

**Patient monitoring**

- If patient takes oral tablets, inspect oral mucous membranes for irritation.
- With topical use, monitor affected area for increase in redness, swelling, or irritation.

**Patient teaching**

- Advise patient to continue taking for at least 48 hours after symptoms resolve.
- Instruct patient to let lozenge dissolve slowly in mouth. Tell her not to chew or swallow it.
- If patient misses a dose, tell her to take dose as soon as possible and then resume her regular dosing schedule.
- Inform patient that diabetes mellitus, reinfection by sexual partner, tight-fitting pantyhose, and use of antibiotics, hormonal contraceptives, or corticosteroids predispose her to vaginal infection. Urge her to wear cotton underwear.
- Tell female patient to practice careful hygiene in affected areas.
- Instruct patient using vaginal tablets to wash applicator thoroughly after each use.
- Tell patient to continue therapy during menstruation.

- As appropriate, review all significant adverse reactions and interactions, especially those related to the drugs and behaviors mentioned above.

**octreotide acetate**

**Sandostatin, Sandostatin LAR**

**Pharmacologic class:** Somatostatin analog

**Therapeutic class:** Antidiarrheal

**Pregnancy risk category B**

**Action**

Suppresses secretion of serotonin, serotonin metabolites, and gastrointestinal peptides, increasing fluid and electrolyte absorption from GI tract. Also suppresses growth hormone, insulin, and glucagon.

**Availability**

- **Depot injection:** 10 mg, 20 mg, 30 mg
- **Injection:** 0.05 mg/ml, 0.1 mg/ml, and 0.5 mg/ml in 1-ml ampules; 0.2 mg/ml and 1 mg/ml in 5-ml vials

**Indications and dosages**

- **Diarrhea and flushing associated with carcinoid tumors**
  - **Adults:** 100 to 600 mcg (Sandostatin) subcutaneously or I.V. daily in two to four divided doses for 2 weeks. Then, depending on response, 20 mg (LAR Depot) I.M. q 4 weeks for 2 months.
  - **Diarrhea caused by vasoactive intestinal peptide tumors (VIPomas)**
  - **Adults:** 200 to 300 mcg (Sandostatin) subcutaneously or I.V. daily in two to four divided doses for 2 weeks.
depending on response, 20 mg (LAR Depot) I.M. q 2 weeks for 2 months.

➣ Acromegaly

Adults: 50 to 100 mcg (Sandostatin) subcutaneously or I.V. two or three times daily. Then, depending on response, 20 mg (LAR Depot) I.M. q 4 weeks for 3 months. Then adjust based on growth hormone levels.

Dosage adjustment
● Renal impairment

Off-label uses
● Dumping syndrome (postprandial hypotension)
● GI and pancreatic fistulas
● Variceal bleeding

Contraindications
● Hypersensitivity to drug or its components

Precautions
Use cautiously in:
● gallbladder disease, renal impairment, hyperglycemia or hypoglycemia, fat malabsorption
● pregnant or breastfeeding patients
● children.

Administration
● When giving subcutaneously, rotate administration site with each injection.
    Don’t give LAR Depot I.V.
   ● Mix I.M. solution and inject deep into gluteal muscle over 3 minutes. Don’t use deltoid.
   ● For I.V. administration, dilute in 50 to 200 ml of dextrose 5% in water or normal saline solution. Infuse over 15 to 30 minutes.
   ● Know that octreotide suppression test and octreotide scintigraphy may be done to determine if drug will aid carcinoid tumor treatment.
   ● Drug may be kept at room temperature for 2 weeks. Refrigerate ampules.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcut., I.V.</td>
<td>Unknown</td>
<td>0.4 hr</td>
<td>Up to 12 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>Unknown</td>
<td>2 wk</td>
<td>Up to 4 wk</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, drowsiness, fatigue, headache, weakness
CV: edema, bradycardia, conduction abnormalities, arrhythmias
EENT: vision disturbances
GI: nausea, vomiting, diarrhea, abdominal pain, cholelithiasis, fat malabsorption
Skin: flushing
Metabolic: hypothyroidism, hyperglycemia, hypoglycemia
Other: injection site pain

Interactions
Drug-drug. Cyclosporine: reduced cyclosporine blood level
Insulin, oral hypoglycemics: altered requirements for these drugs
Orally administered drugs: altered absorption of these drugs
Drug-diagnostic tests. Glucose: increased or decreased level
Hepatic enzymes: slightly increased levels
Schilling’s test: abnormal results
Thyroxine, vitamin B12: decreased levels
Drug-food. Fats: altered octreotide absorption

Patient monitoring
● Assess bowel sounds and stool frequency and consistency.
● Monitor vital signs and fluid intake and output. Stay alert for dehydration or edema.
● Evaluate diabetic patient for hypoglycemia or hyperglycemia.
● Know that in women with active acromegaly, normalization of growth hormone and insulin-like growth factor-1 may restore fertility.

Patient teaching
● Tell patient being treated for carcinoid tumor to keep track of number of daily stools or flushing episodes.
● Instruct patient to weigh himself daily and report significant changes.
● Advise female with childbearing potential to use adequate contraception while taking drug.
● If patient will use drug at home, teach correct methods for injection, storage, and needle disposal.
● Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, and alertness.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

**ofloxacin**

**Exocin®, Floxin, Ocuflox, Tarivid®**

**Pharmacologic class:** Fluoroquinolone  
**Therapeutic class:** Anti-infective  
**Pregnancy risk category C**

**FDA BOXED WARNING**

● Fluoroquinolones for systemic use are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in patients usually over age 60, with concomitant use of corticosteroids, and in kidney, heart, and lung transplant recipients.

**Action**

Inhibits bacterial DNA synthesis by inhibiting DNA gyrase in susceptible bacteria

**Availability**

*Injection:* 40 mg/ml  
*Ophthalmic solution:* 3 mg/ml (0.3%)  
*Otic solution:* 0.3%

**Indications and dosages**

**Prostatitis caused by *Escherichia coli***

**Adults:** 300 mg P.O. or I.V. q 12 hours for 6 weeks

**Complicated urinary tract infections caused by *E. coli, Klebsiella pneumoniae*, or *Proteus mirabilis***

**Adults:** 200 mg P.O. or I.V. q 12 hours for 10 days

**Uncomplicated cystitis caused by *E. coli* or *K. pneumoniae***

**Adults:** 200 mg P.O. or I.V. q 12 hours for 3 days

**Acute uncomplicated urethral and cervical gonorrhea***

**Adults:** 400 mg P.O. or I.V. as a single dose

**Nongonococcal cervicitis or urethritis caused by *Chlamydia trachomatis*; mixed infections of cervix or urethra caused by *C. trachomatis* or *Neisseria gonorrhoeae***

**Adults:** 300 mg P.O. or I.V. q 12 hours for 7 days

**Acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, and uncomplicated skin and skin-structure infections caused by susceptible organisms***

**Adults:** 400 mg P.O. or I.V. q 12 hours for 10 days

**Acute pelvic inflammatory disease***

**Adults:** 400 mg P.O. or I.V. q 12 hours for 10 to 14 days

**Bacterial conjunctivitis***

**Adults and children ages 1 and older:** One to two drops of ophthalmic solution in affected eye q 2 to 4 hours on days 1 and 2; then one to two drops q.i.d. on days 3 through 7

**Corneal ulcers***

**Adults:** One to two drops of ophthalmic solution in affected eye q 30 minutes while awake on days 1 and 2, then one to two drops q hour while awake

Reactions in **bold** are life-threatening.

- Clinical alert
on days 3 to 7, then one to two drops q.i.d. while awake on days 7 to 9

> **Otitis externa**

**Adults and children ages 13 and older:** 10 drops of otic solution into affected ear daily for 7 days

> **Chronic suppurative otitis media** with perforated tympanic membrane

**Adults and children ages 12 and older:** 10 drops of otic solution into affected ear b.i.d. for 14 days

**Dosage adjustment**

- Renal impairment
- Severe hepatic impairment

**Contraindications**

- Hypersensitivity to drug or other fluoroquinolones

**Precautions**

Use cautiously in:

- underlying CNS disease, renal impairment, cirrhosis, bradycardia, acute myocardial ischemia
- history of tendinitis or tendon rupture with fluoroquinolone use
- dialysis patients
- elderly patients
- pregnant or breastfeeding patients (safety not established except in postexposure inhalation or cutaneous anthrax).
- children younger than age 18 (except in postexposure inhalation or cutaneous anthrax and in ophthalmic and otic use).

**Administration**

- For intermittent I.V. infusion, dilute to a concentration of 4 mg/ml using normal saline solution, dextrose 5% in water (D₅W), dextrose 5% in normal saline solution, or dextrose 5% in lactated Ringer’s solution. Infuse slowly over at least 60 minutes.
- Don’t give zinc- or iron-containing drugs within 2 hours of ofloxacin.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>1-2 hr</td>
<td>12 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>End of infusion</td>
<td>12 hr</td>
</tr>
<tr>
<td>Ophthalmic, Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown otic</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- CNS: dizziness, drowsiness, headache, light-headedness, insomnia, acute psychoses, agitation, confusion, tremors, hallucinations, **increased intracranial pressure**, seizures
- CV: chest pain, vasodilation
- GI: nausea, diarrhea, constipation, abdominal pain, **pseudomembranous colitis**
- GU: interstitial cystitis, vaginitis
- Hematologic: eosinophilia, leukopenia
- Musculoskeletal: tendinitis, tendon rupture, joint pain, back pain
- Skin: rash, photosensitivity, phototoxicity, **Stevens-Johnson syndrome**
- Other: altered taste, superinfection, phlebitis at I.V. site, hypersensitivity reactions including **anaphylaxis**

**Interactions**

**Drug-drug.** Amiodarone, bepridil, disopyramide, erythromycin, pentamidine, phenothiazines, pimozide, procainamide, quinidine, sotalol, tricyclic antidepressants: increased risk of serious adverse cardiovascular reactions
- Antacids, bismuth subsalicylate, iron or zinc salts, sucralfate: decreased ofloxacin absorption
- Corticosteroids: increased risk of tendon rupture
- Probenecid: decreased renal elimination of ofloxacin
- Theophylline: increased theophylline blood level and possible toxicity
- Warfarin: increased warfarin effects

**Drug-diagnostic tests.** Alanine aminotransferase, aspartate aminotransferase, platelets: increased levels
- Hemoglobin, hematocrit: decreased values

Canada  UK  Hazardous drug  High alert drug
Drug-food. Milk or yogurt (consumed alone), tube feedings: impaired drug absorption

Drug-herbs. Fennel: decreased drug absorption
Dong quai, St. John’s wort: phototoxicity

Drug-behaviors. Sun exposure: phototoxicity

Patient monitoring
● Assess patient for signs and symptoms of superinfection.
● Inspect for rash. Check for signs and symptoms of hypersensitivity reaction.

Watch for fever with diarrhea; diarrhea containing pus; or severe, persistent diarrhea; and tendinitis or tendon rupture.
● Evaluate neurologic status closely.

Patient teaching
● Encourage patient to maintain fluid intake of at least 1,500 ml daily to prevent crystalluria.
● Inform patient being treated for gonorrhea that partners must be treated.

Tell patient to immediately report fever and diarrhea, especially if stool contains blood, pus, mucus. Caution him not to treat diarrhea without consulting prescriber.

Instruct patient to stop taking drug and immediately report rash or tendon pain or inflammation.
● Instruct patient not to take iron- or zinc-containing drugs or antacids within 2 hours of ofloxacin.

Teach patient ways to counteract photosensitivity, such as by wearing sunglasses and avoiding excessive exposure to bright light.
● Teach patient how to use eye or ear drops. Caution him not to touch dropper tip to any surface (including eye or ear).

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

Olanzapine
Zyprexa, Zyprexa IntraMuscular, Zyprexa, Zydis
Pharmacologic class: Thienobenzodiazepine
Therapeutic class: Antipsychotic
Pregnancy risk category C

FDA BOXED WARNING
● Elderly patients with dementia-related psychosis are at increased risk for death. Over course of 10-week controlled trial, death rate in drug-treated patients was about 4.5%, compared to about 2.6% in placebo group. Although causes of death varied, most appeared to be cardiovascular or infectious. Don’t give drug to patients with dementia-related psychosis.

Action
Unknown. Thought to antagonize dopamine and serotonin type 2 in CNS. Also antagonizes muscarinic receptors in respiratory tract, causing cholinergic activation.

Availability
Solution for injection: 10-mg vials
Tablets: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg
Tablets (orally disintegrating): 5 mg, 10 mg, 15 mg, 20 mg

Indications and dosages
➣ Schizophrenia
Adults: Initially, 5 to 10 mg P.O. daily; may increase q week by 5 mg/day (not to exceed 20 mg/day)
➣ Psychotic disorders, including acute manic episodes
Adults: Initially, 10 to 15 mg P.O. daily; may increase q 24 hours by 5 mg/day

Reactions in bold are life-threatening.
(not to exceed 20 mg/day). Or 10 mg I.M.; maximum dosage is three 10-mg doses given I.M. 2 to 4 hours apart.

> Maintenance treatment of bipolar disorder

**Adults:** 12.5 mg P.O. daily

### Dosage adjustment
- Elderly or debilitated patients
- Patients predisposed to hypotensive reactions

### Off-label uses
- Borderline personality disorder (with oral use)

### Contraindications
- Hypersensitivity to drug

### Precautions
Use cautiously in:
- hepatic impairment, cardiovascular or cerebrovascular disease, diabetes mellitus, prostatic hypertrophy, angle-closure glaucoma, phenylketonuria (with orally disintegrating tablets)
- history of seizures, paralytic ileus, or suicide attempt
- elderly patients
- pregnant or breastfeeding patients
- children younger than age 18 (safety not established).

### Administration
- Give without regard to meals.
- To remove orally disintegrating tablet from package, peel back foil; don’t push tablet through foil.
- Reconstitute for I.M. injection with 2.1 ml of sterile water for injection only, into single-packaged vial.
- After reconstitution, withdraw total contents of vial for 10-mg dose; 1.5 ml for 7.5-mg dose; 1 ml for 5-mg dose, or 0.5 ml for 2.5-mg dose.
- Use solution for I.M. injection within 1 hour of reconstitution.
- Don’t combine in syringe with diazepam, lorazepam, or haloperidol.

- Be aware that total daily dosages above 30 mg P.O. or 10 mg I.M. given more often than 2 hours after initial dose and 4 hours after second dose aren’t recommended.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>6 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.M.</td>
<td>Rapid</td>
<td>15-45 min</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

### Adverse reactions
- **CNS:** dizziness, headache, weakness, fatigue, restlessness, sedation, insomnia, mood changes, agitation, personality disorder, impaired speech, tardive dyskinesia, dystonia, tremor, extrapyramidal effects, neuroleptic malignant syndrome, coma
- **CV:** orthostatic hypotension, chest pain, tachycardia
- **EENT:** amblyopia, rhinitis, pharyngitis
- **GI:** nausea, constipation, abdominal pain, increased salivation, dry mouth
- **GU:** urinary incontinence, urinary tract infection
- **Hematologic:** leukopenia
- **Metabolic:** goiter, increased thirst, severe hyperglycemia
- **Musculoskeletal:** hypertonia, joint pain
- **Respiratory:** cough, dyspnea
- **Skin:** ecchymosis, photosensitivity
- **Other:** increased appetite, weight gain or loss, fever, flulike symptoms, impaired body temperature regulation, death

### Interactions
- **Drug-drug.** **Antihypertensives:** additive hypotension
  - Carbamazepine, omeprazole, rifampin: decreased olanzapine effects
- **CNS depressants:** additive CNS depression
  - Dopamine agonists, levodopa: antagonism of these drugs’ effects
- **Drug-diagnostic tests.** **Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, glucose, creatinine phosphokinase, gamma-glutamyltransferase:** elevated levels
Platelets: decreased count

Drug-behaviors. Alcohol use: additive CNS depression
Smoking: increased drug clearance
Sun exposure: increased risk of photosensitivity

Patient monitoring
● Assess patient’s mental status during therapy.
● Monitor vital signs during dosage adjustment periods.
● Make sure patient takes drug and doesn’t hoard it.

Watch for signs and symptoms of neuroleptic malignant syndrome (fever, respiratory distress, tachycardia, seizures, diaphoresis, hypertension or hypotension, tiredness, severe muscle stiffness, loss of bladder control).
● Evaluate patient for onset of akathisia, tardive dyskinesia, and extrapyramidal effects.

Watch for signs of increasing depression.

Monitor blood glucose level closely, especially in patient with diabetes mellitus. Severe hyperglycemia, coma, and death may occur.
● Watch for orthostatic hypotension before I.M. injection. Keep patient recumbent if drowsiness or dizziness follows injection.

Patient teaching
● Tell patient he may take without regard to meals.
● Instruct patient to remove orally disintegrating tablet from package by peeling back foil—not by pushing tablet through foil. Instruct him to remove tablet from foil using dry hands, and place entire tablet in mouth. Tell him tablet will disintegrate with or without liquid.
● Tell patient drug may cause extrapyramidal symptoms, akathisia, and tardive dyskinesia leading to involuntary movements, tremors, rigidity, muscle contractions, and restlessness.

Caution patient with diabetes mellitus to monitor blood glucose closely.
● Tell patient to move slowly when sitting up or standing to avoid dizziness. Advise him to dangle legs briefly before getting out of bed.
● Advise patient to avoid smoking, alcohol, or other CNS depressants.
● Tell patient to exercise in moderation and to avoid overly hot baths and showers, because drug impairs body temperature regulation.
● Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

olmesartan medoxomil
Benicar, Olmetec

Pharmacologic class: Angiotensin II type 1-receptor antagonist
Therapeutic class: Antihypertensive
Pregnancy risk category C (first trimester), D (second and third trimesters)

FDA BOXED WARNING
● When used during second or third trimester of pregnancy, drug may cause fetal harm or death. Discontinue as soon as possible when pregnancy is detected.

Action
Selectively blocks binding of angiotensin II to specific tissue receptors in vascular smooth muscle and adrenal
gland. This action blocks vasoconstrictive effects of renin-angiotensin system as well as aldosterone release, thereby reducing blood pressure and possibly preventing vascular remodeling related to arteriosclerosis.

### Availability

**Tablets:** 5 mg, 20 mg, 40 mg

### Indications and dosages

**Hypertension**

Adults: 20 mg P.O. once daily; may titrate to 40 mg daily after 2 weeks, if needed

### Dosage adjustment

- Volume depletion

### Contraindications

- Hypersensitivity to drug or its components

### Precautions

Use cautiously in:

- hepatic disease, renal dysfunction, hypovolemia, sodium depletion
- elderly patients
- pregnant patients (first trimester; not recommended in second and third trimesters)
- breastfeeding patients
- children (safety and efficacy not established)

### Administration

- Give with or without food.
- Know that drug may be used alone or with other antihypertensives.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Variable</td>
<td>1-2 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

### Adverse reactions

**CNS:** fatigue, dizziness, headache, insomnia

**CV:** orthostatic hypotension, chest pain, peripheral edema, syncope, tachycardia

**EENT:** sinusitis, rhinitis, pharyngitis

**GI:** nausea, diarrhea, constipation, abdominal pain, dry mouth

**GU:** hematuria

**Hematologic:** hyperglycemia

**Musculoskeletal:** back pain, arthritis, muscle weakness

**Respiratory:** upper respiratory infection symptoms, bronchitis, cough

**Skin:** dry skin, rash, inflammation, pruritus, alopecia, angioedema

**Other:** dental pain, flulike symptoms

### Interactions

**Drug-diagnostic tests.** *Triglycerides:* increased level

**Drug-herbs.** *Ephedra (ma huang):* antagonism of antihypertensive effect

### Patient monitoring

- Monitor vital signs and cardiovascular status. Stay alert for orthostatic hypotension, syncope, and peripheral edema.
- Check temperature and watch for signs and symptoms of flu and other infections (especially respiratory and EENT infections).
- Watch for angioedema.
- In volume-depleted patient, monitor blood pressure carefully after initial dose. Transient blood pressure drop may occur.

### Patient teaching

- Tell patient to take at same time each day, with or without food.
- Advise patient to promptly report signs and symptoms of infection, particularly respiratory symptoms.
- Inform patient that when he begins therapy, inadequate fluid intake, excessive perspiration, vomiting, or diarrhea may cause blood pressure to drop. Tell him to change position slowly to avoid dizziness or fainting.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
Tell female patient to notify prescriber immediately if she suspects pregnancy.

- As appropriate, review all other significant adverse reactions and interactions, especially those related to the tests and herbs mentioned above.

**olsalazine sodium**

**Dipentum**

*Pharmacologic class:* Salicylate  
*Therapeutic class:* Anti-inflammatory  
*Pregnancy risk category C*

**Action**  
Unknown. Converts to active form, mesalamine, which blocks cyclooxygenase and inhibits prostaglandin production in colon.

**Availability**  
*Capsules:* 250 mg

**Indications and dosages**  
*Ulcerative colitis in patients who can’t tolerate sulfasalazine*  
**Adults:** 500 mg P.O. b.i.d.

**Contraindications**  
- Hypersensitivity to drug or other salicylates

**Precautions**  
Use cautiously in:  
- hepatic or renal impairment, severe allergy, bronchial asthma  
- pregnant or breastfeeding patients  
- children younger than age 14.

**Administration**  
- Give with meals to reduce GI irritation.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Variable</td>
<td>60 min</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**  
*CNS:* headache, fatigue, depression, vertigo  
*GI:* nausea, vomiting, diarrhea, abdominal pain, cramps, dyspepsia, bloating, stomatitis  
*Musculoskeletal:* joint pain  
*Respiratory:* upper respiratory infection  
*Skin:* rash, itching

**Interactions**  
*Drug-drug.* _Anticoagulants, coumarin derivatives:* prolonged prothrombin time, increased International Normalized Ratio  
*Drug-food.* _Any food:* decreased GI irritation

**Patient monitoring**  
- Monitor neurologic status. Stay alert for depression.  
- Assess GI symptoms. Encourage adequate fluid intake to avoid dehydration.  
- Monitor urinalysis, blood urea nitrogen, and creatinine in patients with renal impairment.

**Patient teaching**  
- Instruct patient to take with food and to continue taking drug even after symptoms improve.  
- Tell patient to eat appropriate foods in small, frequent servings to minimize GI upset.  
- Advise patient to contact prescriber if symptoms worsen or don’t improve after 1 to 2 months of therapy.  
- Tell patient he may require periodic proctoscopy and sigmoidoscopy to determine response to drug.  
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects mood and wakefulness.  
- As appropriate, review all significant adverse reactions and interactions, especially those related to the drugs and foods mentioned above.

Reactions in **bold** are life-threatening.
omalizumab
Xolair

**Pharmacologic class:** Recombinant DNA-derived immunoglobulin G subclass 1 (IgG1) monoclonal antibody

**Therapeutic class:** Monoclonal antibody

**Pregnancy risk category B**

**Action**
Inhibits binding of IgE to high-affinity IgE receptors on surface of mast cells and basophils

**Availability**
*Powder for injection: 150 mg/vial*

**Indications and dosages**
➢ Persistent asthma in patients with positive skin tests or in vitro reactivity to perennial allergens whose symptoms aren’t adequately controlled by inhaled corticosteroids

**Adults and adolescents ages 12 and older:** 150 to 375 mg subcutaneously q 2 to 4 weeks, with dosing frequency determined by serum IgE level and weight

**Dosage adjustment**
● Significant weight change

**Contraindications**
● Hypersensitivity to drug

**Precautions**
Use cautiously in:
● elderly patients
● pregnant or breastfeeding patients
● children younger than age 12.

**Administration**
▨ Don’t discontinue abruptly.
● Don’t administer more than 150 mg per injection site.
● Prepare injection only with sterile water for injection.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcut.</td>
<td>Unknown</td>
<td>7-8 days</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
*CNS:* headache, fatigue, dizziness
*EENT:* sinusitis, pharyngitis, earache
*Musculoskeletal:* arthralgia, fracture, leg or arm pain
*Respiratory:* upper respiratory infection
*Skin:* pruritus, dermatitis
*Other:* injection-site reaction, viral infection, pain, *cancer, anaphylaxis*

**Interactions**
*Drug-diagnostic tests. Serum IgE: elevated level*

**Patient monitoring**
▨ Monitor patient for severe hypersensitivity reactions, including anaphylaxis.
▨ Watch for signs and symptoms of cancer (rare).

**Patient teaching**
▨ Tell patient to take exactly as prescribed and not to change dosage or stop drug abruptly (unless hypersensitivity reaction occurs).
▨ Instruct patient to discontinue drug and notify prescriber immediately at first sign of hypersensitivity reaction, such as rash, hives, or itching.
● Inform patient that asthma symptoms may not improve immediately after starting drug.
● Tell patient drug isn’t intended for acute asthma attacks.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.
omeprazole

Heartburn Relief®, Losec®, Mepradec®, Prilosec, Prilosec OTC, Ratio-Omeprazole®, Sandoz Omeprazole®, Zanprol®, Zegerid

Pharmacologic class: Proton pump inhibitor
Therapeutic class: Antiulcer drug
Pregnancy risk category C

Action
Reduces gastric acid secretion and increases gastric mucus and bicarbonate production, creating protective coating on gastric mucosa and easing discomfort from excess gastric acid

Availability
Capsules (delayed-release): 10 mg, 20 mg, 40 mg
Powder for oral suspension: 20 mg
Tablets (delayed-release): 20 mg

Indications and dosages
➤ Gastroesophageal reflux disease
Adults: 20 mg P.O. (capsules, powder) daily for 4 weeks
➤ Erosive esophagitis
Adults: 20 mg P.O. (capsules, powder) daily for 4 to 8 weeks
➤ Short-term treatment of active duodenal ulcer
Adults: 20 mg P.O. (capsules, powder) daily for 4 weeks. Some patients may need 4 additional weeks of therapy.
➤ To reduce risk of duodenal ulcers caused by Helicobacter pylori
Adults: 40 mg P.O. (capsules) daily in morning, given with clarithromycin t.i.d. for 2 weeks; then 20 mg daily for 2 weeks
➤ Gastric ulcers
Adults: 40 mg P.O. (capsules) daily for 4 to 8 weeks

➤ Pathologic hypersecretory conditions, including Zollinger-Ellison syndrome
Adults: Initially, 60 mg P.O. (capsules) daily; may increase up to 120 mg t.i.d. Divide daily dosages above 80 mg.
➤ Frequent heartburn (two or more episodes a week)
Adults ages 18 and older: 20 mg P.O. (OTC tablets) daily for 14 days

Off-label uses
• Posterior laryngitis
• To enhance pancreatin efficacy in treating steatorrhea in cystic fibrosis patients

Contraindications
• Hypersensitivity to drug or its components

Precautions
Use cautiously in:
• hepatic disease
• pregnant or breastfeeding patients
• children (safety not established).

Administration
• Give 30 to 60 minutes before a meal, preferably in morning.
• If desired, give concurrently with antacids.
• Know that if patient has ulcer at start of therapy, treatment may be extended.
• When giving through nasogastric tube, use powder for oral suspension, or separate capsule and mix pellets with water. Agitate syringe while injecting. After administration, flush with 30 to 60 ml of water.
• Don’t crush capsules.
• Be aware that symptomatic response doesn’t rule out gastric cancer.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Within 1 hr</td>
<td>Within 2 hr</td>
<td>72-96 hr</td>
</tr>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>10-90 min</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Reactions in bold are life-threatening.
Adverse reactions
CNS: dizziness, headache, asthenia
GI: nausea, vomiting, diarrhea, constipation, abdominal pain
Musculoskeletal: back pain
Respiratory: cough, upper respiratory tract infection
Skin: rash

Interactions
Drug-drug. Ampicillin, cyanocobalamin, iron salts, ketoconazole: reduced absorption of these drugs
Clarithromycin: increased omeprazole blood level
Diazepam, phenytoin, warfarin: prolonged elimination and increased effects of these drugs
Digoxin: increased digoxin absorption and blood level, possible digoxin toxicity
Drugs metabolized by CYP450 system: competitive metabolism
Drug-diagnostic tests. Alanine phosphatase, alkaline aminotransferase, aspartate aminotransferase, bilirubin: increased levels
Gastrin: increased level during first 1 to 2 weeks of therapy

Patient monitoring
- Assess vital signs.
- Check for abdominal pain, emesis, diarrhea, or constipation.
- Evaluate fluid intake and output.
- Watch for elevated liver function test results (rare).

Patient teaching
- Tell patient to take 30 to 60 minutes before a meal, preferably in morning.
- Instruct patient to swallow capsules or tablets whole and not to chew or crush them. If he can’t swallow capsule, tell him he may open it, carefully sprinkle and mix entire contents into 1 tbsp of cool applesauce, and swallow immediately with glass of water.
- Inform patient taking OTC delayed-release tablets for heartburn that full effect may take 1 to 4 days. Advise him not to take tablets for more than 14 days without consulting healthcare professional.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

ondansetron hydrochloride

Pharmacologic class: Serotonin type 3 (5-HT₃) antagonist
Therapeutic class: Antiemetic
Pregnancy risk category B

Action
Blocks serotonin at 5-HT₃ receptor sites in vagal nerve terminals by disrupting CNS chemoreceptor trigger zone

Availability
Injection: 2 mg/ml in 2- and 20-ml vials
Injection (premixed): 32 mg/50 ml single-dose containers
Injection USP (preservative-free): 2 mg/ml in 2-ml single-dose vials
Oral solution: 4 mg/5 ml
Tablets: 4 mg, 8 mg, 24 mg
Tablets (orally disintegrating): 4 mg, 8 mg
Indications and dosages

To prevent nausea and vomiting caused by moderately emetogenic chemotherapy

**Adults and children older than age 12:** 8 mg (tablet) or 10 ml (oral solution) P.O. b.i.d.; give first dose 30 minutes before chemotherapy and repeat dose 8 hours later. Give 8 mg (tablet) or 10 ml (oral solution) P.O. q 12 hours for 1 to 2 days after chemotherapy ends.

**Children ages 4 to 11:** 4 mg (tablet) or 5 ml (oral solution) P.O. q 8 hours; give first dose 30 minutes before chemotherapy and repeat dose 4 and 8 hours later. Give 4 mg (tablet) or 5 ml (oral solution) P.O. q 8 hours for 1 to 2 days after chemotherapy ends.

**To prevent nausea and vomiting caused by highly emetogenic chemotherapy**

**Adults and children older than age 12:** 32 mg I.V. as a single dose infused over 15 minutes, starting 30 minutes before chemotherapy; or three 0.15-mg/kg doses I.V., with first dose infused over 15 minutes, starting 30 minutes before chemotherapy and repeated 4 hours and 8 hours later.

**To prevent nausea and vomiting caused by radiation**

**Adults and children older than age 12:** 8 mg (tablet) or 10 ml (oral solution) P.O. 1 to 2 hours before radiation and repeated q 8 hours, depending on radiation type, location, and extent

**Prevention and treatment of postoperative nausea and vomiting**

**Adults and children older than age 12:**

- 16 mg (tablet) or 20 ml (oral solution) P.O. 1 hour before anesthesia induction, or 4 mg I.V. or I.M. before anesthesia or postoperatively
- **Children ages 2 to 12 weighing more than 40 kg (88 lb):** 4 mg I.V. before anesthesia or postoperatively
- **Children ages 2 to 12 weighing less than 40 kg (88 lb):** 0.1 mg/kg I.V. before anesthesia or postoperatively

Dosage adjustment
- Hepatic impairment

Contraindications
- Hypersensitivity to drug

Precautions

Use cautiously in:
- hepatic disease
- phenylketonuria (with orally disintegrating tablets)
- pregnant or breastfeeding patients
- children younger than age 12.

Administration

- Give first dose before emetogenic event.
- Remove orally disintegrating tablet by peeling back foil with dry hands; don’t push tablet through foil backing. After removing, place tablet on patient’s tongue, where it will dissolve within seconds. Tell patient to swallow saliva.
- Give undiluted when administering I.M. before anesthesia induction.
- Give undiluted by direct I.V. immediately before anesthesia induction, or postoperatively if nausea and vomiting occur. Administer slowly, over at least 30 seconds (preferably over 2 to 5 minutes).
- For intermittent I.V. infusion, dilute in 50 ml of dextrose 5% in water (D₅W) and normal saline solution or D₅W and half-normal saline solution. Infuse over 15 minutes.
- When giving I.V., don’t use flexible plastic container in series connection.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O., I.V.</td>
<td>Rapid</td>
<td>15-30 min</td>
<td>4-8 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>Rapid</td>
<td>40 min</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: headache, dizziness, malaise, drowsiness, fatigue, weakness, extrapyramidal reactions

Reactions in **bold** are life-threatening.

Clinical alert
CV: chest pain, hypotension
GI: constipation, diarrhea, abdominal pain, dry mouth
GU: urinary retention
Respiratory: bronchospasm
Skin: rash
Other: pain at injection site, shivering, anaphylaxis

Interactions
Drug-drug. *Drugs that alter hepatic enzyme activity:* altered pharmacokinetics of ondansetron
*Drug-diagnostic tests.* *Alanine aminotransferase, aspartate aminotransferase, bilirubin:* transient elevations

Patient monitoring
- Monitor GI status.
- Assess for extrapyramidal reactions.
- Check vital signs. Watch for hypotension and bronchospasm.
- Monitor fluid intake and output. Stay alert for urinary retention.

Patient teaching
- Tell patient to remove orally disintegrating tablet by peeling back foil with dry hands—not by pushing tablet through foil backing. Instruct him to place tablet on tongue, where it will dissolve within seconds, and then to swallow saliva.
- Instruct patient to immediately report extrapyramidal symptoms or allergic reaction.
- Inform patient with phenylketonuria (or caregiver) that powder contains phenylalanine.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**orlistat**
Alli, Xenical

*Pharmacologic class:* GI lipase inhibitor
*Therapeutic class:* Weight control drug
*Pregnancy risk category B*

**Action**
Inhibits absorption of dietary fats in stomach and small intestine

**Availability**
Capsules: 60 mg (over-the-counter drug), 120 mg

**Indications and dosages**
- Obesity management (in conjunction with reduced-calorie diet); to reduce risk of regaining after weight loss
  - **Adults:** 120 mg (Xenical) P.O. t.i.d. with each meal containing fat
  - Weight loss in overweight adults (in conjunction with reduced-calorie and low-fat diet)
  - **Adults ages 18 and older:** 60 mg (Alli) P.O. t.i.d. with each meal containing fat

**Contraindications**
- Hypersensitivity to drug or its components
- Chronic malabsorption syndrome or cholestasis
- Patients who have had organ transplant or are taking drugs to reduce organ rejection (such as cyclosporine), patients with known problems absorbing food (Alli)

**Precautions**
Use cautiously in:
- hypothyroidism, nephrolithiasis, diabetes mellitus, clinically significant GI disease, fat-soluble vitamin deficiencies
- history of bulimia or anorexia nervosa
- pregnant or breastfeeding patients
- children.
Administration

- Know that organic causes of obesity should be ruled out before therapy starts.
- Give three times daily with meal containing fat (Alli) or up to 1 hour after a meal (Xenical).
- If patient misses a meal or eats a fat-free meal, omit dose.
- Know that orlistat therapy is frequently combined with psychotherapy.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>8 hr</td>
<td>48-72 hr</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: Xenical: dizziness, headache, fatigue, insomnia, depression, anxiety
EENT: Xenical: ear, nose, and throat symptoms
GI: fecal urgency, flatus with discharge, oily or increased bowel movements, oily spotting, fecal incontinence
GU: Xenical: urinary tract infection (UTI), vaginitis, menstrual irregularities
Musculoskeletal: Xenical: back pain, arthritis, myalgia, tendinitis
Respiratory: Xenical: upper or lower respiratory infection
Skin: Xenical: dry skin, rash
Other: Xenical: dental pain, tooth disorder, influenza

Interactions

Drug-drug. Beta-carotene, fat-soluble vitamins: reduced vitamin absorption
Cyclosporine: reduced cyclosporine blood level (Xenical)
Pravastatin: increased lipid-lowering effects (Xenical)
Warfarin: altered coagulation parameters

Patient monitoring

- Watch for signs and symptoms of UTI, respiratory infection, and EENT disorders.
- Monitor patient for weight loss.
- Evaluate patient’s diet for appropriate caloric intake.

Patient teaching

- Instruct patient to take with meals as directed. Tell him he may omit a dose if he misses a meal or eats a fat-free meal.
- Advise patient to consume reduced-calorie diet and to spread daily fat intake over three main meals.
- Inform patient that drug predisposes him to EENT, respiratory, and urinary infections. Instruct him to promptly report signs and symptoms.
- Tell patient about common adverse GI reactions, including problems controlling bowel movements. If significant GI upset occurs, encourage him to consult prescriber about taking psyllium at bedtime or with each dose.
- Advise patient to ask prescriber if he should take a daily multivitamin containing vitamins A, D, E, K, and beta-carotene at least 2 hours before or after taking drug.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

Reactions in bold are life-threatening.
Availability
Capsules: 30 mg, 45 mg, 75 mg
Powder for oral suspension: 12 mg/ml

Indications and dosages
➣ To prevent influenza type A
Adults and children older than age 13:
75 mg P.O. daily for more than 7 days, starting within 2 days of exposure
➣ Treatment of influenza type A
Adults and children older than age 13:
75 mg P.O. b.i.d. for 5 days, starting within 2 days of symptom onset
Children ages 1 and older who weigh more than 40 kg (88 lb):
75 mg P.O. b.i.d. for 5 days, starting within 2 days of symptom onset
Children ages 1 and older who weigh more than 23 kg and up to 40 kg (51 to 88 lb):
60 mg P.O. b.i.d. for 5 days, starting within 2 days of symptom onset
Children ages 1 year and older who weigh more than 15 kg and up to 23 kg (33 to 51 lb):
45 mg P.O. b.i.d. for 5 days, starting within 2 days of symptom onset
Children ages 1 year and older who weigh less than 15 kg (33 lb):
30 mg P.O. b.i.d. for 5 days, starting within 2 days of symptom onset

Dosage adjustment
● Renal impairment

Contraindications
● Hypersensitivity to drug or its components

Precautions
Use cautiously in:
● chronic cardiac or renal disease, respiratory disorders
● elderly patients
● pregnant or breastfeeding patients

Administration
● For flu treatment, give first dose at onset of symptoms. For flu prevention, give within 2 days of exposure.

Route | Onset | Peak | Duration
--- | --- | --- | ---
P.O. | Variable | 2.5 | 6 hr

Adverse reactions
CNS: headache, dizziness, fatigue, insomnia
GI: nausea, vomiting, diarrhea
Respiratory: cough, bronchitis

Interactions
None significant

Patient monitoring
● Monitor respiratory status. Watch for signs and symptoms of secondary infection.

Patient teaching
● Instruct patient to take as soon as flu symptoms occur and to complete entire course of therapy.
● Advise patient to take with food or milk to minimize GI irritation.
● Tell patient to prepare oral solution by adding water to powder and shaking well.
● Caution patient not to share drug with others, even if they have similar symptoms.
● Instruct patient to consult prescriber before taking other drugs.
● As appropriate, review all other significant adverse reactions.

oxaliplatin
Eloxitan

Pharmacologic class: Alkylator
Therapeutic class: Antineoplastic
Pregnancy risk category D

FDA BOXED WARNING
● Anaphylaxis may occur within minutes of administration. Epinephrine,
corticosteroids, and antihistamines have been used to relieve symptoms.

**Action**
Unclear. Thought to form reactive platinum complexes that inhibit DNA synthesis through formation of interstrand and intrastrand cross-linking of DNA molecules. Cell-cycle-phase non-specific.

**Availability**
*Powder for injection:* 50 mg, 100 mg in single-use vials

**Indications and dosages**

▶ Metastatic cancer of colon or rectum, given with 5-fluorouracil (5-FU) and leucovorin

**Adults:** On day 1, 85 mg/m² oxaliplatin I.V. infusion and 200 mg/m² leucovorin; give both drugs simultaneously over 2 hours, followed by 400 mg/m² I.V. bolus of 5-FU over 2 to 4 minutes, then 600 mg/m² 5-FU I.V. as 22-hour continuous infusion. On day two, 200 mg/m² leucovorin I.V. infusion over 2 hours, followed by 400 mg/m² 5-FU I.V. bolus over 2 to 4 minutes, then 600 mg/m² 5-FU I.V. as 22-hour continuous infusion.

**Contraindications**
- Hypersensitivity to drug or platinum products

**Precautions**
Use cautiously in:
- thrombocytopenia
- radiation therapy
- recent pneumococcal or smallpox vaccination
- elderly patients
- pregnant or breastfeeding patients
- children.

**Administration**

▶ Follow facility policy for preparing, handling, and administering

mutagenic, teratogenic, and carcinogenic drugs.
- Premedicate patient with antiemetics, as prescribed.
- Reconstitute with sterile water or dextrose 5% in water (D₅W)—never with normal saline solution or other solutions containing chloride.
- Further dilute reconstituted drug in 250 to 500 ml of D₅W.
- Infuse over 2 hours simultaneously with leucovorin, but in a separate I.V. bag.
- Don’t use administration sets or needles that contain aluminum.
- Be aware of importance of using leucovorin rescue with this drug.
- Avoid extravasation, which may cause necrosis and other severe reactions.
- Know that treatment cycles are usually repeated every 2 weeks.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- **CNS:** headache, dizziness, fatigue, insomnia, peripheral neuropathy
- **CV:** cardiac abnormalities
- **EENT:** decreased visual acuity, hearing loss, tinnitus, rhinitis, pharyngitis
- **GI:** severe nausea, vomiting, diarrhea, constipation, dyspepsia, gastroesophageal reflux, mucositis, flatulence, stomatitis, anorexia
- **GU:** hematuria, dysuria
- **Hematologic:** anemia, thrombocytopenia, leukopenia, pancytopenia, neutropenia, hemolytic uremic syndrome
- **Metabolic:** hypokalemia
- **Respiratory:** dyspnea, cough, upper respiratory infection, pulmonary fibrosis
- **Skin:** alopecia, rash, flushing, extravasation, redness, swelling, angioedema
- **Other:** weight loss, increased cold sensitivity, pain at injection site, anaphylaxis

Reactions in **bold** are life-threatening.
Interactions

Drug-drug. Aminoglycosides, loop diuretics: increased risk of nephrotoxicity
Aspirin, nonsteroidal anti-inflammatory drugs: increased risk of bleeding
Live-virus vaccines: decreased antibody response to vaccine
Myelosuppressants: increased bone marrow depression

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, bilirubin, creatinine: increased levels
Hemoglobin, neutrophils, platelets, white blood cells: decreased levels

Drug-behaviors. Alcohol use: increased risk of bleeding

Patient monitoring
- Monitor I.V. site frequently to avoid extravasation.
- Monitor CBC, blood chemistry, and kidney and liver function tests before each treatment cycle.
- Watch closely for blood dyscrasias, hemolytic uremic syndrome, serious pulmonary problems, and anaphylaxis.
- Conduct complete neurologic exam before and after each dose.
- Monitor vital signs and ECG. Evaluate cardiovascular and respiratory status closely.
- Assess patient's comfort level. Keep him warm during infusion to minimize neurologic effects.
- Watch for signs and symptoms of toxicity (paresthesia, nausea, vomiting).

Patient teaching
- Inform patient that chemotherapy drugs can cause many adverse effects.
- Tell patient he'll receive drug from trained healthcare professionals in hospital setting.
- Instruct patient to inform nurse immediately if drug contacts his skin, eyes, or mouth.
- Advise patient to notify nurse if pain or redness occurs at I.V. site.
- Instruct patient to stay warm and avoid iced drinks to minimize neurologic symptoms.
- Tell patient to report itching, hives, swelling of hands or face, chest tightness, difficulty breathing, unsteadiness, severe diarrhea or vomiting, or tingling sensation in hands, arms, legs, or feet.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

oxandrolone
Oxandrin

Pharmacologic class: Hormone
Therapeutic class: Anabolic steroid
Controlled substance schedule III
Pregnancy risk category X

FDA BOXED WARNING
- Drug may cause peliosis hepatis (condition marked by replacement of liver and sometimes splenic tissue with blood-filled cysts). Commonly, this condition isn’t recognized until life-threatening liver failure or intra-abdominal hemorrhage develops. With drug withdrawal, lesions usually disappear completely.
- Liver cell tumors may occur. Usually, these are benign and androgen-dependent, but fatal malignant tumors have been reported. Drug withdrawal causes tumor to regress or stop progressing. However, hepatic tumors linked to androgens or anabolic steroids may be silent until life-threatening intra-abdominal hemorrhage develops.
- Drug may result in blood lipid changes with known link to increased
risk of atherosclerosis and coronary artery disease.

**Action**
Promotes body-tissue building process, reverses catabolic or tissue-depleting processes, and increases hemoglobin and red cell mass. Also has androgenic and anabolic properties.

**Availability**
*Tablets*: 2.5 mg, 10 mg

**Indications and dosages**

> To promote weight gain; to relieve bone pain accompanying osteoporosis

**Adults**: 2.5 mg P.O. two to four times daily, to a maximum of 20 mg/day, usually for 2 to 4 weeks. Repeat intermittently p.r.n.

**Children**: Total daily dosage of 0.1 mg/kg P.O. or less

**Off-label uses**
- Alcoholic hepatitis

**Contraindications**
- Hypersensitivity to anabolic steroids
- Nephrotic phase of nephritis
- Women with breast cancer and hypercalcemia
- Men with prostate or breast cancer
- Pregnancy

**Precautions**
Use cautiously in:
- renal, hepatic, or cardiac impairment; benign prostatic hypertrophy; pituitary insufficiency; myocardial infarction
- breastfeeding patients.

**Administration**

- Verify that patient isn’t pregnant before giving.
- Give with food or meals if GI upset occurs.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Slow</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS**: insomnia, excitation, toxic confusion

**GI**: nausea, vomiting, diarrhea, abdominal fullness, burning sensation of tongue, anorexia, **intra-abdominal hemorrhage**

**GU**: increased risk of prostatic hypertrophy, virilization, phallic enlargement in prepubertal boys, inhibited testicular function in postpubertal males, gynecomastia, priapism, epididymitis, libido changes, clitoral enlargement, menstrual irregularities

**Hematologic**: iron deficiencies

**Hepatic**: hepatotoxicity, peliosis hepatis, hepatic cell tumor

**Metabolic**: fluid retention, hypercalcemia

**Musculoskeletal**: ankle swelling, premature epiphyseal closure in children

**Skin**: acne, increased skin pigmentation, hirsutism and male-pattern baldness in women

**Other**: chills, hoarseness, deepening of voice in women

**Interactions**

**Drug-drug. Anticoagulants**: potentiation of anticoagulant action

**Insulin, oral hypoglycemics**: decreased requirements for these drugs

**Drug-diagnostic tests. Creatinine, creatinine clearance**: increased values

**Cholesterol, lipids**: altered levels

**Glucose tolerance tests**: altered results

**Thyroid function**: decreased values

**Patient monitoring**

- Assess patient for edema and need for diuretic therapy.
- Monitor periodic liver function tests and electrolyte levels.
- Assess periodic cholesterol levels in patients at increased risk for coronary artery disease.
- Monitor diabetic patients carefully (drug may alter glucose tolerance).

Reactions in **bold** are life-threatening.
Patient teaching
- Tell patient to take with food or meals.
- Inform patient that drug shouldn’t be taken to increase muscle strength; it doesn’t enhance athletic ability and can cause serious side effects.
- Advise diabetic patient to monitor urine or blood glucose carefully and report abnormal levels.
- Instruct patient to report ankle swelling, skin color changes, severe nausea or vomiting, unusual body hair growth, acne, and menstrual changes.
- Advise female patient not to take drug if she is or plans to become pregnant.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

oxaprozin
Apo-Oxaprozin, Daypro, Rhoxal-Oxaprozin

oxaprozin potassium
Pharmacologic class: Propionic acid derivative, nonsteroidal anti-inflammatory drug (NSAID)
Therapeutic class: Anti-inflammatory, analgesic
Pregnancy risk category C (first and second trimesters), D (third trimester)

FDA BOXED WARNING
- Drug may increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke. Risk may increase with duration of use. Patients with cardiovascular disease or risk factors for it may be at greater risk.
- Drug increases risk of serious GI adverse events, including bleeding, ulcers, and stomach or intestinal perforation. These events can occur at any time during use and without warning. Elderly patients are at greater risk.
- Drug is contraindicated for treatment of perioperative pain in setting of coronary artery bypass graft surgery.

Action
Unclear. Thought to inhibit prostaglandin synthesis by blocking cyclooxygenase (COX-2), thereby reducing inflammation.

Availability
Tablets: 600 mg
Caplets: 600 mg

Indications and dosages
- Rheumatoid arthritis; osteoarthritis
Adults: 1,200 mg daily in two to three divided doses. Maximum daily dosage is 1,800 mg (1,200 mg for potassium form).

Dosage adjustment
- Mild disease
- Renal impairment
- Low body weight

Contraindications
- Hypersensitivity to drug
- Concurrent use of other NSAIDs (including aspirin)
- Active GI bleeding or ulcer disease

Precautions
Use cautiously in:
- severe cardiovascular or hepatic disease, renal impairment
- history of ulcer disease
- pregnant or breastfeeding patients
- children (safety not established).

Administration
- Give with food or after meals if GI upset occurs.
- Use lowest effective dosage to minimize adverse reactions.
Adverse reactions
CNS: dizziness, fatigue, headache, agitation, anxiety, confusion, depression, insomnia, malaise, paresthesia, tremor
CV: edema, vasculitis, blood pressure changes
EENT: abnormal vision, tinnitus
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, gastritis, dyspepsia, duodenal ulcer, flatulence, stomatitis, dry mouth, anorexia, GI bleeding
GU: albuminuria, azotemia, interstitial nephritis, acute renal failure
Hematologic: anemia
Hepatic: cholestatic jaundice, hepatitis
Respiratory: dyspnea, hypersensitivity pneumonitis
Skin: rash, pruritus, diaphoresis, photosensitivity, angioedema, Stevens-Johnson syndrome
Other: appetite and weight increases, allergic reactions including anaphylaxis

Interactions
Drug-drug. Alcohol, aspirin and other NSAIDs, corticosteroids, potassium supplements: additive adverse GI effects and toxicity
Anticoagulants, cefamandole, cefoperazone, cefotetan, clopidogrel, epifibatide, plicamycin, thrombolytics, ticlopidine, tirofiban, vitamin A: increased risk of bleeding
Antineoplastics: increased risk of adverse hematologic reactions
Insulin, oral hypoglycemics: increased hypoglycemic effects of these drugs
Methotrexate: increased risk of methotrexate toxicity
Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, blood urea nitrogen, creatinine, lactate dehydrogenase, potassium: increased levels
Bleeding time: prolonged (for up to 2 weeks after drug discontinuation)
Creatinine clearance, glucose, hemoglobin, hematocrit, platelets, white blood cells: decreased levels
Liver function tests: abnormal results

Drug-hers. Alfalfa, anise, arnica, astragalus, bilberry, black currant seed oil, bladderwrack, bogbean, boldo (with fenugreek), borago oil, buchu, capsaicin, cat’s claw, celery, chamomile, chapparal, chinchona bark, clove, clove oil, dandelion, dong quai, evening primrose oil, fenugreek, feverfew, garlic, ginger, ginkgo, ginseng, guggul, licorice, papaya extract, red clover, rhubarb, safflower oil, skullcap, tan-shen: increased anticoagulant effect and bleeding risk

Patient monitoring
• Monitor kidney and liver function tests, coagulation studies, and CBC.
  Watch for signs and symptoms of acute renal failure, nephritis, hepatitis, bleeding tendency, and anemia.
• Monitor hearing and vision, including results of eye exams.
  Watch for and promptly report rash or swelling.
• Assess respiratory status closely. Stay alert for dyspnea and pneumonitis.

Patient teaching
• Instruct patient to take with food or meal.
• Inform patient that many common over-the-counter drugs (including acetaminophen, aspirin, and other NSAIDs) and herbal preparations increase drug’s adverse effects. Tell him to consult prescriber before taking these products.
  Instruct patient to immediately report rash, unusual tiredness, yellowing of skin or eyes, easy bruising or bleeding, change in urination pattern, weight gain, arm or leg swelling, vision changes, and black or tarry stools.
Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.

Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

Advise patient on long-term therapy to have periodic eye exams.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

oxazepam


Pharmacologic class: Benzodiazepine
Therapeutic class: Anxiolytic, sedative-hypnotic
Controlled substance schedule IV
Pregnancy risk category D

Action
Suppresses CNS stimulation at limbic and subcortical levels by potentiating effects of gamma-aminobutyrate, an inhibitory neurotransmitter. This suppression reduces anxiety and diminishes alcohol withdrawal symptoms.

Availability
Capsules: 10 mg, 15 mg, 30 mg
Tablets: 15 mg

Indications and dosages
➤ Minor to moderate anxiety
Adults: 10 to 15 mg P.O. three to four times daily
➤ Severe anxiety; alcohol withdrawal symptoms
Adults: 15 to 30 mg P.O. three to four times daily

Dosage adjustment
• Elderly patients

Off-label uses
• Insomnia

Contraindications
• Hypersensitivity to drug or tartrazine (some products)

Precautions
Use cautiously in:
• hepatic dysfunction, severe chronic obstructive pulmonary disease, myasthenia gravis, CNS depression, uncontrolled severe pain
• history of suicide attempt or drug abuse
• concurrent use of other benzodiazepines
• elderly or debilitated patients
• pregnant or breastfeeding patients.

Administration
• Administer with or without food.
• Taper dosage after long-term therapy.

Route Onset Peak Duration
P.O. 45-90 min 3 hr 6-12 hr

Adverse reactions
CNS: dizziness, drowsiness, headache, confusion, poor memory, hangover effect, slurred speech, depression, paradoxical stimulation
CV: orthostatic hypotension, hypotension, ECG changes, tachycardia
EENT: blurred vision, mydriasis, tinnitus
GI: nausea, vomiting, constipation, diarrhea
GU: urinary retention, urinary incontinence
Hematologic: leukopenia
Hepatic: jaundice, hepatitis
Respiratory: respiratory depression
Skin: rash, dermatitis, itching

Canada UK Hazardous drug High alert drug
Other: physical and psychological drug dependence, drug tolerance, withdrawal symptoms

Interactions
Drug-drug. Azole antifungals: increased oxazepam blood level, greater risk of toxicity
Hormonal contraceptives, phenytoin: decreased oxazepam efficacy
Levodopa: decreased levodopa efficacy
Other CNS depressants (including antidepressants, antihistamines, other benzodiazepines, sedative-hypnotics, opioids): additive CNS depression
Theophylline: decreased sedative effect of oxazepam

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, lactate dehydrogenase: increased levels
Hematocrit, thyroid uptake of sodium iodide $^{123}$I and $^{131}$I, white blood cells: decreased values

Drug-food. Cabbage: decreased drug blood level

Drug-herbs. Chamomile, hops, kava, valerian, skullcap: increased CNS depression

Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring
- Monitor liver function tests and watch for signs and symptoms of hepatitis.
- Check vital signs. Stay alert for respiratory depression, orthostatic hypotension, and tachycardia.
- Monitor neurologic status. As needed, take measures to prevent injury.
- Watch for signs and symptoms of psychological or physical dependence.
- When tapering, watch for withdrawal symptoms.

Patient teaching
- Tell patient he may take with or without meals, but should avoid cabbage.
- Advise patient to take exactly as prescribed. Tell him drug can cause dependence, and emphasize importance of following tapering instructions to avoid withdrawal symptoms.
- Urge patient to immediately report unusual tiredness, nausea, appetite loss, or yellowing of skin or eyes.
- Tell patient to change position slowly to avoid blood pressure decrease.
- Instruct patient to report severe dizziness, weakness, persistent drowsiness, palpitations, or visual changes.
- Advise patient not to drink alcohol.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects vision, cognition, and balance.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

oxcarbazepine
Apo-Oxcarbazepine®, Trileptal

Pharmacologic class: Carboxamide derivative
Therapeutic class: Anticonvulsant
Pregnancy risk category C

Action
Blocks sodium channels in neural membranes, stabilizing hyperexcitable states and inhibiting neuronal firing and impulse transmission in brain

Availability
Oral suspension: 300 mg/5-ml bottle
Tablets: 150 mg, 300 mg, 600 mg

Reactions in bold are life-threatening.
Indications and dosages

> Adjunctive therapy for partial seizures

Adults: 300 mg P.O. b.i.d. May increase by up to 600 mg/day q week, to a maximum of 1,200 mg/day.

Children ages 4 to 16: Initially, 8 to 10 mg/kg/day P.O. to a maximum of 600 mg/day

> Conversion to monotherapy for partial seizures

Adults: 300 mg P.O. b.i.d. May increase by 600 mg/day at weekly intervals over 2 to 4 weeks, to a maximum of 2,400 mg/day

Children ages 4 to 16: Initially, 8 to 10 mg/kg/day P.O. given in two divided doses, increased to a maximum of 10 mg/kg/day

> Initiation of monotherapy

Adults: 300 mg P.O. b.i.d., increased by 300 mg/day P.O. q 3 days up to 1,200 mg/day

Children ages 4 to 16: Initially, 8 to 10 mg/kg/day P.O. given in two divided doses; increase by 5 mg/kg q 3 days to a maximum of 1,200 mg/day

Dosage adjustment

- Renal impairment

Contraindications

- Hypersensitivity to drug or its components

Precautions

Use cautiously in:

- renal impairment
- pregnant or breastfeeding patients
- children younger than age 4 (safety not established).

Administration

- Administer twice daily with or without food.
- Shake oral suspension well. If desired, mix in small glass of water.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: dizziness, vertigo, drowsiness, fatigue, headache, ataxia, tremor, emotional lability

EENT: abnormal vision, diplopia, nystagmus, rhinitis

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia

Metabolic: hyponatremia

Skin: acne, rash

Other: thirst, allergic reactions, edema, lymphadenopathy

Interactions

Drug-drug. Carbamazepine, valproic acid, verapamil: decreased oxcarbazepine blood level

CNS depressants (including antidepressants, antihistamines, opioids, sedative-hypnotics): additive CNS depression

Felodipine, hormonal contraceptives: decreased blood levels of these drugs

Phenobarbital: decreased oxcarbazepine and increased phenobarbital blood levels

Phenytoin: increased phenytoin blood level

Drug-diagnostic tests. Sodium: decreased level

Drug-behaviors. Alcohol use: additive CNS depression

Patient monitoring

- Monitor neurologic status closely for changes in cognition, mood, wakefulness, balance, and gait.
- Check sodium level. Watch for signs and symptoms of hyponatremia.

Patient teaching

- Instruct patient to take at same time each day, with or without food.
- Tell patient to report vision changes and significant neurologic changes.
- Advise patient to have periodic eye exams.
- Tell female patient that drug makes hormonal contraceptives less effective.
- Inform patient that he may need frequent tests to check drug blood levels.
Tell patient not to drink alcohol.

- Caution patient to avoid driving and other hazardous activities until he knows how drug affects him.
- As appropriate, review all significant adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

**oxybutynin**

Cystrin®, Kentera®, Oxytrol

**oxybutynin chloride**

Apo-Oxybutinin®, Ditropan, Ditropan XL, Dom-Oxybutin®, Gen-Oxybutinin®, Lyrinel XL®, Novo-Oxybutinin®, Nu-Oxybutinin®, PHL-Oxybutinin®, PMS-Oxybutinin®, Uromax®

**Pharmacologic class:** Anticholinergic

**Therapeutic class:** Urinary tract anti-spasmodic

**Pregnancy risk category B**

**Action**

Inhibits acetylcholine action at post-ganglionic receptors, relaxing smooth muscle lining of GU tract and preventing bladder irritability

**Availability**

- **Syrup:** 5 mg/5 ml
- **Tablets:** 5 mg
- **Tablets (extended-release):** 5 mg, 10 mg, 15 mg
- **Transdermal system (patch):** 39 cm²/36 mg

**Indications and dosages**

- Frequent urination, urinary urgency or incontinence, and nocturia caused by neurogenic bladder; overactive bladder

**Adults:** 5 mg P.O. two to three times daily (not to exceed 5 mg q.i.d.); or 5 to 15 mg P.O. once daily (extended-release); or one 3.9 mg/day transdermal system applied twice weekly

**Children older than age 5:** 5 mg P.O. b.i.d., to a maximum of 5 mg t.i.d.

**Dosage adjustment**

- Elderly patients

**Contraindications**

- Hypersensitivity to drug
- Glaucoma
- Intestinal obstruction, severe colitis, atony, paralytic ileus, megacolon, or hemorrhage
- Obstructive uropathy, urinary retention
- Myasthenia gravis
- Acute hemorrhage with shock

**Precautions**

Use cautiously in:

- cardiovascular disease, hyperthyroidism, GI disease
- elderly patients
- pregnant or breastfeeding patients
- children younger than age 5 (safety not established).

**Administration**

- Give without regard to food.
- Don’t crush or break tablets.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30-60 min</td>
<td>3-6 hr</td>
<td>6-10 hr</td>
</tr>
<tr>
<td>P.O. (extended)</td>
<td>30-60 min</td>
<td>3-6 hr</td>
<td>Up to 24 hr</td>
</tr>
<tr>
<td>Transdermal</td>
<td>24-48 hr</td>
<td>48-96 hr</td>
<td>96 hr after removal</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** dizziness, drowsiness, hallucinations, insomnia, weakness, anxiety, restlessness, headache

**CV:** palpitations, hypotension, tachycardia

**EENT:** blurred vision, cycloplegia, increased intraocular pressure, mydriasis, photophobia

Reactions in **bold** are life-threatening.

**Clinical alert**
GI: nausea, vomiting, diarrhea, constipation, bloating, dry mouth
GU: urinary hesitancy, urinary retention, erectile dysfunction, suppressed lactation
Metabolic: hyperthermia
Skin: decreased sweating, urticaria
Other: allergic reactions, fever, hot flashes

Interactions
Drug-drug. Anticholinergics, anti-cholinergic-like drugs (including amantadine, antidepressants, disopyramide, haloperidol, phenothiazines): additive anticholinergic effects
Atenolol: increased atenolol absorption
CNS depressants (including antidepressants, antihistamines, opioids, sedative-hypnotics): additive CNS depression
Digoxin: increased digoxin blood level (with extended-release oxybutynin)
Haloperidol: decreased haloperidol blood level, tardive dyskinesia, worsening of schizophrenia
Levodopa: decreased levodopa efficacy
Nitrofurantoin: increased nitrofurantoin blood level, greater risk of toxicity
Drug-herbs. Angel’s trumpet, jimsonweed, scopolia: increased anticholinergic effects
Drug-behaviors. Alcohol use: additive CNS depression

Patient monitoring
- Monitor vital signs and temperature. Watch for hypotension, fever, and tachycardia.
- Evaluate patient’s vision.
- Assess results of cystometric studies. Stay alert for urinary retention.

Patient teaching
- Tell patient he may take with or without food. Caution him not to crush, break, or chew extended-release tablets.
- Instruct patient to apply transdermal patch to dry, intact skin on abdomen, hip, or buttock. Tell him to use a new skin area with each new system and not to reapply new patch to same site within 7 days. Caution him not to cut or puncture patch.
- Tell patient to report blurred vision, fever, skin rash, nausea, or vomiting.
- Advise patient he’ll need to undergo periodic bladder exams.
- Caution patient to avoid driving and other hazardous activities if drug causes drowsiness or blurred vision.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, herbs, and behaviors mentioned above.
Instruct patients to swallow extended-release tablets whole. Caution them not to break, chew, or crush them, as this causes rapid release and absorption of potentially fatal dose.

**Action**
Unknown. Thought to interact with opioid receptor sites primarily in limbic system, thalamus, and spinal cord, blocking transmission of pain impulses.

**Availability**
- **Capsules (immediate-release):** 5 mg
- **Solution (oral):** 5 mg/5 ml
- **Solution (oral concentrate):** 20 mg/ml
- **Tablets:** 5 mg
- **Tablets (controlled-release):** 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg
- **Tablets (immediate-release):** 15 mg, 30 mg

**Indications and dosages**
- Moderate to severe pain
  - **Adults:** 5 mg P.O. q 6 hours p.r.n., increased gradually to 10 to 30 mg q 6 hours p.r.n.
- Moderate or severe pain when continuous around-the-clock analgesia is needed
  - **Adults:** 10 mg P.O. (controlled-release) q 12 hours. For patients already taking opioids, use total oral oxycodone daily equianalgesic dosage and then round down to closest tablet strength. For breakthrough pain, give supplemental immediate-release doses.

**Dosage adjustment**
- Hepatic disease
- Renal impairment
- Debilitated or opioid-naive patients

**Off-label uses**
- Postherpetic neuralgia (controlled-release form)

**Contraindications**
- Hypersensitivity to drug
- Paralytic ileus
- When opioids are contraindicated (as in respiratory depression, severe bronchial asthma, hypercarbia)

**Precautions**
Use cautiously in:
- head trauma; increased intracranial pressure (ICP); severe renal, hepatic, or pulmonary disease; hypothyroidism; adrenal insufficiency; undiagnosed abdominal pain or prostatic hyperplasia; extensive burns; alcoholism
- history of substance abuse
- prolonged or high-dose therapy
- elderly or debilitated patients
- labor and delivery
- pregnant or breastfeeding patients
- children younger than age 18.

**Administration**
- Be aware that drug has high abuse potential.
- Know that controlled-release OxyContin isn’t indicated for p.r.n. pain control but is reserved for patients who need continuous, around-the-clock analgesia.
- Be aware that 80-mg controlled-release tablets are for opioid-tolerant patients only.
- Never break, crush, or let patient chew controlled-release forms. Otherwise, rapid release and absorption of potentially fatal dose may occur.
- Add concentrated solution to juice, applesauce, pudding, or other semi-solid food immediately before giving.
- When discontinuing, taper dosage gradually to prevent withdrawal symptoms.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>15-30 min</td>
<td>1 hr</td>
<td>4-6 hr</td>
</tr>
<tr>
<td>P.O. (controlled)</td>
<td>Unknown</td>
<td>24-36 hr</td>
<td>&gt;12 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
CNS: dizziness, asthenia, drowsiness, euphoria, light-headedness, insomnia,
confusion, anxiety, twitching, abnormal dreams and thoughts
CV: orthostatic hypotension, circulatory depression, bradycardia, shock
GI: nausea, vomiting, constipation, diarrhea, ileus, abdominal pain, dyspepsia, gastritis, anorexia
GU: urinary retention
Respiratory: apnea, respiratory depression, respiratory arrest
Skin: pruritus, sweating
Other: chills, fever, hiccups, physical and psychological drug dependence

Interactions
Drug-drug. Antihistamines, sedative-hypnotics: additive CNS depression
Barbiturates, protease inhibitors: increased respiratory and CNS depression
Opioid agonist-antagonists: precipitation of opioid withdrawal in physically dependent patients
Drug-diagnostic tests. Amylase, lipase: increased levels
Drug-behaviors. Alcohol use: additive CNS depression

Patient monitoring
- Monitor vital signs and respiratory status. Withhold drug in significant respiratory or CNS depression.
- Assess patient’s pain level frequently.
- Monitor bowel and bladder function.
- Assess patient for anxiety, twitching, and other CNS symptoms.
- Closely monitor head-trauma patient. Drug may increase ICP while masking signs and symptoms.
- Carefully assess patient with acute abdominal pain. Drug may obscure diagnosis.
- Stay alert for drug hoarding, tolerance, and dependence.

Patient teaching
- Caution patient not to break, crush, chew, or dissolve controlled-release tablets. Warn him that doing so may cause rapid drug release and absorption (possibly fatal).
- Tell patient taking controlled-release form not to drive for 3 to 4 days after dosage increase, after consuming even a single alcoholic beverage, or if also taking antihistamines or other drugs that cause drowsiness.
- Instruct patient to promptly report adverse reactions, especially difficulty breathing or slow pulse.
- Advise patient not to drink alcohol.
- Tell patient not to be alarmed if tablets appear in stools; drug has already been absorbed.
- Advise ambulatory patient to change position slowly, to avoid dizziness from orthostatic hypotension.
- Instruct patient to consult prescriber before taking other drugs.
- Caution patient to avoid driving and other hazardous activities, because drug may cause drowsiness or dizziness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

oxymorphone hydrochloride
Opana, Opana ER, Oxynorm®
Pharmacologic class: Opioid agonist
Therapeutic class: Narcotic analgesic
Controlled substance schedule II
Pregnancy risk category C

FDA BOXED WARNING
- Drug is morphine-like opioid agonist and Schedule II controlled substance, with abuse potential similar to other opioids. This potential must be considered when prescribing or dispensing drug.
Drug is indicated for managing moderate to severe pain when continuous, around-the-clock opioid is needed for extended period. It isn't intended for as-needed analgesia.

- Instruct patients to swallow extended-release tablets whole. Caution them not to break, chew, dissolve, or crush them, as this causes rapid release and absorption of potentially fatal dose.
- Caution patient not to consume alcoholic beverages or take prescription or nonprescription medications containing alcohol during therapy, as this may increase drug blood levels and cause potentially fatal overdose.

**Action**

Unknown. Thought to interact with opioid receptor sites primarily in limbic system, thalamus, and spinal cord, blocking pain impulse transmission.

**Availability**

*Injection:* 1 mg/ml, 1.5 mg/ml

*Tablets:* 5 mg, 10 mg

*Tablets (extended-release):* 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg

**Indications and dosages**

> **Moderate to severe pain**

**Adults:** 1 to 1.5 mg I.M. or subcutaneously q 4 to 6 hours p.r.n.; or initially, 0.5 mg I.V., increased cautiously until pain relief is satisfactory

> **To reduce labor pain**

**Adults:** 0.5 to 1 mg I.M.

> **Initiation of therapy for moderate to severe acute pain in opioid-naïve patients**

**Adults:** 10 to 20 mg (Opana) P.O. q 4 to 6 hours depending on initial pain intensity. If deemed necessary to initiate therapy at lower dose, start with 5 mg. Adjust dosage based on patient’s response to initial dose. Dose can then be adjusted to acceptable level of analgesia taking into account pain intensity and adverse effects experienced. For chronic around-the-clock opioid therapy, give 5 mg (Opana ER) q 12 hours; thereafter, individually adjust dosage, preferably at increments of 5 to 10 mg q 12 hours every 3 to 7 days to level that provides adequate analgesia and minimizes side effects; give under close supervision of prescribing physician.

> **Moderate to severe acute pain when converting from parenteral to oral form in patients requiring continuous, around-the-clock opioid treatment for extended period**

**Adults:** 10 times patient’s total daily parenteral oxymorphone dose as Opana, in four or six equally divided doses (for example, approximately 10 mg Opana may be needed to provide pain relief equivalent to total daily I.M. dose of 4 mg oxymorphone); titrate dosage to optimal pain relief or combine with acetaminophen/nonsteroidal anti-inflammatories for optimal pain relief. Or 10 times patient’s total daily parenteral oxymorphone dose as Opana ER, in two equally divided doses (for example, approximately 20 mg Opana ER q 12 hours may be needed to provide pain relief equivalent to total daily parenteral dose of 4 mg oxymorphone.

> **Moderate to severe acute pain when converting from other oral opioids to Opana or Opana ER**

**Adults:** Refer to published relative potency information, keeping in mind that conversion ratios are only approximate. In general, it’s safest to start Opana therapy by administering half of calculated total daily dose of Opana in four to six equally divided doses P.O. q 4 to 6 hours. Or, for patients requiring continuous, around-the-clock opioid treatment for extended period, give Opana ER in two divided doses P.O. q 12 hours. Gradually adjust initial dosage of Opana or Opana ER until adequate pain relief.

Reactions in **bold** are life-threatening.
and acceptable adverse effects have been achieved.

Moderate to severe acute pain in opioid-experienced patients when converting from Opana to Opana ER

**Adults:** Administer half patient’s total daily oral Opana dose as Opana ER P.O. q 12 hours.

**Dosage adjustments**
- Mild hepatic impairment (Opana, Opana ER)
- Severe hepatic impairment (Numorphan)
- Moderate to severe renal impairment (Opana, Opana ER)
- Concurrent use of other CNS depressants (Opana, Opana ER)
- Elderly or delirious patients

**Contraindications**
- Hypersensitivity to drug or its components, or morphine analogs
- Any situation in which opioids are contraindicated, such as respiratory depression (in absence of resuscitative equipment or in unmonitored settings) and acute or severe bronchial asthma or hypercarbia
- Pulmonary edema secondary to chemical respiratory irritant (Numorphan)
- Suspected or existing paralytic ileus
- Moderate and severe hepatic impairment (Opana, Opana ER)

**Precautions**
Use cautiously in:
- head trauma, increased intracranial pressure, severe renal disease, hypothyroidism, adrenal insufficiency, urethral stricture, undiagnosed abdominal pain or prostatic hyperplasia, biliary tract disease, pancreatitis, extensive burns, alcoholism
- history of substance abuse
- prolonged or high-dose therapy
- elderly or debilitated patients
- labor and delivery
- pregnant or breastfeeding patients
- Pain in immediate postoperative period (first 12 to 24 hours), or if pain is mild or not expected to persist for extended period (Opana ER)
- Children younger than age 18.

**Administration**
- Give oral on empty stomach at least 1 hour before or 2 hours after eating.
- Tell patient to swallow extended-release tablets whole and not to break, chew, dissolve, or crush tablets.
- Be aware that extended-release tablets are not for p.r.n. use.
- Be aware that extended-release tablets are indicated only for postoperative use if patient had already been receiving drug before surgery or if postoperative pain is expected to be moderate or severe and persist for extended period.
- Be aware that administration from any source (such as beverages or drugs) may result in increased plasma drug levels and potentially fatal overdosage of oxymorphone.
- Keep naloxone available to reverse respiratory depression, if necessary.
- Give I.V. dose by direct injection over 2 to 3 minutes.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V.</td>
<td>5-10 min</td>
<td>30-60 min</td>
<td>3-6 hr</td>
</tr>
<tr>
<td>I.M., subcut.</td>
<td>10-15 min</td>
<td>30-60 min</td>
<td>3-6 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- CNS: somnolence (Opana, Opana ER), sedation, headache, drowsiness, confusion, dysphoria, euphoria, dizziness, hallucinations, lethargy, impaired mental and physical performance, depression, restlessness, insomnia, paradoxical stimulation, seizures
- CV: hypotension, orthostatic hypotension, palpitations, bradycardia, tachycardia
- EENT: blurred vision, miosis, diplopia, visual disturbances, tinnitus

---

Canada UK Hazardous drug High alert drug
GI: abdominal distention, flatulence (Opana), abdominal pain, dyspepsia (Opana ER), nausea, vomiting, constipation, biliary tract spasm, cramps, dry mouth, anorexia, paralytic ileus, toxic megacolon

GU: urinary hesitancy or retention, urethral spasm, antidiuretic effect

Respiratory: suppressed cough reflex, hypoxia (Opana), atelectasis, respiratory depression, allergic bronchospastic reaction, allergic laryngeal edema or laryngospasm, apnea

Skin: rash, urticaria, pruritus, facial flushing, diaphoresis

Other: pyrexia (Opana, Opana ER), physical or psychological drug dependence, drug tolerance, allergic reaction, injection site reaction (Numorphan)

Interactions

Drug-drug. Agonist/antagonist analgesia (such as buprenorphine, butorphanol, naltbuphine, or pentazocine): reduced oxymorphone effect; may precipitate withdrawal symptoms (Opana, Opana ER)

Anticholinergics: increased risk of urinary retention or severe constipation

Antihistamines (first-generation), antipsychotics, barbiturates, general anesthetics, MAO inhibitors, sedative-hypnotics, skeletal muscle relaxants, tricyclic antidepressants: increased risk of respiratory depression

Propofol: increased risk of bradycardia (Numorphan)

Drug-diagnostic tests. Amylase, lipase: increased levels

Drug-behaviors. Alcohol use or abuse, opiate abuse: increased risk of respiratory depression

Patient monitoring

- With prolonged use, watch for signs and symptoms of drug dependence.
- Assess neurologic status carefully. Institute protective measures as needed.
- Monitor patient receiving Opana or Opana ER for breakthrough pain and adverse reaction (especially severe constipation).

Patient teaching

- Instruct patient to immediately report seizures or difficulty breathing.
- Tell patient to rise slowly when changing position, to avoid dizziness from blood pressure decrease.
- Instruct patient taking Opana or Opana ER to report episodes of breakthrough pain and adverse reactions (especially severe constipation that may lead to paralytic ileus).
- Advise patient not to drink alcohol from any source because doing so may result in fatal overdose.
- Caution patient not to drive or perform other hazardous activities.
- Tell patient not to stop taking drug suddenly after several weeks, because withdrawal symptoms may occur.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

oxytocin

Pitocin, Syntocinon, Syntometrine

Pharmacologic class: Posterior pituitary hormone

Therapeutic class: Uterine-active agent

Pregnancy risk category NR

Reactions in bold are life-threatening.
FDA BOXED WARNING
● Drug isn’t indicated for elective induction of labor (defined as initiation of labor in pregnant woman with no medical indications for induction). Available data aren’t adequate to evaluate benefits versus risk.

Action
Unknown. Thought to directly stimulate smooth muscle contractions in uterus and cervix.

Availability
Injection: 10 units/ml ampule or vial

Indications and dosages
➢ To induce or stimulate labor
Adults: Initially, 1-ml ampule (10 units) in compatible I.V. solution infused at 1 to 2 milliunits/minute (0.001 to 0.002 units/minute). Increase rate in increments of 1 to 2 milliunits/minute q 15 to 30 minutes until acceptable contraction pattern is established.
➢ To control postpartum bleeding
Adults: 10 to 40 units in compatible I.V. solution infused at rate adequate to control bleeding; or 10 units I.M. after placenta delivery
➢ Incomplete abortion
Adults: 10 units in compatible I.V. solution infused at 10 to 20 milliunits/minute (0.01 to 0.02 units/minute)

Off-label uses
● Antepartal fetal heart rate testing
● Breast enlargement

Contraindications
● Hypersensitivity to drug
● Cephalopelvic disproportion
● Fetal distress when delivery is not imminent
● Prolonged use in uterine inertia or severe toxemia
● Hypertonic or hyperactive uterine pattern
● Unfavorable fetal position or presentation that’s undeliverable without conversion
● Labor induction or augmentation when vaginal delivery is contraindicated (as in invasive cervical cancer, active genital herpes, or total placenta previa)

Precautions
Use cautiously in:
● previous cervical or uterine surgery, history of uterine sepsis
● breastfeeding patients.

Administration
● Reconstitute by adding 1 ml (10 units) to 1,000 ml of normal saline solution, lactated Ringer’s solution, or dextrose 5% in water.
➢ Don’t give by I.V. bolus injection.
● Infuse I.V. using controlled-infusion device.
● Be aware that drug isn’t routinely given I.M.
● Know that drug should be given only to inpatients at critical care facilities when prescriber is immediately available.

Route Onset Peak Duration
I.V. Immediate 40 min 1 hr
I.M. 3-5 min 40 min 2-3 hr

Adverse reactions
CNS: seizures, coma, neonatal brain damage, subarachnoid hemorrhage
CV: premature ventricular contractions, arrhythmias, neonatal bradycardia
GI: nausea, vomiting
GU: postpartal hemorrhage; pelvic hematoma; uterine hypertonicity, spasm, or tetanic contraction; abruptio placentae; uterine rupture (with excessive doses)
Hematologic: afibrinogenemia  
Hepatic: neonatal jaundice  
Other: hypersensitivity reactions including **anaphylaxis, low 5-minute Apgar score** (neonate)

**Interactions**

**Drug-drug.** *Sympathomimetics:* postpartal hypertension  
*Thiopental anesthetics:* delayed anesthesia induction  
*Vasoconstrictors:* severe hypertension (when given within 3 to 4 hours of oxytocin)  

**Drug-herbs.** *Ephedra (ma huang):* increased hypertension

**Patient monitoring**

- Continuously monitor contractions, fetal and maternal heart rate, and maternal blood pressure and ECG. Discontinue infusion if uterine hyperactivity occurs.  
- Monitor patient extremely closely during first and second stages of labor because of risk of cervical laceration, uterine rupture, and maternal and fetal death.  
- When giving drug to control postpartal bleeding, monitor and record vaginal bleeding.  
- Assess fluid intake and output. Watch for signs and symptoms of water intoxication.

**Patient teaching**

- Inform patient about risks and benefits of oxytocin-induced labor.  
- Teach patient to recognize and immediately report adverse drug effects.

---

**paclitaxel**  
Apo-Paclitaxel®, Onxol, Paxene®, Taxol  

**Pharmacologic class:** Antimicrotubule agent  
**Therapeutic class:** Antineoplastic  
**Pregnancy risk category D**

---

**FDA BOXED WARNING**

- Give injection under supervision of physician experienced in use of cancer chemotherapy, in facility with adequate diagnostic and treatment resources.  
- Anaphylaxis and severe hypersensitivity reactions may occur despite premedication. All patients should be pretreated with corticosteroids, diphenhydramine, and histamine₂ antagonists. Don’t give drug to patients who’ve had previous severe reactions.  
- Don’t administer drug to patients with solid tumors whose baseline neutrophil counts are below 1,500 cells/mm³ or to patients with AIDS-related Kaposi’s sarcoma whose baseline neutrophil counts are below 1,000 cells/mm³. To monitor for bone marrow suppression, obtain frequent peripheral blood cell counts on all patients.  
- Albumin form of drug may substantially affect drug’s functional properties. Don’t substitute for or use with other paclitaxel forms.

---

**Action**

Stabilizes cellular microtubules to prevent depolymerization. This action inhibits microtubule network (essential for vital interphase and mitotic cellular functions) and induces

---

Reactions in **bold** are life-threatening.  

Clinical alert
abnormal microtubule arrays or bundles throughout cell cycle and during mitosis.

**Availability**

*Concentrate for injection: 30 mg/5-ml vial, 100 mg/16.7-ml vial, 300 mg/50-ml vial*

**Indications and dosages**

- **Advanced ovarian cancer**
  - **Adults:** As first-line therapy, 175 mg/m² I.V. over 3 hours q 3 weeks, or 135 mg/m² I.V. over 24 hours q 3 weeks, followed by cisplatin. After failure of first-line therapy, 135 mg/m² I.V. or 175 mg/m² I.V. over 3 hours q 3 weeks.

- **Breast cancer after failure of combination chemotherapy**
  - **Adults:** As adjuvant treatment for node-positive breast cancer, 175 mg/m² I.V. over 3 hours q 3 weeks for four courses given sequentially with doxorubicin combination chemotherapy. After chemotherapy failure for metastatic disease or relapse within 6 months of adjuvant therapy, 175 mg/m² I.V. over 3 hours q 3 weeks.

- **Non-small-cell lung cancer**
  - **Adults:** 135 mg/m² I.V. over 24 hours q 3 weeks, followed by cisplatin

- **AIDS-related Kaposi’s sarcoma**
  - **Adults:** 135 mg/m² I.V. over 3 hours q 3 weeks, or 100 mg/m² I.V. over 3 hours q 2 weeks

**Dosage adjustment**

- Advanced human immunodeficiency virus infection (when used for Kaposi’s sarcoma)

**Off-label uses**

- Advanced head and neck cancer
- Small-cell lung cancer
- Upper GI tract adenocarcinoma
- Non-Hodgkin’s lymphoma
- Pancreatic cancer
- Polycystic kidney disease

**Contraindications**

- hypersensitivity to drug or castor oil
- Solid tumors when baseline neutrophil count is below 1,500 cells/mm³
- AIDS-related Kaposi’s sarcoma when baseline neutrophil count is below 1,000 cells/mm³

**Precautions**

Use cautiously in:

- severe hepatic impairment, active infection, decreased bone marrow reserve, chronic debilitating illness
- patients with childbearing potential
- breastfeeding patients (not recommended)
- children (safety not established).

**Administration**

- Follow facility protocol for handling chemotherapeutic drugs and preparing solutions.
- Dilute in dextrose 5% in water, normal saline solution, or dextrose 5% in lactated Ringer’s solution per manufacturer’s guidelines.
- Inspect solution for particles. Administer through polyethylene-lined administration set attached to 0.22-micron in-line filter.
- To prevent severe hypersensitivity reaction, presymptomatically, give dexamethasone 20 mg 12 and 6 hours before infusion, as prescribed. Also give diphenhydramine 50 mg I.V., plus either cimetidine 300 mg or ranitidine 50 mg I.V. 30 to 60 minutes before paclitaxel.
- Keep epinephrine available. If severe hypersensitivity reaction occurs, stop infusion immediately and give epinephrine, I.V. fluids, and additional antihistamine and corticosteroid doses, as indicated and prescribed.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: peripheral neuropathy
CV: hypotension, hypertension, syncope, abnormal ECG, bradycardia, venous thrombosis
GI: nausea, vomiting, diarrhea, stomatitis, mucositis
Hematologic: anemia, leukopenia, neutropenia, bleeding, thrombocytopenia
Musculoskeletal: joint pain, myalgia
Skin: alopecia, radiation reactions
Other: infection, injection site reaction, hypersensitivity reactions including anaphylaxis

Interactions
Drug-drug. Carbamazepine, phenobarbital: decreased paclitaxel blood level and efficacy
Cisplatin: increased bone marrow depression (when paclitaxel dose follows cisplatin dose)
Cyclosporine, diazepam, doxorubicin, felodipine, ketoconazole, midazolam: inhibited paclitaxel metabolism and greater risk of toxicity
Doxorubicin: increased doxorubicin blood level and toxicity
Live-virus vaccines: decreased antibody response to vaccine, increased risk of adverse reactions
Other antineoplastics: increased risk of bone marrow depression

Drug-diagnostic tests. Liver function tests: abnormal results
Triglycerides: increased levels

Patient teaching
- Instruct neutropenic patient to minimize infection risk by avoiding crowds, plants, and fresh fruits and vegetables.
- Tell thrombocytopenic patient to avoid activities that can cause injury. Advise him to use soft toothbrush and electric razor.
- Advise patient to promptly report signs and symptoms of infection, bleeding, or peripheral neuropathy (such as numbness and tingling of feet and hands).
- Explain that temporary hair loss may occur.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

palifermin
Kepivance

Pharmacologic class: Keratinocyte growth factor (KGF) (rDNA origin)
Therapeutic class: Biologic and immunologic agent
Pregnancy risk category C

Action
Produced by recombinant DNA technology in Escherichia coli; binds to KGF receptor on cell surface, resulting in epithelial cell proliferation, differentiation, and migration

Availability
Powder for injection (lyophilized): 6.25 mg in single-use vials
Indications and dosages

To decrease incidence and duration of severe oral mucositis in patients with hematologic malignancies who are receiving myelotoxic therapy requiring hematopoietic stem cell support

**Adults:** 60 mcg/kg/day I.V. bolus injection for 3 consecutive days before and 3 consecutive days after myelotoxic therapy, for a total of six doses. Give first three doses before myelotoxic therapy, with third dose given 24 to 48 hours before such therapy. Administer last three doses after myelotoxic therapy, with first of these given after (but on same day of) hematopoietic stem cell infusion and at least 4 days after most recent palifermin dose.

Contraindications

- Hypersensitivity to drug, its components, or *E. coli*–derived proteins

Precautions

Use cautiously in:

- patients with nonhematologic cancers
- elderly patients
- pregnant or breastfeeding patients
- children (safety and efficacy not established)

Administration

- Reconstitute powder with 1.2 ml sterile water for injection to yield final concentration of 5 mg/ml.
- Swirl vial gently during dissolution; don’t shake or vigorously agitate.
- Don’t filter reconstituted solution during preparation or administration.
- Use immediately (within 1 hour) after reconstituting; protect from light.
- When heparin is used to maintain I.V. line, use normal saline solution to rinse line before and after palifermin administration.
- Administer by I.V. bolus injection.
- Don’t give within 24 hours before, during infusion of, or within 24 hours after myelotoxic chemotherapy.

Adverse reactions

CNS: dysesthesia
CV: hypertension
EENT: tongue discoloration or thickening
Musculoskeletal: pain, arthralgias
Skin: rash, pruritus, skin toxicities, erythema
Other: altered taste, edema, fever

Interactions

Drug-drug. *Heparin:* possible binding
Drug-diagnostic tests. *Amylase, lipase:* increased

Patient monitoring

- Monitor serum amylase and lipase levels frequently.

Patient teaching

- Instruct patient to report adverse reactions, including rash, itching, skin redness, swelling, discolored tongue, and altered taste.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Paliperidone

*Pharmacologic class:* Benzisoxazole derivative

*Therapeutic class:* Antipsychotic

*Pregnancy risk category C*

**FDA BOXED WARNING**

- Elderly patients with dementia-related psychosis are at increased risk for death. Over course of 10-week controlled trial, death rate in drug-treated
patients was about 4.5%, compared to about 2.6% in placebo group. Although causes of death varied, most appeared to be cardiovascular or infectious. Don’t give drug to patients with dementia-related psychosis.

**Action**
Unknown. In schizophrenia, therapeutic activity may be mediated through combination of central serotonin₂- and dopamine₂-receptor antagonism. Drug is a major active metabolite of risperidone.

**Availability**
_Tablets (extended-release): 3 mg, 6 mg, 9 mg_

**Indications and dosages**

* Acute and maintenance treatment of schizophrenia

**Adults:** 6 mg P.O. once daily. Some patients may benefit from daily dosages as high as 12 mg or as low as 3 mg. If indicated, increase in increments of 3 mg/day at intervals of more than 5 days.

**Dosage adjustment**
- Renal impairment

**Contraindications**
- Hypersensitivity to drug, its components, or risperidone

**Precautions**
Use cautiously in:
- GI strictures (use should be avoided), cardiovascular or cerebrovascular disease, diabetes mellitus, Parkinson’s disease, or conditions that raise body temperature (such as exercise, exposure to extreme heat, and concomitant anticholinergics use)
- increased risk of hypotension (as from dehydration, hypovolemia, or antihypertensives), aspiration pneumonia, or suicide attempt
- concurrent use of other drugs that are centrally acting or prolong the QT interval (use should be avoided)
- history of seizures or breast cancer
- elderly patients with dementia-related psychosis
- pregnant or breastfeeding patients
- children younger than age 18 (safety and efficacy not established).

**Administration**
- Give in morning with or without food.
- Administer tablets whole. Ensure that patient doesn’t chew, divide, or crush them.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>24 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** dizziness, headache, akathisia, tardive dyskinesia, dystonia, extrapyramidal disorder, hypertonia, parkinsonism, sedation, somnolence, tremor, anxiety, asthenia, fatigue, _seizure_, _stroke_ (in elderly patients with dementia-related psychosis), _neuropsychiatric malignant syndrome_ (NMS)

**CV:** first-degree atrioventricular block, bundle-branch block, sinus arrhythmia, tachycardia, hypertension, orthostatic hypotension, prolonged QT interval, abnormal T wave, palpitations

**EENT:** blurred vision

**GI:** upper abdominal pain, dyspepsia, nausea, antiemetic effect, esophageal dysmotility, salivary hypersecretion, dry mouth

**GU:** hyperprolactinemia

**Musculoskeletal:** back pain, extremity pain

**Respiratory:** cough, dyspnea, aspiration pneumonia

**Other:** fever, weight gain, possible drug tolerance or dependency

**Interactions**

**Drug-drug.** _Antihypertensives:_ increased risk of hypotension

Reactions in _bold_ are life-threatening.
Centrally acting drugs with sedative effect: increased sedation
Class IA antiarrhythmics (such as procainamide, quinidine), Class III antiarrhythmics (such as amiodarone, sotalol), anti-infectives (such as gatifloxacin, moxifloxacin), other antipsychotics (such as chlorpromazine, thioridazine), other drugs that prolong the QT interval: increased risk of prolonged QT interval
Dopamine agonists (such as levodopa): antagonized effects of these drugs

Drug-diagnostic tests. Blood glucose, serum prolactin: increased levels
Drug-food. Any food: possibly increased paliperidone effects
Drug-behaviors. Alcohol use: increased sedation

Patient monitoring
- Closely monitor patient at risk for suicide attempts.
- Monitor patient with diabetes regularly for signs and symptoms of worsening glycemic control.
- Stay alert for orthostatic hypotension.
- Monitor patient for signs and symptoms of NMS (extremely high fever, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, diaphoresis, arrhythmias).
- Watch for signs and symptoms of drug tolerance, dependency, and abuse.

Patient teaching
- Inform patient he may take drug with or without food.
- Teach patient to take tablets whole and not to chew, divide, or crush them.
- Inform patient that tablet shell doesn’t dissolve and may look like a complete tablet in stool.
- Instruct patient to immediately report signs or symptoms of NMS (such as high fever, muscle rigidity, altered mental status, irregular pulse or blood pressure, fast heart rate, or excessive sweating).
- Tell patient drug may cause temporary blood pressure decrease if he stands or sits up suddenly. Instruct him to rise slowly and carefully.
- Advise patient to take precautions against dehydration and overheating.
- Caution patient not to consume alcohol during therapy.
- Caution patient to avoid hazardous activities until drug’s effects on concentration, coordination, vision, and alertness are known.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and behaviors mentioned above.

palivizumab
Synagis
Pharmacologic class: Monoclonal antibody
Therapeutic class: Immunologic agent
Pregnancy risk category C

Action
Neutralizes and suppresses activity of syncytial virus in respiratory tract, inhibiting respiratory syncytial virus (RSV) replication

Availability
Injection: 50 mg, 100-mg vial

Indications and dosages
➢ To prevent serious lower respiratory disease caused by RSV in high-risk children
Children: 15 mg/kg I.M. q month throughout RSV season

Contraindications
- Hypersensitivity to drug or its components
Precautions
Use cautiously in:
● thrombocytopenia, coagulation disorders, established RSV infection.

Administration
Keep epinephrine 1:1,000 available in case anaphylaxis occurs. (However, drug isn’t known to cause anaphylaxis.)
● Dilute in sterile water for injection. Gently swirl for 30 seconds to avoid foaming.
● Keep reconstituted solution at room temperature for at least 20 minutes before administering. Give within 6 hours of reconstitution.
● Inject I.M. into anterolateral thigh. Avoid gluteal injection, which may damage sciatic nerve.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.M.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: nervousness, pain
EENT: conjunctivitis, otitis media, rhinitis, pharyngitis, sinusitis
GI: vomiting, diarrhea, gastroenteritis, oral moniliasis
Hematologic: anemia
Respiratory: upper respiratory tract infection, cough, wheezing, dyspnea, bronchiolitis, bronchitis, pneumonia, croup, asthma, apnea
Skin: rash, fungal dermatitis, eczema
Other: hernia, pain, fever, injection site reaction, viral infection, flulike symptoms, failure to thrive

Interactions
Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase: increased levels
Hemoglobin: decreased level

Patient monitoring
Watch closely for signs and symptoms of anaphylaxis immediately after dosing.

Assess for signs and symptoms of infection, particularly EENT and respiratory infection.
Monitor liver function tests and CBC.
Assess patient’s weight and hydration status.

Patient teaching
Tell parent that monthly injections are necessary during RSV season (November through April).
Inform parent that drug may cause GI symptoms and failure to thrive. Provide dietary consultation as needed.
Caution parent that EENT and respiratory infections may follow administration. Advise parent to contact prescriber immediately if child has fever or other signs or symptoms of infection.
As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

Palonosetron hydrochloride
Aloxi
Pharmacologic class: Selective serotonin subtype 3 (5-HT₃) receptor antagonist
Therapeutic class: Antiemetic
Pregnancy risk category B

Action
Selectively binds to and antagonizes 5-HT₃ receptors on vagal nerve terminals and in chemoreceptor trigger zone. This action blocks serotonin release, reducing the vomiting reflex.

Availability
Capsules: 0.5 mg
Solution: 0.25 mg (free base) in 5-ml vial

Reactions in bold are life-threatening.
Indications and dosages

➢ To prevent nausea and vomiting caused by cancer chemotherapy
Adults: 0.25 mg I.V. as a single dose 30 minutes before chemotherapy. Repeat-ed doses within 7 days aren’t recommended.
➢ To prevent acute nausea and vom-iting caused by moderately emetogenic cancer chemotherapy
Adults: 0.5 mg P.O. 1 hour before chemotherapy
➢ To prevent postoperative nausea and vomiting
Adults: 0.075 mg I.V. as a single dose given over 10 seconds immediately be-
fore anesthesia induction

Contraindications
● Hypersensitivity to drug or its components

Precautions
Use cautiously in:
● hypersensitivity to other 5-HT₃ re-
ceptor antagonists
● diabetes mellitus, hepatic dysfunction
● pregnant or breastfeeding patients
● children.

Administration
● Give capsules with or without food.
● Flush I.V. line with normal saline so-
lution before and after giving.
● Deliver into I.V. line over 30 seconds. Don’t mix with other drugs.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, fatigue, insomnia, dizziness, anxiety
CV: hypotension, vein discoloration and distention, nonsustained tachycar-
dia, bradycardia
GI: constipation, diarrhea, abdominal pain, anorexia
GU: glycosuria

Metabolic: fluctuating electrolyte levels, hyperglycemia, metabolic acidosis, hyperkalemia
Musculoskeletal: joint pain
Other: fever, flulike symptoms

Interactions
Drug-diagnostic tests: Alanine aminotransferase, aspartate aminotransferase, bilirubin, blood and urine glucose, po-
tassium: increased levels

Patient monitoring
● Monitor vital signs and ECG. Watch closely for tachycardia, bradycardia, and hypotension.
● Watch electrolyte levels for fluctua-
tions (especially hyperkalemia and metabolic acidosis).
● Evaluate temperature. Stay alert for flulike symptoms.
● Closely monitor blood and urine glucose levels in diabetic patients. Stay alert for hyperglycemia.

Patient teaching
● Instruct patient to take capsules with
or without food.
● Explain that drug helps prevent nau-
sea and vomiting caused by chemo-
therapy.
● Teach patient to recognize and report
signs and symptoms of hyperkalemia
and metabolic acidosis.
● Advise patient to report flulike
symptoms.
● Instruct diabetic patient to closely
watch blood and urine glucose
levels.
● As appropriate, review all other
significant and life-threatening adverse
reactions and interactions, especially
those related to the tests mentioned
above.
pamidronate disodium
Aredia

Pharmacologic class: Bisphosphonate, hypocalcemic
Therapeutic class: Bone resorption inhibitor
Pregnancy risk category C

Action
Inhibits normal and abnormal bone resorption and decreases calcium levels

Availability
Injection: 30 mg/vial, 90 mg/vial

Indications and dosages
- Hypercalcemia caused by cancer
  Adults: For moderate hypercalcemia, 60 to 90 mg as a single-dose I.V. infusion over 2 to 24 hours. For severe hypercalcemia, 90 mg as a single-dose I.V. infusion over 2 to 24 hours.
  ➢ Osteolytic lesions caused by multiple myeloma
  Adults: 90 mg I.V. as a 4-hour infusion q month
  ➢ Osteolytic bone metastases of breast cancer
  Adults: 90 mg I.V. as a 2-hour infusion q 3 to 4 weeks
  ➢ Paget’s disease
  Adults: 30 mg I.V. daily as a 4-hour infusion for 3 days

Contraindications
- Hypersensitivity to drug, its components, or other bisphosphonates

Precautions
Use cautiously in:
- renal impairment
- pregnant or breastfeeding patients
- children (safety not established).

Administration
- Hydrate patient with saline solution as needed before starting therapy.
- Because of risk of renal failure, give no more than 90 mg in single doses.
  ➢ Reconstitute vial using 10 ml of sterile water for injection. When completely dissolved, dilute in 250 to 1,000 ml of half-normal or normal saline solution or dextrose 5% in water.
  ➢ Don’t mix with solutions containing calcium, such as lactated Ringer’s solution.
- Administer in I.V. line separate from all other drugs and fluids.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
- CNS: anxiety, headache, insomnia, psychosis, drowsiness, weakness
- CV: hypertension, syncope, tachycardia, atrial flutter, arrhythmias, heart failure
- EENT: sinusitis
- GI: nausea, vomiting, diarrhea, abdominal pain, constipation, dyspepsia, stomatitis, anorexia, GI hemorrhage
- GU: urinary tract infection
- Hematologic: anemia, neutropenia, leukopenia, granulocytopenia, thrombocytopenia
- Metabolic: hypothyroidism
- Musculoskeletal: bone pain, joint pain, myalgia
- Respiratory: crackles, coughing, dyspnea, upper respiratory infection, pleural effusion
- Other: fever, generalized pain, injection site reaction

Interactions
Drug-diagnostic tests. Creatinine: increased level
Electrolytes, hemoglobin, magnesium, phosphorus, platelets, potassium, red

Reactions in bold are life-threatening.
blood cells, white blood cells: decreased levels

Patient monitoring
- Monitor hydration status carefully.
- Monitor vital signs and ECG. Evaluate cardiovascular and respiratory status closely.
- Assess hematologic studies and creatinine level before each treatment course.
- Assess electrolyte levels, especially calcium, magnesium, and phosphorus.
- Closely monitor fluid intake and output. Watch for signs and symptoms of urinary tract infection.

Patient teaching
- Instruct patient to weigh himself regularly and report sudden gains.
- Advise patient to promptly report significant respiratory problems, peripheral edema, or GI bleeding.
- Inform patient that drug lowers resistance to some infections. Tell him to immediately report fever and other signs and symptoms of infection.
- Explain importance of undergoing laboratory tests before, during, and after therapy.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, cognition, and alertness.
- Tell patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

---

pantoprazole sodium

Apo-Pantoprazole®, Co Pantoprazole®, Gen-Pantoprazole®, Novo-Pantoprazole®, Pantoloc®, PMS-Pantoprazole®, Protium®, Protonix, Protonix IV, Ran-Pantoprazole®, Ratio-Pantoprazole®, Sandoz Pantoprazole®

Pharmacologic class: Proton pump inhibitor
Therapeutic class: GI agent
Pregnancy risk category B

Action
Reduces gastric acid secretion and increases gastric mucus and bicarbonate production, creating protective coating on gastric mucosa

Availability
- Granules (delayed-release oral suspension): 40 mg
- Powder for injection (freeze-dried): 40 mg/vial
- Tablets (delayed-release): 20 mg, 40 mg

Indications and dosages
- Erosive esophagitis caused by gastroesophageal reflux disease (GERD)
  Adults: 40 mg I.V. daily for 7 to 10 days or 40 mg P.O. daily for 8 weeks. May repeat P.O. course for 8 additional weeks.
- Erosive esophagitis
  Adults: 40 mg P.O. daily
- Pathologic hypersecretory conditions
  Adults: Initially, 40 mg P.O. b.i.d., increased as needed to maximum of 240 mg P.O. daily; some patients may need up to 2 years of therapy. Alternatively, 80 mg I.V. q 12 hours, to a maximum of 240 mg/day (80 mg q 8 hours).
Contraindications
● Hypersensitivity to drug

Precautions
Use cautiously in:
● severe hepatic disease
● pregnant or breastfeeding patients
● children.

Administration
● Be aware that oral granules may be mixed with applesauce or apple juice and given 30 minutes before a meal. Once mixed, give drug within 10 minutes.
● Know that oral granules may be mixed with 10 ml apple juice and administered into nasogastric tube using 60-ml catheter-tip syringe. Rinse syringe with additional apple juice so that no granules remain in syringe.
● For I.V. administration, use in-line filter provided. If Y-site is used, place filter below Y-site closest to patient.
● Dilute I.V. form with 10 ml of normal saline solution; further dilute in dextrose 5% in water, normal saline solution, or lactated Ringer’s solution, as directed. Give over 15 minutes at a rate no faster than 3 mg/minute.
● Don’t give I.V. form with other I.V. solutions.
● Know that I.V. form is indicated for short-term treatment of GERD in patients with history of erosive esophagitis as alternative to P.O. therapy.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>2.5 hr</td>
<td>&gt;24 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>Unknown</td>
<td>&gt;24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, headache
CV: chest pain
EENT: rhinitis
GI: vomiting, diarrhea, abdominal pain, dyspepsia
Metabolic: hyperglycemia

Skin: rash, pruritus
Other: injection site reaction

Interactions
Drug-drug. Ampicillin, cyanocobalamin, digoxin, iron salts, ketoconazole: delayed absorption of these drugs Clarithromycin, diazepam, flurazepam, phenytoin, triazolam: increased pantoprazole blood level Sucralfate: delayed pantoprazole absorption Warfarin: increased bleeding

Drug-diagnostic tests. Aspartate aminotransferase, glucose: increased levels Tetrahydrocannabinol test: false-positive result

Patient monitoring
● Assess for symptomatic improvement.
● Monitor blood glucose level in diabetic patient.

Patient teaching
● Tell patient to swallow delayed-release tablets whole without crushing, chewing, or splitting.
● Tell patient he may take tablets with or without food.
● Explain that antacids don’t affect drug absorption.
● Instruct diabetic patients to monitor blood glucose level carefully and stay alert for signs and symptoms of hyperglycemia.
● As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and tests mentioned above.
paroxetine hydrochloride
Apo-Paroxetine, Co Paroxetine, Dom-Paroxetine, Gen-Paroxetine, Novo-Paroxetine, Paxil, Paxil CR, PHL-Paroxetine, PMS-Paroxetine, Riva-Paroxetine, Sandoz Paroxetine, Seroxat

paroxetine mesylate
Pexeva

Pharmacologic class: Selective serotonin reuptake inhibitor (SSRI)
Therapeutic class: Antidepressant, anxiolytic
Pregnancy risk category C

FDA BOXED WARNING
• Drug may increase risk of suicidal thinking and behavior in children and adolescents with major depressive disorder and other psychiatric disorders. Risk must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family and caregivers to observe patient closely and communicate with prescriber as needed.
• Drug isn’t approved for use in pediatric patients.

Action
Unknown. Thought to inhibit neuronal reuptake of serotonin in CNS.

Availability
paroxetine hydrochloride—
Oral suspension: 10 mg/5 ml in 250-ml bottle
Tablets: 10 mg, 20 mg, 30 mg, 40 mg
Tablets (controlled-release): 12.5 mg, 25 mg, 37.5 mg

paroxetine mesylate—
Tablets: 10 mg, 20 mg, 30 mg, 40 mg

Indications and dosages
➤ Major depressive disorder
Adults: Initially, 20 mg/day P.O. (immediate-release) as a single dose; may increase as needed by 10 mg/day at weekly intervals (range is 20 to 50 mg); daily dosages of approximately 30 mg may maintain efficacy for up to 1 year. Or initially, 25 mg P.O. (controlled-release) daily; may increase by 12.5 mg/day at weekly intervals, up to 62.5 mg/day. Or, 20 mg/day P.O. (paroxetine mesylate) as a single dose in morning; may increase as needed by 10 mg/day at weekly intervals up to maximum of 50 mg/day; daily dosages of approximately 30 mg may maintain efficacy for up to 1 year.
➤ Obsessive-compulsive disorder
Adults: Initially, 20 mg/day P.O. (immediate-release); increase as needed by 10 mg/day at weekly intervals, up to 60 mg P.O. (range is 20 to 60 mg/day). Or, initially 20 mg P.O. (paroxetine mesylate); may increase as needed by 10 mg/day at weekly intervals up to maximum of 60 mg/day; recommended dosage is 40 mg/day.
➤ Panic disorder
Adults: Initially, 10 mg/day P.O. (immediate-release); may increase as needed by 10 mg/day at weekly intervals, up to 40 mg P.O. (range is 10 to 60 mg/day); maximum dosage is 60 mg/day, with dosage adjustments made to maintain patient on lowest effective dosage. Or initially, 12.5 mg/day P.O. (controlled-release); may increase by 12.5 mg/day at weekly intervals, to a maximum of 75 mg/day. Or, 10 mg/day P.O. (paroxetine mesylate) daily in morning; may increase as needed by 10 mg/day at weekly intervals up to maximum of 60 mg/day. Target dosage is 40 mg/day. Maintain patient on lowest effective dosage.
➤ Posttraumatic stress disorder
Adults: Initially, 20 mg/day P.O.; range is 20 to 50 mg/day. Make any dosage increases if needed in increments of 10 mg/day at intervals of at least 1 week. For maintenance, adjust to lowest effective dosage.

Generalized anxiety disorder
Adults: Initially, 20 mg/day P.O.; range is 20 to 50 mg/day; however, dosages greater than 20 mg/day may not provide added benefit. Make any dosage increases if needed in increments of 10 mg/day at intervals of at least 1 week. Or, 20 mg/day P.O. (paroxetine mesylate) daily in morning.

Premenstrual dysphoric disorder
Adults: 12.5 to 25 mg/day P.O. (controlled-release) daily. May give either daily throughout menstrual cycle or only during luteal phase cycle (per prescriber). Make any dosage changes if needed at intervals of at least 1 week.

Dosage adjustment
- Hepatic impairment, severe renal impairment
- Elderly or debilitated patients

Contraindications
- Hypersensitivity to drug or its components
- MAO inhibitor use within past 14 days
- Concurrent thioridazine use

Precautions
Use cautiously in:
- severe renal or hepatic impairment
- narrow-angle glaucoma
- diseases or conditions that may affect metabolism or hemodynamic responses
- history of seizures, mania, or suicide attempt
- increased risk of suicide attempt, hyponatremia, or abnormal bleeding
- elderly or debilitated patients
- pregnant or breastfeeding patients
- children younger than age 18 (safety not established).

Administration
- Give with or without food.
- Give controlled-release tablets whole. Make sure patient doesn’t chew or crush them.
- Don’t give to patients receiving MAO inhibitors or thioridazine.
- Reassess patient periodically to gauge need for continued therapy.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2-8 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>6-10 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

(controlled)

Adverse reactions
CNS: anxiety, agitation, dizziness, drowsiness, asthenia, vascular headache, confusion, hangover, depression, paresthesia, tremor, twitching, myoclonus, amnesia, insomnia, abnormal dreams, unusual or severe mood changes, fatigue, cerebral ischemia, suicidal behavior or ideation (especially in child or adolescent)
CV: chest pain, hypertension, hypotension, palpitations, orthostatic hypotension, angina pectoris, ventricular or supraventricular extrasystoles, tachycardia, bradycardia, thrombophlebitis, myocardial ischemia
EENT: blurred vision, rhinitis, dry mouth
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, anorexia
GU: urinary frequency, urinary disorders, urinary tract infection, genital disorders, ejaculatory disturbance, decreased libido
Musculoskeletal: back pain, myalgia, myasthenia, myopathy, joint pain
Respiratory: cough, bronchitis, respiratory disorders
Skin: sweating, pruritus, pallor, rash, photosensitivity
Other: chills, edema, appetite and weight changes, accidental injury, yawning

Reactions in bold are life-threatening.

Clinical alert
Interactions

Drug-drug. Cimetidine: increased paroxetine blood level
Digoxin: decreased digoxin efficacy
Drugs metabolized by liver (such as amitriptyline, class IC antiarrhythmics, desipramine): decreased metabolism and increased effects of these drugs
5-hydroxytryptamine receptor agonists (such as frovatriptan, naratriptan, rizatriptan): weakness, hyperreflexia, incoordination
MAO inhibitors: potentially fatal reactions (hyperthermia, rigidity, myoclonus, autonomic instability, fluctuating vital signs, extreme agitation, delirium, coma)
Phenobarbital, phenytoin: decreased paroxetine efficacy
Theophylline: increased risk of theophylline toxicity
Thioridazine: increased thioridazine blood level, serious ventricular arrhythmias, sudden death
Tryptophan: headache, nausea, sweating, dizziness
Warfarin: increased risk of bleeding (without altering prothrombin time)

Drug-diagnostic tests. Alkaline phosphatase, bilirubin, glucose: increased levels
5-hydroxyindole acetic acid, vanillylmandelic acid: decreased levels
Urinary catecholamines: false increases

Drug-herbs. S-adenosylmethionine (SAM-e), St. John’s wort: increased risk of adverse serotonergic effects, including serotonin syndrome

Patient monitoring

- Check for signs and symptoms of toxicity, including drowsiness, nausea, tremor, tachycardia, confusion, and dizziness.
- Assess vital signs and cardiovascular status.
- Monitor neurologic status. Watch closely for depression and suicidal behavior and ideation (especially in child or adolescent).
- Evaluate respiratory status. Stay alert for signs and symptoms of infection.

Patient teaching

- Tell patient to swallow controlled-release tablets whole without chewing or crushing them.
- Describe signs and symptoms of drug toxicity. Tell patient to report these immediately.
- Teach patient or caregiver to recognize and immediately report signs of suicidal intent or expressions of suicidal ideation (especially in child or adolescent).
- Tell patient to continue to take drug even if he feels better. Caution him not to stop therapy abruptly.
- Advise patient to consult prescriber before taking other prescription drugs or over-the-counter preparations.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects him.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

Pegaptanib sodium injection

Macugen

Pharmacologic class: Selective vascular endothelial growth factor (VEGF) antagonist
Therapeutic class: Ophthalmic agent
Pregnancy risk category B

Action

Binds to extracellular VEGF, which contributes to progression of neovascular age-related macular degeneration; this action suppresses pathologic
neovascularization and macular degeneration progression.

**Availability**
*Solution for ophthalmic injection: 0.3 mg/90-microliter single-dose syringe*

**Indications and dosages**

- **Neovascular (wet) age-related macular degeneration**
  - **Adults:** 0.3 mg by intravitreous injection into affected eye once every 6 weeks

**Contraindications**
- Hypersensitivity to drug or its components
- Ocular or periocular infection

**Precautions**
Use cautiously in:
- pregnant or breastfeeding patients
- children (safety and efficacy not established)

**Administration**
- Administer only by ophthalmic intravitreous injection under controlled aseptic conditions.
- Inspect drug for particulates and discoloration before administering.
- Attach threaded plastic plunger rod to rubber stopper inside syringe barrel. Don’t pull back on plunger.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intravitreous</td>
<td>Unknown</td>
<td>1-4 days</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- **CNS:** dizziness, headache, vertigo
- **CV:** hypertension, carotid artery occlusion, chest pain, transient ischemic attack, **cerebrovascular accident**
- **EENT:** anterior chamber inflammation, blurred vision, cataract, conjunctival hemorrhage, corneal edema, eye discharge, eye inflammation or swelling, eye irritation or pain, increased intraocular pressure, ocular discomfort, punctate keratitis, reduced visual acuity, visual disturbance, vitreous disorder or hemorrhage, vitreous floaters or opacities, blepharitis, conjunctivitis, photopsia, allergic conjunctivitis, conjunctival edema, corneal abrasion, corneal deposits, corneal epithelial disorder, endophthalmitis, eyelid irritation, meibomianitis, mydriasis, periorbital hematoma, retinal edema, hearing loss
- **GI:** diarrhea, nausea, vomiting, dyspepsia
- **GU:** urinary tract infection, urinary retention
- **Metabolic:** diabetes mellitus
- **Musculoskeletal:** arthritis, bone spur
- **Respiratory:** bronchitis, pleural effusion
- **Skin:** contact dermatitis, contusion
- **Other:** anaphylaxis, including angioedema (rare)

**Interactions**
None

**Patient monitoring**
- Watch for increased intraocular pressure, especially within 30 minutes of injection. Be prepared to intervene appropriately.
- Monitor patient for endophthalmitis during week after injection to promote early detection and treatment.

**Patient teaching**
- Instruct patient to contact ophthalmologist immediately if treated eye becomes red, light-sensitive, or painful or if vision change occurs.
- As appropriate, review all other significant and life-threatening adverse reactions.

Reactions in **bold** are life-threatening.
pegalaspargase
(PEG-L-asparaginase)
Oncaspar

**Pharmacologic class:** Enzyme  
**Therapeutic class:** Antineoplastic  
**Pregnancy risk category C**

**Action**  
Stimulates production of effector proteins, such as serum neopterin and 2', 5' oligodenedylate synthetase; raises body temperature and reversibly lowers white blood cell and platelet counts.

**Availability**  
*Injection:* 750 international units/ml, 5-ml vial in phosphate-buffered saline solution.

**Indications and dosages**

- **Acute lymphoblastic leukemia**
  - **Adults and children with body surface area (BSA) greater than 0.6 m²:** 2,500 international units/m² I.M. or I.V. q 14 days.
  - **Adults and children with BSA less than 0.6 m²:** 82.5 international units/m² I.M. or I.V. q 14 days.

**Contraindications**
- Hypersensitivity or previous serious allergic reaction (such as generalized urticaria, bronchospasm, laryngeal edema, hypotension) to drug.
- Pancreatitis or history of pancreatitis.
- Previous hemorrhagic events related to L-asparaginase therapy.

**Precautions**
Use cautiously in:
- renal or hepatic disease, CNS disorders.
- concurrent use of hepatotoxic agents, anticoagulants, aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs).
- pregnant or breastfeeding patients.

**Administration**
- Follow facility protocol for handling, preparing, and disposing of chemotherapy drugs.
- Avoid inhaling vapors and contact with skin or mucous membranes.
- Keep resuscitation equipment, epinephrine, oxygen, steroids, and antihistamines readily available.
- Know that I.M. route is preferred because it’s less likely to cause hepatotoxicity, coagulopathy, and GI or renal disorders. For single I.M. injection, don’t exceed volume of 2 ml.
- For I.V. use, dilute in 100 ml of normal saline solution or dextrose 5% in water. Infuse over 1 to 2 hours.
- Don’t freeze; freezing inactivates drug.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>72-96 hr</td>
<td>2 wk</td>
</tr>
<tr>
<td>I.M.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- **CNS:** dizziness, headache, confusion, hallucinations, emotional lability, drowsiness, neuritis, Parkinson-like syndrome, malaise, coma, seizures
- **CV:** hypertension, hypotension, chest pain, peripheral edema, tachycardia, endocarditis
- **GI:** nausea, vomiting, diarrhea, constipation, abdominal pain, flatulence, anorexia, pancreatitis
- **GU:** glycosuria, polyuria, urinary frequency, hematuria
- **Hematologic:** hemolytic anemia, leukopenia, pancytopenia, thrombocytopenia, disseminated intravascular coagulation
- **Hepatic:** jaundice, fatty liver deposits, hepatotoxicity, hepatomegaly
- **Metabolic:** hypoproteinemia, hyperuricemia, hyperammonemia, hyponatremia, hyperglycemia, hypoglycemia
Respiratory: dyspnea, cough, bronchospasm
Skin: rash, urticaria, pruritus, night sweats, alopecia
Other: increased appetite and thirst, weight loss, chills, fever, injection site reaction, facial or lip edema, hypersensitivity reactions including anaphylaxis, septic shock

Interactions
Drug-drug. Aspirin, dipyridamole, heparin, NSAIDs, warfarin: increased risk of bleeding or thrombosis
Methotrexate: decreased methotrexate action

Drug-diagnostic tests. Amylase, blood urea nitrogen, creatinine, lipase, uric acid: increased levels
Glucose: increased or decreased level
Liver function tests: abnormal results
Lymphoblasts: decreased count
Plasma proteins: altered levels

Patient monitoring
Watch for anaphylaxis and other hypersensitivity reactions, especially during first hour of therapy.

- Monitor CBC (including platelet count); fibrinogen; prothrombin and partial thromboplastin times; International Normalized Ratio; and serum amylase, lipase, and uric acid levels.
- Assess neurologic status. Stay alert for decreased level of consciousness and evidence of impending seizure.
- Check for signs and symptoms of bleeding, infection, and hyperglycemia.
- Monitor heart rate, blood pressure, respiratory rate, temperature, and fluid intake and output.

Patient teaching
Teach patient to recognize and immediately report signs and symptoms of hypersensitivity reactions, bleeding, infection, and other adverse reactions.
- Tell patient drug is likely to cause reversible hair loss.
- Stress importance of undergoing follow-up laboratory tests.
- Advise patient to avoid situations that increase risk for infection.
- Instruct patient to consult prescriber before taking other prescription drugs or over-the-counter preparations.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

pegfilgrastim
Neulasta

Pharmacologic class: Granulocytic colony stimulating factor
Therapeutic class: Hematopoietic drug
Pregnancy risk category C

Action
Binds to specific cell-surface receptors on hematopoietic cells, stimulating their proliferation and differentiation in bone marrow

Availability
Injection: 6 mg/0.6 ml in prefilled syringes

Indications and dosages
To reduce risk of infection in nonmyeloid cancer patients who are receiving myelosuppressive drugs
Adults: 6 mg subcutaneously as a single dose once per chemotherapy cycle

Contraindications
- Hypersensitivity to drug, Escherichia coli-derived proteins, filgrastim, or other drug components

Reactions in bold are life-threatening.
Precautions
Use cautiously in:
● myeloid cancers, sickle cell disease
● patients undergoing chemotherapy or radiation
● pregnant or breastfeeding patients
● children (safety and efficacy not established).

Administration
● Inspect solution for particles; discard if particles or discoloration appear.
● Don’t give 14 days before to 24 hours after administration of cytotoxic chemotherapy.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcut.</td>
<td>Variable</td>
<td>Variable</td>
<td>Variable</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, weakness, fatigue, dizziness, insomnia
CV: peripheral edema
GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia, stomatitis, splenic rupture
Hematologic: leukocytosis, granulocytopenia
Musculoskeletal: bone pain, myalgia, joint pain
Respiratory: adult respiratory distress syndrome (ARDS) in septic patients
Skin: alopecia, mucositis
Other: taste perversion, allergic reaction, increased pain, fever, neutropenic fever, aggravation of sickle cell disease

Interactions
Drug-drug. Lithium: potentiation of neutrophil release
Drug-diagnostic tests. Alkaline phosphatase, lactate dehydrogenase, uric acid: increased levels

Patient monitoring
Assess for signs and symptoms of impending splenic rupture, such as left upper abdominal quadrant or shoulder pain and splenic enlargement.

Patient teaching
● Teach patient or caregiver how to administer injection and dispose of syringes at home, if appropriate.
● Teach patient to recognize and immediately report respiratory distress or signs and symptoms of splenic rupture.
● Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
● Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
● Instruct patient to have follow-up laboratory tests as needed.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

peginterferon alfa-2a
Pegasys

Pharmacologic class: Interferon
Therapeutic class: Biological response modifier
Pregnancy risk category C

FDA BOXED WARNING
• Drug may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Monitor patient closely with periodic clinical and laboratory evaluations. Withdraw drug in patients who have persistently severe or worsening signs or symptoms of these conditions.
In most cases, these disorders resolve once therapy ends.
- Concurrent use with ribavirin may cause birth defects or fetal death. Use extreme care to avoid pregnancy in female patients and female partners of male patients.

**Action**
Unclear. Thought to bind to specific cell-surface receptors, suppressing cell proliferation and viral replication. Also increases effector protein levels and reduces white blood cell (WBC) and platelet counts.

**Availability**
*Injection:* 180-mcg/ml vial

**Indications and dosages**
- **Chronic hepatitis C virus infection**
  - **Adults:** 180 mcg subcutaneously q week for 48 weeks. If poorly tolerated, reduce to 135 mcg weekly; some patients may need reduction to 90 mcg.

**Dosage adjustment**
- Neutrophil count less than 750 cells/mm³ or platelet count less than 50,000 cells/mm³
- Hepatic disease
- End-stage renal disease requiring dialysis
- Serious adverse reactions

**Off-label uses**
- Renal cell carcinoma

**Contraindications**
- Hypersensitivity to drug
- Autoimmune hepatitis
- Decompensated hepatic disease
- Infants and neonates (due to benzyl alcohol content)

**Precautions**
Use cautiously in:
- thyroid disorders; bone marrow depression; hepatic, renal, or cardiac disease; pancreatitis; autoimmune disorders; pulmonary disorders; colitis; ophthalmic disorders; depression
- elderly patients
- pregnant or breastfeeding patients
- children younger than age 18.

**Administration**
- Keep refrigerated. Before giving, roll vial between palms for 1 minute to warm; don’t shake. Protect solution from light.
- Don’t use if solution is cloudy or contains visible particles.
- Administer undiluted in abdomen or thigh by subcutaneous injection.
- Know that drug may be used alone or with ribavirin.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcut.</td>
<td>Gradual</td>
<td>72-96 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- CNS: dizziness, vertigo, insomnia, fatigue, rigors, poor memory and concentration, asthenia, depression, irritability, anxiety, peripheral neuropathy, mood changes, **suicidal ideation**
- CV: hypertension, chest pain, **supraventricular arrhythmias, myocardial infarction**
- EENT: vision loss, blurred vision, retinal artery or vein thrombosis, retinal hemorrhage, optic neuritis, retinopathy, **papilledema**
- GI: nausea, vomiting, diarrhea, abdominal pain, dry mouth, anorexia, **GI tract bleeding, ulcerative and hemorrhagic colitis, pancreatitis**
- Hematologic: anemia, **leukopenia, thrombocytopenia, neutropenia**
- Metabolic: diabetes mellitus, aggravated hypothyroidism or hyperthyroidism
- Musculoskeletal: myalgia, back pain, joint pain
- Respiratory: pneumonia, **interstitial pneumonitis, bronchoconstriction, respiratory failure**
- Skin: alopecia, pruritus, diaphoresis, rash, dermatitis, dry skin, eczema

Reactions in **bold** are life-threatening.
Other: weight loss, flulike symptoms, injection-site reaction, pain, autoimmune phenomena, severe and possibly fatal bacterial infections, severe hypersensitivity reactions including angioedema and anaphylaxis

**Interactions**

**Drug-drug.** Theophylline: increased theophylline blood level

**Drug-diagnostic tests.** Absolute neutrophil count, hematocrit, hemoglobin, platelets, WBCs: decreased values

Alanine aminotransferase: transient increase

Glucose, thyroid function tests: decreased or increased levels

Triglycerides: increased levels

**Patient monitoring**

- Assess cardiac and pulmonary status closely. Watch for evidence of infections and hypersensitivity reactions, including anaphylaxis.
- Before therapy begins, assess CBC (including platelet count), blood glucose level, and thyroid, kidney, and liver function tests. Continue to monitor at 1, 2, 4, 6, and 8 weeks and then every 4 weeks during therapy (more often if abnormalities occur). Monitor thyroid function tests every 12 weeks.
- Monitor for development of diabetes mellitus, hypothyroidism, and hyperthyroidism.
- If serious adverse reaction occurs, discontinue drug or adjust dosage until reaction abates, as prescribed. If reaction persists or recurs despite adequate dosage adjustment, discontinue drug.

**Patient teaching**

- Teach patient or caregiver how to administer injection subcutaneously in thigh or abdomen and how to dispose of equipment properly, if appropriate.
- Advise patient to promptly report rash, bleeding, bloody stools, infection symptoms (such as fever), decreased vision, chest pain, severe stomach or lower back pain, shortness of breath, depression, or suicidal thoughts.
- Instruct patient to administer drug exactly as prescribed. If he misses a dose but remembers it within 2 days, tell him to take missed dose as soon as possible; if more than 2 days have elapsed, tell him to contact prescriber.
- Caution patient not to switch brands without prescriber’s approval.
- Instruct patient to have periodic eye exams.
- Advise female patient of childbearing age to avoid pregnancy and use two birth control methods before, during, and up to 6 months after therapy. Instruct male patient to use condoms.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**PEG-Intron, PegIntron®, Unitron Peg®, ViraferonPeg®**

**Pharmacologic class:** Immunomodulator

**Therapeutic class:** Immunologic agent

**Pregnancy risk category C** (monotherapy), X (when given with ribavirin)

**FDA BOXED WARNING**

- Drug may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Monitor patient closely with periodic clinical and laboratory evaluations. Withdraw drug in patients with persistently severe or worsening signs or symptoms of these conditions. In most cases, these disorders resolve once therapy ends.
• Concurrent use with ribavirin may cause birth defects or fetal death. Use extreme care to avoid pregnancy in female patients and female partners of male patients.

Action
Binds to specific cell-surface membrane receptors, causing suppression of cell proliferation, enhanced phagocytic macrophage activity, and inhibition of viral replication

Availability
Powder for injection with diluent: 50 mcg/0.5-ml vial, 80 mcg/0.5-ml vial, 120 mcg/0.5-ml vial, 150 mcg/0.5-ml vial (Redipen)

Indications and dosages
➣ Chronic hepatitis C virus infection (HCV)
Adults ages 18 and older: For monotherapy, 1 mcg/kg/week subcutaneously for 1 year. When given with ribavirin, 1.5 mcg/kg/week subcutaneously.

Dosage adjustment
• Serious adverse reactions

Contraindications
• Hypersensitivity to drug or its components
• Autoimmune hepatitis
• Decompensated hepatic damage

Precautions
Use cautiously in:
• human immunodeficiency virus, hepatitis B infection
• patients who have failed other interferon alfa therapy
• patients who develop neutralizing antibodies
• organ transplant recipients
• elderly patients
• pregnant or breastfeeding patients
• children.

Adverse reactions
CNS: fatigue, headache, malaise, asthenia, dizziness, insomnia, depression, anxiety, emotional lability, irritability, poor concentration, agitation, nervousness, rigors, suicidal behavior, suicidal or homicidal ideation
CV: hypotension, tachycardia, chest pain, angina pectoris, arrhythmias, cardiomyopathy, myocardial infarction
EENT: vision decrease or loss, retinal artery or vein thrombosis, retinal hemorrhage, cotton-wool spots in visual field, rhinitis, sinusitis, pharyngitis
GI: nausea; vomiting; diarrhea; constipation; abdominal pain; dyspepsia; right upper abdominal quadrant pain; anorexia; dry mouth; ulcerative, hemorrhagic, or ischemic colitis; pancreatitis
GU: menstrual disorder
Hematologic: neutropenia, thrombocytopenia
Hepatic: hepatomegaly
Metabolic: aggravated hypothyroidism or hyperthyroidism
Musculoskeletal: myalgia, arthralgia, musculoskeletal pain
Respiratory: dyspnea, pneumonia, bronchiolitis obliterans, cough,

Reactions in bold are life-threatening.

Clinical alert
sarcoidosis, pulmonary infiltrates, interstitial pneumonitis, bronchoconstriction

**Skin:** rash, dry skin, pruritus, sweating, flushing, alopecia

**Other:** exacerbation or development of autoimmune disorders, injection-site reaction, fever, viral or fungal infection, systemic lupus erythematosus, severe hypersensitivity reactions including angioedema and anaphylaxis

**Interactions**

**Drug-diagnostic tests.** Bilirubin, triglycerides, uric acid: increased levels
Glucose, thyroid function tests: decreased or increased levels
Hemoglobin, neutrophils, platelets, white blood cells: decreased levels

**Patient monitoring**

- Before therapy begins, assess CBC (including platelet count); blood glucose level, and thyroid, kidney, and liver function tests. Continue to monitor at weeks 2, 4, 8, and 12 and then every 6 weeks during therapy (more often if abnormalities occur). Monitor thyroid function tests every 12 weeks.

  - Assess cardiac and pulmonary status closely. Watch for signs and symptoms of infection and hypersensitivity reactions, including anaphylaxis.

  - Monitor neurologic status. Stay alert for such behavioral changes as irritability, anxiety, depression, and homicidal or suicidal ideation.

  - If serious adverse reaction occurs, know that drug will be discontinued or dosages adjusted accordingly.

- Monitor patient for development of diabetes mellitus, hypothyroidism, or hyperthyroidism.
- Be aware that if HCV level remains high after 6 months, drug should be discontinued.

**Patient teaching**

- Tell patient to take exactly as prescribed. If he misses a dose but remembers it within 2 days, instruct him to take it as soon as possible. However, if more than 2 days have elapsed, advise him to contact prescriber.

  - Teach patient or caregiver how to administer injection subcutaneously into thigh or abdomen, if appropriate, and how to properly dispose of equipment.

  - Advise patient to stop drug and promptly report infection symptoms, such as high fever, easy bruising or bleeding, decreased vision, chest pain, shortness of breath, severe stomach or lower back pain, depression, or suicidal or homicidal thoughts.

  - Urge patient to have periodic eye exams.

  - Instruct female patient of childbearing age to avoid pregnancy and to use two birth control methods before, during, and up to 6 months after therapy. Instruct male patient to use condoms.

  - As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

**pegvisomant**

**Somavert**

**Pharmacologic class:** Growth hormone (GH) receptor antagonist

**Therapeutic class:** GH analog

**Pregnancy risk category B**

**Action**

Selectively binds to GH receptors on cell surfaces, where it blocks binding of endogenous GH and interferes with GH signal transduction. This action decreases blood levels of insulin-like growth factor-1 (IGF-1) and other GH-responsive serum proteins.
Availability
Solution: 10-mg, 15-mg, and 20-mg vials

Indications and dosages
> Acromegaly
Adults: Initial subcutaneous loading dose of 40 mg, followed by 10 mg/day subcutaneously. May adjust in 5-mg increments after serum IGF-1 measurement q 4 to 6 weeks; don’t exceed maximum daily maintenance dosage of 30 mg.

Contraindications
• Hypersensitivity to drug, its components, or latex (in vial stopper)

Precautions
Use cautiously in:
• GH-excreting tumors, diabetes mellitus, hepatic dysfunction
• pregnant or breastfeeding patients
• children.

Administration
• Reconstitute in vial with 1 ml of sterile water for injection.
• Roll vial gently between palms to mix; don’t shake. Withdraw prescribed dosage and administer subcutaneously.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcut</td>
<td>Unknown</td>
<td>Unknown</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, paresthesia
CV: chest pain, hypertension, peripheral edema
EENT: sinusitis
GI: nausea, diarrhea, abdominal pain
Musculoskeletal: back pain
Other: infection, pain, injection site reaction, accidental injury, flulike symptoms, lipohypertrophy

Interactions
Drug-drug. Insulin, oral hypoglycemics: decreased insulin sensitivity, reduced requirements for these drugs

Opioids: increased pegvisomant requirement

Drug-diagnostic tests. GH assays: interference with GH measurement
Liver function tests: abnormal results

Drug-behaviors. Opioid addiction: increased pegvisomant requirement

Patient monitoring
• Assess liver function tests; watch for signs and symptoms of hepatic dysfunction.
• Monitor serum IGF-1 level. If appropriate, discuss dosage adjustments with prescriber.
• Monitor vital signs; check for hypertension, chest pain, and peripheral edema.
• Measure temperature. Watch for signs and symptoms of infection, especially sinusitis or flulike symptoms.
• Assess blood glucose level closely in diabetic patient. Notify prescriber of significant decrease.

Patient teaching
• Teach patient proper technique for reconstituting and administering drug subcutaneously.
  Instruct patient to immediately report chest pain, peripheral edema, or signs or symptoms of infection.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects him.
• Teach diabetic patient to monitor blood glucose level closely and report significant decrease.
  Instruct patient to report yellowing of skin or eyes and other signs and symptoms of hepatic dysfunction. Tell him he’ll undergo frequent liver function tests.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

Reactions in bold are life-threatening.
Pemetrexed
Alimta

**Pharmacologic class:** Folic acid antagonist  
**Therapeutic class:** Antineoplastic, antimetabolite  
**Pregnancy risk category D**

**Action**  
Disrupts folate-dependent metabolic processes essential for cell replication

**Availability**  
*Powder for injection:* 500 mg sterile lyophilized powder in single-use vials

**Indications and dosages**  
- **Malignant pleural mesothelioma** in patients whose disease is unresectable or who otherwise aren’t eligible for curative surgery (given with cisplatin)  
  **Adults:** 500 mg/m² I.V. infusion over 10 minutes on day 1 of each 21-day cycle (given in combination with cisplatin infused over 2 hours starting approximately 30 minutes after pemetrexed administration ends)  
- **Non-small-cell lung cancer**  
  **Adults:** 500 mg/m² I.V. infusion over 10 minutes on day 1 of each 21-day cycle

**Dosage adjustment**  
- Hematologic toxicities, based on nadir absolute neutrophil and platelet counts  
- Grade 2 to 4 neurotoxicity  
- Grade 3 or higher nonhematologic toxicities (except neurotoxicity)  
- Grade 3 or 4 diarrhea or any diarrhea requiring hospitalization  
- Creatinine clearance below 45 ml/minute

**Contraindications**  
- Severe hypersensitivity reaction to drug or its components

**Precautions**  
Use cautiously in:  
- hepatic or renal impairment, neurotoxicity  
- pregnant or breastfeeding patients  
- children (safety and efficacy not established).

**Administration**  
- Reconstitute 500-mg vial with 20 ml preservative-free normal saline solution injection, yielding 25 mg/ml. Gently swirl vial until powder dissolves completely.  
- Further dilute appropriate volume of reconstituted solution to 100 ml with preservative-free normal saline solution injection; administer I.V. over 10 minutes.  
- Know that drug is physically incompatible with diluents containing calcium, including Ringer’s and lactated Ringer’s solutions. Administration with other drugs and diluents isn’t recommended.  
- Administer I.V. only.  
- As ordered, pretreat with dexamethasone (or equivalent) 4 mg P.O. twice daily on day before, day of, and day after pemetrexed administration to minimize cutaneous reactions.  
- When administering with cisplatin, hydrate patient with 1 to 2 L fluid infused over 8 to 12 hours before and after cisplatin administration. Maintain adequate hydration and urine output for 24 hours.  
- To reduce toxicity, ensure that patient receives at least five daily doses of low-dose folic acid or multivitamin with folic acid within 7 days before first pemetrexed dose. Folic acid therapy should continue throughout course of therapy and for 21 days after final dose. Patient also must receive one...
I.M. injection of vitamin B₁₂ during week before first pemetrexed dose and every three cycles thereafter.

- Discontinue drug if creatinine clearance is below 45 ml/minute or patient has hematologic or nonhematologic Grade 3 or 4 toxicity after two dosage reductions (except Grade 3 transaminase elevation).
- Withdraw drug immediately in patients with Grade 3 or 4 neurotoxicity.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

### Adverse reactions

- **CNS:** fatigue, sensory neuropathy, altered mood, depression
- **CV:** thrombosis, embolism
- **EENT:** pharyngitis
- **GI:** nausea, vomiting, constipation, diarrhea without colostomy, dysphagia, esophagitis, pain on swallowing, stomatitis, anorexia
- **GU:** renal failure
- **Hematologic:** neutropenia, leukopenia, anemia, thrombocytopenia, febrile neutropenia
- **Hepatic:** abnormal liver function
- **Musculoskeletal:** myalgia, arthralgia
- **Respiratory:** dyspnea
- **Skin:** rash, desquamation, alopecia
- **Other:** fever, dehydration, noncardiac chest pain, infection without neutropenia or with Grade 3 or Grade 4 neutropenia, edema, other constitutional symptoms, allergic reaction, hypersensitivity reaction

### Interactions

- **Drug-drug.** Ibuprofen: decreased pemetrexed clearance and increased concentration
- **Nephrotoxic agents:** possible decrease in pemetrexed clearance

### Drug-diagnostic tests.

- **Alanine aminotransferase, aspartate aminotransferase, serum creatinine:** increased
- **Creatinine clearance, hematocrit, hemoglobin, platelets, WBCs:** decreased

### Patient monitoring

- Monitor CBC and platelet counts frequently.
- Monitor renal and liver function tests and blood chemistry results (especially serum creatinine) periodically.
- Know that patients with mild to moderate renal insufficiency should avoid taking nonsteroidal anti-inflammatory drugs (NSAIDs) with short elimination half-lives (such as aspirin, diclofenac, and ibuprofen) for 5 days before, on day of, and for 2 days after pemetrexed administration. If concomitant NSAID use is necessary, monitor patient closely for toxicities (especially myelosuppression and renal and GI toxicity).
- Be aware that all patients should avoid NSAIDs with long half-lives (such as diflunisal, piroxicam, and sulindac) for at least 5 days before, on day of, and for 2 days after pemetrexed administration. If concomitant NSAID use is necessary, monitor patient closely for toxicities (especially myelosuppression and renal and GI toxicity).

### Patient teaching

- Instruct patient to take folic acid and vitamin B₁₂ before and during therapy, as prescribed.
- Advise patient to drink ten 8-oz glasses of fluid and to urinate frequently during first 24 hours after therapy that includes cisplatin.
- Teach patient to recognize signs and symptoms of anemia and to contact prescriber if temperature above 100.4°F (38°C) develops.
- Tell patient to consult prescriber before taking products containing ibuprofen.
- Advise female with childbearing potential to avoid pregnancy during therapy.
- Instruct breastfeeding patient to stop breastfeeding during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially

Reactions in **bold** are life-threatening.

Clinical alert
those related to the drugs and tests mentioned above.

**penicillin G benzathine**
Bicillin L-A, Permapen

**Pharmacologic class:** Penicillin  
**Therapeutic class:** Anti-infective  
**Pregnancy risk category B**

**Action**  
Inhibits biosynthesis of cell-wall mucopeptide; kills penicillin-susceptible bacteria during active multiplication stage

**Availability**  
*Suspension for I.M. injection:* 600,000 units/ml in 1-, 2-, and 4-ml prefilled syringes

**Indications and dosages**  
➤ Upper respiratory infections  
**Adults:** 1.2 million units I.M. as a single dose  
**Children weighing 27 kg (60) or more:** 900,000 units I.M. as a single dose  
**Infants and children weighing less than 27 kg (60 lb):** 300,000 to 600,000 units I.M. as a single dose  
➤ Early syphilis (primary, secondary, or latent)  
**Adults:** 2.4 million units I.M. as a single dose  
**Children:** 50,000 units/kg I.M. as a single dose, increased as needed up to adult dosage  
➤ Congenital syphilis  
**Children younger than age 2:** 50,000 units/kg I.M. as a single dose  
➤ Late (tertiary) syphilis and neurosyphilis  
**Adults:** 2.4 million units I.M. q week for up to 3 weeks, after aqueous penicillin G or procaine penicillin therapy  
➤ Gummas and cardiovascular syphilis  
**Adults:** 2.4 million units I.M. q week for 3 weeks  
➤ Yaws, bejel, and pinta  
**Adults:** 1.2 million units I.M. as a single dose  
➤ Prophylaxis of rheumatic fever and glomerulonephritis  
**Adults:** After acute attack, 1.2 million units I.M. q month or 600,000 units q 2 weeks

**Contraindications**  
• Hypersensitivity to penicillins, beta-lactamase inhibitors (piperacillin/tazobactam), or benzathine

**Precautions**  
Use cautiously in:  
• severe renal insufficiency, significant allergies, asthma  
• pregnant or breastfeeding patients

**Administration**  
• Before giving, ask patient about allergy to penicillin, beta-lactamase inhibitors, and benzathine. Be aware that cross-sensitivity to cephalosporins and imipenem also may occur.  
• Inject deep I.M. into upper outer quadrant of buttock in adult or mid-lateral thigh in infant or small child. Don’t inject into gluteal muscle in child younger than age 2. Rotate injection sites with repeated doses.  
• If using prefilled syringes, follow manufacturer’s instructions carefully.  
➤ Keep epinephrine and emergency equipment at hand in case of anaphylaxis.  
• Be aware that Hoigne’s syndrome (transient bizarre behavior and neurologic reactions) may immediately follow I.M. injection.  
• Know that in syphilis treatment, Jarisch-Hersheimer reaction (fever, chills, headache, sweating, malaise, hypotension or hypertension) may occur 2 to 12 hours after therapy begins and usually subsides within 24 hours.
Route | Onset | Peak | Duration
--- | --- | --- | ---
I.M. | Delayed | Dose dependent | Dose dependent

**Adverse reactions**

CNS: headache, lethargy, hallucinations, anxiety, neuropathy, fatigue, nervousness, tremors, euphoria, asthenia, Hoigne's syndrome, cerebrovascular accident, seizures, coma

CV: hypotension, pulmonary hypertension, vasodilation, vasovagal reaction, syncope, palpitations, tachycardia, cardiac arrest, pulmonary embolism

EENT: blurred vision, vision loss, laryngeal edema

GI: nausea, vomiting, diarrhea, epigastric distress, abdominal pain, colitis, blood in stool, glossitis, pseudomembranous colitis

GU: hematuria, proteinuria, urogenic bladder, erectile dysfunction, priapism, nephropathy, renal failure

Hematologic: hemolytic anemia, leukopenia, thrombocytopenia

Metabolic: hypernatremia, hyperkalemia

Respiratory: dyspnea, hypoxia, apnea, pulmonary embolism

Skin: rash, urticaria, sweating

Other: fever, superinfection, injection site reactions and pain, Jarisch-Hersheimer reaction, anaphylaxis, serum sickness

**Interactions**

Drug-drug. Aspirin, probenecid: increased penicillin blood level

Erythromycins, tetracyclines: decreased antimicrobial activity of penicillin

Hormonal contraceptives: decreased contraceptive efficacy

Drug-diagnostic tests. Alanine amino-transferase, blood urea nitrogen, creatinine, eosinophils, granulocytes, hemoglobin, platelets, potassium, white blood cells: increased levels

Direct Coombs' test: positive result

Sodium: decreased level

---

**Urine glucose, urine protein: false-positive results**

**Patient monitoring**

- Watch closely for anaphylaxis and serum sickness.
- In long-term therapy, monitor electrolyte levels and CBC with white cell differential; watch for electrolyte imbalances and blood dyscrasias.
- Assess neurologic status, especially for seizures and decreasing level of consciousness.
- Watch for evidence of superinfection and pseudomembranous colitis.

**Patient teaching**

- Teach patient to recognize anaphylaxis symptoms and to contact emergency medical services immediately if these occur.
- Tell patient drug may cause diarrhea. Instruct him to immediately report severe, persistent diarrhea, and fever.
- Urge patient to complete entire course of therapy as prescribed, even after symptoms improve.
- Advise patient to contact prescriber if infection symptoms get worse.
- Tell female patient that drug may make hormonal contraceptives ineffective. Advise her to use barrier birth control if she wishes to avoid pregnancy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

---

penicillin G potassium

**Pharmacologic class:** Penicillin

**Therapeutic class:** Anti-infective

**Pregnancy risk category B**
Action
Inhibits biosynthesis of cell-wall mucopeptide; bactericidal against penicillin-susceptible microorganisms during active multiplication stage

Availability
Powder for injection: 1 million, 5 million, and 20 million units/vial
Premixed (frozen) solution for injection: 1 million, 2 million, and 3 million units/50 ml

Indications and dosages
➤ Meningococcal meningitis
Adults: 1 to 2 million units I.M. q 2 hours or 20 to 30 million units/day by continuous I.V. infusion for 14 days, or until afebrile for 7 days
➤ Meningitis caused by susceptible pneumococcal or meningococcal strains
Children: 250,000 units/kg/day in equally divided doses I.M. or by continuous I.V. infusion q 4 hours for 7 to 14 days (depending on causative organism)
Infants older than 7 days: 200,000 to 300,000 units/kg/day I.V. in divided doses q 6 hours
Infants less than 7 days old: 100,000 to 150,000 units/kg/day I.V. in divided doses q 12 hours
➤ Actinomycosis
Adults: 1 to 6 million units/day I.M. or I.V. for cervicofacial infections; 10 to 20 million units/day I.V. q 4 to 6 hours for 6 weeks for thoracic and abdominal infections
➤ Clostridial infections
Adults: 20 million units/day I.M. or I.V. infusion q 4 to 6 hours, given with antitoxin therapy
➤ Fusospirochetal infections
Adults: 5 to 10 million units/day I.M. or 200,000 to 500,000 units I.V. infusion q 4 to 6 hours
➤ Rat bite fever; Haverhill fever
Adults: 12 to 20 million units/day I.M. or I.V. infusion q 4 to 6 hours for 3 or 4 weeks

➤ Pasteurella infections
Adults: 4 to 6 million units/day I.M. or I.V. infusion q 4 to 6 hours for 2 weeks
➤ Erysipeloid endocarditis
Adults: 12 to 20 million units/day I.M. or I.V. infusion q 4 to 6 hours for 4 to 6 weeks
➤ Diphtheria (as adjunctive therapy with antitoxin to prevent carrier state)
Adults: 2 to 3 million units/day I.M. or I.V. infusion in divided doses q 4 to 6 hours for 10 to 12 days
➤ Anthrax
Adults: At least 5 million units/day I.M. or I.V. infusion
➤ Serious streptococcal infections
Adults: 5 to 24 million units/day I.M. or I.V. infusion in divided doses q 4 to 6 hours
➤ Neurosyphilis
Adults: 18 to 24 million units/day I.V. (given in doses of 3 to 4 million units q 4 hours) for 10 to 14 days
➤ Listeria infections
Adults: 15 to 20 million units/day I.M. or I.V. infusion q 4 to 6 hours for 2 weeks in meningitis or 4 weeks in endocarditis
➤ Disseminated gonococcal infections
Adults: 10 million units/day I.V. (3 to 4 million units q 4 hours) for 10 to 14 days

Off-label uses
• Lyme disease
• Predental prophylaxis against bacterial endocarditis

Contraindications
• Hypersensitivity to penicillins or beta-lactamase inhibitors (piperacillin/tazobactam)

Precautions
Use cautiously in:
• severe renal insufficiency, significant allergies, asthma
• pregnant or breastfeeding patients.
Administration

- Before giving, ask patient about allergy to penicillin, beta-lactamase inhibitors, or benzathine. Know that cross-sensitivity to imipenem and cephalosporins also may occur.
- Keep epinephrine and emergency equipment at hand in case anaphylaxis occurs.
- For I.V. use, dilute in sterile water for injection, normal saline solution, or dextrose 5% in water (D₅W). For continuous infusion, further dilute in 1 to 2 L of compatible solution and infuse over 24 hours. For intermittent infusion, further dilute in 50 or 100 ml of normal saline solution or D₅W; administer over 1 to 2 hours in adults or 15 to 30 minutes in children and infants.
- Know that drug also may be given by intrapleural or intrathecal route.
- Be aware that in syphilis treatment, Jarisch-Hersheimer reaction (fever, chills, headache, sweating, malaise, hypotension or hypertension) may occur 2 to 12 hours after therapy starts and usually subsides within 24 hours.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.M.</td>
<td>Rapid</td>
<td>15-30 min</td>
<td>4-6 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>End of infusion</td>
<td>4-6 hr</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: hyperreflexia, neuropathy, coma, seizures
CV: arrhythmias, cardiac arrest, heart failure (with high I.V. doses)
GI: nausea, vomiting, diarrhea, epigastric distress, abdominal pain, colitis, blood in stool, glossitis, pseudomembranous colitis
GU: nephropathy
Hematologic: hemolytic anemia, leukopenia, thrombocytopenia
Metabolic: hyperkalemia (with high-dose, continuous I.V. infusion)
Skin: rash, urticaria, exfoliative dermatitis

Other: pain at I.M. injection site, phlebitis at I.V. site, Jarisch-Hersheimer reaction, superinfection, anaphylaxis, serum sickness

Interactions

Drug-drug. Aspirin, probenecid: increased penicillin blood level
Erythromycins, tetracyclines: decreased antimicrobial activity of penicillin
Hormonal contraceptives: decreased contraceptive efficacy

Drug-diagnostic tests. Alanine aminotransferase, eosinophils, granulocytes, hemoglobin, platelets, potassium, white blood cells: increased levels
Direct Coombs’ test: positive result
Sodium: decreased level
Urine glucose, urine protein: false-positive results

Patient monitoring

- Watch closely for signs and symptoms of anaphylaxis and serum sickness.
- In long-term therapy, monitor electrolyte levels and CBC with white cell differential; watch for electrolyte imbalances and blood dyscrasias.
- Closely monitor neurologic status, especially for seizures and decreasing level of consciousness.
- Stay alert for signs and symptoms of superinfection and pseudomembranous colitis.

Patient teaching

- Teach patient to recognize signs and symptoms of anaphylaxis. Tell him to contact emergency medical services immediately if these occur.
- Tell patient drug may cause diarrhea. Instruct him to immediately report severe, persistent diarrhea and fever.
- Urge patient to complete entire course of therapy as prescribed, even after symptoms improve.
- Tell patient to contact prescriber if infection symptoms worsen.

Reactions in bold are life-threatening.

Clinical alert
• Inform female patient that drug may make hormonal contraceptives ineffective. Advise her to use barrier birth-control method if she wishes to avoid pregnancy.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

penicillin G procaine
Aycillin®, Crysticillin-AS®

Pharmacologic class: Penicillin
Therapeutic class: Anti-infective
Pregnancy risk category B

Action
Inhibits biosynthesis of cell-wall mucopeptide; bactericidal against penicillin-susceptible microorganisms during active multiplication stage

Availability
Suspension for I.M. injection: 600,000 units/ml vial, 1.2 million units/2-ml vial, 2.4 million units/4-ml vial, 3 million units/10-ml vial

Indications and dosages
➤ Anthrax; bacterial endocarditis; erysipelas and fusospirochetal infections; group A streptococcal infections; moderately severe, uncomplicated pneumococcal pneumonia and staphylococcal infections; rat-bite fever
Adults: 600,000 to 1 million units/day I.M.
➤ Diphtheria
Adults: 300,000 to 600,000 units/day I.M. given with antitoxin for 14 days. For carrier state, 300,000 units/day I.M. for 10 days.
➤ Syphilis, yaws, bejel, pinta

Adults and children older than age 12:
600,000 units/day I.M. for 8 days; for late infections, continue for 10 to 15 days. For neurosyphilis, 2.4 million units/day I.M. for 10 to 14 days, given with probenecid.
➤ Congenital syphilis
Children: 50,000 units/kg I.M. daily for at least 10 days
➤ Uncomplicated gonorrhea
Adults: 4.8 million units/day I.M., divided into at least two doses and two sites at one visit, with P.O. probenecid given 30 minutes before injection

Off-label uses
• Lyme disease
• Predental prophylaxis against bacterial endocarditis

Contraindications
• Hypersensitivity to penicillins, beta-lactamase inhibitors (piperacillin/tazobactam), or procaine

Precautions
Use cautiously in:
• severe renal insufficiency, significant allergies, asthma
• pregnant or breastfeeding patients
• neonates.

Administration
• Before giving, ask patient about allergy to penicillin, beta-lactamase inhibitors, or benzathine. Know that cross-sensitivity to imipenem and cephalosporins may occur.
➤ Keep epinephrine and emergency equipment at hand in case anaphylaxis occurs.
• In adults, inject I.M. deep into upper outer aspect of buttocck.
• In infants and small children, inject at a slow, steady rate into midlateral aspect of thigh.
• Be aware that Hoigne’s syndrome (transient bizarre behavior and neurological reactions) may immediately follow I.M. injection.
• Know that in syphilis treatment, Jarisch-Hersheimer reaction (fever, chills, headache, sweating, malaise, hypotension or hypertension) may occur 2 to 12 hours after therapy starts and usually subsides within 24 hours.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.M.</td>
<td>Delayed</td>
<td>1-3 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

### Adverse reactions

- **CNS:** lethargy, hallucinations, anxiety, depression, twitching, Hoigne’s syndrome, **seizures, coma**
- **EENT:** laryngeal edema
- **GI:** nausea, vomiting, diarrhea, epigastric distress, abdominal pain, colitis, blood in stool, glossitis, **pseudomembranous colitis**
- **GU:** interstitial nephritis
- **Hematologic:** increased bleeding, hemolytic anemia, bone marrow depression, leukopenia, thrombocytopenia, granulocytopenia
- **Skin:** rash, urticaria
- **Other:** pain at I.M. injection site, fever, superinfection, Jarisch-Hersheimer reaction, sterile abscess, procaine toxicity, **anaphylaxis, serum sickness**

### Interactions

**Drug-drug.** *Aspirin, probenecid:* increased penicillin blood level

*Erythromycins, tetracyclines:* decreased antimicrobial activity of penicillin

*Hormonal contraceptives:* decreased contraceptive efficacy

**Drug-diagnostic tests.** *Alanine aminotransferase, eosinophils, granulocytes, hemoglobin, platelets, potassium, white blood cells:* increased levels

*Direct Coombs’ test:* positive result

*Sodium:* decreased level

*Urine glucose, urine protein:* false-positive results

### Patient monitoring

- Watch closely for signs and symptoms of anaphylaxis and serum sickness.
- In long-term therapy, monitor electrolyte levels and CBC with white cell differential. Watch for electrolyte imbalances and blood dyscrasias.
- Assess neurologic status, especially for seizures and decreasing level of consciousness.
- Monitor patient for signs and symptoms of superinfection and pseudomembranous colitis.

### Patient teaching

- Teach patient to recognize signs and symptoms of anaphylaxis. Tell him to contact emergency medical services immediately if these occur.
- Tell patient drug may cause diarrhea. Instruct him to immediately report severe, persistent diarrhea and fever.
- Stress importance of completing entire course of therapy as prescribed, even after symptoms improve.
- Advise patient to contact prescriber if infection symptoms worsen.
- Tell female patient that drug may make hormonal contraceptives ineffective. Encourage her to use barrier birth-control method if she wishes to avoid pregnancy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

---

**penicillin V potassium**  
Apo-Pen VK®, Novo-Pen-VK®, Pen-Vee

**Pharmacologic class:** Penicillin  
**Therapeutic class:** Anti-infective  
**Pregnancy risk category B**
**Action**
Inhibits biosynthesis of cell-wall mucopeptide; bactericidal against penicillin-susceptible microorganisms during active multiplication stage

**Availability**
*Oral solution:* 200,000 units (125 mg)/5 ml, 400,000 units (250 mg)/5 ml
*Tablets:* 400,000 units (250 mg), 800,000 units (500 mg)

**Indications and dosages**
- **Upper respiratory streptococcal infections,** including scarlet fever and mild erysipelas
  - **Adults and children ages 12 and older:** 125 to 250 mg P.O. q 6 to 8 hours for 10 days
  - **Children younger than age 12:** 25 to 50 mg/kg/day P.O. in divided doses q 6 hours for 10 days
  - **Pneumococcal respiratory infections,** including otitis media
  - **Adults and children ages 12 and older:** 250 to 500 mg P.O. q 6 hours until afebrile for at least 2 days
  - **Skin and soft-tissue staphylococcal infections; fusospirochetosis (Vincent’s infection) of oropharynx**
  - **Adults and children ages 12 and older:** 250 to 500 mg P.O. q 6 to 8 hours
  - To prevent recurrence of rheumatic fever or chorea
  - **Adults and children ages 12 and older:** 125 to 250 mg P.O. b.i.d. on a continuing basis

**Off-label uses**
- Prophylaxis of *Streptococcus pneumoniae* septicemia in children with sickle cell anemia or splenectomy
- Early Lyme disease
- Actinomycosis
- Preexposure prophylaxis of anthrax
- Prophylaxis of bacterial endocarditis for dental procedures

**Contraindications**
- Hypersensitivity to penicillins or beta-lactamase inhibitors (piperacillin/tazobactam)

**Precautions**
Use cautiously in:
- severe renal insufficiency
- pregnant or breastfeeding patients.

**Administration**
- Before giving, ask patient about allergies to penicillin, beta-lactamase inhibitors, or benzathine. Know that cross-sensitivity to imipenem and cephalosporins may occur.
- Keep epinephrine and emergency equipment at hand in case anaphylaxis occurs.
- Give with water 1 hour before or 2 hours after meals. Don’t give with fruit juice or carbonated beverages.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1 hr</td>
<td>6 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- **CNS:** lethargy, hallucinations, anxiety, depression, twitching, seizures, coma
- **GI:** nausea, vomiting, diarrhea, epigastric distress, abdominal pain, colitis, blood in stool, glossitis, pseudomembranous colitis
- **GU:** interstitial nephritis
- **Hematologic:** anemia, hemolytic anemia, increased bleeding, leukopenia, granulocytopenia, bone marrow depression, thrombocytopenia, thrombocytopenic purpura
- **Metabolic:** hypokalemia, hyperkalemia, metabolic alkalosis
- **Skin:** rash, urticaria
- **Other:** fever, superinfection, anaphylaxis, serum sickness

**Interactions**
- **Drug-drug.** Aspirin, probenecid: increased penicillin blood level
- Erythromycins, tetracyclines: decreased antimicrobial activity of penicillin
Hormonal contraceptives: decreased contraceptive efficacy

Drug-diagnostic tests. Alanine aminotransferase, eosinophils, granulocytes, hemoglobin, platelets: increased levels Albumin, lymphocytes, protein, sodium, uric acid, white blood cells: decreased levels

Direct Coombs’ test: positive result

Potassium: increased or decreased level

Urine glucose, urine protein: false-positive results

Drug-herbs. Khat: delayed and reduced penicillin absorption

Patient monitoring

Watch for signs and symptoms of anaphylaxis and serum sickness.

- In long-term therapy, monitor electrolyte levels and CBC with white cell differential; watch for electrolyte imbalances and blood dyscrasias.

- Assess neurologic status, especially for seizures and decreasing level of consciousness.

Monitor patient closely for signs and symptoms of superinfection and pseudomembranous colitis.

Patient teaching

- Instruct patient to take with water 1 hour before or 2 hours after meals. Tell him not to take with fruit juice or carbonated beverages.

- Teach patient to recognize anaphylaxis symptoms. Tell him to immediately contact emergency medical services if these occur.

- Instruct patient to report signs and symptoms of superinfection.

- Advise patient to contact prescriber if infection symptoms get worse.

- Tell patient drug may cause diarrhea. Instruct him to immediately report severe, persistent diarrhea and fever.

- Instruct patient to complete entire course of therapy as prescribed, even after symptoms improve.

- Tell female patient drug may make hormonal contraceptives ineffective.

Advise her to use barrier birth-control method if she wishes to avoid pregnancy.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

pentamidine isethionate

NebuPent, Pentacarinat, Pentam 300

Pharmacologic class: Antiprotozoal

Therapeutic class: Anti-infective

Pregnancy risk category C

Action

Unknown. May interfere with nuclear metabolism and synthesis of DNA, RNA, and proteins.

Availability

Aerosol: 300 mg

Injection: 300 mg/vial

Indications and dosages

➣ Pneumocystis jiroveci pneumonia

Adults and children ages 5 and older: 4 mg/kg I.V. or deep I.M. daily for 14 days

➣ To prevent P. jiroveci pneumonia in high-risk patients with human immunodeficiency virus

Adults: 300 mg by inhalation once q 4 weeks using Respigard II nebulizer

Off-label uses

- Trypanosomiasis

- Visceral leishmaniasis

Contraindications

- History of anaphylaxis from pentamidine or diamidine compounds (inhalation only)

(Note: No absolute contraindications exist for patients with P. jiroveci.)
Precautions
Use cautiously in:
- anemia, blood dyscrasias, hepatic or renal disease, hypoglycemia, diabetes mellitus, ventricular tachycardia, hypocalcemia, hypertension, hypotension
- pregnant or breastfeeding patients
- children (safety and efficacy of inhalation solution not established).

Administration
- For I.V. infusion, dilute 300 mg-vial with sterile water for injection. Withdraw prescribed dosage, then dilute further in 50 to 250 ml of dextrose 5% in water; infuse over 60 to 120 minutes.
- For I.M. use, dilute 300 mg-vial with 3 ml of sterile water for injection. Withdraw prescribed dosage; administer deep I.M. using Z-track method.
- Keep patient supine during I.M. or I.V. administration to minimize hypotension.
- For inhalation, dilute in 6 ml of sterile water and administer through nebulizer at a flow rate of 6 L/minute from 50-psi compressed air source. Don’t mix inhalation solution with other drugs.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>1 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.M.</td>
<td>Unknown</td>
<td>0.5 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, disorientation, hallucinations, dizziness, confusion, fatigue, neuralgia
CV: chest pain, ECG abnormalities, syncope, vasodilation, vasculitis, phlebitis, hypertension, palpitations, arrhythmias, severe hypotension
EENT: pharyngitis
GI: nausea, vomiting, diarrhea, abdominal pain, anorexia, acute pancreatitis
Hematologic: anemia, leukopenia, thrombocytopenia
Metabolic: hypocalcemia, hyperglycemia, hypoglycemia, hyperkalemia
Musculoskeletal: myalgia
Respiratory: cough, dyspnea, congestion, pneumothorax, bronchospasm
Skin: rash, night sweats, urticaria, sterile abscess or induration at injection site
Other: metallic or bad taste, fever, chills, pain at injection site or elsewhere, edema, allergic reactions

Interactions
Drug-diagnostic tests. Blood urea nitrogen, creatinine, liver function tests, potassium: increased values
Calcium, hemoglobin, hematocrit, platelets, white blood cells: decreased levels
ECG: alterations
Glucose: increased or decreased level

Patient monitoring
- Closely monitor blood pressure and blood glucose. Watch for arrhythmias and evidence of pulmonary infection, blood dyscrasias, and pancreatitis during and after I.M. or I.V. administration, until patient is stable. (Severe, life-threatening reactions may occur.)
- Assess I.V. site closely during and after I.V. administration. Know that sterile abscess, pain, or induration may occur at injection site.
- Evaluate neurologic status.
- Monitor CBC (including platelet count), calcium and potassium levels, and kidney and liver function tests.

Patient teaching
- Explain purpose of therapy. Stress importance of completing entire course of treatment.
- Teach patient to recognize and immediately report serious cardiovascular and neurologic reactions, abdominal pain, and easy bruising or bleeding.
- Teach patient how to use aerosol.
- Tell patient to notify prescriber if infection worsens.
Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.

Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

pentazocine lactate
Talwin

pentazocine hydrochloride and acetaminophen
Fortral®, Talacen

pentazocine hydrochloride and naloxone hydrochloride
Talwin Nx

Pharmacologic class: Opioid agonist-antagonist

Therapeutic class: Opioid analgesic, adjunct to anesthesia

Controlled substance schedule IV

Pregnancy risk category C

FDA BOXED WARNING

- Talwin Nx is for oral use only. Severe, potentially lethal reactions may result from misuse by injection, alone or in combination with other substances.

Action

Unknown. Thought to interact with opioid receptor sites primarily in limbic system, thalamus, and spinal cord, blocking transmission of pain impulses.

Availability

Injection: 30 mg/ml (as lactate salt)
Tablets: 50 mg pentazocine and 0.5 mg naloxone (Talwin NX); 25 mg pentazocine and 650 mg acetaminophen (Talacen)

Indications and dosages

Moderate to severe pain; preoperative or preanesthetic medication; adjunct to surgical anesthesia

Adults: 30 mg subcutaneously, I.M., or I.V. q 3 to 4 hours (not to exceed 60 mg/dose subcutaneously or I.M., or 30 mg/dose I.V.). Maximum daily dosage is 360 mg.

Moderate to severe pain

Adults: Initially, one tablet (Talwin Nx) q 3 to 4 hours, increased to two tablets p.r.n., up to a maximum of 12 tablets daily

Mild to moderate pain

Adults: One tablet (Talacen) P.O. q 4 hours; up to a maximum of six tablets daily

Labor

Adults: 20 mg I.V. for two or three doses at 2- to 3-hour intervals, or 30 mg I.M. as a single dose

Contraindications

- Hypersensitivity to drug, acetaminophen, or naloxone (with oral form)

Precautions

Use cautiously in:

- head trauma, increased intracranial pressure, respiratory conditions, adrenal insufficiency, seizure disorder, acute CNS manifestations, hepatic impairment, acute myocardial infarction, alcohol or narcotic use
- sulfite sensitivity (Talacen)
- history of drug abuse
- pregnant or breastfeeding patients
- children (safety not established).

Reactions in bold are life-threatening.
Administration
● Administer each 5-mg I.V. dose by slow direct infusion over 1 minute, with patient lying supine.
● Use subcutaneous route only when necessary (may cause tissue damage).

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O. (Talwin NX)</td>
<td>15-30 min</td>
<td>1-3 hr</td>
<td>3 hr</td>
</tr>
<tr>
<td>P.O. (Talacen)</td>
<td>15-30 min</td>
<td>60-90 min</td>
<td>3 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>12-30 min</td>
<td>Unknown</td>
<td>3 hr</td>
</tr>
<tr>
<td>I.M., subcut.</td>
<td>15-20 min</td>
<td>15-60 min</td>
<td>3 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, drowsiness, euphoria, hallucinations, headache, sedation, dysphoria, insomnia, unusual dreams, weakness, depression, irritability, excitement, tremor, paresthesia
CV: hypertension, hypotension, syncope, tachycardia, circulatory depression, shock
EENT: blurred vision, diplopia, nystagmus, miosis (with high doses), tinnitus
GI: nausea, vomiting, constipation, diarrhea, dry mouth, ileus, cramps, abdominal distress, anorexia
GU: urinary retention, altered rate and strength of labor contractions
Hematologic: thrombocytopenia purpura (with Talacen)
Respiratory: dyspnea, transient apnea in neonates whose mothers received pentazocine during labor, respiratory depression
Skin: clammy skin, diaphoresis, rash, urticaria, nodules, cutaneous depression, skin and subcutaneous sclerosis, dermatitis, pruritus, flushing
Other: altered taste, chills, soft-tissue induration, stinging on injection, facial edema, physical or psychological drug dependence, drug tolerance, anaphylaxis

Interactions
Drug-drug. Barbiturates, first-generation (sedating) antihistamines, other sedating drugs: additive CNS depression
MAO inhibitors: unpredictable reactions
Opioids: decreased analgesic effects

Drug-diagnostic tests. Amylase, lipase: increased levels
Granulocytes, white blood cells: reduced counts

Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression

Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring
○ Monitor vital signs. Watch closely for evidence of shock, dyspnea, and circulatory or respiratory depression.
● Monitor drug efficacy.
● In prolonged use, assess for signs and symptoms of drug dependence.

Patient teaching
○ Tell patient receiving Talacen or Talwin NX that drug is for oral use only. Life-threatening reactions may result from misusing drug by injection.
● Inform patient that withdrawal symptoms may occur if he stops taking drug suddenly after prolonged use.
● Urge patient to avoid alcohol.
● Advise patient to consult prescriber before taking other prescription drugs or over-the-counter preparations.
● Caution patient to avoid driving and other hazardous activities until he knows how drug affects him.
● Advise patient to have periodic eye exams.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.
pentobarbital sodium
Nembutal Sodium

**Pharmacologic class:** Barbiturate  
**Therapeutic class:** Sedative-hypnotic, anticonvulsant  
**Controlled substance schedule II**  
**Pregnancy risk category D**

**Action**
Depresses sensory cortex, decreases motor activity, and alters cerebellar function; may interfere with nerve impulse transmission in brain.

**Availability**
- Capsules: 100 mg
- Elixir: 20 mg/5 ml
- Injection: 50 mg/ml in 2-ml prefilled syringes
- Suppositories: 30 mg, 120 mg, 200 mg

**Indications and dosages**

**Sedation**
- **Adults:** 20 to 30 mg P.O. three to four times daily. Alternatively, 120 to 200 mg P.R. as a single dose.
- **Children:** 2 to 6 mg/kg P.O. daily in divided doses; maximum of 100 mg/dose daily.
  - Alternatively, for P.R. dosing—
    - Children ages 12 to 14 weighing 36.4 to 50 kg (80 to 110 lb): 60 or 120 mg P.R.
    - Children ages 5 to 12 weighing 18.2 to 36.4 kg (40 to 80 lb): 60 mg P.R.
    - Children ages 1 to 4 weighing 9 to 18.2 kg (20 to 40 lb): 30 or 60 mg P.R.
    - Children ages 2 months to 1 year weighing 4.5 to 9 kg (10 to 20 lb): 30 mg P.R.
- **Preoperative sedation**
  - **Adults:** Initially, 100 mg P.O., 150 to 200 mg I.M., or 100 mg I.V.
  - **Seizures**
  - **Adults:** Initially, 100 mg. I.V.; may give additional doses after 1 minute. Maximum dosage is 500 mg.

**Children:** Initially, 50 mg. I.V.; may give additional doses until desired response occurs. Don’t exceed 100 mg/dose.

**Contraindications**
- Hypersensitivity to drug or other barbiturates
- Nephritis (with large doses)
- Severe hepatic impairment
- Severe respiratory disease with dyspnea or obstruction
- Manifest or latent porphyria
- History of sedative-hypnotic abuse
- Subcutaneous or intra-arterial administration

**Precautions**
Use cautiously in:
- hepatic or renal impairment, increased risk for suicide, alcohol use
- history of drug addiction
- labor and delivery
- elderly or debilitated patients.

**Administration**

- **When giving I.V., make sure resuscitation equipment is available.**
- Give I.V. by direct injection no faster than 50 mg/minute.
- Inject I.M. deep into large muscle mass.
- Don’t give by subcutaneous or intra-arterial routes, because severe reactions (such as tissue necrosis and gangrene) may occur.
- Know that drug is for short-term use only, losing efficacy after about 2 weeks.
- Be aware that rectal suppositories are used when P.O. or parenteral administration is undesirable.
- Don’t divide rectal suppositories.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>15-60 min</td>
<td>3-4 hr</td>
<td>3-4 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>1 min</td>
<td>3-4 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>10-25 min</td>
<td>Unknown</td>
<td>3-4 hr</td>
</tr>
<tr>
<td>Rectal</td>
<td>20-60 min</td>
<td>Unknown</td>
<td>3-4 hr</td>
</tr>
</tbody>
</table>

Reactions in **bold** are life-threatening.  

Clinical alert
Adverse reactions
CNS: drowsiness, agitation, confusion, hyperkinesia, ataxia, nightmares, nervousness, hallucinations, insomnia, anxiety, abnormal thinking
CV: hypotension, syncope, bradycardia (all with I.V. use)
GI: nausea, vomiting, constipation
Hepatic: hepatic damage
Musculoskeletal: joint pain, myalgia, neuralgia
Respiratory: laryngospasm (with I.V. use), bronchospasm, respiratory depression
Skin: rash, urticaria, exfoliative dermatitis
Other: phlebitis at I.V. site, physical or psychological drug dependence, fever, hypersensitivity reactions including angioedema

Interactions
Drug-drug. Acetaminophen: increased risk of hepatotoxicity
Activated charcoal: decreased pentobarbital absorption
Anticoagulants, beta-adrenergic blockers (except timolol), carbamazepine, clonazepam, corticosteroids, digoxin, doxorubicin, doxycline, felodipine, fentanyl, griseofulvin, hormonal contraceptives, metronidazole, quinidine, theophylline, verapamil: decreased efficacy of these drugs
Antihistamines (first-generation), opioids, other sedative-hypnotics: additive CNS depression
Chloramphenicol, hydantoins, narcotics: increased or decreased effects of either drug
Divalproex, MAO inhibitors, valproic acid: decreased pentobarbital metabolism, increased sedation
Rifampin: increased pentobarbital metabolism and decreased effects
Drug-diagnostic tests. Sulfoamophthalein: false increase
Drug-herbs. Chamomile, hops, kava, valerian, or skullcap: increased CNS depression
St. John’s wort: decreased pentobarbital effects

Drug-behaviors. Alcohol use: increased sedation, additive CNS depression

Patient monitoring
● Closely monitor blood pressure and heart and respiratory rates. Watch for evidence of respiratory depression.
● Monitor neurologic status before and during therapy.
● Assess CBC and kidney and liver function tests.
● In long-term therapy, monitor patient for signs of drug dependence.

Patient teaching
● Instruct patient to take exactly as prescribed.
● Tell patient that increasing dosage without prescriber’s approval may lead to dependence.
● Advise patient to avoid other CNS depressants, alcohol, and herbs.
● Caution patient to avoid driving and other hazardous activities.
● Advise patient taking hormonal contraceptives to use alternate birth-control method during therapy.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

pentostatin
Nipent

Pharmacologic class: Antimetabolite
Therapeutic class: Antineoplastic
Pregnancy risk category D

FDA BOXED WARNING
● Give under supervision of physician experienced in cancer chemotherapy,
in facility with adequate diagnostic and treatment resources.

- Use of higher dosages than those specified isn’t recommended, as dose-limiting severe renal, liver, pulmonary, and CNS toxicities may occur.
- In study of patients with refractory chronic lymphocytic leukemia receiving drug at recommended dosage in combination with fludarabine, four of six patients had severe or fatal pulmonary toxicity. Use in combination with fludarabine isn’t recommended.

**Action**

Unknown. Thought to inhibit adenosine deaminase, thereby increasing levels of deoxyadenosine triphosphate in cells, blocking DNA synthesis, and inhibiting ribonucleotide reductase.

**Availability**

*Powder for injection: 10-mg vials*

**Indications and dosages**

> Hairy cell leukemia

**Adults:** 4 mg/m² I.V. every other week

**Contraindications**

- Hypersensitivity to drug

**Precautions**

Use cautiously in:

- renal disease, bone marrow depression
- pregnant or breastfeeding patients
- children.

**Administration**

- Before giving, hydrate patient with 500 to 1,000 ml of dextrose 5% and normal saline solution (or its equivalent). After administering, give 500 ml of dextrose 5% in water (D₃W) or its equivalent.
- Follow facility protocol for handling, administering, and disposing of chemotherapeutic drugs.
- Give by direct I.V. bolus injection or dilute with 25 to 50 ml of D₃W or normal saline solution; infuse over 20 to 30 minutes.

**Adverse reactions**

- **CNS:** headache, malaise, anxiety, confusion, depression, dizziness, insomnia, nervousness, paresthesia, drowsiness, abnormal thinking, fatigue, asthenia, hallucinations, hostility, amnesia
- **CV:** peripheral edema, cellulitis, vasculitis, hypotension, angina, tachycardia, bradycardia, phlebitis, thrombophlebitis, cardiac arrest, heart failure, hemorrhage, ventricular asystole, pericardial effusion, sinus arrest
- **EENT:** abnormal vision, nonreactive pupils, photophobia, retinopathy, eye pain, conjunctivitis, dry or watery eyes, hearing loss, tinnitus, ear pain, episptaxis, pharyngitis, rhinitis
- **GI:** nausea, vomiting, diarrhea, constipation, dyspepsia, abdominal pain, ileus, flatulence, stomatitis, glossitis, anorexia
- **GU:** amenorrhea, breast lump, erectile dysfunction, decreased libido, renal calculi, renal dysfunction, renal insufficiency, renal failure
- **Hematologic:** ecchymosis, anemia, hemolytic anemia, agranulocytosis, aplastic anemia, leukopenia, thrombocytopenia
- **Metabolic:** hyperuricemia, hypercalcemia, hyponatremia
- **Musculoskeletal:** myalgia, joint pain
- **Respiratory:** cough, dyspnea, respiratory tract infection, pulmonary embolism
- **Skin:** rash, eczema, petechiae, dry skin, pruritus, skin disorder, furunculosis, acne, alopecia, diaphoresis, photosensitivity
- **Other:** unusual taste, gingivitis, fever, chills, pain, facial edema, lymphadenopathy, herpes simplex or herpes zoster infection, flulike symptoms, viral or bacterial infection, allergic reaction, sepsis, neoplasm

Reactions in **bold** are life-threatening.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Clinical alert**

Pentostatin 917
Interactions

Drug-drug. Allopurinol: hypersensitivity vasculitis
Carmustine, cyclophosphamide, etoposide: potentially fatal acute pulmonary edema and hypotension
Fludarabine: severe or fatal pulmonary toxicity
Vidarabine: increased risk and severity of adverse reactions

Drug-diagnostic tests. Calcium, liver function tests, serum uric acid: increased values
Granulocytes, platelets, sodium, white blood cells: decreased levels

Patient monitoring

- Monitor CBC (including platelet count). Watch for evidence of blood dyscrasias.
- Assess kidney and liver function tests. Stay alert for evidence of organ dysfunction.
- Monitor temperature. Watch for signs and symptoms of bacterial and viral infection.
- Closely monitor vital signs and ECG, particularly for life-threatening arrhythmias, heart failure, and pulmonary edema.

Patient teaching

- Tell patient drug lowers resistance to infection. Instruct him to avoid crowds and to immediately report fever, cough, sore throat, and other infection symptoms.
- Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
- Instruct female patient of childbearing age to avoid pregnancy during drug therapy and to seek medical advice before becoming pregnant.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

pentoxifylline

Apo-Pentoxiphylline, Neotren®, Pentoxil, Pentoxiphylline®, Pentoxiphylline SR®, Trental

Pharmacologic class: Hemorrheologic, xanthine derivative
Therapeutic class: Hematologic agent
Pregnancy risk category C

Action

Unknown. Thought to enhance blood flow to the circulatory system by increasing vasoconstriction and oxygen concentrations.

Availability

Tablets (controlled-release, extended-release): 400 mg

Indications and dosages

- Intermittent claudication

Adults: 400 mg t.i.d. If adverse reactions occur, decrease to 400 mg b.i.d.

Dosage adjustment

- Renal impairment

Off-label uses

- Diabetic angiopathies and neuropathies
- Transient ischemic attacks
- Severe idiopathic recurrent aphthous stomatitis
- Raynaud’s phenomenon

Contraindications

- Hypersensitivity to drug or methylxanthines (such as caffeine, theophylline, theobromine)
- Recent cerebral or retinal hemorrhage
Precautions
Use cautiously in:
- patients at risk for bleeding
- pregnant or breastfeeding patients
- children (safety not established).

Administration
- Give with meals to minimize GI distress.
- Make sure patient swallows tablets whole without crushing, breaking, or chewing.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Variable</td>
<td>2-4 hr</td>
<td>8 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: agitation, dizziness, drowsiness, headache, insomnia, nervousness, tremor, anxiety, confusion, malaise
CV: angina, edema, hypotension, arrhythmias
EENT: blurred vision, epistaxis, laryngitis, nasal congestion, sore throat
GI: nausea, vomiting, constipation, diarrhea, abdominal discomfort, belching, bloating, dyspepsia, flatulence, cholecystitis, dry mouth, excessive salivation, anorexia
Hematologic: leukopenia
Respiratory: dyspnea
Skin: rash, urticaria, pruritus, brittle fingernails, flushing, angioedema
Other: bad taste, weight changes, thirst, flulike symptoms, lymphadenopathy

Interactions
Drug-drug. Anticoagulants, nonsteroidal anti-inflammatory drugs (NSAIDs): increased risk of bleeding
Antihypertensives: additive hypotension
Theobromide, theophylline: increased risk of theophylline toxicity
Drug-herbs. Anise, arnica, asafetida, chamomile, clove, dong quai, fennel, feverfew, garlic, ginger, ginkgo, ginseng, licorice: increased risk of bleeding

Drug-behaviors. Smoking: decreased pentoxifylline efficacy

Patient monitoring
- Monitor vital signs and cardiovascular status. Watch for arrhythmias, angina, edema, and hypotension.
- Frequently monitor prothrombin time and International Normalized Ratio in patients receiving warfarin concurrently.
- Assess theophylline level in patients receiving theophylline-containing drugs concurrently.

Patient teaching
- Instruct patient to take with meals and to swallow tablets whole without crushing, breaking, or chewing.
- Inform patient that drug can cause serious adverse effects. Instruct him to immediately report chest pain, swelling, and flulike symptoms.
- Tell patient smoking may make drug less effective and that many over-the-counter preparations (including aspirin, NSAIDs, and herbs) increase risk of bleeding.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, herbs, and behaviors mentioned above.

perindopril erbumine
Aceon, Apo-Perindopril®️, Coversyl®️

Pharmacologic class: Angiotensin-converting enzyme (ACE) inhibitor
Therapeutic class: Antihypertensive
Pregnancy risk category C (first trimester), D (second and third trimesters)

Reactions in bold are life-threatening.
FDA BOXED WARNING

- When used during second or third trimester of pregnancy, drug may cause fetal harm or death. Discontinue as soon as pregnancy is detected.

Action
Inhibits conversion of angiotensin I to angiotensin II (a potent vasoconstrictor). This effect leads to decreased plasma angiotensin II, reduced vasoconstriction, enhanced plasma renin activity, and decreased aldosterone activity.

Availability
Tablets: 2 mg, 4 mg, 8 mg

Indications and dosages
➤ Essential hypertension
Adults: 4 mg P.O. daily; may titrate upward to 16 mg/day, given as a single dose or in two divided doses. (Start with 2 to 4 mg/day in patients receiving diuretics.)
➤ Coronary artery disease
Adults: Initially, 4 mg P.O. daily for 2 weeks; then increase as tolerated to a maintenance dosage of 8 mg P.O. daily.

Dosage adjustment
- Renal impairment
- Elderly patients

Off-label uses
- Heart failure
- Diabetic nephropathy

Contraindications
- Hypersensitivity to drug or other ACE inhibitors
- Angioedema during previous ACE inhibitor use
- Pregnancy

Precautions
Use cautiously in:
- hepatic failure, renal impairment, renal artery stenosis, hyperkalemia, cough
- black patients with hypertension
- breastfeeding patients
- children (safety not established).

Administration
- Give without regard to food.

Know that drug (especially first dose) may cause angioedema. Keep epinephrine and antihistamines at hand in case of airway obstruction.
- For elderly patient, titrate dosage upward very slowly.
- Know that drug may be given alone or with other drugs.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1 hr</td>
<td>3-7 hr</td>
<td>12-24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, fatigue, headache, insomnia, sleep disorder, weakness, asthenia, drowsiness, vertigo, depression, paresthesia
CV: hypotension, angina pectoris, palpitations, chest pain, abnormal ECG, tachycardia
EENT: ear infection, sinusitis, rhinitis, pharyngitis
GI: nausea, vomiting, diarrhea, abdominal pain, flatulence
GU: proteinuria, urinary tract infection, erectile or other male sexual dysfunction, decreased libido, menstrual disorder
Metabolic: hyperkalemia
Musculoskeletal: back, arm, leg, neck, or joint pain; hypertonia; myalgia; arthritis
Respiratory: cough, upper respiratory infection
Skin: rash, angioedema
Other: fever, viral infection, edema

Interactions
Drug-drug. Antacids: decreased perindopril absorption
Antihypertensives, general anesthetics, nitrates, phenothiazines: additive hypotension
Cyclosporine, heparin, indomethacin, potassium-sparing diuretics, potassium supplements: hyperkalemia
Diuretics: excessive hypotension
Lithium: increased lithium toxicity
Nonsteroidal anti-inflammatory drugs: blunted antihypertensive response

Drug-diagnostic tests. Alanine amino-transferase, aspartate aminotransferase, blood urea nitrogen, creatinine, potassium, triglycerides: increased levels
Hematocrit, hemoglobin: decreased values

Drug-food. Salt substitutes containing potassium: hyperkalemia
Drug-herbs. Capsaicin: cough
Drug-behaviors. Acute alcohol ingestion: additive hypotension

Patient monitoring
- Assess blood pressure. Be aware that dosage increases or concomitant diuretic use may cause severe hypotension.
- Watch for angioedema, especially after first dose.
- Stay alert for signs and symptoms of infection, particularly EENT and respiratory infections.
- Monitor potassium level. Watch for signs and symptoms of hyperkalemia.
- Monitor liver and kidney function tests before and during therapy.
- In black patients, watch closely for angioedema and monitor drug efficacy. Monotherapy may be less effective in these patients.

Patient teaching
- Tell patient to take at same time each day, with or without food.
- Instruct patient to stop using drug and contact prescriber immediately if hoarseness or difficulty swallowing or breathing occurs.
- Tell patient to avoid excessive perspiration or decreased fluid intake, which may cause symptomatic blood pressure drop. Inform him that vomiting or diarrhea also may lower blood pressure.
- Tell patient to report signs and symptoms of infection.
- Advise patient not to use potassium-containing salt substitutes.

Caution female patient of child-bearing age to contact prescriber immediately if she suspects pregnancy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

perphenazine

Apo-Perphenazine
Fentazin

Pharmacologic class: Phenothiazine, dopaminergic antagonist
Therapeutic class: Antipsychotic, antiemetic
Pregnancy risk category NR

Action
Unknown. Thought to antagonize dopamine and serotonin type 2 in CNS. Also antagonizes muscarinic receptors in respiratory tract, causing cholinergic activation.

Availability
Injection: 5 mg/ml
Oral concentrate: 16 mg/5 ml
Tablets: 2 mg, 4 mg, 8 mg, 16 mg

Indications and dosages
Schizophrenia in nonhospitalized patients
Adults and children older than age 12: Initially, 4 to 8 mg P.O. t.i.d.
Schizophrenia in hospitalized patients
Adults and children older than age 12: Initially, 8 to 16 mg P.O. two to four times daily, increased p.r.n.; avoid dosages greater than 64 mg daily. Or 5 to
10 mg by deep I.M. injection q 6 hours p.r.n., not to exceed 30 mg/day.

Severe nausea and vomiting

Adults: 8 to 16 mg P.O. daily in divided doses, to a maximum of 24 mg; or 5 to 10 mg by deep I.M. injection p.r.n.; or up to 5 mg I.V. by slow injection or infusion.

Off-label uses
- Intractable hiccups

Contraindications
- Hypersensitivity to drug, its components, or related compounds
- Blood dyscrasias
- Bone marrow depression
- Hepatic damage
- Subcortical damage
- Coma
- Concurrent use of high-dose CNS depressants

Precautions
Use cautiously in:
- respiratory disorders, hepatic or renal dysfunction, breast cancer, alcohol withdrawal symptoms, suicidal tendency, surgery
- patients taking CNS depressants or anticholinergics
- elderly patients
- pregnant or breastfeeding patients
- children younger than age 12.

Administration
- Give oral forms with food to avoid GI upset.
- Dilute oral solution in water or fruit juice just before giving; use at least 60 ml of diluent for each 5 ml of solution.
- Avoid contact with oral or injection solution; contact dermatitis may occur.
- Administer I.M. injection deep into upper outer aspect of buttocks. Massage site to prevent abscess.
- Know that I.V. route is rarely indicated and should be used only in recumbent hospitalized patients. For I.V. use, dilute with normal saline solution to a concentration of 0.5 mg/ml; give slowly (no more than 1 mg q 2 minutes).
- I.V. dose shouldn’t exceed 5 mg.
- Replace parenteral therapy with oral therapy as soon as possible.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Variable</td>
<td>1-3 hours</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.M., I.V.</td>
<td>5-10 min</td>
<td>1-2 hr</td>
<td>6 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: drowsiness, dizziness, insomnia, vertigo, headache, hyperactivity, nocturnal confusion, bizarre dreams, tremor, ataxia, slurring, exacerbation of psychotic symptoms, parapsychotic reactions, parkinsonism, dystonias, akathisia, tardive dyskinesia, hyperreflexia, cerebrospinal fluid abnormality, catatonic-like state, paradoxical stimulation, seizures, neuroleptic malignant syndrome
CV: hypotension, orthostatic hypotension, hypertension, peripheral edema, ECG changes, tachycardia, bradycardia, cardiac arrest, heart failure
EENT: glaucoma, blurred vision, miosis, mydriasis, corneal and lens deposits, pigmentary retinopathy, oculargic crisis, photophobia, nasal congestion, dysphagia
GI: nausea, vomiting, diarrhea, constipation, obstruction, abnormal tongue color or movement, dry mouth, anorexia, adynamic ileus
GU: dark urine, urinary retention, urinary frequency, urinary incontinence, bladder paralysis, galactorrhea, lactation, breast enlargement, menstrual irregularities, inhibited ejaculation, libido changes
Hematologic: hemolytic anemia, leukopenia, agranulocytosis, thrombocytopenic purpura
Hepatic: jaundice, biliary stasis
Metabolic: hyponatremia, glycosuria, hyperglycemia, hypoglycemia, syndrome of inappropriate antidiuretic hormone secretion, pituitary tumor
Musculoskeletal: numbness and aching of arms and legs

Canada UK Hazardous drug High alert drug
Respiratory: dyspnea, suppressed cough reflex, asthma, bronchospasm, laryngospasm, laryngeal edema

Skin: urticaria, pallor, erythema, eczema, pruritus, perspiration, pigmentation changes, photosensitivity, angioedema, exfoliative dermatitis

Other: increased appetite, weight gain, fever, systemic lupus erythematosus-like syndrome, pain at I.M. injection site, hypersensitivity reactions including anaphylactoid reaction

Interactions

Drug-drug. Anticholinergics: increased risk of adverse anticholinergic reactions
CNS depressants: increased perphenazine effects, increased adverse CNS reactions
Tricyclic antidepressants: increased perphenazine blood level, greater risk of adverse reactions

Drug-diagnostic tests. Eosinophils, liver function tests: increased values
Glucose: increased or decreased level
Granulocytes, hemoglobin, platelets, sodium, white blood cells: decreased levels
Pregnancy test: false-positive result

Drug-herbs. Kava: dystonic reactions
St. John’s wort: photosensitivity
Yohimbe: yohimbe toxicity

Drug-behaviors. Alcohol use: increased CNS depression
Sun exposure: increased risk of photosensitivity reaction

Patient monitoring

Watch for anaphylactoid reaction and angioedema. Monitor neurologic status; stay alert for signs and symptoms of neuroleptic malignant syndrome (high fever, unstable blood pressure, stupor, muscle rigidity, autonomic dysfunction), parkinsonian symptoms, and catatonic-like state.

- Assess blood pressure and heart rate continuously during I.V. use. Monitor cardiovascular status and vital signs periodically.

Evaluate respiratory status, especially for dyspnea and airway spasm.
Monitor CBC, glucose level, and liver function tests. Watch for evidence of blood dyscrasias.

Patient teaching

- Explain importance of combining drug therapy with psychotherapy.
- Tell patient to take exactly as prescribed and to report adverse reactions promptly.
- Instruct patient to avoid sun exposure and to wear sunscreen outdoors to prevent photosensitivity reaction.
- Advise patient to consult prescriber before taking other prescription drugs or over-the-counter preparations.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects him.
- Instruct patient to avoid alcohol, smoking, caffeine, and herbs.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

phenazopyridine hydrochloride

AZO-Gesic, Azo-Standard, Baridium, Phenozo, Prodium, Pyridium, ReAzo, UTI Relief

Pharmacologic class: Nonopioid analgesic

Therapeutic class: Urinary analgesic

Pregnancy risk category B

Action

Unknown. Thought to act locally on urinary tract mucosa to produce analgesic or anesthetic effects, relieving urinary burning, urgency, and frequency.

Reactions in bold are life-threatening.
Availability
Tablets: 95 mg, 97.2 mg, 100 mg, 200 mg

Indications and dosages
➣ Pain caused by lower urinary tract irritation
Adults: 200 mg P.O. t.i.d.
Children: 12 mg/kg P.O. daily in three divided doses

Contraindications
● Hypersensitivity to drug
● Renal insufficiency

Precautions
Use cautiously in:
● hepatitis
● pregnant or breastfeeding patients
● children younger than age 12.

Administration
● Give with or after meals.
● Discontinue after 2 days, as prescribed, when administering with antibiotics.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>6-8 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache
EENT: contact lens staining
GI: GI disturbances
GU: bright orange urine, renal toxicity
Hepatic: hepatotoxicity
Hematologic: hemolytic anemia, methemoglobinemia
Skin: rash, pruritus
Other: anaphylactoid-like reaction

Interactions
Drug-diagnostic tests. Bilirubin, glucose, ketones, protein, steroids: interference with urine tests based on spectrophotometry or color reactions

Patient monitoring
● Monitor patient for symptomatic improvement of urinary tract infection (UTI).

● Assess follow-up urine culture after antibiotic therapy ends.

Patient teaching
● Explain drug therapy and measures to help prevent UTI recurrence.
● Tell patient drug may discolor urine and tears and may stain clothing and contact lenses.

● Advise patient to contact prescriber promptly if symptoms don’t improve or if skin or eyes become yellow.

● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

Pharmacologic class: MAO inhibitor
Therapeutic class: Antidepressant
Pregnancy risk category C

FDA BOXED WARNING
● Drug may increase risk of suicidal thinking and behavior in children and adolescents with major depressive disorder and other psychiatric disorders. Risk must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family and caregivers to observe patient closely and communicate with prescriber as needed.

● Drug isn’t approved for use in pediatric patients.
Action
Nonselectively inhibits metabolism of MAO, an enzyme that increases accumulation of endogenous epinephrine, norepinephrine, and serotonin in CNS.

Availability
Tablets: 15 mg

Indications and dosages
● Atypical or neurotic depression
Adults: Initially, 15 mg P.O. t.i.d.; may increase rapidly to at least 60 mg/day, then 90 mg/day if needed for adequate response. Then reduce slowly to a maintenance dosage as low as 15 mg/day.

Contraindications
● Hypersensitivity to drug
● Pheochromocytoma
● Heart failure or other cardiovascular disease
● Abnormal liver function tests, history of hepatic disease
● History of headache
● Concurrent use of sympathomimetics, guanethidine, dextromethorphan, CNS depressants, buspirone, or serotonergic drugs

Precautions
Use cautiously in:
● hyperthyroidism, seizure disorders, hypotension, hypomania, diabetes mellitus, hepatic complications, myocardial ischemia
● patients switching from other MAO inhibitors
● suicidal or drug-dependent patients
● elderly patients
● pregnant or breastfeeding patients
● children younger than age 16.

Administration
–– If hypertensive crisis occurs, discontinue drug immediately and give phen tolamine 5 mg I.V. slowly as ordered.
–– Ask patient about other drugs he’s using; MAO inhibitors can cause dangerous interactions with many drugs.

Route Onset Peak Duration
P.O. Unknown 2-6 hr Variable

Adverse reactions
CNS: dizziness, headache, drowsiness, hyperreflexia, hyp oversomnia, tremors, fatigue, insomnia, palilalia, euphoria, paresthesia, ataxia, manic reaction, acute anxiety reaction, schizophrenia precipitation, shock-like coma, seizures, toxic delirium, suicidal behavior or ideation (especially in child or adolescent)
CV: orthostatic hypotension, edema, hypertensive crisis, arrhythmias
EENT: blurred vision, glaucoma, nystagmus
GI: nausea, vomiting, diarrhea, constipation, GI disturbances, epigastric or abdominal pain, dry mouth
GU: urinary retention, sexual disturbances
Hematologic: leukopenia
Hepatic: jaundice, fatal progressive necrotizing hepatocellular disease
Metabolic: hypernatremia, hypermetabolic syndrome
Musculoskeletal: muscle twitching
Skin: pruritus, rash, sweating
Other: weight changes, fever, lupus-like syndrome, edema

Interactions
Drug-drug. Amphetamines, CNS depressants, dextromethorphan, dibenzepine derivatives, other MAO inhibitors, serotonergic agents (such as fluoxetine, paroxetine), tryptophan: hypertensive crisis, seizures, fever, diaphoresis, excitation, delirium, tremor, coma, circulatory collapse
Antidepressants, buspirone: hypertension
Antihypertensives, beta-adrenergic blockers, thiazide diuretics: increased hypotensive effect
Epinephrine, guanadrel, guanethidine, norepinephrine, reserpine, vasoconstrictors: hypertensive crisis
Insulin, oral hypoglycemics: additive hypoglycemia

Reactions in bold are life-threatening.

Clinical alert
Drug-diagnostic tests. *Sodium, transaminases*: increased levels  
*White blood cells*: decreased count  

**Drug-food.** Aged, pickled, fermented, or smoked foods; wine; alcohol-free wine and beer; broad bean pods; cheese (except cottage and cream cheese); excessive amounts of chocolate or caffeine; dry sausage (including hard salami, pepperoni, and Lebanon bologna); foods containing *L*-tryptophan (such as dairy foods, soy, poultry, and meat); liver; spoiled or improperly refrigerated, handled, or stored protein-rich foods; yeast extract; yogurt: hypertensive crisis  

**Drug-herbs.** Ephedra (*ma huang*), *L*-tryptophan: hypertensive crisis  

**Drug-behaviors.** Alcohol use: hypertensive crisis

### Patient monitoring
- Monitor blood pressure. Drug may cause orthostatic hypotension or hypertensive crisis.  
- Assess patient for symptomatic improvement.  
- Monitor CBC, liver function tests, and blood glucose level before and during therapy.  
- Watch for increasing depression, suicide attempt, or suicidal ideation (especially in child or adolescent).

### Patient teaching
- Explain importance of taking drug exactly as prescribed.  
- Tell patient to discontinue drug at least 10 days before elective surgery.  
- Stress importance of avoiding alcohol, certain foods and beverages, prescription drugs, and over-the-counter preparations during and for 14 days after therapy. Ask pharmacist to provide patient with complete list of foods to avoid.  
- Instruct patient to immediately report occipital headache, palpitations, stiff neck, nausea, sweating, dilated pupils, and photophobia (indications of hypertensive crisis).  
- Advise patient or caregiver to immediately report increasing depression, suicide attempt, or suicidal ideation (especially in child or adolescent).  
- Tell patient to immediately report nausea, unusual tiredness, yellowing of skin or eyes, or irregular heart beats.  
- Advise patient to rise slowly to avoid dizziness.  
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, and alertness.  
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

---

**phenobarbital**

PMS-Phenobarbital, Solfoton

**phenobarbital sodium**

*Luminal Sodium*

- **Pharmacologic class:** Barbiturate  
- **Therapeutic class:** Anxiolytic, anticonvulsant, sedative-hypnotic  
- **Controlled substance schedule IV**  
- **Pregnancy risk category D**

### Action
Interferes with gamma-aminobutyric acid receptors, blocking nerve impulse transmission in CNS, which reduces motor activity and raises seizure threshold.

### Availability
- **Capsules:** 16 mg  
- **Elixir:** 15 mg/5 ml, 20 mg/5 ml  
- **Injection:** 30 mg/ml and 60 mg/ml in 1-ml prefilled syringes; 65 mg/ml in 1-ml vials; 130 mg/ml in 1-ml prefilled syringes, 1-ml vials, and 1-ml ampules
Tablets: 15 mg, 16 mg, 30 mg, 60 mg, 90 mg, 100 mg

Indications and dosages

➤ Tonic-clonic (grand mal) and partial seizures; febrile seizures in children

Adults: 60 to 100 mg/day P.O. as a single dose or in two or three divided doses; or initially, 100 to 320 mg I.V. p.r.n. (a total of 600 mg I.V. in a 24-hour period).

Infants and children: Loading dose of 15 to 20 mg/kg P.O. (produces drug blood level of 20 mcg/ml shortly after dosing). To achieve therapeutic blood level (10 to 25 mcg/ml), children usually need higher dosage/kg than adults. Follow loading dose with 3 to 6 mg/kg/day P.O. Alternatively, 4 to 6 mg/kg/day I.M. or I.V. for 7 to 10 days to achieve blood level of 10 to 15 mcg/ml.

➤ Status epilepticus

Adults: 200 to 320 mg I.M. or I.V., repeated q 6 hours p.r.n.

Children: 15 to 20 mg/kg I.V. given over 10 to 15 minutes

 ➤ Sedation or hypnotic effect

Adults: For sedation, 30 to 120 mg/day P.O. or 30 to 120 mg/day I.M. or I.V. in two or three divided doses. As a hypnotic, 100 to 200 mg P.O. or 100 to 320 mg I.M. or I.V. at bedtime. Don’t exceed 400 mg in a 24-hour period.

➤ Preoperative sedation

Adults: 100 to 200 mg I.M. 60 to 90 minutes before surgery

Children: 1 to 3 mg/kg I.M. or I.V., as prescribed.

Dosage adjustment

● Impaired hepatic or renal function
● Elderly or debilitated patients

Off-label uses

● Prevention and treatment of hyperbilirubinemia

Contraindications

● Hypersensitivity to drug or other barbiturates
● Manifest or latent porphyria
● Nephritis (with large doses)
● Severe respiratory disease with dyspnea or obstruction
● History of sedative-hypnotic abuse
● Subcutaneous or intra-arterial administration

Precautions

Use cautiously in:

● hepatic dysfunction, renal impairment, seizure disorder, fever, hyperthyroidism, diabetes mellitus, severe anemia, pulmonary or cardiac disease
● history of suicide attempt or drug abuse
● chronic phenobarbital use
● elderly or debilitated patients
● pregnant or breastfeeding patients
● children younger than age 6.

Administration

● Inject I.M. deep into large muscle mass; limit volume to 5 ml.

➤ Give I.V. no faster than 60 mg/minute. Keep resuscitation equipment at hand.

➤ Stop injection immediately if patient complains of pain or if circulation at injection site diminishes (indicating inadvertent intra-arterial injection).

➤ Don’t give by subcutaneous route; severe reactions (such as pain and tissue necrosis) may occur.

➤ Know that when given I.V. for status epilepticus, drug may take 15 minutes to attain peak blood level in brain. If injected continuously until seizures stop, drug brain level would keep rising and could exceed that required to control seizures. To avoid barbiturate-induced depression, use minimal amount required and wait for anticonvulsant effect to occur before giving second dose.

➤ Use parenteral route only when patient can’t receive drug P.O.

➤ Know that drug is intended only for short-term use, losing efficacy after about 2 weeks.

Reactions in bold are life-threatening.

Clinical alert
<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30-60 min</td>
<td>Unknown</td>
<td>10-16 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>5 min</td>
<td>30 min</td>
<td>10-16 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>10-30 min</td>
<td>Unknown</td>
<td>10-16 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: headache, dizziness, anxiety, depression, drowsiness, excitation, delirium, lethargy, agitation, confusion, hyperkinesia, ataxia, vertigo, nightmares, nervousness, paradoxical stimulation, abnormal thinking, hallucinations, insomnia, CNS depression

CV: hypotension, syncope, bradycardia (with I.V. use)

GI: nausea, vomiting, constipation

Hematologic: megaloblastic anemia

Hepatic: hepatic damage

Musculoskeletal: joint pain, myalgia

Respiratory: hypoventilation, laryngospasm, bronchospasm, apnea (with I.V. use); respiratory depression

Skin: rash, urticaria, exfoliative dermatitis, Stevens-Johnson syndrome

Other: phlebitis at I.V. site, drug dependence, hypersensitivity reactions including angioedema

**Interactions**

**Drug-drug.** Acetaminophen: increased risk of hepatotoxicity

Activated charcoal: decreased phenobarbital absorption

Anticoagulants, beta-adrenergic blockers (except timolol), carbamazepine, clonazepam, corticosteroids, digoxin, doxorubicin, doxycycline, felodipine, fenoprofen, griseofulvin, hormonal contraceptives, metronidazole, quinidine, theophylline, verapamil: decreased efficacy of these drugs

Chloramphenicol, hydantoins, narcotics: increased or decreased effects of either drug

Cyclophosphamide: increased risk of hematologic toxicity

**Divalproex, MAO inhibitors, valproic acid:** decreased phenobarbital metabolism, increased sedative effect

**Other CNS depressants (including first-generation antihistamines, opioids, other sedative-hypnotics):** additive CNS depression

**Rifampin:** increased phenobarbital metabolism and decreased effects

**Drug-diagnostic tests.** Bilirubin: decreased level in neonates and patients with seizure disorders or congenital nonhemolytic unconjugated hyperbilirubinemia

**Drug-herbs.** Chamomile, hops, kava, skullcap, valerian: increased CNS depression

St. John’s wort: decreased drug effects

**Drug-behaviors.** Alcohol use: additive CNS effects

**Patient monitoring**

- Monitor vital signs; watch for bradycardia and hypotension.

  - In patients with seizure disorders, know that drug withdrawal may cause status epilepticus.

- Assess neurologic status. Institute safety measures as needed.

- Closely monitor respiratory status, especially for respiratory depression and airway spasm.

- Monitor phenobarbital blood level, CBC, and kidney and liver function tests.

- Watch for signs of drug dependence.

**Patient teaching**

- Instruct patient to promptly report rash, facial and lip edema, syncope, dyspnea, or depression.

- Stress importance of taking exactly as prescribed, with or without food. Caution patient not to stop therapy abruptly, especially if he’s taking drug for seizures.

- Tell patient that prolonged use may lead to dependence.
● Instruct patient to seek medical advice before taking other prescription or over-the-counter drugs.
● Caution patient to avoid driving and other hazardous activities until he knows how drug affects him.
● Advise patient to avoid herbs, alcohol, and other CNS depressants.
● Instruct patient taking hormonal contraceptives to use alternate birth-control method.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

**phentolamine mesylate**

**Rogitine**

**Pharmacologic class:** Alpha-adrenergic blocker

**Therapeutic class:** Diagnostic agent, antihypertensive agent in pheochromocytoma

**Pregnancy risk category C**

**Action**

Competitively blocks postsynaptic (alpha_1) and presynaptic (alpha_2) adrenergic receptors. Acts on arterial tree and venous bed, reducing total peripheral resistance and lowering venous return to heart.

**Availability**

*Powder for injection:* 5 mg

**Indications and dosages**

➢ To prevent or control hypertensive episodes before or during pheochromocytectomy

**Adults:** 5 mg I.V. or I.M. 1 to 2 hours before surgery, then 5 mg I.V. during surgery as indicated

➢ To aid pheochromocytoma diagnosis

**Adults:** 2.5 or 5 mg (in 1 ml of sterile water) by I.V. injection; record blood pressure q 30 seconds for 3 minutes, then q minute for next 7 minutes. Or 5 mg (in 1 ml sterile water) I.M.; record blood pressure q 5 minutes for 30 to 45 minutes.

➢ To prevent or treat dermal necrosis after norepinephrine extravasation

**Adults:** For prevention, add 10 mg to each liter of I.V. solution containing norepinephrine. For treatment, inject 5 to 10 mg in 10 ml of normal saline solution into extravasated area within 12 hours.

**Off-label uses**

● Hypertensive crisis caused by MAO inhibitors
● Rebound hypertension caused by withdrawal of clonidine, propranolol, or other antihypertensives
● Erectile dysfunction (given with papaverine)

**Contraindications**

● Hypersensitivity to drug
● Coronary artery disease
● Myocardial infarction (MI) or history of MI
● Coronary insufficiency
● Angina

**Precautions**

Use cautiously in:

● patients receiving cardiac glycosides concurrently
● pregnant or breastfeeding patients.

**Administration**

● Reconstitute powder by diluting with 1 ml of sterile water for injection.
● For pheochromocytoma diagnosis, withhold sedatives, analgesics, and nonessential drugs for 24 to 72 hours before test (until hypertension returns). Keep patient supine until blood

Reactions in **bold** are life-threatening. ☢ Clinical alert
pressure stabilizes; then rapidly inject drug I.V. Maximum effect usually occurs within 2 minutes of dosing.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V., I.M.</td>
<td>Immediate</td>
<td>Unknown</td>
<td>Brief</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: weakness, dizziness
CV: tachycardia, acute and prolonged hypotension, orthostatic hypotension, arrhythmias
EENT: nasal congestion
GI: nausea, vomiting, diarrhea
Skin: flushing

**Interactions**

Drug-drug. Ephedrine, epinephrine: antagonism of these drugs’ effects
Drug-herbs. Ephedra (ma huang): antagonism of vasoconstrictive effects

**Patient monitoring**

- When using for norepinephrine extravasation, monitor injection site closely and assess blood pressure, heart rate, and respiratory rate.
- For pheochromocytoma diagnosis, monitor blood pressure. In pheochromocytoma, systolic and diastolic pressures drop immediately and steeply. Monitor and record blood pressure immediately after injection, at 30-second intervals for first 3 minutes, and at 1-minute intervals for next 7 minutes. Systolic decrease of 60 mmHg and diastolic decrease of 25 mmHg within 2 minutes after I.V. administration indicates a positive reaction for pheochromocytoma.

**Patient teaching**

- Explain drug administration procedure.
- Instruct patient to promptly report adverse reactions. Assure him he’ll be monitored closely.
- Tell patient to withhold other drugs (especially sedatives and analgesics) for at least 24 hours before pheochromocytoma testing, if appropriate.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and herbs mentioned above.

**phenylephrine hydrochloride**

Afrin Children’s Pump Mist, AH-Chew D, Coricidin, Fenox®, Minims Phenylephrine®, Mydfrin®, Neo-Synephrine, Preferin®, Rhinall, Sudafed PE, Vicks Sinex Ultra Fine Mist

**Pharmacologic class:** Sympathomimetic, alpha-adrenergic agonist

**Therapeutic class:** Vasopressor, nasal decongestant, ophthalmic vasoconstrictor

**Pregnancy risk category C**

**FDA BOXED WARNING**

- Clinicians should be completely familiar with package insert before using injection form.

**Action**

Stimulates alpha-adrenergic receptors, increasing blood pressure and causing pronounced vasoconstriction in skin, mucous membranes, and mucosa. Produces mydriasis by contracting pupillary dilator muscle.

**Availability**

*Injection:* 10 mg/ml
*Nasal solution:* 0.125%, 0.25%, 0.5%, 1%
*Ophthalmic solution:* 0.12%, 2.5%, 10%
*Tablets (chewable):* 10 mg
**Indications and dosages**

**Mild to moderate hypotension**
- **Adults:** 1 to 10 mg subcutaneously or I.M.; don’t exceed an initial dosage of 5 mg.

**Severe hypotension and shock**
- **Adults:** 0.1 to 0.18 mg/minute I.V. infusion. For maintenance infusion, 40 to 60 mcg/minute.

**To prevent hypotension during spinal anesthesia**
- **Adults:** 2 to 3 mg subcutaneously or I.M. 3 to 4 minutes before spinal anesthetic is injected

**Hypotensive emergency during spinal anesthesia**
- **Adults:** 0.2 mg I.V., up to a maximum of 0.5 mg/dose

**To prolong spinal anesthesia**
- **Adults:** 2 to 5 mg added to anesthetic solution (prolongs spinal block by up to 50%)

**Vasoconstrictor for regional anesthesia**
- **Adults:** 1 mg of phenylephrine added to every 20 ml of local anesthetic solution

**Paroxysmal supraventricular tachycardia**
- **Adults:** 0.5 mg by rapid I.V. injection, not to exceed initial dosage of 0.5 mg. Subsequent dosages (determined by blood pressure) shouldn’t exceed preceding dosage by more than 0.1 to 0.2 mg; maximum dosage is 1 mg.

**Nasal congestion**
- **Adults:** One or two sprays of 0.25% or 0.5% nasal solution in each nostril q 3 to 4 hours p.r.n.; severe congestion may warrant 1% solution. Or 10 to 20 mg P.O. (chewable tablets) q 4 hours.

**Vasoconstriction and pupil dilation**
- **Adults:** After topical anesthetic is applied, instill one drop of 2.5% ophthalmic solution into lacrimal sac; repeat 1 hour later.

**Uveitis**
- **Adults:** Instill one drop of 2.5% or 10% ophthalmic solution to upper surface of cornea. May repeat up to three times p.r.n.

**Open-angle glaucoma**
- **Adults:** Instill one drop of 10% ophthalmic solution to upper surface of cornea as often as necessary.

**For wide pupil dilation before intraocular surgery**
- **Adults:** Instill 2.5% or 10% ophthalmic solution, as prescribed, into lacrimal sac 30 to 60 minutes before surgery.

**Refraction**
- **Adults:** Before procedure, instill one drop of 2.5% ophthalmic solution combined with a rapid-acting cycloplegic into lacrimal sac, as prescribed.
- **Children:** Before procedure, instill one drop of 2.5% ophthalmic solution into lacrimal sac 5 minutes after cycloplegic administration, as prescribed.

**Provocative test for angle-closure glaucoma**
- **Adults:** 2.5% ophthalmic solution applied to dilate pupil, with intraocular pressure (IOP) measured before application and after dilation. IOP rise of 3 to 5 mm Hg suggests angle block in patients with glaucoma; however, negative response doesn’t rule out glaucoma from other causes.

**Retinoscopy (shadow test)**
- **Adults:** 2.5% ophthalmic solution

**Blanching test**
- **Adults:** Instill one to two drops of 2.5% ophthalmic solution into affected eye.

**Decongestant to relieve minor eye irritation**
- **Adults:** Instill one or two drops of 0.12% ophthalmic solution into eye(s) up to q.i.d. p.r.n.

**Dosage adjustment**
- Hyperthyroidism
- Cardiac disease
- Elderly patients

Reactions in **bold** are life-threatening.
Contraindications
- Hypersensitivity to drug or its components
- Severe hypertension
- Ventricular tachycardia
- Angle-closure glaucoma
- Aneurysm (10% ophthalmic solution)
- During intraocular surgery when corneal epithelial barrier has been disturbed (ophthalmic solution)
- Elderly patients with severe arteriosclerotic or cerebrovascular disease
- Some low-birth-weight infants

Precautions
Use cautiously in:
- sulfite sensitivity (some products)
- hyperthyroidism, partial heart block, bradycardia, hypertension, cardiac disease, arteriosclerosis, unstable vasomotor syndrome
- type 1 (insulin-dependent) diabetes mellitus, hypertension, hyperthyroidism, arteriosclerosis or other cardiac disease (10% ophthalmic solution)
- within 21 days of MAO inhibitors (2.5% or 10% ophthalmic solution)
- elderly patients
- pregnant or breastfeeding patients.

Administration
In emergencies, drug may be given by direct I.V. injection. Dilute 1 ml of solution containing 10 mg/ml with 9 ml of sterile water for injection.

For I.V. infusion, dilute 10 mg in 500 ml of dextrose 5% in water or normal saline solution; titrate dosage until blood pressure is slightly below patient’s normal level or until maximum dosage is reached. Infuse I.V. in large vein (preferably through central venous catheter) using infusion pump. After condition stabilizes, taper dosage gradually; don’t withdraw abruptly. Avoid extravasation.

Be aware that systemic absorption of ophthalmic solution during pupil dilation in patients with angle-closure glaucoma may trigger asthma attack.
- As ordered, apply a drop of suitable topical anesthetic before instilling ophthalmic solution, to prevent pain and drug dilution (caused by excessive lacrimation induced by pain).

Compress lacrimal sac for 1 minute after instilling 10% ophthalmic solution, to avoid excessive systemic absorption (which could cause serious cardiovascular problems, especially in elderly patients).
- Be aware that patients with heavily pigmented irides may require larger ophthalmic doses for diagnostic procedures.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>Unknown</td>
<td>15-20 min</td>
</tr>
<tr>
<td>I.M., subcut.</td>
<td>10-15 min</td>
<td>Unknown</td>
<td>0.5-2 hr</td>
</tr>
<tr>
<td>Nasal</td>
<td>15-20 min</td>
<td>Unknown</td>
<td>0.5-4 hr</td>
</tr>
<tr>
<td>Ophth. (0.12%)</td>
<td>Rapid</td>
<td>Unknown</td>
<td>30 min-4 hr</td>
</tr>
<tr>
<td>Ophth. (2.5%)</td>
<td>Rapid</td>
<td>15-60 min</td>
<td>3 hr</td>
</tr>
<tr>
<td>Ophth. (10%)</td>
<td>Rapid</td>
<td>10-60 min</td>
<td>6 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, weakness, anxiety, restlessness, tremor, light-headedness, dizziness, drowsiness, insomnia, hallucinations, nervousness, restlessness, giddiness, prolonged psychosis, orofacial dystonia
CV: hypertension, palpitations, tachycardia, bradycardia, **arrhythmias**
EENT: with ophthalmic solution—transient pigment floaters in aqueous humor; rebound miosis; rebound hypopemia (with prolonged use); light sensitivity; photophobia; blurred vision; allergic conjunctivitis, eye burning, stinging, and irritation; transient epithelial keratitis; decreased IOP; with nasal solution—rebound congestion,
burning, stinging, sneezing, dryness, local irritation
GI: nausea, vomiting, gastric irritation, anorexia
GU: urinary retention (in males with prostatitis)
Hematologic: leukopenia, agranulocytosis, thrombocytopenia
Musculoskeletal: brow ache (with ophthalmic solution)
Respiratory: asthmatic episodes
Skin: sweating, rash, urticaria, contact dermatitis, necrosis and sloughing
(with extravasation at I.V. site)

Interactions
Drug-drug. Beta-adrenergic blockers: blocked cardiostimulatory effects of phenylephrine
Bretylium, sympathomimetics: serious arrhythmias
Furazolidone: excessive hypertension
Guanethidine, methyldopa: decreased antihypertensive effects
Halogenated hydrocarbon anesthetics: serious arrhythmias
MAO inhibitors: severe headache, hypertension, hyperpyrexia
Oxytocics, tricyclic antidepressants: increased pressor response

Drug-diagnostic tests. Tonometry: false-normal readings (with ophthalmic form)

Drug-behaviors. Sun exposure: photophobia

Patient monitoring
- Monitor ECG continuously during I.V. administration; monitor blood pressure every 5 to 15 minutes until it stabilizes, then every 30 to 60 minutes.
- Monitor central venous pressure and fluid intake and output. Keep in mind that drug doesn’t eliminate need for fluid resuscitation.
- Assess CBC; watch for evidence of blood dyscrasias.
- Monitor I.V. site; extravasation can cause tissue damage.

- Assess for symptomatic improvement in patients using nasal form.

Monitor for adverse reactions, particularly life-threatening asthmatic episodes.

Patient teaching
- Tell patient to take exactly as directed and not to exceed recommended dosage.
- Advise patient using nasal solution that dropper, inhaler, or spray dispenser shouldn’t be used by more than one person. Teach proper instillation technique: instill nasal solution into dependent nostril with head down and in lateral position. Stay in this position for 5 minutes; then instill solution in other nostril in same manner. Advise patient to rinse container tip with hot water after each use. Instruct him to discontinue use and contact prescriber if symptoms don’t improve after 3 days. Tell him not to use for more than 3 days and to contact prescriber if symptoms persist.
- Teach proper technique for instilling eye drops. Stress importance of compressing lacrimal sac after instilling, to decrease systemic drug absorption. Tell patient that ophthalmic solution may cause light sensitivity lasting several hours. Inform elderly patient that he may see transient floaters 40 to 45 minutes after administration.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

Reactions in bold are life-threatening.
**phenytoin**
(diphenylhydantoin)
Dilantin-125, Dilantin Infatabs

**phenytoin sodium**
(diphenylhydantoin sodium)
Dilantin Kapseals, Diphenylan®, Epanutin®, Phenytek®

**Pharmacologic class:** Hydantoin derivative  
**Therapeutic class:** Anticonvulsant  
**Pregnancy risk category D**

**Action**  
Thought to limit seizure activity by promoting sodium efflux from neurons in motor cortex and reducing activity in brainstem centers responsible for tonic phase of tonic-clonic seizures

**Availability**  
*Capsules (prompt-release):* 30 mg, 100 mg  
*Capsules (extended-release):* 30 mg, 100 mg  
*Injection:* 50 mg/ml in 2- and 5-ml ampules  
*Oral suspension:* 30 mg/5 ml, 125 mg/5 ml  
*Tablets (chewable):* 50 mg

**Indications and dosages**

- Status epilepticus

**Adults:** Loading dose of 10 to 15 mg/kg by slow I.V., then a maintenance dosage of 100 mg P.O. or I.V. q 6 to 8 hours

**Neonates and children:** Loading dose of 15 to 20 mg/kg I.V. in divided doses of 5 to 10 mg/kg

- Generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures

**Adults:** Loading dose of 1 g P.O. (extended-release) in three divided doses (400 mg, 300 mg, and 300 mg) at 2-hour intervals in hospitalized patients requiring rapid steady-state serum levels (when I.V. route isn’t desired). Maintenance dosing usually starts 24 hours after loading dose. Patients who haven’t had previous treatment usually start at 100 mg (125 mg suspension) P.O. t.i.d., adjusted as needed to a maximum of 600 mg (625 mg suspension) P.O. daily. Alternatively, if divided doses control seizures, one daily dose of 300 mg P.O. (extended-release phenytoin sodium).

**Children:** Initially, 5 mg/kg/day P.O. in two or three equally divided doses; maintenance dosage individualized and given in two to three divided doses (not to exceed 300 mg/day).

- To prevent seizures during neurosurgery

**Adults:** 100 to 200 mg I.M. at 4-hour intervals

**Off-label uses**
- Arrhythmias
- Severe preeclampsia
- Trigeminal neuralgia
- Recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa

**Contraindications**
- Hypersensitivity to drug
- Sinus bradycardia, sinoatrial block, second- or third-degree atrioventricular block, Adams-Stokes syndrome

**Precautions**
Use cautiously in:
- hepatic disease, diabetes mellitus, skin rash
- pregnant or breastfeeding patients (safety not established).

**Administration**
- Before I.V. use, check designated line for patency and flush with normal

- Canada
- UK
- Hazardous drug
- High alert drug
saline solution. Deliver no faster than 50 mg/minute for adults or 1 to 3 mg/kg/minute in children and neonates; then flush with normal saline solution. Avoid extravasation (can cause severe tissue damage).

Don’t administer I.V. into dorsal hand veins, because purple glove syndrome may occur.

- When giving oral solution through nasogastric tube, dilute dose with sterile water or normal saline solution; after administration, flush tube with at least 20 ml of diluent.
- Withhold enteral feedings for at least 1 hour before and 1 hour after oral administration.
- Give I.M. only as last resort (may cause pain and reduce drug absorption).
- Know that patients with history of renal or hepatic disease should not receive P.O. loading dose.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>3 hr</td>
<td>6-12 hr</td>
</tr>
<tr>
<td>P.O. (extended)</td>
<td>Unknown</td>
<td>4-12 hr</td>
<td>12-36 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Rapid</td>
<td>12-24 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>Unknown</td>
<td>Erratic</td>
<td>12-24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** headache, fatigue, dizziness, drowsiness, weakness, depression, ataxia, slurred speech, confusion, agitation, dysarthria, dyskinesia, extrapyramidal symptoms, insomnia, irritability, twitching, nervousness, numbness, psychotic disturbances, tremor, CNS depression (with I.V. use), coma

**CV:** vasodilation, edema, chest pain, *tachycardia, hypotension* (increased with I.V. use), cardiovascular collapse (with I.V. use)

**EENT:** diplopia, amblyopia, nystagmus, visual field defect, eye pain, conjunctivitis, photophobia, mydriasis, hearing loss, tinnitus, ear pain, epistaxis, rhinitis, sinusitis, pharyngitis

**GI:** nausea, vomiting, diarrhea, constipation, lip enlargement, dry mouth

**GU:** pink, red, or reddish-brown urine; gynecomastia; Peyronie’s disease

**Hepatic:** jaundice, toxic hepatitis, hepatic damage

**Hematologic:** macrocytosis, simple anemia, megaloblastic anemia, monocytosis, leukocytosis, hemolytic anemia, thrombocytopenia, agranulocytosis, granulocytopenia, leukopenia, pancytopenia

**Metabolic:** hypocalcemia, diabetes insipidus, hyperglycemia

**Musculoskeletal:** back pain, pelvic pain, osteomalacia

**Respiratory:** dyspnea, increased cough and sputum, pneumonia, hyperventilation, hypoxia, hemoptysis, bronchitis, apnea, asthma, aspiration pneumonia, pulmonary fibrosis, atelectasis, pneumothorax

**Skin:** rash, pruritus, bruising, exfoliative dermatitis, hypertrichosis, hirsutism, alopecia, *Stevens-Johnson syndrome*

**Other:** gingival hyperplasia, altered taste, fever, lymphadenopathy, weight gain or loss, injection site reaction, coarsened facial features, lupus erythematosus syndrome, allergic reactions

**Interactions**

**Drug-drug.** Acetaminophen, amiodarone, carbamazepine, cardiac glycosides, corticosteroids, dicumarol, disopyramide, doxycycline, estrogen, haloperidol, hormonal contraceptives, methadone, metapyrone, mexiletine, quinidine, theophylline, valproic acid: increased metabolism and decreased effects of these drugs

Activated charcoal, antacids, sucralfate: decreased phenytoin absorption

Allopurinol, amiodarone, benzodiazepines, chloramphenicol, chlorpheniramime, cimetidine, disulfiram, fluconazole, ibuprofen, isoniazid, metronidazole, miconazole, omeprazole, phenacemide, phenothiazines, phenylbutazone,

Reactions in **bold** are life-threatening. 

Clinical alert
salicylates, succinimides, sulfonamides, tricyclic antidepressants, trimethoprim, valproic acid: increased phenytoin effects
Antineoplastics, barbiturates, carbamazepine, diazoxide, folic acid, influenza vaccine, loxapine, nitrofurantoin, pyridoxine, rifampin, theophylline: decreased phenytoin effects
Cyclosporine, dopamine, furosemide, levodopa, levonorgestrel, mebendazole, muscle relaxants, nondepolarizing phe-nothiazines, sulfonylureas: decreased effects of these drugs

**Drug-diagnostic tests.** Alkaline phosphatase, eosinophils, gamma-glutamyltransferase, glucose: increased levels
Dexamethasone (1-mg) suppression test, metyrapone test: interference with test results
Free thyroxine, serum thyroxine: decreased levels

**Drug-food.** Enteral tube feedings: decreased phenytoin absorption
Folic acid: decreased folic acid absorption

**Drug-behaviors.** Acute alcohol ingestion: increased phenytoin blood level
Chronic alcohol ingestion: decreased phenytoin blood level

**Patient monitoring**
- Assess blood pressure, ECG, and heart rate, especially during I.V. loading dose. Watch for adverse reactions.
- Monitor phenytoin blood level; therapeutic range is 10 to 20 mcg/ml.
- Evaluate CBC and kidney and liver function tests.
- Closely monitor prothrombin time and Internationalized Normal Ratio in patients receiving warfarin concurrently.
- Monitor drug efficacy.

**Patient teaching**
- Explain drug therapy, need for follow-up tests, and importance of taking drug exactly as prescribed.
- Caution patient not to stop therapy abruptly.
- Advise patient to avoid alcohol.
- Inform patient that drug may discol- or urine.
- Tell female patient drug may make hormonal contraceptives ineffective.
- Instruct patient to practice good dental hygiene to minimize gingival hyperplasia.
- Encourage patient to seek medical advice before taking over-the-counter preparations.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and behaviors mentioned above.

---

**pimecrolimus**

**Elidel**

**Pharmacologic class:** Dermatologic agent

**Therapeutic class:** Immunomodulator

**Pregnancy risk category C**

---

**FDA BOXED WARNING**
- Drug’s long-term safety hasn’t been established.
- Rare cases of lymphoma and skin cancer have occurred in patients who used drug. Avoid continuous long-term use in any age-group and limit application to areas of atopic dermatitis.
- Drug isn’t indicated for use in children younger than age 2.

---

**Action**
Unknown. Thought to inhibit T-cell activation by blocking transcription of early cytokines. Also blocks release of inflammatory cytokines and mediators
from mast cells after stimulation by antigen/immunoglobulin E.

Availability

Cream: 1%

Indications and dosages

- Mild to moderate atopic dermatitis

Adults and children ages 2 and older:
Apply 1% cream topically b.i.d. to clean, dry, affected area.

Contraindications

- Hypersensitivity to drug or its components

Precautions

Use cautiously in:
- eczema herpeticum (Kaposi’s varicelliform eruption), varicella zoster (chickenpox or shingles), herpes simplex infection, lymphadenopathy, mononucleosis, acute infectious Netherton’s syndrome, skin infections or papilloma, warts, immunocompromised state
- concurrent use of CYP3A inhibitors
- pregnant or breastfeeding patients
- children younger than age 2 (safety not established).

Administration

- Apply thin layer to affected area.
- Don’t use with occlusive dressing (may increase systemic absorption).

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Topical</td>
<td>Not systemically absorbed</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: headache
EENT: sinus congestion, rhinorrhea
GI: nausea, vomiting, diarrhea, gastritis
Respiratory: upper respiratory tract infection
Skin: pruritus, application-site reaction or discomfort
Other: pyrexia, increased risk of viral or bacterial infections

Interactions

Drug-drug. CYP3A inhibitors (such as calcium channel blockers, cimetidine, erythromycin): inhibition of action by hepatic enzymes that eliminate pimecrolimus

Drug-behaviors. Sunbathing: possible increased risk of skin cancer

Patient monitoring

- Reevaluate at 6 weeks if lesions haven’t healed.
- Discontinue therapy, as prescribed, if disease resolves.

Patient teaching

- Tell patient to apply to clean, dry skin and to wash hands afterward (unless hands are being treated).
- Caution patient not to use occlusive dressings.
- Tell patient drug may cause local reaction, such as a feeling of warmth or burning sensation. Advise him to contact prescriber if reaction is severe or lasts more than 1 week.
- Advise patient to apply missed dose as soon as possible. If it’s almost time for next dose, tell him to skip missed dose and resume regular schedule.
- Tell patient to avoid natural or artificial sunlight and to use adequate sunscreen on skin and lips.
- Instruct patient to contact prescriber if no improvement occurs after 6 weeks or if condition worsens.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and behaviors mentioned above.

Reactions in **bold** are life-threatening.

Clinical alert
**pimozide**
Apo-Pimozide®, Orap, PMS-Pimozide®

**Pharmacologic class:** Diphenylbutylpiperidine  
**Therapeutic class:** Antipsychotic  
**Pregnancy risk category C**

**Action**
Unclear. Thought to relieve tics by blocking dopaminergic receptors on neurons in CNS.

**Availability**
*Tablets:* 1 mg, 2 mg

**Indications and dosages**
- Motor and phonic tics in Tourette’s syndrome  
**Adults:** Initially, 1 to 2 mg P.O. daily in divided doses, increased every other day p.r.n. For maintenance, 0.2 mg/kg/day or 10 mg/day (whichever is smaller).

**Contraindications**
- Hypersensitivity to drug  
- Severe toxic CNS depression  
- Congenital long-QT syndrome  
- History of arrhythmias  
- Concurrent use of itraconazole, ketoconazole, macrolide antibiotics, protease inhibitors, nefazodone, or other drugs that prolong QT interval or cause motor and phonic tics  
- Simple tics or tics other than those associated with Tourette syndrome

**Precautions**
Use cautiously in:
- history of seizures, cardiovascular disorders, hepatic or renal dysfunction, ECG abnormalities  
- disorders that could be aggravated by adverse anticholinergic effects

**Adverse reactions**
- CNS: drowsiness, headache, dizziness, insomnia, akathisia, rigidity, speech disorder, handwriting changes, sedation, depression, excitement, nervousness, abnormal dreams, hyperkinesia, tardive dyskinesia, parkinsonian-like symptoms, tremor, *neuroleptic malignant syndrome*  
- CV: abnormal ECG, hypotension, orthostatic hypotension, hypertension, palpitations, chest pain, tachycardia, *prolonged QT interval*  
- EENT: visual disturbance, perception of spots before eyes, decreased visual accommodation  
- GI: nausea, vomiting, diarrhea, constipation, eructation, dysphagia, excessive salivation, dry mouth  
- GU: urinary frequency, menstrual disorder, breast secretions, erectile dysfunction, libido loss  
- Musculoskeletal: muscle cramps or tightness, stooped posture, torticollis  
- Skin: rash, skin irritation, sweating, photosensitivity  
- Other: taste changes, thirst, appetite changes, weight gain or loss

**Interactions**
**Drug-drug.** Amphetamines, methylphenidate, pemoline: tics  
Antiarrhythmics,azole antifungals, macrolide antibiotics, phenothiazines, protease inhibitors, tricyclic antidepressants: ECG abnormalities  
**Anticholinergics:** increased anticholinergic effects

- pregnant or breastfeeding patients  
- children younger than age 12.

**Administration**
- Give with or without food.  
- To minimize daytime sedation, give entire daily dose at bedtime.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>6-8 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Canadian Uk Hazardous Drug**

- **Caution:** Use cautiously in:
  - history of seizures, cardiovascular disorders, hepatic or renal dysfunction, ECG abnormalities  
  - disorders that could be aggravated by adverse anticholinergic effects  
  - pregnant or breastfeeding patients  
  - children younger than age 12.

**Interactions**
- Drug-drug. Amphetamines, methylphenidate, pemoline: tics  
- Antiarrhythmics,azole antifungals, macrolide antibiotics, phenothiazines, protease inhibitors, tricyclic antidepressants: ECG abnormalities  
- Anticholinergics: increased anticholinergic effects

- **Canada**  
- **UK**  
- **Hazardous drug**  
- **High alert drug**
CNS depressants: additive CNS depression

Drug-diagnostic tests. ECG: abnormalities

Drug-food. Grapefruit juice: inhibited pimozide metabolism

Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring
- Assess neurologic status, especially for signs and symptoms of neuroleptic malignant syndrome (high fever, stupor, sweating, unstable blood pressure, muscle rigidity, and autonomic dysfunction) and parkinsonian-like symptoms.
- Monitor for tardive dyskinesia, even after drug therapy ends.
- Assess vital signs and ECG. Stay alert for prolonged QT interval, hypertension, or orthostatic hypotension.

Patient teaching
- Tell patient he may take with or without food but not with grapefruit juice.
- Caution patient not to stop taking suddenly. Dosage must be tapered.
- Teach patient to recognize and immediately report signs and symptoms of neuroleptic malignant syndrome and tardive dyskinesia. Tell patient tardive dyskinesia may develop long after drug therapy ends.
- Instruct patient to rise slowly and carefully, because blood pressure may drop if he stands up suddenly.
- Advise patient that drug may cause erectile dysfunction and libido loss. Encourage him to discuss these problems with prescriber.
- Tell patient drug may cause appetite changes. Encourage good nutrition.
- Inform patient that drug may cause vision changes and photosensitivity, which he should report.
- Instruct patient not to drink alcohol or grapefruit juice while taking drug.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and behaviors mentioned above.

pindolol

Apo-Pindol®, Dom-Pindolol®, Gen-Pindolol®, Novo-Pindol®, Nu-Pindol®, PMS-Pindolol®, Sandoz-Pindolol®, Visken

Pharmacologic class: Beta-adrenergic blocker (nonselective)

Therapeutic class: Antihypertensive

Pregnancy risk category B

Action
Competes with beta-adrenergic agonists for receptor sites, inhibiting both beta₁ (myocardial) and beta₂ (respiratory) sites

Availability
Tablets: 5 mg, 10 mg

Indications and dosages
Hypertension
Adults: Initially, 5 mg b.i.d.; may increase by 10 mg/day q 3 to 4 weeks p.r.n. to a maximum of 60 mg/day

Contraindications
- Hypersensitivity to beta-adrenergic blockers
- Overt heart failure
- Cardiogenic shock
- Severe bradycardia
- Second- or third-degree heart block
- Bronchial asthma (including severe chronic obstructive pulmonary disease)

Reactions in bold are life-threatening.
Precautions
Use cautiously in:
- renal or hepatic impairment, pulmonary disease, diabetes mellitus, thyrotoxicosis, severe allergic reactions, major surgery
- elderly patients
- pregnant or breastfeeding patients
- children (safety not established).

Administration
- Give with or without food.
- Know that drug may be used alone or with other antihypertensives.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>1 hr</td>
<td>8-15 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, drowsiness, lethargy, weakness, anxiety, depression, insomnia, nervousness, paresthesia
CV: orthostatic hypotension, peripheral vasoconstriction, chest pain, palpitations, tachycardia, bradycardia, heart failure
EENT: blurred vision, dry eyes
GI: nausea, vomiting, constipation, diarrhea
GU: erectile dysfunction, decreased libido
Musculoskeletal: joint pain, back pain, muscle cramps
Metabolic: hyperglycemia, hypoglycemia
Respiratory: wheezing, dyspnea, bronchospasm
Skin: itching, rash
Other: drug-induced lupus syndrome, edema, cold extremities

Interactions
Drug-drug. Amphetamines, ephedrine, epinephrine, norepinephrine, phentylephrine, pseudoephedrine: excessive hypertension and bradycardia
Beta-adrenergic bronchodilators, theophylline: decreased theophylline antagonism or antagonism of both drugs
Catecholamine-depleting drugs (such as reserpine): additive beta blockade

Insulin, oral hypoglycemics: altered efficacy of these drugs
Nonsteroidal anti-inflammatory drugs: decreased antihypertensive action
Other antihypertensives, nitrates: additive hypotension
Thyroid preparations: decreased pindolol efficacy

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, lactate dehydrogenase, uric acid: increased levels
Glucose: increased or decreased level

Drug-herbs. Cocaine, ephedra (ma huang): unopposed alpha-adrenergic stimulation

Patient monitoring
- Monitor apical heart rate. Withhold drug and notify prescriber if rate is below 60 beats/minute.
- Closely monitor ECG, vital signs, and cardiovascular status. Stay alert for signs and symptoms of heart failure.
- Assess respiratory status, especially for wheezing and dyspnea.
- Monitor blood glucose level in patients with diabetes. (Drug may mask signs and symptoms of hypoglycemia.)

Patient teaching
- Instruct patient to take at same time each day, with or without food.
- Caution patient that stopping drug abruptly may worsen angina or cause severe cardiac problems.
- Advise patient to rise slowly from a lying or sitting position, to avoid dizziness from sudden blood pressure drop.
- Instruct patient to report signs and symptoms of heart failure (such as swelling in legs and shortness of breath when lying down) or other breathing difficulties.
- Advise diabetic patient to monitor blood glucose level closely.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially
pioglitazone hydrochloride

Actos, Apo-Pioglitazone®, Co Pioglitazone®, Gen-Pioglitazone®, Novo-Pioglitazone®, PMS-Pioglitazone®, Ratio-Pioglitazone®, Sandoz Pioglitazone®

Pharmacologic class: Thiazolidinedione
Therapeutic class: Hypoglycemic
Pregnancy risk category C

FDA BOXED WARNING

- Drug may cause or exacerbate heart failure. After starting therapy or increasing dosage, observe patient carefully for signs and symptoms of heart failure. If these develop, manage patient according to current standards of care and consider discontinuing drug or reducing dosage.
- Drug isn’t recommended in patients with symptomatic heart failure. In patients with established New York Heart Association Class III or IV heart failure, drug initiation is contraindicated.

Action
Enhances insulin sensitivity in muscle and adipose tissue; inhibits hepatic gluconeogenesis

Availability
Tablets: 15 mg, 30 mg, 45 mg

Indications and dosages
Adjuvant to diet and exercise to improve glycemic control in type 2 (non-insulin-dependent) diabetes mellitus
Adults: 15 to 30 mg/day; may increase to 45 mg/day if needed

Contraindications
- Hypersensitivity to drug, its components, or rosiglitazone
- Established New York Heart Association Class III or IV heart failure

Precautions
Use cautiously in:
- edema, hepatic impairment
- symptomatic heart failure (use not recommended)
- female patients of childbearing age
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

Administration
- Give with or without food.
- Know that drug may be used with sulfonylureas, metformin, or insulin when combination of diet, exercise, and monotherapy doesn’t achieve adequate glycemic control.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30 min</td>
<td>2 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache
CV: congestive heart failure (CHF) or exacerbation of CHF
EENT: sinusitis, pharyngitis
Hematologic: anemia
Metabolic: aggravation of diabetes mellitus, hypoglycemia, hyperglycemia
Musculoskeletal: myalgia
Respiratory: upper respiratory infection
Other: tooth disorders, pain, edema

Interactions
Drug-drug. Hormonal contraceptives: decreased contraceptive efficacy
Ketoconazole: increased pioglitazone effects
Drug-diagnostic tests. Creatine kinase: transient increase
Hematocrit, hemoglobin: decreased values (usually during first 4 to 12 weeks of therapy)

Reactions in bold are life-threatening.
Drug-herbs.

Chromium, coenzyme Q10, fenugreek: additive hypoglycemic effects

Glucosamine: poor glycemic control

Patient monitoring

- Monitor patient carefully for signs and symptoms of heart failure (including excessive, rapid weight gain; dyspnea, and edema) after initiation and after dosage increases. Consider discontinuation or dosage reduction if these symptoms appear.
- Assess patient’s weight and compliance with diet and exercise program.
- Monitor liver function tests before and during therapy.
- Monitor glycosylated hemoglobin, hemoglobin, hematocrit, and blood glucose levels.
- Assess for signs and symptoms of hypoglycemia or hyperglycemia.

Patient teaching

- Instruct patient to take exactly as prescribed. Tell him he may take drug without regard to food.
- Tell patient drug may increase his risk for EENT and respiratory infections. Instruct him to contact prescriber if symptoms occur.
- Advise patient to immediately report unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, dark urine, fever, trauma, infection, rapid weight gain, edema, or shortness of breath.
- Tell premenopausal anovulatory patient that drug may cause ovulation. Recommend use of reliable contraception.
- Advise female of childbearing age to contact prescriber promptly if pregnancy occurs.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

piperacillin sodium

Pharmacologic class: Penicillin (extended-spectrum)

Therapeutic class: Anti-infective

Pregnancy risk category B

Action

Inhibits bacterial cell-wall synthesis during active multiplication stage, resulting in cell death

Availability

Injection: 2 g, 3 g, 4 g, 40 g

Indications and dosages

- To prevent infection during abdominal and vaginal surgery

  Adults: For intra-abdominal surgery, 2 g I.V. just before surgery, followed by 2 g during surgery, then 2 g q 6 hours postoperatively for no more than 24 hours. For vaginal hysterectomy, 2 g I.V. just before surgery, followed by 2 g at 6 hours and 2 g at 12 hours after the initial dose. In cesarean delivery, 2 g I.V. after umbilical cord is clamped, followed by 2 g at 4 hours and 2 g at 8 hours after the initial dose. In abdominal hysterectomy, 2 g I.V. just before surgery, followed by 2 g on return to recovery room and 2 g 6 hours later.

  - Serious infections

  Adults: 12 to 18 g/day I.V. in divided doses q 4 to 6 hours

  - Complicated urinary tract infection (UTI)

  Adults: 8 to 16 g/day I.V. in divided doses q 6 to 8 hours

  - Uncomplicated UTI or community-acquired pneumonia

  Adults: 6 to 8 g/day I.M. or I.V. in divided doses q 6 to 12 hours

  - Uncomplicated gonorrhea

  Adults: 2 g I.M. as a single dose, with 1 g probenecid P.O. given 30 minutes before piperacillin injection
Dosage adjustment
- Renal impairment
- Elderly patients
- Children

Contraindications
- Hypersensitivity to penicillin or cephalosporins

Precautions
Use cautiously in:
- uremia, hypokalemia, cystic fibrosis, bleeding tendencies, drug allergies, sodium restriction
- pregnant or breastfeeding patients
- children younger than age 12.

Administration
- Ask patient about allergy to penicillin and cephalosporins before administering.
  - Keep epinephrine and emergency equipment available.
- For I.M. use, dilute in sterile water for injection or normal saline solution, to yield a final concentration of 400 mg/ml. Limit dosage to 2 g. Preferably, inject into upper outer buttock area.
- For intermittent I.V. infusion, dilute reconstituted solution in 50 ml of dextrose 5% in water, normal saline solution, dextrose 5% in normal saline solution, or lactated Ringer’s solution. Infuse over 20 to 30 minutes.
- When giving I.V. bolus, inject reconstituted solution over 3 to 5 minutes.
- Don’t mix with aminoglycosides in syringe or infusion container; doing so inactivates aminoglycoside.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>Immediate</td>
<td>Dose dependent</td>
</tr>
<tr>
<td>I.M.</td>
<td>Unknown</td>
<td>30-50 min</td>
<td>Dose dependent</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, dizziness, fatigue, seizures
CV: thrombophlebitis, deep-vein thrombosis
GI: nausea, vomiting, constipation, diarrhea, bloody diarrhea, pseudomembranous colitis
Hematologic: hematomas, eosinophilia, neutropenia, leukopenia, thrombocytopenia
Hepatic: cholestatic hepatitis
Metabolic: hypokalemia, hypernatremia, sodium overload
Skin: rash, erythema, induration, bruising, erythema multiforme, Stevens-Johnson syndrome
Other: pain, superinfection, anaphylaxis

Interactions
Drug-drug. Aminoglycosides: aminoglycoside inactivation
Aspirin, probenecid: increased piperacillin blood level
Hormonal contraceptives: decreased contraceptive efficacy
Methotrexate: increased risk of methotrexate toxicity
Tetracyclines: decreased piperacillin efficacy
Vecuronium: prolonged neuromuscular blockade

Drug-diagnostic tests. Bilirubin, blood urea nitrogen, creatinine, eosinophils, hepatic enzymes: increased values
Coombs’ test (with I.V. piperacillin): false-positive result
Granulocytes, hemoglobin, platelets, white blood cells: decreased levels

Patient monitoring
- Monitor for signs and symptoms of anaphylaxis or superinfection.
- Be aware that high doses may cause seizures.
- Watch for signs and symptoms of thrombophlebitis and deep-vein thrombosis.
- Assess drug efficacy. Obtain repeat cultures after therapy ends.
- Monitor potassium level and CBC with white cell differential. Check for blood dyscrasias and hypokalemia.

Reactions in bold are life-threatening.
Assess for signs and symptoms of erythema multiforme (sore throat, rash, cough, iris lesions, mouth sores, cough, fever). Report early signs before condition can progress to Stevens-Johnson syndrome.

**Patient teaching**
- Stress importance of completing entire course of therapy.
- Instruct patient to immediately report allergic reactions, rash, or severe diarrhea.
- Instruct patient to contact prescriber if signs and symptoms of infection worsen or if new symptoms develop.
- Advise female patient taking hormonal contraceptives to use alternate birth-control method.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

### piperacillin sodium and tazobactam sodium

**Tazocin**, **Zosyn**

**Pharmacologic class:** Penicillin (extended-spectrum), beta-lactamase inhibitor

**Therapeutic class:** Anti-infective

**Pregnancy risk category B**

**Action**

Piperacillin inhibits bacterial cell-wall synthesis, resulting in cell death. Tazobactam increases piperacillin efficacy.

**Availability**

*Powder for injection:* 2 g piperacillin and 0.25 g tazobactam/vial, 3 g piperacillin and 0.375 g tazobactam/vial, 4 g piperacillin and 0.5 g tazobactam/vial

**Indications and dosages**

- Community-acquired pneumonia; ruptured appendix; peritonitis; pelvic inflammatory disease; skin and skin-structure infections
- **Adults and children older than age 12:** 3.375 g (3 g piperacillin and 0.375 g tazobactam) I.V. q 6 hours for 7 to 10 days
- **Nosocomial pneumonia**
- **Adults and children ages 12 and older:** 3.375 g (3 g piperacillin and 0.375 g tazobactam) I.V. over 30 minutes q 4 hours for 7 to 14 days, given with an aminoglycoside

**Dosage adjustment**

- Renal impairment

**Contraindications**

- Hypersensitivity to penicillins, cephalosporins, imipenems, or beta-lactamase inhibitors
- Neonates

**Precautions**

Use cautiously in:
- heart failure, renal insufficiency (in children), seizures, bleeding disorders, uremia, hypokalemia, cystic fibrosis
- patients with sodium restrictions
- pregnant or breastfeeding patient
- children younger than age 12 (safety and efficacy not established).

**Administration**

- Ask patient about allergy to penicillins, cephalosporins, imipenems, or beta-lactamase inhibitors before giving.
- Dilute each gram with 5 ml of diluent, such as sterile or bacteriostatic water for injection, normal saline solution for injection, dextrose 5% in water, dextrose 5% in normal saline solution for injection, or 6% dextran in normal saline solution. Don’t use lactated Ringer’s solution.
- Shake vial until drug dissolves. Dilute again to a final volume of 50 ml; infuse over 30 minutes.
Don’t mix with other drugs. If possible, stop primary infusion while piperacillin infuses.

Don’t mix in same container with aminoglycosides, which are chemically incompatible with piperacillin.

### Route

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>Immediate</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

### Adverse reactions

**CNS:** headache, insomnia, agitation, dizziness, anxiety, lethargy, hallucinations, depression, twitching, **coma**, **seizures**

**CV:** hypertension, chest pain, tachycardia

**EENT:** rhinitis, glossitis

**GI:** nausea, vomiting, diarrhea, constipation, abdominal pain, **pseudomembranous colitis**

**GU:** proteinuria, hematuria, vaginal candidiasis, vaginitis, **oliguria**, **interstitial nephritis**, **glomerulonephritis**

**Hematologic:** anemia, increased bleeding, bone marrow depression, leukopenia, thrombocytopenia

**Metabolic:** hypokalemia, hypernatremia

**Respiratory:** dyspnea

**Skin:** rash, pruritus

**Other:** fever; pain, edema, inflammation, or phlebitis at I.V. site; superinfection; hypersensitivity reactions including **serum sickness and anaphylaxis**

### Interactions

**Drug-drug.** Aminoglycosides: aminoglycoside inactivation

Aspirin, probenecid: increased piperacillin blood level

Hormonal contraceptives: decreased contraceptive efficacy

Methotrexate: increased risk of methotrexate toxicity

Tetracyclines: decreased piperacillin efficacy

Vecuronium: prolonged neuromuscular blockade

**Drug-diagnostic tests.** Coombs’ test, urine glucose tests using copper

### Patient monitoring

- Assess neurologic status, especially for seizures.
- Monitor vital signs and fluid intake and output.
- Evaluate electrolyte levels, CBC with white cell differential, and culture and sensitivity tests. Watch for evidence of hypokalemia and blood dyscrasias.
- In patients receiving high doses or prolonged therapy, monitor for signs and symptoms of bacterial or fungal superinfection and pseudomembranous colitis.
- Monitor patient’s dietary sodium intake (drug has high sodium content).

Immediately report rash, hives, severe diarrhea, black tongue, sore throat, fever, or unusual bleeding or bruising.

### Patient teaching

- Tell patient to monitor urinary output and report significant changes.
- Instruct patient to report unusual pain, redness, swelling, or other changes at infusion site.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

---

**Clinical alert**

Reactions in **bold** are life-threatening.
**Action**
Increases production of cyclic adenosine monophosphate at beta-adrenergic receptors, producing bronchodilation and inhibiting histamine release. Primarily selective for beta₂-adrenergic (pulmonary) receptors, with minimal effect on beta₁-adrenergic (cardiac) receptors.

**Availability**
*Inhalation aerosol:* 200 mcg/spray (up to 400 inhalations/14.0-g canister)

**Indications and dosages**

- **Reversible airway disease**
  - Adults and children older than age 12: One or two inhalations q 4 to 6 hours (not to exceed 12 inhalations/day)

**Contraindications**
- Hypersensitivity to drug, adrenergic amines, or fluorocarbons

**Precautions**
Use cautiously in:
- cardiac disease, hypertension, hyperthyroidism, diabetes mellitus, glaucoma, hypokalemia
- elderly patients
- pregnant (near term) or breastfeeding patients
- children younger than age 12 (safety not established).

**Administration**
- If patient also uses a corticosteroid inhaler, give pirbuterol first, then wait 5 minutes before giving steroid.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhalation</td>
<td>Within 5 min</td>
<td>1.5 hr</td>
<td>6-8 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- CNS: headache, nervousness, restlessness, tremor, insomnia
- CV: angina, hypertension, tachycardia, arrhythmias
- GI: nausea, vomiting
- Metabolic: hyperglycemia

**Respiratory:** paradoxical bronchospasm

**Interactions**

- **Drug-drug.** Beta-adrenergic blockers: negation of pirbuterol’s therapeutic effects
- Diuretics: hypokalemia, exacerbation of ECG changes
- MAO inhibitors: hypertensive crisis
- Other adrenergics: additive adverse adrenergic effects

**Drug-diagnostic tests.** Glucose: increased level

**Drug-food.** Caffeine-containing foods and beverages: increased stimulant effect

**Drug-herbs.** Caffeine-containing herbs (such as cola nut, guarana, yerba mate), ephedra (ma huang): increased stimulant effect

**Patient monitoring**
- Be aware that excessive use may lead to tolerance and paradoxical bronchospasm.
- Monitor respiratory status before and after administering. Note improvements.
- Assess dosage and dosing frequency needed to control symptoms. Notify prescriber if patient needs higher dosage to control symptoms.
- Assess vital signs and cardiovascular status. Stay alert for angina, hypertension, and arrhythmias.
- Monitor patient for worsening bronchospasm after administration.

**Patient teaching**
- Teach patient how to use metered-dose inhaler or autoinhaler.
- Instruct patient to wait at least 2 minutes between inhalations.
- If patient also uses inhaled corticosteroid, tell him to use pirbuterol first and then wait 5 minutes before using steroid.
- Advise patient to contact prescriber if he needs higher or more frequent doses to control symptoms.
Teach patient to recognize signs and symptoms of bronchospasm. Advise him to notify prescriber if these worsen after he takes drug.

Tell patient that herbs containing ephedra or caffeine may increase stimulant effects, such as nervousness and tremors.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

Drug is contraindicated for treatment of perioperative pain in setting of coronary artery bypass graft surgery.

**Action**

Inhibits cyclooxygenase (an enzyme needed for prostaglandin synthesis), stimulating anti-inflammatory response and blocking pain impulses

**Availability**

_Capsules:_ 10 mg, 20 mg

**Indications and dosages**

- **Inflammatory disorders** (such as arthritis)
  - **Adults:** 20 mg P.O. daily as a single dose or in two divided doses

**Dosage adjustment**

- Hepatic or renal impairment
- Elderly patients

**Off-label uses**

- Dysmenorrhea
- Ankylosing spondylitis
- Gout

**Contraindications**

- Hypersensitivity to drug or other NSAIDs (including aspirin)
- Active GI bleeding or ulcer disease
- Third trimester of pregnancy

**Precautions**

Use cautiously in:

- renal impairment, severe cardiovascular or hepatic disease
- history of ulcer disease
- pregnant patients in first or second trimester
- breastfeeding patients (not recommended)
- children (safety not established).

**Administration**

- Give with milk, antacids, or food to minimize GI upset.

Reactions in **bold** are life-threatening.
**Route Onset Peak Duration**

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1 hr</td>
<td>Unknown</td>
<td>48-72 hr</td>
</tr>
<tr>
<td></td>
<td>(analgesia)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>P.O.</td>
<td>7-12 days</td>
<td>2-3 wk</td>
</tr>
<tr>
<td></td>
<td>(anti-inflam.)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: headache, drowsiness, dizziness
CV: edema, hypertension, vasculitis, tachycardia, **arrhythmias**
EENT: blurred vision, tinnitus
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, flatulence, dyspepsia, anorexia, **severe GI bleeding**
GU: proteinuria, **renal failure**
Hematologic: anemia, **blood dyscrasias**
Hepatic: jaundice, **hepatitis**
Skin: rash
Other: allergic reactions including **anaphylaxis**

**Interactions**

**Drug-drug.** Acetaminophen (chronic use), cyclosporine, gold compounds: increased risk of adverse renal reactions
Anticoagulants, cefamandole, cefoperazone, cefotetan, clopidogrel, epifibatide, heparin, plicamycin, thrombolitics, ticlopidine, tirofiban, valproic acid, vitamin A: increased risk of bleeding
Antineoplastics: increased risk of hematologic toxicity
Aspirin: decreased piroxicam blood level and efficacy
Corticosteroids, other NSAIDs: additive adverse GI reactions
Diuretics, other antihypertensives: decreased response to these drugs
Insulin, oral hypoglycemics: increased risk of hypoglycemia
Lithium: increased lithium blood level and risk of toxicity
Probenecid: increased piroxicam blood level and risk of toxicity

**Drug-diagnostic tests.** Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, blood urea nitrogen, creatinine, electrolytes, lactate dehydrogenase: increased levels

**Bleeding time:** prolonged
Hematocrit, hemoglobin, platelets, white blood cells: decreased levels
Liver function tests: abnormal results

**Drug-herbs.** Alfalfa, anise, arnica, astragalus, bilberry, black currant seed oil, bladderwrack, bogbean, boldo, borage oil, buchu, capsaicin, cat’s claw, celery, chaparral, cinchona bark, clove oil, coenzyme Q10, dandelion, danshen, dong quai, evening primrose oil, fenugreek, feverfew, garlic, ginger, ginkgo, guggul, papaya extract, red clover, rhubarb, safflower oil, skullcap, St. John’s wort: increased anticoagulant effect, greater bleeding risk

**Patient monitoring**
- Monitor vital signs and cardiovascular status. Stay alert for hypertension and arrhythmias.
- Monitor kidney and liver function tests, hearing, and CBC.
- Watch for signs and symptoms of drug-induced hepatitis and GI toxicity, including ulcers and bleeding.
- Monitor for signs and symptoms of infection, which drug may mask.

**Patient teaching**
- Advise patient to take with milk, antacids, or food to minimize GI upset.
- Tell patient drug may mask signs and symptoms of infection. Instruct him to contact prescriber if he suspects he has an infection.
- Teach patient to recognize and immediately report signs and symptoms of allergic reaction or GI bleeding.
- Inform patient that many herbs increase the risk of GI bleeding. Caution him not to use herbs without prescriber’s approval.
- Instruct patient to drink plenty of fluids and to report decreased urination.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
Tell female patient to inform prescriber if she is pregnant or breastfeeding.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

**FDA BOXED WARNING**

- Drug is for I.V. use only.
- Due to risk of severe reactions, give only to hospitalized patients under supervision of qualified physician experienced in use of cancer chemotherapy, where laboratory resources are available for necessary tests.
- Severe thrombocytopenia, hemorrhagic tendency, and even death may occur. Severe toxicity is more likely in patients with far-advanced disease or who otherwise are poor risks for therapy. However, serious toxicity also may occur in patients in relatively good condition.
- Before therapy starts, clinician must weigh potential benefits against toxicity risk and thoroughly review data regarding drug use in treating testicular tumors and hypercalcemic or hypercalciuric conditions linked to advanced cancers.

### plicamycin (mithramycin)

**Mithracin**

**Pharmacologic class:** Crystalline compound produced by *Streptomyces plicatus*

**Therapeutic class:** Antibiotic antineoplastic

**Pregnancy risk category X**

### Action

Unknown. Thought to form complex that causes cross-linking of DNA strands, inhibiting cellular RNA and enzymatic RNA synthesis.

### Availability

*Injection:* 2.5-mg vials

### Indications and dosages

- **Testicular cancer**
  - **Adults:** 25 to 30 mcg/kg/day I.V. over 4 to 6 hours for 8 to 10 days, unless significant adverse effects or toxicity occur. Treatment course exceeding 10 daily doses not recommended.
- **Hypercalcemia and hypercalciuria related to advanced cancer**
  - **Adults:** 25 mcg/kg/day I.V. over 4 to 6 hours for 3 to 4 days; may repeat weekly until adequate response occurs

### Dosage adjustment

- Renal failure

### Contraindications

- Hypersensitivity to drug
- Thrombocytopenia, thrombocytopathy
- Bone marrow depression
- Coagulation disorders or increased risk of bleeding
- Females of childbearing potential
- Pregnancy or breastfeeding

### Precautions

Use cautiously in:

- renal or hepatic disease, electrolyte imbalances.

### Administration

- Follow facility policy for preparing, handling, and administering carcinogenic, mutagenic, or teratogenic drugs. Don't let drug touch skin or mucous membranes.
- Give antiemetic before plicamycin, as prescribed, to reduce nausea and vomiting.

Reactions in **bold** are life-threatening.
Dilute with 4.9 ml of sterile water for injection. Shake vial to dissolve.
Further dilute in 1,000 ml of dextrose 5% in water or normal saline solution.
Infuse I.V. over 4 to 6 hours. Discard unused portion.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>1-2 days</td>
<td>3 days</td>
<td>3-15 days</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, malaise, drowsiness, asthenia, lethargy, depression
CV: phlebitis
GI: nausea, vomiting, diarrhea, stomatitis, anorexia
GU: proteinuria
Hematologic: leukopenia, thrombocytopenia, bleeding syndrome
Hepatic: mild and reversible hepatotoxicity
Metabolic: hypokalemia, hypocalcemia, hypophosphatemia
Skin: facial flushing; rash; pain, redness, or swelling at injection site; cellulitis with extravasation
Other: fever

Interactions
Drug-drug. Other antineoplastics: increased plicamycin toxicity
Drug-diagnostic tests. Blood urea nitrogen, creatinine, hepatic enzymes: increased levels
Calcium, phosphate, potassium, platelets, white blood cells (WBCs): decreased levels
Drug-herbs. Anise, arnica, chamomile, clove, dong quai, fenugreek, garlic, ginger, ginkgo, ginseng, licorice: increased risk of bleeding
Chaparral, comfrey, eucalyptus, germander, jin bu huan, kava, pennyroyal, skullcap, valerian: increased risk of hepatotoxicity

Patient teaching
Teach patient to recognize and immediately report easy bruising, bleeding, and hypocalcemia. Inform him that nosebleed may be first sign of a bleeding problem.
Instruct patient to report unusual pain, redness, swelling, or other changes at infusion site.
Caution female of childbearing age to avoid pregnancy during therapy. Advise her to report suspected pregnancy right away.
Instruct patient to avoid herbs, because many herbs increase the risk of liver damage.
As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

poractant alfa
Curosurf
Pharmacologic class: Porcine lung extract
Therapeutic class: Exogenous pulmonary agent
Pregnancy risk category NR
**Action**
Stabilizes and expands alveoli by reducing their surface tension and replenishing surfactant, preventing alveolar collapse

**Availability**
*Suspension for endotracheal instillation:*
120 mg (1.5 ml), 240 mg (3 ml)

**Indications and dosages**
- Respiratory distress syndrome (RDS) in premature infants
  **Infants:** 2.5 ml/kg birth weight endotracheally, with half of dose instilled into each bronchus; up to two subsequent doses of 1.25 ml/kg birth weight at 12-hour intervals may be needed. Maximum dosage is 5 ml/kg (initial dose plus two subsequent doses).

**Off-label uses**
- Adult RDS caused by viral pneumonia or near-drowning
- Infants with human immunodeficiency virus accompanied by *Pneumocystis jiroveci* pneumonia

**Contraindications**
None

**Precautions**
Use cautiously in:
- bradycardia, crackles, infection
- family history of pork allergy.

**Administration**
- Know that drug should be given only by clinicians experienced in intubation, ventilatory management, and resuscitation of neonates, because it can rapidly affect oxygenation and pulmonary function.
- Give first dose as soon as possible after RDS diagnosis, when patient is on ventilator.
- Be aware that drug is meant for endotracheal use only.
- Before use, slowly warm vial to room temperature and gently turn upside-down to ensure uniform suspension. Don’t shake.
- Using large-gauge needle, withdraw entire contents of vial into 3-ml or 5-ml syringe. Attach precut, 8-cm #5 French catheter to syringe. Fill catheter with drug; discard excess drug through catheter so that only prescribed dose remains in syringe.
- Before giving, verify proper placement and patency of endotracheal tube. Make sure catheter doesn’t extend beyond endotracheal tube.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intratracheal</td>
<td>Immediate</td>
<td>3 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- CV: transient hypotension and bradycardia
- Respiratory: transient endotracheal tube blockage, decreased oxygen saturation, airway obstruction

**Interactions**
None significant

**Patient monitoring**
- Monitor vital signs and ECG. Watch for hypotension and bradycardia.
- Assess closely for endotracheal tube blockage and proper ventilation.

**Patient teaching**
- Reassure parents that infant will be monitored closely.

---

**Reactions in bold are life-threatening.**
Action
Inhibits fungal ergosterol synthesis (key component of fungal cell membrane) by inhibiting lanosterol 14-alpha demethylase and causing methylated sterol precursors to accumulate

Availability
Oral suspension (immediate-release): 40 mg/ml in 123-ml bottle

Indications and dosages
➣ Prophylaxis of invasive Aspergillus and Candida infections in patients at risk for these infections because of severe immunocompromise (such as hematopoietic stem-cell transplant recipients with graft-versus-host disease and those who have hematologic cancers with prolonged neutropenia from chemotherapy)
   Adults and children age 13 and older: 200 mg (5 ml) P.O. three times daily for duration of therapy based on recovery from neutropenia or immunosuppression
   ➣ Oropharyngeal candidiasis
   Adults and children age 13 and older: Loading dose of 100 mg (2.5 ml) P.O. twice daily on first day, then 100 mg P.O. once daily for 13 days
   ➣ Oropharyngeal candidiasis refractory to itraconazole or fluconazole
   Adults and children age 13 and older: 400 mg (10 ml) P.O. twice daily for duration of therapy based on disease severity and clinical response

Off-label uses
● Esophageal candidiasis
● Fusarium infection
● Mycosis

Contraindications
● Hypersensitivity to drug or its components
● Concurrent use of astemizole, cisapride, ergot alkaloids, halofantrine, pimozide, quinidine, or terfenadine

Precautions
Use cautiously in:
● hypersensitivity to other azoles
● potentially proarrhythmic conditions, severe underlying medical conditions (such as hematologic cancers), preexisting hepatic impairment
● pregnant or breastfeeding patients
● children younger than age 13 (safety and efficacy not established).

Administration
● Before starting drug, make rigorous attempts to correct potassium, magnesium, and calcium imbalances.
● Advise patient to take each dose with full meal or liquid nutritional supplement to enhance drug absorption.
   ➥ Don’t give concurrently with astemizole, cisapride, ergot alkaloids, halofantrine, pimozide, quinidine, or terfenadine.

Adverse reactions
CNS: seizure, insomnia, anxiety, headache, fatigue, dizziness, weakness
CV: prolonged QT interval, hypertension, hypotension, tachycardia
EENT: blurred vision, epistaxis, pharyngitis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, mucositis, dry mouth, oral candidiasis, anorexia
GU: vaginal hemorrhage
Hematologic: anemia, neutropenia, febrile neutropenia, thrombocytopenia
Hepatic: cholestasis, hepatic damage, hepatic failure
Metabolic: adrenal insufficiency (rare), dehydration
Musculoskeletal: arthralgia, back pain
Respiratory: cough, dyspnea, upper respiratory tract infection, pneumonia
Skin: rash, pruritus, petechiae
Other: unusual taste, weight loss, fever, bacteremia, herpes simplex, edema, leg
edema, rigors, cytomegalovirus infection

**Interactions**

**Drug-drug.** Astemizole, cisapride, halofantrine, pimozide, quinidine, terfenadine: elevated blood levels of these drugs, leading to prolonged QT interval and increased risk of life-threatening arrhythmias (including torsades de pointes)

Benzodiazepines metabolized through CYP3A4 (such as midazolam), phenytoin, rifabutin: increased blood levels of these drugs

Calcium channel blockers metabolized through CYP3A4 (such as amlodipine, diltiazem, felodipine): increased blood levels of these drugs, causing increased toxicity risk

Cimetidine, phenytoin, rifabutin: decreased posaconazole blood level

Cyclosporine, sirolimus, tacrolimus: elevated blood levels of these drugs, causing increased risk of nephrotoxicity and other serious adverse reactions

Ergot derivatives (dihydroergotamine, ergotamine): increased blood levels of these drugs, causing increased ergotism risk

HMG-CoA reductase inhibitors metabolized through CYP3A4 (such as atorvastatin, fluvastatin, lovastatin): increased blood levels of these drugs, causing increased risk of rhabdomyolysis

Vinca alkaloids (such as vinblastine, vincristine): increased vinca alkaloid blood levels, causing increased neurotoxicity risk

**Drug-diagnostic tests.** Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, gamma-glutamyltransferase, serum creatinine: increased levels

**Drug-food.** Nonfat, high-fat, or liquid nutritional supplements: approximately three- to fourfold increase in drug mean $C_{\text{max}}$ and area under the curve values

**Patient monitoring**

- Monitor serum potassium, magnesium, and calcium levels before and frequently during therapy.
- Obtain liver function tests and bilirubin level at start of therapy and periodically throughout. If liver function tests become abnormal during therapy, stay alert for signs and symptoms of more severe hepatic injury; consider withdrawing drug if these occur.
- Monitor blood drug levels frequently if patient is receiving concurrent cyclosporine, sirolimus, or tacrolimus. Consider reducing dosage as appropriate.

Monitor ECG if patient has potentially proarrhythmic condition or is receiving concurrent drugs that may prolong QT interval and are metabolized through CYP3A4. Stay alert for prolonged QT interval.

- Watch for breakthrough fungal infections in patients with severe diarrhea, vomiting, or severe renal impairment and in those receiving drugs that may decrease blood drug level or who can’t eat a full meal or tolerate oral nutritional supplements.

**Patient teaching**

- Instruct patient to take each dose with full meal or liquid nutritional supplement.
- Advise patient to inform prescriber of all drugs he is taking because serious interactions may occur.

Urge patient to contact prescriber immediately if he develops signs or symptoms of liver impairment, such as unusual tiredness, weakness, nausea, itching, yellowing of eyes or skin, upper right abdominal tenderness, or flu-like symptoms.

Tell patient to contact prescriber immediately if he develops irregular heartbeats or other cardiac symptoms.

Advertise patient to notify prescriber of severe diarrhea or vomiting, because

Reactions in **bold** are life-threatening.  

Clinical alert
these conditions may alter blood drug level.
- Stress importance of keeping appointments for follow-up laboratory tests.
- Caution patient to avoid driving and other hazardous activities because drug may alter vision.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

**potassium acetate**

**Pharmacologic class:** Mineral, electrolyte  
**Therapeutic class:** Electrolyte replacement, nutritional supplement  
**Pregnancy risk category C**

**Action**
Maintains acid-base balance, isotonicity, and electrophysiologic balance throughout body tissues; crucial to nerve impulse transmission and contraction of cardiac, skeletal, and smooth muscle. Also essential for normal renal function and carbohydrate metabolism.

**Availability**
*Concentrate for injection:* 2 mEq/ml in 20-, 50-, and 100-ml vials; 4 mEq/ml in 50-ml vials

**Indications and dosages**
- **To prevent or treat potassium depletion; diabetic acidosis; metabolic alkalosis; arrhythmias; periodic paralysis attacks; hyperadrenocorticism; primary aldosteronism; healing phase of burns or scalds; overmedication with adrenocorticoids, testosterone, or corticotropin**

**Adults:** Dosage highly individualized. For potassium level above 2.5 mEq/L, give 40 mEq/L as additive to I.V. infusion at a maximum rate of 10 mEq/hour; maximum daily dosage is 200 mEq. For potassium level less than 2 mEq/L, give 80 mEq/L as additive to I.V. infusion at a maximum rate of 40 mEq/hour (with cardiac monitoring); maximum daily dosage is 400 mEq.  
**Children:** Dosage highly individualized; up to 3 mEq/kg or 40 mEq/m²/day as additive to I.V. infusion.

**Contraindications**
- Acute dehydration  
- Heat cramps  
- Hyperkalemia  
- Hyperkalemic familial periodic paralysis  
- Severe renal impairment  
- Severe hemolytic reactions  
- Untreated Addison’s disease  
- Severe tissue trauma  
- Concurrent use of potassium-sparing diuretics, angiotensin-converting enzyme (ACE) inhibitors, or salt substitutes containing potassium

**Precautions**
Use cautiously in:
- cardiac disease, renal impairment, diabetes mellitus, hypomagnesemia  
- pregnant or breastfeeding patients  
- children (safety and efficacy not established).

**Administration**
- Make sure patient is well hydrated and urinating before starting therapy.  
- Give only as additive to I.V. infusion. Never give by I.V. push or I.M. route, and never give undiluted. Use peripheral line with maximum rate of 40 mEq/hour (with cardiac monitoring).  
- To ensure that potassium is well mixed in compatible solution, don’t add potassium to I.V. bottle in hanging position.
Dilute in compatible I.V. solution. Administer slowly to reduce risk of fatal hyperkalemia.
- Know that maximum infusion rate without cardiac monitoring is 20 mEq/hour. Infusion rates above 20 mEq/hour necessitate cardiac monitoring.
- If patient complains of burning with I.V. administration, decrease flow rate.
- Be aware that potassium preparations are not interchangeable.
- Know that dosages are expressed in mEq of potassium and that potassium acetate contains 10.2 mEq/g.

### Route Onset Peak Duration
<p>| | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>i.V.</td>
<td>Rapid</td>
<td>End of infusion</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

### Adverse reactions

**CNS:** confusion, unusual fatigue, restlessness, asthenia, flaccid paralysis, parasthesia, absent reflexes  
**CV:** ECG changes, hypotension, arrhythmias, heart block, cardiac arrest  
**GI:** nausea, vomiting, diarrhea, abdominal discomfort, flatulence  
**Metabolic:** hyperkalemia  
**Musculoskeletal:** weakness and heaviness of legs  
**Respiratory:** respiratory paralysis  
**Other:** irritation at I.V. site

### Interactions

**Drug-drug.** ACE inhibitors, potassium-sparing diuretics, other potassium-containing preparations: increased risk of hyperkalemia  
**Drug-diagnostic tests.** Potassium: increased level  
**Drug-food.** Salt substitutes containing potassium: increased risk of hyperkalemia  
**Drug-herbs.** Dandelion: increased risk of hyperkalemia  
Licorice: decreased response to potassium

### Patient monitoring

- Monitor renal function, fluid intake and output, and potassium, creatinine, and blood urea nitrogen levels.  
- Know that potassium is contraindicated in severe renal impairment and must be used with extreme caution (if at all) in patients with any degree of renal impairment, because of risk of life-threatening hyperkalemia.  
- Assess vital signs and ECG. Watch for arrhythmias.  
- Evaluate patient’s ECG. Watch for arrhythmias.  
- Stay alert for neurologic status.  
- Monitor I.V. site for irritation.

### Patient teaching

- Instruct patient to report unusual pain, redness, swelling, or other reactions at infusion site.  
- Advise patient to report nausea, vomiting, diarrhea, abdominal discomfort, flatulence.  
- Unusual tiredness or weakness, or heavy feeling in legs.  
- Instruct patient to avoid salt substitutes.  
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

### Pharmacologic class

**Potassium bicarbonate**  
K-Effervescent, K-Vescent  
**Pharmacologic class:** Mineral, electrolyte  
**Therapeutic class:** Electrolyte replacement, nutritional supplement

### Pregnancy risk category

**C**

### Action

Maintains acid-base balance, isotonicity, and electrophysiologic balance throughout body tissues; crucial to...
nerve impulse transmission and contraction of cardiac, skeletal, and smooth muscle. Also essential for normal renal function and carbohydrate metabolism.

**Availability**

*Tablets for effervescent oral solution: 25 mEq*

**Indications and dosages**

➢ To prevent potassium depletion

**Adults:** Dosage highly individualized. Usual dosage is 25 mEq/day P.O. in divided doses.

➢ To treat potassium depletion

**Adults:** 50 to 100 mEq/day P.O. in divided doses, not to exceed a maximum daily dosage of 150 mEq

**Contraindications**

- Hypersensitivity to tartrazine or alcohol (with some products)
- Acute dehydration
- Heat cramps
- Hyperkalemia
- Hyperkalemic familial periodic paralysis
- Severe renal impairment
- Severe hemolytic reaction
- Severe tissue trauma
- Untreated Addison’s disease
- Concurrent use of potassium-sparing diuretics, angiotensin-converting enzyme (ACE) inhibitors, or salt substitutes containing potassium

**Precautions**

Use cautiously in:

- cardiac disease, renal impairment, diabetes mellitus, hypomagnesemia
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

**Administration**

- Ensure that patient is adequately hydrated and urinating before starting therapy.
- Give with meals and a full glass of water or juice to minimize GI upset.
- Be aware that potassium preparations aren’t interchangeable.
- Know that dosages are expressed in mEq of potassium and that potassium bicarbonate contains 10 mEq potassium/g.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1-2 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: confusion, unusual fatigue, restlessness, asthenia, flaccid paralysis, paresthesia
CV: ECG changes, hypotension, heart block, arrhythmias, cardiac arrest
GI: nausea, vomiting, diarrhea, abdominal discomfort, flatulence
Metabolic: hyperkalemia
Musculoskeletal: weakness and heaviness of legs

**Interactions**

Drug-drug. *ACE inhibitors, potassium-sparing diuretics, other potassium-containing preparations: increased risk of hyperkalemia*

Drug-diagnostics tests. *Potassium: increased level*

Drug-food. *Salt substitutes containing potassium: increased risk of hyperkalemia*

Drug-herbs. *Dandelion: increased risk of hyperkalemia, Licorice: decreased response to potassium*

**Patient monitoring**

- Monitor renal function, fluid intake and output, and potassium, creatinine, and blood urea nitrogen levels.
- Be aware that potassium is contraindicated in patients with severe renal impairment and must be used with extreme caution (if at all) in patients with any degree of renal impairment, because of risk of life-threatening hyperkalemia.
- Assess vital signs. Check ECG for arrhythmias.

» Canada  🇬🇧 UK  🆕️ Hazardous drug  🟢 High alert drug
• Monitor neurologic status. Stay alert for neurologic complications.

Patient teaching
• Instruct patient to dissolve tablets thoroughly in 4 to 8 oz of cold water or juice and to sip solution over 5 to 10 minutes with a meal.
• Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
• Tell patient to report nausea, vomiting, confusion, numbness and tingling, unusual tiredness or weakness, or a heavy feeling in legs.
• Instruct patient to avoid salt substitutes.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

potassium chloride

Pharmacologic class: Mineral, electrolyte
Therapeutic class: Electrolyte replacement, nutritional supplement
Pregnancy risk category C

Action
Maintains acid-base balance, isotonicity, and electrophysiologic balance throughout body tissues; crucial to nerve impulse transmission and contraction of cardiac, skeletal, and smooth muscle. Also essential for normal renal function and carbohydrate metabolism.

Availability
Capsules (extended-release): 8 mEq, 10 mEq
Powder for oral solution: 20 mEq, 25 mEq
Parenteral injection (concentrate): 2 mEq/ml
Parenteral solution: 0.1 mEq/ml, 0.2 mEq/ml, 0.3 mEq/ml, 0.4 mEq/ml
Potassium chloride in 5% dextrose injection: 10 mEq/L, 20 mEq/L, 30 mEq/L, 40 mEq/L
Potassium chloride in 0.9% sodium chloride injection: 20 mEq/L, 40 mEq/L
Potassium chloride in dextrose and lactated Ringer’s injection: various strengths

Potassium chloride in dextrose and sodium chloride injection: various strengths
Solution (oral): 6.7 mEq, 10 mEq, 13.3 mEq, 15 mEq, 20 mEq, 30 mEq, 40 mEq
Tablets: 500 mg, 595 mg
Tablets (effervescent): 25 mEq, 50 mEq
Tablets (extended-release): 8 mEq, 10 mEq, 20 mEq
Tablets (extended-release crystals): 10 mEq, 20 mEq
Tablets (extended-release, film coated): 8 mEq, 10 mEq
Tablets (film-coated): 2.5 mEq, 10 mEq

Indications and dosages
➢ To prevent potassium depletion
Adults: Dosage highly individualized. Usual single dosage is 20 mEq/day P.O. in divided doses.
➢ Potassium depletion; diabetic acidosis; metabolic alkalosis; arrhythmias; periodic paralysis attacks; hyperadrenocorticism; primary aldosteronism; healing phase of scalds or burns; overmedication with adrenocorticoids, testosterone, or corticotropin
Adults: Dosage highly individualized. 40 to 100 mEq/day P.O. in divided doses, not to exceed 20 mEq in a single dose. For serum potassium level above 2.5 mEq/L, 40 mEq/L as additive to I.V. infusion at a maximum rate of 10 mEq/hour; maximum daily dosage is
200 mEq. For serum potassium level less than 2 mEq/L, 80 mEq/L as additive to I.V. infusion at a maximum rate of 40 mEq/hour (with cardiac monitoring); maximum daily dosage is 400 mEq.

**Children:** Dosage highly individualized; give up to 3 mEq/kg or 40 mEq/m²/day as additive to I.V. infusion.

**Contraindications**
- Hypersensitivity to tartrazine or alcohol (with some products)
- Acute dehydration
- Heat cramps
- Hyperkalemia
- Hyperkalemic familial periodic paralysis
- Severe renal impairment
- Severe hemolytic reactions
- Severe tissue trauma
- Untreated Addison’s disease
- Esophageal compression caused by enlarged left atrium (with wax matrix forms)
- Concurrent use of potassium-sparing diuretics, angiotensin-enzyme converting (ACE) inhibitors, or salt substitutes containing potassium

**Precautions**
Use cautiously in:
- cardiac disease, renal impairment, diabetes mellitus, hypomagnesemia
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

**Administration**
- Know that I.V. potassium chloride is a high-alert drug.
- Give I.V. form as additive by infusion only. Never give undiluted or by I.V. push or I.M. route. Use peripheral line and infuse at a maximum rate of 40 mEq/hour (with cardiac monitoring).
- Dilute in compatible I.V. solution per manufacturer’s instructions.

Administer slowly to reduce risk of fatal hyperkalemia.
- To ensure that potassium is well mixed in compatible solution, don’t add potassium to I.V. bottle in hanging position.
- Be aware that maximum infusion rate without cardiac monitoring is 20 mEq/hour. Rates above 20 mEq/hour require cardiac monitoring.
- Make sure patient is well-hydrated and urinating before starting therapy.
- If patient complains of burning with I.V. administration, decrease flow rate.
- Give P.O. form with meals and a full glass of water or juice, to minimize GI upset.
- Ensure that patient swallows wax-matrix tablets completely, to avoid serious esophageal problems.
- Don’t give wax matrix tablets to patients who have swallowing problems or possible esophageal compression.
- Be aware that potassium preparations aren’t interchangeable.
- Know that dosages are expressed in mEq of potassium and that potassium chloride contains 13.4 mEq potassium/g.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1-2 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>End of infusion</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** confusion, unusual fatigue, restlessness, asthenia, flaccid paralysis, paresthesia, absent reflexes

**CV:** ECG changes, hypotension, arrhythmias, heart block, cardiac arrest

**GI:** nausea, vomiting, diarrhea, abdominal discomfort, flatulence

**Metabolic:** hyperkalemia

**Musculoskeletal:** weakness and heaviness of legs

**Respiratory:** respiratory paralysis

**Other:** irritation at I.V. site
**Interactions**

**Drug-drug.** *ACE inhibitors, potassium-sparing diuretics, other potassium-containing preparations:* increased risk of hyperkalemia

**Drug-diagnostic tests.** *Potassium:* increased level

**Drug-food.** *Salt substitutes containing potassium:* increased risk of hyperkalemia

**Drug-herbs.** *Dandelion:* increased risk of hyperkalemia

*Licorice:* decreased response to potassium

---

**Patient monitoring**

- Monitor renal function, fluid intake and output, and potassium, creatinine, and blood urea nitrogen levels.
- Assess vital signs and ECG. Stay alert for arrhythmias.
- Monitor neurologic status. Watch for neurologic complications.
- Monitor I.V. site for irritation.
- Know that potassium is contraindicated in patients with severe renal impairment and must be used with extreme caution (if at all) in patients with any degree of renal impairment, because of risk of life-threatening hyperkalemia.

---

**Patient teaching**

- Instruct patient to mix and dissolve powder completely in 3 to 8 oz of water or juice.
- Tell patient to swallow extended-release capsules whole without crushing or chewing them.
- Instruct patient to take oral form with or just after a meal, with a glass of water or fruit juice.
- Tell patient to sip diluted liquid form over 5 to 10 minutes.
- Advise patient to report nausea, vomiting, confusion, numbness and tingling, unusual fatigue or weakness, or a heavy feeling in legs.
- Tell patient to minimize GI upset by eating frequent, small servings of food and drinking plenty of fluids.

- Inform patient that although wax matrix form may appear in stool, drug has already been absorbed.
- Advise patient not to use salt substitutes.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

---

**potassium gluconate**

**PMS-Potassium Gluconate**

**Pharmacologic class:** Mineral, electrolyte

**Therapeutic class:** Electrolyte replacement, nutritional supplement

**Pregnancy risk category C**

---

**Action**

Maintains acid-base balance, isotonicity, and electrophysiologic balance throughout body tissues; crucial to nerve impulse transmission and contraction of cardiac, skeletal, and smooth muscle. Also essential for normal renal function and carbohydrate metabolism.

---

**Availability**

*Elixir:* 20 mEq/15 ml

*Tablets:* 2 mEq, 5 mEq

---

**Indications and dosages**

➢ To prevent potassium depletion

**Adults:** Dosage highly individualized. Usual daily dosage is 20 mEq P.O. in divided doses.

➢ To treat potassium depletion

**Adults:** 40 to 100 mEq/day P.O. in divided doses, not to exceed 20 mEq in a single dose

---

**Contraindications**

- Hypersensitivity to tartrazine or alcohol (with some products)

---

Reactions in **bold** are life-threatening.
- Acute dehydration
- Heat cramps
- Hyperkalemia
- Hyperkalemic familial periodic paralysis
- Severe renal impairment
- Severe hemolytic reactions
- Severe tissue trauma
- Untreated Addison’s disease
- Concurrent use of potassium-sparing diuretics, angiotensin-converting enzyme (ACE) inhibitors, or salt substitutes containing potassium

Precautions
Use cautiously in:
- cardiac disease, renal impairment, diabetes mellitus, hypomagnesemia
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

Administration
- Make sure patient is adequately hydrated and urinating before starting therapy.
- Give with food or meals and a full glass of water or juice to minimize GI upset.
- Be aware that potassium preparations are not interchangeable.
- Know that dosages are expressed in mEq of potassium and that potassium gluconate contains 4.3 mEq/g.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1-2 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: confusion, unusual tiredness, restlessness, asthenia, flaccid paralysis, paresthesia
CV: ECG changes, hypotension, arrhythmias, heart block, cardiac arrest
GI: nausea, vomiting, diarrhea, abdominal discomfort, flatulence
Metabolic: hyperkalemia
Musculoskeletal: weakness and heaviness of legs

Interactions
Drug-drug. ACE inhibitors, potassium-sparing diuretics, other potassium preparations: increased risk of hyperkalemia

Drug-diagnostic tests. Potassium: increased level

Drug-food. Salt substitutes containing potassium: increased risk of hyperkalemia

Drug-herbs. Dandelion: increased risk of hyperkalemia
Licorice: decreased response to potassium

Patient monitoring
- Monitor renal function, fluid intake and output, and potassium, creatinine, and blood urea nitrogen levels.
- Know that potassium is contraindicated in patients with severe renal impairment and must be used with extreme caution (if at all) in patients with any degree of renal impairment, because of risk of life-threatening hyperkalemia.
- Monitor vital signs and check ECG for arrhythmias.
- Monitor patient’s neurologic status for signs or symptoms of complications.

Patient teaching
- Tell patient to take oral form with or just after meals, with a glass of water or fruit juice.
- Instruct patient to dilute liquid form in water or juice and to sip it over 5 to 10 minutes.
- Advise patient to report nausea, vomiting, confusion, numbness and tingling, unusual tiredness or weakness, or a heavy feeling in legs.
- Tell patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
- Advise patient not to use salt substitutes.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.
**Potassium Iodide**

*Iostat, Pima, SSKI, Thyrosafe, ThyroShield*

**Pharmacologic class:** Iodine, iodide

**Therapeutic class:** Antithyroid agent, expectorant

**Pregnancy risk category D**

**Action**

Rapidly inhibits thyroid hormone release, reduces thyroid vascularity, and decreases thyroid uptake of radioactive iodine after radiation emergencies or administration of radioactive iodine isotopes. As expectorant, thought to increase respiratory tract secretions, thereby decreasing mucus viscosity.

**Availability**

*Satrated solution (SSKI):* 1 g potassium iodide/ml in 30- and 240-ml bottles

*Solution (strong iodine solution, Lugol’s solution):* 5% iodine and 10% potassium iodide in 120-ml bottle

*Syrup:* 325 mg potassium iodide/5 ml

*Tablets:* 130 mg (available only through state and federal agencies)

**Indications and dosages**

▸ Preparation for thyroidectomy

**Adults and children:** One to five drops SSKI P.O. t.i.d. or three to six drops strong iodine solution P.O. t.i.d. for 10 days before surgery

▸ Thyrotoxic crisis

**Adults and children:** 500 mg P.O. (approximately 10 drops SSKI) q 4 hours or 1 ml P.O. (strong iodine solution) t.i.d., at least 1 hour after initial propylthiouracil or methimazole dose

▸ Radiation protectant in emergencies

**Adults older than age 40 with predicted thyroid exposure of 500 centigrays (cGy), adults ages 18 to 40 with predicted exposure of 10 cGy, pregnant or breastfeeding women with predicted exposure of 5 cGy, and adolescents weighing 70 kg (154 lb) or more with predicted exposure of 5 cGy:** 130 mg P.O. (tablet)

**Children ages 3 to 18** (except adolescents weighing 70 kg [154 lb] or more) with predicted thyroid exposure of 5 cGy: 65 mg P.O. (tablet)

**Children ages 1 month to 3 years with predicted thyroid exposure of 5 cGy:** 32 mg P.O. (tablet)

**Infants from birth to age 1 month with predicted thyroid exposure of 5 cGy:** 16 mg P.O. (tablet)

▸ Expectorant

**Adults:** 300 to 650 mg P.O. (SSKI) three or four times daily, given with at least 6 oz of fluid

**Children:** 60 to 250 mg P.O. (SSKI) q.i.d., given with at least 6 oz of fluid

**Off-label uses**

• Lymphocutaneous sporotrichosis

**Contraindications**

• Hypersensitivity to iodine, shellfish, or bisulfites (with some products)

• Hypothyroidism

• Renal impairment

• Acute bronchitis

• Addison’s disease

• Acute dehydration

• Heat cramps

• Hyperkalemia

• Tuberculosis

• Iodism

• Concurrent use of potassium-containing drugs, potassium-sparing diuretics, or salt substitutes containing potassium

**Precautions**

Use cautiously in:

• Cystic fibrosis, adolescent acne, hypocomplementemic vasculitis, goiter, autoimmune thyroid disease

Reactions in bold are life-threatening.
• pregnant or breastfeeding patients
• children.

Administration
• Dilute saturated solution with at least 6 oz of water.
• Don’t give concurrently with other potassium-containing drugs or potassium-sparing diuretics, because of increased risk of hyperkalemia, arrhythmias, and cardiac arrest.
• Know that U.S. government stockpiles potassium iodide 130-mg tablets for emergency use.
• When giving to very young children or patients who can’t swallow tablets, crush tablet, dissolve in 20 ml of water, and add 20 ml of selected beverage (such as orange juice).
• Be aware that potassium iodide use as expectorant has been largely replaced by safer and more effective drugs.

Route Onset Peak Duration
P.O. 24 hr 10-15 days Variable

Adverse reactions
CNS: confusion; unusual fatigue; paresthesia, pain, or weakness in hands or feet
Metabolic: thyroid hyperplasia, goiter (with prolonged use), thyroid adenoma, severe hypothyroidism, hyperkalemia, iodism (with large doses or prolonged use)
Musculoskeletal: weakness and heaviness of legs
Other: tooth discoloration (with strong iodide solution), hypersensitivity reactions including angioedema, fever, cutaneous and mucosal hemorrhage, serum sickness–like reaction

Interactions
Drug-drug. Lithium, other thyroid drugs: additive hypothyroidism
Potassium-sparing diuretics, other potassium preparations: increased risk of hyperkalemia, arrhythmias, and cardiac arrest
Drug-diagnostic tests. Radionuclide thyroid imaging: altered test results Thyroid uptake of $^{131}$I, $^{123}$I, sodium pertechnetate Tc $^{99m}$: decreased uptake
Drug-food. Salt substitutes containing potassium: increased risk of hyperkalemia

Patient monitoring
• In long-term use, check for signs and symptoms of iodism (metallic taste, sore teeth and gums, sore throat, burning of mouth and throat, cold-like symptoms, severe headache, productive cough, GI irritation, diarrhea, angioedema, rash, fever, and cutaneous or mucosal hemorrhage). Discontinue drug immediately if these occur.
• Monitor potassium level; watch for signs and symptoms of potassium toxicity.
• Assess ECG, renal function, fluid intake and output, and creatinine and blood urea nitrogen levels.
• Monitor thyroid function tests. Watch for evidence of hypothyroidism or hyperthyroidism.

Patient teaching
• Tell patient to dilute in at least 6 oz of water or juice and to take with meals.
• Advise patient to sip strong iodine solution through a straw to help prevent tooth discoloration.
• Teach patient to recognize and immediately report signs and symptoms of iodism and potassium toxicity.
• Instruct patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
• Inform patient that many salt substitutes are high in potassium. Advise him not to use these without prescriber’s approval.
• Caution patient not to take drug if she is pregnant or breastfeeding (except in emergency use).
As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

**pramipexole dihydrochloride**
Apo-Pramipexole®, Mirapex, Mirapexin®, Novo-Pramipexole®, PMS-Pramipexole®

*Pharmacologic class:* Non-ergot dopamine agonist  
*Therapeutic class:* Antidyskinetic  
*Pregnancy risk category C*

**Action**
Unknown. May directly stimulate postsynaptic dopamine receptors in corpus striatum (unlike levodopa, which may increase brain’s dopamine concentration).

**Availability**
*Tablets:* 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg

**Indications and dosages**

- Idiopathic Parkinson’s disease  
  **Adults:** Initially, 0.125 mg P.O. t.i.d.; may increase by 0.125 mg q 5 to 7 days over 6 to 7 weeks. Maintenance dosage ranges from 1.5 to 4.5 mg/day in three divided doses.

- Moderate to severe primary restless leg syndrome  
  **Adults:** Initially, 0.125 mg P.O. once daily 2 to 3 hours before bedtime. For patients requiring additional symptomatic relief, increase dosage as needed every 4 to 7 days, up to dosage of 0.5 mg once daily.

**Dosage adjustment**
- Renal impairment

**Contraindications**
- Hypersensitivity to drug or its components

**Precautions**
- Use cautiously in:  
  - renal impairment  
  - elderly patients  
  - pregnant or breastfeeding patients  
  - children (safety not established).

**Administration**
- Don’t give at same time as other CNS depressants.  
- Don’t stop therapy abruptly. Taper dosage over 1 week.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2 hr</td>
<td>8 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- **CNS:** headache, dizziness, drowsiness, hallucinations, asthenia, confusion, dyskinesia, insomnia, hypertonia, unsteadiness, sleep attacks, abnormal dreams, amnesia  
- **CV:** orthostatic hypotension  
- **GI:** nausea, constipation, dyspepsia, dry mouth  
- **GU:** urinary frequency, erectile dysfunction  
- **Musculoskeletal:** leg cramps  
- **Respiratory:** fibrotic complications (such as retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion or thickening)  
- **Other:** accidental injury, edema

**Interactions**
- **Drug-drug.** Cimetidine: increased pramipexole blood level  
  Dopamine antagonists (such as butyrophenones, metoclopramide, phenothiazines, thioxanthenes): decreased pramipexole efficacy  
  Levodopa: increased risk of hallucinations and dyskinesia

Reactions in **bold** are life-threatening.  

---

Clinical alert
Patient monitoring
- Evaluate patient for therapeutic and adverse effects.
- Assess blood pressure; watch for orthostatic hypotension.
- Monitor neurologic status, especially for sleep attacks and extrapyramidal symptoms.
- Watch closely for pulmonary complications.

Patient teaching
- Instruct patient to take drug with food if it causes nausea. Tell him not to take at the same time as other CNS depressants.
- Advise patient to report respiratory problems, dyskinesia, hallucinations, and sleep attacks.
- Tell patient drug may cause erectile dysfunction. Encourage him to discuss this effect with prescriber.
- Inform patient and family that drug’s neurologic and motor effects increase risk of accidental injury. Teach them ways to prevent injury.
- Tell patient to move slowly when sitting up or standing, to avoid dizziness from sudden blood pressure decrease.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

pramlintide acetate
Symlin
Pharmacologic class: Synthetic amylin
Therapeutic class: Hypoglycemic
Pregnancy risk category C

FDA BOXED WARNING
- Drug is used with insulin and has been linked to increased risk of insulin-induced severe hypoglycemia, especially in patients with type 1 diabetes. When severe hypoglycemia occurs, it arises within 3 hours after injection. If it occurs while patient operates a motor vehicle or heavy machinery or performs other high-risk activities, serious injuries may occur. Careful patient selection, patient instruction, and insulin dosage adjustments are crucial to reduce risk.

Action
Mimics amylin activity to modulate gastric emptying, prevent postprandial rise in plasma glucagons, and cause feeling of satiety leading to decreased caloric intake and potential weight loss

Availability
Solution for injection: 0.6 mg/ml in 5-ml vials; 1.5-ml disposable multidose pen-injector containing 1,000 mcg/ml; 2.7-ml disposable multidose 120 pen-injector containing 1,000 mcg/ml

Indications and dosages
➣ Type 1 diabetes mellitus as adjunct treatment in patients who take insulin with meals but haven’t obtained desired glycemic control despite optimal insulin therapy
Adults: Initially, 15 mcg subcutaneous injection immediately before major meals; after 3 days, increase in 15-mcg increments to maintenance dosage of 30 or 60 mcg as tolerated. Decrease preprandial rapid- or short-acting insulin dosages (including fixed-mix insulins) by 50%.
➣ Type 2 diabetes mellitus as adjunct treatment in patients who take insulin with meals but haven’t obtained desired glycemic control despite optimal insulin therapy, with or without concurrent sulfonylurea, metformin, or both
Adults: Initially, 60 mcg subcutaneous injection immediately before major meals; after 3 to 7 days, increase to
120 mcg as tolerated. Decrease preprandial rapid- or short-acting insulin dosages (including fixed-mix insulins) by 50%.

Contraindications
- Hypersensitivity to drug or its components
- Confirmed gastroparesis
- Hypoglycemia unawareness

Precautions
Use cautiously in:
- patients with poor compliance to insulin therapy or hemoglobin A1c levels above 9%
- patients with recurrent or severe hypoglycemia who’ve required treatment during past 6 months
- concurrent insulin therapy for type 1 diabetes
- concurrent use of drugs that stimulate GI motility
- elderly patients
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

Administration
- Administer immediately before major meals (at least 250 kcal or 30 g carbohydrates).
- Give pramlintide and insulin as separate injections.
- Inject pramlintide and insulin more than 2” apart.

Route Onset Peak Duration
Subcut. Unknown 19-21 min Unknown

Adverse reactions
CNS: headache, dizziness, fatigue
EENT: pharyngitis
GI: nausea, vomiting, abdominal pain, anorexia
Metabolic: severe hypoglycemia
Musculoskeletal: arthralgia
Respiratory: cough
Other: allergic reaction

Reactions in bold are life-threatening.

Interactions
Drug-drug. Angiotensin-converting enzyme inhibitors, disopyramide, fibrac acid derivatives, fluoxetine, monoamine oxidase inhibitors, oral hypoglycemics, pentoxifylline, propoxyphene, salicylates, sulfonamide antibiotics: increased hypoglycemic effect, increased risk of hypoglycemia
Beta-adrenergic blockers, clonidine, guanethidine, reserpine: blunting of early hypoglycemia symptoms
Drugs that delay gastric emptying (such as atropine) or slow food absorption (such as acarbose): exacerbated delay in gastric emptying, slow food absorption
Insulin: severe hypoglycemia (may occur within 3 hours of insulin administration)
Oral drugs for which rapid effect is desired (such as analgesics): delayed absorption of these drugs

Patient monitoring
- Monitor premeal and postmeal blood glucose levels closely; watch for hypoglycemia.

Patient teaching
- Instruct patient to take drug immediately before major meals.
- Teach patient how to self-administer injection; describe proper storage, handling, and disposal of drug and supplies.
- Instruct patient to inject pramlintide and insulin separately, more than 2” apart. Caution patient not to mix them together.
- Teach patient to recognize and immediately report hypoglycemia symptoms; tell him these may occur within 3 hours after pramlintide injection.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.
pravastatin sodium

Apo-Pravastatin®, CO Pravastatin®, Dom-Pravastatin®, Gen-Pravastatin®, Lipostat®, Novo-Pravastatin®, Nu-Pravastatin®, PHL-Pravastatin®, PMS-Pravastatin®, Pravachol, Ran-Pravastatin®, Ratio-Pravastatin®, Riva-Pravastatin®, Sandoz Pravastatin®

Pharmacologic class: HMG-CoA reductase inhibitor

Therapeutic class: Antilipemic

Pregnancy risk category X

Action
Inhibits HMG-CoA reductase, an enzyme that catalyzes cholesterol synthesis pathway. This action decreases cholesterol, triglyceride, apolipoprotein B, and low-density lipoprotein (LDL) levels and increases high-density lipoprotein levels.

Availability
Tablets: 10 mg, 20 mg, 40 mg, 80 mg

Indications and dosages
> Adjunct to diet to control levels of total cholesterol, LDL, triglycerides, and apolipoprotein B in primary hypercholesterolemia, mixed dyslipidemia (including Fredrickson types IIa and IIb), primary dysbetalipoproteinemia (Fredrickson type III), and hypertriglyceridemia (including Fredrickson type IV); primary and secondary prevention of cardiovascular events

Adults: 10 to 80 mg P.O. daily. Usual dosage is 40 mg/day.

Children ages 5 to 13: 20 mg daily

Contraindications
• Hypersensitivity to drug or other HMG-CoA reductase inhibitors
• Active hepatic disease or unexplained, persistent transaminase elevations
• Pregnancy, breastfeeding, females of childbearing age

Precautions
Use cautiously in:
• renal impairment; severe hypotension or hypertension; severe acute infection; severe metabolic, endocrine, or electrolyte disorders; uncontrolled seizures; visual disturbances; myopathy; major surgery; trauma; alcoholism
• history of hepatic disease
• concurrent use of gemfibrozil orazole antifungals
• children under age 18 (safety not established).

Administration
• If patient’s also receiving bile-acid resin, give pravastatin at bedtime, at least 4 hours after resin.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, malaise, fatigue, dizziness, insomnia, anxiety, depression, tremor, vertigo, memory loss, peripheral nerve palsy, paresthesia, peripheral neuropathy, asthma

EENT: impaired extraocular eye movements, cataract progression, ophthalmoplegia, dry eyes

GI: nausea, vomiting, diarrhea, constipation, abdominal or biliary pain, flatulence, dyspepsia, heartburn, anorexia, pancreatitis

GU: decreased libido, erectile dysfunction, gynecomastia

Hematologic: anemia, thrombocytopenia, leukopenia

Hepatic: jaundice, cholestatic jaundice, fatty liver changes, hepatoma, hepatic necrosis, hepatitis

Musculoskeletal: joint pain, myalgia, myositis, rhabdomyolysis

Respiratory: dyspnea

Canada UK Hazardous drug High alert drug
Skin: nodules, skin discoloration, alopecia, dry skin, pruritus, rash, urticaria, nail changes, photosensitivity

Other: altered taste, localized pain, rare hypersensitivity reactions (including polymyalgia rheumatica, arthritis, dermatomyositis, vasculitis, purpura, positive antinuclear antibody, eosinophilia, fever, chills, flushing, hemolytic anemia, epidermal necrosis, erythema multiforme, Stevens-Johnson syndrome, angioedema, lupus erythematosus–like reaction, and anaphylaxis)

Interactions

Drug-drug. Antacids, colestipol: decreased pravastatin blood level
Azole antifungals, cyclosporine, erythromycin, gemfibrozil, niacin, other HMG-CoA reductase inhibitors: increased risk of myopathy

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, creatine kinase, creatinine phosphokinase: increased levels

Drug-herbs. Chaparral, comfrey, eucalyptus, germander, jin bu huan, kava, pennyroyal, skullcap, valerian: increased risk of hepatotoxicity
Red yeast rice: increased risk of adverse drug reactions

Patient monitoring

• Watch for signs and symptoms of allergic reaction.
• Monitor vital signs and cardiovascular status.
• Evaluate liver function tests before starting therapy, 6 to 12 weeks later, and at least semiannually thereafter. Also monitor lipid levels, and watch for evidence of hepatic disorders (rare).
• Assess creatine kinase level if patient has muscle pain or is receiving other drugs associated with myopathy.
• Monitor for signs and symptoms of rhabdomyolysis (rare).

Patient teaching

• Caution patient not to take with antacids.
• Teach patient to recognize and immediately report signs and symptoms of allergic response and other adverse reactions, especially myositis.
• Tell patient drug may cause headache and musculoskeletal pain. Encourage him to discuss activity recommendations and pain management with prescriber.
• Advise patient to promptly report unusual fatigue, yellowing of skin or eyes, and unexplained muscle pain, tenderness, or weakness.
• Advise female of childbearing age to notify prescriber of suspected pregnancy. Caution her not to breastfeed during therapy.
• Tell male patient that drug may cause erectile dysfunction and abnormal ejaculation. Suggest that he discuss these issues with prescriber.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, alertness, and vision.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

Prazosin hydrochloride

Apo-Prazo®, Hypovase®, Minipress, Novo-Prazin®, Nu-Prazo®

Pharmacologic class: Alpha1-adrenergic blocker (peripherally acting)

Therapeutic class: Antihypertensive

Pregnancy risk category C

Action

Induces peripheral vasodilation by blocking postsynaptic alpha1-adrenergic
receptors, thereby lowering blood pressure. Decreases smooth muscle contractions of prostatic capsule and relaxes smooth muscles in bladder neck and prostate.

Availability
Capsules: 1 mg, 2 mg, 5 mg

Indications and dosages
➢ Hypertension
Adults: Initially, 1 mg P.O. two or three times daily for 3 days, with first dose at bedtime; increase gradually to a maintenance dosage of 6 to 15 mg/day given in two or three divided doses.

Off-label uses
• Benign prostatic hypertrophy

Contraindications
• Hypersensitivity to drug or other quinazoline alpha₁-adrenergic blockers

Precautions
Use cautiously in:
• renal insufficiency, angina pectoris, hepatic impairment
• patients receiving diuretics concurrently
• pregnant or breastfeeding patients
• children (safety not established).

Administration
• Give test dose of 1 mg at bedtime to prevent first-dose syncope.
• Don’t stop therapy suddenly. Dosage must be tapered.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>2 hr</td>
<td>2-4 hr</td>
<td>10 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, headache, asthenia, drowsiness, depression, syncope
CV: first-dose orthostatic hypotension, palpitations, angina
EENT: blurred vision, nasal congestion, epistaxis
GI: nausea, vomiting, diarrhea, abdominal cramps, dry mouth

GU: erectile dysfunction, priapism
Musculoskeletal: joint and bone pain, myalgia
Other: edema

Interactions
Drug-drug. Antihypertensives, nitrates: additive hypotension
Nonsteroidal anti-inflammatory drugs: decreased antihypertensive effect
Drug-diagnostic tests. Pheochromocytoma screening test: false-positive result
Sodium, urinary vanillylmandelic acid: increased levels
Drug-herbs. Ephedra (ma huang): acute hypertension

Patient monitoring
• After first dose, observe closely for hypotension and syncope.
• Monitor blood pressure and pulse. Watch for orthostatic hypotension.

Patient teaching
• Caution patient not to stop therapy suddenly. Dosage must be tapered.
• Tell patient drug may cause headache, muscle aches, or bone pain. Encourage him to discuss activity recommendations and pain management with prescriber.
• Inform patient that drug may cause sexual dysfunction. Advise him to discuss this issue with prescriber.
• Instruct patient to move slowly when sitting up or standing, to avoid dizziness from sudden blood pressure decrease.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.
prednisolone  
Delacortril®, Deltastab®, Precortisyl®, Prelone

prednisolone acetate  
Diopred®, Omnipred, Pred Forte Ophthalmic, Pred Mild Ophthalmic

prednisolone sodium phosphate  
Inflamase Mild Ophthalmic®, Orapred, Orapred ODT, Pediapred, Predsol®

Pharmacologic class: Corticosteroid (intermediate-acting)  
Therapeutic class: Anti-inflammatory, immunosuppressant  
Pregnancy risk category C

Action  
Exerts potent anti-inflammatory (glucocorticoid) and weak sodium-retaining (mineralocorticoid) activity. Glucocorticoid activity causes profound and varied metabolic effects.

Availability  
Oral solution: 5 mg/ml  
Suspension for injection (acetate): 25 mg/ml, 40 mg/ml, 50 mg/ml  
Suspension (ophthalmic): 0.12%, 0.125%, 1%  
Syrup: 5 mg/5 ml, 15 mg/5 ml  
Tablets: 5 mg  
Tablets (orally disintegrating, sodium phosphate): 10 mg, 15 mg, 30 mg

Indications and dosages  
> Severe inflammation; immunosuppression  
Adults: Dosage individualized based on diagnosis, severity of condition, and response. Usual dosage ranges from 5 to 60 mg P.O. (prednisolone) daily in two to four divided doses, or 4 to 60 mg I.M. (acetate) daily in divided doses, or 5 to 50 mg P.O. (sodium phosphate) daily in divided doses.  
> Acute exacerbation of multiple sclerosis  
Adults: 200 mg P.O. daily for 1 week, followed by 80 mg every other day for 1 month  
> Refractory bronchial asthma  
Children: 1 to 2 mg/kg/day (sodium phosphate) as a single dose or in divided doses; may continue for 3 to 10 days or until symptoms resolve or patient achieves peak expiratory flow rate of 80% of personal best  
> Nephrotic syndrome in children  
Children: 60 mg/m² P.O. (sodium phosphate solution) daily in three divided doses for 4 weeks, then 4 weeks of alternate-day therapy at single doses of 40 mg/m²  
> Various allergic conditions and dermatologic, endocrine, GI, hematologic, neoplastic, nervous system, ophthalmic, respiratory, and rheumatic disorders  
Adults: Variable and individualized depending on condition being treated and patient response. Initially, 10 to 60 mg (ODT) P.O. daily.  
Children: Variable and individualized depending on condition being treated. Initial dosage range is 0.14 to 2 mg/kg/day P.O. in three or four divided doses.  
> Steroid-responsive inflammatory eye conditions  
Adults: In severe cases, initially one to two drops (acetate or sodium phosphate) instilled into conjunctival sac q hour during day and q 2 hours at night. In mild or moderate inflammation or in severe cases that respond favorably, one to two drops q 3 to 12 hours.

Contraindications  
• Hypersensitivity to drug, other corticosteroids, alcohol, bisulfite, or tartrazine (with some products)

Reactions in bold are life-threatening.  
 País Clinical alert
● Systemic fungal infections
● Active untreated infections (except in selected patients with meningitis)
● Acute superficial herpes simplex, keratitis, fungal or viral eye diseases, tuberculosis of eye, or after uncomplicated removal of superficial corneal foreign body (ophthalmic use)
● Idiopathic thrombocytopenic purpura (with I.M. use)
● Live-virus vaccines (with immunosuppressive prednisolone dosages)

Precautions
Use cautiously in:
● diabetes mellitus, glaucoma, renal or hepatic disease, hypothyroidism, cirrhosis, diverticulitis, nonspecific ulcerative colitis, recent intestinal anastomoses, inflammatory bowel disease, thromboembolic disorders, seizures, myasthenia gravis, heart failure, hypertension, osteoporosis, ocular herpes simplex, immunosuppression, emotional instability
● pregnant or breastfeeding patients
● children younger than age 6 (younger than age 2 when treated for nephrotic syndrome; younger than age 1 month when treated for aggressive lymphomas and leukemias with ODT form).

Administration
Be aware that prednisolone has many different formulations that may be given by various routes: P.O., I.M., or ophthalmic. Before administering, make sure formulation can be given by prescribed route.
• Don’t break ODT tablets.
• Place ODT tablet on tongue and either swallow tablet whole or allow it to dissolve in mouth with or without water.
• Inject I.M. form deep into gluteal muscle. Rotate injection sites.
• Avoid subcutaneous injection.
In systemic therapy, don’t discontinue drug abruptly, even if inhaled steroid is added.

Know that additional corticosteroids are needed during stress or trauma.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O. (prednisolone, sod. phos.)</td>
<td>Unknown</td>
<td>1-2 hr</td>
<td>1.25-1.5 days</td>
</tr>
<tr>
<td>I.M. (acetate)</td>
<td>Slow</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>Ophth. (acetate, sod. phos.)</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, nervousness, depression, euphoria, personality changes, psychosis, vertigo, paresthesia, insomnia, restlessness, seizures, meningitis, increased intracranial pressure, hypertrophic cardiomyopathy in premature infants
CV: hypotension, hypertension, vasculitis, thrombophlebitis, thromboembolism, fat embolism, arrhythmias, heart failure, shock
EENT: cataracts, glaucoma, visual disturbances, exacerbation of ocular infection, secondary ocular infections, globe perforation at corneal or scleral thinning site, transient stinging or burning of eyes, dry eyes, corneal ulcers, mydriasis (all with ophthalmic use); posterior subcapsular cataracts (especially in children), glaucoma, nasal irritation and congestion, rebound congestion, sneezing, epistaxis, nasopharyngeal and oropharyngeal fungal infections, perforated nasal septum, anosmia, dysphonia, hoarseness, throat irritation (with long-term use)
GI: nausea, vomiting, abdominal distention, rectal bleeding, dry mouth, esophageal candidiasis, esophageal ulcer, pancreatitis, peptic ulcer
GU: amenorrhea, irregular menses
Hematologic: purpura
Metabolic: sodium and fluid retention, hypokalemia, hypocalcemia, hyperglycemia, decreased carbohydrate tolerance, growth retardation (in
children), diabetes mellitus, cushingoid effects (with long-term use), **hypothalamic-pituitary-adrenal suppression** (with systemic use longer than 5 days), **adrenal suppression** (with high-dose, long-term use)

**Musculoskeletal:** muscle weakness or atrophy, myalgia, myopathy, osteoporosis, aseptic joint necrosis, spontaneous fractures (with long-term use), osteonecrosis, tendon rupture

**Respiratory:** cough, wheezing, **bronchospasm**

**Skin:** urticaria, rash, pruritus, contact dermatitis, acne, striae, poor wound healing, thin fragile skin, bruising, hirsutism, petechiae, subcutaneous fat atrophy, urticaria, angioedema

**Other:** aggravation or masking of infections, increased or decreased appetite, weight gain (with long-term use), facial edema and erythema, edema, hypersensitivity reaction

**Interactions**

**Drug-drug.** Amphotericin B, mezlocillin, piperacillin, thiazide and loop diuretics, ticarcillin: additive hypokalemia

**Anticholinesterase drugs:** decreased anticholinesterase effect (when prednisolone is used for myasthenia gravis)

**Aspirin, other nonsteroidal anti-inflammatory drugs:** increased risk of GI discomfort and bleeding

**Cardiac glycosides:** increased risk of digitalis toxicity due to hypokalemia

**Cyclosporine:** therapeutic benefits in organ transplant recipients, but with increased risk of toxicity

**Erythromycin, indinavir, itraconazole, ketoconazole, ritonavir, saquinavir:** increased prednisolone blood level and effects

**Hormonal contraceptives:** impaired metabolism and increased effects of prednisolone

**Isoniazid:** decreased isoniazid blood level

**Live-virus vaccines:** decreased antibody response to vaccine, increased risk of adverse effects

**Oral anticoagulants:** reduced anticoagulant requirement, opposition to anticoagulant action

**Phenobarbital, phenytoin, rifampin:** decreased prednisolone efficacy

**Salicylates:** reduced salicylate blood level

**Somatrem:** inhibition of somatrem’s growth-promoting effects

**Theophylline:** altered pharmacologic effects of either drug

**Skin tests:** suppressed results

**Drug-diagnostic tests.** Calcium, potassium, thyroid 131I uptake, thyroxine, triiodothyronine: decreased levels

**Cholesterol, glucose:** increased levels

**Nitroblue tetrazolium test for bacterial infection:** false-negative result

**Skin tests:** suppressed results

**Drug-herbs.** Alfalfa: activation of quiescent systemic lupus erythematosus

**Echinacea:** increased immune-stimulating effects

**Ephedra (ma huang):** decreased drug blood level

**Ginseng:** potentiation of immunomodulating effect

**Licorice:** prolonged drug activity

**Drug-behaviors.** Alcohol use: increased risk of gastric irritation and GI ulcers

**Patient monitoring**

- Monitor weight, blood pressure, and electrolyte levels.
- Watch for cushingoid effects (moon face, central obesity, buffalo hump, hair thinning, high blood pressure, frequent infections).
- Assess patient for depression and psychosis.
- Monitor blood glucose level carefully in diabetic patient.
- Evaluate for signs and symptoms of infection, which drug may mask or exacerbate.

Reactions in **bold** are life-threatening.  

Clinical alert
Monitor for signs and symptoms of early adrenal insufficiency (fatigue, weakness, joint pain, fever, anorexia, shortness of breath, dizziness, syncope).
- Assess musculoskeletal status for joint, tendon, and muscle pain.

Patient teaching
- Tell patient to take oral dose with food or milk to reduce GI upset.
- Instruct patient to remove ODT tablet from blister just before taking.
- Instruct patient to place ODT tablet on tongue and either swallow tablet whole or allow it to dissolve in mouth with or without water. Caution patient not to cut, split, or break tablet.
- Teach patient to recognize and immediately report cushingoid effects and signs and symptoms of early adrenal insufficiency.
- Advise patient and significant other to immediately report depression or psychosis.
- Explain that drug increases risk of infection. Instruct patient to contact prescriber at first sign of infection.
- Caution patient not to suddenly stop drug (including ophthalmic forms). Instruct him to discuss any changes in therapy with prescriber.
- Tell patient to immediately report bleeding or joint, muscle, tendon, or abdominal pain.
- Inform patient that he may need higher dosage during periods of stress. Encourage him to wear or carry medical identification stating this.
- Tell patient to avoid vaccinations during therapy. Mention that others in household shouldn't receive oral polio vaccine because they could pass poliovirus to him.
- Caution patient not to take over-the-counter drugs or herbs during therapy.
- Teach patient how to use eye drops. Caution him not to touch dropper tip to eye or any other surface.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

**Prednisone**
Apo-Prednisone®, Winpred®

**Pharmacologic class:** Corticosteroid (intermediate acting)
**Therapeutic class:** Anti-inflammatory, immunosuppressant
**Pregnancy risk category C**

**Action**
Decreases inflammation by reversing increased cell capillary permeability and inhibiting migration of polymorphonuclear leukocytes. Suppresses immune system by reducing lymphatic activity.

**Availability**
- Oral solution: 5 mg/ml, 5 mg/5 ml
- Syrup: 5 mg/5 ml
- Tablets: 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, 50 mg

**Indications and dosages**
- Severe inflammation; immunosuppression
- **Adults:** Dosage individualized based on diagnosis, severity of condition, and response. Usual dosage is 5 to 60 mg P.O. daily as a single dose or in divided doses.
- Acute exacerbation of multiple sclerosis
- **Adults:** 200 mg P.O. daily for 1 week, then 80 mg every other day for 1 month
- Adjunctive therapy for *Pneumocystis jiroveci* pneumonia in AIDS patients
- **Adults:** 40 mg P.O. b.i.d. for 5 days, then 40 mg once daily for 5 days, then 20 mg once daily for 11 days
Contraindications
- Hypersensitivity to drug, other corticosteroids, alcohol, bisulfite, or tartrazine (with some products)
- Systemic fungal infections
- Live-virus vaccines (with immunosuppressant doses)
- Active untreated infections (except in selected meningitis patients)

Precautions
Use cautiously in:
- diabetes mellitus, glaucoma, renal or hepatic disease, hypothyroidism, cirrhosis, diverticulitis, nonspecific ulcerative colitis, recent intestinal anastomoses, inflammatory bowel disease, thromboembolic disorders, seizures, myasthenia gravis, heart failure, hypertension, osteoporosis, hypothyroidism, ocular herpes simplex, immune suppression, emotional instability
- pregnant or breastfeeding patients
- children under age 6.

Administration
- Give with food or milk to reduce GI upset.
- Administer once-daily dose early in morning.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1-2 hr</td>
<td>1.25-1.5 days</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, nervousness, depression, euphoria, personality changes, psychosis, vertigo, paresthesia, insomnia, restlessness, seizures, meningitis, increased intracranial pressure
CV: hypotension, hypertension, vasculitis, heart failure, thrombophlebitis, thromboembolism, fat embolism, arrhythmias, shock
EENT: posterior subcapsular cataracts (especially in children), glaucoma, nasal irritation and congestion, rebound congestion, sneezing, epistaxis, nasopharyngeal and oropharyngeal fungal infections, perforated nasal septum, anosmia, dysphonia, hoarseness, throat irritation (all with long-term use)
GI: nausea, vomiting, abdominal distention, rectal bleeding, esophageal candidiasis, dry mouth, esophageal ulcer
GU: amenorrhea, irregular menses

Hematologic: purpura

Metabolic: sodium and fluid retention, hypokalemia, hypocalcemia, hyperglycemia, decreased carbohydrate tolerance, diabetes mellitus, growth retardation (in children), cushingoid effects (with long-term use), hypothalamic-pituitary-adrenal suppression (with systemic use longer than 5 days), adrenal suppression (with high-dose, long-term use)

Musculoskeletal: muscle weakness or atrophy, myalgia, myopathy, osteoporosis, aseptic joint necrosis, spontaneous fractures (with long-term use), osteonecrosis, tendon rupture

Respiratory: cough, wheezing, bronchospasm

Skin: rash, pruritus, contact dermatitis, acne, striae, poor wound healing, hirsutism, thin fragile skin, petechiae, bruising, subcutaneous fat atrophy, urticaria, angioedema

Other: bad taste, increased or decreased appetite, weight gain (with long-term use), facial edema, aggravation or masking of infections, hypersensitivity reaction

Interactions
Drug-drug: Amphotericin B, mezlocillin, piperacillin, thiazide and loop diuretics, ticarcillin: additive hypokalemia
Aspirin, other nonsteroidal anti-inflammatory drugs: increased risk of GI discomfort and bleeding
Cardiac glycosides: increased risk of digitalis toxicity due to hypokalemia
Cyclosporine: therapeutic benefits in organ transplant recipients, but with increased risk of toxicity

Reactions in bold are life-threatening.
Erythromycin, indinavir, itraconazole, ketoconazole, ritonavir, saquinavir: increased prednisone blood level and effects

**Hormonal contraceptives:** impaired metabolism and increased effects of prednisone

**Isoniazid:** decreased isoniazid blood level

**Live-virus vaccines:** decreased antibody response to vaccine, increase risk of adverse effects

**Oral anticoagulants:** reduced anticoagulant requirements, opposition to anticoagulant action

**Phenobarbital, phenytoin, rifampin:** decreased prednisone efficacy

**Salicylates:** reduced salicylate blood level

**Somatrem:** inhibition of somatrem’s growth-promoting effects

**Theophylline:** altered pharmacologic effects of either drug

**Drug-diagnostic tests.** Calcium, potassium, thyroid $^{131}$I uptake, thyroxine, triiodothyronine: decreased levels

**Cholesterol, glucose:** increased levels

**Nitroblue tetrazolium test for bacterial infection:** false-negative result

**Drug-herbs.** *Alfalfa:* activation of quiescent systemic lupus erythematosus

**Echinacea:** increased immune-stimulating effects

**Ephedra (ma huang):** decreased drug blood level

**Ginseng:** potentiation of immunomodulating effect

**Licorice:** prolonged drug activity

**Drug-behaviors.** *Alcohol use:* increased risk of gastric irritation and GI ulcers

**Patient monitoring**

- Monitor weight, blood pressure, and electrolyte levels.
- Watch for cushingoid effects (moon face, central obesity, buffalo hump, hair thinning, high blood pressure, frequent infections).
- Check for signs and symptoms of depression and psychosis.
- Assess blood glucose level carefully in diabetic patient.
- Monitor patient for signs and symptoms of infection, which drug may mask or exacerbate.
- Assess for early indications of adrenal insufficiency (fatigue, weakness, joint pain, fever, appetite loss, shortness of breath, dizziness, syncope).
- Monitor musculoskeletal status for joint, tendon, and muscle pain.

**Patient teaching**

- Tell patient to take with food or milk to reduce GI upset.
- Teach patient to recognize and immediately report signs and symptoms of early adrenal insufficiency and cushingoid effects.
- Inform patient that drug increases his risk of infection. Instruct him to contact prescriber at first sign of infection.
- Caution patient not to stop drug suddenly. Advise him to discuss any changes in therapy with prescriber.
- Tell patient to immediately report bleeding or joint, muscle, tendon, or abdominal pain.
- Advise patient or significant other to immediately report depression or psychosis.
- Caution patient not to take herbs or over-the-counter drugs during therapy.
- Instruct patient to avoid vaccinations during therapy. Tell him that others in household shouldn’t receive oral polio vaccine because they could pass poliovirus to him.
- Tell patient he may need higher dosage during periods of stress. Encourage him to wear or carry medical identification stating this.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.
**pregabalin capsules CV**  
**Lyrica**

**Pharmacologic class:** Miscellaneous anticonvulsant  
**Therapeutic class:** Anticonvulsant  
**Pregnancy risk category C**

**Action**  
Unclear. Binds with high affinity to CNS alpha2-delta site (auxiliary subunit of voltage-gated calcium channels), possibly resulting in antinoceptive and antiseizure effects.

**Availability**  
Capsules: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, 300 mg

**Indications and dosages**  
**➣ Adjunct for partial-onset seizures in adults**  
**Adults:** Initially, 75 mg P.O. b.i.d. or 50 mg P.O. t.i.d.; may increase to maximum of 600 mg P.O. daily given in divided doses based on response and tolerance  
**➣ Neuropathic pain related to diabetic peripheral neuropathy**  
**Adults:** Initially, 50 mg P.O. t.i.d. in patients with creatinine clearance of at least 60 ml/minute; may increase to maximum of 100 mg P.O. t.i.d. within 1 week based on efficacy and tolerance  
**➣ Postherpetic neuralgia**  
**Adults:** Initially, 75 mg P.O. b.i.d., or 50 mg P.O. t.i.d. in patients with creatinine clearance of at least 60 ml/minute; may increase to maximum of 300 mg P.O. daily within 1 week based on efficacy and tolerance. Tolerant patients who don’t obtain sufficient pain relief after 2 to 4 weeks of 300 mg daily may receive up to 300 mg b.i.d. or 200 mg t.i.d. Reserve dosages above 300 mg daily for patients with ongoing pain who tolerate 300 mg daily.  
**Fibromyalgia**  
**Adults:** Initially, 75 mg P.O. b.i.d. in patients with creatinine clearance of at least 60 ml/minute; may increase to 150 mg P.O. b.i.d. within 1 week based on efficacy and tolerance. If patient doesn’t obtain sufficient benefit at 300 mg daily, dosage may be increased further to 225 mg b.i.d. Dosages above 450 mg daily aren’t recommended.

**Dosage adjustment**  
- Renal impairment

**Contraindications**  
- Hypersensitivity to drug or its components

**Precautions**  
Use cautiously in:  
- abnormal creatinine clearance  
- concurrent use of thiazolidinedione antidiabetics  
- history of angioedema episode  
- concurrent use of drugs associated with angioedema (such as angiotensin-converting enzyme inhibitors)  
- elderly patients  
- children (safety and efficacy not established).

**Administration**  
- Give with or without food.  
- To discontinue drug, withdraw gradually over at least 1 week to reduce risk of increased seizure frequency in patients with history of seizure disorders.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1.5 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**  
**CNS:** dizziness, somnolence, euphoria, balance disorder, abnormal thinking, asthenia, neuropathy, ataxia, vertigo, confusion, incoordination, abnormal gait, tremor, amnesia, nervousness, headache, speech disorder, twitching, reactions in **bold** are life-threatening.  

- Clinical alert
myoclonus, fatigue, feeling drunk, hypertonia, hypoesthesia, paresthesia, lethargy, anxiety, disorientation, depression, depersonalization, stupor

EENT: abnormal or blurred vision, diplopia, nystagmus, conjunctivitis, sinusitis, otitis media, tinnitus, pharyngolaryngeal pain

GI: vomiting, constipation, flatulence, abdominal distention, gastroenteritis, dry mouth

GU: urinary incontinence, urinary frequency, decreased libido, anorgasmia, erectile dysfunction

Metabolic: hypoglycemia, fluid retention

Musculoskeletal: back pain, myasthenia, arthralgia, muscle spasms

Respiratory: dyspnea, bronchitis

Skin: ecchymosis, pruritus

Other: increased appetite, weight gain, edema, peripheral edema, accidental injury, pain, chest pain, infection, allergic reaction, angioedema, hypersensitivity reactions including anaphylactoid reactions (rare)

Interactions

Drug-drug. Gabapentin: slight decrease in pregabalin rate of absorption

Lorazepam, oxycodone: exacerbated effects on cognitive and gross motor functioning

Drug-diagnostic tests. Serum glucose: decreased level

Drug-behaviors. Alcohol use: exacerbated effects on cognitive and gross motor functioning

Patient teaching

- Instruct patient to take drug with or without food.
- Teach patient to recognize signs and symptoms of angioedema and to discontinue drug and seek immediate medical care if these arise.
- Inform patient that drug may cause hypersensitivity reactions, such as wheezing, dyspnea, rash, hives, and blisters. Advise patient to discontinue drug and seek medical care if these reactions occur.
- Inform patient that drug may cause weight gain and edema.
- Advise patient to avoid driving and other hazardous activities until drug’s effects on vision and alertness are known.
- Caution patient to avoid alcohol while taking drug.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

Primaquine phosphate

Pharmacologic class: 8-aminoquinoline compound

Therapeutic class: Antimalarial

Pregnancy risk category C

FDA BOXED WARNING

- Familiarize yourself completely with full contents of accompanying leaflet before prescribing or administering.

Action

Unknown. Thought to disrupt parasitic mitochondria and bind to native DNA, leading to structural changes that disrupt metabolic processes and to inhibition of gametocyte and
erythrocyte forms. Destroys some gametocytes and makes others incapable of undergoing maturation division.

**Availability**

*Tablets:* 26.3 mg (15 mg base)

**Indications and dosages**

➢ To prevent or treat relapse of malaria caused by *Plasmodium vivax*

**Adults:** 15 mg base P.O. daily for 14 days

**Children:** 0.3 mg base/kg/day P.O. for 14 days, to a maximum of 15 mg base daily

**Off-label uses**

● *Pneumocystis jiroveci* pneumonia

**Contraindications**

● Hypersensitivity to drug

● Concurrent use of quinacrine, other hemolytic drugs, or myelosuppressants

● Bone marrow depression

● Systemic disease with history of or tendency to granulocytopenia (such as lupus erythematosus or rheumatoid arthritis)

**Precautions**

Use cautiously in:

● Porphyria, methemoglobinemia, methemoglobin reductase deficiency, hemolytic anemia in G6PD deficiency (particularly in Blacks, Asians, and persons of Mediterranean descent), iodine deficiency, anemia

● Pregnant patients.

**Administration**

精品 Before giving, check prescription to see if dosage is written as mg or mg base.

● Start therapy during last 2 weeks of suppression course with chloroquine or comparable drug, or after suppression course ends.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1-3 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: headache, dizziness, asthenia

CV: hypertension

EENT: blurred vision, difficulty focusing

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, epigastric distress

Hematologic: mild anemia, leukocytosis, hemolytic anemia, methemoglobinemia

Skin: pruritus, skin eruptions, pallor

**Interactions**

Drug-drug.

Aluminum and magnesium salts: decreased GI absorption of primaquine

Quinacrine: increased risk of primaquine toxicity

Drug-diagnostic tests.

Hemoglobin, red blood cells: decreased levels

White blood cells: increased or decreased count

**Patient monitoring**

精品 Monitor CBC. Watch for evidence of blood dyscrasias or hemolytic reaction (dark urine, chills, fever, chest pain, bluish skin). Stop drug and notify prescriber at once if these occur.

● Monitor blood pressure.

**Patient teaching**

● Advise patient to take with food to minimize GI upset.

精品 Teach patient to recognize and immediately report signs and symptoms of hemolytic reactions.

● Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, and alertness.

● Instruct patient to complete entire course of therapy as prescribed, even after symptoms improve.

● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Reactions in **bold** are life-threatening.

精品 Clinical alert
**primidone**

**Apo-Primidone**, Mysoline

**Pharmacologic class:** Barbiturate  
**Therapeutic class:** Anticonvulsant  
**Pregnancy risk category NR**

**Action**  
Unknown. May raise seizure threshold by decreasing neuronal firing after being converted to phenobarbital.

**Availability**  
- Suspension: 250 mg/5 ml  
- Tablets: 50 mg, 250 mg

**Indications and dosages**  
- > Grand mal, psychomotor, or focal epileptic seizures  
- **Adults and children ages 8 and older:** Initially, 100 to 125 mg P.O. at bedtime on days 1 to 3, then 100 to 125 mg P.O. b.i.d. on days 4 to 6, then 100 to 125 mg P.O. t.i.d. on days 7 to 9, followed by a maintenance dosage of 250 mg P.O. three or four times daily  
- **Children younger than age 8:** Initially, 50 mg P.O. at bedtime on days 1 to 3, then 50 mg P.O. b.i.d. on days 4 to 6, then 100 mg P.O. b.i.d. on days 7 to 9. For maintenance, 125 to 250 mg t.i.d. or 10 to 25 mg/kg/day in divided doses.

**Dosage adjustment**  
- Renal impairment

**Off-label uses**  
- Benign familial (essential) tremor

**Contraindications**  
- Hypersensitivity to drug or phenobarbital  
- Porphyria

**Precautions**  
Use cautiously in:  
- hepatic, renal, or chronic obstructive pulmonary disease  
- pregnant or breastfeeding patients  
- hyperactive children.

**Administration**  
- Don’t change brands. Bioequivalency problems have occurred.  
- Don’t stop therapy suddenly. Dosage must be tapered.  
- Know that drug may be given alone or with other anticonvulsants.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>3-4 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**  
- **CNS:** headache, dizziness, stimulation, drowsiness, sedation, confusion, hallucinations, psychosis, ataxia, vertigo, hyperirritability, emotional disturbances, paranoid symptoms, coma  
- **EENT:** diplopia, nystagmus, eyelid edema  
- **GI:** nausea, vomiting, anorexia  
- **GU:** erectile dysfunction  
- **Hematologic:** megaloblastic anemia, thrombocytopenia  
- **Skin:** flushing, rash

**Interactions**  
- **Drug-drug.** Acetazolamide, succinimide: decreased primidone blood level  
- Carbamazepine: decreased primidone blood level, increased carbamazepine blood level  
- Hydantoins, isoniazid, nicotinamide: increased primidone blood level  
- **Drug-diagnostic tests.** Hemoglobin, platelets: decreased levels  
- Liver function tests: altered results

**Patient monitoring**  
- Monitor primidone and phenobarbital blood levels.  
- Monitor CBC and blood chemistry. Watch for evidence of blood dyscrasias.

-important information in red

- Canada  
- UK  
- Hazardous drug  
- High alert drug
Assess neurologic status regularly. Stay alert for excessive drowsiness and emotional status changes.

Patient teaching
- Caution patient not to discontinue therapy suddenly. Advise him to discuss dosage changes with prescriber.
- Instruct patient to immediately report unusual bleeding, bruising, or rash.
- Tell patient drug may cause sexual dysfunction. Advise him to discuss this issue with prescriber.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Probenecid
Benuryl

Pharmacologic class: Sulfonamide-derived uricosuric
Therapeutic class: Antigout drug, tubular blocking agent
Pregnancy risk category B

Action
Promotes uric acid excretion from kidney by blocking tubular reabsorption; also inhibits tubular secretion of weak organic acids (most penicillins and cephalosporins, some beta-lactams)

Availability
Tablets: 0.5 g

Indications and dosages
- Hyperuricemia caused by gout
  - Adults and children weighing more than 50 kg (110 lb): After acute gout attack subsides, 250 mg P.O. b.i.d. for 1 week, then 500 mg b.i.d.; may increase by 500 mg/day q 4 weeks (not to exceed 3 g/day)
  - To prolong action or increase blood level of penicillins or cephalosporins
    - Adults: 500 mg P.O. q.i.d.
    - Children ages 2 to 14: Initially, 25 mg/kg or 0.7 g/m², then a maintenance dosage of 40 mg/kg/day or 1.2 g/m² in four divided doses
  - Gonorrhea
    - Adults: 1 g P.O. as a single dose given with or immediately before prescribed ampicillin dose

Dosage adjustment
- Renal impairment

Off-label uses
- Hyperuricemia secondary to thiazide therapy

Contraindications
- Hypersensitivity to drug
- Acute gout attack
- Uric acid calculi
- Blood dyscrasias
- Concurrent salicylate use
- Concurrent penicillin use in patients with renal impairment
- Children younger than age 2

Precautions
Use cautiously in:
- peptic ulcer, renal impairment
- pregnant or breastfeeding patients.

Administration
- Don’t give until acute gout attack subsides.
- Ensure high fluid intake and alkaline urine during therapy.

Adverse reactions
CNS: headache, dizziness
GI: nausea, vomiting, diarrhea, abdominal pain, anorexia

Reactions in bold are life-threatening.

Clinical alert
GU: urinary frequency, uric acid calculi, renal colic, **nephrotic syndrome**

Hematologic: anemia, **hemolytic anemia**, aplastic anemia

Hepatic: hepatitis, hepatic necrosis

Metabolic: gout exacerbation

Musculoskeletal: costovertebral pain

Skin: flushing, rash, pruritus

Other: sore gums, fever, hypersensitivity reactions including **anaphylaxis**

**Interactions**

**Drug-drug.** Acyclovir, allopurinol, barbiturates, cephalosporins, pantothenic acid, penicillins: increased blood levels of these drugs, enhanced uric acid—reducing effect of probenecid

Benzodiazepines: faster onset and prolonged effects of these drugs

Clofibrate: increased clofibrate blood level

Dapsone: accumulation of dapsone and its metabolites

Dyphylline: increased half-life and decreased clearance of dyphylline

Methotrexate, nonsteroidal anti-inflammatory drugs, rifampin, sulfonamides: increased blood levels, therapeutic effects, and toxicity of these drugs

Oral hypoglycemics: increased half-life and effects of these drugs

Penicillamine: increased pharmacologic effect of penicillamine

Salicylates: decreased probenecid or salicylate activity

Thiopental: extended anesthetic effect of thiopental

Zidovudine: increased risk of zidovudine toxicity

**Drug-diagnostic tests.** Urine glucose tests using copper reduction method (such as Clinitest): false-positive result

**Patient monitoring**

- Monitor kidney and liver function tests, CBC, and blood urea nitrogen level.
- Assess fluid intake and output to ensure good hydration and reduce urinary side effects.

- **During first 6 to 12 months of therapy,** monitor pattern and severity of acute gout attacks to assess need for additional anti-inflammatory drugs.

**Patient teaching**

- Advise patient to take with food or milk to minimize GI upset.
- Teach patient about causes of gout and proper use of drug. Stress that he must wait until acute attack subsides and then take drug regularly to prevent further attacks.
- Tell patient drug may exacerbate acute gout attacks for first 6 to 12 months, necessitating colchicine or other anti-inflammatory drug for 3 to 6 months.
- Instruct patient to drink 2 to 3 liters of fluids daily.
- Tell patient with gout to limit foods high in purine (such as anchovies, organ meats, and legumes).
- Instruct diabetic patient to test urine glucose level during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.
Prolonged use often leads to positive antinuclear antibody (ANA) test, with or without symptoms of lupus erythematosus–like syndrome. If positive ANA titer develops, weigh benefits versus risks of continued therapy.

**Action**
Decreases myocardial excitability by inhibiting conduction velocity. Also depresses myocardial contractility.

**Availability**
- **Capsules:** 250 mg, 375 mg, 500 mg
- **Injection:** 100 mg/ml, 500 mg/ml
- **Tablets:** 250 mg, 375 mg, 500 mg
- **Tablets (extended-release):** 250 mg, 500 mg, 750 mg, 1,000 mg

**Indications and dosages**
- **Life-threatening ventricular arrhythmias**
  - **Adults:** 100 mg by slow I.V. push at a rate of 50 mg/minute, repeated q 5 minutes until arrhythmia subsides, up to a maximum advisable dosage of 1 g. Alternatively, loading dose of 500 to 600 mg by I.V. infusion over 25 to 30 minutes. With either I.V. method, maximum loading dose is 1 g. When arrhythmia subsides, give continuous I.V. infusion of 2 to 6 mg/minute. Or 50 mg/kg I.M. in divided doses q 3 to 6 hours until patient can tolerate P.O. therapy.
  
  For long-term maintenance, usual dosage is 50 mg/kg (extended-release) P.O. daily in equally divided doses q 6 hours. Or 50 mg/kg/day P.O. (prompt-release) in divided doses at 3-, 4-, or 6-hour intervals.

**Dosage adjustment**
- **Renal impairment**

**Contraindications**
- Hypersensitivity to drug, tartrazine, procaine, or sulfites
- Complete heart block
- Torsades de pointes
- Lupus erythematosus

**Precautions**
Use cautiously in:
- procaine hypersensitivity, renal impairment, ischemic heart disease, heart failure, first-degree heart block, atypical ventricular tachycardia, myasthenia gravis, systemic lupus erythematosus, cytopenia
- patients receiving other antiarrhythmics concurrently
- pregnant or breastfeeding patients
- children.

**Administration**
- **Ask patient about procaine sensitivity before giving; cross-sensitivity may occur.**
- **Don’t crush tablets.**
- For I.V. use, dilute with dextrose 5% in water.
- **Administer I.V. doses with patient in supine position to avoid hypotensive effects.**
- When giving by I.V. infusion, use infusion pump to ensure that drug infuses at 50 mg/minute or less.
- **Don’t leave patient’s bedside during I.V. administration.**

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>90-120 min</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>Immediate</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.M.</td>
<td>10-30 min</td>
<td>15-60 min</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- **CNS:** headache, dizziness, confusion, psychosis, restlessness, asthenia, depression, neuropathy, **seizures**
- **CV:** hypotension, bradycardia, **atrioventricular block, ventricular fibrillation, ventricular asystole, cardiovascular collapse, cardiac arrest**
- **GI:** nausea, vomiting, diarrhea, anorexia
- **Hematologic:** hemolytic anemia, agranulocytosis, thrombocytopenia, neutropenia

Reactions in **bold** are life-threatening.
Skin: rash, urticaria, pruritus, flushing
Other: bitter taste, lupuslike syndrome, edema

Interactions
Drug-drug. Amiodarone: increased procarbamide blood level and risk of toxicity Anticholinesterase drugs: decreased anticholinesterase effects Antihypertensives: additive hypotension Beta-adrenergic blockers, cimetidine, ranitidine, trimethoprim: increased procarbamide blood level Lidocaine: additive cardiodepressant action, conduction abnormalities Neuromuscular blockers: increased skeletal muscle relaxation Other antiarrhythmics: additive or antagonistic effects, additive toxicity Trimethoprim: increased pharmacologic effect of procarbamide
Drug-behaviors. Alcohol use: altered drug blood level

Patient monitoring
● When giving I.V., stay at patient’s bedside and monitor blood pressure and ECG continuously.
● If ECG shows prolonged QT interval and QRS complexes, heart block, or worsening arrhythmia, stop drug therapy, run rhythm strip, and contact prescriber immediately.
● Assess blood levels of procarbamide and N-acetylprocarbamide (drug’s active metabolite).
● Monitor electrolyte levels, CBC, and antinuclear antibody titers. Watch for signs and symptoms of blood dyscrasias.
● Evaluate patient for signs and symptoms of lupuslike syndrome.

Patient teaching
● Tell patient not to crush tablets.
● Advise patient to immediately report cardiovascular symptoms or bleeding tendency.
● Emphasize importance of taking exactly as prescribed. Advise patient to use alarm clock to help him remember to take nighttime doses.
● Advise patient to avoid alcohol.
● Instruct patient not to take herbal remedies unless prescriber approves.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, herbs, and behaviors mentioned above.

FDA BOXED WARNING
● Give under supervision of physician experienced in use of potent antineoplastics, in setting with adequate clinical and laboratory facilities to monitor patient.

Action
Thought to inhibit DNA, RNA, and protein synthesis, resulting in death of rapidly dividing cells. Also inhibits MAO.

Availability
Capsules: 50 mg

Indications and dosages
➢ Hodgkin’s disease
Adults: 2 to 4 mg/kg P.O. daily as a single dose or in divided doses for 1 week,
then 4 to 6 mg/kg P.O. daily until white blood cell (WBC) count is less than 4,000/mm³ or platelet count is less than 100,000/mm³, or until desired response occurs. With desired response, give maintenance dosage of 1 to 2 mg/kg P.O. daily (rounded off to nearest 50 mg). As component of MOPP ( mechlorethamine, vincristine, procarbazine, prednisone) regimen for advanced Hodgkin's disease, usual dosage is 100 mg/m² P.O. daily on days 1 to 14 of 28-day cycle.

Children: Dosage highly individualized. Usual dosage is 50 mg/m² P.O. daily for first week, then 100 mg/m² P.O. daily until leukopenia, thrombocytopenia, or desired response occurs. With desired response, maintenance dosage is 50 mg/m² P.O. daily.

Off-label uses
- Brain tumor
- Lymphoma

Contraindications
- Hypersensitivity to drug
- Inadequate bone marrow reserve

Precautions
Use cautiously in:
- infection, chronic debilitating illness, headache, hepatic or renal impairment, cardiovascular disease, heart failure, diarrhea, stomatitis, pheochromocytoma, psychiatric illness, alcoholism
- patients who have undergone radiation therapy or received other chemotherapy drugs within previous month
- elderly patients
- pregnant or breastfeeding patients
- females of childbearing age.

Administration
- Weigh patient; know that dosages are based on weight. However, use caution in patients with edema or ascites.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>1 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: confusion, dizziness, drowsiness, hallucinations, headache, mania, depression, nightmares, psychosis, syncope, tremor, neuropathy, paresthesia, seizures
CV: edema, hypotension, tachycardia
EENT: nystagmus, photophobia, retinal hemorrhage
GI: nausea, vomiting, diarrhea, dysphagia, ascites, stomatitis, dry mouth, anorexia
GU: gonadal suppression, gynecomastia
Hematologic: anemia, leukopenia, thrombocytopenia
Hepatic: hepatic dysfunction
Respiratory: cough, pleural effusion
Skin: alopecia, photosensitivity, pruritus, rash

Interactions
Drug-drug. Digoxin: decreased digoxin blood level
Levodopa: flushing, hypertension
Opioids: deep coma, death
Sympathomimetics (indirect-acting): abrupt, life-threatening hypertension
Tricyclic antidepressants: severe toxicity and fatal reactions (including blood pressure fluctuations, seizures, and coma)
Drug-diagnostic tests. Hematocrit, hemoglobin, platelets, reticulocytes, WBCs: decreased levels
Drug-food. Caffeine-containing foods and beverages: hypertension, arrhythmias
Tyramine-containing foods and beverages: life-threatening hypertension
Drug-behaviors. Alcohol use: disulfiram-like reaction

Patient monitoring
- Monitor vital signs and nutritional status.
- Assess fluid intake and output. Watch for evidence of fluid overload.

Reactions in bold are life-threatening.
confusion. Discontinue drug and notify prescriber if these occur.

Monitor CBC and platelet count. Discontinue drug and contact prescriber if WBC count falls below 4,000/mm³ or platelet count falls below 100,000/mm³.

Evaluate patient’s concurrent drug use to ensure that he isn’t receiving other drugs that could cause potentially fatal interactions.

Check for diarrhea. Discontinue drug and contact prescriber if patient has frequent bowel movements or watery stools.

Monitor blood urea nitrogen level, liver and kidney function tests, and urinalysis.

Discontinue drug at first sign of hypersensitivity, stomatitis, diarrhea, or bleeding.

Patient teaching

Instruct patient to avoid caffeine-containing foods and beverages.

Tell patient to avoid foods and beverages containing tyramine (such as cheese, Chianti wine, tea, coffee, cola, and bananas).

Advise patient to avoid alcohol.

Tell female of childbearing age to discuss contraception with prescriber.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and behaviors mentioned above.

---

**prochlorperazine maleate**

**Pharmacologic class:** Phenothiazine

**Therapeutic class:** Antiemetic, antipsychotic, anxiolytic

**Pregnancy risk category C**

**Action**

Exerts anticholinergic, CNS depressant, and antihistaminic effects. Depresses release of hypothalamic and hypophyseal hormones, decreases sensitivity of middle-ear labyrinth, and reduces conduction in vestibular-cerebellar pathways.

**Availability**

Capsules (extended-release, maleate): 10 mg, 15 mg, 30 mg

Injection (edisylate): 5 mg/ml

Oral solution (edisylate): 5 mg/5 ml

Suppositories: 2.5 mg, 5 mg, 25 mg

Tablets: 5 mg, 10 mg, 25 mg

**Indications and dosages**

**Nausea**

Adults: 5 to 10 mg P.O. three to four times daily or 15 mg P.O. once daily or 10 mg P.O. (extended-release) b.i.d., up to 40 mg/day. Or 2.5 to 10 mg I.V., not to exceed 40 mg/day.

Children weighing 18 to 38 kg (40 to 85 lb): 2.5 mg P.O. or P.R. t.i.d. or 5 mg P.O. or P.R. b.i.d., not to exceed 15 mg/day

Children weighing 13.6 to 17.7 kg (30 to 39 lb): 2.5 mg P.O. or P.R. two or three times daily, not to exceed 10 mg/day

Children weighing 9 to 13 kg (20 to 29 lb): 2.5 mg P.O. or P.R. daily to b.i.d., not to exceed 7.5 mg/day

**Nausea and vomiting related to surgery**

Adults: 5 to 10 mg I.V. 15 to 30 minutes before anesthesia induction, repeated once if necessary; or 5 to 10 mg I.M. 1
to 2 hours before anesthesia induction, repeated once in 30 minutes if necessary

**Schizophrenia**

**Adults and children older than age 12:**
For mild symptoms, 5 to 10 mg P.O. three to four times daily; for moderate to severe symptoms in hospitalized or supervised patients, 10 mg P.O. three to four times daily, increased p.r.n. q 2 to 3 days to 50 to 75 mg P.O. daily or up to 150 mg/day as tolerated p.r.n. for more severely disturbed patients. Or 10 to 20 mg I.M.; may repeat q 2 to 4 hours for up to four doses p.r.n.

**Children ages 2 to 12:** Initially, 2.5 mg P.O. or P.R. two or three times daily (maximum of 10 mg on day 1); then increase based on response. Don’t exceed 25 mg/day for children ages 6 to 12 or 20 mg/day for children ages 2 to 5.

**Anxiety**

**Adults and children older than age 12:**
5 mg P.O. three to four times daily; or 15 mg P.O. (extended-release) once daily or 10 mg P.O. (extended-release) q 12 hours; up to 20 mg/day for a maximum of 12 weeks

**Off-label uses**
- Migraine

**Contraindications**
- Hypersensitivity to drug or other phenothiazines
- Coma
- Concurrent use of large amounts of CNS depressants
- Pediatric surgery
- Children younger than age 2 or weighing less than 9 kg (20 lb)

**Precautions**
Use cautiously in:
- cardiovascular or hepatic disease, glaucoma, seizures
- anticipated exposure to extreme heat
- children with acute illness.

**Administration**
- For I.V. infusion, dilute 20 mg in 1 L of compatible I.V. solution, such as normal saline solution.
- Don’t mix in same syringe with other drugs.
- Know that injection solution may cause contact dermatitis. Don’t get it on hands or clothing.
- Give I.V. by slow infusion only. Don’t give as bolus.
- Know that I.M. injection is not preferred because it can cause local irritation. However, if I.M. route is prescribed, inject deep into upper outer quadrant of gluteal area.
- Don’t give by subcutaneous route.
- After desired response, switch to P.O. form as prescribed.
- When infusing I.V., watch for hypotension. Keep patient supine for 30 minutes after infusion.

**Route**
- Onset
- Peak
- Duration

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30-40 min</td>
<td>Unknown</td>
<td>3-4 hr</td>
</tr>
<tr>
<td>P.O.</td>
<td>30-40 min</td>
<td>Unknown</td>
<td>10-12 hr</td>
</tr>
<tr>
<td>(extended)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid (min)</td>
<td>10-30 min</td>
<td>3-4 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>10-20 min</td>
<td>10-30 min</td>
<td>3-4 hr</td>
</tr>
<tr>
<td>P.R.</td>
<td>60 min</td>
<td>Unknown</td>
<td>3-4 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** sedation, extrapyramidal reactions, tardive dyskinesia, **neuroleptic malignant syndrome**

**CV:** orthostatic hypotension, ECG changes, tachycardia

**EENT:** blurred vision, lens opacities, pigmentary retinopathy, dry eyes

**GI:** constipation, ileus, dry mouth, anorexia

**GU:** pink or reddish-brown urine, urinary retention, galactorrhea

**Hematologic:** agranulocytosis, leukopenia

**Hepatic:** cholestatic jaundice, **hepatitis**

**Metabolic:** hyperthermia

**Skin:** photosensitivity, pigmentation changes, rash

**Other:** allergic reactions

Reactions in **bold** are life-threatening.
Interactions

Drug-drug. Anticonvulsants: reduced seizure threshold
Antineoplastics: masking of antineoplastic toxicity
CNS depressants (including antihistamines, anticholinergics, opioids, other phenothiazines, sedative-hypnotics): additive CNS depression
Guanethidine: inhibition of antihypertensive effects
Oral anticoagulants: decreased anticoagulant effect
Phenytoin: increased or decreased phenytoin blood level
Propranolol: increased blood levels of both drugs
Thiazide diuretics: increased risk of orthostatic hypotension

Drug-diagnostic tests. Liver function tests: abnormal results
Phenylketonuria test: false-positive result

Drug-herbs. Betel nut: increased risk of extrapyramidal reactions
Evening primrose oil: increased risk of seizures
Kava: increased risk of drug-related adverse reactions

Drug-behaviors. Alcohol use: additive CNS depression

Patient monitoring

Monitor neurologic status, especially for signs and symptoms of neuroleptic malignant syndrome (high fever, sweating, unstable blood pressure, stupor, muscle rigidity, and autonomic dysfunction).
- In long-term therapy, assess for other adverse CNS effects, including extrapyramidal symptoms and tardive dyskinesia.
- Monitor patient closely if he’s receiving drug for nausea and vomiting associated with chemotherapy, because it may mask symptoms of chemotherapy toxicity.
- Evaluate CBC and liver function tests.

Patient teaching

- Instruct patient to dilute oral solution with tomato or fruit juice, milk, coffee, soda, tea, water, or soup.
- Teach patient to recognize and immediately report signs and symptoms of an allergic reaction or neuroleptic malignant syndrome.
- Inform patient about drug’s other CNS effects. Tell him to contact prescriber if these occur.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, alertness, and motor skills.
- Tell patient drug may turn urine pink or reddish brown.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

Progesterone

Crinone, Endometrin, Prometrium

Pharmacologic class: Progestin
Therapeutic class: Hormone
Pregnancy risk category B (oral), D (injection), NR (vaginal)

Action

Suppresses ovulation by altering the vaginal epithelium, relaxing uterine smooth muscle, and promoting mammary tissue growth. Also inhibits pituitary activity and causes withdrawal bleeding in presence of estrogen.

Availability

Injection (in sesame or peanut oil with benzyl alcohol): 50 mg/ml in 10-ml vials
Micronized capsules (oral) in peanut oil: 100 mg, 200 mg
Micronized vaginal gel: 4%, 8%
Indications and dosages

Secondary amenorrhea

**Adults:** 400 mg/day P.O. in evening for 10 days, or 5 to 10 mg/day I.M. for 6 to 8 days, given 8 to 10 days before expected menstrual period. Or 45 mg (one applicatorful of 4% gel) vaginally once every other day for up to six doses; may increase to 90 mg (one applicatorful of 8% gel) once every other day for up to six doses.  

Dysfunctional uterine bleeding

**Adults:** 5 to 10 mg I.M. daily for 6 days  

To prevent postmenopausal estrogen-induced endometrial hyperplasia

**Adults:** 200 mg/day P.O. at bedtime for 14 days on days 8 to 21 of 28-day cycle or on days 12 to 25 of 30-day cycle. If patient currently receives estrogen 1.25 mg/day, 300 mg progesterone in two divided doses (100 mg 2 hours after breakfast and 200 mg at bedtime); further adjustment may be required.  

Corpus luteum insufficiency; assisted reproduction technology

**Adults:** For luteal-phase support, 90 mg (one applicatorful of 8% gel) vaginally once daily. For in vitro fertilization, 90 mg (one applicatorful of 8% gel) vaginally once daily, starting within 24 hours of embryo transfer and continued through day 30 after transfer; if pregnancy occurs, treatment may continue for up to 12 weeks. For partial or complete ovarian failure, 90 mg (one applicatorful of 8% gel) vaginally b.i.d. while patient undergoes donor oocyte transfer; if pregnancy occurs, treatment may last up to 12 weeks.

Contraindications

- Hypersensitivity to drug, peanuts (injection, micronized capsules), or sesame (injection)
- Thromboembolic disease
- Cerebrovascular disease
- Severe hepatic disease
- Porphyria
- Breast or reproductive system cancer
- Missed abortion
- Undiagnosed vaginal bleeding
- Diagnosis of pregnancy

Precautions

Use cautiously in:

- renal or cardiovascular disease, seizure disorders, fluid retention, diabetes mellitus, asthma, migraine, depression
- history of hepatic disease
- breastfeeding patients.

Administration

- Before first dose, make sure patient has read package insert regarding adverse effects. Reinforce written information with oral review.
- Before first I.M. dose, ask if patient has allergy to peanuts or sesame. Before giving micronized capsules, ask about peanut allergy.
- Inject I.M. dose deep into muscle. Rotate injection sites.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2-4 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.M.,</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: depression, emotional lability, cerebrovascular accident  
CV: thrombophlebitis, thromboembolism  
EENT: retinal thrombosis  
GI: abdominal cramps  
GU: amenorrhea, breakthrough bleeding, spotting, cervical erosions, breast tenderness, menstrual flow changes, galactorrhea  
Hepatic: hepatitis  
Respiratory: pulmonary embolism  
Skin: melasma, rash, angioedema  
Other: gingival bleeding, weight gain or loss, hypersensitivity reactions including anaphylaxis

Interactions

Drug-drug. **Conjugated estrogens:** increased levels of both drugs

Reactions in **bold** are life-threatening.
Drug-diagnostic tests. Alkaline phosphatase, amino acids, low-density lipoproteins: increased levels
Chloride and sodium excretion: reduced (with high doses)
High-density lipoproteins: decreased level
Pregnancediaiol excretion: reduced
Thyroid function tests: altered results

Drug-herbs. Red clover: interference with drug effects

Drug-behaviors. Smoking: increased risk of thromboembolic effects

Patient monitoring

- Watch for evidence of thromboembolic disorders, including cerebrovascular accident, pulmonary embolism, diplopia, proptosis, or sudden partial or complete vision loss (may signal retinal thrombosis). If these occur, discontinue drug and notify prescriber immediately.
- Assess for emotional lability and depression.

Patient teaching

- Teach patient to recognize and immediately report signs and symptoms of thromboembolic disorders.
- Instruct patient and significant other to stay alert for and immediately report depression.
- Advise patient to monitor weight regularly and report significant changes.
- Tell female patient that drug may cause menstrual abnormalities.
- Advise female patient to discuss breastfeeding with prescriber before taking drug.
- Instruct patient to immediately report possible pregnancy.
- Tell patient that smoking increases thromboembolism risk. Encourage her to stop smoking if she smokes.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

promethazine hydrochloride
Avomine®, Histantil®, Phenergan®, PMS-Promethazine, Promethegan, Sominex®, Ziz®

Pharmacologic class: Phenothiazine (nonselective)
Therapeutic class: Antihistamine, antiemetic, sedative-hypnotic
Pregnancy risk category C

FDA BOXED WARNING

- Don’t use suppositories in patients younger than age 2 due to potential for fatal respiratory depression. (Postmarketing cases of respiratory depression have been reported in these patients.)
- Use caution when administering to pediatric patients age 2 years and older. Preferably, use lowest effective dosage in these patients and avoid concurrent use of other drugs with respiratory depressant effects.

Action
Blocks effects but not release of histamine and exerts strong alpha-adrenergic effect. Also inhibits chemoreceptor trigger zone in medulla and alters dopamine effects by indirectly reducing reticular stimulation in CNS.

Availability
Injection: 25 mg/ml and 50 mg/ml in 1-ml ampules and 1- and 10-ml vials
Suppositories: 12.5 mg, 25 mg, 50 mg
Syrup: 6.25 mg/5 ml
Tablets: 12.5 mg, 25 mg, 50 mg

Indications and dosages
- Type 1 hypersensitivity reaction
Adults: 25 mg P.O. or P.R. at bedtime or 12.5 mg P.O. before meals and at
bedtime. Or 25 mg I.M. or I.V.; may repeat in 2 hours.

**Children older than age 2:** 25 mg P.O. or P.R. at bedtime or 6.25 to 12.5 mg P.O. t.i.d.

Motion sickness

**Adults:** Initially, 25 mg P.O. or P.R. 30 to 60 minutes before traveling; may repeat 8 to 12 hours later if needed. On successive travel days, 25 mg P.O. or P.R. b.i.d. (on arising and before evening meal).

**Children older than age 2:** 12.5 to 25 mg P.O. or P.R. b.i.d.

Sedation

**Adults:** 25 to 50 mg P.O., I.M., I.V., or P.R. at bedtime

**Children older than age 2:** 12.5 to 25 mg P.O. or P.R. at bedtime

Adjunct to preoperative or postoperative analgesia

**Adults:** 25 to 50 mg P.O., P.R., I.M., or I.V. given with appropriately reduced dosage of narcotic or barbiturate and required dosage of belladonna alkaloid

**Children older than age 2:** 0.5 mg/lb P.O., P.R., I.M., or I.V., given with appropriately reduced dosage of narcotic or barbiturate and required dosage of belladonna alkaloid

Nausea

**Adults:** 25 mg P.O. or P.R.; may repeat doses of 12.5 to 25 mg P.O. or P.R. q 4 to 6 hours p.r.n. Or 12.5 to 25 mg I.M. or I.V.; may repeat q 4 hours p.r.n.

**Children older than age 2:** 25 mg or 0.5 mg/lb P.O. or P.R.; may repeat doses of 12.5 to 25 mg P.O. or P.R. q 4 to 6 hours p.r.n. May give I.M. or I.V. as no more than half of adult dosage. Know that drug should not be given if cause of vomiting is unknown.

**Contraindications**

- Hypersensitivity to drug
- Previous idiosyncratic reaction to phenothiazines
- Asthma, chronic obstructive pulmonary disease, sleep apnea
- Coma

**Precautions**

Use cautiously in:

- cardiovascular or hepatic disease, seizures, bone marrow depression, narrow-angle glaucoma, prostatic hypertrophy, stenosing peptic ulcer, pyloroduodenal or bladder neck obstruction
- CNS depression caused by narcotics, barbiturates, general anesthesia, tranquilizers, or alcohol
- pregnant or breastfeeding patients
- children younger than age 2 (safety and efficacy not established).

**Administration**

- Don’t give I.V. at concentrations greater than 25 mg/ml or faster than 25 mg/minute.
- Use light-resistant covering for I.V. drug.

Inject I.M. deep into large muscle. Don’t give by subcutaneous route.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O., I.M.</td>
<td>20 min</td>
<td>Unknown</td>
<td>4-12 hr</td>
</tr>
<tr>
<td>P.R.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I.V.</td>
<td>3-5 min</td>
<td>Unknown</td>
<td>4-12 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: confusion, disorientation, fatigue, marked drowsiness, sedation, dizziness, extrapyramidal reactions, insomnia, nervousness, **neuroleptic malignant syndrome**

CV: hypertension, hypotension, bradycardia, tachycardia

EENT: blurred vision, diplopia, tinnitus

GI: constipation, dry mouth

Hematologic: blood dyscrasias

Hepatic: cholestatic jaundice

Respiratory: respiratory depression

Skin: photosensitivity, rash

Other: hypersensitivity reaction

Reactions in **bold** are life-threatening.
Interactions

Drug-drug. *Anticholinergics*: additive anticholinergic effects  
*CNS depressants*: additive CNS depression  
*Epinephrine*: reversal of epinephrine’s vasopressor effects  
*MAO inhibitors*: increased extrapyramidal effects

Drug-diagnostic tests. *Glucose*: increased level  
*Granulocytes, platelets, white blood cells*: decreased counts  
*Pregnancy test*: false-positive or false-negative result  
*Skin tests using allergen extracts*: false-negative results

Drug-herbs. *Betel nut*: increased risk of extrapyramidal reactions  
*Evening primrose oil*: increased risk of seizures  
*Kava*: increased risk of adverse drug effects

Drug-behaviors. *Alcohol use*: additive CNS depression  
*Sun exposure*: increased risk of photosensitivity

Patient monitoring

- Monitor neurologic status. Stay alert for signs and symptoms of neuroleptic malignant syndrome (high fever, sweating, unstable blood pressure, stupor, muscle rigidity, and autonomic dysfunction).
- In long-term therapy, assess for other adverse CNS effects, including extrapyramidal reactions.
- Monitor CBC and liver function tests.

Patient teaching

- Teach patient to recognize and immediately report signs and symptoms of hypersensitivity reaction or neuroleptic malignant syndrome.
- Tell patient about drug’s other significant neurologic effects. Instruct him to contact prescriber if these occur.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, alertness, and motor skills.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

---

**propafenone hydrochloride**

APO-Propafenone®, Arythmol®, Gen-Propafenone®, PMS-Propafenone®, Rythmol

**Pharmacologic class:** Direct membrane stabilizer  
**Therapeutic class:** Antiarrhythmic (class IC)  
**Pregnancy risk category C**

---

**FDA BOXED WARNING**

- In study of patients with asymptomatic, non-life-threatening ventricular arrhythmias who’d had myocardial infarctions more than 6 days but less than 2 years previously, excessive mortality or nonfatal cardiac arrest rate occurred in those treated with encainide or flecainide, compared with patients in carefully matched placebo groups. Given drug’s known proarrhythmic properties and lack of evidence of improved survival for any antiarrhythmic in patients without life-threatening arrhythmias, reserve drug for patients with life-threatening ventricular arrhythmias.

---

**Action**

Slows conduction velocity in atrioventricular (AV) node, decreases automaticity, and increases ratio of effective refractory period to action potential
duration; also has mild beta-adrenergic blocking properties

**Availability**

*Tablets:* 150 mg, 225 mg, 300 mg

**Indications and dosages**

Life-threatening ventricular arrhythmias; paroxysmal atrial fibrillation or flutter; paroxysmal supraventricular tachycardia

**Adults:** Dosage highly individualized based on response and tolerance. Initially, 150 mg P.O. q 8 hours (450 mg/day); may increase after 3 to 4 days to 225 mg P.O. q 8 hours (675 mg/day) or, if necessary, up to 300 mg P.O. q 8 hours (900 mg/day). Don’t exceed 900 mg/day P.O.

**Dosage adjustment**

- Hepatic disease
- Supraventricular tachycardia, arrhythmias associated with Wolff-Parkinson-White syndrome
- Elderly patients

**Contraindications**

- Hypersensitivity to drug
- Sick-sinus syndrome, sinoatrial or AV block (unless patient has artificial pacemaker)
- Cardiogenic shock
- Bradycardia
- Uncontrolled heart failure
- Marked hypotension
- Bronchospastic disorders
- Electrolyte imbalances

**Precautions**

Use cautiously in:

- hepatic or renal impairment, myasthenia gravis
- pregnant or breastfeeding patients
- children.

**Administration**

- Give with food (but not with grapefruit juice) in three divided doses daily, once every 8 hours.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Variable</td>
<td>3.5 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** headache, dizziness, drowsiness, syncope, vertigo, confusion, asthenia, speech disturbances, memory loss, ataxia, paresthesia, anxiety, abnormal dreams, insomnia, tremor

**CV:** palpitations, angina, chest pain, hypotension, bradycardia, premature ventricular contractions, **first-degree AV block, supraventricular or ventricular arrhythmias, heart failure, atrial fibrillation, intraventricular conduction delay**

**EENT:** blurred vision, tinnitus

**GI:** nausea, vomiting, diarrhea, constipation, dyspepsia, abdominal pain or cramps, flatulence, dry mouth, anorexia

**GU:** reversible disorders of spermatogenesis

**Hematologic:** purpura, hemolytic anemia, leukopenia, agranulocytosis, thrombocytopenia, neutropenia

**Hepatic:** cholestasis, abnormal hepatic function

**Musculoskeletal:** muscle weakness, myalgia, leg cramps, myasthenia gravis exacerbation

**Respiratory:** dyspnea

**Skin:** rash, alopecia, diaphoresis

**Other:** altered taste, edema

**Interactions**

**Drug-drug. Beta-adrenergic blockers:** increased blood level and effects of beta-adrenergic blockers metabolized by liver

- **Cimetidine:** increased propafenone blood level
- **Cyclosporine, desipramine, digoxin, theophylline, warfarin:** increased blood levels of these drugs
- **Quinidine:** delayed propafenone metabolism
- **Rifampin:** decreased blood level and antiarrhythmic efficacy of propafenone

Reactions in **bold** are life-threatening.
**Drug-diagnostic tests.** *Antinuclear antibody:* positive titer  
*Bleeding time:* prolonged  
*Creatine kinase, glucose:* increased levels  
*Granulocytes, white blood cells:* decreased counts  
**Drug-herbs.** *Aloe, buckthorn, cascara sagrada, senna pod or leaf:* increased antiarrhythmic action, decreased potassium level

**Patient monitoring**  
- Monitor ECG and vital signs.  
- Evaluate neurologic status. Stay alert for decreasing level of consciousness.  
- Monitor CBC and liver function tests. Watch for evidence of blood dyscrasias and abnormal hepatic function.  
- Monitor respiratory status for dyspnea.

**Patient teaching**  
- Tell patient which cardiac, neurologic, and respiratory adverse effects to report immediately.  
- Instruct patient to immediately report unusual bleeding or bruising.  
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, and alertness.  
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

---

**propantheline bromide**  
Pro-Banthine

**Pharmacologic class:** Parasympatholytic  
**Therapeutic class:** Anticholinergic, antimuscarinic, antispasmodic  
**Pregnancy risk category C**

**Action**  
Prevents muscarinic action of acetylcholine at postganglionic parasympathetic neuroeffector sites, relaxing GI tract and blocking gastric acid secretion

**Availability**  
*Tablets:* 7.5 mg, 15 mg

**Indications and dosages**  
- **Peptic ulcer**  
  *Adults:* 15 mg P.O. 30 minutes before each meal and 30 mg at bedtime, for a total of four daily doses  
  *Adults of small stature:* 7.5 mg P.O. t.i.d. before each meal

**Dosage adjustment**  
- Mild peptic ulcer symptoms  
- Elderly patients

**Off-label uses**  
- Neurogenic bladder  
- Urinary incontinence  
- Antisecretory and antispasmodic effects

**Contraindications**  
- Hypersensitivity to drug or other anticholinergics  
- Angle-closure glaucoma  
- Unstable cardiovascular adjustment in acute hemorrhage  
- GI tract obstruction  
- GI atony in elderly or debilitated patients  
- Toxic megacolon, severe ulcerative colitis  
- GU tract obstruction  
- Myasthenia gravis

**Precautions**  
Use cautiously in:  
- heart failure, hypertension, arrhythmias, coronary artery disease, hepatic disease, hiatal hernia, chronic lung disease in debilitated patients, hyperthyroidism, autonomic neuropathy  
- elderly patients
- pregnant or breastfeeding patients
- children.

**Administration**
- Give 30 minutes before meals and at bedtime—except in adults of small stature, who should receive doses three times daily before meals.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30-60 min</td>
<td>2-6 hr</td>
<td>6 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- **CNS:** confusion, stimulation, headache, insomnia, dizziness, anxiety, asthenia, hallucinations
- **CV:** palpitations, orthostatic hypotension, tachycardia
- **EENT:** blurred vision, photophobia, mydriasis, cycloplegia, increased intraocular pressure, nasal congestion
- **GI:** nausea, vomiting, constipation, heartburn, dysphagia, bloating, gastroesophageal reflux disease (GERD), dry mouth, paralytic ileus
- **GU:** urinary hesitancy or retention, erectile dysfunction, suppressed lactation
- **Skin:** rash, urticaria, pruritus, anhidrosis
- **Other:** taste loss, fever, heat prostration, allergic reaction

**Interactions**
- **Drug-drug.** Amantadine: increased propantheline effects
  - Atenolol: increased pharmacologic effects of atenolol
  - Phenothiazines: decreased antipsychotic efficacy of phenothiazines, increased adverse effects of propantheline
  - Tricyclic antidepressants: increased anticholinergic effects
- **Drug-herbs.** Henbane, jimsonweed, scopolia: increased anticholinergic effects

**Patient monitoring**
- Monitor vital signs. Watch for orthostatic hypotension.
- Assess patient for sensory and neuropsychologic impairment.

**Patient teaching**
- Tell patient drug may inhibit sweating and make him susceptible to heat prostration. Teach him effective ways to maintain normal body temperature.
- Describe drug's adverse anticholinergic effects. Recommend appropriate measures to minimize these.
- Advise patient to report GERD symptoms.
- Tell male patient drug may cause erectile dysfunction. Encourage him to discuss this problem with prescriber.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, and alertness.
- Instruct patient to move slowly when sitting up or standing, to avoid dizziness from sudden blood pressure decrease.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and herbs mentioned above.

Reactions in **bold** are life-threatening.
FDA BOXED WARNING

- Don’t administer to patients who are suicidal or addiction-prone.
- Give cautiously to patients who take tranquilizers or antidepressants or who use alcohol in excess.
- Advise patient not to exceed recommended dosage and to limit alcohol intake during therapy.
- When used in excessive dosages (alone or in combination with alcohol or other CNS depressants), propoxyphene products are a major cause of drug-related deaths. Deaths may arise within first hour of overdose; many have occurred in patients with history of emotional disturbances or suicidal ideation or attempts or history of misuse of tranquilizers, alcohol, and other CNS drugs.

Action
Alters perception of and emotional response to pain by binding with opiate receptors in brain, causing CNS depression

Availability
propoxyphene hydrochloride
Capsules: 65 mg
propoxyphene napsylate
Tablets: 100 mg

Indications and dosages
➣ Mild to moderate pain
Adults: 65 mg (hydrochloride) P.O. q 4 hours or 100 mg (napsylate) P.O. q 4 hours as needed. Don’t exceed 390 mg/day hydrochloride or 600 mg/day napsylate.

Dosage adjustment
- Hepatic or renal impairment
- Elderly or debilitated patients

Contraindications
- Hypersensitivity to drug or its components
- Suicidal or substance abuse–prone patients

Precautions
Use cautiously in:
- head trauma; increased intracranial pressure; severe renal, hepatic, or pulmonary disease; hypothyroidism; adrenal insufficiency; prostatic hypertrophy; undiagnosed abdominal pain; alcoholism
- patients receiving MAO inhibitors
- elderly or debilitated patients
- pregnant or breastfeeding patients
- children.

Administration
- Give with milk or food to reduce GI upset.
- Be aware that 100 mg propoxyphene napsylate is equivalent to 65 mg propoxyphene hydrochloride.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>15-60 min</td>
<td>2-3 hr</td>
<td>4-6 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, headache, dysphoria, euphoria, insomnia, paradoxical excitement, asthenia, sedation
CV: hypotension
EENT: blurred vision
GI: nausea, vomiting, constipation, abdominal pain
Skin: rash
Other: physical or psychological drug dependence, drug tolerance

Interactions
Drug-drug. Antidepressants, sedative-hypnotics: additive CNS depression
Buprenorphine, dezocine, nalbuphine, pentazocine: decreased analgesic effect
MAO inhibitors: unpredictable and potentially fatal effects
Partial-antagonist opioid analgesics: precipitation of withdrawal in physically dependent patients
Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase: altered levels

Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression

Drug-behaviors. Alcohol use: increased CNS depression
Smoking: increased metabolism and decreased analgesic efficacy of propoxyphene

Patient monitoring
- Assess patient's pain level 30 minutes after giving drug.
- Evaluate CNS effects. As needed, institute measures to prevent injury.
- In long-term therapy, monitor liver function tests and evaluate patient regularly for signs of physical or psychological drug dependence.

Patient teaching
- Advise patient to take with milk or food to minimize GI upset.
- Inform patient that drug may cause physical or psychological dependence. Stress that he should take it only when needed and only as prescribed.
- Tell patient that alcohol use and smoking affect drug blood level. Discourage these habits.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, and alertness.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

Propranolol hydrochloride

Apo-Propranolol®, Bedranol SR®, Betachron E-R, Beta-Prograne®, Dom-Propranolol®, Half Beta-Prograne®, Half Inderal LA®, Inderal, Inderal LA, Innopropan XL, Novopranol®, Nu-Propranolol®, PMS Propranolol®, Rapranol SR®, Slo-Pro®, Syprol®

Pharmacologic class: Beta-adrenergic blocker (nonselective)

Therapeutic class: Antianginal, anti-arrhythmic (class II), antihypertensive, vascular headache suppressant

Pregnancy risk category C

FDA BOXED WARNING
- In patients with angina pectoris, exacerbations of angina and, in some cases, myocardial infarction (MI) have followed abrupt drug withdrawal. For planned withdrawal, reduce dosage gradually over at least a few weeks and caution patient not to interrupt or stop therapy without physician’s advice. If therapy is interrupted and angina exacerbation occurs, consider reinstituting drug and taking other measures to manage unstable angina. As coronary artery disease may be unrecognized, it may be prudent to follow same advice in patients at risk for occult atherosclerotic heart disease who receive drug for other indications.

Action
Blocks stimulation of beta₁-adrenergic (myocardial) and beta₂-adrenergic (pulmonary, vascular, and uterine) receptor sites. This action decreases cardiac output, slows heart rate, and reduces blood pressure.
Availability
Capsules (extended-release, sustained-release): 60 mg, 80 mg, 120 mg, 160 mg
Injection: 1 mg/ml
Oral solution: 4 mg/ml, 8 mg/ml, 80 mg/ml
Tablets: 10 mg, 20 mg, 40 mg, 60 mg, 90 mg

Indications and dosages

➣ Angina pectoris
Adults: 80 to 320 mg P.O. daily in three to four divided doses or 160 mg (extended- or sustained-release) P.O. daily; maximum daily dosage is 320 mg.

➣ Hypertension
Adults: 40 mg P.O. b.i.d. or 80 mg (extended- or sustained-release) P.O. daily. Maximum daily dosage is 640 mg; usual maintenance dosage is 120 to 240 mg/day.

➣ Prophylaxis after MI
Adults: 180 to 240 mg P.O. daily in three to four divided doses; maximum daily dosage is 240 mg.

➣ Hypertrophic subaortic stenosis
Adults: 20 to 40 mg P.O. three to four times daily (before meals and at bedtime) or 80 to 160 mg (extended- or sustained-release) P.O. daily

➣ Adjunctive therapy in pheochromocytoma
Adults: 60 mg P.O. daily in divided doses for 3 days, given after primary therapy with alpha-adrenergic blocker

➣ To prevent migraine or vascular headache
Adults: 80 mg P.O. (extended- or sustained-release) daily; may increase as needed up to 240 mg/day. Effective range is 160 mg to 240 mg/day.

➣ Essential tremor
Adults: 40 mg P.O. b.i.d.; if necessary, 240 mg to 320 mg/day. Maximum daily dosage is 320 mg.

➣ Arrhythmias
Adults: 10 to 30 mg P.O. (tablets or oral solution) three or four times daily

Contraindications
- Hypersensitivity to drug, its components, or other beta-adrenergic blockers
- Uncompensated heart failure
- Cardiogenic shock
- Sinus bradycardia, heart block greater than first degree
- Bronchodystrophic disease

Precautions
Use cautiously in:
- renal or hepatic impairment, sinus node dysfunction, pulmonary disease, diabetes mellitus, hyperthyroidism, Raynaud’s syndrome, hypertensive emergencies, myasthenia gravis
- concurrent thioridazine use
- history of severe allergic reactions
- elderly patients
- pregnant or breastfeeding patients
- children (safety not established).

Administration
- Take apical pulse for 1 full minute. Withhold dose and notify prescriber if patient has bradycardia or tachycardia.
- Be aware that I.V. use is usually reserved for arrhythmias that are life-threatening or occur during anesthesia.
- Inject I.V. dose directly into large vein or into tubing of compatible I.V. solution (dextrose 5% in water, normal or half-normal saline solution, or lactated Ringer’s solution).
- Don’t give as continuous I.V. infusion.
- For intermittent I.V. infusion, dilute with normal saline solution and infuse in 0.1- to 0.2-mg increments over 10 to 15 minutes.
- Keep I.V. isoproterenol, atropine, or glucagon at hand in case of emergency.
Don’t stop giving drug suddenly. Dosage must be tapered.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30 min</td>
<td>60-90 min</td>
<td>6-12 hr</td>
</tr>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>6 hr</td>
<td>24 hr</td>
</tr>
<tr>
<td></td>
<td>(extended, sustained)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>1 min</td>
<td>4-6 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: fatigue, asthenia, anxiety, dizziness, drowsiness, insomnia, memory loss, depression, mental status changes, nervousness, paresthesia, nightmares
CV: peripheral vasoconstriction, orthostatic hypotension, bradycardia, arrhythmias, heart failure, myocardial infarction and sudden death (with abrupt withdrawal in angina therapy)
EENT: blurred vision, dry eyes, nasal congestion, rhinitis, sore throat
GI: nausea, vomiting, diarrhea, constipation, dry mouth
GU: erectile dysfunction, decreased libido
Hematologic: purpura, thrombocytopenic purpura
Metabolic: fluid retention, hyperglycemia, hypoglycemia (increased in children), thyrotoxicosis (with abrupt withdrawal in hypertension therapy)
Musculoskeletal: joint pain, back pain, myalgia, muscle cramps
Respiratory: wheezing, bronchospasm, pulmonary edema
Skin: pruritus, rash
Other: fever

Reactions in **bold** are life-threatening.

**Clinical alert**

**Diuretics, other antihypertensives:** increased hypotensive effect
**Glucagon, isoproterenol:** antagonism of propranolol’s effects
**Insulin, oral hypoglycemics:** impaired glucose tolerance, increased risk of hypoglycemia
**Neuromuscular blockers:** increased neuromuscular blockade (with high propranolol doses)
**Nonsteroidal anti-inflammatory drugs:** decreased hypotensive effect
**Theophylline:** decreased theophylline clearance, antagonism of theophylline’s bronchodilating effect
**Thioridazine:** increased thioridazine blood level, leading to prolonged QT interval

**Drug-diagnostic tests.** Alkaline phosphatase, blood urea nitrogen, eosinophils, lactate dehydrogenase, serum transaminases, triiodothyronine: increased levels
**Glucose:** decreased or increased level
**Platelets, thyroxine:** decreased levels

**Drug-behaviors.** Acute alcohol ingestion: additive hypotension

**Patient monitoring**
- Monitor vital signs, ECG, and central venous pressure.
- Assess fluid balance. Check for signs and symptoms of heart failure.
- Monitor CBC and liver and thyroid function tests.
- Watch closely for signs and symptoms of hypoglycemia, which drug may mask.
- Monitor blood glucose level in diabetic patient, to identify need for altered insulin or oral hypoglycemic dosage. Be aware that in labile diabetes, hypoglycemia may be accompanied by steep blood pressure rise.

**Patient teaching**
- Advise patient to take with meals at same time every day to minimize GI upset.
Caution patient not to stop taking drug suddenly. Tell him dosage must be tapered.

- Tell patient to monitor pulse and to promptly report bradycardia or tachycardia.
- Inform patient that drug may cause muscle aches or bone pain. Advise him to discuss activity recommendations and pain management with prescriber.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

Propylthiouracil (PTU)

Propyl-Thyracil

Pharmacologic class: Thioamide derivative
Therapeutic class: Antithyroid agent
Pregnancy risk category D

Action
Directly interferes with thyroid synthesis by preventing iodine from combining with thyroglobulin, leading to decreased thyroid hormone levels

Availability
Tablets: 50 mg

Indications and dosages

- Hyperthyroidism
  Adults: Initially, 300 to 450 mg P.O. daily in equally divided doses q 8 hours; for maintenance, 100 to 150 mg P.O. daily.
- Thyrotoxic crisis

Contraindications
- Hypersensitivity to drug
- Pregnancy and breastfeeding

Precautions
Use cautiously in:
- decreased bone marrow reserve.

Administration
- Give with meals to reduce GI upset.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1-1.5 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: drowsiness, headache, vertigo, neuritis, paresthesia
GI: nausea, vomiting, diarrhea, epigastric distress
Hematologic: agranulocytosis, leukopenia, thrombocytopenia
Hepatic: jaundice, hepatic necrosis
Metabolic: hypothyroidism
Musculoskeletal: joint pain, myalgia
Skin: rash, urticaria, pruritus, skin discoloration, alopecia, cutaneous vasculitis
Other: taste loss, fever, lymphadenopathy, parotitis, edema

Interactions
Drug-drug. Anticoagulants: potentiation of anticoagulant effect
Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, lactate dehydrogenase: increased levels
Granulocytes, platelets: decreased levels
Prothrombin time: prolonged

Patient monitoring
- Monitor CBC and liver and thyroid function tests.
- Assess for signs and symptoms of hypothyroidism (cold intolerance, non-pitting edema, fatigue, weight gain, and depression).

Canada  UK  Hazardous drug  High alert drug
Monitor for severe rash, fever, or enlarged cervical lymph nodes. If present, stop therapy and notify prescriber.

**Patient teaching**
- Instruct patient to take with meals to reduce GI upset.
- Teach patient to recognize and report signs and symptoms of hypothyroidism and jaundice.
- Advise patient to discuss iodine intake (as in iodized salt and shellfish) with prescriber.
- Tell patient to avoid over-the-counter cold remedies that contain iodine.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Advise female patient of childbearing age to discuss pregnancy or breastfeeding with prescriber before taking.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**pseudoephedrine hydrochloride**
Contac Non Drowsy®, Galsud®, Genaphed, Kidkare Decongestant, Meltus Decongestant®, Non-Drowsy Sudafed Decongestant®, Robidrine®, Silfedrine Children's, Sudafed, Sudafed Children's Nasal Decongestant, Sudafed 12 Hour, Sudo-Tab, Sudodrin, SudoGest

**pseudoephedrine sulfate**
Drixoral Nasal Decongestant, Drixoral Non-Drowsy Formula

**Pharmacologic class:** Sympathomimetic  
**Therapeutic class:** Decongestant (systemic)  
**Pregnancy risk category C**

**Action**
Stimulates alpha-adrenergic receptors, causing vasoconstriction of respiratory tract; relaxes bronchial smooth muscle through beta₂-adrenergic stimulation

**Availability**
**pseudoephedrine hydrochloride**
Capsules: 60 mg  
Capsules (extended-release): 120 mg, 240 mg  
Capsules (soft gel): 30 mg  
Oral solution: 15 mg/5 ml, 30 mg/5 ml  
Syrup: 30 mg/5 ml  
Tablets: 30 mg, 60 mg  
Tablets (chewable): 15 mg  
Tablets (extended-release): 120 mg, 240 mg  
**pseudoephedrine sulfate**
Tablets (extended-release, film-coated): 120 mg

**Indications and dosages**
- Nasal, sinus, or eustachian tube congestion  
**Adults and children ages 12 and older:**  
60 mg P.O. q 4 to 6 hours p.r.n. (not to exceed 240 mg/day); or 120 mg (extended-release) q 12 hours or 240 mg (extended-release) q 24 hours

**Contraindications**
- Hypersensitivity to drug or other sympathomimetics  
- Alcohol intolerance (with some liquid products)  
- Hypertension  
- Severe coronary artery disease
- MAO inhibitor use within past 14 days
- Children younger than age 12 (extended-release forms)

Precautions
Use cautiously in:
- hyperthyroidism, diabetes mellitus, prostatic hypertrophy, ischemic heart disease, glaucoma
- elderly patients (more sensitive to drug’s CNS effects)
- pregnant or breastfeeding patients.

Administration
- Give at least 2 hours before bedtime to minimize insomnia.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30 min</td>
<td>Unknown</td>
<td>4-8 hr</td>
</tr>
<tr>
<td>P.O.</td>
<td>60 min</td>
<td>Unknown</td>
<td>12 hr (extended)</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: anxiety, nervousness, dizziness, drowsiness, excitability, fear, hallucinations, headache, insomnia, restlessness, asthenia, seizures
CV: palpitations, hypertension, tachycardia, cardiovascular collapse
GI: anorexia, dry mouth
GU: dysuria
Respiratory: respiratory difficulty

Interactions
Drug-drug. Beta-adrenergic blockers: increased pressor effects of pseudoephedrine
MAO inhibitors: hypertensive crisis
Mecamylamine, methyldopa, reserpine: decreased antihypertensive effect of these drugs
Other sympathomimetics: additive effects, greater risk of toxicity
Drug-food. Foods that acidify urine: decreased drug efficacy
Foods that alkalize urine: increased drug efficacy

Patient monitoring
- Monitor vital signs.
- Assess neurologic and cardiovascular status regularly.

Patient teaching
- Advise patient to take at least 2 hours before bedtime to reduce insomnia.
- Tell patient not to crush or break extended-release tablets or capsules.
- Advise patient to discontinue use and consult prescriber if he experiences nervousness, dizziness, or insomnia.
- Tell patient to consult prescriber before taking other over-the-counter products.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and foods mentioned above.

psyllium
Fiberall, Fibrelief®, Fibro-Lax, Fibro-XL, Fybogel®, Genfiber, Hydrocil Instant, Isogel®, Ispagel®, KaracilW, Konsyl, Metamucil, Metamucil Orange Flavor, Metamucil Sugar Free, Modane Bulk, Natural Fiber Therapy, Prodiem PlainW, Regulan®, Reguloid, Reguloid Sugar Free

Pharmacologic class: Psyllium colloid
Therapeutic class: Bulk-forming laxative
Pregnancy risk category B

Action
Stimulates lining of colon, increasing peristalsis and water absorption of stool and promoting evacuation
Availability
Chewable pieces: 1.7 g/piece, 3.4 g/piece
Granules: 2.5 g/tsp, 4.03 g/tsp
Powder: 3.3 g/tsp, 3.4 g/tsp, 3.5 g/tsp, 4.94 g/tsp
Powder (effervescent): 3.4 g/packet, 3.7 g/packet
Wafers: 3.4 g/wafer

Indications and dosages
➣ Chronic constipation; ulcerative colitis; irritable bowel syndrome
Adults and children ages 12 and older:
30 g daily in divided doses of 2.5 to 7.5 g/dose P.O. in 8 oz of water or juice

Contraindications
● Hypersensitivity to drug
● Intestinal obstruction
● Abdominal pain or other appendicitis symptoms
● Fecal impaction

Precautions
Use cautiously in:
● phenylketonuria
● pregnant patients.

Administration
● Mix powder with 8 oz of cold liquid (such as orange juice) to mask taste.
● Give diluted drug immediately after mixing, before it congeals. Follow with another glass of fluid.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>12-24 hr</td>
<td>3 days</td>
<td>Variable</td>
</tr>
</tbody>
</table>

Adverse reactions
GI: nausea; vomiting; diarrhea (with excessive use); abdominal cramps with severe constipation; anorexia; esophageal, gastric, small-intestine, or rectal obstruction (with dry form)
Respiratory: asthma (rare)
Other: severe allergic reactions including anaphylaxis

Interactions
None significant

Patient monitoring
● Monitor patient’s bowel movements.
● Check for signs and symptoms of severe (but rare) allergic reactions, such as anaphylaxis and asthma.

Patient teaching
● Tell patient to dissolve in 8 oz of cold beverage and drink immediately, followed by another glass of liquid.
● Caution patient not to take without dissolving in liquid.
● Instruct patient to take after meals if drug decreases his appetite.
● Tell patient drug usually causes bowel movement within 12 to 24 hours but may take as long as 3 days.
● Instruct patient to immediately stop taking drug and notify prescriber if signs and symptoms of allergic reaction occur.
● Advise diabetic patient to use sugar-free drug form.
● Instruct patient with phenylketonuria to avoid forms containing phenylalanine.
● As appropriate, review all other significant and life-threatening adverse reactions.

pyrantel pamoate
Combantrin®, Pin-X

Pharmacologic class: Pyrimidine derivative
Therapeutic class: Anthelmintic
Pregnancy risk category C

Action
Stimulates ganglionic receptors in worm, paralyzing it; worm is then expelled through normal peristalsis.

Availability
Capsules: 180 mg
Liquid: 50 mg/ml
Oral suspension: 50 mg/ml, 144 mg/ml

Reactions in bold are life-threatening.
**Indications and dosages**

- Pinworm (enterobiasis); roundworm (ascariasis)

**Adults and children older than age 2:**
11 mg/kg P.O. as a single dose (maximum of 1 g/day), repeated in 2 weeks

**Contraindications**
- Hypersensitivity to drug

**Precautions**
Use cautiously in:
- malnutrition, dehydration, hepatic disease, seizure disorder
- *Trichostrongylus* infection
- pregnant or breastfeeding patients
- children younger than age 2.

**Administration**
- Shake suspension well.
- Give all forms without regard to food, milk, or juice intake.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Slow</td>
<td>1-3 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- CNS: dizziness, headache, drowsiness, insomnia, asthenia
- GI: nausea, vomiting, diarrhea, abdominal cramps, gastralgia, anorexia
- Skin: rash
- Other: fever

**Interactions**
- Drug-drug. *Piperazine*: antagonism of both drugs’ effects
- Drug-diagnostic tests. *Aspartate aminotransferase*: transient increase

**Patient monitoring**
- Monitor for rash and fever.

**Patient teaching**
- Tell patient to shake suspension well. Inform him that he may take it with or without food, juice, or milk.
- Instruct patient to report rash or fever.
- If pinworm is suspected, tell patient that everyone in household should be treated.
- Advise patient to practice strict hygiene to prevent reinfection.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

---

**pyrazinamide**

PMS Pyrazinamide®, Tebrazid®

**Pharmacologic class:** Niacinamide derivative

**Therapeutic class:** Antitubercular

**Pregnancy risk category C**

**Action**
Unknown. Thought to exert bacteriostatic activity.

**Availability**
Tablets: 500 mg

**Indications and dosages**

- Tuberculosis

**Adults and children**:
15 to 30 mg/kg/day P.O., not to exceed 2 g/day; or 50 to 70 mg/kg P.O. twice weekly, up to a maximum of 4 g/dose; or 50 to 70 mg/kg/dose P.O. three times weekly, up to a maximum of 3 g/dose

**Dosage adjustment**
- Renal impairment

**Contraindications**
- Hypersensitivity to drug
- Severe hepatic disease
- Acute gout
Precautions
Use cautiously in:
● renal failure, diabetes mellitus, porphyria, chronic gout, history of gout
● pregnant or breastfeeding patients
● children younger than age 13.

Administration
● Give with other antituberculars, as prescribed, to reduce risk of resistant organisms.
● Be aware that drug therapy may last 6 months or longer.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>2 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache
GI: nausea, vomiting, diarrhea, peptic ulcer, abdominal cramps, anorexia
GU: dysuria, increased uric acid secretion
Hematologic: hemolytic anemia
Hepatic: hepatotoxicity
Metabolic: hyperuricemia, gout
Musculoskeletal: joint pain
Skin: urticaria, photosensitivity

Interactions
Drug-drug. Ethionamide: increased risk of hepatotoxicity
Probenecid: decreased probenecid efficacy (possibly precipitating gout)
Drug-diagnostic tests. Acetest or Ketostix urine test: false interpretation
Liver function tests: abnormal results
Uric acid: increased level

Patient monitoring
● Monitor CBC, uric acid level, and liver and kidney function tests.
● Assess for signs and symptoms of gout, hepatic failure, and hemolytic anemia.
❖ Discontinue at first sign of hepatic impairment or hyperuricemia accompanied by acute gouty arthritis.

Patient teaching
● Advise patient to take regularly with other antituberculars, as prescribed.

❖ Teach patient to recognize and immediately report signs and symptoms of gout and liver impairment.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

pyridostigmine bromide
Mestinon, Mestinon-SR, Mestinon Timespan, Regonol

Pharmacologic class: Anticholinesterase
Therapeutic class: Muscle stimulant, antymyasthenic
Pregnancy risk category C

Action
Prevents acetylcholine destruction, resulting in stronger contractions of muscles weakened by myasthenia gravis or curare-like neuromuscular blockers

Availability
Injection: 5 mg/ml
Syrup: 60 mg/5 ml
Tablets: 60 mg
Tablets (extended-release): 180 mg

Indications and dosages
➣ Myasthenia gravis
Adults: 600 mg P.O. given over 24 hours, with doses spaced for maximum symptom relief. For myasthenic crisis, 2 mg or 1/30 of oral dose I.M. or very slow I.V. q 2 to 3 hours.
➣ Postoperative reversal of nondepolarizing neuromuscular blockers
Adults: 10 to 20 mg slow I.V. injection (range is 0.1 to 0.25 mg/kg) with or immediately after 0.6 to 1.2 mg atropine sulfate I.V.
Dosage adjustment
- Renal impairment
- Seizure disorders

Off-label uses
- Myasthenia gravis in children
- Constipation in patients with Parkinson’s disease
- Nerve agent prophylaxis

Contraindications
- Hypersensitivity to drug or bromides
- Mechanical intestinal or urinary tract obstruction

Precautions
Use cautiously in:
- seizure disorders, bronchial asthma, coronary occlusion, arrhythmias, bradycardia, hyperthyroidism, peptic ulcer, vagotonia, cholinergic crisis
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

Administration
- Don’t exceed I.V. injection rate of 1 mg/minute.
- Don’t give concurrently with other anticholinesterase drugs.
- Have atropine available for use in emergencies.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>20-30 min</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>P.O.</td>
<td>30-60 min</td>
<td>Unknown</td>
<td>6-12 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>2-5 min</td>
<td>Unknown</td>
<td>2-4 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>&lt;15 min</td>
<td>Unknown</td>
<td>2-4 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, dysarthria, dysphoria, drowsiness, dizziness, headache, syncope, loss of consciousness, seizures
CV: decreased cardiac output leading to hypotension, bradycardia, nodal rhythm, atrioventricular block, cardiac arrest, arrhythmias

EENT: diplopia, lacrimation, miosis, spasm of accommodation, conjunctival hyperemia
GI: nausea, vomiting, diarrhea, abdominal cramps, increased peristalsis, flatulence dysphagia, increased salivation
GU: urinary frequency, urgency, or incontinence
Musculoskeletal: muscle weakness, fasciculations, and cramps; joint pain
Respiratory: increased pharyngeal and tracheobronchial secretions, dyspnea, central respiratory paralysis, respiratory muscle paralysis, laryngospasm, bronchospasm, bronchiolar constriction
Skin: diaphoresis, flushing, rash, urticaria
Other: thrombophlebitis at I.V. site, cholinergic crisis, anaphylaxis

Interactions
Drug-drug. Aminoglycosides: potentiation of neuromuscular blockade
Anesthetics (general and local), antiarrhythmics: decreased anticholinesterase effects
Atropine, belladonna derivatives: suppression of parasympathomimetic GI symptoms (leaving only fasciculations and voluntary muscle paralysis as signs of anticholinesterase overdose)
Corticosteroids: decreased anticholinesterase effects; after corticosteroid withdrawal, increased anticholinesterase effects
Ganglionic blockers (such as mecamylamine): increased anticholinesterase effects
Magnesium: antagonism of beneficial anticholinesterase effects
Nondepolarizing neuromuscular blockers (atropine, pancuronium, tubocurarine): antagonism of neuromuscular blockade and reversal of muscle relaxation after surgery (with parenteral pyridostigmine)
Other anticholinesterase drugs: in patients with myasthenia gravis, symptoms of anticholinesterase overdose
that mimic underdose, causing patient’s condition to worsen.

Succinylcholine: increased and prolonged neuromuscular blockade (including respiratory depression).

**Patient monitoring**
- Assess patient’s response to each dose.
- Monitor vital signs, ECG, and cardiovascular and respiratory status.
- Assess for signs and symptoms of overdose, which indicate cholinergic crisis.

**Patient teaching**
- If patient is using syrup, advise him to pour it over ice.
- Instruct patient using extended-release tablets not to crush them.
- Teach patient to recognize and promptly report signs and symptoms of overdose, including muscle fasciculations, sweating, excessive salivation, and constricted pupils.
- Tell patient drug may cause headache and muscle cramps. Encourage him to discuss activity recommendations and pain management with prescriber.
- Advise patient to monitor and report his response to ongoing therapy so that optimal dosage can be determined.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

---

**Pyrimethamine**

Daraprim

**Pharmacologic class:** Folic acid antagonist

**Therapeutic class:** Antiprotozoal, antimalarial

**Pregnancy risk category C**

**Action**
Inhibits reduction of dihydrofolic acid to tetrahydrofolic acid (folinic acid) by binding to and reversibly inhibiting dihydrofolate reductase.

**Availability**

*Tablets: 25 mg*

**Indications and dosages**

- **To control plasmodia transmission and suppress susceptible strains**
  - **Adults and children ages 10 and older:**
    - 25 mg P.O. daily for 2 days, given with a sulfonamide
  - **Toxoplasmosis**
    - **Adults:** Initially, 50 to 75 mg P.O. daily for 1 to 3 weeks, given with a sulfonamide. Depending on response and tolerance, reduce dosages of both drugs by 50% and continue therapy for 4 to 5 more weeks.
    - **Children:** 1 mg/kg P.O. daily in two equally divided doses for 2 to 4 days, then reduced to 0.5 mg/kg/day for approximately 1 month. Alternatively, 2 mg/kg (up to 100 mg) P.O. daily in two equally divided doses for 3 days, then 1 mg/kg (up to 25 mg) in two equally divided doses for 4 weeks, given with sulfadiazine for 4 weeks.
  - **Prophylaxis of malaria caused by susceptible plasmodia strains**
    - **Adults and children older than age 10:**
      - 25 mg P.O. weekly
    - **Children ages 4 to 10:** 12.5 mg P.O. weekly
    - **Infants and children younger than age 4:** 6.25 mg P.O. weekly

**Off-label uses**
- Isosporiasis
- Prophylaxis of *Pneumocystis jiroveci* pneumonia

**Contraindications**
- Hypersensitivity to drug
- Megaloblastic anemia caused by folate deficiency
- Concurrent folic acid antagonist therapy

Reactions in **bold** are life-threatening.
Precautions
Use cautiously in:
- anemia, bone marrow depression, hepatic or renal impairment, G6PD deficiency
- history of seizures
- patients more than 16 weeks pregnant
- breastfeeding patients.

Administration
- Administer with meals.
- When giving tablets to young children, crush them and administer as oral suspension in water, cherry syrup, or sweetened solution.
- Know that because of worldwide resistance to pyrimethamine, its use alone to prevent or treat acute malaria is no longer recommended.
- Be aware that fixed combination of pyrimethamine and sulfadoxine is available and has been used for uncomplicated mild to moderate malaria caused by chloroquine-resistant *Plasmodium falciparum* and for presumptive self-treatment by travelers.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2-6 hr</td>
<td>2 wk</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, light-headedness, insomnia, malaise, depression, seizures
CV: arrhythmias
EENT: dry throat
GI: nausea, vomiting, diarrhea, anorexia, atrophic glossitis
GU: hematuria
Hematologic: megaloblastic anemia, leukopenia, pancytopenia, thrombocytopenia
Metabolic: hyperphenylalaninemia
Respiratory: pulmonary eosinophilia
Skin: pigmentation changes, dermatitis, erythema multiforme, toxic epidermal necrolysis, Stevens-Johnson syndrome
Other: fever, anaphylaxis

Interactions
Drug-drug. *Lorazepam:* hepatotoxicity
*Myelosuppressants (including antineoplastics):* increased risk of bone marrow depression
Drug-diagnostic tests. *Platelets, white blood cells:* decreased counts

Patient monitoring
- Monitor CBC. Watch for evidence of blood dyscrasias.
- Assess for signs and symptoms of folic acid deficiency.
- Closely monitor neurologic and cardiovascular status. Stay alert for seizures and arrhythmias.
- Watch for evidence of erythema multiforme, including sore throat, cough, mouth sores, rash, iritic lesions, and fever. Report early signs before condition can progress to Stevens-Johnson syndrome.

Patient teaching
- Advise patient to take with meals.
- Tell patient to discontinue drug and contact prescriber at first sign of rash.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.
**quetiapine fumarate**
Seroquel, Seroquel XR

*Pharmacologic class:* Dibenzothiazepine derivative  
*Therapeutic class:* Atypical antipsychotic  
*Pregnancy risk category C*

---

**FDA BOXED WARNING**

- Elderly patients with dementia-related psychosis are at increased risk for death. Over course of 10-week controlled trial, death rate in drug-treated patients was about 4.5%, compared to about 2.6% in placebo group. Although causes of death varied, most appeared to be cardiovascular or infectious. Don’t give drug to patients with dementia-related psychosis.  
- Drug may increase risk of suicidal thinking and behavior in children and adolescents with major depressive disorder and other psychiatric disorders. Risk must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family and caregivers to observe patient closely and communicate with prescriber as needed.  
- Drug isn’t approved for use in pediatric patients.

**Action**  
Unknown. Antipsychotic effects may occur through antagonism of dopamine D₂ and serotonin 5-HT₂ receptors. Other effects may result partly from antagonism of other receptors, such as histamine H₁ and alpha₁-adrenergic receptors.  

**Availability**  
*Tablets:* 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg  
*Tablets (extended-release):* 200 mg, 300 mg, 400 mg

**Indications and dosages**

- **Schizophrenia**  
  **Adults:** Initially, 25 mg P.O. b.i.d., increased by 25 to 50 mg given two to three times daily as tolerated over 3 days, up to 300 to 400 mg/day in two to three divided doses by day 4 (not to exceed 800 mg/day). Or, 300 mg P.O. (extended-release tablet) once daily, preferably in evening; dosage should be titrated to 400 to 800 mg based on response and tolerability. Dosage increases may be done at 1-day intervals at increments of up to 300 mg.  
- **Acute manic episodes associated with bipolar I disorder**  
  **Adults:** 100 mg on day 1, 200 mg on day 2, 300 mg on day 3, 400 mg on day 4, up to 600 mg on day 5, and up to 800 mg on day 6. Maximum daily dosage is 800 mg. May be given as monotherapy or as adjunctive therapy with lithium or divalproex.  
- **Depression associated with bipolar disorder**  
  **Adults:** Day 1, 50 mg P.O.; day 2, 100 mg P.O.; day 3, 200 mg P.O.; day 4, 300 mg P.O.

**Dosage adjustment**

- Hepatic impairment  
- History of hypotensive reactions  
- Elderly or debilitated patients

**Off-label uses**

- Bipolar disorder  
- Mania  
- Obsessive-compulsive disorder  
- Posttraumatic stress disorder  
- Psychosis related to Parkinson’s disease

Reactions in **bold** are life-threatening.
Contraindications
- Hypersensitivity to drug or its components

Precautions
Use cautiously in:
- diabetes mellitus, hepatic impairment, cardiovascular or cerebrovascular disease, dehydration, hypovolemia, Alzheimer’s dementia, hypothyroidism
- history of seizures, suicide attempt, or hypotensive reactions
- elderly or debilitated patients
- pregnant patients
- children (safety not established).

Administration
- Give immediate-release tablets with or without food; give extended-release tablets without food or with a light meal.

Don’t confuse Seroquel with Serzone (an antidepressant).

Route Onset Peak Duration
P.O. Rapid 1.5 hr 8-12 hr

Adverse reactions
CNS: dizziness, sedation, cognitive impairment, extrapyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome, seizures
CV: palpitations, peripheral edema, orthostatic hypotension
EENT: cataracts, ear pain, rhinitis, pharyngitis
GI: constipation, dyspepsia, dry mouth, anorexia
Hematologic: leukopenia
Respiratory: cough, dyspnea
Skin: diaphoresis
Other: weight gain, flulike symptoms

Interactions
Drug-drug. Antihistamines, opioids, sedative-hypnotics, other CNS depressants: additive CNS depression
Antihypertensives: increased risk of hypotension
Barbiturates, carbamazepine, corticosteroids, phenytoin, rifampin, thioridazine: increased clearance and decreased efficacy of quetiapine
Dopamine agonists, levodopa: antagonism of these drugs’ effects
Erythromycin, fluconazole, itraconazole, ketoconazole, other CYP450-3A4 inhibitors: increased quetiapine effects

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase: asymptomatic elevations
Total cholesterol, triglycerides: increased levels
Urine tricyclic antidepressant assay: false-positive screen
White blood cells: decreased count

Drug-behaviors. Alcohol use: increased CNS effects

Patient monitoring
- Monitor neurologic status, especially for signs and symptoms of tardive dyskinesia or neuroleptic malignant syndrome.
- Be aware that patient should undergo lens examination when starting treatment and at 6-month intervals during long-term treatment.
- Monitor blood pressure for orthostatic hypertension.

Patient teaching
- Tell patient he can take immediate-release tablets with or without food and to take extended-release form without food or with a light meal.
- Instruct patient not to crush, break, or chew extended-release tablets.
- Teach patient to recognize and immediately report signs and symptoms of neuroleptic malignant syndrome (such as high fever, sweating, unstable blood pressure, stupor, muscle rigidity, and tardive dyskinesia).
- Instruct patient to move slowly when sitting up or standing, to avoid dizziness from sudden blood pressure decrease.
- Tell patient not to stop taking drug abruptly. Tell him dosage must be tapered.
Caution patient not to drink alcohol.
Instruct patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

### quinapril hydrochloride
**Accupril, Accupro®, Quinil®**

**Pharmacologic class:** Angiotensin-converting enzyme (ACE) inhibitor  
**Therapeutic class:** Antihypertensive  
**Pregnancy risk category C** (first trimester), **D** (second and third trimesters)

**FDA BOXED WARNING**
- When used during second or third trimester of pregnancy, drug may cause fetal harm or death. Discontinue as soon as pregnancy is detected.

**Action**
Inhibits conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; decreases cardiac output. Increases plasma renin levels and reduces aldosterone levels, causing systemic vasodilation.

**Availability**
*Tablets:* 5 mg, 10 mg, 20 mg, 40 mg

**Indications and dosages**
- **Hypertension**
  - **Adults:** Initially, 10 to 20 mg P.O. daily for patients not receiving diuretics, with subsequent dosages adjusted at 2-week intervals according to blood pressure response at peak (2 to 6 hours) and trough (predose) blood levels; for maintenance, 20 to 80 mg/day as a single dose or in two divided doses. In patients receiving diuretics, discontinue diuretic 2 to 3 days before starting quinapril; if blood pressure isn’t controlled, resume diuretic. If diuretic can’t be discontinued, start therapy with 5 mg/day quinapril.
  - Adjunct in heart failure
  - **Adults:** Initially, 5 mg P.O. b.i.d., titrated weekly until effective dosage is determined. For maintenance, 20 to 40 mg/day in two evenly divided doses.

**Dosage adjustment**
- Renal impairment
- Elderly patients

**Off-label uses**
- Aortic insufficiency
- Atherosclerosis
- Postoperative hypertension
- Myocardial infarction
- Diabetic or nondiabetic neuropathy

**Contraindications**
- Hypersensitivity to drug or other ACE inhibitors
- Angioedema caused by other ACE inhibitors
- Pregnancy (second and third trimesters)

**Precautions**
Use cautiously in:
- autoimmune diseases, aortic stenosis, renal artery stenosis, hypertrophic cardiomyopathy, cerebrovascular or cardiac insufficiency, collagen vascular disease, hepatic or renal impairment, hypovolemia, hyponatremia, hypotension, neutropenia, chronic cough, proteinuria, febrile illness
- family history of angioedema
- concurrent immunosuppressant or diuretic therapy

Reactions in **bold** are life-threatening.
● black patients
● elderly patients
● pregnant (first trimester) or breastfeeding patients
● children (safety not established).

Administration
● Administer with or without food, but not with high-fat meal.
● Know that if quinapril alone doesn’t adequately control blood pressure, a diuretic may be added.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>0.5-1 hr</td>
<td>2-6 hr</td>
<td>Up to 24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, drowsiness, fatigue, headache, insomnia, depression, vertigo, paresthesia, asthenia, malaise, nervousness, syncope
CV: hypotension, angina pectoris, palpitations, chest pain, tachycardia,
arrhythmias
EENT: amblyopia, sinusitis, pharyngitis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, anorexia, dry mouth
GU: erectile dysfunction
Metabolic: hyperkalemia
Musculoskeletal: back pain
Respiratory: cough, dyspnea
Skin: rash, pruritus, alopecia, flushing, diaphoresis, photosensitivity
Other: taste disturbances, fever, viral infections, hypersensitivity reactions including anaphylaxis

Interactions
Drug-drug. Allopurinol: increased risk of hypersensitivity reactions
Antacids: decreased quinapril absorption
Digoxin, lithium: increased blood levels and risk of toxicity of these drugs
Diuretics, other antihypertensives: increased hypotension
Indomethacin: decreased hypertensive effect of quinapril
Phenothiazines: increased pharmacologic effect of quinapril

Potassium-sparing diuretics, potassium supplements: increased risk of hyperkalemia
Tetracyclines: decreased tetracycline absorption

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, potassium: increased levels

Drug-food. High-fat foods: decreased rate and extent of drug absorption
Salt substitutes containing potassium: increased risk of hyperkalemia

Drug-herbs. Capsaicin: increased incidence of cough
Ephedra (ma huang): decreased drug efficacy, exacerbation of hypertension
Yohimbe: interference with drug’s antihypertensive effect

Drug-behaviors. Alcohol use: increased hypotension

Patient monitoring
● Monitor vital signs and cardiovascular status. Be sure to ask patient if he’s experiencing angina.
● Assess CBC and liver function tests.
● Monitor potassium level. Watch for evidence of hyperkalemia.

Watch closely for signs and symptoms of angioedema, especially in black patients after first dose.
● Assess for dry, nonproductive cough and signs and symptoms of infection.

Patient teaching
● Tell patient he may take with or without food, but not with high-fat meal.

Advise patient to immediately report facial or tongue swelling or difficulty breathing.
● Instruct patient to monitor and record his blood pressure.
● Tell patient to promptly report dry, nonproductive cough and signs and symptoms of infection.
● Instruct patient to move slowly when sitting up or standing, to avoid
dizziness or light-headedness from sudden blood pressure decrease.
- Tell patient that excessive fluid loss (as from sweating, vomiting, or diarrhea) and inadequate fluid intake increase the risk of light-headedness (especially in hot weather).
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Advise patient to avoid herbal products and salt substitutes containing potassium.
- Tell female patient to notify prescriber of possible pregnancy. Caution her not to breastfeed.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

---

**Quinidine Gluconate**

Apo-Quin-G

**Quinidine Sulfate**

Apo-Quinidine

**Pharmacologic class:** Cinchona alkaloid

**Therapeutic class:** Antiarrhythmic (class IA), antimalarial

**Pregnancy risk category C**

---

**FDA BOXED WARNING**

- In many trials of antiarrhythmic therapy for non-life-threatening arrhythmias, active antiarrhythmic therapy has led to increased deaths; risk of active therapy is probably greatest in patients with structural heart disease. Deaths associated with quinidine were more than three times as high as deaths in placebo group. Another analysis showed that in patients with non-life-threatening ventricular arrhythmias, quinidine-associated deaths were consistently higher than those linked to various alternative antiarrhythmics.

---

**Action**

Slows conduction and prolongs refractory period, reducing myocardial irritability and interrupting or preventing certain arrhythmias. As an antimalarial, acts primarily as intra-erythrocytic schizonticide.

**Availability**

**Quinidine Gluconate**  
Injection: 80 mg/ml  
Tablets (extended-release): 324 mg

**Quinidine Sulfate**  
Tablets: 200 mg, 300 mg  
Tablets (extended-release): 300 mg

---

**Indications and dosages**

- **Test dose**  
  **Adults:** 200 mg sulfate P.O. as a single dose or 200 mg gluconate I.M. to check for idiosyncratic reaction

- **Premature atrial and ventricular contractions**  
  **Adults:** 200 to 300 mg sulfate P.O. three to four times daily, or gluconate (extended-release) given as 324 to 660 mg P.O. q 8 to 12 hours

- **Paroxysmal supraventricular tachycardia (PSVT)**  
  **Adults:** 400 to 600 mg sulfate P.O. q 2 or 3 hours until arrhythmia ends; or 324 to 660 mg (extended-release) P.O. q 8 to 12 hours. For parenteral use, 400 mg gluconate I.M., repeated q 2 hours if necessary; or 330 mg gluconate I.V. (up to 750 mg) in diluted solution, infused no faster than 1 ml/minute.

- **To convert atrial fibrillation to sinus rhythm**  
  **Adults:** 200 mg sulfate P.O. q 2 or 3 hours for five to eight doses,

Reactions in **bold** are life-threatening.
increased daily until sinus rhythm returns or toxic effects occur; maximum daily dosage is 4 g. Or 300 mg sulfate (extended-release) P.O. q 8 to 12 hours, increased cautiously if necessary. Or 324 to 660 mg gluconate (extended-release) P.O. q 8 to 12 hours. For parenteral use, 800 mg gluconate I.V. in diluted solution, infused no faster than 0.25 mg/kg/minute.

Severe, life-threatening Plasmodium falciparum malaria

Adults: Loading dose of 10 mg/kg gluconate I.V. diluted in 5 ml/kg of normal saline solution (or 250 ml of normal saline solution in otherwise healthy, 50-kg [110-lb] patient) by continuous infusion over 1 to 2 hours, then a continuous maintenance infusion of 0.02 mg/kg/minute for 72 hours or until parasitemia drops to less than 1% or oral therapy can begin. Or alternative loading dose of 24 mg/kg gluconate I.V. diluted in 250 ml of 0.9% sodium chloride injection by intermittent infusion over 4 hours, followed by maintenance dosage of 12 mg/kg gluconate I.V. at 8-hour intervals, starting 8 hours after loading dose, infused over 4 hours for 7 days or until patient tolerates oral therapy.

Dosage adjustment
- Hepatic insufficiency

Off-label uses
- Myocardial infarction

Contraindications
- Hypersensitivity to drug or related cinchona derivatives
- Thrombocytopenia with previous quinidine therapy
- Myasthenia gravis
- Complete heart block
- Left bundle-branch block or other severe intraventricular conduction defects
- Aberrant ectopic impulses and abnormal rhythm
- History of prolonged QT interval or drug-induced torsades de pointes
- Digoxin toxicity

Precautions
Use cautiously in:
- potassium imbalance, renal or hepatic disease, heart failure, respiratory depression
- elderly patients
- pregnant or breastfeeding patients
- children.

Administration
Before first dose, assess apical pulse and blood pressure. If patient has bradycardia or tachycardia, withhold dose and contact prescriber.
- If patient has atrial fibrillation, expect to give digoxin, calcium channel blocker, beta-adrenergic blocker, and possibly an anticoagulant before administering quinidine.
- If sinus rhythm isn’t restored after patient has received a total of 10 mg/kg quinidine gluconate, other means of cardioversion may be considered.
- Monitor blood pressure and ECG; titrate flow rate to correct arrhythmia.
- When giving large doses, monitor blood pressure and ECG continuously.
- Know that quinidine gluconate is the only parenteral cinchona alkaloid antimalarial commercially available in U.S. Because newer antiarrhythmics have replaced quinidine in many cardiac uses, it may not be readily available and prescribers may not be familiar with its use. For information about availability or use, contact manufacturer at 800-821-0538.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O. (extended)</td>
<td>Unknown</td>
<td>3-5 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>P.O. (sulfate)</td>
<td>Unknown</td>
<td>1-3 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>Immediate</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.M.</td>
<td>30-90 sec</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>
Adverse reactions

CNS: vertigo, headache, ataxia, apprehension, excitement, delirium, syncope, confusion, depression, dementia
CV: ECG changes, hypotension, vasculitis, tachycardia, premature ventricular contractions, paradoxical tachycardia, ventricular tachycardia, ventricular fibrillation, ventricular flutter, ventricular ectopy, torsades de pointes, complete atrioventricular (AV) block, widened QRS complex, prolonged QT interval, asystole, aggravated heart failure, arterial embolism, vascular collapse
EENT: diplopia, blurred vision, mydriasis, abnormal color perception, scotoma, photophobia, night blindness, optic neuritis, decreased hearing, tinnitus
GI: nausea, vomiting, diarrhea, abdominal pain, increased salivation, anorexia
GU: lupus nephritis
Hematologic: purpura, hemolytic anemia, hypothrombinemia, leukocytosis, shift to left in white blood cell differential, neutropenia, thrombocytopenia, thrombocytopenic purpura, agranulocytosis
Hepatic: hepatotoxicity
Respiratory: acute asthma attack, respiratory arrest
Skin: rash, pruritus, urticaria, photosensitivity, angioedema
Other: fever, cinchonism, lupus-like syndrome, hypersensitivity reaction

Drug-food. Grapefruit juice: inhibited drug metabolism
Reduced sodium intake: increased quinidine blood level

Drug-herbs. Jimsonweed: adverse cardiovascular effects
Licorice: additive effects

Drug-diagnostic tests. Granulocytes, hemoglobin, platelets: decreased levels
Creatine kinase, hepatic enzymes: increased levels
Renal function tests: altered results

Interactions

Drug-drug. Amiodarone: increased quinidine blood level, causing potentially fatal arrhythmias
Antacids, cimetidine: increased quinidine blood level
Anticholinergics: additive vagolytic effect
Anticoagulants, beta-adrenergic blockers, procainamide, propafenone, tricyclic antidepressants: increased effects of these drugs
Barbiturates, hydantoins, nifedipine, rifampin, sucralfate: decreased therapeutic effect of quinidine
Cardiac glycosides: increased cardiac glycoside blood level, greater risk of toxicity
Cholinergics: decreased quinidine effect (may cause failure to terminate PSVT)
Depolarizing (decamethonium, succinylcholine) and nondepolarizing (tubocurarine, pancuronium) neuromuscular blockers: potentiation of neuromuscular blockade
Diltiazem, verapamil: decreased quinidine clearance, resulting in hypotension, bradycardia, ventricular tachycardia, AV block, or pulmonary edema
Disopyramide: increased disopyramide or decreased quinidine blood level
Potassium, urinary alkalizers: increased blood level and effects of quinidine

Patient monitoring

Monitor ECG and vital signs closely. Assess for worsening heart failure, especially with I.V. use.
Assess CBC, kidney and liver function tests and quinidine blood level.
Watch for signs and symptoms of blood dyscrasias.
Closely monitor respiratory status. Stay alert for asthma attacks and impending respiratory arrest.
Monitor for adverse GI effects, which may signify drug toxicity.
Patient teaching
● Advise patient to take with food to reduce GI upset.
● Instruct patient not to crush or chew extended-release tablets.
● Teach patient to recognize and immediately report signs and symptoms of toxicity, including tinnitus, nausea, headache, dizziness, and visual disturbances.
● Caution patient to avoid potassium supplements, licorice, and grapefruit juice. Tell him to maintain constant level of sodium intake.
● Advise patient to consult prescriber before taking herbs.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

quinine sulfate
Apo-Quinine®, Novo-Quinine®

Pharmacologic class: Cinchona alkaloid
Therapeutic class: Antimalarial
Pregnancy risk category X

Action
Unknown. Thought to interfere with DNA synthesis by increasing pH in intracellular organelles of susceptible parasites.

Availability
Capsules: 200 mg, 325 mg
Tablets: 260 mg

Indications and dosages
➣ Chloroquine-resistant Plasmodium falciparum malaria
Adults: 650 mg P.O. q 8 hours for 3 to 7 days, given with another oral antimalarial

Children: 10 mg/kg P.O. q 8 hours for 7 days, given with another oral antimalarial

Off-label uses
● Nocturnal recumbency leg cramps

Contraindications
● Hypersensitivity to drug or other cinchona alkaloids
● G6PD deficiency
● Optic neuritis
● Tinnitus
● History of blackwater fever or thrombocytopenic purpura
● Pregnancy

Precautions
Use cautiously in:
● myasthenia gravis, recurrent or interrupted malaria therapy
● history of arrhythmias (especially prolonged QT interval), asthma, or heart disease
● breastfeeding patients.

Administration
● Give with or without food.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1-3 hr</td>
<td>4-11 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, vertigo, syncope, apprehension, restlessness, excitement, confusion, delirium, dizziness, seizures
CV: angina, vasculitis
EENT: diplopia, amblyopia, blurred vision, scotoma, abnormal color perception, photophobia, night blindness, mydriasis, optic atrophy, hearing loss, tinnitus
GI: nausea, vomiting, diarrhea, abdominal cramps, epigastric pain, dysphagia
Hematologic: hemolytic anemia, hypoprothrombinemia, acute hemolysis, thrombocytopenic purpura, agranulocytosis
Hepatic: hepatotoxicity
Metabolic: hypothermia, hypoglycemia

Canada  UK  Hazardous drug  High alert drug
**Respiratory:** asthma  
**Skin:** rash, pruritus, photosensitivity, flushing, diaphoresis  
**Other:** cinchonism, facial edema, hypersensitivity reactions including fever and hemolytic uremic syndrome

**Interactions**  
**Drug-drug.** *Aluminum-containing antacids:* delayed or decreased quinine absorption  
*Cimetidine:* decreased metabolism and increased effects of quinine  
*Digoxin:* increased digoxin blood level  
*Mefloquine:* increased risk of seizures, ECG abnormalities, and cardiac arrest  
*Nevromuscular blockers:* increased effects of these drugs, leading to respiratory difficulty  
*Rifabutin, rifampin:* increased metabolism and decreased effects of quinine  
*Succinylcholine:* delayed succinylcholine metabolism  
*Urinary alkalinizers (such as acetazolamide, sodium bicarbonate):* increased quinine blood level and risk of toxicity  
*Warfarin:* increased warfarin effects, increased risk of bleeding

**Drug-diagnostic tests.** *Urinary 17-ketogenic steroids:* elevated levels

**Patient monitoring**  
- Monitor for signs and symptoms of hypersensitivity reaction, including fever and hemolytic uremic syndrome.  
- Stay alert for signs and symptoms of cinchonism, including tinnitus, headache, nausea, and visual disturbances.  
- Assess for bleeding tendency and hepatotoxicity.  
- Monitor CBC, liver function tests, and quinine and glucose levels.  
- Monitor patient for recumbency leg cramps. After several nights without such cramps, drug may be withdrawn.

**Patient teaching**  
- Tell patient he may take with or without food.

---

### quinupristin and dalfopristin

**Synercid**

**Pharmacologic class:** Streptogramin  
**Therapeutic class:** Anti-infective  
**Pregnancy risk category B**

**FDA BOXED WARNING**

- Drug combination is approved for treating serious or life-threatening infections related to vancomycin-resistant Enterococcus faecium bacteremia under the Food and Drug Administration's accelerated approval regulations that allow marketing of products for use in life-threatening conditions when other therapies aren’t available.

**Action**  
Synergistic effects of drug combination interfere with bacterial cell-wall synthesis by disrupting DNA and RNA transcription

**Availability**  
*Injection:* 500 mg/10 ml (150 mg quinupristin, 350 mg dalfopristin), 600 mg/10 ml (180 mg quinupristin, 420 mg dalfopristin)

Reactions in **bold** are life-threatening.  
- **Clinical alert**
Indications and dosages

➣ Serious or life-threatening infections caused by vancomycin-resistant Enterococcus faecium
Adults and adolescents ages 16 and older: 7.5 mg/kg by I.V. infusion over 1 hour q 8 hours

➣ Complicated skin and skin-structure infections caused by Staphylococcus aureus (methicillin-susceptible) or Streptococcus pyogenes
Adults and adolescents ages 16 and older: 7.5 mg/kg by I.V. infusion over 1 hour q 12 hours for at least 7 days

Dosage adjustment

● Hepatic impairment

Contraindications

● Hypersensitivity to drug or other streptogramins

Precautions

Use cautiously in:
● hepatic impairment
● breastfeeding patients
● children younger than age 16 (safety and efficacy not established).

Administration

่า Don’t mix with other drugs or saline solution.

● For intermittent infusion through a common I.V. line, flush line with dextrose 5% in water (D5W) before and after giving drug.
● Add 5 ml of sterile water or D5W to powdered drug in vial, and swirl gently by hand until powder dissolves; don’t shake vial. Solution should be clear.
● Within 30 minutes of first dilution, draw up prescribed dosage and dilute further in D5W to a final concentration of 2 mg/ml or less.
● Know that if patient has a central venous catheter and is fluid-restricted, drug may be given in 100 ml of D5W.
● Administer by infusion pump over 60 minutes.

● If significant peripheral vein irritation occurs, dilute in 500 to 750 ml of D5W.
● Be aware that duration of therapy depends on infection site and severity.

Route Onset Peak Duration
I.V. Unknown Unknown Unknown

Adverse reactions

CNS: headache
CV: thrombophlebitis
GI: nausea, vomiting, diarrhea
Musculoskeletal: joint pain, myalgia
Skin: rash, pruritus
Other: inflammation, pain, or edema at infusion site

Interactions

Drug-drug. Drugs metabolized by CYP450-3A4 (antiretrovirals; antineoplastics, such as vinca alkaloids, docetaxel, and paclitaxel; astemizole; benzodiazepines; calcium channel blockers; carbamazepine; cisapride; corticosteroids; disopyramide; HMG-CoA reductase inhibitors; immunosuppressants such as cyclosporine and tacrolimus; lidocaine; quinidine; terfenadine): increased therapeutic and adverse effects of these drugs

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, bilirubin: increased levels

Patient monitoring

● Monitor closely for infusion site reactions and thrombophlebitis. If these problems occur, consider increasing infusion volume, changing infusion site, or infusing through peripherally inserted central catheter or central venous catheter.
● Assess weight and fluid intake and output to help detect edema.
● Monitor bilirubin level.

Patient teaching

่า Instruct patient to immediately report pain or redness at infusion site.
● Tell patient to report muscle aches and pains.
As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**rabeprazole sodium**
AcipHex, Novo-Rabeprazole®, Pariet®, PMS-Rabeprazole®, Ran-Rabeprazole®

**Pharmacologic class:** Proton pump inhibitor

**Therapeutic class:** Gastric anti-secretory agent

**Pregnancy risk category B**

**Action**
Reduces gastric acid secretion and increases gastric mucus and bicarbonate production, creating a protective coating on gastric mucosa.

**Availability**
*Tablets (delayed-release):* 20 mg

**Indications and dosages**

- **Erosive or ulcerative gastroesophageal reflux disease (GERD)**
  - **Adults:** 20 mg P.O. daily for 4 to 8 weeks. If healing doesn’t occur within 8 weeks, another 8 weeks of therapy may be considered. Maintenance dosage is 20 mg P.O. daily.

- **GERD**
  - **Adults:** 20 mg P.O. daily for 4 weeks. If symptoms don’t resolve after 4 weeks, another course of therapy may be considered.

- **Hypersecretory conditions, including Zollinger-Ellison syndrome**
  - **Adults:** Initially, 60 mg P.O. daily; adjust dosage as needed up to 100 mg P.O. daily as a single dose or 60 mg P.O. b.i.d. Maximum daily dosage is 120 mg.

- **Duodenal ulcer**

- **Adults:** 20 mg P.O. daily for up to 4 weeks

- **Helicobacter pylori eradication**

- **Adults:** 20 mg P.O. b.i.d. for 7 days (given with amoxicillin and clarithromycin)

**Off-label uses**
- Dyspepsia
- Benign gastric ulcer

**Contraindications**
- Hypersensitivity to drug, its components, or benzimidazoles

**Precautions**
- Use cautiously in:
  - severe hepatic impairment
  - pregnant patients
  - breastfeeding patients (not recommended)
  - children (safety not established).

**Administration**
- Don’t crush or split tablets.
- Give without regard to food.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Within 1 hr</td>
<td>Unknown</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- **CNS:** headache

**Interactions**

- **Drugs.** Gastric pH–dependent drugs (such as digoxin, ketoconazole): increased or decreased absorption
- **Warfarin:** increased risk of bleeding

**Patient monitoring**
- Stay alert for symptomatic response, but know that a positive response doesn’t rule out gastric cancer.

**Patient teaching**
- Tell patient he may take with or without food. Instruct him not to crush, chew, or split tablets.

Reactions in **bold** are life-threatening.
Caution female patient not to breastfeed during therapy.
As appropriate, review all significant adverse reactions and interactions, especially those related to the drugs mentioned above.

raloxifene
Evista

**Pharmacologic class:** Nonsteroidal benzothiophene derivative

**Therapeutic class:** Selective estrogen receptor modulator, bone resorption inhibitor

**Pregnancy risk category X**

**Action**
Binds to estrogen receptors, activating estrogen pathways and increasing bone mineral density. These effects decrease bone resorption and turnover.

**Availability**
*Tablets:* 60 mg

**Indications and dosages**
- Treatment and prevention of osteoporosis in postmenopausal women; reduction of invasive breast cancer risk in postmenopausal women with osteoporosis; reduction of invasive breast cancer risk in postmenopausal women at high risk for invasive breast cancer
- **Adults:** 60 mg P.O. daily

**Off-label uses**
- Prophylaxis of cardiovascular disease

**Contraindications**
- Hypersensitivity to drug or its components
- History of thromboembolic events
- Premenopausal women
- Females of childbearing age
- Pregnancy or breastfeeding
- Children

**Precautions**
Use cautiously in:
- altered lipid metabolism, hepatic dysfunction
- concurrent estrogen therapy (use not recommended)
- immobilized patients and others at increased risk for thromboembolic events.

**Administration**
- Give with or without food.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>6 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: depression, insomnia, vertigo, syncope, hypoesthesia, migraine, neuralgia

CV: chest pain, peripheral edema, varicose veins, deep-vein thrombosis, thrombophlebitis

EENT: conjunctivitis, sinusitis, rhinitis, pharyngitis, laryngitis

GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia, flatulence, gastroenteritis

GU: urinary tract infection or disorder, cystitis, vaginitis, leukorrhea, endometrial disorder, vaginal hemorrhage

Musculoskeletal: leg cramps, joint pain, myalgia, arthritis, tendon disorder

Respiratory: cough, pneumonia, bronchitis, pulmonary embolism

Skin: rash, diaphoresis

Other: weight gain, hot flashes, infection, pain, flu-like symptoms

**Interactions**

Drug-drug. *Cholestyramine:* reduced raloxifene absorption

*Highly protein-bound drugs (such as diazepam, diazoxide, lidocaine):* interference with binding of these drugs
Warfarin: decreased prothrombin time

**Drug-diagnostic tests.** Albumin, apolipoprotein B, calcium, fibrinogen, inorganic phosphate, low-density lipoproteins, platelets, protein, total cholesterol: decreased levels

Apolipoprotein A1; corticosteroid-binding, sex steroid–binding, and thyroid-binding globulin: increased levels

**Patient monitoring**
- Watch for thromboembolic events, especially during first 4 months of therapy.
- Stay alert for other adverse effects, particularly leg cramps, other musculoskeletal complaints, and respiratory disorders.
- Assess bone mineral density test results.
- Monitor for unexplained vaginal bleeding.

**Patient teaching**
- Tell patient she may take with or without food.
- Instruct patient to read package insert before starting drug and then periodically.
- Teach patient to recognize and immediately report symptoms of blood clots.
- Instruct patient to stop taking drug 3 days before anticipated period of prolonged immobility, and to restart it only after she regains normal mobility.
- Tell patient that drug may cause hot flashes, but that these are normal effects.
- Advise patient to report unexplained vaginal bleeding or leg cramps.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

---

**raltegravir**

**Isentress**

**Pharmacologic class:** Human immunodeficiency virus (HIV) integrase-strand transfer inhibitor

**Therapeutic class:** Antiretroviral

**Pregnancy risk category C**

**Action**
Rapidly blocks HIV integrase (enzyme needed for HIV replication), leading to viral load reduction and increased CD4+ count

**Availability**
Tablets: 400 mg

**Indications and dosages**
- HIV-1 infection in treatment-experienced adults with evidence of viral replication and HIV-1 strains resistant to multiple antiretrovirals, used in combination with other antiretrovirals

**Adults:** 400 mg P.O. b.i.d.

**Contraindications**
None

**Precautions**
Use cautiously in:
- treatment-naive adults (safety and efficacy not established)
- increased risk of myopathy or rhabdomyolysis (such as with concomitant use of drugs known to cause these conditions)
- elderly patients
- pregnant patients
- breastfeeding patients (use not recommended)
- children younger than age 16 (safety and efficacy not established).

**Administration**
- Administer with or without food.
**Adverse reactions**

CNS: headache, fatigue, asthenia, dizziness
CV: myocardial infarction
GI: nausea, vomiting, diarrhea, abdominal pain, gastritis
GU: toxic nephropathy, renal failure, renal tubular necrosis
Hematologic: anemia, neutropenia
Hepatic: hepatitis
Musculoskeletal: myopathy, rhabdomyolysis
Skin: lipodystrophy
Other: fever, herpes simplex, immune reconstitution syndrome, hypersensitivity reaction

**Interactions**

Drug-drug. **Strong UGT1A1 inducers (such as rifampin):** reduced raltegravir blood level

**UGT1A1 inhibitors (such as atazanavir):** increased raltegravir blood level

Drug-diagnostic tests. **Absolute neutrophil count, hemoglobin, platelets:** decreased levels

ALP, ALT, AST, blood glucose, creatine kinase, lipase, pancreatic enzymes, total bilirubin: increased levels

**Patient monitoring**

- Monitor renal function tests.
- Be aware that immune reconstitution syndrome has occurred in patients receiving drug with combination antiretroviral therapy. During initial phase of therapy, patient whose immune system responds may develop inflammatory response to indolent or residual opportunistic infections (such as *Mycobacterium avium* complex, cytomegalovirus, *Pneumocystis jiroveci* pneumonia, or tuberculosis), which may necessitate further evaluation and treatment.

**Patient teaching**

- Tell patient drug may be taken with or without food.
- Inform patient that drug doesn’t cure HIV infection or reduce risk of passing it to others through sexual contact, needle sharing, or blood exposure.
  - Advise patient to immediately report muscle weakness, urinary problems, new infections, or chest pain.
- Instruct female patient to notify prescriber if she is pregnant or intends to become pregnant.
- Caution breastfeeding patient to discontinue breastfeeding while taking drug, because of potential HIV transmission and adverse reactions in infants.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

---

**ramelteon**

Rozerem

*Pharmacologic class:* Melatonin receptor agonist

*Therapeutic class:* Hypnotic

*Pregnancy risk category C*

**Action**

Promotes sleep through activity at melatonin MT₁ and MT₂ receptors, which are thought to be involved in maintaining circadian rhythm underlying normal sleep-wake cycle

**Availability**

*Tablets:* 8 mg

**Indications and dosages**

- Insomnia marked by difficulty with sleep onset

**Adults:** 8 mg P.O. within 30 minutes of going to bed
Contraindications
- Hypersensitivity to drug or its components

Precautions
Use cautiously in:
- sleep apnea, chronic obstructive pulmonary disease, hepatic impairment
- concurrent use of fluvoxamine
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

Administration
- Give within 30 minutes of patient’s bedtime.
- Don’t give with or immediately after a high-fat meal.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>0.5-1.5 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, somnolence, fatigue, dizziness, exacerbated insomnia, depression
GI: nausea, diarrhea
Musculoskeletal: myalgia, arthralgia
Respiratory: upper respiratory tract infection
Other: altered taste, influenza

Interactions
Drug-drug: Fluconazole, fluvoxamine, ketoconazole: increased ramelteon blood level
Rifampin: decreased ramelteon efficacy

Drug-diagnostic tests. Blood cortisol: decreased

Drug-food. High-fat meals: altered ramelteon absorption

Drug-herbs. American elder, bishop’s weed, cat’s claw, devil’s claw, eucalyptus, feverfew, ginkgo, kava, licorice, pomegranate: increased ramelteon blood level
Valerian: additive sedation, increased ramelteon blood level

Drug-behaviors. Alcohol use: additive psychomotor impairment

Patient monitoring
- Monitor prolactin and testosterone levels, if ordered, in patient who develops unexplained amenorrhea, galactorrhea, decreased libido, or fertility problems.
- Evaluate patient for physical and psychiatric disorders before and during therapy. Worsening of insomnia or onset of new behavioral or cognitive symptoms could signal underlying psychiatric disorder.

Patient teaching
- Instruct patient to take drug within 30 minutes of going to bed.
- Advise patient not to take drug with or immediately after a high-fat meal.
- Caution patient to avoid driving and other hazardous activities until drug effects are known.
- Advise patient to contact prescriber if insomnia worsens.
- Instruct patient to report menses cessation, excessive or spontaneous lactation, decreased libido, or fertility problems.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, food, herbs, and behaviors mentioned above.

ramipril
Altace, Apo-Ramipril®, Co Ramipril®, Lopace®, Novo-Ramipril®, Ratio-Ramipril®, Sandoz Ramipril®, Tritace®

Pharmacologic class: Angiotensin-converting enzyme (ACE) inhibitor
Therapeutic class: Antihypertensive
Pregnancy risk category C (first trimester), D (second and third trimesters)
**FDA BOXED WARNING**

- When used during second or third trimester of pregnancy, drug may cause fetal harm or death. Discontinue as soon as pregnancy is detected.

**Action**

Inhibits conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. Increases plasma renin levels and reduces aldosterone levels, causing systemic vasodilation and decreased cardiac output.

**Availability**

*Capsules:* 1.25 mg, 2.5 mg, 5 mg, 10 mg

**Indications and dosages**

- **Hypertension**
  - **Adults:** Initially, 2.5 mg P.O. daily in patients not receiving diuretics; may increase dosage slowly p.r.n. according to response. For maintenance, 2.5 to 20 mg/day P.O. as a single dose or in two equally divided doses. If ramipril alone doesn’t control blood pressure, a diuretic may be added.
  - **To reduce the risk of myocardial infarction (MI), cerebrovascular accident, or death from cardiovascular causes**
    - **Adults:** Initially, 2.5 mg P.O. daily for 1 week, followed by 5 mg P.O. daily for the next 3 weeks, then increased as tolerated to a maintenance dosage of 10 mg P.O. daily. In hypertensive patients and those who’ve had a recent MI, may divide maintenance dose.
  - **Heart failure after MI**
    - **Adults:** Initially, 2.5 mg P.O. b.i.d.; may decrease to 1.25 mg b.i.d. if higher dosage causes hypotension. Titrate toward target dosage of 5 mg b.i.d. at 3-week intervals.

**Dosage adjustment**

- Renal impairment
- Concurrent diuretic use

**Off-label uses**

- Angina associated with syndrome X
- Atherosclerosis
- Mitral insufficiency
- Renovascular hypertension
- Diabetic or nondiabetic nephropathy
- Erythrocytosis

**Contraindications**

- Hypersensitivity to drug or other ACE inhibitors
- Angioedema with previous ACE inhibitor use
- Pregnancy (second and third trimesters)

**Precautions**

Use cautiously in:

- autoimmune diseases, aortic stenosis, hypertrophic cardiomyopathy, cerebrovascular or cardiac insufficiency, collagen vascular disease, febrile illness, hepatic or renal impairment, hypotension, neutropenia, chronic cough, proteinuria, renal artery stenosis
- family history of angioedema
- concurrent immunosuppressant or diuretic therapy
- black patients
- elderly patients
- pregnant (first trimester) or breastfeeding patients
- children (safety not established).

**Administration**

- If possible, discontinue diuretics 2 to 3 days before ramipril therapy begins to prevent severe hypotension.
- If patient can’t swallow capsule, open it and mix contents in water or apple juice or sprinkle in small amount of applesauce.
- Know that drug may be used alone or with other antihypertensives.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1-2 hr</td>
<td>2-4 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>
Adverse reactions
CNS: dizziness, light-headedness, fatigue, headache, vertigo, asthenia
CV: hypotension, orthostatic hypotension, angina pectoris, tachycardia, MI, heart failure
EENT: blurred vision, sinusitis
GI: nausea, vomiting, diarrhea
Hematologic: purpura, agranulocytosis
Metabolic: hyperkalemia
Musculoskeletal: muscle cramps
Respiratory: cough, asthma, upper respiratory tract infection, bronchospasm
Skin: rash, pruritus, urticaria, photosensitivity, angioedema, anaphylactic reactions
Other: fever

Interactions
Drug-drug. Allopurinol: increased risk of hypersensitivity reaction
Antacids: decreased ramipril absorption
Digoxin, lithium: increased blood levels and risk of toxicity from these drugs
Diuretics, other antihypertensives: increased hypotension
Indomethacin: reduced hypotensive effect of ramipril
Phenothiazines: increased pharmacologic effects of ramipril
Potassium-sparing diuretics, potassium supplements: increased risk of hyperkalemia
Tetracyclines: decreased tetracycline absorption

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, potassium: increased levels

Drug-food. Any food: decreased rate (but not extent) of drug absorption
Salt substitutes containing potassium: increased risk of hyperkalemia

Drug-herbs. Capsaicin: increased incidence of cough
Ephedra (ma huang): decreased drug efficacy, exacerbation of hypertension

Yohimbe: interference with drug’s antihypertensive effect

Patient monitoring
- Assess vital signs and cardiovascular status. Ask patient if he’s experiencing angina.
- Monitor CBC and liver function tests.
- Closely monitor potassium level. Watch for signs and symptoms of hyperkalemia.
- Stay alert for signs and symptoms of hypersensitivity reactions (including angioedema), especially in black patients after first dose
- Evaluate for dry, nonproductive cough.

Patient teaching
- Tell patient he may take with or without food.
- Instruct patient to immediately report swelling of tongue or face or difficulty breathing.
- Teach patient how to monitor and record blood pressure.
- Tell patient drug may cause dry, nonproductive cough. Instruct him to report this problem if it becomes bothersome.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Advise patient to move slowly when sitting up or standing, to avoid dizziness from sudden blood pressure decrease.
- Inform patient that excessive fluid loss (as from sweating, vomiting, or diarrhea) and inadequate fluid intake increase risk of light-headedness (especially in hot weather).
- Tell patient to avoid salt substitutes containing potassium and herbs.
- Advise female patient to tell prescriber if she is pregnant. Caution her

Reactions in bold are life-threatening.
not to take drug during third trimester or when breastfeeding.

- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

**ranitidine hydrochloride**
Acid Reducer , Apo-Ranitidine ,
Co Ranitidine , Gavilast , Histac ,
Raciran , Ranitil , Rantek ,
Zantac, Zantac 75, Zantac
EFFERdose

Pharmacologic class: Histamine\(_{2}\) receptor antagonist

Therapeutic class: Antiulcer drug

Pregnancy risk category B

**Action**
Reduces gastric acid secretion and increases gastric mucus and bicarbonate production, creating a protective coating on gastric mucosa

**Availability**
Capsules (liquid-filled): 150 mg, 300 mg
Solution for injection: 25 mg/ml in 2-, 6-, and 40-ml vials
Solution for injection (pre-mixed): 50 mg/50 ml in 0.45% sodium chloride
Syrup: 15 mg/ml
Tablets: 150 mg, 300 mg
Tablets (effervescent): 150 mg

**Indications and dosages**

- **Active duodenal ulcer**
  
  **Adults:** 150 mg or 10 ml P.O. b.i.d. For maintenance, 150 mg or 10 ml P.O. or 50 mg I.V. or I.M. q 6 to 8 hours.

- **To maintain healing of duodenal ulcers**
  
  **Adults:** 150 mg or 10 ml P.O. b.i.d.

- **Benign gastric ulcer**
  
  **Adults:** 150 mg or 10 ml P.O. b.i.d. For maintenance, 150 mg or 10 ml P.O. or 50 mg I.V. or I.M. q 6 to 8 hours.

- **Active duodenal and gastric ulcers**
  
  **Children ages 1 month to 16 years:** 2 to 4 mg/kg/day P.O., up to a maximum of 300 mg/day

- **To maintain healing of duodenal and gastric ulcers**
  
  **Children ages 1 month to 16 years:** 2 to 4 mg/kg/day P.O., up to a maximum of 150 mg/day

- **Erosive esophagitis**
  
  **Adults:** 150 mg or 10 ml P.O. q.i.d.

- **Gastroesophageal reflux disease**
  
  **Adults:** 150 mg or 10 ml P.O. b.i.d.

- **Pathologic hypersecretory conditions, including Zollinger-Ellison syndrome**
  
  **Adults:** 150 mg or 10 ml P.O. b.i.d., adjusted according to patient’s needs. In severe cases, up to 6 g/day may be needed. Continue therapy as long as indicated.

  - **Hospitalized patients with pathologic hypersecretory conditions, including Zollinger-Ellison syndrome; intractable duodenal ulcers; patients who can’t receive oral drugs**
  
  **Adults:** 50 mg I.M. q 6 to 8 hours, or 50 mg intermittent I.V. bolus q 6 to 8 hours, or 50 mg intermittent I.V. infusion q 6 to 8 hours.

  **Children ages 1 month to 16 years:** 2 to 4 mg/kg/day I.V. in divided doses q 6 to 8 hours, up to a maximum of 50 mg q 6 to 8 hours

**Dosage adjustment**

- Renal or hepatic impairment
- Debilitated patients
Off-label uses
- Asthma
- GI hemorrhage
- *Helicobacter pylori* infection
- Short-bowel syndrome
- Immunosuppression reversal
- Psoriasis
- Aspiration pneumonitis prophylaxis

Contraindications
- Hypersensitivity to drug or its components
- Alcohol intolerance (with some oral products)
- History of acute porphyria

Precautions
Use cautiously in:
- renal or hepatic impairment, heart rhythm disturbances, phenylketonuria (effervescent tablets)
- elderly patients
- pregnant or breastfeeding patients.

Administration
- For intermittent I.V. bolus injection, dilute in normal saline solution or other compatible solution to a concentration not exceeding 2.5 mg/ml. Inject no faster than 4 ml/minute (5 minutes).
- For continuous I.V. infusion in patients with Zollinger-Ellison syndrome, add to dextrose 5% in water (D₅W) or other compatible solution; dilute to a concentration not exceeding 2.5 mg/ml, and start infusion at 1 mg/kg/hour. After 4 hours, if measured gastric acid output exceeds 10 mEq/hour or symptoms occur, increase dosage in increments of 0.5 mg/kg/hour, and remeasure acid output.
- Give P.O. doses with or without food. Give once-daily dose at bedtime.
- For intermittent I.V. infusion, dilute in D₅W or other compatible solution to a concentration not exceeding 0.5 mg/ml. Infuse no faster than 7 ml/minute (15 to 20 minutes).
- Be aware that premixed Zantac solution of 50 mg in half-normal saline solution (50 ml) doesn’t require dilution. Infuse over 15 to 20 minutes.
- Know that I.V. form may be added to total parenteral nutrition solutions.
- Inject I.M. undiluted deep into large muscle.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1-3 hr</td>
<td>8-12 hr</td>
</tr>
<tr>
<td>I.V., I.M.</td>
<td>Unknown</td>
<td>15 min</td>
<td>8-12 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, agitation, anxiety
GI: nausea, vomiting, diarrhea, constipation, abdominal discomfort or pain
Hematologic: reversible granulocytopenia and thrombocytopenia
Hepatic: hepatitis
Skin: rash
Other: pain at I.M. injection site, burning or itching at I.V. site, hypersensitivity reaction

Interactions
Drug-drug. *Antacids*: decreased ranitidine absorption
*Propantheline*: delayed ranitidine absorption and increased peak blood level
Drug-diagnostic tests. *Creatinine*: slight elevation
*Hepatic enzymes*: increased levels
*Urine protein tests using Multistix*: false-negative results
Drug-herbs. *Yerba maté*: decreased drug clearance
Drug-behaviors. *Smoking*: decreased ranitidine effects

Patient monitoring
- Assess vital signs.
- Monitor CBC and liver function tests.

Patient teaching
- Tell patient he may take oral drug with or without food. Advise him to take once-daily prescription drug at bedtime.
- Instruct patient to dissolve EFFER-dose in 6 to 8 oz of water before taking.

Reactions in **bold** are life-threatening.

Clinical alert
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• Tell patient smoking may decrease drug effects.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

---

**ranolazine**
Ranexa

*Pharmacologic class:* Piperazine derivative  
*Therapeutic class:* Antianginal  
*Pregnancy risk category C*

**Action**  
Unclear. Appears to modulate myocardial metabolism by partially inhibiting fatty acid oxidation, thereby increasing glucose oxidation and generating more adenosine triphosphate.

**Availability**  
*Tablets (extended-release):* 500 mg, 1,000 mg

**Indications and dosages**

> **Chronic angina**

**Adults:** Initially, 500 mg P.O. twice daily, increased to maximum recommended dosage of 1,000 mg P.O. twice daily if needed

**Contraindications**

- Hypersensitivity to drug or its components
- Hepatic impairment
- Preexisting QT interval prolongation

**Precautions**

- Concurrent use of drugs that cause QT interval prolongation or inhibit CYP3A (including diltiazem)

**Administartion**

- Administer without regard to meals.
- Don’t give with grapefruit juice.

**Route** | **Onset** | **Peak** | **Duration**  
--- | --- | --- | ---  
P.O. | Unknown | 2-5 hr | Unknown

**Adverse reactions**

- **CNS:** dizziness, headache, vertigo
- **CV:** palpitations
- **EENT:** tinnitus, dry mouth
- **GI:** nausea, vomiting, constipation, abdominal pain
- **Respiratory:** dyspnea
- **Other:** peripheral edema

**Interactions**

**Drug-drug.** CYP3A inhibitors such as diltiazem, ketoconazole, macrolide antibiotics, paroxetine, protease inhibitors, verapamil: increased ranolazine blood level

*Digoxin, simvastatin:* increased blood levels of these drugs

**Drug-food.** *Grapefruit juice:* increased ranolazine blood level

**Patient monitoring**

- Obtain baseline and follow-up ECGs to evaluate drug effects on QT interval.
- Monitor blood pressure regularly in patients with severe renal impairment.

**Patient teaching**

- Inform patient that drug can be taken with or without food, but not with grapefruit juice.
rasagiline
Azilect

**Pharmacologic class:** MAO inhibitor (type B)

**Therapeutic class:** Antiparkinsonian agent, antidyskinetic

**Pregnancy risk category C**

**Action**
Unknown. Thought to increase dopaminergic activity by irreversibly inhibiting MAO type B in nerve cells, increasing dopamine availability to brain cells

**Availability**
Tablets: 0.5 mg, 1 mg

**Indications and dosages**

- Initial monotherapy for idiopathic Parkinson’s disease
- **Adults:** 1 mg P.O. daily
- Adjunctive treatment of idiopathic Parkinson’s disease in patients receiving levodopa

**Adults:** 0.5 mg P.O. once daily. If patient doesn’t achieve sufficient clinical response, dosage may be increased to 1 mg P.O. once daily.

**Dosage adjustment**
- Mild hepatic impairment
- Concurrent use of ciprofloxacin and other CYP1A2 inhibitors

**Contraindications**
- Pheochromocytoma
- Within 14 days of other MAO inhibitors or meperidine
- Concurrent use with cyclobenzaprine; dextromethorphan; methadone; mirtazapine; propoxyphene; tramadol; or sympathomimetic amines, including amphetamines, cold products, and anorexiants that contain vasoconstrictors (such as pseudoephedrine, phenylephrine, phenylpropanolamine, ephedrine); and St. John’s wort

**Precautions**
Use cautiously in:
- mild hepatic impairment (use not recommended in moderate or severe hepatic impairment), melanoma
- concurrent use of levodopa, antidepressants, or CYP1A2 inhibitors (such as ciprofloxacin)
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

**Administration**
- Give with or without food.
- Don’t give tyramine-rich foods, beverages, dietary supplements, or over-the-counter (OTC) cough or cold medications during therapy because of possible hypertensive crisis.
- Don’t give within 14 days of other MAO inhibitors, cyclobenzaprine, dextromethorphan, meperidine, methadone, mirtazapine, propoxyphene, tramadol, sympathomimetic amines (including amphetamines, cold products, and anorexiants

Reactions in **bold** are life-threatening.
that contain vasoconstrictors, such as pseudoephedrine, phenylephrine, phenylpropanolamine, ephedrine), or St. John’s wort.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** headache, vertigo, dizziness, agitation, anxiety, somnolence, amnesia, confusion, dystonia, hypertonia, abnormal gait, ataxia, dyskinesia, hyperkinesia, paresthesia, neuropathy, tremor, depression, malaise, abnormal dreams, asthenia, myasthenia, hallucinations, stroke

**CV:** orthostatic hypotension, syncope, angina, bundle-branch block

**EENT:** conjunctivitis, epistaxis, rhinitis

**GI:** abdominal pain, dyspepsia, indigestion, nausea, vomiting, diarrhea, constipation, dysphagia, gastroenteritis, dry mouth, gingivitis, anorexia, GI hemorrhage

**GU:** hematuria, urinary incontinence, erectile dysfunction, decreased libido

**Hematologic:** leukopenia, anemia, hemorrhage

**Musculoskeletal:** arthralgia, arthritis, neck pain, tenosynovitis, bursitis, leg cramps

**Respiratory:** asthma, dyspnea, increased cough

**Skin:** alopecia, skin cancer, rash, sweating, pruritus, skin ulcer, ecchymosis, photosensitivity reaction

**Other:** falls, accidental injury, flu-like syndrome, chest pain, fever, infection, hernia, weight loss, allergic reaction

**Interactions**

**Drug-drug.** *Antidepressants (selective serotonin reuptake inhibitors, tricyclic and tetracyclic antidepressants):* severe CNS toxicity, high fever, possible death

*CYP1A2 inhibitors (including ciprofloxacin):* increased rasagiline blood level and possible increased adverse reactions

*Dextromethorphan:* bizarre behavior

*Mepedrine, methadone, propoxyphene, tramadol:* increased risk of serious and possibly fatal reactions

*Other MAO inhibitors, vitamin supplements containing tyramine:* increased risk of hypertensive crisis

**Sympathomimetics (including amphetamines, cold remedies, nasal decongestants, and weight-loss preparations containing vasoconstrictors):** severe hypertensive reactions

**Drug-diagnostic tests.** *Albumin:* increased value

**Drug-food.** *Tyramine-containing foods:* aged, dried, fermented meats; pickled fish; improperly stored meats and fish; broad bean pods; aged cheeses; unpasteurized beers; red wines; concentrated yeast extracts; sauerkraut; soybean products; increased risk of hypertensive crisis

**Drug-herbs.** *St. John’s wort:* bizarre behavior

**Drug-behaviors.** *Alcohol use:* hypertensive crisis

**Patient monitoring**

- Stay alert for hypertensive crisis in patients using concurrent drugs that may cause this serious interaction.
  - Be alert for dopaminergic adverse effects and exacerbation of preexisting dyskinasias when rasagiline is used as adjunct to levodopa. Levodopa dosage may need to be reduced.
  - Monitor for orthostatic hypotension during first 2 months of therapy, especially when drug is used as adjunct to levodopa.
  - Inspect patient frequently for signs of melanoma.
  - In patient with hepatic insufficiency, obtain periodic liver function tests.
Patient teaching

- Tell patient he may take drug with or without food.
- Stress importance of avoiding alcohol and certain foods, beverages, prescription drugs, and OTC preparations during therapy and for 14 days afterward. Ask pharmacist to give patient complete list of foods, beverages, and medications to avoid.
- Instruct patient to avoid using herbs during therapy unless prescriber approves.
- Advise patient to discontinue drug at least 10 days before elective surgery, as instructed.
- Instruct patient or caregiver to immediately report occipital headache, confusion, palpitations, stiff neck, unexplained nausea or vomiting, sweating, dilated pupils, and visual disturbances (indications of hypertensive crisis).
- Instruct patient to immediately report skin changes.
- Tell patient drug may cause blood pressure to drop if he stands or sits up suddenly. Advise him to rise slowly and carefully.
- Instruct patient to report hallucinations promptly.
- Caution patient to avoid hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

FDA BOXED WARNING

- Drug may cause severe hypersensitivity reactions (including anaphylaxis), severe hemolysis in patients with G6PD deficiency, and methemoglobinemia. Withdraw immediately and permanently if patient shows evidence of these problems. Before starting therapy, screen patients at higher risk for G6PD deficiency (those of African or Mediterranean ancestry).
- Drug causes spuriously low uric acid levels.

Action
Catalyzes oxidation of uric acid into an inactive soluble metabolite

Availability
Powder for injection: 1.5 mg/vial

Indications and dosages
- Chemotherapy-induced hyperuricemia in children with leukemia, lymphoma, or solid-tumor cancers
  - **Children:** 0.15 to 0.2 mg/kg by I.V. infusion over 30 minutes as a single daily dose for 5 days. Chemotherapy should begin 4 to 24 hours after first dose.

Off-label uses
- Chemotherapy-induced hyperuricemia in adults with leukemia, lymphoma, or solid-tumor cancers

Contraindications
- Hypersensitivity to drug or its components
- History of anaphylaxis, hemolytic anemia, or methemoglobinemia as a reaction to rasburicase
- G6PD deficiency

Precautions
Use cautiously in:
- pregnant or breastfeeding patients
- children younger than age 2.

rasburicase
Elitek, Fasturtek

Pharmacologic class: Recombinant urate oxidase enzyme
Therapeutic class: Antimetabolite
Pregnancy risk category C

Reactions in bold are life-threatening.
Administration

- Know that patients at high risk for G6PD deficiency (those of African or Mediterranean descent) should be screened for this disorder before therapy starts.
- Give 4 to 24 hours before first chemotherapy dose, as ordered.
- Dilute by adding 1-ml vial of diluent provided. Swirl gently; don’t shake. Dilute further by injecting diluted dose into infusion bag containing appropriate volume of normal saline solution, to achieve final volume of 50 ml.
- Administer daily by I.V. infusion over 30 minutes.
- Don’t give as I.V. bolus.
- Don’t use I.V. filters.
- Don’t mix with other drugs. Use a separate I.V. line, or flush line with 15 ml of normal saline solution before and after infusing rasburicase.
- Know that more than one course of treatment isn’t recommended.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>4 hr</td>
<td>96 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: headache
GI: nausea, vomiting, diarrhea, constipation, abdominal pain
Hematologic: neutropenia, methemoglobinemia, severe hemolysis (in patients with G6PD deficiency)
Respiratory: respiratory distress
Skin: rash
Other: fever, mucositis, hypersensitivity reactions including anaphylaxis, sepsis

Interactions

Drug-diagnostic tests. Neutrophils: decreased count
Uric acid: interference with measurement (if blood is at room temperature)

Patient monitoring

- Monitor for signs and symptoms of hypersensitivity reaction.
- Assess for respiratory distress and signs and symptoms of infection.
- Monitor CBC and uric acid level frequently.
- Watch closely for signs and symptoms of hemolysis, especially in patients of African or Mediterranean descent.

Patient teaching

- Teach parents and patient (as appropriate) to recognize and immediately report adverse effects, including hypersensitivity reaction.
- Tell parents drug may cause sepsis. Instruct them to monitor child’s temperature and immediately report fever and other signs and symptoms of infection.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

repaglinide

Gluconorm®, NovoNorm®, Prandin

Pharmacologic class: Meglitinide
Therapeutic class: Hypoglycemic
Pregnancy risk category C

Action

Inhibits alpha-glucosidases, enzymes that convert oligosaccharides and disaccharides to glucose. This inhibition lowers blood glucose level, especially in postprandial hyperglycemia.

Availability

Tablets: 0.5 mg, 1 mg, 2 mg

Indications and dosages

- Adjunct to diet and exercise in type 2 (non-insulin-dependent) diabetes mellitus uncontrolled by diet and exercise alone, or combined with metformin in type 2 diabetes mellitus
uncontrolled by diet, exercise, and either repaglinide or metformin alone

**Adults:** 0.5 to 4 mg P.O. before each meal; may adjust at 1-week intervals based on blood glucose response. Maximum daily dosage is 16 mg.

**Contraindications**
- Hypersensitivity to drug or its components
- Diabetic ketoacidosis
- Type 1 (insulin-dependent) diabetes mellitus

**Precautions**
Use cautiously in:
- Renal or hepatic impairment; adrenal or pituitary insufficiency; stress caused by infection, fever, trauma, or surgery
- Elderly or malnourished patients
- Pregnant or breastfeeding patients
- Children.

**Administration**
- Give 15 to 30 minutes before meals. Administer two, three, or four times daily, if needed, to adapt to patient’s meal pattern.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Within 30 min</td>
<td>60-90 min</td>
<td>&lt;4 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- **CNS:** headache, paresthesia
- **CV:** angina, chest pain
- **EENT:** sinusitis, rhinitis
- **GI:** nausea, vomiting, diarrhea, constipation, dyspepsia
- **GU:** urinary tract infection
- **Metabolic:** hyperglycemia, **hypoglycemia**
- **Musculoskeletal:** joint pain, back pain
- **Respiratory:** upper respiratory infection, bronchitis
- **Other:** tooth disorder, hypersensitivity reaction

**Interactions**

**Drug-drug.** *Barbiturates, carbamazepine, rifampin:* decreased repaglinide blood level
*Beta-adrenergic blockers, chloramphenicol, MAO inhibitors, nonsteroidal anti-inflammatory drugs, probenecid, sulfonamides, warfarin:* potentiation of repaglinide effects
*Calcium channel blockers, corticosteroids, estrogens, hormonal contraceptives, isoniazid, phenothiazines, phenytoin, nicotinic acid, sympathomimetics, thyroid preparations:* loss of glycemic control
*Erythromycin, ketoconazole, miconazole:* decreased repaglinide metabolism, increased risk of hypoglycemia

**Drug-food.** *Any food:* decreased drug bioavailability

**Drug-herbs.** *Aloe gel (oral), bitter melon, chromium, coenzyme Q10, fenugreek, gymnema sylvestre, psyllium, St. John’s wort:* additive hypoglycemic effects
*Glucosamine:* poor glycemic control

**Patient monitoring**
- Monitor blood glucose and glycosylated hemoglobin levels.
- Monitor patient’s meal pattern. Consult prescriber about adjusting dosage if patient adds or misses a meal.
- Assess for angina, shortness of breath, or other discomforts.
- Watch for signs and symptoms of bronchitis and upper respiratory, urinary, and EENT infections.

**Patient teaching**
- Tell patient to take 15 to 30 minutes before each meal.
- Instruct patient to monitor blood glucose level carefully. Teach him to recognize signs and symptoms of hypoglycemia and hyperglycemia.
- Advise patient to report signs and symptoms of infection.
- As appropriate, review all other significant and life-threatening adverse reactions in **bold** are life-threatening.
reactions and interactions, especially those related to the drugs, foods, and herbs mentioned above.

reteplase, recombinant
Rapilysin®, Retavase

Pharmacologic class: Tissue plasminogen activator
Therapeutic class: Thrombolytic enzyme
Pregnancy risk category C

Action
Converts plasminogen to plasmin, which in turn breaks down fibrin and fibrinogen, thereby dissolving thrombus

Availability
Injection: Retivase Half-Kit—one vial of 10.4 units (18.1 mg)/vial; Retavase Kit—two vials of 10.4 units (18.1 mg)/vial

Indications and dosages
➣ Acute myocardial infarction
Adults: 10 units by I.V. bolus over 2 minutes, repeated in 30 minutes

Off-label uses
● Pulmonary embolism

Contraindications
● Hypersensitivity to drug or alteplase
● Active internal bleeding
● Bleeding diathesis
● Recent intracranial or intraspinal surgery or trauma
● Intracranial neoplasm
● Arteriovenous malformation or aneurysm
● Severe uncontrolled hypertension
● History of cerebrovascular accident

Precautions
Use cautiously in:
● previous puncture of noncompressible vessels, major surgery, obstetric delivery, organ biopsy, trauma, hypertension, conditions that may cause left-sided heart thrombus (including mitral stenosis), acute pericarditis, subacute bacterial endocarditis, hemostatic defects, diabetic hemorrhagic retinopathy, cerebrovascular disease, severe hepatic or renal dysfunction, septic thrombophlebitis or occluded AV cannula at a seriously infected site, other conditions in which bleeding poses a significant hazard
● concurrent use of oral anticoagulants (such as warfarin)
● patients older than age 75
● pregnant or breastfeeding patients.

Administration
If patient shows signs or symptoms of bleeding or anaphylaxis after first bolus dose, withhold second bolus and contact prescriber immediately.
● Use only diluent supplied (preservative-free sterile water for injection) to reconstitute drug into colorless solution of 1 unit/ml.
● If drug foams, let it sit until foam subsides.
● Don’t use solution if it is discolored or contains visible precipitates.
● Don’t give with other drugs in same I.V. line. Know that drug is incompatible with heparin.

Route Onset Peak Duration
I.V. Immediate End of Variable

Adverse reactions
CNS: intracranial hemorrhage
CV: arrhythmias, hemorrhage
GI: nausea, vomiting, GI bleeding
GU: hematuria
Hematologic: anemia, bleeding tendency
Other: fever, bleeding at puncture sites

---

加拿大大警戒药物

高危药物
Interactions
Drug-drug. Anticoagulants, indomethacin, phenylbutazone, platelet aggregation inhibitors (such as abciximab, aspirin, dipyridamole): increased risk of bleeding
Drug-diagnostic tests. Hemoglobin: decreased level
International Normalized Ratio, partial thromboplastin time, prothrombin time: increased
Drug-herbs. Ginkgo, many other herbs: increased risk of bleeding

Patient monitoring
- Check closely for signs and symptoms of bleeding in all body systems. Monitor coagulation studies and CBC.
  - Monitor ECG for arrhythmias caused by coronary thrombolysis.
  - Assess neurologic status to detect early signs and symptoms of intracranial hemorrhage.

Patient teaching
- Teach patient about drug’s anticoagulant effect. Review safety measures to avoid injury, which can cause uncontrollable bleeding.
- Instruct patient to immediately report signs and symptoms of bleeding problems.
- Tell patient he’ll undergo frequent blood testing during therapy.

FDA BOXED WARNING
- Ribavirin monotherapy isn’t effective in treating chronic hepatitis C infection and shouldn’t be used alone for this indication.
- Drug’s main clinical toxicity is hemolytic anemia, which may worsen cardiac disease and lead to fatal and nonfatal myocardial infarctions. Don’t administer to patients with history of significant or unstable cardiac disease.
- Drug is contraindicated in pregnant women and their male partners. Caution female patients and female partners of male patients receiving ribavirin to use extreme care to avoid pregnancy during therapy and for 6 months afterward.

Action
Unknown. Thought to inhibit RNA and DNA synthesis by depleting nucleotides and blocking replication and maturation of viral cells.

Availability
Capsules: 200 mg
Powder to be reconstituted for inhalation (Virazole): 6 g in 100-ml glass vial
Tablets: 200 mg

Indications and dosages
- Chronic hepatitis C infection
  Note: Dosage calculated solely on basis of patient’s weight.
Adults and children weighing 75 kg (165 lb) or more: 600 mg P.O. morning and evening, given with interferon alfa-2b
Adults weighing less than 75 kg (165 lb) and children weighing more than 61 kg (134 lb): 400 mg P.O. q morning and 600 mg P.O. q evening, given with interferon alfa-2b
Children weighing 50 to 61 kg (110 to 134 lb): 400 mg P.O. b.i.d., given with interferon alfa-2b

ribavirin
Copegus, Rebetol, Ribosphere, Virazole
Pharmacologic class: Synthetic nucleoside analog
Therapeutic class: Antiviral
Pregnancy risk category X

Reactions in bold are life-threatening.
Children weighing 37 to 49 kg (81 to 108 lb): 200 mg P.O. every morning and 400 mg P.O. every evening, given with interferon alfa-2b

Children weighing 25 to 36 kg (55 to 79 lb): 200 mg P.O. b.i.d., given with interferon alfa-2b

Hospitalized children with severe lower respiratory infection caused by respiratory syncytial virus

Infants and young children: 20 mg/ml by inhalation as a starting solution in Viratek Small Particle Aerosol Generator (SPAG-2) for 12 to 18 hours daily for 3 to 7 days. Give by oxygen hood from SPAG-2 unit to infant who isn’t mechanically ventilated.

Dosage adjustment

- Cardiovascular disease
- Chronic obstructive pulmonary disease (COPD)
- Renal impairment
- Hemoglobin below 10 g/dl

Off-label uses

- Influenza A or B
- Pneumonia caused by adenovirus
- Severe lower respiratory tract infection in adults
- Genital herpes
- Hemorrhagic fever

Contraindications

- Hypersensitivity to drug or its components
- Autoimmune hepatitis (oral combination therapy)
- Creatinine clearance below 50 ml/minute
- Significant or unstable cardiac disease
- Hemoglobinopathy (such as sickle cell anemia, thalassemia major)
- Females of childbearing age (inhalation form)
- Pregnancy, pregnant partner of male patient (oral drug)
- Breastfeeding

Precautions

Use cautiously in:

- decompensated hepatic disease, coinfection with hepatitis B or human immunodeficiency virus, COPD
- liver or other transplant recipients
- patients who don’t respond to interferon.

Administration

Be aware that oral form must be given with interferon alfa-2b injection.
- Give aerosol by Viratek SPAG-2 only. Don’t use other aerosol-generating equipment.
- Dilute powder in sterile water for injection. Don’t use solutions with antimicrobial ingredients.
- Know that drug may be given by oral or nasal inhalation.
- Discard solution in SPAG-2 every 24 hours before adding new solution.

Avoid prolonged contact with aerosol, which can cause headache or eye irritation.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>Inhalation</td>
<td>Slow</td>
<td>60-90 min</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: fatigue, headache, nervousness, depression, suicidal ideation
CV: hypotension, bradycardia (with inhalation form), cardiac arrest
EENT: conjunctivitis, eyelid erythema or rash
GI: nausea, dyspepsia, anorexia, pancreatitis
Hematologic: reticulocytosis, hemolytic anemia
Respiratory: bacterial pneumonia, pneumothorax, bronchospasm, pulmonary edema, apnea, worsening respiratory status (with inhalation form)
Skin: rash, pruritus
Interactions

Drug-drug. Abacavir, didanosine, lamivudine, stavudine, zalcitabine, zidovudine: potentially fatal lactic acidosis
Stavudine, zidovudine: decreased antiviral activity

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, bilirubin: increased levels
Hemoglobin: decreased level
Reticulocytes: increased count

Patient monitoring

▫ Carefully monitor patient’s respiratory status. Check ventilator often to ensure that drug precipitates don’t impede function.
▫ Monitor ECG and vital signs. Watch for hypotension, bradycardia, and other signs of impending cardiac arrest or worsening respiratory condition.
▫ Assess neurologic status. Stay alert for depression and suicidal ideation.
▫ Monitor liver function tests and CBC with white cell differential.

Patient teaching

▫ Explain drug delivery system and precautions carefully to patient or to parents of children receiving inhalation form.
▫ Tell patient or parents that drug may cause depression or suicidal thoughts, which should be reported immediately.
▫ Instruct patient or parents to immediately report new or worsening respiratory symptoms.
▫ Counsel sexually active patients (both males and females) about appropriate birth control. Tell them to use extreme care to avoid pregnancy. Stress importance of using two forms of effective contraception during and for 6 months after treatment (when using oral ribavirin).
▫ Advise female patient not to breastfeed.
▫ As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

rifabutin

Mycobutin

Pharmacologic class: Rifamycin derivative
Therapeutic class: Antimycobacterial
Pregnancy risk category B

Action
Inhibits RNA synthesis by blocking RNA transcription in susceptible organisms (mycobacteria and some gram-positive and gram-negative bacteria)

Availability
Capsules: 150 mg

Indications and dosages
➢ To prevent disseminated Mycobacterium avium intracellulare complex in patients with advanced human immunodeficiency virus (HIV) infection
Adults: 300 mg P.O. daily as a single dose or in two divided doses

Off-label uses
▫ Tuberculosis
▫ Prophylaxis and treatment of M. avium intracellulare in children

Contraindications
▫ Hypersensitivity to drug
▫ Active tuberculosis

Precautions
Use cautiously in:
▫ severe hepatic disease
▫ pregnant or breastfeeding patients.
Administration

- Give in divided doses twice daily with food to reduce GI upset.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2-3 hr</td>
<td>&gt;24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: headache, asthenia, weakness
CV: pressure sensation in chest
EENT: uveitis; discolored tears, saliva, or sputum
GI: nausea, vomiting, diarrhea, dyspepsia, abdominal pain, eructation, flatulence, discolored feces, anorexia
GU: discolored urine
Hematologic: eosinophilia, neutropenia, leukopenia, thrombocytopenia
Musculoskeletal: joint pain, myalgia
Respiratory: dyspnea
Skin: rash, discolored skin or sweat
Other: abnormal taste, fever, flulike symptoms

Interactions

Drug-drug. Clarithromycin, itraconazole, saquinavir: reduced blood levels and efficacy of these drugs
Delavirdine: decreased delavirdine blood level, increased rifabutin blood level
Drugs metabolized by liver (such as zidovudine): altered blood levels of these drugs
Hormonal contraceptives: decreased contraceptive efficacy
Indinavir, nelfinavir, ritonavir: increased rifabutin blood level

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, eosinophils: increased levels
Neutrophils, platelets, white blood cells: decreased counts

Drug-food. High-fat foods: delayed drug absorption

Patient teaching

- Advise patient to take twice daily with food (but not high-fat food) if GI upset occurs. To further minimize GI upset, teach him to eat small, frequent servings of healthy food and drink plenty of fluids.
- Instruct patient to take exactly as prescribed, even after symptoms subside.
- Tell patient to immediately report easy bruising or bleeding.
- Tell patient drug may turn tears, urine, and other body fluids reddish or brownish orange. Instruct him not to wear contact lenses during therapy because drug may stain them permanently.
- Inform patient that drug occasionally causes eye inflammation. Instruct him to report symptoms promptly.
- Caution patient to avoid driving and other hazardous activities until effects of drug are known.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

rifampin (rifampicin®)
Rifadin, Rofact®

Pharmacologic class: Rifamycin derivative

Therapeutic class: Antitubercular

Pregnancy risk category C

Action

Inhibits RNA synthesis by blocking RNA transcription in susceptible organisms (mycobacteria and some...
gram-positive and gram-negative bacteria)

Availability
Capsules: 150 mg, 300 mg
Powder for injection: 600 mg/vial

Indications and dosages
➢ Tuberculosis
Adults: 10 mg/kg/day (up to 600 mg/day) P.O. or I.V. infusion as a single dose
Children: 10 to 20 mg/kg/day (up to 600 mg/day) P.O. or I.V. infusion as a single dose
➢ Asymptomatic Neisseria meningitidis carriers
Adults: 600 mg P.O. or I.V. infusion b.i.d. for 2 days
Children ages 1 month and older: 10 mg/kg/day P.O. or I.V. infusion (up to 600 mg/day) q 12 hours for 2 days
Infants younger than 1 month old: 5 mg/kg P.O. or I.V. infusion q 12 hours for 2 days

Off-label uses
● Mycobacterium avium intracellulare complex infection
● Brucellosis
● Haemophilus influenzae type B
● Severe staphylococcal bone and joint infections
● Prosthetic valve endocarditis caused by coagulase-negative staphylococci
● Leprosy
● Prophylaxis in high-risk close contact of patients with N. meningitidis infections

Contraindications
● Hypersensitivity to drug or other rifamycin derivatives

Precautions
Use cautiously in:
● porphyria
● history of hepatic disease
● concurrent use of other hepatotoxic drugs
● pregnant or breastfeeding patients.

Administration
● Add 10 ml of sterile water to vial to yield a 60-mg/ml solution for I.V. infusion.
● Further dilute in 100 ml of dextrose 5% in water (D₃W) and infuse over 30 minutes, or add to 500 ml of D₃W and infuse over 3 hours.
● Give oral doses with a full glass of water 1 hour before or 2 hours after a meal.
● For an adult who can’t swallow capsules or for a young child, mix capsule contents with syrup, shake well, and administer.
● If patient can’t receive dextrose, use normal saline solution to dilute. Don’t use other I.V. solutions.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>2-4 hr</td>
<td>12-24 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>End of infusion</td>
<td>12-24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: ataxia, confusion, drowsiness, fatigue, headache, asthenia, psychosis, generalized numbness
EENT: conjunctivitis; discolored tears, saliva, and sputum
GI: nausea, vomiting, diarrhea, abdominal cramps, dyspepsia, epigastric distress, flatulence, discolored feces, anorexia, sore mouth and tongue, pseudomembranous colitis
GU: discolored urine
Hematologic: eosinophilia, transient leukopenia, hemolytic anemia, hemolysis, disseminated intravascular coagulation (DIC), thrombocytopenia
Hepatic: jaundice
Metabolic: hyperuricemia
Musculoskeletal: myalgia, joint pain
Respiratory: dyspnea, wheezing
Skin: flushing, rash, pruritus, discolored sweat, erythema multiforme, toxic epidermal necrolysis, Stevens-Johnson syndrome

Reactions in bold are life-threatening.
Other: flulike symptoms, hypersensitivity reactions including vasculitis

Interactions

Drug-drug. Barbiturates, beta-adrenergic blockers, cardiac glycosides, clarithromycin, clofibrate, cyclosporine, dapsone, diazepam, doxycycline, fluoroquinolones (such as ciprofloxacin), haloperidol, levothryoxine, methadone, progestins, quinine, tacrolimus, theophylline, tricyclic antidepressants, zidovudine: increased metabolism of these drugs Chloramphenicol, corticosteroids, disopyramide, efavirenz, estrogens, fluconazole, hormonal contraceptives, itraconazole, ketoconazole, nevirapine, quinidine, opioid analgesics, oral hypoglycemics, phenytoin, quinidine, ritonavir, theophylline, tocamide, verapamil, warfarin: decreased efficacy of these drugs Delavirdine, indinavir, nelfinavir, saquinavir: decreased blood levels of these drugs Hepatotoxic drugs (including isoniazid, ketoconazole, pyrazinamide): increased risk of hepatotoxicity

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, uric acid: increased levels Dexamethasone suppression test: interference with results Direct Coombs’ test: false-positive result Folate, vitamin B12 assay: interference with standard assays Hemoglobin: decreased value Liver function tests: abnormal values (transient) Sulfobromophthalein uptake and excretion test: delayed hepatic uptake and excretion

Drug-behaviors. Alcohol use: increased risk of hepatotoxicity

Patient monitoring

- Monitor kidney and liver function tests, CBC, and uric acid level.
- Assess for signs and symptoms of hepatic impairment.
- Monitor bowel movements for diarrhea, which may signal pseudomembranous colitis.

Patient teaching

- Advise patient to take oral dose 1 hour before or 2 hours after meals. If drug causes significant GI upset, instruct him to take it with meals. To further minimize GI upset, teach him to eat small, frequent servings of food and drink plenty of fluids.
- Instruct patient to immediately report easy bruising or bleeding, fever, malaise, appetite loss, nausea, vomiting, or yellowing of skin or eyes.
- Tell patient drug may color his tears, urine, and other body fluids reddish or brownish orange. Instruct him not to wear contact lenses during therapy, because drug may stain them permanently.
- Instruct patient not to drink alcohol.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

rifapentine

Priftin

Pharmacologic class: Rifamycin derivative

Therapeutic class: Antitubercular

Pregnancy risk category C

Action

Inhibits RNA synthesis by blocking RNA transcription in susceptible
organisms (mycobacteria and some gram-positive and gram-negative bacteria)

**Availability**

*Tablets: 150 mg*

**Indications and dosages**

➤ Pulmonary tuberculosis (TB)

**Adults:** *Intensive-phase treatment*—600 mg P.O. twice weekly for 2 months, with doses spaced 72 hours apart; must be given with at least one other antitubercular. *Continuation-phase treatment*—600 mg P.O. once weekly for 4 months, given with another antitubercular.

**Off-label uses**

● *Mycobacterium avium intracellulare* complex infection

**Contraindications**

● Hypersensitivity to drug or other rifamycin derivatives

**Precautions**

Use cautiously in:

● hepatic disorders, porphyria
● concurrent protease inhibitor therapy for human immunodeficiency virus infection
● elderly patients
● pregnant or breastfeeding patients
● children younger than age 12.

**Administration**

● Know that drug is given with at least one other antitubercular.
● Expect to give drug with pyridoxine to adolescents, malnourished patients, and patients at risk for neuropathy.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Slow</td>
<td>5-6 hr</td>
<td>17-18 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: headache, fatigue, anxiety, dizziness, aggressive behavior
CV: hypertension, peripheral edema

EENT: visual disturbances; discolored tears, sputum, and saliva
GI: nausea, vomiting, diarrhea, dyspepsia, esophagitis, gastritis, discolored feces, anorexia, *pancreatitis*
GU: hematuria, pyuria, proteinuria, urinary casts, discolored urine
Hematologic: anemia, thrombocytosis, hematoma, purpura, eosinophilia, *neutropenia, leukopenia*
Hepatic: *hepatitis*
Metabolic: hyperuricemia, hypovolemia, hyperkalemia
Musculoskeletal: gout, arthritis, joint pain
Skin: rash, pruritus, acne, urticaria, discolored skin and sweat
Other: edema

**Interactions**

**Drug-drug.** Amitriptyline, anticoagulants, barbiturates, beta-adrenergic blockers, chloramphenicol, clofibrate, corticosteroids, cyclosporine, dapson, delavirdine, diazepam, digoxin, diltiazem, disopyramide, doxycycline, fentanyl, fluconazole, fluoroquinolones, haloperidol, hormonal contraceptives, indinavir, itraconazole, ketoconazole, methadone, mexiletine, nelfinavir, nifedipine, nor triptyline, oral hypoglycemics, phenothiazines, progestin, quinidine, quinine, ritonavir, saquinavir, sildenafil, tacrolimus, theophylline, thyroid preparations, toco nide, verapamil, warfarin, zidovudine: decreased actions of these drugs

**Antiretroviral drugs:** decreased efficacy of these drugs

**Drug-diagnostic tests.** Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, eosinophils, lactate dehydrogenase, potassium, uric acid: increased levels

Folate, vitamin B₁₂ assays: interference with standard assays

Hemoglobin, neutrophils, platelets, white blood cells: decreased values

Reactions in **bold** are life-threatening.
Patient monitoring

- Monitor CBC, uric acid level, and liver function tests. Watch for signs and symptoms of blood dyscrasias and hepatitis.
- Assess vital signs and fluid intake and output. Stay alert for hypertension and edema.
- Closely monitor nutritional status and hydration.

Patient teaching

- Instruct patient to immediately report fever, malaise, appetite loss, nausea, vomiting, or yellowing of skin or eyes.
- Emphasize importance of taking with companion drugs, as prescribed, to prevent growth of resistant TB strains.
- Tell patient drug may color tears, urine, and other body fluids reddish or brownish orange. Instruct him not to wear contact lenses during therapy, because drug may stain them permanently.
- Advise patient to take with meals and to minimize GI upset by eating small, frequent servings of healthy food and drinking plenty of fluids.
- Tell patient to monitor his weight and report sudden gains. Also tell him to report swelling.
- Instruct patient to immediately report rash or unusual bleeding or bruising.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

### rifixinin

**Xifaxan**

**Pharmacologic class:** Rifampin-related antibiotic

**Therapeutic class:** Anti-infective

**Pregnancy risk category C**

**Action**

Binds to beta-subunit of bacterial DNA-dependent RNA polymerase, inhibiting bacterial RNA synthesis

**Availability**

*Tablets: 200 mg*

**Indications and dosages**

- **Travelers’ diarrhea caused by non-invasive strains of *Escherichia coli***
  - **Adults and children age 12 and older:** 200 mg P.O. three times daily for 3 days

**Off-label uses**

- Hepatic encephalopathy

**Contraindications**

- Hypersensitivity to drug, its components, or rifamycin anti-infectives

**Precautions**

Use cautiously in:

- elderly patients
- pregnant or breastfeeding patients
- children (safety and efficacy not established in those younger than age 12).

**Administration**

- Administer with or without food.
- Don’t give to patients with diarrhea complicated by fever or blood in stool or to patients with suspected *Campylobacter jejuni, Shigella,* or *Salmonella* infection.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>
Adverse reactions
CNS: headache
GI: nausea, vomiting, constipation, flatulence, abdominal pain, rectal tenesmus, defecation urgency, pseudomembranous colitis
Other: pyrexia, overgrowth of susceptible organisms

Interactions
None

Patient monitoring
● Monitor for fever, blood in stools, and worsening of diarrhea.
● Monitor patient’s fluid and electrolyte status.
● Monitor for new infections; if needed, consider alternative therapy.

Patient teaching
● Tell patient drug can be taken with or without food.
⚠ Advise patient to stop drug and notify prescriber if diarrhea symptoms worsen or last beyond 48 hours.
● As appropriate, review all other significant or life-threatening adverse reactions.

Availability
Tablets: 50 mg

Indications and dosages
ALS
Adults: 50 mg P.O. q 12 hours

Off-label uses
● Cervical dystonia
● Huntington’s disease

Contraindications
● Hypersensitivity to drug or its components

Precautions
Use cautiously in:
● hepatic or renal insufficiency, neutropenia, febrile illness
● elderly patients
● female patients and Japanese patients (may have decreased metabolic capacity to eliminate drug)
● pregnant or breastfeeding patients
● children.

Administration
● Give at least 1 hour before or 2 hours after a meal to maximize absorption.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, dizziness, drowsiness, asthenia, hypertonia, depression, insomnia, malaise, vertigo, circumoral paresthesia
CV: hypertension, orthostatic hypotension, tachycardia, palpitations, peripheral edema, phlebitis, cardiac arrest
EENT: rhinitis, sinusitis, oral candidiasis
GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia, flatulence, stomatitis, dry mouth, anorexia
GU: urinary tract infection, dysuria
Hematologic: neutropenia
Musculoskeletal: back pain, joint pain
Respiratory: decreased lung function, increased cough, pneumonia

Reactions in bold are life-threatening.
Skin: pruritus, eczema, alopecia, exfoliative dermatitis
Other: tooth disorders, weight loss

Interactions
Drug-drug. Allopurinol, methyldopa, sulfasalazine: increased risk of hepatotoxicity
CYP450-1A2 inducers (such as omeprazole, rifampin): increased riluzole elimination
CYP450-1A2 inhibitors (such as amitriptyline, phenacetin, quinolones, theophylline): decreased riluzole elimination

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, bilirubin, gamma-glutamyltransferase: increased levels

Drug-food. High-fat foods: decreased riluzole absorption

Drug-behaviors. Alcohol use: increased risk of hepatotoxicity

Patient monitoring
- Monitor liver function tests and CBC.
- Assess vital signs and cardiovascular status, particularly for hypertension, orthostatic hypotension, and peripheral edema.
- Closely monitor respiratory status for decreased lung function and pneumonia.
- Monitor weight, nutritional status, and hydration.
- Closely monitor females and patients of Japanese origin, who are at increased risk for adverse reactions.

Patient teaching
- Tell patient to take 1 hour before or 2 hours after a meal, at same time each day.
- Instruct patient to take his temperature regularly and report fever.
- Teach patient to immediately report arm or leg swelling, difficulty breathing, and other signs of decreased lung function.
- Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
- Caution patient to avoid high-fat foods and alcohol.
- Instruct patient to move slowly when sitting up or standing, to avoid dizziness from sudden blood pressure decrease.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and behaviors mentioned above.
Contraindications
- Hypersensitivity to drug or amantadine

Precautions
Use cautiously in:
- history of seizures or renal or hepatic disease
- pregnant or breastfeeding patients
- children younger than age 1.

Administration
- Give several hours before bedtime.
- Start therapy within 48 hours of symptom onset and continue for at least 1 week.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Slow</td>
<td>6 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, dizziness, fatigue, depression, insomnia, poor concentration, asthenia, nervousness
CV: hypotension
EENT: tinnitus
GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia, dry mouth, anorexia
Respiratory: dyspnea
Skin: rash

Interactions
Drug-drug. Acetaminophen, aspirin: decreased rimantadine peak blood level Cimetidine: increased rimantadine blood level

Patient monitoring
- Assess patient’s flu symptoms. Notify prescriber if symptoms don’t improve within 2 to 3 days.
- Monitor vital signs; watch for hypotension.
- Closely monitor nutritional status and hydration.

Patient teaching
- Advise patient to take several hours before bedtime.
- If patient’s taking syrup, tell him to use specially marked oral syringe or measuring device to ensure accurate dose.
- Instruct patient to contact prescriber if symptoms don’t improve within 2 to 3 days.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, motor function, and alertness.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

risedronate sodium
Actonel
Pharmacologic class: Bisphosphonate
Therapeutic class: Calcium regulator
Pregnancy risk category C

Action
Inhibits osteoclast-mediated bone resorption. Also exerts antiresorptive effect, probably by directly inhibiting mature osteoclast activity or indirectly inhibiting osteoblasts.

Availability
Tablets: 5 mg, 30 mg, 35 mg, 75 mg

Indications and dosages
➤ Osteoporosis
Adults: 5 mg P.O. daily. Alternatively, for men and postmenopausal women, 35 mg P.O. weekly.
➤ Prevention and treatment of postmenopausal osteoporosis
Adults: 1 (75-mg) tablet P.O. daily on 2 consecutive days for total of 2 tablets monthly
➤ Paget’s disease
Adults: 30 mg P.O. daily for 2 months. If indicated, may retreat with same Reactions in bold are life-threatening.
dosage after post-treatment observation period of at least 2 months.

**Off-label uses**
- Hypercalcemia of malignancy
- Primary hyperparathyroidism

**Contraindications**
- Hypersensitivity to drug or other bisphosphonates
- Hypocalcemia
- Inability to stand or sit upright for at least 30 minutes

**Precautions**
Use cautiously in:
- renal disease, hypotension, upper GI disorders, difficulty swallowing
- pregnant or breastfeeding patients.

**Administration**
- Give with 6 to 8 oz of water 30 minutes before first food or beverage of day (other than water).
  - Make sure patient stays upright for at least 30 minutes after taking.
- Be aware that patient with poor dietary intake may need calcium and vitamin D supplements.
- Give calcium, magnesium, or aluminum supplements or antacids at different time of day so they don’t interfere with risedronate absorption.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>1 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
**CNS:** headache, anxiety, depression, dizziness, vertigo, syncope, asthenia
**CV:** hypertension, vasodilation, angina, chest pain, cardiovascular disorder, peripheral edema
**EENT:** cataract, conjunctivitis, dry eyes, otitis media, rhinitis, sinusitis, pharyngitis
**GI:** nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, gastroenteritis, colitis, esophageal irritation, dry mouth, anorexia
**GU:** urinary tract infection
**Hematologic:** anemia
**Musculoskeletal:** bone, back, or joint pain; bone fracture; bursitis; myalgia; arthritis; leg and muscle cramps
**Respiratory:** crackles, cough, bronchitis, pneumonia
**Skin:** rash, pruritus, ecchymosis, skin cancer
**Other:** accidental injury, infection, neck pain, flulike symptoms, allergic reactions, neoplasm

**Interactions**
**Drug-drug.** Antacids, aspirin, calcium or magnesium supplements: decreased risedronate absorption
Nonsteroidal anti-inflammatory drugs, salicylates: increased GI irritation
**Drug-diagnostic tests.** Bone-imaging diagnostic agents: interference with test agents
Calcium, phosphorus: decreased levels

**Drug-food.** Any food: decreased drug absorption

**Patient monitoring**
- Watch for difficulty swallowing and signs and symptoms of esophageal irritation.
- Assess skin for unusual findings that may indicate skin cancer.

**Patient teaching**
- Advise patient to read patient information insert before starting therapy.
- Stress importance of taking with a full glass (6 to 8 oz) of water at least 30 minutes before first food or drink of day and staying upright for at least 30 minutes afterward.
- Instruct patient to stop taking drug and notify prescriber if she experiences difficulty or pain on swallowing, midline chest pain, or severe, persistent heartburn.
- Tell patient that chewing or sucking tablet may cause mouth irritation.
Tell patient to report signs and symptoms of colitis.
If patient must take calcium, magnesium, or aluminum supplements or antacids, tell her to take them at least 2 hours after risedronate.
Inform patient that drug may cause leg cramps and bone or joint pain. Advise her to discuss these problems with prescriber.
As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

**risperidone**

Novo-Risperidone, PHL-Risperidone, PMS-Risperidone, Ran-Risperidone, Ratio-Risperidone, Risperdal, Risperdal Consta, Risperdal M-Tab, Riva-Risperidone, Sandoz Risperisone

**Pharmacologic class:** Benzisoxazole derivative

**Therapeutic class:** Antipsychotic

**Pregnancy risk category C**

**FDA BOXED WARNING**

- Elderly patients with dementia-related psychosis are at increased risk for death. Over course of 10-week controlled trial, death rate in drug-treated patients was about 4.5%, compared to about 2.6% in placebo group. Although causes of death varied, most appeared to be cardiovascular or infectious. Don’t give drug to patients with dementia-related psychosis.

**Action**

Antagonizes serotonin_2_ and dopamine_2_ receptors in CNS. Also binds to alpha_1_- and alpha_2_-adrenergic receptors and histamine H_1_ receptors.

**Availability**

**Oral solution:** 1 mg/ml in 30-ml bottles

**Powder for injection (extended-release):**
12.5 mg, 25-mg, 37.5-mg, 50-mg vials in dose pack with diluent in prefilled syringes

**Tablets:** 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg

**Tablets (orally disintegrating):** 0.5 mg, 1 mg, 2 mg

**Indications and dosages**

- **Schizophrenia**
  
  **Adults:** 1 mg P.O. b.i.d., increased by 1 mg b.i.d. as tolerated on days 2 and 3, up to a target dosage of 3 mg b.i.d. by day 3. May adjust in increments or decrements of 1 mg b.i.d. at weekly intervals; usual dosage range is 4 to 8 mg/day. Alternatively, may give as a single daily dose after initial titration. Or 25 mg deep I.M. q 2 weeks. Maximum dosage is 50 mg q 2 weeks.
  
  **Adolescents ages 13 to 17:** 0.5 mg P.O. as single daily dose in morning or evening. Dosage adjustments, if indicated, should occur at intervals of not less than 24 hours, in increments of 0.5 or 1 mg/day, as tolerated, to recommended dosage of 3 mg/day.

- **Bipolar mania**
  
  **Adults:** Initially, 2 to 3 mg/day P.O. May adjust in increments or decrements of 1 mg/day at 24-hour intervals. Range is 1 to 6 mg/day.
  
  **Children:** 0.5 mg P.O. as single daily dose in morning or evening. Dosage adjustments, if indicated, should occur at intervals of not less than 24 hours, in increments of 0.5 or 1 mg/day, as tolerated, to recommended dosage of 2.5 mg/day.

- **Irritability symptoms of aggression toward others, deliberate self-injury,**
and temper tantrums associated with autistic disorder

**Adolescents and children:** Initially, 0.25 mg P.O. (Risperdal) daily for patients weighing less than 20 kg (44 lb) and 0.5 mg/day for patients weighing 20 kg or more. After minimum of 4 days, increase as needed to recommended dosage of 0.5 mg/day for patients weighing less than 20 kg and 1 mg/day for patients weighing 20 kg or more. Maintain this dosage for minimum of 14 days. If sufficient clinical response not achieved, consider dosage increases at 2-week or more intervals in increments of 0.25 mg/day for patients weighing less than 20 kg or 0.5 mg/day for patients weighing 20 kg or more. Once sufficient clinical response has been achieved and maintained, consider gradually lowering dosage to achieve optimal balance of efficacy and safety.

**Dosage adjustment**
- Hepatic or renal impairment
- Elderly or debilitated patients

**Off-label uses**
- Tourette syndrome

**Contraindications**
- Hypersensitivity to drug

**Precautions**
Use cautiously in:
- renal or hepatic impairment, cardiovascular disease, prolonged QT interval, dysphagia, hyperprolactinemia, hypothermia or hyperthermia, Parkinson’s disease, phenylketonuria, tardive dyskinesia, previous diagnosis of breast cancer or prolactin-dependent tumors
- history of seizures, drug abuse, or suicide attempt
- elderly or debilitated patients
- pregnant patients
- breastfeeding patients (use not recommended)
- children (safety not established for Risperdal Consta, Risperdal M-Tab, and Risperdal in children weighing less than 33 lb [15 kg]).

**Administration**
- Do not give powder for injection I.V.
- When reconstituting powder for injection, use only the diluent and needle supplied.
- Shake vial vigorously for a minimum of 10 seconds to ensure homogeneous suspension. When properly mixed, the suspension appears uniform, thick, and milky with visible particles.
- If 2 minutes elapse before giving injection, shake vial vigorously before administering. Give injection within 6 hours of reconstitution.
- Record baseline blood pressure before starting therapy.
- For I.M. use, inject deep into buttock; rotate injection sites between buttocks.
- Be aware that children and adolescents experiencing persistent somnolence may benefit from once-daily Risperdal dose administered at bedtime, from administering half daily dose twice daily, or from reduction of dose.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1-2 wk</td>
<td>Unknown</td>
<td>Up to 6 wk</td>
</tr>
<tr>
<td>I.M.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: aggressive behavior, dizziness, drowsiness, extrapyramidal reactions, headache, increased dreams, longer sleep periods, insomnia, sedation, fatigue, nervousness, agitation, anxiety, tardive dyskinesia, hyperkinesia, akathisia, **transient ischemic attack** (TIA), **cerebrovascular accident** (CVA), **neuroleptic malignant syndrome**

CV: orthostatic hypotension, chest pain, tachycardia, **arrhythmias**

EENT: vision disturbances, rhinitis, sinusitis, pharyngitis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, dry mouth, increased salivation, anorexia
GU: difficulty urinating, polyuria, galactorrhea, dysmenorrhea, menorrhagia, decreased libido
Musculoskeletal: joint or back pain
Respiratory: cough, dyspnea, upper respiratory tract infection
Skin: pruritus, diaphoresis, rash, dry skin, seborrhea, increased pigmentation, photosensitivity
Other: toothache, fever, impaired temperature regulation, weight changes

Interactions
Drug-drug. Antihistamines, opioids, sedative-hypnotics: additive CNS depression
Carbamazepine: increased metabolism and decreased efficacy of risperidone
Clozapine: decreased metabolism and increased effects of risperidone
Levodopa, other dopamine agonists: decreased antiparkinsonian effects of these drugs
Drug-behaviors. Alcohol use: increased CNS depression
Sun exposure: increased risk of photosensitivity

Patient monitoring
Closely monitor neurologic status, especially for neuroleptic malignant syndrome (high fever, sweating, unstable blood pressure, stupor, muscle rigidity, and autonomic dysfunction), extrapyramidal reactions, TIA, CVA, and tardive dyskinesia.
- Monitor blood pressure, particularly for orthostatic hypotension.
- Assess body temperature. Check for fever and other signs and symptoms of infection.

Patient teaching
- Instruct patient to remove orally disintegrating tablet from blister pack, place on tongue immediately, and swallow as tablet dissolves.
- Tell patient to mix oral solution with water, coffee, orange juice, or low-fat milk. Tell him solution isn’t compatible with cola or tea.
- Advise patient to use effective bedtime routine to avoid sleep disorders.
- Teach patient to recognize and immediately report signs and symptoms of serious adverse reactions, including tardive dyskinesia and neuroleptic malignant syndrome.
- Instruct patient to move slowly when sitting up or standing, to avoid dizziness from sudden blood pressure decrease.
- Tell patient that excessive fluid loss (as from sweating, vomiting, or diarrhea) and inadequate fluid intake increase risk of light-headedness (especially in hot weather).
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Advise female patient to tell prescriber if she is or plans to become pregnant. Caution her not to breast-feed during therapy.
- Advise patient not to drink alcohol.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and behaviors mentioned above.

FDA BOXED WARNING
Coadministration with certain nonsedating antihistamines, sedative

Reactions in **bold** are life-threatening.

---

**ritonavir**
**Norvir**

*Pharmacologic class*: Protease inhibitor
*Therapeutic class*: Antiretroviral
*Pregnancy risk category B*
hypnotics, antiarrhythmics, or ergot alkaloids may cause potentially serious or life-threatening adverse events.

**Action**
Inhibits human immunodeficiency virus (HIV) nonnucleoside reverse transcriptase by binding directly to reverse transcriptase and blocking RNA-dependent and DNA-dependent polymerase activity.

**Availability**
Capsules: 100 mg
Oral solution: 80 mg/ml

**Indications and dosages**
- HIV in combination with other antiretrovirals
  - Adults: Initially, 300 mg P.O. b.i.d.; increase by 100 mg b.i.d. q 2 to 3 days, up to a usual maintenance dosage of 600 mg b.i.d.
  - Children ages 2 and older: 400 mg/m² b.i.d., not to exceed 600 mg b.i.d. Start with 250 mg/m² to minimize nausea.

**Off-label uses**
- Chronic hepatitis B

**Contraindications**
- Hypersensitivity to drug or its components
- Concurrent use of astemizole and terfenadine (not available in U.S.), amiodarone, bepridil, cisapride, dihydroergotamine, ergotamine, ergonovine, midazolam, pimozide, propafenone, quinidine, or triazolam

**Precautions**
Use cautiously in:
- hepatic disease, diabetes mellitus, hemophilia types A and B
- underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, cardiomyopathies

- concurrent use with drugs that prolong PR interval (including calcium channel blockers, beta-adrenergic blockers, digoxin, atazanavir)
- concurrent use with drugs for erectile dysfunction (such as sildenafil, tadalafil, vardenafil)
- concurrent use with fluticasone, atorvastatin, lovastatin, simvastatin, and St. John's wort (use not recommended)
- pregnant or breastfeeding patients.

**Administration**
- Give with meals to increase absorption.
- Mix oral solution with chocolate milk or liquid nutritional supplement to mask taste.
- Know that drug is usually given with other antiretrovirals.
- Don’t give concurrently with amiodarone, astemizole, bepridil, cisapride, dihydroergotamine, ergonovine, ergotamine, flecainide, methylergonovine, midazolam, pimozide, propafenone, quinidine, terfenadine, or triazolam. Serious interactions may occur.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>2-4 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
CNS: headache, dizziness, depression, insomnia, drowsiness, asthenia, paresthesia, syncope, malaise
CV: vasodilation, prolonged PR interval
EENT: pharyngitis
GI: nausea, vomiting, diarrhea, constipation, dyspepsia, flatulence, abdominal pain, anorexia, pancreatitis
Musculoskeletal: myalgia
Skin: diaphoresis, mild skin eruptions, Stevens-Johnson syndrome (rare)
Respiratory: bronchospasm
Other: abnormal taste, fever, pain, allergic reactions including anaphylaxis (rare), immune reconstitution syndrome
Interactions

**Drug-drug.** Amiodarone, bepridil, cisapride, flecainide, midazolam, pimozide, propafenone, quinidine, triazolam: inhibited metabolism of these drugs, leading to life-threatening reactions (such as arrhythmias, prolonged sedation, and respiratory depression)

Amitriptyline, anticoagulants, atovaquone, carbamazepine, clozapine, cyclosporine, desipramine, diltiazem, disopyramide, divalproex, doxylamine, drospirenone, ethinyl estradiol, lamotrigine, phenytoin, sulfamethoxazole, theophylline, zidovudine: increased risk of toxicity of these drugs

Amprenavir: increased amprenavir blood level

Astemizole, cisapride, encainide: increased risk of arrhythmias

Atorvastatin, cerivastatin, lovastatin, simvastatin, terfenadine: increased blood levels of these drugs, increased risk of rhabdomyolysis

Barbiturates, nevirapine, phenytoin, rifamycins: decreased ritonavir blood level

Bupropion: increased risk of seizures

Clarithromycin, efavirenz: increased blood levels of both drugs

Dihydroergotamine, ergonovine, ergotamine, methylergonovine: ergot toxicity

Fluconazole: increased ritonavir blood level

Fluticasone: increased fluticasone exposure resulting in decreased cortisol concentration

**Drug-diagnostic tests.** Alanine aminotransferase, aspartate aminotransferase, cholesterol, creatine kinase, gamma-glutamyltransferase, triglycerides, uric acid: increased levels

Hematocrit, hemoglobin, neutrophils, red blood cells, white blood cells: decreased levels

**Drug-herbs.** *St. John’s wort:* decreased ritonavir blood level

Patient monitoring

- Monitor CBC, liver function tests, electrolyte levels, and lipid panel.
- Assess neurologic status closely. Stay alert for depression.
- Monitor bone mineral density in patients with history of pathologic fractures or who are at risk for osteopenia.

Monitor for signs and symptoms of immune reconstitution syndrome, especially during initial phase of combination antiretroviral treatment when patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as *Mycobacterium avium* infection, cytomegalovirus, *Pneumocystis jirovecii* pneumonia, or tuberculosis), which may necessitate further evaluation and treatment.

- Monitor vital signs and watch for syncope.
- Closely monitor nutritional and hydration status.

Patient teaching

- Advise patient to take with meals to increase absorption.
- Encourage patient to mix oral solution with chocolate milk or liquid nutritional supplement to mask taste.
- Tell patient drug may cause numbness, tingling, weakness, and other CNS effects that increase his injury risk. Urge him to use appropriate safety precautions.
- Instruct patient to report depression.
- Tell female patient not to breastfeed because of risk of serious adverse reactions and possible HIV transmission to infant.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

Reactions in **bold** are life-threatening.
rituximab
MabThera®, Rituxan

**Pharmacologic class:** Murine/human monoclonal antibody  
**Therapeutic class:** Antineoplastic  
**Pregnancy risk category C**

**FDA BOXED WARNING**
- Deaths from infusion reactions have occurred within 24 hours of rituximab infusion. Approximately 80% of fatal reactions were linked to first infusion. If severe infusion reaction develops, discontinue infusion and intervene appropriately.
- Acute renal failure requiring dialysis, severe mucocutaneous reactions, and progressive multifocal leukoencephalopathy have been reported.

**Action**
Binds to CD20 antigen on malignant B lymphocytes; recruits immune effector functions to mediate B-cell lysis (possibly through complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity)

**Availability**
*Injection:* 10 mg/ml in 10-ml (100-mg) and 50-ml (500-mg) vials

**Indications and dosages**

> Low-grade or follicular CD20-positive B-cell non-Hodgkin's lymphoma  
**Adults:** Initially, 375 mg/m² by I.V. infusion once weekly for four or eight doses at 50 mg/hour; increase rate by 50 mg/hour q 30 minutes to a maximum of 400 mg/hour. If patient tolerates first infusion, subsequent infusions may begin at 100 mg/hour, then increase by 100 mg/hour q 30 minutes to a maximum of 400 mg/hour as tolerated.

Moderately- to severely-active rheumatoid arthritis in patients who have had an inadequate response to one or more tumor necrosis factor antagonist  
**Adults:** Two 1,000 mg I.V. infusions separated by 2 weeks in combination with methotrexate

**Off-label uses**
- Waldenström's macroglobulinemia

**Contraindications**
- Hypersensitivity to drug, its components, or murine products

**Precautions**
Use cautiously in:
- history of drug allergy or sensitivity
- previous exposure to murine-based monoclonal antibodies
- high level of circulating malignant cells
- cardiac or pulmonary conditions
- pregnant or breastfeeding patients
- children.

**Administration**
- Follow facility policy regarding handling, administration, and disposal of chemotherapeutic drugs.
- To reduce the incidence and severity of infusion reactions, premedicate patient with diphenhydramine and acetaminophen, as prescribed. In addition, for patients with rheumatoid arthritis, give I.V. methylprednisolone (or its equivalent) 30 minutes before each infusion.
- Consider withholding antihypertensive agents 12 hours before giving drug to help prevent hypotension.
- Give drug as I.V. infusion.

Never give as I.V. bolus or I.V. push.
- Don't mix or dilute with other drugs.
- Dilute in dextrose 5% in water (D₅W) or normal saline solution to a
concentration of 1 to 4 mg/ml. Invert bag gently to mix solution.
- Administer the first infusion at an initial rate of 50 mg/hr. If no infusion reaction occurs, increase the infusion rate in 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.
- If the patient tolerates the first infusion well, administer subsequent infusions at an initial rate of 100 mg/hr and increase by 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr, as tolerated.

Be aware that a severe infusion reaction may occur usually after first infusion. This reaction consists of a complex of hypoxia, pulmonary infiltrates, acute respiratory distress syndrome, M.I., ventricular fibrillation, or cardiogenic shock. If such a reaction occurs, stop infusion immediately and treat appropriately.
- If hypersensitivity reaction (non-IgE-mediated) or infusion reaction that is not severe occurs, interrupt or temporarily slow infusion. When symptoms improve, infusion can continue at half of previous rate.

Adverse reactions
CNS: dizziness, headache, nervousness, hypertension, hyperesthesia, insomnia, agitation, malaise, paresthesia, asthemia, fatigue, tremor, rigors
CV: hypotension, hypertension, peripheral edema, chest pain, tachycardia, bradycardia, angina, arrhythmias
EENT: conjunctivitis, lacrimation disorders, rhinitis, sinusitis, pharyngitis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia
GU: renal toxicity
Hematologic: anemia, neutropenia, leukopenia, thrombocytopenia
Metabolic: hyperglycemia, hypocalcemia

Musculoskeletal: myalgia, back pain
Respiratory: dyspnea, cough, bronchitis, bronchospasm
Skin: pruritus, rash, urticaria, flushing, dermatitis, angioedema, toxic epidermal necrolysis, Stevens-Johnson syndrome
Other: altered taste, fever, chills, pain at injection site, hypersensitivity reactions including sepsis, severe infusion reaction

Interactions
Drug-drug. Cisplatin: increased risk of renal failure
Live-virus vaccines: increased risk of infection from vaccine
Drug-diagnostic tests. Calcium, hemoglobin, neutrophils, platelets, white blood cells: decreased values
Glucose, lactate dehydrogenase: increased levels

Patient monitoring
- Monitor closely for signs and symptoms of hypersensitivity reaction.
- Stop drug immediately and notify prescriber if patient develops signs or symptoms of Stevens-Johnson syndrome or other severe mucocutaneous reactions (including severe rash).
- Monitor pulse and blood pressure throughout I.V. infusion. Stop infusion if hypotension, bronchospasm, or angioedema occurs. Then consult prescriber about restarting infusion at half of previous rate.
- Monitor ECG throughout infusion. Stop infusion if serious arrhythmia develops.
- Monitor CBC, blood glucose, and electrolyte levels.
- Assess for signs and symptoms of infection, including fever.

Patient teaching
- Tell patient to immediately report signs and symptoms of hypersensitivity reaction or severe skin reaction.
Instruct patient to take his temperature daily and immediately report fever and other signs or symptoms of infection.

Instruct patient to immediately report unusual bleeding or bruising.

- Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

### rivastigmine tartrate

**Exelon**

**Pharmacologic class:** Cholinesterase inhibitor  
**Therapeutic class:** Anti-Alzheimer’s drug  
**Pregnancy risk category B**

**Action**

Unknown. Thought to enhance cholinergic function by elevating acetylcholine levels in brain through reversible inhibition of its hydrolysis by cholinesterase.

**Availability**

Capsules: 1.5 mg, 3 mg, 4.5 mg, 6 mg  
*Oral solution:* 2 mg/ml

**Indications and dosages**

- **Mild to moderate dementia of Alzheimer’s disease**  
  **Adults:** Initially, 1.5 mg P.O. b.i.d. May increase to 3 mg b.i.d. after 2 weeks; may increase further to 4.5 mg b.i.d. and 6 mg b.i.d., if tolerated, after 2 weeks at previous dosage. Typical effective range is 6 to 12 mg/day, up to a maximum of 12 mg/day.

**Off-label uses**

- Huntington’s disease  
- Parkinson’s disease

**Contraindications**

- Hypersensitivity to drug, its components, or carbamate derivatives

**Precautions**

Use cautiously in:

- renal or hepatic impairment, diabetes mellitus, obstructive pulmonary disease, neurologic conditions that can cause seizures, peptic ulcers, GI bleeding, supraventricular conduction disorders  
- patients older than age 85  
- pregnant patients.

**Administration**

- Give with food in morning and evening.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1 hr</td>
<td>12 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** depression, dizziness, headache, confusion, insomnia, psychosis, hallucinations, anxiety, tremor, drowsiness, fatigue, syncope, asthenia  
**CV:** chest pain, hypertension, peripheral edema  
**EENT:** rhinitis, pharyngitis  
**GI:** nausea, vomiting, diarrhea, constipation, abdominal pain, flatulence, eructation, dyspepsia, anorexia  
**GU:** urinary tract infection, urinary incontinence  
**Musculoskeletal:** back pain, joint pain, bone fractures  
**Respiratory:** upper respiratory infection, cough, bronchitis  
**Skin:** rash, diaphoresis  
**Other:** weight loss, pain, flulike symptoms

**Interactions**

**Drug-drug. Anticholinergics:** interference with anticholinergic effects

---

itories
Cholinergic agonists (such as bethanechol), succinylcholine and similar neuromuscular blockers: synergistic effects

Drug-herbs. S-adenosylmethionine (SAM-e), St. John’s wort: increased risk of serotonin syndrome

Drug-behaviors. Nicotine use: increased drug clearance

Patient monitoring
- Monitor patient’s nutritional and hydration status, especially at start of therapy.
- Assess vital signs and cardiovascular status. Stay alert for chest pain and peripheral edema.
- Closely monitor cognitive status, particularly memory. Report significant decline or improvement.
- Assess temperature. Watch for fever and other signs and symptoms of infection.

Patient teaching
- Instruct caregiver to give with food in morning and evening.
- Inform caregiver that drug initially may worsen CNS impairment. Recommend appropriate safety measures.
- Tell caregiver that memory improvement generally is subtle and that drug works by preventing further memory loss.
- Inform caregiver that drug commonly causes nausea, vomiting, decreased appetite, and weight loss, especially at start of therapy.
- Advise caregiver to watch for and report weight loss, dehydration, and signs and symptoms of GI bleeding.
- Tell caregiver that drug interacts with many over-the-counter products and nicotine. Advise him to discuss these products with prescriber before giving to patient.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, herbs, and behaviors mentioned above.

Action
Thought to act as agonist at specific 5-HT$_1$ receptor sites in intracranial vessels, causing vasoconstriction. Also may act on sensory trigeminal nerves, reducing transmission along pain pathways.

Availability
Tablets: 5 mg, 10 mg
Tablets (orally disintegrating): 5 mg, 10 mg

Indications and dosages
> Acute migraine
Adults: 5 to 10 mg P.O.; may repeat in 2 hours, not to exceed 30 mg in 24 hours. For patients receiving propranolol concurrently, 5 mg P.O., up to a maximum of three doses in 24 hours.

Contraindications
- Hypersensitivity to drug or its components
- Ischemic heart disease or other significant cardiovascular disease
- Ischemic bowel disease
- Transient ischemic attacks
- Basilar or hemiplegic migraine
- Uncontrolled hypertension
- Use of other 5-HT$_1$ agonists or ergot-type compounds (dihydroergotamine, methysergide) within 24 hours
- MAO inhibitor use within past 14 days

Reactions in bold are life-threatening.
Precautions
Use cautiously in:
- severe renal impairment (especially in dialysis patients), moderate hepatic impairment, cardiovascular risk factors
- phenylketonuria (PKU) in patients receiving orally disintegrating tablets
- pregnant or breastfeeding patients
- children younger than age 18 (safety not established).

Administration
- Place orally disintegrating tablet on patient’s tongue to dissolve. Make sure he swallows it with saliva only. Don’t give with beverages.
- Don’t give within 14 days of MAO inhibitors (may cause serious adverse reactions).

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30 min</td>
<td>1-1.5 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, dizziness, drowsiness, asthenia, fatigue, paresthesia, decreased mental acuity, euphoria, tremor
CV: chest pain, tightness, heaviness, or pressure
GI: nausea, vomiting, diarrhea, dry mouth
Respiratory: dyspnea
Skin: flushing
Other: neck, throat, or jaw pain, tightness, or pressure; hot flashes; warm or cold sensations

Interactions
Drug-drug. Ergot or ergot-type compounds (such as dihydroergotamine, methysergide), other 5-HT1 agonists: additive vasoactive effects
MAO inhibitors, propranolol: increased rizatriptan blood level, greater risk of adverse effects
Selective serotonin reuptake inhibitors: weakness, hyperreflexia, incoordination
Drug-herbs. S-adenosylmethionine (SAM-e), St. John’s wort: increased risk of adverse serotonergic effects, including serotonin syndrome

Patient monitoring
- Assess vital signs and cardiovascular status, especially if patient has cardiovascular risk factors.

Patient teaching
- Teach patient how to use drug. Stress that it’s effective only in treating diagnosed migraine—not in preventing migraine or treating other types of headache.
- Advise patient to peel back blister pack of Maxalt-MLT with dry hands and place tablet on tongue. Tell him to swallow drug with saliva only, not beverages.
- Tell patient he may repeat dose in 2 hours if headache recurs, but should take no more than 30 mg in 24 hours.
- Inform patient with PKU that orally disintegrating tablets contain phenylalanine.
- Instruct female patient to immediately report possible pregnancy.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and herbs mentioned above.

ropinirole hydrochloride
Adartrel®, Requip, Requip XL

Pharmacologic class: Dopamine agonist
Therapeutic class: Antidyskinetic
Pregnancy risk category C

Action
Unknown. Thought to stimulate dopamine receptors in brain.
Availability

Tablets: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg
Tablets (extended-release): 2 mg, 4 mg, 6 mg, 8 mg

Indications and dosages

Idiopathic Parkinson’s disease

Adults: For conventional tablets, initially, 0.25 mg P.O. t.i.d. for 1 week, followed by 0.5 mg P.O. t.i.d. for 1 week, then 0.75 mg t.i.d. for 1 week, and then 1 mg t.i.d. for 1 week. After week 4, may increase by 1.5 mg/day q week, up to 9 mg/day; then may increase further by up to 3 mg/day q week, up to 24 mg/day. For extended-release tablets, initially 2 mg P.O. once daily for 1 to 2 weeks, followed by increases of 2 mg/day at 1-week or longer intervals as appropriate, depending on therapeutic response and tolerability, up to a recommended maximum dosage of 24 mg/day.

Moderate to severe primary restless leg syndrome

Adults: Initially, 0.25 mg P.O. once daily, 1 to 3 hours before bedtime. After 2 days, may increase dosage to 0.5 mg once daily and to 1 mg once daily during week 2. For weeks 3 through 6, may increase dosage by 0.5 mg/week, to a dosage of 3 mg; at week 7, dosage may be increased to 4 mg (immediate-release tablets only).

Contraindications

- Hypersensitivity to drug or its components

Precautions

Use cautiously in:
- severe hepatic impairment or cardiovascular disease, bradycardia
- elderly patients
- pregnant patients
- breastfeeding patients (use not recommended)

Administration

- Give with food if drug causes nausea.
- Assess patient for therapeutic response and tolerability at 1-week intervals (minimum) or longer after each dosage increment.
- Know that drug withdrawal should occur over 7 days, with frequency reduced to twice-daily dosing for first 4 days and then to once-daily dosing for next 3 days.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30-60 min</td>
<td>1-2 hr</td>
<td>16 hr</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: headache, dizziness, confusion, drowsiness, fatigue, neuralgia, amnesia, hyperesthesia, yawning, dystonia, increased dyskinesia, hyperkinesia, akathisia, hallucinations, abnormal thinking, poor concentration, syncope, vertigo, myoclonus, asthenia, malaise, sleep attacks

CV: orthostatic hypotension, hypertension, palpitations, extrasystole, peripheral edema, peripheral ischemia, chest pain, tachycardia, atrial fibrillation

EENT: abnormal vision, rhinitis, sinusitis, pharyngitis

GI: nausea, vomiting, flatulence, abdominal pain, dyspepsia, dry mouth, anorexia

GU: urinary tract infection, decreased libido, erectile dysfunction

Respiratory: bronchitis, dyspnea

Skin: diaphoresis, flushing

Other: viral infection, pain, edema

Interactions

Drug-drug: Butyrophenones (such as haloperidol), metoclopramide, phenothiazines, thioxanthenes: decreased ropinirole effects

Ciprofloxacin, estrogens: increased ropinirole effects

Drugs that alter activity of CYP450-1A2 enzyme system: altered ropinirole clearance

Levodopa: increased levodopa effects

Reactions in bold are life-threatening.
Drug-diagnostic tests. Alkaline phosphatase, blood urea nitrogen: increased levels

Drug-herbs. Kava: decreased ropinirole efficacy

Patient monitoring
- Monitor vital signs, especially for orthostatic hypotension. Assess for peripheral edema.
- Monitor nutritional and hydration status.

Patient teaching
- Encourage patient to take drug with food if it causes nausea.
- Instruct patient to swallow extended-release tablets whole and not to chew, crush, or divide them.
- Inform patient that hallucinations may occur during ropinirole therapy.
- Advise patient that he may experience the urge to gamble, increased sexual urges, or other intense urges and the inability to control these urges.
- Inform patient (and caregiver, as appropriate) that drug can cause serious CNS reactions; tell him which ones to report. Recommend appropriate safety measures.
- Instruct patient to move slowly when sitting up or standing, to avoid dizziness from sudden blood pressure decrease.
- Caution patient not to stop drug abruptly. Dosage must be tapered.
- Advise patient to report swelling of hands or feet.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

rosiglitazone maleate
Avandia

Pharmacologic class: Thiazolidinedione
Therapeutic class: Hypoglycemic
Pregnancy risk category C

FDA BOXED WARNING
- Drug may cause or exacerbate heart failure in some patients. After initiating therapy or increasing dosage, observe patient carefully for heart failure signs and symptoms. If these occur, manage condition per current standards of care and consider withdrawing drug or lowering dosage.
- Drug isn’t recommended in patients with symptomatic heart failure and is contraindicated in those with established New York Heart Association Class III or IV heart failure.

Action
Inhibits alpha-glucosidases, enzymes that convert oligosaccharides and disaccharides to glucose. This inhibition lowers blood glucose level, especially in postprandial hyperglycemia.

Availability
Tablets: 2 mg, 8 mg

Indications and dosages
- Adjunct to diet and exercise in type 2 (non-insulin-dependent) diabetes mellitus (used alone); given with metformin, insulin, or a sulfonylurea when combination of diet, exercise, and monotherapy with another hypoglycemic drug don’t achieve glycemic control
- Adults: 4 mg P.O. once daily or 2 mg b.i.d. After 12 weeks, may increase to 8 mg daily or 4 mg b.i.d. if needed.
**Off-label uses**
- Polycystic ovary syndrome

**Contraindications**
- Hypersensitivity to drug or its components

**Precautions**
Use cautiously in:
- diabetic ketoacidosis, type 1 (insulin-dependent) diabetes mellitus (use not recommended)
- edema, heart failure, jaundice, hypertension, hepatic impairment
- NYHA Class III or IV cardiac status
- pregnant patients
- breastfeeding patients (use not recommended)
- children (safety and efficacy not established).

**Administration**
- Give with or without food.
- Be aware that drug is active only in presence of endogenous insulin and thus is ineffective in diabetic ketoacidosis or type 1 diabetes mellitus.

**Adverse reactions**
- CNS: fatigue, headache
- EENT: sinusitis
- GI: diarrhea
- Hematologic: anemia
- Metabolic: hyperglycemia, hypoglycemia
- Musculoskeletal: back pain
- Respiratory: upper respiratory infection
- Other: edema, injury, weight gain

**Interactions**
**Drug-diagnostic tests.** Free fatty acids, high-density lipoproteins, low-density lipoproteins, total cholesterol: increased levels
Hematocrit, hemoglobin: decreased levels

**Drug-herbs.** Aloe, bitter melon, chromium, coenzyme Q10, fenugreek, glucomannan, gymnema sylvestre, psyllium, St. John’s wort: additive hypoglycemic effects
Glucosamine: poor glycemic control

**Patient monitoring**
- Monitor CBC, lipid panel, blood glucose, and glycosylated hemoglobin levels.
- Monitor patient’s weight. Assess for fluid retention, which may lead to heart failure.
- Closely monitor liver function tests; drug may cause hepatotoxicity.

**Patient teaching**
- Tell patient he may take with or without food.
- Advise patient to monitor blood glucose level regularly and report significant changes.
- Inform patient that drug may increase fluid retention, causing or exacerbating heart failure. Encourage him to weigh himself regularly and report sudden weight gain, swelling, or shortness of breath.
- Tell patient he’ll undergo regular blood testing during therapy.
- Caution female patient not to breastfeed during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests and herbs mentioned above.

---

**rosuvastatin calcium**
Crestor

**Pharmacologic class:** HMG-CoA reductase inhibitor

**Therapeutic class:** Antilipemic

**Pregnancy risk category X**
Action
Selectively and competitively inhibits HMG-CoA reductase, which catalyzes its conversion to the cholesterol precursor mevalonate and thus limits cholesterol synthesis. This action increases high-density lipoprotein level and decreases low-density lipoprotein (LDL) level.

Availability
Tablets: 5 mg, 10 mg, 20 mg, 40 mg

Indications and dosages
➤ Primary heterozygous hypercholesterolemia; mixed dyslipidemia (Fredrickson types IIa and IIb)
Adults: Initially, 10 mg/day P.O. Patients who need less aggressive cholesterol reduction or have predisposing factors for myopathy may start at 5 mg/day. Patients with marked hypercholesterolemia (LDL above 190 mg/dl) and more aggressive LDL goals may start at 20 mg/day. For maintenance, 5 to 40 mg/day P.O.
➤ Homozygous familial hypercholesterolemia
Adults: 20 mg/day P.O. Maximum recommended dosage is 40 mg/day.
➤ Hypertriglyceridemia (Fredrickson type IV)
Adults: Initially, 10 mg/day P.O. For maintenance, 5 to 40 mg/day P.O.

Contraindications
• Hypersensitivity to drug or its components
• Active hepatic disease or persistent, unexplained hepatic enzyme elevations
• Pregnancy or breastfeeding

Precautions
Use cautiously in:
• predisposing factors for myopathy (such as renal impairment, advanced age, hypothyroidism)
• heavy alcohol use
• history of hepatic disease or hypersensitivity to other HMG-CoA reductase inhibitors (such as fluvastatin, simvastatin)
• patients of Japanese or Chinese descent
• women of childbearing age (except those who are highly unlikely to conceive and have been informed of potential hazards)
• children (safety and efficacy not established).

Administration
➤ Check liver function tests before therapy starts.
• Give with or without food.
• Measure lipid levels within 2 to 4 weeks after therapy starts and after titration.
• Know that drug should be used as adjunct to other lipid-lowering treatments, such as diet.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>3-5 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, dizziness, anxiety, depression, insomnia, hypertonia, paresthesia, asthenia, tremor, vertigo, neuralgia
CV: palpitations, tachycardia, chest pain, angina pectoris, hypertension, vasodilation, peripheral edema
EENT: rhinitis, sinusitis, pharyngitis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, gastritis, gastroenteritis
GU: urinary tract infection, acute renal failure
Hematologic: anemia
Metabolic: hypokalemia, hyperglycemia, hypoglycemia
Musculoskeletal: myalgia; myopathy; arthritis; pathologic fractures; back, pelvic, neck, or joint pain; rhabdomyolysis
Respiratory: respiratory tract infection, bronchitis, increased cough, dyspnea, pneumonia, asthma
Skin: rash, pruritus, bruising
Other: periodontal abscess, flulike symptoms, infection

Interactions
Drug-drug. Antacids: decreased rosuvastatin blood level
Cyclosporine, gemfibrozil: increased rosuvastatin bioavailability
Hormonal contraceptives: increased contraceptive blood level
Warfarin: increased International Normalized Ratio

Drug-diagnostic tests. Alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), bilirubin, creatine kinase (CK), glucose: increased levels
Potassium: decreased level
Thyroid function tests: altered results
Urinary protein: present beyond trace

Drug-food. Caffeine-containing foods and beverages: increased stimulant effect
Oat bran, pectin: impaired drug absorption
Urine-acidifying foods: increased drug blood level

Drug-herbs. Caffeine-containing herbs (such as cola nut, yerba maté), ephedra (ma huang): increased stimulant effect

Patient monitoring
Monitor CK, creatinine, and urinary protein levels closely. Also watch for signs and symptoms of rhabdomyolysis with acute renal failure: CK level above 10 times normal limits, muscle ache or weakness, creatinine elevation, and urinary protein level beyond trace, accompanied by hematuria. If these findings occur, withhold drug and notify prescriber immediately.
Monitor liver function tests 12 weeks after therapy begins, after dosage increases, and at least semiannually thereafter. Reduce dosage or withdraw drug if ALT or AST persists at three times normal levels.

Reactions in bold are life-threatening.

Clinical alert
Temporarily withhold drug in patients with acute, serious conditions predisposing to renal failure caused by rhabdomyolysis (such as sepsis, hypotension, major surgery, trauma, uncontrolled seizures, or severe metabolic, endocrine, and electrolyte disorders).
- Monitor blood glucose, electrolyte levels, and lipid panel.
- Assess vital signs and cardiovascular status, especially for tachycardia and palpitations.
- Monitor for signs and symptoms of respiratory tract infection.
- Stay alert for tremor and asthenia.

Patient teaching
- Tell patient he may take with or without food. If he’s using antacids, instruct him to take these 2 hours after rosuvastatin.
- Instruct patient to maintain a standard cholesterol-lowering diet.
- Tell patient to immediately report unexplained muscle pain, tenderness, or weakness (particularly if accompanied by malaise or fever).
- Caution female patient of childbearing age not to take drug if she is pregnant, plans to become pregnant, or is breastfeeding.
- Teach patient how to check blood or urine glucose level and recognize signs and symptoms of hypoglycemia and hyperglycemia.
- Tell patient that foods, beverages, and preparations containing caffeine or ephedra may increase drug’s stimulant effect. Encourage him to limit caffeine intake and avoid ephedra.
- Advise patient against heavy alcohol use, which increases risk of liver disease.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.
salmeterol xinafoate
Serevent®, Serevent Diskus

Pharmacologic class: Beta<sub>2</sub>-adrenergic receptor agonist (long-acting)
Therapeutic class: Bronchodilator
Pregnancy risk category C

FDA BOXED WARNING
- Drug may increase risk of asthma-related death. When treating asthmatic patients, use only as additional therapy for those not adequately controlled on other asthma-controller medications or whose disease severity clearly warrants treatment with two maintenance therapies (including salmeterol).

Action
Stimulates intracellular adenylate cyclase, an enzyme that catalyzes conversion of adenosine triphosphate to cyclic-3', 5'-adenosine monophosphate (cAMP). Increased cAMP levels relax bronchial smooth muscle and inhibit release of mediators of immediate hypersensitivity (especially from mast cells).

Availability
Powder for inhalation using Diskus delivery system: 50 mcg/blister (60 blisters)

Indications and dosages
- Maintenance treatment of asthma; prevention of bronchospasm in patients with reversible obstructive airway disease; maintenance treatment of bronchospasm in patients with chronic obstructive pulmonary disease (COPD)
- Prevention of exercise-induced bronchospasm
- Adults and children older than age 4: 50 mcg (one inhalation) b.i.d. approximately 12 hours apart

Off-label uses
- Cystic fibrosis
- High-altitude pulmonary edema
- Atopic asthma

Contraindications
- Hypersensitivity to drug or its components
- Acute asthma attack

Precautions
Use cautiously in:
- cardiovascular disease, diabetes mellitus, hyperthyroidism
- concurrent use of MAO inhibitors or tricyclic antidepressants (extreme caution required)
- pregnant or breastfeeding patients
- children younger than age 4

Administration
- To use Serevent Diskus, activate device and hold in horizontal position.
- Make sure patient doesn’t exhale into device.
- Preferably, give doses 12 hours apart in morning and evening.

Adverse reactions
CNS: headache, nervousness, dizziness, tremor
CV: palpitations, hypertension, tachycardia, arrhythmias
GI: nausea, diarrhea, abdominal pain
Metabolic: hyperglycemia, hypokalemia
Musculoskeletal: muscle cramps and soreness
Respiratory: paradoxical bronchospasm
Skin: urticaria, angioedema, rash
Other: hypersensitivity reaction

Interactions
Drug-drug. Beta-adrenergic blockers: decreased salmeterol efficacy, increased risk of severe bronchospasm in patients with asthma or COPD
Diuretics (except potassium-sparing): increased risk of hypokalemia and ECG changes
MAO inhibitors, tricyclic antidepressants: potentiation of salmeterol’s cardiovascular actions
Drug-diagnostic tests. Glucose: increased level
Potassium: decreased level
Drug-food. Caffeine-containing foods and beverages: increased stimulant effect
Urine-acidifying foods: increased drug blood level
Drug-herbs. Caffeine-containing herbs (such as cola nut, yerba maté), ephedra (ma huang): increased stimulant effect

Patient monitoring
- Assess pulmonary status and vital signs.
- Stay alert for signs and symptoms of hypersensitivity reaction, particularly rash, urticaria, angioedema, and paradoxical bronchospasm.

Patient teaching
- Remind patient that drug isn’t a rescue bronchodilator and won’t give immediate relief in emergency.
- Teach patient proper technique for using inhaler or Diskus. Instruct him not to exhale into device or use a spacer with Diskus.
- Advise patient to keep Diskus dry. Tell him not to rinse, wash, or take it apart.
- Instruct patient to take regular doses 12 hours apart. Tell him to take doses for exercise-induced bronchospasm 30 to 60 minutes before exercising.
- Advise patient to take drug exactly as prescribed and not to exceed one inhalation twice daily.
- Tell patient to consult prescriber if he needs more inhalations than usual.
- Caution patient not to stop taking drug without consulting prescriber.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

salsalate
Pharmacologic class: Salicylate
Therapeutic class: Nonopioid analgesic, anti-inflammatory
Pregnancy risk category C

Action
Breaks down into salicylic acid, which lowers elevated body temperature by dilating peripheral vessels. Also reduces inflammation and relieves pain, probably by inhibiting prostaglandin synthesis.

Availability
Tablets: 500 mg, 750 mg

Indications and dosages
Rheumatoid arthritis; nonarticular rheumatism; osteoarthritis; polyarthritis
Adults: Initially, 1 g P.O. t.i.d., titrated as needed

Contraindications
- Hypersensitivity to salicylates, other nonsteroidal anti-inflammatory drugs (NSAIDs), or tartrazine
- Hemophilia
- Bleeding ulcers

Reactions in bold are life-threatening.
Hemorrhagic states
• Blood coagulation defects
• Children and adolescents with viral infections

Precautions
Use cautiously in:
• severe renal disease, hepatic damage, asthma, rhinitis, nasal polyps, hypoprothrombinemia, vitamin K deficiency, chronic alcohol use or abuse
• history of GI bleeding or ulcer disease
• elderly patients
• pregnant (especially during third trimester) or breastfeeding patients.

Administration
• Give with food to minimize GI upset.

Don’t administer to children or adolescents with viral infections, because of increased risk of Reye’s syndrome.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>5-30 min</td>
<td>1-3 hr</td>
<td>3-6 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: drowsiness, dizziness, confusion, headache, stimulation, hallucinations, depression, seizures, coma
CV: rapid pulse
EENT: hearing loss, tinnitus, laryngeal edema
GI: nausea, vomiting, dyspepsia, epigastric distress, heartburn, abdominal pain, anorexia, GI bleeding
Hematologic: hemolytic anemia, leukopenia, agranulocytosis, thrombocytopenia
Hepatic: hepatitis, hepatotoxicity
Metabolic: hyponatremia, hypokalemia, hypoglycemia
Respiratory: wheezing, hyperpnea, pulmonary edema
Skin: rash, flushing, urticaria, bruising, angioedema
Other: salicylism, Reye’s syndrome, anaphylaxis

Interactions
Drug-drug. Activated charcoal: decreased salsalate absorption
Angiotensin-converting enzyme inhibitors: decreased antihypertensive effect
Antacids, urinary alkalizers: decreased salsalate efficacy
Beta-adrenergic blockers, probenecid, spironolactone, sulfispyrazone, sulfonylureas: decreased effects of these drugs
Carbonic anhydrase inhibitors: increased risk of salicylism
Cefamandole, clopidogrel, eptifibatide, heparin, oral anticoagulants, plicamycin, thrombolytics, ticloidipine, tirofiban: increased bleeding
Corticosteroids: increased excretion and decreased blood level of salsalate
Insulin, oral hypoglycemics, penicillin, phenytoin, sulfonamide, valproic acid: increased effects of these drugs
Methotrexate: increased methotrexate blood level and risk of toxicity
NSAIDs: decreased NSAID blood level, increased risk of adverse GI effects
Vancomycin: increased risk of ototoxicity

Drug-diagnostic tests. Activated partial thromboplastin time, bleeding time, prothrombin time: increased
Alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, carbon dioxide, coagulation studies, uric acid, urinary protein: increased levels
Cholesterol, potassium, protein-bound iodine: decreased levels
Erythrocyte survival time: reduced
Pregnancy test, protirelin-induced thyroid-stimulating hormone test, radionuclide thyroid imaging, uric acid, urine catecholamines, urine glucose, urine hydroxyindoleacetic acid, urine ketone tests using ferric chloride method, urine vanillylmandelic acid: interference with test results

Drug-food. Urine-acidifying foods: increased salsalate blood level

Drug-herbs. Anise, arnica, chamomile, clove, fenugreek, feverfew, garlic, ginger,
ginkgo, ginseng, horse chestnut, kelp ware, licorice: increased risk of bleeding

Drug-behaviors. Alcohol use: increased risk of GI bleeding

Patient monitoring
• Monitor for signs and symptoms of anaphylaxis.
• Assess hearing and neurologic status.
• Monitor liver function tests, coagulation studies, and electrolyte and glucose levels.
• Assess for bleeding tendency and angioedema.

Patient teaching
apeut patient to recognize and immediately report signs or symptoms of severe hypersensitivity reaction.
• Caution parents not to give drug to child with symptoms of viral illness.
• Instruct patient to immediately report unusual bleeding or bruising.
• Tell patient that many common herbs increase risk of bleeding. Advise him to consult prescriber before using.
• Caution patient to avoid alcohol, which increases risk of GI bleeding.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

saquinavir mesylate
Invirase

Pharmacologic class: Protease inhibitor
Therapeutic class: Antiretroviral
Pregnancy risk category B

Action
Inhibits human immunodeficiency virus (HIV) protease, preventing cleavage of HIV polyproteins and blocking virus replication and maturation

Availability
saquinavir mesylate
Capsules: 200 mg

Indications and dosages
Advanced HIV infection in selected patients
Adults older than age 16: 1,000 mg P.O. b.i.d. given only in combination with ritonavir b.i.d.

Contraindications
• Hypersensitivity to drug or its components
• Concurrent use of antiarrhythmics (amiodarone, bepridil, flecainide, propafenone, quinidine); astemizole, cisapride, or terfenadine (not available in United States); ergot derivatives; midazolam; pimozide; rifampin; or triazolam
• Severe hepatic impairment
• Monotherapy

Precautions
Use cautiously in:
• hepatic disease, hemophilia types A and B, diabetes mellitus
• pregnant or breastfeeding patients
• children younger than age 16.

Administration
• Give around the clock without missing doses, within 2 hours of a full meal.
• If prescribed in combination with ritonavir, give both drugs at same time.
• Know that drug is given only in combination with ritonavir, which inhibits its metabolism.
• Don’t give concurrently with antiarrhythmics (amiodarone, bepridil, flecainide, propafenone, quinidine); astemizole, cisapride, terfenadine, ergot derivatives, midazolam, pimozide,
rifampin, or triazolam. Life-threatening reactions may occur.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: headache, dizziness, paresthesia, asthenia, depression, insomnia, anxiety, confusion, ataxia, **seizures**, suicidal ideation, intracranial hemorrhage

CV: chest pain, peripheral vasocstriction, **thrombophlebitis**

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, flatulence, dyspepsia, buccal mucosal ulcers, pancreatitis

GU: urinary retention, nephrolithiasis, oliguria, acute renal insufficiency

Hematologic: hemolytic anemia, pancytopenia, thrombocytopenia, acute myeloblastic leukemia

Hepatic: jaundice, portal hypertension, exacerbation of chronic hepatic disease (with grade 4 elevated liver function test results)

Metabolic: hyperglycemia, diabetes mellitus (exacerbation or new onset), hypercalcemia, **hyperkalemia**, hyperglycemia

Musculoskeletal: musculoskeletal pain

Respiratory: bronchitis, cough

Skin: rash, Stevens-Johnson syndrome

Other: altered taste, drug fever

**Interactions**

**Drug-drug.** Antiarrhythmics (amiodarone, bepridil, flecaainide, propafenone, quinidine), astemizole, cisapride, pimozide, terfenadine: increased blood levels of these drugs, life-threatening arrhythmias

Benzodiazepines, calcium channel blockers: increased blood levels of these drugs

Carbamazepine, dexamethasone, nelfinavir, phenobarbital, phenytoin, rifabutin, rifampin: reduced saquinavir steady-state level

Clarithromycin, indinavir, ketoconazole, nelfinavir, ritonavir: increased saquinavir blood level

Ergot derivatives: elevated blood level of these drugs, life-threatening reactions such as acute ergot toxicity (peripheral vasospasm and ischemia of extremities and other tissues)

HMG-CoA reductase inhibitors: increased risk of myopathy (including rhabdomyolysis)

Midazolam, triazolam: increased risk of life-threatening prolonged or increased sedation or respiratory depression

Nonnucleoside reverse transcriptase inhibitors (delavirdine, nevirapine): increased saquinavir blood level

Sildenafil, tadalafil, tricyclic antidepressants, vardenafil: increased blood levels of these drugs

Warfarin: altered International Normalized Ratio

**Drug-diagnostic tests.** Alanine aminotransferase (ALT), amylase, aspartate aminotransferase (AST), bilirubin, calcium, creatinine phosphokinase, potassium: increased levels

Blood glucose: increased or decreased level

Phosphate: decreased level

Platelets, red blood cells, white blood cells: decreased counts

**Drug-food.** Any food: increased drug absorption

Grapefruit juice: elevated drug blood level, increased pharmacologic and adverse effects

**Drug-herbs.** Garlic capsules: decreased saquinavir blood level

St. John’s wort: 50% reduction in saquinavir blood level

**Patient monitoring**

- Monitor platelet count, CBC, liver function tests, electrolytes, and uric acid and bilirubin levels. Watch for evidence of life-threatening blood dyscrasias and portal hypertension.
- Assess nutritional status and hydration.
Monitor neurologic status. Stay alert for depression, suicidal ideation, seizures, and signs or symptoms of intracranial hemorrhage.

**Patient teaching**
- Tell patient to take with food (but not grapefruit juice) or within 2 hours of a full meal. Stress importance of taking doses around the clock on a regular schedule.
- Inform patient (and significant other as appropriate) that drug may cause depression and suicidal thoughts, which should be reported immediately.
- Advise patient to notify prescriber if rash occurs.
- Teach patient to recognize and immediately report signs and symptoms of liver disorder or bleeding tendency.
- Tell patient drug interacts with many other drugs, causing serious reactions. Advise him to discuss all drug use with prescriber before therapy starts.
- Caution patient to avoid St. John’s wort and garlic capsules during therapy.
- Instruct female patient not to breastfeed, because she may transmit drug effects and HIV to infant.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

---

**sargramostim (GM-CSF)**

**Leukine**

**Pharmacologic class:** Granulocyte-macrophage colony stimulating factor

**Therapeutic class:** Hematopoietic agent

**Pregnancy risk category C**

---

**Action**

Stimulates proliferation and differentiation of hematopoietic cells that activate mature granulocytes and macrophages of target cells

**Availability**

*Liquid:* 500 mcg/ml

*Powder for injection:* 250 mcg

---

**Indications and dosages**

- Post peripheral blood progenitor cell (PBPC) transplantation
  - **Adults:** 250 mcg/m²/day I.V. over 24 hours or subcutaneously once daily, starting immediately after progenitor cell infusion
  - **Mobilization of PBPCs into peripheral blood for collection by leukapheresis**
    - **Adults:** 250 mcg/m²/day I.V. over 24 hours or subcutaneously once daily, continued throughout harvesting
  - **Neutrophil recovery after chemotherapy in acute myelogenous leukemia**
    - **Adults:** 250 mcg/m²/day I.V. over 4 hours, starting 4 days after completion of chemotherapy induction
  - **Bone-marrow transplantation failure or engraftment delay**
    - **Adults:** 250 mcg/m²/day as 2-hour I.V. infusion for 14 days. If engraftment doesn’t occur, may repeat after 7 days of drug hiatus.
  - **Myeloid reconstitution after autologous or allogeneic bone-marrow transplantation**
    - **Adults:** 250 mcg/m²/day as a 2-hour I.V. infusion for 14 days. If engraftment doesn’t occur, may repeat after 7 days of drug hiatus.

---

**Off-label uses**

- Crohn’s disease
- Melanoma
- Wound healing
- Mucositis
- Stomatitis
- Vaccine adjuvant

Reactions in bold are life-threatening.
Contraindications
- Hypersensitivity to drug, its components, or yeast products
- Excessive leukemic myeloid blasts in bone marrow or peripheral blood (10% or more)
- Within 24 hours before or after chemotherapy or radiation therapy

Precautions
Use cautiously in:
- renal or hepatic insufficiency, fluid retention, pulmonary disorders, pulmonary infiltrates, heart failure, leukocytosis, transient supraventricular arrhythmias
- cancer patients undergoing sargramostim-mobilized PBPC collection
- patients receiving purged bone marrow or previously exposed to intensive chemotherapy or radiation therapy
- pregnant or breastfeeding patients
- children.

Administration
- Don’t give within 24 hours of chemotherapy or radiation therapy.
- Add 1 ml of sterile water to powder for injection by directing water stream against side of vial and swirling vial gently to disperse contents.
- Avoid shaking or agitating solution.
- For a final drug concentration below 10 mcg/ml, add human albumin 0.1% to saline solution; then dilute drug in normal saline solution.
- Infuse as soon as possible after reconstitution, but no more than 6 hours after mixing.
- Don’t add other drugs to infusion; don’t use in-line filter.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>2 hr</td>
<td>3-6 hr</td>
</tr>
<tr>
<td>Subcut.</td>
<td>15 min</td>
<td>1-3 hr</td>
<td>6 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
- CNS: malaise, asthenia
- CV: peripheral edema, tachycardia, hypotension, transient supraventricular tachycardia, pericardial effusion
- GI: nausea, vomiting, diarrhea, anorexia, stomatitis, GI hemorrhage
- GU: urinary tract disorder, abnormal renal function

Hematologic: blood dyscrasias, hemorrhage
- Hepatic: hepatic damage
- Musculoskeletal: joint pain, myalgia, bone pain
- Respiratory: dyspnea, lung disorder
- Skin: rash, alopecia
- Other: fever, chills, sepsis, edema, first-dose reaction (respiratory distress, hypoxia, syncope, tachycardia, hypotension, flushing)

Interactions
- Drug-drug. Corticosteroids, lithium: potentiation of myeloproliferative effects
- Vincristine: severe peripheral neuropathy

Patient monitoring
- Monitor for dyspnea. Halve dosage and contact prescriber if dyspnea occurs.
- Assess CBC with white cell differential. Check for presence of blast cells, and watch for signs and symptoms of blood dyscrasias.
- Closely monitor vital signs and fluid intake and output. Stay alert for signs and symptoms of fluid overload.
- Monitor liver function tests, and watch for evidence of hepatic damage and bleeding (especially GI hemorrhage).

Patient teaching
- Tell patient sargramostim is a powerful drug that can cause significant adverse reactions. Teach him to recognize and report serious reactions at once.
- Instruct patient to immediately report unusual bleeding or bruising or yellowing of skin or eyes.
Tell patient drug may cause weakness and musculoskeletal pain.
Inform patient that he’ll undergo regular blood testing during therapy.
As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

**scopolamine (hyoscine)**
Scopoderm TTS®, Transderm-Scop, Transderm-V

**scopolamine hydrobromide (hyoscine hydrobromide)**
Buscovan®, Kwells®, Scopace

*Pharmacologic class:* Antimuscarinic, belladonna alkaloid

*Therapeutic class:* Antiemetic, anti-vertigo agent, anticholinergic

*Pregnancy risk category C*

**Action**
Acts as competitive inhibitor at postganglionic muscarinic receptor sites of parasympathetic nervous system and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. May block cholinergic transmission from vestibular nuclei to higher CNS centers and from reticular formation to vomiting center.

**Availability**
*Injection:* 0.3 mg/ml and 1 mg/ml in 1-ml vials, 0.4 mg/ml in 0.5-ml ampules and 1-ml vials, 0.86 mg/ml in 0.5-ml ampules
*Tablets:* 0.4 mg
*Transdermal system (Transderm-Scop):* 1.5 mg/patch (releases 0.5 mg scopolamine over 3 days)

**Indications and dosages**
- Excessive GI motility and hypotonia in irritable bowel syndrome, mild dysentery, diverticulitis, pylorospasm, and cardiopasm

  **Adults:** 0.4 to 0.8 mg P.O. daily

  ➢ Preanesthetic sedation and obstetric amnesia

  **Adults:** 0.3 to 0.6 mg I.M., I.V., or subcutaneously 45 to 60 minutes before anesthesia, usually given with analgesics

  ➢ Postoperative nausea and vomiting

  **Adults:** One transdermal patch placed behind ear on evening before surgery and kept in place for 24 hours after surgery. For cesarean section, one transdermal patch placed behind ear 1 hour before surgery.

  ➢ Motion sickness

  **Adults:** One transdermal patch placed behind ear 4 hours before anticipated need, replaced q 3 days if needed

**Off-label uses**
- Drooling

**Contraindications**
- Hypersensitivity to scopolamine, other belladonna alkaloids, or barbiturates
- Hypersensitivity to bromides (injection only)
- Angle-closure glaucoma
- Acute hemorrhage
- Myasthenia gravis
- Obstructive uropathy (including prostatic hypertrophy)
- Obstructive GI disease (including paralytic ileus and intestinal atony)
- Reflux esophagitis
- Ulcerative colitis or toxic megacolon
- Hepatic or renal impairment
- Chronic lung disease (with repeated doses)

**Precautions**
Use cautiously in:
- suspected intestinal obstruction; pulmonary or cardiac disease;

Reactions in **bold** are life-threatening.
tachyarrhythmia or tachycardia; open-angle glaucoma; autonomic neuropathy; hypertension; hyperthyroidism; ileostomy or colostomy
• history of seizures or psychosis
• elderly patients
• pregnant or breastfeeding patients (safety not established)
• children.

Administration
• For I.V. use, give by direct injection at prescribed rate after diluting with sterile water.
• After removing protective strip from transdermal patch, avoid finger contact with exposed adhesive layer to prevent contamination.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O., I.M., subcut.</td>
<td>30 min</td>
<td>1 hr</td>
<td>4-6 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>10 min</td>
<td>1 hr</td>
<td>2-4 hr</td>
</tr>
<tr>
<td>Transdermal</td>
<td>4 hr</td>
<td>Unknown</td>
<td>72 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: drowsiness, dizziness, confusion, restlessness, fatigue
CV: tachycardia, palpitations, hypotension, transient heart rate changes
EENT: blurred vision, mydriasis, photophobia, conjunctivitis
GI: constipation, dry mouth
GU: urinary hesitancy or retention
Skin: decreased sweating, rash

Interactions
Drug-drug. Antidepressants, antihistamines, disopyramide, quinidine: additive anticholinergic effects
Antidepressants, antihistamines, opioid analgesics, sedative-hypnotics: additive CNS depression
Oral drugs: altered absorption of these drugs
Wax-matrix potassium tablets: increased GI mucosal lesions

Drug-herbs. Angel’s trumpet, jimsonweed, scopolia: increased anticholinergic effects
Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring
• Assess vital signs and neurologic, cardiovascular, and respiratory status.
• Monitor patient for urinary hesitancy or retention.

Patient teaching
• Tell patient transdermal patch is most effective if applied to dry skin behind ear 4 hours before traveling.
• Caution patient to avoid touching exposed adhesive layer of transdermal patch.
• Advise patient to wash and dry hands thoroughly before and after applying patch.
• If patch becomes dislodged, instruct patient to remove it and apply new patch on a different site behind ear.
• Tell patient that using patch for more than 72 hours may cause withdrawal symptoms (headache, nausea, vomiting, dizziness). Advise him to limit use when feasible.
• Inform patient that his eyes may be markedly sensitive to light during patch use. Instruct him to wear sunglasses and use other measures to guard eyes from light.
• Caution patient to avoid alcohol because it may increase CNS depression.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, herbs, and behaviors mentioned above.
secobarbital
Seconal

**Pharmacologic class:** Barbiturate

**Therapeutic class:** Sedative-hypnotic, preanesthetic

**Controlled substance schedule II**

**Pregnancy risk category D**

**Action**
Depresses sensory cortex, decreases motor activity, alters cerebellar function, and produces drowsiness, sedation, and hypnosis

**Availability**
Capsules: 100 mg

**Indications and dosages**
- **Insomnia**
  - **Adults:** 100 mg P.O. at bedtime
- **Preanesthetic sedation**
  - **Adults:** 200 to 300 mg P.O. 1 to 2 hours before surgery
  - **Children:** 2 to 6 mg/kg (maximum of 100 mg) P.O. 1 to 2 hours before surgery

**Dosage adjustment**
- Renal impairment
- Elderly or debilitated patients

**Contraindications**
- Hypersensitivity to drug or other barbiturates
- Marked hepatic impairment
- Respiratory disease with obvious dyspnea or obstruction
- History of manifest or latent porphyria

**Precautions**
Use cautiously in:
- patients with suicidal tendencies or a history of substance abuse
- mild hepatic impairment

- alcohol use
- elderly patients
- labor and delivery
- pregnant or breastfeeding patients.

**Administration**
- Give with or without food when used for insomnia; give without food when used for preanesthetic sedation.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>10-15 min</td>
<td>Unknown</td>
<td>3-4 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** somnolence

**CV:** bradycardia, hypotension, syncope

**Hepatic:** hepatic damage

**Respiratory:** hypoventilation

**Skin:** exfoliative dermatitis, angioedema

**Other:** drug dependence or tolerance, hypersensitivity reaction

**Interactions**

**Drug-drug.**
- **Corticosteroids:** enhanced metabolism of these drugs
- **Doxycycline:** shortened doxycycline half-life
- **Estradiol:** increased estradiol metabolism
- **Griseofulvin (oral):** interference with griseofulvin absorption
- **MAO inhibitors:** prolonged barbiturate activity
- **Oral anticoagulants:** decreased anticoagulant response
- **Other CNS depressants (such as antihistamines, narcotics, tranquilizers):** additive CNS depression
- **Phenprocycline:** increased or decreased phenytoin blood level
- **Valproic acid derivatives:** increased secobarbital blood level

**Drug-herbs.**
- **St. John’s wort:** decreased secobarbital blood level

**Drug-behaviors.**
- **Alcohol use:** increased sedation, additive CNS depression

**Patient monitoring**
- Closely monitor blood pressure and heart and respiratory rates. Watch

Reactions in **bold** are life-threatening.

Clinical alert
for signs and symptoms of respiratory depression, especially with preoperative use.
- Assess CBC and kidney and liver function tests.
- In long-term therapy, monitor patient for drug dependence.

**Patient teaching**
- Tell patient to take only as prescribed. Caution him that drug is habit forming.
- Advise patient to avoid alcohol, St. John’s wort, and other CNS depressants during drug therapy.
- Caution patient to avoid driving and other hazardous activities.
- Advise patient taking hormonal contraceptives to use alternative birth control method.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, herbs, and behaviors mentioned above.

---

**selegiline hydrochloride**

*Pharmacologic class: MAO inhibitor (type B)
*Therapeutic class: Antidyskinetic
*Pregnancy risk category C

---

**FDA BOXED WARNING**
- Drug may increase risk of suicidal thinking and behavior in children and adolescents with major depressive disorder (MDD) and other psychiatric disorders. Anyone considering using it for MDD in a child or adolescent must balance risk with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family and caregivers to observe patient closely and communicate with prescriber as needed.
- Drug isn’t approved for use in pediatric patients.

**Action**
Unknown. Thought to increase dopaminergic activity by inhibiting MAO type B in nerve cells, increasing dopamine availability to brain cells.

**Availability**
Capsules: 5 mg
Tablets: 5 mg
Transdermal system: 6 mg/24 hours, 9 mg/24 hours, 12 mg/24 hours

**Indications and dosages**
- Adjunctive treatment of Parkinson’s disease in patients who don’t respond to carbidopa-levodopa alone
  - **Adults:** 10 mg P.O. daily in divided doses. After 2 to 3 days, attempt to reduce carbidopa-levodopa dosage (typically by 10% to 30%).
  - **Major depressive disorder**
  - **Adults:** Initially, apply 6 mg/24 hours patch; increase in dose increments of 2 mg/24 hours up to a maximum dose of 12 mg/24 hours at intervals of no less than two weeks, if needed.

**Off-label uses**
- Initial therapy for Parkinson’s disease
- Alzheimer’s disease
- Narcolepsy
- Adjunct in schizophrenia

**Contraindications**
- Hypersensitivity to drug or its components
- Concurrent meperidine therapy
Precautions
Use cautiously in:
- patients receiving tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), or dextromethorphan, carbamazepine, and analgesics such as tramadol, methadone, and propoxyphene
- patients with pheochromocytoma
- elderly patients
- pregnant or breastfeeding patients
- children.

Administration
- Give with breakfast and lunch, but restrict foods high in tyramine (such as aged cheese, red wine, yogurt, and smoked high-protein foods).
- Don’t give within 14 days of TCAs or SSRIs (5 weeks for fluoxetine because of its long half-life).
- Apply patch to dry, intact skin on the upper torso (below the neck and above the waist), upper thigh, or the outer surface of the upper arm once every 24 hours.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>0.5-2 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: agitation, anxiety, bradykinesia, chorea, confusion, delusions, depression, dizziness, hallucinations, headache, dyskinesias, increased akinetic involuntary movements, insomnia, lethargy, light-headedness, loss of balance, syncope, vivid dreams
CV: orthostatic hypotension, hypertension, new or increased angina, palpitations, arrhythmias
GI: nausea, diarrhea, abdominal pain, dry mouth
GU: urinary retention
Musculoskeletal: leg pain, low back pain
Other: generalized aches, weight loss

Interactions
Drug-drug. Adrenergics: increased pressor response
Buspirone: elevated blood pressure
Dextromethorphan: brief episodes of psychosis or bizarre behavior
Levodopa: increased adverse reactions to levodopa
Meperidine and analgesics such as tramadol, methadone, and propoxyphene: stupor, muscle rigidity, severe agitation, fever, death
Other MAO inhibitors: hypertensive crisis
SSRIs, TCAs: severe mental status changes, CNS toxicity (with possible hyperpyrexia and death)

Drug-food. Tyramine-rich foods (such as aged cheese, red wine, yogurt, smoked high-protein foods): hypertensive crisis

Drug-herbs. Cacao: vasopressor effects
Ginseng: headache, tremor, mania
St. John’s wort: life-threatening adverse reactions

Patient monitoring
- Monitor vital signs and cardiovascular status.
- Assess neurologic status and motor function. Institute safety measures as needed to prevent injury.
- Monitor weight and fluid intake and output.
- Monitor CBC and liver and kidney function tests.

Patient teaching
- Tell patient he may take capsules or tablets with or without food, but he should avoid foods and beverages high in tyramine. Provide a list of these foods and beverages.
- Inform patient to avoid tyramine-rich foods and beverages beginning on the first day of application of 9mg/24hours- or 12mg/24hours-patch and continue to avoid these foods and beverages for two weeks after a dose reduction to the 6mg/24hours-patch or following the discontinuation of the 9mg/ 24hours- or 12mg/24hours-patch.
- Instruct patient (and caregiver as appropriate) to monitor neurologic

Reactions in bold are life-threatening.

Clinical alert
status and motor function and to institute safety precautions as needed to prevent injury.

- Instruct patient to move slowly when sitting up or standing, to avoid dizziness from sudden blood pressure decrease.
- Tell patient (or caregiver) that drug may cause serious interactions with many drugs. Instruct him to tell all prescribers he’s taking it.
- Tell patient not to use St. John’s wort without consulting with prescriber.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, foods, and herbs mentioned above.

### senna, sennosides

Argoral®, Black Draught, Ex-Lax Gentle, Fletcher’s, Maximum Relief Ex-Lax, Nu-Lax®, Senexon, Senna-Gen, Sennatural, Senokot, Senokot Granules, SenokotXTRA, Senolax, Sure-Lax®, Uni-Senna

**Pharmacologic class:** Anthraquinone laxative  
**Therapeutic class:** Laxative (stimulant)  
**Pregnancy risk category C**

### Action

Causes local irritation in colon, which promotes peristalsis and bowel evacuation. Softens feces by increasing water and electrolytes in large intestine.

### Availability

**Granules:** 15 mg/tsp  
**Liquid:** 8.8 mg/5 ml, 25 mg/5 ml, 33.3 mg/ml (concentrate)  
**Tablets:** 8.6 mg, 10 mg, 15 mg, 17 mg, 25 mg  
**Tablets (chewable):** 15 mg

### Indications and dosages

- **Acute constipation; preparation for bowel examination**  
  - **Adults and children ages 12 and older:** For acute constipation, 12 to 50 mg P.O. daily or b.i.d. For bowel preparation, 105 to 157.5 mg (concentrate) 12 to 14 hours before scheduled procedure.  
  - **Children ages 6 to 11:** 50% of adult dosage  
  - **Children ages 2 to 5:** 33% of adult dosage

### Contraindications

- Hypersensitivity to drug or its components
- GI bleeding or obstruction
- Suspected appendicitis or undiagnosed abdominal pain
- Acute surgical abdomen
- Fecal impaction
- Inflammatory bowel disease (such as Crohn’s disease)

### Precautions

Use cautiously in:  
- pregnant or breastfeeding patients  
- children.

### Administration

- Give with a full glass of cold water.  
- To prepare patient for bowel examination, give 12 to 14 hours before procedure, followed by a clear liquid diet.

### Adverse reactions

**GI:** nausea, vomiting, diarrhea, abdominal cramps, nutrient malabsorption, yellow or yellowish-green feces, loss of normal bowel function (with excessive use), dark pigmentation of rectal mucosa (with long-term use), protein-losing enteropathy  
**GU:** reddish-pink discoloration of alkaline urine, yellowish-brown discoloration of acidic urine
Metabolic: electrolyte imbalances (such as hypokalemia)
Other: laxative dependence (with long-term or excessive use)

Interactions
Drug-diagnostic tests. Calcium, potassium: decreased levels

Patient monitoring
- Assess bowel movements to determine laxative efficacy.
- In long-term use, monitor fluid balance, nutritional status, and electrolyte levels and watch for laxative dependence.

Patient teaching
- Tell patient using drug for constipation to take at bedtime with a glass of water.
- In long-term use, advise patient to watch for and report signs and symptoms of nutritional deficiencies and fluid and electrolyte imbalance.
- If patient will undergo bowel examination, advise him to take drug 12 to 14 hours before procedure, followed by a clear liquid diet.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the tests mentioned above.

sertraline hydrochloride
Apo-Sertraline®, Co Sertraline, Dom-Sertraline, Gen-Sertraline®, Lustral®, Novo-Sertraline®, Nus-Sertraline®, PHL-Sertraline®, PMS-Sertraline®, Ratio-Sertraline®, Riva-Sertraline®, Sandoz Sertraline®, Zoloft

Pharmacologic class: Selective serotonin reuptake inhibitor (SSRI)
Therapeutic class: Antidepressant
Pregnancy risk category C

FDA BOXED WARNING
- Drug may increase risk of suicidal thinking and behavior in children and adolescents with major depressive disorder (MDD) and other psychiatric disorders. Risk must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family and caregivers to observe patient closely and communicate with prescriber as needed.
- Drug isn’t approved for treating MDD in pediatric patients.

Action
Inhibits neuronal uptake of serotonin in CNS, potentiating serotonin activity; has little effect on norepinephrine or dopamine uptake

Availability
Oral concentrate: 20 mg/ml
Tablets: 25 mg, 50 mg, 100 mg

Indications and dosages
➣ Depression
Adults: Initially, 50 mg/day P.O. depending on response. May increase at weekly intervals to a maximum of 200 mg/day.
➣ Obsessive-compulsive disorder
Adults and children ages 13 to 17: Initially, 50 mg/day P.O. May increase at weekly intervals to a maximum of 200 mg/day.
Children ages 6 to 12: 25 mg/day P.O.
➣ Panic disorder; social anxiety disorder; posttraumatic stress disorder
Adults: Initially, 25 mg/day P.O. After 1 week, may increase to 50 mg/day; depending on response, may then increase at weekly intervals to a maximum of 200 mg/day.
➣ Premenstrual dysphoric disorder
Adults: Initially, 50 mg/day P.O., either throughout entire menstrual cycle or
only during luteal phase. For maintenance, 50 to 150 mg/day.

**Off-label uses**
- Premature ejaculation

**Contraindications**
- Hypersensitivity to drug or its components
- MAO inhibitor use within past 14 days
- Concurrent pimozide use
- Concurrent use of disulfiram (oral concentrate)

**Precautions**
Use cautiously in:
- seizures disorders, severe hepatic or renal impairment, increased risk for suicide
- history of mania
- pregnant or breastfeeding patients
- children.

**Administration**
- Give as a single dose in morning or evening.
  - Don’t use rubber dropper when giving concentrate to patient with latex allergy.
  - Don’t give concurrently with pimozide or within 14 days of MAO inhibitors.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>4.5–8.5 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
CNS: dizziness, drowsiness, fatigue, headache, insomnia, agitation, anxiety, confusion, emotional lability, poor concentration, mania, nervousness, weakness, yawning, tremor, hypotonia, hypoesthesia, paresthesia, suicidal behavior or ideation (especially in child or adolescent)
CV: chest pain, palpitations
EENT: vision abnormalities, tinnitus, rhinitis, pharyngitis

GI: nausea, vomiting, diarrhea, constipation, dyspepsia, flatulence, abdominal pain, dry mouth, anorexia
GU: urinary frequency, urinary disorders, sexual dysfunction, menstrual disorders
Musculoskeletal: back pain, myalgia
Skin: diaphoresis, rash
Other: altered taste, increased appetite, fever, thirst, hot flashes

**Interactions**
**Drug-drug.** Adrenergics: increased adrenergic sensitivity, increased risk of serotonin syndrome
Cimetidine: increased sertraline blood level and effects
Clozapine, most benzodiazepines, phenytoin, tricyclic antidepressants, tolbutamide, warfarin: increased blood levels and effects of these drugs
Disulfiram: disulfiram reaction, indicated by nausea, vomiting, flushing, throbbing headache, diaphoresis, cardiovascular and respiratory reactions (with sertraline oral concentrate)
Drugs metabolized by CYP450-2DC or CYP450-3A4: increased blood levels of these drugs
MAO inhibitors: potentially fatal reactions (hyperthermia, rigidity, myoclonus, autonomic instability)
Pimozide: increased pimozide blood level
Sumatriptan: weakness, hyperreflexia, incoordination

**Drug-diagnostic tests.** Alanine aminotransferase, aspartate aminotransferase: increased levels

**Drug-herbs.** S-adenosylmethionine (SAM-e), St. John’s wort: increased risk of serotonergic side effects, including serotonin syndrome

**Drug-behaviors.** Alcohol use: increased CNS effects

**Patient monitoring**
- Monitor patient’s mental status carefully. Stay alert for mood changes and indications of suicidal ideation, especially in child or adolescent.
● Evaluate neurologic status regularly. Institute safety measures, as appropriate, to prevent injury.
● Monitor temperature. Watch for fever and other signs or symptoms of infection.

Patient teaching
● Advise patient to take once a day, either in morning or night, with or without food.
● If evening dose causes insomnia, recommend switching to morning dose.
● Instruct patient to mix oral concentrate with 4 oz of recommended liquid only. Advise him to swallow diluted drug immediately after mixing.
● Tell patient using oral concentrate that drug contains alcohol.
  Caution patient not to stop taking drug suddenly. Dosage must be tapered.
● Inform patient that drug may cause serious interactions with many common drugs. Instruct him to tell all prescribers he’s taking it.
  Advise patient (and significant other as appropriate) to monitor his mental status carefully and to immediately report increased depression or suicidal thoughts or behavior (especially in child or adolescent).
● Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

sildenafil citrate
Revatio, Viagra

Pharmacologic class: Phosphodiesterase type 5 (PDE5) inhibitor
Therapeutic class: Anti-erectile dysfunction agent
Pregnancy risk category B

Action
Inhibits PDE5, enhancing the effects of nitric oxide released during sexual stimulation. This action inactivates cyclic guanosine monophosphate (cGMP), which then increases cGMP levels in corpus cavernosum. Resulting smooth muscle relaxation promotes increased blood flow and subsequent erection.

Availability
Tablets: 25 mg, 50 mg, 100 mg

Indications and dosages
Erectile dysfunction
Adults: 50 mg P.O., preferably 1 hour before anticipated sexual activity. Range is 25 to 100 mg taken 30 minutes to 4 hours before sexual activity, not to exceed one dose daily.

Dosage adjustment
● Hepatic or renal impairment
● Concurrent use of hepatic isoenzyme inhibitors (such as cimetidine, erythromycin, itraconazole, ketoconazole)
● Elderly patients

Contraindications
● Hypersensitivity to drug
● Concurrent use of nitrates (nitroglycerin, isosorbide mononitrate or dinitrate)

Precautions
Use cautiously in:
● serious cardiovascular disease (such as history of myocardial infarction,
cerebrovascular accident, or serious arrhythmia within past 6 months); coronary artery disease (current or previous) with unstable angina; resting blood pressure below 90/50 mm Hg or above 170/110 mm Hg (current or previous); heart failure (current or previous); renal or hepatic impairment (current or previous); bleeding disorder; active peptic ulcer; anatomic penile deformity; retinitis pigmentosa; conditions associated with priapism (sickle cell anemia, multiple myeloma, leukemia)

- history of uncontrolled hypertension or hypotension
- concurrent use of antihypertensives, erythromycin, ketoconazole, itraconazole, or saquinavir
- patients older than age 65.

**Administration**

- Don’t give concurrently with nitrates.
- Administer 30 minutes to 4 hours before sexual activity.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Within 1 hr</td>
<td>Unknown</td>
<td>Up to 4 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: headache, dizziness, anxiety, drowsiness, vertigo, transient global amnesia, seizures, cerebrovascular hemorrhage, transient ischemic attack
CV: hypertension, myocardial infarction (MI), cardiovascular collapse, ventricular arrhythmias, sudden death
EENT: transient vision loss, blurred or color-tinged vision, increased light sensitivity, ocular redness, retinal bleeding, vitreous detachment or traction, photophobia, nasal congestion
GI: diarrhea, dyspepsia
GU: hematuria, urinary tract infection, priapism
Skin: flushing, rash

**Interactions**

**Drug-drug.** Antihypertensives, nitrates: increased risk of hypotension
Enzyme inducers, rifampin: reduced sildenafil blood level
Hepatic isoenzyme inhibitors (such as cimetidine, erythromycin, itraconazole, ketoconazole), protease inhibitors (such as indinavir, nelfinavir, ritonavir, saquinavir): increased sildenafil blood level and effects

**Drug-food.** High-fat diet: reduced drug absorption, decreased peak level

**Patient monitoring**

- Monitor cardiovascular status carefully.
- Evaluate patient’s vision.
- Assess for drug efficacy.

**Patient teaching**

- Advise patient to take 30 minutes to 4 hours before sexual activity.
- Tell patient not to exceed prescribed dosage or take more than one dose daily.
- Instruct patient to stop sexual activity and contact prescriber immediately if chest pain, dizziness, or nausea occurs.
- Teach patient to recognize and immediately report serious cardiac and vision problems.
- Inform patient that drug can cause serious interactions with many common drugs. Instruct him to tell all prescribers he’s taking it.
- Caution patient never to take drug with nitrates, because of risk of potentially fatal hypotension.
- Instruct patient to report priapism (persistent, painful erection) or erections lasting more than 4 hours.
- Tell patient that high-fat diet may interfere with drug efficacy.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and foods mentioned above.

**Simethicone (Simeticone)**


**Pharmacologic class:** Methylated linear siloxane mixture  
**Therapeutic class:** Antiflatulent, antifoam agent  
**Pregnancy risk category NR**

**Action**

Causes gas bubbles to coalesce and allows gas to pass through GI tract via belching or passing of flatus. Silicone antifoam spreads on surface of aqueous liquids, forming a film of low surface tension that causes foam bubbles to collapse.

**Availability**

*Capsules:* 95 mg, 125 mg  
*Capsules (liquid-filled):* 125 mg, 166 mg  
*Drops:* 40 mg/0.6 ml, 40 mg/1 ml, 95 mg/1.425 ml  
*Suspension:* 40 mg/0.6 ml, 50 mg/5 ml  
*Tablets:* 60 mg, 62.5 mg, 80 mg, 95 mg  
*Tablets (chewable):* 40 mg, 80 mg, 125 mg, 150 mg, 166 mg

**Indications and dosages**

- Excess gas in GI tract after surgery or from air swallowing, dyspepsia, peptic ulcer, or diverticulitis
- Adults and children older than age 12: 40 to 125 mg P.O. q.i.d. after meals and at bedtime, up to 500 mg/day  
- Children ages 2 to 12: 40 mg P.O. q.i.d., up to 240 mg/day  
- Children younger than age 2: 20 mg P.O. q.i.d.

**Contraindications**

- Hypersensitivity to drug  
- Intestinal perforation or obstruction

**Precautions**

Use cautiously in:  
- abdominal pain of unknown cause (especially when accompanied by fever).

**Administration**

- Give as needed after meals and at bedtime.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Immediate</td>
<td>Unknown</td>
<td>3 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

None significant

**Interactions**

None significant

**Patient monitoring**

- Monitor GI status to assess drug efficacy.

**Patient teaching**

- Tell patient to take after meals and at bedtime.  
- Caution patient not to take dose higher than indicated on package unless prescriber approves.

Reactions in **bold** are life-threatening.
**simvastatin**
Apo-Simvastatin, Co Simvastatin, Dom-Simvastatin, Gen-Simvastatin, Novo-Simvastatin, Nu-Simvastatin, PHL-Simvastatin, PMS-Simvastatin, Ranzolont, Ratio-Simvastin, Riva-Simvastatin, Sandoz Simvastatin, Simvador, Zocor

*Pharmacologic class:* HMG-CoA reductase inhibitor

*Therapeutic class:* Antihyperlipidemic

*Pregnancy risk category X*

**Action**
Inhibits hepatic enzyme HMG-CoA reductase, interrupting cholesterol synthesis and low-density lipoprotein (LDL) consumption. Net effect is total cholesterol and serum triglyceride reductions.

**Availability**
*Tablets:* 5 mg, 10 mg, 20 mg, 40 mg, 80 mg

**Indications and dosages**
*Coronary artery disease; hyperlipidemia*

**Adults:** 20 to 40 mg P.O. daily in evening, adjusted q 4 weeks based on response. Range is 5 to 80 mg/day.

*Hypercholesterolemia*

**Adults:** Initially, 40 mg P.O. daily at bedtime. Alternatively, 80 mg daily divided as 20 mg in morning, 20 mg in afternoon, and 40 mg at bedtime.

**Children and adolescents ages 10 to 17:** Initially, 10 mg P.O. daily in evening. Range is 10 to 40 mg daily, adjusted at intervals of 4 weeks or longer.

**Dosage adjustment**
- Severe renal impairment
- Concurrent use of amiodarone, fibrates, niacin, or verapamil
- Elderly patients

**Contraindications**
- Hypersensitivity to drug or its components
- Active hepatic disease or unexplained persistent serum transaminase elevations
- Pregnancy or breastfeeding

**Precautions**
Use cautiously in:
- renal impairment; severe acute infection; hypotension; severe metabolic, endocrine, or electrolyte problems; uncontrolled seizures; visual disturbances; myopathy; major surgery; trauma; alcoholism
- history of hepatic disease
- concurrent use of amiodarone, clarithromycin, cyclosporine, digoxin, erythromycin, gemfibrozil and other fibrates, itraconazole, ketoconazole, nefazodone, nicotinic acid, protease inhibitors, verapamil, or warfarin
- cross-sensitivity to other drugs that can affect steroid levels
- females of childbearing age
- children younger than age 18 (safety not established).

**Administration**
*Check liver function tests before starting therapy.*
*Give with evening meal. Don’t give with large amounts of grapefruit juice.*

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

*CNS:* headache, asthenia

*GI:* nausea, vomiting, diarrhea, constipation, abdominal pain or cramps, flatulence, dyspepsia

*Musculoskeletal:* myalgia, rhabdomyolysis

*Respiratory:* upper respiratory infection

**Interactions**

*Drug-drug.* Amiodarone, verapamil: increased risk of severe myopathy or rhabdomyolysis
Digoxin: increased digoxin blood level and possible toxicity  
Other lipid-lowering drugs (such as fibrates, gemfibrozil, nicotinic acid): myopathy  
Potent CYP3A4 inhibitors (clarithromycin, cyclosporine, erythromycin, itraconazole, ketoconazole, nefazodone, protease inhibitors): increased risk of severe myopathy or rhabdomyolysis  
Propranolol: decreased bioavailability of both drugs  
Warfarin: increased anticoagulant effects  

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase: increased levels  
Drug-food. Grapefruit juice (more than 1 qt daily): increased drug blood level, greater risk of adverse reactions  
Drug-herbs. Red yeast rice: increased risk of adverse reactions  
Drug-behaviors. Alcohol use: increased risk of hepatotoxicity

Patient monitoring
- Watch closely for myositis and other adverse musculoskeletal reactions. Know that drug may cause rhabdomyolysis.  
- Monitor liver function tests, CBC, and lipid levels.  
- In patients receiving warfarin concurrently, closely monitor prothrombin time and International Normalized Ratio.

Patient teaching
- Advise patient to take with evening meal, but not with large amounts of grapefruit juice.  
- Tell patient drug may take up to 4 weeks to be effective.  
- Caution patient to stop taking drug and contact prescriber if she suspects she is pregnant.  
- Teach patient to recognize and report signs and symptoms of myopathy or hepatic disorders.  
- Instruct patient to avoid alcohol and red yeast rice.

- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

sirolimus
Rapamune

Pharmacologic class: Macro cyclic lactone  
Therapeutic class: Immunosuppressant  
Pregnancy risk category C

FDA BOXED WARNING
- Immunosuppression may increase patient’s susceptibility to infection and lymphoma development. Give under supervision of physician experienced in immunosuppressive therapy and management of renal transplant patients, in facility with adequate diagnostic and treatment resources. Physician responsible for maintenance therapy should have complete information needed for patient follow-up.

Action
Inhibits early activation and proliferation of T lymphocytes and inhibits cell cycle progression at a later stage

Availability
Oral solution: 1 mg/ml  
Tablets: 1 mg, 2 mg

Indications and dosages
- Prevention of organ rejection in patients with kidney transplants  
Adults and adolescents older than age 13 who weigh more than 40 kg (88 lb): Initially, 6 mg P.O. as a single dose as soon as possible after transplantation, then a maintenance dosage of 2 mg

Reactions in bold are life-threatening.
P.O. once daily. Usually given with cyclosporine and corticosteroids.

**Dosage adjustment**
- Mild to moderate hepatic failure

**Contraindications**
- Hypersensitivity to drug or its components

**Precautions**
- Use cautiously in:
  - renal or hepatic disease, cancer, diabetes mellitus, hyperlipidemia, infectious complications
  - patients with liver or lung transplants (use not recommended)
  - pregnant or breastfeeding patients
  - children younger than age 13.

**Administration**
- Administer consistently either with or without food.
- Use syringe provided to withdraw prescribed amount. Dilute oral solution in a glass or plastic (not Styrofoam) cup containing at least 2 oz of water or orange juice. Don’t use other fluids, especially grapefruit juice.
- Swirl cup to mix drug thoroughly; discard syringe. Administer diluted drug right away. Then fill cup with 4 oz of water or orange juice, and have patient drink fluid right away.
- If solution touches skin or mucous membranes, immediately wash affected area with soap and water.
- Wait 4 hours after the cyclosporine dose (if prescribed) before giving sirolimus.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1-3 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** headache, drowsiness, paresthesia, hypoesthesia, hypertonia, hyperesthesia, emotional lability, dizziness, confusion, syncope, malaise, asthenia, depression, anxiety, tremor, insomnia

**CV:** hypertension, hypotension, tachycardia, chest pain, edema, palpitations, vasodilation, peripheral edema, peripheral vascular disorders, thrombophlebitis, thrombosis, heart failure, atrial fibrillation, hemorrhage

**EENT:** abnormal vision, cataract, conjunctivitis, hearing loss, ear pain, otitis media, tinnitus, epistaxis, rhinitis, sinusitis, pharyngitis

**GI:** nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, hernia, enlarged abdomen, ascites, esophagitis, eructation, flatulence, gastritis, gastroenteritis, dysphagia, stomatitis, mouth ulcers, oral candidiasis, anorexia, peritonitis

**GU:** dysuria, nocturia, pyuria, urinary retention, hematuria, albuminuria, urinary frequency or incontinence, urinary tract infection, pelvic pain, kidney or bladder pain, hydronephrosis, erectile dysfunction, scrotal edema, testes disorders, oliguria, GU tract hemorrhage, renal tubular necrosis, toxic nephropathy

**Hematologic:** anemia, bruising, polycythemia, leukocytosis, thrombocytopenia, leukopenia, thrombotic thrombocytopenia

**Metabolic:** glycosuria, hyperglycemia, diabetes mellitus, hypokalemia, hypophosphatemia, hypovolemia, hypercalcemia, dehydation, Cushing’s syndrome, acidosis

**Respiratory:** dyspnea, cough, upper respiratory infection, bronchitis, hypoxia, pneumonia, atelectasis, pleural effusion, pulmonary edema, asthma

**Skin:** skin ulcers, skin hypertrophy, pruritus, fungal dermatitis, hirsutism, rash, acne, cellultes, non-melanoma skin cancer

**Other:** gingivitis, gum hyperplasia, weight changes, neck pain, fever, abscess, chills, facial edema, flu-like symptoms, infection, lymphadenopathy, abnormal healing, sepsis, lymphoma
Interactions

Drug-drug. Aminoglycosides, amphotericin, other nephrotoxic drugs: increased risk of nephrotoxicity
Bromocriptine, cimetidine, clarithromycin, danazol, erythromycin, fluconazole, indinavir,itraconazole, metoclopramide, nicardipine, ritonavir, verapamil, other CYP3A4 inhibitors: decreased sirolimus metabolism and increased blood level
Carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, other CYP3A4 inducers: decreased sirolimus blood level
Cyclosporine, diltiazem: increased sirolimus blood level
Live-virus vaccines: reduced vaccine efficacy

Drug-diagnostic tests. Blood urea nitrogen, cholesterol, creatinine, hepatic enzymes, lipids, red blood cells: increased levels
Calcium, glucose, phosphate, white blood cells: increased or decreased levels
Hemoglobin, magnesium, platelets, sodium: decreased levels

Drug-food. Grapefruit juice: decreased sirolimus metabolism and increased blood level

Drug-herbs. Astragalus, echinacea, melatonin, St. John’s wort: decreased sirolimus efficacy

Patient monitoring
• Watch closely for signs and symptoms of infection.
• Monitor renal function tests, lipid panel, electrolyte levels, blood chemistry studies, and sirolimus blood level.
• Evaluate all body systems carefully, especially cardiovascular and renal.
• Assess neurologic status closely. Implement safety precautions as needed to prevent injury.

Patient teaching
• Teach patient correct procedure for taking drug.
• Advise patient to take consistently either with or without food, but not with grapefruit juice.
• Instruct patient to wait 4 hours after cyclosporine dose (if prescribed) before taking sirolimus.
• Tell patient to wash affected area with soap and water immediately if drug touches his skin or mucous membranes.
• Inform patient that drug affects almost every body system. Advise him to report significant adverse reactions.
• Advise patient that drug lowers resistance to infection. Instruct him to immediately report fever, cough, breathing problems, sore throat, or other signs and symptoms of infection.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• Instruct patient to immediately report unusual bleeding or bruising.
• Advise female patient to use effective contraception before and during therapy and for 12 weeks after discontinuation.
• Caution patient to limit exposure to sunlight and ultraviolet light. Advise him to wear protective clothing and to use sunscreen with a high protection factor to help prevent skin cancer.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

Clinical alert
Reactions in bold are life-threatening.
Action
Inhibits DPP-4 and slows inactivation of incretin hormones, helping to regulate glucose homeostasis through increased insulin release and decreased glucagon levels.

Availability
Tablets: 25 mg, 50 mg, 100 mg

Indications and dosages
Arrows Adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus
Adults: 100 mg P.O. once daily

Dosage adjustment
- Moderate to severe renal insufficiency

Contraindications
- Hypersensitivity to drug or its components

Precautions
Use cautiously in:
- concurrent administration of drugs that cause hypoglycemia (such as sulfonylureas or insulin)
- renal impairment
- pregnant or breastfeeding patients
- children younger than age 18 (safety and efficacy not established).

Administration
- Assess renal function before starting therapy.
- Give with or without food.
- Know that when drug is used with a sulfonylurea, a lower dose of sulfonylurea may be required, to reduce risk of hypoglycemia.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>1-4 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache
EENT: nasopharyngitis

GI: abdominal pain, nausea, vomiting, diarrhea
Respiratory: upper respiratory tract infection
Other: hypersensitivity reactions (including anaphylaxis, angioedema, exfoliative skin conditions such as Stevens-Johnson syndrome)

Interactions
Drug-drug. Digoxin: minimally increased digoxin effect and blood level Insulin, sulfonylureas: possible increased hypoglycemia risk

Patient monitoring
- Monitor renal function periodically.
- Measure patient’s weight and body mass index periodically during therapy.
- Monitor blood glucose and hemoglobin A1c levels periodically during therapy.
- Monitor patient for signs and symptoms of hypersensitivity reactions and immediately stop drug and institute emergency measures if such reactions occur.
- Check for diabetes signs and symptoms and disease progression routinely during therapy.

Patient teaching
- Instruct patient to take drug with or without food.
- Teach patient about signs and symptoms of hypoglycemia (such as blurred vision, confusion, tremor, sweating, excessive hunger, drowsiness, and fast heart rate).
- Teach patient about signs and symptoms of hypersensitivity reactions (such as rash, throat swelling, or difficulty breathing) and to immediately contact prescriber if these occur.
- Instruct patient to routinely monitor blood glucose levels at home.
- As appropriate, review all other significant adverse reactions and
interactions, especially those related to the drugs mentioned above.

**sodium bicarbonate**

Arm & Hammer Baking Soda, Bell/ans, Citrocarbonate, Naturalyte

**Pharmacologic class:** Fluid and electrolyte agent  
**Therapeutic class:** Alkalinizer, antacid  
**Pregnancy risk category C**

**Action**  
Restores body’s buffering capacity; neutralizes excess acid

**Availability**  
**Injection:** 4% (2.4 mEq/5 ml), 4.2% (5 mEq/10 ml), 5% (297.5 mEq/500 ml), 7.5% (8.92 mEq/10 ml and 44.6 mEq/50 ml), 8.4% (10 mEq/10 ml and 50 mEq/50 ml)  
**Oral solution (Citrocarbonate):** sodium 30.46 mEq/3.9 g and sodium citrate 1.82 g/3.9 g  
**Tablets:** 325 mg, 650 mg

**Indications and dosages**

> **Metabolic acidosis**  
**Adults and children:** 2 to 5 mEq/kg by I.V. infusion over 4 to 8 hours. However, dosage highly individualized based on patient’s condition and blood pH and carbon dioxide content.

> **Urinary alkalization**  
**Adults:** Initially, 4 g P.O.; then 1 to 2 g P.O. q 4 hours  
**Children:** 1 to 10 mEq/kg/day P.O. in divided doses given q 4 to 6 hours

> **Renal tubular acidosis**  
**Adults:** For distal tubular acidosis, 0.5 to 2 mEq/kg P.O. daily in four to five equal doses. For proximal tubular acidosis, 4 to 10 mEq/kg P.O. daily in divided doses.

> **Antacid**  
**Adults:** 300 mg to 2 g P.O. up to q.i.d., given with a glass of water

**Contraindications**  
- Hypocalcemia  
- Metabolic or respiratory alkalosis  
- Hypernatremia  
- Hypokalemia  
- Severe pulmonary edema  
- Seizures  
- Vomiting resulting in chloride loss  
- Diuretic use resulting in hypochloremic alkalosis  
- Acute ingestion of mineral acids (with oral form)

**Precautions**  
Use cautiously in:  
- renal insufficiency, heart failure, hypertension, peptic ulcer, cirrhosis, toxemia  
- pregnant patients.

**Administration**  
- For I.V. use, infuse at prescribed rate using controlled infusion device.

> Don’t give concurrently with calcium or catecholamines (such as norepinephrine, dobutamine, dopamine). If patient is receiving sodium bicarbonate with any of these drugs, flush I.V. line thoroughly after each dose to prevent contact between drugs.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>Immediate</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**  
**CNS:** headache, irritability, confusion, stimulation, tremors, twitching, hyperreflexia, weakness, seizures of alkalosis, tetany  
**CV:** irregular pulse, edema, cardiac arrest  
**GI:** gastric distention, belching, flatulence, acid reflux, paralytic ileus  
**GU:** renal calculi

Reactions in bold are life-threatening.
Metabolic: hypokalemia, fluid retention, hypernatremia, hyperosmolarity (with overdose), metabolic alkalosis
Respiratory: slow and shallow respirations, cyanosis, apnea
Other: weight gain, pain and inflammation at I.V. site

Interactions
Drug-drug. Anorexiants, flecainide, mecamylamine, methenamine, quinidine, sympathomimetics: increased urinary alkalization, decreased renal clearance of these drugs Chlorpropamide, lithium, methotrexate, salicylates, tetracycline: increased renal clearance and decreased efficacy of these drugs Enteric-coated tablets: premature gastric release of these drugs

Drug-diagnostic tests. Lactate, potassium, sodium: increased levels

Drug-herbs. Oak bark: decreased sodium bicarbonate action

Patient monitoring
- When giving I.V., closely monitor arterial blood gas results and electrolyte levels.
- Stay alert for signs and symptoms of metabolic alkalosis and electrolyte imbalances.
- Monitor fluid intake and output. Assess for fluid overload.
- Avoid rapid infusion, which may cause tetany.
- Watch for inflammation at I.V. site.

Patient teaching
- Tell patient using drug as antacid that too much sodium bicarbonate can cause systemic problems. Urge him to use only the amount approved by prescriber.
- Advise patient not to take oral form with milk. Caution him to avoid the herb oak bark.
- Tell patient sodium bicarbonate interferes with action of many common drugs. Instruct him to notify all prescribers if he’s taking oral sodium bicarbonate on a regular basis.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

sodium chloride
Minims Sodium Chloride加拿大, Slo-Salt, Slow Sodium

Pharmacologic class: Electrolyte supplement
Therapeutic class: Sodium replacement
Pregnancy risk category C

Action
Replaces deficiencies of sodium and chloride and maintains these electrolytes at adequate levels

Availability
Injection: 0.45% sodium chloride—25 ml, 50 ml, 150 ml, 250 ml, 500 ml, 1,000 ml; 0.9% sodium chloride—2 ml, 3 ml, 5 ml, 10 ml, 20 ml, 25 ml, 30 ml, 50 ml, 100 ml, 150 ml, 250 ml, 500 ml, 1,000 ml; 3% sodium chloride—500 ml; 5% sodium chloride—500 ml; 14.6% sodium chloride—20 ml, 40 ml, 200 ml; 23.4% sodium chloride—30 ml, 50 ml, 100 ml, 200 ml
Tablets: 650 mg, 1 g, 2.25 g
Tablets (slow-release): 600 mg

Indications and dosages
- Water and sodium chloride replacement; metabolic alkalosis; to dilute or dissolve drugs for I.V., I.M., or subcutaneous use; to flush I.V. catheter; as a priming solution in hemodialysis; to initiate or end blood transfusions
Adults: 0.9% sodium chloride (isotonic solution) with dosage individualized
➤ Hydrating solution; hyperosmolar diabetes
Adults: 0.45% sodium chloride (hypotonic solution) with dosage individualized
➤ Rapid fluid and electrolyte replacement in hyponatremia and hypochloremia; severe sodium depletion; drastic body water dilution after excessive water intake
Adults: 3% or 5% sodium chloride (hypertonic solution) with dosage individualized, given by slow I.V. infusion with close monitoring of electrolyte levels
➤ Heat cramps caused by excessive perspiration
Adults: See product label.

Contraindications
• Normal or elevated electrolyte levels (with 3% and 5% solutions)
• Fluid retention

Precautions
Use cautiously in:
• renal impairment, heart failure, edema or sodium retention, hypoproteinemia
• surgical patients.

Administration
➤ Be aware that sodium chloride injection is a high-alert drug.
• Dilute I.V. dose per product label. Infuse slow I.V. to minimize risk of pulmonary edema.
➤ Don’t confuse normal saline solution for injection with concentrates meant for use in total parenteral nutrition.
• Avoid salt tablets for heat cramps; they may pass through GI tract undigested, causing vomiting and potassium loss.

Adverse reactions
CV: edema (when given too rapidly or in excess), thrombophlebitis, heart failure exacerbation
Metabolic: fluid and electrolyte disturbances (such as hypernatremia and hyperphosphatemia), aggravation of existing metabolic acidosis (with excessive infusion)
Respiratory: pulmonary edema
Other: pain, swelling, local tenderness, abscess, or tissue necrosis at I.V. site

Interactions
Drug-diagnostic tests. Phosphate, potassium, sodium: increased levels

Patient monitoring
• Monitor electrolyte levels and blood chemistry results.
➤ Watch for signs and symptoms of pulmonary edema or worsening heart failure.
• Carefully monitor vital signs, fluid balance, weight, and cardiovascular status.
• Assess injection site closely to help prevent tissue necrosis and thrombophlebitis.

Patient teaching
➤ Teach patient to recognize and immediately report serious adverse reactions, such as breathing problems or swelling.
• Instruct patient to report pain, tenderness, or swelling at injection site.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>Immediate</td>
<td>Unknown</td>
</tr>
</tbody>
</table>
sodium iodide $^{131}I$

Iodotope, Sodium Iodide $^{131}I$

Therapeutic

**Pharmacologic class:** Radiopharmaceutical  
**Therapeutic class:** Antithyroid drug  
**Pregnancy risk category X**

**Action**
Incorporated into iodoamino acids in thyroid and deposited in follicular colloid, from where drug is slowly released. Destructive beta particles in follicle act on thyroidal parenchymal cells, minimizing damage to surrounding tissue.

**Availability**

**Iodotope**
*Capsules:* radioactivity ranging from 1 to 130 millicuries (mCi)/capsule at time of calibration  

**Sodium Iodide $^{131}I$ Therapeutic**
*Capsules:* radioactivity ranging from 0.75 to 100 mCi/capsule at time of calibration  
*Oral solution:* radioactivity ranging from 3.5 to 150 mCi/vial at time of calibration

**Indications and dosages**

> Thyroid cancer

**Adults:** Dosage highly individualized. Usual dosage for ablation of normal thyroid tissue is 50 mCi P.O., with subsequent dosages of 100 to 150 mCi P.O.

> Hyperthyroidism

**Adults:** 4 to 10 mCi P.O. (usually achieves remission without destroying thyroid). Toxic nodular goiter may require higher dosages.

**Contraindications**
- Vomiting and diarrhea
- Known or suspected pregnancy

**Precautions**
Use cautiously in:
- hypersensitivity to sulfites (with some products)
- breastfeeding
- children (safety and efficacy not established).

**Administration**

- Don’t administer if you’re pregnant.
- Make sure all antithyroid drugs and thyroid preparations are discontinued 7 days before radioactive iodine therapy begins. Otherwise, consult prescriber about giving thyroid-stimulating hormone for 3 days.
- Instruct patient to fast for 12 hours before therapy starts.
- Know that all doses must be measured by suitable radioactivity calibration system immediately before use.
- For female patient of childbearing age, give drug the week of or week after menstruation.
- Be aware that drug rarely is used to treat hyperthyroidism in patients younger than age 30.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: unusual fatigue  
CV: chest pain, tachycardia  
EENT: pain on swallowing, sore throat  
GI: nausea, vomiting, severe salivary gland inflammation  
Hematologic: anemia, leukopenia, thrombocytopenia, acute leukemia, bone marrow depression, other blood dyscrasias  
Metabolic: hypothyroidism, transient thyroiditis, acute thyroid crisis  
Respiratory: cough  
Skin: temporary hair thinning, rash, hives, urticaria  
Other: chromosomal abnormalities, neck tenderness and swelling, lymphedema, increase in clinical
symptoms, weight gain, radiation sickness, death

Interactions
Drug-drug. Other antithyroid drugs (such as methimazole), iodine, thyroid agents: altered uptake of sodium iodide $^{131}$I

Drug-diagnostic tests. Hemoglobin, platelets, white blood cells: decreased levels
Procedures using contrast media: altered sodium iodide $^{131}$I uptake

Patient monitoring
- Monitor patient to make sure he’s following full radiation precautions, including proper body fluid disposal.
- If you’re pregnant, don’t provide care to patient who has received this drug.
- If patient has received drug for thyroid cancer, limit contact with him to 30 minutes per shift on first day. Increase as required to 1 hour on second day and longer on subsequent days.
- Monitor thyroxine and thyroid-stimulating hormone blood levels, along with CBC with white cell differential.
- Assess fluid intake and output 48 hours after administration. Encourage high fluid intake.
- Watch for signs and symptoms of hypothyroidism, including fatigue, cold intolerance, depression, and sudden weight gain.
- Monitor for bleeding tendency and signs and symptoms of radiation sickness (vomiting, dehydration, skin lesions, and fatigue).

Patient teaching
- Instruct patient to fast for 12 hours before therapy starts and to drink as much fluid as possible for 48 hours after administration.
- Teach patient and significant other how to follow full radiation exposure precautions.
- If patient is receiving drug for thyroid cancer, instruct him to avoid contact with small children. Tell him not to sleep in same room with anyone else for 7 days after receiving dose.
- Teach patient to recognize and report signs and symptoms of hypothyroidism and radiation sickness.
- Advise patient to immediately report unusual bleeding or bruising.
- Tell female patient to inform prescriber if she is pregnant or plans to become pregnant. Caution her not to breastfeed during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

sodium phosphates

Fleet Enema, Fleet Pediatric Enema, Fleet Phospho-Soda, Visicol

Pharmacologic class: Phosphoric acid salt
Therapeutic class: Saline laxative
Pregnancy risk category NR

Action
Promote hyperosmotic effect in small intestine and increase water retention, which indirectly stimulates peristalsis

Availability
Enema: 160 mg/ml sodium phosphate and 60 mg/ml dibasic sodium phosphate
Liquid: 2.4 g/5 ml monobasic sodium phosphate and 900 mg/5 ml dibasic sodium phosphate
Tablets: 1.102 g sodium phosphate and 0.398 g dibasic sodium phosphate

Reactions in bold are life-threatening.
Indications and dosages

Bowel evacuation before colonoscopy

Adults: On night before procedure, three tablets P.O. with 240 ml of clear liquid q 15 minutes; repeat dose until patient has received 7.96 g dibasic sodium phosphate and 22.04 g sodium phosphate (20 tablets). On day of procedure, repeat dose 3 to 5 hours before procedure.

> Constipation

Adults and children older than age 12: 20- to 30-ml solution mixed with 120 ml cold water P.O., or 60 to 135 ml P.R. as an enema

Contraindications

- Hypertension
- Signs or symptoms of appendicitis (nausea, vomiting, abdominal pain)
- Acute surgical abdomen
- Renal impairment
- Megacolon
- Intestinal obstruction or perforation
- Edema
- Heart failure
- Sodium-restricted diet

Precautions

Use cautiously in:
- anal excoriation or large hemorrhoids
- pregnant patients.

Administration

- Mix oral solution as indicated on label. Have patient drink it right away.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>0.5-3 hr</td>
<td>Variable</td>
<td>Variable</td>
</tr>
<tr>
<td>P.R.</td>
<td>5-10 min</td>
<td>Variable</td>
<td>Variable</td>
</tr>
</tbody>
</table>

Adverse reactions

CV: hypotension, widened QRS complex, arrhythmias, cardiac arrest
GI: nausea, diarrhea, cramps
Metabolic: fluid and electrolyte disturbances (such as hypernatremia and hyperphosphatemia)
Other: laxative dependence

Interactions

Drug-diagnostic tests. Electrolytes:
decreased levels (with prolonged use)
Phosphate, sodium: increased levels

Patient monitoring

- Monitor fluid balance, electrolyte levels, and cardiovascular status if patient is using drug regularly.

Patient teaching

- Tell patient to mix oral solution as indicated on label and to drink it right after mixing.
- For enema use, instruct patient (or caregiver as appropriate) to use water-based lubricant to coat tip of applicator bottle.
- Teach patient to recognize and report signs or symptoms of fluid and electrolyte imbalances.
- Inform patient that drug can cause significant cardiovascular and metabolic effects. Instruct him to use it only for short-term therapy.
- Tell patient that long-term use can cause laxative dependence. Encourage him to increase dietary fiber and fluid intake (unless otherwise contraindicated) to help prevent constipation.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

ㄏ Canada  ᘕ UK  ᘧ Hazardous drug  ᘡ High alert drug
sodium polystyrene sulfonate

Kayexalate, K-Exit Poudre®, Kionex, PHL-Sodium Polystyrene Sulfonate®, PMS-Sodium Polystyrene Sulfonate®, Resonium A®, SPS Sodium Polystyrene Sulfonate

**Pharmacologic class:** Cation exchange resin  
**Therapeutic class:** Potassium-removing resin  
**Pregnancy risk category C**

**Action**  
Exchanges sodium ions for potassium ions in intestine; potassium is then eliminated in feces, which decreases serum potassium level.

**Availability**  
**Oral or rectal powder for suspension:** 1.25 g/5 ml  
**Suspension:** 15 g/60 ml

**Indications and dosages**

**Hyperkalemia**  
**Adults:** 15 g P.O. one to four times daily in water or syrup, or 30 to 50 g P.R. q 6 hours; may instill through nasogastric tube as necessary

**Contraindications**

- Hypersensitivity to drug  
- Severe hyperkalemia  
- Hypokalemia or other electrolyte imbalances

**Precautions**  
Use cautiously in:  
- renal or heart failure, severe edema, severe hypertension  
- pregnant patients.

**Administration**

- Know that drug may take hours to days to lower serum potassium level. Thus, it shouldn’t be used alone to treat severe hyperkalemia.  
- For rectal use, mix resin in water or sorbitol only; never use mineral oil. Insert #28F rubber tube 20 cm into sigmoid colon, and tape it in place. Or use indwelling urinary catheter with 30-ml balloon inflated distal to anal sphincter. Keep rectal solution at room temperature; swirl gently while administering. After giving dose, flush tubing with approximately 100 ml of sodium-free fluid; then flush rectum to remove drug residue.  
- In elderly patients prone to fecal impaction, give cleansing enema before sodium polystyrene enema.

**Route** | **Onset** | **Peak** | **Duration**
--- | --- | --- | ---
P.O. | 2-12 hr | Unknown | Unknown
P.R. | Unknown | Unknown | Unknown

**Adverse reactions**

**GI:** nausea, vomiting, constipation, fecal impaction, gastric irritation, anorexia  
**Metabolic:** hypokalemia, sodium retention, other electrolyte abnormalities

**Interactions**

**Drug-drug.** Antacids, laxatives: systemic alkalosis  
**Drug-diagnostic tests.** Calcium, magnesium, potassium: decreased levels  
Sodium: increased level

**Patient monitoring**

- Monitor electrolyte levels. Watch for signs and symptoms of electrolyte imbalances, particularly sodium overload.  
- Monitor bowel movements. Use measures to prevent or correct constipation or diarrhea, as needed.

**Patient teaching**

- Tell patient drug may cause constipation (or diarrhea, if given with

Reactions in **bold** are life-threatening.
sorbitol). Instruct him to report these problems.
- Teach patient about recommended diet (generally, low in sodium and potassium).
- For oral use, instruct patient to mix only with water, syrup, or sorbitol—never with orange juice.
- Advise patient to refrigerate oral solution to improve taste.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

solifenacin succinate
VESIcare, Vesicare®

Pharmacologic class: Anticholinergic
Therapeutic class: Renal and genitourinary agent
Pregnancy risk category C

Action
Antagonizes muscarinic receptors, reducing urinary bladder smooth-muscle contractions

Availability
Tablets: 5 mg, 10 mg

Indications and dosages
Overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency
Adults: 5 mg P.O. daily initially; may increase to 10 mg P.O. daily if well tolerated

Dosage adjustment
- Moderate hepatic impairment
- Severe renal impairment
- Concurrent use of potent CYP3A4 inhibitors (such as ketoconazole)

Contraindications
- Hypersensitivity to drug or its components
- Urinary retention
- Gastric retention
- Uncontrolled angle-closure glaucoma

Precautions
Use cautiously in:
- hepatic or renal impairment, bladder outflow obstruction, decreased GI motility, GI obstructive disorder, controlled angle-closure glaucoma, congenital or acquired QT interval prolongation
- increased risk of urinary retention or heat prostration
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

Administration
- Give with liquids, with or without food. Make sure patient swallows tablet whole.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>3-8 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, depression, fatigue, asthenia
CV: hypertension
EENT: dry eyes, blurred vision, dry throat, pharyngitis
GI: nausea, vomiting, constipation, upper abdominal pain, dyspepsia, dry mouth
GU: urinary tract infection, urinary retention
Respiratory: cough
Skin: dry skin, rash, pruritus
Other: influenza, leg or foot edema

Interactions
Drug-drug. Anticholinergics: increased frequency or severity of adverse reactions
CYP3A4 inhibitors (such as ketoconazole): increased solifenacin blood level

Canada UK Hazardous drug High alert drug
Patient monitoring
- Monitor GI, renal, and hepatic function frequently.
- Monitor patient for ophthalmic disorders, especially angle-closure glaucoma. If present, stop drug until condition stabilizes.

Patient teaching
- Instruct patient to take drug with liquids, with or without food, and to swallow tablet whole.
- Advise patient to contact prescriber if severe abdominal pain or constipation lasting 3 or more days occurs.
- Caution patient to avoid driving and other hazardous activities until drug effects are known.
- Advise patient of risk for heat prostration; describe symptoms.
- Instruct patient to consult prescriber before taking over-the-counter products such as antihistamines because these may increase risk of side effects.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

somatropin, recombinant
Genotropin, Humatrope, Norditropin, Nutropin AQ, Nutropin AQ Pen, Nutropin Depot, Omnitrope, Saizen, Serostim, Tev-Tropin, Zomacton®, Zorbtive

Pharmacologic class: Posterior pituitary hormone
Therapeutic class: Growth hormone (GH)

Pregnancy risk category B (Genotropin, Saizen, Serostim), C

Action
Stimulates linear and skeletal growth, increases number and size of muscle cells, and influences internal organ size

Availability
Genotropin injection: 1.5 mg (about 4 international units/vial), 5.8 mg (about 15 international units/vial), 13.8 mg (about 41.4 international units/vial)
Humatrope injection: 2 mg (about 6 international units/vial), 5 mg (about 15 international units/vial), 6 mg (about 18 international units/vial), 12 mg (about 36 international units/vial), 24 mg (about 72 international units/vial)
Norditropin injection: 4 mg (12 international units/vial), 8 mg (24 international units/vial)
Norditropin injection cartridge: 5 mg/1.5 ml, 10 mg/1.5 ml, 15 mg/1.5 ml
Nutropin AQ injection: 10 mg
Nutropin AQ Pen injection cartridge: 10 mg
Nutropin Depot: 13.5-mg, 18-mg, and 22.5-mg single-use vials; 13.5-mg, 18-mg, and 22.5-mg kits
Nutropin injection: 5 mg (about 15 international units/vial), 10 mg (about 30 international units/vial)
Saizem injection: 5 g (about 15 international units/vial)
Serostim injection: 5 mg (about 15 international units/vial), 6 mg (about 18 international units/vial)
Tev-Tropin injection: 5 mg
Zorbtive injection: 8.8 mg in 10-ml vial

Indications and dosages
- Growth failure in children with inadequate endogenous GH

Children: 0.16 to 0.24 mg/kg (Genotropin) subcutaneously q week in six or seven divided doses. Or 0.18 mg/kg/week (Humatrope) subcutaneously or I.M., divided equally and given on three alternate days six times weekly (or daily, if epiphyseal closure hasn’t occurred). Or 0.024 to 0.034 mg/kg (Norditropin) subcutaneously six or
seven times each week using NordiPen injection pen. Or 0.3 mg/kg/week (Nutropin AQ, Nutropin AQ Pen, Tev-Tropin) subcutaneously in equally divided daily doses. Or 0.06 mg/kg (Saizen) subcutaneously or I.M. three times weekly.

Endogenous GH replacement in adults with GH deficiency

**Adults:** 0.04 mg/kg/week (Genotropin) subcutaneously in six or seven divided doses. Or 0.006 mg/kg/day (Humatrope) subcutaneously. Or initially, no more than 0.006 mg/kg/day (Nutropin AQ, Nutropin AQ Pen, Tev-Tropin) subcutaneously; may increase to a maximum of 0.025 mg/kg/day after 4 weeks, depending on patient tolerance.

Short stature related to Turner’s syndrome

**Children:** Up to 0.375 mg/kg/week (Humatrope) subcutaneously, divided into equal doses given on 3 alternate days or daily. Or up to 0.375 mg/kg/week (Nutropin AQ, Nutropin AQ Pen) subcutaneously, divided into equal doses given three or seven times weekly.

Idiopathic short stature (non-GH-deficient) in children whose epiphyses haven’t closed

**Children:** Up to 0.37 mg/kg (Humatrope) subcutaneously q week. Divide dosage and give in equal doses six or seven times weekly.

Growth failure in children with Prader-Willi syndrome

**Children:** 0.24 mg/kg/week (Genotropin) subcutaneously in six or seven divided doses

Infants born small for gestational age

**Children:** 0.48 mg/kg/week (Genotropin) subcutaneously in six or seven divided doses

AIDS wasting or cachexia

Adults and children weighing more than 55 kg (121 lb): 6 mg (Serostim) subcutaneously at bedtime

Adults and children weighing 45 to 55 kg (99 to 121 lb): 5 mg (Serostim) subcutaneously at bedtime

Adults and children weighing 35 to 45 kg (77 to 99 lb): 4 mg (Serostim) subcutaneously at bedtime

Adults and children weighing less than 35 kg (77 lb): 0.1 mg/kg/day (Serostim) subcutaneously at bedtime

Growth failure due to chronic renal insufficiency (up to time of kidney transplantation)

**Children:** Up to 0.35 mg/kg/weekly (Nutropin AQ, Nutropin AQ Pen) subcutaneously, divided into daily doses

Short bowel syndrome in patients receiving specialized nutritional support

**Adults:** 0.1 mg/kg/day subcutaneously (Zorbtive), to a maximum of 8 mg/day for no more than 4 weeks

**Contraindications**
- Hypersensitivity to drug, benzyl alcohol, glycerin, or metacresol (with some diluents)
- Active neoplasia
- Acute, critical illness after open-heart surgery, acute respiratory failure, or multiple trauma
- Children with closed epiphyses
- Neonates (Zorbtive)

**Precautions**
Use cautiously in:
- hypothyroidism
- diabetes mellitus.

**Administration**
- Reconstitute by injecting supplied diluent through rubber top of vial and aiming liquid stream at side of vial. Swirl vial gently to mix; don’t shake.
• Inspect reconstituted solution. Don’t use if it has visible particles or is cloudy.
• Keep diluted drug refrigerated; use within 14 days.
• When using prefilled cartridges, follow manufacturer’s instructions carefully.
• Know that patients receiving Zorb-tive for short bowel syndrome may receive specialized nutritional support as needed.

Route Onset Peak Duration
I.M., subcut. Unknown 1-5 hr 12-48 hr

Adverse reactions
CNS: headache, weakness
CV: mild and transient edema
GU: hypercalciuria
Hematologic: leukemia
Metabolic: fluid retention, mild hyperglycemia, hypothyroidism, ketosis
Musculoskeletal: localized muscle pain, tissue swelling, joint pain
Skin: rash, urticaria
Other: pain, inflammation at injection site

Interactions
Drug-drug. Androgens, thyroid hormone: epiphyseal closure
Corticotrophin, corticosteroids: inhibited growth response (with long-term use)
Drug-diagnostic tests. Alkaline phosphatase, glucose, inorganic phosphorus, parathyroid hormone: increased levels

Patient monitoring
• Monitor patient’s height, X-rays, blood chemistry results, blood glucose level, and thyroid function studies.
• Watch for signs and symptoms of leukemia.

Patient teaching
• Advise patient and parents that regular check-ups and blood tests are needed to detect adverse reactions.
• Teach parents how to reconstitute and administer drug. Stress importance of following manufacturer’s instructions carefully when using prefilled cartridges.
• Teach parents about proper handling and disposal of syringes, needles, and cartridges.
• As appropriate, review all significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

sorafenib
Nexavar
Pharmacologic class: Multikinase inhibitor
Therapeutic class: Antineoplastic
Pregnancy risk category D

Action
Decreases tumor cell proliferation in vitro and inhibits tumor growth of murine renal cell carcinoma; interacts with multiple intracellular and cell-surface kinases, several of which are involved with angiogenesis

Availability
Tablets: 200 mg

Indications and dosages
Advanced renal cell carcinoma; unresectable hepatocellular carcinoma
Adults: 400 mg P.O. twice daily, continued until patient no longer benefits from therapy or experiences unacceptable toxicity

Dosage adjustment
• Bleeding event
• Cardiac ischemia or infarction
• Severe or persistent hypertension

Reactions in bold are life-threatening.
● Skin toxicity
● Major surgery

**Off-label uses**
- Advanced pancreatic cancer
- Recurrent epithelial ovarian cancer
- Hepatocellular, breast, colon, colorectal, non-small-cell lung, and thyroid cancers
- Melanoma and sarcoma

**Contraindications**
- Hypersensitivity to drug or its components

**Precautions**
Use cautiously in:
- skin toxicities, hypertension, bleeding, cardiac ischemia, myocardial infarction (MI)
- concurrent use of CYP3A4 inducers, doxorubicin, irinotecan, or CYP2B6 and CYP2C8 substrates
- patients undergoing surgery
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

**Administration**
- Administer without food (1 hour before or 2 hours after eating).

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>3 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** fatigue, sensory neuropathy, headache, asthenia, depression

**CV:** hypertension, myocardial ischemia, MI, heart failure, hypertensive crisis

**EENT:** hoarseness

**GI:** nausea, vomiting, diarrhea, constipation, abdominal pain, mouth pain, mucositis, stomatitis, dyspepsia, dysphagia, anorexia

**GU:** erectile dysfunction

**Hematologic:** lymphopenia, anemia, leukopenia, thrombocytopenia, neutropenia, hemorrhage

**Musculoskeletal:** arthralgia, myalgia

**Respiratory:** cough, dyspnea

**Skin:** rash, desquamation, palmar-plantar erythrodysesthesia (PPE), alopecia, pruritus, dry skin, erythema, acne, flushing, exfoliative dermatitis

**Other:** decreased appetite, weight loss, flu-like syndrome, fever

**Interactions**

**Drug-drug.** CYP3A4 inducers (such as carbamazepine, dexamethasone, phenytoin, phenobarbital, rifampin): increased sorafenib metabolism and decreased blood level

**Docetaxel:** increased docetaxel area under the curve (AUC) and plasma concentration

**Doxorubicin, irinotecan:** increased absorption of these drugs

**Warfarin:** increased risk of bleeding, elevated INR

**Drug-diagnostic tests.** Amylase, lipase: increased

Hemoglobin, platelets, serum phosphates, WBCs: decreased

Liver enzymes: transient increases

**Drug-food.** High-fat meal: reduced drug bioavailability

**Drug-herbs.** St. John’s wort: decreased sorafenib blood level

**Patient monitoring**
- Monitor CBC with differential, platelets, serum phosphate, INR, amylase, lipase, and liver enzyme levels.
- Watch closely for PPE.
- Measure blood pressure weekly during first 6 weeks of therapy and thereafter as needed.
- Monitor for cardiac symptoms.

**Patient education**
- Instruct patient to take drug 1 hour before or 2 hours after eating.
- Urge patient to immediately report rash, bleeding, or chest pain.
- Advise patient to report symptoms of PPE (redness, pain, swelling, or blisters on hands and soles). Mention that these symptoms may warrant dosage decrease.
Stress importance of weekly blood pressure checks during first 6 weeks of therapy.

Instruct males and females to use effective birth control during therapy.

Tell female with childbearing potential to avoid pregnancy during therapy and for at least 2 weeks after.

Advise breastfeeding patient to stop breastfeeding during therapy.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

**sotalol hydrochloride**

Apo-Sotalol®, Beta-Cardone®, Betapace, Betapace AF, Co Sotalol®, Dom-Sotalol®, Gen-Sotalol®, Med Sotalol®, Novo-Sotalol®, Nu-Sotalol®, PHL-Sotalol®, PMS-Sotalol®, Ratio-Sotalol®, Rhoxal-Sotalol®, Rylosol®, Sandoz Sotalol®, Sorine, Sotacor®

**Pharmacologic class:** Beta-adrenergic blocker (nonselective)

**Therapeutic class:** Antiarrhythmic (classes II and III)

**Pregnancy risk category B**

**FDA BOXED WARNING**

- To minimize risk of induced arrhythmia, patients starting or restarting drug should be placed for at least 3 days (on maintenance dosage) in facility that can provide cardiac resuscitation, continuous ECG monitoring, and creatinine clearance calculations.
- Drug also is indicated to treat documented life-threatening ventricular arrhythmias and marketed as Betapace. However, don’t substitute Betapace for Betapace AF because of significant labeling differences.

**Action**

Blocks stimulation of cardiac beta₁-adrenergic and pulmonary, vascular, and uterine beta₂-adrenergic receptor sites. This action reduces cardiac output and blood pressure, depresses sinus heart rate, and prolongs refractory period in atria and ventricles.

**Availability**

*Tablets:* 80 mg, 120 mg, 160 mg, 240 mg

*Tablets (Betapace AF):* 80 mg, 120 mg, 160 mg

**Indications and dosages**

- **Ventricular arrhythmias**
  - **Adults:** 80 mg P.O. b.i.d. (Betapace); may increase dosage gradually. For maintenance, 160 to 320 mg/day in two to three divided doses; some patients may require 240 to 320 mg/day in divided doses. For refractory ventricular fibrillation, may increase to 480 to 640 mg/day in divided doses.
  - **Atrial fibrillation or atrial flutter**
    - **Adults:** 80 mg P.O. b.i.d. (Betapace AF). With careful monitoring, may increase to 120 mg b.i.d. p.r.n., to a maximum of 160 P.O. b.i.d.

**Dosage adjustment**

- Renal impairment

**Contraindications**

- Hypersensitivity to drug
- Uncontrolled heart failure
- Bronchial asthma, chronic obstructive pulmonary disease
- Congenital or acquired long-QT syndrome
- Sinus bradycardia, second- or third-degree atrioventricular (AV) block (unless patient has pacemaker)
- Sick sinus syndrome
- Cardiogenic shock

Reactions in bold are life-threatening.
Hypokalemia
- Creatinine clearance below 40 ml/minute

Precautions
Use cautiously in:
- renal or hepatic impairment, diabetes mellitus, hyperthyroidism
- history of severe allergic reactions
- elderly patients
- pregnant or breastfeeding patients
- children (safety not established).

Administration
- Give 1 hour before or 2 hours after meals or antacids.
- Keep in mind that Betapace and Betapace AF have different indications and are not interchangeable or therapeutically equivalent.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2-4 hr</td>
<td>8-12 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: fatigue, weakness, anxiety, dizziness, drowsiness, insomnia, memory loss, depression, mental status changes, nervousness, paresthesia, nightmares
CV: orthostatic hypotension, peripheral vasoconstriction, bradycardia, arrhythmias, heart failure, AV block
EENT: blurred vision, dry eyes, nasal stuffiness
GI: nausea, constipation, diarrhea
GU: erectile dysfunction, decreased libido
Metabolic: hyperglycemia, hypoglycemia
Musculoskeletal: joint pain, back pain, muscle cramps
Respiratory: wheezing, bronchospasm
Skin: itching, rash
Other: lupus syndrome, hypersensitivity reaction

Interactions
Drug-drug. Amphetamines, ephedrine, epinephrine, norepinephrine, phenylephrine, pseudoephedrine: unopposed alpha-adrenergic stimulation, causing excessive hypotension and bradycardia
- Beta-adrenergic bronchodilators, theophylline: decreased efficacy of these drugs
- Calcium channel blockers: increased risk of adverse cardiovascular reactions
- Class IA antiarrhythmics (such as amiodarone, quinidine): increased risk of arrhythmias
- Clonidine: excessive rebound hypertension with clonidine withdrawal
- Ergot alkaloids: peripheral withdrawal
- General anesthetics, phenytoin (I.V.), verapamil: additive myocardial depression
- Lidocaine: increased lidocaine blood level, resulting in toxicity
- Sulfonylureas: increased hypoglycemic effect

Drug-diagnostic tests. Antinuclear antibody: increased titers
- Blood urea nitrogen, glucose, lipoproteins, potassium, triglycerides, uric acid: increased levels

Drug-food. Any food: decreased drug absorption

Patient monitoring
- Monitor ECG, electrolyte levels, and vital signs closely for first 3 days of therapy.
- Assess patient closely for signs and symptoms of heart failure.
- In long-term use, watch for signs and symptoms of drug-induced lupus syndrome.

Patient teaching
- Tell patient drug may cause significant cardiac effects. Explain need for ECG monitoring during first few days of therapy.
- Teach patient to recognize and immediately report signs and symptoms of heart failure and electrolyte imbalances.
- Inform patient that drug can cause serious interactions with many

加拿大

警告药物
高警示药物
common drugs. Instruct him to tell all prescribers he’s taking it.

Teach patient to recognize and promptly report signs and symptoms of drug-induced lupus syndrome.

- Advise patient that drug may cause CNS effects that increase his injury risk. Encourage him to use appropriate safety precautions.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

**spironolactone**
Aldactone, Novo-Spiroton

**Pharmacologic class:** Aldosterone inhibitor

**Therapeutic class:** Potassium-sparing diuretic

**Pregnancy risk category D**

**FDA BOXED WARNING**

- Drug induced tumors in chronic toxicity studies in rats. Use only in conditions listed under “Indications and dosages.” Avoid unnecessary use.

**Action**
Inhibits aldosterone effects in distal renal tubule, promoting sodium and water excretion and potassium retention

**Availability**
Tablets: 25 mg, 50 mg, 100 mg

**Indications and dosages**

- Edema caused by heart failure, hepatic cirrhosis, or nephrotic syndrome

**Adults:** As sole diuretic, initially 100 mg/day P.O. (range of 25 to 200 mg) in single or divided doses, continued for 5 or more days and then adjusted to optimal therapeutic level

**Children:** 1 to 3 mg/kg/day P.O. as a single dose or in divided doses

- Essential hypertension

**Adults:** Initially, 50 to 100 mg/day P.O. as a single dose or in divided doses, continued for at least 2 weeks

**Children:** 1 to 2 mg/kg P.O. b.i.d.

- Hypokalemia

**Adults:** 25 to 100 mg/day P.O.

- Diagnosis and treatment of primary hyperaldosteronism

**Adults:** For diagnosis, 400 mg/day P.O. for 4 days in short test or for 3 to 4 weeks in long test. Resolution of hypokalemia and hypertension confirm diagnosis of primary hyperaldosteronism. Dosages of 100 to 400 mg/day P.O. may be used as a bridge to surgical therapy; in patients unsuitable for this therapy, lowest effective dosage may be used for long-term maintenance.

**Off-label uses**
- Acne vulgaris
- Familial male precocious puberty (given with other drugs)
- Premenstrual syndrome

**Contraindications**
- Hypersensitivity to drug
- Anuria
- Acute or chronic renal insufficiency
- Hyperkalemia
- Concurrent use of other potassium-sparing diuretics (such as amiloride, triamterene) or potassium supplements

**Precautions**
Use cautiously in:
- hepatic dysfunction, diabetes mellitus, fluid and electrolyte imbalances
- elderly or debilitated patients
- pregnant or breastfeeding patients
- children (safety not established).

Reactions in bold are life-threatening.
Administration
- Give single daily dose with breakfast. If two daily doses are prescribed, give second dose with food in mid-afternoon.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1-2 hr</td>
<td>2-3 days</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, drowsiness, lethargy, ataxia, confusion
GI: vomiting, diarrhea, cramping, gastritis, GI ulcers, GI bleeding
GU: gynecomastia, irregular menses or amenorrhea, postmenopausal bleeding, erectile dysfunction, breast cancer
Hematologic: agranulocytosis
Metabolic: hyponatremia, hyperchloremic metabolic acidosis, hyperkalemia
Skin: rash, pruritus, hirsutism
Other: deepening of voice, drug fever

Interactions
Drug-drug. Angiotensin-converting enzyme inhibitors, potassium-sparing diuretics, potassium supplements, other potassium-containing drugs: increased risk of hyperkalemia
Anticoagulants, heparin: reduced hypoprothrombinic effects of these drugs
Digoxin: increased digoxin blood level
Salicylates: decreased diuretic effect
Drug-diagnostic tests. Blood urea nitrogen, potassium: increased levels
Digoxin assays: false digoxin elevation
Granulocytes: decreased count
Drug-food. Potassium-containing salt substitutes: increased risk of hyperkalemia
Drug-herbs. Licorice: potassium loss

Patient monitoring
- Monitor electrolyte levels (especially potassium). Watch for signs and symptoms of imbalances and metabolic acidosis.
- Monitor weight and fluid intake and output. Stay alert for indications of fluid imbalance.
- Monitor CBC with white cell differential.

Patient teaching
- Tell patient to take daily dose with breakfast. If two daily doses are prescribed, advise him to take second dose with food in mid-afternoon.
- Advise patient to restrict intake of high-potassium foods and to avoid licorice and salt substitutes containing potassium.
- Tell male patient drug may cause breast enlargement.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

stavudine (d4T)
Zerit
Pharmacologic class: Nucleoside reverse transcriptase inhibitor
Therapeutic class: Antiretroviral
Pregnancy risk category C

FDA BOXED WARNING
- Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have occurred with use of drug alone or in combination with other nucleoside analogs. Fatal lactic acidosis has been reported in pregnant women who received stavudine-didanosine combination with other antiretrovirals. Use this combination cautiously in pregnant women and only if potential benefit clearly outweighs potential risk.

Canada UK Hazardous drug High alert drug
Pancreatitis (fatal and nonfatal cases) has occurred when stavudine was used as part of combination regimen that included didanosine, in both treatment-naive and treatment-experienced patients.

Action
Inhibits replication of human immunodeficiency virus (HIV) by interfering with the enzyme reverse transcriptase, thereby terminating DNA chain.

Availability
Capsules: 15 mg, 20 mg, 30 mg, 40 mg
Powder for oral solution: 1 mg/ml

Indications and dosages
➣ HIV-1 infection
Adults weighing 60 kg (132 lb) or more: 40 mg P.O. q 12 hours
Adults and children weighing less than 60 kg (132 lb): 30 mg P.O. q 12 hours
Children weighing 30 kg (66 lb) or more: 30 mg P.O. q 12 hours
Children 14 days and older who weigh less than 30 kg (66 lb): 1 mg/kg P.O. q 12 hours
Newborns to infants 13 days old: 0.5 mg/kg P.O. q 12 hours

Dosage adjustment
• Renal impairment
• Elderly patients

Contraindications
• Hypersensitivity to drug or its components
• Lactic acidosis
• Hyperlactatemia
• Severe hepatotoxicity

Precautions
Use cautiously in:
• advanced HIV infection, bone marrow depression, renal failure, peripheral neuropathy
• pregnant or breastfeeding patients.

Administration
• Give with or without food.
• Know that drug is usually given with other antiretrovirals.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Variable</td>
<td>60-90 min</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, insomnia, peripheral neuropathy
GI: nausea, vomiting, diarrhea, abdominal pain, anorexia, pancreatitis
Hematologic: anemia, leukopenia, thrombocytopenia
Hepatic: hepatic steatosis, hepatitis, hepatic failure
Metabolic: increased glucose tolerance, lactic acidosis
Musculoskeletal: myalgia
Skin: rash
Other: chills, fever, allergic reaction

Interactions
Drug-drug. Chloramphenicol, dapsone, didanosine, ethambutol, hydralazine, hydroxyurea, lithium, phenytoin, vincristine, zalcitabine: increased risk of peripheral neuropathy
Doxorubicin, ribavirin, zidovudine: inhibition of stavudine's absorption and metabolism
Myelosuppressants: increased bone marrow depression
Drug-diagnostic tests. Alanine aminotransferase, amylase, aspartate aminotransferase, bilirubin, gamma-glutamyl transferase, lipase: increased levels
Neutrophils, platelets: decreased counts

Patient monitoring
• Monitor closely for signs and symptoms of lactic acidosis. Consult prescriber about drug discontinuation if these occur.
• Watch for and report onset and worsening of peripheral neuropathy.
• Monitor CBC. Report evidence of bone marrow depression.

Reactions in bold are life-threatening.

Clinical alert
Monitor liver function tests and blood chemistry results.

**Patient teaching**
- Tell patient he may take with or without food.
- Teach patient to recognize and promptly report signs and symptoms of lactic acidosis (such as fatigue, GI distress, and difficult or rapid breathing).
- Instruct patient to report numbness or tingling in arms, legs, hands, or feet.
- Caution female patient not to breastfeed, because she may transmit drug effects and HIV to infant.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

---

**streptokinase**

**Streptase**

*Pharmacologic class:* Group C beta-hemolytic streptococcal nonenzymatic protein  
*Therapeutic class:* Thrombolytic  
*Pregnancy risk category C*

**Action**  
Converts plasminogen to plasmin, an enzyme that degrades fibrin clots and lyses thrombi and emboli

**Availability**  
*Powder for injection:* 250,000, 750,000, and 1.5 million international units/vial

**Indications and dosages**  
➤ Acute evolving transmural myocardial infarction  
**Adults:** 1.5 million international units by I.V. infusion over 1 hour as soon as possible after symptom onset. For intracoronary infusion, 20,000 international units by I.V. bolus via coronary catheter, followed by infusion of 2,000 international units/minute over 1 hour (total of 140,000 international units).

➤ Deep-vein thrombosis (DVT)  
**Adults:** Loading dose of 250,000 international units by I.V. infusion over 30 minutes, followed by 100,000 international units/hour I.V. for 72 hours. Begin therapy as soon as possible after thrombotic symptoms begin (preferably within 7 days).

➤ Pulmonary emboli  
**Adults:** Loading dose of 250,000 international units by I.V. infusion over 30 minutes, then 100,000 international units/hour I.V. for 24 hours (or 72 hours if concurrent DVT is suspected). Begin therapy as soon as possible after thrombotic symptoms begin (preferably within 7 days).

➤ Arterial thrombosis or emboli  
**Adults:** Loading dose of 250,000 international units by I.V. infusion over 30 minutes, then 100,000 international units/hour I.V. for 24 to 72 hours. Begin therapy as soon as possible after thrombotic symptoms begin (preferably within 7 days).

**Contraindications**
- Hypersensitivity to drug or anistreplase
- Cerebrovascular accident, intracranial or intraspinal surgery within past 2 months
- Active internal bleeding
- Intracranial neoplasm
- Severe, uncontrolled hypertension

**Precautions**
Use cautiously in:  
- severe hepatic or renal disease, recent major surgery or trauma, obstetric delivery, acute pericarditis, infectious endocarditis, atrioventricular
malformation or aneurysm, suspected thrombus in left side of heart, septic thrombophlebitis or occluded arteriovenous cannula at seriously infected site

- conditions in which bleeding may be hard to manage (such as organ biopsy, peptic ulcer, previous puncture of noncompressible blood vessel)
- history of cerebrovascular disease
- use of drug within past 2 years
- concurrent anticoagulant use
- elderly patients
- pregnant or breastfeeding patients.

**Administration**

- Before giving, make sure hydrocortisone is available to treat allergic reaction and aminocaproic acid is available to treat excessive bleeding.
- As ordered, give test dose of 100 international units intradermally to check for hypersensitivity. Wheal-and-flare response within 20 minutes indicates probable allergy.
- To reconstitute, add 5 ml of normal saline solution or dextrose 5% in water to each vial, then dilute again to 45 ml. Roll vial gently between hands; don’t shake.
- If necessary, dilute further to 50 ml in plastic container or to 500 ml in glass bottle.
- Don’t mix with other drugs or give other drugs through same I.V. line.

### Route Onset Peak Duration

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>1 hr</td>
<td>4 hr</td>
</tr>
<tr>
<td>Intra-coronary</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** headache, intracranial hemorrhage  
**CV:** hypotension, arrhythmias  
**EENT:** periorbital swelling  
**GI:** nausea, vomiting, GI hemorrhage  
**GU:** hematuria  
**Hematologic:** anemia, bleeding tendency

**Musculoskeletal:** musculoskeletal pain  
**Respiratory:** minor breathing difficulties, bronchospasm, apnea  
**Skin:** urticaria, itching, flushing  
**Other:** bleeding at puncture sites, delayed hypersensitivity reaction

**Interactions**

**Drug-drug.** Anticoagulants, aspirin, dipyridamole, indomethacin, phenylbutazone: increased risk of bleeding

**Drug-diagnostic tests.** Hemoglobin: decreased value  
International Normalized Ratio, transaminases: increased values  
Partial thromboplastin time (PTT), prothrombin time (PT): prolonged

**Patient monitoring**

- Monitor vital signs and neurologic status carefully after giving test dose and throughout therapy.
- Watch for signs and symptoms of hypersensitivity reaction. Stop drug if these occur.
- Check for bleeding every 15 minutes for first hour, every 30 minutes for next 7 hours, then every 4 hours.
- Stop therapy and contact prescriber immediately if excessive bleeding occurs.
- Assess neurologic status closely. Watch for indications of intracranial bleeding.
- Handle patient gently and sparingly. If necessary, pad bed rails to prevent injury.
- Monitor pulse rate every hour. Also monitor distal circulation.
- Monitor PTT, PT, plasma thrombin time, hemoglobin, hematocrit, and platelet count.
- Avoid giving I.M. injections during therapy.

**Patient teaching**

- Tell patient why he’s receiving drug.
- Teach patient to recognize and immediately report signs or symptoms of hypersensitivity reaction or excessive bleeding.
Instruct patient to report unusual bruising or bleeding. Teach him safety measures to avoid bruising and bleeding.

Advise patient that he’ll undergo regular blood testing during therapy.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

streptomycin sulfate

**Pharmacologic class:** Aminoglycoside  
**Therapeutic class:** Anti-infective  
**Pregnancy risk category D**

---

**Action**

Binds to 30S ribosomal subunit, inhibiting protein synthesis in bacterial cell, which causes misreading of genetic code and, ultimately, cell death

**Availability**

*Injection:* 400 mg/ml in 2.5-ml ampules, 200 mg/ml in 1-g vials

**Indications and dosages**

- **Adjunct in tuberculosis and other mycobacterial infections**
  - **Adults:** 15 mg/kg/day I.M., up to 1 g/day  
  - **Children:** 20 to 40 mg/kg I.M. daily, up to 1 g/day
- **Enterococcal or streptococcal infections**
  - **Adults:** 1 g I.M. b.i.d. for 1 week, then 500 mg I.M. b.i.d. for 1 week. For enterococcal endocarditis, 1 g I.M. b.i.d. given with penicillin for 1 week, then 500 mg I.M. b.i.d. for 4 weeks.
- **Brucellosis**
  - **Adults:** 1 g I.M. once or twice daily with tetracycline or doxycycline for 1 week, then once daily for at least 1 more week
- **Tularemia**
  - **Adults:** 1 to 2 g I.M. daily in divided doses for 7 to 14 days until patient is afebrile for 5 to 7 days. For tularemia caused by *Francisella tularensis*, 1 g I.M. b.i.d. for 10 days or 7.5 to 10 mg/kg I.M. b.i.d. for 10 to 14 days.
- **Plague caused by Yersinis pestis**
  - **Adults:** 1 g I.M. b.i.d. for 10 to 14 days

**Dosage adjustment**

- Renal impairment
- Elderly patients

**Off-label uses**

- *Mycobacterium avium-intracellulare* complex in AIDS patients

**Contraindications**

- Hypersensitivity to drug, other aminoglycosides, or bisulfites
Precautions
Use cautiously in:
- renal impairment, hearing impairment, neuromuscular disease (such as myasthenia gravis)
- elderly patients
- pregnant or breastfeeding patients
- infants and neonates (safety not established).

Administration
- Inject I.M. deep into upper outer quadrant of buttoc.
- Alternate injection sites.
- Know that drug may be given with other antituberculars.
- Be aware that streptomycin will be withdrawn after several months or when bacteriologic smears are negative and other antituberculars are continued for 1 year.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.M.</td>
<td>Rapid</td>
<td>30-90 min</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: vertigo, numbness and tingling, peripheral neuropathy, myasthenia gravis–like syndrome, neuromuscular blockade, seizures
CV: myocarditis
EENT: amblyopia, ototoxicity
GI: nausea, vomiting
GU: azotemia, nephrotoxicity
Hematologic: eosinophilia, hemolytic anemia, pancytopenia, leukopenia, thrombocytopenia
Hepatic: hepatic necrosis
Musculoskeletal: muscle weakness, twitching
Respiratory: apnea
Skin: rash, urticaria, exfoliative dermatitis, toxic epidermal necrolysis, angioedema
Other: fever, superinfection, serum sickness, anaphylaxis

Interactions
Drug-drug. Acyclovir, amphotericin B, cephalosporin, cisplatin, potent diuretics, vancomycin: increased risk of ototoxicity and nephrotoxicity
Depolarizing and nondepolarizing neuro muscular blockers, general anesthetics: potentiation of neuromuscular blockade
Dimenhydrinate: masking of ototoxicity symptoms
Indomethacin: increased streptomycin peak and trough blood levels
Parenteral penicillins (ampicillin, ticarcillin): streptomycin inactivation
Drug-diagnostic tests. Bilirubin, blood urea nitrogen, creatinine, lactate dehydrogenase, nonprotein nitrogen: increased levels
Granulocytes, hemoglobin, platelets, white blood cells: decreased levels

Patient monitoring
- Draw blood for peak drug level 1 hour after I.M. injection. Draw blood for trough level just before next dose.
- Monitor liver and kidney function tests. Watch for evidence of hepatotoxicity and nephrotoxicity.
- Monitor temperature. Stay alert for fever and other signs and symptoms of superinfection.
- Assess neurologic status and sensory function carefully. Watch closely for neurotoxicity, neuromuscular blockade, and seizures.
- Assess for signs and symptoms of ototoxicity.
- Monitor CBC. Watch for evidence of blood dyscrasias.

Patient teaching
- Instruct patient to report unusual bleeding or bruising.
  - Inform patient that drug can be toxic to many body systems. Teach him to recognize and immediately report serious adverse reactions.
  - Tell patient drug may promote growth of certain organisms. Advise him to immediately report signs and symptoms of superinfection.
- Inform patient that drug may impair cognitive, motor, and sensory function.

Reactions in bold are life-threatening.
Advise him to use caution when driving and performing other hazardous activities.

- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**sucralfate**

Antepsin®, Apo-Sucralfate®, Carafate, Dom-Sucralfate®, Novo-Sucralfate®, Nu-Sucralfate®, PMS-Sucralfate®, Sulcrate®

**Pharmacologic class:** GI protectant  
**Therapeutic class:** Antiulcer agent  
**Pregnancy risk category B**

**Action**
Combines with gastric acid to form protective coating on ulcer surface, inhibiting gastric acid secretion, pepsin, and bile salts

**Availability**

- **Oral suspension:** 500 mg/5 ml  
- **Tablets:** 1 g

**Indications and dosages**

- **Active duodenal ulcer**
  - **Adults:** 1 g P.O. q.i.d. 1 hour before meals and at bedtime or 2 g b.i.d. for 4 to 8 weeks. For maintenance, 1 g P.O. b.i.d.

**Off-label uses**
- Gastroesophageal reflux  
- GI symptoms caused by nonsteroidal anti-inflammatory drugs (including aspirin)  
- Prevention of stress ulcers and GI bleeding in critically ill patients  
- Oral and esophageal ulcers caused by radiation, chemotherapy, or sclerotherapy (oral suspension)

**Contraindications**
None

**Precautions**

- Use cautiously in:
  - renal failure  
  - pregnant or breastfeeding patients  
  - children.

**Administration**

- When giving through nasogastric tube, reconstitute drug and flush tube with water after administration.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>6 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- **EENT:** rhinitis  
- **GI:** constipation  
- **Respiratory:** respiratory difficulty  
- **Skin:** pruritus, rash  
- **Other:** facial swelling, hypersensitivity reaction

**Interactions**

**Drug-drug.** *Aluminum-containing antacids:* increased total body burden of aluminum  
*Anticoagulants:* decreased hypoprothrombinemic effect  
*Diclofenac:* decreased pharmacologic effects of diclofenac  
*Digoxin, quinidine:* reduced blood levels and efficacy of these drugs  
*Histamine₂-receptor antagonists (such as cimetidine, ranitidine), fluoroquinolones, ketoconazole, tetracyclines, theophylline:* decreased bioavailability of these drugs  
*Levothyroxine, penicillamine:* decreased efficacy of these drugs  
*Phenytoin:* decreased phenytoin absorption

**Patient monitoring**

- Monitor bowel pattern. Report severe, ongoing constipation.  
- Assess for rash and itching.
Patient teaching
- Tell patient to take 1 hour before meals and again at bedtime.
- Caution patient not to take within 30 minutes of antacids or other drugs.
- Explain importance of completing entire course of therapy as prescribed, even after pain and other ulcer symptoms improve.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

**sulfacetamide sodium**
AK-Sulf, Bleph-10, Diosulf, Klaron, Ocu-Sul 10, Ocu-Sul 15, Ocu-Sul 30, Ovace, Ovace Wash, PMS-Sulfacetamide

*Pharmacologic class:* Sulfonamide  
*Therapeutic class:* Anti-infective  
*Pregnancy risk category C*

**Action**
Inhibits bacterial synthesis of folic acid by preventing condensation of pteridine with aminobenzoic acid through competitive inhibition of dihydropteroylglutamate synthetase

**Availability**
Lotion: 10% in 2-oz and 4-oz bottles  
Ointment: 10% in 5-g tubes  
Ophthalmic solution: 10%, 15%, and 30% in 5-ml and 15-ml dropper bottles

**Indications and dosages**

- **Acne vulgaris**

  - **Adults and children ages 12 and older:** Apply thin film topically to affected areas b.i.d.

- **Superficial ocular infections (including conjunctivitis)**

  - **Adults and children ages 2 months and older:** Initially, apply one to two drops of ophthalmic solution into conjunctival sac of affected eye q 2 to 3 hours, or apply approximately ⅛” ribbon of ophthalmic ointment into conjunctival sacs of affected eye q 3 to 4 hours and at bedtime. Taper by increasing dosing intervals as condition responds. Usual duration is 7 to 10 days.

  > Adjunct in trachoma

  - **Adults:** Apply two drops of ophthalmic solution into conjunctival sac of affected eye q 2 hours; must be accompanied by systemic sulfonamide therapy.

**Contraindications**
- Hypersensitivity to drug or other sulfonamides

**Precautions**
Use cautiously in:
- sulfite allergy
- dry eye syndrome.

**Administration**
- To avoid contamination, don’t touch container tip to eye, eyelid, or any other surface.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ophth.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
EENT: conjunctival hyperemia, eye burning, stinging, tearing (ophthalmic form)  
Skin: local irritation, erythema, itching and edema (topical form), photosensitivity reaction  
Other: secondary infections

**Interactions**
Drug-drug. *Porfimer:* increased severity of photosensitivity reaction, leading to excessive tissue damage  
*Silver preparations:* precipitation

Reactions in **bold** are life-threatening.
Patient monitoring
- Monitor patient for drug efficacy. Know that drug may be inactivated by purulent exudate.

Patient teaching
- Tell patient to apply a thin film of lotion to affected areas, as prescribed.
- Teach patient how to apply ophthalmic form. Instruct him to always wash hands first and to clean eye area of discharge by wiping from inner to outer area before applying.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

Sulfamethoxazole-trimethoprim
(co-trimoxazole®)
Apo-Sulfatrim®, Apo-Sulfatrim DS®, Bactrim, Bactrim DS, Fectrim®, Novo-Trimel®, Novo-Trimel DS®, Nu-Cotrimox®, Nu-Cotrimox DS®, Protrin®, Protrin DS®, Septra, Septra DS, Septrin®, Sulfatrim, Trisulfa®, Trisulfa DS®, Trisulfa S Suspension®

Pharmacologic class: Sulfonamide
Therapeutic class: Anti-infective
Pregnancy risk category C

Action
Sulfamethoxazole inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA). Trimethoprim inhibits enzymes of folic acid pathways.

Availability
Injection: 80 mg/ml sulfamethoxazole and 16 mg/ml trimethoprim
Suspension: 200 mg sulfamethoxazole and 40 mg trimethoprim/5 ml
Tablets: 400 mg sulfamethoxazole and 80 mg trimethoprim (single strength); 800 mg sulfamethoxazole and 160 mg trimethoprim (double strength)

Indications and dosages
➢ Urinary tract infections caused by susceptible organisms
Adults: One double-strength tablet or two single-strength tablets or 20 ml suspension P.O. q 12 hours for 10 to 14 days
Children ages 2 months and older: 40 mg/kg sulfamethoxazole and 8 mg/kg trimethoprim P.O. q 12 hours for 10 days
➢ Severe urinary tract infections caused by susceptible strains of Shigella flexneri or Shigella sonnei
Adults: One double-strength tablet or two single-strength tablets or 20 ml suspension P.O. q 12 hours for 10 to 14 days. Alternatively, 8 to 10 mg/kg (based on trimethoprim component) I.V. q 6, 8, or 12 hours for up to 14 days
Children ages 2 months and older: 40 mg/kg (sulfamethoxazole) and 8 mg/kg (trimethoprim) P.O. q 12 hours for 5 days. Alternatively, 8 to 10 mg/kg (based on trimethoprim component) I.V. q 6, 8, or 12 hours for up to 5 days.
➢ Shigellosis caused by susceptible strains of Shigella flexneri or Shigella sonnei
Adults: One double-strength tablet or two single-strength tablets or 20 ml suspension P.O. q 12 hours for 10 to 14 days. Alternatively, 8 to 10 mg/kg (based on trimethoprim component) I.V. q 6, 8, or 12 hours for 5 days.
Children ages 2 months and older: 40 mg/kg sulfamethoxazole and 8 mg/kg trimethoprim P.O. q 12 hours for 5 days. Alternatively, 8 to 10 mg/kg (based on trimethoprim component) I.V. q 6, 8, or 12 hours for up to 5 days.
➢ Acute exacerbation of chronic bronchitis caused by susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae
Adults: One double-strength tablet or two single-strength tablets or 20 ml suspension P.O. q 12 hours for 10 to 14 days
Pneumocystis jiroveci pneumonia
Adults and children older than 2 months: 75 to 100 mg/kg
(sulfamethoxazole) and 15 to 20 mg/kg (trimethoprim) P.O. daily in equally divided doses q 6 hours for 14 to 21 days. Alternatively, 15 to 20 mg/kg (based on trimethoprim component) I.V. q 6 to 8 hours for up to 14 days.

Prophylaxis of *P. jiroveci* pneumonia

**Adults:** One double-strength tablet P.O. daily

**Children ages 2 months and older:** 750 mg/m² (sulfamethoxazole) and 150 mg/m² (trimethoprim) P.O. b.i.d. in equally divided doses on 3 consecutive days each week. Total dosage should not exceed 1,600 mg sulfamethoxazole and 320 mg trimethoprim.

Traveler’s diarrhea caused by susceptible strains of enterotoxigenic *Escherichia coli*

**Adults:** One double-strength tablet or two single-strength tablets or 20 ml suspension q 12 hours for 5 days

Acute otitis media caused by susceptible strains of *S. pneumoniae* or *H. influenzae*

**Children ages 2 months and older:** 40 mg/kg sulfamethoxazole and 8 mg/kg trimethoprim P.O. q 12 hours for 10 days

**Off-label uses**
- Granuloma inguinale
- Toxoplasmonic encephalitis (as primary prophylaxis)

**Dosage adjustment**
- Renal impairment

**Contraindications**
- Hypersensitivity to sulfonamides, trimethoprim, sulfonylureas, thiazides, or loop diuretics
- Porphyria
- Marked renal or hepatic impairment
- Megaloblastic anemia caused by folate deficiency
- Pregnancy at term or when premature birth is possible
- Infants younger than 2 months (except in *P. jiroveci* pneumonia prophylaxis)

**Precautions**
Use cautiously in:
- urinary obstruction, renal or hepatic disease, bronchial asthma, G6PD deficiency, group A beta-hemolytic streptococcal infection, blood dyscrasias
- history of multiple allergies
- elderly patients
- pregnant (before term) or breastfeeding patients
- children.

**Administration**
- Dilute each 5 ml of I.V. drug in 125 ml of dextrose 5% in water.
- Infuse I.V. over 60 to 90 minutes. Avoid rapid infusion.
- Don’t mix with other drugs or solutions. Don’t refrigerate. Use within 6 hours after dilution.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>1-4 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>1 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** headache, depression, hallucinations, insomnia, drowsiness, fatigue, apathy, anxiety, ataxia, vertigo, polyneuritis, peripheral neuropathy, seizures

**CV:** allergic myocarditis or pericarditis

**EENT:** periorbital edema, optic neuritis, transient myopia, tinnitus

**GI:** nausea, vomiting, abdominal pain, stomatitis, glossitis, dry mouth, pancreatitis, anorexia, *pseudomembranous colitis*

**GU:** hematuria, proteinuria, *crystaluria*, *toxic nephrosis with oliguria* and anuria, renal failure

**Hematologic:** megaloblastic anemia, agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, hemolytic anemia

**Hepatic:** jaundice, *hepatitis, hepatocellular necrosis*
Respiratory: shortness of breath, pleuritis, allergic pneumonitis, pulmonary infiltrates, fibrosing alveolitis
Skin: generalized skin eruption, urticaria, pruritus, alopecia, local irritation, exfoliative dermatitis, photosensitivity reaction, epidermal necrolysis, erythema multiforme, Stevens-Johnson syndrome
Other: irritation at I.V. site, chills, drug fever, hypersensitivity reactions including anaphylaxis, serum sickness, lupus-like syndrome

Interactions
Drug-drug. Cyclosporine: increased nephrotoxicity
Dapsone: increased blood levels of both drugs
Hydantoins, zidovudine: increased blood levels of these drugs
Indomethacin, probenecid: increased sulfamethoxazole blood level
Methotrexate: increased risk of bone marrow suppression
Oral anticoagulants: increased anticoagulant effect
PABA, PABA-derived local anesthetics: inhibited sulfamethoxazole action
Sulfonylureas: increased risk of hypoglycemia
Thiazide diuretics: increased risk of thrombocytopenic effects
Thiazide diuretics: increased uricosuric effects

Drug-diagnostic tests. Bilirubin, blood urea nitrogen, creatinine, eosinophils, transaminases: increased levels
Granulocytes, hemoglobin, platelets, white blood cells: decreased levels
Urine glucose tests: false-positive results

Drug-herbs. Dong quai, St. John’s wort: increased risk of photosensitivity

Drug-behaviors. Sun exposure: increased risk of photosensitivity

Patient monitoring
Monitor CBC with white cell differential. Watch for evidence of blood dyscrasias.

Stay alert for erythema multiforme. Report early signs before condition can progress to Stevens-Johnson syndrome.

Monitor patient for signs and symptoms of superinfection, including fever, tachycardia, and chills.

Monitor liver function tests and assess for evidence of hepatitis.

Check kidney function tests weekly. Evaluate patient’s fluid intake, urine output, and urine pH. Report hematuria, oliguria, or anuria right away.

Monitor neurologic status. Report seizures, hallucinations, or depression.

Patient teaching

Advise patient to take on regular schedule as prescribed, along with a full glass of water. Tell him to drink plenty of fluids to minimize crystal formation in urine.

If suspension is prescribed, make sure patient has a specially marked measuring spoon or other device so he can measure doses accurately.

Instruct patient to complete full course of treatment even if he starts to feel better.

Teach patient to recognize and immediately report signs and symptoms of hypersensitivity, especially rash.

Inform patient that drug can cause blood disorders, GI and liver problems, serious skin reactions, and other infections. Describe key warning signs and symptoms (easy bruising or bleeding, severe diarrhea, unusual tiredness, yellowing of skin or eyes, sore throat, rash, cough, mouth sores, fever). Tell him to report these right away.

Urge patient to promptly report scant or bloody urine or inability to urinate.

Tell patient to contact prescriber if he develops depression.

Teach patient effective ways to counteract photosensitivity effect. Advise him that dong quai and St. John’s wort
increase phototoxicity risk and should be avoided during therapy.
- Advise female patient to inform prescriber if she is pregnant. Tell her not to take drug near term.
- Caution female patient not to breastfeed, because she could pass drug effects to infant.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

---

**sulfasalazine**

APC Sulfasalazine®, Azulfidine, Azulfidine EN-tabs, PMS-Sulfasalazine®, PMS-Sulfasalazine-E.C.®, Salazopyrin®, Salazopyrin EN-Tabs®, SAS Tab®, Sulazine®, Sulfazine, Sulfazine EC

**Pharmacologic class:** Sulfonamide  
**Therapeutic class:** Anti-infective, GI tract anti-inflammatory, antirheumatic  
**Pregnancy risk category B**

**Action**  
Unknown. Thought to inhibit prostaglandin synthesis by interfering with secretions in colon and causing local anti-inflammatory action.

**Availability**  
*Tablets:* 500 mg  
*Tablets (Azulfidine EN-tabs—delayed-release, enteric-coated):* 500 mg

**Indications and dosages**

- **Ulcerative colitis**
  - **Adults:** Initially, 1 to 2 g P.O. daily in equally divided doses q 6 to 8 hours, then 3 to 4 g P.O. daily in equally divided doses q 6 to 8 hours. For maintenance, 500 mg q 6 hours.
  - **Children ages 6 and older:** 40 to 60 mg/kg P.O. daily in three to six divided doses. For maintenance, 30 mg/kg P.O. q 6 hours in four divided doses.

- **Acute rheumatoid arthritis**
  - **Adults:** Initially, 500 mg to 1 g (delayed-release) P.O. daily for 1 week; then increase by 500 mg/day P.O. q week up to 2 g/day in two divided doses. If no benefit after 12 weeks, increase to 3 g/day given in two divided doses.
  - **Polyarticular-course juvenile rheumatoid arthritis**
  - **Children ages 6 and older:** 30 to 50 mg/kg P.O. daily in two evenly divided doses. Maximum dosage is 2 g daily.

**Off-label uses**
- Ankylosing spondylitis
- Crohn’s disease
- Psoriatic arthritis

**Contraindications**
- Hypersensitivity to drug, other sulfonamides, sulfonylureas, thiazides, loop diuretics, or salicylates
- Porphyria
- Marked renal or hepatic impairment
- Urinary tract or intestinal obstruction
- Pregnancy at term or when premature birth is possible
- Children younger than age 2

**Precautions**
Use cautiously in:
- renal or hepatic disease, bronchial asthma, G6PD deficiency, group A beta-hemolytic streptococcal infections, blood dyscrasias
- history of multiple allergies
- pregnant (before term) or breastfeeding patients
- children (use in systemic-course rheumatoid arthritis not recommended).

**Administration**
- Give after meals and space doses evenly to reduce GI effects.

Reactions in **bold** are life-threatening.
Give with a full glass of water.
- Administer delayed-release tablets whole. Don’t let patient crush or chew them.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1.5 hr</td>
<td>10 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
- CNS: headache, depression, hallucinations, insomnia, drowsiness, vertigo, fatigue, apathy, anxiety, ataxia, polyneuritis, peripheral neuropathy, seizures
- CV: allergic myocarditis or pericarditis
- EENT: peri orbital edema, optic neuritis, transient myopia, tinnitus
- GI: nausea, vomiting, abdominal pain, stomatitis, glossitis, pancreatitis, dry mouth, anorexia, pseudomembranous colitis
- GU: hematuria, proteinuria, orange-yellow urine, reversible oligospermia, crystalluria, toxic nephrosis with oliguria and anuria, renal failure
- Hematologic: megaloblastic anemia, agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, hemolytic anemia
- Hepatic: jaundice, hepatitis, hepatocellular necrosis
- Respiratory: shortness of breath, pleuritis, cyanosis, allergic pneumonitis, pulmonary infiltrates, fibrosing alveolitis
- Skin: generalized skin eruption, urticaria, pruritus, alopecia, local irritation, orange-yellow skin discoloration, exfoliative dermatitis, photosensitivity reaction, erythema multiforme, epidermal necrolysis, Stevens-Johnson syndrome
- Other: reversible immunoglobulin suppression, chills, drug fever, hypersensitivity reactions including anaphylaxis, serum sickness, lupus-like syndrome

Interactions
- Drug-drug. Cyclosporine: increased nephrotoxicity
- Folic acid: decreased folic acid absorption
- Hydantoins: increased hydantoin blood level
- Indomethacin, probenecid: increased sulfasalazine blood level
- Iron: decreased sulfasalazine absorption
- Methenamine: increased risk of crystalluria, causing serious adverse reactions
- Methotrexate: increased risk of bone marrow depression
- Oral anticoagulants: increased anticoagulant effect
- Other anti-infectives: altered sulfasalazine metabolism
- Para-aminobenzoic acid (PABA), PABA-derived local anesthetics: inhibited sulfasalazine action
- Sulfonyleureas: increased risk of hypoglycemia
- Thiazide diuretics: increased thrombocytopenic effects
- Uricosuric drugs: increased effects of these drugs

Drug-diagnostic tests. Bilirubin, blood urea nitrogen, creatinine, eosinophils, transaminases: increased levels
- Granulocytes, hemoglobin, platelets, white blood cells: decreased levels
- Urine glucose test: false-positive result

Drug-food. Folic acid, iron: decreased folic acid or iron absorption

Drug-herbs. Dong quai, St. John’s wort: increased risk of photosensitivity

Drug-behaviors. Sun exposure: increased risk of photosensitivity

Patient monitoring

- Monitor CBC with white cell differential. Watch for evidence of blood dyscrasias.
- Stay alert for signs of erythema multiforme. Report early signs before condition can progress to Stevens-Johnson syndrome.
- Monitor patient for signs and symptoms of superinfection, including fever, tachycardia, and chills.
Monitor liver function tests; watch for signs and symptoms of hepatitis.

Check kidney function tests weekly. Evaluate patient’s fluid intake, urine output, and urine pH. Report hematuria, oliguria, or anuria right away.

- Monitor neurologic status. Report seizures, hallucinations, or depression.
- If patient takes drug for rheumatoid arthritis, monitor therapeutic response 4 to 12 weeks after therapy begins.

**Patient teaching**

- Tell patient to take on regular schedule as prescribed, along with a full glass of water. Instruct him to drink plenty of fluids to minimize crystal formation in urine.
- Urge patient to complete full course of treatment, even if he feels better after a few days.
- Instruct patient to watch for and immediately report signs and symptoms of hypersensitivity reaction, especially rash.
- Tell patient drug can cause blood disorders, GI and liver problems, serious skin reactions, and other infections. Describe key warning signs and symptoms (easy bruising or bleeding, severe diarrhea, unusual tiredness, yellowing of skin or eyes, sore throat, rash, cough, mouth sores, fever). Instruct him to report these right away.
- Advise patient to promptly report scant or bloody urine or inability to urinate.
- Instruct patient to contact prescriber if he develops depression.
- Teach patient effective ways to counteract photosensitivity effect. Tell him that dong quai and St. John’s wort increase phototoxicity risk and should be avoided during therapy.
- Inform patient that drug may discolor skin and body fluids orange-yellow and may permanently stain contact lenses.
- Advise female patient to inform prescriber if she is pregnant. Caution her not to take drug near term or when breastfeeding.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

**sulfisoxazole acetyl**

**Gantrisin Pediatric Suspension**

**Pharmacologic class:** Sulfonamide (short-acting)

**Therapeutic class:** Anti-infective

**Pregnancy risk category C**

**Action**

Inhibits formation of bacterial folic acid from para-aminobenzoic acid (PABA), preventing bacterial cell-wall synthesis and exerting a bacteriostatic effect.

**Availability**

- Suspension: 500 mg/5 ml
- Tablets: 500 mg

**Indications and dosages**

- **Urinary tract and systemic infections**
  
  **Adults:** Initially, 2 to 4 g P.O.; then 4 to 8 g daily in four to six equally divided doses
  
  **Children ages 2 months and older:**
  
  Initially, 75 mg/kg P.O. or 2 g/m², then 150 mg/kg or 4 g/m² daily in four to six equally divided doses. Total daily dosage shouldn’t exceed 6 g.

**Dosage adjustment**

- Renal impairment

**Contraindications**

- Hypersensitivity to drug, other sulfonamides, sulfonylureas, or thiazide or loop diuretics

Reactions in bold are life-threatening.
Pregnancy at term or when premature birth is possible
Infant younger than 2 months (except in congenital toxoplasmosis)
Porphyria

**Precautions**
Use cautiously in:
- urinary obstruction, renal or hepatic disease, bronchial asthma, G6PD deficiency, group A beta-hemolytic streptococcal infections
- history of multiple allergies
- pregnant (before term) or breastfeeding patients.

**Administration**
- Give with a full glass of water. Encourage good fluid intake to minimize crystal formation in urine.

### Route Onset Peak Duration
P.O. Unknown 1-4 hr Unknown

### Adverse reactions
**CNS:** headache, depression, hallucinations, insomnia, drowsiness, vertigo, fatigue, apathy, anxiety, ataxia, polyneuritis, peripheral neuropathy, seizures
**CV:** allergic myocarditis or pericarditis
**EENT:** optic neuritis, transient myopia, periorbital edema, tinnitus
**GI:** nausea, vomiting, abdominal pain, pancreatitis, stomatitis, glossitis, dry mouth, anorexia, pseudomembranous colitis
**GU:** hematuria, proteinuria, crystalluria, toxic nephrosis with oliguria and anuria, renal failure
**Hematologic:** megaloblastic anemia, agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, hemolytic anemia
**Hepatic:** jaundice, hepatitis, hepato-cellular necrosis
**Respiratory:** shortness of breath, pleuritis, allergic pneumonitis, pulmonary infiltrates, fibrosing alveolitis

### Skin:
- local irritation, urticaria, pruritus, generalized skin eruption, alopecia, exfoliative dermatitis, photosensitivity reaction, epidermal necrolysis, erythema multiforme, Stevens-Johnson syndrome

### Other:
- chills, drug fever, hypersensitivity reactions including anaphylaxis, serum sickness, lupus-like syndrome

### Interactions
**Drug-drug.**
- **Cyclosporine:** increased nephrotoxicity
- **Hydantoins:** increased hydantoin blood level
- **Indomethacin, probenecid:** increased sulfisoxazole blood level
- **Methenamine:** increased risk of crystalluria, causing serious adverse reactions
- **Methotrexate:** increased risk of bone marrow depression
- **Oral anticoagulants:** increased anticoagulant effect
- **PABA, PABA-derived local anesthetics:** inhibited sulfisoxazole action
- **Sulfonylureas:** increased risk of hypoglycemia
- **Thiazide diuretics:** increased thrombocytopenic effect
- **Thiopental, uricosuric drugs:** increased effects of these drugs

**Drug-diagnostic tests.**
- **Bilirubin, blood urea nitrogen, creatinine, eosinophils, transaminases:** increased levels
- **Granulocytes, hemoglobin, platelets, white blood cells:** decreased levels
- **Urine glucose test:** false-positive result

**Drug-herbs.**
- **Dong quai, St. John's wort:** increased risk of photosensitivity

**Drug-behaviors.**
- **Sun exposure:** increased risk of photosensitivity

### Patient monitoring
- **Monitor CBC with white cell differential.** Watch for evidence of blood dyscrasias.
- **Stay alert for signs of erythema multiforme.** Report early signs before condition can progress to Stevens-Johnson syndrome.
Monitor patient for signs and symptoms of superinfection, including fever, tachycardia, and chills.

- Monitor liver function tests. Be alert for signs and symptoms of hepatitis.

- Check kidney function test results weekly. Evaluate patient’s fluid intake, urine output, and urine pH. Report hematuria, oliguria, or anuria right away.

- Monitor neurologic status. Report seizures, hallucinations, or depression.

**Patient teaching**

- Tell patient to take on regular schedule as prescribed, along with a full glass of water. Advise him to drink plenty of fluids to minimize crystal formation in urine.

- Instruct patient to complete full course of treatment, even if he feels better after a few days.

- Tell patient to watch for and immediately report signs and symptoms of hypersensitivity reaction, especially rash.

- Advise patient that drug can cause blood disorders, GI and liver problems, serious skin reactions, and other infections. Describe key warning signs and symptoms (easy bruising or bleeding, severe diarrhea, unusual tiredness, yellowing of skin or eyes, sore throat, rash, cough, mouth sores, fever). Tell him to report these right away.

- Encourage patient to promptly report scant urine, bloody urine, or inability to urinate.

- Instruct patient to contact prescriber if he develops depression.

- Teach patient effective ways to counteract photosensitivity effect. Tell him that dong quai and St. John’s wort increase phototoxicity risk and should be avoided during therapy.

- Advise female patient to inform prescriber if she is pregnant. Caution her not to take drug near term or when breastfeeding.

- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

**sumatriptan succinate**


**Pharmacologic class:** Selective 5-hydroxytryptamine_1_ (5-HT_1_) agonist

**Therapeutic class:** Vascular headache suppressant

**Pregnancy risk category C**

**Action**

Selectively activates vascular 5-HT_1_ receptor sites, causing vasoconstriction in intracranial arteries

**Availability**

- **Injection:** 6 mg/0.5-ml prefilled syringes, 0.6 mg/0.5-ml vials, self dose injection kit (containing two prefilled syringes)
- **Nasal spray:** 5 mg in 100-mcl unit dose spray device (package of six), 20 mg in 100-mcl unit dose spray device (package of six)
- **Tablets:** 25 mg, 50 mg, 100 mg

**Indications and dosages**

- **Acute migraine**

**Adults:** Initially, 25 mg P.O.; if response inadequate after 2 hours, may give up to 100 mg P.O. If migraine recurs, repeat dose q 2 hours, not to exceed 200 mg/day. Or 6 mg subcutaneously, repeated as needed after

**Reactions in **bold** are life-threatening.
1 hour, not to exceed 12 mg in 24 hours. If P.O. therapy will follow subcutaneous injection, additional P.O. sumatriptan may be given q 2 hours, not to exceed 100 mg/day. Or a single dose of 5, 10, or 20 mg intranasally in one nostril, repeated p.r.n. in 2 hours, not to exceed 40 mg in 24 hours.

Dosage adjustment
- Hepatic impairment

Contraindications
- Hypersensitivity to drug
- Hemiplegic or basilar migraine headache
- Ischemic cardiac, cerebrovascular, or peripheral vascular disease (such as a history of myocardial infarction, stroke, angina, or ischemic bowel)
- Uncontrolled hypertension
- Severe hepatic impairment
- MAO inhibitor use within past 14 days
- Use of other 5-HT1 agonists, ergotamine-containing drugs, or ergot-type products within past 24 hours

Precautions
Use cautiously in:
- patients with cardiovascular risk factors (hypertension, hypercholesterolemia, smoking, obesity, diabetes, family history of cardiovascular disease, men over age 40, menopausal women)
- elderly patients
- women of childbearing age
- pregnant or breastfeeding patients
- children younger than age 18 (safety not established).

Administration
- If patient has risk factors for coronary artery disease, know that first dose should be given in medical setting with emergency equipment at hand.
- Don’t give within 14 days of MAO inhibitors.
- Don’t administer within 24 hours of other 5-HT1 agonists,

Adverse reactions
CNS: headache, malaise, dizziness, drowsiness, fatigue, vertigo, anxiety, tight feeling in head, numbness
CV: angina, chest pressure or tightness, transient hypertension, ECG changes, coronary vasospasm, myocardial infarction
EENT: vision changes, nasal sinus discomfort, throat discomfort
GI: abdominal discomfort, dysphagia
Musculoskeletal: jaw discomfort, muscle cramps, myalgia, neck pain or stiffness
Skin: flushing; tingling; warm, cool or, burning sensation
Other: injection site reaction, feeling of heaviness or tightness

Interactions
Drug-drug. Dihydroergotamine, ergotamine, methysergide: increased risk of vasospastic reaction
Lithium, MAO inhibitors, selective serotonin reuptake inhibitors: weakness, hypoperflexia, incoordination
Drug-herbs. Horehound: enhanced serotonergic effects

Patient monitoring
- Monitor cardiovascular status closely. Be aware that drug may cause serious and possibly fatal cardiac disorders.
- Watch for neurologic and vision changes. Institute safety measures as needed to prevent injury.
- Watch for injection site reaction, which should subside within 1 hour.
Patient teaching

- Instruct patient to take as soon as possible after migraine onset.
- Teach patient to recognize and immediately report serious cardiovascular reactions.
- Explain proper drug use. Stress that drug is effective only in treating diagnosed migraine, not other headache types. Tell patient it doesn’t prevent migraine.
- With subcutaneous use, instruct patient to inject dose using spring-loaded injector system included in package. If headache recurs after dose, tell him he may take a second dose, but should wait at least 1 hour after initial dose and shouldn’t exceed two 6-mg injections in a 24-hour period. Instruct him to report injection site reaction that doesn’t subside within 1 hour.
- With oral use, tell patient he may take a second dose 2 hours after first dose if migraine recurs. Tell him he may repeat oral doses every 2 hours as needed, up to 200 mg in a 24-hour period.
- With intranasal use, tell patient to spray 5, 10, or 20 mg into one nostril, as prescribed. Tell him he may repeat dose after 2 hours but shouldn’t exceed 40 mg in a 24-hour period.
- Advise patient not to use drug for more than four episodes per month.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and herbs mentioned above.

---

sunitinib malate

**Sutent**

**Pharmacologic class:** Receptor tyrosine kinase inhibitor  
**Therapeutic class:** Antineoplastic  
**Pregnancy risk category D**

**Action**

Inhibits multiple receptor tyrosine kinases, some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic cancer progression.

**Availability**

Capsules: 12.5 mg, 25 mg, 50 mg

**Indications and dosages**

- GI stromal tumor after disease progression with or intolerance to imatinib mesylate; advanced renal cell carcinoma

**Adults:** 50 mg P.O. daily on cycle of 4 weeks on and 2 weeks off treatment; may increase or decrease dosage in 12.5-mg increments based on safety and tolerance.

**Dosage adjustment**

- Concurrent use of strong CYP3A4 inducers or inhibitors

**Contraindications**

- Hypersensitivity to drug or its components

**Precautions**

Use cautiously in:

- left ventricular dysfunction, hypertension
- patients who’ve experienced cardiac events within previous 12 months
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

Reactions in **bold** are life-threatening.
Administration
● Administer with or without food.
● Interrupt therapy or reduce dosage, as prescribed, in patients who lack clinical evidence of heart failure but have ejection fractions (EFs) below 50% and above 20% below baseline.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>6-12 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, asthenia
CV: hypertension, left ventricular dysfunction
EENT: epistaxis, oral pain
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, mucositis, stomatitis, anorexia
Hematologic: bleeding, anemia, thrombocytopenia, neutropenia, lymphopenia, hemorrhage
Metabolic: acquired hypothyroidism, adrenal toxicity
Musculoskeletal: arthralgia, back pain, limb pain, myalgia
Respiratory: dyspnea, cough, pulmonary embolism
Skin: skin abnormalities, skin discoloration, rash, palmar-plantar erythrodysesthesia, alopecia, hair color changes
Other: altered taste, fatigue, fever

Patient monitoring
● Obtain CBC with platelet count and blood chemistries (including phosphate) at start of each treatment cycle and frequently thereafter.
● Know that physician may order baseline and periodic evaluation of left ventricular EF in patients who experienced cardiac events within 12 months before starting drug. Watch closely for signs and symptoms of left ventricular dysfunction (especially heart failure).
● Be aware that physician may order baseline EF testing for patients without cardiac risk factors.
● Monitor for hypertension; administer standard antihypertensive therapy as ordered and needed.
● Monitor for adrenal insufficiency if patient experiences stress (as from surgery, trauma, or severe infection).

Patient teaching
● Instruct patient to take drug with or without food.
 помещение
● Urge patient to immediately report sudden chest pain, swelling, or difficulty breathing.
● Tell patient drug may cause skin changes (yellowing, drying, cracking, or rashes on hands or feet) and hair color changes.
● Advise patient to consult prescriber before taking other drugs, including over-the-counter drugs and herbs.
● Caution patient not to take St. John’s wort during therapy.

Drug-food. Grapefruit juice, pomegranate: increased sunitinib blood level
Drug-herbs. Alpha-lipoic acid: decreased chemotherapeutic efficacy
American elder, bishop’s weed, cat’s claw, devil’s claw, eucalyptus, feverfew, Siberian ginseng, valerian: increased sunitinib blood level
St. John’s wort: unpredictable decrease in sunitinib blood level

Patient monitoring
● Obtain CBC with platelet count and blood chemistries (including phosphate) at start of each treatment cycle and frequently thereafter.
● Know that physician may order baseline and periodic evaluation of left ventricular EF in patients who experienced cardiac events within 12 months before starting drug. Watch closely for signs and symptoms of left ventricular dysfunction (especially heart failure).
● Be aware that physician may order baseline EF testing for patients without cardiac risk factors.
● Monitor for hypertension; administer standard antihypertensive therapy as ordered and needed.
● Monitor for adrenal insufficiency if patient experiences stress (as from surgery, trauma, or severe infection).

Patient teaching
● Instruct patient to take drug with or without food.
 помещение
● Urge patient to immediately report sudden chest pain, swelling, or difficulty breathing.
● Tell patient drug may cause skin changes (yellowing, drying, cracking, or rashes on hands or feet) and hair color changes.
● Advise patient to consult prescriber before taking other drugs, including over-the-counter drugs and herbs.
● Caution patient not to take St. John’s wort during therapy.

Drug-food. Grapefruit juice, pomegranate: increased sunitinib blood level
Drug-herbs. Alpha-lipoic acid: decreased chemotherapeutic efficacy
American elder, bishop’s weed, cat’s claw, devil’s claw, eucalyptus, feverfew, Siberian ginseng, valerian: increased sunitinib blood level
St. John’s wort: unpredictable decrease in sunitinib blood level

Patient monitoring
● Obtain CBC with platelet count and blood chemistries (including phosphate) at start of each treatment cycle and frequently thereafter.
● Know that physician may order baseline and periodic evaluation of left ventricular EF in patients who experienced cardiac events within 12 months before starting drug. Watch closely for signs and symptoms of left ventricular dysfunction (especially heart failure).
● Be aware that physician may order baseline EF testing for patients without cardiac risk factors.
● Monitor for hypertension; administer standard antihypertensive therapy as ordered and needed.
● Monitor for adrenal insufficiency if patient experiences stress (as from surgery, trauma, or severe infection).

Patient teaching
● Instruct patient to take drug with or without food.
 помещение
● Urge patient to immediately report sudden chest pain, swelling, or difficulty breathing.
● Tell patient drug may cause skin changes (yellowing, drying, cracking, or rashes on hands or feet) and hair color changes.
● Advise patient to consult prescriber before taking other drugs, including over-the-counter drugs and herbs.
● Caution patient not to take St. John’s wort during therapy.

Drug-food. Grapefruit juice, pomegranate: increased sunitinib blood level
Drug-herbs. Alpha-lipoic acid: decreased chemotherapeutic efficacy
American elder, bishop’s weed, cat’s claw, devil’s claw, eucalyptus, feverfew, Siberian ginseng, valerian: increased sunitinib blood level
St. John’s wort: unpredictable decrease in sunitinib blood level

Patient monitoring
● Obtain CBC with platelet count and blood chemistries (including phosphate) at start of each treatment cycle and frequently thereafter.
● Know that physician may order baseline and periodic evaluation of left ventricular EF in patients who experienced cardiac events within 12 months before starting drug. Watch closely for signs and symptoms of left ventricular dysfunction (especially heart failure).
● Be aware that physician may order baseline EF testing for patients without cardiac risk factors.
● Monitor for hypertension; administer standard antihypertensive therapy as ordered and needed.
● Monitor for adrenal insufficiency if patient experiences stress (as from surgery, trauma, or severe infection).

Patient teaching
● Instruct patient to take drug with or without food.
 помещение
● Urge patient to immediately report sudden chest pain, swelling, or difficulty breathing.
● Tell patient drug may cause skin changes (yellowing, drying, cracking, or rashes on hands or feet) and hair color changes.
● Advise patient to consult prescriber before taking other drugs, including over-the-counter drugs and herbs.
● Caution patient not to take St. John’s wort during therapy.
Advise female with childbearing potential to avoid pregnancy and breastfeeding during therapy.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

**tacrine hydrochloride**

**Cognex**

**Pharmacologic class:** Cholinergic (cholinesterase inhibitor)

**Therapeutic class:** Anti-Alzheimer’s agent

**Pregnancy risk category C**

**Action**

Inhibits acetylcholine breakdown in cerebral cortex, increasing acetylcholine levels

**Availability**

Capsules: 10 mg, 20 mg, 30 mg, 40 mg

**Indications and dosages**

Mild to moderate dementia of Alzheimer’s disease

**Adults:** 10 mg P.O. q.i.d. for 4 weeks. If alanine aminotransferase (ALT) level doesn’t change, increase to 20 mg q.i.d. As tolerated, increase incrementally at 4-week intervals, up to 160 mg/day (30 to 40 mg P.O. q.i.d.).

**Dosage adjustment**

- Elevated transaminase levels

**Contraindications**

- Hypersensitivity to drug or other acridine derivatives
- Jaundice with previous tacrine therapy
- Bilirubin level above 3 mg/dl
- Hypersensitivity symptoms accompanied by transaminase elevations

**Precautions**

Use cautiously in:

- sick sinus syndrome, bradycardia, hepatic or renal disease, bladder obstruction, asthma, seizure disorders, prostatic hyperplasia
- history of ulcers or increased risk of GI bleeding (as from concurrent use of nonsteroidal anti-inflammatory drugs)
- pregnant or breastfeeding patients
- children.

**Administration**

- Preferably, give 1 hour before or 2 hours after meals. However, if GI upset occurs, drug can be given with meals (although food slows its absorption).

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1-2 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** dizziness, headache, confusion, insomnia, tremor, ataxia, drowsiness, anxiety, agitation, depression, hallucinations, hostility, abnormal thinking, fatigue, malaise

**CV:** hypotension, hypertension, chest pain, peripheral edema

**EENT:** conjunctivitis, rhinitis, sinusitis, pharyngitis

**GI:** nausea, vomiting, diarrhea, constipation, dyspepsia, abdominal pain, anorexia

**GU:** urinary frequency or incontinence, urinary tract infection

**Musculoskeletal:** back pain, myalgia

**Respiratory:** upper respiratory infection, cough, bronchitis, pneumonia, dyspnea

**Skin:** rash, flushing, purpura

**Other:** chills, fever

Reactions in bold are life-threatening.
Interactions

**Drug-drug.** *Anticholinergics:* interference with anticholinergic action
- *Cholinergics (including bethanechol), succinylcholine:* synergistic effects
- *Cimetidine:* increased tacrine blood level
- *Theophylline:* increased theophylline blood level, greater risk of toxicity

**Drug-diagnostic tests.** *Hepatic enzymes:* increased levels

**Drug-food.** *Any food:* decreased tacrine bioavailability

Patient monitoring

- Monitor neurologic status to assess drug efficacy and determine optimal dosage.
- Check ALT level weekly for first 18 weeks. If level doesn’t change markedly by end of this period, monitor level every 3 months. Otherwise, continue weekly monitoring.

Patient teaching

- Tell patient or caregiver that drug should be taken 1 hour before or 2 hours after meals.
- Advise caregiver to monitor patient’s neurologic status carefully and to use safety measures at home to prevent injury.
- Recommend small, frequent servings of food and adequate fluid intake to minimize GI upset.
- Explain that drug doesn’t change underlying dementia but may improve symptoms or slow further deterioration.
- Stress importance of taking drug as prescribed. Caution against sudden dosage decreases or abrupt withdrawal.
- Tell patient or caregiver that if drug is stopped for 4 weeks or longer, dosage adjustment and monitoring schedule should be discussed with prescriber before restarting.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

### tacrolimus

**Advagraf, Prograf, Protopic**

**Pharmacologic class:** Macrolide

**Therapeutic class:** Immunosuppressant

**Pregnancy risk category C**

### FDA BOXED WARNING

- Immunosuppression may increase patient’s susceptibility to infection and lymphoma development. Give under supervision of physician experienced in immunosuppressive therapy and management of organ transplant patients, in facility with adequate diagnostic and treatment resources. Physician responsible for maintenance therapy should have complete information needed for patient follow-up.

### Action

Unknown. Thought to inhibit T-lymphocyte activation.

### Availability

- **Capsules:** 0.5 mg, 1 mg, 5 mg
- **Injection:** 5 mg/ml
- **Topical ointment:** 0.03%, 0.1%

### Indications and dosages

#### Prevention of organ rejection in patients with allogeneic liver transplants

**Adults:** Initially, 0.1 to 0.15 mg/kg/day P.O. in two divided doses q 12 hours. Alternatively, 0.03 to 0.05 mg/kg/day by continuous I.V. infusion.

**Children:** 0.15 to 0.2 mg/kg/day P.O. in two divided doses q 12 hours. Alternatively, 0.03 to 0.05 mg/kg/day by continuous I.V. infusion.

#### Prevention of organ rejection in patients with allogeneic kidney transplants
**Adults:** Initially, 0.2 mg/kg/day P.O. in two divided doses q 12 hours. Alternatively, 0.03 to 0.05 mg/kg/day by continuous I.V. infusion.

> Prevention of heart transplant rejection

**Adults:** Initially, 0.075 mg/kg/day P.O. q 12 hours in two divided doses.

> Moderate to severe atopic dermatitis

**Children ages 2 and older:** 0.03% ointment applied b.i.d. to affected area, continued 1 week after dermatitis symptoms resolve

**Dosage adjustment**

- Hepatic or renal impairment

**Contraindications**

- Hypersensitivity to drug or its components (including castor oil derivatives)

**Precautions**

Use cautiously in:

- severe hepatic disease, renal impairment, diabetes mellitus, hypertension, hyperkalemia, hyperuricemia, lymphoma
- pregnant or breastfeeding patients
- children younger than age 12 (age 2 for ointment use).

**Administration**

- Give oral form without food.
- Give I.V. doses by infusion only.
- Start therapy within 24 hours of kidney transplantation and no earlier than 6 hours after liver or heart transplantation. Switch to oral dosing as soon as tolerable, starting 8 to 12 hours after I.V. dosing ends.

- Before giving I.V., ensure that ephedrine 1:1,000 and oxygen are at hand in case of emergency.
- For I.V. use, dilute in normal saline solution or dextrose 5% in water to a concentration of 0.004 to 0.02 mg/ml. Give by infusion only.

- After applying ointment, don’t place occlusive dressing or wrapping over affected area.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1.5-3.5 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>1-2 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>Ointment</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** tremor, headache, insomnia, paresthesia, delirium, asthenia, coma
**CV:** hypertension, peripheral edema
**GI:** nausea, vomiting, diarrhea, coma
**GU:** hematuria, proteinuria, urinary tract infection, albuminuria, abnormal renal function, oliguria, renal failure
**Hematologic:** anemia, leukocytosis, thrombocytopenia
**Metabolic:** hyperglycemia, hypomagnesemia, hypokalemia, hyperkalemia
**Musculoskeletal:** back pain
**Respiratory:** dyspnea, pleural effusion, atelectasis
**Skin:** burning (with ointment), rash, flushing, pruritus, alopecia
**Other:** pain, fever, chills, anaphylaxis

**Interactions**

**Drug-drug:** Bromocriptine, chloramphenicol, cimetidine, clarithromycin, clotrimazole, cyclosporine, danazol, diliazem, erythromycin, fluconazole, itraconazole, ketoconazole, methylprednisolone, metoclopramide, metronidazole, nicardipine, omeprazole, protease inhibitors, verapamil: increased tacrolimus blood level
**Cyclosporine:** increased risk of nephrotoxicity
**CYP450 inducers (such as carbamazepine, phenobarbital, phenytoin, rifampin):** decreased tacrolimus metabolism
**Immunosuppressants (except adrenocorticoids):** immunologic oversuppression

**Live-virus vaccines:** interference with immune response to vaccine

Reactions in **bold** are life-threatening.

---

*Clinical alert*
Mycophenolate mofetil: increased mycophenolate blood level
Nephrotoxic drugs (such as aminoglycosides, amphotericin B, cisplatin, cyclosporine): additive or synergistic effects

**Drug-diagnostic tests.** Blood urea nitrogen, creatinine, glucose: increased levels
Hemoglobin, magnesium, platelets, white blood cells: decreased levels
Liver function tests: abnormal values

Potassium: increased or decreased level

**Drug-food.** Any food: inhibited drug absorption
Grapefruit juice: increased drug blood level

**Drug-herbs.** Astragalus, echinacea, melatonin: decreased immunosuppression
St. John’s wort: decreased tacrolimus blood level

**Patient monitoring**
- Once I.V. infusion starts, watch closely for signs and symptoms of anaphylaxis.
- Monitor cardiac, liver, and kidney function test results. Watch for signs and symptoms of cardiovascular disorder, nephrotoxicity, and hepatic dysfunction.
- Assess neurologic status for evidence of neurotoxicity.
- Monitor potassium level closely. Stay alert for signs and symptoms of hyperkalemia.
- Monitor blood glucose. Watch for indications of hyperglycemia.
- Evaluate respiratory status regularly.

**Patient teaching**
- Teach patient to recognize and immediately report serious adverse reactions.
- Tell patient to take oral doses without food.
- Tell diabetic patient to expect increased blood glucose level, which may warrant further antidiabetic therapy. Advise him to monitor glucose level carefully.
- Instruct patient not to place occlusive dressings or wrappings over affected area after applying ointment. Tell him to use drug for 1 week after dermatitis symptoms resolve.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

**tadalafil**
Cialis

**Pharmacologic class:** Phosphodiesterase type 5 (PDE5) inhibitor

**Therapeutic class:** Anti-erectile dysfunction agent

**Pregnancy risk category B**

**Action**
Inhibits PDE5, increasing cyclic guanosine monophosphate level and enhancing erectile function

**Availability**
Tablets: 2.5 mg, 5 mg, 10 mg, 20 mg

**Indications and dosages**
- Erectile dysfunction (for as-needed use)
  **Adults:** Initially, 10 mg P.O. before anticipated sexual activity; may increase to 20 mg or decrease to 5 mg based on patient response and tolerance. For most patients, maximum recommended dosing frequency is once daily.
- Erectile dysfunction (for daily use)
  **Adults:** 2.5 mg P.O. once daily, given at approximately the same time without regard to sexual activity; may increase to 5 mg P.O. once daily based on efficacy and tolerability

Canada UK Hazardous drug High alert drug
Dosage adjustment
● Mild to moderate hepatic impairment or renal insufficiency

Contraindications
● Hypersensitivity to drug or its components
● Concurrent use of organic nitrates (regularly or intermittently)
● Concurrent use of alpha-adrenergic agonists (except tamsulosin 0.4 mg/day)

Precautions
Use cautiously in:
● cardiac risk that makes sexual activity inadvisable, renal insufficiency, hepatic impairment, left ventricular outflow obstruction, erectile dysfunction whose cause hasn’t been evaluated, conditions that increase risk of priapism
● concurrent use of potent CYP450-3A4 inhibitors.

Administration
● Know that patient should take drug (with or without food) before anticipated sexual activity when given on an as-needed basis.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>30 min-6 hr</td>
<td>Up to 36 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, fatigue, dizziness, insomnia, hyperesthesia, paresthesia, drowsiness, vertigo, asthenia, transient global amnesia
CV: angina pectoris, chest pain, hypertension, hypotension, orthostatic hypotension, palpitations, syncope, tachycardia, myocardial infarction
EENT: blurred vision, color vision changes, conjunctivitis, eye pain, increased lacrimation, eyelid swelling, epistaxis, nasal congestion, pharyngitis
GI: nausea, vomiting, diarrhea, dyspepsia, esophagitis, gastroesophageal reflux, gastritis, upper abdominal pain, dysphagia, dry mouth
GU: increased or spontaneous erection
Musculoskeletal: myalgia; back, neck, limb, and joint pain
Respiratory: dyspnea
Skin: pruritus, rash, sweating
Other: facial edema, pain

Interactions
Drug-drug. Alpha-adrenergic blockers (except tamsulosin 0.4 mg/day): marked blood pressure decrease
Angiotensin receptor blockers, enalapril, metoprolol: decreased blood pressure
CYP450-3A4 inducers (such as carbamazepine, phenobarbital, phenytoin, rifampin): decreased tadalafil blood level
CYP450-3A4 inhibitors (such as erythromycin, itraconazole, ketoconazole, ritonavir): increased tadalafil blood level
Theophylline: slight increase in heart rate

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, lactate dehydrogenase, uric acid: increased levels

Drug-food. Grapefruit juice: increased drug blood level

Patient monitoring
● Monitor for drug efficacy.

Patient teaching
● Advise patient to take before anticipated sexual activity when used on an as-needed basis.
● Instruct patient that when taking medication on a daily basis he should take tablet at approximately the same time every day, without regard to sexual activity.

Caution patient never to take concurrently with nitrates.

Instruct patient to stop sexual activity and contact prescriber immediately if chest pain, dizziness, or nausea occurs.
● Instruct patient to contact prescriber if erection lasts more than 4 hours.
● Tell patient drug can cause serious interactions with many common

Reactions in **bold** are life-threatening.
tamoxifen citrate

Apo-Tamox , Gen-Tamoxifen , Nolvadex, Nolvadex-D , Novo-Tamoxifen , PMS-Tamoxifen , Soltamox, Tamofen

Pharmacologic class: Nonsteroidal antiestrogen
Therapeutic class: Antineoplastic
Pregnancy risk category D

FDA BOXED WARNING

● For women with ductal carcinoma in situ or high risk of breast cancer, serious and life-threatening events associated with drug use in risk-reduction setting include stroke, pulmonary embolism, and uterine cancer. Some of these events were fatal. Discuss potential benefits versus potential risks of these events with these patients. In women already diagnosed with breast cancer, drug’s benefits outweigh risks.

Action
Competes with estrogen receptors in tumor cells for binding to target tissues (such as breast); reduces DNA synthesis and estrogen response

Availability
Oral solution: 10 mg/5 ml
Tablets: 10 mg, 20 mg
Tablets (enteric-coated): 20 mg

Indications and dosages
➢ Adjunctive treatment of breast cancer
Adults: 20 to 40 mg P.O. daily for 5 years. Daily dosages of 20 mg may be taken as a single dose; daily dosages above 20 mg should be divided and taken b.i.d. (morning and evening).
➢ To reduce breast cancer incidence in high-risk women; treatment of ductal carcinoma in situ
Adults: 20 mg P.O. daily for 5 years

Off-label uses
● Mastalgia
● Ovulation stimulation

Contraindications
● Hypersensitivity to drug
● Concurrent warfarin use
● Women with a history of deep-vein thrombosis or pulmonary embolism
● Pregnancy or breastfeeding

Precautions
Use cautiously in:
● decreased bone marrow reserve, leukopenia, thrombocytopenia, cataracts, hyperlipidemia
● females of childbearing age.

Administration
● Don’t break or crush enteric-coated tablets.
● Know that drug is indicated for reducing breast cancer risk only in high-risk women, defined as those
older than age 35 who have at least a 1.67% chance of developing breast cancer over 5 years.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>5 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

### Adverse reactions

- **CNS:** confusion, depression, headache, weakness, fatigue, light-headedness
- **CV:** chest pain, **deep-vein thrombosis**
- **EENT:** blurred vision, ocular lesion, retinopathy, corneal opacity
- **GI:** nausea, vomiting, abdominal cramps, anorexia
- **GU:** vaginal bleeding, discharge, or dryness; irregular menses; amenorrhea; oligomenorrhea; ovarian cyst; pruritus vulvae; **endometrial or uterine cancer**
- **Hematologic:** leukopenia, thrombocytopenia
- **Metabolic:** hypercalcemia, fluid retention
- **Musculoskeletal:** bone pain
- **Respiratory:** cough, **pulmonary embolism**
- **Skin:** skin changes, hair thinning or partial hair loss
- **Other:** altered taste, weight loss, tumor flare, tumor pain, hot flashes, edema

### Interactions

**Drug-drug.** *Aminoglutethimide, estrogens:* decreased tamoxifen effects

*Antineoplastics:* increased risk of thromboembolic events

*Bromocriptine:* increased tamoxifen blood level

*Warfarin:* increased anticoagulant effect

**Drug-diagnostic tests.** *Aspartate aminotransferase, bilirubin, calcium, creatinine, hepatic enzymes:* increased levels

*Platelets, white blood cells:* decreased counts

### Patient monitoring

- Monitor lipid panel, calcium level, mammography results, and gynecologic exam results.

> Watch for signs and symptoms of thromboembolic events, including cerebrovascular accident and pulmonary embolism.

- Monitor menstrual cycle pattern for changes that may signal endometrial or uterine cancer.

### Patient teaching

- Tell patient to swallow enteric-coated tablets whole without breaking or crushing.

- Instruct patient to immediately report leg or calf pain, swelling, or tenderness; unexpected shortness of breath; sudden chest pain; coughing up blood; new breast lumps; vaginal bleeding; menstrual irregularities; changes in vaginal discharge; pelvic pain or pressure; and vision changes.

- Inform patient that increase in bone or tumor pain usually means drug will be effective. Advise her to discuss pain management with prescriber.

- Stress importance of undergoing regular blood tests, mammograms, and gynecologic exams to identify early signs of serious adverse reactions.

- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

---

**tamsulosin hydrochloride**

Bazetham®, Contiflo XL®, Flomax, Flomax CR®, Flomaxtrax®, Novo-Tamsulosin®, Omnic MR®, Ran-Tamsulosin®, Ratio-Tamsulosin®, Sandoz Tamsulosin, Stronazon®, Tabphyn®

**Pharmacologic class:** Alpha-adrenergic blocker

**Therapeutic class:** Anti-adrenergic

**Pregnancy risk category B**
**Action**
Decreases smooth muscle contractions of prostate by binding to \( \alpha_1 \)-adrenergic receptors. This action increases urine flow and reduces symptoms of benign prostatic hyperplasia (BPH).

**Availability**
*Capsules: 0.4 mg*

**Indications and dosages**

- **BPH**
  - **Adults:** 0.4 mg/day P.O. after a meal. After 2 to 4 weeks, may increase to 0.8 mg/day.

**Contraindications**
- Hypersensitivity to drug or its components

**Precautions**
Use cautiously in:
- Patients receiving other \( \alpha \)-adrenergic blockers concurrently
- Patients at increased risk for prostate cancer.

**Administration**
- Give 30 minutes after same meal each day.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>4-5 hr</td>
<td>9-15 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- **CNS:** dizziness, headache, asthenia, insomnia, drowsiness, syncope, vertigo
- **CV:** orthostatic hypotension, chest pain
- **EENT:** rhinitis, amblyopia, pharyngitis, sinusitis
- **GU:** retrograde or diminished ejaculation, decreased libido
- **Musculoskeletal:** back pain
- **Respiratory:** increased cough
- **Other:** tooth disorder, infection

**Interactions**

- **Drug-drug.** *Cimetidine:* increased tamsulosin blood level, greater risk of toxicity
- *Doxazosin, prazosin, terazosin:* increased risk of hypotension
- **Drug-behaviors.** *Alcohol use:* increased risk of hypotension

**Patient monitoring**
- Monitor blood pressure. Stay alert for orthostatic hypotension.

**Patient teaching**
- Tell patient to take 30 minutes after same meal each day.
- Instruct patient not to chew or open capsule. Advise him to swallow it whole.
- Tell patient to move slowly when sitting up or standing, to avoid dizziness or light-headedness from sudden blood pressure decrease.
- Caution patient to avoid hazardous activities on first day of therapy.
- Inform patient that drug may cause abnormal ejaculation. Advise him to discuss this issue with prescriber.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and behaviors mentioned above.

---

**telithromycin**
Ketek

**Pharmacologic class:** Ketolide antibiotic

**Therapeutic class:** Anti-infective

**Pregnancy risk category C**

**FDA BOXED WARNING**
- Drug is contraindicated in myasthenia gravis because life-threatening or fatal respiratory failure has occurred in these patients.
**Action**
Blocks protein synthesis by binding to domains II and V of 23S rRNA of 50S ribosomal subunit. Binding at domain II enables drug to retain activity against gram-positive cocci in resistance mediated by methylases that alter domain-V binding site.

**Availability**
*Tablets (film-coated):* 300 mg, 400 mg

**Indications and dosages**
> **Mild to moderate community-acquired pneumonia caused by Streptococcus pneumoniae** (including multidrug-resistant isolates), *Haemophilus influenzae*, *Moraxella catarrhalis*, *Chlamydophila pneumoniae*, or *Mycoplasma pneumoniae*

**Adults age 18 and older:** 800 mg P.O. daily for 7 to 10 days

**Dosage adjustment**
- Severe renal impairment, with or without coexisting hepatic impairment

**Contraindications**
- Hypersensitivity to drug, its components, or macrolide antibiotics
- History of hepatitis or jaundice with previous use of telithromycin or macrolide antibiotics
- Concurrent use of cisapride or pimozide
- Myasthenia gravis

**Precautions**
Use cautiously in:
- severe renal impairment, hepatic dysfunction, congenital prolongation of QT interval, ongoing proarrhythmic conditions (such as uncorrected hypokalemia or hypomagnesemia), clinically significant bradycardia (use should be avoided)
- concurrent use of some HMG-CoA reductase inhibitors (atorvastatin, lovastatin, simvastatin), rifampin, and Class IA or Class III antiarrhythmics (use should be avoided)
- concurrent use of midazolam and other benzodiazepines metabolized by CYP3A4 that undergo high first-pass effect (such as triazolam)
- concurrent use of ergot alkaloid derivatives, metoprolol, or rifampin (use not recommended)
- pregnant or breastfeeding patients
- children younger than age 18 (safety and efficacy not established).

**Administration**
- Administer tablets whole with or without food.
- Give at least 1 hour before or after theophylline (if prescribed).
- Don’t give currently with cisapride or pimozide.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- **CNS:** headache, dizziness, fatigue, loss of consciousness
- **CV:** prolonged QT interval with increased risk of *ventricular arrhythmias* and *torsades de pointes*
- **EENT:** visual disturbances, poor visual accommodation
- **GI:** nausea, vomiting, diarrhea, loose stools, light-colored stools, dysgeusia, anorexia, *pseudomembranous colitis* (possibly caused by *Clostridium difficile*)
- **GU:** dark urine
- **Hepatic:** abnormal hepatic function, fulminant hepatitis, hepatic necrosis, hepatic failure
- **Skin:** pruritus
- **Other:** superinfection, hypersensitivity reactions including angioedema and anaphylaxis (rare), acute myasthenia gravis exacerbation

**Interactions**
- **Drug-drug:** *Atorvastatin, lovastatin, simvastatin:* increased blood levels of these drugs, increased myopathy risk

Reactions in **bold** are life-threatening.
Benzodiazepines metabolized by CYP3A4 (such as midazolam, triazolam): increased blood levels of these drugs

Cisapride, pimozide: increased blood levels of these drugs, increasing risk of significantly prolonged QT interval

Class IA antiarrhythmics (such as procainamide, quinidine), Class III antiarrhythmics (such as dofetilide): interference with antiarrhythmic efficacy

Colchicine: increased serum colchicine blood level and toxicity risk

Cyclosporine, sirolimus, tacrolimus: increased blood levels of these drugs, with increased toxicity risk

CYP3A4 inducers (such as carbamazepine, phenobarbital, phenytoin, rifampin): subtherapeutic telithromycin blood level

CYP3A4 inhibitors (such as itraconazole, ketoconazole): increased telithromycin blood level

Digoxin: increased peak and trough digoxin levels

Ergot alkaloid derivatives (such as dihydroergotamine, ergotamine): acute ergot toxicity

Hexobarbital: increased hexobarbital blood level and toxicity risk

Metoprolol: increased metoprolol effect

Oral anticoagulants: possible potentiation of these drugs

Sotalol: decreased sotalol absorption

Theophylline: increased theophylline blood level, with exacerbated adverse GI reactions

Verapamil: increased verapamil blood level, causing increased risk of cardiotoxicity

**Drug-diagnostic tests.** Alanine aminotransferase, aspartate aminotransferase: increased levels

**Patient monitoring**

- Monitor liver function tests frequently.
- Discontinue drug permanently if patient develops clinical hepatitis or transaminase elevations and other systemic symptoms.
- Monitor patient closely for adverse GI reactions, especially diarrhea.
- In patients receiving drug concurrently with anticoagulants, stay alert for potentiation of anticoagulant effects.
- In patients receiving drug concurrently with midazolam, stay alert for need to adjust midazolam dosage.
- In patients receiving drug concurrently with digoxin, monitor peak and trough digoxin levels periodically, and stay alert for adverse reactions to digoxin.

**Patient teaching**

- Ensure that patient has received and read medication guide that comes with drug.
- Instruct patient to take tablet whole with or without food.
- Advise patient to take drug at least 1 hour before or after theophylline (if prescribed).
- Stress importance of completing full course of therapy, even if patient feels better.
- Urge patient to immediately stop taking drug and report signs and symptoms of liver damage, such as nausea, fatigue, appetite loss, yellowing of skin or eyes, dark urine, light-colored stools, itching, and tender abdomen.
- Instruct patient to immediately report fainting episodes or signs of heartbeat irregularities.
- Urge patient to immediately report watery or loose stools even as late as several months after taking the last dose.
- Advise patient to immediately report itching, throat swelling, and other signs or symptoms of allergic reaction.
- Inform patient that drug may cause visual disturbances.
- Caution patient to avoid driving and other hazardous activities until he
knows how drug affects vision and alertness.

- Advise patient to consult prescriber before taking other prescription or over-the-counter drugs or dietary supplements.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

---

**telmisartan**

**Micardis**

**Pharmacologic class:** Angiotensin II receptor antagonist  
**Therapeutic class:** Antihypertensive  
**Pregnancy risk category C** (first trimester), **D** (second and third trimesters)

---

**FDA BOXED WARNING**

- When used during second or third trimester of pregnancy, drug may cause fetal harm or death. Discontinue as soon as pregnancy is detected.

---

**Action**

Inhibits vasoconstricting effects and blocks aldosterone-producing effects of angiotensin II at various receptor sites, including vascular smooth muscle and adrenal glands

**Availability**

*Tablets:* 20 mg, 40 mg, 80 mg

---

**Indications and dosages**

> Hypertension  

**Adults:** 40 mg P.O. daily, titrated up or down within range of 20 to 80 mg daily based on response and tolerance

---

**Contraindications**

- Hypersensitivity to drug or its components  
- Pregnancy (second and third trimesters), breastfeeding

---

**Precautions**

Use cautiously in:  
- heart failure, impaired renal function secondary to primary renal disease or renal stenosis, obstructive biliary disorders, hepatic impairment, volume or sodium depletion  
- patients receiving high-dose diuretics  
- pregnant patients in first trimester  
- females of childbearing age  
- children younger than age 18 (safety not established).

---

**Administration**

- Don’t remove tablet from blister pack until just before giving.  
- Know that drug may be used alone or with other antihypertensives.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>0.5-1 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

---

**Adverse reactions**

**CNS:** dizziness, headache, fatigue  
**CV:** chest pain, peripheral edema, hypertension  
**EENT:** sinusitis, pharyngitis  
**GI:** nausea, vomiting, diarrhea, dyspepsia, abdominal pain  
**GU:** urinary tract infection  
**Musculoskeletal:** myalgia, back and leg pain  
**Respiratory:** cough, upper respiratory infection  
**Other:** pain, flu or flulike symptoms

---

**Interactions**

**Drug-drug.** *Antihypertensives, diuretics:* increased risk of hypotension  
*Digoxin:* increased digoxin blood level  
*Warfarin:* decreased warfarin blood level  
**Drug-diagnostic tests.** *Creatinine:* slight elevation

---

Reactions in bold are life-threatening.
Drug-food. Any food: slightly reduced drug bioavailability

Patient monitoring
- Watch for signs and symptoms of hypotension.
- Correct volume deficits as appropriate before therapy starts. Monitor fluid intake and output and creatinine level during therapy.

Patient teaching
- Tell patient to take 1 hour before or 2 hours after meals.
- Caution patient not to remove tablet from blister pack until just before taking.
- Advise patient to report swelling or chest pain.
- Teach patient to measure blood pressure regularly and report significant changes.
- Tell patient to report suspected pregnancy to prescriber. Caution her not to breastfeed.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

temazepam
Apo-Temazepam, Co Temazepam, Dom-Temazepam, Gen-Temazepam, Novo-Temazepam, Nu-Temazepam, PHL-Temazepam, PMS-Temazepam, Ratio-Temazepam, Restoril

Pharmacologic class: Benzodiazepine
Therapeutic class: Sedative-hypnotic
Controlled substance schedule IV
Pregnancy risk category X

Action
Depresses CNS at limbic, thalamic, and hypothalamic levels. Enhances effects of gamma-aminobutyric acid, resulting in sedation, hypnosis, skeletal muscle relaxation, and anticonvulsant and anxiolytic activity.

Availability
Capsules: 7.5 mg, 15 mg, 22.5 mg, 30 mg

Indications and dosages
➢ Insomnia
Adults: 15 mg P.O. at bedtime p.r.n. Range is 7.5 to 30 mg.

Dosage adjustment
- Elderly or debilitated patients

Contraindications
- Hypersensitivity to drug or other benzodiazepines
- Pregnancy

Precautions
Use cautiously in:
- chronic pulmonary insufficiency, hepatic dysfunction, renal disease, psychoses, drug abuse
- history of suicide attempt or drug abuse
- elderly or debilitated patients
- breastfeeding patients
- children younger than age 15.

Administration
- Give at bedtime with or without food.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30 min</td>
<td>1.2-1.6 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: hangover, headache, dizziness, drowsiness, lethargy, fatigue, paradoxical stimulation, light-headedness, talkativeness, irritability, nervousness, confusion, euphoria, relaxed feeling, tremor, incoordination, impaired memory, nightmares, paresthesia
CV: chest pain, palpitations, tachycardia
EENT: eye irritation, pain, and swelling; photophobia; tinnitus
GI: nausea, vomiting, constipation, diarrhea, heartburn, abdominal pain, dry mouth, anorexia
Musculoskeletal: joint pain
Other: altered taste, body pain, psychological or drug dependence, drug tolerance

Interactions
Drug-drug. Antidepressants, antihistamines, opioid analgesics, other sedative-hypnotics: additive CNS depression
Digoxin: increased digoxin blood level, greater risk of toxicity
Probenecid: faster temazepam onset and prolonged effects
Theophylline: antagonism of temazepam’s sedative effects

Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression

Drug-behaviors. Alcohol use: additive CNS depression
Smoking: increased drug metabolism

Patient monitoring
• Monitor neurologic status carefully. Check for paradoxical reactions, especially in elderly patient.
• Watch for signs and symptoms of physical and psychological drug dependence. Stay alert for drug hoarding.

Patient teaching
• Advise patient to establish effective bedtime routine, to minimize insomnia.
• Inform patient (and significant other if appropriate) that drug may cause psychological and physical dependence and should be used only as prescribed and needed.
• Caution patient to avoid driving and other hazardous activities on day after taking drug, until he knows how it affects concentration and alertness.
• Instruct patient not to drink alcohol.

• Advise patient not to smoke or use herbs without consulting prescriber.
• Instruct patient to report suspected pregnancy.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, herbs, and behaviors mentioned above.

temozolomide
Temodal, Temodar
Pharmacologic class: Alkylating agent
Therapeutic class: Antineoplastic
Pregnancy risk category D

Action
Rapidly converts to monomethyl triazeno imidazole carboxamide, an active compound that prevents DNA transcription

Availability
Capsules: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, 250 mg

Indications and dosages
Refractory anaplastic astrocytoma
Adults: 150 mg/m² P.O. daily for 5 consecutive days of each 28-day treatment cycle. Adjust dosage as appropriate based on absolute neutrophil count.

Contraindications
• Hypersensitivity to drug, its components, or dacarbazine
• Pregnancy or breastfeeding

Precautions
Use cautiously in:
• severe hepatic or renal impairment, active infection, decreased bone marrow reserve, other chronic debilitating illness
• elderly patients

Reactions in bold are life-threatening.
tenecteplase

Metalyse®, TNKase

**Pharmacologic class:** Tissue plasminogen activator  
**Therapeutic class:** Thrombolytic enzyme  
**Pregnancy risk category C**

**Action**
Binds to fibrin and converts plasminogen to plasmin, which breaks down fibrin.

**Patient monitoring**

- Monitor CBC with white cell differential. Stay alert for evidence of bone marrow depression.
- Assess neurologic status carefully.
- Monitor fluid intake and output, and weigh patient regularly.

**Patient teaching**

- Tell patient to take consistently with or without food, and with a full glass of water.
- If drug causes nausea or vomiting, advise patient to take it 1 hour before or 2 hours after a meal.
- Inform patient that drug may cause abnormal gait and dizziness.
- Instruct patient to immediately report unusual bleeding or bruising.
- Advise patient to avoid live-virus vaccines.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, alertness, and vision.
- Instruct patient to report suspected pregnancy. Caution her not to breastfeed.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**Adverse reactions**

**CNS:** fatigue, headache, dysphasia, poor coordination, ataxia, anxiety, depression, dizziness, drowsiness, confusion, amnesia, insomnia, mental status changes, weakness, paresis, hemiparesis, paresthesias, seizures  
**CV:** peripheral edema  
**EENT:** abnormal vision, diplopia, pharyngitis, sinusitis  
**GI:** nausea, vomiting, constipation, diarrhea, abdominal pain, anorexia  
**GU:** urinary incontinence or frequency, urinary tract infection, breast pain (in women)  
**Hematologic:** anemia, leukopenia, thrombocytopenia  
**Metabolic:** adrenal hypercorticism  
**Musculoskeletal:** abnormal gait, back pain, myalgia  
**Respiratory:** cough, upper respiratory infection  
**Skin:** pruritus, rash  
**Other:** fever, viral infection, weight gain

**Route** | **Onset** | **Peak** | **Duration**  
--- | --- | --- | ---  
P.O. | Rapid | 1 hr | Unknown

**Interactions**

**Drug-drug.** Antineoplastics: additive bone marrow depression  
Live-virus vaccines: decreased antibody response to vaccine, greater risk of adverse reactions  
Valproic acid: decreased oral clearance of temozolomide  
Drug-diagnostic tests. Neutrophils, platelets: decreased counts

- patients with childbearing potential  
- children (safety not established).

**Administration**

- Follow facility policy for handling and disposing of chemotherapeutic drugs.
- Give daily with a full glass of water, consistently either with or without food.
- Be aware that dosages in 28-day cycle depend on nadir neutrophil and platelet counts.

**Route** | **Onset** | **Peak** | **Duration**  
--- | --- | --- | ---  
P.O. | Rapid | 1 hr | Unknown
fibrin clots and lyses thrombi and emboli. Causes systemic fibrinolysis.

**Availability**
*Powder for injection*: 50 mg/vial with 10-ml syringe and TwinPak Dual Cannula Device and 10-ml vial of sterile water for injection

**Indications and dosages**
> To reduce mortality associated with acute myocardial infarction

**Adults weighing 90 kg (198 lb) or more**: 50 mg I.V. bolus given over 5 seconds

**Adults weighing 80 kg to 89 kg (176 to 197 lb)**: 45 mg I.V. bolus given over 5 seconds

**Adults weighing 70 kg to 79 kg (154 to 175 lb)**: 40 mg I.V. bolus given over 5 seconds

**Adults weighing 60 to 69 kg (132 to 153 lb)**: 35 mg I.V. bolus given over 5 seconds

**Adults weighing less than 60 kg (132 lb)**: 30 mg I.V. bolus given over 5 seconds

**Contraindications**
- Hypersensitivity to drug or other tissue plasminogen activators
- Active internal bleeding
- Bleeding diathesis
- Recent intracranial or intraspinal surgery or trauma
- Severe uncontrolled hypertension
- Intracranial neoplasm
- Arteriovenous malformation or aneurysm
- History of cerebrovascular accident (CVA)

**Precautions**
Use cautiously in:
- previous puncture of noncompressible vessels, organ biopsy, hypertension, acute pericarditis, high risk of left ventricular thrombosis, subacute bacterial endocarditis, hemostatic defects, diabetic hemorrhagic retinopathy, septic thrombophlebitis, obstetric delivery
- patients taking warfarin concurrently
- patients older than age 75
- pregnant or breastfeeding patients.

**Administration**
- Reconstitute by mixing contents of prefilled syringe with 10 ml of sterile water for injection. Swirl gently; don’t shake. Draw up prescribed dosage from vial, then discard remainder. Give I.V. over 5 seconds through designated line.
- Don’t deliver in same I.V. line with dextrose solutions. Flush I.V. line with normal saline solution before giving drug if patient has been receiving dextrose.
- Give with heparin if ordered, but not through same I.V. line.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
*CNS*: intracranial hemorrhage, CVA
*CV*: hypotension, arrhythmia, myocardial rupture, myocardial reinfarction, cardiogenic shock, atrioventricular block, cardiac arrest, cardiac tamponade, heart failure, pericarditis, pericardial effusion, mitral regurgitation, thrombosis, embolism, hemorrhage

**EENT**: epistaxis, minor pharyngeal bleeding

**GI**: nausea, vomiting, hemorrhage

**GU**: hematuria

**Hematologic**: anemia, bleeding tendency

**Respiratory**: respiratory depression, pulmonary edema, apnea

**Skin**: bleeding at puncture sites, hematoma

**Interactions**
*Drug-drug*. Anticoagulants, aspirin, dipyridamole, indomethacin, phenylbutazone: increased bleeding risk

*Drug-diagnostic tests*. Coagulation tests: fibrinogen degradation in blood sample

Reactions in **bold** are life-threatening.

Clinical alert
Patient monitoring

- Monitor ECG. Stay alert for reperfusion arrhythmias.
- Monitor vital signs carefully. Watch for signs and symptoms of respiratory depression and reinfarction.
- Evaluate all body systems closely for signs and symptoms of bleeding. If bleeding occurs, stop drug and give antiplatelet agents, as ordered.
- Monitor CBC and coagulation studies. However, know that drug may skew coagulation results.

Patient teaching

- Inform patient that drug increases risk of bleeding. Advise him to immediately report signs and symptoms of bleeding.
- Teach patient safety measures to avoid bruising and bleeding.
- Tell patient he’ll undergo regular blood tests during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

---

tenoforv disoproxil fumarate

Viread

Pharmacologic class: Nucleoside analog reverse transcriptase inhibitor

Therapeutic class: Antiretroviral

Pregnancy risk category B

---

FDA BOXED WARNING

- Severe acute exacerbations of hepatitis have been reported in patients with hepatitis B virus (HBV) infection who have discontinued anti–hepatitis B therapy. Monitor hepatic function closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti–hepatitis B therapy. If appropriate, resumption of anti–hepatitis B therapy may be warranted
- Drug should not be given with adefovir dipivoxil.
- Because of risk of development of human immunodeficiency virus-1 (HIV-1) resistance, drug should only be used in HIV-1 and HBV co-infected patients as part of an appropriate antiretroviral combination regimen.
- HIV-1 antibody testing should be offered to all HBV-infected patients before start of therapy. It is also recommended that all patients with HIV-1 infection be tested for presence of chronic HBV infection before start of drug therapy.
- Drug’s effects on bone haven’t been studied in patients with chronic HBV infection.
- In HIV-infected patients, redistribution or accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and cushingoid appearance, has been observed in patients receiving combination antiretroviral therapy.
- Immune reconstitution syndrome has been reported in HIV-infected patients treated with combination antiretroviral therapy.

Action

Inhibits activity of HIV by competing with natural substrate deoxyadenosine 5’-triphosphate; disrupts cellular DNA by causing chain termination

Availability

Tablets: 300 mg

Indications and dosages

- HIV-1 infection

Adults: 300 mg P.O. daily
Dosage adjustment
● Moderate to severe renal impairment

Contraindications
● None

Precautions
Use cautiously in:
● renal impairment
● lactic acidosis
● exacerbation of hepatitis, hepatomegaly with steatosis
● co-administration of adefovir dipivoxil or other tenofovir-containing products
● decreased bone marrow density
● redistribution or accumulation of body fat
● immune reconstitution syndrome
● elderly patients
● pregnant or breastfeeding patients
● children younger than age 18.

Administration
● Give without regard to meals.
● Know that drug is usually given with other antiretrovirals. If patient is also receiving didanosine, give tenofovir at least 2 hours before or 1 hour after didanosine.

Route Onset Peak Duration
P.O. Rapid 45-75 min Unknown

Adverse reactions
CNS: headache, asthenia, depression
GI: nausea, vomiting, diarrhea, abdominal pain, flatulence, anorexia
GU: renal impairment, glycosuria
Skin: rash
Hepatic: severe hepatomegaly with steatosis
Metabolic: hyperglycemia, lactic acidosis
Other: body fat redistribution, pain, immune reconstitution syndrome

Interactions
Drug-drug. Acyclovir, cidofovir, didanosine, ganciclovir, indinavir, lopinavir, probenecid, ritonavir, valacyclovir, valganciclovir, other drugs eliminated by active tubular secretion (such as adefovir dipivoxil): increased blood level of either drug
Atazanavir, lopinavir/ritonavir: increased tenofovir concentration

Drug-diagnostic tests. Alanine aminotransferase, amylase, aspartate aminotransferase, blood and urine glucose, creatine kinase, triglycerides: increased levels
Neutrophils: decreased count

Drug-food. Any food: decreased drug bioavailability and efficacy

Patient monitoring
⚠️ Watch for and report signs and symptoms of lactic acidosis or hepatotoxicity.
● Monitor bone mineral density in patients with history of pathologic fractures or who are at risk for osteopenia.
⚠️ Monitor for signs of immune reconstitution syndrome, especially during initial phase of combination antiretroviral treatment when patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, cytomegalovirus, Pneumocystis jirovecii pneumonia, or tuberculosis), which may necessitate further evaluation and treatment.
● Monitor kidney and liver function tests.
● Assess nutritional status and hydration in light of adverse GI reactions and underlying disease.

Patient teaching
● Tell patient to take once daily with or without food.
● If patient is also receiving didanosine, instruct him to take tenofovir at least 2 hours before or 1 hour after didanosine.

Reactions in bold are life-threatening.
Instruct patient to immediately report unusual tiredness or yellowing of skin or eyes.
● Tell patient drug may cause weakness and headache. Caution him to avoid driving and other hazardous activities until he knows how drug affects performance.
● Caution female patient not to breastfeed.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

**terazosin hydrochloride**

Apo-Terazosin®, Dom-Terazosin®, Hytrin, Novo-Terazosin®, Nu-Terazosin®, PHL-Terazosin®, PMS-Terazosin®, Ratio-Terazosin®

**Pharmacologic class:** Anti-adrenergic (peripherally acting)

**Therapeutic class:** Antihypertensive

**Pregnancy risk category C**

**Action**
Blocks postsynaptic alpha₁-adrenergic receptors, causing vasodilation and decreasing smooth muscle contractions in bladder neck and prostate

**Availability**
Tablets: 1 mg, 2 mg, 5 mg, 10 mg

**Indications and dosages**

> **Hypertension**

**Adults:** Initially, 1 mg P.O., increased slowly as needed up to 5 mg/day. Usual range is 1 to 5 mg/day, not to exceed 20 mg/day.

> **Benign prostatic hyperplasia**

**Adults:** 1 mg P.O. at bedtime. To achieve desired response, may increase gradually to 2 mg/day, then to 5 mg/day, and then to a maximum of 10 mg/day.

**Contraindications**

● Hypersensitivity to drug or other quinazoline derivatives

**Precautions**

Use cautiously in:
● prostate cancer, hepatic disease, dehydration, volume or sodium depletion
● pregnant or breastfeeding patients
● children (safety not established).

**Administration**

> Don’t stop therapy suddenly. Dosage must be tapered.

● Know that drug may be given as a single dose at bedtime or in two divided doses.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>15 min</td>
<td>2-3 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: dizziness, headache, weakness, drowsiness, nervousness, paresthesia, vertigo, fatigue, syncope
CV: orthostatic hypotension (with first dose), rebound hypertension, chest pain, palpitations, peripheral edema, tachycardia, arrhythmias
EENT: blurred vision, conjunctivitis, amblyopia, nasal congestion, sinusitis
GI: nausea, vomiting, diarrhea, abdominal pain, dry mouth
GU: urinary frequency or incontinence, erectile dysfunction, priapism
Musculoskeletal: joint, back, and extremity pain; arthritis
Respiratory: dyspnea
Skin: pruritus
Other: fever, weight gain, flulike symptoms

**Interactions**

Drug-drug. Estrogens, nonsteroidal anti-inflammatory drugs (NSAIDs), sympathomimetics: decreased antihypertensive effects
Midodrine: antagonism of terazosin’s action
Nitrates, other antihypertensives: additive hypotension
Drug-herbs. Ephedra (ma huang): antagonism of terazosin’s action
Drug-behaviors. Alcohol use: additive hypotension

Patient monitoring
• Monitor blood pressure. Stay alert for orthostatic hypotension (first-dose effect) when therapy begins.
• Assess cardiovascular status. Report chest pain, peripheral edema, palpitations, and other significant effects.

Patient teaching
• Instruct patient to take at same time every day, with or without food.
  Caution patient not to stop therapy abruptly. Dosage must be tapered.
  Advise patient to immediately report swelling, breathing difficulty, palpitations, chest pain, and other cardiovascular reactions.
• Tell patient drug may cause erectile dysfunction and other sexual problems.
• Caution patient not to use NSAIDs or drink alcohol.
• Instruct patient to move slowly when sitting up or standing, to avoid dizziness from sudden blood pressure decrease.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, herbs, and behaviors mentioned above.

Action
Unclear. Thought to interfere with sterol biosynthesis of fungal cell membrane permeability by inhibiting enzymes responsible for normal fungal growth and maturation, resulting in cell death.

Availability
Cream: 1%
Oral granules: 125 mg, 187.5 mg
Tablets: 250 mg

Indications and dosages
➢ Tinea cruris; tinea corporis; tinea pedis; tinea versicolor
Adults and children: Massage cream into affected area and surrounding area once or twice daily for 7 to 14 days, not to exceed 4 weeks.
➢ Onychomycosis of fingernail or toenail
Adults: For fingernail infection, 250 mg P.O. daily for 6 weeks. For toenail infection, 250 mg P.O. daily for 12 weeks.
➢ Tinea capitis
Children ages 4 and older weighing less than 25 kg (55 lb): 125 mg P.O. daily for 6 weeks
Children ages 4 and older weighing 25 to 35 kg (55 to 77 lb): 187.5 mg P.O. daily for 6 weeks
Children ages 4 and older weighing more than 35 kg (77 lb): 250 mg P.O. daily for 6 weeks

Contraindications
• Hypersensitivity to drug or its components
• Chronic active hepatic disease

Precautions
Use cautiously in:
• renal impairment (use not recommended)
• pregnant or breastfeeding patients (use not recommended)
• children (safety and efficacy not established).

terbinafine hydrochloride
Desenex Max, Lamisil, Lamisil AT
Pharmacologic class: Synthetic allylamine derivative
Therapeutic class: Antifungal
Pregnancy risk category B

Reactions in bold are life-threatening.
Administration

- Give with or without food, but not with coffee, cola, or tea.
- Know that oral granules should be sprinkled on nonacidic food, such as pudding or mashed potatoes. Fruit-based food such as applesauce shouldn’t be used.
- Know that oral granules should be swallowed without being chewed.
- Don’t put occlusive dressing over affected area after cream application.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>≤ 2 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>Topical</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: headache
EENT: visual disturbances
GI: nausea, diarrhea, dyspepsia, abdominal pain, flatulence
Hematologic: neutropenia
Hepatic: hepatic failure
Skin: burning, stinging, dryness, itching, and local irritation (with topical form); rash; pruritus; urticaria; erythema multiforme; Stevens-Johnson syndrome
Other: taste disturbances

Interactions

Drug-drug. Cimetidine: decreased terbinafine clearance
Cyclosporine: increased cyclosporine clearance
Dextromethorphan: increased dextromethorphan blood level
Rifampin: increased terbinafine clearance
Warfarin: altered warfarin efficacy

Drug-diagnostic tests. Hepatic enzymes: increased levels
Neutrophils: decreased count

Drug-food. Caffeine-containing foods and beverages: decreased caffeine clearance

Drug-herbs. Chaparral, comfrey, germander, jin bu huan, kava, pennyroyal: increased risk of hepatotoxicity

Cola nut, guarana, yerba maté: decreased clearance of these herbs

Patient monitoring

- Monitor CBC and liver function tests.
- Watch for signs and symptoms of erythema multiforme. Report early indications before they progress to Stevens-Johnson syndrome.

Patient teaching

- Tell patient he may take with or without food.
- Advise caregiver that oral granules should be sprinkled on nonacidic food, such as pudding or mashed potatoes and not to use fruit-based food such as applesauce.
- Advise caregiver that oral granules should be swallowed without being chewed
- Instruct patient to avoid coffee, tea, and colas, which can worsen adverse drug reactions.
- Tell patient drug may take 4 weeks to be effective in fingernail infections and 10 weeks in toenail infections. Urge him to keep taking it even though symptoms don’t improve right away.
- Advise patient to immediately report rash, sore throat, cough, fever, or yellowing of skin or eyes.
- Instruct patient not to place occlusive dressing over affected area after applying cream.
- Caution patient not to let cream contact eyes, nose, or mouth.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.
**terbutaline sulfate**  
Bricanyl, Bricanyl®, Monovent®

**Pharmacologic class:** Selective beta₂-adrenergic receptor agonist  
**Therapeutic class:** Bronchodilator  
**Pregnancy risk category B**

**Action**  
Relaxes bronchial smooth muscle by stimulating beta₂-adrenergic receptors; inhibits release of hypersensitivity mediators, especially from mast cells.

**Availability**  
*Inhaler:* 0.2 mg/inhalation  
*Injection:* 1 mg/ml  
*Tablets:* 2.5 mg, 5 mg

**Indications and dosages**  
> Bronchospasm in reversible obstructive airway disease  
**Adults and children older than age 12:** 0.25 mg subcutaneously, repeated in 15 to 30 minutes p.r.n., up to a maximum of 0.5 mg in 4 hours. Or 2.5 to 5 mg P.O. q 6 hours t.i.d. while awake, up to a maximum of 15 mg/day in adults; 2.5 mg P.O. q 6 hours t.i.d. while awake, up to a maximum of 7.5 mg/day in children. Or 0.2 to 0.5 mg by inhaler (one to two inhalations) q 4 to 6 hours.

**Dosage adjustment**  
- Renal impairment

**Off-label uses**  
- Tocolytic in preterm labor

**Contraindications**  
- Hypersensitivity to drug, its components, or sympathomimetic amines

**Precautions**  
Use cautiously in:  
- cardiovascular disorders, hypertension, arrhythmias, hyperthyroidism, diabetes mellitus, seizure disorders, glaucoma  
- concurrent use of MAO inhibitors, tricyclic antidepressants, or beta-adrenergic blockers  
- elderly patients  
- breastfeeding patients.

**Administration**  
- Inject subcutaneously into lateral deltoid.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30 min</td>
<td>2-3 hr</td>
<td>4-8 hr</td>
</tr>
<tr>
<td>Subcut.</td>
<td>15 min</td>
<td>30 min</td>
<td>1.5-4 hr</td>
</tr>
<tr>
<td>Inhalation</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**  
- **CNS:** tremors, anxiety, nervousness, insomnia, headache, dizziness, drowsiness, stimulation  
- **CV:** palpitations, chest discomfort, tachycardia  
- **GI:** nausea, vomiting  
- **Skin:** diaphoresis, flushing

**Interactions**  
**Drug-drug.** Beta-adrenergic blockers: blockage of bronchodilating effect  
**MAO inhibitors, tricyclic antidepressants:** potentiation of terbutaline’s adverse cardiovascular reactions  
**Other sympathomimetic amines:** additive adverse cardiovascular reactions

**Patient monitoring**  
- Monitor vital signs.  
- Assess neurologic status.

**Patient teaching**  
- Tell patient he may take with or without food.  
- Advise patient or parents to establish effective bedtime routine to minimize insomnia.
Instruct patient or parents to space doses evenly during waking hours, to avoid taking drug at bedtime.

As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

teriparatide (recombinant)
Forsteo®, Forteo

Pharmacologic class: Biosynthetic fragment of human parathyroid hormone

Therapeutic class: Parathyroid hormone

Pregnancy risk category C

FDA BOXED WARNING

In male and female rats, drug increased incidence of osteosarcoma (malignant bone tumor). Because of uncertain relevance of this finding to humans, use drug only in patients for whom potential benefits outweigh potential risk. Don’t administer to patient at increased baseline risk for osteosarcoma.

Action
Stimulates new bone growth by binding to specific high-affinity cell-surface receptors

Availability
Injection: 750 mcg/3 ml (controlled pen device)

Indications and dosages

Osteoporosis in patients at high risk for bone fracture

Adults: 20 mcg/day subcutaneously for up to 2 years

Contraindications

- Hypersensitivity to drug
- Conditions that increase osteosarcoma risk (such as Paget’s disease, unexplained alkaline phosphatase elevation, open epiphyses, skeletal radiation therapy)
- Bone cancer metastases or history of bone cancer
- Metabolic bone disease other than osteoporosis
- Hypercalcemia

Precautions
Use cautiously in:
- urolithiasis, hypotension
- concurrent use of cardiac glycosides
- pregnant or breastfeeding patients.

Administration

- Inject subcutaneously into thigh or abdominal wall, with patient lying down.
- Know that prefilled injection pen delivers 20 mcg of drug per actuation and may be reused for up to 28 days after first injection. Discard pen in protected container after 28 days, even if it’s not empty.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcut.</td>
<td>Rapid</td>
<td>Rapid</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: dizziness, headache, insomnia, depression, vertigo, asthenia
CV: hypertension, angina, syncope
EENT: rhinitis, pharyngitis
GI: nausea, vomiting, diarrhea, dyspepsia, anorexia
Metabolic: hyperuricemia
Musculoskeletal: joint pain, cramps
Respiratory: cough, dyspnea, pneumonia
Skin: rash, sweating
Other: pain

Interactions

Drug-drug. Digoxin: increased digoxin toxicity
Drug-diagnostic tests. Calcium: increased level
Patient monitoring
- Monitor respiratory and neurologic status and assess patient’s mood.
- Monitor bone mineral density tests and calcium level.

Patient teaching
- Instruct patient to promptly report such adverse reactions as cough and difficulty breathing.
- Tell patient that prefilled injection pen delivers 20 mcg of drug per actuation. Inform him that he may reuse it for up to 28 days after first injection, and should then discard it in appropriate receptacle, even if it’s not empty.
- Advise patient to establish effective bedtime routine to minimize insomnia.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects strength and balance.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Action
Responsible for normal growth and development of male sex organs and maintenance and maturation of secondary sex characteristics. Also decreases estrogen activity, which aids treatment of some breast cancers.

Availability

**testosterone**
- Buccal system: 30 mg
- Gel: 1% (25 mg, 50 mg)
- Injection (aqueous suspension): 100 mg/ml
- Pellets (subcutaneous implant): 75 mg
- Transdermal system: 2.5 mg/24 hours, 4 mg/24 hours, 5 mg/24 hours, 6 mg/24 hours

**testosterone cypionate**
- Injection: 100 mg/ml, 200 mg/ml

**testosterone enanthate**
- Injection (in oil): 200 mg/ml

**Indications and dosages**

> **Male hypogonadism**

**Adult males:** 10 to 25 mg (testosterone) I.M. two to three times weekly or 50 to 400 mg (enanthate) I.M. q 2 to 4 weeks for 3 to 4 years. Or 150 to 450 mg (pellet) implanted subcutaneously q 3 to 6 months. Or 5 mg daily transdermal (nonscrotal) system (Androderm); may increase up to 7.5 mg daily or 5 mg daily (Testoderm TTS), adjusted after 3 to 4 weeks and possibly increased to 10 mg daily. Or 4 to 6 mg daily transdermal scrotal system (Testoderm), adjusted after 3 to 4 weeks. Or 50 mg testosterone gel (AndroGel 1%) daily applied topically, adjusted up to 75 mg daily within 14 days, with subsequent dosages up to 100 mg daily. Or 30 mg (buccal system) to gum region b.i.d. Or 50 to 400 mg I.M. (cypionate) q 2 to 4 weeks.

> **Delayed puberty**

**Adult males:** 50 to 200 mg I.M. (enanthate only) q 2 to 4 weeks for limited duration (4 to 6 months); or 150 to
450 mg subcutaneously (pellets) q 3 to 6 months

➣ Inoperable breast cancer in women 1 to 5 years after menopause

Adults: 200 to 400 mg I.M. (enanthate) q 2 to 4 weeks

Contraindications
- Hypersensitivity to drug, its components, or tartrazine
- Serious cardiac, hepatic, or renal disease
- Males with breast cancer or suspected prostate cancer
- Females (buccal or transdermal systems or gel)
- Pregnancy or breastfeeding

Precautions
Use cautiously in:
- diabetes mellitus, cardiovascular or hepatic disease, sleep apnea, or hypercalcemia.

Administration
- Inspect aqueous solution for injection. If crystals are visible, warm bottle and shake contents to dissolve crystals.
- Rotate I.M. injection sites within upper outer quadrant of gluteus maximus. Inject deeply into muscle.
- Apply gel once daily to clean, dry, intact skin on shoulder, upper arm, or abdomen.
- Place buccal system just above incisor tooth. Have patient hold it in place for 30 seconds to ensure adhesion. Rotate to other side of mouth with each application.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buccal</td>
<td>Slow</td>
<td>10-12 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.M.</td>
<td>Unknown</td>
<td>10-100 min</td>
<td>Unknown</td>
</tr>
<tr>
<td>Subcut.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>3-4 mo</td>
</tr>
<tr>
<td>Topical gel</td>
<td>30 min</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>Transdermal</td>
<td>Unknown</td>
<td>2-4 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, depression, emotional lability, nervousness, anxiety, asthenia, memory loss, dizziness, vertigo, cerebrovascular accident
CV: edema, peripheral edema, deep-vein phlebitis, heart failure
GI: bleeding
GU: hematuria, urinary tract infection, impaired urination, scrotal cellulitis, benign prostatic hyperplasia, scrotal papilloma (with transdermal use), prostatitis, libido changes, breast pain or tenderness, gynecomastia, virilization in females, excessive hormonal effects in males
Hematologic: polycythemia, leukopenia, suppressed clotting factors
Hepatic: hepatic adenoma (with long-term enanthate use)
Metabolic: hyperphosphatemia, hypernatremia, hypercalcemia, hypoglycemia, hyperkalemia
Musculoskeletal: myalgia
Respiratory: sleep apnea
Skin: acne; rash, itching, burning, discomfort, irritation, burn-like blister, erythema (with transdermal use); pain, local edema, and induration at injection site (with I.M. or subcutaneous use)
Other: accidental injury, flulike symptoms, hypersensitivity reaction

Interactions
Drug-drug. Corticosteroids: increased risk of edema
Hepatotoxic drugs: increased risk of hepatotoxicity
Insulin, oral hypoglycemics: decreased blood glucose level
Oral anticoagulants: increased anticoagulant effect
Oxyphenbutazone: increased oxyphenbutazone blood level
Propranolol: increased propranolol clearance
Drug-diagnostic tests. Bilirubin, liver function tests: abnormal results
Calcium, cholesterol, hematocrit, hemoglobin, phosphate, prostate-specific antigen (with topical use), sodium: increased levels
Clotting factors, creatine excretion, glucose, serum creatinine, thyroxine, thyroxine-binding globulin: decreased levels
Urine creatine and creatinine: decreased excretion
Urine 17-ketosteroids: increased excretion

Drug-herbs. Chaparral, comfrey, germander, jin bu huan, kava, pennyroyal: increased risk of hepatotoxicity

Patient monitoring
- Monitor electrolyte levels, liver function tests, blood and urine calcium levels, lipid panels, CBC with white cell differential, and semen studies.
- Assess diabetic patient carefully for hypoglycemia.
- Closely monitor neurologic status. Stay alert for sleep apnea.
- Assess for early signs of excessive hormonal effects in females (virilization). If these occur, drug withdrawal may be indicated.

Patient teaching
- Instruct patient to immediately report signs and symptoms of liver problems, including nausea, vomiting, yellowing of skin or eyes, and ankle swelling.
- Teach prepubertal male about signs and symptoms of excessive hormonal effects, such as acne, priapism, increased body and facial hair, and penile enlargement.
- Teach postpubertal male about signs and symptoms of excessive adverse hormonal effects, such as erectile dysfunction, gynecomastia, epididymitis, testicular atrophy, and infertility.
- Tell female patient to immediately report signs of masculinization, such as excessive body or facial hair, deepening of voice, clitoral enlargement, and menstrual irregularities.
- Advise female of childbearing age to use barrier contraceptives. Caution her not to breastfeed.
- Tell patient which transdermal patches can be applied to scrotum. Instruct him to apply patch daily to clean, dry skin after removing protective liner to expose drug-containing film. To prevent irritation, instruct him to apply each patch to a different site, waiting at least 1 week before using same site.
- Advise patient to apply topical gel once daily to clean, dry skin on shoulder, upper arm, or abdomen. Tell him that after opening packet, he should squeeze entire contents into palm and apply immediately. Instruct him to wait until gel dries before getting dressed.
- Teach patient to place buccal system in comfortable position just above incisor tooth and hold it in place for about 30 seconds to ensure adhesion. Tell him to use opposite side of mouth with each application. Caution him not to dislodge buccal system, especially when eating, drinking, brushing teeth, or using mouthwash. If system doesn’t properly adhere or falls out during 12-hour dosing interval, tell him to discard it and apply new system. If it falls out within 4 hours of next dose, tell him to apply new system and keep it in place until next regularly scheduled dose.
- Tell patient drug shouldn’t be used to enhance athletic performance or physique.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

Reactions in **bold** are life-threatening. ▶️Clinical alert
tetracycline hydrochloride

Apo-Tetra®, Novotetra®, Nu-Tetra®, Topicycline®

**Pharmacologic class:** Tetracycline  
**Therapeutic class:** Anti-infective  
**Pregnancy risk category B** (topical form), **D** (oral form)

**Action**  
Unknown. Thought to inhibit bacterial protein synthesis at level of 30S and 50S bacterial ribosomes and to alter cytoplasmic membrane of susceptible organisms.

**Availability**  
Capsules: 250 mg, 500 mg  
Ointment: 3%  
Oral suspension: 125 mg/5 ml

**Indications and dosages**

- **Mild to moderate infections caused by susceptible organisms**  
  **Adults:** 500 mg P.O. b.i.d. or 250 mg P.O. q.i.d.  
  **Severe infections caused by susceptible organisms**  
  **Adults:** 500 mg P.O. q.i.d.  
  **Children older than age 8:** 25 to 50 mg/kg P.O. q.i.d.

- **Syphilis in penicillin-allergic patients**  
  **Adults:** 500 mg P.O. q.i.d. for 14 days  
  **Late syphilis (except neurosyphilis)**  
  **Adults:** 500 mg P.O. q.i.d. for 28 days  
  **Leptospirosis when penicillin is contraindicated or ineffective**  
  **Adults:** 1 to 2 g P.O. daily in two to four divided doses for 5 to 7 days  
  **Yaws**  
  **Adults:** 1 to 2 g P.O. daily in two to four divided doses for 10 to 14 days  
  **Gonorrhea in penicillin-allergic patients**  
  **Adults:** Initially, 1.5 g P.O., followed by 500 mg P.O. q 6 hours for 4 days, up to a total of 9 g  
  **Uncomplicated urethral, endocervical, or rectal infections caused by *Chlamydia trachomatis***  
  **Adults:** 500 mg P.O. q.i.d. for 7 days  
  **Rickettsial and mycoplasmal infections**  
  **Adults:** 1 to 2 g P.O. daily in two to four divided doses for 7 days  
  **Helicobacter pylori infection**  
  **Adults:** In patients with active duodenal ulcer, 500 mg P.O. q.i.d. at meals and bedtime for 14 days, given with other drugs (such as metronidazole, bismuth subsalicylate, amoxicillin, or omeprazole)  
  **Brucellosis**  
  **Adults:** 500 mg P.O. q.i.d. for 3 weeks, given with streptomycin I.M. b.i.d. during week 1 and streptomycin once daily during week 2  
  **Granuloma inguinale; chancroid**  
  **Adults:** 1 to 2 g P.O. daily in two to four divided doses for 2 to 4 weeks  
  **Cholera**  
  **Adults:** 500 mg P.O. q 6 hours for 48 to 72 hours  
  **Plague when streptomycin is contraindicated or ineffective**  
  **Adults:** 2 to 4 g P.O. q.i.d. for 10 days  
  **Children older than age 8:** 30 to 40 mg/kg P.O. q.i.d. for 10 to 14 days  
  **Tularemia as an alternative to streptomycin**  
  **Adults:** 1 to 2 g P.O. daily in two to four divided doses for 1 to 2 weeks  
  **Campylobacter infection**  
  **Adults:** 1 to 2 g P.O. daily in two to four divided doses for 10 days  
  **Relapsing fever caused by *Borrelia recurrentis***  
  **Adults:** 1 to 2 g P.O. daily in two to four divided doses for 7 days or until patient is afebrile  
  **Adjunctive treatment of inflammatory acne**
Adults and adolescents: 500 mg to 1 g P.O. q.i.d. for 1 to 2 weeks, decreased gradually to 125 to 500 mg P.O. daily

➤ Acne vulgaris

Adults and children older than age 11: 3% ointment applied to affected area b.i.d. (morning and evening) until skin is thoroughly wet

Dosage adjustment
• Renal impairment

Off-label uses
• Rosacea
• Anthrax
• Arthritis
• Lyme disease
• Sclerosing agent to control pleural effusions

Contraindications
• Hypersensitivity to drug, other tetracyclines, bisulfites, or alcohol (in some products)

Precautions
Use cautiously in:
• renal disease, hepatic impairment, nephrogenic diabetes insipidus
• cachectic or debilitated patients
• pregnant or breastfeeding patients (except in anthrax treatment or with topical form)
• children younger than age 11 (with topical form)
• children younger than age 8 (except in anthrax treatment).

Administration
• Give with 8 oz of water at least 1 hour before or 2 hours after a meal (especially if it includes milk or other dairy products), antacids, laxatives, or antiarrheal drugs.

Adverse reactions
CNS: paresthesia, benign intracranial hypertension
CV: pericarditis
EENT: abnormal conjunctival pigmentation, hoarseness, pharyngitis
GI: nausea, vomiting, diarrhea, loose bulky stools, esophageal ulcers, epigastric distress, enterocolitis, oral and anogenital candidiasis, stomatitis, black hairy tongue, glossitis, anorexia, pancreatitis
GU: dark yellow or brown urine, vaginal candidiasis, anogenital lesions
Hematologic: eosinophilia, hemolytic anemia, neutropenia, thrombocytopenia, thrombocytopenia purpura
Hepatic: fatty liver
Musculoskeletal: retarded bone growth, polyarthralgia
Respiratory: pulmonary infiltrates
Skin: stinging and yellowing of skin (with topical form), photosensitivity, maculopapular or erythematous rash, increased pigmentation, urticaria, onycholysis
Other: permanent tooth discoloration (in children younger than age 8), tooth enamel defects, superinfection, hypersensitivity reactions including anaphylaxis, serum sickness–like reaction, exacerbation of systemic lupus erythematous

Interactions
Drug-drug. Adsorbent antiarrheals, antacids, calcium, cholestyramine, cimetidine, colestipol, iron, magnesium, sodium bicarbonate: decreased tetracycline absorption
Digoxin: increased digoxin blood level, greater risk of toxicity
Hormonal contraceptives: decreased contraceptive efficacy
Insulin: reduced insulin requirement
Lithium: increased or decreased lithium blood level
Methoxyflurane: increased risk of nephrotoxicity
Penicillin: decreased penicillin activity

Reactions in bold are life-threatening.
Sucralfate: prevention of tetracycline absorption from GI tract
Warfarin: enhanced warfarin effects

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, bilirubin, blood urea nitrogen: increased levels
Hemoglobin, neutrophils, platelets, white blood cells: decreased levels
Urinary catecholamines: false elevation

Drug-food. Dairy products, foods containing calcium: decreased drug absorption

Drug-behaviors. Alcohol use: decreased drug efficacy
Sun exposure: increased risk of photosensitivity

Patient monitoring
- Monitor for signs and symptoms of superinfection and hypersensitivity reaction.
- With long-term use, monitor CBC, liver function tests, and (in prepubertal patients) bone growth.
- Assess neurologic status. Stay alert for benign intracranial hypertension (especially in children).

Patient teaching
- Tell patient to take oral form with 8 oz of water at least 1 hour before or 2 hours after eating a meal, consuming dairy products, or taking antacids, laxatives, or antidiarrheal drugs. Advise him to take last daily dose at least 1 hour before bedtime.
- Stress importance of completing entire course of therapy as ordered, even after symptoms improve.
- Caution patient not to use outdated tetracycline, because it may cause serious kidney disease.
- Teach patient to recognize and report signs and symptoms of yeast infection and other infections.
- With long-long therapy, tell patient he’ll undergo regular blood testing.

Advise parents that prepubertal child should have periodic bone X-rays.
- Instruct patient using topical form not to let drug touch eyes, nose, or mouth. Tell him drug may turn skin yellow.
- Caution patient to avoid alcohol during therapy.
- Tell parents that tetracycline use during tooth development period (last half of pregnancy, infancy, and childhood to age 8) may cause permanent yellow, gray, or brownish tooth discoloration.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and behaviors mentioned above.

thalidomide
Thalomid

Pharmacologic class: Synthetic glutamic acid derivative
Therapeutic class: Immunomodulator, angiogenesis inhibitor
Pregnancy risk category X

FDA BOXED WARNING
- When taken during pregnancy, drug may cause severe, life-threatening birth defects or fetal death. Never administer to women who are pregnant or could become pregnant during therapy. Because of its toxicity and to reduce risk of fetal exposure, drug is approved for marketing only under special Food and Drug Administration–approved restricted distribution program, called System for Thalidomide Education and Prescribing Safety (S.T.E.P.S(TM)). Only prescribers and pharmacists registered with program are allowed to prescribe and dispense drug. Also, patients must be advised of, agree to, and

Canada UK Hazardous drug High alert drug
comply with program requirements. For special information about this distribution program for prescribers and patients, see complete boxed warnings in package insert.

**Action**
Suppresses excess levels of tumor necrosis factor-alpha in patients with erythema nodosum leprosum (ENL). Alters leukocyte migration by changing cell surface characteristics.

**Availability**
Capsules: 50 mg, 100 mg, 200 mg

**Indications and dosages**
> Cutaneous manifestations of moderate to severe ENL; to prevent and suppress recurrent ENL

**Adults weighing 50 kg (110 lb) or more:**
100 to 300 mg P.O. daily, or up to 400 mg P.O. daily, depending on disease severity or previous response. Continue therapy until symptoms of active reactions subside (usually after 2 weeks); then may taper in 50-mg decrements q 2 to 4 weeks.

**Adults weighing less than 50 kg (110 lb):**
Initially, 100 mg P.O. daily, or up to 400 mg P.O. daily, depending on disease severity or previous response. Continue therapy until symptoms of active reactions subside (usually after 2 weeks); then may taper in 50-mg decrements q 2 to 4 weeks.

**Off-label uses**
- Aphthous stomatitis
- Wasting syndrome associated with human immunodeficiency virus (HIV)
- Multiple myeloma
- Refractory Crohn's disease

**Precautions**
Use cautiously in:
- breastfeeding patients (use not recommended)
- children younger than age 12 (safety not established).

**Administration**
- Give with 8 oz of water just before bedtime, at least 1 hour after evening meal.
- Know that patients who need prolonged maintenance therapy to prevent cutaneous ENL recurrence and those who have flares during tapering should receive minimum effective dosage, with tapering attempted every 3 to 6 months. To taper, decrease dosage by 50 mg every 2 to 4 weeks.

**Route Onset Peak Duration**
| P.O. | 48 hr | 1-2 mo | Unknown |

**Adverse reactions**

**CNS:** drowsiness, dizziness, vertigo, sedation, tremor, asthenia, peripheral neuropathy

**CV:** bradycardia, orthostatic hypotension, peripheral edema

**EENT:** rhinitis, sinusitis, pharyngitis

**GI:** nausea, constipation, diarrhea, abdominal pain, oral moniliasis

**GU:** erectile dysfunction

**Hematologic: neutropenia**

**Musculoskeletal:** back pain

**Skin:** exfoliative, purpuric, bullous, or maculopapular rash; pruritus; fungal dermatitis; nail disorder; photosensitivity; toxic epidermal necrolysis, Stevens-Johnson syndrome

**Other:** tooth pain, chills, accidental injury, hypersensitivity reactions, increased HIV viral load, severe birth defects, fetal death

Reactions in **bold** are life-threatening.
Interactions

Drug-drug. Barbiturates, chlorpromazine, reserpine, sedative-hypnotics, and other CNS depressants: increased sedation

Drugs linked to peripheral neuropathy: increased risk of peripheral neuropathy

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, lipids, liver function tests: increased values

Hemoglobin, neutrophils, white blood cells: decreased values

Drug-food. High-fat meal: interference with drug absorption

Drug-behaviors. Alcohol use: increased sedation

Patient monitoring

- Monitor for signs and symptoms of hypersensitivity reaction. If rash occurs, discontinue drug and contact prescriber immediately. Don’t restart drug if Stevens-Johnson syndrome, toxic epidermal necrolysis, or exfoliative, purpuric, or bullous rash occurs.
- Watch for and report signs and symptoms of peripheral neuropathy.
- Assess CBC with white cell differential.
- Carefully monitor patient’s reproductive status.

Patient teaching

- Instruct patient to take with 8 oz of water just before bedtime, at least 1 hour after dinner.
- Tell patient to immediately report signs and symptoms of hypersensitivity reaction, especially rash.
- Teach patient about risks of fetal exposure to drug. Carefully review relevant portions of S.T.E.P.S™ program with patient.
- Instruct female of childbearing age to use two highly effective birth control methods simultaneously, from 1 month before first thalidomide dose until 1 month after last dose.
- Explain mandatory pregnancy testing schedule to female patient, and stress importance of compliance.
- Advise female patient to contact prescriber immediately if she suspects she’s pregnant.
- Caution female patient not to breastfeed.
- Instruct male patient to use latex condoms during every sexual encounter.
- Tell patient to avoid alcohol during drug therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and behaviors mentioned above.

theophylline


Pharmacologic class: Xanthine derivative

Therapeutic class: Bronchodilator, spasmolytic

Pregnancy risk category C

Action

Relaxes bronchial smooth muscles, suppressing airway response to stimuli. Also inhibits phosphodiesterase and release of slow-reacting substance of anaphylaxis and histamine.

Availability

Capsules (immediate-release): 100 mg, 200 mg
Capsules (timed-release, 8 to 12 hours): 50 mg, 60 mg, 65 mg, 75 mg, 100 mg, 125 mg, 130 mg
Capsules (timed-release, 12 hours): 50 mg, 125 mg, 130 mg, 250 mg, 260 mg
Capsules (timed-release, 24 hours): 100 mg, 200 mg, 300 mg
Elixir: 80 mg/15 ml
Injection (with dextrose): 0.4 mg/ml, 0.8 mg/ml, 1.6 mg/ml, 2 mg/ml, 3.2 mg/ml, 4 mg/ml
Solution: 80 mg/15 ml, 150 mg/15 ml
Syrup (cherry): 80 mg/15 mg, 150 mg/15 ml
Tablets (immediate-release): 100 mg, 125 mg, 200 mg, 250 mg, 300 mg, 500 mg
Tablets (timed-release, 8 to 12 hours): 100 mg, 200 mg, 250 mg, 300 mg
Tablets (timed-release, 8 to 24 hours): 100 mg, 200 mg, 300 mg, 450 mg
Tablets (timed-release, 12 to 24 hours): 100 mg, 200 mg, 300 mg, 450 mg
Tablets (timed-release, 24 hours): 200 mg, 250 mg, 260 mg, 400 mg, 600 mg

Indications and dosages

➣ Acute bronchospasm in patients not receiving theophylline

Adults (otherwise healthy nonsmokers): Initially, 6 mg/kg P.O., followed in next 12 to 16 hours by 3 mg/kg P.O. q 6 hours for two doses, then a maintenance dosage of 3 mg/kg P.O. q 8 hours

Children ages 9 to 16; young adult smokers: Initially, 6 mg/kg P.O., followed in next 12 to 16 hours by 3 mg/kg P.O. q 4 hours for three doses, then a maintenance dosage of 3 mg/kg P.O. q 6 hours

Children ages 1 to 9: Initially, 6 mg/kg P.O., followed in next 12 to 16 hours by 4 mg/kg P.O. q 4 hours for three doses, then a maintenance dosage of 4 mg/kg P.O. q 6 hours

➣ Acute bronchospasm in patients receiving theophylline

Adults and children: Loading dose based partly on time, amount, and administration route of last dose and on expectation that each 0.5 mg/kg will produce 1 mcg/ml rise in theophylline blood level. In significant respiratory distress, loading dose may be 2.5 mg/kg P.O. or I.V. to increase theophylline level by approximately 5 mcg/ml.

➣ Chronic bronchospasm

Adults and children: Immediate-release forms—16 mg/kg or 400 mg P.O. daily (whichever is lower) in three to four divided doses q 6 to 8 hours.

Timed-release forms—12 mg/kg or 400 mg P.O. daily (whichever is lower) in three to four divided doses q 8 to 12 hours. May increase dosage of either immediate- or timed-release form at 2- to 3-day intervals, to a maximum of 13 mg/kg or 900 mg daily (whichever is lower) in patients older than age 16, 18 mg/kg daily in children ages 12 to 16, 20 mg/kg daily in children ages 9 to 12, or 24 mg/kg daily in children up to age 9.

Dosage adjustment

- Cor pulmonale or heart failure
- Elderly patients
- Young adults

Off-label uses

- Essential tremor
- Apnea and bradycardia in premature infants

Contraindications

- Hypersensitivity to drug or other xanthines (such as coffee, theobromine)
- Active peptic ulcer
- Seizure disorder

Precautions

Use cautiously in:
- alcoholism; heart failure or other cardiac or circulatory impairment; hypertension; renal or hepatic disease; COPD; hypoxemia; hyperthyroidism; diabetes mellitus; glaucoma; peptic ulcer disease
- elderly patients
- children younger than age 1.

Reactions in bold are life-threatening.
Administration

- For I.V. delivery, use infusion solution designed for drug, or mix with dextrose 5% in water. Administer by controlled infusion pump.
- Know that for acute bronchospasm, theophylline preferably is given I.V. as 20 mg/ml of theophylline (or 25 mg/ml of aminophylline).
- Don’t give timed-release form to patient with acute bronchospasm.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>1-2 hr</td>
<td>6 hr</td>
</tr>
<tr>
<td>P.O. (timed)</td>
<td>Delayed</td>
<td>4-8 hr</td>
<td>8-24 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>End of infusion</td>
<td>6-8 hr</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: irritability, dizziness, nervousness, restlessness, headache, insomnia, reflex hyperexcitability, seizures
CV: palpitations, marked hypotension, sinus tachycardia, extrasystole, circulatory failure, ventricular arrhythmias
GI: nausea, vomiting, diarrhea, hematemesis, gastroesophageal reflux
GU: increased diuresis, proteinuria
Metabolic: hyperglycemia, syndrome of inappropriate antidiuretic hormone secretion
Musculoskeletal: muscle twitching
Respiratory: tachypnea, respiratory arrest
Skin: urticaria, rash, alopecia, flushing
Other: fever, hypersensitivity reaction

Interactions

Drug-drug. Allopurinol, calcium channel blockers, cimetidine, corticosteroids, disulfiram, epididine, hormonal contraceptives, influenza virus vaccine, interferon, macrolides, mexiletine, nonselective beta-adrenergic blockers, quinolones, thiabendazole: increased theophylline blood level, greater risk of toxicity Carbamazepine, isoniazid, loop diuretics: increased or decreased theophylline blood level
Halothane: increased risk of arrhythmias
Hydantoins: decreased hydantoin blood level
Lithium: decreased therapeutic effect of lithium
Nondepolarizing muscle relaxants: reversal of neuromuscular blockade
Propofol: antagonism of propofol’s sedative effects
Tetracyclines: increased risk of adverse reactions to theophylline

Drug-diagnostic tests. Glucose: increased level

Drug-food. Any food: altered bioavailability and absorption of some timed-release theophylline forms, causing rapid release and possible toxicity Caffeine- or xanthine-containing foods and beverages: increased theophylline blood level and greater risk of adverse CNS and cardiovascular reactions Diet high in protein and charcoal-broiled beef and low in carbohydrates: increased theophylline elimination, decreased efficacy
High-carbohydrate, low-protein diet: decreased theophylline elimination, increased risk of adverse reactions

Drug-herbs. Caffeine-containing herbs (such as cola nut, guarana, maté): increased theophylline blood level, greater risk of adverse CNS and cardiovascular reactions Ephedra (ma huang): increased stimulant effect St. John’s wort: decreased theophylline blood level and efficacy

Drug-behaviors. Nicotine (in cigarettes, gum, transdermal patches): increased theophylline metabolism, decreased efficacy

Patient monitoring

- Monitor for signs and symptoms of hypersensitivity reaction, including rash and fever.
Assess respiratory status. Monitor pulmonary function tests to gauge drug efficacy and identify adverse effects.

- Monitor cardiovascular and neurologic status carefully.
- Assess glucose level in diabetic patient.

**Patient teaching**

- Advise patient to take oral form with 8 oz of water 1 hour before or 2 hours after meals.
- Tell patient not to crush or chew timed-release form.
- Caution patient not to use different drug brands interchangeably.
- Instruct patient to immediately report worsening dyspnea and other respiratory problems.
- Teach patient to recognize and report adverse neurologic reactions.
- Tell patient that all nicotine forms (including cigarettes, patches, and gum) decrease drug efficacy. Discourage nicotine use.
- Advise patient that a diet high in protein and charcoal-broiled beef and low in carbohydrates makes drug less effective.
- Tell patient that a high-carbohydrate, low-protein diet increases risk of adverse reactions, as do products containing caffeine.
- Caution patient to avoid herbs, especially ephedra and St. John's wort.
- Advise patient not to take over-the-counter drugs without prescriber's approval. Tell him to inform all prescribers he's taking drug, because it interacts with many other drugs.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

---

**thioridazine hydrochloride**

**Pharmacologic class:** Phenothiazine  
**Therapeutic class:** Antipsychotic  
**Pregnancy risk category C**

**FDA BOXED WARNING**

- Drug prolongs QTC interval in dose-related manner and may lead to torsades de pointes–type arrhythmias and sudden death. Reserve it for treatment of schizophrenic patients who don’t respond acceptably to adequate courses of other antipsychotic drugs.

**Action**

Blocks dopamine receptors in CNS. Exerts strong alpha-adrenergic and anticholinergic blocking activity; also depresses cerebral cortex, hypothalamus, and limbic system.

**Availability**

- **Oral solution (concentrated):** 30 mg/ml, 100 mg/ml  
- **Oral suspension:** 10 mg/5 ml, 25 mg/5 ml, 100 mg/5 ml  
- **Tablets:** 10 mg, 15 mg, 25 mg, 50 mg, 100 mg, 150 mg, 200 mg

**Indications and dosages**

- **Schizophrenia**
  - **Adults:** Initially, 50 to 100 mg P.O. t.i.d.; may increase gradually as needed to a maintenance dosage of up to 800 mg/day
  - **Severely disturbed, hospitalized children ages 2 to 12:** Initially, 0.5 mg/kg/day P.O. in divided doses. May increase gradually as needed until optimal effects occur; maximum daily dosage is 3 mg/kg.

Reactions in **bold** are life-threatening.  

---

Clinical alert
Dosage adjustment
- Renal or hepatic impairment
- Elderly patients

Contraindications
- Hypersensitivity to drug, its components, or other phenothiazines
- Severe CNS depression
- Severe hypertension or hypotension
- Bone marrow depression or blood dyscrasias
- Genetic defect that inhibits CYP450-2D6
- Congenital long-QT syndrome
- Prolonged QTc interval
- History of arrhythmias
- Concurrent use of other drugs that prolong the QTc interval (such as fluoxetine, paroxetine) or reduce phenothiazine clearance by other means (such as fluvoxamine, pindolol, propranolol)

Precautions
Use cautiously in:
- cardiovascular or respiratory disease, mitral insufficiency, hepatic or renal impairment, glaucoma, depression, seizure disorder, risk factors for electrolyte imbalance (such as dehydration or diuretic therapy)
- sulfite or tartrazine sensitivity (with some products)
- alcohol intolerance (with concentrate)
- elderly or debilitated patients
- pregnant or breastfeeding patients.

Administration
- Due to risk of potentially life-threatening proarrhythmic effects, know that drug is indicated only for schizophrenic patients who don’t respond adequately to other antipsychotics.
- Keep liquid form away from skin to avoid contact dermatitis.
- Before starting therapy, correct hypokalemia as ordered.
- Discontinue at least 48 hours before myelography, because of seizure risk.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>8-12 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: sedation, extrapyramidal reactions, tardive dyskinesia, neuroleptic malignant syndrome, seizures
CV: orthostatic hypotension, tachycardia, prolonged QTc interval, arrhythmias
EENT: lens opacities, pigmentary retinopathy, dry eyes
GI: constipation, ileus, dry mouth, anorexia
GU: urinary retention, dark urine, galactorrhea, gynecomastia
Hepatic: jaundice
Hematologic: agranulocytosis, leukopenia
Skin: rash, photosensitivity reaction, pigmentation changes
Other: allergic reactions, hyperthermia

Interactions
Drug-drug. Anticholinergic and anticholinergic-like drugs (such as antihistamines, antidepressants, atropine, disopyramide, haloperidol, other phenothiazines): additive anticholinergic effects
Antihypertensives, nitrates: additive hypotension
CNS depressants (such as antihistamines, general anesthetics, opioid analgesics, sedative-hypnotics): additive CNS depression
Diuretics: increased risk of electrolyte imbalances and arrhythmias
Drugs that inhibit CYP450-2D6 (such as fluoxetine, paroxetine), prolong the QTc interval (such as arsenic trioxide,azole antifungals, floxin antibiotics, octreotide), or decrease phenothiazine clearance by other means (such as fluvoxamine, pindolol, propranolol): increased risk of life-threatening arrhythmias
Lithium: disorientation, loss of consciousness, increased risk of extrapyramidal reactions
Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, serum bilirubin: increased levels
Granulocytes, hematocrit, hemoglobin, platelets, white blood cells: decreased levels
Pregnancy tests, urine bilirubin: false-positive results

Drug-herbs. Kava: increased risk of adverse drug reactions

Drug-behaviors. Alcohol use: additive hypotension

Patient monitoring
- Monitor neurologic status closely. Stay alert for signs and symptoms of neuroleptic malignant syndrome.
- Watch for tardive dyskinesia and extrapyramidal symptoms.
- Assess for urinary retention, constipation, and blurred vision.
- Monitor bilirubin level, CBC, liver function tests, and vision exams. Be aware that signs and symptoms of agranulocytosis, leukopenia, or hepatic dysfunction may warrant withdrawal.
- Closely monitor depressed patient for suicidal ideation.

Patient teaching
- Instruct patient to dilute concentrate with water or fruit juice and then take dose right away, with or without food.
- Caution patient not to stop therapy suddenly. Dosage must be tapered.
- Tell patient or caregiver to immediately report signs and symptoms of serious CNS reactions, including high fever, sweating, unstable blood pressure, stupor, muscle rigidity, tongue protrusion, cheek puffing, mouth puckering, chewing movements, and involuntary leg or arm movements.
- Caution patient to keep liquid form away from skin. If it contacts skin, advise him to wash it off thoroughly and immediately.
- Tell patient to report urinary retention, blurred vision, or constipation.
- Advise patient to avoid driving and other hazardous activities.
- Caution patient not to drink alcohol. Tell him that concentrate form contains alcohol.
- Teach patient effective ways to counteract photosensitivity.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

FDA BOXED WARNING
- Drug shouldn’t be used alone or with other agents to treat obesity or weight loss. In euthyroid patients, doses within range of daily hormonal requirements are ineffective for weight loss. Larger doses may cause serious or life-threatening toxicity, particularly when given with sympathomimetic amines (such as those used for anorectic effects).

Action
Regulates cell growth and differentiation and increases metabolic rate of body tissues; effects mediated at cellular level

Availability
Tablets: 15 mg, 30 mg, 60 mg, 90 mg, 120 mg, 180 mg, 240 mg, 300 mg

Reactions in bold are life-threatening.
Indications and dosages

➣ Mild hypothyroidism
Adults: Initially, 60 mg/day P.O.; may increase by 60 mg q 30 days to desired response. Usual maintenance dosage is 60 to 180 mg/day.

➣ Severe hypothyroidism
Adults: Initially, 15 mg/day P.O. daily; may increase to 30 mg/day after 2 weeks and then to 60 mg/day 2 weeks later. Assess after 1 month, and again 1 month later at 60 mg-dose. If necessary, dosage may then increase to 120 mg/day P.O. for 2 months, with assessment repeated. Subsequent assessments and dosage increases may occur up to a maximum of 180 mg/day.

➣ Congenital or severe hypothyroidism
Children: Initially, 15 mg P.O. daily; may increase to 30 mg/day after 2 weeks, with subsequent increases at 2-week intervals. Maintenance dosage may be higher in growing children than in hypothyroid adults.

Dosage adjustment
- Cardiovascular disease
- Elderly patients

Contraindications
- Hypersensitivity to drug or its components
- Adrenal insufficiency
- Thyrotoxicosis

Precautions
Use cautiously in:
- tartrazine sensitivity (some products)
- cardiovascular disease
- elderly patients
- breastfeeding patients.

Administration
- Give before breakfast each day.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>12-48 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: insomnia, tremors, headache
CV: palpitations, angina pectoris, hypertension, tachycardia, arrhythmias, cardiac arrest
GI: nausea, vomiting, diarrhea
GU: menstrual irregularities
Metabolic: heat intolerance, thyroid storm
Musculoskeletal: accelerated bone maturation (in children)
Skin: sweating
Other: weight loss, appetite changes, fever

Interactions
Drug-drug. Anticoagulants, catecholamines, sympathomimetics: increased effects of these drugs
Bile acid sequestrants: decreased thyroid hormone absorption
Digoxin, insulin, oral hypoglycemics: decreased effects of these drugs
Estrogen: decreased thyroid hormone effects
Oral anticoagulants: increased risk of bleeding

Drug-diagnostic tests. Aspartate aminotransferase, creatine kinase, glucose, lactate dehydrogenase, protein-bound iodine: increased levels
Thyroid function tests: decreased values

Drug-herbs. Bugleweed, soy: increased adverse drug reactions

Patient monitoring
- Monitor for chest pain. If it occurs, withhold drug and contact prescriber.
- Assess vital signs and temperature frequently.
- Monitor thyroid function tests closely. Immediately report evidence of thyroid storm.
- In diabetic patient, monitor blood glucose level closely.
- In children, monitor sleeping pulse rate and morning basal temperature.
- In female on long-term therapy, monitor bone density tests.
Patient teaching
- Tell patient to take each morning before breakfast.
  - Caution patient not to stop therapy abruptly. Dosage must be tapered.
  - Advise patient to immediately report chest pain or signs and symptoms of drug toxicity (fever, chest pain, rapid pulse, skipped heartbeats, heat intolerance, excessive sweating, nervousness, emotional instability).
- Instruct patient to tell all prescribers he's taking drug. Caution him not to use over-the-counter preparations without consulting prescriber.
- Tell diabetic patient that drug may alter blood glucose level. Encourage frequent glucose self-monitoring.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

tiagabine hydrochloride
Gabitril Filmtabs

**Pharmacologic class:** Nipecotic acid derivative  
**Therapeutic class:** Anticonvulsant  
**Pregnancy risk category C**

**Action**
Unknown. Thought to raise seizure threshold by enhancing activity of gamma-aminobutyric acid (a major inhibitory neurotransmitter in CNS).

**Availability**
Tablets: 2 mg, 4 mg, 12 mg, 16 mg, 20 mg

**Indications and dosages**
- Adjunctive treatment of partial seizures

**Adults older than age 18:** Initially, 4 mg P.O. once daily for 1 week; may increase as needed by 4 to 8 mg/day at weekly intervals, up to 56 mg/day in two to four divided doses.

**Adolescents ages 12 to 18:** Initially, 4 mg P.O. once daily. May increase total daily dosage by 4 mg at start of week 2; thereafter, may increase by 4 to 8 mg q week until clinical response occurs or patient is receiving up to 32 mg/day. Give total daily dosage in two to four divided doses.

**Dosage adjustment**
- Hepatic impairment

**Off-label uses**
- Anxiety

**Contraindications**
- Hypersensitivity to drug or its components

**Precautions**
Use cautiously in:
- hepatic impairment
- pregnant or breastfeeding patients
- children younger than age 12 (safety not established).

**Administration**
- Don’t stop drug suddenly. Dosage must be tapered.
- Be aware that concomitant anticonvulsant therapy need not be modified unless indicated.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>45 min</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- CNS: dizziness, insomnia, drowsiness, nervousness, asthenia, confusion, poor concentration, impaired memory, depression, emotional lability, hostility, agitation, ataxia, abnormal gait, tremors, paresthesia, speech disorder, language problems

Reactions in **bold** are life-threatening.

Clinical alert
CV: vasodilation  
EENT: nystagmus, epistaxis, pharyngitis  
GI: nausea, vomiting, diarrhea, abdominal pain, mouth ulcers  
Musculoskeletal: myasthenia  
Respiratory: increased cough  
Skin: rash, pruritus  
Other: increased appetite, weight changes, pain, allergic reaction

Interactions  
Drug-drug. Carbamazepine, phenobarbital, phenytoin, primidone: increased tiagabine clearance, decreased blood level

Patient monitoring  
Watch for signs or symptoms of depression and suicidal ideation.  
Assess vital signs and cardiovascular status.  
Monitor closely for severe generalized weakness. If present, consult prescriber regarding possible dosage reduction.

Patient teaching  
Tell patient to take on regular schedule with food.  
Caution patient not to stop therapy suddenly. Dosage must be tapered.  
Instruct patient to report signs or symptoms of depression.  
Advising patient to report neurologic reactions. Tell him to contact prescriber immediately if severe overall weakness or severe depression occurs.  
Advise female patient to tell prescriber if she suspects she is pregnant.  
As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

Ticarcillin disodium and clavulanate potassium

Pharmacologic class: Penicillin (extended-spectrum)  
Therapeutic class: Anti-infective  
Pregnancy risk category B

Action  
Ticarcillin disodium inhibits bacterial cell-wall synthesis during replication; clavulanic acid extends ticarcillin's antibiotic spectrum by inactivating beta-lactamase enzymes (which otherwise would degrade ticarcillin).

Availability  
Injection: 3 g ticarcillin and 100 mg clavulanic acid in 3.1-g vials

Indications and dosages  
Systemic and urinary tract infections caused by susceptible organisms  
Adults weighing more than 60 kg (132 lb): 3.1 g (30:1 fixed-ratio combination of 3 g ticarcillin and 100 mg clavulanic acid) by I.V. infusion q 4 to 6 hours  
Adults weighing less than 60 kg (132 lb): 200 to 300 mg/kg/day (based on ticarcillin content) by I.V. infusion in divided doses q 4 to 6 hours  
Gynecologic infections caused by susceptible organisms  
Adults weighing more than 60 kg (132 lb): For moderate infections, 200 mg/kg/day (based on ticarcillin content) by I.V. infusion in divided doses q 6 hours. For severe infections, 300 mg/kg/day (based on ticarcillin content) by I.V. infusion in divided doses q 4 hours.  
Adults weighing less than 60 kg (132 lb): 200 to 300 mg/kg/day by I.V. infusion q 4 to 6 hours
Mild to moderate or severe infections in children caused by susceptible organisms

**Children weighing more than 60 kg (132 lb):** For mild to moderate infections, 3.1 g (30:1 fixed-ratio combination of 3 g ticarcillin and 100 mg clavulanic acid) by I.V. infusion q 6 hours. For severe infections, 3.1 g (30:1 fixed-ratio combination of 3 g ticarcillin and 100 mg clavulanic acid) by I.V. infusion q 4 hours.

**Children ages 3 months to 16 years weighing less than 60 kg (132 lb):** For mild to moderate infections, 200 mg/kg/day (based on ticarcillin content) by I.V. infusion in divided doses q 6 hours. For severe infections, 300 mg/kg/day (based on ticarcillin content) by I.V. infusion in divided doses q 4 hours.

**Dosage adjustment**
- Renal impairment

**Contraindications**
- Hypersensitivity to drug or other penicillins

**Precautions**
Use cautiously in:
- Cystic fibrosis, renal or hepatic disease
- Pregnant or breastfeeding patients

**Administration**
- Ask patient about penicillin allergy before giving.
- Add 13 ml of sterile water or normal saline solution to vial; shake gently. Dilute further to 10 to 100 mg/ml of ticarcillin; infuse I.V. over 30 minutes.
- Give at least 1 hour before I.V. aminoglycosides (such as amikacin or gentamicin).

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>Immediate</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** headache, giddiness, dizziness, lethargy, fatigue, hyperreflexia, neuromuscular excitability, asterixis, hallucinations, stupor, **seizures**

**GI:** nausea, vomiting, diarrhea, flatulence, **pseudomembranous colitis**

**Hematologic:** eosinophilia, transient **neutropenia and leukopenia** (with high doses)

**Skin:** urticaria, rash

**Other:** unpleasant taste; fever; overgrowth of nonsusceptible organisms; pain, vein irritation, erythema, phlebitis, and **thrombophlebitis** at I.V. site; hypersensitivity reactions including **anaphylaxis**

**Interactions**

**Drug-drug.** Aminoglycosides: physical incompatibility, causing aminoglycoside inactivation when mixed in same I.V. solution

Aminoglycosides, tetracyclines: additive activity against some bacteria

Lithium: altered lithium elimination

Probenecid: increased ticarcillin blood level

**Drug-diagnostic tests.** Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, eosinophils, lactate dehydrogenase, sodium: increased levels

Bleeding time: prolonged

Granulocytes, hemoglobin, platelets, white blood cells: decreased levels

Liver function tests: transient increases

Urine glucose, urine protein: false-positive results

**Patient monitoring**
- Monitor liver function tests and CBC with white cell differential.
- Watch closely for signs and symptoms of superinfection and severe allergic reactions.
- Assess neurologic status, and stay alert for seizures.

**Patient teaching**

- Advise patient to report skin reactions and severe diarrhea right away.
Tell patient drug may increase risk of other infections. Advise him to promptly report signs and symptoms of new infection.

- Instruct patient to limit sodium intake (drug contains sodium).
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

### ticlopidine hydrochloride

*Pharmacologic class:* Platelet aggregation inhibitor  
*Therapeutic class:* Antiplatelet agent  
*Pregnancy risk category B*

#### FDA BOXED WARNING

- Drug may cause life-threatening hematologic adverse reactions, including neutropenia, agranulocytosis, thrombotic thrombocytopenic purpura (TTP), and aplastic anemia. Such reactions may arise within several days of starting therapy. TTP incidence peaks after about 3 to 4 weeks; neutropenia, at approximately 4 to 6 weeks; and aplastic anemia, after about 4 to 8 weeks. Thereafter, incidence of hematologic reactions declines.

- During first 3 months of therapy, monitor patient hematologically and clinically for evidence of neutropenia or TTP. If it occurs, discontinue drug immediately.

#### Action

Inhibits release of first and second phases of adenosine diphosphate–induced effects on platelet aggregation, preventing thrombus formation.

#### Availability

*Tablets:* 250 mg

#### Indications and dosages

To reduce risk of thrombotic cerebrovascular accident when aspirin is ineffective or intolerable

- **Adults:** 250 mg P.O. b.i.d. with meals
- **Adjunctive therapy to prevent sub-acute stent thrombosis in patients with implanted coronary stents**
  - **Adults:** 250 mg P.O. b.i.d. with meals, given with antiplatelet doses of aspirin for up to 30 days after successful stent implantation

#### Dosage adjustment

- Renal impairment

#### Off-label uses

- Chronic arterial occlusion  
- Coronary artery bypass graft  
- Open-heart surgery  
- Intermittent claudication  
- Primary glomerulonephritis  
- Sickle cell disease  
- Subarachnoid hemorrhage  
- Uremic patients with atrioventricular shunts or fistulas

#### Contraindications

- Hypersensitivity to drug  
- Hematopoietic disorders  
- Hemostatic disorders or active bleeding  
- Severe hepatic disease  
- History of thrombotic thrombocytopenia purpura (TTP) or aplastic anemia

#### Precautions

Use cautiously in:

- renal or hepatic impairment  
- high risk for bleeding
• elderly patients
• pregnant or breastfeeding patients
• children younger than age 18 (safety not established).

Administration
• Give with meals.
• Don’t give within 2 hours of antacids.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Within 8-11 days</td>
<td>2 wk</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4 days</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, headache, weakness, intracerebral bleeding
EENT: conjunctival hemorrhage, tinnitus, epistaxis
GI: nausea, vomiting, diarrhea, full sensation, GI pain, dyspepsia, flatulence, anorexia, GI bleeding
GU: hematuria
Hematologic: ecchymosis, eosinophilia, purpura, TTP, thrombotic thrombocytopenia purpura, agranulocytosis, bone marrow depression
Skin: rashes, bruising, pruritus, urticaria
Other: pain, posttraumatic or perioperative bleeding

Interactions
Drug-drug. Antacids: decreased ticlopidine blood level  
Aspirin: potentiation of aspirin’s effect on platelets  
Cimetidine (long-term use): reduced ticlopidine clearance  
Digoxin: slightly decreased digoxin blood level  
Phenytoin: increased phenytoin blood level, greater risk of toxicity  
Theophylline: decreased theophylline clearance, greater risk of toxicity  
Vitamin A: altered anticoagulant effects
Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase: increased levels

Reactions in **bold** are life-threatening.

Clinical alert

Patient monitoring
- Closely monitor coagulation studies and CBC with white cell differential. Watch for evidence of bleeding tendency and blood dyscrasias.
- Assess neurologic status carefully. Stay alert for signs and symptoms of intracranial bleeding.
- Monitor liver function tests.

Patient teaching
- Tell patient to take with meals, but not within 2 hours of antacids.
- Instruct patient to immediately report easy bruising or bleeding.
- Advise patient to stop taking drug 10 to 14 days before elective surgery.
- Tell patient to inform all prescribers that he is taking drug.
- Inform patient that aspirin-containing products and many herbs increase risk of bleeding. Urge him to consult prescriber before taking over-the-counter drugs or herbs.
- Caution patient to avoid activities that can cause injury. Tell him to use soft toothbrush and electric razor to avoid gum and skin injury.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.
**tigecycline**
Tygacil

**Pharmacologic class:** Glycylcycline antibiotic  
**Therapeutic class:** Anti-infective  
**Pregnancy risk category D**

**Action**
Inhibits protein translation in bacteria by binding to 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into ribosomal A site, which in turn prevents incorporation of amino acid residues into elongating peptide chains

**Availability**
Powder for injection (lyophilized): 50 mg/5 ml in single-dose vial

**Indications and dosages**
>- Skin and skin-structure infections caused by susceptible strains of *Escherichia coli*, *Enterococcus faecalis* (vancomycin-susceptible isolates only), *Staphylococcus aureus* (methicillin-susceptible and -resistant isolates), *Streptococcus agalactiae*, *Streptococcus anginosus* group, *Streptococcus pyogenes*, and *Bacteroides fragilis*; complicated intra-abdominal infections caused by *Citrobacter freundii*, *E. coli*, *Enterobacter cloacae*, *E. faecalis* (vancomycin-susceptible isolates only), *Klebsiella oxytoca*, *Klebsiella pneumoniae*, *S. aureus* (methicillin-susceptible isolates only), *S. anginosus* group, *S. pyogenes*, *B. fragilis*, *Bacteroides thetaiotaomicron*, *Bacteroides uniformis*, *Bacteroides vulgatus*, *Clostridium perfringens*, and *Peptostreptococcus micros*

**Adults age 18 and older:** 100 mg I.V. initially, followed by 50 mg I.V. every 12 hours for 5 to 14 days, depending on infection site and severity and patient’s clinical and bacteriologic process

**Dosage adjustment**
- Severe hepatic impairment

**Contraindications**
- Hypersensitivity to drug or its components

**Precautions**
Use cautiously in:
- mild to moderate hepatic impairment, complicated intra-abdominal infections secondary to perforation
- pregnant and breastfeeding patients
- children younger than age 18.

**Administration**
- Reconstitute with 5.3 ml of normal saline solution injection or 5% dextrose injection to yield a concentration of 10 mg/ml (50 mg).
- Swirl vial gently until drug dissolves. Immediately withdraw 5 ml of reconstituted solution from vial and add to 100-ml I.V. bag for infusion. Maximum concentration in I.V. bag should be 1 mg/ml.
- Discard reconstituted solution that isn't yellow or orange.
- Administer through dedicated I.V. line or Y-site. If same I.V. line is used for sequential infusion of several drugs, flush before and after infusion, using either normal saline solution injection or 5% dextrose injection. Use infusion solution compatible with tigecycline and other drugs given through same line.
- Administer over 30 to 60 minutes.
- Don’t give amphotericin B, chlorpromazine, methylprednisolone, or voriconazole simultaneously through same Y-site.

**Route** | **Onset** | **Peak** | **Duration**
--- | --- | --- | ---
I.V. | Unknown | Unknown | Unknown

- Canada  
- UK  
- Hazardous drug  
- High alert drug
Adverse reactions
CNS: headache, dizziness, insomnia, asthenia
CV: hypertension, hypotension, phlebitis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, increased GI enzymes, pseudomembranous colitis
Hematologic: anemia, leukocytosis, thrombocytopenia
Musculoskeletal: back pain
Respiratory: increased cough, dyspnea
Skin: pruritus, rash, sweating, photosensitivity
Other: abscess, fever, infection, pain, peripheral edema, abnormal healing, superinfection, allergic reaction

Interactions
Drug-drug. Hormonal contraceptives: reduced contraceptive efficacy
Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, bilirubin, blood glucose, blood urea nitrogen: increased
Blood protein, potassium, WBCs: decreased

Patient monitoring
- Monitor prothrombin time or other suitable anticoagulation tests if patient is receiving warfarin concomitantly.
- Closely monitor patients with severe hepatic impairment.

Patient teaching
- Instruct patient to report rash and other signs or symptoms of allergic reaction.
- Tell patient to complete full course of therapy, even if he feels better.
- Advise patient taking oral hormonal contraceptives to use alternative birth control method during therapy.
- Caution female with childbearing potential to avoid pregnancy because drug may harm fetus.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

timolol maleate
Apo-Timol®, Betim®, Betimol, Dom-Timolol®, Gen-Timolol®, Istalol, Novo-Timol®, NU-Timolol®, PMS-Timolol®, Rhoxal-Timolol®, Sandoz Timolol®, Timoptic, Timoptic-XE

Pharmacologic class: Beta-adrenergic blocker (nonselective)
Therapeutic class: Antihypertensive, vascular headache suppressant, antiglaucoma agent
Pregnancy risk category C

FDA BOXED WARNING
- Exacerbations of angina pectoris and myocardial infarction (MI) may follow abrupt withdrawal of some beta blockers. When discontinuing long-term therapy, particularly in patients with ischemic heart disease, reduce dosage gradually over 1 to 2 weeks and monitor patient carefully. If angina worsens markedly or acute coronary insufficiency develops, reinstate drug promptly (at least temporarily) and take other appropriate measures to manage unstable angina. Caution patient not to interrupt or discontinue therapy without prescriber’s advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue drug abruptly even in patients treated only for hypertension.

Reactions in bold are life-threatening.
**Action**
Blocks stimulation of beta₁-adrenergic (myocardial) and beta₂-adrenergic (pulmonary, vascular, uterine) receptor sites. May reduce aqueous production, which decreases intraocular pressure (IOP).

**Availability**
*Ophthalmic gel*: 0.25%, 0.5%
*Ophthalmic solution*: 0.25%, 0.5%
*Tablets*: 5 mg, 10 mg, 20 mg

**Indications and dosages**
- **Hypertension**
  - **Adults**: Initially, 10 mg P.O. b.i.d., given alone or with a diuretic; may increase at 7-day intervals as needed. Usual maintenance dosage is 10 to 20 mg daily in two divided doses, up to 60 mg/day.

- **Acute MI**
  - **Adults**: 10 mg P.O. b.i.d. starting 1 to 4 weeks after MI

- **To prevent vascular headaches**
  - **Adults**: Initially, 10 mg P.O. b.i.d. For maintenance, 20 mg may be given as a single daily dose. Total daily dosage may be increased to a maximum of 30 mg in divided doses or decreased to 10 mg/day, depending on response and tolerance. Withdraw drug if satisfactory response doesn’t occur after 6 to 8 weeks at maximum dosage.

- **Elevated IOP in patients with ocular hypertension or open-angle glaucoma**
  - **Adults**: One drop of 0.25% to 0.5% ophthalmic solution in affected eye b.i.d., or 0.25% to 0.5% ophthalmic gel in affected eye once daily

**Off-label uses**
- Angina pectoris
- Supraventricular arrhythmias

**Contraindications**
- Hypersensitivity to drug or other beta-adrenergic blockers
- Uncompensated heart failure
- Bradycardia or heart block
- Cardiogenic shock
- Bronchial asthma (current or previous), severe chronic obstructive pulmonary disease

**Precautions**
Use cautiously in:
- renal or hepatic impairment, diabetes mellitus, thyrotoxicosis
- elderly patients
- pregnant or breastfeeding patients
- children (safety not established).

**Administration**
- Measure apical pulse before giving. If patient has significant bradycardia or tachycardia, withhold dose and consult prescriber.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1-2 hr</td>
<td>12-24 hr</td>
</tr>
<tr>
<td>Ophthalmic</td>
<td>≤ 30 min</td>
<td>1-2 hr</td>
<td>≤ 24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- **CNS**: fatigue, dizziness, asthenia, insomnia, headache, vertigo, nervousness, depression, paresthesia, hallucinations, memory loss, disorientation, emotional lability, clouded sensorium
- **CV**: hypotension, angina pectoris exacerbation, bradycardia, atrioventricular or sinoatrial block, arrhythmias, heart failure
- **EENT**: visual disturbances, dry eyes, tinnitus, nasal congestion
- **GI**: nausea, constipation, diarrhea, abdominal discomfort
- **GU**: erectile dysfunction, decreased libido
- **Metabolic**: hyperuricemia, hypoglycemia, hyperkalemia
- **Musculoskeletal**: joint pain
- **Respiratory**: dyspnea, crackles, bronchospasm, pulmonary edema
- **Skin**: itching, rash

---

*Canada*  *UK*  *Hazardous drug*  *High alert drug*
Interactions

Drug-drug. Antihypertensives, nitrates: additive hypotension
Insulin, oral hypoglycemics: altered efficacy of these drugs
Nonsteroidal anti-inflammatory drugs: decreased antihypertensive effect of timolol
Quinidine: inhibited timolol metabolism, leading to increased beta-adrenergic blockade and bradycardia
Reserpine: increased risk of hypotension and bradycardia
Theophylline: reduced effects of both drugs

Drug-diagnostic tests. Antinuclear antibodies: increased titer
Blood urea nitrogen, liver function tests, potassium, uric acid: increased values
Glucose, high-density lipoproteins, hematocrit, hemoglobin: decreased values

Drug-herbs. Ephedra (ma huang), St. John’s wort, yohimbine: decreased timolol efficacy

Patient monitoring
- Closely monitor vital signs, blood pressure, cardiovascular status, and ECG.
- Assess respiratory status. Check breath sounds for wheezing and bronchospasm.
- Monitor blood glucose level in patient with diabetes mellitus.

Patient teaching
- Teach patient how to measure pulse before each dose. Instruct him to contact prescriber if pulse is outside established safe range.
- Caution patient not to stop taking drug abruptly. Dosage must be tapered.
- Teach patient how to administer eye drops. Instruct him to use drops only as prescribed, because they are absorbed systemically. Caution him not to touch dropper tip to eye or any other surface.

FDA BOXED WARNING
- Prolonged use of metronidazole (a structurally related drug with similar biologic effects) has caused cancer in mice and rats. Reserve tinidazole for conditions listed under “Indications and dosages.”

Action
Free nitro radical (generated from tinidazole reduction by Trichomonas cell extracts) may explain activity against Trichomonas species; activity against Giardia and Entamoeba species is unknown.

Availability
Tablets: 250 mg, 500 mg

Reactions in bold are life-threatening.
**Indications and dosages**

- **Trichomoniasis caused by *Trichomonas vaginalis***
  - **Adults**: Single dose of 2 g P.O. with food, given to both sexual partners simultaneously
  - **Bacterial vaginosis in nonpregnant females**
    - **Adults**: 2 g P.O. once daily with food for 2 days, or 1 g P.O. once daily with food for 5 days
  - **Giardiasis caused by *Giardia duodenalis* (Giardia lamblia)**
    - **Adults**: Single dose of 2 g P.O. with food
    - **Children older than age 3**: Single dose of 50 mg/kg (up to 2 g) with food
  - **Amebiasis caused by *Entamoeba histolytica***
    - **Adults**: 2 g P.O. daily with food for 3 days
    - **Children older than age 3**: 50 mg/kg (up to 2 g) P.O. daily with food for 3 days
  - **Amebic liver abscess caused by *E. histolytica***
    - **Adults**: 2 g P.O. daily with food for 3 to 5 days
    - **Children older than age 3**: 50 mg/kg (up to 2 g) P.O. daily with food for 3 to 5 days

**Dosage adjustment**
- Hemodialysis patients

**Contraindications**
- Hypersensitivity to drug, its components, or other nitroimidazole derivatives
- First trimester of pregnancy

**Precautions**
Use cautiously in:
- CNS disease, hepatic dysfunction
- history of blood dyscrasias
- elderly patients
- pregnant or breastfeeding patients
- children (except to treat giardiasis and amebiasis in children older than age 3).

**Administration**
- Give with food to minimize GI discomfort.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1.6 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- **CNS**: weakness, fatigue, malaise, dizziness, vertigo, ataxia, insomnia, drowsiness, giddiness, headache, transient peripheral neuropathy, seizures
- **CV**: palpitations
- **GI**: nausea, vomiting, diarrhea, constipation, dyspepsia, gastric discomfort, tongue discoloration, stomatitis, anorexia
- **Hematologic**: transient neutropenia and leukopenia
- **Musculoskeletal**: arthralgia, myalgia, arthritis
- **Other**: altered taste, overgrowth of susceptible organisms, hypersensitivity reactions including angioedema

**Interactions**
**Drug-drug.** *Cyclosporine, lithium, tacrolimus*: possible increase in blood levels of these drugs
- *Cholestyramine*: decreased oral bioavailability of tinidazole
- *CYP450 inducers (such as phenobarbital, rifampin)*: increased tinidazole elimination and decreased blood level
- *CYP450 inhibitors (such as cimetidine, ketoconazole)*: increased tinidazole blood level
- *Fluorouracil*: decreased fluorouracil clearance
- *Fosphenytoin, phenytoin*: prolonged half-life and reduced clearance of these drugs
- *Oxytetracycline*: antagonism of therapeutic effects of tinidazole
- *Warfarin, other oral coumarin anticoagulants*: increased effects of these drugs

**Drug-diagnostic tests.** *Alanine aminotransferase, aspartate aminotransferase, hexokinase glucose, lactate*
dehydrogenase, triglycerides: interference with test results

Drug-behaviors. Alcohol use: disulfiram-like reaction during tinidazole therapy and for 3 days after

Patient monitoring

- Closely monitor patient for neurologic abnormalities, such as seizures and peripheral neuropathy. If these occur, withdraw drug immediately.
- Monitor blood chemistry tests, especially liver function tests.

Patient teaching

- Advise patient to take drug with food.
- For child or other patient unable to swallow tablets, inform parent or caregiver that drug can be crushed in artificial cherry syrup and given with food.
- Caution patient or caregiver to stop therapy and call prescriber immediately if seizures or numbness or tingling in extremities occurs.
- Instruct patient to avoid alcohol use during therapy.
- Advise female patient to avoid pregnancy during therapy.
- Counsel female patient to avoid breastfeeding during therapy and for 3 days after last dose.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

FDA BOXED WARNING

- During epidural or spinal anesthesia or puncture, patients receiving drug or scheduled to receive it for thromboprophylaxis are at risk for epidural or spinal hematoma, which can lead to long-term or permanent paralysis. Risk increases with use of indwelling epidural catheter for analgesia administration and with concurrent use of drugs affecting hemostasis (such as nonsteroidal anti-inflammatory drugs [NSAIDs], platelet inhibitors, and other anticoagulants). Risk also rises with traumatic or repeated epidural or spinal puncture. Before neuraxial intervention, physician should weigh drug’s potential benefit against risk.
- Monitor patient frequently for signs and symptoms of neurologic impairment. If these occur, provide urgent interventions.

Action

Enhances inhibition of factor Xa and thrombi by binding to and accelerating activity of antithrombin III; has only slight effect on thrombin and clotting time

Availability

Injection: 20,000 anti-Xa international units/ml in 2-ml vials

Indications and dosages

- Deep-vein thrombosis

Adults: 175 anti-Xa international units/kg subcutaneously daily for at least 6 days and until patient is adequately anticoagulated with warfarin for 2 consecutive days

Off-label uses

- Pulmonary embolism

Contraindications

- Hypersensitivity to drug, heparin, sulfites, benzyl alcohol, or pork products
• Active major bleeding
• History of heparin-induced thrombocytopenia

Precautions
Use cautiously in:
• renal impairment; bacterial endocarditis; uncontrolled hypertension; congenital or acquired bleeding disorders; hepatic failure and GI ulcers; recent brain, spinal, or ophthalmic surgery; diabetic retinopathy
• pregnant or breastfeeding patients
• elderly patients.

Administration
➤ Be aware that tinzaparin sodium is a high-alert drug.
• Give by deep subcutaneous injection into abdominal wall while patient is sitting or lying down.
• Don’t rub injection site after removing needle.
• Observe injection site closely for hematoma.
• Rotate injection sites among four quadrants of abdominal wall.
➤ Don’t give I.V. or I.M.
• Know that warfarin therapy usually starts within 1 to 3 days after tinzaparin therapy begins.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcut.</td>
<td>2-3 hr</td>
<td>4-5 hr</td>
<td>18-24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, insomnia, confusion, headache, cerebral or intracranial bleeding
CV: hypotension, hypertension, angina pectoris, chest pain, tachycardia, dependent edema, thromboembolism, arrhythmias, myocardial infarction (MI)
EENT: ocular hemorrhage, epistaxis
GI: nausea, vomiting, constipation, flatulence, dyspepsia, melena, GI hemorrhage, retroperitoneal or intra-abdominal bleeding
GU: urinary tract infection, hematuria, urinary retention, dysuria, vaginal hemorrhage
Hematologic: anemia, thrombocytopenia, granulocytopenia, agranulocytosis, pancytopenia, hemorrhage
Musculoskeletal: back pain, intra-articular hemorrhage
Respiratory: dyspnea, pneumonia, respiratory disorder, pulmonary embolism
Skin: pruritus, rash, bullous eruption, cellulitis, purpura, skin necrosis
Other: injection site hematoma and reactions, pain, fever, impaired healing, infection, hypersensitivity reaction, congenital anomaly, fetal distress, fetal death

Interactions
Drug-drug. Oral anticoagulants, platelet inhibitors (such as dextran, dipyridamole, NSAIDs, salicylate, sulfinpyrazone), thrombolytics: increased risk of bleeding
Vitamin A: increased anticoagulant effect

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase: reversible elevations
Granulocytes, hemoglobin, platelets, red blood cells, white blood cells: decreased values
Drug-herbs. Alfalfa, anise, arnica, astragalus, bilberry, black currant seed oil, bladderwrack, bogbean, boldo (with fenugreek), borage oil, buchu, capsacin, cat’s claw, celery, chaparral, cinchona bark, clove oil, dandelion, dong quai, evening primrose oil, fenugreek, feverfew, garlic, ginger, ginkgo, guggul, papaya extract, red clover, rhubarb, safflower oil, skullcap, tan-shen: increased anticoagulant effect

Patient monitoring
• Monitor vital signs and ECG closely.
➤ Assess neurologic status. Stay alert for indications of intracranial or intracerebral bleeding.
• Evaluate closely for signs and symptoms of bleeding in all body systems.
Monitor respiratory status carefully to detect pneumonia, pulmonary embolism, and other serious adverse reactions.
- Monitor cardiovascular status closely. Watch for signs and symptoms of thrombophlebitis and edema.
- Monitor CBC, platelet count, and coagulation studies. Assess stools for occult blood.

**Patient teaching**
- Tell patient to immediately report unusual bleeding or bruising. Inform him that drug can cause serious adverse reactions, especially bleeding. Instruct him to report new symptoms right away.
- Advise patient that aspirin products, NSAIDs, and many herbs increase the bleeding risk. Urge him to consult prescriber before using these products.
- Instruct patient to avoid activities that can cause injury. Tell him to use soft toothbrush and electric razor to avoid gum and skin injury.
- Tell patient he’ll undergo regular blood tests during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

**tiotropium**
Spriva®, Spiriva HandiHaler

**Pharmacologic class:** Antimuscarinic, anticholinergic

**Therapeutic class:** Bronchodilator

**Pregnancy risk category C**

**Action**
Inhibits smooth-muscle muscarinic M3-receptors, leading to bronchodilation.

**Availability**
*Capsules for inhalation:* 18 mcg

**Indications and dosages**
- Long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease

**Adults:** Contents of one capsule inhaled orally once daily using supplied HandiHaler

**Contraindications**
- Hypersensitivity to atropine or its derivatives (including ipratropium) or drug components

**Precautions**
Use cautiously in:
- angle-closure glaucoma, prostatic hyperplasia, bladder neck obstruction, moderate to severe renal impairment
- concurrent use of other anticholinergics
- pregnant or breastfeeding patients
- children (safety and efficacy not established).

**Administration**
- Give contents of one capsule once daily using HandiHaler.
- Don’t let patient swallow capsule.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhalation (P.O.)</td>
<td>30 min</td>
<td>3 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- CNS: depression, paresthesia
- CV: angina, increased heart rate
- EENT: eye pain or discomfort, blurred vision, visual halos, cataract, colored images in association with red eyes (with inadvertent eye exposure), epistaxis, rhinitis, sinusitis, laryngitis, pharyngitis, dysphonia

Reactions in bold are life-threatening.
GI: vomiting, constipation, dyspepsia, abdominal pain, gastroesophageal reflux, stomatitis, dry mouth
GU: urinary tract infection, urinary retention, urinary difficulty
Musculoskeletal: myalgia, skeletal pain, arthritis, leg pain
Respiratory: upper respiratory tract infection, coughing, paradoxical bronchospasm
Skin: rash
Other: nonspecific chest pain, edema, infection, candidiasis, flulike symptoms, herpes zoster, allergic reaction

Interactions
Drug-diagnostic tests. Blood glucose, cholesterol: increased

Patient monitoring
- Closely monitor patient for allergic reaction and paradoxical bronchospasm; if these occur, discontinue drug and consider alternative therapy.
- Closely monitor patients with moderate to severe renal impairment.

Patient teaching
- Give patient information portion of package insert on HandiHaler use.
- Inform patient that drug is once-daily maintenance medicine that opens narrowed airways and helps keep them open for 24 hours. Stress that it’s not for immediate (rescue) relief of breathing problems.
- Tell patient that capsules are intended for oral inhalation only and should be used only with HandiHaler device. Emphasize that HandiHaler must not be used to take any other drug.
- Caution patient not to let powder get into eyes.
- Teach patient to take prescribed dose in these steps: Immediately before use, open one sealed blister foil and HandiHaler device, insert capsule, press HandiHaler button once to pierce capsule, and exhale completely before placing mouthpiece into mouth with head upright. Then breathe in slowly and deeply at a rate fast enough to hear capsule vibrate, until lungs are full. Holding breath as long as comfortable, take HandiHaler device out of mouth. Then place device back in mouth and inhale again to get full dose.
- Tell patient not to exhale into HandiHaler mouthpiece at any time.
- Caution patient not to swallow capsules.
- Tell patient not to store capsules in HandiHaler device.
- Instruct patient to clean device as shown in patient information sheet.
- Instruct patient to discard any capsules inadvertently exposed to air while preparing dose.
- Tell patient to contact prescriber immediately if eye pain or discomfort, blurred vision, visual halos, or colored images occur.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

tipranavir
Aptivus
Pharmacologic class: Nonpeptidic protease inhibitor of human immunodeficiency virus type 1 (HIV-1)
Therapeutic class: Antiretroviral
Pregnancy risk category C

FDA BOXED WARNING
- When given concurrently with ritonavir 200 mg, drug has been linked to reports of fatal and nonfatal intracranial hemorrhage and clinical hepatitis and hepatic decompensation. Use extra vigilance in patients with chronic hepatitis B or hepatitis C co-infection.
**Action**
Inhibits virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, preventing formation of mature virions

**Availability**
*Capsules: 250 mg*

**Indications and dosages**
Combination antiretroviral treatment of HIV-1 in patients with evidence of viral replication who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors

**Adults:** 500 mg P.O. twice daily given with 200 mg ritonavir

**Children ages 2 to 18:** 14 mg/kg P.O. with ritonavir 6 mg/kg (or 375 mg/m² with ritonavir 150 mg/m²) twice daily, not to exceed maximum dosage of tipranavir 500 mg with ritonavir 200 mg twice daily. For children who develop intolerance or toxicity and can’t continue with tipranavir 14 mg/kg with ritonavir 6 mg/kg, consider decreasing dosage to tipranavir 12 mg/kg with ritonavir 5 mg/kg (or tipranavir 290 mg/m² with ritonavir 115 mg/m²) twice daily provided virus isn’t resistant to multiple protease inhibitors.

**Contraindications**
- Hypersensitivity to drug or its components
- Moderate to severe hepatic impairment
- Concurrent use of amiodarone, astemizole, bepridil, cisapride, dihydropyrimidines, ergonovine, ergotamine, flecainide, methyl ergonovine, midazolam, pimozide, propafenone, quinidine, terfenadine, or triazolam

**Precautions**
Use cautiously in:
- sulfonamide allergy
- hepatic insufficiency, diabetes mellitus, hyperglycemia, hemophilia, increased risk of bleeding
- concurrent use of drugs known to increase risk of bleeding
- pregnant or breastfeeding patients.

**Administration**
- Administer with or without food.
- Give 2 hours before or 1 hour after antacids.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2.9-3 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- **CNS:** fatigue, headache, depression, insomnia, asthenia, **intracranial hemorrhage**
- **GI:** diarrhea, nausea, vomiting, abdominal pain, dyspepsia, flatulence
- **Hematologic:** leukopenia, anemia, neutropenia, thrombocytopenia
- **Hepatic:** hepatotoxicity
- **Respiratory:** bronchitis, cough
- **Skin:** rash
- **Other:** pyrexia, fat accumulation or redistribution

**Interactions**
- **Drug-drug.** Antacids: decreased tipranavir peak concentration
- Atorvastatin, desipramine, fluticasone, itraconazole, ketoconazole, rifabutin, selective serotonin reuptake inhibitors, sildenafil, tadalafil, trazodone, vardenafil, voriconazole: increased levels of these drugs
- Calcium channel blockers: possible unpredictable effects
- Clarithromycin: increased levels of both drugs
- Didanosine, ethinyl estradiol, methadone: decreased levels of these drugs
- Fluconazole: increased tipranavir level
- Hormonal contraceptives: decreased hormonal concentration, increased risk of rash
- Lovastatin, simvastatin: increased potential for serious reactions (such as myopathy and rhabdomyolysis)

Reactions in **bold** are life-threatening.
Metronidazole: disulfiram-like interaction
Rifampin: loss of virologic response, tipranavir resistance
Warfarin: altered warfarin blood level

Drug-diagnostic tests. Alanine aminotransferase, amylase, aspartate aminotransferase, cholesterol, triglycerides: increased
Platelets, WBCs: decreased

Drug-food. High-fat meal: increased drug bioavailability

Drug-herbs. St. John’s wort: loss of virologic response, tipranavir resistance

Patient monitoring
● Monitor liver function tests and watch for signs and symptoms of hepatic impairment before and during therapy.
● Monitor triglyceride and cholesterol levels before therapy starts and at periodic intervals during therapy.
● Monitor CBC, platelets, and serum amylase levels.
● Monitor INR frequently when therapy starts in patients receiving warfarin.
● Closely monitor patients with hyperglycemia or chronic hepatitis B or C.
● Because this drug interacts with many other drugs, closely monitor patient’s drug regimen for possible interactions and adjust dosage, as appropriate.

Patient teaching
● Instruct patient to take drug with food and to swallow capsule whole, without chewing.
● Tell patient to take drug 2 hours before or 1 hour after antacids.
● Emphasize that patient must take prescribed ritonavir dosage with this drug to achieve desired therapeutic effect.
● Instruct patient not to alter dosage or discontinue tipranavir or ritonavir without consulting prescriber.
● Advise patient to take a missed dose as soon as possible and then return to normal schedule. Caution against taking double doses.
● Instruct patient to immediately stop taking drug and contact prescriber if he develops unusual fatigue, general ill feeling, flulike symptoms, appetite loss, nausea, yellowing of skin or eyes, dark urine, pale stools, or right-sided abdominal pain.
● Tell patient to report rash to prescriber.
● Inform patient that because drug may cause many interactions, he shouldn’t take other prescription or over-the-counter drugs without consulting prescriber.
● Tell patient drug may cause body fat redistribution or accumulation.
● Instruct patient to store capsules in refrigerator and to use contents within 60 days of opening bottle.
● Advise female taking estrogen-based hormonal contraceptives to use additional or alternative birth control method during therapy.
● Instruct female not to breastfeed because of risk of transmitting HIV infection and adverse drug effects to infant.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.

---

**tirofiban hydrochloride**
Aggrastat

Pharmacologic class: Glycoprotein (GP IIb/IIIa)-receptor inhibitor
Therapeutic class: Platelet aggregation inhibitor
Pregnancy risk category B
**Action**
Inhibits reversible platelet aggregation by binding to GP IIb/IIIa receptor on platelets

**Availability**
*Injection:* 25-ml and 50-ml vials (250 mcg/ml), 100-ml and 250-ml premixed vials (50 mcg/ml)

**Indications and dosages**
- Acute coronary syndrome (given with heparin); patients undergoing percutaneous transluminal coronary angioplasty (PTCA) or atherectomy

**Adults:** Loading dose of 0.4 mcg/kg/minute I.V. for 30 minutes, followed by continuous I.V. infusion of 0.1 mcg/kg/minute for 48 to 108 hours in patients being managed medically. Continue infusion for 12 to 24 hours after PTCA or atherectomy.

**Dosage adjustment**
- Renal insufficiency

**Contraindications**
- Hypersensitivity to drug or its components
- Active internal bleeding or history of bleeding diathesis within past 30 days
- Cerebrovascular accident (CVA) within past 30 days, or history of hemorrhagic CVA
- History of intracranial hemorrhage, intracranial neoplasm, arteriovenous malformation, aneurysm, or thrombocytopenia after previous tirofiban use
- History, symptoms, or findings that suggest aortic dissection
- Severe hypertension
- Acute pericarditis
- Major surgery or severe trauma within past 30 days
- Concurrent use of other parenteral GP IIb/IIIa inhibitors

**Precautions**
Use cautiously in:
- renal disease
- elderly patients
- pregnant or breastfeeding patients
- children younger than age 18 (safety not established).

**Administration**
- Know that drug comes both in premixed vials of 50 mcg/ml and injection concentrate of 250 mcg/ml.
- Dilute injection concentrate to same concentration as premixed vial (50 mcg/ml) by withdrawing and discarding 50 ml of solution from 250-ml plastic bag of normal saline solution or dextrose 5% in water, or by withdrawing and discarding 100 ml of solution from 500-ml plastic bag of same solution and replacing with equal volume of concentrated drug form.
- Mix I.V. solution well and inspect visually before administering.
- Squeeze plastic bag and check for leaks; discard if it has leaks.
- Don’t use drug in series connections with other plastic bags. Don’t add other drugs to bag containing tirofiban.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>Immediate</td>
<td>4-6 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

| CNS: | headache, dizziness, spinal-epidural hematoma, intracranial hemorrhage |
| CV: | vasovagal reaction, bradycardia, hemopericardium, coronary artery dissection |
| GI: | nausea, vomiting, occult bleeding, hematemesis, retroperitoneal hemorrhage |
| GU: | pelvic pain, hematuria |
| Hematologic: | bleeding, thrombocytopenia |
| Musculoskeletal: | leg pain |
| Respiratory: | pulmonary hemorrhage |
| Skin: | diaphoresis |
| Other: | infusion site bleeding, chills, fever, edema, allergic reactions, anaphylaxis |

Reactions in bold are life-threatening.
Interactions

Drug-drug. Clopidogrel, dipyridamole, nonsteroidal anti-inflammatory drugs, oral antiocoagulants (such as thrombolytics, ticlopidine, warfarin), other drugs affecting hemostasis: increased risk of bleeding

Levothyroxine, omeprazole: increased renal clearance of tirofiban

Vitamin A: increased risk of bleeding

Drug-diagnostic tests. Hematocrit, hemoglobin, platelets: decreased values

Drug-herbs. Alfalfa, anise, arnica, astragalus, bilberry, black currant seed oil, bladderwrack, bogbean, boldo (with fenugreek), borage oil, buchu, capsaicin, cat’s claw, celery, chaparral, chinchona bark, clove oil, dandelion, dong quai, evening primrose oil, fenugreek, feverfew, garlic, ginger, ginkgo, guggul, papaya extract, red clover, rhubarb, safflower oil, skullcap, tan-shen: increased risk of bleeding

Patient monitoring

- Monitor CBC, platelet count, and coagulation studies. Assess stool for occult blood.
- Watch for bleeding at puncture sites, especially at cardiac catheterization access site. Immobilize access site to reduce bleeding risk.
- Monitor for signs and symptoms of bleeding in cranium and other body systems (especially respiratory, GI, and GU).
- Monitor vital signs and ECG.
- Assess cardiovascular status. Stay alert for signs and symptoms of coronary artery dissection or hemopericardium.

Patient teaching

- Teach patient to recognize and immediately report serious adverse reactions.
- Tell patient he will be closely monitored and undergo regular blood testing during therapy.

---

tizanidine hydrochloride

Apo-Tizanidine®, Gen-Tizanidine®, Zanaflex

**Pharmacologic class:** Alpha-adrenergic agonist (centrally acting)

**Therapeutic class:** Skeletal muscle relaxant

**Pregnancy risk category C**

**Action**

Stimulates alpha₂-adrenergic agonist receptor sites and reduces spasticity by inhibiting presynaptic motor neurons

**Availability**

Tablets: 2 mg, 4 mg

**Indications and dosages**

- Increased muscle tone associated with spasticity

**Adults:** Initially, 4 mg P.O. q 6 to 8 hours (no more than three doses in 24 hours). Increase in increments of 2 to 4 mg, up to 8 mg/dose or 24 mg/day (not to exceed 36 mg/day), as needed.

**Contraindications**

- Hypersensitivity to drug or its components

**Precautions**

Use cautiously in:

- renal or hepatic impairment
- elderly patients
- pregnant or breastfeeding patients
- children (safety not established).

**Administration**

- Give with or without food.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1-2 hr</td>
<td>3-6 hr</td>
</tr>
</tbody>
</table>
Adverse reactions
CNS: drowsiness, asthenia, dizziness, speech disorder, dyskinesia, nervousness, anxiety, depression, hallucinations, sedation, paresthesia
CV: hypotension, bradycardia
EENT: blurred vision, pharyngitis, rhinitis
GI: vomiting, diarrhea, constipation, abdominal pain, dyspepsia, dry mouth
GU: urinary frequency, urinary tract infection
Hepatic: hepatitis
Musculoskeletal: back pain, myasthenia
Skin: rash, skin ulcers, sweating
Other: fever, infection, flulike symptoms

Interactions
Drug-drug. Alpha2-adrenergic agonist antihypertensives: increased risk of hypotension
CNS depressants (such as antihistamines, opioids, sedative-hypnotics): additive CNS depression
Hormonal contraceptives: increased tizanidine blood level, greater risk of adverse reactions

Drug-diagnostic tests. Alanine amino transferase, alkaline phosphatase, aspartate aminotransferase, glucose: increased levels

Drug-food. Any food: increased drug bioavailability, shorter time to peak concentration (with no effect on absorption)

Drug-behaviors. Alcohol use: additive CNS depression

Patient monitoring
• Monitor temperature and vital signs. Watch for orthostatic hypotension, bradycardia, and fever or other signs and symptoms of infection.
• Assess liver function tests.

Patient teaching
• Advise patient he may take with or without food.

• Tell patient to report signs or symptoms of infection or depression.
• Instruct patient to move slowly when sitting up or standing, to avoid dizziness from sudden blood pressure decrease.
• Tell patient to immediately report unusual tiredness or yellowing of skin or eyes.
• Caution patient not to drink alcohol.
• Instruct patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and behaviors mentioned above.

Reactions in bold are life-threatening.
also may develop, mainly in patients with preexisting renal damage and in those with normal renal function who receive drug for longer periods or in higher doses than those recommended. Other neurotoxicity manifestations may include numbness, skin tingling, muscle twitching, and seizures. Risk of drug-induced hearing loss increases with degree of exposure to high peak or high trough drug blood levels. Patients who develop cochlear damage may lack symptoms during therapy to warn of eighth-nerve toxicity, and partial or total irreversible bilateral deafness may continue to develop after withdrawal.

- Monitor renal and eighth-nerve function closely in patients with known or suspected renal impairment and in those whose renal functional initially is normal but who develop signs of renal dysfunction during therapy. Monitor peak and trough drug blood levels periodically during therapy; avoid levels above 12 mcg. Rising trough levels (above 2 mcg) may indicate tissue accumulation. Such accumulation, excessive peak levels, advanced age, and cumulative dose may contribute to ototoxicity and nephrotoxicity. Examine urine for decreased specific gravity and increased protein, cells, and casts. Measure blood urea nitrogen (BUN), serum creatinine, and creatinine clearance periodically. When feasible, obtain serial audiograms. Evidence of impairment of renal, vestibular, or auditory function warrants drug withdrawal or dosage adjustment.

- Avoid concurrent or sequential use of other neurotoxic or nephrotoxic antibiotics, especially other aminoglycosides (such as amikacin, gentamicin, kanamycin, neomycin, and streptomycin), cephadolinid, cipstatin, colistin, polymyxin B, vancomycin, and viomycin. Advanced age and dehydration also increase risk.

- Don’t give concurrently with potent diuretics (such as furosemide and ethacrynic acid), because these drugs are also ototoxic. Also, I.V. diuretics may increase tobramycin toxicity by altering antibiotic serum and tissue levels.

- Use drug cautiously in premature infants and neonates.

- Drug may harm fetus when given to pregnant women.

### Action

Interferes with protein synthesis in bacterial cell by binding to 30S ribosomal subunit

### Availability

*Injection*: 10 mg/ml, 40 mg/ml, 1.2-g vial
*Nebulizer solution*: 300 mg/5 ml in 5-ml ampule
*Ophthalmic ointment*: 0.3%
*Ophthalmic solution*: 0.3%
*Pediatric solution for injection*: 20 mg/2 ml

### Indications and dosages

- **Serious infections caused by susceptible organisms**
  - **Adults**: 3 mg/kg/day I.V. or I.M. in evenly divided doses q 8 hours. For life-threatening infections, may increase up to 5 mg/kg/day I.V. or I.M. in three or four evenly divided doses, then reduce to 3 mg/kg/day as soon as possible.
  - **Children older than 1 week**: 6 to 7.5 mg/kg/day in three or four evenly divided doses, such as 2 to 2.5 mg/kg I.V. or I.M. q 8 hours or 1.5 to 1.9 mg/kg I.V. or I.M. q 6 hours
  - **Neonates less than 1 week old**: Up to 4 mg/kg/day I.V. or I.M. in evenly divided doses q 12 hours
  - **Pseudomonas aeruginosa in cystic fibrosis patients**
  - **Adults and children older than age 6**: 300 mg inhalation b.i.d. (preferably q 12 hours but no less than 6 hours apart) for 28 days, then off for 28 days; then repeat cycle
  - **Ocular infections caused by susceptible organisms**
Adults and children: For mild to moderate infections, apply a ribbon of ophthalmic ointment (approximately 1 cm) to infected eye two or three times daily, or instill one to two drops of ophthalmic solution into infected eye q 4 hours. For severe infections, apply ophthalmic ointment q 3 to 4 hours or instill two drops of ophthalmic solution into infected eye q 30 to 60 minutes; decrease dosing frequency when improvement occurs. Therapy should continue for at least 48 hours after infection is under control.

Dosage adjustment
● Renal impairment

Contraindications
● Hypersensitivity to drug, other aminoglycosides, bisulfites (with some products), or benzyl alcohol (in neonates, with some products)

Precautions
Use cautiously in:
● renal or hearing impairment, neuromuscular diseases, obesity
● elderly patients
● pregnant or breastfeeding patients
● neonates and premature infants.

Administration
● Dilute I.V. dose in 50 to 100 ml of normal saline solution or dextrose 5% in water. For child, smaller volumes are needed.
● Infuse over at least 30 minutes. Flush line after administration.
● Give cephalosporins or penicillin, if ordered, 1 hour before or after tobramycin.
● Give inhalation doses by nebulizer over 10 to 15 minutes.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>15-30 min</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.M.</td>
<td>Rapid</td>
<td>30-90 min</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Reactions in bold are life-threatening.
Patient monitoring
- Draw sample for peak drug level 1 hour after I.M. or 30 minutes after I.V. administration. Draw sample for trough level just before next dose.
- Assess liver and kidney function tests.
- Monitor CBC with white cell differential.
- Closely monitor patient’s hearing.

Patient teaching
- Tell patient drug may cause hearing impairment and other serious adverse reactions, such as unusual bleeding or bruising. Instruct him to report these reactions at once.
- Advise patient to report new signs or symptoms of infection.
- With inhalation form, teach patient how to use nebulizer. Instruct him to administer dose over 10 to 15 minutes by breathing normally through mouthpiece while sitting or standing. Remind him to use only the hand-held nebulizer and compressor originally dispensed with drug. Advise him to use a nose clip to help him breathe through his mouth. If he uses other inhaled drugs, instruct him to take tobramycin last.
- Teach patient proper use of eye drops. Caution him not to touch dropper to eye or any other surface.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

FDA BOXED WARNING
- Before prescribing or administering drug, make sure you’re thoroughly familiar with prescribing information.
- Don’t administer until prescriber has discussed risks with patient and patient has provided written acknowledgment that risks have been explained.
- Due to risk of hepatocellular injury (including potentially fatal, acute fulminant liver failure), drug ordinarily should be used in patients with Parkinson’s disease who are receiving L-dopa/carbidopa, experiencing symptom fluctuations, and not responding satisfactorily to or not appropriate candidates for other adjunctive therapies. Withdraw therapy if patient doesn’t show substantial benefit within 3 weeks of starting drug.
- Don’t initiate therapy if patient has clinical evidence of hepatic disease. Don’t restart therapy if patient developed hepatocellular injury while receiving drug and was withdrawn from therapy for any reason.
- Before and during therapy, obtain appropriate tests to exclude liver disease. Discontinue drug if alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceed two times the upper limit of normal or if clinical signs and symptoms suggest onset of hepatic dysfunction.

**tolcapone**
* Taser

**Pharmacologic class:** Catecholamine inhibitor
**Therapeutic class:** Antiparkinsonian
**Pregnancy risk category C**

**Action**
Unknown. When given with levodopa-carbidopa, thought to reversibly inhibit catechol O-methyaltansferase, leading to increased levodopa bioavailability and stimulation in brain.

**Availability**
* Tablets: 100 mg, 200 mg
Indications and dosages

Adjunct to levodopa-carbidopa in idiopathic Parkinson’s disease

Adults: Initially, 100 mg P.O. t.i.d. given with levodopa-carbidopa. If beneficial, may increase dosage to 200 mg P.O. t.i.d.; maximum dosage is 600 mg daily. If response inadequate after 3 weeks, stop therapy.

Contraindications

- Hypersensitivity to drug
- Nontraumatic rhabdomyolysis
- Drug-related hyperpyrexia or confusion
- Hepatic disease, alanine aminotransferase or aspartate aminotransferase elevation
- History of tolcapone-induced hepatocellular injury

Precautions

Use cautiously in:
- renal or cardiac disease, hypertension, asthma
- concurrent use of nonselective MAO inhibitor (such as phenelzine, tranylcypromine)
- pregnant or breastfeeding patients

Administration

Before giving first dose, obtain patient’s written informed consent for drug therapy.
- Check liver function tests before starting drug.
- Don’t stop drug abruptly, because this may cause a syndrome similar to neuroleptic malignant syndrome.
- Know that levodopa-carbidopa dosage may be decreased to minimize dyskinesia.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: dizziness, asthenia, headache, fatigue, hypokinesia, mental deficiency, agitation, tremor, hyperactivity, paresthesia, irritability, syncope, depression, speech disorder, confusion, sleep disorder, excessive dreaming, hallucinations, drowsiness, hypotonia, imbalance, falling, hyperkinesias, dystonia, dyskinesia

CV: hypotension, chest discomfort or pain, orthostatic hypotension, palpitations

EENT: tinnitus, sinus congestion, pharyngitis

GI: nausea, vomiting, diarrhea, constipation, dyspepsia, abdominal pain, flatulence, dry mouth, anorexia

GU: hematuria, urinary tract infection (UTI), urinary incontinence, urine discoloration, urinary disorder, erectile dysfunction

Hepatic: jaundice, severe hepatocellular injury (including fulminant hepatic failure, death)

Musculoskeletal: neck pain, arthritis, muscle cramps, stiffness, rhabdomyolysis

Respiratory: upper respiratory infection, dyspnea, bronchitis

Skin: rash, dermal bleeding, diaphoresis

Other: fever, influenza

Interactions

Drug-drug. Desipramine: increased risk of adverse tolcapone reactions
Nonselective MAO inhibitors (such as phenelzine, tranylcypromine): inhibition of principal pathways of tolcapone metabolism
Warfarin: increased warfarin blood level

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase: increased levels

Patient monitoring

- Monitor parkinsonian symptoms during first 3 weeks of therapy. Report improvement (or lack thereof) to help determine if therapy should continue.
- Assess neurologic status closely.
Monitor liver function tests. Watch closely for signs and symptoms of hepatic impairment.
- Closely monitor temperature. Stay alert for fever and other indications of infection (particularly upper respiratory infection, influenza, and UTI).

**Patient teaching**
- Tell patient to take drug with first levodopa-carbidopa dose of day.
- Advise patient to immediately report signs or symptoms of liver problems (persistent nausea, fatigue, appetite loss, dark urine, itching, tenderness on right side of abdomen, and yellowing of skin or eyes).
- Instruct patient to promptly report signs and symptoms of infection.
- Advise female patient to immediately report suspected pregnancy. Caution her not to breastfeed.
- Tell patient drug may cause involuntary movements, hallucinations, light-headedness, and other significant reactions. Urge him to use safety measures as needed.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
- Advise patient to move slowly when sitting up or standing, to avoid dizziness from sudden blood pressure decrease.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**tolterodine**
Detrol, Detrol LA, Detrusitol®, Detrusitol XL®

**Pharmacologic class:** Anticholinergic

**Therapeutic class:** Urinary tract antispasmodic

**Pregnancy risk category C**

**Action**
Competitively antagonizes muscarinic receptors, inhibiting bladder contractions and reducing urinary frequency

**Availability**
Capsules (extended-release): 2 mg, 4 mg
Tablets: 1 mg, 2 mg

**Indications and dosages**

> Overactive bladder

**Adults:** 2 mg (immediate-release) P.O. b.i.d.; may decrease to 1 mg P.O. b.i.d. depending on response and tolerance. Or 4 mg (extended-release) P.O. daily; may decrease to 2 mg P.O. daily, depending on response.

**Dosage adjustment**
- Hepatic impairment or disease
- Renal impairment
- Concurrent use of potent CYP3A4 inhibitors

**Contraindications**
- Hypersensitivity to drug or its components
- Urinary or gastric retention
- Uncontrolled angle-closure glaucoma

**Precautions**
Use cautiously in
- GI obstruction, significant bladder outlet obstruction, controlled angle-closure glaucoma, significant hepatic impairment, renal impairment

Canada  UK  Hazardous drug  High alert drug
pregnant or breastfeeding patients
• children (safety not established).

**Administration**

• Give with food to increase bioavailability.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>12 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS: headache, dizziness, vertigo, drowsiness, paresthesia, fatigue
CV: chest pain
EENT: vision abnormalities, xerophthalmia, pharyngitis
GI: diarrhea, constipation, abdominal pain, dyspepsia, dry mouth
GU: dysuria, urinary retention or frequency, urinary tract infection
Musculoskeletal: joint pain
Skin: dry skin
Other: weight gain, flulike symptoms, infection

**Interactions**

**Drug-drug.** Clarithromycin, erythromycin, itraconazole, ketoconazole, miconazole: inhibited metabolism and increased effects of tolterodine

**Drug-food.** Any food: increased drug bioavailability

**Patient monitoring**

• Monitor bladder function.
• Assess blood pressure and stay alert for chest pain.
• Monitor neurologic status. Report paresthesia or visual impairment.

**Patient teaching**

• Tell patient to take with food.
• If patient takes extended-release form, instruct him not to chew or crush it.
• Advise patient to use sugarless gum or hard candy to relieve dry mouth.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and foods mentioned above.

**topiramate**

Apo-Topiramate, Co-Topiramate, Dom-Topiramate, Gen-Topiramate, Novo-Topiramate, PHL-Topiramate, PMS-Topiramate, Ratio-Topiramate, Sandoz-Topiramate, Topamax

**Pharmacologic class:** Sulfamate-substituted monosaccharide derivative

**Therapeutic class:** Anticonvulsant

**Pregnancy risk category C**

**Action**

Blocks sodium channels, enhancing the action of gamma-aminobutyrate (a neurotransmitter); also inhibits amino acid excitatory receptors

**Availability**

Sprinkle capsules: 15 mg, 25 mg
Tablets: 25 mg, 50 mg, 100 mg, 200 mg

**Indications and dosages**

► Adjunct in partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome

**Adults and children older than age 17:** Initially, 25 to 50 mg P.O. daily. To achieve adequate response, may increase by 25 to 50 mg weekly, up to 200 mg b.i.d.

**Children ages 2 to 16:** Initially, less than 25 mg P.O. daily; increase at 1- or 2-week intervals in increments of 1 to 3 mg/kg/day given in two divided doses to achieve adequate response.

► Migraine prophylaxis

**Adults:** Dosage titrated to 100 mg P.O. daily as follows: 25 mg/day during week 1, 25 mg b.i.d. during week 2, 25 mg in morning and 50 mg in evening during week 3, and 50 mg b.i.d. during week 4

Reactions in **bold** are life-threatening.
Dosage adjustment
- Renal impairment

Off-label uses
- Cluster headaches
- Infantile spasms
- Mood stabilization

Contraindications
- Hypersensitivity to drug or its components

Precautions
Use cautiously in:
- renal or hepatic impairment, dehydration, urolithiasis, glaucoma, myopia
- pregnant or breastfeeding patients.
- children younger than age 2 (safety and efficacy not established).

Administration
- Give without regard to meals.
- Don’t break tablets, because of bitter taste.
- Administer capsules either whole or by opening capsule carefully and sprinkling entire contents into small amount of soft food. Instruct patient to swallow mixture immediately without chewing sprinkles.
- Don’t stop therapy suddenly. Dosage must be tapered.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2 hr</td>
<td>12 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, drowsiness, fatigue, malaise, poor memory and concentration, nervousness, psychomotor slowing, speech and language problems, aggressive reaction, agitation, anxiety, confusion, depression, irritability, ataxia, paresthesia, hyperesthesia, tremor, suicide attempt, increased seizures
EENT: abnormal vision, diplopia, nystagmus, acute myopia, secondary angle-closure glaucoma, decreased hearing, rhinitis, sinusitis, epistaxis, pharyngitis
GI: nausea, constipation, abdominal pain, dry mouth, gastroenteritis, increased salivation (in children), anorexia
GU: renal calculi, urinary incontinence, leukorrhea
Hematologic: purpura, leukopenia, thrombocytopenia
Metabolic: hypocalcemia, hyperchloremia, hypernatremia, hyponatremia, hypophosphatemia, hypoglycemia
Musculoskeletal: myalgia, back pain, leg pain
Respiratory: pneumonia
Skin: rash, skin disorder, alopecia, dermatitis, hypertrichosis, eczema, seborrhea, skin discoloration
Other: altered taste, weight loss, thirst, fever, flulike symptoms, hot flashes, infection, edema, allergic reaction

Interactions
Drug-drug. Carbamazepine: decreased topiramate blood level and effects
Carbonic anhydrase inhibitors (such as acetazolamide): increased risk of renal calculi
CNS depressants: increased risk of CNS depression and other adverse cognitive or neuropsychiatric reactions
Hormonal contraceptives: decreased contraceptive efficacy
Phenytoin: increased phenytoin blood level and effects, decreased topiramate blood level and effects
Valproic acid: decreased effects of both drugs
Drug-diagnostic tests. ALT, AST: increased levels
Calcium, cholesterol, glucose, phosphate: decreased levels
Sodium: increased or decreased level
Drug-behaviors. Alcohol use: increased CNS depression
Patient monitoring

- Monitor seizure type and pattern. Report new seizure types or worsening seizure pattern.
- Assess neurologic status closely. Report significant adverse reactions.
- Watch for and immediately report signs and symptoms of depression or suicidal ideation.
- Monitor vision. If patient becomes acutely nearsighted with symptoms of angle-closure glaucoma (cloudy vision, eye pain), stop drug and contact prescriber right away.

Patient teaching

- Tell patient he may take with or without food.
- Caution patient not to crush or break tablets.
- If patient takes capsules, tell him he may open them, sprinkle contents onto small amount of soft food, and consume immediately. Tell him not to store this mixture.
- Caution patient not to stop drug suddenly. Dosage must be tapered.
- Instruct patient to drink plenty of fluids to reduce risk of kidney stones.
- Tell patient drug may cause new seizure types or worsen seizure pattern. Instruct him to report these developments immediately.
- Instruct patient (and significant other as appropriate) to immediately report signs or symptoms of depression or suicidal thoughts.
- Advise patient to immediately report vision changes, especially nearsightedness, cloudy vision, or eye pain.
- Caution patient not to drive or perform other hazardous activities.
- Tell patient not to drink alcohol during drug therapy.
- Advise female patient to notify prescriber of suspected pregnancy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

Reactions in **bold** are life-threatening.
Dosage adjustment
- Renal impairment
- Neutropenia

Contraindications
- Hypersensitivity to drug or its components
- Severe bone marrow depression
- Pregnancy or breastfeeding

Precautions
Use cautiously in:
- children (safety and efficacy not established).

Administration
- Before starting therapy, check blood counts. Patient must have baseline neutrophil count above 1,500 cells/mm³ and platelet count above 100,000 cells/mm³ to receive drug.
- Prepare drug under vertical laminar-flow hood, wearing gloves and protective clothing. Follow facility policy for discarding used drug containers and I.V. equipment.
- If skin contacts drug, wash immediately with soap and water.
- To reconstitute, add 4 ml of sterile water to 4-mg vial. Dilute further in normal saline solution or dextrose 5% in water. Give immediately over 30 minutes using infusion pump.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: asthenia, headache, fatigue, paresthesia
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, stomatitis, anorexia
Hematologic: anemia, leukopenia, thrombocytopenia, neutropenia
Musculoskeletal: back pain, skeletal pain
Respiratory: coughing, dyspnea

Skin: erythematous or maculopapular rash, pruritus, urticaria, dermatitis, bullous eruption, alopecia
Other: fever, body pain, sepsis

Interactions
Drug-drug. Cisplatin: severe bone marrow depression
Granulocyte colony-stimulating factor: prolonged neutropenia
Live-virus vaccines: increased risk of infection from vaccine
Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, bilirubin: increased levels

Patient monitoring
- Closely monitor CBC with white cell differential.
- Assess for signs and symptoms of bleeding tendency.
- Monitor closely for sepsis, other infections, and increased hepatic enzyme levels.

Patient teaching
- Advise patient to immediately report unusual bleeding or bruising, sore throat, fever, or chills.
- Teach patient safety measures to avoid bruising and bleeding.
- Tell patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
- Advise female patient to notify prescriber of suspected pregnancy. Caution her not to breastfeed during therapy.
- Inform patient that drug may cause hair loss.
- Tell patient he’ll undergo regular blood testing during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.
torsemide (torasemide®)
Demadex, Torem®

Pharmacologic class: Loop diuretic
Therapeutic class: Diuretic, antihypertensive
Pregnancy risk category B

Action
Inhibits sodium and chloride reabsorption from the ascending loop of Henle and distal renal tubule; increases renal excretion of water, sodium, chloride, magnesium, calcium, and hydrogen. Also may exert renal and peripheral vasodilatory effects. Net effect is natriuretic diuresis.

Availability
Injection: 10 mg/ml
Tablets: 5 mg, 10 mg, 20 mg, 100 mg

Indications and dosages
Heart failure
Adults: 10 to 20 mg P.O. or I.V. daily. If response inadequate, double dosage until desired response occurs. Don’t exceed 200 mg as a single dose.
Hypertension
Adults: 5 mg P.O. daily. May increase to 10 mg daily after 4 to 6 weeks; if drug still isn’t effective, additional antihypertensives may be prescribed.
Chronic renal failure
Adults: 20 mg P.O. or I.V. daily. If response inadequate, double dosage until desired response occurs. Don’t exceed 200 mg as a single dose.
Hepatic cirrhosis
Adults: 5 or 10 mg P.O. or I.V. daily, given with aldosterone antagonist or potassium-sparing diuretic. If response inadequate, double dosage. Don’t exceed 40 mg as a single dose.

Contraindications
- Hypersensitivity to drug, thiazides, or sulfonylureas
- Anuria

Precautions
Use cautiously in:
- severe hepatic disease accompanied by cirrhosis or ascites, preexisting uncorrected electrolyte imbalances, diabetes mellitus, worsening azotemia
- elderly patients
- pregnant or breastfeeding patients
- children younger than age 18.

Administration
- Give I.V. by direct injection over at least 2 minutes or by continuous I.V. infusion.
- Flush I.V. line with normal saline solution before and after administering.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Within 1 hr</td>
<td>1-2 hr</td>
<td>6-8 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Within 10 min</td>
<td>Within 1 hr</td>
<td>6-8 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, headache, asthenia, insomnia, nervousness, syncope
CV: hypotension, ECG changes, chest pain, volume depletion, atrial fibrillation, ventricular tachycardia, shunt thrombosis
EENT: rhinitis, sore throat
GI: nausea, diarrhea, vomiting, constipation, dyspepsia, anorexia, rectal bleeding, GI hemorrhage
GU: excessive urination
Metabolic: hyperglycemia, hyperuricemia, hypokalemia
Musculoskeletal: joint pain, myalgia
Respiratory: increased cough
Skin: rash
Other: edema

Interactions
Drug-drug. Aminoglycosides, cisplatin: increased risk of ototoxicity

Reactions in bold are life-threatening.

Clinical alert
Amphotericin B, corticosteroids, mezlocillin, piperacillin, potassium-wasting diuretics, stimulant laxatives: additive hypokalemia

Antihypertensives, nitrates: additive hypotension

Lithium: increased lithium blood level and toxicity

Neuromuscular blockers: prolonged neuromuscular blockade

Nonsteroidal anti-inflammatory drugs, probenecid: inhibited diuretic response

Sulfonylureas: decreased glucose tolerance, hyperglycemia in patients with previously well-controlled diabetes

Drug-diagnostic tests. Glucose, uric acid: increased levels

Potassium: decreased level

Drug-herbs. Dandelion: interference with diuresis

Ephedra (ma huang): reduced hypotensive effect of torsemide

Geranium, ginseng: increased risk of diuretic resistance

Licorice: rapid potassium loss

Drug-behaviors. Acute alcohol ingestion: additive hypotension

Patient monitoring

● Monitor vital signs, especially for hypotension.

● Assess ECG for arrhythmias and other changes.

● Monitor weight and fluid intake and output to assess drug efficacy.

● Monitor electrolyte levels, particularly potassium. Stay alert for signs and symptoms of hypokalemia.

● Assess hearing for signs and symptoms of ototoxicity.

● Monitor blood glucose level carefully in diabetic patient.

Patient teaching

● Advise patient to take in morning with or without food.

● Instruct patient to move slowly when sitting up or standing, to avoid dizziness from sudden blood pressure drop.

● Tell patient to monitor weight and report sudden increases.

● Instruct diabetic patient to monitor blood glucose level carefully.

● Caution patient to avoid alcohol during drug therapy.

● Advise patient to consult prescriber before using herbs.

● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

tramadol hydrochloride

Dromadol SR®, Dromadol XL®, Larapam SR®, Mabron®, Nobligan Retard®, Ralivia®, Tradorec XL®, Tramake®, Tridural®, Ultram, Ultram ER, Zamadol®, Zydol®, Zytram XL®

Pharmacologic class: Opioid agonist

Therapeutic class: Analgesic

Pregnancy risk category C

Action

Inhibits reuptake of serotonin and nor epinephrine in CNS

Availability

Tablets: 50 mg

Tablets (extended-release): 100 mg, 200 mg, 300 mg

Indications and dosages

Moderate to moderately severe pain

Adults: In rapid titration, 50 to 100 mg P.O. q 4 to 6 hours p.r.n. (not to exceed 400 mg/day, or 300 mg/day in patients older than age 75). In gradual titration, initially 25 mg P.O. daily; increase by 25 mg/day q 3 days to 100 mg/day, then increase by 50 mg/day q 3 days,
up to 200 mg/day p.r.n. Alternately, 100 mg P.O (extended-release) up to a maximum of 300 mg daily.

**Dosage adjustment**
- Renal or hepatic impairment

**Contraindications**
- Hypersensitivity to drug, its components, or opioids
- Acute intoxication with alcohol, sedative-hypnotics, centrally acting analgesics, opioid analgesics, or psychotropic agents
- Physical opioid dependence

**Precautions**
Use cautiously in:
- seizure disorder or risk factors for seizures, renal or hepatic impairment, increased intracranial pressure, head trauma, acute abdomen
- history of opioid dependence or recent use of large opioid doses
- elderly patients
- pregnant or breastfeeding patients
- children younger than age 16 (safety not established).

**Administration**
- Give as prescribed, preferably before pain becomes severe.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1 hr</td>
<td>2-3 hr</td>
<td>4-6 hr</td>
</tr>
<tr>
<td>P.O (ER)</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** dizziness, vertigo, headache, drowsiness, anxiety, stimulation, confusion, incoordination, euphoria, nervousness, sleep disorder, asthenia, hypotonia, seizures

**CV:** vasodilation

**EENT:** visual disturbances

**GI:** nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, dry mouth, anorexia

**GU:** urinary retention and frequency, proteinuria, menopausal symptoms

**Respiratory:** respiratory depression (with large doses, concomitant anesthetic use, or alcohol ingestion)

**Skin:** pruritus, sweating

**Other:** physical or psychological drug dependence, drug tolerance

**Interactions**

**Drug-drug.** Anesthetics, antihistamines, CNS depressants, other opioids, psychotropic agents, sedative-hypnotics: increased risk of CNS depression

Carbamazepine: increased tramadol metabolism and decreased efficacy

MAO inhibitors: increased risk of serotonin syndrome and seizures

**Drug-diagnostic tests.** Creatinine, hepatic enzymes: increased levels

Hemoglobin: decreased level

**Drug-herbs.** Chamomile, hops, kava, skullcap, valerian: increased CNS depression

**Drug-behaviors.** Alcohol use: increased CNS depression

**Patient monitoring**
- Assess patient’s response to drug 30 minutes after administration.
- Monitor respiratory status. Withhold drug and contact prescriber if respirations become shallow or slower than 12 breaths/minute.
- Monitor for physical and psychological drug dependence. Report signs to prescriber.

**Patient teaching**
- Tell patient drug works best when taken before pain becomes severe.
- Inform patient (and significant other as appropriate) that drug may cause respiratory depression if used with alcohol. Recommend abstinence.
- Instruct patient to immediately report seizure.
- Tell patient drug interacts with many common over-the-counter drugs and herbal remedies. Instruct him to consult prescriber before taking these products.
Inform patient that drug can cause physical and psychological dependence. Urge him to take it only as prescribed and needed.

Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

**trandolapril**
Goptin®, Mavik

**Pharmacologic class:** Angiotensin-converting enzyme (ACE) inhibitor

**Therapeutic class:** Antihypertensive

**Pregnancy risk category C** (first trimester), **D** (second and third trimesters)

**FDA BOXED WARNING**

- When used during second or third trimester of pregnancy, drug may cause fetal harm or death. Discontinue as soon as pregnancy is detected.

**Action**
Inhibits conversion of angiotensin I to the potent vasoconstrictor angiotensin II, promoting vasodilation. Also increases plasma renin and stimulates aldosterone secretion, inducing diuresis.

**Availability**
Tablets: 1 mg, 2 mg, 4 mg

**Indications and dosages**

- **Hypertension**

  **Adults:** For patients not receiving diuretics, 1 mg/day P.O. in nonblack patients or 2 mg/day P.O. in black patients. If response inadequate, may increase at weekly intervals up to 4 mg/day. For patients receiving diuretics, start with 0.5 mg/day P.O.

  **Heart failure or left ventricular dysfunction after myocardial infarction**

  **Adults:** Initially, 1 mg P.O. daily. Titrate up to 4 mg daily, if tolerated.

**Dosage adjustment**

- Renal or hepatic impairment

**Contraindications**

- Hypersensitivity to drug or other ACE inhibitors
- Angioedema with previous ACE inhibitor use
- Pregnancy (second and third trimesters)

**Precautions**
Use cautiously in:

- renal or hepatic impairment, hypovolemia, hyponatremia, aortic stenosis or hypertrophic cardiomyopathy, cerebrovascular or cardiac insufficiency, surgery and anesthesia
- family history of angioedema
- concurrent diuretic therapy
- black patients with hypertension
- elderly patients
- pregnant patients (first trimester) or breastfeeding patients
- children (safety not established).

**Administration**

- Give once or twice daily as prescribed, with or without food.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Within 1 hr</td>
<td>4-10 hr</td>
<td>Up to 24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- CNS: insomnia, paresthesia, dizziness, drowsiness, asthenia, syncope, cerebrovascular accident
- CV: chest pain, hypotension, palpitations, intermittent claudication,
bradycardia, first-degree atrioventricular block, cardiogenic shock

EENT: epistaxis, sinusitis, throat inflammation

GI: vomiting, diarrhea, constipation, abdominal pain or distention, gastritis, dyspepsia, pancreatitis

GU: urinary tract infection, erectile dysfunction, decreased libido

Hematologic: agranulocytosis, neutropenia

Metabolic: hypocalcemia, gout, hyperkalemia

Musculoskeletal: muscle cramps, myalgia, extremity pain

Respiratory: cough, dyspnea, upper respiratory infection

Skin: rash, flushing, pruritus, angioedema

Other: edema

**Patient monitoring**
- Monitor vital signs, especially for hypotension and bradycardia when therapy begins.
- Assess CBC with white cell differential. Watch for signs and symptoms of bleeding and infection.
- Monitor electrolyte levels, especially potassium. Stay alert for hyperkalemia.
- Assess renal function tests and fluid intake and output.

**Patient teaching**
- Tell patient drug may cause bleeding tendency or increase his infection risk. Teach him which warning signs to report.
- Teach patient to recognize and report signs or symptoms of hyperkalemia.
- Instruct patient to move slowly when sitting up or standing, to avoid dizziness from sudden blood pressure drop.
- Caution patient not to exercise vigorously in hot environments.
- Advise patient not to use salt substitutes containing potassium. Tell him to avoid high-potassium foods.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

**Interactions**

**Drug-drug.** Antacids: decreased trandolapril absorption

Digoxin: increased digoxin blood level, greater risk of toxicity

Diuretics, general anesthetics, nitrates, other antihypertensives: additive hypotension

Indomethacin: reduced hypotensive effect of trandolapril

Lithium: increased lithium blood level, greater risk of toxicity

Phenothiazines: increased trandolapril effects

Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium: additive hyperkalemia

**Drug-diagnostic tests.** Neutrophils, platelets: decreased counts

Potassium: increased level

**Drug-food.** Salt substitutes containing potassium: hyperkalemia

**Drug-herbs.** Capsaicin: increased incidence of cough

Ephedra (ma huang), yohimbine: antagonism of trandolapril effects

**Drug-behaviors.** Acute alcohol ingestion: additive hypotension

Reactions in bold are life-threatening.

---

**tranylcypromine sulfate**

**Parnate**

**Pharmacologic class:** MAO inhibitor

**Therapeutic class:** Antidepressant

**Pregnancy risk category C**

---

**FDA BOXED WARNING**

- Drug may increase risk of suicidal thinking and behavior in children and adolescents with major depressive
disorder and other psychiatric disorders. Risk must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family and caregivers to observe patient closely and communicate with prescriber as needed.

- Drug isn’t approved for use in pediatric patients.

**Action**
Unknown. Thought to increase concentrations of serotonin, epinephrine, and norepinephrine in CNS by inhibiting effects of MAO.

**Availability**
*Tablets: 10 mg*

**Indications and dosages**
- **Depression**
  - **Adults:** 10 mg P.O. t.i.d., increased if needed by 10 mg P.O. daily at intervals of 1 to 3 weeks. Maximum dosage is 60 mg daily.

**Contraindications**
- Hypersensitivity to drug or other MAO inhibitors
- Pheochromocytoma
- Heart failure or other cardiovascular disease
- Confirmed or suspected cerebrovascular disorder
- Severe renal impairment
- Hypertension
- History of hepatic disease or elevated liver function tests
- History of headache
- Upcoming elective surgery
- Concurrent use of other MAO inhibitors, dibenzazepine derivatives, CNS depressants, anesthetics, antihypertensives, bupropion, sympathomimetics, selective serotonin reuptake inhibitors (SSRIs), or dextromethorphan
- Consumption of caffeine, certain cheeses, and other foods with high tryptophan or tyramine content

**Precautions**
Use cautiously in:
- seizure disorders, diabetes mellitus, hyperactivity, schizophrenia, severe depression, suicidal attempt or ideation
- pregnant or breastfeeding patients
- children.

**Administration**
- Don’t stop therapy suddenly. Dosage must be tapered.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1-3.5 hr</td>
<td>10 days</td>
</tr>
</tbody>
</table>

**Adverse reactions**
CNS: dizziness, headache, hyperreflexia, tremor, mania, hypomania, confusion, impaired memory, hypersomnia or insomnia, weakness, fatigue, drowsiness, restlessness, increased anxiety, myoclonic movements, suicidal behavior or ideation (especially in child or adolescent)
CV: orthostatic hypotension, tachycardia, palpitations, syncope, paradoxical hypertension, hypertensive crisis
EENT: blurred vision
GI: nausea, diarrhea, constipation, GI disturbances, abdominal pain, dry mouth, anorexia
GU: urinary retention, impaired ejaculation, erectile dysfunction
Hematologic: anemia, agranulocytosis, leukopenia, thrombocytopenia
Musculoskeletal: muscle twitching
Other: weight gain, chills, edema

**Interactions**
Drug-drug. *Anesthetics, antihypertensives, bupropion, CNS depressants, dextromethorphan, dibenzazepine derivatives, other MAO inhibitors, SSRIs, sympathomimetics: potentially fatal reactions*
Beta-adrenergic blockers: bradycardia
Carbamazepine: hypertensive crisis, severe seizures, coma, circulatory collapse
Hypoglycemics: potentiation of hypoglycemic response
Levodopa: hypertensive reactions
Methylphenidate: increased risk of hypertensive crisis
Sulfonamides: sulfonamide or tranylcypromine toxicity
Thiazide diuretics: exaggerated hypotension

Drug-diagnostic tests. Transaminases: increased levels
Drug-food. Foods containing high caffeine, tyramine, or tryptophan content: hypertension
Drug-herbs. Cacao: vasopressor effects
Ephedra (ma huang): severe reactions, including hypertensive crisis
Ginseng: tremor, headache, mania
Licorice: increased tranylcypromine activity
L-tryptophan: serotonin syndrome (overreactive reflexes, high body temperature, jaw clenching, sweating, drowsiness, euphoria, and even death)

Patient monitoring
- Monitor vital signs and cardiovascular status carefully. Stay alert for indications of impending hypertensive crisis (palpitations, frequent headaches). Keep phentolamine at hand to lower blood pressure if needed.
- Monitor CBC and liver function tests.
- Observe patient closely for suicidal ideation and drug hoarding.

Patient teaching
- Instruct patient or caregiver to immediately report rapid heartbeat and frequent headaches (possible symptoms of hypertensive crisis).
- Advise patient to read food labels carefully and to avoid foods high in tyramine, tryptophan, and caffeine.
- Tell patient drug causes serious interactions with many common drugs. Instruct him to tell all prescribers he is taking it.
- Teach patient or caregiver to recognize and immediately report increasing depression or suicidal ideation (especially in child or adolescent).
- Advise patient to avoid alcohol and herbal remedies, because serious reactions may occur.
- Caution patient not to stop therapy suddenly. Dosage must be tapered.
- Instruct patient to move slowly when sitting up or standing, to avoid dizziness from sudden blood pressure drop.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, and alertness.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

Reactions in bold are life-threatening.
received drug in combination with anthracyclines and cyclophosphamide.

**Action**
Selectively binds to human epidermal growth factor receptor 2 (HER2), inhibiting proliferation of human tumor cells that overexpress HER2.

**Availability**
*Lyophilized powder:* 440-mg vial (each vial contains 20 ml bacteriostatic water for injection, 1.1% benzyl alcohol)

**Indications and dosages**
- Metastatic breast cancer in patients whose tumors overexpress HER2
  - **Adults:** As monotherapy, loading dose of 4 mg/kg I.V. infusion over 90 minutes, followed by weekly maintenance dose of 2 mg/kg I.V. infusion given over 30 minutes if loading dose was tolerated. Don’t give by I.V. push.

**Contraindications**
- Hypersensitivity to drug

**Precautions**
Use cautiously in
- hypersensitivity to Chinese hamster ovary cell protein or to benzyl alcohol
- cardiac disease, anemia, leukopenia
- elderly patients
- pregnant or breastfeeding patients
- children younger than age 18 (safety and efficacy not established).

**Administration**
- Follow facility policy for handling, administering, and disposal of carcinogenic, mutagenic, and teratogenic agents.
  - Give antiemetic, as prescribed, before administering trastuzumab.
    - Administer by I.V. infusion only. Don’t give by I.V. push or bolus.
    - To reconstitute, add 20 ml of bacteriostatic water for injection to vial, pointing diluent stream at lyophilized cake. Swirl vial gently; don’t shake. Withdraw prescribed dose and add it to 250 ml of normal saline solution. (Don’t use dextrose 5% in water.)
    - Infuse loading dose I.V. over 90 minutes. Infuse weekly doses I.V. over 30 minutes.
    - Immediately after reconstituting, write a date that is 28 days from reconstitution date in the space after “Do not use after” on vial label.
    - If patient has benzyl alcohol hypersensitivity, reconstitute with sterile water for injection. Use immediately after reconstitution; discard unused portion.
    - Never administer intrathecally; doing so causes death.
- Know that for patient who hasn’t previously received chemotherapy for metastatic disease, drug is given at same dosage but in combination with paclitaxel.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- **CNS:** dizziness, headache, depression, paresthesia, insomnia, ataxia, confusion, manic reaction, seizures
- **CV:** peripheral edema, hypotension, tachycardia, syncope, arrhythmias, shock, pericardial effusion, vascular thrombosis, heart failure, cardiotoxicity, cardiac arrest
- **EENT:** amblyopia, hearing loss
- **GI:** nausea, vomiting, diarrhea, gastroenteritis, hematemesis, colitis, esophageal ulcer, stomatitis, ileus, anorexia, intestinal obstruction, pancreatitis
- **GU:** urinary tract infection, hematuria, hemorrhagic cystitis, hydronephrosis, pyelonephritis, renal failure
- **Hematologic:** coagulation disorder, pancytopenia, leukemia
- **Hepatic:** ascites, hepatitis, hepatic failure
- **Metabolic:** hypothyroidism, hypercalcemia, hyponatremia

© Canada © UK © Hazardous drug © High alert drug
Musculoskeletal: back, bone, or joint pain; myopathy; fractures; bone necrosis
Respiratory: upper respiratory infection, dyspnea, acute respiratory distress syndrome
Skin: cellulitis, rash, acne, herpes simplex, herpes zoster, skin ulcers
Other: weight loss, edema, infection, fever, chills, flulike syndrome, lymphangitis, hypersensitivity reactions including anaphylaxis, infusion reaction

Interactions
Drug-drug. Anthracyclines, cyclophosphamide: cardiotoxicity

Patient monitoring
● Monitor closely for signs and symptoms of infusion reaction (including respiratory distress). Halt infusion if these occur.
● Monitor vital signs, especially for hypotension and bradycardia.
● Use with extreme caution in patients with cardiac dysfunction. Assess cardiovascular status carefully; stay alert for heart failure and peripheral edema.
● Assess neurologic status for depression and paresthesia.
● Monitor respiratory status. Report increased dyspnea or flulike symptoms.
● Watch closely for signs and symptoms of infection, including herpes simplex.
● Monitor electrolyte levels and CBC with white cell differential.

Patient teaching
● Instruct patient to immediately report difficulty breathing, flulike symptoms, and fever, chills, and other signs and symptoms of infection.
● Advise patient to monitor weight. Tell him to report sudden weight gain as well as swelling and other signs and symptoms of heart failure.
● Instruct patient to immediately report abdominal pain, change in bowel habits, yellowing of skin or eyes, and easy bruising or bleeding.
● Tell patient drug may cause depression. Advise him (or significant other as appropriate) to contact prescriber if this occurs.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

Evaluation
Reactions in bold are life-threatening.

FDA BOXED WARNING
● Drug may increase risk of suicidal thinking and behavior in children and adolescents with major depressive disorder and other psychiatric disorders. Risk must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family and caregivers to observe patient closely and communicate with prescriber as needed.
● Drug isn’t approved for use in pediatric patients.
Action
Unclear. Thought to selectively inhibit serotonin and norepinephrine uptake in brain.

Availability
Tablets: 50 mg, 100 mg, 150 mg, 300 mg

Indications and dosages
➣ Major depression
Adults: 150 mg/day P.O. in three divided doses; may increase by 50 mg/day q 3 to 4 days until desired response occurs. Don’t exceed 400 mg/day in outpatient or 600 mg/day in hospitalized patient.

Dosage adjustment
• Elderly patients

Off-label uses
• Alcohol dependence
• Cocaine withdrawal
• Anxiety neurosis
• Insomnia

Contraindications
• Hypersensitivity to drug
• Recovery period after myocardial infarction

Precautions
Use cautiously in:
• cardiovascular disease, severe hepatic or renal disease, suicidal behavior or ideation
• elderly patients
• pregnant or breastfeeding patients
• children (safety not established).

Administration
• Give after meals or snacks.
• Know that drug is often used in conjunction with psychotherapy.

Rou.te Onset Peak Duration
P.O. 1-2 wk 2-4 wk Wks

Adverse reactions
CNS: drowsiness, confusion, dizziness, fatigue, hallucinations, headache, insomnia, nightmares, slurred speech, syncope, weakness, tremor, suicidal behavior or ideation (especially in child or adolescent)
CV: chest pain, hypotension, hypertension, palpitations, tachycardia, arrhythmias
EENT: blurred vision, tinnitus
GI: nausea, vomiting, diarrhea, constipation, excessive salivation, flatulence, dry mouth
GU: urinary frequency, hematuria, erectile dysfunction, priapism
Hematologic: anemia, leukopenia
Musculoskeletal: myalgia
Skin: rash

Interactions
Drug-drug. Antihypertensives, nitrates: additive hypotension
Digoxin, phenytoin: increased blood levels of these drugs
Fluoxetine: increased trazodone blood level, greater risk of toxicity
Other CNS depressants (such as opioid analgesics, sedative-hypnotics): additive CNS depression
Drug-diagnostic tests. Alkaline phosphatase, bilirubin, glucose: increased levels
Urinary catecholamines: false increases
Urinary 5-hydroxyindole acetic acid, vanillylmandelic acid: decreased levels
Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression
S-adenosylmethionine (SAM-e), St. John’s wort: increased risk of serotonergic effects (including serotonin syndrome)
Drug-behaviors. Alcohol use: additive CNS depression and hypotension

Patient monitoring
• Monitor vital signs and ECG.
• Monitor neurologic status. Report significant adverse reactions.
● Assess patient’s mood frequently. Stay alert for worsening depression and suicidal ideation.
● Watch for drug hoarding or overuse.

**Patient teaching**

● Tell patient to take with meals or snacks to improve drug absorption.
● Instruct patient to take only as prescribed. Caution him not to overuse or hoard drug.
● Advise patient (and significant other as appropriate) to monitor his mood. Explain that drug should ease depression.

**Clinical alert** Caution patient (and parent or significant other) to immediately report suicidal thoughts or behavior, especially in child or adolescent.

● Tell patient drug may cause significant adverse reactions. Instruct him to report priapism, hallucinations, fainting spells, and other serious problems.
● Instruct patient not to drink alcohol during drug therapy.
● Tell patient that many common herbs worsen drug’s adverse reactions. Tell him to consult prescriber before taking these products.
● Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, and alertness. Reassure him that dizziness and drowsiness usually subside after first few weeks.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

---

**treprostinil sodium**

**Remodulin**

**Pharmacologic class:** Synthetic prostacyclin analog

**Therapeutic class:** Antiplatelet agent, vasodilator

**Pregnancy risk category B**

**Action**

Dilates pulmonary and systemic arterial vascular beds, reducing right and left ventricular afterload and increasing cardiac output and stroke volume. Also inhibits platelet aggregation.

**Availability**

*Injection:* 1 mg/ml, 2.5 mg/ml, 5 mg/ml, 10 mg/ml

**Indications and dosages**

To diminish exercise-induced symptoms of pulmonary artery hypertension (PAH) in patients with NYHA class II-IV symptoms

**Adults:** Initially, 1.25 ng/kg/minute by continuous subcutaneous infusion; if initial dose isn’t tolerated, reduce infusion rate to 0.625 ng/kg/minute. For maintenance, may increase infusion rate in increments of no more than 1.25 ng/kg/minute q week for first 4 weeks, then in increments of no more than 2.5 ng/kg/minute q week, if needed. Maximum dosage is 40 ng/kg/minute.

**Dosage adjustment**

● Hepatic insufficiency

**Contraindications**

● Hypersensitivity to drug, its components, or structurally related compounds

**Precautions**

Use cautiously in:

● renal disease
● history of hepatic disease

Reactions in **bold** are life-threatening. **Clinical alert**
• elderly patients
• pregnant or breastfeeding patients
• children.

Administration

Give first dose in setting where resuscitation equipment is available and other health care personnel can assist if an emergency arises.

Administer by continuous subcutaneous infusion through subcutaneous catheter with infusion pump made specifically for subcutaneous infusions.

Expect to adjust dosage for first 6 to 12 weeks as prescriber balances symptom improvement against adverse reactions.

Don’t stop infusion abruptly (may worsen PAH).

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcut.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: dizziness, headache, anxiety, restlessness
CV: vasodilation, edema, hypotension
EENT: jaw pain
GI: nausea, vomiting, diarrhea
Skin: rash, pruritus
Other: infusion site pain or reaction (such as erythema, rash, induration)

Interactions

Drug-drug. Anticoagulants: increased risk of bleeding
Antihypertensives, diuretics, other vasodilators: increased risk of hypotension
Vitamin A: increased risk of bleeding

Drug-herbs. Alfalfa, anise, arnica, astragalus, bilberry, black currant seed oil, bladderwrack, bogbean, boldo (with fenugreek), borago oil, buchu, capsaicin, cat’s claw, celery, chaparral, chincona bark, clove oil, dandelion, dong quai, evening primrose oil, fenugreek, feverfew, garlic, ginger, ginkgo, guggul, papaya extract, red clover, rhubarb, safflower oil, skullcap, tan-shen: increased risk of bleeding

Patient monitoring

Especially after first dose, watch closely for severe vasodilation leading to chest pain and hypotension. These signs and symptoms call for emergency measures.

Monitor vital signs. Assess carefully for indications of right ventricular failure.

Assess neurologic status. Institute safety measures as needed to prevent injury.

Watch for infusion site reaction.

Patient teaching

Tell patient drug is a long-term measure to control PAH and requires a commitment to maintain infusion system.

Instruct patient to immediately report signs and symptoms of infusion site reaction (such as redness, rash, and hardened tissue).

Teach patient which symptoms reflect underlying disease and which may reflect adverse reactions that he should report.

As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and herbs mentioned above.

tretinoin

Atralin, Avita, Renova, Retin-A, Retin-A Micro, Vesanoid

Pharmacologic class: Retinoid
Therapeutic class: Antineoplastic, dermatologic agent (topical)
Pregnancy risk category C (topical), D (oral)
Patients with acute promyelocytic leukemia (APL) are at high risk in general and may have severe adverse reactions. Give drug under supervision of physician experienced in managing patients with acute leukemia, in facility with laboratory and supportive resources sufficient to monitor drug tolerance and protect and maintain patient compromised by drug toxicity.

Before using drug, physician must conclude that possible benefit to patient outweighs the following known adverse effects:

- Retinoic acid-APL (RA-APL syndrome), which may be accompanied by impaired myocardial contractility, hypotension, and progressive hypoxemia. Several patients have died with multiorgan failure. Syndrome generally occurs during first month of therapy (in some cases, after first dose).
- Leukocytosis at presentation or evolving rapidly during drug therapy. Patients with high white blood cell (WBC) at diagnosis (above $5 \times 10^9/L$) have increased risk of further rapid rise in WBC counts. Rapidly evolving leukocytosis raises risk of life-threatening complications.
- Teratogenic effects. Drug therapy during pregnancy carries high risk of severe birth defects. Nonetheless, if drug is best available treatment for pregnant woman or woman of childbearing potential, ensure that she has received full information and warnings of risk to fetus and of risk of possible contraception failure, and has been taught to use two reliable contraceptive methods simultaneously during therapy and for 1 month afterward.

**Action**

Unknown. Thought to cause differentiation of promyelocytic leukemic blast cells, leading to apoptosis (cell shrinkage and death) and cancer remission.

Reactions in **bold** are life-threatening.

### Availability

**Capsules:** 10 mg  
**Topical cream:** 0.02%, 0.025%, 0.05%, 0.1%  
**Topical gel:** 0.01%, 0.025%, 0.04%, 0.1%

### Indications and dosages

➤ APL when anthracycline chemotherapy fails or is contraindicated  
**Adults and children ages 1 and older:** 45 mg/m²/day P.O. in two evenly divided doses. Discontinue after 90 days of therapy or 30 days after complete remission occurs, whichever comes first.  
➤ Acne vulgaris  
**Adults:** Apply Avita cream, Retin-A cream gel, or Retin-A Micro gel daily before bedtime or in evening. Cover entire affected area lightly.  
➤ Adjunct for mitigating fine wrinkles in patients who use comprehensive skin care and sun avoidance programs  
**Adults:** Apply Renova 0.02% cream to face daily in evening for up to 52 weeks, using only enough to lightly cover entire affected area.  
➤ Adjunct for mitigating fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin when comprehensive skin care and sun avoidance programs alone fail  
**Adults ages 50 and younger:** Apply Renova 0.05% cream to face daily in evening for up to 48 weeks, using only enough to lightly cover entire affected area.

### Contraindications

- Hypersensitivity to drug or parabens  
- Pregnancy or breastfeeding (oral use)

### Precautions

Use cautiously in:  
- eczema, sunburn, photosensitivity  
- concurrent use of over-the-counter (OTC) acne products or abrasive soaps or cleansers with strong drying effects
or high alcohol or lime content (with all topical forms)

- concurrent use of astringents, spices, permanent wave solutions, electrolysis, hair depilatories or waxes, or photosensitizing drugs (such as fluoroquinolones, phenothiazines, tetracyclines, thiazides)
- heavily pigmented, elderly, pregnant, or breastfeeding patients (safety and efficacy not established for topical use)
- children younger than age 1 for oral use or younger than age 18 for topical use (safety and efficacy not established).

Administration

- Verify that female patient has had required pregnancy test before P.O. therapy starts.
- Know that Renova topical cream isn’t indicated for acne vulgaris, and that other topical forms are indicated only for acne vulgaris. Also know that some absorption of topical products occurs.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1-2 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>Topical</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: dizziness, headache, asthenia, paresthesia, confusion, agitation, hallucinations, anxiety, apathy, depression, agnosia, insomnia, asthenia, cerebellar edema, hypotaxia, drowsiness, slow speech, facial paralysis, hemiplegia, hyporeflexia, hypotaxia, dementia, spinal cord disorder, tremors, dysarthria, cerebrovascular accident (CVA), coma, seizures, intracranial hypertension, cerebral hemorrhage

CV: heart murmur, chest discomfort, peripheral edema, hypertension, hypotension, phlebitis, edema, enlarged heart, ischemia, arrhythmias,

secondary cardiomyopathy, myocarditis, myocardial infarction (MI), heart failure, pericardial effusion, impaired myocardial contractility, progressive hypoxemia

EENT: vision disturbances, visual acuity changes, visual field defect, absence of light reflex, hearing loss, earache, full sensation in ears

GI: nausea, vomiting, constipation, diarrhea, abdominal pain and distention, GI disorders, mucositis, dyspepsia, ulcer, anorexia, GI hemorrhage

GU: dysuria, urinary frequency, enlarged prostate, renal insufficiency, renal tubular necrosis, acute renal failure

Hematologic: leukocytosis, disseminated intravascular coagulation (DIC), hemorrhage

Hepatic: ascites, hepatosplenomegaly, hepatitis

Metabolic: fluid imbalance, acidosis

Musculoskeletal: bone pain or inflammation, myalgia, flank pain

Respiratory: respiratory tract disorders, dyspnea, expiratory wheezing, crackles, pneumonia, laryngeal edema, pulmonary infiltrates, pleural effusion, bronchial asthma, pulmonary hypertension

Skin: rash; pallor; flushing; diaphoresis; alopecia; dry skin and mucous membranes; skin changes; pruritus; cellulitis; burning, erythema, peeling, and stinging (with topical use)

Other: weight changes, fever, lymphatic disorder, hypothermia, infections, facial edema, pain, RA-APL syndrome, multisystem failure, septicemia

Interactions

Drug-drug. Photosensitizing drugs (such as fluoroquinolones, phenothiazines, tetracyclines, thiazides): increased risk of photosensitivity reaction (with topical forms)

Drug-diagnostic tests. Cholesterol, triglycerides: increased levels
Drug-food. *Any food:* enhanced tretinoin absorption

Drug-behaviors. *Sun exposure:* increased risk of photosensitivity

Patient monitoring
- Watch closely for septicemia, multisystem failure, and retinoic acid-APL syndrome (which causes pulmonary and pericardial effusion, fever, weight gain, and dyspnea).
- Monitor for significant adverse CNS reactions, including seizures, CVA, and cerebral hemorrhage.
- Closely monitor liver and kidney function tests. Watch for evidence of hepatitis and renal failure.
- Monitor coagulation studies. Watch closely for DIC and hemorrhage.
- Evaluate respiratory status. Stay alert for indications of pulmonary hypertension and respiratory insufficiency.
- Frequently assess lipid panel and CBC with white cell differential.

Patient teaching
- Instruct patient to take oral doses with food.
- Teach patient to recognize and immediately report serious adverse reactions.
- Tell patient he will undergo regular blood testing during oral therapy.
- Instruct patient using topical form to gently wash face with mild soap, pat skin dry, and then wait 20 to 30 minutes before applying. Advise him to apply to face in evening, using only enough to cover entire affected area lightly and only for prescribed duration.
- Caution patient to avoid OTC acne drugs and extreme weather conditions (such as wind and cold). Urge him to adhere to prescribed skin care and sunlight avoidance programs when using topical form.
- Tell patient using topical form that transient burning, erythema, peeling, pruritus, and stinging may occur. Advise him to notify prescriber if these symptoms become severe.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and behaviors mentioned above.

---

triamcinolone

triamcinolone acetonide
Adcortyl®, Azmacort Inhalation Aerosol, Kenalog, Kenalog-10, Kenalog-40, Nasacort AQ, Triaderm®

triamcinolone hexacetonide
Aristospan Intra-Articular, Aristospan Intraleisonal

Pharmacologic class: Synthetic corticosteroid
Therapeutic class: Anti-inflammatory (steroidal)
Pregnancy risk category C

Action
Unknown. Thought to decrease inflammation mainly by inhibiting activities of mast cells, macrophages, and other mediators of allergic reactions. Also suppresses immune system by depressing lymphatic activity.

Availability
triamcinolone
Tablets: 1 mg, 2 mg, 4 mg, 8 mg

Reactions in bold are life-threatening.
triamcinolone acetonide
Cream: 0.025%, 0.1%, 0.5%
Inhalation aerosol (intranasal): 55 mcg/inhalation (metered spray) in 20-g canister (240 metered inhalations)
Inhalation aerosol (oral): 100 mcg/inhalation (metered spray)
Injectable suspension: 3 mg/ml, 10 mg/ml, 40 mg/ml
Lotion: 0.025%, 0.1%
Ointment: 0.025%, 0.1%, 0.5%
Solution: 50 mcg/metered spray
Suspension: 55 mcg/metered spray

triamcinolone diacetate
Injectable suspension: 25 mg/ml, 40 mg/ml

triamcinolone hexacetonide
Injectable suspension: 5 mg/ml, 20 mg/ml

Indications and dosages
➣ Allergic rhinitis
Adults and children older than age 12:
8 to 12 mg (tablets) P.O. daily. Or 110 mcg (two sprays of inhalation aerosol or acetonide suspension) in each nostril daily; may increase to 220 mcg (four sprays) in each nostril daily (110 mcg b.i.d. or 55 mcg q.i.d.). Or 100 mcg (two sprays of acetonide solution) in each nostril daily; may increase to 400 mcg (four sprays) in each nostril daily or two sprays in each nostril b.i.d.
Children ages 6 to 12: 55 mcg (one spray of inhalation aerosol or acetonide suspension) in each nostril daily
➣ Chronic asthma
Adults and children older than age 12:
Two metered inhalations three to four times daily or four metered inhalations b.i.d. (100 mcg/metered inhalation), not to exceed 16 inhalations/day
Children ages 6 to 12: One to two metered inhalations three to four times daily or two to four metered inhalations b.i.d. (100 mcg/metered inhalation), not to exceed 12 inhalations/day
➣ Severe inflammation; immunosuppression

Adults and children older than age 12:
4 to 48 mg (tablets) P.O. daily in one to four divided doses. Or 60 mg (acetonide) I.M. at 6-week intervals. For intralesional or sublesional use, 1 mg at each injection site, repeated one or more times weekly; for intra-articular, intrasynovial, or soft-tissue injection, 2.5 to 40 mg, repeated when symptoms recur. Or 200 mcg (two sprays of acetonide inhalation aerosol) three to four times daily. Or 40 mg (diacetate) I.M. weekly. Or 5 to 48 mg (diacetate) by intralesional or sublesional injection, not to exceed 75 mg/week intralesionally. Or 2 to 40 mg (diacetate) by intra-articular, intrasynovial, or soft-tissue injection; may repeat at 1- to 8-week intervals. Or 0.5 mg/square inch of affected skin (hexacetonide) by intralesional or sublesional injection or 2 to 20 mg by intra-articular injection; may repeat at 3- to 4-week intervals.
Children ages 6 to 12: 100 or 200 mcg (one or two sprays of acetonide inhalation aerosol) three to four times daily, or 0.03 to 0.2 mg/kg or 1 to 6.25 mg/m² I.M. at intervals of 1 to 7 days
➣ Corticosteroid-responsive dermatoses
Adults and children older than age 12:
Apply cream, ointment, or lotion sparingly to affected area two to four times daily.
➣ Adrenocortical insufficiency
Adults and children older than age 12:
4 to 12 mg (tablets) P.O. daily, used with mineralocorticoid therapy
➣ Rheumatic disorders; dermatologic disorders; severe psoriasis
Adults and children older than age 12:
8 to 16 mg (tablets) P.O. daily
➣ Systemic lupus erythematosus
Adults and children older than age 12:
Initially, 20 to 32 mg (tablets) P.O. daily, continued until desired response occurs. Severe symptoms may warrant initial dosage of 48 mg.
➣ Acute rheumatic carditis

Canada UK Hazardous drug High alert drug
Adults and children older than age 12:
Initially, 20 to 60 mg (tablets) P.O. daily (usually given with anti-infectives and salicylates) until desired clinical response occurs. Then dosage may be reduced to maintenance level and continued for 6 weeks or up to 3 months.  
➢ Ophthalmic inflammatory diseases; sympathetic ophthalmia

Adults and children older than age 12:
12 to 40 mg (tablets) P.O. daily, depending on severity of condition and degree of ocular structure involvement. Response is usually rapid and length of therapy is usually brief.  
➢ Respiratory diseases, tuberculous meningitis, nephrotic syndrome

Adults and children older than age 12:
16- to 48-mg tablets P.O. daily; or 32- to 48-mg tablets P.O. daily in divided doses in tuberculous meningitis. For tuberculosis, give with antitubercular therapy, as prescribed.  
➢ Thrombocytopenia (in adults); autoimmune hemolytic anemia; erythroblastopenia; congenital hypoplastic anemia

Adults and children older than age 12:
16 to 60 mg (tablets) P.O. daily. Reduce dosage after adequate response.  
➢ Palliative therapy in acute leukemia of childhood

Children: 1 to 2 mg/kg (tablets) P.O. daily, with expected initial response occurring in 6 to 21 days. Therapy usually continues for 4 to 6 weeks.  
➢ Palliative therapy in acute leukemia or lymphoma in adults

Adults: 16 to 40 mg P.O. daily; may increase to 100 mg daily in leukemia

Contraindications
➢ Idiopathic thrombocytopenic purpura (I.M. use)
➢ Administration of live-virus vaccines (with immunosuppressant doses of triamcinolone)

Precautions
Use cautiously in:
➢ active untreated infection, systemic infection, immunosuppression, hypertension, osteoporosis, diabetes mellitus, glaucoma, renal disease, hypothyroidism, cirrhosis, diverticulitis, nonspecific ulcerative colitis, recent intestinal anastomoses, thromboembolic disorders, seizures, myasthenia gravis, heart failure, ocular herpes simplex, emotional instability
➢ pregnant or breastfeeding patients
➢ children younger than age 6 (safety not established).

Administration
➢ Don’t withdraw systemic corticosteroids abruptly when patient begins inhalation steroid therapy.
➢ Know that patient will need additional steroids during times of stress or trauma.
➢ Use hand-held nebulizer supplied with aerosol form.
➢ Apply cream, lotion, or ointment sparingly. Know that triamcinolone is a high-potency steroid; it can be absorbed systemically and should not be withdrawn abruptly.
➢ Avoid intralesional injection to face or head (may cause blindness).
➢ Don’t apply topical form near eyes.
➢ Know that occlusive dressing may be used with topical form when treating psoriasis or other recalcitrant conditions, but should be removed if infection occurs.

Reactions in bold are life-threatening.
Adverse reactions

**CNS:** headache, vertigo, paresthesia, syncope, personality changes, pseudotumor cerebri, seizures

**CV:** hypertension, thrombophlebitis, arrhythmias, thromboembolism, heart failure

**EENT:** cataract, glaucoma, increased intraocular pressure, exophthalmos, otitis, nasal or sinus congestion, rhinitis, epistaxis, sneezing, dry mucous membranes, pharyngitis, throat discomfort

**GI:** nausea, vomiting, dyspepsia, abdominal distention or pain, peptic ulcer, ulcerative esophagitis, oral candidiasis, dry mouth, pancreatitis

**GU:** cystitis, urinary tract infection, glycosuria, menstrual irregularities, vaginal candidiasis

**Metabolic:** fluid retention, hypernatremia, hypokalemia, hyperglycemia, hypocalcemia, decreased growth (in children), carbohydrate intolerance, exacerbation of latent diabetes mellitus, cushingoid appearance (moon face, buffalo hump), hypokalemic alkalosis, acute adrenal insufficiency (with abrupt withdrawal or acute stress in long-term use)

**Musculoskeletal:** muscle weakness; steroid myopathy; loss of muscle mass; myalgia; bursitis; tenosynovitis; osteoporosis; fractures; aseptic necrosis; with intra-articular injection—osteonecrosis, tendon rupture, post-injection flare

**Respiratory:** cough, wheezing, chest congestion

**Skin:** delayed wound healing; thin and fragile skin; petechiae; bruising; with topical use—local eruptions, pruritus, hypopigmentation or hyperpigmentation, scarring, stinging, skin maceration, secondary infection, cutaneous or subcutaneous atrophy, diaphoresis, facial erythema

**Other:** toothache, weight gain, fever, pain, voice alteration, hypersensitivity reaction

Interactions

**Drug-drug.** Erythromycin, indinavir, itraconazole, ketoconazole, ritonavir, saquinavir: increased triamcinolone blood level and effects

Fluoroquinolones: increased risk of tendon rupture

Live-virus vaccines: decreased antibody response to vaccine

Nonsteroidal anti-inflammatory drugs (including aspirin): increased risk of adverse GI reactions

Potassium-wasting drugs (including amphotericin B, thiazide and loop diuretics, mezlocillin, piperacillin, ticarcillin): additive hypokalemia

**Drug-diagnostic tests.** Cholesterol: increased level

**Skin tests:** suppressed reaction

Patient monitoring

- Monitor respiratory status. Watch for worsening signs and symptoms.
- With long-term use, assess for adverse endocrine and musculoskeletal reactions.
- Monitor carefully for signs and symptoms of infection, which drug may mask.

Patient teaching

- Teach patient correct use of drug.
- Make sure he has received manufacturer’s patient information sheet.
- Advise patient to contact prescriber immediately if acute asthma attack.
occurs. Tell him inhalation aerosol isn’t meant for rapid relief of bronchospasm.

- Inform patient that drug can affect many body systems. Urge him to report serious adverse effects promptly.
- Tell parents drug may make child more vulnerable to childhood infections, such as chicken pox and measles.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

---

**triamterene**
Dyrenium, Dytac

**Pharmacologic class:** Potassium-sparing diuretic  
**Therapeutic class:** Diuretic  
**Pregnancy risk category B**

---

**FDA BOXED WARNING**

- Abnormal serum potassium elevation may occur, and is more likely in patients with renal impairment or diabetes and in elderly or severely ill patients. As uncorrected hyperkalemia may be fatal, monitor serum potassium levels frequently, especially when dosage is changed or patient has an illness that may influence renal function.

---

**Action**
Depresses sodium resorption and potassium excretion in renal distal tubule

---

**Availability**
Capsules: 50 mg, 100 mg

---

**Indications and dosages**

- **Edema**
  - **Adults:** 100 mg P.O. b.i.d. Do not exceed 300 mg/day.

---

**Dosage adjustment**
- Concurrent antihypertensive drug therapy
- Elderly patients

---

**Off-label uses**
- Diabetes insipidus

---

**Contraindications**
- Hypersensitivity to drug
- Hyperkalemia
- Severe hepatic disease
- Anuria, severe renal dysfunction (except nephrosis)
- Concurrent use of other potassium-sparing diuretics or potassium supplements

---

**Precautions**
Use cautiously in:
- hepatic dysfunction, renal insufficiency, diabetes mellitus
- history of gout or renal calculi
- elderly or debilitated patients
- pregnant or breastfeeding patients
- children (safety not established).

---

**Administration**
- Give after meals.
- Know that drug may be used alone or as adjunct to thiazide or loop diuretics.
- Make sure patient stops taking potassium supplements before starting triamterene.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>2-4 hr</td>
<td>Unknown</td>
<td>12-16 hr</td>
</tr>
</tbody>
</table>

---

**Adverse reactions**
- CNS: headache, fatigue, asthenia, dizziness
- GI: nausea, vomiting, diarrhea, dry mouth
- GU: azotemia, renal calculi
- Hematologic: megaloblastic anemia, thrombocytopenia
- Hepatic: jaundice
- Metabolic: hyperglycemia, hyperkalemia, metabolic acidosis

Reactions in **bold** are life-threatening.
Skin: rash, photosensitivity
Other: anaphylaxis

Interactions
Drug-drug. Amantadine: increased amantadine blood level, greater risk of toxicity
Angiotensin-converting enzyme inhibitors, cyclosporine, indomethacin, potassium-sparing diuretics, potassium supplements, other potassium-containing preparations: increased risk of hyperkalemia
Antihypertensives, nondepolarizing muscle relaxants, other diuretics, pre-anesthetic and anesthetic agents: potentiated effects of these drugs
Chlorpropamide: increased risk of hyponatremia
Cimetidine: increased bioavailability and decreased renal clearance of triamterene
Indomethacin: increased risk of acute renal failure
Lithium: decreased lithium clearance, greater risk of lithium toxicity
Drug-diagnostic tests. Alkali reserves, hemoglobin, platelets: decreased values
Blood urea nitrogen (BUN), creatinine, glucose, hepatic enzymes, potassium: increased levels
Liver function tests: increased values
Quinidine blood level: interference with fluorescent measurement
Drug-food. Salt substitutes containing potassium: increased risk of hyperkalemia
Drug-herbs. Gossypol, licorice: increased risk of hypokalemia

Patient monitoring
- Monitor BUN, creatinine, and electrolyte levels. Stay alert for hyperkalemia.
- Assess CBC with white cell differential.

Patient teaching
- Advise patient to take after meals to reduce nausea.
- Instruct patient to take last daily dose in early evening to avoid nocturia.
- Teach patient to recognize and report signs and symptoms of electrolyte imbalances.
- Tell patient to avoid salt substitutes. Advise him not to use herbs without consulting prescriber.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.
Contraindications
- Hypersensitivity to drug or other benzodiazepines
- Concurrent use of itraconazole, ketoconazole, or nefazodone
- Pregnancy

Precautions
Use cautiously in:
- hepatic or renal dysfunction, sleep apnea, respiratory compromise, psychosis
- history of suicide attempt or drug abuse
- elderly or debilitated patients
- breastfeeding patients
- children younger than age 18 (safety and efficacy not established).

Administration
- Don’t give with grapefruit juice.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>15-30 min</td>
<td>2 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, excessive sedation, hangover, headache, anterograde or traveler’s amnesia, confusion, incoordination, lethargy, depression, paradoxical excitation, light-headedness, psychological disturbance, euphoria
GI: nausea, vomiting
Other: physical or psychological drug dependence, drug tolerance, withdrawal symptoms (tremor, abdominal and muscle cramps, vomiting, diaphoresis, dysphoria, perceptual disturbances, insomnia)

Interactions
Drug-drug. Antidepressants, antihistamines, chloral hydrate, opioid analgesics, other psychotropic drugs: additive CNS depression
Cimetidine, disulfiram, fluconazole, hormonal contraceptives, isoniazid, itraconazole, ketoconazole, nefazodone, rifampin, and other drugs that inhibit CYP450-3A4–mediated metabolism: decreased oxidative metabolism and increased action of triazolam
Digoxin: increased digoxin blood level, greater risk of toxicity
Macrolide anti-infectives (such as azithromycin, clarithromycin, erythromycin): increased triazolam bioavailability
Probucol: rapid onset and prolonged effects of triazolam
Ranitidine: increased triazolam blood level
Theophylline: decreased sedative effect of triazolam

Drug-food. Grapefruit juice: increased triazolam blood level and effects

Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression

Drug-behaviors. Alcohol use: increased CNS depression
Smoking: increased triazolam clearance

Patient monitoring
- Monitor neurologic status. Watch for paradoxical or rebound drug effects.
- Observe for signs of drug hoarding and drug abuse.

Patient teaching
- Tell patient to take at bedtime with a liquid other than grapefruit juice.
- Explain that drug is meant only for short-term use (7 to 10 days).
- Tell patient rebound insomnia may occur for 1 to 2 nights after he discontinues drug.
- Instruct patient to avoid alcohol use and smoking.
- Caution patient to avoid driving and other hazardous activities while under drug’s influence.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, foods, herbs, and behaviors mentioned above.

Reactions in bold are life-threatening.
trifluoperazine hydrochloride

Apo-Trifluoperazine®, Novo-Trifluazine®, PMS-Trifluoperazine®, Terfluzine®

**Pharmacologic class:** Piperazine phenothiazine  
**Therapeutic class:** Antipsychotic  
**Pregnancy risk category C**

**Action**  
Unknown. Thought to act on subcortical levels of hypothalamic and limbic systems by producing antidopaminergic effects. Also lowers seizure threshold and exhibits some adrenergic, muscarinic, and anticholinergic activity.

**Availability**  
*Injection:* 2 mg/ml in 10-ml vials  
*Oral solution:* 10 mg/ml in 60-ml bottles  
*Tablets:* 1 mg, 2 mg, 5 mg, 10 mg, 20 mg

**Indications and dosages**

- **Schizophrenia**
  - **Adults:** 2 to 5 mg P.O. b.i.d.; may increase gradually to obtain adequate response. Usual maintenance dosage is 15 to 20 mg/day. For prompt control of severe symptoms, 1 to 2 mg I.M. q 4 to 6 hours; some patients may need more than 6 mg/day.  
  - **Children ages 6 to 12:** Initially, 1 mg P.O. once or twice daily in hospitalized patients or those under close supervision; may increase gradually up to 15 mg/day P.O. until symptoms are controlled or adverse reactions are intolerable. For prompt control of severe symptoms, 1 mg I.M. once or twice daily.

- **Nonpsychotic anxiety**
  - **Adults:** 1 to 2 mg P.O. b.i.d. Do not exceed 6 mg/day or 12 weeks’ duration.

**Dosage adjustment**
- Hepatic disease  
- Elderly or debilitated patients

**Contraindications**
- Hypersensitivity to drug, other phenothiazines, or bisulfites  
- Severe hepatic disease  
- Bone marrow depression  
- Blood dyscrasias  
- Coma  
- Concomitant use of other CNS depressants in high doses

**Precautions**
Use cautiously in:
- seizure disorders, cardiovascular disorders, GI obstruction, glaucoma, retinopathy  
- elderly or debilitated patients  
- pregnant or breastfeeding patients.

**Administration**
- Mix oral solution in at least 60 ml of liquid or semisolid food just before giving.  
- Administer I.M. injection deep into muscle.  
- Know that parenteral solution should be colorless to pale yellow; discard if it’s markedly discolored.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2-4 hr</td>
<td>12-24 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>4-6 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- CNS: sedation, dizziness, drowsiness, insomnia, fatigue, extrapyramidal effects, neuroleptic malignant syndrome  
- CV: tachycardia, hypotension, orthostatic hypotension, peripheral edema, prolonged QT interval, torsades de pointes  
- EENT: dry eyes, blurred vision, miosis, mydriasis, epithelial keratopathy, pigmentary retinopathy

*Canada* *UK* *Hazardous drug* *High alert drug*
GI: constipation, biliary stasis, dry mouth, anorexia, **dynamic ileus**

GU: urinary retention, glycosuria, amenorrhea, ejaculatory disorders, galactorrhea, gynecomastia

Hematologic: leukopenia, agranulocytosis

Hepatic: cholestatic jaundice

Musculoskeletal: muscle weakness

Skin: photosensitivity, altered pigmentation, erythema, rash

Other: mild fever, weight gain, allergic reaction

**Interactions**

**Drug-drug.** Alpha-adrenergic blockers: additive effect

*Antacids containing aluminum:* decreased trifluoperazine absorption

*Anticholinergics, anticholinergic-like drugs (including antidepressants, antihistamines, disopyramide, other phenothiazines, quinidine):* additive anticholinergic effects

*Anticonvulsants:* decreased seizure threshold

*Antihistamines, CNS depressants, general anesthetics, opioids, sedative-hypnotics:* additive CNS depression

*Barbiturates:* decreased blood levels of both drugs

*Guanethidine:* decreased antihypertensive effect

*Lithium:* increased risk of extrapyramidal reactions, disorientation, and unconsciousness

*Oral anticoagulants:* decreased anticoagulant effect

*Phenytoin:* interference with phenytoin metabolism, causing phenytoin toxicity

*Propranolol:* increased blood levels of both drugs

*Thiazide diuretics:* additive orthostatic hypotension

**Drug-diagnostic tests.** **Hepatic enzymes:** increased levels

*Phenylketonuria test:* false-positive result

*Prolactin:* increased level, causing interference with gonadotropin tests

*Urine bilirubin:* false-positive result

**Drug-herbs.** *St. John's wort:* increased risk of photosensitivity

**Drug-behaviors.** *Alcohol use:* additive CNS depression and hypotension

*Sun exposure:* increased risk of photosensitivity

**Patient monitoring**

- Monitor ECG and blood pressure. Watch closely for hypotension.
- Assess CBC (including platelet count) and liver function tests. Stay alert for signs and symptoms of hepatic damage and blood dyscrasias.

- Monitor neurologic status, especially for indications of neuroleptic malignant syndrome (unstable blood pressure, high fever, sweating, stupor, muscle rigidity, and autonomic dysfunction).

**Patient teaching**

- Instruct patient taking oral solution to add solution to 60 ml or more of liquid (tomato or fruit juice, milk, carbonated beverage, coffee, tea, or water) or semisolid food (such as soup or pudding) just before taking.
- Tell patient that drug’s full effect usually occurs in 1 to 2 weeks.
- Instruct patient to move slowly when sitting up or standing, to avoid dizziness from sudden blood pressure drop.
- Teach patient to recognize and immediately report signs and symptoms of neuroleptic malignant syndrome.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects him.
- Tell patient to avoid alcohol and certain herbs.
- Advise patient to avoid sun exposure and to wear sunscreen and protective clothing when going outdoors.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

Reactions in **bold** are life-threatening.
trihexyphenidyl hydrochloride
Apo-Trihex®, Broflex®, PMS-Trihexyphenidyl®

Pharmacologic class: Anticholinergic
Therapeutic class: Antidyskinetic
Pregnancy risk category C

Action
Inhibits parasympathetic nervous system, relaxing smooth muscles and decreasing involuntary movements

Availability
Capsules (sustained-release): 5 mg
Elixir: 2 mg/5 ml
Tablets: 2 mg, 5 mg

Indications and dosages
➣ Adjunct in idiopathic, postencephalic, or arteriosclerotic parkinsonism
Adults: 1 mg P.O. on first day; may increase in 2-mg increments q 3 to 5 days, up to a maximum of 6 to 10 mg/day. In postencephalitic parkinsonism, 12 to 15 mg P.O. daily. May give sustained-release form (Artane Sequels) in same dosage as conventional form, as a single dose or in two divided doses q 12 hours after daily dosage is determined using conventional tablets or liquid.
➣ Drug-induced extrapyramidal symptoms
Adults: Initially, 1 mg P.O. daily, increased progressively if extrapyramidal symptoms aren’t controlled within several hours. Usual dosage range is 5 to 15 mg/day P.O. in divided doses.

Dosage adjustment
● Concurrent use of levodopa or other parasympathetic inhibitor
● Elderly patients

Off-label uses
● Dystonia

Contraindications
● Hypersensitivity to drug, its components, or alcohol (elixir only)
● Angle-closure glaucoma
● Pyloric or duodenal obstruction
● Stenosing peptic ulcer
● Megacolon
● Prostatic hypertrophy or bladder-neck obstruction
● Achalasia
● Myasthenia gravis

Precautions
Use cautiously in:
● chronic renal, hepatic, pulmonary, or cardiac disease; hypertension; tachycardia secondary to cardiac insufficiency; hyperthyroidism
● elderly patients
● pregnant or breastfeeding patients
● children (safety not established).

Administration
● Give with meals. However, if drug causes severe dry mouth, give before meals.
● Administer last dose at bedtime.
● Know that sustained-release capsules shouldn’t be used for initial therapy because of their greater strength. Once patient is stabilized on conventional form, he may be switched to sustained-release capsules on basis of milligram-per-milligram of total daily dosage.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1 hr</td>
<td>2-3 hr</td>
<td>6-12 hr</td>
</tr>
<tr>
<td>P.O. (sustained)</td>
<td>Unknown</td>
<td>Unknown</td>
<td>12-24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, nervousness, drowsiness, asthenia, headache
CV: orthostatic hypotension, tachycardia
EENT: blurred vision, mydriasis, increased intraocular pressure (IOP),
angle-closure glaucoma (with long-term use)
GI: nausea, vomiting, constipation, dry mouth
GU: urinary hesitancy or retention

**Interactions**

**Drug-drug.** Amantadine, other anticholinergics (including disopyramide, phenothiazines, quinidine, tricyclic antidepressants): additive anticholinergic effects
Other CNS depressants (such as antihistamines, opioids, sedative-hypnotics): additive CNS depression
Phenothiazines: decreased phenothiazine effects

**Drug-herbs.** Angel’s trumpet, jimsonweed, scopolia: increased anticholinergic effects

**Drug-behaviors.** Alcohol use: additive CNS depression

**Patient monitoring**
- With prolonged use, monitor vision and IOP regularly.
- Assess drug efficacy to help guide dosage titration.
- Monitor vital signs. Watch for orthostatic hypotension.
- Closely monitor fluid intake and output. Stay alert for urinary retention.

**Patient teaching**
- Instruct patient to take with meals or, if severe dry mouth occurs, before meals.
- Tell patient drug has a bitter taste, which may be followed by numbness and tingling in mouth.
- Stress importance of follow-up eye exams.
- Instruct patient to consult prescriber before taking over-the-counter preparations or herbs.
- Advise patient to avoid alcohol and hazardous activities during drug therapy.
- Tell patient to move slowly when sitting up or standing, to avoid dizziness from sudden blood pressure decrease.
- As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, herbs, and behaviors mentioned above.

**Trimethobenzamide hydrochloride**

**Tigan**

**Pharmacologic class:** Anticholinergic

**Therapeutic class:** Antiemetic

**Pregnancy risk category C**

**Action**
Unclear. Thought to block dopamine receptors and emetic impulses in chemoreceptor trigger zone, preventing nausea and vomiting.

**Availability**
Capsules: 100 mg, 250 mg, 300 mg
Injection: 100 mg/ml in 2-ml ampules and prefilled syringes and in 20-ml vials

**Indications and dosages**

- **Nausea and vomiting**
  - **Adults:** 250 mg P.O. three to four times daily or 200 mg I.M. three to four times daily
  - **Children weighing 13.6 to 40.8 kg (30 to 90 lb):** 100 to 200 mg P.O. three to four times daily

**Contraindications**
- Hypersensitivity to drug
- Parenteral form in children

**Precautions**
Use cautiously in:
- arrhythmias, encephalitis, gastroenteritis, dehydration, electrolyte imbalances
- elderly or debilitated patients

Reactions in **bold** are life-threatening.
• pregnant or breastfeeding patients
• children with known or suspected viral illnesses.

**Administration**
• In I.M. use, inject deep into upper outer quadrant of gluteus maximus.
• Withhold drug in children with signs or symptoms of Reye’s syndrome.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>10-40 min</td>
<td>Unknown</td>
<td>3-4 hr</td>
</tr>
<tr>
<td>I.M.</td>
<td>15-35 min</td>
<td>Unknown</td>
<td>2-3 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
**CNS:** drowsiness, dizziness, headache, depression, disorientation, parkinsonian symptoms, coma, seizures
**CV:** hypotension
**EENT:** blurred vision
**Hematologic:** blood dyscrasias
**Hepatic:** jaundice
**Musculoskeletal:** muscle cramps, opisthotonos
**Skin:** rash, urticaria, flushing
**Other:** pain and stinging at I.M. injection site, hypersensitivity reaction

**Interactions**
**Drug-drug.** Antidepressants, antihistamines, CNS depressants, opioids, sedative-hypnotics: additive CNS depression
**Drug-behaviors.** Alcohol use: additive CNS depression

**Patient monitoring**
• Monitor neurologic status, especially for parkinsonian symptoms and other serious adverse reactions.
• Assess CBC and liver function tests. Watch for blood dyscrasias and jaundice.
• Evaluate injection site for pain and stinging.
• Closely monitor patient’s nutritional and hydration status. Report continuing nausea.

Patient teaching
• Advise patient to take as needed for nausea and vomiting, but only as prescribed.
• Tell patient to contact prescriber promptly if nausea persists despite therapy.
• Instruct patient to minimize nausea and vomiting by eating small, frequent servings of healthy food and drinking plenty of fluids.
• Advise patient to avoid alcohol.
• Caution patient to avoid driving and other hazardous activities until drug effects are known.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and behaviors mentioned above.

**trimipramine maleate**
Apo-Trimip®, Novo-Tripramine®, Nu-Trimipramine, Surmontil

**Pharmacologic class:** Dibenzazepine derivative tricyclic
**Therapeutic class:** Tricyclic antidepressant

**Pregnancy risk category C**
**FDA BOXED WARNING**
• Drug may increase risk of suicidal thinking and behavior in children and adolescents with major depressive disorder and other psychiatric disorders. Risk must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family and caregivers to observe patient closely and communicate with prescriber as needed.
Drug isn’t approved for use in pediatric patients.

Action
Unknown. Thought to inhibit presynaptic norepinephrine and serotonin reuptake at CNS and peripheral receptors, causing increased synaptic concentrations of these neurotransmitters.

Availability
Capsules: 25 mg, 50 mg, 100 mg

Indications and dosages
➣ Depression
Adults: In outpatients, 75 mg/day P.O. in divided doses, increased gradually p.r.n. to a maximum of 200 mg/day; maintenance dosage is 50 to 150 mg/day P.O. for approximately 3 months. In hospitalized patients, 100 mg/day P.O. in divided doses, increased over several days p.r.n. to 200 mg/day; if no improvement occurs in 2 to 3 weeks, may increase to a maximum of 300 mg/day.

Dosage adjustment
● Hepatic disease
● Elderly patients

Off-label uses
● Depression in adolescents

Contraindications
● Hypersensitivity to drug or other dibenzazepines
● Acute recovery phase after myocardial infarction (MI)
● MAO inhibitor use within past 14 days

Precautions
Use cautiously in:
● increased intraocular pressure, angle-closure glaucoma, urinary retention, cardiac or hepatic disease, hyperthyroidism, urethral or ureteral spasm, seizure disorders, severe depression, suicidal ideation or behavior
● elderly patients
● pregnant or breastfeeding patients.

Administration
 songwriter Don’t give within 14 days of MAO inhibitors.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: confusion, drowsiness, dizziness, asthenia, fatigue, headache, disorientation, hallucinations, delusions, restlessness, anxiety, agitation, insomnia, nightmares, hypomania, psychosis exacerbation, paresthesia, incoordination, ataxia, tremor, peripheral neuropathy, extrapyramidal symptoms, EEG changes, seizures, cerebrovascular accident (CVA), suicide or suicidal ideation (especially in child or adolescent)
CV: hypotension, hypertension, tachycardia, palpitations, heart block, arrhythmias, MI
EENT: blurred vision, mydriasis, abnormal accommodation, tinnitus
GI: nausea, vomiting, diarrhea, constipation, epigastric distress, abdominal cramps, stomatitis, black tongue, dry mouth, paralytic ileus
GU: urinary retention or frequency, delayed voiding, urinary tract dilation, gynecomastia, galactorrhea, increased or decreased libido, erectile dysfunction, testicular swelling
Hematologic: eosinophilia, purpura, thrombocytopenia, agranulocytosis
Hepatic: jaundice, hepatic dysfunction
Metabolic: hyperglycemia, hypoglycemia, syndrome of inappropriate antidiuretic hormone secretion
Skin: rash, petechiae, pruritus, urticaria, alopecia, diaphoresis, flushing, photosensitivity
Other: abnormal taste, swollen face and tongue, weight changes, parotid gland swelling

Reactions in bold are life-threatening.

Clinical alert
Interactions

Drug-drug. Anticholinergics (such as some antidepressants, antihistamines, atropine, disopyramide, haloperidol, phenothiazines, quinidine): additive anticholinergic effects
Antihistamines, CNS depressants, opioids, sedative-hypnotics: additive CNS depression
Antithyroid drugs: increased risk of cardiotoxicity
Barbiturates: decreased trimipramine blood level, increased depressant effect
Cimetidine, flecainide, fluoxetine, paroxetine, phenothiazines, quinidine, sertraline: increased trimipramine blood level, greater risk of toxicity
Clonidine: increased risk of hypertensive crisis
Guanethidine: blocked guanethidine effects
Local anesthetics containing epinephrine, local decongestants, sympathomimetic amines: increased effects of these drugs
MAO inhibitors: hypertension, hyperpyrexia, seizures, death

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase: increased levels
Glucose: increased or decreased level

Drug-herbs. Angel’s trumpet, belladonna, henbane, jimsonweed, scopolia: increased anticholinergic effects
Chamomile, hops, kava, scopolia, skullcap, valerian: increased CNS depression
St. John’s wort: decreased trimipramine blood level and efficacy

Drug-behaviors. Alcohol use: increased CNS depression
Sun exposure: increased risk of photosensitivity

Patient monitoring

- Monitor neurologic status. Watch for improvement in depression, as well as signs and symptoms of CVA or seizures.
- Assess for suicide risk and drug hoarding.
- Monitor CBC and liver function tests. Stay alert for blood dyscrasias and hepatic dysfunction.

Patient teaching

- Tell patient he may take with or without food.
- Instruct patient to use only as prescribed.
- Caution patient not to stop drug abruptly, because doing so may cause nausea, headache, and malaise.
- Instruct patient (or parent, as appropriate) to promptly report loss of consciousness, worsening depression, bleeding, bruising, or suicidal thoughts or behavior (especially in child or adolescent).
- Advise patient to avoid alcohol and herbs.
- Tell patient to avoid exposure to sun and to wear sunscreen and protective clothing when going outdoors.
- Caution patient to avoid driving and other hazardous activities until drug effects are known.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

triptorelin pamoate

Decapeptyl SR®, Gonapeptyl Depot®, Trelstar Depot, Trelstar LA

Pharmacologic class: Synthetic agonist analog of luteinizing hormone-releasing hormone (LH-RH)
Therapeutic class: Antineoplastic
Pregnancy risk category X

Action

Initially causes surge in luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone levels.
After several weeks of therapy, LH and FSH secretion decrease, causing sustained testosterone reduction equivalent to pharmacologic castration.

**Availability**

*Microgranules for injection (lyophilized):* 3.75 mg (depot), 11.25 mg (long-acting)

**Indications and dosages**

- Palliative treatment of advanced prostate cancer
  - Adults: 3.75 mg (depot) I.M. monthly as a single injection or 11.25 mg (long-acting) I.M. q 84 days as a single injection

**Off-label uses**

- Infertility
- Endometriosis
- Uterine fibroids
- Precocious puberty

**Contraindications**

- Hypersensitivity to drug, LHRH, or other LHRH agonists
- Pregnancy
- Women of childbearing potential

**Precautions**

- Use cautiously in:
  - renal insufficiency
  - prostate cancer with impending spinal cord compression or severe urinary tract disorder
  - breastfeeding patients (use not recommended).

**Administration**

- Reconstitute with 2 ml of sterile water for injection, using accompanying syringe (don’t use other diluents). Add syringe contents to vial containing particles; shake well. Withdraw vial contents and inject I.M. immediately.
- Inject deep I.M. into either buttock. Rotate injection sites.

**Adverse reactions**

- CNS: insomnia, dizziness, headache, emotional lability, fatigue
- CV: hypertension
- GI: vomiting, diarrhea
- GU: urinary retention, urinary tract infection, gynecomastia, erectile dysfunction
- Hematologic: anemia
- Musculoskeletal: skeletal or leg pain
- Skin: pruritus
- Other: temporary worsening of disease, edema, hot flashes, pain at injection site, hypersensitivity reactions including anaphylaxis

**Interactions**

- Drug-drug. Metoclopramide and other drugs that can cause hyperprolactinemia: increased prolactin production and risk of severe hyperprolactinemia

**Drug-diagnostic tests.** Hemoglobin: decreased value

- Pituitary-gonadal function tests: misleading results (with continuous or long-term use)

**Patient monitoring**

- Monitor serum testosterone and prostate-specific antigen levels periodically to assess drug efficacy.

**Patient teaching**

- Explain drug therapy to patient. Stress need for follow-up laboratory tests.
- Tell patient prostate cancer symptoms may worsen during first few weeks of therapy.

Reactions in bold are life-threatening.
• Instruct patient to monitor weight and report sudden weight gain or leg swelling.
• Advise female patient to tell prescriber before starting therapy if she is or plans to become pregnant. Caution her not to breastfeed during therapy.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**tromethamine**

*Tham*

**Pharmacologic class:** Protein substrate  
**Therapeutic class:** Systemic alkalizer  
**Pregnancy risk category C**

**Action**
Combines with hydrogen ions to form bicarbonate and a buffer, correcting acidosis. Also shows some diuretic activity.

**Availability**
*Injection:* 18 g/500 ml

**Indications and dosages**

– Metabolic acidosis associated with cardiac bypass surgery  
  **Adults:** 9 ml/kg (0.32 g/kg) by slow I.V. infusion; 500 ml (18 g) is usually adequate. Maximum single dosage is 500 mg/kg infused over at least 1 hour.  
– Metabolic acidosis associated with cardiac arrest  
  **Adults:** 3.6 to 10.8 g by I.V. injection into large peripheral vein if chest isn’t open, or 2 to 6 g I.V. directly into ventricular cavity if chest is open. After reversal of cardiac arrest, patient may need additional amounts to control persistent acidosis.

> To correct acidity of acid-citrate-dextrose (ACD) blood in cardiac bypass surgery  
**Adults:** 0.5 to 2.5 g added to each 500 ml of ACD blood used for priming pump-oxygenator. Usual dosage is 2 g.

**Dosage adjustment**
• Elderly patients

**Contraindications**
• Hypersensitivity to drug  
• Anuria  
• Uremia

**Precautions**
Use cautiously in:  
• renal disease, severe respiratory disease, respiratory depression  
• pregnant patients  
• infants.

**Administration**

– Keep intubation equipment nearby in case respiratory depression occurs.  
– For metabolic acidosis associated with cardiac bypass surgery, give by slow I.V. infusion through large-bore I.V. catheter into large antecubital vein. Elevate arm after infusion.  
– If extravasation occurs, discontinue drug and infiltrate affected area with 1% procaine hydrochloride (containing hyaluronidase).  
– Be aware that in cardiac arrest, drug is used with standard resuscitative measures. When giving by direct I.V. injection into open chest, never inject into cardiac muscle.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>Immediate</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

GU: oliguria  
Hepatic: hemorrhagic hepatic necrosis  
Metabolic: metabolic alkalosis, transient hypoglycemia, fluid-solute overload, hyperkalemia  
Respiratory: respiratory depression

 música de fondo
Other: fever; I.V. site infection; extravasation with venous thrombosis or phlebitis, inflammation, necrosis, and sloughing

Interactions
Drug-diagnostic tests. Glucose: decreased level
Potassium: increased level

Patient monitoring
● Maintain continuous cardiac monitoring.
● Monitor arterial blood gas levels. Watch for alkalosis and signs and symptoms of respiratory depression.
● Assess liver function tests. Stay alert for signs and symptoms of hepatic impairment.
● Monitor glucose and potassium levels. Watch for hypoglycemia and hyperkalemia.
● Closely monitor fluid intake and output. Check for fluid and electrolyte imbalances and oliguria related to hyperkalemia.

Patient teaching
● Explain drug therapy to patient. Assure him he will be monitored continuously.
● As appropriate, review all significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

Action
Antagonizes effects of acetylcholine on muscarinic receptors in cholinergically innervated organs, reducing bladder smooth muscle tone

Availability
Capsules (extended-release): 60 mg
Tablets: 20 mg

Indications and dosages
➣ Overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency
Adults: 20 mg P.O. twice daily 1 hour before meals or on empty stomach, or 1 60-mg capsule daily in morning with water at least 1 hour before a meal

Dosage adjustment
● Severe renal impairment
● Patients age 75 and older

Contraindications
● Hypersensitivity to drug or its components
● Preexisting or risk of urinary or gastric retention or uncontrolled angle-closure glaucoma

Precautions
Use cautiously in:
● renal insufficiency, hepatic impairment, decreased GI motility, controlled angle-closure glaucoma
● risk of urinary retention or heat prostration
● elderly patients
● pregnant or breastfeeding patients
● children (safety and efficacy not established).

Administration
● Give at least 1 hour before meals or on empty stomach.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>5-6 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Reactions in bold are life-threatening.
Adverse reactions
CNS: headache, fatigue, syncope, hallucinations, delirium, dizziness, drowsiness
CV: tachycardia, chest pain
EENT: dry eyes, blurred vision, dry throat
GI: vomiting, constipation (new-onset or aggravated), upper abdominal pain, dyspepsia, flatulence, abdominal distention, dry mouth
GU: urinary retention
Skin: dry skin
Other: altered taste, heat prostration

Interactions
Drug-drug. Anticholinergics: additive anticholinergic effects
Digoxin, metformin, morphine, pancuronium, procainamide, tenofovir, vancomycin: increased blood levels of both drugs

Drug-behaviors. Alcohol use: increased risk of drowsiness

Patient monitoring
• Monitor renal and hepatic function tests.
• Monitor patient for decreased GI motility and urinary retention.
• If patient has controlled angle-closure glaucoma, stay alert for severe eye pain accompanied by nausea, rainbows around lights, red eye, and blurred vision. Be prepared to treat immediately, as appropriate.

Patient teaching
• Instruct patient to take tablet 1 hour before meals on an empty stomach or to take capsule in morning with water at least 1 hour before a meal.
• Instruct patient not to consume alcohol within 2 hours of taking extended-release capsule.
• Advise patient to consult prescriber before taking over-the-counter products such as antihistamines because these may increase risk of side effects.
• Inform patient that drug increases risk of heat prostration; describe symptoms and advise him to seek prompt medical attention if these occur.
• Caution patient to avoid driving and other hazardous activities until drug effects are known.
• Advise patient to avoid alcohol use.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and behaviors mentioned above.

urea
Pharmacologic class: Diamide salt of carbonic acid
Therapeutic class: Osmotic diuretic
Pregnancy risk category C

Action
Increases osmotic pressure of glomerular filtrate, inhibits tubular reabsorption of water and electrolytes, and elevates plasma osmolarity, increasing water influx into extracellular fluid

Availability
Powder for reconstitution: 40 g/150 ml

Indications and dosages
Increased intracranial pressure (ICP) or intraocular pressure (IOP)
Adults: 1 to 1.5 g/kg as 30% solution I.V., infused slowly over 1 to 2½ hours at a rate no faster than 4 ml/minute. Maximum dosage is 120 g/day.

Off-label uses
• Abortifacient
Contraindications
- Hypersensitivity to drug
- Severe renal impairment
- Marked dehydration
- Active intracranial bleeding
- Hepatic failure
- Infusion into lower leg veins in elderly patients

Precautions
Use cautiously in:
- hepatic or renal disease, electrolyte imbalances, diabetes mellitus, sickle cell disease, membrane rupture, cervical stenosis, uterine fibroids
- pregnant or breastfeeding patients.

Administration
- Add dextrose 5% or 10% in water to container with 40 g of urea, to yield a final concentration of 300 mg/ml. Infuse I.V. no faster than 4 ml/minute.
- Infuse through large-bore catheter into large vein only.
- Don’t stop infusion abruptly.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>30-45 min</td>
<td>1-2 hr</td>
<td>3-10 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, dizziness, agitation, confusion, disorientation, syncope, nervousness, drowsiness (with prolonged use in sickle cell patients), subdural hemorrhage
CV: hypotension, tachycardia, ECG changes, capillary bleeding, cardiotoxicity
GI: nausea, vomiting
GU: oliguria
Hematologic: hemolysis (with rapid administration)
Metabolic: hypervolemia, hyponatremia, hypokalemia, electrolyte imbalances
Skin: irritation or necrotic sloughing with extravasation
Other: pain, thrombosis, chemical phlebitis, or infection at injection site; fever; hyperthermia

Interactions
Drug-drug. Lithium: increased lithium clearance and decreased efficacy
Drug-diagnostic tests. Potassium, sodium: decreased levels

Patient monitoring
- Institute continuous cardiac monitoring.
- Closely monitor vital signs, ICP, and neurologic and cardiac status.
- Monitor electrolyte levels and kidney function tests.
- Assess fluid intake and output.
- When drug is used for IOP reduction, monitor IOP.

Patient teaching
- Explain drug therapy to patient.
- Tell patient drug may affect many body systems. Instruct him to immediately report such symptoms as headache or confusion.
- As appropriate, review all significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

valacyclovir hydrochloride (valaciclovir)<sup>®</sup>
Apo-Valacyclovir<sup>®</sup>, Valtrex

Pharmacologic class: Acyclic purine nucleoside analog
Therapeutic class: Antiviral
Pregnancy risk category B
Action
Rapidly converts to acyclovir, which interferes with viral DNA synthesis and replication

Availability
Caplets: 500 mg, 1 g

Indications and dosages
➣ Herpes zoster (shingles)
  Adults: 1 g P.O. t.i.d. for 7 days. Therapy should begin at first sign or symptom of herpes zoster, within 48 hours of onset of zoster rash.
  ➢ Genital herpes
   Adults: For initial episode, 1 g P.O. b.i.d. for 10 days. For recurrent episodes, 500 mg P.O. b.i.d. for 3 days. For chronic suppression, 1 g P.O. daily for no more than 1 year; in patients with history of fewer than nine yearly recurrences, 500 mg P.O. daily for no more than 1 year.
  ➢ To reduce risk of genital herpes in immunocompetent patients
   Adults: 500 mg P.O. daily for source partner, along with counseling regarding safe sex practices
  ➢ Herpes labialis
   Adults: 2 g b.i.d. for 1 day taken 12 hours apart. Begin therapy at first symptom of lesion.

Dosage adjustment
● Renal impairment

Off-label uses
● Cytomegalovirus prophylaxis

Contraindications
● Hypersensitivity to drug, its components, or acyclovir

Precautions
Use cautiously in:
● renal impairment
● pregnant or breastfeeding patients
● children.

Administration
● Be aware that therapy may be ineffective if begun more than 72 hours after initial genital herpes outbreak, or more than 24 hours after symptom onset in herpes recurrence.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1.5-2.5 hr</td>
<td>8-24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, dizziness, depression
GI: nausea, vomiting, diarrhea, abdominal pain
GU: dysmenorrhea
Hematologic: anemia, leukopenia, thrombocytopenia
Musculoskeletal: joint pain
Other: hypersensitivity reaction

Interactions
Drug-drug. Cimetidine, probenecid: increased valacyclovir blood level
Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase: increased levels

Patient monitoring
● Monitor CBC. Stay alert for signs and symptoms of blood dyscrasias.
● Assess liver and kidney function tests.

Patient teaching
● Inform patient that herpes transmission can occur even when he is asymptomatic.
● Tell patient and significant other that no cure exists for herpes. Urge them to practice safe sex.
● Inform pregnant patient of risk of neonatal herpes infection.
● Instruct pregnant patient or female of childbearing age to tell health care provider that she has herpes. After delivery, tell her to inform neonatal care providers.
  ➢ Instruct patient to promptly report unusual bleeding or bruising.
urinary changes, or serious adverse CNS reactions.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

valganciclovir hydrochloride
Valcyte

Pharmacologic class: Synthetic guanine derivative
Therapeutic class: Antiviral
Pregnancy risk category C

FDA BOXED WARNING
• Clinical toxicities of drug (which is metabolized to ganciclovir) include granulocytopenia, anemia, and thrombocytopenia. In animal studies, ganciclovir caused cancer, birth defects, and aspermatogenesis.

Action
Converts to its active form, inhibiting activity of cytomegalovirus (CMV)

Availability
Tablets: 450 mg

Indications and dosages
➢ Active CMV retinitis in AIDS patients
Adults: For induction therapy, 900 mg P.O. b.i.d. for 21 days. For maintenance, 900 mg P.O. daily.
➢ CMV prevention in high-risk kidney, heart, and kidney-pancreas transplant patients
Adults: 900 mg P.O. daily with food, starting within 10 days of transplantation and continuing until 100 days after transplantation

Dosage adjustment
• Renal impairment

Contraindications
• Hypersensitivity to drug, its components, or ganciclovir
• Absolute neutrophil count below 500 cells/mm³, platelet count below 25,000 cells/mm³, or hemoglobin below 8 g/dl

Precautions
Use cautiously in:
• cytopenia, impaired renal function
• patients receiving myelosuppressive drug therapy or radiation therapy
• elderly patients
• pregnant or breastfeeding patients.

Administration
• Avoid direct contact with broken or crushed tablet. If skin contact occurs, wash thoroughly with soap and water; if eye contact occurs, rinse eyes thoroughly with plain water.

Route Onset Peak Duration
P.O. Unknown 1-3 hr Unknown

Adverse reactions
CNS: headache, insomnia, sedation, dizziness, peripheral neuropathy, paresthesia, hallucinations, confusion, agitation, psychosis, ataxia, seizures
EENT: retinal detachment
GI: nausea, vomiting, diarrhea, abdominal pain
Hematologic: anemia, bone marrow depression, aplastic anemia, pancytopenia, thrombocytopenia, neutropenia
Other: fever, catheter-related infection, local or systemic infection, hypersensitivity reaction, sepsis

Interactions
Drug-drug. Cytotoxic drugs (such as adriamycin, amphotericin B, co-trimoxazole, dapsone, doxorubicin, flucytosine,
pentamidine, vinblastine, vincristine): additive toxicity
Cilastatin, imipenem: seizures
Didanosine: decreased valganciclovir blood level, increased didanosine blood level
Nephrotoxic drugs (such as amphotericin B, cyclosporine): increased creatinine level
Probenecid: decreased renal clearance of valganciclovir
Zidovudine: increased risk of granulocytopenia and anemia

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, creatinine: increased levels
Creatinine clearance: decreased value
Granulocytes, hemoglobin, neutrophils, platelets, white blood cells: decreased levels

Drug-food. Any food: increased drug absorption

Patient monitoring
- Monitor CBC with white cell differential and platelet count. Watch for signs and symptoms of blood dyscrasias.
- Stay alert for hypersensitivity reaction and signs and symptoms of infection.
- Closely monitor neurologic status. Observe for signs and symptoms of impending seizure.
- Periodically assess creatinine level and creatinine clearance.

Patient teaching
- Instruct patient to take with food.
- Explain drug therapy to patient. Stress importance of taking drug exactly as prescribed to prevent overdose.
- Tell patient drug can cause serious adverse reactions. Teach him which ones to report immediately.
- Advise patient to avoid driving and other hazardous activities.
- Caution female of childbearing age to avoid pregnancy and breastfeeding.
- Urge male patient to use barrier contraception during and for 90 days after therapy.
- Instruct patient to have follow-up eye exams every 4 to 6 weeks, as well as periodic laboratory tests.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

valproate sodium

Apo-Divalproex, Apo-Valproic Syrup, Depacon, Dom-Divalproex, Dom-Valproic Acid, Epilem, Epilem Chrono, Episenta, Epival CR, Epival ECT, Gen-Divalproex, Gen-Valproic-Cap, Novo-Divalproex, Novo-Valproic ECC, Nu-Divalproex, Nu-Valproic, Orlept, PHL-Divalproex, PHL-Valproic Acid, PMS-Divalproex, PMS-Valproic Acid, Ratio-Valproic, Ratio-Valproic ECC, Sandoz Valproic

valproic acid
Convulex, Depakene
divalproex sodium
Depakote, Depakote ER, Depakote Sprinkle

Pharmacologic class: Carboxylic acid derivative
Therapeutic class: Anticonvulsant, mood stabilizer, antimigraine agent
Pregnancy risk category D
FDA BOXED WARNING

- Hepatic failure resulting in death has occurred in patients receiving Depacon. Children younger than age 2 are at considerably increased risk for fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders or organic brain disease, and those with severe seizure disorders accompanied by mental retardation. In this patient group, use Depacon with extreme caution and as sole agent. Weigh benefits of therapy against risks. Above this age-group, incidence of fatal hepatotoxicity decreases considerably in progressively older patients.
- Valproate can cause teratogenic effects, such as neural tube defects. When using it in women with childbearing potential, weigh benefits against risk of fetal injury.
- Life-threatening pancreatitis has occurred in both children and adults receiving valproate. Some cases were hemorrhagic, with rapid progression from initial symptoms to death.

Action
Increases level of gamma-aminobutyric acid in brain, reducing seizure activity

Availability
valproate sodium
Injection: 100 mg/ml in 5-ml vial
Syrup: 250 mg/5 ml
valproic acid
Capsules (liquid-filled): 250 mg
divalproex sodium
Capsules (containing coated particles or sprinkles): 125 mg
Tablets (enteric-coated, delayed-release): 125 mg, 250 mg, 500 mg
Tablets (extended-release): 250 mg, 500 mg

Indications and dosages

- Complex partial seizures
  Adults and children older than age 10: Initially, 10 to 15 mg/kg/day P.O. or I.V. May increase by 5 to 10 mg/kg/day q week until blood drug level is 50 to 100 mcg/ml or adverse reactions occur; don’t exceed 60 mg/kg/day. If daily dosage exceeds 250 mg, give in two divided doses.
  Simple or complex absence seizures
  Adults and children older than age 10: Initially, 15 mg/kg/day P.O. or I.V. May increase by 5 to 10 mg/kg/day at weekly intervals until therapeutic blood drug level is reached or adverse reactions occur; don’t exceed 60 mg/kg/day. If daily dosage exceeds 250 mg, give in two divided doses.
  Mania associated with bipolar disorder
  Adults: Initially, 750 mg (divalproex delayed-release) P.O. daily in divided doses. Titrate rapidly to desired effect or trough level of 50 to 125 mcg/ml. Don’t exceed 60 mg/kg/day.
  To prevent migraine
  Adults: 250 mg (divalproex delayed-release) P.O. b.i.d. Or 500 mg (divalproex extended-release) P.O. daily for 1 week (up to 1 g/day). Maximum dosage is 1 g/day.

Off-label uses
- Chorea
- Photosensitivity-related seizures
- Sedative-hypnotic withdrawal

Contraindications
- Hypersensitivity to drug or tartrazine (some products)
- Hepatic impairment
- Urea cycle disorders
- Pregnancy

Precautions
Use cautiously in:
- bleeding disorders, organic brain disease, bone marrow depression, renal impairment

Reactions in bold are life-threatening.
posttraumatic seizures caused by head injury (use not recommended)

- history of hepatic disease
- breastfeeding patients
- children.

**Administration**
- Give I.V. only when oral therapy isn’t feasible.
- For I.V. use, dilute valproate sodium in at least 50 ml of dextrose 5% in water, lactated Ringer’s solution, or normal saline solution. Infuse over 1 hour at a rate slower than 20 mg/minute.
- Know that I.V. and P.O. dosages and dosing frequencies are identical. However, patient should be switched to oral therapy as soon as possible.
- Give oral forms with food.
- Be aware that divalproex extended-release and delayed-release forms are not bioequivalent.
- Make sure patient swallows divalproex extended-release tablets whole without chewing or crushing.
- If patient can’t swallow capsule containing coated particles, sprinkle entire contents of capsule onto about 5 ml of semisolid food, such as pudding or applesauce, immediately before giving.
- Don’t give syrup in carbonated beverages (may cause mouth and throat irritation).

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O. (capsules)</td>
<td>Rapid</td>
<td>1-4 hr</td>
<td>6-24 hr</td>
</tr>
<tr>
<td>P.O. (delayed, extended)</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>P.O. (syrup)</td>
<td>Rapid</td>
<td>15-120 min</td>
<td>6-24 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>End of 1-hr infusion</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

- CNS: confusion, dizziness, headache, sedation, ataxia, paresthesia, asthenia, tremor, drowsiness, emotional lability, abnormal thinking, amnesia
- EENT: amblyopia, blurred vision, nystagmus, tinnitus, pharyngitis
- GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia, anorexia, pancreatitis
- Hematologic: leukopenia, thrombocytopenia
- Hepatic: hepatotoxicity
- Musculoskeletal: back pain
- Respiratory: dyspnea
- Skin: rash, alopecia, bruising
- Other: abnormal taste, increased appetite, weight gain, fulike symptoms, infection, infusion site pain and reaction

**Interactions**

- Drug-drug. **Activated charcoal, cholestyramine:** decreased valproate absorption
- Antiplatelet agents (including abciximab, aspirin and other nonsteroidal anti-inflammatory drugs, etoposide, tiopronin), cefamandole, cefoperazone, cefotetan, heparin, thrombolytics, warfarin: increased risk of bleeding
- Barbiturates, primidone: decreased metabolism and greater risk of toxicity of these drugs, decreased valproate efficacy
- Carbamazepine: increased carbamazepine blood level, decreased valproate blood level, poor seizure control
- Chlorpromazine: decreased valproate clearance and increased trough level
- Cimetidine: decreased valproate clearance
- Clonazepam: absence seizures in patients with history of these seizures
- CNS depressants (such as antihistamines and antidepressants, MAO inhibitors, opioid analgesics, sedative-hypnotics): additive CNS depression
- Diazepam: displacement of diazepam from binding site, inhibited diazepam metabolism
- Erythromycin, felbamate: increased valproate blood level, greater risk of toxicity
- Ethosuximide: inhibited ethosuximide metabolism
Lamotrigine: decreased valproate blood level, increased lamotrigine blood level
Phenytoin: increased phenytoin effects and risk of toxicity, decreased valproate effects
Salicylates (large doses in children): increased valproate effects
Tricyclic antidepressants: increased blood levels of these drugs, greater risk of adverse reactions
Zidovudine: decreased zidovudine clearance in patients with human immunodeficiency virus

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin: increased levels
Bleeding time: prolonged
Ketone bodies: false-positive results
Platelets, white blood cells: decreased counts
Thyroid function tests: interference with results

Drug-behaviors. Alcohol use: additive CNS depression

Patient monitoring
- Closely monitor neurologic status. Watch for seizures.
- Evaluate GI status. Stay alert for signs and symptoms of pancreatitis.
  - Monitor I.V. infusion site for local reactions.
  - Assess CBC (including platelet count), prothrombin time, International Normalized Ratio, and liver function tests.
  - Monitor valproate blood level; therapeutic range is 50 to 100 mcg/ml.

Patient teaching
- Instruct patient to take with food to minimize GI upset.
- Tell patient taking extended-release tablets to swallow them whole without chewing or breaking.
- Inform patient taking capsules that he may swallow them whole or open them and sprinkle contents onto a teaspoon of semisolid food, such as pudding or applesauce.
- Tell patient (or parents) that valproate syrup shouldn’t be taken with carbonated beverages.
- Advise patient to immediately report malaise, weakness, lethargy, appetite loss, vomiting, or yellowing of skin or eyes.
- If patient’s taking drug for seizure control, tell him to avoid driving and other hazardous activities.
- Caution patient not to stop therapy abruptly.
- Instruct patient to avoid alcohol.
- Stress importance of follow-up laboratory tests.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

valsartan 1219

valsartan
Diovan

Pharmacologic class: Angiotensin II receptor antagonist

Therapeutic class: Antihypertensive

Pregnancy risk category C (first trimester), D (second and third trimesters)

FDA BOXED WARNING
- When used during second or third trimester of pregnancy, drug may cause fetal harm or death. Discontinue as soon as pregnancy is detected.

Action
Blocks the vasoconstrictive and aldosterone-producing effects of angiotensin II at various receptor sites,

Reactions in bold are life-threatening.
including vascular smooth muscle and adrenal glands

**Availability**

*Tablets:* 40 mg, 80 mg, 160 mg, 320 mg

**Indications and dosages**

- **Hypertension**
  - **Adults:** Initially, 80 to 160 mg P.O. daily. May increase as needed to a maximum of 320 mg P.O. daily, or a diuretic may be added.
  - **Children ages 6 to 16:** Initially, 1.3 mg/kg (up to 40 mg total) P.O. once daily; dosage range is 1.3 to 2.7 mg/kg (40 to 160 mg total).

- **Heart failure**
  - **Adults:** 40 mg P.O. b.i.d., titrated to 80 mg or 160 mg P.O. b.i.d., as tolerated
  - **Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction**
  - **Adults:** 20 mg P.O. b.i.d., followed by titration to 40 mg P.O. b.i.d., with subsequent titration to a target maintenance dosage of 160 mg P.O. b.i.d., as tolerated

**Dosage adjustment**

- Symptomatic hypotension
- Renal dysfunction

**Off-label uses**

- Left ventricular hypertrophy
- Diabetic nephropathy

**Contraindications**

- None

**Precautions**

Use cautiously in:

- Severe heart failure; volume or sodium depletion; hepatic or renal impairment; obstructive biliary disorders; angioedema; aortic, mitral valve, or renal artery stenosis; hyperkalemia, hypotension
- Pregnant or breastfeeding patients
- Children younger than age 6 (safety not established)

**Administration**

- Give with or without food.
- For children who can’t swallow tablets or children for whom calculated dosage doesn’t correspond to available tablet strength, use a suspension but be aware that exposure to the suspension is 1.6 times greater than the tablet.
- To prepare 160 ml of a 4-mg/ml suspension, add 80 ml of Ora-Plus to bottle containing eight valsartan 80-mg tablets and shake for at least 2 minutes. Allow suspension to stand for at least 1 hour. Then shake for at least 1 additional minute. Add 80 ml of Ora-Sweet to bottle and shake for at least 10 seconds before giving appropriate dose. May store suspension for 30 days at room temperature or up to 75 days if refrigerated.

Be aware that drug isn’t recommended for children with glomerular filtration rate of less than 30 ml/minute/1.73².

**Route**  |  **Onset** |  **Peak** |  **Duration**
--- | --- | --- | ---
P.O. | Within 2 hr | 4-6 hr | 24 hr

**Adverse reactions**

- **CNS:** dizziness, fatigue, headache
- **CV:** hypotension, palpitations
- **EENT:** sinus disorders, rhinitis, pharyngitis
- **GI:** nausea, diarrhea, constipation, abdominal pain, dry mouth
- **GU:** albuminuria, renal impairment
- **Hematologic:** neutropenia
- **Metabolic:** hyperkalemia
- **Musculoskeletal:** back pain, joint pain, muscle cramps
- **Respiratory:** cough, upper respiratory tract infection
- **Skin:** alopecia, angioedema
- **Other:** dental pain, fever, viral infection, edema

Canada  |  UK  |  Hazardous drug  |  High alert drug
Interactions

Drug-drug. Other antihypertensives: increased risk of hypotension
Potassium-sparing diuretics, potassium supplements: increased risk of hyperkalemia

Drug-diagnostic tests. Serum creatinine, serum and urine albumin, urine potassium: increased levels

Drug-food. Salt substitutes containing potassium: increased risk of hyperkalemia

Drug-herbs. Ephedra (ma huang): reduced hypotensive effect of valsartan

Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring

- Monitor blood pressure closely, especially during initial therapy and dosage adjustments.
- Assess potassium level. Stay alert for hyperkalemia.
- Be aware that in black patients, drug may be ineffective when used alone. Additional agents may be required.

Patient teaching

- Tell patient he may take with or without food.
- For children who can’t swallow tablets or children for whom calculated dosage doesn’t correspond to available tablet strength, show caregiver how to prepare a suspension.
- Instruct female of childbearing age to report pregnancy immediately.
- Advise breastfeeding patient to avoid breastfeeding while taking drug.
- Advise patient to avoid potassium-containing salt substitutes.
- Caution patient to avoid alcohol.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

vancomycin hydrochloride

PMS-Vancomycin®, Vancocin

Pharmacologic class: Tricyclic glycopeptide

Therapeutic class: Anti-infective

Pregnancy risk category C

Action

Binds to bacterial cell wall, inhibiting cell-wall synthesis and causing secondary damage to bacterial membrane

Availability

Capsules: 125 mg, 250 mg
Powder for injection: 500-mg vial, 1-g vial, 5-g vial, 10 g-vial
Powder for oral solution: 1-g and 10-g bottles

Indications and dosages

Severe, life-threatening infections caused by susceptible strains of methicillin-resistant staphylococci, Staphylococcus epidermidis, Streptococcus viridans or Streptococcus bovis (alone or combined with an aminoglycoside), or Enterococcus faecalis (combined with an aminoglycoside)

Adults: 500 mg I.V. q 6 hours or 1 g I.V. q 12 hours

Children: 10 mg/kg I.V. q 6 hours

Infants and neonates: Initially, 15 mg/kg I.V., followed by 10 mg/kg I.V. q 8 hours in infants 8 days to 1 month old, or 10 mg/kg I.V. q 12 hours in infants less than 8 days old

Endocarditis prophylaxis in penicillin-allergic patients at moderate risk who are scheduled for dental and other invasive procedures

Adults: 1 g I.V. slowly over 1 to 2 hours, with infusion completed 30 minutes before invasive procedure begins

Reactions in bold are life-threatening.
Children: 20 mg/kg I.V. over 1 to 2 hours, with infusion completed 30 minutes before invasive procedure begins. Enterocolitis caused by *Streptococcus aureus*; antibiotic-related pseudomembranous diarrhea caused by *Clostridium difficile*

Adults: 500 mg to 2 g P.O. daily in three or four divided doses for 7 to 10 days

Children: 40 mg/kg P.O. daily in three or four divided doses for 7 to 10 days, up to a maximum of 2 g/day

Dosage adjustment
- Renal impairment
- Elderly patients

Off-label uses
- Peritonitis
- Meningitis
- Intraocular infections
- Febrile neutropenia

Contraindications
- Hypersensitivity to drug

Precautions
Use cautiously in:
- renal impairment, preexisting hearing loss
- concurrent use of anesthetics, immunosuppressants, or nephrotoxic or ototoxic drugs
- elderly patients
- pregnant or breastfeeding patients
- neonates.

Administration
- Know that I.V. therapy is ineffective against enterocolitis and pseudomembranous diarrhea.
- For intermittent I.V. infusion, dilute by adding 10 or 20 ml of sterile water for injection to vial containing 500 mg or 1 g of drug, respectively, to yield a concentration of 50 mg/ml. Dilute further by adding at least 100 ml or 200 ml, respectively, of dextrose 5% in water or normal saline solution; infuse over at least 1 hour.
- Don’t give by I.M. route.
- Keep emergency equipment and epinephrine on hand in case of anaphylaxis.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>Immediate</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CV: hypotension, cardiac arrest, vascular collapse
EENT: permanent hearing loss, ototoxicity, tinnitus
GI: nausea, vomiting, pseudomembranous colitis
GU: nephrotoxicity, severe uremia
Hematologic: eosinophilia, leukopenia, neutropenia
Respiratory: wheezing, dyspnea
Skin: “red man” syndrome (nonallergic histamine reaction with rapid I.V. infusion), rash, urticaria, pruritus, necrosis
Other: chills, fever, thrombophlebitis at injection site, anaphylaxis

Interactions
Drug-drug. *Aminoglycosides, amphotericin B, bacitracin, cephalosporins, cisplatin, colistin, nondepolarizing neuromuscular blockers, pentamidine*: increased risk of nephrotoxicity and ototoxicity
*Warfarin*: increased risk of bleeding

Drug-diagnostic tests. *Albumin, blood urea nitrogen (BUN), creatinine*: increased levels
*Eosinophils, neutrophils*: decreased counts

Patient monitoring
- Monitor closely for signs and symptoms of hypersensitivity reactions, including anaphylaxis.
- Check drug blood level weekly. Therapeutic peak ranges from 30 to 40 g/L; therapeutic trough, 5 to 10 mg/L.
Assess BUN and creatinine levels every 2 days, or daily in patients with unstable renal function.

- Monitor urine output daily. Weigh patient at least weekly.
- Assess hearing before and during therapy; stay alert for hearing loss. Patient may require baseline and weekly audiograms.
- Check I.V. site often for phlebitis.
- Watch for “red-man” syndrome, which can result from rapid infusion. Signs and symptoms include hypotension, pruritus, and maculopapular rash on face, neck, trunk, and limbs.
- Monitor CBC. Watch for signs and symptoms of blood dyscrasias.
- Closely monitor respiratory status. Stay alert for wheezing and dyspnea.
- Monitor vital signs and cardiovascular status, especially for vascular collapse and other signs of impending cardiac arrest.

**Patient teaching**

- Tell patient he may take with or without food.
- Instruct patient to take oral drug exactly as prescribed for as long as prescribed, even if symptoms improve.
- Explain importance of prophylactic I.V. therapy to patients at risk for endocarditis who are scheduled for invasive procedures.
- Advise patient to promptly report rash, hearing loss, breathing problems, and signs and symptoms of “red-man” syndrome, nephrotoxicity, and blood dyscrasias.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**vardenafil hydrochloride**

**Levitra**

**Pharmacologic class:** Phosphodiesterase-5 (PDE5) inhibitor  
**Therapeutic class:** Erectile dysfunction agent

**Pregnancy risk category B**

**Action**

Selectively blocks PDE5, which neutralizes cyclic guanosine monophosphate, resulting in enhanced erectile function.

**Availability**

*Tablets:* 2.5 mg, 5 mg, 10 mg, 20 mg

**Indications and dosages**

- **Erectile dysfunction**
  - **Adult males:** 10 or 20 mg P.O. approximately 1 hour before anticipated sexual activity. Maximum dosing frequency is once daily.

**Dosage adjustment**

- Patients older than age 65
- Concurrent use of CYP450-3A4 inhibitors
- Concurrent HIV therapy (except highly active antiretroviral therapy)

**Contraindications**

- Hypersensitivity to drug
- Concurrent use of nitrates or nitrate patches to treat angina
- Concurrent use of alpha-adrenergic blockers

**Precautions**

Use cautiously in:

- cardiovascular disease, retinitis pigmentosa, hepatic or renal impairment, reduced hepatic blood flow
- patients at increased risk for priapism (as from sickle-cell disease, leukemia, multiple myeloma, polycythemia, or history of priapism).

Reactions in **bold** are life-threatening.
varenicline
Champix®, Chantix

Pharmacologic class: Autonomic drug, miscellaneous
Therapeutic class: Smoking cessation agent
Pregnancy risk category C

Action
In smoking cessation, action presumably results from activity at nicotinic receptor subtype, where its binding produces agonist activity while simultaneously preventing nicotine binding to alpha4-beta2 receptors.

Availability
Tablets (film coated): 0.5 mg, 1 mg

Indications and dosages
➣ To aid smoking-cessation treatment

Adults: Begin with 1-week titration of 0.5 mg P.O. daily on days 1 to 3; then, 0.5 mg P.O. b.i.d. on days 4 to 7. Starting on day 8, give 1 mg P.O. b.i.d. till end of treatment. If patient has successfully stopped smoking at end of 12 weeks, additional course of 12 weeks is recommended to improve likelihood of long-term abstinence.

Dosage adjustment
● Severe renal impairment

Contraindications
None

Precautions
Use cautiously in:
● renal impairment
● concurrent use of drugs affected by smoking, such as insulin, theophylline, and warfarin (whose dosages may need to be adjusted)
● elderly patients

Administration
● Advise patient not to take more than one tablet daily.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>1 hr</td>
<td>4 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache
CV: hypotension
EENT: blurred vision, altered color perception, light sensitivity, rhinitis
GI: dyspepsia
Skin: flushing
Other: flulike symptoms

Interactions
Drug-drug. Alpha-adrenergic blockers, nitrates: hypotension
Erythromycin, itraconazole, ketoconazole, protease inhibitors: increased vardenafil blood level

Drug-diagnostic tests. Creatine kinase: increased level

Patient monitoring
● Monitor blood pressure and heart rate, particularly if patient has cardiovascular disease.

Patient teaching
● Tell patient he may take with or without food.
● Instruct patient to take one tablet about 1 hour before anticipated sexual activity. Caution him not to take more than one tablet daily.
● Instruct patient to promptly contact prescriber if erection lasts more than 4 hours, because irreversible damage to penis may occur.
● Caution patient not to take nitrates. Tell him to inform prescriber of other drugs he’s taking.
● As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

varenicline

Pharmacologic class: Autonomic drug, miscellaneous
Therapeutic class: Smoking cessation agent
Pregnancy risk category C

Action
In smoking cessation, action presumably results from activity at nicotinic receptor subtype, where its binding produces agonist activity while simultaneously preventing nicotine binding to alpha4-beta2 receptors.

Availability
Tablets (film coated): 0.5 mg, 1 mg

Indications and dosages
➣ To aid smoking-cessation treatment

Adults: Begin with 1-week titration of 0.5 mg P.O. daily on days 1 to 3; then, 0.5 mg P.O. b.i.d. on days 4 to 7. Starting on day 8, give 1 mg P.O. b.i.d. till end of treatment. If patient has successfully stopped smoking at end of 12 weeks, additional course of 12 weeks is recommended to improve likelihood of long-term abstinence.

Dosage adjustment
● Severe renal impairment

Contraindications
None

Precautions
Use cautiously in:
● renal impairment
● concurrent use of drugs affected by smoking, such as insulin, theophylline, and warfarin (whose dosages may need to be adjusted)
● elderly patients
• pregnant or breastfeeding patients
• children younger than age 18 (safety and efficacy not established).

Administration
• Give with full glass of water after a meal.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>3-4 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, migraine, somnolence, lethargy, dizziness, syncope, attention disturbance, sensory disturbance, anxiety, depression, emotional disorder, irritability, restlessness, sleep disorders, normal dreams, nightmares, insomnia, fatigue, malaise, asthenia, aggression, agitation, amnesia, dissociation, mood swings, parosmia, psychomotor hyperactivity, restless leg syndrome, abnormal thinking, tremor, vertigo, suicidal ideation (rare)

CV: hot flushes, hypertension, angina pectoris, bradycardia, hypotension, palpitations, peripheral ischemia, tachycardia, thrombosis, ventricular extrasystoles, arrhythmia, myocardial infarction

EENT: tinnitus, epistaxis, rhinorrhea

GI: nausea, vomiting, constipation, abdominal pain, flatulence, dyspepsia, gastroesophageal reflux disease, gingivitis, anorexia, increased or decreased appetite, dysgeusia, dry mouth, intestinal obstruction (rare), acute pancreatitis (rare)

GU: polyuria, menstrual disorder, decreased libido, acute renal failure (rare)

Hematologic: anemia, lymphadenopathy

Musculoskeletal: arthralgia, back pain, muscle cramp, musculoskeletal pain, myalgia

Respiratory: dyspnea, upper respiratory tract disorders, pulmonary embolism (rare)

Skin: rash, pruritus, hyperhidrosis

Other: chest pain, flulike illness, edema, thirst, increased weight, nicotine withdrawal symptoms

Interactions
Drug-diagnostic tests. Liver function tests: abnormal

Patient monitoring

- Monitor patient for serious neuropsychiatric symptoms, including behavior changes, agitation, depressed mood, and suicidal ideation and behavior.
- Monitor patients taking drugs that may be affected by smoking; dosages of these drugs may need to be adjusted once patient quits smoking.
- Monitor liver function tests.
- Monitor renal function, especially in elderly patients.

Patient teaching

- Advise patient to set date to quit smoking and to start drug 1 week before quit date. Teach patient how to titrate drug for first week of therapy.
- Instruct patient to take drug with full glass of water after eating.
- Give patient educational materials and counseling referral to support smoking-cessation attempt.
- Encourage patient who relapses after quit day to continue to try to quit smoking.
- Inform patient that nausea and insomnia are side effects and usually disappear. However, if these symptoms remain troubling, advise patient to notify prescriber, who may consider dosage reduction.
- Inform patient that some drugs may require dosage adjustment after smoking cessation.
- Caution patient to avoid driving and other hazardous activities until effects of drug and smoking cessation are known.

Reactions in bold are life-threatening.

Clinical alert
As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

### venlafaxine hydrochloride

Co Venlafaxine®, Co Venlafaxine XR, Efexor®, Effexor, Effexor XR, Gen-Venlafaxine XR®, Novo-Venlafaxine XR®, PMS-Venlafaxine XR®, Ratio-Venlafaxine XR®, Riva-Venlafaxine XR®, Sandoz Venlafaxine XR®

**Pharmacologic class:** Phenethylamine derivative  
**Therapeutic class:** Antidepressant, anxiolytic  
**Pregnancy risk category C**

### FDA BOXED WARNING

- Drug may increase risk of suicidal thinking and behavior in children and adolescents with major depressive disorder and other psychiatric disorders. Risk must be balanced with clinical need, as depression itself increases suicide risk. With patient of any age, observe closely for clinical worsening, suicidality, and unusual behavior changes when therapy begins. Advise family and caregivers to observe patient closely and communicate with prescriber as needed.  
- Drug isn’t approved for use in pediatric patients.

### Action

Inhibits neuronal serotonin and norepinephrine reuptake and slightly inhibits dopamine reuptake

### Availability

**Capsules (extended-release):** 37.5 mg, 75 mg, 150 mg  
**Tablets:** 25 mg, 37.5 mg, 50 mg, 75 mg, 100 mg

### Indications and dosages

#### > Depression

**Adults:** In outpatients, 75 mg P.O. daily in two or three divided doses; may increase in increments of 75 mg/day q 4 or more days to a maximum of 225 mg/day; extended-release form can be given as a single daily dose. In hospitalized patients, 75 mg P.O. daily in two or three divided doses; may increase in increments of 75 mg/day q 4 days to a maximum of 375 mg/day given in three divided doses.

#### > Generalized anxiety disorder

**Adults:** Single dose of 37.5 to 75 mg (extended-release) P.O. daily; may increase in increments of 75 mg/day q 4 days to a maximum of 225 mg/day

#### > Panic disorder

**Adults:** 37.5 mg (extended-release) P.O. daily for 7 days; increase to 75 mg P.O. daily for 7 days; then increase by 75 mg daily at weekly intervals to a maximum of 225 mg P.O. daily

#### > Social anxiety disorder

**Adults:** 75 mg (extended-release capsule) P.O. daily as a single dose

### Dosage adjustment

- Hepatic or renal impairment

### Off-label uses

- Premenstrual dysphoric disorder

### Contraindications

- Hypersensitivity to drug  
- MAO inhibitor use within past 14 days

### Precautions

Use cautiously in:  
- cardiovascular disease; hypertension; heart failure, recent myocardial
infarction, and other conditions in which increased heart rate poses a danger; hepatic or renal impairment; glaucoma; hyperthyroidism; hyponatremia; syndrome of inappropriate antidiuretic hormone secretion (SIADH)

- history of seizures, neurologic impairment, or drug abuse
- pregnant or breastfeeding patients
- children younger than age 18.

Administration

- Don’t give within 14 days of MAO inhibitors.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Within 2 wk</td>
<td>2-4 wk</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: abnormal dreams, anxiety, dizziness, headache, insomnia, nervousness, abnormal thinking, agitation, confusion, depersonalization, drowsiness, emotional lability, worsening depression, twitching, tremor, asthenia, parasthesia, mania, hypomania, **suicidal ideation or behavior** (especially in child or adolescent)

CV: chest pain, hypertension, palpitations, tachycardia, vasodilation

EENT: visual disturbances, blurred vision, mydriasis, tinnitus, rhinitis

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, dry mouth, anorexia

GU: urinary frequency or retention, sexual dysfunction, abnormal ejaculation, anorgasmia, erectile dysfunction

Metabolic: hyponatremia, SIADH

Skin: bruising, pruritus, rash, diaphoresis, photosensitivity

Other: altered taste, weight loss, chills, yawning

Interactions

Drug-drug. Cimetidine: increased venlafaxine effects

MAO inhibitors: potentially fatal reactions

**Sumatriptan, trazodone: serotonin syndrome** (including altered level of consciousness)

Drug-diagnostic tests. Sodium: decreased level

Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression

S-adenosylmethionine (SAM-e), St. John’s wort: increased risk of sedative or hypnotic effects

Patient monitoring

- Monitor neurologic status, particularly for seizures, worsening depression, and suicidal ideation.
- Closely monitor vital signs and cardiovascular status. Stay alert for hypertension and tachycardia.
- Monitor nutritional status, hydration, and weight.

Patient teaching

- Tell patient taking extended-release capsules to swallow them whole without chewing, breaking, dividing, or dissolving.
- Caution patient not to stop therapy abruptly.
- Advise patient to promptly report seizures, worsening depression, or suicidal thoughts (especially in child or adolescent).
- Caution patient to avoid driving and other dangerous activities until drug effects are known.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.
verapamil hydrochloride


Pharmacologic class: Calcium channel blocker
Therapeutic class: Antianginal, anti-arrhythmic (class IV), antihypertensive
Pregnancy risk category C

Action
Decreases conduction of sinoatrial and atrioventricular (AV) nodes by inhibiting calcium influx into cardiac and vascular smooth muscle cells, inhibiting excitatory contraction. These effects prolong AV node refractoriness and decrease myocardial oxygen consumption.

Availability
Capsules (extended-release): 100 mg, 120 mg, 180 mg, 200 mg, 240 mg, 300 mg, 360 mg
Capsules (sustained-release): 120 mg, 180 mg, 240 mg, 360 mg
Injection: 2.5 mg/ml in 2- and 4-ml vials, ampules, and syringes
Tablets (extended-release): 120 mg, 180 mg, 240 mg
Tablets (immediate-release): 40 mg, 80 mg, 120 mg

Indications and dosages
▸ Angina
   Adults: Initially, 80 mg (immediate-release) P.O. t.i.d.; may titrate at daily or weekly intervals to 360 mg/day. Or initially, 180 mg (extended-release) P.O. once daily at bedtime, titrated up to 480 mg/day at bedtime.
   ➢ Supraventricular tachyarrhythmias (SVTs)
   Adults: 5 to 10 mg (0.075 to 0.15 mg/kg) I.V. bolus over 2 minutes; may give additional 10 mg after 30 minutes if response inadequate. Or 240 to 480 mg (immediate-release) P.O. daily in three or four divided doses.
   ➢ To control ventricular rate in chronic atrial flutter or atrial fibrillation in patients receiving digoxin
   Adults: 240 to 320 mg P.O. daily in three or four divided doses
   ➢ Hypertension
   Adults: Initially, 180 mg (extended-release tablet) or 200 mg (extended-release capsule) P.O. daily at bedtime. For maintenance, may titrate up to 480 mg (extended-release tablet) or 400 mg (extended-release capsule) P.O. daily at bedtime. Or initially, 80 mg (immediate-release tablet) P.O. t.i.d.; may titrate at daily or weekly intervals up to 360 to 480 mg/day. Or initially, 240 mg (sustained-release capsule) P.O. q day in morning; for maintenance, may titrate up to 240 mg P.O. b.i.d. or 480 mg P.O. once daily in morning. Titrate based on response.

Dosage adjustment
• Renal or hepatic impairment
• Concurrent digoxin therapy

Off-label uses
• Ventricular tachycardia
• Migraine headache prophylaxis
• Neurogenic bladder
• Premature labor
Contraindications
- Hypersensitivity to drug or other calcium channel blockers
- Sick sinus syndrome
- Second- or third-degree AV block (except in patients with artificial pacemakers)
- Hypotension
- Heart failure, severe ventricular dysfunction, or cardiogenic shock (except when associated with SVTs)
- Atrial flutter or atrial fibrillation associated with accessory bypass tracts (such as Wolff-Parkinson-White or Lown-Ganong-Levine syndrome)

Precautions
Use cautiously in:
- renal or severe hepatic impairment; first-degree AV block; idiopathic hypertrophic cardiomyopathy; neuromuscular transmission defects (such as Duchenne's muscular dystrophy); respiratory depression; digital ulcers, ischemia, or gangrene
- elderly patients
- pregnant or breastfeeding patients.

Administration
- Give I.V. over at least 2 minutes.
- Discontinue disopyramide 48 hours before starting verapamil. Don’t restart disopyramide for at least 24 hours after verapamil therapy ends.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30 min</td>
<td>1-2 hr</td>
<td>3-7 hr</td>
</tr>
<tr>
<td></td>
<td>(immediate)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>5-7 hr</td>
<td>24 hr</td>
</tr>
<tr>
<td></td>
<td>(extended)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>(sustained)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I.V.</td>
<td>Immediate</td>
<td>3-5 min</td>
<td>2 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: anxiety, confusion, dizziness, syncope, drowsiness, headache, jitteriness, abnormal dreams, disturbed equilibrium, psychiatric disturbances, asthenia, paresthesia, tremor, fatigue

CV: chest pain, hypotension, palpitations, peripheral edema, tachycardia, arrhythmias, heart failure, bradycardia, AV block
EENT: blurred vision, epistaxis, tinnitus
GI: nausea, vomiting, diarrhea, constipation, dyspepsia, dry mouth, anorexia
GU: dysuria, urinary frequency, nocturia, polyuria, sexual dysfunction, gynecomastia
Hematologic: anemia, leukopenia, thrombocytopenia
Metabolic: hyperglycemia
Musculoskeletal: joint stiffness, muscle cramps
Respiratory: cough, dyspnea, shortness of breath, pulmonary edema
Skin: dermatitis, flushing, diaphoresis, photosensitivity, pruritus, urticaria, rash, erythema multiforme, Stevens-Johnson syndrome
Other: gingival hyperplasia, edema, weight gain

Interactions
Drug-drug. Antihypertensives: additive hypotension
Aspirin: increased risk of bleeding
Beta-adrenergic blockers, other antiarrhythmics: additive adverse cardiovascular reactions
Carbamazepine, cyclosporine: increased blood levels of these drugs
CYP450-3A4 inducers (such as rifampin): decreased verapamil blood level
CYP450-3A4 inhibitors (such as erythromycin, ritonavir): increased verapamil blood level
Digoxin: increased digoxin blood level, greater risk of toxicity
Lithium: increased or decreased lithium blood level
Neuromuscular blockers (succinylcholine, tubocurarine, vecuronium): prolonged neuromuscular blockade
Theophylline: decreased verapamil clearance, increased blood level, and possible toxicity

Reactions in bold are life-threatening.
Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, blood urea nitrogen, glucose, lactate dehydrogenase: increased levels

Granulocytes: decreased count

Drug-food. Coffee, tea: increased caffeine blood level
Grapefruit juice: increased verapamil blood level and effects

Drug-herbs. Black catechu: increased drug effects
Cola nut, guarana: increased caffeine blood level
Ephedra (ma huang), St. John’s wort: reduced hypotensive effect of verapamil
Yerba maté: decreased clearance of this herb

Drug-behaviors. Alcohol use: additive hypotension

Patient monitoring
- With I.V. use, monitor vital signs and ECG continuously.
- Assess blood pressure when therapy begins and when dosage is adjusted.
- Watch closely for signs and symptoms of heart failure.
- Monitor for signs and symptoms of erythema multiforme (fever, rash, sore throat, mouth sores, cough, iris lesions). Report early indications immediately, before condition can progress to Stevens-Johnson syndrome.
- Assess CBC. Watch for blood dyscrasias.
- Monitor blood glucose level. Stay alert for hyperglycemia in diabetic patients.

Patient teaching
- Instruct patient to avoid chewing, breaking, or crushing extended-release form.
- Advise patient to immediately report rash, unusual bleeding or bruising, fainting, and (in long-term use) fatigue, nausea, or yellowing of skin or eyes.
- Caution patient not to take with grapefruit juice.
- Instruct patient to limit caffeine intake and avoid alcohol.
- Advise patient to seek medical advice before using over-the-counter medications or herbs.
- Tell patient to avoid sun exposure and to wear sunscreen and protective clothing when going outdoors.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

vinblastine sulfate (VLB)

Pharmacologic class: Vinca alkaloid
Therapeutic class: Antineoplastic
Pregnancy risk category D

FDA BOXED WARNING
- Drug should be administered only by individuals experienced in giving it. Make sure needle is positioned properly in vein before injecting drug. Leakage into surrounding tissue during I.V. administration may cause considerable irritation. If it does, discontinue injection immediately and inject remaining portion of dose into another vein. To treat extravasation, administer local injection of hyaluronidase and apply moderate heat to affected area.
- Drug is fatal if given intrathecally. Give I.V. only.

Action
Arrests mitosis and blocks cell division, interfering with nucleic acid synthesis. Cell-cycle-phase specific.

Availability
Lyophilized powder for injection: 10-mg vial
Indications and dosages

Hodgkin’s disease; advanced testicular cancer; lymphoma; AIDS-related Kaposi’s sarcoma; bladder cancer; renal cancer; non-small-cell lung cancer; melanoma; breast cancer; choriocarcinoma; histiocytosis X; mycosis fungoides

**Adults:** 3.7 mg/m² I.V. weekly; may increase to a maximum of 18.5 mg/m² I.V. weekly, based on response. Withhold weekly dose if white blood cell (WBC) count is less than 4,000 cells/mm³. May increase dosage in increments of 1.8 mg/m² if needed, but not after WBC count drops to approximately 3,000 cells/mm³.

Dosage adjustment

- Hepatic impairment

Contraindications

- Hypersensitivity to drug
- Significant granulocytopenia from causes other than disease being treated
- Uncontrolled bacterial infections
- Intrathecal use
- Elderly patients with cachexia or skin ulcers

Precautions

Use cautiously in:

- hepatic or pulmonary dysfunction, renal disease with hypertension, malignant-cell infiltration of bone marrow, neuromuscular disease
- females of childbearing age
- pregnant or breastfeeding patients (use not recommended).

Administration

- Follow facility protocol for handling and preparing chemotherapeutic drugs. Take special care to avoid eye contamination.
- Know that patient is usually premedicated with antiemetic.
- Give by I.V. route only. (Intrathecal injection is fatal.)
- Reconstitute powder in 10-mg vial with 10 ml of normal saline solution for injection, to a concentration of 1 mg/ml. Refrigerate solution and protect from light; discard after 28 days.
- Inject I.V. dose into tubing of running I.V. line, or inject directly into vein over about 1 minute.
- Avoid extravasation, which may cause tissue necrosis. If extravasation occurs, stop injection, inject hyaluronidase locally, and apply moderate heat.

Adverse reactions

**CNS:** headache, malaise, depression, paresthesia, loss of deep tendon reflexes, peripheral neuropathy and neuritis, **cerebrovascular accident, seizures**

**CV:** hypertension, tachycardia, **myocardial infarction**

**EENT:** pharyngitis

**GI:** nausea, vomiting, diarrhea, constipation, bleeding ulcer, abdominal pain, stomatitis, anorexia, **paralytic ileus**

**GU:** aspermia

**Hematologic:** anemia, **thrombocytopenia, leukopenia**

**Metabolic:** hyperuricemia, **syndrome of inappropriate antidiuretic hormone secretion**

**Musculoskeletal:** bone pain, muscle pain and weakness

**Respiratory:** shortness of breath, **acute bronchospasm, pulmonary infiltrates**

**Skin:** alopecia, skin irritation

**Other:** weight loss; jaw pain; tumor site pain; sloughing, cellulitis, and phlebitis at I.V. site; tissue necrosis (with extravasation)

Interactions

**Drug-drug.** Erythromycin, other CYP450 inhibitors: increased vinblastine toxicity

**Mitomycin:** increased risk of bronchospasm and shortness of breath
Phenytoin: decreased phenytoin blood level

Patient monitoring
- Assess respiratory status closely. Drug may cause acute shortness of breath and bronchospasm, especially in patients who previously received mitomycin.
- Check injection site for extravasation.
- Monitor blood pressure.
- Assess CBC. Stay alert for signs and symptoms of infection.
- Monitor closely for numbness and tingling of hands or feet and other adverse reactions.

Patient teaching
- Explain drug therapy to patient. Emphasize importance of follow-up laboratory tests.
- Tell patient to promptly report signs and symptoms of infection and to take his temperature daily.
- Inform patient that drug may cause pain over tumor site.
- Instruct female of childbearing age to avoid pregnancy. Caution her not to breastfeed during therapy.
- Encourage patient to practice good oral hygiene to help prevent infected mouth sores.
- Inform patient that hair loss is a common side effect but typically reverses after treatment ends.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

FDA BOXED WARNING
- Drug should be administered only by individuals experienced in giving it. Make sure needle is positioned properly in vein before injecting drug. Leakage into surrounding tissue during I.V. administration may cause considerable irritation. If it does, discontinue injection immediately and inject remaining portion of dose into another vein. To treat extravasation, administer local injection of hyaluronidase and apply moderate heat to affected area.
- Drug is fatal if given intrathecally. Give I.V. only.

Action
Unknown. Thought to block cell division and interfere with synthesis of nucleic acid. Cell-cycle-phase specific.

Availability
Solution for injection: 1 mg/ml in 1-, 2-, and 5-ml vials

Indications and dosages
- Acute leukemia
  - Adults: 0.4 to 1.4 mg/m² I.V. weekly, not to exceed 2 mg/dose. (Dosages higher than 2 mg may be used depending on patient, physician, protocol, and facility.)
  - Children weighing more than 10 kg (22 lb): 2 mg/m² I.V. weekly
  - Children weighing 10 kg (22 lb) or less: 0.05 mg/kg I.V. weekly

Dosage adjustment
- Hepatic impairment

Off-label uses
- Brain, hepatic, ovarian, testicular, and other cancers
- Neuroblastoma
- Kaposi’s sarcoma
- Idiopathic thrombocytopenic purpura

vincristine sulfate (VCR)
Pharmacologic class: Vinca alkaloid
Therapeutic class: Antineoplastic
Pregnancy risk category D

Canada UK Hazardous drug High alert drug
**Contraindications**
- Hypersensitivity to drug
- Demyelinating form of Charcot-Marie-Tooth disease
- Intrathecal use

**Precautions**
Use cautiously in:
- infections, decreased bone marrow reserve, hepatic impairment, acute uric acid nephropathy, neuromuscular disease, pulmonary dysfunction, other chronic debilitating illnesses
- females of childbearing age
- pregnant or breastfeeding patients (use not recommended).

**Administration**
- Follow facility protocol for handling and preparing chemotherapeutic drugs. Be especially careful to avoid eye contamination.
- Be aware that patient is usually premedicated with antiemetic.
- Give by I.V. route only. (Intrathecal injection is fatal.)
- Inject into tubing of running I.V. line, or inject directly into vein over 1 minute.
- Avoid extravasation (may cause tissue necrosis). If extravasation occurs, stop injection, inject hyaluronidase locally, and apply moderate heat.
- Know that drug may be used with other antineoplastics in some diseases.

**Adverse reactions**
- **CNS:** agitation, insomnia, depression, mental status changes, ascending peripheral neuropathy, transient cortical blindness, **seizures, coma**
- **EENT:** diplopia
- **GI:** nausea, vomiting, constipation, abdominal cramps, stomatitis, anorexia, **paralytic ileus**
- **GU:** nocturia, urinary retention, gonadal suppression, **oliguria**

**Hematologic:** anemia, **leukopenia, thrombocytopenia** (mild and brief)
**Metabolic:** hyperuricemia, **syndrome of inappropriate antidiuretic hormone secretion**
**Respiratory:** bronchospasm
**Skin:** alopecia
**Other:** tissue necrosis (with extravasation), phlebitis at I.V. site

**Interactions**
- **Drug-drug.** Asparaginase: decreased hepatic metabolism of vincristine
- Live-virus vaccines: decreased antibody response to vaccine, increased risk of adverse reactions
- Mitomycin: increased risk of bronchospasm and shortness of breath

**Drug-diagnostic tests.** Platelets: increased or decreased count
- Uric acid: increased level
- White blood cells: decreased count (slight leukopenia) 4 days after therapy, resolving within 7 days

**Patient monitoring**
- Assess respiratory status. Drug may cause bronchospasm, especially in patients who previously received mitomycin.
- Monitor blood pressure.
- Evaluate neurologic status. Know that neurotoxicity is a dose-limiting adverse reaction.
- Monitor CBC with platelet count. Watch for signs and symptoms of blood dyscrasias.
- Stay alert for signs and symptoms of infection.

**Patient teaching**
- Explain drug therapy to patient. Emphasize importance of follow-up laboratory tests.
- Advise patient to promptly report signs and symptoms of infection and to take his temperature daily.
- Urge patient to practice good oral hygiene, to help prevent infected mouth sores.

Reactions in **bold** are life-threatening.
• Instruct female of childbearing age to avoid pregnancy. Caution her not to breastfeed during therapy.
• Tell patient that hair loss is a common side effect but typically reverses once treatment ends.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

**vinorelbine tartrate**

**Navelbine**

**Pharmacologic class:** Vinca alkaloid  
**Therapeutic class:** Antineoplastic  
**Pregnancy risk category D**

**FDA BOXED WARNING**

• Give under supervision of physician experienced in use of cancer chemotherapy, in facility with adequate diagnostic and treatment resources.  
• **Product is for I.V. use only.** Intrathecal administration of other vinca alkaloids has resulted in death. Syringes containing this product should be labeled “WARNING. FOR I.V. USE ONLY. FATAL IF GIVEN INTRATHECALLY.”
• Severe granulocytopenia causing increased susceptibility to infection may occur. Before starting drug, patient’s granulocyte count should be at least 1,000 cells/mm³. Adjust dosage according to complete blood counts (CBCs) with differentials obtained on day of treatment.
• **Make sure I.V. needle or catheter is properly positioned before injecting drug.** Administration may lead to extravasation, causing local tissue necrosis and thrombophlebitis.

**Action**

Blocks cell division and interferes with nucleic acid synthesis. Cell-cycle-phase specific.

**Availability**

*Injection:* 10 mg/ml in 1-ml and 5-ml vials

**Indications and dosages**

*Inoperable non-small-cell lung cancer*  
**Adults:** As monotherapy, 30 mg/m² I.V. weekly given over 6 to 10 minutes. In combination therapy, 25 mg/m² weekly given with cisplatin q 4 weeks. Alternatively, in combination therapy, 30 mg/m² I.V. given with cisplatin on days 1 and 29, then q 6 weeks.

**Dosage adjustment**

• Hepatic impairment  
• Neurotoxicity

**Off-label uses**

• Cervical, breast, or ovarian cancer

**Contraindications**

• Hypersensitivity to drug  
• Pretreatment granulocyte count below 1,000 cells/mm³

**Precautions**

Use cautiously in:  
• hepatic impairment, decreased bone marrow reserve, past or present neuropathy  
• history of radiation therapy  
• females of childbearing age  
• pregnant or breastfeeding patients (use not recommended)  
• children (safety not established).

**Administration**

*Follow facility protocols for handling and preparing chemotherapeutic drugs. Be especially careful to avoid eye contamination.*
Know that patient is usually premedicated with antiemetic.

Give by I.V. route only. (Intrathecal injection is fatal.)

Before use, dilute drug in syringe with dextrose 5% in water or normal saline solution to yield a concentration of 1.5 to 3 mg/ml. Or dilute in I.V. bag of compatible solution to yield a concentration of 0.5 to 2 mg/ml.

Administer into tubing of running I.V. line or directly into vein over 6 to 10 minutes. Immediately after injection, flush line with 75 to 125 ml of compatible I.V. solution.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>7-10 days</td>
<td>7-15 days</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: fatigue, neurotoxicity
CV: chest pain, phlebitis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, anorexia, pancreatitis, intestinal obstruction, paralytic ileus

Hematologic: anemia, bone marrow depression, severe granulocytopenia, neutropenia, thrombocytopenia

Metabolic: hyponatremia

Musculoskeletal: joint, back, or jaw pain; myalgia

Respiratory: acute respiratory distress syndrome, acute shortness of breath, bronchospasm, interstitial pulmonary changes

Skin: alopecia, rash, skin reactions

Other: tumor site pain; irritation, pain, and phlebitis at I.V. site; sepsis

Interactions

Drug-drug. Cisplatin, other antineoplastics: increased risk and severity of bone marrow depression

Mitomycin: increased risk of acute pulmonary reaction

Drug-diagnostic tests. Bilirubin, hepatic enzymes, liver function tests: increased values

Reactions in bold are life-threatening.

Patient monitoring

Monitor vital signs closely.

Assess liver function tests and CBC with platelet count.

Watch for signs and symptoms of infection.

Observe injection site closely for reactions and extravasation.

Closely monitor neurologic and respiratory status. Drug may lead to acute pulmonary changes, especially in patients who previously received mitomycin.

Patient teaching

Explain drug therapy to patient. Emphasize importance of follow-up laboratory tests.

Advise patient to promptly report signs and symptoms of infection and to take his temperature daily.

Tell patient that hair loss is a common side effect but typically reverses once treatment ends.

Instruct female of childbearing age to avoid pregnancy. Caution her not to breastfeed during therapy.

Urge patient to practice good oral hygiene, to help prevent infected mouth sores.

As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.
**Action**
Inhibits fungal cytochrome P450–mediated 14-alpha-lanosterol demethylation, preventing fungal biosynthesis and inactivating fungal cell

**Availability**
*Lyophilized powder for injection:* 200 mg  
*Powder for oral suspension:* 45 g in 100-ml bottle  
*Tablets:* 50 mg, 200 mg

**Indications and dosages**
- **Invasive aspergillosis:** serious fungal infections caused by *Scedosporium apiospermum* and *Fusarium* species  
  **Adults and children older than age 12:** Initially, 6 mg/kg I.V. q 12 hours for two doses (each dose infused over 1 to 2 hours), followed by a maintenance dose of 4 mg/kg I.V. q 12 hours given no faster than 3 mg/kg/hour. Change to oral dosing as described below when patient can tolerate it.  
  **Adults and children older than age 12 weighing more than 40 kg (88 lb):** 200 mg P.O. q 12 hours 1 hour before or after a meal; may increase to 300 mg P.O. q 12 hours p.r.n.  
  **Adults and children older than age 12 weighing less than 40 kg (88 lb):** 100 mg P.O. q 12 hours at least 1 hour before or after a meal; may increase to 150 mg P.O. q 12 hours p.r.n.  
- **Esophageal candidiasis**  
  **Adults and children older than age 12 weighing 40 kg (88 lb) or more:** 200 mg P.O. q 12 hours for at least 14 days, and for at least 7 days after symptoms resolve  
  **Adults and children older than age 12 weighing less than 40 kg (88 lb):** 100 mg P.O. q 12 hours for at least 14 days, and for at least 7 days after symptoms resolve

**Dosage adjustment**
- Hepatic cirrhosis
- Renal impairment

**Off-label uses**
- Febrile neutropenia (as empiric therapy)

**Contraindications**
- Hypersensitivity to drug or its components  
- Concurrent use of long-acting barbiturates, ergot alkaloids, rifabutin, rifampin, CYP450-3A4 substrates (such as astemizole, cisapride, pimozide, quinidine, terfenadine), sirolimus, ritonavir, efavirenz, or carbamazepine

**Precautions**
Use cautiously in:  
- Hypersensitivity to other azoles  
- Renal disease, mild to moderate hepatic cirrhosis, lactose or galactose intolerance  
- Pregnant or breastfeeding patients

**Administration**
- Correct electrolyte disturbances before therapy starts.  
  **Don’t give concurrently with astemizole, cisapride, or terfenadine (no longer available in U.S.):** carba-  
  mazepine; efavirenz; ergot alkaloids; long-acting barbiturates; pimozide; quinidine; rifabutin; rifampin; riton- 
  avir; or sirolimus.  
- Reconstitute powder with 19 ml of water for injection, to yield a volume of 20 ml. Shake vial until powder dis- 
  solves. Withdraw prescribed dose, then dilute further in compatible I.V. solution to a final concentration of  
  0.5 to 5 mg/ml. Give I.V. over 1 to 2 hours at a rate not exceeding 3 mg/kg/hour.  
- Don’t give through same I.V. line with other drugs, blood products, or electrolytes.  
- To reconstitute powder for oral sus- 
  pension, tap bottle to release powder. Add 46 ml of water, and shake vigorously for about 1 minute. Remove cap, 
  push bottle adapter into neck of bottle, and replace cap. After reconstitution,
suspension volume is 75 ml, providing usable volume of 70 ml (40 mg/ml). Shake bottle before each use. Use only 5-ml oral dispenser supplied. Don’t mix with other drugs, and don’t dilute further.
● Give oral suspension 1 hour before or after a meal.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>1-2 hr</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.V.</td>
<td>Start of infusion</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** dizziness, headache, hallucinations
**CV:** hypotension, hypertension, tachycardia, chest pain, vasodilation, peripheral edema
**EENT:** photophobia, blurred vision, visual disturbances, eye hemorrhage, chromatopsia
**GI:** nausea, vomiting, diarrhea, abdominal pain, dry mouth
**GU:** renal dysfunction, acute renal failure
**Hematologic:** anemia, pancytopenia, leukopenia, thrombocytopenia
**Hepatic:** cholestatic jaundice, hepatic failure
**Metabolic:** hypomagnesemia, hypokalemia
**Respiratory:** respiratory disorders
**Skin:** pruritus, maculopapular rash, erythema multiforme, toxic epidermal necrolysis, Stevens-Johnson syndrome
**Other:** chills, fever, sepsis, anaphylaxis

**Interactions**

**Drug-drug.** Barbiturates (long-acting), carbamazepine, phenytoin, rifampin: decreased voriconazole blood level
**Benzodiazepines:** sedation
**Calcium channel blockers, HMG-CoA reductase inhibitors:** increased blood levels of these drugs
**Cyclosporine, sirolimus, tacrolimus:** increased blood levels of these drugs, greater risk of nephrotoxicity

**CYP450-3A4 substrates:** increased blood levels of these drugs, causing prolonged QT interval and risk of torsades de pointes

**Ergot alkaloids:** increased blood levels of these drugs, resulting in ergotism

**Non-nucleoside reverse transcriptase inhibitors, protease inhibitors:** inhibited voriconazole metabolism

**Rifabutin:** decreased voriconazole blood level, increased rifabutin blood level

**Sulfonureas:** increased sulfonylurea blood level, greater risk of hypoglycemia

**Vinca alkaloids:** increased risk of neurotoxicity

**Warfarin, other coumarin derivatives:** increased partial thromboplastin time

**Drug-diagnostic tests.** Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, creatinine: increased levels

**Drug-herbs.** Gossypol: increased risk of nephrotoxicity

**Patient monitoring**

● Monitor kidney and liver function tests. Watch for signs and symptoms of organ toxicity.
● Assess electrolyte levels and CBC, including platelet count.

**Clinical alert**

● Monitor ECG. Stay alert for prolonged QT interval.
● Check for vision problems in therapy exceeding 28 days.

**Patient teaching**

● Explain therapy to patient. Stress importance of follow-up laboratory tests.
● Tell patient using oral form to take doses 1 hour before or after a meal.
● Emphasize importance of taking drug exactly as directed for entire duration prescribed.
● Instruct patient to promptly report adverse reactions.
● Tell female of childbearing age to immediately report pregnancy.

Reactions in **bold** are life-threatening.
● Caution patient to avoid driving and other hazardous activities, because drug may cause visual disturbances.
● Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
● As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

warfarin sodium
Apo-Warfarin®, Coumadin, Gen-Warfarin®, Jantoven, Marevan®, Novo-Warfarin®, Taro-Warfarin®

**Pharmacologic class:** Coumarin derivative

**Therapeutic class:** Anticoagulant

**Pregnancy risk category X**

**Action**
Interferes with synthesis of vitamin K–dependent clotting factors (II, VII, IX, and X) and anticoagulant proteins C and S in liver

**Availability**
*Injection:* 5.4 mg/vial (2 mg/ml when reconstituted)
*Tablets:* 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg, 10 mg

**Indications and dosages**
- Venous thrombosis; pulmonary embolism; atrial fibrillation; myocardial infarction (MI); thromboembolic complications of cardiac valve placement

**Adults:** Initially, 2.5 to 10 mg P.O. or I.V. daily for 2 to 4 days, then adjusted based on prothrombin time (PT) or International Normalized Ratio (INR). Usual maintenance dosage is 2 to 10 mg P.O. daily.

**Dosage adjustment**
● Elderly or debilitated patients

**Off-label uses**
- Acute coronary syndrome
- Intracoronary stent placement
- Prevention of catheter thrombosis

**Contraindications**
- Hypersensitivity to drug
- Uncontrolled bleeding
- Open wounds
- Severe hepatic disease
- Hemorrhagic or bleeding tendency
- Cerebrovascular hemorrhage
- Cerebral aneurysm or dissecting aorta
- Blood dyscrasias
- Pericarditis or pericardial effusion
- Bacterial endocarditis
- Malignant hypertension
- Recent brain, eye, or spinal cord injury or surgery
- Lumbar puncture and other procedures that may cause uncontrollable bleeding
- Major regional or lumbar block anesthesia
- Threatened abortion, eclampsia, pre eclampsia
- Unsupervised senile, alcoholic, or psychotic patients
- Pregnancy, females of childbearing potential

**Precautions**
Use cautiously in:
- cancer, heparin-induced thrombocytopenia, moderate to severe renal impairment, infectious GI disease, known or suspected deficiency in protein C–mediated anticoagulant response, polycythemia vera, vasculitis, severe diabetes mellitus
- indwelling catheter use
- history of poor compliance
- elderly or debilitated patients
- breastfeeding patients
- children younger than age 18 (safety and efficacy not established).

**Administration**

Be aware that warfarin is a high-alert drug.
- Know that I.V. form is reserved for patients who can’t tolerate oral form. I.V. and oral dosages are identical.
- For I.V. use, reconstitute vial with 2.7 ml of sterile water for injection; administer over 1 to 2 minutes. After reconstitution, drug is stable for 4 hours at room temperature.
- Be aware that vitamin K reverses warfarin effects. If major bleeding occurs, fresh frozen plasma may be given.
- When converting to warfarin from heparin, give both drugs concomitantly for 4 to 5 days until therapeutic effect of warfarin occurs.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Several hr</td>
<td>0.5-3 days</td>
<td>2-5 days</td>
</tr>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Adverse reactions**
- GI: nausea, vomiting, diarrhea, abdominal cramps, stomatitis, anorexia
- GU: hematuria
- Hematologic: eosinophilia, bleeding, hemorrhage, agranulocytosis, leukopenia
- Hepatic: hepatitis
- Skin: rash, dermatitis, urticaria, pruritus, alopecia, dermal necrosis
- Other: fever, “purple toes” syndrome (bilateral painful, purple lesions on toes and sides of feet), hypersensitivity reaction

**Interactions**

**Drug-drug.** Abciximab, acetaminophen (chronic use), androgens, aspirin, cephalosporins, cefamandole, cefoperazone, cefotetan, chloral hydrate, chloramphenicol, clopidogrel, disulfiram, epitiobidate, fluconazole, fluoroquinolones, itraconazole, metronidazole (including vaginal use), nonsteroidal anti-inflammatory drugs, plicamycin, quinidine, quinine, sulfonamides, thrombolytics, ticlopidine, tirofiban, valproic acid, zafirlukast: increased response to warfarin, greater risk of bleeding
- Barbiturates, hormonal contraceptives containing estrogen: decreased anticoagulant effect

**Drug-diagnostic tests.** Alanine aminotransferase, aspartate aminotransferase, INR: increased values
- Partial thromboplastin time, PT: prolonged

**Drug-food.** Vitamin K–rich foods (large amounts): antagonism of anticoagulant effect

**Drug-herbs.** Angelica: prolonged PT
- Anise, arnica, asafetida, bromelain, chamomile, clove, dansen, devil’s claw, dong quai, fenugreek, feverfew, garlic, ginger, ginkgo, ginseng, horse chestnut, licorice, meadowsweet, motherwort, onion, papain, parsley, passionflower, quassia, red clover, Reishi mushroom, rue, sweet clover, turmeric, white willow: increased risk of bleeding

Reactions in **bold** are life-threatening.  

Clinical alert
Coenzyme Q10, green tea, St. John’s wort: decreased anticoagulant effect

Drug-behaviors. Alcohol use: enhanced warfarin activity

Patient monitoring
- Monitor PT, INR, and liver function tests.
- Watch for signs and symptoms of bleeding and hepatitis.

Patient teaching
- Explain therapy to patient. Stress importance of adhering to schedule for laboratory tests.
- Instruct patient to promptly report unusual bleeding or bruising.
- Caution patient to consult prescriber before taking over-the-counter preparations or herbs.
- Advise patient to inform all other health care providers (including dentist) that he is taking warfarin.
- Tell patient not to vary his intake of foods high in vitamin K (such as leafy green vegetables, fish, pork, green tea, and tomatoes), to avoid alterations in drug’s anticoagulant effect.
- Instruct females of childbearing age to report pregnancy immediately.
- Stress importance of avoiding contact sports and other activities that could cause injury and bleeding.
- Caution patient to avoid alcohol during therapy.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

Zafirlukast

Accolate

Pharmacologic class: Leukotriene receptor antagonist

Therapeutic class: Antiasthmatic, bronchodilator

Pregnancy risk category B

Action
Antagonizes activity of three leukotrienes at specific receptor sites in airway smooth muscle, inhibiting inflammation

Availability
Tablets (coated): 10 mg, 20 mg

Indications and dosages
- Prophylaxis and long-term treatment of asthma

Adults and children ages 12 and older: 20 mg P.O. b.i.d.

Children ages 5 to 11: 10 mg P.O. b.i.d.

Dosage adjustment
- Hepatic impairment

Off-label uses
- Exercise-induced bronchospasm
- Chronic urticaria

Contraindications
- Hypersensitivity to drug or its components

Precautions
Use cautiously in:
- hepatic disease, acute asthma attacks
- patients older than age 55
- pregnant patients
- breastfeeding patients (use not recommended)
● children younger than age 7 (safety not established).

**Administration**
● Give at least 1 hour before or 2 hours after a meal.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>30 min</td>
<td>3.5 hr</td>
<td>12 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**
CNS: headache, dizziness, asthenia
GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia
Musculoskeletal: joint or back pain, myalgia
Other: fever, infection, pain

**Interactions**
Drug-drug. **Aspirin**: increased zafirlukast blood level
**Erythromycin, theophylline**: decreased zafirlukast blood level
**Warfarin**: increased warfarin effects, greater risk of bleeding
Drug-food. Any food: decreased rate and extent of zafirlukast absorption

**Patient monitoring**
● Assess patient’s respiratory status to help evaluate drug efficacy.

**Patient teaching**
● Tell patient to take at least 1 hour before or 2 hours after a meal.
● Advise patient to take exactly as prescribed, even if he is symptom-free.
_purchase_ Tell patient to immediately report asthma attack. Advise him not to use drug for rapid relief of bronchospasm.
● Instruct patient to continue taking other asthma drugs unless prescriber directs otherwise.
● Instruct female patient to consult prescriber if she plans to breastfeed.
● As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and foods mentioned above.

---

**zaleplon**
Sonata

**Pharmacologic class:** Pyrazolopyrimidine, nonbenzodiazepine hypnotic
**Therapeutic class:** Sedative-hypnotic
**Controlled substance schedule IV**
**Pregnancy risk category C**

**Action**
Binds to omega-1 receptor of gamma-aminobutyric acid receptor complex, relaxing smooth muscles, reducing anxiety, and producing sedation. Also has anticonvulsant effect.

**Availability**
Capsules: 5 mg, 10 mg

**Indications and dosages**
(gt) Insomnia
**Adults younger than age 65:** 10 mg P.O. at bedtime. Dosage above 20 mg is not recommended.

**Dosage adjustment**
● Mild to moderate hepatic impairment
● Elderly or debilitated patients

**Contraindications**
● Hypersensitivity to drug or its components

**Precautions**
Use cautiously in:
● tartrazine sensitivity
● severe renal impairment (use not recommended), mild to moderate hepatic impairment, respiratory impairment, depression
● history of suicide attempt
● patients weighing less than 50 kg (110 lb)
● patients older than age 65
● pregnant or breastfeeding patients (use not recommended)
• children younger than age 18 (safety not established).

**Administration**
• Give at bedtime.
• Don’t administer with high-fat meal.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>1 hr</td>
<td>3-4 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

**CNS:** headache, amnesia, anxiety, hallucinations, light-headedness, dizziness, drowsiness, depersonalization, transient memory or psychomotor impairment, incoordination, malaise, vertigo, asthenia, hyperesthesia, paresthesia, tremor

**CV:** peripheral edema

**EENT:** abnormal vision, eye pain, ear pain, hearing sensitivity, epistaxis

**GI:** nausea, abdominal pain, colitis, dyspepsia, anorexia

**GU:** dysmenorrhea

**Musculoskeletal:** myalgia

**Skin:** photosensitivity

**Other:** altered sense of smell, fever

**Interactions**

**Drug-drug.** Cimetidine: decreased metabolism and increased effects of zaleplon

CNS depressants (including antihistamines, opioids, other sedative-hypnotics, phenothiazines, tricyclic antidepressants): additive CNS depression

CYP450-3A4 inducers (such as carbamazepine, phenobarbital, phenytoin, rifampin): decreased blood level and reduced efficacy of zaleplon

CYP450-3A4 inhibitors (such as erythromycin, ketoconazole): increased zaleplon blood level

**Drug-food.** High-fat meal: delayed drug absorption

**Drug-herbs.** Chamomile, hops, kava, skullcap, valerian: increased CNS depression

**Drug-behaviors.** Alcohol use: increased CNS depression

**Patient monitoring**
• Monitor drug efficacy. Insomnia persisting after 7 to 10 days warrants re-evaluation for underlying psychological or physical illness.
• Stay alert for adverse drug reactions.

**Patient teaching**
• Explain therapy to patient. Emphasize importance of taking drug just before bedtime or after trying to sleep—but only if he will be able to get at least 4 hours of sleep.
• Inform patient that high-fat meal slows drug absorption and delays drug effects.
• Caution patient to avoid driving and other hazardous activities while under drug’s influence.
• Instruct patient to avoid alcohol during therapy.
• Tell patient rebound insomnia may occur for 1 or 2 nights after he stops taking drug.
• Advise female of childbearing age to notify prescriber if she is or plans to become pregnant or if she is breastfeeding.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, foods, herbs, and behaviors mentioned above.

**zanamivir**

**Relenza**

**Pharmacologic class:** Neuraminidase inhibitor

**Therapeutic class:** Antiviral

**Pregnancy risk category C**

**Action**
Inhibits influenza virus neuraminidase, an enzyme essential for viral replication
Availability

Powder for inhalation: 5 mg/blister

Indications and dosages

➣ Prevention of influenza

Adults and children ages 5 and older:
Prophylaxis in the household setting, 2 inhalations (10 mg) once daily for 10 days. Prophylaxis during community outbreaks, 2 inhalations (10 mg) once daily for 28 days.

➣ Influenza virus A or B

Adults and children ages 7 and older:
Two oral inhalations (5 mg/inhalation) b.i.d. for 5 days

Contraindications

• Hypersensitivity to drug or its components

Precautions

Use cautiously in:
• chronic obstructive pulmonary disease, asthma, lactose intolerance
• pregnant or breastfeeding patients
• children younger than age 7 (safety not established).

Administration

• Give two doses on day 1, spaced at least 2 hours apart. On subsequent days, space doses 12 hours apart, and give at approximately same time each day.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhalation</td>
<td>Rapid</td>
<td>1-2 hr</td>
<td>12 hr</td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: headache, dizziness
EENT: sinusitis, EENT infections
GI: nausea, vomiting, diarrhea
Respiratory: bronchitis, cough
Other: allergic reaction

Interactions

None significant

Patient teaching

• Explain therapy to patient. Demonstrate how to use Diskhaler device.
• Tell patient to take drug exactly as prescribed for as long as directed, even if symptoms improve.
• If patient is also taking an inhaled bronchodilator, advise him to take bronchodilator before zanamivir.
• Emphasize that drug doesn’t prevent spread of influenza to others.
• Instruct patient to immediately report worsening respiratory symptoms.
• As appropriate, review other significant adverse reactions.

zidovudine

Apo-Zidovudine®, Novo-AZT®, Retrovir

Pharmacologic class: Nucleoside reverse transcriptase inhibitor
Therapeutic class: Antiretroviral
Pregnancy risk category C

FDA BOXED WARNING

• Drug has been linked to hematologic toxicity (including neutropenia and severe anemia), particularly in patients with advanced human immunodeficiency virus (HIV) infection. Prolonged use is associated with symptomatic myopathy.
• Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have occurred with use of nucleoside analogs alone or in combination, including zidovudine and other antiretrovirals.

Action

After conversion to its active metabolite, inhibits activity of HIV reverse transcriptase and terminates viral DNA growth
Availability
Capsules: 300 mg
Injection: 10 mg/ml in 20-ml vial
Syrup: 50 mg/5 ml
Tablets: 100 mg

Indications and dosages ➢ HIV infection
Adults and children older than age 12: 200 mg P.O. t.i.d. or 300 mg P.O. b.i.d. for a total daily dosage of 600 mg/day, or 1 mg/kg I.V. five to six times daily; usually given with other antiretrovirals
Children ages 6 weeks to 12 years: 160 mg/m² P.O. q 8 hours (480 mg/m²/day, to a maximum of 200 mg q 8 hours), given with other antiretrovirals ➢ To prevent maternal-fetal HIV transmission
Pregnant women: 500 mg P.O. daily in divided doses (usually as five 100-mg doses) until labor begins; then 2 mg/kg I.V. over 1 hour followed by a continuous infusion of 1 mg/kg/hour until umbilical cord is clamped
Neonates: 2 mg/kg P.O. q 6 hours starting within 12 hours of delivery and continuing for 6 weeks

Dosage adjustment
● Hepatic or renal impairment

Off-label uses
● Occupational exposure to HIV

Contraindications
● Hypersensitivity to drug or its components
● Concomitant use of Combivir or Trizivir (zidovudine-containing products)

Precautions
Use cautiously in:
● renal or hepatic impairment, decreased bone marrow reserve, hemoglobin less than 9.5 g/dl, granulocyte count less than 1,000 cells/mm³
● pregnant or breastfeeding patients.

Administration
● For I.V. use, remove dose from vial and add to I.V. solution containing dextrose 5% in water, to yield a final concentration no higher than 4 mg/ml. Infuse over 1 hour.
● In adults, give by I.V. route only until patient can tolerate oral dose.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Variable</td>
<td>30-90 min</td>
<td>4 hr</td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>End of infusion</td>
<td>4 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: headache, paresthesia, malaise, insomnia, dizziness, drowsiness, asthenia, seizures
GI: nausea, vomiting, constipation, abdominal pain, dyspepsia, anorexia, pancreatitis
Hematologic: severe anemia (necessitating transfusions), agranulocytopenia, severe bone marrow depression
Musculoskeletal: myalgia, back pain, myopathy
Respiratory: dyspnea
Skin: diaphoresis, rash, altered nail pigmentation
Other: abnormal taste, fever

Interactions
Drug-drug. Acetaminophen, aspirin, indomethacin: increased risk of zidovudine toxicity
Amphotericin B, dapsone, flucytosine, pentamidine: increased risk of nephrotoxicity and bone marrow depression
Cyclosporine: extreme drowsiness, lethargy
Cytotoxic drugs, myelosuppressants, nephrotoxic drugs (such as ganciclovir, interferon alfa): increased risk of hematologic toxicity
Fluconazole, methadone, probenecid, valproic acid: increased zidovudine blood level, greater risk of toxicity
Ribavirin: antagonism of zidovudine’s antiviral activity

Drug-diagnostic tests. Granulocytes, hemoglobin, platelets: decreased levels

Canada UK Hazardous drug High alert drug
Drug-herbs. St. John’s wort: decreased zidovudine efficacy

Patient monitoring
- Monitor neurologic status, especially for signs and symptoms of impending seizure.
  - Periodically assess CBC and kidney and liver function tests. Be aware that drug can cause hepatotoxicity.
- Watch for signs and symptoms of pancreatitis.

Patient teaching
- Tell patient he may take with or without food.
- Instruct patient to take capsules with at least 4 oz of fluid and to stay upright after taking.
- Explain therapy to patient. Emphasize that drug doesn’t cure HIV infection.
- Urge patient to take drug exactly as prescribed.
- Teach patient to recognize and immediately report signs and symptoms of serious side effects, such as seizures.
- Stress importance of follow-up laboratory testing.
- Advise female of childbearing age to use effective contraception.
- Inform pregnant patient that drug reduces risk of, but may not prevent, HIV transmission to neonate.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

FDA BOXED WARNING
- Elderly patients with dementia-related psychosis are at increased risk for death. Although causes of death varied, most appeared to be cardiovascular or infectious.
- Drug isn’t approved for treatment of dementia-related psychosis.

Action
Unknown. Thought to antagonize dopamine₂ and serotonin₂ receptors.

Availability
Capsules: 20 mg, 40 mg, 60 mg, 80 mg
Injection: 20 mg/ml

Indications and dosages
Schizophrenia
Adults: Initially, 20 mg P.O. b.i.d. with food; may increase q 2 days up to 80 mg b.i.d. Usual maintenance dosage is 20 to 80 mg P.O. b.i.d.; maximum recommended dosage is 80 mg b.i.d. For prompt control of acute agitation, 10 to 20 mg I.M. as a single dose; depending on patient’s response, may repeat 10-mg I.M. dose q 2 hours or 20-mg I.M. dose q 4 hours to a maximum daily dosage of 40 mg.

Contraindications
- Hypersensitivity to drug
- History of arrhythmias, prolonged QT interval
- Recent myocardial infarction
- Uncompensated heart failure
- Concomitant use of arsenic trioxide, chlorpromazine, class IA or III anti-arrhythmics, or other drugs that prolong the QT interval

Precautions
Use cautiously in:
- cardiovascular disorders, dysphagia, hyperprolactinemia, bradycardia, hypokalemia, hypomagnesemia
• adverse reactions with previous use of atypical antipsychotics (such as risperidone or clozapine)
• pregnant patients.

Administration
• Give with food.
• Know that P.O. therapy should replace I.M. therapy as soon as possible.
• Don’t give with drugs that prolong the QT interval.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Several hr</td>
<td>1-3 days</td>
<td>Unknown</td>
</tr>
<tr>
<td>I.M.</td>
<td>Unknown</td>
<td>1 hr</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: dizziness, drowsiness, dystonia, hypertonia, asthenia, akathisia, extrapyramidal reactions, agitation, headache, insomnia, personality disorder, paresthesia, speech disorder, neuroleptic malignant syndrome, seizures, suicide attempt
CV: orthostatic hypotension, hypertension, tachycardia, arrhythmias (from prolonged QT interval)
EENT: abnormal vision, rhinitis
GI: nausea, vomiting, diarrhea, constipation, dyspepsia, dry mouth, anorexia
GU: dysmenorrhea, priapism
Musculoskeletal: myalgia
Respiratory: cough, cold symptoms
Skin: urticaria, rash, fungal dermatitis, diaphoresis, photosensitivity
Other: accidental injury, pain at I.M. injection site

Interactions
Drug-drug. Antihypertensives: additive hypotension
Carbamazepine: decreased ziprasidone blood level
Centrally acting drugs: additive CNS effects
Dopamine agonists, levodopa: antagonism of these drugs’ effects
Drugs that decrease potassium or magnesium level (such as diuretics) or prolong QT interval (such as dofetilide, moxifloxacin, pimozide, quinidine, sotalol, sparfloxacin, thioridazine): increased risk of arrhythmias
Ketoconazole: increased ziprasidone blood level
Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression

Patient monitoring
• Monitor ECG before and during therapy. Stay alert for prolonged QT interval.
• Assess blood pressure for hypertension and orthostatic hypotension.
  ⬤ Monitor neurologic status, especially for and neuroleptic malignant syndrome.
  ⬤ Watch for adverse reactions. Know that dizziness, syncope, or palpitations may signify life-threatening arrhythmias caused by prolonged QT interval.
  ⬤ Be aware that patient with bradycardia, hypokalemia, or hypomagnesemia is at greater risk for torsades de pointes and sudden death.

Patient teaching
• Tell patient to take with food.
• Explain therapy and need for follow-up laboratory testing.
  ⬤ Advise patient to promptly report fainting, seizures, high fever, sweating, unstable blood pressure, stupor, muscle rigidity, or suspected infection.
• Instruct patient to consult prescriber before taking over-the-counter preparations.
• Caution patient to avoid driving and other hazardous activities until drug effects are known.
• Instruct patient to move slowly when sitting up or standing, to avoid dizziness from sudden blood pressure drop.
• Advise patient to avoid sun exposure and to wear sunscreen and protective clothing when going outdoors.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially

Canada UK Hazardous drug High alert drug
those related to the drugs and herbs mentioned above.

zoledronic acid
Aclasta®, Reclast, Zometa

*Pharmacologic class:* Third-generation bisphosphonate

*Therapeutic class:* Calcium regulator

*Pregnancy risk category D*

**Action**
Inhibits osteoclast-mediated bone by blocking resorption of mineralized bone and cartilage, eventually causing cell death and limiting tumor growth. Also limits calcium release produced by tumor.

**Availability**
*Lyophilized powder for injection (Zometa):* 4 mg/ vial

*Solution for infusion (Reclast):* 5 mg/100 ml

**Indications and dosages**

➤ Hypercalcemia caused by cancer

**Adults:** 4 mg (Zometa) I.V. as a single dose infused over 15 minutes. If albumin-corrected calcium level doesn’t return to normal or stay normal, retreatment with 4 mg I.V. begins no sooner than 7 days after initial treatment. For single dose, maximum recommended dosage is 4 mg.

➤ Multiple myeloma; bone metastasis from solid tumors

**Adults:** 4 mg I.V. (Zometa) as a single dose infused over 15 minutes q 3 to 4 weeks. Treatment may continue for 9 to 15 months, depending on clinical condition.

➤ Paget’s disease of bone

**Adults:** 5 mg (Reclast) I.V. as single dose in 100 ml ready-to-infuse solution infused over 15 minutes with constant infusion rate by vented infusion line

➤ Osteoporosis in postmenopausal women

**Adults:** 5 mg (Reclast) I.V. as single 5-mg infusion over 15 minutes once yearly

**Dosage adjustment**

● Renal impairment

**Contraindications**

● Hypersensitivity to drug, its components, or other bisphosphonates

● Hypocalcemia (Reclast)

● Pregnancy (Zometa)

● Breastfeeding (Reclast)

**Precautions**

Use cautiously in:

● Bone metastasis with severe renal impairment

● Asthma, renal dysfunction, hepatic insufficiency, history of hypoparathyroidism

● Pregnant patients (Reclast use not recommended).

**Administration**

● Before starting therapy, make sure patient is adequately hydrated.

● Don’t allow drug to come in contact with calcium-containing solutions; administer as single I.V. solution.

● Reconstitute Zometa by adding 5 ml of sterile water for injection to 4-mg vial. Dilute further by adding reconstituted drug to 100 ml of normal saline solution or dextrose 5% in water.

● Give Reclast I.V. in 100 ml ready-to-infuse solution administered by vented infusion line. Infusion time must not be less than 15 minutes, with constant infusion rate.

● Be aware that a single Reclast dose shouldn’t exceed 5 mg.

➤ Give by I.V. infusion over no less than 15 minutes. (Faster infusion may cause renal failure.)
Be aware that patient receiving Zomata usually receives daily oral calcium supplement of 500 mg and multivitamin containing 400 international units of vitamin D.

Patients with Paget’s disease should receive 1,500 mg elemental calcium and 800 international units vitamin D daily, particularly during the 2 weeks after Reclast dosing.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.V.</td>
<td>Unknown</td>
<td>Unknown</td>
<td>7-28 days</td>
</tr>
<tr>
<td>(Zometa)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I.V.</td>
<td>Rapid</td>
<td>End of infusion</td>
<td>Short</td>
</tr>
<tr>
<td>(Reclast)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adverse reactions

CNS: dizziness, lethargy, rigors, asthenia, headache, agitation, confusion, insomnia, anxiety, drowsiness, fatigue, paresthesia
CV: hypotension
EENT: conjunctivitis
GI: nausea, vomiting, diarrhea, constipation, dysphagia, anorexia
GU: urinary tract infection, renal toxicity
Hematologic: anemia, neutropenia
Metabolic: dehydration, hypomagnesemia, hypocalcemia, hypophosphatemia
Musculoskeletal: myalgia, joint or bone pain osteonecrosis of jaw
Respiratory: dyspnea, cough, pleural effusion
Skin: rash
Other: flulike syndrome, pyrexia, pain, peripheral edema, infection, fever, chills, infusion site reactions

Interactions

Drug-drug. Aminoglycosides, loop diuretics, other nephrotoxic agents, thalidomide: increased risk of renal toxicity

Drug-diagnostic tests. Calcium, hemoglobin, magnesium, phosphorus, platelets, potassium, red blood cells, white blood cells: decreased levels
Creatinine: increased or decreased level

Patient monitoring

- Monitor electrolyte levels (especially calcium). Watch for signs and symptoms of electrolyte imbalance.
- Assess vital signs. Stay alert for hypotension, dyspnea, and pleural effusion.
  - Closely monitor fluid intake and output and creatinine level. Check for signs and symptoms of renal toxicity.
  - Monitor CBC with platelet count.

Patient teaching

- Explain therapy to patient, including associated risk of renal failure and need for follow-up laboratory tests.
- Tell patient to report shortness of breath, unusual bleeding or bruising, decreased urine output, or other significant problems.
- Instruct patient to take daily oral calcium supplement and multivitamin containing vitamin D as prescribed.
- Tell patient to avoid invasive dental procedures while taking this drug.
- Advise female of childbearing age to avoid pregnancy and breastfeeding.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

zolmitriptan

Zomig Rapimelt, Zomig-ZMT

Pharmacologic class: Selective 5-hydroxytryptamine receptor agonist

Therapeutic class: Antimigraine agent

Pregnancy risk category C

Action

Blocks serotonin release, constricting inflamed and dilated cerebral and cranial blood vessels and reducing nerve transmission in trigeminal pain pathways
Availability
Nasal spray: 5-mg single-use spray device
Tablets (immediate-release): 2.5 mg, 5 mg
Tablets (orally disintegrating): 2.5 mg

Indications and dosages
Adults: 1.25 to 2.5 mg (immediate-release) P.O., repeated if migraine returns in 2 hours or less; maximum dosage is 10 mg in any 24-hour period. Or 2.5 mg (orally disintegrating tablet) P.O., repeated if migraine returns in 2 hours or less; maximum dosage is 10 mg in any 24-hour period. Alternatively, one dose of nasal spray (5 mg); if migraine returns, may repeat dose after 2 hours; don’t exceed maximum daily dosage of 10 mg in any 24-hour period.

Dosage adjustment
• Hepatic impairment

Contraindications
• Hypersensitivity to drug
• Hemiplegic or basilar migraine
• Ischemic cardiac disease or other significant cardiac disease
• Uncontrolled hypertension
• Cerebrovascular accident or transient ischemic attack
• Peripheral vascular disease, including ischemic bowel disease
• Use of ergot-type or ergot-containing drugs or other 5-HT\textsubscript{1} agonists within past 24 hours
• MAO inhibitor use within past 14 days

Precautions
Use cautiously in:
• hepatic or renal impairment
• risk factors for coronary artery disease (such as strong family history of this disease, diabetes mellitus, obesity, cigarette smoking, high cholesterol level, men older than age 40, postmenopausal women)

• elderly patients
• pregnant or breastfeeding patients
• children.

Administration
• Place orally disintegrating tablet on patient’s tongue, where it should dissolve.
• Don’t break orally disintegrating tablet in half.
• Know that each nasal spray unit is intended for one use only.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2 hr</td>
<td>Unknown</td>
</tr>
<tr>
<td>Nasal</td>
<td>15 min</td>
<td>2-5 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: paresthesia, asthenia, dizziness, insomnia, hyperesthesia, drowsiness, syncope, vertigo, agitation, depression, anxiety, emotional lability, fatigue, malaise
CV: chest pain, heaviness, or tightness; hypertension; palpitations; angina; arrhythmias
EENT: dry eyes, ear pain, tinnitus, epistaxis, altered sense of smell, laryngitis
GI: nausea, vomiting, dyspepsia, dysphagia, gastroenteritis, esophagitis, dry mouth
GU: urinary frequency, hematuria, polyuria, cystitis
Hepatic: hepatic dysfunction
Metabolic: hyperglycemia
Musculoskeletal: leg cramps, neck pain, tenosynovitis, myasthenia, myalgia, back pain
Respiratory: bronchitis, hiccups
Skin: pruritus, rash, diaphoresis, bruising, urticaria, photosensitivity
Other: unusual taste, flushing, sweating or redness in face (with nasal spray); fever; chills; excessive thirst; facial or tongue edema; pressure or tightness in throat or jaw; yawning; warm or cold sensation

Interactions
Drug-drug. Cimetidine: doubling of zolmitriptan’s half-life

Reactions in **bold** are life-threatening.
Ergot-containing drugs: vasospasm
Fluoxetine, fluvoxamine, paroxetine, sertraline: weakness, incoordination, hyperreflexia
MAO inhibitors: increased zolmitriptan effects

Drug-diagnostic tests. Blood glucose: increased level

Drug-herbs. S-adenosylmethionine (SAM-e), St. John’s wort: serotonin syndrome

Drug-behaviors. Smoking: increased risk of adverse cardiovascular effects

Patient monitoring
- Assess therapeutic response to help gauge drug efficacy.
- Watch for adverse cardiovascular and respiratory reactions, particularly dyspnea and chest pain or tightness.
- Assess blood glucose level in diabetic patient.

Patient teaching
- Tell patient to immediately report shortness of breath or pain or tightness in chest or throat.
- Explain that drug is intended to treat migraine, not prevent it.
- Tell patient to remove orally disintegrating tablet from blister pack just before taking it, and then place it on his tongue and let it dissolve. Instruct him not to break it.
- Teach patient proper use of nasal spray. Tell him each unit is intended for one use only.
- Caution patient to avoid driving and other hazardous activities during severe migraine or if drug causes adverse CNS effects.
- Inform patient that smoking may increase drug’s cardiovascular risks.
- Advise female of childbearing age not to take drug if she is, might be, or plans to become pregnant.
- Advise patient to avoid sun exposure and to wear sunscreen and protective clothing when going outdoors.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

zolpidem tartrate
Ambien, Ambien CR, Stilnoct®

Pharmacologic class: Imidazopyridine
Therapeutic class: Sedative-hypnotic
Controlled substance schedule IV
Pregnancy risk category B

Action
Depresses CNS by binding to gamma-aminobutyric acid receptors

Availability
Tablets: 5 mg, 6.25 mg, 10 mg, 12.5 mg

Indications and dosages
Insomnia
Adults: 10 mg P.O. (Ambien) or 12.5 mg P.O. (Ambien CR) immediately before bedtime

Dosage adjustment
- Hepatic impairment
- Elderly or debilitated patients

Off-label uses
- Long-term treatment of insomnia
- Insomnia related to selective serotonin reuptake inhibitors
- Postoperative sedation

Contraindications
- Hypersensitivity to drug

Precautions
Use cautiously in:
- pulmonary disease, hepatic or severe renal impairment
- history of psychiatric illness, suicide attempt, or substance abuse
● elderly or debilitated patients
● pregnant or breastfeeding patients
● children (safety not established).

Administration
● Don’t give with or immediately after a meal.
● Know that dosage may need to be decreased if patient’s receiving other CNS depressants.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Rapid</td>
<td>30 min-2 hr</td>
<td>6-8 hr</td>
</tr>
</tbody>
</table>

Adverse reactions
CNS: amnesia, ataxia, confusion, euphoria, vertigo, daytime drowsiness, dizziness, drugged feeling
EENT: diplopia, abnormal vision
GI: nausea, vomiting, diarrhea, dry mouth
Other: hypersensitivity reaction, physical or psychological drug dependence, drug tolerance

Interactions
Drug-drug. Antihistamines, opioid analgesics, phenothiazines, sedative-hypnotics, tricyclic antidepressants: increased CNS depression
Ketoconazole, ritonavir: increased blood level and enhanced effects of zolpidem
Rifampin: decreased zolpidem efficacy
Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression
Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring
● Monitor for physical and psychological drug dependence. Watch for drug hoarding.
● Assess for adverse reactions, including confusion, ataxia, and amnesia.

Patient teaching
● Tell patient to take immediately before bedtime (and not after a meal), because it works quickly.
● Advise patient to take only when he is able to get a full night’s sleep (7 to 8 hours) before he needs to be active again.
● Stress that drug is meant only for short-term use (7 to 10 days).
● Tell patient rebound insomnia may occur for 1 to 2 nights after he discontinues drug.
● Inform patient that drug may cause amnesia, drowsiness, and a drugged feeling the next day.
● Caution patient to avoid driving and other hazardous activities while under drug’s influence.
● As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, herbs, and behaviors mentioned above.

Reactions in bold are life-threatening.

Clinical alert
Zonisamide

**Dosage adjustment**
- Hepatic or renal impairment
- Elderly patients

**Off-label uses**
- Infantile spasms
- Progressive myoclonic epilepsy
- Weight loss

**Contraindications**
- Hypersensitivity to drug or other sulfonamides

**Precautions**
Use cautiously in:
- hepatic or renal disease
- pregnant or breastfeeding patients
- children younger than age 16 (safety not established)

**Administration**
- Give with or without food.

<table>
<thead>
<tr>
<th>Route</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>P.O.</td>
<td>Unknown</td>
<td>2-6 hr</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

**Adverse reactions**

CNS:
- drowsiness, fatigue, agitation, irritability, depression, dizziness, psychomotor slowing, psychosis, asthenia, abnormal gait, incoordination, tremor, ataxia, headache, confusion, impaired memory, hyperesthesia, paresthesia, seizures

EENT:
- diplopia, amblyopia, nystagmus, tinnitus, rhinitis, pharyngitis

GI:
- nausea, vomiting, diarrhea, dyspepsia, dry mouth, anorexia

GU:
- renal calculi

Hematologic:
- anemia, leukopenia

Respiratory:
- cough

Skin:
- rash, pruritus, bruising, Stevens-Johnson syndrome

Other:
- abnormal taste, weight loss, allergic reactions, oligohydrosis and hyperthermia (in children), flulike symptoms, accidental injury

**Interactions**

**Drug-drug.**
- Carbamazepine, phenobarbital, phenytoin, valproic acid: decreased zonisamide blood level and effects
- CYP450-3A4 inducers: decreased zonisamide half-life
- CYP450-3A4 inhibitors: increased zonisamide blood level

**Drug-diagnostic tests.**
- Blood urea nitrogen, creatinine: increased levels
- Platelets, white blood cells: decreased counts

**Patient monitoring**
- Monitor CBC with white cell differential.
- Assess neurologic status; report significant adverse reactions.
- Monitor renal function tests. Watch for signs and symptoms of renal calculi.
- Monitor for rash, which may be first sign of Stevens-Johnson syndrome. If rash occurs, discontinue drug and notify prescriber immediately.

**Patient teaching**
- Explain therapy to patient. Instruct him to keep seizure diary and show it to prescriber.
- Instruct patient to swallow capsules whole. Advise him to drink 6 to 8 glasses of water daily to help prevent kidney stones.
- Warn patient that stopping drug abruptly may cause status epilepticus.
- Caution patient to avoid driving and other hazardous activities until he knows how drug affects him and until seizures are well controlled.
- Tell patient to immediately report rash, fever, sore throat, sudden back pain, depression, speech or language problems, or painful urination.
- As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.
Part 2

Drug classes
Vitamins and minerals
Herbs and supplements
This page intentionally left blank
Drug classes

The collective monographs below cover the most common drug classes, and provide general information for the most commonly used generic drugs in each class. The drugs listed in each class are those covered in individual monographs in this book; the list is not intended to be comprehensive.

Keep in mind that drugs in the same class may vary as to contraindications, precautions, adverse reactions, interactions, and patient monitoring. For specific information on a particular drug, see the individual monograph. Also, because pregnancy risk category and interactions may differ for the drugs in a given class, this information is not included in the monographs below.

alpha₁-adrenergic agents

Alpha₁-adrenergic blockers:
alfuzosin hydrochloride, doxazosin mesylate, prazosin hydrochloride, tamsulosin hydrochloride, terazosin hydrochloride

Centrally acting alpha-adrenergic agonists: clonidine hydrochloride, methyldopa

Peripherally acting alpha-adrenergic agonists: midodrine hydrochloride

Action

Alpha₁-adrenergic blockers selectively block postsynaptic alpha₁-adrenergic receptors, causing dilation of arterioles and veins, in turn lowering supine and standing blood pressure. Centrally acting alpha-adrenergic agonists reduce sympathetic outflow from CNS and decrease peripheral resistance, renal vascular resistance, heart rate, and blood pressure. Peripherally acting alpha-adrenergic agonists activate alpha-adrenergic receptors of the arteriolar and venous vasculature, increasing vascular tone and blood pressure.

Indications

Hypertension, refractory heart failure, peripheral vascular disorders, benign prostatic hypertrophy, orthostatic hypotension (midodrine only), severe pain in cancer patients (injectable clonidine only)

Contraindications and precautions

- Contraindicated in hypersensitivity to drug
- Use cautiously in renal insufficiency, angina pectoris, overt heart failure, when adding diuretics to drug regimen, in pregnant or breastfeeding patients, and in children (safety not established).

Adverse reactions

CNS: dizziness, headache, asthenia, drowsiness, nervousness, paresthesia, vertigo, fatigue
CV: orthostatic hypotension (with first dose of alpha₁-adrenergic blocker), rebound hypertension, chest pain, palpitations, peripheral edema, tachycardia, arrhythmias
EENT: blurred vision, conjunctivitis, nasal congestion, sinusitis
GI: nausea, vomiting, diarrhea, abdominal pain, dry mouth
GU: urinary frequency or incontinence, priapism, erectile dysfunction, gynecomastia (with centrally acting agonists)
Musculoskeletal: joint, back, or extremity pain
Respiratory: dyspnea

Reactions in bold are life-threatening.
Skin: pruritus, angioedema, urticaria, alopecia (with centrally acting agonists)
Other: fever, weight gain

Patient monitoring
- Monitor electrolyte levels, ECG, and vital signs.

antacids
aluminum hydroxide, calcium carbonate, magnesium hydroxide, magnesium oxide, sodium bicarbonate

Action
Neutralize gastric acidity, which increases pH of stomach and duodenal bulb. Aluminum-containing antacids bind with phosphate ions in intestine to form insoluble aluminum phosphate, which is excreted in feces.

Indications
Peptic ulcer, gastric hyperacidity, upset stomach associated with hyperacidity. Magnesium oxide is indicated for magnesium deficiency or depletion caused by malnutrition, restricted diet, alcoholism, or magnesium-depleting drugs.

Contraindications and precautions
- Contraindicated in hypersensitivity to drug, renal calculi, hypercalcemia, and hypophosphatemia
- Use cautiously in renal impairment, chronic pain syndrome, recent massive GI hemorrhage, and pregnant patients.

Adverse reactions
CNS: aluminum toxicity, encephalopathy (aluminum-containing antacids)
GI: diarrhea (magnesium-containing antacids); constipation, possibly leading to intestinal obstruction (aluminum-containing antacids)
Metabolic: dose-dependent rebound hyperacidity; milk-alkali syndrome; hypermagnesemia in renal failure patients (magnesium-containing antacids); hypophosphatemia, aluminum accumulation in blood (aluminum-containing antacids)
Musculoskeletal: osteomalacia, aluminum accumulation in bone (aluminum-containing antacids)

Patient monitoring
- Assess for constipation.
- Monitor serum electrolyte levels as appropriate.

anti-Alzheimer's agents
donepezil hydrochloride, galantamine hydrobromide, memantine, rivastigmine tartrate, tacrine hydrochloride

Action
Reversibly inhibit acetylcholinesterase hydrolysis in CNS, which increases acetylcholine level and promotes nerve impulse transmission. Unlike donepezil, galantamine, and rivastigmine, memantine binds preferentially to cation channels operated by N-methyl-D-aspartate and doesn’t affect reversible acetylcholinesterase inhibition.

Indications
Mild to moderate Alzheimer’s disease, moderate to severe Alzheimer’s disease (memantine only)

Contraindications and precautions
- Contraindicated in hypersensitivity to drug, piperidine derivatives, or acridines; angle-closure glaucoma; undiagnosed skin lesions; and jaundice with previous use of these drugs
• Use cautiously in moderate to severe renal or hepatic dysfunction, GI bleeding, seizures, cardiovascular disease, sick sinus syndrome, asthma or chronic obstructive pulmonary disease, impaired urinary outflow, diabetes mellitus, obesity, history of ulcer, postmenopausal patients, elderly patients, pregnant or breastfeeding patients, and children.

Adverse reactions

CNS: tremor, confusion, insomnia, psychosis, hallucinations, depression, dizziness, headache, anxiety, nervousness, drowsiness, fatigue, abnormal dreams, irritability, paresthesia, aggression, vertigo, ataxia, restlessness, abnormal crying, syncope, aphasia, seizures

CV: chest pain, hypotension, hypertension, peripheral edema, vasodilation, atrial fibrillation

EENT: cataract, blurred vision, eye irritation, rhinitis, pharyngitis, sore throat

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, flatulence, eructation, anorexia

GU: urinary tract infection, urinary frequency or incontinence, increased libido

Metabolic: dehydration, hot flashes

Musculoskeletal: back and joint pain, bone fracture, muscle cramps, arthritis

Respiratory: upper respiratory infection, cough, bronchitis, dyspnea, influenza

Skin: rash, pruritus, urticaria, diaphoresis, flushing

Other: toothache, weight loss, pain, accidental trauma, flulike symptoms

Patient monitoring

• Assess for severe nausea, vomiting, and diarrhea (which may lead to dehydration and weight loss).

Watch closely for adverse reactions in patients with a history of GI bleeding, arrhythmias, seizures, pulmonary conditions, or use of nonsteroidal anti-inflammatory drugs.

• Monitor alanine aminotransferase level weekly during first 18 weeks of therapy.

antiarrhythmics

acebutolol hydrochloride, adenosine, amiodarone hydrochloride, digoxin, disopyramide phosphate, esmolol, flecainide acetate, ibutilide fumarate, lidocaine hydrochloride, mexiletine, phenytoin, phenytoin sodium, procainamide hydrochloride, propafenone hydrochloride, propranolol hydrochloride, quinidine gluconate, quinidine sulfate, sotalol hydrochloride, tocainide hydrochloride, verapamil hydrochloride

Action

Varies with classification and subdivision (which are based on drug’s action on cardiac muscle). 

Class I antiarrhythmics decrease rate of sodium entry during depolarization, reduce rate of action potential, and lengthen effective refractory period of fast-response fibers. Class I antiarrhythmics fall into three subdivisions. Class IA drugs (such as disopyramide, procainamide, and quinidine) depress phase 0 and lengthen the action potential. Class IB drugs (such as lidocaine, phenytoin, and tocainide) somewhat depress phase 0 and shorten the action potential. Class IC drugs (such as flecainide and propafenone) greatly depress phase 0 and slow conduction. Moricizine shares properties of class IA, IB, and IC antiarrhythmics.

Class II antiarrhythmics (such as propranolol) competitively block
beta-adrenergic receptors and depress phase 4 depolarization.

*Class III* antiarrhythmics (such as amiodarone, bretylium, dofetilide, ibutilide, and sotalol) prolong duration of the action potential but don’t affect polarization phase or resting membrane potential.

*Class IV* antiarrhythmics (calcium channel blockers such as verapamil) slow conduction velocity and increase atrioventricular (AV) node refractoriness.

**Indications**

Arrhythmias, premature ventricular tachycardia, atrial flutter, atrial fibrillation, AV heart block

**Contraindications and precautions**

- Contraindicated in hypersensitivity to drug, congenital or acquired long-QT syndrome, baseline QT or QTc interval greater than 440 msec, sick sinus syndrome, second- or third-degree AV block (unless patient has an artificial pacemaker), systolic pressure below 90 mm Hg, recent myocardial infarction or pulmonary congestion, pulmonary hypertension, aortic stenosis, severe renal impairment, digoxin toxicity, pregnancy, breastfeeding, and neonates
- Use cautiously in mild to moderate renal or hepatic impairment, enlarged prostate, myasthenia gravis, glaucoma, diabetes mellitus, potassium imbalance, conduction abnormalities, ventricular tachycardia, ventricular arrhythmias, history of serious ventricular arrhythmias or heart failure, elderly patients, and children (safety not established).

**Adverse reactions**

**CNS:** dizziness, light-headedness, agitation, jitteriness, anxiety, depression, fatigue, drowsiness, headache, syncope, malaise, involuntary movements, ataxia, paresthesia, peripheral neuropathy, incoordination, tremor, abnormal dreams, insomnia, confusion, acute psychosis, psychiatric disturbances

**CV:** chest pain, palpitations, peripheral edema, bradycardia, tachycardia, hypotension, development or worsening of arrhythmias, heart failure, heart block

**EENT:** blurred vision, angle-closure glaucoma, corneal microdeposits, optic neuritis or neuropathy, photophobia, dry eyes, tinnitus, disturbed equilibrium, epistaxis, dry nose, altered smell perception

**GI:** nausea, vomiting, diarrhea, constipation, abdominal pain, bloating, flatulence, dry mouth, anorexia

**GU:** dysuria, nocturia, polyuria, urinary hesitancy, urinary retention, erectile or other sexual dysfunction, decreased libido, epididymitis

**Hematologic:** anemia, leukopenia, thrombocytopenia, agranulocytosis

**Hepatic:** jaundice, hepatic dysfunction

**Metabolic:** hypokalemia, hypothyroidism, hyperthyroidism, hypoglycemia

**Musculoskeletal:** muscle weakness, aches, or cramps; joint stiffness

**Respiratory:** cough, dyspnea, pneumonia, pulmonary fibrosis, adult respiratory distress syndrome

**Skin:** bluish skin discoloration, rash, dermatosis, pruritus, alopecia, flushing, photosensitivity, toxic epidermal necrolysis, *Stevens-Johnson syndrome*

**Other:** gingival hyperplasia, edema, weight gain

**Patient monitoring**

- Monitor antiarrhythmic blood level.
- Assess blood pressure and pulse. Report heart rate below 50 or above 120 beats/minute.
- Monitor blood glucose and electrolyte levels and liver and kidney function tests.
Closely monitor extent of palpitations. Stay alert for fluttering or missed heartbeats, chest pain, and fainting episodes. Obtain ECG to document arrhythmias.

**anticholinergics**

atropine sulfate, benztropine mesylate, biperiden, dicyclomine hydrochloride, dimenhydrinate, glycopyrrolate, hyoscyamine, hyoscyamine sulfate, ipratropium bromide, meclizine hydrochloride, oxybutynin chloride, propantheline bromide, scopolamine hydrobromide, trihexyphenidyl hydrochloride, trimethobenzamide hydrochloride, tolterodine tartrate

**Action**
Block acetylcholine action in CNS and on autonomic effectors; also block vagal effects on sinoatrial and atrioventricular nodes, causing heart rate to increase. Small doses decrease salivary and bronchial secretions and reduce sweating; intermediate doses dilate pupils, inhibit accommodation, and increase heart rate; large doses decrease GI and GU motility; even higher doses reduce gastric acid secretion.

**Indications**
Bradyarrhythmias, symptomatic bradycardia, heart block caused by vagal activity, peptic ulcer disease, pylorospasm, small-intestine hypertoxicity, colonic hypermotility, mild dysentery, diverticulitis, bronchospasm, spastic or overactive bladder, cystitis, infant colic, biliary or renal colic, pancreatitis, acute iritis, acute rhinitis, sialorrhea, hyperhidrosis, anticholinesterase poisoning, nausea, vomiting, dizziness, motion sickness, drug-induced extrapyramidal disorders, parkinsonism, adjunct for Parkinson’s disease. Also used for cycloplegic refraction, to control gastric secretions and block cardiac vagal reflexes preoperatively, to promote diagnostic hypotonic duodenography, and to increase radiologic visibility of kidney.

**Contraindications and precautions**
- Contraindicated in hypersensitivity to drug, GI or GU tract obstruction, reflux esophagitis, severe ulcerative colitis, glaucoma, myasthenia gravis, intestinal atony, unstable cardiovascular status in acute hemorrhage, arrhythmias, tachycardia caused by cardiac insufficiency or thyrotoxicosis, toxic megacolon, GI infection, severe prostatic hypertrophy, bladder neck obstruction, bronchial asthma, chronic obstructive pulmonary disease, breastfeeding, and infants less than 6 months old
- Use cautiously in alcohol, sulfite, or tartrazine intolerance; high environmental temperatures; hepatic or renal impairment; autonomic neuropathy; mild to moderate prostatic hypertrophy; hyperthyroidism; coronary disease; heart failure; hypertension; hiatal hernia; ulcerative colitis; brain damage; Down syndrome; spasticity; phenylketonuria; elderly patients; pregnant patients (safety not established); neonates; and immature infants.

**Adverse reactions**

- **CNS:** asthenia, nervousness, stimulation, insomnia, drowsiness, dizziness, headache, confusion
- **CV:** palpitations, tachycardia
- **EENT:** increased intraocular pressure, dilated pupils, blurred vision, photophobia
- **GI:** nausea, vomiting, constipation, abdominal distention, epigastric distress, heartburn, gastroesophageal reflux, dry mouth, **paralytic ileus**

Reactions in **bold** are life-threatening.

**Clinical alert**
GU: urinary hesitancy or retention, erectile dysfunction, lactation suppression
Skin: urticaria, decreased diaphoresis
Other: taste loss, fever, irritation at I.M. injection site, allergic reaction, anaphylaxis

Patient monitoring
- Closely monitor vital signs and urine output.

Anticoagulants
argatroban, bivalirudin, dalteparin sodium, danaparoid sodium, enoxaparin sodium, fondaparinux sodium, heparin calcium, heparin sodium, lepirudin, tinzaparin sodium, warfarin sodium

Action
Interfere with one or more parts of the pathways that lead to stable fibrin clot formation. May inhibit coagulation factors, bind to antithrombin, cause release of tissue factor pathway inhibitors, and prevent conversion of fibrinogen to fibrin.

Indications
Treatment or prophylaxis of venous thrombosis, pulmonary embolism, atrial fibrillation with embolization, myocardial infarction, or thromboembolic events (including deep-vein thrombosis); during cardiovascular surgery; prevention of thrombus formation and embolization after prosthetic valve placement; after abdominal surgery or total hip or knee replacement surgery

Contraindications and precautions
- Contraindicated in hypersensitivity to drug, uncontrolled or active major bleeding, or thrombocytopenia caused by antiplatelet antibodies associated with low-molecular-weight heparins
- Use cautiously in severe hepatic or renal disease; hypertensive or diabetic retinopathy; untreated or severe uncontrolled hypertension; hemorrhagic stroke; severe thrombocytopenia; active GI bleeding or ulcers or recent history of ulcer disease; cancer; bacterial endocarditis; history of congenital or acquired bleeding disorder; recent brain, spinal, or ophthalmic surgery; spinal or epidural anesthesia; patients weighing less than 45 kg (99 lb); elderly patients; pregnant or breastfeeding patients; and children (safety not established).

Adverse reactions
CNS: headache, dizziness, insomnia, confusion, spinal hematoma, cerebral or intracranial bleeding
CV: hypotension, hypertension, angina pectoris, tachycardia, arrhythmias, pulmonary embolism, thromboembolism, myocardial infarction
EENT: ocular hemorrhage, rhinitis, epistaxis
GI: nausea, vomiting, constipation, dyspepsia, hematemeses, anorectal bleeding, melena, flatulence, retroperitoneal or intra-abdominal bleeding, GI hemorrhage
GU: dysuria, hematuria, urinary tract infection, urinary retention, vaginal hemorrhage
Hematologic: purpura, anemia, granulocytopenia, thrombocytopenia, agranulocytosis, pancytopenia, hemorrhage
Hepatic: hepatitis
Musculoskeletal: back pain
Respiratory: dyspnea, pneumonia, respiratory disorder
Skin: rash, pruritus, bullous eruption, skin necrosis, urticaria, cellulitis, injection site or wound hematoma, alopecia
Other: fever, pain, infection, dependent edema, impaired healing, hypersensitivity
reaction, congenital anomalies, fetal distress, fetal death

Patient monitoring

- Watch for tarry stools and unusual bleeding or bruising.
- Assess baseline coagulation tests and CBC with white cell differential.
- Monitor venipuncture sites for bleeding, hematoma, and inflammation.

anticonvulsants

carbamazepine, clonazepam, clorazepate dipotassium, diazepam, divalproex sodium, fosphenytoin sodium, gabapentin, lamotrigine, levetiracetam, magnesium sulfate, oxcarbazepine, pentobarbital, phenobarbital sodium, phenytoin, phenytoin sodium, pregabalin, primidone, tiagabine hydrochloride, topiramate, valproate sodium, valproic acid, zonisamide

Action
Selectively depress hyperactive brain areas responsible for seizures

Indications
Prophylaxis and treatment of status epileptics and generalized tonic-clonic, mixed, petit mal, petit mal variant, akinetic, complex-partial, and myoclonic seizures; management of panic disorder, trigeminal neuralgia, migraine, anxiety, psychoneurotic reactions, and alcohol withdrawal; skeletal muscle relaxation for endoscopy or cardioversion

Contraindications and precautions
- Contraindicated in hypersensitivity to drug or intolerance of alcohol, propylene glycol, tartrazine, or tricyclic antidepressants; bone marrow depression; severe hepatic disease; and MAO inhibitor use within past 14 days
- Use cautiously in mild to moderate hepatic or renal disease, severe cardiac or respiratory disease, acute or chronic pain, fever, hyperthyroidism, diabetes mellitus, severe anemia, uremia, angle-closure glaucoma, coma, CNS depression, sinus bradycardia, sinoatrial block, second- or third-degree heart block, Stokes-Adams syndrome, obesity, history of suicide attempt or drug abuse, elderly or debilitated patients, and pregnant or breastfeeding patients.

Adverse reactions
CNS: dizziness, light-headedness, syncope, drowsiness, lethargy, sedation, depression, apathy, fatigue, disorientation, anger, hostility, mania or hypomania, restlessess, confusion, crying, delirium, headache, slurred speech, dysarthria, stupor, rigidity, tremor, dystonia, vertigo, euphoria, nervousness, poor concentration, vivid dreams, psychomotor retardation, paresthesia, extrapyramidal symptoms, mild paradoxical stimulation (first 2 weeks of therapy)
CV: hypertension, hypotension, palpitations, bradycardia, tachycardia, aggravation of coronary artery disease, cardiovascular collapse, heart failure, arrhythmias
EENT: blurred vision, diplopia, corneal opacities, nystagmus and other abnormal eye movements, conjunctivitis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dysphagia, gastric disorders, stomatitis, glossitis, dry mouth, increased salivation, pharyngeal dryness, anorexia
GU: urinary hesitancy, retention, frequency, or incontinence; albuminuria; glycosuria; dysuria; nocturia; menstrual irregularities; libido changes; erectile dysfunction; gynecomastia
Hematologic: eosinophilia, leukopenia, agranulocytosis, aplastic anemia, thrombocytopenia

Reactions in bold are life-threatening.
Hepatic: hepatitis
Metabolic: syndrome of inappropriate antidiuretic hormone secretion
Musculoskeletal: muscle rigidity
Respiratory: pneumonitis
Skin: photosensitivity, rash, urticaria, diaphoresis, erythema multiforme, Stevens-Johnson syndrome
Other: chills, fever, hiccups, weight changes, edema, lymphadenopathy, physical and psychological drug dependence, drug tolerance

Patient monitoring
- Monitor CBC, glucose and uric acid levels, urinalysis, and kidney and liver function tests.
- With I.V. use, watch closely for respiratory depression and cardiovascular collapse.
- Monitor for sore throat, easy bruising and bleeding, and epistaxis.
- Stay alert for oversedation.

antidepressants
amitriptyline hydrochloride, amoxapine, bupropion hydrochloride, clataropam hydrobromide, clomipramine hydrochloride, desipramine hydrochloride, desvenlafaxine, doxepin hydrochloride, duloxetine hydrochloride, escitalopram oxalate, fluoxetine hydrochloride, fluvoxamine maleate, imipramine pamoate, mirtazapine, nefazodone hydrochloride, nortriptyline hydrochloride, paroxetine hydrochloride, phenerazine, sertraline hydrochloride, tranylcypromine sulfate, trazodone hydrochloride, trimipramine maleate, venlafaxine hydrochloride

Action
Produce changes in serotonin or noradrenergic receptor systems; inhibit neuronal serotonin, norepinephrine, or dopamine reuptake

Indications
Endogenous or reactive depression, including depression associated with anxiety and sleep disturbances

Contraindications and precautions
- Contraindicated in hypersensitivity to drug
- Use cautiously in cardiovascular disease; hypertension; hepatic or renal impairment; severe depression; increased intraocular pressure; angle-closure glaucoma; hyperthyroidism; prostatic hypertrophy; acute recovery phase after myocardial infarction (MI); electroshock therapy; elective surgery; suicidal tendency; history of seizures, neurologic impairment, mania, or drug abuse; pregnant or breastfeeding patients; and children younger than age 18.

Adverse reactions
CNS: lethargy, sedation, hallucinations, delusions, disorientation, anxiety, nervousness, EEG changes, fatigue, peripheral neuropathy, insomnia, restlessness, drowsiness, dizziness, syncope, extrapyramidal effects, neuroleptic malignant syndrome, seizures, coma, cerebrovascular accident (CVA)
CV: hypotension, hypertension, ECG changes, tachycardia, palpitations, chest pain, arrhythmias, MI
EENT: visual disturbances, blurred vision, mydriasis, increased intraocular pressure, dry eyes, tinnitus, rhinitis
GI: nausea, vomiting, diarrhea, constipation, epigastric or abdominal pain, dyspepsia, dry mouth, anorexia, paralytic ileus
GU: urinary frequency or retention, gynecomastia, sexual dysfunction
Hematologic: leukopenia, agranulocytosis, thrombocytopenia
Hepatic: hepatitis
Metabolic: blood glucose changes
Skin: rash, urticaria, diaphoresis, bruising, pruritus, photosensitivity
Other: altered taste, increased appetite, weight changes, edema, chills, yawning, hypersensitivity reaction

**Patient monitoring**
- Monitor CBC, blood glucose level, and kidney and liver function tests.
- Assess ECG and heart sounds. Watch for tachycardia and more frequent angina attacks (which may precede MI or CVA).
- Evaluate neurologic function.
- Watch for sleep disturbances, lethargy, apathy, impaired thought processes, and poor therapeutic response.
- Check results of periodic eye exams. Report vision changes, perception of halos, eye pain, dilated pupils, headache, and nausea.

---

**antidiabetic drugs** (hypoglycemics)

acarbose, chlorpropamide, diazoxide, glimepiride, glipizide, glyburide, insulins, metformin hydrochloride, miglitol, nateglinide, pioglitazone hydrochloride, repaglinide, rosiglitazone maleate, sitagliptin, tolazamide

**Action**

Bind to plasma membrane of functional pancreatic beta cells, decreasing potassium permeability and membrane depolarization. These effects increase intracellular calcium transport and enhance release of secretory granules containing insulin.

Insulins promote glucose transport and stimulate carbohydrate metabolism, which inhibits the release of free fatty acids and stimulates protein metabolism and synthesis.

**Indications**

Type 1 (insulin-dependent) or type 2 (non-insulin-dependent) diabetes mellitus

**Contraindications and precautions**

- Contraindicated in hypersensitivity to drug and in diabetes mellitus complicated by ketoacidosis
- Use cautiously in severe cardiovascular, hepatic, or renal disease; heart failure; intestinal disorders; thyroid, pituitary, or adrenal dysfunction; malnutrition; high fever; prolonged nausea or vomiting; dehydration; hypoxemia; excessive alcohol ingestion (acute or chronic); elderly patients; and pregnant or breastfeeding patients.

**Adverse reactions**

CNS: lethargy, sedation, hallucinations, delusions, disorientation, peripheral neuropathy, EEG changes, nervousness, restlessness, anxiety, fatigue, insomnia, drowsiness, dizziness, syncope, asthenia, extrapyramidal effects, neuroleptic malignant syndrome, seizures, coma, cerebrovascular accident

CV: hypotension, hypertension, ECG changes, tachycardia, palpitations, chest pain, arrhythmias, myocardial infarction

EENT: blurred vision, visual disturbances, mydriasis, dry eyes, increased intraocular pressure, tinnitus, rhinitis

GI: nausea, vomiting, diarrhea, anorexia, paralytic ileus

GU: urinary frequency or retention, gynecomastia, sexual dysfunction

Hematologic: leukopenia, agranulocytosis, thrombocytopenia

Hepatic: hepatitis

Metabolic: hypokalemia, sodium retention, blood glucose changes, hypoglycemia

Reactions in **bold** are life-threatening.
Skin: rash, urticaria, pruritus, diaphoresis, bruising, photosensitivity
Other: altered taste, increased appetite, weight changes, edema, chills, yawning, hypersensitivity reaction, injection site reaction

Patient monitoring
- Monitor blood glucose level, especially during times of increased stress (such as infection, fever, surgery, and trauma).
- Assess weight and nutritional status.
- Evaluate liver and kidney function tests.

antiemetics

5-HT$_3$ receptor antagonists:
dolasetron mesylate, granisetron hydrochloride, ondansetron hydrochloride, palonosetron hydrochloride

Anticholinergics: dimenhydrinate, diphenhydramine hydrochloride, meclizine hydrochloride, trimethobenzamide hydrochloride

Antidopaminergics: chlorpromazine hydrochloride, metoclopramide hydrochloride, perphenazine, prochlorperazine, promethazine hydrochloride

Other: aprepitant, dronabinol

Action
Block activity of central neurotransmitters, dopamine in chemoreceptor trigger zone, acetylcholine in vomiting center, or 5-HT$_3$ receptors on vagal neurons in GI tract

Indications
Prevention of nausea and vomiting caused by chemotherapy or radiation therapy, prevention or treatment of postoperative nausea or vomiting

Contraindications and precautions
- 5-HT$_3$ receptor antagonists are contraindicated in hypersensitivity to drug. Antidopaminergics are contraindicated in coma and drug- or alcohol-induced CNS depression.
- Use cautiously in hepatic disease; premature infants (if drug contains benzyl alcohol); or sulfite or tartrazine sensitivity (if drug contains sulfite or tartrazine). Also use cautiously in patients who have or may develop prolonged conduction intervals, especially marked QTc prolongation.

Adverse reactions
CNS: anxiety, agitation, confusion, asthenia, dizziness, drowsiness, sedation, headache, malaise, fatigue, weakness, pain, vertigo, paresthesia, tremor, sleep disorder, depersonalization, ataxia, twitching, extrapyramidal syndrome
CV: hypertension, hypotension, angina, syncope, bradycardia, tachycardia, arrhythmias, Mobitz I heart block
EENT: epistaxis
GI: nausea, vomiting, diarrhea, constipation, dyspepsia, abdominal pain, dry mouth, anorexia
GU: hematuria, dysuria, polyuria, urinary retention, oliguria
Hematologic: anemia, purpura, hema-
toma, leukopenia, thrombocytopenia
Respiratory: hypoxia
Skin: rash, flushing, increased diaphoresis, pruritus
Other: altered taste, fever, chills, cold sensation, edema, facial or peripheral edema, injection site reaction, anaphylaxis

Patient monitoring
- Monitor CBC, liver function tests, and ECG changes.

Stay alert for prolonged PR interval and widened QRS complexes, especially in patients receiving concurrent antiarrhythmics.
Watch for excessive diuresis.
• When giving antidopaminergics, monitor for signs and symptoms of neuroleptic malignant syndrome.

antifungals
amphotericin B, caspofungin acetate, fluconazole, flucytosine, griseofulvin, itraconazole, ketoconazole, micafungin sodium, miconazole, nystatin, posaconazole, terbinafine hydrochloride, voriconazole

Action
Varies with specific drug. See individual monographs.

Indications
Meningitis, visceral leishmaniasis in immunocompetent patients, invasive fungal infections, systemic fungal infections (histoplasmosis, coccidioidomycosis, blastomycosis, cryptococcosis, phymycosis, disseminated candidiasis, zygomycosis), oral and perioral candidal infections, GI tract infections caused by *Candida albicans*

Contraindications and precautions
• Contraindicated in hypersensitivity to antifungals and concurrent use of cisapride or pimozide
• Use cautiously in renal, hepatic, or cardiac disease; achlorhydria; pregnant or breastfeeding patients; and children younger than age 2.

Adverse reactions
CNS: anxiety, confusion, headache, insomnia, asthenia, abnormal thinking, agitation, depression, dizziness, hallucinations, hypertonia, vertigo, psychosis, drowsiness, speech disorder, malaise, stupor, seizures

CV: chest pain, vasodilation, hypotension, orthostatic hypotension, hypertension, phlebitis, tachycardia, bradycardia, supraventricular tachycardia, cardiac arrest, asystole, atrial fibrillation, shock

EENT: diplopia, amblyopia, blurred vision, eye hemorrhage, hearing loss, tinnitus, epistaxis, rhinitis, sinusitis, pharyngitis

GI: nausea, vomiting, diarrhea, abdominal pain, abdominal distention, melena, stomatitis, dry mouth, oral candidiasis, anorexia, GI hemorrhage

GU: dysuria, hematuria, albuminuria, glycosuria, urinary retention or incontinence, oliguria, renal failure, abnormal renal function with hypokalemia

Hematologic: anemia, eosinophilia, leukocytosis, thrombocytopenia, leukopenia, agranulocytosis

Hepatic: jaundice, acute hepatic failure, hepatitis

Metabolic: dehydration, hypomagnesemia, hypokalemia, hypocalcemia, hypernatremia, hyperglycemia, hypoprotenemia, hyperlipidemia, acidosis

Musculoskeletal: myalgia; joint, neck, or back pain

Respiratory: increased cough, wheezing, dyspnea, tachypnea, hypoxia, hyperventilation, hemoptysis, asthma, pulmonary edema, pleural effusion, bronchospasm, respiratory failure

Skin: pruritus, acne, alopecia, diaphoresis, skin discoloration, nodules, ulcers, urticaria, maculopapular rash

Other: gingivitis, weight changes, chills, fever, infection, peripheral or facial edema, pain or reaction at injection site, tissue damage (with extravasation), allergic reactions including anaphylaxis, sepsis, multisystem failure

Patient monitoring
• Monitor vital signs and fluid intake and output.
• Assess electrolyte levels, CBC, and kidney and liver function tests.

Reactions in **bold** are life-threatening.
**antigout agents (anti-hyperuricemia agents)**
allopurinol, colchicine, probenecid, rasburicase

**Action**
Decrease uric acid levels by inhibiting uric acid production or tubular reabsorption of urate or by catalyzing enzymatic oxidation of uric acid into allantoin (an inactive and soluble metabolite)

**Indications**
Primary or secondary gout, calcium oxalate calculi, management of uric acid levels during chemotherapy

**Contraindications and precautions**
- Contraindicated in hypersensitivity to drug, blood dyscrasias, or methemoglobinemia and G6PD deficiency
- Use cautiously in acute gout attack during initiation of therapy, bone marrow depression, renal or hepatic disease, cardiac disease, idiopathic hemochromatosis, seizure disorders, peptic ulcer, and children (except those with cancer-related hyperuricemia).

**Adverse reactions**
- **CNS**: headache, somnolence, peripheral neuropathy, neuritis, paresthesia
- **CV**: vasculitis, necrotizing angiitis
- **EENT**: epistaxis
- **GI**: nausea, vomiting, diarrhea, abdominal pain, gastritis, dyspepsia
- **GU**: uremia, renal failure
- **Hematologic**: ecchymosis, purpura, eosinophilia, leukopenia, leukocytosis, thrombocytopenia
- **Hepatic**: cholestatic jaundice, hepatic megaly, granulomatous hepatitis, hepatic necrosis
- **Metabolic**: acute gout attack

**Patient monitoring**
- Assess fluid intake and output. Intake should be sufficient to yield daily output of at least 2 liters of slightly alkaline urine.
- Monitor uric acid level.

**antihistamines**
brompheniramine, cetirizine hydrochloride, chlorpheniramine maleate, cyproheptadine hydrochloride, desloratadine, diphenhydramine hydrochloride, fexofenadine hydrochloride, hydroxyzine hydrochloride, hydroxyzine pamoate, levocetirizine, loratadine, promethazine

**Action**
Bind either nonselectively to central and peripheral histamine\(_1 (H_1)\) receptors or selectively to peripheral \(H_1\) receptors, causing either CNS stimulation or depression

**Indications**
Sedation, nausea and vomiting, cough, parkinsonian symptoms, motion sickness, allergy symptoms, adjunct to pre- or postoperative analgesia

**Contraindications and precautions**
- Contraindicated in hypersensitivity to specific or structurally related antihistamines, angle-closure glaucoma, stenosing peptic ulcer, symptomatic prostatic hypertrophy, bladder neck

Canada UK Hazardous drug High alert drug
obstruction, pyloroduodenal obstruction, MAO inhibitor use within past 14 days, elderly or debilitated patients (cyproheptadine), premature infants, and neonates

- Use cautiously in respiratory or cardiovascular disease, seizure disorders, ulcer disease, sleep apnea, renal or hepatic impairment, elderly patients, pregnant or breastfeeding patients, and children.

Adverse reactions

CNS: drowsiness, sedation, weakness, dizziness, syncope, incoordination, fatigue, lassitude, confusion, restlessness, excitation, euphoria, tremor, headache, insomnia, nightmares, paresthesia, catatonic-like state, hallucinations, disorientation, pseudoschizophrenia, vertigo, hysteria, tongue protrusion, neu- ritis, seizures

CV: orthostatic hypotension, hypotension, hypertension, palpitations, brady-cardia, tachycardia, reflex tachycardia, extrasystoles, ECG changes, venous thrombosis at injection site (with I.V. promethazine), cardiac arrest

EENT: blurred vision; diplopia; oculo- gyric crisis; tinnitus; labyrinthitis; nasal stuffiness; dry mouth, nose, and throat; sore throat; laryngeal edema

GI: nausea, vomiting, diarrhea, constipation, epigastric distress, stomatitis, anorexia

GU: dysuria, glycosuria, urinary frequency, urinary retention, lactation, early menses, gynecomastia, inhibited ejaculation

Hematologic: thrombocytopenic purpura; hemolytic, hypoplastic, or aplastic anemia; thrombocytopenia; leukopenia; agranulocytosis; pancytopenia

Musculoskeletal: torticollis; tingling, heaviness, and weakness of hands

Respiratory: thickened bronchial secretions, chest tightness, wheezing, asthma, respiratory depression

Skin: rash, dermatitis, erythema, urticaria, excessive perspiration, angioedema, photosensitivity

Other: appetite increase, weight gain, peripheral edema, chills, lupus erythematosus–like syndrome, anaphylaxis

Patient monitoring

- Monitor cardiovascular status, especially in patients with cardiovascular disease.

- Use side rails as needed. Supervise patient during ambulation.

antihyperlipidemics

Bile acid suppressants: cholestyramine, colesvelem hydrochloride, colestipol hydrochloride

Fibric acid derivatives: fenofibrate, gemfibrozil

HMG-CoA reductase inhibitors: atorvastatin calcium, fluvastatin sodium, lovastatin, pravastatin sodium, rosuvastatin, simvastatin

Other: ezetimibe, niacin

Action

Bile acid suppressants bind bile acids in intestine to form an insoluble complex that’s excreted in feces; increased fecal loss of bile acids enhances cholesterol oxidation to bile acids, which lowers low-density lipoprotein (LDL) and cholesterol levels. Fibric acid derivatives inhibit peripheral lipolysis and decrease hepatic extraction of free fatty acids, reducing hepatic triglyceride production. They also inhibit synthesis and increase clearance of apolipoprotein B (which carries very-low-density lipoproteins [VLDLs]), thus lowering VLDL production. HMG-CoA reductase inhibitors competitively inhibit HMG-CoA reductase (an enzyme that

Reactions in bold are life-threatening.
catalyzes the first step in cholesterol synthesis pathway); this inhibition decreases total cholesterol, LDL, VLDL, triglyceride, and apolipoprotein B levels while increasing high-density lipoprotein levels.

**Indications**

Elevated LDL, total cholesterol, triglyceride, or apolipoprotein B levels in primary hypercholesterolemia or mixed dyslipidemia (Fredrickson types IIa and IIb); primary dysbetalipoproteinemia (Fredrickson type III); adjunct to diet in hypertriglyceridemia (Fredrickson type IV)

**Contraindications and precautions**

- Contraindicated in hypersensitivity to drug; active hepatic disease; complete biliary obstruction; persistent, unexplained elevations in liver function tests; pregnancy; and breastfeeding
- Use cautiously in severe metabolic, endocrine, or electrolyte disorders; visual disturbances; uncontrolled seizures; myopathy; cerebral arteriosclerosis; coronary artery disease; severe hypotension or hypertension; history of hepatic disease, alcoholism, renal impairment, severe acute infection, major surgery, or trauma; females of childbearing age; and children younger than age 18 (safety not established).

**Adverse reactions**

**CNS:** amnesia, abnormal dreams, malaise, asthenia, emotional lability, facial paralysis, headache, hyperkinesia, incoordination, paresthesia, drowsiness, syncope, peripheral neuropathy

**CV:** orthostatic hypotension, palpitations, vasodilation, phlebitis, arrhythmias

**EENT:** eye hemorrhage, amblyopia, glaucoma, altered refraction, dry eyes, hearing loss, tinnitus, epistaxis, sinusitis, pharyngitis

**GI:** nausea, vomiting, diarrhea, constipation, abdominal cramps, abdominal or biliary pain, dyspepsia, gastroenteritis, colitis, flatulence, melena, tenesmus, dysphagia, esophagitis, pancreatitis, dry mouth, stomatitis, glossitis, anorexia, GI ulcers, rectal hemorrhage

**GU:** dysuria, nocturia, hematuria, urinary frequency or urgency, urinary retention, cystitis, renal calculi, nephritis, abnormal ejaculation, decreased libido, epididymitis, erectile dysfunction

**Hematologic:** anemia, thrombocytopenia

**Hepatic:** jaundice, hepatic failure, hepatitis

**Metabolic:** gout, hyperglycemia, hypoglycemia

**Musculoskeletal:** joint or back pain, bursitis, leg cramps, neck rigidity, torticollis, myalgia, myositis, myasthenia gravis

**Respiratory:** dyspnea, pneumonia, bronchitis

**Skin:** diaphoresis, acne, pruritus, rash, urticaria, alopecia, contact dermatitis, eczema, dry skin, skin ulcers, seborrhea, photosensitivity

**Other:** gingival hemorrhage, taste loss, increased appetite, weight gain, flu-like symptoms, infection, fever, allergic reaction

**Patient monitoring**

- Monitor liver function tests and blood lipid panel.
anti-infectives

Aminoglycosides: amikacin sulfate, gentamicin sulfate, kanamycin, neomycin sulfate, streptomycin sulfate, tobramycin sulfate

Carbapenems: doripenem monohydrate, ertapenem sodium, imipenem cilastatin, meropenem

Cephalosporins, first generation: cefadroxil, cefazolin sodium, cepalexin hydrochloride

Cephalosporins, second generation: cefaclor, cefamandole, cefmetazole sodium, cefonicid sodium, cefotetan disodium, cefoxitin sodium, cefprozil, cefuroxime axetil, loracarbef

Cephalosporins, third generation: cefdinir, cefditoren pivoxil, cefepime hydrochloride, cefixime, cefoperazone sodium, cefotaxime sodium, ceftibuten, ceftriaxone sodium

Fluoroquinolones: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin hydrochloride, moxifloxacin hydrochloride, nalidixic acid, norfloxacin, ofloxacin

Lincosamides: clindamycin hydrochloride, clindamycin palmitate hydrochloride, clindamycin phosphate

Macrolides: azithromycin, clarithromycin, dirithromycin, erythromycin

Monobactams: aztreonam

Penicillins: amoxicillin, amoxicillin trihydrate, amoxicillin and clavulanate potassium, ampicillin sodium, ampicillin sodium and sulbactam sodium, nafcillin sodium, oxacillin sodium, penicillin G benzathine, penicillin G potassium, penicillin G procaine, penicillin V potassium, piperacillin sodium, piperacillin sodium and tazobactam sodium

Streptogramins: quinupristin

Sulfonamides: sulfadiazine, sulfasalazine, sulfisoxazole, sulfisoxazole acetyl

Tetracyclines: demeclocycline hydrochloride, doxycycline, minocycline hydrochloride, tetracycline hydrochloride

Other: chloramphenicol, dapsone, linezolid, metronidazole, nitrofurantoin, pentamidine, telithromycin, vancomycin

Action

Bactericidal anti-infectives (aminoglycosides, cephalosporins, carbapenems, dapsone, fluoroquinolones, lincosamides, linezolid, macrolides and nitrofurantoin at high concentrations, metronidazole, monobactams, penicillins, quinupristin, and vancomycin) kill bacterial cells by inhibiting cell-wall synthesis of actively dividing bacterial cells via binding to one or more penicillin-bound proteins or 30S ribosomal subunits or via inhibition of DNA gyrase and topoisomerase IV.

Bacteriostatic anti-infectives (chloramphenicol, dapsone, linezolid [against enterococci and staphylococci only], macrolides and nitrofurantoin at low concentrations, quinupristin/dalfopristin [bacteriostatic against Enterococcus faecium], sulfonamides, telithromycin, and tetracyclines) inhibit bacterial cell growth or multiplication by

Reactions in bold are life-threatening.
giving the host immune system adequate time to mount a lethal response.

**Indications**
Vary with drug. See individual monographs.

**Contraindications and precautions**
- Contraindicated in hypersensitivity to drug. (For additional contraindications, see individual monographs.)
- Use cautiously in renal impairment, cirrhosis or other hepatic disease, neuromuscular disease, CNS disease, bradycardia, acute myocardial ischemia, parkinsonism, hearing impairment, dialysis patients, obese patients, elderly patients, pregnant or breastfeeding patients, neonates, and premature infants.

**Adverse reactions**
- **CNS:** dizziness, vertigo, tremor, numbness, depression, confusion, lethargy, nystagmus, headache, paresthesia, neuromuscular blockade, seizures, neurotoxicity
- **CV:** hypotension, hypertension, palpitations, phlebitis, thrombophlebitis
- **EENT:** visual disturbances; eye stinging, redness, itching, or dryness; photophobia; tinnitus; hearing loss; ototoxicity; increased salivation; hoarseness (with tetracyclines)
- **GI:** nausea, vomiting, diarrhea, abdominal cramps, stomatitis, oral candidiasis, black “hairy” tongue, anorexia, splenomegaly, pseudomembranous colitis
- **GU:** polyuria, dysuria, azotemia, increased urinary cast excretion, erectile dysfunction, vaginal candidiasis, nephrotoxicity, renal failure
- **Hematologic:** purpura, eosinophilia, lymphocytosis, leukemoid reaction, hemolytic or aplastic anemia, neutropenia, agranulocytosis, leukopenia, thrombocytopenia, pancytopenia, hypoprothrombinemia, bone marrow depression
- **Hepatic:** hepatomegaly, hepatic necrosis
- **Metabolic:** blood glucose changes
- **Musculoskeletal:** joint pain, tendinitis, tendon rupture
- **Respiratory:** dyspnea, apnea
- **Skin:** rash, urticaria, pruritus, exfoliative dermatitis, alopecia, sterile abscess, Stevens-Johnson syndrome
- **Other:** permanent tooth discoloration, tooth enamel defects, weight loss, superinfection, pain, irritation at I.M. injection site, induration, chills, fever, edema, serum sickness, anaphylaxis

**Patient monitoring**
- Monitor vital signs and fluid intake and output. Push fluids to help prevent renal tubular irritation.
- Monitor drug blood level.
- Watch for signs and symptoms of overgrowth of resistant organisms.
- Assess CBC and kidney function tests.
- Monitor International Normalized Ratio in prolonged therapy and in patients with malnutrition or high risk of renal or hepatic impairment.
- Assess for ototoxicity by comparing current and baseline audiograms.

**antimalarials**
chloroquine hydrochloride, chloroquine phosphate, doxycycline, hydroxychloroquine sulfate, mefloquine hydrochloride, primaquine hydrochloride, pyrimethamine, quinine sulfate

**Action**
Varies. See individual monographs.

**Indications**
Prophylaxis or treatment of malaria
Contraindications and precautions
- Contraindicated for prophylactic use in severe renal insufficiency, marked hepatic parenchymal damage, or blood dyscrasias. Also contraindicated in hypersensitivity to drug, megaloblastic anemia caused by folate deficiency, depression (current or previous), generalized anxiety disorder, psychosis, schizophrenia or other major psychiatric disorder, history of seizures, pregnancy at term, breastfeeding, and infants younger than 2 months old.
- Use cautiously in hepatic dysfunction, cardiac disease, and ocular lesions.

Adverse reactions
CNS: headache, psychic stimulation, psychotic episodes, seizures
CV: hypotension, ECG changes, cardiomyopathy
EENT: irreversible retinal damage; visual disturbances; night blindness; scotomatus vision with field defects of paracentral and pericentral ring types and typically temporal scotomas
GI: vomiting, abdominal cramps, atrophic glossitis, anorexia
GU: hematuria
Hematologic: hemolytic or megaloblastic anemia, leukopenia, thrombocytopenia, megalobloblinemia, agranulocytosis
Skin: pruritus, lichen planus–like eruptions, skin and mucosal pigment changes, pleomorphic skin eruptions, alopecia, toxic epidermal necrolysis, erythema multiforme, Stevens-Johnson syndrome
Other: hypersensitivity reactions including anaphylaxis

Patient monitoring
- Monitor liver function tests, CBC, and G6PD levels in susceptible patients before and periodically during therapy.

Reactions in bold are life-threatening.

Clinical alert

antimigraine drugs
Ergotamine derivatives: dihydroergotamine mesylate, ergotamine tartrate
Serotonin (5-hydroxytryptamine [5-HT$_1$]) receptor agonists: almotriptan malate, eletriptan, frovatriptan, naratriptan hydrochloride, rizatriptan hydrochloride, sumatriptan, topiramate, zolmitriptan

Action
Ergotamine derivatives exert partial agonist or antagonist activity against tryptaminergic, dopaminergic, and alpha-adrenergic receptors (depending on their site), causing peripheral and cranial vasoconstriction and depression of central vasomotor centers.
5-HT$_1$ receptor agonists activate serotonin 5-HT$_1$B/1D receptors, causing cranial vasoconstriction, inhibition of neuropeptide release, and reduced impulse transmission in trigeminal pain pathways.

Indications
Migraine

Contraindications and precautions
- Contraindicated in hypersensitivity to drug; hemiplegic or basilar migraine; ischemic heart or bowel disease; severe renal or hepatic impairment; Prinzmetal’s angina or other significant underlying cardiovascular disease; uncontrolled hypertension; use of ergotamine-containing preparations, ergot-type drugs, or other 5-HT$_1$ agonists within past 24 hours; MAO inhibitor use within past 14 days; and I.V. use.
- Use cautiously in hypertension, hypercholesterolemia, diabetes mellitus, cardiovascular disease, smoking, obesity,
men older than age 40, menopausal women, pregnant or breastfeeding patients, and children younger than age 18.

**Adverse reactions**

**CNS:** dizziness, paresthesia, hypoesthesia, asthenia, drowsiness, somnolence, fatigue, headache, myasthenia, vertigo

**CV:** chest tightness, pressure, or heaviness

**EENT:** rhinitis, sinusitis, pharyngitis

**GI:** nausea; vomiting; diarrhea; abdominal pain or discomfort; stomach pain, cramps, or pressure; dyspepsia; dysphagia; dry mouth

**Musculoskeletal:** neck, throat, or jaw pain; stiffness

**Other:** altered taste, hot or cold sensations, hot flushes, application site reaction

**Patient monitoring**

- Monitor ECG for changes.

---

**antineoplastics**

**Alkylating agents:** bendamustine hydrochloride, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, lomustine, melphalan hydrochloride, oxaliplatin, procarbazine hydrochloride, streptozocin, temozolomide, thiopheta

**Antibiotic antineoplastics:** bleomycin, daunorubicin hydrochloride, doxorubicin hydrochloride, epirubicin, idarubicin, mitomycin, mitoxantrone, plicamycin

**Antimetabolites:** capecitabine, cytarabine, flouxuridine, fludarabine phosphate, fluorouracil, gemcitabine, mercaptopurine, methotrexate sodium, pentostatin

**Antimitotics:** docetaxel, paclitaxel, vinblastine, vincristine, vinorelbine

**Biological antineoplastics:** aldesleukin, alemtuzumab, denileukin diftitox, ibritumomab tiuxetan, interferon alfa-2b, rituximab, trastuzumab

**Cytoprotective agents:** amifostine, mesna

**DNA topoisomerase inhibitors:** irinotecan, topotecan

**Enzyme antineoplastics:** asparaginase, pegasparaginase

**Epipodophyllotoxins:** etoposide, teniposide

**Hormonal antineoplastics:** anastrozole, bicalutamide, exemestane, flutamide, fulvestrant, goserelin, letrozole, leuprolide, medroxyprogesterone acetate, megestrol, nilotinib, raloxifene, tamoxifen citrate, triptorelin pamoate

**Other:** arsenic trioxide, bexarotene, bortezomib, dasatinib, gefitinib, hydroxyurea, imatinib, lenalidomide, nilotinib, porfimer, tretinoin

**Action**

Varies with specific drug. Generally, antineoplastics inhibit normal substrate use in tumor cells, forming dysfunctional macromolecules by inserting themselves into abnormal cells; also intercalate between DNA strands and interfere with DNA templates. Some antineoplastics modify growth of hormone-dependent tumors.

**Indications**

Hodgkin’s or non-Hodgkin’s lymphoma, testicular teratomas, mycosis fungoides, breast cancer, ovarian cancer,
prostate cancer, lung cancer, head and neck cancer, colorectal cancer, pancreatic cancer, bronchogenic carcinoma, malignant melanoma, chronic lymphatic or chronic myeloid leukemia, other cancers

**Contraindications and precautions**
- Contraindicated in hypersensitivity to drug or its components
- Use cautiously in heart disease, renal or hepatic impairment, decreased bone marrow reserve, active infections, severe myocardial insufficiency, coagulation and bleeding disorders, active thrombophlebitis or thromboembolic disorders, shock, trauma, major surgery within previous month, elderly or debilitated patients, patients with childbearing potential, and pregnant or breastfeeding patients.

**Adverse reactions**

**CNS:** dizziness, fatigue, lethargy, asthenia, drowsiness, malaise, headache, sensory or motor dysfunction, impaired memory, confusion, agitation, depression, emotional lability, sleep disturbances, hallucinations, rigors, peripheral neuropathy, parasthesia, tremor, ataxia, flaccid paresis, abnormal gait, vertigo, syncope, cranial nerve dysfunction, hemiparesis, mental status changes, acute cerebellar dysfunction, demyelination, seizures, leukencephalopathy, cerebrovascular accident, suicidal ideation

**CV:** hypotension, hypertension, chest pain, peripheral edema, tachycardia, cardiomegaly, prolonged QT interval, thromboembolic events, arrhythmias, cardiac tamponade, torsades de pointes, cardiac arrest, capillary leak syndrome, myocardial infarction, left-sided heart failure, pericardial effusion

**EENT:** retinal thrombosis, corneal opacity, photophobia, diplopia, visual changes, nystagmus, lacrimation, lacrimal duct stenosis, stye, epistaxis, pharyngitis

**GI:** nausea, vomiting, diarrhea, constipation, fecal incontinence, abdominal pain, dyspepsia, GI ulcer, ascites, dry mouth, mucositis, oral candidiasis, dysphagia, anorexia, intestinal perforation, paralytic ileus, GI bleeding

**GU:** proteinuria, hematuria, dysuria, urinary hesitancy or retention, urinary obstruction, cystitis, bladder fibrosis, vaginitis, vaginal hemorrhage, breast swelling and tenderness, menstrual abnormalities, abortion, gynecostasia, sterility, libido loss, erectile dysfunction, decreased testes size, reduced sperm count, progressive azotemia, hemolytic uremic syndrome, nephrotoxicity, oliguria or anuria, renal failure

**Hematologic:** anemia, eosinophilia, neutropenia, thrombocytopenia, leukopenia, leukocytosis, bone marrow depression, agranulocytosis, pancytopenia, coagulation disorders, hemorrhage

**Hepatic:** jaundice, hepatitis, hepatotoxicity

**Metabolic:** hyperglycemia, fluid retention, hyperkalemia

**Musculoskeletal:** muscle twitching, joint or bone pain, decreased bone density, carpal tunnel syndrome

**Respiratory:** tachypnea, dyspnea, wheezing, pulmonary congestion, cough, chronic obstructive pulmonary disease, upper respiratory tract infection, tracheoesophageal fistula, pleural effusion, interstitial pneumonitis, bronchospasm, pulmonary toxicity, pulmonary edema, respiratory failure, apnea, development or worsening of pulmonary fibrosis

**Skin:** erythema, pruritus, rash, diaphoresis, night sweats, dry skin, urticaria, alopecia, phlebitis at I.V. site, palmar-plantar erythrodysesthesia, nail loss, bruising, petechiae, exacerbation of

Reactions in **bold** are life-threatening.
postradiation erythema, painful plaque erosions, epidermal necrolysis, exfoliative dermatitis, Stevens-Johnson syndrome
Other: increased appetite, weight gain, fever, chills, pain, flu-like symptoms, herpes simplex or other infection, tumor flare, hypersensitivity reaction, risk of second malignancy, anaphylaxis, sepsis, tumor lysis syndrome

Patient monitoring
- Watch for bleeding. If platelet count is low, avoid giving I.M. injections and taking rectal temperature.
- Stay alert for bone marrow depression, neutropenia, and anemia.
- Monitor fluid intake and output.
- Monitor for GI upset. Give antiemetics as needed and prescribed.

antiparkinsonian drugs

Anticholinergics: benztropine, biperiden, trihexyphenidyl hydrochloride
Antivirals: amantadine hydrochloride
Dopaminergics: bromocriptine mesylate, carbidopa-levodopa, carbidopa-levodopa-entacapone, entacapone, levodopa, pramipexole, ropinirole hydrochloride, tolcapone
MAO inhibitor: rasagiline, selegiline

Action
Block central cholinergic receptors or inhibit prolactin secretion; also may act as dopamine receptor agonists by activating postsynaptic dopamine receptors

Indications
Parkinson’s disease

Contraindications and precautions
- Contraindicated in hypersensitivity to drug, angle-closure glaucoma, tardive dyskinesia, stenosing peptic ulcer, achalasia, pyloric or duodenal obstruction, prostatic hypertrophy, bladder neck obstruction, myasthenia gravis, and children younger than age 3
- Use cautiously in seizure disorders, arrhythmias, tachycardia, hypertension, hypotension, hepatic or renal dysfunction, alcoholism, exposure to hot environments, elderly patients, and pregnant or breastfeeding patients (safety not established).

Adverse reactions
CNS: confusion, headache, dizziness, fatigue, light-headedness, drowsiness, nervousness, insomnia, nightmares, mania, delusions, seizures, cerebrovascular accident
CV: hypotension, palpitations, extrasystole, bradycardia, arrhythmias, acute myocardial infarction
EENT: diplopia, blurred vision, burning sensation of eyes, nasal congestion
GI: nausea, vomiting, diarrhea, constipation, abdominal cramps, dry mouth, anorexia, GI hemorrhage
GU: urinary incontinence, frequency, or retention; diuresis; erectile dysfunction
Hepatic: hepatic failure
Musculoskeletal: leg cramps, numb fingers
Skin: urticaria; pale, cool fingers and toes; facial and arm rash; alopecia
Other: hyperthermia, heat stroke

Patient monitoring
- Monitor fluid intake and output and assess vital signs (especially blood pressure).
**antiplatelet drugs**

abciximab, anagrelide hydrochloride, cilostazol, clopidogrel bisulfate, dipyridamole, eptifibatide, ticlopidine hydrochloride, treprostinil sodium

**Action**
Inhibit platelet aggregation by reversibly preventing fibrinogen, von Willebrand’s factor, and other adhesion ligands from binding to glycoprotein (GP) IIb/IIIa receptor or by inhibiting platelet fibrinogen induced by adenosine diphosphate

**Indications**
Acute coronary syndrome, cerebrovascular accident (CVA)

**Contraindications and precautions**
- Contraindicated in hypersensitivity to drug, CVA or abnormal bleeding within past 30 days, history of bleeding diathesis, history of hemorrhagic CVA, major surgery within past 6 weeks, concurrent or planned use of other parenteral GP IIb/IIIa inhibitors, dependence on renal dialysis, severe uncontrolled hypertension (systolic pressure above 200 mm Hg or diastolic pressure above 110 mm Hg), platelet count below 100,000/mm³, or serum creatinine of 4 mg/dl or more
- Use cautiously in hemorrhagic retinopathy; severe renal insufficiency; chronic hemodialysis; hepatic failure; platelet count below 150,000/mm³; hypotension, pulmonary edema, or pulmonary veno-occlusive disease (treprostinil); or concurrent use of thrombolytics or other drugs that affect hemostasis.

**Adverse reactions**

CNS: depression, somnolence, confusion, insomnia, nervousness, amnesia, migraine, dizziness, headache, **intracranial hemorrhage**

CV: chest pain, angina pectoris, orthostatic hypotension, hypertension, vasodilation, syncope, bradycardia, cardiovascular disease, **arrhythmias, thrombosis, aortic dissection, heart failure**

EENT: amblyopia, abnormal vision, visual field abnormality, diplopia, tinnitus, epistaxis, rhinitis, sinusitis

GI: nausea, diarrhea, constipation, gastritis, abdominal pain, dyspepsia, melena, eructation, aphthous stomatitis, **GI hemorrhage**

GU: dysuria, hematuria, urinary tract infection

Hematologic: anemia, ecchymosis, bleeding, thrombocytopenia

Hepatic: hemorrhage

Metabolic: dehydration

Musculoskeletal: arthralgia, myalgia, leg cramps or pain, pelvic pain

Respiratory: respiratory disease, pneumonia, bronchitis, asthma

Skin: skin disease, diaphoresis, alopecia, photosensitivity

Other: lymphadenopathy, fever, chills, edema, flulike symptoms, accidental injury

**Patient monitoring**
- Monitor CBC, platelet count, and coagulation studies.
- Watch for unusual bleeding or bruising.
- Assess vital signs and cardiovascular status.

Reactions in **bold** are life-threatening.
antipsychotics

ariprazole, atomoxetine hydrochloride, chlorpromazine hydrochloride, clozapine, fluphenazine, haloperidol, lithium carbonate, lithium citrate, loxapine, olanzapine, paliperidone, perphenazine, pimozide, prochlorperazine, quetiapine fumarate, risperidone, thioridazine hydrochloride, trifluoperazine hydrochloride, ziprasidone

Action
Block postsynaptic mesolimbic and mesocortical dopamine receptors in brain, relieving hallucinations, delusions, and psychoses. Also thought to relieve anxiety by filtering internal arousal stimuli to reticular system in brain stem.

Indications
Acute or chronic psychosis, acute intermittent porphyria, nausea and vomiting, intractable hiccups, preoperative sedation

Contraindications and precautions
- Contraindicated in hypersensitivity to drug, phenothiazines, sulfites (when injected), or benzyl alcohol (sustained-release forms); angle-closure glaucoma; bone marrow depression; blood dyscrasias; myeloproliferative disorders; subcortical brain damage; cerebral arteriosclerosis; hepatic damage; coronary artery disease; severe hypotension or hypertension; coma; and severe depression
- Use cautiously in diabetes mellitus; respiratory disease; prostatic hypertrophy; CNS tumors; seizure disorders; intestinal obstruction; elderly or debilitated patients; pregnant or breastfeeding patients (safety not established); and children with acute illness, infection, gastroenteritis, or dehydration.

Adverse reactions
CNS: drowsiness, sedation, extrapyramidal reactions, tardive dyskinesia, pseudoparkinsonism, seizures, neuroleptic malignant syndrome
CV: hypotension (increased with I.M. or I.V. use), tachycardia
EENT: blurred vision, lens opacities, dry eyes, nasal congestion
GI: constipation, anorexia, dry mouth, paralytic ileus
GU: urinary retention, menstrual irregularities, inhibited ejaculation, priapism, galactorrhea
Hematologic: eosinophilia, hemolytic anemia, agranulocytosis, leukopenia, aplastic anemia, thrombocytopenia
Hepatic: jaundice, hepatitis
Skin: photosensitivity, pigmentation changes, rash, sterile abscess
Other: allergic reactions, hyperthermia, pain at injection site

Patient monitoring
- Monitor vital signs (especially blood pressure), ECG, CBC, urinalysis, liver and kidney function tests, and periodic eye exams.

antirheumatic drugs

Biological response modifiers: adalimumab, anakinra, etanercept, infliximab

Disease-modifying agents: auranofin, aurothioglucone, azathioprine, cyclosporine, hydroxychloroquine sulfate, leflunomide, methotrexate, methotrexate sodium

Action
Biological response modifiers bind specifically to tumor necrosis factor
(TNF) alpha or competitively inhibit binding of interleukin-1 (IL-1) to IL-1 type I receptors, thereby blocking biologic activity of TNF alpha or IL-1.

**Disease-modifying agents** suppress the immune system and decrease inflammation.

**Indications**
Rheumatoid arthritis

**Contraindications and precautions**
- Contraindicated in hypersensitivity to drug, moderate to severe heart failure, demyelinating CNS disorder, hematologic abnormalities, poorly controlled or advanced diabetes mellitus, and significant exposure to varicella virus
- Use cautiously in severe myocardial, hepatic, or renal disease; decreased bone marrow reserve; active infection; hypotension; coma; history of or exposure to tuberculosis; elderly patients; pregnant or breastfeeding patients; and children.

**Adverse reactions**
*CNS:* confusion, hallucinations, headache, fatigue, insomnia, depression, EEG abnormalities, peripheral neuropathy, sensorimotor effects, encephalitis, seizures
*CV:* hypertension
*EENT:* iritis, corneal ulcers, gold deposits in ocular tissues, rhinitis, pharyngitis, sinusitis
*GI:* nausea, vomiting, diarrhea, constipation, abdominal cramps, flatulence, dyspepsia, dysphagia, ulcerative enterocolitis, melena, occult blood in stool, anorexia, **GI bleeding**
*GU:* hematuria, proteinuria, urinary tract infection, nephrotic syndrome or glomerulitis, acute renal failure, acute tubular necrosis, acute nephritis, degeneration of proximal tubular epithelium

**Hematologic:** eosinophilia, anemia, thrombocytopenia, leukopenia, neutropenia, agranulocytosis, pancytopenia, hypoplastic anemia, aplastic anemia, pure red-cell aplasia, granulocytopenia, pancytopenia, panmyelopathy, hemorrhagic diathesis

**Hepatic:** jaundice, intrahepatic cholestasis, hepatitis with jaundice, toxic hepatitis

**Musculoskeletal:** arthralgia, back pain, myalgia, synovial destruction

**Respiratory:** upper respiratory infection, cough, dyspnea, tuberculosis

**Skin:** rash; urticaria; pruritus; erythema; papular, vesicular, or exfoliative dermatitis; abscess; alopecia; nail shedding; angioedema; photosensitivity

**Other:** bad taste, fever, chest pain, candidiasis, infection, chrysiasis, lupus-like syndrome, lymphoproliferative disease, hypersensitivity reaction, cancer

**Patient monitoring**
- Monitor for signs and symptoms of hypersensitivity reaction and infection.
- Monitor CBC with white cell differential and platelet count; assess liver and kidney function tests.
- Assess for heart failure in patients with history of cardiac disease.

**antituberculars**
dapsone, ethambutol hydrochloride, isoniazid, pyrazinamide, rifabutin, rifampin, rifapentine, streptomycin sulfate

**Action**
Unknown. May interfere with synthesis of one or more bacterial metabolites, altering RNA synthesis during cell division.
Indications
Tuberculosis and atypical mycobacterial infections caused by *Mycobacterium tuberculosis*.

Contraindications and precautions
- Contraindicated in hypersensitivity to drug (including drug-induced hepatitis).
- Use cautiously in severe renal impairment, malnutrition, diabetes mellitus, chronic alcoholism, diabetic retinopathy, cataracts, optic neuritis and other ocular defects, history of hepatic damage or chronic alcohol ingestion, patients older than age 50, Black or Hispanic females, postpartal patients, pregnant or breastfeeding patients, and children younger than age 13.

Adverse reactions
- **CNS:** confusion, dizziness, hallucinations, headache, malaise, peripheral neuropathy
- **EENT:** optic neuritis, blurred vision, decreased visual acuity, eye pain, red-green color blindness
- **GI:** nausea, vomiting, abdominal pain, anorexia
- **Hematologic:** thrombocytopenia
- **Hepatic:** hepatitis
- **Metabolic:** hyperuricemia
- **Musculoskeletal:** joint pain, gouty arthritis
- **Respiratory:** bloody sputum
- **Skin:** rash, toxic epidermal necrolysis
- **Other:** fever, anaphylaxis

Patient monitoring
- Monitor vital signs (especially blood pressure), ECG, CBC, urinalysis, liver and kidney function tests, and periodic eye exams.

antiulcer drugs

*Histamine*$_2$ (H$_2$)-receptor antagonists: cimetidine hydrochloride, famotidine, nizatidine, ranitidine hydrochloride

*Proton pump inhibitors:* esomeprazole magnesium, lansoprazole, omeprazole, pantoprazole sodium, rabeprazole sodium

*Other:* bismuth subsalicylate, misoprostol, sucralfate

Action
Reduce gastric acid level either by blocking H$_2$ receptors or by inhibiting the proton pump

Indications
Short-term treatment of active duodenal ulcer or benign gastric ulcer; prophylaxis of duodenal ulcer (at lower doses); treatment of gastroesophageal reflux disease, heartburn, acid indigestion, and gastric hypersecretory states (such as Zollinger-Ellison syndrome); prevention and treatment of stress-induced upper GI bleeding in critically ill patients

Contraindications and precautions
- Contraindicated in hypersensitivity to any antiulcer drug and in alcohol intolerance
- Use cautiously in renal impairment, elderly patients, and pregnant or breastfeeding patients.

Adverse reactions
- **CNS:** confusion, dizziness, drowsiness, hallucinations, headache, peripheral neuropathy, brain stem dysfunction
- **CV:** hypotension, arrhythmias, cardiac arrest
GI: nausea, diarrhea, constipation
GU: decreased sperm count, erectile dysfunction, gynecomastia
Hematologic: anemia, neutropenia, thrombocytopenia, agranulocytosis, aplastic anemia
Hepatic: hepatitis
Other: altered taste, pain at I.M. injection site, hypersensitivity reaction

Patient monitoring
- Monitor for resolution of GI symptoms.
- Assess CBC and liver function tests.

**antivirals and antiretrovirals**

*Antivirals:* acyclovir sodium, amantadine hydrochloride, famciclovir, foscarnet sodium, ganciclovir, oseltamivir phosphate, ribavirin, rimantadine hydrochloride, valacyclovir hydrochloride, valganciclovir hydrochloride, zanamivir

*Antiretrovirals:* abacavir sulfate, adefovir dipivoxil, cidofovir, darunavir, delavirdine mesylate, didanosine, efavirenz, emtricitabine, enfuvirtide, etravirine, fosamprenavir calcium, indinavir sulfate, lamivudine, nelfinavir mesylate, nevirapine, raltegravir, ritonavir, saquinavir, stavudine, tenofovir disoproxil fumarate, zalcitabine, zidovudine

**Action**

*Antivirals* kill viral cells by inhibiting release of enzymes required for DNA synthesis; inhibiting viral nucleic acid, DNA, or protein synthesis; inhibiting viral replication; or inhibiting protease reaction.

*Antiretrovirals* inhibit activity of human immunodeficiency virus (HIV) protease or HIV-1 reverse transcriptase, or bind directly to reverse transcriptase and block RNA- and DNA-dependent DNA polymerase activities. These actions inhibit HIV replication.

**Indications**

Genital herpes, herpes simplex, varicella zoster, herpes zoster (shingles), influenza type A virus, hepatitis, cytomegalovirus, HIV

**Contraindications and precautions**

- Contraindicated in hypersensitivity to drug or its components
- Use cautiously in renal or hepatic impairment; peripheral neuropathy; phenylketonuria; hyperuricemia; hypercholesterolemia; amylase elevation; history of mental illness, substance abuse, or hepatic impairment (including hepatitis B or C infection); sodium-restricted diet; elderly or debilitated patients; pregnant or breast-feeding patients; and children.

**Adverse reactions**

CNS: dizziness, asthenia, anxiety, abnormal thinking, hypoesthesia, agitation, confusion, hypertonia, *seizures*, coma
CV: hypotension, palpitations, bradycardia, weak pulse, pseudoaneurysm, embolism, thrombophlebitis, nodal arrhythmias, atrioventricular block, ventricular tachycardia
EENT: ocular hypotony, iritis, retinal detachment, diplopia
GI: nausea, vomiting, diarrhea, abdominal distention, dyspepsia, gastrointestinal reflux, hematemesis, dysphagia, dry mouth, *paralytic ileus*
GU: urinary retention, frequency, or incontinence; dysuria; prostatitis; *nephrotoxicity*
Hematologic: anemia, petechiae, leukocytosis, thrombocytopenia, neutropenia, bleeding
Hepatic: hepatomegaly

Reactions in **bold** are life-threatening.
Metabolic: diabetes mellitus, hyperkalemia
Musculoskeletal: muscle contractions
Respiratory: bronchitis, dyspnea, wheezing, pneumonia, pleurisy, pleural effusion, pulmonary edema, bronchospasm, pulmonary embolism
Skin: rash, diaphoresis, urticaria, pruritus, bullous eruptions, pallor
Other: pain, peripheral coldness, edema, drug toxicity

Patient monitoring
- Monitor CBC and liver and kidney function tests.
- As indicated, monitor viral load and T-cell levels.

anxiolytics

Benzodiazepines: alprazolam, chlordiazepoxide hydrochloride, clonazepam, clorazepate, diazepam, lorazepam, oxazepam
Other: buspirone hydrochloride, doxepin, hydroxyzine hydrochloride, hydroxyzine pamoate

Action
Benzodiazepines potentiate effects of gamma-aminobutyric acid (GABA) and other inhibitory transmitters by binding to specific benzodiazepine receptor sites.
Other anxiolytics have unknown actions. They are thought to act on brain by inhibiting neuronal firing and reducing serotonin transmission.

Indications
Anxiety disorders

Contraindications and precautions
- Contraindicated in hypersensitivity to drug, psychosis, acute angle-closure glaucoma, significant hepatic disease, intra-arterial use (lorazepam injection), concurrent use of ketoconazole or itraconazole, breastfeeding (diazepam), and children younger than 6 months
- Use cautiously in hepatic disease, asthma, severe pulmonary disease, open-angle glaucoma, obesity, or concurrent use of CNS depressants.

Adverse reactions
CNS: sedation, somnolence, depression, lethargy, apathy, fatigue, hypoactivity, light-headedness, dizziness, memory impairment, disorientation, anterograde amnesia, restlessness, confusion, crying, sobbing, delirium, agitation, headache, slurred speech, aphonia, dysarthria, stupor, syncope, vertigo, euphoria, nervousness, irritability, poor concentration, inability to perform complex mental functions, rigidity, tremor, dystonia, akathisia, hemiparesis, paresthesia, hypotonia, unsteadiness, ataxia, incoordination, weakness, vivid dreams, psychomotor retardation, extrapyramidal symptoms, paradoxical reactions, behavior problems, hysteria, psychosis, seizures, coma, suicidal tendency
CV: bradycardia, tachycardia, hypertension, hypotension, palpitations, decreased systolic pressure, cardiovascular collapse
EENT: visual disturbances, diplopia, nystagmus, decreased hearing, auditory disturbances, nasal congestion
GI: nausea, vomiting, diarrhea, constipation, gastritis, coated tongue, difficulty swallowing, increased salivaion, dry mouth, anorexia
GU: urinary incontinence or retention, menstrual irregularities, gynecomastia, galactorrhea, libido changes
Hematologic: anemia, eosinophilia, leukopenia, agranulocytosis, thrombocytopenia
Hepatic: hepatic dysfunction
Metabolic: dehydration
Musculoskeletal: muscle disturbances, joint pain
Respiratory: respiratory disturbances, partial airway obstruction
Skin: urticaria; pruritus; morbilliform, urticarial, or maculopapular rash; dermatitis; alopecia; hirsutism; ankle or facial edema; diaphoresis
Other: sore gums; appetite and weight changes; glassy-eyed appearance; fever; hiccups; edema; lymphadenopathy; pain, burning, and redness at I.M. injection site; phlebitis and thrombosis at I.V. site

Patient monitoring
- Monitor CBC and kidney and liver function tests.
- Taper dosage gradually to termination; do not withdraw quickly.

beta-adrenergic blockers
Alpha/beta-adrenergic blockers: carvedilol, labetalol
Beta-adrenergic blockers: acebutolol hydrochloride, atenolol, bisoprolol fumarate, carteolol hydrochloride, esmolol hydrochloride, metoprolol, nadolol, nebivolol, pindolol, propranolol hydrochloride, sotalol hydrochloride, timolol maleate

Action
Alpha/beta-adrenergic blockers combine selective competitive postsynaptic alpha1-adrenergic blockade with nonselective, competitive beta-adrenergic blockade, causing blood pressure to decrease.

Beta-adrenergic blockers combine reversibly with beta-adrenergic receptors, blocking responses to sympathetic nerve impulses, catecholamines, or adrenergic drugs. Beta2 blockade decreases heart rate, myocardial contractility, and cardiac output while slowing atrioventricular conduction. Beta2 blockade increases bronchial airway resistance and enhances the inhibitory effect of catecholamines on peripheral vessels.

Indications
Hypertension; angina pectoris; myocardial infarction (MI); stable, symptomatic (class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin; ventricular arrhythmias or tachycardia; tremors; chronic intraocular glaucoma; aggressive behavior; drug-induced akathisia; anxiety; migraine prophylaxis

Contraindications and precautions
- Contraindicated in hypersensitivity to drug, heart failure (unless secondary to tachyarrhythmia treatable with specific beta-adrenergic blocker), shock, sinus bradycardia, and heart block greater than first degree. Alpha/beta-adrenergic blockers are contraindicated in bronchial asthma and symptomatic hepatic impairment.
- Use cautiously in renal or hepatic impairment, pulmonary disease (especially asthma), pulmonary edema, diabetes mellitus, thyrotoxicosis, history of severe allergic reactions, elderly patients, pregnant or breastfeeding patients, and children (safety not established).

Adverse reactions
CNS: insomnia, headache, hyperactivity, malaise, CNS stimulation, dizziness, drowsiness, syncope, tremor, restlessness, nervousness, apprehension, anxiety, hyperkinesia, asthenia, vertigo, paresthesia
CV: hypertension, hypotension, tachycardia, angina, chest pain, palpitations, arrhythmias
EENT: abnormal vision, dry eyes, epistaxis, nasal congestion, sore throat
(inhaled drug form), nasal dryness and irritation, hoarseness
GI: nausea, vomiting, heartburn, cholestasis, anorexia
GU: acute urinary bladder retention, difficulty voiding, ejaculation failure, erectile dysfunction, priapism, Peyronie's disease
Metabolic: hypokalemia, hypoglycemia
Musculoskeletal: muscle cramps
Respiratory: cough, wheezing, dyspnea, bronchitis, increased sputum, paradoxical airway resistance (with repeated, excessive use of inhaled form), pulmonary edema, bronchospasm
Skin: pallor; flushing; diaphoresis; generalized maculopapular, lichenoid, urticarial, or psoriasis rash; bullous lichen planus; facial erythema; reversible alopecia
Other: bad or unusual taste, increased appetite, edema, fever, antimitochondrial antibodies, hypersensitivity reaction, systemic lupus erythematosus

Patient monitoring
- Monitor CBC, ECG, blood glucose and electrolyte levels, and liver and kidney function tests.
- Assess vital signs, fluid intake and output, and weight.

bisphosphonates
alendronate sodium, etidronate disodium, pamidronate disodium, risendronate, zoledronic acid

Action
Inhibit normal and abnormal bone resorption

Indications
Osteoporosis in postmenopausal women and men, glucocorticoid-induced osteoporosis, Paget's disease, heterotopic ossification, hypercalcemia of malignancy, breast cancer, multiple myeloma, bone metastases of solid tumors

Contraindications and precautions
- Contraindicated in hypersensitivity to drug, hypocalcemia, esophageal abnormalities, clinically overt osteomalacia, renal impairment (class Dc and higher), inability to stand or sit upright for at least 30 minutes after dosing, and pregnancy
- Use cautiously in renal impairment less than class Dc; history of hypoparathyroidism or aspirin-sensitive asthma; or concurrent use of loop diuretics, aminoglycosides, or other nephrotoxic drugs.

Adverse reactions
CNS: agitation, anxiety, confusion, asthenia, depression, dizziness, headache, hypertonia, hypoesthesia, insomnia, neuralgia, fatigue, paresthesia, psychosis, somnolence, vertigo, seizures
CV: angina pectoris, cardiovascular disorder, chest pain, hypertension, hypotension, syncope, vasodilation, tachycardia, atrial flutter or fibrillation, heart failure
EENT: amblyopia, cataract, conjunctivitis, dry eyes, tinnitus, rhinitis, sinusitis, pharyngitis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, abdominal distention, acid reflux, belching, colitis, dyspepsia, gastritis, gastroenteritis, dysphagia, flatulence, esophageal ulcer, dry mouth, anorexia, GI hemorrhage
Hematologic: anemia, ecchymosis, granulocytopenia, leukopenia, neutropenia, thrombocytopenia
Metabolic: dehydration, fluid overload
Musculoskeletal: arthralgia, arthritis, arthrosis, back or neck pain, bone disorder, bone fracture, bone or skeletal pain, bursitis, joint disorder, leg or other muscle cramps, myalgia
Respiratory: bronchitis, cough, dyspnea, pneumonia, crackles, upper respiratory infection, pleural effusion
Skin: alopecia, dermatitis, pruritus, rash
Other: taste perversion, weight loss, pain, edema, fever, flulike symptoms, infection, infusion-site reaction, allergic reaction

Patient monitoring
- Watch for signs and symptoms of GI irritation, including ulcers.
- Monitor blood pressure and calcium, potassium, phosphate, and creatinine levels.
- Monitor vital signs, ECG, and fluid intake and output.

bronchodilators
albuterol, aminophylline, dyphylline, epinephrine, ipratropium bromide, isoproterenol, levalbuterol hydrochloride, metaproterenol sulfate, pirbuterol acetate, salmeterol, terbutaline sulfate, theophylline

Action
Inhibit phosphodiesterase, an enzyme that degrades cyclic adenosine monophosphate (cAMP) by stimulating cAMP release and inhibiting release of slow-reacting substance of anaphylaxis and histamine. These actions cause bronchodilation, produce CNS and cardiac stimulation, promote diuresis, and increase gastric acid secretion.

Indications
Prevention of exercise-induced bronchospasm, prevention and treatment of bronchospasm in reversible obstructive airway disease

Contraindications and precautions
- Contraindicated in hypersensitivity to drug, angina, arrhythmias associated with tachycardia, ventricular arrhythmias that warrant inotropic therapy, cardiac dilatation or insufficiency, cerebral arteriosclerosis, organic brain damage, angle-closure glaucoma, local anesthesia of certain areas (such as toes or fingers), and labor
- Use cautiously in heart failure or other cardiac or circulatory impairment, hypertension, chronic obstructive pulmonary disease, renal or hepatic disease, hyperthyroidism, peptic ulcer, severe hypoxemia, diabetes mellitus, seizure disorders, glaucoma, elderly patients, pregnant or breastfeeding patients, young children, and infants.

Adverse reactions
CNS: insomnia, headache, hyperactivity, asthenia, malaise, dizziness, apprehension, anxiety, restlessness, CNS stimulation, nervousness, hypokalemia, vertigo, drowsiness, tremor
CV: hypertension, hypotension, tachycardia, angina, chest pain, palpitations, tachycardia, angina, chest pain, palpitations, arrhythmias
EENT: nasal congestion, nasal dryness and irritation, epistaxis, sore throat (with inhaled drug), hoarseness
GI: nausea, vomiting, heartburn, anorexia
Metabolic: hypokalemia, hypoglycemia
Musculoskeletal: muscle cramps
Respiratory: cough, wheezing, dyspnea, bronchitis, paradoxical airway resistance (with repeated, excessive use of inhaled drug), increased sputum, bronchospasm, pulmonary edema
Skin: pallor, flushing, diaphoresis
Other: unusual or bad taste, increased appetite, hypersensitivity reaction

Patient monitoring
- Monitor vital signs, ECG, and fluid intake and output.

Reactions in bold are life-threatening.
calcium channel blockers
amlodipine, diltiazem hydrochloride, felodipine, isradipine, nicardipine hydrochloride, nifedipine, nimodipine, nisoldipine, verapamil hydrochloride

Action
Inhibit calcium influx through membranes of cardiac and smooth-muscle cells; this action depresses automaticity and conduction velocity in cardiac muscle, reducing myocardial contractility. Also decrease depolarization rate, atrial conduction, and total peripheral resistance.

Indications
Hypertension, angina pectoris, vasospastic (Prinzmetal’s) angina, supraventricular tachyarrhythmias, rapid ventricular rate in atrial flutter or fibrillation

Contraindications and precautions
- Contraindicated in hypersensitivity to drug, sick sinus syndrome, second- or third-degree atrioventricular block (unless patient has artificial pacemaker in place), and systolic pressure below 90 mm Hg
- Use cautiously in severe renal or hepatic impairment, advanced aortic stenosis, cardiogenic shock (unless associated with supraventricular tachyarrhythmias), history of serious ventricular arrhythmias or heart failure, concurrent use of I.V. beta-adrenergic blockers, elderly patients, pregnant or breastfeeding patients, and children (safety not established).

Adverse reactions
CNS: headache, abnormal dreams, anxiety, confusion, dizziness, syncope, drowsiness, nervousness, paresthesia, tremor, asthenia, psychiatric disturbances
CV: peripheral edema, chest pain, hypotension, palpitations, bradycardia, tachycardia, arrhythmias, heart failure
EENT: blurred vision, disturbed equilibrium, tinnitus, epistaxis
GI: nausea, vomiting, diarrhea, constipation, dyspepsia, dry mouth, anorexia
GU: dysuria, nocturia, polyuria, sexual dysfunction, gynecomastia
Hematologic: anemia, leukopenia, thrombocytopenia
Metabolic: hyperglycemia
Musculoskeletal: joint stiffness, muscle cramps
Respiratory: cough, dyspnea
Skin: rash, dermatitis, pruritus, urticaria, flushing, diaphoresis, photosensitivity reaction, erythema multiforme, Stevens-Johnson syndrome
Other: gingival hyperplasia, altered taste, weight gain

Patient monitoring
- Monitor blood glucose and electrolyte levels, fluid intake and output, and liver and kidney function tests.
- Assess vital signs, ECG, weight, and blood pressure in both arms (with patient lying down, sitting, and standing).

cholinergics
bethanechol chloride, cevimeline hydrochloride, neostigmine, pyridostigmine bromide

Action
Stimulate cholinergic receptors, causing urinary bladder contraction, decreased bladder capacity, more frequent ureteral peristaltic waves, increased GI tone and peristalsis, increased lower
esophageal sphincter pressure, and increased gastric secretions

Indications
Postpartum or postoperative nonobstructive urinary retention, urinary retention caused by neurogenic bladder, diagnosis of myasthenia gravis (Tensilon test), antidote for curare (to reverse nondepolarizing neuromuscular blockade)

Contraindications and precautions
- Contraindicated in hypersensitivity to drug or sulfites, hyperthyroidism, peptic ulcer, latent or active bronchial asthma, pronounced bradycardia or atrioventricular (AV) conduction defects, vasomotor instability, coronary artery disease, coronary occlusion, hypotension, hypertension, seizure disorders, Parkinsonism, GI or GU tract obstruction, impaired GI or GU wall integrity, spastic GI disturbances, acute inflammatory GI tract lesions, peritonitis, marked vagotonia, and when GI tract or urinary bladder activity is undesirable (for instance, postoperatively)
- Use cautiously in arrhythmias, toxic megacolon, poor GI motility, and pregnant patients.

Adverse reactions
CNS: asthenia, dysarthria, dysphonia, dizziness, drowsiness, headache, syncope, loss of consciousness, seizures
CV: hypotension, AV block, bradycardia, cardiac arrest, thrombophlebitis
(with I.V. use)
EENT: diplopia, miosis, conjunctival hyperemia, excessive lacrimation and salivation
GI: nausea, vomiting, diarrhea, abdominal cramps, dysphagia
GU: urinary frequency or incontinence
Musculoskeletal: muscle cramps, fasciculations

Respiratory: dyspnea, respiratory muscle paralysis, central respiratory paralysis, laryngospasm, bronchospasm, respiratory arrest
Skin: rash, diaphoresis, flushing
Other: anaphylaxis

Patient monitoring
- Monitor ECG, glucose and electrolyte levels, urinalysis, and liver and kidney function tests.

CNS stimulants
amphetamine, dexamphetamine hydrochloride, dextroamphetamine sulfate, doxapram, lisdexamfetamine dimesylate, methylphenidate hydrochloride, modafinil, pemoline

Action
Cause norepinephrine release from central adrenergic neurons and increase central stimulation, which enhances motor activity and mental alertness, lifts mood, and suppresses appetite

Indications
Attention deficit hyperactivity disorder, narcolepsy

Contraindications and precautions
- Contraindicated in hypersensitivity to drug or tartrazine, advanced atherosclerosis, cardiovascular disease, moderate to severe hypertension, agitation, hyperexcitable states (including hyperthyroidism), glaucoma, history of Tourette’s syndrome or drug abuse, suicidal or homicidal tendency, concurrent MAO inhibitor use, breastfeeding, and children younger than age 6

Reactions in bold are life-threatening.
• Use cautiously in mild hypertension, diabetes mellitus, depression, seizures, psychosis, long-term amphetamine use, elderly or debilitated patients, and pregnant patients.

**Adverse reactions**

**CNS:** nervousness, insomnia, dizziness, headache, dyskinesia, chorea, drowsiness, hyperactivity, restlessness, tremor, depression, Tourette’s syndrome, **toxic psychosis**

**CV:** angina, palpitations, hypertension, hypotension, tachycardia, **arrhythmias**

**EENT:** blurred vision, poor accommodation

**GI:** nausea, vomiting, diarrhea, constipation, abdominal pain and cramps, anorexia, dry mouth

**GU:** erectile dysfunction, increased libido

**Hematologic:** anemia, leukopenia, thrombocytopenia

**Hepatic:** hepatic dysfunction, hepatic coma

**Skin:** rash, alopecia, exfoliative dermatitis

**Other:** metallic taste, weight loss, fever, psychological or physical drug dependence, drug tolerance, abnormal behavior (with abuse)

**Patient monitoring**

• Watch for and report fever, excitation, delirium, tremors, and twitching.

• Monitor vital signs. Stay alert for arrhythmias, tachycardia, hypertension, and cardiovascular changes with psychotic syndrome.

• Watch for and report signs of drug abuse.

---

**corticosteroids**

beclomethasone dipropionate, betamethasone, budesonide, cortisone acetate, dexamethasone, hydrocortisone, methylprednisolone, mometasone, prednisolone, prednisone, triamcinolone

**Action**

Reduce the immune response by inhibiting prostaglandin synthesis, macrophage and leukocyte accumulation at inflammation site, phagocytosis, and lysosomal enzyme release. Also reduce numbers of T lymphocytes, monocytes, and eosinophils and interfere with immunoglobulin binding to cell-surface receptors. Some corticosteroids regulate metabolic pathways involving protein, carbohydrate, and fat; others regulate electrolyte and water balance.

**Indications**

Adrenocortical insufficiency; adrenal, inflammatory, allergic, hematologic, neoplastic, and autoimmune disorders; asthma; cerebral edema; Crohn’s disease; hypercalcemia; acute spinal cord injury; nausea and vomiting caused by chemotherapy; prevention of organ rejection in transplant patients; prevention of neonatal respiratory distress in high-risk pregnancies

**Contraindications and precautions**

• Contraindicated in hypersensitivity to drug or intolerance of alcohol, bisulfites, or tartrazine and in active untreated infections

• Use cautiously in hypertension, osteoporosis, diabetes mellitus, glaucoma, immunosuppression, seizure disorders, renal disease, hypothyroidism, cirrhosis, diverticulitis, active or latent

---

Canada UK Hazardous drug High alert drug
peptic ulcer, inflammatory bowel disease, ulcerative colitis, thromboembolic disorder or tendency, myasthenia gravis, heart failure, metastatic cancer, emotional instability, recent GI surgery, pregnant or breastfeeding patients, and children younger than age 6 (safety not established).

Adverse reactions
CNS: headache, nervousness, restlessness, depression, euphoria, personality changes, psychosis, vertigo, paresthesia, insomnia, increased intracranial pressure, seizures
CV: hypotension, hypertension, Churg-Strauss syndrome, heart failure, thrombophlebitis, thromboembolism, fat embolism, arrhythmias, shock
EENT: glaucoma (with long-term use), increased intraocular pressure, cataract, nasal congestion and irritation, perforated nasal septum, epistaxis, nasopharyngeal or oropharyngeal fungal infection, sneezing, dysphonia, hoarseness, throat irritation
GI: nausea, vomiting, abdominal distention, peptic ulcer, esophageal candidiasis or ulcer, pancreatitis, dry mouth, anorexia
GU: amenorrhea, irregular menses
Metabolic: decreased growth (in children), diabetes mellitus, cushingoid state, sodium and fluid retention, hyperglycemia, hypokalemia, hypocalcemia, hypercholesterolemia, adrenal suppression, hypothalamic-pituitary-adrenal suppression (with systemic use for more than 5 days)
Musculoskeletal: muscle wasting, muscle pain and weakness, myopathy, spontaneous fractures, aseptic joint necrosis, tendon rupture, osteoporosis, osteonecrosis
Respiratory: cough, wheezing, bronchospasm
Skin: rash, pruritus, contact dermatitis, acne, decreased wound healing, bruising, hirsutism, thin and fragile skin, petechiae, purpura, striae, subcutaneous fat atrophy, injection site atrophy, angioedema
Other: bad taste, increased appetite (with long-term use), weight gain, facial edema, increased susceptibility to infection, aggravation or masking of infection, immunosuppression, hypersensitivity reaction

Patient monitoring
- Monitor ECG, blood glucose and electrolyte levels, urinalysis, and kidney and liver function tests.
- Assess platelet count in long-term therapy. Report unusual bleeding or bruising, petechiae, skin disorders, and signs and symptom of diabetes mellitus.
- Monitor appearance for changes that suggest Cushing’s syndrome.

**diuretics**

**Carbonic anhydrase inhibitor:** acetazolamide

**Loop diuretics:** bumetanide, furosemide, torsemide

**Osmotic diuretics:** mannitol, urea

**Potassium-sparing diuretics:** amiloride hydrochloride, spironolactone, triamterene

**Thiazide and thiazide-like diuretics:** chlorothiazide, chlorthalidone, hydrochlorothiazide, indapamide, metolazone

**Action**
Carbonic anhydrase inhibitors inhibit carbonic anhydrase in kidneys, decreasing reabsorption of water, sodium, potassium, and bicarbonate. Loop diuretics inhibit reabsorption of sodium and chloride (and therefore water)
in proximal and distal tubules and loop of Henle. Osmotic diuretics increase plasma osmolality, drawing water from body tissues into extracellular fluid and then out through the kidney. Potassium-sparing diuretics inhibit sodium reabsorption in distal renal tubule, causing sodium and water loss. Thiazide and thiazide-like diuretics decrease rate of sodium and chloride reabsorption by distal renal tubule and increase water excretion.

**Indications**
Hypertension or edema secondary to heart failure or other causes, cerebral edema, hemolytic transfusion reaction, drug toxicity, prevention of oliguria or acute renal failure

**Contraindications and precautions**
- Contraindicated in hypersensitivity to drug, alcohol intolerance (some liquid furosemide forms), anuria, renal decompensation, hepatic coma or precoma, severe electrolyte depletion, severe pulmonary congestion or edema, severe dehydration, and active intracranial bleeding (except during craniotomy)
- Use cautiously in severe hepatic disease accompanied by cirrhosis or ascites, electrolyte depletion, worsening azotemia, renal insufficiency (blood urea nitrogen above 30 mg/dl or creatinine clearance below 30 ml/minute), diabetes mellitus, elderly or debilitated patients, pregnant or breastfeeding patients, and children younger than age 18.

**Adverse reactions**
CNS: dizziness, headache, insomnia, nervousness, vertigo, asthenia, paresthesia, confusion, fatigue, drowsiness, encephalopathy
CV: hypotension, chest pain, volume depletion, thrombophlebitis, arrhythmias

**Erectile dysfunction agents**
Phosphodiesterase type 5 (PDE5) inhibitors: sildenafil citrate, tadalafil, vardenafil hydrochloride
Other: alprostadil

**Action**
PDE5 inhibitors cause degradation of cyclic guanylic acid in smooth-muscle cells of corpus cavernosum, enhancing effects of nitric oxide released during sexual stimulation. These actions increase blood flow to penis and induce erection.
Alprostadil relaxes the trabecular smooth muscle and dilates cavernosal arteries, causing expansion of lacunar spaces and blood entrapment from compression of venules against the tunica albuginea. These effects induce erection.

**Indications**
Erectile dysfunction

**Contraindications and precautions**
- Contraindicated in hypersensitivity to drug or its components and in concurrent use of nitrates (regularly or intermittently), nitric oxide donors, or alpha-adrenergic blockers
- Use cautiously in anatomic penile deformation, conditions that predispose to priapism (such as sickle cell anemia, multiple myeloma, leukemia), bleeding disorders, active peptic ulcer, retinitis pigmentosa or other retinal abnormality, coronary ischemia, heart failure, multidrug antihypertensive regimen, or concurrent use of erythromycin, cimetidine, or other drugs that could prolong the half-life of erectile dysfunction agent.

**Adverse reactions**

**CNS:** dizziness, headache, fainting, hypohesthesia  
**CV:** abnormal ECG, hypertension, hypotension, vasodilation, vasovagal reaction, peripheral vascular disorder, supraventricular extrasystoles  
**EENT:** abnormal vision, mydriasis, nasal congestion, rhinitis, sinusitis  
**GI:** nausea, diarrhea, dyspepsia, dry mouth  
**GU:** urinary frequency and urgency, impaired urination, hematuria, urinary tract infection, inguinal hernia, prostate disorder, scrotal disorder or edema, testicular pain  
**Metabolic:** hyperglycemia  
**Musculoskeletal:** back or limb pain, leg cramps, myalgia

**Respiratory:** cough  
**Skin:** rash, nonapplication site pruritus, diaphoresis, flushing, skin disorder or neoplasm  
**Other:** accidental injury, flulike symptoms, infection, localized pain

**Patient monitoring**
- Monitor cardiovascular status and vision.  
- Assess for drug efficacy. Watch for priapism or erections lasting beyond 4 hours, which may permanently damage penile tissue.

**hematopoietic agents**

**Colony-stimulating factors:** filgrastim, pegfilgrastim, sargramostim  
**Human erythropoietins:** darbepoetin alfa, epoetin alfa

**Action**
Varies with specific drug. See individual monographs.

**Indications**
**Colony-stimulating factors**—to reduce incidence of infection in myelospressive chemotherapy; to reduce time to neutrophil recovery and fever duration in patients with acute myelogenous leukemia and nonmyeloid cancer who are undergoing myeloablative chemotherapy followed by bone marrow transplant; mobilization of peripheral blood progenitor cell collection; severe chronic neutropenia  
**Human erythropoietins**—anemia associated with chronic renal failure, zidovudine therapy in patients with human immunodeficiency virus, cancer patients on chemotherapy, reduction of allogeneic blood transfusions in surgery patients

Reactions in **bold** are life-threatening.
Contraindications and precautions

- Contraindicated in hypersensitivity to drug or human albumin and in uncontrolled hypertension
- Use cautiously in cardiac disease, hypertension, seizures, and porphyria.

Adverse reactions

CNS: fatigue, headache, generalized weakness
CV: chest pain, hypertension, tachycardia
GI: nausea, vomiting, diarrhea, constipation, mucositis, stomatitis, anorexia
Metabolic: hyperkalemia
Musculoskeletal: skeletal pain, arthralgia, myalgia
Hematologic: neutropenic fever
Respiratory: dyspnea, cough, sore throat
Skin: alopecia, rash, urticaria
Other: fever, stinging at injection site, flulike symptoms, hypersensitivity reaction

Patient monitoring

- Monitor CBC before and frequently throughout therapy. Also monitor liver function tests and uric acid levels.
- Assess for signs and symptoms of splenic rupture, such as left upper quadrant abdominal pain, shoulder pain, and splenic enlargement.
- Watch for signs and symptoms of infection, sepsis, adult respiratory distress syndrome, and neutropenic fever.
abnormalities, *torsades de pointes,* prolonged QT interval

**EENT:** blurred vision, painful red eye, dry and irritated eyes, eyelid edema, earache, tinnitus, nasopharyngitis, epistaxis, postnasal drip, sinusitis, sore throat

**GI:** nausea, vomiting, diarrhea, constipation, fecal incontinence, dyspepsia, abdominal pain, dry mouth, oral blisters, oral candidiasis, anorexia, **GI hemorrhage**

**GU:** urinary incontinence, breakthrough bleeding, **vaginal hemorrhage,** renal impairment, oliguria, renal failure

**Hematologic:** anemia, **thrombocytopenia,** neutropenia, hemorrhage, disseminated intravascular coagulation

**Metabolic:** hypomagnesemia, hyperglycemia, hypokalemia, **hyperkalemia,** hypoglycemia, **acidosis**

**Musculoskeletal:** myalgia; joint, bone, back, neck, or limb pain

**Respiratory:** dyspnea, cough, hypoxia, wheezing, tachypnea, decreased or abnormal breath sounds, hemoptysis, upper respiratory infection, **pleural effusion**

**Skin:** pruritus, dermatitis, bruising, dry skin, diaphoresis, night sweats, flushing, erythema, petechiae, hyperpigmentation, urticaria, skin lesions, pallor, local exfoliation

**Other:** weight changes, fever, lymphadenopathy, edema, facial edema, bacterial infection, herpes simplex infection, pain, hypersensitivity reaction, sepsis

**Patient monitoring**
- Assess for signs and symptoms of infection and injection site reaction.
- Monitor vital signs, CBC with platelet count, fluid intake and output, electrolyte and blood glucose levels, and liver and kidney function tests.

---

**Inotropic**

**digoxin, inamrinone lactate, milrinone lactate**

**Action**

Inhibit sodium- and potassium-activated adenosine triphosphatase phosphodiesterase, which raises intracellular and extracellular calcium levels. These effects increase myocardial contractility, prolong atrioventricular (AV) node refractory period, decrease conduction through sinoatrial and AV nodes, and relax and dilate vascular smooth muscle to reduce preload and afterload.

**Indications**

Heart failure, tachyarrhythmias, atrial fibrillation or flutter, paroxysmal atrial tachycardia

**Contraindications and precautions**

- Contraindicated in hypersensitivity to drug, known alcohol intolerance (elixir only), and ventricular fibrillation
- Use cautiously in electrolyte abnormalities (such as hypokalemia, hypercalcemia, hypomagnesemia), myocardial infarction, AV block, idiopathic hypertrophic subaortic stenosis, constrictive pericarditis, renal impairment, obesity, elderly patients, pregnant or breastfeeding patients, and children.

**Adverse reactions**

**CNS:** fatigue, headache, asthenia

**CV:** bradycardia, ECG changes, **arrhythmias**

**EENT:** blurred or yellow vision

**GI:** nausea, vomiting, diarrhea, anorexia

**GU:** gynecomastia

**Hematologic:** **thrombocytopenia**

---

Reactions in **bold** are life-threatening.
Patient monitoring
- Monitor vital signs, weight, electrolyte levels, fluid intake and output, drug blood level, and kidney function tests.

laxatives
bisacodyl, calcium polycarbophil, castor oil, docusate, glycerin, lactulose, magnesium salts, methylcellulose, psyllium, senna, sodium phosphate

Action
Stimulate smooth muscle of bowel, increasing intestinal contractions; increase stool bulk by causing water retention and inhibiting digestion in stomach. Also soften hard feces, promoting their passage through lower intestine.

Indications
Treatment of constipation, prevention of constipation in patients who should not strain during defecation (for example, after anorectal surgery or myocardial infarction), colonic evacuation for rectal and bowel examination

Contraindications and precautions
- Contraindicated in hypersensitivity to drug or its components, intestinal obstruction, undiagnosed abdominal pain, suspected appendicitis, and fecal impaction
- Use cautiously in severe cardiovascular disease, anal or rectal fissures, enteritis, ulcerative colitis, diverticulitis, pregnant or breastfeeding patients, and children younger than age 2.

Adverse reactions
GI: nausea; vomiting; diarrhea; esophageal, gastric, small-intestine, or rectal obstruction (with dry form of drug); abdominal cramps in severe constipation; anorexia
GU: reddish-pink discoloration of alkaline urine, yellow-brown discoloration of acidic urine
Metabolic: alkalosis, fluid and electrolyte imbalances
Musculoskeletal: tetany
Other: laxative dependence (with excessive long-term use)

Patient monitoring
- Monitor fluid and electrolyte balance.

neuromuscular blockers
Depolarizing blocker: succinylcholine chloride
Nondepolarizing blockers: atracurium besylate, botulinum toxin type A, cisatracurium besylate, doxacurium chloride, mivacurium chloride, pancuronium bromide, rocuronium bromide, tubocurarine chloride, vecuronium bromide

Action
Depolarizing neuromuscular blockers initially excite skeletal muscle, then prevent muscle contraction by prolonging the refractory period. Nondepolarizing (competitive) neuromuscular blockers bind competitively to cholinergic receptors on motor end plates, preventing muscle contraction.

Indications
Adjunct to anesthesia to facilitate endotracheal intubation; skeletal and smooth muscle relaxation; to facilitate orthopedic manipulation; reduction of muscle contractions during pharmacologically or electrically induced seizures; myasthenia gravis diagnosis
Contraindications and precautions
- Contraindicated in hypersensitivity to drug, low plasma pseudocholinesterase level, angle-closure glaucoma, myopathy with elevated creatine kinase level, penetrating eye injury, and personal or family history of malignant hyperthermia
- Use cautiously in heart disease; electrolyte imbalance; dehydration; neuromuscular, respiratory, or hepatic disease; pregnant or breastfeeding patients, and children younger than age 2.

Adverse reactions
CV: hypotension, bradycardia, arrhythmias, cardiac arrest
Musculoskeletal: profound and prolonged muscle relaxation, residual muscle weakness
Respiratory: cyanosis, prolonged apnea, bronchospasm, respiratory depression
Skin: rash, flushing, pruritus, urticaria
Other: hypersensitivity reaction

Patient monitoring
Monitor vital signs, pulmonary status, and temperature continuously.

nonopioid analgesics
acetaminophen, acetylsalicylic acid, celecoxib, diclofenac, diflunisal, etodolac, ibuprofen, indomethacin, ketorolac tromethamine, meloxicam, nabumetone, naproxen, naproxen sodium, oxaprozin, piroxicam, salicylate, valdecoxib

Action
Inhibit cyclooxygenase, an enzyme needed for prostaglandin synthesis. This inhibition stimulates the anti-inflammatory response and blocks pain impulses.

Indications
Inflammatory conditions (such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis), dysmenorrhea, actinic keratoses, fever

Contraindications and precautions
- Contraindicated in hypersensitivity to drug or sulfonamides and in history of asthma, urticaria, or allergic reaction to aspirin or other nonsteroidal anti-inflammatory drugs
- Use cautiously in severe cardiovascular, renal, or hepatic disease; GI disorders; cardiac decompensation; active GI bleeding or ulcer; asthma; history of ulcer disease; and chronic alcohol use or abuse.

Adverse reactions
CNS: dizziness, headache, insomnia, fatigue, paresthesia, tremor, vertigo, syncope, anxiety, confusion, depression, nervousness, drowsiness, malaise, seizures
CV: palpitations, tachycardia, angina pectoris, hypertension, hypotension, arrhythmias, heart failure, myocardial infarction
EENT: abnormal vision, conjunctivitis, hearing loss, tinnitus, pharyngitis
GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, colitis, duodenal or gastric ulcer, gastritis, gastroesophageal reflux, esophagitis, dry mouth, GI hemorrhage, pancreatitis
GU: albuminuria, hematuria, urinary frequency, urinary tract infection, renal failure
Hematologic: anemia, purpura, leukopenia, thrombocytopenia, other blood dyscrasias
Hepatic: hepatitis
Metabolic: dehydration
Musculoskeletal: myalgia, joint or back pain

Reactions in bold are life-threatening.
Respiratory: dyspnea, cough, asthma, upper respiratory infection, bronchospasm
Skin: rash, urticaria, diaphoresis, pruritus, alopecia, bullous eruption, angioedema, photosensitivity
Other: altered taste, increased appetite, weight changes, flulike symptoms, edema, accidental injury, fever, allergic reaction

Patient monitoring
- Monitor CBC and liver and kidney function tests.

opioid analgesics
alfentanil, buprenorphine hydrochloride, butorphanol tartrate, codeine, fentanyl, hydrocodone, hydromorphone, levorphanol tartrate, meperidine hydrochloride, methadone hydrochloride, methylnaltrexone bromide, morphine sulfate, nalbuphine hydrochloride, oxycodone, oxymorphone hydrochloride, pentazocine, propoxyphene, remifentanil hydrochloride, sufentanil, tramadol

Action
Attach to specific CNS receptors, decreasing cell membrane permeability, slowing pain impulse transmission, and altering response to pain

Indications
Moderate to severe pain, intraoperative anesthesia, labor, cough, diarrhea

Contraindications and precautions
- Contraindicated in hypersensitivity to drug, diarrhea caused by poisoning, acute bronchial asthma, and upper airway obstruction
- Use cautiously in severe cardiovascular, renal, or hepatic disease; cardiac decompensation; GI disorders; history of ulcer disease; chronic alcohol use or abuse; elderly patients; pregnant or breastfeeding patients; and children younger than age 13.

Adverse reactions
CNS: drowsiness, sedation, dizziness, tremor, irritability, syncope, stimulation (in children)
CV: hypertension, hypotension, palpitations, bradycardia, tachycardia, extrasystole, arrhythmias
EENT: blurred vision, nasal dryness and congestion, dry or sore throat
GI: nausea, vomiting, constipation, epigastric distress, dry mouth, anorexia, intestinal obstruction
GU: urinary retention or hesitancy, dysuria, early menses, decreased libido, erectile dysfunction
Hematologic: hemolytic anemia, hypoplastic anemia, thrombocytopenia, agranulocytosis, leukopenia, pancytopenia
Respiratory: thickened bronchial secretions, chest tightness, wheezing
Skin: urticaria, rash, diaphoresis
Other: hypersensitivity reaction (with I.V. use), anaphylactic shock

Patient monitoring
- Assess vital signs and respiratory status.
- Monitor CBC, electrolyte levels, and liver and kidney function tests.

plasma expanders
albumin (human normal serum), dextran, hetastarch, plasma protein fraction

Action
Maintain plasma colloid osmotic pressure and carry intermediate metabolites
in transport and exchange of tissue products; crucial to regulation of circulating blood volume

**Indications**
Shock, burns, hypoproteinemia, adult respiratory distress syndrome, cardiopulmonary bypass, acute hepatic failure, acute nephrosis, hyperbilirubinemia and erythroblastosis fetalis, sequestration of protein-rich fluids, leukapheresis, erythrocyte resuspension, renal dialysis

**Contraindications and precautions**
- Contraindicated in hypersensitivity to drug, severe anemia, heart failure, severe bleeding disorders, and renal failure with oliguria or anuria
- Use cautiously in normal or increased intravascular volume, cardiopulmonary bypass, chronic nephrosis, hepatic or renal failure caused by increased protein load, sodium restriction, and critically ill patients.

**Adverse reactions**
CNS: headache
CV: hypotension, tachycardia, pulse and blood pressure changes, *vascular overload*
EENT: blurred vision, throat tightness
GI: nausea, vomiting, increased salivation, submaxillary and parotid gland enlargement
Musculoskeletal: back pain, muscle pain
Respiratory: dyspnea, respiratory changes, *pulmonary edema*
Skin: flushing, urticaria, rash, pruritus
Other: allergic or pyrogenic reactions, chills, flulike symptoms

**Patient monitoring**
- Monitor for hemorrhagic shock after injury or surgery. (Rapid postinfusion blood pressure rise may cause bleeding from severed vessels.)
- Check vital signs frequently.
- Watch for signs and symptoms of heart failure and pulmonary edema.
- Evaluate fluid intake and output.
- Monitor hemoglobin, hematocrit, urine protein, and electrolyte levels.

**renin-angiotensin system antagonists**

**Angiotensin-converting enzyme (ACE) inhibitors:** benazepril hydrochloride, captopril, enalapril maleate, enalaprilat, fosinopril sodium, lisinopril, moexipril, perindopril erbumine, quinapril hydrochloride, ramipril, trandolapril

**Angiotensin II receptor antagonists:** candesartan cilexetil, eprosartan mesylate, irbesartan, losartan potassium, olmesartan medoxomil, telmisartan, valsartan

**Selective aldosterone receptor antagonist:** eplerenone

**Action**
*ACE inhibitors* lower blood pressure by preventing conversion of angiotensin I to angiotensin II, a potent vasoconstrictor that decreases peripheral resistance and aldosterone secretion.

*Angiotensin II receptor antagonists* block vasoconstrictive and aldosterone-secreting effects of angiotensin II by selectively blocking binding of angiotensin II to angiotensin I receptors in vascular smooth muscle, adrenal, and other tissues.

*Selective aldosterone receptor antagonists* bind to mineralocorticoid receptors and block binding of aldosterone, a component of the renin-angiotensin-aldosterone system. This effect decreases blood pressure.
Indications
Hypertension, heart failure, left ventricular dysfunction, multiple sclerosis, diabetic neuropathy

Contraindications and precautions
- Contraindicated in hypersensitivity to drug
- Use cautiously in renal or hepatic impairment, hypovolemia, hyponatremia, aortic stenosis and hypertrophic cardiomyopathy, cerebrovascular or cardiac insufficiency, surgery and anesthesia, concurrent diuretic therapy, family history of angioedema, Black patients with hypertension, elderly patients, pregnant or breastfeeding patients, and children (safety not established for most ACE inhibitors).

Adverse reactions
CNS: dizziness, fatigue, headache, insomnia, asthenia, drowsiness, vertigo
CV: hypotension, angina pectoris, tachycardia, myocardial infarction
EENT: sinusitis
GI: nausea, diarrhea, anorexia
GU: proteinuria, erectile dysfunction, decreased libido, renal failure
Hematologic: bone marrow depression, agranulocytosis
Hepatic: cholestatic jaundice progressing to hepatic necrosis and death
Metabolic: hyperkalemia
Respiratory: cough, bronchitis, dyspnea, asthma, eosinophilic pneumonia
Skin: rash, angioedema
Other: taste disturbances, fever, anaphylaxis

Patient monitoring
- Monitor vital signs, including blood pressure in both arms with patient lying down, standing, and sitting.
- Assess fluid intake and output, electrolyte levels, CBC, and kidney and liver function tests.
- Evaluate urine for protein.
- Watch for microalbuminuria, especially in diabetic patients.

sedative-hypnotics

Barbiturates: pentobarbital, phenobarbital
Nonbarbiturates: chloral hydrate, dexmedetomidine hydrochloride, flurazepam hydrochloride, temazepam, triazolam, zaleplon, zolpidem tartrate

Action
Barbiturates cause drowsiness, sedation, and hypnosis by depressing the sensory cortex, decreasing motor activity, and altering cerebellar function. Nonbarbiturates produce sedative, anxiolytic, muscle relaxant, and anti-convulsant effects by interacting with the gamma-aminobutyric acid–benzodiazepine receptor complex.

Indications
Short-term treatment of insomnia, sedation, preanesthesia

Contraindications and precautions
- Contraindicated in hypersensitivity to drug, barbiturate sensitivity, manifest or latent porphyria, marked hepatic dysfunction, severe respiratory disease, and nephritis
- Use cautiously in depression, respiratory compromise, pulmonary insufficiency, seizure disorders, hepatic or severe renal impairment, anxiety, elderly or debilitated patients, or history of drug abuse.

Adverse reactions
CNS: headache, nervousness, talkativeness, slurred speech, apprehension,
irritability, anxiety, light-headedness, dizziness, euphoria, relaxed feeling, weakness, poor concentration, incoordina-tion, confusion, memory impair-ment, depression, abnormal dreams, nightmares, insomnia, paresthesia, restlessness, fatigue, dysesthesia, drowsiness, somnolence, staggering, falling, ataxia, agitation, hyperkinesia, psychi-atric disturbances, hallucinations, abnormal thinking, vertigo, lethargy, hangover effect

CV: palpitations, chest pain, tachycardia, hypotension, bradycardia, circula-tory collapse, thrombophlebitis (with I.V. use)

EENT: blurred vision, burning eyes, difficulty focusing, visual disturbances, tinnitus

GI: nausea, vomiting, diarrhea, consti-pation, dyspepsia, GI pain, dry mouth, excessive salivation, glossitis, stomati-tis, anorexia

Hepatic: jaundice, hepatic failure (in patients also receiving diuretics)

Hematologic: leukopenia, granulocytopenia

Musculoskeletal: joint pain

Respiratory: shortness of breath, hypoventilation, respiratory depression

Skin: dermatitis, diaphoresis, flushing, pruritus, rash, angioedema, exfoliative dermatitis

Other: altered taste, body pain, pain at I.M. injection site, fever (especially with long-term phenobarbital use)

Patient monitoring

- Monitor vital signs, respiratory sta-tus, CBC with white cell differential, liver function tests, and blood urea ni-trogen, creatinine, and electrolyte lev-els. Stay alert for hyperkalemia.
- Assess neurologic status. Watch for signs and symptoms of drug dependence.

Reactions in bold are life-threatening.
• Use cautiously in endometrial or ovarian cancer, endometriosis, gallbladder disease, vision disturbances, hypertension, familial hyperlipoproteinemia, hypothyroidism, conditions that predispose to fluid retention, hypocalcemia, asthma, diabetes mellitus, seizure disorders, migraine, hepatic or renal disease, and elderly patients.

Adverse reactions
CNS: headache, migraine, syncope, depression, insomnia, vertigo, neuralgia, hypoesthesia
CV: chest pain, varicose veins
EENT: conjunctivitis, neuro-ocular lesions (such as retinal thrombosis, optic neuritis), steepened corneal curvature, contact lens intolerance, sinusitis, rhinitis, laryngitis, pharyngitis
GI: nausea, vomiting, diarrhea, dyspepsia, flatulence, abdominal pain, GI disorder, gastroenteritis
GU: urinary tract infection, cystitis, leukorrhea, uterine or endometrial disorder, urinary tract disorder, breast tenderness or pain, breast enlargement, decreased lactation, amenorrhea, vaginal candidiasis, vaginitis, vaginal hemorrhage, invasive cervical cancer
Musculoskeletal: arthralgia, myalgia, leg cramps, arthritis, tendon disorder
Respiratory: cough, bronchitis, pneumonia
Skin: rash, diaphoresis, hot flashes
Other: fever, infection, flulike symptoms

Patient monitoring
• Monitor liver function tests, fluid intake and output, and phosphatase, calcium glucose, and folic acid levels.
• Assess abdomen for liver enlargement.
• Monitor for breast tenderness and swelling.
• Assess bone density annually.

skeletal muscle relaxants
baclofen, carisoprodol, chlorzoxazone, cyclobenzaprine hydrochloride, dantrolene sodium, diazepam, methocarbamol, tizanidine hydrochloride

Action
Unknown. Thought to cause muscle relaxation through sedative properties and by inhibiting activity in descending reticular formation and spine. Also decrease muscle tone and involuntary movements.

Indications
Muscle spasms (as from trauma or inflammation), hyperreflexia and hypertonia (as in parkinsonism), tetanus, cerebral palsy, multiple sclerosis, tension headache

Contraindications and precautions
• Contraindicated in hypersensitivity to drug or polyethylene glycol (parenteral forms), renal impairment (parenteral forms), active hepatic disease, upper motor neuron disorder, and patients who use spasticity to maintain posture or balance
• Use cautiously in cardiac, hepatic, or renal dysfunction; history of allergies; seizure disorders (parenteral forms); pregnant or breastfeeding patients; and children (safety not established).

Adverse reactions
CNS: dizziness, anxiety, abnormal thinking, hyperesthesia, agitation, confusion, hypertonia, seizures, coma
CV: palpitations, hypotension, bradycardia, weak pulse, fistula, pseudoaneurysm, thrombophlebitis, complete or incomplete atrioventricular block, pulmonary embolism, nodal
arrhythmias, ventricular tachycardia
EENT: diplopia
GI: nausea, vomiting, diarrhea, dyspepsia, gastroesophageal reflux, hematemesis, dysphagia, paralytic ileus, GI bleeding
GU: urinary frequency or incontinence, dysuria, cystalgia, prostatitis, renal dysfunction
Hepatic: hepatitis
Musculoskeletal: muscle rigidity
Respiratory: abnormal breath sounds, dyspnea, wheezing, bronchitis, pneumonia, pleurisy, pleural effusion, pulmonary edema, pulmonary embolism, bronchospasm
Skin: rash, urticaria, pruritus, edema
Other: chills, fever

Patient monitoring
- Monitor vital signs and liver function tests.

---

thrombolytics
alteplase, anistreplase, drotrecogin alfa, reteplase, streptokinase, tenecteplase, urokinase

Action
Convert plasminogen to plasmin, an enzyme that degrades fibrin clots and lyses thrombi and emboli

Indications
Acute massive pulmonary embolism, acute ischemic cerebrovascular accident (CVA), thrombotic coronary arterial obstruction in acute myocardial infarction, deep-vein thrombosis, arterial embolism or thromboses, occlusion of venous access device

Contraindications and precautions
- Contraindicated in hypersensitivity to drug or other thrombolytics, active internal bleeding, bleeding diathesis, severe uncontrolled hypertension, intracranial neoplasm, arteriovenous malformation or aneurysm, recent CVA, or recent intracranial or intraspinal surgery or trauma
- Use cautiously in GI or GU bleeding, hypertension, left-sided cardiac thrombus (including mitral stenosis), acute pericarditis, subacute bacterial endocarditis, hemostatic defects, diabetic hemorrhagic retinopathy, septic thrombophlebitis, previous puncture of noncompressible vessels, trauma, obstetric delivery, organ biopsy, major surgery, patients older than age 75, and pregnant or breastfeeding patients.

Adverse reactions
CNS: intracranial hemorrhage
CV: hypotension, arrhythmias, cholesterol embolization, venous thrombosis
GI: nausea, vomiting, GI or retroperitoneal bleeding
GU: hematuria
Hematologic: anemia, bone marrow depression, hemorrhage, bleeding tendency
Respiratory: respiratory depression, apnea
Skin: bruising, urticaria
Other: fever, edema, phlebitis or hemorrhage at I.V. site, hypersensitivity reactions including anaphylaxis, sepsis

Patient monitoring
- Monitor vital signs and neurologic status closely.
- Assess for unusual bleeding or bruising.
- Monitor International Normalized Ratio, prothrombin time, and partial thromboplastin time.

Reactions in **bold** are life-threatening.
**thyroid hormones**
levothyroxine sodium; liothyronine sodium; liotrix; thyroid, desiccated

**Action**
Regulate growth and development by controlling protein synthesis; stimulate normal metabolism by oxygenating body tissues

**Indications**
Hypothyroidism, euthyroid or multinodular goiter, subacute or chronic lymphocytic thyroiditis

**Contraindications and precautions**
- Contraindicated in hypersensitivity to drug, recent myocardial infarction, adrenal insufficiency, and thyrotoxicosis
- Use cautiously in cardiovascular disease, severe renal insufficiency, uncorrected adrenocortical disorders, angina pectoris, ischemia, diabetes mellitus, myxedema, elderly patients, and pregnant or breastfeeding patients.

**Adverse reactions**
CNS: insomnia, irritability, nervousness, tremor, headache
CV: tachycardia, angina pectoris, hypotension, hypertension, increased cardiac output, palpitations, arrhythmias, cardiovascular collapse
GI: vomiting, diarrhea, abdominal cramps
GU: menstrual irregularities
Metabolic: hyperthyroidism
Musculoskeletal: accelerated bone maturation in children
Skin: alopecia (in children), diaphoresis
Other: weight loss, appetite changes, heat intolerance

**Patient monitoring**
- Monitor vital signs, weight, ECG, and thyroid function tests.

**thyroid hormone antagonists**
methimazole, potassium iodide, propylthiouracil, sodium iodide 131I

**Action**
Rapidly inhibit iodine release and synthesis in thyroid gland, decreasing thyroid vascularity and preventing iodine uptake

**Indications**
Hyperthyroidism, thyroid cancer, thyrotoxicosis, to control hyperthyroidism before thyroidectomy or radioactive iodine therapy

**Contraindications and precautions**
- Contraindicated in hypersensitivity to thyroid hormone antagonists and in breastfeeding
- Use cautiously in bone marrow depression, tuberculosis, bronchitis, hyperkalemia, renal impairment, recent myocardial infarction, large nodular goiter, vomiting and diarrhea, patients younger than age 30, and pregnant patients.

**Adverse reactions**
CNS: headache, vertigo, paresthesia, neuritis, neuropathy, CNS stimulation, depression, drowsiness
CV: chest pain, tachycardia
EENT: pain on swallowing, sore throat
GI: nausea, vomiting, diarrhea, constipation, epigastric distress, GI irritation, dry mouth, salivary gland enlargement, anorexia, paralytic ileus
GU: nephritis

Canada UK Hazardous drug High alert drug
Hematologic: anemia, eosinophilia, bone marrow depression, leukopenia, thrombocytopenia, leukemia, agranulocytosis
Hepatic: jaundice, hepatic dysfunction, hepatitis
Metabolic: hypothyroidism, thyroid hyperplasia, hyperkalemia
Musculoskeletal: joint pain, myalgia
Respiratory: cough
Skin: rash, skin discoloration, pruritus, erythema nodosum, exfoliative dermatitis, alopecia, acneiform eruption
Other: taste loss, fullness in neck, fever, lupuslike syndrome, lymphadenopathy, lymphedema, radiation sickness (with sodium iodide ¹³¹I)

Patient monitoring
● Monitor CBC and thyroid function tests.

vasodilators
bosentan, hydralazine hydrochloride,isosorbide dinitrate, isosorbide mononitrate, minoxidil, nesiritide, nitroglycerin, nitroprusside sodium

Action
Relax vascular smooth muscle by stimulating intracellular production of cyclic guanosine monophosphate

Indications
Acute angina, prophylaxis and long-term management of recurrent angina, heart failure associated with acute myocardial infarction (MI), to control blood pressure in perioperative hypertension associated with surgery

Contraindications and precautions
● Contraindicated in hypersensitivity to drug, severe anemia, angle-closure glaucoma, orthostatic hypotension, early MI, head trauma, cerebral hemorrhage, and as primary therapy in cardiogenic shock or systolic pressure below 90 mm Hg
● Use cautiously in acute MI (associated with hypertension, tachycardia, or congestive heart failure), cerebral hemorrhage, gastric hypermotility or malabsorption syndrome (with sustained-release forms), head trauma, hyperthyroidism, hypertrophic cardiomyopathy, increased intraocular pressure, orthostatic hypotension, volume depletion, and alcohol use.

Adverse reactions
CNS: headache, apprehension, malaise, rigors, restlessness, weakness, asthenia, vertigo, dizziness, agitation, anxiety, confusion, insomnia, nervousness, nightmares, incoordination, hypothyroidism, hypokinesia
CV: tachycardia, retrosternal discomfort, palpitations, orthostatic hypotension, rebound hypertension, hypotension, syncope, crescendo angina, premature ventricular contractions, arrhythmias, atrial fibrillation
EENT: blurred vision, diplopia
GI: nausea, vomiting, diarrhea, dyspepsia, abdominal pain, tenesmus, fecal incontinence
GU: dysuria, urinary frequency, urinary incontinence, erectile dysfunction
Hematologic: methemoglobinemia, hemolytic anemia
Musculoskeletal: arthralgia, muscle twitching, stiff neck
Respiratory: bronchitis, pneumonia, upper respiratory infection
Skin: pallor; cold sweats; increased perspiration; rash; contact or exfoliative dermatitis; cutaneous vasodilation with flushing; crusty skin lesions; pruritus; topical allergic reaction; erythematous, vesicular, or pruritic lesions; local burning or tingling sensation in oral cavity (with sublingual forms);

Reactions in bold are life-threatening.
anaphylactoid reactions with oral mucosal and conjunctival edema
Other: tooth disorder, increased appetite, edema

Patient monitoring
• Closely monitor ECG and vital signs (especially blood pressure).
• In suspected overdose, assess for signs and symptoms of increased intracranial pressure.
• Check arterial blood gas values and methemoglobin levels.
Vitamins and minerals

**Ascorbic acid (vitamin C)**
Cecon, Cevi-Bid, Dull-C, Vita-C

**Action**
Water-soluble vitamin with antioxidant properties; stimulates collagen formation and enhances tissue repair.

**Availability**
- **Capsules:** 500 mg
- **Crystals:** 1,000 mg/½ tsp
- **Injection:** 250 mg/ml, 500 mg/ml
- **Liquid:** 50 mg/ml, 500 mg/5 ml
- **Powder:** 60 mg/½ tsp, 1,060 mg/½ tsp
- **Solution:** 100 mg/ml
- **Tablets:** 25 mg, 50 mg, 100 mg, 125 mg, 250 mg, 500 mg, 1,000 mg, 1,500 mg
- **Tablets (chewable):** 60 mg, 100 mg, 250 mg, 500 mg, 1,000 mg
- **Tablets (timed-release):** 500 mg, 1,000 mg, 1,500 mg

**Indications and dosages**

- **Recommended dietary allowance**
  - **Adults:** 60 mg daily
  - **Scurvy**
    - **Adults:** 300 mg to 1 g P.O., subcutaneously, I.M., or I.V. daily
    - **Children:** 100 to 300 mg P.O., subcutaneously, I.M., or I.V. daily depending on severity

**Contraindications and precautions**
- Prolonged use of excessive doses contraindicated in diabetes mellitus, sodium-restricted diet, concurrent anticoagulant use, and history of recurrent renal calculi
  - Use cautiously in hypersensitivity to tartrazine or sulfites (if product contains these compounds), before tests for occult blood in stool, and in breastfeeding patients. Don’t exceed recommended amount in pregnant patients.
  - Avoid rapid I.V. infusion.

**Adverse reactions**
Transient mild soreness at I.M. or subcutaneous injection site; transient light-headedness or dizziness (with rapid I.V. administration)

**Cholecalciferol (vitamin D3)**
Delta-D

**Action**
Biologically active vitamin D metabolite; controls intestinal absorption of dietary calcium, tubular reabsorption of calcium by kidney, and (in conjunction with parathyroid hormone [PTH]), calcium mobilization from skeleton. Acts directly on bone cells to stimulate skeletal growth and on parathyroid glands to suppress PTH synthesis and secretion.

**Availability**
- **Tablets:** 400 international units, 1,000 international units

**Indications and dosages**

- **Recommended dietary allowance (RDA)**
  - **Adults:** 400 to 1,000 international units/day
  - **Children:** 400 international units/day

**Contraindications and precautions**
- Contraindicated in hypercalcemia, vitamin D toxicity, malabsorption

Reactions in **bold** are life-threatening.
syndrome, and abnormal sensitivity to vitamin D effects
- Don’t exceed RDA during normal pregnancy. Use cautiously in breastfeeding patients. Safety and efficacy of dosages exceeding RDA have not been established for children.

**Adverse reactions**
Nausea, vomiting, constipation, pancreatitis, weakness, headache, irritability, drowsiness, overt psychosis, dry mouth, metallic taste, muscle or bone pain, hypertension, hypotension, polyuria, polydipsia, anorexia, weight loss, hypercalcemia, reversible azotemia, nephrocalcinosis, conjunctivitis, photophobia, pruritus, albuminuria, elevated liver function tests results, arrhythmias

---

**chromium (chromic chloride)**
Chroma-Pak

**Action**
Serves as a component of glucose tolerance factor, which activates insulin-mediated reactions; helps maintain normal glucose metabolism and peripheral nerve function

**Availability**
*Injection:* 4 mcg/ml (as 20.5 mcg chromic chloride hexahydrate), 20 mcg/ml (as 102.5 mcg chromic chloride hexahydrate)

**Indications and dosages**
> Supplement to I.V. solutions used in total parenteral nutrition
**Adults:** 10 to 15 mcg/day. For metabolically stable adults with intestinal fluid loss, 20 mcg/day.
**Children:** 0.14 to 0.2 mcg/kg/day

**Contraindications and precautions**
- Preparations containing benzyl alcohol contraindicated in premature infants (may cause fatal gasping syndrome)
- Avoid use or adjust dosage in patients with renal or GI dysfunction.
- Use cautiously in pregnant patients.
- Multiple trace element solutions may cause overdose if patient’s requirement for one element in formulation exceeds that for others. Chromium may need to be given separately.

**Adverse reactions**
Toxicity is rare at recommended dosages; hypersensitivity reaction to iodide may occur.

---

**copper**
Cupric Sulfate

**Action**
Serves as cofactor for ceruloplasmin, an oxidase needed for proper formation of transferrin (an iron carrier protein); helps maintain normal rate of red and white blood cell formation

**Availability**
*Injection:* 0.4 mg/ml, 2 mg/ml

**Indications and dosages**
> Supplement to I.V. solutions used in total parenteral nutrition
**Adults:** 0.5 to 1.5 mg/day to prevent deficiency; 3 mg/day to treat deficiency
**Children:** 20 mcg/kg/day to prevent deficiency; 20 to 30 mcg/kg/day to treat deficiency

**Contraindications and precautions**
- Multidose preparations contraindicated in patients with sensitivity to benzyl alcohol (such as premature
infants, who may experience fatal gasping syndrome)

- Use cautiously in renal or GI dysfunction, Wilson's disease, and pregnant patients.
- Be aware that giving copper without zinc (or vice versa) may decrease blood level of the other mineral. Monitor levels before giving subsequent doses.
- Multiple trace element solutions may cause overdose if patient’s requirement for one element in formulation exceeds that for others. Copper may need to be given separately.

Adverse reactions
None known

cyanocobalamin
(vitamin B₁₂)
Big Shot B-12, Cyanoject, Rubramin

hydroxocobalamin,
crystalline (vitamin B₁₂)
Hydro-Crysti-12, LA-12

Action
Essential to growth, cell reproduction, hematopoiesis, and nucleoprotein and myelin synthesis; also participates in nucleic acid synthesis. Plays a role in red blood cell formation through activation of folic acid coenzymes.

Availability

cyanocobalamin
Injection: 100 mcg/ml, 1,000 mcg/ml
Intranasal gel: 500 mcg/0.1 ml
Tablets: 25 mcg, 50 mcg, 100 mcg, 200 mcg, 250 mcg, 500 mcg, 1,000 mcg, 1,500 mcg
Tablets (extended-release): 100 mcg, 200 mcg, 500 mcg, 1,000 mcg

hydroxocobalamin
Injection: 1,000 mcg/ml

Indications and dosages

- Recommended dietary allowance
- Adults and children older than age 11: 2 mcg cyanocobalamin daily
- Children ages 9 to 11: 1.8 mcg daily
- Children ages 4 to 8: 1.2 mcg daily
- Children ages 1 to 3: 0.9 mcg daily

- Vitamin B₁₂ deficiency
- Adults: 30 mcg hydroxocobalamin I.M. daily for 5 to 10 days, depending on cause and severity; for maintenance, 100 to 200 mcg I.M. monthly
- Children: Total dosage of 1 to 5 mg hydroxocobalamin I.M. given over 2 or more weeks in divided doses of 100 mcg; then a maintenance dosage of 30 to 50 mcg I.M. q 4 weeks

- Pernicious anemia
- Adults: 100 mcg cyanocobalamin subcutaneously or I.M. daily for 7 days; then 100 mcg subcutaneously or I.M. every other day for 14 days; then 100 mcg subcutaneously or I.M. q 3 to 4 days for 2 to 3 weeks or until remission; then 100 mcg I.M. monthly or 1,000 to 2,000 mcg P.O. daily

- Vitamin B₁₂ deficiency and malabsorption in patients in remission
- Adults: 500 mcg nasal gel intranasally once weekly

Contraindications and precautions
- Contraindicated in hypersensitivity to vitamin B₁₂, cobalt, or product components

Adverse reactions
Mild transient diarrhea, nausea, vomiting, dyspepsia, headache, anxiety, dizziness, nervousness, hypoesthesia, sore throat, severe and rapid optic nerve atrophy, back pain, myalgia, arthritis, paresthesia, abnormal gait, dyspnea, rhinitis, itching, rash, polycythemia vera; with parenteral forms—injection site pain, pulmonary edema, heart failure, peripheral vascular thrombosis, anaphylactic shock

Reactions in bold are life-threatening.
doxercalciferol
Hectorol

**Action**
Synthetic vitamin D analogue; acts directly on parathyroid gland to stimulate and suppress parathyroid hormone (PTH) synthesis and secretion

**Availability**
*Capsules:* 0.5 mcg, 2.5 mcg
*Injection:* 2 mcg/vial

**Indications and dosages**
- Elevated intact PTH levels (iPTH) in secondary hyperparathyroidism caused by chronic renal dialysis
  - **Adults:** Dosage individualized. Recommended initial dosage is 10 mcg P.O. three times weekly at dialysis (approximately every other day). Adjust as needed to lower blood iPTH level to 150 to 300 pg/ml. Maximum dosage is 20 mcg P.O. three times weekly.

**Contraindications and precautions**
- Contraindicated in hypersensitivity to product components, hypercalcemia, and evidence of vitamin D toxicity
- Use cautiously in elderly patients with coronary disease, renal impairment, or arteriosclerosis.

**Adverse reactions**
Nausea, vomiting, constipation, dyspepsia, headache, malaise, dizziness, sleep disorder, weight gain, anorexia, edema, arthralgia, abscess, dyspnea, pruritus, Bradycardia

---

folic acid
Folvite

**Action**
Stimulates production of red and white blood cells and platelets in some megaloblastic anemias

**Availability**
*Injection:* 5 mg/ml
*Tablets:* 0.4 mg, 0.8 mg, 1 mg

**Indications and dosages**
- Recommended dietary allowance
  - **Adults and children older than age 11:** 150 to 400 mcg
  - **Children younger than age 11:** 25 to 100 mcg
- Megaloblastic anemia related to folic acid deficiency in sprue, nutritional deficiency, pregnancy, childhood, or infancy
  - **Adults:** Up to 1 mg/day P.O., I.M., I.V., or subcutaneously (given P.O. except in severe disease or severely impaired GI absorption). Higher dosages may be needed in severe cases, with a maintenance dosage of 0.4 mg/day. In pregnant or breastfeeding patients, 0.8 mg/day.
  - **Children older than age 4:** Maintenance dosage of 0.4 mg/day P.O., I.M., or subcutaneously (given P.O. except in severe disease or severely impaired GI absorption)
  - **Children younger than age 4:** Maintenance dosage of up to 0.3 mg/day P.O., I.M., or subcutaneously (given P.O. except in severe disease or severely impaired GI absorption)

**Contraindications and precautions**
- Contraindicated in pernicious, aplastic, or normocytic anemia
- Use cautiously in breastfeeding patients.

Reactions in **bold** are life-threatening.
**Adverse reactions**
Altered sleep pattern, malaise, poor concentration, impaired judgment, hyperactivity, anorexia, nausea, flatulence, bitter taste, allergic reaction (including rash, pruritus, erythema), bronchospasm

---

**Manganese, chelated manganese chloride**

**Action**
Serves as a cofactor in various enzyme systems; stimulates hepatic cholesterol and fatty acid synthesis and influences mucopolysaccharide synthesis

**Availability**
*Injection:* 0.1 mg/ml (as 0.36 mg manganese chloride)
*Tablets:* 20 mg and 50 mg of chelated manganese

**Indications and dosages**

- **Recommended dietary allowance**
  - **Adults:** 1.9 to 2.3 mg/day in males; 1.6 to 1.8 mg/day in females
  - **Supplement to I.V. solutions used for total parenteral nutrition**
  - **Adults:** 0.15 to 0.8 mg/day
  - **Children:** 2 to 10 mcg/kg/day

**Contraindications and precautions**
- Use cautiously in pregnant patients and premature infants (may reach toxic levels in kidney).
- Reduce dosage in renal or GI dysfunction.
- Multiple trace element solutions may cause overdose if patient’s requirement for one element in formulation exceeds that for others. Manganese may need to be given separately.

---

**Adverse reactions**
None known

---

**Niacin (nicotinic acid, vitamin B₃)**
Slo-Niacin

**Niacinamide (nicotinamide)**

**Action**
Serves as a component of two coenzymes essential to oxidation-reduction reactions

**Availability**
*Capsules (extended-release):* 100 mg, 250 mg, 400 mg, 500 mg
*Capsules (sustained-release):* 125 mg, 500 mg
*Capsules (timed-release):* 250 mg, 500 mg
*Tablets:* 25 mg, 50 mg, 100 mg, 125 mg, 250 mg, 400 mg, 500 mg
*Tablets (extended-release):* 250 mg, 500 mg, 750 mg, 1,000 mg
*Tablets (sustained-release):* 500 mg
*Tablets (timed-release):* 250 mg, 500 mg

**Indications and dosages**

- **Recommended dietary allowance (RDA)**
  - **Adults:** 15 to 20 mg P.O. daily in males; 13 to 15 mg P.O. daily in females
  - **Pellagra**
    - **Adults:** Up to 500 mg daily P.O. given in divided doses
  - **Niacin deficiency**
    - **Adults:** Up to 100 mg P.O. daily
  - **Hyperlipidemia**
    - **Adults:** Initially, 250 mg P.O. daily; increase up to 1 or 2 g/day (given in divided doses) at 4- to 7-day intervals. Don’t exceed 6 g/day.

Reactions in bold are life-threatening.
Contraindications and precautions
- Contraindicated in hypersensitivity to niacin, hepatic dysfunction, active peptic ulcer, severe hypotension, and arterial bleeding
- Use cautiously in heart disease (give only under doctor’s supervision), gout, regular consumption of large amounts of alcohol, history of hepatic disease, and pregnant or breastfeeding patients. Don’t exceed RDA in children (safety and efficacy not established).

Adverse reactions
Flushing, pruritus, urticaria, rash, dry skin, tingling, acanthosis nigricans, hyperpigmentation, diaphoresis, nausea, vomiting, diarrhea, dyspepsia, GI distress, abdominal pain, peptic ulcer, hyperuricemia, gout, decreased glucose tolerance, chills, dizziness, insomnia, migraine, transient headache, toxic amblyopia, cystoid macular edema, orthostasis, edema, hypotension, palpitations, syncope, dyspnea, abnormal liver function tests, fulminant hepatic necrosis, hepatotoxicity, atrial fibrillation, other arrhythmias

Phytonadione (vitamin K₁)
AquaMEPHYTON, Mephyton

Action
Promotes hepatic synthesis of active prothrombin, proconvertin, plasma thromboplastin component, and Stuart factor

Availability
Aqueous colloidal solution for injection: 2 mg/ml
Tablets: 5 mg

Indications and dosages
- Hypoprothrombinemia caused by anticoagulant therapy
  Adults: Initially, 2.5 to 10 mg P.O., I.M., subcutaneously, or I.V. (at doses not exceeding 1 mg/minute); repeat if needed within 12 to 48 hours after P.O. dose or within 6 to 8 hours of I.M., subcutaneous, or I.V. dose. Subsequent dosages determined by prothrombin time or clinical condition.
- Hypoprothrombinemia secondary to other causes
  Adults: 2.5 to 25 mg (rarely, up to 50 mg at a single time)

Reactions in **bold** are life-threatening.
mg); dosage and administration route depend on severity and response. **Children:** 5 to 10 mg; dosage and administration route depend on severity and response.

➣ Prevention and treatment of hemorrhagic disease of newborn

**Neonates:** For prevention, 0.5 to 1 mg I.M. as a single dose within 1 hour of birth. For treatment, 1 mg I.M. or subcutaneously if mother received oral anticoagulants.

**Contraindications and precautions**
- Contraindicated in hypersensitivity to drug or its components. (Life-threatening reactions resembling hypersensitivity or anaphylaxis have occurred during and immediately after I.V. injection.)
- Use cautiously in pregnant or breastfeeding patients, children, and neonates (if product contains benzyl alcohol).
- Avoid P.O. use in disorders that may prevent adequate absorption.

**Adverse reactions**
Hyperbilirubinemia (in infants); with parenteral administration—pain, swelling, tenderness at injection site; itchy rash after repeated injections; transient flushing sensations; peculiar taste; **anaphylactoid reactions**

**Availability**
- **Capsules (extended-release):** 150 mg
- **Injection:** 100 mg/ml
- **Tablets:** 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, 500 mg
- **Tablets (enteric-coated):** 20 mg
- **Tablets (extended-release):** 100 mg, 200 mg, 500 mg

**Indications and dosages**
➤ **Recommended dietary allowance (RDA)**
- **Adults:** 1.7 to 2 mg daily in males; 1.4 to 1.6 mg daily in females
- **Prophylaxis or treatment of pyridoxine deficiency, including drug-induced deficiency (as from isoniazid, hydralazine, or hormonal contraceptives)**
- **Adults:** For prophylaxis, 25 to 100 mg daily P.O., I.V., or I.M. For established neuropathy, 200 mg daily.

**Contraindications and precautions**
- Contraindicated in hypersensitivity to pyridoxine or components of formulation
- Don’t exceed RDA in children (safety and efficacy not established).
- Use cautiously in breastfeeding patients.
- Be aware that drug abuse and dependence have occurred after withdrawal from dosage of 200 mg/day.

**Adverse reactions**
Sensory neuropathic syndrome (including unstable gait, ataxia, clumsiness of hands, pedal and perioral numbness, paresthesia, and decreased sensation to touch, temperature, and vibration), photoallergic reaction, nausea, headache, decreased folic acid level, aspartate aminotransferase elevation, **seizures**

Reactions in **bold** are life-threatening.
**retinol (vitamin A)**

**Aquasol A, Palmitate-A 5000**

**Action**
Stimulates and supports retinal function, reproduction, bone growth, epithelial tissue differentiation, and embryonic development

**Availability**
*Capsules:* 10,000 international units, 15,000 international units, 25,000 international units
*Injection:* 50,000 international units/ml
*Tablets:* 5,000 international units

**Indications and dosages**

- **Recommended dietary allowance (RDA)**
  - **Adults:** 1,000 mcg retinol equivalents (RE) daily in males; 800 mcg RE daily in females
- **Severe vitamin A deficiency with corneal changes**
  - Adults and children older than age 8: 100,000 international units I.M. daily for first 3 days, followed by 50,000 international units I.M. daily for 2 weeks. Or 500,000 international units P.O. for 3 days, followed by 50,000 international units P.O. daily for 14 days, then 10,000 to 20,000 international units P.O. daily for 60 days. Or 50,000 to 100,000 international units P.O. daily for 1 to 7 days, followed by 5,000 to 75,000 international units daily for several weeks.
- **Vitamin A deficiency with xerophthalmia**
  - **Children:** 5,000 to 15,000 international units (1,500 to 4,500 RE) I.M. for 10 days or 5,000 international units/kg P.O. for 5 days or until recovery

**Contraindications and precautions**
- Hypersensitivity to vitamin A or components of formulation, hypervitaminosis A
- Don’t exceed RDA during normal pregnancy.
- Use cautiously in patients with renal failure and in I.V. use.

**Adverse reactions**
Headache, irritability, vertigo, lethargy, malaise, fever, headache, hypercalcemia, weight loss, vision changes, anorexia, sticky skin, hypervitaminosis A, increased intracranial pressure, anaphylactic shock and death (with I.V. use)

---

**riboflavin (lactoflavin, vitamin B₂)**

**Action**
Serves as two coenzymes that catalyze oxidation-reduction reactions, such as glucose oxidation, amino acid deamination, and fatty acid breakdown

**Availability**
*Tablets:* 10 mg, 25 mg, 50 mg, 100 mg, 250 mg

**Indications and dosages**

- **Recommended dietary allowance (RDA)**
  - **Adults:** 1.4 to 1.8 mg in males; 1.2 to 1.3 mg in females
- **Riboflavin deficiency**
  - **Adults:** 5 to 30 mg P.O. daily in divided doses

**Contraindications and precautions**
- Use cautiously when giving more than RDA to pregnant or breastfeeding women.

**Adverse reactions**
None known

Reactions in **bold** are life-threatening.
**selenium**
Sele-Pak, Selepen

**Action**
Guards cell components against oxidative damage caused by peroxides generated during cellular metabolism

**Availability**
*Injection:* 40 mcg/ml

**Indications and dosages**
➢ Recommended dietary allowance
   **Adults:** 40 to 70 mcg in males; 45 to 55 mcg in females
➢ Supplement to I.V. solutions used in total parenteral nutrition for prophylaxis and treatment of selenium deficiency
   **Adults and adolescents:** 20 to 40 mcg daily for prophylaxis; 100 mcg daily for 24 to 31 days for treatment
   **Children:** 3 mcg/kg daily (for prophylaxis or treatment)

**Contraindications and precautions**
● Use cautiously in renal or GI dysfunction, pregnant patients, or premature infants (if product contains benzy alcohol, which is associated with fatal gasping syndrome). May need to decrease dosage in renal or GI dysfunction.
● Multiple trace element solutions may cause overdose if patient’s requirement for one element in formulation exceeds that for others. Selenium may need to be given separately.

**Adverse reactions**
Lethargy, alopecia, hair discoloration, vomiting, abdominal pain, garlic breath, tremor, diaphoresis

---

**thiamine (vitamin B₁)**
Biamine, Thiamilate, Thiamine Hydrochloride

**Action**
Water-soluble vitamin; combines with adenosine triphosphate and thiamine diphosphokinase to form thiamine pyrophosphate, a coenzyme essential for normal growth and aerobic metabolism, nerve impulse transmission, and acetylcholine synthesis

**Availability**
*Injection:* 100 mg/ml
*Tablets:* 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 250 mg, 500 mg
*Tablets (enteric-coated):* 20 mg

**Indications and dosages**
➢ Recommended dietary allowance
   **Adults:** 1.2 to 1.5 mg/day in males; 1 to 1.1 mg/day in females
➢ Thiamine deficiency (beriberi)
   **Adults:** 10 to 20 mg I.M. t.i.d. for 2 weeks, then 5 to 30 mg P.O. daily for 1 month
➢ Wernicke’s encephalopathy
   **Adults:** Initially, 100 mg I.V., followed by 50 to 100 mg daily I.M. until patient can consume a regular balanced diet

**Contraindications and precautions**
● Contraindicated in thiamine hypersensitivity
● Use cautiously in pregnant or breastfeeding patients.

**Adverse reactions**
Warm sensation, pruritus, urticaria, weakness, diaphoresis, tenderness and induration (with I.M. use), hypersensitivity reaction, cyanosis, pulmonary edema, GI tract hemorrhage, cardiovascular collapse, angioedema, anaphylactic shock, death

Reactions in **bold** are life-threatening.
tocopherols (alpha tocopherols, vitamin E)
Aquavit E, d’Apha E, Nutr-E-Sol, Vita-Plus E

Action
Protects cellular components from oxidation, prevents formation of toxic oxidation products, maintains integrity of red blood cell (RBC) wall, protects RBCs against hemolysis, stimulates steroid metabolism, suppresses prostaglandin production, and inhibits platelet aggregation

Availability
Capsules: 100, 200, 400, 600, and 1,000 international units
Drops: 15 international units/0.3 ml
Liquid: 15 international units/30 ml
Solution (water-miscible): 50 international units/ml
Tablets: 100, 200, 400, 500, 600, 800, and 1,000 international units

Indications and dosages
➢ Recommended dietary allowance
Adults: 15 international units in males; 12 international units in females
➢ To prevent or treat vitamin E deficiency
Adults: 60 to 75 international units P.O. daily, to a maximum of 1,000 international units daily

Contraindications and precautions
None

Adverse reactions
Hypervitaminosis E, nausea, vomiting, diarrhea, fatigue, weakness, blurred vision, headache, rash, gonadal dysfunction, bleeding, necrotizing enterocolitis (in infants)

zinc chloride
zinc gluconate
zinc sulfate
Zinca-Pak

Action
Serves as cofactor for more than 70 enzymes; promotes wound healing and helps maintain normal growth rate, normal skin hydration, and taste and smell sensations

Availability
Capsules: 220 mg
Injection: 1 mg/ml (as 2.09 mg chloride)
Tablets (gluconate): 10 mg, 15 mg, 50 mg
Tablets (sulfate): 66 mg, 110 mg

Indications and dosages
➢ Recommended dietary allowance
Adults: 12 to 15 mg
➢ Dietary supplement
Adults: 25 to 50 mg P.O. daily
➢ Supplement to I.V. solution used in total parenteral nutrition (TPN)
Metabolically stable adults: 2.5 to 4 mg/day; may give additional 2 mg/day in acute catabolic states. In patients with fluid loss from small bowel, give additional 12.2 mg/L of TPN solution.

Contraindications and precautions
● Use cautiously in renal or GI dysfunction, pregnant patients, and premature infants (if product contains benzyl alcohol, which is associated with fatal gasping syndrome).
● Dosage may need to be decreased in renal or GI dysfunction.

Reactions in bold are life-threatening.
Multiple trace element solutions may cause overdose if patient’s requirement for one element in formulation exceeds that for others. Zinc may need to be given separately.

**Adverse reactions**
Restlessness, dizziness, nausea, vomiting, diarrhea, gastric ulcer

Reactions in **bold** are life-threatening.
Herbs and supplements

The information provided in these monographs reflects commonly held beliefs about the actions and uses of common herbs and nutritional supplements. However, not all of these beliefs have been confirmed by clinical trials. Although herbal remedies have been used for thousands of years, few have undergone well-designed scientific studies to determine how they work, if they’re safe, and whether they’re effective in treating the medical conditions for which they’re commonly used. Advise patients to consult a health care practitioner before using herbs or supplements to help determine if such use may be safe.

Aloe

Purported action
With topical use, exerts a moisturizing effect on burns and wounds, which prevents air from drying the wound and increases blood flow to stimulate healing. With internal use, may exert a laxative effect by stimulating the large intestine and increasing peristalsis.

Reported uses
Used topically (as a gel) to inhibit infection and promote healing of minor burns, abrasions, wounds, and frostbite and to treat certain skin diseases (such as psoriasis and seborrheic dermatitis). Used internally (as liquid extract, concentrate, capsules, or dried aloe latex) as a strong laxative.

Contraindications and precautions
Internal use is contraindicated in inflammatory bowel disease, elderly patients with suspected intestinal obstruction, pregnant or breastfeeding patients, and children younger than age 12.

Adverse reactions
- With topical use: redness, itching, and burning sensation in dermabraded skin
- With P.O. use: edema, cramps, diarrhea, weight loss, electrolyte abnormalities, arrhythmias

Interactions
Antiarrhythmics, corticosteroids, licorice, stimulant laxatives, thiazide diuretics: hypokalemia
Cardiac glycosides: increased effects of these drugs

Bilberry

Purported action
Relieves mild GI tract inflammation, easing diarrhea; reduces oral mucous membrane irritation; increases microcirculation by redistributing new capillary formation; strengthens capillary walls; promotes overall health of circulatory system; and exerts a protective effect on stomach and liver (possibly through increased prostaglandin production)

Reported uses
Nonspecific diarrhea, mouth and throat irritation, to improve visual acuity and accommodation. Further studies are needed to confirm that
Bilberry promotes circulatory, GI, or hepatic health.

**Contraindications and precautions**
Contraindicated in bleeding disorders, pregnancy, and breastfeeding

**Adverse reactions**
- At typical dosages: GI distress, rash, drowsiness
- At higher dosages: unknown

**Interactions**
*Anticoagulants, antiplatelet drugs, salicylates:* potentiated effects, causing increased prothrombin time
*Hypoglycemics:* reduced blood glucose level

---

**Black cohosh**

**Purported action**
Binds to estrogen receptors, directly or indirectly influencing luteinizing hormone release. Studies show black cohosh increases bone mineral density in rats but not in humans.

**Reported uses**
Menopause symptoms (as alternative to hormone replacement therapy), premenstrual syndrome, dysmenorrhea, arthritis, renal problems, malaria, sore throat

**Contraindications and precautions**
Contraindicated in pregnancy (may cause premature birth or miscarriage)

**Adverse reactions**
Headache, dizziness, CNS and visual disturbances, GI distress, nausea, vomiting, reduced heart rate, increased perspiration, weight gain

**Interactions**
*Antihypertensives:* additive hypotension
*Docetaxel:* increased docetaxel blood level
*Hepatotoxic drugs:* increased risk of hepatotoxicity

---

**Cat’s claw**

**Purported action**
Stimulates the immune system, enhances phagocytosis, dilates peripheral vessels, inhibits sympathetic nervous system activity, slows heart rate, decreases cholesterol levels, promotes diuresis, inhibits urinary bladder contraction, relaxes smooth muscle, and exerts local anesthetic effects. Studies show cat’s claw has some anticancer and immunostimulant properties.

**Reported uses**
AIDS; inflammation; GI disorders (including colitis, inflammatory bowel disease, Crohn’s disease); as astringent, antiviral, anti-infective, and general tonic

**Contraindications and precautions**
Contraindicated in multiple sclerosis, tuberculosis, autoimmune disease, pregnancy, and breastfeeding. Use cautiously in GI disease (increases stomach acid secretion).

**Adverse reactions**
- Hypotension
- With decoction: few known risks

**Interactions**
*Anticoagulants, antiplatelets:* inhibited platelet aggregation, prolonged bleeding time
*Antihypertensives:* potentiated antihypertensive effects

---

Reactions in **bold** are life-threatening.
**Benzodiazepines**: increased CNS depression

CYP450-3A4 substrates (such as amiodarone, amlodipine, fentanyl, flutamide, imipramine): increased levels of these drugs

**Food**: enhanced cat’s claw absorption

**Immunosuppressants**: negated immunosuppressant effects

---

**chamomile**

**Purported action**
Reduces inflammation and fever, promotes healing of burns, and prevents ulcer formation. May also exert antispasmodic, anxiolytic, and sedative effects through action on CNS receptors.

**Reported uses**
Vomiting, flatulence, colic, fever, cystitis, parasitic worm infections, spasms, inflammation, anxiety; as an antibacterial, astringent, deodorant, or skin wash (to increase sloughing of necrotic tissue and promote granulation and epithelialization)

**Contraindications and precautions**
Contraindicated in ragweed allergy, hepatic or renal disease, pregnancy, and breastfeeding. Use cautiously in patients receiving anticoagulants.

**Adverse reactions**
Contact dermatitis in patients allergic to ragweed, asters, chrysanthemums, or other members of the Compositae family (such as arnica, feverfew, tansy, and yarrow), **anaphylaxis, other severe hypersensitivity reactions**

**Interactions**
**Anticoagulants**: increased anticoagulant effect

**Concurrently administered drugs**: delayed drug absorption

**Sedatives (such as benzodiazepines)**: enhanced sedative effects

---

**chondroitin**

**Purported action**
A glycosaminoglycan (complex polysaccharide) found in extracellular matrix of connective tissue, including cornea and cartilage; thought to have protective properties (as for corneal endothelial cells and other ocular structures) without interfering with epithelialization and healing

**Reported uses**
Osteoarthritis, hyperlipidemia, ischemic heart disease, dry eyes, surgical aid in cataract extraction or lens implantation

**Contraindications and precautions**
Contraindicated in clotting disorders, prostate cancer, risk factors for prostate cancer, and patients receiving anticoagulants. Use cautiously in asthma.

**Adverse reactions**
Allergic reactions, alopecia, nausea, diarrhea, constipation, epigastric pain, extrasystoles, edema

**Interactions**
**Warfarin**: increased warfarin effects (with high chondroitin doses)

---

**coenzyme Q10**

**Purported action**
Fat-soluble, vitamin-like compound present in cells (especially concentrated

Reactions in bold are life-threatening.
in heart, liver, kidney, and pancreas). Exerts antioxidant activity, stabilizes
membranes, and serves as cofactor in
many metabolic pathways, especially
adenosine triphosphate production in
oxidative respiration.

Reported uses
Mitochondrial cytopathies (FDA-ap-
proved claim), cardiac risk reduction,
heart failure, hypertension, prophyaxis
of doxorubicin-induced cardiotoxicity,
diabetes mellitus, immunostimulation,
muscular dystrophy, statin-induced
myopathy, chronic fatigue syndrome,
breast cancer, Huntington’s disease,
Parkinson’s disease, periodontal
disease

Contraindications and
precautions
Use cautiously in biliary obstruction,
hepatic insufficiency, hypertension, di-
abetes mellitus, patients receiving anti-
hypertensives, and patients undergoing
chemotherapy or radiation therapy.

Adverse reactions
Anxiety, nausea, vomiting, diarrhea,
flatulence, headache, mania or
hypomania

Interactions
Antihypertensives: additive blood pres-
sure reduction
Chemotherapy: possible cancer-cell
protection
Warfarin: reduced warfarin effects

dong quai
Purported action
Exerts antispasmodic effect on smooth
muscles, including those of airway and
uterus. Forms containing coumarin
have anticoagulant effects.

Reported uses
Asthma, allergies, menstrual disorders,
menopausal symptoms, rheumatic
pain, anemia, constipation, hyperten-
sion, psoriasis, skin depigmentation,
ulcers; as an antispasmodic, anti-in-
flammatory, and anticoagulant

Contraindications and
precautions
Contraindicated in patients receiving
warfarin concurrently and in pregnant
or breastfeeding patients (may influ-
ence uterine contractions or cause un-
known effects in fetus)

Adverse reactions
● With authentic dong quai: no known
reactions
● With other dong quai forms: in-
creased risk of phototoxicity, abortion,
uterine stimulation, and altered men-
strual cycle

Interactions
Anticoagulants: increased anticoagu-
ulant effect

Purported action
Stimulates immune system; with topi-
cal use, may have mild antibacterial
and antiviral properties

Reported uses
Urinary tract and yeast infections, pro-
motion of wound healing, prevention
and treatment of upper respiratory in-
fecions (including colds and flu), al-
lergic rhinitis, psoriasis, herpes simplex
infection (topical form)

Reactions in bold are life-threatening.
Contraindications and precautions
Contraindicated in patients receiving immunosuppressant therapy (because of immune-stimulating properties)

Adverse reactions
Nausea, mild GI upset, allergic reactions, anaphylaxis
Note: Adverse reactions may be more common in patients with allergies to daisy-type plants.

Interactions
Corticosteroids: interference with chemotherapeutic effects of these drugs
CYP450-3A4 substrates (such as amiodarone, amlodipine, fentanyl, flutamide, imipramine): increased levels of these drugs
Immunosuppressants: interference with immunosuppressant effects

Contraindications and precautions
Contraindicated in pregnancy, breastfeeding, and history of seizures or allergy to evening primrose oil

Adverse reactions
Headache, nausea, vomiting, diarrhea, abdominal pain, indigestion, flatulence, allergic reaction

Interactions
Anesthetics, phenothiazines: lowered seizure threshold
Anticoagulants: bleeding, bruising
Anticonvulsants: lowered seizure threshold, decreased anticonvulsant efficacy

feverfew

Purported action
Inhibits prostaglandin synthesis and serotonin release from platelets and polymorphonuclear leukocyte granules; extract may inhibit phagocytosis and platelet deposition on collagen surfaces. Exhibits antithrombotic potential and in vitro antibacterial activity, inhibits mast cell release of histamine, exerts cytotoxic activity, and suppresses enzyme release from white blood cells in inflamed joints and skin. May promote contraction and relaxation of vascular smooth muscle.

Reported uses
Menstrual pain, allergies, tinnitus, vertigo, asthma, dermatitis, psoriasis, arthritis, fever, migraine prophylaxis

Contraindications and precautions
Contraindicated in pregnancy, breastfeeding, and children younger than age 2

evening primrose oil

Purported action
Contains essential fatty acids (EFAs) that may improve cellular structural elements and serve as precursors to prostaglandins, which help regulate metabolic functions (including cervical ripening)

Reported uses
Disorders thought to stem from EFA deficiency or disturbed EFA metabolism, including cardiovascular disease, premenstrual syndrome, mastalgia and other breast disorders, rheumatoid arthritis, multiple sclerosis, atopic dermatitis and other dermatologic disorders, Raynaud’s disease, Sjögren’s syndrome, Alzheimer’s disease, schizophrenia, and attention deficit hyperactivity disorder

Reactions in bold are life-threatening.
Adverse reactions
● Hypersensitivity reaction, increased heart rate, oral mucosa and tongue inflammation
● After withdrawal: cluster of CNS reactions (rebound migraine, anxiety, disturbed sleep pattern), muscle and joint stiffness

Interactions
Anticoagulants, aspirin: increased antithrombotic effect of these drugs

fish oils

Purported action
Contain omega-3 fatty acids, which exert anti-inflammatory and antithrombotic effects by competing with arachidonic acid in cyclooxygenase and lipooxygenase pathways and which also may suppress cyclooxygenase-2, interleukin-1 alpha, and tumor necrosis factor-alpha. Also inhibit arachidonic acid synthesis of thromboxane A2, which causes platelet aggregation and vasoconstriction; and increase production of prostacyclin, a prostaglandin that causes vasoconstriction and reduces platelet aggregation.

Reported uses
Coronary heart disease, cardiovascular disease, cerebrovascular accident, hypertension, asthma, Crohn’s disease, type 2 (non-insulin-dependent) diabetes mellitus, dysmenorrhea, fatigue, headache, herpes simplex virus type 2, hypercholesterolemia, hypertriglycerideremia, multiple sclerosis, rheumatoid arthritis, acne, rosacea, eczema, psoriasis, scleroderma, immune support; to improve circulation; to enhance cognitive performance and memory

Contraindications and precautions
Avoid large doses (more than 3 g/day) in diabetes mellitus and immunodeficiency. Use cautiously in aspirin sensitivity, bleeding disorders, cirrhosis, familial adenomatous polyposis, major depressive disorders, bipolar disorder, and concurrent antihypertensive use.

Adverse reactions
● Belching, halitosis, heartburn, increased low-density lipoprotein level, weight gain
● With large doses: bleeding, hemorrhagic stroke, immunosuppression, loose stools, nausea, hyperglycemia

Interactions
Anticoagulants, antiplatelet drugs, salicylates: increased risk of bleeding Antihypertensives: additive hypotension Hormonal contraceptives: interference with triglyceride-lowering effects of fish oils

flaxseed oil

Purported action
Contains linolenic, linoleic, and alpha-linolenic acid. Linoleic acid and alpha-linolenic acid are required for structural integrity of cell membranes. Alpha-linolenic acid increases blood levels of omega-3 polyunsaturated fatty acids, including eicosapentaenoic acid and docosahexaenoic acid.

Reported uses
Atherosclerosis, hyperlipidemia, benign prostatic hypertrophy, constipation, diverticulitis, enteritis, gastritis, irritable bowel syndrome, menopausal symptoms, skin inflammation, systemic lupus erythematosus, nephritis, cancer prevention

Reactions in bold are life-threatening.
Contraindications and precautions
Contraindicated in bowel obstruction, breast cancer, endometriosis, esophageal stricture, intestinal inflammation, ovarian cancer, uterine cancer, and uterine fibroids. Avoid medicinal doses in pregnant patients. Use cautiously in bleeding disorders or diabetes mellitus.

Adverse reactions
Diarrhea, allergic reactions, anaphylactoid reactions, intestinal obstruction

Interactions
Anticoagulants, antiplatelet drugs, salicylates: increased risk of bleeding
Hypoglycemics, insulins: increased risk of hypoglycemia

Purported action
Inactivates thiol enzymes (such as coenzyme A and HMG-CoA reductase) and oxidizes glutamate synthase complex, both of which are required for lipid synthesis. Also may exert mild antibacterial, antifungal, and hypotensive activity.

Reported uses
To reduce blood lipid levels (transient effect); as an antibacterial, antiseptic, or antithrombotic. Insufficient data exist regarding effects of garlic on clinical cardiovascular conditions, such as claudication and myocardial infarction.

Contraindications and precautions
Pregnant and breastfeeding patients should avoid large amounts. Use cautiously in severe renal or hepatic disease and in children.

Adverse reactions
Headache, insomnia, fatigue, vertigo, GI distress, shortness of breath, facial flushing, contact dermatitis, allergic reaction

Interactions
Anticoagulants, antiplatelet drugs, nonsteroidal anti-inflammatory drugs, other drugs and herbs with anticoagulant effects: increased prothrombin time, bleeding time, and International Normalized Ratio
Cyclosporine: decreased cyclosporine efficacy
Hormonal contraceptives: decreased contraceptive efficacy
Nonnucleoside reverse-transcriptase inhibitors, protease inhibitors: decreased efficacy of these drugs

Purported action
Inhibits prostaglandin and thromboxane biosynthesis and promotes platelet aggregation. Also possesses antiemetic, antithrombotic, antibacterial, antioxidant, antihematotoxic, anti-inflammatory, antimitogenic, stimulant, cardiotonic, immunostimulant, diuretic, and spasmolytic properties.

Reported uses
Dyspepsia, colic, anorexia, bronchitis, and rheumatism; to stimulate digestion, increase intestinal peristalsis, promote gastric secretions, reduce cholesterol level, raise blood glucose level, and stimulate peripheral circulation; to treat nausea and vomiting associated with motion sickness, hyperemesis gravidarum, and migraine

Reactions in bold are life-threatening.
Contraindications and precautions
Large amounts are controversial in pregnant patients. Avoid use in gallstones, bleeding disorders, hypertension, hypotension, and diabetes mellitus.

Adverse reactions
CNS depression, interference with cardiac function or anticoagulant activity

Interactions
Anticoagulants: increased bleeding time
Antacids, histamine, blockers, hypoglycemics, insulin, proton pump inhibitors: interference with actions of these drugs
Barbiturates: enhanced barbiturate effects

Ginkgo

Purported action
Exerts antioxidant and neuroprotective activity, including arteriolar vasodilation, increased tissue perfusion and cerebral blood flow, decreased arterial spasms, and reduced platelet aggregation

Reported uses
Raynaud’s disease, cerebral insufficiency, anxiety, stress, tinnitus, dementia, circulatory disorders, asthma, memory impairment, headache, depression, impotence; as an adjunct in schizophrenia treatment

Contraindications and precautions
Pregnant or breastfeeding patients should avoid ginkgo. Use cautiously in diabetes mellitus, hypertension, and in patients receiving antiplatelet drugs or anticoagulants.

Adverse reactions
- Headache, dizziness, palpitations, GI and skin disorders
- With excessive use: seizures, subdural hematoma
- Ginkgo pollen can be strongly allergenic; contact with fleshy fruit pulp causes allergic dermatitis similar to that from poison ivy.

Interactions
Anticonvulsants: decreased efficacy of these drugs, increased risk of seizures
Buspirone, fluoxetine: hypomania
Drugs that lower seizure threshold: increased risk of seizures
Insulin: altered insulin metabolism and excretion
Thiazide diuretics: increased blood pressure
Trazodone: possible coma

Ginseng

Purported action
Increases natural “killer” cell activity, stimulates interferon production, accelerates nuclear RNA synthesis, decreases blood glucose level, and increases high-density lipoprotein level; also possesses depressant, anticonvulsant, and analgesic properties

Reported uses
Fatigue, poor concentration, nervousness, hypertension or hypotension, erectile dysfunction, gastritis, cancer, some CNS and endocrine conditions

Contraindications and precautions
Contraindicated in pregnant or breastfeeding patients. Patients taking MAO inhibitors should avoid ginseng. Use cautiously in hypertension or diabetes mellitus.

Reactions in bold are life-threatening.
Adverse reactions
Nervousness, stimulation, hypoglycemia, diffuse mammary nodules, vaginal bleeding, ginseng abuse

Interactions
* Alcohol: increased alcohol clearance
  Antipsychotics, MAO inhibitors: inhibition of antipsychotic effect
  Caffeine-containing preparations, stimulants: stimulant potentiation
  Hypoglycemics, insulin: increased hypoglycemic effect
  Immunosuppressants: decreased immunosuppressant activity
  Loop diuretics: poor diuretic response
  Warfarin: decreased warfarin efficacy

Gastric discomfort (such as nausea, vomiting, diarrhea, heartburn), headache, drowsiness, insomnia, tachycardia, pruritus

Interactions
* Acetaminophen: interference with glucosamine activity
  Antimitotic therapy: resistance to chemotherapeutic effects of these drugs
  Diuretics: decreased glucosamine effects

Purported action
Contains alkaloids (hydrastine and berberine) that exert modest antimicrobial activity. May have cardiostimulatory, anti-inflammatory, peripheral vasoconstrictive, antihemorrhagic, and muscle relaxant effects.

Reported uses
Topical infections (such as wounds and herpes labialis lesions), conjunctivitis, inflamed mucous membranes (as an ingredient in cold and flu preparations), postpartum hemorrhage; as a diuretic or laxative

Contraindications and precautions
Contraindicated in hypertension, heart disease (especially arrhythmias), heart failure, and pregnancy

Adverse reactions
Rash, headache, insomnia, nausea, vomiting, abdominal pain, tachycardia, bradycardia, seizures, respiratory depression (with high doses)

Interactions
* Antacids, histamine2 antagonists, proton pump inhibitors: decreased effects of these drugs
  Antihypertensives: decreased antihypertensive effect
  CNS depressants: additive sedation

Reactions in **bold** are life-threatening.
**grapeseed**

**Purported action**
Exerts antioxidant, anticarcinogenic, cytoprotective, and vascular activity; also inhibits proteolytic enzymes, causing collagen stabilization

**Reported uses**
Prevention of cancer, cardiovascular disease, and dental caries; treatment of venous insufficiency, edema, and allergic rhinitis

**Contraindications and precautions**
Contraindicated in known hypersensitivity to grapeseed. Use cautiously in hepatic disease. Safety during pregnancy has not been established.

**Adverse reactions**
Hepatotoxicity

**Interactions**
Warfarin: increased risk of bleeding

---

**green tea**

**Purported action**
Maintains significant blood levels of catechin, which may exert antioxidant activity against lipoproteins. Delays lipid peroxidation, exerts antimicrobial effects against oral bacteria and diarrhea-causing bacteria, and contributes antimutagenic potential against dietary carcinogens.

**Reported uses**
Atherosclerosis, headache, diarrhea, stomach disorders, cancer, elevated lipid levels, wounds, dental caries prophylaxis

**Contraindications and precautions**
Because of caffeine content, green tea should be avoided by pregnant or breastfeeding patients and by females who may become pregnant. Use cautiously in cardiac disease, renal disease, and hyperthyroidism.

**Adverse reactions**
Nervousness, insomnia, tachycardia, constipation, diarrhea, increased blood glucose and cholesterol levels, impaired iron metabolism, asthma, esophageal cancer (with heavy use)

**Interactions**
Hypoglycemics, insulin: interference with blood glucose control
Stimulants: increased stimulant effect
Warfarin: increased risk of bleeding

---

**hawthorn**

**Purported action**
Increases coronary blood flow and heart rate; exerts antiarrhythmic and positive inotropic effects

**Reported uses**
Atherosclerosis, angina pectoris; to regulate blood pressure and heart rhythm; as an antispasmodic or sedative

**Contraindications and precautions**
Contraindicated in severe renal or hepatic disease and in pregnancy and breastfeeding

**Adverse reactions**
Agitation, dizziness, hypotension, sedation, nausea, sweating, toxicity (with high doses)

Reactions in **bold** are life-threatening.
Interactions

Antiarrhythmics: enhanced antiarhythmic action
Antihypertensives, nitrates: increased effects of these drugs
Cardiac glycosides: increased risk of cardiac glycoside toxicity
CNS depressants: increased CNS effects

kava

Purported action
Produces mild anxiolytic and anticonvulsant effects; also may exert anti-thrombotic effect on platelets

Reported uses
Anxiety, stress, restlessness, seizure disorders, headache, infection, local anesthesia

Contraindications and precautions
Contraindicated in history of hepatic problems. Pregnant or breastfeeding patients should avoid kava. Use cautiously in neutropenia, renal disease, and thrombocytopenia.

Adverse reactions
Morning fatigue, headache, drowsiness, mydriasis, mild GI disturbances, diarrhea, hematuria, hypertension, shortness of breath, visual disturbances, scaly rash (with heavy use)

Interactions
CNS depressants: potentiation of CNS effects
Hepatotoxic drugs: increased hepatotoxicity
Levodopa: reduced levodopa efficacy

licorice

Purported action
Licorice root derivative (carbenoxolone) soothes inflamed mucous membranes, increases life span of gastric epithelial cells by stimulating secretin release, and inhibits peptic and prostaglandin activity

Reported uses
GI complaints, cough, asthma, gastric and duodenal ulcers; used investigationally in lupus and inflammation

Contraindications and precautions
Contraindicated in renal, hepatic, and cardiovascular disease. Pregnant or breastfeeding patients should avoid licorice.

Adverse reactions
- Headache, lethargy, water retention, hypokalemia, hypernatremia, visual disturbances, hypertension, pulmonary edema
- With prolonged, daily use of large amounts: reactions ranging from muscle weakness to quadriplegia

Interactions
Antihypertensives, corticosteroids, diuretics: increased blood pressure
Corticosteroids, furosemide, thiazide diuretics: increased potassium loss
Digoxin: increased risk of digoxin toxicity
Estrogen: interference with estrogen therapy
Ethacrynic acid: increased mineralocorticoid activity
Insulin: hypokalemia, sodium retention

Reactions in bold are life-threatening.
**lutein**

**Purported action**
Serves as antioxidant and blue light filter, protecting underlying ocular tissues from photodamage. Evidence links high dietary lutein intake with reduced risk of age-related macular degeneration and cataracts. Also, serum lutein level may be inversely related to breast cancer risk.

**Reported uses**
Cataracts, macular degeneration, colorectal cancer

**Contraindications and precautions**
Use with caution in bleeding disorders and diabetes mellitus.

**Adverse reactions**
None reported

**Interactions**
*Beta carotene*: interference with lutein availability

---

**melatonin**

**Purported action**
Endogenous melatonin plays a role in circadian rhythms: light inhibits melatonin synthesis and darkness stimulates it. Exogenous melatonin increases melatonin blood levels without affecting endogenous melatonin production; also affects body temperature regulation, cardiovascular function, and reproduction.

**Reported uses**
Short-term sleep pattern regulation, jet lag, tinnitus, depression, cluster headaches, cancer, thrombocytopenia caused by chemotherapy

**Contraindications and precautions**
Contraindicated in hepatic insufficiency, cerebrovascular disease, depression, and neurologic disorders

**Adverse reactions**
Headache, depression, confusion, tachycardia, pruritus

**Interactions**
*Anticoagulants, antiplatelet drugs*: increased risk of bleeding
*Benzodiazepines*: decreased endogenous melatonin
*CNS depressants*: additive sedation
*Flumazenil*: inhibition of melatonin effects
*Fluvoxamine*: increased melatonin blood level and effects
*Hormonal contraceptives*: increased melatonin effects
*Hypoglycemics, insulin*: increased insulin resistance, impaired glucose use
*Immunosuppressants*: interference with immunosuppressant effects
*Nifedipine*: interference with antihypertensive effect, increased heart rate
*Verapamil*: increased melatonin excretion

---

**milk thistle**

**Purported action**
Exerts a hepatoprotective effect, possibly by stimulating RNA and DNA synthesis. Thought to scavenge pro-oxidant free radicals and increase intracellular concentrations of glutathione (a substance needed to detoxify hepatic cell reactions). Also alters the outer membrane of hepatic cells and may produce an anti-inflammatory effect on platelets.
Reported uses
Hepatic dysfunction (including damage caused by acute viral hepatitis and long-term phenothiazine or butyrophenone use), dyspepsia, gallbladder and spleen disorders; antidote for Amanita mushroom poisoning; to reduce increased total cholesterol and low-density lipoprotein levels

Contraindications and precautions
Contraindicated in pregnancy and breastfeeding

Adverse reactions
Brief GI disturbances, diarrhea, cramping, mild allergic reactions, urticaria

Interactions
Estrogens, glucuronidated drugs: increased clearance of these drugs

red yeast rice

Purported action
Contains mevinic acids (including lovastatin), which competitively inhibit HMG-CoA reductase, thereby blocking cholesterol biosynthesis

Reported uses
Diarrhea, indigestion, hyperlipidemia, poor blood circulation; to improve spleen and stomach health

Contraindications and precautions
Contraindicated in pregnancy and breastfeeding. Use cautiously in hepatic dysfunction, abnormal liver function tests, concurrent use of hepatotoxic drugs, and in persons who consume more than two alcoholic drinks daily.

Adverse reactions
Gastritis, abdominal discomfort, heartburn, flatulence, dizziness, hepatic enzyme and creatine kinase elevations, anaphylaxis

Interactions
Cyclosporine: increased risk of myopathy
CYP450-3A4 inhibitors: increased red yeast blood level, increased adverse reactions
Gemfibrozil, niacin: increased risk of myopathy
Grapefruit juice, HMG-CoA inhibitors (statins): increased risk of adverse reactions
Levothyroxine: abnormal thyroid function

S-adenosylmethionine (SAM-e)

Purported action
Naturally occurring molecule; plays an essential role in biochemical reactions involving enzymatic transmethylation. Contributes to synthesis, activation, and metabolism of hormones, neurotransmitters, nucleic acids, proteins, phospholipids, and some drugs.

Reported uses
Cardiovascular disease, fibromyalgia, headache, insomnia, hepatic disease, osteoarthritis, rheumatoid arthritis, depression

Contraindications and precautions
Contraindicated in concurrent use of MAO inhibitors. Use cautiously in bleeding disorders and diabetes mellitus.

Adverse reactions
Anxiety, nausea, vomiting, diarrhea, flatulence, headache, mania or hypomania

Reactions in bold are life-threatening.
saw palmetto

Purported action
Reduces enlarged prostate by inhibiting testosterone 5-alpha reductase (an enzyme that converts testosterone to 5-alpha-testosterone in prostate). Inhibits cell proliferation induced by prolactin and growth factor; also may exert anti-inflammatory, immunostimulant, antiandrogenic, antiestrogenic, and astringent activity.

Reported uses
Symptomatic treatment of benign prostatic hypertrophy, including urinary frequency, reduced urinary flow, and nocturia; bronchitis; asthma

Contraindications and precautions
Contraindicated in pregnancy and in patients receiving concurrent hormone therapy (including hormonal contraceptives and hormone replacement therapy). Use cautiously in patients receiving drugs that may alter immunostimulant or anti-inflammatory activity.

Adverse reactions
Headache, hypertension, nausea, diarrhea, constipation, abdominal pain, GI upset, urinary retention

Interactions
Anticoagulants, antiplatelet drugs: increased risk of bleeding
Estrogens: interference with estrogen activity
Hormonal contraceptives: interference with contraceptive activity

shark cartilage

Purported action
Helps control cancer by inhibiting new blood vessel formation (angiogenesis) in tumors; also may have anti-inflammatory effects

Reported uses
Prostate cancer, AIDS-associated Kaposi’s sarcoma, arthritis, eczema

Contraindications and precautions
Contraindicated in pregnancy or breastfeeding and in children. Use cautiously in hepatic disease.

Adverse reactions
Hepatitis

Interactions
None known

soy

Purported action
Isoflavones (phytoestrogens found in soybean) produce effects similar to those of estradiol (a female hormone). They also limit cholesterol absorption in intestine by binding to cholesterol and may enhance immune function, produce antioxidant effects, and exert beneficial effects on GI function.

Reported uses
Menopausal symptoms, osteoporosis, minor GI problems; to reduce total cholesterol and low-density lipoprotein levels. Also serves as source of fiber, protein, and minerals.

Reactions in bold are life-threatening.
Contraindications and precautions
Contraindicated in estrogen-dependent tumors and peanut allergy (cross-sensitivity may occur)

Adverse reactions
Some experts are concerned that phytoestrogens in soy-based infant formulas may influence CNS and psychomotor development.

Interactions
- **Antibiotics:** decreased action of isoflavones
- **Estrogens:** interference with hormone replacement therapy
- **Tamoxifen:** antagonism of tamoxifen
- **Warfarin:** decreased International Normalized Ratio, inhibited platelet aggregation

St. John’s wort

Purported action
Inhibits postsynaptic serotonin reuptake or antagonizes MAO

Reported uses
Depression, wounds, muscle pain, burns; used investigationally to treat human immunodeficiency virus and certain other viruses

Contraindications and precautions
Contraindicated in concurrent use of antidepressants, in pregnant patients, and in patients planning pregnancy

Adverse reactions
Abdominal pain, constipation, other GI symptoms, dry mouth, dizziness, confusion, fatigue, mania, photosensitivity

Interactions
- **Bexarotene:** decreased effects of St. John’s wort and bexarotene
- **Cyclosporine, digoxin, paclitaxel, protease inhibitors, telithromycin, theophylline, tricyclic antidepressants, vinca alkaloids, warfarin:** decreased efficacy of these drugs
- **Hormonal contraceptives:** breakthrough bleeding
- **MAO inhibitors, selective serotonin reuptake inhibitors, serotonin agonists:** increased risk of serotonin syndrome

valerian

Purported action
Binds to gamma-aminobutyric acid (GABA) and benzodiazepine receptors, stimulating release of these substances. Glutamine, a free amino acid in valerian extract, can cross the blood-brain barrier and may be metabolized to GABA, causing sedation.

Reported uses
Anxiety, nervousness, attention deficit hyperactivity disorder, depression, seizures, menopausal symptoms, menstrual cramps, tremors, restlessness, sleep disorders; as an antispasmodic

Contraindications and precautions
Avoid use in hepatic dysfunction and in pregnant or breastfeeding patients.

Adverse reactions
With overdose or prolonged use: excitability, headache, insomnia, nausea, blurred vision, cardiac dysfunction, hepatotoxicity

Interactions
- **Alcohol, antihistamines, CNS depressants:** additive sedation

Reactions in bold are life-threatening.
Part 3

Appendices
Selected references
Index
Common anesthetic drugs

This chart describes the indications, dosages, administration, and patient monitoring for commonly used anesthetic drugs. Although these potent and potentially dangerous drugs are usually given by specially trained personnel (such as anesthesiologists or anesthetists), the nurse is responsible for monitoring the patient during and after administration.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Indications and dosages</th>
</tr>
</thead>
<tbody>
<tr>
<td>atracurium besylate</td>
<td>➢ Adjunct to general anesthesia to promote endotracheal intubation and relax skeletal muscles during surgery</td>
</tr>
<tr>
<td>Tracrium</td>
<td><strong>Adults and children ages 2 and older:</strong> Initially, 0.4 to 0.5 mg/kg by I.V. bolus. For prolonged surgery, give maintenance dosage of 0.08 to 0.1 mg/kg within 20 to 45 minutes of initial dose; may repeat q 15 to 25 minutes p.r.n. During prolonged procedures, give an initial infusion of 9 to 10 mcg/kg/minute to rapidly counteract spontaneous recovery of neuromuscular function, as required; thereafter, administer at a rate of 5 to 9 mcg/kg/minute by I.V. infusion. <strong>Children ages 1 month to 2 years:</strong> 0.3 to 0.4 mg/kg I.V. Repeat if needed.</td>
</tr>
<tr>
<td>etomidate</td>
<td>➢ To induce general anesthesia</td>
</tr>
<tr>
<td>Amidate</td>
<td><strong>Adults and children older than age 10:</strong> Individualized, 0.2 to 0.6 mg/kg I.V. Usual dosage is 0.3 mg/kg I.V.</td>
</tr>
<tr>
<td></td>
<td>➢ Adjunct to anesthesia with subpotent anesthetics, such as nitrous oxide in oxygen, during maintenance of anesthesia for short operative procedures</td>
</tr>
<tr>
<td></td>
<td><strong>Adults:</strong> Individualized in smaller increments than induction dosage</td>
</tr>
</tbody>
</table>
Before giving, make sure emergency respiratory equipment is at hand and that patient receives a sedative or general anesthetic.

- Give by I.V. route only (bolus, intermittent infusion, or continuous infusion). Never give I.M.
- Know that patient can hear while drug is in effect. Explain events as they occur and provide ongoing reassurance.
- Be ready to reverse drug’s effects with anticholinesterase drug once spontaneous recovery begins.

Watch for anaphylaxis and injection site reaction.

- Check vital signs and airway patency until patient recovers completely from drug effects.
- Assess for pain; give analgesics p.r.n. Be aware that patient may be unable to verbalize pain while drug is in effect.
- Be aware that effect of this drug is potentiated by inhalation anesthesia; consider reduction of atracurium besylate infusion rate.
- Evaluate patient’s recovery with muscle strength tests, nerve stimulation, and train-of-four monitoring.

- Before giving, ask patient about other drug usage.
- Administer slowly over 30 to 60 seconds.
- Know that solution may cause venous pain; more frequently when smaller, more distal, hand or wrist veins are used.
- Know that drug may cause cardiac depression in elderly patients, particularly those with hypertension.
- Know that drug may cause a brief period of apnea.
- Monitor respiratory status (for conscious sedation, including pulse oximetry), cardiovascular status, and CNS status.
- Know that drug isn’t intended for prolonged infusion due to hazards associated with prolonged suppression of endogenous cortisol and aldosterone.
Common anesthetic drugs (continued)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Indications and dosages</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>fentanyl citrate</strong>&lt;br&gt;Sublimaze&lt;br&gt;<strong>fentanyl transmucosal</strong>&lt;br&gt;Actiq, Fentanyl Oralet</td>
<td>➤ Short-term analgesia during anesthesia and immediate preoperative and postoperative periods&lt;br&gt;<strong>Adults:</strong> 0.05 to 0.1 mg I.M. 30 to 60 minutes before surgery as adjunct to general anesthesia. &lt;br&gt;<strong>Low dose:</strong> 0.002 mg/kg for minor, but painful surgical procedures; maintenance dosages are rarely needed. &lt;br&gt;<strong>Moderate dose:</strong> 0.002 to 0.02 mg/kg, when surgery becomes major; 0.025 to 0.1 mg may be administered I.V. or I.M. as maintenance dosage. &lt;br&gt;<strong>High dose:</strong> 0.02 to 0.05 mg/kg during open heart surgery and certain more complicated neurosurgical and orthopedic procedures where surgery is more prolonged; 0.025 mg to one half the initial loading dose as maintenance dosage &lt;br&gt;<strong>Children ages 2 to 12:</strong> 2 to 3 mcg/kg I.V., depending on vital signs; or 5 to 15 mcg/kg transmucosally &lt;br&gt;➤ Adjunct to regional anesthesia&lt;br&gt;<strong>Adults:</strong> 0.05 to 0.1 mg I.M. or slow I.V. over 1 to 2 minutes</td>
</tr>
</tbody>
</table>

| **ketamine** | ➤ To induce anesthesia<br>**Adults:** Individualized, with initial dosage range of 1 to 4.5 mg/kg I.V (average amount needed to produce 5 to 10 minutes of surgical anesthesia is usually 2 mg/kg). Or, 1 to 2 mg/kg I.V. at rate of 0.5 mg/kg/minute may be used. Or, initial dosage may range from 6.5 to 13 mg/kg I.M. Dose of 10 mg/kg will usually produce 12 to 25 minutes of surgical anesthesia. <br>➤ To maintain anesthesia<br>**Adults:** Maintenance dosage should be adjusted according to patient’s anesthetic needs and whether an additional anesthetic is used. Increments of one-half to full induction dose may be repeated as needed for anesthesia maintenance. For patients receiving I.V. diazepam—augmented anesthesia: 0.1 to 0.5 mg/minute by slow I.V. microdrip infusion augmented with diazepam 2 to 5 mg I.V. as needed |
## Administration and patient monitoring

- Know that I.V. dose is given slowly over 1 to 2 minutes.
- Keep narcotic antagonist (naloxone) and emergency equipment at hand when giving I.V.
- Know that drug is not recommended for control of mild or intermittent pain.
- Assess for muscle rigidity in patients receiving high doses. Discuss need for neuromuscular blocker with prescriber. If blocker is given, patient will require ventilator.
- Monitor respiratory and cardiovascular functions and urinary output.
- If patient develops fever, assess for signs and symptoms of opioid toxicity, because more drug is absorbed at higher body temperatures.
- Carefully monitor hematologic studies and hepatic enzyme levels.

- Be aware that atropine, scopolamine, or another drying agent should be given at an appropriate interval before induction.
- Be aware that the 100-mg/ml concentration shouldn’t be given I.V. without proper dilution.
- Dilute with an equal volume of sterile water for injection, normal saline for injection, or D5W.
- Administer slowly over 60 seconds. Know that more rapid administration may result in respiratory depression and enhanced pressor response.
- Continually monitor cardiac function during procedure in patients with hypertension or cardiac decompensation.
- Know that if ketamine is augmented with diazepam, the two drugs must be given separately. Don’t mix ketamine and diazepam in syringe or infusion bag.
- To prepare a dilute solution containing 1 mg ketamine/ml, transfer 10 ml (50-mg/ml vial) or 5 ml (100-mg/ml vial) to 500 ml of D5W or normal saline for injection to obtain a 1-mg/ml solution.
- Know that during ketamine administration, resuscitative equipment should be present and ready for use.
- Use with caution in patient with chronic alcoholism and the acutely alcohol-intoxicated patient.
- An increase in cerebrospinal fluid pressure has occurred after ketamine administration. Use with extreme caution in patients with preanesthesia elevated cerebrospinal fluid pressure.

(continued)
### Common anesthetic drugs (continued)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Indications and dosages</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Midazolam hydrochloride</strong></td>
<td>➢ To induce general anesthesia</td>
</tr>
<tr>
<td>Apo-Midazolam, Versed</td>
<td><strong>Adults younger than age 55:</strong> 0.3 to 0.35 mg/kg I.V. over 20 to 30 seconds if patient is not premedicated, or 0.15 to 0.35 mg/kg (usual dosage of 0.25 mg/kg) I.V. over 20 to 30 seconds if patient is premedicated. Wait 2 minutes to evaluate effect. Additional increments of 25% of initial dosage may be needed to complete induction. <strong>Adults older than age 55 who have not been premedicated:</strong> Initially, 300 mcg/kg I.V. for induction</td>
</tr>
<tr>
<td><strong>Continuous infusion to initiate sedation</strong></td>
<td><strong>Adults:</strong> For rapid sedation, loading dose of 0.01 to 0.05 mg/kg by slow I.V.; repeat dose q 10 to 15 minutes until adequate sedation occurs. To maintain sedation, infuse at initial rate of 0.02 to 0.10 mg/kg/hour (1 to 7 mg/hour); adjust rate as needed.</td>
</tr>
<tr>
<td><strong>Adjunct to balanced anesthesia</strong></td>
<td><strong>Adults:</strong> 0.3 mg to 3 mg/kg I.V. over 10 to 15 minutes, followed by a maintenance dosage of 0.25 mg to 0.50 mg/kg I.V. in single doses p.r.n.</td>
</tr>
<tr>
<td><strong>Pancuronium bromide</strong></td>
<td>➢ Adjunct to balanced anesthesia to relax skeletal muscles for intubation</td>
</tr>
<tr>
<td>Pavulon</td>
<td><strong>Adults and children ages 1 month and older:</strong> Initially, 0.04 to 0.1 mg/kg I.V.; may follow with 0.01 mg/kg q 25 to 60 minutes if needed. (Dosage and infusion rates are based on type of anesthesia used and patient needs and response. Dosages listed here are typical.)</td>
</tr>
<tr>
<td><strong>Pentazocine lactate</strong></td>
<td>➢ Preoperative or preanesthetic medication; adjunct to surgical anesthesia</td>
</tr>
<tr>
<td>Talwin lactate</td>
<td><strong>Adults:</strong> 30 mg subcutaneously, I.M., or I.V. q 3 to 4 hours (not to exceed 30 mg I.V. or 60 mg I.M. or subcutaneously) <strong>Children ages 1 year and older:</strong> 0.5 mg/kg I.M. <strong>Labor</strong></td>
</tr>
<tr>
<td><strong>Adults:</strong> 20 mg I.V. for two or three doses at 2- to 3-hour intervals, or 30 mg I.M. as a single dose</td>
<td></td>
</tr>
</tbody>
</table>
Administration and patient monitoring

- Keep oxygen and resuscitation equipment at hand in case severe respiratory depression occurs.
  - Inject I.M. deep into large muscle mass.
  - Know that drug may be mixed in same syringe as atropine, meperidine, morphine, or scopolamine.
  - Dilute concentrate for I.V. infusion to 0.5 mg/ml using dextrose 5% in water or normal saline solution. Infuse over at least 2 minutes; wait at least 2 minutes before giving second dose. Be aware that excessive dose or rapid I.V. delivery may cause severe respiratory depression.
- Monitor vital signs, ECG, respiratory status, and oxygen saturation.
- Assess neurologic status closely, especially in children.
- Monitor for nausea and vomiting.

- Make sure emergency resuscitation equipment and naloxone (antidote) are at hand before administration begins.
  - Monitor vital signs. Watch for respiratory depression and heart rate changes.
  - Evaluate patient for CNS changes. Institute safety measures as needed to prevent injury.
  - Watch for hypersensitivity reactions, such as anaphylaxis.
  - In patients receiving morphine, meperidine, codeine, or other opiate agonists with a similar duration of action, reduce to 25% of usual initial dose.

- Know that drug should be given only by specially trained personnel in settings where respiratory support is available.
  - Administer through established I.V. line containing normal saline solution, lactated Ringer’s solution, or dextrose 5% in water.
  - Know that neostigmine can reverse drug’s effects.
- Make sure patient’s analgesic and sedative needs are met; drug doesn’t relieve pain or provide sedation.
  - Monitor heart rhythm, vital signs, and pulse oximetry during and after administration.
  - Evaluate fluid intake and output and potassium level.
  - Assess muscle recovery using peripheral nerve stimulator and train-of-four monitoring.

- Inject each 5-mg dose over 1 minute by slow, direct I.V. infusion, with patient lying supine.
- Use subcutaneous route only when necessary (may cause tissue damage).
- Don’t mix in the same syringe with barbiturates because precipitation may occur.
- Monitor vital signs. Stay alert for shock, dyspnea, and circulatory or respiratory depression.
- Monitor drug efficacy.

(continued)
Common anesthetic drugs (continued)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Indications and dosages</th>
</tr>
</thead>
</table>
| procaine hydrochloride Novocain | ➢ Infiltration anesthesia  
Adults: 350 to 600 mg of 0.25% to 0.5% of diluted solution injected as a single dose into area to be anesthetized  
➢ Peripheral nerve block  
Adults: 100 ml of 1% diluted solution or 50 ml of 2% solution injected into area where peripheral nerve block is needed, or up to 200 ml of 0.5% diluted solution  
➢ Spinal anesthesia  
Adults: 0.5, 1, or 2 ml of 10% solution injected into spinal area to be anesthetized, diluted in 0.5, 1, or 2 ml (respectively) of normal saline solution, sterile distilled water, or spinal fluid. Administer at 1 ml/5 seconds. |
| remifentanil hydrochloride Ultiva | ➢ To induce anesthesia through intubation  
Adults: 0.5 to 1 mcg/kg/minute I.V., given with a hypnotic or volatile drug. May administer 1 mcg/kg I.V. over 30 to 60 seconds if endotracheal intubation will occur less than 8 minutes after drug infusion starts.  
➢ To maintain anesthesia  
Adults: 0.25 to 0.4 mcg/kg/minute I.V. Increase dosage by 25% to 100% or decrease by 25% to 50% q 2 to 5 minutes p.r.n. If rate exceeds 1 mcg/kg/minute, consider increasing dosage of concomitant anesthetics to increase the depth of anesthesia. Supplemental I.V. bolus of remifentanil 1 mcg/kg may be given.  
Children ages 1 to 12: 0.25 mcg/kg/min I.V. in conjunction with halothane, sevoflurane, or isoflurane; may administer supplemental bolus of 1 mcg/kg.  
Infants birth to 2 months: 0.4 mcg/kg/minute with nitrous oxide; may administer supplemental bolus of 1 mcg/kg.  
➢ To continue analgesic effect during immediate postoperative period  
Adults: Initially, 0.1 mcg/kg/minute I.V. Adjust in increments of 0.025 mcg/kg/minute q 5 minutes p.r.n.  
➢ Analgesic component of monitored anesthesia care  
Adults: 0.5 to 1 mcg/kg I.V. over 30 to 60 seconds, given 90 seconds before anesthetic. As a continuous infusion, 0.05 to 0.1 mcg/kg/minute I.V. 5 minutes before anesthetic. After anesthetic is given, titrate rate to 0.025 to 0.05 mcg/kg/minute, then adjust by 0.025 mcg/kg/minute q 5 minutes p.r.n. |
Administration and patient monitoring

Know that drug should be given only by specially trained personnel with expertise in avoiding intravascular injections and in assessing and managing dose-related toxicities and other acute emergencies that may arise.

Make sure emergency resuscitation equipment is at hand before drug is given.

- Follow label directions to reconstitute drug for selected route.
- Be aware that if necessary, epinephrine may be added to slow procaine absorption, prolong its action, or maintain hemostasis.
- Monitor vital signs and ECG closely, especially when drug is used for spinal anesthesia. Stay alert for evidence of impending cardiac arrest.
- Watch for signs and symptoms of status asthmaticus and anaphylaxis.
- Monitor patient’s position carefully, especially after spinal anesthesia, to help prevent damage to nerves and other body tissues.
- Inspect infusion site for extravasation.

Keep emergency resuscitation equipment and naloxone at hand in case of respiratory arrest.
- Add 1 ml of diluent/mg of drug. Shake well to produce a clear, colorless solution of 1 mg/ml.
- Dilute drug further in normal or half-normal saline solution, dextrose 5% in water, dextrose 5% in normal saline solution, or dextrose 5% in lactated Ringer’s solution.
- Drug is for I.V. use only.
- Use infusion control pump for continuous infusion. Choose site close to venous cannula. After administering, flush I.V. tubing to clear.
- Know that delivery rates above 0.2 mcg/kg/minute may cause respiratory depression.
- When giving high doses, assess for muscle rigidity. Be prepared to stop therapy.
- Continuously monitor respiratory and cardiovascular function, oxygenation, and vital signs.
- Assess fluid intake and output. Watch for urinary retention.
## Appendix A: Common anesthetic drugs

### Common anesthetic drugs (continued)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Indications and dosages</th>
</tr>
</thead>
</table>
| **rocuronium bromide**        | ➢ Adjunct to general anesthesia to allow endotracheal intubation and relax skeletal muscles during mechanical ventilation or surgery  
**Adults:** Initially, I.V. bolus of 0.6 to 1.2 mg/kg (usually allows endotracheal intubation within 2 minutes and paralyzes muscles for 30 minutes). Boluses of 0.1 to 0.2 mg/kg may be given at 25% recovery for maintenance. For continuous I.V. infusion, 0.01 to 0.012 mg/kg/minute only after early evidence of recovery from intubating dose. |
| Zemuron (P/F)                 |                                                                                                                                                       |
| **ropivacaine hydrochloride** | ➢ Lumbar epidural block  
**Adults:** 15 to 30 ml (75 to 150 mg) I.V. of 0.5% solution, or 15 to 25 ml (113 to 188 mg) I.V. of 0.75% solution, or 15 to 20 ml (150 to 200 mg) of a 1% solution  
**Lumbar epidural block during labor**  
**Adults:** 10 to 20 ml (20 to 40 mg) of 0.2% solution, then 6 to 14 ml/hour (12 to 28 mg/hour) as a continuous I.V. infusion; or 10 to 15 ml/hour (20 to 30 mg/hour) of 0.2% solution as an incremental “top-up” injection  
**Lumbar epidural block for cesarean section**  
**Adults:** 20 to 30 ml (100 to 150 mg) I.V. of 0.5% solution, or 15 to 20 ml (113 to 150 mg) of 0.75% solution |
| Naropin                       |                                                                                                                                                       |
| **succinylcholine chloride**  | ➢ Adjunct to anesthesia to relax skeletal muscles during short surgical procedures; endotracheal intubation with mechanical ventilation; electrically induced convulsive therapy  
**Adults:** 0.6 mg/kg I.V. over 10 to 30 seconds, or a continuous I.V. infusion at 0.5 to 10 mg/minute, or 0.04 to 0.07 mg/kg I.V. intermittently p.r.n.  
**Older children and adolescents:** 1 mg/kg I.V. over 10 to 30 seconds  
**Infants and young children:** 2 mg/kg I.V. over 10 to 30 seconds |
| Anectine, Quelicin            |                                                                                                                                                       |
Administration and patient monitoring

Keep emergency resuscitation equipment at hand when giving.
Be aware that drug should be given only by personnel who are specially trained in administering anesthesia and neuromuscular blockers.
Verify that patient has received a sedative or general anesthetic before therapy begins.
Give by rapid I.V. injection or continuous I.V. infusion in compatible solution (dextrose 5% in water or normal saline solution, normal saline solution, sterile water for injection, or lactated Ringer’s solution).
Know that maintenance dose of 0.1 mg/kg provides an extra 12 minutes of muscle relaxation; 0.15 mg/kg, an extra 17 minutes; and 0.2 mg/kg, an extra 24 minutes.
Assess respiratory status frequently.
Monitor vital signs and ECG continuously until patient recovers fully from neuromuscular blockade. Closely monitor recovery with nerve stimulator and train-of-four monitoring.

Know that drug should be given only by personnel specially trained in use of epidural blocks.
Be aware that test dose (containing epinephrine) should be given.
Use small, incremental doses for titration. Avoid rapid I.V. infusion.
Monitor vital signs, ECG, and cardiovascular status continuously.
Assess neurologic status. Stay alert for signs and symptoms of impending seizure.
Watch carefully for warning signs of allergic reaction and respiratory distress.

Make sure patient has received a sedative or general anesthetic before administering.
Verify that emergency resuscitation equipment is at hand before giving.
As ordered, give test dose of 5 to 10 mg I.V. after anesthesia administration. Drug may be given if test dose does not cause respiratory depression or if such depression lasts no longer than 5 minutes.
For I.V. use, reconstitute with dextrose 5% in water or normal saline solution; administer via intermittent or continuous I.V. infusion. Don’t mix with alkaline solution, such as sodium bicarbonate, barbiturates, or thiopental sodium.
Be aware that continuous I.V. infusion isn’t recommended for children or adolescents.
Watch for life-threatening adverse reactions, including anaphylaxis, malignant hyperthermia, and hypersensitivity reaction.
Monitor ECG and vital signs (especially respirations) until patient recovers fully.
Assess recovery by checking hand grip, head lift, and voluntary cough response.

(continued)
### Common anesthetic drugs (continued)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Indications and dosages</th>
</tr>
</thead>
</table>
| sufentanil            | ➡️ As a primary anesthetic to induce and maintain anesthesia  
Adults: Initially, 8 to 30 mcg/kg I.V., given with oxygen and a muscle relaxant. Maintenance dosage is 0.5 to 10 mcg/kg p.r.n.  
➡️ Analgesic adjunct to maintain balanced general anesthesia  
Adults: 1 to 8 mcg/kg I.V., with 75% of dose given immediately before intubation. Remainder can be given as 10- to 50-mcg bolus doses to maintain analgesia.  
➡️ Epidural analgesia during labor and delivery  
Adults: 10 to 15 mcg epidurally with bupivacaine, with or without epinephrine. May repeat twice at intervals of less than 1 hour, for a total of three doses. |
| thiopental sodium     | ➡️ Slow anesthesia induction and maintenance  
Adults: 50 to 75 mg I.V. given slowly at 20- to 40-second intervals, based on response. May give additional doses of 25 to 50 mg I.V. p.r.n.  
➡️ Rapid anesthesia induction and maintenance before other general anesthetics are given  
Adults: 210 to 280 mg (3 to 4 mg/kg) I.V. in two to four divided doses  
➡️ Anesthesia maintenance without other general anesthetics for short procedures  
Adults: 0.2% or 0.4% solution intermittently by I.V. injection or continuous I.V. infusion  
➡️ Seizures associated with anesthesia or other causes in mechanically ventilated patients  
Adults: 75 to 125 mg I.V. infusion as soon as possible after seizure onset  
➡️ Increased intracranial pressure  
Adults: 1.5 to 3.5 mg/kg intermittent I.V. infusion |
| vecuronium bromide    | ➡️ Adjunct to anesthesia to facilitate endotracheal intubation and relax skeletal muscles during surgery or mechanical ventilation  
Adults and children older than age 9: Initially, 0.08 to 0.1 mg/kg by I.V. bolus. During prolonged surgery, maintenance dose of 0.01 to 0.015 mg/kg is given by continuous I.V. infusion within 25 to 40 minutes of initial dose. In patients receiving balanced anesthesia, maintenance dose may be given q 12 to 15 minutes. |
Appendix A: Common anesthetic drugs

**Administration and patient monitoring**

1. Know that drug should be given only by personnel who are specially trained in using I.V. and epidural anesthetics and in managing respiratory effects of potent opioids.
2. Keep oxygen and resuscitation and intubation equipment at hand.
3. Be aware that dosage is based on mean body weight.
5. Assess airway patency closely. Watch for respiratory depression and airway spasms.
6. Monitor neurologic status during and after administration. Institute safety measures as needed to prevent injury.
7. Monitor fluid intake and output. Check for oliguria or urinary retention.

1. Know that drug should be given only by personnel qualified in using I.V. anesthetics.
2. Keep resuscitation equipment on hand.
3. Reconstitute drug according to manufacturer’s directions.
4. Give test dose of 25 to 75 mg I.V., as ordered. Assess tolerance and monitor for hypersensitivity reaction for 1 minute.
5. Administer I.V. injection over 20 to 30 seconds or by continuous I.V. infusion using infusion pump.
6. Avoid extravasation to prevent severe tissue reaction (necrosis, sloughing). If extravasation occurs, stop infusion immediately, contact prescriber, apply moist heat, and inject 1% procaine hydrochloride, as prescribed.
7. Monitor vital signs and ECG carefully.
8. Closely monitor respiratory status, particularly for respiratory depression.
9. Assess patient closely to detect early signs and symptoms of shock. Stop drug and contact prescriber immediately if these occur.
10. Monitor neurologic status. Institute safety measures if seizures, agitation, or anxiety occurs.
11. Assess injection site closely and frequently to prevent extravasation and detect thrombophlebitis.

1. Know that drug should be given by specially trained personnel and only when respiratory support is available.
2. When giving by I.V. bolus, administer over 1 to 2 minutes.
3. When giving by continuous I.V. infusion, reconstitute by adding bacteriostatic water for injection to yield a concentration of 1 mg/ml. Dilute further with dextrose 5% in water, normal saline solution, or lactated Ringer’s solution. Administer with infusion-control device.
4. Monitor heart rhythm, blood pressure, and pulse oximetry during and after administration.
5. Monitor fluid intake and output and measure temperature.
6. Assess muscle recovery using peripheral nerve stimulator and train-of-four monitoring.
7. Make sure patient’s analgesic and sedative needs are met. (Drug doesn’t relieve pain or provide sedation.)
## Common combination drug products

Many drugs (especially over-the-counter preparations) are combination products that contain several active ingredients and are sold under a discrete trade name. The combination products below are listed by trade name, followed by active ingredients and therapeutic class.

<table>
<thead>
<tr>
<th>Trade name</th>
<th>Active ingredients</th>
<th>Therapeutic class</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Accuretic</strong></td>
<td>hydrochlorothiazide, quinapril hydrochloride</td>
<td>Antihypertensive</td>
</tr>
<tr>
<td><strong>Actifed</strong></td>
<td>codeine phosphate, pseudoephedrine hydrochloride, tripolidine hydrochloride</td>
<td>Adrenergic, antihistamine, antitussive</td>
</tr>
<tr>
<td><strong>Activella Tablets</strong></td>
<td>estradiol, norethindrone acetate</td>
<td>Estrogen, progestin</td>
</tr>
<tr>
<td><strong>Actonel with Calcium</strong></td>
<td>riseredrone sodium tablets with calcium carbonate tablets</td>
<td>Bone resorption inhibitor</td>
</tr>
<tr>
<td><strong>Actoplus Met</strong></td>
<td>metformin hydrochloride, pioglitazone hydrochloride</td>
<td>Antidiabetic agent</td>
</tr>
<tr>
<td><strong>Adderall</strong></td>
<td>amphetamine aspartate, amphetamine sulfate, dextroamphetamine saccharate,</td>
<td>CNS stimulant</td>
</tr>
<tr>
<td></td>
<td>dextroamphetamine sulfate</td>
<td></td>
</tr>
<tr>
<td><strong>Advair Diskus</strong></td>
<td>fluticasone propionate, salmeterol xinafoate</td>
<td>Corticosteroid, bronchodilator</td>
</tr>
<tr>
<td><strong>Advicor</strong></td>
<td>lovastatin, niacin</td>
<td>Antihyperlipidemic</td>
</tr>
<tr>
<td><strong>Aggrenox</strong></td>
<td>aspirin, dipyridamole</td>
<td>Antiplatelet drug</td>
</tr>
<tr>
<td><strong>Aldactazide</strong></td>
<td>hydrochlorothiazide, spironolactone</td>
<td>Diuretic</td>
</tr>
<tr>
<td><strong>Aldoril</strong></td>
<td>hydrochlorothiazide, methyldopa</td>
<td>Antihypertensive</td>
</tr>
<tr>
<td><strong>Allegra-D</strong></td>
<td>fexofenadine hydrochloride, pseudoephedrine hydrochloride</td>
<td>Antihistamine, adrenergic</td>
</tr>
<tr>
<td><strong>Apri</strong></td>
<td>desogestrel, ethinyl estradiol</td>
<td>Estrogen, progestin</td>
</tr>
<tr>
<td><strong>Arthrotec</strong></td>
<td>diclofenac sodium, misoprostol</td>
<td>Anti-inflammatory, gastric protectant</td>
</tr>
<tr>
<td><strong>Atacand HCT</strong></td>
<td>candesartan cilexetil, hydrochlorothiazide</td>
<td>Antihypertensive</td>
</tr>
<tr>
<td><strong>Atripla</strong></td>
<td>efavirenz, emtricitabine, tenofovir disoproxil fumarate</td>
<td>Antiviral</td>
</tr>
<tr>
<td><strong>Augmentin</strong></td>
<td>amoxicillin, clavulanate potassium</td>
<td>Anti-infective</td>
</tr>
<tr>
<td><strong>Avalide</strong></td>
<td>hydrochlorothiazide, irbesartan</td>
<td>Antihypertensive</td>
</tr>
<tr>
<td><strong>Avandaryl</strong></td>
<td>rosiglitazone maleate and glimepiride</td>
<td>Hypoglycemic</td>
</tr>
<tr>
<td><strong>Azor</strong></td>
<td>amlodipine, olmesartan medoxomil</td>
<td>Antihypertensive</td>
</tr>
</tbody>
</table>
Appendix B: Common combination drug products

Bactrim
sulfamethoxazole, trimethoprim
Therapeutic class: Anti-infective

Caduet
amlodipine besylate, atorvastatin calcium
Therapeutic class: Antihypertensive, antihyperlipidemic

Capozide
captopril, hydrochlorothiazide
Therapeutic class: Antihypertensive

Ciprodex
ciprofloxacin, dexamethasone
Therapeutic class: Anti-infective, anti-inflammatory drug

Clarinex-D 12 hour
desloratidine and pseudoephedrine
Therapeutic class: Antihistamine and vasoconstrictor

Claritin-D
loratadine, pseudoephedrine sulfate
Therapeutic class: Antihistamine, adrenergic

CombiPatch
estradiol, norethindrone acetate
Therapeutic class: Estrogen, progestin

Combivent
albuterol sulfate, ipratropium bromide
Therapeutic class: Bronchodilator

Combivir
lamivudine, zidovudine
Therapeutic class: Antiviral

Combunox
ibuprofen, oxycodone hydrochloride
Therapeutic class: Opioid analgesic

Corzide
bendroflumethiazide, nadolol
Therapeutic class: Antihypertensive

Cosopt
dorzolamide, timolol maleate
Therapeutic class: Anti-infective, carbonic anhydrase inhibitor

Darvocet N-100
acetaminophen, propoxyphene
Therapeutic class: Opioid analgesic

Duetact
glimepiride, pioglitazone
Therapeutic class: Antihyperglycemic

Dyazide
hydrochlorothiazide, triamterene
Therapeutic class: Diuretic

EMLA Cream
lidocaine, prilocaine
Therapeutic class: Anesthetic

Endocet
acetaminophen, oxycodone hydrochloride
Therapeutic class: Opioid analgesic

Epzicom
abacavir sulfate, lamivudine
Therapeutic class: Antiviral

Exforge
amlodipine, valsartan
Therapeutic class: Antihypertensive

Fansidar
pyrimethamine, sulfadoxine
Therapeutic class: Antimalarial drug

Femhrt
ethinyl estradiol, norethindrone acetate
Therapeutic class: Estrogen, progestin

Fioricet
acetaminophen, butalbital, caffeine
Therapeutic class: Barbiturate analgesic

Fiorinal
aspirin, butalbital, caffeine
Therapeutic class: Barbiturate analgesic

Fosamax Plus D
alendronate sodium, cholecalciferol
Therapeutic class: Bone resorption inhibitor

Glucovance
gliburide, metformin hydrochloride
Therapeutic class: Hypoglycemic

Helidak
bismuth subsalicylate, metronidazole, tetracycline hydrochloride
Therapeutic class: Anti-infective

Humulin 70/30
insulin, recombinant human; insulin suspension, isophane
Therapeutic class: Hypoglycemic

(continued)
<table>
<thead>
<tr>
<th>Drug</th>
<th>Active Ingredients</th>
<th>Therapeutic Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hycodan</td>
<td>homatropine methylbromide, hydrocodone bitartrate</td>
<td>Opioid analgesic</td>
</tr>
<tr>
<td>Hydrocodet</td>
<td>acetaminophen, hydrocodone bitartrate</td>
<td>Opioid analgesic</td>
</tr>
<tr>
<td>Hyzaar</td>
<td>hydrochlorothiazide, losartan potassium</td>
<td>Antihypertensive</td>
</tr>
<tr>
<td>Inderide</td>
<td>hydrochlorothiazide, propranolol hydrochloride</td>
<td>Antihypertensive</td>
</tr>
<tr>
<td>Janumet</td>
<td>metformin hydrochloride, sitagliptin</td>
<td>Antihyperglycemic</td>
</tr>
<tr>
<td>Kaletra</td>
<td>lopinavir, ritonavir</td>
<td>Antiviral</td>
</tr>
<tr>
<td>Librax</td>
<td>chlordiazepoxide hydrochloride, clidinium bromide</td>
<td>Anxiolytic</td>
</tr>
<tr>
<td>Loestrin 24 FE</td>
<td>norethindrone acetate/ethinyl estradiol and ferrous fumarate</td>
<td>Hormonal contraceptive with iron</td>
</tr>
<tr>
<td>Lomotil</td>
<td>atropine sulfate, diphenoxylate hydrochloride</td>
<td>Antidiarrheal, anticholinergic</td>
</tr>
<tr>
<td>Lopressor HCT</td>
<td>hydrochlorothiazide, metoprolol tartrate</td>
<td>Antihypertensive</td>
</tr>
<tr>
<td>Lortab</td>
<td>acetaminophen, hydrocodone bitartrate</td>
<td>Opioid analgesic</td>
</tr>
<tr>
<td>Lotensin HCT</td>
<td>benazepril hydrochloride, hydrochlorothiazide</td>
<td>Antihypertensive</td>
</tr>
<tr>
<td>Lotrel</td>
<td>amlodipine besylate, benazepril hydrochloride</td>
<td>Antihypertensive</td>
</tr>
<tr>
<td>Maxzide</td>
<td>hydrochlorothiazide, triamterene</td>
<td>Antihypertensive, diuretic</td>
</tr>
<tr>
<td>Minizide</td>
<td>polythiazide, prazosin hydrochloride</td>
<td>Antihypertensive</td>
</tr>
<tr>
<td>Moduretic</td>
<td>amiloride hydrochloride, hydrochlorothiazide</td>
<td>Diuretic</td>
</tr>
<tr>
<td>NovoLog Mix 70/30</td>
<td>insulin aspart (recombinant), insulin aspart protamine</td>
<td>Hypoglycemic</td>
</tr>
<tr>
<td>NuLYTELY</td>
<td>polyethylene glycol, potassium chloride, sodium bicarbonate, sodium chloride</td>
<td>Laxative</td>
</tr>
<tr>
<td>Ortho-Cyclen</td>
<td>ethinyl estradiol, norgestimate</td>
<td>Contraceptive</td>
</tr>
<tr>
<td>Pediazole</td>
<td>erythromycin ethylsuccinate, sulfisoxazole acetyl</td>
<td>Anti-infective</td>
</tr>
<tr>
<td>Percocet</td>
<td>acetaminophen, oxycodone hydrochloride</td>
<td>Opioid analgesic</td>
</tr>
<tr>
<td>Percodan</td>
<td>aspirin, oxycodone hydrochloride, oxycodone terephthalate</td>
<td>Opioid analgesic</td>
</tr>
<tr>
<td>Premphase</td>
<td>conjugated estrogens, medroxyprogesterone acetate</td>
<td>Contraceptive</td>
</tr>
<tr>
<td>Primaxin</td>
<td>cilastatin sodium, imipenem</td>
<td>Anti-infective</td>
</tr>
</tbody>
</table>
Appendix B: Common combination drug products

Rifamate
isoniazid, rifampin
Therapeutic class: Antitubercular

Rifater
isoniazid, pyrazinamide, rifampin
Therapeutic class: Antitubercular

Roxicet
acetaminophen, oxycodone hydrochloride
Therapeutic class: Antitubercular

Seasonale
ethinyl estradiol, levonorgestrel
Therapeutic class: Estrogen, progestin

Septra
sulfamethoxazole, trimethoprim
Therapeutic class: Anti-infective

Solage
mequinol, tretinoin
Therapeutic class: Antineoplastic

Stalevo
carbidopa, entacapone, levodopa
Therapeutic class: Antiparkinsonian

Symbyax
fluoxetine hydrochloride, olanzapine
Therapeutic class: Mood stabilizer

Taclonex
calcipotriene and betamethasone
Therapeutic class: Antiparkinsonian

Tarka
trandolapril, verapamil hydrochloride
Therapeutic class: Antihypertensive

Tenoretic
atenolol, chlorthalidone
Therapeutic class: Antihypertensive

Trizivir
abacavir sulfate, lamivudine, zidovudine
Therapeutic class: Antiviral

Truvada
emtricitabine, tenofovir disoproxil fumarate
Therapeutic class: Antiviral

Tussionex
chlorpheniramine polistirex, hydrocodone polistirex
Therapeutic class: Antitussive, antihista-
mine

Tylox
acetaminophen, oxycodon hydrochloride
Therapeutic class: Antitussive, antihista-
mine

Ultrace
acetaminophen, tramadol hydrochloride
Therapeutic class: Antitussive, antihista-
mine

Ultrase
amylase, lipase, protease
Therapeutic class: Digestive enzyme

Unasyn
ampicillin sodium, sulbactam sodium
Therapeutic class: Anti-infective

Vaseretic
enalapril maleate, hydrochlorothiazide
Therapeutic class: Antihypertensive, diuretic

Vicodin
acetaminophen, hydrocodone bitartate
Therapeutic class: Antihypertensive, diuretic

Vusion
miconazole, sodium bicarbonate
Therapeutic class: Steroid-free agent for diaper dermatitis

Vytorin
ezetimibe, simvastatin
Therapeutic class: Antihyperlipidemic

Zestoretic
hydrochlorothiazide, lisinopril
Therapeutic class: Antihypertensive

Ziac
bisoprolol fumarate, hydrochlorothiazide
Therapeutic class: Antihypertensive

Ziana Gel
clindamycin phosphate, tretinoin
Therapeutic class: Antibiotic, retinoid

Zyrtec-D
cetirizine hydrochloride, pseudo-
ephedrine hydrochloride
Therapeutic class: Antihistamine/ decongestant
This 2007 schedule shows the recommended age groups for routine administration of vaccines for adults ages 19 and older. A person may receive a combination vaccine if any components of the combination are indicated (unless the vaccine’s other components are contraindicated). Consult the package insert for detailed recommendations.

For more information about recommended vaccines and contraindications for immunization, visit www.cdc.gov/nip or call the National Immunization Hotline at 800-232-2522 (English) or 800-232-0233 (Spanish).

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Ages 19-49</th>
<th>Ages 50-64</th>
<th>Ages 65 and older</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tetanus, diphtheria (Td)</td>
<td></td>
<td>1 dose annually</td>
<td>1 dose booster every 10 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Substitute 1 dose or Tdap for Td</td>
</tr>
<tr>
<td>Influenza</td>
<td></td>
<td>1 dose annually</td>
<td>1 dose annually</td>
</tr>
<tr>
<td>Pneumococcal (polysaccharide)</td>
<td>1 to 2 doses</td>
<td>1 dose</td>
<td></td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>3 doses (0, 1 to 2 months, and 4 to 6 months)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>2 doses (0, 6 to 12 months or 0, 6 to 18 months)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, Mumps, Rubella (MMR)</td>
<td>1 or 2 doses</td>
<td>1 dose</td>
<td></td>
</tr>
<tr>
<td>Varicella</td>
<td>2 doses (0, 4-8 wks)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal (polysaccharide)</td>
<td>1 or more doses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zoster</td>
<td>1 dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human papilloma-virus (HPV)2</td>
<td>3 doses (females) (0, 2, 6 mos)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

KEY:  
- For all persons in this age group
- For persons with medical or exposure indications

Approved by Advisory Committee on Immunization Practices, American College of Obstetricians and Gynecologists, and American Academy of Family Physicians. Published by Advisory Committee on Immunization Practices, Department of Health and Human Services, Centers for Disease Control and Prevention.
This 2007 schedule shows recommended ages for routine administration of childhood vaccines for children from birth through 6 years of age. A child who doesn’t receive a given dose at the recommended age should receive it at a subsequent visit. “Catch-up immunization” indicates ages at which children should receive the vaccine if they haven’t previously received it. Consult the package insert for detailed recommendations.

For more information about vaccines, visit www.cdc.gov/nip or call the National Immunization Information Hotline at 800-232-2522 (English) or 800-232-0233 (Spanish).

---

### Childhood immunization schedule by age group

**Vaccine** | **Birth** | **1 mo** | **2 mo** | **4 mo** | **6 mo** | **12 mo** | **15 mo** | **18 mo** | **19-23 mo** | **2-3 yrs** | **4-6 yrs**
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
**Hepatitis B** | HepB #1 | only if mother HBsAg(-) | | | | | | | | | HepB series
| HepB #2 | | | | | | | | | | |
| HepB #3 | | | | | | | | | | |
**Diphtheria, Tetanus, Pertussis** | DTaP | DTaP | DTaP | | DTaP | | | | | DTaP
**Haemophilus influenzae Type b** | Hib | Hib | Hib | Hib | Hib | Hib |
**Inactivated poliovirus** | IPV | IPV | | IPV | | | | | | IPV
**Measles, Mumps, Rubella** | | | | | | | | | | MMR
**Rotavirus** | Rota | Rota | Rota | | | | | | | |
**Varicella** | | | | | | | | | | Varicella
**Meningococcal** | | | | | | | | | | MPSV4
**Pneumococcal** | PCV | PCV | PCV | PCV | | | | | | PCV
**Influenza** | | | | | | | | | | Influenza (Yearly)
**Hepatitis A** | | | | | | | | | HepA (2 doses) | HepA series

---

Range of recommended ages | Catch-up immunization | Selected populations
--- | --- | ---
DTaP: Diphtheria, Tetanus, Pertussis | HepA: Hepatitis A vaccine | HepB: Hepatitis B vaccine
IPV: Inactivated poliovirus | MMR: Measles, Mumps, Rubella | MPSV4: Meningococcal polysaccharide vaccine
PPV: Pneumococcal polysaccharide vaccine
Adolescent immunization schedule by age group

This 2007 schedule shows recommended ages for routine administration of currently licensed vaccines to adolescent children ages 7 to 18. An adolescent who doesn’t receive a given dose at the recommended age should receive it at a subsequent visit. “Catch-up immunization” indicates ages at which adolescents should receive the vaccine if they haven’t previously received it. Consult the package insert for detailed recommendations.

For more information about vaccines (including precautions and contraindications for immunization and vaccine shortages), visit www.cdc.gov/nip or call the National Immunization Information Hotline at 800-232-2522 (English) or 800-232-0233 (Spanish).

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>7-10 yrs</th>
<th>11-12 yrs</th>
<th>13-14 yrs</th>
<th>15 yrs</th>
<th>16-18 yrs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tetanus, Diphtheria, Pertussis</td>
<td>DTaP</td>
<td>DTaP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human papillomavirus</td>
<td>HPV (3 doses)</td>
<td>HPV Series</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>HepB Series</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated poliovirus</td>
<td>IPV Series</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, Mumps, Rubella</td>
<td>MMR Series</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella</td>
<td>Varicella Series</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal</td>
<td>MPSV4</td>
<td>MCV4</td>
<td></td>
<td>MCV4</td>
<td></td>
</tr>
<tr>
<td>Pneumococcal</td>
<td>PPV</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza</td>
<td>Influenza (yearly)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>HepA Series</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

KEY: Range of recommended ages

DTaP: Diphtheria, Tetanus, Pertussis
HepA: Hepatitis A vaccine
HepB: Hepatitis B vaccine
HPV: Human papillomavirus
IPV: Inactivated poliovirus
MMR: Measles, Mumps, Rubella
MPSV4: Meningococcal polysaccharide vaccine
MCV4: Meningococcal conjugate vaccine
PPV: Pneumococcal polysaccharide vaccine

Approved by Advisory Committee on Immunization Practices, American Academy of Pediatrics, and American Academy of Family Physicians. Published by Advisory Committee on Immunization Practices, Department of Health and Human Services, Centers for Disease Control and Prevention.
Normal laboratory values for blood tests

The table below shows normal laboratory values for commonly ordered blood tests. Results may vary slightly among laboratories. Many of these values are monitored regularly to assess patient response and drug efficacy.

<table>
<thead>
<tr>
<th>Hematology</th>
<th>Coagulation studies</th>
<th>Chemistry (continued)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>White blood cell count</strong></td>
<td><strong>Partial thromboplastin time</strong></td>
<td><strong>Globulin</strong></td>
</tr>
<tr>
<td>4,100 to 10,900/mm³</td>
<td>60 to 70 seconds</td>
<td>2.3 to 3.5 g/dl</td>
</tr>
<tr>
<td><strong>Red blood cell count</strong></td>
<td><strong>Prothrombin time</strong></td>
<td><strong>Sodium</strong></td>
</tr>
<tr>
<td>Men: 4.5 to 6.2 million/mm³</td>
<td>10 to 14 seconds</td>
<td>135 to 145 mEq/L</td>
</tr>
<tr>
<td>Women: 4.2 to 5.4 million/mm³</td>
<td><strong>International Normalized Ratio</strong></td>
<td><strong>Potassium</strong></td>
</tr>
<tr>
<td><strong>Hemoglobin</strong></td>
<td>2.0 to 3.0 in patients receiving warfarin</td>
<td>3.5 to 5.0 mEq/L</td>
</tr>
<tr>
<td>Men: 14 to 18 g/dl</td>
<td><strong>Bleeding time</strong></td>
<td><strong>Anion gap</strong></td>
</tr>
<tr>
<td>Women: 12 to 16 g/dl</td>
<td>3 to 6 minutes (template and Ivy methods)</td>
<td>8 to 16 mEq/L</td>
</tr>
<tr>
<td><strong>Hematocrit</strong></td>
<td>1 to 3 minutes (Duke method)</td>
<td><strong>Chloride</strong></td>
</tr>
<tr>
<td>Men: 42% to 54%</td>
<td><strong>D-Dimer</strong></td>
<td>100 to 108 mEq/L</td>
</tr>
<tr>
<td>Women: 38% to 46%</td>
<td>&lt; 250 µg/L</td>
<td><strong>Carbon dioxide</strong></td>
</tr>
<tr>
<td><strong>Platelet count</strong></td>
<td><strong>Fibrinogen</strong></td>
<td>22 to 34 mEq/L</td>
</tr>
<tr>
<td>140,000 to 400,000/mm³</td>
<td>215 to 519 mg/dl</td>
<td><strong>Albumin</strong></td>
</tr>
<tr>
<td><strong>Red blood cell indices</strong></td>
<td><strong>Fibrinogen degradation products</strong></td>
<td>3.3 to 4.5 g/dl</td>
</tr>
<tr>
<td>MCH: 26 to 32 pg</td>
<td>&lt; 1:10</td>
<td><strong>Calcium</strong></td>
</tr>
<tr>
<td>MCHC: 32 to 36 g/dl</td>
<td></td>
<td>9 to 10.5 mg/dl</td>
</tr>
<tr>
<td>MCV: 80 to 95 µm³</td>
<td></td>
<td><strong>Magnesium</strong></td>
</tr>
<tr>
<td><strong>Reticulocyte count</strong></td>
<td></td>
<td>1.5 to 2.5 mEq/L</td>
</tr>
<tr>
<td>0.5% to 2% of total red blood cell count</td>
<td></td>
<td><strong>Phosphorus</strong></td>
</tr>
<tr>
<td><strong>White blood cell differential</strong></td>
<td></td>
<td>2.5 to 4.5 mg/dl</td>
</tr>
<tr>
<td>Basophils: 0.3% to 2%</td>
<td></td>
<td><strong>Amylase</strong></td>
</tr>
<tr>
<td>Eosinophils: 0.3% to 7%</td>
<td></td>
<td>60 to 180 units/L</td>
</tr>
<tr>
<td>Lymphocytes: 16.2% to 43%</td>
<td></td>
<td><strong>Lipase</strong></td>
</tr>
<tr>
<td>Monocytes: 4% to 10%</td>
<td></td>
<td>0 to 110 units/L</td>
</tr>
<tr>
<td>Neutrophils: 47.6% to 76.8%</td>
<td></td>
<td><strong>Lactate dehydrogenase</strong></td>
</tr>
<tr>
<td><strong>Blood urea nitrogen (BUN)</strong></td>
<td></td>
<td>48 to 115 IU/L</td>
</tr>
<tr>
<td>8 to 20 mg/dl</td>
<td></td>
<td><strong>Lactic acid</strong></td>
</tr>
<tr>
<td><strong>Creatinine</strong></td>
<td></td>
<td>3 to 12 mg/dl</td>
</tr>
<tr>
<td>Men: 0.8 to 1.2 mg/dl</td>
<td></td>
<td><strong>Protein</strong></td>
</tr>
<tr>
<td>Women: 0.6 to 1.1 mg/dl</td>
<td></td>
<td>6.0 to 8.5 g/dl</td>
</tr>
<tr>
<td><strong>BUN/creatinine ratio</strong></td>
<td></td>
<td><strong>Uric acid</strong></td>
</tr>
<tr>
<td>6 to 22 (calculated)</td>
<td></td>
<td>Men: 4.0 to 8.5 mg/dl</td>
</tr>
<tr>
<td><strong>Chemistry (continued)</strong></td>
<td></td>
<td>Women: 2.5 to 7.5 mg/dl</td>
</tr>
</tbody>
</table>

**KEY**
- MCH: Mean corpuscular hemoglobin
- MCHC: Mean corpuscular hemoglobin concentration
- MCV: Mean corpuscular volume

(continued)
### Chemistry (continued)

- **Erythrocyte sedimentation rate**
  - Men: 0 to 15 mm/hour
  - Women: 0 to 20 mm/hour
- **Glucose-6-phosphate dehydrogenase**
  - 5 to 13 units/g hemoglobin
- **Hemoglobin A1c**
  - < 6.0% of total hemoglobin
- **B-Type natriuretic peptide**
  - < 100 pg/ml
- **Zinc**
  - 60 to 130 mcg/dl
- **Serotonin**
  - Men: 21 to 321 ng/ml
  - Women: 0 to 420 ng/ml

### Arterial blood gases

- **pH**
  - 7.35 to 7.45 mmHg
- **Paco₂**
  - 35 to 45 mmHg
- **Pao₂**
  - 75 to 100 mmHg
- **HCO₃⁻**
  - 22 to 26 mEq/L
- **SaO₂**
  - 94% to 100%

### Lipid studies

- **Low-density lipoproteins**
  - Optimal: < 100 mg/dl
  - Near optimal: 100 to 129 mg/dl
- **High-density lipoproteins**
  - Desirable: ≥ 60 mg/dl
- **Total cholesterol**
  - Desirable: < 200 mg/dl
- **Triglycerides**
  - Desirable: < 200 mg/dl

### Liver function studies

- **Alanine aminotransferase**
  - Men: 10 to 35 units/L
  - Women: 9 to 24 units/L
- **Alkaline phosphatase**
  - Men: 8 to 20 units/L
  - Women: 5 to 40 units/L
- **Aspartate aminotransferase**
  - Men: 8 to 20 units/L
  - Women: 5 to 40 units/L
- **Serum bilirubin**
  - Direct: ≤ 0.4 mg/dl
  - Indirect: ≤ 1.3 mg/dl
  - Total: ≤ 1.3 mg/dl

### Cardiac studies

- **Cardiac troponin I**
  - < 1.0 µg/ml
- **Creatine kinase (CK)**
  - Total CK—
    - Men: 54 to 186 IU/L
    - Women: 41 to 117 IU/L
  - Isoenzymes—
    - CK-MM: 96% to 100% of total
    - CK-MB: 0% to 4% of total
    - CK-BB: 0% of total
- **High sensitivity C-reactive protein**
  - Low cardiovascular risk: < 1.0 mg/L
  - Average cardiovascular risk: 1.0 to 3.0 mg/L

### Tumor-related marker studies

- **Carbohydrate antigen (CA) 15.3**
  - > 25 U/ml
- **CA 19-9 (Siemens Chemiluminescent Method)**
  - < 37 U/ml
- **CA 125 (Siemens Chemiluminescent Method)**
  - < 21 U/ml
- **Carcinoembryonic antigen**
  - < 3 ng/ml, individualized and variable (non-smokers)
  - < 5 ng/ml, individualized and variable (smokers)
- **Prostate-specific antigen**
  - ≤ 4 ng/ml
- **Prostatic acid phosphatase**
  - < 0 to 2.7 ng/ml

### Lymphocyte surface markers

- **CD3**
  - Absolute: 840 to 3,060 cells/µL
  - Percentage: 57% to 85%
- **CD4**
  - Absolute: 490 to 1,740 cells/µL
  - Percentage: 30% to 61%
- **CD8**
  - Absolute: 180 to 1,170 cells/µL
  - Percentage: 12% to 42%
- **Helper: suppressor (CD4: CD8) ratio**
  - 0.86 to 5
Appendix F: Normal laboratory values for blood tests

Iron studies

**Serum iron**
40 to 180 mcg/dl

**Ferritin**
Men: 18 to 270 µg/ml
Women: 18 to 160 µg/ml

**Iron-binding capacity**
200 to 450 mcg/dl

**Transferrin**
88 to 341 mg/dl

**Transferrin saturation**
12% to 57%

Hormone studies

**Cortisol, free**
- 8:00 to 10:00 A.M.: 0.07 to 0.93 mcg/dl
- 4:00 to 6:00 P.M.: 0.04 to 0.45 mcg/dl
- 10:00 to 10:00 P.M.: 0.04 to 0.35 mcg/dl

**Cortisol, total**
- 8:00 to 10:00 A.M.: 4.6 to 20.6 mcg/dl
- 4:00 to 6:00 P.M.: 1.8 to 13.6 mcg/dl

**Estradiol**
Men: < 50 pg/ml
Women: Menstruating (day of cycle relative to LH peak) —
  - Follicular (-12): 19 to 83 pg/ml
  - Follicular (-4): 64 to 183 pg/ml
  - Midcycle (-1): 150 to 528 pg/ml
  - Luteal (+2): 58 to 157 pg/ml
  - Luteal (+6): 60 to 211 pg/ml
  - Luteal (+12): 55 to 150 pg/ml
Postmenopausal (no treatment): 0 to 31 pg/ml

**Free thyroxine**
0.7 to 1.9 ng/dl

**Free thyroxine fraction**
0.03% to 0.005%

**Growth hormone**
Age 1 day: 5 to 53 ng/ml
Age 1 week: 5 to 27 ng/ml
Age 1 to 12 months: 2 to 10 ng/ml
Age 1 year and older: < 5 ng/ml

**17-Hydroxyprogesterone**
Men: 0.06 to 3.0 mg/L
Women (follicular phase): 0.2 to 1.0 mg/L

**Parathyroid hormone, intact**
Ages 2 to 20 years: 9 to 52 pg/ml
Older than age 20: 8 to 97 pg/ml

**Radioactive iodine uptake**
10% to 30%

**Testosterone**
Males > age 18: 241 to 827 ng/dl
Females > age 18: 14 to 76 ng/dl

**Triiodothyronine (T₃)**
60 to 181 ng/dl

**Thyroxine (T₄)**
4.5 to 12.5 mcg/dl

**Thyroid hormone binding ratio**
0.9 to 1.1

**Thyroid-stimulating hormone**
0.5 to 4.70 microIU/ml
Appendix G: Drug infusion rates

Drug infusion rates

The tables below show infusion rates for common drug infusions. Before using these tables as your administration guide, make sure the concentration of the prescribed infusion matches the concentration shown in the table.

Adenosine (Adenoscan) infusion rates
Using this table, you can determine that the appropriate infusion rate is corrected for total body weight.

<table>
<thead>
<tr>
<th>Patient’s weight</th>
<th>Infusion rate (ml/minute)</th>
</tr>
</thead>
<tbody>
<tr>
<td>kg</td>
<td>lb</td>
</tr>
<tr>
<td>45</td>
<td>99</td>
</tr>
<tr>
<td>50</td>
<td>110</td>
</tr>
<tr>
<td>55</td>
<td>121</td>
</tr>
<tr>
<td>60</td>
<td>132</td>
</tr>
<tr>
<td>65</td>
<td>143</td>
</tr>
<tr>
<td>70</td>
<td>154</td>
</tr>
<tr>
<td>75</td>
<td>165</td>
</tr>
<tr>
<td>80</td>
<td>176</td>
</tr>
<tr>
<td>85</td>
<td>187</td>
</tr>
<tr>
<td>90</td>
<td>198</td>
</tr>
</tbody>
</table>

Aminophylline infusion rates
Although aminophylline infusion rates are highly individualized, this table can help you determine the infusion rate for an infusion containing aminophylline 500 mg (= 400 mg theophylline) in 500 ml D₂W that must be controlled by an automated infusion control device.

<table>
<thead>
<tr>
<th>Dosage (mg/hour)</th>
<th>Dosage (mg/hour)</th>
<th>Rate (ml/hour)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aminophylline</td>
<td>Theophylline</td>
<td>Rate</td>
</tr>
<tr>
<td>10</td>
<td>8</td>
<td>10</td>
</tr>
<tr>
<td>15</td>
<td>12</td>
<td>15</td>
</tr>
<tr>
<td>20</td>
<td>16</td>
<td>20</td>
</tr>
<tr>
<td>25</td>
<td>20</td>
<td>25</td>
</tr>
<tr>
<td>30</td>
<td>24</td>
<td>30</td>
</tr>
<tr>
<td>35</td>
<td>28</td>
<td>35</td>
</tr>
<tr>
<td>40</td>
<td>32</td>
<td>40</td>
</tr>
<tr>
<td>45</td>
<td>36</td>
<td>45</td>
</tr>
<tr>
<td>50</td>
<td>40</td>
<td>50</td>
</tr>
<tr>
<td>55</td>
<td>44</td>
<td>55</td>
</tr>
<tr>
<td>60</td>
<td>48</td>
<td>60</td>
</tr>
<tr>
<td>65</td>
<td>52</td>
<td>65</td>
</tr>
<tr>
<td>70</td>
<td>56</td>
<td>70</td>
</tr>
<tr>
<td>75</td>
<td>60</td>
<td>75</td>
</tr>
<tr>
<td>80</td>
<td>64</td>
<td>80</td>
</tr>
</tbody>
</table>
**Argatroban infusion rates**
Using this table, you can determine the infusion rate for argatroban (for a 2-mcg/kg/minute dose) that has been diluted in normal saline solution, D₅W, or lactated Ringer’s solution to a concentration of 1 mg/ml.

<table>
<thead>
<tr>
<th>Patient’s weight (kg)</th>
<th>Dosage (mcg/minute)</th>
<th>Infusion rate (ml/hour)</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
<td>100</td>
<td>6</td>
</tr>
<tr>
<td>60</td>
<td>120</td>
<td>7</td>
</tr>
<tr>
<td>70</td>
<td>140</td>
<td>8</td>
</tr>
<tr>
<td>80</td>
<td>160</td>
<td>10</td>
</tr>
<tr>
<td>90</td>
<td>180</td>
<td>11</td>
</tr>
<tr>
<td>100</td>
<td>200</td>
<td>12</td>
</tr>
<tr>
<td>110</td>
<td>220</td>
<td>13</td>
</tr>
<tr>
<td>120</td>
<td>240</td>
<td>14</td>
</tr>
<tr>
<td>130</td>
<td>260</td>
<td>16</td>
</tr>
<tr>
<td>140</td>
<td>280</td>
<td>17</td>
</tr>
</tbody>
</table>

**Clindamycin phosphate infusion rates**
Using this table, you can determine dilution and infusion rates after diluting I.V. solution to a concentration of not more than 18 mg/ml using normal saline solution, D₅W, or lactated Ringer’s solution.

<table>
<thead>
<tr>
<th>Dosage (mg)</th>
<th>Diluent (ml)</th>
<th>Infusion rate (minutes)</th>
</tr>
</thead>
<tbody>
<tr>
<td>300</td>
<td>50</td>
<td>10</td>
</tr>
<tr>
<td>600</td>
<td>50</td>
<td>20</td>
</tr>
<tr>
<td>900</td>
<td>50 to 100</td>
<td>30</td>
</tr>
<tr>
<td>1,200</td>
<td>100</td>
<td>40</td>
</tr>
</tbody>
</table>

**Dobutamine infusion rates**
Using this table, you can determine the infusion rate for an infusion containing dobutamine 250 mg mixed in 250 ml of dextrose 5% in water (1,000 mcg/ml).

<table>
<thead>
<tr>
<th>Dosage (mcg/kg/minute)</th>
<th>Patient’s weight (kg)</th>
<th>Infusion rate (ml/hour)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5</td>
<td>40 45 50 55 60 65 70 75 80 85 90 95 100 105 110</td>
<td>0.5 1 1.5 2 2.5 5 7.5 10 12.5 15 20 25 30 35 40</td>
</tr>
<tr>
<td>1.5</td>
<td>1 2 2 2 2 2 2 2 2 2 2 2 2 2 2</td>
<td>1 1.5 2 2.5 5 7.5 10 12.5 15 20 25 30 35 40</td>
</tr>
<tr>
<td>2.5</td>
<td>4 4 5 5 5 5 6 6 6 6 6 6 6 6 6</td>
<td>4 4 5 5 5 5 6 6 6 6 6 6 6 6 6</td>
</tr>
<tr>
<td>5.0</td>
<td>6 7 8 8 8 9 10 10 10 10 10 10 10 10 10</td>
<td>6 6 7 8 8 9 10 10 10 10 10 10 10 10 10</td>
</tr>
<tr>
<td>7.5</td>
<td>12 14 15 17 18 20 21 21 21 21 21 21 21 21 21</td>
<td>12 12 14 15 17 18 20 21 21 21 21 21 21 21 21</td>
</tr>
<tr>
<td>10.0</td>
<td>18 20 23 25 27 29 32 32 32 32 32 32 32 32 32</td>
<td>18 18 20 23 25 27 29 32 32 32 32 32 32 32 32</td>
</tr>
<tr>
<td>12.5</td>
<td>24 27 30 33 36 39 42 42 42 42 42 42 42 42 42</td>
<td>24 24 27 30 33 36 39 42 42 42 42 42 42 42 42</td>
</tr>
<tr>
<td>15.0</td>
<td>30 34 38 41 45 49 53 56 56 56 56 56 56 56 56</td>
<td>30 30 34 38 41 45 49 53 56 56 56 56 56 56 56</td>
</tr>
<tr>
<td>20.0</td>
<td>36 41 45 50 54 59 63 68 72 72 72 72 72 72 72</td>
<td>36 36 41 45 50 54 59 63 68 72 72 72 72 72 72</td>
</tr>
<tr>
<td>25.0</td>
<td>48 54 60 66 72 78 84 90 96 102 108 114 120 126 132</td>
<td>48 48 54 60 66 72 78 84 90 96 102 108 114 120 126 132</td>
</tr>
<tr>
<td>30.0</td>
<td>60 68 75 83 90 98 105 113 120 128 135 143 150 158 165</td>
<td>60 60 68 75 83 90 98 105 113 120 128 135 143 150 158 165</td>
</tr>
<tr>
<td>35.0</td>
<td>72 81 90 99 108 117 126 135 144 153 162 171 180 189 198</td>
<td>72 72 81 90 99 108 117 126 135 144 153 162 171 180 189 198</td>
</tr>
<tr>
<td>40.0</td>
<td>84 95 105 116 126 137 147 158 168 179 189 200 210 221 231</td>
<td>84 84 95 105 116 126 137 147 158 168 179 189 200 210 221 231</td>
</tr>
<tr>
<td>45.0</td>
<td>96 108 120 132 144 156 168 180 192 204 216 228 240 252 264</td>
<td>96 96 108 120 132 144 156 168 180 192 204 216 228 240 252 264</td>
</tr>
</tbody>
</table>

(continued)
Drug infusion rates (continued)

Dopamine infusion rates
Using this table, you can determine the infusion rate for an infusion containing dopamine 400 mg in 250 ml of dextrose 5% in water (1,600 mcg/ml).

<table>
<thead>
<tr>
<th>Dosage (mcg/kg/minute)</th>
<th>Patient's weight (kg)</th>
<th>Infusion rate (ml/hour)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>40 45 50 55 60 65 70 75 80 85 90 95 100 105</td>
<td></td>
</tr>
<tr>
<td>0.5</td>
<td>1 1 1 1 1 1 1 1 2 2 2 2 2 2 2</td>
<td></td>
</tr>
<tr>
<td>1.5</td>
<td>2 3 3 3 3 4 4 4 5 5 5 6 6 6 6</td>
<td></td>
</tr>
<tr>
<td>2.5</td>
<td>4 4 5 5 5 6 6 7 7 8 8 8 8 8 8</td>
<td></td>
</tr>
<tr>
<td>5.0</td>
<td>8 8 9 10 11 12 13 14 15 16 17 18 19 20 20</td>
<td></td>
</tr>
<tr>
<td>7.5</td>
<td>11 13 14 15 17 18 20 21 23 24 25 27 28 30 30</td>
<td></td>
</tr>
<tr>
<td>10.0</td>
<td>15 17 19 21 23 24 26 28 30 32 34 36 38 39 39</td>
<td></td>
</tr>
<tr>
<td>12.5</td>
<td>19 21 23 26 28 30 33 35 38 40 42 45 47 49 49</td>
<td></td>
</tr>
<tr>
<td>15.0</td>
<td>23 25 28 31 34 37 39 42 45 48 51 53 56 59 59</td>
<td></td>
</tr>
<tr>
<td>20.0</td>
<td>30 34 38 41 45 49 53 56 60 64 68 71 75 79 79</td>
<td></td>
</tr>
<tr>
<td>25.0</td>
<td>38 42 47 52 56 61 66 70 75 80 84 89 94 98 98</td>
<td></td>
</tr>
<tr>
<td>30.0</td>
<td>45 51 56 62 67 73 79 84 90 96 101 107 113 118 118</td>
<td></td>
</tr>
<tr>
<td>35.0</td>
<td>53 59 66 72 79 85 92 98 105 112 118 125 131 138 138</td>
<td></td>
</tr>
<tr>
<td>40.0</td>
<td>60 68 75 83 90 98 105 113 120 128 135 143 150 158 158</td>
<td></td>
</tr>
<tr>
<td>45.0</td>
<td>68 76 84 93 101 110 118 127 135 143 152 160 169 177</td>
<td></td>
</tr>
<tr>
<td>50.0</td>
<td>75 84 94 103 113 122 131 141 150 159 169 178 188 197</td>
<td></td>
</tr>
</tbody>
</table>

Epinephrine infusion rates
Use this table to determine the rate at which to infuse epinephrine 1 mg in 250 ml of dextrose 5% in water (4 mcg/ml).

<table>
<thead>
<tr>
<th>Dosage (mcg/minute)</th>
<th>Infusion rate (ml/hour)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>15</td>
</tr>
<tr>
<td>2</td>
<td>30</td>
</tr>
<tr>
<td>3</td>
<td>45</td>
</tr>
<tr>
<td>4</td>
<td>60</td>
</tr>
<tr>
<td>5</td>
<td>75</td>
</tr>
<tr>
<td>6</td>
<td>90</td>
</tr>
<tr>
<td>7</td>
<td>105</td>
</tr>
<tr>
<td>8</td>
<td>120</td>
</tr>
<tr>
<td>9</td>
<td>135</td>
</tr>
<tr>
<td>10</td>
<td>150</td>
</tr>
<tr>
<td>15</td>
<td>225</td>
</tr>
</tbody>
</table>
## Nitroglycerin infusion rates

When infusing nitroglycerin, first find the prescribed concentration and then determine the infusion rate in ml/hour.

<table>
<thead>
<tr>
<th>Dosage (mcg/minute)</th>
<th>Nitroglycerin 25 mg/250 ml D5W (100 mcg/ml) Infusion rate (ml/hour)</th>
<th>Nitroglycerin 50 mg/250 ml D5W (200 mcg/ml) Infusion rate (ml/hour)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>10</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td>15</td>
<td>9</td>
<td>5</td>
</tr>
<tr>
<td>20</td>
<td>12</td>
<td>6</td>
</tr>
<tr>
<td>25</td>
<td>15</td>
<td>8</td>
</tr>
<tr>
<td>30</td>
<td>18</td>
<td>9</td>
</tr>
<tr>
<td>40</td>
<td>24</td>
<td>12</td>
</tr>
<tr>
<td>50</td>
<td>30</td>
<td>15</td>
</tr>
<tr>
<td>60</td>
<td>36</td>
<td>18</td>
</tr>
<tr>
<td>70</td>
<td>42</td>
<td>21</td>
</tr>
<tr>
<td>80</td>
<td>48</td>
<td>24</td>
</tr>
<tr>
<td>90</td>
<td>54</td>
<td>27</td>
</tr>
<tr>
<td>100</td>
<td>60</td>
<td>30</td>
</tr>
</tbody>
</table>

**KEY**  
D5W: dextrose 5% in water

## Nitroprusside infusion rates

Using this table, you can determine the infusion rate for an infusion containing nitroprusside 50 mg in 250 ml of dextrose 5% in water (200 mcg/ml).

<table>
<thead>
<tr>
<th>Dosage (mcg/kg/minute)</th>
<th>Patient’s weight (kg)</th>
<th>Infusion rate (ml/hour)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.3</td>
<td>40 45 50 55 60 65 70 75 80 85 90 95 100 105 110</td>
<td>4 4 5 5 5 6 6 7 7 8 8 9 9 9 9</td>
</tr>
<tr>
<td>0.5</td>
<td>6 7 8 8 9 10 11 11 12 13 14 14 15 16 17</td>
<td>12 14 15 17 18 20 21 23 24 26 27 29 30 32 33</td>
</tr>
<tr>
<td>1.0</td>
<td>18 20 23 25 27 29 32 34 36 38 41 43 45 47 50</td>
<td>24 27 30 33 36 39 42 45 48 51 54 57 60 63 66</td>
</tr>
<tr>
<td>1.5</td>
<td>24 27 30 33 36 39 42 45 48 51 54 57 60 63 66</td>
<td>36 41 45 50 54 59 63 68 72 77 81 86 90 95 99</td>
</tr>
<tr>
<td>2.0</td>
<td>48 54 60 66 72 78 84 90 96 102 108 114 120 126 132</td>
<td>50 56 62 68 74 80 86 92 98 104 110 116 122 128 134</td>
</tr>
<tr>
<td>3.0</td>
<td>60 68 75 83 90 98 105 113 120 128 135 143 150 158 165</td>
<td>62 69 76 83 90 98 106 114 122 130 138 146 154 162 170</td>
</tr>
<tr>
<td>4.0</td>
<td>72 81 90 99 108 117 126 135 144 153 162 171 180 189 198</td>
<td>75 84 93 102 111 120 129 138 147 156 165 174 183 192 201</td>
</tr>
<tr>
<td>5.0</td>
<td>84 95 105 116 126 137 147 158 168 179 190 201 212 223 234</td>
<td>88 98 109 120 131 142 153 164 175 186 197 208 219 230 241</td>
</tr>
<tr>
<td>6.0</td>
<td>96 108 120 132 144 156 168 180 192 204 216 228 240 252 264</td>
<td>92 104 116 128 140 152 164 176 188 200 212 224 236 248 260</td>
</tr>
<tr>
<td>7.0</td>
<td>108 122 135 149 162 176 189 203 216 230 243 257 270 284 297</td>
<td>104 118 132 146 160 174 188 202 216 230 244 258 272 286 300</td>
</tr>
<tr>
<td>8.0</td>
<td>120 135 150 165 180 195 210 225 240 255 270 285 300 315 330</td>
<td>116 130 144 158 172 186 200 214 228 242 256 270 285 300 315</td>
</tr>
</tbody>
</table>

(continued)
Drug infusion rates (continued)

**Phenylephrine infusion rates**

Using this table, you can determine the infusion rate for an infusion containing phenylephrine 20 mg in 250 ml of dextrose 5% in water or normal saline solution (80 mcg/ml).

<table>
<thead>
<tr>
<th>Dosage (mcg/minute)</th>
<th>Rate (ml/hour)</th>
<th>Dosage (mcg/minute)</th>
<th>Rate (ml/hour)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>7</td>
<td>25</td>
<td>19</td>
</tr>
<tr>
<td>11</td>
<td>8</td>
<td>27</td>
<td>20</td>
</tr>
<tr>
<td>12</td>
<td>9</td>
<td>29</td>
<td>22</td>
</tr>
<tr>
<td>13</td>
<td>10</td>
<td>32</td>
<td>24</td>
</tr>
<tr>
<td>15</td>
<td>11</td>
<td>35</td>
<td>26</td>
</tr>
<tr>
<td>16</td>
<td>12</td>
<td>37</td>
<td>28</td>
</tr>
<tr>
<td>17</td>
<td>13</td>
<td>40</td>
<td>30</td>
</tr>
<tr>
<td>19</td>
<td>14</td>
<td>43</td>
<td>32</td>
</tr>
<tr>
<td>20</td>
<td>15</td>
<td>45</td>
<td>34</td>
</tr>
<tr>
<td>21</td>
<td>16</td>
<td>48</td>
<td>36</td>
</tr>
<tr>
<td>23</td>
<td>17</td>
<td>51</td>
<td>38</td>
</tr>
<tr>
<td>24</td>
<td>18</td>
<td>53</td>
<td>40</td>
</tr>
</tbody>
</table>
Appendix H: Identifying life-threatening adverse reactions

Identifying life-threatening adverse reactions

Early recognition of a life-threatening adverse drug reaction is a crucial aspect of patient care and safety. This appendix helps you identify life-threatening adverse reactions that are relatively rare or cause symptoms you may not be readily familiar with. Some reactions are potentially lethal from the onset; others can become lethal if they progress.

**Acute pancreatitis**

Inflammation of the pancreas

*Signs and symptoms:* sudden onset of epigastric pain, nausea, and vomiting

**Acute respiratory distress syndrome (ARDS)**

Respiratory insufficiency in which abnormal permeability of the alveolar-capillary membrane causes fluid to fill the alveoli, disrupting gas exchange

*Signs and symptoms:* dyspnea, tachypnea, and progressive hypoxemia despite oxygen therapy; pulmonary edema

**Adrenal suppression**

Condition marked by inhibition of one or more of the enzymes essential to adrenocortical hormone production

*Signs and symptoms:* weakness, fatigue, abdominal pain, appetite and weight loss, dizziness, orthostatic hypotension, increased skin pigmentation

**Adynamic ileus**

Intestinal obstruction caused by a reduction in intestinal motility

*Signs and symptoms:* nausea, vomiting, decreased or absent bowel sounds, abdominal distention

**Agranulocytopenia**

Acute condition caused by deficiencies of neutrophils, basophils, and eosinophils in the blood

*Signs and symptoms:* chills, fever, headache, malaise, weakness, fatigue

**Alkalosis**

Increase in blood alkalinity caused by buildup of alkalis or reduction of acids

*Signs and symptoms:* in metabolic alkalosis—apathy, confusion, stupor (when severe); in respiratory alkalosis—air hunger, muscle twitching, numbness or tingling of extremities or circumoral area

**Amyloidosis**

Metabolic disorder caused by deposition of protein-containing fibrils in tissues, which may attack the heart and blood vessels, brain, kidneys, liver, spleen, intestines, or endocrine glands

*Signs and symptoms:* vary with area of invasion

**Anaphylactoid shock**

Hypersensitivity reaction marked by acute airway obstruction and vascular collapse within minutes of exposure to an antigen

*Signs and symptoms:* edema, rash, tachycardia, hypotension, respiratory distress, seizures, unconsciousness

**Anaphylaxis**

Hypersensitivity reaction to an antigen to which the patient has been previously sensitized, causing sudden release of immunologic mediators either locally or throughout the body

*Signs and symptoms:* urticaria, angioedema, flushing, wheezing, dyspnea, increased mucus production, nausea, vomiting

(continued)
Angioedema
Vascular reaction involving deep dermal, submucosal, or subcutaneous tissues in which capillaries become dilated and more permeable; also called angioneurotic edema
**Signs and symptoms:** edema of skin, mucous membranes, and internal organs; urticaria; giant wheals; respiratory distress

Autoimmune phenomena
Immunologic responses, such as serum sickness, lupus, vasculitis, and hepatitis, associated with development of antibodies (as to a particular drug)
**Signs and symptoms:** possibly none; or signs and symptoms specific to the particular autoimmune condition

Bone marrow depression
Disruption of healthy blood cell development in the bone marrow (including red and white blood cells and platelets), which impairs or weakens the body’s defense against pathogenic organisms, toxins, and irritants
**Signs and symptoms:** increased susceptibility to infection, fever, weakness

Cardiac tamponade
Condition marked by increased cardiac pressure, which inhibits filling of the heart chambers during diastole
**Signs and symptoms:** chest pain, weak peripheral pulses, distended neck veins, dyspnea, orthopnea, diaphoresis, anxiety, restlessness, pallor

Cardiomyopathy
Any disease or disorder of the heart that impairs normal cardiac performance
**Signs and symptoms:** shortness of breath, orthopnea, fatigue, chest pain, syncope

Cardiotoxicity
The quality of being poisonous or harmful to the heart (as with certain drugs)
**Signs and symptoms:** variable cardiac-related symptoms

Cardiovascular collapse
Sudden loss of effective blood flow to body tissues
**Signs and symptoms:** hypotension, vasovagal syncope, cardiogenic shock, cardiac arrest

Cerebral ischemia
Temporary lack of arterial or circulatory blood flow to the brain, possibly causing localized tissue death
**Signs and symptoms:** persistent focal neurologic deficit in the area of distribution of the involved cerebral artery

Chemical arachnoiditis
Inflammation of the arachnoid (middle) layer of the meninges of the brain and spinal cord in response to exposure to a toxic substance
**Signs and symptoms:** mild nausea or vomiting, headache, fever, neck or back pain and stiffness

Cholesterol embolism
Sudden obstruction of a blood vessel by cholesterol-containing plaques
**Signs and symptoms:** hypotension, sudden shortness of breath, weak pulse, cyanosis, chest pain, decreased level of consciousness

Clostridium difficile–associated diarrhea
Antibiotic-associated diarrhea caused by *Clostridium difficile*, a spore-forming, gram-positive, anaerobic bacillus that produces two exotoxins: toxin A and toxin B
**Signs and symptoms:** watery diarrhea, fever, loss of appetite, nausea, abdominal pain, abdominal tenderness, colon perforation, sepsis, and death (rarely)
**Disseminated intravascular coagulation**
Disorder marked by abnormal activation of coagulation factors in the blood, causing hemostasis, thrombosis, and possibly, organ damage
*Signs and symptoms:* bleeding (possibly from multiple sites), hematomas, thrombosis, petechiae, ecchymosis, cutaneous oozing

**Disulfiram-like reaction**
Acute, unpleasant reaction to alcohol ingestion in a patient taking disulfiram (Antabuse) for alcohol aversion therapy
*Signs and symptoms:* flushing, dyspnea, headache, nausea, copious vomiting, blood pressure fluctuations

**Encephalopathy**
Generalized dysfunction of the brain
*Signs and symptoms:* impaired speech, orientation, or cognition; sluggish reaction to stimuli

**Eosinophilic pneumonitis**
Infiltration of pulmonary alveoli by large numbers of eosinophils and mononuclear cells, causing inflammation
*Signs and symptoms:* dyspnea, cough, fever, night sweats, pulmonary edema, weight loss

**Epileptiform seizures**
Sudden, uncontrolled electrical discharge from the cerebral cortex caused by epilepsy
*Signs and symptoms:* variable; may include a cry, a fall, unconsciousness, overt seizure, amnesia, or incontinence

**Erythema multiforme**
Hypersensitivity reaction of the skin and mucous membranes; may take a severe multisystemic form
*Signs and symptoms:* rash, macules, papules, or blisters on the face, palms, and extremities

**Fanconi syndrome**
Congenital form of anemia caused by excessive amino acids in the blood secondary to renal tubular failure
*Signs and symptoms:* polyuria; growth impairment; soft, flexible, brittle bones

**Granulocytopenia**
Abnormal reduction in the number of granulocytes in the blood
*Signs and symptoms:* increased susceptibility to infection

**Heart block**
Interference with the normal electrical impulses of the heart, classified by the level of impairment that results (first-, second-, or third-degree block)
*Signs and symptoms:* prolonged PR interval, widened QRS interval, and delayed or dropped beats on ECG; other symptoms vary with the degree of heart block and may include dizziness, syncope, shortness of breath, fatigue, and orthostatic hypotension

**Hepatomegaly**
Liver enlargement
*Signs and symptoms:* possibly none; or abdominal distention, abdominal pain, and constipation

**Hepatotoxicity**
Liver inflammation caused by exposure to a toxin or a toxic amount of a substance in the body
*Signs and symptoms:* jaundice, fatigue, weakness, altered mental status

**Hyperkalemia**
A condition marked by an excessive amount of potassium in the blood
*Signs and symptoms:* possibly none; with severe hyperkalemia—muscle weakness, arrhythmias
Identifying life-threatening adverse reactions (continued)

Hypertensive crisis
Severe blood pressure elevation, usually defined as diastolic pressure higher than 130 mmHg
**Signs and symptoms:** severe headache, dizziness, light-headedness

Hypertonia
Excessive tension or pressure within a muscle or an artery
**Signs and symptoms:** muscle pain and spasms

Hypervolemia
Abnormal increase in volume of circulating body fluid
**Signs and symptoms:** weight gain, peripheral edema, ascites, dyspnea, pulmonary edema, paroxysmal nocturnal dyspnea

Immune reconstitution syndrome
Enhanced immunologic response, especially during the initial phase of combination antiretroviral treatment, when patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as *Mycobacterium avium* infection, cytomegalovirus, *Pneumocystis jirovecii* pneumonia, or tuberculosis).
**Signs and symptoms:** possibly nonspecific, including new or worsening fever, persistent or cyclic fever, new pleural effusions, new or worsening lymphadenopathy, fatigue, weakness, night sweats, anorexia, weight loss, chronic diarrhea, abdominal pain, and vulnerability to infection

Impaired myocardial contractility
Decreased contractile ability of the middle layer of the heart muscle wall
**Signs and symptoms:** shortness of breath, chest pain, edema

Increased intracranial pressure
Increased pressure within the brain, as from increased cerebrospinal fluid pressure or a brain lesion or swelling; also called intracranial hypertension
**Signs and symptoms:** in infants—bulging fontanel, separated sutures, lethargy, vomiting; in older children and adults—lethargy, vomiting, headache, behavior changes, seizures, neurologic deficits, progressive decrease in level of consciousness

Interstitial pneumonia
Chronic, noninfectious inflammation of the pulmonary alveolar walls
**Signs and symptoms:** shortness of breath, either with activity or at rest

Ischemic colitis
Inflammation of the colon caused by lack of blood supply to mesenteric arteries of the small intestine
**Signs and symptoms:** abdominal pain, weight loss

Lactic acidosis
Accumulation of lactic acid in the blood caused by reduced oxygenation and perfusion to tissues, muscles, and major organs
**Signs and symptoms:** muscle pain, fatigue, hyperventilation, nausea, vomiting, dizziness, light-headedness

Leukocytosis
Abnormal increase in the number of white blood cells (leukocytes) in the blood
**Signs and symptoms:** fever, hemorrhage

Leukopenia
Abnormal reduction (below 5,000 cells/mm^3) in circulating white blood cells, as from drug-induced impairment of blood cell production
**Signs and symptoms:** infection, fever, stomatitis, sinusitis
Lupuslike syndrome
A syndrome similar to systemic lupus erythematosus that occurs in response to drug therapy and resolves when the drug is withdrawn
*Signs and symptoms*: fever; red, scaly, macular skin rash; joint inflammation

Lupus nephritis
Kidney inflammation associated with systemic lupus erythematosus (SLE), marked by deposition of antigen-antibody complexes in the mesangium and basement membrane
*Signs and symptoms*: hypertension, peripheral edema, proteinuria, renal failure, cardiac decompensation, other symptoms of active SLE (such as fatigue, fever, rash, arthritis, CNS disease)

Megaloblastic anemia
Anemia marked by production and proliferation of megaloblasts (large immature red blood cells) in the bone marrow or circulation
*Signs and symptoms*: weakness, fatigue, light-headedness, headache, rapid pulse, breathlessness

Metabolic acidosis
Increase in blood acidity caused by buildup of acids or loss of bicarbonate
*Signs and symptoms*: lethargy, drowsiness, headache, diminished muscle tone and reflexes, hyperventilation, arrhythmias, nausea, vomiting, diarrhea, abdominal pain

Methemoglobinemia
Condition in which a portion of the iron component of hemoglobin has been oxidized to the ferric state, making it incapable of transporting oxygen
*Signs and symptoms*: cyanosis, dizziness, drowsiness, headache

Neoplasm
Abnormal growth of new tissue, such as a tumor
*Signs and symptoms*: vary with tumor site

Nephrotoxicity
The quality of causing damage to the kidney (as from a drug); usually leads to increased permeability to proteins, which results in edema and hypoalbuminemia
*Signs and symptoms*: proteinuria, hematuria, fluid retention

Neuroleptic malignant syndrome
Reaction to a drug that alters the brain’s dopamine level or to withdrawal of a drug that increases the dopamine level
*Signs and symptoms*: sweating, altered mental status, seizures, renal failure

Neutropenia
Abnormal decrease in the level of neutrophils in the blood (usually below 1,500 per µL)
*Signs and symptoms*: infection, fever, mouth and throat sores

Osmotic nephrosis
Disruption of osmotic pressure in the kidney’s renal tubule
*Signs and symptoms*: fluid retention, edema

Pancytopenia
Deficiency of all cellular elements of the blood, including red blood cells, white blood cells, and platelets
*Signs and symptoms*: bleeding from the nose and gums, easy bruising, fatigue, shortness of breath

Papilledema
Swelling and inflammation of the optic nerve
*Signs and symptoms*: severe headache, visual disturbances, blindness

Pericardial effusion
Escape of fluid from blood vessels into the pericardium
*Signs and symptoms*: hypotension, tachycardia, muffled heart sounds, decreased breath sounds, distended jugular vein, pulsus paradoxus, widened pulse pressure, weak peripheral pulses, pericardial friction rub, tachypnea, edema, cyanosis

(continued)
Appendix H: Identifying life-threatening adverse reactions

Pseudomembranous colitis
Condition in which an inflammatory exudate forms on epithelial tissues of the colon
**Signs and symptoms:** diarrhea with blood and mucus, abdominal cramps

Pseudotumor cerebri
Benign intracranial hypertension without evidence of a brain tumor
**Signs and symptoms:** headache, papilledema, elevated cerebrospinal fluid pressure

Pulmonary toxicity
The quality of causing damage to the lungs and alveoli (as from certain drugs)
**Signs and symptoms:** any respiratory sign or symptom

Renal acidosis
Acidosis caused by accumulation of phosphoric and sulfuric acids in the body, which the kidneys fail to excrete
**Signs and symptoms:** appetite loss, altered level of consciousness, altered respiratory rate or effort

Renal failure
Condition marked by a serum creatinine increase of 25% or more, which impairs the kidney's ability to excrete wastes, concentrated urine, and conserve electrolytes
**Signs and symptoms:** dehydration, fluid overload, altered neurologic status, appetite loss, weight gain, bleeding

Respiratory acidosis
Acidosis resulting from accumulation and retention of carbon dioxide in the lungs
**Signs and symptoms:** dyspnea, diaphoresis, tremors, decreased reflexes, decreased level of consciousness

Rhabdomyolysis
Acute disorder in which byproducts of skeletal muscle destruction accumulate in the renal tubules, causing renal failure
**Signs and symptoms:** See “Hyperkalemia” and “Metabolic acidosis.”

Salicylate toxicity
Toxic condition caused by overdose of a salicylate, such as aspirin or an aspirin derivative
**Signs and symptoms:** rapid breathing, irritability, headache, vomiting, and (if extreme) seizures and respiratory failure

Sarcoidosis
Multisystemic disease that causes granulomatous lesions of organs or tissues throughout the body
**Signs and symptoms:** fatigue, weight loss, shortness of breath, anorexia, skin lesions, cough, skeletal changes (in later stages)

Sepsis
Systemic inflammatory response caused by pathogenic microorganisms or their toxins
**Signs and symptoms:** tachycardia, fever, rapid breathing, hypothermia, evidence of reduced blood flow to major organs

Serum sickness
Hypersensitivity reaction to administration of a nonprotein drug
**Signs and symptoms:** fever, rash, joint pain, edema, lymphadenopathy

Steatosis
Fatty liver degeneration
**Signs and symptoms:** possibly none; or right upper abdominal quadrant pain, abdominal discomfort, fatigue, malaise

Stevens-Johnson syndrome
Severe allergic reaction marked by severe skin and mucous membrane lesions, most often in response to a drug
**Signs and symptoms:** respiratory tract infection, fever, sore throat, chills, headache, malaise, vomiting, diarrhea, tachycardia, hypotension, corneal ulcers, conjunctivitis, epistaxis, dysuria, erosive vulvovaginitis, balanitis, seizures, altered level of consciousness, coma
Syndrome of inappropriate antidiuretic hormone secretion
Metabolic disturbance marked by an increase in antidiuretic hormone, which causes a decrease in serum sodium concentration
**Signs and symptoms:** weakness, fatigue, malaise, headache, altered mental status, lethargy, irritability, delirium, psychosis, personality changes, anorexia, nausea, vomiting, thirst, abdominal and muscle cramps

Tardive dyskinesia
Disorder marked by slow, rhythmic involuntary movements of the face, limbs, and torso in patients who have received long-term dopaminergic antagonist therapy
**Signs and symptoms:** involuntary, repetitive facial grimacing and twisting; tongue protrusion; lip puckering and smacking; chewing or sucking motions; involuntary, snakelike writhing movements (such as wiggling or twisting); excessive blinking; involuntary flexion and extension movements of the fingers and hands

Tetany
Hyperexcitability of nerves and muscles caused by a decrease in extracellular calcium
**Signs and symptoms:** muscle twitching, cramps, sharp flexion of wrist and ankle joints, seizures

Thrombocytopenia
Abnormal decrease in the number of platelets caused by destruction of erythroid tissue in the bone marrow
**Signs and symptoms:** purpura, ecchymosis, petechiae, internal hemorrhage, hematuria, abdominal distention, melena

Torsade de pointes
Rapid form of ventricular tachycardia that appears as twisting or shifting QRS complexes on the ECG
**Signs and symptoms:** pallor, diaphoresis, rapid pulse, low or normal blood pressure, transient or prolonged loss of consciousness

Toxic epidermal necrolysis
Exfoliative skin condition that represents a severe cutaneous reaction (as to a drug, infection, or chemical exposure)
**Signs and symptoms:** scalded appearance of the skin, skin erosion and redness

Tumor lysis syndrome
Complication that usually follows chemotherapy treatment of myelolymphoproliferative diseases in which a metabolic derangement produced by rapid tumor breakdown is a consequence of therapy
**Signs and symptoms:** possibly no symptoms in early stages, but progression of the syndrome may lead to cardiac arrhythmias, shortness of breath, hyperkalemia, hyperuricemia, hyperphosphatemia, hypocalcemia, impaired mental ability, and renal failure

Withdrawal phenomena
Physiologic changes caused by discontinuation of a drug or alcohol after prolonged use
**Signs and symptoms:** vary with type of substance used. In opioid withdrawal—rapid pulse and breathing, runny nose, yawning, restlessness, insomnia, fatigue, pupil dilation, nausea, vomiting, diarrhea, abdominal cramps, weakness, muscle aches, joint pain, hot and cold flushes. In benzodiazepine withdrawal—headache; aches and pains; anxiety; sleep disturbances; feelings of unreality; impaired memory; palpitations; hypersensitivity to noise, light, and touch.
Potentially inappropriate drugs for elderly patients

Drug-drug interactions can have potentially life-threatening consequences in older adults, who often take several drugs at once for multiple diseases. Elderly patients are more susceptible to drug interactions than younger patients because of the physiologic changes associated with aging and the sheer number of drugs older patients are taking. Beers criteria, originally published in the *Archives of Internal Medicine* in 1991, with updated articles in 1997 and again in 2003, identified several drugs that adults ages 65 and older should avoid. This list is based on those criteria.

<table>
<thead>
<tr>
<th>Generic drug or class</th>
<th>Brand names</th>
</tr>
</thead>
<tbody>
<tr>
<td>alprazolam</td>
<td>Niravam, Xanax (&gt; 2 mg), Xanax X</td>
</tr>
<tr>
<td>amiodarone hydrochloride</td>
<td>Cordarone, Pacerone</td>
</tr>
<tr>
<td>amitriptyline hydrochloride</td>
<td></td>
</tr>
<tr>
<td>amphetamines (excluding methylphenidate and anorexics)</td>
<td>Adderall, Adderall XR, Desoxyn, Dexedrine, DextroStat, Liquadd</td>
</tr>
<tr>
<td>anorexics</td>
<td>Adipex-P, Bontril, Bontril PDM, Didrex, Meridia, Pro-Fast HS, Pro-Fast SA</td>
</tr>
<tr>
<td>barbiturates (except phenobarbital for seizure control)</td>
<td>Butisol Sodium, Mebaral, Seconal Sodium</td>
</tr>
<tr>
<td>belladonna alkaloids</td>
<td>Donnatal</td>
</tr>
<tr>
<td>carisoprodol</td>
<td>Soma</td>
</tr>
<tr>
<td>chlordiazepoxide hydrochloride</td>
<td>Librium</td>
</tr>
<tr>
<td>chlordiazepoxide and amtriptyline chlordiazepoxide hydrochloride and clidinium bromide</td>
<td>Limbitrol, Limbitrol DS Librax</td>
</tr>
<tr>
<td>chlorpheniramine maleate</td>
<td>Ahist, Aller-Chlor, Chlorphen, Chlor-Trimeton, CPM-12, Diabetic Tussin Allergy Relief, QDALL AR, Teldrin HBP</td>
</tr>
<tr>
<td>chlorpropamide</td>
<td>Diabenese</td>
</tr>
<tr>
<td>chlorzoxazone</td>
<td>Parafon Forte DSC</td>
</tr>
<tr>
<td>cimetidine</td>
<td>Tagamet, Tagamet HB 200</td>
</tr>
<tr>
<td>clonidine hydrochloride</td>
<td>Catapres, Catapres-TTS, Duraclon</td>
</tr>
<tr>
<td>clorazepate</td>
<td>Tranxene</td>
</tr>
<tr>
<td>cyclobenzaprine hydrochloride</td>
<td>Amrix, Fexmid, Flexeril</td>
</tr>
<tr>
<td>cyproheptadine hydrochloride</td>
<td></td>
</tr>
<tr>
<td>dextchlorpheniramine</td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Alternative Names</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>--------------------------------------------------------</td>
</tr>
<tr>
<td>Diazepam</td>
<td>Valium</td>
</tr>
<tr>
<td>Dicyclomine</td>
<td>Bentyl</td>
</tr>
<tr>
<td>Digoxin</td>
<td>Digitek, Lanoxin (&gt; 0.125 mg/day except when treating atrial arrhythmias)</td>
</tr>
<tr>
<td>Diphenhydramine hydrochloride</td>
<td>Aler-Cap, Aler-Dryl, Aler-Tab, AlerMax, Altaryl, Banophen, Benadryl, Compoz, Diphen, Diphenhist, Genahist, Hydramine, Nytol, Siladryl, Silphen, Simply Sleep, Sleep-ettes D, Sleepinal, Sominex, Twilite, Unisom</td>
</tr>
<tr>
<td>Dipyridamole</td>
<td>Persantine</td>
</tr>
<tr>
<td>Disopyramide</td>
<td>Norpace, Norpace CR</td>
</tr>
<tr>
<td>Doxazosin mesylate</td>
<td>Cardura, Cardura XR</td>
</tr>
<tr>
<td>Doxepin hydrochloride</td>
<td></td>
</tr>
<tr>
<td>Ergot mesyloids</td>
<td></td>
</tr>
<tr>
<td>Estrogens (in older women)</td>
<td>Cenestin, Enjuvia, Premarin</td>
</tr>
<tr>
<td>Ethacrynic acid</td>
<td>Edecrin</td>
</tr>
<tr>
<td>Ferrous sulfate (&gt; 325 mg/day)</td>
<td>Feosol, Feratab, Fer-Gen-Sol, Fer-In-Sol, Fer-Iron, Slow FE</td>
</tr>
<tr>
<td>Fluoxetine hydrochloride (daily)</td>
<td>Prozac, Sarafem, Selfemra</td>
</tr>
<tr>
<td>Flurazepam hydrochloride</td>
<td>Dalmane</td>
</tr>
<tr>
<td>Hydroxyzine</td>
<td>Atarax, Vistaril</td>
</tr>
<tr>
<td>Hyoscyamine sulfate</td>
<td>Levsin</td>
</tr>
<tr>
<td>Indomethacin</td>
<td>Indocin, Indocin SR</td>
</tr>
<tr>
<td>Isoxsuprinal</td>
<td></td>
</tr>
<tr>
<td>Ketorolact tromethamine</td>
<td></td>
</tr>
<tr>
<td>Lorazepam</td>
<td>Ativan (&gt; 3 mg)</td>
</tr>
<tr>
<td>Meperidine hydrochloride</td>
<td>Demerol</td>
</tr>
<tr>
<td>Meprobamate</td>
<td></td>
</tr>
<tr>
<td>Metaxalone</td>
<td>Skelaxin</td>
</tr>
<tr>
<td>Methocarbamol</td>
<td>Robaxin</td>
</tr>
<tr>
<td>Methyldopa</td>
<td></td>
</tr>
<tr>
<td>Methyldopa and hydrochlorothiazide</td>
<td></td>
</tr>
<tr>
<td>Methyltestosterone</td>
<td>Android, Methitest, Testred, Virilon</td>
</tr>
<tr>
<td>Mineral oil</td>
<td></td>
</tr>
<tr>
<td>Nifedipine (short-acting)</td>
<td>Procardia</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Brand Names</th>
</tr>
</thead>
<tbody>
<tr>
<td>nitrofurantoin</td>
<td>Furadantin, Macrobid, Macrobid</td>
</tr>
<tr>
<td>non–COX-selective NSAIDs (long-term use of full dose):</td>
<td></td>
</tr>
<tr>
<td>naproxen</td>
<td>Aleve, Anaprox, Naprosyn</td>
</tr>
<tr>
<td>oxaprozin</td>
<td>Daypro</td>
</tr>
<tr>
<td>piroxicam</td>
<td>Feldene</td>
</tr>
<tr>
<td>orphenadrine</td>
<td>Norflex</td>
</tr>
<tr>
<td>oxazepram</td>
<td>Serax (&gt; 60 mg)</td>
</tr>
<tr>
<td>oxybutynin chloride</td>
<td>Ditropan, Ditropan XL</td>
</tr>
<tr>
<td>pentoxyfylline</td>
<td>Talwin</td>
</tr>
<tr>
<td>perphenazine and amitriptyline</td>
<td></td>
</tr>
<tr>
<td>promethazine hydrochloride</td>
<td>Phenadoz, Phenergan, Promethagan</td>
</tr>
<tr>
<td>propantheline bromide</td>
<td>Pro-Banthine</td>
</tr>
<tr>
<td>propoxyphene and combination products</td>
<td>Darvocet-N, Darvon, Darvon-N</td>
</tr>
<tr>
<td>quazepam</td>
<td>Doral</td>
</tr>
<tr>
<td>reserpine (dosages &gt; 0.25 mg)</td>
<td></td>
</tr>
<tr>
<td>stimulant laxatives (except when used for chronic pain requiring opioid analgesics):</td>
<td>Dulcolax</td>
</tr>
<tr>
<td>bisacodyl</td>
<td></td>
</tr>
<tr>
<td>temazepam</td>
<td>Restoril (&gt; 15 mg)</td>
</tr>
<tr>
<td>Thiocyanate</td>
<td></td>
</tr>
<tr>
<td>thyroxine, desiccated</td>
<td>Armour Thyroid, Nature-Throid, Westhroid</td>
</tr>
<tr>
<td>ticlopidine hydrochloride</td>
<td>Ticlid</td>
</tr>
<tr>
<td>Triazolam</td>
<td>Halcion (&gt; 0.25 mg)</td>
</tr>
<tr>
<td>trimethobenzamide hydrochloride</td>
<td>Tigan</td>
</tr>
</tbody>
</table>
Hazardous drugs

The drugs listed below have been designated as hazardous by the National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, and/or the American Society of Health-System Pharmacists. The list doesn't include all hazardous drugs. The agents listed here meet one or more of the following criteria: carcinogenicity, teratogenicity or other developmental toxicity, reproductive toxicity, organ toxicity at low doses, genotoxicity, or structure and toxicity profiles that mimic existing drugs determined to be hazardous by the above criteria. All healthcare workers handling these drugs must follow appropriate precautions along with recommendations included in the manufacturer’s complete package insert.

Aldesleukin
Alemtuzumab
Alitretinoin
Altretamine
Amifostine
Aminoglutethimide
Amsacrine
Anastrozole
Arsenic trioxide
Asparaginase
Azacitidine
Azathioprine
Bacillus Calmette-Guerin vaccine
Bendamustine hydrochloride
Bexarotene
Bicalutamide
Bleomycin
Bortezomib
Busulfan
Capecitabine
Carboplatin
Carmustine
Cetrorelix acetate
Chlorambucil
Chloramphenicol
Chlorotrianisene
Chlorozotocin
Choriogonadotropin alfa
Cidofovir
Cisplatin
Cladribine
Clofarabine
Colchicine
Cyclophosphamide
Cyclosporine
Cytrabine
Dacarbazine
Dactinomycin
Dasatinib
Daunorubicin HCl
Denileukin
Dienestrol
Diethylstilbestrol
Dinoprostone
Docetaxel
Doxorubicin
Dutasteride
Epirubicin
Ergonovine/methylergonovine
Estradiol
Estramustine phosphate sodium
Estrogen-progestin combinations
Estrogens, conjugated
Estrogens, esterified
Estrone
Estropipate
Ethiny estradiol
Etoposide
Exemestane
Finasteride
Flouxuridine
Fludarabine
Fluorouracil
Fluoxymesterone
Flutamide
Fulvestrant
Ganciclovir
Ganirelix acetate
Gemcitabine
Gemtuzumab ozogamicin
Hazardous drugs (continued)

Gonadotropin, chorionic
Goserelin
Hydroxyurea
Ibritumomab tiuxetan
Idarubicin
Ifosfamide
Imatinib mesylate
Interferon alfa-2a
Interferon alfa-2b
Interferon alfa-n1
Interferon alfa-n3
Irinotecan HCl
Isotretinoin
Leflunomide
Lenalidomide
Letrozole
Leuprolide acetate
Levamisole
Lomustine
Mechlorethamine
Medroxyprogesterone
Megestrol
Melphalan
Menotropins
Mercaptopurine
Methotrexate
Methyltestosterone
Mifepristone
Mitomycin
Mitotane
Mitoxantrone HCl
Myocophenolate mofetil
Nafarelin
Nilotinib
Nilutamide
Oxaliplatin
Oxytocin
Paclitaxel
Pegasparagase
Pentamidine isethionate

Pentostatin
Perphosphamidate
Pipobroman
Pirritrexim isethionate
Plicamycin
Podofilox
Podophyllum resin
Prednimustine
Procabazine
Progesterone
Progestins
Raloxifene
Raltitrexed
Ribavirin
Streptozocin
Tacrolimus
Tamoxifen
Temozolomide
Teniposide
Testolactone
Testosterone
Thalidomide
Thioguanine
Thiotepa
Topotecan
Toremifene citrate
Tositumomab
Tretinoin
Trifluridine
Trimetrexate glucuronate
Triptorelin
Uracil mustard
Valganciclovir
Valrubycin
Vidarabine
Vindesine
Vinblastine sulfate
Vincristine sulfate
Vindesine
Vinorelbine tartrate
Zidovudine
Most commonly used drugs in nursing specialties

Nurses are often required to float to units in which they’re not accustomed to working, where they might have to administer unfamiliar drugs. If you know ahead of time which drugs are most commonly used in the various nursing specialties, you’ll be able to increase your confidence—and reduce the chance of making a drug error. The table below shows the 10 most commonly used drugs in nine nursing specialties.

<table>
<thead>
<tr>
<th>Specialty</th>
<th>Top 10 drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Critical care nursing</td>
<td>amiodarone hydrochloride, diltiazem hydrochloride, dopamine hydrochloride, epinephrine hydrochloride, furosemide, insulin, lorazepam, morphine sulfate, nitroglycerin, propofol</td>
</tr>
<tr>
<td>Emergency care nursing</td>
<td>acetaminophen, aspirin, diltiazem hydrochloride, diphtheria and tetanus toxoids, famotidine, ibuprofen, ketorolac, levofloxacin, metoclopramide, nitroglycerin</td>
</tr>
<tr>
<td>Home care nursing</td>
<td>acetaminophen, acetaminophen/oxycodone, acetaminophen/prophyxphene napsylate, digoxin, diltiazem hydrochloride, docusate sodium, furosemide, metformin hydrochloride, potassium chloride, warfarin</td>
</tr>
<tr>
<td>Long-term care nursing</td>
<td>carbidopa/levodopa, digoxin, docusate sodium, donepezil hydrochloride, enalapril maleate, furosemide, metoprolol tartrate, mirtazapine, pantoprazole sodium, potassium chloride</td>
</tr>
<tr>
<td>Medical-surgical nursing</td>
<td>acetaminophen, diltiazem hydrochloride (continued)</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Specialty</th>
<th>Top 10 drugs</th>
</tr>
</thead>
</table>
| Medical-surgical nursing (continued) | enalapril maleate  
furosemide  
heparin sodium  
insulin  
levofloxacin  
morphine sulfate  
metoprolol tartrate  
potassium chloride |
| Obstetric nursing               | acetaminophen/codeine  
acetaminophen/oxycodone  
dinoprostone  
ibuprofen  
magnesium sulfate  
nalbuphine hydrochloride  
oxycodone  
penicillin  
promethazine hydrochloride  
terbutaline sulfate |
| Pediatric nursing               | albuterol  
amoxicillin/clavulanate potassium  
amoxicillin trihydrate  
cetirizine hydrochloride  
co-trimoxazole  
fluticasone propionate  
gentamicin sulfate  
hydrocortisone (topical)  
methylphenidate hydrochloride  
midazolam hydrochloride  
morphine sulfate  
ondansetron hydrochloride |
| Post-anesthesia care nursing    | bupivacaine hydrochloride  
fentanyl citrate  
hydromorphone hydrochloride  
lidocaine hydrochloride  
lorazepam  
meperidine hydrochloride  
methadone hydrochloride  
midazolam hydrochloride  
morphine sulfate  
ondansetron hydrochloride |
| Psychiatric nursing             | carbamazepine  
clonazepam  
divalproex sodium  
escitalopram oxalate  
lithium carbonate  
olanzapine  
paroxetine hydrochloride  
risperidone  
sertaline hydrochloride  
venlafaxine hydrochloride |
## Top 200 most commonly prescribed drugs

The table below lists the top 200 drugs ranked by the number of prescriptions sold in the United States in 2007.

| 1. Lipitor | 37. Lyrica |
| 2. Nexium  | 38. Wellbutrin XL |
| 3. Advair Diskus | 39. Aricept |
| 4. Prevacid  | 40. Imitrex Oral |
| 5. Plavix   | 41. Ambien |
| 6. Singulair | 42. Lotrel |
| 7. Seroquel  | 43. Nasonex |
| 8. Effexor XR| 44. Toprol XL |
| 9. Lexapro  | 45. Ambien CR |
| 10. Actos   | 46. Enbrel |
| 11. Protonix| 47. Spiriva |
| 12. Vytorin | 48. Viagra |
| 13. Topamax | 49. Lidoderm |
| 14. Risperdal| 50. Actonel |
| 15. Abilify | 51. Chantix |
| 16. Cymbalta | 52. Norvasc |
| 17. Lamictal | 53. Lovenox |
| 18. Zyprexa | 54. Provigil |
| 19. Levaquin | 55. Lunesta |
| 20. Celebrex| 56. Altace |
| 22. Valtrex | 58. Geodon Oral |
| 23. Crestor | 59. Cozaar |
| 24. Fosamax | 60. Detrol LA |
| 25. Zyrtec  | 61. Atripla |
| 26. Lantus  | 62. Truvada |
| 27. Adderall XR | 63. CellCept |
| 28. Diovan | 64. Pulmicort Respules |
| 29. Avandia | 65. Humalog |
| 30. Tricor  | 66. Depakote ER |
| 31. Aciphex | 67. Depakote |
| 32. Diovan HCT | 68. Premarin Tabs |
| 33. OxyContin | 69. Synthroid |
| 34. Concerta | 70. Niaspan |
| 35. Coreg  | 71. Byetta |
| 36. Flomax  | 72. Budeprion XL |

(continued)
### Top 200 most commonly prescribed drugs (continued)

<table>
<thead>
<tr>
<th>73.</th>
<th>Strattera</th>
<th>111.</th>
<th>Duragesic</th>
</tr>
</thead>
<tbody>
<tr>
<td>74.</td>
<td>Combivent</td>
<td>112.</td>
<td>Copaxone</td>
</tr>
<tr>
<td>75.</td>
<td>Trileptal</td>
<td>113.</td>
<td>RenaGel</td>
</tr>
<tr>
<td>76.</td>
<td>Yasmin 28</td>
<td>114.</td>
<td>Femara</td>
</tr>
<tr>
<td>77.</td>
<td>Flovent HFA</td>
<td>115.</td>
<td>Enbrel Sureclick</td>
</tr>
<tr>
<td>78.</td>
<td>Skelaxin</td>
<td>116.</td>
<td>NovoLog Mix 70/30</td>
</tr>
<tr>
<td>79.</td>
<td>Prograf</td>
<td>117.</td>
<td>Clarinex</td>
</tr>
<tr>
<td>80.</td>
<td>Arimidex</td>
<td>118.</td>
<td>Aldara</td>
</tr>
<tr>
<td>81.</td>
<td>Evista</td>
<td>119.</td>
<td>Forteo</td>
</tr>
<tr>
<td>82.</td>
<td>Hyzaar</td>
<td>120.</td>
<td>Suboxone</td>
</tr>
<tr>
<td>83.</td>
<td>Namenda</td>
<td>121.</td>
<td>Avodart</td>
</tr>
<tr>
<td>84.</td>
<td>Januvia</td>
<td>122.</td>
<td>Paxil CR</td>
</tr>
<tr>
<td>85.</td>
<td>Humira</td>
<td>123.</td>
<td>Norvir</td>
</tr>
<tr>
<td>86.</td>
<td>Cialis</td>
<td>124.</td>
<td>Avandamet</td>
</tr>
<tr>
<td>87.</td>
<td>Reyataz</td>
<td>125.</td>
<td>Restasis</td>
</tr>
<tr>
<td>88.</td>
<td>Xalatan</td>
<td>126.</td>
<td>Avonex</td>
</tr>
<tr>
<td>89.</td>
<td>Omnichic</td>
<td>127.</td>
<td>Sensipar</td>
</tr>
<tr>
<td>90.</td>
<td>Avelox</td>
<td>128.</td>
<td>Tarceva</td>
</tr>
<tr>
<td>91.</td>
<td>ProAir HFA</td>
<td>129.</td>
<td>Patanol</td>
</tr>
<tr>
<td>92.</td>
<td>Asacol</td>
<td>130.</td>
<td>Yaz .254</td>
</tr>
<tr>
<td>93.</td>
<td>Benicar HCT</td>
<td>131.</td>
<td>Lovaza</td>
</tr>
<tr>
<td>94.</td>
<td>Fentanyl Oral Citra</td>
<td>132.</td>
<td>Mirapex</td>
</tr>
<tr>
<td>95.</td>
<td>Requip</td>
<td>133.</td>
<td>Focalin XR</td>
</tr>
<tr>
<td>96.</td>
<td>Boniva</td>
<td>134.</td>
<td>Cosopt</td>
</tr>
<tr>
<td>97.</td>
<td>Caduet</td>
<td>135.</td>
<td>Zyvox</td>
</tr>
<tr>
<td>98.</td>
<td>Avapro</td>
<td>136.</td>
<td>Epzicom</td>
</tr>
<tr>
<td>99.</td>
<td>Gleevec</td>
<td>137.</td>
<td>NuvaRing</td>
</tr>
<tr>
<td>100.</td>
<td>Kaletra</td>
<td>138.</td>
<td>Actiq</td>
</tr>
<tr>
<td>101.</td>
<td>Ortho Tri-Cyclen Lo</td>
<td>139.</td>
<td>Fosamax Plus D</td>
</tr>
<tr>
<td>102.</td>
<td>Benicar</td>
<td>140.</td>
<td>Actoplus Met</td>
</tr>
<tr>
<td>103.</td>
<td>AndroGel</td>
<td>141.</td>
<td>Lumigan</td>
</tr>
<tr>
<td>104.</td>
<td>Xopenex</td>
<td>142.</td>
<td>Rhinocort Aqua</td>
</tr>
<tr>
<td>105.</td>
<td>Procrit</td>
<td>143.</td>
<td>Solodyn</td>
</tr>
<tr>
<td>106.</td>
<td>Lamisil Oral</td>
<td>144.</td>
<td>Thalomid</td>
</tr>
<tr>
<td>107.</td>
<td>Avalide</td>
<td>145.</td>
<td>Fuzeon</td>
</tr>
<tr>
<td>108.</td>
<td>Nasacort AQ</td>
<td>146.</td>
<td>Astelin</td>
</tr>
<tr>
<td>110.</td>
<td>Allegra-D 12 Hour</td>
<td>148.</td>
<td>Relpax</td>
</tr>
</tbody>
</table>

(continued)
149. Viread  
150. Casodex  
151. Vigamox  
152. Vesicare  
153. Humalog Mix 75/25  
154. Trizivir  
155. Budeprion SR  
156. Xeloda  
157. Sustiva  
158. Levitra  
159. Endocet  
160. Risperdal Consta  
161. Aggrenox  
162. Humira Pen  
163. Kadian  
164. Differin  
165. Catapres-TTS  
166. Alphagan P  
167. Tussionex  
168. Zyrtec Syrup  
169. Maxalt  
170. Zoloft  
171. Prilosec  
172. Ciprodex Otic  
173. Temodar  
174. Tobradex  
175. Zyrtec-D  
176. Welchol  
177. Maxalt MLT  
178. Asmanex  
179. Atacand  
180. Coumadin Tabs  
181. Dovonex  
182. Klor-Con  
183. Pegasys  
184. Ultram ER  
185. Betaseron  
186. Zovirax Topical  
187. Trinessa  
188. Pulmozyme  
189. Neupogen  
190. Humulin N  
191. Micardis HCT  
192. Ortho Evra  
193. Allegra-D 24 Hour  
194. Fentora  
195. Enablex  
196. Famvir  
197. Avinza  
198. Prempro  
199. Coreg CR  
200. Marinol

Source: Verispan, VONA
Selected references

Publications


Selected references


Websites
American Heart Association: www.americanheart.org
Centers for Disease Control and Prevention (hepatitis C information): www.cdc.gov/mmwr/preview/mmwrhtml/rr5203a1.htm
Centers for Disease Control and Prevention (immunization schedules): www.cdc.gov/vaccines/recs/schedules; www.cdc.gov/mmwr/PDF/wk/mm5451-Immunization.pdf
Drugs.com (drug information): www.drugs.com
Drugs@FDA (catalog of FDA-approved drugs): www.accessdata.fda.gov/scripts/cder/drugsatfda
Health Canada (Canadian drug product database): www.hc-sc.gc.ca/hpb/drugs-dpd
Institute for Safe Medication Practices: www.ismp.org
RxList (drug information): www.rxlist.com
U.S. Pharmacopeia: www.usp.org
A
abacavir sulfate, 3–4
abacavir sulfate and lamivudine, 4–6
abatacept, 6–7
Abbreviations, dangerous, xvi
abciximab, 7–9
Abdominal cramping, bismuth for, 143
Abdominal distention, neostigmine for, 813
Abdominal infection. See Intra-abdominal infection.
Abelcet, 80
Abenol, 14
Abilify, 102, P2
Abortion
dinoprostone for, 355
mifepristone for, 762
oxytocin for, 878
Academia
acitretin, 24–26
Aclasta, 1247
Acne
clindamycin for, 264
erythromycin for, 424
minocycline for, 765
sulfacetamide for, 1105
tetracycline for, 1142, 1143
tretinoin for, 1193
Acova, 100
Acquired immunodeficiency syndrome. See Human immunodeficiency virus infection.
Acromegaly
bromocriptine for, 154
octreotide for, 848
pegvisomant for, 901
Actidose, 26
Actidose-Aqua, 26
Actifed, 1342
Actilyse, 52
Actimmune, 604
Actinomycosis, penicillin G potassium for, 906
Acute coronary syndrome
clotidogrel for, 273, 274
eptifibatide for, 418
tirofiban for, 1169
treatment guidelines for, S24–S25
Acute intermittent porphyria, chlorpromazine for, 241
Acute lymphoblastic leukemia
clofarabine for, 265
imatinib for, 573
mercaptopurine for, 714
methotrexate for, 732
nelarabine for, 808
pegaspargase for, 894
Acute lymphocytic leukemia
sargramostim for, 1065
Acute myelogenous leukemia
sargramostim for, 106
Acute myeloid leukemia
idarubicin for, 570
Acute myeloid leukemia
Idarubicin for, 570
Acute promyelocytic leukemia
tretinoin for, 1193
Acute respiratory distress syndrome, 1357
Acute rheumatic carditis, triamcinolone for, 1196
acyclovir, 27–29
acyclovir sodium, 27–29
Acyclovir, 27–29
Acular, 625
Acular LS, 625
Acular RT-PA, 52
Activated charcoal, 26–27
Activated charcoal, 26–27 for calcium channel blockers overdose, S30
Actinomycin, penicillin G potassium for, 906
Actiprofen Caplets, 566
Actiq, 464, 1332–1333t
Activase, 52
Activase rt-PA, 52
Acetaminoen overdose, acetacylestrie for, 19, S30
Acetaminophen with Codeine, P5
Acetazolamide, 16
Acetazolam, 16
Acetylsalicylic acid, 21–24
Acetaminophen, 14–16 therapeutic and toxic blood levels for, S16
Acetaminophen overdose, acetacylestrie for, 19, S30
Adalat CC, 822
Adalat LA, 822
Adalat PA, 822
Adalat Retard, 822
Adalat XL, 822
adalimumab, 29–31
Adaril, 1054
Adcal, 170
Adderall, 1342, P2
Adderall XR, P2
Addison’s disease. See Adrenocortical insufficiency.
Adefovir dipivoxil, 31–32
Adenacor, 32
Adenocard, 32
Adenoscan, 32
Adenoscan infusion rates, 1352t
adenosine, 32–34
Adenosine infusion rates, 1352t
Adipine, 822
Adizem, 351
Administration rates, calculating, S6
Adoxa, 383
Adrenal insufficiency, cortisone for, 286
Adrenal suppression, 1357
Adrenalin Chloride, 409
Adrenocortical insufficiency hydrocortisone for, 552
triamcinolone for, 1196
Adrenocorticoid overdose potassium acetate for, 954
potassium chloride for, 957
Adriamycin PFS, 378
Adriamycin RDF, 378
Adrucil, 479
Adult Dry Cough, 336
Advagraf, 1118
Advair Diskus, 1342
Advate, 94
Adverse reactions, life-threatening, identifying, 1357–1363
Adviscort, 1342
Advil, 566
Advil Extra Strength, 566
Advil Migraine, 566
Advil Pediatric Drops, 566
Adynamic ileus, 1357
Aerius, 326, 683
AeroBec, 129
Afeditab CR, 822
Aflaxen, 800
Afrin Children’s Pump Mist, 930
agalsidase beta, 34–35
Aggrastat, 1168
Aggrenox, 1342
Aggression, risperidone for, 1045
Agitation, amoxapine for, 73
Agranulocytopenia, 1357
Agrylin, 89
AH-Chew D, 930
AHF, 94
A-hydroCort, 551
AIDS wasting, somatropin, recombinant for, 1092
AK-Sulf, 1105
AK-Zol, 16
Akne-Mycin, 423
Aknenin, 765
Aktob, 1171
Ala-Cort, 551
Ala-Scalp, 551
Alavert, 683
albuterol, 35–37
albuterol sulfate, 35–37
Alcohol dependence acamprosate for, 9
hydroxyzine for, 559
Alcohol withdrawal clordiazepoxide for, 234
clorazepate for, 275
diazepam for, 340
oxazepam for, 868
Alcomicin, 523
Aldactazide, 1342
Aldactone, 1097
alesleukin, 34–35
Aldomet, 736
Alderil, 1342
alendronate sodium, 41–42, P1
Aler-Cap, 356
Aler-Dryl, 356
Alertec, 776
Alopecia areata, minoxidil for, 768
Alophen, 141
Aloprin, 45
Alora, 429
Aleve, 800
Alferon N, 597
alfuzosin, 42–43
Alimta, 902
Alinia, 829
aliskiren, 43–44
alitretinoin, 44–45
Alka, 21
Alka-Mints, 170
Alkalosis, 1357
Alkeran, 707
Alkylating agents, 1272–1274
Allegra, 468, P6
Allegra ODT, 468
Allegra-D, 1342
Allegron, 844
Aller-Relief, 226
Allercalm, 239
Allerdyl, 356
Allergic dermatoses, diphenhydramine for, 356
Allergies betamethasone for, 135
brompheniramine for, 155
cetirizine for, 226
chlorpheniramine for, 239
cortisone for, 286
cromolyn for, 288
cyproheptadine for, 296
dexamethasone for, 331
diphenhydramine for, 356
loratadine for, 683
methylprednisolone for, 744
montelukast for, 779
prednisolone for, 969
Allergy Relief, 226
Allerfest, 239
AllerMax, 356
Allertin, 683
Alli, 860
allopurinol, 45–47
allopurinol sodium, 45–47
almotriptan malate, 47–48
Alodex, 383
aloe, 1314
Alopecia areata, minoxidil for, 768
Alphapril, 45
Aloril, 356
Alora, 429

**Boldface:** Color section
alosetron hydrochloride, 49–50
Aloxi, 885
5-Alpha reductase inhibitors, 1297–1298
alpha tocopherols, 1312
Alpha1-adrenergic agents, 1255–1256
Alphanate, 94
AlphaNine SD, 455
alprazolam, 50–52, P1
therapeutic and toxic blood levels for,
AmBisome, 80
Amebiasis
diazoquin for, 12
erythromycin for, 423
tinidazole for, 1162
Ameclobenz, 89–91
tamibromidine hydrochloride, 55–57
Anabact, 752
Anamin, 760
Ambien, 1250
Ambien CR, 1250
AmBisome, 80
Ambeiasis
diazoquin for, 12
tinidazole for, 1162
Amegnecce, 75
Amylin, 826
Analgesia. See also Labor pain; Pain.
diclofenac for, 343
tamamul, for, 466,
levorphanol for, 658
promethazine for, 989
sufentanil for,
Analgesics
nonopioid, 1293–1294
opioid, 1294
Anadrol, 826
Anapen, 409
amoxicillin trihydrate, 75–77, P1, P2
Aneurx, 75
Ampumol, 80
amphotericin B cholesteryl sulfate, 80–84
amphotericin B
desoxycorticosterone, 80–84
amphotericin B lipid complex, 80–84
amphotericin B liposome, 80–84
ampicillin sodium, 84–86
ampicillin sodium and sulbactam sodium, 86–88
Amrix, 289
Amybex, 64
Amyl Nitrite, 88
amyl nitrite, 88–89
Amyloidosis, 1357
acetylcysteine for, 19
Amyotrophic lateral sclerosis, riluzole for, 1041
Anabact, 752
Anadin Ibuprofen, 566
Anadin Paracetamol, 14
Anadin Ultra, 566
Anafranil, 268
Anafranil SR, 268
angerein hydrochloride, 89–91
anakinra, 91–92
Analgesia. See also Labor pain; Pain.
diflunisal for, 343
tamamul, for, 466,
levorphanol for, 658
promethazine for, 989
sufentanil for,
Anaphylactic reactions, cyproheptadine as adjunct to, 296
Anaphylactoid shock, 1357
Anaphylaxis, 1357
chlorpheniramine for, 239
diphenhydramine for, 356
epinephrine for, 410
treatment guidelines for, S21
Anaplastic astrocytoma, temozolomide for, 1129
Anaprox, 800
Anaprox DS, 800
Anaspaz, 560
anastrozole, 92–93
Ancef, 201
Ancobon, 476
Ancotil, 476
Ancylostoma duodenale infection, mebendazole for, 698
Androderm, 1139
AndroGel, 1139
Androgens, 1297–1298
Andropatch, 1139
Anectine, 1338t–1339t
Anemia
azacitidine for, 117
darbepoetin alfa for, 309
epoetin alfa for, 415, 416
folic acid for, 1306
iron dextran for, 610
iron sucrose for, 612
lenalidomide for, 642
leucovorin calcium for, 646
leuprolide for, 648
lymphocyte immune globulin for, 692
triamcinolone for, 1197
Anesthesia
acetylcysteine for, 19
butorphanol for, 168
epinephrine for prolonging, 410
etomidate for,
1330t–1331t
fentanyl for, 466,
1332t–1333t
lidocaine for, 663, 664
meperidine for, 712
Anesthesia (continued)
midazolam for, 758,
1334t–1335t
nalbuphine for, 799,
1334t–1335t
pancuronium for,
1334t–1335t
pentazocine for, 913,
1334t–1335t
phenylephrine for, 931
procaine for,
1336t–1337t
remifentanil for,
1336t–1337t
rocuronium for,
1338t–1339t
succinylcholine for,
1338t–1339t
sufentanil for,
1340t–1341t
thiopental for,
1340t–1341t
vecuronium for,
1340t–1341t
Anesthetic drugs, common,
1330t–1334t
Anestheticca, 662
Anesticon, 662
Anexia, 549
Anettes, 21
Angeze, 618
Angina
abciximab for, 8
acetylsalicylic acid for, 22
amlodipine for, 69
amyl nitrite for, 88
atenolol for, 109
bivalirudin for, 145
clopidogrel for, 274
dalteparin for, 303
diltiazem for, 351
enoxaparin for, 405
epitifibatide for, 418
isosorbide for, 619
metoprolol for, 750
nadolol for, 795
nicardipine for, 818
nifedipine for, 822
nitroglycerin for, 832
propranolol for, 996
ranolazine for, 1026
verapamil for, 1228
Angioedema, 1358
cloproheptadine for, 296
Angiomax, 145
Angiopine, 822
Angiotensin II receptor antagonists, 1295–1296
Angiotensin-converting enzyme inhibitors, 1295–1296
Angiox, 145
Angitak, 618
Angitil, 351
anidulafungin, 93–94
Ankylosing spondylitis
adalimumab for, 30
celecoxib for, 223
diclofenac for, 343
etanercept for, 438
indomethacin for, 586
naproxen for, 800
Anorexia, megestrol for, 704
Antacids, 1256
Antara, 460
Antepsin, 1104
Anthrax
amoxicillin for, 76
ciprofloxacin for, 255
doxycycline for, 384
levofloxacin for, 654
penicillin G potassium for, 906
penicillin G procaine for, 908
anti-Alzheimer’s agents, 1256–1257
Anti-infectives, 1269–1270
Antiarrhythmics, 1257–1259
Anticholinergic overdose, managing, S30
Anticholinergics, 1259–1260, 1264–1265, 1274
Anticholinesterase insecticide poisoning, atropine for, 114
Anticoagulant overdose, factor IX for, 455
Anticoagulants, 1260–1261
Anticoagulation argatroban for, 101
heparin for, 544
Anticonvulsants, 1261–1262
Antidepressants, 1262–1263
Antidiabetic drugs, 1263–1264
Antidopaminergics, 1264–1265
Antiemetics, 1264–1265
Antifungals, 1265
Antigout agents, 1266
antihemophilic factor, 94–96
Antihistamine overdose, managing, S30
Antihistamines, 1266–1267
Antihyperlipidemics, 1267–1268
Antihyperuricemia agents, 1266
Antilirium, S30
Antimalarials, 1270–1271
Antimetabolites, 1272–1274
Antimigraine drugs, 1271–1272
Antimitotics, 1272–1274
Antineoplastics, 1272–1274
Antiparkinsonian drugs, 1274
Antiplatelet drugs, 1275
Antipsychotics, 1276
Antiretrovirals, 1279–1280
Antirheumatic drugs, 1276–1277
antithrombin III, human, 96–97
antithymocyte globulin equine, 691–693
Antituberculars, 1277–1278
Antivirals and antiretrovirals, 1274, 1279–1280
Antizol, S31
Anxiety. See also
Generalized anxiety disorder.
alprazolam for, 50
amoxapine for, 73
buspirone for, 164
Anxiety (continued)
chlordiazepoxide for, 234
clorazepate for, 275
diazepam for, 339
doxepin for, 376
duloxetine for, 390
hydroxyzine for, 559
lorazepam for, 684
midazolam for, 758, 759
oxazepam for, 868
prochlorperazine for, 985
trifluoperazine for, 1202
Anxiolytics, 1280–1281
Anzemet, 367
Azemet, 367
Apidra, 590
Apo-Acetaminophen, 14
Apo-Acetazolamide, 16
Apo-Alendronate, 41
Apo-Allopurinol, 45
Apo-Alpraz, 50
Apo-Amoxi-Clav, 78
Apo-Asa, 21
Apo-ASEN, 21
Apo-Azathioprine, 118
Apo-Baclofen, 124
Apo-Beclomethasone, 129
Apo-Benazepril, 130
Apo-Besylamidine, 140
Apo-Bisacodyl, 141
Apo-Bisoprolol, 144
Apo-Bromocriptine, 154
Apo-Buthanol, 167
Apo-Calcitonin, 169
Apo-Captopril, 177
Apo-Carbamazepine, 180
Apo-Carvedilol, 194
Apo-Cefaclor, 198
Apo-Cefprozil, 214
Apo-Cefuroxime, 221
Apo-Cephalin, 224
Apo-Chlordiazepoxide, 234
Apo-Chlorpromazine, 241
Apo-Chlorpropamide, 243
Apo-Chlorthalidone, 245
Apo-Cimétidine, 252
Apo-Clindamycin, 263
Apo-Clomipramine, 268
Apo-Clonazepam, 270
Apo-Clonidine, 272
Apo-Clobazam, 275
Apo-Clopazepam, 276
Apo-Cromolyn, 287
Apo-Cyclobenzaprine, 289
Apo-Cyclosporine, 293
Apo-Desipramine, 324
Apo-Desmopressin, 327
Apo-Dexamethasone, 331
Apo-Diazepam, 339
Apo-Diclo, 343
Apo-Digoxin, 348
Apo-Diltiaz, 351
Apo-Diltiazem, 351
Apo-Dimethyldihydronitril, 353
Apo-Dipyridamole FC, 359
Apo-Dipyridamole SC, 359
Apo-Divalproex, 1216
Apo-Docusate Calcium, 366
Apo-Docusate Sodium, 366
Apo-Doxepin, 376
Apo-Doxy, 383
Apo-Enalpril, 401
Apo-Erythro, 423
Apo-Erythro-EC, 423
Apo-Erythro-ES, 423
Apo-Etoprolol, 442
Apo-Famicliclovir, 456
Apo-Famotidine, 457
Apo-Fenofibrate, 460
Apo-Flucainide, 472
Apo-Flucanazole, 474
Apo-Flunisolide, 478
Apo-Fluvonazone, 483
Apo-Fluzazepam, 486
Apo-Flutamide, 487
Apo-Fluvoxamine, 493
Apo-Fosinopril, 501
Apo-Furosemide, 507
Apo-Gabapentin, 510
Apo-Gain, 767
Apo-Gemfibrozil, 520
Apo-Glimepiride, 527
Apo-Glyburide, 547
Apo-Glyburide, 547
Apo-Glyburide, 556

**Boldface:** Color section
<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Page Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apo-Hydroxyzine, 559</td>
<td></td>
</tr>
<tr>
<td>Apo-Ibuprofen, 566</td>
<td></td>
</tr>
<tr>
<td>Apo-Imipramine, 576</td>
<td></td>
</tr>
<tr>
<td>Apo-Indapamide, 583</td>
<td></td>
</tr>
<tr>
<td>Apo-Indomethacin, 586</td>
<td></td>
</tr>
<tr>
<td>Apo-ISDN, 618</td>
<td></td>
</tr>
<tr>
<td>Apo-K, 957</td>
<td></td>
</tr>
<tr>
<td>Apo-Ketoconazole, 623</td>
<td></td>
</tr>
<tr>
<td>Apo-Ketorolac, 625</td>
<td></td>
</tr>
<tr>
<td>Apo-Lactulose, 630</td>
<td></td>
</tr>
<tr>
<td>Apo-Lamotrigine, 633</td>
<td></td>
</tr>
<tr>
<td>Apo-Leflunomide, 640</td>
<td></td>
</tr>
<tr>
<td>Apo-Levetiracetam, 651</td>
<td></td>
</tr>
<tr>
<td>Apo-Levocarb, 182</td>
<td></td>
</tr>
<tr>
<td>Apo-Lisinopril, 675</td>
<td></td>
</tr>
<tr>
<td>Apo-Lithium Carbonate, 677</td>
<td></td>
</tr>
<tr>
<td>Apo-Loperamide, 681</td>
<td></td>
</tr>
<tr>
<td>Apo-Lorazepam, 684</td>
<td></td>
</tr>
<tr>
<td>Apo-Lovastatin, 687</td>
<td></td>
</tr>
<tr>
<td>Apo-Loxapine, 689</td>
<td></td>
</tr>
<tr>
<td>Apo-Medroxy, 700</td>
<td></td>
</tr>
<tr>
<td>Apo-Mefloquine, 702</td>
<td></td>
</tr>
<tr>
<td>Apo-Megestrol, 704</td>
<td></td>
</tr>
<tr>
<td>Apo-Meloxicam, 705</td>
<td></td>
</tr>
<tr>
<td>Apo-Metformin, 723</td>
<td></td>
</tr>
<tr>
<td>Apo-Methimazole, 728</td>
<td></td>
</tr>
<tr>
<td>Apo-Methotrexate, 731</td>
<td></td>
</tr>
<tr>
<td>Apo-Methylprednisolone, 736</td>
<td></td>
</tr>
<tr>
<td>Apo-Methylphenidate, 740</td>
<td></td>
</tr>
<tr>
<td>Apo-Metoclopramide, 746</td>
<td></td>
</tr>
<tr>
<td>Apo-Metoprolol, 750</td>
<td></td>
</tr>
<tr>
<td>Apo-Metronidazole, 752</td>
<td></td>
</tr>
<tr>
<td>Apo-Midazolam, 758, 1334t</td>
<td>1335t</td>
</tr>
<tr>
<td>Apo-Midodrine, 760</td>
<td></td>
</tr>
<tr>
<td>Apo-Milrinone, 764</td>
<td></td>
</tr>
<tr>
<td>Apo-Mirtazapine, 769</td>
<td></td>
</tr>
<tr>
<td>Apo-Misoprostol, 771</td>
<td></td>
</tr>
<tr>
<td>Apo-Mofafinil, 776</td>
<td></td>
</tr>
<tr>
<td>Apo-Nadolol, 794</td>
<td></td>
</tr>
<tr>
<td>Apo-Naproxen, 800</td>
<td></td>
</tr>
<tr>
<td>Apo-Nefedipine, 822</td>
<td></td>
</tr>
<tr>
<td>Apo-Nitrofurantoin, 830</td>
<td></td>
</tr>
<tr>
<td>Apo-Nizatidine, 836</td>
<td></td>
</tr>
<tr>
<td>Apo-Nortriptyline, 844</td>
<td></td>
</tr>
<tr>
<td>Apo-Ondansetron, 858</td>
<td></td>
</tr>
<tr>
<td>Apo-Oxybutinin, 871</td>
<td></td>
</tr>
<tr>
<td>Apo-Paeoniflorin, 879</td>
<td></td>
</tr>
<tr>
<td>Apo-Pantoprazole, 888</td>
<td></td>
</tr>
<tr>
<td>Apo-Paroxetine, 890</td>
<td></td>
</tr>
<tr>
<td>Apo-Pen VK, 909</td>
<td></td>
</tr>
<tr>
<td>Apo-Pentoxifylline, 918</td>
<td></td>
</tr>
<tr>
<td>Apo-Pendiprol, 919</td>
<td></td>
</tr>
<tr>
<td>Apo-Perphenazine, 921</td>
<td></td>
</tr>
<tr>
<td>Apo-Pimozide, 938</td>
<td></td>
</tr>
<tr>
<td>Apo-Pindolol, 939</td>
<td></td>
</tr>
<tr>
<td>Apo-Pioglitazone, 941</td>
<td></td>
</tr>
<tr>
<td>Apo-Piroxicam, 947</td>
<td></td>
</tr>
<tr>
<td>Apo-Pramipexole, 963</td>
<td></td>
</tr>
<tr>
<td>Apo-Pravastatin, 966</td>
<td></td>
</tr>
<tr>
<td>Apo-Prazo, 967</td>
<td></td>
</tr>
<tr>
<td>Apo-Prednisone, 972</td>
<td></td>
</tr>
<tr>
<td>Apo-Primidone, 978</td>
<td></td>
</tr>
<tr>
<td>Apo-Procaainamide, 980</td>
<td></td>
</tr>
<tr>
<td>Apo-Propafenone, 990</td>
<td></td>
</tr>
<tr>
<td>Apo-Propafenol, 995</td>
<td></td>
</tr>
<tr>
<td>Apo-Quin-G, 1011</td>
<td></td>
</tr>
<tr>
<td>Apo-Quinidine, 1011</td>
<td></td>
</tr>
<tr>
<td>Apo-Quinine, 1014</td>
<td></td>
</tr>
<tr>
<td>Apo-Ramipril, 1021</td>
<td></td>
</tr>
<tr>
<td>Apo-Ranitidine, 1024</td>
<td></td>
</tr>
<tr>
<td>Apo-Selegiline, 1070</td>
<td></td>
</tr>
<tr>
<td>Apo-Sertraline, 1073</td>
<td></td>
</tr>
<tr>
<td>Apo-Simvastatin, 1078</td>
<td></td>
</tr>
<tr>
<td>Apo-Sotalol, 1095</td>
<td></td>
</tr>
<tr>
<td>Apo-Sucralfate, 1104</td>
<td></td>
</tr>
<tr>
<td>Apo-Sulfatrim, 1106</td>
<td></td>
</tr>
<tr>
<td>Apo-Sulfatrim DS, 1106</td>
<td></td>
</tr>
<tr>
<td>Apo-Sumatriptan, 1113</td>
<td></td>
</tr>
<tr>
<td>Apo-Temazepam, 1128</td>
<td></td>
</tr>
<tr>
<td>Apo-Terazosin, 1134</td>
<td></td>
</tr>
<tr>
<td>Apo-Tetra, 1142</td>
<td></td>
</tr>
<tr>
<td>Apo-Theo LA, 1146</td>
<td></td>
</tr>
<tr>
<td>Apo-Ticlopidine, 1156</td>
<td></td>
</tr>
<tr>
<td>Apo-Timol, 1159</td>
<td></td>
</tr>
<tr>
<td>Apo-Tizanidin, 1170</td>
<td></td>
</tr>
<tr>
<td>Apo-Tobramycin, 1171</td>
<td></td>
</tr>
<tr>
<td>Apo-Tomax, 1122</td>
<td></td>
</tr>
<tr>
<td>Apo-Topiramate, 1177</td>
<td></td>
</tr>
<tr>
<td>Apo-Trazodone, 1189</td>
<td></td>
</tr>
<tr>
<td>Apo-Triazolam, 1200</td>
<td></td>
</tr>
<tr>
<td>Apo-Trifluoperazine, 1202</td>
<td></td>
</tr>
<tr>
<td>Apo-Trihex, 1204</td>
<td></td>
</tr>
<tr>
<td>Apo-Trimip, 1206</td>
<td></td>
</tr>
<tr>
<td>Apo-Valacyclovir, 1213</td>
<td></td>
</tr>
<tr>
<td>Apo-Valproic Acid, 1216</td>
<td></td>
</tr>
<tr>
<td>Apo-Verapamil, 1228</td>
<td></td>
</tr>
<tr>
<td>Apo-Verapamil, 1228</td>
<td></td>
</tr>
<tr>
<td>Apo-Warfarin, 1238 invention, 1238</td>
<td></td>
</tr>
<tr>
<td>Apo-Zidovudine, 1243</td>
<td></td>
</tr>
<tr>
<td>Apokyn, 97</td>
<td></td>
</tr>
<tr>
<td>apomorphine hydrochloride, 97–99</td>
<td></td>
</tr>
<tr>
<td>Appendicitis, ruptured, piperacillin and tazobactam for, 944</td>
<td></td>
</tr>
<tr>
<td>Appetite stimulant, dronabinol as, 386</td>
<td></td>
</tr>
<tr>
<td>Aprepitant, 99–100</td>
<td></td>
</tr>
<tr>
<td>Aprepitant, 99–100</td>
<td></td>
</tr>
<tr>
<td>Aranesp, 308</td>
<td></td>
</tr>
<tr>
<td>Arava, 640</td>
<td></td>
</tr>
<tr>
<td>Arbil, 180</td>
<td></td>
</tr>
<tr>
<td>Aredia, 887</td>
<td></td>
</tr>
<tr>
<td>argatroban, 100–102</td>
<td></td>
</tr>
<tr>
<td>Argatroban infusion rates, 1353t</td>
<td></td>
</tr>
<tr>
<td>Argoral, 1353t</td>
<td></td>
</tr>
<tr>
<td>Aricept, 365</td>
<td></td>
</tr>
<tr>
<td>Arimidex, 92</td>
<td></td>
</tr>
<tr>
<td>Aripiprazole, 102–104, P2</td>
<td></td>
</tr>
<tr>
<td>Aristospan Intra-Articular, 1195</td>
<td></td>
</tr>
<tr>
<td>Aristospan Intradermal, 1195</td>
<td></td>
</tr>
<tr>
<td>Arinex, 495</td>
<td></td>
</tr>
<tr>
<td>Arlevert, 353</td>
<td></td>
</tr>
<tr>
<td>Arm &amp; Hammer Baking Soda, 1083</td>
<td></td>
</tr>
<tr>
<td>Armour Thyroid, 1151</td>
<td></td>
</tr>
<tr>
<td>Aromasin, 449</td>
<td></td>
</tr>
<tr>
<td>Arranon, 808</td>
<td></td>
</tr>
<tr>
<td>Arret, 681</td>
<td></td>
</tr>
<tr>
<td>Arrhythmias</td>
<td></td>
</tr>
<tr>
<td>acetobutolol for, 13</td>
<td></td>
</tr>
<tr>
<td>adenosine for, 32</td>
<td></td>
</tr>
<tr>
<td>amiodarone for, 65</td>
<td></td>
</tr>
<tr>
<td>atropine for, 114</td>
<td></td>
</tr>
<tr>
<td>digoxin for, 348</td>
<td></td>
</tr>
<tr>
<td>diltiazem for, 351</td>
<td></td>
</tr>
<tr>
<td>disopyramide for, 360</td>
<td></td>
</tr>
<tr>
<td>esmolol for, 427</td>
<td></td>
</tr>
<tr>
<td>flecainide for, 473</td>
<td></td>
</tr>
<tr>
<td>ibutilide for, 569</td>
<td></td>
</tr>
<tr>
<td>isoproterenol for, 617</td>
<td></td>
</tr>
<tr>
<td>lidocaine for, 663</td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Page</td>
</tr>
<tr>
<td>---------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>Avomine</td>
<td>988</td>
</tr>
<tr>
<td>Avonex</td>
<td>602</td>
</tr>
<tr>
<td>Axert</td>
<td>47</td>
</tr>
<tr>
<td>Avid</td>
<td>836</td>
</tr>
<tr>
<td>Axid</td>
<td>836</td>
</tr>
<tr>
<td>Ayercillin</td>
<td>908</td>
</tr>
<tr>
<td>Aygestin</td>
<td>841</td>
</tr>
<tr>
<td>Azymetrel</td>
<td>55</td>
</tr>
<tr>
<td>azacitidine</td>
<td>116–118</td>
</tr>
<tr>
<td>Azactam</td>
<td>122</td>
</tr>
<tr>
<td>Azasan</td>
<td>118</td>
</tr>
<tr>
<td>azathioprine</td>
<td>118–120</td>
</tr>
<tr>
<td>Azilect</td>
<td>1027</td>
</tr>
<tr>
<td>azithromycin</td>
<td>120–122</td>
</tr>
<tr>
<td>Azithromycin dihydrate</td>
<td>120–122</td>
</tr>
<tr>
<td>Azmacort Inhalation</td>
<td>Aerosol, 1195</td>
</tr>
<tr>
<td>AZO-Gesic</td>
<td>923</td>
</tr>
<tr>
<td>Azo-Standard</td>
<td>923</td>
</tr>
<tr>
<td>Azor</td>
<td>1342</td>
</tr>
<tr>
<td>aztreonam</td>
<td>122–124</td>
</tr>
<tr>
<td>Azulfidine</td>
<td>1109</td>
</tr>
<tr>
<td>Azulfidine EN-tabs</td>
<td>1109</td>
</tr>
<tr>
<td>Backache, acetaminophen</td>
<td>for 15</td>
</tr>
<tr>
<td>Baclofen</td>
<td>124</td>
</tr>
<tr>
<td>baclofen</td>
<td>124–126</td>
</tr>
<tr>
<td>Bacteremia, chloramphenicol for</td>
<td>233</td>
</tr>
<tr>
<td>Bacterial vaginosis</td>
<td>tinidazole for, 1162</td>
</tr>
<tr>
<td>Bacterial vaginosis</td>
<td>metronidazole for, 753</td>
</tr>
<tr>
<td>Bactrim</td>
<td>1106, 1343</td>
</tr>
<tr>
<td>Bactrim DS</td>
<td>1106</td>
</tr>
<tr>
<td>Bactroban</td>
<td>785</td>
</tr>
<tr>
<td>Bactroban Nasal 2%</td>
<td>785</td>
</tr>
<tr>
<td>Balminil DM</td>
<td>336</td>
</tr>
<tr>
<td>Balminil Expectorant</td>
<td>539</td>
</tr>
<tr>
<td>balsalazide disodium</td>
<td>126–127</td>
</tr>
<tr>
<td>Banophen</td>
<td>356</td>
</tr>
<tr>
<td>Baraclidue</td>
<td>408</td>
</tr>
<tr>
<td>Barbiturates</td>
<td>1296–1297</td>
</tr>
<tr>
<td>Baridium</td>
<td>923</td>
</tr>
<tr>
<td>Basal cell carcinoma</td>
<td>fluorouracil for, 479</td>
</tr>
<tr>
<td>basiliximab</td>
<td>127–128</td>
</tr>
<tr>
<td>Baxan</td>
<td>200</td>
</tr>
<tr>
<td>Bayer</td>
<td>21</td>
</tr>
<tr>
<td>Bazetham</td>
<td>1123</td>
</tr>
<tr>
<td>BD Glucose</td>
<td>337</td>
</tr>
<tr>
<td>Bebulin VH</td>
<td>455</td>
</tr>
<tr>
<td>Beclodisk</td>
<td>129</td>
</tr>
<tr>
<td>Becloforte</td>
<td>129</td>
</tr>
<tr>
<td>beclomethasone dipropionate,</td>
<td>129–130</td>
</tr>
<tr>
<td>Beconase AQ Nasal Spray</td>
<td>129</td>
</tr>
<tr>
<td>Bedol</td>
<td>429</td>
</tr>
<tr>
<td>Bedranol SR</td>
<td>995</td>
</tr>
<tr>
<td>Beesix</td>
<td>1309</td>
</tr>
<tr>
<td>Bejel</td>
<td>penicillin G benzathine for, 904</td>
</tr>
<tr>
<td>Bejel</td>
<td>penicillin G procaine for, 908</td>
</tr>
<tr>
<td>Bell/ans</td>
<td>1083</td>
</tr>
<tr>
<td>Benadryl</td>
<td>356</td>
</tr>
<tr>
<td>Benadryl Allergy</td>
<td>356</td>
</tr>
<tr>
<td>Benadryl Allergy Oral</td>
<td>Solution, 226</td>
</tr>
<tr>
<td>Benadryl Child Chesty</td>
<td>Cough, 356</td>
</tr>
<tr>
<td>Benadryl Dye-Free Allergy</td>
<td>356</td>
</tr>
<tr>
<td>Benadryl One a Day</td>
<td>226</td>
</tr>
<tr>
<td>benazepril hydrochloride</td>
<td>130–132, P3</td>
</tr>
<tr>
<td>bendamustine hydrochloride</td>
<td>132–133</td>
</tr>
<tr>
<td>BeneFix</td>
<td>455</td>
</tr>
<tr>
<td>Benicar</td>
<td>853, P11</td>
</tr>
<tr>
<td>Benign prostatic hyperplasia</td>
<td>alfuzosin for, 42</td>
</tr>
<tr>
<td>benzofurazin</td>
<td>for, 375</td>
</tr>
<tr>
<td>dutasteride for, 393</td>
<td></td>
</tr>
<tr>
<td>finasteride for, 471</td>
<td></td>
</tr>
<tr>
<td>tamsulosin for, 1124</td>
<td></td>
</tr>
<tr>
<td>terazosin for, 1134</td>
<td></td>
</tr>
<tr>
<td>Benilyn Childrens Chesty</td>
<td>Coughs, 539</td>
</tr>
<tr>
<td>Benyl</td>
<td>345</td>
</tr>
<tr>
<td>Benylol</td>
<td>345</td>
</tr>
<tr>
<td>Benuryl</td>
<td>979</td>
</tr>
<tr>
<td>Benyl-E</td>
<td>539</td>
</tr>
<tr>
<td>Benzodiazepine overdose,</td>
<td>managing, S30</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>1280–1281</td>
</tr>
<tr>
<td>benztrpine mesylate</td>
<td>134–135</td>
</tr>
<tr>
<td>bepridil, therapeutic and</td>
<td>toxic blood levels for, S16</td>
</tr>
<tr>
<td>Beriberi, thiamine for,</td>
<td>1311</td>
</tr>
<tr>
<td>Besavar</td>
<td>42</td>
</tr>
<tr>
<td>beta-adrenergic blockers,</td>
<td>1281–1282</td>
</tr>
<tr>
<td>Beta-Cardone</td>
<td>1095</td>
</tr>
<tr>
<td>Beta-Prograne</td>
<td>995</td>
</tr>
<tr>
<td>Betachron E-R</td>
<td>995</td>
</tr>
<tr>
<td>Betaferon</td>
<td>602</td>
</tr>
<tr>
<td>Betaloc</td>
<td>750</td>
</tr>
<tr>
<td>Betaloc Durules</td>
<td>750</td>
</tr>
<tr>
<td>betamethasone, 135–137</td>
<td></td>
</tr>
<tr>
<td>betamethasone acetate</td>
<td>and sodium phosphate, 135–137</td>
</tr>
<tr>
<td>Betapace</td>
<td>1095</td>
</tr>
<tr>
<td>Betapace AF</td>
<td>1095</td>
</tr>
<tr>
<td>Betaseron</td>
<td>602</td>
</tr>
<tr>
<td>bethenochloride</td>
<td>137–138</td>
</tr>
<tr>
<td>Betim</td>
<td>1159</td>
</tr>
<tr>
<td>Betimol</td>
<td>1159</td>
</tr>
<tr>
<td>Betnelan</td>
<td>135</td>
</tr>
<tr>
<td>bevacizumab</td>
<td>138–140</td>
</tr>
<tr>
<td>Biamine</td>
<td>1311</td>
</tr>
<tr>
<td>Bixa, P4</td>
<td></td>
</tr>
<tr>
<td>Bixa</td>
<td>Filmtab, 261</td>
</tr>
<tr>
<td>Bixa Granules</td>
<td>261</td>
</tr>
<tr>
<td>Bixa XL, P4</td>
<td></td>
</tr>
<tr>
<td>Bixa XL Filmtab</td>
<td>261</td>
</tr>
<tr>
<td>bicalutamide</td>
<td>140–141</td>
</tr>
<tr>
<td>Bicillin L-A, 904</td>
<td></td>
</tr>
<tr>
<td>BiCNU</td>
<td>190</td>
</tr>
<tr>
<td>Big Shot B-12</td>
<td>1305</td>
</tr>
<tr>
<td>bilberry</td>
<td>1314–1315</td>
</tr>
<tr>
<td>Bile acid suppressants,</td>
<td>1267–1268</td>
</tr>
<tr>
<td>Biliary tract infection,</td>
<td>cefazolin for, 202</td>
</tr>
<tr>
<td>Bio-Carbamazepine</td>
<td>180</td>
</tr>
<tr>
<td>Bio-Diazepam</td>
<td>339</td>
</tr>
<tr>
<td>Bio-Flurazepam</td>
<td>486</td>
</tr>
<tr>
<td>Bio-Furosemide</td>
<td>507</td>
</tr>
<tr>
<td>Bio-Oxazepam</td>
<td>868</td>
</tr>
<tr>
<td>Bio-Statin</td>
<td>846</td>
</tr>
<tr>
<td>Biocef</td>
<td>224</td>
</tr>
<tr>
<td>Biolax</td>
<td>141</td>
</tr>
<tr>
<td>Biological response</td>
<td>modifiers, 1276–1277</td>
</tr>
<tr>
<td>Biphen (4)</td>
<td>740</td>
</tr>
<tr>
<td>Bipolar disorder. See also</td>
<td>Mania.</td>
</tr>
<tr>
<td>aripiprazole for, 102</td>
<td></td>
</tr>
</tbody>
</table>
Bipolar disorder

Blood transfusions

epoetin alfa to reduce
need for, 416
sodium chloride for, 1084

Breast cancer (continued)
cyclophosphamide for,
291
doctaxel for, 364
doxorubicin for, 379
epirubicin for, 412
estradiol for, 430
estrogens, conjugated
for, 432
estrogens, esterified for,
434
exametane for, 449
fluorouracil for, 479
fulvestrant for, 506
gemcitabine for, 519
goserelin for, 536
letrazole for, 644
megestrol for, 704
paclitaxel for, 880
pamidronate for, 887
raloxifene for, 1018
tamoxifen for, 1122
testosterone for, 1140
trastuzumab for, 1188
vinblastine for, 1231

Brevibloc, 427
Brevidol, 947
Bricanyl, 1137
Broflex, 1204
Bromfenac, 155
bromocriptine mesylate,
154–155
brompheniramine, 155–157
Bronchial studies,
acetylcysteine for,
19
Bronchiectasis,
acetylcysteine for,
19
Bronchitis
acetylcysteine for, 19
cefaclor for, 199
cefdinir for, 204
cefixime for, 207
cefpodoxime for,
212
cefprozil for, 214
ceftibuten for, 217
clarithromycin for, 261,
262
gemifloxacin for, 522
levofoxacin for, 654
moxifloxacin for,
784
ofloxacin for, 849
<table>
<thead>
<tr>
<th>Bronchitis (continued)</th>
<th>Candidiasis</th>
<th>Calcium channel blockers</th>
</tr>
</thead>
<tbody>
<tr>
<td>sulfamethoxazole-trimethoprim for, 1106</td>
<td>amphotericin B for, 81</td>
<td>overdose, 170–172, 175–176</td>
</tr>
<tr>
<td>Broncho-Grippol-DM, 336</td>
<td>anidulafungin for, 93</td>
<td>calcium chloride, 170–172, 175–176</td>
</tr>
<tr>
<td>Bronchoconstriction, montelukast for, 779</td>
<td>caspofungin for, 196</td>
<td>calcium citrate, 170–172</td>
</tr>
<tr>
<td>Bronchodilation, epinephrine for, 410</td>
<td>micafungin for, 756</td>
<td>calcium Folinate, 645</td>
</tr>
<tr>
<td>Bronchodilators, 1283</td>
<td>candidiasis, 196</td>
<td>calcium glubionate, 171–172</td>
</tr>
<tr>
<td>Bronchopulmonary disease, acetylcysteine for, 19</td>
<td>Cancidas, 196</td>
<td>calcium gluconate, 171–172</td>
</tr>
<tr>
<td>Bronchospasm</td>
<td>Campath, 39</td>
<td>calcium lactate, 171–172</td>
</tr>
<tr>
<td>albuterol for, 35, 36</td>
<td>Camptosar, 608</td>
<td>Calcium oxalate calculi, allopurinol for, 46</td>
</tr>
<tr>
<td>aminophylline for, 62</td>
<td>Campto, 608</td>
<td>calcium polycarbofiphol, 173–174</td>
</tr>
<tr>
<td>cromolyn for, 288</td>
<td>Campral, 9</td>
<td>calcium, therapeutic and toxic blood levels for, 516</td>
</tr>
<tr>
<td>formoterol for, 497</td>
<td>Calmolin, 239</td>
<td>Calmin #1, 336</td>
</tr>
<tr>
<td>ipratropium for, 605</td>
<td>Calmylin Expectorant, 539</td>
<td>Calmylin #1, 336</td>
</tr>
<tr>
<td>levalbuterol for, 617</td>
<td>Caliol, 14</td>
<td>Calmin #1, 336</td>
</tr>
<tr>
<td>metaproterenol for, 720</td>
<td>Calprofen, 566</td>
<td>Calfactant, 174</td>
</tr>
<tr>
<td>salmeterol for, 1060</td>
<td>Caltrate, 169</td>
<td>Caltrate Injection, 159</td>
</tr>
<tr>
<td>theophylline for, 1147</td>
<td>Calcimar, 169</td>
<td>Caltrate Injection, 159</td>
</tr>
<tr>
<td>tiotropium for, 1165</td>
<td>Calciparine, 543</td>
<td>Cancidas, 196</td>
</tr>
<tr>
<td>Bronitin Mist, 409</td>
<td>calcitonin (salmon), 169–170</td>
<td>Candesartan cilexetil, 175–176</td>
</tr>
<tr>
<td>Brove X, 155</td>
<td>calcium acetate, 170–172</td>
<td>Candidemia</td>
</tr>
<tr>
<td>Brucellosis streptomycin for, 1102</td>
<td>calcium carbonate, 170–172</td>
<td>anidulafungin for, 93</td>
</tr>
<tr>
<td>tetracycline for, 1142</td>
<td>Calcium channel blockers overdose, managing, 530</td>
<td>caspofungin for, 196</td>
</tr>
<tr>
<td>Brufen, 566</td>
<td>calcium chloride, 170–172, 531</td>
<td>micafungin for, 756</td>
</tr>
<tr>
<td>Buccastem, 984</td>
<td>calcium citrate, 170–172</td>
<td>Candidiasis</td>
</tr>
<tr>
<td>Budenofalk, 157</td>
<td>calcitonin (salmon), 169–170</td>
<td>amphotericin B for, 81</td>
</tr>
<tr>
<td>Budeprion SR, 162</td>
<td>calcium acetate, 170–172</td>
<td>anidulafungin for, 93</td>
</tr>
<tr>
<td>Budeprion XL, 162</td>
<td>calcium carbonate, 170–172</td>
<td>Candesartan cilexetil, 175–176</td>
</tr>
<tr>
<td>budesonide, 157–159</td>
<td>Calcium channel blockers overdose, managing, 530</td>
<td>Candidiasis</td>
</tr>
<tr>
<td>Bulimia nervosa, fluoxetine for, 482</td>
<td>calcium chloride, 170–172, 531</td>
<td>anidulafungin for, 93</td>
</tr>
<tr>
<td>bumetanide, 159–161</td>
<td>calcium citrate, 170–172</td>
<td>caspofungin for, 196</td>
</tr>
<tr>
<td>Bumetanide Injection, 159</td>
<td>calcitonin (salmon), 169–170</td>
<td>micafungin for, 756</td>
</tr>
<tr>
<td>Bumex, 159</td>
<td>calcium acetate, 170–172</td>
<td>Candidiasis</td>
</tr>
<tr>
<td>Buprenex, 161</td>
<td>calcium carbonate, 170–172</td>
<td>anidulafungin for, 93</td>
</tr>
<tr>
<td>buprenorphine hydrochloride, 161–162</td>
<td>Calcium channel blockers overdose, managing, 530</td>
<td>Candidiasis</td>
</tr>
<tr>
<td>bupropion hydrochloride, 162–164, P3</td>
<td>calcium carbonate, 170–172</td>
<td>anidulafungin for, 93</td>
</tr>
<tr>
<td>Burinex, 161</td>
<td>Calcium channel blockers overdose, managing, 530</td>
<td>Candidiasis</td>
</tr>
<tr>
<td>Burkitt’s lymphoma, methotrexate for, 732</td>
<td>calcium carbonate, 170–172</td>
<td>anidulafungin for, 93</td>
</tr>
</tbody>
</table>
Candidiasis (continued)
caspofungin for, 197
fluconazole for, 474, 475
itraconazole for, 621
ketoconazole for, 624
micafungin for, 756, 757
nystatin for, 846
posaconazole for, 952
voriconazole for, 1236
Candiduria, ketoconazole for, 624
Candistatin, 846
Canesten Oral, 474
Canusal, 543
capecitabine, 176–177
Caplenol, 45
Capoten, 177
Capozide, 1343
Caprin, 21
Capsules not to crush, S11–S12
captopril, 177–179
Carace, 675
Carafate, 1104
Carbagen, 180
Carbamaz, 180
carbamazepine, 180–182
therapeutic and toxic blood levels for, S16
Carbapenems, 1269–1270
Carbatrol, 180
caridopla-levodopa, 182–184
caridopla-levodopa-entacapone, 185–186
Carbolith, 677
Carbonix, 26
Carbonic anhydrase inhibitors, 1287–1288
carboplatin, 187–188
Cardene, 818
Cardene IV, 818
Cardene SR, 818
Cardiac arrest
calcium for, 171
epinephrine for, 410
treatment guidelines for, S22, S23
tromethamine for, 1210
Cardiac bypass surgery, tromethamine for, 1210
Cardiac decompensation, dobutamine for, 362
Cardiac surgery, dobutamine for, 362
Cardiac tamponade, 1358
Cardiac vagal reflex blockade
tropine for, 115
glycopyrrolate for, 534
Cardiac valve placement, warfarin for, 1238
Cardicor, 144
Cardilate MR, 822
Cardiovascular collapse, 1358
Cardiovascular disease, amlodipine and atorvastatin for prevention of, 70
Cardiovascular events, pravastatin for prevention of, 966
Cardiovascular surgery, heparin for, 544
Cardioversion, diazepam as preparation for, 339
Cardizem, 351
Cardizem CD, 351
Cardizem LA, 351
Cardoxin XL, 375
Cardura, 375
Cardura XL, 375
Carimune NF, 579
carisoprodol, 188–189
carmustine, 190–191
carteolol hydrochloride, 191–193
Carter’s Little Pills, 141
Cartia XT, 351
carvedilol, 194–196, P3
carvedilol phosphate, 194–196
Casodex, 140
caspofungin, 196–198
cat’s claw, 1315–1316
Cataflam, 343
Catapres, 272
Catapres-TTS, 272
Cathflo Activase, 52
Cecon, 1303
Cedax, 217
Cedocard, 618
Cedocard-SR, 618
CeeNU, 679
cefaclor, 196–198
ceftazidime, 212–214
ceftibuten, 217–219
Cefin, 221
ceftiraxone sodium, 219–221
cefuroxime axetil, 221–223
cefuroxime sodium, 221–223
Cefzil, 214, P4
Celebrex, 223, P4
celcoxib, 223–224, P4
Celestone, 135
Celestone Soluspan, 135
Celevac, 735
Celexa, 259, P4
CellCept, 788
CellCept Intravenous, 788
Central nervous system depression, doxapram for, 373
Central nervous system stimulants, 1285–1286
Central venous access device, restoration, alteplase for, 53
cephalexin, 224–226, P4
Cephalosporin blood level, probenecid to increase, 979
Cephalosporins, 1269–1270
Cerebral ischemia, 1358
Cerebral palsy
dantrolene for, 307
diazepam for, 339
Cerebrovascular accident
acetylsalicylic acid for, 21
alteplase for, 53
atorvastatin for, 112
clopidogrel for, 273
losartan for, 686
ramipril for, 1022
ticlopidine for, 1156
treatment guidelines for,
S26
Cerebyx, 503
Cerubidine, 318
Cervical cancer, bleomycin for, 147
cervical ripening, dinoprostone for,
355
Cervicitis
azithromycin for, 121
ceftoxime for, 209
ofloxacin for, 849
Cervidil Vaginal Insert, 354
C.E.S., 432
Cesamet, 791
Cesarean delivery
ceftoxime for, 209
ropivacaine for,
1338t–1339t
Ceta-Plus, 549
Cetacort, 551
Cetaphen, 14
cetirizine hydrochloride,
cetuximab, 227–229
Cevi-Bid, 1303
Chamomile, 1316
Champix, 1224
Chancroid
azithromycin for, 121
tetracycline for, 1142
Chantix, 1224
Char-Caps, 26
Charcodate, 26
Charco Caps, 26
Chemydur, 618
Chibroxin, 842
Chickenpox. See Varicella.
Children’s Advil, 566
Children’s Allergy Fastmelt,
356
Children’s Motrin, 566
Children’s Pepto Chooz, 170
Children’s Tylenol Soft Chews, 14
Chlamydial infection,
ofloxacin for, 849
Chlor-Trimeton, 239
Chlor-Trimeton Allergy 12
Hour, 239
Chlor-Trimeton Allergy 4
Hour, 239
Chlor-Trimeton Allergy 8
Hour, 239
Chlor-Tripolon, 239
chloral hydrate, 230–231
chlorambucil, 231–232
chloramphenicol, 232–234
chlor Diazepoxide
hydrochloride, 234–235
Chloromycetin Ophthalmic,
232
chloroquine phosphate,
235–237
chlorothiazide, 237–239
Chlorphen, 239
chlorpheniramine maleate,
239–240
chlorpromazine
hydrochloride, 241–243
chlorpropamide, 243–245
chlorthalidone, 245–247
chlorzoxazone, 247–248
cholecalciferol, 1303–1304
Cholera, tetracycline for,
1142
Cholestagel, 283
Cholesterol embolism, 1358
cholestyramine, 248–249
cholinergic agonists
overdose, managing, S31
Cholinergic effects,
glycopyrrolate for blocking, 534
Cholinergic, 1284–1284
chondroitin, 1316
Chorea, penicillin V potassium for,
910
Choriocarcinoma
methotrexate for, 732
vinblastine for, 1231
Christmas disease, factor
IX for, 455
Chroma-Pak, 1304
chromic chloride, 1304
chromium, 1304
Chromomycosis, ketoconazole for,
624
Chronic granulomatous
disease, interferon gamma-1b for, 604
Chronic lymphocytic
leukemia
alemtuzumab for, 40
bendamustine for, 132
chlorambucil for, 231
immune globulin for,
580
Chronic myelocytic
leukemia
dasatinib for, 314
imatinib for, 573
Chronic myelogenous
leukemia
busulfan for, 166
hydroxyurea for, 558
chronic myelogenous
leukemia
nilotinib for, 824
Chronic myelomonocytic
leukemia, azacitidine for, 117
Chronic obstructive
pulmonary disease. See also Asthma;
Bronchitis;
Bronchospasm
azithromycin for, 121
formoterol for, 497
ipratropium for, 605
salmeterol for, 1060
tiotropium for, 1165
Chronic renal failure,
torsemide for,
1181
Cialis, 1120, P14
Cibral, 618
Cibral XL, 618
cidofovir, 249–251
Cidomycin, 523
cilostazol, 251–252
Ciloxam, 255
cimetidine, 252–253
cinacalcet hydrochloride,
253–255
Cipalex, 425
Cipro, 255, P4
Cipro I.V., 255
Cipro XR, 255
Ciprodex, 1343
ciprofloxacin hydrochloride, 255–258, P4
Ciproxin, 255
Cirrhosis
clofibrate for, 237
clofibrate sodium for, 238
clofibrate sulfinpyrazone for, 238
clomabenz for, 237
clopheniramine for, 237
cloxacillin for, 239
cloxacillin sodium for, 239
cloxacillin sodium potassium for, 239

Cloroxylon, 270
Clonazepam, 270
clonazepam, 270

Clofibrate, 237
Clofibrate sodium, 238
Clomabenz, 237
Clompheniramine, 237
Cloxacillin, 239
Cloxacillin sodium, 239
Cloxacillin sodium potassium, 239

Co-Gesic, 549
Co-Lisinopril, 675
co-phenotrope, 357–359
Co-Topiramate, 1177
co-trimoxazole, 1106–1109
coagulation factor VIIa (recombinant), 278–279
Coccidioidomycosis
amphotericin B for, 80
ketoconazole for, 624
codeine phosphate, 280–281
codeine sulfate, 280–281
codeine acetaminophen, P5
coenzyme Q10, 1316–1317
Cogentin, 134
Cognex, 1117
Colace, 366
Colazal, 126
Colazide, 126
colchicine, 281–283
Cold sores, acyclovir for, 28
colestipol hydrochloride, 284–285
colesevelam hydrochloride, 283–284
Colestid, 284
colonic polyps, 223
Combination drug products, 1342–1345
Colonoscopy, sodium phosphates for, 1088
Colony-stimulating factors, 1289–1290
Colorectal cancer
bevacizumab for, 139
capcitabine for, 176
cetuximab for, 227
fluorouracil for, 479
irinotecan for, 609
leucovorin calcium for, 646
oxaliplatin for, 863
Colorectal polyps, 223
Combination drug products, 1342–1345
Cushing's syndrome 1389

CombiPatch, 1343
Combivent, 1343
Combivir, 1343
Commit, 819
Common cold acetaminophen for, 15
ipratropium for, 605
Compazine, 984
Compoz Nighttime Sleep Aid, 356
Compro, 984
Comtan, 407
Comtess, 407
Concerta, 740, P10
Concerta XL, 740
Condylomata acuminata. See Genital warts.
Congenital hypoplastic anemia, triamcinolone for, 1197
Congest, 432
Conjunctivitis
ciprofloxacin for, 256
cromolyn for, 424
gatifloxacin for, 516
levofloxacin for, 654
moxifloxacin for, 784
norfloxacin for, 842
ofloxacin for, 849
sulfacetamide for, 1105
Constipation
bisacodyl for, 141
calcium polycarbophil for, 173
lactulose for, 630
lubiprostone for, 690
magnesium for, 694
methylcellulose for, 735
methylparoxetine for, 738
psyllium for, 1001
senna for, 1072
sodium phosphates for, 1088
Constulose, 630
Contac Non Drowsy, 999
Contifilo XL, 1123
Contraception
etonogestrel and ethinyl estradiol vaginal ring, 444
levonorgestrel for, 656
Contraception (continued)
medroxyprogesterone for, 701
norelgestromin/ethinyl estradiol for, 837
Controlled substance schedules, xviii
Convulex, 1216
Convulsive therapy, succinylcholine for, 1338t–1339t
Copaxone, 526
Copegus, 1033
copper, 1304–1305
Coracten, 822
Cordarone, 64
Cordarone X, 64
Cordilox MR, 1228
Coreg, 194, P3
Coreg CR, 194
Corgard, 794
Coricidin, 930
Corlom, 462
Corneal ulcers
ciprofloxacin for, 256
levofloxacin for, 654
ofloxacin for, 849
Coronary artery disease
adenosine for diagnosis of, 33
amilodipine and atorvastatin for, 70
perindopril for, 920
simvastatin for, 1078
Coronary heart disease
atorvastatin for, 112
fluvastatin for, 491
Coronary stents, ticlopidine for, 1156
Corpus luteum insufficiency, progesterone for, 987
Correctol, 141
Correctol Stool Softener, 366
Cortef, 551
Cortenema, 551
Corticosteroid therapy
chlorothiazide as adjunct to, 237
chlordialdone as adjunct to, 245
hydrochlorothiazide as adjunct to, 547
Corticosteroids, 1286–1287
Corticosterone overdose
potassium acetate for, 954
potassium chloride for, 957
Cortifoam, 551
cortisone acetate, 285–287
Cortisyl, 285
Coryphen, 21
Corzide, 1343
Cosmofer, 610
Cosopt, 1343
Cosuric, 45
Cough
codeine for, 280
dextromethorphan for, 337
diphenhydramine for, 356
guaifenesin for, 539
hydrocode for, 550
Coumadin, 1238, P16
Covera-HS, 1228
Coversyl, 919
Cooza, 685, P9
creatinine, therapeutic and toxic blood levels for, S16
Creo-Terpin, 336
Creamulsion, 336
Crestor, 1057, P14
Crinone, 986
Critical care nursing, most commonly used drugs in, 1369–1370
Crixivan, 584
Crohn's disease
adalimumab for, 30
budesonide for, 157
infliximab for, 588
Crolo, 287
cromolyn sodium, 287–289
Cryptococcal infection
ampoteriain B for, 81
fluconazole for, 475
flucytosine for, 476
Cryscill-AS, 908
Cupric Sulfate, 1304–1305
Cuprofen, 566
Curosurf, 950
Cushing's syndrome, dexamethasone for diagnosis of, 331
Cutivate, 488
Cyanide poisoning, amyl nitrite as antidote for, 88
cyanocobalamin, 1305
Cyanoject, 1305
cyclobenzaprine hydrochloride, 289–291
Cyclomen, 304
cyclophosphamide, 291–293
Cycloplegia, atropine for, 115
cyclosporine, 293–296, therapeutic and toxic blood levels for, S16
Cyclosporine ophthalmic emulsion, 293–296
Cymbalta, 390
Cymevene, 513
cyproheptadine hydrochloride, 296–297
Cystic fibrosis acetylcysteine for, 19
tobramycin for, 1172
Cystitis hyoscyamine for, 561
ofloxacin for, 849
Cystospaz, 560
Cynexin, 1302
cytarabine, 297–299
Cytomegalovirus prophylaxis
ganciclovir for, 513
valganciclovir for, 1215
Cytomegalovirus retinitis
cidofovir for, 249
ganciclovir for, 513
valganciclovir for, 1215
Cytomel, 669
Cytoprotective agents, 1272–1274
Cytosar, 297
Cytosar-U, 297
Cytotec, 771
Cytovene, 513

D
dacarbazine, 299–300
daclizumab, 300–302
Dactarin Gold, 623
Dalacin C, 263
Dalacin C Flavored Granules, 263
Dalacin C Phosphate, 263
Dalacin T, 263
Dalmane, 486
dalteparin sodium, 302–304
danazol, 304–306
Dandrazol, 623
dantrolene sodium, 306–308
Danol, 304
Dantrium, 306
Dantrium Intravenous, 306
dantrene sodium, 306–308
Danoil, 532
d’Apha E, 1312
Daraprim, 1005
darbepeotin alfa, 308–310
darifenacin hydrobromide, 311–310
darunavir ethanolate, 311–313
Darvocet N-100, 1343, P12
Darvocet-N 50, P12
Darvon, 993
Darvon-N, 993
dasatinib, 311–316
daunorubicin citrate liposome, 316–317
daunorubicin hydrochloride, 318–319
DaunoXome, 316
Daypro, 866
Daytrana, 740
DC Softgels, 366
DDAVP, 327
ddl, 346–348
1-deamino-8-D-arginine vasopressin, 327–329
Decapeptyl SR, 1208
Decongestant, phenylephrine for, 931
Deep vein thrombosis dalteparin for, 302
enoxaparin for, 405, 406
ondaparinux for, 495
streptokinase for, 1100
tinzaparin for, 1163
deferasirox, 319–321
deferoxamine, S32
Defix, 455
Delacortril, 969
Delavirdine mesylate, 321–323
Delestrogen, 430
Delsym, 336
Delta-D, 1303
Deltastab, 969
Demadex, 1181
Dementia. See also Alzheimer’s dementia.
galantamine for, 512
tacrine for, 1117
Demerol, 712
Denzapine, 276
denileukin difitox, 323–324
Dentinox Colic Drops, 1077
Dentomycin, 765
Depacon, 1216
Depade, S32
Depakene, 1216
Depakote, 1216, P5
Depakote ER, 1216, P5
Depakote Sprinkle, 1216
Depo-Estradiol, 429
Depo-Medrol, 744
Depo-Medrone, 744
Depo-Provera, 700
Depo-SUBQ-Provera 104, 700
Depo-Testosterone, 1139
DepoCyt, 297
DepoCyte, 297
Depression. See also Major depressive disorder.
amitriptyline for, 67
amoxapine for, 73
bupropion for, 163
citalopram for, 260
desipramine for, 325
desvenlafaxine for, 329
doxepin for, 376
duloxetine for, 390
escitalopram for, 425
fluoxetine for, 481
imipramine for, 577
isocarboxazid for, 613
mirtazapine for, 769
nefazodone for, 807
nortriptyline for, 844
phenelzine for, 925
quetiapine for, 1007
Depression (continued)
sertraline for, 1073
tranylcypromine for, 1186
trazodone for, 1190
trimipramine for, 1207
venlafaxine for, 1226
Dermaprotuberans
imatinib for, 574
Dermatologic disorders
hydrocortisone for, 552
prednisolone for, 969
triamcinolone for, 1196
Dermatoses, corticosteroid-responsive
fluticasone for, 489
triamcinolone for, 1196
Dermographism, cyproheptadine for, 296
Desenex Max, 1135
Desferal, S32
desipramine hydrochloride, 324-326
therapeutic and toxic blood levels for, S16
desloratadine, 326-327, P5
DesmoMelt, 327
desmopressin acistrate for, 590
Desmospray, 327
desvenlafaxine, 329-331
Dialar, 339
dexamethasone, 331-333
dexamethasone sodium phosphate, 331-333
Dexasone, 331
dexedrine spansule, 334
DexFerrum, 610
dextroamphetamine sulfate, 334-336
dextromethorphan hydrobromide, 333-334
dextroamphetamine sulfate, 334-336
d4T, 1098-1100
d-glucose, 337-339
DHPG, 513-515
DiaBeta, 532
Diabetes insipidus, desmopressin for, 328
Diabetes mellitus
acarbose for, 11
chlorpropamide for, 244
colesevelam for, 283
exenatide for, 451
glimepiride for, 527
glipizide for, 529
glyburide for, 532
insulin aspart for, 593
insulin for, 590
insulin glargine for, 595
losartan for, 686
metformin for, 726
nateglinide for, 804
pioglitazone for, 941
pramlintide for, 964
repaglinide for, 1030
rosiglitazone for, 1056
sitagliptin for, 1082
Diabetic acidosis
potassium acetate for, 954
potassium chloride for, 957
Diabetic gastroparesis, metoclopramide for, 747
Diabetic ketoacidosis, insulin for, 590
Diabetic nephropathy, captopril for, 178
Diabetic peripheral neuropathy, pregabalin for, 975
Diabetic Tussin Allergy Relief, 239
Diabetic Tussin EX, 539
Diabinese, 243
Diah-Limit, 681
Dialar, 339
Dialysis, effects of, on drug therapy, S18-S20
Diamode, 681
Diamox, 16
Diamox Sequels, 16
Diaquite, 681
Diareze, 681
Diarr-Eze, 681
Diarrhea. See also
Traveler’s diarrhea.
bismuth for, 143
calcium polycarbophil for, 173
ciprofloxacin for, 255
Clostridium difficile, 1358
diphenoxylate and atropine for, 358
loperamide for, 681, 682
nitazoxanide for, 829
octreotide for, 847
rifaximin for, 1040
vancomycin for, 1222
Diarrhea Relief, 681
Diastat, 339
Diazemuls, 339
diazepam, 339-341
therapeutic and toxic blood levels for, S16
Diazepam Intensol, 339
diazoxide, 341-343
diclofenac potassium, 343-345
diclofenac sodium, 343-345
Dicolofex, 343
Dilocphene, 345
dicyclomine, 345-346
dicycloverine, 345-346
didanosine, 346-348
2,3-dideoxyinosine, 346-348
Didronel, 441
Didronel PMO, 441
Dietary supplement calcium as, 172
zinc as, 1312
Diflucan, 474, P6
Digibind, S31
DigitFab, S31
Digitek, 348
digoxin, 348-351, P5
therapeutic and toxic blood levels for, S16
digoxin immune Fab, S31
Digoxin overdose, managing, S31
Dilacor-XR, 351
Dilantin, P12
Dilantin Infatabs, 934
Dilantin Kapsules, 934
Dilantin-125, 934
Dilatrate-SR, 618

Boldface: Color section
<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dilaudid, 554</td>
<td></td>
</tr>
<tr>
<td>Dilaudid-5, 554</td>
<td></td>
</tr>
<tr>
<td>Dilaudid-HP, 554</td>
<td></td>
</tr>
<tr>
<td>Dilcardia, 351</td>
<td></td>
</tr>
<tr>
<td>Dilt-CD, 351</td>
<td></td>
</tr>
<tr>
<td>Dilt-XR, 351</td>
<td></td>
</tr>
<tr>
<td>Diltia XT, 351</td>
<td></td>
</tr>
<tr>
<td>diltiazem hydrochloride, 351–353, P5</td>
<td></td>
</tr>
<tr>
<td>therapeutic and toxic blood levels for, S16</td>
<td></td>
</tr>
<tr>
<td>Dilution, body water, sodium chloride for, 1085</td>
<td></td>
</tr>
<tr>
<td>Dilution, drug, sodium chloride for, 1084</td>
<td></td>
</tr>
<tr>
<td>Dilzem, 351</td>
<td></td>
</tr>
<tr>
<td>dimenhydrinate, 353–354</td>
<td></td>
</tr>
<tr>
<td>dimercaprol (BAL), S30</td>
<td></td>
</tr>
<tr>
<td>Dimetane, 155</td>
<td></td>
</tr>
<tr>
<td>Dimetapp Allergy, 155</td>
<td></td>
</tr>
<tr>
<td>dinoprostone, 354–355</td>
<td></td>
</tr>
<tr>
<td>Diocalm Ultra, 681</td>
<td></td>
</tr>
<tr>
<td>Diocaps, 681</td>
<td></td>
</tr>
<tr>
<td>Diocto, 366</td>
<td></td>
</tr>
<tr>
<td>Diocyl, 366</td>
<td></td>
</tr>
<tr>
<td>Diomycin, 423</td>
<td></td>
</tr>
<tr>
<td>Diopred, 969</td>
<td></td>
</tr>
<tr>
<td>Biosulf, 1105</td>
<td></td>
</tr>
<tr>
<td>Diotame, 142</td>
<td></td>
</tr>
<tr>
<td>Diovon, 1219, P16</td>
<td></td>
</tr>
<tr>
<td>Diovon HCT, P16</td>
<td></td>
</tr>
<tr>
<td>Dipentum, 855</td>
<td></td>
</tr>
<tr>
<td>Diphen AF, 356</td>
<td></td>
</tr>
<tr>
<td>Diphenhist, 356</td>
<td></td>
</tr>
<tr>
<td>diphenhydramine hydrochloride, 356–357</td>
<td></td>
</tr>
<tr>
<td>diphenoxylate hydrochloride and atropine sulfate, 357–359</td>
<td></td>
</tr>
<tr>
<td>Diphenyalan, 934</td>
<td></td>
</tr>
<tr>
<td>diphenhydantoin, 934–936</td>
<td></td>
</tr>
<tr>
<td>diphenhydantoin sodium, 934–936</td>
<td></td>
</tr>
<tr>
<td>diphenylhydantoin, therapeutic and toxic blood levels for, S16</td>
<td></td>
</tr>
<tr>
<td>Diphtheria, penicillin G potassium for, 906</td>
<td></td>
</tr>
<tr>
<td>penicillin G procaine for, 908</td>
<td></td>
</tr>
<tr>
<td>Diphtheria, tetanus, pertussis immunization schedule, 1346t, 1347t, 1348t</td>
<td></td>
</tr>
<tr>
<td>dipyridamole, 359–360</td>
<td></td>
</tr>
<tr>
<td>Disease-modifying agents, 1276–1277</td>
<td></td>
</tr>
<tr>
<td>Disogram, 351</td>
<td></td>
</tr>
<tr>
<td>disopyramide, 360–362</td>
<td></td>
</tr>
<tr>
<td>disopyramide phosphate, 360–362</td>
<td></td>
</tr>
<tr>
<td>Dispirin, 21</td>
<td></td>
</tr>
<tr>
<td>Disprol, 14</td>
<td></td>
</tr>
<tr>
<td>Disseminated intravascular coagulation, 1359</td>
<td></td>
</tr>
<tr>
<td>Distaclor, 198</td>
<td></td>
</tr>
<tr>
<td>Disulfiram-like reaction, 1359</td>
<td></td>
</tr>
<tr>
<td>Ditropan, 871</td>
<td></td>
</tr>
<tr>
<td>Ditropan XL, 871, P11</td>
<td></td>
</tr>
<tr>
<td>Diuchlor H, 547</td>
<td></td>
</tr>
<tr>
<td>Diuresis, mannitol for, 697</td>
<td></td>
</tr>
<tr>
<td>Diuretics, 1287–1288</td>
<td></td>
</tr>
<tr>
<td>Diuril, 237</td>
<td></td>
</tr>
<tr>
<td>divalproex sodium, 1216–1219, P5</td>
<td></td>
</tr>
<tr>
<td>Diverticulitis, scopolamine for, 1067</td>
<td></td>
</tr>
<tr>
<td>simethicone for, 1077</td>
<td></td>
</tr>
<tr>
<td>Dixerit, 272</td>
<td></td>
</tr>
<tr>
<td>Dizziness, dimenhydrinate for, 353</td>
<td></td>
</tr>
<tr>
<td>DNA topoisomerase inhibitors, 1272–1274</td>
<td></td>
</tr>
<tr>
<td>dobutamine hydrochloride, 362–363</td>
<td></td>
</tr>
<tr>
<td>Dobutamine infusion rates, 1353t</td>
<td></td>
</tr>
<tr>
<td>docetaxel, 363–365</td>
<td></td>
</tr>
<tr>
<td>docusate calcium, 366–367</td>
<td></td>
</tr>
<tr>
<td>docusate sodium, 366–367</td>
<td></td>
</tr>
<tr>
<td>Docusol, 366</td>
<td></td>
</tr>
<tr>
<td>dolasetron mesylate, 367–368</td>
<td></td>
</tr>
<tr>
<td>Dolophine, 725</td>
<td></td>
</tr>
<tr>
<td>Dom-Alendronate, 41</td>
<td></td>
</tr>
<tr>
<td>Dom-Amantadine, 55</td>
<td></td>
</tr>
<tr>
<td>Dom-Bicalutamide, 140</td>
<td></td>
</tr>
<tr>
<td>Dom-Bromocriptine, 154</td>
<td></td>
</tr>
<tr>
<td>Dom-Captopril, 177</td>
<td></td>
</tr>
<tr>
<td>Dom-Carbamazepine, 180</td>
<td></td>
</tr>
<tr>
<td>Dom-Carvedilol, 194</td>
<td></td>
</tr>
<tr>
<td>Dom-Cephalexin, 224</td>
<td></td>
</tr>
<tr>
<td>Dom-Clomipramine, 268</td>
<td></td>
</tr>
<tr>
<td>Dom-Conazepam, 270</td>
<td></td>
</tr>
<tr>
<td>Dom-Clonidine, 272</td>
<td></td>
</tr>
<tr>
<td>Dom-Cyclobenzaprine, 289</td>
<td></td>
</tr>
<tr>
<td>Dom-Desipramine, 324</td>
<td></td>
</tr>
<tr>
<td>Dom-Diclofenac, 343</td>
<td></td>
</tr>
<tr>
<td>Dom-Divalproex, 1216</td>
<td></td>
</tr>
<tr>
<td>Dom-Docusate Sodium, 366</td>
<td></td>
</tr>
<tr>
<td>Dom-Fluconazole, 474</td>
<td></td>
</tr>
<tr>
<td>Dom-Fluvoxamine, 493</td>
<td></td>
</tr>
<tr>
<td>Dom-Furosemide, 507</td>
<td></td>
</tr>
<tr>
<td>Dom-Gabapentin, 510</td>
<td></td>
</tr>
<tr>
<td>Dom-Gemfibrozil, 520</td>
<td></td>
</tr>
<tr>
<td>Dom-Glyburide, 532</td>
<td></td>
</tr>
<tr>
<td>Dom-Indapamide, 583</td>
<td></td>
</tr>
<tr>
<td>Dom-Ipratropium, 605</td>
<td></td>
</tr>
<tr>
<td>Dom-Isoniazid, 615</td>
<td></td>
</tr>
<tr>
<td>Dom-Levetiracetam, 651</td>
<td></td>
</tr>
<tr>
<td>Dom-Levo-Carbipoda, 182</td>
<td></td>
</tr>
<tr>
<td>Dom-Lisinopril, 675</td>
<td></td>
</tr>
<tr>
<td>Dom-Loperamide, 681</td>
<td></td>
</tr>
<tr>
<td>Dom-Lorazepam, 684</td>
<td></td>
</tr>
<tr>
<td>Dom-Lovastatin, 687</td>
<td></td>
</tr>
<tr>
<td>Dom-Loxapine, 689</td>
<td></td>
</tr>
<tr>
<td>Dom-Medroxyprogesterone, 700</td>
<td></td>
</tr>
<tr>
<td>Dom-Meloxicam, 705</td>
<td></td>
</tr>
<tr>
<td>Dom-Metformin, 723</td>
<td></td>
</tr>
<tr>
<td>Dom-Metoprolol, 750</td>
<td></td>
</tr>
<tr>
<td>Dom-Minocycline, 765</td>
<td></td>
</tr>
<tr>
<td>Dom-Mirtazapine, 769</td>
<td></td>
</tr>
<tr>
<td>Dom-Nizatidine, 836</td>
<td></td>
</tr>
<tr>
<td>Dom-Nortriptyline, 844</td>
<td></td>
</tr>
<tr>
<td>Dom-Nystatin, 846</td>
<td></td>
</tr>
<tr>
<td>Dom-Ondansetron, 858</td>
<td></td>
</tr>
<tr>
<td>Dom-Oxybutinin, 871</td>
<td></td>
</tr>
<tr>
<td>Dom-Paroxetine, 890</td>
<td></td>
</tr>
<tr>
<td>Dom-Pindolol, 939</td>
<td></td>
</tr>
<tr>
<td>Dom-Piroxicam, 947</td>
<td></td>
</tr>
<tr>
<td>Dom-Pravastatin, 966</td>
<td></td>
</tr>
<tr>
<td>Dom-Propranolol, 995</td>
<td></td>
</tr>
<tr>
<td>Dom-Selegiline, 1070</td>
<td></td>
</tr>
<tr>
<td>Dom-Sertraline, 1073</td>
<td></td>
</tr>
<tr>
<td>Dom-Simvastatin, 1078</td>
<td></td>
</tr>
<tr>
<td>Dom-Sotalol, 1095</td>
<td></td>
</tr>
<tr>
<td>Dom-Sucralfate, 1104</td>
<td></td>
</tr>
<tr>
<td>Dom-Sumatriptan, 1113</td>
<td></td>
</tr>
<tr>
<td>Dom-Tenazepam, 1128</td>
<td></td>
</tr>
<tr>
<td>Dom-Terazosin, 1134</td>
<td></td>
</tr>
<tr>
<td>Dom-Ticlopidine, 1156</td>
<td></td>
</tr>
<tr>
<td>Dom-Timolol, 1159</td>
<td></td>
</tr>
<tr>
<td>Dom-Topiramate, 1177</td>
<td></td>
</tr>
</tbody>
</table>

**t**: table  
**Boldface**: Color section
<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Page Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>EC-Naprosyn</td>
<td>1393</td>
</tr>
<tr>
<td>Dom-Trazodone</td>
<td>1189</td>
</tr>
<tr>
<td>Dom-Valproic Acid</td>
<td>1216</td>
</tr>
<tr>
<td>Dom-Verapamil SR</td>
<td>1228</td>
</tr>
<tr>
<td>donepezil hydrochloride</td>
<td>368–369</td>
</tr>
<tr>
<td>dong quai</td>
<td>1317</td>
</tr>
<tr>
<td>dopamine hydrochloride</td>
<td>369–371</td>
</tr>
<tr>
<td>Dopamine infusion rates</td>
<td>1354t</td>
</tr>
<tr>
<td>Dopaminergics</td>
<td>1274</td>
</tr>
<tr>
<td>Dornpram</td>
<td>371</td>
</tr>
<tr>
<td>dornepram monohydrate</td>
<td>371–372</td>
</tr>
<tr>
<td>dornase alpha</td>
<td>372–373</td>
</tr>
<tr>
<td>Doryx</td>
<td>383</td>
</tr>
<tr>
<td>D.O.S. Softgels</td>
<td>366</td>
</tr>
<tr>
<td>Dosages, calculating</td>
<td>S6</td>
</tr>
<tr>
<td>Doxxadura</td>
<td>375</td>
</tr>
<tr>
<td>doxapram hydrochloride</td>
<td>373–375</td>
</tr>
<tr>
<td>doxazosin mesylate</td>
<td>375–376</td>
</tr>
<tr>
<td>doxepin hydrochloride</td>
<td>376–378</td>
</tr>
<tr>
<td>doxercalferol</td>
<td>1306</td>
</tr>
<tr>
<td>Doxidan</td>
<td>141</td>
</tr>
<tr>
<td>Doxil</td>
<td>381</td>
</tr>
<tr>
<td>Doxine</td>
<td>1309</td>
</tr>
<tr>
<td>doxorubicin hydrochloride</td>
<td>378–381</td>
</tr>
<tr>
<td>doxorubicin hydrochloride, liposomal</td>
<td>381–383</td>
</tr>
<tr>
<td>Doxy 100</td>
<td>383</td>
</tr>
<tr>
<td>doxycycline</td>
<td>383–385</td>
</tr>
<tr>
<td>doxycycline calcium</td>
<td>383–385</td>
</tr>
<tr>
<td>doxycycline hyclate</td>
<td>383–385</td>
</tr>
<tr>
<td>doxycycline monohydrate</td>
<td>383–385</td>
</tr>
<tr>
<td>Doxytab</td>
<td>383</td>
</tr>
<tr>
<td>Dozic</td>
<td>541</td>
</tr>
<tr>
<td>Dramamine</td>
<td>353</td>
</tr>
<tr>
<td>Dramamine Less Drowsy</td>
<td>Formula, 699</td>
</tr>
<tr>
<td>Dramanate</td>
<td>353</td>
</tr>
<tr>
<td>Drixoral Nasal Decongestant</td>
<td>999</td>
</tr>
<tr>
<td>Drixoral Non-Drowsy</td>
<td>Formula, 999</td>
</tr>
<tr>
<td>Drogenil</td>
<td>487</td>
</tr>
<tr>
<td>Dromadol SR</td>
<td>1182</td>
</tr>
<tr>
<td>Dromadol XL</td>
<td>1182</td>
</tr>
<tr>
<td>dronabinol</td>
<td>386–387</td>
</tr>
<tr>
<td>droperidol</td>
<td>387–389</td>
</tr>
<tr>
<td>drotrecogin alfa (activated)</td>
<td>389–390</td>
</tr>
<tr>
<td>Droxia</td>
<td>557</td>
</tr>
<tr>
<td>Drug administration</td>
<td></td>
</tr>
<tr>
<td>five rights of, xiv</td>
<td></td>
</tr>
<tr>
<td>general guidelines for, xiii–xv</td>
<td></td>
</tr>
<tr>
<td>safe, S1–S32</td>
<td></td>
</tr>
<tr>
<td>Drug classes, 1255–1302</td>
<td></td>
</tr>
<tr>
<td>Drug compatibilities, S2–S5</td>
<td></td>
</tr>
<tr>
<td>Drug conversion and calculations</td>
<td>S6</td>
</tr>
<tr>
<td>Drug desensitization,</td>
<td></td>
</tr>
<tr>
<td>asparaginase for, 107</td>
<td></td>
</tr>
<tr>
<td>Drug names that look or sound alike, S7–S9</td>
<td></td>
</tr>
<tr>
<td>Drug therapy, effects of dialysis on, S18–S20</td>
<td></td>
</tr>
<tr>
<td>Drugs</td>
<td></td>
</tr>
<tr>
<td>200 most commonly prescribed,</td>
<td></td>
</tr>
<tr>
<td>1371–1373</td>
<td></td>
</tr>
<tr>
<td>hazardous, guidelines for</td>
<td></td>
</tr>
<tr>
<td>handling, preparing, and</td>
<td></td>
</tr>
<tr>
<td>administering, S27–S29</td>
<td></td>
</tr>
<tr>
<td>high-alert, xix</td>
<td></td>
</tr>
<tr>
<td>D-S-S</td>
<td>366</td>
</tr>
<tr>
<td>DTIC</td>
<td>299</td>
</tr>
<tr>
<td>DTIC-Dome</td>
<td>299</td>
</tr>
<tr>
<td>Duetact</td>
<td>1343</td>
</tr>
<tr>
<td>DulcoCase</td>
<td>366</td>
</tr>
<tr>
<td>Dulcolax</td>
<td>141</td>
</tr>
<tr>
<td>Dulcolax Milk of Magnesia</td>
<td>693</td>
</tr>
<tr>
<td>Dull-C</td>
<td>1303</td>
</tr>
<tr>
<td>duloxetine hydrochloride</td>
<td>390–393</td>
</tr>
<tr>
<td>Duodenal ulcer</td>
<td></td>
</tr>
<tr>
<td>amoxicillin for, 76</td>
<td></td>
</tr>
<tr>
<td>cimetidine for, 252</td>
<td></td>
</tr>
<tr>
<td>esomeprazole for, 428</td>
<td></td>
</tr>
<tr>
<td>famotidine for, 458</td>
<td></td>
</tr>
<tr>
<td>lansoprazole for, 637</td>
<td></td>
</tr>
<tr>
<td>nizatidine for, 836</td>
<td></td>
</tr>
<tr>
<td>omeprazole for, 857</td>
<td></td>
</tr>
<tr>
<td>rabeprazole for, 1017</td>
<td></td>
</tr>
<tr>
<td>Duodenal ulcer (continued)</td>
<td></td>
</tr>
<tr>
<td>ranitidine for, 1024</td>
<td></td>
</tr>
<tr>
<td>sucralfate for, 1104</td>
<td></td>
</tr>
<tr>
<td>Duodenography</td>
<td></td>
</tr>
<tr>
<td>hyoscyamine for, 561</td>
<td></td>
</tr>
<tr>
<td>Duphalac</td>
<td>630</td>
</tr>
<tr>
<td>Duracolon</td>
<td>272</td>
</tr>
<tr>
<td>Duragesic</td>
<td>464</td>
</tr>
<tr>
<td>Duralith</td>
<td>677</td>
</tr>
<tr>
<td>Duramorph</td>
<td>780</td>
</tr>
<tr>
<td>Durogesic</td>
<td>464</td>
</tr>
<tr>
<td>dutasteride</td>
<td>393–394</td>
</tr>
<tr>
<td>Duvoid</td>
<td>137</td>
</tr>
<tr>
<td>Dyazide</td>
<td>1343</td>
</tr>
<tr>
<td>Dymotil</td>
<td>357</td>
</tr>
<tr>
<td>Dynacin</td>
<td>765</td>
</tr>
<tr>
<td>DynaCirc CR</td>
<td>620</td>
</tr>
<tr>
<td>Dynamin</td>
<td>618</td>
</tr>
<tr>
<td>Dynamin XL</td>
<td>618</td>
</tr>
<tr>
<td>Dyrenium</td>
<td>1199</td>
</tr>
<tr>
<td>Dysbeta lipoproteinemia</td>
<td></td>
</tr>
<tr>
<td>amlodipine and atorvastatin for, 71</td>
<td></td>
</tr>
<tr>
<td>atorvastatin for, 112</td>
<td></td>
</tr>
<tr>
<td>pravastatin for, 966</td>
<td></td>
</tr>
<tr>
<td>Dysentery, scopolamine for, 1067</td>
<td></td>
</tr>
<tr>
<td>Dyskinesia, diphenhydramine for, 356</td>
<td></td>
</tr>
<tr>
<td>Dyslipidemia, mixed</td>
<td></td>
</tr>
<tr>
<td>atorvastatin for, 112</td>
<td></td>
</tr>
<tr>
<td>fenofibrate for, 461</td>
<td></td>
</tr>
<tr>
<td>pravastatin for, 966</td>
<td></td>
</tr>
<tr>
<td>rosuvastatin for, 1058</td>
<td></td>
</tr>
<tr>
<td>Dysmenorrhea</td>
<td></td>
</tr>
<tr>
<td>celecoxib for, 223</td>
<td></td>
</tr>
<tr>
<td>diclofenac for, 343</td>
<td></td>
</tr>
<tr>
<td>ibuprofen for, 567</td>
<td></td>
</tr>
<tr>
<td>naproxen for, 800, 801</td>
<td></td>
</tr>
<tr>
<td>Dyspareut</td>
<td>252</td>
</tr>
<tr>
<td>Dyspepsia, simethicone for, 1077</td>
<td></td>
</tr>
<tr>
<td>Dystonic reactions, benztrapine for, 134</td>
<td></td>
</tr>
<tr>
<td>E</td>
<td></td>
</tr>
<tr>
<td>Ear infection, amoxicillin for, 76</td>
<td></td>
</tr>
<tr>
<td>Easprin</td>
<td>21</td>
</tr>
<tr>
<td>Easyhaler Budesonide</td>
<td>157</td>
</tr>
<tr>
<td>Ebita</td>
<td>709</td>
</tr>
<tr>
<td>EC-Naprosyn</td>
<td>800</td>
</tr>
</tbody>
</table>
Eccoxolac, 442
Echinacea, 1317–1318
Ecotrin, 21
Edema
  acetazolamide for, 17
  bumetanide for, 159
  chlorothiazide for, 237
  chlorthalidone for, 245
  dexamethasone for, 331
  furosemide for, 508
  hydrochlorothiazide for, 547
  indapamide for, 583
  methylprednisolone for, 744
  metolazone for, 748
  spironolactone for, 1097, 1199
Eddate disodium, S31
E.E.S., 423
Efavirenz, 394–395
Effexor, 1226
Effexor XR, 1226, P16
Efudex, 479
E-Glades, 423
Elantan, 618
Elantan LA, 618
Eldepryl, 1070
Elderly
  potentially inappropriate drugs for, 1364–1366
Electrolyte replacement, sodium chloride for, 1085
Elestrin, 429
eletriptan hydrobromide, 396–397
Elidel, 936
Eligard, 647
Elitek, 1029
Elixisth:Cough, 336
Elixophyllin, 1146
Ellence, 412
Elleste, 429
Elleste-Solo, 429
Eloxitan, 862
Elspar, 106
Eltroxin, 660
Elyzol, 752
Embolus, cholesterol, 1358
Emcor, 144
Emcor LS, 144
Emend, 99
Emergency care nursing,
  most commonly used drugs in, 1369
EMLA Cream, 1343
Emphysema, acetylcysteine for, 19
Emsam, 1070
Emselex, 310
Emtricitabine, 397–399
Emtricitabine and tenofovir disoproxil fumarate, 399–401
Emtriva, 397
Enablex, 310
Enalapril maleate, 401–403
Enalaprilat, 401–403
Enbrel, 437
Encephalitis, acyclovir for, 28
Encephalopathy, 1359
Endocarditis
  cefazolin for, 202
  flucytosine for, 476
  imipenem and clastatin for, 575
  penicillin G potassium for, 906
  penicillin G procaine for, 908
Endocarditis prophylaxis
  amoxicillin for, 76
  ampicillin for, 84, 85
  gentamicin for, 524
  vancomycin for, 1221
Endocervical infection, tetracycline for, 1142
Endocet, 1343
Endocrine disorders
  methylprednisolone for, 744
  prednisolone for, 969
Endometrial cancer
  medroxyprogesterone for, 701
  megestrol for, 704
Endometrial changes,
  medroxyprogesterone to prevent, 701
Endometrial hyperplasia,
  progesterone to prevent, 987
Endometrin, 986
Endometriosis
  danazol for, 305
  goserelin for, 536
  leuprolide for, 648
  medroxyprogesterone for, 701
  nafarelin for, 796
  norethindrone for, 841
Endoscopy
  diazepam for, 339
  hyoscymine for, 561
Endotracheal intubation
  atracurium for, 1330–1331
  pancuronium for, 1334–1335
  rocuronium for, 1338–1339
  succinylcholine for, 1338–1339
  vecuronium for, 1340–1341
Endoxana, 291
Endrate, S31
Enfuvirtide, 403–405
Enoxaparin sodium, 405–407
Enpirin, 21
Entacapone, 407–408
Entecavir, 408–409
Enterobiasis
  mebendazole for, 698
  pyrantel for, 1002
Enterocolitis, vancomycin for, 1222
Enthanate, 1139
Entocalm, 681
Entocort CR, 157
Entocort EC, 157
Entocort Enema, 157
Entrocel, 735
Entrophen, 21
Enulose, 630
Enuresis
  imipramine for, 577
  Eosinophilic pneumonitis, 1359
Epanutin, 934
Epi-E-Z Pen, 409
Epilem, 1216
Epilem Chrono, 1216
Epilepsy. See Seizures.
  Epileptiform seizures, 1359
Epimaz, 180

| t: table

**Boldface:** Color section
epinephrine, 409–411
  for cholinergic overdose, S31
epinephrine bitartrate, 409–411
epinephrine hydrochloride, 409–411
Epinephrine infusion rates, 1354t
EpiPen, 409
EpiPen Jr., 409
Epipodophyllotoxins, 1272–1274
epirubicin hydrochloride, 412–413
Episenta, 1216
Epitol, 180
Epival CR, 1216
Epival ECT, 1216
Epivir, 631
Epivir-HBV, 631
eplerenone, 414–415
epoetin alfa, 415–417
Epogen, 415
Eposin, 446
Eprex, 415
eprosartan mesylate, 417–418
Epsom Salts, 694
eptadone, 725–728
eptifibatide, 418–419
Epzicom, 4, 1343
Equalactin, 173
Equalizer Gas Relief, 1077
Equasym, 740
Equasym XL, 740
Equetro, 180
Eraxis, 836
Estrace, 429
Estraderm, 429
estradiol acetate, 429–431
estradiol cypionate, 429–431
estradiol hemihydrate, 429–431
estradiol valerate, 430–431
Estradot, 429
Estrasorb, 429
Estring, 429
Estrogel, 429
Estrogen therapy
  chlorothiazide as
    adjunct to, 237
  chlorothalidone as
    adjunct to, 245
  hydrochlorothiazide as
    adjunct to, 547
  Estrogens, 1297–1298
  estrogen, conjugated, 432–434, P6
  estrogens, esterified, 434–436
ezetimibe, 1318
Eucardic, 194
Eudemine, 341
Euflex, 487
Euglucon, 532
Euro-Lac, 630
Euro-Lithium, 677
Eustachian tube congestion,
  pseudoephedrine for, 999
Euthyrox, 660
evening primrose, 1318
Evista, 1018, P13
Evoltra, 265

**Boldface:** Color section

---

Evoltra 1395
Gastrointestinal bleeding

Flovent, 488
Flovent HFA, 488
Floxin, 849
fluconazole, 474–476, P6
   therapeutic and toxic
   blood levels for, S16
flucytosine, 476–477
Fluid and electrolyte
   replacement, sodium chloride
   for, 1084, 1085
Flumadine, 1042
flumazenil, S30
flunisolide, 478–479
Fluoroplex, 479
Fluoroquinolones, 1269–1270
fluorouracil, 479–481
5-fluorouracil, 479–481
fluoxetine hydrochloride,
   481–483, P7
   therapeutic and toxic
   blood levels for, S16
fluphenazine decanoate,
   483–485
fluphenazine hydrochloride,
   483–485
Fluphenazine Omega, 483
flurazepam hydrochloride,
   486–487
Flushing, octreotide for,
   847
flutamide, 487–488
fluticasone furoate,
   488–491
fluticasone propionate,
   488–491
fluvastatin sodium,
   491–493
fluvoxamine maleate,
   493–495
Focalin, 333
Focalin XR, 333
folic acid, 1306–1307
Folic acid antagonist
   overdose, leucovorin calcium for,
   646
Folic acid deficiency, folic
   acid for, 1306
folinic acid, 645–647
Folvite, 1306
fomepizole, S31
fondaparinux sodium,
   495–496
Foradil, 497
Foradil Aerolizer, 497
formoterol fumarate,
   497–498
Formulex, 345
Forsteo, 1138
Fortaz, 215
Forteo, 1138
Fortical, 169
Fortipine, 822
Fortral, 913
Fortum, 215
Fosamax, 41, P1
Fosamax Plus D, 1343
fosamprenavir calcium,
   498–501
fosinopril sodium,
   501–503, P7
fosphenytoin sodium,
   503–505
Fosrenol, 639
Fragmin, 302
Frova, 505
frovatriptan succinate,
   505–506
Frosol, 507
5-FU, 479–481
fulvestrant, 506–507
Fungal infection
   amphotericin B for, 82
   caspofungin for, 197
   fluconazole for, 476
   voriconazole for, 1236
Fungilin, 80
Fungizone Intravenous, 80
Furadantin, 830
furosemide, 507–510, P7
Fusospirochetal infection
   penicillin G potassium
   for, 906
   penicillin G procaine for,
   908
   penicillin V potassium
   for, 910
Fuzeon, 403
Fybogel, 1000
G
   gabapentin, 510–511, P7
   Gabarone, 510
   Gabitril Filmtabs, 1153
galantamine
   hydrobromide, 512–513
Galenmet, 252
Galpamol, 14
Galsud, 999
Gammumine N 5% S/D, 579
Gammagard S/D 0.5 g, 579
Gamma-P IV, 579
GammaSTAN S/D, 579
Gamunex, 579
ganciclovir, 513–515
ganirelix acetate, 515–516
Gantrisin Pediatric
   Suspension, 1111
Garamycin, 523
garlic, 1320
Gas, excessive, simethicone
   for, 1077
Gas-X, 1077
Gas-X Extra Strength, 1077
GasAid, 1077
Gastric cancer
docetaxel for, 364
doxorubicin for, 379
fluorouracil for, 479
mitomycin for, 772
Gastric ulcer
cimetidine for, 252
esomeprazole for, 428
famotidine for, 458
lansoprazole for, 637
misoprostol for, 771
nizatidine for, 836
omeprazole for, 857
ranitidine for, 1024
Gastrobid, 746
Gastrocrom, 287
Gastroesophageal reflux
disease
cimetidine for, 252
esomeprazole for, 428
famotidine for, 458
lansoprazole for, 637
metoclopramide for, 747
nizatidine for, 836
omeprazole for, 857
ranitidine for, 1024
Gastrointestinal bleeding,
cimetidine for
   prevention of, 252
<table>
<thead>
<tr>
<th>Gastrointestinal disorders</th>
<th>Gen-Minocycline, 765</th>
<th>Gen-Minoxidil, 767</th>
</tr>
</thead>
<tbody>
<tr>
<td>hyoscyamine for, 561</td>
<td>Gen-Mirtazapine, 769</td>
<td></td>
</tr>
<tr>
<td>methylprednisolone for, 744</td>
<td>Gen-Nabumetone, 793</td>
<td></td>
</tr>
<tr>
<td>prednisolone for, 969</td>
<td>Gen-Naproxen EC, 800</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal infection</td>
<td>Gen-Nifedical, 822</td>
<td></td>
</tr>
<tr>
<td>ampicillin for, 84</td>
<td>Gen-Nizatidine, 836</td>
<td></td>
</tr>
<tr>
<td>nystatin for, 846</td>
<td>Gen-Nortriptyline, 844</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal stromal tumor</td>
<td>Gen-Ondansetron, 858</td>
<td></td>
</tr>
<tr>
<td>imatinib for, 574</td>
<td>Gen-Oxybutinin, 871</td>
<td></td>
</tr>
<tr>
<td>sunitinib for, 1115</td>
<td>Gen-Pantoprazole, 888</td>
<td></td>
</tr>
<tr>
<td>GastroMax, 746</td>
<td>Gen-Paroxetine, 890</td>
<td></td>
</tr>
<tr>
<td>gatifloxacin, 516–517</td>
<td>Gen-Pindolol, 939</td>
<td></td>
</tr>
<tr>
<td>Gavilast, 1024</td>
<td>Gen-Pioglitazone, 941</td>
<td></td>
</tr>
<tr>
<td>gefitinib, 517–518</td>
<td>Gen-Piroxicam, 947</td>
<td></td>
</tr>
<tr>
<td>gemcitabine hydrochloride, 518–520</td>
<td>Gen-Pravastatin, 966</td>
<td></td>
</tr>
<tr>
<td>gemfibrozil, 520–521</td>
<td>Gen-Propafenone, 990</td>
<td></td>
</tr>
<tr>
<td>gemfloxacin mesylate, 521–523</td>
<td>Gen-Salbutamol, 35</td>
<td></td>
</tr>
<tr>
<td>Gemzar, 518</td>
<td>Gen-Selegiline, 1070</td>
<td></td>
</tr>
<tr>
<td>Gen Naproxen, 800</td>
<td>Gen-Sertraline, 1073</td>
<td></td>
</tr>
<tr>
<td>Gen-Alendronate, 41</td>
<td>Gen-Simvastatin, 1078</td>
<td></td>
</tr>
<tr>
<td>Gen-Amantadine, 55</td>
<td>Gen-Sotalol, 1095</td>
<td></td>
</tr>
<tr>
<td>Gen-Azathioprine, 118</td>
<td>Gen-Sumatriptan, 1113</td>
<td></td>
</tr>
<tr>
<td>Gen-Baclofen, 124</td>
<td>Gen-Tamoxifen, 1122</td>
<td></td>
</tr>
<tr>
<td>Gen-Bicalutamide, 140</td>
<td>Gen-Temazepam, 1128</td>
<td></td>
</tr>
<tr>
<td>Gen-Captopril, 177</td>
<td>Gen-Ticlopidine, 1156</td>
<td></td>
</tr>
<tr>
<td>Gen-Carbamazepine, 180</td>
<td>Gen-Timolol, 1159</td>
<td></td>
</tr>
<tr>
<td>Gen-Clomipramine, 268</td>
<td>Gen-Tizanidine, 1170</td>
<td></td>
</tr>
<tr>
<td>Gen-Clonazepam, 270</td>
<td>Gen-Topiramate, 1177</td>
<td></td>
</tr>
<tr>
<td>Gen-Clozapine, 276</td>
<td>Gen-Trazodone, 1189</td>
<td></td>
</tr>
<tr>
<td>Gen-Diltiazem, 351</td>
<td>Gen-Triazolam, 1200</td>
<td></td>
</tr>
<tr>
<td>Gen-Divalproex, 1216</td>
<td>Gen-Valproic-Cap, 1216</td>
<td></td>
</tr>
<tr>
<td>Gen-Enalpril, 401</td>
<td>Gen-Venlafaxine XR, 1226</td>
<td></td>
</tr>
<tr>
<td>Gen-Etoprozin, 442</td>
<td>Gen-Verapamil, 1228</td>
<td></td>
</tr>
<tr>
<td>Gen-Famotidine, 457</td>
<td>Gen-Verapamil SR, 1228</td>
<td></td>
</tr>
<tr>
<td>Gen-Fluconazole, 474</td>
<td>Gen-Warfarin, 1238</td>
<td></td>
</tr>
<tr>
<td>Gen-Fosinopril, 501</td>
<td>Genahist, 356</td>
<td></td>
</tr>
<tr>
<td>Gen-Gabapentin, 510</td>
<td>Genasoft Softgels, 366</td>
<td></td>
</tr>
<tr>
<td>Gen-Gemfibrozil, 520</td>
<td>Genasyme, 1077</td>
<td></td>
</tr>
<tr>
<td>Gen-Glybe, 532</td>
<td>Genatuss, 539</td>
<td></td>
</tr>
<tr>
<td>Gen-Hydroxychloroquine, 556</td>
<td>Genes, 14</td>
<td></td>
</tr>
<tr>
<td>Gen-Indapamide, 583</td>
<td>Generalized anxiety disorder</td>
<td></td>
</tr>
<tr>
<td>Gen-Ipratropium, 605</td>
<td>escitalopram for, 426</td>
<td></td>
</tr>
<tr>
<td>Gen-Lac, 630</td>
<td>paroxetine for, 891</td>
<td></td>
</tr>
<tr>
<td>Gen-Lamotrigine, 633</td>
<td>venlafaxine for, 1226</td>
<td></td>
</tr>
<tr>
<td>Gen-Lisinopril, 675</td>
<td>Generlac, 630</td>
<td></td>
</tr>
<tr>
<td>Gen-Lovastatin, 687</td>
<td>Genfiber, 1000</td>
<td></td>
</tr>
<tr>
<td>Gen-Medrox, 700</td>
<td>Gengraf, 93</td>
<td></td>
</tr>
<tr>
<td>Gen-Meloxicam, 705</td>
<td>Genital herpes</td>
<td></td>
</tr>
<tr>
<td>Gen-Metformin, 723</td>
<td>acyclovir for, 27, 28</td>
<td></td>
</tr>
<tr>
<td>Gen-Metoprolol, 750</td>
<td>famciclovir for, 456</td>
<td></td>
</tr>
<tr>
<td>t: table</td>
<td>valacyclovir for, 1214</td>
<td></td>
</tr>
<tr>
<td>Boldface: Color section</td>
<td>Genital infection, cefazolin for, 202</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Genital ulcer, azithromycin for, 121</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Genital warts</td>
<td></td>
</tr>
<tr>
<td></td>
<td>interferon alfa-2b for, 599</td>
<td></td>
</tr>
<tr>
<td></td>
<td>interferon alfa-n3 for, 597</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Genitourinary infection</td>
<td></td>
</tr>
<tr>
<td></td>
<td>amoxicillin for, 76</td>
<td></td>
</tr>
<tr>
<td></td>
<td>cephalaxin for, 225</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ertapenem for, 421</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Genotropin, 1091</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gentacidin, 523</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gentak, 523</td>
<td></td>
</tr>
<tr>
<td></td>
<td>gentamicin sulfate, 523–525</td>
<td></td>
</tr>
<tr>
<td></td>
<td>therapeutic and toxic blood levels for, 516</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Genticin, 523</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gentilax, 141</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Goedon, 1245</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Giardiasis, tinidazole for, 1162</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ginger, 1320–1321</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ginkgo, 1321</td>
<td></td>
</tr>
<tr>
<td></td>
<td>gingens, 1321–1322</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glabellar lines, botulinum toxin for, 152</td>
<td></td>
</tr>
<tr>
<td></td>
<td>glatiramer acetate, 526–527</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glaucoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>acetazolamide for, 17</td>
<td></td>
</tr>
<tr>
<td></td>
<td>carteolol for, 192</td>
<td></td>
</tr>
<tr>
<td></td>
<td>epinephrine for, 410</td>
<td></td>
</tr>
<tr>
<td></td>
<td>phenylephrine for, 931</td>
<td></td>
</tr>
<tr>
<td></td>
<td>timolol for, 1160</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gleevec, 573</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gliadel Wafer, 190</td>
<td></td>
</tr>
<tr>
<td></td>
<td>glibenclamide, 532–533</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glibenese, 529</td>
<td></td>
</tr>
<tr>
<td></td>
<td>glimepiride, 529–530</td>
<td></td>
</tr>
<tr>
<td></td>
<td>glucagon, 529–530, P7</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glimepiride, 527–528, P7</td>
<td></td>
</tr>
<tr>
<td></td>
<td>glucipide, 529–530, P7</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glivec, 573</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glomerulonephritis, penicillin G benzathine as prophylaxis for, 904</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GlucaGen, 530</td>
<td></td>
</tr>
<tr>
<td></td>
<td>glucagon, 530–531</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glucobay, 11</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gluconorm, 1030</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glucophage, 723, P10</td>
<td></td>
</tr>
</tbody>
</table>
Heart failure

Glucophage XR, 723, P10
glucosamine, 1322
glucose, therapeutic and toxic blood levels for, S16
Glucotrol, 529, P7
Glucotrol XL, 529, P7
Glucovance, 1343, P8
Glumetza, 723

Glutathione, therapeutic and toxic blood levels for, S16
Glutose, 337
glyburide, 532–533
glyburide and metformin hydrochloride, P8
glycerol guaiacolate, 539–540
Glycon, 723
glycopyrrolate, 534–535
glycopyrronium, 534–535
Glynase PresTab, 532
Glyset, 763
GM-CSF, 1065–1067

Goiter
levothyroxine for, 660
liothyronine for, 669
goldenseal, 1322

Gonapeptyl Depot, 1208
Gonococcal infection
ampicillin for, 84
ceftaxime for, 212
penicillin G potassium for, 906

Gonorrhoea
amoxicillin for, 76
cefixime for, 207
cefotaxime for, 209
cefpodoxime for, 212
ceftazidime for, 216
ceftriaxone for, 219
cefuroxime for, 221
ciprofloxacin for, 255
doxycycline for, 384
minocycline for, 765
norfloxacin for, 842
ofloxacin for, 849
penicillin G procaine for, 908
pipemidic acid for, 942
probenecid for, 979
tetracycline for, 1142
Goptin, 1184
goserelin acetate, 535–537

Gout
allopurinol for, 45, 46
naproxen for, 801
Gouty arthritis
colchicine for, 282
indomethacin for, 586
GPI-Lactulose, 630
Graft-versus-host disease, immune globulin for, 580
granisetron hydrochloride, 537–538
Granisil, 537
Granulocyteopenia, 1359
Granuloma inguinale, tetracycline for, 1142
grapeseed, 1323
Gravel, 353
green tea, 1323
Growth failure, somatropin, recombinant for, 1091, 1092
Growth hormone deficiency, somatropin, recombinant for, 1091, 1092
Gummas, penicillin G benzathine for, 904
Gynecologic infection
ampicillin and sulbactam for, 87
cefoxitin for, 211
ceftazidime for, 216
cefuroxime for, 221
imipenem and cilastatin for, 575
ticarcillin and clavulanate for, 1154
Gynodiol, 429

H
Haemophilus influenzae
type B
immunization schedule, 1347t

Hair loss
finasteride for, 472
minoxidil for, 767
Hair transplantation, minoxidil as adjunct to, 767
Hairy cell leukemia
interferon alfa-2b for, 598
pentostatin for, 917
Halcion, 1200
Haldol, 541
Haldol Decanoate 50, 541
Haldol LA Omega, 541
Half Beta-Prograne, 995
Half Inderal LA, 995
Half Securon, 1228

Hawthorn, 1323–1324
Hayfever Relief, 129

Hazardous drugs
1367–1368
guidelines for handling, preparing, and administering, S27–S29

Head and neck cancer
amifostine for, 57
bleomycin for, 147
cetuximab for, 228
docetaxel for, 364
hydroxyurea for, 558

Headache. See also
Migraine.
acetaminophen for, 15
propranolol for, 996
timolol for, 1160

Headache Table 2, 21
Heart block, 1359
hyoscine for, 561
isoproterenol for, 617

Heart failure
acetazolamide for, 17
captopril for, 178
carvedilol for, 194
chlorothiazide for, 237
chlophalilone for, 245
digoxin for, 348
dobutamine for, 362
dopamine for, 370
enalapril for, 402

| t: table | Boldface: Color section |
Heart failure (continued)
eplerenone for, 414
fosinopril for, 502
hydrochlorothiazide for, 547
indapamide for, 583
lisinopril for, 674
mexiletine for, 815
nitroglycerin for, 832
quinapril for, 1009
ramipril for, 1022
spironolactone for, 1097
torsemide for, 1181
valsartan for, 1220
Heart transplant rejection,
preventing

cyclosporine for, 293
muromonab-CD3 for, 787
mycophenolate for, 789
tacrolimus for, 1119
Heart transplantation,
valganciclovir for, 1215
Heartburn. See also Acid
indigestion.

bismuth for, 143
cimetidine for, 252
famotidine for, 458
omeprazole for, 857
Heartburn Relief, 857
Heat cramps, sodium
chloride for, 1085
Hectorol, 1306
Hedex, 566
Helicobacter pylori
infection
clarithromycin for, 262
rabeprazole for, 1017
tetrazycline for, 1142
Helidac, 1343
Hematologic disorders
betamethasone for, 135
cortisone for, 286
dexamethasone for, 552
methylprednisolone for, 744
prednisolone for, 696
Hematopoietic agents,
1289–1290
Hemodialysis, sodium
chloride for, 1084
Hemodynamic imbalance,
dopamine for, 370
Hemofil M, 94
Hemophilia
antihemophilic factor
for, 95
cogulation factor VIII
(recombinant) for, 279
desmopressin for, 328
factor IX for, 455
Hemorrhage, antihemophilic
factor for, 95
Hemorrhagic cystitis,
mesna for, 719
Hemorrhagic disease of
newborn, phytodione for, 1309
Hep-Lock, 543
Hep-Lock U/P, 543
Hepalean, 543
heparin cofactor 1, 96–97
Heparin Leo, 543
Hepatitis A immunization
schedule, 1346t, 1347t, 1348t
Hepatitis A virus infection,
immune globulin
for, 579
Hepatitis B immunization
schedule, 1346t, 1347t, 1348t
Hepatitis B virus infection
adefovir for, 31
entecavir for, 408
interferon alfa-2b for,
598
lamivudine for, 632
Hepatitis C virus infection
interferon alfa-2b for,
598
interferon alfacon-1 for,
601
peginterferon alfa-2a
for, 897
peginterferon alfa-2b
for, 899
Hepatitis C virus infection
interferon alfa-2b for,
598
interferon alfacon-1 for,
601
peginterferon alfa-2a
for, 897
peginterferon alfa-2b
for, 899
ribavirin for, 1033
Hepatocellular carcinoma,
sorafenib for, 1093
Hepatomegaly, 1359
Hepatotoxicity, 1359
Hepal, 543
Hepatitis B virus infection
adefovir for, 31
interferon alfa-2b for,
598
peginterferon alfa-2a
for, 897
peginterferon alfa-2b
for, 899
ribavirin for, 1033
Herpes labialis
acyclovir for, 28
famciclovir for, 456
valacyclovir for, 1214
Herpes simplex virus
infection
acyclovir for, 28
famciclovir for, 456
Herpes zoster immunization
schedule,
1346t
Herpes zoster infection
acyclovir for, 27
famciclovir for, 456
valacyclovir for, 1214
Hexit Lotion, 665
Hexit Shampoo 1, 665
Hi-Co, 551
Hiccups, chlorpromazine
for, 241
High-alert drugs, xix
High-altitude sickness,
acetazolamide for,
17
Hipfix, 455
Histac, 1024
Histamine-receptor antagonists,
1278–1279
Histantil, 988
Histergan, 356
Histiocytosis X, vinblastine
for, 1231
Histoplasmosis
amphotericin B for, 80
itraconazole for, 621
ketoconazole for, 624
Hives, desloratadine for, 326
HMG-CoA reductase
inhibitors,
1267–1268
Hodgkin’s disease
bleomycin for, 147
carmustine for, 190
Hodgkin’s disease (continued)
chlorambucil for, 231
cyclophosphamide for, 291
dacarbazine for, 299
doxorubicin for, 379
lomustine for, 680
procarbazine for, 982
vinblastine for, 1231

Hold DM, 336
Home care nursing, most commonly used drugs in, 3, 1369
Hookworm infestation, mebendazole for, 698
5-HT3 receptor antagonists, 1264–1265
Humalog, 589
Humalog Mix 50/50, 590
Humalog Mix 75/25 Z, 590
Humalog Pen, 589
Human erythropoietins, 1289–1290
Human immunodeficiency virus infection
abacavir and lamivudine for, 5
abacavir for, 3
cidofovir for, 249
darunavir for, 311
delavirdine for, 321
didanosine for, 347
efavirenz for, 394
emtricitabine and tenofovir for, 399
emtricitabine for, 397
enfuvirtide for, 403
etravirine for, 447
fosamprenavir for, 498
ganciclovir for, 513
immune globulin for, 581
indinavir for, 584
lamivudine for, 632
nelfinavir for, 810
nevirapine for, 816
raltegravir for, 1019
ritonavir for, 1035
ritonavir for, 1048
saquinavir for, 1063
stavudine for, 1099
tenofovir for, 1132
Humalog, 589
Humalog Mix 50/50, 590
Humalog Mix 75/25 Z, 590
Humalog Pen, 589
Human erythropoietins, 1289–1290
Human immunodeficiency virus infection
abacavir and lamivudine for, 5
abacavir for, 3
cidofovir for, 249
darunavir for, 311
delavirdine for, 321
didanosine for, 347
efavirenz for, 394
emtricitabine and tenofovir for, 399
emtricitabine for, 397
enfuvirtide for, 403
etravirine for, 447
fosamprenavir for, 498
ganciclovir for, 513
immune globulin for, 581
indinavir for, 584
lamivudine for, 632
nelfinavir for, 810
nevirapine for, 816
raltegravir for, 1019
ritonavir for, 1035
ritonavir for, 1048
saquinavir for, 1063
stavudine for, 1099
tenofovir for, 1132
Human immunodeficiency virus infection (continued)
tipranavir for, 1167
zidovudine for, 1244
Human papillomavirus immunization schedule, 1346, 1348
Humatrope, 1091
Humira, 29
Humulin 50/50, 590
Humulin 50/50 (50% asphen insulin and 50% insulin injection), 590
Humulin 70/30, 590, 1343
Humulin 70/30 PenFill, 590
Humulin N, 590
Humulin R, 589
Humulin-R Regular U-500 (concentrate), 589
Hyacint, 1179
Hycodan, 549, 1344
Hycort, 551
Hydatidiform mole, methotrexate for, 732
hydralazine hydrochloride, 546–547
Hydramine, 356
Hydration, sodium chloride for, 1085
Hydrea, 557
Hydro-Crysti-12, 1305
Hydro-Par, 547
Hydrocet, 549, 1344
Hydantoin mole, methotrexate for, 732
Hydralazine hydrochloride, 546–547
Hydramine, 356
Hydration, sodium chloride for, 1085
Hydrea, 557
Hydro-Crysti-12, 1305
Hydro-Par, 547
Hydrocet, 549, 1344
Hydrochlorothiazide, 547–549
Hydrocortisone, 551–554
hydrocortisone acetate, 551–554
Hydrocortisone butyrate, 551–554
hydrocortisone sodium succinate, 551–554
hydrocortisone valerate, 551–554
Hydrocortisab, 551
Hydromorph Contin, 554
Hydromorph-IR, 554
hydromorphone hydrochloride, 554–556
therapeutic and toxic blood levels for, 516
hydroxocobalamin crystalline, 1305
hydroxychloroquine sulfate, 556–557
hydroxyurea, 557–559
hydroxyzyne hydrochloride, 559–560
hydroxyzyne pamoate, 559–560
Hygroton, 245
hyoscine, 1067–1068
hyoscine hydrobromide, 1067–1068
hyoscine, 1067–1068
hyoscine hydrobromide, 1067–1068
hyoscyamine, 560–562
hyoscyamine sulfate, 560–562
Hyospz, 560
Hyperacidity, aluminum hydroxide for, 54
Hyperactivity, haloperidol for, 542
Hyperadrenocorticism potassium acetate for, 954
potassium chloride for, 957
Hypercalcemia calcitonin for, 169
cinacalcet for, 254
etidronate for, 441
hydrocortisone for, 552
 pamidronate for, 887
plicamycin for, 949
zoledronic acid for, 1247
Hypercalcemic emergency, managing, 531
Hypercalciuria, plicamycin for, 949

Boldface: Color section
<table>
<thead>
<tr>
<th>Condition</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypercholesterolemia</td>
<td>amlodipine and atorvastatin for, 71</td>
</tr>
<tr>
<td></td>
<td>atorvastatin for, 112</td>
</tr>
<tr>
<td></td>
<td>cholestyramine for, 248</td>
</tr>
<tr>
<td></td>
<td>colesevelam for, 283</td>
</tr>
<tr>
<td></td>
<td>colestipol for, 284</td>
</tr>
<tr>
<td></td>
<td>ezetimibe for, 452</td>
</tr>
<tr>
<td></td>
<td>ezetimibe/simvastatin for, 453</td>
</tr>
<tr>
<td></td>
<td>fenofibrate for, 461</td>
</tr>
<tr>
<td></td>
<td>fluvastatin for, 491</td>
</tr>
<tr>
<td></td>
<td>lovastatin for, 687</td>
</tr>
<tr>
<td></td>
<td>pravastatin for, 966</td>
</tr>
<tr>
<td></td>
<td>rosuvastatin for, 1058</td>
</tr>
<tr>
<td></td>
<td>simvastatin for, 1078</td>
</tr>
<tr>
<td>Hypereosinophilic syndrome/chronic eosinophilic leukemia, imatinib for, 573</td>
<td></td>
</tr>
<tr>
<td>Hyperkalemia, 1359</td>
<td>sodium polystyrene sulfonate for, 1089</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>cholestyramine for, 248</td>
</tr>
<tr>
<td></td>
<td>ezetimibe/simvastatin for, 453</td>
</tr>
<tr>
<td></td>
<td>gemfibrozil for, 520</td>
</tr>
<tr>
<td></td>
<td>niacin for, 1307</td>
</tr>
<tr>
<td></td>
<td>simvastatin for, 1078</td>
</tr>
<tr>
<td>Hyperosmolar diabetes, sodium chloride for, 1085</td>
<td></td>
</tr>
<tr>
<td>Hyperparathyroidism</td>
<td>cinacalcet for, 254</td>
</tr>
<tr>
<td></td>
<td>doxercalciferol for, 1306</td>
</tr>
<tr>
<td></td>
<td>paricalcitol for, 1306</td>
</tr>
<tr>
<td>Hyperphosphatemia, calcium for, 171</td>
<td></td>
</tr>
<tr>
<td>Hyperpigmentation, tretinoin for, 1193</td>
<td></td>
</tr>
<tr>
<td>Hyperprolactinemia, bromocriptine for, 154</td>
<td></td>
</tr>
<tr>
<td>Hypersecretory conditions (continued)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>rabeprazole for, 1017</td>
</tr>
<tr>
<td></td>
<td>ranitidine for, 1024</td>
</tr>
<tr>
<td></td>
<td>Hypersensitivity reaction</td>
</tr>
<tr>
<td></td>
<td>brompheniramine for, 156</td>
</tr>
<tr>
<td></td>
<td>epinephrine for, 410</td>
</tr>
<tr>
<td></td>
<td>promethazine for, 988</td>
</tr>
<tr>
<td>Hypersecretory conditions (continued)</td>
<td>Hyperstat IV, 341</td>
</tr>
<tr>
<td></td>
<td>amlodipine and atorvastatin for, 70</td>
</tr>
<tr>
<td></td>
<td>amlodipine for, 69</td>
</tr>
<tr>
<td></td>
<td>atenolol for, 108</td>
</tr>
<tr>
<td></td>
<td>benazepril for, 130</td>
</tr>
<tr>
<td></td>
<td>bisoprolol for, 144</td>
</tr>
<tr>
<td></td>
<td>bosentan for, 151</td>
</tr>
<tr>
<td></td>
<td>candesartan for, 175</td>
</tr>
<tr>
<td></td>
<td>captorpril for, 178</td>
</tr>
<tr>
<td></td>
<td>carteolol for, 192</td>
</tr>
<tr>
<td></td>
<td>carvedilol for, 194</td>
</tr>
<tr>
<td></td>
<td>chlorothiazide for, 238</td>
</tr>
<tr>
<td></td>
<td>clortalidone for, 245</td>
</tr>
<tr>
<td></td>
<td>clonidine for, 272</td>
</tr>
<tr>
<td></td>
<td>diltiazem for, 351</td>
</tr>
<tr>
<td></td>
<td>doxazosin for, 375</td>
</tr>
<tr>
<td></td>
<td>enalapril for, 401</td>
</tr>
<tr>
<td></td>
<td>eplerenone for, 414</td>
</tr>
<tr>
<td></td>
<td>eprosartan for, 417</td>
</tr>
<tr>
<td></td>
<td>esmolol for, 427</td>
</tr>
<tr>
<td></td>
<td>felodipine for, 459</td>
</tr>
<tr>
<td></td>
<td>fenoldopam for, 462</td>
</tr>
<tr>
<td></td>
<td>furosemide for, 502</td>
</tr>
<tr>
<td></td>
<td>guanfacine for, 540</td>
</tr>
<tr>
<td></td>
<td>hydralazine for, 546</td>
</tr>
<tr>
<td></td>
<td>hydrochlorothiazide for, 547</td>
</tr>
<tr>
<td></td>
<td>ibesartan for, 607</td>
</tr>
<tr>
<td></td>
<td>isradipine for, 620</td>
</tr>
<tr>
<td></td>
<td>labetalol for, 628</td>
</tr>
<tr>
<td></td>
<td>lisinopril for, 675</td>
</tr>
<tr>
<td></td>
<td>losartan for, 686</td>
</tr>
<tr>
<td></td>
<td>methyldopa for, 736</td>
</tr>
<tr>
<td></td>
<td>metolazone for, 748</td>
</tr>
<tr>
<td></td>
<td>metoprolol for, 750</td>
</tr>
<tr>
<td></td>
<td>minoxidil for, 767</td>
</tr>
<tr>
<td></td>
<td>moexipril for, 777</td>
</tr>
<tr>
<td></td>
<td>nadolol for, 795</td>
</tr>
<tr>
<td></td>
<td>nebivolol for, 805</td>
</tr>
<tr>
<td></td>
<td>nicardipine for, 818</td>
</tr>
<tr>
<td></td>
<td>nifedipine for, 822</td>
</tr>
<tr>
<td>Hypertension (continued)</td>
<td>nisoldipine for, 828</td>
</tr>
<tr>
<td></td>
<td>nitroglycerin for, 832</td>
</tr>
<tr>
<td></td>
<td>olmesartan for, 854</td>
</tr>
<tr>
<td></td>
<td>perindopril for, 920</td>
</tr>
<tr>
<td></td>
<td>phenolamine, 929</td>
</tr>
<tr>
<td></td>
<td>pindolol for, 939</td>
</tr>
<tr>
<td></td>
<td>prazosin for, 968</td>
</tr>
<tr>
<td></td>
<td>propranolol for, 996</td>
</tr>
<tr>
<td></td>
<td>quinapril for, 1009</td>
</tr>
<tr>
<td></td>
<td>ramipril for, 1022</td>
</tr>
<tr>
<td></td>
<td>spironolactone for, 1097</td>
</tr>
<tr>
<td></td>
<td>telmisartan for, 1127</td>
</tr>
<tr>
<td></td>
<td>terazosin for, 1134</td>
</tr>
<tr>
<td></td>
<td>timolol for, 1160</td>
</tr>
<tr>
<td></td>
<td>torsemide for, 1181</td>
</tr>
<tr>
<td></td>
<td>trandolapril for, 1184</td>
</tr>
<tr>
<td></td>
<td>valsartan for, 1220</td>
</tr>
<tr>
<td></td>
<td>verapamil for, 1228</td>
</tr>
<tr>
<td></td>
<td>Hypertensive crisis, 1360</td>
</tr>
<tr>
<td></td>
<td>diazoxide for, 341</td>
</tr>
<tr>
<td></td>
<td>labetalol for, 628</td>
</tr>
<tr>
<td></td>
<td>nitroprusside for, 835</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td>methimazole for, 728</td>
</tr>
<tr>
<td></td>
<td>propylthiouracil for, 998</td>
</tr>
<tr>
<td></td>
<td>sodium iodide 131I for, 1086</td>
</tr>
<tr>
<td>Hypertonia, 1360</td>
<td></td>
</tr>
<tr>
<td>Hypertriglyceridemia</td>
<td>amlodipine and atorvastatin for, 71</td>
</tr>
<tr>
<td></td>
<td>fenofibrate for, 461</td>
</tr>
<tr>
<td></td>
<td>lovastatin for, 687</td>
</tr>
<tr>
<td></td>
<td>pravastatin for, 966</td>
</tr>
<tr>
<td></td>
<td>rosuvastatin for, 1058</td>
</tr>
<tr>
<td>Hypertrophic subaortic stenosis, propranolol for, 996</td>
<td></td>
</tr>
<tr>
<td>Hyperuricemia</td>
<td>probenecid for, 979</td>
</tr>
<tr>
<td></td>
<td>rasburicase for, 1029</td>
</tr>
<tr>
<td>Hypervolemia, 1360</td>
<td></td>
</tr>
<tr>
<td>Hypnotic effect, phenobarbital for, 927</td>
<td></td>
</tr>
<tr>
<td>Hypnovel, 758</td>
<td></td>
</tr>
<tr>
<td>Hypocalcemic emergency, calcium for, 171</td>
<td></td>
</tr>
<tr>
<td>Hypocalcemic tetany, calcium for, 171</td>
<td></td>
</tr>
<tr>
<td>Hypochloremia, sodium chloride for, 1085</td>
<td></td>
</tr>
<tr>
<td>Hypogammaglobulinemia, immune globulin for, 580</td>
<td></td>
</tr>
</tbody>
</table>

**Boldface:** Color section

<table>
<thead>
<tr>
<th>Table</th>
</tr>
</thead>
<tbody>
<tr>
<td>t:</td>
</tr>
</tbody>
</table>

**Table:** Color section
Infection 1403

Hypoglycemia
dextrose for, 338
diazoxide for, 342
glucagon for, 531
Hypoglycemics, 1263–1264
Hypogonadism
estradiol for, 430
estrogens, conjugated for, 432
estrogens, esterified for, 434
testosterone for, 1139
Hypokalemia, spironolactone for, 1097
Hypomagnesemia, magnesium for, 694
Hyponatremia, sodium chloride for, 1085
Hypoprothrombinemia, phytonadione for, 1308
Hypotension
dopamine for, 370
nitroprusside for, 835
norepinephrine for, 839
phenylephrine for, 931
Hypotensive emergency, phenylephrine for, 931
Hypothyroidism
levothyroxine for, 660
liothyrone for, 669
liotrix for, 671
thyroid, desiccated for, 1152
Hypovase, 967
Hytone, 551
Hytrin, 1134
Hyzaar, 1344, P10
Ibandronate sodium, 562–564
Ibandronic acid, 562–564
Ibritumomab tiuxetan, 564–566
Ibugel, 566
Ibuleve, 566
Ibumousse, 566
Ibuprofen, 566–568, P8
Ibuprofen, 566
Ibutilide fumarate, 568–570
Idamycin PFS, 570
Idarubicin hydrochloride, 570–571
Idiopathic thrombocytopenic purpura, immune globulin for, 580
Ifex, 571
Ifofamid, 571–573
IGIM, 579–581
IGIV, 579–581
IL-2, 37–39
Imatinib mesylate, 573–575
Imazin XL, 618
Imdur, 618
Imigran, 1113
Imitrex, 1113, P14
Immukin, 604
Immune globulin for I.M. use, 579–581
Immune globulin for I.V. use, human, 579–581
Immunodeficiency, immune globulin for, 579
Immunoglobulin deficiency, immune globulin for, 579
Immunoprin, 118
Immunosuppressants, 1290–1291
Immunosuppression
prednisolone for, 969
prednisone for, 972
triamicinolone for, 1196
Im LA, 618
Imodium, 681
Imodium A-D, 681
Impetigo, mupirocin for, 786
Impri, 576
Imuran, 118
Inamrinone lactate, 582–583
Indameth, 586
Indapamide, 583–584
Inderal, 995
Inderal LA, 995
Indere, 1344
Indigestion. See Acid indigestion; Heartburn.
indinavir sulfate, 584–586
Indocid, 586
Indocid PDA, 586
Indocid-R, 586
Indocin SR, 586
Indolar, 586
Indomax SR, 586
Indometacin, 586–587
Indomethacin, 586–587
Indotec, 586
Inegy, 453
Infacol, 1077
Infantaire Gas, 1077
Infasurf, 174
Infection. See also specific type.
amikacin for, 59
amoxicillin and clavulanate for, 78
aztreonam for, 122
ceftaxime for, 209
ceftriaxone for, 219
chloramphenicol for, 233
clarithromycin for, 262
clindamycin for, 263
doxycycline for, 383
filgrastim for, 470
gentamicin for, 524
imipenem and cilastatin for, 575
immune globulin for, 580, 581
linezolid for, 667
mebendazole for, 698
metronidazole for, 753
minocycline for, 765
nafcillin for, 797
neomycin for, 812
pegfilgrastim for, 895

Boldface: Color section

| t: table |
Infection (continued)
- penicillin G potassium for, 906
- penicillin G procaine for, 908
- penicillin V potassium for, 910
- piperacillin for, 942
- quinupristin and dallopristin for, 1016
- streptomycin for, 1102
- sulfisoxazole for, 1111
- tetracycline for, 1142
- ticarcillin and clavulanate for, 1155
- tobramycin for, 1172
- vancomycin for, 1221

InFeD, 610
Infergen, 600
Inflamase Mild
- Ophthalmic, 969

Inflammation
- acetylsalicylic acid for, 21
- betamethasone for, 135
- cortisone for, 286
- dexamethasone for, 331
- hydrocortisone for, 552
- methylprednisolone for, 744
- piroxicam for, 947
- prednisolone for, 969
- prednisone for, 972
- triamcinolone for, 1196

infliximab, 587–589

Influenza
- amantadine for, 56
- oseltamivir for, 862
- rimantadine for, 1042
- zanamivir for, 1243

Influenza immunization schedule, 1346t, 1347t, 1348t

Infumorph, 780

Infusion rates, 1352t–1356t

INH, 615–617
INH, 615–617

Injection sites, identifying, S14–S15

Innofem, 429

Innohep, 1163

Innopran XL, 995

Innovace, 401

Inotropics, 1291–1292

Insecticide poisoning,
- atropine for, 114

Insomnia
- eszopiclone for, 436
- flurazepam for, 486
- lorazepam for, 684
- ramelteon for, 1020
- secobarbital for, 1069
- temazepam for, 1128
- triazolam for, 1200
- zaleplon for, 1241
- zolpidem for, 1250

Inspira, 414

Insta-Glucose, 337

insulin (lispro), 589–592

insulin aspart (rDNA origin), 592–594

insulin aspart and insulin aspart protamine, 592–594

insulin glargine (rDNA origin), 595–596

insulin glulisine, recombinant, 590–592

insulin injection, 589–592

insulin lispro protamine, human, 590–592

insulin, regular, 589–592

Insulin-Toronto, 589

Intal, 287

Integrilin, 418

Intelec, 447

interferon alfa-2b, recombinant, 598–600

interferon alfa-n3, 597–598

interferon alfacon-1, 600–602

interferon beta-1a, 602–604

interferon beta-1b, 602–604

interferon gamma-1b, 604–605

interleukin-2, 37–39

Intermittent claudication
- cilostazol for, 251
- pentoxifylline for, 918

Intestinal antisepsis,
- preoperative, 812

Intestinal abscesses, anidulafungin for, 93

Intra-abdominal infection
- ampicillin and sulfactam for, 87
- cefepime for, 205
- ceftazidime for, 216
- ciprofloxacin for, 255
- doripenem for, 371
- ertapenem for, 421
- imipenem and cilastatin for, 575
- meropenem for, 715
- tigecycline for, 1158

Intracranial pressure,
- increased, 1360
- mannitol for, 696
- thiopental for, 1340t–1341t
- urea for, 1212

Intramuscular injections, sites for, S14

Intraocular pressure,
- increased. See Ocular hypertension

Intravenous injections, sites for, S15

Intron A, 598

Intropin, 369

Invanz, 421

Invega, 882

Invirase, 1063

Iodotope, 1086

Ionsys, 464

Iostat, 961

Ipocol, 717

ipratropium bromide, 605–607

Iquix, 653

irbesartan, 607–608, P8

Iressa, 517

irinotecan hydrochloride, 608–610

iron dextran, 610–611

Iron overdose, managing, S32

Iron overload, deferasirox for, 320

Iron replacement, iron dextran for, 611
Labetalol hydrochloride 1405

Iron sucrose, 611–613
Iron-deficiency anemia
  iron dextran for, 610
  iron sucrose for, 612
Irritability, risperidone for, 1045
Irritable bowel syndrome
  alosetron for, 49
  calcium polycarbophil for, 173
  dicyclomine for, 345
  lubiprostone for, 690
  psyllium for, 1001
  scopolamine for, 1067
Isentress, 1019
Isib, 618
ISMO, 618
isocarboxazid, 613–615
Isochron, 618
Isodur, 618
Isogel, 1000
Isoket, 618
isoniazid, 615–617
Isophane insulin suspension, 590–592
Isophane insulin suspension and insulin injection, 590–592
Isoproterenol hydrochloride, 617–618
Ispagel, 1000
Ispagelen, 1228
Isoptin, 1228
Isoptin SR, 1228
Isoto Atropine, 114
Isordil Titradose, 618
isosorbide dinitrate, 618–620
isosorbide mononitrate, 618–620
Ispagelen, 1228
Isradipine, 620–621
Istalol, 1159
Isuprel, 617
Itraconazole, 621–623
I.V. catheter, sodium chloride for, 1084
Iveegam EN, 579
I.V. flush, heparin for, 544
Junior Strength Motrin, 566
Juvenile rheumatoid arthritis
  acetylsalicylic acid for, 21
  etanercept for, 438
  ibuprofen for, 567
  meloxicam for, 706
  sulfasalazine for, 1109
K
K10, 957
Kadian, 780
Kaletra, 1344
Kao-Tin, 142
Kaon, 957
Kaopectate, 142
Kaopectate Extra Strength, 142
Kapostis’s sarcoma
  alitretinoin for, 44
  daunorubicin citrate liposome for, 316
  doxorubicin hydrochloride, liposomal for, 381
  interferon alfa-2b for, 598
  paclitaxel for, 880
  vinblastine for, 1231
KaraciW, 1000
Kava, 1324
Kavexa, 4
Kawasaki disease
  acetylsalicylic acid for, 22
  immune globulin for, 580
Kay-Cee-L, 957
Kayexalate, 1089
K-Dur, 957
K-Effervescent, 955
Keflex, 224, P4
Keloc, 459
Kemicetine, 232
Kemstro, 124
Kenalog, 1195
Kenalog-10, 1195
Kenalog-40, 1195
Kentera, 871
Kepivance, 881
Keppra, 651
Keppra XR, 651
Keratitis, cromolyn for, 288
Keratoconjunctivitis, cromolyn for, 288
Ketamine, 1332t–1333t
Ketanov, 618
Ketek, 1124
Ketoconazole, 623–625
Ketorolac tromethamine, 625–628
K-Exit Poudre, 1089
Kidkare Decongestant, 999
Kidney transplant rejection, preventing
  azathioprine for, 119
  basiliximab for, 127
  cyclosporine for, 293
  daclizumab for, 301
  lymphocyte immune globulin for, 692
  muromonab-CD3 for, 787
  mycophenolate for, 789
  sirolimus for, 1079
  tacrolimus for, 1118
Kidney transplantation, valganciclovir for, 1215
Kidrolase, 106
Kineret, 91
Kionex, 1089
Klaricid, 261
Klaron, 1105
K-Lor, 957
Klonopin, 651
Klorent, 957
K-Lyte, 957
K-Med, 957
Koate-DVI, 94
Koffex Expectorant, 539
Koffex-DM, 336
Kogenate FS, 94
Konsyl, 173, 1000
K-Pek II, 681
Kristaloise, 630
Kryoxolr, 623
K-Tab, 957
K-Vescent, 955
Kwells, 1067
Kytril, 537
LA-12, 1305
Labetalol hydrochloride, 628–630

Boldface: Color section

Lightface: Section titles

Italic: Table headings

Bold: Boldface

t: table
Labor induction, oxytocin for, 878
Lipostat, 966
lisdexamfetamine dimesylate, 673–675
lisinopril, 675–677
lisinopril and hydrochlorothiazide, P9
Liskonum, 677
Listeria infection, penicillin G potassium for, 906
Lithane, 677
lithium carbonate, therapeutic and toxic blood levels for, S17
lithium citrate, 677–679
Lithobid, 677
Lithonate, 677
Little Fevers, 14
Liver transplant rejection, preventing
cyclosporine for, 293
muromonab-CD3 for, 787
mycophenolate for, 789
tacrolimus for, 1118
LoCHOLEST, 248
LoCHOLEST Light, 248
Locoid, 551
Loestrin 24 FE, 1344
Lofibra, 460
Lomine, 345
Lomotil, 357, 1344
Lomustine, 679–681
Long-term care nursing, most commonly used drugs in, 1369
Loniten, 767
Lonox, 357
Lopace, 1021
Loperacap, 681
loperamide hydrochloride, 681–683
Lopid, 520
Lopressor, 750
Lopressor SR, 750
Lopressor, 750
Lopressor HCT, 1344
loratadine, 683–684
lorazepam, 684–685
loratadine, therapeutic and toxic blood levels for, S17
Lortab, 549, 1344
losartan potassium, 685–687
losartan potassium and hydrochlorothiazide, P9
Losec, 857
Lotensin, 130
Lotensin HCT, 1344
Lotrel, 1344
Lotronex, 49
lovastatin, 687–689
Lovenox 3, 405
loxapine succinate, 689–690
Lozide, 583
Lozol, 583
L-PAM, 707–709
L-phenylalanine mustard, 707–709
L-sarcolysin, 707–709
L-thyroxine, 660–662
Luminal Sodium, 926
Lunesta, 436
Lung cancer
bevacizumab for, 138
docetaxel for, 364
doxorubicin for, 379
erlotinib for, 420
etoposide for, 446
gefitinib for, 517
gemcitabine for, 519
paclitaxel for, 880
pemetrexed for, 902
topotecan for, 1179
vinblastine for, 1231
vinorelbine for, 1234
Lupron, 647
Lupron Depot, 647
Lupron Depot-3 Month SR Depot, 647
Lupron Depot-4 Month, 647
Lupron Depot-Ped, 647
Lupron-3 Month SR Depot, 647
Lupus nephritis, 1361
Lupuslike syndrome, 1361
Luocaine, 662
Lustral, 1073
Iutein, 1325
Luvox CR, 493
Lyflex, 124
Lyme disease, doxycycline for, 384
lymphocyte immune globulin, 691–693
Lymphoma. See also Non-Hodgkin’s lymphoma.
bortezomib for, 149
carmustine for, 190
chlorambucil for, 231
cyclophosphamide for, 291
denileukin for, 323
doxorubicin for, 379
triamcinolone for, 1197
vinblastine for, 1231
Lymphosarcoma, methotrexate for, 733
Lyrica, 975
Lyrinel XL, 871
Lysovir, 55
M
Maalox H2 Acid Controller, 457
Maalox Regular Chewable, 170
Maalox Total Stomach Relief, 142
MabCampath, 39
Mabron, 1182
MabThera, 1050
Macrodantin, 830, P11
Macrolides, 1269–1270
Macugen, 892
Macular degeneration, pegaptanib sodium injection for, 893
Mag G, 693
Mag-ox, 693
magnesium, therapeutic and toxic blood levels for, S17

Boldface: Color section
magnesium chloride, 693–696
magnesium citrate, 693–696
magnesium gluconate, 693–696
magnesium hydroxide, 693–696
Magnesium intoxication, calcium for, 171
magnesium oxide, 693–696
magnesium sulfate, 694–696
Magonate, 693
Major depressive disorder
aripiprazole for, 103
desvenlafaxine for, 329
duloxetine for, 390
paroxetine for, 890
selegiline for, 1070
Malaria
chloroquine for, 236
doxycycline for, 384
hydroxychloroquine for, 556
mefloquine for, 702
primaquine for, 977
pyrimethamine for, 1005
quinidine for, 1012
quine for, 1014
Male-pattern baldness. See Hair loss.
Malignant hyperthermia, dantrolene for, 307
Malignant melanoma
aldesleukin for, 38
dacarbazine for, 300
hydroxyurea for, 558
interferon alfa-2b for, 598
vinblastine for, 1231
Malignant pleural mesothelioma, pemetrexed for, 902
Mandalyn Paedetriac, 356
Mandanol, 14
manganese chloride, 1307
manganese, chelated, 1307
Mania. See also Bipolar disorder.
chlorpromazine for, 241
divalproex sodium for, 1217
olanzapine for, 851
Mania (continued)
quetiapine for, 1007
risperidone for, 1045
mannitol, 696–698
Mapap, 14
Marevan, 1238
Marinol, 386
Marplan, 613
Mastocytosis
cromolyn for, 288
imatinib for, 573
Matrifil, 464
Matulane, 982
Mavik, 1184
Maxair Autohaler, 945
Maxalt, 1053
Maxalt RPD, 1053
Maxalt-MLT, 1053
Maxeran, 746
Maximum Relief Ex-Lax, 1072
Maximum Strength
Mylanta Gas, 1077
Maxipime, 205
Maxolon, 746
Maxolon SR, 746
Maxtrex, 731
Maxzide, 1344
Measles, immune globulin for, 579
Measles, mumps, rubella immunization schedule, 1346t, 1347t, 1348t
Megaloblastic anemia, 1361
folinic acid for, 1306
meggstrol acetate, 704–705
melatonin, 1325
meloxicam, 705–707
melphalan, 707–709
melphalan hydrochloride, 707–709
Meltus Decongestant, 999
memantine, 709–710, P10
Menest, 434
Meningeal leukemia
cytarabine for, 298
mestranolate for, 732
Meningitis
amphotericin B for, 81
ampicillin for, 84
ceftaxime for, 219
cefuroxime for, 221
chloramphenicol for, 233
cytarabine for, 298
fluconazole for, 475
flucytosine for, 476
meropenem for, 715
methylprednisolone for, 744
penicillin G potassium for, 906
triamcinolone for, 1197
Meningococcal meningitis
immunization schedule, 1346t, 1347t, 1348t
Meningococcal meningitis, penicillin G potassium for, 906
Menopausal symptoms
estriol for, 430
Menopausal symptoms

**Menopur, 710**

Menostar, 429

menotropins, 710–712

Menses induction, medroxyprogesterone for, 701

Menstrual cramps, acetaminophen for, 15

meperidine hydrochloride, 712–714

therapeutic and toxic blood levels for, **S17**

Merbentyl, 345

mercaptopurine, 714–715

6-mercaptopurine, 714–715

Meronem, 715

meropenem, 715–717

mesalamine, 717–718

mesalazine, 717–718

Mesasal, 717

therapeutic and toxic blood levels for,** S17**

Mesen, 717

Mesothelioma, malignant pleural, pemetrexed for, 902

Mesren, 717

Mestinon, 1003

Mestinon Timespan, 1003

Mestinon-SR, 1003

Metabolic acidosis, sodium bicarbonate for, 1083

tromethamine for, 1210

Metabolic alkalosis, potassium acetate for, 954

potassium chloride for, 957

sodium chloride for, 1084

Metadate CD, 740

Metadate ER, 740

Metadol, 725

Metalyse, 1130

Metamucil, 1000

Metamucil Orange Flavor, 1000

Metamucil Sugar Free, 1000

metaprotenerol sulfate, 720–722

metaxalone, 722–723

Metenix, 748

metformin hydrochloride, 723–725, **P10**

Methadose, 725

Methemoglobinemia, 1361

Methergine, 739

methimazole, 728–729

methocarbamol, 730–731

methotrexate, 731–735

methotrexate sodium, 731–735

methsuximide, therapeutic and toxic blood levels for, **S17**

methotrexate sodium, 731–735

Methylcellulose, 735–736

methylprednisolone, 744–746

methylprednisolone acetate, 744–746

methylprednisolone succinate, 744–746

mefloquine hydrochloride, 746–748

Migraine

**almotriptan for, 47**

divalproex sodium for, 1217

eletriptan for, 396

frovatriptan for, 505
Migraine (continued)
naratriptan for, 802
propranolol for, 996
rizatriptan for, 1053
sumatriptan for, 1113
topiramat for, 1177
zolmitriptan for, 1249
milk thistle, 1325–1326
Milophene, 267
milrinone lactate, therapeutic and toxic blood levels for, S17
Mimpara, 253
Minims Phenylephrine, 930
Minims Sodium Chloride, 1084
Minipress, 967
Minirin, 327
Ministran, 832
Minizide, 1344
Minocin, 765
minocycline hydrochloride, 765–767
Minodiab, 529
Minox, 767
minoxidil, 767–769
Mirapex, 963
Mirapexin, 963
Mirena, 656
mitazapine, 769–770
misoprostol, 771–772
Mithracin, 949
mithramycin, 949–950
mitomycin, 772–773
Mitoxana, 571
mitoxantrone hydrochloride, 773–775
Mobic, 705
Mobicox, 705
modafinil, 776–777
Modane Bulk, 1000
Modecate, 483
Modasil, 618
Moditen, 483
Moduretic, 1344
moexipril hydrochloride, 777–778
Molipaxin, 1189
Monarc-M, 94
Monigen, 618
Monigen XL, 618
Monit, 618
Monit LS, 618
Monitan, 12
Monobactams, 1269–1270
Monoclate-P, 94
Monocor, 144
Monodox, 383
Monoket, 618
Monomax, 618
Monomax SR, 618
Monomax XL, 618
Monomil, 618
Mononine, 455
Monoparin, 543
Monopril, 501, P7
Monosorb, 618
Monovent, 1137
montelukast sodium, 778–780, P10
Morcap SR, 780
morphine hydrochloride, 780–783
morphine sulfate, 780–783
morphine sulphate, 780–783
Morphitec, 780
Morphogesic, 780
Morphogesic SR, 780
Motion sickness
meclizine for, 699
promethazine for, 989
scopolamine for, 1067
Motor neuron disorders
dantrolene for, 307
Motrin, 566, P8
Motrin IB, 566
Motrin Infant, 566
Mountain sickness
acetazolamide for, 17
Moxatag, 75
moxifloxacin hydrochloride, 783–785
6-MP, 714–715
MS Contin, 780
MST Continus, 780
MTX, 731–735
Mucinex, 539
Mucolytic agent, acetylcysteine as, 19
Mucomyst, 19, S30
Mucomyst 10, 19
Mucomysosis, amphotericin B for, 81
Mucosil-10, 19
Mucosil-20, 19
Multiparin, 543
Multiple myeloma
bortezomib for, 149
carmustine for, 190
cyclophosphamide for, 291
doxorubicin for, 379
lenalidomide for, 642
melphalan for, 707
pamidronate for, 887
zoledronic acid for, 1247
Multiple sclerosis
baclofen for, 124
dantrolene for, 307
glatiramer for, 526
hydrocortisone for, 552
interferon beta-1a for, 602
interferon beta-1b for, 602
methylprednisolone for, 744–726
mitoxantrone for, 774
prednisolone for, 969
prednisone for, 972
Mumps immunization schedule, 1346t, 1347t, 1348t
muromonab-CD3, 787–788
Muscarnic toxicity, hyoscyamine for, 561
Muscle ache, acetaminophen for, 15
Muscle spasm
baclofen for, 124
carisoprodol for, 189
clopxozamide for, 247
cyclobenzaprine for, 289
dantrolene for, 307
diazepam for, 339
methocarbamol for, 730
tizanidine for, 1170
Muscle tone, increased, tizanidine for, 1170
Musculoskeletal conditions
carisoprodol for, 189
clopxozamide for, 247
cyclobenzaprine for, 289
metaxalone for, 722
methocarbamol for, 730
Mushroom toxicity, muscarinic-induced, atropine for, 115
Mutamycin, 772

Boldface: Color section
Necator americanus infection

- MXL, 780
- Myambutol, 439
- Myasthenia gravis
  - neostigmine for, 813
  - pyridostigmine for, 1003
- Mycamine, 756
- Mycobacterial infection
  - azithromycin for, 121
  - clarithromycin for, 262
  - ethambutol for, 439
  - rifabutin for, 1035
  - streptomycin for, 1102
- Mycobutin, 1035
- mycophenolate mofetil,
  - 788–791
- mycophenolate mofetil hydrochloride,
  - 788–791
- mycophenolate sodium,
  - 788–791
- Mycoplasmal infection,
  - tetracycline for, 1142
- Mycosis fungoides
  - cyclophosphamide for, 291
  - methotrexate for, 732
  - vinblastine for, 1231
- Mycostatin, 846
- Mydfrin, 930
- Mydriasis, atropine for, 115
- Myelodysplastic syndromes,
  - azacitidine for, 117
- Myeloid reconstitution,
  - sargramostim for, 1065
- Myfortic, 788
- Mylanta AR, 457
- Mylanta Children’s, 170
- Mylanta Gas, 1077
- Myleran, 165
- Mylicon, 1077
- Mylicon Infant Drops, 1077
- Myobloc, 152
- Myocardial infarction
  - impaired, 1360
- Myocardial infarction
  - (continued)
  - clopidogrel for, 273
  - dalteparin for, 303
  - enoxaparin for, 405
  - eplerenone for, 414
  - eptifibatide for, 418
  - lisinopril for, 675
  - metoprolol for, 750
  - nitroglycerin for, 832
  - propranolol for, 996
  - ramipril for, 1022
  - reteplase for, 1032
  - streptokinase for, 1100
  - tenecteplase for, 1131
  - timolol for, 1160
  -trandolapril for, 1184
  - valsartan for, 1220
  - warfarin for, 1238
  - (continued)
  - alteplase for, 52
  - atorvastatin for, 112
  - celiprolol for, 178
  - carvedilol for, 194
  - dextran for, 367
  - diltiazem for, 387
  - dipyridamole for, 388
  - dipyridamole for, 388
  - desflurane for, 362
  - dobutamine for, 395
  - enoximone for, 406
  - eptifibatide for, 418
  - clopidogrel for, 437
  - nitroglycerin for, 832
  - phenobarbital for, 672
  - phenytoin for, 1212
  - propofol for, 1216

N
- nabilone, 791–793
- nabumetone, 793–794
- N-acetylcysteine, 19–20
- nadolol, 794–796
- Nadostine, 846
- nafarelin acetate, 796–797
- nafcillin sodium, 797–798
- nalbuphine hydrochloride,
  - 798–800,
  - 1334t–1335t
- Nalcam, 287
- naloxone hydrochloride,
  - 32
- naltrexone, 32
- Namenda, 709,
  - P10
- Napratex, 800
- Naprelan, 800
- Naprosyn, 800
- Naprosyn SR, 800
- Naprosyn-E, 800
- Naprosyn-EC, 800
- naproxen, 800–802
- naproxen sodium, 800–802
- Naramig, 802
- naratriptan hydrochloride,
  - 802–803
- Narcan, 32
- Narcolepsy
  - dextroamphetamine for, 335
  - methylphenidate for, 742
  - modafinil for, 776
- Nardil, 924
- Naropin, 1338t–1339t
- Nasacort AQ, 1195
- Nasal congestion
  - phenylephrine for, 931
  - pseudoephedrine for, 999
- Nasalcrom, 287
- Nasarel, 478
- Nasobec, 129
- nateglinide, 803–804
- Natrecor, 815
- Natrilix, 583
- Natural Fiber Therapy, 1000
- Naturalyte, 1083
- Nature Throid, 1151
- Nausea and vomiting
  - aprepitant for, 99
  - bismuth for, 143
  - chlorpromazine for, 241
  - dimenhydrinate for, 353
  - diphenhydramine for, 356
  - dolasetron for, 367
  - dronabinol for, 386
  - droperidol for, 387
  - granisetron for, 537
  - hydroxyzine for, 559
  - metoclopramide for, 747
  - nabilone for, 791
  - ondansetron for, 859
  - palonosetron for, 886
  - perphenazine for, 922
  - prochlorperazine for, 984
  - promethazine for, 989
  - scopolamine for, 1067
  - trimethobenzamide for, 1205
- Navelbine, 1234
- ND-Stat, 155
- nebivolol, 804–806
- NebuPent, 911
- Necator americanus infection
  - elimination, 698
Neck cancer. See Head and neck cancer.

Neck pain, botulinum toxin for, 152

Necrosis, dermal, phentolamine for, 929

Nefazodone hydrochloride, 806–808

Neisseria meningitidis carriers, rifampin for, 1037

Nelarabine, 808–810

Nelfinavir mesylate, 810–811

Nembutal Sodium, 915

Neo-Codema, 547

Neo-DM, 336

Neo-Fradin, 812

Neo-Synephrine, 930

Neoclarityn, 326

Neofel, 459

Neomycin sulfate, 812–813

Neonatal group B streptococcal disease, ampicillin as prophylaxis for, 85

Neoplasm, 1361

Neoplastic disorders betamethasone for, 135 cortisone for, 286 methylprednisolone for, 744 prednisolone for, 969

Neo-Profen, 566

Neoral, 293

Neostigmine bromide, 813–814

Neostigmine methylsulfate, 813–814

Neotigason, 24

Neotrex, 918

Neozipine XL, 822

Nephritis, acute, magnesium for, 695

Nephro-Calci, 170

Nephrotic syndrome cyclophosphamide for, 291 hydrocortisone for, 552 prednisolone for, 969 spironolactone for, 1097 triamcinolone for, 1197

Nephrotoxicity, 1361

Nerve block lidocaine for, 663 procaine for, 1336t–1337t

Nervous system disorders, prednisolone for, 969

Nesiritide, 815–816

Nestrex, 1309

Neulasta, 818–819

Neupogen, 470

Neuroblastoma cyclophosphamide for, 291 doxorubicin for, 379

NeuroBloc, 152

Neuroleptic malignant syndrome, 1361 bromocriptine for, 154

Neuromuscular block, reversing neostigmine for, 814 pyridostigmine for, 1003

Neuromuscular blockers, 1292–1293

Neurontin, 510, P7

Neurophil recovery, sargramostim for, 1065

Nevirapine, 816–817

Nexavar, 1093

Nexium, 428, P6

Niacin deficiency, niacin for, 1307

Niacinamide, 1307–1308

Nicardipine, 818–819

Nicoderm CQ, 819

Nicopatch, 819

Nicorette, 819

Nicorette Patch, 819

Nicotine polacrilex, 819–822

Nicotine transdermal system, 819–822

Nicotinamide, 1307–1308

Nicotinamide, 1307–1308

Nifedipine, 822–823 therapeutic and toxic blood levels for, 517

Nifoldpress MR, 822

Nifopress MR, 822

Nightcalm, 356

Nilandron, 826

Nitotinib, 823–824

Nilstat, 846

Nifurtimox, 826–827

Nitomide, 827–828

Nimotop, 827

Nindaqa, 583

Nipen, 916

Nipride, 834

NitQuitin, 819

Niravam, 50

Nisoldipine, 828–829

Ninazoxanide, 828–830

Nitrek, 832

Niro-Dur, 832

Nitrofurantoin, 830–832, P11

Nitrofurantoin macrystals, 830–832, P11

Nitroglycerin, 832–834

Nitroglycerin infusion rates, 1355t

Nitroject, 832

Nitrolingual, 832

Nitromid, 832

Nitroprusside infusion rates, 1355t

Nitroprusside sodium, 834–836

Nitroquick, 832

Nitrostat, 832

Nivemycin, 812

Nizatidine, 836–837
Novo-Tamoxifen 1413

Nizoral, 623
Nizoral A-D, 623
Nobligan Retard, 1182
Nocturia
  bumetanide for, 159
  oxybutynin for, 871
Nolvadex, 1122
Nolvadex-D, 1122
Non-Drowsy Sudafed
  Decongestant, 999
Non-Hodgkin’s lymphoma
  bleomycin for, 147
  ibritumomab for, 565
  interferon alfa-2b for, 599
  rituximab for, 1050
Nonpsychotic behavior
  disorder, haloperidol for, 542
Noradrenaline, 839
Norco, 549
Norcuron, 1340t–1341t
Norditropin, 1091
norelgestromin/ethinyl
  estradiol, 837–839
norepinephrine bitartrate,
  839–840
Norepinephrine extravasation,
  phentolamine for, 929
norethindrone acetate,
  841–842
norfloxacin, 842–844
Norgalax, 366
Norimode, 681
Noritrate, 752
Normaloe, 681
Noroxin, 842
Norpace, 360
Norpace CR, 360
Norpramin, 324
Nortemp, 14
Nortemp Children’s, 14
nortriptyline hydrochloride,
  844–846
  therapeutic and toxic blood levels for,
  517
Norvasc, 69, P1
Norventyl, 844
Norvir, 1047
Nose infection
  amoxicillin for, 76
  mupirocin for, 786
Novamoxin, 75
Novantrone, 773
Novaser, 21
Novo Docusate, 366
Novo-5-ASA-Ect, 717
Novo-Alprazol, 50
Novo-Ampicillin, 84
Novo-Atenol, 108
Novo-Azathioprine, 118
Novo-AZT, 1243
Novo-Bicalutamide, 140
Novo-Bisporalol, 144
Novo-Carbamazepine, 180
Novo-Carvediol, 194
Novo-Cefadroxil, 200
Novo-Chlorpromazine, 241
Novo-Cholamine, 248
Novo-Cholamine Light, 248
Novo-Cimetidine, 252
Novo-Clavamoxin, 78
Novo-Clonazepam, 270
Novo-Clonidine, 272
Novo-Clopamine, 268
Novo-Clopat, 275
Novo-Cycloprrin, 289
Novo-Desipramine, 324
Novo-Difenac, 343
Novo-Difenac-K, 343
Novo-Difenac-SR, 343
Novo-Diltazem, 351
Novo-Dipam, 339
Novo-Divalproex, 1216
Novo-Docusate Calcium,
  366
Novo-Doxepin, 376
Novo-Doxylin, 383
Novo-Enalpril, 401
Novo-Famotidine, 457
Novo-Flucanazole, 474
Novo-Flupam, 486
Novo-Flutamide, 487
Novo-Fluvaxamine, 493
Novo-Fosinopril, 501
Novo-Furantoin, 830
Novo-Gabapentin, 510
Novo-Gemfibrozil, 520
Novo-Gesic, 14
Novo-Glimepiride, 527
Novo-Glyburide, 532
Novo-Hydrazide, 547
Novo-Hydroxyzin, 559
Novo-Hylazin, 546
Novo-Indapamide, 583
Novo-Ipramide, 605
Novo-Ketoconazole, 623
Novo-Lamotrigine, 633
Novo-Leflunomide, 640
Novo-Levocarbidopa, 182
Novo-Levofloxacin, 653
Novo-Lexin, 224
Novo-Lisinopril, 675
Novo-Loperamide, 681
Novo-Lorazem, 684
Novo-Lovastatin, 687
Novo-Medrone, 700
Novo-Meloxicam, 705
Novo-Metformin, 723
Novo-Methacin, 586
Novo-Metoprol, 750
Novo-Mexiletine, 754
Novo-Minocycline, 765
Novo-Mirtazapine, 769
Novo-Misoprostol, 771
Novo-Morphine, 780
Novo-Nabumetone, 793
Novo-Nadolol, 794
Novo-Naprox, 800
Novo-Naprox Sodium, 800
Novo-Naprox Sodium DS,
  800
Novo-Nidazol, 752
Novo-Nifedin, 822
Novo-Nizatidine, 836
Novo-Nortriptyline, 844
Novo-Ondansetron, 858
Novo-Oxybutinin, 871
Novo-Paroxetine, 888
Novo-Pen-VK, 909
Novo-Peridol, 541
Novo-Pheniram, 239
Novo-Pindol, 939
Novo-Pioglitazone, 941
Novo-Pirocam, 947
Novo-Pramipexole, 963
Novo-Pravastatin, 966
Novo-Prazin, 967
Novo-Profen, 566
Novo-Propamidine, 243
Novo-Quinine, 1014
Novo-Rabeprazole, 1017
Novo-Ramipril, 1021
Novo-Risperidone, 1045
Novo-Risperidone, 1045
Novo-Scilegiline, 1070
Novo-Sertraline, 1073
Novo-Simvastatin, 1078
Novo-Sotalol, 1095
Novo-Spiroton, 1097
Novo-Sucralfate, 1104
Novo-Sumatriptan, 1113
Novo-Tamoxifen, 1122

*Boldface: Color section*
Novo-Tamsulosin, 1123
Novo-Temazepam, 1128
Novo-Terazosin, 1134
Novo-Thalidone, 245
Novo-Theophyl SR, 1146
Novo-Ticlopidine, 1156
Novo-Timol, 1159
Novo-Topiramate, 1177
Novo-Trazodone, 1189
Novo-Trifluzine, 1202
Novo-Tvalproic ECC, 1216
Novo-Veramil, 1228
Novo-Warfarin, 1238
Novochlorocap, 232
Novolin 70/30, 590
Novolin 70/30 PenFill, 590
Novolin N, 590
Novolizer Budesonide, 157
NovoLog, 592
NovoLog Mix 70/30, 592, 1344
Novomedopa, 736
NovoNorm, 1030
Novopramine, 576
Novopranol, 995
Novosemide, 507
NovoSeven, 278
NovoSeven RT, 278
Novotriptyn, 67
Novoxapam, 868
Noxafil, 951
NPH insulin, 590–592
Nu-Alpraz, 50
Nu-Amoxil, 75
Nu-Ampi, 84
Nu-Baclo, 124
Nu-Cal, 170
Nu-Carbamazepine, 180
Nu-Cephalex, 224
Nu-Cimet, 252
Nu-Clonidine, 272
Nu-Cotrimox, 1106
Nu-Cotrimox DS, 1106
Nu-Cromolyn, 287
Nu-Desipramine, 324
Nu-Diclo, 343
Nu-Diltiaz, 351
Nu-Divalproex, 1216
Nu-Famotidine, 457
Nu-Fenofibrate, 460
Nu-Flovoxamine, 493
Nu-Furosemide, 507
Nu-Gemfibrozil, 520
Nu-Glyburide, 532
Nu-Hydral, 546
Nu-Hydroxyzine, 559
Nu-Ibuprofen, 566
Nu-Indapamide, 583
Nu-Indo, 586
NU-Ipratropium, 605
Nu-Ketocon, 623
Nu-Ketoconazole, 623
Nu-Lax, 1072
Nu-Levocarb, 182
Nu-Loraz, 684
Nu-Lovastatin, 687
Nu-Loxapine, 689
Nu-Medopa, 736
Nu-Megestrol, 704
Nu-Metformin, 746
Nu-Metop, 750
Nu-Naprox, 800
Nu-Nifed, 822
Nu-Nortriptyline, 844
Nu-Oxybutinin, 871
Nu-Pindol, 939
Nu-Pirox, 947
Nu-Pravastatin, 966
Nu-Prazo, 967
Nu-Propranolol, 995
Nu-purol, 45
Nu-Salbutamol, 35
Nu-Seals, 21
Nu-Selegiline, 1070
Nu-Seringaline, 1073
Nu-Simvastatin, 1078
Nu-Sotalol, 1095
Nu-Sucralfate, 1104
Nu-Tetra, 1142
Nu-Thyro, 660
NU-Ticlopidine, 1156
NU-Timolol, 1159
Nu-Trazodone, 1189
Nu-Trimipramine, 1206
Nu-Valproic, 1216
Nu-Verap, 1228
Nu-Verap SR, 1228
Nubain, 798,
1334t–1335t
Nuvel SA, 1146
NuLYTELY, 1344
Nurofen, 566
Nursing specialties, most commonly used drugs in, 1369–1370
Nut-E-Sol, 1312
Nutropin AQ, 1091
Nutropin AQ Pen, 1091
Nutropin Depot, 1091
NuvaRing, 444
Nyaderm, 846
Nycopren, 800
Nystan, 846
nystatin, 846–847
Nystop, 846
Nytol, 356

O

Obesity, orlistat for, 860
Obsessive-compulsive disorder
clomipramine for, 268
fluoxetine for, 481
fluvoxamine for, 493
paroxetine for, 890
sertraline for, 1073
Obstetric amnesia, scopolamine for, 1067
Obstetric nursing, most commonly used drugs in, 1370
Obstructive airway disease, reversible
albuterol for, 35
pirbuterol for, 946
Octagam, 579
Octaplex, 455
octreotide acetate, 847–849
Ocu-Sul 10, 1105
Ocu-Sul 15, 1105
Ocu-Sul 30, 1105
Ocufox, 849
Ocular hypertension
cartolol for, 192
mannitol for, 696
timolol for, 1160
urea for, 1212
Ocular infection
chloramphenicol for, 233
gentamicin for, 524
sulfacetamide for, 1105
tobramycin for, 1172
Ocular inflammation,
ketorolac for, 626

Boldface: Color section
t: table
Ocular itching, ketorolac for, 626
Ocular pain, ketorolac for, 626
Ocupress, 191
Oestrogel, 429
ofloxacin, 849–851
Olmetec, 853
Olsalazine sodium, 855
Omalizumab, 856
Omeprazole, 857–858
Oncaspar, 894
Ondansetron hydrochloride, 858–860
Ondemet, 858
Onkotrone, 773
Onicaprumide, 969
Onmitrope, 1091
Oncaspar, 894
Ondanestron hydrochloride, 858–860
Ondemet, 858
Oncicatal, 773
Oncipran, 894
Onychomycosis
itraconazole for, 622
Onychomycosis
terbinafine for, 1135
Opana, 874
Opana ER, 874
Ophthamia neonatorum, erythromycin as prophylaxis for, 423
Ophthalmic disorders, prednisolone for, 969
Ophthalmic inflammatory diseases, triamcinolone for, 1197
Opioid detoxification, methadone for, 726
Opioid overdose and dependence buprenorphine for, 161 managing, S32
Optil, 351
Oracea, 383
Oral cavity disorders, lidocaine for, 664
Oral mucositis, palifermin for, 882
Oral thrush, ketoconazole for, 624
Oramorph SR, 780
Orap, 938
Orapred, 969
Orexin ODT, 969
Oraxyl, 383
oriprenaline, 720–722
Orelox, 212
Orenica, 6
Orgalutran, 515
Organ transplant rejection, preventing azathioprine for, 119
basiliximab for, 127
betamethasone for, 135
cortisone for, 286
cyclosporine for, 293
daclizumab for, 301
lymphocyte immune globulin for, 692
muromonab-CD3 for, 787
methylprednisolone for, 887
sirolimus for, 1079
tacrolimus for, 1118, 1119
Organ transplantation, ganciclovir for, 513
Organidin NR, 539
Organophosphatase insecticide overdose, managing, S32
Orlept, 1216
orlistat, 860–861
Ortho Evra, 837
Ortho-Cyclen, 1344
Orthoclone OKT3, 787
Orthostatic hypotension, midodrine for, 760
Orthovit, 760
Os-Cal, 170
Os-Cal 500, 170
Oseltamivir phosphate, 861–862
Osmotrol, 696
Osmotic nephrosis, 1361
Ossification, heterotropic, etidronate for, 441
Osteitis deformans. See Paget’s disease of bone.
Osteoarthritis acetylsalicylic acid for, 21
Osteoarthritis (continued) betamethasone for, 135
calcitonin for, 423
calcitriol for, 430
calcitriol, conjugated for, 432
calcitriol, esterified for, 434
calcitriol, ibandronate for, 562
calcitriol, oxandrolone for, 865
calcitriol, raloxifene for, 1018
calcitriol, risedronate for, 1043
calcitriol, teriparatide for, 1138
calcitriol, zoledronic acid for, 1247
Osteosarcoma, methotrex-ate for, 732
Otitis externa, ofloxacin for, 850
Otitis media amoxicillin and clavulananate for, 78
azithromycin for, 121
cefaclor for, 199
cefdinir for, 204
cefixime for, 207
cefpodoxime for, 212
cefprozil for, 214
ceftibuten for, 218
ceftiraxone for, 219
cefuroxime for, 221
cephalexin for, 225
clarithromycin for, 262
cefuroxime for, 423
ofloxacin for, 850
penicillin V potassium for, 190

Boldface: Color section
Otitis media (continued)
sulfamethoxazole-trimethoprim for, 1107
Ovace, 1105
Ovace Wash, 1105
Ovarian cancer
amifostine for, 57
carboplatin for, 187
cisplatin for, 258
cyclophosphamide for, 291
doxorubicin hydrochloride, liposomal for, 381
gemcitabine for, 519
hydroxyurea for, 558
melphalan for, 707
paclitaxel for, 880
topotecan for, 1179
Ovarian failure
clophosphamide for, 267
estradiol for, 430
estrogens, conjugated for, 432
Ovarian hyperstimulation, ganirelix for, 515
Ovarian stimulation, menotropins for, 710
Ovariectomy, estrogens, conjugated for, 432
Overactive bladder
darifenacin for, 310
oxybutynin for, 871
solifenacin for, 1090
tolerodine for, 1176
trospium for, 1211
Overdoses, managing, S30–S32
Ovex, 698
Ovol, 1077
oxaliplatin, 862–864
Oxandrin, 864
oxandrolone, 864–866
oxaprozin, 866–868
oxaprozin potassium, 866–868
oxazepam, 868–869
therapeutic and toxic blood levels for, $17
oxcarbazepine, 869–871, P11
Oxeze, 497
Oxis, 497
Oxy-IR, 872
oxybutynin, 871–872
oxybutynin chloride, 871–872, P11
oxycodone hydrochloride, 872–874, P11
OxyContin, 872, P11
OxyFast, 872
oxymorphine hydrochloride, 874–877
Oxynorm, 872, 874
oxytocin, 877–879
Oxylot, 871
Oysco, 170
Oyst-Cal 500, 170
Oystercal 500, 170
P
Pacerone, 64
paclitaxel, 879–881
Paget’s disease of bone
alendronate for, 41
calcitonin for, 169
etidronate for, 441
pamidronate for, 887
risedronate for, 1043
zoledronic acid for, 1247
Pain. See also Analgesia.
acetaminophen for, 15
acetylsalicylic acid for, 21
buprenorphine for, 161
butorphanol for, 168
celecoxib for, 223
clofidine for, 272
codeine for, 280
duloxetine for, 390
dextrodone for, 442
dextrodone for, 465
hydrocodone for, 550
hydromorphine for, 555
hyoscymine for, 561
pencuronium bromide, 1334t–1335t
Pancytopenia, 1361
Panic disorder
alprazolam for, 51
fluoxetine for, 482
paroxetine for, 890
sertraline for, 1073
venlafaxine for, 1226
Paniel Dose, 224
Panretin, 44
Pantoloc, 888
pantoprazole sodium, 888–889, P11
Papilledema, 1361
Paracoccidioidomycosis, ketoconazole for, 624
Paragon Forte DSC, 247
Paralysis attack
potassium acetate for, 954
potassium chloride for, 957
Paramax, 746
Pardelprin, 586
paricalcitol, 1308
Pariet, 1017
Parkinsonism
atropine for, 115
benztropine for, 134
carbidopa-levodopa for, 182
trihexyphenidyl for, 1204
Parkinson’s disease
amantadine for, 56
apomorphine for, 98
bromocriptine for, 154
carbidopa-levodopa for, 183
carbidopa-levodopa-entacapone for, 185
diphenhydramine for, 356
entacapone for, 407
yoscamine for, 561
pramipexole for, 1363
tolcapone for, 1175
Parlodol, 154
Parnate, 1185
Parovelex, 19
paroxetine hydrochloride, 890–892, P12
paroxetine mesylate, 890–892
therapeutic and toxic blood levels for, S17
Pasteurella infection, penicillin G potassium for, 906
Pavulon, 1334t–1335t
Paxene, 879
Paxil, 890, P12
Paxil CR, 890, P12
PCE, 423
Pedi-Dri, 846
Pediatric nursing, most commonly used drugs in, 1370
Pediatr, 14
Pediatrtix, 14
Pediazole, 1344
Pediculosis infestation, lindane for, 666
PEG-Intron, 898
PEG-L-asparaginase, 894–895
pegaptanib sodium injection, 892–893
pegaspargase, 894–895
Pegasys, 896
pegfilgrastim, 895–896
peginterferon alfa-2a, 896–898
peginterferon alfa-2b, 898–900
PegIntron, 898
peximomant, 900–901
Pellagra, niacin for, 1307
Pelvic infection, ertapenem for, 421
Pelvic inflammatory disease
azithromycin for, 121
clinamycin for, 264
ethyromycin for, 423
ofloxacin for, 849
piperacillin and tazobactam for, 944
pemtrexed, 902–904
Pen-Vee, 909
Penbritin, 84
Penicillin blood level, probenecid to increase, 979
penicillin G benzathine, 904–905
penicillin G potassium, 905–908
penicillin G procaine, 908–909
penicillin V potassium, 909–911, P12
Penile cancer, bleomycin for, 147
Pentacarinat, 911
Pentam 300, 911
pentamidine isethionate, 911–913
Pentamycin, 232
Pentasa, 717
pentazocine hydrochloride and naloxone hydrochloride, 913–914
pentazocine lactate, 913–914
pentobarbital sodium, 915–916
pentostatin, 916–918
Pentothal, 1334t–1335t
tetaxifillin, 918–919
Pentoxifylline, 918
Pentoxifylline SR, 918
Pepcid, 457
Pepcid AC, 457
Peptic ulcer
atropine for, 115
glycopyrrolate for, 534
propantheline for, 992
simethicone for, 1077
Pepto-Bismol, 142
Pepto-Bismol Bismuth Maximum Strength, 142
Perfocet, 1344
Percodan, 1344
Percutaneous coronary intervention
abciximab for, 8
argatroban for, 101
bivalirudin for, 146
epifibatide for, 418
fluvastatin for, 491
Percutaneous transluminal coronary angioplasty
angioplasty, tirofiban for, 1169
Peridix, 777
Perforomist, 497
Periactin, 296
Periactin, 296
Percutaneous coronary intervention
abciximab for, 8
argatroban for, 101
bivalirudin for, 146
epifibatide for, 418
fluvastatin for, 491
Percutaneous transluminal coronary angioplasty
angioplasty, tirofiban for, 1169
Peridix, 777
Perforomist, 497
Periactin, 296
Pericardial effusion, 1361
Peridol, 541
perindopril erbumine, 919–921
Peridol, 541
perindopril erbumine, 919–921
Periodontitis, doxycycline for, 384
Perioestat, 383
Peripheral arterial disease, clopidogrel for, 273
Peripheral arterial disease, clopidogrel for, 273
Peripheral blood progenitor cell transplantation, sargramostim for, 1065
Peritonitis
  anidulafungin for, 93
  fluconazole for, 475
  micafungin for, 756
  piperacillin and tazobactam for, 944
Permapen, 904
Pernicious anemia, cyanocobalamin for, 1305
perphenazine, 921–923
Persantin, 359
Persantine, 359
Pertussis
  erythromycin for, 424
  immunization schedule for, 1347t, 1348t
pethidine hydrochloride, 712–714
Pexeva, 890
Pfizerpen, 905
PGE2, 354–355
Phanacin XPECT, 539
Pharmorubicin PMS, 412
Pharyngeal disorders, lidocaine for, 664
Pharyngitis
  azithromycin for, 121
  cefaclor for, 199
  cefadroxil for, 200
  cefdinir for, 204
  cefixime for, 207
  cefpodoxime for, 212
  cefprozil for, 214
  cefditoren for, 217
  cefuroxime for, 221
  clarithromycin for, 261
Phazyme, 1077
Phenazo, 923
phenazopyridine hydrochloride, 923–924
phenelzine sulfate, 924–926
Phenergan, 988
phenobarbital, 926–929
  therapeutic and toxic blood levels for, 517
phenobarbital sodium, 926–929
  phenolamine for, 929
phenylephrine hydrochloride, 930–933
phenylephrine infusion rates, 1356t
Phenytek, 934
phenytoin, 934–936
  therapeutic and toxic blood levels for, S17
  phenytoin sodium, 934–936, P12
Pheochromocytoma
  phenolamine for diagnosis of, 929
  propranolol for, 996
Phillips Milk of Magnesia, 693
Phillips Milk of Magnesia Concentrate, 693
PHL-Bicalutamide, 140
PHL-Carbamazepine, 180
PHL-Carvedilol, 194
PHL-Clomipramine, 268
PHL-Clonazepam, 270
PHL-Cyclobenzaprine, 289
PHL-Desipramine, 324
PHL-Divalproex, 1216
PHL-Docusate Sodium, 366
PHL-Fluconazole, 474
PHL-Fluvoxamine, 493
PHL-Gabapentin, 510
PHL-Hydromorphone, 554
PHL-Indapamide, 583
PHL-Ipratropium, 605
PHL-Levetiracetam, 651
PHL-Lisinopril, 675
PHL-Lithium Carbonate, 677
PHL-Loperamide, 681
PHL-Lorazepam, 684
PHL-Lovastatin, 687
PHL-Loxapine, 689
PHL-Meloxicam, 705
PHL-Metformin, 732
PHL-Methylphenidate, 740
PHL-Metoprolol, 750
PHL-Mirtazapine, 769
PHL-Nizatidine, 836
PHL-Ondansetron, 858
PHL-Oxybutinin, 871
PHL-Paroxetine, 890
PHL-Pravastatin, 966
PHL-Risperidone, 1045
PHL-Sertraline, 1073
PHL-Simvastatin, 1078
PHL-Sodium Polystyrene Sulfonate, 1089
PHL-Sotalol, 1095
PHL-Sumatriptan, 1113
PHL-Temazepam, 1128
PHL-Terazosin, 1134
PHL-Topiramate, 1177
PHL-Trazodone, 1189
PHL-Valproic Acid, 1216
PHL-Verapamil SR, 1228
Phos-Ex, 170
PhosLo, 170
PhosLo Gelcap, 170
Phosphodiesterase type 5 inhibitors, 1288–1289
Phylocontin, 62
Physeptone, 725
physostigmine, S30
phytonadione, 1308–1309, S32
Pima, 961
pimecrolimus, 936–937
pimozone, 938–939
Pin-X, 1001
pindolol, 939–941
Pink Bismuth, 142
Pinta
  penicillin G benzathine for, 904
  penicillin G procaine for, 908
Pinworm infestation, mebendazole for, 698
pyrantel for, 1002
pioglitazone hydrochloride, 941–942, P12
piperacillin sodium, 942–944
piperacillin sodium and tazobactam sodium, 944–945
pirbuterol acetate, 945–947
Piriton, 226
Piriton, 239
piroxicam, 947–949
Pitocin, 877
Pituitary tumors, bromocriptine for, 154
Plague
  streptomycin for, 1102
  tetracycline for, 1142
<table>
<thead>
<tr>
<th>Drug</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plan B, 656</td>
<td></td>
</tr>
<tr>
<td>Plaquenil, 556</td>
<td></td>
</tr>
<tr>
<td>Plasma expanders, 1294–1295</td>
<td></td>
</tr>
<tr>
<td>Plasmodia transmission, pyrimethamine to control, 1005</td>
<td></td>
</tr>
<tr>
<td>Platinex, 258</td>
<td></td>
</tr>
<tr>
<td>Platinitol, 258</td>
<td></td>
</tr>
<tr>
<td>Plavix, 273, P4</td>
<td></td>
</tr>
<tr>
<td>Plendil, 459</td>
<td></td>
</tr>
<tr>
<td>Pletal, 251</td>
<td></td>
</tr>
<tr>
<td>Pleural effusion, bleomycin for, 147</td>
<td></td>
</tr>
<tr>
<td>Plicamycin, 949–950</td>
<td></td>
</tr>
<tr>
<td>PMS Benztropine, 134</td>
<td></td>
</tr>
<tr>
<td>PMS Digoxin, 348</td>
<td></td>
</tr>
<tr>
<td>PMS Haloperidol, 541</td>
<td></td>
</tr>
<tr>
<td>PMS Morphine Sulfate SR, 780</td>
<td></td>
</tr>
<tr>
<td>PMS Propranolol, 995</td>
<td></td>
</tr>
<tr>
<td>PMS Pyrazinamide, 1002</td>
<td></td>
</tr>
<tr>
<td>PMS-Amantadine, 55</td>
<td></td>
</tr>
<tr>
<td>PMS-ASA, 21</td>
<td></td>
</tr>
<tr>
<td>PMS-Baclofen, 124</td>
<td></td>
</tr>
<tr>
<td>PMS-Bethaneol Chloride, 137</td>
<td></td>
</tr>
<tr>
<td>PMS-Bicalutamide, 140</td>
<td></td>
</tr>
<tr>
<td>PMS-Bisoprolol, 144</td>
<td></td>
</tr>
<tr>
<td>PMS-Bromocriptine, 154</td>
<td></td>
</tr>
<tr>
<td>PMS-Butorphanol, 167</td>
<td></td>
</tr>
<tr>
<td>PMS-Carbamazepine, 180</td>
<td></td>
</tr>
<tr>
<td>PMS-Carvedilol, 194</td>
<td></td>
</tr>
<tr>
<td>PMS-Cefaclor, 198</td>
<td></td>
</tr>
<tr>
<td>PMS-Clonazepam, 270</td>
<td></td>
</tr>
<tr>
<td>PMS-Clozapine, 276</td>
<td></td>
</tr>
<tr>
<td>PMS-Cyclobenzapine, 289</td>
<td></td>
</tr>
<tr>
<td>PMS-Cyproheptadine, 296</td>
<td></td>
</tr>
<tr>
<td>PMS-Desipramine, 324</td>
<td></td>
</tr>
<tr>
<td>PMS-Diazepam, 339</td>
<td></td>
</tr>
<tr>
<td>PMS-Diclofenac, 343</td>
<td></td>
</tr>
<tr>
<td>PMS-Dimethyldrostanol, 353</td>
<td></td>
</tr>
<tr>
<td>PMS-Diphenhydramine, 356</td>
<td></td>
</tr>
<tr>
<td>PMS-Divalprox, 1216</td>
<td></td>
</tr>
<tr>
<td>PMS-Docusate Calcium, 366</td>
<td></td>
</tr>
<tr>
<td>PMS-Docusate Sodium, 366</td>
<td></td>
</tr>
<tr>
<td>PMS-Enalpril, 401</td>
<td></td>
</tr>
<tr>
<td>PMS-Famciclovir, 456</td>
<td></td>
</tr>
<tr>
<td>PMS-Fluconazole, 474</td>
<td></td>
</tr>
<tr>
<td>PMS-Flunisolide, 478</td>
<td></td>
</tr>
<tr>
<td>PMS-Fluphenazine, 483</td>
<td></td>
</tr>
<tr>
<td>PMS-Flurazepam, 486</td>
<td></td>
</tr>
<tr>
<td>PMS-Flutamide, 487</td>
<td></td>
</tr>
<tr>
<td>PMS-Fluvoxamine, 493</td>
<td></td>
</tr>
<tr>
<td>PMS-Fosinopril, 501</td>
<td></td>
</tr>
<tr>
<td>PMS-Furosemide, 507</td>
<td></td>
</tr>
<tr>
<td>PMS-Gabapentin, 510</td>
<td></td>
</tr>
<tr>
<td>PMS-Gemfibrozil, 520</td>
<td></td>
</tr>
<tr>
<td>PMS-Gentamicin, 523</td>
<td></td>
</tr>
<tr>
<td>PMS-Glimepiride, 527</td>
<td></td>
</tr>
<tr>
<td>PMS-Glyburide, 532</td>
<td></td>
</tr>
<tr>
<td>PMS-Hydrochlorothiazide, 547</td>
<td></td>
</tr>
<tr>
<td>PMS-Hyrdromorphone, 554</td>
<td></td>
</tr>
<tr>
<td>PMS-Hydroxyzine, 559</td>
<td></td>
</tr>
<tr>
<td>PMS-Ibuprofen, 566</td>
<td></td>
</tr>
<tr>
<td>PMS-Impiramine, 576</td>
<td></td>
</tr>
<tr>
<td>PMS-Indapamide, 583</td>
<td></td>
</tr>
<tr>
<td>PMS-Ipratropium, 605</td>
<td></td>
</tr>
<tr>
<td>PMS-Isoxoridine, 618</td>
<td></td>
</tr>
<tr>
<td>PMS-Lactulose, 630</td>
<td></td>
</tr>
<tr>
<td>PMS-Lamotrigine, 633</td>
<td></td>
</tr>
<tr>
<td>PMS-Leflunomide, 640</td>
<td></td>
</tr>
<tr>
<td>PMS-Levetiracetam, 651</td>
<td></td>
</tr>
<tr>
<td>PMS-Lindane LDT, 665</td>
<td></td>
</tr>
<tr>
<td>PMS-Lindane SHP, 665</td>
<td></td>
</tr>
<tr>
<td>PMS-Lithium Carbonate, 677</td>
<td></td>
</tr>
<tr>
<td>PMS-Lithium Citrate, 677</td>
<td></td>
</tr>
<tr>
<td>PMS-Loperamide, 681</td>
<td></td>
</tr>
<tr>
<td>PMS-Lorazepam, 684</td>
<td></td>
</tr>
<tr>
<td>PMS-Lovastatin, 687</td>
<td></td>
</tr>
<tr>
<td>PMS-Loxapine, 689</td>
<td></td>
</tr>
<tr>
<td>PMS-Medroxypregesterone, 700</td>
<td></td>
</tr>
<tr>
<td>PMS-Metformin, 723</td>
<td></td>
</tr>
<tr>
<td>PMS-Methocarbamol, 730</td>
<td></td>
</tr>
<tr>
<td>PMS-Methylphenidate, 740</td>
<td></td>
</tr>
<tr>
<td>PMS-Metoclopramide, 746</td>
<td></td>
</tr>
<tr>
<td>PMS-Metoprolol-L, 750</td>
<td></td>
</tr>
<tr>
<td>PMS-Metronidazole, 752</td>
<td></td>
</tr>
<tr>
<td>PMS-Minocycline, 765</td>
<td></td>
</tr>
<tr>
<td>PMS-Mirtazapine, 769</td>
<td></td>
</tr>
<tr>
<td>PMS-Misoprostol, 771</td>
<td></td>
</tr>
<tr>
<td>PMS-Naproxen EC, 800</td>
<td></td>
</tr>
<tr>
<td>PMS-Neostigmine, Meylsulfate, 813</td>
<td></td>
</tr>
<tr>
<td>PMS-Nizatidine, 836</td>
<td></td>
</tr>
<tr>
<td>PMS-Nortriptyline, 844</td>
<td></td>
</tr>
<tr>
<td>PMS-Nystatin, 846</td>
<td></td>
</tr>
<tr>
<td>PMS-ondansetron, 858</td>
<td></td>
</tr>
<tr>
<td>PMS-Oxazepam, 868</td>
<td></td>
</tr>
<tr>
<td>PMS-Oxybutinin, 871</td>
<td></td>
</tr>
<tr>
<td>PMS-Pantoprazole, 888</td>
<td></td>
</tr>
<tr>
<td>PMS-Paroxetine, 890</td>
<td></td>
</tr>
<tr>
<td>PMS-Phenobarbital, 926</td>
<td></td>
</tr>
<tr>
<td>PMS-Pimoizde, 938</td>
<td></td>
</tr>
<tr>
<td>PMS-Pindolol, 939</td>
<td></td>
</tr>
<tr>
<td>PMS-Pioglitazone, 941</td>
<td></td>
</tr>
<tr>
<td>PMS-Piroxicam, 947</td>
<td></td>
</tr>
<tr>
<td>PMS-Potassium Gluconate, 959</td>
<td></td>
</tr>
<tr>
<td>PMS-Pramipexole, 963</td>
<td></td>
</tr>
<tr>
<td>PMS-Pramastatin, 966</td>
<td></td>
</tr>
<tr>
<td>PMS-Promethazine, 988</td>
<td></td>
</tr>
<tr>
<td>PMS-Propanol, 990</td>
<td></td>
</tr>
<tr>
<td>PMS-Rabeprazole, 1017</td>
<td></td>
</tr>
<tr>
<td>PMS-Risperidone, 1045</td>
<td></td>
</tr>
<tr>
<td>PMS-Selegiline, 1070</td>
<td></td>
</tr>
<tr>
<td>PMS-Sertaline, 1073</td>
<td></td>
</tr>
<tr>
<td>PMS-Simvastatin, 1078</td>
<td></td>
</tr>
<tr>
<td>PMS-Sodium Polystyrene Sulfonate, 1089</td>
<td></td>
</tr>
<tr>
<td>PMS-Sotalol, 1095</td>
<td></td>
</tr>
<tr>
<td>PMS-Succubalate, 1104</td>
<td></td>
</tr>
<tr>
<td>PMS-Sulfacetamide, 1105</td>
<td></td>
</tr>
<tr>
<td>PMS-Sulfasalazine, 1109</td>
<td></td>
</tr>
<tr>
<td>PMS-Sulfasalazine-E.C., 1109</td>
<td></td>
</tr>
<tr>
<td>PMS-Sumatriptan, 1113</td>
<td></td>
</tr>
<tr>
<td>PMS-Tamoxifen, 1122</td>
<td></td>
</tr>
<tr>
<td>PMS-Tamazepam, 1128</td>
<td></td>
</tr>
<tr>
<td>PMS-Terazosin, 1134</td>
<td></td>
</tr>
<tr>
<td>PMS-Testosterone, 1139</td>
<td></td>
</tr>
<tr>
<td>PMS-Theophylline, 1146</td>
<td></td>
</tr>
<tr>
<td>PMS-Ticlopidine, 1156</td>
<td></td>
</tr>
<tr>
<td>PMS-Timolol, 1159</td>
<td></td>
</tr>
<tr>
<td>PMS-Tobramycin, 1171</td>
<td></td>
</tr>
<tr>
<td>PMS-Tipiramate, 1177</td>
<td></td>
</tr>
<tr>
<td>PMS-Trazadone, 1189</td>
<td></td>
</tr>
<tr>
<td>PMS-Trifluoperazine, 1202</td>
<td></td>
</tr>
<tr>
<td>PMS-Trihexyphenidyl, 1204</td>
<td></td>
</tr>
<tr>
<td>PMS-Trihexyphenidyl, 1204</td>
<td></td>
</tr>
<tr>
<td>PMS-Trihexyphenidyl, 1204</td>
<td></td>
</tr>
<tr>
<td>PMS-Trihexyphenidyl, 1204</td>
<td></td>
</tr>
<tr>
<td>PMS-Trihexyphenidyl, 1204</td>
<td></td>
</tr>
<tr>
<td>PMS-Vancomycin, 1221</td>
<td></td>
</tr>
<tr>
<td>PMS-Venlafaxine XR, 1226</td>
<td></td>
</tr>
<tr>
<td>PMS-Verapamil SR, 1228</td>
<td></td>
</tr>
<tr>
<td>Pneumococcal immunization schedule, 1346t, 1347t, 1348t</td>
<td></td>
</tr>
<tr>
<td>Pneumonist, 539</td>
<td></td>
</tr>
<tr>
<td>Pneumonia</td>
<td></td>
</tr>
<tr>
<td>acetylcysteine for, 19</td>
<td></td>
</tr>
<tr>
<td>amoxicillin and clavulanate for, 78</td>
<td></td>
</tr>
<tr>
<td>azithromycin for, 120</td>
<td></td>
</tr>
<tr>
<td>cefazolin for, 202</td>
<td></td>
</tr>
<tr>
<td>cefdinir for, 204</td>
<td></td>
</tr>
</tbody>
</table>
Pneumonia (continued)

- cefepime for, 206
- cefpodoxime for, 212
- ciprofloxacin for, 256
- clarithromycin for, 262
- ertapenem for, 421
- erythromycin for, 424
- gemifloxacin for, 522
- hydrocortisone for, 552
- immune globulin for, 580
- levofloxacin for, 654
- linezolid for, 667
- moxifloxacin for, 849
- penicillin G procaine for, 908
- pentamidine for, 911
- piperacillin and tazobactam for, 944
- piperacillin for, 942
- prednisone for, 972
- sulfamethoxazole-trimethoprim for, 1106, 1107
- telithromycin for, 1125
- Poisson, activated charcoal for, 26
- Poisonings and overdoses, managing, S30–S32
- Poliovirus immunization schedule, 1347t, 1348t
- Pollenase Nasal, 129
- Pollenshield Hayfever, 226
- Polyarthritis, salsalate for, 1061
- Polyfusor, 696
- Polygam S/D, 579
- poractant alfa, 950–951
- Portal-system encephalopathy, lactulose for, 630
- posaconazole, 951–954
- Posanol, 951
- Post-anesthesia care nursing, most commonly used drugs in, 1370
- Postherpetic neuralgia gabapentin for, 510
- pregabalin for, 975
- PostMI, 21
- Postpartum bleeding methylergonovine for, 739
- oxytocin for, 878
- Posttraumatic stress disorder paroxetine for, 890
- sertraline for, 1073
- Posture, 171
- potassium acetate, 954–955
- potassium bicarbonate, 955–957
- potassium chloride, 957–959
- Potassium depletion potassium acetate for, 954
- potassium bicarbonate for, 956
- potassium chloride for, 957
- potassium gluconate for, 959
- potassium gluconate, 959–960
- potassium iodide, 961–963
- potassium, therapeutic and toxic blood levels for, S17
- Prader-Willi syndrome, somatropin, recombinant for, 1092
- pralidoxime, S32
- pramipexole dihydrochloride, 963–964
- pramipexide acetate, 964–965
- Prandase, 11
- Prandin, 1030
- Pravachol, 966, P12
- pravastatin sodium, 966–967, P12
- prazoxin hydrochloride, 967–968
- Precortisyl, 969
- Precose, 11
- Pred Forte Ophthalmic, 969
- Pred Mild Ophthalmic, 969
- prednisolone, 969–972
- prednisolone acetate, 969–972
- prednisolone sodium phosphate, 969–972
- prednisone, 972–974
- Predsol, 969
- Preferin, 930
- pregabalin capsules CV, 975–976
- Pregnancy preventing (See Contraception.) terminating (See Abortion)
- Pregnancy risk categories, xvii
- Preloke, 969
- Premarin, 432, P6
- Premarin Intravenous, 432
- Premenstrual dysphoric disorder fluoxetine for, 482
- paroxetine for, 891
- sertraline for, 1073
- Premphase, 1344
- Prepidil Endocervical Gel, 354
- Prescal, 620
- Prevacid, 637, P8
- Prevacid SoluTab, 637
- Prevalite, 248
- Prezista, 311
- Priadel, 677
- Priprin, 1038
- Prilosec, 857, P11
- Prilosec OTC, 857
- primary aldosteronism potassium acetate for, 954
- potassium chloride for, 957
- Primary hyperaldosteronism, spironolactone for, 1097
- Primatene Mist, 409
- Primaxin, 575, 1344
- primidone, 978–979
- therapeutic and toxic blood levels for, S17
- Prinivil, 675, P9
- Pripsen, 698
- Pristiq, 329
- Privigen, 579
- Pro-Banthine, 992
- Pro-Epanutin, 503
- Pro-Indo, 586
- Pro-Lorazepam, 684
- PRO-Piroxicam, 947

Boldface: Color section
Pulmonary artery hypertension  1421

ProAmatine, 760
probenecid, 979–980
procainamide hydrochloride, 982–984
  therapeutic and toxic blood levels for, *S17*
procaine hydrochloride, 1336t–1337t
Procan SR, 980
procarbazine hydrochloride, 982–984
Procardia, 822
Procardia XL, 822
prochlorperazine, 984–986
prochlorperazine edisylate, 984–986
prochlorperazine maleate, 984–986
Procrit, 415
Proctitis
  hydrocortisone for, 552
  mesalamine for, 717
Proctosigmoiditis, mesalamine for, 717
Procytox, 291
Prodiem PlainW, 1000
Proflnine SD, 455
progesterone, 986–988
Proglycem, 341
Prograf, 1118
Progynova, 429
Proleukin, 37
promethazine hydrochloride, 988–990
Prometrium, 986
Promestyl, 980
propafenone hydrochloride, 990–992
propantheline bromide, 992–993
Propecia, 471
Proplex T (heat-treated), 455
propoxyphene hydrochloride, 993–995
propanolol hydrochloride, 995–998
  therapeutic and toxic blood levels for, *S17*
Propress, 354
Propyl-Thyracil, 998
propranolol hydrochloride, 995–998
  therapeutic and toxic blood levels for, *S17*
Prostaglandin E2, 354–355
Prostap, 647
Prostate cancer
  bicalutamide for, 140
  docetaxel for, 364
  estradiol for, 430
  estrogens, conjugated for, 432
  estrogens, esterified for, 434
  flutamide for, 487
  goserelin for, 535, 536
  leuprolide for, 648
  mitoantrone for, 774
  nilutamide for, 826
  triptorelin for, 1209
Prostate, transurethral resection of,
mannitol for, 697
Prostatitis
  ciprofloxacin for, 255
  levofloxacin for, 654
  norfloxacin for, 842
  ofloxacin for, 849
Prostep, 819
Prostigmin, 813
Prostin E2 Vaginal Suppository, 354
Protamine sulfate, *S31*
Protium, 888
Proton pump inhibitors, 1278–1279
Protonix, 888, *P11*
Protonix IV, 888
Protopam, *S32*
Protopic, 1118
Protrin, 1106
Protrin DS, 1106
Proviril, 776
Prozac, 481, *P7*
Prozac Weekly, 481
Proziere, 984
Prozit, 481
Prudoxin, 376
Psychiatric emergencies, hydroxyzine for, 559
Psychiatric nursing, most commonly used drugs in, 1370
Psoriasis
  acitretin for, 24
  cyclosporine for, 293
  etanercept for, 438
  methotrexate for, 733
  triamcinolone for, 1196
Psoriatic arthritis
  adalimumab for, 30
  etanercept for, 438
Psychotropic disorders
  fluphenazine for, 484
  haloperidol for, 541, 542
  olanzapine for, 851
  pismylium, 1000–1001
PSU, 998–999
Puberty
  delayed, testosterone for, 1139
  precocious
    leuprolide for, 648
    nafarelin for, 796
Pulmicort Flexhaler, 157
Pulmicort Respules, 157
Pulmonary artery hypertension, treprostinil for, 1191

Boldface: Color section

t: table
Pulmonary complications, surgical, acetylcysteine for, 19
Pulmonary disease, doxapram for, 373
Pulmonary edema, furosemide for, 508
Pulmonary embolism alteplase for, 53
dalteparin for, 302
enoxaparin for, 405
fondaparinux for, 495
streptokinase for, 1100
warfarin for, 1238
Pulmonary function, dornase alfa for improving, 372
Pulmonary infection, flucytosine for, 476
Pulmonary toxicity, 1362
Pulmophyllin ELX, 1146
Pulmozyme, 372
Pupil dilation atropine for, 115
phenylephrine for, 931
R
rabeprazole sodium, 1017–1018, P13
Raciran, 1024
Radiation protectant, potassium iodide as, 961
Radiologic examination glucagon for, 531
metoclopramide for, 747
Ralivia, 1182
raloxifene, 1018–1019, P13
raltegravir, 1019–1020
ramelteon, 1020–1021
ramipril, 1021–1024, P13
Ran-Cefprozil, 214
Ran-Fentanyl, 464
Ran-Fosinopril, 501
Ran-Gabapentin, 510
Ran-Glyburide, 532
Ran-Indomethacin, 586
Ran-Ipratropium, 605
Ran-Ketoconazole, 623
Ran-Lactulose, 630
Ran-Lamotrigine, 633
Ran-Lisinopril, 675
Ran-Lovastatin, 687
Ran-Meloxicam, 705
Ran-Metformin, 723
Ran-Methotrexate Sodium, 731
Ran-Methylphenidate, 740
Ran-Minocycline, 765
Ran-Mirtazapine, 769
Ran-Morinone Sulfate SR, 780
Ran-MPA, 700
Ran-Nortriptyline, 844
Ran-Nystatin, 846
Ran-Omeprazole, 857
Ran-Ondansetron, 858
Ran-Pantoprazole, 888
Ran-Pravastatin, 966
Ran-Rabeprazole, 1017
Ran-Risperidone, 1045
ranolazine, 1026–1027
ranolazine, 1026–1027
ranolazine, 1026–1027
ranolazine, 1026–1027
ranolazine, 1026–1027
ranolazine, 1026–1027
ranolazine, 1026–1027
ranolazine, 1026–1027
ranolazone, 1026–1027
Ran-Tezepilide, 1078
Ran-Torpin, 1078
Ran-Torpin, 1078
Ran-Torpin, 1078
Ran-Torpin, 1078
Ran-Torpin, 1078
Ran-Torpin, 1078
Ran-Torpin, 1078
Ran-Torpin, 1078
Ran-Torpin, 1078
Ran-Torpin, 1078
Ran-Torpin, 1078
Ran-Torpin, 1078
Ran-Torpin, 1078
Ran-Torpin, 1078
Ran-Torpin, 1078
Ran-Torpin, 1078
Ran-Torpin, 1078
Ran-Torpin, 1078
Restless leg syndrome

Ratio-Sertraline, 1073
Ratio-Simvastatin, 1078
Ratio-Sotalol, 1095
Ratio-Sumatriptan, 1113
Ratio-Tamsulosin, 1123
Ratio-Temazepam, 1128
Ratio-Terazosin, 1134
Ratio-Theo-Bronc, 1146
Ratio-Topiramate, 1177
Ratio-Trazodone, 1189
Ratio-Valproic, 1216
Ratio-Venlafaxine XR, 1226
Razadyne, 512
Razadyne ER, 512
Reactine, 226
ReAzo, 923
Rebetol, 1033
Rebif, 602
Reclast, 1247
Recombinate, 94
Recommended dietary allowance
for ascorbic acid, 1303
for cholecalciferol, 1303
for cyanocobalamin, 1305
for folic acid, 1306
for manganese, 1307
for niacin, 1307
for pyridoxine, 1309
for retinol, 1310
for riboflavin, 1310
for selenium, 1311
for thiamine, 1311
for tocopherols, 1312
for zinc, 1312
Rectal cancer. See Colorectal cancer
Rectal infection, tetracycline for, 1142
red yeast rice, 1326
ReFacto, 94
ReFludan, 643
Refolinon, 645
Refraction, phenylephrine for, 931
Regaine, 767
Reglan, 746
Regonol, 1003
Regulax, 1000
Reguloid, 1000
Reguloid Sugar Free, 1000
Regulose, 630
Regurin, 1211
Relenza, 1242
Relifex, 793
Relistor, 738
Relpax, 396
Remegol, 170
Remeuron, 769
Remeuron RD, 769
Remeuron Soltab, 769
Remicade, 587
Remifentanil hydrochloride, 1336t–1337t
Reminyl, 512
Reminyl XL, 512
Remodulin, 1191
Renal acidosis, 1362
Renal colic, hyoscyamine for, 561
Renal disorders
chlorothiazide for, 237
chlordiazepoxide for, 245
lantabon for, 639
metolazone for, 748
Renal dysfunction,
hydrochlorothiazide for, 547
Renal failure, 1362
mannitol for, 696
Renal function, inadequate,
mannitol as test dose for, 96
Renal tubular necrosis,
sodium bicarbonate for, 1083
Renedil, 459
Renin-angiotensin system antagonists,
1295–1296
Rennie Soft Chews, 170
Renova, 1192
ReoPro, 7
repaglinide, 1030–1032
Repletrin, 455
Reproductive technologies, assisted
menotropins for, 710
progesterone for, 987
Repronex, 710
Requip, 1054
Requip XL, 1054
Resectiorp, 321
Resecitisol, 696
Resonium A, 1089
Respiratory acidosis, 1362
Respiratory depression, doxapram for, 373
Respiratory disorders
betamethasone for, 135
methylprednisolone for, 744
palivizumab for, 884
prednisolone for, 969
triamcinolone for, 1197
Respiratory distress syndrome
calfactant for, 174
poractant alfa for, 951
Respiratory syncytial virus infection
palivizumab for, 884
ribavirin for, 1034
Respiratory tract infection
amoxicillin and clavulanate for, 78
amoxicillin for, 76
ampicillin for, 84
cefaclor for, 199
cefazolin for, 202
cefoxitin for, 211
ceftazidine for, 216
ceftiraxone for, 219
cefuroxime for, 221
cephalaxin for, 225
ciprofloxacin for, 256
dornase alfa for, 372
erthyromycin for, 423
flucytosine for, 476
guaiifenesin for, 539
imipenem and cilastatin for, 575
penicillin G benzathine for, 904
penicillin V potassium for, 910
ribavirin for, 1034
Respostin, 605
Restasis, 293
Restless leg syndrome
Restless leg syndrome
(continued)
pramipexole for, 963
ropinirole for, 1055
Restoril, 1128
Resyl, 539
Retavase, 1032
treteplase, recombinant,
1032–1033
Retin A, 1192
Retin A Micro, 1192
retinol, 1310
Retinoscopy, phenylephrine
for, 931
Retrovir, 1243
Revatio, 1075
ReVia, S32
Revlimid, 641
Rhabdomyolysis, 1362
Rheumacin, 586
Rheumatic disorders
methylprednisolone for,
744
prednisolone for, 969
triamcinolone for,
1196
Rheumatic fever
acetylsalicylic acid for,
21
penicillin G benzathine
as prophylaxis for,
904
penicillin V potassium
for, 910
Rheumatism, salsalate for,
1061
Rheumatoid arthritis. See
also Juvenile
rheumatoid arthritis.
abatacept for, 6
acetylsalicylic acid for, 21
adalimumab for, 30
anakinra for, 91
azathioprine for, 119
betamethasone for, 135
celecoxib for, 223
cyclosporine for, 293
diclofenac for, 343
etanercept for, 438
etodolac for, 442
hydroxychloroquine for,
557
ibuprofen for, 567
indomethacin for, 586
infliximab for, 588
Rheumatoid arthritis
(continued)
leflunomide for, 640
meloxicam for, 706
methotrexate for, 733
nabumetone for, 793
oxaprozin for, 866
rituximab for, 1050
salsalate for, 1061
sulfasalazine for, 1109
Rhinalar Nasal Mist, 478
Rhinall, 930
Rhinitis
beclomethasone for, 129
budesonide for, 157
cromolyn for, 288
cyproheptadine for, 296
desloratadine for, 326
diphenhydramine for,
356
fexofenadine for, 468
flunisolide for, 478
fluticasone for, 489
hyoscyamine for, 561
ipratropium for, 605
levocetirizine for, 653
montelukast for, 779
triamcinolone for, 1196
Rhinocort Aqua, 157
Rhodamine, 586
Rhotarid, 780
Rhotral, 12
Rhoxal-Metformin, 723
Rhoxal-Oxaprozin, 866
Rhoxal-Sotalol, 1095
Rhoxal-Timolol, 1159
Rhythmmodan, 360
Rhythmmodan-LA, 360
Ribaphersine, 1033
ribavirin, 1033–1035
riboflavin, 1310
Riboflavin deficiency,
riboflavin for, 1310
Rickettsial infection, tetra-
cycline for, 1142
rifabutin, 1035–1036
Rifadin, 1036
Rifamate, 1345
rifampicin, 1036–1038
rifampin, 1036–1038
rifapentine, 1038–1040
Rifax, 615, 1345
Rifinah, 615
rifiximin, 1040–1041
Rilutek, 1041
riluzole, 1041–1042
Rimac, 586
Rimactin, 84
Rimactazid, 615
rimantadine hydrochloride,
1042–1043
Rimapurinol, 45
Rinatcon, 605
Riomet, 723
risperidone, 1045–1047,
P13
Risperdal, 1045, P13
Risperdal Consta, 1045
Risperdal M-Tab, 1045
Riva K 20 SR, 957
Riva OXazepam, 868
Riva-Cyclosporine, 289
Riva-Enalpril, 401
Riva-Flucnazole, 474
Riva-Fluvoxamine, 493
Riva-Fosinopril, 501
Riva-Gabapentin, 510
Riva-Gemfibrozil, 520
Riva-Glyburide, 532
Riva-Hydroxyzine, 559
Riva-Indapamide, 583
Riva-Lisinopril, 675
Riva-Loperamide, 681
Riva-Metformin, 723
Riva-Minocycline, 765
Riva-Mirtazapine, 769
Riva-Naproxen, 800
Riva-Naproxen Sodium, 800
Riva-Paroxetine, 890
Riva-Pravastatin, 966
Riva-Risperidone, 1045
Riva-Sertaline, 1073
Riva-Simvastatin, 1078
Riva-Sumatriptan, 1226
Riva-Verapamil SR, 1228
Rivanese, 129
rivastigmine tartrate,
P13
Rivotril, 270
rizatriptan benzoate,
1053–1054

Boldface: Color section

1424 Restless leg syndrome
Schizophrenia    1425

Robaxin, 730
Robidrine, 999
Robinul, 534
Robinul Forte, 534
Robitussin, 539
Robitussin Chesty Cough, 539
Robitussin CoughGels, 336
Robitussin for Dry Coughs, 336
Robitussin Maximum Strength Cough Suppressant, 336
Robitussin Pediatric Cough, 336
Rocephin, 219
rocuronium bromide, 1338t–1339t
Rodex, 1309
Rofact, 1036
Rogaine, 767
Rogaine Extra Strength, 767
Rogitine, 929
Rolaids Calcium Rich, 170
Romazicon, S30
Rommix, 423
ropinirole hydrochloride, 1054–1056
ropivacaine hydrochloride, 1338t–1339t
Rosacea, metronidazole for, 753
Rosasol, 752
Rosiglitazone maleate, 1056–1057, P13
Rosuvastatin calcium, 1057–1059, P14
Rotavirus immunization schedule, 1347t
Roundworm infestation mebendazole for, 698 pyrantel for, 1002
Rowasa, 717
Roxicet, 1345
Roxicodone, 872
Rozerem, 1020
Rozex, 752
RU-486, 761–763
Rubella exposure, immune globulin for, 579
Rubella immunization schedule, 1346t, 1347t, 1348t
Rubex, 378
Rubramin, 1305
Rylosol, 1095
Rythmol, 990
S
S-adenosylmethionine, 1326–1327
Safe drug administration, S1–S32
Saizen, 1091
Sal-Adult, 21
Sal-Infant, 21
Salazopyrin, 1109
Salazopyrin EN-Tabs, 1109
salbutamol, 35–37
salbutamol sulfate, 35–37
Salicylate toxicity, 1362
Salicylates, therapeutic and toxic blood levels for, S17
Salmeterol xinafoate, 1060–1061
Salofalk, 717
salsalate, 1061–1063
SAM-e, 1326–1327
Sandimmune, 293
Sandoglobulin, 579
Sandimmune, 293
Sandostatin LAR, 847
sandostatin, 1211
Sanctura, 1211
Sanctura XR, 1211
Sancuso, 537
Sandimmune, 293
Sandoglobulin, 579
Sandostatin, 847
Sandoz Alendronate, 41
Sandoz Bicalutamide, 140
Sandoz Bisoprolol, 144
Sandoz Calcitonin, 169
Sandoz Carbamazepine, 180
Sandoz Cefprozil, 214
Sandoz Cyclosporine, 293
Sandoz Diltiazem, 351
Sandoz Famiclouic, 456
Sandoz Fluvoxamine, 493
Sandoz Gilmepride, 527
Sandoz Glyburide, 532
Sandoz Indomethacin, 586
Sandoz Leflunomide, 640
Sandoz Loperamide, 681
Sandoz Lovastatin, 687
Sandoz Metformin, 687
Sandoz Metformin, 723
Sandoz Metoprolol, 750
Sandoz Minocycline, 765
Sandoz Mirtazapine, 769
Sandoz Nabumetone, 793
Sandoz Omeprazole, 857
Sandoz Ondansetron, 858
Sandoz Pantoprazole, 888
Sandoz Paroxetine, 890
Sandoz Pioglitazone, 941
Sandoz Pravastatin, 966
Sandoz Ramipril, 1021
Sandoz Risperidone, 1045
Sandoz Sertraline, 1073
Sandoz Simvastatin, 1078
Sandoz Sotalol, 1095
Sandoz Sumatriptan, 1113
Sandoz Tamsulosin, 1123
Sandoz Ticlopidine, 1156
Sandoz Timolol, 1159
Sandoz Valproic, 1216
Sandoz Venlafaxine XR, 1226
Sandoz-Enalpril, 401
Sandoz-Pindolol, 939
Sandoz-Topiramate, 1177
Sandrena, 429
Sans-Acne, 423
saquinavir mesylate, 1063–1065
Sarafem, 481
Sarcoidosis, 1362
sargramostim, 1065–1067
SAS Tab, 1109
saw palmetto, 1327
Scabies, lindane for, 666
Scalp
potassium acetate for, 954
potassium chloride for, 957
Scaling, ketoconazole for, 624
Scarlet fever, penicillin V potassium for, 910
Schizophrenia
aripiprazole for, 102
chlorpromazine for, 241
diazepam for, 277
haloperidol for, 541
loxapine for, 689
olanzapine for, 851
paliperidone for, 883
perphenazine for, 921
prochlorperazine for, 985
quetiapine for, 1007
risperidone for, 1045
thioridazine for, 1149
trifluoperazine for, 1202
zidovudine for, 1245
Scopace, 1067
Scopoderm TTS, 1067
scopolamine, 1067–1068
scopolamine hydrobromide, 1067–1068
Scot-tussin Expectorant, 539
Scurvy, ascorbic acid for, 1303
Sea-Legs, 699
SeapCal, 170
Seasonale, 1345
Sebomin, 765
Seborrheic dermatitis, ketoconazole for, 624
Sebren, 765
secobarbital, 1069–1070
Seconal, 1069
Secretions, diminishing atropine for, 115
glycopyrrolate for, 534
hyoscyamine for, 561
Sectral, 12
Securon SR, 1228
Sedation
chloral hydrate for, 230
chlorpromazine for, 241
diphenhydramine for, 356
hydroxyzine for, 559
lorazepam for, 684
meperidine for, 712
midazolam for, 758, 1334–1335t
pentazocine for, 913
pentobarbital for, 915
phenobarbital for, 927
promethazine for, 989
scopolamine for, 1067
secobarbital for, 1069
Sedative-hypnotics, 1296–1297
Sedatuss, 336
Seizures. See also Status epilepticus.
acetazolamide for, 17
carbamazepine for, 180
diazepam for, 339
divalproex sodium for, 1217
fosphenytoin for, 503
gabapentin for, 510
lamotrigine for, 633, 634, 635
Seizures (continued)
levetiracetam for, 651
magnesium for, 695
oxcarbazepine for, 870
pentobarbital for, 915
phenobarbital for, 927
phenytoin for, 934
pregabalin for, 975
primidone for, 978
thiopental for, 1340–1341t
tiagabine for, 1153
topiramate for, 1177
valproate for, 1217
valproic acid for, 1217
zonisamide for, 1251
Selax, 366
Sele-Pak, 1311
Selective aldosterone receptor antagonists, 1295–1296
Selective estrogen receptor modulators, 1297–1298
selegiline hydrochloride, 1070–1072
selenium, 1311
Selenium deficiency, selenium for, 1311
Selepen, 1311
Self-injury, risperidone for, 1045
Semi-Daonil, 532
Senexon, 1072
Senna, 1072–1073
Sennatural, 1072
sennosides, 1072–1073
Senokot, 1072
Senokot Granules, 1072
SenokotXTRA, 1072
Senolax, 1072
Sensipar, 253
Sepsis, 1362
Septicemia
ampicillin for, 84
cefazolin for, 202
cefotaxime for, 209
cefoxitin for, 211
tazidime for, 216
ceftixime for, 219
drotrecogin alfa for, 389
flucytosine for, 476
immune globulin for, 580
Septra, 1106, 1345
Septra DS, 1106
Seprin, 1106
Serenace, 541
Serevent, 1060
Serevent Diskus, 1060
Serophene, 267
Seroquel, 1007, P12
Seroquel XR, 1007
Serostim, 1091
Serotonin receptor agonists, 1271–1272
Seroxat, 890
sertraline hydrochloride, 1073–1075, P14
therapeutic and toxic blood levels for, S17
Serum sickness, 1362
Setlers, 170
Sevredol, 780
Sex hormones, 1297–1298
Sexually transmitted disease, ampicillin as prophylaxis for, 85
Shadow test, phenylephrine for, 931
shark cartilage, 1327
Shigellosis, sulfamethoxazole-trimethoprim for, 1106
Shingles. See Herpes zoster infection.
Shock
dopamine for, 370
isoproterenol for, 617
phenylephrine for, 931
Short bowel syndrome, somatropin, recombinant for, 1092
Short stature, somatropin, recombinant for, 1092
Sickle cell anemia, hydroxyurea for, 558
Silace, 366
Siladryl, 356
Silapap, 14
sildenafil citrate, 1075–1077, P14
Silfedrine Children’s, 999
Siltussin SA, 539
simethicone, 1077
simeticone, 1077
Simply Sleep, 356
Simulect, 127
Simvadot, 1078
simvastatin, 1078–1079, P14
Sinemet, 182, 1345
Sinemet CR, 182
Sinepin, 376
Singular, 778, P10
Sinus congestion, pseudoephedrine for, 999
Sinusitis
amoxicillin and clavulanate for, 78
azithromycin for, 121
cefdinir for, 204
cefprozil for, 214
ciprofloxacin for, 255
clarithromycin for, 261
levofoxacin for, 654
moxifloxacin for, 784
sirolimus, 1079–1081
sitagliptin phosphate, 1081–1083
Sitosterolemia, ezetimibe for, 452
Skelaxin, 722
Skeletal muscle relaxants, 1298–1299
Skeletal muscle relaxation
atracurium for, 1330t–1331t
botulinum toxin for, 152
pancuronium for, 1334t–1335t
rocuronium for, 1338t–1339t
succinylcholine for, 1338t–1339t
vecuronium for, 1340t–1341t
Skin and skin-structure infection
amoxicillin and clavulanate for, 78
amoxicillin for, 76
ampicillin and sulbactam for, 87
ampicillin for, 84
azithromycin for, 121
cefaclor for, 199
cefadroxil for, 200
Skin and skin-structure infection (continued)
cefazolin for, 202
cefdinir for, 204
cefepime for, 205
cefoxitin for, 211
cefpodoxime for, 212
cefprozil for, 214
ceftazidime for, 216
ceftriaxone for, 219
cefuroxime for, 221
cephalexin for, 225
ciprofloxacin for, 256
clarithromycin for, 262
erhapem for, 421
erthyromycin for, 423
imipenem and cilastatin for, 575
levofoxacin for, 654
linezolid for, 667
moxifloxacin for, 784
ofloxacin for, 849
penicillin V potassium for, 910
piperacillin and tazobactam for, 944
quinupristin and dalfo-
bristin for, 1016
tigecycline for, 1158
Skin cancer, bleomycin for, 147
Skin disorders, methylprednisolone for, 744
Skin lesions, mupirocin for, 786
Sleepeaze, 356
Slo-Indo, 586
Slo-Niacin, 1307
Slo-Phyllin, 1146
Slo-Pro, 822
Slow Sodium, 1084
Slow-Pot, 957
Skin and skin-structure infection
bupropion for, 163
nicotine for, 820
varenicline for, 1224
Social anxiety disorder
fluvoxamine for, 493
sertraline for, 1073
venlafaxine for, 1226
sodium bicarbonate, 1083–1084
sodium chloride, 1084–1085
therapeutic and toxic blood levels for, S17
Sodium chloride replacement, sodium chloride for, 1084
Sodium depletion, sodium chloride for, 1085
sodium iodide 131I, 1086–1087
Sodium Iodide 131I Therapeutic, 1086
sodium phosphates, 1087–1088
sodium polystyrene sulfonate, 1089–1090
Softlax C, 366
Soft-tissue infection
amoxicillin for, 76
ampicillin for, 84
cefdinir for, 204
cefpodoxime for, 212
linezolid for, 667
penicillin V potassium for, 910
Solage, 1345
Solar keratoses, fluorouracil for, 479
Solfoton, 926
solifenacin succinate, 1090–1091
Solody, 765
Solu-Crom, 287
Solu-Medrol, 744
Solu-Medrone, 744
Soma, 188
Soma 1427
Smoking cessation
bupropion for, 163
nicotine for, 820
varenicline for, 1224
Social anxiety disorder
fluvoxamine for, 493
sertraline for, 1073
venlafaxine for, 1226
sodium bicarbonate, 1083–1084
sodium chloride, 1084–1085
therapeutic and toxic blood levels for, S17
Sodium chloride replacement, sodium chloride for, 1084
Sodium depletion, sodium chloride for, 1085
sodium iodide 131I, 1086–1087
Sodium Iodide 131I Therapeutic, 1086
sodium phosphates, 1087–1088
sodium polystyrene sulfonate, 1089–1090
Softlax C, 366
Soft-tissue infection
amoxicillin for, 76
ampicillin for, 84
cefdinir for, 204
cefpodoxime for, 212
linezolid for, 667
penicillin V potassium for, 910
Solage, 1345
Solar keratoses, fluorouracil for, 479
Solfoton, 926
solifenacin succinate, 1090–1091
Solody, 765
Solu-Crom, 287
Solu-Medrol, 744
Solu-Medrone, 744
Soma, 188

Boldface: Color section

T: table
somatropin, recombinant, 1091–1093
Somavert, 900
Sominex, 356, 988
Somnol, 486
Somnol, 486
Sonata, 1241
Soni-Slo SR, 618
sorafenib, 1093–1095
Sorbid, 618
Soriatane, 24
Sorine, 1095
Sotacor, 1095
sotalol hydrochloride, 1095–1097
Sour stomach, famotidine for, 458
soy, 1327–1328
Spasticity. See Muscle spasm.
Spinal cord injury, dantrolene for, 307
Spinal cord lesions, baclofen for, 124
Spiriva HandiHaler, 1165
spironolactone, 1097–1098
Sporanox, 621
Sporotrichosis, amphotericin B for, 81
Stem cell transplantation
busulfan for, 166
filgrastim for, 470
micafungin for, 757
Stemetil, 984
Stesolid, 339
Stevens-Johnson syndrome, 1362
Stie-Cort, 551
Stiemycin, 423
Stiff-man syndrome, diazepam for, 339
Stilnot, 1250
Stimate, 327
Stomach cancer. See Gastric cancer.
Stool Softener DC, 366
Stool softener, docusate as, 366
Strabismus, botulinum toxin for, 152
Strattera, 110, P3
Streptase, 1100
Streptogramins, 1269–1270
streptokinase, 1100–1102
streptomycin sulfate, 1102–1104
therapeutic and toxic blood levels for, S17
Striant, 1139
Strifon Forte, 247
Stroke. See Cerebrovascular accident.
Synergic, 1015
Surmontil, 1206
Sustiva, 394
Sutent, 1115
Symax, 560
Symax-SL, 560
Symax-SR, 560
Symbyax, 1345
Symmetrel, 55
Sympathetic ophthalmia, triamcinolone for, 1197
Synercid, 1015
sulfacetamide sodium, 1105–1106
sulfamethoxazole-trimethoprim, 1106–1109
sulfadiazine, 1109–1111
Sulfate SR, 780
Sulfatrim, 1106
Sulfazine, 1109
Sulfazine EC, 1109
sulfisoxazole acetyl, 1111–1113
Sulfonamides, 1269–1270
sumatriptan succinate, 1113–1115, P14
sunitinib malate, 1115–1117
Supasa, 21
Supeudol, 872
Supralip, 460
Suprax, 207
Sure-Lax, 1072
Surfax Liquigels, 366
Surgical complications, acetylcysteine for, 19
Surgical prophylaxis
cefazolin for, 202
cefotaxime for, 209
cefoxitin for, 211
ceftiraxone for, 219
erapenem for, 421
gentamicin for, 524
metronidazole for, 753
neomycin for, 812
Surmontil, 1206
St. John’s wort, 1328
St. Joseph, 21
Stadol, 167
Stagesic, 549
Stalevo, 185, 1345
Staril, 501
Starlix, 803
Statex, 780
Status epilepticus
diazepam for, 339
fosphenytoin for, 503
lorazepam for, 684
phenobarbital for, 927
phenytoin for, 934
stavudine, 1098–1100
Steatosis, 1362
Stem cell transplantation
busulfan for, 166
filgrastim for, 470
micafungin for, 757
Stemetil, 984
Stesolid, 339
Stevens-Johnson syndrome, 1362
Stie-Cort, 551
Stiemycin, 423
Stiff-man syndrome, diazepam for, 339
Stilnot, 1250
Stimate, 327
Stomach cancer. See Gastric cancer.
Stool Softener DC, 366
Stool softener, docusate as, 366
Strabismus, botulinum toxin for, 152
Strattera, 110, P3
Streptase, 1100
Streptogramins, 1269–1270
streptokinase, 1100–1102
streptomycin sulfate, 1102–1104
therapeutic and toxic blood levels for, S17
Striant, 1139
Strifon Forte, 247
Stroke. See Cerebrovascular accident.
Stronazon, 1123
Subarachnoid hemorrhage, nimodipine for, 827
Subcutaneous injections, sites for, S15
Sublimaze, 464, 1332t–1333t
Subutex, 161
succinylcholine chloride, 1338t–1339t
sucralfate, 1104–1105
Sudafed, 999
Sudafed 12 Hour, 999
Sudafed Children’s Nasal Decongestant, 999
Sudafed PE, 930
Sudo-Tab, 999
Sudodrin, 999
Sudogest, 999
Sufenta, 1340t–1341t
sufentanil, 1340t–1341t
Sular, 828
Sulazine, 1109
Sulcrate, 1104
Sulfaemethoxazole-trimethoprim, 1106–1109
sulfadiazine, 1109–1111
Sulfate SR, 780
Sulfatrim, 1106
Sulfazine, 1109
Sulfazine EC, 1109
sulfisoxazole acetyl, 1111–1113
Sulfonamides, 1269–1270
sumatriptan succinate, 1113–1115, P14
sunitinib malate, 1115–1117
Supasa, 21
Supeudol, 872
Supralip, 460
Suprax, 207
Sure-Lax, 1072
Surfax Liquigels, 366
Surgical complications, acetylcysteine for, 19
Surgical prophylaxis
cefazolin for, 202
cefotaxime for, 209
cefoxitin for, 211
ceftiraxone for, 219
erapenem for, 421
gentamicin for, 524
metronidazole for, 753
neomycin for, 812
Surmontil, 1206
Sustiva, 394
Sutent, 1115
Symax, 560
Symax-SL, 560
Symax-SR, 560
Symbyax, 1345
Symlin, 964
Symmetrel, 55
Sympathetic ophthalmia, triamcinolone for, 1197
Synacort, 551
Synagis, 884
Synarel, 796
Synastone, 725
Syndrome of inappropriate diuretic hormone secretion, 1363
Synercid, 1015
Boldface: Color section
Synflex, 800
Synthroid, 660, P9
Sytocinon, 877
Syntometrine, 877
Syphilis
erythromycin for, 423
minocycline for, 765
penicillin G benzathine for, 904
penicillin G procaine for, 908
tetracycline for, 1142
Syprol, 995
Syscor, 828
Systemic infection, tetracycline and clavulanate for, 1154
Systemic lupus erythematosus hydroxychloroquine for, 557
triamcinolone for, 1196
T
T₃, 669–671
T₃ suppression test, liothyronine for, 669
T₄, 660–662
Tablets and capsules not to crush, S11–S12
Tabphyn, 1123
Taclonex, 1345
Tasict, 215
Telzir, 498
temazepam, 1128–1129
temgesic, 161
temodal, 1129
temodar, 1129
temozolomide, 1129–1130
Temferon, 1139
Tenax, 879
Tazocin, 944
Tazorit, 351
Tear production, increasing, cyclosporine for, 294
Tebrazid, 1002
Terflox, 180
Terflox-XR, 180
Tekturna, 68
Telfast, 468
telithromycin, 1124–1127
telmisartan, 1127–1128
Telzir, 498
temazepam, 1128–1129
Temgesic, 14
Temgesic, 161
Temgesc, 180
Temgess, 180
Tendinitis
betamethasone for, 135
indomethacin for, 586
naproxen for, 800
tenecteplase, 1130–1132
Tenex, 540
tenofovir disoproxil fumarate, 1132–1134
Tenofovir, 822
Tenormin, 108
Tenastrin, 351
Tenosynovitis, betamethasone for, 135
Tenosynovitis. See also Tendinitis
Thalitone, 1429
Thalitone, 245
Tear production, increasing, cyclosporine for, 294
Tebrazid, 1002
Terflox, 180
Terflox-XR, 180
Tekturna, 68
Telfast, 468
Telithromycin, 1124–1127
Telmisartan, 1127–1128
Telzir, 498
Temazepam, 1128–1129
Temgesic, 14
Temgesic, 161
Temgesic, 180
Temgesic, 180
Tendinitis
Betamethasone for, 135
Indomethacin for, 586
Naproxen for, 800
Tenecteplase, 1130–1132
Tenex, 540
Tenofovir Disoproxil Fumarate, 1132–1134
Tenex, 540
Tenofovir, 822
Tenormin, 108
Tenosynovitis, Betamethasone for, 135
Tenosynovitis. See Also Tendinitis
Thalitone, 1429
Thalitone, 245

**Boldface**: Color section
Thallium myocardial perfusion imaging, dipyridamole for, 359

Thalomid, 1144

Tham, 1210

The-24, 1146

Theo-Time, 1146

Theochron, 1146

Theolair, 1146

Theophyl SR, 1146

theophylline, 62–64, 1146–1149

therapeutic and toxic blood levels for, S17

Thiamilate, 1311

thiamine, 1311

Thiamine deficiency, thiamine for, 1311

Thiamine Hydrochloride, 1311

thiopental sodium, 1340–1341t

thioridazine hydrochloride, 1149–1151

Throat infection, amoxicillin for, 76

Thrombate III, 96

Thrombocythemia, anagrelide for, 90

Thrombocytopenia, 1363

argatroban for, 100, 101

bivalirudin for, 146

lepirudin for, 643

triamcinolone for, 1197

Thrombolysis, 1299

Thrombosis. See also Deep vein thrombosis, argatroban for, 100, 101

bivalirudin for, 146

lepirudin for, 643

triamcinolone for, 1197

Thrombolytics, 1299

Thrombosis. See also Deep vein thrombosis, argatroban for, 100, 101

bivalirudin for, 146

lepirudin for, 643

triamcinolone for, 1197

Thrombus lysis alteplase for, 52

Thyroid cancer (continued) sodium iodide 1311 for, 1086

Thyroid cancer, Tirofiban hydrochloride, 1168–1170

tissue plasminogen activator, recombinant, 52–54

Tixylix Chesty Cough, 539

tizanidine hydrochloride, 1170–1171

TNKase, 1130

TOBI, 1171

tobramycin, 1171–1174

therapeutic and toxic blood levels for, S17

tobramycin sulfate, 1171–1174

Tobrex, 1171

tocainide, therapeutic and toxic blood levels for, S17
tocopherols, 1312

Tofranil, 576

Tofranil-PM, 576
tolcapone, 1174–1176
tolterodine, 1176–1177, P15

Tonsillitis

azithromycin for, 121

cefadroxil for, 199
cefadroxil for, 200
cefdinir for, 204
cefixime for, 207
cefpodoxime for, 212
cefprozil for, 214
ceftibuten for, 217
cefuroxime for, 221

clarithromycin for, 261
Toothache, acetaminophen for, 15

Topamax, 1177, P15

Topamax Sprinkle, P15

Topicycline, 1142

topiramate, 1177–1179, P15

Toposar, 446

topolacific hydrochloride, 1179–1180

Toprol-XL, 750, P10
torsemide, 1181–1182

Torem, 1181

Torsades de pointes, 1363
torsemide, 1181–1182

Total parenteral nutrition chromium as supplement in, 1304
copper as supplement in, 1304
Total parenteral nutrition (continued)
magnesium as supplement in, 694
manganese as supplement in, 1307
selenium as supplement in, 1311
zinc as supplement in, 1312
Tourette syndrome
haloperidol for, 541, 542
pimozide for, 938
Toxic epidermal necrolysis, 1363
Toxoplasmosis, pyrimethamine for, 1005
Tracheobronchitis, acetylcysteine for, 19
Tracheostomy care, acetylcysteine for, 19
Trachoma, sulfacetamide for, 1105
Tracleer, 150
Tracrium, 1330t–1331t
Tradorec XL, 1182
tramadol hydrochloride, 1182–1184, P15
Tramake, 1182
Trandate, 628
trandolapril, 1184–1185
Trangina, 618
Trangina XL, 618
Tranquilyn, 740
Transderm-Scop, 1067
Transderm-V, 1067
Transfusion reactions, chlorpheniramine for, 239
Transfusions, exchange, calcium for, 171
Transient ischemic attack, acetylsalicylic acid for, 21
Transtec, 161
Tranxene, 275
Tranxene-SD, 275
Tranxene-SD Half Strength, 275
Tranxene-T, 275
tranylcypromine sulfate, 1185–1187
trastuzumab, 1187–1189
Travamine, 353
Traveleeze, 699
Traveler’s diarrhea, rifaximin for, 1040
sulfamethoxazole-trimethoprim for, 1107
trazodone hydrochloride, 1189–1191
Trazorel, 1189
Treanda, 132
Trelstar Depot, 1208
Trelstar LA, 1208
Trental, 918
treprostinil sodium, 1191–1192
tretinoin, 1192–1195
Triaderm, 1195
triamcinolone, 1195–1199
triamcinolone acetonide, 1195–1199
triamcinolone hexacetonide, 1195–1199
triamterene, 1199–1200
triazolam, 1200–1201
tromethamine, 1210–1211
Trophoblastic tumors, methotrexate for, 732
trospium chloride, 1211–1212
Truvada, 399, 1345
Tuberculosis
acetylcysteine for, 19
ethambutol for, 439
isoniazid for, 615
pyrazinamide for, 1002
rifampin for, 1037
rifapentine for, 1039
streptomycin for, 1102
Tuberculous meningitis
methylprednisolone for, 744
triamcinolone for, 1197
Tularemia
streptomycin for, 1102
tetracycline for, 1142
Tumor lysis syndrome, 1363
Tumors, solid, doxorubicin for, 379
Tums, 170
Tums E-X, 170
Tums Ultra, 170
Turner’s syndrome, somatropin, recombinant for, 1092
Tussionex, 1345
Twilite, 356
Twijnject, 409
Tycoclene, 14
Tygacil, 1158

**Boldface**: Color section

| t: table | }
Tylenol, 14
Tylenol 8 Hour, 14
Tylenol Arthritis, 14
Tylox, 1345
Typhoid fever, ciprofloxacin for, 256

U
Ucerax, 559
Ulcerative colitis
  balsalazide for, 126
  hydrocortisone for, 552
  infliximab for, 588
  mesalamine for, 717
  olsalazine for, 855
  psyllium for, 1001
  sulfasalazine for, 1109
Ulcer disease, bismuth for, 143
Ulcers. See specific type.
Ulcidine, 457
Ultiva, 1336t–1337t
Ultra Heartburn Relief, 457
Ultracet, 1345, P15
Ultradol, 442
Ultram, 1182, P15
Ultram ER, 1182, P15
Ultrase, 1345
Unasyn, 86, 1345
Uni-Senna, 1072
Unimed, 744
Uniphyllin Continus, 1146
Unisom Maximum Strength SleepGels, 356
Unithroid, 660
Unitron Peg, 898
Univasc, 777
Univer, 1228
urea, 1212–1213
Urecholine, 137
Urethritis
  ampicillin for, 85
  azithromycin for, 121
  cefotaxime for, 209
  minocycline for, 765
  ofloxacin for, 849
  tetracycline for, 1142
Uric acid nephropathy, allopurinol for prevention of, 46
Uridon, 245

Urinary alkalization, sodium bicarbonate for, 1083
Urinary frequency
  darifenac for, 310
  oxybutynin for, 871
  solifenac for, 1090
  trospium for, 1211
Urinary incontinence
  darifenac for, 310
  oxybutynin for, 871
  solifenac for, 1090
  trospium for, 1211
Urinary tract infection
  amikacin, 59
  amoxicillin and clavulanate for, 78
  ampicillin for, 84
  cefaclor for, 199
  cefadroxil for, 200
  cefazolin for, 202
  cepheim for, 205
  cefixime for, 207
  cefotixin for, 211
  cefpodoxime for, 212
  cefotaxime for, 216
  cefuroxime for, 221
  ciprofloxacin for, 256
  doripenem for, 371
  fluconazole for, 475
  flucytosine for, 476
  imipenem and clastatin for, 575
  levoflaxacin for, 654
  nitrofurantoin for, 830
  norfloxacin for, 842
  ofloxacin for, 849
  piperacillin for, 942
  sulfamethoxazole-trimethoprim for, 1106
  sulfisoxazole for, 1111
  ticarcillin and clavulanate for, 1154
Urinary tract irritation, phenazopyridine for, 924
Urinary urgency
  oxybutynin for, 871
  solifenac for, 1090
  trospium for, 1211
Urine retention, bethanechol for, 137
Uro-Mag, 693
Uromax, 871
Uromitexan, 719
Uroxatral, 42
Urozide, 547
Urticaria
  cyproheptadine for, 296
  desloratadine for, 326
  fexofenadine for, 468
  levocetirizine for, 653
  loratadine for, 683
Uterine bleeding
  estrogens, conjugated for, 432
  goserelin for, 536
  medroxyprogesterone for, 701
  norethindrone for, 841
  progesterone for, 987
UTI Relief, 923
Utinor, 842
Uveitis
  atropine for, 115
  phenylephrine for, 931

V
Vagifem, 429
valaciclovir, 1213–1215
valacyclovir hydrochloride, 1213–1215, P15
Valclair, 339
Valcyte, 513, 1215
valerian, 1328
valganciclovir hydrochloride, 1215–1216
Valium, 339
Valni Retard, 822
Valni XL, 822
Valorin, 14
valproate sodium, 1216–1219
valproic acid, 1216–1219
  therapeutic and toxic blood levels for, S17
valsartan, 1219–1221, P16
valsartan and hydrochlorothiazide, P16
Valtrex, 1213, P15
Vancocin, 1221
vancomycin hydrochloride, 1221–1223
  therapeutic and toxic blood levels for, S17
Vantin, 212
vardenafil hydrochloride, 1223–1224, P16
varenicline, 1224–1226
Varicella
  acyclovir for, 28
  immune globulin for, 579
Varicella immunization schedule, 1346t, 1347t, 1348t
Varicella zoster infection, acyclovir for, 28
Vascalpha, 459
Vaseretic, 1345
Vasodilators, 1301–1302
Vasomotor symptoms, estrogens, esterified for, 434
Vasotec, 401
Vasotec IV, 401
VCR, 1232–1234
vecuronium bromide, 1340t–1341t
Velcade, 149
Venereal warts, interferon alfa-2b for, 599
venlafaxine hydrochloride, 1226–1227, P16
Venofer, 611
Venoglobulin-I, 579
Venoglobulin-S, 579
Venos for Kids, 539
Venous thrombosis, warfarin for, 1238
Ventolin HFA, 35
VePesid, 446
Vera-Til SR, 1228
Veramyst, 488
verapamil hydrochloride, 1228–1230
  therapeutic and toxic blood levels for, S17
Verapress, 1228
Veralan, 1228
Verelan PM, 1228
Vermox, 698
Versed, 1334t–1335t
Vertab SR, 1228
Vertigo
  dimenhydrinate for, 353
diphenhydramine for,
  meclizine for, 699
Vesamoid, 1192
VESicare, 1090
Vescare, 1090
Viadur, 647
Viagra, 1075, P14
Viazem, 351
Vibra-Tabs, 383
Vibramycin, 383
Vibramycin Calcium, 383
Vibramycin Hyclate, 383
Vibramycin-D, 383
Vicks 44 Cough Relief, 336
Vicks Sinex Ultra Fine Mist, 930
Vicks Vaposyrup for Chesty Coughs, 539
Vicks Vaposyrup for Dry Cough, 336
Vicodin, 549, 1345
Vicodin ES, 549
Vicodin HP, 549
Vicopren, 549
Vidaza, 116
Videx, 346
Videx EC, 346
Vigamox, 783
vinblastine sulfate,
  Vincent’s infection, penicillin V potassium for, 910
vincristine sulfate,
  vinorelbine tartrate,
  Viracept, 810
  Virafoner, 598
  VirafonerPeg, 898
  Virmune, 816
  Virazole, 1033
  Viread, 1132
  Visicol, 1087
  Visken, 939
  Vistaril, 559
  Vistide, 249
  Vita-C, 1303
  Vita-Plus E, 1312
  vitamin A, 1310
Vitamin A deficiency, retinol for, 1310
vitamin B1, 1311
vitamin B12, 1305
Vitamin B12 deficiency, cyanocobalamin for, 1305
vitamin B2, 1310
vitamin B3, 1307–1308
vitamin B6, 1309
vitamin C, 1303
vitamin D3, 1303–1304
vitamin E, 1312
Vitamin E deficiency, tocopherols for, 1312
vitamin K, 1308–1309, S32
Vitamin B1, 1311
Vitamin B2, 1310
Vitamin B3, 1307–1308
Vitamin B6, 1309
Vitamin C, 1303
Vitamin D3, 1303–1304
Vitamin E, 1312
Vitamin E deficiency, tocopherols for, 1312
Vitamin K, 1308–1309, S32
Vitamins and minerals, 1303–1313
Vitrasert, 513
Vivaglobulin, 579
Vivelle, 429
Vivol, 339
VLB, 1230–1232
Voltaren, 343
Voltaren XR, 343
Voltarol, 343
Vomiting. See Nausea and vomiting.
von Willebrand’s disease, desmopressin for, 328
voriconazole, 1235–1238
Vospire-ER, 35
VP-16-213, 446–447
Vulva cancer, bleomycin for, 147
Vusion, 1345
Vytorin, 453, 1345
Vyanse, 673
W
Warfarin overdose, managing, S32
warfarin sodium, 1238–1240, P16
Water replacement, sodium chloride for, 1084
Weight gain, promoting mestrol for, 704
oxandrolone for, 865
Weight loss, orlistat for, 860
Welchol, 283
Wellbutrin, 162, P3
Wellbutrin SR, 162, P3

Boldface: Color section
t: table
| **Wellbutrin XL**, 162                                | **Zamadol**, 1182                                                                 |
| **Wernicke’s encephalopathy**, thiamine for, 1311 | **Zanaflex**, 1170                                                                |
| **Westcort**, 551                                   | **zanamivir**, 1242–1243                                                          |
| **Westhroid**, 1151                                 | **Zanprol**, 857                                                                  |
| **Whipworm infestation**, mebendazole for, 698     | **Zantac**, 1024                                                                  |
| **Wilms’ tumor**, doxorubicin for, 1363              | **Zantac 75**, 1024                                                                |
| **Wind-Eze**, 1077                                   | **Zantac EFFERdose**, 1024                                                         |
| **Winpred**, 972                                    | **Zapornex**, 27                                                                  |
| **Withdrawal phenomena**, 1363                       | **Zaroxyl**, 748                                                                  |
| **Wolff-Parkinson-White syndrome**, adenosine for, 32| **Zavedos**, 570                                                                  |
| **Wrinkles**, tretinoin for, 1193                   | **Zebeta**, 144                                                                   |
|                                                         | **Zeefix**, 631                                                                   |
|                                                         | **Zegerid**, 857                                                                  |
|                                                         | **Zeferal**, 1070                                                                 |
|                                                         | **Zemtard**, 351                                                                  |
|                                                         | **Zemuron (P/F)**, 1338t–1339t                                                     |
|                                                         | **Zenapax**, 300                                                                  |
|                                                         | **Zerit**, 1098                                                                   |
|                                                         | **Zestoretic**, 1345, **P9**                                                       |
|                                                         | **Zestrol**, 675, **P9**                                                           |
|                                                         | **Zevelin**, 564                                                                  |
|                                                         | **Ziac**, 1345                                                                    |
|                                                         | **Ziagen**, 3                                                                     |
|                                                         | **Ziana Gel**, 1345                                                               |
|                                                         | **Zidovudine**, 1243–1245                                                         |
|                                                         | **Zinc chloride**, 1312–1313                                                      |
|                                                         | **Zinc gluconate**, 1312–1313                                                     |
|                                                         | **Zinc sulfate**, 1312–1313                                                       |
|                                                         | **Zinc-Pak**, 1312                                                                |
|                                                         | **Zindaclin**, 263                                                                |
|                                                         | **Zinga**, 836                                                                    |
|                                                         | **Zinnat**, 221                                                                   |
|                                                         | **Zirpasilone hydrochloride**, 1245–1247                                           |
|                                                         | **Zirtec**, 226                                                                   |
|                                                         | **Zispin**, 769                                                                   |
|                                                         | **Zithromax**, 120, **P3**                                                        |
|                                                         | **Ziz**, 988                                                                       |
|                                                         | **Zmax**, 120                                                                     |
|                                                         | **Zocor**, 1078, **P14**                                                          |
|                                                         | **Zofran**, 858                                                                    |
|                                                         | **Zofran OD**, 858                                                                |
|                                                         | **Zofran Preservative Free**, 858                                                  |
|                                                         | **Zoladex**, 535                                                                  |
|                                                         | **Zoladex 3-Month**, 535                                                          |
|                                                         | **Zoladex LA**, 535                                                               |
|                                                         | **zoldipem, therapeutic and toxic blood levels for, S17**                          |
|                                                         | **Zoledronic acid**, 1247–1248                                                     |
|                                                         | **Zollinger-Ellison syndrome cimetidine for, 252**                                  |
|                                                         | **esomeprazole for, 428**                                                         |
|                                                         | **famotidine for, 458**                                                           |
|                                                         | **lansoprazole for, 637**                                                         |
|                                                         | **omeprazole for, 857**                                                           |
|                                                         | **rabeprazole for, 1017**                                                         |
|                                                         | **ranitidine for, 1024**                                                          |
|                                                         | **zolmitriptan, 1248–1250**                                                       |
|                                                         | **Zoloft**, 1073, **P14**                                                          |
|                                                         | **zolpidem tartrate, 1250–1251**                                                  |
|                                                         | **Zolvera**, 1228                                                                 |
|                                                         | **Zomacton**, 1091                                                                |
|                                                         | **Zometa**, 1247                                                                  |
|                                                         | **Zomig Rapimelt**, 1248                                                          |
|                                                         | **Zomig-ZMT**, 1248                                                               |
|                                                         | **Zomorph**, 780                                                                  |
|                                                         | **Zonalon**, 376                                                                  |
|                                                         | **Zonegran**, 1251                                                                |
|                                                         | **zonisamide, 1251–1252**                                                        |
|                                                         | **Zorbtive**, 1091                                                                |
|                                                         | **ZORprin**, 21                                                                   |
|                                                         | **Zosyn**, 944                                                                    |
|                                                         | **Zoton**, 637                                                                    |
|                                                         | **Zovirax**, 27                                                                   |
|                                                         | **Zumenon**, 429                                                                  |
|                                                         | **Zyban**, 162                                                                    |
|                                                         | **Zydos**, 851                                                                    |
|                                                         | **Zydone**, 549                                                                   |
|                                                         | **Zygomycosis, amphotericin B for, 81**                                             |
|                                                         | **Zyloprim**, 45                                                                  |
|                                                         | **Zymar**, 516                                                                    |
|                                                         | **Zyomet**, 752                                                                   |
|                                                         | **Zyprex, 851, **P11**                                                            |
|                                                         | **Zyprex IntraMuscular**, 851                                                      |
|                                                         | **Zytec**, 226                                                                    |
|                                                         | **Zytec-D**, 1345                                                                 |
|                                                         | **Zytram XL**, 1182                                                               |
|                                                         | **Zyvox**, 667                                                                    |
|                                                         | **Zyvoxam, 667**                                                                  |

t: table

**Boldface:** Color section